Entry ID,Experimental Method,Matthews Coefficient,Percent Solvent Content,Crystallization Method,pH,Crystal Growth Procedure,Temp (K),Deposition Date,Release Date,PDB ID,Number of Non-Hydrogen Atoms per Deposited Model,Total Number of Polymer Instances (Chains),Total Number of Polymer Residues per Deposited Model,Number of Water Molecules per Deposited Model,Disulfide Bond Count per Deposited Model,Molecular Weight per Deposited Model,Number of Distinct Protein Entities,Refinement Resolution (Ã…),Structure Determination Methodology,Average B Factor,R Free,R Work,Structure Title
6SJZ,X-RAY DIFFRACTION,2.2,44.16,"VAPOR DIFFUSION, HANGING DROP",5.5,"22% PEG6K, 100mM Sodium Citrate pH 5.5, 100mM MgCl2, 100mM NaCl.",293,2019-08-14,2020-03-18,6SJZ,7209,4,822,596,,97.2,2,1.995,experimental,27.1155,0.2016,0.1716,HsNMT1 in complex with both MyrCoA and Acetylated-GNCFSKPR substrates
5C37,X-RAY DIFFRACTION,2.26,45.64,"VAPOR DIFFUSION, HANGING DROP",8,"PEG3350, Tris, KCl",298,2015-06-17,2016-06-22,5C37,9702,2,1328,235,,146.72,1,2.3,experimental,,0.2507,0.2097,Structure of the beta-ketoacyl reductase domain of human fatty acid synthase bound to a spiro-imidazolone inhibitor
6NNA,X-RAY DIFFRACTION,2.26,45.48,"VAPOR DIFFUSION, HANGING DROP",7.6,"0.19 M ammonium sulfate, 5 mM sodium cacodylate,pH7.6 and 27 % w/v PEG 3350",291,2019-01-14,2019-02-20,6NNA,10100,2,1320,594,,147.01,1,2.26,experimental,34.873,0.2508,0.2008,Human Fatty Acid Synthase Psi/KR Tri-Domain with NADPH and Compound 22
7M4C,X-RAY DIFFRACTION,2.83,56.57,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4C,3248,4,351,244,,44.09,1,1.95,experimental,42.179,0.2141,0.1813,"DNA Polymerase Lambda, TTP:At Mn2+ Product State Ternary Complex, 960 min"
7M4E,X-RAY DIFFRACTION,2.84,56.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4E,2981,4,351,127,,44.19,1,1.903,experimental,58.3837,0.2328,0.2086,"DNA Polymerase Lambda, dCTP:At Mg2+ Reaction State Ternary Complex, 120 min"
7M4F,X-RAY DIFFRACTION,2.84,56.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4F,2901,4,351,133,,43.66,1,1.947,experimental,56.0292,0.2409,0.2075,"DNA Polymerase Lambda, dCTP:At Mg2+ Product State Ternary Complex, 300 min"
7M4H,X-RAY DIFFRACTION,2.85,56.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4H,3296,4,351,242,,44.33,1,1.923,experimental,46.8253,0.2275,0.1923,"DNA Polymerase Lambda, dCTP:At Mn2+ Reaction State Ternary Complex, 225 min"
7M4I,X-RAY DIFFRACTION,2.85,56.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4I,2938,4,351,82,,43.95,1,2.005,experimental,59.4261,0.247,0.2218,"DNA Polymerase Lambda, dCTP:At Mn2+ Product State Ternary Complex, 420 min"
7M4L,X-RAY DIFFRACTION,2.82,56.44,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4L,3239,4,351,248,,44.24,1,1.701,experimental,45.6853,0.2153,0.1894,"DNA Polymerase Lambda, TTPaS:At Mn2+ Product State Ternary Complex, 60 min"
5OOG,X-RAY DIFFRACTION,2.34,47.5,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 3350, 0.2 M AMMONIUM SULFATE, 0.1 M SODIUM CACODYLATE PH 6.5. NADP ADDED TO A FINAL CONCENTRATION OF 2.5 MM",293,2017-08-07,2018-03-07,5OOG,2002,1,206,297,,23.86,1,1.33,experimental,,0.1451,0.1169,Human biliverdin IX beta reductase: NADP/Phloxine B ternary complex
6QRM,X-RAY DIFFRACTION,2.24,45,"VAPOR DIFFUSION, HANGING DROP",5.5,"24% PEG8K, 100mM Sodium Citrate pH 5.5, 100mM MgCl2, 100mM NaCl.",293,2019-02-19,2020-03-18,6QRM,7003,4,824,396,,97.57,2,2.3,experimental,30.6342,0.2033,0.172,HsNMT1 in complex with both MyrCoA and GNCFSKRRAA substrates
6SK2,X-RAY DIFFRACTION,2.16,43.02,"VAPOR DIFFUSION, HANGING DROP",5.6,"22% PEG8K, 100mM Sodium Citrate pH 5.6, 100mM MgCl2, 100mM NaCl",293,2019-08-14,2020-03-18,6SK2,7411,4,822,727,,97.05,2,1.90000651019,experimental,31.6244340982,0.219991662291,0.171966781113,HsNMT1 in complex with both MyrCoA and Acetylated-GKSFSKPR peptide reveals N-terminal Lysine Myristoylation
6SKJ,X-RAY DIFFRACTION,2.21,44.47,"VAPOR DIFFUSION, HANGING DROP",5.6,"19% PEG6K, 100mM Sodium Citrate pH 5.6, 100mM MgCl2, 100mM NaCl",293,2019-08-15,2020-03-18,6SKJ,6773,4,816,90,,97.52,2,2.8,experimental,27.2781,0.2188,0.189,DeltaC2 C-terminal truncation of HsNMT1 in complex with MyrCoA and GNCFSKPR substrates
7M44,X-RAY DIFFRACTION,2.82,56.43,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M44,3181,4,351,241,,44.55,1,1.901,experimental,42.93,0.2264,0.1949,"DNA Polymerase Lambda, TTP:At Mg2+ Reaction State Ternary Complex, 90 sec"
7M46,X-RAY DIFFRACTION,2.84,56.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M46,3204,4,351,251,,43.91,1,1.92,experimental,43.332,0.2165,0.1862,"DNA Polymerase Lambda, TTP:At Mg2+ Product State Ternary Complex, 5 min"
7M47,X-RAY DIFFRACTION,2.82,56.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M47,3281,4,351,294,,44.06,1,1.648,experimental,39.3116,0.2082,0.1797,"DNA Polymerase Lambda, TTP:At Mg2+ Product State Ternary Complex, 60 min"
7M4A,X-RAY DIFFRACTION,2.84,56.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4A,3079,4,351,171,,44.02,1,1.868,experimental,50.2203,0.2202,0.1875,"DNA Polymerase Lambda, TTP:At Mn2+ Product State Ternary Complex, 20 min"
7M4B,X-RAY DIFFRACTION,2.83,56.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4B,3313,4,351,265,,44.14,1,1.66,experimental,43.5286,0.2017,0.1807,"DNA Polymerase Lambda, TTP:At Mn2+ Product State Ternary Complex, 60 min"
7M49,X-RAY DIFFRACTION,2.85,56.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M49,3331,4,351,276,,44.59,1,1.6,experimental,46.2289,0.216,0.1876,"DNA Polymerase Lambda, TTP:At Mn2+ Reaction State Ternary Complex, 5 min"
7M45,X-RAY DIFFRACTION,2.83,56.47,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M45,3251,4,351,250,,44.36,1,1.889,experimental,42.3298,0.2421,0.2045,"DNA Polymerase Lambda, TTP:At Mg2+ Reaction State Ternary Complex, 120 sec"
7M4D,X-RAY DIFFRACTION,2.74,55.08,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4D,3074,4,350,201,,43.86,1,1.817,experimental,52.2665,0.254,0.2104,"DNA Polymerase Lambda, dCTP:At Ca2+ Ground State Ternary Complex"
7M4G,X-RAY DIFFRACTION,2.83,56.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4G,3020,4,351,146,,43.79,1,1.88,experimental,55.727,0.2395,0.2115,"DNA Polymerase Lambda, dCTP:At Mg2+ Product State Ternary Complex, 960 min"
7M4J,X-RAY DIFFRACTION,2.87,57.19,"VAPOR DIFFUSION, HANGING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4J,2850,4,351,68,,43.87,1,2.377,experimental,53.3011,0.2612,0.2256,"DNA Polymerase Lambda, dCTP:At Mn2+ Product State Ternary Complex, 960 min"
7M4K,X-RAY DIFFRACTION,2.85,56.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M4K,3044,4,350,201,,44.07,1,1.719,experimental,49.2118,0.2268,0.1955,"DNA Polymerase Lambda, TTPaS:At Ca2+ Ground State Ternary Complex"
8Q24,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, HANGING DROP",5.6,"22% PEG6K, 100mM Sodium Citrate pH 5.6, 0.1 M MgCL2, 0.1 M NaCl",293,2023-08-01,2024-08-14,8Q24,7129,4,818,487,,97.06,2,1.9,experimental,38,0.215,0.1719,HsNMT1 in complex with both MyrCoA and (DAB)SFSKPR inhibitor peptide
7UN7,X-RAY DIFFRACTION,2.89,57.44,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2022-04-09,2023-03-29,7UN7,2984,5,351,150,,44.27,1,2.04,experimental,44.1816,0.2471,0.2199,DNA Polymerase lambda in complex with a 1nt microhomology substrate
8Q23,X-RAY DIFFRACTION,2.23,44.95,"VAPOR DIFFUSION, HANGING DROP",5.6,"19% PEG6K, 0.1M Sodium citrate, 0.1 MgCl2, 0.1 M NaCl",293,2023-08-01,2024-08-14,8Q23,7348,4,820,616,,97.11,2,1.9,experimental,31.09,0.1948,0.1578,HsNMT1 in complex with both MyrCoA and Ac-D-ORN-SFSKPR inhibitor peptide
7M48,X-RAY DIFFRACTION,2.84,56.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M48,3162,4,351,255,,43.88,1,1.93,experimental,42.2932,0.2204,0.1839,"DNA Polymerase Lambda, TTP:At Mg2+ Product State Ternary Complex, 960 min"
7M43,X-RAY DIFFRACTION,2.86,56.94,"VAPOR DIFFUSION, SITTING DROP",7.5,"80-95mM BICINE pH 8.3, 0.3M Na-K Tartrate, 18-22.5% PolyPure PEG",277,2021-03-21,2022-07-06,7M43,3142,4,350,248,,44.07,1,1.978,experimental,41.5763,0.231,0.1925,"DNA Polymerase Lambda, TTP:At Ca2+ Ground State Ternary Complex"
5IRQ,X-RAY DIFFRACTION,2.6,52.77,"VAPOR DIFFUSION, HANGING DROP",,"175 mM Tris-HCl, pH 8.0, 30% w/v PEG3350, 200 mM lithium sulfate, 12% glycerol",293,2016-03-14,2017-03-15,5IRQ,15690,4,1976,525,,226.66,1,2.202,experimental,,0.2486,0.2013,Human cytochrome P450 17A1 bound to inhibitors (R)- and (S)- orteronel
6SK3,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, HANGING DROP",5.6,"19% PEG6K, 100mM Sodium Citrate pH 5.6, 100mM MgCl2, 100mM NaCl.",293,2019-08-14,2020-03-18,6SK3,6514,4,814,15,,96.23,2,2.7,experimental,39.0239,0.2686,0.2459,C-terminal HsNMT1 deltaC3 truncation in complex with both MyrCoA and GNCFSKPR substrates
6SK8,X-RAY DIFFRACTION,2.22,44.57,"VAPOR DIFFUSION, HANGING DROP",5.6,"19% PEG8K, 100mM Sodium Citrate pH 5.6, 100mM MgCl2, 100mM NaCl",293,2019-08-14,2020-03-18,6SK8,7493,4,814,843,,96.62,2,1.87,experimental,30.2305,0.2439,0.2078,DeltaC3 C-terminal truncation of HsNMT1 in complex with MyrCoA and GDCFSKPR substrates
6HFQ,X-RAY DIFFRACTION,2.52,51.11,"VAPOR DIFFUSION, HANGING DROP",7.5,"Protein at 2-3 mg/ml in 20 mM Tris pH 8, 0.15 M NaCl, 0.02 mM zinc sulfate, 0.2 mM TCEP with 4 mM carbamoyl asparate.
Mother liquor: 2.5-3 M potassium formate, 0.1 M HEPES pH 7.5",291,2018-08-21,2018-10-24,6HFQ,3305,1,393,350,2,43.55,1,1.14542458871,experimental,20.7193285176,0.137050568255,0.124958636067,Human dihydroorotase mutant F1563T co-crystallized with carbamoyl aspartate at pH 7.5
5YNZ,X-RAY DIFFRACTION,2.81,56.16,"VAPOR DIFFUSION, HANGING DROP",6.5,"2M sodium chloride, 100mM MES sodium salt pH6.5, 200mM sodium acetate",298,2017-10-26,2018-10-24,5YNZ,2803,1,391,14,,42.73,1,2.774,experimental,,0.2889,0.226,Crystal structure of the dihydroorotase domain (K1556A) of human CAD
6HG1,X-RAY DIFFRACTION,2.39,48.48,"VAPOR DIFFUSION, HANGING DROP",,"Protein at 2-3 mg/ml in 20 mM Tris pH 8, 0.15 M NaCl, 0.02 mM zinc sulfate, 0.2 mM TCEP
Mother liquor: 2.5-3 M potassium formate, 0.1 M HEPES pH 7.5",291,2018-08-22,2018-10-24,6HG1,2974,1,371,57,1,40.51,1,2.12,experimental,,0.2091,0.1737,Hybrid dihydroorotase domain of human CAD with E. coli flexible loop in apo state
6HFN,X-RAY DIFFRACTION,2.51,50.97,"VAPOR DIFFUSION, HANGING DROP",7.5,"Protein at 2-3 mg/ml in 20 mM Tris pH 8, 0.15 M NaCl, 0.02 mM zinc sulfate, 0.2 mM TCEP with 4 mM carbamoyl asparate.
Mother liquor: 2.5-3 M potassium formate, 0.1 M HEPES pH 7.5",291,2018-08-21,2018-10-24,6HFN,3305,1,393,413,2,43.36,1,1.44965143011,experimental,31.0201743887,0.144833022799,0.118473620561,Human dihydroorotase mutant F1563L co-crystallized with carbamoyl aspartate at pH 7.5
6HFP,X-RAY DIFFRACTION,2.53,51.3,"VAPOR DIFFUSION, HANGING DROP",7,"Protein at 2-3 mg/ml in 20 mM Tris pH 8, 0.15 M NaCl, 0.02 mM zinc sulfate, 0.2 mM TCEP with 4 mM carbamoyl asparate.
Mother liquor: 2.5-3 M potassium formate, 0.1 M HEPES pH 7.0",291,2018-08-21,2018-10-24,6HFP,3449,1,393,509,2,43.46,1,1.19822864429,experimental,21.0978390917,0.1366740553,0.121748467499,Human dihydroorotase mutant F1563T co-crystallized with carbamoyl aspartate at pH 7.0
4WJX,X-RAY DIFFRACTION,2.23,44.79,"VAPOR DIFFUSION, HANGING DROP",,"25 % (w/v) polyethylene glycol (PEG) 3350, 0.2 M potassium sodium tartrate (PST) at pH 7.2",290,2014-10-01,2015-07-08,4WJX,4085,1,377,536,2,42.52,1,1,experimental,,0.1475,0.1352,Crystal structure of human chitotriosidase-1 catalytic domain at 1.0 A resolution
6VF0,X-RAY DIFFRACTION,2.51,50.98,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF0,3597,4,374,388,,47.09,1,1.58,experimental,29.8993,0.1872,0.1635,"DNA Polymerase Mu, 8-oxorGTP:At Reaction State Ternary Complex, 50 mM Mg2+ (30 min)"
6VF4,X-RAY DIFFRACTION,2.51,50.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF4,3425,4,374,287,,47.13,1,1.75,experimental,31.8205,0.1923,0.168,"DNA Polymerase Mu, 8-oxorGTP:At Reaction State Ternary Complex, 50 mM Mn2+ (30 min)"
6VFB,X-RAY DIFFRACTION,2.45,49.75,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VFB,3398,4,374,302,,47.28,1,1.55,experimental,30.545,0.1815,0.1669,"DNA Polymerase Mu, 8-oxorGTP:Ct Reaction State Ternary Complex, 50 mM Mn2+ (960 min)"
7OWN,X-RAY DIFFRACTION,2.21,44.3,"VAPOR DIFFUSION, HANGING DROP",5.6,"22% PEG6K, 100mM Sodium Citrate pH 5.6, 100mM MgCl2, 100mM NaCl",293,2021-06-18,2022-12-21,7OWN,7096,3,812,535,,96.18,2,2.1,experimental,32.23,0.215,0.1663,HsNMT1 in complex with both MyrCoA and peptide AKSFSKPR
7OWP,X-RAY DIFFRACTION,2.23,45,"VAPOR DIFFUSION, HANGING DROP",5.6,"18% PEG8K, 100mM Sodium Citrate pH 5.6, 100mM MgCl2, 100mM NaCl",293,2021-06-18,2022-12-21,7OWP,7472,4,822,790,,96.91,2,1.81,experimental,31.89,0.191,0.1552,HsNMT1 in complex with both MyrCoA and ACE-G-(L-ORN)SFSKPR
7OWR,X-RAY DIFFRACTION,2.34,47.36,"VAPOR DIFFUSION, HANGING DROP",4.6,"16% PEG6K, 100mM Sodium Acetate 4.6",293,2021-06-18,2022-12-21,7OWR,6897,3,813,366,,96.13,2,2.39,experimental,30.4,0.2187,0.1734,HsNMT1 in complex with both MyrCoA and peptide GGKSFSKPR
5IIJ,X-RAY DIFFRACTION,2.87,57.07,"VAPOR DIFFUSION, HANGING DROP",,0.1 M sodium cacodylate pH 7.0 and 1.0 M sodium acetate trihydrate,277,2016-03-01,2016-08-17,5IIJ,3254,4,355,409,,44.25,1,1.724,experimental,,0.224,0.1969,Crystal structure of the pre-catalytic ternary complex of DNA polymerase lambda with a templating 8-oxo-dG and an incoming dCTP
6UOL,X-RAY DIFFRACTION,2.32,46.97,"VAPOR DIFFUSION, SITTING DROP",,"19% PEG3350, 0.35 M sodium acetate, 0.05 M Imidazole, pH 8.0.",291,2019-10-15,2020-01-08,6UOL,3491,4,366,203,,48.51,1,1.936,experimental,25.205,0.2496,0.1865,Y271G DNA polymerase beta substrate complex with a templating cytosine and incoming rGTP
4RPZ,X-RAY DIFFRACTION,2.13,42.16,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RPZ,3530,4,375,158,,50.41,1,2.19,experimental,27.937,0.2514,0.19545,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dCTP soaked with MgCl2 for 60 s"
4RQ0,X-RAY DIFFRACTION,2.14,42.46,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RQ0,3453,4,375,126,,49.92,1,2.2,experimental,27.769,0.26822,0.20751,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dCTP soaked with MgCl2 for 80 s"
4RQ2,X-RAY DIFFRACTION,2.14,42.52,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RQ2,3533,4,375,155,,49.88,1,2.2,experimental,35.986,0.26868,0.19404,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dCTP soaked with MnCl2 for 35 s"
4RQ4,X-RAY DIFFRACTION,2.12,41.93,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RQ4,3546,4,375,195,,50.08,1,2.1,experimental,34.463,0.24363,0.18961,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dATP soaked with MgCl2 for 30 s"
4RQ5,X-RAY DIFFRACTION,2.12,42.02,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RQ5,3416,4,375,76,,50.03,1,2.32,experimental,39.173,0.26586,0.19644,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dATP soaked with MgCl2 for 60 s"
4RQ6,X-RAY DIFFRACTION,2.19,43.89,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RQ6,3375,4,375,71,,49.41,1,2.25,experimental,44.391,0.25204,0.19766,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dATP soaked with MgCl2 for 80 s"
4RQ8,X-RAY DIFFRACTION,2.16,43.08,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RQ8,3648,4,375,231,,50.34,1,2,experimental,28.409,0.27049,0.20688,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dATP soaked with MnCl2 for 35 s"
7M0A,X-RAY DIFFRACTION,3,59.1,"VAPOR DIFFUSION, SITTING DROP",6.5,"80mM Na cacodylate pH 6.5, 0.16M calcium acetate, 14.4% (w/v) PEG 8000, 20% (v/v) glycerol",277,2021-03-10,2022-03-16,7M0A,3547,5,368,409,,46.19,1,1.83,experimental,26.5,0.1933,0.169,Incomplete in crystallo incorporation by DNA Polymerase Lambda bound to blunt-ended DSB substrate and incoming dTTP
7M0C,X-RAY DIFFRACTION,3.03,59.4,"VAPOR DIFFUSION, SITTING DROP",6.5,"76.5mM Na cacodylate pH 6.5, 0.153M ammonium sulfate, 22.95% (w/v) PEG 8000, 13.5% (v/v) glycerol, 0.2M NDSB-201",277,2021-03-10,2022-03-16,7M0C,3121,5,368,108,,45.69,1,2.65,experimental,31.27,0.2286,0.1804,Post-catalytic nicked complex of DNA Polymerase Lambda with bound mismatched DSB substrate
6Z1W,X-RAY DIFFRACTION,2.1,41,"VAPOR DIFFUSION, HANGING DROP",5.4,"2.2 M ammonium sulfate, 0.2 M NaCl and 0.1 M citric acid",277,2020-05-14,2021-03-03,6Z1W,938,1,120,9,,14.04,1,2.48,experimental,53.158,0.2678,0.2081,Crystal structure of human steroid carrier protein SL (SCP-2L) mutant A100C
6Z1X,X-RAY DIFFRACTION,2.1,41,"VAPOR DIFFUSION, HANGING DROP",5.4,"2.2 M ammonium sulfate, 0.2 M NaCl and 0.1 M citric acid",277,2020-05-14,2021-03-03,6Z1X,1017,1,120,62,,14.66,1,2.09,experimental,20.315,0.237,0.1806,Crystal structure of human steroid carrier protein SL (SCP-2L) mutant V83C
5TBA,X-RAY DIFFRACTION,2.34,47.42,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM
 ACETATE, 17% PEG3350 , PH 8.0",295,2016-09-11,2017-01-11,5TBA,3260,4,374,59,,49.33,1,2.49,experimental,41.5,0.273,0.205,"Postcatalytic ternary complex of Human DNA Polymerase Beta with Gapped DNA substrate, incorporated (-)3TC and PPi."
5TBB,X-RAY DIFFRACTION,2.38,48.31,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM
 ACETATE, 17% PEG3350, PH 8.0,",295,2016-09-11,2017-01-11,5TBB,3076,4,374,35,,49.5,1,2.39,experimental,41.67,0.269,0.213,"Postcatalytic ternary complex of Human DNA Polymerase Beta with Gapped DNA substrate, incorporated (-)FTC and PPi."
5V1I,X-RAY DIFFRACTION,2.27,45.92,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium chloride, 17% PEG3350",291,2017-03-02,2017-05-10,5V1I,3496,4,367,235,,48.45,1,2.035,experimental,,0.2374,0.184,DNA polymerase beta ternary product complex with 8-oxoG:C and inserted dCTP
5V1O,X-RAY DIFFRACTION,2.26,45.66,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium acetate, 17% PEG3350",291,2017-03-02,2017-05-10,5V1O,3659,4,367,333,,48.44,1,1.801,experimental,,0.215,0.1789,DNA polymerase beta product complex with 8-oxoG:A and inserted dCTP
5V1R,X-RAY DIFFRACTION,2.28,46.04,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, 350 mM sodium acetate, 17% PEG3350",291,2017-03-02,2017-05-10,5V1R,3484,4,367,230,,48.92,1,2.077,experimental,,0.2369,0.1799,DNA polymerase beta reactant complex with 8-oxoG:C at the primer terminus and incoming dCTP
6ILD,X-RAY DIFFRACTION,2.65,53.52,"VAPOR DIFFUSION, SITTING DROP",8,"8 % PEG 20000, 0.1 M Tris pH 8.0, 0.1 M sodium chloride",291,2018-10-17,2019-02-27,6ILD,9203,3,1070,910,2,124.78,2,1.882,experimental,27.0836,0.1844,0.1535,Crystal Structure of Human LysRS: P38/AIMP2 Complex II
4RPY,X-RAY DIFFRACTION,2.13,42.34,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RPY,3679,4,375,286,,50.64,1,1.9,experimental,22.407,0.22982,0.18965,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dCTP soaked with MgCl2 for 30 s"
6ZE8,X-RAY DIFFRACTION,2.36,47.78,"VAPOR DIFFUSION, HANGING DROP",7.2,"31% (w/v) polyethylene glycol (PEG) 3350, 200 mM potassium sodium tartrate (PST)",291,2020-06-16,2020-11-11,6ZE8,20052,6,2190,2370,13,247.28,1,1.5,experimental,23.62,0.1679,0.1227,Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound OATD-01
5U9H,X-RAY DIFFRACTION,2.2,44.12,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium chloride, 17% PEG3350, pH 8.0",291,2016-12-16,2017-02-08,5U9H,3603,4,367,351,,48.43,1,1.85,experimental,,0.2329,0.1945,DNA polymerase beta product complex with inserted Sp-isomer of dCTP-alpha-S
4D4Z,X-RAY DIFFRACTION,2.49,51,,7.2,"30% POLYETHYLENE GLYCOL 6000 (W/V), 100 MM BIS-TRIS PROPANE PH 7.2 - 7.4, 15% GLYCEROL",,2014-10-31,2015-04-15,4D4Z,4831,2,588,335,,64.71,1,1.7,experimental,20.665,0.19283,0.17024,STRUCTURE OF HUMAN DEOXYHYPUSINE HYDROXYLASE in complex with glycerol
6I7K,X-RAY DIFFRACTION,4.96,75.24,"VAPOR DIFFUSION, SITTING DROP",,1.0 M Sodium Chloride; 10% Ethanol,293,2018-11-16,2019-09-25,6I7K,2823,1,343,92,,40.03,1,2.54,experimental,58.033,0.25206,0.23254,Crystal structure of monomeric FICD mutant L258D complexed with MgATP
7OWO,X-RAY DIFFRACTION,2.15,42.87,"VAPOR DIFFUSION, HANGING DROP",5.6,"23% PEG 6K, 100mM NaCitrate 5.6, 100mM MgCl2, 100mM NaCl",293,2021-06-18,2022-12-21,7OWO,7372,4,820,676,,97.82,2,1.7,experimental,26.33,0.2232,0.1829,HsNMT1 in complex with both MyrCoA and N-acetylated KSFSKPR peptide
5O9V,X-RAY DIFFRACTION,2.16,43.16,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG8000, 0.1M sodium citrate pH5.6, 0.1 M magnesium chloride, 0.1M sodium chloride",293,2017-06-20,2018-06-27,5O9V,7170,4,820,494,,97.1,2,2.201,experimental,,0.2056,0.1647,HsNMT1 in complex with CoA and Myristoylated-GGCFSKPK octapeptide
5TZV,X-RAY DIFFRACTION,2.39,48.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"50 MM IMIDAZOLE, 350 MM SODIUM CHLORIDE, 17% PEG3350, pH 7.5",291,2016-11-22,2016-12-07,5TZV,3847,4,366,591,,47.8,1,2,experimental,,0.2291,0.1735,Binary complex crystal structure of DNA Polymerase Beta with G:T mismatch at the primer terminus
6EZB,X-RAY DIFFRACTION,2.94,58.17,"VAPOR DIFFUSION, HANGING DROP",,2.2 M ammonium sulfate,292,2017-11-14,2018-09-26,6EZB,2448,1,327,41,,37.74,1,2.25,experimental,55.39,0.223,0.181,Crystal Structure of human tRNA-dihydrouridine(20) synthase catalytic domain Q305K mutant
5EOZ,X-RAY DIFFRACTION,2.23,44.83,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2015-11-10,2016-11-23,5EOZ,3475,4,366,202,,48.29,1,2.088,experimental,,0.2382,0.1835,Mutagenicity of 7-Benzyl guanine lesion and Replication by Human DNA Polymerase beta
7OWU,X-RAY DIFFRACTION,2.24,45.07,"VAPOR DIFFUSION, HANGING DROP",4.6,"21% PEG 8K, 100mM Sodium Acetate 4.6",293,2021-06-18,2022-12-21,7OWU,7193,4,820,525,,97.23,2,2.08,experimental,30.27,0.2233,0.1787,HsNMT1 in complex with both CoA and Myr-ANCFSKPR peptide
6FLM,X-RAY DIFFRACTION,3.41,63.94,"VAPOR DIFFUSION, SITTING DROP",6.5,15 mg/ml protein mixed in 1:1 ratio with reservoir containing 0.1 M bis-TRIS pH 6.5 and 2M ammonium sulphate.,293,2018-01-26,2018-05-23,6FLM,5422,3,597,511,,69.37,1,2.009,experimental,,0.2061,0.1649,Crystal structure of the human TRIM25 PRYSPRY domain
4YMO,X-RAY DIFFRACTION,2.23,44.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"14 to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",297,2015-03-07,2016-03-09,4YMO,3460,4,366,180,,48.44,1,2.148,experimental,,0.226,0.1938,Structure of human DNA polymerase beta complexed with N7BG in the template opposite to incoming non-hydrolyzable CTP WITH MANGANESE IN THE ACTIVE SITE
4YN4,X-RAY DIFFRACTION,2.39,48.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"14 to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",295,2015-03-09,2016-03-09,4YN4,3385,4,366,119,,48.45,1,2.243,experimental,,0.2547,0.2026,Structure of human DNA polymerase beta complexed with N7BG in the template opposite to incoming non-hydrolyzable dTTP WITH MANGANESE IN THE ACTIVE SITE
4YMN,X-RAY DIFFRACTION,2.37,48.2,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",297,2015-03-06,2016-03-09,4YMN,3341,4,366,84,,48.35,1,2.591,experimental,,0.2692,0.1998,Structure of human DNA polymerase beta complexed with N7BG in the template base paired with incoming non-hydrolyzable CTP
6YWU,X-RAY DIFFRACTION,2.46,49.96,"VAPOR DIFFUSION, HANGING DROP",,"Crystallization: 100 mM Tris/HCl pH 7.8, 1.8 - 2.0 M Ammonium sulfate, 10 mM Glutathion, 5% (v/v) Glycerol, 12.5 mM UMP
Cryo-protection: 100 mM Tris/HCl pH 7.8, 2.0 M Ammonium sulfate, 10 mM Glutathion, 5% (v/v) Glycerol, 12.5 mM UMP, 2 M L-proline",293,2020-04-30,2022-02-23,6YWU,2602,1,260,317,,28.89,1,1.1,experimental,13.673,0.1584,0.138,Human OMPD-domain of UMPS (K314AcK) in complex with UMP at 1.1 Angstroms resolution
6CU9,X-RAY DIFFRACTION,2.24,45.15,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",293,2018-03-24,2019-03-27,6CU9,3441,4,366,168,,48.36,1,2.04,experimental,,0.2408,0.1937,Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable CTP and MANGANESE
6CUA,X-RAY DIFFRACTION,2.38,48.26,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",293,2018-03-24,2019-03-27,6CUA,3378,4,366,117,,48.4,1,2.17,experimental,,0.2593,0.2094,Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable GTP and MANGANESE
6CUB,X-RAY DIFFRACTION,2.38,48.26,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",293,2018-03-25,2019-03-27,6CUB,3450,4,366,190,,48.39,1,2.05,experimental,,0.2541,0.1966,Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable ATP and MANGANESE
4Z6E,X-RAY DIFFRACTION,2.24,45.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2015-04-04,2016-04-13,4Z6E,3340,4,366,70,,48.3,1,2.752,experimental,,0.2482,0.1775,Structure of human DNA polymerase beta 279NA mutant complexed with G in the template base paired with incoming non-hydrolyzable TTP and MANGANESE
4Z6F,X-RAY DIFFRACTION,2.25,45.34,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2015-04-04,2016-04-13,4Z6F,3350,4,366,79,,48.31,1,2.444,experimental,,0.2483,0.1949,Structure of human DNA polymerase beta 279NA mutant complexed with G in the template base paired with incoming non-hydrolyzable TTP and MANGANESE
7AOU,X-RAY DIFFRACTION,2.28,46.06,"VAPOR DIFFUSION, HANGING DROP",7.5,"32% PEG-3350, 0.2 M NH4-acetate and HEPES-NaOH pH 7.5",293,2020-10-15,2021-04-21,7AOU,1312,1,128,194,,14.69,1,1.16,experimental,17.696,0.1753,0.1428,"The Fk1 domain of FKBP51 in complex with (2'R,5'S,12'R)-12'-cyclohexyl-2'-[2-(3,4-dimethoxyphenyl)ethyl]-3',19'-dioxa-10',13',16'-triazaspiro[cyclopropane-1,15'- tricyclo[18.3.1.0-5,10]tetracosane]-1'(24'),20',22'-triene-4',11',14',17'-tetrone"
4Z6C,X-RAY DIFFRACTION,2.12,42,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2015-04-04,2016-04-13,4Z6C,3305,4,366,49,,48.22,1,2.677,experimental,,0.2723,0.2006,Structure of human DNA polymerase beta 279NA mutant complexed with G in the template base paired with incoming non-hydrolyzable CTP
4Z6D,X-RAY DIFFRACTION,2.34,47.39,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2015-04-04,2016-04-13,4Z6D,3328,4,366,74,,48.22,1,2.51,experimental,,0.2696,0.1976,Structure of human DNA polymerase beta 279NA mutant complexed with G in the template base paired with incoming non-hydrolyzable TTP
6EZA,X-RAY DIFFRACTION,2.45,49.86,"VAPOR DIFFUSION, HANGING DROP",5.5,"30% PEG 2000 MME
200 mM ammonium sulfate
50 mM sodium acetate",292,2017-11-14,2018-09-26,6EZA,5308,2,654,361,,75.55,1,2,experimental,33.32,0.227,0.191,Crystal Structure of human tRNA-dihydrouridine(20) synthase catalytic domain E294K mutant
6EZC,X-RAY DIFFRACTION,2.66,53.8,"VAPOR DIFFUSION, HANGING DROP",5,"30% PEG 2000 MME
200 mM ammonium sulfate
50 mM sodium acetate",292,2017-11-14,2018-09-26,6EZC,2683,1,327,230,,38.11,1,2,experimental,39.49,0.223,0.182,Crystal Structure of human tRNA-dihydrouridine(20) synthase catalytic domain E294K Q305K double mutant
5DBA,X-RAY DIFFRACTION,2.37,48.06,"VAPOR DIFFUSION, SITTING DROP",,"14 to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",295,2015-08-21,2015-11-11,5DBA,3390,4,366,173,,47.77,1,1.965,experimental,,0.2445,0.2015,Structure of human DNA polymerase beta Host-Guest complex with the dG base paired with a dT
4YMM,X-RAY DIFFRACTION,2.39,48.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",295,2015-03-06,2016-03-09,4YMM,3345,4,366,110,,47.86,1,2.199,experimental,,0.2573,0.1961,Structure of human DNA polymerase beta complexed with 7BG as the template base in a 1-nucleotide gapped DNA
7MZ0,X-RAY DIFFRACTION,2.43,49.48,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2021-05-23,2022-05-25,7MZ0,3395,4,360,169,,47.03,1,2.021,experimental,28.93,0.2757,0.2211,Structure of human DNA polymerase beta complexed with dzA as the template base in a 1-nucleotide gapped DNA
7RBI,X-RAY DIFFRACTION,2.12,41.88,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBI,3459,4,373,158,,50.4,1,1.93,experimental,30.486,0.2204,0.1857,"Human DNA polymerase beta crosslinked complex, 20 s Ca to Mg exchange"
7RBJ,X-RAY DIFFRACTION,2.24,45.01,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBJ,3432,4,373,143,,50.33,1,1.91,experimental,30.312,0.2289,0.1878,"Human DNA polymerase beta crosslinked complex, 30 s Ca to Mg exchange"
7RBK,X-RAY DIFFRACTION,2.2,44.2,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBK,3468,4,373,116,,50.36,1,2.2,experimental,31.515,0.2513,0.1977,"Human DNA polymerase beta crosslinked complex, 40 s Ca to Mg exchange"
7RBL,X-RAY DIFFRACTION,2.22,44.6,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBL,3421,4,373,139,,49.37,1,1.98,experimental,38.191,0.2363,0.1877,"Human DNA polymerase beta crosslinked complex, 60 s Ca to Mg exchange"
7RBM,X-RAY DIFFRACTION,2.13,42.33,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBM,3299,4,373,87,,49.9,1,2.21,experimental,42.531,0.247,0.2045,"Human DNA polymerase beta crosslinked complex, 60 s Ca to Mn exchange"
5VS0,X-RAY DIFFRACTION,2.23,44.95,"VAPOR DIFFUSION, HANGING DROP",,"50 mM imidazole pH 7.0-7.5, 350 mM sodium acetate, 16-18% PEG 3350",293,2017-05-11,2017-07-19,5VS0,3424,4,373,145,,49.3,1,2.1,experimental,32.588,0.2621,0.2019,Human DNA polymerase beta 8-oxoG:dC extension with dTTP after 80 s
5VS3,X-RAY DIFFRACTION,2.2,44.17,"VAPOR DIFFUSION, HANGING DROP",,"50 mM imidazole pH 7.0-7.5, 350 mM sodium acetate, 16-18% PEG 3350",293,2017-05-11,2017-07-19,5VS3,3673,4,373,337,,49.87,1,1.7,experimental,27.439,0.2487,0.2062,Human DNA polymerase beta 8-oxoG:dA extension with dTTP after 90 s
5VS4,X-RAY DIFFRACTION,2.23,44.78,"VAPOR DIFFUSION, HANGING DROP",,"50 mM imidazole pH 7.0-7.5, 350 mM sodium acetate, 16-18% PEG 3350",293,2017-05-11,2017-07-19,5VS4,3686,4,373,340,,49.37,1,1.87,experimental,26.703,0.2569,0.1988,Human DNA polymerase beta 8-oxoG:dA extension with dTTP after 120 s
6NFL,X-RAY DIFFRACTION,2.24,45,"VAPOR DIFFUSION, SITTING DROP",,PEG3350,293,2018-12-20,2019-12-25,6NFL,1707,1,193,134,1,23.26,1,1.731,experimental,,0.1935,0.1623,Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B with loop 7 from APOBEC3G complexed with 2-HP
6N2R,X-RAY DIFFRACTION,2.45,49.7,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-11-14,2019-04-03,6N2R,3501,4,366,264,,47.76,1,2.1,experimental,,0.2661,0.2098,Binary complex crystal structure of DNA polymerase Beta with 5-carboxy-dC (5-caC) at the templating position
6N2S,X-RAY DIFFRACTION,2.23,44.74,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 2000 Monomethyl Ether,291,2018-11-14,2019-03-27,6N2S,3356,4,366,81,,48.31,1,2.457,experimental,44.6413,0.2896,0.2024,Ternary complex crystal structure of DNA polymerase Beta with 5-carboxy-dC (5-caC) at the templating position
6N2T,X-RAY DIFFRACTION,2.28,46.02,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-11-14,2019-03-27,6N2T,3322,4,366,48,,48.3,1,2.6,experimental,54.7694,0.2905,0.1981,Ternary complex crystal structure of DNA polymerase Beta with 5-hydroxymethyl-dC (5-hmC) at the templating position
6NKR,X-RAY DIFFRACTION,2.28,46.08,"VAPOR DIFFUSION, SITTING DROP",7.5,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2019-01-07,2020-01-08,6NKR,3335,4,366,67,,48.33,1,2.45,experimental,50.7388,0.2897,0.2074,Ternary complex crystal structure of K289M variant of DNA polymerase Beta with dGTP
6NKS,X-RAY DIFFRACTION,2.3,46.42,"VAPOR DIFFUSION, SITTING DROP",7.5,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2019-01-07,2020-01-08,6NKS,3337,4,366,67,,48.38,1,2.349,experimental,41.9592,0.2553,0.1888,Ternary complex crystal structure of K289M variant of DNA polymerase Beta with beta-gamma CHF analog of dGTP
6NKT,X-RAY DIFFRACTION,2.48,50.42,"VAPOR DIFFUSION, SITTING DROP",7.5,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2019-01-07,2020-01-08,6NKT,3272,4,366,45,,48.24,1,2.6,experimental,51.6866,0.3027,0.1994,Ternary complex crystal structure of K289M variant of DNA polymerase Beta with beta-gamma difluoro analogue of dGTP
6NKU,X-RAY DIFFRACTION,2.28,46.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"16-18% PEG 3350, 350 mM Sodium Acetate, 50 mM Imidazole",291,2019-01-07,2020-01-08,6NKU,3695,4,366,394,,48.42,1,1.9,experimental,32.1551,0.2107,0.1741,"Ternary complex crystal structure of DNA polymerase Beta with ""hot-spot sequence"" with dGTP"
6NKV,X-RAY DIFFRACTION,2.29,46.23,"VAPOR DIFFUSION, SITTING DROP",7.5,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2019-01-07,2020-01-08,6NKV,3846,4,366,553,,48.4,1,1.85,experimental,23.8888,0.2028,0.1643,"Ternary complex crystal structure of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma CHF analogue of dGTP"
6NKW,X-RAY DIFFRACTION,2.26,45.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2019-01-07,2020-01-08,6NKW,3727,4,366,427,,48.41,1,1.98,experimental,27.976,0.2166,0.1741,"Ternary complex crystal structure of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma-methylene dGTP"
6NKX,X-RAY DIFFRACTION,2.27,45.88,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2019-01-07,2020-01-08,6NKX,3596,4,366,302,,48.29,1,1.98,experimental,31.5593,0.232,0.1806,"Ternary complex crystal structure of K289M variant of DNA polymerase Beta with ""hot-spot sequence"" with dGTP"
6NKY,X-RAY DIFFRACTION,2.29,46.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"16-18% PEG 3350, 7.5, 50 mM Imidazole, 350 mM Sodium Acetate",291,2019-01-07,2020-01-08,6NKY,3520,4,366,234,,48.37,1,2.094,experimental,40.3725,0.2556,0.1985,"Ternary complex crystal structure of K289M variant of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma CHF analogue of dGTP"
6NL0,X-RAY DIFFRACTION,2.26,45.63,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2019-01-07,2020-01-08,6NL0,3518,4,366,233,,48.32,1,1.97,experimental,40.1983,0.2374,0.1928,"Ternary complex crystal structure of K289M variant of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma CF2 analogue of dGTP"
7BO5,X-RAY DIFFRACTION,1.93,36.39,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-23,2022-03-02,7BO5,2903,1,382,97,6,44.73,1,1.38,experimental,24.8757,0.2014,0.178,"Notum Fragment_130_methyEster (methyl 4H-thieno[3,2-c]chromene-2-carboxylate)"
8OKT,X-RAY DIFFRACTION,2.05,40.09,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-29,2024-04-10,8OKT,2476,1,260,283,,29.64,1,1.5,experimental,15.54,0.17752,0.15729,Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor VK42
8OMB,X-RAY DIFFRACTION,2.08,40.77,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-31,2024-04-10,8OMB,2450,1,260,269,,29.7,1,1.35,experimental,14.791,0.17503,0.15626,Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl VK42
4WK9,X-RAY DIFFRACTION,2.23,44.88,"VAPOR DIFFUSION, HANGING DROP",,"25 % (w/v) polyethylene glycol (PEG) 3350, 0.2 M potassium sodium tartrate at pH 7.2, 0.3mM 4-methylumbelliferyl triacetylchitotrioside",290,2014-10-02,2015-07-08,4WK9,3624,1,377,530,2,42.65,1,1.102,experimental,,0.1537,0.1393,Crystal structure of human chitotriosidase-1 catalytic domain in complex with chitobiose (0.3mM) at 1.10 A resolution
4WKF,X-RAY DIFFRACTION,2.18,43.51,"VAPOR DIFFUSION, HANGING DROP",,"25 % (w/v) polyethylene glycol (PEG) 3350, 0.2 M potassium sodium tartrate at pH 7.2
2.5mM 4-methylumbelliferyl triacetylchitotrioside",290,2014-10-02,2015-07-08,4WKF,3444,1,377,362,2,42.65,1,1.101,experimental,,0.1622,0.1433,Crystal structure of human chitotriosidase-1 catalytic domain in complex with chitobiose (2.5mM) at 1.10 A resolution
4WKH,X-RAY DIFFRACTION,2.22,44.49,"VAPOR DIFFUSION, HANGING DROP",,"25 % (w/v) polyethylene glycol (PEG) 3350, 0.2 M potassium sodium tartrate at pH 7.2, 0.3mM 4-methylumbelliferyl triacetylchitotrioside",290,2014-10-02,2015-07-08,4WKH,3702,1,377,516,2,42.65,1,1.05,experimental,,0.1534,0.1434,Crystal structure of human chitotriosidase-1 catalytic domain in complex with chitobiose (1mM) at 1.05 A resolution
5HPT,X-RAY DIFFRACTION,2.77,55.54,"VAPOR DIFFUSION, HANGING DROP",5.2,"isopropanol 10%, PEG3350 8%, sodium citrate 0.1 M",293,2016-01-20,2016-03-16,5HPT,13529,8,1720,5,,200.91,3,2.84,experimental,,0.237,0.2183,"System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes: WWP1, Ubv P2.3 and UBCH7"
6W13,X-RAY DIFFRACTION,3.16,65.42,"VAPOR DIFFUSION, HANGING DROP",,"100 mM sodium cacodylate, pH 6.1, 200 mM MgOAc, and 17 % polyethylene glycol 8000",293,2020-03-03,2020-09-23,6W13,2870,3,330,85,,39.97,1,2.38,experimental,52.078,0.2711,0.2137,Human 8-oxoguanine glycosylase interrogating fully intrahelical oxoG lesion DNA
4YGK,X-RAY DIFFRACTION,2.13,42.29,"VAPOR DIFFUSION, HANGING DROP",7.8,"100 mM Tris-Cl, 1.15 M sodium citrate, pH 7.8",277,2015-02-26,2015-03-25,4YGK,2317,1,258,229,,29.14,1,1.5,experimental,10.01,0.21335,0.17337,NaSCN--Interactions between Hofmeister Anions and the Binding Pocket of a Protein
4YGL,X-RAY DIFFRACTION,2.11,41.68,"VAPOR DIFFUSION, HANGING DROP",7.8,"100 mM Tris-Cl, 1.15 M sodium citrate, pH 7.8",277,2015-02-26,2015-03-25,4YGL,2309,1,258,215,,29.38,1,1.51,experimental,11.346,0.21335,0.18783,NaClO4--Interactions between Hofmeister Anions and the Binding Pocket of a Protein
4XZF,X-RAY DIFFRACTION,2.62,53.03,VAPOR DIFFUSION,,"PEG 3350, Na acetate",293,2015-02-04,2015-04-15,4XZF,1519,2,135,297,,17.3,1,1.38,experimental,20.981,0.20668,0.16458,Crystal structure of HIRAN domain of human HLTF in complex with DNA
6CLY,X-RAY DIFFRACTION,2.42,49.17,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2018-03-02,2019-03-06,6CLY,3354,4,366,126,,47.79,1,2.186,experimental,,0.2678,0.2188,Structure of human DNA polymerase beta complexed with 8-ClG as the template base in a 1-nucleotide gapped DNA
6CPQ,X-RAY DIFFRACTION,2.26,45.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2018-03-13,2019-03-20,6CPQ,3688,4,366,415,,48.3,1,1.93,experimental,,0.2388,0.191,Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable CTP
6E3X,X-RAY DIFFRACTION,2.41,48.98,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% TO 23% PEG3400, AND 350 MM SODIUM
 ACETATE IN 50 MM IMIDAZOLE (PH 7.5), VAPOR DIFFUSION, SITTING
 DROP, TEMPERATURE 298K",298,2018-07-15,2019-04-03,6E3X,3340,4,366,81,,48.29,1,2.65,experimental,,0.266,0.192,Structure of human DNA polymerase beta complexed with 8OA in the template base paired with incoming non-hydrolyzable ATP
7MZ1,X-RAY DIFFRACTION,2.28,45.95,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2021-05-23,2022-05-25,7MZ1,3363,4,357,103,,47.21,1,2.175,experimental,32.24,0.2589,0.2009,Structure of human DNA polymerase beta complexed with dzA in the template base paired with incoming non-hydrolyzable TTP
7MZ2,X-RAY DIFFRACTION,2.31,46.69,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2021-05-23,2022-05-25,7MZ2,3418,4,357,146,,47.21,1,2.088,experimental,20.48,0.2428,0.1965,Structure of human DNA polymerase beta complexed with dzA at N-1 of the template base paired with incoming dTTP
7MZ3,X-RAY DIFFRACTION,2.42,49.27,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2021-05-24,2022-06-01,7MZ3,3298,4,360,79,,47.04,1,2.418,experimental,36.55,0.2662,0.2039,Structure of human DNA polymerase beta complexed with 3-deaza-3-methyladenine (3dMeA) as the template base in a 1-nucleotide gapped DNA
7MZ4,X-RAY DIFFRACTION,2.45,49.73,"VAPOR DIFFUSION, SITTING DROP",,"14 to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2021-05-24,2022-06-01,7MZ4,3432,4,360,179,,47.57,1,2.076,experimental,31.96,0.2698,0.2161,Structure of human DNA polymerase beta complexed with 3-deaza-3-methyladenine (3dMeA) in the template base paired with incoming dTTP
7MZ8,X-RAY DIFFRACTION,2.38,48.37,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2021-05-24,2022-06-01,7MZ8,3325,4,360,68,,47.55,1,2.6,experimental,47.48,0.2634,0.2013,Structure of human DNA polymerase beta complexed with 3-deaza-3-methyladenine (3dMeA) at N-1 of the template base paired with incoming dTTP
5DB6,X-RAY DIFFRACTION,2.35,47.73,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole",295,2015-08-20,2015-11-11,5DB6,3290,4,366,61,,47.79,1,2.83,experimental,,0.2659,0.185,Structure of human DNA polymerase beta Host-Guest complex with the N7MG base paired with a dC
5DB7,X-RAY DIFFRACTION,2.4,48.67,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",295,2015-08-21,2015-11-11,5DB7,3325,4,366,95,,47.8,1,2.209,experimental,,0.273,0.2207,Structure of human DNA polymerase beta Host-Guest complex with the N7MG base paired with a dT
5DB8,X-RAY DIFFRACTION,2.36,47.89,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole",295,2015-08-21,2015-11-11,5DB8,3307,4,366,76,,47.81,1,2.547,experimental,,0.2577,0.1799,Structure of human DNA polymerase beta Host-Guest complex with the N7MG base paired with a dA
5DB9,X-RAY DIFFRACTION,2.37,48.08,"VAPOR DIFFUSION, SITTING DROP",,"14 to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",295,2015-08-21,2015-11-11,5DB9,3312,4,366,80,,47.83,1,2.45,experimental,,0.2597,0.1867,Structure of human DNA polymerase beta Host-Guest complex with the N7MG base paired with a dG
5DBB,X-RAY DIFFRACTION,2.39,48.62,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",295,2015-08-21,2015-11-11,5DBB,3392,4,366,163,,47.78,1,2.25,experimental,,0.2645,0.2056,Structure of human DNA polymerase beta Host-Guest complex with the dG base paired with a dA
5DBC,X-RAY DIFFRACTION,2.39,48.59,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",295,2015-08-21,2015-11-11,5DBC,3338,4,366,108,,47.79,1,2.402,experimental,,0.2792,0.2135,Structure of human DNA polymerase beta Host-Guest complex with the dG base paired with a dG
6CRH,X-RAY DIFFRACTION,2.4,48.7,"VAPOR DIFFUSION, SITTING DROP",,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",293,2018-03-17,2019-03-20,6CRH,3355,4,366,94,,48.34,1,2.327,experimental,,0.2438,0.1974,Structure of human DNA polymerase beta complexed with 8-ClG in the template base paired with incoming non-hydrolyzable GTP
6E3R,X-RAY DIFFRACTION,2.44,49.52,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% TO 23% PEG3400, AND 350 MM SODIUM
 ACETATE IN 50 MM IMIDAZOLE (PH 7.5), VAPOR DIFFUSION, SITTING
 DROP, TEMPERATURE 298K",298,2018-07-14,2019-04-03,6E3R,3325,4,366,109,,47.75,1,2.26,experimental,36.4,0.272,0.204,Structure of human DNA polymerase beta complexed with 8OA as the template base in a 1-nucleotide gapped DNA
6E3V,X-RAY DIFFRACTION,2.28,45.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% TO 23% PEG3400, AND 350 MM SODIUM
 ACETATE IN 50 MM IMIDAZOLE (PH 7.5), VAPOR DIFFUSION, SITTING
 DROP, TEMPERATURE 298K",298,2018-07-15,2019-04-03,6E3V,3469,4,366,196,,48.28,1,1.96,experimental,,0.24,0.195,Structure of human DNA polymerase beta complexed with 8OA in the template base paired with incoming non-hydrolyzable TTP
6E3W,X-RAY DIFFRACTION,2.28,45.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% TO 23% PEG3400, AND 350 MM SODIUM
 ACETATE IN 50 MM IMIDAZOLE (PH 7.5), VAPOR DIFFUSION, SITTING
 DROP, TEMPERATURE 298K",298,2018-07-15,2019-04-03,6E3W,3457,4,366,182,,48.31,1,2.02,experimental,,0.245,0.193,Structure of human DNA polymerase beta complexed with 8OA in the template base paired with incoming non-hydrolyzable GTP
6CR3,X-RAY DIFFRACTION,2.31,46.76,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-16,2018-06-27,6CR3,3780,4,366,499,,48.52,1,1.95,experimental,27.4564,0.2266,0.1748,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CBr2, beta, gamma dATP analogue"
6U2O,X-RAY DIFFRACTION,2.37,48.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"23% PEG 3350, 50 mM Tris (pH 6.5), and 350 mM sodium acetate",295.15,2019-08-20,2020-08-26,6U2O,3275,4,366,69,,48.57,1,2.3,experimental,38.251,0.2481,0.201,Structure of human DNA polymerase beta misinserting dAMPNPP opposite the 5'G of the cisplatin Pt-GG intrastrand crosslink
4RPX,X-RAY DIFFRACTION,2.16,43.03,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RPX,3599,4,374,246,,50.2,1,1.9,experimental,24.155,0.22667,0.18886,"Precatalytic ternary complex of Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG) and dCTP in the presence of CaCl2"
4RQ1,X-RAY DIFFRACTION,2.38,48.22,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RQ1,3330,4,375,10,,49.14,1,2.7,experimental,60.551,0.28031,0.20322,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine(8-oxoG) and dCTP soaked with MgCl2 for 1hr"
4RQ3,X-RAY DIFFRACTION,2.14,42.61,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RQ3,3562,4,374,242,,49.72,1,2,experimental,27.921,0.24551,0.1915,"Precatalytic ternary complex of Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG) and dATP in the presence of CaCl2"
4RQ7,X-RAY DIFFRACTION,2.36,47.92,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM Acetate, 17% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295,2014-10-31,2015-04-15,4RQ7,3542,4,375,202,,49.34,1,2,experimental,33.646,0.2609,0.20653,"Human DNA Polymerase Beta With Gapped DNA Containing an 8-oxo-7,8-dihydro-Guanine (8-oxoG)and dATP soaked with MgCl2 for 1hr"
5UGP,X-RAY DIFFRACTION,2.31,46.81,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium chloride, 17% PEG3350",291,2017-01-09,2017-07-26,5UGP,3627,4,366,318,,48.22,1,1.955,experimental,,0.2334,0.1825,DNA polymerase beta complex with a 1nt gap and dCMPPNP
5V1J,X-RAY DIFFRACTION,2.49,50.66,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, 350 mM sodium acetate, 17% PEG3350",291,2017-03-02,2017-05-10,5V1J,3102,4,367,32,,48.06,1,2.616,experimental,,0.2852,0.2172,DNA polymerase beta open product complex with 8-oxoG:C and inserted dCTP
6BTE,X-RAY DIFFRACTION,2.26,45.49,"VAPOR DIFFUSION, HANGING DROP",7.5,"18-20% PEG 3350, 175-250 mM sodium acetate, 50 mM HEPES pH 7.5, 2 mM TCEP, 1% tert-butanol",291,2017-12-06,2018-09-26,6BTE,3636,4,366,427,,48.04,1,2.2,experimental,18.9345,0.229,0.1852,DNA Polymerase Beta I260Q Binary Complex
4XUS,X-RAY DIFFRACTION,2.94,58.19,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium acetate trihydrate
2.0 M sodium formate",278,2015-01-26,2016-02-03,4XUS,3202,4,345,255,,43.34,1,2.4,experimental,29.24,0.2358,0.1874,Crystal structure of the pre-catalytic ternary complex of DNA polymerase lambda with a templating A and an incoming dTTP
6FZ5,X-RAY DIFFRACTION,2.31,46.67,"VAPOR DIFFUSION, HANGING DROP",4.5,"24% PEG 4000
5 mM NiCl2
0.1 M Na citrate
5% Glycerol",293,2018-03-14,2019-03-27,6FZ5,6731,2,764,385,,92.37,1,1.89,experimental,33.694,0.22339,0.18936,Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor bound
5VRY,X-RAY DIFFRACTION,2.26,45.46,"VAPOR DIFFUSION, HANGING DROP",,"50 mM imidazole pH 7.0-7.5, 350 mM sodium acetate, 16-18% PEG 3350",293,2017-05-11,2017-07-19,5VRY,3662,4,373,305,,49.75,1,1.9,experimental,27.365,0.2435,0.2028,Human DNA polymerase beta 8-oxoG:dC extension with dTTP after 20 s
5VRZ,X-RAY DIFFRACTION,2.23,44.74,VAPOR DIFFUSION,,"50 mM imidazole pH 7.0-7.5, 350 mM sodium acetate, 16-18% PEG 3350",293,2017-05-11,2017-07-19,5VRZ,3539,4,373,221,,49.85,1,2.05,experimental,30.666,0.2417,0.1968,Human DNA polymerase beta 8-oxoG:dC extension with dTTP after 60 s
5U2R,X-RAY DIFFRACTION,2.22,44.59,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM
 ACETATE, 17% PEG3350,",295,2016-11-30,2017-05-24,5U2R,3624,4,374,286,,49.5,1,1.8,experimental,20.28,0.229,0.191,"PRECATALYTIC TERNARY COMPLEX OF HUMAN DNA POLYMERASE BETA WITH GAPPED DNA SUBSTARTE, INCOMING L-DCTP AND CA2+"
5U2S,X-RAY DIFFRACTION,2.35,47.75,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM
 ACETATE, 17% PEG3350",295,2016-11-30,2017-05-24,5U2S,3394,4,374,94,,49.68,1,2.3,experimental,39.93,0.284,0.23,Pre-catalytic ternary complex of Human DNA Polymerase Beta With Gapped DNA substrate incoming (-)3TC-TP and Ca2+.
5U2T,X-RAY DIFFRACTION,2.32,47.07,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM
 ACETATE, 17% PEG3350",295,2016-11-30,2017-05-24,5U2T,3534,4,374,242,,49.54,1,1.79,experimental,44.31,0.247,0.2,Pre-catalytic ternary complex of Human DNA Polymerase Beta With Gapped DNA substrate incoming (-)FTC-TP and Ca2+.
4XA5,X-RAY DIFFRACTION,2.96,58.46,"VAPOR DIFFUSION, HANGING DROP",,0.1 M sodium cacodylate trihydrate pH 7.4 and 1.9 M sodium acetate trihydrate,278,2014-12-12,2016-02-10,4XA5,3118,4,346,247,,43.83,1,1.9,experimental,41.509,0.22725,0.19903,Crystal structure of the pre-catalytic ternary complex of DNA polymerase lambda with a templating A and an incoming 8-oxo-dGTP
4WTV,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM MES/Imidazole pH = 6.5, 10% w/v PEG 4000, 20% v/v glycerol, 20 mM 1,6-hexanediol, 20 mM 1-butanol, 20 mM 1,2-propanediol, 20 mM 2-propanol, 20 mM 1,4-butanediol, 20 mM 1,3-propanediol",291,2014-10-30,2015-07-15,4WTV,7414,2,1028,279,,119.75,1,1.9,experimental,,0.2404,0.2088,Crystal structure of the phosphatidylinositol 4-kinase IIbeta
6DIM,X-RAY DIFFRACTION,2.47,50.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-05-23,2019-05-29,6DIM,7849,2,922,582,,105,1,1.81,experimental,,0.2267,0.1863,Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment ZT1982 from cocktail soak
6DJD,X-RAY DIFFRACTION,2.45,49.88,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-05-25,2019-05-29,6DJD,7965,2,922,727,,104.88,1,1.777,experimental,,0.2272,0.1864,Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment ZT1982 (single soak)
6VEZ,X-RAY DIFFRACTION,2.5,50.88,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VEZ,3500,4,373,341,,46.44,1,1.875,experimental,28.6796,0.2052,0.1664,"DNA Polymerase Mu, 8-oxorGTP:At Pre-Catalytic Ternary Complex, 20 mM Ca2+ (60 min)"
6VF1,X-RAY DIFFRACTION,2.5,50.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF1,3495,4,374,370,,46.2,1,1.68,experimental,23.8084,0.188,0.1625,"DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mg2+ (120 min)"
6VF2,X-RAY DIFFRACTION,2.44,49.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF2,3372,4,374,316,,46.31,1,1.6,experimental,29.4835,0.1926,0.1681,"DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mg2+ (960 min)"
6VF3,X-RAY DIFFRACTION,2.46,50.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF3,3428,4,373,334,,46.76,1,1.521,experimental,28.3511,0.1799,0.1627,"DNA Polymerase Mu, 8-oxorGTP:At Ground State Ternary Complex, 50 mM Mn2+ (15 min)"
6VF5,X-RAY DIFFRACTION,2.5,50.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF5,3431,4,374,352,,46.65,1,1.6,experimental,26.751,0.191,0.1648,"DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mn2+ (120 min)"
6VF6,X-RAY DIFFRACTION,2.45,49.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF6,3296,4,374,307,,46.59,1,1.69,experimental,29.5815,0.189,0.1655,"DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mn2+ (960 min)"
6VF7,X-RAY DIFFRACTION,2.53,51.47,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF7,3408,4,373,322,,46.74,1,1.871,experimental,30.6038,0.1967,0.1658,"DNA Polymerase Mu, 8-oxodGTP:At Ground State Ternary Complex, 50 mM Mn2+ (15 min)"
6VF8,X-RAY DIFFRACTION,2.46,49.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF8,3335,4,373,312,,46.31,1,1.7,experimental,27.9614,0.1916,0.1684,"DNA Polymerase Mu, 8-oxorGTP:Ct Pre-Catalytic Ternary Complex, 20 mM Ca2+ (120 min)"
6VF9,X-RAY DIFFRACTION,2.45,49.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VF9,3395,4,373,356,,45.9,1,1.56,experimental,26.8957,0.1818,0.165,"DNA Polymerase Mu, 8-oxorGTP:Ct Ternary Complex, 50 mM Mg2+ (2160 min)"
6VFA,X-RAY DIFFRACTION,2.46,50.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VFA,3301,4,373,304,,46.67,1,1.76,experimental,30.2455,0.2029,0.175,"DNA Polymerase Mu, 8-oxorGTP:Ct Ground State Ternary Complex, 50 mM Mn2+ (15 min)"
6VFC,X-RAY DIFFRACTION,2.47,50.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-01-03,2021-09-01,6VFC,3365,4,374,322,,46.78,1,1.59,experimental,28.2396,0.1921,0.1724,"DNA Polymerase Mu, 8-oxorGTP:Ct Product State Ternary Complex, 50 mM Mn2+ (2160 min)"
4X5V,X-RAY DIFFRACTION,2.89,57.4,"VAPOR DIFFUSION, HANGING DROP",,0.1 M sodium citrate pH 5.6 and 1 M ammonium phosphate monobasic,278,2014-12-05,2015-10-28,4X5V,3019,4,347,180,,43.39,1,2.15,experimental,,0.245,0.2144,Crystal structure of the post-catalytic nick complex of DNA polymerase lambda with a templating A and incorporated 8-oxo-dGMP
6BEM,X-RAY DIFFRACTION,2.25,45.43,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2017-10-25,2018-10-31,6BEM,3838,4,366,524,,48.72,1,1.88,experimental,,0.2263,0.187,Ternary complex crystal structure of DNA polymerase Beta with S-isomer of beta-gamma-CHCL-dCTP
7WUZ,X-RAY DIFFRACTION,2.81,56.21,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG 2000MME, 0.1M Bis-Tris pH 6.5, 0.2 M Lithium sulfate",291,2022-02-09,2023-02-15,7WUZ,2277,1,241,206,,29.19,1,1.93,experimental,28.9752,0.2072,0.1652,Structural study of the complex of cblC methylmalonic aciduria and homocysteinuria-related protein MMACHC with cyanocobalamin
6BEL,X-RAY DIFFRACTION,2.28,46.16,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2017-10-25,2018-10-31,6BEL,3816,4,366,504,,48.63,1,1.898,experimental,,0.2015,0.1678,Ternary complex crystal structure of DNA polymerase Beta with R-isomer of beta-gamma-CHF-dCTP
6CR4,X-RAY DIFFRACTION,2.3,46.54,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-16,2018-07-18,6CR4,3756,4,366,475,,48.39,1,1.8,experimental,21.8704,0.2135,0.173,Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with dATP
6CR5,X-RAY DIFFRACTION,2.27,45.88,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-16,2018-07-18,6CR5,3508,4,366,231,,48.25,1,1.982,experimental,29.8107,0.2318,0.1778,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CH2-beta, gamma dATP analogue"
6CR6,X-RAY DIFFRACTION,2.22,44.65,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-16,2018-08-22,6CR6,3398,4,366,120,,48.26,1,2.097,experimental,,0.293,0.2161,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CH-CH3, beta, gamma dATP analogue"
6CR7,X-RAY DIFFRACTION,2.26,45.64,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-16,2018-07-04,6CR7,3418,4,366,137,,48.37,1,2.29,experimental,40.8207,0.2403,0.1738,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHF, beta, gamma dATP analogue"
6CR8,X-RAY DIFFRACTION,2.26,45.6,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-16,2018-07-04,6CR8,3599,4,366,311,,48.35,1,2.05,experimental,32.3015,0.2483,0.1906,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL (R & S isomers), beta, gamma dATP analogue"
6CR9,X-RAY DIFFRACTION,2.29,46.4,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-16,2018-07-04,6CR9,3754,4,366,474,,48.34,1,1.96,experimental,29.6465,0.2237,0.1797,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CFCL, beta, gamma dATP analogue"
6CRB,X-RAY DIFFRACTION,2.38,48.34,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-16,2018-07-18,6CRB,3441,4,366,175,,48.3,1,2.151,experimental,44.3399,0.2748,0.2175,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CF2, beta, gamma dATP analogue"
6CRC,X-RAY DIFFRACTION,2.39,48.64,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-16,2018-07-25,6CRC,3388,4,366,118,,48.32,1,2.3,experimental,40.8377,0.285,0.2065,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CCL2, beta, gamma dATP analogue"
6CTI,X-RAY DIFFRACTION,2.28,45.96,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTI,3621,4,366,326,,48.43,1,2.001,experimental,33.471,0.2266,0.1768,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CCL2, beta, gamma dTTP analogue"
6CTJ,X-RAY DIFFRACTION,2.14,42.43,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTJ,3486,4,366,209,,48.39,1,2.1,experimental,37.4867,0.2572,0.1907,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCH3, beta, gamma dTTP analogue"
6CTK,X-RAY DIFFRACTION,2.28,46.02,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTK,3500,4,366,228,,48.31,1,2.153,experimental,38.6754,0.244,0.1787,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHF-R/S isomers, beta, gamma dTTP analogue"
6CTL,X-RAY DIFFRACTION,2.28,46.14,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTL,3576,4,366,298,,48.36,1,2,experimental,36.5864,0.2253,0.1792,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL-R/S isomers, beta, gamma dTTP analogue"
6CTM,X-RAY DIFFRACTION,2.13,42.25,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTM,3531,4,366,255,,48.37,1,2.101,experimental,,0.2575,0.1858,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL(R-isomer), beta, gamma dTTP analogue"
6CTN,X-RAY DIFFRACTION,2.3,46.41,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTN,3727,4,366,450,,48.34,1,1.92,experimental,28.0978,0.2347,0.1866,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CFCL,beta-gamma dTTP analogue"
6CTO,X-RAY DIFFRACTION,2.29,46.22,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTO,3579,4,366,293,,48.4,1,2.04,experimental,31.775,0.2319,0.1788,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CF2, beta, gamma dTTP analogue"
6CTP,X-RAY DIFFRACTION,2.25,45.41,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTP,3384,4,366,107,,48.4,1,2.2,experimental,46.017,0.2901,0.2247,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CH2, beta, gamma dTTP analogue"
6CTQ,X-RAY DIFFRACTION,2.3,46.5,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTQ,3808,4,366,496,,48.7,1,1.87,experimental,29.7868,0.2283,0.1751,Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with dCTP
6CTU,X-RAY DIFFRACTION,2.29,46.34,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTU,3824,4,366,511,,48.71,1,1.9,experimental,27.1002,0.2064,0.1713,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CFCL, beta, gamma dCTP analogue"
6CTV,X-RAY DIFFRACTION,2.27,45.79,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTV,3701,4,366,388,,48.69,1,2.02,experimental,31.4264,0.2202,0.18,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CF2, beta, gamma dCTP analogue"
6CTW,X-RAY DIFFRACTION,2.29,46.35,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTW,3780,4,366,467,,48.73,1,1.981,experimental,26.4114,0.2194,0.1741,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CCL2, beta, gamma dCTP analogue"
6CTX,X-RAY DIFFRACTION,2.29,46.32,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTX,3767,4,366,454,,48.82,1,2.02,experimental,28.3893,0.2286,0.1766,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CBr2, beta, gamma dCTP analogue"
6G2Q,X-RAY DIFFRACTION,2.11,41.79,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-07-04,6G2Q,3437,4,366,161,,48.32,1,2.148,experimental,39.344,0.2595,0.1956,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL (S-isomer), beta, gamma dTTP analogue"
6BTF,X-RAY DIFFRACTION,2.27,45.73,"VAPOR DIFFUSION, HANGING DROP",7.5,"18-20% PEG 3350, 175-250 mM sodium acetate, 50 mM HEPES pH 7.5, 2 mM TCEP, 1% tert-butanol",291,2017-12-06,2018-09-26,6BTF,3436,4,364,337,,47.69,1,1.75,experimental,31.3994,0.2138,0.1749,DNA Polymerase Beta I260Q Ternary Complex
6PH5,X-RAY DIFFRACTION,2.41,48.97,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2019-06-25,2019-12-11,6PH5,3302,4,368,54,,48.33,1,2.602,experimental,51.9991,0.2787,0.2052,Binary product complex crystal structure of DNA polymerase Beta with an extra-helical template base
6PH6,X-RAY DIFFRACTION,2.3,46.49,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2019-06-25,2019-12-11,6PH6,3326,4,365,73,,47.98,1,2.6,experimental,35.2774,0.276,0.185,Ternary complex crystal structure of DNA polymerase Beta with 2nt-gap with dCTP bound downstream
4YC4,X-RAY DIFFRACTION,2.54,51.66,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES pH = 7.0, 10% w/v PEG 4000, 10% v/v 2-propanol",291,2015-02-19,2015-07-15,4YC4,3931,1,556,3,,63.93,1,2.58,experimental,,0.2558,0.214,Crystal structure of phosphatidyl inositol 4-kinase II alpha in complex with nucleotide analog
5UGO,X-RAY DIFFRACTION,2.25,45.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"50 mM imidazole, 350 mM sodium chloride, 17% PEG3350, pH 7.5",291,2017-01-09,2017-07-26,5UGO,3712,4,367,376,,48.25,1,1.897,experimental,,0.2356,0.1794,DNA polymerase beta nick complex with imidodiphosphate
7ZIH,X-RAY DIFFRACTION,2.13,42.18,"VAPOR DIFFUSION, SITTING DROP",,"28% w/v PEG 3350, 0.2 M NaCl",293.15,2022-04-08,2022-09-07,7ZIH,2692,1,326,311,,38.08,1,1.46890830792,experimental,22.360747231,0.177262994214,0.146319411729,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor AG-01-128
5V1G,X-RAY DIFFRACTION,2.48,50.37,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium acetate, 17% PEG3350",291,2017-03-02,2017-05-10,5V1G,3642,4,366,439,,47.75,1,1.798,experimental,,0.2272,0.1868,DNA polymerase beta binary complex with 8-oxoG at the primer terminus
5V1H,X-RAY DIFFRACTION,2.46,49.96,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium acetate, 17% PEG3350",291,2017-03-02,2017-05-10,5V1H,3637,4,366,431,,47.75,1,1.946,experimental,,0.2724,0.2193,DNA polymerase beta binary complex with 8-oxoG:A at the primer terminus
5IIO,X-RAY DIFFRACTION,2.89,57.47,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M KCl, 0.01 M CaCl2, 0.05 M HEPES pH 7.0, and 10% PEG 400",278,2016-03-01,2016-08-17,5IIO,13086,16,1420,1213,2,175.1,1,2.08,experimental,,0.2351,0.1913,Crystal structure of the DNA polymerase lambda binary complex
5ITQ,X-RAY DIFFRACTION,2.62,53.03,EVAPORATION,6.5,"0.1M cacodylic acid (pH 7.0), 0.1M NaCl, 0.05 M MgCl2, 24%(w/v) PEG 8000",277,2016-03-17,2016-07-06,5ITQ,2781,1,290,465,,32.74,1,1.48,experimental,,0.196,0.156,"Crystal Structure of Human NEIL1, Free Protein"
6LWR,X-RAY DIFFRACTION,2.78,55.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWR,5150,8,640,40,,81.9,1,2.9,experimental,92.059,0.2477,0.2084,Crystal structure of human NEIL1(K242) bound to duplex DNA containing a cleaved C:T mismatch
5TB8,X-RAY DIFFRACTION,2.08,40.77,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM
 ACETATE, 17% PEG3350, PH 8.0",295,2016-09-11,2017-01-11,5TB8,3558,4,374,201,,50.06,1,2,experimental,22.35,0.23,0.182,Precatalytic ternary complex of Human DNA Polymerase Beta in closed conformation With Gapped DNA substrate incoming (-)3TC-TP and Mn2+.
5TB9,X-RAY DIFFRACTION,2.15,42.75,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM
 ACETATE, 17% PEG3350, PH 8.0",295,2016-09-11,2017-01-11,5TB9,3387,4,374,74,,49.81,1,2.49,experimental,31.86,0.267,0.205,Precatalytic ternary complex of Human DNA Polymerase Beta in closed conformation With Gapped DNA substrate incoming (-)FTC-TP and Mn2+.
5TBC,X-RAY DIFFRACTION,2.38,48.41,"VAPOR DIFFUSION, HANGING DROP",8,"50 MM IMIDAZOLE, 350 MM SODIUM
 ACETATE, 17% PEG3350 , PH 8.0",295,2016-09-11,2017-01-11,5TBC,3290,4,374,252,,49.68,1,1.85,experimental,32.22,0.279,0.228,"PRECATALYTIC TERNARY COMPLEX OF HUMAN DNA POLYMERASE BETA WITH GAPPED DNA SUBSTRATE, INCORPORATED (-)3TC-MP AND AN ANOTHER INCOMING (-)3TC-TP NUCLEOTIDE."
5V1F,X-RAY DIFFRACTION,2.2,44.04,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium chloride, 17% PEG3350",291,2017-03-02,2017-05-10,5V1F,3303,4,366,46,,48.27,1,2.181,experimental,,0.2965,0.2263,DNA polymerase beta substrate complex with 8-oxoG at the primer terminus and incoming dCTP
5V1N,X-RAY DIFFRACTION,2.28,46.08,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, 350 mM sodium acetate, 17% PEG3350",291,2017-03-02,2017-05-10,5V1N,3589,4,366,305,,48.39,1,2.005,experimental,,0.2366,0.1808,DNA polymerase beta substrate complex with 8-oxoG:A at the primer terminus and incoming dCTP
5V1P,X-RAY DIFFRACTION,2.26,45.49,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, 350 mM sodium acetate, 17% PEG3350",291,2017-03-02,2017-05-10,5V1P,3566,4,366,278,,48.43,1,1.991,experimental,,0.231,0.1753,DNA polymerase beta substrate complex with 8-oxoG:C at the primer terminus and incoming dCTP analog
5VEZ,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, 350 mM sodium chloride, 17% PEG3350",291,2017-04-06,2017-05-10,5VEZ,3562,4,366,253,,48.31,1,2.039,experimental,,0.2319,0.1873,DNA polymerase beta substrate complex with 8-oxoG:A at the primer terminus and incoming dCTP analog
7K96,X-RAY DIFFRACTION,2.31,46.85,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, 350 mM sodium chloride, 16-17% PEG3350",291,2020-09-28,2021-02-03,7K96,3491,4,366,162,,48.87,1,2.1,experimental,33.39,0.2458,0.1831,Human DNA polymerase beta ternary complex with templating cytosine and incoming deoxyguanosine diphosphate
6LWA,X-RAY DIFFRACTION,2.76,55.5,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWA,7504,9,963,138,,123.54,1,2.76,experimental,81.026,0.2459,0.2075,"Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing 5-hydroxyuracil (5-OHU)"
6LWB,X-RAY DIFFRACTION,2.76,55.47,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWB,7570,9,963,260,,123.63,1,2.55,experimental,77.872,0.253,0.2096,"Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing 5-hydroxyuracil (5-OHU)"
6LWI,X-RAY DIFFRACTION,2.77,55.6,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWI,7762,9,963,312,,123.63,1,2.72,experimental,59.21,0.248,0.205,"Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing dihydrothymine (DHT)"
6LWQ,X-RAY DIFFRACTION,2.81,56.25,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWQ,7521,9,963,98,,123.75,1,2.89,experimental,80.78,0.2828,0.2372,Crystal structure of human NEIL1(R242) bound to duplex DNA containing a C:T mismatch
8FDX,X-RAY DIFFRACTION,3.47,64.54,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris-HCl, pH 7.5, 0.33 M sodium chloride, 16-21% PEG4000, 2% PEG400",277,2022-12-05,2023-05-10,8FDX,1654,1,210,91,,23.56,1,2.07,experimental,,0.2404,0.2016,"AGF271 and GAR in complex with human recombinant GARFTase, ligase, purine biosynthesis, transfers formyl group from 10-formyl tetrahydrofolate to glycinamide ribonucleotide (GAR) to form tetrahydrofolate and formyl GAR"
6GQ3,X-RAY DIFFRACTION,2.31,46.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M NaCl, 0.1 M sodium HEPES buffer, pH 7.5, and 12% w/v PEG 8000",290,2018-06-07,2019-09-18,6GQ3,8899,2,1122,568,5,130,1,1.85,experimental,33.556,0.22462,0.17764,Human asparagine synthetase (ASNS) in complex with 6-diazo-5-oxo-L-norleucine (DON) at 1.85 A resolution
5III,X-RAY DIFFRACTION,2.86,57.02,"VAPOR DIFFUSION, HANGING DROP",,,,2016-03-01,2016-08-17,5III,3173,4,355,332,,44.29,1,1.8,experimental,,0.2251,0.2007,Crystal structure of the pre-catalytic ternary complex of DNA polymerase lambda with a templating 8-oxo-dG and an incoming dATP
5IIM,X-RAY DIFFRACTION,2.94,58.11,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium acetate, 0.1 M sodium citrate pH 4.8, and 3-5% PEG 4000",278,2016-03-01,2016-09-07,5IIM,3301,4,355,349,,44.26,1,1.941,experimental,,0.2159,0.1834,Crystal structure of the pre-catalytic ternary extension complex of DNA polymerase lambda with an 8-oxo-dG:dA base-pair
5IIN,X-RAY DIFFRACTION,2.89,57.41,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium acetate, 0.1 M sodium citrate pH 4.8, and 3-5% PEG 4000",278,2016-03-01,2016-08-17,5IIN,3198,4,355,239,,44.24,1,2.15,experimental,,0.2314,0.1872,Crystal structure of the pre-catalytic ternary extension complex of DNA polymerase lambda with an 8-oxo-dG:dC base-pair
7M07,X-RAY DIFFRACTION,3,59,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5mM Na cacodylate pH 6.5, 150mM KCl, 75mM magnesium acetate, 7.5% (w/v) PEG 8000",293,2021-03-10,2022-03-16,7M07,3511,4,367,445,,45.8,1,1.57,experimental,26.72,0.1877,0.1705,Pre-catalytic ternary complex of DNA Polymerase Lambda with bound 1-nt gapped SSB substrate and incoming dUMPNPP
7M08,X-RAY DIFFRACTION,2.6,52.78,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5mM Na cacodylate pH 6.5, 150mM KCl, 75mM magnesium acetate, 7.5% (w/v) PEG8000",293,2021-03-10,2022-03-16,7M08,3365,4,368,345,,45.5,1,1.7,experimental,31.17,0.2093,0.1855,Post-catalytic nicked complex of DNA Polymerase Lambda with bound 1-nt gapped SSB substrate and incoming dUMPNPP
7JL5,X-RAY DIFFRACTION,2.93,57.15,VAPOR DIFFUSION,8.5,PEG 6000,293,2020-07-29,2020-09-09,7JL5,1332,2,216,,,24.49,1,2.6,experimental,51.86,0.2661,0.2268,Crystal structure of human NEIL3 tandem zinc finger GRF domains
8U0O,X-RAY DIFFRACTION,2.48,50.35,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M ADA pH 6.5, 1 M ammonium phosphate dibasic",294,2023-08-29,2024-03-13,8U0O,2689,3,357,85,,43.08,1,2.05,experimental,58.81,0.2586,0.2148,Synaptic complex of human DNA polymerase Lambda DL variant engaged on a DNA double-strand break containing an unpaired 3' primer terminus
5IIK,X-RAY DIFFRACTION,2.89,57.51,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium acetate, 0.1 M sodium citrate pH 4.8, and 2-7% PEG 4000",278,2016-03-01,2016-08-17,5IIK,3370,4,356,395,,44.27,1,1.982,experimental,,0.2378,0.1916,Crystal structure of the post-catalytic nick complex of DNA polymerase lambda with a templating 8-oxo-dG and incorporated dC
5IIL,X-RAY DIFFRACTION,2.89,57.41,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium acetate, 0.1 M sodium citrate pH 4.8, and 3-5% PEG 4000",278,2016-03-01,2016-08-17,5IIL,3420,4,356,405,,44.29,1,1.96,experimental,,0.2172,0.1791,Crystal structure of the post-catalytic nick complex of DNA polymerase lambda with a templating 8-oxo-dG and incorporated dA
7M09,X-RAY DIFFRACTION,2.6,52.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"80mM Na cacodylate pH 6.5, 0.16mM calcium acetate, 14.4% (w/v) PEG 8000, 20% (v/v) glycerol",277,2021-03-10,2022-03-16,7M09,3546,5,367,457,,45.75,1,1.65,experimental,25.41,0.1861,0.1677,Pre-catalytic quaternary complex of DNA Polymerase Lambda with blunt-ended DSB substrate and incoming dUMPNPP
5ITY,X-RAY DIFFRACTION,2.19,43.84,EVAPORATION,6.5,"0.1M cacodylic acid (pH 7.0), 0.1M NaCl, 0.05M MgCl2, 24%(w/v) PEG 8000",277,2016-03-17,2016-07-06,5ITY,8239,6,1278,360,,158.74,1,2.48,experimental,,0.22456,0.17552,Crystal Structure of Human NEIL1(P2G) bound to duplex DNA containing Thymine Glycol
6LWC,X-RAY DIFFRACTION,2.77,55.59,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWC,5234,6,642,55,,82.47,1,2.91,experimental,115.328,0.2429,0.1906,"Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing spiroiminodihydantoin (Sp)"
6LWF,X-RAY DIFFRACTION,2.74,55.04,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWF,5271,6,642,65,,82.42,1,2.79,experimental,106.906,0.2433,0.1856,"Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing guanidinohydantoin (Gh)"
6CTR,X-RAY DIFFRACTION,2.29,46.36,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTR,3800,4,366,459,,49.16,1,1.85,experimental,29.59,0.222,0.172,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHF (R & S isomers), beta, gamma dCTP analogue"
6CTT,X-RAY DIFFRACTION,2.29,46.34,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2018-03-23,2018-06-20,6CTT,3812,4,366,471,,49.19,1,2,experimental,26.56,0.222,0.176,"Ternary complex crystal structure of DNA polymerase Beta with a dideoxy terminated primer with CHCL (R & S isomers, beta, gamma dCTP analogue"
6WH1,X-RAY DIFFRACTION,2.36,47.97,"VAPOR DIFFUSION, HANGING DROP",5.5,8-10% isopropanol and 0.1M Bis-Tris pH 5.5,295,2020-04-07,2020-12-02,6WH1,1392,2,174,18,,20.38,2,2.4,experimental,67.21,0.272,0.221,Structure of the complex of human DNA ligase III-alpha and XRCC1 BRCT domains
6WTG,X-RAY DIFFRACTION,2.32,47,"VAPOR DIFFUSION, HANGING DROP",9,"0.1 M bicine pH 9.0, 65% (v/v) MPD",298,2020-05-02,2021-03-03,6WTG,1885,2,269,27,,29.52,2,2.63,experimental,37.02,0.2428,0.204,SdeA DUB Domain in complex with Ubiquitin
5ITU,X-RAY DIFFRACTION,2.23,44.92,EVAPORATION,6.5,"0.1 M cacodylic acid (pH 7.0), 0.1 M NaCl, 0.05 M MgCl2 and 24% (w/v) PEG 8000",277,2016-03-17,2016-07-06,5ITU,8023,9,1278,179,,158.4,1,2.41,experimental,,0.26,0.21,Crystal Structure of Human NEIL1(242K) bound to duplex DNA containing THF
6UDL,X-RAY DIFFRACTION,3.52,65.09,"VAPOR DIFFUSION, SITTING DROP",,"0.18 M sodium phosphate dibasic, 18% PEG3350, 5 mM (S)-O-methyl-serine dodecylamide hydrochloride",277.15,2019-09-19,2020-09-23,6UDL,15242,4,1964,1,,227,1,2.85,experimental,75.1579,0.2867,0.2378,Structure of Human Cytochrome P450 1A1 with Duocarmycin Prodrug (S) ICT-2700
5MNJ,X-RAY DIFFRACTION,2.31,46.84,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris-HCl, pH 8.5, 0.175 M Li2SO4 and 16-20 %(v/v) PEG 3350",292,2016-12-13,2017-05-31,5MNJ,5413,8,756,77,,86.01,4,2.16,experimental,,0.2308,0.1901,Structure of MDM2-MDMX-UbcH5B-ubiquitin complex
6LWD,X-RAY DIFFRACTION,2.75,55.29,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWD,7656,9,963,294,,123.89,1,2.41,experimental,72.969,0.254,0.2111,"Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing spiroiminodihydantoin (Sp)"
6LWG,X-RAY DIFFRACTION,2.75,55.33,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWG,7518,9,963,291,,123.99,1,2.53,experimental,73.162,0.2537,0.2075,"Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing guanidinohydantoin (Gh)"
6LWH,X-RAY DIFFRACTION,2.73,54.99,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWH,7515,9,963,153,,123.64,1,2.78,experimental,80.261,0.2422,0.2004,"Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing dihydrothymine (DHT)"
6LWJ,X-RAY DIFFRACTION,2.73,54.99,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWJ,7552,9,963,156,,123.59,1,2.83,experimental,80.815,0.2412,0.1998,"Crystal structure of human NEIL1(P2G, E3Q, K242) bound to duplex DNA containing dihydrouracil (DHU)"
6LWK,X-RAY DIFFRACTION,2.75,55.23,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWK,7672,9,963,146,,123.68,1,2.88,experimental,84.067,0.2399,0.201,"Crystal structure of human NEIL1(P2G, E3Q, R242) bound to duplex DNA containing dihydrouracil (DHU)"
6LWL,X-RAY DIFFRACTION,2.77,55.53,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWL,7719,9,963,222,,123.86,1,2.55,experimental,80.307,0.2525,0.2091,"Crystal structure of human NEIL1(R242) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine"
6LWM,X-RAY DIFFRACTION,2.78,55.76,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWM,7479,9,963,201,,123.77,1,2.67,experimental,81.369,0.2582,0.2048,"Crystal structure of human NEIL1(K242) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine"
6LWN,X-RAY DIFFRACTION,2.82,56.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWN,7853,9,963,256,,123.98,1,2.74,experimental,80.522,0.2454,0.1992,"Crystal structure of human NEIL1(R242, G249P) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine"
6LWO,X-RAY DIFFRACTION,3.04,59.5,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWO,7588,9,963,277,,123.78,1,2.51,experimental,75.438,0.2428,0.2027,"Crystal structure of human NEIL1(R242, Y244H) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine"
6LWP,X-RAY DIFFRACTION,2.82,56.32,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M cacodylic acid (pH 6.5), 0.1 M NaCl, 0.05 M MgCl2 and 18% (w/v) PEG 8000",277.15,2020-02-07,2021-06-09,6LWP,7673,9,963,216,,123.84,1,2.64,experimental,81.84,0.2319,0.2034,"Crystal structure of human NEIL1(R242, Y244R) bound to duplex DNA containing 2'-fluoro-2'-deoxy-5,6-dihydrouridine"
7TMY,X-RAY DIFFRACTION,3.46,64.42,"VAPOR DIFFUSION, HANGING DROP",6,"sodium citrate buffer (pH 6.0), sodium citrate and DTT",291,2022-01-20,2023-08-02,7TMY,3346,2,468,178,,50.8,2,2.21,experimental,56.068,0.2168,0.1857,Structure of Mouse Importin alpha NEIL3 NLS Peptide Complex
5ITR,X-RAY DIFFRACTION,2.19,43.77,EVAPORATION,6.5,"0.1M cacodylic acid (pH 7.0), 0.1M NaCl, 0.05 M MgCl2, 24%(w/v) PEG 8000",277,2016-03-17,2016-07-06,5ITR,7925,6,1278,125,,158.64,1,2.46,experimental,,0.263,0.211,Crystal Structure of Human NEIL1(P2G) bound to duplex DNA containing THF
5UGN,X-RAY DIFFRACTION,2.23,44.8,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium chloride, 17% PEG3350",291,2017-01-09,2017-07-26,5UGN,3605,4,367,256,,48.69,1,1.997,experimental,,0.2432,0.181,DNA polymerase beta imidodiphosphate reactant complex
7M0E,X-RAY DIFFRACTION,2.58,52.38,"VAPOR DIFFUSION, SITTING DROP",,"0.138M sodium sulfate, 20% (w/v) PEG 3350",277,2021-03-10,2022-03-16,7M0E,11774,16,1460,354,,177.8,1,2.25,experimental,48.64,0.2221,0.1835,Pre-catalytic synaptic complex of DNA Polymerase Lambda with gapped DSB substrate and incoming dUMPNPP
8U0P,X-RAY DIFFRACTION,2.69,54.28,"VAPOR DIFFUSION, SITTING DROP",6.5,"85 mM Na cacodylate pH 6.5, 0.17 M ammonium sulfate, 25.5 % (w/v) PEG 8000, 15% (v/v) glycerol",294,2023-08-29,2024-03-13,8U0P,3353,4,361,350,,44.93,1,1.9,experimental,32.17,0.1926,0.1724,Synaptic complex of human DNA polymerase Lambda DL variant engaged on a noncomplementary DNA double-strand break
4ZZ3,X-RAY DIFFRACTION,3.92,68.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,2015-05-22,2015-12-16,4ZZ3,1565,1,210,27,,23.52,1,2.504,experimental,48.8973,0.2433,0.1955,Human GAR transformylase in complex with GAR and pemetrexed
8FJV,X-RAY DIFFRACTION,3.59,65.74,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris (pH 7.5), 0.333 mM NaCl, 20% polyethylene glycol (PEG) 4000, and 2% PEG 400",277,2022-12-20,2023-09-06,8FJV,1584,1,210,40,,23.57,1,2.69,experimental,,0.2446,0.1917,Human GAR transformylase in complex with GAR substrate and AGF362 inhibitor
8FJW,X-RAY DIFFRACTION,3.51,64.97,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris (pH 7.5), 0.333 mM NaCl, 20% polyethylene glycol (PEG) 4000, and 2% PEG 400",277,2022-12-20,2023-09-06,8FJW,1639,1,210,91,,23.57,1,2.08,experimental,,0.2361,0.2075,Human GAR transformylase in complex with GAR substrate and AGF347 inhibitor
8FJX,X-RAY DIFFRACTION,3.58,65.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris (pH 7.5), 0.333 mM NaCl, 20% polyethylene glycol (PEG) 4000, and 2% PEG 400",277,2022-12-20,2023-09-06,8FJX,1650,1,210,76,,23.57,1,2.17,experimental,,0.2458,0.2027,Human GAR transformylase in complex with GAR substrate and AGF320 inhibitor
8FJY,X-RAY DIFFRACTION,3.63,66.14,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris (pH 7.5), 0.333 mM NaCl, 20% polyethylene glycol (PEG) 4000, and 2% PEG 400",277,2022-12-20,2023-09-06,8FJY,1554,1,210,15,,23.54,1,2.98,experimental,,0.2511,0.2059,Human GAR transformylase in complex with GAR substrate and AGF291 inhibitor
5ITT,X-RAY DIFFRACTION,2.22,44.55,EVAPORATION,6.5,"0.1 M cacodylic acid (pH 7.0), 0.1 M NaCl, 0.05 M MgCl2 and 24% (w/v) PEG 8000",288,2016-03-17,2016-07-06,5ITT,8033,6,1278,182,,158.78,1,2.53,experimental,,0.27788,0.21016,Crystal Structure of Human NEIL1 bound to duplex DNA containing THF
8FTJ,X-RAY DIFFRACTION,2.73,54.9,"VAPOR DIFFUSION, HANGING DROP",,"0.01 M magnesium sulfate and 1.8 M lithium sulfate, 0.05 M sodium cacodylate, pH 6.0",287,2023-01-12,2023-04-26,8FTJ,2793,3,323,127,,41.99,1,2.3,experimental,32.47,0.2434,0.2008,Crystal structure of human NEIL1 (P2G (242K) C(delta)100) glycosylase bound to DNA duplex containing urea
6DCM,X-RAY DIFFRACTION,1.78,30.91,EVAPORATION,,"PEG 4000, Sodium acetate, Ammonium acetate",298,2018-05-07,2019-05-15,6DCM,822,1,85,100,3,9.93,1,1.031,experimental,,0.1569,0.1412,The atomic resolution crystal structure of Kringle 2 variant bound with EACA
8OGD,X-RAY DIFFRACTION,2.08,40.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM HEPES, 2.9 M ammonium sulfate, 1 mM 4-hydroxymercuric benzoic acid sodium salt.",298,2023-03-20,2024-02-07,8OGD,2466,1,260,362,,29.7,1,1.75,experimental,14.98,0.1981,0.1713,Structure of zinc(II) double mutant human carbonic anhydrase II bound to thiocyanate
8OGE,X-RAY DIFFRACTION,2.09,41.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM HEPES, 2.9 M Ammonium Sulfate, 1 mM 4-hidroxymercuric benzoic acid sodium salt",298,2023-03-20,2024-02-07,8OGE,2397,1,260,293,,29.7,1,1.46,experimental,17.78,0.1623,0.1349,Structure of cobalt(II) substituted double mutant human carbonic anhydrase II bound to thiocyanate
5J9F,X-RAY DIFFRACTION,3.64,66.23,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Tris (pH 7.5), 0.333 mM NaCl, 18% polyethylene glycol (PEG) 3350, and 2% PEG 400",277,2016-04-09,2016-08-10,5J9F,1601,1,210,52,,23.48,1,2.1,experimental,,0.213,0.174,"Human GAR transformylase in complex with GAR and (4-{[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]amino}benzoyl)-L-glutamic acid (AGF183)"
7M0B,X-RAY DIFFRACTION,3.03,59.4,"VAPOR DIFFUSION, SITTING DROP",6.5,"76.5mM Na cacodylate pH 6.5, 0.153M ammonium sulfate, 22.95% (w/v) PEG8000, 13.5% (v/v) glycerol, 0.2M NDSB-201",277,2021-03-10,2022-03-16,7M0B,3458,5,367,385,,45.84,1,2,experimental,24.95,0.2004,0.1705,Pre-catalytic quaternary complex of DNA Polymerase Lambda with bound mismatched DSB and incoming dUMPNPP
6W0M,X-RAY DIFFRACTION,2.91,57.78,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM sodium cacodylate, pH 6.5, 200 mM MgCl2, and 18 % polyethylene glycol 8000.",293,2020-03-02,2020-09-23,6W0M,3181,3,345,100,,44.36,1,2.37,experimental,42.974,0.2655,0.1967,Human 8-oxoguanine glycosylase crosslinked with oxoG lesion containing DNA
6W0R,X-RAY DIFFRACTION,2.99,58.89,"VAPOR DIFFUSION, HANGING DROP",,"200 mM NH4NO3, and 20 % polyethylene glycol 3350",293,2020-03-02,2020-09-23,6W0R,2827,3,326,115,,38.97,1,2.35,experimental,39.7253,0.2491,0.2084,Human 8-oxoguanine glycosylase interrogating fully intrahelical undamaged DNA
7OWM,X-RAY DIFFRACTION,2.31,46.69,"VAPOR DIFFUSION, HANGING DROP",5.6,"20% PEG8K, 100mM Sodium Citrate pH 5.6, 100mM MgCl2, 100mM NaCl",293,2021-06-18,2022-12-21,7OWM,7658,3,812,1006,,96.19,2,1.5,experimental,25.18,0.1958,0.1544,HsNMT1 in complex with both MyrCoA and HCPA substrate peptide GKQNSKLR
5HHH,X-RAY DIFFRACTION,2.46,49.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"14% to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",295,2016-01-11,2017-01-18,5HHH,3308,4,358,90,,46.82,1,2.363,experimental,,0.2652,0.2129,Structure of human DNA polymerase beta Host-Guest complexed with the control G for N7-CBZ-platination
8K62,X-RAY DIFFRACTION,2.02,39.03,"VAPOR DIFFUSION, SITTING DROP",,"0.1M imidazole, pH7.0, 20% Polyrthylene glycol 6000",289,2023-07-24,2024-07-31,8K62,2682,1,389,42,,44.32,1,1.991,experimental,,0.2777,0.2043,Crystal structure of ALKBH1 and 13h complex.
5ITX,X-RAY DIFFRACTION,2.23,44.81,EVAPORATION,6.5,"0.1 M cacodylic acid (pH 7.0), 0.1 M NaCl, 0.05 M MgCl2 and 24% (w/v) PEG 8000",277,2016-03-17,2016-07-06,5ITX,8021,6,1258,183,,156.39,2,2.65,experimental,,0.23544,0.19214,Crystal Structure of Human NEIL1(P2G R242K) bound to duplex DNA containing Thymine Glycol
8J2O,X-RAY DIFFRACTION,2.05,39.89,"VAPOR DIFFUSION, SITTING DROP",7.4,"Crystallization solution was comprised of Tris-HCl buffer (50 mM, pH=7.4), and 2.9 M ammonium sulfate in sitting drop vapor diffusion setup. Crystallization drop was comprised of hCA-II, Acetohexamide and reservoir buffer.  25% v/v glycerol was used as cryoprotectant.",291,2023-04-14,2024-04-24,8J2O,2162,1,260,85,,29.77,1,2.6,experimental,12.813,0.25858,0.17656,Crystal Structure of Human Carbonic Anhydrase II In-complex with Acetohexamide at 2.6 A Resolution
8KHN,X-RAY DIFFRACTION,2.23,44.76,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES pH 7.2, 0.1M Carboxylic acids, 17% (v/v) MPD, 17% (w/v) PEG 1000, 17% (w/v) PEG 3350",287,2023-08-22,2024-01-24,8KHN,2560,1,313,318,,34.65,1,1.51,experimental,,0.2136,0.1926,Crystal structure of human methionine aminopeptidase 12 (MAP12) in complex with two cobalt ions
5W4G,X-RAY DIFFRACTION,2.95,58.26,"VAPOR DIFFUSION, HANGING DROP",7,"0.1 M Bis Tris Propane
1.4 M Ammonium Sulfate",293,2017-06-10,2018-06-13,5W4G,3544,2,539,251,,59.13,2,2.038,experimental,,0.1998,0.1707,Importin binding to NLS peptide of DNA polymerase lambda
8KHM,X-RAY DIFFRACTION,2.39,43.65,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES pH 7.2, 0.1M Carboxylic acids, 17% (v/v) MPD, 17% (w/v) PEG 1000, 17% (w/v) PEG 3350",287,2023-08-22,2024-01-24,8KHM,2545,1,313,261,,34.72,1,1.39,experimental,,0.2081,0.1889,Crystal structure of human methionine aminopeptidase 12 (MAP12) in the unbound form
7JG3,X-RAY DIFFRACTION,3.52,65.07,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris (pH 7.5), 0.333 mM NaCl, 20% polyethylene glycol (PEG) 4000, and 2% PEG 400",277,2020-07-18,2021-03-31,7JG3,1699,1,210,114,,23.58,1,2.091,experimental,45.7681,0.2327,0.187,Human GAR transformylase in complex with GAR substrate and AGF103 inhibitor
7JG4,X-RAY DIFFRACTION,3.5,64.87,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris (pH 7.5), 0.333 mM NaCl, 18-22% polyethylene glycol (PEG) 4000, and 2% PEG 400",277,2020-07-18,2021-03-31,7JG4,1596,1,210,43,,23.58,1,2.455,experimental,55.2894,0.2545,0.1875,Human GAR transformylase in complex with GAR substrate and AGF131 inhibitor
6SG0,X-RAY DIFFRACTION,2.14,42.64,"VAPOR DIFFUSION, HANGING DROP",7.8,"Sodium citrate 1.4 M, TRIS 0.1, saturated with para-Chloromercuribenzoic acid",291,2019-08-02,2020-08-26,6SG0,2517,1,265,211,,30.98,1,1.13,experimental,14.25,0.145,0.1257,Atomic resolution structure of Human Carbonic Anhydrase II in complex with furosemide
7D8E,X-RAY DIFFRACTION,2.69,54.34,"VAPOR DIFFUSION, SITTING DROP",6,"100 mM MES buffer pH 6.0-6.5, 46-67 mM NaOH, 100 mM ammonium sulfate",277.15,2020-10-08,2021-12-08,7D8E,8075,3,987,342,,114.82,1,2,experimental,18.19,0.2519,0.2087,Crystal Structure of double mutant Y115E Y117E human Secretory Glutaminyl Cyclase in complex with LSB-09
6UMQ,X-RAY DIFFRACTION,2.44,49.64,"VAPOR DIFFUSION, SITTING DROP",8.5,"18% PEG 4000, 200mM MgCl2, 100mM Tris-HCl pH 8.5",277.15,2019-10-10,2020-07-29,6UMQ,7471,2,882,575,,102.56,1,1.85,experimental,16.26,0.224,0.1964,Structure of DUF89
6UMR,X-RAY DIFFRACTION,2.49,50.63,"VAPOR DIFFUSION, SITTING DROP",8.5,"18% PEG 4000, 200mM MgCl2, 100mM Tris-HCl pH 8.5",277.15,2019-10-10,2020-07-29,6UMR,7342,2,882,446,,102.42,1,2.21,experimental,21.99,0.2566,0.2206,Structure of DUF89 - D291A mutant
7M0D,X-RAY DIFFRACTION,4.03,69.5,"VAPOR DIFFUSION, SITTING DROP",,"0.192M tri-potassium citrate, 18.8% (w/v) PEG 3350",277,2021-03-10,2022-03-16,7M0D,7458,10,734,1091,1,92.56,1,1.8,experimental,22.68,0.1887,0.1643,Pre-catalytic quaternary complex of DNA Polymerase Lambda with bound complementary DSB substrate and incoming dUMPNPP
7TMX,X-RAY DIFFRACTION,3.25,62.12,"VAPOR DIFFUSION, HANGING DROP",6,"sodium citrate buffer (pH 6.0), sodium citrate and DTT",291,2022-01-20,2023-08-02,7TMX,3341,3,500,91,,54.41,2,2.3,experimental,60.454,0.254,0.2199,Structure of Mouse Importin alpha NEIL1 NLS Peptide Complex
4ZZ1,X-RAY DIFFRACTION,3.86,68.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,2015-05-22,2015-12-16,4ZZ1,1985,1,210,328,,23.54,1,1.351,experimental,23.5851,0.1577,0.1396,"HUMAN GAR TRANSFORMYLASE IN COMPLEX WITH GAR AND (S)-2-({4-[3-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-6-YL)-PROPYL]-THIOPHENE-2-CARBONYL}-AMINO)-PENTANEDIOIC ACID"
4ZZ2,X-RAY DIFFRACTION,3.9,68.47,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,2015-05-22,2015-12-16,4ZZ2,1929,1,210,300,,23.54,1,1.451,experimental,22.9184,0.1624,0.1415,"HUMAN GAR TRANSFORMYLASE IN COMPLEX WITH GAR AND (S)-2-({5-[3-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-6-YL)-PROPYL]-THIOPHENE-3-CARBONYL}-AMINO)-PENTANEDIOIC ACID"
8VF8,X-RAY DIFFRACTION,2.39,48.58,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VF8,3506,4,366,307,,47.75,1,1.98,experimental,30.61,0.2216,0.1919,Binary DNA Polymerase Beta bound to DNA containing primer terminal dC base-paired with FapydG
8VF9,X-RAY DIFFRACTION,2.31,46.84,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VF9,3503,4,366,259,,47.78,1,1.9,experimental,25.16,0.2317,0.2081,Binary DNA Polymerase Beta bound to DNA containing primer terminal dA base-paired with FapydG
8VFA,X-RAY DIFFRACTION,2.37,48.02,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VFA,3337,4,366,91,,48.36,1,2.05,experimental,33.63,0.2667,0.2256,Ternary DNA Polymerase Beta bound to DNA containing primer terminal dC base-paired with FapydG
8VFB,X-RAY DIFFRACTION,2.39,48.62,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VFB,3253,4,366,2,,48.36,1,2.64,experimental,33.3,0.2275,0.1955,Ternary DNA Polymerase Beta bound to DNA containing primer terminal dA base-paired with FapydG
8VFC,X-RAY DIFFRACTION,2.47,50.16,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VFC,3322,4,366,100,,47.75,1,2.48,experimental,40.74,0.2552,0.197,Binary DNA Polymerase Beta bound to DNA containing primer terminal T base-paired with FapydG
8VFD,X-RAY DIFFRACTION,2.35,47.74,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VFD,3308,4,366,104,,48.34,1,2.1,experimental,33.12,0.2422,0.1997,Ternary DNA Polymerase Beta bound to DNA containing template FapydG incoming TTP analog
8VFE,X-RAY DIFFRACTION,2.4,48.7,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VFE,3391,4,366,162,,47.79,1,2.09,experimental,32.21,0.2349,0.1999,Binary DNA Polymerase Beta bound to DNA containing primer terminal FapydG base-paired with a T
8VFF,X-RAY DIFFRACTION,2.43,49.45,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-15,8VFF,3594,4,366,368,,47.8,1,1.69,experimental,21.58,0.2319,0.2148,Binary DNA Polymerase Beta bound to DNA containing primer terminal FapydG base-paired with a dA
8VFG,X-RAY DIFFRACTION,2.43,49.44,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VFG,3827,4,366,606,,47.73,1,1.54,experimental,20.76,0.2365,0.2006,Binary DNA Polymerase Beta bound to DNA containing primer terminal FapydG base-paired with a dC
8VFH,X-RAY DIFFRACTION,2.31,46.72,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VFH,3597,4,366,283,,48.26,1,2.01,experimental,31.81,0.2456,0.1768,Ternary DNA Polymerase Beta bound to DNA containing primer terminal FapydG base-paired with a dC
6WV5,X-RAY DIFFRACTION,3.96,68.94,LIPIDIC CUBIC PHASE,6.5,"25% PEG400, 0.1 M ammonium citrate dibasic, 0.1 M MES, pH 6.5",295,2020-05-05,2020-11-11,6WV5,2961,1,390,,1,44.65,1,2.8,experimental,62.1792,0.2704,0.2311,Human VKOR C43S mutant with vitamin K1 epoxide
5BOM,X-RAY DIFFRACTION,2.38,48.52,VAPOR DIFFUSION,7.5,"50mM Imidazole, 350mM Sodium Acetate, 18% Peg3350, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2015-05-27,2015-08-19,5BOM,3489,4,366,280,,47.77,1,2.0002,experimental,36.2168,0.2138,0.1895,DNA polymerase beta binary complex with a templating 5ClC
7S9J,X-RAY DIFFRACTION,2.39,48.54,"VAPOR DIFFUSION, SITTING DROP",8,"14-19% PEG 3350, 50 mM Imidazole pH 8.0, 350 mM Sodium Acetate",291,2021-09-21,2022-08-03,7S9J,3712,4,366,464,,47.82,1,1.91,experimental,24.43,0.2379,0.1879,Crystal Structure of DNA Polymerase Beta with Fapy-dG base-paired with a dC
7S9K,X-RAY DIFFRACTION,2.38,48.33,"VAPOR DIFFUSION, SITTING DROP",8,"14-19% PEG 3350, 50 mM Imidiazole pH 8.0, 350 mM Sodium Acetate",291,2021-09-21,2022-08-03,7S9K,3611,4,366,361,,47.84,1,1.97,experimental,30.75,0.2241,0.1718,Crystal Structure of DNA Polymerase Beta with Fapy-dG base-paired with a dA
7S9N,X-RAY DIFFRACTION,2.35,47.65,"VAPOR DIFFUSION, SITTING DROP",,"14-19% PEG 3350, 50 mM Imidazole pH 8.0, 350 mM Sodium Acetate",291,2021-09-21,2022-08-03,7S9N,3759,4,366,466,,47.72,1,1.71,experimental,27.45,0.2364,0.1916,Binary complex of DNA Polymerase Beta with Fapy-dG in the template position
7S9O,X-RAY DIFFRACTION,2.35,47.75,VAPOR DIFFUSION,8,"14-19% PEG 3350, 50 mM Imidazole pH 8.0, 350 mM Sodium Acetate",291,2021-09-21,2022-08-03,7S9O,3287,4,366,49,,47.8,1,2.23,experimental,35.54,0.2777,0.2015,Binary complex of DNA Polymerase Beta with Ring open Intermediate Fapy-dG in the template position
8VFJ,X-RAY DIFFRACTION,2.62,52.99,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-08,8VFJ,3397,4,366,144,,47.81,1,2.14,experimental,33.44,0.2649,0.2107,Polymerase Beta Host Guest Complex Containing FapydG base paired with TMP
5GNS,X-RAY DIFFRACTION,2.68,54.07,"VAPOR DIFFUSION, HANGING DROP",,"200mM sodium phosphate monobasic monohydrate, 20%(w/v) PEG3350",289,2016-07-24,2016-12-07,5GNS,3051,1,421,8,,47.86,1,2.702,experimental,,0.283,0.212,Structures of human Mitofusin 1 provide insight into mitochondrial tethering
6WVH,X-RAY DIFFRACTION,3.03,59.45,LIPIDIC CUBIC PHASE,6.5,"32% PEG400, 0.1 M ammonium acetate, 1% 1,2,3-heptanetriol, 0.1 M MES, pH 6.5",295,2020-05-06,2020-11-11,6WVH,6682,2,780,461,4,90.15,1,1.99,experimental,29.69,0.215,0.1946,Human VKOR with Brodifacoum
5FL4,X-RAY DIFFRACTION,3.41,63.97,"VAPOR DIFFUSION, SITTING DROP",4.5,"1.0 M DI-AMMONIUM HYDROGEN PHOSPHATE, 0.1 M SODIUM ACETATE PH 4.5, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K",294,2015-10-21,2015-11-11,5FL4,8966,4,1028,1050,4,115.11,1,1.82,experimental,31.758,0.22431,0.19034,"Three dimensional structure of human carbonic anhydrase IX in complex with 5-(1-naphthalen-1-yl-1,2,3-triazol-4-yl)thiophene-2-sulfonamide"
5FL6,X-RAY DIFFRACTION,3.43,64.14,"VAPOR DIFFUSION, SITTING DROP",4.5,"1.0 M DI-AMMONIUM HYDROGEN PHOSPHATE, 0.1 M SODIUM ACETATE PH 4.5, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K",294,2015-10-21,2015-11-11,5FL6,8975,4,1028,1145,4,114.72,1,1.95,experimental,23.692,0.20004,0.16912,"Three dimensional structure of human carbonic anhydrase IX in complex with 5-(1-(4-Methylphenyl)-1H-1,2,3-triazol-4-yl)thiophene-2- sulfonamide"
7U0T,X-RAY DIFFRACTION,2.42,49.27,"VAPOR DIFFUSION, SITTING DROP",8,"Microlytics MCSG-1 C5: 0.2M Magnesium Acetate, 20% PEG 3,350, HosaA.18272.a.TM11.PD38439 at 20mg/ml + FK-520 (Purified from SEC): cryo: 20% ethylene glycol: tray 318701c5, puck oxo8-2",287,2022-02-18,2022-08-03,7U0T,2400,2,394,62,,44.76,2,2.45,experimental,50.5788,0.2604,0.2111,Crystal Structure of a human Calcineurin A - Calcineurin B fusion bound to FKBP12 and FK-520
6AK5,X-RAY DIFFRACTION,2.62,53.08,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298,2018-08-30,2019-05-29,6AK5,3117,1,356,346,,41.36,1,1.7,experimental,17.245,0.24764,0.20838,Binary Complex of Human DNA Polymerase Mu with MnGTP
6Z1Q,X-RAY DIFFRACTION,2.75,55.21,VAPOR DIFFUSION,7.6,"12-20% Ethanol, 0.1M Hepes pH 7.6",277,2020-05-14,2020-07-08,6Z1Q,5279,2,702,77,,78.52,1,2.42,experimental,,0.24588,0.1902,MAP3K14 (NIK) in complex with DesF-3R/4076
6Z1T,X-RAY DIFFRACTION,2.8,56.03,VAPOR DIFFUSION,7.6,"12-20% Ethanol, 0.1M Hepes pH 7.6",277,2020-05-14,2020-07-08,6Z1T,5313,2,702,155,,78.32,1,2.31,experimental,,0.25614,0.19722,MAP3K14 (NIK) in complex with 4S/3694
5HHI,X-RAY DIFFRACTION,2.4,48.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"14 to 23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",295,2016-01-11,2017-01-18,5HHI,3281,4,360,36,,47.52,1,2.517,experimental,,0.2792,0.2223,Structure of human DNA polymerase beta Host-Guest complexed with CBZ-platinated N7-G
5BOL,X-RAY DIFFRACTION,2.28,45.98,VAPOR DIFFUSION,7.5,"50mM Imidazole, 350mM Sodium Acetate, 18% Peg3350, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2015-05-27,2015-08-19,5BOL,3642,4,366,319,,48.28,1,1.981,experimental,,0.2467,0.1896,DNA polymerase beta ternary complex with a templating 5ClC and incoming dGTP analog
5BPC,X-RAY DIFFRACTION,2.28,46.05,VAPOR DIFFUSION,7.5,"50mM Imidazole, 350mM Sodium Acetate, 18% Peg3350, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2015-05-28,2015-08-19,5BPC,3415,4,366,188,,48.43,1,2,experimental,,0.2591,0.2101,DNA polymerase beta ternary complex with a templating 5ClC and incoming dATP analog
6UOM,X-RAY DIFFRACTION,2.33,47.27,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium chloride, 19% PEG3350, pH 8.0",292,2019-10-15,2020-01-08,6UOM,3529,4,365,223,,48.45,1,2.05,experimental,32.1484,0.2438,0.1936,Y271G DNA polymerase beta ternary complex with templating adenine and incoming r8-oxo-GTP
7S9P,X-RAY DIFFRACTION,2.22,44.71,"VAPOR DIFFUSION, SITTING DROP",8,"14-19% PEG 3350, 50 mM Imidazole pH 8.0, 350 mM Sodium Acetate",291,2021-09-21,2022-08-03,7S9P,3738,4,366,434,,48.47,1,1.86,experimental,24.77,0.2278,0.1764,Ternary complex of DNA Polymerase Beta with Template Fapy-dG and an incoming dCTP analog
7S9Q,X-RAY DIFFRACTION,2.28,46.14,"VAPOR DIFFUSION, SITTING DROP",8,"14-19% PEG 3350, 50 mM Imidazole pH 8.0, 350 mM Sodium Acetate",291,2021-09-21,2022-08-03,7S9Q,3776,4,366,423,,48.5,1,1.9,experimental,28.02,0.2474,0.193,Ternary complex of DNA Polymerase Beta with Template Fapy-dG and an incoming dATP analog
8KHO,X-RAY DIFFRACTION,2.24,45.09,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES pH 7.2, 0.1M Carboxylic acids, 17% (v/v) MPD, 17% (w/v) PEG 1000, 17% (w/v) PEG 3350",287,2023-08-22,2024-01-24,8KHO,2480,1,313,217,,34.8,1,1.45,experimental,,0.209,0.183,Crystal structure of human methionine aminopeptidase 12 (MAP12) in complex with two Cobalt ions and Methionine
6W2M,X-RAY DIFFRACTION,2.25,45.36,"VAPOR DIFFUSION, SITTING DROP",,16-18% PEG 3350,291,2020-03-06,2020-07-22,6W2M,3742,4,367,446,,48.67,1,1.998,experimental,23.8971,0.2381,0.1931,Abortive ternary complex crystal structure of DNA polymerase Beta with 8OG-dC base pair at the primer terminus and flipped out dA
6WV6,X-RAY DIFFRACTION,3.17,61.17,LIPIDIC CUBIC PHASE,6.5,"34% PEG400, 80 mM lithium sulfate, 0.1 M MES, pH 6.5",295,2020-05-05,2020-11-11,6WV6,3097,1,390,33,2,45.13,1,2.7,experimental,50.9532,0.2678,0.2261,Human VKOR with phenindione
7L9F,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium acetate buffer pH 4.5, 0.1 M CaCl2, and 24 % polyethylene glycol (PEG) 4000",298,2021-01-04,2021-04-28,7L9F,11380,4,1464,1214,,159.67,1,1.75,experimental,21.46,0.1877,0.1494,Crystal structure of human ARH3 bound to calcium and ADP-ribose
7L9H,X-RAY DIFFRACTION,2.23,44.96,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium acetate buffer pH 4.5, 0.1 M MgCl2, and 22 % polyethylene glycol (PEG) 4000",298,2021-01-04,2021-04-28,7L9H,10902,4,1464,909,,159.27,1,1.85,experimental,22.78,0.2273,0.1801,Crystal structure of human ARH3-D77A bound to magnesium and ADP-ribose
7L9I,X-RAY DIFFRACTION,2.42,49.12,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium acetate buffer pH 4.5, 0.1 M MgCl2, and 24 % polyethylene glycol (PEG) 4000",298,2021-01-04,2021-04-28,7L9I,10973,4,1464,839,,159.27,1,1.8,experimental,22.18,0.2284,0.1887,Crystal structure of human ARH3-D314A bound to magnesium and ADP-ribose
6UOK,X-RAY DIFFRACTION,2.36,47.92,"VAPOR DIFFUSION, SITTING DROP",8,"19% PEG3350, 0.05M Imidazole (pH 8.0), 0.35 Sodium Acetate",291,2019-10-15,2020-01-08,6UOK,6475,8,732,47,,96.76,1,2.55,experimental,43.09,0.2787,0.2243,Y271G DNA polymerase beta substrate complex with templating cytosine and incoming r8-oxo-GTP
8VFI,X-RAY DIFFRACTION,2.31,46.7,"VAPOR DIFFUSION, SITTING DROP",,"14-22% PEG 3350
0.05 M Imidazole pH 8.0
0.35 M Sodium Acetate",291,2023-12-21,2024-05-15,8VFI,3770,4,366,424,,48.42,1,1.77,experimental,26.24,0.2287,0.1806,Ternary DNA Polymerase Beta bound to DNA containing primer terminal FapydG base-paired with a dA
6MR7,X-RAY DIFFRACTION,2.47,50.24,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole pH 7.5, 16% PEG3350, and 350 mM sodium acetate",292,2018-10-11,2019-01-30,6MR7,3530,4,366,286,,48.64,1,2.144,experimental,35.7238,0.2516,0.1856,DNA polymerase beta substrate complex with templating adenine and incoming Fapy-dGTP analog
6MR8,X-RAY DIFFRACTION,2.5,50.85,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, pH 8.0, 18% PEG3350 and 350 mM sodium acetate",292,2018-10-11,2019-01-30,6MR8,3589,4,366,372,,48.46,1,1.897,experimental,30.1597,0.2387,0.1961,D276G DNA polymerase beta substrate complex with templating adenine and incoming Fapy-dGTP analog
7S9L,X-RAY DIFFRACTION,2.38,48.27,"VAPOR DIFFUSION, SITTING DROP",8,"14-19% PEG 3350, 50 mM Imidazole pH 8.0, 350 mM Sodium Acetate",291,2021-09-21,2022-08-03,7S9L,3401,4,366,166,,47.91,1,2.05,experimental,30.95,0.2627,0.1961,Crystal Structure of DNA Polymerase Beta with Ring open intermediate Fapy-dG base-paired with a dC
7S9M,X-RAY DIFFRACTION,2.5,50.81,"VAPOR DIFFUSION, SITTING DROP",8,"14-19% PEG 3350, 50 mM Imidazole pH 8.0, 350 mM Sodium Acetate",291,2021-09-21,2022-08-03,7S9M,3285,4,366,49,,47.92,1,2.31,experimental,40.56,0.2996,0.2182,Crystal Structure of DNA Polymerase Beta with Ring open intermediate Fapy-dG base-paired with a dA
5DVX,X-RAY DIFFRACTION,2.84,56.69,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris HCl, pH 8.5, 8% (w/v) PEG 8000",290,2015-09-21,2016-08-03,5DVX,4847,2,520,641,2,58.08,1,1.598,experimental,,0.1913,0.1678,Crystal structure of the catalytic-domain of human carbonic anhydrase IX at 1.6 angstrom resolution
5JNC,X-RAY DIFFRACTION,2.5,51.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AMSO4 and 16% PEG 3350",277,2016-04-29,2017-05-03,5JNC,9451,4,1064,937,8,123.93,1,2,experimental,25.03,0.218,0.174,Crystal structure for the complex of human carbonic anhydrase IV and 4-aminomethylbenzene sulfonamide
4YX4,X-RAY DIFFRACTION,2.07,40.58,"VAPOR DIFFUSION, HANGING DROP",7.8,"2.5 uL of the protein solution (10 mg/ml hCAII in 50 mM Tris pH 7.8) were mixed with 2.5 uL of the well solution (2.7 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with p-chloromercurybenzoicacid) and placed as a hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with the inhibitor, for 1 day.",291,2015-03-22,2016-02-03,4YX4,2394,1,260,255,,29.93,1,1.01,experimental,,0.1703,0.1509,Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (1).
4YXO,X-RAY DIFFRACTION,2.08,40.75,"VAPOR DIFFUSION, HANGING DROP",7.8,"2.5 uL of the protein solution (10 mg/ml hCAII in 50 mM Tris pH 7.8) were mixed with 2.5 uL of the well solution (2.7 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with p-chloromercurybenzoicacid) and placed as a hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with the inhibitor, for 1 day.",291,2015-03-23,2016-02-03,4YXO,2362,1,260,239,,30.14,1,1.06,experimental,,0.164,0.1486,Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (3).
4YXU,X-RAY DIFFRACTION,2.08,40.81,"VAPOR DIFFUSION, HANGING DROP",7.8,"2.5 uL of the protein solution (10 mg/ml hCAII in 50 mM Tris pH 7.8) were mixed with 2.5 uL of the well solution (2.7 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with p-chloromercurybenzoicacid) and placed as a hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with the inhibitor, for 1 day.",291,2015-03-23,2016-02-03,4YXU,2403,1,260,246,,30.17,1,1.08,experimental,,0.1633,0.1441,Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (4).
4YYT,X-RAY DIFFRACTION,2.09,41.03,"VAPOR DIFFUSION, HANGING DROP",,"2.5 uL of the protein solution (10 mg/ml hCAII in 50 mM Tris pH 7.8) were mixed with 2.5 uL of the well solution (2.7 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with p-chloromercurybenzoicacid) and placed as a hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with the inhibitor, for 1 day.",291,2015-03-24,2016-02-03,4YYT,2442,1,260,248,,30.57,1,1.07,experimental,,0.1658,0.143,Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (5).
6FW2,X-RAY DIFFRACTION,2.45,49.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"Bis-TRIS propane, Na2MoO4, PEG3350",291,2018-03-05,2018-10-31,6FW2,4072,1,459,439,,53.39,1,1.78,experimental,29.685,0.2082,0.1694,Crystal Structure of human mARC1
6SFQ,X-RAY DIFFRACTION,2.13,42.39,"VAPOR DIFFUSION, HANGING DROP",7.8,"Sodium citrate 1.4 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-08-02,2020-08-26,6SFQ,2627,1,265,245,,30.91,1,1,experimental,13.65,0.1468,0.1261,"Atomic resolution structure of human Carbonic Anhydrase II in complex with (R)-5-phenyloxazolidine-2,4-dione"
8JEE,X-RAY DIFFRACTION,2.12,42.12,"VAPOR DIFFUSION, SITTING DROP",7.4,"Crystallization solution was comprised of Tris-HCl buffer (50 mM, pH=7.4), and 2.9 M ammonium sulfate. Crystallization drop was comprised of hCA-II, Acetohexamide and reservoir buffer.",293,2023-05-15,2024-05-15,8JEE,2134,1,257,45,,29.62,1,2.96,experimental,,0.2482,0.2176,Crystal Structure of Human Carbonic Anhydrase II In-complex with Levosulpiride at 2.96 A Resolution
8FAL,X-RAY DIFFRACTION,2.08,40.84,"VAPOR DIFFUSION, HANGING DROP",,2.6-3.0 M Ammonium sulfate in 50 mM Tris-Sulfate (pH 8),293,2022-11-28,2023-03-01,8FAL,2384,1,260,307,,29.92,1,1.37,experimental,18.02,0.2224,0.1897,Masking thiol reactivity with thioamide-based MBPs- carbonic anhydrase II complexed with benzo[d]thiazole-2(3H)-thione
6WV3,X-RAY DIFFRACTION,2.91,57.69,LIPIDIC CUBIC PHASE,6.5,"37% PEG400, 0.1 M MES, pH 6.5",295,2020-05-05,2020-11-11,6WV3,3222,1,390,144,2,45.58,1,2.197,experimental,46.3503,0.2227,0.2009,Human VKOR with warfarin
8A5X,X-RAY DIFFRACTION,2.41,48.96,"VAPOR DIFFUSION, SITTING DROP",,"10% w/v PEG 8.000, 20% v/v ethylene glycol, 3% v/v DMSO,
100 mM bicine/Trizma base pH 8.5,
20 mM 1,6-hexanediol, 20 mM 1-butanol, 20 mM 1,2-propanediol, 20 mM 2-propanol, 20 mM 1,4-butanediol, 20 mM 1,3-propanediol",291,2022-06-16,2022-10-05,8A5X,3909,1,514,106,,59.66,1,2.4,experimental,43.98,0.231,0.2105,Crystal structure of phosphatidyl inositol 4-kinase II beta in complex with MM1373
4XI6,X-RAY DIFFRACTION,2.61,52.92,"VAPOR DIFFUSION, HANGING DROP",7.6,"1.5 M (NH4)2SO4, 20% v/v glycerol, HEPES pH 7.6",293.15,2015-01-06,2015-03-18,4XI6,3034,1,380,186,,42.47,1,2.04,experimental,39.8021,0.2481,0.2085,Crystal structure of the MZM-REP domains of Mind bomb 1
4PGY,X-RAY DIFFRACTION,2.36,47.92,"VAPOR DIFFUSION, SITTING DROP",7.5,"14%?23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2014-05-03,2015-05-06,4PGY,3353,4,361,106,,47.35,1,2.26,experimental,40.66,0.2646,0.21,Structure of human DNA polymerase beta complexed with a nicked DNA containing a GT at N-1 position and GC at N position
4PH5,X-RAY DIFFRACTION,2.28,46.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"14%?23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2014-05-04,2015-05-06,4PH5,3335,4,358,68,,47.11,1,2.55,experimental,30.31,0.2612,0.191,Structure of human DNA polymerase beta complexed with a nicked DNA containing a AC at N-1 position and GC at N position
4PHP,X-RAY DIFFRACTION,2.28,46.08,"VAPOR DIFFUSION, SITTING DROP",,"14%?23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2014-05-06,2015-05-06,4PHP,3355,4,357,82,,47.29,1,2.6,experimental,21.53,0.2616,0.1813,Structure of human DNA polymerase beta complexed with T in the template base paired with incoming non-hydrolyzable GTP and MANGANESE
5J0O,X-RAY DIFFRACTION,2.42,49.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"50 mM Imidazole, pH 7.5, 350 mM Sodium Acetate, 16-18 % PEG3350",291,2016-03-28,2016-10-26,5J0O,3668,4,366,419,,47.75,1,2,experimental,33.4081,0.264,0.2097,Binary complex crystal structure of DNA polymerase Beta with A:A mismatch at the primer terminus
5J0P,X-RAY DIFFRACTION,2.41,49,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350,50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-28,2016-10-26,5J0P,3533,4,366,261,,47.72,1,2.2,experimental,44.7023,0.3198,0.2488,Binary complex crystal structure of DNA polymerase Beta with A:C mismatch at the primer terminus
5J0Q,X-RAY DIFFRACTION,2.44,49.56,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-28,2016-10-26,5J0Q,3892,4,366,617,,47.76,1,2,experimental,24.2186,0.2612,0.2069,Binary complex crystal structure of DNA polymerase Beta with A:G mismatch at the primer terminus
5J0R,X-RAY DIFFRACTION,2.44,49.66,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-28,2016-10-26,5J0R,3729,4,366,476,,47.77,1,2.001,experimental,,0.2724,0.2082,Binary complex crystal structure of DNA polymerase Beta with C:A mismatch at the primer terminus
5J0S,X-RAY DIFFRACTION,2.44,49.54,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-28,2016-10-26,5J0S,3854,4,366,602,,47.76,1,2,experimental,25.4648,0.2455,0.1987,Binary complex crystal structure of DNA polymerase Beta with C:T mismatch at the primer terminus
5J0T,X-RAY DIFFRACTION,2.4,48.85,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-28,2016-10-26,5J0T,3751,4,366,501,,47.81,1,2,experimental,26.0252,0.2581,0.2014,Binary complex crystal structure of DNA polymerase Beta with G:A mismatch at the primer terminus
5J0U,X-RAY DIFFRACTION,2.44,49.51,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-28,2016-10-26,5J0U,3636,4,366,400,,47.82,1,2.1,experimental,,0.2812,0.2046,Binary complex crystal structure of DNA polymerase Beta with G:G mismatch at the primer terminus
5J0W,X-RAY DIFFRACTION,2.4,48.83,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-28,2016-10-26,5J0W,3521,4,366,263,,47.71,1,2.4,experimental,29.2081,0.3064,0.2344,Binary complex crystal structure of DNA polymerase Beta with T:C mismatch at the primer terminus
5J0X,X-RAY DIFFRACTION,2.42,49.07,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-28,2016-10-26,5J0X,3803,4,366,547,,47.8,1,2,experimental,25.6852,0.2417,0.1931,Binary complex crystal structure of DNA polymerase Beta with T:G mismatch at the primer terminus
5J0Y,X-RAY DIFFRACTION,2.41,48.98,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-28,2016-10-26,5J0Y,3805,4,366,560,,47.82,1,2,experimental,24.8978,0.2448,0.189,Binary complex crystal structure of DNA polymerase Beta with T:T mismatch at the primer terminus
5J29,X-RAY DIFFRACTION,2.3,46.52,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J29,3621,4,366,349,,48.26,1,2.2,experimental,27.7056,0.2829,0.2115,Ternary complex crystal structure of DNA polymerase Beta with A:A mismatch at the primer terminus
5J2A,X-RAY DIFFRACTION,2.27,45.83,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2A,3529,4,366,257,,48.31,1,2.5,experimental,27.1632,0.2957,0.2247,Ternary complex crystal structure of DNA polymerase Beta with A:C mismatch at the primer terminus
5J2B,X-RAY DIFFRACTION,2.3,46.52,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2B,3500,4,366,225,,48.35,1,2.5,experimental,28.2514,0.2875,0.21,Ternary complex crystal structure of DNA polymerase Beta with A:C mismatch at the primer terminus
5J2C,X-RAY DIFFRACTION,2.31,46.81,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2C,3639,4,366,328,,48.38,1,2.1,experimental,29.7909,0.2655,0.2119,Ternary complex crystal structure of DNA polymerase Beta with C:A mismatch at the primer terminus
5J2D,X-RAY DIFFRACTION,2.3,46.62,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2D,3628,4,366,356,,48.36,1,2.1,experimental,26.1582,0.2557,0.2005,Ternary complex crystal structure of DNA polymerase Beta with C:C mismatch at the primer terminus
5J2E,X-RAY DIFFRACTION,2.31,46.75,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2E,3637,4,366,359,,48.41,1,2.1,experimental,26.4381,0.292,0.2392,Ternary complex crystal structure of DNA polymerase Beta with C:T mismatch at the primer terminus
5J2F,X-RAY DIFFRACTION,2.3,46.41,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2F,3649,4,366,365,,48.45,1,2.1,experimental,30.6364,0.2609,0.1977,Ternary complex crystal structure of DNA polymerase Beta with G:A mismatch at the primer terminus
5J2G,X-RAY DIFFRACTION,2.3,46.6,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2G,3616,4,366,333,,48.47,1,2.1,experimental,27.7782,0.2652,0.2062,Ternary complex crystal structure of DNA polymerase Beta with G:G mismatch at the primer terminus
5J2H,X-RAY DIFFRACTION,2.3,46.42,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2H,3572,4,366,273,,48.45,1,2.3,experimental,30.1557,0.2664,0.2051,Ternary complex crystal structure of DNA polymerase Beta with G:T mismatch at the primer terminus
5J2I,X-RAY DIFFRACTION,2.31,46.65,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2I,3505,4,366,234,,48.23,1,2.4,experimental,,0.2685,0.1821,Ternary complex crystal structure of DNA polymerase Beta with T:C mismatch at the primer terminus
5J2J,X-RAY DIFFRACTION,2.31,46.69,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2J,3684,4,366,385,,48.41,1,2.2,experimental,26.0554,0.2659,0.2008,Ternary complex crystal structure of DNA polymerase Beta with T:G mismatch at the primer terminus
5J2K,X-RAY DIFFRACTION,2.3,46.59,"VAPOR DIFFUSION, SITTING DROP",,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291,2016-03-29,2016-10-26,5J2K,3698,4,366,389,,48.39,1,2.1,experimental,27.986,0.2837,0.2204,Ternary complex crystal structure of DNA polymerase Beta with T:T mismatch at the primer terminus
7RBN,X-RAY DIFFRACTION,2.48,50.38,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBN,3155,4,373,5,,49.15,1,2.9,experimental,81.199,0.2679,0.2245,"Human DNA polymerase beta crosslinked complex, 20 min Ca to Mg exchange"
7RBO,X-RAY DIFFRACTION,2.46,49.98,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBO,3176,4,373,12,,49.12,1,2.96,experimental,71.55,0.2837,0.2481,"Human DNA polymerase beta crosslinked complex, 60 min Ca to Mg exchange"
5U8G,X-RAY DIFFRACTION,2.37,48.02,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 400, 30 mM potassium sodium tartrate, 1% 1,4-dioxane",291,2016-12-14,2017-04-26,5U8G,3373,4,366,266,,47.77,1,2.166,experimental,40.6452,0.2248,0.1793,DNA Polymerase Beta crystallized in PEG 400
5U8H,X-RAY DIFFRACTION,2.36,47.94,"VAPOR DIFFUSION, HANGING DROP",7.5,"22% PEG 400, 100 mM potassium sodium tartrate, 1% isopropanol",291,2016-12-14,2017-04-26,5U8H,3365,4,366,249,,47.8,1,2.155,experimental,37.5002,0.2338,0.1819,DNA Polymerase Beta G231D crystallized in PEG 400
5U8I,X-RAY DIFFRACTION,2.35,47.77,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 400, 30 mM potassium sodium tartrate, 1% 1,4-dioxane",291,2016-12-14,2017-04-26,5U8I,3173,4,366,89,,47.76,1,2.45,experimental,33.846,0.2306,0.1836,DNA Polymerase Beta S229L crystallized in PEG 400
8FAU,X-RAY DIFFRACTION,2.07,40.56,"VAPOR DIFFUSION, HANGING DROP",,2.6-3.0 M Ammonium sulfate in 50 mM Tris-Sulfate (pH 8),293,2022-11-28,2023-03-01,8FAU,2397,1,260,330,,29.64,1,1.44,experimental,19.61,0.2086,0.1756,Masking thiol reactivity with thioamide-based MBPs- carbonic anhydrase II complexed with 4-phenylthiazole-2(3H)-thione
5WNX,X-RAY DIFFRACTION,2.27,45.85,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, pH 7.5, 16% PEG3350 and 350 mM sodium acetate",295,2017-08-01,2017-09-13,5WNX,3244,4,366,7,,48.35,1,2.55,experimental,44.8,0.2895,0.206,DNA polymerase beta substrate complex with incoming 6-TdGTP
5WNY,X-RAY DIFFRACTION,2.29,46.31,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, pH 7.5, 16% PEG3350 and 350 mM sodium acetate",295,2017-08-01,2017-09-13,5WNY,3536,4,366,243,,48.45,1,2.1,experimental,35.9008,0.2372,0.1806,DNA polymerase beta substrate complex with incoming 5-FdUTP
5WNZ,X-RAY DIFFRACTION,2.3,46.51,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, pH 7.5, 16% PEG3350, and 350 mM sodium acetate.",295,2017-08-01,2017-09-13,5WNZ,3333,4,366,88,,48.36,1,2.2,experimental,43.4228,0.2541,0.1929,DNA polymerase beta substrate complex with incoming 5-FodCTP
5WO0,X-RAY DIFFRACTION,2.29,46.22,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, pH 7.5, 16% PEG3350 and 350 mM sodium acetate",295,2017-08-01,2017-09-13,5WO0,3659,4,366,354,,48.42,1,1.6,experimental,26.4991,0.2305,0.2001,DNA polymerase beta substrate complex with incoming 5-FodUTP
6DIA,X-RAY DIFFRACTION,2.5,50.83,"VAPOR DIFFUSION, SITTING DROP",8,"50 mM imidazole, 350 mM sodium chloride, 15% PEG3350, pH 8.0",291,2018-05-23,2019-01-30,6DIA,3615,4,366,375,,48.36,1,1.969,experimental,32.6009,0.2462,0.1964,DNA polymerase beta substrate complex with templating cytosine and incoming Fapy-dGTP analog
6DIC,X-RAY DIFFRACTION,2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",8,"50mM Imidazole, 350mM Sodium Acetate, 16% Peg3350",291,2018-05-23,2019-01-30,6DIC,3714,4,366,399,,48.45,1,1.992,experimental,28.8741,0.2317,0.1753,D276G DNA polymerase beta substrate complex with templating cytosine and incoming Fapy-dGTP analog
6E7F,X-RAY DIFFRACTION,3.05,65.17,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium citrate, pH 3.5, 0.8 M (NH4)2 SO4, 1 mM AMPPNP, 1 mM MnCl2, 0.73 mM Inositol (1,3,4,6)tetra phosphate (IP4)",298,2018-07-26,2018-11-07,6E7F,3923,2,556,72,,64.02,1,2.5,experimental,57,0.2803,0.2265,Crystal Structure of Human Inositol Polyphosphate Multikinase (IPMK) Catalytic Core Domain
5LL8,X-RAY DIFFRACTION,2.1,41.3,"VAPOR DIFFUSION, HANGING DROP",7.8,"2.0 uL of protein solution (10.5 mg/mL in 50 mM Tris pH=7.8) were mixed with 2.0 uL of the well solution (2.7 M (NH4)2SO4, 100 mM Tris, pH=7.8, saturated with PCMB) and placed as hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)2SO4, 100 mM Tris, pH=7.8, saturated with inhibitor) for 1 day.",291,2016-07-27,2017-08-16,5LL8,2477,1,265,285,,31.01,1,1.03,experimental,,0.1432,0.1204,Human Carbonic Anhydrase II in complex with aliphatic Benzenesulfonamide inhibitor.
7P41,X-RAY DIFFRACTION,2.45,49.79,VAPOR DIFFUSION,6.5,"100 mM bis-tris-propane, 5 mM sodium molybdate, 27.5 % PEG3350",291,2021-07-09,2021-08-18,7P41,4164,1,448,574,,51.39,1,1.6,experimental,28.6048,0.1863,0.16,Crystal Structure of human mARC1 A165T Variant
6PVA,X-RAY DIFFRACTION,2.31,46.85,"VAPOR DIFFUSION, HANGING DROP",,1.5 M lithium sulfate; 0.1 M sodium HEPES 7.5,293,2019-07-20,2020-08-19,6PVA,2001,2,247,154,,28.14,2,1.84,experimental,38.0236,0.2318,0.1958,The structure of NTMT1 in complex with compound 11
7KTF,X-RAY DIFFRACTION,2.5,50.76,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KTF,3531,4,374,423,,46.61,1,1.489,experimental,24.2053,0.1871,0.1674,"DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 50 mM Mg2+ (180min)"
5JN9,X-RAY DIFFRACTION,2.5,51.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AmSO4 and 16% PEG 3350",277,2016-04-29,2017-05-03,5JN9,9431,4,1064,915,8,124.01,1,2.1,experimental,29.55,0.22,0.17,Crystal structure for the complex of human carbonic anhydrase IV and ethoxyzolamide
5KU6,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AmSO4 and 23% PEG 4000",277,2016-07-12,2017-07-26,5KU6,9433,4,1064,915,8,124.07,1,1.8,experimental,22.503,0.21585,0.18416,Crystal structure for the complex of human carbonic anhydrase IV and methazolamide
8VM2,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, SITTING DROP",4.1,"PEG/Ion (containing 0.06 M Citric acid, 0.04 M BIS-TRIS propane)/pH 4.1, 16% w/v Polyethylene glycol 3350",298,2024-01-12,2024-05-01,8VM2,4818,3,570,419,,68.04,1,1.74,experimental,,0.2026,0.1721,Crystal Structure of NRAS Q61K bound to GTP
6I7L,X-RAY DIFFRACTION,4.95,75.19,"VAPOR DIFFUSION, SITTING DROP",,1.5 M Sodium Chloride; 10% Ethanol,293,2018-11-16,2019-09-25,6I7L,2937,1,343,184,,39.98,1,2.32,experimental,56.459,0.25095,0.21453,Crystal structure of monomeric FICD mutant L258D complexed with MgAMP-PNP
6FJJ,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.15,42.75,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.2 M sodium citrate, 100 mM Tris pH 8.5",293,2018-01-22,2019-02-06,6FJJ,2287,1,260,194,,29.45,1,"1.5, 2",experimental,,0.1657,0.1345,Joint neutron and x-ray crystal structure of human carbonic anhydrase IX mimic (saccharin).
,,,,,,,,,,,,,,,,,,,,,0.2305,0.2048,
8EMU,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",,2.6-3.0 M Ammonium sulfate in 50 mM Tris-Sulfate (pH 8),298,2022-09-28,2023-02-15,8EMU,2354,1,260,250,,30.19,1,1.13,experimental,13.56,0.2325,0.2147,Human Carbonic Anhydrase II Heterobifunctional Degraders
8R1I,X-RAY DIFFRACTION,2.07,40.53,"VAPOR DIFFUSION, SITTING DROP",,10 mg/mL hCAII with ligand (at 1:1 molar ratio) in 50 mM deuterated TRIS buffer and 2.7-3.0 M ammonium sulfate at pH 7.8-8.0,277,2023-11-02,2023-12-06,8R1I,2394,1,265,272,,30.24,1,1.46,experimental,,0.1917,0.168,Human Carbonic Anhydrase II (hCAII) in complex with (R)-N-(3-Indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide
6CFT,X-RAY DIFFRACTION,2.38,48.34,"VAPOR DIFFUSION, HANGING DROP",,"20% polyethylene glycol 3350, 0.15 M DL-malate, pH 7.0, 50 mM MgCl2, 0.05 M L-lysine and 8 mM  beta-mercaptoethanol",290,2018-02-17,2018-05-09,6CFT,2036,1,262,75,,29.74,1,2.43,experimental,,0.2757,0.2085,Structure of Human alpha-Phosphomannomutase 1 containing mutations R180T and R183I
4WZ3,X-RAY DIFFRACTION,2.46,49.97,"VAPOR DIFFUSION, HANGING DROP",8.5,"15 mg/ml of E2D2.(C85S)-Ub conjugate and an equimolar concentration of LubX (1-186), 0.2 M sodium tartrate, 0.1 M Tris-Cl (pH 8.5) and 25% PEG3350",298,2014-11-18,2015-01-07,4WZ3,2730,2,363,54,,41.61,2,2.7,experimental,,0.2228,0.1668,Crystal structure of the complex between LubX/LegU2/Lpp2887 U-box 1 and Homo sapiens UBE2D2
6CFV,X-RAY DIFFRACTION,2.45,49.79,"VAPOR DIFFUSION, HANGING DROP",,"20% polyethylene glycol 3350, 0.15 M DL-malate, pH 7.0, 50 mM MgCl2, and 8 mM beta-mercaptoethanol",290,2018-02-17,2018-05-09,6CFV,2281,1,262,287,,30.18,1,1.918,experimental,,0.2256,0.1723,Structure of Human alpha-Phosphomannomutase 1 in complex with Inosine Monophosphate
8TBI,X-RAY DIFFRACTION,2.34,47.46,"VAPOR DIFFUSION, SITTING DROP",8,"27% PEG4000, 0.1 M Tris-HCl, pH 8.0",291,2023-06-28,2024-02-07,8TBI,6201,4,678,738,,78.39,2,1.59,experimental,32.38,0.2078,0.1806,"Tricomplex of RMC-7977, NRAS WT, and CypA"
8CIJ,X-RAY DIFFRACTION,2.77,55.62,"VAPOR DIFFUSION, SITTING DROP",,"10 % PEG 4000, 120 mM NaCl, 01. M HEPES, pH = 7.75",293,2023-02-09,2023-08-16,8CIJ,2140,1,307,7,,34.88,1,2.821,experimental,97.68,0.266,0.2373,"CRYSTAL STRUCTURE OF HUMAN HPK1 (MAP4K1) COMPLEX WITH 2-[8-Amino-7-fluoro-6-(8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)-isoquinolin-3-ylamino]-6-isopropyl-5,6-dihydro-4H-1,6,8a-triaza-azulen-7-one"
7RBE,X-RAY DIFFRACTION,2.37,48.06,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",294,2021-07-06,2022-03-09,7RBE,3663,4,372,443,,49.31,1,1.89,experimental,28.592,0.2677,0.2164,Human DNA polymerase beta crosslinked binary complex - A
6D4F,X-RAY DIFFRACTION,2.63,53.32,"VAPOR DIFFUSION, HANGING DROP",8,"0.1 M imidazole pH 8.0, 0.2 M calcium acetate hydrate, 20% (w/v) polyethylene glycol 1000",292,2018-04-18,2018-10-17,6D4F,2389,1,279,140,,32.67,1,1.909,experimental,,0.225,0.19,Crystal structure of PTP epsilon D2 domain (A455N/V457Y/E597D)
8TBH,X-RAY DIFFRACTION,2.35,47.57,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG4000, 0.1 M imidazole, pH 8.0",291,2023-06-28,2024-02-07,8TBH,6026,4,672,588,,77.99,2,1.5,experimental,35.51,0.2251,0.1959,"Tricomplex of RMC-7977, KRAS G12R, and CypA"
8TBN,X-RAY DIFFRACTION,2.36,47.78,"VAPOR DIFFUSION, SITTING DROP",7,"22% PEG6000, 0.1 M imidazole, pH 7",291,2023-06-28,2024-02-07,8TBN,6218,4,672,746,,77.85,2,1.46,experimental,30.79,0.1966,0.1529,"Tricomplex of RMC-7977, KRAS G12S, and CypA"
6PKZ,X-RAY DIFFRACTION,2.36,47.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"14-23% PEG3400, 350 MM SODIUM ACETATE
 IN 50 MM IMIDAZOLE, PH 7.5, VAPOR DIFFUSION, SITTING DROP,
 TEMPERATURE 295K",298,2019-06-30,2020-07-01,6PKZ,3317,4,366,61,,48.24,1,2.74,experimental,,0.249,0.175,Structure of human DNA polymerase beta N279A complexed with 8OA in the template base paired with incoming non-hydrolyzable GTP
4RT2,X-RAY DIFFRACTION,2.23,44.73,VAPOR DIFFUSION,7.5,"16-18% PEG3350, pH 7.5, vapor diffusion, temperature 291K",291,2014-11-12,2015-07-01,4RT2,3659,4,366,387,,48.28,1,1.92,experimental,29.3692,0.2108,0.1764,"Ternary complex crystal structure of DNA polymerase Beta with (alpha,beta)-CH2-(beta,gamma)-NH-dTTP"
4RT3,X-RAY DIFFRACTION,2.24,45.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"50 mM Imidazole, pH 7.5, 350 mM Sodium Acetate, 18 % PEG3350, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-11-12,2015-07-01,4RT3,3602,4,366,328,,48.35,1,1.92,experimental,35.2626,0.2256,0.1798,"Ternary complex crystal structure of DNA polymerase Beta with (alpha, beta)-NH-(beta,gamma)-CH2-dTTP"
5VRW,X-RAY DIFFRACTION,2.23,44.91,"VAPOR DIFFUSION, HANGING DROP",,"50 mM imidizole pH 7-7.5, 350 mM sodium acetate, 16-18 % PEG 3350",293,2017-05-11,2017-07-19,5VRW,3324,4,372,48,,49.51,1,2.58,experimental,35.854,0.306,0.2342,Human DNA polymerase beta pre-catalytic 8-oxoG:dC extension complex with dTTP bound in non-planar conformation
5VS1,X-RAY DIFFRACTION,2.26,45.52,"VAPOR DIFFUSION, HANGING DROP",,"50 mM imidazole pH 7.0-7.5, 350 mM sodium acetate, 16-18% PEG 3350",293,2017-05-11,2017-07-19,5VS1,3297,4,372,50,,49.35,1,2.5,experimental,38.657,0.2721,0.2106,Human DNA polymerase beta pre-catalytic 8-oxoG:dA extension complex with dTTP bound in non-planar conformation
5VS2,X-RAY DIFFRACTION,2.28,46.12,"VAPOR DIFFUSION, HANGING DROP",,"50 mM imidazole pH 7.0-7.5, 350 mM sodium acetate, 16-18% PEG 3350",293,2017-05-11,2017-07-19,5VS2,3423,4,372,147,,49.21,1,2.33,experimental,25.526,0.2498,0.1874,Human DNA polymerase beta pre-catalytic 8-oxoG:dA extension complex with dTTP bound in Watson-Crick conformation
7K97,X-RAY DIFFRACTION,2.27,45.87,"VAPOR DIFFUSION, SITTING DROP",,"50 mM imidazole, 350 mM sodium acetate, 18% PEG3350",292,2020-09-28,2021-02-03,7K97,3362,4,358,56,,47.52,1,2.4,experimental,45.41,0.2397,0.1852,Human DNA polymerase beta dGDP product complex with Mn2+
7RBF,X-RAY DIFFRACTION,2.46,49.91,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBF,3653,4,372,384,,49.17,1,1.84,experimental,26.104,0.2083,0.1759,Human DNA polymerase beta crosslinked binary complex - B
7RBG,X-RAY DIFFRACTION,2.36,47.8,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBG,3542,4,372,266,,49.54,1,1.9,experimental,21.27,0.2225,0.1789,Human DNA polymerase beta crosslinked ternary complex 1
7RBH,X-RAY DIFFRACTION,2.24,45.15,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Citrate pH 5.5, 18% PEG6000",298,2021-07-06,2022-03-09,7RBH,3646,4,372,288,,49.89,1,1.75,experimental,32.189,0.2245,0.1793,Human DNA polymerase beta crosslinked ternary complex 2
7LAD,X-RAY DIFFRACTION,2.23,44.83,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2M ADA, 30% PEG 3350",293,2021-01-06,2021-10-27,7LAD,3528,1,481,4,,56.15,1,2.65,experimental,65.8,0.2783,0.2496,Clobetasol propionate bound to CYP3A5
5VZ8,X-RAY DIFFRACTION,2.51,50.96,"VAPOR DIFFUSION, HANGING DROP",7.5,"50mM HEPES pH 7.5, 10% PEG4K",293,2017-05-27,2017-07-05,5VZ8,3473,4,372,368,,46.27,1,1.601,experimental,,0.1936,0.1718,Post-catalytic complex of human Polymerase Mu (G433A) mutant with incoming UTP
7JUW,X-RAY DIFFRACTION,3.67,72.43,"VAPOR DIFFUSION, HANGING DROP",,"PEG 2000, MES pH 6.5, Magnesium Acetate",293,2020-08-20,2020-09-30,7JUW,4751,2,718,8,,82.78,2,2.88,experimental,,0.2859,0.2432,Crystal Structure of KSR1:MEK1 in complex with AMP-PNP
6I7J,X-RAY DIFFRACTION,4.07,69.77,"VAPOR DIFFUSION, SITTING DROP",8.5,0.1 M Tris pH 8.5; 2.0 M Ammonium Sulphate,293,2018-11-16,2019-09-25,6I7J,2951,1,343,70,,42.02,1,2.65,experimental,50.929,0.28281,0.22812,Crystal structure of monomeric FICD mutant L258D
6MKM,X-RAY DIFFRACTION,2.24,45.06,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 200 mM sodium chloride, 18-21% PEG4000",293,2018-09-25,2019-01-30,6MKM,2429,1,285,158,,32.41,1,1.673,experimental,24.53,0.2497,0.2046,Crystallographic solvent mapping analysis of DMSO/Tris bound to APE1
7F68,X-RAY DIFFRACTION,2.71,54.63,VAPOR DIFFUSION,,"0.2 M ammonium sulphate, 0.1 M sodium acetate pH 4.6, 23% PEG4000",297,2021-06-24,2022-06-29,7F68,1695,1,169,226,,19.92,1,1.24,experimental,24.178,0.1443,0.1226,Crystal structure of N-ras S89D
8GHO,X-RAY DIFFRACTION,2.25,45.28,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 200 mM Lithium Sulfate, bis-tris pH 5.5",291,2023-03-10,2023-08-30,8GHO,4460,6,522,537,6,57.44,3,1.6,experimental,32.66,0.217,0.197,GUCY2C-peptide bound to anti-GUCY2C-scFv antibody
8PPZ,X-RAY DIFFRACTION,2.55,51.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% PEG8000, 0.1 M HEPES pH 7.5, 0.2 M calcium actetate",293,2023-07-10,2023-08-09,8PPZ,1766,2,205,130,,24.39,2,1.85,experimental,29.647,0.2383,0.192,"Co-crystal structure of FKBP12, compound 7 and the FRB fragment of mTOR"
5OMP,X-RAY DIFFRACTION,3.07,59.94,"VAPOR DIFFUSION, SITTING DROP",6,"20 %w/v PEG MME 5K, 0.2 M NH4SO4, 0.1 M MES 6 pH",277,2017-08-01,2017-11-08,5OMP,3654,1,462,348,,51.99,1,1.88,experimental,57.66,0.247,0.198,Human FKBP5 protein
7JUR,X-RAY DIFFRACTION,4.73,73.98,"VAPOR DIFFUSION, HANGING DROP",6.5,"12% PEG-3350, 100 mM MES pH
6.25, 200 mM Magnesium Acetate",293,2020-08-20,2020-09-30,7JUR,4770,2,726,7,,84.54,2,2.82,experimental,,0.2774,0.237,"Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Trametinib"
8OKG,X-RAY DIFFRACTION,2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-28,2024-04-24,8OKG,2386,1,260,230,,29.65,1,1.45,experimental,19.829,0.18121,0.16824,Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor AKI_13
8OKJ,X-RAY DIFFRACTION,2.04,39.57,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-28,2024-04-10,8OKJ,2410,1,260,263,,29.66,1,1.4,experimental,12.614,0.1847,0.1628,Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor AKI_12
8OLA,X-RAY DIFFRACTION,2.06,40.41,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-30,2024-04-10,8OLA,2510,1,260,311,,29.66,1,1.4,experimental,13.209,0.17014,0.14633,Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor VK4
8OLI,X-RAY DIFFRACTION,2.07,40.47,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-30,2024-04-10,8OLI,2447,1,260,291,,29.75,1,1.4,experimental,12.87,0.19965,0.17729,Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI_12
8OLK,X-RAY DIFFRACTION,2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-30,2024-04-10,8OLK,2512,1,260,314,,29.8,1,1.27,experimental,16.484,0.16888,0.13594,Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI_13
8OMN,X-RAY DIFFRACTION,2.08,40.8,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-31,2024-04-10,8OMN,2420,1,260,263,,29.75,1,1.4,experimental,15.666,0.19003,0.16268,Carbonic Anhydrase II in Complex with Steriod_Sulphamoyl VK4
4PHE,X-RAY DIFFRACTION,2.42,49.18,"VAPOR DIFFUSION, SITTING DROP",,"14%?23% PEG3400, and 350 mM sodium acetate in 50 mM imidazole (pH 7.5)",298,2014-05-06,2015-05-06,4PHE,3388,4,360,146,,47.58,1,2.15,experimental,32.95,0.2608,0.2155,Structure of human DNA polymerase beta complexed with T in the template base paired with incoming non-hydrolyzable GTP
7KST,X-RAY DIFFRACTION,2.49,50.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-01,7KST,3519,4,374,377,,47.22,1,1.599,experimental,25.7713,0.1852,0.1635,"DNA Polymerase Mu, dGTP:Ct Reaction State Ternary Complex, 10 mM Mn2+ (2min)"
7KSU,X-RAY DIFFRACTION,2.49,50.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG 4000",277,2020-11-24,2022-01-19,7KSU,3380,4,374,301,,46.77,1,1.65,experimental,32.4157,0.1916,0.1731,"DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (4min)"
7KSW,X-RAY DIFFRACTION,2.51,50.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-01,7KSW,3666,4,374,428,,47,1,1.49,experimental,26.1433,0.1718,0.1544,"DNA Polymerase Mu, dGTP:Ct Reaction State Ternary Complex, 10 mM Mg2+ (10min)"
7KSX,X-RAY DIFFRACTION,2.5,50.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-01,7KSX,3452,4,374,358,,46.37,1,1.57,experimental,28.8059,0.186,0.1633,"DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mg2+ (30min)"
7KT4,X-RAY DIFFRACTION,2.51,50.92,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KT4,3448,4,374,335,,47.05,1,1.922,experimental,26.2696,0.2037,0.1664,"DNA Polymerase Mu, 8-oxodGTP:At Reaction State Ternary Complex, 10 mM Mn2+ (30min)"
7KT7,X-RAY DIFFRACTION,2.49,50.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KT7,3540,4,374,359,,47.13,1,1.76,experimental,25.4768,0.1865,0.1614,"DNA Polymerase Mu, 8-oxodGTP:At Reaction State Ternary Complex, 50 mM Mg2+ (60min)"
7KT8,X-RAY DIFFRACTION,2.5,50.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KT8,3342,4,374,293,,46.45,1,1.701,experimental,31.4606,0.1912,0.1682,"DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 50 mM Mg2+ (180min)"
7Q44,X-RAY DIFFRACTION,2.96,58.49,"VAPOR DIFFUSION, HANGING DROP",8,"20% PEG 3350
0.18M tris amonium citrate",293.15,2021-10-29,2022-11-16,7Q44,9139,6,1260,644,,133.55,2,2.20007772782,experimental,37.187308999,0.231046732051,0.182249275454,Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of deubiquitinase USP35
7RDS,X-RAY DIFFRACTION,3.32,62.96,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 5K MME, Sodium chloride, Tricine",291,2021-07-11,2021-12-29,7RDS,1925,1,257,115,,29.02,1,2.5,experimental,88.64,0.2445,0.1996,Structure of human NTHL1
7RDT,X-RAY DIFFRACTION,2.35,47.7,"VAPOR DIFFUSION, HANGING DROP",8.3,"PEG 6K, Sodium chloride, Tricine,",291,2021-07-11,2021-12-29,7RDT,1898,1,250,199,,28.28,1,2.1,experimental,29.49,0.2306,0.1812,Structure of human NTHL1 - linker 1 chimera
6D3F,X-RAY DIFFRACTION,2.45,49.78,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Bicine/Trizma base pH 8.5, 0.03 mM diethylene glycol, 0.03 M triethylene glycol, 0.03 M tetraethylne glycol, 0.03 M pentaethylene glycol, 10% (w/v) polyethylene glycol 4000, 20% (v/v) glycerol",292,2018-04-16,2018-10-17,6D3F,4549,2,558,198,,64.67,1,2.271,experimental,,0.2359,0.1729,Crystal Structure of the PTP epsilon D2 domain
5AN4,X-RAY DIFFRACTION,2.19,43.8,,,"0.1 M SODIUM CITRATE, PH=5.5, 0.2 M AMMONIUM SULFATE, 24 % PEG 3350",,2015-09-04,2016-04-13,5AN4,2586,1,312,157,,35.28,1,1.6,experimental,18.633,0.21427,0.18362,Crystal structure of the human 8-oxoguanine glycosylase (OGG1) processed with the CrystalDirect automated mounting and cryo-cooling technology
5HKW,X-RAY DIFFRACTION,3.36,63.39,"VAPOR DIFFUSION, SITTING DROP",,"20% (w/v) PEG 3350, 0.2M sodium citrate dibasic trihyrate",293,2016-01-14,2017-01-18,5HKW,7511,3,924,246,,107.18,1,2.25,experimental,52.2536,0.2338,0.1798,Crystal Structure of Apo c-Cbl TKBD Refined to 2.25 A Resolution
6PEA,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M NaCitrate, 50mM Tris",298,2019-06-20,2020-03-11,6PEA,2375,1,260,211,,29.41,1,1.36,experimental,18.8117,0.1643,0.1485,High Resolution Apo Carbonic Anhydrase II
8EXC,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, HANGING DROP",8,2.6-3.0 M Ammonium sulfate in 50 mM Tris-Sulfate (pH 8),293,2022-10-25,2023-02-22,8EXC,2350,1,260,235,,30.32,1,1.9,experimental,23.77,0.2267,0.1768,"Human Carbonic Anhydrase II bound tert-butyl (3-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propoxy)butoxy)propyl)carbamate"
8EXG,X-RAY DIFFRACTION,2.09,41.23,"VAPOR DIFFUSION, HANGING DROP",,2.6-3.0 M Ammonium sulfate in 50 mM Tris-Sulfate (pH 8),293,2022-10-25,2023-02-22,8EXG,2252,1,260,140,,30.28,1,1.99,experimental,20.67,0.2233,0.1872,"Human Carbonic Anhydrase II bound N-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)-4-sulfamoylbenzamide"
8EYL,X-RAY DIFFRACTION,2.03,39.37,"VAPOR DIFFUSION, HANGING DROP",,2.6-3.0 M Ammonium sulfate in 50 mM Tris-Sulfate (pH 8),293,2022-10-27,2023-02-22,8EYL,2343,1,260,219,,30.84,1,1.18,experimental,23.84,0.1932,0.1815,"Human Carbonic Anhydrase II with Tert-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamate"
5JN8,X-RAY DIFFRACTION,2.5,51.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AmSO4 and 21% PEG 4000",277,2016-04-29,2017-05-03,5JN8,9519,4,1064,962,8,124.52,1,1.85,experimental,22.215,0.22805,0.18473,Crystal Structure for the complex of human carbonic anhydrase IV and acetazolamide
7T9Z,X-RAY DIFFRACTION,2.09,41.03,"VAPOR DIFFUSION, HANGING DROP",6,"Purified holo-hOAT was buffer-exchanged into 100 mM MES, 200 mM NaCl, 100 uM PLP, pH 6.0 buffer, and then concentrated to ~6 mg/mL. The crystallization was performed via the hanging drop vapor diffusion method according to previously published conditions with 50 mM Tricine pH 7.8 substituted to 50 mM MES pH 6.0 buffer. The crystals grew at room temperature within three days and reached their maximum size in a week.",293,2021-12-20,2022-05-04,7T9Z,10079,3,1317,576,,146.52,1,2.15,experimental,23.88,0.2759,0.2656,Human Ornithine Aminotransferase (hOAT) crystallized at pH 6.0
7JUS,X-RAY DIFFRACTION,3.76,67.25,"VAPOR DIFFUSION, HANGING DROP",,"PEG 2000, MES, pH 6.5, Magnesium acetate",293,2020-08-20,2020-09-30,7JUS,4756,2,726,11,,84.46,2,2.99,experimental,,0.2649,0.2477,"Crystal Structure of KSR2:MEK1 in complex with AMP-PNP, and allosteric MEK inhibitor Cobimetinib"
4Q78,X-RAY DIFFRACTION,2.12,41.9,,,,,2014-04-24,2015-03-18,4Q78,2347,1,258,214,,30.02,1,1,experimental,10.679,0.2008,0.1746,Structure-assisted design of carborane-based inhibitors of carbonic anhydrase
9EU6,X-RAY DIFFRACTION,2.25,45.32,"VAPOR DIFFUSION, HANGING DROP",,"45% Pentaerythritol propoxylate 5/4 PO/OH, 15% ethanol",293,2024-03-27,2024-06-12,9EU6,2000,2,256,111,,28.54,1,1.54,experimental,24.975,0.2224,0.1931,The FK1 domain of FKBP51 in complex with SAFit-analog 23j
9EU7,X-RAY DIFFRACTION,1.9,35.2,"VAPOR DIFFUSION, HANGING DROP",,"14% PEG3350, 0.2M ammonium acetate, 0.1M HEPES-NaOH pH 7.5",293,2024-03-27,2024-06-12,9EU7,2014,2,256,69,,29.07,1,2.21,experimental,30.423,0.2738,0.1921,The FK1 domain of FKBP51 in complex with SAFit-analog 15b
9EU8,X-RAY DIFFRACTION,2.24,44.99,"VAPOR DIFFUSION, HANGING DROP",,"12% PEG3350, 0.2M ammonium acetate, 0.1M HEPES-NaOH pH 7.5",293,2024-03-27,2024-06-12,9EU8,1912,2,256,20,,29.07,1,2.3,experimental,54.53,0.2595,0.2328,The FK1 domain of FKBP51 in complex with SAFit-analog 15h
9EU9,X-RAY DIFFRACTION,2.4,48.79,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG3350, 0.2M ammonium acetate, 0.1M HEPES-NaOH pH 7.5",293,2024-03-27,2024-06-12,9EU9,2041,2,256,119,,29.11,1,1.8,experimental,36.181,0.2573,0.2197,The FK1 domain of FKBP51 in complex with SAFit-analog 15i
9EUA,X-RAY DIFFRACTION,2.42,49.17,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG3350, 0.2M ammonium thiocyanate, 0.1M HEPES-NaOH pH 7.5 10% ethylene glycol",293,2024-03-27,2024-06-12,9EUA,1860,2,256,9,,29.09,1,2.5,experimental,45.416,0.3042,0.2562,The FK1 domain of FKBP51 in complex with SAFit-analog 23d
9EUB,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG3350, 0.2M sodium thiocyanate, 0.1M HEPES-NaOH pH 7.5 10% ethylene glycol",293,2024-03-27,2024-06-12,9EUB,1889,2,256,38,,29.1,1,2,experimental,40.351,0.2772,0.2393,The FK1 domain of FKBP51 in complex with SAFit-analog 24e
9EUC,X-RAY DIFFRACTION,2.41,49.06,"VAPOR DIFFUSION, HANGING DROP",,"14% PEG3350, 0.2M sodium thiocyanate, 0.1M HEPES-NaOH pH 7.5 10% ethylene glycol",293,2024-03-27,2024-06-12,9EUC,1818,2,256,20,,29.06,1,2.4,experimental,46.746,0.2788,0.2505,The FK1 domain of FKBP51 in complex with SAFit-analog 23b
9EUD,X-RAY DIFFRACTION,2.3,46.51,"VAPOR DIFFUSION, HANGING DROP",,"14% PEG3350, 0.2M sodium thiocyanate, 0.1M HEPES-NaOH pH 7.5 10% ethylene glycol",293,2024-03-27,2024-06-12,9EUD,1850,2,256,25,,29.09,1,2.022,experimental,37.001,0.307,0.264,The FK1 domain of FKBP51 in complex with SAFit-analog 23c
9EUE,X-RAY DIFFRACTION,2.44,49.55,"VAPOR DIFFUSION, HANGING DROP",,"18% PEG3350, 0.2M ammonium acetate, 0.1M HEPES-NaOH pH 7.5 10% ethylene glycol",293,2024-03-27,2024-06-12,9EUE,2014,2,256,84,,29.04,1,2,experimental,40.664,0.2502,0.2117,The FK1 domain of FKBP51 in complex with SAFit-analog 23a
5TWP,X-RAY DIFFRACTION,2.52,51.2,"VAPOR DIFFUSION, SITTING DROP",7.5,"95mM HEPES pH 7.5, 19% PEG4K",294,2016-11-14,2017-07-05,5TWP,3266,4,371,274,,45.65,1,2.001,experimental,,0.2379,0.1852,Pre-catalytic ternary complex of human Polymerase Mu with incoming nonhydrolyzable UMPNPP
5TWR,X-RAY DIFFRACTION,2.82,56.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"57mM HEPES pH 7.5, 13.4% PEG4K",294,2016-11-14,2017-07-05,5TWR,3451,4,371,361,,45.92,1,1.9,experimental,,0.1943,0.1628,Pre-catalytic ternary complex of human Polymerase Mu (H329A) mutant with incoming nonhydrolyzable UMPNPP
5VZ7,X-RAY DIFFRACTION,2.51,51.01,"VAPOR DIFFUSION, HANGING DROP",7.5,"50mM HEPES pH 7.5, 10% PEG4K",293,2017-05-27,2017-07-05,5VZ7,3560,4,371,416,,45.87,1,1.551,experimental,,0.188,0.1701,Pre-catalytic ternary complex of human Polymerase Mu (G433A) mutant with incoming nonhydrolyzable UMPNPP
5VZ9,X-RAY DIFFRACTION,2.55,51.72,"VAPOR DIFFUSION, HANGING DROP",7.5,"50mM HEPES pH 7.5, 10% PEG4K",293,2017-05-27,2017-07-05,5VZ9,3527,4,372,448,,46.02,1,1.65,experimental,,0.1905,0.1604,Post-catalytic complex of human Polymerase Mu (G433A) mutant with incoming dTTP
5VZA,X-RAY DIFFRACTION,2.52,51.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"90mM HEPES pH 7.5, 18% PEG4K",293,2017-05-27,2017-07-05,5VZA,3607,4,371,437,,45.68,1,1.501,experimental,,0.1838,0.1688,Pre-catalytic ternary complex of human Polymerase Mu (G433S) mutant with incoming nonhydrolyzable UMPNPP
5VZB,X-RAY DIFFRACTION,2.5,50.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"90mM HEPES pH 7.5, 18% PEG4K",293,2017-05-27,2017-07-05,5VZB,3534,4,372,396,,46.08,1,1.5,experimental,,0.1874,0.1707,Post-catalytic complex of human Polymerase Mu (G433S) mutant with incoming UTP
5VZD,X-RAY DIFFRACTION,2.84,56.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"90mM HEPES pH 7.5, 18% PEG4K",293,2017-05-27,2017-07-05,5VZD,3545,4,371,387,,45.77,1,1.602,experimental,,0.1828,0.166,Pre-catalytic ternary complex of human Polymerase Mu (W434A) mutant with incoming nonhydrolyzable UMPNPP
5VZF,X-RAY DIFFRACTION,2.85,56.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"90mM HEPES pH 7.5, 18% PEG4K",293,2017-05-27,2017-07-05,5VZF,3530,4,372,412,,46.33,1,1.65,experimental,,0.1952,0.1694,Post-catalytic complex of human Polymerase Mu (W434A) mutant with incoming dTTP
5VZG,X-RAY DIFFRACTION,2.83,56.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"90mM HEPES pH 7.5, 18% PEG4K",293,2017-05-27,2017-07-05,5VZG,3380,4,371,309,,45.67,1,1.85,experimental,,0.2015,0.1754,Pre-catalytic ternary complex of human Polymerase Mu (W434H) mutant with incoming nonhydrolyzable UMPNPP
5VZH,X-RAY DIFFRACTION,2.81,56.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"90mM HEPES pH 7.5, 18% PEG4K",293,2017-05-27,2017-07-05,5VZH,3343,4,372,273,,45.99,1,1.95,experimental,,0.2108,0.1789,Post-catalytic complex of human Polymerase Mu (W434H) mutant with incoming UTP
5VZI,X-RAY DIFFRACTION,2.88,57.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"95mM HEPES, 19% PEG4K",293,2017-05-27,2017-07-05,5VZI,3600,4,372,456,,46.58,1,1.5,experimental,,0.1936,0.171,Post-catalytic complex of human Polymerase Mu (W434H) mutant with incoming dTTP
6E8P,X-RAY DIFFRACTION,2.17,43.33,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M NaCitrate
50mM Tris",298,2018-07-30,2019-04-03,6E8P,2203,1,257,87,,29.34,1,1.9,experimental,24.0514,0.1908,0.1484,CA IX mimic Complexed with Steroidal Sulfamate Compound STX 49
6E8X,X-RAY DIFFRACTION,2.17,43.25,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M NaCitrate
50mM Tris",298,2018-07-31,2019-03-27,6E8X,2270,1,257,94,,29.36,1,1.6,experimental,18.6405,0.1886,0.1663,CA IX mimic Complexed with Steroidal Sulfamate Compound STX 140
7DYU,X-RAY DIFFRACTION,2.36,47.85,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES sodium, 200mM magnesium chloride hexahydrate, 25% w/v PEG 3350, 1mM manganese chloride",277,2021-01-23,2022-02-02,7DYU,2180,1,235,182,,27.88,1,1.72,experimental,30.67,0.1946,0.1595,"Human JMJD5 in complex with MN and 5-((4-phenylbutyl)amino)pyridine-2,4-dicarboxylic acid."
6PGX,X-RAY DIFFRACTION,2.1,41.54,"VAPOR DIFFUSION, SITTING DROP",,"250 nL 7.5 mg/mL protein + 225 nL well solution (2.5-3.0 M ammonium sulfate, 100 mM Tris buffer, pH 8.0-8.5) + 25 nL microseeds",281,2019-06-25,2019-08-21,6PGX,2509,1,260,268,,31.3,1,1.36,experimental,13.65,0.15237,0.11781,Synthesis of novel tellurides bearing benzensulfonamide moiety as carbonic anhydrase inhibitors with antitumor activity
5BXJ,X-RAY DIFFRACTION,2.24,45.09,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 3350, 0.2 M Ammonium Acetate and 0.1 M HEPES pH 7.5",289,2015-06-09,2016-05-25,5BXJ,1123,1,129,137,,14.3,1,1.24,experimental,,0.2056,0.1771,Complex of the Fk1 domain mutant A19T of FKBP51 with 4-Nitrophenol
5OBK,X-RAY DIFFRACTION,2.32,47.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"30 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,2017-06-28,2018-04-04,5OBK,1358,1,128,263,,14.51,1,1,experimental,14.554,0.1356,0.119,"The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-(hydroxymethyl)-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one"
7A6X,X-RAY DIFFRACTION,1.78,30.88,"VAPOR DIFFUSION, HANGING DROP",7.5,"30% PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,2020-08-27,2021-03-17,7A6X,999,1,130,50,,14.99,1,1.67,experimental,17.831,0.1985,0.1505,Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 56
5JNA,X-RAY DIFFRACTION,2.5,51.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AmSO4 and 21% PEG 4000",277,2016-04-29,2017-05-03,5JNA,9442,4,1064,888,8,124.3,1,2,experimental,27.743,0.21835,0.17223,Crystal structure for the complex of human carbonic anhydrase IV and topiramate
5VRX,X-RAY DIFFRACTION,2.27,45.91,"VAPOR DIFFUSION, HANGING DROP",,"50 mM imidazole pH 7.0-7.5, 350 mM sodium acetate, 16-18% PEG 3350",293,2017-05-11,2017-07-19,5VRX,3427,4,372,136,,49.45,1,2.2,experimental,32.456,0.26,0.1869,Human DNA polymerase beta pre-catalytic 8-oxoG:dC extension complex with dTTP bound in Watson-Crick conformation
5C6D,X-RAY DIFFRACTION,2.56,51.92,"VAPOR DIFFUSION, HANGING DROP",9,"100 mM CHES (pH 9.0), 20% PEG8000",293,2015-06-22,2015-09-09,5C6D,5165,4,710,118,,81.49,2,2.292,experimental,,0.2337,0.1858,Crystal structure of USP7 in complex with UHRF1
7MHE,X-RAY DIFFRACTION,1.73,28.92,"VAPOR DIFFUSION, SITTING DROP",,"0.3 uL of 8 mg/ml FAS-TE in 100 mM NaCl, 50 mM BisTris pH 6.0, 10 mM DTT, 0.5 mM of the inhibitor and 1% DMSO was mixed with 0.2 uL of well solution 10% PEG400, 50 mM Tris-Cl pH 8.5, 1.0 mM DTT, 1.0 mM Ethylenediaminetetraacetic acid disodium salt (EDTA), 300 mM NaCl.",293,2021-04-15,2022-04-20,7MHE,2211,1,298,15,,32.99,1,2.8,experimental,59.85,0.2836,0.2132,Thioesterase Domain of Human Fatty Acid Synthase (FASN-TE) binding a competitive inhibitor SBP-7957
6MK3,X-RAY DIFFRACTION,2.27,45.77,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 200 mM sodium chloride, 18-21% PEG4000",293,2018-09-24,2019-01-30,6MK3,2548,1,285,252,,32.35,1,1.478,experimental,21.43,0.2186,0.1908,Crystallographic solvent mapping analysis of DMSO bound to APE1
6MKK,X-RAY DIFFRACTION,2.34,47.42,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 200 mM sodium chloride, 18-21% PEG4000",293,2018-09-25,2019-01-30,6MKK,2551,1,285,261,,32.3,1,1.442,experimental,19.48,0.2121,0.1828,Crystallographic solvent mapping analysis of DMSO/Mg bound to APE1
5CFG,X-RAY DIFFRACTION,2.36,47.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 8000, 0.2 M MgAc and 0.1 M Cacodylate",295,2015-07-08,2016-07-06,5CFG,2345,1,275,152,1,31.14,1,1.8,experimental,29.63,0.2041,0.1846,C2 crystal form of APE1 with Mg2+
7AWX,X-RAY DIFFRACTION,2.25,45.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"40% PEG3350 
0.1 M HEPES-NaOH pH 7.5
0.2M ammonium thiocyanate",293,2020-11-09,2021-03-17,7AWX,1931,2,256,11,,29.41,1,2.2,experimental,53.947,0.303,0.2327,Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 55
6TX4,X-RAY DIFFRACTION,2.33,47.25,"VAPOR DIFFUSION, HANGING DROP",7.5,"28-41% PEG3350, 0.2 M NH4OAc, 0.1 M HEPES",293.15,2020-01-13,2020-05-27,6TX4,1359,1,128,218,,14.3,1,1.06,experimental,15.94,0.1298,0.1131,CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH 2-PYRIDONE
6TX5,X-RAY DIFFRACTION,2.32,46.87,"VAPOR DIFFUSION, HANGING DROP",7.5,"28-41% PEG3350, 0.2M NH4OAc, 0.1M HEPES",293.15,2020-01-13,2020-05-27,6TX5,1333,1,128,192,,14.15,1,1.08,experimental,15.76,0.1392,0.122,CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH 4-METHYLIMIDAZOLE
6TX7,X-RAY DIFFRACTION,2.33,47.32,"VAPOR DIFFUSION, HANGING DROP",7.5,"28-41% PEG3350, 0.2 M NH4OAc, 0.1 M HEPES",293.15,2020-01-13,2020-05-27,6TX7,1302,1,128,172,,14.31,1,1.13,experimental,18.8,0.1522,0.1273,CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH 2-PIPERIDONE
6TX9,X-RAY DIFFRACTION,2.32,47.07,"VAPOR DIFFUSION, HANGING DROP",7.5,"28-41% PEG3350, 0.2 M NH4OAc, 0.1 M HEPES",293.15,2020-01-13,2020-05-27,6TX9,1340,1,128,202,,14.17,1,1.42,experimental,20.96,0.187,0.162,CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH HYDANTOIN
7ETT,X-RAY DIFFRACTION,2.21,44.45,"VAPOR DIFFUSION, HANGING DROP",,"30%-36% PEG 3350, 0.2 M Ammonium Acetate and 0.1 M HEPES pH 7.5",298,2021-05-14,2022-02-23,7ETT,1082,2,133,83,,14.66,2,1.5,experimental,15.927,0.1977,0.185,The FK1 domain of FKBP51 in complex with peptide-inhibitor hit QFPFV
7ETU,X-RAY DIFFRACTION,2.22,44.54,"VAPOR DIFFUSION, HANGING DROP",,"30%-36% PEG 3350, 0.2 M Ammonium Acetate and 0.1 M HEPES pH 7.5",298,2021-05-14,2022-02-23,7ETU,1183,2,133,187,,14.62,2,1.39,experimental,10.95,0.1955,0.1686,The FK1 domain of FKBP51 in complex with peptide-inhibitor hit SFPFT
7ETV,X-RAY DIFFRACTION,2.2,44.21,"VAPOR DIFFUSION, HANGING DROP",,"30%-36% PEG 3350, 0.2 M Ammonium Acetate and 0.1 M HEPES pH 7.5",298,2021-05-14,2022-02-23,7ETV,1195,2,134,181,,14.78,2,1.31,experimental,10.744,0.1895,0.1712,The FK1 domain of FKBP51 in complex with peptide-inhibitor hit DFPFV
8CHP,X-RAY DIFFRACTION,2.32,46.97,"VAPOR DIFFUSION, HANGING DROP",,"32% PEG3350, 0.2 M ammonium acetate, 0.1M HEPES-NaOH pH 7.5",293,2023-02-08,2023-09-06,8CHP,1224,1,128,207,,14.47,1,1,experimental,9.241,0.1871,0.1751,"The FK1 domain of FKBP51 in complex with (1S,5S,6R)-10-((S)-(3,5-dichlorophenyl)sulfinyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one"
8CHQ,X-RAY DIFFRACTION,2.34,47.45,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG3350, 0.2 M ammonium acetate, 0.1M HEPES-NaOH pH 7.5",293,2023-02-08,2023-09-06,8CHQ,1227,1,128,224,,14.5,1,1.01,experimental,11.947,0.1661,0.149,"The FK1 domain of FKBP51 in complex with (1S,5S,6R)-10-((S)-3,5-dichloro-N-methylphenylsulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one"
8CHR,X-RAY DIFFRACTION,2.28,46.15,"VAPOR DIFFUSION, HANGING DROP",,"32% PEG3350, 0.2 M ammonium acetate, 0.1M HEPES-NaOH pH 7.5",293,2023-02-08,2023-09-06,8CHR,1183,1,128,190,,14.48,1,1.1,experimental,13.353,0.1923,0.1594,"The FK1 domain of FKBP51 in complex with (1S,5S,6R)-10-((R)-(3,5-dichlorophenyl)sulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one"
6RLW,X-RAY DIFFRACTION,2.3,46.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.12 M Alcohols, 0.1 M Buffer System 2 pH 7.5, 48 % v/v Precipitant Mix from 4 Morpheus screen (Molecular Dimensions)",294,2019-05-03,2020-07-22,6RLW,13184,5,1685,771,,192.32,1,2,experimental,41.301,0.2741,0.2225,Structure of the human 8-oxoguanine DNA Glycosylase hOGG1 in complex with inhibitor TH5487
8ZWV,X-RAY DIFFRACTION,1.94,36.63,"VAPOR DIFFUSION, SITTING DROP",,"0.2M CaCl2, 0.1M Hepes pH7.5, 30% PEG4,000",293,2024-06-13,2024-07-03,8ZWV,2372,1,261,244,,29.69,1,1.5,experimental,16.999,0.1874,0.1523,The Crystal Structure of carbonic anhydrase II from Biortus.
7LO0,X-RAY DIFFRACTION,3.25,62.2,"VAPOR DIFFUSION, HANGING DROP",5.6,"18% PEG3350, 0.2 M of trisodium citrate, pH 5.6 and 2% Octyl-D-glucose",293,2021-02-08,2022-02-16,7LO0,11548,24,1592,166,,182.64,2,2.71,experimental,63.0621,0.2256,0.213,Structure of human ASF1a in complex with a TLK2 peptide
4WNH,X-RAY DIFFRACTION,2.42,49.13,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Li2SO4, 0.1 M Bis-Tris, pH 6.5, and 21% PEG3350",293,2014-10-11,2015-09-30,4WNH,2841,2,356,88,5,41.91,2,1.95,experimental,33.55,0.22448,0.1927,"Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese,acceptor ligand and UDP-Xylose"
6HNO,X-RAY DIFFRACTION,2.57,52.14,"VAPOR DIFFUSION, SITTING DROP",7,PEG 6000 20%; Hepes 0.1 M pH 7.00; DMSO 5%,291,2018-09-17,2019-07-31,6HNO,2094,1,274,192,,29.27,1,1.68,experimental,,0.205,0.1681,17beta-hydroxysteroid dehydrogenase 14 variant S205 - mutant H93A
7KTE,X-RAY DIFFRACTION,2.5,50.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KTE,3751,4,374,460,,47.23,1,1.479,experimental,23.8562,0.1774,0.1568,"DNA Polymerase Mu, 8-oxodGTP:Ct Reaction State Ternary Complex, 50 mM Mg2+ (90min)"
8WIK,X-RAY DIFFRACTION,2.93,58.05,"VAPOR DIFFUSION, HANGING DROP",,"HEPES , MgCl2, PEG3350",291,2023-09-24,2024-05-08,8WIK,3083,1,373,197,,42.04,1,2,experimental,35.59,0.2627,0.2245,Crystal structure of human FSP1
5WN5,X-RAY DIFFRACTION,2.65,53.57,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2017-07-31,2018-02-28,5WN5,5405,5,594,159,,75.46,1,2.2,experimental,54.69,0.261,0.226,APE1 exonuclease substrate complex with a C/T mismatch and Mn2+
6W0Q,X-RAY DIFFRACTION,2.59,52.55,"VAPOR DIFFUSION, SITTING DROP",5,"10% PEG20000, 100 mM sodium citrate, pH 5.0, and 200 mM MgCl2",291,2020-03-02,2020-06-10,6W0Q,5697,5,594,451,,75.52,1,1.89,experimental,29.92,0.2229,0.186,APE1 endonuclease product complex D148E
6W2P,X-RAY DIFFRACTION,2.57,52.12,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG20000, 100 mM sodium citrate, pH 5.0, and 200 mM MgCl2",291,2020-03-06,2020-06-10,6W2P,5624,5,594,400,,75.31,1,1.94,experimental,31.98,0.2376,0.2008,APE1 endonuclease product complex L104R
6W43,X-RAY DIFFRACTION,2.6,52.65,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG20000, 100 mM sodium citrate, pH 5.0, and 200 mM MgCl2",291,2020-03-10,2020-06-10,6W43,5638,5,594,429,,75.42,1,1.99,experimental,33.19,0.2244,0.1829,APE1 AP-endonuclease product complex R237C
6QE3,X-RAY DIFFRACTION,2.53,51.31,"VAPOR DIFFUSION, SITTING DROP",6,"0.1 M MES, 20% PEG3350",293,2019-01-04,2019-03-13,6QE3,2477,1,309,129,,33.28,1,1.75,experimental,,0.1971,0.1746,Re-refinement of 6ESR human IBA57 at 1.75 A resolution
7AYY,X-RAY DIFFRACTION,2.27,45.8,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.12 M Alcohols, 0.1 M Buffer System 2 pH 7.5 and 48 % v/v Precipitant Mix 4 (Morpheus screen, Molecular Dimensions)",293.15,2020-11-13,2022-06-01,7AYY,13010,5,1685,704,,191.72,1,2,experimental,27.778,0.2503,0.207,Structure of the human 8-oxoguanine DNA Glycosylase hOGG1 in complex with activator TH10785
8TBJ,X-RAY DIFFRACTION,2.27,45.9,"VAPOR DIFFUSION, SITTING DROP",8,"24% PEG4000, 0.1 M Tris-HCl, pH 8.0",291,2023-06-28,2024-02-07,8TBJ,6264,4,672,752,,77.97,2,1.45,experimental,24.95,0.2155,0.1853,"Tricomplex of RMC-7977, KRAS G12A, and CypA"
8TBM,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, SITTING DROP",7,"24% PEG6000, 0.1 M imidazole, pH 7",291,2023-06-28,2024-02-07,8TBM,6070,4,672,630,,77.96,2,1.57,experimental,30.24,0.2107,0.1782,"Tricomplex of RMC-7977, KRAS G12V, and CypA"
6P93,X-RAY DIFFRACTION,2.54,51.58,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG20000, 100 mM sodium citrate, pH 5.0, and 200 mM MgCl2",291,2019-06-09,2020-01-01,6P93,5481,5,594,292,,75.41,1,2.1,experimental,29.093,0.2262,0.1719,Human APE1 K98A AP-endonuclease product complex
6P94,X-RAY DIFFRACTION,2.47,50.16,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG20000, 100 mM sodium citrate, pH 5.0, and 200 mM MgCl2",291,2019-06-09,2020-01-01,6P94,5484,5,594,290,,75.46,1,2.09,experimental,,0.2445,0.1862,Human APE1 C65A AP-endonuclease product complex
6D4D,X-RAY DIFFRACTION,2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris-HCl pH 8.5, 0.2 M sodium chloride, 22% (w/v) polyethylene glycol 3350",292,2018-04-18,2018-10-17,6D4D,5106,2,584,532,2,67.83,1,1.765,experimental,,0.2223,0.1782,Crystal structure of the PTP epsilon D1 domain
6WFV,X-RAY DIFFRACTION,2.85,56.85,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M magnesium chloride, 30% PEG 400, 0.1 M HEPES, pH 7.5. Additive: 0.002 M manganese chloride, 0.01 M UDP-Galactose",277,2020-04-04,2021-04-14,6WFV,2191,1,247,229,,28.96,1,1.7,experimental,34.1078,0.1722,0.1516,The crystal structure of a collagen galactosylhydroxylysyl glucosyltransferase from human
,,,,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M magnesium chloride, 30% PEG 400, 0.1 M HEPES, pH 7.5. Additive: 0.002 M manganese chloride, 0.01 M UDP-Galactose, crystal soaked in higher Mn and UDP-Glc prior to flash cooling.",277,,,,,,,,,,,,,,,,
,,,,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M magnesium chloride, 30% PEG 400, 0.1 M HEPES, pH 7.5. Additive: 0.002 M manganese chloride, 0.01 M UDP-Galactose. Crystal soaked in 1 M NaI prior to flash cooling",277,,,,,,,,,,,,,,,,
6MKO,X-RAY DIFFRACTION,2.26,45.61,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 200 mM sodium chloride, 18-21% PEG4000",293,2018-09-25,2019-01-30,6MKO,2376,1,285,141,,32.2,1,2.09,experimental,21.3212,0.2279,0.1758,Crystallographic solvent mapping analysis of glycerol bound to APE1
5WN0,X-RAY DIFFRACTION,2.6,52.7,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2017-07-31,2018-02-28,5WN0,5216,5,594,69,,75.16,1,2.6,experimental,46.33,0.2749,0.2169,APE1 exonuclease substrate complex with a C/G match
5WN1,X-RAY DIFFRACTION,2.6,52.78,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2017-07-31,2018-02-28,5WN1,5358,5,593,165,,74.96,1,2.3,experimental,47.8056,0.27,0.2127,APE1 exonuclease product complex
5WN2,X-RAY DIFFRACTION,2.62,53.13,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2017-07-31,2018-02-28,5WN2,5519,5,593,243,,75.35,1,2.288,experimental,36.6578,0.2395,0.1891,APE1 exonuclease substrate complex with phosphoglycolate
5WN3,X-RAY DIFFRACTION,2.68,54.13,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2017-07-31,2018-02-28,5WN3,5597,5,594,243,,75.42,1,2,experimental,41.79,0.258,0.21,APE1 F266A exonuclease substrate complex with a C/T mismatch
5WN4,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2017-07-31,2018-02-28,5WN4,5528,5,594,182,,75.42,1,2.1,experimental,51.3,0.249,0.204,APE1 exonuclease substrate complex with a C/T mismatch
6W3L,X-RAY DIFFRACTION,2.65,53.55,"VAPOR DIFFUSION, SITTING DROP",,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2020-03-09,2020-06-10,6W3L,5363,5,594,100,,75.36,1,2.59,experimental,61.25,0.277,0.217,APE1 exonuclease substrate complex wild-type
6W3N,X-RAY DIFFRACTION,2.66,53.75,"VAPOR DIFFUSION, SITTING DROP",,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2020-03-09,2020-06-10,6W3N,5251,5,594,42,,75.34,1,2.69,experimental,57.64,0.3084,0.2491,APE1 exonuclease substrate complex D148E
6W3Q,X-RAY DIFFRACTION,2.73,54.86,"VAPOR DIFFUSION, SITTING DROP",,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2020-03-09,2020-06-10,6W3Q,5284,5,594,27,,75.36,1,2.49,experimental,75.43,0.2593,0.2216,APE1 exonuclease substrate complex L104R
6W3U,X-RAY DIFFRACTION,2.67,53.95,"VAPOR DIFFUSION, SITTING DROP",,"7% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",291,2020-03-09,2020-06-10,6W3U,5408,5,595,154,,75.33,1,2.4,experimental,51.39,0.25,0.184,APE1 exonuclease substrate complex R237C
5DIT,X-RAY DIFFRACTION,2.4,48.74,"VAPOR DIFFUSION, HANGING DROP",7.5,"22 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,2015-09-01,2015-10-14,5DIT,1090,1,128,55,,14.71,1,2.25,experimental,39.584,0.2841,0.2111,"The Fk1 domain of FKBP51 in complex with the new synthetic ligand (1R)-3-(3,4-dimethoxyphenyl)-1-f3-[2-(morpholin-4-yl)ethoxy]phenylgpropyl(2S)-1-[(2S,3R)-2-cyclohexyl-3-hydroxybutanoyl]piperidine-2-carboxylate"
5DIU,X-RAY DIFFRACTION,2.21,44.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"10 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,2015-09-01,2016-03-23,5DIU,1232,1,128,141,,14.77,1,1.3,experimental,21.323,0.1852,0.1441,"The Fk1 domain of FKBP51 in complex with the new synthetic ligand 2-(3-((R)-1-((S)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxamido)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid"
5DIV,X-RAY DIFFRACTION,3.54,65.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"16 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,2015-09-01,2016-03-23,5DIV,1067,1,127,63,,14.43,1,1.65,experimental,26.366,0.2967,0.2608,"The Fk1 domain of FKBP51 in complex with the new synthetic ligand (S)-N-(1-carbamoylcyclopentyl)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxamide"
6SAF,X-RAY DIFFRACTION,2.4,48.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"28 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,2019-07-16,2019-12-18,6SAF,1096,1,128,67,,14.72,1,2.05,experimental,48.131,0.2731,0.1903,"The Fk1 domain of FKBP51 in complex with (S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-((1R,4aR,8aR)-4-oxodecahydronaphthalene-1-carbonyl)piperidine-2-carboxylate"
5TYX,X-RAY DIFFRACTION,2.68,54.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-21,2017-08-30,5TYX,3452,4,374,354,,46.49,1,1.948,experimental,30.734,0.2161,0.1854,"DNA Polymerase Mu Product Complex, Mn2+ (15 min)"
7KTL,X-RAY DIFFRACTION,2.44,49.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KTL,3522,4,374,407,,46.67,1,1.421,experimental,26.2035,0.1738,0.1584,"DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Product State Ternary Complex, 50 mM Mn2+ (90min)"
7KTM,X-RAY DIFFRACTION,2.45,49.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KTM,3570,4,374,391,,47.22,1,1.528,experimental,27.3935,0.1805,0.1604,"DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Reaction State Ternary Complex, 50 mM Mn2+ (30min)"
6NM0,X-RAY DIFFRACTION,2.13,42.31,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sodium citrate, 50 mM Tris-HCl, pH 7.8",298,2019-01-10,2020-01-15,6NM0,2261,1,257,148,,29.52,1,1.44,experimental,17.4209,0.1803,0.1663,"Selective inhibition of carbonic anhydrase IX activity, using compound SLC-149, displays limited anticancer effects in breast cancer cell lines"
8TBF,X-RAY DIFFRACTION,2.33,47.15,"VAPOR DIFFUSION, SITTING DROP",8,"24% PEG4000, 0.1 M Tris-HCl, pH 8.0",291,2023-06-28,2024-02-07,8TBF,6458,4,672,939,,77.85,2,1.5,experimental,25.56,0.2104,0.1778,"Tricomplex of RMC-7977, KRAS WT, and CypA"
7N8S,X-RAY DIFFRACTION,3.84,67.97,EVAPORATION,4.5,0.2M NH4 CH3 CO2; 15% PEG 4000,298,2021-06-15,2021-10-13,7N8S,2527,3,268,,1,36.25,1,2.79,experimental,64.29,0.3218,0.2635,LINE-1 endonuclease domain complex with DNA
5GOF,X-RAY DIFFRACTION,2.74,55.11,"VAPOR DIFFUSION, HANGING DROP",,"1mM ZnCl2, 100mM Tris-HCl (pH 8.0~9.0), 15~16% PEG 3350, 10~15% glycerol",293,2016-07-26,2017-01-25,5GOF,3685,1,422,427,,48.43,1,1.604,experimental,,0.2145,0.1793,"Truncated mitofusin-1, GTP-bound"
7TGT,X-RAY DIFFRACTION,2.46,50,"VAPOR DIFFUSION, HANGING DROP",7.3,"29% PEG 3350
0.5 M KH2PO4
Protein and inhibitor were mixed in ratio 1:1.5
1 uL of protein:inhibitor complex was mixed with 1 uL mother liquor",298,2022-01-09,2022-08-24,7TGT,1570,1,164,256,,18.44,1,1.06,experimental,12.17,0.1447,0.1364,Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor A26
7TGU,X-RAY DIFFRACTION,2.17,43.4,"VAPOR DIFFUSION, HANGING DROP",7.3,"23% PEG 3350
0.5 M KH2PO4
Protein and inhibitor were mixed in ratio 1:3
1 uL of protein:inhibitor complex was mixed with 1 uL mother liquor",298,2022-01-09,2022-08-24,7TGU,1461,1,164,127,,18.55,1,1.21,experimental,15.3,0.1604,0.1513,Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B1
7TGV,X-RAY DIFFRACTION,2.44,49.6,"VAPOR DIFFUSION, HANGING DROP",7.3,"28% PEG 3350
0.5 M KH2PO4
Protein and inhibitor were mixed in ratio 1:3
1 uL of protein:inhibitor complex was mixed with 1 uL mother liquor",298,2022-01-09,2022-08-24,7TGV,1454,1,164,112,,18.51,1,1.46,experimental,12.06,0.1786,0.1654,Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B2
7TH1,X-RAY DIFFRACTION,2.19,43.9,"VAPOR DIFFUSION, HANGING DROP",7.3,"28% PEG 3350
0.5 M KH2PO4
Protein and inhibitor were mixed in ratio 1:3
1 uL of protein:inhibitor complex was mixed with 1 uL mother liquor",298,2022-01-10,2022-08-24,7TH1,1524,1,165,191,,18.57,1,1.52,experimental,18.44,0.1886,0.169,Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B3
7TH7,X-RAY DIFFRACTION,2.47,51.59,"VAPOR DIFFUSION, HANGING DROP",8.2,"21% PEG 3350
0.5 M KH2PO4
Protein and inhibitor were mixed in ratio 1:3
1 uL of protein:inhibitor complex was mixed with 1 uL mother liquor",298,2022-01-10,2022-08-24,7TH7,1557,1,163,220,,18.53,1,1.3,experimental,12.77,0.1473,0.135,Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B23
7THC,X-RAY DIFFRACTION,2.56,51.98,"VAPOR DIFFUSION, HANGING DROP",8,"13% PEG 3350
0.5 M KH2PO4
7.5% glycerol
Protein and inhibitor were mixed in ratio 1:2
1 uL of protein:inhibitor complex was mixed with 1 uL mother liquor",298,2022-01-10,2022-08-24,7THC,1555,1,163,243,,18.52,1,1.57,experimental,13.25,0.1635,0.1339,Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B25
7THD,X-RAY DIFFRACTION,2.39,48.6,"VAPOR DIFFUSION, HANGING DROP",6,"15% PEG 3350
0.5 M KH2PO4
1 mM NaCl
Protein and inhibitor were mixed in ratio 1:2
1 uL of protein:inhibitor complex was mixed with 1 uL mother liquor",298,2022-01-10,2022-08-24,7THD,1478,1,163,163,,18.57,1,1.16,experimental,12.43,0.1516,0.1357,Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B52
7THF,X-RAY DIFFRACTION,2.38,48.3,"VAPOR DIFFUSION, HANGING DROP",6,"22.5% PEG 3350
0.5 M KH2PO4
1 mM NaCl
Protein and inhibitor were mixed in ratio 1:2
1 uL of protein:inhibitor complex was mixed with 1 uL mother liquor",298,2022-01-10,2022-08-24,7THF,1556,1,164,212,,18.64,1,1.1,experimental,12.37,0.1477,0.1369,Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor B53
6TXX,X-RAY DIFFRACTION,2.24,45.16,"VAPOR DIFFUSION, HANGING DROP",,"28-43% PEG3350, 0.2M NH4OAc, 0.1M HEPES",293.15,2020-01-14,2020-05-27,6TXX,2335,2,256,283,,28.85,1,2.1,experimental,29.62,0.2479,0.1897,CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH SAFit2
7CJX,X-RAY DIFFRACTION,2.49,50.53,"VAPOR DIFFUSION, SITTING DROP",,"18% PEG 6000, 0.2M Na-Tartrate, 0.2M KCl, 2% glycerol",298,2020-07-14,2021-07-14,7CJX,5157,4,664,11,,73.72,1,1.98641400743,experimental,37.3560036169,0.258794832993,0.232779673254,UDP-glucuronosyltransferase 2B15 C-terminal domain-L446S
6HYJ,X-RAY DIFFRACTION,2.46,50.09,"VAPOR DIFFUSION, HANGING DROP",6.5,CaCl2 0.15 M; sodium cacodylate 0.1 M pH 6.5; PEG 2000 20%,293,2018-10-22,2019-06-12,6HYJ,3678,2,448,185,,50.4,1,1.929,experimental,48.8391,0.2634,0.1998,PSPH Human phosphoserine phosphatase
5DG0,X-RAY DIFFRACTION,2.56,52.03,"VAPOR DIFFUSION, SITTING DROP",5,"10% Peg 20000, 100 mM sodium citrate, 200 mM MgCl2",291,2015-08-27,2015-10-14,5DG0,5715,4,594,470,,75.97,1,1.8,experimental,,0.205,0.166,Human APE1 phosphorothioate substrate complex with Mn2+
5GPG,X-RAY DIFFRACTION,2.47,50.2,"VAPOR DIFFUSION, HANGING DROP",6.5,"30% polyethyleneglycol 8000, 100mM sodium cacodylate, 200mM sodium acetate, 10mM manganese chloride",293,2016-08-02,2016-10-12,5GPG,2009,2,210,288,,25.31,2,1.67,experimental,,0.212,0.174,"Co-crystal structure of the FK506 binding domain of human FKBP25, Rapamycin and the FRB domain of human mTOR"
5VZC,X-RAY DIFFRACTION,2.53,51.39,"VAPOR DIFFUSION, SITTING DROP",7.5,"90mM HEPES pH 7.5, 18% PEG4K",293,2017-05-27,2017-07-05,5VZC,3523,4,372,451,,46.25,1,1.552,experimental,,0.1902,0.1654,Post-catalytic complex of human Polymerase Mu (G433S) mutant with incoming dTTP
8ER6,X-RAY DIFFRACTION,4.11,70.09,"VAPOR DIFFUSION, HANGING DROP",,3.0-3.3 M sodium formate and 0.1 M HEPES pH 7.0-7.5,293,2022-10-11,2022-12-28,8ER6,5146,6,606,25,,72.49,2,2.81,experimental,74.5,0.2241,0.2007,FKBP12-FRB in Complex with Compound 11
5TYE,X-RAY DIFFRACTION,2.68,54.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-19,2017-08-30,5TYE,3433,4,374,319,,46.46,1,2.047,experimental,27.3899,0.2282,0.1858,"DNA Polymerase Mu Product Complex, 10 mM Mg2+ (60 min)"
5TYY,X-RAY DIFFRACTION,2.69,54.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-21,2017-08-30,5TYY,3485,4,374,367,,46.52,1,1.931,experimental,28.7414,0.2179,0.1859,"DNA Polymerase Mu Product Complex, Mn2+ (60 min)"
7KTB,X-RAY DIFFRACTION,2.46,49.98,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KTB,3575,4,374,382,,47.42,1,1.576,experimental,29.1787,0.1771,0.1582,"DNA Polymerase Mu, 8-oxodGTP:Ct Reaction State Ternary Complex, 10 mM Mn2+ (40min)"
7KTC,X-RAY DIFFRACTION,2.46,49.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KTC,3517,4,374,415,,46.91,1,1.653,experimental,18.2024,0.1761,0.1557,"DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (120min)"
7KTD,X-RAY DIFFRACTION,2.46,50.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KTD,3400,4,374,348,,46.67,1,1.551,experimental,30.1668,0.1784,0.1599,"DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (960min)"
7KTI,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KTI,3559,4,374,411,,46.63,1,1.57,experimental,26.8009,0.1791,0.1618,"DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 20 uM Mn2+ (120min)"
8PTS,X-RAY DIFFRACTION,2.31,46.78,"VAPOR DIFFUSION, SITTING DROP",,"12 -17 % PEG330
66mM Na Cacodylate
33mM MES
66mM MgCl2",293.15,2023-07-14,2024-07-24,8PTS,3194,2,394,119,,44.36,1,1.76,experimental,,0.26,0.2481,human GUK1 in complex with compound AT8001
9BFY,X-RAY DIFFRACTION,2.19,43.93,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 3350, 0.1M Bis Tris, pH 5.5, 150 mM NaCl",291,2024-04-18,2024-06-12,9BFY,6787,4,672,1268,,77.96,2,1.26,experimental,17.91,0.1894,0.1685,"Tri-complex of Compound-12, KRAS G12C, and CypA"
9BG1,X-RAY DIFFRACTION,2.24,44.97,"VAPOR DIFFUSION, SITTING DROP",,"28% PEG 3350, 0.1M Bis Tris, pH 5.5, 150 mM NaCl",291,2024-04-18,2024-06-12,9BG1,6451,4,672,965,,77.71,2,1.51,experimental,20.34,0.2264,0.1874,"Tri-complex of Compound-3, KRAS G12V, and CypA"
8TBK,X-RAY DIFFRACTION,2.31,46.74,"VAPOR DIFFUSION, SITTING DROP",7,"27% PEG4000, 0.1 M imidazole, pH 7.0",291,2023-06-28,2024-02-07,8TBK,6513,4,672,984,,77.88,2,1.26,experimental,25.86,0.1839,0.1462,"Tricomplex of RMC-7977, KRAS G12C, and CypA"
8TBL,X-RAY DIFFRACTION,2.35,47.57,"VAPOR DIFFUSION, SITTING DROP",8,"25% PEG4000, 0.1 M Tris-HCl, pH 8.0",291,2023-06-28,2024-02-07,8TBL,6177,4,672,715,,77.86,2,1.88,experimental,30.47,0.2271,0.1714,"Tricomplex of RMC-7977, KRAS G12D, and CypA"
9AX6,X-RAY DIFFRACTION,2.37,48.17,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris, pH 8.0, 25% PEG4000",291,2024-03-05,2024-04-17,9AX6,5991,4,672,562,,77.75,2,1.65,experimental,37.61,0.2265,0.1846,"Tricomplex of RMC-6236, KRAS G12D, and CypA"
6BDN,X-RAY DIFFRACTION,2.59,52.52,"VAPOR DIFFUSION, HANGING DROP",,"Drops: 1.8 uL protein + 1.0 uL well solution, protein solution: 6.5 mg/mL TAO3K in 0.7 mM ADP, 5 mM magnesium chloride, 100 mM sodium chloride, 25 mM Tris, pH 8.0, 2 mM BME, 0.3 mM EDTA, well solution: 20% PEG3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris, pH 6.5, cryoprotectant: 20% PEG1500",279.15,2017-10-23,2019-04-10,6BDN,2792,1,320,246,,37.04,1,1.5,experimental,24.183,0.2145,0.1856,Crystal structure of human TAO3 kinase binding ADP
7DYT,X-RAY DIFFRACTION,2.31,46.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES sodium, 200mM magnesium chloride hexahydrate, 25% w/v PEG 3350, 1mM manganese chloride",277,2021-01-23,2022-02-02,7DYT,2324,1,235,228,,27.62,1,1.62,experimental,26.98,0.189,0.1625,"Human JMJD5 in complex with MN and 5-((4-methoxybenzyl)amino)pyridine-2,4-dicarboxylic acid."
7DYV,X-RAY DIFFRACTION,2.32,47.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES sodium, 200mM magnesium chloride hexahydrate, 25% w/v PEG 3350, 1mM manganese chloride",277,2021-01-23,2022-02-02,7DYV,2179,1,235,129,,27.59,1,1.92,experimental,38.19,0.2401,0.2044,"Human JMJD5 in complex with MN and 5-(benzylamino)pyridine-2,4-dicarboxylic acid."
7DYW,X-RAY DIFFRACTION,2.36,47.84,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES sodium, 200mM magnesium chloride hexahydrate, 25% w/v PEG 3350, 1mM manganese chloride",277,2021-01-23,2022-02-02,7DYW,2154,1,236,72,,27.75,1,2.13,experimental,53.09,0.2392,0.2142,"Human JMJD5 in complex with MN and 5-((2-methoxybenzyl)amino)pyridine-2,4-dicarboxylic acid."
7DYX,X-RAY DIFFRACTION,2.28,46.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES sodium, 200mM magnesium chloride hexahydrate, 25% w/v PEG 3350, 1mM manganese chloride",277,2021-01-23,2022-02-02,7DYX,2086,1,235,57,,27.63,1,2.27,experimental,48.82,0.2801,0.2417,"Human JMJD5 in complex with MN and 5-((2-cyclopropylbenzyl)amino)pyridine-2,4-dicarboxylic acid."
6P1Q,X-RAY DIFFRACTION,2.82,57,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES pH 7.5, 100mM NaCl, 10% w/v PEG4000",277,2019-05-20,2019-09-04,6P1Q,3334,4,372,325,,45.88,1,1.9,experimental,,0.2064,0.1689,Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated dCMP
7TGS,X-RAY DIFFRACTION,2.43,49.48,"VAPOR DIFFUSION, HANGING DROP",7.3,"19% PEG 3350
0.5 M KH2PO4
1:3 ratio of protein to inhibitor
1 uL of protein:inhibitor complex was mixed with 1 uL of mother liquor",298,2022-01-09,2022-08-24,7TGS,1387,1,164,90,,18.33,1,1.75,experimental,22.3,0.1842,0.1702,Structure of Cyclophilin D Peptidyl-Prolyl Isomerase Domain bound to Macrocyclic Inhibitor JOMBt
5UUT,X-RAY DIFFRACTION,2.25,45.41,"VAPOR DIFFUSION, HANGING DROP",4.5,"22.5% PEG 4000, 5 mM NiCl2, 100 mM sodium citrate pH 4.5, and 2.5% glycerol",293,2017-02-17,2018-01-17,5UUT,6716,2,782,340,,93.25,1,2.252,experimental,,0.2211,0.1708,N-myristoyltransferase 1 (NMT) bound to myristoyl-CoA
7A6W,X-RAY DIFFRACTION,1.96,37.38,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG-3350, 0.2 M NH4-acetate, 0.1 M HEPES-NaOH pH 7.5",293,2020-08-27,2021-03-17,7A6W,2032,2,260,42,,30.09,1,1.85,experimental,16.591,0.2671,0.1827,Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 33-(Z)
4YZ9,X-RAY DIFFRACTION,3.01,59.12,"VAPOR DIFFUSION, SITTING DROP",7,"Crystals of pIRE1alpha (547 - 977) with GSK2850163 were prepared by mixing pIRE1alpha with 0.5 mM GSK2850163 and incubating overnight on ice. The crystals were grown at 20 C by vapor diffusion in sitting drops containing 2 ul of protein (13 mg/ml in 50 mM Hepes, pH 7.5, 200 mM NaCl, 5 mM DTT, 1 mM EDTA , 0.5 mM GSK2850163, 0.25% DMSO ) and 2 ul reservoir solution containing PEG 3350 (16%-22%), 100 mM Hepes pH 7.0, 200 mM Ca2+ acetate.  The crystals were thick rods that appeared over 2-5 days and reached full size (0.05 X 0.025 X 0.3 mm) in 2 weeks. Seeding was used to improve crystal quality. The pIRE1alpha + GSK2850163 crystals were frozen in a solution of 20% ethylene glycol, 22% PEG 3350, 0.2 M calcium acetate added in a stepwise manner to the protein drop before mounting the crystal on the loop.",293,2015-03-24,2015-11-11,4YZ9,9129,3,1215,80,,141.17,1,2.463,experimental,,0.2829,0.2354,Crystal Structure of human phosphorylated IRE1alpha in complex with a type III kinase inhibitor (GSK2850163A)
5DFH,X-RAY DIFFRACTION,2.52,51.25,"VAPOR DIFFUSION, SITTING DROP",5,"10% Peg20000, 100 mM sodium citrate, 200 mM MgCl",291,2015-08-26,2015-10-14,5DFH,5501,5,594,377,,75.21,1,1.949,experimental,,0.2187,0.1789,Human APE1 mismatch product complex
5DFI,X-RAY DIFFRACTION,2.57,52.16,"VAPOR DIFFUSION, SITTING DROP",5,"10% PEG20000, 100 mM sodium citrate, 200 mM MgCl",291,2015-08-26,2015-10-14,5DFI,5951,4,594,665,,75.68,1,1.63,experimental,,0.195,0.167,Human APE1 phosphorothioate substrate complex
6BOQ,X-RAY DIFFRACTION,2.29,46.35,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG 20K, 100mM sodium Citrate, 15% glycerol, 5mM CaCl2",291,2017-11-20,2018-08-15,6BOQ,5373,4,678,219,,84.12,1,1.96,experimental,,0.2583,0.2174,Human APE1 substrate complex with an A/A mismatch adjacent the THF
6BOR,X-RAY DIFFRACTION,2.27,45.88,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG 20K, 100mM sodium Citrate, 15% glycerol, 5mM CaCl2",291,2017-11-20,2018-08-15,6BOR,5727,4,678,564,,84.3,1,1.84,experimental,22.2407,0.2092,0.1703,Human APE1 substrate complex with an G/G mismatch adjacent the THF
6BOS,X-RAY DIFFRACTION,2.27,45.8,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG 20K, 100mM sodium Citrate, 15% glycerol, 5mM CaCl2",291,2017-11-20,2018-08-15,6BOS,5375,4,678,200,,83.98,1,2.304,experimental,37.3302,0.2358,0.1927,Human APE1 substrate complex with an A/C mismatch adjacent the THF
6BOT,X-RAY DIFFRACTION,2.29,46.32,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG 20K, 100mM sodium Citrate, 15% glycerol, 5mM CaCl2",291,2017-11-20,2018-08-15,6BOT,5346,4,678,225,,83.95,1,2.3,experimental,,0.245,0.202,Human APE1 substrate complex with an C/C mismatch adjacent the THF
6BOU,X-RAY DIFFRACTION,2.29,46.39,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG 20K, 100mM sodium Citrate, 15% glycerol, 5mM CaCl2",291,2017-11-20,2018-08-15,6BOU,5149,4,678,60,,83.91,1,2.538,experimental,,0.2677,0.2082,Human APE1 substrate complex with an T/C mismatch adjacent the THF
6BOV,X-RAY DIFFRACTION,2.28,46,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG 20K, 100mM sodium Citrate, 15% glycerol, 5mM CaCl2",291,2017-11-20,2018-08-15,6BOV,5391,4,678,281,,84.04,1,1.975,experimental,,0.2423,0.2109,Human APE1 substrate complex with an A/G mismatch adjacent the THF
6BOW,X-RAY DIFFRACTION,2.3,46.5,"VAPOR DIFFUSION, SITTING DROP",5,"7% PEG 20K, 100mM sodium Citrate, 15% glycerol, 5mM CaCl2",291,2017-11-20,2018-08-15,6BOW,5579,4,678,524,,83.92,1,1.59,experimental,,0.241,0.214,Human APE1 substrate complex with an T/T mismatch adjacent the THF
6W4I,X-RAY DIFFRACTION,3.04,59.58,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 3350, 0.1 M Bis Tris Propane (pH 6.5), 0.2 M Sodium Fluoride",291,2020-03-10,2020-06-17,6W4I,6435,8,636,363,,87.71,1,2.2,experimental,37.63,0.2268,0.1851,APE1 Y269A product complex with abasic DNA
6W4T,X-RAY DIFFRACTION,2.96,58.38,"VAPOR DIFFUSION, SITTING DROP",6.5,"27% PEG 3350, 100 mM Bis Tris Propane (pH 6.5), 200 mM Sodium Fluoride",291,2020-03-11,2020-06-17,6W4T,6132,6,636,39,,87.72,1,2.77,experimental,53.9,0.2741,0.2214,APE1 Y269A phosphorothioate substrate complex with abasic DNA
7LPG,X-RAY DIFFRACTION,2.54,51.64,"VAPOR DIFFUSION, SITTING DROP",5,"200 mM MgCl2, 100 mM Sodium Citrate (pH 5), 10-15% PEG 20,000",291,2021-02-11,2021-08-04,7LPG,5411,5,594,239,,75.05,1,2.08,experimental,46.64,0.2627,0.2194,APE1 product complex with abasic ribonucleotide DNA
7LPH,X-RAY DIFFRACTION,2.58,52.27,"VAPOR DIFFUSION, SITTING DROP",,"200 mM MgCl2, 100 mM Sodium Citrate (pH 5), 10-15% PEG 20,000",291,2021-02-11,2021-08-04,7LPH,5579,5,594,325,,75.1,1,1.99,experimental,33.67,0.2366,0.1919,APE1 Mn-bound product complex with abasic ribonucleotide DNA
7LPI,X-RAY DIFFRACTION,2.53,51.45,"VAPOR DIFFUSION, SITTING DROP",4,"50 mM tri-Sodium Citrate (pH 4), 100 mM NaCl, 10% Peg 6,000",291,2021-02-11,2021-08-04,7LPI,5368,4,594,190,,75.11,1,2.05,experimental,37.12,0.2447,0.1968,APE1 phosphorothioate substrate complex with abasic ribonucleotide DNA
7LPJ,X-RAY DIFFRACTION,2.52,51.26,"VAPOR DIFFUSION, SITTING DROP",4,"50 mM tri-Sodium Citrate (pH 4), 100 mM NaCl, 10% Peg 6,000",291,2021-02-11,2021-08-04,7LPJ,5274,4,594,47,,75.17,1,2.56,experimental,39.69,0.2481,0.1829,APE1 Mn-bound phosphorothioate substrate complex with abasic ribonucleotide DNA
7SUV,X-RAY DIFFRACTION,2.71,54.53,"VAPOR DIFFUSION, SITTING DROP",5,"7 - 14% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",293.15,2021-11-18,2022-09-07,7SUV,5553,5,594,263,,75.19,1,1.99,experimental,45.81,0.2649,0.226,APE1 exonuclease substrate complex with 8oxoG opposite A
7SVB,X-RAY DIFFRACTION,2.65,53.5,"VAPOR DIFFUSION, SITTING DROP",5,"7 - 14% PEG20000, 100 mM sodium citrate, 15% glycerol, 5 mM calcium chloride",293.15,2021-11-18,2022-09-07,7SVB,5503,5,594,243,,75.17,1,2.24,experimental,42.98,0.2452,0.1997,APE1 exonuclease substrate complex with 8oxoG opposite C
7TR7,X-RAY DIFFRACTION,3.12,60.52,"VAPOR DIFFUSION, SITTING DROP",6,"0.05M KCl, 0.05M sodium cacodylate pH 6, 10% PEG 8,000, 5mM spermine, 5mM L-Argininamide dihydrochloride",291,2022-01-28,2023-04-12,7TR7,5054,4,566,356,,66.34,1,2,experimental,28.45,0.2147,0.1821,APE1 product complex with abasic ssDNA
7TA1,X-RAY DIFFRACTION,2.27,45.85,"VAPOR DIFFUSION, HANGING DROP",7.8,"Once hOAT was purified, it was transferred to a 10 kDa centrifugal filter tube and concentrated to ~6 mg/mL. The holoenzyme crystals were first grown via a hanging drop vapor diffusion method. Each drop contained 2 uL of protein and 2 uL of well solution. The best crystallization condition contained 8% PEG 6000, 100 mM NaCl, 5% glycerol, and 50 mM Tricine pH 7.8. Once holoenzyme crystals reached their maximum size within seven days, 1 uL of 10 mM GABA was added to the drop with crystals. The crystals were soaked for different time periods from 50 minutes to 2.5 hours. After soaking, crystals were transferred into a cryoprotective solution (well solution supplemented with 30% glycerol), and then flash-frozen in liquid nitrogen.",293,2021-12-20,2022-05-04,7TA1,19965,6,2634,896,,293.39,1,2.2,experimental,39.81,0.2681,0.2508,Human Ornithine Aminotransferase (hOAT) soaked with gamma-Aminobutyric acid
7N94,X-RAY DIFFRACTION,2.34,47.54,EVAPORATION,6,"0.1M MES pH 6.0, 0.2M NaCl, 30% Jeffamine ED-2003",293,2021-06-16,2021-10-13,7N94,5149,6,548,,,76.21,1,2.85,experimental,43.29,0.2803,0.2143,LINE-1 endonuclease domain complex with DNA
4R0X,X-RAY DIFFRACTION,2.07,40.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"26% PEG 3350, 0.1 M HEPES, pH 7.5, 0.2 M ammonium acetate, 5% isopropanol, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-08-02,2015-05-13,4R0X,1146,1,122,193,,13.49,1,1.2,experimental,,0.1674,0.1589,Allosteric coupling of conformational transitions in the FK1 domain of FKBP51 near the site of steroid receptor interaction
7APQ,X-RAY DIFFRACTION,2.3,46.48,"VAPOR DIFFUSION, HANGING DROP",7.5,"36% PEG-3350, 0.2 M NH4-acetate and HEPES-NaOH pH 7.5",293,2020-10-19,2021-11-10,7APQ,1229,1,128,122,,14.51,1,1.09,experimental,14.79,0.2147,0.1812,"The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-(benzo[d]thiazol-6-ylsulfonyl)-5-(methoxymethyl)-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one"
7APT,X-RAY DIFFRACTION,2.29,46.38,"VAPOR DIFFUSION, HANGING DROP",7.5,"38% PEG-3340, 0.2 M NH4-acetate and HEPES-NaOH, pH 7.5",293,2020-10-19,2021-11-10,7APT,1228,1,128,155,,14.47,1,1.131,experimental,19.058,0.2155,0.1671,"The Fk1 domain of FKBP51 in complex with ((1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)acetic acid"
7AWF,X-RAY DIFFRACTION,2.23,44.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"28% PEG3350 
0.1M HEPES pH 7.5
0.2M ammonium thiocyanate NH4 SCN",293,2020-11-07,2021-04-21,7AWF,1133,1,128,113,,14.68,1,1.4,experimental,21.766,0.2434,0.1941,"The Fk1 domain of FKBP51 in complex with (2R,5S,12R)-12-cyclohexyl-2-[2-(3,4-dimethoxyphenyl)ethyl]-15,15,16-trimethyl-3,19-dioxa-10,13,16-triazatricyclo[18.3.1.0^5,^10]tetracosa-1(24),20,22-triene-4,11,14,17-tetrone"
7B9Y,X-RAY DIFFRACTION,2.52,51.13,"VAPOR DIFFUSION, SITTING DROP",,"18% PEG 3350, 0.1 M HEPES pH 7.5, 0.2M ammonium acetate",293,2020-12-15,2021-03-17,7B9Y,1286,1,130,159,,15.04,1,1.35,experimental,22.85,0.1583,0.1353,Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 64a
7B9Z,X-RAY DIFFRACTION,2.46,50.06,"VAPOR DIFFUSION, SITTING DROP",,"18% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammoniumthiocyanat",293,2020-12-15,2021-03-17,7B9Z,1244,1,130,110,,15.18,1,1.44,experimental,30.723,0.1663,0.1397,Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 35-(E)
7BA0,X-RAY DIFFRACTION,1.76,30.04,"VAPOR DIFFUSION, SITTING DROP",,"24% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammonium thiocyanate",293,2020-12-15,2021-03-17,7BA0,1141,1,130,99,,15.04,1,1.14,experimental,15.859,0.1623,0.1415,Structure of the FKBP51FK1 domain in complex with the macrocyclic SAFit analogue 63
8BA6,X-RAY DIFFRACTION,2.31,46.8,"VAPOR DIFFUSION, HANGING DROP",7.5,30% PEG3350 0.2M ammonium acetate 0.1 M HEPES-NaOH pH 7.5,293,2022-10-11,2022-11-16,8BA6,1318,1,128,222,,14.71,1,1.1,experimental,12.06,0.1604,0.1397,"Structure of the FK1 domain of the FKBP51 G64S variant in complex with (2R,5S,12R)-12-cyclohexyl-2-[2-(3,4-dimethoxyphenyl)ethyl]-15,15,16-trimethyl-3,19-dioxa-10,13,16-triazatricyclo[18.3.1.0^5,^10]tetracosa-1(24),20,22-triene-4,11,14,17-tetrone"
8BAJ,X-RAY DIFFRACTION,2.24,45.21,"VAPOR DIFFUSION, SITTING DROP",7.5,40% PEG3350 0.1M HEPES-NaOH pH 7.5 0.2M ammonium acetate,293,2022-10-11,2022-11-16,8BAJ,1141,1,128,156,,14.52,1,1.2,experimental,13.269,0.2096,0.1751,"Structure of the FK1 domain of the FKBP51 G64S variant in complex with (1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-(hydroxymethyl)-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one"
8CCA,X-RAY DIFFRACTION,2.27,45.82,"VAPOR DIFFUSION, HANGING DROP",,"18% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammonium acetate",293,2023-01-27,2023-04-26,8CCA,1182,1,128,151,,14.75,1,1.33,experimental,18.489,0.2007,0.1654,The Fk1 domain of FKBP51 in complex with SAFit1
8CCB,X-RAY DIFFRACTION,2.78,55.74,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammonium acetate",293,2023-01-27,2023-04-26,8CCB,1102,1,128,129,,14.7,1,1.7,experimental,24.522,0.2358,0.2092,"The Fk1 domain of FKBP51 in complex with 2-(3-((1R)-1-(((2S)-1-(2-(5-chlorothiophen-2-yl)-2-cyclohexylacetyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid"
8CCC,X-RAY DIFFRACTION,2.57,52.1,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammonium acetate",293,2023-01-27,2023-04-26,8CCC,1066,1,128,84,,14.63,1,1.55,experimental,32.336,0.2389,0.2161,"The Fk1 domain of FKBP51 in complex with 2-(3-((R)-1-(((S)-1-((S)-2-(5-chlorothiophen-2-yl)propanoyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid"
8CCD,X-RAY DIFFRACTION,2.24,45.01,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammonium acetate",293,2023-01-27,2023-04-26,8CCD,990,1,128,7,,14.79,1,2.1,experimental,45.756,0.2722,0.2253,"The Fk1 domain of FKBP51 in complex with 2-(3-((R)-1-(((S)-1-((S)-2-(5-chlorothiophen-2-yl)-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid"
8CCF,X-RAY DIFFRACTION,2.33,47.31,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammonium acetate",293,2023-01-27,2023-04-26,8CCF,1007,1,128,22,,14.66,1,2,experimental,46.877,0.2463,0.2089,"The Fk1 domain of FKBP51 in complex with 2-(3-((R)-1-(((S)-1-((S)-2-(5-chlorothiophen-2-yl)pent-4-enoyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid"
8CCG,X-RAY DIFFRACTION,2.4,48.81,"VAPOR DIFFUSION, HANGING DROP",,"32% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammonium acetate",293,2023-01-27,2023-04-26,8CCG,1158,1,128,160,,14.67,1,1.3,experimental,19.858,0.1998,0.1665,"The Fk1 domain of FKBP51 in complex with (2R,5S,12S)-12-(thiophen-2-yl)-2-[2-(3,4-dimethoxyphenyl)ethyl]-15,15-dimethyl-3,19-dioxa-10,13,16-triazatricyclo[18.3.1.0^5,^10]tetracosa-1(24),20,22-triene-4,11,14,17-tetrone"
8CCH,X-RAY DIFFRACTION,2.77,55.52,"VAPOR DIFFUSION, HANGING DROP",,"26% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammonium acetate, 10% ethylene glycol",293,2023-01-27,2023-04-26,8CCH,1060,1,128,78,,14.67,1,1.73,experimental,33.938,0.2349,0.2098,"The Fk1 domain of FKBP51 in complex with 2-(3-((1R)-1-(((2S)-1-(2-cyclohexyl-2-(thiophen-2-yl)acetyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid"
9EY3,X-RAY DIFFRACTION,2.31,46.71,"VAPOR DIFFUSION, HANGING DROP",,"34% PEG3350, 0.2M ammonium acetate, 0.1M HEPES-NaOH pH 7.5",293,2024-04-09,2024-06-12,9EY3,1233,1,128,239,,14.48,1,1.16,experimental,13.515,0.168,0.1392,"The FK1 domain of FKBP51 in complex with (3S,11S,11aS)-12-((3,5-dichlorophenyl)sulfonyl)-5-oxo-11-vinyldecahydro-1H-6,10-epiminopyrrolo[1,2-a]azonine-3-carboxylic acid"
9EY4,X-RAY DIFFRACTION,2.31,46.67,"VAPOR DIFFUSION, HANGING DROP",,"34% PEG3350, 0.2M ammonium acetate, 0.1M HEPES-NaOH pH 7.5",293,2024-04-09,2024-06-12,9EY4,1208,1,128,216,,14.48,1,1.16,experimental,14.223,0.1686,0.1424,"The FK1 domain of FKBP51 in complex with (3S,11S)-12-((3,5-dichlorophenyl)sulfonyl)-5-oxo-11-vinyldecahydro-1H-6,10-epiminopyrrolo[1,2-a]azonine-3-carboxamide"
5A4P,X-RAY DIFFRACTION,1.79,31,,,"17% (W/V) PEG1500, 0.1M MMT PH 6.5",,2015-06-11,2015-11-18,5A4P,1911,1,354,23,,38.97,1,2.1,experimental,58.3,0.2782,0.2352,Structure of UBE2Z provides functional insight into specificity in the FAT10 conjugation machinery
6WQX,X-RAY DIFFRACTION,2.6,52.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M KCl, 0.1 M HEPES pH 7.5, 15% PEG 6000",289,2020-04-29,2021-02-17,6WQX,6531,4,892,65,,100.86,2,2.53,experimental,,0.265,0.2113,Human PRPK-TPRKB complex
7SZA,X-RAY DIFFRACTION,2.26,45.59,"VAPOR DIFFUSION, HANGING DROP",5.2,"100mM Sodium citrate pH 5.2, 12.8% PEG8000, 10mM MgCl2, 10mM TCEP",300,2021-11-27,2023-01-25,7SZA,6964,4,866,640,,97.59,2,1.9,experimental,36.4617,0.2163,0.1728,Crystal Structure Analysis of human PRPK complex with a compound
7SZB,X-RAY DIFFRACTION,2.25,45.29,"VAPOR DIFFUSION, HANGING DROP",5.2,"100mM Sodium citrate pH 5.2, 12.8% PEG8000, 10mM MgCl2, 10mM TCEP",293,2021-11-27,2023-01-25,7SZB,6781,4,866,493,,97.59,2,2.02,experimental,37.3591,0.209,0.1698,Crystal Structure Analysis of human PRPK complex with a compound
7SZD,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.5, 12% PEG 5000 MME, 10mM TCEP",293,2021-11-27,2022-12-14,7SZD,6315,4,866,48,,97.3,2,2.05,experimental,52.16,0.2754,0.2207,Crystal Structure Analysis of human PRPK complex with a compound
6I1S,X-RAY DIFFRACTION,2.79,55.88,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.05M ammonium sulfate, 30% pentaerythritol ethoxylate 15/4, 0.1M bis-tris pH 6.5",277,2018-10-30,2019-09-11,6I1S,3767,2,439,237,,50.47,2,1.52,experimental,17.43,0.1927,0.1767,Crystal structure of the ACVR1 (ALK2) kinase in complex with FKBP12 and the inhibitor E6201
6OZE,X-RAY DIFFRACTION,2.84,56.71,"VAPOR DIFFUSION, HANGING DROP",,3.6 M sodium acetate,293,2019-05-15,2019-09-04,6OZE,2183,1,246,146,,27.51,1,1.5,experimental,37.4917,0.191,0.1719,Crystal structure of the catalytic domain of human Endonuclease V (C140S/C225S/C226A/C228S)
8PJ8,X-RAY DIFFRACTION,2.24,45.2,"VAPOR DIFFUSION, HANGING DROP",7.5,"30% PEG3350, 0.2M NH4-acetate, 0.1M HEPES-NaOH pH 7.5",293,2023-06-23,2024-03-06,8PJ8,1119,1,128,104,,14.68,1,1.5,experimental,24.414,0.2069,0.1838,"FKBP51FK1 F67E/K60Orn (i, i+7) in complex with SAFit1"
8PJA,X-RAY DIFFRACTION,2.05,40.01,"VAPOR DIFFUSION, HANGING DROP",7.5,"32% PEG 3350, 0.2M NH4-acetate, 0.1 M HEPES-NaOH pH 7.5",293,2023-06-23,2024-03-06,8PJA,1064,1,128,54,,14.7,1,1.6,experimental,24.129,0.2105,0.186,"FKBP51FK1 F67E/K58 (i, i+9) in complex with SAFit1"
6I9M,X-RAY DIFFRACTION,2.33,47.33,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris pH 6.5, 15.0 % PEG3350, 0.002 M MnCl2",298,2018-11-23,2019-12-04,6I9M,2194,1,256,193,,30.34,1,1.65,experimental,24,0.181,0.151,JmjC domain-containing protein 5 (JMJD5) in complex with Mn and R-2-hydroxyglutarate
6I9N,X-RAY DIFFRACTION,2.33,47.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 15.0 % PEG3350, 0.002 M MnCl2",298,2018-11-24,2019-12-04,6I9N,2305,1,256,295,,30.15,1,1.361,experimental,22,0.1589,0.1496,JmjC domain-containing protein 5 (JMJD5) in complex with Mn and L-2-hydroxyglutarate
6TX8,X-RAY DIFFRACTION,2.34,47.36,"VAPOR DIFFUSION, HANGING DROP",7.5,"28-41% PEG3350, 0.2 M NH4OAc, 0.1 M HEPES",293.15,2020-01-13,2020-05-27,6TX8,1268,1,128,195,,14.18,1,1.2,experimental,17.79,0.1554,0.1286,CRYSTAL STRUCTURE OF HUMAN FKBP51 FK1 DOMAIN A19T MUTANT IN COMPLEX WITH IMIDAZOLE
8CCE,X-RAY DIFFRACTION,2.29,46.36,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG3350, 0.1 M HEPES pH 7.5, 0.2 M ammonium acetate",293,2023-01-27,2023-04-26,8CCE,1070,1,128,97,,14.74,1,1.4,experimental,22.432,0.2337,0.1977,"The Fk1 domain of FKBP51 in complex with 2-(3-((R)-1-(((S)-1-((S)-2-(5-chlorothiophen-2-yl)butanoyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid"
7DUO,X-RAY DIFFRACTION,2.79,55.96,"EVAPORATION, RECRYSTALLIZATION",,"0.2M Sodium phosphate monobasic monohydrate, 20% w/v Polyethylene glycol 3350",291,2021-01-10,2021-03-10,7DUO,5085,3,665,,8,73.55,3,2.81,experimental,36.1454,0.2376,0.2305,Crystal structure of daratumumab fab and CD38 complex
6NLV,X-RAY DIFFRACTION,2.07,40.49,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sodium citrate, 50 mM Tris HCl, pH 7.8",298,2019-01-09,2020-01-15,6NLV,2130,1,257,55,,29.34,1,1.794,experimental,20.4085,0.2554,0.2167,"Selective inhibition of carbonic anhydrase IX activity, using compound SLC-149, displays limited anticancer effects in breast cancer cell lines"
7JMS,X-RAY DIFFRACTION,1.97,37.68,"VAPOR DIFFUSION, HANGING DROP",,"0.3 M calcium chloride, 20% PEG 4000",293,2020-08-02,2020-10-21,7JMS,7706,8,1012,270,,114.92,2,2.78,experimental,43.34,0.2731,0.2348,Structure of the Hazara virus OTU bound to ubiquitin
6EHJ,X-RAY DIFFRACTION,2.32,47.02,"VAPOR DIFFUSION, SITTING DROP",,"16-18% (v/w) PEG 4K, 5 mM NiCl2, 100 mM sodium citrate pH 4.5, and 2.5% (v/v) glycerol",293,2017-09-13,2019-03-27,6EHJ,6609,2,782,237,,96.19,1,2.1,experimental,37.5869,0.2386,0.1843,Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and peptide bound
9CPL,X-RAY DIFFRACTION,2.83,56.48,"VAPOR DIFFUSION, SITTING DROP",6,"100mM BisTris, pH 6.0, 960mM Mg-formate",298,2024-07-18,2024-08-14,9CPL,1808,1,251,17,,29.14,1,2.4,experimental,82.94,0.2634,0.2294,"The ubiquitin-associated domain of human thirty-eight negative kinase 1, fused to the 2TEL crystallization chaperone via a 2-glycine linker"
5SD7,X-RAY DIFFRACTION,4.59,73.2,"VAPOR DIFFUSION, SITTING DROP",,"MCSG1 H9 (271587h9): 100mM Bis-Tris pH5.5, 25% (w/v) PEG3350, prot conc 26mg/mL, cryo 15% EG, puck yrc3-1",289,2021-12-20,2022-02-09,5SD7,1857,1,187,174,,23.14,1,1.8,experimental,34.9574,0.1916,0.1686,Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-735
5SD9,X-RAY DIFFRACTION,4.64,73.5,"VAPOR DIFFUSION, SITTING DROP",6.5,"MCSG2 E5 (284882e5): 1600mM Ammonium sulfate, 100mM MES pH6.5, 10% dioxane, 10mg/mL, 20% eg, puck rfh2-6",289,2021-12-20,2022-02-09,5SD9,1788,1,187,153,,22.97,1,2.1,experimental,35.2468,0.1842,0.1582,Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-1096
8GK3,X-RAY DIFFRACTION,2.55,51.7,"VAPOR DIFFUSION, SITTING DROP",7.9,"20% (w/v) PEG 3350, 0.2 M Lithium acetate dihydrate, pH 7.9",298,2023-03-16,2023-07-26,8GK3,45416,12,5832,32,,680.81,1,2.6,experimental,78.63,0.2731,0.2098,Cytochrome P450 3A7 in complex with Dehydroepiandrosterone sulfate
5NJX,X-RAY DIFFRACTION,3.01,59.17,"VAPOR DIFFUSION, SITTING DROP",6,"18 %w/v PEG MME 5K, 0.2 M NH4SO4, 0.1 M MES pH 6",277,2017-03-30,2017-11-08,5NJX,3542,2,478,175,,54.02,2,2.49,experimental,61.32,0.26,0.195,Human FKBP51 protein in complex with C-terminal peptide of Human HSP 90-alpha
6HM8,X-RAY DIFFRACTION,3.22,61.76,"VAPOR DIFFUSION, SITTING DROP",,"10% w/v PEG 8000, 6% v/v 1,5-pentanediol, 14% v/v PEG 200, 10 mM spermine, 10 mM spermidine, 10 mM DL-ornithine, 10 mM 1,4-diaminobutane, 200 mM NaCl, 100 mM GlyGly/AMPD pH 8.5",291,2018-09-12,2019-07-24,6HM8,1401,2,218,,,24.9,2,2.277,experimental,59.8,0.2332,0.2177,Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of enterovirus-D68 (fusion protein)
9F98,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"12 % PEG8K, pH 5.5",293,2024-05-07,2024-07-03,9F98,5178,4,1268,181,,140.61,2,2.15,experimental,45.7,0.2549,0.2163,"Crystal structure of MUS81-EME1, apo form."
4Z7H,X-RAY DIFFRACTION,2.83,56.52,"VAPOR DIFFUSION, HANGING DROP",,"Apo-hIRE1 was crystallized by hanging-drop vapor diffusion by mixing IRE1 (at 2 mg/mL) with reservoir solution containing 18-20% PEG3350, 0.2 M sodium malonate and 0.1 Bis-Trispropane (pH 6.5) in a 1:1 ratio.  Crystals were briefly (30 sec) soaked in 22% PEG3350, 0.2 M Na Malonate, 0.1 M Bis-Trispropane (pH 7.5) and 25% ethylene glycol before plunging into liquid N2.",291,2015-04-07,2015-05-27,4Z7H,6260,2,832,21,,96.26,1,2.9,experimental,86.73,0.2248,0.2002,Crystal structure of human IRE1 cytoplasmic kinase-RNase region - complex with imidazopyridine compound 3
5VZE,X-RAY DIFFRACTION,2.85,56.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"90mM HEPES pH 7.5, 18% PEG4K",293,2017-05-27,2017-07-05,5VZE,3475,4,372,373,,45.91,1,1.506,experimental,,0.2001,0.1771,Post-catalytic complex of human Polymerase Mu (W434A) mutant with incoming UTP
6HX1,X-RAY DIFFRACTION,3,59.01,"VAPOR DIFFUSION, SITTING DROP",,"0 % Isopropanol
10 % PEG4000
0.10 M Na-citrate pH=5.75
Protein at 9mg/mL was in 20 mM TRIS/Cl pH=8.0, 150 mM NaCl, 5 mM DTT, and 2mM compound was added to the protein before setting up trays.",277,2018-10-15,2019-02-27,6HX1,3302,1,403,122,,46.76,1,2.14,experimental,38.771,0.2676,0.21673,"IRE1 ALPHA IN COMPLEX WITH imidazo[1,2-b]pyridazin-8-amine compound 2"
6HV0,X-RAY DIFFRACTION,2.77,55.53,"VAPOR DIFFUSION, HANGING DROP",,"20% polyethylene glycol 3350, 0.2 M sodium acetate and 0.1 bis-tris propane (pH 6.5)",293,2018-10-09,2019-02-27,6HV0,3078,1,416,57,,48.08,1,2.73,experimental,,0.2689,0.2116,"IRE1 kinase/RNase in complex with imidazo[1,2-b]pyridazin-8-amine compound 33"
4UE1,X-RAY DIFFRACTION,2.8,56,,4.2,"0.1 M SODIUM CITRATE PH 4.2, 0.2 M SODIUM CHLORIDE AND 20 % PEG8000",,2014-12-14,2016-01-13,4UE1,4072,8,520,267,,58.62,2,1.45,experimental,21.362,0.18367,0.14048,Structure of the stapled peptide YS-01 bound to MDM2
6I9L,X-RAY DIFFRACTION,2.33,47.33,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M BIS-TRIS PH 6.5, 15.0 % PEG3350, 0.002 M MNCL2, 300 NL SITTING DROPS (SAMPLE:WELL, 2:1 RATIO)",298,2018-11-23,2019-12-04,6I9L,2330,1,256,320,,30.08,1,1.53,experimental,,0.1638,0.1464,"JmjC domain-containing protein 5 (JMJD5) in complex with Mn and pyridine-2,4-dicarboxylic acid (2,4-PDCA)"
6MV2,X-RAY DIFFRACTION,2.63,53.19,"VAPOR DIFFUSION, SITTING DROP",7,"10% (w/v) PEG 6000, 0.1 M Hepes, 0.3 M NDSB-195",291,2018-10-24,2019-07-17,6MV2,3099,1,367,221,,43.65,1,2.05,experimental,34.7297,0.2237,0.1742,2.05A resolution structure of the CS-b5R domains of human Ncb5or (NADP+ form)
7ZOM,X-RAY DIFFRACTION,2.65,53.61,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Hepes-NaOH pH7.0-7.5, 45-70% MPD",277,2022-04-26,2023-04-26,7ZOM,990,1,132,52,,15.18,1,1.601,experimental,38.16,0.2091,0.1846,Crystal structure of N-terminal catalytic domain of human PLAAT3
6M4U,X-RAY DIFFRACTION,2.72,54.79,"VAPOR DIFFUSION, SITTING DROP",,"100 mM cacodylic acid buffer (pH 6.5), 350 mM zinc acetate and 8% (w/v) isopropanol",293,2020-03-09,2020-08-26,6M4U,3724,4,410,308,,50.2,2,2.2,experimental,26.727,0.25766,0.19782,Crystal structure of FKBP-FRB T2098L mutant in complex with rapamycin
8G9P,X-RAY DIFFRACTION,2.16,43.06,"VAPOR DIFFUSION, SITTING DROP",5.5,"22% PEG 3350, 100 mM NaCl",291,2023-02-21,2023-08-16,8G9P,6650,4,672,1017,,78.19,2,1.5,experimental,20.03,0.1875,0.1563,"Tricomplex of RMC-4998, KRAS G12C, and CypA"
4YZC,X-RAY DIFFRACTION,3.2,61.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"The complex of pIRE1a (547-977) with staurosporine was prepared by mixing the protein with 0.5 mM staurosporine and incubated overnight on ice.  The crystals were grown at 20C by vapor diffusion in sitting drop containing 2 ul of protein (13 mg/ml in 50 mM Hepes, pH 7.5, 200 mM NaCl, 5 mM DTT, 1 mM EDTA) and 2ul reservoir solution containing PEG 300 (30%-40%), 100 mM Hepes pH 7.5, 200 mM KCl. Small hexagonal plates appeared over 5-10 days and reached full size (0.05 X 0.75 X 0.15 mm) in ~20 days. The crystals were flash-frozen in liquid N2 directly from the crystallization drop. All diffraction data was collected at the Advanced Photon Source, Argonne National Laboratories, Life Sciences CAT, Sector 21",293,2015-03-24,2015-11-11,4YZC,6173,2,810,58,,94.63,1,2.494,experimental,,0.2892,0.2468,Crystal structure of pIRE1alpha in complex with staurosporine
4Z7G,X-RAY DIFFRACTION,2.8,56.08,"VAPOR DIFFUSION, HANGING DROP",,"Apo-hIRE1 was crystallized by hanging-drop vapor diffusion by mixing IRE1 (at 2 mg/mL) with reservoir solution containing 18-20% PEG3350, 0.2 M sodium malonate and 0.1 Bis-Trispropane (pH 6.5) in a 1:1 ratio",291,2015-04-07,2015-05-27,4Z7G,6042,2,832,15,,95.56,1,2.6,experimental,100.97,0.2259,0.203,Crystal structure of human IRE1 cytoplasmic kinase-RNase region - apo
6URC,X-RAY DIFFRACTION,2.52,51.1,"VAPOR DIFFUSION, HANGING DROP",,"0.1M trisodium citrate pH 5.6, 10% isopropanol, 10% PEG4000, and cesium chloride",277,2019-10-23,2019-11-06,6URC,7116,2,868,589,,100.42,1,2.2,experimental,26.4432,0.274,0.2202,Crystal structure of IRE1a in complex with compound 18
8IGF,X-RAY DIFFRACTION,2.07,40.62,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization solution was comprised of Tris-HCl buffer (50 mM, pH=7.4), and 2.9 M ammonium sulfate in sitting drop vapor diffusion setup. Crystallization drop was comprised of hCA-II (10 mg/mL), compound (5 mM) and reservoir buffer.",293,2023-02-20,2024-02-28,8IGF,2164,1,257,91,,29.35,1,2.6,experimental,12.2,0.2526,0.1968,Crystal Structure of Human Carbonic Anhydrase II In-complex with 4-Acetylphenylboronic acid at 2.6 A Resolution
8POD,X-RAY DIFFRACTION,2.33,47.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 10% ethylene glycol, 0.1M bis-tris-propane pH 7.5, 0.2M sodium fluoride",277,2023-07-04,2024-06-19,8POD,3341,2,439,76,,49.88,2,2.59,experimental,43.41,0.2553,0.2353,Crystal structure of the kinase domain of ACVR1 (ALK2) in complex with FKBP12 and MU1700
7UQ3,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, SITTING DROP",6.5,"Sample: 22 mg/mL JMJD5, 1.5 mM MnCl2, 5 mM compound (IS-52); Reservoir: 0.1 M Bis-Tris pH 6.5, 15.0 % PEG3350, 0.002 M MnCl2; Cryo-protection: 25% (v/v) glycerol; Method: 300 nL sitting drops (sample:well, 2:1 ratio)",298,2022-04-19,2022-12-21,7UQ3,2220,1,256,291,,30.15,1,1.49,experimental,21.1625,0.1349,0.1339,"JmjC domain-containing protein 5 (JMJD5) in complex with Mn and (S)-2-(1-hydroxy-2,5-dioxopyrrolidin-3-yl)acetic acid"
6SSO,X-RAY DIFFRACTION,2,38.53,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM sodium cacodylate, pH 7 and 1.6 M sodium acetate",297,2019-09-08,2021-10-06,6SSO,1410,1,135,160,4,15.7,1,1.211,experimental,12.4024,0.1512,0.1346,EDN mutant L45H
7R0L,X-RAY DIFFRACTION,2.23,44.92,"VAPOR DIFFUSION, HANGING DROP",7.5,"12% PEG3350, 0.2 M NH4-acetate and HEPES-NaOH pH 7.5",293,2022-02-02,2022-11-16,7R0L,1222,1,128,147,,15.2,1,1.1,experimental,15.762,0.1706,0.1431,Structure of the FK1 domain of the FKBP51 G64S variant in complex with SAFit1
7SZC,X-RAY DIFFRACTION,2.34,47.38,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG3350, 200mM Potassium sodium tartrate",293,2021-11-27,2022-12-14,7SZC,6815,4,866,654,,97.55,2,1.71,experimental,37.0314,0.2071,0.1772,Crystal Structure Analysis of human PRPK complex with a compound
5A1N,X-RAY DIFFRACTION,2.73,55.01,,5.5,"17% PEG 3350, 0.1M BIS-TRIS PH 5.5, 2MM DTT",,2015-05-03,2016-06-01,5A1N,3079,2,415,199,,46.31,2,2.1,experimental,,0.2313,0.1933,The crystal structure of the GST-like domains complex of EPRS-AIMP2 mutant S156D
5O6J,X-RAY DIFFRACTION,2.29,46.35,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.4M Sodium phosphate buffer, 17.5% PEG3350",291,2017-06-06,2018-05-16,5O6J,7681,2,782,820,,94.35,1,1.45,experimental,20.092,0.24416,0.21346,Human NMT1 in complex with myristoyl-CoA and inhibitor IMP-1031
8OKE,X-RAY DIFFRACTION,2.07,40.61,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-28,2024-04-10,8OKE,2489,1,260,312,,29.63,1,1.05,experimental,14.184,0.17044,0.14289,Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor AKI_1
8OKP,X-RAY DIFFRACTION,2.07,40.6,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-28,2024-04-10,8OKP,2422,1,260,269,,29.65,1,1.25,experimental,15.078,0.16515,0.13159,Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor AKI_33
8OKQ,X-RAY DIFFRACTION,2.09,41.06,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-29,2024-04-10,8OKQ,2420,1,260,277,,29.72,1,1,experimental,17.255,0.17912,0.16771,Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI_2
8OMP,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-31,2024-04-10,8OMP,2449,1,260,289,,29.74,1,1.41,experimental,12.5,0.1845,0.16141,Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI33
8UVL,X-RAY DIFFRACTION,2.84,56.65,VAPOR DIFFUSION,7.5,"89mM HEPES pH 7.5, 32% PEG 200, 3% 6-aminohexanoic acid, 100mM lithium chloride",277,2023-11-03,2024-05-29,8UVL,3356,1,448,77,,52.46,1,2.43,experimental,75.76,0.251,0.1808,Crystal structure of selective IRE1a inhibitor 29 at the enzyme active site
6XDB,X-RAY DIFFRACTION,2.97,58.52,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Hepes pH 7.5, 42% PEG200, 1 M Lithium chloride, 3% w/v 6-Aminohexanoic acid",277,2020-06-10,2021-04-21,6XDB,3343,1,434,20,,50.38,1,2.45,experimental,79.0287,0.2274,0.193,Crystal structure of IRE1a in complex with G-6904
5JDV,X-RAY DIFFRACTION,2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",,"We soaked these crystals with BTA and TA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-17,2017-01-11,5JDV,2589,1,258,438,,29.39,1,1.34,experimental,,0.1694,0.1364,Human carbonic anhydrase II (F131W) complexed with benzo[d]thiazole-2-sulfonamide
5JG3,X-RAY DIFFRACTION,2.13,42.25,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA and TA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-19,2017-01-11,5JG3,2629,1,259,417,,29.65,1,1.21,experimental,,0.1517,0.1318,Human carbonic anhydrase II (121T/N67Q) complexed with benzo[d]thiazole-2-sulfonamide
4UEZ,X-RAY DIFFRACTION,2.2,44.19,,,"0.2 M CALCIUM CHLORIDE, 0.1 M HEPES PH 7.0 AND 17% W/V PEG6000",,2014-12-22,2016-01-20,4UEZ,5248,2,618,277,2,70.55,1,2.29,experimental,9.005,0.20519,0.15036,Crystal structure of the human CARBOXYPEPTIDASE A1 in complex with the PHOSPHINIC INHIBITOR Acetyl-Leu-Phe-Y(PO2CH2)-Phe-OH
4WMB,X-RAY DIFFRACTION,2.42,49.16,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Li2SO4, 0.1 M Bis-Tris, pH 6.5, and 21% PEG3350",293,2014-10-08,2015-09-30,4WMB,2825,2,356,71,5,41.87,2,2.05,experimental,38.507,0.23466,0.20073,"crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese, acceptor ligand and UDP"
8G9Q,X-RAY DIFFRACTION,2.15,42.91,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG 3350, 100 mM NaCl, 100 mM Bis-Tris pH 5.5",291,2023-02-21,2023-08-16,8G9Q,3098,2,336,360,,38.65,2,1.4,experimental,27.18,0.214,0.1864,"Tricomplex of Compound-1, KRAS G12C, and CypA"
5D6B,X-RAY DIFFRACTION,2.62,53.11,"VAPOR DIFFUSION, SITTING DROP",5,"100 mM sodium malonate, 12% polyethylene glycol (PEG) 3350",293,2015-08-11,2016-08-24,5D6B,3726,1,462,250,,49.74,1,2.1,experimental,19.663,0.2393,0.1796,Human fumarase (wild type)
5EUT,X-RAY DIFFRACTION,2.51,50.97,"VAPOR DIFFUSION, SITTING DROP",,"12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD, 0.1 M bicine/Trizma base pH 8.5",291,2015-11-19,2015-12-23,5EUT,3894,1,556,,,63.24,1,2.802,experimental,,0.2889,0.2464,Crystal structure of phosphatidyl inositol 4-kinase II alpha in the apo state
8GDY,X-RAY DIFFRACTION,1.95,36.98,MICROBATCH,6,"0.1 M potassium thiocyanate, 0.1 M MES, and 24% (w/v) PEG 20k",277,2023-03-06,2024-01-24,8GDY,2049,2,282,142,,31.84,1,2.05,experimental,,0.2391,0.1924,Crystal structure of the human PDI first domain with 9 mutations
6WV7,X-RAY DIFFRACTION,3,58.98,LIPIDIC CUBIC PHASE,6.5,"33% PEG400, 5% DMSO, 0.1 M sodium acetate, 0.1 M MES, pH 6.5",295,2020-05-05,2020-11-11,6WV7,6371,2,780,203,4,89.14,1,2.483,experimental,39.7837,0.2447,0.1997,Human VKOR with Chlorophacinone
5TYV,X-RAY DIFFRACTION,2.67,53.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-21,2017-08-30,5TYV,3526,4,374,350,,46.97,1,1.93,experimental,29.658,0.2176,0.1885,"DNA Polymerase Mu Reactant Complex, Mn2+ (7.5 min)"
6M7P,X-RAY DIFFRACTION,2.09,41.22,"VAPOR DIFFUSION, HANGING DROP",,"16 % PEG 2000 MME
100 mM MES, pH 6.0",295,2018-08-20,2018-09-12,6M7P,4272,3,455,382,,55.31,1,1.75,experimental,29.24,0.2176,0.1812,Human DNA polymerase eta extension complex with cdA at the -2 position
8EFG,X-RAY DIFFRACTION,2.44,49.7,"VAPOR DIFFUSION, HANGING DROP",7,"19% PEG 8000, 100 mM HEPES pH 7.0",293,2022-09-08,2023-02-22,8EFG,2887,1,295,417,1,34.98,1,1.5,experimental,23.162,0.1888,0.1627,Crystal structure of human TATDN1 bound to dAMP and two zinc ions
6XDD,X-RAY DIFFRACTION,2.93,58.04,"VAPOR DIFFUSION, SITTING DROP",,"10% 2-propanol, 0.1 M sodium citrate tribasic dihydrate pH 5.0, and 26% PEG400, 4% pentaerythritol ethoxylate (3/4 EO/OH), 4% 1,3-Propanediol",277,2020-06-10,2021-04-21,6XDD,6671,2,868,31,,100.82,1,2.4,experimental,63.8392,0.2381,0.1984,Crystal structure of IRE1 in complex with G-3053
4XSV,X-RAY DIFFRACTION,2.43,49.39,"VAPOR DIFFUSION, SITTING DROP",6.6,"17% PEG3350, 0.2M magnesium formate, 0.1M HEPES, 0.01M CTP, 0.01M magnesium chloride",293,2015-01-22,2016-03-16,4XSV,2522,1,341,21,,39.69,1,2.7,experimental,34.017,0.26417,0.191,Human CTP: Phosphoethanolamine Cytidylyltransferase in complex with CTP
5TXZ,X-RAY DIFFRACTION,2.67,53.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-17,2017-08-30,5TXZ,3727,4,374,439,,47.08,1,1.651,experimental,24.3037,0.194,0.166,"DNA Polymerase Mu Reactant Complex, 100mM Mg2+ (15 min)"
5TYB,X-RAY DIFFRACTION,2.67,53.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-19,2017-08-30,5TYB,3627,4,374,392,,46.81,1,1.848,experimental,23.4292,0.1988,0.1672,"DNA Polymerase Mu Reactant Complex, 10mM Mg2+ (7.5 min)"
5TYC,X-RAY DIFFRACTION,2.67,53.98,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-19,2017-08-30,5TYC,3481,4,374,323,,46.71,1,2.101,experimental,26.7653,0.2366,0.1964,"DNA Polymerase Mu Reactant Complex, 10mM Mg2+ (15 min)"
5TYD,X-RAY DIFFRACTION,2.68,54.03,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-19,2017-08-30,5TYD,3548,4,374,354,,46.85,1,1.899,experimental,22.759,0.2116,0.171,"DNA Polymerase Mu Reactant Complex, 10 mM Mg2+ (45 min)"
5TYU,X-RAY DIFFRACTION,2.62,53.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-21,2017-08-30,5TYU,3375,4,374,252,,47,1,2.048,experimental,32.3326,0.2125,0.1868,"DNA Polymerase Mu Reactant Complex, Mn2+ (4 min)"
5TYW,X-RAY DIFFRACTION,2.67,53.85,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-21,2017-08-30,5TYW,3595,4,374,389,,47.14,1,1.88,experimental,29.1709,0.2078,0.1768,"DNA Polymerase Mu Reactant Complex, Mn2+ (10 min)"
6HLT,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, SITTING DROP",,"10% w/v PEG 8000, 20% v/v ethylene glycol, 30 mM MgCl2, 30 mM CaCl2, 100 mM bicine/Tris pH 8.5",291,2018-09-11,2019-07-24,6HLT,2748,4,450,,,52.09,2,2.815,experimental,55.2,0.2394,0.2104,Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of rhinovirus-14 (HRV14)
6ERH,X-RAY DIFFRACTION,2.89,57.5,"VAPOR DIFFUSION, SITTING DROP",8.5,"18% PEG 3350, 150 mM sodium sulfate, and 100 mM Bis-Tris-Propane",293,2017-10-18,2018-10-17,6ERH,18810,10,2380,33,,294.38,3,2.8,experimental,87.61,0.252,0.225,Complex of XLF and heterodimer Ku bound to DNA
5WCJ,X-RAY DIFFRACTION,2.19,43.74,"VAPOR DIFFUSION, SITTING DROP",7.4,"20% PEG3350, 200mM Ammonium Chloride",291,2017-06-30,2017-07-19,5WCJ,1759,1,248,62,,27.92,1,1.7,experimental,35.246,0.2125,0.1869,Crystal Structure of Human Methyltransferase-like protein 13 in complex with SAH
4YD2,X-RAY DIFFRACTION,2.58,52.37,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris, 20% PEG8K, 0.2M MgCl2",294,2015-02-20,2015-08-05,4YD2,3031,4,373,146,,45.94,1,2.471,experimental,,0.2423,0.2124,Nicked complex of human DNA Polymerase Mu with 2-nt gapped DNA substrate
7DHA,X-RAY DIFFRACTION,2.51,51.09,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M Lithium sulfate
0.1 M Bis-Tris
25% PEG3350",277,2020-11-13,2021-09-22,7DHA,5425,3,713,143,9,79.13,3,2.55,experimental,50.41,0.2614,0.207,crystal structure of CD38 in complex with daratumumab
8BYU,X-RAY DIFFRACTION,2.36,47.99,"VAPOR DIFFUSION, HANGING DROP",7,0.15 M (NH4)2SO4; 0.1 M HEPES: pH:7.0; 20.0 %w/v PEG 4K,293.15,2022-12-14,2023-07-12,8BYU,6308,3,711,619,9,79.57,3,1.85,experimental,27.405,0.22976,0.1876,Crystal Structure of HexaBody-CD38 Fab in complex with CD38
5EPL,X-RAY DIFFRACTION,2.7,53.9,"VAPOR DIFFUSION, SITTING DROP",5.5,"30% PEG3350, 0.2M sodium chloride, 0.1 M sodium cacodylate",293,2015-11-11,2015-12-23,5EPL,1195,4,132,118,,16.3,2,1.81,experimental,26.15,0.216,0.183,Crystal Structure of chromodomain of CBX4 in complex with inhibitor UNC3866
5JE7,X-RAY DIFFRACTION,2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-17,2017-01-11,5JE7,2599,1,257,462,,29.44,1,1.15,experimental,,0.1435,0.1215,Human carbonic anhydrase II (F131Y) complexed with benzo[d]thiazole-2-sulfonamide
5JEG,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-18,2017-01-11,5JEG,2611,1,259,396,,29.65,1,1.19,experimental,,0.1561,0.1322,Human carbonic anhydrase II (V121I) complexed with benzo[d]thiazole-2-sulfonamide
5JEH,X-RAY DIFFRACTION,2.06,40.41,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII in BTA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-18,2017-01-11,5JEH,2798,1,259,424,,29.38,1,1.13,experimental,,0.1591,0.1294,Human carbonic anhydrase II (L198A) complexed with benzo[d]thiazole-2-sulfonamide
5JEP,X-RAY DIFFRACTION,2.1,41.33,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-18,2017-01-11,5JEP,2670,1,258,459,,29.55,1,1.19,experimental,,0.1475,0.1233,Human carbonic anhydrase II (T199S) complexed with benzo[d]thiazole-2-sulfonamide
5JES,X-RAY DIFFRACTION,2.05,40.03,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-18,2017-01-11,5JES,2543,1,258,374,,29.57,1,1.205,experimental,,0.1466,0.1209,Human carbonic anhydrase II (V121T) complexed with benzo[d]thiazole-2-sulfonamide
5JG5,X-RAY DIFFRACTION,2.11,41.59,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-19,2017-01-11,5JG5,2647,1,259,445,,29.65,1,1.19,experimental,,0.1411,0.1205,Human carbonic anhydrase II (V121T/F131Y) complexed with benzo[d]thiazole-2-sulfonamide
5JGS,X-RAY DIFFRACTION,2.12,42.07,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-20,2017-01-11,5JGS,2625,1,257,441,,29.4,1,1.11,experimental,,0.1314,0.1189,Human carbonic anhydrase II (F131Y/L198A) complexed with benzo[d]thiazole-2-sulfonamide
9F9L,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"20 % PEG3350, pH 5.5",293,2024-05-07,2024-07-03,9F9L,5417,4,1268,254,,141.45,2,2.02,experimental,35.02,0.2616,0.2245,Crystal structure of MUS81-EME1 bound by compound 16.
6CCF,X-RAY DIFFRACTION,2.49,50.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"33% PEG2000 MME, 0.1 M potassium thiocyanate, 0.1 M CHC buffer, pH 7.5, cryoprotectant: 30% polyethylene glycol",280,2018-02-07,2018-03-07,6CCF,4375,2,580,271,,66.56,1,2.1,experimental,34.479,0.24384,0.21049,Crystal Structure of the Human CAMKK1A in complex with Hesperadin
5O9T,X-RAY DIFFRACTION,2.18,43.69,"VAPOR DIFFUSION, HANGING DROP",,"21% PEG 6000, 0.1M sodium citrate pH 5.6, 0.1M Magnesium chloride, 0.1M sodium chloride.",293,2017-06-20,2018-06-27,5O9T,6984,4,818,368,,97.28,2,2.15,experimental,,0.2158,0.1649,HsNMT1 in complex with CoA and acetylated-NCFSKPK peptide
4WM0,X-RAY DIFFRACTION,2.43,49.3,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Li2SO4, 0.1 M Bis-Tris, and 21% PEG3350",293,2014-10-08,2015-09-30,4WM0,2799,2,356,76,5,41.32,2,2.37,experimental,35.665,0.23283,0.18758,Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with acceptor ligand
6ERG,X-RAY DIFFRACTION,2.75,55.35,"VAPOR DIFFUSION, SITTING DROP",8.5,"18% PEG 3350, 150 mM Na sulfate , 100 mM Bis-Tris-Propane",293,2017-10-18,2018-10-17,6ERG,18989,10,2368,20,,293,3,2.9,experimental,100.04,0.244,0.218,Complex of XLF and heterodimer Ku bound to DNA
6XDF,X-RAY DIFFRACTION,3.06,59.85,"VAPOR DIFFUSION, SITTING DROP",,"10% (v/v) isopropanol, 11% (w/v) PEG4000, 0.1 M Na-citrate, pH 5.6",277,2020-06-10,2021-04-21,6XDF,6680,2,862,108,,99.12,1,2.54,experimental,61.138,0.2627,0.207,Crystal structure of IRE1a in complex with G-4100
5SD6,X-RAY DIFFRACTION,4.59,73.18,"VAPOR DIFFUSION, SITTING DROP",,"MCSG2 E5 (273901e5): 200mM Lithium sulfate, 100mM Sodium acetate:Acetic acid pH4.5, 20% (w/v) PEG8000; prot conc 26mg/mL, cryo 20% EG, puck ogi6-6",289,2021-12-20,2022-02-09,5SD6,1767,1,187,127,,23.14,1,2.15,experimental,38.7809,0.2044,0.167,Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-892
5SD8,X-RAY DIFFRACTION,4.57,73.08,"VAPOR DIFFUSION, SITTING DROP",,"JCSG+ D9 (284871d9): 170mM Ammonium sulfate, 25.5% (w/v) PEG4000, 15% (v/v) glycerol, 10mg/mL, dc, puck rfh2-7",289,2021-12-20,2022-02-09,5SD8,1784,1,187,144,,23.27,1,2.05,experimental,37.48,0.18,0.162,Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-1190 (racemic mixture)
5SDA,X-RAY DIFFRACTION,4.61,73.34,"VAPOR DIFFUSION, SITTING DROP",,"MCSG2 E5 (273949e5): 200mM Lithium sulfate, 100mM Sodium acetate:acetic acid pH4.5, 30% (w/v) PEG8000; prot conc 26mg/mL, cryo 20% EG, puck ogi6-2",289,2021-12-20,2022-02-09,5SDA,1754,1,187,106,,23.05,1,2.45,experimental,34.7762,0.2054,0.161,Crystal Structure of Dihydrofolate Reductase from Homo sapiens bound to NADP and SDDC Inhibitor SDDC-774
6UMA,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, HANGING DROP",6,"Sodium malonate pH 6.0, glycerol",283,2019-10-09,2021-04-14,6UMA,3065,2,354,202,,41.14,1,1.6,experimental,26.102,0.2059,0.1741,Crystal structure of the TRIM7 B30.2 domain at 1.6 angstrom resolution
7L35,X-RAY DIFFRACTION,2.5,50.77,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6, 100 mM lithium acetate, 15% (w/v) polyethylene glycol PEG3350",293,2020-12-17,2021-01-13,7L35,6538,4,683,608,,83.65,1,2,experimental,40.6345,0.1948,0.1626,Human DNA Ligase 1 - R771W nicked DNA complex
8AF3,X-RAY DIFFRACTION,2.11,41.79,"VAPOR DIFFUSION, HANGING DROP",5.6,"well solution 2.3M ammonium sulphate, 100 mM citric acid pH 5.6 and 200 mM NaCl",278,2022-07-15,2023-08-16,8AF3,990,1,120,44,,14.02,1,1.52,experimental,56.8164,0.2389,0.2266,"Sterol carrier protein Artifical metalloenzyme incorporating Q111C mutation coupled to 2,2'-bipyridine"
5HNU,X-RAY DIFFRACTION,2.06,40.33,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, NaCl, MES",289,2016-01-18,2017-01-25,5HNU,5322,2,630,158,,73.57,1,2,experimental,19.179,0.239,0.1954,Crystal Structure of AKR1C3 complexed with octyl gallate
6ELW,X-RAY DIFFRACTION,1.7,27.74,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 % (w/v) PEG 1500, 10 % (v/v) isopropanol, 0.1 M calcium chloride and 0.1 M imidazole/ hydrochloric acid pH 6.5",293,2017-09-29,2018-06-20,6ELW,1613,1,192,217,,21.91,1,1.3,experimental,13.116,0.15541,0.1238,High resolution structure of selenocysteine containing human GPX4
5BNL,X-RAY DIFFRACTION,2.12,42.08,"VAPOR DIFFUSION, HANGING DROP",,"Tris.HCl pH 7.7-7.8 , sodium 4-(hydroxymercury)benzoate",277,2015-05-26,2015-07-15,5BNL,2297,1,257,223,,29.36,1,2,experimental,13.443,0.2932,0.2231,Deciphering the Mechanism of Carbonic Anhydrase Inhibition with Coumarins and Thiocoumarins
7NRB,X-RAY DIFFRACTION,2.38,48.28,"VAPOR DIFFUSION, SITTING DROP",,"10%-15% PEG 3350, 100mM BisTris propane/citric acid, pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 296K",296,2021-03-03,2022-01-12,7NRB,2387,1,336,140,,38.92,1,1.9,experimental,47.59,0.2355,0.2124,Re-refinement of MK3-inhibitor complex
6CD6,X-RAY DIFFRACTION,2.3,46.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"33.75% PEG2000 MME, 0.15 M potassium thiocyanate, 0.1 M CHC buffer, pH 7.0, cryoprotectant: 30% polyethylene glycol",280,2018-02-08,2018-03-07,6CD6,8439,4,1160,110,,132.48,1,2.2,experimental,59.267,0.2849,0.23213,Crystal Structure of the Human CAMKK1A in complex with GSK650394
9F99,X-RAY DIFFRACTION,3.12,60.63,"VAPOR DIFFUSION, SITTING DROP",,15% ethanol,293,2024-05-07,2024-06-19,9F99,10145,8,2536,,,282.48,2,2.803,experimental,70,0.2804,0.2401,Crystal structure of MUS81-EME1 bound by compound 10.
9F9A,X-RAY DIFFRACTION,2.69,54.29,"VAPOR DIFFUSION, SITTING DROP",,20 % ethanol,297,2024-05-07,2024-06-19,9F9A,10093,8,2536,,,282.54,2,2.911,experimental,70,0.2782,0.2429,Crystal structure of MUS81-EME1 bound by compound 12.
6YF2,X-RAY DIFFRACTION,1.88,34.44,"VAPOR DIFFUSION, HANGING DROP",,"1.9 M AmSO4, 0.15 M CdCl2",298,2020-03-25,2021-03-10,6YF2,1109,1,109,144,,13.02,1,1.03,experimental,10.47,0.1488,0.1409,FKBP12 in complex with the BMP potentiator compound 6 at 1.03A resolution
6YF3,X-RAY DIFFRACTION,1.86,33.77,"VAPOR DIFFUSION, HANGING DROP",,"2.2 M AmSO4, 0.2 M CdCl2",298,2020-03-25,2021-03-10,6YF3,1090,1,109,142,,12.97,1,1,experimental,12.409,0.1582,0.1574,FKBP12 in complex with the BMP potentiator compound 10 at 1.00A resolution
8JC5,X-RAY DIFFRACTION,3.04,59.48,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Lithium chloride, 0.1 M TRIS pH=7.6, 18% (w/v) PEG 8000",298,2023-05-10,2024-03-27,8JC5,6083,4,730,288,,83.69,2,2.01,experimental,51.15,0.2009,0.1669,Crystal structure of PLEKHM1 RUN domain in complex with GTP-bound Arl8b(Q75L)
8ASC,X-RAY DIFFRACTION,3.3,62.78,"VAPOR DIFFUSION, HANGING DROP",8.5,12% PEG- 3350; 0.1 M Bis-Tris Propane pH 8.5; 0.3 M Ammonium Sulfate,290,2022-08-19,2023-06-21,8ASC,36383,18,4700,20,2,573.91,3,2.95,experimental,101.0598,0.2981,0.252,Ku70/80 binds to the Ku-binding motif of PAXX
6FZ2,X-RAY DIFFRACTION,2.33,47.22,"VAPOR DIFFUSION, HANGING DROP",4.5,"24% PEG 4000
5 mM NiCl2
0.1 M Na citrate
5% Glycerol",293,2018-03-13,2019-03-27,6FZ2,6426,2,806,256,,96.76,1,2.05,experimental,32.57,0.27786,0.23657,Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor bound
6FZ3,X-RAY DIFFRACTION,2.16,43.08,VAPOR DIFFUSION,4.5,"24% PEG 4000
5 mM NiCl2
0.1 M Na citrate
5% Glycerol",293,2018-03-13,2019-03-27,6FZ3,6489,2,806,181,,97.04,1,2,experimental,27.798,0.23492,0.19865,Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor bound
6HLN,X-RAY DIFFRACTION,3.99,69.16,"VAPOR DIFFUSION, SITTING DROP",,"10% w/v PEG 8000, 6% v/v 1,5-pentanediol, 14% v/v PEG 200, 10 mM spermine, 10 mM spermidine, 10 mM DL-ornithine, 10 mM 1,4-diaminobutane, 300 mM NaCl, 100 mM GlyGly/AMPD pH 8.5",291,2018-09-11,2019-07-24,6HLN,1458,2,229,33,,26.3,2,2.1,experimental,47.7,0.2508,0.2206,Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of enterovirus-D68
6HMV,X-RAY DIFFRACTION,2.85,56.82,"VAPOR DIFFUSION, SITTING DROP",,"12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD, 30 mM MgCl2, 30 mM CaCl2, 100 mM bicine/Tris pH 8.5",291,2018-09-13,2019-07-24,6HMV,1391,2,218,,,24.71,2,2.244,experimental,,0.2652,0.2305,"Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of enterovirus-D68 (fusion protein, LVVY mutant)"
9F9K,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"12 % PEG8000, pH 5.5",293,2024-05-07,2024-07-03,9F9K,4919,4,1268,,,141.27,2,2.728,experimental,70.97,0.2543,0.2327,Crystal structure of MUS81-EME1 bound by compound 15.
9F9M,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"15 % PEG10K, pH 6.5",293,2024-05-08,2024-06-19,9F9M,4941,4,1268,,,141.34,2,2.469,experimental,75.63,0.3256,0.3059,Crystal structure of MUS81-EME1 bound by compound 21.
6FJI,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.15,42.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.2 M sodium citrate
100 mM Tris pH 8.5",293,2018-01-22,2019-02-06,6FJI,2303,1,260,199,,29.27,1,"1.6, 2.033",experimental,,0.1613,0.1297,Joint neutron and x-ray crystal structure of human carbonic anhydrase IX mimic (apo).
,,,,,,,,,,,,,,,,,,,,,0.2216,0.1854,
5D0K,X-RAY DIFFRACTION,3.62,66.01,"VAPOR DIFFUSION, HANGING DROP",,"MES, sodium chloride, PEG 6000",291.15,2015-08-03,2015-12-09,5D0K,9395,12,1280,3,,144.85,3,2.65,experimental,,0.2377,0.1919,Structure of UbE2D2:RNF165:Ub complex
5HKX,X-RAY DIFFRACTION,2.36,47.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"10% (w/v) PEG 5000 MME, 0.1M MES, 12% (v/v) 1-propanol",293,2016-01-14,2017-01-18,5HKX,3219,1,392,235,,45.38,1,1.85,experimental,28.318,0.2136,0.1667,Crystal Structure of c-Cbl TKBD-RING domains (Y371E mutant) Refined to 1.85 A Resolution
7S0Z,X-RAY DIFFRACTION,2.62,52.99,"VAPOR DIFFUSION, HANGING DROP",,"0.2M ammonium acetate, 0.1M sodium citrate tribasic dihydrate, pH 4.8, and 17% PEG 4000",291,2021-08-31,2021-09-08,7S0Z,12426,4,1440,539,,169.42,2,2.34,experimental,37.61,0.241,0.201,Structures of TcdB in complex with R-Ras
8JP2,X-RAY DIFFRACTION,2.2,44.19,"VAPOR DIFFUSION, HANGING DROP",7.3,"23-27% (w/v) PEG 4000, 100 mM Hepes , 10 mM CaCl2 and 0.4 M NaCl",298,2023-06-10,2024-04-24,8JP2,3065,1,323,443,,37.84,1,1.8,experimental,,0.2491,0.1965,Crystal structure of AKR1C1 in complex with DFV
5D0M,X-RAY DIFFRACTION,2.27,45.71,"VAPOR DIFFUSION, HANGING DROP",,"SPG buffer, PEG 1500",291.15,2015-08-03,2015-12-09,5D0M,2307,3,315,100,,35.82,3,1.913,experimental,,0.2127,0.1787,Structure of UbE2D2:RNF165:Ub complex
6RQN,X-RAY DIFFRACTION,2.17,43.44,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% (w/v) PEG 4000, 0.2 M sodium acetate, 0.1 M Tris-HCl pH 8.5",298,2019-05-16,2019-09-11,6RQN,2396,1,256,248,1,28.22,1,1.777,experimental,27.2776,0.2052,0.1698,X-ray crystal structure of protiated (H) small monoclinic unit cell CA IX SV.
6RQU,X-RAY DIFFRACTION,2.2,44.06,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% (w/v) PEG 4000, 0.2 M sodium acetate, 0.1 M Tris-HCl pH 8.5",298,2019-05-16,2019-10-16,6RQU,2381,1,256,255,1,28.22,1,1.393,experimental,29.7701,0.1881,0.1726,X-ray crystal structure of H/D exchanged (H/D) small monoclinic unit cell CA IX SV.
7BD2,X-RAY DIFFRACTION,1.99,38.09,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BD2,2849,1,383,92,6,44.45,1,1.52,experimental,27.1214,0.221,0.1995,Notum Fragment 810
6QGS,X-RAY DIFFRACTION,2.52,51.2,"VAPOR DIFFUSION, SITTING DROP",,"10% of polyethylene glycol (PEG) 8000, 0.2 M potassium bromide, 01.M sodium acetate at pH 5.5,10%w/v PEG1000",291,2019-01-12,2020-02-05,6QGS,10240,6,1398,196,,150.51,1,2.755,experimental,,0.2301,0.1837,Crystal structure of APT1 bound to palmitic acid.
5D75,X-RAY DIFFRACTION,2.57,52.08,"VAPOR DIFFUSION, HANGING DROP",7,"30% v/v Jeffamine ED-2001, 0.1M HEPES pH 7.0",291,2015-08-13,2016-04-06,5D75,1146,1,124,106,,16.03,1,1.83,experimental,25.411,0.23311,0.187,Crystal structure of Human FKBD25 in complex with FK506
6NJ6,X-RAY DIFFRACTION,2.5,50.8,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M AMMONIUM SULFATE, 30% PEG 4000,
 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 278K",278,2019-01-02,2019-10-02,6NJ6,5018,2,532,630,,61.62,1,1.6,experimental,,0.193,0.164,Thermostable variant of human carbonic anhydrase with tetrazine 2.0 at site 186 reacted with sTCO in crystallo
8AF2,X-RAY DIFFRACTION,,35.13,"VAPOR DIFFUSION, HANGING DROP",,"well solution 2.3M ammonium sulphate, 100 mM citric acid pH 5.6 and 200 mM NaCl",281,2022-07-15,2023-08-16,8AF2,2052,2,256,21,,29.98,1,2.51,experimental,48.14,0.2997,0.2338,"Human Sterol Carrier Protein with unnatural amino acid 2,2'-bipyridine alanine incorporated at position 111"
8CPQ,X-RAY DIFFRACTION,2.29,46.33,"VAPOR DIFFUSION, SITTING DROP",,"1.9M (NH4)2SO4, 0.1M Hepes 7.0, 1% DMSO",293,2023-03-03,2024-03-13,8CPQ,1322,1,174,153,1,19.19,1,1.8,experimental,,0.2115,0.1759,Crystal structure of human protein disulfide isomerase PDIA6 domain b
6GCY,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.16,43.07,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.2 M sodium citrate, 0.1 M Tris pH 8.5 in Hampton sandwich box set-ups. Drops were 150-250 uL and we set-up in a 1:1 ratio. To get the complex with SGC ligand we did ""dry co-crystallization"".",293,2018-04-20,2019-02-06,6GCY,2381,1,260,208,,29.71,1,"1.3, 2",experimental,,0.1551,0.1478,Joint neutron and x-ray crystal structure of human carbonic anhydrase IX mimic (saccharin-sugar conjugate complex)
,,,,,,,,,,,,,,,,,,,,,0.2122,0.191,
6P1O,X-RAY DIFFRACTION,2.863,57.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES pH 7.5, 100mM NaCl, 10% w/v PEG4000",277,2019-05-20,2019-09-04,6P1O,3418,4,372,372,,46.51,1,1.65,experimental,,0.187,0.1672,Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated dAMP
6P1U,X-RAY DIFFRACTION,2.86,57,"VAPOR DIFFUSION, SITTING DROP",7.5,"94mM HEPES pH 7.5, 94mM NaCl, 9.4% v/s PEG4000",277,2019-05-20,2019-09-04,6P1U,3369,4,372,306,,46.53,1,1.75,experimental,,0.1926,0.1693,Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated CMP
7BSD,X-RAY DIFFRACTION,3.48,64.65,"VAPOR DIFFUSION, SITTING DROP",,14% v/vPoly(acrylic acid-co-maleic acid) solution,291,2020-03-30,2020-12-23,7BSD,7896,6,1244,195,14,137.89,3,2.53,experimental,49.73,0.2388,0.2208,Complex structure of 1G5.3 Fab bound to ZIKV NS1c
7N8K,X-RAY DIFFRACTION,2.22,44.51,EVAPORATION,6,0.1M LiSO4; 26% PEG 2000 MME,298,2021-06-15,2021-10-13,7N8K,4045,2,476,256,,55.2,1,2.01,experimental,33.53,0.2361,0.192,LINE-1 endonuclease domain complex with Mg
6KYZ,X-RAY DIFFRACTION,2.59,52.53,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M citrate
40% PEG600",293,2019-09-20,2020-05-27,6KYZ,6813,6,872,532,,93.18,3,1.845,experimental,23.4076,0.2081,0.1745,HRV14 3C in complex with single chain antibody YDF
5FIW,X-RAY DIFFRACTION,2.39,48.54,,6,"15% PEG 3350, 100 MM NACL, pH 6",,2015-10-02,2015-10-14,5FIW,10331,4,1142,926,13,134.94,2,1.7,experimental,23.238,0.19267,0.16296,CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE AT 1.7 ANGSTROMS RESOLUTION
8RNH,X-RAY DIFFRACTION,2.56,51.93,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Lithium Acetate, 20% w/v PEG 3350, and 10 mM MgCl2",293,2024-01-10,2024-05-08,8RNH,3510,3,385,241,3,44.98,3,1.6,experimental,24.48,0.2345,0.2016,"Crystal structure of HLA B*18:01 in complex with EEIEITTHF, an 9-mer epitope from Influenza A"
6F56,X-RAY DIFFRACTION,2.28,45.99,"VAPOR DIFFUSION, HANGING DROP",4.6,"PEG 4000 22 %
Sodium citrate 0.1 M
Glycerol 2.5 %",293.15,2017-11-30,2019-03-20,6F56,13363,4,1640,463,,195.22,1,1.9401987668,experimental,34.4604115534,0.239438285168,0.199550279057,Mutant of Human N-myristoyltransferase with bound myristoyl-CoA
6M7T,X-RAY DIFFRACTION,3.43,64.12,"VAPOR DIFFUSION, HANGING DROP",,"16 % PEG 2000 MME
100 mM MES, pH 6.0",295,2018-08-21,2018-09-12,6M7T,3809,3,454,33,,55.32,1,2.8,experimental,,0.2612,0.2201,Human DNA polymerase eta in a non-productive ternary complex with Ca2+ and dTTP oppositing cdA
5MU6,X-RAY DIFFRACTION,2.27,45.96,"VAPOR DIFFUSION, SITTING DROP",,"23% (v/w) MME2K, 0.2M KBr, 100 mM sodium citrate pH 4.5, and 5% (v/v) glycerol",293,2017-01-12,2018-02-14,5MU6,6941,2,782,456,,94.19,1,1.88,experimental,17.82,0.2467,0.2038,Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and IMP-1088 inhibitor bound
5UWL,X-RAY DIFFRACTION,4.47,72.49,"VAPOR DIFFUSION, SITTING DROP",7,"0.2 M sodium chloride, 0.1 M Tris pH 7, 1.0 M sodium citrate",277,2017-02-21,2017-07-12,5UWL,2686,2,344,62,,40.09,1,2.55,experimental,,0.2395,0.1988,Matrix metalloproteinase-13 complexed with selective inhibitor compound (S)-17a
6IIE,X-RAY DIFFRACTION,2.82,56.33,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M HEPES, 1.0 M succinic acid, 2 % PEG monomethyl ether 2000, 10 % glycerol",296,2018-10-04,2019-02-20,6IIE,749,1,93,9,,11.27,1,2.142,experimental,60.056,0.2376,0.1854,Crystal structure of human diacylglycerol kinase alpha EF-hand domains bound to Ca2+
4UZ7,X-RAY DIFFRACTION,2.3,47,,8.5,20 %V/V GLYCEROL 24 %W/V PEG4000 0.160 M MGCL2 0.080 M TRIS-HCL PH 8.5 20MM SOS,,2014-09-04,2015-02-25,4UZ7,5921,2,766,208,14,87.17,1,2.2,experimental,33.807,0.22864,0.18271,STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM VI - 2.2A
4YR8,X-RAY DIFFRACTION,2.14,42.44,"VAPOR DIFFUSION, HANGING DROP",7,"0.1M HEPES, pH 7.0, 14% PEG 3350, 0.2M MgCl2, 6% 1,6-Hexanediol, 0.005M EDTA",294,2015-03-14,2016-03-16,4YR8,14988,8,2152,356,,247.14,2,2.4,experimental,46.81,0.239,0.217,Crystal structure of JNK in complex with a regulator protein
5TDC,X-RAY DIFFRACTION,1.73,28,"VAPOR DIFFUSION, HANGING DROP",,"2.2 M (NH4)2SO4, 0.2 K/Na Tartrate",293,2016-09-19,2017-03-22,5TDC,1252,4,160,71,,18.3,2,1.607,experimental,,0.1804,0.1489,Crystal structure of the human UBR-box domain from UBR1 in complex with monomethylated arginine peptide.
5IPZ,X-RAY DIFFRACTION,2.21,43.9,"VAPOR DIFFUSION, SITTING DROP",6.5,"Crystallization buffer was 0.2 M ammonium sulfate, 0.1 M sodium MES (pH 6.5) and 20% PEG MME 2,000",291,2016-03-10,2017-03-29,5IPZ,8427,4,1068,120,7,123.11,1,2.1,experimental,50.333,0.306,0.225,"Crystal structure of human carbonic anhydrase isozyme IV with 5-(2-amino-1,3-thiazol-4-yl)-2-chlorobenzenesulfonamide"
6QVS,X-RAY DIFFRACTION,3.31,62.84,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.1 M Ammonium Acetate, 8% (w/v) PEG 20.000",293,2019-03-04,2020-06-10,6QVS,4886,2,550,409,7,63.91,1,1.6,experimental,29.3099,0.2005,0.1811,"Unliganded structure of the human wild type Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6Gal1)"
5NPQ,X-RAY DIFFRACTION,2.27,45.89,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1M NaCit pH 4.5, 5mM NiCl2, 2.5% glycerol and PEG 4K 18%
Protein concentration: 7.05 mg/ml",293,2017-04-18,2018-05-30,5NPQ,6174,2,782,129,,93.32,1,2.372,experimental,34.6127,0.2606,0.1991,Human N-myristoyltransferase 1 (MNT1) with Myristoyl-CoA analogue X10 bound
6A7A,X-RAY DIFFRACTION,2.21,44.29,"VAPOR DIFFUSION, HANGING DROP",,"23-27% (w/v) PEG 4000, 100 mM Hepes, 10mM CaCl2, 0.4M NaCl",289,2018-07-02,2019-07-03,6A7A,2782,1,338,161,,39.87,1,2.37,experimental,,0.2233,0.1552,AKR1C1 complexed with new inhibitor with novel scaffold
7ERE,X-RAY DIFFRACTION,2.21,44.38,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.9-2.0M Ammonium sulfate, 0.1M Bis-tris(pH 6.5)",291.15,2021-05-06,2022-01-19,7ERE,7467,4,828,792,,94.35,1,1.6,experimental,23.39,0.198,0.1709,Crystal structure of human Biliverdin IX-beta reductase B with Pyrantel Pamoate (PPA)
5G0C,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, SITTING DROP",8.5,SITTING DROP PLATES WITH 200 NL PROTEIN AT 5 MG/ML AND 200 NL RESERVOIR WITH 2.6 TO 2.8 M AMMONIUM SULFATE AND 100 MM TRIS AT PH 8.5,,2016-03-17,2016-05-25,5G0C,2616,1,260,323,,29.7,1,1.28,experimental,13.377,0.1631,0.12992,"An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C"
6IJX,X-RAY DIFFRACTION,2.16,43.13,"VAPOR DIFFUSION, HANGING DROP",,"23-27% (w/v) PEG 4000, 100 mM Hepes, 10mM CaCl2, 0.4M NaCl",289,2018-10-12,2019-10-16,6IJX,2830,1,323,231,,37.88,1,2.2,experimental,,0.214,0.1591,Crystal Structure of AKR1C1 complexed with meclofenamic acid
4PXX,X-RAY DIFFRACTION,1.93,36.18,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2M MgCl2, 0.1M Tris-HCl, 30% (w/v) PEG 4000, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-03-25,2015-06-10,4PXX,2225,1,260,127,1,29.78,1,1.851,experimental,11.98,0.2287,0.1861,Crystal structure of a highly thermal stabilized variant of Human Carbonic Anhydrase II
6HLW,X-RAY DIFFRACTION,2.7,54.43,"VAPOR DIFFUSION, SITTING DROP",,"5% w/v PEG 20.000, 25% v/v 1,1,1-tris(hydroxymethyl)propane, 1% w/v NDSB 201, 0.5 mM MgCl2, 0.5mM CoCl2, 0.5 mM NiCl2, 0.5 mM ZnCl2, 100 mM BES/TEA pH 7.5",291,2018-09-11,2019-07-24,6HLW,2690,4,432,,,49.29,2,2.728,experimental,75.8,0.2559,0.2422,Crystal structure of human ACBD3 GOLD domain in complex with 3A protein of enterovirus-A71 (fusion protein)
4WMA,X-RAY DIFFRACTION,2.46,50.03,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Li2SO4, 0.1 M Bis-Tris, and 21% PEG3350",293,2014-10-08,2015-09-30,4WMA,2905,2,356,135,5,42.04,2,1.62,experimental,31.982,0.24252,0.21914,"Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese,acceptor ligand and UDP-Glucose"
4WMI,X-RAY DIFFRACTION,2.39,48.47,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Li2SO4, 0.1 M Bis-Tris, pH 6.5, and 21% PEG3350",293,2014-10-09,2015-09-30,4WMI,2883,2,356,120,5,42.01,2,1.87,experimental,30.483,0.22565,0.19477,"Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese, product ligand and UDP (Product complex I)"
4WMK,X-RAY DIFFRACTION,2.38,48.22,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Li2SO4, 0.1 M Bis-Tris, and 21% PEG3350",293,2014-10-09,2015-09-30,4WMK,2849,2,356,86,5,42.01,2,2.08,experimental,32.348,0.24571,0.19119,"Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese, product ligand and UDP (Product complex II)"
4WN2,X-RAY DIFFRACTION,2.43,49.35,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Li2SO4, 0.1 M Bis-Tris, and 21% PEG3350",293,2014-10-10,2015-09-30,4WN2,2880,2,356,92,5,42.01,2,1.95,experimental,36.386,0.23853,0.19485,"Crystal structure of mouse Xyloside xylosyltransferase 1 complexed with manganese, product ligand and UDP (Product complex III)"
7ERA,X-RAY DIFFRACTION,2.18,43.6,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.9-2.0M Ammonium sulfate, 0.1M Bis-tris (pH 6.5)",291.15,2021-05-06,2022-01-19,7ERA,3882,2,414,524,,47.24,1,1.35,experimental,20.61,0.1738,0.1543,Crystal structure of human Biliverdin IX-beta reductase B with Olsalazine Sodium (OSS)
5C8I,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.16,43.03,"VAPOR DIFFUSION, SITTING DROP",7.8,"1.6M Na-citrate, 50 mM Tris",298,2015-06-25,2016-07-20,5C8I,2141,1,260,77,,29.59,1,"1.56, 2.2",experimental,21.3,0.221,0.204,Joint X-ray/neutron structure of Human Carbonic Anhydrase II in complex with Methazolamide
,,,,,,,,,,,,,,,,,,,,21.3,0.276,0.225,
6O33,X-RAY DIFFRACTION,2.25,45.44,"VAPOR DIFFUSION, HANGING DROP",7.2,"100 mM HEPES, pH 7.2, 3.0 M ammonium sulfate",298,2019-02-25,2020-02-26,6O33,1366,2,169,116,,19,2,1.74,experimental,39.7863,0.2375,0.1979,Crystal Structure Analysis of PIN1
6O34,X-RAY DIFFRACTION,2.25,45.32,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES, pH 7.2, 3.0 M ammonium sulfate",298,2019-02-25,2020-02-26,6O34,1346,2,169,93,,19.56,2,1.57,experimental,38.6968,0.2513,0.2033,Crystal Structure Analysis of PIN1
6MV1,X-RAY DIFFRACTION,2.61,52.9,"VAPOR DIFFUSION, SITTING DROP",7,"10% (w/v) PEG 6000, 0.1 M Hepes, 0.2 M NDSB-201",291,2018-10-24,2019-07-17,6MV1,2982,1,367,132,,43.57,1,2.15,experimental,38.2472,0.2301,0.1828,2.15A resolution structure of the CS-b5R domains of human Ncb5or (NAD+ form)
4YVP,X-RAY DIFFRACTION,2.3,46.58,"VAPOR DIFFUSION, HANGING DROP",7.3,"23-27% (w/v) PEG 4000, 100 mM Hepes, 10mM CaCl2, 0.4M NaCl",289,2015-03-20,2015-11-25,4YVP,5390,2,646,136,,76.15,1,2.6,experimental,19.05,0.24724,0.21159,Crystal Structure of AKR1C1 complexed with glibenclamide
6U5L,X-RAY DIFFRACTION,3.45,64.34,"VAPOR DIFFUSION, HANGING DROP",7.25,"PEG 6000, Imidazole",298,2019-08-28,2019-12-25,6U5L,2449,1,287,156,,33.19,1,1.75,experimental,45.8982,0.2165,0.191,Structure of human ULK4 in complex with an inhibitor
6Y3E,X-RAY DIFFRACTION,2.67,53.86,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.17 M Sodium acetate trihydrate,0.085 M Sodium cacodylate trihydrate pH 6.5,25.5% w/v Polyethylene glycol 8,000.",298,2020-02-18,2020-03-04,6Y3E,1506,1,165,190,,19.35,1,1.45,experimental,24.8851,0.2342,0.1948,Scaffold-ligand complex with ligand unmodelled
6HEM,X-RAY DIFFRACTION,2.59,52.6,"VAPOR DIFFUSION, SITTING DROP",6.5,"20% (w/v) PEG 4000, 600 mM sodium chloride, 100 mM MES pH 6.5",291,2018-08-20,2019-03-27,6HEM,2793,1,303,349,,36.12,1,1.72,experimental,,0.2087,0.181,Structure of the C-terminal domain of USP25 (748-1048)
5O6H,X-RAY DIFFRACTION,2.28,45.95,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.4M Sodium phosphate buffer, 17.5% PEG 3350",291,2017-06-06,2018-05-16,5O6H,7829,2,782,1018,,94.87,1,1.29,experimental,17.134,0.19348,0.16384,Human NMT1 in complex with myristoyl-CoA and inhibitor IMP-917
7BO1,X-RAY DIFFRACTION,2,38.49,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-23,2022-03-02,7BO1,3006,1,382,133,6,44.96,1,1.4,experimental,22.5012,0.2159,0.1819,Notum Fragment_274 [(4-fluorophenyl)amino]thiourea
5I0N,X-RAY DIFFRACTION,2.51,51.02,"VAPOR DIFFUSION, SITTING DROP",,"12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD, 0.1 M bicine/Trizma base pH 8.5",295,2016-02-04,2016-03-09,5I0N,4228,1,556,222,,64.34,1,2.28,experimental,,0.2577,0.2192,PI4K IIalpha bound to calcium
4WEV,X-RAY DIFFRACTION,2.47,50.22,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2014-09-11,2015-01-14,4WEV,2937,1,316,213,,37.51,1,1.453,experimental,20.0131,0.2067,0.1877,Crystal structure of human AKR1B10 complexed with NADP+ and sulindac
6VCU,X-RAY DIFFRACTION,2.2,44.03,"VAPOR DIFFUSION, HANGING DROP",4.6,"2.5M Ammonium sulfate, 0.1M Sodium acetate trihydrate",293,2019-12-23,2020-12-16,6VCU,4239,4,444,591,,52.74,1,1.69,experimental,15.68,0.1955,0.1559,Homo sapiens FKBP12 protein bound with APX879 in P32 space group
8UC5,X-RAY DIFFRACTION,2.78,55.73,"VAPOR DIFFUSION, SITTING DROP",7,"Well solution: 2.1 M DL-Malic acid pH 7.0.
Protein solution: 15 mg/mL protein, 20 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT, and 5% glycerol.
Drop: 1 uL protein, 1 uL well solution",293,2023-09-25,2024-09-04,8UC5,4190,3,498,349,,54.61,1,1.43,experimental,18.71,0.1754,0.1442,Apo X-ray crystal structure of Cyclophilin D with a surface entropy reduction mutation (K175I)
6WR1,X-RAY DIFFRACTION,2.5,50.81,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris HCl, pH 8.5, 30% PEG 3350, 250 mM Li2SO4, 3% glycerol, covered with Al's oil",293.15,2020-04-29,2021-05-05,6WR1,8068,2,988,494,,113.51,1,1.85,experimental,40.5,0.2179,0.1897,Human steroidogenic cytochrome P450 17A1 mutant N52Y with inhibitor abiraterone
6QVT,X-RAY DIFFRACTION,3.21,61.62,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.1 M Ammonium Acetate, 10% (w/v) PEG 6000",293,2019-03-04,2020-06-10,6QVT,4835,2,550,258,6,65.05,1,1.7,experimental,35.2105,0.2042,0.1817,"CMP-Sialic acid bound structure of the human wild type Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6Gal1)"
8SW0,X-RAY DIFFRACTION,2.69,54.24,"VAPOR DIFFUSION, HANGING DROP",8.5,"5-8 mg/ml PSA mixed 1:1 with 15% PEG 4K, 0.1 M Tris (pH 8.5), 0.5 M sodium chloride, and 1.5% v/v dioxane",289,2023-05-17,2023-07-26,8SW0,7055,1,902,184,,102.14,1,2.301,experimental,67.995,0.2406,0.2233,Puromycin sensitive aminopeptidase
7B2Z,X-RAY DIFFRACTION,1.93,36.11,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-11-28,2021-08-04,7B2Z,2952,1,383,108,6,44.62,1,1.24,experimental,23.1365,0.2087,0.1958,Notum complex with ARUK3003907
7B3X,X-RAY DIFFRACTION,1.93,36.36,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-12-01,2021-12-08,7B3X,2823,1,383,98,6,44.48,1,1.34,experimental,22.7327,0.2035,0.1982,Notum complex with ARUK3003748
7B50,X-RAY DIFFRACTION,1.93,36.37,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-12-03,2022-01-12,7B50,2848,1,383,104,6,44.6,1,1.33,experimental,24.1392,0.2051,0.2008,Notum complex with ARUK3003778
7ZDD,X-RAY DIFFRACTION,2.24,45.09,"VAPOR DIFFUSION, SITTING DROP",5,"0.2 M ammonium chloride, 0.1 M sodium acetate pH 5.0, 20% w/v PEG 6000",295.15,2022-03-29,2022-06-29,7ZDD,1700,2,204,183,,23.83,2,1.625,experimental,24.22,0.2502,0.2077,Crystal structure of TRIM33 PHD-Bromodomain isoform B in complex with H3K10ac histone peptide.
5GVC,X-RAY DIFFRACTION,2.72,54.83,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES-Na, 0.2 M MgCl2, 25% PEG3350",277,2016-09-05,2017-06-14,5GVC,10004,2,1230,411,,138.68,1,2.436,experimental,,0.2292,0.182,Human Topoisomerase IIIb topo domain
8XI9,X-RAY DIFFRACTION,2.45,49.9,"VAPOR DIFFUSION, SITTING DROP",7.4,4.4M Sodium Acetate,293,2023-12-19,2024-08-07,8XI9,1809,1,202,115,,24.24,1,1.85,experimental,30.64,0.2184,0.1872,Crystal structure of FRB-FKBP fusion protein in complex with rapamycin
8EXN,X-RAY DIFFRACTION,3.64,66.17,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Calcium Acetate, 12.5% PEG 4K, 0.05 M MES (pH 6.5)",281.15,2022-10-25,2023-07-05,8EXN,2492,2,314,74,,36.9,2,2.151,experimental,64.5384,0.2408,0.2177,Crystal structure of PTP1B D181A/Q262A phosphatase domain with TYK2 activation loop phosphopeptide
7B4X,X-RAY DIFFRACTION,1.93,36.18,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-12-02,2022-01-12,7B4X,2929,1,383,128,6,44.98,1,1.24,experimental,24.5443,0.2191,0.2024,Notum complex with ARUK3002697
5OOH,X-RAY DIFFRACTION,2.4,48.76,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 3350, 0.2 M AMMONIUM SULFATE, 0.1 M SODIUM CACODYLATE PH 6.5. NADP ADDED TO A FINAL CONCENTRATION OF 2.5 MM",293,2017-08-07,2018-03-07,5OOH,2009,1,206,319,,23.82,1,1.2,experimental,,0.1474,0.122,Human biliverdin IX beta reductase: NADP/Erythrosin extra bluish ternary complex
7ER6,X-RAY DIFFRACTION,2.26,45.46,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.9M-2.0M Ammonium sulfate, 0.1M Bis-tris (pH 6.5)",291.15,2021-05-06,2022-01-19,7ER6,3640,2,412,413,,46.07,1,1.6,experimental,23.9,0.198,0.1619,Crystal structure of human Biliverdin IX-beta reductase B
7ER7,X-RAY DIFFRACTION,2.23,44.83,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.9M-2.0M Ammonium sulfate, 0.1M Bis-tris (pH 6.5)",291.15,2021-05-06,2022-01-19,7ER7,3597,2,414,305,,46.99,1,1.7,experimental,27.31,0.2096,0.1766,Crystal structure of hyman Biliverdin IX-beta reductase B with Tamibarotene (A80)
7ER9,X-RAY DIFFRACTION,2.19,43.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.9-2.0M Ammonium sulfate, 0.1M Bis-tris (pH 6.5)",291.15,2021-05-06,2022-01-19,7ER9,3789,2,432,463,,49.56,1,1.45,experimental,24.35,0.1904,0.1552,Crystal structure of human Biliverdin IX-beta reductase B with Febuxostat (TEI)
7ERC,X-RAY DIFFRACTION,2.27,45.76,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.9-2.0M Ammonium sulfate, 0.1M Bis-tris (pH 6.5)",291.15,2021-05-06,2022-01-19,7ERC,3580,2,412,326,,46.25,1,1.5,experimental,30.38,0.2274,0.1951,Crystal structure of human Biliverdin IX-beta reductase B with Deferasirox (ICL)
7ERD,X-RAY DIFFRACTION,2.25,45.29,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.9-2.0M Ammonium sulfate, 0.1M Bis-tris (pH 6.5)",291.15,2021-05-06,2022-01-19,7ERD,3469,2,412,207,,46.57,1,2,experimental,35.41,0.229,0.1796,Crystal structure of human Biliverdin IX-beta reductase B with Flunixin Meglumin (FMG)
5E2M,X-RAY DIFFRACTION,2.26,45.3,"VAPOR DIFFUSION, SITTING DROP",8.4,"Crystallization buffer contains 0.1M TrisHCl (pH 8.5), 0.2M ammonium acetate, 28% of PEG4000",291,2015-10-01,2016-10-05,5E2M,4745,2,520,535,,58.96,1,1.41,experimental,21.131,0.207,0.182,"Crystal structure of human carbonic anhydrase isozyme I with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
6DTN,X-RAY DIFFRACTION,2.27,45.91,"VAPOR DIFFUSION, HANGING DROP",,1.5 M lithium sulfate; 0.1 M sodium HEPES 7.5,293,2018-06-18,2019-04-03,6DTN,2174,2,249,249,,28.41,2,1.475,experimental,,0.1893,0.1681,The structure of NTMT1 in complex with compound DC100-1
5XVA,X-RAY DIFFRACTION,2.08,40.98,VAPOR DIFFUSION,6.5,"0.1 M Imidazole pH 6.5, 1.0 M sodium acetate trihydrate",291,2017-06-27,2018-02-07,5XVA,2543,1,293,184,,33.67,1,1.847,experimental,26.904,0.2092,0.1679,Crystal Structure of PAK4 in complex with inhibitor CZH216
4RIV,X-RAY DIFFRACTION,2.08,40.91,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-10-07,2015-02-04,4RIV,2375,1,260,210,,29.72,1,1.631,experimental,,0.1898,0.165,A Carbonic Anhydrase IX Mimic in Complex with Saccharin
6AK7,X-RAY DIFFRACTION,4.77,74.19,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris, pH 8.5, 12% PEG 3350, 0.2 M MgCl2, 10 mM Mercaptoethanol",293,2018-08-30,2019-09-11,6AK7,2089,1,257,104,,28.45,1,2.605,experimental,47.1155,0.2243,0.1924,Crystal structure of PPM1K-N94K
4XZM,X-RAY DIFFRACTION,2.49,50.62,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2015-02-04,2015-11-18,4XZM,2846,1,316,180,,37.22,1,1.75,experimental,,0.2499,0.203,Crystal structure of the methylated wild-type AKR1B10 holoenzyme
4XZN,X-RAY DIFFRACTION,2.56,52.04,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2015-02-04,2015-11-18,4XZN,2865,1,316,181,,37.25,1,1.7,experimental,,0.2283,0.1955,Crystal structure of the methylated K125R/V301L AKR1B10 Holoenzyme
6OPL,X-RAY DIFFRACTION,2.95,58.34,"VAPOR DIFFUSION, SITTING DROP",6.5,"mother liquor: 0.1 M MES monohydrate, 12% w/v PEG20000, 1 M sodium chloride",277,2019-04-25,2020-04-29,6OPL,1844,1,205,247,,22.79,1,1.37,experimental,,0.2617,0.2323,Human biliverdin IX beta reductase Q14R mutant: NADP complex
5KRE,X-RAY DIFFRACTION,2.09,41.04,"VAPOR DIFFUSION, HANGING DROP",8,"Reservoir: 22% PEG 3350 and 100mM ammonium nitrate, Protein Buffer: 20mM Tris pH 8.0, 30mM NaCl, 1mM TCEP",293,2016-07-07,2016-07-20,5KRE,1942,1,239,153,,26.77,1,2,experimental,24.46,0.2125,0.1653,Covalent inhibitor of LYPLAL1
5F85,X-RAY DIFFRACTION,3.15,60.99,"VAPOR DIFFUSION, HANGING DROP",,1.62M ammonium sulfate,293,2015-12-09,2016-07-20,5F85,3504,2,452,125,7,53.51,2,2.15,experimental,44.259,0.24265,0.2112,Crystal structure of Drosophila Poglut1 (Rumi) complexed with its substrate protein (EGF repeat) and UDP
5LRX,X-RAY DIFFRACTION,2.45,49.89,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES/imidazole (pH 6.5), 7% (w/v) PEG 8K, 20% ethylene glycol",287,2016-08-22,2016-10-19,5LRX,11566,6,1636,,,191.24,3,2.85,experimental,,0.2457,0.1952,Structure of A20 OTU domain bound to ubiquitin
7ER8,X-RAY DIFFRACTION,2.2,43.98,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.9-2.0M Ammonium sulfate, 0.1M Bis-tris (pH 6.5)",291.15,2021-05-06,2022-01-19,7ER8,3700,2,432,380,,49.82,1,1.45,experimental,25.22,0.1991,0.1655,Crystal structure of human Biliverdin IX-beta reductase B with Sulfasalazine (SAS)
5Y7N,X-RAY DIFFRACTION,2.53,51.39,"VAPOR DIFFUSION, HANGING DROP",9,"100mM Tris, 30-35% PEG 6000, 3-5% 1,6-Hexanediol, pH 9.0, VAPOR DIFFUSION, HANGING DROP, temperature 289K",289,2017-08-17,2018-08-29,5Y7N,2692,1,316,98,,37.11,1,2.5,experimental,31.637,0.24471,0.17789,Crystal structure of AKR1B10 in complex with NADP+ and Androst-4-ene-3-beta-6-alpha-diol
6UMB,X-RAY DIFFRACTION,2.29,46.25,"VAPOR DIFFUSION, SITTING DROP",6,Sodium malonate pH 6.0,283,2019-10-09,2021-04-14,6UMB,2971,2,354,165,,40.83,2,1.8,experimental,24.54,0.2234,0.1841,Crystal structure of TRIM7 B30.2 domain at 1.8 angstrom resolution
7ABS,X-RAY DIFFRACTION,2.43,49.47,"VAPOR DIFFUSION, HANGING DROP",,"50 mM MES pH 6.5, 0.1 M LiCl, 0.01 M MgCl2, 12% PEG 4000 (w/v)",300,2020-09-08,2021-08-04,7ABS,3282,3,398,105,,50.47,1,1.97,experimental,53.197,0.27588,0.2152,Structure of human DCLRE1C/Artemis in complex with DNA - re-evaluation of 6WO0
6KZ0,X-RAY DIFFRACTION,2.98,58.7,"VAPOR DIFFUSION, HANGING DROP",8.6,"0.1 M Tris-HCl, 
25% MPEG5000,
0.2 M Li2SO4",293,2019-09-21,2020-05-27,6KZ0,12416,12,1736,450,8,185.49,3,2.4,experimental,31.68,0.2234,0.1853,HRV14 3C in complex with single chain antibody GGVV
8G7X,X-RAY DIFFRACTION,2.24,45.19,"VAPOR DIFFUSION, SITTING DROP",,"13% PEG 3350, 200 mM sodium thiocyanate",277.15,2023-02-17,2023-06-07,8G7X,4195,2,498,363,,55.79,1,1.815,experimental,,0.204,0.1679,Human fatty acid synthase dehydratase domain
8GML,X-RAY DIFFRACTION,2.13,42.16,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 6.5, 20% PEG2000 MME, 5 mM calcium chloride",293,2023-03-26,2023-09-20,8GML,3790,3,452,48,,54.94,1,2.567,experimental,50.44,0.2603,0.2008,Crystal structure of human DNA polymerase eta incorporating 5F-dUTP across dG
8SKI,X-RAY DIFFRACTION,2.09,41.15,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.5, 20% PEG2000 MME, 5 mM calcium chloride",293,2023-04-19,2023-09-20,8SKI,3889,3,452,156,,54.93,1,2.163,experimental,42.81,0.2493,0.1996,Crystal structure of human DNA polymerase eta incorporating 5F-dUTP across HX
6YW1,X-RAY DIFFRACTION,2.53,51.41,"VAPOR DIFFUSION, SITTING DROP",,"Sample: 1.0 mM PHD2, 1.5 mM MnCl2, 2.0 mM compound, 1.0 mM 3C; Reservoir: 0.1 M Bis-Tris pH 6.5, 15.0 % PEG 3350, 0.002 M MnCl2; Sitting drop (300 nl), protein-to-well ratio, 1:2",293,2020-04-29,2020-12-30,6YW1,2121,2,247,245,,28.1,2,1.46,experimental,34.1839,0.1746,0.1642,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with 2OG and RaPID-derived silent allosteric cyclic peptide 3C (14-mer)
6YW2,X-RAY DIFFRACTION,2.5,50.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"Sample: 1.0 mM PHD2, 1.5 mM MnCl2, 2.0 mM compound, 1.0 mM 3C; Reservoir: 22% w/v polyethylene glycol 3350, 0.25 M magnesium formate, 2 mM MnCl2; Sitting drop (2 ul), protein-to-well ratio, 1:1",293,2020-04-29,2020-12-30,6YW2,1853,2,247,98,,28.17,2,2.14,experimental,46.3511,0.1962,0.1701,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with bicyclic FG2216 and RaPID-derived cyclic peptide 3C (14-mer)
6YW4,X-RAY DIFFRACTION,2.56,51.96,"VAPOR DIFFUSION, SITTING DROP",8.5,"Sample: 1.0 mM cPHD2, 1.5 mM MnCl2, 2.0 mM compound, 1.0 mM 3C; Reservoir: 0.2 M lithium sulfate, 0.1 M Tris-HCl pH 8.5, 1.26 M ammonium sulfate; Sitting drop (300 nl), protein-to-well ratio, 1:1",293,2020-04-29,2020-12-30,6YW4,2008,2,247,193,,28.11,2,1.528,experimental,34.4686,0.177,0.162,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with N-oxalylglycine (NOG) and a RaPID-derived silent allosteric cyclic peptide 3C (14-mer)
7L34,X-RAY DIFFRACTION,2.37,48.02,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6, 100 mM lithium acetate, 15% (w/v) polyethylene glycol PEG3350",293,2020-12-17,2021-01-13,7L34,6275,4,683,547,,83.32,1,1.901,experimental,38.0687,0.1933,0.1693,Human DNA Ligase 1 - R641L nicked DNA complex
7M10,X-RAY DIFFRACTION,2.86,56.93,"VAPOR DIFFUSION, HANGING DROP",8.2,"3.5M Sodium Formate,100mM TRIS pH 8.2",292,2021-03-11,2021-05-26,7M10,790,2,86,124,,10.26,2,1.15,experimental,20.61,0.1648,0.1565,PHF2 PHD Domain Complexed with Peptide From N-terminus of VRK1
8BBS,X-RAY DIFFRACTION,2.02,39.23,"VAPOR DIFFUSION, SITTING DROP",8.5,"12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD and 0.02 M each of DL-glutamic acid monohydrate, DL-alanine, glycine, DL-lysine monohydrochloride, and DL-serine; in 0.1 M bicine/Trizma base, pH 8.5",295,2022-10-14,2023-03-08,8BBS,6240,2,652,728,,76.93,1,1.4,experimental,17.31,0.1775,0.1546,Structure of AKR1C3 in complex with a bile acid fused tetrazole inhibitor
8QGV,X-RAY DIFFRACTION,2.34,47.47,"VAPOR DIFFUSION, HANGING DROP",9,"28-31% PEG4000, 0.2 M sodium acetate, 0.1 M Tris pH 8.5-9.0",296,2023-09-05,2024-09-11,8QGV,4292,2,522,215,,58.62,1,1.84,experimental,31.709,0.2403,0.1978,"Human Carbonic Anhydrase I in complex with 4-(5-acetyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-4-yl)benzenesulfonamide"
5L0S,X-RAY DIFFRACTION,2.41,49.04,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG5000 MME, 50 mM MES pH 6.5, 2mM CaCl2, 250mM NaCl, 5% glycerol",295,2016-07-28,2017-08-09,5L0S,3747,2,399,377,7,47.89,2,1.45,experimental,29.8733,0.1588,0.1394,human POGLUT1 in complex with Factor VII EGF1 and UDP
5LIK,X-RAY DIFFRACTION,2.37,48.03,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2016-07-14,2016-07-27,5LIK,2771,1,316,94,,37.6,1,2.05,experimental,34.63,0.2444,0.2009,Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK181
5LIW,X-RAY DIFFRACTION,2.51,51.02,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2016-07-15,2016-07-27,5LIW,2851,1,316,168,,38.05,1,1.75,experimental,,0.2086,0.1778,Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK319
5LIX,X-RAY DIFFRACTION,2.51,51.05,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2016-07-15,2016-07-27,5LIX,2805,1,316,56,,37.77,1,1.95,experimental,,0.2433,0.1948,Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK184
5LIY,X-RAY DIFFRACTION,2.48,50.43,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2016-07-15,2016-10-12,5LIY,2801,1,316,41,,37.82,1,2.05,experimental,,0.2216,0.1813,Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK204
6YA7,X-RAY DIFFRACTION,2.12,41.91,"VAPOR DIFFUSION, HANGING DROP",7,"0.1M PCTP pH7, 18% PEG 1500, 8% MPD",291.15,2020-03-11,2020-05-27,6YA7,4129,3,517,366,,59.51,3,1.67,experimental,24.91,0.1852,0.1562,Cdc7-Dbf4 bound to an Mcm2-S40 derived bivalent substrate
4XZL,X-RAY DIFFRACTION,2.49,50.61,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2015-02-04,2015-11-18,4XZL,2864,1,316,148,,37.81,1,1.7,experimental,,0.2385,0.2085,Crystal structure of human AKR1B10 complexed with NADP+ and JF0049
5XLN,X-RAY DIFFRACTION,2.36,47.78,"VAPOR DIFFUSION, SITTING DROP",9.5,"20% PEG 8000,  0.1 M CHES (pH 9.5)",295,2017-05-11,2018-11-21,5XLN,1754,2,235,177,,27.05,2,1.9,experimental,,0.1964,0.161,Crystal structure of the TRS_UNE-T and 4EHP complex
7BCK,X-RAY DIFFRACTION,2,38.55,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-19,2022-01-12,7BCK,2810,1,383,67,6,43.99,1,1.7,experimental,25.674,0.2552,0.2205,Notum Fragment 791
6RQQ,X-RAY DIFFRACTION,2.17,43.23,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% (w/v) PEG 4000, 0.2 M ammonium formate, 0.1 M Tris-HCl pH 8.5",298,2019-05-16,2019-09-11,6RQQ,4898,2,512,678,2,56.41,1,1.276,experimental,22.8766,0.1961,0.1811,X-ray crystal structure of protiated (H) large monoclinic unit cell CA IX SV.
6H4K,X-RAY DIFFRACTION,2.34,47.42,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris pH 8.5
22% w/v PEG4000
0.2M SrCl2",293,2018-07-21,2019-03-27,6H4K,2255,1,293,57,,35.18,1,2.05,experimental,,0.2224,0.1915,Structure of the Usp25 C-terminal domain
5D1K,X-RAY DIFFRACTION,2.23,44.86,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG-10000, 8% ethylene glycol, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K",292,2015-08-04,2015-10-28,5D1K,2494,2,280,272,,32.86,2,1.78,experimental,29.4482,0.202,0.1696,Crystal Structure of UbcH5B in Complex with the RING-U5BR Fragment of AO7
5D1L,X-RAY DIFFRACTION,2.33,47.31,"VAPOR DIFFUSION, HANGING DROP",6.5,"15% PEG 20000, 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K",292,2015-08-04,2015-10-28,5D1L,2674,2,280,396,,32.59,2,1.618,experimental,30.6192,0.1995,0.1817,Crystal Structure of UbcH5B in Complex with the RING-U5BR Fragment of AO7 (Y165A)
5D1M,X-RAY DIFFRACTION,2.32,46.96,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 10000, 8% Ethylene glycol, 0.1M HEPS, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K",292,2015-08-04,2015-10-28,5D1M,2638,2,280,384,,32.78,2,1.581,experimental,27.7522,0.2231,0.1882,Crystal Structure of UbcH5B in Complex with the RING-U5BR Fragment of AO7 (P199A)
6IPF,X-RAY DIFFRACTION,2.48,50.34,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 18% PEG 4000",277,2018-11-03,2019-05-29,6IPF,3383,4,374,278,,46.7,1,1.77,experimental,34.539,0.21818,0.18811,Post-catalytic Complex of Human DNA Polymerase Mu with Templating Cytosine and Mn-8oxodGMP
5OAB,X-RAY DIFFRACTION,2.45,49.87,"VAPOR DIFFUSION, HANGING DROP",7,1.3 M SODIUM/POTASSIUM PHOSPHATE,293,2017-06-21,2018-08-01,5OAB,1554,1,128,322,4,15.59,1,1.111,experimental,13.76,0.1412,0.1173,A novel crystal form of human RNase6 at atomic resolution
6ENP,X-RAY DIFFRACTION,1.79,31.16,"VAPOR DIFFUSION, HANGING DROP",4.5,"1 M ammonium phosphate, 100 mM sodium acetate pH 4.5",293,2017-10-05,2018-10-24,6ENP,1507,1,128,228,4,15.26,1,1.042,experimental,19.33,0.1449,0.1215,Atomic resolution structure of human RNase 6 in the presence of phosphate anions in P21 space group.
8BQ3,X-RAY DIFFRACTION,2.39,48.44,"VAPOR DIFFUSION, HANGING DROP",7,"25% w/vPEG 1500, 0.1M MIB (Sodium malonate dibasic monohydrate, Imidazole, Boric acid) pH 7.0",291,2022-11-18,2023-11-29,8BQ3,509,2,98,,,11.18,2,2.66,experimental,,0.2815,0.23,Crystal structure of human R13 mutant of the c-Src SH3 domain in complex with VSL12-peptide
6RQW,X-RAY DIFFRACTION,2.18,43.5,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% (w/v) PEG 4000, 0.2 M ammonium formate, 0.1 M Tris-HCl pH 8.5",298,2019-05-16,2019-09-11,6RQW,2283,1,256,212,1,28.2,1,1.488,experimental,30.2325,0.2033,0.1725,X-ray crystal structure of perdeuterated (D) small monoclinic unit cell CA IX SV.
6WH8,X-RAY DIFFRACTION,3.04,59.53,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Na-HEPES, pH 7.5, 1.6 M ammonium sulfate, and 2% PEG 1000",293,2020-04-07,2020-08-26,6WH8,4266,4,492,560,,56.48,2,1.729,experimental,,0.1999,0.1799,The structure of NTMT1 in complex with compound BM-30
6MV6,X-RAY DIFFRACTION,2.06,40.39,VAPOR DIFFUSION,,"Peg 4000, 50mM Sodium phosphate",280,2018-10-24,2019-11-13,6MV6,1090,1,126,107,4,14.75,1,1.5,experimental,,0.2271,0.169,Crystal structure of RNAse 6
5LF8,X-RAY DIFFRACTION,2.52,51.12,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M SPG pH 7.0
30% PEG1K",277,2016-06-30,2017-08-16,5LF8,1784,1,328,3,,36.52,1,2.56,experimental,69.608,0.29823,0.2272,Human Nucleoside diphosphate-linked moiety X motif 17 (NUDT17)
7U83,X-RAY DIFFRACTION,2.09,41.12,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG2000 MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U83,4401,3,455,418,,55.48,1,1.55,experimental,33.8148,0.2321,0.1896,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 3.0 mM Mn2+ for 600s
6VUA,X-RAY DIFFRACTION,2.73,55,"VAPOR DIFFUSION, HANGING DROP",7,"1) 100mM HEPES pH 7.0, 2) 38-42%  Morpheus Precipitant mix 1 (MD2-250-84) containing PEG 1K, 3350 and MPD, 3) 100mM Potassium phosphate dibasic",295,2020-02-14,2020-06-03,6VUA,4973,2,514,512,12,61.95,1,1.5,experimental,30.512,0.1902,0.1664,X-ray structure of human CD38 catalytic domain with 2'-Cl-araNAD+
7ERB,X-RAY DIFFRACTION,2.27,45.73,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.9-2.0M Ammonium sulfate, 0.1M Bis-tris(pH 6.5)",291.15,2021-05-06,2022-01-19,7ERB,7574,4,824,994,,93.28,1,1.5,experimental,20.74,0.1986,0.1708,Crystal structure of human Biliverdin IX-beta reductase B with Ataluren (PTC)
8ASN,X-RAY DIFFRACTION,2.8,56.09,"VAPOR DIFFUSION, HANGING DROP",,"4 % Tacsimate pH 6.0, 12 % PEG3350",294,2022-08-19,2022-09-21,8ASN,26206,9,3467,458,,397.28,4,2.571,experimental,67.6,0.2731,0.2428,Crystal structure of the apo human TTL in complex with tubulin-stathmin
7B3H,X-RAY DIFFRACTION,1.94,36.45,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-11-30,2021-12-08,7B3H,2950,1,383,129,6,44.74,1,1.28,experimental,20.9757,0.2038,0.195,Notum complex with ARUK3003909
7B3I,X-RAY DIFFRACTION,1.93,36.38,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-12-01,2021-12-08,7B3I,2907,1,383,90,6,44.94,1,1.34,experimental,25.865,0.1969,0.1958,Notum complex with ARUK3003776
7B3P,X-RAY DIFFRACTION,1.93,36.42,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-12-01,2021-12-08,7B3P,2881,1,383,113,6,44.7,1,1.28,experimental,22.2427,0.1986,0.1876,Notum complex with ARUK3003775
7ESE,X-RAY DIFFRACTION,1.9,35.17,"VAPOR DIFFUSION, SITTING DROP",,"0.15M KBr, 30% PEGMME 2000",277,2021-05-10,2021-05-26,7ESE,1652,1,204,77,,24.68,1,1.85,experimental,32.357,0.285,0.2405,The Crystal Structure of human DHFR from Biortus
5F86,X-RAY DIFFRACTION,3.17,61.22,"VAPOR DIFFUSION, HANGING DROP",,1.62M ammonium sulfate,293,2015-12-09,2016-07-20,5F86,3503,2,452,133,7,53.2,2,1.9,experimental,25.723,0.2212,0.19553,Crystal structure of Drosophila Poglut1 (Rumi) complexed with its substrate protein (EGF repeat)
8EJX,X-RAY DIFFRACTION,2,38.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% (w/v) PEG 4000, 100 mM Hepes, 200 NaCl",291,2022-09-19,2023-10-18,8EJX,1342,1,165,115,,18.03,1,1.65,experimental,28.453,0.1984,0.1641,Crystal structure of human cyclophilin D (CypD) with in complex with the covalently bound Ebselen inhibitor
5A7R,X-RAY DIFFRACTION,2.54,51,,8,"20% PEG3350, 0.2 M AMMONIUM SULFATE, 0.1 M PCTP PH 7.5",,2015-07-09,2015-07-22,5A7R,4830,1,531,422,,64.26,1,1.95,experimental,22.196,0.1789,0.1373,Human poly(ADP-ribose) glycohydrolase in complex with synthetic dimeric ADP-ribose
5KFN,X-RAY DIFFRACTION,2.1,41.39,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFN,4348,3,455,421,,55.49,1,1.45,experimental,24.0414,0.2165,0.1875,Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 1 mM Mg2+ for 1800s
7REI,X-RAY DIFFRACTION,2.6,52.63,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M LiSO4, 0.1 M Bis-Tris pH 5.5, 20% w/v PEG 3350",289,2021-07-12,2021-09-15,7REI,2199,1,270,212,,30.46,1,1.78,experimental,32.4678,0.2093,0.1801,The crystal structure of nickel bound human ADO C18S C239S variant
8FN3,X-RAY DIFFRACTION,2.1,41.42,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.5, 20% PEG2000 MME, 5 mM calcium chloride",293,2022-12-26,2023-05-03,8FN3,3842,3,452,88,,54.95,1,2.17,experimental,43.52,0.2531,0.2073,Crystal structure of human DNA polymerase eta incorporating dITP across dC
8FOG,X-RAY DIFFRACTION,2.11,41.73,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.5, 5 mM magnesium chloride, 18% PEG2000 MME",293,2022-12-30,2023-05-03,8FOG,3797,3,452,43,,54.92,1,2.29,experimental,53.68,0.2896,0.2255,Crystal structure of human DNA polymerase eta incorporating dITP across dT
8GKR,X-RAY DIFFRACTION,2.06,40.3,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.5, 20% PEG2000 MME, 5 mM calcium chloride",293,2023-03-20,2023-09-20,8GKR,3779,3,452,5,,55.43,1,2.784,experimental,53.97,0.2815,0.1997,Crystal structure of human DNA polymerase eta incorporating 5F-dUTP across dA
8EXJ,X-RAY DIFFRACTION,3.65,66.28,"VAPOR DIFFUSION, SITTING DROP",,"12% Peg 4K, 0.1 M Calcium acetate, 0.05 M MES (pH 6.5)",281.15,2022-10-25,2023-07-05,8EXJ,2499,2,315,52,,36.99,2,2.301,experimental,69.3133,0.238,0.2069,Crystal structure of PTP1B D181A/Q262A phosphatase domain in complex with a JAK1 activation loop phosphopeptide
4Z49,X-RAY DIFFRACTION,2.24,45.03,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG-3350, 0.2M potassium chloride",277,2015-04-01,2016-03-16,4Z49,4975,2,564,699,,62.07,1,1.7,experimental,20.85,0.2123,0.171,"Homo Sapiens Fatty Acid Synthetase, Thioesterase Domain at 1.7 Angstroms Resolution"
6DJH,X-RAY DIFFRACTION,2.46,49.9,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-05-25,2019-05-29,6DJH,7845,2,922,586,,104.98,1,1.918,experimental,,0.2303,0.1773,Crystal structure of Tdp1 catalytic domain in complex with compound XZ515
8JCA,X-RAY DIFFRACTION,2.5,50.8,"VAPOR DIFFUSION, SITTING DROP",,"800mM Potassiam phosphate dibasic
1.2 M Sodium phosphate monobasic
0.1M CAPS/Sodium hydroxide
0.2M Lithium sulfate pH10.5",298,2023-05-10,2024-03-27,8JCA,2994,2,334,296,,39.13,2,1.65,experimental,,0.206,0.1746,Cyrstal structure of SKIP RUN domain in complex with GTP-bound Arl8b(Q75L)
5GL7,X-RAY DIFFRACTION,2.6,52.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM Tris pH 7.5, 200mM magnesium chloride, 5mM DTT, 21% PEG 8000",294,2016-07-08,2017-07-12,5GL7,5138,1,624,345,,71.36,1,2.013,experimental,,0.2256,0.1944,Crystal structure of a truncated human cytosolic methionyl-tRNA synthetase
8EYC,X-RAY DIFFRACTION,2.71,54.55,"VAPOR DIFFUSION, SITTING DROP",,"14% PEG 8K, 0.20 M Magnesium Acetate, 0.1 M MES (pH 6.5)",281.15,2022-10-26,2023-08-16,8EYC,2403,2,314,4,,36.68,2,2.99,experimental,,0.2543,0.2174,Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with TYK2 activation loop phosphopeptide
8SWY,X-RAY DIFFRACTION,2.7,54.41,"VAPOR DIFFUSION, SITTING DROP",,"21% PEG3350, 0.2M sodium citrate tribasic dihydrate, 1% ethylene glycol, 800uM NADH",293,2023-05-19,2023-11-08,8SWY,5841,3,777,51,,87.64,1,2.55,experimental,,0.2536,0.2108,PARP4 ART domain bound to NADH
6HVH,X-RAY DIFFRACTION,3.9,68.47,"VAPOR DIFFUSION, SITTING DROP",7,"2% Tacsimate, 10% PEG3350, 0.1M MES/imidazole pH 7.0",277,2018-10-11,2018-11-14,6HVH,3787,1,520,188,,60.8,1,2.36,experimental,39.819,0.2375,0.1953,Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 1
6IBZ,X-RAY DIFFRACTION,3.88,68.31,"VAPOR DIFFUSION, SITTING DROP",,"2% Tacsimate, pH7.0; 5% 2-propanol; 0.1M imidazole; 8% PEG3350",277,2018-12-01,2019-01-23,6IBZ,3711,1,431,126,,51.21,1,2.44,experimental,42.094,0.2335,0.1924,Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 7
6KY0,X-RAY DIFFRACTION,2.61,52.85,"VAPOR DIFFUSION, HANGING DROP",7.5,3M sodium acetate trihydrate (pH 7.0),295,2019-09-16,2020-07-29,6KY0,4212,3,543,71,,61.34,1,2.06,experimental,36.14,0.2583,0.2253,Crystal structural of active-site human glutathione-specific gamma-glutamylcyclotransferase 2(ChaC2) mutant with Glutamate 74 replaced by Glutamine
6KY1,X-RAY DIFFRACTION,2.57,52.2,"VAPOR DIFFUSION, HANGING DROP",7.5,3 M sodium acetate trihydrate (pH 7.0),295,2019-09-16,2020-07-29,6KY1,4185,3,546,85,,61.68,1,2.04,experimental,59.567,0.2555,0.2254,Crystal structural of human glutathione-specific gamma-glutamylcyclotransferase 2 (ChaC2)mutant with Glutamate 83 replaced by Glutamine
5FL5,X-RAY DIFFRACTION,3.39,63.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LITHIUM SULFATE, 1.26 M AMMONIUM SULFATE, TRIS- HCL, PH 8.5, PROTEIN 10 MG/ML, 5-10 MM INHIBITOR(STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K",294,2015-10-21,2015-11-11,5FL5,8842,4,1028,901,4,116.86,1,2.05,experimental,26.4,0.19563,0.15788,"Three dimensional structure of human carbonic anhydrase IX in complex with 5-(1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)thiophene-2- sulfonamide"
4U9V,X-RAY DIFFRACTION,2.13,42.18,"VAPOR DIFFUSION, HANGING DROP",5.5,"20% PEG 3350, 100 mM sodium citrate tribasic dihydrate, 100 mM citric acid",298,2014-08-06,2015-01-28,4U9V,1799,1,197,166,1,23.72,1,1.78,experimental,24.7146,0.2063,0.1674,Crystal structure of NatD (Naa40p) bound to acetyl CoA
5KFA,X-RAY DIFFRACTION,2.1,41.44,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFA,4419,3,455,442,,55.53,1,1.51,experimental,21.8471,0.2027,0.1728,Human DNA polymerase eta-DNA ternary complex: ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
5KFB,X-RAY DIFFRACTION,2.09,41.08,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFB,4340,3,455,440,,55.51,1,1.55,experimental,20.9156,0.2058,0.1743,Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 90s
5KFC,X-RAY DIFFRACTION,2.09,41.08,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFC,4357,3,455,441,,55.51,1,1.5,experimental,21.9741,0.2098,0.1802,Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 180s
5KFD,X-RAY DIFFRACTION,2.1,41.52,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFD,4342,3,455,441,,55.51,1,1.65,experimental,21.9874,0.2197,0.1825,Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 300s
5KFE,X-RAY DIFFRACTION,2.1,41.52,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFE,4335,3,455,441,,55.51,1,1.55,experimental,21.847,0.2031,0.1729,Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 600s
5KFF,X-RAY DIFFRACTION,2.1,41.31,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFF,4324,3,455,437,,55.47,1,1.7,experimental,22.6442,0.2208,0.1825,Human DNA polymerase eta-DNA ternary complex: reaction with 1 mM Mn2+ for 1800s
5KFG,X-RAY DIFFRACTION,2.1,41.4,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-29,5KFG,4343,3,455,438,,55.57,1,1.55,experimental,22.4785,0.2042,0.1737,Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 30s
5KFH,X-RAY DIFFRACTION,2.07,40.69,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFH,4410,3,456,465,,56.23,1,1.72,experimental,26.6808,0.2152,0.1698,Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 90s
5KFI,X-RAY DIFFRACTION,2.09,41.01,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-29,5KFI,4428,3,456,464,,56.14,1,1.65,experimental,23.7877,0.2208,0.1898,Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 120s
5KFJ,X-RAY DIFFRACTION,2.08,40.82,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFJ,4430,3,456,465,,56.14,1,1.7,experimental,24.6077,0.2098,0.1676,Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 180s
5KFK,X-RAY DIFFRACTION,2.08,40.82,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFK,4398,3,456,462,,56.14,1,1.7,experimental,24.4782,0.2102,0.172,Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 300s
5KFL,X-RAY DIFFRACTION,2.08,41.01,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFL,4389,3,456,466,,56.1,1,1.65,experimental,30.1366,0.2083,0.1715,Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 600s
5KFM,X-RAY DIFFRACTION,2.09,41.15,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFM,4364,3,455,450,,55.51,1,1.6,experimental,28.7414,0.234,0.1941,Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
5KFO,X-RAY DIFFRACTION,2.11,41.79,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFO,4321,3,455,421,,55.52,1,1.52,experimental,22.7829,0.2121,0.179,Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 1 mM Mn2+ for 1800s
5KFP,X-RAY DIFFRACTION,2.09,41.2,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFP,4450,3,456,459,,56.08,1,1.7,experimental,29.1675,0.2209,0.1769,Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 20 mM Mg2+ for 600s
5KFQ,X-RAY DIFFRACTION,2.09,41.1,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-29,5KFQ,4372,3,456,460,,56.12,1,1.55,experimental,32.733,0.223,0.1918,Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 10 mM Mn2+ for 600s
5KFR,X-RAY DIFFRACTION,2.06,40.28,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFR,4416,3,456,461,,56.08,1,1.75,experimental,35.5241,0.2229,0.1752,Human DNA polymerase eta-DNA ternary complex with Sp-dATP-alpha-S: reaction with 20 mM Mn2+ for 600s
5KFS,X-RAY DIFFRACTION,2.11,41.73,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-29,5KFS,4432,3,455,447,,55.44,1,1.46,experimental,22.81,0.205,0.176,Human DNA polymerase eta R61A-DNA ternary complex: ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
5KFT,X-RAY DIFFRACTION,2.1,41.35,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFT,4310,3,455,436,,55.4,1,1.52,experimental,23.8,0.211,0.182,Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 40s
5KFU,X-RAY DIFFRACTION,2.09,41.21,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFU,4307,3,455,433,,55.4,1,1.55,experimental,23.74,0.211,0.181,Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 80s
5KFV,X-RAY DIFFRACTION,2.09,41.12,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFV,4301,3,455,435,,55.4,1,1.6,experimental,23.64,0.229,0.196,Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 140s
5KFW,X-RAY DIFFRACTION,2.08,40.81,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFW,4424,3,456,467,,56,1,1.62,experimental,25.27,0.21,0.179,Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 200s
5KFX,X-RAY DIFFRACTION,2.09,41.21,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFX,4424,3,456,467,,56,1,1.52,experimental,22.22,0.212,0.181,Human DNA polymerase eta R61A-DNA ternary complex: reaction with 1 mM Mg2+ for 300s
5KFY,X-RAY DIFFRACTION,2.11,41.78,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFY,4338,3,455,439,,55.53,1,1.7,experimental,23.8309,0.2282,0.2017,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 4 degree
5KFZ,X-RAY DIFFRACTION,2.09,41.22,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KFZ,4450,3,456,474,,56.16,1,1.44,experimental,23.5282,0.2154,0.1847,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 14 degree
5KG0,X-RAY DIFFRACTION,2.07,40.52,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-29,5KG0,4429,3,456,466,,56.1,1,1.6,experimental,25.1894,0.2113,0.1761,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 22 degree
5KG1,X-RAY DIFFRACTION,2.08,40.79,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KG1,4388,3,456,465,,56.1,1,1.62,experimental,23.4248,0.2219,0.1811,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 30 degree
5KG2,X-RAY DIFFRACTION,2.08,40.95,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KG2,4381,3,456,467,,56.1,1,1.6,experimental,25.8716,0.2036,0.1839,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 5 mM Mn2+ for 60s at 37 degree
5KG3,X-RAY DIFFRACTION,2.08,40.9,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KG3,4400,3,456,466,,56.1,1,1.7,experimental,22.7138,0.2366,0.1972,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Mn2+ for 60s
5KG4,X-RAY DIFFRACTION,2.08,40.85,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KG4,4388,3,456,465,,56.07,1,1.6,experimental,24.9825,0.2232,0.1879,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Mg2+ for 60s
5KG5,X-RAY DIFFRACTION,2.08,40.81,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KG5,4379,3,456,465,,56.1,1,1.6,experimental,24.6855,0.2188,0.1841,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Cd2+ for 60s
5KG6,X-RAY DIFFRACTION,2.07,40.61,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-29,5KG6,4383,3,456,464,,56.1,1,1.55,experimental,25.5566,0.2289,0.1922,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Ca2+ for 60s
5KG7,X-RAY DIFFRACTION,2.08,40.84,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5KG7,4379,3,456,465,,56.1,1,1.75,experimental,22.2381,0.2278,0.1861,Human DNA polymerase eta-DNA ternary complex: reaction first with 1 mM Mn2+ for 1800s then with 10 mM Zn2+ for 60s
5D2M,X-RAY DIFFRACTION,2.96,58.45,"VAPOR DIFFUSION, HANGING DROP",7.5,"6 % (w/v) PEG 8000, 0.2 M ammonium citrate and 0.1 M HEPES pH 7.5",291,2015-08-05,2015-11-04,5D2M,7146,7,895,702,,100,4,2.4,experimental,,0.2344,0.1947,"Complex between human SUMO2-RANGAP1, UBC9 and ZNF451"
6EDR,X-RAY DIFFRACTION,2.55,51.72,"VAPOR DIFFUSION, HANGING DROP",7,"100mM HEPES pH 7.0, 14-18% PEG 4000",295,2018-08-10,2018-11-21,6EDR,4083,2,514,87,10,60.89,1,2.4,experimental,48.4,0.2618,0.2157,Crystal Structure of Human CD38 in Complex with 4'-Thioribose NAD+
5AFW,X-RAY DIFFRACTION,2.77,56,,,"0.1 M HEPES PH 7.5, 0.2 M L-PROLINE, 10% (W/V) PEG3350",,2015-01-26,2016-01-13,5AFW,1579,2,186,119,,22.73,2,1.6,experimental,56.96,0.2269,0.2094,Assembly of methylated LSD1 and CHD1 drives AR-dependent transcription and translocation
7BBU,X-RAY DIFFRACTION,2.04,39.59,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M NH4NO3, 5 mM L-Pro, 2mM NCP26",293.15,2020-12-18,2022-01-12,7BBU,3963,1,515,125,,59.66,1,2.19,experimental,48.9392,0.2327,0.2057,Crystal Structure of human Prolyl-tRNA synthetase in complex with NCP26 and L-Proline
8JSC,X-RAY DIFFRACTION,2.11,41.68,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Ammonium nitrate.",289.15,2023-06-19,2024-03-13,8JSC,3038,1,372,152,,41.99,1,2.16,experimental,18.72,0.2267,0.1866,Structure of the FSP1 protein from Human
7U77,X-RAY DIFFRACTION,2.1,41.3,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG 2000MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U77,4456,3,455,428,,55.46,1,1.58,experimental,30.4478,0.2026,0.1839,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 40s
7U78,X-RAY DIFFRACTION,2.06,40.36,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG 2000MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U78,4327,3,455,309,,55.49,1,1.61,experimental,31.8631,0.2174,0.1863,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 80s
7U79,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG 2000MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U79,4628,3,456,527,,56.04,1,1.69,experimental,34.1954,0.2206,0.1756,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 140s
7U7A,X-RAY DIFFRACTION,2.05,40.14,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG 2000MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U7A,4402,3,456,299,,55.86,1,1.58,experimental,28.5412,0.2169,0.1869,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 200s
7U7B,X-RAY DIFFRACTION,2.07,40.53,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG 2000MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U7B,4516,3,456,452,,55.95,1,1.58,experimental,29.0154,0.2063,0.1783,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 250s
7U7C,X-RAY DIFFRACTION,2.09,41.03,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG 2000MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U7C,4524,3,456,454,,55.86,1,1.55,experimental,28.1981,0.2122,0.1801,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 300s
7U7L,X-RAY DIFFRACTION,2.07,40.59,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG 2000MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U7L,4453,3,456,445,,55.49,1,1.47,experimental,26.3343,0.1936,0.1871,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 300s with flipped-out product
7U7W,X-RAY DIFFRACTION,2.07,40.62,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG 2000MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U7W,4411,3,455,417,,55.42,1,1.66,experimental,33.0794,0.2078,0.1838,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 1.0 mM Mg2+ for 600s
7U82,X-RAY DIFFRACTION,2.07,40.61,"VAPOR DIFFUSION, HANGING DROP",6,"10% PEG2000 MME, 0.1 M MES",298,2022-03-07,2022-05-04,7U82,4372,3,455,419,,55.48,1,1.55,experimental,32.5677,0.2213,0.1915,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 1.0 mM Mn2+ for 600s
5HQG,X-RAY DIFFRACTION,2.24,45.13,"VAPOR DIFFUSION, HANGING DROP",,"sodium nitrate 0.5M
10% PEG 3350",293,2016-01-21,2016-04-20,5HQG,2594,1,362,104,,40.95,1,2,experimental,,0.2417,0.2105,WD40 domain of Human E3 Ubiquitin Ligase COP1 (RFWD2)
6F6D,X-RAY DIFFRACTION,2.53,51.44,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M TRIS pH 8.0, 15%(v/v) Tert-butanol,",277,2017-12-05,2018-10-17,6F6D,4240,2,527,453,,60.34,2,1.81810675209,experimental,35.2566323525,0.213586891495,0.165095998862,The catalytic domain of KDM6B in complex with H3(17-33)K18IA21M peptide
8C12,X-RAY DIFFRACTION,2.47,50.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.12 M Alcohols (0.2 M 1,6-Hexanediol, 0.2 M 1-Butanol, 0.2 M 1,2_Propanediol, 0.2 M 2-Propanol, 0.2 M 1,4-Butanediol, 0.2 M 1,3-Propanediol), 0.1 M Buffer System 2 (1.0 M Sodium HEPES, MOPS) pH 7.5, 37.5% precipitant (M1K3350)",291,2022-12-19,2023-10-25,8C12,3252,2,401,195,,46.06,2,1.549,experimental,40.435,0.2341,0.1972,Identification of an intermediate activation state of PAK5 reveals a novel mechanism of kinase inhibition.
6Z6Q,X-RAY DIFFRACTION,2.7,54.39,"VAPOR DIFFUSION, SITTING DROP",7,"100 mM HEPES sodium, 200 mM ammonium chloride, 20% w/v PEG 6000, 1 mM manganese chloride, 2 mM 3-ethyl-2-oxoglutarate, 18 mg/ml protein",277,2020-05-29,2021-03-17,6Z6Q,3895,2,468,268,2,53.92,2,1.81,experimental,49.6,0.2321,0.2076,"Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 3-ethyl-2-oxoglutarate, and factor X substrate peptide fragment(39mer-4Ser)"
6Z6R,X-RAY DIFFRACTION,2.67,53.97,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM Bis Tris propane, 200 mM sodium bromide, 20% w/v PEG 3350, 1 mM manganese chloride, 2 mM N-oxalyl-alpha-methylalanine, 18 mg/ml protein",277,2020-05-29,2021-03-17,6Z6R,3684,2,468,109,2,54,2,2.13,experimental,45.62,0.2424,0.2116,"Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, N-oxalyl-alpha-methylalanine, and factor X substrate peptide fragment(39mer-4Ser)"
8UC4,X-RAY DIFFRACTION,2.49,50.64,"VAPOR DIFFUSION, HANGING DROP",7,"Well solution: 40% w/v PEG3350, 30 mM NaCl, 50 mM potassium phosphate monobasic pH 7.0
Protein Solution: 15 mg/mL protein, 20 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT, and 5% glycerol
Drop: 1 uL protein solution, 1 uL well solution",293,2023-09-25,2024-08-07,8UC4,1401,1,166,119,,21.16,1,1.87,experimental,25.14,0.2109,0.1822,Apo X-ray crystal structure of Cyclophilin D with a surface entropy reduction mutation (K175I)
6WR0,X-RAY DIFFRACTION,2.75,55.25,"VAPOR DIFFUSION, HANGING DROP",8.5,"175 mM Tris HCl, pH 8.5, 30% PEG-3350, 350 mM LiSO4, and 3% glycerol",293.15,2020-04-29,2021-05-05,6WR0,15302,4,1976,118,,226.92,1,2.7,experimental,56.83,0.2465,0.209,Human steroidogenic cytochrome P450 17A1 with 3-keto-delta4-abiraterone analog
8ODO,X-RAY DIFFRACTION,2.42,49.24,"VAPOR DIFFUSION, SITTING DROP",,"protein: RTCB 160 uM, Archease 200 uM, 2 mM manganese chloride, 2 mM GTP
reservoir: 10% w/v PEG 8000, 0.1 M HEPES pH 7.5, 8% v/v ethylene glycol
drop: 200 nl protein + 200 nl reservoir",291.15,2023-03-09,2024-03-27,8ODO,21728,8,2828,643,,315.91,2,2.2,experimental,65.24,0.2176,0.1933,Structure of human guanylylated RTCB in complex with Archease
8ODP,X-RAY DIFFRACTION,2.34,47.45,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium nitrate, 20% w/v PEG 3350",291.15,2023-03-09,2024-03-27,8ODP,21414,8,2760,297,,308.83,2,2.3,experimental,63.07,0.2158,0.1807,Structure of human RTCB with GMPCPP in complex with Archease
5LIU,X-RAY DIFFRACTION,2.5,50.89,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2016-07-15,2016-07-27,5LIU,2853,1,316,175,,37.62,1,1.75,experimental,,0.2525,0.2079,Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor IDD388
5M2F,X-RAY DIFFRACTION,2.49,50.65,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,2016-10-12,2017-02-15,5M2F,2807,1,316,121,,37.68,1,1.503,experimental,,0.2407,0.21,Crystal structure of human AKR1B10 complexed with NADP+ and the synthetic retinoid UVI2008
5JKV,X-RAY DIFFRACTION,5.84,78.94,"VAPOR DIFFUSION, SITTING DROP",7.4,"20-30% PEG 4000, PHOSPHATE BUFFER, PH 7.4",277,2016-04-26,2017-04-26,5JKV,3811,1,503,43,,59.48,1,2.75,experimental,71.622,0.2357,0.21433,HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1) AT 2.75 ANGSTROM WITH BOUND POLYETHYLENE GLYCOL
5FYI,X-RAY DIFFRACTION,2.64,53.44,,6,0.1M BIS-TRIS PH 6.0 -- 0.2M AMMONIUM SULFATE -- 28% PEG3350,,2016-03-07,2016-03-16,5FYI,6036,2,762,325,,90.57,1,2.096,experimental,,0.2358,0.1965,Crystal structure of human JMJD2A in complex with pyruvate
4WUP,X-RAY DIFFRACTION,2.37,47.6,"VAPOR DIFFUSION, SITTING DROP",8.5,"Crystallization buffer: 0.1M TrisHCl (pH 8.5), 
0.2M ammonium acetate and 24% of PEG4000",291,2014-11-03,2015-07-01,4WUP,4517,2,520,370,,58.43,1,1.75,experimental,24.864,0.232,0.185,Crystal structure of human carbonic anhydrase isozyme I with 4-[(2-Hydroxyethyl)thio]benzenesulfonamide
5EUN,X-RAY DIFFRACTION,2.4,48.1,"VAPOR DIFFUSION, HANGING DROP",,"Protein (1 uL) at a concentration of 7 mg/mL were mixed with an equal volume of a reservoir solution containing 200 mM NaCl, 0.1M NaCitrate pH 5.6, 24% PEG4K and equilibrated against 1 mL of a reservoir solution at 293 K.",293,2015-11-18,2015-12-16,5EUN,3785,1,425,438,,47.63,1,1.825,experimental,,0.199,0.1733,"The Crystal Structure of Human Kynurenine Aminotransferase II, PLP-bound form, at 1.83 A"
5SDB,X-RAY DIFFRACTION,2.24,45,"VAPOR DIFFUSION, SITTING DROP",8.5,"Wizard 3/4 H10 (296175h10): 100 mM Tris base/ Hydrochloric acid pH 8.5, 30% (w/v) PEG3350, 30% (v/v) 2-propanol, protein conc. 28.74 mg/mL, protein batch ID XP819, 10 mM NADP, 3.75 mM BSI108214, seeded from 293949g10, cryoprotected with 20% eg, puck izs6-6",290,2021-12-20,2022-02-09,5SDB,3539,2,374,331,,45.58,1,1.55,experimental,32.178,0.2044,0.1652,Crystal Structure of Human DHFR complexed with NADP and N10-formyl-tetrahydrofolate
6DAV,X-RAY DIFFRACTION,2.24,45,"VAPOR DIFFUSION, SITTING DROP",8.5,"Wizard 3/4 H10 (296175h10): 100 mM Tris base/ Hydrochloric acid pH 8.5, 30% (w/v) PEG3350, 30% (v/v) 2-propanol, protein conc. 28.74 mg/mL, protein batch ID XP819, 10 mM NADP, 3.75 mM BSI108214, seeded from 293949g10, cryoprotected with 20% eg, puck izs6-6",290,2018-05-02,2018-05-16,6DAV,3539,2,374,331,,45.58,1,1.55,experimental,32.178,0.2044,0.1652,Crystal Structure of Human DHFR complexed with NADP and N10formyltetrahydrofolate
7B7Z,X-RAY DIFFRACTION,2.7,54.52,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5
10% PEG 4000
0.2 M NaCl",298,2020-12-12,2021-07-07,7B7Z,7868,2,866,960,,97.49,2,1.7,experimental,28.996,0.2208,0.1948,DeAMPylation complex of monomeric FICD and AMPylated BiP (state 1)
7B80,X-RAY DIFFRACTION,2.72,54.74,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M Tris pH 8.0
25% PEG 400",298,2020-12-12,2021-07-07,7B80,7575,2,866,590,,98.4,2,1.87,experimental,37.354,0.2278,0.2008,DeAMPylation complex of monomeric FICD and AMPylated BiP (state 2)
7B8D,X-RAY DIFFRACTION,1.98,37.93,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B8D,2962,1,383,121,6,44.6,1,1.62,experimental,23.9334,0.2284,0.2066,Notum-Fragment 151
4UYZ,X-RAY DIFFRACTION,2.09,41.26,,6,pH 6.0,,2014-09-03,2015-02-25,4UYZ,10991,5,1894,,28,213.38,2,2.8,experimental,46.978,0.29294,0.24761,STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM II - 2.8A
7LS3,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, HANGING DROP",,"17.% PEG 3350, 0.35M Calcium Cl",293,2021-02-17,2021-08-25,7LS3,3704,1,474,185,,55.44,1,2.15,experimental,37.98,0.2439,0.1944,Co-complex CYP46A1 with 8114 (3f)
7N3M,X-RAY DIFFRACTION,2.33,42.62,"VAPOR DIFFUSION, HANGING DROP",,"17.5% PEG 3350, 0.4M Calcium Cl",290,2021-06-01,2022-02-23,7N3M,4041,1,474,390,,55.36,1,1.698,experimental,22.586,0.1918,0.1642,Co-complex CYP46A1 with 0431 (compound 17)
3WV1,X-RAY DIFFRACTION,2.27,45.77,"VAPOR DIFFUSION, HANGING DROP",8.5,"8-16%(w/v) PEG8000, 1.0-1.5M ammonium formate, 0.1M Tris HCl, pH 8.5, vapor diffusion, hanging drop, temperature 293K",293,2014-05-12,2015-05-20,3WV1,2990,2,342,246,,40.01,1,1.98,experimental,27.5761,0.2197,0.1747,"Crystal structure of the catalytic domain of MMP-13 complexed with 4-(2-((6-fluoro-2-((3-methoxybenzyl)carbamoyl)-4-oxo-3,4-dihydroquinazolin-5-yl)oxy)ethyl)benzoic acid"
5WY5,X-RAY DIFFRACTION,3.25,62.14,EVAPORATION,5.5,"22%(V/V) PEG 500, 0.1M SODIUM CITRATR
 PH5.5, 2%(V/V) 1,1,1,3,3,3-HEXAFLUORO-2-PROPANOL, VAPOR
 DIFFUSION, HANGING DROP, TEMPERATURE 291K",291,2017-01-11,2017-05-03,5WY5,3483,2,455,17,,53.29,2,2.92,experimental,,0.27,0.216,Crystal structure of MAGEG1 and NSE1 complex
4QK1,X-RAY DIFFRACTION,1.82,32.56,"VAPOR DIFFUSION, HANGING DROP",8,"1.4 M sodium citrate, 50 mM sodium phosphate dibasic, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-06-05,2015-03-04,4QK1,2252,1,260,193,,29.32,1,1.599,experimental,31.3991,0.2181,0.1721,Structural and Catalytic Effects of Proline Substitution and Surface Loop Deletion in the Extended Active Site of Human Carbonic Anhydrase II - K170P
4QK3,X-RAY DIFFRACTION,1.92,35.83,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 100 mM Tris-HCl, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-06-05,2015-03-04,4QK3,2163,1,249,167,,28.14,1,1.345,experimental,21.77,0.2495,0.2166,Structural and Catalytic Effects of Proline Substitution and Surface Loop Deletion in the Extended Active Site of Human Carbonic Anhydrase II - [delta]230-240
7BM7,X-RAY DIFFRACTION,1.92,36.01,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-19,2022-03-02,7BM7,2903,1,383,66,6,44.56,1,1.87,experimental,32.8788,0.2549,0.2193,Notum fragment 5e
7BM1,X-RAY DIFFRACTION,2.02,39.1,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-19,2022-03-02,7BM1,3030,1,383,130,6,45.41,1,1.37,experimental,24.7359,0.2177,0.1836,Notum_Valsartan complex
5L9X,X-RAY DIFFRACTION,2.08,40.88,EVAPORATION,6,"17% PEG 2000MME, 0.1 M MES",298,2016-06-12,2016-06-22,5L9X,4432,3,456,465,,56.14,1,1.9,experimental,26.7949,0.2143,0.1646,Human DNA polymerase eta-DNA ternary complex: reaction with 10 mM Mn2+ for 60s
7OAT,X-RAY DIFFRACTION,2.63,53.24,"VAPOR DIFFUSION, SITTING DROP",,"16% PEG 8000, 0.2 M calcium acetate, 0.1 M MES (pH 6.5)",277,2021-04-20,2022-08-03,7OAT,6558,3,895,58,,101.51,3,2.995,experimental,78.66,0.2704,0.2253,Structural basis for targeted p97 remodelling by ASPL as prerequisite for p97 trimethylation by METTL21D
5DFL,X-RAY DIFFRACTION,2.71,54.69,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M di-ammonium citrate pH 5.0, 20% PEG 3350",291,2015-08-27,2015-12-02,5DFL,2247,2,276,57,,31.26,2,2.1,experimental,46.479,0.2348,0.1951,Crystal structure of Ube2K~Ubiquitin conjugate
5E2N,X-RAY DIFFRACTION,2.15,42.4,"VAPOR DIFFUSION, SITTING DROP",6,"Crystallization buffer: 0.1M sodium citrate (pH 5.5), 0.1M sodium acetate (pH 4.5) and
 26% PEG4000.",291,2015-10-01,2016-10-05,5E2N,4795,2,526,483,,60.98,1,1.53,experimental,22.272,0.212,0.176,"Crystal structure of human carbonic anhydrase isozyme XIII with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
7B99,X-RAY DIFFRACTION,2.01,38.86,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-14,2022-01-12,7B99,2950,1,383,124,6,44.96,1,1.81,experimental,26.1277,0.2491,0.2141,Notum Fragment 283
7B9I,X-RAY DIFFRACTION,2,38.42,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-14,2022-01-12,7B9I,3063,1,383,129,8,44.91,1,1.34,experimental,21.8374,0.2307,0.2152,Notum Fragment 297
7B9N,X-RAY DIFFRACTION,1.99,38.06,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-14,2022-01-12,7B9N,2906,1,383,112,6,44.93,1,1.38,experimental,21.8929,0.2288,0.2038,Notum Fragment 588
7BA1,X-RAY DIFFRACTION,1.98,38,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-15,2022-01-12,7BA1,2826,1,383,77,6,44.5,1,1.93,experimental,29.4323,0.2639,0.2274,Notum Fragment 634
7BAC,X-RAY DIFFRACTION,1.97,37.57,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-15,2022-01-12,7BAC,3010,1,383,105,8,44.82,1,1.54,experimental,27.6758,0.2479,0.2112,Notum Fragment 646
7BAP,X-RAY DIFFRACTION,1.99,38.1,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-16,2022-01-12,7BAP,2963,1,383,101,6,44.78,1,1.53,experimental,25.4996,0.2133,0.2006,Notum Fragment 648
7BCD,X-RAY DIFFRACTION,1.99,38.05,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-19,2022-01-12,7BCD,2850,1,383,98,6,44.5,1,1.51,experimental,22.948,0.2379,0.212,Notum Fragment 714
7BCL,X-RAY DIFFRACTION,2.01,38.83,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-19,2022-01-12,7BCL,2776,1,383,51,6,44.25,1,1.84,experimental,30.4345,0.2713,0.2228,Notum Fragment 792
7BD8,X-RAY DIFFRACTION,1.99,38.28,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BD8,2930,1,383,134,6,44.63,1,1.42,experimental,21.507,0.2068,0.1921,Notum Fragment 872
7BD9,X-RAY DIFFRACTION,2,38.44,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BD9,2916,1,383,115,6,44.38,1,1.59,experimental,25.6172,0.2137,0.1955,Notum Fragment 886
7BDA,X-RAY DIFFRACTION,1.99,38.07,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BDA,2908,1,383,109,6,44.69,1,1.47,experimental,25.1782,0.2014,0.194,Notum Fragment 900
7BDD,X-RAY DIFFRACTION,1.99,38.29,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BDD,2876,1,383,102,6,44.4,1,1.47,experimental,22.9907,0.2106,0.1985,Notum Fragment 924
7BDF,X-RAY DIFFRACTION,1.98,37.93,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BDF,2943,1,383,121,6,44.39,1,1.4,experimental,21.8248,0.215,0.2005,Notum Fragment 927
7BDG,X-RAY DIFFRACTION,1.98,37.92,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BDG,3040,1,383,129,8,44.55,1,1.6,experimental,23.819,0.2426,0.2086,Notum Fragment 934
7BDH,X-RAY DIFFRACTION,1.98,37.79,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BDH,2908,1,383,108,6,44.54,1,1.54,experimental,24.327,0.2172,0.1969,Notum Fragment 955
9BC4,X-RAY DIFFRACTION,1.54,20.21,"VAPOR DIFFUSION, SITTING DROP",,"15% PEG4K, 0.15 M Ammonium sulfate, 0.1 M HEPES (pH 7.0).",298,2024-04-07,2024-07-03,9BC4,3865,2,694,334,,78.27,2,1.84,experimental,25.782,0.2301,0.18625,Transglutaminase 2 - Intermediate State
8P6U,X-RAY DIFFRACTION,2.06,40.23,"VAPOR DIFFUSION, SITTING DROP",,2.9M ammonium sulfate,293,2023-05-30,2024-03-06,8P6U,2393,1,258,308,,29.71,1,1.3,experimental,,0.1753,0.1443,Human carbonic anhydrase II containing 5-fluorotryptophanes
7Z36,X-RAY DIFFRACTION,3.32,62.93,"VAPOR DIFFUSION, SITTING DROP",7,"11% (w/v) PEG 5000 MME
5% Tacsimate
0.1 M HEPES pH 7",291,2022-03-01,2022-11-02,7Z36,7897,5,1180,,,134.61,3,2.8,experimental,68.52,0.274,0.2267,Crystal structure of the KAP1 tripartite motif in complex with the ZNF93 KRAB domain
6HVI,X-RAY DIFFRACTION,3.88,68.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.16M Monosaccharides, 30% GOL_P4K, 0.1M MOPS/Hepes pH 7.5",277,2018-10-11,2018-11-14,6HVI,4021,1,520,373,,60.82,1,1.96,experimental,31.937,0.2084,0.1863,Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 2
6IBX,X-RAY DIFFRACTION,3.89,68.37,"VAPOR DIFFUSION, SITTING DROP",,"2% Tacsimate, 10% PEG3350, 0.1M MES/imidazole pH 7.0",277,2018-12-01,2019-01-23,6IBX,3819,1,429,231,,51.08,1,2.11,experimental,38.185,0.2199,0.1871,Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 5
6IC0,X-RAY DIFFRACTION,3.79,67.57,"VAPOR DIFFUSION, SITTING DROP",,"2% Tacsimate, pH7.0; 5% 2-propanol; 0.1M imidazole; 8% PEG3350",277,2018-12-01,2019-01-23,6IC0,3617,1,428,74,,50.94,1,2.6,experimental,47.159,0.2547,0.1907,Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 4
8G8H,X-RAY DIFFRACTION,2.14,42.49,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.5, 20% PEG2000 MME, 5 mM calcium chloride",293,2023-02-17,2024-02-21,8G8H,4051,3,452,311,,54.92,1,1.64,experimental,34.34,0.2415,0.2098,Crystal structure of human DNA polymerase eta incorporating ITP across dC
8G8J,X-RAY DIFFRACTION,2.12,41.97,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.5, 20% PEG2000 MME, 5 mM calcium chloride",293,2023-02-17,2024-02-21,8G8J,3922,3,452,167,,54.94,1,1.74,experimental,36.66,0.2452,0.2114,Crystal structure of human DNA polymerase eta incorporating ITP across dT
8GBF,X-RAY DIFFRACTION,2.14,42.4,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.25, 18% PEG2000 MME, 5 mM calcium chloride",293,2023-02-25,2024-02-28,8GBF,3912,3,452,157,,54.94,1,2.11,experimental,38.92,0.2568,0.205,Crystal structure of human DNA polymerase eta incorporating syn-ITP across dT
5UYS,X-RAY DIFFRACTION,2.6,52.76,"VAPOR DIFFUSION, HANGING DROP",,"175 mM Tris HCl, pH 8.5, 30% PEG-3350, 300 mM LiSO4, 3% glycerol",293,2017-02-24,2018-02-28,5UYS,15630,4,1976,339,,226.83,1,2.392,experimental,42.63,0.245,0.1895,Human steroidogenic cytochrome P450 17A1 with 3alphaOH-5alpha-abiraterone analog
6WW0,X-RAY DIFFRACTION,2.6,52.74,"VAPOR DIFFUSION, HANGING DROP",8.5,"175 mM Tris HCl (pH = 8.5), 30% PEG 3350, 300 mM LiSO4, 3% glycerol",293.15,2020-05-07,2021-05-26,6WW0,16124,4,1976,967,,226.9,1,2.01,experimental,34.58,0.2184,0.1854,Human steroidogenic cytochrome P450 17A1 with 3-keto-5alpha-abiraterone analog
7XN9,X-RAY DIFFRACTION,2.36,47.77,LIPIDIC CUBIC PHASE,7,"100-400 mM lithium nitrate, 6-10% PEG2000, 100 mM L-054,522, and 0.1 M HEPES, pH 7.0",293,2022-04-28,2022-08-03,7XN9,3787,1,589,,1,66.94,1,2.6,experimental,64.25,0.2647,0.2126,"Crystal structure of SSTR2 and L-054,522 complex"
5TDI,X-RAY DIFFRACTION,2.11,41.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.05 M cadmium sulfate hydrate, 0.1 M HEPES pH 7.5, 1.0 M sodium acetate trihydrate",295,2016-09-19,2017-01-25,5TDI,1973,1,215,278,3,24.04,1,1.4,experimental,15.2,0.1705,0.1427,Crystal structure of Cathepsin K with a covalently-linked inhibitor at 1.4 Angstrom resolution.
8FH5,X-RAY DIFFRACTION,2.21,44.5,"VAPOR DIFFUSION, HANGING DROP",5.5,"25% PEG 3350, 100 mM Bis-Tris",298,2022-12-13,2023-12-20,8FH5,2739,1,315,141,,36.93,1,1.62,experimental,14.03,0.1672,0.143,Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And AT-001
4QK2,X-RAY DIFFRACTION,2.07,40.47,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 100 mM Tris-HCl, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-06-05,2015-03-04,4QK2,2384,1,260,275,,29.41,1,1.519,experimental,17,0.1784,0.1589,Structural and Catalytic Effects of Proline Substitution and Surface Loop Deletion in the Extended Active Site of Human Carbonic Anhydrase II - E234P
6I7S,X-RAY DIFFRACTION,2.79,55.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Tris pH 8.25, 0.2 M Li2SO4, 32% v/v PEG 400, 2% Polypropylene glycol P425",277,2018-11-17,2019-08-21,6I7S,21452,4,2752,222,8,313.65,2,2.5,experimental,72.488,0.2571,0.2045,Microsomal triglyceride transfer protein
6BBS,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.48,50.33,"VAPOR DIFFUSION, SITTING DROP",8,"1.6 M sodium citrate, 50 mM TRIS pH 8.0",290,2017-10-19,2018-02-28,6BBS,2157,1,260,84,,29.74,1,2,experimental,,0.287,0.276,Joint X-ray/neutron structure of human carbonic anhydrase II in complex with brinzolamide
8GTJ,X-RAY DIFFRACTION,2.52,51.21,"VAPOR DIFFUSION, SITTING DROP",7.2,1.2 M Sodium potassium phosphate,293,2022-09-08,2023-04-12,8GTJ,9607,4,1310,152,,149.94,2,2.7,experimental,63.16,0.276,0.2407,Crystal structure of IpaH7.8-LRR and GSDMB isoform-4 complex
8FH8,X-RAY DIFFRACTION,2.24,45.17,"VAPOR DIFFUSION, HANGING DROP",5.5,"25% PEG 3,350, 100 mM Bis-Tris",298,2022-12-13,2023-12-20,8FH8,2761,1,316,128,,37.72,1,1.6,experimental,18.543,0.1948,0.1666,Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And AT-003 Soaked In Hydrogen Peroxide
8DBB,X-RAY DIFFRACTION,2.15,42.89,"VAPOR DIFFUSION, HANGING DROP",5.2,"0.1 M sodium citrate, pH 5.20, 0.2 M ammonium acetate, 24-30% PEG4000",293,2022-06-14,2023-03-08,8DBB,3192,3,354,505,,38.87,1,1.3,experimental,9.603,0.15663,0.12119,"Crystal structure of DDT with the selective inhibitor 2,5-Pyridinedicarboxylic Acid"
8VDS,X-RAY DIFFRACTION,2.78,55.8,"VAPOR DIFFUSION, HANGING DROP",6.4,"100 mM MES, pH 6.4, 100 mM Lithium acetate, 12% PEG3350",298.15,2023-12-17,2024-05-22,8VDS,5502,3,694,14,,84.08,1,2.79,experimental,90.32,0.252,0.196,DNA Ligase 1 with nick DNA 3'rG:C
8Q7G,X-RAY DIFFRACTION,2.34,47.51,"VAPOR DIFFUSION, HANGING DROP",,"28-31% PEG4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5-9.0",293,2023-08-16,2024-08-28,8Q7G,4478,2,522,386,,58.33,1,1.43,experimental,23.904,0.2175,0.1927,"Human Carbonic Anhydrase I in complex with 3,4-dihydro-1H-benzo[c][1,2]oxaborinin-1-ol pH 7.0"
6YSK,X-RAY DIFFRACTION,1.94,36.57,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium sulphate
0.1 M Sodium citrate, pH4.2",300,2020-04-22,2020-09-16,6YSK,3122,1,383,123,8,45.04,1,1.21,experimental,26.6138,0.2098,0.195,1-phenylpyrroles and 1-enylpyrrolidines as inhibitors of Notum
6IBY,X-RAY DIFFRACTION,3.87,68.18,"VAPOR DIFFUSION, SITTING DROP",,"25% GOL-P4K, 0.12M Monosaccharides, Buffer System2, pH 7.0",277,2018-12-01,2019-01-23,6IBY,3704,1,428,142,,51.07,1,2.51,experimental,39.581,0.232,0.1935,Human PFKFB3 in complex with a N-Aryl 6-Aminoquinoxaline inhibitor 6
8BTT,X-RAY DIFFRACTION,2.33,47.28,"VAPOR DIFFUSION, SITTING DROP",7,"protein: 125 uM in 25 mM Tris pH 7.5, 200 mM NaCl, 10 % glycerol, 1mM TCEP, 2 mM manganese chloride
reservoir: 0.1 M magnesium chloride, 0.1 M HEPES pH 7.0, 15 % PEG 4000
drop: 800 nl protein + 600 nl reservoir",293.15,2022-11-30,2023-12-13,8BTT,7529,2,1060,37,,116.88,1,2.6,experimental,71.34,0.2556,0.1992,Structure of human RTCB
5LLN,X-RAY DIFFRACTION,2.18,43.7,"VAPOR DIFFUSION, SITTING DROP",5,Crystallization buffer: 0.1M ammonium citrate (pH 5) and 20% PEG4000,291,2016-07-28,2017-08-16,5LLN,4908,2,526,574,,60.54,1,1.6,experimental,16.125,0.2057,0.1682,"Crystal structure of human carbonic anhydrase isozyme XIII with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide"
5JTC,X-RAY DIFFRACTION,2.75,55.25,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% PEG3350, 200mM NaBr, 100mM BisTris Propane, 1mM MnCl2, 2mM 2,4-PDCA, 330uM ASPH, 726uM Factor X",277,2016-05-09,2017-05-24,5JTC,3815,2,468,216,2,53.99,2,2.24,experimental,48.1335,0.2085,0.1812,"Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, 2,4-pyridine dicarboxylate and factor X substrate peptide fragment(39mer-4Ser)"
6YYW,X-RAY DIFFRACTION,2.75,55.33,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM Bis Tris Propane, 200 mM sodium acetate trihydrate, 20% w/v PEG 3350, 1 mM manganese chloride, 2 mM 2-oxoglutarate, 18 mg/ml protein",277,2020-05-06,2021-03-17,6YYW,3721,2,468,143,2,53.8,2,2.27,experimental,56.89,0.2237,0.1875,"Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 2-oxoglutarate, and factor X substrate peptide fragment(39mer-4Ser)"
6YYX,X-RAY DIFFRACTION,2.6,52.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"200 mM Bis Tris Propane, 200 mM sodium/potassium phosphate, 20% w/v PEG 3350, 1 mM manganese chloride, 2 mM 3-methyl-2-oxoglutarate, 18 mg/ml protein",277,2020-05-06,2021-03-17,6YYX,4059,2,468,474,2,53.81,2,1.53,experimental,31.61,0.1922,0.1624,"Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 3-methyl-2-oxoglutarate, and factor X substrate peptide fragment(39mer-4Ser)"
6YYY,X-RAY DIFFRACTION,2.68,54.07,"VAPOR DIFFUSION, SITTING DROP",,"200 mM sodium bromide, 20% w/v PEG 3350, 1 mM manganese chloride, 2 mM 4,4-dimethyl-2-oxoglutarate, 18 mg/ml protein",277,2020-05-06,2021-03-17,6YYY,3587,2,468,87,2,53.82,2,2.29,experimental,42.85,0.2438,0.209,"Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 4,4-dimethyl-2-oxoglutarate, and factor X substrate peptide fragment(39mer-4Ser)"
7XNA,X-RAY DIFFRACTION,2.24,45.18,LIPIDIC CUBIC PHASE,7,"100-300 mM ammonium sulphate, 6-10% PEG2000, 1 mg/ml CYN 154806, and 0.1 M HEPES, pH 7.0",293,2022-04-28,2022-08-03,7XNA,3778,2,593,,2,66.68,2,2.65,experimental,,0.2904,0.2196,Crystal structure of somatostatin receptor 2 (SSTR2) with peptide antagonist CYN 154806
5HVQ,X-RAY DIFFRACTION,3.24,62.08,VAPOR DIFFUSION,,As for entry 3nw0,277,2016-01-28,2016-10-26,5HVQ,3537,2,455,,,53.25,2,2.923,experimental,,0.2678,0.2367,Alternative model of the MAGE-G1 NSE-1 complex
5DOH,X-RAY DIFFRACTION,2.01,38.5,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2015-09-11,2016-09-28,5DOH,4952,2,520,538,,60.03,1,1.05,experimental,16.924,0.172,0.144,"Crystal structure of human carbonic anhydrase isozyme II with 2-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide"
8FDA,X-RAY DIFFRACTION,2.52,51.27,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris-HCl (pH 8.5), 0.25 M LiSO4, 30% PEG 3350, and 7% sucrose",295,2022-12-02,2023-08-23,8FDA,15467,4,1976,268,,227.57,1,2.2,experimental,55.7,0.2594,0.2158,Human Cytochrome P450 17A1 in complex with steroidal isonitrile inhibitor
6IC2,X-RAY DIFFRACTION,2.1,41.37,VAPOR DIFFUSION,8,"1.7 M sodium citrate, 50 mM Tris pH 8.0",296,2018-12-01,2019-05-15,6IC2,2335,1,260,196,,29.79,1,1.15,experimental,19.944,0.26841,0.24251,Polypharmacology of Epacadostat: a Potent and Selective Inhibitor of the Tumor Associated Carbonic Anhydrases IX and XII
6PDV,X-RAY DIFFRACTION,2.09,41.21,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M NaCitrate, 50mM Tris",298,2019-06-19,2020-03-11,6PDV,2398,1,260,205,,29.58,1,1.23,experimental,21.0295,0.1745,0.1566,"Cu-Carbonic Anhydrase II, A Nitrite Reductase"
6J4U,X-RAY DIFFRACTION,2.76,55.48,EVAPORATION,5,"by introducing three mutations E71S/A72H/K79M into V1c allowed us to solve the V1c-SVBP to high resolution. Well diffracting crystals of the mutant V1c-SVBP complex were obtained in 1.0 M lithium chloride, 0.1 M citric acid, pH 5.0, 20% PEG 6000.",293,2019-01-10,2019-05-01,6J4U,2489,2,317,238,,36.86,2,1.998,experimental,,0.2036,0.1681,Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
6TJJ,X-RAY DIFFRACTION,3.25,62.15,"VAPOR DIFFUSION, HANGING DROP",4.6,"1.1 M (NH4)2SO4, 0.19 M guanidine HCl, 0.04 M KCl, 0.1 M Na acetate, pH 4.6",293,2019-11-26,2020-06-10,6TJJ,8973,2,994,721,4,115.31,1,1.59,experimental,32.082,0.2448,0.2146,Structure of Cerezyme at pH 4.6
7OPS,X-RAY DIFFRACTION,3.05,59.61,"VAPOR DIFFUSION, SITTING DROP",,"60% MPD, 0.1M SPG 6.5",277.15,2021-06-01,2021-07-21,7OPS,2807,1,357,155,,41.08,1,2.38,experimental,38.815,0.2285,0.1765,Crystal structure of haspin in complex with ZW282 (compound 2a)
8SS0,X-RAY DIFFRACTION,3.83,67.85,"VAPOR DIFFUSION, HANGING DROP",7.4,"CALCIUM ACATATE, PEG 4000, ANAPOE 80, 14 ALPHA ALDEHYDE DERIVATIVE OD DIHYDROLANOSTEROL",290,2023-05-08,2024-01-17,8SS0,7379,2,916,107,,106.83,1,2.25,experimental,37.13,0.249,0.219,Human sterol 14 alpha-demethylase (CYP51) in complex with the reaction intermediate 14 alpha-aldehyde dihydrolanosterol
7QEI,X-RAY DIFFRACTION,2.06,40.22,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M NaF, 20 % PEG3350",293,2021-12-03,2022-10-12,7QEI,2437,1,299,165,,33.33,1,2.1,experimental,21.772,0.2311,0.18738,Structure of human MTHFD2L in complex with TH7299
4ZAJ,X-RAY DIFFRACTION,2.63,53.17,"VAPOR DIFFUSION, SITTING DROP",6.5,25% PEG 1000,293,2015-04-13,2016-03-30,4ZAJ,4744,1,601,106,,68.94,1,2.22,experimental,33.206,0.2643,0.2189,2.2 Angstrom Crystal Structure of a Human Arginyl-tRNA Synthetase
5O07,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M SODIUM CITRATE, 100 MM TRIS-HCL",293,2017-05-16,2017-08-02,5O07,2309,1,260,237,,29.6,1,1.8,experimental,13.2664,0.1954,0.1571,The crystal structure of the human carbonic anhydrase II in complex with a nitroimidazole sulfamate inhibitor
7RRF,X-RAY DIFFRACTION,2.12,42.09,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris pH 7.8",293,2021-08-09,2022-08-24,7RRF,2336,1,257,213,,29.89,1,1.45,experimental,17.9886,0.1693,0.1529,Carbonic Anhydrase IX-mimic in complex with Beta-Galactose_2C
9C1A,X-RAY DIFFRACTION,2.52,51.14,"VAPOR DIFFUSION, HANGING DROP",,"0.2M CaCl2, 20% PEG3350",295,2024-05-28,2024-09-11,9C1A,1632,1,193,217,,23.02,1,1.96,experimental,28.97,0.1999,0.1718,Crystal structure of GDP-bound human M-RAS protein in crystal form I
5OY3,X-RAY DIFFRACTION,2.27,45.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M TRIS pH 7.5, 15%(v/v) Tert-butanol,",277,2017-09-07,2017-09-20,5OY3,4096,2,526,300,,60.58,2,2.136,experimental,,0.2207,0.165,The structural basis of the histone demethylase KDM6B histone 3 lysine 27 specificity
6BC9,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.16,43.16,"VAPOR DIFFUSION, SITTING DROP",,"1.6 M sodium citrate, 50 mM TRIS pH 8.0",293,2017-10-20,2018-02-28,6BC9,2192,1,260,123,,29.68,1,1.8,experimental,,0.196,0.178,Joint X-ray/neutron structure of human carbonic anhydrase II in complex with dorzolamide
6CIR,X-RAY DIFFRACTION,2.63,53.27,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.175 M Tris, pH 8.5 containing 30% PEG 3350, 3% glycerol, and 0.250-0.275 M lithium sulfate",293,2018-02-25,2018-06-06,6CIR,15348,4,1976,133,,226.95,1,2.648,experimental,,0.2405,0.187,Human Cytochrome P450 17A1 in complex with inhibitor: abiraterone C6 oxime
6CIZ,X-RAY DIFFRACTION,2.6,52.77,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.175 M Tris, pH 8.5 containing 35% PEG 3350, 3% glycerol, and 0.250-0.275 M lithium sulfate",277,2018-02-25,2018-06-06,6CIZ,15415,4,1976,139,,226.92,1,2.601,experimental,,0.243,0.1849,Human Cytochrome P450 17A1 in complex with inhibitor: abiraterone C6 nitrile
5EIJ,X-RAY DIFFRACTION,2.15,42.86,"VAPOR DIFFUSION, SITTING DROP",7.8,"1.6M sodium citrate, 50mM Tris",298,2015-10-29,2016-11-09,5EIJ,2183,1,257,92,,29.77,1,1.99,experimental,15.8026,0.2188,0.1586,Carbonic Anhydrase II in complex with Sulfonamide Inhibitor
5FNH,X-RAY DIFFRACTION,2.1,41.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-11-15,2016-03-02,5FNH,2444,1,260,253,,30.04,1,1.66,experimental,14.283,0.17965,0.13707,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
6WQ4,X-RAY DIFFRACTION,2.1,41.49,"VAPOR DIFFUSION, HANGING DROP",7.8,1.6M sodium citrate and 50mM Tris at pH 7.8,298,2020-04-28,2020-06-24,6WQ4,2310,1,260,209,,30.09,1,1.35,experimental,16.1773,0.1724,0.1539,Carbonic Anhydrase II Complexed with 2-((2-Cyanoethyl)(phenethyl)amino)-N-phenethyl-N-(4-sulfamoylphenethyl)acetamide
6WQ8,X-RAY DIFFRACTION,2.1,41.33,"VAPOR DIFFUSION, HANGING DROP",7.8,1.6M sodium citrate and 50mM tris,298,2020-04-28,2020-06-24,6WQ8,2395,1,260,235,,30.6,1,1.405,experimental,18.0568,0.1715,0.1462,Carbonic Anhydrase II Complexed with 3-((2-((Furan-2-ylmethyl)(4-sulfamoylphenethyl)amino)-2-oxoethyl)(phenethyl)amino)propanoic acid
6WQ9,X-RAY DIFFRACTION,2.09,41.18,"VAPOR DIFFUSION, HANGING DROP",7.8,1.6M sodium citrate and 50mM tris,298,2020-04-28,2020-06-24,6WQ9,2384,1,260,248,,30.14,1,1.305,experimental,17.8272,0.1729,0.1488,Carbonic Anhydrase II Complexed with 3-((2-((Naphthalen-2-ylmethyl)(4-sulfamoylphenethyl)amino)-2-oxoethyl)(phenethyl)amino)propanoic acid
7NZR,X-RAY DIFFRACTION,2.06,40.33,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2021-03-24,2022-04-13,7NZR,2461,1,260,288,,29.93,1,1.284,experimental,18.362,0.1586,0.1239,"Crystal structure of chimeric carbonic anhydrase VA with 2-(cyclooctylamino)-3,5,6-trifluoro-4-[(2-hydroxyethyl)sulfanyl]benzenesulfonamide"
7NZT,X-RAY DIFFRACTION,2.07,40.45,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2021-03-24,2022-04-13,7NZT,2466,1,260,295,,30.04,1,1.35,experimental,14.846,0.1657,0.1225,"Crystal structure of chimeric carbonic anhydrase VA with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
4Z1E,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,2015-03-27,2015-08-26,4Z1E,2265,1,259,191,,29.57,1,2.01,experimental,32.97,0.2437,0.1719,"Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)"
6U4Q,X-RAY DIFFRACTION,2.11,41.65,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M sodium citrate, 50 mM Tris",298,2019-08-26,2020-01-22,6U4Q,2278,1,257,203,,29.21,1,1.306,experimental,18.4899,0.1665,0.1512,Carbonic anhydrase 2 in complex with SB4197
6U4T,X-RAY DIFFRACTION,2.12,41.98,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M NaCitrate, 50 mM Tris",298,2019-08-26,2020-01-22,6U4T,2297,1,257,193,,29.33,1,1.356,experimental,21.9586,0.1729,0.154,Carbonic anhydrase 9 in complex with SB4197
7OYQ,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2021-06-24,2023-01-18,7OYQ,2429,3,266,290,,30.27,2,1.15,experimental,16.202,0.1805,0.1432,Carbonic anhydrase II in complex with Hit3-t2 (MH174)
7OYR,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2021-06-24,2023-01-18,7OYR,2505,3,272,300,,30.75,2,1.15,experimental,16.213,0.1507,0.1232,Carbonic anhydrase II in complex with Hit3-t4 (MH181)
6HN3,X-RAY DIFFRACTION,1.91,35.61,"VAPOR DIFFUSION, HANGING DROP",6,"Protein 17.6 mg/ml in 0.050 M TRIS-HCL PH 8.0, 0.15 M NACL, 0.005 M TCEP. Reservoir solution 0.1 M MES PH 6.0, 18% (w/v) PEG 3350, 5% (v/v) ethanol. Cryo buffer was reservoir buffer supplemented with 15% glycerol",298,2018-09-13,2020-04-01,6HN3,1723,1,176,245,,20.64,1,1.01,experimental,14.34,0.137,0.114,wildtype form (apo) of human GPX4 with Se-Cys46
9BC3,X-RAY DIFFRACTION,1.57,21.46,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 4K, 10% 2-propanol, 0.1 M HEPES (pH 7.0)",298,2024-04-07,2024-07-03,9BC3,7215,4,1388,245,,156.35,2,2.52,experimental,28.32,0.26452,0.20501,Transglutaminase 2 - Alternate state
7VKE,X-RAY DIFFRACTION,2.91,57.73,"VAPOR DIFFUSION, SITTING DROP",,"Sodium Citrate, PEG 8000",293,2021-09-29,2022-08-03,7VKE,3394,2,394,316,7,45.61,2,1.9,experimental,37.307,0.2308,0.1927,Crystal structure of human CD38 ECD in complex with UniDab(TM) F11A
7WJQ,X-RAY DIFFRACTION,2.19,43.86,LIQUID DIFFUSION,,"NaCl, HEPES sodium, PEG 8000, ammonium sulfate, 1,6-hexanediol",291.15,2022-01-07,2023-01-11,7WJQ,4555,2,631,21,,72.38,2,2.7,experimental,53.35,0.2522,0.2102,Crystal structure of GSDMB in complex with Ipah7.8
6R8P,X-RAY DIFFRACTION,2,38.4,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5M Ammonium sulfate
0.1 M Sodium citrate
pH4.2",300,2019-04-02,2019-05-08,6R8P,3107,1,383,145,8,45.45,1,1.45,experimental,25.7151,0.2267,0.1969,Notum fragment 723
6TR5,X-RAY DIFFRACTION,2,38.46,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M ammonium sulphate 
0.1 M sodium citrate pH 4.2",300,2019-12-17,2020-01-15,6TR5,2978,1,383,116,6,45.1,1,1.509,experimental,27.4968,0.2256,0.1964,Melatonin-Notum complex
6YUY,X-RAY DIFFRACTION,1.96,37.16,"VAPOR DIFFUSION, SITTING DROP",4,"1.4 M AMMONIUM SULPHATE, 0.1 M CITRIC ACID, PH 4.0",295,2020-04-27,2020-05-06,6YUY,3106,1,383,117,8,45.6,1,2,experimental,42.77,0.2308,0.1944,STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLE-3-CARBOXYLIC ACID FRAGMENT 471
6YXI,X-RAY DIFFRACTION,2.09,41.18,"VAPOR DIFFUSION, SITTING DROP",4,"1.4 M ammonium sulphate, 0.1 M citric acid, pH 4",300,2020-05-01,2020-08-19,6YXI,3196,1,383,198,6,44.91,1,1.34,experimental,29.51,0.1855,0.1587,"Structure of Notum in complex with a 1-(3-Chlorophenyl)-2,5-dimethyl-1H-pyrrole-3-carboxylic acid inhibitor"
5DAB,X-RAY DIFFRACTION,2.92,61.65,"VAPOR DIFFUSION, HANGING DROP",5.6,"10%(w/v) polyethylene glycol (PEG) 3350, 0.1 M trisodium citrate dehydrate, 3.0 mM N-oxalylglycine (NOG)",293,2015-08-19,2016-08-24,5DAB,3673,1,479,118,,55.93,1,2.1,experimental,,0.2409,0.21,Crystal structure of FTO-IN115
5F8P,X-RAY DIFFRACTION,3.24,62.06,"VAPOR DIFFUSION, HANGING DROP",,"10 %(w/v) polyethylene glycol (PEG) 3350, 0.1 M trisodium citrate dehydrate, 3.0 mM N-oxalylglycine (NOG)",293,2015-12-09,2016-12-14,5F8P,3631,1,476,89,3,55.49,1,2.2,experimental,,0.2339,0.1878,A Novel Inhibitor of the Obesity-Related Protein FTO
4YE6,X-RAY DIFFRACTION,4.73,74,"VAPOR DIFFUSION, SITTING DROP",6,"0.1M calcium acetate, 0.1M Tris, pH 6.0, 12.5% (w/v) PEG 3,350, 60mM gly-gly-gly",289.15,2015-02-23,2016-02-17,4YE6,5477,1,776,237,,88.06,1,2.4,experimental,,0.2391,0.2105,The crystal structure of the intact human GlnRS
7BLS,X-RAY DIFFRACTION,1.94,36.51,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-18,2022-03-02,7BLS,3007,1,383,96,7,44.73,1,1.19,experimental,17.439,0.2121,0.1928,Notum-maybridge_18
5FDC,X-RAY DIFFRACTION,2.08,40.81,"VAPOR DIFFUSION, HANGING DROP",,"2.5 M ammonium sulphate, 0.3 M sodium chloride, 0.1 M Tris-HCl, pH 8.4 and 5 mM 4-(hydroxymercurybenzoate)",293,2015-12-16,2016-05-18,5FDC,2384,1,260,264,,30.03,1,1.75,experimental,,0.204,0.17,"Crystal structure of Human Carbonic Anhydrase II in complex with the anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog."
5FDI,X-RAY DIFFRACTION,2.07,40.47,"VAPOR DIFFUSION, HANGING DROP",,"2.5 M ammonium sulphate, 0.3 M sodium chloride, 0.1 M Tris-HCl, pH 8.4 and 5 mM 4-(hydroxymercurybenzoate)",293,2015-12-16,2016-05-18,5FDI,2352,1,260,224,,30.06,1,1.85,experimental,,0.1925,0.1616,"Crystal structure of Human Carbonic Anhydrase II with the anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog."
5N1R,X-RAY DIFFRACTION,2.08,40.92,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM pH 8.0",296,2017-02-06,2017-12-27,5N1R,2481,1,260,339,,29.76,1,1.3,experimental,14.515,0.1953,0.166,Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4'-Pyrazol-1-ylmethyl-biphenyl-4-sulfonamide
5N1S,X-RAY DIFFRACTION,2.08,40.97,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM",296,2017-02-06,2017-12-27,5N1S,2509,1,260,362,,29.72,1,1.3,experimental,13.328,0.1805,0.1553,Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-(1H-Indol-2-yl)-benzenesulfonamide
5N24,X-RAY DIFFRACTION,2.04,39.67,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM",296,2017-02-07,2017-12-27,5N24,2435,1,260,306,,29.96,1,1.5,experimental,20.299,0.2091,0.1703,Crystal structure of human carbonic anhydrase II in complex with the inhibitor b4'-Cyano-biphenyl-4-sulfonic acid amide
5N25,X-RAY DIFFRACTION,2.07,40.65,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM",296,2017-02-07,2017-12-27,5N25,2475,1,260,338,,29.92,1,1.4,experimental,14.02,0.1991,0.1722,Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-Pyridin-3-yl-benzenesulfonamide
8CR0,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, HANGING DROP",8,"1.3 M sodium citrate, 60 mM Tris-HCl",298,2023-03-07,2023-06-21,8CR0,2294,1,260,177,,29.77,1,1.22,experimental,13.595,0.17862,0.14428,Crystal structure of human carbonic anhydrase II in complex with a triazolyl benzoxaborole inhibitor
6CHI,X-RAY DIFFRACTION,2.59,52.59,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.175 M Tris, pH 8.5 containing 35% PEG 3350, 3% glycerol, and 0.250-0.275 M lithium sulfate",277,2018-02-22,2018-06-06,6CHI,15324,4,1976,86,,227,1,2.698,experimental,,0.242,0.1868,Human Cytochrome P450 17A1 in complex with inhibitor: abiraterone C6 amide
6Q9F,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, SITTING DROP",8,0.2 M sodium chloride 0.1 M Tris-HCl 8.0 20 % w/v PEG 6000,277,2018-12-18,2020-01-15,6Q9F,4186,2,468,394,2,54.01,2,1.63,experimental,46,0.1999,0.1812,"Aspartyl/Asparaginyl beta-hydroxylase (AspH) H679A in complex with Mn, NOG and Factor X peptide fragment (39mer-4Ser)"
7N03,X-RAY DIFFRACTION,2.01,39,"VAPOR DIFFUSION, SITTING DROP",3,"29.5% (w/v) PEG 6k, 200 mM lithium sulfate, 100 mM sodium acetate pH 3.0",277,2021-05-24,2021-11-03,7N03,1561,1,158,178,,18.68,1,1.13,experimental,18.354,0.1831,0.1514,Crystal structure of MTH1 in complex with compound 31
5FP3,X-RAY DIFFRACTION,2.29,46.3,,8,"0.1M TRIS HCL, BICINE PH 8.5, 37.5% MPD, PEG1K, PEG3350, 0.03M MGCL2, 0.03M CACL2",,2015-11-27,2016-01-27,5FP3,7843,2,1020,835,,117.67,1,2.05,experimental,25.083,0.24322,0.20464,Cell penetrant inhibitors of the JMJD2 (KDM4) and JARID1 (KDM5) families of histone lysine demethylases
5JW7,X-RAY DIFFRACTION,2.17,43.32,"VAPOR DIFFUSION, SITTING DROP",,"28% w/v Polyacrylate 2100 sodium salt, 0.2M NaCl, 0.1M MES pH 6",293,2016-05-11,2017-02-15,5JW7,2395,2,375,1,,41.37,2,2.849,experimental,,0.278,0.2234,Crystal structure of SopA-Trim56 complex
5A6H,X-RAY DIFFRACTION,2.11,41.8,VAPOR DIFFUSION,8,"EQUAL VOLUMES OF PROTEIN AND RESERVOIR (250 NL EACH) AT 8C WITH THE PROTEIN AT 7.5 MG/ML AND THE RESERVOIR BEING 2.6 M AMMONIUM SULFATE, 100 MM TRIS PH 8",281,2015-06-26,2016-05-25,5A6H,2488,1,260,274,,30.57,1,1.57,experimental,16.18,0.1932,0.1454,"Synthesis, carbonic anhydrase inhibition and protein X-ray structure of the unusual natural product primary sulfonamide Psammaplin C"
5FLR,X-RAY DIFFRACTION,2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-10-28,2016-03-02,5FLR,2418,1,260,264,,29.8,1,1.68,experimental,16.523,0.2046,0.14663,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5FNI,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-11-15,2016-03-02,5FNI,2412,1,260,241,,29.77,1,1.6,experimental,16.744,0.19286,0.14899,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5FNJ,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-11-15,2016-03-02,5FNJ,2442,1,260,244,,30.01,1,1.67,experimental,14.31,0.18286,0.13765,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5FNL,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-11-15,2016-09-28,5FNL,2536,1,260,283,,29.84,1,1.59,experimental,14.423,0.19711,0.14805,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
6SB7,X-RAY DIFFRACTION,2.15,42.89,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-07-19,2020-04-15,6SB7,2412,1,265,153,,31.43,1,1.09,experimental,11.43,0.1367,0.1183,Human Carbonic Anhydrase II in complex with fragment.
7JNV,X-RAY DIFFRACTION,2.06,40.18,"VAPOR DIFFUSION, HANGING DROP",7.8,1.6M Sodium Citrate and 50mM Tris,298,2020-08-05,2020-11-04,7JNV,2399,1,260,215,,30.12,1,1.49,experimental,16.38,0.1961,0.146,"Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)butyramide"
6Z56,X-RAY DIFFRACTION,3.09,60.17,"VAPOR DIFFUSION, SITTING DROP",6,"60.0% MPD, 0.1M MMT pH 6.0",277.15,2020-05-26,2020-06-03,6Z56,3160,1,357,436,,41.23,1,1.9,experimental,17.534,0.221,0.1755,Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003208
6Z5B,X-RAY DIFFRACTION,3.09,60.23,"VAPOR DIFFUSION, SITTING DROP",7,"60.0% MPD, 0.1M SPG pH 7.0",277.15,2020-05-26,2020-06-03,6Z5B,3202,1,357,449,,41.32,1,1.9,experimental,15.938,0.1977,0.1554,Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003128
5UC8,X-RAY DIFFRACTION,2.17,43.44,VAPOR DIFFUSION,,"0.1 M Bis-Tris (pH 6.5) and 24% (w/v) PEG 2,000 monomethyl ether",293,2016-12-22,2017-02-15,5UC8,7601,4,904,686,,105.15,1,2,experimental,37.9007,0.2509,0.196,Crystal structure of human Heme Oxygenase-2
7BLU,X-RAY DIFFRACTION,1.95,36.8,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-19,2022-03-02,7BLU,3000,1,383,91,7,44.73,1,1.21,experimental,17.4254,0.1888,0.193,Notum_Maybridge_56
7BMB,X-RAY DIFFRACTION,1.93,36.33,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-19,2022-03-02,7BMB,2944,1,383,89,6,44.76,1,1.83,experimental,32.2222,0.2375,0.1908,Notum PPOH complex
7BMD,X-RAY DIFFRACTION,2.02,39,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-20,2022-03-02,7BMD,2995,1,383,123,6,45.51,1,1.45,experimental,24.7233,0.1871,0.1615,Notum TDZD8 complex
6USN,X-RAY DIFFRACTION,4.91,74.96,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES pH 6.5,
2.3 M Ammonium Sulfate,
2% PEG1000",298,2019-10-28,2019-12-11,6USN,8297,4,1052,174,,119.7,1,2.773,experimental,53.1271,0.2011,0.1681,Co-crystal structure of SPR with compound 5
6WID,X-RAY DIFFRACTION,2.43,49.4,"VAPOR DIFFUSION, SITTING DROP",5.6,"40-45.5 mM MES, pH 5.6, 0.16-0.182 M potassium chloride, 8.2-9.1 mM magnesium sulfate, 8.2-9.1% w/v PEG400",277,2020-04-09,2020-10-07,6WID,3575,5,374,354,,46.72,1,1.5,experimental,19.95,0.1774,0.1639,Nucleotide incorporation intermediate into quaternary complex of human Polymerase Mu on a complementary DNA double-strand break substrate
6WIE,X-RAY DIFFRACTION,2.43,49.47,"VAPOR DIFFUSION, SITTING DROP",5.6,"40-45.5 mM MES, pH 5.6, 0.16-0.182 M potassium chloride, 8.2-9.1 mM magnesium sulfate, 8.2-9.1% w/v PEG400",277,2020-04-09,2020-10-07,6WIE,3505,5,374,354,,46.38,1,1.5,experimental,21.57,0.1868,0.1699,Post-catalytic nicked complex of human Polymerase Mu on a complementary DNA double-strand break substrate
7ZOT,X-RAY DIFFRACTION,2.17,43.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"Morpheus screen condition H12 
0.1M Amino acids,
0.1M Tris Bicine pH 8.5
37.5% v/v MPD PEG1000 PEG 3350",293,2022-04-26,2022-10-26,7ZOT,2031,2,252,98,,28.2,1,1.735,experimental,21.369,0.2009,0.184,crystal structure of PLAAT4 N-terminal domain
4QSB,X-RAY DIFFRACTION,2.05,39.99,"VAPOR DIFFUSION, SITTING DROP",7,"2.2M sodium malonate pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-07-03,2015-01-21,4QSB,2374,1,260,215,,30.05,1,1.4,experimental,16.535,0.22,0.188,"Crystal structure of human carbonic anhydrase isozyme II with 3-{[(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]acetyl}benzenesulfonamide"
6T4N,X-RAY DIFFRACTION,2.06,40.27,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2019-10-14,2020-10-14,6T4N,2523,1,260,303,,29.93,1,1.4,experimental,17.946,0.1959,0.1697,"Human Carbonic anhydrase II bound by 2,4,6-trimethylbenzenesulfonamide"
6T4O,X-RAY DIFFRACTION,2.08,40.93,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2019-10-14,2020-10-14,6T4O,2593,1,260,388,,29.78,1,1.133,experimental,15.297,0.1661,0.1389,"Human Carbonic anhydrase II bound by 3,5-dimethylbenzenesulfonamide"
6T4P,X-RAY DIFFRACTION,2.06,40.17,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2019-10-14,2020-10-14,6T4P,2337,1,260,247,,29.94,1,1.75,experimental,16.051,0.1993,0.1615,Human Carbonic anhydrase II bound by napthalene-1-sulfonamide
6T5C,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2019-10-15,2020-10-14,6T5C,2687,1,260,391,,30.07,1,1.22,experimental,14.862,0.1532,0.1228,Human Carbonic anhydrase II bound by anthracene-9-sulfonamide
6TJK,X-RAY DIFFRACTION,2.47,50.14,"VAPOR DIFFUSION, SITTING DROP",7,"0.2 M Na2SO4, 14% (v/v) PEG3350, 0.1 M bis-tris-propane pH 7.0",293,2019-11-26,2020-06-10,6TJK,9312,2,994,907,4,117.67,1,1.56,experimental,22.553,0.1985,0.1646,Crystal Structure of Recombinant GBA in Complex with Bis-Tris Propane.
4XZH,X-RAY DIFFRACTION,1.87,34.11,"VAPOR DIFFUSION, HANGING DROP",5,"PEG 6000, ammonium citrate, pH 5, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277,2015-02-04,2015-11-18,4XZH,6150,2,632,807,,73.96,1,1,experimental,,0.161,0.1488,Crystal structure of human Aldose Reductase complexed with NADP+ and JF0048
5HA7,X-RAY DIFFRACTION,2.6,52.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.04 M Ammonium Sulfate, 0.1M HEPES pH 7.5, 7% polyethylene glycol 400",277,2015-12-30,2016-09-28,5HA7,5846,2,632,569,,74.7,1,1.65,experimental,23.631,0.1953,0.1679,Human Aldose Reductase in Complex with NADP+ and WY14643 in Space Group P212121
6WXZ,X-RAY DIFFRACTION,2.65,53.55,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2020-05-12,2020-10-14,6WXZ,9836,4,1144,432,10,136.23,2,2.226,experimental,58.81,0.2419,0.2107,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-29 A.K.A 7-(1,2-DIPHENYLETHYL)-1H-[1,2,3]TRIAZOLO[4,5-B]PYRIDIN-5-AMINE"
6WY5,X-RAY DIFFRACTION,2.68,54.15,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2020-05-12,2020-10-14,6WY5,9075,4,1144,,4,136.12,2,2.898,experimental,97.75,0.245,0.2222,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-37 A.K.A 7-(1-phenyl-3-(((1S,3S)-3-phenyl-2,3-dihydro-1H-inden-1-yl)amino)propyl)-1H-[1,2,3]triazolo[4,5-b]pyridin-5-amine"
6WY7,X-RAY DIFFRACTION,2.37,48.09,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2020-05-12,2020-10-14,6WY7,10328,4,1144,949,11,135.7,2,2.089,experimental,24.38,0.1854,0.1585,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-41 A.K.A 7-[1-phenyl-3-({4-phenylbicyclo[2.2.2]octan-1-yl}amino)propyl]-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine"
5A5H,X-RAY DIFFRACTION,2.59,52.6,,7.5,"20% PEG3350, 0.2 M SODIUM FORMATE, pH 7.5",,2015-06-18,2016-06-29,5A5H,11755,8,1660,409,,184.78,2,2.318,experimental,,0.227,0.1723,The crystal structure of the GST-like domains complex of EPRS C92SC105SC123S mutant-AIMP2
7NTB,X-RAY DIFFRACTION,2.08,41,"VAPOR DIFFUSION, HANGING DROP",8.5,"2.6 M ammonium sulphate, 0.3 M sodium chloride, 0.1 M Tris-HCl, pH 8.5, 5 mM 4-(hydroxymercurybenzoate)",293,2021-03-09,2022-03-16,7NTB,2423,1,259,299,,29.94,1,1.7,experimental,12.3701,0.2168,0.1726,Crystal structure of human carbonic anhydrase with a benzophenone-derivative
6OTI,X-RAY DIFFRACTION,2.16,43.08,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris-HCL, pH 7.8",298,2019-05-03,2020-05-06,6OTI,2109,1,257,36,,29.35,1,2,experimental,27.3923,0.2543,0.199,Carbonic Anhydrase IX mimic complexed with ureic benzene sulfonamide MB9-561B
7B8X,X-RAY DIFFRACTION,1.99,38.33,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-13,2022-01-12,7B8X,2873,1,383,104,6,44.35,1,1.51,experimental,23.8167,0.2539,0.2234,Notum-Fragment 210
7B8Y,X-RAY DIFFRACTION,1.99,38.05,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-13,2022-01-12,7B8Y,2863,1,383,86,6,44.55,1,1.57,experimental,24.452,0.2454,0.221,Notum-Fragment 276
7B8Z,X-RAY DIFFRACTION,1.98,37.8,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-13,2022-01-12,7B8Z,2826,1,383,77,6,44.78,1,1.73,experimental,29.8592,0.2434,0.2265,Notum-Fragment 277
4Q06,X-RAY DIFFRACTION,2.03,38.9,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-04-01,2015-01-28,4Q06,2568,1,260,292,,29.96,1,1.15,experimental,17.922,0.168,0.137,Crystal structure of chimeric carbonic anhydrase IX with inhibitor
4Q07,X-RAY DIFFRACTION,2.01,38.4,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-04-01,2015-01-28,4Q07,3103,1,260,307,,29.99,1,1.15,experimental,14.353,0.158,0.128,Crystal structure of chimeric carbonic anhydrase IX with inhibitor
4Q09,X-RAY DIFFRACTION,1.97,37.2,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-04-01,2015-01-28,4Q09,2502,1,260,252,,30.12,1,1.2,experimental,17.485,0.178,0.139,Crystal structure of chimeric carbonic anhydrase XII with inhibitor
6ODZ,X-RAY DIFFRACTION,2.09,41.21,"VAPOR DIFFUSION, SITTING DROP",,"200 nL 7 mg/mL protein + 200 nL reservoir (50 mM Tris, pH 8.0-8.2, 2.5-2.8 M ammonium sulfate)",281,2019-03-27,2019-06-12,6ODZ,2671,1,260,382,,30.18,1,1.3,experimental,9.027,0.14494,0.1201,Benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects
6OE0,X-RAY DIFFRACTION,2.1,41.31,"VAPOR DIFFUSION, SITTING DROP",,"200 nL 7 mg/mL protein + 200 nL reservoir (50 mM Tris, pH 8.0-8.2, 2.5-2.8 M ammonium sulfate)",281,2019-03-27,2019-06-12,6OE0,2531,1,260,320,,29.84,1,1.3,experimental,9.326,0.23855,0.2138,Benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects
6OE1,X-RAY DIFFRACTION,2.09,41.2,"VAPOR DIFFUSION, SITTING DROP",,"200 nL 7 mg/mL protein + 200 nL reservoir (50 mM Tris, pH 8.0-8.2, 2.5-2.8 M ammonium sulfate)",281,2019-03-27,2019-06-12,6OE1,2556,1,260,316,,29.92,1,1.45,experimental,9.234,0.166,0.14734,Benzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects
6SDS,X-RAY DIFFRACTION,2.07,40.7,"VAPOR DIFFUSION, HANGING DROP",8,"1.3 M SODIUM CITRATE, 60 mM TRIS-HCL",293,2019-07-29,2020-06-10,6SDS,2335,1,260,190,,29.75,1,1.26,experimental,11.079,0.1741,0.1462,HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH A SULFONAMIDE INHIBITOR
6WQ5,X-RAY DIFFRACTION,2.09,41.25,"VAPOR DIFFUSION, HANGING DROP",7.8,1.6M sodium citrate and 50mM Tris,298,2020-04-28,2020-06-24,6WQ5,2358,1,260,239,,29.98,1,1.304,experimental,18.0129,0.1807,0.1602,Carbonic Anhydrase II Complexed with 2-((3-Aminopropyl)(phenethyl)amino)-N-(furan-2-ylmethyl)-N-(4-sulfamoylphenethyl)acetamide
6WQ7,X-RAY DIFFRACTION,2.08,40.73,"VAPOR DIFFUSION, HANGING DROP",7.8,1.6M sodium citrate and 50mM Tris,298,2020-04-28,2020-06-24,6WQ7,2361,1,260,239,,30,1,1.304,experimental,19.0922,0.1813,0.1597,Carbonic Anhydrase II Complexed with 2-((3-Aminopropyl)(phenethyl)amino)-N-(4-fluorobenzyl)-N-(4-sulfamoylphenethyl)acetamide
7JNW,X-RAY DIFFRACTION,2.05,40.04,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris",298,2020-08-05,2020-11-04,7JNW,2531,1,260,342,,30.03,1,1.292,experimental,15.0365,0.1518,0.126,"Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)isobutyramide"
7JNZ,X-RAY DIFFRACTION,2.04,39.61,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris",298,2020-08-05,2020-11-04,7JNZ,2354,1,260,183,,29.82,1,1.289,experimental,17.0323,0.1893,0.1535,"Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)cyclohexanecarboxamide"
7OYO,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2021-06-24,2023-01-18,7OYO,2535,1,260,382,,29.82,1,1.03,experimental,15.252,0.167,0.1362,Carbonic anhydrase II in complex with Hit4 (MH70)
6ZMD,X-RAY DIFFRACTION,3.04,59.49,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M NaCl, 0.1 M Na/K phosphate pH 6.2 and 10% (w/v) PEG 8000",292,2020-07-02,2021-04-14,6ZMD,6858,2,871,74,,98.33,2,2.64,experimental,73.52,0.2351,0.1924,Crystal structure of HYPE covalently tethered to BiP bound to AMP-PNP
4YE9,X-RAY DIFFRACTION,4.85,74.64,"VAPOR DIFFUSION, SITTING DROP",5.5,"ammonium acetate, bis-tris, PEG 20,000, EDTA",289,2015-02-23,2016-02-17,4YE9,5288,1,776,87,,88.1,1,2.7,experimental,,0.2623,0.2282,The crystal structure of the G45V mutant of human GlnRS
6RMX,X-RAY DIFFRACTION,2.09,41.05,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2019-05-07,2020-06-03,6RMX,2335,1,257,217,,29.64,1,1.6,experimental,18.907,0.2127,0.1702,"Human Carbonic anhydrase II mutant T199V bound by 2-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide"
5KSZ,X-RAY DIFFRACTION,3.07,59.91,"VAPOR DIFFUSION, SITTING DROP",,"12 mg/mL protein, 6 mM magnesium chloride, 10 mM GMPPCP, 0.2 M ammonium sulfate, 0.1 M trisodium citrate, pH 5.6, 17.5% w/v PEG4000",294,2016-07-10,2016-09-21,5KSZ,3281,1,424,30,,49.67,1,2.5,experimental,,0.2657,0.2106,hMiro EF hand and cGTPase domains in the GMPPCP-bound state
6OAK,X-RAY DIFFRACTION,2.43,49.28,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M PCTP, pH 7.5, 0.2 M (NH3)2SO4, 17%  PEG3350",295,2019-03-16,2020-03-18,6OAK,4324,1,529,360,,61.57,1,1.7,experimental,,0.2088,0.1821,Structure of human PARG complexed with JA2131
6OAL,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M PCTP, pH 7.5, 0.2 M (NH3)2SO4, 17% PEG3350",295,2019-03-16,2020-03-18,6OAL,4411,1,529,359,,61.55,1,1.6,experimental,,0.2099,0.181,Structure of human PARG complexed with JA2120
5G01,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, SITTING DROP",8.5,200 NL PLUS 200 NL OF PROTEIN AT 5 MGS/ML AND RESERVOIR IN SITTING DROP PLATES. RESERVOIR WAS 2.6 TO 2.8 M AMMONIUM SULFATE WITH 100 MM TRIS PH 8.5,,2016-03-16,2016-05-25,5G01,2500,1,260,274,,30.18,1,1.4,experimental,16.176,0.16534,0.1281,"An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C"
7KT5,X-RAY DIFFRACTION,2.49,50.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KT5,3477,4,374,377,,46.78,1,1.46,experimental,26.0838,0.1825,0.1618,"DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 10 mM Mn2+ (120min)"
6QL3,X-RAY DIFFRACTION,2.07,40.62,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2019-01-31,2019-09-25,6QL3,2482,1,260,275,,30.65,1,1.35,experimental,15.152,0.1558,0.1163,"Crystal structure of chimeric carbonic anhydrase VI with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
6VCJ,X-RAY DIFFRACTION,2.33,47.26,"VAPOR DIFFUSION, SITTING DROP",7.4,"Protein solution: 9mg/ml in 50mM NaCl, 10mM Tris, 5mM NADP+, 10mM 2,4-diaminopyrimidine, 20mM R-Naproxen
Mother Liquor: 20% PEG 20,000",293,2019-12-21,2020-10-28,6VCJ,6253,4,752,76,,92.25,1,2.34,experimental,37.18,0.2382,0.1916,"Crystal structure of hsDHFR in complex with NADP+, DAP, and R-naproxen"
5GOY,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM Tris pH8.0, 200 mM magnesium chloride, 100 mM potassium sodium tartrate tetrahydrate, 16% PEG8000",294,2016-07-30,2017-08-02,5GOY,5022,1,624,232,,71.32,1,2.278,experimental,,0.2416,0.1964,The crystal structure of human cytosolic methionyl-tRNA synthetase in complex with methionine
7BLW,X-RAY DIFFRACTION,2,38.52,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-19,2022-03-02,7BLW,2943,1,383,97,6,44.71,1,1.45,experimental,25.2974,0.2111,0.1741,Notum_Piperine complex
7BNB,X-RAY DIFFRACTION,2.01,38.7,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-21,2022-03-02,7BNB,2970,1,383,115,6,44.83,1,1.16,experimental,19.287,0.2223,0.1964,Notum fragment_50 (3-(quinazolin-4-ylsulfanyl)propanoic acid)
7BNJ,X-RAY DIFFRACTION,1.93,36.15,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-22,2022-03-02,7BNJ,2972,1,383,95,6,45.43,1,1.49,experimental,31.2828,0.1972,0.1641,Notum Riluzole
7BNL,X-RAY DIFFRACTION,1.93,36.13,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-22,2022-03-02,7BNL,3001,1,383,139,6,45.04,1,1.23,experimental,28.6284,0.1978,0.178,Notum ARUK3003710
7BO2,X-RAY DIFFRACTION,2.01,38.71,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-23,2022-03-02,7BO2,3121,1,382,141,8,45.14,1,1.21,experimental,16.9047,0.2194,0.1991,"Notum Fragment_130 (4H-thieno[3,2-c]chromene-2-carboxylic acid)"
7QVZ,X-RAY DIFFRACTION,1.94,36.45,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-01-24,2022-05-04,7QVZ,3040,1,383,136,7,44.48,1,1.47,experimental,26.9544,0.2171,0.171,ARUK3001043_Notum
8BSP,X-RAY DIFFRACTION,1.93,36.42,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-26,2022-12-14,8BSP,2979,1,383,118,7,44.65,1,1.55,experimental,,0.2055,0.1877,Notum Inhibitor ARUK3006560
8BSQ,X-RAY DIFFRACTION,1.94,36.65,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-26,2022-12-14,8BSQ,2943,1,383,108,6,44.66,1,1.45,experimental,,0.2001,0.1926,Notum Inhibitor ARUK3006561
8BSR,X-RAY DIFFRACTION,1.94,36.64,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-26,2022-12-14,8BSR,3009,1,383,116,7,44.98,1,1.45,experimental,,0.2061,0.1992,Notum Inhibitor ARUK3006562
8BSZ,X-RAY DIFFRACTION,1.91,35.58,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-27,2022-12-14,8BSZ,3066,1,383,99,6,44.8,1,1.7,experimental,,0.2201,0.1957,Notum Inhibitor ARUK3005522
8BT2,X-RAY DIFFRACTION,1.93,36.23,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-27,2022-12-14,8BT2,3087,1,383,109,7,44.89,1,1.7,experimental,,0.2226,0.1983,Notum Inhibitor ARUK3004876
8BT5,X-RAY DIFFRACTION,1.93,36.16,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-27,2022-12-14,8BT5,3093,1,383,104,8,44.89,1,1.4,experimental,,0.2043,0.1706,Notum Inhibitor ARUK3004877
8BT7,X-RAY DIFFRACTION,1.92,35.96,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-28,2022-12-14,8BT7,3088,1,383,108,8,44.96,1,1.4,experimental,,0.2096,0.1769,Notum Inhibitor ARUK3004903
8BT8,X-RAY DIFFRACTION,1.93,36.29,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-28,2022-12-28,8BT8,3087,1,383,120,7,45.03,1,1.28,experimental,,0.208,0.196,Notum Inhibitor ARUK3004048
8BTA,X-RAY DIFFRACTION,1.94,36.56,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-28,2022-12-14,8BTA,3037,1,383,94,7,44.71,1,1.34,experimental,,0.2261,0.2105,Notum Inhibitor ARUK3004308
8BTC,X-RAY DIFFRACTION,1.93,36.34,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-28,2022-12-14,8BTC,3006,1,383,98,6,44.63,1,1.54,experimental,,0.2303,0.2107,Notum Inhibitor ARUK3004558
8BTE,X-RAY DIFFRACTION,1.93,36.19,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-28,2022-12-14,8BTE,3005,1,383,111,6,44.87,1,1.62,experimental,,0.2334,0.2042,Notum Inhibitor ARUK3004470
8BTH,X-RAY DIFFRACTION,1.92,36.06,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-28,2022-12-14,8BTH,3046,1,383,123,7,44.78,1,1.3,experimental,,0.2126,0.1835,Notum Inhibitor ARUK3004552
8BTI,X-RAY DIFFRACTION,1.93,36.23,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-28,2022-12-14,8BTI,2997,1,383,111,6,45.07,1,1.31,experimental,,0.2183,0.1844,Notum Inhibitor ARUK3004556
5YUJ,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, HANGING DROP",,"1.3M sodium citrate, 100mM TrisHCl pH 7.8",293,2017-11-22,2018-08-01,5YUJ,2414,1,260,310,,29.45,1,1.25,experimental,16.137,0.12957,0.09981,CO2 release in human carbonic anhydrase II crystals: reveal histidine 64 and solvent dynamics
5YUK,X-RAY DIFFRACTION,2.07,40.69,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 100 mM TrisHCl pH 7.8",293,2017-11-22,2018-08-01,5YUK,2366,1,260,271,,29.45,1,1.45,experimental,17.984,0.13641,0.09654,CO2 release in human carbonic anhydrase II crystals: reveal histidine 64 and solvent dynamics
8FR1,X-RAY DIFFRACTION,2.16,43.08,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2023-01-06,2023-02-01,8FR1,2109,1,257,36,,29.35,1,2,experimental,,0.2543,0.199,Carbonic Anhydrase IX in complex with the alkyl urea compound 3g
8JFX,X-RAY DIFFRACTION,2.12,41.96,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 2000, 0.15M Potassium bromide",277,2023-05-19,2024-05-22,8JFX,1766,1,263,53,,28.77,1,2.2,experimental,,0.2418,0.2052,TruB domain of TruB1
6WPP,X-RAY DIFFRACTION,2.42,49.13,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG1500, pH 7",278,2020-04-27,2020-08-26,6WPP,4989,2,694,118,,76.41,1,2.55,experimental,41.104,0.256,0.205,HUMAN NIK IN COMPLEX WITH LIGAND COMPOUND X
5Y6L,X-RAY DIFFRACTION,1.72,28.3,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 3000
Na/K phosphate pH 6.2",293.15,2017-08-12,2018-08-15,5Y6L,6458,5,1354,78,,152.86,5,2.9,experimental,,0.2518,0.1765,A subcomplex crystal structure of human cytosolic aspartyl-tRNA synthetase and heterotetrameric glutathione transferase-homology domains in multi-tRNA synthetase complex
4WXI,X-RAY DIFFRACTION,3.48,64.61,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277,2014-11-13,2015-01-28,4WXI,2054,1,244,134,4,28.39,1,2.6,experimental,22.37,0.2261,0.1764,FACTOR XIA IN COMPLEX WITH THE INHIBITOR trans-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)pyridin-2-yl]-2-phenylethyl}-4-(aminomethyl)cyclohexanecarboxamide
6USY,X-RAY DIFFRACTION,2.3,46.57,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M Bit-Tris pH 7.0, 0.6 M NaCl, 25 % (w/v) PEG3,350",277,2019-10-28,2020-07-01,6USY,2370,1,238,432,4,27.31,1,1.26,experimental,19.62,0.188,0.166,COAGULATION FACTOR XI CATALYTIC DOMAIN (C123S) IN COMPLEX WITH NVP-XIV936
7SUW,X-RAY DIFFRACTION,2.13,42.19,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2021-11-18,2022-04-06,7SUW,2310,1,257,185,,29.55,1,1.456,experimental,24.3086,0.1904,0.1614,Carbonic Anhydrase IX-mimic with 2-((3-Aminopropyl)(phenethyl)amino)-N-(furan-2-ylmethyl)-N-(4-sulfamoylphenethyl)acetamide
7SUY,X-RAY DIFFRACTION,2.1,41.52,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM tris base",293,2021-11-18,2022-04-06,7SUY,2284,1,257,198,,29.37,1,1.405,experimental,19.3444,0.1873,0.1653,Carbonic Anhydrase IX-mimic Complexed with 2-((3-Aminopropyl)(phenethyl)amino)-N-(4-fluorobenzyl)-N-(4-sulfamoylphenethyl)acetamide
7SV1,X-RAY DIFFRACTION,2.11,41.57,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2021-11-18,2022-04-06,7SV1,2248,1,257,154,,29.56,1,1.559,experimental,22.8239,0.1983,0.1707,Carbonic Anhydrase IX-mimic Complexed with 3-((2-((Naphthalen-2-ylmethyl)(4-sulfamoylphenethyl)amino)-2-oxoethyl)(phenethyl)amino)propanoic acid
7SV8,X-RAY DIFFRACTION,2.11,41.73,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM tris base",293,2021-11-18,2022-04-06,7SV8,2303,1,257,182,,29.61,1,1.388,experimental,22.4309,0.177,0.154,Carbonic Anhydrase IX-mimic Complexed with 3-((2-((Furan-2-ylmethyl)(4-sulfamoylphenethyl)amino)-2-oxoethyl)(phenethyl)amino)propanoic acid
6YH5,X-RAY DIFFRACTION,2.05,39.99,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2020-03-28,2021-04-07,6YH5,2496,1,260,334,,29.83,1,1.2,experimental,17.055,0.159,0.123,Crystal structure of chimeric carbonic anhydrase XII with 2-Chloro-4-[(pyrimidin-2-ylsulfanyl)acetyl]benzenesulfonamide
6N3G,X-RAY DIFFRACTION,3.09,60.14,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, Ethanol, Water, 1 M Tris",294,2018-11-15,2019-11-20,6N3G,3633,1,433,79,,51.31,1,2.43,experimental,37.8088,0.2224,0.1747,Crystal structure of histone lysine methyltransferase SmyD2 in complex with polyethylene glycol
7B2V,X-RAY DIFFRACTION,1.92,36.07,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-11-28,2021-08-04,7B2V,3087,1,383,128,7,45.03,1,1.24,experimental,22.9295,0.1994,0.1844,Notum complex with ARUK3003906
7B2Y,X-RAY DIFFRACTION,1.92,36.01,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-11-28,2021-08-04,7B2Y,3063,1,383,114,7,45.16,1,1.23,experimental,22.9289,0.2076,0.1863,Notum complex with ARUK3003910
7B84,X-RAY DIFFRACTION,1.98,37.82,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B84,3136,1,383,135,6,45.7,1,1.36,experimental,21.9708,0.2259,0.2137,Notum-Fragment065
7B87,X-RAY DIFFRACTION,1.98,37.72,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B87,3016,1,383,118,6,44.91,1,1.58,experimental,23.5545,0.2414,0.221,Notum-Fragment074
7B8C,X-RAY DIFFRACTION,1.98,37.99,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B8C,3054,1,383,136,8,44.83,1,1.43,experimental,22.7138,0.2337,0.206,Notum-Fragment 147
7B9U,X-RAY DIFFRACTION,1.99,38.22,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-14,2022-01-12,7B9U,3059,1,383,134,8,44.72,1,1.5,experimental,22.7521,0.2324,0.2099,Notum Fragment 609
7BC9,X-RAY DIFFRACTION,1.97,37.68,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-18,2022-01-12,7BC9,2907,1,383,114,6,44.69,1,1.73,experimental,26.9878,0.2521,0.2271,Notum Fragment 690
7BD6,X-RAY DIFFRACTION,1.99,38.12,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BD6,3037,1,383,154,7,44.5,1,1.7,experimental,24.079,0.2201,0.1942,Notum Fragment 863
7BDB,X-RAY DIFFRACTION,1.97,37.64,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BDB,2915,1,383,114,6,44.39,1,1.46,experimental,24.7256,0.2107,0.1963,Notum Fragment 916
7BDC,X-RAY DIFFRACTION,1.99,38.31,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BDC,2930,1,383,132,6,44.59,1,1.32,experimental,20.1133,0.2054,0.1943,Notum Fragment 923
7PJR,X-RAY DIFFRACTION,1.97,37.68,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-08-24,2022-09-07,7PJR,2937,1,383,77,6,44.58,1,1.51,experimental,30.9702,0.206,0.1843,Notum_ARUK3000438
7PK3,X-RAY DIFFRACTION,1.93,36.31,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-08-25,2022-09-07,7PK3,3003,1,383,127,7,44.63,1,1.41,experimental,24.8021,0.2037,0.1747,Notum_ARUK3001185
7PKV,X-RAY DIFFRACTION,1.95,36.99,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-08-26,2022-09-07,7PKV,2926,1,383,84,6,44.72,1,1.68,experimental,33.7745,0.2271,0.2042,Notum_Inhibitor ARUK3000223
4WUQ,X-RAY DIFFRACTION,2.36,47.5,"VAPOR DIFFUSION, SITTING DROP",8.4,"Crystallization buffer: 0.1M TrisHCl (pH 8.5), 
0.2M sodium acetate (pH 8.3), 28% of PEG3350.",291,2014-11-03,2015-07-01,4WUQ,4525,2,520,360,,58.53,1,1.75,experimental,21.769,0.21,0.173,"Crystal structure of human carbonic anhydrase isozyme I with 2,3,5,6-Tetrafluoro-4-piperidin-1-ylbenzenesulfonamide"
6ZX9,X-RAY DIFFRACTION,3.16,61.04,"VAPOR DIFFUSION, SITTING DROP",,"8-10% PEG 4000 (w/v), 200 mM MgCl2, 100 mM HEPES-NaOH, pH 7.0-8.2.",277.15,2020-07-29,2021-07-21,6ZX9,13858,3,1760,253,,198.62,3,2.5197288426,experimental,71.2991472108,0.260498009517,0.216112029271,"Crystal structure of SIV Vpr,fused to T4 lysozyme, isolated from moustached monkey, bound to human DDB1 and human DCAF1 (amino acid residues 1046-1396)"
7Q0C,X-RAY DIFFRACTION,2.08,40.78,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer: 0.1M sodium bicine (pH 9.0), 0.2 M ammonium sulfate and 2M sodium malonate (pH 7.0)",291,2021-10-14,2022-01-12,7Q0C,5079,2,520,602,,59.56,1,1.12,experimental,18.286,0.1937,0.1603,Mimic carbonic anhydrase IX in complex with Methyl 2-chloro-4-(cyclohexylsulfanyl)-5-sulfamoylbenzoate
8VDT,X-RAY DIFFRACTION,2.72,54.8,"VAPOR DIFFUSION, HANGING DROP",6.4,"100mM MES, pH 6.4,  100mM Lithium Acetate, 12 w/vPEG 3350",298.5,2023-12-17,2024-05-22,8VDT,5292,3,694,25,,84.17,1,2.78,experimental,91.66,0.249,0.203,DNA Ligase 1 with nick DNA 3'rA:T
4YGJ,X-RAY DIFFRACTION,2.12,42,"VAPOR DIFFUSION, HANGING DROP",7.8,"100 mM Tris-Cl, 1.15 M sodium citrate, pH 7.8",277,2015-02-26,2015-03-25,4YGJ,2400,1,258,269,,29.86,1,1.1,experimental,14.148,0.14675,0.12714,NaBr--Interactions between Hofmeister Anions and the Binding Pocket of a Protein
4YGN,X-RAY DIFFRACTION,2.13,42.32,"VAPOR DIFFUSION, HANGING DROP",7.8,"100 mM Tris-Cl, 1.15 M sodium citrate, pH 7.8",277,2015-02-26,2015-03-25,4YGN,2220,1,258,138,,29.7,1,1.23,experimental,14.768,0.20937,0.17525,NaI--Interactions between Hofmeister Anions and the Binding Pocket of a Protein
5FLO,X-RAY DIFFRACTION,2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-10-28,2016-03-02,5FLO,2405,1,260,240,,29.57,1,1.66,experimental,14.928,0.21513,0.15831,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5FNG,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-11-15,2016-03-02,5FNG,2166,1,260,100,,29.55,1,2.05,experimental,21.689,0.22918,0.17576,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5FNM,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-11-15,2016-03-02,5FNM,2401,1,260,249,,29.55,1,1.59,experimental,16.009,0.20213,0.15656,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
8AA6,X-RAY DIFFRACTION,2.09,41.02,"VAPOR DIFFUSION, HANGING DROP",7.8,50 mM Tris 1.6 M Natrium Citrate,291,2022-06-30,2023-05-10,8AA6,2360,1,260,238,,29.61,1,1.15,experimental,21.202,0.1805,0.1617,CAII in complex with meta-carboran-propylsulfonamid
5O9S,X-RAY DIFFRACTION,2.18,43.57,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG 6000, 0.1M sodium citrate pH 5.6, 0.1M magnesium chloride, 0.2M sodium chloride",293,2017-06-20,2018-06-27,5O9S,6438,4,820,174,,95.59,2,2.7,experimental,,0.2274,0.1751,HsNMT1 in complex with CoA and Myristoylated-GKSNSKLK octapeptide
7MSR,X-RAY DIFFRACTION,2.27,45.9,"VAPOR DIFFUSION, HANGING DROP",,"22.5% (w/v) PEG3350, 100 mM ammonium succinate pH 7.5, 100 mM Tris-HCl pH 7.4",294,2021-05-12,2022-10-12,7MSR,5739,2,710,299,,77.54,2,1.58,experimental,40.8869,0.2213,0.1987,"Human E105Qa GTP-specific succinyl-CoA synthetase complexed with succinyl-phosphate, magnesium ion and desulfo-coenzyme A"
7MST,X-RAY DIFFRACTION,2.27,45.83,"VAPOR DIFFUSION, HANGING DROP",,"Polyethylene glycol 3350, sodium fluoride, Tris-HCl pH 7.3",294,2021-05-12,2022-10-12,7MST,5839,2,710,445,,77.43,2,1.61,experimental,30.739,0.1943,0.1784,Phosphorylated human E105Qa GTP-specific succinyl-CoA synthetase complexed with coenzyme A
5A34,X-RAY DIFFRACTION,2.61,52.83,,7.5,"PEG 3350 22% , 0.2 M AMMONIUM CHLORIDE, pH 7.5",,2015-05-27,2015-10-21,5A34,11266,8,1660,67,,184.78,2,2.6,experimental,,0.2473,0.1886,The crystal structure of the GST-like domains complex of EPRS-AIMP2
7B8J,X-RAY DIFFRACTION,1.98,37.72,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B8J,2784,1,383,78,6,44.48,1,1.75,experimental,24.7037,0.2407,0.2168,Notum-Fragment 163
5TDB,X-RAY DIFFRACTION,1.73,28.96,"VAPOR DIFFUSION, SITTING DROP",,0.1 M Bis-Tris pH 5.5 and 25% PEG 3350,293,2016-09-19,2017-03-22,5TDB,627,2,80,54,,9.16,2,1.101,experimental,,0.134,0.1248,Crystal structure of the human UBR-box domain from UBR2 in complex with asymmetrically double methylated arginine peptide
5FLP,X-RAY DIFFRACTION,2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-10-28,2016-03-02,5FLP,2406,1,260,234,,29.85,1,1.71,experimental,14.401,0.19245,0.14564,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5FLS,X-RAY DIFFRACTION,2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-10-28,2016-03-02,5FLS,2356,1,260,223,,29.63,1,1.67,experimental,16.918,0.22586,0.17263,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5WEX,X-RAY DIFFRACTION,2.11,41.67,"VAPOR DIFFUSION, SITTING DROP",8.3,"concentrated CA II at about 10 mg/mL was set up in SD-2 plates with the following ratio of protein plus reservoir plus seeds: 250nL plus 225 nL plus 25 nL. The plate was incubated at 8C and the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.
3",281,2017-07-10,2017-10-11,5WEX,2464,1,260,237,,29.85,1,1.26,experimental,16.971,0.14655,0.11785,Discovery of new selenoureido analogs of 4-(4-fluorophenylureido) benzenesulfonamides as carbonic anhydrase inhibitors
6MBV,X-RAY DIFFRACTION,2.08,40.88,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M NaCitrate, 50 mM Tris",298,2018-08-30,2019-03-13,6MBV,2209,1,257,138,,29.21,1,1.695,experimental,23.2248,0.177,0.1516,Carbonic Anhydrase II in complex with Nicotinic Acid
6QL1,X-RAY DIFFRACTION,2.06,40.24,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2019-01-31,2019-09-25,6QL1,2553,1,260,285,,30.49,1,1.42,experimental,16.7794,0.1857,0.1583,"Crystal structure of chimeric carbonic anhydrase VI with 4-[(4,6-dimethylpyrimidin-2-yl)thio]-2,3,5,6-tetrafluorobenzenesulfonamide"
6R6F,X-RAY DIFFRACTION,2.11,41.82,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2019-03-27,2019-12-18,6R6F,2502,1,260,340,,29.83,1,1.2,experimental,19.0325,0.185,0.1457,Crystal structure of human carbonic anhydrase isozyme II with 4-chloro-2-cyclohexylsulfanyl-N-(2-hydroxyethyl)-5-sulfamoyl-benzamide
6R6J,X-RAY DIFFRACTION,2.04,39.72,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2019-03-27,2020-04-08,6R6J,2353,1,260,182,,30.05,1,1.55,experimental,18.9587,0.2233,0.188,Crystal structure of human carbonic anhydrase isozyme II with 2-(benzenesulfonyl)-4-chloro-N-(2-hydroxyethyl)-5-sulfamoyl-benzamide
7Q0E,X-RAY DIFFRACTION,2.09,41.2,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer: 0.1M sodium bicine (pH 9.0), 0.2 M ammonium sulfate and 2M sodium malonate (pH 7.0)",291,2021-10-14,2022-01-12,7Q0E,2600,1,258,349,,29.86,1,1.3,experimental,12.855,0.1691,0.1261,Human Carbonic Anhydrase II in complex with Methyl 2-(benzenesulfonyl)-4-chloro-5-sulfamoylbenzoate
8DJ9,X-RAY DIFFRACTION,2.15,42.69,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sodium Citrate, 50 mM Tris base pH 7.8",293,2022-06-30,2022-11-09,8DJ9,2483,1,260,327,,29.99,1,1.54,experimental,17.9474,0.1688,0.1427,Carbonic Anhydrase II in complex with Ibuprofen
5F84,X-RAY DIFFRACTION,3.19,61.45,"VAPOR DIFFUSION, HANGING DROP",,1.62M ammonium sulfate,293,2015-12-09,2016-07-20,5F84,3479,2,452,95,7,53.6,2,2.5,experimental,30.046,0.23932,0.19209,Crystal structure of Drosophila Poglut1 (Rumi) complexed with its glycoprotein product (glucosylated EGF repeat) and UDP
4TVR,X-RAY DIFFRACTION,2.43,49.41,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG-3350, 0.2 M
NaCl, 0.1 M HEPES pH 7.5, 5% glycerol",298,2014-06-27,2015-06-24,4TVR,1806,1,280,55,,31.56,1,2.29,experimental,81.091,0.25982,0.22902,Tandem Tudor and PHD domains of UHRF2
7BLI,X-RAY DIFFRACTION,2.01,38.84,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-18,2022-03-02,7BLI,2950,1,383,110,6,44.79,1,1.47,experimental,21.843,0.2342,0.2122,Notum-Bepridil complex
6BCC,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.15,42.77,"VAPOR DIFFUSION, SITTING DROP",,"1.6 M sodium citrate, 50 mM TRIS pH 8.0",293,2017-10-20,2018-02-28,6BCC,2148,1,260,82,,29.61,1,1.8,experimental,,0.176,0.168,Joint X-ray/neutron structure of human carbonic anhydrase II in complex with ethoxzolamide
7SQM,X-RAY DIFFRACTION,3.01,59.08,EVAPORATION,,"0.1M NA CITRATE PH5, 20% PEG6K",294,2021-11-05,2021-12-29,7SQM,3206,1,357,423,,40.92,1,1.78,experimental,26.61,0.2046,0.1734,"Discovery and Preclinical Pharmacology of INE963, A Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cure in Uncomplicated Malaria"
5BMU,X-RAY DIFFRACTION,2.94,58.18,"VAPOR DIFFUSION, SITTING DROP",8.4,"Ammonium sulfate, Sodium chloride, Tris-HCl",293.15,2015-05-23,2015-10-21,5BMU,10463,8,1384,6,,154.96,2,2.6,experimental,31.298,0.16957,0.13801,The crystal structure of the GST-like domains complex of AIMP3-EPRS mutant C92SC105SC123S
5G03,X-RAY DIFFRACTION,2.09,41.2,"VAPOR DIFFUSION, SITTING DROP",8.5,150 NL PROTEIN AT 5.5 MG/ML PLUS 120 NL RESERVOIR AND 30 NL SEEDS IN SITTING DROP PLATES. RESERVOIR WAS 2.6 TO 2.8 M AMMONIUM SULFATE PLUS 100 MM TRIS PH 8.5,,2016-03-16,2016-05-25,5G03,2487,1,260,261,,29.77,1,1.35,experimental,15.29,0.16005,0.1275,"An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C"
7B37,X-RAY DIFFRACTION,1.93,36.26,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-11-28,2021-08-04,7B37,2954,1,383,90,6,44.75,1,1.34,experimental,20.9722,0.2026,0.1926,Notum complex with ARUK3003718
7B3F,X-RAY DIFFRACTION,1.93,36.31,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-11-30,2021-08-04,7B3F,3008,1,383,89,7,44.73,1,1.39,experimental,24.7805,0.2162,0.1897,Notum S232A in complex with ARUK3003718
9BC2,X-RAY DIFFRACTION,2.54,51.62,"VAPOR DIFFUSION, SITTING DROP",,"1.3-1.5M Ammonium Sulfate, 0.050 M Tris.HCl(pH8.9), 0.050M Bicine (pH 9)",292,2024-04-07,2024-07-03,9BC2,5235,2,694,67,1,78.51,2,2.75,experimental,64.747,0.29916,0.2456,Transglutaminase 2 - Open State
5JMZ,X-RAY DIFFRACTION,2.11,41.75,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M Na-Citrate, 50 mM Tris, pH 7.8",293,2016-04-29,2017-05-03,5JMZ,2244,1,257,170,,29.32,1,1.9,experimental,21.6614,0.1952,0.1615,Carbonic Anhydrase IX-mimic IN Complex WITH U-NO2
5JN3,X-RAY DIFFRACTION,2.11,41.83,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M Na-Citrate, 50 mM Tris, pH 7.8",293,2016-04-29,2017-05-03,5JN3,2340,1,257,187,,29.38,1,1.6,experimental,17.9029,0.1961,0.1694,Carbonic Anhydrase IX-mimic IN Complex WITH U-F
6OTQ,X-RAY DIFFRACTION,2.1,41.31,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M sodium citrate, 50mM Tris-HCl, pH 7.8",298,2019-05-03,2020-05-06,6OTQ,2360,1,257,269,,29.46,1,1.467,experimental,19.7935,0.1853,0.1644,Carbonic Anhydrase II complexed with ureic benzene sulfonamide MB10-596B
6YQT,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, HANGING DROP",8,"1.3 M sodium citrate, 100 mM Tris-HCl",293,2020-04-18,2020-07-01,6YQT,2351,1,260,196,,29.89,1,1.5,experimental,12.7325,0.2056,0.1781,CRYSTAL STRUCTURE OF HUMAN CA II IN COMPLEX WITH A SULFONAMIDE DERIVATIVE OF 2-MERCAPTOBENZOXAZOLE
5DOG,X-RAY DIFFRACTION,2.04,39.2,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2015-09-11,2016-09-28,5DOG,2454,1,260,294,,30.17,1,1.7,experimental,16.753,0.214,0.162,"Crystal structure of human carbonic anhydrase isozyme II with 2-(Benzylamino)-3,5,6-trifluoro-4-[(2-phenylethyl)thio]benzene- sulfonamide"
5JN7,X-RAY DIFFRACTION,2.11,41.8,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M Na-Citrate, 50 mM Tris, pH 7.8",293,2016-04-29,2017-05-03,5JN7,2302,1,257,208,,29.64,1,1.517,experimental,17.9859,0.1892,0.1654,Carbonic Anhydrase II In Complex WITH U-CH3
6GXE,X-RAY DIFFRACTION,2.1,41.34,"VAPOR DIFFUSION, HANGING DROP",7.8,"Complex was prepared by adding 1-fold molar excess of inhibitor (dissolved in pure DMSO) to 25 mg/mL protein solution in water. 2 uL of complex solution were mixed with 1 uL of precipitant solution containing 1.6M sodium citrate, 50mM Tris H2SO4 pH 7.8",291,2018-06-27,2019-05-08,6GXE,2363,1,257,232,,30.3,1,1.3,experimental,15.254,0.15433,0.12489,Carbonic Anhydrase CAIX mimic in complex with inhibitor JS14
6OTO,X-RAY DIFFRACTION,2.04,39.82,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris Hal, pH7.8",298,2019-05-03,2020-05-06,6OTO,2338,1,260,225,,29.85,1,1.496,experimental,22.9427,0.191,0.1711,Carbonic Anhydrase II complexed with ureic benzene sulfonamide MB9-561B
6OUD,X-RAY DIFFRACTION,2.07,40.46,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M sodium citrate, 50mM Tris Hal, pH 7.8",298,2019-05-04,2020-05-06,6OUD,2396,1,257,276,,29.6,1,1.256,experimental,21.149,0.1905,0.1737,Carbonic Anhydrase IX mimic complexed with benzene sulfonamide MB11-694B
6OUI,X-RAY DIFFRACTION,2.15,42.86,"VAPOR DIFFUSION, HANGING DROP",,"1.6M sodium citrate, 50mM Tris HCl, pH 7.8",298,2019-05-04,2020-05-06,6OUI,2375,1,257,231,,30.01,1,1.528,experimental,22.5232,0.2067,0.1767,Carbonic Anhydrase IX mimic complexed with benzene sulfonamide MB11-710A
6OUJ,X-RAY DIFFRACTION,2.09,41.22,"VAPOR DIFFUSION, HANGING DROP",,"1.6M sodium citrate, 50mM Tris HCl, pH 7.8",298,2019-05-04,2020-05-06,6OUJ,2321,1,257,237,,29.53,1,1.466,experimental,19.1195,0.1808,0.1564,Carbonic Anhydrase II complexed with benzene sulfonamide MB11-689A
6ROF,X-RAY DIFFRACTION,2.09,41.16,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2019-05-12,2020-06-03,6ROF,2615,1,260,351,,30.03,1,1.5,experimental,14.565,0.1916,0.1546,"Human Carbonic anhydrase II mutant T199V bound by 2-(cyclooctylamino)-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide"
6YQU,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, HANGING DROP",8,"1.3 M sodium citrate, 100 mM Tris-HCl",293,2020-04-18,2020-07-01,6YQU,2346,1,260,212,,29.75,1,1.478,experimental,10.7329,0.1928,0.1741,CRYSTAL STRUCTURE OF HUMAN CA II IN COMPLEX WITH 2-MERCAPTOBENZOXAZOLE
7NZS,X-RAY DIFFRACTION,2.05,39.88,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2021-03-24,2022-04-13,7NZS,2430,1,260,261,,30.45,1,1.5,experimental,19.408,0.2018,0.1692,"Crystal structure of chimeric carbonic anhydrase VA with 2,3,5,6-tetrafluoro-4-(propylsulfanyl)benzenesulfonamide"
7NZU,X-RAY DIFFRACTION,2.06,40.15,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2021-03-24,2022-04-13,7NZU,2534,1,260,291,,30.3,1,1.24,experimental,17.031,0.166,0.1326,"Crystal structure of chimeric carbonic anhydrase VA with 3-(benzylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
7NZW,X-RAY DIFFRACTION,2.06,40.17,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2021-03-24,2022-04-13,7NZW,2423,1,260,261,,29.91,1,1.45,experimental,18.753,0.2062,0.1722,"Crystal structure of chimeric carbonic anhydrase VA with 4-[(4,6-dimethylpyrimidin-2-yl)thio]-2,3,5,6-tetrafluorobenzenesulfonamide"
7NZX,X-RAY DIFFRACTION,2.06,40.23,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2021-03-24,2022-04-13,7NZX,2496,1,260,300,,30.04,1,1.33,experimental,19.694,0.1703,0.1242,"Crystal structure of chimeric carbonic anhydrase VA with 2,3,5,6-tetrafluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
7RRE,X-RAY DIFFRACTION,2.09,41.19,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris pH 7.8",293,2021-08-09,2022-08-24,7RRE,2299,1,260,201,,29.97,1,1.44,experimental,16.3259,0.1674,0.1467,Carbonic Anhydrase II in complex with Beta-Galactose-2C
8BJX,X-RAY DIFFRACTION,2.07,40.45,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2022-11-08,2023-11-22,8BJX,2276,1,260,167,,29.95,1,1.283,experimental,18.559,0.2033,0.1562,Crystal structure of human Carbonic anhydrase II in complex with (R)-4-(3-(1-(6-nitropyridin-2-yl)pyrrolidin-3-yl)thioureido)benzenesulfonamide
8QF7,X-RAY DIFFRACTION,2.11,41.61,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2023-09-04,2024-09-11,8QF7,2429,1,260,258,,30.01,1,1.225,experimental,17.268,0.1524,0.1167,Human Carbonic Anhydrase II in complex with (3-((N-(4-sulfamoylbenzyl)phenylsulfonamido)methyl)phenyl)glycine
5MFA,X-RAY DIFFRACTION,2.59,52.51,"VAPOR DIFFUSION, HANGING DROP",,"10% w/v PEG20000, 20% PEG MME 550, 0.1 mM Tris-Bicine, pH 8.5, 0.05 mM CaCl2",295.15,2016-11-17,2017-04-05,5MFA,5972,1,697,766,8,82.74,1,1.2,experimental,,0.1429,0.1233,Crystal structure of human promyeloperoxidase (proMPO)
4V3L,X-RAY DIFFRACTION,2.5,50.72,,,"50 MM HEPES, PH 7.5, 0.2 M MAGNESIUM ACETATE AND 13% (W/V) PEG 8K",,2014-10-20,2015-04-08,4V3L,3308,4,387,387,,43.88,3,1.53,experimental,31.1,0.1926,0.1828,RNF38-UB-UbcH5B-Ub complex
4Q7P,X-RAY DIFFRACTION,2.07,40.72,VAPOR DIFFUSION,8,"Ammonium Sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-25,2015-03-11,4Q7P,2225,1,260,144,,29.9,1,1.65,experimental,12.121,0.20944,0.17001,Crystal Structure of 1-hydroxy-3-methylpyridine-2(1H)-thione bound to hCAII
4Q7V,X-RAY DIFFRACTION,2.05,40,VAPOR DIFFUSION,8,"Ammonium sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-25,2015-03-11,4Q7V,2242,1,260,161,,29.9,1,1.6,experimental,11.924,0.21171,0.16728,Crystal structure of 1-hydroxy-5-methylpyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q7W,X-RAY DIFFRACTION,2.08,40.99,VAPOR DIFFUSION,8,"Ammonium Sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-25,2015-03-11,4Q7W,2284,1,260,183,,29.92,1,1.45,experimental,12.475,0.21088,0.1789,Crystal structure of 1-hydroxy-6-methylpyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q81,X-RAY DIFFRACTION,2.08,40.84,VAPOR DIFFUSION,8,"Ammonium sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-25,2015-03-11,4Q81,2278,1,260,188,,29.91,1,1.55,experimental,12.477,0.19984,0.17409,"Crystal structure of 1-hydroxy-4,6-dimethylpyridine-2(1H)-thione bound to human carbonic anhydrase II"
4Q87,X-RAY DIFFRACTION,2.09,41.22,VAPOR DIFFUSION,8,"Ammonium Sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-25,2015-03-11,4Q87,2275,1,260,182,,29.95,1,1.55,experimental,9.077,0.20561,0.1691,Crystal structure of 1-hydroxy-4-(trifluoromethyl)pyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q8X,X-RAY DIFFRACTION,2.07,40.51,VAPOR DIFFUSION,8,"Ammonium sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-28,2015-03-11,4Q8X,2279,1,260,170,,29.95,1,1.55,experimental,10.955,0.20077,0.16336,Crystal structure of 1-hydroxy-5-(trifluoromethyl)pyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q90,X-RAY DIFFRACTION,2.1,41.31,VAPOR DIFFUSION,8,"Ammonium sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-28,2015-03-11,4Q90,2281,1,260,187,,29.96,1,1.54,experimental,10.025,0.20414,0.16542,Crystal structure of 4-methylpyridine-2(1H)-thione bound to human carbonic anhydrase II
5TI0,X-RAY DIFFRACTION,2.06,40.25,"VAPOR DIFFUSION, SITTING DROP",8,"Ammonium Sulfate, Tris, pH 8.0 VAPOR DIFFUSION, temperature 291K",291,2016-09-30,2017-04-26,5TI0,2348,1,260,195,,29.59,1,1.42,experimental,13.294,0.19574,0.16272,"Crystal Structure of 2-Hydroxycyclohepta-2,4,6-triene-1-thione bound to human carbonic anhydrase 2 L198G"
5LVS,X-RAY DIFFRACTION,2.91,57.77,"VAPOR DIFFUSION, HANGING DROP",5.3,"Ammonium sulfate 200 mM
Sodium acetate 100 mM
PEG 4000 24%
NaN3 3 mM",293,2016-09-14,2017-03-08,5LVS,5063,5,535,575,,63.23,3,1.42,experimental,27.484,0.1782,0.1494,Self-assembled protein-aromatic foldamer complexes with 2:3 and 2:2:1 stoichiometries
4Q99,X-RAY DIFFRACTION,2.07,40.45,VAPOR DIFFUSION,8,"Ammonium sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-29,2015-03-11,4Q99,2285,1,260,187,,29.99,1,1.5,experimental,10.959,0.19229,0.16398,Crystal structure of 2-mercapto-4-methylphenol bound to human carbonic anhydrase II
4Q9Y,X-RAY DIFFRACTION,2.08,40.91,VAPOR DIFFUSION,8,"Ammonium Sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-05-02,2015-03-11,4Q9Y,2294,1,260,200,,29.97,1,1.55,experimental,10.099,0.19685,0.15873,Crystal structure of 3-methylthiophenol bound to human carbonic anhydrase II
5G0B,X-RAY DIFFRACTION,2.09,41.2,"VAPOR DIFFUSION, SITTING DROP",8.5,SITTING DROPS WITH 150 NL PROTEIN AT 5.5 MG/ML WITH 120 NL RESERVOIR AND 30 NL SEEDS. THE RESERVOIR HAD 2.6 TO 2.8 M AMMONIUM SULFATE WITH 100 MM TRIS PH 8.5,,2016-03-17,2016-05-25,5G0B,2425,1,260,243,,29.61,1,1.55,experimental,16.503,0.17851,0.13248,"An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C"
5LJQ,X-RAY DIFFRACTION,2.11,41.77,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM",296,2016-07-19,2017-06-21,5LJQ,2555,1,258,418,,29.56,1,1.05,experimental,12.319,0.1485,0.1335,"Crystal structure of human carbonic anhydrase II in complex with the 4-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide inhibitor"
5TH4,X-RAY DIFFRACTION,2.11,41.66,"VAPOR DIFFUSION, SITTING DROP",8,"Ammonium Sulfate, Tris, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2016-09-29,2017-04-26,5TH4,2346,1,260,192,,29.6,1,1.47,experimental,15.888,0.21184,0.18085,Crystal Structure of 1-hydroxypyridine-2(1H)-thione bound to human carbonic anhydrase 2 L198G
6TJQ,X-RAY DIFFRACTION,2.43,49.36,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Na2SO4, 14% (v/v) PEG3350, 0.25 M HEPES pH 7.0",293,2019-11-26,2020-06-10,6TJQ,4730,1,497,480,2,58.46,1,1.41,experimental,20.829,0.2053,0.1776,Crystal Structure of Recombinant GBA in Complex with 2-Deoxy-2-fluoro-beta-D-glucopyranoside
4PYY,X-RAY DIFFRACTION,2.04,39.2,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-03-28,2015-01-28,4PYY,2465,1,260,296,,29.8,1,1.75,experimental,15.231,0.2,0.149,Crystal structure of human carbonic anhydrase isozyme II with inhibitor
4Z0Q,X-RAY DIFFRACTION,2.12,42.09,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,2015-03-26,2015-08-26,4Z0Q,2273,1,258,197,,29.45,1,1.45,experimental,12.374,0.1914,0.1464,"Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)"
4Z1J,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,2015-03-27,2015-08-26,4Z1J,2338,1,258,248,,29.45,1,1.27,experimental,12.726,0.1703,0.137,"Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)"
4Z1K,X-RAY DIFFRACTION,2.1,41.37,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,2015-03-27,2015-08-26,4Z1K,2366,1,257,258,,29.35,1,1.35,experimental,14.446,0.1696,0.1338,"Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)"
4Z1N,X-RAY DIFFRACTION,2.1,41.45,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,2015-03-27,2015-08-26,4Z1N,2280,1,258,195,,29.51,1,1.47,experimental,10.329,0.2138,0.1886,"Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)"
5DSK,X-RAY DIFFRACTION,2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,2015-09-17,2016-05-04,5DSK,2502,1,260,399,,29.45,1,1.3,experimental,16.096,0.14422,0.11039,Structure of CO2 released holo-form of human carbonic anhydrase II with 3 min warming
5DSL,X-RAY DIFFRACTION,2.08,40.77,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,2015-09-17,2016-05-04,5DSL,2506,1,260,403,,29.45,1,1.45,experimental,17.243,0.14712,0.10179,Structure of CO2 released holo-form of human carbonic anhydrase II with 10 min warming
5DSM,X-RAY DIFFRACTION,2.08,40.78,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,2015-09-17,2016-05-04,5DSM,2492,1,260,389,,29.45,1,1.3,experimental,13.923,0.14001,0.11216,Structure of CO2 released holo-form of human carbonic anhydrase II with 25 min warming
5DSP,X-RAY DIFFRACTION,2.07,40.46,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,2015-09-17,2016-05-04,5DSP,2506,1,260,379,,29.38,1,1.4,experimental,17.515,0.15667,0.11482,Structure of CO2 released apo-form of human carbonic anhydrase II with 40 sec warming
5DSQ,X-RAY DIFFRACTION,2.05,40.11,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,2015-09-17,2016-05-04,5DSQ,2502,1,260,375,,29.38,1,1.5,experimental,17.537,0.1514,0.10743,Structure of CO2 released apo-form of human carbonic anhydrase II with 3 min warming
5DSR,X-RAY DIFFRACTION,2.09,41.02,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,2015-09-17,2016-05-04,5DSR,2571,1,260,444,,29.38,1,1.3,experimental,13.589,0.15274,0.1225,Structure of CO2 released apo-form of human carbonic anhydrase II with 10 min warming
5SZ0,X-RAY DIFFRACTION,2.1,41.39,"VAPOR DIFFUSION, SITTING DROP",,"1.6M Sodium Citrate, 50mM Tris pH 7.8",296,2016-08-12,2016-12-21,5SZ0,2247,1,257,161,,29.31,1,1.63,experimental,18.6622,0.1924,0.1651,Carbonic anhydrase II in complex with 4-(phenyl)-benzenesulfonamide
5SZ3,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, SITTING DROP",,"1.6M Sodium Citrate, 50mM Tris pH 7.8",296,2016-08-12,2016-12-21,5SZ3,2332,1,257,221,,29.67,1,1.689,experimental,18.2427,0.2031,0.1633,Carbonic anhydrase II in complex with 4-(3-quinolinyl)-benzenesulfonamide
5SZ4,X-RAY DIFFRACTION,2.12,41.84,"VAPOR DIFFUSION, SITTING DROP",,"1.6M Sodium Citrate, 50mM Tris pH 7.8",296,2016-08-12,2016-12-21,5SZ4,2270,1,257,182,,29.3,1,1.6,experimental,,0.217,0.1831,Carbonic anhydrase IX-mimic in complex with 4-(phenyl)-benzenesulfonamide
5SZ5,X-RAY DIFFRACTION,2.11,41.81,"VAPOR DIFFUSION, SITTING DROP",,"1.6M Sodium Citrate, 50mM Tris pH 7.8",296,2016-08-12,2016-12-28,5SZ5,2359,1,257,276,,29.24,1,1.274,experimental,,0.1644,0.1478,Carbonic anhydrase IX-mimic in complex with 4-(2-methylphenyl)-benzenesulfonamide
5SZ7,X-RAY DIFFRACTION,2.11,41.66,"VAPOR DIFFUSION, SITTING DROP",,"1.6M Sodium Citrate, 50mM Tris pH 7.8",296,2016-08-12,2016-12-21,5SZ7,2249,1,257,155,,29.51,1,1.776,experimental,,0.1946,0.161,Carbonic anhydrase IX-mimic in complex with 4-(3-quinolinyl)-benzenesulfonamide
5TFX,X-RAY DIFFRACTION,2.11,41.8,"VAPOR DIFFUSION, SITTING DROP",8.3,"2.7 M ammonium sulfate, 100 mM Tris pH 8.3 with protein at 7 mg/mL",281,2016-09-26,2017-08-09,5TFX,2427,1,260,270,,29.76,1,1.5,experimental,13.662,0.24619,0.18661,New method for synthesis of benzoxazole amide inhibitors of carbonic anhydrase
6EBE,X-RAY DIFFRACTION,2.19,43.72,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sodium citrate, 50 mM Tris-HCl, pH 7.8",298,2018-08-06,2018-11-28,6EBE,2119,1,257,41,,29.42,1,1.88,experimental,23.9742,0.2277,0.1682,Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6ECZ,X-RAY DIFFRACTION,2.19,43.87,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sodium citrate, 50 mM Tris-HCl",298,2018-08-08,2018-11-28,6ECZ,2097,1,257,18,,29.47,1,2.21,experimental,36.5656,0.2198,0.164,Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6EDA,X-RAY DIFFRACTION,2.19,43.89,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sodium citrate, 50 mM Tris-HCl",298,2018-08-09,2018-11-28,6EDA,2119,1,257,41,,29.42,1,1.879,experimental,23.9742,0.2277,0.1682,Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6EEA,X-RAY DIFFRACTION,2.18,43.64,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sosium citrate, 50 mM Tris-HCl",298,2018-08-13,2018-11-28,6EEA,2138,1,257,39,,29.75,1,1.63,experimental,19.4199,0.1973,0.1721,Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6EEH,X-RAY DIFFRACTION,2.18,43.58,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sodium citrate, 50 mM Tris-HCl",298,2018-08-14,2018-11-28,6EEH,2211,1,257,81,,30.33,1,1.629,experimental,20.7556,0.1871,0.1595,Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6EEO,X-RAY DIFFRACTION,2.19,43.71,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sodium citrate, 50 mM Tris-HCl",298,2018-08-15,2018-11-28,6EEO,2130,1,257,24,,29.29,1,1.719,experimental,24.4039,0.2069,0.1729,Bioreductive 4-hydroxy-3-nitro-5-ureido-benzenesulfonamides selectively target the tumor-associated carbonic anhydrase isoforms IX and XII and show hypoxia-enhanced cytotoxicity against human cancer cell lines.
6GOT,X-RAY DIFFRACTION,2.09,41.18,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 100 mM",296,2018-06-04,2018-10-03,6GOT,2218,1,260,124,,29.83,1,1.56,experimental,15.776,0.2233,0.1988,Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-(phenethylthio)benzenesulfonamide
6RHJ,X-RAY DIFFRACTION,2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",8.3,1.6 sodium citrate,296,2019-04-21,2020-05-13,6RHJ,2269,1,260,173,,29.82,1,1.44,experimental,13.218,0.20089,0.17596,"Crystal structure of human carbonic anhydrase isozyme II with 4-(4-benzyl-1,4-diazepane-1-carbonyl)benzenesulfonamide"
6RHK,X-RAY DIFFRACTION,2.12,41.99,"VAPOR DIFFUSION, HANGING DROP",8.3,1.6 M sodium citrate,296,2019-04-22,2020-05-13,6RHK,2347,1,260,230,,29.88,1,1.44,experimental,13.325,0.17514,0.15461,The crystal structure of human carbonic anhydrase II in complex with 4-(3-benzylimidazolidine-1-carbonyl)benzenesulfonamide
6RM1,X-RAY DIFFRACTION,2.12,42.08,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, pH = 7.8, saturated with para-Chloromercuribenzoic acid",291,2019-05-03,2020-04-15,6RM1,2222,1,265,166,,30.46,1,1.68,experimental,,0.1806,0.1528,Human Carbonic Anhydrase II in complex with fragment.
6RMP,X-RAY DIFFRACTION,2.2,44.11,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-05-07,2020-04-15,6RMP,2433,1,265,208,,30.49,1,1.22,experimental,,0.162,0.1315,Human Carbonic Anhydrase II in complex with fragment.
6SAS,X-RAY DIFFRACTION,2.13,42.48,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-07-17,2020-04-15,6SAS,2524,1,265,211,,30.67,1,1.1,experimental,12.38,0.1486,0.1319,Human Carbonic Anhydrase II in complex with fragment.
6UZU,X-RAY DIFFRACTION,2.11,41.75,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M Na-Citrate, 50 mM Tris, pH 7.8",293,2019-11-15,2020-10-21,6UZU,2263,1,257,184,,29.39,1,1.5,experimental,17.3568,0.1842,0.1611,Carbonic Anhydrase IX-mimic In Complex WITH U-CH3
7K6U,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.6M Sodium Citrate, 50mM Tris, pH 6.4",295,2020-09-21,2020-12-23,7K6U,2235,1,260,145,,29.76,1,1.605,experimental,20.0873,0.1961,0.1776,Carbonic Anhydrase IX mimic complexed with 4-(2-(3-(4-methylphenyl)ureido)ethylsulfonamido)benzenesulfonamide
7K6X,X-RAY DIFFRACTION,2.12,41.88,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.6M Sodium Citrate, 50mM Tris, pH 6.4",295,2020-09-21,2020-12-23,7K6X,2226,1,260,131,,29.77,1,1.76,experimental,20.2543,0.2233,0.1798,"Carbonic Anhydrase IX mimic complexed with 4-(2-(3-(3,5-dimethylphenyl)ureido)ethylsulfonamido)benzenesulfonamide"
7K6Z,X-RAY DIFFRACTION,2.13,42.14,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.6M Sodium Citrate, 50mM Tris, pH 6.4",295,2020-09-21,2020-12-23,7K6Z,2220,1,260,130,,29.76,1,1.657,experimental,21.3857,0.2119,0.1837,Carbonic Anhydrase IX mimic complexed with 4-(2-(3-(4-fluorophenyl)ureido)ethylsulfonamido)benzenesulfonamide
7OYP,X-RAY DIFFRACTION,2.09,41.25,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2021-06-24,2023-01-18,7OYP,2551,1,260,372,,29.87,1,1.05,experimental,13.688,0.1343,0.1175,Carbonic anhydrase II in complex with Hit3-t1 (MH172)
7QSI,X-RAY DIFFRACTION,2.1,41.35,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2022-01-13,2023-01-25,7QSI,2337,1,260,220,,29.64,1,1.304,experimental,14.568,0.1845,0.1627,human Carbonic Anhydrase II in complex with indoline-1-sulfonamide
8FQZ,X-RAY DIFFRACTION,2.07,40.58,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2023-01-06,2023-02-01,8FQZ,2362,1,260,271,,29.81,1,1.467,experimental,,0.1853,0.1644,Carbonic Anhydrase II in complex with the alkyl urea 3j
8D35,X-RAY DIFFRACTION,2.65,51.36,"VAPOR DIFFUSION, HANGING DROP",,"20-21.5% PEG3350, 100 mM sodium chloride, diffraction-quality crystals obtained from seeding",293.15,2022-05-31,2023-03-01,8D35,5099,3,627,359,,69.58,2,1.9,experimental,30.9,0.2244,0.1888,Crystal structure of SARS-CoV-2 main protease (Mpro) C145A mutant in complex with peptide from human tRNA methyltransferase TRMT1
7OK8,X-RAY DIFFRACTION,2.11,41.57,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2021-05-17,2022-06-01,7OK8,2376,1,260,242,,30.25,1,1.43,experimental,13.047,0.1651,0.1417,Crystal structure of human carbonic anhydrase II with 4-((2-hydroxy-3-(phenylselanyl)propyl)thio)benzenesulfonamide
7ORP,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2021-06-06,2022-06-22,7ORP,2328,1,260,205,,30.62,1,1.43,experimental,15.861,0.1659,0.1498,"crystal structure of human carbonic anhydrase II in complex with 4-((2-hydroxy-3-((3,4,5-trimethoxyphenyl)tellanyl)propyl)selanyl)benzenesulfonamide"
7ORQ,X-RAY DIFFRACTION,2.1,41.52,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2021-06-06,2022-06-22,7ORQ,2334,1,260,212,,30.31,1,1.43,experimental,15.449,0.1707,0.1485,crystal structure of human carbonic anhydrase II in complex with 4-((3-(butylselanyl)-2-hydroxypropyl)selanyl)benzenesulfonamide
4U9Y,X-RAY DIFFRACTION,2.11,41.61,"VAPOR DIFFUSION, HANGING DROP",7,"0.1M HEPES, 20% PEG 3350, 0.2M NaBr",293,2014-08-07,2015-08-12,4U9Y,1674,1,201,106,,23.78,1,2.201,experimental,27.1101,0.2297,0.195,Structure of the alpha-tubulin acetyltransferase alpha-TAT1/Mec-17 in complex with CoA
4U9Z,X-RAY DIFFRACTION,2.02,39.16,"VAPOR DIFFUSION, HANGING DROP",9,"0.1M Tris, 25% PEG 3350",293,2014-08-07,2015-08-12,4U9Z,1666,1,201,102,,23.7,1,1.802,experimental,25.1548,0.2578,0.2159,Structure of the alpha-tubulin acetyltransferase alpha-TAT1/Mec-17 in complex with CoA
6LPF,X-RAY DIFFRACTION,2.84,56.63,EVAPORATION,,"20% (w/v) PEG 6000, 100 mM Tris-cl, pH 8.0, and 200 mM Lithium chloride",289,2020-01-10,2020-03-25,6LPF,16988,2,2184,682,,251.75,1,2.49,experimental,49.4063,0.2421,0.1985,The crystal structure of human cytoplasmic LRS
4QTL,X-RAY DIFFRACTION,1.99,37.8,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M sodium BICINE (pH 9), 0.2M ammonium sulfate, 2M sodium malonate, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-07-08,2015-04-15,4QTL,2376,1,260,211,,30.05,1,1.8,experimental,17.363,0.203,0.161,Crystal structure of human carbonic anhydrase isozyme II with inhibitor
5LJT,X-RAY DIFFRACTION,2.11,41.67,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM",296,2016-07-19,2017-06-21,5LJT,2651,1,258,439,,29.56,1,1,experimental,11.64,0.1572,0.1382,"Crystal structure of human carbonic anhydrase II in complex with the 4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)benzenesulfonamide inhibitor"
5SZ1,X-RAY DIFFRACTION,2.1,41.39,"VAPOR DIFFUSION, SITTING DROP",,"1.6M Sodium Citrate, 50mM Tris pH 7.8",296,2016-08-12,2016-12-21,5SZ1,2359,1,257,239,,29.66,1,1.55,experimental,18.9588,0.1854,0.1568,Carbonic anhydrase II in complex with 4-(2-methylphenyl)-benzenesulfonamide
5SZ2,X-RAY DIFFRACTION,2.11,41.72,"VAPOR DIFFUSION, SITTING DROP",,"1.6M Sodium Citrate, 50mM Tris pH 7.8",296,2016-08-12,2016-12-21,5SZ2,2307,1,257,190,,29.93,1,1.63,experimental,17.032,0.1797,0.1503,Carbonic anhydrase II in complex with 4-(3-formylphenyl)-benzenesulfonamide
5SZ6,X-RAY DIFFRACTION,2.12,41.96,"VAPOR DIFFUSION, SITTING DROP",,"1.6M Sodium Citrate, 50mM Tris pH 7.8",296,2016-08-12,2016-12-28,5SZ6,2482,1,257,376,,29.42,1,1.15,experimental,,0.1588,0.1436,Carbonic anhydrase IX-mimic in complex with 4-(3-formylphenyl)-benzenesulfonamide
5WLV,X-RAY DIFFRACTION,2.15,42.83,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate
50mM Tris-HCl",298,2017-07-27,2018-08-01,5WLV,2404,1,257,234,,30.04,1,1.4,experimental,19.168,0.1669,0.1446,Carbonic Anhydrase II in complex with aryloxy-2-hydroxypropylammine sulfonamide
6B4D,X-RAY DIFFRACTION,2.13,42.26,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50mM Tris HCl",298,2017-09-26,2018-02-07,6B4D,2491,1,257,341,,29.52,1,1.196,experimental,16.0164,0.156,0.1389,Crystal structure of human carbonic anhydrase II in complex with a heteroaryl-pyrazole carboxylic acid derivative.
6B59,X-RAY DIFFRACTION,2.16,43.12,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M NaCitrate
50mM Tris-HCl",298,2017-09-28,2018-09-05,6B59,2254,1,257,155,,29.54,1,1.638,experimental,18.9451,0.1707,0.1403,Carbonic anhydrase II in complex with nitrogenous base-bearing benezenesulfonamide
6MBY,X-RAY DIFFRACTION,2.1,41.48,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M NaCitrate, 50 mM Tris",298,2018-08-30,2019-03-13,6MBY,2295,1,257,207,,29.36,1,1.496,experimental,17.9939,0.1742,0.1518,Carbonic Anhydrase II in complex with Ferulic Acid
6VJ3,X-RAY DIFFRACTION,2.12,41.87,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M NaCitrate, 50 mM Tris",298,2020-01-14,2020-03-11,6VJ3,2355,1,258,245,,29.55,1,1.35,experimental,18.507,0.1728,0.1507,Carbonic Anhydrase II in complex with pyrimidine-based inhibitor
6YH4,X-RAY DIFFRACTION,2.04,39.68,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2020-03-28,2021-04-07,6YH4,2394,1,260,231,,29.7,1,1.3,experimental,19.736,0.1658,0.1318,"Crystal structure of chimeric carbonic anhydrase XII with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide"
6YH7,X-RAY DIFFRACTION,2.03,39.39,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2020-03-28,2021-04-07,6YH7,2451,1,260,284,,30.27,1,1.12,experimental,17.513,0.1629,0.1334,"Crystal structure of chimeric carbonic anhydrase XII with 3-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
6YH8,X-RAY DIFFRACTION,2.05,39.9,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2020-03-28,2021-04-07,6YH8,2672,1,260,295,,29.88,1,1.2,experimental,17.256,0.1721,0.1356,"Crystal structure of chimeric carbonic anhydrase XII with 2-[(1S)-1,2,3,4-Tetrahydronapthalen-1-ylamino)-3,5,6-trifluorobenzenesulfonamide"
6YHC,X-RAY DIFFRACTION,2.04,39.59,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2020-03-28,2021-04-07,6YHC,2369,1,260,229,,30.21,1,1.28,experimental,21.824,0.1721,0.1304,"Crystal structure of chimeric carbonic anhydrase XII with 3-(benzylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
7JO1,X-RAY DIFFRACTION,2.04,39.78,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris",298,2020-08-05,2020-11-04,7JO1,2330,1,260,150,,29.85,1,1.499,experimental,16.5621,0.2131,0.1823,"Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)butyramide"
7JO3,X-RAY DIFFRACTION,2.06,40.19,"VAPOR DIFFUSION, HANGING DROP",,"1.6M Sodium Citrate, 50mM Tris",298,2020-08-05,2020-11-04,7JO3,2428,1,260,211,,29.61,1,1.454,experimental,17.5297,0.173,0.161,"Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)pivalamide"
7JOB,X-RAY DIFFRACTION,2.03,39.55,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris",298,2020-08-06,2020-11-04,7JOB,2418,1,260,209,,29.63,1,1.381,experimental,17.1064,0.191,0.1702,"Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)cyclohexanecarboxamide"
7K6I,X-RAY DIFFRACTION,2.11,41.72,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.6M Sodium Citrate, 50mM Tris, pH 6.4",295,2020-09-20,2020-12-23,7K6I,2338,1,260,203,,30.72,1,1.406,experimental,14.9726,0.1854,0.1642,Carbonic Anhydrase II complexed with 4-(2-(3-phenylureido)ethylsulfonamido)benzenesulfonamide
7K6J,X-RAY DIFFRACTION,2.11,41.61,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.6M Sodium Citrate, 50mM Tris, pH 6.4",295,2020-09-20,2020-12-23,7K6J,2218,1,260,111,,29.94,1,1.755,experimental,19.163,0.2177,0.1868,Carbonic Anhydrase II complexed with 4-(2-(3-(4-methylphenyl)ureido)ethylsulfonamido)benzenesulfonamide
7K6K,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.6M Sodium Citrate, 50mM Tris, pH 6.4",295,2020-09-20,2020-12-23,7K6K,2265,1,260,173,,29.95,1,1.306,experimental,14.7727,0.1936,0.1805,"Carbonic Anhydrase II complexed with 4-(2-(3-(3,5-dimethylphenyl)ureido)ethylsulfonamido)benzenesulfonamide"
8FQX,X-RAY DIFFRACTION,2.02,39.08,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2023-01-06,2023-02-01,8FQX,2341,1,260,228,,29.85,1,1.496,experimental,,0.191,0.1711,Carbonic Anhydrase II in complex with the alkyl ureas 3g
6PVB,X-RAY DIFFRACTION,2.31,46.7,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M lithium sulfate, 0.1 M sodium HEPES 7.5",293,2019-07-20,2020-08-19,6PVB,2058,2,249,163,,28.75,2,1.5,experimental,38.2219,0.2243,0.2048,The structure of NTMT1 in complex with compound 6
5L2X,X-RAY DIFFRACTION,2.22,50.47,"VAPOR DIFFUSION, SITTING DROP",7.5,17-23% PEG 3350,293,2016-08-02,2016-11-23,5L2X,5001,6,766,98,,101.35,1,2.2,experimental,,0.255,0.2056,Crystal structure of human PrimPol ternary complex
8RDK,X-RAY DIFFRACTION,2.9,57.58,"VAPOR DIFFUSION, SITTING DROP",7.5,"51% MPD
0.1M SPG 7.5",277,2023-12-08,2024-03-06,8RDK,2780,1,357,133,,41.14,1,2,experimental,39.312,0.23294,0.19695,Crystal structure of human Haspin (GSG2) kinase bound to MD420
6UX1,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M NaCitrate
50mM Tris
pH 7.8",298,2019-11-06,2020-04-22,6UX1,2351,1,260,176,,30.12,1,1.36,experimental,24.5433,0.1668,0.1544,Carbonic Anhydrase II Complexed with Salicylic Acid
4Z9L,X-RAY DIFFRACTION,2.3,46.5,"VAPOR DIFFUSION, HANGING DROP",7,"PEG MME 550, ETHYLENE GLYCOL,  HEPES",293,2015-04-10,2015-05-06,4Z9L,2780,1,364,67,,43.02,1,2.1,experimental,29.49,0.2258,0.1997,THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
5U30,X-RAY DIFFRACTION,3.19,61.39,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.2 M ammonium acetate, 0.1 M HEPES (pH 7.5), and 25% PEG3350 (v/v)",293,2016-12-01,2017-01-25,5U30,11907,4,1288,7,,182.27,1,2.92,experimental,,0.2441,0.2054,Crystal structure of AacC2c1-sgRNA-extended target DNA ternary complex
5U31,X-RAY DIFFRACTION,3.2,61.52,EVAPORATION,7.2,"0.2 M ammonium acetate, 0.1 M HEPES (pH 7.5), and 25% PEG3350 (v/v)",293,2016-12-01,2017-01-25,5U31,11871,5,1286,,,181.55,1,2.89,experimental,,0.2393,0.1976,Crystal structure of AacC2c1-sgRNA-8mer substrate DNA ternary complex
4S3O,X-RAY DIFFRACTION,2.16,43.01,VAPOR DIFFUSION,6.5,"13.5% PEG 550 MME, 10 mM TCEP, 0.1 M MES pH 6.5, 100 mM KCl, VAPOR DIFFUSION, temperature 277K",277,2015-03-23,2015-07-15,4S3O,5635,6,766,153,,88.36,3,2,experimental,,0.2368,0.1939,PCGF5-RING1B-UbcH5c complex
5O0Y,X-RAY DIFFRACTION,2.47,50.3,"VAPOR DIFFUSION, SITTING DROP",,"20 mM HEPES pH 7, 2M Li2SO4, 10mM MgCl2

1M Na/K tartrate, 0.1M Tris pH7, 200mM LiSO4",277,2017-05-17,2018-05-30,5O0Y,2390,1,579,,,67.92,1,2.86,experimental,101.882,0.20979,0.18251,TLK2 kinase domain from human
7P1A,X-RAY DIFFRACTION,2.14,42.47,"VAPOR DIFFUSION, HANGING DROP",8.5,"17% PEG 3350, 0.2 M Ammonium acetate, 0.1 M Tris-HCl (pH 8.5)",293,2021-07-01,2021-11-17,7P1A,2304,1,274,179,1,31.51,1,1.58,experimental,17.555,0.2062,0.1892,Carbonic Anhydrase VII Sultam Based Inhibitors
7E7F,X-RAY DIFFRACTION,2.44,49.56,"VAPOR DIFFUSION, SITTING DROP",7.4,"100mM potassium phosphate, 150mM NaCl, 4% w/v PEG 3350",277,2021-02-26,2022-01-05,7E7F,4433,1,486,418,,57.67,1,1.4,experimental,28.886,0.1634,0.1397,Human CYP11B1 mutant in complex with metyrapone
4XZI,X-RAY DIFFRACTION,2.3,46.55,"VAPOR DIFFUSION, HANGING DROP",8,"10 mM Tris-HCl,  pH 8.0, 20% polyethylene glycol, PEG 6000",277,2015-02-04,2015-11-18,4XZI,2712,1,316,39,,37.25,1,2.45,experimental,,0.2895,0.2188,Crystal structure of human Aldose Reductase complexed with NADP+ and JF0049
4YS1,X-RAY DIFFRACTION,2.15,42.72,"VAPOR DIFFUSION, HANGING DROP",5,50 mM di-Ammoniumhydrogen citrate pH 5.0 PEG6000= 5 % (m/V) DTT= 5.15 g/L NADP+= 0.66 g/L and Human Aldose Reductase= 15 mg/ml. Afterwards the crystals were soaked into Tris 100 mM 25% (m/V) PEG6000 pH 8.0 saturated with the inhibitor.,291,2015-03-16,2016-03-23,4YS1,3096,1,316,411,,36.99,1,1.07,experimental,,0.1484,0.1315,Human Aldose Reductase complexed with a ligand with an IDD structure (2) at 1.07 A.
6R8R,X-RAY DIFFRACTION,1.94,36.6,"VAPOR DIFFUSION, SITTING DROP",4,"1.4 M ammonium sulphate, 0.1 M citric acid, pH 4",300,2019-04-02,2019-05-08,6R8R,3287,1,383,183,8,45.86,1,1.27,experimental,23.2508,0.1777,0.1478,Structure of the Wnt deacylase Notum in complex with isoquinoline 45
6T2H,X-RAY DIFFRACTION,1.93,36.12,EVAPORATION,4.2,1.5M Ammonium sulfate 0.1 M Sodium citrate pH4.2,300,2019-10-08,2020-01-01,6T2H,3138,1,383,109,6,45.7,1,1.41,experimental,27.9502,0.1979,0.1764,"Furano[2,3-d]prymidine amides as Notum inhibitors"
6TR6,X-RAY DIFFRACTION,1.93,36.38,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M ammonium sulphate 
0.1 M sodium citrate pH 4.2.",300,2019-12-17,2020-01-08,6TR6,3039,1,383,152,6,45.05,1,1.35,experimental,23.9797,0.1928,0.1806,N-acetylserotonin-Notum complex
6ZVL,X-RAY DIFFRACTION,1.92,36.02,EVAPORATION,4.2,"1.5 M  Ammonium Sulphate
0.1 M Sodium Citrate, pH 4.2",293,2020-07-24,2020-11-11,6ZVL,3000,1,383,120,6,44.66,1,1.3,experimental,24.8594,0.2226,0.2007,ARUK3000263 complex with Notum
6MAL,X-RAY DIFFRACTION,2.11,41.76,"VAPOR DIFFUSION, HANGING DROP",7.5,"Magnesium Chloride, HEPES pH 7.5, PEG 400",293,2018-08-28,2018-09-05,6MAL,2434,1,312,37,,35.51,1,2.6,experimental,,0.3069,0.2522,Structure of human Nocturnin C-terminal domain
8DPE,X-RAY DIFFRACTION,2.11,41.78,"VAPOR DIFFUSION, HANGING DROP",,"1 uL 8 mg/mL DDX42 (in 25 mM Tris, pH 7.5, 300 mM sodium chloride, 1 mM TCEP) + 1 uL reservoir solution (6-10% PEG8000, 0.1 M Tris, pH 8.5-9.0)",296,2022-07-15,2022-08-24,8DPE,3802,1,444,353,,49.87,1,1.531,experimental,25.6866,0.2552,0.2121,Crystal structure of ATP-dependent RNA helicase DDX42
7LAN,X-RAY DIFFRACTION,2.4,48.78,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2021-01-06,2021-04-21,7LAN,19605,8,2284,966,24,272.23,2,2.28,experimental,44.53,0.2394,0.2003,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH COMPOUND-30 AKA 7-[(3~{S},4~{R},6~{R})-4-benzyl-2-oxa-7,13,14-triazatetracyclo[14.3.1.1^{3,6}.1^{11,14}]docosa-1(19),11(21),12,16(20),17-pentaen-10-yl]-3~{H}-triazolo[4,5-b]pyridin-5-amine"
5HKY,X-RAY DIFFRACTION,3.29,62.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"30% (v/v) PEG 400, 0.1M HEPES, 200 mM MgCl2",293,2016-01-14,2017-01-18,5HKY,2943,2,334,282,,39.03,2,1.8,experimental,27.744,0.1801,0.1569,"Crystal structure of c-Cbl TKBD domain in complex with SPRY2 peptide (36-60, pY55) Refined to 1.8A Resolution (P6 form)"
5HKZ,X-RAY DIFFRACTION,2.04,39.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% (w/v) PEG 2000 MME, 0.1M HEPES",293,2016-01-14,2017-01-18,5HKZ,2795,2,334,206,,38.72,2,1.8,experimental,25.0576,0.2126,0.1618,"Crystal Structure of c-Cbl TKBD in complex with SPRY2 peptide (36-60, pY55) Refined to 1.8 A Resolution (P21 form)"
5HL0,X-RAY DIFFRACTION,3.4,63.8,"VAPOR DIFFUSION, SITTING DROP",,"16% (w/v) PEG 8000, 0.04M Potassium phosphate (monobasic), 20% (v/v) glycerol",293,2016-01-14,2017-01-18,5HL0,2543,2,316,85,,36.63,2,2.2,experimental,45.8552,0.2366,0.1902,"Crystal Structure of c-Cbl TKBD in complex with SPRY2 peptide (54-60, pY55) Refined to 2.2A Resolution"
5J3X,X-RAY DIFFRACTION,3.22,61.79,"VAPOR DIFFUSION, HANGING DROP",8.5,"Equal volume protein at 10 mg/mL + well containing 3.0-3.1 M sodium formate
0.1 M Tris-HCl, pH 8.5
5 mM DTT",281.15,2016-03-31,2016-09-21,5J3X,18284,6,2346,94,,271.37,1,2.822,experimental,,0.2541,0.2124,Structure of c-CBL Y371F
4QSJ,X-RAY DIFFRACTION,2.21,44.4,"VAPOR DIFFUSION, SITTING DROP",5,"0.1M sodium citrate (pH 5.5), 0.2M sodium acetate (pH 4.5), 28% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-07-04,2015-01-21,4QSJ,4942,2,526,543,,60.96,1,1.7,experimental,17.402,0.20422,0.1637,"Crystal structure of human carbonic anhydrase isozyme XIII with 2-chloro-4-{[(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]acetyl}benzenesulfonamide"
6RVF,X-RAY DIFFRACTION,2.07,40.72,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 0.1 M Tris-HCl, pH 8.5",293,2019-05-31,2019-08-28,6RVF,2169,1,262,108,,29.83,1,2.07,experimental,13.96,0.229,0.184,"Crystal structure of hCA II in complex with Urea, N-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-N'-phenyl"
6RVK,X-RAY DIFFRACTION,2.08,40.82,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 0.1 M Tris-HCl, pH 8.5",293,2019-05-31,2019-08-28,6RVK,2277,1,262,207,,29.84,1,1.58,experimental,14.4499,0.197,0.1694,"Crystal structure of hCA II in complex with Urea, N-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-N'-(phenylmethyl)-"
6RVL,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 0.1 M Tris-HCl, pH 8.5",293,2019-05-31,2019-08-28,6RVL,2229,1,262,156,,29.84,1,1.72,experimental,12.7683,0.2093,0.1758,"Crystal structure of hCA II with Urea, N-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-?N'-phenyl-"
6RW1,X-RAY DIFFRACTION,2.08,40.99,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 0.1 M Tris-HCl, pH 8.5",293,2019-06-03,2019-08-28,6RW1,2226,1,262,152,,29.86,1,1.7,experimental,15.6271,0.2053,0.179,"Crystal structure of hCA II in complex with Urea, N-(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-6-yl)-N'-(phenylmethyl)-"
8EM3,X-RAY DIFFRACTION,2.12,42.03,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris base",293,2022-09-26,2023-09-27,8EM3,2275,1,260,185,,29.68,1,1.62,experimental,22.9338,0.1844,0.1528,Carbonic Anhydrase II in complex with the diaryl urea molecule J2
6BMT,X-RAY DIFFRACTION,2.54,51.54,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M acetate, pH 4.5-4.6, 25% w/v PEG3350",298,2017-11-15,2018-01-03,6BMT,5335,2,850,105,6,96.71,2,2.403,experimental,56.7987,0.2181,0.1853,Crystal Structure of a Recombinant form of Human Myeloperoxidase Bound to an Inhibitor from Staphylococcus delphini
5LP8,X-RAY DIFFRACTION,4.56,73.03,"VAPOR DIFFUSION, SITTING DROP",,"Hepes pH 7, PEG20000",293,2016-08-12,2017-02-22,5LP8,7015,2,900,32,,105.9,1,2.7,experimental,,0.225,0.194,Crystal structure of an asymmetric dimer of the ubiquitin ligase HUWE1
7KTN,X-RAY DIFFRACTION,2.52,51.13,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KTN,3718,4,374,485,,46.21,1,1.33,experimental,21.7684,0.1626,0.1414,"DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 10 mM Mg2+ (2160min)"
7LAL,X-RAY DIFFRACTION,2.67,53.88,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2021-01-06,2021-04-21,7LAL,9008,4,1142,3,12,135.39,2,2.75,experimental,70,0.2697,0.227,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH COMPOUND-18 AKA 7-(3-(2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-1-PHENYLPROPYL)-1H-[1,2,3]TRIAZOLO[4,5-B]PYRIDIN-5-AMINE"
7YB9,X-RAY DIFFRACTION,2.61,52.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M lithium chloride, 20 % w/v Polyethylene glycol 6,000, 0.1 M Bis-Tris propane",277,2022-06-29,2023-07-05,7YB9,4030,2,469,408,2,53.93,2,1.54,experimental,43.47,0.2147,0.1849,Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with L-2-hydroxyglutarate and factor X-derived peptide (39mer-4Ser)
7YBB,X-RAY DIFFRACTION,2.53,51.39,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.02 M Sodium/potassium phosphate, 20 % w/v Polyethylene glycol 3,350, 0.1 M Bis-Tris propane",277,2022-06-29,2023-07-05,7YBB,4005,2,468,414,2,53.81,2,1.68,experimental,23.01,0.2193,0.1945,Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with D-4-hydroxy-2-oxoglutarate and factor X-derived peptide (39mer-4Ser)
4ZGY,X-RAY DIFFRACTION,2.46,49.94,"VAPOR DIFFUSION, HANGING DROP",5.6,"100MM MAGNESIUM ACETATE, 50MM MES PH
 5.6, 20% 2-METHYL-2, 4-PENTANEDIOL(MPD), VAPOR DIFFUSION, HANGING
 DROP, TEMPERATURE 277K",277,2015-04-24,2015-09-02,4ZGY,3983,2,557,13,,62.82,2,2.63,experimental,83.34,0.256,0.203,STRUCTURE of HUMAN ORNITHINE DECARBOXYLASE IN COMPLEX WITH A C-TERMINAL FRAGMENT OF ANTIZYME
5ULN,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, SITTING DROP",8.3,"concentrated CA II at ~10 mg/mL was set up in SD-2 plates (Molecular Dimensions) with the following ratio of protein plus reservoir plus
 seeds: 250 nL + 225 nL + 25 nL. The plate was incubated at 8 C and the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 
M Tris buffer at pH 8.3.  Dry compound was added to the crystallization drop after crystals had formed and several days before data were c
ollected.",281,2017-01-25,2017-10-11,5ULN,2586,1,260,327,,29.82,1,1.35,experimental,13.843,0.14261,0.10571,"Synthesis of novel seleno ureido containing compounds as SLC-0111 analogs. Investigations on carbonic anhydrases activity, glutathione peroxidase and X-ray crystallography"
5UMC,X-RAY DIFFRACTION,2.11,41.62,"VAPOR DIFFUSION, SITTING DROP",,"concentrated CA II at ~10 mg/mL was set up in SD-2 plates (Molecular Dimensions) with the following ratio of protein plus reservoir plus
 seeds: 250 nL + 225 nL + 25 nL. The plate was incubated at 8 C and the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 
M Tris buffer at pH 8.3.  Dry compound was added to the crystallization drop after crystals had formed and several days before data were 
collected.",281,2017-01-26,2017-12-06,5UMC,2254,1,260,97,,29.54,1,2.15,experimental,20.219,0.26112,0.19628,"Synthesis of novel seleno ureido containing compounds as SLC-0111 analogs. Investigations on carbonic anhydrases activity, glutathione peroxidase and X-ray crystallography"
7V0Z,X-RAY DIFFRACTION,2.24,44.97,"VAPOR DIFFUSION, HANGING DROP",5,"24% PEG 4000, 100mM Na Citrate pH 5.0",293,2022-05-11,2022-08-03,7V0Z,2005,1,238,69,4,27.41,1,1.8,experimental,27.6547,0.2024,0.1761,Factor XIa in Complex with Compound 2a
6GXB,X-RAY DIFFRACTION,2.09,41.04,"VAPOR DIFFUSION, HANGING DROP",7.8,"protein 25 mg/mL, 1.6M sodium citrate, 50mM Tris H2SO4 pH 7.8",291,2018-06-27,2019-05-08,6GXB,2429,1,257,287,,29.33,1,1.35,experimental,13.18,0.15376,0.11277,Carbonic Anhydrase CAIX mimic in complex with inhibitor JS13
7U5W,X-RAY DIFFRACTION,1.89,34.76,"VAPOR DIFFUSION, HANGING DROP",,0% PEG1000 and 0.1M Tris pH 8.0,293,2022-03-02,2023-03-15,7U5W,2415,1,260,358,,29.55,1,1.13,experimental,17.4522,0.18,0.1571,Crystal Structure Analysis of human Carbonic anhydrase 2
7Y2F,X-RAY DIFFRACTION,2.09,41.15,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2F,2384,1,260,243,,29.35,1,1.2,experimental,14.303,0.14926,0.12201,Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 140 K
7Y2I,X-RAY DIFFRACTION,2.1,41.43,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2I,2383,1,260,242,,29.35,1,1.4,experimental,20.482,0.15874,0.11128,Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 200 K
7Y2J,X-RAY DIFFRACTION,2.07,40.71,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2J,2518,1,260,351,,29.29,1,1.25,experimental,14.455,0.16734,0.12185,apo-Carbonic Anhydrase II soaked in 3NPA before UV at 90 K
7Y2K,X-RAY DIFFRACTION,2.08,40.75,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2K,2518,1,260,351,,29.29,1,1.25,experimental,14.564,0.16314,0.12086,apo-Carbonic Anhydrase II soaked in 3NPA after UV at 90 K
7Y2L,X-RAY DIFFRACTION,2.08,40.89,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2L,2518,1,260,351,,29.29,1,1.25,experimental,14.75,0.16385,0.11979,apo-Carbonic Anhydrase II soaked in 3NPA after UV at 120 K
7Y2M,X-RAY DIFFRACTION,2.08,41.01,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2M,2518,1,260,351,,29.29,1,1.25,experimental,15.142,0.15949,0.11821,apo-Carbonic Anhydrase II soaked in 3NPA after UV at 140 K
5JGT,X-RAY DIFFRACTION,2.12,41.86,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,2016-04-20,2017-01-11,5JGT,2635,1,259,423,,29.51,1,1.1,experimental,,0.1378,0.1194,"Human carbonic anhydrase II (F131Y/L198A) complexed with 1,3-thiazole-2-sulfonamide"
5FNK,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-11-15,2016-03-02,5FNK,2464,1,260,283,,29.76,1,1.59,experimental,14.128,0.19522,0.14675,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5M78,X-RAY DIFFRACTION,2.06,40.38,"VAPOR DIFFUSION, HANGING DROP",7.8,"Crystallization: 2 uL protein solution in 50 mM Tris, pH=7.8 mixed with 2 uL (NH4)2SO4, 100 mM Tris, pH=7.8, satured with PCMB and placed as hanging drop. Crystals appeared after a few days. The crystal for data collection was soaked in 5 uL containing 35 % PEG 3350 (50 % w/v), 20 % NaCl (1 M), 25 % PEG 400, 10 % H2O, 10 % Ligandstock in DMSO (1 M)",291,2016-10-27,2017-12-20,5M78,2499,1,265,249,,30.41,1,1.077,experimental,,0.144,0.1252,Human Carbonic Anhydrase II in complex with fragment-like inhibitor.
5FLQ,X-RAY DIFFRACTION,2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-10-28,2016-03-02,5FLQ,2412,1,260,246,,29.69,1,1.7,experimental,15.597,0.21511,0.15455,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5FLT,X-RAY DIFFRACTION,2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,2015-10-28,2016-03-02,5FLT,2430,1,260,263,,29.66,1,1.67,experimental,15.085,0.20162,0.1475,"Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination"
5LLC,X-RAY DIFFRACTION,2.02,38.6,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2 M ammonium sulfate and 2M sodium malonate (pH 7)",291,2016-07-27,2017-08-16,5LLC,2562,1,260,302,,30.17,1,1.1,experimental,17.652,0.1611,0.1377,"Crystal structure of human carbonic anhydrase isozyme II with 3-(Methylamino)-2,5,6-trifluoro-4-[(2-phenylethyl)sulfonyl]benzenesulfonamide"
5LLE,X-RAY DIFFRACTION,2,37.9,"VAPOR DIFFUSION, SITTING DROP",7.5,Crystallization buffer: 2.5M sodium malonate (Ph 7.5) and 0.075M sodium bicine (pH 9),291,2016-07-27,2017-08-16,5LLE,2297,1,260,184,,30.17,1,1.9,experimental,15.436,0.215,0.1585,"Crystal structure of human carbonic anhydrase isozyme II with 4-(1-Adamantylamino)-2,3,5,6-tetrafluorobenzenesulfonamide"
5LLG,X-RAY DIFFRACTION,2.01,38.4,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2016-07-27,2017-08-16,5LLG,2495,1,260,306,,30.14,1,1.12,experimental,17.787,0.1671,0.138,Crystal structure of human carbonic anhydrase isozyme II with 4-Propylthiobenzenesulfonamide
5T71,X-RAY DIFFRACTION,2.11,41.67,"VAPOR DIFFUSION, HANGING DROP",,"3 M (NH4)2SO4, 50 mM Tris-HCl",293,2016-09-02,2017-09-06,5T71,2392,1,260,309,,30.06,1,1.3,experimental,15.292,0.17137,0.14807,Human carboanhydrase F131C_C206S double mutant in complex with SA-2
5T72,X-RAY DIFFRACTION,2.09,41.16,"VAPOR DIFFUSION, HANGING DROP",8.5,"3 M (NH4)2SO4, 50 mM Tris-HCl",293,2016-09-02,2017-09-06,5T72,2472,1,260,371,,30.03,1,1.3,experimental,14.517,0.16634,0.14779,Human carboanhydrase F131C_C206S double mutant in complex with 2
5T74,X-RAY DIFFRACTION,2.1,41.3,"VAPOR DIFFUSION, HANGING DROP",8.5,"3 M (NH4)2SO4, 50 mM Tris-HCl",293,2016-09-02,2017-09-06,5T74,2453,1,260,369,,30.06,1,1.2,experimental,13.24,0.16852,0.14942,Human carboanhydrase F131C_C206S double mutant in complex with 14
5YUI,X-RAY DIFFRACTION,2.09,41.2,"VAPOR DIFFUSION, HANGING DROP",,"1.3M sodium citrate, 100mM TrisHCl pH 7.8",293,2017-11-22,2018-08-01,5YUI,2502,1,260,392,,29.53,1,1.2,experimental,13.961,0.13395,0.10467,CO2 release in human carbonic anhydrase II crystals: reveal histidine 64 and solvent dynamics
6CEH,X-RAY DIFFRACTION,2.11,41.68,"VAPOR DIFFUSION, SITTING DROP",,"200 nL 7 mg/mL protein + 200 nL reservoir solution (2.9 M ammonium sulfate, 100 mM Tris buffer, pH 8.3), equilibriated at 281K",281,2018-02-11,2018-05-23,6CEH,2553,1,259,371,,30.06,1,1.43,experimental,11.03,0.208,0.152,"Design, Synthesis, X-ray and Biological Activities of Selenides Bearing the Benzenesulfonamide Moiety as New Class of Agents for Prevention of Diabetic Cerebrovascular Pathology"
6D1L,X-RAY DIFFRACTION,2.09,41.01,"VAPOR DIFFUSION, SITTING DROP",8.6,"200 nL 7 mg/mL protein + 200 nL reservoir (2.8 M ammonium sulfate, 100 mM Tris, pH 8.6)",281,2018-04-12,2018-06-13,6D1L,2573,1,260,325,,30.02,1,1.4,experimental,9.525,0.18077,0.16144,"Design, synthesis, and X-ray of selenides bearing benzenesulfonamide moiety with neuropathic pain modulating effects"
6D1M,X-RAY DIFFRACTION,2.11,41.6,"VAPOR DIFFUSION, SITTING DROP",8.6,"200 nL 7 mg/mL protein + 200 nL reservoir (2.8 M ammonium sulfate, 100 mM Tris, pH 8.6)",281,2018-04-12,2018-06-13,6D1M,2669,1,260,363,,30.08,1,1.21,experimental,10.171,0.15721,0.1321,"Design, synthesis, and X-ray of selenides bearing benzenesulfonamide moiety with neuropathic pain modulating effects"
6G6T,X-RAY DIFFRACTION,2.07,40.2,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2018-04-03,2019-03-13,6G6T,2521,1,260,328,,29.92,1,1.12,experimental,16.1384,0.1774,0.1433,"Crystal structure of human carbonic anhydrase isozyme II with N-butyl-2,4-dichloro-5-sulfamoyl-benzamide"
6YH6,X-RAY DIFFRACTION,1.96,37.2,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE a
nd 3.4M sodium malonate",291,2020-03-28,2021-04-07,6YH6,2313,1,260,207,,29.7,1,1.4,experimental,17.878,0.1971,0.1388,"Crystal structure of chimeric carbonic anhydrase XII with 2-(Cyclooctylamino)-3,5,6-trifluorobenzenesulfonamide"
4V3K,X-RAY DIFFRACTION,2.48,50.33,,,"50 MM TRIS-HCL, PH 8.5 AND 2.3 M AMMONIUM SULFATE",,2014-10-20,2015-04-08,4V3K,5105,6,612,368,,70.34,3,2.04,experimental,26.7,0.2234,0.1807,RNF38-UbcH5B-UB complex
5HTB,X-RAY DIFFRACTION,3.08,60.07,"VAPOR DIFFUSION, SITTING DROP",,52-60% MPD and 0.1 M SPG pH 6.5-7.0,277.15,2016-01-26,2016-05-11,5HTB,3192,2,365,370,,42.36,2,1.7,experimental,24.567,0.18075,0.16171,Crystal structure of haspin (GSG2) in complex with bisubstrate inhibitor ARC-3353
5HTC,X-RAY DIFFRACTION,2.93,58.06,"VAPOR DIFFUSION, SITTING DROP",,52-60% MPD and 0.1 M SPG pH 6.5-7.0,277.15,2016-01-26,2016-03-16,5HTC,3346,2,364,405,,42.36,2,1.5,experimental,21.768,0.17125,0.14962,Crystal structure of haspin (GSG2) in complex with bisubstrate inhibitor ARC-3372
6G38,X-RAY DIFFRACTION,3.04,59.54,"VAPOR DIFFUSION, SITTING DROP",,"51-63% MPD and 0.1M SPG buffer, pH 6.0-6.5",277.15,2018-03-24,2018-04-18,6G38,2907,1,357,269,,41.39,1,1.47,experimental,22.281,0.16544,0.14326,Crystal structure of haspin in complex with tubercidin
6G3A,X-RAY DIFFRACTION,3.03,59.34,"VAPOR DIFFUSION, SITTING DROP",,"51-63% MPD and 0.1M SPG buffer, pH 6.0-6.5",277.15,2018-03-24,2018-04-18,6G3A,2916,1,357,227,,41.48,1,1.43,experimental,20.94,0.175,0.15,Crystal structure of haspin F605T mutant in complex with 5-iodotubercidin
7AVQ,X-RAY DIFFRACTION,2.9,57.63,"VAPOR DIFFUSION, SITTING DROP",,"63% MPD and 0.1 M SPG, pH 6.5",277.15,2020-11-05,2020-11-18,7AVQ,3027,1,357,294,,41.36,1,1.65,experimental,32.098,0.1794,0.1593,"Crystal structure of haspin in complex with disubstituted imidazo[1,2- b]pyridazine inhibitor (compound 12)"
4RFC,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris-HCL pH 7.8, 0.24 mM (final concentration) tert-butyl 6-(4-sulfamoylphenoxy)hexylcarbamate, Vapor diffusion, hanging drop, temperature 298K",298,2014-09-25,2015-04-15,4RFC,2160,1,260,50,,29.7,1,1.645,experimental,20.3204,0.2603,0.2237,Human carbonic anhydrase II in complex with tert-butyl 4-(4-sulfamoylphenoxy)butylcarbamate
5E2S,X-RAY DIFFRACTION,2.09,41.18,"VAPOR DIFFUSION, SITTING DROP",8,"1.5 M sodium citrate, Tris 50 mM",296,2015-10-01,2016-01-20,5E2S,2491,1,258,362,,29.41,1,1.5,experimental,14.272,0.1963,0.1702,Crystal structure of human carbonic anhydrase II in complex with the 4-(2-iso-propylphenyl)benzenesulfonamide inhibitor
5GMN,X-RAY DIFFRACTION,1.87,34.16,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 28% PEGmme2K",277,2016-07-14,2017-05-24,5GMN,2356,1,260,282,,29.72,1,1.8,experimental,,0.2018,0.1547,Crystal structure of human carbonic anhydrase II in complex with polmacoxib
5MJN,X-RAY DIFFRACTION,2.1,42,"VAPOR DIFFUSION, SITTING DROP",9,"1,54 M  SODIUM CITRATE 60 MM TRIS- HCL, PH 9.0, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100%             DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP,                  
TEMPERATURE 294K,  TIME 2-5 DAYS",294,2016-12-01,2017-12-06,5MJN,2427,1,259,319,,29.54,1,1.17,experimental,16.697,0.17349,0.13989,Three dimensional structure of human carbonic anhydrase II in complex with 5-[(4Chlorobenzyl)sulfanyl]thiophene-2-sulfonamide
5N0E,X-RAY DIFFRACTION,2.07,40.61,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 0.1 M Tris-HCl, pH 8.5.",293,2017-02-02,2017-05-10,5N0E,2332,1,262,234,,29.97,1,1.75,experimental,11.6,0.198,0.166,"Crystal structure of human carbonic anhydrase II in complex with (S)-4-(6,7-dihydroxy-1-phenyl-3,4-tetrahydroisoquinoline-1H-2-carbonyl)benzenesulfonamide."
5OGP,X-RAY DIFFRACTION,2.09,41.03,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate 
50 mM Tris-HCl pH 7.8.",291,2017-07-13,2018-08-01,5OGP,2689,1,259,362,,29.53,1,1.1,experimental,16.139,0.1499,0.1244,Metalacarborane inhibitors of Carbonic Anhydrase IX
6E91,X-RAY DIFFRACTION,2.17,43.28,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M NaCitrate
50mM Tris",298,2018-07-31,2019-03-27,6E91,2261,1,257,114,,29.35,1,1.8,experimental,24.1425,0.174,0.1402,CA IX mimic Complexed with Steroidal Sulfamate Compound STX 2484
6E92,X-RAY DIFFRACTION,2.17,43.19,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M NaCitrate
50mM Tris",298,2018-07-31,2019-03-27,6E92,2174,1,257,55,,29.32,1,1.772,experimental,23.2475,0.1891,0.1514,CA IX mimic Complexed with Steroidal Sulfamate Compound STX 2845
6NJ3,X-RAY DIFFRACTION,2.01,38.78,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M AMMONIUM ACETATE, 0.1 M SODIUM
 ACETATE TRIHYDRATE PH 4.6, 30% PEG 4000, VAPOR DIFFUSION,
 HANGING DROP, TEMPERATURE 278K",278,2019-01-02,2019-10-02,6NJ3,2768,1,266,443,,30.37,1,1.01,experimental,,0.125,0.1,Thermostable variant of human carbonic anhydrase with ordered tetrazine 2.0 at site 233
6NJ4,X-RAY DIFFRACTION,1.97,37.67,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M SODIUM CHLORIDE, 0.1 M TRIS PH
 8.5, 25% PEG 3350, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE
 278K",278,2019-01-02,2019-10-02,6NJ4,2697,1,266,393,,30.31,1,1.3,experimental,,0.178,0.154,Thermostable variant of human carbonic anhydrase with disordered tetrazine 2.0 reacted with strained trans-cyclooctene at site 233
6NJ5,X-RAY DIFFRACTION,1.98,37.9,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M SODIUM CHLORIDE, 0.1 M TRIS PH
 8.5, 25% PEG 3350, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE
 278K",278,2019-01-02,2019-10-02,6NJ5,2651,1,266,362,,30.31,1,1.25,experimental,,0.206,0.166,Thermostable variant of human carbonic anhydrase II with disordered tetrazine 2.0 at site 233
6YJ3,X-RAY DIFFRACTION,2.12,41.96,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 MM TRIS-HCL, 1.6 M SODIUM CITRATE",290,2020-04-02,2020-09-09,6YJ3,2533,1,260,305,,30.42,1,1.55,experimental,14.681,0.1545,0.1335,Metala-Carborane di-propyl-sulfonamide
6YKC,X-RAY DIFFRACTION,2.07,40.68,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-04-06,2020-09-09,6YKC,2486,1,260,304,,30.3,1,1.2,experimental,18.981,0.179,0.1474,Metala-Carborane di-ethyl-sulfonamide (trans isomer) in complex with CA IX mimic
6YKH,X-RAY DIFFRACTION,2.04,39.57,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-04-06,2020-09-09,6YKH,2445,1,260,293,,29.79,1,1.1,experimental,17.828,0.1846,0.1491,Metala-Carborane di-ethyl-sulfonamide (cis isomer) in complex with CA IX mimic
6ZR8,X-RAY DIFFRACTION,2.06,40.21,"VAPOR DIFFUSION, HANGING DROP",,"1.2 M Sodium Citrate, 0.1 M Tris-HCl pH 8.5",293,2020-07-11,2021-06-16,6ZR8,2332,1,262,206,,30.01,1,1.79,experimental,13.5192,0.1991,0.1637,The crystal structure of 2-(4-Benzhydrylpiperazin-1-yl)-N-(4-sulfamoylphenyl)acetamide in complex with human carbonic anhydrase II
7JO0,X-RAY DIFFRACTION,2.05,39.93,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris",298,2020-08-05,2020-11-04,7JO0,2398,1,260,218,,29.5,1,1.607,experimental,17.8422,0.183,0.154,"Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)propionamide"
7JO2,X-RAY DIFFRACTION,2.07,40.55,"VAPOR DIFFUSION, HANGING DROP",,"1.6M Sodium Citrate, 50mM Tris",298,2020-08-05,2020-11-04,7JO2,2368,1,260,194,,29.52,1,1.307,experimental,16.7907,0.1905,0.1712,"Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)isobutyramide"
8AAE,X-RAY DIFFRACTION,2.13,42.17,"VAPOR DIFFUSION, HANGING DROP",7.4,"50 mM Tris
1.6 M Natrium Citrate",291,2022-07-01,2023-05-10,8AAE,2507,1,260,282,,29.61,1,1.15,experimental,19.077,0.1831,0.1537,CAII in complex with para-carboran-propylsulfonamid
8C0Q,X-RAY DIFFRACTION,2.09,41.1,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M SODIUM CITRATE, 100 mM TRIS-HCL",293,2022-12-19,2023-03-08,8C0Q,2336,1,261,219,,29.66,1,1.67,experimental,15.487,0.2182,0.1749,Crystal structure of human carbonic anhydrase II in complex with a coumarin derivative.
8C0R,X-RAY DIFFRACTION,2.09,41.23,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M SODIUM CITRATE, 100 mM TRIS-HCL",293,2022-12-19,2023-03-08,8C0R,2373,1,260,238,,29.64,1,1.56,experimental,12.6628,0.2005,0.1768,Crystal structure of human carbonic anhydrase II in complex with a coumarin derivative.
8PHL,X-RAY DIFFRACTION,2,38.55,"VAPOR DIFFUSION, SITTING DROP",,2.9 Ammonium sulfate,293,2023-06-20,2024-03-06,8PHL,2337,1,258,256,,29.67,1,1.3,experimental,14.147,0.19448,0.17787,Human carbonic anhydrase II containing 4-fluorophenylalanine
8Q0C,X-RAY DIFFRACTION,2.04,39.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"2.9M Ammonium sulfate, 0.1M Tris-HCl",293,2023-07-28,2024-03-06,8Q0C,2329,1,258,228,,29.6,1,1.3,experimental,,0.1974,0.1649,Human carbonic anhydrase II containing 3-fluorotyrosine
8SD1,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM tris base",293,2023-04-06,2024-03-13,8SD1,2345,1,260,215,,29.35,1,1.298,experimental,,0.1491,0.1403,Carbonic anhydrase II radiation damage RT 1-30
8SD6,X-RAY DIFFRACTION,2.11,41.6,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2023-04-06,2024-03-13,8SD6,2293,1,260,177,,29.35,1,1.397,experimental,,0.1536,0.1374,Carbonic anhydrase II radiation damage RT 31-60
8SD7,X-RAY DIFFRACTION,2.13,42.38,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2023-04-06,2024-03-13,8SD7,2297,1,260,174,,29.35,1,1.704,experimental,,0.153,0.1315,Carbonic anhydrase II radiation damage RT 61-90
8SD8,X-RAY DIFFRACTION,2.13,42.34,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M sodium citrate, 50 mM Tris base",293,2023-04-06,2024-03-13,8SD8,2304,1,260,184,,29.35,1,1.789,experimental,,0.16,0.1358,Carbonic anhydrase II radiation damage RT 91-120
8SD9,X-RAY DIFFRACTION,2.14,42.46,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2023-04-06,2024-03-13,8SD9,2299,1,260,183,,29.35,1,1.904,experimental,,0.1632,0.136,Carbonic anhydrase II radiation damage RT 121-150
8SF1,X-RAY DIFFRACTION,2.19,43.78,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM tris base",293,2023-04-10,2024-03-13,8SF1,2240,1,260,116,,29.35,1,1.7,experimental,,0.2074,0.1815,Carbonic anhydrase II XFEL radiation damage RT
5DRS,X-RAY DIFFRACTION,1.99,37.7,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2015-09-16,2016-09-28,5DRS,2451,1,260,250,,30.24,1,1.1,experimental,17.214,0.173,0.144,"Crystal structure of human carbonic anhydraseisozyme II with 3-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
7KG6,X-RAY DIFFRACTION,2.35,47.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M PCTP, pH 7.5, 0.2 M AmSO4, 18-23% PEG3350",295,2020-10-16,2021-03-10,7KG6,4186,1,531,301,,61.39,1,1.96,experimental,31.02,0.2047,0.1725,Structure of human PARG complexed with PARG-322
6Z57,X-RAY DIFFRACTION,3.06,59.79,"VAPOR DIFFUSION, SITTING DROP",6,"57% MPD, 0.1M MIB pH 6.0",277.15,2020-05-26,2020-06-03,6Z57,3146,1,357,378,,41.57,1,1.5,experimental,28.705,0.1875,0.1627,Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004078
6Z5A,X-RAY DIFFRACTION,3.11,60.49,"VAPOR DIFFUSION, SITTING DROP",6,"60.0% MPD, 0.1M SPG pH 6.0",277.15,2020-05-26,2020-06-03,6Z5A,3412,1,357,509,,41.68,1,1.55,experimental,13.897,0.1822,0.1559,Crystal structure of haspin (GSG2) in complex with macrocycle ODS2002941
5UCA,X-RAY DIFFRACTION,2.13,42.38,VAPOR DIFFUSION,,0.1 M Bis-Tris (pH 6.5) and 24% (w/v) PEG 2000 monomethyl ether,293,2016-12-22,2017-02-15,5UCA,7371,4,904,414,,105.75,1,2.117,experimental,40.7213,0.2492,0.1933,Crystal structure of human Heme Oxygenase-2 in complex with Laurate
6DAJ,X-RAY DIFFRACTION,2.2,44.09,MICROBATCH,7,"PEG 3350, malonate",293,2018-05-01,2019-04-03,6DAJ,3729,1,487,,,57.13,1,2.45,experimental,,0.2874,0.2028,Human CYP3A4 bound to an inhibitor
6P0E,X-RAY DIFFRACTION,2.52,51.25,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, 100 mM Lithium Acetate, 15%  (w/v) PEG 3350",293,2019-05-16,2019-12-11,6P0E,6665,4,681,735,,83.4,1,1.85,experimental,44.4857,0.1838,0.1546,"Human DNA Ligase 1 (E346A,E592A) bound to adenylated DNA containing an 8-oxo guanine:adenine base-pair"
6Q1V,X-RAY DIFFRACTION,2.53,51.36,VAPOR DIFFUSION,,"100 mM MES, 100 mM Lithium Acetate, 15% (w/v) PEG 3350",277,2019-08-06,2019-12-11,6Q1V,6365,4,681,466,,83.44,1,1.85,experimental,48.2933,0.1936,0.1625,"Human DNA Ligase 1 (E592R) Bound to an Adenylated, hydroxyl terminated DNA nick"
8RB6,X-RAY DIFFRACTION,2.16,43,"VAPOR DIFFUSION, HANGING DROP",6,"0.1 M MESH, 25% PEG3350",279,2023-12-03,2024-03-06,8RB6,5410,2,646,239,,76.06,1,2,experimental,,0.2266,0.1899,"Structure of Aldo-Keto Reductase 1C3 (AKR1C3) in complex with an inhibitor M689, with the 3-hydroxy-benzoisoxazole moiety. Resolution 2.0A"
8FH6,X-RAY DIFFRACTION,2.71,54.55,"VAPOR DIFFUSION, HANGING DROP",5.5,"25%PEG 3,350, 100 mM Bis-Tris",298,2022-12-13,2023-12-20,8FH6,2860,1,316,220,,37.69,1,1.952,experimental,22.923,0.2056,0.1669,Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And Two AT-001
8FH7,X-RAY DIFFRACTION,2.21,44.22,"VAPOR DIFFUSION, HANGING DROP",5.5,"25%PEG 3,350, 100 mM Bis-Tris",298,2022-12-13,2023-12-20,8FH7,2784,1,316,180,,37.23,1,1.45,experimental,16.608,0.1689,0.1451,Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And AT-003
8FH9,X-RAY DIFFRACTION,2.19,43.9,"VAPOR DIFFUSION, HANGING DROP",5.5,"25%
PEG 3,350, 100 mM Bis-Tris",298,2022-12-13,2023-12-20,8FH9,2765,1,316,148,,37.38,1,1.7,experimental,16.5,0.1818,0.1501,Crystal Structure Of Aldose Reductase (AKR1B1) Complexed With NADP+ And AT-007
5K00,X-RAY DIFFRACTION,2.6,52.71,"VAPOR DIFFUSION, SITTING DROP",,"100mM Hepes pH 7.6, 0.2M NaCl, 13.3% PEG 3350",294,2016-05-17,2017-03-01,5K00,2841,1,335,235,,39.53,1,1.77,experimental,38.41,0.1955,0.1742,MELK in complex with NVS-MELK5
9C1B,X-RAY DIFFRACTION,1.94,36.5,"VAPOR DIFFUSION, HANGING DROP",,20% PEG3350,295,2024-05-28,2024-09-11,9C1B,5932,4,876,351,,103.96,1,2.27,experimental,38.65,0.2469,0.1992,Crystal structure of GDP-bound human M-RAS protein in crystal form II
6C7W,X-RAY DIFFRACTION,2.1,41.3,"VAPOR DIFFUSION, SITTING DROP",8,"Protein was at 10 mg/mL and was set up in 250 plus 250 nL drops with a reservoir of 50 mM Tris pH 8.0, 2.8 M ammonium sulfate",281,2018-01-23,2018-05-23,6C7W,2579,1,260,322,,29.72,1,1.28,experimental,14.74,0.1515,0.11741,"Carbonic anhydrase 2 in complex with [(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDRO-2-FURANYL]METHYL SULFAMATE inhibitor"
6C7X,X-RAY DIFFRACTION,2.1,41.37,"VAPOR DIFFUSION, SITTING DROP",8,"Protein was at 10 mg/mL and was set up in 250 plus 250 nL drops with a reservoir of 50 mM Tris pH 8.0, 2.8 M ammonium sulfate at 8C",281,2018-01-23,2018-05-23,6C7X,2470,1,260,289,,29.76,1,1.5,experimental,14.567,0.18757,0.15368,Carbonic anhydrase 2 in complex with 2-chloro-5'-O-sulfamoyladenosine
6YPW,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, HANGING DROP",8,"1.2 M sodium citrate, 50 mM Tris pH 8.0",293,2020-04-16,2021-04-28,6YPW,2438,1,260,306,,29.83,1,1.1,experimental,12.45,0.132,0.1143,"Crystal structure for the complex of human carbonic anhydrase II and 4-((1-(2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)benzenesulfonamide"
7QGX,X-RAY DIFFRACTION,2.06,40.37,"VAPOR DIFFUSION, SITTING DROP",,Crystallization buffer was 0.1M sodium BICINE (pH 9.0) and 2M sodium malonate (pH 7.0),291,2021-12-10,2022-05-04,7QGX,2550,1,260,360,,29.93,1,1.19,experimental,14.856,0.2111,0.1859,Human carbonic anhydrase II in complex with 3-((5-chloro-4-(4-chlorophenyl)thiazol-2-yl)(4-sulfamoylphenyl)amino)propanoic acid
7QGY,X-RAY DIFFRACTION,2.07,40.58,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer: 0.1M sodium bicine (pH 9.0), 0.2M ammonium sulfate and 2M sodium malonate (pH 7.0).",291,2021-12-10,2022-05-04,7QGY,2453,1,260,296,,29.77,1,1.5,experimental,14.09,0.1943,0.1549,Human carbonic anhydrase II in complex with 3-((5-(ethoxycarbonyl)-4-methylthiazol-2-yl)(4-sulfamoylphenyl)amino)propanoic acid
7QGZ,X-RAY DIFFRACTION,2.08,40.84,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer: 0.1M sodium bicine (pH 9.0), 0.2M ammonium sulfate and 2M sodium malonate (pH 7.0)",291,2021-12-10,2022-05-04,7QGZ,2473,1,260,296,,29.71,1,1.13,experimental,13.507,0.2173,0.1983,Human carbonic anhydrase II in complex with Methyl 3-((4-methylthiazol-2-yl)(4-sulfamoylphenyl)amino)propanoate
4YBS,X-RAY DIFFRACTION,2.36,47.96,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.2-2.4M ammonium sulfate, 0.1M HEPES buffer pH 7.5, 2% PEG400 and 8-9% glycerol",298,2015-02-19,2015-06-24,4YBS,1633,1,184,146,,22.03,1,1.83,experimental,38.63,0.231,0.167,"Crystal structure of TRIM24 PHD-bromodomain complexed with N-{1,3-dimethyl-6-[3-(2-methylpropoxy)phenoxy]-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl}-1,2-dimethyl-1H-imidazole-4-sulfonamide (7g)"
4YBT,X-RAY DIFFRACTION,2.37,48.01,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.2-2.4M ammonium sulfate, 0.1M HEPES buffer pH 7.5, 2% PEG400 and 8-9% glycerol",298,2015-02-19,2015-06-24,4YBT,1638,1,184,150,,22.04,1,1.82,experimental,42.04,0.209,0.167,"Crystal structure of TRIM24 PHD-bromodomain complexed with N-{1,3-dimethyl-2-oxo-6-[3-(oxolan-3-ylmethoxy)phenoxy]-2,3-dihydro-1H-1,3-benzodiazol-5-yl}-1-methyl-1H-imidazole-4-sulfonamide (7l)"
5UZU,X-RAY DIFFRACTION,2.82,56.4,"VAPOR DIFFUSION, HANGING DROP",7,"20% w/v PEG-3350
0.2M ammonium citrate, pH 7.0",298,2017-02-27,2017-07-26,5UZU,5425,2,649,169,6,75.27,2,2.403,experimental,,0.2414,0.184,Immune evasion by a Staphylococcal Peroxidase Inhibitor that blocks myeloperoxidase
6AZP,X-RAY DIFFRACTION,2.88,57.33,"VAPOR DIFFUSION, HANGING DROP",7,"20% w/v PEG3350, 0.2 M ammonium citrate, pH 7.0",298,2017-09-11,2017-12-27,6AZP,5432,2,637,282,6,73.85,2,2.291,experimental,42.0145,0.2291,0.179,A Structurally Dynamic N-terminal Region Drives Function of the Staphylococcal Peroxidase Inhibitor (SPIN)
5EHE,X-RAY DIFFRACTION,2.01,38.5,"VAPOR DIFFUSION, SITTING DROP",7.5,Crystallization buffer contains 0.1M sodium bicine (pH 9) and 2.6M sodium malonate (pH 7.5),291,2015-10-28,2016-11-09,5EHE,2400,1,260,218,,30.24,1,1.5,experimental,16.823,0.211,0.18,"Crystal structure of human carbonic anhydrase isozyme II with 3-(benzylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
9FLC,X-RAY DIFFRACTION,3.03,59.37,"VAPOR DIFFUSION, SITTING DROP",,"63% MPD, 0.1M SPG 7.0",277,2024-06-04,2024-09-11,9FLC,2841,1,357,173,,41.21,1,2.18,experimental,39.187,0.19705,0.16485,Crystal structure of haspin (GSG2) in complex with MU1668
8BBH,X-RAY DIFFRACTION,2.51,51.01,EVAPORATION,,"0.2 M Calcium acetate hydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 18% w/v Polyethylene glycol 8,000",300,2022-10-13,2022-12-21,8BBH,3681,3,450,336,4,48.74,3,1.619,experimental,25.727,0.2291,0.1976,The crystal structure of a mouse Fab fragment TL1 in complex with a human Glucose-6-phosphate isomerase peptide 293-307
7MSS,X-RAY DIFFRACTION,2.27,45.84,"VAPOR DIFFUSION, HANGING DROP",,"22.5% (w/v) PEG3350, 100 mM Ammonium succinate pH 7.5, 100 mM Tris-HCl 7.4",294,2021-05-12,2022-10-12,7MSS,5628,2,710,273,,77.53,2,1.75,experimental,42.4354,0.2269,0.2019,"Human E105Qa GTP-specific succinyl-CoA synthetase complexed with succinate, magnesium ion and CoA"
8BT0,X-RAY DIFFRACTION,1.92,35.9,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2022-11-27,2022-12-14,8BT0,3036,1,383,102,7,44.83,1,1.6,experimental,,0.2149,0.1889,Notum Inhibitor ARUK3005518
7YBC,X-RAY DIFFRACTION,2.54,51.66,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M Sodium acetate trihydrate, 20 % w/v Polyethylene glycol 3,350, 0.1 M Bis Tris propane",277,2022-06-29,2023-07-05,7YBC,3937,2,468,310,2,53.92,2,1.84,experimental,37.06,0.1987,0.1776,Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with (S)-4-hydroxy-4-methyl-2-oxoglutarate and factor X-derived peptide (39mer-4Ser)
5TL6,X-RAY DIFFRACTION,2.53,51.34,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M lithium sulfate, 0.1 M Bis-tris [pH 6.5], 22% PEG 3350, supplemented with 30% (v/v) glycerol additive in a 1:5 dilution",293,2016-10-10,2017-05-03,5TL6,6323,4,796,131,,89.66,2,2.618,experimental,,0.2496,0.1909,Crystal structure of SARS-CoV papain-like protease in complex with the C-terminal domain of human ISG15
5CLU,X-RAY DIFFRACTION,2.1,41.44,"VAPOR DIFFUSION, HANGING DROP",,"2.5 M (NH4)2SO4, 0.3 M NaCl, 100 mM Tris-HCl (pH 8.2)",293,2015-07-16,2015-11-11,5CLU,2396,1,257,266,,29.33,1,1.55,experimental,,0.186,0.16,THE CRYSTAL STRUCTURE OF THE COMPLEX of HCAII WITH A SACCHARINE DERIVATIVE
6SDH,X-RAY DIFFRACTION,2.08,40.89,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-07-27,2020-08-26,6SDH,2486,1,265,162,,30.73,1,1.04,experimental,14.88,0.1475,0.1311,Human Carbonic Anhydrase II in complex with an inhibitor soaked at a concentration of 5 mM
6SDI,X-RAY DIFFRACTION,2.07,40.64,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-07-27,2020-08-26,6SDI,2475,1,265,174,,30.73,1,1.03,experimental,13.79,0.1408,0.1248,Human Carbonic Anhydrase II in complex with an inhibitor soaked at a concentration of 0.01 mM
6SDL,X-RAY DIFFRACTION,2.07,40.61,"VAPOR DIFFUSION, HANGING DROP",7.8,"Sodium citrate 1.4 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-07-28,2020-08-26,6SDL,2568,1,265,213,,30.9,1,1.08,experimental,14.07,0.154,0.1363,Human Carbonic Anhydrase II in complex with (R)-N-(3-(1H-indol-1-yl)-2-methylpropyl)-4-sulfamoylbenzamide
6SFU,X-RAY DIFFRACTION,2.08,40.86,"VAPOR DIFFUSION, HANGING DROP",7.8,"Sodium citrate 1.4 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-08-02,2020-08-26,6SFU,2624,1,265,231,,31.06,1,1.04,experimental,11.55,0.1383,0.1255,Human Carbonic Anhydrase II in complex with a furan-containing benzenesulfonamide
5DKA,X-RAY DIFFRACTION,,,EVAPORATION,,"0.1 M HEPES, 10% PEG 8K",273,2015-09-03,2016-07-27,5DKA,1653,2,464,132,,53.54,1,1.55,experimental,28.216,0.2392,0.20983,A C2HC zinc finger is essential for the activity of the RING ubiquitin ligase RNF125
6NJ2,X-RAY DIFFRACTION,2.42,49.08,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M AMMONIUM SULFATE, 30% PEG 4000,
 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 278K",278,2019-01-02,2019-10-02,6NJ2,4807,2,532,579,,61.08,1,1.5,experimental,,0.196,0.172,thermostable carbonic anhydrase II variant with tetrazine 2.0 at site 186
5YWM,X-RAY DIFFRACTION,2.06,36.49,VAPOR DIFFUSION,,"PEG 4000, Lithium sulfate monohydrate",277,2017-11-29,2018-12-05,5YWM,2799,1,339,142,,40.48,1,1.939,experimental,,0.2435,0.1907,Crystal structure of CK2a2 form-1
5E50,X-RAY DIFFRACTION,2.01,38.8,"VAPOR DIFFUSION, HANGING DROP",,"Protein complex at 10 mg/ml, in 50 mM HEPES pH 7.5, 150 mM NaCl, 5 mM beta-mercaptoethanol.  The complex crystallised from hanging drops set up at 18 oC with equal volumes of protein and reservoir solution 0.1M Tris pH 8.0, 30% w/v PEG 3350, 0.2M MgCl2.",293,2015-10-07,2015-11-18,5E50,2285,4,240,402,,26.66,2,1.376,experimental,,0.1737,0.1365,APLF/XRCC4 complex
5W7W,X-RAY DIFFRACTION,2.04,39.67,"VAPOR DIFFUSION, SITTING DROP",7,3.5M sodium formate,293,2017-06-21,2018-05-02,5W7W,2019,2,216,337,,24.05,1,1.348,experimental,,0.1642,0.1472,Crystal Structure of FHA domain of human APLF
7B8N,X-RAY DIFFRACTION,1.98,37.75,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-13,2022-01-12,7B8N,2929,1,383,124,6,44.95,1,1.56,experimental,26.5241,0.2478,0.214,Notum-Fragment 197
6TUZ,X-RAY DIFFRACTION,2,38.51,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium sulphate
0.1 M sodium citrate pH4.2",300,2020-01-08,2020-10-28,6TUZ,3219,1,383,177,7,46,1,1.24,experimental,21.2903,0.2167,0.2013,Theophylline-Notum complex
4QSA,X-RAY DIFFRACTION,2,38,"VAPOR DIFFUSION, SITTING DROP",7,"2M sodium malonate pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-07-03,2015-01-21,4QSA,2475,1,260,270,,30.11,1,1.501,experimental,15.163,0.205,0.166,"Crystal structure of human carbonic anhydrase isozyme II with 2-chloro-4-{[(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]acetyl}benzenesulfonamide"
4QSI,X-RAY DIFFRACTION,2.04,39.73,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M sodium BICINE, pH 9, 3.1M sodium malonate pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-07-04,2015-01-21,4QSI,2295,1,260,176,,30.07,1,1.95,experimental,19.583,0.209,0.157,"Crystal structure of human carbonic anhydrase isozyme II with 5-{[(4-tert-buthyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]acetyl}-2-chlorobenzenesulfonamide"
7QNG,X-RAY DIFFRACTION,4.04,69.59,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Gly-Gly, AMPD, pH 8.5, 300 mM lithium sulfate, 300 mM sodium sulfate, 300 mM potassium sulfate, 20% (v/v) PEG8000, 40% (v/v) 1,5-pentanediol",291.15,2021-12-20,2022-09-28,7QNG,9726,4,1301,52,7,146.4,4,2.7,experimental,106.17,0.2289,0.1983,Structure of a MHC I-Tapasin-ERp57 complex
4XE1,X-RAY DIFFRACTION,2.07,40.7,"VAPOR DIFFUSION, HANGING DROP",,"AMMONIUM SULPHATE 2.6M, TRIS-HCL 0.1M, SODIUM CHLORIDE 0.3M, 4-HYDROXYMERCURYBENZOATE",293,2014-12-21,2015-03-18,4XE1,2317,1,262,219,,30.33,1,1.8,experimental,14.2,0.214,0.168,Human carbonic anhydrase II in complex with 6-SULFAMOYL-SACCHARIN
4ZWI,X-RAY DIFFRACTION,2.1,41.51,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl, pH 7.8",293,2015-05-19,2015-08-26,4ZWI,2416,1,257,271,,30.03,1,1.6,experimental,20.7386,0.2247,0.1789,Surface Lysine Acetylated Human Carbonic Anhydrase II in Complex with a Sulfamate-Based Inhibitor
4ZWX,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCL, pH 7.8",293,2015-05-19,2015-10-28,4ZWX,2338,1,257,198,,29.64,1,1.696,experimental,,0.2121,0.1742,Engineered Carbonic Anhydrase IX mimic in complex with glucosyl sulfamate inhibitor
4ZWZ,X-RAY DIFFRACTION,2.06,40.32,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl pH 7.8",293,2015-05-19,2015-08-05,4ZWZ,2351,1,257,232,,29.52,1,1.62,experimental,21.6383,0.2113,0.1607,Engineered Carbonic Anhydrase IX mimic in complex with a glucosyl sulfamate inhibitor
4ZX1,X-RAY DIFFRACTION,2.09,41.28,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl",293,2015-05-20,2015-10-28,4ZX1,2382,1,257,264,,29.51,1,1.501,experimental,21.1787,0.1955,0.1566,Engineered Carbonic Anhydrase IX mimic in complex with a glucosyl sulfamate inhibitor
5DSO,X-RAY DIFFRACTION,2.06,40.19,"VAPOR DIFFUSION, HANGING DROP",,"1.3M sodium citrate, 100mM TrisHCl pH 7.8",293,2015-09-17,2016-05-04,5DSO,2562,1,260,429,,29.47,1,1.4,experimental,15.859,0.15907,0.11209,Structure of CO2 bound apo-form of human carbonic anhydrase II with 0 sec (no) warming
5E28,X-RAY DIFFRACTION,2.1,41.52,"VAPOR DIFFUSION, SITTING DROP",8,"1.5 M sodium citrate, Tris 50 mM",296,2015-09-30,2016-01-20,5E28,2452,1,257,343,,29.34,1,1.3,experimental,12.948,0.202,0.1779,Crystal structure of human carbonic anhydrase II in complex with the 4-(4-aminophenyl)benzenesulfonamide inhibitor
5E2K,X-RAY DIFFRACTION,2.12,41.9,"VAPOR DIFFUSION, SITTING DROP",8,"1.5 M sodium citrate, Tris 50 mM",296,2015-10-01,2016-01-20,5E2K,2462,1,257,338,,29.59,1,1.4,experimental,13.924,0.1931,0.1677,Crystal structure of human carbonic anhydrase II in complex with the 4-(3-aminophenyl)benzenesulfonamide inhibitor
5E2R,X-RAY DIFFRACTION,2.07,40.58,"VAPOR DIFFUSION, HANGING DROP",8.6,"Na-Citrate,  Tris-HCl",293,2015-10-01,2015-11-04,5E2R,2410,1,262,267,,29.99,1,1.6,experimental,15.6,0.197,0.172,"The crystal structure of the human carbonic anhydrase II in complex with a 1,1'-biphenyl-4-sulfonamide inhibitor"
5J8Z,X-RAY DIFFRACTION,2.07,40.64,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M sodium citrate, 0.1 M TRIS-HCl",293.15,2016-04-08,2016-06-29,5J8Z,2409,1,262,234,,30.61,1,1.7,experimental,12.637,0.1948,0.1624,Human carbonic anhydrase II in complex with ligand
5LLH,X-RAY DIFFRACTION,2.01,38.5,"VAPOR DIFFUSION, SITTING DROP",7.5,Crystallization buffer: 2.03M sodium malonate (pH 7.5),291,2016-07-27,2017-08-16,5LLH,2265,1,260,156,,30.26,1,1.9,experimental,15.821,0.242,0.1822,"Crystal structure of human carbonic anhydrase isozyme II with 4-(1,3-Benzothiazol-2-ylthio)-2,3,5,6-tetrafluorobenzenesulfonamide"
5N0D,X-RAY DIFFRACTION,2.06,40.4,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 0.1 M Tris-HCl, pH 8.5.",293,2017-02-02,2017-05-10,5N0D,2371,1,262,240,,30.06,1,1.7,experimental,12.9,0.209,0.173,"Crystal structure of human carbonic anhydrase II in complex with (R)-4-(6,7-dihydroxy-1-phenyl-3,4-tetrahydroisoquinoline-1H-2-carbonyl)benzenesulfonamide."
6RG3,X-RAY DIFFRACTION,2.09,41.12,"VAPOR DIFFUSION, HANGING DROP",8.3,1.5 M sodium citrate,286,2019-04-16,2020-05-13,6RG3,2405,1,260,261,,29.81,1,1.32,experimental,17.156,0.1973,0.1771,Crystal structure of human Carbonic anhydrase II in complex with (R)-4-(2-benzylpiperazin-1-yl)benzenesulfonamide
6RG4,X-RAY DIFFRACTION,2.08,40.91,"VAPOR DIFFUSION, HANGING DROP",8.3,1.6 sodium citrate,286,2019-04-16,2020-05-13,6RG4,2422,1,260,279,,29.91,1,1.25,experimental,18.175,0.2002,0.1556,Crystal structure of human Carbonic anhydrase II in complex with (R)-4-(2-benzyl-4-methylpiperazin-1-yl)benzenesulfonamide
6SAC,X-RAY DIFFRACTION,2.06,40.02,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 Mte, Tris 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-07-16,2020-04-15,6SAC,2724,1,265,199,,31.07,1,1.02,experimental,11.76,0.1418,0.126,N-terminal expression tag remainder of human Carbonic Anhydrase II covalently modified by fragment
6T9Z,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",,"50 mM TRIS-HCl
1.6 M Sodium Citrat",290,2019-10-29,2020-06-17,6T9Z,2449,1,260,287,,29.59,1,1.12,experimental,11.209,0.1598,0.1435,Nidocarborane inhibitor of Carbonic Anhydrase IX
6UFB,X-RAY DIFFRACTION,2.09,41.19,"VAPOR DIFFUSION, SITTING DROP",,"200 nL 7 mg/mL protein + 200 nL reservoir solution (2.5-2.8 M ammonium sulfate, 100 mM Tris, pH 8.5-9.0)",281,2019-09-24,2020-08-05,6UFB,2466,1,260,258,,30.01,1,1.67,experimental,14.896,0.1859,0.1506,Carbonic anhydrase 2 with inhibitor (2Z)-2-benzylidene-3-oxo-N-(4-sulfamoylphenyl)butanamide (11a/D1)
6UFC,X-RAY DIFFRACTION,2.11,41.78,"VAPOR DIFFUSION, SITTING DROP",,"200 nL 7 mg/mL protein + 200 nL reservoir solution (2.5-2.8 M ammonium sulfate, 100 mM Tris, pH 8.5-9.0)",281,2019-09-24,2020-08-05,6UFC,2510,1,260,270,,29.84,1,1.325,experimental,14.341,0.1443,0.1168,Carbonic anhydrase 2 with inhibitor (2Z)-2-[(4-methoxyphenyl)methylidene]-3-oxo-N-(4-sulfamoylphenyl)butanamide (11d/D4)
6UFD,X-RAY DIFFRACTION,2.12,41.96,"VAPOR DIFFUSION, SITTING DROP",,"200 nL 7 mg/mL protein + 200 nL reservoir solution (2.5-2.8 M ammonium sulfate, 100 mM Tris, pH 8.5-9.0)",281,2019-09-24,2020-08-05,6UFD,2496,1,260,250,,30.02,1,1.48,experimental,13.836,0.1674,0.1494,Carbonic anhydrase 2 with inhibitor (2Z)-3-oxo-N-(4-sulfamoylphenyl)-2-[(thiophen-2-yl)methylidene]butanamide (11g/D7)
7JNR,X-RAY DIFFRACTION,2.06,40.23,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Na Citrate, 50mM Tris",298,2020-08-05,2020-11-04,7JNR,2247,1,260,113,,29.68,1,1.443,experimental,15.6715,0.2488,0.2188,"Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)propionamide"
7JOC,X-RAY DIFFRACTION,2.14,42.53,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris",298,2020-08-06,2020-11-04,7JOC,2391,1,260,200,,29.7,1,1.385,experimental,21.5575,0.1762,0.1573,"Carbonic Anhydrase IX Mimic Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)adamantanecarboxamide"
7NH6,X-RAY DIFFRACTION,2.08,40.89,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2021-02-10,2022-02-23,7NH6,2369,1,260,249,,29.97,1,1.28,experimental,14.394,0.1754,0.1525,"Crystal structure of human carbonic anhydrase II with 3-(3-((1-(2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl)ureido)benzenesulfonamide"
8BOE,X-RAY DIFFRACTION,2.14,42.53,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2022-11-15,2023-11-29,8BOE,2357,1,260,248,,29.87,1,1.55,experimental,11.002,0.1723,0.1535,Human Carbonic Anhydrase I in complex with (S)-4-(3-(1-(6-nitropyridin-2-yl)pyrrolidin-3-yl)thioureido)benzenesulfonamide
5A1R,X-RAY DIFFRACTION,2.36,47.36,,5,"12% PEG 3350, 4% TACSIMATE PH 5.0",,2015-05-04,2015-06-24,5A1R,3798,1,487,7,,56.69,1,2.45,experimental,,0.2617,0.1917,Crystal structure of cytochrome P450 3A4 bound to progesterone
7VTW,X-RAY DIFFRACTION,3.24,62.03,"VAPOR DIFFUSION, HANGING DROP",,"100mM Cacodylate Sodium pH 6.5, 15% Isopropanol, 30% Ethylene Glycol, 11% PEG 3350",277,2021-10-31,2022-11-02,7VTW,2790,1,338,37,1,39.58,1,2.79971328057,experimental,46.2347383513,0.306544390431,0.269541640617,Crystal structure of PDE8A catalytic domain in complex with 17
5KKP,X-RAY DIFFRACTION,2.22,44.52,"VAPOR DIFFUSION, SITTING DROP",7,"23% PEG 3350, 0.2 M Sodium formate, pH7.0",293,2016-06-22,2016-08-17,5KKP,4027,1,563,82,,65.31,1,2.26,experimental,59.6,0.263,0.209,Crystal Structure of Human Pseudouridylate Synthase 7
7LUN,X-RAY DIFFRACTION,2.37,48.05,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Sodium Acetate pH 4.5, 3.0 M Sodium Chloride, 0.2% w/v 2,2'-Thiodiglycolic acid, 0.2% w/v Adipic acid, 0.2% w/v Benzoic acid, 0.2% w/v Oxalic acid anhydrous, 0.2% w/v Terephthalic acid, 0.02 M HEPES sodium pH 6.8",291,2021-02-22,2021-04-21,7LUN,12718,8,1552,405,2,180.73,1,2.57,experimental,38.306,0.2784,0.2321,"Human PARP14 (ARTD8), catalytic fragment in complex with RBN011980"
6OHP,X-RAY DIFFRACTION,2.28,46.16,"VAPOR DIFFUSION, SITTING DROP",,"0.2M ammonium tartrate di-basic, 22% PEG 3350",298,2019-04-06,2020-02-19,6OHP,19201,4,2560,245,,294.13,1,2.6,experimental,,0.2758,0.2397,Structure of compound 1 (halopemide) bound human Phospholipase D2 catalytic domain
6YUW,X-RAY DIFFRACTION,1.96,37.17,"VAPOR DIFFUSION, SITTING DROP",4,"1.4 M AMMONIUM SULPHATE, 0.1 M CITRIC ACID, PH 4.0",295,2020-04-27,2020-05-06,6YUW,3087,1,383,150,7,44.17,1,1.94,experimental,37.9,0.2268,0.1925,STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLE-3-CARBOXYLIC ACID FRAGMENT 454
6YV0,X-RAY DIFFRACTION,1.96,37.4,"VAPOR DIFFUSION, SITTING DROP",4,"1.4 M AMMONIUM SULPHATE, 0.1 M CITRIC ACID, PH 4.0",295,2020-04-27,2020-05-13,6YV0,3059,1,383,109,8,44.36,1,2,experimental,47.18,0.2343,0.2114,STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLIDINE-3-CARBOXYLIC ACID FRAGMENT 587
6YV2,X-RAY DIFFRACTION,1.97,37.7,"VAPOR DIFFUSION, SITTING DROP",4,"1.4 M AMMONIUM SULPHATE, 0.1 M CITRIC ACID, PH 4.0",295,2020-04-27,2020-05-13,6YV2,3063,1,383,107,7,44.45,1,2.1,experimental,47.81,0.2263,0.2126,STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLIDINE-3-CARBOXYLIC ACID FRAGMENT 598
6YV4,X-RAY DIFFRACTION,1.98,37.95,"VAPOR DIFFUSION, SITTING DROP",4,"1.4 M AMMONIUM SULPHATE, 0.1 M CITRIC ACID, PH 4.0",295,2020-04-27,2020-05-06,6YV4,3103,1,383,135,7,44.47,1,2,experimental,45.91,0.2327,0.1814,STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLE-3-CARBOXYLIC ACID FRAGMENT 686
4UYU,X-RAY DIFFRACTION,2.31,46.66,,7.5,20 %W/V PEG 3350 0.1 M BT PROPANE PH 6.5 0.2 M NAI,,2014-09-03,2015-02-25,4UYU,5644,2,766,62,14,89.04,1,2.3,experimental,46.897,0.24346,0.20838,STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM I IODIDE COMPLEX - 2.3A
4UZL,X-RAY DIFFRACTION,2.2,45,,5,"10 %W/V POLYETHYLENE GLYCOL 6000, 0.1 M CITRATE PH 5.0",,2014-09-05,2015-02-25,4UZL,5626,2,772,45,14,88.62,1,2.1,experimental,65.249,0.25332,0.21358,STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM I MYRISTOLEATE COMPLEX - 2.1A
5H1V,X-RAY DIFFRACTION,2.39,48.43,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, 2%(v/v) Polyethylene glycol 400, 2.0 M Ammonium sulfate",293,2016-10-11,2017-02-22,5H1V,2941,2,366,143,,43.25,1,2.002,experimental,34.8989,0.2203,0.1804,Complex structure of TRIM24 PHD-bromodomain and inhibitor 6
5WY9,X-RAY DIFFRACTION,1.88,34.75,"VAPOR DIFFUSION, SITTING DROP",,"0.05M Potassium thiocyanate, 30%PEG MME 2000",277.15,2017-01-11,2017-01-25,5WY9,1454,1,176,129,,20.24,1,1.45,experimental,20.528,0.2109,0.17625,Apo form crystal structure of human Lipocalin PGDS .
4PYX,X-RAY DIFFRACTION,2,38,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-03-28,2015-01-28,4PYX,2284,1,260,168,,30.04,1,1.8,experimental,18.991,0.23,0.178,Crystal structure of human carbonic anhydrase isozyme II with inhibitor
4PZH,X-RAY DIFFRACTION,2,38,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-03-31,2015-01-28,4PZH,2527,1,260,277,,30.19,1,1.06,experimental,16.575,0.162,0.135,"Crystal structure of human carbonic anhydrase isozyme II with 2,3,5,6-tetrafluoro-4[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
4Q08,X-RAY DIFFRACTION,1.99,37.7,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-04-01,2015-01-28,4Q08,2663,1,260,338,,30.14,1,1.07,experimental,14.485,0.156,0.128,Crystal structure of chimeric carbonic anhydrase XII with inhibitor
7JNX,X-RAY DIFFRACTION,2.04,39.61,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris",298,2020-08-05,2020-11-04,7JNX,2374,1,260,220,,29.79,1,1.286,experimental,13.7922,0.1762,0.1589,"Carbonic Anhydrase II Complexed with N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)pivalamide"
4YU1,X-RAY DIFFRACTION,2.15,42.9,"VAPOR DIFFUSION, HANGING DROP",5,Crystallization solution: 50 mM di-Ammoniumhydrogen citrate pH 5.0 PEG6000= 5 % (m/V) DTT= 5.15 g/L NADP+= 0.66 g/L and Human Aldose Reductase= 15 mg/ml.Afterwards the crystals were soaked into Tris 100 mM 25% (m/V) PEG6000 pH 8.0 saturated with the inhibitor.,291,2015-03-18,2016-03-23,4YU1,3144,1,316,427,,36.92,1,1.02,experimental,,0.1497,0.1326,Human Aldose Reductase complexed with Schl12134 (3-[5-(3-nitrophenyl)-2-thienyl]propanoic acid) at 1.02 A
4UZ6,X-RAY DIFFRACTION,2.6,53,,7.5,"20 %W/V PEG3350, 0.2 M AMMONIUM SULFATE 20MM SOS, pH 7.5",,2014-09-04,2015-02-25,4UZ6,6042,2,766,206,14,89.61,1,1.9,experimental,38.157,0.23513,0.19455,STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM V - SOS COMPLEX - 1.9A
6MV7,X-RAY DIFFRACTION,1.78,30.71,VAPOR DIFFUSION,,"PEG 4000, 50mM Sodium phosphate",298,2018-10-24,2019-11-13,6MV7,1063,1,128,27,4,15.15,1,2.59,experimental,19.0356,0.2519,0.2168,Crystal structure of RNAse 6
6OHM,X-RAY DIFFRACTION,2.09,41.22,"VAPOR DIFFUSION, SITTING DROP",6.7,"0.2M ammonium sulfate, 20% PEG3350, 0.1M bis-tris pH 6.7",298,2019-04-06,2020-02-19,6OHM,10417,2,1280,998,,147.32,1,1.895,experimental,,0.2057,0.1824,Structure of tungstate bound human Phospholipase D2 catalytic domain
7ARG,X-RAY DIFFRACTION,1.92,35.92,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citric, pH4.6",296,2020-10-24,2021-08-04,7ARG,3082,1,383,130,7,44.99,1,1.24,experimental,28.0147,0.1983,0.1803,Notum in complex with ARUK3002704
7B3G,X-RAY DIFFRACTION,1.93,36.3,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-11-30,2021-12-08,7B3G,2942,1,383,121,6,45.1,1,1.28,experimental,23.1599,0.2151,0.2023,Notum complex with ARUK3003902
7B45,X-RAY DIFFRACTION,1.94,36.46,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-12-02,2022-01-12,7B45,2947,1,383,111,6,45.05,1,1.38,experimental,23.7603,0.1941,0.1896,Notum complex with ARUK3003934
4D50,X-RAY DIFFRACTION,2.14,42,,7.2,"30% POLYETHYLENE GLYCOL 6000 (W/V), 100 MM BIS-TRIS PROPANE PH 7.2 - 7.4, 400 MM GUANIDINE CHLORIDE",,2014-10-31,2015-04-15,4D50,4897,2,588,440,,64.57,1,1.7,experimental,18.899,0.2465,0.20261,Structure of human deoxyhypusine hydroxylase
7SVP,X-RAY DIFFRACTION,2.28,46.01,"VAPOR DIFFUSION, SITTING DROP",7.6,"0.08 M sodium cacodylate pH 6.6, 14% PEG 8000, 20% glycerol, 0.16 M calcium acetate",291,2021-11-19,2023-01-25,7SVP,17334,4,2560,197,,292.93,1,2.9,experimental,63.88,0.3266,0.29,Structure of compound 34 bound to human Phospholipase D2 catalytic domain
7R2I,X-RAY DIFFRACTION,1.99,38.04,"VAPOR DIFFUSION, SITTING DROP",7,"15 % PEG 3350, 0.1M K2HPO4",277.15,2022-02-04,2023-02-15,7R2I,1606,1,165,322,,18.32,1,1.31,experimental,12.17,0.1792,0.1396,Human Cyclophilin D in complex with fragment
7R2J,X-RAY DIFFRACTION,1.9,35.14,"VAPOR DIFFUSION, SITTING DROP",7,"15 % PEG 3350, 0.1M K2HPO4",277.15,2022-02-04,2023-02-15,7R2J,1587,1,165,322,,18.14,1,1.26,experimental,11.65,0.1656,0.1401,"Human Cyclophilin D in complex with N-(4-aminophenyl)-7-methyl-2-oxo-1H,2H-pyrazolo[1,5-a]pyrimidine-6-carboxamide"
7R2L,X-RAY DIFFRACTION,2.01,38.88,"VAPOR DIFFUSION, SITTING DROP",7,"15 % PEG 3350, 0.1M K2HPO4",277.15,2022-02-04,2023-02-15,7R2L,1528,1,165,249,,18.35,1,1.1,experimental,14.36,0.1533,0.134,"Human Cyclophilin D in complex with N-(4-aminophenyl)-7-methyl-2-oxo-1H,2H-pyrazolo[1,5-a]pyrimidine-6-carboxamide"
6WYD,X-RAY DIFFRACTION,2.39,48.64,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2020-05-12,2020-10-14,6WYD,18734,8,2288,260,19,271.96,2,2.55,experimental,50.55,0.2539,0.1935,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-12 (AKA; 7-benzyl-1H-[1,2,3]triazolo[4,5-b]pyrid"
5BNB,X-RAY DIFFRACTION,2.31,46.76,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M Tris, 20% PEG 4000",293,2015-05-25,2016-02-17,5BNB,6235,8,928,60,2,104.16,2,2.49,experimental,,0.304,0.243,Crystal structure of a Ube2S-ubiquitin conjugate
6WY0,X-RAY DIFFRACTION,2.43,49.29,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2020-05-12,2020-10-14,6WY0,18744,8,2288,149,17,272.21,2,2.799,experimental,55.74,0.2162,0.1846,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-40 A.K.A 7-[(1R)-1-phenyl-3-{[(1r,4r)-4-phenylcyclohexyl]amino}propyl]-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine"
4ZFC,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, HANGING DROP",6,"15%-20% PEG8000, 100mM MES, 0.14M NaCl",289,2015-04-21,2015-11-25,4ZFC,5596,2,646,367,,75.95,1,2,experimental,22.204,0.21757,0.17284,Crystal structure of AKR1C3 complexed with glicazide
6RL9,X-RAY DIFFRACTION,2.06,40.38,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7, TRIS 0.1 M, pH = 7.8, saturated with para-Chloromercuribenzoic acid",291,2019-05-01,2020-04-15,6RL9,2798,1,265,220,,31.69,1,1,experimental,,0.1296,0.1185,Human Carbonic Anhydrase II in complex with 4-Aminobenzenesulfonamide
6Q9I,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M sodium formate, 20 % w/v PEG 3350",277,2018-12-18,2020-01-15,6Q9I,3972,2,468,330,2,53.85,2,1.852,experimental,59,0.2233,0.202,Aspartyl/Asparaginyl beta-hydroxylase (AspH) H679A in complex with Factor X peptide fragment (39mer-4Ser)
7WKV,X-RAY DIFFRACTION,2.28,45.96,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) monohydrate, 16% (w/v) PEG 6000 and 5% (v/v) 2-methyl-2,4-pentanediol (MPD)",293,2022-01-11,2022-03-30,7WKV,5527,6,684,89,,83.69,1,2.1,experimental,50.5165,0.2275,0.188,Crystal structure of human ALKBH5 in complex with 2-oxoglutarate (2OG) and m6A-containing ssRNA
5QJ2,X-RAY DIFFRACTION,2.42,49.24,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2018-09-26,2019-02-06,5QJ2,18513,8,2288,63,17,272.4,2,2.82,experimental,58.87,0.2716,0.2063,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) OMPLEX WITH COMPOUND-20 AKA 7-((3-(1-METHYL-1H-PYRAZOL-3- YL)BENZYL)OXY)- 1H-[1,2,3]TRIAZOLO[4,5-B]PYRIDIN-5-AMINE"
4Q7B,X-RAY DIFFRACTION,2.17,43.39,"VAPOR DIFFUSION, HANGING DROP",8,"Crystallization solution: 50 mM di-Ammoniumhydrogen citrate pH 5.0 PEG6000= 5 % (m/V) DTT= 5,15 g/L NADP+= 0,66 g/L and Human Aldose Reductase= 15 mg/ml.  
Afterwards the crystals were soaked into Tris 100 mM 25% (m/V) PEG6000 saturated with the inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291,2014-04-24,2015-06-10,4Q7B,2995,1,315,370,,36.81,1,1.19,experimental,,0.1603,0.1376,Human Aldose Reductase complexed with a ligand with an IDD structure ([2-(benzylcarbamoyl)-5-fluorophenoxy]acetic acid) at 1.19 A
4QR6,X-RAY DIFFRACTION,2.18,43.46,"VAPOR DIFFUSION, HANGING DROP",8,"Crystallization solution: 50 mM di-Ammoniumhydrogen citrate pH 5.0 PEG6000= 5 % (m/V) DTT= 5.15 g/L NADP+= 0.66 g/L and Human Aldose Reductase= 15 mg/ml.Afterwards the crystals were soaked into Tris 100 mM 25% (m/V) PEG6000 pH 8.0 saturated with the inhibitor.The well solution was for crystallization was 120mM di-Ammonium hydrogen citrate with 20% PEG6000 pH 5.0., VAPOR DIFFUSION, HANGING DROP, temperature 291K",291,2014-06-30,2015-08-12,4QR6,2976,1,316,355,,37,1,1.05,experimental,,0.1569,0.1405,"Human Aldose Reductase complexed with a ligand with an IDD structure (2-[2-(1,3-benzothiazol-2-ylmethylcarbamoyl)-5-fluoro-phenoxy]acetic acid) at 1.05 A"
4RPQ,X-RAY DIFFRACTION,2.18,43.59,"VAPOR DIFFUSION, HANGING DROP",8,"Crystallization solution: 50 mM di-Ammoniumhydrogen citrate pH 5.0 PEG6000= 5 % (m/V) DTT= 5.15 g/L NADP+=0.66 g/L and Human Aldose Reductase= 15 mg/ml. Afterwards the crystals were soaked into Tris 100 mM 25% (m/V) PEG6000 saturated with the inhibitor., VAPOR DIFFUSION, HANGING DROP, temperature 291K",291,2014-10-31,2015-11-18,4RPQ,2866,1,315,293,,36.92,1,1.2,experimental,,0.1645,0.1421,Human Aldose Reductase complexed with a ligand with an IDD structure at 1.20 A (1)
7B8U,X-RAY DIFFRACTION,1.99,38.33,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-13,2022-01-12,7B8U,2840,1,383,91,6,44.53,1,1.54,experimental,23.112,0.2321,0.2092,Notum-Fragment 201
5IH8,X-RAY DIFFRACTION,2.53,51.37,"VAPOR DIFFUSION, SITTING DROP",,"100mM Hepes pH 7.5, 0.2M sodium chloride, 25% PEG 3350",293,2016-02-29,2016-06-01,5IH8,2782,1,335,247,,39.31,1,1.85,experimental,37.11,0.1995,0.1766,MELK in complex with NVS-MELK1
5IHA,X-RAY DIFFRACTION,2.6,52.62,"VAPOR DIFFUSION, HANGING DROP",,"100mM Hepes, pH 7.6, 0.2M NaCl, 4.5-16.5% PEG3350",277,2016-02-29,2016-06-01,5IHA,2733,1,335,203,,39.35,1,1.96,experimental,41.52,0.2022,0.1733,MELK in complex with NVS-MELK8F
5IHC,X-RAY DIFFRACTION,2.59,52.56,"VAPOR DIFFUSION, HANGING DROP",,"100mM Hepes, pH 7.6, 0.2M NaCl, 4.5-16.5% PEG3350",277,2016-02-29,2016-06-01,5IHC,2663,1,335,106,,39.31,1,2.14,experimental,55.08,0.2084,0.1779,MELK in complex with NVS-MELK12B
7BMJ,X-RAY DIFFRACTION,2.63,53.3,"VAPOR DIFFUSION, SITTING DROP",,"200 mM sodium nitrate, 20% w/v PEG 3350, 1 mM manganese chloride, 18 mg/ml protein",277,2021-01-20,2021-06-02,7BMJ,7546,3,897,351,3,103.48,2,1.75,experimental,62.53,0.2512,0.2208,"Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 5-fluoropyridine-2,4-dicarboxylic acid, and factor X substrate peptide fragment (39mer-4Ser)"
7AGN,X-RAY DIFFRACTION,2.06,40.31,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2020-09-23,2021-09-01,7AGN,10132,4,1040,1336,,119.44,1,1.15,experimental,16.849,0.1861,0.1474,"Human carbonic anhydrase II in complex with 4-(2-aminoethylsulfanyl)-2,3,5,6-tetrafluoro-N-methyl-benzenesulfonamide"
5JQY,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, SITTING DROP",8,"100mM SPG buffer, 25% PEG 1500, 2mM NOG, 1mM MnCl2, 18mg/ml protein",277,2016-05-05,2017-05-24,5JQY,3878,2,468,283,2,53.86,2,1.99,experimental,43.6616,0.2053,0.1914,"Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, N-oxalylglycine and factor X substrate peptide fragment(39mer-4Ser)"
5JZ8,X-RAY DIFFRACTION,2.73,54.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM Bis-tris propane, 200mM sodium acetate, 20% PEG 3350, 1 mM manganese chloride, 2 mM N-oxalylglycine, 726 uM FX peptide, 18 mg/ml protein",277,2016-05-16,2017-05-24,5JZ8,3900,2,468,305,2,53.92,2,2.095,experimental,41.9062,0.2162,0.1881,"Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, N-oxalylglycine, and factor X substrate peptide fragment (39mer)"
5JZU,X-RAY DIFFRACTION,2.79,55.86,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM Bis-tris propane, 20 mM sodium/potassium phosphate, 20% PEG 3350, 1 mM manganese chloride, 2 mM N-oxalylglycine, 1.65 mM factor X peptide, 18 mg/ml asph protein",277,2016-05-17,2017-06-07,5JZU,3561,2,455,87,2,52.39,2,2.5,experimental,55.2026,0.229,0.1925,"Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, N-oxalylglycine and factor X substrate peptide fragment (26mer)"
7BMI,X-RAY DIFFRACTION,2.59,52.6,"VAPOR DIFFUSION, SITTING DROP",7,"100 mM HEPES sodium, 200 mM ammonium chloride, 20% w/v PEG 4000, 1 mM manganese chloride, 2 mM 2-oxoglutarate, 18 mg/ml protein",277,2021-01-20,2021-06-02,7BMI,4009,2,468,375,2,53.84,2,1.66,experimental,48.41,0.2203,0.189,"Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese, 3-fluoropyridine-2,4-dicarboxylic acid, and factor X substrate peptide fragment (39mer-4Ser)"
5QJ3,X-RAY DIFFRACTION,2.59,52.6,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2018-09-26,2019-02-06,5QJ3,9480,4,1144,176,11,135.69,2,2.76,experimental,37.4,0.2282,0.1836,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH COMPOUND-24 AKA 7-({4-CHLORO-3'-FLUORO-[1,1'- BIPHENYL]-3-YL}METHOXY)-3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDIN- 5-AMINE"
6ZYF,X-RAY DIFFRACTION,2.46,50.06,EVAPORATION,7,"0.1 M Hepes pH 7.0
0.1 M KCl
15% PEG MME 5000",296,2020-07-31,2021-03-10,6ZYF,5730,2,766,56,14,88.1,1,2.19,experimental,56.5252,0.2523,0.231,Notum_Ghrelin complex
6OTK,X-RAY DIFFRACTION,2.13,42.27,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris-HCl, pH 7.8",298,2019-05-03,2020-05-06,6OTK,2294,1,257,206,,29.31,1,1.123,experimental,18.5047,0.1731,0.1686,Carbonic Anhydrase IX mimic complexed with ureido benzene sulfonamide MB10-596B
6OTM,X-RAY DIFFRACTION,2.09,41.14,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate, 50mM Tris-HCl, pH 7.8",298,2019-05-03,2020-05-06,6OTM,2412,1,257,315,,29.43,1,1.307,experimental,18.226,0.1792,0.1642,Carbonic Anhydrase IX mimic complexed with ureic benzene sulfonamide MB10-586B
6OUB,X-RAY DIFFRACTION,2.09,41.02,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M sodium citrate, 50mM Tris-HCl, pH7.8",298,2019-05-04,2020-05-06,6OUB,2433,1,257,289,,29.79,1,1.418,experimental,19.9365,0.1925,0.1602,Carbonic Anhydrase II complexed with benzene sulfonamide MB11-694B
6OUE,X-RAY DIFFRACTION,2.06,40.4,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M sodium citrate, 50mM Tris HCl, pH 7.8",298,2019-05-04,2020-05-06,6OUE,2409,1,257,273,,29.66,1,1.415,experimental,20.5845,0.1947,0.1673,Carbonic Anhydrase II complexed with benzene sulfonamide MB11-707A
6OUF,X-RAY DIFFRACTION,2.11,41.68,"VAPOR DIFFUSION, HANGING DROP",,"1.6M sodium citrate, 50mM Tris HCl, pH 7.8",298,2019-05-04,2020-05-06,6OUF,2391,1,257,269,,29.58,1,1.358,experimental,20.4111,0.1755,0.1625,Carbonic Anhydrase IX mimic complexed with benzene sulfonamide MB11-707A
6OUH,X-RAY DIFFRACTION,2.1,41.46,"VAPOR DIFFUSION, HANGING DROP",,"1.6M sodium citrate, 50mM Tris HCl, pH 7.8",298,2019-05-04,2020-05-06,6OUH,2400,1,257,287,,29.76,1,1.449,experimental,20.0084,0.1937,0.162,Carbonic Anhydrase II mimic complexed with benzene sulfonamide MB11-710A
6OUK,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",,"1.6M sodium citrate, 50mM Tris HCl, pH 7.8",298,2019-05-04,2020-05-06,6OUK,2388,1,257,248,,29.64,1,1.498,experimental,20.3682,0.1857,0.1677,Carbonic Anhydrase II complexed with benzene sulfonamide MB10-580B
6OUM,X-RAY DIFFRACTION,2.09,41.28,"VAPOR DIFFUSION, HANGING DROP",,"1.6M sodium citrate, 50mM Tris HCl, pH 7.8",298,2019-05-04,2020-05-06,6OUM,2226,1,257,155,,29.23,1,1.559,experimental,17.5746,0.3035,0.2533,Carbonic Anhydrase IX mimic complexed with benzene sulfonamide MB10-580B
7BI5,X-RAY DIFFRACTION,2.08,40.94,"VAPOR DIFFUSION, HANGING DROP",8,"1.3 M sodium citrate, 0.1 M Tris-HCl",293,2021-01-12,2021-03-17,7BI5,2260,1,260,194,,29.46,1,1.74,experimental,11.7522,0.1938,0.1695,Human CA II in complex with benzyl alcohol
7NH8,X-RAY DIFFRACTION,2.13,42.35,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2021-02-10,2022-02-23,7NH8,2331,1,260,204,,29.89,1,1.369,experimental,17.412,0.1899,0.1618,"Crystal structure of human carbonic anhydrase II with N-((1-(6-((3aR,7R,7aS)-7-hydroxy-2,2-dimethyltetrahydro-[1,3]dioxolo[4,5-c]pyridin-5(4H)-yl)hexyl)-1H-1,2,3-triazol-4-yl)methyl)-4-sulfamoylbenzamide"
7QRK,X-RAY DIFFRACTION,2.08,40.79,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",293,2022-01-11,2023-01-25,7QRK,2352,1,260,227,,29.91,1,1.428,experimental,15.347,0.1696,0.1515,Human Carbonic Anhydrase II in complex with N-(2-aminophenyl)-4-((2-oxo-2-((4-sulfamoylphenethyl)amino)ethyl)amino)benzamide
7QSE,X-RAY DIFFRACTION,2.08,40.89,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",293,2022-01-13,2023-01-25,7QSE,2332,1,260,221,,29.9,1,1.428,experimental,14.597,0.1642,0.147,human Carbonic Anhydrase II in complex with N-(2-aminophenyl)-4-((2-oxo-2-((4-sulfamoylbenzyl)amino)ethyl)amino)benzamide
8BZZ,X-RAY DIFFRACTION,2.1,41.39,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2022-12-15,2023-12-27,8BZZ,2458,1,260,299,,29.94,1,1.07,experimental,13.724,0.154,0.1303,Crystal structure of carbonic anhydrase 2 4-(dimethylamino)-N-nitrobenzenesulfonamide
8OTP,X-RAY DIFFRACTION,2.1,41.49,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2023-04-21,2024-05-01,8OTP,2379,1,260,199,,29.96,1,1.4,experimental,16.103,0.177,0.1242,"Crystal structure of human carbonic anhydrase II with 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(4-sulfamoylbenzoyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid"
8QF9,X-RAY DIFFRACTION,2.12,41.89,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2023-09-04,2024-09-11,8QF9,2430,1,260,259,,30.45,1,1.277,experimental,12.063,0.1631,0.1299,Human Carbonic Anhydrase II in complex with (3-((N-(4-sulfamoylphenethyl)phenylsulfonamido)methyl)phenyl)glycine
8QFK,X-RAY DIFFRACTION,2.12,42.03,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 50 mM Tris pH  8.0",296,2023-09-04,2024-09-11,8QFK,2437,1,260,316,,29.87,1,1.11,experimental,15.508,0.1397,0.1163,Human Carbonic Anhydrase II in complex with (3-((N-(4-sulfamoylbenzyl)methylsulfonamido)methyl)phenyl)glycine
8SAG,X-RAY DIFFRACTION,2.12,41.97,"VAPOR DIFFUSION, HANGING DROP",7.8,1.6 M sodium citrate 50mM tris base,293,2023-03-31,2024-04-03,8SAG,2313,1,260,224,,29.83,1,1.52,experimental,,0.1909,0.1726,Carbonic anhydrase II in complex with the coumarin benzene sulfonamide SG1-57
6I3E,X-RAY DIFFRACTION,2.06,40.41,"VAPOR DIFFUSION, HANGING DROP",7.8,"Trisodium citrate dihydrate 1.40 M, Tris 0.1 M, pH = 7.8, saturated with para-Chloromercuribenzoic acid.",291,2018-11-05,2019-11-20,6I3E,2731,1,265,237,,31.25,1,1.07,experimental,,0.1465,0.1292,Human Carbonic Anhydrase II in complex with 4-Butylbenzenesulfonamide
6QL2,X-RAY DIFFRACTION,2.05,40.01,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2019-01-31,2019-09-25,6QL2,2379,1,260,225,,30.19,1,1.3,experimental,20.4793,0.1573,0.1189,Crystal structure of chimeric carbonic anhydrase VI with ethoxzolamide.
4WR7,X-RAY DIFFRACTION,2.36,47.5,"VAPOR DIFFUSION, SITTING DROP",8.4,"0.1M TrisHCl (pH 8.5), 0.2M sodium acetate (pH 8.3), 28% PEG3350",291,2014-10-23,2015-07-01,4WR7,4744,2,520,516,,58.76,1,1.5,experimental,21.009,0.232,0.195,"Crystal structure of human carbonic anhydrase isozyme I with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide."
5OGN,X-RAY DIFFRACTION,1.95,36.8,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl pH 7.8",291,2017-07-13,2018-08-01,5OGN,4507,2,518,329,,59.29,1,1.1,experimental,18.018,0.202,0.1752,Metalacarborane inhibitors of Carbonic Anhydrase IX
6H6S,X-RAY DIFFRACTION,2.06,40.25,"VAPOR DIFFUSION, SITTING DROP",8,"100 mM HEPES, 2.9 M ammonium sulfate",293,2018-07-30,2019-01-09,6H6S,4779,2,518,659,,58.55,1,1.45,experimental,16.416,0.20365,0.14973,Sad phasing on nickel-substituted human carbonic anhydrase II
7LAG,X-RAY DIFFRACTION,2.36,47.81,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2021-01-06,2021-04-21,7LAG,18458,8,2284,,22,271.31,2,2.85,experimental,43.9,0.2354,0.1925,"CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-14 AKA 7-({1-[(3-phenoxyphenyl)methyl]-1H-pyrazol-4-yl}methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine"
7QNV,X-RAY DIFFRACTION,2.1,41.31,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",293,2021-12-22,2023-01-18,7QNV,2354,1,260,233,,29.84,1,1.278,experimental,11.008,0.1839,0.1635,human carbonic anhydrase II bound to 3-methylbenzoselenoate
5WG7,X-RAY DIFFRACTION,2.1,41.53,"VAPOR DIFFUSION, SITTING DROP",7.8,1.6 M sodium citrate and 50 mM Tris,298,2017-07-13,2018-02-07,5WG7,2349,1,257,161,,30.25,1,1.45,experimental,,0.1761,0.1418,Human Carbonic Anhydrase II complexed with AceK
7B8G,X-RAY DIFFRACTION,1.98,37.93,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B8G,2863,1,383,118,6,44.56,1,1.58,experimental,26.053,0.2416,0.2197,Notum-Fragment 159
7B9D,X-RAY DIFFRACTION,2.03,39.26,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-14,2022-01-12,7B9D,2754,1,383,52,6,44.38,1,1.93,experimental,29.1566,0.2641,0.236,Notum Fragment 290
7BCC,X-RAY DIFFRACTION,1.98,38.02,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-19,2022-01-12,7BCC,2982,1,383,92,8,44.5,1,1.58,experimental,25.0381,0.2346,0.2177,Notum Fragment 705
7BCF,X-RAY DIFFRACTION,2.01,38.75,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-19,2022-01-12,7BCF,2816,1,383,81,6,44.52,1,1.86,experimental,29.693,0.2592,0.2227,Notum Fragment 722
7BCH,X-RAY DIFFRACTION,2,38.61,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-19,2022-01-12,7BCH,2822,1,383,94,6,44.35,1,1.7,experimental,25.7531,0.2469,0.2159,Notum Fragment 772
7BCI,X-RAY DIFFRACTION,1.98,37.95,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-19,2022-01-12,7BCI,2750,1,383,49,6,44.63,1,1.94,experimental,27.1844,0.2482,0.2372,Notum Fragment 784
7BD3,X-RAY DIFFRACTION,2,38.58,"VAPOR DIFFUSION, SITTING DROP",,"ETGSAQQLNEDLRLHLLLNTSVTCNDGSPAGYYLKESRGSRRW
LLFLEGGWYCFNRENCDSRYDTMRRLMSSRDWPRTRTGTGILSSQPEENPYWWNANMVFI
PYCSSDVWSGASSKSEKNEYAFMGALIIQEVVRELLGRGLSGAKVLLLAGSSAGGTGVLL
NVDRVAEQLEKLGYPAIQVRGLADSGWFLDNKQYRHTDCVDTITCAPTEAIRRGIRYWNG
VVPERCRRQFQEGEEWNCFFGYKVYPTLRSPVFVVQWLFDEAQLTVDNVHLTGQPVQEGL
RLYIQNLGRELRHTLKDVPASFAPACLSHEIIIRSHWTDVQVKGTSLPRALHCWDRSLHD
SHKASKTPLKGCPVHLVDSCPWPHCNPSCPTGTKHHHHHH",296,2020-12-21,2022-01-12,7BD3,2993,1,383,97,7,44.47,1,1.91,experimental,30.9556,0.2648,0.2151,Notum Fragment 823
7BD4,X-RAY DIFFRACTION,1.97,37.55,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BD4,2995,1,383,115,8,44.42,1,1.8,experimental,23.8522,0.2307,0.2066,Notum Fragment 828
7BD5,X-RAY DIFFRACTION,2.01,38.75,"VAPOR DIFFUSION, SITTING DROP",,".5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-21,2022-01-12,7BD5,2774,1,383,75,6,44.16,1,1.69,experimental,24.8058,0.2327,0.201,Notum Fragment 830
5J87,X-RAY DIFFRACTION,2.29,46.36,EVAPORATION,6.5,"0.2M magnesium chloride ,0.1M sodium cacodylate pH6.5, 31% PEG 2000 , 0.1M sodium iodide",298,2016-04-07,2017-04-19,5J87,9721,4,1096,864,,130.06,1,1.59,experimental,,0.2477,0.2165,"Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a Highly Selective Irreversible BTK Kinase Inhibitor"
7SUM,X-RAY DIFFRACTION,2.87,57.13,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.6, 100 mM lithium acetate, 20% w/v PEG3350",293,2021-11-17,2022-07-13,7SUM,5887,4,694,140,,84.38,1,2.9,experimental,53.89,0.227,0.18,Crystal structure of human ligase I with nick duplexes containing cognate A:T
7SX5,X-RAY DIFFRACTION,2.6,52.68,"VAPOR DIFFUSION, HANGING DROP",6.6,"100 mM MES pH 6.6, 100 mM lithium acetate, 20% (w/v) polyethylene glycol PEG3350",293,2021-11-22,2022-07-13,7SX5,5877,4,705,182,,85.65,1,2.8,experimental,38.3039,0.2119,0.1752,Crystal structure of ligase I with nick duplexes containing mismatch A:C
8VDN,X-RAY DIFFRACTION,2.79,55.9,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.4, 100 mM Lithium acetate, 12% w/v PEG 3350",298.15,2023-12-16,2024-05-22,8VDN,5505,4,694,38,,84.38,1,2.39,experimental,85.23,0.2414,0.2068,DNA Ligase 1 with nick dG:C
8VZL,X-RAY DIFFRACTION,2.72,54.83,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES (pH 7.0), 100 mM lithium acetate, 14% (w/v) PEG3350",298.1,2024-02-11,2024-05-22,8VZL,5914,4,705,232,,85.68,1,2.41,experimental,65.9,0.2194,0.1787,DNA Ligase 1 captured with pre-step 3 ligation at the rG:C nicksite
8VZM,X-RAY DIFFRACTION,2.71,54.65,"VAPOR DIFFUSION, HANGING DROP",6.7,"100 mM MES (pH 6.7), 100 mM lithium acetate, 16% (w/v) PEG3350",298.1,2024-02-11,2024-05-22,8VZM,5814,4,705,148,,85.68,1,2.51,experimental,75.54,0.2326,0.1795,DNA Ligase 1 captured with pre-step 3 ligation at the rA:T nicksite
6ASH,X-RAY DIFFRACTION,2.23,44.85,"VAPOR DIFFUSION, SITTING DROP",4.6,"8% polyethylene glycol (PEG) 4000, 0.1 M sodium acetate",295,2017-08-24,2018-08-29,6ASH,1982,1,215,283,3,24.27,1,1.423,experimental,,0.1463,0.1158,Crystal structure of human Cathepsin K with a non-active site inhibitor at 1.42 Angstrom resolution
6PXF,X-RAY DIFFRACTION,2.1,41.51,VAPOR DIFFUSION,,"0.04 M Potassium phosphate monobasic, 16% w/v PEG8000, 20% v/v glycerol",295,2019-07-25,2020-07-29,6PXF,1887,1,215,135,3,25.01,1,1.85,experimental,23.96,0.188,0.1697,Structure of human Cathepsin K with an ectosteric inhibitor at 1.85 Angstrom resolution
7ASJ,X-RAY DIFFRACTION,2.09,41.03,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, Tris 50 mM",298,2020-10-27,2021-11-24,7ASJ,2331,1,260,205,,29.8,1,1.43,experimental,15.516,0.1791,0.1487,Crystal structure for the complex of human carbonic anhydrase II and 3-(3-methyl-3-phenethylureido)benzenesulfonamide
6SD7,X-RAY DIFFRACTION,2.05,40.09,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-07-26,2020-04-15,6SD7,2530,1,265,171,,31.33,1,1.05,experimental,12.87,0.1385,0.1236,Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide and its dimer
7AEQ,X-RAY DIFFRACTION,2.05,40.01,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2020-09-18,2021-09-01,7AEQ,2361,1,260,222,,29.94,1,1.5,experimental,22.285,0.2137,0.1723,"Human carbonic anhydrase II in complex with 2,3,5,6-tetrafluoro-4-(2-hydroxyethylsulfanyl)-N-methyl-benzenesulfonamide"
7AES,X-RAY DIFFRACTION,2.05,40.13,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2020-09-18,2021-09-01,7AES,2464,1,260,261,,30.08,1,1.4,experimental,21.161,0.2091,0.17,"Human carbonic anhydrase II in complex with 2,3,5,6-tetrafluoro-N-methyl-4-propylsulfanyl-benzenesulfonamide"
7QR9,X-RAY DIFFRACTION,2.48,50.45,"VAPOR DIFFUSION, SITTING DROP",4.6,"10% PEG 3350, 0.1M sodium sulfate, 0.1M citrate 4.6",277.15,2022-01-10,2023-01-18,7QR9,9847,4,1184,349,,140.57,1,2.3,experimental,35.529,0.3051,0.2519,Crystal structure of CK1 delta in complex with PK-09-82
7QRB,X-RAY DIFFRACTION,2.45,49.77,"VAPOR DIFFUSION, SITTING DROP",5,"10% PEG 3350, 0.1M sodium sulfate, 0.1M citrate 5.0",277.15,2022-01-10,2023-01-18,7QRB,9977,4,1184,250,,140.85,1,2.6,experimental,35.131,0.2734,0.2284,Crystal structure of CK1 delta in complex with PK-09-129
5TDD,X-RAY DIFFRACTION,1.8,30,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 12% PEG 20000",293,2016-09-19,2017-03-22,5TDD,649,2,80,44,,9.17,2,1.55,experimental,,0.1521,0.1059,Human UBR-box from UBR2 in complex with HIFS peptide
7AYE,X-RAY DIFFRACTION,2.15,42.89,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium sulfate, 0.1 M Sodium cacodylate pH 6.5",291,2020-11-12,2021-08-18,7AYE,1656,2,251,,1,28.72,2,2.95,experimental,86.097,0.2599,0.1971,Crystal structure of the computationally designed chemically disruptable heterodimer LD6-MDM2
5LJN,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, SITTING DROP",,"1.7-1.9 M (NH4)2SO4, 50 mM sodium cacodylate pH 6.4-7.0, 15 mM MgCl2

Protein:precipitant ratio; 1:2
200 nl drops",293,2016-07-18,2016-08-24,5LJN,2716,4,362,,1,41.53,2,2.701,experimental,61.8122,0.2805,0.2325,Structure of the HOIP PUB domain bound to SPATA2 PIM peptide
4RFD,X-RAY DIFFRACTION,2.09,41.27,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris-HCL pH 7.8, 0.24 mM (final concentration) 6-(4-sulfamoyl-phenoxy)-hexyl-ammonium trifluoroacetate salt, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-09-25,2015-04-15,4RFD,2283,1,260,142,,29.9,1,1.631,experimental,24.7976,0.2056,0.1783,Human carbonic anhydrase II in complex with 4-(4-sulfamoyl-phenoxy)-butylammonium
4RUX,X-RAY DIFFRACTION,2.07,40.61,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl, 3mM 4-(allyloxy)benzenesulfonamide, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-11-23,2015-04-22,4RUX,2382,1,260,239,,29.87,1,1.14,experimental,12.4376,0.1623,0.152,Crystal structure of human Carbonic Anhydrase II in complex with 4-(allyloxy)benzenesulfonamide
4RUY,X-RAY DIFFRACTION,2.06,40.29,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl, 3mM 4-propoxybenzenesulfonamide, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-11-23,2015-04-22,4RUY,2328,1,260,196,,29.88,1,1.14,experimental,12.1359,0.2165,0.2013,Crystal structure of human Carbonic Anhydrase II in complex with 4-propoxybenzenesulfonamide
4RUZ,X-RAY DIFFRACTION,2.07,40.65,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl, 3mM 4-Ethoxybenzenesulfonamide, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,2014-11-23,2015-04-22,4RUZ,2431,1,260,271,,29.85,1,1.63,experimental,21.7759,0.1922,0.1545,Crystal structure of human Carbonic Anhydrase II in complex with 4-ethoxybenzenesulfonamide
6KM3,X-RAY DIFFRACTION,2.07,40.65,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 100 mM Tris-HCl",293,2019-07-30,2020-08-05,6KM3,2494,1,260,265,,29.45,1,1.15,experimental,13.117,0.1278,0.1036,Human Carbonic Anhydrase II native 00 atm CO2
6LUU,X-RAY DIFFRACTION,2.08,40.83,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LUU,2544,1,260,371,,29.38,1,1.2,experimental,13.342,0.1375,0.1099,apo- Carbonic Anhydrase II pH 7.8 0 atm CO2
6LUW,X-RAY DIFFRACTION,2.08,40.88,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LUW,2417,1,260,263,,29.45,1,1.2,experimental,13.109,0.1409,0.1165,Zn- Carbonic Anhydrase II pH 7.8 0 atm CO2
6LUY,X-RAY DIFFRACTION,2.08,40.89,"VAPOR DIFFUSION, HANGING DROP",11,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LUY,2418,1,260,264,,29.45,1,1.2,experimental,10.945,0.1308,0.1106,Zn- Carbonic Anhydrase II pH 11.0 0 atm CO2
6LV3,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, HANGING DROP",11,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LV3,2419,1,260,265,,29.44,1,1.2,experimental,13.94,0.1489,0.1229,Co- Carbonic Anhydrase II pH 11.0 0 atm CO2
6LV9,X-RAY DIFFRACTION,2.08,40.92,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LV9,2444,1,260,286,,29.51,1,1.2,experimental,12.654,0.1443,0.1172,Cu- Carbonic Anhydrase II pH 7.8 0 atm CO2
6YH9,X-RAY DIFFRACTION,2.01,38.93,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2020-03-28,2021-04-07,6YH9,2269,1,260,202,,29.82,1,1.55,experimental,21.023,0.2041,0.166,"Crystal structure of chimeric carbonic anhydrase XII with 2,3,6-trifluoro-5-{[(1R,2S)-2-hydroxy-1,2-diphenylethyl]amino}-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
6YHB,X-RAY DIFFRACTION,2.01,38.74,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2020-03-28,2021-04-07,6YHB,2172,1,260,116,,29.65,1,1.65,experimental,26.854,0.2228,0.1773,"Crystal structure of chimeric carbonic anhydrase XII with 4-[(4,6-dimethylpyrimidin-2-yl)thio]-2,3,5,6-tetrafluorobenzenesulfonamide"
7BFA,X-RAY DIFFRACTION,2.11,41.67,"VAPOR DIFFUSION, HANGING DROP",8,"1.5-1.7 M sodium citrate
0.1 M Tris pH 8.0",296,2021-01-02,2022-01-12,7BFA,2332,1,260,205,,29.91,1,1.6,experimental,11.924,0.182,0.1461,4-(2-(3-(4-iodophenyl)thioureido)ethyl)benzenesulfonamide in complex with Carbonic Anhydrase II
7BG5,X-RAY DIFFRACTION,2.09,41.25,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2021-01-05,2022-01-12,7BG5,2354,1,260,236,,29.89,1,1.428,experimental,13.842,0.1649,0.1443,4-(2-(3-(4-iodophenyl)ureido)ethyl)benzenesulfonamide in complex with Carbonic Anhydrase II
7BHH,X-RAY DIFFRACTION,2.09,41.1,"VAPOR DIFFUSION, HANGING DROP",8,"1.5-1.7 M sodium citrate, 0.1 M Tris pH 8.0",296,2021-01-11,2022-03-02,7BHH,2452,1,260,302,,29.95,1,1.4,experimental,17.6,0.1701,0.1504,4-(2-(3-(4-iodophenyl)selenoureido)ethyl)benzenesulfonamide in complex with Carbonic Anhydrase II
8FR2,X-RAY DIFFRACTION,2.09,41.14,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2023-01-06,2023-02-01,8FR2,2421,1,257,324,,29.43,1,1.307,experimental,,0.1792,0.1642,Carbonic Anhydrase IX-mimic in complex with the alkyl urea compound 3h
8FR4,X-RAY DIFFRACTION,2.13,42.27,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2023-01-06,2023-02-01,8FR4,2296,1,257,208,,29.31,1,1.123,experimental,,0.1731,0.1686,Carbonic Anhydrase IX-mimic in complex with the alkyl urea compound 3j
6CSD,X-RAY DIFFRACTION,3.25,62.16,"VAPOR DIFFUSION, HANGING DROP",,"mixing 1.5 ul of protein solution, 0.25 ul 70 mM HEGA-10, and 0.3 ul of the reservoir solution containing 10-20% of PEG400, 0.1 M cacodylate, pH 7.0, 2 mM ZnSO4, and 200 mM MgAc2",293,2018-03-20,2019-03-27,6CSD,7727,2,958,413,,111.22,1,2.391,experimental,,0.2361,0.1978,V308E mutant of cytochrome P450 2D6 complexed with prinomastat
4QX4,X-RAY DIFFRACTION,2.18,43.67,"VAPOR DIFFUSION, HANGING DROP",8,"50 mM di-Ammoniumhydrogen citrate pH 5.0 PEG6000= 5 % (m/V) DTT= 5.15 g/L NADP+= 0.66 g/L and Human Aldose Reductase= 15 mg/ml. Afterwards the crystals were soaked into Tris 100 mM 25% (m/V) PEG6000 pH 8.0 saturated with the inhibitor. The well solution for crystallization was 120mM di-Ammonium hydrogen citrate with 20% PEG6000, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291,2014-07-18,2015-04-01,4QX4,2991,1,316,334,,37.16,1,1.259,experimental,,0.1531,0.1325,Human Aldose Reductase complexed with a ligand with a new scaffold at 1.26 A
4XEM,X-RAY DIFFRACTION,2.12,41.89,VAPOR DIFFUSION,8.5,PEG3350,293,2014-12-24,2016-02-17,4XEM,3595,1,475,490,,54.04,1,1.278,experimental,18.117,0.1787,0.161,Crystal Structure of wild type human AlaRS catalytic domain
4YVY,X-RAY DIFFRACTION,2.09,41.19,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M sodium citrate and 0.1 M Tris-HCl, pH 8.5",293,2015-03-20,2016-03-30,4YVY,2436,1,259,332,,29.34,1,1.45,experimental,,0.192,0.162,"Crystal structure of human carbonic anhydrase II in complex with hydroxylamine-O-sulfonamide, a molecule incorporating two zinc-binding groups."
7Y2A,X-RAY DIFFRACTION,2.08,40.74,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2A,2396,1,260,242,,29.54,1,1.2,experimental,12.026,0.15578,0.12708,Zn-Carbonic Anhydrase II complexed with 3NPA before UV at 90 K
7Y2C,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2C,2393,1,260,242,,29.49,1,1.2,experimental,13.339,0.15336,0.12416,Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 90 K
7Y2E,X-RAY DIFFRACTION,2.09,41.05,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2E,2393,1,260,242,,29.49,1,1.2,experimental,13.796,0.15466,0.12465,Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 120 K
7Y2N,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2N,2521,1,260,351,,29.33,1,1.25,experimental,15.591,0.16062,0.11796,apo-Carbonic Anhydrase II soaked in 3NPA after UV at 160 K
7Y2O,X-RAY DIFFRACTION,2.09,41.27,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2O,2519,1,260,349,,29.33,1,1.25,experimental,16.383,0.16014,0.11836,apo-Carbonic Anhydrase II soaked in 3NPA after UV at 180 K
7Y2Q,X-RAY DIFFRACTION,2.1,41.56,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2Q,2518,1,260,348,,29.33,1,1.35,experimental,18.763,0.15668,0.10973,apo-Carbonic Anhydrase II soaked in 3NPA after UV at 200 K
7Y2R,X-RAY DIFFRACTION,2.07,40.62,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2R,2426,1,260,240,,29.59,1,1.2,experimental,14.127,0.1547,0.12758,Ni-Carbonic Anhydrase II complexed with 3NPA before UV at 100 K
7Y2S,X-RAY DIFFRACTION,2.07,40.68,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2S,2426,1,260,240,,29.59,1,1.2,experimental,14.547,0.15352,0.12604,Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 100 K
7Y2T,X-RAY DIFFRACTION,2.08,40.78,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2T,2426,1,260,240,,29.59,1,1.2,experimental,14.911,0.15333,0.12559,Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 120 K
7Y2U,X-RAY DIFFRACTION,2.08,40.91,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2U,2426,1,260,240,,29.59,1,1.2,experimental,15.29,0.1523,0.12527,Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 140 K
7Y2V,X-RAY DIFFRACTION,2.09,41.03,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2V,2426,1,260,240,,29.59,1,1.2,experimental,15.935,0.15301,0.12532,Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 160 K
7Y2W,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2W,2426,1,260,240,,29.59,1,1.2,experimental,17.146,0.15552,0.12813,Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 180 K
7Y2X,X-RAY DIFFRACTION,2.09,41.22,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2X,2415,1,260,242,,29.59,1,1.5,experimental,21.333,0.15796,0.1107,Ni-Carbonic Anhydrase II complexed with 3NPA after UV at 200 K
5U0D,X-RAY DIFFRACTION,2.1,41.35,"VAPOR DIFFUSION, SITTING DROP",,the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.3; concentrated CA II at ~10 mg mL-1 was set up with seeding; dry compound was added to crystals several days before harvesting and data collection,281,2016-11-23,2017-08-30,5U0D,2488,1,260,250,,29.7,1,1.59,experimental,15.669,0.15449,0.11848,Identification of a New Zinc Binding Chemotype by Fragment Screening
5U0E,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, SITTING DROP",,the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.3; concentrated CA II at ~10 mg mL-1 was set up with seeding; dry compound was added to crystals several days before harvesting and data collection,281,2016-11-23,2017-08-30,5U0E,2602,1,260,311,,29.73,1,1.27,experimental,14.068,0.14751,0.12585,Identification of a New Zinc Binding Chemotype by Fragment Screening
5U0G,X-RAY DIFFRACTION,2.1,41.55,"VAPOR DIFFUSION, SITTING DROP",,the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.3; concentrated CA II at ~10 mg mL-1 was set up with seeding; dry compound was added to crystals several days before harvesting and data collection,281,2016-11-23,2017-08-30,5U0G,2495,1,260,255,,29.78,1,1.54,experimental,16.441,0.16578,0.12727,Identification of a New Zinc Binding Chemotype by Fragment Screening
4QIY,X-RAY DIFFRACTION,2,38.2,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M sodium BICINE, pH 9, 0.2M ammonium sulfate, 2M sodium malonate pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-06-03,2015-04-15,4QIY,9716,4,1040,1013,,120.51,1,1.3,experimental,16.645,0.192,0.151,Crystal structure of human carbonic anhydrase isozyme II with inhibitor
7KSV,X-RAY DIFFRACTION,2.5,50.78,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-01,7KSV,3376,4,374,343,,46.83,1,1.64,experimental,28.0946,0.1877,0.1624,"DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (960min)"
7KSY,X-RAY DIFFRACTION,2.46,49.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-01,7KSY,3365,4,374,336,,46.33,1,1.577,experimental,29.4751,0.1695,0.1558,"DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mg2+ (960min)"
7KSZ,X-RAY DIFFRACTION,2.5,50.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG 4000",277,2020-11-24,2022-01-19,7KSZ,3583,4,373,444,,46.62,1,1.417,experimental,21.6426,0.1747,0.1573,"DNA Polymerase Mu, dGTP:At Pre-Catalytic Ground State Ternary Complex, 10 mM Ca2+ (960min)"
7KT0,X-RAY DIFFRACTION,2.51,50.92,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG 4000",277,2020-11-24,2022-01-19,7KT0,3606,4,373,431,,46.56,1,1.36,experimental,24.8486,0.1788,0.1613,"DNA Polymerase Mu, dGTP:At Ground State Ternary Complex, 50 mM Mg2+ (60min)"
7KT2,X-RAY DIFFRACTION,2.5,50.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG 4000",277,2020-11-24,2022-01-19,7KT2,3425,4,374,345,,47.06,1,1.499,experimental,27.2252,0.189,0.1679,"DNA Polymerase Mu, dGTP:At Product State Ternary Complex, 50 mM Mn2+ (225min)"
7KT3,X-RAY DIFFRACTION,2.5,50.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KT3,3566,4,373,375,,46.68,1,1.879,experimental,23.0042,0.188,0.1596,"DNA Polymerase Mu, 8-oxodGTP:At Pre-Catalytic Ground State Ternary Complex, 20 mM Ca2+ (120min)"
7KT6,X-RAY DIFFRACTION,2.5,50.88,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KT6,3429,4,374,313,,46.53,1,1.87,experimental,31.0192,0.1932,0.1652,"DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 10 mM Mn2+ (960min)"
7KT9,X-RAY DIFFRACTION,2.52,51.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KT9,3686,4,374,465,,46.28,1,1.482,experimental,22.8378,0.1755,0.1552,"DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 50 mM Mg2+ (960min)"
7KTG,X-RAY DIFFRACTION,2.5,50.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KTG,3670,4,374,440,,46.45,1,1.445,experimental,24.8233,0.183,0.1577,"DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 50 mM Mg2+ (960min)"
4ZCG,X-RAY DIFFRACTION,2.93,57.99,"VAPOR DIFFUSION, HANGING DROP",6,"PEG3350, NH4Cl",298,2015-04-15,2015-06-03,4ZCG,4620,2,542,428,2,60.12,2,2.22,experimental,35.053,0.1852,0.1463,Crystal Structure of human GGT1 in complex with Glutamate (with all atoms of glutamate)
5TY1,X-RAY DIFFRACTION,2.1,41.47,"VAPOR DIFFUSION, SITTING DROP",8.3,the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.3; concentrated CA II at ~10 mg mL-1 was set up with seeding; dry compound was added to crystals several days before harvesting and data collection,281,2016-11-18,2017-10-04,5TY1,2560,1,260,310,,29.61,1,1.6,experimental,13.386,0.18733,0.13726,Identification of a New Zinc Binding Chemotype by Fragment Screening
5TY8,X-RAY DIFFRACTION,2.1,41.44,"VAPOR DIFFUSION, SITTING DROP",8.3,the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.3; concentrated CA II at ~10 mg mL-1 was set up with seeding; dry compound was added to crystals several days before harvesting and data collection,281,2016-11-18,2017-08-30,5TY8,2557,1,260,315,,29.53,1,1.45,experimental,14.582,0.16269,0.12106,Identification of a New Zinc Binding Chemotype by Fragment Screening
5TY9,X-RAY DIFFRACTION,2.11,41.57,"VAPOR DIFFUSION, SITTING DROP",8.3,the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.3; concentrated CA II at ~10 mg mL-1 was set up with seeding; dry compound was added to crystals several days before harvesting and data collection,281,2016-11-18,2017-08-30,5TY9,2535,1,260,302,,29.59,1,1.53,experimental,14.416,0.18145,0.12964,Identification of a New Zinc Binding Chemotype by Fragment Screening
5TYA,X-RAY DIFFRACTION,2.09,41.29,"VAPOR DIFFUSION, SITTING DROP",8.3,the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.3; concentrated CA II at ~10 mg mL-1 was set up with seeding; dry compound was added to crystals several days before harvesting and data collection,281,2016-11-18,2017-08-30,5TYA,2532,1,260,315,,29.55,1,1.5,experimental,14.646,0.16486,0.10597,Identification of a New Zinc Binding Chemotype by Fragment Screening
5U0F,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, SITTING DROP",,the reservoir condition consisted of 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.3; concentrated CA II at ~10 mg mL-1 was set up with seeding; dry compound was added to crystals several days before harvesting and data collection,281,2016-11-23,2017-08-30,5U0F,2672,1,260,400,,29.64,1,1.21,experimental,11.445,0.18023,0.15554,Identification of a New Zinc Binding Chemotype by Fragment Screening
4WW6,X-RAY DIFFRACTION,2,38.2,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.25 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2014-11-10,2015-07-01,4WW6,2585,1,260,268,,30.5,1,1.06,experimental,15.737,0.151,0.128,"Crystal structure of human carbonic anhydrase isozyme II with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide"
5MGV,X-RAY DIFFRACTION,2.48,50.37,"VAPOR DIFFUSION, HANGING DROP",,"2 mM DTT, 100 mM bis-Tris propane pH 7 and 1.8 M sodium acetate pH 7",292,2016-11-22,2017-05-03,5MGV,3607,1,405,249,,47.52,1,2.05,experimental,31.0362,0.2711,0.2275,"Kinetic and Structural Changes in HsmtPheRS, Induced by Pathogenic Mutations in Human FARS2"
6WHE,X-RAY DIFFRACTION,1.96,37.35,VAPOR DIFFUSION,7,"20% PEG3350,
0.1M Hepes pH 7",289,2020-04-08,2021-03-10,6WHE,3209,2,368,316,,43.34,1,1.73,experimental,19.8405,0.2304,0.1866,Structure of phosphomimetic Rab8a GTPase (T72E) in the GTP-bound state
6OHQ,X-RAY DIFFRACTION,2.01,38.71,"VAPOR DIFFUSION, SITTING DROP",,"0.2M ammonium sulfate, 20% PEG3350, 0.1M bis-tris pH 6.7",298,2019-04-06,2020-02-19,6OHQ,9692,2,1280,201,,148.79,1,2.694,experimental,48.1632,0.2587,0.2064,Structure of compound 4 bound human Phospholipase D2 catalytic domain
7ZEG,X-RAY DIFFRACTION,2.19,43.92,VAPOR DIFFUSION,6.2,"22% PEG 3350, 0.1M MES pH 6.2",277.15,2022-03-31,2022-04-13,7ZEG,4846,2,604,386,,70.69,1,1.56,experimental,37.89,0.273,0.2396,"Human cytosolic 5' nucleotidase IIIB in complex with 3,4-diF-Bn7GMP"
8T2J,X-RAY DIFFRACTION,1.9,35.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES pH 7.5, 10% (w/v) PEG 3000, 20% PEG 400 (v/v), and 10% glycerol (v/v)",298,2023-06-06,2024-06-12,8T2J,2781,1,345,125,,38.6,1,1.8,experimental,37.69,0.2192,0.1747,Structure of the catalytic domain of PPM1D/Wip1 serine/threonine phosphatase
6G36,X-RAY DIFFRACTION,3.01,59.09,"VAPOR DIFFUSION, SITTING DROP",,"51-63% MPD and 0.1M SPG buffer, pH 6.0-6.5",277.15,2018-03-24,2018-04-18,6G36,3048,1,357,253,,41.61,1,1.46,experimental,22.125,0.17564,0.14945,Crystal structure of haspin in complex with 5-chlorotubercidin
6G3Q,X-RAY DIFFRACTION,2.09,41.19,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM",296,2018-03-26,2018-11-28,6G3Q,2682,1,260,432,,29.79,1,1.01,experimental,17.115,0.1515,0.1271,Crystal structure of human carbonic anhydrase II in complex with the inhibitor famotidine
4ONM,X-RAY DIFFRACTION,2.17,43.27,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM sodium citrate, 15% PEG 8000, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K",298,2014-01-28,2015-05-06,4ONM,2619,2,313,212,,35.47,2,1.35,experimental,25.06,0.1923,0.159,Crystal structure of human Mms2/Ubc13 - NSC697923
4ONN,X-RAY DIFFRACTION,2.17,43.39,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM sodium citrate, 15% PEG 8000, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K",298,2014-01-28,2015-05-06,4ONN,2562,2,313,183,,35.59,2,1.5,experimental,28.85,0.2132,0.1791,Crystal structure of human Mms2/Ubc13 - BAY 11-7082
5KTY,X-RAY DIFFRACTION,3.11,60.39,"VAPOR DIFFUSION, SITTING DROP",,"10 mg/mL protein, 5 mM calcium chloride, 1 mM GDP, 0.04 M potassium phosphate, 16% w/v PEG8000, 20% v/v glycerol",294,2016-07-12,2016-09-21,5KTY,3364,1,424,76,,50.06,1,2.522,experimental,,0.2492,0.2095,"hMiro EF hand and cGTPase domains, GDP and Ca2+ bound state"
5FY9,X-RAY DIFFRACTION,2.11,41.64,,7.5,"0.1M HEPES PH 7.5, 0.8M POTASSIUM PHOSPHATE DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,2016-03-04,2017-03-22,5FY9,4036,1,479,228,,56.39,1,2.03,experimental,,0.2342,0.1991,Crystal structure of the catalytic domain of human JARID1B in complex with pyruvate
7L97,X-RAY DIFFRACTION,2.19,43.78,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 1500, 0.2M NaCl, 0.1M HEPES pH7.5",291,2021-01-02,2021-08-25,7L97,2040,2,254,61,,28.88,2,2.01,experimental,37.279,0.2137,0.1846,Crystal structure of STAMBPL1 in complex with an engineered binder
4QJM,X-RAY DIFFRACTION,2.02,38.6,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M sodium BICINE pH 9, 0.2M ammonium sulfate, 2M sodium malonate pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-06-04,2015-04-15,4QJM,2453,1,260,286,,30.28,1,1.75,experimental,17.018,0.212,0.161,Crystal structure of human carbonic anhydrase isozyme II with inhibitor
6YHA,X-RAY DIFFRACTION,2,38.43,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer was 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,2020-03-28,2021-04-07,6YHA,2432,1,260,255,,30.33,1,1.25,experimental,17.706,0.1708,0.1283,"Crystal structure of chimeric carbonic anhydrase XII with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide"
4YC9,X-RAY DIFFRACTION,2.27,45.9,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.2-2.4M ammonium sulfate, 0.1M HEPES buffer pH 7.5, 2% PEG400 and 8-9% glycerol",298,2015-02-19,2015-06-24,4YC9,1715,1,184,214,,22.18,1,1.82,experimental,36.339,0.2035,0.155,"Crystal structure of TRIM24 PHD-bromodomain complexed with N-(6-{3-[4-(dimethylamino)butoxy]-5-propoxyphenoxy}-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-3,4-dimethoxybenzene-1-sulfonamide (8i)"
4U8Z,X-RAY DIFFRACTION,2.74,55.06,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris-HCl (pH 8.5), 180mM MgCl2, 5mM Manganese (II) acetate, 10-17% PEG3350",293,2014-08-05,2015-03-18,4U8Z,2605,1,290,262,,33.32,1,1.63,experimental,38.48,0.2218,0.19,Crystal structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06447475)
4W8D,X-RAY DIFFRACTION,2.74,55.15,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris-HCL (pH 8.5), 180mM MgCl2, 5mM Manganese acetate, 10-17% PEG 3350",293,2014-08-24,2015-03-18,4W8D,2631,1,290,291,,33.24,1,1.77,experimental,37.84,0.1824,0.1711,Crystal structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06454589).
4W8E,X-RAY DIFFRACTION,2.31,46.75,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris-HCl (pH 8.5), 180mM MgCl2, 5mM Manganese acetate, 10-17% PEG3350",293,2014-08-24,2015-03-18,4W8E,2575,1,291,221,,33.43,1,1.79,experimental,46.26,0.2125,0.1748,Structure of MST3 with a pyrrolopyrimidine inhibitor (PF-06645342)
4TMF,X-RAY DIFFRACTION,2.26,45.67,"VAPOR DIFFUSION, HANGING DROP",4,"0.1M sodium acetate pH4.0, 0.2M ammonium acetate, 3% isopropanol, 15% PEG10000",298,2014-06-01,2015-05-13,4TMF,4092,2,514,80,11,60.66,1,2.05,experimental,67.282,0.227,0.198,Crystal structure of human CD38 in complex with hydrolysed compound JMS713
5OGJ,X-RAY DIFFRACTION,2.18,43.56,EVAPORATION,5,"Crystallization buffer: 0.1M ammonium citrate (pH 7), 0.1M  sodium acetate (pH 4.5) and 26% PEG3350",291,2017-07-13,2018-08-01,5OGJ,5216,2,526,714,,61.49,1,1.06,experimental,15.406,0.155,0.132,"Crystal structure of human carbonic anhydrase isozyme XIII with 2-(Cyclooctylamino)-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide"
9FCR,X-RAY DIFFRACTION,1.95,37.01,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350/PEG 1K/MPD (1:1:1) 37.5%, 0.1 M MES/imidazole pH 6.5, 4mM Morpheus II Alkalis, 2.5% (w/v) Morpheus Fusion Cryopolyols",290,2024-05-15,2024-09-11,9FCR,3307,2,372,385,,42.05,1,1.37,experimental,22.39,0.2335,0.2017,Crystal structure of RBBP9 with spacegroup p212121
6OHO,X-RAY DIFFRACTION,2.06,40.27,"VAPOR DIFFUSION, SITTING DROP",6.7,"0.2M ammonium sulfate, 20% PEG3350, 0.1M bis-tris pH 6.7",298,2019-04-06,2020-02-19,6OHO,9866,2,1280,394,,148.22,1,2,experimental,,0.2239,0.1813,Structure of human Phospholipase D2 catalytic domain
4PUW,X-RAY DIFFRACTION,2.17,43.37,"VAPOR DIFFUSION, HANGING DROP",5,"Crystallization solution: 50 mM di-Ammoniumhydrogen citrate pH 5.0 PEG6000= 5 % (m/V) DTT= 5.15 g/L NADP+= 0.66 g/L and Human Aldose Reductase= 15 mg/ml.        
9 microliter of the crystallization  solution were mixed with 3 microliter of a 5 mM solution of the inhibitor in 120 mM di-Ammoniumhydrogen citrate pH 5.0 with 25 % (m/V) PEG 6000 and 5 % DMSO, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291,2014-03-14,2015-04-08,4PUW,3063,1,316,402,,37.09,1,1.12,experimental,,0.1568,0.137,Human Aldose Reductase complexed with a ligand with an IDD structure (2-[5-fluoro-2-(prop-2-ynylcarbamoyl)phenoxy]acetic acid) at 1.12 A
8T75,X-RAY DIFFRACTION,3.96,68.93,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium acetate (pH 4.6), 2 M sodium formate",293,2023-06-19,2024-02-14,8T75,9860,8,1260,77,,147.97,2,2.65,experimental,76.6592,0.219,0.178,Crystal Structure of KRAS4a (GMPPNP) in complex with RAF1 (RBD-CRD)
7ZIJ,X-RAY DIFFRACTION,2.37,48.07,"VAPOR DIFFUSION, SITTING DROP",,"20% w/v PEG 5000 MME, 200 mM ammonium fluoride",293.15,2022-04-08,2022-09-07,7ZIJ,2536,1,326,191,,37.89,1,1.94678362883,experimental,35.6474442556,0.225544799513,0.186253646429,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-05-080
9FLO,X-RAY DIFFRACTION,3.06,59.78,"VAPOR DIFFUSION, SITTING DROP",6.5,"55-65% MPD, 0.1M SPG 6.5",277,2024-06-05,2024-09-11,9FLO,2577,1,357,3,,41.1,1,2.9,experimental,90.624,0.24678,0.2123,Crystal structure of human Haspin (GSG2) kinase bound to MU2181
9FLT,X-RAY DIFFRACTION,3.16,61.01,"VAPOR DIFFUSION, SITTING DROP",6.5,"45% MPD
0.1M SPG 6.5",278,2024-06-05,2024-09-11,9FLT,2643,1,336,66,,38.62,1,2.4,experimental,54.563,0.23881,0.18392,Crystal structure of human Haspin (GSG2) kinase bound to chemical probe MU1920
4Y1L,X-RAY DIFFRACTION,2.58,52.31,VAPOR DIFFUSION,8,"10% (w/v) PEG8000, 100 mM HEPES, pH 8.0, 8% ethylene glycol",293,2015-02-08,2015-05-06,4Y1L,3531,3,429,149,,48.92,2,2.7,experimental,,0.2782,0.2252,Ubc9 Homodimer The Missing Link in Poly-SUMO Chain Formation
8FH4,X-RAY DIFFRACTION,2.2,44.18,VAPOR DIFFUSION,,"15 mg/mL protein + reservoir (0.1 M Tris, pH 8.0, 17.5% 1,6-hexanediol, 10 mM magnesium sulfate, 24 mM barium acetate)",286.15,2022-12-13,2023-04-05,8FH4,10077,4,1324,834,,150.35,1,1.827,experimental,31.69,0.2152,0.1874,"Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with 3-[6-chloro-4-(9-methyl-1-oxa-4,9-diazaspiro[5.5]undec-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile"
8DYL,X-RAY DIFFRACTION,2.55,51.75,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium sulfate, 0.1 M BIS-TRIS, pH 5.5, 16% PEG 3350",293,2022-08-04,2023-07-12,8DYL,5682,1,762,246,,86.72,1,1.9,experimental,36.6386,0.2093,0.1745,Crystal structure of human methylmalonyl-CoA mutase bound to aquocobalamin
4XVK,X-RAY DIFFRACTION,5.66,78.11,"VAPOR DIFFUSION, HANGING DROP",6,"1.5 M Ammonium Sulfate, 100 mM MES",293,2015-01-27,2015-03-11,4XVK,5558,3,693,24,,83.23,1,2.95,experimental,75.1607,0.2411,0.2221,Binary complex of human polymerase nu and DNA with the finger domain closed
4YPA,X-RAY DIFFRACTION,2.34,47.34,"VAPOR DIFFUSION, SITTING DROP",,"PEG 4000, magnesium chloride, Tris",290,2015-03-12,2015-09-02,4YPA,7254,4,904,214,5,106.22,1,2.3,experimental,38.039,0.303,0.2489,ASH1L SET domain Q2265A mutant in complex with S-adenosyl methionine (SAM)
6A33,X-RAY DIFFRACTION,3.14,60.81,EVAPORATION,7.5,"0.1 M HEPES sodium, pH 7.5, 1M Sodium citrate tribasic dihydrate, and 10 mM TCEP",277,2018-06-14,2018-12-05,6A33,1426,2,176,123,,20.47,2,2.1,experimental,,0.2468,0.1937,Binding and Enhanced Binding between Key Immunity Proteins TRAF6 and TIFA
4NKC,X-RAY DIFFRACTION,2.15,42.92,"VAPOR DIFFUSION, HANGING DROP",5.5,"di-Ammoniumhydrogen citrate,  
PEG6000= 5 % (m/V), DTT= 5,15 g/L, NADP+= 0,66 g/L    
Human Aldose Reductase= 15 mg/ml.    
Afterwards soaked into MES buffer, MES 50 mM 25% (m/V) PEG6000, saturated with the inhibitor, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291,2013-11-12,2015-03-04,4NKC,2936,1,315,360,,36.78,1,1.12,experimental,,0.1419,0.1222,Human Aldose Reductase complexed with Schl7764 at 1.12 A
4PR4,X-RAY DIFFRACTION,2.17,43.34,"VAPOR DIFFUSION, HANGING DROP",5.5,"di-Ammoniumhydrogen citrate, 5 % m/V PEG6000, DTT= 5.15 g/L, NADP+= 0.66 g/L  
protein 15 mg/ml. Afterwards soaked into MES buffer, MES 50 mM, 25% m/V PEG6000, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291,2014-03-05,2015-04-08,4PR4,2993,1,315,359,,36.78,1,1.06,experimental,,0.1525,0.1373,Human Aldose Reductase complexed with Schl7802 at 1.06 A
4PRR,X-RAY DIFFRACTION,2.17,43.41,"VAPOR DIFFUSION, HANGING DROP",8,"di-Ammoniumhydrogen citrate pH 5.0, PEG6000= 5 % (m/V), DTT= 5.15 g/L, ADP= 0,66 g/L, protein 15 mg/ml. Soaking conditions: Tris buffer, Tris 100 mM 25 %(m/V) PEG6000 pH 8.0 saturated with the inhibitor, VAPOR DIFFUSION, HANGING DROP",,2014-03-06,2015-04-08,4PRR,2973,1,315,334,,36.77,1,1.01,experimental,,0.155,0.1437,Human Aldose Reductase complexed with Schl7815 ((3-[3-(5-NITROFURAN-2-YL)PHENYL]PROPANOIC ACID)at 1.01 A
4RN4,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",8.5,"2.9 M ammonium sulfate with 0.1 M Tris buffer, Protein at 14 mg/mL, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293,2014-10-22,2015-01-28,4RN4,2546,1,260,276,,30.07,1,1.53,experimental,,0.1986,0.1685,Human Carbonic anhydrases II in complex with a acetazolamide derivative comprising one hydrophobic and one hydrophilic tail moiety
6RMY,X-RAY DIFFRACTION,2.09,41.16,"VAPOR DIFFUSION, SITTING DROP",7,Crystallization buffer was 0.1M sodium BICINE (pH 9) and 2M sodium malonate (pH 7).,291,2019-05-07,2020-06-03,6RMY,2518,1,260,307,,30.23,1,1.5,experimental,16.721,0.2049,0.1646,"Human Carbonic anhydrase II mutant T199V bound by 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide"
8CJI,X-RAY DIFFRACTION,2.1,41.55,"VAPOR DIFFUSION, SITTING DROP",,"21% PEG3350, 0.2 M NaCl",293.15,2023-02-13,2024-01-10,8CJI,2673,1,326,286,,38.03,1,1.65,experimental,28.94,0.2652,0.2365,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-07-052
8CJJ,X-RAY DIFFRACTION,2.14,42.65,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 5000 MME, 0.2 M lithium acetate",293.15,2023-02-13,2024-01-10,8CJJ,2668,1,326,265,,37.88,1,1.66415657298,experimental,26.3932631618,0.203226343466,0.175245155349,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-06-057
8CJK,X-RAY DIFFRACTION,2.38,48.35,"VAPOR DIFFUSION, SITTING DROP",,"27% PEG 3350, 0.2 M NaCl",293.15,2023-02-13,2024-01-10,8CJK,2746,1,326,354,,37.98,1,1.45914977372,experimental,24.6504132848,0.183981915097,0.154573739291,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-06-098
8CJL,X-RAY DIFFRACTION,2.32,46.97,"VAPOR DIFFUSION, SITTING DROP",,"18% PEG6000, 0.1 M Tris pH 8.5",293.15,2023-02-13,2024-01-10,8CJL,2602,1,326,273,,37.88,1,1.83,experimental,33.55,0.225,0.1951,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor TPT-004
8CJM,X-RAY DIFFRACTION,1.95,37,"VAPOR DIFFUSION, SITTING DROP",,19% PEG 3350,293.15,2023-02-13,2024-01-10,8CJM,2410,1,326,120,,37.86,1,1.9,experimental,37.58,0.2539,0.2154,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-07-047
8CJN,X-RAY DIFFRACTION,2.13,42.18,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M NaF",293.15,2023-02-13,2024-01-10,8CJN,2700,1,326,302,,37.96,1,1.6808093833,experimental,23.7949368912,0.197210123888,0.165640890825,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-06-070
8CJO,X-RAY DIFFRACTION,2.39,48.61,"VAPOR DIFFUSION, SITTING DROP",,"20 % PEG 3350, 0.2 M Potassium acetate",293.15,2023-02-13,2024-01-10,8CJO,2652,1,326,285,,37.96,1,1.86633703305,experimental,29.0152353772,0.209339830182,0.169398029353,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-06-004
6XWZ,X-RAY DIFFRACTION,2.1,41.34,"VAPOR DIFFUSION, HANGING DROP",8,"solution of 1.5-1.7 M sodium citrate, 0.1 M Tris pH 8.0",296,2020-01-24,2021-02-03,6XWZ,2233,1,260,168,,29.6,1,1.38,experimental,16.639,0.2042,0.1804,Carbonic Anhydrase II-mediated hydrolysis of selenolester
6TV4,X-RAY DIFFRACTION,1.93,36.25,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium citrate pH 4.2",300,2020-01-08,2020-10-28,6TV4,3057,1,383,114,6,45.75,1,1.53,experimental,22.657,0.2142,0.1704,CFF-Notum complex
4YNM,X-RAY DIFFRACTION,2.34,47.41,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, 20 mM Tris",277,2015-03-10,2015-09-02,4YNM,3497,2,452,104,1,53.22,1,2.19,experimental,42.453,0.2775,0.2421,ASH1L wild-type SET domain in complex with S-adenosyl methionine (SAM)
4YNP,X-RAY DIFFRACTION,2.39,48.46,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, 20 mM Tris",277,2015-03-10,2015-09-02,4YNP,3364,2,452,,3,53.31,1,2.9,experimental,54.671,0.3194,0.2619,ASH1L SET domain S2259M mutant in complex with S-adenosyl methionine (SAM)
4YPE,X-RAY DIFFRACTION,2.31,46.69,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, 20 mM Tris",277,2015-03-12,2015-09-02,4YPE,3572,2,452,107,2,53.24,1,2.2,experimental,32.169,0.2625,0.2165,ASH1L SET domain H2193F mutant in complex with S-adenosyl methionine (SAM)
4YPU,X-RAY DIFFRACTION,2.19,43.89,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, 20 mm Tris",277,2015-03-13,2015-09-02,4YPU,3373,2,452,36,2,53.19,1,2.6,experimental,53.136,0.3053,0.2379,ASH1L SET domain K2264L mutant in complex with S-adenosyl methionine (SAM)
5E1E,X-RAY DIFFRACTION,2.5,50.72,"VAPOR DIFFUSION, HANGING DROP",6,"27% (m/v) PEG6000, 0.1 M MES/NaOH pH 6.0 and 5 mM DTT",277,2015-09-29,2015-11-25,5E1E,4944,2,580,227,,67.92,1,2.3,experimental,43.37,0.2683,0.2247,Human JAK1 kinase in complex with compound 30 at 2.30 Angstroms resolution
5LL4,X-RAY DIFFRACTION,2.02,38.6,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,2016-07-26,2017-08-16,5LL4,5178,2,520,652,,60.14,1,1.12,experimental,17.837,0.1713,0.1312,Crystal structure of human carbonic anhydrase isozyme II with 4-(1H-benzimidazol-1-ylacetyl)benzenesulfonamide
5KSP,X-RAY DIFFRACTION,2.07,40.6,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 mg/mL protein, 6 mM magnesium chloride, 0.1 M Tris, pH 8.5, 12% w/v PEG4000, GDP observed in the structure was carried through from the expression system during purification",294,2016-07-08,2016-09-21,5KSP,2863,2,380,292,,44.96,1,2.162,experimental,,0.2412,0.1929,hMiro1 C-domain GDP Complex C2221 Crystal Form
6XVH,X-RAY DIFFRACTION,2.11,41.82,VAPOR DIFFUSION,,"Tris, Ammonium sulfate",298,2020-01-22,2021-02-03,6XVH,2277,1,257,210,,29.2,1,1.8,experimental,32.3301,0.2451,0.1932,carbonic anhydrase with bound arylsulfonamide- boronic acid
4ZL1,X-RAY DIFFRACTION,3.47,64.53,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM UDAO, 20.8mM N,N-dimethyldecylamine-N-oxide(DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate, 1mM inhibitor",293,2015-05-01,2016-05-04,4ZL1,3102,1,390,222,,44,1,1.86,experimental,23.267,0.17893,0.15993,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with 18X at 1.86 A resolution
6F78,X-RAY DIFFRACTION,2.4,48.78,VAPOR DIFFUSION,,"100mM MES pH 6.0, 25% PEG 8000",277,2017-12-07,2018-04-04,6F78,6028,2,636,693,,74.89,1,1.3,experimental,,0.1694,0.1431,Potent and selective Aldo-Keto Reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: Application of a Bioisosteric Scaffold Hopping Approach to Flufenamic acid
4YVV,X-RAY DIFFRACTION,2.41,49.06,"VAPOR DIFFUSION, HANGING DROP",6,"15-20% (w/v) PEG 8000, 100 mM MES, 0.14M NaCl",289,2015-03-20,2015-11-25,4YVV,5536,2,646,328,,76.29,1,2.3,experimental,27.935,0.25341,0.19842,Crystal structure of AKR1C3 complexed with glibenclamide
7L8L,X-RAY DIFFRACTION,1.68,26.73,MICROBATCH,6.9,"0.2 M sodium thiocyanate, pH 6.9, and 20% (w/v) PEG 8000",293,2020-12-31,2021-12-29,7L8L,1420,1,192,142,,21.93,1,1.61,experimental,13.9155,0.2233,0.1796,Crystal structure of human R152H GPX4-U46C
5H1T,X-RAY DIFFRACTION,2.38,48.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, 2%(v/v) Polyethylene glycol 400, 2.0 M Ammonium sulfate",293,2016-10-11,2017-02-22,5H1T,5998,4,732,242,,86.43,1,1.951,experimental,36.6442,0.2204,0.1771,Complex structure of TRIM24 PHD-bromodomain and inhibitor 1
5H1U,X-RAY DIFFRACTION,2.36,47.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, 2%(v/v) Polyethylene glycol 400, 2.0 M Ammonium sulfate",293,2016-10-11,2017-02-22,5H1U,5932,4,732,211,,86.46,1,1.901,experimental,34.2598,0.2692,0.2252,Complex structure of TRIM24 PHD-bromodomain and inhibitor 2
5KNN,X-RAY DIFFRACTION,2.55,51.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Hepes pH 7.5, 20% Polyethylene glycol 3350, 0.2 M MgCl2",289,2016-06-28,2016-09-28,5KNN,28584,8,3600,,,408.33,1,2.68,experimental,55.755,0.2542,0.216,Evolutionary gain of alanine mischarging to non-cognate tRNAs with a G4:U69 base pair
7KSS,X-RAY DIFFRACTION,2.52,51.19,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KSS,3519,4,373,390,,46.43,1,1.503,experimental,26.204,0.1769,0.1599,"DNA Polymerase Mu, dGTP:Ct Pre-Catalytic Ground State Ternary Complex, 10 mM Ca2+ (20min)"
7KT1,X-RAY DIFFRACTION,2.49,50.58,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG 4000",277,2020-11-24,2022-01-19,7KT1,3497,4,374,297,,47.01,1,1.665,experimental,32.0771,0.1886,0.1647,"DNA Polymerase Mu, dGTP:At Reaction State Ternary Complex, 50 mM Mn2+ (180min)"
7KTA,X-RAY DIFFRACTION,2.52,51.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2021-12-15,7KTA,3285,4,373,190,,46.24,1,1.844,experimental,38.5364,0.1984,0.1672,"DNA Polymerase Mu, 8-oxodGTP:Ct Pre-Catalytic Ground State Ternary Complex, 20 mM Ca2+ (120min)"
4Y8X,X-RAY DIFFRACTION,3.59,65.73,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM sodium acetate, pH 4.6, 26% w/v MEPEG2000, 200 mM ammonium sulfate (crystals were grown at pH4.6 and transferred to pH 7 prior to soaking with compound)",277,2015-02-16,2015-05-27,4Y8X,2177,1,244,215,5,28.95,1,1.9,experimental,27.12,0.1644,0.1575,Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate
4Y8Z,X-RAY DIFFRACTION,3.59,65.73,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM sodium acetate, pH 4.6, 26% w/v MEPEG2000, 200 mM ammonium sulfate (crystals were grown at pH4.6 and transferred to pH 7 prior to soaking with compound)",277,2015-02-16,2015-05-27,4Y8Z,1984,1,244,66,4,28.67,1,2.2,experimental,40.85,0.2608,0.2391,"Factor XIa in complex with the inhibitor (2E)-N-[(1S)-1-[5-chloro-4-(4-hydroxy-2-oxo-1,2-dihydroquinolin-6-yl)-1H-imidazol-2-yl]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enamide"
6A7B,X-RAY DIFFRACTION,2.1,41.54,"VAPOR DIFFUSION, HANGING DROP",,"15-20% (w/v) PEG 8000, 100 mM MES, 0.14M NaCl",289,2018-07-02,2019-07-03,6A7B,5296,2,646,208,,76.33,1,2.37,experimental,,0.2311,0.1635,AKR1C3 complexed with new inhibitor with novel scaffold
6Q2T,X-RAY DIFFRACTION,2.68,54.02,"VAPOR DIFFUSION, HANGING DROP",7.4,"15 mM sodium cholate, 8% PEG3350, 0.2 M potassium formate, pH 7.4",289,2019-08-08,2019-11-13,6Q2T,7658,2,892,29,,108.51,1,2.8,experimental,,0.2559,0.2268,"Human sterol 14a-demethylase (CYP51) in complex with the functionally irreversible inhibitor (R)-N-(1-(3-chloro-4'-fluoro-[1,1'-biphenyl]-4-yl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-(3-fluoro-5-(5-fluoropyrimidin-4-yl)phenyl)-1,3,4-oxadiazol-2-yl)benzamide"
5KSO,X-RAY DIFFRACTION,2.32,47.1,"VAPOR DIFFUSION, SITTING DROP",5,"19 mg/mL protein, 5 mM magnesium chloride, 0.1 M SPG buffer, pH 5.0, 25% w/v PEG1500, GDP observed in the structure was carried through from the expression system during purification",294,2016-07-08,2016-09-21,5KSO,1416,1,190,58,,22.54,1,2.25,experimental,,0.209,0.175,hMiro1 C-domain GDP-Pi Complex P3121 Crystal Form
5KSY,X-RAY DIFFRACTION,2.29,46.34,"VAPOR DIFFUSION, SITTING DROP",8.5,"12 mg/mL protein, 0.1 M Tris, pH 8.5, 16% w/v PEG10000, GDP observed in the structure was carried through from the expression system during purification",294,2016-07-10,2016-09-21,5KSY,1213,1,192,8,,22.63,1,2.482,experimental,,0.3149,0.2659,hMiro1 C-domain GDP Complex P41212 Crystal Form
7V4G,X-RAY DIFFRACTION,2.16,43.08,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M sodium sulfate decahydrate, 20% (w/v) PEG 3350",293,2021-08-13,2022-03-30,7V4G,5570,6,684,235,,83.91,1,2.1,experimental,30.9377,0.2236,0.1851,Crystal structure of human ALKBH5 in complex with m6A-containing ssRNA
6F0A,X-RAY DIFFRACTION,3.1,60.3,"VAPOR DIFFUSION, SITTING DROP",8.5,"27-33% PEG 8000/Ethylene glycol mix
100mM Tris/Bicine mix pH 8.5
20-40mM L-alanine",298,2017-11-17,2017-12-27,6F0A,6364,2,786,217,1,90.25,1,2.26,experimental,56.12,0.225,0.1908,"Crystal structure of human indoleamine 2,3-dioxygenase bound to a triazole inhibitor and alanine molecule."
5WG8,X-RAY DIFFRACTION,2.43,49.4,"VAPOR DIFFUSION, SITTING DROP",8,"10 mM Tris-HCl pH 8.0, 35% 2-methyl-2,4-pentanediol, and 10% polyethylene glycol methyl ether 5000",289.15,2017-07-13,2018-07-18,5WG8,2890,1,333,262,,38.5,1,1.65,experimental,,0.1961,0.1587,"Structure of PP5C with LB-100; 7-oxabicyclo[2.2.1]heptane-2,3-dicarbonyl moiety modeled in the density"
4PUU,X-RAY DIFFRACTION,2.15,42.85,"VAPOR DIFFUSION, HANGING DROP",8,"50 mM di-Ammoniumhydrogen citrate pH 5.0, PEG6000= 5 % (m/V), DTT= 5,15 g/L, NADP+= 0,66 g/L  
Human Aldose Reductase= 15 mg/ml. Afterwards the crystals have been transferred into Tris 100 mM 25% (m/V) PEG6000 pH 8.0 saturated with the inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291,2014-03-14,2015-04-08,4PUU,3015,1,316,380,,36.85,1,1.14,experimental,,0.1561,0.1369,Human Aldose Reductase complexed with a ligand with an IDD structure (2-(2-carbamoyl-5-fluoro-phenoxy)acetic acid) at 1.14 A
6HMB,X-RAY DIFFRACTION,2.49,50.6,"VAPOR DIFFUSION, SITTING DROP",8.5,"180 MICROLITER ENZYME STOCK SOLUTION (6 MG/ML IN 500 MM NACL, 25 MM TRIS/HCL, PH 8.5) WERE MIXED and incubated WITH 20 MIKROLITER of a STOCK SOLUTION of the inhibitor 4B0 (10 MM 4B0 IN DMSO). 20 MICROLITERS OF the resulting solution WERE MIXED WITH 10 MICROLITERS OF RESERVOIR SOLUTION (900 MM LICL, 28 % (W/V) PEG 6000, 100 MM TRIS/HCL, PH 8.5) IN EACH WELL OF A CRYSTALLIZATION PLATE. A SINGLE MACROSEED, grown UNDER THE SAME CONDITIONS, WAS ADDED TO EACH DROPLET of the plate. THE DROPLETS WERE EQUILIBRATED AT 293.15 K using the sitting drop variant of the VAPOR DIFFUSION method. This procedure generated large single crystals of a CK2alpha'/4B0 complex. Afterwards, the inhibitor 4B0 was exchanged against CX-4945 by an extensive soaking procedure of several steps.",293.15,2018-09-12,2019-03-27,6HMB,3491,1,364,466,,43.92,1,1.04,experimental,,0.1463,0.1343,STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 Gene product) IN COMPLEX WITH the inhibitor CX-4945 (Silmitasertib)
6HMC,X-RAY DIFFRACTION,2.41,48.91,"VAPOR DIFFUSION, SITTING DROP",8.5,"180 MICROLITER ENZYME STOCK SOLUTION (6 MG/ML IN 500 MM NACL, 25 MM TRIS/HCL, PH 8.5) WERE MIXED and incubated WITH 20 MIKROLITER of a STOCK SOLUTION of the inhibitor 4B0 (10 MM 4B0 IN DMSO). 20 MICROLITERS OF the resulting solution WERE MIXED WITH 10 MICROLITERS OF RESERVOIR SOLUTION (900 MM LICL, 28 % (W/V) PEG 6000, 100 MM TRIS/HCL, PH 8.5) IN EACH WELL OF A CRYSTALLIZATION PLATE. A SINGLE MACROSEED, grown UNDER THE SAME CONDITIONS, WAS ADDED TO EACH DROPLET of the plate. THE DROPLETS WERE EQUILIBRATED AT 293.15 K using the sitting drop variant of the VAPOR DIFFUSION method. This procedure generated large single crystals of a CK2alpha'/4B0 complex. Afterwards, the inhibitor 4B0 was exchanged against THN27 by an extensive soaking procedure of several steps.",293.15,2018-09-12,2019-03-27,6HMC,3394,1,364,446,,43.71,1,1.03,experimental,,0.1361,0.1229,STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 gene product) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR THN27
6HMD,X-RAY DIFFRACTION,2.24,44.98,"VAPOR DIFFUSION, SITTING DROP",8.5,"180 MICROLITER ENZYME STOCK SOLUTION (6 MG/ML IN 500 MM NACL, 25 MM TRIS/HCL, PH 8.5) WAS MIXED and incubated WITH 20 MIKROLITER of a STOCK SOLUTION of the inhibitor 4B0 (10 MM 4B0 IN DMSO). 20 MICROLITERS OF the resulting solution WAS MIXED WITH 10 MICROLITERS OF RESERVOIR SOLUTION (700 MM LICL, 28 % (W/V) PEG 6000, 100 MM TRIS/HCL, PH 8.5) IN EACH WELL OF A CRYSTALLIZATION PLATE. A SINGLE MACROSEED, grown UNDER THE SAME CONDITIONS, WAS ADDED TO EACH DROPLET of the plate. THE DROPLETS WERE EQUILIBRATED AT 293.15 K using the sitting drop variant of the VAPOR DIFFUSION method. This procedure generated large single crystals of a CK2alpha'/4B0 complex. Afterwards, the inhibitor 4B0 was exchanged against AR18 by an extensive soaking procedure of several steps.",293.15,2018-09-12,2019-03-27,6HMD,3477,1,365,516,,43.51,1,1,experimental,,0.1718,0.1493,STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 gene product) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR AR18
5SSX,X-RAY DIFFRACTION,2.03,39.52,"VAPOR DIFFUSION, SITTING DROP",8.5,"9.6 mg/mL protein in 20mM Tris/HCl pH8.0 mixed 1:1 with reservoir 0.1M Tris/HCl pH 8.5, 20-25% PEG4000, 0.2-0.3M CaCl2",293,2022-08-12,2023-08-23,5SSX,2756,1,323,430,2,36.68,1,1.02,experimental,14.0685,0.1375,0.123,Crystal Structure human formylglycine generating enzyme E130D mutant
8ARU,X-RAY DIFFRACTION,2.03,39.38,"VAPOR DIFFUSION, SITTING DROP",8.5,"7-8 mg/mL protein in 20mM Tris/HCl pH8.0 mixed 1:1 with reservoir 0.1M Tris/HCl pH 8-9, 20-25% PEG4000, 0.25M CaCl2",293,2022-08-17,2023-08-23,8ARU,2763,1,323,419,3,36.58,1,1.08,experimental,12.7678,0.1736,0.1403,Crystal Structure of human formylglycine generating enzyme
4WDT,X-RAY DIFFRACTION,2.2,44.07,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M sodium citrate, 0.4 M ammonium acetate, 2.5% (v/v) 2-methyl-2,4-pentanediol, 22-30% (w/v) PEG4000",298,2014-09-09,2015-04-15,4WDT,2798,1,331,207,,38.99,1,1.5,experimental,12.94,0.20422,0.17642,17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol
4WDU,X-RAY DIFFRACTION,2.18,43.64,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M sodium citrate, 0.4 M ammonium acetate, 2.5% (v/v) 2-methyl-2,4-pentanediol, 22-30% (w/v) PEG4000",298,2014-09-09,2015-04-15,4WDU,2701,1,331,109,,39.03,1,1.7,experimental,15.905,0.23115,0.19708,17beta-HSD5 in complex with 4-chloro-N-(4-chlorobenzyl)-5-nitro-1H-pyrazole-3-carboxamide
4XVE,X-RAY DIFFRACTION,2.18,43.5,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M sodium citrate, 0.4 M ammonium acetate, 2.5% (v/v) 2-methyl-2,4-pentanediol, 22-30% (w/v) PEG4000",298,2015-01-27,2015-04-15,4XVE,2800,1,331,197,,39.16,1,1.55,experimental,14.869,0.20308,0.17912,17beta-HSD5 in complex with 3-pentyl-2-[(pyridin-2-ylmethyl)sulfanyl]-7-(pyrrolidin-1-ylcarbonyl)quinazolin-4(3H)-one
7QS3,X-RAY DIFFRACTION,2.52,51.22,"VAPOR DIFFUSION, SITTING DROP",6.5,"20% PEG3350, 10% ethylene glycol, 0.1M bis-tris-propane pH 6.5, 0.2M sodium bromide",293.15,2022-01-12,2022-05-04,7QS3,1835,1,209,149,,25.54,1,1.75,experimental,38.628,0.1979,0.163,Crystal structure of B30.2 PRYSPRY domain of TRIM16
6BKG,X-RAY DIFFRACTION,2.51,50.92,"VAPOR DIFFUSION, SITTING DROP",7.5,"78.2mM HEPES pH 7.5, 15.64% PEG4000, 7.82% isopropanol, 13.8% glycerol",293,2017-11-08,2018-07-18,6BKG,5531,4,657,114,,82.19,1,2.402,experimental,,0.245,0.2014,Human LigIV catalytic domain with bound DNA-adenylate intermediate in closed conformation
5ZUJ,X-RAY DIFFRACTION,3.14,60.79,EVAPORATION,7.5,"0.1 M HEPES sodium, pH 7.5, 1M Sodium citrate tribasic dihydrate, 10 mM TCEP",277,2018-05-07,2018-12-05,5ZUJ,1390,2,176,63,,20.5,2,2.6,experimental,46.2,0.2416,0.1929,Binding and Enhanced Binding between Key Immunity Proteins TRAF6 and TIFA
4XNC,X-RAY DIFFRACTION,2.11,41.6,"VAPOR DIFFUSION, SITTING DROP",7.3,25% (w/v) PEG4000,298,2015-01-15,2015-08-12,4XNC,1328,1,164,65,,17.9,1,2.23,experimental,17.087,0.1863,0.14,Crystal structure at room temperature of cyclophilin D in complex with an inhibitor
4ZSC,X-RAY DIFFRACTION,2.1,41.36,"VAPOR DIFFUSION, SITTING DROP",7.3,30% PEG4000,291,2015-05-13,2015-08-12,4ZSC,1369,1,164,91,,17.9,1,1.5,experimental,9.817,0.1628,0.1336,Human Cyclophilin D Complexed with an Inhibitor at room temperature
4ZSD,X-RAY DIFFRACTION,2.11,41.59,"VAPOR DIFFUSION, SITTING DROP",7.3,30% PEG4000,291,2015-05-13,2015-08-12,4ZSD,1394,1,164,106,,18.12,1,1.45,experimental,12.549,0.1554,0.1338,Human Cyclophilin D Complexed with an Inhibitor at room temperature
6DE4,X-RAY DIFFRACTION,4.63,73.41,VAPOR DIFFUSION,,"0.1M Tris Ph 7.6,0.2M LiSo4, 15mM CaCl2, 6% EtOH, 15% Ethylene glycol",277,2018-05-11,2018-05-23,6DE4,3380,2,372,70,,45.73,1,2.411,experimental,,0.2205,0.1812,"Homo sapiens dihydrofolate reductase complexed with beta-NADPH and 3'-[(2R)-4-(2,4-diamino-6-ethylphenyl)but-3-yn-2-yl]-5'-methoxy-[1,1'-biphenyl]-4-carboxylic acid"
7KFP,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M PCTP, pH 7.5, 0.2 M AmSO4, 18-23% PEG3350",295,2020-10-14,2021-03-10,7KFP,4138,1,531,254,,62.03,1,1.9,experimental,37.574,0.1953,0.1746,Structure of human PARG complexed with PARG-119
6AX1,X-RAY DIFFRACTION,2.46,50.04,"VAPOR DIFFUSION, SITTING DROP",,"Reservoir Buffer: 0.07M sodium cacodylate pH 5.1-5.9 and 33-51% MPD

The protein is 20 mg/mL in a buffer of 15 mM HEPES pH 8.2; 2 mM TCEP; and 10% glycerol, with hexaethylene glycol monododecyl ether added to 0.1 mM.

Apo protein crystals obtained in this manner were transferred to a cryo-protectant solution consisting of 70 mM NaCacodylate pH 5.1; 10% MPD; 30% PEG-MME-2K, and 1mM of inhibitor compound. Crystals were soaked overnight, then flash-frozen in LN2.",298,2017-09-06,2017-12-27,6AX1,4823,2,696,409,,77.58,1,2.26,experimental,44.77,0.1984,0.163,Structure of human monoacylglycerol lipase bound to a covalent inhibitor
8ELL,X-RAY DIFFRACTION,2.27,45.73,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M MES pH 6.5, 1-4% PEG 20000. Equilibrated over 0.25-0.5 M NaCl.
BLVRB 18 mg/mL.",293,2022-09-26,2023-09-06,8ELL,2014,1,206,325,,22.19,1,1.52,experimental,18.6,0.1875,0.1595,Apo human biliverdin reductase beta (cryogenic)
8ELM,X-RAY DIFFRACTION,2.3,46.49,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M MES pH 6.5, 1-4% PEG 20000.  Equilibrated over 0.25-0.5 M NaCl.  BLVRB 18 mg/mL.",293,2022-09-26,2023-09-06,8ELM,1639,1,206,49,,22.17,1,2.19,experimental,39.67,0.226,0.1752,Apo human biliverdin reductase beta (293K)
6HZX,X-RAY DIFFRACTION,3.14,60.82,EVAPORATION,6,"Ammonium sulfate 0.2M, sodium acetate 0.1M, ph 6.0, PEG 4000 16%, sodium azide 3 mM.
HCA 0.3 mM, foldamere 0.3 mM.",293,2018-10-24,2019-09-18,6HZX,4687,6,558,25,,67.22,2,2.91,experimental,80.678,0.2105,0.1709,Protein-aromatic foldamer complex crystal structure
7OGI,X-RAY DIFFRACTION,2.01,38.88,"VAPOR DIFFUSION, SITTING DROP",7,"15 % PEG 3350, 0.1M K2HPO4",277.15,2021-05-06,2022-06-01,7OGI,1568,1,165,282,,18.45,1,1.01,experimental,10.48,0.1435,0.1352,"Human Cyclophilin D in complex with N-(5-ethyl-4-oxo-1,2,3,4,5,6-hexahydro-1,5-benzodiazocin-8-yl)-7methyl-2-oxo-1H,2H-pyrazolo[1,5-a]pyrimidine-6-carboxamide"
6XGU,X-RAY DIFFRACTION,3.21,61.73,"VAPOR DIFFUSION, SITTING DROP",7.8,"100 mM Tris 7.8, 200 mM KBr, 200 mM KSCN, 3% PGA, 0.35 mM D-myo-phosphatidylinositol 3,4,5-triphosphate",293,2020-06-18,2021-01-13,6XGU,2483,2,307,24,,36.17,2,2.7,experimental,94.6213,0.2357,0.1873,Crystal Structure of KRAS-Q61R (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF
6XGV,X-RAY DIFFRACTION,3.22,61.76,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM sodium cacodylate pH 6.5, 700 mM sodium acetate, 0.35 mM D-myo-phosphatidylinositol 3,4,5-triphosphate",293,2020-06-18,2021-01-13,6XGV,2566,2,307,113,,36.24,2,2.11,experimental,53.533,0.2043,0.1844,Crystal Structure of KRAS-G13D (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF
6XHA,X-RAY DIFFRACTION,3.23,61.96,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM sodium cacodylate pH 6.5, 200 mM MgCl2, 8% PGA, 0.35 mM D-myo-phosphatidylinositol 3,4,5-triphosphate",293,2020-06-18,2021-01-13,6XHA,2459,2,307,12,,36.36,2,2.87,experimental,102.9443,0.2691,0.2167,Crystal Structure of KRAS-G12V (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF
6Z59,X-RAY DIFFRACTION,2.88,57.24,"VAPOR DIFFUSION, SITTING DROP",6,"63% MPD, 0.1M MMT pH 6.0",277.15,2020-05-26,2020-06-03,6Z59,2874,1,357,207,,41.06,1,2,experimental,32.113,0.2398,0.1991,Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003816
9FLB,X-RAY DIFFRACTION,3.03,59.34,"VAPOR DIFFUSION, SITTING DROP",,"57% MPD, 0.1M MMT 6.0",277,2024-06-04,2024-09-11,9FLB,2700,1,357,34,,41.03,1,2.5,experimental,77.965,0.24487,0.19259,Crystal structure of haspin (GSG2) in complex with MU1464
6UQI,X-RAY DIFFRACTION,2.1,41.53,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES, 5 mM MgCl2, 12-21% (w/v) PEG 2K-MME, pH 6.0",293,2019-10-19,2020-10-28,6UQI,3825,3,455,42,,55.27,1,2.5,experimental,43.75,0.239,0.179,Crystal structure of Q38A human DNA polymerase eta bound with 8-oxoadenine (oxoA) and non-hydrolyzable dGTP analog (dGTP*)
6V5K,X-RAY DIFFRACTION,2.12,42.1,"VAPOR DIFFUSION, HANGING DROP",,"PEG2K-MME, MnCl2, MES, pH 6.0",293,2019-12-04,2020-12-09,6V5K,3777,3,452,23,,55.12,1,2.69,experimental,66.83,0.2424,0.1875,Crystal structure of human DNA polymerase eta complexed with N7-nitrogen half-mustard guanine (NHMG) and dCTP*
7RNY,X-RAY DIFFRACTION,2.09,41.06,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM tris base",293,2021-07-30,2022-06-08,7RNY,2323,1,260,215,,29.77,1,1.29,experimental,12.871,0.174,0.154,Carbonic Anhydrase II in complex with 3-ureido benzenesulfonamide derivative
7RNZ,X-RAY DIFFRACTION,2.09,41.12,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM tris base",293,2021-07-30,2022-06-08,7RNZ,2298,1,260,219,,29.72,1,1.3,experimental,15.6086,0.1836,0.1582,Carbonic Anhydrase II in complex with 4-ureido benzenesulfonamide derivative
4RH2,X-RAY DIFFRACTION,2.09,41.06,VAPOR DIFFUSION,8,"1.6 M sodium citrate, Tris 50 mM, pH 8.0, VAPOR DIFFUSION, temperature 296K",296,2014-10-01,2015-11-11,4RH2,2620,1,260,385,,30.09,1,1.3,experimental,13,0.1712,0.1557,"Crystal structure of human carbonic anhydrase II in complex with 2-(6-hydroxy-3-Oxo-3H-xanthen-9-yl)-5-{3-1-(4-sulfamoyl-phenyl)-1h-[1,2,3]triazol-4-ylmethyl-thioureido}-benzoic acid"
5WLR,X-RAY DIFFRACTION,2.16,43,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M sodium citrate
50mM Tris-HCl",298,2017-07-27,2018-08-01,5WLR,2334,1,257,199,,29.58,1,1.49,experimental,19.5808,0.1723,0.1519,Carbonic Anhydrase IX-mimic in complex with aryloxy-2-hydroxypropylammine sulfonamide
6RSZ,X-RAY DIFFRACTION,2.06,39.99,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-05-22,2020-04-15,6RSZ,2435,1,265,261,,30.87,1,1.089,experimental,,0.129,0.1229,Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6S9G,X-RAY DIFFRACTION,2.06,40.27,"VAPOR DIFFUSION, HANGING DROP",,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-07-12,2020-04-15,6S9G,2539,1,265,269,,31.15,1,1.14,experimental,15.82,0.1471,0.1229,Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
8OGF,X-RAY DIFFRACTION,2.11,41.6,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2023-03-20,2024-03-27,8OGF,2492,1,260,277,,30.38,1,1.321,experimental,16.229,0.1559,0.1173,"Human Carbonic Anhydrase II in complex with 4-(((1-(3-((3aR,7R,7aS)-7-hydroxy-2,2-dimethyltetrahydro-[1,3]dioxolo[4,5-c]pyridin-5(4H)-yl)propyl)-1H-1,2,3-triazol-4-yl)methyl)amino)benzenesulfonamide"
7LAE,X-RAY DIFFRACTION,2.62,53.03,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 20-25%(V/V)PEG3350.Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296,2021-01-06,2021-04-21,7LAE,9149,4,1142,4,10,135.97,2,2.97,experimental,68.24,0.2673,0.2164,CRYSTAL STRUCTURE OF MYELOPEROXIDASE SUBFORM C (MPO) COMPLEX WITH Compound-4
4ONL,X-RAY DIFFRACTION,2.16,43.11,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM sodium citrate, 15% PEG 8000, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K",298,2014-01-28,2015-05-06,4ONL,2548,2,313,197,,35.05,2,1.35,experimental,24.14,0.1994,0.1711,"Crystal structure of human Mms2/Ubc13_D81N, R85S, A122V, N123P"
6Q4R,X-RAY DIFFRACTION,2.39,48.45,"VAPOR DIFFUSION, SITTING DROP",7,"100 mM DL-malic acid, Bis-tris propane, pH 7.0, 25% PEG 1500",289,2018-12-06,2019-04-10,6Q4R,8229,1,912,814,3,108.76,1,1.6,experimental,,0.2133,0.1804,High-resolution crystal structure of ERAP1 with bound phosphinic transition-state analogue inhibitor
7M7R,X-RAY DIFFRACTION,2.1,41.3,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-28,2021-06-02,7M7R,4194,3,455,245,,55.71,1,1.81,experimental,21.3475,0.2209,0.183,Human DNA Pol eta S113A with rA-ended primer and dAMPNPP
7Y3B,X-RAY DIFFRACTION,2.45,49.88,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES monohydrate pH 6.0, 14% w/v Polyethylene glycol 4,000",291,2022-06-10,2022-08-03,7Y3B,1602,1,191,180,,21.2,1,1.76,experimental,22.94,0.1889,0.1629,Crystal structure of TRIM7 bound to GN1
7Y3C,X-RAY DIFFRACTION,2.29,46.22,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M Potassium sodium tartrate tetrahydrate, 26% w/v Polyethylene glycol 3,350",291,2022-06-10,2022-08-03,7Y3C,1617,1,194,151,,21.39,1,1.71,experimental,25.9,0.1976,0.1627,Crystal structure of TRIM7 bound to RACO-1
7ZIK,X-RAY DIFFRACTION,2.16,42.93,"VAPOR DIFFUSION, SITTING DROP",,"27% w/v PEG 3350, 0.1 M Bis-Tris pH 6.5",293.15,2022-04-08,2022-09-07,7ZIK,4599,2,652,76,,76.05,1,2.58925907124,experimental,37.9885529752,0.259070423425,0.223576011016,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor LP533401
6G35,X-RAY DIFFRACTION,3,59.04,"VAPOR DIFFUSION, SITTING DROP",,"51-63% MPD and 0.1M SPG buffer, pH 6.0-6.5",277.15,2018-03-24,2018-04-18,6G35,3156,1,357,318,,41.45,1,1.55,experimental,28.455,0.18269,0.1602,Crystal structure of haspin in complex with 5-bromotubercidin
6G37,X-RAY DIFFRACTION,3.04,59.49,"VAPOR DIFFUSION, SITTING DROP",,"51-63% MPD and 0.1M SPG buffer, pH 6.0-6.5",277.15,2018-03-24,2018-04-18,6G37,2852,1,357,215,,41.09,1,1.48,experimental,19.777,0.16741,0.14823,Crystal structure of haspin in complex with 5-fluorotubercidin
6G39,X-RAY DIFFRACTION,3.04,59.54,"VAPOR DIFFUSION, SITTING DROP",,"51-63% MPD and 0.1M SPG buffer, pH 6.0-6.5",277.15,2018-03-24,2018-04-18,6G39,3124,1,357,339,,41.51,1,1.45,experimental,25.173,0.17543,0.15762,Crystal structure of haspin F605Y mutant in complex with 5-iodotubercidin
6WO0,X-RAY DIFFRACTION,2.57,52.14,"VAPOR DIFFUSION, HANGING DROP",,"50 mM MES pH 6.5, 0.1 M LiCl, 0.01 M MgCl2, 12% PEG 4000 (w/v)",300,2020-04-23,2020-07-01,6WO0,3040,1,375,105,,43.61,1,1.97,experimental,53.457,0.2695,0.2177,"human Artemis/SNM1C catalytic domain, crystal form 1"
6TUC,X-RAY DIFFRACTION,2.18,43.5,"VAPOR DIFFUSION, HANGING DROP",5,"PEG 6000, DTT, diammonium hydrogen citrate, NADP+",291,2020-01-06,2021-01-27,6TUC,3365,1,316,489,,37.18,1,1.06,experimental,10.6,0.1433,0.1264,Human Aldose Reductase in complex with ALR25
6TUF,X-RAY DIFFRACTION,2.15,42.7,"VAPOR DIFFUSION, HANGING DROP",5,"PEG 6000, DTT, diammonium hydrogen citrate, NADP+",291,2020-01-07,2021-01-27,6TUF,3195,1,316,384,,37.2,1,1.15,experimental,14.91,0.1524,0.1292,Human Aldose Reductase in complex with ALR43
4RIU,X-RAY DIFFRACTION,2.07,40.5,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M Sodium Citrate, 50mM Tris, pH 7.8, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K",298,2014-10-07,2015-02-04,4RIU,2340,1,260,202,,29.98,1,1.651,experimental,,0.1761,0.1514,A Carbonic Anhydrase IX Mimic in Complex with a Saccharin-Based Inhibitor
4ZWY,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl pH 7.8",293,2015-05-19,2015-08-05,4ZWY,2408,1,257,285,,29.67,1,1.5,experimental,24.1905,0.1733,0.1553,Human Carbonic Anhydrase II in complex with a glucosyl sulfamate inhibitor
4ZX0,X-RAY DIFFRACTION,2.12,42.11,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl",293,2015-05-19,2015-10-28,4ZX0,2398,1,257,296,,29.58,1,1.6,experimental,17.7991,0.1785,0.1517,Human Carbonic Anhydrase II in complex with a glucosyl sulfamate inhibitor
5EH5,X-RAY DIFFRACTION,2.06,40.19,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris-chloride",280,2015-10-28,2016-03-09,5EH5,2601,1,260,401,,29.57,1,1.207,experimental,,0.1867,0.171,human carbonic anhydrase II in complex with ligand
5EH7,X-RAY DIFFRACTION,2.1,41.43,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris chloride",280,2015-10-28,2016-03-09,5EH7,2588,1,260,411,,29.67,1,1.425,experimental,,0.1743,0.1454,human carbonic anhydrase II in complex with ligand
5EH8,X-RAY DIFFRACTION,2.08,40.73,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris chloride",280,2015-10-28,2016-03-09,5EH8,2495,1,260,302,,29.59,1,1.381,experimental,,0.1733,0.1503,human carbonic anhydrase II in complex with ligand
5EKH,X-RAY DIFFRACTION,2.12,42,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris, pH 7.0, 1.3 M sodium citrate",294,2015-11-03,2016-01-06,5EKH,2317,1,260,255,,29.7,1,1.34,experimental,12.5262,0.1618,0.1371,Human Carbonic Anhydrase II complexed with a two-faced guest
5EKJ,X-RAY DIFFRACTION,2.11,41.61,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris, pH 7.0, 1.3 M sodium citrate",294,2015-11-03,2016-01-06,5EKJ,2346,1,260,272,,29.77,1,1.129,experimental,10.7384,0.1505,0.1344,Human Carbonic Anhydrase II complexed with a two-faced guest
5EKM,X-RAY DIFFRACTION,2.11,41.78,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris, pH 7.0, 1.3 M sodium citrate",294,2015-11-03,2016-01-06,5EKM,2306,1,260,231,,29.74,1,1.33,experimental,12.6001,0.1666,0.142,Human Carbonic Anhydrase II complexed with a two-faced guest
5NEA,X-RAY DIFFRACTION,2.08,40.95,VAPOR DIFFUSION,8,"1.6 M sodium citrate, Tris 50 mM",296,2017-03-10,2017-12-06,5NEA,2564,1,260,380,,29.99,1,1.3,experimental,13.206,0.1863,0.1658,"Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-(2-methyl-1,3-oxazol-5-yl)benzene-1-sulfonammide"
5NEE,X-RAY DIFFRACTION,2.07,40.7,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM",296,2017-03-10,2017-12-06,5NEE,2398,1,260,289,,29.79,1,1.7,experimental,13.396,0.2223,0.1841,"Crystal structure of human carbonic anhydrase II in complex with the inhibitor 5-[2-(morpholine-4-carbonyl)1,3-oxazol-5-yl)]thiophene-2-sulfonammide"
5W8B,X-RAY DIFFRACTION,2.11,41.62,"VAPOR DIFFUSION, HANGING DROP",7.4,"1.4M Sodium Citrate, 50mM Tris, pH 7.8",296,2017-06-21,2018-05-30,5W8B,2270,1,257,151,,29.51,1,1.601,experimental,17.085,0.1832,0.1559,Carbonic anhydrase II in complex with activating histamine pyridinium derivative
5WLT,X-RAY DIFFRACTION,2.16,42.96,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate
50mM Tris-HCl",298,2017-07-27,2018-08-01,5WLT,2390,1,257,213,,30.24,1,1.57,experimental,18.2664,0.1758,0.1452,Carbonic Anhydrase IX-mimic in complex with aryloxy-2-hydroxypropylammine sulfonamide
5Y2R,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,2017-07-27,2018-02-14,5Y2R,2604,1,260,441,,29.49,1,1,experimental,12.893,0.13095,0.11408,2.5 atm CO2-pressurized human carbonic anhydrase II
6H2Z,X-RAY DIFFRACTION,2.05,40.05,"VAPOR DIFFUSION, HANGING DROP",8.5,"sodium citrate 1.3M, Tris-HCl 0.1 M, pH 8.5",293,2018-07-17,2018-12-19,6H2Z,2234,1,262,158,,30.07,1,1.94,experimental,,0.214,0.179,The crystal structure of human carbonic anhydrase II in complex with 4-(4-phenylpiperidine-1-carbonyl)benzenesulfonamide.
6H33,X-RAY DIFFRACTION,2.06,40.21,"VAPOR DIFFUSION, HANGING DROP",8.5,"sodium citrate 1.3 M, Tris-HCl 0.1 M, pH 8.5",293,2018-07-17,2018-12-19,6H33,2350,1,262,225,,30,1,1.58,experimental,,0.194,0.166,The crystal structure of human carbonic anhydrase II in complex with 4-(4-phenyl)-4-hydroxy-1-piperidine-1-carbonyl)benzenesulfonamide.
6H34,X-RAY DIFFRACTION,2.07,40.67,"VAPOR DIFFUSION, HANGING DROP",8.5,"Sodium citrate 1.3 M, Tris-HCl 0.1 M pH 8.5",293,2018-07-17,2018-12-19,6H34,2325,1,262,229,,30.01,1,1.55,experimental,,0.206,0.171,The crystal structure of human carbonic anhydrase II in complex with 4-[(4-fluorophenyl)methyl]-1-piperazinyl]benzenesulfonamide.
6HQX,X-RAY DIFFRACTION,2.06,40.18,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.70 M, pH = 7.8, saturated with p-Chloromercuribenzoic acid",291,2018-09-25,2019-10-09,6HQX,2535,1,265,275,,30.98,1,1.097,experimental,,0.1389,0.1218,Human Carbonic Anhydrase II in complex with 4-Ethylbenzenesulfonamide
6HR3,X-RAY DIFFRACTION,2.06,40.37,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammoniumsulfate 2.70 M, pH = 7.8, saturated with para-Chloromercuribenzoic acid.",291,2018-09-26,2019-10-09,6HR3,2550,1,265,244,,30.77,1,1.02,experimental,,0.1452,0.1286,Human Carbonic Anhydrase II in complex with 4-Propylbenzenesulfonamide
6HXD,X-RAY DIFFRACTION,2.06,40.18,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammoniumsulfate 2.70 M, pH 0 7.8, staurated para-Chloromercuribenzoic acid.",291,2018-10-17,2019-10-30,6HXD,2570,1,265,252,,30.79,1,1.119,experimental,,0.1311,0.1147,Human Carbonic Anhydrase II in complex with 4-Butylbenzenesulfonamide
6I2F,X-RAY DIFFRACTION,2.05,39.96,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammoniumsulfate 2.70 M, pH = 7.8, saturated with para-Chloromercuribenzoic acid.",291,2018-11-01,2019-11-20,6I2F,2543,1,265,282,,30.99,1,1.198,experimental,,0.1388,0.1162,Human Carbonic Anhydrase II in complex with 4-Propoxybenzenesulfonamide
6KM1,X-RAY DIFFRACTION,2.09,41.14,"VAPOR DIFFUSION, HANGING DROP",8,"1.3 M sodium citrate, 100 mM Tris-HCl",293,2019-07-30,2020-08-05,6KM1,2680,1,260,373,,29.61,1,1.05,experimental,11.403,0.1214,0.1035,Human Carbonic Anhydrase II V143I variant 13 atm CO2
6KM4,X-RAY DIFFRACTION,2.08,41,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 100 mM Tris-HCl",293,2019-07-30,2020-08-05,6KM4,2606,1,260,364,,29.53,1,1.15,experimental,14.62,0.1242,0.098,Human Carbonic Anhydrase II native 07 atm CO2
6KM5,X-RAY DIFFRACTION,2.08,40.79,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 100 mM Tris-HCl",293,2019-07-30,2020-08-05,6KM5,2589,1,260,364,,29.53,1,1.151,experimental,16.179,0.1288,0.1028,Human Carbonic Anhydrase II native 13 atm CO2
6KM6,X-RAY DIFFRACTION,2.07,40.72,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 100 mM Tris-HCl",293,2019-07-30,2020-08-05,6KM6,2588,1,260,363,,29.53,1,1.15,experimental,17.558,0.1336,0.1052,Human Carbonic Anhydrase II native 15 atm CO2
6LUV,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LUV,2536,1,260,373,,29.47,1,1.2,experimental,14.896,0.1483,0.1169,apo- Carbonic Anhydrase II pH 7.8 20 atm CO2
6LUX,X-RAY DIFFRACTION,2.1,41.36,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LUX,2521,1,260,367,,29.53,1,1.2,experimental,14.193,0.1418,0.1128,Zn- Carbonic Anhydrase II pH 7.8 20 atm CO2
6LUZ,X-RAY DIFFRACTION,2.1,41.42,"VAPOR DIFFUSION, HANGING DROP",11,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LUZ,2519,1,260,365,,29.53,1,1.2,experimental,12.078,0.1273,0.1033,Zn- Carbonic Anhydrase II pH 11.0 20 atm CO2
6LV1,X-RAY DIFFRACTION,2.08,40.86,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LV1,2444,1,260,283,,29.5,1,1.2,experimental,14.04,0.1497,0.12,Co- Carbonic Anhydrase II pH 7.8 0 atm CO2
6LV2,X-RAY DIFFRACTION,2.09,41.19,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LV2,2485,1,260,333,,29.55,1,1.2,experimental,13.704,0.1392,0.1138,Co- Carbonic Anhydrase II pH 7.8 20 atm CO2
6LV4,X-RAY DIFFRACTION,2.1,41.51,"VAPOR DIFFUSION, HANGING DROP",11,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LV4,2488,1,260,333,,29.59,1,1.2,experimental,13.542,0.1394,0.1125,Co- Carbonic Anhydrase II pH 11.0 20 atm CO2
6LV5,X-RAY DIFFRACTION,2.08,41.01,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LV5,2437,1,260,279,,29.5,1,1.2,experimental,11.725,0.141,0.1163,Ni- Carbonic Anhydrase II pH 7.8 0 atm CO2
6LV6,X-RAY DIFFRACTION,2.1,41.29,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LV6,2500,1,260,347,,29.6,1,1.2,experimental,11.027,0.138,0.1124,Ni- Carbonic Anhydrase II pH 7.8 20 atm CO2
6LV7,X-RAY DIFFRACTION,2.09,41.05,"VAPOR DIFFUSION, HANGING DROP",11,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LV7,2437,1,260,279,,29.5,1,1.2,experimental,12.257,0.1394,0.1171,Ni- Carbonic Anhydrase II pH 11.0 0 atm CO2
6LV8,X-RAY DIFFRACTION,2.1,41.41,"VAPOR DIFFUSION, HANGING DROP",11,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LV8,2499,1,260,346,,29.6,1,1.2,experimental,11.329,0.1364,0.1121,Ni- Carbonic Anhydrase II pH 11.0 20 atm CO2
6LVA,X-RAY DIFFRACTION,2.1,41.45,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2020-02-02,2020-08-19,6LVA,2509,1,260,360,,29.55,1,1.2,experimental,11.628,0.1419,0.113,Cu- Carbonic Anhydrase II pH 7.8 20 atm CO2
6XXT,X-RAY DIFFRACTION,2.08,40.89,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.2 M sodium citrate
0.1 M Tris-HCl",293,2020-01-28,2020-06-03,6XXT,2459,1,262,271,,30.01,1,1.05,experimental,10.499,0.1455,0.1348,The crystal structure of hCA II in complex with a 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamide derivative.
6YRI,X-RAY DIFFRACTION,2.07,40.6,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 0.1 M Tris-HCl, pH 8.5",293,2020-04-20,2021-03-31,6YRI,2411,1,262,278,,29.91,1,1.6,experimental,12.2197,0.1925,0.159,THE CRYSTAL STRUCTURE OF THE COMPLEX OF HCAII WITH CAFFEIC ACID
7A6V,X-RAY DIFFRACTION,2.07,40.66,"VAPOR DIFFUSION, SITTING DROP",8,"1,5-1,8 M sodium citrate",295,2020-08-26,2021-10-06,7A6V,2146,1,258,38,,29.59,1,2,experimental,17.657,0.2581,0.209,Human Carbonic Anhydrase II in complex with 4-(3-(3-phenoxypropyl)thioureido)benzenesulfonamide
7K6T,X-RAY DIFFRACTION,2.05,39.94,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.6M Sodium Citrate, 50mM Tris, pH 6.4",295,2020-09-21,2020-12-23,7K6T,2234,1,260,147,,29.76,1,1.759,experimental,12.6367,0.2118,0.1805,Carbonic Anhydrase IX mimic complexed with 4-(2-(3-phenylureido)ethylsulfonamido)benzenesulfonamide
7QZX,X-RAY DIFFRACTION,2.11,41.82,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2022-02-01,2023-02-15,7QZX,2319,1,260,225,,29.88,1,1.24,experimental,16.14,0.179,0.1588,"Human Carbonic Anhydrase II in complex with 4-oxo-N-(4-sulfamoylphenethyl)-1,3,4,6,7,11b-hexahydro-2H-pyrazino[2,1-a]isoquinoline-2-carboxamide"
7R1X,X-RAY DIFFRACTION,2.11,41.7,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2022-02-03,2023-02-15,7R1X,2327,1,260,229,,29.89,1,1.35,experimental,16.188,0.1763,0.1572,"human Carbonic Anhydrase II in complex with 4-oxo-N-(4-sulfamoylphenethyl)-1,3,4,6,7,11b-hexahydro-2H-pyrazino[2,1-a]isoquinoline-2-carbothioamide"
7YWT,X-RAY DIFFRACTION,2.1,41.3,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2022-02-14,2023-02-22,7YWT,2380,1,260,248,,29.85,1,1.106,experimental,12.097,0.1774,0.1615,"human Carbonic Anhydrase II in complex with 4-oxo-N-(4-sulfamoylphenyl)-1,3,4,6,7,11b-hexahydro-2H-pyrazino[2,1-a]isoquinoline-2-carboxamide"
5TJL,X-RAY DIFFRACTION,2.26,45.66,VAPOR DIFFUSION,,"The first crystals of GTA/GTB were grown as mercury derivatives (Patenaude, S.I., et al. 2002): 10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000. Crystals were washed with artificial mother liquor ML-1 consisting of 10% polyethylene glycol (PEG) 4000, 30 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) buffer pH 7.5, 30 mM sodium acetate buffer pH 4.6, 100 mM ammonium sulfate, 10 mM MnCl2 and 30% glycerol as the cryoprotectant. Crystals of GTA/GTB in complex with the A and B trisaccharides were obtained by soaking them in mother liquor ML-1 with 30% glycerol and 45-50 mM substrates for 2-5 days at 18 degrees Celsius",277,2016-10-04,2017-06-14,5TJL,2226,1,297,86,,36.01,1,1.89,experimental,31.273,0.2236,0.1879,Crystal structure of GTA + A trisaccharide (mercury derivative)
5TJO,X-RAY DIFFRACTION,2.27,45.76,VAPOR DIFFUSION,,"The first crystals of GTA/GTB were grown as mercury derivatives (Patenaude, S.I., et al. 2002): 10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000. Crystals were washed with artificial mother liquor ML-1 consisting of 10% polyethylene glycol (PEG) 4000, 30 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) buffer pH 7.5, 30 mM sodium acetate buffer pH 4.6, 100 mM ammonium sulfate, 10 mM MnCl2 and 30% glycerol as the cryoprotectant. Crystals of GTA/GTB in complex with the A and B trisaccharides were obtained by soaking them in mother liquor ML-1 with 30% glycerol and 45-50 mM substrates for 2-5 days at 18 degrees Celsius",277,2016-10-04,2017-06-14,5TJO,2366,1,297,200,,36.33,1,1.57,experimental,24.013,0.1958,0.1736,Crystal structure of GTB + B trisaccharide (mercury derivative)
8YHW,X-RAY DIFFRACTION,2.67,53.94,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MMT pH9.0, 25% PEG1500",293,2024-02-28,2024-03-13,8YHW,10676,4,1404,147,,157.78,1,2.9,experimental,49.624,0.2412,0.194,The Crystal Structure of NF-kB-inducing Kinase (NIK) from Biortus
6WW4,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M ammonium acetate, 0.1 M Bis-Tris, pH 5.5, and 17% PEG 10000",298,2020-05-07,2020-08-05,6WW4,973,2,112,53,,13.5,1,2.252,experimental,29.9424,0.2434,0.1985,Crystal structure of HERC2 ZZ domain in complex with histone H3 tail
4YVX,X-RAY DIFFRACTION,2.44,49.52,"VAPOR DIFFUSION, HANGING DROP",6,"15-20% (w/v) PEG 8000, 100 mM MES, 0.14M NaCl",289,2015-03-20,2015-11-25,4YVX,5460,2,646,248,,76.28,1,2.3,experimental,26.613,0.23234,0.1843,Crystal structure of AKR1C3 complexed with glimepiride
7BN5,X-RAY DIFFRACTION,1.92,35.97,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-21,2022-03-02,7BN5,2834,1,383,27,6,44.39,1,2.22,experimental,51.4891,0.2547,0.2127,Notum fragment_1 (2-(isoquinolin-1-ylsulfanyl)acetic acid)
7BNC,X-RAY DIFFRACTION,1.92,36.04,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-21,2022-03-02,7BNC,2902,1,383,46,7,44.8,1,1.86,experimental,36.68,0.2436,0.2049,"Notum fragment_126 (2-(1,2-dihydroacenaphthylen-5-ylsulfanyl)acetic acid)"
7BND,X-RAY DIFFRACTION,1.95,36.78,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-21,2022-03-02,7BND,2934,1,383,48,7,44.7,1,2.1,experimental,42.4413,0.2464,0.2029,"Notum_Fragment41 (N-methyl-4,5-dihydronaphtho,2-bthiophene-2-carboxamide)"
7BNF,X-RAY DIFFRACTION,1.95,36.79,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-22,2022-03-02,7BNF,3042,1,383,141,6,45.28,1,1.45,experimental,22.1774,0.1804,0.1561,Notum Cotinine
5KU1,X-RAY DIFFRACTION,2.96,58.43,"VAPOR DIFFUSION, HANGING DROP",,"9 mg/mL protein, 5 mM magnesium chloride, 1 mM GDP, 0.2 M ammonium sulfate, 0.1 M trisodium citrate, pH 5.6, 25% w/v PEG4000",294,2016-07-12,2016-09-21,5KU1,3280,1,424,38,,49.59,1,2.501,experimental,,0.2639,0.2262,hMiro1 EF hand and cGTPase domains in the GDP-bound state
4WDW,X-RAY DIFFRACTION,2.33,47.11,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M HEPES, 0.2M ammonium dihydrogen phosphate, 20-25% (w/v) PEG3350",298,2014-09-09,2015-04-15,4WDW,5069,2,662,149,,77.9,1,1.94,experimental,30.507,0.25334,0.19875,"17beta-HSD5 in complex with 3,6-dihydropyridin-1(2H)-yl(5-methyl-1H-indol-2-yl)methanone"
4WDX,X-RAY DIFFRACTION,2.19,43.71,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M HEPES, 0.2M ammonium dihydrogen phosphate, 20-25% (w/v) PEG3350",298,2014-09-09,2015-04-15,4WDX,5218,2,662,276,,77.99,1,1.64,experimental,27.64,0.24879,0.21429,17beta-HSD5 in complex with [4-(2-hydroxyethyl)piperidin-1-yl](5-methyl-1H-indol-2-yl)methanone
6EI8,X-RAY DIFFRACTION,3.9,68.45,"VAPOR DIFFUSION, HANGING DROP",6,"2M ammonium sulfate
50 mM sodium cacodylate
15 mM magnesium acetate",292,2017-09-18,2018-10-10,6EI8,840,1,120,48,,13.94,1,2.25,experimental,52.3,0.286,0.259,Crystal structure of human tRNA-dihydrouridine (20) synthase dsRBD F359A mutant
6RCY,X-RAY DIFFRACTION,2.97,58.55,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.8M potassium phosphate, 0.8M sodium phosphate, 0.1M HEPES, pH 7.5",293,2019-04-12,2020-05-13,6RCY,1077,1,148,12,,16.91,1,2.3,experimental,88.89,0.244,0.218,CRYSTAL STRUCTURE OF FK1 DOMAIN OF FKBP52 IN COMPLEX WITH A BIO-INSPIRED HYBRID FLUORESCENT LIGAND
7ZEE,X-RAY DIFFRACTION,2.23,44.77,VAPOR DIFFUSION,6.2,"0.1 M MES pH 6.2, 27% PEG 3350",277.15,2022-03-31,2022-04-13,7ZEE,2642,1,302,295,,35.7,1,1.36,experimental,28.56,0.1965,0.1586,Human cytosolic 5' nucleotidase IIIB
7L8M,X-RAY DIFFRACTION,1.68,26.76,MICROBATCH,6,"0.1 M sodium chloride, 0.1 M MES, 40% (w/v) PEG 8000",293,2020-12-31,2021-12-29,7L8M,1388,1,192,60,,21.87,1,2.07,experimental,34.1753,0.236,0.1701,Crystal structure of human GPX4-U46C mutant K48L
7Y2G,X-RAY DIFFRACTION,2.09,41.25,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2G,2391,1,260,243,,29.46,1,1.2,experimental,14.96,0.14857,0.11946,Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 160 K
7Y2H,X-RAY DIFFRACTION,2.1,41.32,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.3 M sodium citrate, 50 mM Tris-HCl",293,2022-06-09,2023-12-20,7Y2H,2391,1,260,243,,29.46,1,1.2,experimental,16.298,0.14926,0.12026,Zn-Carbonic Anhydrase II complexed with 3NPA after UV at 180 K
8SP5,X-RAY DIFFRACTION,2.27,45.78,"VAPOR DIFFUSION, SITTING DROP",,"0.14 M ammonium sulfate, 24% polyethylene glycol 5000 monomethyl ether, 5 mM magnesium chloride",298,2023-05-02,2024-05-22,8SP5,4020,2,478,236,,55.09,1,2.23,experimental,,0.25,0.203,LINE-1 retrotransposon endonuclease domain complex with Mn2+
7LYX,X-RAY DIFFRACTION,2.45,50,"VAPOR DIFFUSION, SITTING DROP",7.5,"2-methyl-2,4-pentanediol, HEPES pH 7.5, PEG 10000",298,2021-03-08,2022-08-17,7LYX,3845,1,489,17,,58.27,1,2.6,experimental,56.87,0.2688,0.214,Crystal structure of human CYP8B1 in complex with (S)-tioconazole
8JP1,X-RAY DIFFRACTION,2.55,51.79,"VAPOR DIFFUSION, HANGING DROP",6,"15-20% (w/v) PEG 8000, 100 mM MES and 0.14 M NaCl",298,2023-06-10,2024-04-24,8JP1,6176,2,662,1092,,77.95,1,2,experimental,,0.257,0.2055,Crystal structure of AKR1C3 in complex with DFV
7B8K,X-RAY DIFFRACTION,2,38.36,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B8K,2854,1,383,108,6,44.3,1,1.6,experimental,25.7608,0.2449,0.2217,Notum-Fragment 173
7B8L,X-RAY DIFFRACTION,1.99,38.3,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-13,2022-01-12,7B8L,2941,1,383,112,6,44.75,1,1.45,experimental,23.0321,0.2471,0.2156,Notum-Fragment 174
7B8M,X-RAY DIFFRACTION,2,38.39,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-13,2022-01-12,7B8M,2884,1,383,113,6,44.42,1,1.48,experimental,23.0347,0.2458,0.2194,Notum-Fragment 193
7B8O,X-RAY DIFFRACTION,1.99,38.12,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-13,2022-01-12,7B8O,2941,1,383,127,6,44.92,1,1.5,experimental,24.4347,0.2335,0.2101,Notum-Fragment 199
5FA6,X-RAY DIFFRACTION,2.34,47.42,"VAPOR DIFFUSION, HANGING DROP",6.5,"MES buffer, PEG 4K, CaAc2 and NaCl",292,2015-12-11,2016-08-17,5FA6,10067,2,1236,199,,144.14,1,2.3,experimental,55.1,0.28,0.225,wild type human CYPOR
6VKG,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, SITTING DROP",,"200 nL 5.9 mg/mL protein + 200 nL reservoir (2.7 M ammonium sulfate, 50 mM Tris buffer, pH 8.2)",293,2020-01-20,2020-03-04,6VKG,2377,1,260,231,,29.92,1,1.37,experimental,14.28,0.1671,0.1269,Human carbonic anhydrase IX mimic with Epacadostat bound
6XI7,X-RAY DIFFRACTION,2.7,54.49,"VAPOR DIFFUSION, SITTING DROP",5.3,"2218.18 mM AMSO4, 6.5% (w/v) PEG 400, pH 5.3",293,2020-06-19,2021-01-13,6XI7,2524,2,307,82,,36.19,2,1.95,experimental,59.7209,0.2321,0.2042,Crystal Structure of wild-type KRAS (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF (crystal form I)
5EHV,X-RAY DIFFRACTION,2.08,40.81,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris-chloride",280,2015-10-29,2016-03-09,5EHV,2578,1,260,382,,29.83,1,1.208,experimental,,0.1746,0.1532,human carbonic anhydrase II in complex with ligand
5EHW,X-RAY DIFFRACTION,2.11,41.79,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris-chloride",280,2015-10-29,2016-03-09,5EHW,2506,1,260,312,,29.73,1,1.392,experimental,,0.1685,0.1514,human carbonic anhydrase II in complex with ligand
5UY9,X-RAY DIFFRACTION,2.76,55.49,"VAPOR DIFFUSION, HANGING DROP",,"140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 , 1.8 mM KH2PO4, PH 7.3",277,2017-02-23,2017-04-26,5UY9,1337,2,170,80,,19.59,2,1.85,experimental,42.425,0.29078,0.23229,Prolyl isomerase Pin1 R14A mutant bound with Brd4 peptide
6QF4,X-RAY DIFFRACTION,2.89,57.43,BATCH MODE,7.5,"0.2M ammonium acetate, 20% PEG 3350, 50mM sodium/potassium tartrate, 0.8mM quercetin",295,2019-01-09,2019-07-10,6QF4,2496,1,327,122,,37.94,1,2.495,experimental,57.04,0.2268,0.1827,X-Ray structure of human Serine/Threonine Kinase 17B (STK17B) aka DRAK2 in complex with ADP obtained by on-chip soaking
5MGU,X-RAY DIFFRACTION,2.51,51.08,"VAPOR DIFFUSION, HANGING DROP",,"2 mM DTT, 100 mM bis-Tris propane pH 7 and 1.8 M sodium acetate pH 7",292,2016-11-22,2017-05-03,5MGU,3611,1,407,235,,47.81,1,1.89,experimental,42.4404,0.2438,0.2017,"Kinetic and Structural Changes in HsmtPheRS, Induced by Pathogenic Mutations in Human FARS2"
5MGW,X-RAY DIFFRACTION,2.51,50.96,"VAPOR DIFFUSION, HANGING DROP",,"2 mM DTT, 100 mM bis-Tris propane pH 7 and 1.8 M sodium acetate pH 7",292,2016-11-22,2017-05-03,5MGW,3887,1,406,522,,47.65,1,1.46,experimental,28.2491,0.2049,0.1851,"Kinetic and Structural Changes in HsmtPheRS, Induced by Pathogenic Mutations in Human FARS2"
8P8X,X-RAY DIFFRACTION,2.43,49.29,"VAPOR DIFFUSION, SITTING DROP",7,"1.7 M sodium acetate trihydrate pH 7, 0.1 M BIS-TRIS propane pH 7, 0.1 M MgCl2, 1% v/v 1,2-Butanediol",296,2023-06-03,2023-08-16,8P8X,3851,1,415,477,,48.58,1,1.46,experimental,,0.1668,0.1455,Crystal structure of a pathogenic mutant variant of human mitochodnrial PheRS
6G5U,X-RAY DIFFRACTION,2.22,44.2,"VAPOR DIFFUSION, SITTING DROP",5,"Crystallization buffer: 0.1M ammonium citrate (pH 5.0) and 18% PEG
4000",291,2018-03-30,2019-03-13,6G5U,4837,2,526,607,,60.39,1,1.7,experimental,16.5456,0.229,0.1924,"Crystal structure of human carbonic anhydrase isozyme XIII with N-butyl-2,4-dichloro-5-sulfamoyl-benzamide"
5SK9,X-RAY DIFFRACTION,2.64,53.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295,2022-02-01,2022-10-12,5SK9,10327,4,1372,95,,158.54,1,2.82,experimental,81.42,0.2389,0.2123,Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-5-methoxy-3-methylquinoxaline
4UZ1,X-RAY DIFFRACTION,1.9,34,,4.6,"1.5 M AMMONIUM SULPHATE, 0.1 M SODIUM ACETATE PH 4.6",,2014-09-04,2015-02-25,4UZ1,3212,1,383,287,7,44.17,1,1.4,experimental,18.766,0.18045,0.14387,STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM III - 1.4A
4UZ5,X-RAY DIFFRACTION,2.5,52,,6,"10 %W/V PEG4000, 0.01 M CACL2, 0.05 M NACACOD PH 6.0, 0.20 M KCL, 1 MM HEPARIN HEXAMER",,2014-09-04,2015-02-25,4UZ5,2901,1,383,84,7,43.82,1,2.1,experimental,43.492,0.2371,0.18746,STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM IV - 2.1A
4XVD,X-RAY DIFFRACTION,2.6,52.67,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M sodium citrate, 0.4 M ammonium acetate, 2.5% (v/v) 2-methyl-2,4-pentanediol, 22-30% (w/v) PEG4000",298,2015-01-27,2015-04-15,4XVD,5173,2,662,13,,78.2,1,2.81,experimental,33.592,0.25873,0.20865,17beta-HSD5 in complex with 4-nitro-2-({4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}methyl)phenol
4ZQL,X-RAY DIFFRACTION,2.4,48.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 2M ammonium sulfate, 2%(v/v) PEG 400",293.15,2015-05-10,2015-06-17,4ZQL,3145,2,368,208,,44.08,1,1.79,experimental,31.473,0.19904,0.15883,"Crystal structure of TRIM24 with 3,4-dimethoxy-N-(6-(4-methoxyphenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide inhibitor"
6TMP,X-RAY DIFFRACTION,3.23,61.92,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.1 M Sodium acetate pH 5.8
0.125 M Magnesium chloride",277,2019-12-05,2020-10-14,6TMP,2977,1,394,140,,45.44,1,2.076,experimental,47.262,0.2401,0.1719,Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6TMZ,X-RAY DIFFRACTION,3.3,62.68,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.1 M Sodium acetate pH 5.8
0.125 M Magnesium chloride",277,2019-12-05,2020-10-14,6TMZ,2797,1,394,31,,45.44,1,2.71,experimental,65.226,0.2619,0.1936,Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
5THJ,X-RAY DIFFRACTION,2.08,40.87,"VAPOR DIFFUSION, SITTING DROP",8,"Ammonium Sulfate, Tris, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2016-09-29,2017-04-26,5THJ,2476,1,260,216,,30.55,1,1.5,experimental,11.493,0.18867,0.15382,"Crystal Structure of 2-hydroxycyclohepta-2,4,6-trien-1-one bound to human carbonic anhydrase 2"
5UC9,X-RAY DIFFRACTION,2.1,41.44,VAPOR DIFFUSION,,"0.1 M Bis-Tris (pH 6.5) and 24% (w/v) PEG 2,000 monomethyl ether",293,2016-12-22,2017-02-15,5UC9,7571,4,904,584,,106.06,1,1.903,experimental,33.3945,0.2437,0.1884,Crystal structure of human Heme Oxygenase-2 in complex with Myristate
6Z5C,X-RAY DIFFRACTION,3.08,60.08,"VAPOR DIFFUSION, SITTING DROP",6,"60.0% MPD, 0.1M SPG pH 6.0",277.15,2020-05-26,2020-06-03,6Z5C,3113,1,357,369,,41.37,1,1.75,experimental,17.664,0.1881,0.158,Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004070
6Z5D,X-RAY DIFFRACTION,3.07,60,"VAPOR DIFFUSION, SITTING DROP",6,"60.0% MPD, 0.1M SPG pH 6.0",277.15,2020-05-26,2020-06-03,6Z5D,3184,1,357,424,,41.5,1,1.75,experimental,15.883,0.1779,0.1527,Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004082
6Z5E,X-RAY DIFFRACTION,3.07,59.99,"VAPOR DIFFUSION, SITTING DROP",6,"60%(v/v) MPD, 0.1M SPG pH 6.0",277.15,2020-05-26,2020-06-03,6Z5E,3210,1,357,429,,41.48,1,1.5,experimental,18.394,0.1831,0.1572,Crystal structure of haspin (GSG2) in complex with macrocycle ODS2004093
6D4P,X-RAY DIFFRACTION,2.55,51.82,"VAPOR DIFFUSION, HANGING DROP",8,"24% PEG2000-MME, 0.2M trimethylamine N-oxide, 0.1M Tris-HCl",293,2018-04-18,2019-07-17,6D4P,1757,2,237,24,,26.73,2,2.11,experimental,56.99,0.231,0.2142,Ube2D1 in complex with ubiquitin variant Ubv.D1.1
7B86,X-RAY DIFFRACTION,1.98,37.97,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B86,3023,1,383,132,6,45.31,1,1.4,experimental,22.086,0.2146,0.1955,Notum-Fragment067
7B89,X-RAY DIFFRACTION,1.98,37.84,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B89,3044,1,383,105,8,45,1,1.84,experimental,23.4477,0.251,0.2367,Notum-Fragment077
7B8F,X-RAY DIFFRACTION,1.97,37.47,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-12,2022-01-12,7B8F,2976,1,383,135,6,44.59,1,1.62,experimental,27.2112,0.2365,0.2058,Notum-Fragment 154
7B98,X-RAY DIFFRACTION,1.99,38.28,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-14,2022-01-12,7B98,2981,1,383,112,7,44.76,1,1.53,experimental,24.8108,0.2354,0.2089,Notum Fragment 282
7BC8,X-RAY DIFFRACTION,1.97,37.67,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-18,2022-01-12,7BC8,2932,1,383,111,6,44.73,1,1.74,experimental,24.8979,0.2385,0.2156,Notum Fragment 658
4YAD,X-RAY DIFFRACTION,2.35,47.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.2-2.4M ammonium sulfate, 0.1M HEPES buffer pH 7.5, 2% PEG400 and 8-9% glycerol",298,2015-02-17,2015-06-24,4YAD,3319,2,368,344,,43.91,1,1.73,experimental,28.52,0.208,0.176,"Crystal structure of TRIM24 PHD-bromodomain complexed with 2,4-dimethoxy-N-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)benzene-1-sulfonamide (3b)"
4YAX,X-RAY DIFFRACTION,2.35,47.74,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.2-2.4M ammonium sulfate, 0.1M HEPES buffer pH 7.5, 2% PEG400 and 8-9% glycerol",298,2015-02-18,2015-06-24,4YAX,3397,2,368,384,,43.97,1,2.25,experimental,26.67,0.235,0.17,"Crystal structure of TRIM24 PHD-bromodomain complexed with N-[6-(4-methoxyphenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl]benzenesulfonamide (5g)"
4YBM,X-RAY DIFFRACTION,2.33,47.18,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.2-2.4M ammonium sulfate, 0.1M HEPES buffer pH 7.5, 2% PEG400 and 8-9% glycerol",298,2015-02-18,2015-06-24,4YBM,3565,2,368,576,,44.61,1,1.46,experimental,26.77,0.196,0.163,"Crystal structure of TRIM24 PHD-bromodomain complexed with N-{6-[3-(benzyloxy)phenoxy]-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl}-3,4-dimethoxybenzene-1-sulfonamide (7b)"
6TMQ,X-RAY DIFFRACTION,3.3,62.75,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.1 M Sodium acetate pH 5.8
0.125 M Magnesium chloride",277,2019-12-05,2020-10-14,6TMQ,2952,1,394,150,,45.49,1,2.112,experimental,45.574,0.2343,0.1758,Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6TN0,X-RAY DIFFRACTION,3.23,61.89,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.1 M Sodium acetate pH 5.8
0.125 M Magnesium chloride",277,2019-12-05,2020-10-14,6TN0,2913,1,394,146,,45.28,1,1.905,experimental,46.489,0.2213,0.1758,Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
6TN2,X-RAY DIFFRACTION,3.19,61.39,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.1 M Sodium acetate pH 5.8
0.125 M Magnesium chloride",277,2019-12-05,2020-10-14,6TN2,3010,1,394,204,,45.41,1,1.768,experimental,40.967,0.2105,0.1706,Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
7K06,X-RAY DIFFRACTION,2.09,41.26,"VAPOR DIFFUSION, HANGING DROP",7.8,"25% MPEG 2K,
15% saturated KCl,
200 mM pH 7.8 imidazole / malate",290,2020-09-03,2021-10-06,7K06,3504,2,432,224,1,50.83,1,1.95,experimental,24.89,0.2226,0.1814,Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
5MGH,X-RAY DIFFRACTION,2.52,51.19,"VAPOR DIFFUSION, HANGING DROP",,"2 mM DTT, 100 mM bis-Tris propane pH 7 and 1.8 M sodium acetate pH 7",292,2016-11-21,2017-05-03,5MGH,3622,1,405,259,,47.61,1,1.87,experimental,42.6683,0.2299,0.1976,Crystal structure of pathogenic mutants of human mitochodnrial PheRS
5O9U,X-RAY DIFFRACTION,2.18,43.67,"VAPOR DIFFUSION, HANGING DROP",,"21% PEG 6000, 0.1M sodium citrate pH 5.6, 0.1M magnesium chloride, 0.1M sodium chloride",293,2017-06-20,2018-06-27,5O9U,7562,4,820,912,,96.88,2,1.85,experimental,16.28,0.1917,0.1555,HsNMT1 in complex with CoA and Myristoylated-GCSVSKKK octapeptide
6SX9,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2019-09-25,2020-10-07,6SX9,2375,1,260,213,,29.81,1,1.43,experimental,15.032,0.1786,0.1505,"Crystal structure of carbonic anhydrase 2 with 4-(2-chlorophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide"
6SYB,X-RAY DIFFRACTION,2.08,40.8,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 50 mM Tris pH 8.0",296,2019-09-27,2020-10-07,6SYB,2305,1,260,182,,29.83,1,1.6,experimental,15.799,0.2164,0.1736,"Crystal structure of carbonic anhydrase 2 with (3aR,4S,9bS)-4-(2-chloro-4-hydroxyphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide"
6SYS,X-RAY DIFFRACTION,2.1,41.49,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 50 mM Tris pH 8.0",296,2019-10-01,2020-10-14,6SYS,2459,1,260,316,,30.13,1,1.3,experimental,15.857,0.1644,0.1194,"Crystal structure of (3aR,4S,9bS)-4-(4-hydroxyphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide with carbonic anhydrase 2"
6HQ9,X-RAY DIFFRACTION,2.22,44.7,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulphate, 0.1 M Acetate pH 4.5, 18% PEG 4000",277,2018-09-24,2018-10-17,6HQ9,952,2,138,39,,15.66,1,1.982,experimental,,0.2473,0.2243,Crystal structure of the Tudor domain of human ERCC6-L2
7C7G,X-RAY DIFFRACTION,2.07,40.55,"VAPOR DIFFUSION, HANGING DROP",,"25-30% (w/v) polyethylene glycol 3350 (PEG3350), 200 mM sodium acetate and 100 mM cacodylate, pH 6.6",293,2020-05-25,2020-09-23,7C7G,5543,2,650,315,,76.18,1,1.86,experimental,42.74,0.265,0.2192,Crystal structures of AKR1C3 ternary complex with NADP+ and the chromene derivative 2j
7C7H,X-RAY DIFFRACTION,2.07,40.55,"VAPOR DIFFUSION, HANGING DROP",,"25-30% (w/v) polyethylene glycol 3350 (PEG3350), 200 mM sodium acetate and 100 mM cacodylate, pH 6.6",293,2020-05-25,2020-09-23,7C7H,5548,2,650,318,,76.2,1,1.86,experimental,42.62,0.2642,0.2173,Crystal structures of AKR1C3 ternary complex with NADP+ and the chromene derivative 2l
5T9Z,X-RAY DIFFRACTION,2.17,43.19,VAPOR DIFFUSION,4.2,"sodium citrate, pH 4.2
25% (w/v) PEG 3350",293,2016-09-09,2017-01-25,5T9Z,1502,1,163,208,,18.41,1,1.4,experimental,15.126,0.1901,0.1628,Discovery of a Potent Cyclophilin Inhibitor (Compound 6) based on Structural Simplification of Sanglifehrin A
9FTW,X-RAY DIFFRACTION,2.13,42.31,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Na Acetate
0.1 M HEPES pH 7.5
22 % PEG 4000",277,2024-06-25,2024-08-14,9FTW,4959,2,820,417,,94.38,1,1.65,experimental,25.4,0.2159,0.1881,Crystal structure of calcium-activated EndoU
8FP3,X-RAY DIFFRACTION,2.4,48.76,"VAPOR DIFFUSION, SITTING DROP",6,"Well Ingredients:
Precipitant: 21.0 %w/v (10.5 uL of stock 50.0 %w/v) PEG 3350
Salt: 0.7 M (2.1875 uL of stock 8.0 M) lithium nitrate
Buffer: 0.1 M (2.5 uL of stock 1.0 M) MES (pH 6.00)
Organic (non-volatile): 7.0 % w/v (2.1875 uL of stock 80.0 % w/v) Glycerol

[Protien] = 12 mg/ml",286.15,2023-01-03,2023-04-05,8FP3,2899,1,353,172,,40.93,1,2.3,experimental,,0.2559,0.1983,PKCeta kinase domain in complex with compound 11
5AEN,X-RAY DIFFRACTION,2.32,47,"VAPOR DIFFUSION, HANGING DROP",6,"1 MICROLITTER OF PROTEIN SOLUTION CONTAINING 10MM TRIS-HCL, 25MM KCL, AND 4 MG/ML TO 8 MG/ML LTA4H (PH 8) WAS MIXED AT DIFFERENT RATIOS (0.5:1, 1:1, AND 1:2) WITH PRECIPITATE SOLUTION CONTAINING 0:15M IMIDAZOLE, 0:1M SODIUM ACETATE PH 6, 14% PEG-8000, AND 5MM YBCL3, AND CRYSTALLIZED AT 17:4 C FOR TWO WEEKS BY HANGING DROP VAPOR-DIFFUSION METHOD",,2015-01-06,2015-02-11,5AEN,5496,1,608,608,,70.16,1,1.864,experimental,14.8,0.1888,0.1704,Structure of human Leukotriene A4 hydrolase in complex with inhibitor dimethyl(2- (4-phenoxyphenoxy)ethyl)amine
6Q8Z,X-RAY DIFFRACTION,2.95,58.37,VAPOR DIFFUSION,,"0.1M MOPS/sodium HEPES pH7-7.5, 40-50% Morpheus precipitant mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1M Morpheus carboxylic acids mix (0.02M each of: sodium formate, ammonium acetate, sodium citrate tribasic dihydrate, sodium oxamate and potassium sodium tartrate tetrahydrate",293,2018-12-16,2019-01-23,6Q8Z,11861,4,1568,739,2,171.52,1,2.4,experimental,47.0671,0.2834,0.2409,"Structure of human galactokinase 1 bound with N-(Cyclobutylmethyl)-1,5-dimethyl-1H-pyrazole-4-carboxamide"
7NI1,X-RAY DIFFRACTION,2.39,48.54,"VAPOR DIFFUSION, HANGING DROP",5.5,"18% PEG 3350, 100 MM NACL, PROTEIN BUFFER  CONTAINED 50 MM AMMOIUM SULPHATE, 20 MM AMMONIUM ACETATE PH 5.5 AND 2 MM CACL",293,2021-02-11,2022-02-23,7NI1,10097,4,1142,643,13,135.74,2,2.11,experimental,24.09,0.256,0.217,CRYSTAL STRUCTURE OF NATIVE HUMAN MYELOPEROXIDASE IN COMPLEX WITH CPD 9
6F00,X-RAY DIFFRACTION,2.84,56.63,"VAPOR DIFFUSION, HANGING DROP",7,"1.6 M ammonium sulfate
100 mM sodium chloride
100 mM HEPES",292,2017-11-17,2018-12-12,6F00,2563,3,360,187,,42.43,1,2.163,experimental,,0.2277,0.1764,Crystal Structure of human tRNA dihydrouridine synthase (20) dsRBD E423A mutant
5MR8,X-RAY DIFFRACTION,2.37,48.16,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M Tris pH 8.5, 25% PEG3350",293.15,2016-12-21,2018-01-17,5MR8,1626,2,203,52,,23.51,2,1.74,experimental,,0.2862,0.2269,Crystal structure of TRIM33 PHD-Bromodomain isoform B in complex with H3K9ac histone peptide
6MSA,X-RAY DIFFRACTION,2.1,41.48,VAPOR DIFFUSION,,"5% Tascimate pH7.0, 100mM HEPES pH7, 10% PMME5000",277,2018-10-16,2019-01-09,6MSA,5579,2,664,275,,77.15,1,2.06,experimental,50.71,0.241,0.198,"Novel, potent, selective and brain penetrant phosphodiesterase 10A inhibitors"
4TSB,X-RAY DIFFRACTION,2.34,47.44,"VAPOR DIFFUSION, SITTING DROP",,"100mM PCPT pH 5.5, 200mM MgCl2, 22 % w/v PEG 3350",293,2014-06-18,2015-07-08,4TSB,4554,3,568,372,8,60.65,3,1.95,experimental,23.59,0.2267,0.1937,Structure of a lysozyme antibody complex
4TSC,X-RAY DIFFRACTION,2.49,50.62,"VAPOR DIFFUSION, SITTING DROP",,"100mM PCTP pH 8.5, 25% w/v Peg3350 Magnesium Chloride 200mM",293,2014-06-18,2015-07-08,4TSC,4316,3,568,194,8,60.59,3,1.92,experimental,41.45,0.2319,0.2089,Structure of a lysozyme antibody complex
6P09,X-RAY DIFFRACTION,2.54,51.56,"VAPOR DIFFUSION, SITTING DROP",6,"100 mM MES, 100 mM Lithium Acetate, 15% (w/v) polyethylene glycol 3350",293,2019-05-16,2019-12-11,6P09,6416,4,681,562,,83.35,1,2.052,experimental,,0.2008,0.17,"Human DNA Ligase 1 Bound to an Adenylated, dideoxy Terminated DNA nick with 200 mM Mg2+"
6P0A,X-RAY DIFFRACTION,2.43,49.45,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, 100 mM Lithium Acetate, 15 % (w/v) PEG 3350",293,2019-05-16,2019-12-11,6P0A,6479,4,681,665,,83.15,1,2.05,experimental,,0.2033,0.1699,"Human DNA Ligase 1 Bound to an Adenylated, dideoxy Terminated DNA nick with 2 mM Mg2+"
6P0B,X-RAY DIFFRACTION,2.55,51.72,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, 100 mM Lithium Acetate, 15% (w/v) PEG 3350",293,2019-05-16,2019-12-11,6P0B,6217,4,681,387,,83.21,1,2.203,experimental,54.7983,0.2056,0.1699,"Human DNA Ligase 1 (E346A/E592A) Bound to an Adenylated, dideoxy Terminated DNA nick with 200 mM Mg2+"
6P0C,X-RAY DIFFRACTION,2.53,51.29,"VAPOR DIFFUSION, SITTING DROP",6,"100 mM MES, 100 mM Lithium Acetate, 15% (w/v) PEG 3350",293,2019-05-16,2019-12-11,6P0C,7036,4,681,1115,,83.25,1,1.55,experimental,30.8197,0.1653,0.1304,"Human DNA Ligase 1 Bound to an Adenylated, hydroxyl terminated DNA nick in EDTA"
6P0D,X-RAY DIFFRACTION,2.53,51.43,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, 100 mM Lithium Acetate, 15% (w/v) PEG 3350",293,2019-05-16,2019-12-11,6P0D,6911,4,681,975,,83.11,1,1.75,experimental,,0.1787,0.1595,"Human DNA Ligase 1 (E346A/E592A) Bound to an Adenylated, hydroxyl terminated DNA nick"
5FGB,X-RAY DIFFRACTION,2.33,47.28,"VAPOR DIFFUSION, HANGING DROP",5.2,"100 mM sodium citrate pH 5.2
300 mM ammonium sulfate
100 mM potassium phosphate
1 M lithium chloride",293,2015-12-20,2016-01-20,5FGB,7252,6,1012,604,14,109.43,3,1.65,experimental,29.36,0.1895,0.1711,Three dimensional structure of broadly neutralizing human anti - Hepatitis C virus (HCV) glycoprotein E2 Fab fragment HC33.4
7B01,X-RAY DIFFRACTION,3.05,59.73,"VAPOR DIFFUSION, HANGING DROP",,"21% (v/v) PEG1500, 100 mM Sodium propionate, sodium cacodylate trihydrate, 200 mM MnCl2, Bis-Tris propane, pH 5",293,2020-11-18,2021-04-28,7B01,4578,1,608,26,3,67.31,1,2.8,experimental,55.869,0.2917,0.201,ADAMTS13-CUB12
5O75,X-RAY DIFFRACTION,2.22,44.72,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M citric acid, pH 5.5, 1.9 M ammonium sulphate",293,2017-06-08,2017-11-01,5O75,643,1,78,44,,9.11,1,1.483,experimental,41.46,0.224,0.1954,Ube4B U-box domain
6MSC,X-RAY DIFFRACTION,2.15,42.71,VAPOR DIFFUSION,,"5% Tascimate pH7.0, 100mM HEPES pH7, 10% PMME5000",277,2018-10-16,2019-01-09,6MSC,5360,2,664,78,,77.55,1,2.36,experimental,75.89,0.242,0.206,"Novel, potent, selective and brain penetrant phosphodiesterase 10A inhibitors"
7OZX,X-RAY DIFFRACTION,2.9,57.54,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MOPS/sodium HEPES pH 7.0-7.5, 40-50 % Morpheus Precipitant Mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1 M Morpheus Carboxylic acids mix (0.02M each of:sodium formate, ammonium acetate, sodium citrate tribasic dehydrate, sodium potassium tartrate tetrahydrate and sodium oxamate).",293,2021-06-29,2022-05-25,7OZX,11815,4,1596,621,,174.48,1,2.3,experimental,48.171,0.2577,0.2083,"Structure of human galactokinase 1 bound with azepan-1-yl(2,6-difluorophenyl)methanone"
6YTP,X-RAY DIFFRACTION,3.2,61.61,"VAPOR DIFFUSION, HANGING DROP",4.6,"1 M (NH3)2SO4, 0.17 M guanidine HCl, 0.02 M KCl, 0.1 M sodium acetate pH 4.6",291,2020-04-24,2021-05-12,6YTP,8899,2,994,661,4,115.81,1,1.7,experimental,31.556,0.2121,0.1859,Structure of recombinant human beta-glucocerebrosidase in complex with azide tagged cyclophellitol epoxide inhibitor
6YUT,X-RAY DIFFRACTION,3.26,62.3,"VAPOR DIFFUSION, HANGING DROP",,"1 M (NH3)2SO4, 0.17 M guanidine HCl, 0.03 M KCl, 0.1 M sodium acetate pH 4.6",291,2020-04-27,2021-05-12,6YUT,8946,2,994,735,4,116.4,1,1.76,experimental,31.049,0.2084,0.183,Structure of recombinant human beta-glucocerebrosidase in complex with N-acyl functionalised cyclophellitol aziridine
6YV3,X-RAY DIFFRACTION,3.25,62.19,"VAPOR DIFFUSION, HANGING DROP",,"1 M (NH3)2SO4, 0.17 M guanidine HCl, 0.02 M KCl, 0.1 M sodium acetate pH 4.8",291,2020-04-27,2021-05-12,6YV3,9030,2,994,855,4,115.73,1,1.8,experimental,28.029,0.2032,0.1755,Structure of recombinant human beta-glucocerebrosidase in complex with galacto-configured cyclophellitol aziridine inhibitor
7WQM,X-RAY DIFFRACTION,2.23,44.82,"VAPOR DIFFUSION, SITTING DROP",,"MES pH 6.0, Ammonium chloride, PEG 6000",291,2022-01-25,2023-01-04,7WQM,5526,2,658,392,,77.66,1,2.13,experimental,22.5212,0.2067,0.1719,Crystal structure of Aldo-keto reductase 1C3 complexed with compound 24
7WQR,X-RAY DIFFRACTION,2.06,40.41,"VAPOR DIFFUSION, SITTING DROP",,"MES pH 6.0, Ammonium chloride, PEG 6000",291,2022-01-25,2023-01-04,7WQR,5285,2,658,204,,77.67,1,2.124,experimental,41.4795,0.2728,0.2214,Crystal structure of Aldo-keto reductase 1C3 complexed with compound 28
7WQS,X-RAY DIFFRACTION,2.23,44.93,"VAPOR DIFFUSION, SITTING DROP",,"MES pH 6.0, Ammonium chloride, PEG 6000",291,2022-01-26,2023-01-04,7WQS,5694,2,658,582,,77.66,1,2.07,experimental,20.7705,0.1999,0.168,Crystal structure of Aldo-keto reductase 1C3 complexed with compound 25
7ZIG,X-RAY DIFFRACTION,2.15,42.91,"VAPOR DIFFUSION, SITTING DROP",,"26% w/v PEG 5000 MME, 200 mM ammonium sulfate, 100 mM Hepes-NaOH pH 7.0",293.15,2022-04-08,2022-09-07,7ZIG,2585,1,326,228,,38.01,1,1.80888497598,experimental,27.1641098215,0.206340566536,0.167897277025,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-05-060
8T74,X-RAY DIFFRACTION,2.48,50.44,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M DL-malic acid (pH 7.0), 20% PEG 3350",293,2023-06-19,2024-02-14,8T74,2172,2,258,197,,30.08,2,1.65,experimental,42.6345,0.1958,0.1728,Crystal structure of KRAS4a (GMPPNP) in complex with RAF1 (RBD)
5CAW,X-RAY DIFFRACTION,2.48,50.39,"VAPOR DIFFUSION, SITTING DROP",,"2% (v/v) PEG400, 2 M NH4SO4, 0.1 M HEPES pH 7.5",291,2015-06-30,2015-07-22,5CAW,5627,4,794,33,,91.01,2,2.62,experimental,,0.2595,0.2276,Structure of Pediculus humanus Parkin bound to phospho-ubiquitin
8HL7,X-RAY DIFFRACTION,3.16,61.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 % (w/v) polyethylene glycol (PEG) 3350, 0.1M Na-HEPES (pH 7.5), 2 % (v/v) Tacsimate (pH 7.0), and 3 % (w/v) 6-aminohexanoic acid",295,2022-11-29,2023-07-12,8HL7,4680,2,644,10,,73.77,2,2.8,experimental,66.14,0.2609,0.2172,Crystal structure of p97 N/D1 in complex with a valosin-containing protein methyltransferase
6Q3X,X-RAY DIFFRACTION,2.78,55.76,VAPOR DIFFUSION,,"0.02M Sodium formate; 0.02M Ammonium acetate; 0.02M Sodium citrate tribasic dihydrate; 0.02M Sodium potassium tartrate tetrahydrate; 0.02M Sodium oxamate
0.1 M pH 7.5, Sodium HEPES; MOPS (acid) pH 7.5
12.5% v/v MPD; 12.5% PEG 1000; 12.5% w/v PEG 3350",298,2018-12-04,2020-07-15,6Q3X,6159,2,786,210,1,86.35,1,2.1,experimental,31.5728,0.2312,0.1908,"Structure of human galactokinase in complex with galactose and 2'-(benzo[d]oxazol-2-ylamino)-7',8'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'(6'H)-one"
8VJW,X-RAY DIFFRACTION,2.74,55.06,"VAPOR DIFFUSION, HANGING DROP",,"17.5 ~ 30 % polyethylene glycol 3,350 and 50 ~ 125 mM Bis-Tris HCl buffer, pH 6.5",295,2024-01-08,2024-08-21,8VJW,10838,6,1354,8,,155.99,3,2.491,experimental,,0.2865,0.2374,Structure of Human Neurolysin in complex with angiotensin I peptide
7L8R,X-RAY DIFFRACTION,2.01,38.83,MICROBATCH,6,"0.1 M sodium chloride, 0.1 M MES, and 40% (w/v) PEG 8000",293,2020-12-31,2021-12-29,7L8R,3053,2,384,414,,43.72,1,1.52,experimental,21.4738,0.1772,0.1576,Crystal structure of human GPX4-U46C mutant K48A
6W5X,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES 6.0
5 mM MnCl2
16% PEG 2000 MME",293,2020-03-14,2021-03-17,6W5X,3800,3,452,23,,55.19,1,2.59,experimental,56.35,0.2557,0.1844,Crystal structure of human polymerase eta complexed with N7-benzylguanine and dCTP*
4WFT,X-RAY DIFFRACTION,2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",,"Protein 20 mg/mL
precipitant: HEPES 100 mM pH 6.5, sodium acetate 100 mM, PEG 2000 MME 30%",292,2014-09-17,2015-10-07,4WFT,2609,3,360,367,,41.19,1,1.7,experimental,,0.1802,0.163,Crystal structure of tRNA-dihydrouridine(20) synthase dsRBD domain
6YVT,X-RAY DIFFRACTION,3.2,61.53,"VAPOR DIFFUSION, SITTING DROP",6.5,"Sample: 19.0 mg/ml PHD2 (50  mM  Tris.HCl  pH  7.5),  1.0  mM  MnCl2  and  1.2  mM  compound.  Reservoir: 1.88 M ammonium sulfate, 0.1 M MES pH 6.5 and 5-7% dioxoane (v/v). Cryo-protection: 30% v/v glycerol.",293,2020-04-28,2020-05-20,6YVT,9358,6,1512,57,,171.21,1,2.847,experimental,55.0728,0.266,0.2368,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with MD-253
6T27,X-RAY DIFFRACTION,2.15,42.83,"VAPOR DIFFUSION, HANGING DROP",5,"50 mM Di-Ammoniumhydrogen citrate pH 5: 15 mg/mL hAR, 5.2 mg/mL DTT, 0.7 mg/mL NADP+, 5% (w/v) PEG 6000
Reservoir: 120 mM Di-Ammoniumhydrogen citrate pH 5, 20% (w/v) PEG 6000",291,2019-10-08,2020-10-21,6T27,3241,1,316,447,,36.98,1,1.11,experimental,11.11,0.1213,0.1037,Structure of Human Aldose Reductase Mutant L301A with a Citrate Molecule Bound in the Anion Binding Pocket
6T5G,X-RAY DIFFRACTION,2.14,42.48,"VAPOR DIFFUSION, HANGING DROP",5,"50 mM Di-Ammoniumhydrogen citrate pH 5.0:
15 mg/mL hAR, 5.2 mg/mL DTT, 0.7 mg/mL NADP+, 5% /w/v) PEG 6000
Reservoir: 120 mM Di-Ammoniumhydrogen citrate pH 5.0, 20% (w/v) PEG 6006",291,2019-10-16,2020-11-18,6T5G,2925,1,316,309,,36.98,1,1.28,experimental,15.53,0.1595,0.1296,Structure of Human Aldose Reductase Mutant L300A with a Citrate Molecule Bound in the Anion Binding Pocket
6T7Q,X-RAY DIFFRACTION,2.18,43.67,"VAPOR DIFFUSION, HANGING DROP",5,"50 mM Di-Ammoniumhydrogen citrate pH 5.0: 15 mg/mL hAR, 5.2 mg/mL DTT, 0.7 mg/mL NADP+, 5% (w/v) PEG 6000
Reservoir: 120 mM Di-Ammoniumhydrogen citrate pH 5.0, 20% (w/v) PEG 6000
Soaking-buffer: 120 mM Di-Ammoniumhydrogen citrate pH 5.0, 25% (w/v) PEG 6000",291,2019-10-23,2020-11-18,6T7Q,3233,1,316,409,,37.14,1,1.01,experimental,11.81,0.1322,0.1177,Human Aldose Reductase Mutant L301A in Complex with a Ligand with an IDD Structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl)benzoic acid)
6Y03,X-RAY DIFFRACTION,2.12,42.01,"VAPOR DIFFUSION, HANGING DROP",5,"50 mM Di-Ammoniumhydrogen citrate pH 5: 15 mg/mL hAR, 5,2 mg/mL DTT, 0.7 mg/mL NADP+, 5% (w/v) PEG 6000
Reservoir: 120 mM Di-Ammoniumhydrogen citrate pH 5, 20% (w/v) PEG 6000",291,2020-02-06,2021-02-17,6Y03,2797,1,316,262,,36.75,1,1.69,experimental,19.87,0.1953,0.1606,Structure of Human Aldose Reductase Mutant L300/301A with a Citrate Molecule Bound in the Anion Binding Pocket
7NXJ,X-RAY DIFFRACTION,2.36,47.83,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M MES (pH 6.8), 24% PEG 3350, 0.2 M MgCl2",293,2021-03-18,2021-05-12,7NXJ,9367,4,1230,83,,145.02,2,2.36,experimental,,0.2518,0.2121,Crystal structure of human Cdk13/Cyclin K in complex with the inhibitor THZ531
7M7L,X-RAY DIFFRACTION,2.11,41.59,EVAPORATION,6,"15% PEG 3350,
100 mM MES",295,2021-03-28,2021-06-02,7M7L,4413,3,455,486,,55.8,1,1.58,experimental,21.1566,0.2132,0.1751,Human DNA Pol eta with dA-ended primer and dAMPNPP
7M7M,X-RAY DIFFRACTION,2.1,41.32,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-28,2021-06-02,7M7M,4476,3,455,517,,56,1,1.46,experimental,24.021,0.2113,0.1807,Human DNA Pol eta with rA-ended primer and dAMPNPP
7M7N,X-RAY DIFFRACTION,2.1,41.42,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-28,2021-06-02,7M7N,4484,3,455,524,,56,1,1.31,experimental,20.1733,0.2103,0.1843,Human DNA Pol eta with 2'-FA-ended primer and dAMPNPP
7M7O,X-RAY DIFFRACTION,2.12,41.9,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-28,2021-06-02,7M7O,4396,3,456,422,,56.2,1,1.8,experimental,23.0885,0.2236,0.1796,Human DNA Pol eta with dT-ended primer and 0.1 mM dAMPNPP
7M7P,X-RAY DIFFRACTION,2.12,41.94,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-28,2021-06-02,7M7P,4419,3,456,439,,56.09,1,1.8,experimental,20.3482,0.2427,0.1999,Human DNA Pol eta S113A with dA-ended primer and dAMPNPP
7M7Q,X-RAY DIFFRACTION,2.1,41.47,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-28,2021-06-02,7M7Q,4266,3,456,385,,56.18,1,2.27,experimental,25.4911,0.2239,0.169,Human DNA Pol eta S113A with dT-ended primer and dAMPNPP
7M7S,X-RAY DIFFRACTION,2.09,41.19,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-28,2021-06-02,7M7S,4419,3,456,391,,56.37,1,1.85,experimental,23.4134,0.2283,0.1801,Human DNA Pol eta S113A with dT-ended primer and 0.1 mM dAMPNPP
7M7T,X-RAY DIFFRACTION,2.11,41.6,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-28,2021-06-02,7M7T,4645,3,455,584,,55.51,1,1.46,experimental,22.7045,0.2081,0.1792,Human DNA Pol eta S113A with dT-ended primer and dATP: in crystallo reaction for 0 s
7M7U,X-RAY DIFFRACTION,2.08,40.89,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-28,2021-06-02,7M7U,4650,3,455,583,,55.52,1,1.94,experimental,27.6212,0.2219,0.1789,Human DNA Pol eta S113A with dT-ended primer and dATP: in crystallo reaction for 480s
7M7Y,X-RAY DIFFRACTION,2.13,42.15,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M7Y,4455,3,454,515,,55.29,1,1.8,experimental,26.2063,0.2214,0.1763,Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 0 s
7M7Z,X-RAY DIFFRACTION,2.11,41.78,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M7Z,4419,3,455,516,,55.74,1,1.82,experimental,23.8487,0.2279,0.1804,Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 40 s
7M80,X-RAY DIFFRACTION,2.11,41.84,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M80,4441,3,455,531,,55.76,1,1.98,experimental,30.6873,0.2142,0.1569,Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 100 s
7M81,X-RAY DIFFRACTION,2.12,42,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M81,4297,3,455,342,,55.67,1,2.05,experimental,38.1078,0.2263,0.1705,Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 100 s
7M82,X-RAY DIFFRACTION,2.11,41.73,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M82,4431,3,455,500,,55.76,1,2.07,experimental,28.3812,0.2246,0.1651,Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 300 s
7M83,X-RAY DIFFRACTION,2.09,41.06,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M83,4500,3,455,491,,55.51,1,1.55,experimental,24.912,0.2082,0.1748,Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 0 s
7M84,X-RAY DIFFRACTION,2.09,41.05,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M84,4621,3,455,532,,55.52,1,1.47,experimental,21.2862,0.1994,0.1723,Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 40 s
7M85,X-RAY DIFFRACTION,2.09,41.09,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M85,4621,3,455,509,,55.34,1,1.75,experimental,25.0601,0.2123,0.174,Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 80 s
7M86,X-RAY DIFFRACTION,2.09,41.05,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M86,4550,3,456,495,,56.03,1,1.55,experimental,21.2058,0.2046,0.1732,Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 140 s
7M87,X-RAY DIFFRACTION,2.08,40.76,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M87,4574,3,456,499,,56.03,1,1.85,experimental,24.6272,0.2276,0.2005,Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 230 s
7M88,X-RAY DIFFRACTION,2.08,40.84,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M88,4576,3,456,480,,56.03,1,1.66,experimental,25.3108,0.2092,0.1732,Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 300 s
7M89,X-RAY DIFFRACTION,2.12,42.08,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M89,4468,3,455,471,,55.53,1,1.83,experimental,25.8221,0.2133,0.1723,Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 0 s
7M8A,X-RAY DIFFRACTION,2.08,40.85,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M8A,4536,3,456,476,,56.03,1,1.91,experimental,28.9432,0.215,0.166,Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 40 s
7M8B,X-RAY DIFFRACTION,2.08,40.97,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M8B,4534,3,456,479,,56.05,1,1.85,experimental,27.6759,0.2099,0.1621,Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 140 s
7M8C,X-RAY DIFFRACTION,2.08,40.97,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M8C,4534,3,456,479,,56.05,1,1.85,experimental,27.6759,0.2099,0.1621,Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 230 s
7M8D,X-RAY DIFFRACTION,2.07,40.59,EVAPORATION,6,"15% PEG 2000 MME,
100 mM MES",295,2021-03-29,2021-06-02,7M8D,4488,3,456,465,,55.92,1,1.92,experimental,28.6416,0.2171,0.1625,Human DNA Pol eta S113A with rA-ended primer and dATP: in crystallo reaction for 300 s
4Z9M,X-RAY DIFFRACTION,2.78,55.7,"VAPOR DIFFUSION, SITTING DROP",6,"17% PEG-3350, 10mM DTT, 0.2M diammonium citrate, 0.1M Bis-TRIS, protein buffer also contained magnesium chloride, creatine, ADP",291,2015-04-10,2015-04-22,4Z9M,23253,8,3136,849,,360.91,1,2.1,experimental,38.291,0.2362,0.2023,Crystal structure of human sarcomeric mitochondrial creatine kinase
6JB6,X-RAY DIFFRACTION,2.51,51.06,"VAPOR DIFFUSION, HANGING DROP",7.5,"HEPES, PEG 400, magnesium chloride",293,2019-01-25,2019-03-20,6JB6,2198,2,281,15,,31.38,2,2.7,experimental,40.89,0.2845,0.2436,"Crystal structure of Ub-conjugated Ube2K C92K&K97A mutant (isopeptide linkage), 2.7 A resolution"
6JB7,X-RAY DIFFRACTION,2.56,54.59,"VAPOR DIFFUSION, HANGING DROP",7.5,"HEPES, PEG 400, magnesium chloride",293,2019-01-25,2019-03-20,6JB7,2229,2,276,52,,30.98,2,2.1,experimental,29.33,0.2503,0.2148,"Crystal structure of Ub-conjugated Ube2K C92K&K97A mutant (isopeptide linkage), 2.1 A resolution"
7L8Q,X-RAY DIFFRACTION,1.65,25.66,MICROBATCH,5,"0.1 M potassium thiocyanate, 0.1 M sodium acetate, and 20% (w/v) PEG 8000",293,2020-12-31,2021-12-29,7L8Q,1553,1,192,212,,22.05,1,1.48,experimental,22.5835,0.1821,0.154,Crystal structure of human GPX4-U46C with oxidized Cys-46
6SZP,X-RAY DIFFRACTION,2.12,42.08,"VAPOR DIFFUSION, SITTING DROP",,"reservoir: 0.1M MES pH 6.0 + 30% PEG6000
drop: 1+1 (v/v)
cryo protectant: reservoir + 20%(v/v) glycerol",277.15,2019-10-02,2019-12-25,6SZP,2272,1,297,137,,32.94,1,1.76,experimental,36.0639,0.2303,0.2006,High resolution crystal structure of human DDAH-1 in complex with N-(4-Aminobutyl)-N'-(2-Methoxyethyl)guanidine
9FLQ,X-RAY DIFFRACTION,2.86,57.01,VAPOR DIFFUSION,,"60% MPD, 0.1M MMT pH 6.0",278,2024-06-05,2024-09-11,9FLQ,2942,1,357,213,,41.95,1,1.85,experimental,31.859,0.20198,0.17496,Crystal structure of human Haspin (GSG2) kinase bound to MU1959
5R50,X-RAY DIFFRACTION,2.03,39.37,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R50,2452,1,304,157,,33.42,1,1.87,experimental,29.098,0.233,0.1793,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13371a
5R51,X-RAY DIFFRACTION,2.02,39.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R51,2446,1,304,160,,33.27,1,1.65,experimental,26.536,0.2393,0.2016,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14003a
5R52,X-RAY DIFFRACTION,2.02,39.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R52,2447,1,304,161,,33.26,1,1.48,experimental,23.167,0.2175,0.1871,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14004a
5R53,X-RAY DIFFRACTION,2.02,39.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R53,2446,1,304,161,,33.24,1,1.4,experimental,20.993,0.2122,0.1845,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13854a
5R54,X-RAY DIFFRACTION,2.02,38.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R54,2448,1,304,161,,33.25,1,1.79,experimental,29.674,0.2313,0.1859,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13582a
5R55,X-RAY DIFFRACTION,2.03,39.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R55,2433,1,304,159,,33.06,1,1.48,experimental,22.118,0.2174,0.1896,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13369a
5R56,X-RAY DIFFRACTION,2.01,38.94,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R56,2458,1,304,163,,33.43,1,1.51,experimental,24.013,0.2156,0.1839,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13688a
5R57,X-RAY DIFFRACTION,2.01,38.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R57,2442,1,304,161,,33.18,1,1.44,experimental,23.309,0.219,0.1869,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N08253b
5R58,X-RAY DIFFRACTION,2.01,38.85,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R58,2446,1,304,161,,33.26,1,1.98,experimental,31.355,0.2664,0.192,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13542a
5R59,X-RAY DIFFRACTION,2.02,38.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R59,2438,1,304,154,,33.25,1,2.11,experimental,35.992,0.2697,0.1918,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13441a
5R5A,X-RAY DIFFRACTION,2.02,39,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5A,2443,1,304,161,,33.22,1,1.44,experimental,22.656,0.2209,0.1887,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13663a
5R5B,X-RAY DIFFRACTION,2.02,39,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5B,2451,1,304,165,,33.25,1,1.53,experimental,24.407,0.2199,0.1884,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13725a
5R5C,X-RAY DIFFRACTION,2.01,38.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5C,2446,1,304,160,,33.25,1,1.68,experimental,28.517,0.2275,0.1843,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13956a
5R5D,X-RAY DIFFRACTION,2.01,38.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5D,2448,1,304,161,,33.26,1,1.65,experimental,27.523,0.2259,0.1872,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13564a
5R5E,X-RAY DIFFRACTION,2.02,39,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5E,2444,1,304,161,,33.23,1,1.58,experimental,26.243,0.2245,0.1888,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13848a
5R5F,X-RAY DIFFRACTION,2,38.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5F,2451,1,304,165,,33.25,1,1.63,experimental,27.899,0.2323,0.1897,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13793a
5R5G,X-RAY DIFFRACTION,2.01,38.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5G,2445,1,304,161,,33.23,1,1.77,experimental,28.153,0.2298,0.1867,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13707a
5R5H,X-RAY DIFFRACTION,2,38.64,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5H,2446,1,304,162,,33.25,1,1.79,experimental,30.043,0.2298,0.1844,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13706a
5R5I,X-RAY DIFFRACTION,2.02,39.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5I,2441,1,304,161,,33.17,1,1.7,experimental,26.231,0.2191,0.182,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N06325b
5R5J,X-RAY DIFFRACTION,2.02,39.15,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5J,2447,1,304,161,,33.27,1,1.98,experimental,35.273,0.2361,0.1783,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13964a
5R5K,X-RAY DIFFRACTION,2.01,38.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5K,2447,1,304,161,,33.26,1,1.6,experimental,25.667,0.229,0.1897,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13960a
5R5L,X-RAY DIFFRACTION,2.02,39.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5L,2440,1,304,157,,33.23,1,1.63,experimental,29.275,0.219,0.1849,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13589a
5R5M,X-RAY DIFFRACTION,2.01,38.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5M,2448,1,304,162,,33.26,1,1.6,experimental,26.711,0.2303,0.1914,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14123a
5R5N,X-RAY DIFFRACTION,2.01,38.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5N,2445,1,304,161,,33.25,1,1.87,experimental,28.338,0.2434,0.1908,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13595a
5R5P,X-RAY DIFFRACTION,2.01,38.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5P,2449,1,304,163,,33.25,1,1.53,experimental,23.82,0.223,0.1884,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13910a
5R5Q,X-RAY DIFFRACTION,2.02,39.15,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5Q,2441,1,304,161,,33.19,1,1.71,experimental,26.433,0.2221,0.1825,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13920a
5R5R,X-RAY DIFFRACTION,2.02,39.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5R,2452,1,304,157,,33.37,1,1.65,experimental,24.618,0.2341,0.1946,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14078a
5R5S,X-RAY DIFFRACTION,2.01,38.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5S,2446,1,304,162,,33.22,1,1.5,experimental,24.529,0.2273,0.1977,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N13775a
5RKZ,X-RAY DIFFRACTION,2.02,39.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-06-19,2020-07-22,5RKZ,2419,1,304,162,,33.02,1,1.38,experimental,21.45,0.2111,0.1833,PanDDA analysis group deposition of ground-state model of human NUDT22 screened against the DSPL fragment library by X-ray Crystallography
7C7F,X-RAY DIFFRACTION,2.06,40.23,"VAPOR DIFFUSION, HANGING DROP",,"25-30% (w/v) polyethylene glycol 3350 (PEG3350), 200 mM sodium acetate and 100 mM cacodylate, pH 6.6",293,2020-05-25,2020-09-23,7C7F,5717,2,650,471,,75.95,1,1.7,experimental,35.18,0.2676,0.2234,Crystal structures of AKR1C3 binary complex with NADP+
5OC4,X-RAY DIFFRACTION,2.84,56.65,"VAPOR DIFFUSION, HANGING DROP",6,"22% PEG 8K
100 mM sodium cacodylate",292,2017-06-29,2018-12-26,5OC4,929,1,119,145,,13.78,1,1.71,experimental,37.02,0.215,0.194,Crystal structure of human tRNA-dihydrouridine(20) synthase dsRBD R361A-R362A mutant
5OC5,X-RAY DIFFRACTION,2.33,47.21,"VAPOR DIFFUSION, HANGING DROP",8.5,"35% PEG 4K
1 M LiCl
100 mM Tris",292,2017-06-29,2018-12-26,5OC5,813,1,120,56,,13.96,1,1.893,experimental,,0.2262,0.1688,Crystal structure of human tRNA-dihydrouridine(20) synthase dsRBD K419A-K420A mutant
8PP9,X-RAY DIFFRACTION,2.69,54.38,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.81 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 17 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking 2h with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 5 mM ligand, 3 mM ADP and 3 mM MnCl2.",291,2023-07-07,2024-02-28,8PP9,4834,2,558,424,,66.3,1,1.73,experimental,39.609,0.20989,0.19381,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with scyllo-inositol 1,2,3,5-tetrakisphosphate/ADP/Mn"
4Z9O,X-RAY DIFFRACTION,2.99,58.86,"VAPOR DIFFUSION, HANGING DROP",6.3,"PEG3350, NH4Cl",298,2015-04-10,2015-06-03,4Z9O,4574,2,542,371,2,60.36,2,2.3,experimental,40.657,0.2005,0.152,Crystal Structure of human GGT1
4ZBK,X-RAY DIFFRACTION,2.93,58.06,"VAPOR DIFFUSION, HANGING DROP",6.3,"PEG3350, NH4Cl",298,2015-04-14,2015-06-03,4ZBK,4567,2,542,337,2,60.56,2,2.18,experimental,40.918,0.2175,0.1594,Crystal Structure of human GGT1 in complex with GGsTop inhibitor
4ZC6,X-RAY DIFFRACTION,2.89,57.49,"VAPOR DIFFUSION, HANGING DROP",6,"PEG3350, NH4Cl",298,2015-04-15,2015-06-03,4ZC6,4532,2,542,335,2,60.14,2,2.1,experimental,28.685,0.2179,0.1746,Crystal Structure of human GGT1 in complex with Serine Borate
6XPB,X-RAY DIFFRACTION,2.93,58.06,"VAPOR DIFFUSION, HANGING DROP",6,"20-25% PEG3350, 0.1M ammonium chloride, 0.1M sodium cacodilate pH6.0",295,2020-07-08,2020-11-25,6XPB,4970,2,542,644,2,60.37,2,1.74,experimental,24.432,0.1889,0.1532,Structure of human GGT1 in complex with 2-amino-4-(((1-((carboxymethyl)amino)-1-oxobutan-2-yl)oxy)(phenoxy)phosphoryl)butanoic acid (ACPB) molecule
6XPC,X-RAY DIFFRACTION,2.93,58.06,"VAPOR DIFFUSION, HANGING DROP",6,"20-25%PEG3350, 0.1M ammonium cloride, 0.1M sodium cacodilate pH 6.0",295,2020-07-08,2020-11-25,6XPC,4484,2,542,247,2,60.28,2,2.26,experimental,42.886,0.2101,0.1594,Structure of human GGT1 in complex with full GSH molecule
7LBC,X-RAY DIFFRACTION,2.89,57.44,"VAPOR DIFFUSION, HANGING DROP",6,"22% PEG 3350, 0.1M ammonium chloride, 0.1M sodium cacodylate",295,2021-01-07,2022-02-09,7LBC,4245,2,542,105,2,60.01,2,2.28,experimental,47.437,0.3057,0.2494,Structure of human GGT1 in complex with Lnt2-65 compound
7LD9,X-RAY DIFFRACTION,2.93,58.06,"VAPOR DIFFUSION, HANGING DROP",6,"20-25%PEG3350, 0.1M ammonium cloride, 0.1M sodium cacodilate pH 6.0",295,2021-01-12,2022-02-23,7LD9,5151,2,542,735,2,60.98,2,1.42,experimental,20.71,0.134,0.107,Structure of human GGT1 in complex with ABBA
5WLU,X-RAY DIFFRACTION,2.13,42.13,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M Sodium Citrate
50mM Tris-HCl",298,2017-07-27,2018-08-01,5WLU,2191,1,257,83,,29.35,1,1.39,experimental,19.1133,0.2705,0.2475,Carbonic Anhydrase IX-mimic in complex with aryloxy-2-hydroxypropylammine sulfonamide
6OTP,X-RAY DIFFRACTION,2.06,40.28,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M sodium citrate, 50mM Tris-JCl, pH 7.8",298,2019-05-03,2020-05-06,6OTP,2350,1,257,264,,29.33,1,1.466,experimental,21.1478,0.1854,0.1686,Carbonic Anhydrase II complexed with ureic benzene sulfonamide MB10-586B
6RG5,X-RAY DIFFRACTION,2.07,40.7,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, Tris 0.1 M, pH = 7.8, saturated with para-Chloromercuribenzenesulfonamide",291,2019-04-16,2020-05-13,6RG5,2739,1,265,214,,31.23,1,1.089,experimental,,0.1273,0.1109,Human Carbonic Anhydrase II in complex with 4-(2-hydroxyethyl)benzenesulfonamide
7U5X,X-RAY DIFFRACTION,2.07,40.56,"VAPOR DIFFUSION, HANGING DROP",,"2.4 M Sodium malate, 100mM Tris pH 8.8",293,2022-03-02,2023-03-15,7U5X,2508,1,260,355,,29.48,1,1.04,experimental,19.106,0.1705,0.147,Crystal Structure Analysis of human Carbonic anhydrase 2
8OKO,X-RAY DIFFRACTION,2.06,40.39,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-28,2024-04-10,8OKO,2491,1,260,240,,29.62,1,1.25,experimental,16.141,0.1726,0.13879,Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor AKI_2
8OLF,X-RAY DIFFRACTION,2.06,40.28,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-30,2024-04-10,8OLF,2428,1,260,266,,29.6,1,1.45,experimental,16.394,0.17721,0.15599,Carbonic Anhydrase IX like mutant in Complex with Steriod_Sulphamoyl inhibitor BS1982
8OLM,X-RAY DIFFRACTION,2.07,40.7,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-30,2024-04-10,8OLM,2387,1,260,241,,29.72,1,1.5,experimental,18.296,0.19746,0.18239,Carbonic Anhydrase 2 in Complex with Steriod_Sulphamoyl AKI1
8OMH,X-RAY DIFFRACTION,2.07,40.71,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2023-03-31,2024-04-10,8OMH,2391,1,260,241,,29.69,1,1.45,experimental,15.513,0.17923,0.1572,Carbonic Anhydrase II in Complex with Steriod_Sulphamoyl (BS1982)
8OO8,X-RAY DIFFRACTION,2.15,42.73,"VAPOR DIFFUSION, SITTING DROP",,"A 9 0.06 M Divalents 0.1 M Buffer System 3 8.5 30 % v/v Precipitant Mix 1

0.06 M Magnesium chloride hexahydrate; 0.06 M Calcium chloride dihydrate, 0.1 M Tris pH 8.5,  20% v/v PEG 500 MME; 10 % w/v PEG 20000. (Morpheus A-9)",294,2023-04-04,2024-04-10,8OO8,2411,1,259,338,,29.65,1,1.4,experimental,11.024,0.21516,0.18455,Three-Dimensional Structure of Human Carbonic Anhydrase II in Complex with a Covalent Inhibitor
8OUB,X-RAY DIFFRACTION,2.11,41.81,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296,2023-04-22,2024-05-01,8OUB,2434,1,260,287,,29.9,1,1.178,experimental,14.138,0.1677,0.1338,"The crystal structure of human carbonic anhydrase II with 1-cyclopropyl-6-fluoro-4-oxo-7-(4-((4-sulfamoylbenzyl)carbamoyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid"
8SAF,X-RAY DIFFRACTION,2.08,40.83,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM tris base",293,2023-03-31,2024-04-03,8SAF,2174,1,260,65,,29.73,1,1.23,experimental,,0.237,0.2159,CA II in complex with the coumarin benzene sulfonamide SG1-51
5THI,X-RAY DIFFRACTION,2.1,41.46,VAPOR DIFFUSION,8,"Ammonium Sulfate, Tris, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2016-09-29,2017-04-26,5THI,2398,1,260,207,,30.12,1,1.5,experimental,13.693,0.19593,0.16864,"Crystal Structure of 2-hydroxycyclohepta-2,4,6-trien-1-one bound to human carbonic anhydrase 2 L198G"
5THN,X-RAY DIFFRACTION,2.05,39.9,"VAPOR DIFFUSION, SITTING DROP",8,"Ammonium Sulfate, Tris, pH 8.0 VAPOR DIFFUSION, temperature 291K",291,2016-09-29,2017-04-26,5THN,2395,1,260,208,,30.1,1,1.33,experimental,12.35,0.20602,0.17575,"Crystal Structure of 2-Hydroxycyclohepta-2,4,6-triene-1-thione bound to human carbonic anhydrase 2"
5YVT,X-RAY DIFFRACTION,3.78,67.48,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES-Na, pH 7.5, 50 mM MgCl2, 30% (v/v) PEGMME 550",293,2017-11-27,2018-03-14,5YVT,5231,2,693,94,,76.9,2,2.4,experimental,64.145,0.23637,0.21136,Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+) and NADH
7DJO,X-RAY DIFFRACTION,3.68,66.61,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dehydrate, 0.01 M sodium borate, pH 7.5-9.5",291,2020-11-20,2021-11-24,7DJO,2774,1,324,108,,38.06,1,2.499,experimental,40.8046,0.2339,0.1779,The co-crystal structure of DYRK2 with a small molecule inhibitor 17
6GEU,X-RAY DIFFRACTION,2.58,52.24,"VAPOR DIFFUSION, SITTING DROP",6,"0.1 M MES, 20% PEG 3350",293,2018-04-27,2019-04-03,6GEU,2484,1,314,130,,33.77,1,1.55,experimental,30.846,0.20332,0.15966,Crystal structure of the C230A mutant of human IBA57
6QE4,X-RAY DIFFRACTION,2.66,53.7,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M HEPES, 20% PEG 6000, PH 7.0,
 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293,2019-01-04,2019-03-13,6QE4,2483,1,327,76,,37.2,1,2.3,experimental,45.89,0.228,0.206,Re-refinement of 5OLI human IBA57-I3C
8GCB,X-RAY DIFFRACTION,2.86,57.03,MICROBATCH,9,"0.1 M BICINE pH 9.0, 20% PEG 6000",289,2023-03-01,2023-07-19,8GCB,1936,2,253,,,28.76,2,2.39,experimental,67.274,0.2708,0.2528,Structure of RNF125 in complex with a UbcH5b~Ub conjugate
8J7Q,X-RAY DIFFRACTION,2.76,55.44,VAPOR DIFFUSION,,"0.2 M (NH4)2SO4, 20% PEG8000, 100 mM MES PH6.0",289,2023-04-28,2024-04-03,8J7Q,2249,1,289,196,,32.55,1,1.69,experimental,,0.2456,0.2155,The active site mutant of human inorganic pyrophosphatase
8CDX,X-RAY DIFFRACTION,2.32,47.07,"VAPOR DIFFUSION, HANGING DROP",,"28-31% PEG4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5-9.0",296,2023-02-01,2024-02-21,8CDX,4592,2,522,504,,58.43,1,1.335,experimental,18.352,0.1794,0.1415,Human carbonic anhydrase I complexed with 4-(3-ethylureido)benzenesulfonamide
8EOH,X-RAY DIFFRACTION,2.52,51.27,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Sodium malonate pH 8.0, 0.1 M Tris pH 8.0, 30% w/v Polyethylene glycol 1,000",298,2022-10-03,2023-08-02,8EOH,3824,1,489,8,,58.11,1,2.65,experimental,65.02,0.2651,0.2229,crystal structure of human Cytochrome P450 8B1 in complex with a C12-Pyridine Containing Steroid
4Y5O,X-RAY DIFFRACTION,2.33,47.2,"VAPOR DIFFUSION, SITTING DROP",,0.2 M potassium phosphate and 20% PEG 3350,293,2015-02-11,2015-07-01,4Y5O,1471,2,224,20,,25.84,2,2.35,experimental,79.879,0.2323,0.2075,CCM2 HHD in complex with MEKK3 NPB1
4Q7S,X-RAY DIFFRACTION,2.08,40.83,VAPOR DIFFUSION,8,"Ammonium Sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-25,2015-03-11,4Q7S,2163,1,260,82,,29.82,1,1.8,experimental,12.42,0.22616,0.18896,Crystal Structure of 1-hydroxy-4-methylpyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q83,X-RAY DIFFRACTION,2.1,41.49,VAPOR DIFFUSION,8,"Ammonium Sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-25,2015-03-11,4Q83,2271,1,260,177,,29.87,1,1.55,experimental,10.337,0.19922,0.16937,Crystal structure of 1-hydroxy-3-(trifluoromethyl)pyridine-2(1H)-thione bound to human carbonic anhydrase II
4Q8Y,X-RAY DIFFRACTION,2.07,40.54,VAPOR DIFFUSION,8,"Ammonium Sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-28,2015-03-11,4Q8Y,2308,1,260,202,,29.85,1,1.45,experimental,11.872,0.19491,0.16183,Crystal structure of 2-hydroxyisoquinoline-1(2H)-thione bound to human carbonic anhydrase II
4Q8Z,X-RAY DIFFRACTION,2.07,40.45,VAPOR DIFFUSION,8,"Ammonium Sulfate, pH 8.0, VAPOR DIFFUSION, temperature 291K",291,2014-04-28,2015-03-11,4Q8Z,2303,1,260,212,,29.8,1,1.5,experimental,12.084,0.17681,0.15298,Crystal structure of 1-hydroxy-4-methylpyridin-2(1H)-one bound to human carbonic anhydrase II
7M24,X-RAY DIFFRACTION,2.09,41.16,"VAPOR DIFFUSION, SITTING DROP",8.3,"Protein concentration was 4 mg/mL; equal volumes (250 nL) of protein plus reservoir were added to the plate; the reservoir was 1.5 M tri-potassium citrate, 0.1 M tris buffer at pH 8.3.",293,2021-03-16,2022-02-02,7M24,2606,1,258,313,,29.49,1,1.3,experimental,12.774,0.1457,0.1158,Human carbonic anhydrase II in complex with (R)-rosiglitazone
7M26,X-RAY DIFFRACTION,2.11,41.67,"VAPOR DIFFUSION, SITTING DROP",8.3,"Protein concentration was 4 mg/mL; equal volumes (250 nL) of protein plus reservoir were added to the plate; the reservoir was 1.5 M tri-potassium citrate, 0.1 M tris buffer at pH 8.3.",293,2021-03-16,2022-02-02,7M26,2591,1,258,290,,29.49,1,1.3,experimental,13.912,0.1454,0.1187,Human carbonic anhydrase II in complex with pioglitazone
5KIJ,X-RAY DIFFRACTION,2.27,45.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"24% PEG 4000, 50mM ammonium sulfate, 0.1M MES, 10% 1,4-butanediol, pH 6.5, 200mM NDSB-200, vapor diffusion, temperature 298K",298,2016-06-16,2017-05-10,5KIJ,4551,1,452,605,1,54.44,1,1.649,experimental,,0.2224,0.1825,"Crystal structure of the class I human endoplasmic reticulum 1,2-alpha-mannosidase and Man9GlcNAc2-PA complex"
6PPM,X-RAY DIFFRACTION,2.35,47.6,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium fluoride, pH 6.2, 20% PEG 3350",277,2019-07-08,2019-11-13,6PPM,7697,12,1000,100,,115.59,3,2.61,experimental,54.5,0.2509,0.1775,Ancestral Caspase 6
4YAB,X-RAY DIFFRACTION,2.28,46.01,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.2-2.4M ammonium sulfate, 0.1M HEPES buffer pH 7.5, 2% PEG400 and 8-9% glycerol",298,2015-02-17,2015-06-24,4YAB,3353,2,368,404,,43.58,1,1.9,experimental,34.27,0.219,0.161,Crystal structure of TRIM24 PHD-bromodomain complexed with 1-methyl-5-(2-methyl-1 3-thiazol-4-yl)-2 3-dihydro-1H-indol-2-one (1)
4YAT,X-RAY DIFFRACTION,2.42,49.09,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.2-2.4M ammonium sulfate, 0.1M HEPES buffer pH 7.5, 2% PEG400 and 8-9% glycerol",298,2015-02-17,2015-06-24,4YAT,3190,2,368,332,,43.59,1,2.18,experimental,34.58,0.165,0.112,"Crystal structure of TRIM24 PHD-bromodomain complexed with N-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-4-methoxybenzene-1-sulfonamide (5b)"
7MU3,X-RAY DIFFRACTION,2.09,41.22,"VAPOR DIFFUSION, SITTING DROP",,Protein at 5.9 mg/mL; 200 nL plus 200 nL drops with the reservoir being 2.7 M ammonium sulfate and 50 mM Tris buffer at pH 8.2,293,2021-05-14,2021-08-25,7MU3,2568,1,260,271,,30.19,1,1.35,experimental,15.42,0.1475,0.1192,human carbonic anhydrase 9 mimic with compound
5LBN,X-RAY DIFFRACTION,2.1,39.8,"VAPOR DIFFUSION, SITTING DROP",,0.1M Sodium citrate pH 6 and 8% (w/v) PEG 8000,277,2016-06-16,2018-02-14,5LBN,1505,1,158,206,,17.8,1,1.42,experimental,17.7812,0.183,0.1543,High-resolution crystal structure of the UBC core domain of UBE2E1/UbcH6
6F82,X-RAY DIFFRACTION,2.17,43.28,"VAPOR DIFFUSION, HANGING DROP",5,"PEG 6000, AmCitrate",298,2017-12-12,2019-03-13,6F82,3227,1,316,422,,37.03,1,1.03,experimental,16,0.139,0.1097,AKR1B1 at 1.65 MGy radiation dose.
6F84,X-RAY DIFFRACTION,2.17,43.28,"VAPOR DIFFUSION, HANGING DROP",5,"PEG 6000, AmCitrate",298,2017-12-12,2019-03-13,6F84,3036,1,316,327,,37.03,1,1.09,experimental,17,0.1516,0.1201,AKR1B1 at 2.55 MGy radiation dose.
6F8O,X-RAY DIFFRACTION,2.17,43.28,"VAPOR DIFFUSION, HANGING DROP",5,"PEG 6000, AmCitrate",298,2017-12-13,2019-03-13,6F8O,2972,1,317,310,,36.83,1,1.17,experimental,,0.163,0.1185,AKR1B1 at 3.45 MGy radiation dose.
7L69,X-RAY DIFFRACTION,2.12,41.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM MES pH 6.5
20% PEG2000 MME
5 mM magnesium chloride",293,2020-12-23,2022-01-05,7L69,3956,3,452,215,,54.52,1,1.91,experimental,35.31,0.2237,0.1867,Crystal structure of human polymerase eta complexed with syn N7-benzylguanine
7LCD,X-RAY DIFFRACTION,2.11,41.82,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 6.5 
20% PEG2000 MME 
5 mM magnesium chloride",293,2021-01-10,2022-02-09,7LCD,3933,3,452,211,,54.55,1,1.98,experimental,33.57,0.2091,0.1823,Crystal structure of human polymerase eta complexed with syn N7-acetophenoneguanine
6VGM,X-RAY DIFFRACTION,2.67,53.91,"VAPOR DIFFUSION, HANGING DROP",7.5,"50 mM Tris
100 mM Magnesium Acetate
16% PEG 3350",293,2020-01-08,2021-01-06,6VGM,6744,6,744,10,,98.07,1,2.84,experimental,75.74,0.2798,0.2302,Crystal structure of DPO4 with 8-oxoadenine (oxoA) and dTTP*
6VKP,X-RAY DIFFRACTION,2.76,55.4,"VAPOR DIFFUSION, HANGING DROP",7.5,"50 mM Tris 7.5
18% PEG 3350
100 mM magnesium acetate",293,2020-01-21,2021-01-27,6VKP,6923,6,748,65,,99.35,1,2.54,experimental,62.78,0.2601,0.2103,Crystal structure of DPO4 extension past 8-oxoadenine (oxoA) and dG
6GXK,X-RAY DIFFRACTION,2.38,48.32,VAPOR DIFFUSION,,"10mM MES pH6.0, 25% PEG8000",277,2018-06-27,2019-05-08,6GXK,5895,2,646,621,,76.32,1,1.7,experimental,,0.1987,0.1601,Crystal structure of Aldo-Keto Reductase 1C3 (AKR1C3) complexed with inhibitor.
4ZAO,X-RAY DIFFRACTION,2.06,40.4,"VAPOR DIFFUSION, SITTING DROP",7.8,10 mg/ml in 50 mM Tris-HCl at ph 7.8,298,2015-04-13,2015-10-14,4ZAO,2302,1,260,169,,29.27,1,1.8,experimental,,0.2048,0.175,Genetically engineered Carbonic anhydrase IX
5AMD,X-RAY DIFFRACTION,2.1,42,"VAPOR DIFFUSION, SITTING DROP",9,"1,54 M SODIUM CITRATE 60 MM TRIS- HCL, PH 9.0, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K, TIME 2-5 DAYS",294,2015-03-10,2015-04-08,5AMD,2493,1,259,384,,29.61,1,1.5,experimental,12.659,0.19802,0.16094,Three dimensional structure of human carbonic anhydrase II in complex with 2-((2-Phenylethyl)sulfamoyl)-4-sulfamoylbenzoic acid
5AMG,X-RAY DIFFRACTION,2.1,42,"VAPOR DIFFUSION, SITTING DROP",9,"1,54 M SODIUM CITRATE 60 MM TRIS- HCL, PH 9.0, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K, TIME 2-5 DAYS",294,2015-03-10,2015-04-08,5AMG,2472,1,259,376,,29.57,1,1.55,experimental,12.532,0.21096,0.16624,Three dimensional structure of human carbonic anhydrase II in complex with 2-(Pentylsulfamoyl)-4-sulfamoylbenzoic acid
5AML,X-RAY DIFFRACTION,2.1,42,"VAPOR DIFFUSION, SITTING DROP",9,"1,54 M SODIUM CITRATE 60 MM TRIS- HCL, PH 9.0, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K, TIME 2-5 DAYS",294,2015-03-10,2015-04-08,5AML,2444,1,259,347,,29.56,1,1.36,experimental,14.963,0.16114,0.11795,Three dimensional structure of human carbonic anhydrase II in complex with 2-(But-2-yn-1-ylsulfamoyl)-4-sulfamoylbenzoic acid
5BRV,X-RAY DIFFRACTION,2.09,41.29,"VAPOR DIFFUSION, HANGING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-HCl",298,2015-06-01,2015-06-24,5BRV,2260,1,260,146,,30.12,1,1.6,experimental,23.532,0.2296,0.1846,Catalytic Improvement of an Artificial Metalloenzyme by Computational Design
5BYI,X-RAY DIFFRACTION,2.1,40.5,"VAPOR DIFFUSION, HANGING DROP",8.5,"3 M Ammoniumsulfate, 50 mM Tris, 2mM PCMB",293,2015-06-10,2015-08-05,5BYI,2437,1,260,356,,30.05,1,1.15,experimental,12.558,0.18727,0.17139,Human carbonic anhydrase II with an azobenzene inhibitor (1d)
5JQ0,X-RAY DIFFRACTION,2.1,41.52,"VAPOR DIFFUSION, HANGING DROP",8.7,"SODIUM CITRATE 1.3M, TRIS-HCL 0.1M",298,2016-05-04,2016-10-19,5JQ0,2414,1,262,238,,29.69,1,1.4,experimental,13.898,0.1461,0.1054,Crystal structure of human carbonic anhydrase II in complex with Benzoxaborole at pH=8.7
5LMD,X-RAY DIFFRACTION,2.13,42.15,"VAPOR DIFFUSION, HANGING DROP",8.7,"1.4 M Sodium Citrate
0.1 M Tris-HCl",293,2016-07-29,2016-10-19,5LMD,2340,1,262,231,,29.87,1,1.7,experimental,14.0393,0.2009,0.1656,The crystal structure of hCA II in complex with a benzoxaborole inhibitor
5NXG,X-RAY DIFFRACTION,2.05,39.86,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris, 1.6 M Natrium Acetate",291.15,2017-05-10,2018-01-17,5NXG,2642,1,257,272,,29.35,1,1.2,experimental,17.079,0.1681,0.1406,Carbonic Anhydrase II Inhibitor RA1
5NXM,X-RAY DIFFRACTION,2.09,41.05,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291.15,2017-05-10,2018-05-30,5NXM,2547,1,258,316,,29.51,1,1.25,experimental,14.001,0.1562,0.1281,Carbonic Anhydrase II Inhibitor RA1
5NXO,X-RAY DIFFRACTION,2.11,41.74,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291,2017-05-10,2018-01-17,5NXO,2524,1,258,353,,29.72,1,1.2,experimental,14.15,0.1502,0.1253,Carbonic Anhydrase II Inhibitor RA6
5NXP,X-RAY DIFFRACTION,2.05,40,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291,2017-05-10,2018-01-17,5NXP,2616,1,258,285,,29.46,1,1.25,experimental,17.478,0.1623,0.1282,Carbonic Anhydrase II Inhibitor RA7
5NXV,X-RAY DIFFRACTION,2.08,40.72,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",273,2017-05-11,2018-01-17,5NXV,2660,1,258,309,,29.51,1,1.1,experimental,14.806,0.1505,0.1383,Carbonic Anhydrase II Inhibitor RA8
5NXW,X-RAY DIFFRACTION,2.11,41.65,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,2017-05-11,2018-01-17,5NXW,2622,1,257,348,,29.69,1,1.1,experimental,12.359,0.1554,0.1267,Carbonic Anhydrase II Inhibitor RA9
5NY1,X-RAY DIFFRACTION,2.1,41.54,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,2017-05-11,2018-01-17,5NY1,2551,1,257,324,,29.37,1,1.1,experimental,13.655,0.1599,0.1367,Carbonic Anhydrase II Inhibitor RA10
5NY3,X-RAY DIFFRACTION,2.1,41.31,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,2017-05-11,2018-01-17,5NY3,2590,1,258,349,,29.49,1,1.4,experimental,19.524,0.1717,0.1563,Carbonic Anhydrase II Inhibitor RA11
5T75,X-RAY DIFFRACTION,2.11,41.69,"VAPOR DIFFUSION, HANGING DROP",8.5,"3 M (NH4)2SO4, 50 mM Tris-HCl",293,2016-09-02,2017-09-06,5T75,2332,1,260,250,,29.94,1,1.5,experimental,16.683,0.17502,0.14487,Human carbonic anhydrase II G132C_C206S double mutant in complex with SA-2
5WGP,X-RAY DIFFRACTION,2.08,40.97,"VAPOR DIFFUSION, SITTING DROP",,"1.6 M sodium citrate, 50 mM Tris",298,2017-07-14,2018-02-07,5WGP,2244,1,257,140,,29.4,1,1.53,experimental,,0.1898,0.1645,Human Carbonic Anhydrase IX-mimic complexed with AceK
5ZXW,X-RAY DIFFRACTION,2.11,41.78,"VAPOR DIFFUSION, HANGING DROP",8.3,2.7M ammonium sulfate,281,2018-05-22,2018-06-13,5ZXW,2377,1,266,333,,29.98,1,1.316,experimental,20.8256,0.1982,0.1709,Crystal structure of human carbonic anhydrase II crystallized by ammonium sulfate
6B5A,X-RAY DIFFRACTION,2.09,41.28,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M NaCitrate
50mM Tris-HCl",298,2017-09-28,2018-09-05,6B5A,2211,1,257,129,,29.29,1,1.622,experimental,19.2481,0.2011,0.1549,Carbonic anhydrase IX-mimic in complex with nitrogenous base-bearing benezenesulfonamide
6EQU,X-RAY DIFFRACTION,2.07,40.46,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M SODIUM CITRATE, 100 mM TRIS-HCl",293,2017-10-15,2017-12-13,6EQU,2364,1,261,195,,29.9,1,1.65,experimental,15.0436,0.2097,0.1746,X-Ray crystal structure of the human carbonic anhydrase II adduct with a membrane-impermeant inhibitor
6H29,X-RAY DIFFRACTION,2.09,41.16,"VAPOR DIFFUSION, HANGING DROP",8,"1.3 M sodium citrate, 60 mM Tris-HCl",293,2018-07-13,2018-09-05,6H29,2418,1,260,263,,29.51,1,1.46,experimental,12.2262,0.1842,0.1691,HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH BENZYL CARBAMATE
6H3Q,X-RAY DIFFRACTION,2.09,41.13,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM",296,2018-07-19,2019-07-17,6H3Q,2330,1,260,254,,29.69,1,1.31,experimental,16.73,0.2069,0.1821,"Crystal structure of human carbonic anhydrase II in complex with the 4-(5-(chloromethyl)-1,3-selenazol-2-yl)benzenesulfonamide"
6HX5,X-RAY DIFFRACTION,2.1,41.29,VAPOR DIFFUSION,8,"1.5 M sodium citrate, Tris 50 mM",296,2018-10-16,2018-12-26,6HX5,2251,1,260,182,,29.51,1,1.44,experimental,14.848,0.20979,0.18821,Selenols: a new class of Carbonic Anhydrase inhibitors
6RZX,X-RAY DIFFRACTION,2.07,40.52,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2019-06-13,2020-06-03,6RZX,2485,1,260,318,,29.55,1,1,experimental,15.319,0.1504,0.1279,Carbonic Anhydrase CAIX mimic in complex with inhibitor FBSA
6SDJ,X-RAY DIFFRACTION,2.05,39.9,"VAPOR DIFFUSION, HANGING DROP",,"Ammonium sulfate 2.7 M, TRIS 0.1, saturated with para-Chloromercuribenzoic acid",291,2019-07-27,2020-04-15,6SDJ,2579,1,265,180,,31.06,1,1.02,experimental,13.52,0.1396,0.1283,Human Carbonic Anhydrase II in complex with (R)-1-aminopropan-2-ol
6T7U,X-RAY DIFFRACTION,2.06,40.4,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM TRIS-HCl
1.6 M Sodium Citrate",290,2019-10-23,2020-06-17,6T7U,2506,1,260,287,,29.52,1,1.2,experimental,13.029,0.1599,0.1372,Carborane inhibitor of Carbonic Anhydrase IX
6YO2,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-04-14,2020-08-19,6YO2,2442,1,260,301,,29.52,1,1.2,experimental,17.013,0.1644,0.1452,Meta-Carborane propyl-sulfonamide in complex with CA IX mimic
6YO4,X-RAY DIFFRACTION,2.08,40.93,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-04-14,2020-08-19,6YO4,2318,1,260,223,,29.52,1,1.7,experimental,12.461,0.2262,0.1928,Para-Carborane propyl-sulfonamide in complex with CA IX mimic
6YO7,X-RAY DIFFRACTION,2.04,39.77,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-04-14,2020-08-19,6YO7,2353,1,260,236,,29.64,1,1.17,experimental,16.799,0.1848,0.1597,Ortho-Carborane di-propyl-sulfonamide in complex with CA IX mimic
6YOI,X-RAY DIFFRACTION,2.06,40.34,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-04-14,2020-08-19,6YOI,2376,1,260,271,,29.64,1,1.2,experimental,14.608,0.1552,0.1335,Meta-Carborane di-propyl-sulfonamide in complex with CA IX mimic
6YOK,X-RAY DIFFRACTION,2.07,40.56,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-04-14,2020-08-19,6YOK,2356,1,260,254,,29.64,1,1.25,experimental,17.425,0.1536,0.1278,Para-Carborane di-propyl-sulfonamide in complex with CA IX mimic
6YOL,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-04-14,2020-08-19,6YOL,2389,1,260,282,,29.51,1,1.15,experimental,18.945,0.1705,0.1409,Meta-Nidocarborane propyl-sulfonamide in complex with CA IX mimic
6YZJ,X-RAY DIFFRACTION,2.05,39.86,"VAPOR DIFFUSION, HANGING DROP",7.8,"10 mM Tris, 1.6 M natrium Citrate",291,2020-05-07,2020-10-28,6YZJ,2439,1,260,250,,29.51,1,1.2,experimental,13.773,0.1632,0.1324,Closo-carborane ethyl-sulfonamide in complex with CA IX mimic
6YZL,X-RAY DIFFRACTION,2.07,40.54,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris pH 7.8
1.6 Natrium Citrate",291,2020-05-07,2020-10-28,6YZL,2425,1,260,266,,29.49,1,1.2,experimental,11.957,0.1788,0.1587,Closo-carborane methyl-sulfonamide in complex with CA IX mimic
6YZM,X-RAY DIFFRACTION,2.02,39.24,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-05-07,2020-10-28,6YZM,2233,1,260,175,,29.54,1,1.5,experimental,21.415,0.1945,0.1629,Carborane nido-pentyl-sulfonamide in complex with CA IX mimic
6YZO,X-RAY DIFFRACTION,2.07,40.48,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-05-07,2020-10-28,6YZO,2225,1,260,122,,29.56,1,1.5,experimental,22.325,0.2123,0.1862,Carborane closo-hexyl-sulfonamide in complex with CA IX mimic
6YZP,X-RAY DIFFRACTION,2.06,40.37,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-05-07,2020-10-28,6YZP,2391,1,260,229,,29.55,1,1.35,experimental,19.567,0.1982,0.1768,Carborane nido-hexyl-sulfonamide in complex with CA IX mimic
6YZQ,X-RAY DIFFRACTION,2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-05-07,2020-10-28,6YZQ,2487,1,260,355,,29.62,1,1.04,experimental,18.645,0.1596,0.141,Carborane closo-butyl-sulfonamide in complex with CA II
6YZR,X-RAY DIFFRACTION,2.08,40.79,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-05-07,2020-10-28,6YZR,2486,1,260,308,,29.61,1,1.2,experimental,17.516,0.162,0.1326,Carborane nido-butyl-sulfonamide in complex with CA II
6YZS,X-RAY DIFFRACTION,2.07,40.55,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-05-07,2020-10-28,6YZS,2537,1,260,367,,29.66,1,1.05,experimental,17.756,0.1716,0.1384,Carborane closo-pentyl-sulfonamide in complex with CA II
6YZT,X-RAY DIFFRACTION,2.1,41.31,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291,2020-05-07,2020-10-28,6YZT,2435,1,260,265,,29.61,1,1.05,experimental,19.593,0.2083,0.1761,Closo-carborane propyl-sulfonamide in complex with CA II
6YZU,X-RAY DIFFRACTION,2.08,40.81,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-05-07,2020-10-28,6YZU,2608,1,260,384,,29.9,1,1,experimental,15.196,0.1402,0.1261,Carborane nido-pentyl-sulfonamide in complex with CA II
6YZV,X-RAY DIFFRACTION,2.07,40.61,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291,2020-05-07,2020-10-28,6YZV,2377,1,260,234,,29.59,1,1.65,experimental,19.895,0.2044,0.1768,Closo-carborane ethyl-sulfonamide in complex with CA II
6YZW,X-RAY DIFFRACTION,2.09,41.14,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-05-07,2020-10-28,6YZW,2520,1,260,339,,29.65,1,1.03,experimental,15.824,0.1549,0.1284,Carborane closo-hexyl-sulfonamide in complex with CA II
6YZX,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2020-05-07,2020-10-28,6YZX,2396,1,260,255,,29.64,1,1.1,experimental,17.428,0.1656,0.1431,Carborane nido-hexyl-sulfonamide in complex with CA II
6Z04,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris pH=7.8
1.6 M Natrium Citrate",291,2020-05-07,2020-10-28,6Z04,2524,1,260,286,,29.52,1,1.05,experimental,15.626,0.1578,0.1408,Nido-carborane butyl-sulfonamide in complex with CA IX mimic
7K6L,X-RAY DIFFRACTION,2.12,42,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.6M Sodium Citrate, 50mM Tris, pH 6.4",295,2020-09-21,2020-12-23,7K6L,2278,1,260,142,,30.6,1,1.655,experimental,18.3506,0.2079,0.1743,Carbonic Anhydrase II complexed with 4-(2-(3-(4-fluorophenyl)ureido)ethylsulfonamido)benzenesulfonamide
7ZL6,X-RAY DIFFRACTION,2.12,41.86,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 50 mM Tris pH 8.0",293,2022-04-14,2023-04-26,7ZL6,2353,1,260,219,,29.73,1,1.383,experimental,17.719,0.1848,0.1614,Azosemide in complex with human Carbonic anhydrase II (hCA II)
7ZWB,X-RAY DIFFRACTION,2.09,41.15,"VAPOR DIFFUSION, HANGING DROP",8,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",298,2022-05-19,2023-05-31,7ZWB,2384,1,260,269,,30.06,1,1.48,experimental,16.003,0.2271,0.2012,"human Carbonic Anhydrase II in complex with 4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)benzenesulfonamide"
8FQY,X-RAY DIFFRACTION,2.03,39.54,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris base",293,2023-01-06,2023-02-01,8FQY,2353,1,260,267,,29.69,1,1.466,experimental,,0.1854,0.1686,Carbonic Anhydrase II in complex with the alkyl urea 3h
7W7Z,X-RAY DIFFRACTION,2.17,43.23,"VAPOR DIFFUSION, SITTING DROP",6.5,1.0 M Lithium sulfate 0.1 M MES pH 6.5,293,2021-12-07,2022-12-21,7W7Z,1155,1,164,23,,18.28,1,2.15,experimental,69.639,0.2392,0.1952,Crystal Structure of human Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
6KZQ,X-RAY DIFFRACTION,1.99,38.26,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 4000, 0.2M KSCN, 10% ethelene glycol, 0.1M bis-tris propane",293,2019-09-25,2020-09-30,6KZQ,2637,2,316,215,,36.39,2,1.7,experimental,23.2073,0.2098,0.1837,structure of PTP-MEG2 and NSF-pY83 peptide complex
6WK6,X-RAY DIFFRACTION,2.12,41.9,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 6
5 mM magnesium chloride
18% PEG 2000 MME",293,2020-04-15,2021-01-06,6WK6,3823,3,452,60,,54.93,1,2.35,experimental,48.18,0.2377,0.1886,Crystal structure of human polymerase eta complexed with Xanthine containing DNA
6DUN,X-RAY DIFFRACTION,1.98,37.8,"VAPOR DIFFUSION, SITTING DROP",6.5,"2 M ammonium citrate, pH 6.5",298,2018-06-21,2019-03-06,6DUN,1929,2,244,154,,27.46,1,1.59,experimental,24.7461,0.1987,0.1521,Crystal Structure Analysis of PIN1
4YWP,X-RAY DIFFRACTION,2.1,41.43,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCL pH 7.4",298,2015-03-20,2015-10-14,4YWP,2361,1,257,288,,29.25,1,1.45,experimental,,0.1899,0.162,Sucrose Binding Site in genetically engineered Carbonic anhydrase IX
6CJV,X-RAY DIFFRACTION,2.09,41.22,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6M sodium citrate, 50mM Tris-HCl",298,2018-02-26,2018-08-08,6CJV,2285,1,257,185,,29.31,1,1.547,experimental,25.5324,0.1854,0.1616,Carbonic anhydrase IX-mimic in complex with sucralose
5HNT,X-RAY DIFFRACTION,2.08,40.73,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, NaCl, MES",289,2016-01-18,2017-03-15,5HNT,5552,2,630,454,,73.85,1,2,experimental,19.084,0.2275,0.1821,Crystal Structure of AKR1C3 complexed with CAPE
5L01,X-RAY DIFFRACTION,1.51,18.76,"VAPOR DIFFUSION, SITTING DROP",7.6,"20% PEG 3350, 0.05M citrate/0.05 M Bis-tris Propane pH 7.6, 5% PEG 400",293,2016-07-26,2017-01-25,5L01,2461,1,444,141,,51.68,1,1.9,experimental,25.226,0.21421,0.16925,"Tryptophan 5-hydroxylase in complex with inhibitor (3~{S})-8-[2-azanyl-6-[(1~{R})-1-(4-chloranyl-2-phenyl-phenyl)-2,2,2-tris(fluoranyl)ethoxy]pyrimidin-4-yl]-2,8-diazaspiro[4.5]decane-3-carboxylic acid"
5SKJ,X-RAY DIFFRACTION,2.6,52.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295,2022-02-01,2022-10-12,5SKJ,10527,4,1372,277,4,159.22,1,2.74,experimental,45.162,0.2489,0.166,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[2-[2-(methylamino)-2-oxoethyl]phenyl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5TPG,X-RAY DIFFRACTION,1.99,38.19,"VAPOR DIFFUSION, SITTING DROP",5.5,"20% PEG 3350, 0.1 Na Citrate, pH 5.5, 4% Acetonitrile",293,2016-10-20,2017-01-25,5TPG,2384,1,307,176,,36.37,1,1.5,experimental,26.679,0.21538,0.18679,Optimization of spirocyclic proline tryptophanhydroxylase-1 inhibitors
5TKS,X-RAY DIFFRACTION,3.44,64.27,"VAPOR DIFFUSION, HANGING DROP",7,"100 MM SODIUM ACETATE, PH 4.6, 25%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE, then transferred to 100 MM TRIS-HCL, pH 7.0, 25%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277,2016-10-07,2017-03-01,5TKS,2271,1,244,246,4,29.24,1,1.55,experimental,22.71,0.176,0.16,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR ((15S)-18-CHLORO- 15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2- PROPENOYL)AMINO)-17,19-DIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE"
6NLQ,X-RAY DIFFRACTION,1.98,38,EVAPORATION,7,"0.1 M Tris-HCl, 100 mM calcium chloride, 18% PEG3350",298,2019-01-08,2020-01-15,6NLQ,3950,4,452,505,,47.23,1,1.15,experimental,18.1394,0.1723,0.1585,Human Mitochondrial Alanyl-tRNA Synthetase C-terminal domain
6HPO,X-RAY DIFFRACTION,2.48,50.35,VAPOR DIFFUSION,,"40 mM PIPES, 20% PEG 2000, pH 6.8",291,2018-09-21,2019-06-05,6HPO,2880,1,452,294,,51.98,1,1.67,experimental,,0.177,0.1607,Crystallographic structure of the catalytic domain of Human Phenylalanine Hydroxylase (hPAH CD) in complex with iron at 1.6 Angstrom
8GBQ,X-RAY DIFFRACTION,2.62,53.08,"VAPOR DIFFUSION, SITTING DROP",9.5,"0.1 M CHES 9.5
20% PEG 8000",289,2023-02-27,2023-07-19,8GBQ,2084,2,253,152,,28.85,2,1.74,experimental,45.1628,0.201,0.1839,Structure of RNF125 in complex with UbcH5b
7V13,X-RAY DIFFRACTION,2.19,43.87,"VAPOR DIFFUSION, HANGING DROP",5,"24% PEG 4000, 100mM Na Citrate pH 5.0",293,2022-05-11,2022-08-03,7V13,2087,1,238,141,4,27.6,1,1.589,experimental,30.5363,0.1886,0.1639,Factor XIa in Complex with Compound 2g
7V14,X-RAY DIFFRACTION,2.23,44.95,"VAPOR DIFFUSION, HANGING DROP",5,"24% PEG 4000, 100mM Na Citrate pH 5.0",293,2022-05-11,2022-08-03,7V14,2101,1,238,146,4,27.56,1,1.697,experimental,31.3738,0.1933,0.1611,Factor XIa in Complex with Compound 2h
7V15,X-RAY DIFFRACTION,2.23,44.78,"VAPOR DIFFUSION, HANGING DROP",5,"24% PEG 4000, 100mM Na Citrate pH 5.0",293,2022-05-11,2022-08-03,7V15,2036,1,238,88,4,27.57,1,1.679,experimental,35.8272,0.1904,0.167,Factor XIa in Complex with Compound 2i
7V16,X-RAY DIFFRACTION,2.21,44.39,"VAPOR DIFFUSION, HANGING DROP",5,"24% PEG 4000, 100mM Na Citrate pH 5.0",293,2022-05-11,2022-08-03,7V16,2110,1,238,152,4,27.55,1,1.505,experimental,30.1471,0.1942,0.1658,Factor XIa in Complex with Compound 2j
7V17,X-RAY DIFFRACTION,2.2,44.07,VAPOR DIFFUSION,5,"24% PEG 4000, 100mM Na Citrate pH 5.0",293,2022-05-11,2022-08-03,7V17,2114,1,238,161,4,27.55,1,1.522,experimental,27.8902,0.1866,0.1616,Factor XIa in Complex with Compound 2k
7V18,X-RAY DIFFRACTION,2.17,43.3,"VAPOR DIFFUSION, HANGING DROP",5,"24% PEG 4000, 100mM Na Citrate pH 5.0",293,2022-05-11,2022-08-03,7V18,2015,1,238,71,4,27.63,1,1.732,experimental,43.5588,0.2069,0.1707,Factor XIa in Complex with Compound 3f
5A1P,X-RAY DIFFRACTION,2.26,45.5,,6.4,"6% PEG 3350, 20 MM BIS-TRIS PROPANE PH 6.4, 12 MM AMMONIUM CITRATE, 5% GLYCEROL",,2015-05-04,2015-06-24,5A1P,3824,1,487,7,,56.88,1,2.5,experimental,,0.2779,0.1908,Crystal structure of cytochrome P450 3A4 bound to progesterone and citrate
4Z97,X-RAY DIFFRACTION,5.17,76.19,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M sodium citrate, pH5.5, 10% PEG6000, 15% glycerol",297,2015-04-09,2016-10-12,4Z97,4127,2,563,,,65.44,2,2.998,experimental,,0.2543,0.2089,Crystal structure of USP7 in complex with DNMT1(K1115Q)
7L8K,X-RAY DIFFRACTION,1.66,25.69,MICROBATCH,8.2,0.056 M sodium phosphate monobasic monohydrate and 1.344 M potassium phosphate,293,2020-12-31,2021-12-29,7L8K,1538,1,192,190,,22.32,1,1.38,experimental,20.3969,0.1651,0.1469,Crystal structure of human GPX4-U46C
4RRT,X-RAY DIFFRACTION,3.27,62.38,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M lithium sulfate monohydrate, 0.1 M HEPES, pH 7.5, 25% w/v PEG3350, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-11-06,2015-01-28,4RRT,8095,2,952,459,,113.95,1,2.2,experimental,33.284,0.22197,0.17027,Crystal structure of a human cytochrome P450 2B6 (Y226H/K262R) in complex with (+)-3-carene
6PL7,X-RAY DIFFRACTION,2.1,41.39,"VAPOR DIFFUSION, HANGING DROP",6,"0.1M MES (pH 5.5), 5 mM MgCl2, and 15 to 20 % PEG 2K-MME",293,2019-06-30,2020-07-01,6PL7,3848,3,455,57,,55.31,1,2.5,experimental,,0.2808,0.2102,Structure of human DNA polymerase eta complexed with A in the template base paired with incoming non-hydrolyzable TTP
6PL8,X-RAY DIFFRACTION,2.1,41.44,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES (pH 5.5), 5 mM MgCl2, and 15 to 20 % PEG 2K-MME",298,2019-06-30,2020-07-01,6PL8,3908,3,455,116,,55.33,1,2.17,experimental,,0.2438,0.1817,Structure of human DNA polymerase eta complexed with 8OA in the template base paired with incoming non-hydrolyzable TTP
6E41,X-RAY DIFFRACTION,2.57,52.12,EVAPORATION,6.2,"0.1 M phosphate (pH 6.2), and 15% (w/v) PEG3350",298,2018-07-16,2018-11-14,6E41,12520,4,1620,286,,186.4,1,2.291,experimental,48.4843,0.2506,0.2031,"CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) in complex with ferric heme and an Epacadostat analog"
6PLC,X-RAY DIFFRACTION,2.09,41.24,"VAPOR DIFFUSION, HANGING DROP",6,"0.1M MES (pH 5.5), 5 mM MgCl2, and 15 to 20 % PEG 2K-MME",298,2019-06-30,2020-04-22,6PLC,3845,3,455,51,,55.35,1,2.5,experimental,40.843,0.2725,0.1789,Structure of human DNA polymerase eta complexed with 8OA in the template base paired with incoming non-hydrolyzable GTP
6UI2,X-RAY DIFFRACTION,2.1,41.48,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES (pH 5.5), 5 mM MgCl2, and 15 to 20 % PEG 2K-MME",298,2019-09-30,2020-01-15,6UI2,3886,3,455,93,,55.35,1,2.35,experimental,24.9462,0.2374,0.1704,Structure of human DNA polymerase eta complexed with N7MG in the template base paired with incoming non-hydrolyzable CTP
4XEO,X-RAY DIFFRACTION,2.3,46.47,VAPOR DIFFUSION,7.5,PEG3350,293,2014-12-24,2015-12-30,4XEO,7168,2,950,810,,108.23,1,1.38,experimental,20.396,0.2139,0.1826,Crystal Structure of human AlaRS catalytic domain with R329H mutation
5NXI,X-RAY DIFFRACTION,2.1,41.47,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291.15,2017-05-10,2018-01-17,5NXI,2478,1,259,330,,29.79,1,1.16,experimental,15.23,0.1465,0.1264,Carbonic Anhydrase II Inhibitor RA2
7Y3A,X-RAY DIFFRACTION,2.48,50.31,"VAPOR DIFFUSION, SITTING DROP",,0.1 M Sodium formate pH 7.0 20%3350 0.2M NaCl,293,2022-06-10,2022-08-03,7Y3A,5053,3,579,715,,63.76,1,1.7,experimental,14.6624,0.1751,0.1484,Crystal structure of TRIM7 bound to 2C
4YOC,X-RAY DIFFRACTION,2.83,56.56,"VAPOR DIFFUSION, HANGING DROP",,"6-8% PEG 3350, 200 mM potassium acetate",291,2015-03-11,2015-05-27,4YOC,11386,2,1552,11,,178.15,2,2.916,experimental,66.1918,0.2584,0.2077,Crystal Structure of human DNMT1 and USP7/HAUSP complex
6G34,X-RAY DIFFRACTION,3.03,59.4,"VAPOR DIFFUSION, SITTING DROP",,"51-63% MPD and 0.1M SPG buffer, pH 6.0-6.5",277.15,2018-03-24,2018-04-18,6G34,2872,1,357,229,,41.56,1,1.76,experimental,21.753,0.17374,0.13833,Crystal structure of haspin in complex with 5-iodotubercidin
4XJV,X-RAY DIFFRACTION,3.02,62.95,"VAPOR DIFFUSION, HANGING DROP",7.6,"Rod-shaped crystals of TE2 (10 mg/ml with 10 mM fresh DTT) were grown using the vapor diffusion method at 25 C, using a 1:1 drop to well ratio. The well solutions contained 1.64 M NaH2PO4, 0.42 M K2HPO4 and 50 mM HEPES. Crystals were cryoprotected by transfer to paratone.",298,2015-01-09,2015-12-16,4XJV,1703,1,271,,,30.64,1,2.8,experimental,94.6564,0.3449,0.2944,Crystal structure of human thioesterase 2
5EE7,X-RAY DIFFRACTION,3,59,LIPIDIC CUBIC PHASE,6,"ADA BUFFER, SODIUM POTASSIUM TARTRATE, PEG 400",293.15,2015-10-22,2016-04-20,5EE7,3619,1,452,24,1,56.37,1,2.5,experimental,,0.2625,0.2256,Crystal structure of the human glucagon receptor (GCGR) in complex with the antagonist MK-0893
8CHJ,X-RAY DIFFRACTION,2.76,55.4,"VAPOR DIFFUSION, HANGING DROP",,"1.32M Na-K tartrate, 0.2 M ammonium citrate, 0.1M MES pH 6.5",293,2023-02-08,2023-09-06,8CHJ,3734,4,428,357,,49.42,1,1.697,experimental,25.864,0.2047,0.1828,"Human FKBP12 in complex with (1S,5S,6R)-10-((R)-(3,5-dichlorophenyl)sulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one"
6Z58,X-RAY DIFFRACTION,2.86,57.02,"VAPOR DIFFUSION, SITTING DROP",6,"54% MPD, 0.1M SPG pH 6.0",277.15,2020-05-26,2020-06-03,6Z58,2985,1,357,293,,41.17,1,1.8,experimental,30.424,0.1897,0.1621,Crystal structure of haspin (GSG2) in complex with macrocycle ODS2003791
6Q9V,X-RAY DIFFRACTION,2.36,47.88,"VAPOR DIFFUSION, HANGING DROP",,"200mM NaCl, 100mM Cacodylate pH 7.4, 1.6M Ammonium Sulfate, 10% 2-Methyl-2,4-pentanediol",293,2018-12-18,2020-01-15,6Q9V,2600,2,317,303,2,35.54,2,1.85,experimental,23.0244,0.2256,0.1819,MSRB3
5TJN,X-RAY DIFFRACTION,2.26,45.55,VAPOR DIFFUSION,,"Native crystals of GTA/GTB lacking any heavy metals were grown at 4 degrees Celsius from much higher concentrations of protein (30-40 mg/mL for GTB and 16-20 mg/mL for GTA) along with 1% PEG 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM ADA buffer pH 7.5, 30 mM sodium acetate buffer pH 4.6 and 5 mM MnCl2 for GTB crystallization and 5-8 mM CoCl2 for GTA crystallization.  10-15 microlitre drops were placed against a reservoir containing 3.7% PEG 4000, 7% MPD, 0.3 M ammonium sulfate, 0.25 M sodium chloride, 0.2 M ADA buffer and 0.1 M sodium acetate.  The crystals were usually grown for 5-10 days. Before making complexes, crystals of GTA/GTB were washed with modified mother liquor ML-2 consisting of 3.5% PEG 4000, 50 mM ammonium sulfate, 40 mM sodium chloride, 35 mM ADA buffer and 15% MPD or glycerol. Crystals of native GTA/GTB in complex with the respective A or B trisaccharide were obtained by soaking them in mother liquor ML-2 with 15% glycerol or MPD and 45-50 mM of each substrate for 2-5 days at 4 degrees Celsius.  Before freezing the crystals for data collection, the concentration of the cryoprotectant was made 30% glycerol or 20% MPD respectively",277,2016-10-04,2017-06-14,5TJN,2580,1,297,243,,35.25,1,1.47,experimental,21.136,0.2044,0.1832,Crystal structure of GTB + B trisaccharide (native)
5C2H,X-RAY DIFFRACTION,1.88,34.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,2015-06-15,2015-10-07,5C2H,5173,2,724,62,1,83.97,1,2.09,experimental,47.13,0.2399,0.2072,"PDE10 complexed with 6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[3-(2-quinolyl)propoxy]pyrimidin-4-amine"
6Q38,X-RAY DIFFRACTION,2.62,53.04,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M HEPES 7.5 pH, 10 %w/v PEG 8K, 8 %v/v Ethelyene glycol",298,2018-12-03,2019-04-24,6Q38,3018,2,342,110,,40.87,2,1.74,experimental,56.92,0.234,0.204,The Crystal structure of CK2a bound to P1-C4
4ZV8,X-RAY DIFFRACTION,3.22,62,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, pH 7.5, 20% w/v Polyethylene glycol 10,000",291,2015-05-18,2016-03-30,4ZV8,4101,1,476,267,,56.41,1,2.24,experimental,38.051,0.23218,0.16904,Structure of CYP2B6 (Y226H/K262R) with additional mutation Y244W in complex with alpha-Pinene
6UEZ,X-RAY DIFFRACTION,2.85,56.81,VAPOR DIFFUSION,7.4,"PEG3350, HEGA-11, potassium phosphate, lanosterol",293,2019-09-23,2020-06-10,6UEZ,7789,2,908,514,,105.7,1,1.98,experimental,53.135,0.2221,0.191,Human sterol 14a-demethylase (CYP51) in complex with the substrate lanosterol
6Q6J,X-RAY DIFFRACTION,2.59,52.51,"VAPOR DIFFUSION, HANGING DROP",6.5,Sodium cacodylate 0.1M pH6.5; CaCl2 0.3M; PEG 2000 20%; DMSO 4%,291,2018-12-11,2019-06-12,6Q6J,3627,2,440,195,,49.25,1,1.985,experimental,46.1001,0.2468,0.1981,Human phosphoserine phosphatase with substrate analogue homo-cysteic acid
7BNE,X-RAY DIFFRACTION,1.94,36.56,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2021-01-22,2022-03-02,7BNE,2959,1,383,99,7,44.33,1,1.7,experimental,32.1858,0.1966,0.1714,Notum Nicotine
4TTD,X-RAY DIFFRACTION,2.39,48.55,"VAPOR DIFFUSION, SITTING DROP",,"100mM PCTP pH 4.5, 25% w/v Peg3350, ethanol 5%",293,2014-06-20,2015-07-08,4TTD,8619,6,1136,323,16,121.16,3,2.15,experimental,53.41,0.2789,0.2549,Structure of a lysozyme antibody complex
7U4N,X-RAY DIFFRACTION,1.85,33.41,MICROBATCH,7.5,0.1 M HEPES and 0.1 M magnesium nitrate hexahydrate,291,2022-02-28,2022-12-07,7U4N,3205,2,384,504,,44.66,1,1.6,experimental,18.0077,0.188,0.1497,Crystal structure of human GPX4-U46C in complex with RSL3
4PYG,X-RAY DIFFRACTION,2.53,51.43,"VAPOR DIFFUSION, HANGING DROP",6.8,"20mM Mes pH 6.8, 200mM sodium chloride, 20mM MgCl2, 6% PEG 3350, 5mM DTT, 24% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 297K",297,2014-03-27,2015-02-11,4PYG,16462,3,2085,109,3,237.02,1,2.8,experimental,75.07,0.31904,0.23557,Transglutaminase2 complexed with GTP
6A8P,X-RAY DIFFRACTION,2.54,51.57,"VAPOR DIFFUSION, HANGING DROP",6.8,"20 mM Mes (pH 6.8), 200 mM sodium chloride, 20 mM MgCl2, 6% PEG 3350, 5 mM DTT, 24% glycerol",293,2018-07-09,2018-09-26,6A8P,16026,3,2085,,,237.02,1,2.537,experimental,,0.2575,0.236,Transglutaminase 2 mutant G224V in complex with GTP
8F0M,X-RAY DIFFRACTION,2.56,52.02,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium sulfate decahydrate, 20% w/v PEG3350, 0.05% w/v benzamidine hydrochloride",291,2022-11-03,2023-07-19,8F0M,4203,4,536,102,,60.92,2,2.44,experimental,,0.245,0.2009,Monobody 12D5 bound to KRAS(G12D)
5ZBZ,X-RAY DIFFRACTION,2.47,50.22,"VAPOR DIFFUSION, HANGING DROP",7,Sodium malonate,293,2018-02-14,2019-02-20,5ZBZ,1896,1,220,132,,25.36,1,1.30860259206,experimental,30.529063773,0.210421443451,0.193698497124,Crystal structure of the DEAD domain of Human eIF4A with sanguinarine
4RQL,X-RAY DIFFRACTION,3.29,62.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 25% w/v PEG3350, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-11-03,2015-01-28,4RQL,8202,2,952,448,,113.89,1,2.105,experimental,26.923,0.25771,0.21101,Crystal structure of a human cytochrome P450 2B6 (Y226H/K262R) in complex with a monoterpene - sabinene
5SH7,X-RAY DIFFRACTION,2.64,53.47,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295,2022-02-01,2022-10-12,5SH7,10775,4,1372,443,4,159.89,1,2.66,experimental,52.8235,0.2531,0.1774,Crystal Structure of human phosphodiesterase 10 in complex with 6-[(5-cyclopropyl-2-oxo-1H-pyridine-3-carbonyl)amino]-N-(oxetan-3-yl)-2-phenyl-3H-benzimidazole-5-carboxamide
5W7Y,X-RAY DIFFRACTION,1.95,36.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.6mM APLF
0.6mM XRCC1 peptide
0.1M Tris
30% PEG 1000",293,2017-06-21,2018-05-02,5W7Y,1826,4,232,125,,25.77,2,2.1,experimental,,0.2373,0.2026,Crystal Structure of FHA domain of human APLF in complex with XRCC1 monophosphorylated mutated peptide
7ZDN,X-RAY DIFFRACTION,2.66,53.7,"VAPOR DIFFUSION, SITTING DROP",8,"18 - 23 % PEG3350, 0.1 M TRIS-HCL",293.15,2022-03-29,2023-04-19,7ZDN,2963,2,330,444,,35.95,1,1.55,experimental,28.06,0.226,0.1899,Human Cyclophilin D in complex with fragment
8CDZ,X-RAY DIFFRACTION,2.34,47.51,"VAPOR DIFFUSION, HANGING DROP",,"28-31% PEG4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5-9.0",296,2023-02-01,2024-02-21,8CDZ,4579,2,522,477,,58.56,1,1.44,experimental,27.561,0.1802,0.1345,human carbonic anhydrase I complexed with 4-(3-butylureido)benzenesulfonamide
8CO3,X-RAY DIFFRACTION,2.11,41.63,"VAPOR DIFFUSION, SITTING DROP",,"0.2M AMMONIUM ACETATE, 0.1M SODIUM CITRATE, PH 5.6, 31% PEG 4000, PROTEIN 10 MG/ML, 5-10 MM INHIBITOR (STOCK SOLUTION WAS DISSOLVED IN 100% DMSO), VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K",294,2023-02-26,2023-12-13,8CO3,9646,4,1052,1202,4,121.22,1,1.68,experimental,14.067,0.25406,0.19939,Three dimensional structure of human carbonic anhydrase XII in complex with sulfonamide
7U4J,X-RAY DIFFRACTION,2.21,44.47,MICROBATCH,7,0.2 M potassium thiocyanate and 20% (w/v) PEG 3350,291,2022-02-28,2022-12-07,7U4J,1483,1,192,159,,22.13,1,1.81,experimental,25.2478,0.2051,0.1703,Crystal structure of human GPX4-U46C-R152H in complex with TMT10
7U4M,X-RAY DIFFRACTION,2.74,55.15,MICROBATCH,4.6,2 M sodium chloride and 0.1 M sodium acetate trihydrate,291,2022-02-28,2022-12-07,7U4M,1539,1,192,135,,22.3,1,1.93,experimental,44.088,0.1971,0.1611,Crystal structure of human GPX4-U46C in complex with LOC1886
5A0E,X-RAY DIFFRACTION,2.04,39.6,"VAPOR DIFFUSION, HANGING DROP",2.9,"HANGING DROP 50:50. PRECIPITANT: 23% POLYETHYLENE GLYCOL (PEG3350), 50 MM SODIUM-CITRATE BUFFER AT PH 2.9 PROTEIN: 30 MG/ML IN 50MM POTASSIUM/SODIUM PHOSPHATE PH 7.3, 100MM NACL, 2MM EDTA, 0.02% SODIUM AZIDE.",,2015-04-19,2015-12-30,5A0E,3050,4,352,304,,38.23,2,1.25,experimental,15.02,0.13122,0.09806,"Crystal structure of cyclophilin D in complex with CsA analogue, JW47."
6G4Q,X-RAY DIFFRACTION,3.78,67.44,"VAPOR DIFFUSION, SITTING DROP",7.5,2.1M DL- malic acid,293.15,2018-03-28,2018-04-11,6G4Q,5144,2,722,82,,78.15,2,2.59,experimental,78.9871,0.2535,0.2075,Structure of human ADP-forming succinyl-CoA ligase complex SUCLG1-SUCLA2
6J6X,X-RAY DIFFRACTION,4.6,77.69,"VAPOR DIFFUSION, SITTING DROP",,"0.04M MgCl2, 0.05M NaCacodylate pH 6, 5% MPD, 8mM CHAPS",293,2019-01-16,2020-01-22,6J6X,4681,2,702,,,79.86,2,2.962,experimental,,0.2975,0.2659,Crystal structure of apo GGTaseIII
7NI3,X-RAY DIFFRACTION,2.39,48.54,"VAPOR DIFFUSION, HANGING DROP",5.5,"18% PEG 3350, 100 MM NACL, PROTEIN IN 50 MM AMMONIUM ACETATE, 2 MM CACL, 20 MM SODIUM ACETATE PH 5.5",293,2021-02-11,2022-02-23,7NI3,10213,4,1142,796,13,135.12,2,2.1,experimental,16.89,0.224,0.175,CRYSTAL STRUCTURE OF NATIVE HUMAN MYELOPEROXIDASE IN COMPLEX WITH CPD 3
7UFY,X-RAY DIFFRACTION,2.42,49.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide and 0.03 M sodium iodide",291,2022-03-23,2023-04-12,7UFY,8195,2,922,808,,105.6,1,1.584,experimental,30.479,0.1934,0.1656,Crystal structure of TDP1 complexed with compound XZ766
7ZIF,X-RAY DIFFRACTION,2.14,42.55,"VAPOR DIFFUSION, SITTING DROP",,"8% w/v PEG 8000, 100 mM Tris-HCl pH 8.5",293.15,2022-04-08,2022-09-07,7ZIF,2633,1,326,227,,38.12,1,1.86859719255,experimental,25.8132692447,0.198808711011,0.159509235052,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-480
7ZII,X-RAY DIFFRACTION,2.14,42.45,"VAPOR DIFFUSION, SITTING DROP",,"20% w/v PEG 3350, 200 mM potassium formate pH 7.3",293.15,2022-04-08,2022-09-07,7ZII,2680,1,326,314,,38.03,1,1.62800050605,experimental,25.8363252539,0.191912784114,0.16709833574,Crystal structure of human tryptophan hydroxylase 1 in complex with inhibitor KM-05-193
7A1B,X-RAY DIFFRACTION,2.62,52.97,"VAPOR DIFFUSION, SITTING DROP",8.5,"Reservoir composition: 28 % (w/v) PEG6000, 0.9 M LiCl, 0.1 M, Tris/HCl, pH 8.5; drop composition prior to equilibration: 0.01 ml reservoir solution + 0.02 ml CK2alpha' (mutant Cys336Ser)/inhibitor MB002 mixture (0.180 ml 6 mg/ml CK2alpha'Cys336Ser, 0.5 M NaCl, 25 mM Tris/HCl, pH 8.5, mixed and pre-equilibrated with 0.02 ml 10 mM MB002 in dimethyl sulfoxide); the initial inhibitor MB002 was replaced by the inhibitor 5,6-dibromo-1H-triazolo[4,5-b]pyridine by extensive crystal soaking.",293,2020-08-12,2020-12-09,7A1B,3257,1,364,306,,43.62,1,1.287,experimental,18.92,0.1925,0.1573,"Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 5,6-dibromo-1H-triazolo[4,5-b]pyridine"
7A22,X-RAY DIFFRACTION,2.63,53.31,"VAPOR DIFFUSION, SITTING DROP",,"Reservoir composition: 28 % (w/v) PEG6000, 0.9 M LiCl, 0.1 M, Tris/HCl, pH 8.5; drop composition prior to equilibration: 0.01 ml reservoir solution + 0.02 ml CK2alpha' (mutant Cys336Ser)/inhibitor MB002 mixture (0.180 ml 6 mg/ml CK2alpha'Cys336Ser, 0.5 M NaCl, 25 mM Tris/HCl, pH 8.5, mixed and pre-equilibrated with 0.02 ml 10 mM MB002 in dimethyl sulfoxide); the initial inhibitor MB002 was replaced by the inhibitor 5,6,7-tribromo-1H-triazolo[4,5-b]pyridine by extensive crystal soaking.",293,2020-08-15,2020-12-09,7A22,3240,1,364,321,,44.04,1,1.01,experimental,17.17,0.166,0.1379,"Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 5,6,7-tribromo-1H-triazolo[4,5-b]pyridine"
7A2H,X-RAY DIFFRACTION,2.67,53.88,"VAPOR DIFFUSION, SITTING DROP",,"Reservoir composition: 28 % (w/v) PEG6000, 0.9 M LiCl, 0.1 M, Tris/HCl, pH 8.5; drop composition prior to equilibration: 0.01 ml reservoir solution + 0.02 ml CK2alpha' (mutant Cys336Ser)/inhibitor MB002 mixture (0.180 ml 6 mg/ml CK2alpha'Cys336Ser, 0.5 M NaCl, 25 mM Tris/HCl, pH 8.5, mixed and pre-equilibrated with 0.02 ml 10 mM MB002 in dimethyl sulfoxide); the initial inhibitor MB002 was replaced by the inhibitor 5,6,7-tribromo-1H-imidazo[4,5-b]pyridine by extensive crystal soaking.",293,2020-08-18,2020-12-09,7A2H,3304,1,364,433,,43.42,1,1.01,experimental,17.38,0.1495,0.1426,"Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 5,6,7-tribromo-1H-imidazo[4,5-b]pyridine"
5CBU,X-RAY DIFFRACTION,2.68,54.09,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH 9, 2% w/v PEG2000mme",294,2015-07-01,2016-07-20,5CBU,1469,1,165,132,,18.86,1,1.4,experimental,16.182,0.19719,0.16712,Human Cyclophilin D Complexed with Inhibitor.
5CCS,X-RAY DIFFRACTION,2.37,48.08,"VAPOR DIFFUSION, SITTING DROP",8,"25% w/v  PEG3350, 0.1M TRIS-HCL pH 8",294,2015-07-02,2016-07-20,5CCS,1375,1,165,109,,18.13,1,2.1,experimental,14.48,0.19561,0.16026,Human Cyclophilin D Complexed with Inhibitor
4XJS,X-RAY DIFFRACTION,1.95,36.8,"VAPOR DIFFUSION, HANGING DROP",7.5,"Protein concentration was 7mgs/ml. Crystals were grown from 23% PEG3350, 0.1mM BisTrisPropane at 22 deg C (2+2uL drops over a 500uL well). Crystals were soaked with 5mM inhibitor for 24 hours prior to data collection. Crystals were flash frozen in PFO.",295,2015-01-09,2015-08-26,4XJS,1962,1,262,23,5,30.96,1,2.8,experimental,53.927,0.2634,0.1863,"Human CD38 complexed with inhibitor 1 [6-fluoro-2-methyl-4-[(2,3,6-trichlorobenzyl)amino]quinoline-8-carboxamide]"
4XJT,X-RAY DIFFRACTION,1.95,36.77,"VAPOR DIFFUSION, HANGING DROP",7.5,"Protein concentration 7mgs/ml. Crystals were grown from 23% PEG3350, 0.1mM BisTrisPropane at 22 deg C (2+2uL drops over a 500uL well). Crystals were soaked with 5mM inhibitor for 24 hours prior to data collection. Crystals were flash frozen in PFO.",295,2015-01-09,2015-08-26,4XJT,2022,1,262,47,5,31.26,1,2.6,experimental,48.013,0.2538,0.1912,"Human CD38 complexed with inhibitor 2 [4-[(2,6-dimethylbenzyl)amino]-2-methylquinoline-8-carboxamide]"
6IPB,X-RAY DIFFRACTION,2.13,42.36,"VAPOR DIFFUSION, SITTING DROP",,"18% PEG 3350, 0.2M Na-Tartrate, 0.2M KCl, 2% glycerol",298,2018-11-02,2020-01-15,6IPB,5899,4,764,655,,86.34,1,1.78,experimental,26.014,0.18025,0.1457,Crystal Structure of the Cofactor-binding Domain of the Human Phase II Drug Metabolism Enzyme UGT2B15
6MXO,X-RAY DIFFRACTION,2.04,39.84,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES, 5mM MgCl2, 15-20%PEG2K-MME",295,2018-10-31,2019-02-13,6MXO,3929,3,463,110,,56.98,1,2.04,experimental,24.097,0.22999,0.17469,Structure of HPoleta incorporating dCTP opposite the 3-prime Pt(DACH)-GG
6R8L,X-RAY DIFFRACTION,2.67,53.91,"VAPOR DIFFUSION, SITTING DROP",7.5,PEG 3350,298,2019-04-02,2019-11-27,6R8L,1450,1,164,167,,18.15,1,1.64,experimental,28.99,0.2028,0.1728,"Human Cyclophilin D in complex with 1-((1S,9S,10S)-10-Hydroxy-12-oxa-8-aza-tricyclo[7.3.1.02,7]trideca-2,4,6-trien-4-ylmethyl)-3- {2-[(R)-2-(2-methylsulfanyl-phenyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-urea"
6R8W,X-RAY DIFFRACTION,2.68,54.1,"VAPOR DIFFUSION, SITTING DROP",7.5,PEG 3350,298,2019-04-02,2019-11-27,6R8W,1473,1,164,143,,18.62,1,1.4,experimental,,0.227,0.198,"Human Cyclophilin D in complex with 2-(exo-3,5-Dioxo-4-aza-tricyclo[5.2.1.02,6]dec-4-yl)-N-((1R,9R,10S)-10-hydroxy-12-oxa-8-aza-tricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ylmethyl)-acetamide"
6R9S,X-RAY DIFFRACTION,1.97,37.47,"VAPOR DIFFUSION, SITTING DROP",7.2,50 mM potassium phosphate,298,2019-04-04,2019-11-27,6R9S,1520,1,164,200,,18.6,1,2,experimental,14.44,0.2284,0.162,Human Cyclophilin D in complex with bicyclic fragment
6R9U,X-RAY DIFFRACTION,2.63,53.32,"VAPOR DIFFUSION, SITTING DROP",7.2,50 mM potassium phosphate,298,2019-04-04,2019-11-27,6R9U,1574,1,164,225,,18.64,1,1.26,experimental,,0.172,0.149,Human Cyclophilin D in complex with fragment
6R9X,X-RAY DIFFRACTION,2.15,42.92,"VAPOR DIFFUSION, SITTING DROP",,PEG4000,298,2019-04-04,2019-11-27,6R9X,1602,1,164,333,,17.9,1,1.66,experimental,10.54,0.193,0.144,Human Cyclophilin D in complex with N-cyclopentyl-N'-pyridin-2-ylmethyl-oxalamide
6RA1,X-RAY DIFFRACTION,2.66,53.79,"VAPOR DIFFUSION, SITTING DROP",7.2,50 mM potassium phosphate,298,2019-04-05,2019-11-27,6RA1,1394,1,164,82,,18.62,1,2,experimental,25.72,0.226,0.192,Human Cyclophilin D in complex with norbornane fragment derivative
6YBM,X-RAY DIFFRACTION,2.92,57.93,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium acetate, 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 30% v/v (+/-)-2-Methyl-2,4-pentanediol",298,2020-03-17,2020-04-15,6YBM,4328,3,495,527,,53.73,1,1.41,experimental,24.4,0.2112,0.1779,Scaffold-ligand complex with ligand unmodelled.
6UV2,X-RAY DIFFRACTION,3.35,63.29,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH 7.5, 40% PEG200",298,2019-11-01,2020-01-01,6UV2,3997,2,458,365,,55.01,1,1.894,experimental,34.2384,0.1908,0.1696,Crystal structure of the core domain of RNA helicase DDX17 with RNA pri-125a-oligo1
6UV3,X-RAY DIFFRACTION,3.31,62.88,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH 7.5, 40% PEG200",298,2019-11-01,2020-01-01,6UV3,3965,2,458,390,,54.97,1,1.597,experimental,26.5409,0.1972,0.1749,Crystal structure of the core domain of RNA helicase DDX17 with RNA pri-125a-oligo2
6UV4,X-RAY DIFFRACTION,2.08,40.73,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium acetate pH 4.6, 0.1M sodium chloride, 14% MDP, 10 mM CaCl2",293,2019-11-01,2020-01-01,6UV4,4028,2,458,445,,54.92,1,1.7,experimental,18.0351,0.204,0.1725,Crystal structure of the core domain of RNA helicase DDX17 with RNA pri-18a-oligo1
6HKQ,X-RAY DIFFRACTION,1.87,34.24,"VAPOR DIFFUSION, HANGING DROP",8,"Reservoir made from 0.2 M ammonium sulfate, 20% (w/v) PEG 3350. Prio to crystal set-up, the protein was modified with covalent inhibitor, purified via gelfiltration and concentrated to 13.5 mg/ml in 50 mM TrisHCl pH 8.0, 150 mM NaCl, 5mM TCEP",293,2018-09-07,2020-04-01,6HKQ,1645,1,176,227,,21.16,1,1.54,experimental,18.524,0.18416,0.1495,Human GPX4 in complex with covalent Inhibitor ML162 (S enantiomer)
8P41,X-RAY DIFFRACTION,3.22,61.77,VAPOR DIFFUSION,,"2 M (NH4)2SO4, 0.1 M Bis-Tris pH 5.5",291,2023-05-18,2024-03-06,8P41,8510,2,994,453,4,114.41,1,1.83,experimental,,0.2383,0.2045,Crystal structure of glucocerebrosidase in complex with allosteric activator
5CLW,X-RAY DIFFRACTION,3.25,62.18,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG 3350 , 0.2M sodium succinate",277,2015-07-16,2015-10-07,5CLW,15864,3,2004,171,,234.59,1,2.8,experimental,55.26,0.2312,0.1952,Crystal structure of human glycogen branching enzyme (GBE1) in complex with maltoheptaose
6VNP,X-RAY DIFFRACTION,2.76,55.46,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris 7.5
20% PEG3350
100 mM Magnesium Acetate",293,2020-01-29,2021-02-03,6VNP,14020,12,1496,363,,198.6,1,2.42,experimental,47.48,0.2416,0.1994,Crystal structure of DPO4 extension past 8-oxoadenine (oxoA) and dT
8B3N,X-RAY DIFFRACTION,2.17,43.35,"VAPOR DIFFUSION, SITTING DROP",5,"50 mM Di-Ammoniumhydrogen citrate pH 5: 15 mg/mL hAR, 5.2 mg/mL DTT, 0.7 mg/mL NADP+, 10% (w/v) PEG 6000
Reservoir: 120 mM Di-Ammoniumhydrogen citrate pH 5, 20% (w/v) PEG 6000
Soaking: 120 mM di-ammonium hydrogen citrate pH 5.0, 25% PEG 6000, saturated with ligand",291,2022-09-16,2023-09-27,8B3N,3158,1,316,448,,37.11,1,1.03,experimental,11.76,0.1543,0.1355,Human Aldose Reductase Mutant A299G/L300G in Complex with a Ligand with an IDD Structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl)benzoic acid)
8OZ2,X-RAY DIFFRACTION,2.16,43.09,"VAPOR DIFFUSION, SITTING DROP",5,"50 mM Di-Ammoniumhydrogen citrate pH 5: 15 mg/mL hAR, 5.2 mg/mL DTT, 0.7 mg/mL NADP+, 11.5% (w/v) PEG 6000;
Reservoir: 120 mM Di-Ammoniumhydrogen citrate pH 5, 20% (w/v) PEG 6000;
Soaking: 120 mM di-ammonium hydrogen citrate pH 5.0, 25% PEG 6000, saturated ligand",291,2023-05-08,2024-05-15,8OZ2,3248,1,316,502,,37.13,1,1.04,experimental,11.58,0.1238,0.1102,Human Aldose Reductase Mutant A299G/L300A in Complex with a Ligand with an IDD Structure ({5-fluoro-2-[(3-nitrobenzyl)carbamoyl]phenoxy}acetic acid)
8P2R,X-RAY DIFFRACTION,2.17,43.41,"VAPOR DIFFUSION, SITTING DROP",5,"50 mM Di-Ammoniumhydrogen citrate pH 5: 15 mg/mL hAR, 5.2 mg/mL DTT, 0.7 mg/mL NADP+, 12% (w/v) PEG 6000;
Reservoir: 120 mM Di-Ammoniumhydrogen citrate pH 5, 20% (w/v) PEG 6000;
Soaking: 120 mM di-ammonium hydrogen citrate pH 5.0, 25% PEG 6000, saturated ligand",291,2023-05-16,2024-06-12,8P2R,3269,1,316,478,,37.13,1,1.25,experimental,13.53,0.1364,0.1068,Human Aldose Reductase Mutant A299G/L300A in Complex with a Ligand with an IDD Structure (3-({[2-(carboxymethoxy)-4-fluorobenzoyl]amino}methyl)benzoic acid)
5SHL,X-RAY DIFFRACTION,2.61,52.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295,2022-02-01,2022-10-12,5SHL,10498,4,1372,262,4,159.01,1,2.35,experimental,55.619,0.2374,0.1753,"Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-2,3-dimethyl-8-pyrrolidin-1-ylimidazo[1,2-b]pyridazine"
5SJ4,X-RAY DIFFRACTION,2.63,53.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295,2022-02-01,2022-10-12,5SJ4,10464,4,1372,172,4,159.37,1,2.77,experimental,63.001,0.2779,0.1952,"Crystal Structure of human phosphodiesterase 10 in complex with 1-methyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-5H-pyrazolo[3,4-d]pyrimidin-4-one"
6YTR,X-RAY DIFFRACTION,3.07,59.88,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Na2SO4, 14% (v/v) PEG3350, 0.25 M HEPES pH 7.0",291,2020-04-24,2021-05-12,6YTR,9172,2,994,877,4,117.01,1,1.7,experimental,24.919,0.2026,0.1592,Structure of recombinant human beta-glucocerebrosidase in complex with cyclophellitol aziridine inhibitor
6E45,X-RAY DIFFRACTION,2.5,50.84,EVAPORATION,6.2,"0.1 M phosphate (pH 6.2), and 15% (w/v) PEG3350",298,2018-07-16,2018-11-14,6E45,12954,4,1620,1047,,184.41,1,2,experimental,33.5063,0.2258,0.1886,"CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) free enzyme in the ferrous state"
6RIT,X-RAY DIFFRACTION,2.09,41.06,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, pH = 7.8, saturated with para-Chloromercuribenzoic acid",291,2019-04-25,2020-04-15,6RIT,2877,1,265,228,,31.32,1,1.007,experimental,,0.14,0.125,Human Carbonic Anhydrase II in complex with 2-Fluorobenzenesulfonamide
6RJJ,X-RAY DIFFRACTION,2.09,41.05,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, pH = 7.8, saturated with para-Chloromercuribenzoic acid",291,2019-04-27,2020-04-15,6RJJ,2713,1,265,263,,31.18,1,1.056,experimental,,0.1381,0.1226,Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RNP,X-RAY DIFFRACTION,2.06,40.37,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-05-09,2020-04-15,6RNP,2667,1,265,276,,31.36,1,1.07,experimental,,0.1361,0.1193,Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RRG,X-RAY DIFFRACTION,2.1,41.41,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-05-17,2020-04-15,6RRG,2733,1,265,251,,31.16,1,1.127,experimental,,0.1401,0.1266,Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RRI,X-RAY DIFFRACTION,2.06,40.23,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-05-18,2020-04-15,6RRI,2684,1,265,247,,31.25,1,1.097,experimental,,0.1393,0.1193,Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RS5,X-RAY DIFFRACTION,2.07,40.54,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated with para-Chloromercuribenzoic acid",291,2019-05-21,2020-04-15,6RS5,2654,1,265,230,,31.28,1,1.07,experimental,,0.1315,0.118,Human Carbonic Anhydrase II in complex with fluorinated benzenesulfonamide
6RQX,X-RAY DIFFRACTION,2.29,46.38,"VAPOR DIFFUSION, SITTING DROP",,"200 mM potassium thiocyanate, 20% PEG 3350",289,2019-05-16,2019-12-18,6RQX,8141,2,947,736,2,112.81,2,1.68,experimental,,0.2093,0.1759,High-resolution crystal structure of ERAP1 in complex with 10mer phosphinic peptide
7P3B,X-RAY DIFFRACTION,2.42,49.25,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M sodium acetate pH 5.5, 0.6 M sodium formate, 14% (w/v) PEG 4000, 5 mM cobalt(II) chloride",293,2021-07-07,2021-12-22,7P3B,7867,2,1014,297,,112.21,1,2.3,experimental,45.09,0.2202,0.1921,Human RNA ligase RTCB in complex with GMP and Co(II)
7BOL,X-RAY DIFFRACTION,2.37,48.12,"VAPOR DIFFUSION, SITTING DROP",,"0.5 M Ammonium sulfate
0.1 M Sodium citrate  pH 5.6
1.0 M Lithium sulfate",291,2020-03-19,2021-03-24,7BOL,1308,1,148,124,,16.84,1,1.797,experimental,18.3873,0.2194,0.1927,"ubiquitin-conjugating enzyme, Ube2D2"
7PLF,X-RAY DIFFRACTION,2.33,47.26,"VAPOR DIFFUSION, SITTING DROP",,"28-31% PEG4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5-9.0",293,2021-08-31,2022-09-07,7PLF,4524,2,522,422,,58.7,1,1.461,experimental,22.143,0.205,0.1772,Human Carbonic Anhydrase I in complex with clorsulon
7B7W,X-RAY DIFFRACTION,1.96,37.37,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate",296,2020-12-11,2021-07-21,7B7W,2941,1,383,124,7,44.34,1,1.6,experimental,25.1576,0.2267,0.205,Notum-Fragment049
7B7X,X-RAY DIFFRACTION,2,38.5,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-11,2021-07-21,7B7X,2946,1,383,36,7,44.56,1,2.41,experimental,37.9012,0.2448,0.2176,Notum-Fragment063
7B7Y,X-RAY DIFFRACTION,2,38.5,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296,2020-12-11,2021-07-21,7B7Y,2940,1,383,145,6,44.89,1,1.48,experimental,23.5511,0.2382,0.2198,Notum-Fragment064
5NOZ,X-RAY DIFFRACTION,2.8,56.06,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOZ,1407,1,165,121,,18.2,1,1.61,experimental,21.286,0.21609,0.18834,"Structure of cyclophilin A in complex with 3,4-diaminobenzohydrazide"
6E43,X-RAY DIFFRACTION,2.55,51.7,EVAPORATION,6.2,"0.1 M phosphate (pH 6.2), and 15% (w/v) PEG3350",298,2018-07-16,2018-11-14,6E43,13245,4,1620,1253,,183.55,1,1.705,experimental,33.019,0.2306,0.1938,"Crystal structure of human indoleamine 2,3-dioxygenase 1 (IDO1) in complex with a BMS-978587 analog"
9FAZ,X-RAY DIFFRACTION,2.16,42.95,"VAPOR DIFFUSION, SITTING DROP",,"0.1M KSCN
25% PEG 3350",293,2024-05-10,2024-07-03,9FAZ,4564,1,546,470,2,63.23,1,1.63,experimental,22.307,0.19461,0.15862,Gcase in complex with small molecule inhibitor 1
6MJM,X-RAY DIFFRACTION,2.36,47.91,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, ADA, Anapoe 20",297,2018-09-21,2019-04-03,6MJM,3740,1,480,49,,55.76,1,2.2,experimental,,0.248,0.2092,Substrate Free Cytochrome P450 3A5 (CYP3A5)
4RUI,X-RAY DIFFRACTION,2.86,56.94,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.3 M sodium acetate, 0.1 M sodium cacodylate, and 25% w/v PEG 2K MME, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-11-19,2015-01-28,4RUI,22515,6,2856,312,,332.55,1,2.61,experimental,65.24,0.26071,0.19658,Crystal structure of a cytochrome P450 2A6 in complex with a monoterpene - sabinene.
7UY2,X-RAY DIFFRACTION,2.11,41.72,"VAPOR DIFFUSION, SITTING DROP",,"0.06 M Divalents (0.3M Magnesium chloride hexahydrate; 0.3M Calcium chloride dihydrate), 0.1 M Buffer System 1 (Imidazole; MES monohydrate (acid) pH 6.5), 37.5% Precipitant Mix 4 (25% v/v MPD; 25% PEG 1000; 25% w/v PEG 3350)",293.15,2022-05-06,2022-12-28,7UY2,3035,4,396,15,1,45.03,2,2.51,experimental,61.82,0.2701,0.2114,"Structure of RNF31 in complex with FP06649, a Helicon Polypeptide"
7UYJ,X-RAY DIFFRACTION,2.7,54.4,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Amino Acids (0.2M DL-Glutamic acid monohydrate; 0.2M DL-Alanine; 0.2M Glycine; 0.2M DL-Lysine monohydrochloride; 0.2M DL-Serine),0.1 M Buffer System 1 (Imidazole; MES monohydrate (acid) pH 6.5), 30.0% Precipitant Mix 1 (40% v/v PEG 500* MME; 20 % w/v PEG 20000)",293.15,2022-05-06,2022-12-28,7UYJ,3072,4,402,26,1,45.76,2,2.32,experimental,68.08,0.2736,0.2176,"Structure of RNF31 in complex with FP06652, a Helicon Polypeptide"
4UZ9,X-RAY DIFFRACTION,2.7,55,,6.5,200 MM AMMONIUM SULFATE 100 MM MES 6.5 35 % W/V PEP 629 20MM SOS,,2014-09-04,2015-02-25,4UZ9,3060,1,383,115,7,44.81,1,2.2,experimental,39.04,0.23653,0.19007,STRUCTURE OF THE WNT DEACYLASE NOTUM - CRYSTAL FORM VII - SOS COMPLEX - 2.2A
6YF0,X-RAY DIFFRACTION,3.17,61.16,"VAPOR DIFFUSION, HANGING DROP",5.6,"2.2 M AmSO4, 0.2 M NaThiocyanate",298,2020-03-25,2021-03-10,6YF0,1083,1,109,171,,12.89,1,1.55,experimental,28.525,0.2571,0.2368,FKBP12 in complex with the BMP potentiator compound 9 at 1.55 A resolution
6YF1,X-RAY DIFFRACTION,2.16,43.06,"VAPOR DIFFUSION, HANGING DROP",,"2.2 M AmSO4, 0.2 M CdCl2",298,2020-03-25,2021-03-10,6YF1,1103,1,109,170,,12.8,1,1.12,experimental,15.209,0.1634,0.1555,FKBP12 in complex with the BMP potentiator compound 8 at 1.12A resolution
5SSZ,X-RAY DIFFRACTION,2.05,40.14,"VAPOR DIFFUSION, SITTING DROP",8.5,"9.6 mg/mL protein in 20mM Tris/HCl pH8.0 mixed 1:1 with reservoir 0.1M Tris/HCl pH 8.5, 20-25% PEG4000, 0.2-0.3M CaCl2",293,2022-08-12,2023-08-23,5SSZ,2760,1,323,430,2,36.49,1,1.02,experimental,12.4298,0.1417,0.1307,Crystal Structure of wild-type human formylglycine generating enzyme bound to Cu(I)
5R5O,X-RAY DIFFRACTION,2.03,39.47,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.3M sodium/potassium phosphate, 15% PEG Smear High, 20% ethylene glycol",277,2020-02-28,2020-07-01,5R5O,2447,1,304,161,,33.27,1,1.79,experimental,27.871,0.238,0.1877,PanDDA analysis group deposition -- Crystal Structure of human NUDT22 in complex with N14027a
4YLR,X-RAY DIFFRACTION,2.71,54.63,"VAPOR DIFFUSION, SITTING DROP",,"PEG 8000, magnesium acetate",289,2015-03-05,2015-06-17,4YLR,2607,1,487,15,,57.69,1,2.55,experimental,66.7442,0.2685,0.2221,Tubulin Glutamylase
4YLS,X-RAY DIFFRACTION,2.73,55.02,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, magnesium acetate",279,2015-03-05,2015-06-17,4YLS,2628,1,487,20,,57.77,1,2.6,experimental,73.26,0.246,0.21,Tubulin Glutamylase
5FDX,X-RAY DIFFRACTION,2.33,47.24,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350
10% ethylene glycol
0.1M bis-tris-propane pH6.5
0.2M sodium acetate",293.15,2015-12-16,2016-10-26,5FDX,4569,2,674,141,1,78.24,1,2.65,experimental,58.82,0.2734,0.194,Structure of DDR1 receptor tyrosine kinase in complex with D2164 inhibitor at 2.65 Angstroms resolution.
8CHL,X-RAY DIFFRACTION,2.56,51.96,"VAPOR DIFFUSION, SITTING DROP",,"2.2 M ammonium sulfate, 0.2 M cadmium sulfate",293,2023-02-08,2023-09-06,8CHL,1961,2,214,200,,26.15,1,1.4,experimental,15.121,0.2128,0.1876,"Human FKBP12 in complex with (1S,5S,6R)-9-((3,5-dichlorophenyl)sulfonyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,9-diazabicyclo[4.2.1]nonan-2-one"
7Z42,X-RAY DIFFRACTION,3.1,60.38,"VAPOR DIFFUSION, HANGING DROP",7.5,"FluPolB PA mutant K135A at 9 mg per ml was mixed with 40 microM of nucleotides 1-13 vRNA 5prime end, 5-pAGUAGUAACAAGA-3, and 1.8 mM 28-mer CTD peptide, YSPTpSPS x 4 in a buffer containing 50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 2 mM TCEP. Hanging drops for crystallization were set up at 20 C.",293,2022-03-03,2022-05-18,7Z42,35949,12,4780,206,,547.04,4,2.418,experimental,54.204,0.2567,0.2233,Influenza B polymerase with Pol II pSer5 CTD peptide mimic bound in site 2B
4QJX,X-RAY DIFFRACTION,2.15,42.3,"VAPOR DIFFUSION, SITTING DROP",5,"0.1M sodium citrate (pH 5.5), 0.2M sodium acetate (pH 4.5), 28% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-06-05,2015-04-15,4QJX,2410,1,263,253,,30.27,1,1.95,experimental,20.57,0.237,0.19,Crystal structure of human carbonic anhydrase isozyme XIII with inhibitor
6GDC,X-RAY DIFFRACTION,2.06,40.27,VAPOR DIFFUSION,7.8,"Ammoniumsulfate 2.70 M, pH=7.8, saturated with para-Chloromercurybenzoic acid",291,2018-04-23,2019-05-01,6GDC,2545,1,265,249,,31.07,1,1.079,experimental,,0.1301,0.1149,Human Carbonic Anhydrase II in complex with Benzenesulfonamide
6GM9,X-RAY DIFFRACTION,2.06,40.44,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammoniumsulfate 2.70 M, pH = 7.8, saturated with p-Chloromercurybenzoic acid",291,2018-05-24,2019-06-19,6GM9,2604,1,265,293,,31.28,1,1.089,experimental,,0.1184,0.1032,Human Carbonic Anhydrase II in complex with 4-Methylbenzenesulfonamide
6I0W,X-RAY DIFFRACTION,2.06,40.34,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammoniumsulfate 2.70 M, pH = 7.8, saturated with para-Chloromercuribenzoic acid.",291,2018-10-26,2019-11-20,6I0W,2707,1,265,266,,31.51,1,1.04,experimental,,0.1322,0.1192,Human Carbonic Anhydrase II in complex with 4-Methoxybenzenesulfonamide
6I1U,X-RAY DIFFRACTION,2.06,40.22,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammoniumsulfate 2.70 M, pH = 7.8, saturated with para-Chloromercuribenzoic acid.",291,2018-10-30,2019-11-20,6I1U,2615,1,265,255,,31.16,1,1.08,experimental,,0.1328,0.1157,Human Carbonic Anhydrase II in complex with 4-Ethoxybenzenesulfonamide
5N85,X-RAY DIFFRACTION,1.81,31.96,"VAPOR DIFFUSION, SITTING DROP",4.5,0.2 M Ammonium acetate 0.1 M Sodium acetate 4.5 20 % w/v PEG 3350,293.15,2017-02-23,2017-06-07,5N85,1148,2,138,74,,15.19,2,2,experimental,26.2015,0.2275,0.187,Structure of RPA70N in complex with PrimPol (fragment 514-525)
6GLQ,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 0.27 M ammonium sulfate, 17% glycerol, 27% PEG4000, 20% DMSO, 10 mM compound",293,2018-05-23,2019-02-20,6GLQ,2964,2,364,360,2,43.23,1,1.601,experimental,,0.2101,0.1723,Crystal structure of hMTH1 N33G in complex with LW14 in the absence of acetate
6GLS,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 0.27 M ammonium sulfate, 17% glycerol, 27% PEG4000, 50 mM compound",293,2018-05-23,2019-02-20,6GLS,2822,2,364,269,2,43.38,1,1.501,experimental,,0.1987,0.1743,Crystal structure of hMTH1 N33G in complex with TH scaffold 1 in the absence of acetate
5N8A,X-RAY DIFFRACTION,1.88,34.66,"VAPOR DIFFUSION, SITTING DROP",6,"0.2M imidazole malate, 30% w/v PEG 4000",293.15,2017-02-23,2017-06-07,5N8A,1200,2,223,140,,24.52,2,1.28,experimental,21.1988,0.1785,0.1537,Structure of RPA70N in complex with PrimPol (fragment 480-560)
5H5Q,X-RAY DIFFRACTION,2.1,41.48,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH 8.5, 0.1M potassium formate, 25% PEG 4000",293,2016-11-09,2016-12-07,5H5Q,1638,2,184,140,1,21.34,2,1.1,experimental,13.236,0.18368,0.16341,Crystal structure of human GPX4 in complex with GXpep-1
5H5R,X-RAY DIFFRACTION,2.16,42.99,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH 8.5, 0.2M sodium acetate, 25% PEG6000",293,2016-11-09,2016-12-07,5H5R,1729,2,184,178,1,21.24,2,1.2,experimental,10.569,0.16249,0.15026,Crystal structure of human GPX4 in complex with GXpep-2
5H5S,X-RAY DIFFRACTION,1.92,35.94,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M MES pH 5.5, 25% PEG 4000",293,2016-11-09,2016-12-07,5H5S,1577,2,183,126,1,21.06,2,1.85,experimental,16.791,0.20383,0.1663,Crystal structure of human GPX4 in complex with GXpep-3
6P1R,X-RAY DIFFRACTION,2.857,57,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES pH 7.5, 100mM NaCl, 10% w/v PEG4000",277,2019-05-20,2019-09-04,6P1R,3414,4,371,328,,45.92,1,1.701,experimental,,0.1944,0.1743,Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound incoming AMPNPP
7X3O,X-RAY DIFFRACTION,2.43,49.3,"VAPOR DIFFUSION, SITTING DROP",,"MES pH 6.0, Ammonium chloride, PEG 6000",291,2022-03-01,2023-03-08,7X3O,5285,2,658,295,,77.48,1,2.001,experimental,23.2394,0.2379,0.1981,Crystal structure of Aldo-keto reductase 1C3 complexed with compound S07054
8DI4,X-RAY DIFFRACTION,2.01,38.94,VAPOR DIFFUSION,,"18% PEG3350, 0.2M MgCl2, 10mM 2-Mercaptoethanol, 0.1M HEPES, pH7.0",293,2022-06-28,2023-02-08,8DI4,5314,2,690,105,1,80.16,1,2.016,experimental,48.45,0.2946,0.2499,"Discovery of MK-8189, a highly potent and selective PDE10A inhibitor for the treatment of schizophrenia"
7X3L,X-RAY DIFFRACTION,2.23,44.79,"VAPOR DIFFUSION, SITTING DROP",6,"MES pH 6.0, Ammonium chloride, PEG 6000",291,2022-03-01,2023-03-08,7X3L,5845,2,658,635,,77.64,1,1.86,experimental,25.7294,0.2114,0.169,Crystal structure of Aldo-keto reductase 1C3 complexed with compound S07044
7X3M,X-RAY DIFFRACTION,2.52,51.25,"VAPOR DIFFUSION, SITTING DROP",6,"MES pH 6.0, Ammonium chloride, PEG 6000",291,2022-03-01,2023-03-08,7X3M,5259,2,658,141,,77.71,1,2.694,experimental,31.9353,0.2297,0.1897,Crystal structure of Aldo-keto reductase 1C3 complexed with compound S07045
8I0C,X-RAY DIFFRACTION,2.28,46.05,"VAPOR DIFFUSION, SITTING DROP",,"MES pH 6.0, Ammonium chloride, PEG 6000",291,2023-01-10,2023-09-20,8I0C,5391,2,658,183,,77.61,1,2.33,experimental,,0.2619,0.1817,Crystal structure of Aldo-keto reductase 1C3 complexed with compound S0703
9FFD,X-RAY DIFFRACTION,2.3,46.42,"VAPOR DIFFUSION, HANGING DROP",6,"0.1 M MES, 24% PEG3350, PH 6.0",279,2024-05-23,2024-08-21,9FFD,5641,2,646,350,,76.8,1,1.75,experimental,,0.1965,0.1608,STRUCTURE OF ALDO-KETO REDUCTASE 1C3 (AKR1C3) IN COMPLEX WITH AN INHIBITOR MEDS765
5TD5,X-RAY DIFFRACTION,2.33,47.13,"VAPOR DIFFUSION, SITTING DROP",,"NaI, PEG3350",298,2016-09-16,2016-12-28,5TD5,1708,2,197,98,,26.12,1,1.718,experimental,,0.2089,0.1801,Crystal Structure of Human APOBEC3B variant complexed with ssDNA
6Q3W,X-RAY DIFFRACTION,2.97,58.57,VAPOR DIFFUSION,,"0.1 M MOPS/sodium HEPES pH 7.0-7.5, 40-50 % Morpheus Precipitant Mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1 M Morpheus Carboxylic acids mix (0.02M each of:sodium formate, ammonium acetate, sodium citrate tribasic dehydrate, sodium potassium tartrate tetrahydrate and sodium oxamate).",293,2018-12-04,2019-01-23,6Q3W,11460,4,1564,641,2,170.11,1,1.962,experimental,51.2843,0.2547,0.2316,Structure of human galactokinase 1 bound with Ethyl 1-(2-pyrazinyl)-4-piperidinecarboxylate
6ZGV,X-RAY DIFFRACTION,2.97,58.54,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MOPS/sodium HEPES pH 7.0-7.5, 40-50 % Morpheus Precipitant Mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1 M Morpheus Carboxylic acids mix (0.02M each of:sodium formate, ammonium acetate, sodium citrate tribasic dehydrate, sodium potassium tartrate tetrahydrate and sodium oxamate).",293,2020-06-20,2020-07-29,6ZGV,11450,4,1596,437,2,174.25,1,2.3,experimental,45.848,0.2458,0.2069,Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
6ZGW,X-RAY DIFFRACTION,2.91,57.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MOPS/sodium HEPES pH 7.0-7.5, 40-50 % Morpheus Precipitant Mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1 M Morpheus Carboxylic acids mix (0.02M each of:sodium formate, ammonium acetate, sodium citrate tribasic dehydrate, sodium potassium tartrate tetrahydrate and sodium oxamate).",293,2020-06-20,2020-07-29,6ZGW,11522,4,1596,480,2,174.25,1,2.3,experimental,47.704,0.2547,0.209,Structure of human galactokinase 1 bound with (4-chlorophenyl)methyl pyridine-3-carboxylate
6ZGX,X-RAY DIFFRACTION,2.97,58.62,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MOPS/sodium HEPES pH 7.0-7.5, 40-50 % Morpheus Precipitant Mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1 M Morpheus Carboxylic acids mix (0.02M each of - sodium formate, ammonium acetate, sodium citrate tribasic dehydrate, sodium potassium tartrate tetrahydrate and sodium oxamate)",293,2020-06-20,2020-07-29,6ZGX,11542,4,1596,456,2,174.25,1,1.86,experimental,38.869,0.2742,0.2491,Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
6ZGY,X-RAY DIFFRACTION,2.89,57.5,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MOPS/sodium HEPES pH 7.0-7.5, 40-50 % Morpheus Precipitant Mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1 M Morpheus Carboxylic acids mix (0.02M each of-sodium formate, ammonium acetate, sodium citrate tribasic dehydrate, sodium potassium tartrate tetrahydrate and sodium oxamate).",293,2020-06-20,2020-07-29,6ZGY,11641,4,1596,446,2,174.46,1,2.3,experimental,49.213,0.2537,0.2059,Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
6ZGZ,X-RAY DIFFRACTION,2.88,57.32,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MOPS/sodium HEPES pH 7.0-7.5, 40-50 % Morpheus Precipitant Mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1 M Morpheus Carboxylic acids mix (0.02M each of - sodium formate, ammonium acetate, sodium citrate tribasic dehydrate, sodium potassium tartrate tetrahydrate and sodium oxamate).",293,2020-06-20,2020-07-29,6ZGZ,11599,4,1596,576,2,174.23,1,2.3,experimental,43.168,0.2563,0.2142,Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
8EYA,X-RAY DIFFRACTION,3.14,60.83,"VAPOR DIFFUSION, SITTING DROP",,"25% w/v PEG 3350, 0.2 M NaCl, 0.1 M Tris Cl (pH 8.5)",281.15,2022-10-26,2023-07-05,8EYA,5083,4,636,175,,74.62,2,2.099,experimental,50.3722,0.2604,0.2206,Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with a JAK2 activation loop phosphopeptide
8EYB,X-RAY DIFFRACTION,3.13,60.75,"VAPOR DIFFUSION, SITTING DROP",,"25% w/v PEG 3350, 0.2 M NaCl, 0.1 M Tris Cl (pH 8.5)",281,2022-10-26,2023-07-05,8EYB,4776,4,624,118,,72.88,2,2.349,experimental,59.3185,0.2431,0.2073,Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with JAK2 activation loop phosphopeptide
6Y3J,X-RAY DIFFRACTION,2.32,73.11,"VAPOR DIFFUSION, SITTING DROP",7.6,Morpheus condition 39 (Molecular Dimensions),292,2020-02-18,2020-09-02,6Y3J,1790,1,235,15,,26.62,1,2.6,experimental,58.0141,0.2822,0.2376,"RING-DTC domains of Deltex 2, bound to ADP-ribose"
5AA9,X-RAY DIFFRACTION,2.1,41,"VAPOR DIFFUSION, HANGING DROP",8,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286,2015-07-23,2016-06-08,5AA9,2564,1,327,181,,37.35,1,1.93,experimental,37,0.237,0.2,"Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile)."
5AAA,X-RAY DIFFRACTION,2.1,0.41,"VAPOR DIFFUSION, HANGING DROP",8,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286,2015-07-23,2016-06-08,5AAA,2607,1,327,227,,37.39,1,1.73,experimental,30.6,0.206,0.2,Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib
5AAB,X-RAY DIFFRACTION,2.1,41,"VAPOR DIFFUSION, HANGING DROP",8,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286,2015-07-23,2016-06-08,5AAB,2559,1,327,192,,37.45,1,2.2,experimental,38.5,0.246,0.21,"Structure of C1156Y,L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib"
8CQZ,X-RAY DIFFRACTION,2.7,54.43,"VAPOR DIFFUSION, SITTING DROP",,"44 % (v/v) 1,2-propanediol, 0.05 M calcium acetate and 0.1 M sodium acetate (pH 5.0)",291,2023-03-07,2023-11-29,8CQZ,3169,2,428,,,48.37,2,2.8,experimental,,0.2832,0.2424,Homo sapiens Get3 in complex with the Get1 cytoplasmic domain
8Q77,X-RAY DIFFRACTION,2.66,53.84,"VAPOR DIFFUSION, SITTING DROP",,"THE CK2ALPHA' SOLUTION AFTER PROTEIN PURIFICATION (5 MG/ML CK2ALPHA' IN 500 MM NACL, 25 MM TRIS/HCl, PH 8.5) WAS MIXED IN 1:10 VOLUME RATIO WITH 10 MM SOLUTION OF THE INHIBITOR MB002 IN DMSO. THIS SOLUTION WAS MIXED IN 2:1 RATIO WITH RESERVOIR SOLUTION [900 MM LICL, 28 % (W/V) PEG 6000, 250 MM TRIS/HCL, PH 8.5] IN SITTING DROP PLATES (VAPOUR DIFFUSION). THE CRYSTAL GROWTH WAS INDUCED BY MICROSEEDING. THE CRYSTALS WERE OPTIMIZED BY MACROSEEDING AND PURGED TWICE WITH RESERVOIR SOLUTION. THEN, ARC-780 WAS ADDED TO AN INITIAL CONCENTRATION OF 1 MM BY ADDING 1 MIKROLITER OF A 10 MM ARC-780 SOLUTION IN DMSO IN A 1:10 RATIO TO THE DROPLET. AFTER EXTENSIVE INTIAL SOAKING, THE SALT CONCENTRATION WAS SUCCESSIVELY LOWERED OVER A PERIOD OF 8 MONTHS WHILE IN PARALLEL THE CONCENTRATIONS OF DMSO AND PEG 6000 WERE INCREASED. THIS WAS DONE BY GRADUALLY REPLACING THE RESERVOIR AND THE DROPLET SOLUTION UNTIL ANY NACL WAS REMOVED, THE LICL CONCENTRATION WAS REDUCED TO 50 MM, THE PEG 6000 CONCENTRATION WAS INCREASED TO SATURATION AND A DMSO CONTENT OF 30% WAS REACHED. MEANWHILE, THE ARC-780 LIGAND WAS INCLUDED IN ANY DESALTING STEP REACHING SATURATION AFTER THE FINAL DILUTION STEP. ALL STEPS WERE PERFORMED AT A TEMPERATURE OF 293 K.",293,2023-08-15,2023-12-06,8Q77,3260,1,364,314,,45.13,1,1.255,experimental,16.47,0.157,0.1197,STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE BISUBSTRATE INHIBITOR ARC-780
4XZ0,X-RAY DIFFRACTION,2.76,55.45,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 3350, ammonium sulfate, TCEP",293,2015-02-03,2015-06-17,4XZ0,2155,1,262,78,,30.1,1,2,experimental,,0.245,0.2124,ZAP-70-tSH2:compound-A complex
6QFU,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, SITTING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-H2SO4",293,2019-01-10,2019-04-17,6QFU,2248,1,260,157,,30.12,1,1.8,experimental,17.635,0.1864,0.1649,Human carbonic anhydrase II with bound IrCp* complex (cofactor 7) to generate an artificial transfer hydrogenase (ATHase)
6QFV,X-RAY DIFFRACTION,2.16,43.06,"VAPOR DIFFUSION, SITTING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-H2SO4",293,2019-01-10,2019-04-17,6QFV,2381,1,260,195,,30.2,1,1.45,experimental,17.442,0.1674,0.1563,Human carbonic anhydrase II with bound IrCp* complex (cofactor 8) to generate an artificial transfer hydrogenase (ATHase)
6QFW,X-RAY DIFFRACTION,2.13,42.26,"VAPOR DIFFUSION, SITTING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-H2SO4",293,2019-01-10,2019-04-17,6QFW,2440,1,260,268,,30.32,1,1.2,experimental,14.7,0.1784,0.1622,Human carbonic anhydrase II with bound IrCp* complex (cofactor 9) to generate an artificial transfer hydrogenase (ATHase)
6QFX,X-RAY DIFFRACTION,2.15,42.69,"VAPOR DIFFUSION, SITTING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-H2SO4",293,2019-01-10,2019-04-17,6QFX,2303,1,260,213,,30.24,1,1.32,experimental,22.3,0.1974,0.1722,Human carbonic anhydrase II with bound IrCp* complex (cofactor 10) to generate an artificial transfer hydrogenase (ATHase)
6WKA,X-RAY DIFFRACTION,2.09,41.06,"VAPOR DIFFUSION, SITTING DROP",,"7.5 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C",281,2020-04-15,2021-02-24,6WKA,2613,1,260,338,,29.83,1,1.34,experimental,11.385,0.1658,0.1267,human carbonic anhydrase II bound to an inhibitor modified with azidothymidine
7M23,X-RAY DIFFRACTION,2.07,40.65,"VAPOR DIFFUSION, SITTING DROP",8.3,"Protein concentration was 4 mg/mL; equal volumes (250 nL) of protein plus reservoir were added to the plate; the reservoir was 1.5 M tri-potassium citrate, 0.1 M tris buffer at pH 8.3.",293,2021-03-16,2022-02-02,7M23,2583,1,258,279,,29.58,1,1.3,experimental,14.036,0.151,0.1204,Human carbonic anhydrase II in complex with troglitazone
7ONM,X-RAY DIFFRACTION,2.04,39.61,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M Tris pH 8.0, 0.2 M lithium chloride, 20% w/v polyethylene glycol 6,000",293,2021-05-25,2021-12-01,7ONM,2320,1,260,216,,30.32,1,1.769,experimental,14.732,0.2233,0.1781,Carbonic anhydrase II mutant (N67G-E69R-I91C) dually binding an IrCp* complex to generate an artificial transfer hydrogenase (ATHase)
7ONQ,X-RAY DIFFRACTION,2.15,42.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium pH 7.5, 1.4 M Sodium citrate tribasic dihydrate",293,2021-05-25,2021-12-01,7ONQ,2441,1,260,179,,31.14,1,1.65,experimental,15.096,0.1699,0.1342,Carbonic anhydrase II mutant (E69C) dually binding an IrCp* complex to generate an artificial transfer hydrogenase (ATHase)
7ONV,X-RAY DIFFRACTION,1.94,36.68,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS 8.5 pH, 0.2 M MgCl2, 25% w/v PEG 3350",293,2021-05-26,2021-12-01,7ONV,2493,1,261,253,,30.73,1,1.04,experimental,13.586,0.2003,0.1831,Carbonic anhydrase II mutant (I91C) dually binding an IrCp* complex to generate an artificial transfer hydrogenase (ATHase)
5H73,X-RAY DIFFRACTION,3.45,64.34,"VAPOR DIFFUSION, HANGING DROP",4.8,"30% glycerol, 2.4M Ammonium sulfate, PH4.8, 0.1M Acetate, 40mM UDAO, 20.8mM DDAO",293,2016-11-16,2017-07-26,5H73,3006,1,390,145,,43.97,1,1.58,experimental,28.425,0.18583,0.1695,Crystal structure of human DHODH with 18F
5HIN,X-RAY DIFFRACTION,3.42,64.01,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM C11DAO, 20.8mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8 M ammonium sulfate",293,2016-01-12,2016-07-20,5HIN,3100,1,390,186,,44.3,1,1.6,experimental,22.369,0.18217,0.16337,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with 18L compound
5HQE,X-RAY DIFFRACTION,3.42,64.04,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM C11DAO, 20.8mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8 M ammonium sulfate",293,2016-01-21,2016-07-27,5HQE,3043,1,390,162,,44.04,1,1.62,experimental,21.41,0.18175,0.16022,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with compound 18T
8CVQ,X-RAY DIFFRACTION,2.42,49.15,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide and 0.03 M sodium iodide",291,2022-05-18,2023-04-12,8CVQ,8189,2,922,793,,106,1,1.65,experimental,23.7898,0.194,0.1666,Crystal structure of TDP1 complexed with compound XZ761
5LVK,X-RAY DIFFRACTION,2.55,51.71,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium sulfate, 0.1 M sodium acetate, 21% PEG4000",298,2016-09-14,2016-09-28,5LVK,2354,2,260,252,8,30.24,1,2.491,experimental,12.2768,0.2811,0.1772,Human Lysozyme co-crystallized with [H2Ind][trans-RuCl4(DMSO)(HInd)]
5F66,X-RAY DIFFRACTION,2.81,56.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,2015-12-05,2015-12-30,5F66,1446,1,165,174,,18.04,1,1.15,experimental,21.3652,0.195,0.1788,High-resolution isotropic multiconformer synchrotron model of CypA at 273 K
5BRU,X-RAY DIFFRACTION,2.11,41.73,"VAPOR DIFFUSION, HANGING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-HCl",298,2015-06-01,2015-06-24,5BRU,2290,1,260,173,,30.34,1,1.6,experimental,18.147,0.19358,0.13717,Catalytic Improvement of an Artificial Metalloenzyme by Computational Design
5BRW,X-RAY DIFFRACTION,2.06,40.42,"VAPOR DIFFUSION, HANGING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-HCl",298,2015-06-01,2015-06-17,5BRW,2419,1,260,308,,29.67,1,1.4,experimental,21.966,0.1936,0.1388,Catalytic Improvement of an Artificial Metalloenzyme by Computational Design
5JQT,X-RAY DIFFRACTION,2.07,40.47,"VAPOR DIFFUSION, HANGING DROP",7.4,2.4 M SODIUM MALONATE,298,2016-05-05,2016-10-19,5JQT,2430,1,262,235,,30.9,1,1.36,experimental,14.163,0.1647,0.121,Crystal structure of human carbonic anhydrase II in complex with Benzoxaborole at pH 7.4
5NY6,X-RAY DIFFRACTION,2.08,40.73,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,2017-05-11,2018-01-17,5NY6,2795,1,258,314,,29.85,1,1.1,experimental,13.955,0.1544,0.1392,Carbonic Anhydrase II Inhibitor RA12
5NYA,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,2017-05-11,2018-01-17,5NYA,2567,1,257,337,,29.29,1,1.2,experimental,14.578,0.1377,0.117,Carbonic Anhydrase II Inhibitor RA13
5VGY,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, SITTING DROP",8.3,concentrated CA II at 10 mg/mL was set up with microseeding over 2.9 M ammonium sulfate with 0.1 M Tris buffer at pH 8.3 at 8 C in 250 nL plus 225 nL plus 25 nL (seeds) ratio.,281,2017-04-11,2017-08-30,5VGY,2487,1,260,288,,29.68,1,1.39,experimental,15.279,0.15646,0.1129,Identification of a New Zinc Binding Chemotype by Fragment Screening
6Q9T,X-RAY DIFFRACTION,2.52,51,"VAPOR DIFFUSION, HANGING DROP",5.7,"Ammonium sulfate 0.2 M, Sodium acetate 0.1 M pH 5.7, PEG 4000 14%, Sodium azide 3 mM",293,2018-12-18,2019-09-18,6Q9T,2009,2,275,6,,32.27,2,2.68,experimental,69.834,0.26025,0.2148,Protein-aromatic foldamer complex crystal structure
6S03,X-RAY DIFFRACTION,2.1,41.35,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-H2SO4",291,2019-06-13,2020-06-03,6S03,2386,1,260,217,,29.73,1,1.38,experimental,16.613,0.1958,0.1705,Carbonic Anhydrase CAIX mimic in complex with inhibitor I39LT379
8PAS,X-RAY DIFFRACTION,2.82,56.34,VAPOR DIFFUSION,,NOT DISCLOSED,293,2023-06-08,2024-06-26,8PAS,4364,2,578,,,65.87,1,2.7,experimental,81.876,0.2997,0.22808,Crystal structure of MAP4K1 with a SMOL inhibitor
8PAU,X-RAY DIFFRACTION,2.82,56.36,VAPOR DIFFUSION,,NOT DISCLOSED,293,2023-06-08,2024-06-26,8PAU,4447,2,576,17,,65.53,1,2.8,experimental,77.824,0.2723,0.21667,Crystal structure of MAP4K1 with a SMOL inhibitor
7KR3,X-RAY DIFFRACTION,2.6,52.69,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, 150 mM lithium acetate, 10% (w/v) polyethylene glycol 3350",293,2020-11-18,2021-02-03,7KR3,5729,4,684,17,,83.6,1,2.778,experimental,87.7862,0.2394,0.1932,Human DNA Ligase 1(E346A/E592A) Bound to a bulged DNA substrate
7KR4,X-RAY DIFFRACTION,2.42,49.24,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, 100 mM lithium acetate, 12% (w/v) polyethylene glycol 3350",293,2020-11-18,2021-02-03,7KR4,6038,4,683,315,,83.49,1,2.2,experimental,42.1382,0.2153,0.1624,Human DNA Ligase 1(E346A/E592A) Bound to a nicked DNA substrate control duplex
7QHG,X-RAY DIFFRACTION,2.48,50.38,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M bis-tris-propane pH 7.5, 
0.2 M Na2SO4, 
10% ethylene glycol, 
17% PEG3.35K",277,2021-12-12,2021-12-22,7QHG,4919,2,610,379,,71.12,1,1.45,experimental,20.83,0.177,0.1652,LIM domain kinase 2 (LIMK2) in complex with TH-470
7RK3,X-RAY DIFFRACTION,2.09,41.24,"VAPOR DIFFUSION, HANGING DROP",,"20% (w/v) PEG 3350, 200mM ammonium formate",295,2021-07-21,2022-07-27,7RK3,3513,2,399,442,,47.13,2,2.05,experimental,34.6862,0.2197,0.1585,Crystal structure of human N-myristoyltransferase 1 fragment (residues 109-496) bound to diacylated human Arf6 octapeptide and Coenzyme A
5FGC,X-RAY DIFFRACTION,1.97,37.7,"VAPOR DIFFUSION, HANGING DROP",8.5,"32% PEG 4000
100 mM Tris-HCl pH 8.5
800 mM lithium chloride 

Crystals obtained using heterologous microseeding.",293,2015-12-20,2016-01-20,5FGC,3530,3,506,116,5,54.44,3,1.9,experimental,61.65,0.2363,0.194,Three dimensional structure of broadly neutralizing human anti - Hepatitis C virus (HCV) glycoprotein E2 Fab fragment HC33.8
5FOT,X-RAY DIFFRACTION,2.11,41.4,,6.2,"8% PEG-1000, 100 MM NAK PHOSPHATE, PH 6.2",,2015-11-26,2016-03-30,5FOT,2328,2,237,351,,26.11,2,1.189,experimental,14.6,0.1567,0.1324,HUMANISED MONOMERIC RADA IN COMPLEX WITH FHTU TETRAPEPTIDE
5FOU,X-RAY DIFFRACTION,2.11,41.8,,6.2,"8% PEG-1000, 100 MM NAK PHOSPHATE, PH 6.2",,2015-11-26,2016-03-30,5FOU,2293,2,237,410,,26.19,2,1.5,experimental,15.7,0.1924,0.1642,HUMANISED MONOMERIC RADA IN COMPLEX WITH FHPA TETRAPEPTIDE
7ZL5,X-RAY DIFFRACTION,2.37,48.18,"VAPOR DIFFUSION, HANGING DROP",9,"28-31% PEG4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5-9.0",293,2022-04-14,2023-04-26,7ZL5,4460,2,522,373,,58.76,1,1.479,experimental,25.308,0.2139,0.1843,Azosemide in complex with Carbonic Anhydrase I
5EMN,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, HANGING DROP",6.5,"100mM MES,pH6.5,50mM CaAc2,0.1M NaCl, 14% PEG4K",292,2015-11-06,2016-08-17,5EMN,10080,2,1236,232,,144.28,1,2.2,experimental,51.5,0.277,0.222,Crystal Structure of Human NADPH-Cytochrome P450 Reductase(A287P mutant)
6R8J,X-RAY DIFFRACTION,2.45,49.8,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 3350, 200mM MgCl2, 100mM BisTris (pH 6.5)",293,2019-04-02,2020-05-13,6R8J,2910,1,337,157,,39.9,1,1.75,experimental,41.867,0.26331,0.21575,Crystal structure of di-phosphorylated human CLK1 in complex with 4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine
8EZG,X-RAY DIFFRACTION,3.96,68.94,"VAPOR DIFFUSION, SITTING DROP",7,2.8 M sodium acetate trihydrate,291,2022-10-31,2023-07-19,8EZG,2194,2,259,130,,29.38,2,2.52,experimental,,0.2131,0.171,Monobody 12D1 bound to KRAS(G12D)
6Z3I,X-RAY DIFFRACTION,2.43,49.45,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Na2SO4, 0.25 M HEPES pH 7, PEG3350 14%, 1:1000 seed",291,2020-05-20,2021-06-30,6Z3I,4505,1,497,340,2,58.61,1,1.8,experimental,25.448,0.1894,0.1782,Structure of recombinant beta-glucocerebrosidase in complex with bifunctional cyclophellitol aziridine activity based probe
7ZEH,X-RAY DIFFRACTION,2.6,52.71,VAPOR DIFFUSION,5.6,"5 % PEG 400, 1.73 M ammonium sulfate, 0.1 M MES pH 5.6",292.15,2022-03-31,2022-05-25,7ZEH,10071,4,1208,1054,,143.08,1,1.5,experimental,28.74,0.2199,0.1877,"Human cytosolic 5' nucleotidase IIIB in complex with 3,4-diF-Bn7Guanine"
6MYZ,X-RAY DIFFRACTION,2.47,50.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",291,2018-11-02,2019-11-06,6MYZ,7918,2,922,627,,104.83,1,1.661,experimental,,0.2272,0.1919,Crystal structure of Tdp1 catalytic domain in complex with compound XZ520
6MZ0,X-RAY DIFFRACTION,2.43,49.46,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",291,2018-11-02,2019-11-06,6MZ0,7896,2,922,649,,104.75,1,1.969,experimental,,0.2259,0.1775,Crystal structure of Tdp1 catalytic domain in complex with compound XZ530
6N0D,X-RAY DIFFRACTION,2.45,49.88,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",291,2018-11-07,2019-11-13,6N0D,8058,2,922,796,,104.75,1,1.453,experimental,,0.1933,0.1669,Crystal structure of Tdp1 catalytic domain in complex with compound XZ575
6N0O,X-RAY DIFFRACTION,2.44,49.53,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",291,2018-11-07,2019-11-13,6N0O,7894,2,922,673,,104.92,1,1.943,experimental,,0.2227,0.1794,Crystal structure of Tdp1 catalytic domain in complex with compound XZ523
6W4R,X-RAY DIFFRACTION,2.44,49.68,"VAPOR DIFFUSION, HANGING DROP",7.5,0.1 M MOPS/HEPES-Na pH 7.5 10% W/V PEG  8000 20% V/V ETHYLENE GLYCOL 0.03M SODIUM FLUORIDE 0.03M SODIUM BROMIDE 0.03M SODIUM IODIDE,292,2020-03-11,2021-03-17,6W4R,8007,2,922,698,,105.55,1,1.819,experimental,24.1507,0.2153,0.182,Structure of Tdp1 catalytic domain in complex with inhibitor XZ633p
6W7J,X-RAY DIFFRACTION,2.45,49.75,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",292,2020-03-19,2021-03-24,6W7J,8059,2,922,764,,105.28,1,1.489,experimental,26.6565,0.1807,0.1506,Structure of Tdp1 catalytic domain in complex with inhibitor XZ635p
4QIB,X-RAY DIFFRACTION,2.95,58.3,"VAPOR DIFFUSION, HANGING DROP",7.4,"20 mg/mL protein, 2.0 to 2.4 M ammonium sulfate, 1% poly(ethylene glycol) 400, 100 mM Hepes, 10 mM H2O2, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277,2014-05-30,2015-02-04,4QIB,1404,1,159,202,,18.38,1,1.865,experimental,,0.1851,0.1528,Oxidation-Mediated Inhibition of the Peptidyl-Prolyl Isomerase Pin1
6N0N,X-RAY DIFFRACTION,2.55,51.83,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",291,2018-11-07,2019-11-13,6N0N,8189,2,922,869,,105.08,1,1.477,experimental,,0.175,0.1634,Crystal structure of Tdp1 catalytic domain in complex with compound XZ574
6N0R,X-RAY DIFFRACTION,2.45,49.77,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",291,2018-11-07,2019-11-13,6N0R,8020,2,922,730,,104.97,1,1.544,experimental,,0.195,0.17,Crystal structure of Tdp1 catalytic domain in complex with compound XZ572
8SWC,X-RAY DIFFRACTION,2.6,52.61,"VAPOR DIFFUSION, HANGING DROP",,"2:1 complex : precipitant (0.1 M sodium acetate, pH 4.6, 8% w/v PEG4000), cryoprotection: mother liquor + 25% v/v glycerol, 1 minute",277,2023-05-18,2024-06-19,8SWC,2052,3,334,5,,46.62,1,2.68,experimental,83.64,0.22,0.1915,RNase H complex with ASO (OOO) and RNA
5MS3,X-RAY DIFFRACTION,2.01,38.92,"VAPOR DIFFUSION, HANGING DROP",5.6,"35% (v/v) tert-Butanol, 0.1 M tri-Na citrate/citric acid",291,2016-12-30,2018-01-17,5MS3,1796,1,228,84,6,24.52,1,2.3,experimental,29.3418,0.2656,0.2213,Kallikrein-related peptidase 8 calcium complex
6GLH,X-RAY DIFFRACTION,1.72,28.54,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 0.27 M ammonium sulfate, 17% glycerol, 27% PEG4000, 20% DMSO, 10 mM compound",293,2018-05-23,2019-02-20,6GLH,1517,1,182,212,,21.36,1,1.201,experimental,,0.2014,0.1935,Crystal structure of hMTH1 F27A in complex with LW14 in the absence of acetate
6GLJ,X-RAY DIFFRACTION,1.71,28.11,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 0.27 M ammonium sulfate, 17% glycerol, 27% PEG4000, 50 mM compound",293,2018-05-23,2019-02-20,6GLJ,1499,1,182,206,,21.58,1,1.301,experimental,,0.1983,0.1774,Crystal structure of hMTH1 F27A in complex with TH scaffold 1 in the absence of acetate
6GLM,X-RAY DIFFRACTION,1.71,28.19,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 0.27 M ammonium sulfate, 17% glycerol, 27% PEG4000, 20% DMSO, 10 mM compound",293,2018-05-23,2019-02-20,6GLM,1469,1,182,196,,21.39,1,1.6,experimental,,0.2205,0.1746,Crystal structure of hMTH1 N33A in complex with LW14 in the absence of acetate
6GLN,X-RAY DIFFRACTION,1.71,28.01,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 0.27 M ammonium sulfate, 17% glycerol, 27% PEG4000, 50 mM compound",293,2018-05-23,2019-02-20,6GLN,1480,1,182,174,,21.62,1,1.401,experimental,,0.2158,0.1833,Crystal structure of hMTH1 N33A in complex with TH scaffold 1 in the absence of acetate
6GLV,X-RAY DIFFRACTION,,27.32,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 0.27 M ammonium sulfate, 17% glycerol, 27% PEG4000, 50 mM compound",293,2018-05-23,2019-02-20,6GLV,1394,1,182,133,,21.66,1,1.601,experimental,,0.2163,0.1771,Crystal structure of hMTH1 D120N in complex with TH scaffold 1 in the absence of acetate
4U84,X-RAY DIFFRACTION,2.7,54.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH7.5
1 % PEG400
1.2-1.5M Ammonium sulfate",277,2014-08-01,2015-04-08,4U84,1296,1,181,101,,21.76,1,1.78,experimental,27.09,0.22432,0.1951,Human Pin1 with S-hydroxyl-cysteine 113
4U85,X-RAY DIFFRACTION,2.68,54.18,"VAPOR DIFFUSION, HANGING DROP",7.5,"50mM HEPES pH 7.5
1% PEG400
1.2-1.5M Ammonium sulfate",277,2014-08-01,2015-04-08,4U85,1291,1,181,102,,21.77,1,1.7,experimental,24.552,0.24479,0.20279,Human Pin1 with cysteine sulfinic acid 113
4U86,X-RAY DIFFRACTION,2.71,54.62,"VAPOR DIFFUSION, HANGING DROP",7.5,"50mM HEPES7.5
1% PEG400
1.2-1.5M Ammonium Sulfate",277,2014-08-01,2015-04-08,4U86,1282,1,181,98,,20.51,1,1.6,experimental,26.896,0.23073,0.19627,Human Pin1 with cysteine sulfonic acid 113
5UAP,X-RAY DIFFRACTION,3.2,61.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Bis-Tris pH 6.5
16% w/v PEG10000",291,2016-12-19,2017-04-12,5UAP,8338,2,952,637,,113.93,1,2.03,experimental,28.08,0.206,0.163,Crystal Structure of CYP2B6 (Y226H/K262R) in complex with Bornyl Bromide
5UDA,X-RAY DIFFRACTION,3.24,62.02,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.2 M Sodium Chloride
0.1 M HEPES
25% w/v Polyethylene glycol 3350",291,2016-12-24,2017-04-12,5UDA,8139,2,952,481,,113.77,1,1.93,experimental,26.458,0.20993,0.17337,Crystal structure of CYP2B6 (Y226H/K262R) in complex with a monoterpene bornane
5Q0D,X-RAY DIFFRACTION,3.44,64.23,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277,2017-05-01,2017-07-12,5Q0D,2188,1,244,208,4,29.18,1,2.12,experimental,26.42,0.192,0.1718,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-oxo-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecin-14-yl]carbamate"
5Q0G,X-RAY DIFFRACTION,3.45,64.32,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277,2017-05-01,2017-07-12,5Q0G,2046,1,244,125,4,28.61,1,2.6,experimental,20.7,0.2293,0.1837,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-3-ethyl-2-oxo-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecin-14-yl]carbamate"
5QCK,X-RAY DIFFRACTION,3.52,65.08,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277,2017-08-10,2017-11-08,5QCK,1946,1,244,39,4,28.43,1,2.64,experimental,57.64,0.209,0.187,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid"
6VNS,X-RAY DIFFRACTION,1.87,34.26,EVAPORATION,8,"0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, 27-33% PEG-3350",298,2020-01-29,2020-04-08,6VNS,2541,1,318,157,,36.96,1,2.09,experimental,38.88,0.2313,0.1853,Crystal structure of TYK2 kinase with compound 13
6VNV,X-RAY DIFFRACTION,1.76,29.98,EVAPORATION,8,"0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, 27-33% PEG-3350",298,2020-01-29,2020-04-08,6VNV,2414,1,318,139,,36.96,1,2.15,experimental,39.2,0.2379,0.1858,Crystal structure of TYK2 kinase with compound 14
6VNX,X-RAY DIFFRACTION,1.9,35.32,EVAPORATION,8,"0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, 27-33% PEG-3350",298,2020-01-29,2020-04-08,6VNX,2503,1,318,125,,36.96,1,2.18,experimental,39.11,0.2383,0.1941,Crystal structure of TYK2 kinase with compound 19
6VNY,X-RAY DIFFRACTION,1.85,33.64,EVAPORATION,8,"0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, 27-33% PEG-3350",298,2020-01-29,2020-04-08,6VNY,2470,1,318,131,,36.94,1,2.3,experimental,40.75,0.2292,0.1736,Crystal structure of TYK2 kinase with compound 10
6M7X,X-RAY DIFFRACTION,3.35,63.29,"VAPOR DIFFUSION, HANGING DROP",7,"0.1 M imidazole (pH 7.0), 12% PEG 20,000",293,2018-08-21,2018-11-21,6M7X,8044,2,968,428,,113.03,1,2.095,experimental,,0.2183,0.1886,Structure of human CYP11B1 in complex with fadrozole
6NLY,X-RAY DIFFRACTION,2.69,54.26,EVAPORATION,8.5,"0.1 M Tris-HCl, 40% PEG200",298,2019-01-09,2020-01-15,6NLY,5425,4,768,21,,83.27,1,2.307,experimental,77.1161,0.257,0.2094,Fragment of human mitochondrial Alanyl-tRNA Synthetase C-Ala domain
5TYF,X-RAY DIFFRACTION,2.68,54.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-19,2017-08-30,5TYF,3507,4,374,355,,46.15,1,1.971,experimental,30.9667,0.205,0.1737,"DNA Polymerase Mu Product Complex, 10 mM Mg2+ (270 min)"
5TYG,X-RAY DIFFRACTION,2.67,53.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-19,2017-08-30,5TYG,3568,4,374,393,,46.21,1,1.726,experimental,32.5416,0.1853,0.1547,"DNA Polymerase Mu Product Complex, 10 mM Mg2+ (960 min)"
7KTH,X-RAY DIFFRACTION,2.51,50.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KTH,3676,4,374,457,,46.38,1,1.476,experimental,23.5721,0.1901,0.1663,"DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 10 mM Mg2+ (2160min)"
5KK7,X-RAY DIFFRACTION,2.23,44.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"24% PEG 4000, 50mM ammonium sulfate, 0.1M MES, 10% 1,4-butanediol, pH 6.5, vapor diffusion, temperature 298K",298,2016-06-21,2017-05-10,5KK7,8916,2,910,1189,2,106.71,1,1.7324,experimental,,0.2088,0.1758,"Crystal structure of the class I human endoplasmic reticulum 1,2-alpha-mannosidase T688A mutant and Thio-disaccharide substrate analog complex"
6HYY,X-RAY DIFFRACTION,2.57,52.06,"VAPOR DIFFUSION, HANGING DROP",6.5,0.05 M CaCl2; sodium cacodylate 0.1 M pH 6.5; PEG 2000 20%,293,2018-10-22,2019-06-12,6HYY,3798,2,442,347,,49.53,1,1.566,experimental,35.0199,0.2256,0.1946,Human phosphoserine phosphatase with serine and phosphate
8OOG,X-RAY DIFFRACTION,2.13,42.2,VAPOR DIFFUSION,8,"8 % PEG8000, 12 % ethylene glycol, 0.1 M Hepes pH 8.0",293,2023-04-05,2023-07-12,8OOG,3164,1,397,176,,44.66,1,1.384,experimental,19.35,0.2001,0.19,Crystal structure of human MAT2a with S-Adenosylmethionine and a fragment bound in a novel pocket
5NOU,X-RAY DIFFRACTION,2.72,54.72,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOU,1480,1,165,182,,18.46,1,1.3,experimental,19.083,0.16324,0.13213,Structure of cyclophilin A in complex with hexahydropyrimidin-2-one
8PPE,X-RAY DIFFRACTION,2.68,54.18,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.81 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 17 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking overnight with 0.83 M sodium citrate, 0.1 M Tris pH 8.5, 0.1 M NaCl, 30 mM ligand, 3 mM ADP and 3 mM MnCl2.                                                     Cryoprotectant: Glycerol 30%.",291,2023-07-07,2024-02-28,8PPE,4872,2,558,388,,65.84,1,1.59,experimental,37.876,0.24002,0.19987,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with DL-6-deoxy-6-phosphoryloxymethyl-scyllo-inositol 1,2,4-trisphosphate/ADP/Mn"
8PC2,X-RAY DIFFRACTION,3.1,60.34,"VAPOR DIFFUSION, SITTING DROP",,"15% PEG3350, 0.2 M tri-sodium citrate, 0.1 M HEPES-NaOH pH 7.5 and 10% glycol",277,2023-06-09,2023-11-15,8PC2,7224,8,982,14,,113.55,4,2.8,experimental,74.69,0.2607,0.2104,SelDeg51 in complex with FKBP51FK1 domain and pVHL:EloB:EloC
5UEC,X-RAY DIFFRACTION,3.2,61.52,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M Magnesium acetate tetrahydrate
25%w/v PEG3350",291,2016-12-30,2017-04-12,5UEC,3964,1,476,125,,56.96,1,2.27,experimental,48.561,0.22893,0.17421,Crystal Structure of CYP2B6 (Y226H/K262R) in complex with myrtenyl bromide.
5UFG,X-RAY DIFFRACTION,3.18,61.29,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5
20%w/v Polyethylene glycol 10K",291,2017-01-04,2017-04-12,5UFG,4204,1,476,335,,56.95,1,1.76,experimental,25.792,0.20394,0.17508,Crystal Structure of CYP2B6 (Y226H/K262R/I114V) in complex with myrtenyl bromide
8CHI,X-RAY DIFFRACTION,3.3,62.72,"VAPOR DIFFUSION, HANGING DROP",,"1.4M Na/K tartrate, 0.2 M ammonium citrate, 0.1M MES pH 6.5",293,2023-02-08,2023-09-06,8CHI,1995,2,214,253,,24.73,1,1.7,experimental,21.329,0.2144,0.178,"Human FKBP12 in complex with (1S,5S,6R)-10-((S)-3,5-dichloro-N-methylphenylsulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one"
5TJK,X-RAY DIFFRACTION,2.25,45.23,"VAPOR DIFFUSION, HANGING DROP",,"Native crystals of GTA/GTB lacking any heavy metals were grown at 4 degrees Celsius from much higher concentrations of protein (30-40 mg/mL for GTB and 16-20 mg/mL for GTA) along with 1% PEG 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM ADA buffer pH 7.5, 30 mM sodium acetate buffer pH 4.6 and 5 mM MnCl2 for GTB crystallization and 5-8 mM CoCl2 for GTA crystallization.  10-15 microlitre drops were placed against a reservoir containing 3.7% PEG 4000, 7% MPD, 0.3 M ammonium sulfate, 0.25 M sodium chloride, 0.2 M ADA buffer and 0.1 M sodium acetate.  The crystals were usually grown for 5-10 days. Before making complexes, crystals of GTA/GTB were washed with modified mother liquor ML-2 consisting of 3.5% PEG 4000, 50 mM ammonium sulfate, 40 mM sodium chloride, 35 mM ADA buffer and 15% MPD or glycerol. Crystals of native GTA/GTB in complex with the respective A or B trisaccharide were obtained by soaking them in mother liquor ML-2 with 15% glycerol or MPD and 45-50 mM of each substrate for 2-5 days at 4 degrees Celsius.  Before freezing the crystals for data collection, the concentration of the cryoprotectant was made 30% glycerol or 20% MPD respectively",277,2016-10-04,2017-06-14,5TJK,2576,1,297,202,,35.3,1,1.45,experimental,21.194,0.1927,0.182,Crystal structure of GTA + A trisaccharide (native)
6X8Z,X-RAY DIFFRACTION,2.6,52.71,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG8000, 100 mM Tris-HCl, pH 8.5, 200 mM magnesium chloride",293,2020-06-02,2020-09-16,6X8Z,2566,2,384,14,,46.31,1,2.5,experimental,64.5675,0.2787,0.2493,Crystal structure of N-truncated human B12 chaperone CblD(C262S)-thiolato-cob(III)alamin complex (108-296)
4PGJ,X-RAY DIFFRACTION,2.61,52.84,"VAPOR DIFFUSION, SITTING DROP",5.4,"Protein at 4.4 mg/mL in 50 mM Tris (pH 7.5) amd 150 mM NaCl. Well solution contained 28% (w/v) PEG1500, 100 mM Na-citrate (pH 5.4). 400 nL of well solution and protein solution were combined.",293,2014-05-02,2015-03-11,4PGJ,3380,4,500,,10,55.01,2,2.6,experimental,15.675,0.2866,0.22482,Human heavy-chain domain antibody in complex with hen egg-white lysozyme
5E13,X-RAY DIFFRACTION,1.69,27.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Sodium Cacodylate, 1.5M Sodium acetate",289,2015-09-29,2015-11-18,5E13,1342,1,161,177,4,18.85,1,1.34,experimental,11.492,0.19833,0.16945,Crystal structure of Eosinophil-derived neurotoxin in complex with the triazole double-headed ribonucleoside 11c
5J6D,X-RAY DIFFRACTION,2.04,39.76,"VAPOR DIFFUSION, SITTING DROP",8.4,"20% PEG 3350, CBTP pH 8.4, 2.5 mM TCEP",293,2016-04-04,2016-05-25,5J6D,4335,2,614,140,,72.54,1,1.9,experimental,46.064,0.24812,0.20984,Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors
8SX2,X-RAY DIFFRACTION,2.42,49.09,"VAPOR DIFFUSION, SITTING DROP",,"23% PEG3350, 0.1 M Bis-Tris pH 6.5, 0.2 M MgCl2, and 600 uM EB47",293,2023-05-19,2023-11-08,8SX2,4976,2,666,37,,75.59,1,2.95,experimental,,0.2616,0.2153,PARP4 catalytic domain bound to EB47
8IPL,X-RAY DIFFRACTION,2.05,39.9,"VAPOR DIFFUSION, SITTING DROP",,"17% w/v PEG 4000, 0.05M Potassium chloride, 0.1M Lithium chloride, 0.012M Spermine tetrahydrochloride, 0.05M MES PH6.5",289,2023-03-14,2024-01-03,8IPL,2401,2,372,32,,41.98,2,2.2,experimental,,0.2346,0.1799,The structure of human mitochondrial methyltransferase METTL15 with RBFA and SAM
5TXX,X-RAY DIFFRACTION,2.64,53.37,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2016-11-17,2017-08-30,5TXX,3498,4,373,355,,46.19,1,1.948,experimental,23.5078,0.1951,0.1587,"DNA Polymerase Mu Pre-Catalytic Ground State Ternary Complex, Ca2+"
7KTJ,X-RAY DIFFRACTION,2.44,49.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KTJ,3539,4,373,397,,46.39,1,1.452,experimental,25.3165,0.1843,0.1607,"DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Pre-Catalytic Ground State Ternary Complex, 20 mM Ca2+ (120min)"
7KTK,X-RAY DIFFRACTION,2.43,49.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277,2020-11-24,2022-05-11,7KTK,3544,4,373,332,,46.66,1,1.419,experimental,24.598,0.1684,0.1428,"DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Ground State Ternary Complex, 50 mM Mg2+ (90min)"
5QIB,X-RAY DIFFRACTION,2.4,48.83,"VAPOR DIFFUSION, SITTING DROP",5.75,"0.1M MIB pH 5.75 - 7.0, 27.5-35% PEG1000",293,2018-05-22,2018-07-18,5QIB,4298,1,369,201,,41.49,1,1.48,experimental,19.462,0.2086,0.1874,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with FMOPL000388a
5QU9,X-RAY DIFFRACTION,2.45,49.84,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-12-13,2020-01-29,5QU9,3118,2,360,341,,41.13,2,2,experimental,30.5209,0.2313,0.1845,PanDDA analysis group deposition of ground-state model of Kalirin/Rac1 screened against a customized urea fragment library by X-ray Crystallography at the XChem facility of Diamond Light Source beamline I04-1
5ZC9,X-RAY DIFFRACTION,2.77,55.55,"VAPOR DIFFUSION, SITTING DROP",,"80mM HEPES (pH7.5), 1120mM tri-sodium citrate, 100mM ammonium sulfate, 20mM Bis-Tris (pH 6.0), 0.2% (w/v) polyethylene glycol 3350, 40mM lithium chloride",293,2018-02-16,2019-01-16,5ZC9,3558,2,404,246,,49.26,1,2,experimental,,0.2305,0.1929,Crystal structure of the human eIF4A1-ATP analog-RocA-polypurine RNA complex
7PPZ,X-RAY DIFFRACTION,2.26,45.48,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES, 50 mM magnesium chloride, 10 % (w/v) 2-propanol, 5 % (w/v) PEG 4000",290,2021-09-15,2022-04-13,7PPZ,4669,2,605,67,,68.49,2,2.52,experimental,27.593,0.2761,0.2016,Crystal structure of the Burkholderia Lethal Factor 1 (BLF1) C94S inactive mutant in complex with human eIF4A - Crystal form A
4WZX,X-RAY DIFFRACTION,2.19,43.83,"VAPOR DIFFUSION, SITTING DROP",6.5,"50mM MES pH 6.5, 5mM Cobalt chloride, 800mM ammonium sulfate",295,2014-11-20,2015-06-03,4WZX,896,2,118,69,,13.44,2,1.3859,experimental,,0.18,0.1513,ULK3 regulates cytokinetic abscission by phosphorylating ESCRT-III proteins
8QBU,X-RAY DIFFRACTION,2.6,52.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"THE CK2ALPHA' SOLUTION AFTER PROTEIN PURIFICATION (5 MG/ML CK2ALPHA' IN 500 MM NACL, 25 MM TRIS/HCl, PH 8.5) WAS MIXED IN 1:10 VOLUME RATIO WITH 10 MM SOLUTION OF THE INHIBITOR MB002 IN DMSO. THIS SOLUTION WAS MIXED IN 2:1 RATIO WITH RESERVOIR SOLUTION [900 MM LICL, 28 % (W/V) PEG 6000, 250 MM TRIS/HCL, PH 8.5] IN SITTING DROP PLATES (VAPOUR DIFFUSION). THE CRYSTAL GROWTH WAS INDUCED BY MICROSEEDING. THE CRYSTALS WERE OPTIMIZED BY MACROSEEDING. A CRYSTAL WAS PURGED TWICE WITH RESERVOIR SOLUTION BEFORE ADDING 1 MIKROLITER DPA (50 MM IN DMSO) AND 1 MIKROLITER CX-4945 (10 MM IN DMSO) TO THE CRYSTAL MOTHOR LIQUOR FOR EXTENSIVE SOAKING AND REPLACEMENT OF THE INITIAL INHIBITOR MB002. ALL STEPS WERE PERFORMED AT A TEMPERATURE OF 293 K.",293,2023-08-25,2023-12-06,8QBU,3275,1,364,293,,44.16,1,1.09,experimental,18.8,0.1793,0.1593,"STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE INHIBITOR CX-4945 AND THE ALPHA-D-POCKET LIGAND 3,4-DICHLORO PHENETHYLAMINE (DPA)"
7RJL,X-RAY DIFFRACTION,2.16,43.12,"VAPOR DIFFUSION, SITTING DROP",7,35% v/v Tacsimate,292,2021-07-21,2022-08-03,7RJL,2324,4,258,194,,31.28,2,1.5,experimental,26.065,0.1847,0.1571,Crystal structure of human Bromodomain containing protein 3 (BRD3) in complex with SHMT
8GMC,X-RAY DIFFRACTION,3.01,59.13,"VAPOR DIFFUSION, HANGING DROP",6,"1.2M AmSO4, 0.1M tri-Na Citrate pH 6.0, 3% isopropanol, 296K",296,2023-03-24,2023-07-12,8GMC,4600,2,636,74,,73.47,1,2.5,experimental,44.67,0.256,0.227,"CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 COMPLEXED WITH 5-[(4-aminopiperidin-1-yl)methyl]-N-{3-[5-(propan-2-yl)-1,3,4-thiadiazol-2-yl]phenyl}pyrrolo[2,1-f][1,2,4]triazin-4-amine"
7U4L,X-RAY DIFFRACTION,2.3,46.45,MICROBATCH,4.6,2 M sodium chloride and 0.1 M sodium acetate trihydrate,291,2022-02-28,2022-12-07,7U4L,5748,4,768,361,,88.45,1,2.25,experimental,34.2225,0.2299,0.1634,Crystal structure of human GPX4-U46C in complex with MAC-5576
4QIZ,X-RAY DIFFRACTION,2.18,43.49,"VAPOR DIFFUSION, SITTING DROP",6,"0.1M ammonium citrate (pH 5.0), 20% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291,2014-06-03,2015-04-15,4QIZ,4865,2,526,484,,60.6,1,1.55,experimental,19.49,0.20936,0.17512,Crystal structure of human carbonic anhydrase isozyme XIII with inhibitor
5GMM,X-RAY DIFFRACTION,2.45,49.79,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH 6.7~8.2, 0.5~1.4 M tri-Na citrate.",277,2016-07-14,2017-05-24,5GMM,4539,2,522,350,,60.18,1,2.003,experimental,,0.2268,0.1751,Crystal structure of human Carbonic anhydrase I in complex with polmacoxib
6BPU,X-RAY DIFFRACTION,3.71,66.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295,2017-11-26,2018-07-04,6BPU,1785,1,200,156,,23.69,1,1.8,experimental,35.5249,0.1892,0.1682,Crystal structure of ferrous form of the F2-Tyr157 human cysteine dioxygenase with both uncrosslinked and crosslinked cofactor
6BPW,X-RAY DIFFRACTION,3.7,66.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295,2017-11-26,2018-07-04,6BPW,1669,1,200,79,,23.91,1,2.43,experimental,41.1118,0.2056,0.1601,Crystal structure of ferrous form of the Cl2-Tyr157 human cysteine dioxygenase with both uncrosslinked and crosslinked cofactor
6CDH,X-RAY DIFFRACTION,3.71,66.8,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295,2018-02-08,2018-07-04,6CDH,1767,1,200,162,,23.51,1,1.821,experimental,36.26,0.1819,0.1648,Crystal structure of ferrous form of the Cl-Tyr157 human cysteine dioxygenase with both uncrosslinked and crosslinked cofactor
5C2E,X-RAY DIFFRACTION,1.88,34.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,2015-06-15,2015-12-02,5C2E,5388,2,724,117,,83.91,1,2.1,experimental,49.28,0.2801,0.2489,"PDE10 complexed with6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[2-(2-pyridyl)ethoxy]pyrimidin-4-amine"
6AOD,X-RAY DIFFRACTION,2.69,54.24,"VAPOR DIFFUSION, HANGING DROP",,"1.86 M ammonium sulfate, 8 mM CoCl2, 30 mM K/Na phosphate, pH 6.5",277,2017-08-15,2018-03-14,6AOD,5751,3,688,560,11,77.68,3,1.8,experimental,37.237,0.2068,0.18192,FXIa antibody complex
5EGG,X-RAY DIFFRACTION,2.14,42.44,"VAPOR DIFFUSION, HANGING DROP",,"2% v/v Tacsimate pH 4.0, 0.1 M Sodium acetate  trihydrate pH 4.6, 16% w/v Polyethylene glycol 3350",289,2015-10-27,2016-11-02,5EGG,1245,1,156,67,,17.78,1,1.76,experimental,,0.2528,0.206,Crystal structure of human ubiquitin-conjugating enzyme UBCH5C
4U3X,X-RAY DIFFRACTION,2.32,46.94,"VAPOR DIFFUSION, HANGING DROP",5.5,"300 mM sodium citrate, 16% PEG 3350",298,2014-07-23,2015-03-11,4U3X,3685,4,500,101,10,55.13,2,2.26,experimental,14.923,0.24839,0.1893,Structure of a human VH antibody domain binding to the cleft of hen egg lysozyme
5TZM,X-RAY DIFFRACTION,2.38,48.4,"VAPOR DIFFUSION, HANGING DROP",7.5,"17% tacsimate, 0.1M HEPES pH 7.5, 4% PEG3350, 10 mg/mL C-terminal his-tagged Ig59",293,2016-11-21,2017-11-08,5TZM,775,1,100,97,1,10.71,1,1.177,experimental,,0.1852,0.1642,59th Ig domain of human obscurin (OBSCN Ig59)
7U4I,X-RAY DIFFRACTION,2.18,43.47,MICROBATCH,7,0.2 M potassium thiocyanate and 20% (w/v) PEG 3350,291,2022-02-28,2022-12-07,7U4I,2811,2,384,179,,44.32,1,1.97,experimental,31.7419,0.2458,0.2007,Crystal structure of human GPX4-U46C-R152H in complex with CDS9
5L04,X-RAY DIFFRACTION,2.55,51.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"7 mg/ml of protein in 50 mM Hepes buffer (pH 7.5) with 150 mM NaCl, mixesd with 1:1 ratio with
18% (w/v) PEG 3350, 0.2 M amonium formate",293,2016-07-26,2016-10-12,5L04,4221,2,598,185,,69.43,2,2.1,experimental,50.996,0.2304,0.1687,STRUCTURE OF INTERFERON LAMBDA 1 RECEPTOR WITH HUMAN KINASE JAK1
6NJ7,X-RAY DIFFRACTION,2.52,51.15,"VAPOR DIFFUSION, HANGING DROP",6.5,"THE 4 UL DROP CONTAINED 2 UL PROTEIN
 (25 MM TRIS, PH 8.0, 250 MM NACL, 4 MM CHAPS, 10 MG/ML PROTEIN)
 AND 2 UL WELL SOLUTION (100 MM MES, PH 6.5, 20 PEG 4000), VAPOR
 DIFFUSION, HANGING DROP, TEMPERATURE 291K",291,2019-01-02,2019-07-24,6NJ7,7396,4,1156,4,,132.68,1,2.6,experimental,93.48,0.264,0.213,11-BETA DEHYDROGENASE ISOZYME 1 IN COMPLEX WITH COLLETOIC ACID
4Y46,X-RAY DIFFRACTION,2.48,50.37,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, ammonium tartrate",277,2015-02-10,2015-05-06,4Y46,2867,1,366,73,,42.67,1,2.04,experimental,,0.2653,0.212,Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitors
4Y5H,X-RAY DIFFRACTION,2.46,49.99,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, ammonium tartrate",277,2015-02-11,2015-05-06,4Y5H,2856,1,366,1,,42.65,1,2.055,experimental,,0.2852,0.2362,Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitors
7KSI,X-RAY DIFFRACTION,1.89,34.92,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium tartrate pH 7.0, 20 % PEG 3350",277.15,2020-11-23,2021-03-03,7KSI,3130,1,464,300,,53.1,1,1.726,experimental,33.77,0.2552,0.2195,"Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors"
7KSJ,X-RAY DIFFRACTION,1.88,34.44,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium tartrate pH 7.0, 20 % PEG 3350",277.15,2020-11-23,2021-03-03,7KSJ,3017,1,464,188,,53.09,1,2.06,experimental,56.77,0.2917,0.23,"Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors"
7KSK,X-RAY DIFFRACTION,1.9,35.17,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium tartrate pH 7.0, 20 % PEG 3350",277.15,2020-11-23,2021-03-03,7KSK,2797,1,464,53,,53.07,1,1.84,experimental,50.18,0.29,0.247,"Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors"
6UEL,X-RAY DIFFRACTION,3.12,60.56,"VAPOR DIFFUSION, HANGING DROP",,"CPS1 protein was buffer exchanged into 50 mM glycyl-glycine pH 7.4, 50 mM KCl, 5% glycerol. CPS1 was concentrated to 10 mg/ml and H3B-4193 was added to a 5x excess molar ratio along with 1mM AMPPNP and 1mM NAG.  Ligand bound complex crystals grew by hanging drop vapor diffusion in 20% PEG 3350 and 0.2M trisodium citrate",293,2019-09-21,2020-03-18,6UEL,22300,2,3000,1622,,331.17,1,1.9,experimental,30.467,0.2086,0.172,CPS1 bound to allosteric inhibitor H3B-193
7EFJ,X-RAY DIFFRACTION,2.63,57.53,"VAPOR DIFFUSION, HANGING DROP",7.4,"2M Ammonium Sulfate, 1% PEG400, 100mM HEPES, pH 7.5",277.15,2021-03-21,2022-02-16,7EFJ,1318,1,183,104,,21.06,1,1.992,experimental,31.3126,0.221,0.1896,Crystal Structure Analysis of human PIN1
7EFX,X-RAY DIFFRACTION,2.62,57.4,"VAPOR DIFFUSION, HANGING DROP",7.4,"2M Ammonium Sulfate, 1% PEG400, 100mM HEPES, pH 7.5",277.15,2021-03-23,2022-02-16,7EFX,1258,1,183,68,,20.76,1,2.41,experimental,33.2301,0.2762,0.2226,Crystal Structure of human PIN1 complexed with covalent inhibitor
7EKV,X-RAY DIFFRACTION,2.67,58.15,"VAPOR DIFFUSION, HANGING DROP",7.4,"2M Ammonium Sulfate, 1% PEG400, 100mM HEPES, pH 7.5",277.15,2021-04-06,2022-02-16,7EKV,1387,1,183,171,,21.13,1,1.95,experimental,20.1142,0.2349,0.1974,Crystal Structure of human Pin1 complexed with a covalent inhibitor
7UFZ,X-RAY DIFFRACTION,2.42,49.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide and 0.03 M sodium iodide",291,2022-03-23,2023-04-12,7UFZ,8174,2,922,777,,106.23,1,1.559,experimental,28.8442,0.1948,0.1708,Crystal structure of TDP1 complexed with compound XZ768
6GRO,X-RAY DIFFRACTION,2.67,53.95,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M sodium/potassium tartrate, 0.1 M bis-tris-propane pH 8.5, 20% PEG3350, 10% ethylene glycol",277,2018-06-12,2018-06-20,6GRO,2846,1,330,365,,39.19,1,1.45,experimental,24.472,0.16732,0.13367,Human CSNK1G3 bound to SB-223133
7U4K,X-RAY DIFFRACTION,2.11,41.61,MICROBATCH,6,8% Tacsimate and 20% (w/v) PEG 3350,291,2022-02-28,2022-12-07,7U4K,1514,1,192,136,,22.47,1,1.69,experimental,35.2649,0.1811,0.1528,Crystal structure of human GPX4-U46C-R152H in complex with ML162
6E46,X-RAY DIFFRACTION,2.48,50.46,EVAPORATION,6.2,"0.1 M phosphate (pH 6.2), and 15% (w/v) PEG3350",298,2018-07-16,2018-11-14,6E46,12439,4,1620,417,,184.68,1,2.09,experimental,44.6973,0.2474,0.2075,"CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) in complex with ferrous heme and tryptophan"
7R71,X-RAY DIFFRACTION,2.17,43.41,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MMT pH 6.0, 25% w/v PEG 1500",289.15,2021-06-24,2022-03-09,7R71,2980,3,411,,,46.26,3,2.8,experimental,75.6127,0.2714,0.2261,Crystal Structure of the UbArk2C-UbcH5b~Ub complex
8BS3,X-RAY DIFFRACTION,2.31,46.64,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M MMT buffer pH 7.0, 25% (w/v) PEG 1500",291,2022-11-24,2023-07-12,8BS3,3350,2,456,269,,50.68,2,2.2,experimental,32.6,0.2272,0.1956,Structure of USP36 in complex with Fubi-PA
5CBT,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH 9, 2% w/v PEG2000mme",291,2015-07-01,2016-07-20,5CBT,1412,1,165,123,,18.55,1,1.45,experimental,16.785,0.19856,0.17749,Human Cyclophilin D Complexed with Inhibitor
5CBW,X-RAY DIFFRACTION,2.66,53.74,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH 9, 2% w/v PEG2000mme",294,2015-07-01,2016-07-20,5CBW,1450,1,165,161,,18.55,1,1.8,experimental,19.684,0.20816,0.17362,Human Cyclophilin D Complexed with Inhibitor.
5CCN,X-RAY DIFFRACTION,2.67,53.86,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane, 2% w/v PEG2000mme",294,2015-07-02,2016-07-20,5CCN,1421,1,164,123,,18.52,1,1.8,experimental,17.658,0.20749,0.17896,Human Cyclophilin D Complexed with Inhibitor
5CCQ,X-RAY DIFFRACTION,2.66,53.79,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH 9, 2% w/v PEG2000mme",294,2015-07-02,2016-07-20,5CCQ,1424,1,164,138,,18.37,1,1.8,experimental,16.281,0.2027,0.16381,Human Cyclophilin D Complexed with Inhibitor
5CCR,X-RAY DIFFRACTION,2.61,52.79,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH9, 2% w/v PEG2000mme",294,2015-07-02,2016-07-20,5CCR,1435,1,165,120,,18.83,1,1.9,experimental,11.787,0.18792,0.15468,Human Cyclophilin D Complexed with Inhibitor
7LRL,X-RAY DIFFRACTION,2.1,41.51,"VAPOR DIFFUSION, SITTING DROP",,"18.5% PEG 3350, 0.4M Calcium Cl",293.15,2021-02-16,2021-08-25,7LRL,3796,1,474,195,,55.42,1,1.995,experimental,16.735,0.2365,0.2193,Co-complex CYP46A1 with 7742 (Soticlestat/TAK-935))
7LS4,X-RAY DIFFRACTION,2.13,42.13,"VAPOR DIFFUSION, HANGING DROP",,"33.375% PEG MME 2000, 0.2M Mg Cl, 0.1M Tris Cl",293,2021-02-17,2021-08-25,7LS4,3773,1,474,222,,55.34,1,2.05,experimental,41.026,0.2345,0.1852,Co-complex CYP46A1 with 9129 (1b)
6ATP,X-RAY DIFFRACTION,2.3,46.56,"VAPOR DIFFUSION, SITTING DROP",8.5,"PEG 2000 MME, 20% (w/v), 0.05 M Tris HCl, pH 8.5",293,2017-08-29,2018-09-12,6ATP,4444,2,442,712,,51.43,1,1.7,experimental,,0.2011,0.1673,Crystal structure of apo-hGSTA1-1 exhibiting a new conformation of C-terminal helix
8PP8,X-RAY DIFFRACTION,2.69,54.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.81 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1.
Protein concentration: 17 mg/ml.
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT.
Soaking 2h with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 5 mM ligand, 3 mM AMP-PNP and 3 mM MnCl2.",291,2023-07-07,2024-02-28,8PP8,4930,2,558,422,,66.29,1,1.59,experimental,37.629,0.21218,0.19257,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with L-scyllo-inositol 1,2,4-trisphosphate/AMP-PNP/Mn"
8PPG,X-RAY DIFFRACTION,2.63,53.23,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.81 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 17 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking overnight with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 7 mM beta-D-glucopyranosyl 1,3,4-trisphosphate (substrate), 10 mM ATP and 10 mM MnCl2.",291,2023-07-07,2024-02-28,8PPG,4694,2,558,339,,66.64,1,1.75,experimental,44.186,0.2435,0.206,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with beta-D-glucopyranosyl 1,3,4,6-tetrakisphosphate/ADP/Mn after reaction"
8PPJ,X-RAY DIFFRACTION,2.68,54.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.80 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 17 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking overnight with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 7 mM beta-D-glucopyranosylmethanol 3,4,1'-trisphosphate (substrate), 10 mM ATP and 10 mM MnCl2.",291,2023-07-07,2024-02-28,8PPJ,4896,2,558,402,,66.63,1,1.75,experimental,40.128,0.23423,0.19706,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with beta-D-glucopyranosylmethanol 3,4,6,1'-tetrakisphosphate/ADP/Mn after reaction"
5HX8,X-RAY DIFFRACTION,2.39,48.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM MES pH 6.25, 33 % PEG 6000",298,2016-01-29,2016-03-16,5HX8,4832,2,604,147,,70.14,1,2.2,experimental,49.8,0.2397,0.197,Jak1 complex with 4-[(4-aminocyclohexyl)amino]-3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one
8CHM,X-RAY DIFFRACTION,2.75,55.26,"VAPOR DIFFUSION, SITTING DROP",,"2.1 M ammonium sulfate, 0.2 M cadmium chloride, 0.1M HEPES-NaOH pH 7.5",293,2023-02-08,2023-09-06,8CHM,1097,1,107,214,,12.91,1,1.12,experimental,10.321,0.1455,0.13,"Human FKBP12 in complex with (1S,5S,6R)-10-((S)-(3,5-dichlorophenyl)sulfinyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one"
6R8O,X-RAY DIFFRACTION,2.6,52.7,"VAPOR DIFFUSION, SITTING DROP",7.5,PEG 3350,298,2019-04-02,2019-11-27,6R8O,1501,1,164,187,,18.53,1,1.36,experimental,,0.182,0.143,"Human Cyclophilin D in complex with 1-(((2R,3S,6R)-3-hydroxy-2,3,4,6-tetrahydro-1H-2,6-methanobenzo[c][1,5]oxazocin-8-yl)methyl)-3-(2-((R)-2-(2-(methylthio)phenyl)pyrrolidin-1-yl)-2-oxoethyl)urea"
5TE1,X-RAY DIFFRACTION,2.63,53.29,"VAPOR DIFFUSION, HANGING DROP",,"12.5% P3350, 200 mM MES pH 5.9, 125 mM ammonium acetate pH 5",294,2016-09-20,2017-08-09,5TE1,12278,2,1656,750,,181.88,1,2.25,experimental,,0.247,0.1881,"C20S, C293G Mutant N-terminal Human ATP Citrate Lyase Bound to 4R-Hydroxycitrate"
5TEQ,X-RAY DIFFRACTION,2.52,51.16,"VAPOR DIFFUSION, HANGING DROP",7,"12.5% P3350, 100-200 mM MES pH 7, 125 mM ammonium citrate pH 4.5",294,2016-09-22,2017-08-09,5TEQ,11963,2,1656,517,,181.84,1,2.3,experimental,,0.2455,0.2017,C20S C293G MUTANT N-TERMINAL HUMAN ATP CITRATE LYASE BOUND TO CITRATE
6AAH,X-RAY DIFFRACTION,2.31,46.74,VAPOR DIFFUSION,,"buffer, salt, precipitant",293,2018-07-18,2018-08-15,6AAH,4938,2,580,232,,67.63,1,1.83,experimental,,0.25502,0.22374,Crystal structure of JAK1 in complex with peficitinib
5W7X,X-RAY DIFFRACTION,2.05,40.01,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.6mM XRCC1 bisphosphopeptide
0.6mM APLF
0.5M lithium chloride
0.1M Tris 
28% PEG 6000",293,2017-06-21,2018-05-02,5W7X,3638,8,468,261,,52.14,2,2.005,experimental,,0.2291,0.1922,Crystal Structure of FHA domain of human APLF in complex with XRCC1 bisphospho peptide
8DEH,X-RAY DIFFRACTION,2.4,48.78,"VAPOR DIFFUSION, HANGING DROP",8,"50 mM EPPS pH 8.0, 35% (v/v) PEP426,
and 250 mM ammonium sulfate",287,2022-06-20,2023-04-19,8DEH,1626,1,223,155,,24.95,1,1.815,experimental,25.9808,0.1894,0.1633,Ankyrin domain of SKD3
9GDK,X-RAY DIFFRACTION,2.43,49.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"LFS well F04
20% PEG3350 
10% ethylene glycol
0.1M bis-tris-propane pH 6.5
0.2M potassium thiocyanate",298,2024-08-05,2024-08-21,9GDK,5918,2,696,592,2,79.9,1,1.78,experimental,33.142,0.2422,0.2093,Jumonji domain-containing protein 1C with crystallization epitope mutations L2440Y:G2444H
6AAM,X-RAY DIFFRACTION,1.83,32.94,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Bis-Tris pH7.5, 0.2M sodium acetate, 10% glycerol, 20% PEG3350",277,2018-07-18,2018-08-15,6AAM,2241,1,298,45,,34.34,1,1.98,experimental,36.732,0.23811,0.20203,Crystal structure of TYK2 in complex with peficitinib
6W8L,X-RAY DIFFRACTION,2.05,40.14,EVAPORATION,8,"0.1 M Tris pH 8.5, 6-9% MPD, 24-29% PEG-1500",298,2020-03-20,2020-04-08,6W8L,2340,1,316,31,,36.8,1,2.11,experimental,46.18,0.226,0.196,Crystal structure of JAK1 kinase with compound 10
6RX7,X-RAY DIFFRACTION,2.46,50.06,"VAPOR DIFFUSION, SITTING DROP",6,"PEG400 1% (v/v)
Ammonium sulfate 2 M
HEPES 0.1 M",294.15,2019-06-07,2020-07-08,6RX7,2350,3,333,223,9,38.69,1,1.63,experimental,22.8234,0.269,0.232,Structure of the KIV type 2 (KIV-2) domain of lipoprotein (a)
7XRB,X-RAY DIFFRACTION,2.53,51.3,"VAPOR DIFFUSION, HANGING DROP",6.5,"2 M ammonium sulfate, 0.1 M MES pH 6.5, 0.2 M NaCl",293,2022-05-10,2023-06-07,7XRB,3906,2,464,372,,52.48,1,1.65,experimental,36.494,0.1938,0.1488,human STK19 dimer
6P1N,X-RAY DIFFRACTION,2.862,57,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES pH 7.5, 100mM NaCl, 10% w/v PEG4000",277,2019-05-20,2019-09-04,6P1N,3464,4,371,397,,45.99,1,1.6,experimental,,0.1866,0.165,Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound incoming dAMPNPP
6P1P,X-RAY DIFFRACTION,2.847,56.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES pH 7.5, 100mM NaCl, 10% w.v PEG4000",277,2019-05-20,2019-09-04,6P1P,3460,4,371,379,,46.06,1,1.75,experimental,,0.184,0.1645,Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound incoming dCMPNPP
6P1T,X-RAY DIFFRACTION,2.85,56.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"94mM HEPES pH 7.5, 94mM NaCl, 9.4% w/v PEG4000",277,2019-05-20,2019-09-04,6P1T,3416,4,371,363,,46.04,1,1.7,experimental,,0.1909,0.1692,Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and bound CMPCPP
6P1V,X-RAY DIFFRACTION,2.841,56.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"80mM HEPES pH 7.5, 80mM NaCl, 8% w/v PEG4000",277,2019-05-20,2019-09-04,6P1V,3396,4,371,374,,45.99,1,1.95,experimental,,0.2038,0.1765,Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing undamaged template dG and bound incoming dCMPNPP
6P1W,X-RAY DIFFRACTION,2.84,56.7,"VAPOR DIFFUSION, SITTING DROP",,"82mM HEPES pH 7.5, 82mM NaCl, 8.2% w/v PEG4000",277,2019-05-20,2019-09-04,6P1W,3558,4,371,401,,45.98,1,1.751,experimental,,0.1899,0.1632,Pre-catalytic ternary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing undamaged template dG and bound incoming CMPCPP
8QCD,X-RAY DIFFRACTION,2.61,52.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"THE CK2ALPHA' SOLUTION AFTER PROTEIN PURIFICATION (5 MG/ML CK2ALPHA' IN 500 MM NACL, 25 MM TRIS/HCl, PH 8.5) WAS MIXED IN A 1:10 RATIO WITH A 20 MM SOLUTION OF 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBBT) IN DMSO. AFTER INCUBATION ON ICE FOR 30 MIN AND CENTRIFUGATION (16100 TIMES G FOR 2 MIN AT ROOM TEMPERATUR) 10 MIKROLITER OF THE SUPERNATANT WERE MIXED WITH 5 MIKORLITER OF THE RESERVOIR SOLUTION [900 MM LICL, 28% (W/V) PEG 6000, 100 MM TRIS/HCl, PH 8.5]. AFTER EQUILIBRATION, MICROSEEDING WAS CARRIED OUT TO INDUCE CRYSTAL GROWTH. SMALL CRYSTALS APPEARED AFTER ONE WEEK. ONE OF THEM WAS USED AS A MACROSEED TRANSFERING IT TO A SECOND DROP PREPARED IN THE SAME MANNER AS THE FIRST ONE. ALL CRSTALLIZATION STEPS WERE PERFORMED AT A TEMPERATURE OF 293 K.",293,2023-08-25,2023-12-06,8QCD,3307,1,364,406,,43.5,1,1.03,experimental,7.66,0.1562,0.1437,"STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE"
5CLL,X-RAY DIFFRACTION,2.14,42.45,"VAPOR DIFFUSION, HANGING DROP",6.25,"18 % PEG 4000, 250 mM ammonium sulfate, 100 mM MES pH 6.25, 1 mM BeF",291,2015-07-16,2015-09-09,5CLL,5280,4,716,33,,82.44,2,2.45,experimental,38.385,0.27225,0.23466,Truncated Ran wild type in complex with GDP-BeF and RanBD1
4XP7,X-RAY DIFFRACTION,2.13,40.2,"VAPOR DIFFUSION, SITTING DROP",4,"0.1 M MES Malic Tris pH 4, 25% PEG 1500",292,2015-01-16,2015-01-28,4XP7,2755,1,346,196,,39.13,1,1.9,experimental,36.622,0.2065,0.1679,Crystal structure of Human tRNA dihydrouridine synthase 2
8QCG,X-RAY DIFFRACTION,2.19,43.77,"VAPOR DIFFUSION, SITTING DROP",,"10 MIKROLITER CK2ALPHA' SOLUTION AFTER PROTEIN PURIFICATION (5 MG/ML CK2ALPHA' IN 500 MM NACL, 25 MM TRIS/HCl, PH 8.5) WERE MIXED WITH 5 MIKROLITER RESERVOIR SOLUTION [810 MM LICL, 28% (W/V) PEG 6000, 100 MM TRIS/HCL, PH 8.5]. AFTER EQUILIBRATION (SITTING DROP PLATES; VAPOUR DIFFUSION), CRYSTALLIZATION WAS INITIATED BY MICROSEEDING. THE CRYSTALS WERE OPTIMIZED BY MACROSEEDING. THE ATP-ANALOGUE AMPPNP WAS COMBINED WITH THESE CRYSTALS BY SOAKING. A 20 MM AMPPNP SOLUTION IN 60 MM MGCL2 WAS PREPARED. FOR SOAKING, 3 MICROLITER OF THE CRYSTAL MOTHER LIQUOR WAS REMOVED AND REPLACED BY 3 MICROLITER OF 20 MM AMPPNP, 60 MM MGCL2. ALL STEPS WERE PERFORMED AT A TEMPERATURE OF 293 K.",293,2023-08-25,2023-12-06,8QCG,6447,2,728,752,,86.85,1,1.04,experimental,20.41,0.1703,0.1506,STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (CK2ALPHA') IN COMPLEX WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMPPNP
6DHU,X-RAY DIFFRACTION,2.45,49.79,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03 M sodium fluoride
0.03 M sodium bromide
0.03 M sodium iodide",292,2018-05-21,2019-05-29,6DHU,8024,2,922,695,,105.29,1,1.63,experimental,,0.2109,0.1812,Crystal structure of Tdp1 catalytic domain in complex with Zenobia fragment ZT0911 from cocktail soak
6DIH,X-RAY DIFFRACTION,2.45,49.88,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-05-23,2019-05-29,6DIH,7972,2,922,711,,104.8,1,1.78,experimental,,0.2172,0.1785,Crystal structure of Tdp1 catalytic domain in complex with Sigma Aldrich compound PH004941
6DJE,X-RAY DIFFRACTION,2.46,50.02,"VAPOR DIFFUSION, HANGING DROP",7.5,".1 M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-05-25,2019-05-29,6DJE,7894,2,922,648,,104.96,1,1.705,experimental,,0.2271,0.1913,Crystal structure of Tdp1 catalytic domain in complex with Sigma Aldrich compound CDS010292
6DJF,X-RAY DIFFRACTION,2.46,49.95,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-05-25,2019-05-29,6DJF,7901,2,922,619,,104.97,1,1.67,experimental,,0.2124,0.188,Crystal structure of Tdp1 catalytic domain in complex with compound XZ502
6DJG,X-RAY DIFFRACTION,2.42,49.25,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-05-25,2019-05-29,6DJG,7861,2,922,608,,104.92,1,1.88,experimental,,0.2249,0.1823,Crystal structure of Tdp1 catalytic domain in complex with compound XZ503
6DJI,X-RAY DIFFRACTION,2.43,49.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-05-25,2019-05-29,6DJI,8081,2,922,779,,104.99,1,1.75,experimental,,0.2117,0.1809,Crystal structure of Tdp1 catalytic domain in complex with compound XZ522
6DJJ,X-RAY DIFFRACTION,2.43,49.48,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-05-25,2019-05-29,6DJJ,8186,2,922,886,,105.05,1,1.741,experimental,,0.2064,0.1736,Crystal structure of Tdp1 catalytic domain in complex with compound XZ532
6MJ5,X-RAY DIFFRACTION,2.47,50.2,"VAPOR DIFFUSION, HANGING DROP",7.5,"protein 22 mg/mL

0.1M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000
20% v/v ethylene glycol
0.03M sodium fluoride
0.03M sodium bromide
0.03M sodium iodide",292,2018-09-20,2019-07-03,6MJ5,7851,2,920,580,,104.86,1,1.853,experimental,,0.2183,0.1775,Crystal structure of Tdp1 catalytic domain in complex with compound XZ519
6N19,X-RAY DIFFRACTION,2.43,49.45,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",291,2018-11-08,2019-07-03,6N19,8106,2,922,796,,105.03,1,1.501,experimental,,0.205,0.1797,Crystal structure of Tdp1 catalytic domain in complex with compound XZ578
6W7K,X-RAY DIFFRACTION,2.44,49.52,"VAPOR DIFFUSION, HANGING DROP",7.5,0.1M MOPS/HEPES-Na pH 7.5 10% w/v PEG 8000 20% v/v ethylene glycol 0.03 M sodium fluoride 0.03 M sodium bromide 0.03 M sodium iodide,292,2020-03-19,2021-03-24,6W7K,7851,2,922,593,,105.25,1,1.7,experimental,26.8934,0.219,0.187,Structure of Tdp1 catalytic domain in complex with inhibitor XZ634p
6W7L,X-RAY DIFFRACTION,2.47,50.11,"VAPOR DIFFUSION, HANGING DROP",,0.1 M MOPS/HEPES-Na pH 7.5 10% w/v PEG 8000 20% v/v ethylene glycol 0.03M sodium fluoride 0.03M sodium bromide 0.03M sodium iodide,292,2020-03-19,2021-03-24,6W7L,7846,2,922,537,,105.25,1,1.856,experimental,38.5065,0.2188,0.182,Structure of Tdp1 catalytic domain in complex with inhibitor XZ632p
7WL0,X-RAY DIFFRACTION,2.19,43.74,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium sulfate decahydrate, 20% (w/v) PEG 3350",293,2022-01-12,2022-03-30,7WL0,9362,10,1140,175,,139.53,1,2.5,experimental,49.1942,0.2404,0.1963,Crystal structure of human ALKBH5 in complex with N-oxalylglycine (NOG) and m6A-containing ssRNA
4YND,X-RAY DIFFRACTION,2.1,41.53,"VAPOR DIFFUSION, HANGING DROP",,"The protein ligand complex was made using a slight molar excess of S adenomethionine (SAM) and A-893 from concentrated DMSO stocks. Co-crystals were grown using the hanging drop format with a 1:1 v/v drop composition of the protein complex: well solution (20% w/v PEG 10,000, 0.1 HEPES pH 7.5) at 17C.",290,2015-03-09,2015-05-20,4YND,3633,1,461,131,,54.38,1,2.79,experimental,33.04,0.2532,0.1979,"The Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2"
6TEW,X-RAY DIFFRACTION,2.35,47.59,"VAPOR DIFFUSION, SITTING DROP",8.5,"RESERVOIR COMPOSITION: 28 % (W/V) PEG6000, 0.9 M LICL, 0.1 M, TRIS/HCL, PH 8.5; CRYSTALLIZATION DROP COMPOSITION PRIOR TO EQUILIBRATION: 0.01 ML RESERVOIR SOLUTION PLUS 0.02 ML CK2ALPHA' (MUTANT CYS336SER)/INHIBITOR MB002 MIXTURE (0.180 ML 6 MG/ML CK2ALPHA-'CYS336SER, 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5, MIXED AND PRE-EQUILIBRATED WITH 0.02 ML 10 MM MB002 IN DIMETHYL SULFOXIDE); the inhibitor MB002 was replaced by extensive soaking with the 2-aminothiazole-type inhibitor 27; VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293,2019-11-12,2020-07-08,6TEW,3091,1,364,261,,43.37,1,1.082,experimental,21.15,0.1687,0.1461,Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the 2-aminothiazole-type inhibitor 27
8EPW,X-RAY DIFFRACTION,1.86,33.9,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M potassium bromide, 30% PEG 2000 MME",293,2022-10-06,2023-06-07,8EPW,2005,2,250,61,,29.04,2,2,experimental,38.0752,0.2528,0.1916,Crystal Structure of KRAS4b-G13D (GMPPNP-bound) in complex with RAS-binding domain (RBD) of RAF1/CRAF
9F9Z,X-RAY DIFFRACTION,2.23,44.88,"VAPOR DIFFUSION, SITTING DROP",,"0.2M KSCN
24% PEG 3350",293,2024-05-09,2024-07-03,9F9Z,4142,1,520,164,2,59.01,1,2.279,experimental,35.359,0.26354,0.17597,Gcase in complex with small molecule inhibitor 1
6UV1,X-RAY DIFFRACTION,2.62,53.12,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium citrate pH 6.0, 2M NaCl",293,2019-11-01,2020-01-01,6UV1,7823,4,916,550,,109.85,1,2.307,experimental,31.1319,0.2553,0.1971,Crystal structure of RNA helicase DDX17 in complex of rU10 RNA
6ZH0,X-RAY DIFFRACTION,2.91,57.77,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MOPS/sodium HEPES pH 7.0-7.5, 40-50 % Morpheus Precipitant Mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1 M Morpheus Carboxylic acids mix (0.02M each of - sodium formate, ammonium acetate, sodium citrate tribasic dehydrate, sodium potassium tartrate tetrahydrate and sodium oxamate).",293,2020-06-20,2022-06-01,6ZH0,11258,4,1596,231,2,174.9,1,2.5,experimental,50.803,0.2897,0.2389,Structure of human galactokinase 1 bound with 2-(4-chlorophenyl)-N-(pyrimidin-2-yl)acetamide
4Z96,X-RAY DIFFRACTION,5.2,76.35,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M sodium citrate, pH5.5, 10% PEG6000, 15% glycerol",277,2015-04-09,2016-10-12,4Z96,4119,2,563,,,65.35,2,2.85,experimental,,0.2456,0.2008,Crystal structure of DNMT1 in complex with USP7
7ONP,X-RAY DIFFRACTION,2.09,41.17,"VAPOR DIFFUSION, SITTING DROP",7.9,"2.6 M (NH4)2SO4, 50 mM Tris-H2SO4, pH 7.9",293,2021-05-25,2021-12-01,7ONP,2344,1,260,200,,30.26,1,1.408,experimental,22.688,0.1821,0.1569,Wild type carbonic anhydrase II with bound IrCp* complex to generate an artificial transfer hydrogenase (ATHase)
4ZAE,X-RAY DIFFRACTION,2.82,56.33,"VAPOR DIFFUSION, HANGING DROP",9,"50 mM CHES, pH 9.0, 1.3 M tri-sodium citrate and 3 mM compound (cross seeded with crystals grown from 50 mM Tris, pH 7.2, 1.45 M ammonium sulfate, 2.0 M sodium chloride and 3 mM compound)",295,2015-04-13,2015-06-03,4ZAE,2567,2,297,260,7,33.68,2,1.86,experimental,32.41,0.1741,0.1477,Development of a novel class of potent and selective FIXa inhibitors
8AMS,X-RAY DIFFRACTION,2.26,45.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M sodium formate, 0.1 M bis-tris propane, 20% PEG 3350",293.15,2022-08-04,2023-11-15,8AMS,4389,5,705,158,,80.84,3,2.4,experimental,50.47,0.2326,0.2141,"Complex of human TRIM2 RING domain, UBCH5C, and Ubiquitin"
8QF1,X-RAY DIFFRACTION,2.19,43.87,"VAPOR DIFFUSION, SITTING DROP",,"10 MIKROLITER CK2ALPHA' SOLUTION AFTER PROTEIN PURIFICATION (5 MG/ML CK2ALPHA' IN 500 MM NACL, 25 MM TRIS/HCl, PH 8.5) WERE MIXED WITH 5 MIKROLITER RESERVOIR SOLUTION [810 MM LICL, 28% (W/V) PEG 6000, 100 MM TRIS/HCL, PH 8.5]. AFTER EQUILIBRATION (SITTING DROP PLATES; VAPOUR DIFFUSION), CRYSTALLIZATION WAS INITIATED BY MICROSEEDING. THE CRYSTALS WERE OPTIMIZED BY MACROSEEDING. THE GTP-ANALOGUE GMPPNP WAS COMBINED WITH THESE CRYSTALS BY SOAKING. A 20 MM GMPPNP SOLUTION IN 60 MM MGCL2 WAS PREPARED. FOR SOAKING, 3 MICROLITER OF THE CRYSTAL MOTHER LIQUOR WAS REMOVED AND REPLACED BY 3 MICROLITER OF 20 MM GMPPNP, 60 MM MGCL2. ALL STEPS WERE PERFORMED AT A TEMPERATURE OF 293 K.",293,2023-09-01,2023-12-06,8QF1,6251,2,728,619,,86.35,1,1.32,experimental,23.67,0.2324,0.2139,STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (CK2ALPHA') IN COMPLEX WITH THE NON-HYDROLYZABLE GTP ANALOGUE GMPPNP
5EXN,X-RAY DIFFRACTION,2.13,42.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 MM SODIUM CITRATE, PH 5.0, 36%(w/v) PEG4000",277,2015-11-23,2016-04-13,5EXN,2142,1,238,221,4,27.66,1,1.49,experimental,22.98,0.195,0.17,"FACTOR XIA (C500S [C122S]) IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate"
6J4P,X-RAY DIFFRACTION,2.33,47.26,EVAPORATION,7,"V2c-SVBP was mixed with the inhibitor epoY at a mole ratio of 1:5 and incubated on ice for 30 min. Then, the resulting co-complex of V2c-SVBP-epoY was crystallized in 1.0 M lithium chloride, 0.1 M HEPES, pH 7.0, 20% PEG 6000.",293,2019-01-10,2019-05-01,6J4P,2891,2,317,478,,37.47,2,1.599,experimental,,0.1877,0.1643,Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
6SMB,X-RAY DIFFRACTION,2.45,49.76,"VAPOR DIFFUSION, SITTING DROP",,"27% (m/v) PEG6000, 0.1 M MES/NaOH pH 6.0 and 5 mM DTT",277,2019-08-21,2020-04-29,6SMB,4924,2,602,211,,70.32,1,2.04,experimental,38.2,0.265,0.221,Human jak1 kinase domain in complex with inhibitor
5KT2,X-RAY DIFFRACTION,2.84,56.71,"VAPOR DIFFUSION, HANGING DROP",6.5,"13% PEG MME 5000, 0.1M MES, 0.3M ammonium sulfate",277.15,2016-07-11,2016-08-31,5KT2,3401,3,437,85,,52.73,1,2.488,experimental,53.9257,0.2488,0.22,Teranry complex of human DNA polymerase iota(26-445) inserting dCMPNPP opposite template G in the presence of Mg2+
5KT3,X-RAY DIFFRACTION,2.85,56.88,"VAPOR DIFFUSION, HANGING DROP",6.5,"18% PEG MME 5000, 0.1M MES buffer, 0.3M ammonium sulfate",277.15,2016-07-11,2016-08-31,5KT3,3374,3,437,65,,52.82,1,2.64,experimental,51.5588,0.248,0.2042,Teranry complex of human DNA polymerase iota(26-445) inserting dCMPNPP opposite template G in the presence of Mn2+
5KT4,X-RAY DIFFRACTION,2.57,57.19,"VAPOR DIFFUSION, HANGING DROP",6.5,"18% PEG MME 5000, 0.1M MES buffer, 0.3M ammonium sulfate",277.15,2016-07-11,2016-08-31,5KT4,3286,3,462,22,,55.27,1,2.78,experimental,65.0422,0.2495,0.217,Teranry complex of human DNA polymerase iota R96G inserting dCMPNPP opposite template G in the presence of Mg2+
5KT5,X-RAY DIFFRACTION,2.54,51.64,"VAPOR DIFFUSION, HANGING DROP",,"18% PEG MME 5000, 0.1M MES buffer, 0.3M ammonium sulfate",277.15,2016-07-11,2016-08-31,5KT5,3272,3,462,10,,55.35,1,2.798,experimental,51.4303,0.2664,0.2236,Teranry complex of human DNA polymerase iota R96G inserting dCMPNPP opposite template G in the presence of Mn2+
5TXY,X-RAY DIFFRACTION,2.08,40.93,"VAPOR DIFFUSION, SITTING DROP",,"2.58 M ammonium sulfate, 
0.1 M tris-chloride (pH 8.9)",280,2016-11-17,2017-08-30,5TXY,2604,1,260,435,,29.58,1,1.206,experimental,,0.1748,0.1589,Identification of a New Zinc Binding Chemotype of by Fragment Screening on human carbonic anhydrase
7OEX,X-RAY DIFFRACTION,1.92,35.9,"VAPOR DIFFUSION, SITTING DROP",6.5,"30% w/v PEG 4K, 0.1 M MES sodium salt pH 6.5",291,2021-05-04,2021-12-22,7OEX,3322,2,388,292,,44.52,1,1.51,experimental,20.106,0.1972,0.161,Crystal structure of RBBP9 in complex with phenylalanine
4W4V,X-RAY DIFFRACTION,2.37,48.07,"VAPOR DIFFUSION, HANGING DROP",,"EG 3350, ammonium tartrate",277,2014-08-15,2015-02-11,4W4V,3130,1,366,323,,42.71,1,2.01,experimental,42.69,0.2341,0.194,JNK2/3 in complex with 3-(4-{[(2-chlorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide
4W4W,X-RAY DIFFRACTION,2.37,48.14,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, ammonium tartrate",277,2014-08-15,2015-02-11,4W4W,3144,1,366,286,,42.67,1,1.9,experimental,43.62,0.219,0.1917,JNK2/3 in complex with N-(2-methylpyridin-4-yl)-3-{4-[(phenylcarbamoyl)amino]-1H-pyrazol-1-yl}benzamide
4W4X,X-RAY DIFFRACTION,2.39,48.5,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, ammonium tartrate",277,2014-08-15,2015-02-11,4W4X,2956,1,366,160,,42.69,1,2.65,experimental,50.73,0.2838,0.1922,JNK2/3 in complex with 3-(4-{[(4-fluorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide
4W4Y,X-RAY DIFFRACTION,2.43,49.32,"VAPOR DIFFUSION, HANGING DROP",,"EG 3350, ammonium tartrate",277,2014-08-15,2015-02-11,4W4Y,3027,1,366,166,,42.69,1,2.3,experimental,67.96,0.2598,0.1959,JNK2/3 in complex with 3-(4-{[(4-methylphenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide
7S1N,X-RAY DIFFRACTION,1.9,35.38,VAPOR DIFFUSION,,"0.2 M ammonium tartrate pH 7.2, 18 % PEG 3350",277.15,2021-09-02,2021-11-03,7S1N,2946,1,464,109,,53.11,1,2.11,experimental,,0.2674,0.2256,N-Aromatic-Substituted Indazole Derivatives as Brain Penetrant and Orally Bioavailable JNK3 Inhibitors
5NW9,X-RAY DIFFRACTION,2.39,48.51,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Ammonium sulphate, 0.1M HEPES, 25% w/v PEG 8000",290,2017-05-05,2018-01-10,5NW9,7120,3,979,57,,112.22,1,2.04,experimental,56.481,0.2709,0.2319,Crystal structure of the complex of Tdp1 with duplex DNA
7F0M,X-RAY DIFFRACTION,2.12,41.92,"VAPOR DIFFUSION, HANGING DROP",8,"30% PEG400, 100mM Tris, pH 8.0",289.15,2021-06-05,2022-02-16,7F0M,5346,4,732,478,,84.55,1,1.9,experimental,23.7461,0.2475,0.2152,Crystal Structure of human Pin1 complexed with a potent covalent inhibitor
6Q4Q,X-RAY DIFFRACTION,2.55,51.68,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.16 M Calcium Acetate pH 6.5, 0.08 M Sodium Cacodylate, 14.4% PEG 8K, 20% Glycerol",298,2018-12-06,2019-04-24,6Q4Q,6406,4,684,435,,82.28,2,1.45,experimental,27.97,0.215,0.205,The Crystal structure of CK2a bound to P2-C4
4TNS,X-RAY DIFFRACTION,1.63,24.58,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium sulfate, 0.1 M HEPES pH7-8.5 and 0.9 M-1.4 M sodium citrate",297,2014-06-04,2015-04-08,4TNS,1999,2,302,127,,33.57,1,1.33,experimental,14.818,0.18694,0.16917,Structure of Pin1 PPIase domain bound with all-trans retinoic acid
6Y2X,X-RAY DIFFRACTION,2.44,49.69,"VAPOR DIFFUSION, SITTING DROP",7.6,Morpheus condition 60,292,2020-02-17,2020-09-02,6Y2X,3259,2,470,257,,52.13,1,1.77,experimental,56.2907,0.2741,0.2421,"RING-DTC domains of Deltex 2, Form 2"
6JX5,X-RAY DIFFRACTION,3.93,68.74,VAPOR DIFFUSION,,"100mM Bis Tris (pH 5.5), 200mM Ammonium sulfate",296.15,2019-04-22,2019-12-04,6JX5,9512,3,1164,366,,133.63,1,2.402,experimental,,0.2181,0.1857,Hect domain of AREL1
8CEW,X-RAY DIFFRACTION,2.12,42.02,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 1000, 0.1M MIB buffer",278,2023-02-02,2024-02-21,8CEW,3027,1,345,255,,39.83,1,1.53,experimental,31.61,0.2236,0.1975,Crystal structure of human DNA cross-link repair 1A in complex with N-hydroxyimide inhibitor H1
8CF0,X-RAY DIFFRACTION,2.11,41.61,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 1000, 0.1M MIB buffer",298,2023-02-02,2024-02-21,8CF0,2997,1,345,249,,39.52,1,1.76,experimental,30.11,0.2567,0.2196,Crystal structure of human DNA cross-link repair 1A in complex with quinoxalinedione inhibitor H2
4MTA,X-RAY DIFFRACTION,3.22,61.75,"VAPOR DIFFUSION, HANGING DROP",5.4,"1.0 M ammonium dihydrogen phosphate, 0.2 M sodium chloride, 0.1 M sodium citrate, pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293,2013-09-19,2015-01-14,4MTA,2400,1,286,167,,33.14,1,2.2,experimental,38.94,0.192,0.1584,Crystal structure of Pim-1 kinase domain in complex with 2-methyl-5-phenylfuran-3-carboxylic acid
5W4W,X-RAY DIFFRACTION,2.16,43.15,"VAPOR DIFFUSION, HANGING DROP",,,295,2017-06-13,2017-06-28,5W4W,10124,4,1324,519,,156.88,1,1.99,experimental,41.86,0.215,0.18,Identification and Profiling of a Selective and Brain Penetrant Radioligand for In Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors
8TK3,X-RAY DIFFRACTION,2.21,44.46,"VAPOR DIFFUSION, SITTING DROP",,"The protein in 50 mM TRIS-Cl pH 8.5, 1 mM TCEP, 0.5 mM EDTA was mixed with the crystallization buffer (100 mM Bis-Tris pH 6.5, 50 mM NH4F, 28% (w/v) PEGME-2000) and equilibrated against the crystallization buffer. The crystals were soaked with 25 mM of the compound in solution (10% DMSO, 100 mM Bis-Tris pH 6.5, 50 mM NH4F, 28% (w/v) PEGME-2000).",294,2023-07-25,2024-08-14,8TK3,1581,1,183,106,,20.84,1,2,experimental,31.256,0.25538,0.18617,HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) having oxidized catalytic cysteine and complexed with 6-(difluoromethyl)pyrimidin-4-ol at two allosteric sites
5TK5,X-RAY DIFFRACTION,2.97,58.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 2% PEG 400, and 2.0 M ammonium sulfate",277,2016-10-06,2017-04-12,5TK5,2414,1,290,173,,33.24,1,1.88,experimental,20.66,0.2177,0.2027,Crystal structure of human 3HAO with iron bound in the active site
5TKQ,X-RAY DIFFRACTION,3.01,59.12,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5, 2% PEG 400, and 2.0 M ammonium sulfate",277,2016-10-07,2017-04-12,5TKQ,2430,1,290,170,,33.44,1,1.75,experimental,28.17,0.2242,0.2018,Crystal structure of human 3HAO with zinc bound in the active site
8XPX,X-RAY DIFFRACTION,2.21,44.33,"VAPOR DIFFUSION, SITTING DROP",,"0.2M NH4Ac, 0.1M Na3 Citrate pH5.2, 30% PEG 4000",293,2024-01-04,2024-03-06,8XPX,3350,2,392,300,,45.54,1,1.75,experimental,27.829,0.1942,0.1636,The Crystal Structure of PARP12 from Biortus.
7UMP,X-RAY DIFFRACTION,2.97,58.61,VAPOR DIFFUSION,5.5,"100 MM SODIUM ACETATE PH 5.5, 21%
 PEG1500, 15% MPD, 300 MM MGSO4, 4 MM AKB-6548",299,2022-04-07,2022-05-18,7UMP,1841,1,216,130,,24.75,1,1.8,experimental,,0.202,0.169,CRYSTAL STRUCTURE OF PHD2 CATALYTIC DOMAIN (CID 7465) IN COMPLEX WITH AKB-6548 AT 1.8 A RESOLUTION
8SG5,X-RAY DIFFRACTION,2.64,53.35,"VAPOR DIFFUSION, SITTING DROP",7.4,"C12E9, PEG 3350, sodium malonate, lithium sulfate",296,2023-04-11,2023-10-11,8SG5,30098,8,3840,,,456.19,1,2.8,experimental,87.4,0.241,0.203,Cytochrome P450 (CYP) 3A5 crystallized with clotrimazole
6CBU,X-RAY DIFFRACTION,2.16,43.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"30% PEG 3350, 200 mM Bis-tris, pH 6.5, 200 mM LiSO4",293,2018-02-05,2019-02-06,6CBU,884,1,100,100,,11.4,1,1.2,experimental,8.508,0.1532,0.143,Crystal structure of C4S3: A computationally designed immunogen to target Carbohydrate-Occluded Epitopes on the HIV envelope
6Y22,X-RAY DIFFRACTION,4.87,74.75,"VAPOR DIFFUSION, SITTING DROP",7.6,"Morpheus condition 60: 0.12 M ethylene glycols (0.3M Diethylene glycol; 0.3M Triethylene glycol; 0.3M Tetraethylene glycol; 0.3M Pentaethylene glycol), 0.1 M Buffer system 3 (1 M Tris-Bicine pH 8.5), 37.5% Precipitation mix 4 (25% v/v MPD; 25% PEG 1000; 25% w/v PEG 3350)",292,2020-02-14,2020-09-02,6Y22,1836,1,235,92,,26.07,1,2.069,experimental,55.9843,0.2083,0.1793,"RING-DTC domains of Deltex 2, Form 1"
6N17,X-RAY DIFFRACTION,2.46,49.91,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",291,2018-11-08,2019-07-03,6N17,8147,2,922,842,,105.2,1,1.639,experimental,,0.2112,0.1838,Crystal structure of Tdp1 catalytic domain in complex with compound XZ577
7N27,X-RAY DIFFRACTION,2.01,38.76,"VAPOR DIFFUSION, SITTING DROP",7,"3.5M Na Formate, 0.1M Bis-Tris propane pH7.0",291,2021-05-28,2021-07-21,7N27,3279,12,378,69,,48.32,2,1.85,experimental,31.01,0.262,0.225,Crystal Structure of chromodomain of CDYL in complex with inhibitor UNC6261
7N6F,X-RAY DIFFRACTION,2.28,41.2,"VAPOR DIFFUSION, HANGING DROP",,"0.4M CaCl2, 10-20% PEG3350",290,2021-06-08,2022-07-27,7N6F,4089,1,474,312,,56.03,1,1.4,experimental,19.303,0.1847,0.1597,Co-complex CYP46A1 with compound 3f
5ZYV,X-RAY DIFFRACTION,2.11,41.72,"VAPOR DIFFUSION, HANGING DROP",,0.1M CHESpH 9.5 and 20% PEG 8000,291.15,2018-05-28,2018-09-19,5ZYV,1700,2,269,13,,34.18,1,2.72,experimental,,0.2539,0.2116,Crystal structure of human MGME1 with single strand DNA2 and Ca2+
5FOX,X-RAY DIFFRACTION,2.18,44,,6,"8% PEG-1000, 100 MM NAK PHOSPHATE, PH 6.2",,2015-11-26,2016-03-30,5FOX,2272,2,237,299,,26.16,2,1.3,experimental,15.72,0.1819,0.1566,HUMANISED MONOMERIC RADA IN COMPLEX WITH FHAA TETRAPEPTIDE
8EXM,X-RAY DIFFRACTION,3.67,66.52,"VAPOR DIFFUSION, HANGING DROP",,"12% Peg 4K, 0.15 M Calcium acetate, 0.05 M MES (pH 6.5)",281.15,2022-10-25,2023-07-05,8EXM,2492,2,315,86,,36.86,2,2.349,experimental,61.5873,0.2475,0.206,Crystal structure of PTP1B D181A/Q262A phosphatase domain with a JAK3 activation loop phosphopeptide
7O7I,X-RAY DIFFRACTION,4,69.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes (pH 7.5), 0.2 M MgCl2, and 15-17% (v/w) medium weight PEG mix",288,2021-04-13,2021-11-24,7O7I,2988,1,404,51,,46.21,1,2.5,experimental,,0.2754,0.2432,Crystal structure of the human HIPK3 kinase domain
6I0J,X-RAY DIFFRACTION,2.33,47.17,"VAPOR DIFFUSION, HANGING DROP",9,"28% PEG4000, 0.2 M Sodium acetate, Tris 100 mM",296,2018-10-26,2019-11-20,6I0J,4712,2,522,581,,59.16,1,1.35,experimental,26.366,0.2325,0.1968,Crystal structure of human carbonic anhydrase I in complex with the 4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenyl sulfamate inhibitor
6I0L,X-RAY DIFFRACTION,2.36,47.88,"VAPOR DIFFUSION, HANGING DROP",9,"28% PEG 4000, 0,2 M Sodium acetate, Tris 100 mM",296,2018-10-26,2019-11-20,6I0L,4618,2,522,504,,59.12,1,1.4,experimental,29.631,0.2369,0.2039,Crystal structure of human carbonic anhydrase I in complex with the 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[2-(4-sulfamoylphenyl)ethyl]urea inhibitor
8AWK,X-RAY DIFFRACTION,2.45,49.81,"VAPOR DIFFUSION, SITTING DROP",7,"0.2 M Na2SO4, 14% (v/v) PEG3350, 0.25 M HEPES pH 7.0",293,2022-08-30,2024-03-13,8AWK,4872,1,497,547,2,58.61,1,1.58,experimental,19.369,0.1849,0.1515,Structure of recombinant human beta-glucocerebrosidase in complex with D-carbaxylosyl chloride
8AWR,X-RAY DIFFRACTION,2.43,49.44,"VAPOR DIFFUSION, SITTING DROP",7,"0.2 M Na2SO4, 14% (v/v) PEG3350, 0.25M HEPES, pH 7.0",293,2022-08-30,2024-03-13,8AWR,4670,1,497,467,2,58.93,1,1.49,experimental,22.777,0.2216,0.1834,Structure of recombinant human beta-glucocerebrosidase in complex with L-carbaxylosyl chloride
5QIO,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, SITTING DROP",7,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293,2018-08-10,2019-12-18,5QIO,2080,1,225,191,,26.61,1,1.46,experimental,18.261,0.1974,0.1725,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with P11
5QIW,X-RAY DIFFRACTION,2.36,47.83,"VAPOR DIFFUSION, SITTING DROP",7,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293,2018-08-10,2019-12-18,5QIW,2073,1,225,194,,26.52,1,1.71,experimental,18.957,0.2153,0.1839,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102660
5QIY,X-RAY DIFFRACTION,2.31,46.78,"VAPOR DIFFUSION, SITTING DROP",7,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293,2018-08-10,2019-12-18,5QIY,2058,1,225,177,,26.57,1,1.58,experimental,21.59,0.1933,0.1764,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102954
5QIZ,X-RAY DIFFRACTION,2.33,47.29,"VAPOR DIFFUSION, SITTING DROP",7,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293,2018-08-10,2019-12-18,5QIZ,2090,1,225,206,,26.55,1,1.63,experimental,19.85,0.2056,0.1781,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0103080
8PI3,X-RAY DIFFRACTION,2.59,52.56,"VAPOR DIFFUSION, SITTING DROP",,"0.2M ammonium sulfate, 0.01M Cadmium chloride hemi(pentahydrate), 0.1M Pipes pH 7, 15% PEG Smear Broad, 10% Ethylene glycol",277,2023-06-21,2024-06-05,8PI3,1928,2,239,65,3,28.02,2,1.73,experimental,38.85,0.2059,0.1761,Cathepsin S Y132D mutant in complex with NNPI-C10 inhibitor
8RND,X-RAY DIFFRACTION,2.2,44.09,"VAPOR DIFFUSION, SITTING DROP",,"0.1M BisTris Propane pH 6.5, 0.2 M NaNO3, 20% w/v PEG3350, 10% ethylene glycol",277,2024-01-09,2024-06-05,8RND,1946,2,234,110,3,26.56,2,1.56,experimental,27.96,0.2251,0.1708,Cathepsin S in complex with NNPI-C10 inhibitor
5WAL,X-RAY DIFFRACTION,2.05,40.12,"VAPOR DIFFUSION, HANGING DROP",6.5,"20-25%(w/v) PEG3350 and 0.2M Mg sulfate, 0.1M MES pH6.5",291,2017-06-26,2017-09-06,5WAL,2498,1,302,92,,35.1,1,2.45,experimental,37.46,0.243,0.182,Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model
5F1Z,X-RAY DIFFRACTION,2.25,45.43,"VAPOR DIFFUSION, SITTING DROP",6,"15% PEG 5000 MME, and 100 mM Sodium Citrate (pH 6.0)",293,2015-12-01,2016-01-13,5F1Z,2478,1,301,155,,35.2,1,2.65,experimental,32.71,0.31,0.216,"Structure of TYK2 with inhibitor 16: 3-azanyl-5-[(2~{S})-3-methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]-1~{H}-pyrazolo[4,3-c]pyridin-4-one"
7W3R,X-RAY DIFFRACTION,2.3,46.46,"VAPOR DIFFUSION, HANGING DROP",,"16% w/v PEG 3350, 0.16M sodium bromide, 0.125M Magnesium formate dihydrate, 0.025M BIS-TRIS",289,2021-11-26,2022-06-01,7W3R,5683,2,768,220,,89.86,1,1.92,experimental,50.2922,0.2615,0.2259,USP34 catalytic domain
6BGM,X-RAY DIFFRACTION,3.74,67.12,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295,2017-10-28,2017-11-22,6BGM,1640,1,200,72,,23.47,1,2.206,experimental,46.7922,0.216,0.1793,Crystal structure of ferrous form of the crosslinked human cysteine dioxygenase
6BPT,X-RAY DIFFRACTION,3.74,67.14,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295,2017-11-26,2018-07-04,6BPT,1698,1,200,118,,23.7,1,2.402,experimental,25.0032,0.2018,0.1563,Crystal structure of ferrous form of the uncrosslinked F2-Tyr157 human cysteine dioxygenase
6E87,X-RAY DIFFRACTION,3.75,67.16,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295,2018-07-27,2019-04-17,6E87,1735,1,200,155,,23.66,1,1.952,experimental,34.9817,0.1973,0.1707,Crystal structure of ferrous form of the crosslinked human cysteine dioxygenase in the anaerobic condition
6YLL,X-RAY DIFFRACTION,2.27,45.76,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.3 M CaCl2, 6% v/v PEG1500, 0.1 M Mes pH 6.5",294,2020-04-07,2020-09-23,6YLL,4358,2,638,26,,72.73,1,2.89,experimental,91.32,0.263,0.245,"Biochemical, Cellular and Structural Characterization of Novel ERK3 Inhibitors"
8CW2,X-RAY DIFFRACTION,2.41,49.04,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS/HEPES-Na pH 7.5, 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.03 M sodium fluoride, 0.03 M sodium bromide and 0.03 M sodium iodide",291,2022-05-18,2023-04-12,8CW2,8062,2,922,699,,106.17,1,1.811,experimental,30.196,0.1914,0.1561,Crystal structure of TDP1 complexed with compound XZ760
6JWN,X-RAY DIFFRACTION,1.85,33.69,"VAPOR DIFFUSION, HANGING DROP",7.6,"0.02M Citric acid, 0.08M Bis-Tris propane pH7.6, 14%(w/v0 Polyethylene glycol 3350",293,2019-04-21,2020-04-22,6JWN,3257,4,436,137,,47.86,2,1.61,experimental,13.634,0.20506,0.18496,"Crystal structure of the SPRY domain of SPSB2 in complex with cR9, a cyclic peptide inhibitor of SPSB-iNOS interaction"
7AT9,X-RAY DIFFRACTION,2.41,48.86,"VAPOR DIFFUSION, SITTING DROP",8.5,"Reservoir composition: 28 % (w/v) PEG6000, 0.9 M LiCl, 0.1 M, Tris/HCl, pH 8.5; drop composition prior to equilibration: 0.01 ml reservoir solution + 0.02 ml CK2alpha' (mutant Cys336Ser)/inhibitor MB002 mixture (0.180 ml 6 mg/ml CK2alpha'Cys336Ser, 0.5 M NaCl, 25 mM Tris/HCl, pH 8.5, mixed and pre-equilibrated with 0.02 ml 10 mM MB002 in dimethyl sulfoxide); the alphaD-pocket ligand 3,4-dichlorophenethylamine was introduced by extensive soaking.",293,2020-10-29,2021-08-04,7AT9,3428,1,364,404,,44.3,1,1.05,experimental,19.12,0.1496,0.1291,"Structure of protein kinase ck2 catalytic subunit (csnk2a2 gene product) in complex with the ATP-competitive inhibitor MB002 and the alphaD-pocket ligand 3,4-dichlorophenethylamine"
6R8Q,X-RAY DIFFRACTION,1.92,36.04,"VAPOR DIFFUSION, SITTING DROP",4,"1.4 M AMMONIUM SULPHATE, 
0.1 M CITRIC ACID, 
PH 4.0",295,2019-04-02,2019-05-08,6R8Q,3203,1,383,202,8,45.15,1,1.5,experimental,21.8566,0.1946,0.1546,STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A BENZOTRIAZOLE FRAGMENT
6T2K,X-RAY DIFFRACTION,1.93,36.17,"VAPOR DIFFUSION, SITTING DROP",4.2,1.5M Ammonium sulfate 0.1 M Sodium citrate pH4.2,300,2019-10-08,2020-01-01,6T2K,3010,1,383,146,6,44.82,1,1.38,experimental,29.5921,0.2142,0.1876,"Furano[2,3-d]prymidine amides as Notum inhibitors"
6TR7,X-RAY DIFFRACTION,2.01,38.69,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.5 M ammonium sulphate 
0.1 M sodium citrate pH 4.2",300,2019-12-17,2020-01-08,6TR7,3161,1,383,150,6,45.55,1,1.47,experimental,23.8728,0.2195,0.1962,N-[2-(5-fluoro-1H-indol-3-yl)ethyl]acetamide-Notum complex
6ZUV,X-RAY DIFFRACTION,1.99,38.13,EVAPORATION,4.2,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",293,2020-07-23,2020-11-11,6ZUV,3074,1,383,133,7,44.76,1,1.54,experimental,27.5284,0.2587,0.2099,Notum fragment 286
6Z2F,X-RAY DIFFRACTION,1.97,37.45,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 0.1 M Tris, pH 8.5, 30% PEG 4000",289.15,2020-05-15,2021-05-26,6Z2F,8314,2,1018,701,,116.37,2,1.7,experimental,24.492,0.226,0.1871,Crystal structure of human AGX1 mutant complexed with UDPGLCNAC
5TKD,X-RAY DIFFRACTION,2.37,48.09,VAPOR DIFFUSION,6.5,,298,2016-10-06,2016-12-28,5TKD,4005,2,596,189,,67.54,1,1.92,experimental,28.94,0.215,0.192,"CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(3,5-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO)IMIDAZO[1,2-B]PYRIDAZINE-3-CARBO XAMIDE"
6X8F,X-RAY DIFFRACTION,1.84,33.09,EVAPORATION,8,"0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, 27-33% PEG-3350",298,2020-06-01,2020-11-25,6X8F,4899,2,636,177,,73.98,1,2.15,experimental,41.27,0.2549,0.2052,Crystal structure of TYK2 with Compound 11
4WNT,X-RAY DIFFRACTION,3.24,62.06,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, SODIUM ACETATE, SODIUM CACODYLATE, POTASSIUM PHOSPHATE, SODIUM CHLORIDE, ZINC CHLORIDE, GLYCEROL, BETA-MERCAPTOETHANOL, THIORIDAZINE, HEGA-10, FACIAL AMPHIPHILE 231_CHOL. Ajmalicine was added to the mother liquor after crystallization of the P450 2D6 thiordidazine complex.",298,2014-10-14,2015-01-14,4WNT,7426,2,958,68,,109.6,1,2.6,experimental,59.9193,0.2366,0.1915,Human Cytochrome P450 2D6 Ajmalicine Complex
6D68,X-RAY DIFFRACTION,2.65,53.52,"VAPOR DIFFUSION, HANGING DROP",8,"25% PEG1500, Succinic acid, Sodium phosphate monobasic monohydrate, Glycine",293,2018-04-20,2019-07-17,6D68,3758,4,514,85,,59.22,2,2.36,experimental,67.09,0.2536,0.2126,Ube2G1 in complex with ubiquitin variant Ubv.G1.1
8Q9W,X-RAY DIFFRACTION,2.2,44.05,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.3-6.9, 50 mM Na2SO4, 18-25 % PEG 6000",290,2023-08-21,2024-09-11,8Q9W,4635,2,552,103,,66.48,1,2.5,experimental,,0.2286,0.1741,Crystal structure of HsRNMT complexed with sinefungin and GMP-PnP
6JWM,X-RAY DIFFRACTION,1.92,35.91,EVAPORATION,6.5,"0.2 M Sodium chloride, 0.1 M BIS-TRIS pH6.5, 25% w/v Polyethylene glycol 3350",293,2019-04-21,2020-04-22,6JWM,1745,2,216,125,,23.7,2,1.23,experimental,9.003,0.20018,0.17688,"Crystal structure of the SPRY domain of SPSB2 in complex with cR7, a potent cyclic peptide inhibitor of SPSB2-iNOS interaction"
6YJY,X-RAY DIFFRACTION,3.05,59.65,"VAPOR DIFFUSION, HANGING DROP",,"1.6M ammonium sulfate, 0.1M MES pH 6.5, 4% (v/v) 1,4-Dioxane",298,2020-04-05,2020-07-01,6YJY,6161,2,658,481,,78.41,1,1.67,experimental,43.0046,0.1884,0.1694,Crystal structure of human glutaminyl cyclase in complex with neurotensin 1-5
6KEY,X-RAY DIFFRACTION,2.01,38.66,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Sodium chloride, 0.1M BIS-TRIS pH5.5, 25% w/v Polyethylene glycol 3350",293,2019-07-05,2020-07-01,6KEY,1724,2,218,122,,23.97,2,1.24,experimental,9.098,0.2043,0.1843,Structural basis for the regulation of inducible nitric oxide synthase (iNOS) by the SPRY domain-containing SOCS box protein 2 (SPSB2)
8CHK,X-RAY DIFFRACTION,2.11,41.7,"VAPOR DIFFUSION, HANGING DROP",,"1.32M Na-K tartrate, 0.2 M ammonium citrate, 0.1M MES pH 6.5",293,2023-02-08,2023-09-06,8CHK,2887,3,321,279,,37.33,1,1.55,experimental,18.287,0.2328,0.1967,"Human FKBP12 in complex with (1S,5S,6R)-10-((S)-(3,5-dichlorophenyl)sulfonimidoyl)-3-(pyridin-2-ylmethyl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-one"
6DBK,X-RAY DIFFRACTION,1.89,34.87,"VAPOR DIFFUSION, HANGING DROP",8,"0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, 27-33% PEG-3350",298,2018-05-03,2018-08-29,6DBK,2530,1,318,157,,36.96,1,2,experimental,42.07,0.2489,0.2006,Tyk2 with compound 8
6DBM,X-RAY DIFFRACTION,1.85,33.42,"VAPOR DIFFUSION, HANGING DROP",8,"0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, 27-33% PEG-3350",298,2018-05-03,2018-08-29,6DBM,2366,1,318,100,,36.94,1,2.368,experimental,28.69,0.2643,0.201,Tyk2 with compound 23
4TSA,X-RAY DIFFRACTION,2.08,40.92,"VAPOR DIFFUSION, SITTING DROP",,"PCTP 100mM pH 6.5, 25% Peg10k",293,2014-06-18,2015-07-08,4TSA,3676,3,568,55,6,60.53,3,2.27,experimental,32.76,0.3098,0.281,Structure of a lysozyme FAb complex
7R2E,X-RAY DIFFRACTION,2.26,45.59,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Sodium HEPES 7.0, 15 % w/v PEG 20,000",291,2022-02-04,2022-12-07,7R2E,5639,4,842,325,,98.04,2,1.74,experimental,36.7846,0.2304,0.1841,Structure of human Senp7 with SUMO2
6EVR,X-RAY DIFFRACTION,2.33,47.24,"VAPOR DIFFUSION, HANGING DROP",9,"28% PEG4000, 0.2 M Sodium acetate, Tris 100 mM",296,2017-11-02,2018-06-06,6EVR,4568,2,522,453,,58.99,1,1.5,experimental,27.172,0.2227,0.1843,Crystal structure of human carbonic anhydrase I in complex with the 4-(4 acetyl-3-benzylpiperazine-1 carbonyl)benzene-1-sulfonamide inhibitor
6EX1,X-RAY DIFFRACTION,2.33,47.12,"VAPOR DIFFUSION, HANGING DROP",9,"28% PEG4000, 0.2 M Sodium acetate, Tris 100 mM",296,2017-11-07,2018-10-10,6EX1,4426,2,522,320,,58.91,1,1.6,experimental,37.328,0.2437,0.21398,Crystal structure of human carbonic anhydrase I in complex with the 4-[(3S)-3 benzyl-4-(4-sulfamoylbenzoyl)piperazine -1-carbonyl]benzene-1-sulfonamide inhibitor
5FUT,X-RAY DIFFRACTION,2.33,47.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"HSCKALPHA1 AT 20 MG/ML WAS PREINCUBATED AT ROOM TEMPERATURE WITH 12 MM OF COMPOUND BR25 IN BUFFER 25 MM TRIS/HCL, 150 MM NACL PH 7.5 (DMSO IS AT 5% FINAL CONCENTRATION IN THE MIX). THE SITTING-DROP VAPOUR DIFFUSION METHOD WAS USED TO PRODUCE CRYSTALS BY MIXING 0.5 MICROL OF THE PROTEIN SOLUTION AND AN EQUAL VOLUME OF MOTHER LIQUOR (20% PEG 5000 MME AND 0.2 M KSCN). TETRAGONAL CRYSTALS (SPACE GROUP P43212) GREW WITHIN 2-4 DAYS AND THEN WERE SOAKED FOR ONE DAY WITH 20 MM COMPOUND BR25 SOLVED IN 100% DMSO. THE CRYSTALS USED IN THIS STUDY WERE CRYOPROTECTED IN MOTHER LIQUOR SOLUTIONS CONTAINING 20 % ETHYLENGLYCOL AND FROZEN IN A NITROGEN GAS STREAM COOLED TO 100 K.",,2016-01-29,2016-09-21,5FUT,3346,1,378,278,,45.53,1,1.6,experimental,,0.205,0.1809,Human choline kinase a1 in complex with compound 4-(dimethylamino)-1-{4-[4-(4-{[4-(pyrrolidin- 1-yl)pyridinium-1-yl]methyl}phenyl)butyl]benzyl}pyridinium (compound BR25)
8VXD,X-RAY DIFFRACTION,2.47,50.14,VAPOR DIFFUSION,5.5,"12%-20% PEG 10 K, 0.1 M Bis Tris (pH 5.5), 0.1 M Ammonium Acetate",293,2024-02-04,2024-05-08,8VXD,4502,2,600,9,,70.15,1,2.47,experimental,,0.295,0.2649,Structure of Casein kinase I isoform delta (CK1d) complexed with inhibitor 7
8VJY,X-RAY DIFFRACTION,2.71,54.55,"VAPOR DIFFUSION, HANGING DROP",,"17.5 ~ 30 % polyethylene glycol 3,350 and 50 ~ 125 mM Bis-Tris HCl buffer, pH 6.5",295,2024-01-08,2024-08-21,8VJY,12083,4,1362,989,,158.45,2,1.95,experimental,,0.2338,0.1976,Structure of Human Neurolysin in complex with Neurotensin peptide
9IT1,X-RAY DIFFRACTION,2.9,57.57,VAPOR DIFFUSION,7.5,"0.1M HEPES PH(7.5), 1% PEG400,2.2M (NH4)2SO4",277,2024-07-19,2024-08-21,9IT1,1197,1,164,24,,18.49,1,2,experimental,,0.3388,0.3183,Crystal structure of Pin1 using laue diffraction
5ZYT,X-RAY DIFFRACTION,2.54,51.57,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH 7.5, 0.8M NaH2PO4, and 0.8M K2HPO4.",291.15,2018-05-28,2018-09-19,5ZYT,8036,8,1368,,,169.81,1,2.702,experimental,,0.2962,0.2495,Crystal structure of human MGME1 with 3' overhang double strand DNA3
6TS7,X-RAY DIFFRACTION,2.15,42.83,"VAPOR DIFFUSION, SITTING DROP",,"25% w/v PEG 3350, Sodium acetate trihydrate pH 4.5",277,2019-12-20,2020-07-08,6TS7,2000,1,238,97,4,27.23,1,2.63,experimental,30.94,0.2759,0.1895,Coagulation factor XI protease domain in complex with active site inhibitor
4Z99,X-RAY DIFFRACTION,2.46,50,"VAPOR DIFFUSION, HANGING DROP",7,"27% (w/v) PEG 2000, 0.1 M malic acid:Tris, molar ratio 1:2, pH 7.0",291,2015-04-10,2015-07-15,4Z99,1416,1,164,122,,18.76,1,2.3,experimental,25.027,0.28682,0.19048,Crystal structure of the apo Low Molecular Weight Protein Tyrosine Phosphatase isoform A
4Z9B,X-RAY DIFFRACTION,2.36,47.87,"VAPOR DIFFUSION, HANGING DROP",7,"32% (w/v) PEG 5000, 0.1 M malic acid:Tris, molar ratio 1:2, pH 7.0",291,2015-04-10,2015-07-15,4Z9B,1340,1,164,69,,18.93,1,2.41,experimental,35.003,0.30148,0.21479,Crystal structure of Low Molecular Weight Protein Tyrosine Phosphatase isoform A complexed with benzylphosphonic acid
5EMY,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM sodium cacodylate, 58% MPD, obtained crystals were soaked in 100mM glucosyl epi-cyclophellitol solution and incubated for up to two weeks to allow complex formation.",293,2015-11-06,2016-07-06,5EMY,4561,1,496,559,5,56.35,1,1.231,experimental,,0.1421,0.1189,Human Pancreatic Alpha-Amylase in complex with the mechanism based inactivator glucosyl epi-cyclophellitol
5OW1,X-RAY DIFFRACTION,2.59,52.54,"VAPOR DIFFUSION, HANGING DROP",,"26-28% PEG3350, 0.1M Bis-Tris pH5.5, 0.2M Lithium sulfate",277,2017-08-30,2017-11-22,5OW1,2632,1,305,302,,35.62,1,2.05,experimental,24.76,0.2115,0.18,X-Ray Characterization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors
7QHJ,X-RAY DIFFRACTION,2.76,55.46,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",278,2021-12-13,2022-12-21,7QHJ,4132,4,458,501,6,51,2,1.4,experimental,26.61,0.2126,0.1858,Peptide GAKSAA in complex with human cathepsin V C25A mutant
6W2J,X-RAY DIFFRACTION,2.8,56.05,"VAPOR DIFFUSION, HANGING DROP",,"CPS1 protein was buffer exchanged into 50 mM glycyl-glycine pH 7.4, 50 mM KCl, 5% glycerol. CPS1 was concentrated to 10 mg/ml and H3B-4193 was added to a 5x excess molar ratio along with 1mM AMPPNP and 1mM NAG.  Ligand bound complex crystals grew by hanging drop vapor diffusion in 20% PEG 3350 and 0.2M trisodium citrate",293,2020-03-05,2021-01-13,6W2J,21756,2,3000,136,,331.29,1,2.62,experimental,60.404,0.2503,0.1897,CPS1 bound to allosteric inhibitor H3B-374
8CZL,X-RAY DIFFRACTION,2.64,53.39,"VAPOR DIFFUSION, HANGING DROP",,"0.70-0.75 M succinic acid pH 7.0, 0.1 M bis-tris-propane pH 7.0.",282.15,2022-05-24,2023-01-25,8CZL,7215.0,2.0,838.0,656.0,,95.78,1.0,1.58,experimental,21.6,0.20388,0.18114,Human LanCL1 bound to methyl glutathione (MeGSH)
5YJO,X-RAY DIFFRACTION,2.25,45.36,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Magnesium acetate, 17% PEG3350",298.0,2017-10-11,2018-10-17,5YJO,3558.0,1.0,423.0,158.0,,49.62,1.0,2.135,experimental,24.2532,0.2317,0.1901,Crystal structure of SmyD3 in complex with covalent inhibitor 4
6IJL,X-RAY DIFFRACTION,2.24,45.08,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Magnesium acetate, 17% PEG 3350",293.0,2018-10-10,2019-08-14,6IJL,3494.0,1.0,428.0,100.0,,50.25,1.0,2.351,experimental,27.8926,0.316,0.2809,Crystal structure of SmyD3 in complex with covalent inhibitor 5
4YCX,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris, 20% PEG 8K, 0.2M MgCl2",294.0,2015-02-20,2015-08-05,4YCX,3305.0,4.0,372.0,291.0,,45.67,1.0,2.1,experimental,,0.234,0.201,Binary complex of human DNA Polymerase Mu with 2-nt gapped DNA substrate
4YD1,X-RAY DIFFRACTION,2.68,54.03,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris, 20% PEG8K, 0.2M MgCl2",294.0,2015-02-20,2015-08-05,4YD1,3581.0,4.0,372.0,472.0,,46.29,1.0,1.75,experimental,,0.19,0.163,Ternary complex of human DNA Polymerase Mu with 2-nt gapped DNA substrate and an incoming nonhydrolyzable dUMPNPP
5XVG,X-RAY DIFFRACTION,2.05,40.08,VAPOR DIFFUSION,7.5,"0.1 M HEPES pH 7.5, 0.5M Magnesium formate dihydrate",291.0,2017-06-27,2018-02-07,5XVG,2473.0,1.0,293.0,97.0,,33.93,1.0,2.1,experimental,33.4953,0.2354,0.1815,Crystal Structure of PAK4 in complex with inhibitor CZH226
5NXD,X-RAY DIFFRACTION,2.3,46.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M bis-tris-propane pH 7.5
0.2 M Na2SO4
10% ethylene glycol
17% PEG3.35K",277.0,2017-05-10,2017-05-24,5NXD,4423.0,2.0,610.0,133.0,,70.61,1.0,1.9,experimental,28.856,0.23042,0.19485,LIM Domain Kinase 2 (LIMK2) In Complex With TH-300
8ELC,X-RAY DIFFRACTION,2.03,39.41,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Potassium phosphate dibasic, 20% w/v Polyethylene glycol 3,350",293.15,2022-09-23,2023-06-28,8ELC,3002.0,1.0,424.0,73.0,,48.78,1.0,2.072,experimental,47.94,0.2603,0.2078,Human JNK2 bound to covalent inhibitor YL2056
6JJR,X-RAY DIFFRACTION,2.24,45.21,"VAPOR DIFFUSION, HANGING DROP",7.2,"25% (w/v) polyethylene glycol (PEG) 3350, 0.2 M potassium sodium tartrate (PST) pH 7.2",277.0,2019-02-26,2020-02-19,6JJR,3322.0,1.0,381.0,365.0,2.0,43.12,1.0,1.834,experimental,,0.194,0.1672,Crystal structure of human chitotriosidase-1 (hChit1) catalytic domain in complex with compound 2-8-14
6JK6,X-RAY DIFFRACTION,2.31,46.64,"VAPOR DIFFUSION, HANGING DROP",7.2,"25% (w/v) polyethylene glycol (PEG) 3350, 0.2 M potassium sodium tartrate (PST), pH 7.2",277.0,2019-02-27,2020-02-19,6JK6,3282.0,1.0,381.0,355.0,2.0,43.56,1.0,1.571,experimental,,0.1875,0.1662,Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 2-8-s2
7MHD,X-RAY DIFFRACTION,1.97,37.64,"VAPOR DIFFUSION, SITTING DROP",,"0.3 ul of 8 mg/ml FASN-TE in 100 mM NaCl, 50 mM BisTris pH 6.0, 10 mM DTT, 0.5 mM of the inhibitor and 1% DMSO were mixed with 0.2 ul of well solution 10% PEG400, 50 mM TRIS-Cl pH 8.5, 1 mM DTT, 1 mM Ethylenediaminetetraacetic acid disodium salt (EDTA), 300 mM NaCl.",293.0,2021-04-15,2022-04-20,7MHD,2374.0,1.0,298.0,106.0,,32.93,1.0,2.03,experimental,42.494,0.2457,0.1928,Thioesterase Domain of Human Fatty Acid Synthase (FASN-TE) binding a competitive inhibitor SBP-7635
7Q8H,X-RAY DIFFRACTION,2.72,54.76,"VAPOR DIFFUSION, SITTING DROP",,"77% MPD, 23 % of 60 mM TRIS, pH 8",277.0,2021-11-11,2022-11-23,7Q8H,4039.0,4.0,460.0,420.0,6.0,51.09,2.0,1.75,experimental,27.79,0.1842,0.1623,Peptide EVCKKKK in complex with human cathepsin V C25A mutant
5I7P,X-RAY DIFFRACTION,3.02,59.23,"VAPOR DIFFUSION, HANGING DROP",,"20 % PEG3350, 0.1 M MgCl2, 0.1 M Hepes pH 7.5",293.0,2016-02-18,2017-03-08,5I7P,1421.0,1.0,161.0,205.0,,18.11,1.0,2.002,experimental,,0.2483,0.2189,"Crystal structure of Fkbp12-IF(SlyD), a chimeric protein of human Fkbp12 and the insert in flap domain of Ecoli SlyD"
6RPS,X-RAY DIFFRACTION,3.59,65.75,"VAPOR DIFFUSION, HANGING DROP",5.5,"1.5M AMMONIUM SULFATE
0.1M SODIUM ACETATE
0.02M CADMIUM CHLORIDE",293.0,2019-05-14,2019-11-13,6RPS,10838.0,6.0,1456.0,23.0,10.0,160.61,3.0,2.79,experimental,36.415,0.2308,0.2026,X-ray crystal structure of carbonic anhydrase XII complexed with a theranostic monoclonal antibody fragment
6R51,X-RAY DIFFRACTION,2.78,55.76,"VAPOR DIFFUSION, SITTING DROP",,"1 microl 12 mg per ml rPPEP-1 E143A Y178F with 6 mM substrate peptide in 20 mM Tris pH 7.5, 200 mM NaCl was mixed with 2 microl precipitant solution containing: 100 mM Tris pH 8.5, 2.1 M ammonium phosphate dibasic. Reservoir volume: 200 microl",293.15,2019-03-24,2019-06-12,6R51,5235.0,6.0,618.0,432.0,,68.11,2.0,1.94,experimental,,0.1787,0.1545,Crystal structure of apo PPEP-1(E143A/Y178F) in complex with fibrinogen-derived substrate peptide Ac-SLRPAPP-CONH2
6TEI,X-RAY DIFFRACTION,3.05,59.66,"VAPOR DIFFUSION, SITTING DROP",,"reservoir composition: 30 % (w/v) PEG8000, 0.2 M ammonium sulfate, 0.1 M sodium cacodylate, pH 6.5;
crystallization drop composition before equilibration: 0.01  ml  reservoir solution plus 0.02 ml enzyme stock solution (6 mg/ml enzyme, 0.5 M NaCl, 25 mM Tris/HCl, pH 8.5); the 2-aminothiazole-type inhibitor 17 was introduced by extensive soaking",293.0,2019-11-12,2020-07-08,6TEI,6076.0,2.0,698.0,387.0,,84.25,1.0,1.756,experimental,42.58,0.2044,0.1817,Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the 2-aminothiazole-type inhibitor 17
6E08,X-RAY DIFFRACTION,2.39,48.52,"VAPOR DIFFUSION, SITTING DROP",7.3,"20% w/v PEG 3350, 0.2 M potassium formate",293.0,2018-07-06,2018-07-25,6E08,4430.0,1.0,515.0,406.0,,60.54,1.0,1.9,experimental,24.422,0.21258,0.17182,Crystal structure of G6PD in complex with structural NADP
5TYZ,X-RAY DIFFRACTION,2.67,53.92,"VAPOR DIFFUSION, SITTING DROP",7.5,"85-90mM HEPES pH 7.5, 17-18% PEG4000",277.0,2016-11-21,2017-08-30,5TYZ,3458.0,4.0,374.0,325.0,,46.64,1.0,1.977,experimental,36.3937,0.2149,0.1755,"DNA Polymerase Mu Product Complex, Mn2+ (960 min)"
6WCV,X-RAY DIFFRACTION,2.26,45.69,"VAPOR DIFFUSION, HANGING DROP",,"17.5% (w/v) polyethylene glycol 3350, 180 mM ammonium tartrate pH 7.0, 100 mM MES pH 6.4",294.0,2020-03-31,2020-07-15,6WCV,5985.0,2.0,710.0,617.0,,77.05,2.0,1.52,experimental,25.0089,0.184,0.1673,Tartryl-CoA bound to human GTP-specific succinyl-CoA synthetase
5ISL,X-RAY DIFFRACTION,2.21,44.23,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-15,2016-07-27,5ISL,2577.0,1.0,330.0,167.0,,38.46,1.0,1.694,experimental,,0.2019,0.1701,Linked KDM5A Jmj Domain Bound to the Inhibitor C49 (2-{[(2-{[(E)-2-(dimethylamino)ethenyl](ethyl)amino}-2-oxoethyl)amino]methyl}pyridine-4-carboxylic acid)
6IUX,X-RAY DIFFRACTION,2.03,39.52,"VAPOR DIFFUSION, SITTING DROP",,"0.2M ammonium chloride pH 6.3, 20% PEG-3350",291.0,2018-12-01,2019-12-04,6IUX,3290.0,1.0,379.0,423.0,,42.56,1.0,1.195,experimental,,0.1828,0.1591,Crystal structure of a hydrolase protein
5KQP,X-RAY DIFFRACTION,2.11,41.67,"VAPOR DIFFUSION, HANGING DROP",6.5,"Crystals grew under the following condition: 30% PEGME 5000, 0.2 M ammonium sulfate, 100 mM MES buffer, pH=6.5. Then crystal were transferred to buffer containing 30% PEGME 5000, 0.2 M ammonium sulfate, 100 mM Bis-Tris, pH=6.5 to deplete the bound MES.",293.0,2016-07-06,2016-10-12,5KQP,1307.0,1.0,178.0,69.0,,20.24,1.0,2.052,experimental,,0.2663,0.1931,Crystal structure of Apo-form LMW-PTP
6PXO,X-RAY DIFFRACTION,2.24,45.05,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.15 M Succinic Acid
17% PEG 3350",295.0,2019-07-26,2020-02-12,6PXO,5012.0,2.0,588.0,285.0,,68.41,1.0,2,experimental,,0.2375,0.1791,Human Casein Kinase 1 delta (anion-free crystallization conditions)
6ALZ,X-RAY DIFFRACTION,2.56,51.89,"VAPOR DIFFUSION, HANGING DROP",8.0,"20% PEG 6000, 1 M lithium chloride, 0.1 M Tris pH 8.0",298.0,2017-08-08,2017-11-29,6ALZ,5101.0,2.0,598.0,288.0,,70.01,1.0,2.208,experimental,,0.2158,0.1842,Crystal structure of Protein Phosphatase 1 bound to the natural inhibitor Tautomycetin
6P1S,X-RAY DIFFRACTION,2.861,57.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM HEPES pH 7.5, 100mM NaCl, 10% PEG4000",277.0,2019-05-20,2019-09-04,6P1S,3403.0,4.0,372.0,340.0,,46.31,1.0,1.75,experimental,,0.1959,0.172,Post-catalytic nicked complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG and newly incorporated AMP
5G3N,X-RAY DIFFRACTION,2.25,45.27,,,3.0-3.5M SODIUM FORMATE AND 100MM HEPES PH 7.5,,2016-04-29,2016-09-14,5G3N,2238.0,2.0,254.0,227.0,14.0,29.41,1.0,1.8,experimental,25.77,0.231,0.1947,Discovery of a novel secreted phospholipase A2 (sPLA2) inhibitor.
7N3L,X-RAY DIFFRACTION,2.13,42.31,"VAPOR DIFFUSION, HANGING DROP",,"17.5% PEG 3350, 0.4M Calcium chloride",290.0,2021-06-01,2022-02-23,7N3L,3979.0,1.0,474.0,366.0,,55.59,1.0,1.631,experimental,20.756,0.2004,0.1669,Co-complex CYP46A1 with 0420 (compound 6)
6N0J,X-RAY DIFFRACTION,2.3,46.58,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Hepes, pH 7.5, 8% Ethylene Glycol, 20% PEG 8000",298.0,2018-11-07,2019-07-10,6N0J,2565.0,1.0,301.0,274.0,,34.06,1.0,1.79,experimental,,0.2056,0.1711,The complex of CCG-222740 bound to pirin
6N0K,X-RAY DIFFRACTION,2.27,45.91,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Hepes pH 7.5, 8% Ethylene Glycol, 20% PEG 8000",295.0,2018-11-07,2019-07-10,6N0K,2713.0,1.0,301.0,404.0,,34.21,1.0,1.46,experimental,,0.2089,0.1774,The complex of CCG-257081 bound to pirin
7B96,X-RAY DIFFRACTION,2.03,39.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"10mg/mL protein in 20mM Tris pH 7.5, 150mM NaCl, 20% (v/v) glycerol and 1mM DTT was added at a 1:1 ratio to the reservoir buffer: 0.2M potassium chloride and 24% (w/v) polyethylene glycol 3350 pH 7.5",293.0,2020-12-14,2022-01-12,7B96,4633.0,2.0,560.0,377.0,,60.24,1.0,1.8,experimental,34.11,0.2192,0.1771,NHL domain of human TRIM2
8FII,X-RAY DIFFRACTION,2.63,53.2,"VAPOR DIFFUSION, HANGING DROP",6.6,"A3A (50 mM MES pH 6.0, 100 mM NaCl, 1 mM TCEP, 0.2 mM EDTA) was mixed with oligonucleotides (10 mM Tris/HCl pH 7.9, 1 mM EDTA) at 0.85 mM and 1.7 mM respectively. Dilution was done with protein buffer. The mixture was added to crystallization liquid 1 to 1 and the mixture was pipetted on siliconized glass disks and sealed on top of a reservoir of crystallization liquid for hanging drop crystallization at 12 degrees Celsius. The crystallization liquid has the following composition: 100 mM Bicine at  pH 6.6, 200 mM NaCl, 20 mM putrescine, 1 mM TCEP, 1 mM inositol hexa phosphate (phytic acid) and 45 % pentaerythritol propoxylate (5/4 PO/OH)",285.0,2022-12-16,2023-09-06,8FII,3375.0,4.0,420.0,,,53.57,1.0,2.94,experimental,54.095,0.3103,0.2512,Wild type APOBEC3A in complex with TT(FdZ)-hairpin inhibitor (crystal form 1)
8FIJ,X-RAY DIFFRACTION,2.3,46.65,"VAPOR DIFFUSION, HANGING DROP",,"A3A-E72A (50 mM MES pH 6.0, 100 mM NaCl, 1 mM TCEP, 0.2 mM EDTA) was mixed with oligonucleotides (10 mM Tris/HCl pH 7.9, 1 mM EDTA) at 0.85 mM and 1.7 mM respectively. Dilution was done with protein buffer. The mixture was added to crystallization liquid 1 to 1 and the mixture was pipetted on siliconized glass disks and sealed on top of a reservoir of crystallization liquid for hanging drop crystallization at 12 degrees Celsius. The crystallization liquid has the following composition: 100 mM Bicine at  pH 6.6, 200 mM NaCl, 20 mM putrescine, 1 mM TCEP, 1 mM inositol hexaphosphate (phytic acid) and 45 % pentaerythritol propoxylate (5/4 PO/OH)",285.0,2022-12-16,2023-09-06,8FIJ,3362.0,4.0,422.0,2.0,,54.08,1.0,2.799,experimental,60.975,0.3182,0.2577,Wild type APOBEC3A in complex with TT(FdZ)-hairpin inhibitor (crystal form 2)
8FIL,X-RAY DIFFRACTION,2.6,52.81,"VAPOR DIFFUSION, HANGING DROP",6.6,"A3A-E72A (50 mM MES pH 6.0, 100 mM NaCl, 1 mM TCEP, 0.2 mM EDTA) was mixed with oligonucleotides (10 mM Tris/HCl pH 7.9, 1 mM EDTA) at 0.85 mM and 1.7 mM respectively. Dilution was done with protein buffer. The mixture was added to crystallization liquid 1 to 1 and the mixture was pipetted on siliconized glass disks and sealed on top of a reservoir of crystallization liquid for hanging drop crystallization at 12 degrees Celsius. The crystallization liquid has the following composition: 100 mM Bicine at  pH 6.6, 200 mM NaCl, 20 mM putrescine, 1 mM TCEP, 1 mM inositol hexaphosphate (phytic acid) and 45 % pentaerythritol propoxylate (5/4 PO/OH)",285.0,2022-12-16,2023-09-06,8FIL,3715.0,4.0,424.0,81.0,,55.23,1.0,2.01,experimental,43.944,0.26586,0.23118,Zinc-free APOBEC3A (inactive E72A mutant) in complex with TTC-hairpin DNA substrate
4YUO,X-RAY DIFFRACTION,2.82,56.36,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-05-20,4YUO,2235.0,1.0,165.0,184.0,,18.04,1.0,1.2,experimental,,0.1463,0.127,High-resolution multiconformer synchrotron model of CypA at 273 K
5HBF,X-RAY DIFFRACTION,2.09,41.16,VAPOR DIFFUSION,,"15% PEG3350, 0.02 M HEPES, pH 6.8, 0.2% MPD, 0.2% 1,2,3-heptanetriol, 0.2% diethylenetriaminepentakis, 0.2% D-sorbitol, 0.2% glycerol",293.0,2015-12-31,2016-05-04,5HBF,6949.0,2.0,960.0,175.0,10.0,107.19,1.0,1.95,experimental,,0.2454,0.2051,Crystal structure of human full-length chitotriosidase (CHIT1)
6JLE,X-RAY DIFFRACTION,3.0,59.0,VAPOR DIFFUSION,5.6,"0.5 M ammonium sulfate, 1.0 M lithium sulfate, 0.1 M sodium citrate tribasic pH 5.6",289.0,2019-03-05,2019-07-24,6JLE,1729.0,2.0,196.0,133.0,,22.53,2.0,1.55,experimental,25.6637,0.186,0.1608,Crystal structure of MORN4/Myo3a complex
4XI7,X-RAY DIFFRACTION,2.66,53.77,"VAPOR DIFFUSION, HANGING DROP",,"Protein at 6 mg/mL in 25 mM HEPES 7.4, 500 mM NaCl, 10% w/v glucose, 100 mM Arg, 2 mM TCEP
Precipitant: 1.5 M (NH4)2SO4, 20% v/v glycerol, HEPES pH 7.6
1:1 drop volume",293.15,2015-01-06,2015-03-18,4XI7,3053.0,2.0,391.0,161.0,,43.75,2.0,2.051,experimental,44.892,0.2236,0.1967,Crystal structure of the MZM-REP domains of Mind bomb 1 in complex with Jagged1 N-box peptide
8SWB,X-RAY DIFFRACTION,2.19,43.85,"VAPOR DIFFUSION, HANGING DROP",4.0,"1:1 complex : precipitant (0.8 M ammonium sulfate, 0.1 M citrate, pH 4.0), cryoprotection: mother liquor + 1.75 M ammonium sulfate, 1 minute",293.0,2023-05-18,2024-05-22,8SWB,2226.0,3.0,189.0,110.0,,30.11,1.0,2,experimental,,0.2238,0.1836,RNase H complex with streopure ASO and RNA
5M4K,X-RAY DIFFRACTION,3.08,60.02,VAPOR DIFFUSION,5.8,"0.1 M SODIUM ACETATE PH 5.8
0.125 M MAGNESIUM CHLORIDE
6% ISOPROPANOL",277.0,2016-10-18,2017-02-22,5M4K,2824.0,1.0,408.0,65.0,,47.02,1.0,2.6,experimental,65.354,0.27289,0.21233,Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
5M4M,X-RAY DIFFRACTION,3.08,60.06,VAPOR DIFFUSION,5.8,"0.1 M SODIUM ACETATE PH 5.8
0.125 M MAGNESIUM CHLORIDE
6% ISOPROPANOL",277.0,2016-10-18,2017-02-22,5M4M,2926.0,1.0,408.0,107.0,,47.28,1.0,2.4,experimental,59.832,0.2617,0.21663,Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
5M4N,X-RAY DIFFRACTION,3.11,60.5,VAPOR DIFFUSION,5.8,"0.1 M SODIUM ACETATE PH 5.8
0.125 M MAGNESIUM CHLORIDE
6% ISOPROPANOL",277.0,2016-10-18,2017-02-22,5M4N,2823.0,1.0,408.0,77.0,,47.22,1.0,2.6,experimental,76.632,0.25958,0.20269,Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
5M4P,X-RAY DIFFRACTION,3.16,61.03,VAPOR DIFFUSION,5.8,"0.1 M SODIUM ACETATE PH 5.8
0.125 M MAGNESIUM CHLORIDE
6% ISOPROPANOL",277.0,2016-10-18,2017-02-22,5M4P,2935.0,1.0,408.0,121.0,,47.25,1.0,2.3,experimental,54.98,0.25178,0.19951,Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase
6XMI,X-RAY DIFFRACTION,2.57,52.08,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2 M Succinic acid pH 7.0 and 20% w/v Polyethylene glycol 3,350",292.0,2020-06-30,2020-08-19,6XMI,8069.0,6.0,982.0,807.0,8.0,106.58,3.0,1.51,experimental,37.3203,0.2032,0.1672,Structure of Fab4 bound to P22 TerL(1-33)
5NR8,X-RAY DIFFRACTION,2.27,45.88,"VAPOR DIFFUSION, HANGING DROP",,"25% (w/v) polyethylene glycol (PEG) 3350, 200 mM potassium sodium tartrate (PST) at pH 7.2",290.0,2017-04-22,2018-02-21,5NR8,3440.0,1.0,377.0,229.0,2.0,43.16,1.0,1.349,experimental,,,,Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 7a
5NRA,X-RAY DIFFRACTION,2.25,45.35,"VAPOR DIFFUSION, HANGING DROP",,"25% (w/v) polyethylene glycol (PEG) 3350, 200 mM potassium sodium tartrate (PST) at pH 7.2",290.0,2017-04-22,2018-03-28,5NRA,3472.0,1.0,377.0,379.0,2.0,42.74,1.0,1.267,experimental,,0.163,0.1369,Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 7g
8PAR,X-RAY DIFFRACTION,2.21,44.23,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M TRIS pH 8.0, 20 % MPD",293.0,2023-06-08,2024-06-26,8PAR,2215.0,1.0,308.0,47.0,,35.03,1.0,2,experimental,56.109,0.29244,0.23953,"Crystal structure of human MAP4K1 with an inhibitor, BAY-405"
5TD4,X-RAY DIFFRACTION,2.32,47.07,EVAPORATION,7.5,"MPD 50-58%, 0.1M sodium cacodylate. After crystal reached full size they were soaked in 200mM octaose for 24h prior to data collection, and then infused with a further aliquot of octaose just before freezing the complexed crystal in liquid nitrogen for use in X-ray diffraction analyses.",293.0,2016-09-16,2016-11-02,5TD4,4352.0,1.0,496.0,157.0,5.0,59.66,1.0,2.3,experimental,,0.1886,0.1511,Starch binding sites on the Human pancreatic alpha amylase D300N variant complexed with an octaose substrate.
5FPA,X-RAY DIFFRACTION,2.49,50.69,,7.4,"0.1M HEPES, PH 7.4, 2.2M AMSO4",,2015-11-27,2016-01-27,5FPA,3350.0,1.0,334.0,563.0,,39.49,1.0,1.96,experimental,24.873,0.2106,0.16928,"Crystal structure of human KDM4D in complex with 3H,4H-pyrido-3,4-d- pyrimidin-4-one"
5FPB,X-RAY DIFFRACTION,2.48,50.37,,7.4,"0.1M HEPES PH 7.4, 2.45M AMMONIUM SULPHATE",,2015-11-27,2016-01-27,5FPB,3284.0,1.0,334.0,472.0,,39.56,1.0,1.91,experimental,25.725,0.20319,0.16035,"Crystal structure of human KDM4D in complex with 2-1H-pyrazol-4-yloxy- 3H,4H-pyrido-3,4-d-pyrimidin-4-one"
4X09,X-RAY DIFFRACTION,1.79,31.27,"VAPOR DIFFUSION, HANGING DROP",6.5,"2M AMMONIUM SULPHATE, 0.1M SODIUM, CACODYLATE, 0.05M SODIUM CHLORIDE, PH 6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293 K",293.0,2014-11-21,2016-04-06,4X09,1225.0,1.0,128.0,131.0,4.0,15.28,1.0,1.722,experimental,31.98,0.2267,0.1928,Structure of human RNase 6 in complex with sulphate anions
5QTW,X-RAY DIFFRACTION,3.44,64.2,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2019-11-13,2020-01-29,5QTW,2151.0,1.0,244.0,189.0,4.0,29.28,1.0,2.12,experimental,25.63,0.248,0.22,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecine-2-carboxylate"
5QTY,X-RAY DIFFRACTION,3.42,64.0,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2019-11-13,2020-01-29,5QTY,2170.0,1.0,244.0,198.0,5.0,29.24,1.0,1.89,experimental,29.4,0.1712,0.1546,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-15-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecine-2-carboxylate"
5KHW,X-RAY DIFFRACTION,2.05,39.95,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG1500, 8% MPD, 0.1M Tris pH 9.0",281.0,2016-06-16,2016-11-09,5KHW,4665.0,2.0,632.0,84.0,,73.74,1.0,2.47,experimental,49.51,0.2312,0.1851,Crystal structure of JAK1 in complex with ADP
4QJC,X-RAY DIFFRACTION,2.51,50.9,"VAPOR DIFFUSION, HANGING DROP",6.0,"30% AmSO4, 3% v/v ETOH, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 287K",287.0,2014-06-03,2015-06-10,4QJC,1678.0,1.0,186.0,105.0,,22.42,1.0,1.62,experimental,23.247,0.2177,0.18328,"Human dihydrofolate reductase ternary complex with NADPH and inhibitor 26 (N~6~-METHYL-N~6~-(3,4,5-TRIFLUOROPHENYL)PYRIDO[2,3-D]PYRIMIDINE-2,4,6-TRIAMINE)"
5HKG,X-RAY DIFFRACTION,2.51,51.04,"VAPOR DIFFUSION, HANGING DROP",7.0,"16 % PEG 8K, 10% Glycerol, 500 mM KCl, 100 mM Hepes",293.0,2016-01-14,2016-10-05,5HKG,1077.0,1.0,107.0,147.0,,12.94,1.0,1.5,experimental,22.88,0.1936,0.1723,"Total chemical synthesis, refolding and crystallographic structure of a fully active immunophilin: calstabin 2 (FKBP12.6)."
6QJE,X-RAY DIFFRACTION,2.98,58.77,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MOPS/sodium HEPES pH 7.0-7.5, 40-50 % Morpheus Precipitant Mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1 M Morpheus Carboxylic acids mix (0.02M each of:sodium formate, ammonium acetate, sodium citrate tribasic dehydrate, sodium potassium tartrate tetrahydrate and sodium oxamate).",293.0,2019-01-24,2019-02-27,6QJE,11053.0,4.0,1568.0,172.0,2.0,171.26,1.0,2.4,experimental,60.7607,0.269,0.217,"Structure of human galactokinase 1 bound with 4-{[2-(Methylsulfonyl)-1H-imidazol-1-yl]methyl}-1,3-thiazole"
5X02,X-RAY DIFFRACTION,3.02,59.21,"VAPOR DIFFUSION, HANGING DROP",6.7,"2.2-2.4M Na/K Phosphate, 0.1M CAPS (pH6.7), 0.2M Litium Sulfate",293.0,2017-01-19,2018-01-24,5X02,2485.0,1.0,347.0,12.0,,40.83,1.0,2.401,experimental,74.3646,0.2766,0.234,Crystal structure of the FLT3 kinase domain bound to the inhibitor FF-10101
9FA3,X-RAY DIFFRACTION,2.15,42.92,"VAPOR DIFFUSION, SITTING DROP",,"0.1M KSCN
25% PEG 3350",293.0,2024-05-10,2024-07-03,9FA3,4510.0,1.0,546.0,430.0,2.0,62.41,1.0,1.36,experimental,20.663,0.20472,0.17294,Gcase in complex with small molecule inhibitor 1
9FA6,X-RAY DIFFRACTION,2.14,42.45,"VAPOR DIFFUSION, SITTING DROP",,"F4
.1M KSCN
25% PEG 3350",293.0,2024-05-10,2024-07-03,9FA6,4580.0,1.0,546.0,457.0,2.0,63.15,1.0,1.49,experimental,18.557,0.23248,0.19763,Gcase in complex with small molecule inhibitor 1
9FAD,X-RAY DIFFRACTION,2.14,42.62,"VAPOR DIFFUSION, SITTING DROP",,"0.1M KSCN
25% PEG 3350",293.0,2024-05-10,2024-07-03,9FAD,4493.0,1.0,546.0,483.0,2.0,62.45,1.0,1.8,experimental,19.543,0.2202,0.17316,Gcase in complex with small molecule inhibitor 1
9FAL,X-RAY DIFFRACTION,2.15,42.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1M KSCN
25% PEG 3350",293.0,2024-05-10,2024-07-03,9FAL,4607.0,1.0,546.0,507.0,2.0,62.9,1.0,1.39,experimental,22.405,0.18266,0.1541,Gcase in complex with small molecule inhibitor 1
9FAY,X-RAY DIFFRACTION,2.15,42.73,"VAPOR DIFFUSION, SITTING DROP",,"0.1M KSCN
25% PEG 3350",293.0,2024-05-10,2024-07-03,9FAY,4708.0,1.0,546.0,627.0,2.0,63.07,1.0,1.4,experimental,23.787,0.1831,0.14812,Gcase in complex with small molecule inhibitor 1
9FB2,X-RAY DIFFRACTION,2.13,42.33,"VAPOR DIFFUSION, SITTING DROP",,"0.1M KSCN
25% PEG 3350",293.0,2024-05-11,2024-07-03,9FB2,4832.0,1.0,546.0,680.0,2.0,63.3,1.0,1.14,experimental,17.029,0.1724,0.15666,Gcase in complex with small molecule inhibitor 1
9FDI,X-RAY DIFFRACTION,2.16,43.05,"VAPOR DIFFUSION, SITTING DROP",,"0.35M KSCN
28% PEG 3350",293.0,2024-05-17,2024-07-03,9FDI,4550.0,1.0,546.0,471.0,2.0,62.76,1.0,1.41,experimental,21.631,0.18319,0.15678,Gcase in complex with small molecule inhibitor 1
6TSZ,X-RAY DIFFRACTION,2.41,48.92,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M citrate pH 5.9, 15% 2 propanol, 6% PEG4K",277.0,2019-12-22,2020-01-01,6TSZ,2346.0,1.0,305.0,83.0,,35.03,1.0,1.9,experimental,34.45,0.2534,0.2008,The ULK4 Pseudokinase Domain Bound To ATPgammaS
8EXK,X-RAY DIFFRACTION,3.63,66.14,"VAPOR DIFFUSION, HANGING DROP",,"14% PEG 8K, 0.10 M Mg Acetate, 0.1 M MES (pH 6.5)",281.15,2022-10-25,2023-07-05,8EXK,2522.0,2.0,313.0,105.0,,36.49,2.0,2.096,experimental,54.6596,0.2502,0.2159,Crystal structure of PTP1B D181A/Q262A phosphatase domain with JAK2 activation loop phosphopeptide
7Q0D,X-RAY DIFFRACTION,2.37,48.03,"VAPOR DIFFUSION, SITTING DROP",,"Crystallization buffer: 0.1 M Tris-HCl (pH 8.5), 0.2 M ammonium acetate and 24% PEG4000",291.0,2021-10-14,2022-01-12,7Q0D,5464.0,2.0,522.0,836.0,,60.85,1.0,1.24,experimental,17.893,0.1577,0.1309,Human carbonic anhydrase I in complex with Methyl 2-(benzenesulfonyl)-4-chloro-5-sulfamoylbenzoate
6DBN,X-RAY DIFFRACTION,2.03,39.5,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M Tris pH 8.5, 6-9% MPD, 24-29% PEG-1500",298.0,2018-05-03,2018-08-29,6DBN,2421.0,1.0,316.0,91.0,,36.81,1.0,2.48,experimental,55.89,0.2619,0.186,Jak1 with compound 23
7AP7,X-RAY DIFFRACTION,1.86,33.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"1.25M (NH4)2SO4, 0.1M cacodylate pH 6.5, 10 mM Tris pH 7, 14.4 TP buffer",293.0,2020-10-16,2021-08-25,7AP7,1261.0,1.0,130.0,164.0,5.0,14.98,1.0,1.15,experimental,16.58,0.1927,0.1606,Structure of the W64R amyloidogenic variant of human lysozyme
5F20,X-RAY DIFFRACTION,2.31,46.74,"VAPOR DIFFUSION, SITTING DROP",6.0,"15% PEG 5000 MME, and 100 mM Sodium Citrate (pH 6.0)",293.0,2015-12-01,2016-01-13,5F20,2299.0,1.0,301.0,31.0,,35.17,1.0,2.91,experimental,96.157,0.2877,0.2013,"Structure of TYK2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1-methylpyrazol-3-yl)-1~{H}-pyrazolo[4,3-c]pyridin-4-one"
5I7Q,X-RAY DIFFRACTION,2.25,45.29,"VAPOR DIFFUSION, HANGING DROP",,"25 % PEG1500, 10 % isopropanol, 0.1 M CaCl2, 0.1 M Mes pH 6.5",293.0,2016-02-18,2017-03-08,5I7Q,1483.0,1.0,162.0,259.0,,18.12,1.0,1.9,experimental,,0.2383,0.2033,"Crystal structure of Fkbp12-IF(SlpA), a chimeric protein of human Fkbp12 and the insert in flap domain of Ecoli SlpA"
5R7X,X-RAY DIFFRACTION,2.79,55.94,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5R7X,6277.0,2.0,744.0,707.0,,86.44,1.0,1.44,experimental,29.205,0.2066,0.1866,PanDDA analysis group deposition of ground-state model of Human JMJD1B
5RAD,X-RAY DIFFRACTION,2.79,55.86,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAD,6283.0,2.0,744.0,695.0,,86.67,1.0,1.9,experimental,35.955,0.2194,0.1802,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001568a
5RAE,X-RAY DIFFRACTION,2.75,55.26,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAE,6284.0,2.0,744.0,693.0,,86.68,1.0,1.88,experimental,38.125,0.2221,0.1802,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001558a
5RAH,X-RAY DIFFRACTION,2.78,55.69,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAH,6283.0,2.0,744.0,696.0,,86.69,1.0,1.66,experimental,31.447,0.2052,0.1803,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010032a
5RAI,X-RAY DIFFRACTION,2.78,55.75,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAI,6267.0,2.0,744.0,684.0,,86.63,1.0,1.54,experimental,33.952,0.2176,0.1908,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS040404c
5RAK,X-RAY DIFFRACTION,2.8,56.06,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAK,6286.0,2.0,744.0,704.0,,86.61,1.0,1.69,experimental,31.198,0.2127,0.1817,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS040486b
5RAL,X-RAY DIFFRACTION,2.78,55.8,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAL,6251.0,2.0,744.0,658.0,,86.62,1.0,1.68,experimental,35.588,0.2213,0.1888,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS039332c
5RAN,X-RAY DIFFRACTION,2.78,55.81,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAN,6274.0,2.0,744.0,683.0,,86.68,1.0,1.95,experimental,41.547,0.2248,0.1828,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS039080d
5RAO,X-RAY DIFFRACTION,2.78,55.72,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAO,6305.0,2.0,744.0,708.0,,86.77,1.0,1.59,experimental,32.548,0.2086,0.1818,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001084a
5RAQ,X-RAY DIFFRACTION,2.77,55.63,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAQ,6301.0,2.0,744.0,700.0,,86.9,1.0,1.85,experimental,36.692,0.2162,0.1809,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001577a
5RAR,X-RAY DIFFRACTION,2.81,56.2,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAR,6295.0,2.0,744.0,705.0,,86.92,1.0,1.47,experimental,27.374,0.2056,0.1829,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with TD000005c
5RAS,X-RAY DIFFRACTION,2.81,56.23,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAS,6293.0,2.0,744.0,704.0,,86.66,1.0,1.58,experimental,30.018,0.216,0.1916,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS036302b
5RAU,X-RAY DIFFRACTION,2.79,55.89,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAU,6278.0,2.0,744.0,696.0,,86.67,1.0,1.73,experimental,31.732,0.2086,0.177,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with DA000165b
5RAX,X-RAY DIFFRACTION,2.79,55.86,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAX,6280.0,2.0,744.0,693.0,,86.63,1.0,2.01,experimental,40.473,0.2311,0.1836,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010054a
5RB0,X-RAY DIFFRACTION,2.77,55.63,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RB0,6273.0,2.0,744.0,684.0,,86.66,1.0,1.95,experimental,39.771,0.2449,0.198,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010020a
5RB1,X-RAY DIFFRACTION,2.79,55.85,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RB1,6287.0,2.0,744.0,696.0,,86.62,1.0,1.76,experimental,32.61,0.2139,0.1813,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001700a
5RB2,X-RAY DIFFRACTION,2.79,55.96,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RB2,6293.0,2.0,744.0,698.0,,86.74,1.0,1.52,experimental,31.951,0.2079,0.1841,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001784a
5RB5,X-RAY DIFFRACTION,2.81,56.24,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RB5,6324.0,2.0,744.0,698.0,,87.09,1.0,1.51,experimental,27.578,0.2085,0.1851,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010010a
5ULW,X-RAY DIFFRACTION,2.67,53.93,"VAPOR DIFFUSION, SITTING DROP",6.0,"50 mM MES, pH 6.0, 18 % PEG 5KMME, 0.4 M Ammonium Sulfate",277.0,2017-01-25,2017-04-19,5ULW,3224.0,3.0,438.0,87.0,,53.02,1.0,2.617,experimental,,0.2484,0.2038,Structure of human DNA polymerase iota bound to template 1-methyl-deoxyadenosine
5ULX,X-RAY DIFFRACTION,2.67,53.88,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 14 % PEG 5KMME, 0.4 M Ammonium Sulfate",277.0,2017-01-25,2017-04-19,5ULX,3416.0,3.0,438.0,291.0,,52.51,1.0,1.96,experimental,,0.239,0.216,Structure of human DNA polymerase iota bound to template 1-methyl-deoxyadenosine crystallized in the presence of dCTP
5LY1,X-RAY DIFFRACTION,2.47,50.33,"VAPOR DIFFUSION, SITTING DROP",9.0,0.1 M propionate-cacodylate-bistris propane pH 9.0 and 25 % w/v polyethylene glycol 1500,277.0,2016-09-23,2017-04-12,5LY1,11711.0,5.0,1538.0,405.0,,180.5,2.0,2.5,experimental,52.0,0.205,0.178,JMJD2A/ KDM4A COMPLEXED WITH NI(II) AND Macrocyclic PEPTIDE Inhibitor CP2 (13-mer)
6C5Z,X-RAY DIFFRACTION,2.84,56.74,"VAPOR DIFFUSION, HANGING DROP",8.8,"20% PEG3350, 50 mM dipotassium phosphate, 100 mM sodium glycine",293.0,2018-01-17,2019-01-23,6C5Z,21261.0,6.0,2964.0,294.0,,337.54,1.0,2.95,experimental,,0.2589,0.2032,Human UDP-Glucose Dehydrogenase A225L substitutuion with UDP-glucose and NADH bound
8P8C,X-RAY DIFFRACTION,1.94,36.56,"VAPOR DIFFUSION, HANGING DROP",9.0,"0.1 M bicine/NaOH pH 9.0, 20% w/v PEG 6000",277.0,2023-05-31,2023-07-26,8P8C,2212.0,1.0,256.0,171.0,5.0,30.61,1.0,1.653,experimental,26.11,0.244,0.2024,HUMAN CD38 ECTODOMAIN BOUND TO COMPOUND 9-ADPR ADDUCT
6Q90,X-RAY DIFFRACTION,2.96,58.51,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MOPS/sodium HEPES, pH 7-7.5; 40-50% morpheus precipitant mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1M morpheus carboxylic acids mix (0.02M each of: sodium formate, ammonium acetate, sodium citrate tribasic dihydrate, sodium oxamate, potassium sodium tartrate tetrahydrate",293.0,2018-12-16,2019-01-23,6Q90,11344.0,4.0,1568.0,231.0,2.0,170.92,1.0,2.4,experimental,43.633,0.2766,0.2201,Structure of human galactokinase 1 bound with 1-(4-Methoxyphenyl)-3-(4-pyridinyl)urea
6Q91,X-RAY DIFFRACTION,2.96,58.52,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MOPS/sodium HEPES, 40-50% Morpheus precipitant mix 4 (50% mix = 12.5% MPD, 12.5% PEG1000, 12.5% PEG3350), 0.1M morpheus carboxylic acids mix (0.02M each of sodium formate, ammonium actetate, sodium citrate tribasic dihydrate, sodium oxamate, potassium sodium tartrate tetrahydrate",293.0,2018-12-17,2019-01-23,6Q91,11516.0,4.0,1568.0,325.0,2.0,171.4,1.0,2.4,experimental,44.518,0.2855,0.2159,Structure of human galactokinase 1 bound with 5-Chloro-N-isobutyl-2-methoxybenzamide
4U6P,X-RAY DIFFRACTION,2.92,57.82,"VAPOR DIFFUSION, HANGING DROP",,PEG 400 and potassium acetate,295.15,2014-07-29,2016-01-27,4U6P,7767.0,6.0,1096.0,103.0,,135.01,1.0,2.593,experimental,,0.239,0.2002,Structural mechanism of error-free bypass of major benzo[a]pyrene adduct by human polymerase kappa
7Z5X,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.66,"11% peg3350, 200mM AmSO4, PCTP 100mM pH 6.66. Grown in 15well plate. Seeded with previous crystals sent. ATP/Mg 10mM",293.15,2022-03-10,2022-08-17,7Z5X,4622.0,2.0,662.0,222.0,,76.25,1.0,2.035,experimental,39.72,0.2656,0.2267,ROS1 with AstraZeneca ligand 2
5A5J,X-RAY DIFFRACTION,2.57,52.08,,,,,2015-06-18,2016-08-03,5A5J,3717.0,1.0,477.0,,,55.38,1.0,2.9,experimental,59.203,0.28792,0.21303,Cytochrome 2C9 P450 inhibitor complex
8E8V,X-RAY DIFFRACTION,2.4,48.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2 M NaCl, 0.1M HEPES, 25% PEG 4000",300.0,2022-08-25,2022-10-05,8E8V,12739.0,4.0,1736.0,,,193.9,1.0,2.45,experimental,84.5537,0.2578,0.234,Structure of the short LOR domain of human AASS bound to N-ethylsuccinimide
8DYJ,X-RAY DIFFRACTION,2.38,48.27,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M lithium sulfate monohydrate, 0.1 M sodium acetate trihydrate, 54% PEG 400",293.0,2022-08-04,2023-07-12,8DYJ,5664.0,1.0,762.0,121.0,,86.59,1.0,2.2,experimental,65.7701,0.225,0.1949,Crystal structure of human methylmalonyl-CoA mutase in complex with ADP and cob(II)alamin
6SNP,X-RAY DIFFRACTION,2.26,45.51,"VAPOR DIFFUSION, HANGING DROP",,"Magnesium chloride, Polyethylene glycol monomethyl ether 550",298.15,2019-08-27,2020-04-08,6SNP,4469.0,1.0,583.0,57.0,,64.07,1.0,2.75,experimental,,0.2702,0.2086,Crystal structures of human PGM1 isoform 2
8TK6,X-RAY DIFFRACTION,2.02,39.25,"VAPOR DIFFUSION, SITTING DROP",,"Protein in 50 mM TRIS-Cl pH 8.5, 1 mM TCEP, 0.5 mM EDTA was mixed with the precipitant solution (100 mM Bis-Tris pH 6.5, 50 mM NH4F, 28% (w/v) PEG-4000) and equilibrated against the precipitant solution.",294.0,2023-07-25,2024-08-14,8TK6,3276.0,2.0,366.0,308.0,,40.57,1.0,1.65,experimental,16.04,0.18336,0.14595,HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) in apo form
7XC5,X-RAY DIFFRACTION,1.95,37.02,EVAPORATION,6.8,PEG 3350,289.0,2022-03-23,2023-01-18,7XC5,1316.0,1.0,198.0,29.0,,22.19,1.0,2.1,experimental,48.9111,0.2362,0.206,Crystal structure of the ANK domain of CLPB
6UV0,X-RAY DIFFRACTION,2.7,54.4,"VAPOR DIFFUSION, HANGING DROP",,"24% PEG, 0.26M NaSCN",298.0,2019-11-01,2020-01-01,6UV0,6761.0,2.0,896.0,98.0,,102.62,1.0,2.601,experimental,70.0,0.2595,0.213,Crystal structure of apo core domain of RNA helicase DDX17
8DYD,X-RAY DIFFRACTION,2.2,44.07,"VAPOR DIFFUSION, HANGING DROP",8.0,"200 mM Ammonium citrate tribasic pH 7.0, 20% w/v Polyethylene glycol 3,350",298.0,2022-08-04,2024-01-10,8DYD,6814.0,3.0,867.0,519.0,,100.56,3.0,1.52,experimental,24.06,0.1842,0.1567,Crystal structure of human SDHA-SDHAF2-SDHAF4 assembly intermediate
6YJM,X-RAY DIFFRACTION,1.89,34.85,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1M HEPES pH 7.0, 300% v/v Jeffamine ED-2001 pH 7.0",293.0,2020-04-03,2021-04-14,6YJM,3435.0,2.0,446.0,94.0,8.0,50.59,1.0,2.25,experimental,18.366,0.25563,0.2125,Crystal Structure of the Catalytic Domain of ADAMTS-5 in Complex with the Inhibitor GLPG1972
5ULH,X-RAY DIFFRACTION,2.73,54.94,"VAPOR DIFFUSION, HANGING DROP",,"200 mM potassium thiocyanate, 20% PEG 3350",289.0,2017-01-24,2017-06-07,5ULH,2289.0,3.0,320.0,68.0,,36.45,3.0,1.95,experimental,37.942,0.2174,0.1888,Structure of RNF165 in complex with a UbcH5b~Ub conjugate
7KZG,X-RAY DIFFRACTION,2.16,43.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG1000, HEPES",293.0,2020-12-10,2021-11-10,7KZG,1993.0,3.0,198.0,241.0,,28.38,1.0,1.68,experimental,27.4813,0.2046,0.1681,Human MBD4 glycosylase domain bound to DNA containing oxacarbenium-ion analog 1-aza-2'-deoxyribose
5AIU,X-RAY DIFFRACTION,2.32,46.96,,,"1,2-ETHANEDIOL",,2015-02-17,2015-07-08,5AIU,4591.0,5.0,593.0,33.0,,67.05,3.0,2.21,experimental,24.191,0.25541,0.21656,"A complex of RNF4-RING domain, Ubc13-Ub (isopeptide crosslink)"
5CJF,X-RAY DIFFRACTION,3.54,65.21,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.9 M ammonium sulfate, 0.1 M TRIS-HCl",293.0,2015-07-14,2015-11-04,5CJF,2513.0,1.0,279.0,228.0,1.0,32.93,1.0,1.83,experimental,20.99,0.216,0.197,"The crystal structure of the human carbonic anhydrase XIV in complex with a 1,1'-biphenyl-4-sulfonamide inhibitor."
8C5Q,X-RAY DIFFRACTION,3.22,61.77,"VAPOR DIFFUSION, HANGING DROP",6.5,"33% polyethylene glycol methyl ether 5000, 0.2 M ammonium sulfate, 0.1 MES pH 6.5",286.0,2023-01-10,2024-01-24,8C5Q,5781.0,2.0,718.0,54.0,,88.43,1.0,2.5,experimental,64.75,0.2553,0.2154,CK2 kinase bound to inhibitor AB668
6UK1,X-RAY DIFFRACTION,2.9,57.58,MICROBATCH,,"24% PEG 8000, 100 mM Li2SO4, 10mM NaBr, 100 mM Bis-Tris Propane pH 6.0",277.0,2019-10-03,2020-10-07,6UK1,7231.0,4.0,916.0,74.0,,104.34,1.0,2.693,experimental,52.7125,0.3036,0.2734,Crystal structure of nucleotide-binding domain 2 (NBD2) of the human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
7YL1,X-RAY DIFFRACTION,1.84,33.04,"VAPOR DIFFUSION, HANGING DROP",7.25,"PEG MME 550, ethylene glycol, HEPES",277.0,2022-07-25,2023-07-26,7YL1,2925.0,1.0,464.0,49.0,,52.93,1.0,2.48,experimental,43.157,0.2944,0.20356,Crystal structure of JNK3 in complex with a fragment molecule
5C7D,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277.0,2015-06-24,2015-08-12,5C7D,1058.0,1.0,110.0,171.0,,13.05,1.0,2.25,experimental,39.778,0.25123,0.20053,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 17
7Z28,X-RAY DIFFRACTION,2.32,47.06,"VAPOR DIFFUSION, SITTING DROP",,0.1 M SPG 7.0 25 % w/v PEG 1500,290.0,2022-02-26,2022-07-27,7Z28,8042.0,1.0,859.0,882.0,3.0,100.99,1.0,1.55,experimental,24.1324,0.1822,0.1649,High-resolution crystal structure of ERAP1 with bound bestatin analogue inhibitor
7ORE,X-RAY DIFFRACTION,2.39,48.63,"VAPOR DIFFUSION, SITTING DROP",7.8,"16% medium-molecular weight PEG smears (MMW PEG Smears) and 0.1 M HEPES, pH 7.8",277.15,2021-06-05,2021-07-21,7ORE,3076.0,1.0,365.0,56.0,,44.0,1.0,2.18,experimental,54.154,0.2759,0.2159,Crystal structure of JNK3 in complex with light-activated covalent inhibitor MR-II-249 with both non-covalent and covalent binding modes (compound 4)
6I99,X-RAY DIFFRACTION,2.35,50.1,"VAPOR DIFFUSION, SITTING DROP",8.0,"imidazole-malate, PEG 600",293.15,2018-11-22,2020-05-27,6I99,4510.0,2.0,556.0,126.0,,66.21,1.0,2.001,experimental,23.6,0.2586,0.2321,Bone Marrow Tyrosine Kinase in Chromosome X in complex with a newly designed covalent inhibitor JS24
6HHC,X-RAY DIFFRACTION,2.74,55.09,EVAPORATION,7.5,"20 mM Tris-HCl pH 7.5,75 mM NaCl",293.0,2018-08-27,2019-09-11,6HHC,5060.0,3.0,681.0,,8.0,74.66,3.0,2.7,experimental,38.936,0.3144,0.2274,"Allosteric Inhibition as a new mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated form of Coagulation Factor XI"
6R3D,X-RAY DIFFRACTION,2.46,49.92,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 3350, 200mM MgCl2, 100mM BisTris (pH 6.5)",293.0,2019-03-20,2020-04-08,6R3D,2834.0,1.0,337.0,97.0,,39.73,1.0,1.85,experimental,45.963,0.26457,0.2209,"Crystal structure of di-phosphorylated human CLK1 in complex with 4-(6,7-dichloro-1H-indol-3-yl)pyrimidin-2-amine"
6R6E,X-RAY DIFFRACTION,2.45,49.88,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 3350, 200mM MgCl2, 100mM BisTris (pH 6.5)",293.0,2019-03-27,2020-05-06,6R6E,2765.0,1.0,337.0,53.0,,39.74,1.0,2.25,experimental,57.429,0.25782,0.20613,"Crystal structure of di-phosphorylated human CLK1 in complex with 5-(6,7-dichloro-1-methyl-1H-indol-3-yl)pyrimidin-4-amine"
6R6X,X-RAY DIFFRACTION,2.47,50.11,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 3350, 200mM MgCl2, 100mM BisTris (pH 6.5)",293.0,2019-03-28,2020-05-06,6R6X,2853.0,1.0,337.0,117.0,,39.67,1.0,2.05,experimental,47.978,0.247,0.19859,Crystal structure of di-phosphorylated human CLK1 in complex with 5-(1-methyl-1H-indol-3-yl)pyrimidin-4-amine
7O9Y,X-RAY DIFFRACTION,2.45,49.8,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG3350, 200mM MgCl2, 100mM BisTris (pH 6.5)",293.0,2021-04-18,2022-05-04,7O9Y,2908.0,1.0,337.0,173.0,,39.66,1.0,1.66,experimental,36.683,0.24626,0.21709,Crystal structure of di-phosphorylated human CLK1 in complex with 4-(1H-indol-3-yl)pyrimidin-2-amine
7OA0,X-RAY DIFFRACTION,2.45,49.8,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG3350, 200mM MgCl2, 100mM BisTris (pH 6.5)",293.0,2021-04-18,2022-05-04,7OA0,2919.0,1.0,337.0,182.0,,39.74,1.0,1.81,experimental,38.601,0.2423,0.1926,"Crystal structure of di-phosphorylated human CLK1 in complex with 5-(6,7-dichloro-1H-indol-3-yl)pyrimidin-4-amine"
5ZYU,X-RAY DIFFRACTION,2.2,44.02,"VAPOR DIFFUSION, HANGING DROP",,0.1 M Phosphoric-citric acid pH 4.2 and 20% PEG300,291.15,2018-05-28,2018-09-19,5ZYU,4369.0,4.0,538.0,532.0,,68.19,1.0,1.752,experimental,,0.1996,0.1735,The crystal structure of humanMGME1 with single strand DNA2
4U7C,X-RAY DIFFRACTION,2.76,55.45,"VAPOR DIFFUSION, HANGING DROP",,"PEG 400, ammonium iodide",295.15,2014-07-30,2016-01-27,4U7C,7889.0,6.0,1028.0,113.0,,127.74,1.0,2.8,experimental,,0.2523,0.2123,Structure of DNA polymerase kappa in complex with benzopyrene adducted DNA
6HWZ,X-RAY DIFFRACTION,2.33,47.18,VAPOR DIFFUSION,9.0,"28-31% PEG4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5-9.0",296.0,2018-10-15,2018-12-26,6HWZ,4140.0,2.0,522.0,104.0,,58.26,1.0,1.64,experimental,38.962,0.26907,0.2245,Selenols: a new class of Carbonic Anhydrase inhibitors
6XZE,X-RAY DIFFRACTION,2.36,47.8,"VAPOR DIFFUSION, SITTING DROP",9.0,"200 mM Na-acetate, 30% PEG 4000, 100 mM Tris-HCl
Inhibitor: 10 mM inhibitor solution (150 mM NaCl, 10% DMSO,  50 mM Tris pH 7)",293.0,2020-02-04,2020-09-23,6XZE,4799.0,2.0,522.0,716.0,,58.68,1.0,1.54,experimental,28.6,0.2141,0.1901,crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((2-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
6XZO,X-RAY DIFFRACTION,2.31,46.71,"VAPOR DIFFUSION, SITTING DROP",,"200 mM Na-acetate, 30% PEG 4000, 100 mM Tris-HCl pH 9.
Inhibitor 150 mM NaCl, 10% DMSO,  50 mM Tris pH 7",293.0,2020-02-05,2020-09-23,6XZO,4937.0,2.0,522.0,851.0,,58.83,1.0,1.44,experimental,21.22,0.2164,0.1823,Crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((4-bromo-2-hydroxybenzyl)amino)ethyl)ureido) benzenesulfonamide
6XZS,X-RAY DIFFRACTION,2.36,47.84,"VAPOR DIFFUSION, SITTING DROP",9.0,"200 mM Na-acetate, 30% PEG 4000, 100 mM Tris-HCl pH 9.
Inhibitor: 150 mM NaCl, 10% DMSO,  50 mM Tris pH 7",293.0,2020-02-05,2020-09-23,6XZS,4757.0,2.0,522.0,673.0,,58.68,1.0,1.53,experimental,28.72,0.2184,0.1962,Crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((4-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
6XZX,X-RAY DIFFRACTION,2.33,47.13,"VAPOR DIFFUSION, SITTING DROP",9.0,"200 mM Na-acetate, 30% PEG 4000, 100 mM Tris-HCl pH 9.
Inhibitor:150 mM NaCl, 10% DMSO,  50 mM Tris pH 7",293.0,2020-02-05,2020-09-23,6XZX,4684.0,2.0,522.0,605.0,,58.64,1.0,1.55,experimental,32.56,0.2241,0.2002,crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((2-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
6XZY,X-RAY DIFFRACTION,2.32,47.09,"VAPOR DIFFUSION, SITTING DROP",9.0,"200 mM Na-acetate, 30% PEG 4000, 100 mM Tris-HCl pH 9.
Inhibitor: 150 mM NaCl, 10% DMSO,  50 mM Tris pH 7",293.0,2020-02-05,2020-09-23,6XZY,4774.0,2.0,522.0,693.0,,58.68,1.0,1.66,experimental,28.38,0.2209,0.1855,crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((2-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
6Y00,X-RAY DIFFRACTION,2.34,47.46,"VAPOR DIFFUSION, SITTING DROP",9.0,"200 mM Na-acetate, 30% PEG 4000, 100 mM Tris-HCl pH 9.
Inhibitor: 150 mM NaCl, 10% DMSO,  50 mM Tris pH 7",293.0,2020-02-05,2020-09-23,6Y00,4819.0,2.0,522.0,736.0,,58.83,1.0,1.37,experimental,25.33,0.2184,0.1978,crystal structure of human carbonic anhydrase I in complex with 4-(3-(2-((2-fluorobenzyl)amino)ethyl)ureido) benzenesulfonamide
7QOB,X-RAY DIFFRACTION,2.31,46.67,"VAPOR DIFFUSION, HANGING DROP",9.0,"28-31% PEG4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5-9.0",293.0,2021-12-23,2023-01-18,7QOB,4286.0,2.0,522.0,240.0,,58.31,1.0,1.8,experimental,28.971,0.2431,0.205,Human Carbonic Anhydrase I in complex with benzoselenoate
6P3Q,X-RAY DIFFRACTION,2.71,54.68,"VAPOR DIFFUSION, HANGING DROP",6.0,"250 mM sodium phosphate, 12 % PEG 8000, 36 mM EDTA, 10 mM Calcium chloride, 0.4 mM H-E(EDANS)-KIEIVRKKPIFKKATV-K(DASBCYL)-OH",291.0,2019-05-24,2020-02-05,6P3Q,5594.0,2.0,718.0,,,82.73,1.0,2.8,experimental,50.18,0.2851,0.2268,Calpain-5 (CAPN5) Protease Core (PC)
5KKN,X-RAY DIFFRACTION,3.41,63.89,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris pH 7, 2.8 M sodium formate",293.0,2016-06-22,2016-07-13,5KKN,7586.0,2.0,1080.0,26.0,,121.32,1.0,2.6,experimental,23.055,0.26563,0.21966,"Crystal structure of human ACC2 BC domain in complex with ND-646, the primary amide of ND-630"
5TKM,X-RAY DIFFRACTION,2.23,44.77,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.01 M Iron (III) chloride hexahydrate, 0.1 M sodium citrate dehydrate pH 5.6, 10% v/v Jeffamine M-600",291.0,2016-10-07,2017-06-14,5TKM,3368.0,2.0,396.0,234.0,,47.3,1.0,1.9,experimental,,0.2027,0.1877,Crystal structure of human APOBEC3B N-terminal Domain
7R70,X-RAY DIFFRACTION,3.46,64.52,"VAPOR DIFFUSION, HANGING DROP",6.5,1.6 M tri-sodium citrate,289.15,2021-06-24,2022-03-09,7R70,2436.0,2.0,366.0,22.0,,41.3,1.0,2.499,experimental,72.3875,0.2446,0.1997,Crystal Structure of the UbArk2C fusion protein
5ZYW,X-RAY DIFFRACTION,2.24,45.14,"VAPOR DIFFUSION, HANGING DROP",,"0.35 M di-sodium tartrate, 21% PEG 3350 and 0.1 M MnCl2",291.15,2018-05-28,2018-09-19,5ZYW,1967.0,1.0,254.0,94.0,,29.92,1.0,2.2,experimental,33.974,0.25234,0.22595,The crystal structure of apo-HsMGME1 with Mn2+
5HQP,X-RAY DIFFRACTION,2.7,54.39,"VAPOR DIFFUSION, HANGING DROP",,"0.1mM MES (pH5.6), 16% PEG 400",289.0,2016-01-22,2016-10-12,5HQP,7219.0,4.0,1256.0,27.0,3.0,144.39,2.0,2.6,experimental,,0.2717,0.2347,Crystal structure of the ERp44-peroxiredoxin 4 complex
6C9M,X-RAY DIFFRACTION,2.85,56.89,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG3350, 10% Tascimate, pH 7.5, 2% acetone",293.0,2018-01-26,2018-06-06,6C9M,15331.0,4.0,2204.0,9.0,,257.46,2.0,2.8,experimental,,0.242,0.187,The Human NatA (Naa10/Naa15) amino-terminal acetyltransferase complex
8CK5,X-RAY DIFFRACTION,2.28,46.02,"VAPOR DIFFUSION, SITTING DROP",6.5,"50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate",293.0,2023-02-14,2023-04-26,8CK5,2128.0,2.0,317.0,73.0,,36.34,2.0,2.1,experimental,,0.2428,0.1905,"VDR LBD complex with 25-nitro derivative of 1,25D3"
6FTY,X-RAY DIFFRACTION,2.11,41.83,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, 100 mM HEPES pH 7.5",295.0,2018-02-26,2018-06-06,6FTY,1951.0,1.0,232.0,171.0,4.0,25.18,1.0,1.67,experimental,14.64,0.214,0.171,COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 5
6UZT,X-RAY DIFFRACTION,2.88,57.0,"VAPOR DIFFUSION, HANGING DROP",6.0,"MES, PEG 20000, DTT",298.0,2019-11-15,2020-03-18,6UZT,11211.0,2.0,1202.0,1529.0,,139.22,1.0,1.8,experimental,35.426,0.191,0.155,Crystal Structure of RPTP alpha
6VJW,X-RAY DIFFRACTION,2.46,49.96,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG1500 
0.1 M MES pH 6.5 
0.2 M sodium acetate",293.0,2020-01-17,2021-01-27,6VJW,1704.0,3.0,162.0,46.0,,23.85,1.0,2.02,experimental,52.45,0.2634,0.2189,Crystal structure of WT hMBD4 complexed with T:G mismatch DNA
8PM3,X-RAY DIFFRACTION,2.57,52.09,"VAPOR DIFFUSION, SITTING DROP",7.5,0.05M magnesium chloride -- 30% PEG500MME -- 0.1M HEPES pH 7.5,293.15,2023-06-28,2023-09-20,8PM3,9087.0,4.0,1160.0,422.0,,131.96,1.0,2,experimental,33.296,0.23615,0.1957,Crystal structure of MAP2K6 with a covalent compound GCL94
6O9X,X-RAY DIFFRACTION,2.22,44.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% (w/v) PEG 3350, 0.1 M PCTP pH 7.5 and 0.15 M MgCl2",295.0,2019-03-15,2019-12-25,6O9X,4455.0,1.0,533.0,409.0,,61.55,1.0,1.7,experimental,25.498,0.19316,0.15577,Structure of human PARG complexed with JA2-4
6NFM,X-RAY DIFFRACTION,2.08,40.73,"VAPOR DIFFUSION, SITTING DROP",,"LiCl, HEPES,PEG3350",293.0,2018-12-20,2019-12-25,6NFM,1533.0,1.0,193.0,22.0,1.0,22.88,1.0,2.53,experimental,,0.2757,0.2181,Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B with loop 7 from APOBEC3G
7APV,X-RAY DIFFRACTION,1.87,34.1,"VAPOR DIFFUSION, SITTING DROP",,15% PEG3350 and 0.2 M Ammonium chloride,277.15,2020-10-20,2020-12-23,7APV,3100.0,1.0,362.0,107.0,,42.76,1.0,1.95,experimental,23.809,0.2272,0.1843,Structure of Artemis/DCLRE1C/SNM1C in complex with Ceftriaxone
7RJP,X-RAY DIFFRACTION,2.01,38.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% w/v PEG3350, 0.2 M ammonium acetate, 0.1 M Bis-Tris",292.0,2021-07-21,2022-08-03,7RJP,1400.0,2.0,133.0,214.0,,16.34,2.0,1.25,experimental,11.789,0.1738,0.1484,Crystal structure of human Bromodomain containing protein 4 (BRD4) in complex with SHMT
7TCY,X-RAY DIFFRACTION,1.79,31.35,"VAPOR DIFFUSION, SITTING DROP",6.8,"100 mM Bis-Tris, pH 6.8, 100 mM magnesium formate",298.0,2021-12-29,2023-01-11,7TCY,1382.0,2.0,156.0,127.0,,17.88,1.0,1.54,experimental,29.35,0.2137,0.1886,The ubiquitin-associated domain of human thirty-eight negative kinase I
8HKS,X-RAY DIFFRACTION,2.09,41.29,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG-3350, 0.1 M Tris-HCl pH 8.5",291.0,2022-11-28,2024-05-01,8HKS,11510.0,4.0,1412.0,157.0,,162.16,1.0,2.8,experimental,31.54,0.2382,0.1812,Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Pamiparib(BGB-290)
5L0U,X-RAY DIFFRACTION,2.41,48.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG5000 MME, 50 mM MES pH 6.5, 10mM CaCl2, 250mM NaCl, 5% MPD",295.0,2016-07-28,2017-08-09,5L0U,3655.0,2.0,399.0,308.0,7.0,47.6,2.0,1.8,experimental,44.2452,0.1942,0.1718,human POGLUT1 in complex with EGF(+) and UDP-phosphono-glucose
5L0V,X-RAY DIFFRACTION,2.38,48.38,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG5000 MME, 50 mM MES pH 6.5, 10mM CaCl2, 250mM NaCl, 5% MPD",295.0,2016-07-28,2017-08-09,5L0V,3933.0,2.0,399.0,582.0,7.0,47.96,2.0,1.305,experimental,25.2504,0.1739,0.1585,human POGLUT1 in complex with 2F-glucose modified EGF(+) and UDP
7NBM,X-RAY DIFFRACTION,2.21,44.4,"VAPOR DIFFUSION, HANGING DROP",,"Human NNMT was crystallized using the following conditions: A protein solution with 6 mg/ml NNMT, 50 mM Tris/HCL, pH 8.0, 1 mM DTT, 0.95mM inhibitor and 5% v/v glycerol was equilibrated at room temperature in a hanging drop setup against 2.2 M ammonium sulfate with 0.1 M HEPES/Na, pH 7.6. Small crystal appeared after 1-2 weeks.",293.0,2021-01-27,2021-03-17,7NBM,8509.0,4.0,1132.0,265.0,,127.81,1.0,2.691,experimental,48.0,0.3144,0.2088,Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the bisubstrate-like inhibitor (33)
4ODR,X-RAY DIFFRACTION,4.83,74.52,"VAPOR DIFFUSION, SITTING DROP",5.0,"20% PEG6000, 0.1 M sodium acetate, pH 5.0, 0.2 M zinc chloride, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-01-10,2015-01-14,4ODR,2122.0,2.0,220.0,311.0,,26.96,1.0,1.929,experimental,,0.1699,0.1527,Structure of SlyD delta-IF from Thermus thermophilus in complex with FK506
8A38,X-RAY DIFFRACTION,2.34,47.55,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.2 M ammonium chloride, 0.1 M sodium acetate, 20% (w/v) PEG 6000, pH 5.0",293.15,2022-06-07,2023-09-20,8A38,1698.0,3.0,288.0,17.0,,32.82,1.0,2.196,experimental,72.03,0.2881,0.2582,RING domain of human TRIM2
5TNO,X-RAY DIFFRACTION,2.77,55.56,"VAPOR DIFFUSION, HANGING DROP",9.0,"50 MM CHES, PH 9.0, 1.3 M TRI-SODIUM CITRATE AND 3 MM COMPOUND (CROSS SEEDED WITH CRYSTALS GROWN FROM REMARK 280 50 MM TRIS, PH 7.2, 1.45 M AMMONIUM SULFATE, 2.0 M SODIUM REMARK 280 CHLORIDE AND 3 MM COMPOUND)",295.0,2016-10-14,2017-04-26,5TNO,2568.0,2.0,297.0,254.0,7.0,33.38,2.0,1.54,experimental,32.9,0.158,0.145,Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors
8SLT,X-RAY DIFFRACTION,2.72,54.77,"VAPOR DIFFUSION, HANGING DROP",5.5,"30% PEG 3350, 200 mM Li2SO4, 100 mM bis-tris pH 5.5",293.15,2023-04-24,2023-06-21,8SLT,2423.0,1.0,282.0,69.0,,32.71,1.0,1.96,experimental,,0.2057,0.1744,Crystal structure of human STEP (PTPN5) at physiological temperature (310 K) and ambient pressure (0.1 MPa)
5LP1,X-RAY DIFFRACTION,2.49,50.58,"VAPOR DIFFUSION, HANGING DROP",7.3,"Sodium chloride, PEG 3350, HEPES.",293.0,2016-08-11,2017-02-01,5LP1,3420.0,1.0,388.0,332.0,,44.93,1.0,1.91,experimental,35.812,0.1922,0.1623,CRYSTAL STRUCTURE OF HUMAN LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN COMPLEX WITH A [1.1.1]BICYCLOPENTANE-CONTAINING INHIBITOR AT 1.91A RESOLUTION.
6ASR,X-RAY DIFFRACTION,4.14,70.29,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M MES pH 6.0, 10 % PEG 8000",291.0,2017-08-25,2018-06-20,6ASR,1553.0,3.0,203.0,73.0,,22.81,2.0,2.356,experimental,,0.2291,0.2008,REV1 UBM2 domain complex with ubiquitin
5WO4,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES pH 6.0, 30% (w/v) PEG 6000",277.0,2017-08-01,2017-12-06,5WO4,5223.0,2.0,604.0,471.0,,70.24,1.0,1.84,experimental,35.14,0.2108,0.1865,JAK1 complexed with compound 28
8FZ3,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.2,1.4 M Sodium phosphate monobasic monohydrate/Potassium phosphate dibasic pH 8.2,298.0,2023-01-27,2023-03-29,8FZ3,2484.0,4.0,680.0,31.0,,79.41,1.0,2.784,experimental,68.27,0.2665,0.2286,"Sterile Alpha Motif of Human Translocation ETS Leukemia, Non-Polymer Crystal Form"
6RYF,X-RAY DIFFRACTION,2.44,49.69,"VAPOR DIFFUSION, SITTING DROP",,"100 mM propionic acid, cacodylate and Bis-tris propane pH 7.0, 25% PEG 1500",293.0,2019-06-10,2019-12-18,6RYF,7863.0,2.0,908.0,589.0,3.0,107.08,2.0,1.72,experimental,,0.2013,0.1765,High-resolution crystal structure of ERAP1 in complex with 15mer phosphinic peptide
6FTZ,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, 100 mM HEPES pH 7.5",295.0,2018-02-26,2018-06-06,6FTZ,2006.0,1.0,232.0,209.0,4.0,25.05,1.0,1.67,experimental,16.11,0.22,0.173,COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 6
6FUH,X-RAY DIFFRACTION,2.08,40.96,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 100 mM TRIS pH 8.5, 200 mM NH4SO2, 2 mM inhibitor",293.0,2018-02-27,2018-06-06,6FUH,1983.0,1.0,232.0,250.0,4.0,25.1,1.0,1.37,experimental,14.488,0.17962,0.13392,Complement factor D in complex with the inhibitor (4-((3-(aminomethyl)phenyl)amino)quinazolin-2-yl)-L-valine
6FUI,X-RAY DIFFRACTION,2.12,41.95,"VAPOR DIFFUSION, SITTING DROP",,"22-25% PEG3350, 100 mM HEPES pH 7.5",293.0,2018-02-27,2018-06-06,6FUI,2081.0,1.0,232.0,317.0,4.0,25.13,1.0,1.38,experimental,18.542,0.1978,0.13232,"Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol"
8ENJ,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,,"0.2 M ammonium tartrate pH 7.2, 18 % PEG 3350",277.0,2022-09-30,2023-10-18,8ENJ,2719.0,1.0,464.0,,,53.17,1.0,2.81,experimental,63.43,0.2948,0.2361,"Design, synthesis, biological evaluation, and X-ray crystallography of diarylpyrazole derivatives possessing terminal arylsulfonamide moieties as anti-proliferative agents targeting c-Jun N-terminal kinase (JNK)"
7L24,X-RAY DIFFRACTION,2.65,53.69,VAPOR DIFFUSION,,UNDISCLOSED,293.0,2020-12-16,2021-03-17,7L24,8982.0,4.0,1152.0,69.0,,131.01,1.0,2.68,experimental,82.986,0.272,0.2257,HPK1 IN COMPLEX WITH COMPOUND 11
7L26,X-RAY DIFFRACTION,2.57,52.14,VAPOR DIFFUSION,,UNDISCLOSED,293.0,2020-12-16,2021-03-17,7L26,9198.0,4.0,1148.0,230.0,,130.58,1.0,2.3,experimental,64.411,0.2983,0.2619,HPK1 IN COMPLEX WITH COMPOUND 38
6ATR,X-RAY DIFFRACTION,2.4,48.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG 2000 MME, 25% (w/v), 0.1 M MES, pH 6.5",293.0,2017-08-29,2018-09-12,6ATR,5079.0,2.0,442.0,881.0,,53.17,1.0,1.29,experimental,,0.1823,0.1683,Crystal structure of hGSTA1-1 complexed with two GSH analogues in each subunit
4TSE,X-RAY DIFFRACTION,2.6,52.6,"VAPOR DIFFUSION, HANGING DROP",7.3,"24% v/v PEK2K MME, 0.8M HCOONa using 6 mg/ml protein",293.0,2014-06-18,2015-03-18,4TSE,2609.0,2.0,348.0,240.0,,37.0,1.0,2.057,experimental,18.72,0.2293,0.1897,Crystal Structure of the Mib Repeat Domain of Mind bomb 1
5LSH,X-RAY DIFFRACTION,1.91,35.51,"VAPOR DIFFUSION, HANGING DROP",,"0.8 M NaCl, 25 mM NaOAc, pH 5.4",291.0,2016-08-26,2017-06-21,5LSH,1414.0,1.0,130.0,160.0,4.0,15.56,1.0,1.061,experimental,,0.2032,0.1801,human lysozyme in complex with a tetrasaccharide fragment of the O-chain of LPS from Klebsiella pneumoniae
6M4V,X-RAY DIFFRACTION,2.55,51.85,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Na-HEPES buffer (pH 7.5), 20% (w/v) PEG 8000",293.0,2020-03-09,2020-08-26,6M4V,7486.0,4.0,962.0,154.0,,107.04,2.0,2.92,experimental,52.568,0.29762,0.20806,Crystal structure of MBP fused split FKBP in complex with rapamycin
7S77,X-RAY DIFFRACTION,2.86,56.98,"VAPOR DIFFUSION, HANGING DROP",8.5,"condition 2-33 of the Morpheus crystal screen (Molecular Dimensions) at a protein concentration of 10 mg/mL from a hanging drop of 1 ml protein and 4 ml well buffer.  Condition 2-33 contains 0.1 M of a carboxylic acid mixture (0.2 M sodium formate, 0.2 M ammonium acetate, 0.2 M sodium citrate tribasic dihydrate, 0.2 M sodium potassium tartrate tetrahydrate, and 0.2 M sodium oxamate), 0.1 M of a buffer system at pH 8.5 (Tris base and BICINE), and a 30% v/v precipitant mix (40% v/v PEG 500 MME and 20% w/v PEG 20000)",293.0,2021-09-15,2022-05-04,7S77,7916.0,2.0,1170.0,31.0,,128.56,1.0,2.8,experimental,82.28,0.2518,0.1927,Crystal structure of the G391V variant of human PGM-1
8G1V,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",6.5,"2M ammonium sulfate, 100 sodium cacodylate, 200 mM NaCl",291.0,2023-02-03,2024-07-10,8G1V,2285.0,1.0,241.0,329.0,3.0,27.81,1.0,1.35,experimental,,0.152,0.1309,Crystal Structure Matriptase (C731S) in Complex with Inhibitor MM1132-2
6N78,X-RAY DIFFRACTION,2.43,49.29,"VAPOR DIFFUSION, HANGING DROP",5.5,0.1 M MES pH 5-6 and 25-35% PEG 6000,277.0,2018-11-27,2019-04-24,6N78,2436.0,1.0,302.0,146.0,,35.26,1.0,1.83,experimental,34.03,0.261,0.234,Structure of the human JAK1 kinase domain with compound 21
6N79,X-RAY DIFFRACTION,2.34,47.45,"VAPOR DIFFUSION, HANGING DROP",5.5,0.1 M MES pH 5-6 and 25-35% PEG 6000,277.0,2018-11-27,2019-04-24,6N79,2401.0,1.0,302.0,98.0,,35.24,1.0,2.27,experimental,41.59,0.27,0.224,Structure of the human JAK1 kinase domain with compound 20
6N7B,X-RAY DIFFRACTION,2.36,47.84,"VAPOR DIFFUSION, HANGING DROP",5.5,0.1 M MES pH 5-6 and 25-35% PEG 6000,277.0,2018-11-27,2019-04-24,6N7B,2471.0,1.0,302.0,157.0,,35.31,1.0,1.81,experimental,27.03,0.264,0.22,Structure of the human JAK1 kinase domain with compound 38
6N7D,X-RAY DIFFRACTION,2.34,47.47,"VAPOR DIFFUSION, HANGING DROP",5.5,0.1 M MES pH 5-6 and 25-35% PEG 6000,277.0,2018-11-27,2019-04-24,6N7D,2532.0,1.0,302.0,227.0,,35.21,1.0,1.78,experimental,32.69,0.234,0.196,Structure of the human JAK1 kinase domain with compound 54
7QFF,X-RAY DIFFRACTION,2.82,56.36,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",277.0,2021-12-06,2022-12-21,7QFF,4152.0,5.0,465.0,530.0,6.0,51.39,3.0,1.5,experimental,29.87,0.1944,0.1691,Peptide VACKSSQP in complex with human cathepsin V C25A mutant
4QHV,X-RAY DIFFRACTION,2.51,51.08,"VAPOR DIFFUSION, HANGING DROP",6.0,"60% AmSO4,3% v/v ETOH, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 287K",287.0,2014-05-29,2015-06-10,4QHV,1757.0,1.0,186.0,154.0,,22.98,1.0,1.61,experimental,19.076,0.22129,0.17705,"Crystal structure of human dihydrofolate reductase as complex with pyridopyrimidine 22 (N~6~-METHYL-N~6~-[4-(PROPAN-2-YL)PHENYL]PYRIDO[2,3-D]PYRIMIDINE-2,4,6-TRIAMINE)"
5HPB,X-RAY DIFFRACTION,2.55,51.73,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, 30% sat AmSO4, 3% v/vEtOH",287.0,2016-01-20,2017-01-25,5HPB,1636.0,1.0,186.0,53.0,,22.64,1.0,1.65,experimental,36.319,0.29278,0.2364,"human dihydrofolate reductase complex with NADPH and 5-methyl-6-(phenylthio-4'trifluoromethyl)thieno[2,3-d]pyrimidine-2,4-diamine"
5HQY,X-RAY DIFFRACTION,2.59,52.43,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KP04, 60% AmSO4, 3%v/v ETOH",287.0,2016-01-22,2017-01-25,5HQY,1687.0,1.0,186.0,93.0,,22.78,1.0,1.46,experimental,29.382,0.27118,0.23284,"human dihydrofolate reductase complex with NADPH and 5-methyl-6-(2',3',4'-trifluorophenylthio)thieno[2,3-d]pyrimidine-2,4-diamine"
7U2P,X-RAY DIFFRACTION,2.68,54.04,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Ammonium sulfate, 0.1 M MES, pH 5.9, and 10% (w/v) PEG 8000",291.0,2022-02-24,2022-05-04,7U2P,5933.0,2.0,729.0,52.0,,85.0,2.0,2.596,experimental,60.029,0.2354,0.2149,Structure of TcdA GTD in complex with RhoA
6WHB,X-RAY DIFFRACTION,2.15,42.8,"VAPOR DIFFUSION, SITTING DROP",6.9,"0.1 M Bis-Tris Propane pH 6.9, 1.5 M sodium acetate",290.15,2020-04-07,2020-08-26,6WHB,2326.0,1.0,350.0,68.0,,38.54,1.0,1.90032055102,experimental,61.378466522,0.229687564641,0.2070807354,MEKK1 TOG domain (548-867)
5MT4,X-RAY DIFFRACTION,2.17,43.27,"VAPOR DIFFUSION, SITTING DROP",,"26% PEGME2000, 100mM Bis-Tris pH 6.5",293.0,2017-01-06,2017-02-15,5MT4,1820.0,1.0,232.0,66.0,4.0,25.01,1.0,1.65,experimental,,0.239,0.19,COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE BENZOIC ACID BASED INHIBITOR
6TS5,X-RAY DIFFRACTION,2.27,45.84,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulfate, 0.1 M BIS-TRIS pH5.5, 25% w/v Polyethylene glycol 3350
Protein at 18mg/ml in 50mM Tris/HCl pH7.4 100mM NaCl",277.0,2019-12-20,2020-07-08,6TS5,2256.0,1.0,238.0,268.0,4.0,27.75,1.0,1.29,experimental,18.48,0.2075,0.1875,Coagulation factor XI protease domain in complex with active site inhibitor
6TS6,X-RAY DIFFRACTION,2.26,45.6,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulfate, 0.1 M BIS-TRIS pH5.5, 25% w/v Polyethylene glycol 3350",277.0,2019-12-20,2020-07-08,6TS6,2201.0,1.0,238.0,224.0,4.0,27.82,1.0,1.33,experimental,16.81,0.2102,0.1929,Coagulation factor XI protease domain in complex with active site inhibitor
4XZ1,X-RAY DIFFRACTION,2.41,48.89,"VAPOR DIFFUSION, HANGING DROP",6.0,"PEG 6000, calcium chloride, MES, TCEP",293.0,2015-02-03,2015-07-29,4XZ1,2195.0,2.0,283.0,,,32.45,2.0,2.8,experimental,,0.2702,0.2155,ZAP-70-tSH2:Compound-B adduct
5SSY,X-RAY DIFFRACTION,2.04,39.63,"VAPOR DIFFUSION, SITTING DROP",8.5,"9.6 mg/mL protein in 20mM Tris/HCl pH8.0 mixed 1:1 with reservoir 0.1M Tris/HCl pH 8.5, 20-25% PEG4000, 0.2-0.3M CaCl2",293.0,2022-08-12,2023-08-23,5SSY,2684.0,1.0,323.0,357.0,2.0,36.67,1.0,1.29,experimental,15.3565,0.2371,0.2116,Crystal Structure of human formylglycine generating enzyme
7AKS,X-RAY DIFFRACTION,2.51,50.91,"VAPOR DIFFUSION, SITTING DROP",,"sodium citrate (pH 6.1), 18% (w/v) PEG4000 and 400 mM ammonium acetate",293.15,2020-10-02,2021-06-16,7AKS,11678.0,8.0,1440.0,785.0,2.0,160.86,2.0,1.86,experimental,29.039,0.1946,0.1685,Human ADP-ribosylserine hydrolase ARH3 mutant E41A in complex with H2B-S7-mar peptide
4MYG,X-RAY DIFFRACTION,2.43,49.31,"VAPOR DIFFUSION, HANGING DROP",6.2,"100 mM Bis-Tris, 21% PEG3350, 200 mM sodium chloride, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 290K",290.0,2013-09-27,2015-03-25,4MYG,5658.0,2.0,744.0,184.0,,85.86,1.0,2.594,experimental,,0.2551,0.2048,"MAPK13, active form"
5C01,X-RAY DIFFRACTION,2.01,38.83,"VAPOR DIFFUSION, SITTING DROP",8.5,"18-22% PEG 4000, 0.1 M Tris, pH 8.5, 200 mM CaCl2",293.0,2015-06-12,2015-09-16,5C01,4435.0,2.0,684.0,245.0,2.0,77.23,1.0,2.15,experimental,29.199,0.2403,0.1946,Crystal Structure of kinase
5C03,X-RAY DIFFRACTION,2.12,42.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"18-22% PEG 4000, 0.1 M Tris, pH 8.5, 200 mM CaCl2",293.0,2015-06-12,2015-09-16,5C03,4568.0,2.0,684.0,298.0,,78.88,1.0,1.9,experimental,25.981,0.2185,0.1815,Crystal Structure of kinase
6WBS,X-RAY DIFFRACTION,2.59,52.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"CFTR NBD1 V510D in buffer A was crystallized by mixing equal amounts of protein at 6 mg/mL with 0.1 M Tris pH 7.6, 28% (w/v) polyethylene glycol 10,000. Crystallization was induced by streak-seeding using crystals grown in 0.1 M HEPES, pH 7.5, 25% (w/v) polyethylene glycol 550 monomethylether, and plates incubated at 4C. Crystals grew over several days and were frozen by quick dip in reservoir solution supplemented with 25% (w/v) ethylene glycol",277.0,2020-03-27,2021-04-07,6WBS,3985.0,2.0,452.0,432.0,,51.39,1.0,1.857,experimental,31.9829,0.2127,0.1697,Human CFTR first nucleotide binding domain with dF508/V510D
6YTD,X-RAY DIFFRACTION,2.69,54.19,"VAPOR DIFFUSION, SITTING DROP",7.0,"17% PEG 3350, 0,2M Na malonate",277.0,2020-04-24,2020-07-15,6YTD,3050.0,1.0,339.0,254.0,,39.8,1.0,2,experimental,28.811,0.228,0.1794,CLK1 V324A mutant bound with benzothiazole Tg003 (Cpd 2)
6YTG,X-RAY DIFFRACTION,2.54,51.59,"VAPOR DIFFUSION, SITTING DROP",8.0,"17% PEG 6k, 0.1M bicine",277.0,2020-04-24,2020-07-15,6YTG,2966.0,1.0,339.0,233.0,,40.31,1.0,1.95,experimental,27.064,0.2609,0.2037,CLK1 bound with beta-carboline KH-CARB13 (Cpd 3)
6YTI,X-RAY DIFFRACTION,2.57,52.11,"VAPOR DIFFUSION, SITTING DROP",9.3,"29% PEG 6k, 0.1M bicine",277.0,2020-04-24,2020-07-15,6YTI,2795.0,1.0,339.0,87.0,,40.21,1.0,2.4,experimental,44.464,0.2555,0.1952,CLK1 bound with ETH1610 (Cpd 17)
5QIP,X-RAY DIFFRACTION,2.35,47.7,"VAPOR DIFFUSION, SITTING DROP",7.0,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293.0,2018-08-10,2019-12-18,5QIP,2063.0,1.0,225.0,197.0,,26.97,1.0,1.63,experimental,24.076,0.2043,0.1756,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102153
5QIQ,X-RAY DIFFRACTION,2.39,48.58,"VAPOR DIFFUSION, SITTING DROP",7.0,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293.0,2018-08-10,2019-12-18,5QIQ,2097.0,1.0,225.0,228.0,,26.76,1.0,1.44,experimental,17.878,0.2008,0.148,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0103050
5QIR,X-RAY DIFFRACTION,2.35,47.63,"VAPOR DIFFUSION, SITTING DROP",7.0,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293.0,2018-08-10,2019-12-18,5QIR,2142.0,1.0,225.0,233.0,,26.96,1.0,1.43,experimental,18.915,0.182,0.1341,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102305
5QIS,X-RAY DIFFRACTION,2.37,48.15,"VAPOR DIFFUSION, SITTING DROP",7.0,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293.0,2018-08-10,2019-12-18,5QIS,2140.0,1.0,225.0,239.0,,26.79,1.0,1.53,experimental,22.078,0.1903,0.1378,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102500
5QIT,X-RAY DIFFRACTION,2.34,47.54,"VAPOR DIFFUSION, SITTING DROP",7.0,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293.0,2018-08-10,2019-12-18,5QIT,2109.0,1.0,225.0,207.0,,26.82,1.0,1.46,experimental,17.96,0.1946,0.1415,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102821
5QIU,X-RAY DIFFRACTION,2.36,47.96,"VAPOR DIFFUSION, SITTING DROP",7.0,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293.0,2018-08-10,2019-12-18,5QIU,2118.0,1.0,225.0,234.0,,26.67,1.0,1.56,experimental,21.006,0.2106,0.1447,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0103011
5QIV,X-RAY DIFFRACTION,2.35,47.6,"VAPOR DIFFUSION, SITTING DROP",7.0,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293.0,2018-08-10,2019-12-18,5QIV,2133.0,1.0,225.0,235.0,,26.91,1.0,1.39,experimental,19.971,0.1838,0.1365,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0102998
5QIX,X-RAY DIFFRACTION,2.37,48.15,"VAPOR DIFFUSION, SITTING DROP",7.0,"16% PEG4K, 0.1M HEPES pH 7.0, 8% 2-propanol, 5 mM DTT",293.0,2018-08-10,2019-12-18,5QIX,2146.0,1.0,225.0,256.0,,26.97,1.0,1.39,experimental,14.222,0.1978,0.1471,Covalent fragment group deposition -- Crystal Structure of OUTB2 in complex with PCM-0103007
6E40,X-RAY DIFFRACTION,2.53,51.35,EVAPORATION,6.2,"0.1 M phosphate (pH 6.2), and 15% (w/v) PEG3350",298.0,2018-07-16,2018-11-14,6E40,12155.0,4.0,1620.0,173.0,,184.98,1.0,2.306,experimental,55.8913,0.2537,0.2077,"Crystal structure of the indoleamine 2,3-dioxygenase 1 (IDO1) in complexed with ferric heme and Epacadostat"
6NSL,X-RAY DIFFRACTION,1.92,36.13,"VAPOR DIFFUSION, HANGING DROP",,"200 mM ammonium sulfate, and 100 mM sodium cacodylate buffer, pH 6.5, 30%(W/V) PEG 5000 (Methyl Ether)",293.0,2019-01-25,2020-01-29,6NSL,3889.0,2.0,634.0,98.0,,72.17,1.0,2.15,experimental,41.78,0.213,0.202,"CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound-6c AKA 6-((1-(4-CYANOPHENY L)-2-OXO-1,2-DIHYDRO-3-PYRIDINYL)AMINO)-N-CYCLOPROPYL-8-(M ETHYLAMINO)IMIDAZO[1,2-B]PYRIDAZINE-3-CARBOXAMIDE"
5QTX,X-RAY DIFFRACTION,3.19,61.48,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2019-11-13,2020-01-29,5QTX,2220.0,2.0,262.0,222.0,5.0,31.39,2.0,2.07,experimental,20.96,0.1777,0.154,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecine-2-carboxylate"
8E85,X-RAY DIFFRACTION,2.08,40.92,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E85,3975.0,3.0,455.0,58.0,,55.31,1.0,1.72,experimental,31.456,0.2338,0.2034,Human DNA polymerase eta-DNA-rG-ended primer-dGMPNPP ternary mismatch complex with Mn2+
8E86,X-RAY DIFFRACTION,2.1,41.33,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E86,3938.0,3.0,455.0,108.0,,55.31,1.0,1.78,experimental,29.342,0.2045,0.1944,Human DNA polymerase eta-DNA-rC-ended primer-dGMPNPP ternary mismatch complex with Mn2+
8E87,X-RAY DIFFRACTION,2.06,40.41,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E87,3902.0,3.0,455.0,7.0,,55.25,1.0,2.19,experimental,40.2789,0.2488,0.1995,Human DNA polymerase eta-DNA-rA-ended primer-dGMPNPP ternary mismatch complex with Mg2+
8E88,X-RAY DIFFRACTION,2.07,40.54,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E88,3925.0,3.0,455.0,2.0,,55.24,1.0,2.4,experimental,41.6633,0.2239,0.195,Human DNA polymerase eta-DNA-rU-ended primer-dGMPNPP ternary mismatch complex with Mg2+
8E89,X-RAY DIFFRACTION,2.02,39.18,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E89,3822.0,3.0,455.0,12.0,,54.68,1.0,2.2,experimental,54.2812,0.2617,0.2006,Human DNA polymerase eta-DNA-rU-ended primer-binary complex
8E8A,X-RAY DIFFRACTION,2.09,41.23,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8A,3907.0,3.0,455.0,84.0,,54.68,1.0,1.8,experimental,36.8759,0.2266,0.2056,Human DNA polymerase eta-DNA-dT-ended primer binary complex
8E8J,X-RAY DIFFRACTION,2.08,40.74,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8J,3893.0,3.0,455.0,10.0,,55.25,1.0,2.4,experimental,33.9189,0.215,0.1923,Human DNA polymerase eta-DNA-rG-ended primer-dGMPNPP ternary mismatch complex with Mg2+
8E8K,X-RAY DIFFRACTION,2.08,40.84,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8K,3834.0,3.0,455.0,9.0,,55.25,1.0,2.4,experimental,40.7357,0.2372,0.1819,Human DNA polymerase eta-DNA-rC-ended primer-dGMPNPP ternary mismatch complex with Mg2+
5OP6,X-RAY DIFFRACTION,3.37,63.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH7.5, 1.1M ammonium sulfate, 2.5% PEG 400",300.0,2017-08-09,2017-10-18,5OP6,2710.0,1.0,351.0,46.0,,41.3,1.0,2.45,experimental,,0.2274,0.2037,Factor Inhibiting HIF (FIH) in complex with zinc and GSK128863
7WMT,X-RAY DIFFRACTION,2.75,55.23,"VAPOR DIFFUSION, SITTING DROP",,"0.04 M Potassium phosphate monobasic, 16 % w/v PEG 8000, 20 % v/v Glycerol",277.0,2022-01-17,2022-08-31,7WMT,2049.0,1.0,250.0,202.0,,28.25,1.0,1.77,experimental,43.953,0.1909,0.1548,Crystal structure of small molecule 13 bound to human Nicotinamide N-methyltransferase
5NB7,X-RAY DIFFRACTION,2.13,42.12,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG 3350, 0.1 m HEPES pH 7.5, 50 mM NaCl",298.0,2017-03-01,2017-06-28,5NB7,1961.0,1.0,230.0,215.0,4.0,25.24,1.0,1.33,experimental,18.658,0.19582,0.14025,Complement factor D
5V1B,X-RAY DIFFRACTION,2.33,47.21,"VAPOR DIFFUSION, SITTING DROP",,"28% PEG 3350, Bis-Tris 7",273.0,2017-03-01,2017-06-21,5V1B,1891.0,1.0,240.0,92.0,,27.03,1.0,2.49,experimental,69.198,0.2363,0.1894,"Structure of PHD1 in complex with 1,2,4-Triazolo-[1,5-a]pyridine"
7U8D,X-RAY DIFFRACTION,2.69,54.27,"VAPOR DIFFUSION, HANGING DROP",,"sodium tartrate, PEG 3350",296.0,2022-03-08,2022-09-21,7U8D,2116.0,2.0,218.0,296.0,,26.0,1.0,1.39,experimental,22.76,0.1723,0.1468,FKBP12 mutant V55G bound to Rapa*-3Z
8SLS,X-RAY DIFFRACTION,2.62,53.01,"VAPOR DIFFUSION, SITTING DROP",5.65,"30% PEG 3350, 200 mM Li2SO4, 100 mM bis-tris pH 5.65",293.15,2023-04-24,2023-06-21,8SLS,2548.0,1.0,282.0,149.0,,32.8,1.0,1.71,experimental,38.06,0.2244,0.1915,Crystal structure of human STEP (PTPN5) at cryogenic temperature (100 K) and ambient pressure (0.1 MPa)
8SLU,X-RAY DIFFRACTION,2.56,52.01,"VAPOR DIFFUSION, SITTING DROP",5.65,"30% PEG 3350, 200 mM Li2SO4, 100 mM bis-tris pH 5.65",293.15,2023-04-24,2023-06-21,8SLU,2547.0,1.0,282.0,98.0,,32.8,1.0,1.84,experimental,41.64,0.2366,0.1948,Crystal structure of human STEP (PTPN5) at cryogenic temperature (100 K) and high pressure (205 MPa)
5EKN,X-RAY DIFFRACTION,2.33,47.15,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 MM AMMONIUM TARTRATE, 18% PEG3350",290.0,2015-11-03,2016-07-06,5EKN,2787.0,1.0,371.0,23.0,,43.02,1.0,2.594,experimental,,0.2731,0.218,Crystal structure of MAPK13 complex with inhibitor
5EKO,X-RAY DIFFRACTION,2.32,47.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 MM AMMONIUM TARTRATE, 18% PEG3350",290.0,2015-11-03,2016-07-06,5EKO,3013.0,1.0,371.0,213.0,,43.0,1.0,2,experimental,,0.2412,0.2001,Crystal structure of MAPK13 complex with inhibitor
5I3O,X-RAY DIFFRACTION,2.87,57.19,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M MES pH 6; 0.2M ammonium chloride, 20% PEG 8000, 10% ethylene glycol",293.15,2016-02-10,2016-03-09,5I3O,5106.0,2.0,604.0,283.0,,69.02,1.0,2.4,experimental,67.32,0.255,0.193,Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor
5I3R,X-RAY DIFFRACTION,2.88,57.36,"VAPOR DIFFUSION, SITTING DROP",6.0,20% PEG 8000; 0.2 M Ammonium chloride; 10% Ethyleneglycol; 0.1M MES pH 6.0,293.15,2016-02-10,2016-03-09,5I3R,4995.0,2.0,604.0,192.0,,69.04,1.0,2.4,experimental,59.66,0.231,0.185,Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor
6HH6,X-RAY DIFFRACTION,2.5,50.73,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M AMMONIUM SULFATE, 0.1 M PCTP PH 7.5",293.15,2018-08-24,2018-11-28,6HH6,4761.0,1.0,531.0,506.0,,61.85,1.0,1.85,experimental,24.94,0.20027,0.16595,Human poly(ADP-ribose) glycohydrolase in complex with ADP-HPM
6O9Y,X-RAY DIFFRACTION,2.26,45.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.05 M PCTP pH 7.5, 0.1 M NaCl, 0.15 M MgCl2",295.0,2019-03-15,2019-12-25,6O9Y,4250.0,1.0,533.0,224.0,,61.55,1.0,2,experimental,29.087,0.2376,0.18229,Structure of human PARG complexed with JA2-8
6OA0,X-RAY DIFFRACTION,2.27,45.73,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.05 M PCTP pH 7.5, 0.1 M NaCl, 0.15 M MgCl2",295.0,2019-03-15,2019-12-25,6OA0,4239.0,1.0,533.0,212.0,,61.49,1.0,2,experimental,29.344,0.21849,0.17182,Structure of human PARG complexed with JA2-9
6OA1,X-RAY DIFFRACTION,2.24,45.06,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.05 M PCTP pH 7.5, 0.1 M NaCl, 0.15 M MgCl2",295.0,2019-03-15,2019-12-25,6OA1,4327.0,1.0,533.0,297.0,,61.55,1.0,1.8,experimental,20.79,0.19937,0.16694,Structure of human PARG complexed with JA2120
6OA3,X-RAY DIFFRACTION,2.25,45.44,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.05 M PCTP pH 7.5, 0.1 M NaCl, 0.15 M MgCl2",295.0,2019-03-15,2019-12-25,6OA3,4278.0,1.0,533.0,246.0,,61.57,1.0,1.9,experimental,25.432,0.22479,0.17835,Structure of human PARG complexed with JA2131
6SNO,X-RAY DIFFRACTION,2.29,46.31,"VAPOR DIFFUSION, HANGING DROP",,"KCl, MgCl2, Na cacodylate pH 6.5 and PEG4000",298.15,2019-08-27,2020-04-08,6SNO,4506.0,1.0,583.0,49.0,,64.45,1.0,2.7,experimental,,0.248,0.197,Crystal structures of human PGM1 isoform 2
6SNQ,X-RAY DIFFRACTION,2.3,46.59,"VAPOR DIFFUSION, HANGING DROP",,"KCl, MgCl2, Na cacodylate pH 6.5 and PEG4000",298.15,2019-08-27,2020-04-08,6SNQ,4502.0,1.0,583.0,84.0,,64.45,1.0,2.7,experimental,,0.2461,0.2059,Crystal structures of human PGM1 isoform 2
5D7V,X-RAY DIFFRACTION,2.48,50.39,"VAPOR DIFFUSION, SITTING DROP",,"0.23M Diammonium Phosphate, 18% PEG 3350, 1M Lithium chloride",298.0,2015-08-14,2016-08-17,5D7V,9141.0,4.0,1076.0,366.0,,126.05,1.0,2.33,experimental,26.633,0.2816,0.2186,Crystal structure of PTK6 kinase domain
5QDD,X-RAY DIFFRACTION,3.03,59.38,hanging drop,5.0,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM PHOSPHATE, 0.1M SODIUM CITRATE PH
5.0. PROTEIN STOCK WAS BACE MUT46B BATCH XIV 6.3MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 7-FOLD EXCESS OF BMC020
ADDED FROM A 50MM STOCK SOLUTION IN 90% DMSO, 10% H2O. CRYO-PROTECTANT WAS 1.2M AMMONIUM PHOSPHATE, 0.1M SODIUM CITRATE,
25%(V/V)GLYCEROL, 2.0% DMSO, 1MM BMC020.",292.0,2017-12-01,2020-06-03,5QDD,9183.0,3.0,1206.0,311.0,9.0,135.87,1.0,2,experimental,48.3,0.187,0.17,Crystal structure of BACE complex with BMC020 hydrolyzed
4R62,X-RAY DIFFRACTION,1.99,38.23,"VAPOR DIFFUSION, HANGING DROP",5.4,"24% PEG 300, 50 mM sodium acetate, pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-08-22,2015-09-02,4R62,1735.0,2.0,250.0,12.0,,28.63,2.0,2.28,experimental,,0.2645,0.2101,Structure of Rad6~Ub
7Q8I,X-RAY DIFFRACTION,2.76,55.44,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM Tris, pH 8",298.0,2021-11-11,2022-11-23,7Q8I,3928.0,4.0,456.0,401.0,7.0,50.2,2.0,1.59,experimental,23.06,0.1893,0.169,Peptide AVAEKQ in complex with human cathepsin V C25S mutant
7Q8O,X-RAY DIFFRACTION,2.75,55.29,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",278.0,2021-11-11,2022-11-23,7Q8O,3779.0,4.0,454.0,330.0,6.0,49.8,2.0,1.9,experimental,23.08,0.2055,0.1779,Peptide LLSGKE in complex with human cathepsin V C25S mutant
7Q8Q,X-RAY DIFFRACTION,2.79,55.87,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",278.0,2021-11-11,2022-11-23,7Q8Q,3777.0,4.0,454.0,284.0,6.0,49.88,2.0,2.13,experimental,42.6,0.2392,0.2114,Peptide RLSAKP in complex with human cathepsin V C25S mutant
6YKY,X-RAY DIFFRACTION,2.49,50.67,"VAPOR DIFFUSION, SITTING DROP",6.0,"100 mM Bis-Tris (pH 6), 100 mM Lithium acetate, 18%v/v Sokalan CP42, 3%vv Glycerol",277.0,2020-04-06,2020-09-23,6YKY,9474.0,4.0,1276.0,189.0,,146.33,1.0,2.52,experimental,70.0,0.251,0.198,"Biochemical, Cellular and Structural Characterization of Novel ERK3 Inhibitors"
6YLC,X-RAY DIFFRACTION,2.49,50.67,"VAPOR DIFFUSION, SITTING DROP",6.0,"100 mM Bis-Tris (pH 6), 100 mM Lithium acetate, 18%v/v Sokalan CP42, 3%v/v Glycerol",277.0,2020-04-07,2020-09-23,6YLC,9452.0,4.0,1276.0,119.0,,146.45,1.0,2.43,experimental,91.82,0.231,0.189,"Biochemical, Cellular and Structural Characterization of Novel ERK3 Inhibitors"
7K07,X-RAY DIFFRACTION,2.11,41.83,"VAPOR DIFFUSION, HANGING DROP",8.0,"35% MPEG 2K,
20% saturated KCl,
200 mM pH 8.0 Imidazole Malate,
5mM MnCl2,
20mM AMP",290.0,2020-09-03,2021-10-06,7K07,3435.0,2.0,432.0,163.0,1.0,51.05,1.0,2.15,experimental,53.63,0.2184,0.177,Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
7KIU,X-RAY DIFFRACTION,2.17,43.0,"VAPOR DIFFUSION, HANGING DROP",8.5,"19% PEG 8000,
250 mM Magnesium Chloride,
100 mM Tris pH 8.5",283.0,2020-10-24,2021-12-01,7KIU,8915.0,4.0,1124.0,174.0,8.0,131.38,1.0,2.22,experimental,64.95,0.2304,0.1906,Structure of recombinant human DNase1L3 in complex with Mg2+
8S98,X-RAY DIFFRACTION,2.15,42.67,"VAPOR DIFFUSION, HANGING DROP",,"The purified protein was used in crystallization trials employing both, a standard screen with approximately 1200 different conditions, as well as crystallization conditions identified using literature data. Conditions initially obtained have been optimised using standard strategies, systematically varying parameters critically influencing crystallization, such as temperature, protein concentration, drop ratio, and others. These conditions were also refined by systematically varying pH or precipitant concentrations.",298.0,2023-03-27,2023-07-26,8S98,6885.0,3.0,885.0,626.0,,100.07,1.0,1.87,experimental,21.432,0.27367,0.22454,Crystal structure of the TYK2 pseudokinase domain in complex with compound 8
6CDT,X-RAY DIFFRACTION,2.12,42.01,"VAPOR DIFFUSION, HANGING DROP",,"crystallized by the hanging drop vapor diffusion method at 13 degrees Celsius by mixing equal volumes of a purified protein (11-15 mg/mL) solution with a crystallization solution containing 0.15 M ammonium sulfate, 9 - 10.5% (w/v) monomethylether polyethylene glycol (MW 5 K) and 0.1 M MES buffer in a pH range of 5.3-5.6.",286.0,2018-02-09,2019-02-20,6CDT,2575.0,1.0,327.0,276.0,,36.91,1.0,1.8,experimental,28.7,0.226,0.194,Structure of Human Anaplastic Lymphoma Kinase Domain
7WMC,X-RAY DIFFRACTION,2.62,53.1,"VAPOR DIFFUSION, SITTING DROP",,"15%(w/v)PEG3350, 0.1 M sodium malonate pH7.5",277.0,2022-01-14,2022-08-31,7WMC,3838.0,5.0,548.0,68.0,,61.42,2.0,2.55,experimental,32.468,0.2555,0.1861,Crystal structure of macrocyclic peptide 1 bound to human Nicotinamide N-methyltransferase
6P1M,X-RAY DIFFRACTION,2.835,56.0,"VAPOR DIFFUSION, SITTING DROP",6.5,"92mM Bis-Tris pH 6.5, 0.276M KBr, 20.7% w/v PolyPure PEGs 0.3-8KDa",277.0,2019-05-20,2019-09-04,6P1M,3408.0,4.0,371.0,401.0,,45.69,1.0,1.65,experimental,,0.1898,0.1657,Binary complex of human DNA Polymerase Mu with 1-nt gapped substrate containing template 8OG
7W9U,X-RAY DIFFRACTION,1.89,34.97,"VAPOR DIFFUSION, SITTING DROP",,"0.05 M Zinc acetate dihydrate, 20% w/v Polyethylene glycol 3,350",293.0,2021-12-10,2022-12-21,7W9U,4209.0,4.0,656.0,96.0,,73.63,1.0,2.163,experimental,50.538,0.275,0.2148,Crystal Structure of Zn bound human Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
6SEY,X-RAY DIFFRACTION,2.11,41.8,"VAPOR DIFFUSION, HANGING DROP",7.8,"Ammonium sulfate 2.7 M, TRIS 0.1 M, saturated para-Chloromercuribenzoic acid",291.0,2019-07-30,2020-08-26,6SEY,2438.0,1.0,265.0,201.0,,31.43,1.0,1.23,experimental,11.92,0.1249,0.1099,Human Carbonic Anhydrase II in complex with aliphatically substituted benzenesulfonamide
6VAJ,X-RAY DIFFRACTION,2.03,39.42,"VAPOR DIFFUSION, SITTING DROP",,"100mM HEPES-7.5, 3.0M ammonium sulfate",293.0,2019-12-17,2020-12-30,6VAJ,1384.0,1.0,178.0,132.0,,20.51,1.0,1.42,experimental,31.7863,0.2143,0.1923,Crystal Structure Analysis of human PIN1
5ULK,X-RAY DIFFRACTION,2.15,42.76,"VAPOR DIFFUSION, HANGING DROP",,"200 mM ammonium nitrate, 20% PEG 3350",289.0,2017-01-24,2017-06-07,5ULK,2166.0,3.0,320.0,,,36.15,3.0,2.38,experimental,83.06,0.2673,0.2065,Crystal Structure of RNF165 in complex with a UbcH5b~Ub conjugate
6QL8,X-RAY DIFFRACTION,2.87,57.2,"VAPOR DIFFUSION, HANGING DROP",6.0,"100mM ADA pH6.0, 500mM ammonium nitrate, 17% PEG 3350",291.0,2019-01-31,2020-02-19,6QL8,2006.0,1.0,217.0,260.0,3.0,24.68,1.0,1.8,experimental,17.394,0.1811,0.149,Cathepsin-K in complex with MIV-711
8VJU,X-RAY DIFFRACTION,2.61,52.95,"VAPOR DIFFUSION, HANGING DROP",,"17.5 ~ 30 % polyethylene glycol 3,350 and 50 ~ 125 mM Bis-Tris HCl buffer, pH 6.5",295.0,2024-01-08,2024-08-21,8VJU,5729.0,2.0,680.0,253.0,,78.93,2.0,1.99,experimental,,0.2184,0.195,Structure of Human Neurolysin in complex with dynorphin A13 peptide
8VJV,X-RAY DIFFRACTION,2.62,53.08,"VAPOR DIFFUSION, HANGING DROP",,"17.5 ~ 30 % polyethylene glycol 3,350 and 50 ~ 125 mM Bis-Tris HCl buffer, pH 6.5",295.0,2024-01-08,2024-08-21,8VJV,5524.0,2.0,675.0,78.0,,77.88,2.0,2.12,experimental,49.11,0.2492,0.2131,Structure of Human Neurolysin in complex with dynorphin A8(1-8) peptide
5Y4H,X-RAY DIFFRACTION,2.68,54.04,"VAPOR DIFFUSION, SITTING DROP",,Potassium phosphate,293.0,2017-08-03,2018-05-16,5Y4H,2120.0,2.0,297.0,5.0,,33.92,2.0,2.6,experimental,61.284,0.26914,0.21514,Human SIRT3 in complex with halistanol sulfate
6TT5,X-RAY DIFFRACTION,1.91,35.76,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350
0.3 M Ammonium Chloride",277.15,2019-12-23,2020-02-12,6TT5,3178.0,1.0,362.0,224.0,,42.33,1.0,1.5,experimental,16.335,0.1918,0.1658,Crystal structure of DCLRE1C/Artemis
7AF1,X-RAY DIFFRACTION,1.19,35.52,"VAPOR DIFFUSION, SITTING DROP",,20% PEG 3350 0.3 M Ammonium Chloride,277.15,2020-09-19,2020-10-28,7AF1,3164.0,1.0,362.0,144.0,,42.47,1.0,1.7,experimental,20.143,0.21169,0.19051,The structure of Artemis/SNM1C/DCLRE1C with 2 Zinc ions
7AFS,X-RAY DIFFRACTION,1.92,36.09,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M Ammonium Acetate, 0.1 M Bis-TRIS pH 5.5, 25% PEG 3350",277.15,2020-09-20,2020-10-28,7AFS,3134.0,1.0,362.0,163.0,,42.04,1.0,1.7,experimental,25.925,0.2161,0.1859,The structure of Artemis variant D37A
7AFU,X-RAY DIFFRACTION,1.91,35.58,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Sodium Citrate pH 5.5, 20% PEG 3350",277.15,2020-09-20,2020-10-28,7AFU,3279.0,1.0,362.0,254.0,,42.45,1.0,1.56,experimental,17.479,0.2125,0.1883,The structure of Artemis variant H33A
7AGI,X-RAY DIFFRACTION,1.93,36.3,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M Sodium Citrate pH 5.5, 20% PEG 3350",277.15,2020-09-22,2020-10-28,7AGI,3319.0,1.0,362.0,164.0,,42.31,1.0,1.7,experimental,18.404,0.2102,0.1897,The structure of Artemis variant H35D
6ZR9,X-RAY DIFFRACTION,2.12,41.96,"VAPOR DIFFUSION, HANGING DROP",8.5,"25% PEG 3350, 0.2 M Ammonium acetate, 0.1 M Tris-HCl (pH 8.5)",293.0,2020-07-11,2021-06-16,6ZR9,2187.0,1.0,274.0,103.0,1.0,31.46,1.0,2.05,experimental,25.2641,0.2411,0.196,The crystal structure of the complex of hCAVII with 2-(4-benzhydrylpiperazin-1-yl)-N-(4-sulfamoylphenyl)acetamide
6ELM,X-RAY DIFFRACTION,2.06,40.3,"VAPOR DIFFUSION, SITTING DROP",8.0,30% PEG1000 -- 0.1M SPG pH 8.0,293.0,2017-09-29,2017-12-20,6ELM,1009.0,1.0,98.0,160.0,,11.34,1.0,1.14,experimental,,0.1683,0.1383,Crystal structure of the human WNK2 CCT1 domain
5IKW,X-RAY DIFFRACTION,2.75,55.25,"VAPOR DIFFUSION, SITTING DROP",7.0,"10% (v/v) Broad MW PEG smear; 3.2 M MgCl2, 100 mM Hepes pH 7.0",291.15,2016-03-04,2016-06-29,5IKW,2434.0,1.0,310.0,89.0,,35.19,1.0,2.41,experimental,53.1,0.216,0.176,Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor
6WFN,X-RAY DIFFRACTION,1.99,38.23,"VAPOR DIFFUSION, SITTING DROP",5.77,"Naa50 apo protein (13.0 mg/ml) was incubated with 4a and AcCoA in a 1:3:3 molar ratio on ice for 60 min.  Reservoir solution containing 0.1 M Bis_tris, pH 5.77 and 21% w/v PEG 3350 was mixed 0.2ul:0.2ul with Naa50:4b:AcCoA complex",294.0,2020-04-03,2020-07-01,6WFN,1510.0,1.0,171.0,180.0,,20.93,1.0,1.07,experimental,16.38,0.201,0.189,Crystal structure of human Naa50 in complex with AcCoA and an inhibitor (compound 4a) identified using DNA encoded library technology
7XV1,X-RAY DIFFRACTION,2.47,50.19,"VAPOR DIFFUSION, HANGING DROP",,20% PEG3350 200 mM Ammonium Acetate,278.0,2022-05-20,2023-06-14,7XV1,1223.0,2.0,149.0,93.0,,16.49,2.0,1.8,experimental,35.3766,0.2158,0.1967,Crystal structure of RPA70N-HelB fusion
5WBG,X-RAY DIFFRACTION,3.77,67.4,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.8M Sodium Formate
0.1 M Tris pH 7.5
8% w/v PEG 20000
8% v/v PEG 550 MME",291.0,2017-06-29,2018-05-02,5WBG,22570.0,6.0,2856.0,155.0,,336.11,1.0,2.99,experimental,49.63,0.262,0.227,Crystal Structure of human Cytochrome P450 2B6 (Y226H/K262R) in complex with an analog of a drug Efavirenz
7OW6,X-RAY DIFFRACTION,3.26,62.3,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulfate, 20% w/v PEG 3350",293.0,2021-06-16,2022-07-20,7OW6,6536.0,5.0,835.0,18.0,8.0,95.42,5.0,2.64,experimental,95.077,0.26764,0.21075,Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS G12D peptide (VVVGADGVGK)
4XBU,X-RAY DIFFRACTION,2.5,50.77,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris-HCl, PEG 8000",298.15,2014-12-17,2015-12-02,4XBU,2569.0,2.0,350.0,150.0,,39.71,2.0,2.06,experimental,40.805,0.24343,0.19856,In vitro Crystal Structure of PAK4 in complex with Inka peptide
7UYR,X-RAY DIFFRACTION,2.2,44.1,VAPOR DIFFUSION,,Crystals of human TYK2 in complex with the ligand were prepared according to established protocols,291.0,2022-05-07,2022-08-24,7UYR,2464.0,1.0,289.0,83.0,,34.06,1.0,2.15,experimental,42.272,0.2592,0.2002,Crystal structure of TYK2 kinase domain in complex with compound 12
7UYS,X-RAY DIFFRACTION,2.17,43.32,VAPOR DIFFUSION,,Crystals of human TYK2 in complex with the ligand were prepared according to established protocols,291.0,2022-05-07,2022-08-24,7UYS,2403.0,1.0,289.0,64.0,,34.01,1.0,2.15,experimental,53.998,0.2716,0.2275,Crystal structure of TYK2 kinase domain in complex with compound 16
7UYT,X-RAY DIFFRACTION,2.15,42.75,VAPOR DIFFUSION,,Crystals of human TYK2 in complex with the ligand were prepared according to established protocols,291.0,2022-05-07,2022-08-24,7UYT,2268.0,1.0,289.0,63.0,,34.07,1.0,2.14,experimental,46.775,0.2929,0.2392,Crystal structure of TYK2 kinase domain in complex with compound 25
7UYU,X-RAY DIFFRACTION,2.16,43.1,VAPOR DIFFUSION,,Crystals of human TYK2 in complex with the ligand were prepared according to established protocols,291.0,2022-05-07,2022-08-24,7UYU,2200.0,1.0,289.0,55.0,,34.17,1.0,2.05,experimental,53.555,0.2566,0.2241,Crystal structure of TYK2 kinase domain in complex with compound 30
6F1D,X-RAY DIFFRACTION,2.91,57.7,"VAPOR DIFFUSION, SITTING DROP",8.5,"50 mM Tris-HCl at pH 8.5 containing 25% PEG-8K, 2 mM CaCl2 and 3% 1,6-diaminohexane",298.0,2017-11-21,2018-01-17,6F1D,1031.0,1.0,117.0,85.0,2.0,13.48,1.0,1.95,experimental,34.3829,0.2016,0.1732,CUB2 domain of C1r
5NRF,X-RAY DIFFRACTION,2.27,45.82,"VAPOR DIFFUSION, HANGING DROP",,"25% (w/v) polyethylene glycol (PEG) 3350, 200 mM potassium sodium tartrate (PST) at pH 7.2",290.0,2017-04-22,2018-03-28,5NRF,3354.0,1.0,377.0,200.0,2.0,42.73,1.0,1.447,experimental,,0.1693,0.144,Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 7i
5AM9,X-RAY DIFFRACTION,2.95,58.0,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",,2015-03-10,2016-01-13,5AM9,22178.0,4.0,2516.0,1649.0,12.0,300.49,1.0,1.8,experimental,27.347,0.22907,0.19674,Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 10-16
8CZK,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.70-0.75 M succinic acid pH 7.0, 0.1 M bis-tris-propane pH 7.0",282.0,2022-05-24,2023-01-25,8CZK,7116.0,4.0,850.0,477.0,,97.18,2.0,1.91,experimental,31.31,0.21338,0.184,Human LanCL1 bound to GSH and Dhb-Erk peptide
4ODP,X-RAY DIFFRACTION,2.46,50.03,"VAPOR DIFFUSION, SITTING DROP",7.5,"28% PEG400, 0.1 M HEPES, pH 7.5, 0.2 M calcium chloride, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-01-10,2015-01-14,4ODP,964.0,2.0,126.0,101.0,,14.18,2.0,1.747,experimental,,0.2018,0.1844,Structure of SlyD delta-IF from Thermus thermophilus in complex with S2-W23A peptide
4ODQ,X-RAY DIFFRACTION,2.44,49.65,"VAPOR DIFFUSION, SITTING DROP",8.0,"25% PEG6000, 0.1 M Tris-HCl, pH 8.0, 0.2 M calcium chloride, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-01-10,2015-01-14,4ODQ,1005.0,2.0,126.0,107.0,,14.22,2.0,2,experimental,,0.2134,0.1942,Structure of SlyD delta-IF from Thermus thermophilus in complex with S3 peptide
5E8F,X-RAY DIFFRACTION,2.61,52.89,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES (pH 7.5), 0.2 M Li2SO4, 25 % PEG4000 and 0.1 M NaOAc",293.0,2015-10-14,2015-11-18,5E8F,2651.0,4.0,308.0,108.0,,36.33,2.0,2.1,experimental,34.13,0.2561,0.1983,Structure of Fully modified geranylgeranylated PDE6C Peptide in complex with PDE6D
7OW5,X-RAY DIFFRACTION,3.36,63.35,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium citrate tribasic pH 7.0, 20% w/v PEG 3350",293.0,2021-06-16,2022-07-20,7OW5,6632.0,5.0,835.0,17.0,8.0,95.46,5.0,2.58,experimental,88.001,0.27356,0.20595,Crystal structure of a TCR in complex with HLA-A*11:01 bound to KRAS peptide (VVVGAGGVGK)
5OVR,X-RAY DIFFRACTION,2.55,51.84,"VAPOR DIFFUSION, HANGING DROP",,"26-28% PEG3350, 0.1M Bis-Tris pH5.5, 0.2M Lithium sulfate",277.0,2017-08-29,2017-11-22,5OVR,2745.0,1.0,305.0,380.0,,35.66,1.0,2.15,experimental,17.17,0.2906,0.2139,X-Ray Characterization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors
6SDT,X-RAY DIFFRACTION,2.11,41.83,"VAPOR DIFFUSION, HANGING DROP",8.5,"25% (W/V) POLYETHYLENE GLYCOL 3350, 0.2 M AMMONIUM ACETATE, 0.1 M TRIS-HCL,",293.0,2019-07-29,2020-06-10,6SDT,2169.0,1.0,274.0,94.0,1.0,31.3,1.0,1.94,experimental,20.985,0.2257,0.1877,HUMAN CARBONIC ANHYDRASE VII IN COMPLEX WITH A SULFONAMIDE INHIBITOR
6NV7,X-RAY DIFFRACTION,3.19,61.4,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M MgSO4
0.1 M sodium citrate
12-14 % PEG4000",295.0,2019-02-04,2019-10-09,6NV7,9528.0,3.0,1170.0,618.0,9.0,132.07,1.0,2.132,experimental,,0.2168,0.1897,BACE1 in complex with a macrocyclic inhibitor
6NV9,X-RAY DIFFRACTION,3.2,61.53,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgSO4
0.1 M Na citrate
14-20 % PEG 4000",293.0,2019-02-04,2019-10-09,6NV9,9541.0,3.0,1170.0,616.0,9.0,132.45,1.0,2.13,experimental,,0.1902,0.1551,BACE1 in complex with a macrocyclic inhibitor
6NW3,X-RAY DIFFRACTION,3.08,60.01,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M MgSO4
0.1 M Na citrate
14-20 % PEG4000",298.0,2019-02-05,2019-10-09,6NW3,9563.0,3.0,1170.0,589.0,9.0,132.6,1.0,2.352,experimental,,0.2131,0.1834,BACE1 in complex with a macrocyclic inhibitor
8BZP,X-RAY DIFFRACTION,2.23,44.81,"VAPOR DIFFUSION, SITTING DROP",6.0,"Protein was concentrated to 7-9 mg/ml and incubated with (final conc.): 1mM AMP-PCP, 0.4 mM Zwittergent and 10% EG. Protein was mixed 2+2 ul with mother liquor containing: 100 mM BisTris pH=6, PEG3350 27% and NaCl 200 mM",291.0,2022-12-15,2023-08-02,8BZP,5834.0,2.0,728.0,287.0,,87.23,1.0,1.86,experimental,46.16,0.2162,0.1894,JNK3 (Mitogen-activated protein kinase 10) in Complex with Compound 23 bearing a C(sp3)F2Br moiety
5LHB,X-RAY DIFFRACTION,2.44,49.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG 3350, 36.4MM PCTP PH 4, 63.6MM  PCTP PH 10, 0.2M AMMONIUM SULPHATE",293.0,2016-07-10,2016-10-12,5LHB,4462.0,1.0,531.0,300.0,,62.08,1.0,2.23,experimental,44.63,0.2115,0.1622,POLYADPRIBOSYL GLYCOSIDASE IN COMPLEX WITH PDD00017262
7UDP,X-RAY DIFFRACTION,2.27,45.78,"VAPOR DIFFUSION, SITTING DROP",8.0,"Crystals were grown in a MRC SD2 plate set by a STP Labtech Mosquito. Protein at 17.89 mg/ml (390 uM) and 500 uM CA157 were inc for 30 min at ambient temp prior to setting the plate.  The droplet providing the crystal used for data collection and refinement was  200 nL of protein-CA157 solution and 25 nL reservoir,  0.65 M sodium succinate pH 7, 0.1M HEPPS buffer, pH 8.0.",293.0,2022-03-20,2023-01-18,7UDP,3096.0,1.0,393.0,18.0,,45.58,1.0,2.01,experimental,97.6354,0.2794,0.2397,Crystal structure of COQ8A-CA157 inhibitor complex in space group C2
7Z5W,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.66,"11% peg3350, 200mM AmSO4, PCTP 100mM pH 6.66. Grown in 15well plate. Seeded with previous crystals. ATP/Mg 10mM",293.15,2022-03-10,2022-08-17,7Z5W,4520.0,2.0,662.0,108.0,,76.34,1.0,2.254,experimental,62.52,0.2755,0.2232,ROS1 with AstraZeneca ligand 1
7B2S,X-RAY DIFFRACTION,1.93,36.21,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 8000, 0.2 M Ammonium sulfate",293.15,2020-11-27,2021-01-13,7B2S,1650.0,1.0,178.0,239.0,,20.05,1.0,1.5,experimental,14.448,0.1738,0.1416,Crystal structure of SPRY domain of TRIM9
7U4W,X-RAY DIFFRACTION,2.09,41.19,"VAPOR DIFFUSION, SITTING DROP",6.5,"1.2 uL of 15 mg/mL protein combined with 1.2 uL of 100 mM Bis-Tris, pH 6.50, 750 mM Mg-Formate",298.0,2022-03-01,2023-03-08,7U4W,1068.0,1.0,155.0,9.0,,17.78,1.0,2.1,experimental,72.8,0.2756,0.2452,The ubiquitin-associated domain of human thirty-eight negative kinase-1 flexibly fused to the 1TEL crystallization chaperone via a 2-glycine linker and crystallized at traditional protein concentration
7U4Z,X-RAY DIFFRACTION,2.04,39.66,"VAPOR DIFFUSION, SITTING DROP",6.0,"1.2 uL of 0.5 mg/mL protein combined with 1.2 uL of 100 mM Bis-Tris, pH 6.00, 630-750 mM Mg-Formate.",298.0,2022-03-01,2023-03-08,7U4Z,1237.0,1.0,155.0,40.0,,17.81,1.0,2.03,experimental,33.07,0.2318,0.2019,The ubiquitin-associated domain of human thirty-eight negative kinase-1 flexibly fused to the 1TEL crystallization chaperone via a 2-glycine linker and crystallized at very low protein concentration
5FZO,X-RAY DIFFRACTION,2.69,54.26,,8.5,20% PEG3350 -- 10% ETHYLENE GLYCOL -- 0.1M BIS-TRIS-PROPANE PH 8.5 -- 0.2M POTASSIUM CITRATE TRIBASIC,,2016-03-15,2016-03-30,5FZO,6004.0,2.0,704.0,502.0,2.0,81.14,2.0,1.84,experimental,,0.2314,0.1925,Crystal structure of the catalytic domain of human JmjD1C
8SBI,X-RAY DIFFRACTION,1.87,34.0,"VAPOR DIFFUSION, HANGING DROP",7.4,"potassium formate, PEG 3350, n-deconyl sucrose",290.0,2023-04-03,2023-04-12,8SBI,7299.0,2.0,906.0,83.0,,104.59,1.0,2.73,experimental,51.162,0.24575,0.23007,Crystal structure of human sterol 14 alpha-demethylase (CYP51) in the ligand-free state
6ATQ,X-RAY DIFFRACTION,2.26,45.66,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG 2000 MME, 25% (w/v), 0.1 M MES, 6.5",293.0,2017-08-29,2018-09-12,6ATQ,4114.0,2.0,442.0,436.0,,51.75,1.0,2,experimental,,0.2348,0.1687,Crystal structure of apo-hGSTA1-1 exhibiting a new conformation of C-terminal helix
5BMY,X-RAY DIFFRACTION,2.2,44.02,"VAPOR DIFFUSION, SITTING DROP",7.0,2.1 M DL-malic acid,293.0,2015-05-25,2016-10-26,5BMY,3372.0,1.0,389.0,345.0,,43.16,1.0,2.001,experimental,,0.1937,0.1537,Crystal structure of hPin1 WW domain (5-21) fused with maltose-binding protein
7DYG,X-RAY DIFFRACTION,2.55,51.82,"VAPOR DIFFUSION, SITTING DROP",,"0.2M potassium citrate tribasic monohydrate PH 8.3, 20% w/v PEG 3350",291.15,2021-01-21,2022-01-26,7DYG,3018.0,1.0,330.0,327.0,2.0,38.34,1.0,2,experimental,27.7658,0.1857,0.1609,Histone lysine demethylase 4D (KDM4D) in complex with the inhibitor 2-(1H-pyrazol-3-yl)isonicotinic acid
7DYQ,X-RAY DIFFRACTION,2.55,51.78,"VAPOR DIFFUSION, SITTING DROP",,"0.2M potassium citrate tribasic monohydrate PH 8.3, 20% w/v PEG 3350",291.15,2021-01-22,2022-01-26,7DYQ,2980.0,1.0,330.0,302.0,3.0,38.37,1.0,1.998,experimental,27.8461,0.1848,0.1609,"Crystal structure of histone lysine demethylase 4D (KDM4D) in complex with the inhibitor 5-hydroxy-2-methylpyrazolo[1,5-a]pyrido[3,2-e]pyrimidine-3-carbonitrile"
6OBN,X-RAY DIFFRACTION,2.46,50.03,"VAPOR DIFFUSION, HANGING DROP",6.2,"14% PEG4000, 6% MPD, sodium/potassium phosphate",289.0,2019-03-21,2019-09-18,6OBN,9480.0,4.0,1230.0,52.0,,143.31,2.0,2.7,experimental,,0.2458,0.2023,The crystal structure of coexpressed SDS22:PP1 complex
4YZU,X-RAY DIFFRACTION,2.75,55.31,"VAPOR DIFFUSION, HANGING DROP",9.5,"0.05 M Tris, pH 7.2, 1.2 M ammonium sulfate, 2.0 M sodium chloride",295.0,2015-03-25,2015-05-20,4YZU,2696.0,2.0,297.0,335.0,9.0,33.57,2.0,1.41,experimental,26.65,0.161,0.145,Rapid development of two Factor IXa inhibitors from Hit to Lead
4Z0K,X-RAY DIFFRACTION,2.78,55.7,"VAPOR DIFFUSION, HANGING DROP",7.2,"50 mM Tris, pH 7.2,  1.2 M ammonium sulfate, 2.0 M sodium chloride",295.0,2015-03-26,2015-05-20,4Z0K,2652.0,2.0,297.0,345.0,7.0,33.61,2.0,1.41,experimental,25.66,0.165,0.147,Rapid development of two Factor IXa inhibitors from Hit to Lead
7OVX,X-RAY DIFFRACTION,1.94,36.44,BATCH MODE,,"20% PEG 4K, 0.1M NaCl, 50 mM HEPES pH7",296.0,2021-06-15,2022-06-22,7OVX,1655.0,2.0,186.0,150.0,,21.46,2.0,1.7,experimental,22.93,0.2259,0.1835,E3 RING ligase binding domain
5FBI,X-RAY DIFFRACTION,2.14,42.47,"VAPOR DIFFUSION, HANGING DROP",,"1 Microliter of protein solution was mixed with 1 microliter of reservoir solution. Protein solution: 18.3 mg/ml factor D, 10 mM Tris pH 7.0, 100 mM sodium chloride; Reservoir solution: 22% PEG3350, 100 mM HEPES pH 7.5; Soaking and cryo: 0.5 ul 100 mM compound 3b in 90% DMSO was added to the crystal containing drop and incubated for 45 min followed by the addition of 0.5 ul glyerol and flash freezing in liquid nitrogen.",293.0,2015-12-14,2016-10-26,5FBI,1956.0,1.0,232.0,165.0,4.0,25.14,1.0,1.47,experimental,24.17,0.1955,0.1732,COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 3b
7LPY,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, HANGING DROP",,"35% PEG 3350,
20% saturated KCl,
200 mM Imidazole / Malate buffer pH 8.0,
5mM MnCl2,
18mM AMP,
3.3 mM N-{2-[4-(thiophen-2-yl)-1H-imidazol-2-yl]ethyl}-2,3-dihydro-1,4-benzodioxine-2-carboxamide (from Life Chemicals)",290.0,2021-02-12,2022-02-16,7LPY,3436.0,2.0,432.0,158.0,1.0,51.14,1.0,1.85,experimental,57.81,0.2051,0.1789,Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
7LPZ,X-RAY DIFFRACTION,2.12,42.03,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 3350,
25% saturated KCl,
200 mM Imidazole / Malate buffer 8.0,
2.5 mM samarium (III) acetate,
18mM AMP,
3.3 mM N-{2-[4-(thiophen-2-yl)-1H-imidazol-2-yl]ethyl}-2,3-dihydro-1,4-benzodioxine-2-carboxamide (from Life Chemicals)",290.0,2021-02-12,2022-02-16,7LPZ,3629.0,2.0,432.0,329.0,1.0,51.52,1.0,1.55,experimental,44.83,0.1968,0.1584,Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
7LQ0,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, HANGING DROP",,"37.5% PEG 3350, 
20% saturated KCl,
200 mM Imidazole / Malate buffer 8.0,
18mM AMP,
3.3 mM N-{2-[4-(thiophen-2-yl)-1H-imidazol-2-yl]ethyl}-2,3-dihydro-1,4-benzodioxine-2-carboxamide (from Life Chemicals)",290.0,2021-02-12,2022-02-16,7LQ0,3596.0,2.0,432.0,304.0,1.0,51.02,1.0,1.6,experimental,47.98,0.1992,0.1623,Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
7D9Y,X-RAY DIFFRACTION,3.26,62.27,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.125 M Tris pH 8.0, 20 % SOKALAN CP 42, 7.5% Methanol",277.15,2020-10-14,2021-02-24,7D9Y,1737.0,1.0,243.0,17.0,,27.66,1.0,2.76,experimental,66.7,0.2757,0.2343,DNA binding domain of human DNA Ligase IV mutant - A3V
8Q1Z,X-RAY DIFFRACTION,2.25,45.41,"VAPOR DIFFUSION, SITTING DROP",,20% PEG3350 -- 0.2M potassium formate,293.0,2023-08-01,2023-08-16,8Q1Z,2546.0,1.0,324.0,121.0,,37.14,1.0,1.85,experimental,31.814,0.25075,0.19992,Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to JA-296
5TDM,X-RAY DIFFRACTION,2.73,55.02,"VAPOR DIFFUSION, HANGING DROP",,"13% P3350, 100 mM TrisHCl pH 8.7, 125 mM ammonium chloride",294.0,2016-09-19,2017-08-09,5TDM,6078.0,2.0,755.0,187.0,,84.39,2.0,2.1,experimental,,0.286,0.216,TEV Cleaved Human ATP Citrate Lyase Bound to 4R-Hydroxycitrate and ADP
7A1L,X-RAY DIFFRACTION,3.44,64.23,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6M AMMONIUM SULPHATE, 6% PEG 400, 0.1M HEPES PH 7.5",277.0,2020-08-13,2021-08-25,7A1L,2842.0,1.0,349.0,57.0,,40.94,1.0,2.29,experimental,83.48,0.2215,0.2078,FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II) AND 3-methyl-2-oxoglutarate
6HMP,X-RAY DIFFRACTION,2.1,41.52,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium citrate tribasic pH 7.0
20 % w/v Polyethylene glycol 3,350",293.0,2018-09-12,2019-09-11,6HMP,4922.0,2.0,628.0,229.0,,74.11,1.0,2.039,experimental,,0.219,0.1853,Crystal structure of human Casein Kinase I delta in complex with a photoswitchable 2-Azoimidazole-based Inhibitor (compound 3)
7NB1,X-RAY DIFFRACTION,2.5,50.81,"VAPOR DIFFUSION, SITTING DROP",7.0,"18-20% Peg-mme 5000, 0.1 M Magnesium Formate, 0.1 M HEPES pH 7.0",293.0,2021-01-25,2021-10-13,7NB1,6039.0,2.0,768.0,142.0,,91.67,1.0,2.3,experimental,55.247,0.2486,0.1946,Crystal structure of human choline alpha in complex with an inhibitor
8Q69,X-RAY DIFFRACTION,2.12,41.9,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.3-6.9, 50 mM Na2SO4, 18-25 % PEG 6000",290.0,2023-08-11,2024-08-21,8Q69,4919.0,2.0,552.0,405.0,,66.81,1.0,1.96,experimental,,0.2892,0.2423,Crystal structure of HsRNMT complexed with inhibitor DDD1060606
5CQI,X-RAY DIFFRACTION,2.07,40.46,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, MES-NaOH",293.0,2015-07-21,2015-10-07,5CQI,1763.0,1.0,186.0,215.0,,22.32,1.0,1.68,experimental,,0.1978,0.1604,Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
4D7G,X-RAY DIFFRACTION,2.75,55.34,,8.5,"2M AMMONIUM SULFATE, 0.1M TRIS-CL PH 8.5, 0.2M NACL",,2014-11-24,2016-01-20,4D7G,2009.0,1.0,238.0,34.0,4.0,28.36,1.0,2.33,experimental,70.57,0.2489,0.2242,Human FXIa in complex with small molecule inhibitors.
8DYE,X-RAY DIFFRACTION,2.43,49.3,"VAPOR DIFFUSION, HANGING DROP",4.7,"100 mM Sodium malonate, 12 % w/v PEG 3350, 1 mM DTT",298.0,2022-08-04,2024-01-10,8DYE,5736.0,2.0,709.0,422.0,,80.58,2.0,1.44,experimental,27.09,0.1728,0.155,Crystal structure of human SDHA-SDHAF4 assembly intermediate
8GTG,X-RAY DIFFRACTION,2.88,57.27,LIPIDIC CUBIC PHASE,4.5,"0.05M Na-Citrate(4.5), 0.06M NaCl 20~30% PEG 400(w/v)",293.0,2022-09-08,2023-09-13,8GTG,3245.0,2.0,444.0,,1.0,51.29,2.0,2.75,experimental,86.59,0.263,0.2354,Corticotropin-releasing hormone receptor 1(CRF1R) bound with BMK-I-152 by XFEL
8GTI,X-RAY DIFFRACTION,2.88,57.27,LIPIDIC CUBIC PHASE,4.5,"0.05M Na-Citrate(4.5), 0.06M NaCl 20~30% PEG 400(w/v)",293.0,2022-09-08,2023-09-13,8GTI,3403.0,2.0,444.0,,1.0,52.7,2.0,2.2,experimental,71.22,0.2368,0.2085,Corticotropin-releasing hormone receptor 1(CRF1R) bound with BMK-C205 by XFEL
8GTM,X-RAY DIFFRACTION,2.82,56.42,LIPIDIC CUBIC PHASE,4.5,"0.05M Na-Citrate(4.5), 0.06M NaCl
20~30% PEG 400(w/v)",293.0,2022-09-08,2023-09-13,8GTM,3303.0,2.0,444.0,,1.0,51.4,2.0,2.6,experimental,66.47,0.2602,0.2193,Corticotropin-releasing hormone receptor 1(CRF1R) bound with BMK-C203 by XFEL
6GGH,X-RAY DIFFRACTION,2.52,51.22,"VAPOR DIFFUSION, HANGING DROP",,"27% (m/v) PEG6000, 0.1 M MES/NaOH pH 6.0 and 5 mM DTT",278.0,2018-05-03,2019-05-22,6GGH,5118.0,2.0,584.0,351.0,,68.36,1.0,1.7,experimental,33.544,0.26186,0.18879,Human jak1 kinase domain in complex with inhibitor
7D9K,X-RAY DIFFRACTION,3.18,61.33,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M Tris pH 8.0, 20 % SOKALAN CP 42, 5% Methanol",277.15,2020-10-13,2021-02-24,7D9K,1713.0,1.0,243.0,21.0,,27.63,1.0,2.9,experimental,63.8416,0.2988,0.2563,DNA binding domain of human DNA Ligase IV - Wild type
6ELR,X-RAY DIFFRACTION,2.53,51.33,"VAPOR DIFFUSION, HANGING DROP",,"2mM ligand, 27% (m/v) PEG6000, 0.1 M MES/NaOH pH 6.0, 5 mM DTT",282.0,2017-09-29,2018-10-10,6ELR,5088.0,2.0,602.0,511.0,,70.27,1.0,1.8,experimental,34.81,0.205,0.181,Human jak1 kinase domain in complex with compound 7
6RSD,X-RAY DIFFRACTION,2.53,51.46,VAPOR DIFFUSION,5.6,"0.1M MES, 25-35% PEG6000",277.0,2019-05-21,2020-07-08,6RSD,5030.0,2.0,604.0,335.0,,70.49,1.0,1.76,experimental,25.615,0.238,0.1998,Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class
6RSE,X-RAY DIFFRACTION,2.52,51.15,VAPOR DIFFUSION,5.6,0.1M MES. 25-35% PEG6000,277.0,2019-05-21,2020-07-08,6RSE,5000.0,2.0,604.0,310.0,,70.44,1.0,1.8,experimental,32.583,0.3035,0.2631,Structure based optimization of JAK1-ATP binding pocket Inhibitors in the aminopyrazole class
6G3V,X-RAY DIFFRACTION,2.34,47.5,VAPOR DIFFUSION,9.0,"28% PEG4000, 0.2 M sodium acetate, Tris 100 mM",296.0,2018-03-26,2018-11-28,6G3V,4264.0,2.0,522.0,159.0,,58.9,1.0,1.69,experimental,30.799,0.2631,0.2142,Crystal structure of human carbonic anhydrase I in complex with the inhibitor famotidine
6TPE,X-RAY DIFFRACTION,2.38,48.43,VAPOR DIFFUSION,,,277.0,2019-12-13,2020-06-10,6TPE,4646.0,2.0,582.0,,,67.78,1.0,2.87,experimental,91.506,0.2981,0.2466,Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity
5QIC,X-RAY DIFFRACTION,2.36,47.85,"VAPOR DIFFUSION, SITTING DROP",5.75,"0.1M MIB pH 5.75 - 7.0, 27.5-35% PEG1000",293.0,2018-05-22,2018-07-18,5QIC,3671.0,1.0,369.0,134.0,,41.53,1.0,1.34,experimental,17.209,0.2061,0.1887,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z30620520
5QIE,X-RAY DIFFRACTION,2.35,47.64,"VAPOR DIFFUSION, SITTING DROP",5.75,"0.1M MIB pH 5.75 - 7.0, 27.5-35% PEG1000",293.0,2018-05-22,2018-07-18,5QIE,2952.0,1.0,369.0,142.0,,41.47,1.0,1.34,experimental,17.532,0.1927,0.1648,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z2856434894
5QIF,X-RAY DIFFRACTION,2.38,48.3,"VAPOR DIFFUSION, SITTING DROP",5.75,"0.1M MIB pH 5.75 - 7.0, 27.5-35% PEG1000",293.0,2018-05-22,2018-07-18,5QIF,3025.0,1.0,369.0,137.0,,41.5,1.0,1.2,experimental,14.218,0.1829,0.163,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z31792168
5QIG,X-RAY DIFFRACTION,2.35,47.65,"VAPOR DIFFUSION, SITTING DROP",5.75,"0.1M MIB pH 5.75 - 7.0, 27.5-35% PEG1000",293.0,2018-05-22,2018-07-18,5QIG,3010.0,1.0,369.0,133.0,,41.58,1.0,1.42,experimental,19.117,0.1868,0.1554,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z1407672867
5QIH,X-RAY DIFFRACTION,2.34,47.48,"VAPOR DIFFUSION, SITTING DROP",5.75,"0.1M MIB pH 5.75 - 7.0, 27.5-35% PEG1000",293.0,2018-05-22,2018-07-18,5QIH,4920.0,1.0,369.0,146.0,,41.45,1.0,1.33,experimental,18.571,0.1981,0.179,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z2697514548
6GID,X-RAY DIFFRACTION,2.35,47.71,"VAPOR DIFFUSION, HANGING DROP",,0.2 M potassium nitrate and 20% (w/v) PEG3350,291.0,2018-05-10,2018-06-27,6GID,6124.0,1.0,696.0,463.0,6.0,81.48,1.0,1.9,experimental,,0.2354,0.1899,High resolution crystal structure of substrate-free human neprilysin
5A9U,X-RAY DIFFRACTION,2.1,41.0,"VAPOR DIFFUSION, HANGING DROP",8.0,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286.0,2015-07-22,2016-06-08,5A9U,2558.0,1.0,327.0,198.0,,37.38,1.0,1.6,experimental,34.2,0.258,0.215,"Structure of C1156Y Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile)."
5AAC,X-RAY DIFFRACTION,2.1,41.0,"VAPOR DIFFUSION, HANGING DROP",8.0,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286.0,2015-07-23,2016-06-08,5AAC,2590.0,1.0,327.0,230.0,,37.42,1.0,1.7,experimental,32.6,0.232,0.207,Structure of C1156Y Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib
7EGU,X-RAY DIFFRACTION,1.97,37.45,"VAPOR DIFFUSION, SITTING DROP",,"0.2M NaCl, 0.1M BisTris pH5.5, 25% w/v PEG 3350",293.0,2021-03-26,2021-12-15,7EGU,2209.0,2.0,271.0,173.0,,30.23,2.0,1.9,experimental,22.27,0.236,0.169,Structure of human NNMT in complex with macrocyclic peptide X
7EHZ,X-RAY DIFFRACTION,2.16,42.97,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Bicine pH9.0, 20% w/v PEG 6000",293.0,2021-03-30,2021-12-15,7EHZ,1890.0,2.0,268.0,24.0,,30.09,2.0,2.5,experimental,49.802,0.2552,0.1933,Structure of human NNMT in complex with macrocyclic peptide 2
7EI2,X-RAY DIFFRACTION,2.02,39.21,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Sodium iodide, 0.1M Bis-Tris propane pH7.5, 20% w/v PEG 3350",277.0,2021-03-30,2022-03-30,7EI2,1965.0,2.0,268.0,68.0,,30.07,2.0,2.08,experimental,46.734,0.2464,0.184,Structure of human NNMT in complex with macrocyclic peptide 8
8G4Y,X-RAY DIFFRACTION,2.28,46.07,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M sodium citrate pH 4.5, 20% PEG 4000 plus silver bullet A5 (Hampton Research)",277.0,2023-02-10,2023-12-20,8G4Y,1661.0,2.0,217.0,141.0,4.0,24.16,2.0,1.41,experimental,,0.2361,0.2134,Structure of ZNRF3 ECD bound to peptide MK1-3.6.10
5TUN,X-RAY DIFFRACTION,2.12,42.02,"VAPOR DIFFUSION, SITTING DROP",4.2,"20% polyethylene glycol (PEG) 8000, 0.1 M phosphate/citrate pH 4.2 and 0.2 M sodium chloride",294.15,2016-11-06,2017-01-18,5TUN,2058.0,1.0,215.0,387.0,3.0,23.52,1.0,1.62,experimental,,0.1945,0.1519,Crystal structure of uninhibited human Cathepsin K at 1.62 Angstrom resolution
5QTV,X-RAY DIFFRACTION,3.45,64.3,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2019-11-13,2020-01-29,5QTV,2196.0,1.0,244.0,198.0,4.0,29.23,1.0,2.2,experimental,25.99,0.202,0.174,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecin-14-yl]carbamate"
8Q8N,X-RAY DIFFRACTION,1.83,32.92,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M MES monohydrate pH 6.0, 6% v/v Tacsimate pH 6.0, 25% w/v Polyethylene glycol 4,000",298.0,2023-08-18,2024-08-28,8Q8N,1420.0,1.0,172.0,78.0,,19.58,1.0,1.9,experimental,21.459,0.29209,0.20201,Crystal structure of human GPX4-U46C-I129S-L130S
4X21,X-RAY DIFFRACTION,2.24,45.08,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES, sodium chloride, magnesium chloride, beta-mercaptoethanol
ethylene glycole, zwittergent 3-14, AMP-PCP
Bis-Tris, sodium chloride, PEG 3350, glycerole",292.15,2014-11-25,2015-11-11,4X21,5595.0,2.0,734.0,342.0,,85.57,1.0,1.95,experimental,35.5,0.2235,0.1998,The MAP kinase JNK3 as target for halogen bonding
6UIQ,X-RAY DIFFRACTION,2.86,57.0,"VAPOR DIFFUSION, HANGING DROP",7.3,"0.2 M Sodium tartrate dibasic dihydrate, 20% w/v Polyethylene glycol 3,350",293.0,2019-10-01,2020-08-12,6UIQ,9256.0,2.0,1170.0,568.0,,128.95,1.0,2.3,experimental,43.1234874366,0.222518346102,0.168233215946,Crystal structure of wild-type human phosphoglucomutase 1 in complex with Glucose-6-Phosphate
6G7O,X-RAY DIFFRACTION,3.33,63.08,LIPIDIC CUBIC PHASE,7.5,"75mM MgSO4, 34-40% PEG400, 5% DMSO",293.15,2018-04-06,2019-01-02,6G7O,3039.0,1.0,350.0,122.0,1.0,41.65,1.0,2.7,experimental,74.44,0.27,0.248,Crystal structure of human alkaline ceramidase 3 (ACER3) at 2.7 Angstrom resolution
5HQZ,X-RAY DIFFRACTION,2.5,50.72,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mMKPO4, 30% sat AmSO4, 3% ETOH",287.0,2016-01-22,2017-01-25,5HQZ,1711.0,1.0,186.0,122.0,,22.47,1.0,1.46,experimental,21.162,0.22667,0.19206,"Fluorine substituted 5-methyl-6-(4'-trifluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine"
4TT7,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",8.5,"2 uL of 17 mg/mL protein (50 mM Bicine pH 8.4, 150 mM NaCl, 5 mM DTT) with 2 uL of  0.1 M TRIS hydrochloride,  0.2 M Sodium acetate trihydrate, 30% w/v Polyethylene glycol 4,000",293.0,2014-06-19,2015-02-11,4TT7,2452.0,1.0,325.0,159.0,2.0,37.24,1.0,2.1,experimental,21.256,0.24403,0.19201,Crystal structure of human ALK with a covalent modification
5H2U,X-RAY DIFFRACTION,2.53,51.48,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M tri-Lithium citrate, 20 %(w/v) PEG 3350",298.0,2016-10-18,2017-01-04,5H2U,9541.0,4.0,1068.0,501.0,,126.52,1.0,2.24,experimental,33.687,0.2601,0.2055,Crystal structure of PTK6 Kinase Domain complexed with Dasatinib
7VJV,X-RAY DIFFRACTION,2.47,50.25,"VAPOR DIFFUSION, SITTING DROP",,"PEG 8000, Tris",277.0,2021-09-29,2022-02-02,7VJV,1802.0,1.0,246.0,86.0,,27.67,1.0,1.75,experimental,20.296,0.2068,0.1901,Human AlkB homolog ALKBH6 in complex with alpha-katoglutarate and Mn
5N8U,X-RAY DIFFRACTION,2.69,54.3,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES monohydrate-imidazole
20mM sodium formate
20mM ammonium acetate
20mM sodium citrate tribasic hydrate
20mM sodium oxamate
20mM potassium sodium tartrate tetrahydrate",298.0,2017-02-24,2018-03-14,5N8U,14110.0,4.0,1904.0,162.0,,221.62,1.0,2.62,experimental,57.46,0.2495,0.1825,Crystal Structure of Drosophila DHX36 helicase in complex with CTCTCCT
5N9F,X-RAY DIFFRACTION,2.69,54.3,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES monohydrate-imidazole
20mM sodium formate
20mM ammonium acetate
20mM sodium citrate tribasic hydrate
20mM sodium oxamate
20mM potassium sodium tartrate tetrahydrate",298.0,2017-02-24,2018-03-21,5N9F,14133.0,4.0,1908.0,,,223.08,1.0,2.969,experimental,,0.2696,0.2142,Crystal Structure of Drosophila DHX36 helicase in complex with ssDNA CpG_A
6A7C,X-RAY DIFFRACTION,2.4,48.81,"VAPOR DIFFUSION, HANGING DROP",,"2.7 M Ammonium sulphate, 100 mM K2HPO4, 3%(v/v) Ethanol",297.0,2018-07-02,2019-04-10,6A7C,1752.0,1.0,186.0,156.0,,22.81,1.0,2.06,experimental,28.022,0.2427,0.1717,Human dihydrofolate reductase complexed with NADPH and BT1
6A7E,X-RAY DIFFRACTION,2.52,51.12,"VAPOR DIFFUSION, HANGING DROP",,"2.78 M AMMONIUM SULPHATE, 100 mM K2HPO4, 3%(V/V) ETHANOL",297.0,2018-07-02,2019-04-10,6A7E,1742.0,1.0,186.0,161.0,,22.52,1.0,1.85,experimental,22.622,0.2375,0.1897,Human dihydrofolate reductase complexed with NADPH and BT2
4WVU,X-RAY DIFFRACTION,1.73,28.97,"VAPOR DIFFUSION, HANGING DROP",,.98 M AMMONIUM SULFATE and .1 M AMMONIUM FORMATE.  Grew single crystals after streak seeding.,291.0,2014-11-07,2015-03-04,4WVU,778.0,2.0,103.0,80.0,,12.36,2.0,2.02,experimental,11.15,0.1781,0.1392,CRYSTAL STRUCTURE OF XIAP-BIR2 DOMAIN COMPLEXED WITH LIGAND BOUND
4Q0L,X-RAY DIFFRACTION,1.92,35.4,"VAPOR DIFFUSION, SITTING DROP",5.0,"Crystallization buffer: 0.1M ammonium citrate with pH 5.0 and 18% of   PEG4000, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291.0,2014-04-02,2015-01-28,4Q0L,8894.0,4.0,1052.0,320.0,4.0,121.71,1.0,2,experimental,20.194,0.328,0.264,Crystal structure of catalytic domain of human carbonic anhydrase isozyme XII with inhibitor
6GTT,X-RAY DIFFRACTION,3.11,60.5,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% PEG6000, 10% ethylene glycol, 0.1M MES pH 6.0, 0.1M magnesium chloride",277.0,2018-06-19,2018-06-27,6GTT,2250.0,1.0,302.0,14.0,,34.77,1.0,2.25,experimental,97.193,0.30104,0.24037,Human STK10 bound to BIRB-796
6RQR,X-RAY DIFFRACTION,2.51,50.98,"VAPOR DIFFUSION, HANGING DROP",,"1.65 M ammonium sulphate, 100 mM tri-sodium citrate pH 5.6",288.0,2019-05-16,2020-02-05,6RQR,2138.0,2.0,288.0,204.0,,32.24,1.0,2.2,experimental,39.3265,0.233,0.2059,Extended NHERF1 PDZ2 domain in complex with the PDZ-binding motif of CFTR
8V7G,X-RAY DIFFRACTION,2.09,41.26,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7G,4169.0,3.0,455.0,324.0,,55.35,1.0,1.52,experimental,,0.1984,0.1842,Human DNA polymerase eta-DNA-gemC-ended primer-dAMPNPP ternary complex with Mg2+
6VO5,X-RAY DIFFRACTION,3.04,59.57,"VAPOR DIFFUSION, SITTING DROP",6.5,12% PEG 20K and 0.1M MES pH6.5,293.0,2020-01-30,2020-03-11,6VO5,6547.0,4.0,688.0,746.0,,82.37,2.0,1.6,experimental,25.604,0.1976,0.1708,Crystal structure of Human histone acetytransferas 1 (HAT1) in complex with isobutryl-COA and K12A mutant variant of histone H4
5OVX,X-RAY DIFFRACTION,2.53,51.29,"VAPOR DIFFUSION, HANGING DROP",,"26-28% PEG3350, 0.1M Bis-Tris pH5.5, 0.2M Lithium sulfate",277.0,2017-08-30,2017-11-22,5OVX,2617.0,1.0,305.0,252.0,,35.66,1.0,2.1,experimental,27.5,0.228,0.1954,X-Ray Characterization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors
8CMS,X-RAY DIFFRACTION,2.27,45.79,"VAPOR DIFFUSION, SITTING DROP",,"20 %v/v 2-Propanol 
13 %w/v PEG 4K 
0.1 M HEPES pH 8",293.0,2023-02-21,2023-11-15,8CMS,1943.0,1.0,236.0,64.0,,27.64,1.0,1.77,experimental,25.72,0.2521,0.2099,OTUB2 in covalent complex with LN5P45
8JVE,X-RAY DIFFRACTION,3.89,68.4,"VAPOR DIFFUSION, SITTING DROP",,3.5 M Sodium formate pH 7.0,293.0,2023-06-28,2023-11-29,8JVE,1379.0,1.0,156.0,123.0,,18.07,1.0,1.76,experimental,,0.2466,0.2168,Identification and characterization of inhibitors covalently modifying catalytic cysteine of UBE2T and blocking ubiquitin transfer
8JVL,X-RAY DIFFRACTION,3.89,68.36,"VAPOR DIFFUSION, SITTING DROP",,2.8 M Sodium formate pH 7.0,293.0,2023-06-28,2023-11-29,8JVL,1357.0,1.0,156.0,104.0,,18.07,1.0,2.06,experimental,,0.2265,0.2037,Identification and characterization of inhibitors covalently modifying catalytic cysteine of UBE2T and blocking ubiquitin transfer
7CMB,X-RAY DIFFRACTION,2.78,55.78,VAPOR DIFFUSION,8.5,"0.2M Ammonium sulfate, 0.1M Tris pH 8.5, 25% PEG3350",291.0,2020-07-26,2021-07-28,7CMB,2333.0,1.0,293.0,4.0,,33.47,1.0,2.592,experimental,75.003,0.2509,0.2059,Crystal Structure of PAK4 in complex with inhibitor 41
7U73,X-RAY DIFFRACTION,2.09,41.09,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U73,4355.0,3.0,455.0,430.0,,55.3,1.0,1.56,experimental,30.9532,0.2132,0.1803,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s
7U7D,X-RAY DIFFRACTION,2.09,41.18,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7D,4423.0,3.0,455.0,429.0,,55.39,1.0,1.57,experimental,31.3039,0.2179,0.1817,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 30s
7U7E,X-RAY DIFFRACTION,2.06,40.43,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7E,4536.0,3.0,455.0,450.0,,55.35,1.0,1.58,experimental,31.1692,0.2171,0.1827,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 60s
8FIK,X-RAY DIFFRACTION,2.55,51.72,"VAPOR DIFFUSION, HANGING DROP",6.6,"A3A-E72A (50 mM MES pH 6.0, 100 mM NaCl, 1 mM TCEP, 0.2 mM EDTA) was mixed with oligonucleotides (10 mM Tris/HCl pH 7.9, 1 mM EDTA) at 0.85 mM and 1.7 mM respectively. Dilution was done with protein buffer. The mixture was added to crystallization liquid 1 to 1 and the mixture was pipetted on siliconized glass disks and sealed on top of a reservoir of crystallization liquid for hanging drop crystallization at 12 degrees Celsius. The crystallization liquid has the following composition: 100 mM Bicine at  pH 6.6, 200 mM NaCl, 20 mM putrescine, 1 mM TCEP, 1 mM inositol hex phosphate (phytic acid) and 45 % pentaerythritol propoxylate (5/4 PO/OH)",285.0,2022-12-16,2023-09-06,8FIK,3937.0,4.0,430.0,157.0,,56.86,1.0,1.912,experimental,34.801,0.2317,0.2001,APOBEC3A E72A inactive mutant in complex with ATTC-hairpin DNA substrate
8FIM,X-RAY DIFFRACTION,2.51,56.3,"VAPOR DIFFUSION, HANGING DROP",6.6,"A3A-E72A (50 mM MES pH 6.0, 100 mM NaCl, 1 mM TCEP, 0.2 mM EDTA) was mixed with oligonucleotides (10 mM Tris/HCl pH 7.9, 1 mM EDTA) at 0.85 mM and 1.7 mM respectively. Dilution was done with protein buffer. The mixture was added to crystallization liquid 1 to 1 and the mixture was pipetted on siliconized glass disks and sealed on top of a reservoir of crystallization liquid for hanging drop crystallization at 12 degrees Celsius. The crystallization liquid has the following composition: 100 mM Bicine at  pH 6.6, 200 mM NaCl, 20 mM putrescine, 1 mM TCEP, 1 mM inositol hexaphosphate (phytic acid) and 45 % pentaerythritol propoxylate (5/4 PO/OH)",285.0,2022-12-16,2023-09-06,8FIM,3657.0,4.0,424.0,16.0,,55.45,1.0,2.22,experimental,62.63,0.2772,0.2376,Structure of APOBEC3A (E72A inactive mutant) in complex with TTC-hairpin DNA substrate
5UWK,X-RAY DIFFRACTION,2.19,39.6,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M magnesium chloride, 0.1 M Tris:HCl pH 8.5, 25% PEG 3350",295.0,2017-02-21,2017-07-12,5UWK,3000.0,2.0,344.0,364.0,,40.26,1.0,1.6,experimental,,0.1989,0.1477,Matrix metalloproteinase-13 complexed with selective inhibitor compound (S)-10a
9BD3,X-RAY DIFFRACTION,3.81,67.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% (w/v) PEG 8000 100 mM HEPES/ Sodium hydroxide, pH 7.5, 200 mM Ammonium sulfate, 10% (v/v) 2-propanol",293.0,2024-04-10,2024-06-05,9BD3,3756.0,4.0,496.0,82.0,,56.71,2.0,2.58,experimental,61.65,0.2255,0.1912,Structure of the MAGEA4 MHD-RAD18 R6BD Complex
7SV2,X-RAY DIFFRACTION,2.21,44.26,"VAPOR DIFFUSION, SITTING DROP",,"Na Malonate, pH 6.5, 30% PEG 3350, n-decyl-beta-D-maltoside",297.0,2021-11-18,2022-05-18,7SV2,15215.0,4.0,1920.0,128.0,,225.75,1.0,2.46,experimental,63.54,0.2233,0.1877,Human Cytochrome P450 (CYP) 3A5 ternary complex with azamulin
6X8G,X-RAY DIFFRACTION,1.81,32.06,EVAPORATION,8.0,"0.1 M bis-tris pH 5.5, 0.25 M NaCl, 10 mM TCEP, 27-33% PEG-3350",298.0,2020-06-01,2020-11-25,6X8G,2461.0,1.0,318.0,133.0,,36.93,1.0,2.21,experimental,42.05,0.2442,0.1911,Crystal structure of TYK2 with Compound 22
5ULF,X-RAY DIFFRACTION,2.14,42.55,"VAPOR DIFFUSION, HANGING DROP",5.5,"100 mM bis-Tris pH 5.5, 150 mM ammonium sulfate, 20% PEG 3350",289.0,2017-01-24,2017-06-07,5ULF,4006.0,4.0,456.0,251.0,,52.04,2.0,1.8,experimental,23.499,0.2612,0.2274,Crystal Structure of a UbcH5b~Ub conjugate
7QM2,X-RAY DIFFRACTION,4.25,71.06,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1 M sodium acetate, 1 M sodium malonate",277.0,2021-12-20,2022-11-02,7QM2,7413.0,4.0,998.0,19.0,,116.71,2.0,2.685,experimental,62.5772,0.2127,0.177,Crystal structure of the PP1/PTG/beta-cyclodextrin ternary complex
4QJP,X-RAY DIFFRACTION,2.14,42.2,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1M sodium citrate (pH 5.5), 0.1M sodium acetate (pH 4.5), 26% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 291K",291.0,2014-06-04,2015-04-15,4QJP,4818.0,2.0,526.0,483.0,,60.87,1.0,1.62,experimental,21.005,0.205,0.168,Crystal structure of human carbonic anhydrase isozyme XIII with inhibitor
5CQK,X-RAY DIFFRACTION,2.07,40.5,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, MES-NaOH",293.0,2015-07-21,2015-10-07,5CQK,1633.0,1.0,186.0,93.0,,22.55,1.0,1.88,experimental,,0.2032,0.1736,Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
6F4R,X-RAY DIFFRACTION,2.28,46.18,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.1M Bis-Tris pH 5.8, 25 % PEG3350, 0.002 M MnCl2, 300 nl sitting drops (sample:well, 1:1 ratio)",298.0,2017-11-30,2018-04-04,6F4R,2628.0,2.0,260.0,372.0,1.0,30.39,2.0,1.3,experimental,24.0,0.1616,0.1427,"Human JMJD5 (N308C) in complex with Mn(II), NOG and RCCD1 (139-143) (complex-3)"
4N1M,X-RAY DIFFRACTION,2.6,52.66,"VAPOR DIFFUSION, HANGING DROP",8.0,"Tris, PEG8000, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2013-10-04,2015-08-12,4N1M,1577.0,1.0,168.0,246.0,,18.58,1.0,1.15,experimental,9.017,0.16337,0.13376,Structure of Cyclophilin A in complex with GlyPro.
6UJ9,X-RAY DIFFRACTION,2.28,46.13,"VAPOR DIFFUSION, HANGING DROP",9.5,"0.1 M CHES, 20% PEG8000",292.0,2019-10-02,2021-05-05,6UJ9,6557.0,5.0,859.0,2.0,7.0,97.77,5.0,2.9,experimental,41.378,0.2868,0.2137,Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide in complex with Fab
8II0,X-RAY DIFFRACTION,3.42,64.04,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6 M AMMONIUM SULPHATE, 6% PEG 400, 0.1 M HEPES.",277.0,2023-02-24,2024-02-28,8II0,2943.0,1.0,349.0,74.0,,41.72,1.0,2.04,experimental,80.26,0.2387,0.2048,FACTOR INHIBITING HIF-1 ALPHA in complex with (5-(3-(3-chlorophenyl)isoxazol-5-yl)-3-hydroxypicolinoyl)glycine
7ZPB,X-RAY DIFFRACTION,3.19,61.44,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2022-04-27,2023-02-01,7ZPB,4615.0,1.0,529.0,112.0,3.0,63.85,1.0,2.31,experimental,58.16,0.2172,0.1771,Structure of hemiacetylated human butyrylcholinesterase upon reaction with 8-(3-(4-(prop-2-yn-1-yl)piperazin-1-yl)propoxy)quinoline-2-carbaldehyde
5CQD,X-RAY DIFFRACTION,2.16,42.99,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, MES-NaOH",293.0,2015-07-21,2015-10-07,5CQD,3182.0,2.0,372.0,75.0,,44.55,1.0,2.08,experimental,,0.2268,0.1877,Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
5MGX,X-RAY DIFFRACTION,2.99,58.93,"VAPOR DIFFUSION, SITTING DROP",,"0.02 M sodium potassium phosphate, 20 % w/v PEG 3350",287.0,2016-11-22,2017-03-22,5MGX,9225.0,8.0,1192.0,1058.0,,131.09,2.0,2.18,experimental,33.57,0.308,0.246,The structure of FKBP38 in complex with the MEEVD tetratricopeptide binding-motif of Hsp90
5NI9,X-RAY DIFFRACTION,2.52,51.11,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M pH 6.5
10% (vol/vol) MPD
15% (vol/vol) PEG3350",293.0,2017-03-23,2018-06-13,5NI9,3606.0,3.0,402.0,312.0,4.0,47.17,3.0,1.33,experimental,24.919,0.17558,0.14576,Crystal structure of HLA-DRB1*04:01 with the alpha-enolase peptide 326-340
7DG4,X-RAY DIFFRACTION,3.65,66.29,"VAPOR DIFFUSION, SITTING DROP",,"0.36M-0.5M sodium citrate tribasic dehydrate, 0.01M sodium borate, pH 7.5-9.5",291.0,2020-11-10,2021-11-10,7DG4,2688.0,1.0,324.0,23.0,,38.04,1.0,2.58,experimental,65.3031,0.2495,0.2013,The co-crystal structure of DYRK2 with a small molecule inhibitor 6
5NIG,X-RAY DIFFRACTION,2.52,51.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5
10% (vol/vol) MPD
15% (vol/vol) PEG 3350",293.0,2017-03-24,2018-06-13,5NIG,3758.0,3.0,402.0,416.0,4.0,47.26,3.0,1.35,experimental,22.68,0.1808,0.14201,Crystal structure of HLA-DRB1*04:01 with modified alpha-enolase peptide 326-340 (arginine 327 to citrulline)
4YQW,X-RAY DIFFRACTION,2.15,42.69,"VAPOR DIFFUSION, HANGING DROP",6.0,"NaMES (pH 6.0), polyethylene glycol monomethyl ether 2000, and calcium chloride",291.0,2015-03-13,2015-05-13,4YQW,4052.0,3.0,455.0,302.0,,55.3,1.0,2.064,experimental,,0.227,0.1742,Mutant Human DNA Polymerase Eta Q38A/R61A Inserting dCTP Opposite Template G
4YR2,X-RAY DIFFRACTION,2.12,42.09,"VAPOR DIFFUSION, HANGING DROP",6.0,"NaMES (pH 6.0), polyethylene glycol monomethyl ether 2000, and calcium chloride",291.0,2015-03-14,2015-05-13,4YR2,4068.0,3.0,455.0,404.0,,55.45,1.0,1.95,experimental,,0.218,0.168,Mutant Human DNA Polymerase Eta R61M Inserting dATP Opposite an 8-Oxoguanine Lesion
5K7K,X-RAY DIFFRACTION,2.53,51.38,VAPOR DIFFUSION,8.5,"100mM Hepes at 8.5  with 2% Peg 4K. crystallizer Alec Tucker
 Cryoprotectand 40% peg 4K",293.0,2016-05-26,2017-06-07,5K7K,3756.0,1.0,477.0,37.0,,55.4,1.0,2.3,experimental,59.48,0.27194,0.22437,Design and Optimization of Biaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7: Discovery of Clinical Candidate PF-05089771
6G77,X-RAY DIFFRACTION,2.71,54.56,"VAPOR DIFFUSION, SITTING DROP",8.0,"20 % PEG 6000, 0.1 M TRIS pH8, 2 mM Zinc chloride",291.0,2018-04-04,2019-04-17,6G77,5104.0,2.0,614.0,262.0,,72.62,1.0,2.499,experimental,27.0382,0.233,0.1851,RSK4 N-terminal Kinase Domain in complex with AMP-PNP
6G78,X-RAY DIFFRACTION,2.95,58.25,"VAPOR DIFFUSION, SITTING DROP",8.0,"20 % PEG 6000, 0.1 M TRIS pH8, 2 mM Zinc chloride",291.0,2018-04-04,2019-04-17,6G78,4652.0,2.0,614.0,85.0,,71.56,1.0,2.5,experimental,37.2913,0.2396,0.2259,RSK4 N-terminal Kinase Domain S232E in complex with AMP-PNP
8TK2,X-RAY DIFFRACTION,2.25,45.32,"VAPOR DIFFUSION, SITTING DROP",,"Protein-compound mixture in 50 mM TRIS-Cl pH 8.5, 1 mM TCEP, 0.5 mM EDTA, 5% DMSO were mixed with the precipitant solution (100 mM Bis-Tris pH 6.5, 50 mM NH4F, 28% (w/v) PEGME-2000) and equilibrated against the precipitant solution.",298.0,2023-07-25,2024-08-14,8TK2,3211.0,2.0,366.0,240.0,,41.18,1.0,1.7,experimental,29.235,0.22265,0.17587,"HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) complexed with 2-((2,4-difluorobenzyl)amino)-2-oxoacetic acid"
8TK5,X-RAY DIFFRACTION,2.2,44.02,"VAPOR DIFFUSION, SITTING DROP",,"Protein in 50 mM TRIS-Cl pH 8.5, 1 mM TCEP, 0.5 mM EDTA was mixed with the precipitant solution (100 mM HEPES pH7.5, 50 mM NH4F, 28% (w/v) PEG 4K) and equilibrated against the precipitant solution.",294.0,2023-07-25,2024-08-14,8TK5,3257.0,2.0,366.0,235.0,,41.82,1.0,1.9,experimental,19.955,0.19124,0.14695,HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) complexed with HEPES
6BRX,X-RAY DIFFRACTION,2.58,52.38,"VAPOR DIFFUSION, HANGING DROP",,15-20% PEG400 and 0.1-0.2 M ammonium iodide (NH4I),295.15,2017-12-01,2018-08-22,6BRX,7902.0,6.0,1146.0,230.0,,141.88,1.0,2.8,experimental,73.975,0.26895,0.21359,Crystal Structure of Human DNA polymerase kappa in complex with DNA containing the major cisplatin lesion
6W50,X-RAY DIFFRACTION,3.47,64.53,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2020-03-12,2020-06-10,6W50,2213.0,1.0,244.0,247.0,4.0,29.13,1.0,1.95,experimental,30.53,0.172,0.154,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((10R,14S)- 14-(4-(3-CHLORO-2,6-DIFLUOROPHENYL)-6-OXO-3,6-DIHYDRO- 1(2H)-PYRIDINYL)-10-METHYL-9-OXO-8,16- DIAZATRICYCLO[13.3.1.0~2,7~]NONADECA-1(19),2,4,6,15,17- HEXAEN-5-YL)CARBAMATE"
5ZLC,X-RAY DIFFRACTION,2.45,49.83,VAPOR DIFFUSION,7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-03-27,2019-05-29,5ZLC,2980.0,1.0,356.0,256.0,,41.15,1.0,2,experimental,29.824,0.2406,0.20153,Binary complex of human DNA Polymerase Mu with MndGTP
6AEH,X-RAY DIFFRACTION,2.46,50.09,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-08-04,2019-05-29,6AEH,3130.0,1.0,356.0,391.0,,41.32,1.0,1.64,experimental,17.268,0.24531,0.20838,Binary complex of human DNA Polymerase Mu with MnUTP
6IPH,X-RAY DIFFRACTION,2.45,49.76,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-11-03,2019-05-29,6IPH,3066.0,1.0,356.0,336.0,,41.04,1.0,1.65,experimental,24.855,0.2156,0.18751,Binary Complex of Human DNA Polymerase Mu with MndATP
6IPI,X-RAY DIFFRACTION,2.46,50.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-11-03,2019-05-29,6IPI,3098.0,1.0,356.0,342.0,,41.02,1.0,1.8,experimental,21.669,0.23377,0.19254,Binary Complex of Human DNA Polymerase Mu with MndCTP
6IPL,X-RAY DIFFRACTION,2.46,50.01,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-11-03,2019-05-29,6IPL,3205.0,1.0,356.0,412.0,,41.15,1.0,1.64,experimental,16.136,0.24008,0.20308,Binary Complex of Human DNA Polymerase Mu with MgdATP
6IPM,X-RAY DIFFRACTION,2.45,49.76,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-11-03,2019-05-29,6IPM,3091.0,1.0,356.0,300.0,,41.22,1.0,1.72,experimental,21.806,0.23632,0.20448,Binary Complex of Human DNA Polymerase Mu with MgdCTP
6IPN,X-RAY DIFFRACTION,2.46,49.92,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-11-03,2019-05-29,6IPN,3247.0,1.0,356.0,447.0,,41.16,1.0,1.6,experimental,16.745,0.2361,0.20772,Binary Complex of Human DNA Polymerase Mu with MgdGTP
6TS4,X-RAY DIFFRACTION,2.28,46.15,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulfate, 0.1 M BIS-TRIS pH5.5, 25% w/v Polyethylene glycol 3350",277.0,2019-12-19,2020-07-08,6TS4,2283.0,1.0,238.0,283.0,4.0,27.9,1.0,1.17,experimental,17.47,0.2033,0.1871,Coagulation factor XI protease domain in complex with active site inhibitor
5QD1,X-RAY DIFFRACTION,3.14,60.82,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE IN WATER. PROTEIN STOCK WAS
BACE MUT46B BATCH XVI 7.0MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 6-FOLD EXCESS OF BMC011 ADDED FROM A 50MM
STOCK SOLUTION IN 90% DMSO-D6 (1.7% DMSO IN DROP). A SOLUTION CONTAINING 1.2M AMMONIUM SULFATE, 25% GLYCEROL, 1MM BMC011
AND 1.8% DMSO WAS USED AS CRYO-PROTECTANT.",292.0,2017-12-01,2020-06-03,5QD1,9420.0,3.0,1206.0,381.0,9.0,135.91,1.0,2.4,experimental,48.06,0.197,0.163,Crystal structure of BACE complex with BMC011
5QD3,X-RAY DIFFRACTION,3.16,61.08,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE IN WATER. PROTEIN STOCK WAS
BACE MUT46B BATCH XVI 7.0MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 6-FOLD EXCESS OF BMC010 ADDED FROM A 50MM
STOCK SOLUTION IN 90% DMSO-D6 (1.7% DMSO IN DROP). A SOLUTION CONTAINING 1.2M AMMONIUM SULFATE, 25% GLYCEROL, 1MM BMC010
AND 1.8% DMSO WAS USED AS CRYO-PROTECTANT.",292.0,2017-12-01,2020-06-03,5QD3,9374.0,3.0,1206.0,353.0,9.0,135.9,1.0,2.46,experimental,47.78,0.2,0.164,Crystal structure of BACE complex with BMC010
6EKD,X-RAY DIFFRACTION,2.07,40.67,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Bis Tris pH 5.5, 200 mM NaCl, 29% PEG 3350, 1 mM AMP-PCP, 0.4 mM Zwittergent 3-14, 10% Ethylene glycol",293.0,2017-09-26,2018-08-08,6EKD,2697.0,1.0,367.0,104.0,1.0,42.78,1.0,2.1,experimental,52.355,0.25902,0.2056,Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitor
5TES,X-RAY DIFFRACTION,2.86,56.97,"VAPOR DIFFUSION, HANGING DROP",8.8,"12.5% P3350, 100 mM TrisHCl pH 8.8, 125 mM ammonium chloride",294.0,2016-09-22,2017-08-09,5TES,6106.0,2.0,755.0,243.0,,83.92,2.0,2.4,experimental,,0.252,0.194,TEV Cleaved Human ATP Citrate Lyase Bound to Citrate and ADP
6XY7,X-RAY DIFFRACTION,2.09,41.03,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM MES/imidazole, pH 6.5, 20 % PEG 500 MME, 10% PEG 20,000",293.0,2020-01-29,2020-02-26,6XY7,4672.0,1.0,463.0,491.0,,53.38,1.0,1.086,experimental,14.339,0.1587,0.1358,Human SHIP1 with magnesium and phosphate bound to the active site
5FBE,X-RAY DIFFRACTION,2.12,42.0,"VAPOR DIFFUSION, HANGING DROP",,"1 MICROLITER PROTEIN SOLUTION WAS MIXED WITH 1 MICROLITER RESERVOIR SOLUTION. PROTEIN SOLUTION: 18 mg/mL FD, 10 mM Tris pH 7.0, 100 mM NaCl; RESERVOIR SOLUTION: 22% PEG3350, 100 mM HEPES pH 7.5; SOAKING AND CRYO: ADDITION of 10 mM COMPOUND2 for 45 min FOLLOWED by the ADDITION OF 0.5 MICROLITER GLYCEROL AND FLASH FREEZING IN LIQUIT NITROGEN.",293.0,2015-12-14,2016-10-26,5FBE,2025.0,1.0,232.0,204.0,4.0,25.3,1.0,1.43,experimental,22.17,0.1879,0.1687,COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND2
5VBI,X-RAY DIFFRACTION,2.99,58.86,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES 7.5, 0.1M Sodium Chloride, 1.5-1.7M Ammonium Sulfate",293.0,2017-03-29,2018-06-20,5VBI,9898.0,2.0,1170.0,1180.0,,130.33,1.0,1.75000083769,experimental,32.065293762,0.19087048899,0.16518324955,Crystal Structure of the R515W missense variant of human PGM1
5VEC,X-RAY DIFFRACTION,2.96,58.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.01 M Cobalt (II) chloride hexahydrate, O.1 M MES monohydrate pH 6.5, Ammonium Sulfate 1.8-1.9M",293.0,2017-04-04,2018-06-27,5VEC,9316.0,2.0,1170.0,635.0,,129.47,1.0,2.20001616144,experimental,52.1669117066,0.250655699293,0.18972110479,Crystal Structure of the R515L missense variant of human PGM1
5VIN,X-RAY DIFFRACTION,3.06,59.82,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.01 M Cobalt (II) chloride hexahydrate, O.1 M MES monohydrate pH 6.5, Ammonium Sulfate 1.8-2.1M",293.0,2017-04-17,2018-06-27,5VIN,8281.0,2.0,1170.0,91.0,,130.24,1.0,2.60004291837,experimental,71.2698705059,0.295418439253,0.238582434806,Crystal Structure of the R515Q missense variant of human PGM1
6LFH,X-RAY DIFFRACTION,1.93,36.35,"VAPOR DIFFUSION, HANGING DROP",4.5,"Lysozyme sample (14 mg/mL) in 2.5 mM HEPES, 0.12 M lithium chloride mixed with reservoir solution containing 30 mM sodium phosphate, 2.5 M sodium chloride",298.0,2019-12-02,2020-07-08,6LFH,1325.0,1.0,130.0,213.0,4.0,14.98,1.0,1.46,experimental,19.1047,0.1957,0.1617,X-ray crystal structure of chemically synthesized human lysozyme
6N77,X-RAY DIFFRACTION,2.48,50.43,"VAPOR DIFFUSION, HANGING DROP",5.5,0.1 M MES pH 5-6 and 25-35% PEG 6000,277.0,2018-11-27,2019-04-24,6N77,5016.0,2.0,604.0,397.0,,70.35,1.0,1.64,experimental,23.64,0.282,0.252,Structure of the human JAK1 kinase domain with compound 15
6N7A,X-RAY DIFFRACTION,2.38,48.38,"VAPOR DIFFUSION, HANGING DROP",5.5,0.1 M MES pH 5-6 and 25-35% PEG 6000,277.0,2018-11-27,2019-04-24,6N7A,5309.0,2.0,608.0,588.0,,70.85,1.0,1.33,experimental,19.75,0.207,0.192,Structure of the human JAK1 kinase domain with compound 39
6N7C,X-RAY DIFFRACTION,2.43,49.37,"VAPOR DIFFUSION, HANGING DROP",5.5,0.1 M MES pH 5-6 and 25-35% PEG 6000,277.0,2018-11-27,2019-04-24,6N7C,5031.0,2.0,604.0,508.0,,70.35,1.0,1.69,experimental,19.81,0.288,0.252,Structure of the human JAK1 kinase domain with compound 56
7ULV,X-RAY DIFFRACTION,1.87,34.27,"VAPOR DIFFUSION, HANGING DROP",,"Purified DDAH1 was concentrated to approximately 10 mg/mL using an Amicon-Ultra centrifugal filter device (10 kDa MWCO). The protein was crystallized at 25 C using the hanging drop method (Hampton Research, Aliso Viejo, CA) from 25 % (w/v) PEG6000, 0.1 M Tris-HCl, pH 8.2. Further optimization was done manually using a 1:1 well solution: DDAH1 stock solution ratio to improve crystal size and morphology.  Crystals grew to their maximum size in 3 weeks and were harvested after approximately 25 days. To determine the structure of DDAH1 in complex with ligand, the crystals were transferred to a reservoir containing 20 uL of 20 mM of the ligand in the crystallization mother liquor (25% PEG 6000, 0.1 M Tris-HCl, pH 8.2) and soaked for 30 min. Before data collection, crystals with good size and morphology were transferred into a cryoprotection solution (Well Solution supplemented with 25 % (v/v) glycerol) for 1 to 5 seconds using a the cryoloop (Hampton Research, Laguna Niguel, CA). Individual hDDAH1:ligand crystals were flash frozen in liquid nitrogen before use.",298.0,2022-04-05,2023-08-30,7ULV,13115.0,6.0,1848.0,509.0,,203.01,1.0,2.37,experimental,45.4034,0.2692,0.237,Human DDAH1 soaked with its inactivator S-((4-chloropyridin-2-yl)methyl)-L-cysteine
6JLR,X-RAY DIFFRACTION,3.23,61.92,"VAPOR DIFFUSION, HANGING DROP",7.7,"23% polyacrylic acid 5100, 2% 2-methyl-2,4-pentane diol, 100mM Hepes pH 7.7",293.0,2019-03-06,2020-02-12,6JLR,2136.0,1.0,316.0,,,35.94,1.0,2.901,experimental,86.4006,0.3514,0.2973,Crystal structure of wild type MNK2 in complex with inhibitor
7NE3,X-RAY DIFFRACTION,2.63,53.3,"VAPOR DIFFUSION, HANGING DROP",6.3,"0.1M MES pH6.3, 23% PEG2000MME",278.0,2021-02-03,2022-03-02,7NE3,3969.0,3.0,487.0,260.0,,59.53,1.0,2.26,experimental,63.02,0.2263,0.1749,Human TET2 in complex with favourable DNA substrate.
7NE6,X-RAY DIFFRACTION,2.54,51.64,"VAPOR DIFFUSION, HANGING DROP",6.3,"0.1M MES pH=6.3, 23% PEG2000MME",278.0,2021-02-03,2022-03-02,7NE6,4040.0,3.0,487.0,313.0,,59.46,1.0,2.3,experimental,51.61,0.227,0.1951,Human TET2 in complex with unfavourable DNA substrate.
6HXS,X-RAY DIFFRACTION,2.72,54.77,"VAPOR DIFFUSION, SITTING DROP",,"16% Poly(ethylene glycol) 3350, 0.4M sodium sulfate, 3mM Carba-NAD",277.0,2018-10-18,2019-10-30,6HXS,5959.0,3.0,894.0,215.0,,102.62,1.0,2.05,experimental,51.81,0.209,0.197,Human PARP16 (ARTD15) IN COMPLEX WITH CARBA-NAD
8TK4,X-RAY DIFFRACTION,2.32,46.92,"VAPOR DIFFUSION, SITTING DROP",,"protein in 50 mM Tris-Cl, pH 8.0, 1 mM TCEP was mixed with the precipitation buffer (0.1M Sodium potassium phosphate pH 7.0, 28% w/v Polyethylene glycol 3,350) and equilibrated against it",294.0,2023-07-25,2024-08-14,8TK4,1670.0,1.0,183.0,208.0,,20.38,1.0,1.8,experimental,17.552,0.19098,0.15454,HUMAN VH1-RELATED DUAL-SPECIFICITY PHOSPHATASE (VHR) complexed with phosphate
7ULU,X-RAY DIFFRACTION,1.95,36.91,"VAPOR DIFFUSION, SITTING DROP",,"Purified DDAH1 was concentrated to approximately 10 mg/mL using an Amicon-Ultra centrifugal filter device (10 kDa MWCO). The protein was crystallized at 25 C using the hanging drop method (Hampton Research, Aliso Viejo, CA) from 25 % (w/v) PEG6000, 0.1 M Tris-HCl, pH 8.2. Further optimization was done manually using a 1:1 well solution: DDAH1 stock solution ratio to improve crystal size and morphology.  Crystals grew to their maximum size in 3 weeks and were harvested after approximately 25 days. To determine the structure of DDAH1 in complex with ligand, the crystals were transferred to a reservoir containing 20 uL of 20 mM of ligand in the crystallization mother liquor (25% PEG 6000, 0.1 M Tris-HCl, pH 8.2) and soaked for 30 min. Before data collection, crystals with good size and morphology were transferred into a cryoprotection solution (Well Solution supplemented with 25 % (v/v) glycerol) for 1 to 5 seconds using a the cryoloop (Hampton Research, Laguna Niguel, CA). Individual hDDAH1:ligand crystals were flash frozen in liquid nitrogen before use.",293.0,2022-04-05,2023-08-30,7ULU,4268.0,2.0,616.0,34.0,,67.64,1.0,2.2,experimental,71.5289,0.2668,0.2075,Human DDAH1 soaked with its inhibitor ClPyrAA
7ULX,X-RAY DIFFRACTION,1.99,38.28,"VAPOR DIFFUSION, HANGING DROP",,"Purified DDAH1 was concentrated to approximately 10 mg/mL using an Amicon-Ultra centrifugal filter device (10 kDa MWCO). The protein was crystallized at 25 C using the hanging drop method (Hampton Research, Aliso Viejo, CA) from 25 % (w/v) PEG6000, 0.1 M Tris-HCl, pH 8.2. Further optimization was done manually using a 1:1 well solution : DDAH1 stock solution ratio to improve crystal size and morphology.  Crystals grew to their maximum size in 3 weeks and were harvested after approximately 25 days. To determine the structure of DDAH1 in complex with the ligand, the crystals were transferred to a reservoir containing 20 uL of 20 mM of the ligand in the crystallization mother liquor (25% PEG 6000, 0.1 M Tris-HCl, pH 8.2) and soaked for 30 min. Before data collection, crystals with good size and morphology were transferred into a cryoprotection solution (Well Solution supplemented with 25 % (v/v) glycerol) for 1 to 5 seconds using a the cryoloop (Hampton Research, Laguna Niguel, CA). Individual hDDAH1:ligand crystals were flash frozen in liquid nitrogen before use.",298.0,2022-04-05,2023-08-30,7ULX,4791.0,2.0,616.0,537.0,,67.67,1.0,1.707,experimental,27.7625,0.2351,0.1913,Human DDAH1 soaked with its inhibitor N4-(4-chloropyridin-2-yl)-L-asparagine
5RAA,X-RAY DIFFRACTION,2.77,55.6,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAA,6271.0,2.0,744.0,688.0,,86.65,1.0,1.57,experimental,32.289,0.2104,0.183,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM009990a
5RAB,X-RAY DIFFRACTION,2.79,55.89,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAB,6290.0,2.0,744.0,702.0,,86.68,1.0,1.52,experimental,32.775,0.2102,0.1851,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001726a
5RAC,X-RAY DIFFRACTION,2.8,56.06,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAC,6282.0,2.0,744.0,681.0,,86.92,1.0,1.73,experimental,36.323,0.2203,0.1866,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001810a
5RAF,X-RAY DIFFRACTION,2.79,55.92,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAF,6263.0,2.0,744.0,693.0,,86.63,1.0,1.62,experimental,34.572,0.2119,0.184,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001559a
5RAG,X-RAY DIFFRACTION,2.79,55.99,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAG,6303.0,2.0,744.0,710.0,,86.65,1.0,1.52,experimental,27.479,0.2024,0.1815,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001767a
5RAJ,X-RAY DIFFRACTION,2.78,55.79,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAJ,6278.0,2.0,744.0,692.0,,86.71,1.0,1.61,experimental,30.425,0.2226,0.1905,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with BD009815a
5RAM,X-RAY DIFFRACTION,2.73,55.01,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAM,6293.0,2.0,744.0,702.0,,86.68,1.0,2.05,experimental,37.736,0.2355,0.1748,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS038544d
5RAP,X-RAY DIFFRACTION,2.77,55.64,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAP,6278.0,2.0,744.0,696.0,,86.69,1.0,1.9,experimental,35.465,0.2155,0.178,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM000707a
5RAV,X-RAY DIFFRACTION,2.8,56.0,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAV,6292.0,2.0,744.0,701.0,,86.69,1.0,1.77,experimental,32.492,0.2088,0.179,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001763a
5RAW,X-RAY DIFFRACTION,2.79,55.97,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAW,6272.0,2.0,744.0,689.0,,86.64,1.0,1.55,experimental,31.827,0.21,0.1851,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM009970a
5RAY,X-RAY DIFFRACTION,2.8,56.06,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAY,6275.0,2.0,744.0,696.0,,86.64,1.0,1.63,experimental,33.493,0.2213,0.1902,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001469a
5RAZ,X-RAY DIFFRACTION,2.78,55.77,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RAZ,6313.0,2.0,744.0,692.0,,87.08,1.0,1.81,experimental,35.107,0.2107,0.1809,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM010013a
5RB3,X-RAY DIFFRACTION,2.83,56.49,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RB3,6303.0,2.0,744.0,700.0,,86.98,1.0,1.53,experimental,32.44,0.2081,0.1866,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with XS039249d
5RB4,X-RAY DIFFRACTION,2.8,56.15,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RB4,6288.0,2.0,744.0,699.0,,86.67,1.0,1.55,experimental,32.391,0.2092,0.1854,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001677a
5RB6,X-RAY DIFFRACTION,2.8,56.1,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RB6,6289.0,2.0,744.0,704.0,,86.68,1.0,1.63,experimental,29.677,0.2077,0.1819,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001569a
5RB7,X-RAY DIFFRACTION,2.81,56.24,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 21% PEG3350  0.3M magnesium chloride,277.0,2020-03-16,2020-04-22,5RB7,6282.0,2.0,744.0,692.0,,86.67,1.0,1.57,experimental,30.166,0.2168,0.193,PanDDA analysis group deposition -- Crystal Structure of JMJD1B in complex with FM001648a
6RBJ,X-RAY DIFFRACTION,2.88,57.3,"VAPOR DIFFUSION, SITTING DROP",6.6,"0.1 M bis-tris pH 6.6 , 0.1 M magnesium chloride, 28% PEG 3350",277.0,2019-04-10,2020-05-13,6RBJ,5561.0,2.0,702.0,130.0,,81.93,1.0,2.093,experimental,43.1198,0.2103,0.1889,Crystal structure of KDM3B in complex with 5-(1H-tetrazol-5-yl)quinolin-8-ol
7USZ,X-RAY DIFFRACTION,2.51,50.98,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris-HCl (pH 8.05), 21% PEG6000",298.0,2022-04-26,2022-05-11,7USZ,4789.0,2.0,578.0,493.0,,63.06,1.0,1.65,experimental,25.4029,0.1994,0.1508,"Human DDAH-1, holo (Zn-bound) form"
7UT0,X-RAY DIFFRACTION,2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris-HCl (pH 8.5), 300 mM sodium acetate, 21% PEG6000",298.0,2022-04-26,2022-05-18,7UT0,4713.0,2.0,572.0,390.0,,62.44,1.0,1.68,experimental,27.3175,0.2079,0.1511,"Human DDAH-1, apo form"
5VEU,X-RAY DIFFRACTION,2.64,53.34,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, PEG 300, ADA, zinc sulfate",297.0,2017-04-05,2017-11-15,5VEU,44740.0,12.0,5760.0,,,667.91,1.0,2.91,experimental,,0.2576,0.2137,Human Cytochrome P450 3A5 (CYP3A5)
7UGB,X-RAY DIFFRACTION,1.97,37.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"10 % PEG 4000, 0.1 M HEPES [pH 7.5] and 5 % Isopropanol",293.0,2022-03-24,2023-03-29,7UGB,3026.0,2.0,395.0,146.0,,45.84,2.0,1.9,experimental,47.4003,0.2276,0.1792,Crystal structure of rat ERK2 complexed with docking peptide from ISG20
7K05,X-RAY DIFFRACTION,2.1,41.31,"VAPOR DIFFUSION, HANGING DROP",8.4,"30% MPEG 2K,
20% saturated KCl,
200 mM pH 8.4 Imidazole / Malate",290.0,2020-09-03,2021-10-06,7K05,3468.0,2.0,432.0,176.0,1.0,51.02,1.0,1.85,experimental,50.3,0.2117,0.1715,Crystal structures and ribonuclease activity of the Flavivirus host factor ERI3 that is involved in viral RNA synthesis define the ERI subfamily of structure-specific 3-prime - 5-prime exoribonucleases
8PDG,X-RAY DIFFRACTION,2.11,41.62,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM MES/imidazole, 20 % PEG 500 MME, 10% PEG 20,000",293.0,2023-06-12,2023-06-28,8PDG,4427.0,1.0,463.0,528.0,,53.35,1.0,1.4,experimental,19.476,0.19,0.1371,The phosphatase and C2 domains of SHIP1 with covalent Z2738285202
8PDI,X-RAY DIFFRACTION,2.09,41.08,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM MES/imidazole 20 % PEG 500 MME, 10% PEG 20,000",293.0,2023-06-12,2023-07-26,8PDI,4494.0,1.0,463.0,536.0,,53.3,1.0,1.3,experimental,19.077,0.1905,0.146,The phosphatase and C2 domains of SHIP1 with covalent Z1763271112
8PDJ,X-RAY DIFFRACTION,2.11,41.83,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM MES/imidazole 20 % PEG 500 MME, 10% PEG 20,000",293.0,2023-06-12,2023-06-28,8PDJ,4404.0,1.0,463.0,495.0,,53.26,1.0,1.4,experimental,21.222,0.1898,0.1326,The phosphatase and C2 domains of SHIP1 with covalent Z56948267
8C8B,X-RAY DIFFRACTION,2.16,43.0,"VAPOR DIFFUSION, SITTING DROP",6.0,"30% PEG 1000, 0.1M MIB buffer",298.0,2023-01-19,2024-01-31,8C8B,3006.0,1.0,343.0,251.0,,39.37,1.0,1.46,experimental,35.27,0.2172,0.1946,Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 48).
8C8D,X-RAY DIFFRACTION,2.14,42.58,"VAPOR DIFFUSION, HANGING DROP",6.0,"30% PEG 1000, 0.1M MIB buffer",298.0,2023-01-19,2024-01-31,8C8D,2869.0,1.0,343.0,112.0,1.0,39.77,1.0,1.46,experimental,35.16,0.233,0.2109,Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 44).
8C8S,X-RAY DIFFRACTION,2.16,43.16,"VAPOR DIFFUSION, SITTING DROP",6.0,"30% PEG 1000, 0.1M MIB buffer",298.0,2023-01-20,2024-01-31,8C8S,2826.0,1.0,343.0,101.0,1.0,39.37,1.0,1.8,experimental,33.92,0.2463,0.2121,Crystal structure of human DNA cross-link repair 1A in complex with hydroxamic acid inhibitor (compound 21).
6HEH,X-RAY DIFFRACTION,3.16,61.1,"VAPOR DIFFUSION, SITTING DROP",6.6,"12% (w/v) PEG 8000, 100 mM sodium chloride, 200 mM lithium sulfate, 100 mM MES pH 6.6",291.0,2018-08-20,2019-03-27,6HEH,2872.0,1.0,382.0,128.0,,44.68,1.0,2.26,experimental,,0.2161,0.1956,Structure of the catalytic domain of USP28 (insertion deleted)
7Q8D,X-RAY DIFFRACTION,2.72,54.85,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM Tris, pH 8",277.0,2021-11-11,2022-11-23,7Q8D,3916.0,4.0,462.0,392.0,6.0,51.02,2.0,1.8,experimental,34.05,0.1978,0.1744,Peptide TRESEDLE in complex with human cathepsin V C25A mutant
7Q8J,X-RAY DIFFRACTION,2.78,55.78,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",298.0,2021-11-11,2022-11-23,7Q8J,3823.0,5.0,459.0,303.0,6.0,50.61,3.0,1.64,experimental,70.05,0.2175,0.1928,Peptide IILKEK in complex with human cathepsin V C25S mutant
7Q8K,X-RAY DIFFRACTION,2.94,58.1,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",278.0,2021-11-11,2022-11-23,7Q8K,3883.0,4.0,454.0,376.0,6.0,50.32,2.0,1.74,experimental,24.92,0.1958,0.1739,Peptide LLKVAL in complex with human cathepsin V C25S mutant
7Q8L,X-RAY DIFFRACTION,2.82,56.37,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",278.0,2021-11-11,2022-11-23,7Q8L,4004.0,4.0,464.0,492.0,6.0,50.93,2.0,1.8,experimental,46.36,0.188,0.1674,Peptide VPCGTAHE in complex with human cathepsin V C25A mutant
7Q8N,X-RAY DIFFRACTION,2.79,55.88,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM Tris, pH 8",278.0,2021-11-11,2022-11-23,7Q8N,3814.0,4.0,464.0,322.0,6.0,50.87,2.0,2,experimental,27.92,0.1996,0.1735,Peptide KKYDAFLA in complex with human cathepsin V C25A mutant
7Q9H,X-RAY DIFFRACTION,2.79,55.99,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",298.0,2021-11-12,2022-11-23,7Q9H,4192.0,5.0,475.0,509.0,6.0,52.55,2.0,1.4,experimental,25.26,0.2088,0.1823,Peptide LLKAVAEKQ in complex with human cathepsin V C25A mutant
6E42,X-RAY DIFFRACTION,2.44,49.65,EVAPORATION,6.2,"0.1 M phosphate (pH 6.2), and 15% (w/v) PEG3350",298.0,2018-07-16,2018-11-14,6E42,12170.0,4.0,1620.0,295.0,,186.62,1.0,2.103,experimental,44.0584,0.2396,0.2026,"CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) in complex with ferric heme and 4-Chlorophenyl imidazole"
8FP1,X-RAY DIFFRACTION,2.35,47.56,"VAPOR DIFFUSION, SITTING DROP",6.0,"Well Ingredients:
Precipitant: 21.0 %w/v (21.0 uL of stock 50.0 %w/v) PEG 3350
Salt: 0.7 M (4.375 uL of stock 8.0 M) lithium nitrate
Buffer: 0.1 M (5.0 uL of stock 1.0 M) MES (pH 6.00)
Organic (non-volatile): 7.0 % w/v (4.375 uL of stock 80.0 % w/v) Glycerol",286.15,2023-01-03,2023-04-05,8FP1,2865.0,1.0,353.0,164.0,,40.99,1.0,1.85,experimental,29.4,0.2344,0.1978,PKCeta kinase domain in complex with compound 2
7VSL,X-RAY DIFFRACTION,3.25,62.17,"VAPOR DIFFUSION, HANGING DROP",,"100mM Cacodylate Sodium pH 6.5, 15% Isopropanol, 30% Ethylene Glycol, 11% PEG3350",277.0,2021-10-26,2022-11-02,7VSL,2827.0,1.0,338.0,67.0,1.0,39.52,1.0,2.50006900162,experimental,46.4085779979,0.259221248638,0.224984393664,Crystal structure of PDE8A catalytic domain in complex with 10
7VTV,X-RAY DIFFRACTION,3.25,62.12,"VAPOR DIFFUSION, HANGING DROP",,"100mM Cacodylate Sodium pH 6.5, 15% Isopropanol, 30% Ethylene Glycol, 11% PEG 3350",277.0,2021-10-31,2022-11-02,7VTV,2806.0,1.0,338.0,56.0,1.0,39.59,1.0,2.8,experimental,30.0212259444,0.324406094087,0.282016164852,Crystal structure of PDE8A catalytic domain in complex with 15
7VTX,X-RAY DIFFRACTION,3.26,62.23,"VAPOR DIFFUSION, HANGING DROP",,"100mM Cacodylate Sodium pH 6.5, 15% Isopropanol, 30% Ethylene Glycol, 11% PEG 3350",277.0,2021-10-31,2022-11-02,7VTX,2849.0,1.0,338.0,67.0,1.0,39.6,1.0,2.50010936848,experimental,49.323980344,0.276666014121,0.246173473109,Crystal structure of PDE8A catalytic domain in complex with 22
8FDS,X-RAY DIFFRACTION,2.32,47.05,"VAPOR DIFFUSION, HANGING DROP",9.0,"4 M potassium formate, 0.1 M Bis-Tris propane, pH 9.0, 2% w/v PEG2000 MME",287.0,2022-12-04,2023-04-19,8FDS,1502.0,1.0,182.0,57.0,,20.6,1.0,1.65,experimental,,0.2207,0.1991,Ankyrin domain of SKD3 isoform 2
5W2A,X-RAY DIFFRACTION,2.45,49.84,"VAPOR DIFFUSION, HANGING DROP",,"25-30% PEG400, 0.2M ammonium nitrate",295.15,2017-06-06,2017-10-18,5W2A,7735.0,6.0,1146.0,28.0,,142.28,1.0,2.9,experimental,109.151,0.26956,0.23104,Structure of human DNA polymerase kappa in complex with Lucidin-derived DNA adduct and incoming dCMPNPP
5W2C,X-RAY DIFFRACTION,2.45,49.82,"VAPOR DIFFUSION, HANGING DROP",,"25-30% PEG400, 0.2M ammonium nitrate",295.15,2017-06-06,2017-10-18,5W2C,7962.0,6.0,1146.0,213.0,,142.15,1.0,2.5,experimental,80.783,0.25325,0.2111,Structure of human DNA polymerase kappa in complex with Lucidin-derived DNA adduct and incoming dAMPNPP
5FQD,X-RAY DIFFRACTION,2.76,55.0,,,70 MM TRIS PH 7.0 140 MM MGCL2 7% W/V PEG 8000,,2015-12-09,2016-02-24,5FQD,23544.0,6.0,3246.0,305.0,,368.75,3.0,2.45,experimental,96.76,0.21,0.181,Structural basis of Lenalidomide induced CK1a degradation by the crl4crbn ubiquitin ligase
7ZMQ,X-RAY DIFFRACTION,3.94,68.79,"VAPOR DIFFUSION, SITTING DROP",8.5,0.2M lithium sulfate -- 25% PEG3350 -- 0.1M tris pH 8.5,293.0,2022-04-19,2022-06-22,7ZMQ,8929.0,4.0,1144.0,52.0,2.0,127.2,2.0,2.7,experimental,61.392,0.2583,0.225,Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G2*-006
7ZMT,X-RAY DIFFRACTION,3.25,62.1,"VAPOR DIFFUSION, SITTING DROP",,0.2M sodium formate -- 20% PEG3350,293.0,2022-04-19,2022-06-22,7ZMT,8893.0,4.0,1144.0,83.0,2.0,126.76,2.0,2.3,experimental,72.529,0.291,0.2636,Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G5-006
9FXH,X-RAY DIFFRACTION,2.63,53.18,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1-0.2 M ammonium sulphate and 0.1 M MES, pH 6.0",281.0,2024-07-01,2024-09-04,9FXH,8853.0,3.0,1023.0,1071.0,,117.24,1.0,2.3,experimental,29.135,0.25657,0.20453,Crystal structure of cobalt(II)-substituted double mutant Y115E Y117E human Glutaminyl Cyclase
6MP3,X-RAY DIFFRACTION,2.11,41.69,"VAPOR DIFFUSION, HANGING DROP",5.5,"100mM MES 5.5, PEG 2K MME, 10mM MgSo4",291.15,2018-10-05,2019-10-16,6MP3,4204.0,3.0,455.0,355.0,,54.74,1.0,1.907,experimental,38.5663,0.209,0.1679,Binary structure of DNA polymerase eta in complex with templating hypoxanthine
5EC3,X-RAY DIFFRACTION,2.72,54.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris Propane, 0.2 M Sodium Acetate, 10% Ethylene Glycol, 18% PEG3,350",289.0,2015-10-20,2015-11-18,5EC3,3354.0,1.0,393.0,267.0,,45.06,1.0,2.1,experimental,,0.1922,0.1542,Structural insight into the catalyitc mechanism of human 4-Hydroxyphenylpyruvate dioxygenase
5IA0,X-RAY DIFFRACTION,2.49,50.68,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.3 M Carboxylic Acids, 0.1 M BufferSystem3 pH 8.5",291.0,2016-02-21,2016-11-09,5IA0,7095.0,3.0,918.0,518.0,,106.19,1.0,1.948,experimental,,0.2249,0.1937,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with alisertib (MLN8237)
6KYQ,X-RAY DIFFRACTION,3.76,67.3,"VAPOR DIFFUSION, HANGING DROP",,"1.6M NaH2PO4, 1.6M K2HPO4, PH7.8",293.0,2019-09-20,2020-09-23,6KYQ,5429.0,2.0,656.0,410.0,,73.39,1.0,2.141,experimental,31.5,0.198,0.1606,Crystal structure of DCLK1 Autoinhibited Kinase Domain
6KYR,X-RAY DIFFRACTION,3.86,68.09,"VAPOR DIFFUSION, HANGING DROP",,"1.6M NaH2PO4/K2HPO4, PH 7.8",293.0,2019-09-20,2020-09-23,6KYR,5318.0,2.0,656.0,382.0,,73.5,1.0,2.206,experimental,35.12,0.201,0.1795,Crystal structure of DCLK1 mutant (P675L) Autoinhibited Kinase Domain
6ATO,X-RAY DIFFRACTION,2.23,44.89,"VAPOR DIFFUSION, SITTING DROP",8.5,"PEG 200 MME, 25% (w/v), 0.1 M Tris HCl, pH 8.5",293.0,2017-08-29,2018-09-12,6ATO,4305.0,2.0,442.0,574.0,,52.52,1.0,1.55,experimental,,0.2079,0.1695,Crystal structure of hGSTA1-1 complexed with GSH and MPD in each subunit
5F5A,X-RAY DIFFRACTION,2.39,48.46,"VAPOR DIFFUSION, SITTING DROP",7.0,"30% PEG3350 , 0.1M HEPES pH 7.0 , 0.25M ammonium sulfate",293.0,2015-12-04,2015-12-16,5F5A,3259.0,1.0,346.0,344.0,,41.56,1.0,1.41,experimental,19.075,0.1647,0.1311,Crystal Structure of human JMJD2D complexed with KDOAM16
5F5C,X-RAY DIFFRACTION,2.41,49.05,"VAPOR DIFFUSION, SITTING DROP",6.8,"26% PEG3350 , 0.1M HEPES pH 6.8 , 0.2M ammonium sulfate",293.0,2015-12-04,2015-12-30,5F5C,3308.0,1.0,346.0,411.0,,41.01,1.0,1.88,experimental,13.863,0.2108,0.1715,Crystal Structure of human JMJD2D complexed with KDOPP7
6ETV,X-RAY DIFFRACTION,2.52,51.16,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-10-27,2019-02-27,6ETV,3646.0,1.0,342.0,494.0,,40.69,1.0,1.18,experimental,18.1518,0.15,0.1213,Crystal structure of KDM4D with tetrazolhydrazide compound 2
6ETW,X-RAY DIFFRACTION,2.54,51.57,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-10-27,2019-02-20,6ETW,3488.0,1.0,342.0,471.0,,40.36,1.0,1.35,experimental,21.1536,0.1587,0.1283,Crystal structure of KDM4D with tetrazolhydrazide compound 3
6QMT,X-RAY DIFFRACTION,1.71,28.2,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% PEGME 3350, 100 mM Bis-Tris pH 5.5",293.0,2019-02-08,2019-04-24,6QMT,3594.0,2.0,508.0,90.0,8.0,54.92,1.0,1.8,experimental,25.871,0.2312,0.202,"Complement factor D in complex with the inhibitor 2-(2-(3'-(aminomethyl)-[1,1'-biphenyl]-3-carboxamido)phenyl)acetic acid"
8AQF,X-RAY DIFFRACTION,2.49,50.53,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES pH 6.5, 6 to 13% PEG MME5K, 12% isopropanol",293.0,2022-08-12,2023-08-23,8AQF,2654.0,1.0,323.0,321.0,,36.0,1.0,1.55,experimental,31.073,0.1781,0.1544,CRYSTAL STRUCTURE OF HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND LEI-515
4TN6,X-RAY DIFFRACTION,2.58,52.33,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1M NaAcetate, pH=5.6, 0.2 M Li2SO4, 14-17.5% PEG3350, 3-5.5% 1,3 propandiol",296.0,2014-06-03,2015-08-12,4TN6,5001.0,2.0,636.0,211.0,,74.42,1.0,2.41,experimental,52.87,0.2387,0.1871,CK1d in complex with inhibitor
5B5O,X-RAY DIFFRACTION,2.31,46.79,"VAPOR DIFFUSION, SITTING DROP",8.5,"100mM TrisHCl, 1500mM ammonium formate, 10.4% PEG8000",293.0,2016-05-13,2017-01-18,5B5O,3299.0,2.0,344.0,555.0,,39.84,1.0,1.2,experimental,15.5145,0.1854,0.1638,"Crystal structure of the catalytic domain of MMP-13 complexed with N-phenyl-4-((4H-1,2,4-triazol-3-ylsulfanyl)methyl)-1,3-thiazol-2-amine"
5B5P,X-RAY DIFFRACTION,2.36,47.86,"VAPOR DIFFUSION, SITTING DROP",8.5,"100mM TrisHCl, 1000mM ammonium formate, 15.3% PEG8000",293.0,2016-05-13,2017-01-18,5B5P,3116.0,2.0,344.0,398.0,,40.08,1.0,1.6,experimental,24.4984,0.208,0.1733,"Crystal structure of the catalytic domain of MMP-13 complexed with 4-oxo-N-(3-(2-(1H-1,2,4-triazol-3-ylsulfanyl)ethoxy)benzyl)-3,4-dihydroquinazoline-2-carboxamide"
6VXR,X-RAY DIFFRACTION,2.37,48.2,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 1,500",293.0,2020-02-24,2020-07-29,6VXR,2512.0,1.0,339.0,47.0,,39.74,1.0,2.1,experimental,51.597,0.2483,0.219,Structure of Maternal embryonic leucine zipper kinase bound to LDSM276
5AA8,X-RAY DIFFRACTION,2.1,41.35,,8.0,pH 8,,2015-07-23,2016-06-08,5AA8,2533.0,1.0,327.0,170.0,,37.41,1.0,1.86,experimental,33.9,0.233,0.209,"Structure of C1156Y,L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile)."
6QTY,X-RAY DIFFRACTION,2.47,50.11,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 3350, 200mM MgCl2, 100mM Bis-Tris (pH 6.5)",273.0,2019-02-26,2020-03-18,6QTY,3001.0,1.0,337.0,236.0,,39.79,1.0,1.65,experimental,19.39,0.20316,0.13549,Non-phosphorylated human CLK1 in complex with an indole inhibitor to 1.65 Ang
6CSB,X-RAY DIFFRACTION,3.23,61.89,"VAPOR DIFFUSION, HANGING DROP",,"mixing 1.5 ul of the protein solution, 0.25 ul 70 mM HEGA-10, and 0.3 ul of the reservoir solution containing 10-20% of PEG 400, 0.1 M cacodylate, pH 7.0, 2 mM ZnSO4, and 200 mM MgAc2",293.0,2018-03-20,2019-03-27,6CSB,15058.0,4.0,1916.0,546.0,,222.35,1.0,2.394,experimental,,0.2292,0.193,V308E mutant of cytochrome P450 2D6 complexed with thioridazine
7VJS,X-RAY DIFFRACTION,2.64,53.48,"VAPOR DIFFUSION, SITTING DROP",,"PEG 8000, Tris",277.0,2021-09-28,2022-02-02,7VJS,1667.0,1.0,246.0,89.0,,27.65,1.0,1.792,experimental,22.654,0.2144,0.1969,Human AlkB homolog ALKBH6 in complex with Tris and Ni
4OFA,X-RAY DIFFRACTION,2.02,38.98,"VAPOR DIFFUSION, HANGING DROP",8.0,"33% ethylene glycol, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295.0,2014-01-14,2015-04-22,4OFA,1919.0,3.0,216.0,221.0,,29.85,1.0,1.55,experimental,31.955,0.18212,0.13448,Structural basis for thymine glycosylase activity on T:O6-methylG mismatch by methyl-CpG binding domain protein 4: Implications for roles of Arg468 in mismatch recognition and catalysis
4OFE,X-RAY DIFFRACTION,2.03,39.37,"VAPOR DIFFUSION, HANGING DROP",8.0,"15% PEG1500, 0.1M MES at pH of 6.5, 0.2M Na Acetate., VAPOR DIFFUSION, HANGING DROP, temperature 295K",295.0,2014-01-14,2015-04-22,4OFE,1829.0,3.0,216.0,133.0,,29.83,1.0,2.15,experimental,28.328,0.20153,0.14223,Structural basis for thymine glycosylase activity on T:O6-methylG mismatch by methyl-CpG binding domain protein 4: Implications for roles of Arg468 in mismatch recognition and catalysis
4OFH,X-RAY DIFFRACTION,2.08,40.86,"VAPOR DIFFUSION, HANGING DROP",8.0,"21% ethylene glycol, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295.0,2014-01-14,2015-04-22,4OFH,1782.0,3.0,216.0,91.0,,29.87,1.0,2.22,experimental,36.708,0.2303,0.18619,Structural basis for thymine glycosylase activity on T:O6-methylG mismatch by methyl-CpG binding domain protein 4: Implications for roles of Arg468 in mismatch recognition and catalysis
7ZMS,X-RAY DIFFRACTION,3.22,61.76,"VAPOR DIFFUSION, SITTING DROP",7.5,0.2M sodium chloride -- 25% PEG3350 -- 0.1M HEPES pH 7.5,293.0,2022-04-19,2022-07-13,7ZMS,4421.0,2.0,571.0,38.0,1.0,63.22,2.0,2.7,experimental,80.715,0.2762,0.235,Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G4-043
5E0F,X-RAY DIFFRACTION,2.29,46.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM sodium cacodylate, 58% MPD",293.0,2015-09-28,2016-09-07,5E0F,4480.0,1.0,496.0,427.0,5.0,56.8,1.0,1.4,experimental,,0.1811,0.155,Human pancreatic alpha-amylase in complex with mini-montbretin A
5F9C,X-RAY DIFFRACTION,2.97,58.65,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M ammonium sulfate with 0.15 lithium sulfate and 0.1 CAPS buffer, pH 10.5",293.0,2015-12-09,2016-04-27,5F9C,8196.0,2.0,1124.0,80.0,,124.34,1.0,2.5,experimental,,0.2427,0.1918,Crystal structure of the G121R mutant of human phosphoglucomutase 1
5TR2,X-RAY DIFFRACTION,2.85,60.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.6 M Ammonium Sulfate, 0.1 M NaCl, and 0.1 M HEPES pH 7.5",292.0,2016-10-25,2017-02-08,5TR2,8233.0,2.0,1170.0,204.0,,128.98,1.0,2.5,experimental,56.38,0.2919,0.22,Crystal structure of the D263G missense variant of human PGM1
6C6M,X-RAY DIFFRACTION,3.22,61.78,"VAPOR DIFFUSION, SITTING DROP",,"200mM ammonium dihydrogen phosphate, 20% PEG3350",277.0,2018-01-19,2019-01-23,6C6M,2302.0,3.0,309.0,57.0,1.0,34.9,1.0,2.5,experimental,81.4,0.272,0.226,IgCam3 of human MLCK1
5MQV,X-RAY DIFFRACTION,4.09,69.94,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Hepes pH 7.0, 0.7 M NaH2PO4, 0.7 M KH2PO4",277.0,2016-12-20,2017-04-05,5MQV,14871.0,6.0,1884.0,697.0,,223.52,1.0,2.154,experimental,57.0082,0.1917,0.1731,"Crystal structure of human Casein Kinase I delta in complex with 4-(2,5-Dimethoxyphenyl)-N-(4-(5-(4-fluorphenyl)-2-(methylthio)-1H-imidazol-4-yl)-pyridin-2-yl)-1-methyl-1H-pyrrole-2-carboxamide"
8VZ7,X-RAY DIFFRACTION,4.0,69.29,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3M Sodium Acetate Trihydrate
0.1 M Tris pH 7.5
25% w/v PEG 2000 MME",291.0,2024-02-11,2024-06-12,8VZ7,3963.0,1.0,476.0,171.0,,55.87,1.0,2.53,experimental,60.981,0.21531,0.15092,Crystal Structure of Human Cytochrome P450 2C9*27 (R150L) Genetic Variant in Complex with the Drug Losartan
5MT0,X-RAY DIFFRACTION,2.09,41.21,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 100 mM BIS-TRIS pH 6.5",293.0,2017-01-06,2017-02-15,5MT0,1972.0,1.0,232.0,190.0,5.0,25.17,1.0,1.29,experimental,,0.196,0.154,COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE INDOLE CARBOXYLIC ACID BASED INHIBITOR
5NAT,X-RAY DIFFRACTION,2.11,41.83,"VAPOR DIFFUSION, SITTING DROP",,"MM NACL
                      + 1 UL RESERVOIR SOLUTION",298.0,2017-02-28,2018-03-21,5NAT,2062.0,1.0,232.0,263.0,4.0,25.37,1.0,1.17,experimental,,,,"Complement factor D in complex with the inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 1-[(1-methyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]"
5NBA,X-RAY DIFFRACTION,2.09,41.24,"VAPOR DIFFUSION, SITTING DROP",,"23% PEG 3350, 0.1 M HEPES pH 7.5, 50 mM NaCl",293.0,2017-03-01,2017-06-28,5NBA,1830.0,1.0,230.0,122.0,4.0,25.09,1.0,1.87,experimental,16.062,0.25999,0.17273,"Complement factor D in complex with the inhibitor (2S,4R)-4-Fluoro-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]"
4YR3,X-RAY DIFFRACTION,2.11,41.65,"VAPOR DIFFUSION, HANGING DROP",6.0,"NaMES (pH 6.0), polyethylene glycol monomethyl ether 2000, and calcium chloride",291.0,2015-03-14,2015-05-13,4YR3,4102.0,3.0,455.0,411.0,,55.23,1.0,2,experimental,,0.219,0.1759,Mutant Human DNA Polymerase Eta R61M Inserting dCTP Opposite Template G
6XL8,X-RAY DIFFRACTION,2.3,46.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"Protein: 14mg/ml 3ost3a in 25mM Tris pH 7.5, 125mM NaCl, 4mM PAP and 5mM 8mer oligosaccharide

Reservoir: 0.2M KI and 20%PEG3350",293.0,2020-06-28,2021-06-23,6XL8,4436.0,2.0,546.0,71.0,2.0,67.65,1.0,2.34,experimental,40.62,0.2709,0.2162,Crystal structure of 3-O-Sulfotransferase isoform 3 in complex with 8mer oligosaccharide with no 6S sulfation
6H8R,X-RAY DIFFRACTION,2.59,52.43,"VAPOR DIFFUSION, HANGING DROP",5.5,"24 % PEG 3350, 0.2 M ammonium sulfate and 0.1 M BIS-Tris pH 5.5",277.0,2018-08-03,2018-09-26,6H8R,2838.0,1.0,305.0,377.0,,35.52,1.0,1.66,experimental,25.36,0.239,0.2,CRYSTAL STRUCTURE OF THE HUMAN PROTEIN TYROSINE PHOSPHATASE PTPN5 (STEP) IN COMPLEX WITH COMPOUND 2
7XQK,X-RAY DIFFRACTION,2.69,54.35,"VAPOR DIFFUSION, SITTING DROP",,"1.6M MgSO4, 0.1M MES pH6.5",293.0,2022-05-07,2023-05-17,7XQK,5147.0,2.0,838.0,428.0,,99.02,2.0,2.25,experimental,38.105,0.2024,0.1599,The Crystal Structure of CDK3 and CyclinE1 Complex from Biortus.
8H4R,X-RAY DIFFRACTION,2.73,54.93,"VAPOR DIFFUSION, SITTING DROP",,"1.6M MgSO4, 0.1M MES pH 6.60",293.0,2022-10-11,2023-10-11,8H4R,4942.0,2.0,838.0,273.0,,98.85,2.0,2.75,experimental,35.299,0.2234,0.1614,The Crystal Structure of CDK3 and CyclinE1 Complex with Dinaciclib from Biortus
4WOV,X-RAY DIFFRACTION,1.97,39.55,"VAPOR DIFFUSION, HANGING DROP",6.5,"30% PEG5000 (methyl ether), 200 mM ammonium sulfate and 100 mM sodium cacodylate buffer, pH 6.5",295.0,2014-10-16,2015-03-18,4WOV,4199.0,2.0,634.0,257.0,1.0,72.24,1.0,1.8,experimental,31.59,0.2144,0.1918,"CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0, 6]DODECA-1(9),2(6),4,7,11-PENTAEN-11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE"
8P7J,X-RAY DIFFRACTION,2.57,52.18,"VAPOR DIFFUSION, SITTING DROP",,0.05M magnesium chloride -- 30% PEG500MME -- 0.1M HEPES pH 7.5,293.15,2023-05-30,2023-07-05,8P7J,4441.0,2.0,580.0,35.0,,66.03,1.0,2.4,experimental,55.382,0.25744,0.19557,Crystal structure of MAP2K6 with a covalent compound GCL96
5Y90,X-RAY DIFFRACTION,2.31,46.82,"VAPOR DIFFUSION, SITTING DROP",7.0,"PEG3350, sodium citrate",277.0,2017-08-22,2017-10-11,5Y90,2925.0,1.0,323.0,341.0,,37.22,1.0,1.3,experimental,30.699,0.16714,0.12685,MAP2K7 mutant -C218S
6RAA,X-RAY DIFFRACTION,2.36,47.94,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Bicine, 14% PEG 6000",277.0,2019-04-05,2019-04-24,6RAA,3016.0,1.0,339.0,187.0,,40.13,1.0,2.1,experimental,33.973,0.233,0.1876,CLK1 Kinase domain with bound imidazopyridin inhibitor TP003
8HY3,X-RAY DIFFRACTION,5.7,78.43,"VAPOR DIFFUSION, HANGING DROP",,"14%-18% (v/v) PEG 4000, 0.2 M MgCl2, 0.1 M Tris-HCl, pH 8.5",293.15,2023-01-05,2024-05-08,8HY3,2675.0,1.0,329.0,42.0,,37.93,1.0,1.952,experimental,,0.2582,0.2264,Crystal structure of human secretory glutaminyl cyclase in complex with 1-benzyl-5-methyl-1H-imidazole
9FXG,X-RAY DIFFRACTION,2.76,55.39,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.2 M ammonium sulphate and 0.1 M MES, pH 6.0",281.0,2024-07-01,2024-09-04,9FXG,9886.0,3.0,1023.0,2105.0,,117.63,1.0,1.96,experimental,22.516,0.25717,0.20804,Crystal structure of double mutant Y115E Y117E human Glutaminyl Cyclase in apo-state
5KHX,X-RAY DIFFRACTION,2.06,40.24,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 1500, 8% MPD, 0.1 M Tris pH 9.0",281.0,2016-06-16,2016-11-09,5KHX,2370.0,1.0,316.0,79.0,,36.71,1.0,2.4,experimental,49.99,0.2416,0.1703,Crystal structure of JAK1 in complex with PF-4950736
6BBU,X-RAY DIFFRACTION,2.05,40.15,"VAPOR DIFFUSION, HANGING DROP",,"250mM NaCl, 5mM TCEP, 10 mM ATP, 10 mM MgCl2, 30% PEG1500, 8% MPD, 0.1M Tris pH 9.0",281.0,2017-10-19,2018-01-17,6BBU,2452.0,1.0,316.0,127.0,,36.74,1.0,2.08,experimental,44.45,0.2135,0.1829,Crystal Structure of JAK1 in complex with compound 25
7CWF,X-RAY DIFFRACTION,3.35,62.21,"VAPOR DIFFUSION, HANGING DROP",,"100mM Cacodylate Sodium pH 6.5, 15% Isopropanol, 30% Ethylene Glycol, 11% PEG3350",277.0,2020-08-28,2021-09-01,7CWF,2804.0,1.0,338.0,52.0,1.0,39.52,1.0,2.8,experimental,47.217,0.29258,0.25675,Crystal structure of PDE8A catalytic domain in complex with 2c
7CWG,X-RAY DIFFRACTION,3.33,62.01,"VAPOR DIFFUSION, HANGING DROP",,"100mM Cacodylate Sodium pH 6.5, 15% Isopropanol, 30% Ethylene Glycol, 11% PEG3350",277.0,2020-08-28,2021-09-01,7CWG,2780.0,1.0,338.0,61.0,1.0,39.53,1.0,2.8,experimental,41.421,0.31747,0.27477,Crystal structure of PDE8A catalytic domain in complex with 3a
7P7F,X-RAY DIFFRACTION,2.49,50.51,"VAPOR DIFFUSION, SITTING DROP",5.9,"20% PEG 3350, 0.1 M sodium sulfate, and 0.1 M citrate, pH 5.9",277.15,2021-07-19,2022-04-13,7P7F,10341.0,4.0,1184.0,639.0,,141.3,1.0,1.96,experimental,42.477,0.221,0.1879,"Crystal structure of phosphorylated pT220 Casein Kinase I delta (CK1d), conformation 1"
6F26,X-RAY DIFFRACTION,2.53,51.4,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES pH 5.5, 10 % (w/v) PEG 4000, 0.2 M lithium sulfate",293.0,2017-11-23,2019-03-13,6F26,5140.0,2.0,628.0,366.0,,75.83,1.0,1.83,experimental,,0.2087,0.1895,Crystal structure of human Casein Kinase I delta in complex with compound 31b
6PXN,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.3 M Ammonium sulfate
0.05 M Sodium Acetate
18% PEG 2000",295.0,2019-07-26,2020-02-12,6PXN,5057.0,2.0,830.0,297.0,,95.19,1.0,1.551,experimental,,0.205,0.1769,Human Casein Kinase 1 delta Tau mutant (R178C)
6PXP,X-RAY DIFFRACTION,2.26,45.56,"VAPOR DIFFUSION, HANGING DROP",6.0,"7.7 mg/mL Protein
0.05 M Sodium Acetate
0.35 M Ammonium Sulfate
17.5% PEG 3500",295.0,2019-07-26,2020-02-12,6PXP,4922.0,2.0,588.0,115.0,,69.37,1.0,2.35,experimental,,0.2433,0.1985,Human Casein Kinase 1 delta Site 2 mutant (K171E)
4ZEG,X-RAY DIFFRACTION,3.23,61.94,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M MgCl2, 0.1M Tris pH 8.5, 25% PEG 3500",293.0,2015-04-20,2016-04-27,4ZEG,2221.0,1.0,281.0,22.0,,33.54,1.0,2.33,experimental,66.242,0.26289,0.20935,Crystal structure of TTK kinase domain in complex with a pyrazolopyrimidine inhibitor
6OVA,X-RAY DIFFRACTION,2.5,50.74,"VAPOR DIFFUSION, SITTING DROP",6.0,"15% PEG 5000 MME, and 100 mM Sodium Citrate (pH 6.0)",293.0,2019-05-07,2020-02-12,6OVA,2312.0,1.0,301.0,50.0,,35.24,1.0,2.5,experimental,73.301,0.2509,0.1968,Crystal Structure of TYK2 with novel pyrrolidinone inhibitor
8PTC,X-RAY DIFFRACTION,2.52,51.28,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES pH 6.5, 6 to 13% PEG MME 5K, 12% isopropanol",293.0,2023-07-14,2024-01-31,8PTC,2606.0,1.0,323.0,239.0,,35.92,1.0,1.51,experimental,36.47,0.2198,0.2015,COMPLEX CRYSTAL STRUCTURE OF MUTANT HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND 5d
4UYA,X-RAY DIFFRACTION,2.37,47.71,,,,,2014-08-29,2015-09-30,4UYA,2083.0,1.0,340.0,39.0,,39.05,1.0,2.8,experimental,82.07,0.2606,0.2011,Structure of MLK4 kinase domain with ATPgammaS
7QUF,X-RAY DIFFRACTION,2.75,55.3,"VAPOR DIFFUSION, SITTING DROP",,"24% PEG3350, 0.2 M ammonium chloride",277.0,2022-01-17,2022-02-02,7QUF,3842.0,2.0,550.0,15.0,,63.8,1.0,2.6,experimental,75.82,0.2937,0.2315,The STK17A (DRAK1) Kinase Domain Bound to CK156
7AQB,X-RAY DIFFRACTION,2.17,43.19,"VAPOR DIFFUSION, SITTING DROP",6.7,1.8M MgSO4; 0.1M MES,277.0,2020-10-20,2020-11-11,7AQB,4213.0,2.0,640.0,77.0,,72.65,1.0,2.25,experimental,49.722,0.2575,0.2224,Crystal structure of human mitogen activated protein kinase 6 (MAPK6)
6NKZ,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"16-18% PEG 3350, 50 mM Imidazole, 350 mM Sodium Acetate",291.0,2019-01-07,2020-01-08,6NKZ,3596.0,4.0,366.0,320.0,,48.25,1.0,2.01,experimental,33.7069,0.2346,0.1862,"Ternary complex crystal structure of K289M variant of DNA polymerase Beta with ""hot-spot sequence"" with beta-gamma methylene dGTP"
6SZQ,X-RAY DIFFRACTION,2.14,42.66,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M NaAc, 0.1M Tris pH 8,5, 30% PEG4000,
cryo: reservoir+20% glycerol",277.15,2019-10-02,2019-12-25,6SZQ,13242.0,6.0,1782.0,380.0,,195.41,1.0,2.412,experimental,48.8041,0.2702,0.223,Crystal structure of human DDAH-1
4XDP,X-RAY DIFFRACTION,2.61,52.88,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.8 M Lithium chloride, 0.1 M TRIS pH 8.5, 28 % w/v PEG 4000",291.15,2014-12-19,2015-03-25,4XDP,6034.0,2.0,676.0,317.0,,80.07,1.0,2.07,experimental,27.402,0.242,0.2066,Crystal structure of human KDM4C catalytic domain bound to tris
6HZU,X-RAY DIFFRACTION,2.45,49.79,VAPOR DIFFUSION,,"30 % PEG6000_50
0.10 M MES pH 6.00",277.0,2018-10-24,2019-10-23,6HZU,5103.0,2.0,604.0,320.0,,70.22,1.0,2.2,experimental,28.682,0.26545,0.20058,HUMAN JAK1 IN COMPLEX WITH LASW1393
5SXG,X-RAY DIFFRACTION,1.94,36.49,"VAPOR DIFFUSION, HANGING DROP",,PEG3350,293.0,2016-08-09,2017-12-27,5SXG,3202.0,2.0,370.0,281.0,,44.3,1.0,1.93,experimental,,0.21,0.1766,Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
5FYM,X-RAY DIFFRACTION,2.84,56.76,,7.4,"0.1M HEPES PH 7.4, 0.2M TRIMETHYLAMINE N-OXIDE, 15% PEG3350",,2016-03-08,2016-03-16,5FYM,7949.0,2.0,956.0,639.0,,112.29,1.0,2,experimental,,0.245,0.1922,Crystal structure of JmjC domain of human histone demethylase UTY in complex with D-2-hydroxyglutarate
7CP3,X-RAY DIFFRACTION,2.84,56.66,VAPOR DIFFUSION,8.5,"0.1M Tris pH 8.5, 25% PEG 3350",291.0,2020-08-05,2021-08-11,7CP3,2329.0,1.0,292.0,,,33.47,1.0,2.9,experimental,94.0323,0.2667,0.2444,Crystal Structure of PAK4 in complex with inhibitor 47
7CP4,X-RAY DIFFRACTION,2.13,42.24,VAPOR DIFFUSION,,"0.2M Ammonium sulfate, 0.1M Bis-tris 5.5, 25% PEG 3350, 0.1M Guanidine hydrochloride",291.0,2020-08-06,2021-08-11,7CP4,2391.0,1.0,292.0,50.0,,33.47,1.0,2.5,experimental,35.9057,0.2517,0.1961,Crystal Structure of PAK4 in complex with inhibitor 55
6FAF,X-RAY DIFFRACTION,2.33,47.15,"VAPOR DIFFUSION, HANGING DROP",9.0,"28% PEG4000, 0.2 M Sodium acetate, Tris 100 mM",296.0,2017-12-15,2018-10-10,6FAF,4307.0,2.0,522.0,189.0,,59.07,1.0,1.99,experimental,42.996,0.2571,0.2029,"Crystal structure of human carbonic anhydrase I in complex with the 3-(2,5-dimethylphenyl)-1-(2-hydroxy-5-sulfamoylphenyl)urea inhibitor"
6FAG,X-RAY DIFFRACTION,2.31,46.79,"VAPOR DIFFUSION, HANGING DROP",9.0,"28% PEG4000, 0.2 M Sodium acetate, Tris 100 mM",296.0,2017-12-15,2018-10-10,6FAG,4297.0,2.0,522.0,210.0,,58.8,1.0,1.79,experimental,35.116,0.26565,0.21697,Crystal structure of human carbonic anhydrase I in complex with the 1-(2-hydroxy-5-sulfamoylphenyl)-3-(2-methoxyphenyl)urea inhibitor
5OWQ,X-RAY DIFFRACTION,2.41,48.91,"VAPOR DIFFUSION, SITTING DROP",,"0.1M sodium formate, 15%(w/v) PEG 3350",277.0,2017-09-04,2017-09-13,5OWQ,3906.0,2.0,604.0,,1.0,69.38,1.0,2.7,experimental,54.895,0.30495,0.26322,Human STK10 bound to dovitinib
5GP7,X-RAY DIFFRACTION,2.15,42.84,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM HEPES/sodium hydroxide, 200 mM sodium chloride, 20% (w/v) PEG 6000",289.0,2016-08-01,2017-07-12,5GP7,1566.0,2.0,179.0,245.0,,19.39,2.0,1.502,experimental,,0.2072,0.1715,Structural basis for the binding between Tankyrase-1 and USP25
7DH3,X-RAY DIFFRACTION,3.62,66.06,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dehydrate, 0.01 M sodium borate, pH 7.5-9.5",291.0,2020-11-12,2021-11-17,7DH3,2742.0,1.0,326.0,64.0,,38.23,1.0,2.33,experimental,56.1622,0.2172,0.1938,The co-crystal structure of DYRK2 with a small molecule inhibitor 5
5HSH,X-RAY DIFFRACTION,2.94,58.12,"VAPOR DIFFUSION, HANGING DROP",9.7,"~1.0M Sodium Citrate, 0.1M CHES Buffer pH 9.7.",292.0,2016-01-25,2016-04-27,5HSH,7521.0,2.0,1124.0,101.0,,123.72,1.0,2.65,experimental,,0.2733,0.23,Crystal structure of the G291R mutant of human phosphoglucomutase 1
5JN5,X-RAY DIFFRACTION,3.04,59.52,"VAPOR DIFFUSION, HANGING DROP",7.5,"LITHIUM OR AMMONIUM SULFATE (1.4 -
1.55 M) WITH 0.1 M TRIS, PH 7.5 OR MES PH 6.0",293.0,2016-04-29,2017-02-08,5JN5,10013.0,2.0,1170.0,1423.0,,129.39,1.0,1.75,experimental,,0.2088,0.1799,Crystal structure of the D263Y missense variant of human PGM1
6UO6,X-RAY DIFFRACTION,2.85,56.91,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.7-1.95 ammonium sulfate, 0.1 M Tris HCl, pH 8.0",293.0,2019-10-14,2020-03-04,6UO6,9185.0,2.0,1170.0,625.0,,129.14,1.0,2.15,experimental,45.04,0.213,0.1752,Crystal Structure of the R422Q missense variant of human PGM1
7NBJ,X-RAY DIFFRACTION,2.28,46.04,"VAPOR DIFFUSION, HANGING DROP",,"Human NNMT was crystallized using the following conditions: A protein solution with 6 mg/ml NNMT, 50 mM Tris/HCL, pH 8.0, 1 mM DTT, 0.95mM inhibitor and 5% v/v glycerol was equilibrated at room temperature in a hanging drop setup against 2.2 M ammonium sulfate with 0.1 M HEPES/Na, pH 7.6. Small crystal appeared after 1-2 weeks.",293.0,2021-01-27,2021-03-17,7NBJ,8928.0,4.0,1132.0,656.0,,127.78,1.0,2.275,experimental,31.17,0.22,0.1687,Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the bisubstrate-like inhibitor (1)
8A2L,X-RAY DIFFRACTION,3.02,59.34,"VAPOR DIFFUSION, HANGING DROP",9.0,"2.0 M magnesium chloride, 0.1 M bicine buffer pH 9.0",293.0,2022-06-03,2023-02-08,8A2L,1635.0,1.0,182.0,172.0,,21.56,1.0,2.301,experimental,34.08,0.2236,0.1706,X-ray structure of TRIL-encapsulated human heavy chain ferritin
6GWJ,X-RAY DIFFRACTION,2.25,45.38,"VAPOR DIFFUSION, HANGING DROP",,"of PEG 4000, 0.1 M Tris HCl pH 8.5 and 0.2 M Magnesium Chloride",277.0,2018-06-25,2019-07-03,6GWJ,3845.0,3.0,584.0,223.0,,63.92,3.0,1.95,experimental,54.83,0.217,0.186,Human OSGEP / LAGE3 / GON7 complex
4Z3D,X-RAY DIFFRACTION,2.59,52.49,EVAPORATION,4.6,"0.2M Ammonium acetate, 0.1M Sodium acetate trihydrate pH 4.6, 28% w/v Polyethylene glycol 4000",293.0,2015-03-31,2015-10-14,4Z3D,9597.0,4.0,1104.0,1045.0,,125.35,1.0,1.8,experimental,20.17,0.212,0.182,Human carbonyl reductase 1 with glutathione in a protective configuration
5M6E,X-RAY DIFFRACTION,4.64,73.48,"VAPOR DIFFUSION, SITTING DROP",8.0,"3.2M NaCl, 0.1M HEPES/NaOHpH=8",277.0,2016-10-25,2017-05-24,5M6E,1134.0,1.0,127.0,207.0,,15.22,1.0,2.32,experimental,43.572,0.23923,0.18326,Small Molecule inhibitors of IAP
5V59,X-RAY DIFFRACTION,2.04,39.74,VAPOR DIFFUSION,8.0,"25% PEG6000, 100 mM Tris-HCl, pH 8.0",310.0,2017-03-13,2018-01-10,5V59,3320.0,1.0,475.0,245.0,,53.74,1.0,2.03,experimental,26.974,0.2146,0.1799,Crystal structure of catalytic fragment of human AlaRS in complex with Aze-SA
6ETE,X-RAY DIFFRACTION,2.53,51.42,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-10-26,2019-02-20,6ETE,3329.0,1.0,342.0,363.0,,40.46,1.0,1.468,experimental,27.331,0.1534,0.1276,Crystal structure of KDM4D with tetrazolhydrazide compound 5
6F5Q,X-RAY DIFFRACTION,2.61,52.9,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-12-02,2018-12-12,6F5Q,3437.0,1.0,342.0,474.0,,40.66,1.0,1.43,experimental,22.2506,0.1736,0.1434,Crystal Structure of KDM4D with GF026 ligand
6F5R,X-RAY DIFFRACTION,2.63,53.17,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-12-02,2018-12-12,6F5R,3152.0,1.0,327.0,342.0,,38.86,1.0,1.607,experimental,32.3693,0.1923,0.1674,Crystal Structure of KDM4D with GF028 ligand
6F5S,X-RAY DIFFRACTION,2.61,52.85,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-12-02,2018-12-12,6F5S,3259.0,1.0,342.0,383.0,,40.57,1.0,1.48,experimental,34.408,0.1832,0.1608,Crystal Structure of KDM4D with tetrazole ligand GF049
6F5T,X-RAY DIFFRACTION,2.6,52.73,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-12-02,2018-12-12,6F5T,3191.0,1.0,330.0,334.0,,39.47,1.0,1.58,experimental,31.8763,0.1982,0.1784,Crystal Structure of KDM4D with tetrazole ligand GF057
6H0X,X-RAY DIFFRACTION,2.57,52.1,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2018-07-10,2020-01-29,6H0X,3252.0,1.0,342.0,458.0,,40.16,1.0,1.64,experimental,20.9608,0.2184,0.1822,Crystal Structure of KDM4D with tetrazolylhydrazide ligand AA040
6H0Y,X-RAY DIFFRACTION,2.53,51.43,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2018-07-10,2020-01-29,6H0Y,3497.0,1.0,342.0,436.0,,40.59,1.0,1.212,experimental,18.9037,0.1584,0.1242,Crystal Structure of KDM4D with tetrazolylhydrazide ligand NS022
6H0Z,X-RAY DIFFRACTION,2.56,51.92,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2018-07-10,2020-01-29,6H0Z,3523.0,1.0,342.0,493.0,,40.73,1.0,1.34,experimental,19.3596,0.1512,0.129,Crystal Structure of KDM4D with tetrazolylhydrazide ligand NR067
6H11,X-RAY DIFFRACTION,2.58,52.24,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2018-07-10,2020-01-29,6H11,3358.0,1.0,342.0,469.0,,40.3,1.0,1.516,experimental,19.7206,0.2223,0.1911,Crystal Structure of KDM4D with tetrazolylhydrazide ligand AA028
4YNO,X-RAY DIFFRACTION,2.29,46.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 MM AMMONIUM TARTRATE, 18% PEG 3350",290.0,2015-03-10,2015-04-08,4YNO,3092.0,1.0,371.0,315.0,,42.63,1.0,1.7,experimental,,0.2245,0.1964,Crystal structure of MAPK13 at INACTIVE FORM
6NRY,X-RAY DIFFRACTION,2.62,53.13,"VAPOR DIFFUSION, SITTING DROP",5.5,"25mM Bis-Tris, 20% PEG3350",277.0,2019-01-24,2020-07-29,6NRY,2067.0,1.0,288.0,75.0,,32.92,1.0,2.184,experimental,,0.2367,0.1947,Crystal structure of human caspase-4
6JFL,X-RAY DIFFRACTION,2.39,48.43,"VAPOR DIFFUSION, HANGING DROP",,"0.19 M Calcium chloride
0.095 M HEPES PH7.5
26.6% (V/V) PEG400
5% (V/V) Glycerol",293.15,2019-02-10,2019-11-13,6JFL,13486.0,4.0,1752.0,132.0,,199.45,1.0,2.806,experimental,,0.2832,0.207,Nucleotide-free Mitofusin2 (MFN2)
7L1T,X-RAY DIFFRACTION,2.26,45.48,"VAPOR DIFFUSION, SITTING DROP",6.3,"0.36 M lithium citrate, 15% PEG 3,350, 0.1 M sodium cacodylic acid, 0.04 M HCl

4 mg/mL SepSecS, 1 mg/mL human tRNASec",285.0,2020-12-15,2022-02-09,7L1T,3610.0,1.0,521.0,96.0,,58.3,1.0,2.25,experimental,65.4207,0.2295,0.1919,Crystal structure of human holo SepSecS
5MKW,X-RAY DIFFRACTION,3.17,61.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% (w/v) PEG10,000 + 100 mM HEPES pH 7.5",277.0,2016-12-05,2017-06-28,5MKW,2249.0,2.0,244.0,232.0,,28.52,1.0,2,experimental,31.134,0.23613,0.19185,Crystal structure of the human ZRANB3 HNH domain
6ZE1,X-RAY DIFFRACTION,3.64,66.22,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M Calcium chloride 0.1 M Tris 8.5 25 % w/v PEG 4000, RT.",293.0,2020-06-15,2021-06-30,6ZE1,2558.0,2.0,408.0,41.0,,46.16,2.0,2.705,experimental,71.06,0.2576,0.2071,human NBD1 of CFTR in complex with nanobody G11a
5ZJW,X-RAY DIFFRACTION,2.07,40.68,VAPOR DIFFUSION,6.5,"0.1 M Bis-tris pH 6.5, 25% PEG 3350, 0.2 M NaCl",291.0,2018-03-22,2019-04-03,5ZJW,2686.0,1.0,293.0,283.0,,34.23,1.0,1.798,experimental,23.9068,0.2147,0.1682,Crystal Structure of PAK4 in complex with inhibitor CZg353
5OWR,X-RAY DIFFRACTION,2.7,54.48,"VAPOR DIFFUSION, SITTING DROP",,"40% PEG 300, 0.20M Ca(ac)2, 0.1M cacodylate pH 6.5",277.0,2017-09-04,2017-09-13,5OWR,2276.0,1.0,302.0,84.0,1.0,34.83,1.0,2.3,experimental,52.702,0.25362,0.21986,Human STK10 bound to dasatinib
8WM0,X-RAY DIFFRACTION,2.48,50.4,"VAPOR DIFFUSION, SITTING DROP",,13% Tacsimate pH6.0,283.0,2023-10-01,2024-03-27,8WM0,2484.0,2.0,320.0,1.0,,37.25,2.0,2.8,experimental,86.357,0.2852,0.227,Crystal structure of TNIK-thiopeptide wTP3 complex
4RNM,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 25% PEG 2000 MME 
, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K",291.0,2014-10-24,2015-02-18,4RNM,4174.0,3.0,455.0,343.0,,55.28,1.0,2.144,experimental,,0.219,0.167,Crystal structure of human polymerase eta inserting dAMPnPP opposite DNA template containing an abasic site
4RNN,X-RAY DIFFRACTION,2.1,41.54,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 25% PEG 2000 MME , VAPOR DIFFUSION, HANGING DROP, temperature 291.0K",291.0,2014-10-24,2015-02-18,4RNN,4245.0,3.0,455.0,409.0,,55.39,1.0,1.808,experimental,,0.2029,0.1679,Crystal structure of human polymerase eta inserting dGMPnPP opposite DNA template containing an abasic site
4RNO,X-RAY DIFFRACTION,2.12,41.88,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 28% PEG 2000 MME , VAPOR DIFFUSION, HANGING DROP, temperature 291.0K",291.0,2014-10-24,2015-02-18,4RNO,3801.0,3.0,455.0,57.0,,55.18,1.0,2.82,experimental,,0.2816,0.2411,Crystal structure of human polymerase eta extending an abasic site-dA pair by inserting dCTP opposite template G
5DG7,X-RAY DIFFRACTION,2.12,41.91,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M MES pH 5.5, 5mM calcium chloride, 16% PEG 2000 MME",291.0,2015-08-27,2016-06-08,5DG7,4165.0,3.0,455.0,351.0,,55.37,1.0,2.26,experimental,29.7,0.2123,0.1559,"CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dTTP ACROSS A DNA TEMPLATE CONTAINING 1,N6-ETHENODEOXYADENOSINE LESION"
5DG8,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M MES pH 5.5, 5mM magnesium chloride, 21% PEG 2000 MME",291.0,2015-08-27,2016-06-08,5DG8,4146.0,3.0,455.0,311.0,,55.53,1.0,2.12,experimental,35.1,0.2392,0.1739,"CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dAMPNPP ACROSS A DNA TEMPLATE CONTAINING 1,N6-ETHENODEOXYADENOSINE LESION"
5DG9,X-RAY DIFFRACTION,2.11,41.7,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 21% PEG 2000 MME",291.0,2015-08-27,2016-06-08,5DG9,4171.0,3.0,455.0,345.0,,55.36,1.0,2.15,experimental,33.0,0.2222,0.17,"CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dGMPNPP ACROSS A DNA TEMPLATE CONTAINING 1,N6-ETHENODEOXYADENOSINE LESION"
5DGB,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 18% PEG 2000 MME",291.0,2015-08-27,2016-06-08,5DGB,4391.0,3.0,455.0,545.0,,55.44,1.0,1.79,experimental,23.0,0.2122,0.1642,"CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA EXTENDING AN 1,N6-ETHENODEOXYADENOSINE : dA PAIR BY INSERTING dTMPNPP OPPOSITE TEMPLATE dA"
5L1I,X-RAY DIFFRACTION,2.11,41.69,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM Calcium chloride, 15% PEG 2000 MME",291.0,2016-07-29,2016-10-05,5L1I,3961.0,3.0,456.0,138.0,,55.74,1.0,2.78,experimental,49.131,0.22835,0.15994,Crystal Structure of Human DNA Polymerase Eta Inserting dCTP Opposite O6-Methyl-2'-deoxyguanosine
5L1J,X-RAY DIFFRACTION,2.11,41.77,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM Magnesium chloride, 16% PEG 2000 MME",291.0,2016-07-29,2016-10-05,5L1J,4292.0,3.0,455.0,410.0,,55.34,1.0,1.94,experimental,33.677,0.20166,0.15857,Crystal Structure of Human DNA Polymerase Eta Inserting dTMPNPP Opposite O6-Methyl-2'-deoxyguanosine
5L1K,X-RAY DIFFRACTION,2.1,41.42,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM Calcium chloride, 18% PEG 2000 MME",291.0,2016-07-29,2016-10-05,5L1K,4329.0,3.0,455.0,491.0,,55.33,1.0,1.82,experimental,23.887,0.18756,0.15252,PostInsertion complex of Human DNA Polymerase Eta bypassing an O6-Methyl-2'-deoxyguanosine : dC site
5L1L,X-RAY DIFFRACTION,2.09,41.22,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM Calcium chloride, 18% PEG 2000 MME",291.0,2016-07-29,2016-10-05,5L1L,4401.0,3.0,455.0,529.0,,55.53,1.0,1.62,experimental,24.47,0.19348,0.15679,PostInsertion complex of Human DNA Polymerase Eta bypassing an O6-Methyl-2'-deoxyguanosine : dT site
6HXF,X-RAY DIFFRACTION,3.48,64.64,"VAPOR DIFFUSION, SITTING DROP",,0.10M MgCl2;  0.1M TRIS pH 8.0;  20.0% PEG 6K;  10.0% EtGly,277.0,2018-10-17,2018-10-31,6HXF,9913.0,4.0,1208.0,725.0,,140.28,1.0,2.09,experimental,49.7376,0.2191,0.1903,Human STK10 bound to a maleimide inhibitor
7RL2,X-RAY DIFFRACTION,3.91,68.55,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.1 M HEPES pH 7.5, 30% w/v Polyethylene glycol 1000",291.0,2021-07-23,2021-10-06,7RL2,3868.0,1.0,476.0,125.0,,55.81,1.0,2.23,experimental,59.62,0.224,0.178,Crystal Structure of the Human Cytochrome P450 2C9*8 (CYP2C9*8) Genetic Variant in Complex with the Drug Losartan
4ZFI,X-RAY DIFFRACTION,2.46,50.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 0.2 M sodium chloride, 25% (w/v) PEG 3350",277.0,2015-04-21,2016-10-19,4ZFI,3414.0,4.0,388.0,313.0,,47.64,1.0,2,experimental,30.395,0.2433,0.1977,Structure of Mdm2 with low molecular weight inhibitor
5FBJ,X-RAY DIFFRACTION,2.3,46.49,EVAPORATION,,"PEG3350
HEPEPS-Na",281.0,2015-12-14,2016-12-14,5FBJ,2041.0,1.0,236.0,90.0,,27.72,1.0,2.42,experimental,,0.2458,0.1898,Complex structure of JMJD5 and substrate
7S7J,X-RAY DIFFRACTION,2.39,48.55,"VAPOR DIFFUSION, SITTING DROP",6.5,"40% v/v PEG 300, 100 mM Sodium cacodylate / Hydrochloric acid pH=6.5, 200 mM Calcium Acetate",278.0,2021-09-16,2022-09-28,7S7J,998.0,2.0,107.0,112.0,,12.94,2.0,1.15,experimental,22.12,0.1572,0.1486,Structure of Human SPASTIN-IST1 complex.
6ETG,X-RAY DIFFRACTION,2.48,50.33,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-10-26,2019-02-20,6ETG,3495.0,1.0,342.0,477.0,,40.73,1.0,1.279,experimental,21.428,0.1575,0.124,Crystal structure of KDM4D with tetrazolhydrazide compound 6
6ETS,X-RAY DIFFRACTION,2.54,51.55,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-10-27,2019-02-20,6ETS,3498.0,1.0,341.0,476.0,,40.51,1.0,1.333,experimental,18.5015,0.1559,0.1287,Crystal structure of KDM4D with tetrazolhydrazide compound 1
6ETT,X-RAY DIFFRACTION,2.53,51.39,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-10-27,2019-02-20,6ETT,3530.0,1.0,342.0,501.0,,40.8,1.0,1.257,experimental,19.0742,0.1455,0.1229,Crystal structure of KDM4D with tetrazole compound 4
6ETU,X-RAY DIFFRACTION,2.56,51.98,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2017-10-27,2019-02-20,6ETU,3583.0,1.0,342.0,496.0,,40.29,1.0,1.33,experimental,21.0938,0.154,0.1231,Crystal structure of KDM4D with tetrazolhydrazide compound 7
4CRC,X-RAY DIFFRACTION,2.76,55.39,,8.5,"2M AMMONIUM SULFATE, 0.1M TRIS-CL PH 8.5, 0.2M NACL",,2014-02-26,2015-02-11,4CRC,2157.0,1.0,238.0,195.0,4.0,27.4,1.0,1.6,experimental,,0.213,0.185,Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
6TWB,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"200 mM (NH4)2SO4, 25% PEG4000, and 100 mM NaOAc, pH 4.6",291.0,2020-01-13,2020-05-13,6TWB,2036.0,3.0,535.0,10.0,5.0,60.79,2.0,2.91,experimental,56.0434,0.2409,0.1789,Crystal Structure of the Catalytic Domain of Coagulation Factor XIa in Complex with Double Bridged Peptide F19
8HJE,X-RAY DIFFRACTION,2.23,68.8,"VAPOR DIFFUSION, HANGING DROP",6.4,"0.1 M Bis-tris propane pH 6.4, 0.2 M potassium thiocyanate, 20% PEG3350 and 3% sucrose",291.0,2022-11-23,2023-05-03,8HJE,2438.0,1.0,380.0,,,44.85,1.0,2.85,experimental,66.552,0.25429,0.22206,Vismodegib binds to the catalytical domain of human Ubiquitin-Specific Protease 28
4ZP5,X-RAY DIFFRACTION,2.55,51.68,"VAPOR DIFFUSION, HANGING DROP",,PEG 3350,293.0,2015-05-07,2016-10-05,4ZP5,4886.0,2.0,618.0,159.0,,70.88,1.0,2.29,experimental,60.05,0.2641,0.2291,MAP4K4 in complex with inhibitor
5J95,X-RAY DIFFRACTION,2.49,50.7,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH=6.5, 0.2 M NaCl, 18% PEG 3350",277.0,2016-04-08,2017-04-19,5J95,4742.0,2.0,624.0,8.0,,71.86,1.0,2.5,experimental,77.06,0.2581,0.215,MAP4K4 in complex with inhibitor
5EPC,X-RAY DIFFRACTION,3.04,59.52,"VAPOR DIFFUSION, HANGING DROP",8.0,"Lithium or ammonium sulfate (1.35 - 1.85 M) with 0.1 M Tris, pH 8.0",293.0,2015-11-11,2016-04-27,5EPC,9413.0,2.0,1170.0,819.0,,130.03,1.0,1.85,experimental,,0.1975,0.1696,Crystal structure of wild-type human phosphoglucomutase 1
7S0W,X-RAY DIFFRACTION,3.07,59.91,VAPOR DIFFUSION,,"1.8 M ammonium sulfate, 0.1 M MES, pH 6.5, 0.01 cobalt chloride",293.0,2021-08-31,2022-05-04,7S0W,7910.0,2.0,1170.0,64.0,,129.9,1.0,2.5,experimental,78.14,0.2696,0.2145,Crystal structure of the T337M variant of human PGM-1
5CPR,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",8.5,"The purified protein was concentrated to 10 mg/mL and with 1 mM SAM. SAM bound protein crystals were obtained by hanging drop vapor diffusion method at 17C using 10% (w/v) ethanol, 5% (w/v) glycerol, 0.1 M tris pH 8.5 as the well solution. A-196 was soaked into the crystals",298.0,2015-07-21,2017-01-25,5CPR,2014.0,1.0,268.0,144.0,,31.75,1.0,2.22,experimental,37.52,0.2486,0.1901,The novel SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity
4U69,X-RAY DIFFRACTION,2.57,52.08,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 2000, potassium chloride, hepes, sodium chloride, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2014-07-28,2015-03-25,4U69,2744.0,1.0,306.0,317.0,,34.79,1.0,1.6,experimental,24.1,0.202,0.17,HsMetAP complex with (1-amino-2-methylpentyl)phosphonic acid
4U6E,X-RAY DIFFRACTION,2.57,52.15,"VAPOR DIFFUSION, HANGING DROP",6.5,"15% PEG-MME 2000, 100 mM HEPES, pH=6.0, VAPOR DIFFUSION, temperature 298K",298.0,2014-07-28,2015-03-25,4U6E,2602.0,1.0,306.0,193.0,,34.76,1.0,1.9,experimental,,0.264,0.212,HsMetAP in complex with (amino(phenyl)methyl)phosphonic acid
4U70,X-RAY DIFFRACTION,2.6,52.69,"VAPOR DIFFUSION, HANGING DROP",6.0,"15% PEGMME, 100mM HEPES PH 6.",298.0,2014-07-30,2015-03-25,4U70,2836.0,1.0,306.0,398.0,,34.8,1.0,1.6,experimental,23.25,0.207,0.164,HsMetAP (F309M) in complex with (1-amino-2-cyclohexylethyl)phosphonic acid
4U73,X-RAY DIFFRACTION,2.57,52.17,"VAPOR DIFFUSION, HANGING DROP",6.0,"15% PEGMME, 100mM HEPES PH 6",298.0,2014-07-30,2015-03-25,4U73,2650.0,1.0,306.0,243.0,,34.78,1.0,1.8,experimental,24.1,0.201,0.171,HsMetAP(F309M) IN COMPLEX WITH (amino(phenyl)methyl)phosphonic acid
8PTQ,X-RAY DIFFRACTION,2.44,49.66,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES pH 6.5, 6 to 13% PEG MME 5K, 12% isopropanol",293.0,2023-07-14,2024-01-31,8PTQ,2504.0,1.0,323.0,242.0,,36.0,1.0,1.55,experimental,35.23,0.2257,0.1946,COMPLEX CRYSTAL STRUCTURE OF MUTANT HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND 5l
8PTR,X-RAY DIFFRACTION,2.44,49.56,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES pH 6.5, 6 to 13% PEG MME 5K, 12% isopropanol",293.0,2023-07-14,2024-01-31,8PTR,2495.0,1.0,323.0,235.0,,36.23,1.0,1.73,experimental,33.97,0.2096,0.1922,COMPLEX CRYSTAL STRUCTURE OF MUTANT HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND 5r
5J5E,X-RAY DIFFRACTION,2.75,55.28,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris, pH 8.5 and 16% PEG8000",277.0,2016-04-02,2017-04-12,5J5E,3328.0,1.0,420.0,,,48.75,1.0,2.8,experimental,28.119,0.2689,0.2067,crystal structure of antigen-ERAP1 domain complex
5O7I,X-RAY DIFFRACTION,3.05,59.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"5 % (v/v) PEG 6000, 0.1 M MES (pH 6.0), 5 mM DTT",293.0,2017-06-08,2018-06-20,5O7I,2901.0,1.0,358.0,109.0,,41.52,1.0,2.38,experimental,59.88,0.2203,0.1805,ERK5 in complex with a pyrrole inhibitor
5L8H,X-RAY DIFFRACTION,3.24,62.04,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.96M Sodium Citrate pH7.5 and 0.1mM zinc chloride

Cryo - 20% Glycerol",293.0,2016-06-07,2016-09-28,5L8H,3439.0,2.0,435.0,250.0,1.0,50.41,2.0,1.85,experimental,31.975,0.19411,0.16617,Structure of USP46-UbVME
5SXP,X-RAY DIFFRACTION,2.14,42.58,"VAPOR DIFFUSION, HANGING DROP",,100 mM MIB buffer pH 5.0 and 25% PEG1500,293.0,2016-08-09,2017-03-01,5SXP,2704.0,6.0,302.0,383.0,,34.01,2.0,1.65,experimental,,0.1613,0.1389,STRUCTURAL BASIS FOR THE INTERACTION BETWEEN ITCH PRR AND BETA-PIX
5IFR,X-RAY DIFFRACTION,2.27,45.75,"VAPOR DIFFUSION, SITTING DROP",,"200mM tripotassium citrate, 20% PEG 3350",291.0,2016-02-26,2016-05-11,5IFR,1854.0,2.0,227.0,77.0,,25.67,2.0,2.2,experimental,,0.2435,0.1909,Structure of the stable UBE2D3-UbDha conjugate
6BGF,X-RAY DIFFRACTION,3.71,66.85,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295.0,2017-10-28,2017-12-13,6BGF,1710.0,1.0,200.0,104.0,,23.87,1.0,2.251,experimental,42.8225,0.2193,0.1648,Crystal structure of cysteine-bound ferrous form of the crosslinked human cysteine dioxygenase
6BPR,X-RAY DIFFRACTION,3.7,66.76,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295.0,2017-11-26,2019-04-17,6BPR,1823.0,1.0,200.0,191.0,,24.12,1.0,1.96,experimental,31.1334,0.188,0.1605,"Crystal structure of cysteine, nitric oxide-bound ferrous form of the uncrosslinked F2-Tyr157 human cysteine dioxygenase"
6BPS,X-RAY DIFFRACTION,3.69,66.68,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295.0,2017-11-26,2018-07-04,6BPS,1758.0,1.0,200.0,156.0,,23.82,1.0,2.1,experimental,28.4391,0.2031,0.1668,Crystal structure of cysteine-bound ferrous form of the uncrosslinked F2-Tyr157 human cysteine dioxygenase
6BPX,X-RAY DIFFRACTION,3.73,67.06,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295.0,2017-11-26,2018-07-04,6BPX,1685.0,1.0,200.0,89.0,,24.03,1.0,2.15,experimental,42.9168,0.2124,0.1779,Crystal structure of cysteine-bound ferrous form of the matured Cl2-Tyr157 human cysteine dioxygenase
6CDN,X-RAY DIFFRACTION,3.69,66.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295.0,2018-02-08,2018-07-04,6CDN,1688.0,1.0,200.0,112.0,,23.63,1.0,2.055,experimental,37.4611,0.1928,0.1621,Crystal structure of cysteine-bound ferrous form of the crosslinked Cl-Tyr157 human cysteine dioxygenase
6N42,X-RAY DIFFRACTION,3.71,66.89,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295.0,2018-11-16,2019-04-17,6N42,1697.0,1.0,200.0,121.0,,23.87,1.0,2.199,experimental,32.1757,0.2101,0.1723,Crystal structure of cysteine-bound ferrous form of the crosslinked human cysteine dioxygenase in the anaerobic condition
5LLA,X-RAY DIFFRACTION,2.16,42.99,EVAPORATION,,"Crystallization buffer: 0.1M ammonium citrate (pH 7), 0.1M sodium acetate (pH 4.5) and 26% PEG3350",291.0,2016-07-27,2017-08-16,5LLA,4853.0,2.0,526.0,550.0,,60.57,1.0,1.5,experimental,20.079,0.2125,0.1787,Crystal structure of human carbonic anhydrase isozyme XIII with 4-(1H-benzimidazol-1-ylacetyl)-2-chlorobenzenesulfonamide
4ZGK,X-RAY DIFFRACTION,2.21,44.38,"VAPOR DIFFUSION, SITTING DROP",,0.1 M HEPES pH 7.5 containing 30% PEG 1000,277.15,2015-04-23,2016-10-19,4ZGK,1760.0,2.0,196.0,114.0,,24.05,1.0,2,experimental,26.686,0.247,0.1881,Structure of Mdm2 with low molecular weight inhibitor.
5LBA,X-RAY DIFFRACTION,2.72,54.72,"VAPOR DIFFUSION, SITTING DROP",,0.1M tris pH 9.0 -- 29% PEG3350 -- 0.1M sodium chloride,293.0,2016-06-15,2016-07-06,5LBA,13954.0,4.0,1780.0,338.0,1.0,200.68,1.0,2.5,experimental,48.293,0.30292,0.23665,"Crystal structure of human RECQL5 helicase in complex with DSPL fragment(1-cyclohexyl-3-(oxolan-2-ylmethyl)urea, SGC - Diamond XChem I04-1 fragment screening."
7NC4,X-RAY DIFFRACTION,2.1,41.55,"VAPOR DIFFUSION, HANGING DROP",,"18% PEG 3350, 0.2 M Sodium Acetate, 0.1 M Tris-HCl pH 8.5",293.0,2021-01-28,2021-07-14,7NC4,2216.0,1.0,274.0,116.0,1.0,31.58,1.0,1.6,experimental,24.712,0.214,0.1959,Crystal structure of human carbonic anhydrase VII (hCA VII) in complex with a 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamide derivative.
8Q3U,X-RAY DIFFRACTION,2.14,42.6,"VAPOR DIFFUSION, HANGING DROP",8.5,"19% (w/v) PEG 3350, 0.2 M ammonium acetate, 0.1 M TRIS-HCl",293.0,2023-08-04,2023-09-20,8Q3U,2358.0,1.0,274.0,171.0,1.0,31.59,1.0,1.1,experimental,15.03,0.15322,0.14956,Crystal structure of a fentanyl derivative in complex with human CA VII
6CJ5,X-RAY DIFFRACTION,3.26,62.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"20-30% (w/v) polyacrylic acid 5100, 1-5% PEG 400, and 50 mM Hepes (pH 7.5)",300.15,2018-02-26,2018-05-09,6CJ5,2190.0,1.0,316.0,8.0,1.0,35.91,1.0,2.8,experimental,68.537,0.28002,0.20371,Crystal Structure of Mnk2-D228G in Complex With Inhibitor
6CK3,X-RAY DIFFRACTION,3.22,61.79,"VAPOR DIFFUSION, SITTING DROP",,"20-30% (w/v) polyacrylic acid 5100, 1-5% PEG 400, and 50 mM Hepes (pH 7.5)",300.11,2018-02-27,2018-05-09,6CK3,2183.0,1.0,316.0,9.0,1.0,35.95,1.0,2.9,experimental,106.718,0.26262,0.18892,Co-crytsal Structure of MNK2 in Complex With an Inhibitor
6CKI,X-RAY DIFFRACTION,3.15,60.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"20-30% (w/v) polyacrylic acid 5100, 1-5% PEG 400, and 50 mM Hepes (pH 7.5)",300.15,2018-02-28,2018-05-09,6CKI,2182.0,1.0,316.0,7.0,1.0,35.94,1.0,2.95,experimental,105.376,0.25739,0.19002,Co-crystal structure of MNK2 in Complex With Inhibitor
4Z9A,X-RAY DIFFRACTION,2.46,49.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"26% (w/v) PEG 5000, 0.2 M ammonium sulfate, 0.2 M MES buffer pH 6.5",291.0,2015-04-10,2015-07-15,4Z9A,1360.0,1.0,164.0,88.0,,19.21,1.0,2.1,experimental,41.696,0.23511,0.17909,Crystal structure of Low Molecular Weight Protein Tyrosine Phosphatase isoform A complexed with phenylmethanesulfonic acid
7YW3,X-RAY DIFFRACTION,2.07,40.59,VAPOR DIFFUSION,,"0.1M Tris pH 8.0
28 % PEG4000",291.0,2022-08-21,2023-07-26,7YW3,1613.0,1.0,253.0,8.0,,28.48,1.0,2.5,experimental,48.2627,0.2949,0.252,Crystal structure of tRNA 2'-phosphotransferase from Homo sapiens
5HSR,X-RAY DIFFRACTION,2.52,51.18,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, pH 6.9, 60% sat AmSO4, 3% v/v ETOH",287.0,2016-01-26,2017-02-01,5HSR,1822.0,1.0,186.0,188.0,,22.78,1.0,1.21,experimental,16.748,0.21903,0.19323,"Fluorine substituted 5-methyl-6-(3',4'-difluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine"
5HSU,X-RAY DIFFRACTION,2.55,51.76,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4 60% sat AmSO4, 3% v/v ETOH",287.0,2016-01-26,2017-02-01,5HSU,1634.0,1.0,186.0,48.0,,22.44,1.0,1.46,experimental,30.574,0.25316,0.23104,"Fluorine substituted 5-methyl-6-(2',4'-difluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine"
5HT4,X-RAY DIFFRACTION,2.55,51.74,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KSO4, 60% sat AmSO4, 3%ETOH",283.0,2016-01-26,2017-02-01,5HT4,1677.0,1.0,186.0,78.0,,22.62,1.0,1.6,experimental,28.158,0.30437,0.24209,"6-substituted pyrrolo[2,3-d]pyrimidine 6-thieno-(4-methoxyphenyl)"
5HT5,X-RAY DIFFRACTION,2.56,51.9,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, pH 6.9, 60 % sat AmSO4,3% v/v ETOH",287.0,2016-01-26,2017-02-01,5HT5,1653.0,1.0,186.0,75.0,,22.41,1.0,1.9,experimental,33.232,0.27561,0.19465,"6-substituted pyrrolo[2,3-d]pyrimidine 6-thieno-(4-methoxyphenyl)"
5HUI,X-RAY DIFFRACTION,2.58,52.38,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, 60& sat AmSO4, 3% v/v ETOH",287.0,2016-01-27,2017-02-01,5HUI,1677.0,1.0,186.0,97.0,,22.54,1.0,1.46,experimental,26.156,0.2432,0.21063,"6-substituted pyrido[3,2-d]pyrimidine--6-4'-trifluoromethoxyphenyl)"
5HVB,X-RAY DIFFRACTION,2.56,51.95,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, 60% sat AmSO4, 3%ETOH",287.0,2016-01-28,2017-02-01,5HVB,1624.0,1.0,186.0,51.0,,22.43,1.0,1.6,experimental,29.246,0.26268,0.2214,"5-methyl-6-(1-naphthylthio)thieno[2,3-d]pyrimidine 2,4-diamine"
5HVE,X-RAY DIFFRACTION,2.53,51.38,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, ph 6.9, 60% sat AmSO4, 3% ETOH",283.0,2016-01-28,2017-02-01,5HVE,1722.0,1.0,186.0,121.0,,22.47,1.0,1.46,experimental,24.047,0.22806,0.19886,"5-methyl-6-(3'-trifluromethoxyphenylthio)[2,3-d]pyrimidine 2,4-diamine"
7XI7,X-RAY DIFFRACTION,2.43,49.48,"VAPOR DIFFUSION, HANGING DROP",7.0,"2.85 M ammonium sulphate, 100 mM potassium phosphate",297.0,2022-04-12,2022-06-29,7XI7,1830.0,1.0,187.0,293.0,,22.04,1.0,1.65,experimental,18.4,0.1936,0.1657,Human dihydrofolate reductase complexed with P39
5E8J,X-RAY DIFFRACTION,2.27,45.9,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES pH 6.5, 30% PEG 4000",291.0,2015-10-14,2016-07-13,5E8J,6084.0,4.0,712.0,219.0,,84.78,2.0,2.35,experimental,25.7436,0.2685,0.2105,Crystal structure of mRNA cap guanine-N7 methyltransferase in complex with RAM
5LB5,X-RAY DIFFRACTION,2.72,54.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M tris pH 7.5, 23% PEG3350, 0.1M sodium chloride",293.0,2016-06-15,2016-07-06,5LB5,13859.0,4.0,1780.0,399.0,,200.45,1.0,2,experimental,56.3,0.2819,0.2444,Crystal structure of human RECQL5 helicase in complex with ADP/Mg (tricilinc form).
5DA3,X-RAY DIFFRACTION,2.48,50.45,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M tri-Lithium citrate, 20% (w/v) PEG 3350",294.0,2015-08-19,2016-08-24,5DA3,2455.0,1.0,265.0,192.0,,31.24,1.0,1.7,experimental,22.476,0.2302,0.1974,Crystal structure of PTK6 Kinase domain with inhibitor
7M4M,X-RAY DIFFRACTION,2.59,52.58,"VAPOR DIFFUSION, SITTING DROP",7.0,"15% PEG 6000, 0.18 M NaCl, 0.09 M Na HEPES pH7.0, 0.1 M KCl",293.0,2021-03-21,2022-01-05,7M4M,3959.0,4.0,706.0,22.0,,81.25,2.0,2.39,experimental,63.54,0.2468,0.2002,Crystal structure of RBR E3 ligase RNF216 with ubiquitin
5X24,X-RAY DIFFRACTION,4.04,69.55,"VAPOR DIFFUSION, SITTING DROP",,"1.8M ammonium sulfate, 0.1M BIS-TRIS pH 6.5 and 2% (v/v) Polyethylene glycol monomethyl ether 550",291.0,2017-01-30,2017-10-25,5X24,3819.0,1.0,476.0,56.0,,55.83,1.0,2.48,experimental,62.852,0.27025,0.22851,Crystal structure of CYP2C9 genetic variant I359L (*3) in complex with multiple losartan molecules
5XXI,X-RAY DIFFRACTION,4.08,69.87,"VAPOR DIFFUSION, SITTING DROP",7.5,20% (w/v) PEG-8000 and 0.1M HEPES pH7.5,291.0,2017-07-04,2017-10-25,5XXI,3922.0,1.0,463.0,103.0,,54.69,1.0,2.3,experimental,67.2,0.26851,0.20385,Crystal structure of CYP2C9 in complex with multiple losartan molecules
6NZP,X-RAY DIFFRACTION,2.33,47.2,"VAPOR DIFFUSION, HANGING DROP",7.5,"200 mM ammonium sulfate, and 100 mM Cacodylate buffer, pH 7.5, 30%(W/V) PEG 5000 (Methyl Ether)",293.0,2019-02-14,2019-07-31,6NZP,4164.0,2.0,634.0,76.0,,71.88,1.0,2.35,experimental,47.74,0.238,0.189,"CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-11 AKA 6-CYCLOPROPANEAMIDO-4-{[2-METHOXY-3-(1-METHYL-1H-1,2,4-TRI AZOL-3-YL)PHENYL]AMINO}-N-(?H?)METHYLPYRIDAZINE-3-CARBOXAMIDE"
8WGN,X-RAY DIFFRACTION,2.5,50.73,"VAPOR DIFFUSION, HANGING DROP",7.0,"2.65 M AMMONIUM SULPHATE, 100 mM POTASSIUM PHOSPHATE, PH 7",297.0,2023-09-22,2024-09-11,8WGN,1802.0,1.0,187.0,204.0,,22.99,1.0,2,experimental,19.7,0.2242,0.1807,Human dihydrofolate reductase (HsDHFR) complexed with NADPH and LA1
5TDE,X-RAY DIFFRACTION,2.75,55.25,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5% P3350, 100 mM Tris-HCL pH 7.0, 125 mM ammonium phosphate pH 7.5",294.0,2016-09-19,2017-08-09,5TDE,6612.0,2.0,755.0,737.0,,84.07,2.0,1.7,experimental,,0.1842,0.1551,TEV Cleaved Human ATP Citrate Lyase Bound to Citrate
6J4Q,X-RAY DIFFRACTION,2.79,55.91,EVAPORATION,7.0,"V2c-SVBP was mixed with the inhibitor TPCK at a mole ratio of 1:5 and incubated on ice for 30 min. Then, the resulting co-complex of V2c-SVBP-TPCK was crystallized in 1.0 M sodium malonate, pH 7.0.",293.0,2019-01-10,2019-05-01,6J4Q,9379.0,8.0,1268.0,251.0,,151.15,2.0,2.7,experimental,,0.247,0.1835,Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
5TVT,X-RAY DIFFRACTION,2.58,52.27,"VAPOR DIFFUSION, SITTING DROP",,"24% PEG3350, 0.1 M MgCl, 0.1M HEPES pH 7.0",298.0,2016-11-10,2017-11-15,5TVT,2667.0,1.0,334.0,97.0,,39.21,1.0,2.28,experimental,,0.2294,0.1897,Structure of Maternal Embryonic Leucine Zipper Kinase
6NCG,X-RAY DIFFRACTION,2.15,42.71,VAPOR DIFFUSION,6.0,27.5% PEG3350; 200 mM LiSO4; 0.1M SBG (each Sodium-tartrate + Bis-Tris + Glycylglycine) pH 6.0,293.0,2018-12-11,2019-01-16,6NCG,4564.0,2.0,648.0,41.0,,74.43,1.0,2.45,experimental,65.063,0.29694,0.22061,Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to pyridin-benzenesulfonamide inhibitor
4WNU,X-RAY DIFFRACTION,3.21,61.72,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, SODIUM ACETATE, SODIUM CACODYLATE, POTASSIUM PHOSPHATE, SODIUM CHLORIDE, ZINC CHLORIDE, GLYCEROL, BETA-MERCAPTOETHANOL, THIORIDAZINE, HEGA-10, FACIAL AMPHIPHILE 231_CHOL. Quinidine was added to the mother liquor after crystallization of the P450 2D6 thiordidazine complex.",298.0,2014-10-14,2015-01-14,4WNU,15307.0,4.0,1916.0,669.0,,220.25,1.0,2.26,experimental,49.8595,0.2318,0.1897,Human Cytochrome P450 2D6 Quinidine Complex
6CMJ,X-RAY DIFFRACTION,2.88,57.26,"VAPOR DIFFUSION, HANGING DROP",7.5,"4 M sodium formate, 3% PEG8000, 20 mM ammonium sulfate",298.0,2018-03-05,2018-04-04,6CMJ,4861.0,2.0,642.0,229.0,,74.63,1.0,2.4,experimental,43.869,0.2192,0.1819,Human CAMKK2 with GSK650393
8V7F,X-RAY DIFFRACTION,2.12,41.88,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7F,3899.0,3.0,455.0,14.0,,55.3,1.0,2.2,experimental,,0.2517,0.2028,Human DNA polymerase eta-DNA-araC-ended primer-dAMPNPP ternary complex with Mn2+
8V7H,X-RAY DIFFRACTION,2.08,40.99,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7H,3938.0,3.0,455.0,77.0,,55.27,1.0,1.68,experimental,,0.2329,0.2081,Human DNA polymerase eta-DNA-araC-ended primer ternary complex:ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
8V7I,X-RAY DIFFRACTION,2.1,41.39,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7I,3989.0,3.0,455.0,93.0,,55.24,1.0,1.72,experimental,,0.2328,0.2124,Human DNA polymerase eta-DNA-araC-ended primer ternary complex:reaction with 1 mM Mg2+ for 1800s
8V7J,X-RAY DIFFRACTION,2.11,41.74,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7J,3987.0,3.0,455.0,133.0,,55.24,1.0,1.66,experimental,,0.2235,0.2008,Human DNA polymerase eta-DNA-araC-ended primer ternary complex:reaction with 20 mM Mg2+ for 600s
8V7K,X-RAY DIFFRACTION,2.09,41.19,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7K,3981.0,3.0,455.0,106.0,,55.3,1.0,1.65,experimental,,0.2328,0.2056,Human DNA polymerase eta-DNA-araC-ended primer ternary complex:reaction with 10 mM Mn2+ for 1800s
7F6J,X-RAY DIFFRACTION,2.62,53.09,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M Tris-HCl pH 8.0, 25% PEG 1000, 0.1 M NaCl",295.0,2021-06-25,2022-02-23,7F6J,3818.0,3.0,533.0,154.0,,61.48,2.0,2.1,experimental,43.16,0.253,0.2069,Crystal structure of the PDZD8 coiled-coil domain - Rab7 complex
8GMN,X-RAY DIFFRACTION,2.61,52.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"22% PEG 3350, 50-100 mM Ammonium Sulphate and 100 mM TRIS pH 7.5-8.0",277.0,2023-03-26,2023-05-17,8GMN,8721.0,4.0,1484.0,239.0,18.0,164.67,1.0,2.6,experimental,50.25,0.28141,0.22428,Crystal structure of human C1s in complex with inhibitor
6HMN,X-RAY DIFFRACTION,2.49,50.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"Protein at 7.5 mg/mL in 50 mM HEPES, pH 7.0, 150 mM NaCl, 2 mM DTT was mixed with precipitant consisting of 18 - 23 percent PEG-3350, 0.2 M ammonium sulphate, 0.1 M PCTP pH 7.5 in a 1:1 ratio to give a 4 microL drop",293.0,2018-09-12,2018-11-14,6HMN,4165.0,1.0,531.0,102.0,,61.71,1.0,2.87,experimental,53.42,0.2388,0.1611,POLYADPRIBOSYL GLYCOSIDASE IN COMPLEX WITH PDD00014909
5Y8U,X-RAY DIFFRACTION,2.63,53.21,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, sodium citrate",277.0,2017-08-21,2017-10-11,5Y8U,2137.0,1.0,323.0,20.0,,36.85,1.0,2.92,experimental,55.161,0.2988,0.23011,Crystal structure of the C276S mutant of MAP2K7
6HML,X-RAY DIFFRACTION,2.52,51.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"Mix 750 nL purified protein at 7.5 mg per mL in 50mM HEPES, pH 7.0, 150 mM NaCl, 2mM DTT with 250 nL of seed stock and 1000 nL of a  precipitant consisting of 18-23 percent PEG 3350, 0.2 M ammonium sulphate, 0.1 M PCTP pH 7.5.  Seed stock was prepared using a Seed Bead from a co-crystal with ADP-ribose, with co-crystallisation mother liquor (19 percent PEG 3350, 0.2 M ammonium sulphate, 0.1 M PCTP pH 7.5) as the stabilising solution",293.0,2018-09-12,2018-11-14,6HML,4465.0,1.0,531.0,325.0,,62.32,1.0,2.25,experimental,47.88,0.1965,0.1622,POLYADPRIBOSYL GLYCOSIDASE IN COMPLEX WITH PDD00017299
7BTN,X-RAY DIFFRACTION,2.79,55.91,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG4000, 50mM magnesium acetate, pH 5.5",289.0,2020-04-02,2020-10-21,7BTN,2275.0,1.0,309.0,76.0,,35.16,1.0,2.382,experimental,39.8589,0.2104,0.1787,Crystal structure of human inorganic pyrophosphatase with metal ions
5HI7,X-RAY DIFFRACTION,2.12,42.1,"VAPOR DIFFUSION, SITTING DROP",,"SMYD3 crystallization and soaking of GSK2807: SMYD3 (1-428) expressed in baculovirus and with SAH in the SAM-binding site was crystallized in sitting drops at 22C using 1uL fresh protein at 8.9mg/mL with the addition of 1uL mother liquor (200mM MgOAc Tetrahydrate, 20% PEG 3350). Crystals grew to a large size but varied in quantity when set up in replicates.  A seed stock was formed from these crystals and added at 20% to the mother liquor solution prior to plate setup. Crystals of large size were then created with 1.3uL protein and 1.3uL of mother liquor containing seeds in a sitting drop MRC-2 plate (Hampton Research).  Crystal nucleation occurred overnight and reached maximum size in 4 days",295.0,2016-01-11,2016-03-30,5HI7,3441.0,1.0,432.0,119.0,,50.32,1.0,2.15,experimental,36.0,0.2257,0.1984,Co-crystal structure of human SMYD3 with an aza-SAH compound
7T8J,X-RAY DIFFRACTION,2.16,43.06,"VAPOR DIFFUSION, SITTING DROP",7.0,"1.2 uL of 1 mg/mL protein in 50 mM Tris pH 8.8, 200 mM KCl combined with 1.2 uL of 100 mM Bis-tris-propane, 2.5 M Ammonium Nitrate",298.0,2021-12-16,2022-12-21,7T8J,1115.0,1.0,157.0,19.0,,17.95,1.0,1.89,experimental,56.32,0.2347,0.2238,The ubiquitin-associated domain of human thirty-eight negative kinase-1 flexibly fused to the 1TEL crystallization chaperone via a GSGG linker
7KG7,X-RAY DIFFRACTION,2.35,47.8,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M PCTP, pH 7.5, 0.2 M AmSO4, 18-23% PEG3350",295.0,2020-10-16,2021-03-10,7KG7,4222.0,1.0,531.0,288.0,,62.19,1.0,1.85,experimental,36.36,0.1955,0.1774,Structure of human PARG complexed with PARG-292
7KG8,X-RAY DIFFRACTION,2.33,47.2,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M PCTP, pH 7.5, 0.2 M AmSO4, 18-23% PEG3350",295.0,2020-10-16,2021-03-10,7KG8,4460.0,1.0,531.0,434.0,,62.09,1.0,1.43,experimental,28.88,0.1923,0.1724,Structure of human PARG complexed with PARG-061
5CQH,X-RAY DIFFRACTION,2.06,40.4,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, MES-NaOH",293.0,2015-07-21,2015-10-07,5CQH,1760.0,1.0,186.0,185.0,,22.64,1.0,1.73,experimental,,0.1859,0.1523,Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B
5IXI,X-RAY DIFFRACTION,3.03,59.38,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M MES pH6.5, 0.2M MgCl2, 9% PEG4K, 25% ethylene glycol",277.0,2016-03-23,2016-05-18,5IXI,3828.0,2.0,597.0,69.0,,69.5,2.0,2.57,experimental,,0.2547,0.2134,Structure of human JAK1 FERM/SH2 in complex with IFNLR1/IL10RA chimera
5UU1,X-RAY DIFFRACTION,2.23,44.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"22.5% PEG 3350; 20 MM MAGNESIUM, CHLORIDE, 0.1M CHC BUFFER pH 7.5, STABILIZED WITH 20% (V/V) GLYCEROL",293.0,2017-02-15,2017-03-01,5UU1,2556.0,1.0,324.0,137.0,,37.18,1.0,2,experimental,42.57,0.221,0.182,Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to BI-D1870
8C7D,X-RAY DIFFRACTION,2.13,42.13,"VAPOR DIFFUSION, SITTING DROP",,"20% W/V PEG3350, 0.1 M succinic acid",293.0,2023-01-14,2024-01-24,8C7D,1619.0,1.0,201.0,72.0,1.0,24.06,1.0,1.86,experimental,33.86,0.2745,0.2273,Structure of the GEF Kalirin DH2 Domain
6SUB,X-RAY DIFFRACTION,2.16,43.12,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M BICINE, pH 9, 1 M lithium chloride, 20% (w/v) polyethylene glycol 6000",293.0,2019-09-13,2020-07-08,6SUB,2139.0,1.0,297.0,117.0,,34.1,1.0,1.72,experimental,29.38,0.2014,0.1819,"Human PTPRU D1 domain, reduced form"
7A1N,X-RAY DIFFRACTION,3.18,61.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6M AMMONIUM SULPHATE, 6% PEG 400, 0.1M HEPES PH 7.5",277.0,2020-08-13,2021-08-25,7A1N,3066.0,2.0,369.0,181.0,,43.58,2.0,2.01,experimental,73.09,0.2343,0.2125,"FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II), 3-methyl-2-oxoglutarate, AND CONSENSUS ANKYRIN REPEAT DOMAIN (20-MER)"
5IXD,X-RAY DIFFRACTION,2.82,56.37,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1-0.2 M Ammonium Citrate tribasic pH 7, 5-15% PEG 3350",277.0,2016-03-23,2016-05-18,5IXD,3466.0,2.0,599.0,,,69.69,2.0,2.85,experimental,,0.2823,0.2488,Structure of human JAK1 FERM/SH2 in complex with IFN lambda receptor
7NB2,X-RAY DIFFRACTION,2.44,49.5,"VAPOR DIFFUSION, SITTING DROP",7.0,"18-20% Peg-mme 5000, 0.1 M Magnesium Formate, 0.1 M HEPES pH 7.0.",293.0,2021-01-25,2021-10-13,7NB2,5870.0,2.0,768.0,69.0,,91.57,1.0,2.4,experimental,62.682,0.2477,0.2017,Crystal structure of human choline alpha in complex with an inhibitor
7NB3,X-RAY DIFFRACTION,2.45,49.78,"VAPOR DIFFUSION, SITTING DROP",7.0,"18-20% Peg-mme 5000, 0.1 M Magnesium Formate, 0.1 M HEPES pH 7.0",293.0,2021-01-25,2021-10-13,7NB3,6175.0,2.0,768.0,283.0,,91.67,1.0,2,experimental,40.519,0.2342,0.1893,Crystal structure of human choline alpha in complex with an inhibitor
4XRZ,X-RAY DIFFRACTION,3.15,61.01,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, SODIUM ACETATE, SODIUM CACODYLATE, POTASSIUM PHOSPHATE, SODIUM CHLORIDE, ZINC CHLORIDE, GLYCEROL, BETA-MERCAPTOETHANOL, THIORIDAZINE, HEGA-10, FACIAL AMPHIPHILE 231_CHOL. Beta-secretase inhibitor was added to the mother liquor after crystallization of the P450 2D6 thiordidazine ternary complex.",298.0,2015-01-21,2015-05-20,4XRZ,15092.0,4.0,1916.0,343.0,,220.04,1.0,2.4,experimental,49.8,0.254,0.2174,Human Cytochrome P450 2D6 BACE1 Inhibitor 6 Complex
5IH9,X-RAY DIFFRACTION,2.86,56.94,"VAPOR DIFFUSION, SITTING DROP",,"100mM Hepes, pH 7.6, 0.2M NaCl, 4.5-16.5% PEG3350",277.0,2016-02-29,2016-06-01,5IH9,2874.0,1.0,335.0,314.0,,39.39,1.0,1.79,experimental,33.17,0.2002,0.1724,MELK in complex with NVS-MELK8A
5EWE,X-RAY DIFFRACTION,2.13,42.25,"VAPOR DIFFUSION, HANGING DROP",6.0,"NaMES (pH 6.0), polyethylene glycol monomethyl ether 2000, and calcium chloride",291.0,2015-11-20,2016-01-13,5EWE,4272.0,3.0,455.0,444.0,,55.45,1.0,1.66,experimental,,0.2074,0.1714,Ternary complex of human DNA polymerase eta inserting rCTP opposite template G
5EWF,X-RAY DIFFRACTION,2.11,41.68,"VAPOR DIFFUSION, HANGING DROP",6.0,"NaMES (pH 6.0), polyethylene glycol monomethyl ether 2000, and calcium chloride",291.0,2015-11-20,2016-01-13,5EWF,4202.0,3.0,455.0,410.0,,55.34,1.0,1.782,experimental,,0.2158,0.1795,Ternary complex of human DNA polymerase eta inserting rCTP opposite an 8-Oxodeoxyguanosine Lesion
7U72,X-RAY DIFFRACTION,2.05,40.14,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U72,4581.0,3.0,455.0,430.0,,55.54,1.0,1.53,experimental,32.6764,0.22,0.1872,Human DNA polymerase eta-DNA ternary mismatch complex:ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
7U74,X-RAY DIFFRACTION,2.11,41.79,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U74,4372.0,3.0,455.0,426.0,,55.54,1.0,1.52,experimental,30.9719,0.2245,0.1898,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s then with 10 mM Mn2+ for 30s
7U75,X-RAY DIFFRACTION,2.11,41.61,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U75,4520.0,3.0,455.0,450.0,,55.63,1.0,1.55,experimental,33.2246,0.2215,0.1868,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s then with 10 mM Mn2+ for 90s
7U76,X-RAY DIFFRACTION,2.04,39.64,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U76,4616.0,3.0,456.0,447.0,,56.04,1.0,1.69,experimental,37.3805,0.2192,0.1825,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s then with 10 mM Mn2+ for 300s
7U7F,X-RAY DIFFRACTION,2.08,40.79,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7F,4619.0,3.0,456.0,448.0,,56.04,1.0,1.65,experimental,35.6271,0.246,0.2,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 90s
7U7G,X-RAY DIFFRACTION,2.06,40.28,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7G,4685.0,3.0,456.0,441.0,,56.13,1.0,1.77,experimental,37.2778,0.2097,0.1751,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 120s
7U7I,X-RAY DIFFRACTION,2.06,40.42,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7I,4680.0,3.0,456.0,453.0,,56.13,1.0,1.57,experimental,32.1094,0.2191,0.1805,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 180s
7U7J,X-RAY DIFFRACTION,2.05,39.97,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7J,4585.0,3.0,456.0,451.0,,56.13,1.0,1.58,experimental,30.9667,0.2129,0.1811,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 300s
7U7K,X-RAY DIFFRACTION,2.05,39.97,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7K,4600.0,3.0,456.0,450.0,,56.04,1.0,1.67,experimental,33.4218,0.2211,0.1765,Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 600s
7U7R,X-RAY DIFFRACTION,2.07,40.53,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7R,4267.0,3.0,455.0,405.0,,55.45,1.0,1.64,experimental,34.8699,0.2186,0.1929,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex:no Me2+ soaking
7U7S,X-RAY DIFFRACTION,2.1,41.52,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7S,4416.0,3.0,455.0,420.0,,55.42,1.0,1.6,experimental,32.3187,0.2074,0.188,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.025 mM Mg2+ for 600s
7U7T,X-RAY DIFFRACTION,2.1,41.57,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7T,4433.0,3.0,455.0,419.0,,55.42,1.0,1.55,experimental,29.2178,0.2022,0.1881,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.05 mM Mg2+ for 600s
7U7U,X-RAY DIFFRACTION,2.1,41.45,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7U,4449.0,3.0,455.0,421.0,,55.42,1.0,1.54,experimental,32.9643,0.2214,0.1936,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.1 mM Mg2+ for 600s
7U7V,X-RAY DIFFRACTION,2.1,41.54,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7V,4428.0,3.0,455.0,423.0,,55.42,1.0,1.65,experimental,32.8244,0.2175,0.1858,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.4 mM Mg2+ for 600s
7U7X,X-RAY DIFFRACTION,2.09,41.14,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7X,4392.0,3.0,455.0,418.0,,55.42,1.0,1.65,experimental,33.4301,0.2098,0.1886,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 2.0 mM Mg2+ for 600s
7U7Y,X-RAY DIFFRACTION,2.1,41.41,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7Y,4391.0,3.0,455.0,424.0,,55.48,1.0,1.78,experimental,35.3445,0.2144,0.1794,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.06 mM Mn2+ for 600s
7U7Z,X-RAY DIFFRACTION,2.09,41.2,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U7Z,4375.0,3.0,455.0,421.0,,55.48,1.0,1.67,experimental,33.3811,0.219,0.1863,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.12 mM Mn2+ for 600s
7U80,X-RAY DIFFRACTION,2.11,41.72,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG 2000MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U80,4409.0,3.0,455.0,420.0,,55.48,1.0,1.83,experimental,38.9452,0.2142,0.1786,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.25 mM Mn2+ for 600s
7U81,X-RAY DIFFRACTION,2.09,41.27,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG2000 MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U81,4413.0,3.0,455.0,420.0,,55.48,1.0,1.6,experimental,32.6149,0.2194,0.1877,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.5 mM Mn2+ for 600s
7U84,X-RAY DIFFRACTION,2.06,40.32,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% PEG2000 MME, 0.1 M MES",298.0,2022-03-07,2022-05-04,7U84,4362.0,3.0,455.0,414.0,,55.48,1.0,1.71,experimental,36.1577,0.2362,0.1847,Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 6.0 mM Mn2+ for 600s
8E8B,X-RAY DIFFRACTION,2.07,40.66,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8B,3976.0,3.0,455.0,40.0,,55.27,1.0,2.2,experimental,42.5509,0.2432,0.1949,Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
8E8C,X-RAY DIFFRACTION,2.06,40.22,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8C,3970.0,3.0,455.0,20.0,,55.3,1.0,2.25,experimental,50.3017,0.2311,0.1916,Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 30s
8E8D,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8D,4016.0,3.0,455.0,39.0,,55.3,1.0,2.09,experimental,43.1919,0.2349,0.1997,Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 60s
8E8E,X-RAY DIFFRACTION,2.07,40.7,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8E,4037.0,3.0,456.0,1.0,,55.8,1.0,2.05,experimental,45.5954,0.2439,0.2091,Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 90s
8E8F,X-RAY DIFFRACTION,2.05,40.12,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8F,4020.0,3.0,456.0,10.0,,55.86,1.0,2.14,experimental,59.0664,0.2736,0.2003,Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 120s
8E8G,X-RAY DIFFRACTION,2.05,39.88,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8G,4058.0,3.0,456.0,4.0,,55.86,1.0,2.13,experimental,60.534,0.2412,0.2012,Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 180s
8E8H,X-RAY DIFFRACTION,2.05,39.88,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2022-08-25,2023-02-01,8E8H,4063.0,3.0,456.0,12.0,,55.86,1.0,2.13,experimental,60.5828,0.2458,0.2034,Human DNA polymerase eta-DNA-rU-ended primer ternary mismatch complex:reaction with 10 mM Mn2+ for 300s
5TDZ,X-RAY DIFFRACTION,2.76,55.42,"VAPOR DIFFUSION, HANGING DROP",8.8,"13% P3350, 100 mM TrisHCl pH 8.8, 100 mM ammonium chloride",294.0,2016-09-20,2017-08-09,5TDZ,6404.0,2.0,755.0,506.0,,84.83,2.0,2,experimental,,0.222,0.175,TEV Cleaved Human ATP Citrate Lyase Bound to Tartrate and ADP
7NUW,X-RAY DIFFRACTION,2.68,54.19,VAPOR DIFFUSION,5.6,"170 mM Ammonium acetate, 85 mM Sodium citrate tribasic dihydrate pH 5.6, 25.5% w/v Polyethylene glycol 4,000, 15% v/v glycerol (#9 from HR2-122 Hampton) + Zinc chloride(molar ratio zinc chloride:protein 1:1).
Growth at +4 for 3-4 months.",277.0,2021-03-15,2021-08-25,7NUW,1330.0,1.0,162.0,39.0,2.0,19.07,1.0,1.9,experimental,57.34,0.2453,0.2151,Crystal structure of the TIR domain of human TLR1 (crystallised with Zn2+ ions)
7NUX,X-RAY DIFFRACTION,2.67,53.95,VAPOR DIFFUSION,5.6,"170 mM Ammonium acetate, 85 mM Sodium citrate tribasic dihydrate pH 5.6, 25.5% w/v Polyethylene glycol 4,000, 15% v/v glycerol (#9 from HR2-122 Hampton)
Growth at +4 for 3-4 months.",277.0,2021-03-15,2021-08-25,7NUX,1313.0,1.0,162.0,11.0,2.0,19.07,1.0,2.47,experimental,55.61,0.2788,0.2292,Crystal structure of the TIR domain of human TLR1 (crystallised without ZN2+ ions)
4QU1,X-RAY DIFFRACTION,2.3,46.45,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M HEPES, pH 7.0, 8% PEG3350, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-07-10,2015-07-15,4QU1,2240.0,1.0,236.0,279.0,,27.62,1.0,1.57,experimental,,0.174,0.1493,Crystal structure of human JMJD5 jmj-c domain
7PVN,X-RAY DIFFRACTION,2.75,55.3,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Na-cacodylate, 0.16 M Ca-acetate, 15% PEG 8000 and 16% Glycerol",293.0,2021-10-05,2022-08-31,7PVN,16110.0,2.0,2104.0,196.0,,239.78,1.0,2.71,experimental,77.09,0.2617,0.2326,Crystal Structure of Human UBA6 in Complex with ATP
6WFO,X-RAY DIFFRACTION,2.71,54.67,"VAPOR DIFFUSION, SITTING DROP",5.77,"Naa50 apo protein (13.0 mg/ml) was incubated with 4b and AcCoA in a 1:3:3 molar ratio on ice for 60 min.  Reservoir solution of 0.1 M Bis_tris, pH 5.77 and 24% w/v PEG 3350 was mixed 0.2ul:0.2ul with Naa50:4b:AcCoA complex",294.0,2020-04-03,2020-07-01,6WFO,4050.0,3.0,513.0,82.0,,62.8,1.0,1.85,experimental,37.24,0.24,0.202,Crystal structure of human Naa50 in complex with AcCoA and an inhibitor (compound 4b) identified using DNA encoded library technology
5X23,X-RAY DIFFRACTION,3.84,67.93,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M ammonium sulfate, 0.1 M Tris pH8.5, 12% glycerol",291.0,2017-01-30,2017-10-25,5X23,4026.0,1.0,476.0,197.0,,56.29,1.0,2,experimental,49.992,0.25308,0.21738,Crystal structure of CYP2C9 genetic variant A477T (*30) in complex with multiple losartan molecules
6K6U,X-RAY DIFFRACTION,2.2,44.21,"VAPOR DIFFUSION, SITTING DROP",,"Tacsimate,Tris,PEG 3350",291.0,2019-06-04,2019-12-25,6K6U,2180.0,2.0,286.0,78.0,,33.11,1.0,2.27,experimental,,0.2459,0.1952,Crystal structure of the human YTHDC2 YTH domain
6Z50,X-RAY DIFFRACTION,2.88,57.35,"VAPOR DIFFUSION, SITTING DROP",,"23% PEG3350, 0.1M sodium malonate",277.15,2020-05-26,2020-06-03,6Z50,3432.0,1.0,339.0,472.0,,41.32,1.0,1.6,experimental,22.633,0.1795,0.1508,Crystal structure of CLK1 in complex with macrocycle ODS2003208
7B36,X-RAY DIFFRACTION,2.6,52.63,"VAPOR DIFFUSION, SITTING DROP",,"solution: protein 12 mg/ml in buffer 25mM HEPES pH 7.5, 200 mM NaCl, 0.5mM TCEP, 5% glycerol
reservoir:
28% PEG6000, 0.1M HEPES pH 7.5",293.0,2020-11-28,2020-12-16,7B36,4323.0,2.0,602.0,83.0,,68.93,1.0,2.10681078505,experimental,54.0893235375,0.244487399643,0.200976456902,MST4 in complex with compound G-5555
4NR1,X-RAY DIFFRACTION,3.24,62.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6M AMMONIUM SULPHATE, 6% PEG 400, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2013-11-26,2015-01-21,4NR1,2871.0,2.0,372.0,54.0,,43.33,2.0,2.68,experimental,63.4135,0.2096,0.1639,Factor inhibiting HIF-1 alpha in complex with consensus ankyrin repeat domain-(d)allyl-GLY peptide
5QID,X-RAY DIFFRACTION,2.34,47.42,"VAPOR DIFFUSION, SITTING DROP",5.75,"0.1M MIB pH 5.75 - 7.0, 27.5-35% PEG1000",293.0,2018-05-22,2018-07-18,5QID,3770.0,1.0,369.0,139.0,,41.51,1.0,1.45,experimental,19.904,0.1975,0.1797,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of HAO1 in complex with Z1787627869
8IHZ,X-RAY DIFFRACTION,3.42,64.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6 M AMMONIUM SULPHATE, 6% PEG 400, 0.1 M HEPES",277.0,2023-02-24,2024-02-28,8IHZ,2911.0,1.0,349.0,77.0,,42.15,1.0,2.22,experimental,96.82,0.2613,0.2267,"FACTOR INHIBITING HIF-1 ALPHA in complex with (5-(1-(3-(4-chlorophenyl)propyl)-1H-1,2,3-triazol-4-yl)-3-hydroxypicolinoyl)glycine"
6Y73,X-RAY DIFFRACTION,1.87,34.16,"VAPOR DIFFUSION, HANGING DROP",6.7,"0.2 M Ammonium tartarate dibasic pH 6.7, 20% PEG 3350",293.0,2020-02-28,2020-09-30,6Y73,15593.0,8.0,2928.0,1603.0,,328.62,1.0,1.7,experimental,25.568,0.2031,0.1821,The crystal structure of human MACROD2 in space group P43
5FTQ,X-RAY DIFFRACTION,2.28,46.0,,,"18% PEG3350, 0.1 M TRIS/HCL PH 8.5",,2016-01-14,2016-04-06,5FTQ,2733.0,1.0,315.0,359.0,,36.0,1.0,1.7,experimental,25.786,0.21995,0.17301,Crystal structure of the ALK kinase domain in complex with Cmpd 17
7BKG,X-RAY DIFFRACTION,2.24,45.14,"VAPOR DIFFUSION, HANGING DROP",,"Human NNMT was crystallized using the following conditions: A protein solution with 6 mg/ml NNMT, 50 mM Tris/HCL, pH 8.0, 1 mM DTT, 86uM S-Adenosyl-L-Homocysteine (SAH), 0.95mM ligand and 5% v/v glycerol was equilibrated at room temperature in a hanging drop setup against 2.2 M ammonium sulfate with 0.1 M HEPES/Na, pH 7.6. Small crystal appeared after 1-2 weeks.",293.0,2021-01-15,2021-03-17,7BKG,8994.0,4.0,1132.0,613.0,,128.16,1.0,2.326,experimental,33.21,0.2361,0.1752,Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the tricyclic inhibitor (2)
7BLE,X-RAY DIFFRACTION,2.23,44.89,"VAPOR DIFFUSION, HANGING DROP",,"Human NNMT was crystallized using the following conditions: A protein solution with 6 mg/ml NNMT, 50 mM Tris/HCL, pH 8.0, 1 mM DTT, 86uM S-Adenosyl-L-Homocysteine (SAH), 0.95mM inhibitor and 5% v/v glycerol was equilibrated at room temperature in a hanging drop setup against 2.2 M ammonium sulfate with 0.1 M HEPES/Na, pH 7.6. Small crystal appeared after 1-2 weeks.",293.0,2021-01-18,2021-03-17,7BLE,8460.0,4.0,1132.0,274.0,,128.21,1.0,2.809,experimental,30.66,0.2696,0.1864,Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the tricyclic inhibitor (3)
7NBQ,X-RAY DIFFRACTION,2.26,45.46,"VAPOR DIFFUSION, HANGING DROP",,"Human NNMT was crystallized using the following conditions: A protein solution with 6 mg/ml NNMT, 50 mM Tris/HCL, pH 8.0, 1 mM DTT, 86uM S-Adenosyl-L-Homocysteine (SAH), 0.95mM inhibitor and 5% v/v glycerol was equilibrated at room temperature in a hanging drop setup against 2.2 M ammonium sulfate with 0.1 M HEPES/Na, pH 7.6. Small crystal appeared after 1-2 weeks.",293.0,2021-01-27,2021-03-17,7NBQ,8751.0,4.0,1132.0,487.0,,128.21,1.0,2.479,experimental,34.08,0.2713,0.1912,Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with the tricyclic inhibitor (4)
4W5V,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, SITTING DROP",8.0,"100 mM Tris, pH 8.0, 20% PEG MME 550,
200 mM potassium formate, 20% glycerol; seeded",293.0,2014-08-19,2015-09-09,4W5V,2179.0,2.0,285.0,74.0,,31.98,2.0,2.5,experimental,,0.2828,0.2211,Crystal structure of Human SUMO E2-conjugating enzyme (Ubc9) in complex with E1-activating enzyme (Uba2) ubiquitin fold domain (Ufd)
6HMR,X-RAY DIFFRACTION,2.17,43.32,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Sodium malonate pH 6.0
20 % Polyethylene glycol 3,350",293.0,2018-09-12,2019-09-11,6HMR,5192.0,2.0,628.0,462.0,,74.1,1.0,1.782,experimental,,0.1993,0.1751,Crystal structure of human Casein Kinase I delta in complex with a photoswitchable 2-Azothiazole-based inhibitor (compound 2)
5MYV,X-RAY DIFFRACTION,4.87,74.72,"VAPOR DIFFUSION, SITTING DROP",5.25,1.0 M ammonium sulfate and 0.1 M acetate pH 5.25,277.15,2017-01-29,2017-05-10,5MYV,11780.0,4.0,1556.0,51.0,,183.52,1.0,2.9,experimental,79.094,0.21694,0.19897,Crystal structure of SRPK2 in complex with compound 1
8QCH,X-RAY DIFFRACTION,2.35,47.58,"VAPOR DIFFUSION, SITTING DROP",6.5,"2000 mM Ammonium sulfate
100 mM Sodium cacodylate/HCl
200 mM Sodium chloride",293.15,2023-08-26,2024-07-31,8QCH,23207.0,8.0,2840.0,817.0,,328.2,1.0,2.442,experimental,50.42,0.2431,0.2143,Human Adenosine deaminase-like protein in complex with compound AT8001
8XN7,X-RAY DIFFRACTION,2.45,49.72,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M sodium chloride, 0.1 M Tris, 
8%(w/v)PEG 20000, pH=8.0",291.0,2023-12-29,2024-04-10,8XN7,4672.0,2.0,592.0,54.0,,67.32,1.0,2.65,experimental,49.62,0.2302,0.2144,"Crystal structure of HPK1 kinase domain T165E,S171E phosphomimetic mutant in complex with compound 9f"
6KDS,X-RAY DIFFRACTION,2.32,47.08,VAPOR DIFFUSION,8.1,"0.1M Tris pH 8.1, 14% w/v Polyethylene glycol 8000",291.0,2019-07-02,2020-07-08,6KDS,2019.0,2.0,250.0,167.0,,28.65,2.0,1.844,experimental,31.1282,0.2047,0.1783,Crystal structure of human NRMT2 in complex with alpha-N-monomethylated human CENP-A peptide
5A7H,X-RAY DIFFRACTION,2.5,50.8,,7.5,"CRYSTALS WERE GROWN AT 4C IN 0.1 M BIS-TRIS PROPANE, PH 7.5, CONTAINING 20 % (W/V) POLYETHYLENE GLYCOL 3350, 0.2 M NAI",277.0,2015-07-04,2016-01-13,5A7H,4359.0,1.0,531.0,221.0,2.0,59.61,1.0,2.01,experimental,43.37,0.22163,0.17897,Comparison of the structure and activity of glycosylated and aglycosylated Human Carboxylesterase 1
5TFT,X-RAY DIFFRACTION,3.19,61.46,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, SODIUM ACETATE, SODIUM    CACODYLATE, POTASSIUM PHOSPHATE, SODIUM CHLORIDE, ZINC CHLORIDE, GLYCEROL, BETA-MERCAPTOETHANOL, THIORIDAZINE, HEGA-10, FACIAL AMPHIPHILE 231_CHOL. BETA-SECRETASE INHIBITOR WAS ADDED TO THE MOTHER LIQUOR AFTER CRYSTALLIZATION OF THE P450 2D6 THIORDIDAZINE TERNARY COMPLEX.",298.0,2016-09-26,2017-01-11,5TFT,14779.0,4.0,1916.0,42.0,,219.23,1.0,2.71,experimental,,0.2452,0.2111,Structure of cytochrome P450 2D6 (CYP2D6) BACE1 inhibitor complex
4QD6,X-RAY DIFFRACTION,2.44,49.67,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2M Sodium Nitrate, 0.1M Bis Tris propane, 20% PEG 3350, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-05-13,2015-01-14,4QD6,3988.0,2.0,532.0,19.0,,61.41,1.0,2.45,experimental,56.672,0.26689,0.20861,ITK kinase domain in complex with inhibitor compound
8D3O,X-RAY DIFFRACTION,2.62,53.0,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris, pH 8.5, 0.38 M Li2SO4, 25% PEG3350",295.0,2022-06-01,2023-11-08,8D3O,6828.0,3.0,1093.0,144.0,,122.3,2.0,2.25,experimental,64.61,0.2369,0.2128,Crystal structure of human Apoptosis-Inducing Factor (AIF) complexed with 8-methoxyquinolin-4-amine
8WTQ,X-RAY DIFFRACTION,2.56,52.05,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG8000/ 50mM KH2PO4/ 1mM DTT. Complex crystal was prepared by soaking in 
20% PEG8000/ 50mM KH2PO4, pH 6/ 1mM DTT",293.0,2023-10-19,2024-05-22,8WTQ,3037.0,1.0,340.0,324.0,,39.86,1.0,2,experimental,16.819,0.20582,0.15668,"HUMAN SQUALENE SYNTHASE IN COMPLEX WITH {1-[2-Chloro-5-(2,2-dimethyl-propyl)-13-(2-methoxy-phenyl)-6-oxo-6,7,10,11-tetrahydro-5H,9H,13H-12-oxa-5,8-diaza-benzocycloundecene-8-carbonyl]-piperidin-4-yl}-acetic acid"
8WTR,X-RAY DIFFRACTION,2.56,51.92,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG8000/ 50mM KH2PO4/ 1mM DTT. Complex crystal was prepared by soaking in 
20% PEG8000/ 50mM KH2PO4, pH 6/ 1mM DTT",293.0,2023-10-19,2024-05-22,8WTR,2996.0,1.0,340.0,298.0,,39.83,1.0,2,experimental,18.952,0.2193,0.1637,"HUMAN SQUALENE SYNTHASE IN COMPLEX WITH (1S,3R)-3-[2-Chloro-5-(2,2-dimethyl-propyl)-13-(2-methoxy-phenyl)-6,8-dioxo-5,6,7,8,10,11-hexahydro-13H-12-oxa-5,9-diaza-benzocycloundecen-9-yl]-cyclohexanecarboxylic acid"
6HMM,X-RAY DIFFRACTION,2.47,50.23,"VAPOR DIFFUSION, SITTING DROP",7.5,"Mix purified protein in 50 mM HEPES, pH 7.0, 150 mM NaCl, 2 mM DTT at 7.5 mg/mL with a precipitant consisting of 28% PEG-3350, 0.2 M magnesium chloride, 0.1 M PCTP (0.04 M sodium propionate, 0.02 M sodium cacodylate, 0.04 M Bis-Tris propane) pH 7.5.",293.0,2018-09-12,2018-11-14,6HMM,4682.0,1.0,531.0,525.0,,61.87,1.0,1.9,experimental,29.59,0.2588,0.2012,POLYADPRIBOSYL GLYCOHYDROLASE IN COMPLEX WITH PDD00013907
5EG3,X-RAY DIFFRACTION,2.59,52.46,"VAPOR DIFFUSION, HANGING DROP",7.5,"25 mM HEPES (pH 7.5), PEG20000 (12% 18%) and 2% (w/v) Benzamidine hydrochloride",277.0,2015-10-26,2016-02-03,5EG3,3414.0,2.0,448.0,55.0,,52.02,2.0,2.606,experimental,,0.2373,0.1854,Crystal Structure of the Activated FGF Receptor 2 (FGFR2) Kinase Domain in complex with the cSH2 domain of Phospholipase C gamma (PLCgamma)
7QGP,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"13% PEG 1k, 10% PEG 8k",277.0,2021-12-09,2022-01-26,7QGP,2390.0,1.0,302.0,164.0,1.0,34.83,1.0,1.9,experimental,37.378,0.2368,0.1995,STK10 (LOK) bound to Macrocycle CKJB51
9EZ3,X-RAY DIFFRACTION,3.19,61.43,"VAPOR DIFFUSION, SITTING DROP",8.0,"15% PEG 6k
0.1M bicine 8.0",278.0,2024-04-10,2024-09-11,9EZ3,2634.0,1.0,360.0,,,43.1,1.0,2.7,experimental,76.141,0.26833,0.20307,Crystal structure of human CLK3 bound to RN129
7QNS,X-RAY DIFFRACTION,2.71,54.65,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",298.0,2021-12-22,2023-01-18,7QNS,3987.0,5.0,462.0,341.0,6.0,51.83,2.0,1.4,experimental,23.92,0.2013,0.1768,Peptide VYEKKP in complex with human cathepsin V C25S mutant
7QO2,X-RAY DIFFRACTION,2.86,57.05,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",278.0,2021-12-23,2023-01-18,7QO2,3997.0,5.0,459.0,401.0,6.0,50.77,3.0,1.77,experimental,29.0,0.2024,0.1762,Peptide GAKSAA in complex with human cathepsin V C25A mutant
6TWC,X-RAY DIFFRACTION,3.14,60.86,"VAPOR DIFFUSION, HANGING DROP",,"200 mM (NH4)2SO4, 25% PEG4000, and 100 mM NaOAc, pH 4.6",291.0,2020-01-13,2020-05-20,6TWC,2053.0,3.0,274.0,,5.0,31.3,3.0,2.86,experimental,67.8712,0.259,0.2131,Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Double Bridged Peptide F21
8JUD,X-RAY DIFFRACTION,2.32,46.93,VAPOR DIFFUSION,7.0,"10% w/v Polyethylene glycol 8000,  100mM Tris pH7.0,  200mM Magnesium chloride",293.0,2023-06-26,2023-11-01,8JUD,1458.0,2.0,182.0,98.0,,20.34,2.0,1.5,experimental,21.416,0.25976,0.23113,Crystal structure of human MMP-7 in complex with inhibitor
8JUF,X-RAY DIFFRACTION,2.33,47.17,VAPOR DIFFUSION,7.0,"10% w/v Polyethylene glycol 8000,  100mM Tris pH7.0,  200mM Magnesium chloride",293.0,2023-06-26,2023-11-01,8JUF,1503.0,2.0,182.0,143.0,,20.37,2.0,1.39,experimental,28.515,0.22006,0.1967,Crystal structure of human MMP-7 in complex with inhibitor
8JUG,X-RAY DIFFRACTION,2.22,44.6,VAPOR DIFFUSION,9.0,"10% w/v Polyethylene glycol 20000,  2% v/v 1,4-Dioxane,  100mM BICINE pH9.0",293.0,2023-06-26,2023-11-01,8JUG,1520.0,2.0,182.0,113.0,,20.49,2.0,1.3,experimental,15.598,0.23789,0.22122,Crystal structure of human MMP-7 in complex with inhibitor
8UDU,X-RAY DIFFRACTION,2.4,48.82,"VAPOR DIFFUSION, HANGING DROP",,"0.10 M Magnesium Chloride,
0.10 M TRIS/HCl pH 8.10,
0.20 M Sodium Chloride,
20.00 % (w/v) PEG 3350",293.0,2023-09-29,2024-02-07,8UDU,4867.0,2.0,594.0,326.0,,68.6,1.0,1.737,experimental,47.52,0.2558,0.2298,The X-RAY co-crystal structure of human FGFR3 and Compound 17
5NGR,X-RAY DIFFRACTION,2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",,"5 mmol/L compound and 6 mmol/L MgCl2 were added to MTH1. Sitting drop vapor diffusion experiments at 293K were performed, and MTH1 (9.34 mg/mL) was mixed with reservoir solution (30% (w/v) PEG6000, 0.1 mol/L Sodium Acetate pH 3.7 and 0.2 mol/L LiSO4 in a 1:1 ratio.",293.0,2017-03-20,2017-10-04,5NGR,2641.0,2.0,318.0,79.0,,37.45,1.0,2.2,experimental,36.83,0.2539,0.21036,Crystal structure of human MTH1 in complex with fragment inhibitor 8-(methylsulfanyl)-7H-purin-6-amine
5NGS,X-RAY DIFFRACTION,2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",,"5 mmol/L compound and 6 mmol/L MgCl2 were added to MTH1. Sitting drop vapor diffusion experiments at 293K were performed, and MTH1 (9.34 mg/mL) was mixed with reservoir solution (28% (w/v) PEG8000, 0.1 mol/L Sodium Acetate pH 4.0 and 0.2 mol/L LiSO4) in a 3:5 ratio.",293.0,2017-03-20,2017-10-04,5NGS,2832.0,2.0,318.0,237.0,,37.97,1.0,1.85,experimental,28.804,0.24832,0.21563,Crystal structure of human MTH1 in complex with inhibitor 6-[(2-phenylethyl)sulfanyl]-7H-purin-2-amine
5FQ2,X-RAY DIFFRACTION,4.65,75.53,,,,,2015-12-04,2016-11-16,5FQ2,2100.0,2.0,266.0,38.0,,30.09,2.0,2.201,experimental,,0.2489,0.2293,Crystal structure of human SUMO E1 UFD domain in complex with Ubc9 in a P422 space group.
7B2R,X-RAY DIFFRACTION,1.88,34.47,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% Medium molecular weight PEG Smears, 0.1M MES pH 6.5",293.15,2020-11-27,2021-01-13,7B2R,4685.0,2.0,554.0,425.0,,60.07,1.0,1.6,experimental,22.533,0.1927,0.1558,Crystal structure of NHL domain of TRIM2
4PES,X-RAY DIFFRACTION,2.44,49.68,VAPOR DIFFUSION,,"20% PEG3350, 0.2 mM sodium thiocyanate",298.0,2014-04-24,2015-06-17,4PES,16206.0,4.0,1984.0,472.0,,230.38,2.0,2.21,experimental,46.756,0.25606,0.20884,"Crystal structure of insulin degrading enzyme complexed with inhibitor tert-butyl [(2S)-2-(2,5-difluorophenyl)-3-(quinolin-3-yl)propyl]carbamate"
5QCU,X-RAY DIFFRACTION,3.02,59.3,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS USING 1.0M UNBUFFERED AMMONIUM SULFATE AS PRECIPITANT.
PROTEIN STOCK WAS BACE MUT46B BATCH X 8.3MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 4-FOLD EXCESS OF BMC022 ADDED
FROM A 50MM STOCK SOLUTION IN DMSO (1.4% DMSO IN DROP). CRYO-PROTECTANT WAS 2.0M LI2SO4, 0.2M SUCROSE, 0.1M CITRATE PH
5.5.",292.0,2017-12-01,2020-06-03,5QCU,9594.0,3.0,1206.0,600.0,9.0,135.82,1.0,1.951,experimental,43.1026,0.1931,0.167,Crystal structure of BACE complex with BMC022
5QD5,X-RAY DIFFRACTION,3.05,59.69,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XIV 6.3MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 7-FOLD EXCESS OF BMC009 ADDED FROM A 50MM STOCK
SOLUTION IN DMSO (2.0% DMSO IN DROP). CRYO- PROTECTANT WAS 1.2M AMMONIUM SULFATE, 25%(V/V)GLYCEROL, 2.0% DMSO, 1MM
BMC009.",292.0,2017-12-01,2020-06-03,5QD5,9380.0,3.0,1206.0,369.0,9.0,135.88,1.0,2.3,experimental,48.64,0.207,0.177,Crystal structure of BACE complex with BMC009
6DGE,X-RAY DIFFRACTION,2.03,39.42,"VAPOR DIFFUSION, SITTING DROP",7.3,"20% PEG 3350
0.2 M NaCl",277.0,2018-05-17,2018-07-25,6DGE,2120.0,1.0,308.0,83.0,,33.85,1.0,1.91,experimental,24.68,0.2507,0.2148,Crystal structure of the dimethylarginine dimethylaminohydrolase adduct with N5-(1-imino-2-chloroethyl)-L-lysine
5XVF,X-RAY DIFFRACTION,2.96,58.47,VAPOR DIFFUSION,7.5,"0.1 M HEPES pH 7.5, 25% PEG3350.",291.0,2017-06-27,2018-02-07,5XVF,2322.0,1.0,290.0,7.0,,33.04,1.0,2.655,experimental,74.48,0.2514,0.1935,Crystal Structure of PAK4 in complex with inhibitor CZH062
5TDF,X-RAY DIFFRACTION,2.71,54.68,"VAPOR DIFFUSION, HANGING DROP",8.4,"15% P3350, 100 mM TrisHCl pH 8.4, 150 mM ammonium chloride",294.0,2016-09-19,2017-08-09,5TDF,6723.0,2.0,755.0,821.0,,84.63,2.0,1.8,experimental,,0.191,0.15,TEV Cleaved Human ATP Citrate Lyase Bound to 4S hydroxycitrate
5TET,X-RAY DIFFRACTION,2.68,54.02,"VAPOR DIFFUSION, HANGING DROP",7.0,"12.5% of P3350, 100 mM TrisHCL pH 7.5, 125 mM ammonium phosphate pH 7.5",294.0,2016-09-22,2017-08-09,5TET,6261.0,2.0,755.0,414.0,,83.76,2.0,2.2,experimental,,0.213,0.156,TEV Cleaved Human ATP Citrate Lyase Bound to 4S Hydroxycitrate
5BX1,X-RAY DIFFRACTION,2.17,43.32,"VAPOR DIFFUSION, HANGING DROP",,"1.9 M amino sulfate, 100 mM sodium acetate, pH 4.6 ~ 4.9",310.0,2015-06-08,2016-12-21,5BX1,1367.0,1.0,157.0,100.0,1.0,18.56,1.0,1.9,experimental,,0.24,0.195,Crystal Structure of PRL-1 complex with compound analogy 3
7YV4,X-RAY DIFFRACTION,2.21,44.39,"VAPOR DIFFUSION, SITTING DROP",,"1.4M Sodium Citrate tribasic dihydrate, 0.1M HEPES Sodium pH 7.0",289.15,2022-08-18,2023-04-19,7YV4,1906.0,1.0,230.0,261.0,,26.51,1.0,1.58,experimental,27.1534,0.2063,0.1789,Crystal structure of human UCHL3 in complex with Farrerol
5E9W,X-RAY DIFFRACTION,2.19,43.87,"VAPOR DIFFUSION, SITTING DROP",,"MES pH 6.5 and 25% PEG 4000,
1/5000 thermolysin",291.0,2015-10-15,2016-07-13,5E9W,9400.0,4.0,1248.0,307.0,,148.4,1.0,2.283,experimental,,0.255,0.2201,Crystal structure of mRNA cap guanine-N7 methyltransferase obtained by limited proteolysis
5DWR,X-RAY DIFFRACTION,3.01,59.07,"VAPOR DIFFUSION, HANGING DROP",5.5,"Crystallant:  0.6 to 1.0 mM Ammonium monophosphate (NH4)2HPO4, 200-350 mM sodium chloride, 0.1 M Citrate, pH 5.5, 1ul (10mg/ml) protein : 1ul crystallant",289.0,2015-09-22,2015-11-11,5DWR,2504.0,1.0,328.0,248.0,,38.04,1.0,2,experimental,32.66,0.2022,0.1734,"Identification of N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1,2 and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies"
6VRD,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"0.8 M Ammonium sulphate, 0.1 M citrate pH 4.0",293.0,2020-02-07,2021-02-10,6VRD,2513.0,3.0,334.0,350.0,,46.96,1.0,1.299,experimental,23.5414,0.2286,0.1895,Crystal structure of RNase H/RNA/PS-ASO complex at an atomic level
5W84,X-RAY DIFFRACTION,2.85,56.88,"VAPOR DIFFUSION, HANGING DROP",,Null,293.0,2017-06-21,2017-10-11,5W84,4324.0,2.0,610.0,27.0,,69.29,1.0,2.9,experimental,83.58,0.248,0.2,"CRYSTAL STRUCTURE OF IRAK-4 WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)"
5LXC,X-RAY DIFFRACTION,3.04,59.5,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% PEG 3350, 0.2 M NaCl and 0.1 M bis-tris, pH 5.5",277.15,2016-09-20,2016-10-26,5LXC,6761.0,2.0,816.0,396.0,,95.43,1.0,2.15,experimental,49.867,0.25401,0.20564,Crystal structure of DYRK2 in complex with EHT 5372 (Compound 1)
5LXD,X-RAY DIFFRACTION,3.12,60.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.5 M Li2SO4 and 0.1 M HEPES, pH 7.5",277.15,2016-09-20,2016-10-26,5LXD,6544.0,2.0,816.0,193.0,,95.33,1.0,2.58,experimental,66.994,0.25303,0.1971,Crystal structure of DYRK2 in complex with EHT 1610 (compound 2)
4U76,X-RAY DIFFRACTION,2.49,50.51,"VAPOR DIFFUSION, HANGING DROP",6.0,"15% PEGMME, 100mM HEPES PH 6",298.0,2014-07-30,2015-03-25,4U76,2611.0,1.0,306.0,183.0,,34.78,1.0,1.87,experimental,35.57,0.223,0.177,HsMetAP (F309M) holo form
4WVS,X-RAY DIFFRACTION,1.68,29.01,"VAPOR DIFFUSION, HANGING DROP",,Crystals were grown in 0.98 M Ammonium Sulfate and 0.1 M Ammonium Formate. Single crystals grew after streak seeding,291.0,2014-11-07,2015-05-06,4WVS,746.0,2.0,103.0,33.0,,12.48,2.0,2.09,experimental,21.88,0.2316,0.1636,Crystal structure of XIAP-BIR2 domain complexed with (S)-3-(4-methoxyphenyl)-2-((S)-2-((S)-1-((S)-2-((S)-2-(methylamino)propanamido)pent-4-ynoyl)pyrrolidine-2-carboxamido)-3-phenylpropanamido)propanoic acid
4RPU,X-RAY DIFFRACTION,2.84,56.75,"VAPOR DIFFUSION, HANGING DROP",6.7,"15.0% PEG 8000, 15 mM TCEP, 80 mM sodium cacodylate pH 6.7, 160 mM calcium acetate, 20% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-10-31,2015-12-09,4RPU,16942.0,2.0,2028.0,811.0,,235.62,2.0,2.265,experimental,,0.2078,0.1755,Crystal Structure of Human Presequence Protease in Complex with Inhibitor MitoBloCK-60
4X6P,X-RAY DIFFRACTION,2.31,46.8,"VAPOR DIFFUSION, HANGING DROP",5.0,"100 MM SODIUM CITRATE, PH 5.0, 36%(w/v) PEG4000",277.0,2014-12-08,2015-02-18,4X6P,4195.0,2.0,476.0,306.0,8.0,56.0,1.0,1.93,experimental,24.3,0.1965,0.164,FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR (2E)-N-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-1H-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enamide
5C91,X-RAY DIFFRACTION,2.29,46.18,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, 35 mM calcium chloride, 5 mM TCEP, 6% PEG400",293.0,2015-06-26,2015-09-30,5C91,3205.0,1.0,375.0,7.0,,45.06,1.0,2.44,experimental,50.376,0.2977,0.2478,NEDD4 HECT with covalently bound indole-based inhibitor
5F9L,X-RAY DIFFRACTION,2.12,42.0,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 22% PEG 2000 MME",291.0,2015-12-09,2016-12-21,5F9L,4018.0,3.0,455.0,163.0,,55.36,1.0,2.592,experimental,,0.2483,0.191,"CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dAMPNPP ACROSS A DNA TEMPLATE CONTAINING 1,N2-ETHENODEOXYGUANOSINE LESION"
5F9N,X-RAY DIFFRACTION,2.12,41.98,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 22% PEG 2000 MME",291.0,2015-12-09,2016-12-21,5F9N,4094.0,3.0,455.0,273.0,,55.34,1.0,2.23,experimental,,0.2101,0.1578,"CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA INSERTING dCMPNPP ACROSS A DNA TEMPLATE CONTAINING 1,N2-ETHENODEOXYGUANOSINE LESION"
6D0M,X-RAY DIFFRACTION,2.08,40.75,"VAPOR DIFFUSION, HANGING DROP",6.0,"MES buffer, 
PEG1500",293.0,2018-04-10,2018-09-05,6D0M,4286.0,3.0,456.0,420.0,,55.13,1.0,1.832,experimental,,0.1962,0.1603,Polymerase Eta post-insertion binary complex with cytarabine (AraC)
6D0Z,X-RAY DIFFRACTION,2.1,41.56,"VAPOR DIFFUSION, HANGING DROP",6.0,"MES  buffer,
PEG1500, magnesium chloride",293.0,2018-04-11,2018-09-05,6D0Z,4242.0,3.0,455.0,374.0,,55.45,1.0,1.75,experimental,,0.1954,0.1684,Polymerase Eta cytarabine (AraC) extension ternary complex
8BC8,X-RAY DIFFRACTION,2.44,49.53,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2022-10-15,2023-03-08,8BC8,16467.0,2.0,2010.0,331.0,,231.55,2.0,2.39,experimental,73.55,0.2447,0.2066,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 18
8BC9,X-RAY DIFFRACTION,2.44,49.54,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2022-10-15,2023-03-08,8BC9,16458.0,2.0,2010.0,418.0,,230.66,2.0,2.3,experimental,67.91,0.249,0.198,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 24
8BCC,X-RAY DIFFRACTION,2.46,49.92,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2022-10-15,2023-03-08,8BCC,16497.0,2.0,2010.0,422.0,,230.94,2.0,2.35,experimental,65.61,0.2584,0.2099,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 39
8BCE,X-RAY DIFFRACTION,2.44,49.52,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2022-10-15,2023-03-08,8BCE,16532.0,2.0,2010.0,527.0,,230.73,2.0,2.05,experimental,63.42,0.2668,0.2204,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 76
8BCF,X-RAY DIFFRACTION,2.4,48.81,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2022-10-15,2023-03-08,8BCF,16362.0,2.0,2010.0,325.0,,230.62,2.0,2.42,experimental,73.86,0.2745,0.2129,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 78
8BCG,X-RAY DIFFRACTION,2.43,49.4,VAPOR DIFFUSION,8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2022-10-15,2023-03-08,8BCG,16360.0,2.0,2010.0,336.0,,230.59,2.0,2.39,experimental,68.15,0.2694,0.214,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 86
5EXL,X-RAY DIFFRACTION,3.47,64.55,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2015-11-23,2016-04-13,5EXL,2104.0,1.0,244.0,172.0,4.0,28.7,1.0,2.3,experimental,29.48,0.2382,0.1943,FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-(aminomethyl)-~{N}-[(1~{S})-1-[4-(3-oxidanyl-1~{H}-indazol-5-yl)pyridin-2-yl]-2-phenyl-ethyl]cyclohexane-1-carboxamide
5EXM,X-RAY DIFFRACTION,3.49,64.74,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2015-11-23,2016-04-13,5EXM,2131.0,1.0,244.0,206.0,4.0,28.59,1.0,2.09,experimental,28.56,0.2259,0.1938,FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]carbonylamino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate
5ZUN,X-RAY DIFFRACTION,2.73,55.03,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M Bis-Tris, 10% PEG3350",293.0,2018-05-08,2018-10-17,5ZUN,2699.0,1.0,305.0,297.0,,34.53,1.0,1.35,experimental,14.803,0.16008,0.14693,Crystal structure of human monoacylglycerol lipase in complex with compound 3l
6ZFH,X-RAY DIFFRACTION,2.42,49.17,"VAPOR DIFFUSION, SITTING DROP",,"Morpheus condition:

Buffer system 1:
0.1 M pH 6.5, Imidazole; MES monohydrate (acid)

Amino acids:
0.02M L-Na-Glutamate; 0.02M Alanine (racemic); 0.02M Glycine; 0.02M Lysine HCl (racemic); 0.02M Serine (racemic)

Precipitant Mix 1:
20% v/v PEG 500 MME; 10 % w/v PEG 20000",293.0,2020-06-17,2021-06-30,6ZFH,22813.0,8.0,3192.0,332.0,4.0,348.62,1.0,2.439,experimental,58.6014,0.2619,0.2097,"Structure of human galactokinase in complex with galactose and 2'-(benzo[d]oxazol-2-ylamino)-7',8'-dihydro-1'H-spiro[cyclopentane-1,4'-quinazolin]-5'(6'H)-one"
7CWA,X-RAY DIFFRACTION,3.38,63.62,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Cacodylate Sodium pH 6.5, 15% Isopropanol, 30% ethylene glycol, 11% PEG 3350",277.0,2020-08-27,2021-09-01,7CWA,2787.0,1.0,338.0,44.0,1.0,39.48,1.0,2.8,experimental,37.493,0.33298,0.28872,Crystal structure of PDE8A catalytic domain in complex with clofarabine
4Y07,X-RAY DIFFRACTION,2.61,52.93,"VAPOR DIFFUSION, HANGING DROP",8.4,"0.2M MgCl2, 0.1M Hepes pH8.4 and 15% ethanol",277.0,2015-02-05,2015-11-04,4Y07,2908.0,1.0,374.0,69.0,,44.77,1.0,2.507,experimental,37.1244,0.2849,0.2441,Crystal structure of the HECT domain of human WWP2
5YJF,X-RAY DIFFRACTION,1.89,34.96,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.2M Sodium chloride, 0.1M BIS-TRIS pH 5.8, 25 %(w/v) PEG 3350",295.0,2017-10-10,2018-03-21,5YJF,8105.0,4.0,1136.0,71.0,,128.63,1.0,2.49,experimental,34.075,0.28553,0.22374,Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with small molecule analog of Nicotinamide
7AX4,X-RAY DIFFRACTION,2.25,45.38,"VAPOR DIFFUSION, SITTING DROP",8.5,"25.5% w/v PEG 4000, 0.21 M calcium chloride, 0.10 M Tris pH 8.5",293.0,2020-11-09,2021-04-14,7AX4,4586.0,2.0,590.0,408.0,,66.62,1.0,2.12,experimental,32.19,0.2288,0.1836,Human TYK2 pseudokinase domain (575-869) in complex with 5-(4-Fluoro-phenyl)-2-ureido-thiophene-3-carboxylic acid amide.
4CRA,X-RAY DIFFRACTION,2.76,55.41,,8.5,"2M AMMONIUM SULFATE, 0.1M TRIS-CL PH 8.5, 0.2M NACL",,2014-02-26,2015-02-11,4CRA,2198.0,1.0,238.0,215.0,4.0,27.73,1.0,1.8,experimental,23.709,0.20868,0.18469,Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4CRB,X-RAY DIFFRACTION,2.76,55.41,,8.5,2M AMMONIUM SULFATE 0.1M TRIS-CL PH 8.5 0.2M NACL,,2014-02-26,2015-02-11,4CRB,2075.0,1.0,238.0,122.0,4.0,27.88,1.0,1.85,experimental,,0.213,0.19,Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4X6M,X-RAY DIFFRACTION,3.57,65.56,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2014-12-08,2015-02-18,4X6M,2090.0,1.0,244.0,154.0,4.0,28.8,1.0,2.4,experimental,26.55,0.23,0.191,FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[2-(aminomethyl)-5-chlorobenzyl]urea
4X6O,X-RAY DIFFRACTION,3.55,65.35,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2014-12-08,2015-02-18,4X6O,2160.0,1.0,244.0,207.0,5.0,28.96,1.0,2.1,experimental,27.25,0.2277,0.1851,FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (4-{4-chloro-2-[(1S)-1-({3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]propanoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate
4N1O,X-RAY DIFFRACTION,2.73,54.87,"VAPOR DIFFUSION, HANGING DROP",8.0,"Tris, PEG8000, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2013-10-04,2015-08-12,4N1O,1614.0,1.0,165.0,249.0,,18.95,1.0,1.75,experimental,29.161,0.22147,0.17901,Structure of Cyclophilin A in complex with Saccharin.
4RU9,X-RAY DIFFRACTION,2.13,42.37,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 25% PEG 2000 MME 
, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K",291.0,2014-11-18,2015-08-05,4RU9,3917.0,3.0,452.0,138.0,,54.96,1.0,2.65,experimental,47.745,0.2293,0.15865,Crystal structure of human DNA polymerase eta inserting dCMPNPP opposite a MeFapy-dG adducted DNA template
5DGA,X-RAY DIFFRACTION,2.09,41.28,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M MES pH 5.5, 5mM magnesium chloride, 18% PEG 2000 MME",291.0,2015-08-27,2016-06-08,5DGA,4105.0,3.0,455.0,333.0,,55.24,1.0,2.3,experimental,27.0,0.2328,0.1564,"CRYSTAL STRUCTURE OF HUMAN DNA POLYMERASE ETA EXTENDING AN 1,N6-ETHENODEOXYADENOSINE : dT PAIR BY INSERTING dTMPNPP OPPOSITE TEMPLATE dA"
5DLF,X-RAY DIFFRACTION,2.13,42.15,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M MES pH 5.5, 5mM magnesium chloride, 18% PEG 2000 MME",291.0,2015-09-04,2016-08-10,5DLF,4318.0,3.0,455.0,495.0,,55.32,1.0,1.97,experimental,23.758,0.21707,0.16368,Crystal Structure of Human DNA Polymerase Eta Inserting dATP Opposite O4-Methylhymidine
5DLG,X-RAY DIFFRACTION,2.11,41.69,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 20% PEG 2000 MME",291.0,2015-09-04,2016-08-10,5DLG,4014.0,3.0,455.0,222.0,,55.34,1.0,2.351,experimental,,0.2475,0.1718,Crystal Structure of Human DNA Polymerase Eta Inserting dGMPNPP Opposite O4-Methylhymidine
5DQG,X-RAY DIFFRACTION,2.11,41.79,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 22% PEG 2000 MME",291.0,2015-09-14,2016-08-10,5DQG,4008.0,3.0,455.0,214.0,,55.34,1.0,2.29,experimental,31.071,0.22678,0.17579,Crystal Structure of Human DNA Polymerase Eta Inserting dAMPNPP Opposite O4-Ethylthymidine
5DQH,X-RAY DIFFRACTION,2.1,41.53,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 22% PEG 2000 MME",291.0,2015-09-14,2016-08-10,5DQH,4195.0,3.0,455.0,363.0,,55.36,1.0,1.99,experimental,,0.2103,0.1612,Crystal Structure of Human DNA Polymerase Eta Inserting dGMPNPP Opposite O4-Ethylthymidine
6PZ3,X-RAY DIFFRACTION,2.07,40.59,"VAPOR DIFFUSION, HANGING DROP",6.0,"MES BUFFER, PEG1500",293.0,2019-07-31,2019-11-20,6PZ3,3880.0,3.0,455.0,123.0,,55.36,1.0,2.395,experimental,40.9214,0.2157,0.1739,Polymerase Eta-catalyzed insertion of correct G opposite template cytarabine (AraC) residue
6Q02,X-RAY DIFFRACTION,2.14,42.56,"VAPOR DIFFUSION, HANGING DROP",6.0,"MES BUFFER, PEG1500",293.0,2019-08-01,2019-11-20,6Q02,4007.0,3.0,455.0,208.0,,55.45,1.0,2.09,experimental,49.2603,0.2398,0.1914,Polymerase Eta-catalyzed insertion of the mismatched A opposite template cytarabine (AraC) residue
6EMH,X-RAY DIFFRACTION,2.36,47.91,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Bis-Tris pH5.5, 200 mM NaCl, 29% PEG 3350, 1mM AMP-PCP, 0.4 mM Zwittergent 3-14, 10% Ethylene glycol",293.0,2017-10-02,2018-08-08,6EMH,12089.0,4.0,1468.0,861.0,,172.2,1.0,1.76,experimental,,,,Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitor
5MHO,X-RAY DIFFRACTION,2.67,53.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"170 mM ammonium sulfate, 85 mM sodium cacodylate, 25.5 % PEG8000, 15 % glycerol",291.0,2016-11-24,2017-12-20,5MHO,10661.0,4.0,1494.0,107.0,,171.04,2.0,2.92,experimental,,0.2483,0.2173,FXIIIa in complex with the inhibitor ZED2369
6VMJ,X-RAY DIFFRACTION,4.35,71.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M sodium cacodylate pH 6.5, 1 M sodium citrate",277.0,2020-01-28,2021-02-03,6VMJ,19932.0,12.0,2660.0,151.0,32.0,287.02,3.0,2.95,experimental,53.17,0.2652,0.2175,Crystal structure of human Complement Factor D with anti-Factor D Fab 20D12
8D0V,X-RAY DIFFRACTION,2.63,53.23,"VAPOR DIFFUSION, HANGING DROP",,"0.70-0.75 M succinic acid pH 7.0, 0.1 M bis-tris-propane pH 7.0.",282.15,2022-05-26,2023-01-25,8D0V,6885.0,2.0,838.0,356.0,,95.69,1.0,1.79,experimental,29.95,0.20186,0.18145,Human LanCL1 C264A mutant bound to GSH
8D19,X-RAY DIFFRACTION,2.53,51.35,"VAPOR DIFFUSION, HANGING DROP",,"0.7-0.75 M succinic acid pH 7.0, 0.1 M bis-tris propane pH 7.0",282.15,2022-05-26,2023-01-25,8D19,7450.0,2.0,838.0,897.0,,95.75,1.0,1.52,experimental,21.88,0.19231,0.17214,Human LanCL1 bound to GSH
6QGN,X-RAY DIFFRACTION,2.82,56.42,"VAPOR DIFFUSION, SITTING DROP",,"D1 Morpheus (Molecular Dimensions)
0.1 M  imidazole, 0.1 M MES monohydrate, 20% v/v PEG 500 MME, 10% w/v PEG 2000, 20 mM  1,6-Hexanediol,  20 mM 1-Butanol, 20 mM 1,2-Propanediol, 20 mM 2- Propanol, 20 mM 1,4-Butanediol, 20 mM 1,3-Propanediol, pH 6.5.",291.0,2019-01-12,2020-02-05,6QGN,7245.0,4.0,932.0,438.0,,101.25,1.0,2.099,experimental,,0.2733,0.23,Crystal structure of APT1 bound to 2-Bromopalmitate
6ENB,X-RAY DIFFRACTION,2.41,49.06,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 M SODIUM ACETATE, 0.005 M YBCL3",298.0,2017-10-04,2017-12-13,6ENB,5559.0,2.0,614.0,676.0,,70.1,2.0,1.84,experimental,27.05,0.1861,0.1554,LTA4 hydrolase (E297Q) mutant in complex with Pro-Gly-Pro peptide
5W6E,X-RAY DIFFRACTION,3.15,60.98,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M TRIS-HCL, 0.2 M MGCL2, 125 UM 5-(5-BROMO-2-PROPOXYPHENYL)-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE, 15% PEG 8000, PH 8.5, VAPOR DIFFUSION, TEMPERATURE 298K",298.0,2017-06-16,2018-05-30,5W6E,2924.0,1.0,369.0,305.0,,42.55,1.0,1.9,experimental,24.3,0.2062,0.1804,PDE1b complexed with compound 3S
5HGZ,X-RAY DIFFRACTION,1.9,35.23,LIQUID DIFFUSION,4.0,"10mM Tris pH 8.0, 75mM NaCl, 0.5% glycerol, 3%(v/v) Tacsimate pH4.0 (Hampton Research) and 7.5%(w/v) polyethylene glycol 3350 (PEG 3350)",293.15,2016-01-09,2016-09-14,5HGZ,2122.0,1.0,243.0,289.0,,28.71,1.0,1.383,experimental,,0.1918,0.1824,Crystal structure of human Naa60 in complex with acetyl-CoA
8PDF,X-RAY DIFFRACTION,2.2,44.09,"VAPOR DIFFUSION, HANGING DROP",,"1.36 Na/K tartrate, 0.2M ammonium citrate, 0.1M MES pH 6.5",293.0,2023-06-12,2023-11-15,8PDF,1061.0,1.0,107.0,152.0,,12.88,1.0,1.2,experimental,17.843,0.1756,0.1516,FKBP12 in complex with PROTAC 6a2
7QUE,X-RAY DIFFRACTION,2.77,55.54,"VAPOR DIFFUSION, SITTING DROP",,"19% PEG3350, 0.3 M ammonium formate",277.0,2022-01-17,2022-02-02,7QUE,3787.0,2.0,550.0,26.0,,63.87,1.0,2.4,experimental,70.55,0.2664,0.2336,The STK17A (DRAK1) Kinase Domain Bound to CKJB68
8PND,X-RAY DIFFRACTION,2.61,52.95,VAPOR DIFFUSION,5.5,"PEG 3350, Ammonium citrate",293.0,2023-06-30,2023-11-01,8PND,5542.0,2.0,728.0,272.0,,82.58,1.0,1.9,experimental,69.79,0.2166,0.1855,The ES3 intermediate of hydroxymethylbilane synthase R167Q variant
6F4T,X-RAY DIFFRACTION,2.3,46.64,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M Bis-Tris pH 6.5, 17.1 % PEG3350, 0.002 M MnCl2, 300 nl sitting drops (sample:well, 1:1 ratio)",298.0,2017-11-30,2018-04-04,6F4T,2561.0,2.0,260.0,353.0,1.0,30.66,2.0,1.22,experimental,26.0,0.1544,0.1413,"Human JMJD5 (W414C) in complex with Mn(II), NOG and RCCD1 (139-143) (complex-5)"
5V8W,X-RAY DIFFRACTION,2.39,48.45,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M Bis-Tris pH 6.5, 21-24% PEG 3350",293.0,2017-03-22,2017-04-12,5V8W,6055.0,8.0,768.0,419.0,2.0,86.71,2.0,2.1,experimental,,0.2203,0.1665,Crystal structure of human Integrator IntS9-IntS11 CTD complex
7Q42,X-RAY DIFFRACTION,2.93,57.99,"VAPOR DIFFUSION, HANGING DROP",8.0,"hanging drop
20% PEG 3350
0.18M tris amonium citrate",293.15,2021-10-29,2022-11-16,7Q42,9343.0,6.0,1260.0,851.0,,134.08,2.0,1.95002486823,experimental,33.9076128539,0.206296338153,0.167870694125,Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of chromatin reader BAZ2B
5W0C,X-RAY DIFFRACTION,2.5,50.88,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 3350, HEPES, CYMAL-5",297.0,2017-05-30,2017-09-13,5W0C,3995.0,1.0,477.0,211.0,,55.41,1.0,2.001,experimental,,0.2258,0.1815,Cytochrome P450 (CYP) 2C9 TCA007 Inhibitor Complex
8S99,X-RAY DIFFRACTION,2.16,43.09,VAPOR DIFFUSION,,"The purified protein was used in crystallization trials employing both, a standard screen with approximately 1200 different conditions, as well as crystallization conditions identified using literature data. Conditions initially obtained have been optimized using standard strategies, systematically varying parameters critically influencing crystallization, such as temperature, protein concentration, drop ratio, and others. These conditions were also refined by systematically varying pH or precipitant concentrations.",298.0,2023-03-27,2023-07-26,8S99,7307.0,3.0,885.0,671.0,,100.87,1.0,1.71,experimental,21.303,0.22541,0.19004,Crystal structure of the TYK2 pseudokinase domain in complex with compound 11
8S9A,X-RAY DIFFRACTION,2.16,43.18,VAPOR DIFFUSION,,"The purified protein was used in crystallization trials employing both, a standard screen with approximately 1200 different conditions, as well as crystallization conditions identified using literature data. Conditions initially obtained have been optimized using standard strategies, systematically varying parameters critically influencing crystallization, such as temperature, protein concentration, drop ratio, and others. These conditions were also refined by systematically varying pH or precipitant concentrations",298.0,2023-03-27,2023-07-26,8S9A,7174.0,3.0,885.0,596.0,,101.5,1.0,1.83,experimental,25.003,0.22398,0.18488,Crystal structure of the TYK2 pseudokinase domain in complex with TAK-279
6X3Y,X-RAY DIFFRACTION,2.74,55.11,"VAPOR DIFFUSION, HANGING DROP",8.5,"20 mM Tris-HCl, pH 8.5, 2 mM DTT, 2 mM EDTA, 20-35% PEG3350, 5% ethanol",277.0,2020-05-21,2020-06-24,6X3Y,1557.0,1.0,167.0,262.0,,18.78,1.0,1.4,experimental,14.12,0.1708,0.1548,Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors
6X4M,X-RAY DIFFRACTION,2.73,54.91,"VAPOR DIFFUSION, HANGING DROP",8.5,"20 mM Tris-HCl, pH 8.5, 2 mM DTT, 2 mM EDTA, 20-35% PEG3350, 5% ethanol",277.0,2020-05-22,2020-06-24,6X4M,1568.0,1.0,167.0,252.0,,18.78,1.0,1.5,experimental,13.56,0.1713,0.1524,"Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: tert-butyl [(2S)-1-{[(3S,17S)-2,16-dioxo-10,15-dioxa-1,21-diazatricyclo[15.3.1.1~5,9~]docosa-5(22),6,8-trien-3-yl]amino}-3-methyl-1-oxobutan-2-yl]carbamate (compound 3)"
4X6N,X-RAY DIFFRACTION,3.47,64.55,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2014-12-08,2015-02-18,4X6N,2160.0,2.0,262.0,177.0,5.0,31.13,2.0,2.1,experimental,28.48,0.2101,0.1711,FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]urea
7NX0,X-RAY DIFFRACTION,2.63,53.16,"VAPOR DIFFUSION, SITTING DROP",,"MOPSO/BIS-TRIS pH 6.5 
20% PEG 8000
40% w/v 1,5-pentanediol
5mM Na2CrO4 . 4H2O
5mM Na2MoO4 . 4H2O
5mM Na2WO4 . 4H2O
5mM Na2VO4 . 4H2O",287.0,2021-03-17,2021-10-27,7NX0,7186.0,5.0,975.0,678.0,10.0,100.66,3.0,1.95,experimental,53.43,0.1958,0.1689,LTK:ALKAL1 complex stabilized by a Nanobody
6D36,X-RAY DIFFRACTION,2.33,47.31,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG4000, 0.1 M sodium acetate pH 4.5, and 0.1 M MgSO4",295.0,2018-04-14,2018-06-20,6D36,11174.0,4.0,1464.0,932.0,,159.54,1.0,1.7,experimental,,0.2178,0.1836,Structure of human ARH3 bound to ADP-ribose and magnesium
6D3A,X-RAY DIFFRACTION,2.26,45.61,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG4000, 0.1 M sodium acetate pH 4.5, and 0.1 M MgSO4",295.0,2018-04-15,2018-06-20,6D3A,11096.0,4.0,1464.0,814.0,,159.5,1.0,1.60001013785,experimental,31.821425451,0.198472784025,0.167047470217,Structure of human ARH3 D314E bound to ADP-ribose and magnesium
6PDM,X-RAY DIFFRACTION,2.19,43.96,VAPOR DIFFUSION,,"20% PEG3350, 0.2M ammonium nitrate",293.0,2019-06-19,2019-07-31,6PDM,4482.0,1.0,720.0,,,80.49,1.0,2.45,experimental,66.62,0.26,0.216,Crystal structure of Human Protein Arginine Methyltransferase 9 (PRMT9)
4WVT,X-RAY DIFFRACTION,1.67,28.73,"VAPOR DIFFUSION, HANGING DROP",,.98 M Ammonium Sulfate and .1M Ammonium Formate.  Single crystals formed after streak seeding.,291.0,2014-11-07,2015-03-04,4WVT,1571.0,4.0,208.0,165.0,,24.41,2.0,1.96,experimental,22.75,0.2303,0.1739,Crystal structure of XIAP-BIR2 domain complexed with ligand bound
7Q8F,X-RAY DIFFRACTION,2.79,55.99,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of Tris, pH 8",278.0,2021-11-11,2022-11-23,7Q8F,4056.0,4.0,462.0,429.0,6.0,51.63,2.0,1.49,experimental,28.62,0.1969,0.175,Peptide GNYKEAKK in complex with human cathepsin V C25A mutant
7Q8G,X-RAY DIFFRACTION,2.85,56.8,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of TRIS, pH 8",278.0,2021-11-11,2022-11-23,7Q8G,3798.0,4.0,453.0,335.0,6.0,49.62,3.0,2.06,experimental,38.03,0.207,0.1845,Peptide ALAASS in complex with human cathepsin V C25S mutant
7Q8M,X-RAY DIFFRACTION,2.79,55.85,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",288.0,2021-11-11,2022-11-23,7Q8M,3970.0,4.0,462.0,395.0,6.0,51.13,2.0,1.57,experimental,32.73,0.208,0.1851,Peptide KPKKKTK in complex with human cathepsin V C25A mutant
7Q8P,X-RAY DIFFRACTION,2.84,56.72,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",278.0,2021-11-11,2022-11-23,7Q8P,3856.0,4.0,453.0,353.0,6.0,50.2,3.0,1.71,experimental,30.48,0.1991,0.1764,Peptide LLKVAL in complex with human cathepsin V C25S mutant
7QHK,X-RAY DIFFRACTION,2.76,55.39,"VAPOR DIFFUSION, SITTING DROP",,"77 % MPD, 23 % of 60 mM TRIS, pH 8",278.0,2021-12-13,2022-12-21,7QHK,3985.0,4.0,454.0,393.0,6.0,50.64,2.0,1.83,experimental,29.9,0.2,0.1731,Peptide QLRQQE in complex with human cathepsin V C25A mutant
6NZQ,X-RAY DIFFRACTION,2.34,47.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"200 mM ammonium sulfate, and 100 mM Sodium Cacodylate, pH 6.5, 30%(W/V) PEG 5000 (Methyl Ether)",293.0,2019-02-14,2019-07-31,6NZQ,4123.0,2.0,634.0,84.0,,72.03,1.0,2.11,experimental,47.13,0.237,0.197,CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_29 AKA 6-[(5-FLUORO-4-METH YLPYRIDIN-2-YL)AMINO]-4-({2-METHOXY-3-[(PYRIDIN-2-YLMETHYL )CARBAMOYL]PHENYL}AMINO)-N-METHYLPYRIDINE-3-CARBOXAMIDE
7LA5,X-RAY DIFFRACTION,2.93,58.06,"VAPOR DIFFUSION, HANGING DROP",6.0,"20-25%PEG3350, 0.1M ammonium cloride, 0.1M sodium cacodilate pH 6.0",293.0,2021-01-05,2022-01-12,7LA5,4321.0,2.0,542.0,157.0,3.0,60.15,2.0,2.07,experimental,36.873,0.2809,0.2225,Structure of human GGT1 in complex with Lnt1-172 compound.
6J7X,X-RAY DIFFRACTION,4.12,70.12,"VAPOR DIFFUSION, SITTING DROP",,"0.1M NaFormate pH 7, 11% PEG 3350, 30% EG",293.0,2019-01-18,2020-01-22,6J7X,6430.0,3.0,861.0,,,98.3,3.0,2.75,experimental,,0.2507,0.2114,"Complex of GGTaseIII, farnesyl-Ykt6, and GGPP"
8BCB,X-RAY DIFFRACTION,2.43,49.32,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2022-10-15,2023-03-08,8BCB,16261.0,2.0,2010.0,214.0,,231.14,2.0,2.38,experimental,70.79,0.2577,0.2049,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 34
7KG1,X-RAY DIFFRACTION,2.35,47.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M PCTP, pH 7.5, 0.2 M AmSO4, 18-23% PEG3350",295.0,2020-10-15,2021-03-10,7KG1,4299.0,1.0,531.0,303.0,,62.44,1.0,1.65,experimental,35.24,0.1981,0.1741,Structure of human PARG complexed with PARG-002
6F4S,X-RAY DIFFRACTION,2.27,45.88,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M Bis-Tris pH 6.5, 29 % PEG3350, 0.002 M MnCl2, 300 nl sitting drops (sample:well, 1:2 ratio)",298.0,2017-11-30,2018-04-04,6F4S,2700.0,2.0,260.0,354.0,1.0,30.53,2.0,1.461,experimental,23.0,0.152,0.1367,"Human JMJD5 (N308C) in complex with Mn(II), 2OG and RCCD1 (139-143) (complex-4)"
8HLT,X-RAY DIFFRACTION,3.17,61.17,"VAPOR DIFFUSION, HANGING DROP",,"0.05M HEPES pH7.0, 12%PEG 3350, 1% Trptone, 1mM NaN3",289.15,2022-12-01,2023-12-13,8HLT,6302.0,2.0,786.0,,,91.39,1.0,2.8,experimental,,0.2669,0.2092,The co-crystal structure of DYRK2 with YK-2-99B
6GLT,X-RAY DIFFRACTION,1.71,28.18,"VAPOR DIFFUSION, HANGING DROP",4.5,"23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5",293.0,2018-05-23,2019-02-20,6GLT,1397.0,1.0,182.0,153.0,,21.18,1.0,1.596,experimental,,0.213,0.1817,Crystal structure of hMTH1 D120N in the presence of acetate
6SM8,X-RAY DIFFRACTION,2.48,50.45,"VAPOR DIFFUSION, SITTING DROP",6.0,"27% (m/v) PEG6000, 0.1 M MES/NaOH pH 6.0 and 5 mM DTT",277.0,2019-08-21,2020-04-29,6SM8,5173.0,2.0,603.0,255.0,,70.45,2.0,1.85,experimental,45.01,0.241,0.212,Human jak1 kinase domain in complex with inhibitor
7AK1,X-RAY DIFFRACTION,2.54,51.64,"VAPOR DIFFUSION, SITTING DROP",,"12.2 mg/ml, 25mM HEPES pH7.5, 50mM NaCL, 1mM TCEP",294.0,2020-09-29,2020-12-09,7AK1,2863.0,1.0,404.0,44.0,,46.16,1.0,2.507,experimental,51.17,0.2651,0.1962,Human MALT1(329-729) in complex with a chromane urea containing inhibitor
6FYI,X-RAY DIFFRACTION,2.12,41.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG3350, 0.1M HEPES",298.0,2018-03-12,2018-07-18,6FYI,2930.0,1.0,368.0,109.0,,43.64,1.0,2.6,experimental,37.337,0.233,0.2178,X-ray Structure of CLK2-KD(130-496)/TG003 at 2.6A
4X5K,X-RAY DIFFRACTION,2.02,39.0,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium formate, 20% PEG 3350",298.0,2014-12-05,2015-12-16,4X5K,1320.0,2.0,174.0,17.0,,20.66,2.0,2.494,experimental,,0.2552,0.2019,Human NAA50 complex with coenzyme A and an acetylated peptide
4WNV,X-RAY DIFFRACTION,3.22,61.81,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, SODIUM ACETATE, SODIUM CACODYLATE, POTASSIUM PHOSPHATE, SODIUM CHLORIDE, ZINC CHLORIDE, GLYCEROL, BETA-MERCAPTOETHANOL, THIORIDAZINE, HEGA-10, FACIAL AMPHIPHILE 231_CHOL. Quinine was added to the mother liquor after crystallization of the P450 2D6 thiordidazine complex.",298.0,2014-10-14,2015-01-14,4WNV,15064.0,4.0,1916.0,296.0,,219.83,1.0,2.35,experimental,35.4643,0.2382,0.2022,Human Cytochrome P450 2D6 Quinine Complex
5F9E,X-RAY DIFFRACTION,2.57,52.12,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7, 0.2M lithium citrate, and 18% PEG M.W. 3,350, 1% hexanediol",290.0,2015-12-09,2016-05-11,5F9E,5508.0,2.0,706.0,164.0,,84.71,1.0,2,experimental,54.729,0.23333,0.19681,"Structure of Protein Kinase C theta with compound 10: 2,2-dimethyl-7-(2-oxidanylidene-3~{H}-imidazo[4,5-b]pyridin-1-yl)-1-(phenylmethyl)-3~{H}-quinazolin-4-one"
9FET,X-RAY DIFFRACTION,2.25,45.27,"VAPOR DIFFUSION, SITTING DROP",,20% PEG6000 -- 10% ethylene glycol -- 0.1M tris pH 7.5 -- 0.1M calcium chloride,293.15,2024-05-21,2024-09-11,9FET,2458.0,1.0,324.0,10.0,,37.12,1.0,2.4,experimental,61.088,0.2687,0.22183,Crystal Structure of Human Vaccinia-related kinase 2 (VRK-2) bound to JA-47
6DWM,X-RAY DIFFRACTION,3.48,64.63,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium phosphate dibasic, 20% PEG3350, 15% glycerol",277.15,2018-06-26,2018-10-03,6DWM,15397.0,4.0,1964.0,46.0,,229.01,1.0,2.85,experimental,82.47,0.2399,0.2042,Structure of Human Cytochrome P450 1A1 with Bergamottin
4XRY,X-RAY DIFFRACTION,3.16,61.04,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, SODIUM ACETATE, SODIUM CACODYLATE, POTASSIUM PHOSPHATE, SODIUM CHLORIDE, ZINC CHLORIDE, GLYCEROL, BETA-MERCAPTOETHANOL, THIORIDAZINE, HEGA-10, FACIAL AMPHIPHILE 231_CHOL. Beta-secretase inhibitor was added to the mother liquor after crystallization of the P450 2D6 thiordidazine ternary complex.",298.0,2015-01-21,2015-05-20,4XRY,14847.0,4.0,1916.0,182.0,,219.96,1.0,2.5,experimental,55.8,0.2513,0.2076,Human Cytochrome P450 2D6 BACE1 Inhibitor 5 Complex
6JVF,X-RAY DIFFRACTION,2.26,45.52,EVAPORATION,3.75,"30% PEG6 000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVF,2911.0,2.0,312.0,435.0,,35.94,1.0,1.73,experimental,20.2542,0.2174,0.1864,Crystal structure of human apo MTH1
6JVG,X-RAY DIFFRACTION,2.28,46.06,EVAPORATION,3.75,"30% PEG6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVG,2917.0,2.0,312.0,409.0,,36.39,1.0,1.844,experimental,20.9759,0.2425,0.1855,Crystal structure of human MTH1 in complex with compound MI0639
6JVH,X-RAY DIFFRACTION,2.27,45.83,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVH,2806.0,2.0,312.0,298.0,,36.38,1.0,2.04,experimental,22.6096,0.2597,0.1999,Crystal structure of human MTH1 in complex with compound MI0320
6JVJ,X-RAY DIFFRACTION,2.27,45.75,EVAPORATION,3.75,"30% PEG6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVJ,2631.0,2.0,312.0,123.0,,36.41,1.0,2.297,experimental,34.1171,0.2585,0.1899,Crystal structure of human MTH1 in complex with compound MI1006
6JVK,X-RAY DIFFRACTION,2.26,45.5,EVAPORATION,3.75,"30% PEG6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVK,2752.0,2.0,312.0,260.0,,36.17,1.0,2.1,experimental,27.003,0.2499,0.1825,Crystal structure of human MTH1 in complex with compound MI1012
6JVL,X-RAY DIFFRACTION,2.26,45.5,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVL,2756.0,2.0,312.0,260.0,,36.22,1.0,1.9,experimental,28.278,0.2473,0.1933,Crystal structure of human MTH1 in complex with compound MI1014
6JVM,X-RAY DIFFRACTION,2.28,45.94,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVM,2710.0,2.0,312.0,215.0,,36.2,1.0,2.098,experimental,30.4818,0.2569,0.1963,Crystal structure of human MTH1 in complex with compound MI1016
6JVN,X-RAY DIFFRACTION,2.28,45.96,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVN,2752.0,2.0,312.0,246.0,,36.36,1.0,2.102,experimental,22.9514,0.2482,0.1904,Crystal structure of human MTH1 in complex with compound MI1020
6JVO,X-RAY DIFFRACTION,2.26,45.55,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVO,2758.0,2.0,310.0,246.0,,36.18,1.0,1.902,experimental,30.0684,0.248,0.1904,Crystal structure of human MTH1 in complex with compound MI1022
6JVP,X-RAY DIFFRACTION,2.27,45.78,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVP,2661.0,2.0,312.0,151.0,,36.41,1.0,2.206,experimental,30.6769,0.2558,0.1927,Crystal structure of human MTH1 in complex with compound MI1024
6JVQ,X-RAY DIFFRACTION,2.28,46.14,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVQ,2657.0,2.0,312.0,147.0,,36.41,1.0,2.197,experimental,39.1969,0.2663,0.1956,Crystal structure of human MTH1 in complex with compound MI1025
6JVR,X-RAY DIFFRACTION,2.27,45.78,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVR,2581.0,2.0,312.0,90.0,,36.15,1.0,2.295,experimental,43.6264,0.2658,0.1976,Crystal structure of human MTH1 in complex with compound MI1026
6JVS,X-RAY DIFFRACTION,2.28,46.16,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVS,2684.0,2.0,312.0,187.0,,36.23,1.0,2.1,experimental,37.3977,0.2522,0.1994,Crystal structure of human MTH1 in complex with compound MI1029
6JVT,X-RAY DIFFRACTION,2.27,45.84,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVT,2852.0,2.0,312.0,338.0,,36.47,1.0,1.801,experimental,23.1269,0.2301,0.1865,Crystal structure of human MTH1 in complex with compound MI1030
5ANT,X-RAY DIFFRACTION,3.1,60.0,,,,,2015-09-08,2016-03-02,5ANT,4058.0,3.0,525.0,227.0,,61.02,1.0,2,experimental,29.8,0.251,0.214,Potent and selective inhibitors of MTH1 probe its role in cancer cell survival
6HDP,X-RAY DIFFRACTION,2.68,54.03,"VAPOR DIFFUSION, SITTING DROP",,0.15M sodium malate and 20% PEG 3350,277.0,2018-08-18,2019-08-28,6HDP,3498.0,1.0,429.0,164.0,,50.01,1.0,2.3,experimental,65.622,0.23776,0.18365,Human DYRK2 bound to Scorzodihydrostilbene A
8SPD,X-RAY DIFFRACTION,2.22,44.6,"VAPOR DIFFUSION, SITTING DROP",7.4,"PEF 3350, HEPES, lithium sulfate, sodium chloride",296.0,2023-05-02,2023-10-11,8SPD,3522.0,1.0,486.0,,,56.56,1.0,2.9,experimental,130.25,0.2694,0.2215,Cytochrome P450 (CYP) 3A4 crystallized with clotrimazole
4YP3,X-RAY DIFFRACTION,2.11,41.83,"VAPOR DIFFUSION, HANGING DROP",6.0,"NaMES (pH 6.0), polyethylene glycol monomethyl ether 2000, and calcium chloride",291.0,2015-03-12,2015-05-13,4YP3,4046.0,3.0,455.0,406.0,,55.31,1.0,1.89,experimental,,0.2155,0.1685,Mutant Human DNA Polymerase Eta Q38A/R61A Inserting dCTP Opposite an 8-Oxoguanine Lesion
4YR0,X-RAY DIFFRACTION,2.12,42.0,"VAPOR DIFFUSION, HANGING DROP",6.0,"NaMES (pH 6.0), polyethylene glycol monomethyl ether 2000, and calcium chloride",291.0,2015-03-13,2015-05-13,4YR0,4218.0,3.0,455.0,507.0,,55.43,1.0,1.78,experimental,,0.2125,0.1724,Mutant Human DNA Polymerase Eta R61M Inserting dCTP Opposite an 8-Oxoguanine Lesion
7ARW,X-RAY DIFFRACTION,2.34,47.33,"VAPOR DIFFUSION, SITTING DROP",4.5,100 mM ammonium acetate (pH 4.5) and 9% (w/v) PEG10000,292.0,2020-10-26,2021-06-16,7ARW,6057.0,2.0,698.0,759.0,,77.88,1.0,1.31,experimental,27.42,0.182,0.166,Structure of human ARH3 E41A bound to alpha-NAD+ and magnesium
6B5J,X-RAY DIFFRACTION,3.06,59.84,"VAPOR DIFFUSION, HANGING DROP",7.0,"15% tascimate, 0.1M Hepes pH 7, 2% PEG3350",283.0,2017-09-29,2018-04-04,6B5J,8360.0,4.0,1244.0,33.0,,141.25,1.0,2.97,experimental,59.083,0.2579,0.201,"TNNI3K complexed with a 4,6-diaminopyrimidine"
3WUP,X-RAY DIFFRACTION,2.25,45.44,"VAPOR DIFFUSION, SITTING DROP",7.5,"4.3M sodium chloride, 0.1M HEPES , pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-05-01,2015-06-17,3WUP,279.0,1.0,38.0,17.0,,4.61,1.0,1.6,experimental,26.698,0.22554,0.16865,Crystal Structure of the Ubiquitin-Binding Zinc Finger (UBZ) Domain of the Human DNA Polymerase Eta
6H0V,X-RAY DIFFRACTION,2.55,51.83,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, cacodylate, Zinc acetate",293.0,2018-07-10,2019-03-27,6H0V,4158.0,1.0,547.0,74.0,2.0,61.44,1.0,2.2,experimental,42.27,0.2505,0.1947,Crystal structure of tabun surrogate NEDPA inhibited recombinant human bile salt activated lipase
6H18,X-RAY DIFFRACTION,2.49,50.56,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, cacodylate, Zinc Acetate",293.0,2018-07-11,2019-03-27,6H18,4335.0,1.0,547.0,186.0,2.0,62.0,1.0,1.85,experimental,,0.2357,0.1981,Crystal structure of sarin surrogate NIMP inhibited recombinant human bile salt activated lipase
6H19,X-RAY DIFFRACTION,2.48,50.46,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, cacodylate, zinc acetate",293.0,2018-07-11,2019-03-27,6H19,4350.0,1.0,547.0,202.0,2.0,61.97,1.0,1.89,experimental,,0.2296,0.193,Crystal structure of ethyl-paraoxon inhibited recombinant human bile salt activated lipase (aged form)
6H1A,X-RAY DIFFRACTION,2.51,50.98,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, cacodylate, zinc acetate",293.0,2018-07-11,2019-03-27,6H1A,4339.0,1.0,547.0,196.0,2.0,61.98,1.0,1.75,experimental,,0.2244,0.194,Crystal structure of VX surrogate NEMP inhibited recombinant human bile salt activated lipase
6FUT,X-RAY DIFFRACTION,3.06,59.74,"VAPOR DIFFUSION, SITTING DROP",,"22-25% PEG3350, 100 mM HEPES pH 7.5",293.0,2018-02-27,2018-06-06,6FUT,2148.0,1.0,232.0,318.0,4.0,25.21,1.0,1.5,experimental,14.489,0.18382,0.15779,"Complement factor D in complex with the inhibitor (S)-3'-(aminomethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-[1,1'-biphenyl]-3-carboxamide"
8EVF,X-RAY DIFFRACTION,2.13,42.34,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES PH 5.5, 5mM calcium chloride, 15-22% PEG 2000 MME",291.0,2022-10-20,2023-08-02,8EVF,3651.0,3.0,455.0,23.0,,55.35,1.0,2.87,experimental,,0.2512,0.2042,HUMAN DNA POLYMERASE ETA EXTENSION COMPLEX WITH AN INCOMING DCTP
7EDP,X-RAY DIFFRACTION,3.29,62.62,"VAPOR DIFFUSION, HANGING DROP",,25% Ethylene glycol,293.0,2021-03-16,2021-04-28,7EDP,687.0,2.0,83.0,34.0,,9.72,2.0,2.2,experimental,57.0047,0.2682,0.2213,Crystal structure of AF10-DOT1L complex
5GHO,X-RAY DIFFRACTION,1.88,34.4,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sodium citrate, Sodium cacodylate, NaCl",293.0,2016-06-20,2017-01-04,5GHO,3305.0,2.0,312.0,449.0,,36.66,1.0,1.191,experimental,,0.1772,0.149,Crystal structure of human MTH1(G2K/D120A mutant) in complex with 8-oxo-dGTP
6F1X,X-RAY DIFFRACTION,2.29,46.26,"VAPOR DIFFUSION, SITTING DROP",3.6,"26% PEG6000, 0.1M Na-acetate pH 3.6, 0.22M LiSO4",277.0,2017-11-23,2018-03-07,6F1X,2752.0,2.0,318.0,125.0,,37.97,1.0,1.9,experimental,28.308,0.24483,0.19409,Complex between MTH1 and compound 7 (a 7-azaindole-2-amide derivative)
6F22,X-RAY DIFFRACTION,2.25,45.43,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG4K, 0.24M AmSO4, 12.5% glycerol",277.0,2017-11-23,2018-03-07,6F22,2841.0,2.0,318.0,176.0,,38.03,1.0,1.55,experimental,18.783,0.20546,0.16941,"Complex between MTH1 and compound 29 (a 4-amino-2,7-diazaindole derivative)"
5NGT,X-RAY DIFFRACTION,2.01,38.83,"VAPOR DIFFUSION, SITTING DROP",,"5 mmol/L compound and 6 mmol/L MgCl2 were added to MTH1. Sitting drop vapor diffusion experiments at 293K were performed, and MTH1 (9.34 mg/mL) was mixed with reservoir solution (32% (w/v) PEG3350, 0.1 mol/L Sodium Acetate pH 4.0 and 0.2 mol/L LiSO4) in a 1:1 ratio.",293.0,2017-03-20,2017-10-04,5NGT,1393.0,1.0,159.0,101.0,,18.66,1.0,1.54,experimental,18.577,0.22031,0.18413,"Crystal structure of human MTH1 in complex with inhibitor 7-(furan-2-yl)-5-methyl-1,3-benzoxazol-2-amine"
8UJT,X-RAY DIFFRACTION,2.13,42.26,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1M MES pH 6.0, 5mM magnesium chloride, 22% PEG MME 2000",291.0,2023-10-11,2024-03-20,8UJT,3851.0,3.0,455.0,87.0,,55.15,1.0,2.31,experimental,,0.2434,0.1778,Crystal structure of human polymerase eta with incoming dAMPnPP nucleotide opposite urea lesion
8UJX,X-RAY DIFFRACTION,2.11,41.7,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 22% PEG  MME 2000",291.0,2023-10-11,2024-03-20,8UJX,3986.0,3.0,455.0,169.0,,55.17,1.0,2.17,experimental,,0.2288,0.1714,Crystal structure of human polymerase eta with incoming dGMPnPP nucleotide opposite urea lesion
8P9B,X-RAY DIFFRACTION,3.79,67.59,"VAPOR DIFFUSION, SITTING DROP",8.0,"24% (w/v) polyacrylic acid 5100, 2% (v/v) 2-Methyl-2,4-pentanediol, 100mM HEPES, pH 8.0",292.0,2023-06-05,2024-06-12,8P9B,2047.0,1.0,316.0,,,36.08,1.0,2.59,experimental,88.708,0.2636,0.2081,Crystal Structure of Mnk2-D228G in complex with Tinodasertib
7XF6,X-RAY DIFFRACTION,1.71,27.96,BATCH MODE,,"Na-acetate, PEG 6K, NaCl",277.5,2022-04-01,2022-04-13,7XF6,1296.0,1.0,130.0,263.0,4.0,14.78,1.0,1.3,experimental,14.9266,0.171,0.1513,Crystal Structure of Human Lysozyme
5UWM,X-RAY DIFFRACTION,2.22,44.64,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M lithium sulfate 0.1 M Tris:HCl pH 8.5, 30% polyethylene glycol 4000",295.0,2017-02-21,2017-07-12,5UWM,3011.0,4.0,354.0,353.0,,41.28,2.0,1.62,experimental,,0.1779,0.1288,Matrix metalloproteinase-13 complexed with selective inhibitor compound (R)-17a
4XQ8,X-RAY DIFFRACTION,2.58,52.27,VAPOR DIFFUSION,,"0.1 M Lithium Sulfate monohydrate, 0.1 M HEPES-Sodium, 0.1 M Potassium Sodium Tartrate",277.0,2015-01-19,2016-02-24,4XQ8,4236.0,4.0,680.0,99.0,1.0,78.83,1.0,2.798,experimental,,0.2399,0.1817,Human DNA polymerase lambda- MgdATP binary complex and complex with 6 paired DNA
5CJ7,X-RAY DIFFRACTION,2.59,52.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Lithium Sulfate monohydrate, 0.1M HEPES-Sodium, 0.1M Potassium Sodium Tartrate",277.0,2015-07-14,2016-02-24,5CJ7,4128.0,4.0,680.0,10.0,1.0,78.74,1.0,2.901,experimental,,0.258,0.2086,Human DNA polymerase lambda L431A mutant- MgdTTP binary and complex with 6 paired DNA
5CP2,X-RAY DIFFRACTION,2.57,52.19,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Lithium Sulfate monohydrate, 0.1M HEPES-Sodium, 0.1M Potassium Sodium Tartrate",277.0,2015-07-21,2016-02-24,5CP2,4326.0,4.0,680.0,278.0,1.0,78.33,1.0,2.36,experimental,,0.238,0.206,Human DNA polymerase lambda L431A mutant- Apoenzyme and complex with 6 paired DNA
5CR0,X-RAY DIFFRACTION,2.63,53.22,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Lithium Sulfate monohydrate, 0.1M HEPES-Sodium, 0.1M Potassium Sodium Tartrate",277.0,2015-07-22,2016-02-24,5CR0,4127.0,4.0,680.0,10.0,1.0,78.72,1.0,2.75,experimental,,0.2815,0.2427,Human DNA polymerase lambda L431A mutant- MgdCTP binary and complex with 6 paired DNA
5DDM,X-RAY DIFFRACTION,2.55,51.76,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Lithium Sulfate monohydrate, 0.1M HEPES-Sodium, 0.1M Potassium Sodium Tartrate",277.0,2015-08-25,2016-02-24,5DDM,4167.0,4.0,682.0,69.0,1.0,78.7,1.0,2.802,experimental,41.23,0.2391,0.2013,Human DNA polymerase lambda- Apoenzyme and complex with 6 paired DNA
7WXX,X-RAY DIFFRACTION,2.29,46.35,VAPOR DIFFUSION,6.0,"20% w/v Polyethylene glycol 6000, 100mM MES pH6.0, 200mM Lithium chloride",293.0,2022-02-15,2022-10-05,7WXX,1520.0,2.0,182.0,148.0,,20.32,2.0,1.5,experimental,25.12,0.20343,0.17018,Crystal structure of human MMP-7 in complex with inhibitor
8V7A,X-RAY DIFFRACTION,2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7A,4266.0,3.0,455.0,401.0,,55.53,1.0,1.95,experimental,,0.2182,0.1711,Human DNA polymerase eta-DNA-dT primer dCTP insertion ternary complex at pH7.0 (K+ MES) with 1 Ca2+ ion
8V7B,X-RAY DIFFRACTION,2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7B,4268.0,3.0,455.0,397.0,,55.55,1.0,1.9,experimental,,0.2146,0.1765,Human DNA polymerase eta-DNA-dT primer araCTP insertion ternary complex at pH7.0 (K+ MES) with 1 Ca2+ ion
8V7C,X-RAY DIFFRACTION,2.12,41.91,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7C,4285.0,3.0,455.0,404.0,,55.57,1.0,1.79,experimental,,0.2071,0.1785,Human DNA polymerase eta-DNA-dT primer gemCTP insertion ternary complex at pH7.0 (K+ MES) with 1 Ca2+ ion
8V7D,X-RAY DIFFRACTION,2.11,41.62,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7D,4288.0,3.0,455.0,401.0,,55.55,1.0,1.95,experimental,,0.2299,0.1822,Human DNA polymerase eta-DNA-dT primer rCTP insertion ternary complex at pH7.0 (K+ MES) with 1 Ca2+ ion
8V7E,X-RAY DIFFRACTION,2.11,41.79,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 2000MME, 0.1 M MES",298.0,2023-12-04,2024-05-15,8V7E,4213.0,3.0,455.0,364.0,,55.42,1.0,1.82,experimental,,0.2038,0.172,Human DNA polymerase eta-DNA-araC-ended primer-dAMPNPP ternary complex with Mg2+
6FDY,X-RAY DIFFRACTION,2.81,56.26,"VAPOR DIFFUSION, SITTING DROP",8.5,0.1 M Tris pH 8.5; 0.2 M sodium citrate; 30% PEG400,277.0,2017-12-27,2018-08-01,6FDY,2247.0,1.0,276.0,127.0,,33.0,1.0,1.7,experimental,24.039,0.23871,0.20521,Unc-51-Like Kinase 3 (ULK3) In Complex With Bosutinib
7L25,X-RAY DIFFRACTION,2.43,49.49,VAPOR DIFFUSION,,NO DISCLOSED,293.0,2020-12-16,2021-03-17,7L25,5043.0,2.0,578.0,394.0,2.0,65.95,1.0,1.85,experimental,39.405,0.2266,0.1855,HPK1 IN COMPLEX WITH COMPOUND 18
7BLT,X-RAY DIFFRACTION,1.94,36.5,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296.0,2021-01-19,2022-03-02,7BLT,2954.0,1.0,383.0,123.0,6.0,44.53,1.0,1.2,experimental,21.2673,0.211,0.1993,Notum_Maybridge_4
7BN8,X-RAY DIFFRACTION,1.99,38.29,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296.0,2021-01-21,2022-03-02,7BN8,2852.0,1.0,383.0,75.0,7.0,44.4,1.0,1.78,experimental,28.6214,0.2325,0.2003,"Notum fragment_3 (4H,5H-naphtho[1,2-b]thiophene-2-carboxylic acid)"
5EWG,X-RAY DIFFRACTION,2.11,41.7,"VAPOR DIFFUSION, HANGING DROP",6.0,"NaMES (pH 6.0), polyethylene glycol monomethyl ether 2000, and calcium chloride",291.0,2015-11-20,2016-01-13,5EWG,4095.0,3.0,455.0,374.0,,55.27,1.0,1.75,experimental,,0.215,0.1781,Ternary complex of human DNA polymerase eta inserting rATP opposite an 8-Oxodeoxyguanosine Lesion
7KG0,X-RAY DIFFRACTION,2.24,45.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M PCTP, pH 7.5, 0.2 M AmSO4, 18-23% PEG3350",295.0,2020-10-15,2021-03-10,7KG0,4438.0,1.0,531.0,432.0,,61.88,1.0,1.66,experimental,29.54,0.219,0.1846,Structure of human PARG complexed with PARG-131
7Q40,X-RAY DIFFRACTION,3.05,59.73,"VAPOR DIFFUSION, HANGING DROP",8.0,"hanging drop
20% PEG 3350
0.18M tris amonium citrate",293.15,2021-10-29,2022-11-16,7Q40,8623.0,3.0,1215.0,237.0,,130.04,1.0,2.35002226075,experimental,56.9293356942,0.230322144529,0.178924037543,Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2
7AHX,X-RAY DIFFRACTION,3.19,61.5,"VAPOR DIFFUSION, SITTING DROP",,"16-19.5% v/v PEG Smear Broad, 
0.2 M (NH4)2SO4, 
0.1 M Tris-HCl",277.0,2020-09-25,2021-01-13,7AHX,17778.0,8.0,2064.0,108.0,,258.86,2.0,2.73,experimental,77.03,0.2536,0.2141,HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND D-ASPARTATE TENOFOVIR WITH BOUND MANGANESE
7AIF,X-RAY DIFFRACTION,3.19,61.5,"VAPOR DIFFUSION, SITTING DROP",,"16-19.5% v/v PEG Smear Broad, 
0.2 M (NH4)2SO4, 
0.1 M Tris-HCl",277.0,2020-09-27,2021-01-13,7AIF,17898.0,8.0,2064.0,226.0,,258.89,2.0,2.75,experimental,85.06,0.2494,0.2183,HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-GLUTAMATE TENOFOVIR WITH BOUND MANGANESE
7AIG,X-RAY DIFFRACTION,3.19,61.5,"VAPOR DIFFUSION, SITTING DROP",,"16-19.5% v/v PEG Smear Broad, 
0.2 M (NH4)2SO4, 
0.1 M Tris-HCl",277.0,2020-09-27,2021-01-13,7AIG,17692.0,8.0,2064.0,52.0,,258.26,2.0,2.95,experimental,106.17,0.257,0.2132,HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-GLUTAMATE TENOFOVIR
7AII,X-RAY DIFFRACTION,3.19,61.5,"VAPOR DIFFUSION, SITTING DROP",,"16-19.5% v/v PEG Smear Broad, 
0.2 M (NH4)2SO4, 
0.1 M Tris-HCl",277.0,2020-09-27,2021-01-13,7AII,17785.0,8.0,2064.0,115.0,,258.9,2.0,2.62,experimental,81.48,0.255,0.2226,HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-METHIONINE TENOFOVIR WITH BOUND MANGANESE
7AIJ,X-RAY DIFFRACTION,3.19,61.5,"VAPOR DIFFUSION, SITTING DROP",,"16-19.5% v/v PEG Smear Broad, 
0.2 M (NH4)2SO4, 
0.1 M Tris-HCl",277.0,2020-09-27,2021-01-13,7AIJ,17687.0,8.0,2064.0,65.0,,258.26,2.0,2.95,experimental,114.08,0.2634,0.226,HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-METHIONINE TENOFOVIR
7OTK,X-RAY DIFFRACTION,3.17,61.19,"VAPOR DIFFUSION, SITTING DROP",,"16-19% V/V PEG SMEAR BROAD, 0.2 M (NH4)2SO4, 0.1 M TRIS-HCL",277.0,2021-06-10,2021-12-08,7OTK,17638.0,8.0,2064.0,3.0,,258.19,2.0,2.95,experimental,118.6106,0.2707,0.2265,HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND INHIBITOR RMC-233
7ORF,X-RAY DIFFRACTION,2.5,50.86,"VAPOR DIFFUSION, SITTING DROP",6.0,"34% PEG400 and 0.1 M MES, pH 6.0",277.15,2021-06-05,2021-07-21,7ORF,3352.0,1.0,365.0,347.0,,44.16,1.0,1.7,experimental,25.265,0.2046,0.167,Crystal structure of JNK3 in complex with FMU-001-367 (compound 1)
4Y2E,X-RAY DIFFRACTION,2.3,46.8,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes,MOPS pH 7.5, 0.009 nitrate-sulfate-phosphate mixture, 37.5% v/v MPD-PEG1000-PEG3350; Morpheus Crystallization screen #32",292.0,2015-02-09,2015-06-03,4Y2E,5593.0,4.0,596.0,744.0,,67.42,1.0,1.67,experimental,9.848,0.1888,0.15533,Crystal structure of the catalytic domain of human dual-specificity phosphatase 7 (C232S)
6E44,X-RAY DIFFRACTION,2.51,51.04,EVAPORATION,6.2,"0.1 M phosphate (pH 6.2), and 15% (w/v) PEG3350",298.0,2018-07-16,2018-11-14,6E44,12847.0,4.0,1620.0,938.0,,183.95,1.0,1.903,experimental,35.3009,0.2347,0.1941,"CRYSTAL STRUCTURE OF HUMAN INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) free enzyme in the ferric state"
6LH4,X-RAY DIFFRACTION,2.78,55.82,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Sodium thiocyanate, 20% PEG 3350",291.1,2019-12-06,2020-12-09,6LH4,7964.0,4.0,940.0,416.0,,107.68,1.0,1.999,experimental,47.8011,0.2848,0.2401,Crystal structural of MacroD1-ADPr complex
7D2C,X-RAY DIFFRACTION,1.77,30.56,"VAPOR DIFFUSION, SITTING DROP",,"0.2M NaCl, 0.1M Tris pH8.5, 25% PEG3350",293.0,2020-09-16,2020-09-30,7D2C,1489.0,1.0,197.0,108.0,,21.83,1.0,1.56,experimental,12.332,0.1969,0.1752,The Crystal Structure of human PARP14 from Biortus.
7KX6,X-RAY DIFFRACTION,2.51,50.99,EVAPORATION,7.25,"PEG400, ammonium sulfphate, Hepes",298.0,2020-12-03,2021-09-22,7KX6,4083.0,2.0,560.0,92.0,,63.52,1.0,2.5,experimental,37.7305,0.2251,0.1924,Crystal structure of DCLK1-KD in complex with XMD8-85
5YKP,X-RAY DIFFRACTION,2.56,51.88,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1M Hepes pH-6.0, 19% PEG MME 2000",298.0,2017-10-15,2018-10-17,5YKP,2691.0,1.0,305.0,212.0,,34.77,1.0,1.68,experimental,28.03,0.2117,0.1751,Human methionine aminopeptidase type 1b (F309M mutant) in complex with ovalicin
7M3Q,X-RAY DIFFRACTION,3.11,60.47,"VAPOR DIFFUSION, SITTING DROP",6.0,1.5 M Ammonium Sulphate and 100 mM MES pH 6.0. Trypsin was added to the protein complex at a final concentration of 10 microgram per mL,298.0,2021-03-18,2021-04-21,7M3Q,3738.0,2.0,485.0,54.0,,57.44,2.0,2.5,experimental,70.6,0.2349,0.2029,Structure of the Smurf2 HECT Domain with a High Affinity Ubiquitin Variant (UbV)
5SJH,X-RAY DIFFRACTION,2.68,54.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJH,11045.0,4.0,1372.0,732.0,,157.71,1.0,2.1,experimental,41.92,0.2036,0.1774,Crystal Structure of human phosphodiesterase 10
7ZML,X-RAY DIFFRACTION,2.68,54.13,"VAPOR DIFFUSION, SITTING DROP",5.9,0.1M bis-tris pH 5.9 -- 0.1M lithium sulfate -- 30% PEG3350,293.0,2022-04-19,2022-06-22,7ZML,17730.0,8.0,2308.0,19.0,,256.19,2.0,2.79,experimental,103.124,0.261,0.2238,Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G1-001
7ZMM,X-RAY DIFFRACTION,2.68,54.13,"VAPOR DIFFUSION, SITTING DROP",6.5,0.2M sodium chloride -- 25% PEG3350 -- 0.1M bis-tris pH 6.5,293.0,2022-04-19,2022-06-22,7ZMM,17749.0,8.0,2308.0,95.0,2.0,255.87,2.0,2.5,experimental,79.866,0.2806,0.2356,Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G2-001
7ZMV,X-RAY DIFFRACTION,3.23,61.89,"VAPOR DIFFUSION, SITTING DROP",7.5,0.2M ammonium sulfate -- 25% PEG3350 -- 0.1M HEPES pH 7.5,293.0,2022-04-19,2022-06-22,7ZMV,18647.0,8.0,2288.0,1028.0,2.0,253.9,2.0,2.002,experimental,48.403,0.2747,0.2431,Crystal structure of human RECQL5 helicase APO form in complex with engineered nanobody (Gluebody) G5-006
6AK6,X-RAY DIFFRACTION,2.47,50.14,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-08-30,2019-05-29,6AK6,3079.0,1.0,356.0,309.0,,41.32,1.0,1.75,experimental,22.37,0.22897,0.20654,Binary Complex of Human DNA Polymerase Mu with MnCTP
6IPJ,X-RAY DIFFRACTION,2.45,49.75,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-11-03,2019-05-29,6IPJ,3020.0,1.0,356.0,246.0,,41.03,1.0,1.98,experimental,27.72,0.23955,0.19767,Binary Complex of Human DNA Polymerase Mu with MndTTP
6IPK,X-RAY DIFFRACTION,2.35,47.6,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-11-03,2019-05-29,6IPK,2734.0,1.0,356.0,94.0,,41.5,1.0,2.15,experimental,54.307,0.25623,0.21292,Binary Complex of Human DNA Polymerase Mu with Mn8oxodGTP
4WFS,X-RAY DIFFRACTION,3.06,58.85,"VAPOR DIFFUSION, HANGING DROP",,"Protein 8 mg/mL in Tris 25 mM pH 8.0 NaCl 150 mM
Precipitant: Ammonium sulfate 2.2 M, isopropanol 2% v/v",292.0,2014-09-17,2015-10-07,4WFS,2445.0,1.0,327.0,28.0,,37.68,1.0,2.68,experimental,53.9,0.2217,0.1973,Crystal Structure of tRNA-dihydrouridine(20) synthase catalytic domain
6HEI,X-RAY DIFFRACTION,1.97,37.5,"VAPOR DIFFUSION, SITTING DROP",8.0,"22% (w/v) PEG 3350, 300 mM potassium sodium tartrate",291.0,2018-08-20,2019-03-27,6HEI,3693.0,2.0,460.0,276.0,,53.36,2.0,1.64,experimental,,0.2138,0.1857,Structure of the catalytic domain of USP28 (insertion deleted) bound to Ubiquitin-PA
7OZ2,X-RAY DIFFRACTION,3.04,59.6,"VAPOR DIFFUSION, SITTING DROP",,"11-12% v/v PEG Smear Broad, 10% w/v sucrose, 50 mM PIPES-NaOH pH 6.5, 0.1 M (NH4)2SO4, 5 mM MgCl2, 5 mM CdCl2",277.0,2021-06-25,2021-12-08,7OZ2,17868.0,8.0,2098.0,160.0,,265.38,2.0,2.85,experimental,63.18,0.257,0.217,Crystal structure of HIV-1 reverse transcriptase with a double stranded DNA showing a transient P-pocket
4XDO,X-RAY DIFFRACTION,2.62,52.99,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.8 M Lithium chloride, 0.1 M Tris pH 8.5, 28 % w/v PEG 4000",291.15,2014-12-19,2015-03-25,4XDO,6046.0,2.0,676.0,377.0,,79.91,1.0,1.97,experimental,24.476,0.254,0.2004,Crystal structure of human KDM4C catalytic domain with OGA
5Y9L,X-RAY DIFFRACTION,2.52,51.12,"VAPOR DIFFUSION, SITTING DROP",,"PEG1000, PEG3350, 2-methyl-2,4-pentanediol, sodium nitrate, sodium hydrogen phosphate, ammonium sulfate, bicine/trizma buffer",293.0,2017-08-25,2017-11-29,5Y9L,1809.0,1.0,224.0,67.0,6.0,25.02,1.0,2.15,experimental,23.168,0.27555,0.20823,"Human kallikrein 7 in complex with 1,3,6-trisubstituted 1,4-diazepane-7-one"
5YJK,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, SITTING DROP",,"PEG1000, PEG3350, 2-methyl-2,4-pentanediol, sodium nitrate, sodium hydrogen phosphate, ammonium sulfate, bicine/trizma buffer",293.0,2017-10-11,2017-12-06,5YJK,1781.0,1.0,224.0,32.0,6.0,25.09,1.0,2.4,experimental,20.916,0.24243,0.20522,"Human kallikrein 7 in complex with 1,4-diazepane-7-one 1-acetamide derivative"
6BFW,X-RAY DIFFRACTION,2.56,52.05,"VAPOR DIFFUSION, HANGING DROP",,"17% PEG 8000, 0.2M ammonium sulfate, 0.1M sodium cacodylate, pH 7.4",277.0,2017-10-27,2017-11-15,6BFW,7138.0,2.0,884.0,817.0,6.0,99.07,1.0,1.84,experimental,21.31,0.206,0.184,BACE crystal structure with hydroxy morpholine inhibitor
6EQ9,X-RAY DIFFRACTION,2.25,45.36,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Bis-Tris pH 5.5, 200 mM NaCl, 29% PEG 3350, 1 mM AMP-PCP, 0.4 mM Zwittergent 3-14, 10% Ethylene glycol",293.0,2017-10-12,2018-08-08,6EQ9,5922.0,2.0,734.0,391.0,,86.37,1.0,1.83,experimental,35.698,0.25179,0.20622,Crystal structure of JNK3 in complex with AMP-PCP
5MHL,X-RAY DIFFRACTION,2.73,54.87,"VAPOR DIFFUSION, SITTING DROP",6.5,"170 mM ammonium sulfate, 85 mM sodium cacodylate, 25.5 % PEG8000, 15 % glycerol",291.0,2016-11-24,2017-12-20,5MHL,11313.0,4.0,1494.0,368.0,,171.42,2.0,2.4,experimental,,0.2305,0.1717,FXIIIa in complex with the inhibitor Mi0621
5MHM,X-RAY DIFFRACTION,2.7,54.4,"VAPOR DIFFUSION, HANGING DROP",6.5,"170 mM ammonium sulfate, 85 mM sodium cacodylate, 25.5 % PEG8000, 15 % glycerol",291.0,2016-11-24,2017-12-20,5MHM,11759.0,4.0,1492.0,841.0,,171.63,2.0,2.12,experimental,,0.213,0.17,FXIIIa in complex with the inhibitor ZED1630
5MHN,X-RAY DIFFRACTION,2.66,53.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"170 mM ammonium sulfate, 85 mM sodium cacodylate, 25.5 % PEG8000, 15 % glycerol",291.0,2016-11-24,2017-12-20,5MHN,10991.0,4.0,1492.0,193.0,,171.59,2.0,2.48,experimental,,0.238,0.1796,FXIIIa in complex with the inhibitor ZED2360
7CO9,X-RAY DIFFRACTION,1.94,36.49,VAPOR DIFFUSION,8.0,"TRIS-HCL, PEG 3350",298.0,2020-08-04,2021-06-30,7CO9,3589.0,4.0,499.0,379.0,,59.5,1.0,1.599,experimental,26.8194,0.1962,0.1707,Ternary complex of DNA polymerase Mu with 1-nt gapped DNA (T:dGMPNPP) and Mg
7COA,X-RAY DIFFRACTION,1.93,36.37,VAPOR DIFFUSION,8.0,"TRIS-HCL, PEG 3350",298.0,2020-08-04,2021-06-30,7COA,3544.0,4.0,499.0,361.0,,59.57,1.0,1.698,experimental,26.8868,0.1991,0.175,Ternary complex of DNA polymerase Mu with 1-nt gapped DNA (T:dGMPNPP) and Mn
8XQD,X-RAY DIFFRACTION,2.25,40.03,"VAPOR DIFFUSION, SITTING DROP",,"0.2M NaSCN, 20% PEG 3350",293.0,2024-01-05,2024-03-06,8XQD,4840.0,2.0,626.0,220.0,,72.18,1.0,2.55,experimental,33.619,0.27749,0.21522,The Crystal Structure of PTPRG from Biortus.
7PRM,X-RAY DIFFRACTION,2.55,51.71,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES 6.5 pH 
6 %w/v PEG MME 5000
12 %v/v iso-propanol",293.0,2021-09-22,2022-02-16,7PRM,2684.0,1.0,323.0,314.0,,36.02,1.0,1.65,experimental,46.48,0.2378,0.2064,CRYSTAL STRUCTURE OF HUMAN MONOGLYCERIDE LIPASE WITH COMPOUND 13
7ZPG,X-RAY DIFFRACTION,2.78,55.73,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES 6.5 pH
10 %w/v PEG MME 5K
12 %v/v iso-propanol",294.0,2022-04-27,2022-09-21,7ZPG,2722.0,1.0,323.0,382.0,,35.93,1.0,1.16,experimental,20.23,0.1845,0.1765,CRYSTAL STRUCTURE OF HUMAN MONOGLYCERIDE LIPASE WITH LIGAND
4U9W,X-RAY DIFFRACTION,2.44,49.51,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% PEG 3350, 200 mM sodium malonate",298.0,2014-08-06,2015-01-28,4U9W,7122.0,8.0,852.0,429.0,,101.44,2.0,2.49,experimental,26.59,0.223,0.176,Crystal Structure of NatD bound to H4/H2A peptide and CoA
6HKM,X-RAY DIFFRACTION,3.01,59.21,"VAPOR DIFFUSION, SITTING DROP",,"11% PEG 4000, 100mM MgCl2, 160mM sodium formate, 100mM MES pH 6.75, 10mM Tris pH 8.5",293.0,2018-09-07,2019-02-27,6HKM,2711.0,1.0,347.0,33.0,,40.19,1.0,2.47,experimental,34.414,0.28,0.2182,Crystal structure of Compound 1 with ERK5
6HKN,X-RAY DIFFRACTION,3.18,61.29,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 4000, 100mM MgCl2, 180mM Sodium formate, 100 mM MES pH 6.5, 10mM Tris pH 8.0",293.0,2018-09-07,2019-02-27,6HKN,2849.0,1.0,340.0,98.0,,39.47,1.0,2.33,experimental,34.764,0.2491,0.2068,Crystal structure of Compound 35 with ERK5
8PPF,X-RAY DIFFRACTION,2.71,54.72,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.81 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 18 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking 2h with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 5 mM ligand, 3 mM AMP-PNP and 3 mM MgCl2.",291.0,2023-07-07,2024-02-28,8PPF,4916.0,2.0,558.0,364.0,,66.18,1.0,1.85,experimental,42.004,0.22779,0.19563,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with beta-D-glucopyranosyl 1,3,4-trisphosphate/AMP-PNP/Mg"
7QRA,X-RAY DIFFRACTION,2.48,50.44,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.1M sodium sulfate, 0.1M citrate 5.0",,2022-01-10,2023-01-18,7QRA,9801.0,4.0,1184.0,333.0,,140.72,1.0,2.4,experimental,32.3,0.2816,0.2385,Crystal structure of CK1 delta in complex with VN725
6SUC,X-RAY DIFFRACTION,2.69,54.21,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M BICINE, pH 9, 1 M lithium chloride, 20% (w/v) polyethylene glycol 6000",293.0,2019-09-13,2020-07-08,6SUC,2047.0,1.0,297.0,94.0,1.0,34.03,1.0,1.97,experimental,37.35,0.2452,0.2139,"Human PTPRU D1 domain, oxidised form"
4RSV,X-RAY DIFFRACTION,2.22,44.68,,7.5,"0.3-0.5M NaCl   
19-23% PEG 3350   
10.52-11.35 mg/ml, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2014-11-11,2016-02-24,4RSV,707.0,1.0,102.0,1.0,,11.42,1.0,2.41,experimental,,0.28,0.26,Human Obscurin Ig58 Domain
6FX4,X-RAY DIFFRACTION,2.51,51.07,"VAPOR DIFFUSION, SITTING DROP",6.5,"1.36M tri-Sodium citrat pH6.5, 15% (v/v) Glycerol",293.0,2018-03-08,2018-07-11,6FX4,3203.0,4.0,396.0,84.0,2.0,45.32,2.0,2.5,experimental,39.1772,0.239,0.1873,Disulfide between E3 HECT ligase Smurf2 and Ubiquitin G76C
7AKF,X-RAY DIFFRACTION,2.67,53.89,"VAPOR DIFFUSION, SITTING DROP",8.5,"25% PEG 4000, 0.1M TRIS buffer pH 8.5, 0.1M Li sulphate",293.0,2020-09-30,2021-05-26,7AKF,3303.0,1.0,429.0,88.0,,49.89,1.0,2.6,experimental,46.712,0.2587,0.1884,Structure of DYRK2 in complex with compound 50
7AKH,X-RAY DIFFRACTION,2.68,54.17,"VAPOR DIFFUSION, SITTING DROP",8.5,"25% PEG 4k, 0.1M Tris buffer pH 8.5, 0.1M Li sulphate",293.0,2020-10-01,2021-05-26,7AKH,3237.0,1.0,429.0,22.0,,50.09,1.0,2.85,experimental,69.943,0.2448,0.1851,Structure of DYRK2 in complex with compound 58
7DH9,X-RAY DIFFRACTION,3.65,66.27,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dehydrate, 0.01 M sodium borate, pH 7.5-9.5",291.0,2020-11-13,2021-11-17,7DH9,2873.0,1.0,324.0,206.0,,38.07,1.0,2.194,experimental,37.0451,0.2176,0.1879,The co-crystal structure of DYRK2 with a small molecule inhibitor 7
7DHC,X-RAY DIFFRACTION,3.63,66.16,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dehydrate, 0.01 M sodium borate, pH 7.5-9.5",291.0,2020-11-13,2021-11-17,7DHC,2715.0,1.0,324.0,47.0,,38.09,1.0,2.592,experimental,42.3104,0.2175,0.1642,The co-crystal structure of DYRK2 with a small molecule inhibitor 10
7DHH,X-RAY DIFFRACTION,3.67,66.53,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dehydrate, 0.01 M sodium borate, pH 7.5-9.5",291.0,2020-11-14,2021-11-17,7DHH,2686.0,1.0,324.0,21.0,,38.05,1.0,2.486,experimental,66.4537,0.2453,0.189,The co-crystal structure of DYRK2 with a small molecule inhibitor 19
7DHK,X-RAY DIFFRACTION,3.58,65.68,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dehydrate, 0.01 M sodium borate, pH 7.5-9.5",291.0,2020-11-16,2021-11-17,7DHK,2740.0,1.0,324.0,69.0,,38.12,1.0,2.341,experimental,42.7477,0.2574,0.1954,The co-crystal structure of DYRK2 with a small molecule inhibitor 13
7DHN,X-RAY DIFFRACTION,3.63,66.14,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dehydrate, 0.01M sodium borate, pH 7.5-9.5",291.0,2020-11-16,2021-11-17,7DHN,2704.0,1.0,324.0,40.0,,38.07,1.0,2.38,experimental,66.7205,0.2232,0.1853,The co-crystal structure of DYRK2 with a small molecule inhibitor 20
7DHV,X-RAY DIFFRACTION,3.63,66.11,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dehydrate, 0.01 M sodium borate, pH 7.5-9.5",291.0,2020-11-17,2021-11-17,7DHV,2723.0,1.0,327.0,32.0,,38.41,1.0,2.679,experimental,51.3565,0.2495,0.1898,The co-crystal structure of DYRK2 with a small molecule inhibitor 8
7DL6,X-RAY DIFFRACTION,3.65,66.34,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dehydrate, 0.01 M sodium borate, pH7.5-9.5",291.0,2020-11-26,2021-12-01,7DL6,2721.0,1.0,324.0,55.0,,38.06,1.0,2.648,experimental,46.2211,0.2322,0.1711,The co-crystal structure of DYRK2 with a small molecule inhibitor 18
4YO6,X-RAY DIFFRACTION,2.63,53.22,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289.0,2015-03-11,2015-05-20,4YO6,9319.0,4.0,1204.0,203.0,,137.42,1.0,2.32,experimental,56.18,0.2249,0.1973,Irak4-inhibitor co-structure
4YP8,X-RAY DIFFRACTION,2.65,53.57,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289.0,2015-03-12,2015-05-20,4YP8,9177.0,4.0,1204.0,63.0,,137.78,1.0,2.641,experimental,72.36,0.2189,0.192,Irak4-inhibitor co-structure
4ZTL,X-RAY DIFFRACTION,2.65,53.65,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289.0,2015-05-14,2015-09-02,4ZTL,9076.0,4.0,1204.0,108.0,,137.49,1.0,2.39,experimental,76.16,0.2508,0.2245,Irak4-inhibitor co-structure
4ZTM,X-RAY DIFFRACTION,2.64,53.39,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289.0,2015-05-14,2015-09-02,4ZTM,9198.0,4.0,1204.0,105.0,,137.54,1.0,2.66,experimental,54.04,0.2259,0.1934,Irak4-inhibitor co-structure
4ZTN,X-RAY DIFFRACTION,2.62,53.01,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289.0,2015-05-14,2015-09-02,4ZTN,9301.0,4.0,1204.0,161.0,,137.47,1.0,2.23,experimental,64.93,0.2243,0.2089,Irak4-inhibitor co-structure
6O94,X-RAY DIFFRACTION,2.78,55.75,VAPOR DIFFUSION,,"2.6-2.9 M Ammonium Sulfate, Hepes",277.0,2019-03-13,2019-05-22,6O94,9907.0,4.0,1280.0,609.0,,146.72,1.0,1.98,experimental,38.6,0.215,0.1826,Structure of the IRAK4 kinase domain with compound 17
5JZJ,X-RAY DIFFRACTION,2.04,39.56,EVAPORATION,6.5,"PEG MME 5000, ammonium sulphate",298.0,2016-05-17,2016-08-24,5JZJ,4683.0,2.0,594.0,493.0,,67.95,1.0,1.71,experimental,25.92,0.2083,0.1768,Crystal structure of DCLK1-KD in complex with AMPPN
5V4Q,X-RAY DIFFRACTION,2.96,58.4,"VAPOR DIFFUSION, HANGING DROP",6.0,"20_25% PEG3350, 0.1 M ammonium chloride,
0.1M Na cacodilate pH6.0",290.0,2017-03-10,2017-04-19,5V4Q,4476.0,2.0,542.0,278.0,2.0,60.13,2.0,2.2,experimental,44.573,0.21893,0.16327,Crystal Structure of human GGT1 in complex with DON
8U37,X-RAY DIFFRACTION,2.27,45.79,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris, pH 5.5, 18% PEG3350, 0.2 M magnesium chloride",277.0,2023-09-07,2024-01-24,8U37,2663.0,1.0,354.0,7.0,,41.21,1.0,2.48,experimental,85.34,0.2578,0.2177,"Crystal structure of the catalytic domain of human PKC alpha (D463N, V568I, S657E) in complex with NVP-CJL037 at 2.48-A resolution"
8UAK,X-RAY DIFFRACTION,2.35,47.7,"VAPOR DIFFUSION, SITTING DROP",,"21 mg/mL protein in 50 mM imidazole, 200 mM sodium chloride, 2 mM TCEP, 1 mM NAF, 1% glycerol, pH 8.0 against 0.1 M Bis-Tris, pH 5.5, 18% PEG3350, 0.2 M magnesium chloride",277.0,2023-09-21,2024-01-24,8UAK,2644.0,1.0,354.0,1.0,,41.15,1.0,2.82,experimental,100.13,0.243,0.206,"Crystal structure of the catalytic domain of human PKC alpha (D463N, V568I, S657E) in complex with Darovasertib (NVP-LXS196) at 2.82-A resolution"
7KZE,X-RAY DIFFRACTION,2.3,46.56,"VAPOR DIFFUSION, SITTING DROP",,"60-75 mM magnesium formate dihydrate,
19-23 % PEG3350",295.15,2020-12-10,2022-06-15,7KZE,15254.0,3.0,1824.0,621.0,,207.76,1.0,2.9,experimental,,0.2088,0.1945,Substrate-dependent divergence of leukotriene A4 hydrolase aminopeptidase activity
7LLQ,X-RAY DIFFRACTION,2.3,46.56,"VAPOR DIFFUSION, SITTING DROP",,"60-90 mM magnesium formate dihydrate,
20-25 % PEG3350",295.15,2021-02-04,2022-06-22,7LLQ,15226.0,3.0,1833.0,365.0,,209.69,1.0,2.85,experimental,20.6,0.229,0.1995,Substrate-dependent divergence of leukotriene A4 hydrolase aminopeptidase activity
8TVT,X-RAY DIFFRACTION,2.96,58.48,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5
22.5 % PEG 400",288.0,2023-08-18,2024-09-11,8TVT,6126.0,4.0,705.0,414.0,,84.14,4.0,2,experimental,,0.1863,0.1501,"Structure of human Cysteine desulfurase Nfs1 with L-propargylglycine bound to active site PLP in complex with ISD11, Acp1 and ISCU2"
5SYM,X-RAY DIFFRACTION,2.19,43.77,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M sodium citrate, 22-24% PEG 3350, 200 mM MgCl2",293.0,2016-08-11,2016-10-26,5SYM,3863.0,2.0,460.0,363.0,,50.79,1.0,1.55,experimental,19.12,0.199,0.179,"Cocrystal structure of the human acyl protein thioesterase 1 with an isoform-selective inhibitor, ML348"
8S9L,X-RAY DIFFRACTION,2.48,50.49,"VAPOR DIFFUSION, SITTING DROP",5.5,"100 mM Bis-Tris, 2 M ammonium sulfate",277.0,2023-03-29,2024-03-20,8S9L,3894.0,2.0,540.0,90.0,,61.87,1.0,1.85,experimental,,0.2524,0.2181,Structure of monomeric FAM111A SPD V347D Mutant
7ET7,X-RAY DIFFRACTION,1.99,38.25,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.2 M Sodium chloride, 0.1 M BIS-TRIS pH 5.8, 25 %(w/v) PEG 3350",295.0,2021-05-12,2022-05-18,7ET7,8221.0,4.0,1124.0,31.0,,127.23,1.0,2.61,experimental,38.825,0.2833,0.2231,Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with tricyclic small molecule inhibitor JBSNF-000028
7EU5,X-RAY DIFFRACTION,2.02,39.07,"VAPOR DIFFUSION, SITTING DROP",5.2,"0.2 M Sodium chloride, 0.1 M BIS-TRIS pH 5.2, 24 %(w/v) PEG 3350",295.0,2021-05-16,2022-05-18,7EU5,8122.0,4.0,1124.0,43.0,,127.31,1.0,2.731,experimental,30.051,0.28,0.2079,Co-crystal structure of Human Nicotinamide N-methyltransferase (NNMT) with tricyclic small molecule inhibitor JBSNF-000107
8JZY,X-RAY DIFFRACTION,2.34,47.48,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,  sodium phosphate",277.0,2023-07-06,2023-09-13,8JZY,1106.0,2.0,139.0,100.0,,15.37,2.0,1.5,experimental,,0.2004,0.1848,RPA70N-RAD9 fusion
6HMK,X-RAY DIFFRACTION,2.47,50.22,"VAPOR DIFFUSION, SITTING DROP",7.5,"750 nL purified protein at 7.5 mg/mL in 50 mM HEPES, pH 7.0, 150 mM NaCl, 2 mM DTT was mixed with 250 nL of seed stock and 1000 nL of a  precipitant consisting of 18-23 % (w/v) PEG-3350, 0.2 M ammonium sulphate, 0.1 M PCTP pH 7.5.  Seed stock was prepared using a Seed BeadTM (Hampton Research) from a co-crystal of GS-PARG(448-976 [K617A, Q618A, K619A, E688A, K689A, K690A]) with ADP-ribose, with co-crystallisation mother liquor (19 % (w/v) PEG-3350, 0.2 M ammonium sulphate, 0.1 M PCTP pH 7.5) as the stabilising solution. The final volume of the seed stock was 100 microL.",293.0,2018-09-12,2018-11-14,6HMK,4608.0,1.0,531.0,448.0,,62.15,1.0,2.06,experimental,33.03,0.1888,0.1536,POLYADPRIBOSYL GLYCOHYDROLASE IN COMPLEX WITH PDD00016690
6HDR,X-RAY DIFFRACTION,2.63,53.15,"VAPOR DIFFUSION, SITTING DROP",,"0.2M sodium potassium phosphate,  20% PEG 3350 and  10% ethylene glycol",277.0,2018-08-18,2019-08-28,6HDR,3394.0,1.0,429.0,128.0,,50.22,1.0,2.2,experimental,72.456,0.24263,0.18974,Human DYRK2 bound to Curcumin
7QLB,X-RAY DIFFRACTION,2.21,44.34,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris pH 8.25-8.75
0.1M Magnesium acetate
15-18 % PEG 3350",298.0,2021-12-20,2023-03-29,7QLB,4003.0,1.0,431.0,510.0,,50.38,1.0,1.8,experimental,27.51,0.1833,0.1503,SMYD3 in complex with fragment FL06268
7QNR,X-RAY DIFFRACTION,2.12,42.06,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris pH 8.25-8.75
0.1M Magnesium acetate
15-18 % PEG 3350",298.0,2021-12-22,2023-04-05,7QNR,3822.0,1.0,431.0,340.0,,50.2,1.0,1.57,experimental,29.62,0.2348,0.2035,SMYD3 in complex with fragment FL01791
7QNU,X-RAY DIFFRACTION,2.1,41.35,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris pH 8.25-8.75
0.1M Magnesium acetate
15-18 % PEG 3350",298.0,2021-12-22,2023-04-05,7QNU,3925.0,1.0,431.0,445.0,,50.21,1.0,1.64,experimental,23.61,0.2295,0.1846,SMYD3 in complex with fragment FL08619
5K76,X-RAY DIFFRACTION,2.95,58.27,"VAPOR DIFFUSION, HANGING DROP",7.2,"2.5 M ammonium sulfate, 0.1 M Hepes",293.0,2016-05-25,2017-12-06,5K76,4522.0,2.0,602.0,47.0,,68.52,1.0,2.74,experimental,84.74,0.246,0.217,IRAK4 in complex with Compound 28
7LEW,X-RAY DIFFRACTION,2.02,38.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 4000, ammonium acetate etc.",292.0,2021-01-15,2021-11-10,7LEW,1674.0,2.0,199.0,160.0,,22.77,2.0,1.736,experimental,36.2691,0.2279,0.1915,Crystal structure of UBE2G2 in complex with the UBE2G2-binding region of AUP1
5BPP,X-RAY DIFFRACTION,2.45,49.86,"VAPOR DIFFUSION, HANGING DROP",6.0,"10MM TRIS-HCL, 25MM KCL, 4(MG/ML) TO 8(MG/ML) LTA4H (PH 8) WAS MIXED AT DIFFERENT RATIOS (0.5:1, 1:1, AND 1:2) WITH PRECIPITATE SOLUTION CONTAINING 0.15M IMIDAZOLE, 0.1M SODIUM ACETATE, 14% PEG8000, 5MM YBCL3",293.0,2015-05-28,2016-08-10,5BPP,5120.0,1.0,631.0,243.0,,72.4,1.0,2.03,experimental,25.765,0.22406,0.18125,Structure of human Leukotriene A4 hydrolase in complex with inhibitor 4AZ
5QC7,X-RAY DIFFRACTION,2.23,44.86,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC7,4069.0,2.0,446.0,545.0,6.0,50.69,1.0,1.9,experimental,,0.204,0.155,Crystal structure of human Cathepsin-S with bound ligand
5BMS,X-RAY DIFFRACTION,2.9,57.64,"VAPOR DIFFUSION, SITTING DROP",,0.2 M Tri-Potassium citrate and 20% PEG3350,277.0,2015-05-22,2015-07-01,5BMS,2326.0,1.0,293.0,,,33.45,1.0,2.903,experimental,,0.2303,0.1735,Crystal structure of P21-activated kinase 4 in complex with an inhibitor compound 29
5VED,X-RAY DIFFRACTION,2.66,53.76,"VAPOR DIFFUSION, HANGING DROP",7.5,0.1 M Tris-HCl (pH 7.5) and 1.5 - 2.0 M Na acetate,298.0,2017-04-04,2017-10-18,5VED,2345.0,1.0,319.0,15.0,,36.49,1.0,2.301,experimental,,0.2774,0.2279,PAK4 kinase domain in complex with Staurosporine
5VEE,X-RAY DIFFRACTION,2.52,51.26,"VAPOR DIFFUSION, HANGING DROP",7.5,0.1 M Tris-HCl (pH 7.5) and 1.5 - 2.0 M Na acetate,298.0,2017-04-04,2017-10-18,5VEE,2330.0,1.0,319.0,,,36.54,1.0,2.5,experimental,115.572,0.27564,0.22839,PAK4 kinase domain in complex with FRAX486
5VEF,X-RAY DIFFRACTION,2.43,49.44,"VAPOR DIFFUSION, HANGING DROP",7.5,0.1 M Tris-HCl (pH 7.5) and 1.5 - 2.0 M Na acetate,298.0,2017-04-04,2017-10-18,5VEF,2469.0,1.0,319.0,136.0,,36.38,1.0,1.752,experimental,,0.239,0.2002,PAK4 kinase domain in complex with fasudil
5DFF,X-RAY DIFFRACTION,2.61,52.82,"VAPOR DIFFUSION, SITTING DROP",5.0,"10% PEG20000, 100 mM sodium citrate, pH 5.0, and 200 mM MgCl2",291.0,2015-08-26,2015-10-14,5DFF,5905.0,5.0,594.0,684.0,,75.63,1.0,1.57,experimental,,0.2113,0.1869,Human APE1 product complex
5UNP,X-RAY DIFFRACTION,3.58,65.6,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M Hepes (pH 7.0), 0.2M KBr, 0.2M KSCN, 0.4-1.8% PGA (poly-gama-glutamic acid) and 1-4% PEG MME M.W. 2,000",277.0,2017-01-31,2018-05-09,5UNP,5824.0,2.0,738.0,4.0,,87.51,1.0,2.92,experimental,106.189,0.23385,0.20062,"Structure of CDC2-Like Kinase 2 (CLK2) in Complex with Compound T-025 [N2-methyl-N4-(pyrimidin-2-ylmethyl)-5-(quinolin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine]"
6FYL,X-RAY DIFFRACTION,2.09,41.15,"VAPOR DIFFUSION, SITTING DROP",7.0,"30% Jeffamine ED-2001, 0.1M HEPES",298.0,2018-03-12,2018-07-18,6FYL,3196.0,1.0,363.0,316.0,,43.12,1.0,1.95,experimental,25.105,0.2127,0.1883,X-ray structure of CLK2-KD(136-496)/CX-4945 at 1.95A
8C2Z,X-RAY DIFFRACTION,2.22,44.5,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris pH 5.5, 25% PEG3350, 0.2 M magnesium chloride, 0.1 M manganese (II) chloride.",293.15,2022-12-23,2024-01-17,8C2Z,2884.0,1.0,372.0,185.0,,43.5,1.0,1.91,experimental,49.03,0.2196,0.1767,Crystal structure of DYRK1B in complex with AZ191
7N8T,X-RAY DIFFRACTION,2.68,54.1,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Potassium phosphate dibasic, 20% w/v Polyethylene glycol 3,350",293.15,2021-06-15,2022-06-22,7N8T,3317.0,1.0,355.0,366.0,,41.51,1.0,1.69,experimental,31.65,0.2203,0.1899,Crystal Structure of AMP-bound Human JNK2
4XUE,X-RAY DIFFRACTION,3.71,66.81,VAPOR DIFFUSION,,"0.1M Tris, 0.2M Lithium Sulfate, 20% PEG 4000; MA000598 (PEGsII), drop c11 :100uM ligand, 7.5mg/ml protein",298.0,2015-01-25,2015-04-15,4XUE,3563.0,2.0,430.0,120.0,,49.24,1.0,2.3,experimental,28.686,0.229,0.1979,Synthesis and evaluation of heterocyclic catechol mimics as inhibitors of catechol-O-methyltransferase (COMT): Structure with Cmpd27b
5CU3,X-RAY DIFFRACTION,2.18,43.51,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-24,2016-07-27,5CU3,5970.0,2.0,704.0,353.0,,84.44,1.0,1.787,experimental,41.94,0.2018,0.1835,Crystal structure of CK2alpha bound to CAM4066
6GS6,X-RAY DIFFRACTION,3.01,59.13,"VAPOR DIFFUSION, HANGING DROP",,2.2 M Ammonium Sulfate,289.15,2018-06-13,2019-06-26,6GS6,1505.0,1.0,165.0,194.0,,18.32,1.0,1.16,experimental,27.891,0.1699,0.1497,Cyclophilin A single mutant D66A in complex with an inhibitor.
4XPD,X-RAY DIFFRACTION,2.42,49.14,"VAPOR DIFFUSION, HANGING DROP",,"17% PEG 550 MME, 0.1 M MES pH 6.5",291.0,2015-01-16,2016-07-20,4XPD,9262.0,4.0,1276.0,13.0,,149.74,4.0,2.81,experimental,48.318,0.29704,0.23637,Crystal structure of yeast N-terminal acetyltransferase NatE (ppGpp) in complex with a bisubstrate
7M1S,X-RAY DIFFRACTION,3.74,67.12,"VAPOR DIFFUSION, HANGING DROP",,"0.7M NaH2PO4, 1.05M K2HPO4, 0.1M sodium acetate pH 3.8",289.15,2021-03-15,2022-04-27,7M1S,4729.0,1.0,591.0,116.0,,67.36,1.0,2.91,experimental,100.5535,0.2736,0.2451,Crystal structure of human guanylate-binding protein 2 (hGBP2) K51A mutant
5W4F,X-RAY DIFFRACTION,2.88,57.26,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M HEPES 
0.8 M Sodium Citrate",293.0,2017-06-10,2018-06-13,5W4F,3666.0,3.0,568.0,318.0,,61.54,2.0,1.984,experimental,,0.1988,0.1695,Importin binding to pol Mu NLS peptide
5ANU,X-RAY DIFFRACTION,2.01,38.68,,4.5,PH 4.5,,2015-09-08,2016-03-02,5ANU,1351.0,1.0,158.0,64.0,,18.54,1.0,1.8,experimental,27.525,0.25745,0.20668,MTH1 in complex with compound 15
5TP0,X-RAY DIFFRACTION,2.19,43.86,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES
2 M Ammonium Sulfate
2 % PEG-400",298.0,2016-10-19,2017-05-17,5TP0,2028.0,1.0,224.0,226.0,6.0,24.98,1.0,1.25,experimental,11.612,0.1372,0.1178,Human mesotrypsin in complex with diminazene
7Q45,X-RAY DIFFRACTION,2.96,58.43,VAPOR DIFFUSION,8.0,"hanging drop
20% PEG 3350
0.18M tris amonium citrate",293.15,2021-10-29,2022-11-16,7Q45,9322.0,6.0,1257.0,840.0,,134.01,2.0,2.09999588083,experimental,35.8498423392,0.22436902922,0.184268613443,Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of Myelin transcription factor 1
6O1F,X-RAY DIFFRACTION,2.98,58.73,"VAPOR DIFFUSION, HANGING DROP",7.5,"5% PEG 4000
0.1M lithium sulfate
0.1M Tris pH 7.5",292.0,2019-02-19,2019-10-16,6O1F,7056.0,4.0,892.0,441.0,12.0,98.48,4.0,2.15,experimental,45.74,0.233,0.1898,Complex between soybean trypsin inhibitor beta1-tryptase and a humanized fab
5ICV,X-RAY DIFFRACTION,2.05,40.09,"VAPOR DIFFUSION, HANGING DROP",,4% Tascimate pH 4.0 and 12% PEG 3500,293.15,2016-02-23,2016-06-22,5ICV,3420.0,4.0,368.0,385.0,,43.62,2.0,1.53,experimental,,0.2084,0.1905,Crystal structure of human NatF (hNaa60) bound to a bisubstrate analogue
5OTH,X-RAY DIFFRACTION,2.2,44.03,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-02-28,5OTH,5897.0,2.0,704.0,240.0,,84.28,1.0,1.69,experimental,49.36,0.265,0.24,The crystal structure of CK2alpha in complex with compound 26
5OTL,X-RAY DIFFRACTION,2.2,44.1,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-02-28,5OTL,5941.0,2.0,704.0,296.0,,84.48,1.0,1.57,experimental,43.39,0.244,0.225,The crystal structure of CK2alpha in complex with compound 29
5OTP,X-RAY DIFFRACTION,2.25,45.25,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-09-05,5OTP,5941.0,2.0,704.0,400.0,,83.83,1.0,1.57,experimental,38.88,0.24,0.222,The crystal structure of CK2alpha in complex with an analogue of compound 22
5VWO,X-RAY DIFFRACTION,2.68,54.03,"VAPOR DIFFUSION, HANGING DROP",,"NaCl (175mM), 8-10% (v/v) PEG 6000",298.0,2017-05-22,2017-08-30,5VWO,10967.0,3.0,1212.0,1309.0,,135.66,1.0,1.773,experimental,25.95,0.21,0.178,"Ornithine aminotransferase inactivated by (1R,3S,4S)-3-amino-4-fluorocyclopentane-1-carboxylic acid (FCP)"
8VJX,X-RAY DIFFRACTION,2.7,54.52,"VAPOR DIFFUSION, HANGING DROP",,"17.5 ~ 30 % polyethylene glycol 3,350 and 50 ~ 125 mM Bis-Tris HCl buffer, pH 6.5",295.0,2024-01-08,2024-08-21,8VJX,5443.0,2.0,676.0,26.0,,77.74,2.0,2.89,experimental,,0.2554,0.2233,Structure of Human Neurolysin in complex with bradykinin peptide
4D75,X-RAY DIFFRACTION,2.53,51.4,"VAPOR DIFFUSION, SITTING DROP",7.0,"VAPOR DIFFUSION SITTING DROP AGAINST 80% OF THE E3 SOLUTION FROM MORPHEUS CRYSTALLIZATION KIT (MOLECULAR DIMENSIONS), PH 7",,2014-11-19,2015-09-23,4D75,3794.0,1.0,487.0,17.0,,56.58,1.0,2.25,experimental,,0.254,0.2,Cytochrome P450 3A4 bound to an inhibitor
5TWL,X-RAY DIFFRACTION,2.79,55.84,"VAPOR DIFFUSION, SITTING DROP",,"magnesium chloride, PEG 3350, BIS-TRIS",293.0,2016-11-14,2017-11-22,5TWL,2600.0,1.0,341.0,36.0,,39.88,1.0,2.42,experimental,59.2616,0.2491,0.1956,Structure of Maternal Embryonic Leucine Zipper Kinase
5TWZ,X-RAY DIFFRACTION,2.43,49.32,"VAPOR DIFFUSION, SITTING DROP",,PEG 4000,293.0,2016-11-15,2017-11-22,5TWZ,2457.0,1.0,341.0,6.0,,39.75,1.0,2.631,experimental,79.0227,0.2585,0.2209,Structure of Maternal Embryonic Leucine Zipper Kinase
6TPU,X-RAY DIFFRACTION,2.22,44.72,VAPOR DIFFUSION,7.0,1.8 M Ammonium citrate tribasic pH 7.0,277.0,2019-12-14,2020-05-13,6TPU,3616.0,2.0,390.0,473.0,,43.83,1.0,1.55,experimental,,0.1933,0.1654,"Crystal structures of FNIII domain three and four of the human leucocyte common antigen-related protein, LAR"
6XKG,X-RAY DIFFRACTION,2.64,53.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"Protein: 15.5mg/ml 3ost3a, 4mM PAP, 5mM 8mer Nac/NS2S6S, 25mM Tris pH 7.5, 125mM NaCl,

Reservoir: 0.1M Bicine and 10% MPD",293.0,2020-06-26,2021-06-23,6XKG,5338.0,2.0,546.0,692.0,2.0,67.85,1.0,1.55,experimental,24.9,0.1826,0.1638,Crystal structure of 3-O-Sulfotransferase isoform 3 in complex with 8mer oligosaccharide with 6S sulfation
8T48,X-RAY DIFFRACTION,1.99,38.21,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris pH 8.5, 30% (w/v) PEG 4K, 0.2 M Li2SO4",293.0,2023-06-08,2024-03-13,8T48,4022.0,4.0,480.0,430.0,,54.18,2.0,2,experimental,,0.2178,0.1603,The N4BP1 CUE-like domain in complex with linear di-Ubiquitin
7KZ0,X-RAY DIFFRACTION,2.23,44.87,"VAPOR DIFFUSION, SITTING DROP",7.4,"PEG3350, potassium sodium tartrate",293.0,2020-12-09,2021-11-10,7KZ0,2022.0,3.0,198.0,270.0,,28.21,1.0,1.57,experimental,28.3962,0.2151,0.1883,Human MBD4 glycosylase domain bound to DNA containing substrate analog 2'-deoxy-pseudouridine
6CYO,X-RAY DIFFRACTION,2.46,49.95,"VAPOR DIFFUSION, SITTING DROP",,50 mM di-Sodium succinate pH 7.0 and 12-14% PEG 3350,291.0,2018-04-06,2018-12-12,6CYO,1294.0,1.0,155.0,72.0,,17.61,1.0,1.85,experimental,46.4198,0.214,0.204,Crystal structure of human UBE2A (RAD6A)
5XS2,X-RAY DIFFRACTION,2.99,58.82,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.05M MgCl, 0.1M MES
pH 6.5, 10% Iso-propanol, 5% PEG4K",293.0,2017-06-12,2017-08-09,5XS2,5418.0,2.0,643.0,190.0,,75.8,2.0,2.04,experimental,29.166,0.22512,0.19566,CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-chloro-4-(4-pyridyl)-1H-pyrrole-2-carboxamide
7TTK,X-RAY DIFFRACTION,2.55,51.71,"VAPOR DIFFUSION, HANGING DROP",6.0,10% Tacsimate,295.0,2022-02-01,2023-02-15,7TTK,11684.0,2.0,1382.0,752.0,,158.98,1.0,1.98,experimental,47.3076,0.201,0.1648,Stable-5-LOX
6HZN,X-RAY DIFFRACTION,5.0,75.38,"VAPOR DIFFUSION, HANGING DROP",6.5,"Ammonium acetate 200 mM,
MES 0.1 M (pH 6.5), 
Glycerol ethoxylate 30% v/v,
Xylitol 6%",293.15,2018-10-23,2020-01-22,6HZN,6304.0,1.0,761.0,153.0,,89.48,1.0,2.41,experimental,,0.2089,0.1756,Crystal structure of human dermatan sulfate epimerase 1
7TTJ,X-RAY DIFFRACTION,2.4,48.75,"VAPOR DIFFUSION, HANGING DROP",6.0,10% Tacsimate,295.0,2022-02-01,2022-08-31,7TTJ,10421.0,2.0,1382.0,359.0,,158.98,1.0,2.1,experimental,62.3206,0.2238,0.1838,Stable-5-LOX elongated Ha2
5ANS,X-RAY DIFFRACTION,2.2,44.0,,,,,2015-09-08,2016-03-02,5ANS,1413.0,1.0,175.0,128.0,,20.33,1.0,1.6,experimental,15.785,0.24194,0.20521,Potent and selective inhibitors of MTH1 probe its role in cancer cell survival
6I9C,X-RAY DIFFRACTION,2.35,47.63,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 18 % (w/v) PEG 6,000, 1M LiCl",277.0,2018-11-22,2019-03-06,6I9C,2444.0,1.0,268.0,253.0,,31.67,1.0,1.77,experimental,33.1145,0.1786,0.1623,Structure of the OTU domain of OTULIN G281R mutant
7CO6,X-RAY DIFFRACTION,1.88,34.67,VAPOR DIFFUSION,5.5,"PEG 4000, 2-Propanol, Sodium citrate tribasic dihydrate",298.0,2020-08-04,2021-06-30,7CO6,3198.0,4.0,499.0,190.0,,59.08,1.0,1.9,experimental,38.6834,0.2144,0.1796,Binary complex of DNA polymerase Mu with 1-nt gapped DNA (templating thymine)
7COD,X-RAY DIFFRACTION,1.95,36.96,VAPOR DIFFUSION,8.0,"1,4-Dioxane, Tris-Hcl, PEG 3350",298.0,2020-08-04,2021-06-30,7COD,3531.0,4.0,500.0,348.0,,59.82,1.0,1.8,experimental,29.7598,0.2109,0.1856,Post insertion complex of DNA polymerase Mu (K438A/Q441A) with 1-nt gapped DNA
5VOF,X-RAY DIFFRACTION,3.28,62.5,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Bicine, 0.1 M Tris base, 0.1 M Carboxylic acids, 10% PEG 20,000, 20% PEG 500 MME",298.0,2017-05-02,2018-06-13,5VOF,3092.0,3.0,320.0,93.0,7.0,43.88,2.0,2.25,experimental,57.44,0.2533,0.22014,DesGla-XaS195A Bound to Aptamer 11F7t and Rivaroxaban
5L4Q,X-RAY DIFFRACTION,1.83,32.81,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M bis-tris pH 5.5, 26% PEG3350",293.0,2016-05-26,2016-06-08,5L4Q,4847.0,2.0,692.0,220.0,,78.71,1.0,1.97,experimental,44.2379,0.2265,0.2071,Crystal Structure of Adaptor Protein 2 Associated Kinase 1 (AAK1) in Complex with LKB1 (AAK1 Dual Inhibitor)
6TPW,X-RAY DIFFRACTION,3.63,66.09,EVAPORATION,,0.2 M Ammonium sulfate and 30% PEG8000,277.0,2019-12-14,2020-05-13,6TPW,2920.0,1.0,402.0,1.0,,44.71,1.0,2.9,experimental,164.0143,0.3012,0.2809,Crystal structures of FNIII domain one through four of the human leucocyte common antigen-related protein ( LAR)
6APL,X-RAY DIFFRACTION,2.5,52.47,MICROBATCH,4.2,"0.1M Sodium Citrate (pH 4.2), 0.1M Ammonium Sulfate, and 24% (w/v) PEG 20000",277.0,2017-08-17,2017-12-20,6APL,14650.0,6.0,2244.0,215.0,11.0,257.78,1.0,2.35,experimental,,0.2357,0.1961,Crystal Structure of human ST6GALNAC2 in complex with CMP
8EVE,X-RAY DIFFRACTION,2.12,41.9,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES PH 5.5, 5mM Calcium Chloride, 15-22% PEG 2000 MME",291.0,2022-10-20,2023-08-02,8EVE,3834.0,3.0,455.0,90.0,,55.2,1.0,2.35,experimental,,0.2443,0.1891,HUMAN DNA POLYMERASE ETA INSERTION COMPLEX
4RFM,X-RAY DIFFRACTION,2.01,38.74,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.2 M Magnesium Chloride, 0.1 M Tris.HCl (pH 8.0), 20 % PEG 6000, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-09-26,2015-04-29,4RFM,2120.0,1.0,266.0,87.0,,30.63,1.0,2.1,experimental,37.73,0.26362,0.20265,"ITK kinase domain in complex with compound 1 N-{1-[(1,1-dioxo-1-thian-2-yl)(phenyl)methyl]-1H- pyrazol-4-yl}-5,5-difluoro-5a-methyl-1H,4H,4aH,5H,5aH,6H-cyclopropa[f]indazole-3-carboxamide"
4XXS,X-RAY DIFFRACTION,2.78,55.7,"VAPOR DIFFUSION, HANGING DROP",6.6,"BACE1 lacking the pro-segment was concentrated to ~14 mg/mL in 20 mM Tris pH 7.4 and 250 mM NaCl.  Crystallization was carried out by the vapor diffusion method against 200 mM sodium citrate tribasic dihydrate, 22% PEG 5K monomethyl ether and 200 mM ammonium iodide.",291.0,2015-01-30,2015-04-01,4XXS,3291.0,1.0,415.0,299.0,3.0,47.48,1.0,1.86,experimental,50.02,0.2076,0.1818,Crystal structure of BACE1 with a pyrazole-substituted tetrahydropyran thioamidine
7KVK,X-RAY DIFFRACTION,2.81,56.24,"VAPOR DIFFUSION, SITTING DROP",8.0,"PEG 4000, HEPES, lithium sulfate",298.0,2020-11-28,2021-01-20,7KVK,7480.0,2.0,974.0,14.0,,114.02,1.0,2.55,experimental,,0.2763,0.2371,Human CYP3A4 bound to an inhibitor
5DQI,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM Calcium chloride, 20% PEG 2000 MME",291.0,2015-09-14,2016-08-10,5DQI,3866.0,3.0,456.0,103.0,,55.57,1.0,2.3,experimental,55.222,0.26587,0.20388,Crystal Structure of Human DNA Polymerase Eta Extending an O4-Ethylthymidine : dA Pair By Inserting dCTP Opposite dG
6MQ8,X-RAY DIFFRACTION,2.11,41.76,"VAPOR DIFFUSION, HANGING DROP",5.5,"100mM MES 5.5, 10% PEG 2K MME, 5mM MgSO4",291.15,2018-10-09,2019-10-23,6MQ8,4214.0,3.0,459.0,365.0,,55.85,1.0,1.969,experimental,34.483,0.2076,0.1709,Binary structure of DNA polymerase eta in complex with templating hypoxanthine
8UJV,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM magnesium chloride, 18% PEG 2000 MME",291.0,2023-10-11,2024-03-20,8UJV,4018.0,3.0,455.0,184.0,,55.22,1.0,2.23,experimental,,0.2224,0.1658,Crystal structure of human polymerase eta with incoming dCMPnPP nucleotide opposite urea lesion
8UDV,X-RAY DIFFRACTION,2.76,55.49,"VAPOR DIFFUSION, HANGING DROP",,"0.10 M BIS-TRIS/HCl pH 6.50,
0.20 M (NH4)2SO4,
25.00 % (w/v) PEG 3350",293.0,2023-09-29,2024-02-07,8UDV,7067.0,3.0,891.0,373.0,,103.63,1.0,2.348,experimental,39.38,0.2612,0.2362,The X-RAY co-crystal structure of human FGFR3 V555M and Compound 17
5NIA,X-RAY DIFFRACTION,2.46,50.0,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 20 000, 15% (w/v) PEG MME 550, 100 mM Hepes/MOPS pH 7.7-8.0, 15 mM CaCl2, 15 mM MgCl2",294.0,2017-03-23,2017-08-23,5NIA,5308.0,1.0,617.0,360.0,,70.26,1.0,1.764,experimental,47.94,0.2074,0.1801,Crystal structure of human LTA4H mutant D375N in open conformation (crystal form I)
5NID,X-RAY DIFFRACTION,2.56,52.0,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 20 000, 15% (w/v) PEG MME 550, 100 mM Hepes/MOPS pH 7.7-8.0, 15 mM CaCl2, 15 mM MgCl2",294.0,2017-03-23,2017-08-23,5NID,5363.0,1.0,617.0,412.0,,70.26,1.0,1.568,experimental,50.64,0.2098,0.1821,Crystal structure of human LTA4H mutant D375N in open conformation (crystal form II)
6C0S,X-RAY DIFFRACTION,3.59,65.75,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% w/v MEPEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% w/v  MEPEG2000, 200 mM ammonium sulfate",277.0,2018-01-02,2018-03-07,6C0S,2105.0,1.0,244.0,141.0,4.0,29.11,1.0,2.35,experimental,37.0,0.226,0.195,Factor XIA in complex with the inhibitor methyl (4-{6-[(1S)-2-[(3R)-1-acetylpiperidin-3-yl]-1-({(2E)-3-[5-chloro-2- (1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)ethyl]-3-chloropyridazin-4-yl}phenyl) carbamate
4UDA,X-RAY DIFFRACTION,2.29,46.0,,7.5,"30% PEG4000, 0.1M NACL, 0.2M PIPES PH 7.5",,2014-12-09,2015-11-25,4UDA,2215.0,2.0,266.0,101.0,,31.37,2.0,2.03,experimental,30.86,0.2401,0.1847,MR in complex with dexamethasone
6K0J,X-RAY DIFFRACTION,3.66,66.41,"VAPOR DIFFUSION, SITTING DROP",,"0.36 M-0.5 M sodium citrate tribasic dihydrate, 0.01 M sodium borate, pH 7.5-9.5",291.0,2019-05-06,2019-11-20,6K0J,2850.0,1.0,327.0,181.0,,38.1,1.0,2.352,experimental,,0.2093,0.172,The co-crystal structure of DYRK2 with a small molecule inhibitor
6V9C,X-RAY DIFFRACTION,2.3,46.45,BATCH MODE,,"100 mM Bis-Tris pH 5.5, 14% (w/v) polyethylene glycol 3,350, 200 mM lithium sulfate and 2% (w/v) glycerol",277.0,2019-12-13,2020-03-25,6V9C,2421.0,1.0,300.0,165.0,,34.58,1.0,1.9,experimental,37.4,0.227,0.199,Crystal structure of FGFR4 kinase domain in complex with covalent inhibitor
6BPV,X-RAY DIFFRACTION,3.71,66.83,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295.0,2017-11-26,2018-07-04,6BPV,1770.0,1.0,200.0,169.0,,23.45,1.0,1.95,experimental,34.2298,0.1792,0.1604,Crystal structure of cysteine-bound ferrous form of the matured F2-Tyr157 human cysteine dioxygenase
6N43,X-RAY DIFFRACTION,3.97,68.99,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES, 2 M ammonium sulfate, 2% PEG400",295.0,2018-11-16,2019-04-17,6N43,1624.0,1.0,200.0,98.0,,23.44,1.0,2.289,experimental,40.0492,0.2135,0.1773,"Crystal structure of cysteine, nitric oxide-bound ferrous form of the crosslinked human cysteine dioxygenase in the anaerobic condition"
6AHV,X-RAY DIFFRACTION,3.32,63.0,EVAPORATION,7.0,"5% v/v TacsimateTM pH 7.0, 100mM Hepes pH 7.0, 10% w/v polyethylene glycol monomethyl ether 5000",277.0,2018-08-20,2018-12-05,6AHV,2832.0,1.0,363.0,26.0,,41.88,1.0,2.6,experimental,49.6534,0.2531,0.2179,Crystal structure of human RPP40
5GHI,X-RAY DIFFRACTION,1.89,35.09,"VAPOR DIFFUSION, HANGING DROP",6.5,"sodium citrate, sodium cacodylate, NaCl",293.0,2016-06-20,2017-01-04,5GHI,3238.0,2.0,312.0,429.0,,37.2,1.0,1.211,experimental,,0.1718,0.1359,Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP
5GHJ,X-RAY DIFFRACTION,1.89,34.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"sodium citrate, sodium cacodylate, NaCl",293.0,2016-06-20,2017-01-04,5GHJ,3292.0,2.0,312.0,433.0,,37.17,1.0,1.2,experimental,,0.176,0.1434,Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP
5GHM,X-RAY DIFFRACTION,1.87,34.35,"VAPOR DIFFUSION, HANGING DROP",7.0,"Sodium citrate, Tris, NaCl",293.0,2016-06-20,2017-01-04,5GHM,3259.0,2.0,312.0,388.0,,37.15,1.0,1.5,experimental,,0.1961,0.173,Crystal structure of human MTH1(G2K/D120N mutant) in complex with 8-oxo-dGTP at pH 7.0
5GHN,X-RAY DIFFRACTION,1.87,34.05,"VAPOR DIFFUSION, HANGING DROP",7.0,"Sodium citrate, Tris, NaCl",293.0,2016-06-20,2017-01-04,5GHN,3292.0,2.0,312.0,388.0,,37.17,1.0,1.391,experimental,,0.1889,0.1487,Crystal structure of human MTH1(G2K/D120N mutant) in complex with 2-oxo-dATP
5GHP,X-RAY DIFFRACTION,1.87,34.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sodium citrate, Sodium cacodylate, NaCl",293.0,2016-06-20,2017-01-04,5GHP,3217.0,2.0,312.0,435.0,,36.05,1.0,1.192,experimental,,0.1789,0.1469,Crystal structure of human MTH1(G2K/D120A mutant) in complex with 2-oxo-dATP
5GHQ,X-RAY DIFFRACTION,1.88,34.59,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sodium citrate, Sodium cacodylate, NaCl",293.0,2016-06-20,2017-01-04,5GHQ,3243.0,2.0,312.0,403.0,,37.08,1.0,1.181,experimental,,0.1796,0.1464,Crystal structure of human MTH1(G2K/D120A mutant) in complex with 2-oxo-dATP under high concentrations of 2-oxo-dATP
5WS7,X-RAY DIFFRACTION,1.9,35.21,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2016-12-05,2017-01-04,5WS7,3814.0,2.0,312.0,521.0,,37.1,1.0,1,experimental,,0.1377,0.1169,Crystal structure of human MTH1(G2K/C87A/C104S mutant) in complex with 2-oxo-dATP
6ILI,X-RAY DIFFRACTION,1.85,33.54,"VAPOR DIFFUSION, HANGING DROP",6.5,"SODIUM CITRATE, cacodylate, NACL",293.0,2018-10-18,2018-11-07,6ILI,3126.0,2.0,312.0,336.0,,37.13,1.0,1.45,experimental,,0.2047,0.1745,Crystal structure of human MTH1(G2K/D120N mutant) in complex with 8-oxo-dGTP at pH 6.5
6AVS,X-RAY DIFFRACTION,2.3,46.45,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES pH 7.0
8% PEG 3350",277.0,2017-09-04,2018-02-28,6AVS,1910.0,1.0,236.0,89.0,,27.54,1.0,2.02,experimental,,0.272,0.241,Complex structure of JMJD5 and Symmetric Monomethyl-Arginine (MMA)
6AX3,X-RAY DIFFRACTION,2.26,45.65,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES pH 7.0
8% PEG 3350",277.0,2017-09-06,2018-02-28,6AX3,1999.0,1.0,236.0,117.0,,27.69,1.0,2.25,experimental,,0.2591,0.206,Complex structure of JMJD5 and Symmetric Dimethyl-Arginine (SDMA)
5JZN,X-RAY DIFFRACTION,3.83,67.89,EVAPORATION,7.5,"PEG400, Hepes",298.0,2016-05-17,2016-08-24,5JZN,4244.0,2.0,560.0,47.0,,63.92,1.0,2.85,experimental,39.2273,0.2248,0.181,Crystal structure of DCLK1-KD in complex with NVP-TAE684
6S8Q,X-RAY DIFFRACTION,2.44,49.5,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2019-07-10,2020-01-22,6S8Q,16866.0,2.0,2010.0,656.0,,229.99,2.0,2.391,experimental,59.2729,0.253,0.1795,Human Brr2 Helicase Region in complex with C-tail deleted Jab1
6S9I,X-RAY DIFFRACTION,2.47,50.14,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2019-07-13,2020-01-22,6S9I,15928.0,2.0,2010.0,102.0,1.0,229.78,2.0,2.598,experimental,69.6232,0.278,0.1967,Human Brr2 Helicase Region D534C/N1866C in complex with C-tail deleted Jab1
5NAR,X-RAY DIFFRACTION,1.98,37.74,"VAPOR DIFFUSION, SITTING DROP",,"MM NACL, 0.5MM NVP-BVT244-NX-1
                      + 1 UL RESERVOIR SOLUTION",298.0,2017-02-28,2017-06-28,5NAR,1881.0,1.0,232.0,187.0,4.0,25.31,1.0,1.55,experimental,13.961,0.23101,0.15515,"Complement factor D in complex with the inhibitor (S)-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]"
5NAW,X-RAY DIFFRACTION,2.1,41.43,"VAPOR DIFFUSION, SITTING DROP",,"27% PEG 3350
100 mM HEPES pH 7.5",298.0,2017-02-28,2017-06-28,5NAW,2055.0,1.0,232.0,294.0,5.0,25.23,1.0,1.25,experimental,18.891,0.17791,0.12789,"Complement factor D in complex with the inhibitor (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-trifluoromethoxy-phenyl)-amide]"
5NB6,X-RAY DIFFRACTION,2.03,39.45,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG3350, 0.1 M HEPES pH 7.5, 50 mM NaCl",298.0,2017-03-01,2017-06-28,5NB6,1849.0,1.0,232.0,185.0,4.0,25.23,1.0,1.75,experimental,,0.297,0.235,"Complement factor D in complex with the inhibitor (2S,4S)-4-Amino-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]"
6IF1,X-RAY DIFFRACTION,2.49,50.53,"VAPOR DIFFUSION, HANGING DROP",10.0,"Tris-HCl,
polyethylene glycol 3350,
ammonium acetate.",293.0,2018-09-18,2018-11-21,6IF1,4366.0,4.0,550.0,26.0,,61.79,2.0,2.466,experimental,,0.2356,0.2152,Crystal structure of Ube2K and K48-linked di-ubiquitin complex
6D1Z,X-RAY DIFFRACTION,2.26,45.5,"VAPOR DIFFUSION, HANGING DROP",7.63,"Well volume: 30.0 uL
Well Ingredients:
Salt: 0.2571428571 M (1.9285714282 uL of stock 4.0 M) potassium formate
Precipitant: 20.0 %w/v (12.0 uL of stock 50.0 %w/v) PEG 3350
Buffer: 0.1 M (3.0 uL of stock 1.0 M) Tris (pH 7.63)
Plate setup temperature: 13 C
Plate incubation temperature: 21 C
Drop volume from well: 0.1 uL
Drop protein volume: 0.3 uL
Protein: 6.00 mg/mL (0.17 mM)
Compound1: small molecule to aid crystallization (1.20 mM)
Soak of 10mM compound 3 for > 1h into co-crystals of TrkA + compound1",294.0,2018-04-12,2018-05-02,6D1Z,2559.0,1.0,320.0,181.0,,36.88,1.0,1.87,experimental,32.38,0.2096,0.1781,"Crystal structure of Tyrosine-protein kinase receptor in complex with 5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one Inhibitor"
7QI1,X-RAY DIFFRACTION,2.26,45.67,"VAPOR DIFFUSION, HANGING DROP",,"Qiagen Cryos Suite #44 (0.09 M HEPES sodium salt pH7.5, 1.26M tri-sodium citrate, 10% (v/v) glycerol) with an extra 2% (v/v) of glycerol.",277.0,2021-12-14,2022-05-25,7QI1,8367.0,6.0,1004.0,539.0,,116.44,2.0,1.76,experimental,35.9,0.2411,0.1952,Crystal structure of human 14-3-3 protein beta in complex with CFTR peptide pS753pS768 and PPI stabilizer CY007424
5CU0,X-RAY DIFFRACTION,2.23,44.77,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-24,2016-11-30,5CU0,5817.0,2.0,704.0,180.0,,84.57,1.0,2.18,experimental,48.36,0.236,0.2044,Crystal structure of CK2alpha with 2-hydroxy-5-methylbenzoic acid and N-(3-(3-chloro-4-(phenyl)benzylamino)propyl)acetamide bound
5CU2,X-RAY DIFFRACTION,2.23,44.8,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-24,2016-11-30,5CU2,6035.0,2.0,704.0,330.0,,85.48,1.0,1.705,experimental,39.14,0.2042,0.1827,Crystal structure of CK2alpha with 2-hydroxy-5-methylbenzoic acid and (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoat bound
6H38,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, HANGING DROP",8.5,"25% v/v Peg3350, 0.2 M Ammonium acetate, 0.1 M Tris-HCl pH 8.5",293.0,2018-07-17,2018-12-19,6H38,2237.0,1.0,274.0,144.0,1.0,31.55,1.0,1.7,experimental,,0.245,0.193,The crystal structure of human carbonic anhydrase VII in complex with 4-[(4-fluorophenyl)methyl]-1-piperazinyl]benzenesulfonamide.
6F3B,X-RAY DIFFRACTION,2.32,47.03,"VAPOR DIFFUSION, HANGING DROP",9.0,"28% PEG4000, 0.2 M Sodium acetate, Tris 100 mM",296.0,2017-11-28,2018-10-10,6F3B,4681.0,2.0,522.0,517.0,,59.01,1.0,1.4,experimental,24.911,0.24579,0.20867,Crystal structure of human carbonic anhydrase I in complex with the 1-(2-hydroxy-5-sulfamoylphenyl)-3-[(4-methylphenyl)methyl]urea inhibitor
7EF8,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, lithium sulfate, ammonium sulfate, Bis-Tris",293.0,2021-03-21,2021-06-23,7EF8,3807.0,3.0,486.0,66.0,,60.77,1.0,2.45,experimental,75.38,0.2206,0.1976,Crystal structure of mouse MUTYH in complex with DNA containing AP site analogue:8-oxoG (Form I)
6X5L,X-RAY DIFFRACTION,3.94,68.78,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1M CITRIC ACID, 20% PEG 6000",277.0,2020-05-26,2020-06-24,6X5L,2443.0,2.0,296.0,131.0,7.0,34.23,2.0,2.246,experimental,58.86,0.2332,0.2047,Discovery of Hydroxy Pyrimidine Factor IXa Inhibitors
6X5P,X-RAY DIFFRACTION,3.75,67.21,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1 M CITRIC ACID, 20% PEG 6000",277.0,2020-05-26,2020-06-24,6X5P,2480.0,2.0,297.0,177.0,7.0,34.25,2.0,1.997,experimental,54.93,0.2393,0.2066,Discovery of Hydroxy Pyrimidine Factor IXa Inhibitors
6CVP,X-RAY DIFFRACTION,2.68,54.05,VAPOR DIFFUSION,6.5,"100 mM MES, 20% w/v polyethylene glycol 3350",277.0,2018-03-28,2018-07-04,6CVP,4320.0,6.0,404.0,510.0,,55.54,1.0,1.999,experimental,,0.2138,0.1644,"Human Aprataxin (Aptx) R199H bound to RNA-DNA, AMP and Zn product complex"
6CVR,X-RAY DIFFRACTION,2.55,51.8,VAPOR DIFFUSION,,"200 mM ammonium formate, 20% w/v polyethylene glycol 3350",277.0,2018-03-28,2018-07-04,6CVR,4419.0,6.0,404.0,589.0,,55.6,1.0,1.88,experimental,,0.1899,0.1661,"Human Aprataxin (Aptx) S242N bound to RNA-DNA, AMP and Zn product complex"
6CVT,X-RAY DIFFRACTION,2.63,53.16,VAPOR DIFFUSION,,"100 mM MES, 20% w/v polyethylene glycol 3350",277.0,2018-03-28,2018-07-04,6CVT,3789.0,6.0,404.0,11.0,,55.47,1.0,2.941,experimental,,0.2892,0.2462,"Human Aprataxin (Aptx) V263G bound to RNA-DNA, AMP and Zn product complex"
6XJO,X-RAY DIFFRACTION,2.2,43.98,"VAPOR DIFFUSION, HANGING DROP",6.5,"187.5 mM Ammonium acetate, 21.5% PEG3350, 100 mM Bis-Tris pH 6.5",293.15,2020-06-24,2021-06-30,6XJO,5083.0,2.0,668.0,240.0,,76.21,1.0,2.1,experimental,53.02,0.2308,0.1785,Human atlastin-3 (residues 1-334) bound to GDP-Mg2+ exhibits an ordered amino terminus
7W8B,X-RAY DIFFRACTION,2.18,43.55,"VAPOR DIFFUSION, SITTING DROP",8.0,2500 mM Sodium chloride 100 mM Imidazole/ Hydrochloric acid pH 8.0,293.0,2021-12-07,2023-07-05,7W8B,1149.0,1.0,164.0,13.0,,18.28,1.0,2.093,experimental,63.82,0.2862,0.2395,Crystal Structure of human Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
7TDY,X-RAY DIFFRACTION,2.24,45.12,"VAPOR DIFFUSION, SITTING DROP",7.0,"1.2 uL of 2 mg/mL protein combined with 1.2 uL of 100 mM Bis-Tris, pH 7.00, 250 mM Mg-Formate.",298.0,2022-01-03,2023-01-11,7TDY,1234.0,1.0,155.0,70.0,,18.05,1.0,1.53,experimental,40.22,0.2174,0.2052,"The ubiquitin-associated domain of human thirty-eight negative kinase 1, flexibly fused to the 1TEL crystallization chaperone via a 2-glycine linker and crystallized at low protein concentration"
5WCG,X-RAY DIFFRACTION,2.62,53.08,"VAPOR DIFFUSION, HANGING DROP",6.4,"20% PEG 3350, 0.04M Citric acid, 0.06M Bis-Tris propane pH6.4",291.0,2017-06-30,2017-08-02,5WCG,3696.0,1.0,433.0,187.0,,50.74,1.0,2.02,experimental,27.487,0.2133,0.1695,SET and MYND Domain Containing protein 2
7R7K,X-RAY DIFFRACTION,2.11,41.84,"VAPOR DIFFUSION, HANGING DROP",,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. EQUAL VOLUMES OF PURIFIED PROTEIN SOLUTION(APPROXIMATELY 13-15 MG/ML)CONTAINING 0.0011M INHIBITOR COMPOUND WERE COMBINED WITH A SOLUTION CONTAINING:  0.15M AMMONIUM SULFATE, 9-10.5% MONOMETHYLETHER PEG5K AND 0.1M MES IN THE PH RANGE 5.3-6.5",286.0,2021-06-24,2022-06-29,7R7K,2563.0,1.0,327.0,259.0,,37.34,1.0,1.831,experimental,27.76,0.2211,0.1938,Structure of Human Anaplastic Lymphoma Kinase Domain in complex with (4-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]isoindolin-1-one)
7R7R,X-RAY DIFFRACTION,2.1,41.44,"VAPOR DIFFUSION, HANGING DROP",,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. EQUAL VOLUMES OF PURIFIED PROTEIN SOLUTION(APPROXIMATELY 13-15 MG/ML)CONTAINING 0.0011M INHIBITOR COMPOUND WERE COMBINED WITH A SOLUTION CONTAINING:  0.15M AMMONIUM SULFATE, 9-10.5% MONOMETHYLETHER PEG5K AND 0.1M MES IN THE PH RANGE 5.3-6.5",286.0,2021-06-25,2022-06-29,7R7R,2526.0,1.0,327.0,217.0,,37.38,1.0,1.935,experimental,28.58,0.2273,0.1911,"Structure of Human Anaplastic Lymphoma Kinase Domain in complex with ((2~{R})-2-[5-[6-amino-5-[(1~{R})-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]-3-pyridyl]-4-methyl-thiazol-2-yl]propane-1,2-diol)"
4U6W,X-RAY DIFFRACTION,2.51,50.91,"VAPOR DIFFUSION, HANGING DROP",6.0,"15% PEG-MME, 100mM Hepes, PH 6",298.0,2014-07-30,2015-03-25,4U6W,2625.0,1.0,306.0,193.0,,34.9,1.0,1.83,experimental,30.68,0.224,0.176,HsMetAP (F220M) in complex with 1-amino-2-propylpentyl]phosphonic acid
5NP8,X-RAY DIFFRACTION,2.07,40.67,"VAPOR DIFFUSION, HANGING DROP",,"2.4-2.8M Sodium potassium phosphate, pH 7.4 - 8.2, 10mM DTT",291.0,2017-04-13,2018-05-16,5NP8,3257.0,1.0,420.0,234.0,,45.7,1.0,1.9,experimental,24.778,0.22183,0.16792,"PGK1 in complex with CRT0063465 (3-[2-(4-bromophenyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-6-yl]propanoic acid)"
5TUT,X-RAY DIFFRACTION,2.2,44.17,"VAPOR DIFFUSION, SITTING DROP",,Hampton PEG/Ion F10,,2016-11-07,2017-11-08,5TUT,1793.0,2.0,226.0,,,25.51,2.0,2.604,experimental,,0.2426,0.2002,UbcH5a-Ub isopeptide conjugate
5YR5,X-RAY DIFFRACTION,2.55,51.69,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M Bistris pH-6.2, 19% PEG3350, 5% glycerol",298.0,2017-11-08,2018-11-14,5YR5,2709.0,1.0,304.0,205.0,,34.64,1.0,1.6,experimental,25.987,0.2012,0.177,Human methionine aminopeptidase type 1b (F309L mutant) in complex with Ovalicin
5DFJ,X-RAY DIFFRACTION,2.61,52.91,"VAPOR DIFFUSION, SITTING DROP",5.0,"10% PEG20000, 100 mM sodium citrate, 200 mM MgCl",291.0,2015-08-26,2015-10-14,5DFJ,5903.0,4.0,594.0,681.0,,75.58,1.0,1.85,experimental,,0.1998,0.1593,Human APE1 E96Q/D210N mismatch substrate complex
6G4T,X-RAY DIFFRACTION,2.26,45.55,"VAPOR DIFFUSION, HANGING DROP",8.5,"25% (w/v) polyethylene glycol 3350, 0.1 M Tris, pH 8.5",293.0,2018-03-28,2018-06-06,6G4T,2225.0,1.0,274.0,162.0,1.0,30.99,1.0,1.91,experimental,21.0916,0.2441,0.1964,The crystal structure of uninhibited C183S/C217S mutant of human CA VII
6H36,X-RAY DIFFRACTION,2.07,40.47,"VAPOR DIFFUSION, HANGING DROP",8.5,"25% v/v Peg3350, 0.2 M Ammonium acetate, 0.1 M Tris-HCl pH 8.5",293.0,2018-07-17,2018-12-19,6H36,2206.0,1.0,274.0,116.0,1.0,31.34,1.0,1.85,experimental,,0.233,0.195,The crystal structure of human carbonic anhydrase VII in complex with 4-(4-phenylpiperidine-1-carbonyl)benzenesulfonamide.
7M4N,X-RAY DIFFRACTION,2.52,51.28,"VAPOR DIFFUSION, SITTING DROP",7.9,"0.2M ammonium sulfate, 30% PEG 4000",293.0,2021-03-21,2022-01-05,7M4N,4424.0,6.0,580.0,73.0,,67.2,2.0,2.52,experimental,46.24,0.2732,0.2163,Crystal structure of RBR E3 ligase RNF216 in complex with K63-linked di-ubiquitin
5FGY,X-RAY DIFFRACTION,3.71,66.85,"VAPOR DIFFUSION, SITTING DROP",6.4,"Grew over one week at 4 degrees Celsius in 0.1 M sodium citrate pH 6.4, 1.7 M sodium acetate, 1 mM DTT",277.15,2015-12-21,2016-01-13,5FGY,1871.0,2.0,215.0,164.0,1.0,24.47,2.0,2.1,experimental,13.214,0.19691,0.17554,Structure of human adenovirus 2 protease with cofactor pVIC
4RXX,X-RAY DIFFRACTION,2.92,57.92,"VAPOR DIFFUSION, HANGING DROP",7.5,"Protein sample was first mixed Hampton Research Additive Screen H03 40% in 10:1 (V/V) Protein:1,3-propanediol ratio, then set up with 15% PEG8000, 0.2 M MgCl2, 0.1 M HEPES, pH 7.5, vapor diffusion, hanging drop, temperature 291K, VAPOR DIFFUSION, HANGING DROP",291.0,2014-12-12,2015-01-21,4RXX,3663.0,1.0,430.0,224.0,,49.66,1.0,2.06,experimental,35.898,0.2419,0.1891,Crystal Structure of the N-terminal Domain of Human Ubiquitin Specific Protease 38
6GLO,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5",293.0,2018-05-23,2019-02-20,6GLO,2859.0,2.0,364.0,373.0,,42.58,1.0,1.701,experimental,,0.2182,0.175,Crystal structure of hMTH1 N33G in the presence of acetate
8I8S,X-RAY DIFFRACTION,1.89,35.06,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-02-05,2023-03-22,8I8S,3124.0,2.0,312.0,398.0,,37.14,1.0,1.42,experimental,20.09,0.2021,0.1537,Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGMP and Mn2+
8I8T,X-RAY DIFFRACTION,1.9,35.19,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-02-05,2023-03-22,8I8T,3401.0,2.0,312.0,455.0,,37.0,1.0,1.22,experimental,21.61,0.1799,0.1498,Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dAMP and Mn2+
7TUN,X-RAY DIFFRACTION,2.29,46.32,"VAPOR DIFFUSION, HANGING DROP",,"1.7M Ammonium citrate, pH 7.4",293.0,2022-02-03,2023-02-15,7TUN,5710.0,2.0,802.0,7.0,,90.46,1.0,2.93,experimental,80.7713,0.2638,0.2047,Crystal structure analysis of human CKB complex with a covalent compound
5KX8,X-RAY DIFFRACTION,2.62,53.12,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289.0,2016-07-20,2016-08-17,5KX8,9115.0,4.0,1204.0,27.0,,137.3,1.0,2.671,experimental,80.08,0.2327,0.2041,Irak4-inhibitor co-structure
5T1S,X-RAY DIFFRACTION,2.81,56.22,"VAPOR DIFFUSION, HANGING DROP",6.4,.80 to 2.0 M Sodium Malonate 0.2 M Sodium Acetate 25 mM Hexamminecobalt(III)chloride 0.05%w/v Pluronic-F-68,289.0,2016-08-22,2017-05-03,5T1S,9178.0,4.0,1204.0,109.0,,137.47,1.0,2.3,experimental,65.42,0.2226,0.2067,Irak4 kinase - compound 1 co-structure
5T1T,X-RAY DIFFRACTION,2.78,55.74,"VAPOR DIFFUSION, HANGING DROP",6.4,1.80 to 2.0 M Sodium Malonate 0.2 M Sodium Acetate 25 mM Hexamminecobalt(III)chloride 0.05%w/v Pluronic-F-68,289.0,2016-08-22,2017-05-03,5T1T,9166.0,4.0,1204.0,81.0,,137.09,1.0,2.34,experimental,62.77,0.2279,0.2057,Irak4 kinase - compound 1 co-structure
5UIQ,X-RAY DIFFRACTION,2.5,50.81,"VAPOR DIFFUSION, HANGING DROP",,"1.6-1.8 M Ammonium Citrate, pH 7.0",295.0,2017-01-14,2017-05-24,5UIQ,8759.0,4.0,1292.0,63.0,,147.05,1.0,2.64,experimental,59.78,0.226,0.198,Crystal structure of IRAK4 in complex with compound 9
5UIS,X-RAY DIFFRACTION,2.49,50.52,"VAPOR DIFFUSION, HANGING DROP",,"1.6-1.6M Ammonium Citrate, pH 7.0",295.0,2017-01-14,2017-05-24,5UIS,8651.0,4.0,1292.0,137.0,,147.33,1.0,2.5,experimental,52.38,0.25,0.234,Crystal structure of IRAK4 in complex with compound 12
7XHK,X-RAY DIFFRACTION,2.82,56.45,"VAPOR DIFFUSION, HANGING DROP",7.0,"20mg/ml Crystal, 100mM Tris,20% PEG 1000, PH 7.0",289.0,2022-04-08,2023-06-14,7XHK,2674.0,1.0,348.0,47.0,,40.86,1.0,2.3,experimental,62.1903,0.264,0.2203,High-resolution X-ray cocrystal structure of USP7 in complex with LX04-46
6Y4Y,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.7,"0.2 M Ammonium tartarate dibasic pH 6.7, 20% PEG 3350",293.0,2020-02-24,2020-09-30,6Y4Y,7402.0,4.0,1464.0,511.0,,163.78,1.0,1.75,experimental,33.887,0.2274,0.2043,The crystal structure of human MACROD2 in space group P41212
6Y4Z,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.7,"0.2 M Ammonium tartarate dibasic pH 6.7, 20% PEG 3350",293.0,2020-02-24,2020-09-30,6Y4Z,7372.0,4.0,1464.0,440.0,,163.78,1.0,1.9,experimental,42.981,0.2277,0.2005,The crystal structure of human MACROD2 in space group P43212
8P14,X-RAY DIFFRACTION,4.1,69.99,"VAPOR DIFFUSION, SITTING DROP",,"0.05 M NaCl
0.1 M Li2SO4
0.1 M MES pH 6.4
14% PEG4000",293.0,2023-05-11,2024-05-22,8P14,2806.0,1.0,377.0,89.0,,44.59,1.0,2.57,experimental,,0.2181,0.1928,USP28 USP domain in complex with Vismodegib
5WI0,X-RAY DIFFRACTION,2.4,48.7,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 10K, sodium chloride, glycerol, Tris",277.0,2017-07-18,2018-01-10,5WI0,8087.0,2.0,982.0,629.0,,111.68,1.0,2.05,experimental,22.81,0.247,0.219,Crystal structure of human NAMPT with fragment 2: 2-[(2-fluorophenyl)amino]-6-propylpyrimidin-4(3H)-one
5KEG,X-RAY DIFFRACTION,2.13,42.13,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM MOPS
50 mM MgCl2
50 mM CaCl2
23% PEG 3350
15% 2-methyl-2,4-pentanediol",293.0,2016-06-09,2017-05-10,5KEG,1643.0,2.0,218.0,100.0,1.0,27.94,1.0,2.2,experimental,,0.225,0.177,Crystal structure of APOBEC3A in complex with a single-stranded DNA
7M4O,X-RAY DIFFRACTION,2.39,48.46,VAPOR DIFFUSION,5.22,"0.259 M ammonium sulfate, 30.1 % PEG monomethyl ether 2000, 0.1M sodium acetate-acetic acid pH 5.22",293.0,2021-03-21,2022-01-05,7M4O,2247.0,3.0,290.0,81.0,,33.89,2.0,2.21,experimental,41.76,0.2519,0.2008,Crystal structure of phosphorylated RBR E3 ligase RNF216 in complex with K63-linked di-ubiquitin
5SJ5,X-RAY DIFFRACTION,2.61,52.87,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJ5,10531.0,4.0,1372.0,315.0,4.0,158.73,1.0,2.49,experimental,49.845,0.2385,0.1687,Crystal Structure of human phosphodiesterase 10 in complex with 6-chloroquinoxalin-2-amine
6TPV,X-RAY DIFFRACTION,2.38,48.24,"VAPOR DIFFUSION, SITTING DROP",8.3,"0.2 M Sodium citrate tribasic dihydrate pH 8.3, 20 % PEG 3,350",277.0,2019-12-14,2020-05-13,6TPV,3325.0,2.0,416.0,341.0,,45.53,1.0,1.8,experimental,41.93,0.22,0.1855,"Crystal structures of FNIII domain one and two of the human leucocyte common antigen-related protein, LAR"
7P1L,X-RAY DIFFRACTION,2.22,44.56,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium formate pH 7.0
24% PEG3350",277.0,2021-07-01,2021-07-14,7P1L,4751.0,2.0,652.0,103.0,,76.5,1.0,1.95,experimental,34.18,0.2419,0.2096,The MARK3 Kinase Domain Bound To AA-CS-1-008
7N2M,X-RAY DIFFRACTION,4.52,72.81,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.8 mM zinc sulfate, 8.8% v/v PEG MME 550, and 50 mM MES pH 6.5",295.0,2021-05-29,2022-04-20,7N2M,7606.0,3.0,948.0,110.0,,114.82,1.0,2.9,experimental,51.1,0.228,0.195,Crystal structure of DNA polymerase alpha catalytic core in complex with dCTP and template/primer having T-C mismatch at the post-insertion site
4XWG,X-RAY DIFFRACTION,2.66,53.68,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium acetate, 0.2 M zinc acetate, 0.01 M cobalt chloride, 4-8% PEG 1500",293.0,2015-01-28,2015-07-29,4XWG,6395.0,3.0,873.0,104.0,6.0,98.08,3.0,2.65,experimental,52.2498,0.2512,0.1762,Crystal Structure of LCAT (C31Y) in complex with Fab1
7F8Y,X-RAY DIFFRACTION,2.76,55.43,LIPIDIC CUBIC PHASE,,"0.1 M HEPES, pH 7.5, 25%  (v/v) PEG400  and 350 mM ammonium acetate",293.0,2021-07-02,2021-10-13,7F8Y,3499.0,1.0,534.0,,1.0,60.86,1.0,2.5,experimental,80.06,0.2676,0.2149,Crystal structure of the cholecystokinin receptor CCKAR in complex with devazepide
7BGF,X-RAY DIFFRACTION,3.48,64.62,"VAPOR DIFFUSION, HANGING DROP",,Condition F6 of the Morpheus crystallisation screen MD-47 (Molecular Dimensions).,291.0,2021-01-07,2021-06-30,7BGF,1911.0,2.0,254.0,36.0,,30.55,1.0,2.802,experimental,101.8615,0.2528,0.2235,CRYSTAL STRUCTURE OF THE N-TERMINAL DIMERIC COILED COIL OF THE HUMAN CTIP PROTEIN
6Z4Z,X-RAY DIFFRACTION,2.5,50.72,"VAPOR DIFFUSION, SITTING DROP",,"17.5% isopropanol, 5% glycerol, 0.1M sodium/potassium phosphate",277.15,2020-05-26,2020-06-03,6Z4Z,8825.0,3.0,1017.0,418.0,,120.24,1.0,2.07,experimental,27.847,0.2128,0.1749,Crystal structure of CLK1 in complex with macrocycle ODS2004070
7OPG,X-RAY DIFFRACTION,2.52,51.13,"VAPOR DIFFUSION, SITTING DROP",,"25% 1,2-propanediol, 10% glycerol, 0.1M sodium/potassium phosphate",277.15,2021-05-31,2021-07-21,7OPG,9093.0,3.0,1017.0,619.0,,120.92,1.0,1.93,experimental,41.413,0.2078,0.1748,Crystal structure of CLK1 in complex with compound 2 (CC513)
5OKT,X-RAY DIFFRACTION,2.4,48.76,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium sulfate, 0.1 M sodium acetate pH 5.0 and 5 % (w/v) PEG 2000 MME",294.0,2017-07-25,2018-04-25,5OKT,9755.0,4.0,1256.0,363.0,,149.85,2.0,2.13,experimental,,0.2206,0.1932,Crystal structure of human Casein Kinase I delta in complex with IWP-2
5VAR,X-RAY DIFFRACTION,2.12,42.08,"VAPOR DIFFUSION, SITTING DROP",6.5,"18%(w/v) PEG 8000, 0.2M calcium acetate, 0.1M sodium cacodylate pH 6.5",290.0,2017-03-27,2018-03-28,5VAR,961.0,1.0,119.0,74.0,,13.79,1.0,1.83,experimental,28.55,0.243,0.194,Crystal structure of KDM4A tandem TUDOR domain in complex with a tri-methyl lysine competitive inhibitor
4Y8Y,X-RAY DIFFRACTION,3.58,65.69,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM sodium acetate, pH 4.6, 26% w/v MEPEG2000, 200 mM ammonium sulfate",277.0,2015-02-16,2015-05-27,4Y8Y,2010.0,1.0,244.0,78.0,4.0,28.87,1.0,2.6,experimental,23.33,0.2406,0.1961,Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-3-(morpholin-4-yl)-3-oxopropyl]-1H-imidazol-5-yl}phenyl)carbamate
5E2O,X-RAY DIFFRACTION,3.45,64.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2015-10-01,2015-12-09,5E2O,2156.0,1.0,244.0,211.0,5.0,28.87,1.0,2.08,experimental,25.92,0.2138,0.1835,FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[(N-{(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}-L-phenylalanyl)amino]benzoic acid
5E2P,X-RAY DIFFRACTION,3.46,64.47,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2015-10-01,2015-12-09,5E2P,2099.0,1.0,244.0,164.0,4.0,28.88,1.0,2.11,experimental,34.75,0.2585,0.2273,FACTOR XIA IN COMPLEX WITH THE INHIBITOR N-[(1S)-1-benzyl-2-[2-[5-chloro-2-(tetrazol-1-yl)phenyl]ethylamino]-2-oxo-ethyl]-4-hydroxy-2-oxo-1H-quinoline-6-carboxamide
4ZS3,X-RAY DIFFRACTION,2.96,58.4,"VAPOR DIFFUSION, HANGING DROP",,"100 mM sodium citrate, 11% PEG3350, 10% isopropanol",289.0,2015-05-13,2015-11-04,4ZS3,3604.0,1.0,478.0,52.0,1.0,55.48,1.0,2.45,experimental,69.274,0.26257,0.20608,Structural complex of 5-aminofluorescein bound to the FTO protein
5UNA,X-RAY DIFFRACTION,2.41,49.05,"VAPOR DIFFUSION, HANGING DROP",8.0,"Pre-incubated with SAM in 10-fold stoichiometric excess. Reservoir: 22% PEG 3350, 0.1 M Ammonium Sulfate, 0.1 M Tris-HCl.",293.0,2017-01-30,2017-03-08,5UNA,9632.0,11.0,1782.0,,3.0,204.91,2.0,2.55,experimental,90.63,0.217,0.204,Fragment of 7SK snRNA methylphosphate capping enzyme
,,,,"VAPOR DIFFUSION, HANGING DROP",8.0,"Purified protein (10 mg/mL) was complexed with S-adenosyl-L-methionine in a 1:10 stoichiometric ratio. This solution (2 muL) was then mixed with precipitant: 22% PEG 3350, 0.1 M ammonium sulfate, 0.1 M TRIS-HCl.",291.0,,,,,,,,,,,,,,,,
4QDE,X-RAY DIFFRACTION,2.35,47.62,"VAPOR DIFFUSION, HANGING DROP",4.0,"1:1 protein (4 mg/mL in 25 mM sodium chloride, 20 mM Tris-HCl, pH 8.0, 1 mM TCEP) to precipitant (23-25% PEG3350, 0.1 M potassium phosphate monobasic, 0.05 M sodium chloride, 26% glycerol), VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-05-13,2015-05-13,4QDE,9642.0,4.0,1348.0,,,155.71,1.0,2.9,experimental,65.73,0.2514,0.2088,Dcps in complex with covalent inhibitor
6EA4,X-RAY DIFFRACTION,3.19,61.38,"VAPOR DIFFUSION, SITTING DROP",6.5,"10% PEG 8000, 20% ethylene glycol, 61 mM MES, 39 mM imidazole, 20 mM sodium-L-glutamate, 20 mM D-L-alanine, 20 mM glycine, 20 mM D-L-lysine, 20 mM D-L-serine (Morpheus H2)",297.0,2018-08-02,2019-12-18,6EA4,15097.0,2.0,1822.0,209.0,4.0,218.81,1.0,2.45,experimental,82.35,0.2361,0.208,ERAP2 bound to Aryl Sulfonamide Uncompetitive Inhibitor
7NEE,X-RAY DIFFRACTION,2.62,53.09,"VAPOR DIFFUSION, SITTING DROP",6.5,"23% PEG 8000, 200mM Ammonium Citrate, 100 mM MES",293.0,2021-02-03,2021-04-07,7NEE,3180.0,1.0,400.0,20.0,3.0,46.34,1.0,2.55,experimental,39.852,0.3156,0.2543,Inhibitor Complex with Thrombin Activatable Fibrinolysis inhibitor (TAFIa)
7P7H,X-RAY DIFFRACTION,2.3,46.53,"VAPOR DIFFUSION, SITTING DROP",5.5,"18% PEG 6000, 1 M LiCl and 0.1 M citrate, pH 5.5",277.15,2021-07-19,2022-04-13,7P7H,4918.0,2.0,592.0,96.0,,69.54,1.0,2.4,experimental,43.573,0.2684,0.223,Crystal structure of Casein Kinase I delta (CK1d) with alphaG-in conformation
5UI1,X-RAY DIFFRACTION,1.98,37.82,"VAPOR DIFFUSION, SITTING DROP",8.0,"20-26% MPD, 4-8% PEG5000MME, 1 mM Manganese chloride, 10 mM Tris",289.0,2017-01-12,2018-01-17,5UI1,10491.0,4.0,1332.0,358.0,,152.74,1.0,1.96,experimental,23.135,0.24565,0.21115,Crystal Structure of Human Protein Phosphatase 5C (PP5C) in complex with a triazole inhibitor
6PGV,X-RAY DIFFRACTION,2.36,47.9,MICROBATCH,4.6,"0.1 M sodium acetate pH 4.6, 0.2 M CaCl2, 22.5% (w/v) PEG 6000; microbatch under Al's Oil",293.0,2019-06-24,2019-10-23,6PGV,1825.0,2.0,263.0,24.0,,29.44,2.0,2.3,experimental,,0.224,0.201,Human Josephin-2 in complex with ubiquitin
5GO4,X-RAY DIFFRACTION,3.46,64.47,"VAPOR DIFFUSION, HANGING DROP",,0.2M sodium citrate tribasic dehydrate and 20~22% PEG3350,293.0,2016-07-26,2017-01-25,5GO4,3475.0,1.0,433.0,184.0,,48.42,1.0,2.202,experimental,,0.2139,0.1751,"Truncated mitofusin-1, nucleotide-free"
6DNB,X-RAY DIFFRACTION,2.32,47.04,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 8.5, 20% w/v/ PEG MME 2,000, 0.2 M Trimethylamine N-oxide dehydrate",298.0,2018-06-06,2018-11-14,6DNB,3566.0,1.0,411.0,237.0,,46.81,1.0,1.7,experimental,24.887,0.22873,0.179,Crystal structure of T110A:S256A mutant human Glutamate oxaloacetate transaminase 1 (GOT1)
5I8P,X-RAY DIFFRACTION,2.48,50.43,"VAPOR DIFFUSION, HANGING DROP",6.6,"0.1M MOPS pH 6.6, 0.4M Li2SO4, 27% (w/v) (NH4)2SO4, 1M Na-Ac, 1.4% 1,4-butanediol",293.0,2016-02-19,2016-06-15,5I8P,5736.0,2.0,776.0,31.0,,88.97,1.0,2.37,experimental,29.0238,0.2745,0.2056,Crystal structure of LP_PLA2 in complex with novel inhibitor
4ZSJ,X-RAY DIFFRACTION,3.04,59.5,"VAPOR DIFFUSION, HANGING DROP",6.25,"4-6 % w/v PEG 6000, 0.1 M MES, 5 mM DTT",293.0,2015-05-13,2016-05-04,4ZSJ,3100.0,1.0,344.0,261.0,,40.09,1.0,2.48,experimental,49.09,0.2303,0.1671,MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
7Q7C,X-RAY DIFFRACTION,2.78,55.82,BATCH MODE,,"20 mg/ml protein in 25 mM HEPES pH 7.5, 500 mM NaCl, 0.5 mM TCEP was mixed 1:1.5 with precipitant solution (0.1 M HEPES 6.5, 0.2M ammonium acetate, 20% PEG 3350, 50mM sodium/potassium tartrate, 0.8mM quercetin). Batch grown crystals were subsequently mixed 1:1 with 100 mM ATP/50mM magnesium chloride in DRAK2 crystallization buffer and incubated for half an hour.",295.0,2021-11-09,2022-11-16,7Q7C,2231.0,1.0,327.0,6.0,,37.78,1.0,2.85,experimental,97.15,0.2376,0.2072,Room temperature structure of the human Serine/Threonine Kinase 17B (STK17B/DRAK2) in complex with ADP at atmospheric pressure
5CVM,X-RAY DIFFRACTION,3.04,59.56,"VAPOR DIFFUSION, HANGING DROP",,3.6 M sodium formate,292.0,2015-07-27,2015-10-07,5CVM,3585.0,2.0,454.0,381.0,,52.77,2.0,1.9,experimental,39.39,0.1972,0.1756,USP46~ubiquitin BEA covalent complex
5G6V,X-RAY DIFFRACTION,2.44,49.51,,5.5,"25% PEG MEDIUM SMEAR (PEG 2000, PEG 3350, PEG 4000, PEG 5000MME) AND 0.1 M CITRATE PH 5.5",,2016-08-16,2016-11-23,5G6V,5172.0,2.0,648.0,262.0,,75.97,1.0,2.2,experimental,40.421,0.2711,0.20785,Crystal structure of the PCTAIRE1 kinase in complex with inhibitor
6JVI,X-RAY DIFFRACTION,2.28,45.99,EVAPORATION,3.75,"30% PEG 6000, 200 mM Lithium sulphate, 100 mM Sodium acetate pH 3.75",298.0,2019-04-17,2020-10-28,6JVI,2671.0,2.0,312.0,145.0,,36.68,1.0,2.249,experimental,29.8308,0.2651,0.1955,Crystal structure of human MTH1 in complex with compound MI0861
6KDR,X-RAY DIFFRACTION,2.98,58.73,VAPOR DIFFUSION,8.3,"0.1M Tris pH 8.3, 6% w/v Polyethylene glycol 8000",291.0,2019-07-02,2020-07-08,6KDR,3935.0,4.0,506.0,246.0,,58.4,2.0,2.112,experimental,43.636,0.2047,0.1783,Crystal structure of human NRMT2 in complex with human centromere protein B peptide
7JQK,X-RAY DIFFRACTION,3.23,61.88,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.0M Ammonium Sulfate 2% PEG400, 10mM CdCl2 at pH 7.5",293.0,2020-08-11,2021-07-21,7JQK,3729.0,2.0,388.0,644.0,8.0,43.06,2.0,1.33,experimental,31.0275,0.1533,0.1189,Crystal structure of the R64A mutant of Bauhinia Bauhinioides Kallikrein Inhibitor complexed with Human Kallikrein 4
4D78,X-RAY DIFFRACTION,2.38,48.3,MICROBATCH,5.0,MICROBATCH UNDER OIL WITH 10% PEG 3350 AND 80 MM SODIUM MALONATE PH 5.0,,2014-11-21,2015-09-23,4D78,3789.0,1.0,487.0,6.0,,56.99,1.0,2.8,experimental,102.012,0.27237,0.19295,Cytochrome P450 3A4 bound to an inhibitor
6DA2,X-RAY DIFFRACTION,2.22,44.53,MICROBATCH,7.0,"peg 3350, malonate",298.0,2018-05-01,2019-04-03,6DA2,3759.0,1.0,487.0,,,56.97,1.0,2.65,experimental,,0.2562,0.1964,Human CYP3A4 bound to an inhibitor
6DAB,X-RAY DIFFRACTION,2.21,44.24,MICROBATCH,7.0,"peg 3350, malonate",293.0,2018-05-01,2019-04-03,6DAB,3609.0,1.0,487.0,11.0,,56.99,1.0,2.35,experimental,,0.2698,0.2149,Human CYP3A4 bound to an inhibitor
6DAL,X-RAY DIFFRACTION,2.22,44.53,MICROBATCH,7.0,"PEG 3350, malonate",293.0,2018-05-01,2019-04-03,6DAL,3752.0,1.0,487.0,,,56.97,1.0,2.65,experimental,,0.2676,0.2003,Human CYP3A4 bound to an inhibitor
6H0W,X-RAY DIFFRACTION,2.53,51.32,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2018-07-10,2020-01-29,6H0W,3547.0,1.0,342.0,479.0,,40.94,1.0,1.23,experimental,18.4929,0.1355,0.1201,Crystal Structure of KDM4D with tetrazolylhydrazide ligand NS035
6H10,X-RAY DIFFRACTION,2.52,51.28,VAPOR DIFFUSION,7.0,"100mM HEPES, 180mM ammonium sulphate, 24% PEG 3350",293.0,2018-07-10,2020-01-29,6H10,3662.0,1.0,342.0,506.0,,41.06,1.0,1.104,experimental,17.4623,0.1331,0.1213,Crystal Structure of KDM4D with tetrazolylhydrazide ligand NR073
6VAX,X-RAY DIFFRACTION,2.67,53.87,"VAPOR DIFFUSION, HANGING DROP",5.0,"100 mM Sodium malonate, 12 % w/v PEG 3350, 10 mM Oxaloacetate",298.0,2019-12-18,2020-08-26,6VAX,11494.0,4.0,1596.0,99.0,,180.84,2.0,2.59,experimental,93.32,0.2489,0.1991,Crystal structure of human SDHA-SDHAF2 assembly intermediate
5ANV,X-RAY DIFFRACTION,1.99,38.3,,4.5,PH 4.5,,2015-09-08,2016-03-02,5ANV,1464.0,1.0,158.0,140.0,,18.49,1.0,1.16,experimental,21.34,0.2114,0.2037,MTH1 in complex with compound 15
5ANW,X-RAY DIFFRACTION,2.01,38.72,,4.5,pH 4.5,,2015-09-08,2016-03-02,5ANW,1352.0,1.0,158.0,73.0,,18.41,1.0,1.37,experimental,14.98,0.2253,0.1989,MTH1 in complex with compound 24
6US2,X-RAY DIFFRACTION,1.99,38.13,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 6000, 0.1M sodium acetate pH 4.0, 0.2M lithium sulfate",293.0,2019-10-24,2020-04-01,6US2,1388.0,1.0,159.0,96.0,,18.55,1.0,1.80012657096,experimental,20.3422922636,0.234421783229,0.176010896719,MTH1 in complex with compound 5
6US3,X-RAY DIFFRACTION,1.98,37.93,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 6000, 0.1M sodium acetate pH 4.0, 0.2M lithium sulfate",293.0,2019-10-24,2020-04-01,6US3,1421.0,1.0,159.0,129.0,,18.55,1.0,1.47028917623,experimental,16.9610286914,0.222219277267,0.1865002798,MTH1 in complex with compound 4
6US4,X-RAY DIFFRACTION,1.99,38.06,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 6000, 0.1M sodium acetate pH 4.0, 0.2M lithium sulfate",293.0,2019-10-24,2020-04-01,6US4,1364.0,1.0,159.0,76.0,,18.53,1.0,1.95032907402,experimental,21.2333500652,0.244401912066,0.175057190813,MTH1 in complex with compound 32
8PHD,X-RAY DIFFRACTION,2.65,53.55,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350
0.2 M lithium citrate
1 mM ATP
5 mM MgCl2",277.0,2023-06-19,2023-08-16,8PHD,6874.0,4.0,934.0,282.0,,108.46,2.0,2.08,experimental,45.92,0.2048,0.1764,Structure of Human Cdc123 bound to domain 3 of eIF2 gamma and ATP
6KZE,X-RAY DIFFRACTION,2.25,45.32,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes (pH 7.5), 0.2 M, MgCl2, 18% PEG 3350, 50 mM 2-mercaptoethanol",277.0,2019-09-24,2020-09-30,6KZE,5236.0,2.0,644.0,86.0,,75.79,1.0,2.50003487525,experimental,43.1291424752,0.327865767607,0.242470513996,The crystal structue of PDE10A complexed with 4d
5C0K,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"3.9M NaCl, 0.1M HEPES/NaOH pH=7.5",277.0,2015-06-12,2015-08-12,5C0K,995.0,1.0,110.0,126.0,,13.06,1.0,2.2,experimental,62.5,0.2239,0.2016,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 3
5C0L,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"3.9M NaCl, 0.1M HEPES/NaOHpH=7.5",277.0,2015-06-12,2015-08-12,5C0L,935.0,1.0,110.0,56.0,,12.98,1.0,2.6,experimental,45.118,0.23234,0.19979,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 2
5C3H,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277.0,2015-06-17,2015-08-12,5C3H,949.0,1.0,110.0,67.0,,12.96,1.0,2.65,experimental,67.677,0.2488,0.2051,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 1
5C3K,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277.0,2015-06-17,2015-08-12,5C3K,1049.0,1.0,110.0,169.0,1.0,12.93,1.0,2.02,experimental,41.124,0.25995,0.21696,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 4
5C7A,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCL",277.0,2015-06-24,2015-08-12,5C7A,1004.0,1.0,110.0,118.0,1.0,13.01,1.0,2.36,experimental,39.267,0.26442,0.21899,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 7
5C7B,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277.0,2015-06-24,2015-08-12,5C7B,975.0,1.0,110.0,93.0,1.0,12.96,1.0,2.68,experimental,39.172,0.26489,0.20248,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 5
5C7C,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277.0,2015-06-24,2015-08-12,5C7C,1014.0,1.0,110.0,117.0,,13.07,1.0,2.32,experimental,43.486,0.28578,0.22347,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 18
5C83,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277.0,2015-06-25,2015-08-12,5C83,1049.0,1.0,110.0,143.0,,13.18,1.0,2.33,experimental,44.985,0.27295,0.20923,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 21
5C84,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277.0,2015-06-25,2015-08-12,5C84,1042.0,1.0,110.0,142.0,,13.12,1.0,2.36,experimental,41.079,0.25852,0.19795,Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 20
5M6F,X-RAY DIFFRACTION,4.67,73.68,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M HEPES/NaOHpH=8, 3.3M NaCl,",277.0,2016-10-25,2017-05-24,5M6F,1050.0,1.0,127.0,159.0,,15.09,1.0,2.39,experimental,45.004,0.261,0.202,Small Molecule inhibitors of IAP
5M6H,X-RAY DIFFRACTION,4.57,73.06,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M HEPES/NaOH pH8, 3.3M NaCl",277.0,2016-10-25,2017-05-24,5M6H,1065.0,1.0,127.0,166.0,,15.16,1.0,2.5,experimental,42.711,0.264,0.184,Small Molecule inhibitors of IAP
5M6L,X-RAY DIFFRACTION,4.62,73.4,"VAPOR DIFFUSION, SITTING DROP",8.0,"3.3M NaCl
.1M pH=8 HEPES/NaOH",277.0,2016-10-25,2017-05-24,5M6L,1016.0,1.0,127.0,111.0,,15.17,1.0,2.61,experimental,43.55,0.263,0.197,Small Molecule inhibitors of IAP
5M6M,X-RAY DIFFRACTION,4.58,73.16,"VAPOR DIFFUSION, SITTING DROP",8.0,"3.3M NaCl
.1M pH=8 HEPES/NaOH",277.0,2016-10-25,2017-05-24,5M6M,1093.0,1.0,127.0,190.0,,15.14,1.0,2.37,experimental,42.763,0.233,0.187,Small Molecule inhibitors of IAP
7L0F,X-RAY DIFFRACTION,2.52,51.1,"VAPOR DIFFUSION, HANGING DROP",,"0.225 M Potassium sodium tartrate tetrahydrate, 15% w/v Polyethylene glycol 3,350",291.0,2020-12-11,2021-03-24,7L0F,8875.0,8.0,1056.0,641.0,,119.07,2.0,1.98,experimental,35.681,0.1912,0.1594,Monobody 12VC3 Bound to HRAS(WT)
5K0X,X-RAY DIFFRACTION,2.25,45.26,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein at 32.5 mg/mL (in 20 mM Tris pH 8.0, 500 mM NaCl, 2mM BME) was incubated overnight with inhibitor at 2.5 mM final concentration, and then was mixed 1:1 with crystallization solution (27-33% (v/v) Peg 400, 200 mM MgCl2, 100 mM Tris pH 8.5).",286.0,2016-05-17,2017-02-22,5K0X,4313.0,2.0,626.0,95.0,,72.9,1.0,2.231,experimental,48.6854,0.239,0.1848,Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC2541
8OQH,X-RAY DIFFRACTION,2.02,38.96,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris pH8.5, 0.2M Sodium acetate trihydrate, 30% w/v PEG 4000",288.0,2023-04-12,2023-11-29,8OQH,1281.0,2.0,182.0,73.0,,19.88,1.0,1.76,experimental,38.94,0.224,0.1942,Structure of the cytosolic domain of lysosome-associated TMEM55B
5SHY,X-RAY DIFFRACTION,3.03,59.43,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHY,2660.0,1.0,343.0,79.0,1.0,40.0,1.0,2.3,experimental,51.62,0.249,0.1932,"Crystal Structure of human phosphodiesterase 10 in complex with [8-[(2-methyl-1,3-thiazol-4-yl)amino]-5-pyridin-3-yl-1,7-naphthyridin-2-yl]methanol"
5TFU,X-RAY DIFFRACTION,3.14,60.88,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, SODIUM ACETATE, SODIUM CACODYLATE, POTASSIUM PHOSPHATE, SODIUM CHLORIDE, ZINC CHLORIDE, GLYCEROL, BETA-MERCAPTOETHANOL, THIORIDAZINE, HEGA-10, FACIAL AMPHIPHILE 231_CHOL. BETA-SECRETASE INHIBITOR WAS ADDED TO THE MOTHER LIQUOR AFTER CRYSTALLIZATION OF THE P450 2D6 THIORDIDAZINE TERNARY COMPLEX.",298.0,2016-09-26,2017-01-11,5TFU,14697.0,4.0,1916.0,124.0,,219.29,1.0,2.75,experimental,,0.2497,0.2115,Structure of cytochrome P450 2D6 (CYP2D6) BACE1 inhibitor complex
6ZKW,X-RAY DIFFRACTION,2.47,50.3,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS pH 8.5, 25 % (w/v) PEG 4000, 15 % Glycerol",293.15,2020-06-30,2022-01-26,6ZKW,6532.0,5.0,829.0,52.0,8.0,93.67,5.0,2.26,experimental,61.858,0.28706,0.24291,Crystal structure of InhA:01 TCR in complex with HLA-E bound to InhA (53-61)
6ZKX,X-RAY DIFFRACTION,2.46,49.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris pH 8.5, 25% (w/v) PEG 4000, 15% Glycerol",293.15,2020-06-30,2022-01-26,6ZKX,6828.0,5.0,833.0,257.0,10.0,94.46,5.0,2.17,experimental,45.68,0.24419,0.20908,Crystal structure of InhA:01 TCR in complex with HLA-E (Y84C) bound to InhA (53-61 GCG)
6ZKY,X-RAY DIFFRACTION,2.54,51.5,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Sodium chloride, 0.1 M BIS-TRIS pH 6.5, 1.5 M Ammonium sulfate",293.15,2020-06-30,2022-01-26,6ZKY,6503.0,5.0,829.0,11.0,8.0,93.71,5.0,2.65,experimental,78.825,0.27281,0.22679,Crystal structure of InhA:01 TCR in complex with HLA-E (S147C) bound to InhA (53-61 H3C)
6ZKZ,X-RAY DIFFRACTION,2.42,49.14,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris pH 8.5, 20% (w/v) PEG 4000, 15% Glycerol",293.15,2020-06-30,2022-01-26,6ZKZ,6582.0,5.0,829.0,99.0,9.0,93.91,5.0,2.3,experimental,55.41,0.26731,0.22361,Crystal structure of InhA:01 TCR in complex with HLA-E (F116C) bound to InhA (53-61 H4C)
5MAI,X-RAY DIFFRACTION,2.51,50.92,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1 M BIS TRIS pH 6.5, 0.6M NaCl",293.0,2016-11-03,2017-12-06,5MAI,2667.0,1.0,347.0,65.0,,40.76,1.0,2.15,experimental,53.954,0.2371,0.18939,Crystal structure of MELK in complex with an inhibitor
5KU9,X-RAY DIFFRACTION,2.07,40.72,"VAPOR DIFFUSION, SITTING DROP",8.0,"30% PEG 4000, 0.1 M Tris",293.0,2016-07-13,2017-01-11,5KU9,2489.0,2.0,324.0,87.0,,37.91,1.0,2.2,experimental,64.61,0.241,0.187,Crystal structure of MCL1 with compound 1
7BDI,X-RAY DIFFRACTION,2.41,48.96,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2020-12-21,2021-06-09,7BDI,16269.0,2.0,2010.0,217.0,,230.89,2.0,2.8,experimental,56.79,0.2974,0.2367,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and ATPgammaS
7BDJ,X-RAY DIFFRACTION,2.41,49.05,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2020-12-21,2021-06-09,7BDJ,16197.0,2.0,2010.0,148.0,,231.16,2.0,2.59,experimental,65.34,0.2891,0.2303,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and mant-ATPgammaS
7BDK,X-RAY DIFFRACTION,2.4,48.83,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2020-12-21,2021-06-09,7BDK,16249.0,2.0,2010.0,309.0,,230.7,2.0,2.52,experimental,55.51,0.2836,0.2281,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and ADP
7BDL,X-RAY DIFFRACTION,2.43,49.29,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2020-12-21,2021-06-09,7BDL,16356.0,2.0,2010.0,292.0,,230.97,2.0,2.69,experimental,59.97,0.2919,0.2316,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and mant-ADP
8BCA,X-RAY DIFFRACTION,2.45,49.76,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Hepes-NaOH, 0.1M MgCl2, 8% PEG 3350",291.15,2022-10-15,2023-03-08,8BCA,16236.0,2.0,2010.0,173.0,,230.88,2.0,2.8,experimental,78.42,0.2575,0.1991,Human Brr2 Helicase Region in complex with C-tail deleted Jab1 and compound 26
5FSM,X-RAY DIFFRACTION,2.01,38.74,,,25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5,,2016-01-06,2016-07-20,5FSM,1446.0,1.0,156.0,176.0,,18.45,1.0,1.67,experimental,17.31,0.2101,0.1795,MTH1 substrate recognition: Complex with a methylbenzimidazolyl acetamide.
5FSN,X-RAY DIFFRACTION,2.01,38.93,,,25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5,,2016-01-06,2016-07-20,5FSN,1424.0,1.0,156.0,158.0,,18.29,1.0,1.69,experimental,19.06,0.2252,0.1884,MTH1 substrate recognition: Complex with a aminomethylpyrimidinyl oxypropanol.
5FSO,X-RAY DIFFRACTION,2.01,38.77,,,25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5,,2016-01-06,2017-01-18,5FSO,1438.0,1.0,156.0,164.0,,18.33,1.0,1.67,experimental,17.08,0.2122,0.1836,MTH1 substrate recognition: Complex with a methylaminopyrimidinedione.
7M2K,X-RAY DIFFRACTION,2.4,48.74,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES pH 7.0
29% PEG3350
40 mM DL-Malic acid
5 mM DTT",293.0,2021-03-16,2021-11-03,7M2K,7347.0,8.0,1040.0,27.0,,119.43,2.0,2.47,experimental,80.2926,0.2758,0.2187,CDC34A-Ubiquitin-2ab inhibitor complex
6F4N,X-RAY DIFFRACTION,3.19,61.48,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M Bis-Tris pH 6.0, 21.4 % PEG3350, 0.07 M MgCl2, 0.002 M MnCl2, 300 nl sitting drops (sample:well, 1:2 ratio)",298.0,2017-11-29,2018-04-04,6F4N,4200.0,2.0,542.0,189.0,1.0,63.12,1.0,2.541,experimental,,0.2299,0.1994,Human JMJD5 in complex with MN and 2OG.
7F8U,X-RAY DIFFRACTION,2.74,55.04,LIPIDIC CUBIC PHASE,,"0.1 M HEPES, pH7.5, 25% PEG400, 250 mM sodium tartrate ,1% 1,2 -butanediol",293.0,2021-07-02,2021-10-13,7F8U,3510.0,1.0,534.0,,1.0,60.86,1.0,2.8,experimental,91.14,0.253,0.236,Crystal structure of the cholecystokinin receptor CCKAR in complex with lintitript
4ZHA,X-RAY DIFFRACTION,1.85,33.59,"VAPOR DIFFUSION, HANGING DROP",,"16-20% PEG 6K, 50 mM Mes-NaOH (pH 5.7-6.0), 5 mM CaCl2, and 50 mM NaCl",293.0,2015-04-24,2016-01-13,4ZHA,2549.0,2.0,388.0,268.0,8.0,44.28,2.0,1.86,experimental,33.901,0.2382,0.1953,Factor Xa complex with GTC000102
6P7Z,X-RAY DIFFRACTION,2.19,43.87,"VAPOR DIFFUSION, HANGING DROP",,"Sitting drop, room temp, reservoir is 20%PEG 3350, 0.2M MgOAc
protein at 5mg/ml ratio to reservoir is 1:1, seed 
Soaking: 0.1ul of 200mM compound in DMSO added to drop for 72 hours before harvest",295.0,2019-06-06,2020-01-15,6P7Z,4048.0,1.0,432.0,560.0,,50.5,1.0,1.19,experimental,15.2884,0.1981,0.1809,Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors
8YHP,X-RAY DIFFRACTION,2.32,46.92,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Na/K PO4, 20% PEG 3,350",293.0,2024-02-28,2024-03-13,8YHP,3432.0,1.0,416.0,288.0,,44.67,1.0,1.95,experimental,37.359,0.2864,0.2337,Structure of the PGK1 from Biortus.
7QBH,X-RAY DIFFRACTION,2.1,41.46,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.5 M sodium citrate, 0.1 M Tris pH 8.0",296.0,2021-11-19,2022-03-16,7QBH,2396.0,1.0,260.0,266.0,,29.53,1.0,1.223,experimental,12.585,0.177,0.1523,Selenocarbamates as a novel prodrug-based approach towards Carbonic Anhydrase inhibition (hCA II)
8W3W,X-RAY DIFFRACTION,2.45,49.87,"VAPOR DIFFUSION, HANGING DROP",7.0,ammonium citrate tribasic,295.0,2024-02-22,2024-05-01,8W3W,9879.0,4.0,1292.0,596.0,,147.6,1.0,1.976,experimental,44.41,0.2126,0.1921,Crystal structure of IRAK4 in complex with compound 4
8W3X,X-RAY DIFFRACTION,2.47,50.12,"VAPOR DIFFUSION, HANGING DROP",,AMMONIUM CITRATE,295.0,2024-02-22,2024-05-01,8W3X,9936.0,4.0,1292.0,728.0,,147.65,1.0,1.765,experimental,37.62,0.2124,0.1901,Crystal structure of IRAK4 in complex with compound 6
5OHK,X-RAY DIFFRACTION,2.46,50.0,"VAPOR DIFFUSION, SITTING DROP",5.4,"10% (w/v) PEG 20000, 0.1 M sodium citrate pH 5.4, 0.2 M lithium sulfate",291.0,2017-07-17,2017-09-20,5OHK,3017.0,2.0,412.0,82.0,,47.15,2.0,2.34,experimental,,0.2605,0.2291,Crystal structure of USP30 in covalent complex with ubiquitin propargylamide (high resolution)
6FYK,X-RAY DIFFRACTION,2.38,48.29,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% PEG2000, 0.2M trimethylamine n-oxide, 0.1M TRIS",298.0,2018-03-12,2018-07-18,6FYK,9306.0,3.0,1089.0,466.0,,129.28,1.0,2.39,experimental,36.307,0.2281,0.1948,X-Ray structure of CLK2-KD(136-496)/Indazole1 at 2.39A
4Y73,X-RAY DIFFRACTION,2.64,53.4,"VAPOR DIFFUSION, HANGING DROP",6.4,"0.03 M hexammine cobalt (III) chloride
0.2 M sodium acetate
0.05 w/v pluronic F-68
1.9 M sodium malonate pH 6.4",291.0,2015-02-13,2015-05-20,4Y73,9744.0,4.0,1208.0,395.0,,137.74,1.0,2.14,experimental,55.82,0.2175,0.1953,Crystal structure of IRAK4 kinase domain with inhibitor
4U1B,X-RAY DIFFRACTION,2.47,50.29,"VAPOR DIFFUSION, HANGING DROP",6.0,"PEG 2000, potassium chloride, hepes, sodium chloride, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2014-07-15,2015-03-25,4U1B,2592.0,1.0,306.0,171.0,,34.87,1.0,1.89,experimental,33.14,0.221,0.169,HsMetAP in complex with (1-amino-2-propylpentyl)phosphonic acid
4U6C,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 2000, potassium chloride, hepes, sodium chloride, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2014-07-28,2015-03-25,4U6C,2555.0,1.0,306.0,138.0,,34.91,1.0,1.91,experimental,41.04,0.229,0.183,HsMetAP in complex with [(1R)-1-amino-3-cyclopentylpropyl]phosphonic acid
4U6Z,X-RAY DIFFRACTION,2.49,50.64,"VAPOR DIFFUSION, HANGING DROP",6.0,"15% PEG-MME, 100mM HEPES, PH 6",298.0,2014-07-30,2015-04-15,4U6Z,2709.0,1.0,306.0,242.0,,34.87,1.0,1.8,experimental,26.23,0.204,0.167,HsMetAP(F309M) in complex with 1-amino-2-propylpentyl)phosphonic acid
4U71,X-RAY DIFFRACTION,2.57,52.18,"VAPOR DIFFUSION, HANGING DROP",6.0,"15% PEGMME, 100mM HEPES PH 6",298.0,2014-07-30,2015-03-25,4U71,2678.0,1.0,306.0,246.0,,34.88,1.0,1.8,experimental,27.81,0.195,0.157,HsMetAP(F309M) IN COMPLEX WITH 1- amino(cyclohexyl)methy)phosphonic acid
6LZB,X-RAY DIFFRACTION,2.42,49.13,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M Bistris pH-6.2, 19% PEG 3350, 5% Glycerol",298.0,2020-02-18,2021-02-24,6LZB,2694.0,1.0,329.0,195.0,,37.67,1.0,1.29,experimental,25.322,0.1998,0.1626,crystal structure of Human Methionine aminopeptidase (HsMetAP1b) in complex with AN-P2-5H-06
6LZC,X-RAY DIFFRACTION,2.42,49.12,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M Bistris pH-6.2, 19% PEG 3350, 5% Glycerol",298.0,2020-02-18,2021-02-24,6LZC,2702.0,1.0,329.0,183.0,,37.64,1.0,1.35,experimental,26.657,0.1972,0.1674,crystal structure of Human Methionine aminopeptidase (HsMetAP1b) in complex with KV-P2-4H-05
5PH0,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, SITTING DROP",7.0,28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate,298.0,2017-02-07,2017-03-15,5PH0,3476.0,1.0,364.0,460.0,,43.43,1.0,1.341,experimental,19.8835,0.1624,0.1281,PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09484a
5PHO,X-RAY DIFFRACTION,2.31,46.84,"VAPOR DIFFUSION, SITTING DROP",7.0,28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate,298.0,2017-02-07,2017-03-15,5PHO,3384.0,1.0,364.0,442.0,,43.13,1.0,1.4,experimental,16.719,0.1892,0.1682,PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 1)
8WXW,X-RAY DIFFRACTION,2.28,46.07,"VAPOR DIFFUSION, SITTING DROP",,"4% w/v PEG 1500, 20% v/v glycerol",293.15,2023-10-30,2024-08-07,8WXW,9724.0,2.0,1172.0,762.0,,137.45,2.0,1.86,experimental,37.72,0.2096,0.1889,Falcilysin in complex with hemoglobin alpha chain peptide
7Z9F,X-RAY DIFFRACTION,2.18,43.62,"VAPOR DIFFUSION, HANGING DROP",7.5,"1 uL protein (15 mg/mL in 20 mM Hepes pH 7.4, 150 mM NaCl, 1 mM CaCl2) + 1 uL well solution (22% PEG 4000, 0.1 M Hepes pH 7.5, 0.1 M NaAc)",293.0,2022-03-21,2022-06-29,7Z9F,4138.0,4.0,448.0,770.0,8.0,48.24,2.0,1.7,experimental,20.03,0.2186,0.187,Human anionic trypsin after autoproteolysis at Arg122
5SGB,X-RAY DIFFRACTION,2.61,52.87,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGB,10676.0,4.0,1372.0,448.0,4.0,159.06,1.0,2.39,experimental,45.704,0.242,0.1791,Crystal Structure of human phosphodiesterase 10 in complex with 5-(4-chloronaphthalen-1-yl)oxythiadiazole
5SJ0,X-RAY DIFFRACTION,2.59,52.57,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJ0,10545.0,4.0,1372.0,317.0,4.0,158.94,1.0,2.35,experimental,49.66,0.2319,0.1793,Crystal Structure of human phosphodiesterase 10 in complex with N-cyclohexyl-N-methyl-9H-purin-6-amine
6RA7,X-RAY DIFFRACTION,2.39,48.57,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350 w/v, 0.1M PCTP (pH 8.0), 200 mM sodium formate w/v",298.0,2019-04-05,2019-11-06,6RA7,2768.0,1.0,306.0,351.0,,35.49,1.0,1.2,experimental,,,,Human tnik in complex with compound 9
5AYR,X-RAY DIFFRACTION,2.24,45.03,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris HCl pH8.5, 0.2 M MgCl2 6H2O and 30% PEG 4000",293.0,2015-09-02,2016-06-08,5AYR,6002.0,4.0,686.0,518.0,,80.06,2.0,2.4,experimental,41.49,0.19767,0.16527,The crystal structure of SAUGI/human UDG complex
5ZQY,X-RAY DIFFRACTION,2.11,41.84,"VAPOR DIFFUSION, HANGING DROP",6.0,"MES pH 6.0, PEG MME 2000",298.0,2018-04-20,2018-08-15,5ZQY,2983.0,1.0,349.0,262.0,,38.46,1.0,1.577,experimental,,0.1799,0.1574,Crystal structure of a poly(ADP-ribose) glycohydrolase
5CA7,X-RAY DIFFRACTION,2.6,52.77,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Lithium Sulfate monohydrate, 0.1M HEPES-Sodium, 0.1M Potassium Sodium Tartrate",277.0,2015-06-29,2016-02-24,5CA7,4320.0,4.0,680.0,184.0,1.0,78.94,1.0,2.522,experimental,,0.2462,0.2085,Human DNA polymerase lambda- MgdGTP binary and complex with 6 paired DNA
5CHG,X-RAY DIFFRACTION,2.59,52.48,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Lithium Sulfate monohydrate, 0.1M HEPES-Sodium, 0.1M Potassium Sodium Tartrate",277.0,2015-07-10,2016-02-24,5CHG,4144.0,4.0,680.0,18.0,1.0,78.88,1.0,2.9,experimental,,0.2474,0.2051,Human DNA polymerase lambda L431A mutant- MgdGTP binary and complex with 6 paired DNA
5CWR,X-RAY DIFFRACTION,3.48,69.58,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.15 M Potassium Bromide, 30% Polyethylene Glycol Monomethyl ether 2000",277.0,2015-07-28,2016-02-24,5CWR,6292.0,8.0,694.0,307.0,1.0,86.86,1.0,2.5,experimental,,0.2335,0.2019,Crystal Structure of human DNA polymerase lambda L431A mutant in complex with a one nucleotide DNA gap and dCTP
6HYS,X-RAY DIFFRACTION,2.51,50.92,"VAPOR DIFFUSION, HANGING DROP",5.5,"15% 2-Methyl-2,4-pentanediol, 100mM Sodium Acetate, 6% DMSO",291.0,2018-10-22,2019-08-28,6HYS,19875.0,4.0,2692.0,447.0,,312.15,1.0,2.6,experimental,67.41,0.214,0.182,Crystal structure of DHX8 helicase domain bound to ADP at 2.6 angstrom
6HYT,X-RAY DIFFRACTION,2.5,50.85,"VAPOR DIFFUSION, HANGING DROP",5.5,"15% 2-Methyl-2,4-pentanediol, 100 mM Sodium Acetate,  6%DMSO",291.0,2018-10-22,2019-08-28,6HYT,20220.0,4.0,2692.0,606.0,,311.38,1.0,2.33,experimental,66.55,0.222,0.187,Crystal structure of DHX8 helicase domain bound to ADP at 2.3 Angstrom
5VG7,X-RAY DIFFRACTION,3.0,58.97,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris/HCl pH:7.5, 1.8 M Ammonium Sulfate, 16mg/mL",293.0,2017-04-10,2018-06-20,5VG7,9725.0,2.0,1128.0,949.0,,125.7,2.0,1.95000322932,experimental,41.8156901318,0.212939082377,0.16934233003,Crystal Structure of the R503Q missense variant of human PGM1
5DI1,X-RAY DIFFRACTION,2.52,51.18,"VAPOR DIFFUSION, HANGING DROP",7.0,"20 mM HEPES pH7.0, 0.3 M NaCl, 30% PEG NNE 2000m 0.1 M KSCN",293.0,2015-08-31,2016-01-13,5DI1,4773.0,2.0,620.0,35.0,,71.24,1.0,2.9,experimental,65.48,0.2492,0.1979,MAP4K4 in complex with an inhibitor
5CT0,X-RAY DIFFRACTION,2.2,44.18,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-23,2016-11-30,5CT0,5800.0,2.0,704.0,228.0,,83.61,1.0,2.008,experimental,51.48,0.2202,0.1998,Crystal structure of CK2alpha with 3-(3-chloro-4-(phenyl)benzylamino)propan-1-ol bound
5CTP,X-RAY DIFFRACTION,2.25,45.44,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-24,2016-11-30,5CTP,5831.0,2.0,704.0,212.0,,83.9,1.0,2.033,experimental,56.12,0.1989,0.1848,Crystal structure of CK2alpha with N-(3-(3-chloro-4-(phenyl)benzylamino)propyl)acetamide bound
5CX9,X-RAY DIFFRACTION,2.22,44.64,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-28,2016-11-30,5CX9,6033.0,2.0,704.0,313.0,,85.26,1.0,1.732,experimental,44.54,0.1982,0.1888,Crystal structure of CK2alpha with (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoate bound
5MMF,X-RAY DIFFRACTION,2.23,44.82,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-09,2017-05-24,5MMF,5832.0,2.0,704.0,235.0,,83.49,1.0,1.99,experimental,51.09,0.2185,0.2021,Crystal Structure of CK2alpha with Compound 7 bound
5MMR,X-RAY DIFFRACTION,2.2,44.07,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-12,2017-05-24,5MMR,5915.0,2.0,704.0,282.0,,84.13,1.0,2,experimental,38.24,0.2257,0.1958,"Crystal Structure of CK2alpha with N-((2-chloro-[1,1'-biphenyl]-4-yl)methyl)butane-1,4-diamine bound"
5MO5,X-RAY DIFFRACTION,2.23,44.74,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-13,2017-05-24,5MO5,5750.0,2.0,704.0,157.0,,83.69,1.0,2.04,experimental,55.59,0.2127,0.1957,"Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound"
5MO6,X-RAY DIFFRACTION,2.23,44.88,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-13,2017-05-24,5MO6,5809.0,2.0,704.0,240.0,,83.6,1.0,1.825,experimental,49.0,0.2311,0.2132,"Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound"
5MO7,X-RAY DIFFRACTION,2.22,44.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-13,2017-05-24,5MO7,5710.0,2.0,704.0,111.0,,83.51,1.0,2.15,experimental,64.71,0.2235,0.1894,"Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound"
5MO8,X-RAY DIFFRACTION,2.2,44.11,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-13,2017-05-24,5MO8,5828.0,2.0,704.0,211.0,,84.26,1.0,1.82,experimental,53.73,0.219,0.2047,"Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound"
5MOD,X-RAY DIFFRACTION,2.23,44.81,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-14,2017-05-24,5MOD,5790.0,2.0,704.0,199.0,,83.37,1.0,2.08,experimental,55.04,0.2242,0.2057,"Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound"
5MOE,X-RAY DIFFRACTION,2.22,44.49,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-14,2017-05-24,5MOE,6006.0,2.0,704.0,216.0,,86.75,1.0,1.89,experimental,55.24,0.2084,0.1968,"Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound"
5MOW,X-RAY DIFFRACTION,2.24,44.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-14,2017-05-24,5MOW,5881.0,2.0,704.0,311.0,,83.24,1.0,1.86,experimental,48.16,0.2037,0.1899,Crystal Structure of CK2alpha with ZT0432 bound
5MP8,X-RAY DIFFRACTION,2.22,44.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-16,2017-05-24,5MP8,5849.0,2.0,704.0,183.0,,84.84,1.0,1.92,experimental,40.61,0.2243,0.2124,Crystal Structure of CK2alpha with ZT0432 bound
5MPJ,X-RAY DIFFRACTION,2.24,45.01,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2016-12-16,2017-05-24,5MPJ,5820.0,2.0,704.0,183.0,,84.27,1.0,2.14,experimental,57.74,0.2412,0.2123,"1-(2-chloro-[1,1'-biphenyl]-4-yl)-N-methylethanamine"
6HVD,X-RAY DIFFRACTION,2.89,57.44,"VAPOR DIFFUSION, SITTING DROP",8.5,0.20M Na2SO4;  0.1M BTProp pH 8.5;  20.0% PEG 3350;  10.0% EtGly,277.0,2018-10-10,2018-10-17,6HVD,2524.0,1.0,304.0,239.0,,35.42,1.0,1.63,experimental,41.5273,0.2075,0.1864,Human SLK bound to a maleimide inhibitor
7P7G,X-RAY DIFFRACTION,2.04,39.81,"VAPOR DIFFUSION, SITTING DROP",,12% PEG 3350 and 0.1 M ammonium citrate,277.15,2021-07-19,2022-04-13,7P7G,5215.0,2.0,592.0,429.0,,70.59,1.0,1.7,experimental,26.34,0.2079,0.1708,"Crystal structure of phosphorylated pT220 Casein Kinase I delta (CK1d), conformation 2 and 3"
5SJE,X-RAY DIFFRACTION,2.63,53.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJE,11126.0,4.0,1372.0,610.0,4.0,161.16,1.0,2.1,experimental,34.385,0.2324,0.1892,"Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2,2-difluoro-1,3-benzodioxol-4-yl)pyrazol-3-yl]-1-(3-methylsulfonylphenyl)pyridazin-4-one"
6CYR,X-RAY DIFFRACTION,2.49,50.65,"VAPOR DIFFUSION, SITTING DROP",,50 mM di-Sodium succinate pH 7.0 and 12-14% PEG 3350,291.0,2018-04-06,2018-12-12,6CYR,1255.0,1.0,155.0,26.0,1.0,17.62,1.0,2.2,experimental,55.5488,0.2492,0.2038,Crystal structure of the UBE2A variant Q93E
5IIS,X-RAY DIFFRACTION,3.47,64.56,"VAPOR DIFFUSION, HANGING DROP",5.5,0.5-1.0 mM (NH4)2HPO4; 0.1 M Sodium citrate pH 5.5; 250 mM Sodium chloride,298.0,2016-03-01,2016-04-06,5IIS,2480.0,1.0,277.0,209.0,,32.53,1.0,2.1,experimental,35.95,0.1934,0.1708,"Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl-amide scaffold"
6BXI,X-RAY DIFFRACTION,3.48,64.62,"VAPOR DIFFUSION, HANGING DROP",,"4 M ammonium acetate, 0.1 M Bis-Tris propane pH 7",298.0,2017-12-18,2018-08-29,6BXI,5872.0,2.0,666.0,441.0,,78.57,1.0,2.2,experimental,,0.2123,0.1705,X-ray crystal structure of NDR1 kinase domain
6F3D,X-RAY DIFFRACTION,3.02,59.31,VAPOR DIFFUSION,,"50 mM Hepes pH 7.5, 0.02% octylglucoside, 10% glycerol, 0.3 M NaCl, 1 mM TCEP",293.0,2017-11-28,2018-05-23,6F3D,4633.0,2.0,590.0,113.0,,67.59,1.0,2.38,experimental,63.65,0.2271,0.1975,IRAK4 IN COMPLEX WITH inhibitor
6F3E,X-RAY DIFFRACTION,2.56,51.95,VAPOR DIFFUSION,,"50 mM Hepes pH 7.5, 0.02% octylglucoside, 10% glycerol, 0.3 M NaCl, 1 mM TCEP",293.0,2017-11-28,2018-05-23,6F3E,4474.0,2.0,590.0,9.0,,67.56,1.0,2.67,experimental,85.09,0.2544,0.1985,IRAK4 IN COMPLEX WITH inhibitor
6F3I,X-RAY DIFFRACTION,2.25,45.39,VAPOR DIFFUSION,,"50 mM Hepes pH 7.5, 0.02% octylglucoside, 10% glycerol, 0.3 M NaCl, 1 mM TCEP",293.0,2017-11-28,2018-05-23,6F3I,4478.0,2.0,644.0,111.0,,74.01,1.0,2.14,experimental,81.86,0.2704,0.2358,IRAK4 IN COMPLEX WITH inhibitor
6RFI,X-RAY DIFFRACTION,2.48,50.42,"VAPOR DIFFUSION, HANGING DROP",,pH7.5,298.0,2019-04-15,2019-10-30,6RFI,4604.0,2.0,644.0,123.0,,74.04,1.0,2.31,experimental,59.87,0.2365,0.2096,IRAK4 IN COMPLEX WITH inhibitor
6RFJ,X-RAY DIFFRACTION,2.56,51.94,"VAPOR DIFFUSION, HANGING DROP",,pH7.5,298.0,2019-04-15,2019-10-30,6RFJ,4450.0,2.0,644.0,24.0,,74.16,1.0,2.61,experimental,92.06,0.254,0.245,IRAK4 IN COMPLEX WITH inhibitor
7QG1,X-RAY DIFFRACTION,2.34,47.39,EVAPORATION,,Ammonium sulfate 0.1 M Hepes pH 6.8-7.4,298.0,2021-12-07,2022-05-04,7QG1,4657.0,2.0,644.0,239.0,,74.1,1.0,2.07,experimental,68.73,0.285,0.247,IRAK4 in complex with inhibitor
7E8Z,X-RAY DIFFRACTION,2.88,57.24,"VAPOR DIFFUSION, HANGING DROP",5.6,"13.5% PEG3350, 100 mM trisodium citrate pH 5.6, 4% tert-butanol, 1 mM NADH",293.0,2021-03-03,2021-10-13,7E8Z,3466.0,1.0,495.0,12.0,,57.22,1.0,2.55,experimental,84.8688,0.237,0.1954,Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with SS81
5NGZ,X-RAY DIFFRACTION,3.2,61.55,"VAPOR DIFFUSION, SITTING DROP",,"potassium acetate, Tris-HCl pH 8.5",293.0,2017-03-21,2017-05-03,5NGZ,1276.0,1.0,197.0,48.0,,22.72,1.0,2.4,experimental,64.201,0.24734,0.20986,Ube2T in complex with fragment EM04
6R75,X-RAY DIFFRACTION,2.21,44.35,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris-HCl pH 8.5, 20% v/v glycerol ethoxylate, 3% v/v poly(ethylene imine)",277.0,2019-03-28,2019-10-16,6R75,1313.0,1.0,201.0,57.0,,22.88,1.0,2,experimental,24.326,0.2644,0.2252,Crystal structure of human Ube2T E54R mutant
7ABT,X-RAY DIFFRACTION,2.77,55.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 25% PEG1000",293.0,2020-09-08,2021-06-23,7ABT,1547.0,2.0,171.0,169.0,,18.81,2.0,1.31,experimental,28.354,0.1655,0.1335,Structure of PPIA in complex with PR dipeptide repeat
5TKT,X-RAY DIFFRACTION,3.43,64.18,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 MM SODIUM ACETATE, PH 4.6, 25%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE, then transferred to 100 MM TRIS-HCL, pH 7.0, 25%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2016-10-07,2017-03-01,5TKT,2201.0,1.0,244.0,238.0,4.0,29.06,1.0,2.12,experimental,24.87,0.1888,0.1667,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((12E,15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,12,16(19)-HEXAEN-5-YL)CARBAMATE"
5TKU,X-RAY DIFFRACTION,3.43,64.11,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 MM SODIUM ACETATE, PH 4.6, 25%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE, then transferred to 100 MM TRIS-HCL, pH 7.0, 25%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2016-10-07,2017-03-01,5TKU,2188.0,1.0,244.0,229.0,4.0,29.0,1.0,2.12,experimental,25.53,0.1846,0.1664,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE"
6J7F,X-RAY DIFFRACTION,3.85,68.06,"VAPOR DIFFUSION, SITTING DROP",,1M Ammonium Tartrate dibasic pH 7,293.0,2019-01-18,2020-01-22,6J7F,6533.0,3.0,858.0,,,98.31,3.0,2.883,experimental,,0.2494,0.2056,"Complex of GGTaseIII, farnesyl-Ykt6 (C-terminal methylated), and GGPP"
8B29,X-RAY DIFFRACTION,2.08,40.78,"VAPOR DIFFUSION, SITTING DROP",8.0,"2.9 M ammonium sulfate, 0.1 M Tris-HCl",293.0,2022-09-13,2023-01-18,8B29,2354.0,1.0,258.0,288.0,,29.26,1.0,1.7,experimental,15.3913,0.2098,0.1623,Human carbonic anhydrase II containing 6-fluorotryptophanes.
6ZOV,X-RAY DIFFRACTION,2.73,55.05,"VAPOR DIFFUSION, SITTING DROP",7.25,PEG20000,293.0,2020-07-07,2020-10-21,6ZOV,8003.0,4.0,940.0,453.0,16.0,106.85,1.0,2.19,experimental,34.429,0.2504,0.2262,ENTEROPEPTIDASE IN COMPLEX WITH COMPOUND 6
6QGV,X-RAY DIFFRACTION,2.19,43.83,"VAPOR DIFFUSION, SITTING DROP",7.5,"2.0 M Ammonium sulfate, 5% v/v 2-propanol",293.0,2019-01-13,2020-02-05,6QGV,1884.0,1.0,233.0,206.0,,26.94,1.0,1.4,experimental,,0.1722,0.1569,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with a Spiro[4.5]decanone inhibitor (JPHM-2-167)
5M1R,X-RAY DIFFRACTION,1.93,35.83,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sodium Citrate, 1.6 M",294.0,2016-10-10,2017-12-20,5M1R,3451.0,1.0,416.0,239.0,,45.08,1.0,1.64,experimental,21.517,0.20095,0.16425,X-ray structure of human G166D PGK-1 mutant
5M3U,X-RAY DIFFRACTION,2.02,38.68,"VAPOR DIFFUSION, HANGING DROP",,"2.2-2.5 M NAKPO4, PH 8.2-8.4,",298.0,2016-10-17,2017-12-20,5M3U,3304.0,1.0,416.0,133.0,,45.28,1.0,1.81,experimental,30.912,0.24159,0.192,The X-ray structure of human V216F phosphoglycerate kinase 1 mutant
5M6Z,X-RAY DIFFRACTION,2.02,38.51,"VAPOR DIFFUSION, HANGING DROP",8.6,"2.5 M Na//KPO4, pH=8.6",294.0,2016-10-26,2017-11-29,5M6Z,3370.0,1.0,416.0,200.0,,45.28,1.0,1.67,experimental,27.804,0.22295,0.18281,The X-ray structure of human M189I PGK-1 mutant in partially closed conformation
5MXM,X-RAY DIFFRACTION,2.14,42.5,"VAPOR DIFFUSION, HANGING DROP",,"PEG MME 30% w/v, Bis Tris 0.1 M pH=7",298.0,2017-01-23,2018-02-14,5MXM,3460.0,1.0,416.0,282.0,,45.37,1.0,2.05,experimental,22.582,0.22554,0.17623,The X-ray structure of human M190I phosphoglycerate kinase 1 mutant
5O7D,X-RAY DIFFRACTION,2.18,43.48,"VAPOR DIFFUSION, HANGING DROP",,"PEG2K-MME 28-34%, bis-tris 0.1M pH 7",293.0,2017-06-08,2018-06-20,5O7D,3195.0,1.0,417.0,61.0,,45.07,1.0,1.84,experimental,21.544,0.26684,0.22573,The X-ray structure of human R38M phosphoglycerate kinase 1 mutant
4XWH,X-RAY DIFFRACTION,5.94,79.3,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.0 M lithium sulfate, 0.01 M nickel chloride, 0.1 M Tris",291.0,2015-01-28,2016-02-03,4XWH,6204.0,1.0,720.0,279.0,2.0,83.18,1.0,2.32,experimental,53.533,0.18579,0.16591,Crystal structure of the human N-acetyl-alpha-glucosaminidase
6UNA,X-RAY DIFFRACTION,2.21,44.45,VAPOR DIFFUSION,7.7,"2.4M Ammonium sulfate, 50mM TRIS pH 7.7.",298.0,2019-10-11,2019-12-18,6UNA,5422.0,2.0,722.0,45.0,,83.24,1.0,2.554,experimental,50.366,0.2455,0.1953,Crystal structure of inactive p38gamma
6M2C,X-RAY DIFFRACTION,2.38,48.39,"VAPOR DIFFUSION, SITTING DROP",6.0,"4% v/v Tacsimate pH 6.0, 12% w/v Polyethylene glycol 3350",291.0,2020-02-27,2021-04-07,6M2C,6499.0,8.0,816.0,62.0,,92.55,2.0,2.702,experimental,41.6533,0.2583,0.2116,Distinct mechanism of MUL1-RING domain simultaneously recruiting E2 enzyme and the substrate p53-TAD domain
7DP3,X-RAY DIFFRACTION,2.21,44.31,"VAPOR DIFFUSION, HANGING DROP",,"0.2M (NH4)2SO4, 20.5-22% (w/v) PEG 3350, 0.1M Tris-Cl, pH 8.5",289.0,2020-12-17,2021-05-19,7DP3,4677.0,2.0,662.0,258.0,1.0,74.46,1.0,2.55,experimental,49.27,0.2718,0.2137,Human MCM8 N-terminal domain
7DPD,X-RAY DIFFRACTION,2.83,56.6,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Li2SO4, 0.1M ADA pH 6.2-6.5, 13-16% (w/v) PEG 4000",289.0,2020-12-18,2021-05-19,7DPD,4574.0,2.0,582.0,217.0,,66.3,1.0,2.55,experimental,48.63,0.2644,0.2083,Human MCM9 N-terminal domain
4YUG,X-RAY DIFFRACTION,2.68,54.04,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-10-14,4YUG,2101.0,1.0,165.0,346.0,,18.04,1.0,1.48,experimental,,0.1833,0.1327,Multiconformer synchrotron model of CypA at 100 K
4YUH,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-10-14,4YUH,2173.0,1.0,165.0,301.0,,18.04,1.0,1.34,experimental,,0.1561,0.1244,Multiconformer synchrotron model of CypA at 150 K
4YUI,X-RAY DIFFRACTION,2.71,54.69,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-10-14,4YUI,1795.0,1.0,165.0,223.0,,18.04,1.0,1.38,experimental,,0.1747,0.133,Multiconformer synchrotron model of CypA at 180 K
4YUJ,X-RAY DIFFRACTION,2.86,56.92,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-10-14,4YUJ,1859.0,1.0,165.0,243.0,,18.04,1.0,1.42,experimental,,0.156,0.1255,Multiconformer synchrotron model of CypA at 240 K
4YUK,X-RAY DIFFRACTION,2.84,56.71,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-10-14,4YUK,2013.0,1.0,165.0,198.0,,18.04,1.0,1.48,experimental,,0.1677,0.1306,Multiconformer synchrotron model of CypA at 260 K
4YUL,X-RAY DIFFRACTION,2.84,56.62,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-10-14,4YUL,2116.0,1.0,165.0,196.0,,18.04,1.0,1.42,experimental,,0.143,0.1112,Multiconformer synchrotron model of CypA at 280 K
4YUM,X-RAY DIFFRACTION,2.84,56.73,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-10-14,4YUM,2061.0,1.0,165.0,144.0,,18.04,1.0,1.5,experimental,,0.1437,0.1084,Multiconformer synchrotron model of CypA at 300 K
4YUN,X-RAY DIFFRACTION,2.83,56.58,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-10-14,4YUN,2114.0,1.0,165.0,111.0,,18.04,1.0,1.58,experimental,,0.1497,0.1167,Multiconformer synchrotron model of CypA at 310 K
4YUP,X-RAY DIFFRACTION,2.7,54.44,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291.0,2015-03-18,2015-10-14,4YUP,1761.0,1.0,165.0,202.0,,18.04,1.0,1.75,experimental,,0.2489,0.2002,Multiconformer fixed-target X-ray free electron (XFEL) model of CypA at 273 K
6EDX,X-RAY DIFFRACTION,2.56,52.04,"VAPOR DIFFUSION, HANGING DROP",5.0,"0.1 M Sodium Citrate, 2M Sodium Malonate (pH 5.0)",293.0,2018-08-12,2018-09-05,6EDX,979.0,1.0,118.0,21.0,,14.09,1.0,2.009,experimental,,0.2128,0.187,Crystal Structure of SGK3 PX domain
8AEC,X-RAY DIFFRACTION,2.03,39.34,"VAPOR DIFFUSION, SITTING DROP",,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",293.0,2022-07-12,2022-10-12,8AEC,3324.0,1.0,328.0,392.0,,40.02,1.0,1.09,experimental,17.11,0.2086,0.195,Structure of Compound 17 bound to CK2alpha
8I1C,X-RAY DIFFRACTION,1.88,34.62,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, caps, NaCl",293.0,2023-01-13,2023-03-22,8I1C,3083.0,2.0,312.0,382.0,,36.27,1.0,1.4,experimental,17.24,0.1844,0.1525,Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP at pH 9.1
8I1G,X-RAY DIFFRACTION,1.9,35.12,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-01-13,2023-03-22,8I1G,3222.0,2.0,312.0,338.0,,36.89,1.0,1.18,experimental,19.57,0.1713,0.1382,Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 9.1
8I1H,X-RAY DIFFRACTION,1.9,35.1,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, caps, NaCl",293.0,2023-01-13,2023-03-22,8I1H,3184.0,2.0,312.0,347.0,,36.34,1.0,1.18,experimental,21.23,0.1656,0.1353,Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 9.7
8Q6F,X-RAY DIFFRACTION,2.21,44.32,"VAPOR DIFFUSION, HANGING DROP",7.0,Sodium Formate,293.0,2023-08-11,2023-12-13,8Q6F,3631.0,1.0,424.0,344.0,,49.41,1.0,1.506,experimental,28.475,0.22386,0.17923,HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 4)
5HDE,X-RAY DIFFRACTION,2.64,53.41,"VAPOR DIFFUSION, HANGING DROP",,"0.04M potassium phosphate, 16% w/v PEG 8000, 20% v/v glycerol",289.0,2016-01-05,2017-01-18,5HDE,2883.0,1.0,307.0,354.0,,36.5,1.0,1.62,experimental,22.591,0.21265,0.16421,Crystal Structure of PTPN12 Catalytic Domain
5U6J,X-RAY DIFFRACTION,3.92,68.66,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2016-12-08,2017-05-10,5U6J,2673.0,2.0,309.0,219.0,8.0,35.34,2.0,2.3,experimental,32.32,0.2198,0.1852,"Factor VIIa in complex with the inhibitor 3-{[(2R)-17-ethyl-4-methyl-3,12-dioxo-7-[(propan-2-yl)sulfonyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-2-yl]amino}benzamide"
5TEG,X-RAY DIFFRACTION,2.47,50.27,VAPOR DIFFUSION,6.5,"33% (v/v) Pentaerythritol ethoxylate, 50 mM ammonium sulfate, 50 mM Bis-Tris pH 6.5",290.0,2016-09-21,2016-12-07,5TEG,3066.0,4.0,336.0,330.0,,39.39,2.0,1.3,experimental,22.03,0.21,0.189,Crystal structure of hSETD8 in complex with histone H4K20 norleucine mutant peptide and S-Adenosylmethionine
8A07,X-RAY DIFFRACTION,2.2,44.09,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M lithium sulfate, 0.1 M sodium acetate trihydrate pH 3.5, 32 % PEG6000",292.0,2022-05-26,2023-09-13,8A07,2708.0,2.0,318.0,122.0,,37.31,1.0,2.19,experimental,26.168,0.29185,0.23556,MTH1 in complex with TH001969
5JUM,X-RAY DIFFRACTION,2.11,41.65,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES pH 5.5, 5mM Calcium chloride, 25% PEG 2000 MME",291.0,2016-05-10,2016-09-07,5JUM,3951.0,3.0,455.0,145.0,,55.68,1.0,2.6,experimental,,0.2388,0.1659,Crystal Structure of Human DNA Polymerase Eta Inserting dCTP Opposite N-(2'-deoxyguanosin-8- yl)-3-aminobenzanthrone (C8-dG-ABA)
7EF9,X-RAY DIFFRACTION,2.63,53.23,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, lithium sulfate, ammonium sulfate, Bis-Tris",293.0,2021-03-21,2021-06-23,7EF9,4120.0,3.0,476.0,236.0,,59.66,1.0,1.97,experimental,57.03,0.1972,0.1778,Crystal structure of mouse MUTYH in complex with DNA containing AP site analogue:8-oxoG (Form II)
7OW3,X-RAY DIFFRACTION,2.57,52.12,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulfate, 0.1 M Sodium cacodylate pH 6, 25% PEG 4000",293.0,2021-06-16,2022-07-20,7OW3,12705.0,12.0,1540.0,187.0,12.0,178.31,3.0,2.46,experimental,35.28,0.25954,0.22804,Crystal structure of HLA-A*11:01 in complex with KRAS peptide (VVVGAGGVGK)
7OW4,X-RAY DIFFRACTION,2.54,51.63,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Lithium sulfate, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3500",293.0,2021-06-16,2022-07-20,7OW4,13589.0,12.0,1544.0,1009.0,12.0,179.41,3.0,1.81,experimental,26.136,0.24917,0.21968,Crystal structure of HLA-A*11:01 in complex with KRAS G12D peptide (VVVGADGVGK)
5CCL,X-RAY DIFFRACTION,2.07,40.72,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.10 M Magnesium formate, 0.1M Tris 8.0, 14% w/v PEG 3350.  Crystals of SMYD3-SAM were produced and compound was soaked into the pre-formed crystals",293.0,2015-07-02,2015-09-09,5CCL,4170.0,1.0,432.0,449.0,,50.85,1.0,1.5,experimental,22.997,0.1643,0.1134,Crystal structure of SMYD3 with SAM and oxindole compound
8OWO,X-RAY DIFFRACTION,2.19,43.85,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris pH 8.25-8.75
0.1 M Magnesium acetate
15-18% PEG 3350",298.0,2023-04-28,2023-08-30,8OWO,3970.0,1.0,431.0,482.0,,50.27,1.0,1.8,experimental,27.21,0.2003,0.1606,SMYD3 in complex with fragment FL01507
5SGM,X-RAY DIFFRACTION,2.99,58.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGM,2793.0,1.0,343.0,199.0,1.0,39.91,1.0,2.2,experimental,38.676,0.231,0.1903,"Crystal Structure of human phosphodiesterase 10 in complex with 3-N-[2-(4-fluorophenyl)imidazo[1,2-a]pyridin-7-yl]-4-N,4-N,2-trimethylpyrazole-3,4-dicarboxamide"
5SIS,X-RAY DIFFRACTION,3.0,59.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIS,2928.0,1.0,343.0,291.0,1.0,39.93,1.0,1.85,experimental,27.727,0.1996,0.1767,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N,2-dimethyl-4-N-[2-(methylamino)ethyl]-3-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide"
5SJC,X-RAY DIFFRACTION,2.98,58.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJC,2750.0,1.0,343.0,150.0,1.0,39.96,1.0,2.08,experimental,46.88,0.2,0.176,"Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-2,5-dimethyl-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3-carboxamide"
6CVS,X-RAY DIFFRACTION,2.54,51.64,VAPOR DIFFUSION,,"100 mM MES, 25% w/v polyethylene glycol 4000",277.0,2018-03-28,2018-07-04,6CVS,4476.0,6.0,404.0,498.0,,55.71,1.0,2.11,experimental,39.2242,0.1964,0.1738,"Human Aprataxin (Aptx) L248M bound to DNA, AMP and Zn product"
7PK4,X-RAY DIFFRACTION,2.01,38.88,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.07 M Ammonium acetate 4.5 18.9% w/v PEG 10,000",291.15,2021-08-25,2022-12-14,7PK4,2518.0,2.0,338.0,187.0,4.0,37.46,2.0,1.92,experimental,27.591,0.2261,0.1859,Tick salivary cystatin Ricistatin in complex with cathepsin V
6HBN,X-RAY DIFFRACTION,2.06,40.35,"VAPOR DIFFUSION, SITTING DROP",5.5,"90 MIKROLITER ENZYME STOCK SOLUTION (6 MG/ML IN 500 MM NACL, 25 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 10 MIKROLITER INHIBITOR STOCK SOLUTION (10 MM INHIBITOR IN DMSO). THIS MIXTURE WAS INCUBATED FOR 30 MIN AT ROOM TEMPERATURE. THE RESERVOIR SOLUTION OF THE CRYSTALLIZATION EXPERIMENT WAS 4.4 M NACL, 0.1 M CITRIC ACID, PH 5.5. PRIOR TO EQUILIBRATION THE CRYSTALLIZATION DROP WAS COMPOSED OF 1 MIKROLITER RESERVOIR SOLUTION PLUS 1 MIKROLITER ENZYME/INHIBITOR MIXTURE.,VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293.15K",293.15,2018-08-10,2019-03-27,6HBN,6388.0,2.0,670.0,643.0,,81.23,1.0,1.59,experimental,,0.2172,0.187,HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA/CSKN2A1 GENE PRODUCT) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR THN27
6HME,X-RAY DIFFRACTION,3.11,60.39,"VAPOR DIFFUSION, SITTING DROP",6.5,"180 MICROLITERS OF ENZYME SOLUTION (6 MG/ML CK2ALPHA, 0.025 M TRIS/HCL, PH 8.5, 0.5 M NACL) WERE MIXED WITH 20 MICROLITERS OF INHIBITOR STOCK SOLUTION (0.010 M INHIBITOR THN27 IN DMSO). THIS MIXTURE WAS INCUBATED FOR 30 MIN AT ROOM TEMPERATURE. THE RESERVOIR SOLUTION OF THE CRYSTALLIZATION EXPERIMENT WAS 0.2 M AMMONIUM SULFATE, 0.1 M SODIUM CACODYLATE TRIHYDRATE, PH 6.5, 30% (W/V) PEG 8,000. PRIOR TO EQUILIBRATION THE CRYSTALLIZATION DROP WAS COMPOSED OF 10 MICROLITERS RESERVOIR SOLUTION PLUS 20 MICROLITERS ENZYME/INHIBITOR MIXTURE.",293.15,2018-09-12,2019-03-27,6HME,6151.0,2.0,698.0,390.0,,85.43,1.0,1.85,experimental,,0.197,0.1749,LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA; CSNK2A1 gene product) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR THN27
6R8X,X-RAY DIFFRACTION,2.21,44.38,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350
9MG/ML                        
SEEDING (ORIGINAL CRYSTAL FROM WHICH SEEDS WERE PREPARED GREW AFTER 3 WEEKS)",277.0,2019-04-02,2019-04-10,6R8X,5484.0,3.0,690.0,413.0,9.0,74.74,3.0,2.04,experimental,,0.2822,0.2201,COAGULATION FACTOR XI CATALYTIC DOMAIN IN COMPLEX WITH FAB-PORTION OF MAA868
5YLT,X-RAY DIFFRACTION,2.25,45.27,"VAPOR DIFFUSION, HANGING DROP",,"0.1M TRIS-HCL PH 8.5, 34% PEG 6000",293.0,2017-10-19,2018-06-20,5YLT,2217.0,1.0,263.0,197.0,1.0,30.04,1.0,1.69,experimental,,0.1998,0.1678,Crystal structure of SET7/9 in complex with a cyproheptadine derivative
5OS8,X-RAY DIFFRACTION,1.95,36.96,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-17,2018-02-28,5OS8,3146.0,1.0,328.0,244.0,,40.49,1.0,1.55,experimental,20.77,0.201,0.1765,The crystal structure of CK2alpha in complex with compound 11
7KNW,X-RAY DIFFRACTION,2.56,51.87,"VAPOR DIFFUSION, SITTING DROP",6.2,"0.1 M MES-NaOH pH 6.2, 1.0 M trisodium citrate",293.15,2020-11-06,2021-12-08,7KNW,9991.0,4.0,1296.0,421.0,,148.82,1.0,2.65,experimental,50.281,0.3376,0.2635,Crystal structure of SND1 in complex with C-26-A2
6L0O,X-RAY DIFFRACTION,2.07,40.49,"VAPOR DIFFUSION, HANGING DROP",,"2.0-2.2M (NH4)2SO4, 0.1M Tris-HCl pH 8.0",293.0,2019-09-26,2020-04-29,6L0O,716.0,1.0,81.0,82.0,,9.74,1.0,1.21,experimental,26.03,0.1465,0.1202,WH domain of human MCM8
8KCA,X-RAY DIFFRACTION,2.1,41.32,"VAPOR DIFFUSION, HANGING DROP",6.7,1 M trisodium citrate,293.0,2023-08-06,2023-08-30,8KCA,2904.0,2.0,384.0,109.0,,44.11,1.0,1.97,experimental,42.91,0.2314,0.1852,Crystal structure of DDX53 helicase domain
8OL9,X-RAY DIFFRACTION,3.42,63.99,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.5 M ammonium sulphate, 0.1 M sodium citrate, pH 5.6, !.0 M lithium sulphate",291.0,2023-03-30,2023-07-19,8OL9,5671.0,4.0,733.0,37.0,12.0,80.9,4.0,2.6,experimental,61.15,0.3233,0.2666,Anti-FIXa Fab in complex with human des-(Gla-EGF1) FIXa
6YTY,X-RAY DIFFRACTION,2.21,44.24,"VAPOR DIFFUSION, SITTING DROP",7.0,"17% PEG 3350, 0,2M NaBr, 10% Ethylene Glycol, 0.1M bis-tris propane",277.0,2020-04-24,2020-07-15,6YTY,3125.0,1.0,360.0,186.0,,42.66,1.0,1.76,experimental,15.915,0.2235,0.1864,CLK3 A319V mutant bound with benzothiazole Tg003 (Cpd 2)
5Y86,X-RAY DIFFRACTION,1.85,33.4,"VAPOR DIFFUSION, SITTING DROP",8.2,1M NaH2PO4 and K2HPO4 (pH8.2),290.15,2017-08-18,2018-05-02,5Y86,3622.0,1.0,588.0,350.0,,67.12,1.0,1.9,experimental,21.25,0.19642,0.16685,Crystal structure of kinase
6CWY,X-RAY DIFFRACTION,2.53,51.36,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M ammonium sulfate, 0.1M Bis-Tris HCl pH 6.5, 20% PEG3350",288.0,2018-04-01,2019-01-16,6CWY,6335.0,2.0,1006.0,45.0,,113.07,2.0,2.462,experimental,75.9999,0.2369,0.1974,Crystal structure of SUMO E1 in complex with an allosteric inhibitor
7B8A,X-RAY DIFFRACTION,1.99,38.11,EVAPORATION,,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296.0,2020-12-12,2022-01-12,7B8A,3148.0,1.0,383.0,170.0,8.0,44.82,1.0,1.23,experimental,17.2315,0.2123,0.1951,Notum-Fragment 110
7BM3,X-RAY DIFFRACTION,2.01,38.9,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M Ammonium Sulphate
0.1 M Sodium Citrate, pH4.2",296.0,2021-01-19,2022-03-02,7BM3,3080.0,1.0,383.0,129.0,6.0,45.98,1.0,1.4,experimental,23.6752,0.2206,0.1934,Notum Rosmarinic acid complex
6GLF,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5",293.0,2018-05-23,2019-02-20,6GLF,1335.0,1.0,182.0,122.0,,21.03,1.0,2,experimental,,0.2473,0.1835,Crystal structure of hMTH1 F27A in the presence of acetate
6GLI,X-RAY DIFFRACTION,1.72,28.47,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5, 20% DMSO, 10 mM compound",293.0,2018-05-23,2019-02-20,6GLI,1502.0,1.0,182.0,222.0,,21.2,1.0,1.6,experimental,,0.2531,0.2015,Crystal structure of hMTH1 F27A in complex with TH scaffold 1 in the presence of acetate
6GLU,X-RAY DIFFRACTION,,27.75,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5, 20% DMSO, 10 mM compound",293.0,2018-05-23,2019-02-20,6GLU,1452.0,1.0,182.0,203.0,,21.24,1.0,1.7,experimental,,0.2645,0.2165,Crystal structure of hMTH1 D120N in complex with LW14 in the presence of acetate
4X0W,X-RAY DIFFRACTION,2.05,40.12,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.0 M ammonium sulfate, 50 mM sodium citrate pH 4.6, 5% PEG 400",298.0,2014-11-24,2015-10-21,4X0W,2071.0,2.0,257.0,29.0,6.0,29.2,2.0,2.1,experimental,43.523,0.27222,0.23603,The crystal structure of mupain-1-17 in complex with murinised human uPA
4X1P,X-RAY DIFFRACTION,2.1,41.36,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG400",298.0,2014-11-25,2015-10-21,4X1P,2247.0,2.0,257.0,174.0,7.0,29.59,2.0,1.6,experimental,23.192,0.21149,0.18051,The crystal structure of mupain-1-17 in complex with murinised human uPA at pH4.6
8V3M,X-RAY DIFFRACTION,2.39,48.48,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.15 M DL-Malic acid, pH7.0, 0.1 M imidazole, pH7.0, 16% PEG MME 550",294.0,2023-11-28,2024-07-17,8V3M,4361.0,1.0,524.0,256.0,,59.64,1.0,1.8,experimental,,0.2009,0.1858,CCP5 apo structure
8V3N,X-RAY DIFFRACTION,2.28,46.14,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M DL-Malic acid, pH7.0, 0.1 M imidazole, pH7.0, 16% PEG MME 550",294.0,2023-11-28,2024-07-17,8V3N,4123.0,1.0,524.0,170.0,,59.88,1.0,2.3,experimental,,0.2218,0.193,CCP5 in complex with Glu-P-Glu transition state analog
6YXH,X-RAY DIFFRACTION,3.45,64.3,LIPIDIC CUBIC PHASE,,"30 or 50 nl bolus overlaid with 600 nl precipitant solution in CrystalDirect plate-2.
41% PEG 400, 100 mM HEPES pH 7.5, 75 mM magnesium sulfate and 5% DMSO.
Crystallisation experiments were carried out at the HTX facility of EMBL Grenoble. LCP bolus were harvested automatically at cryogenic condition using CrystalDirect technology.",293.0,2020-05-01,2021-05-12,6YXH,2951.0,1.0,350.0,60.0,,41.27,1.0,2.6,experimental,84.84,0.28,0.2315,Cryogenic human alkaline ceramidase 3 (ACER3) at 2.6 A resolution determined by Serial Crystallography (SSX) using CrystalDirect
5FCK,X-RAY DIFFRACTION,1.95,37.01,"VAPOR DIFFUSION, HANGING DROP",,"1 uL FD solution (18 mg/mL FD, 10 mM Tris pH 7.0, 100 mM NaCl) was mixed with 1 uL reservoir solution (25% PEG3350, 100 mM TRIS pH 8.0) and equilibrated against 1 mL reservoir solution.",293.0,2015-12-15,2016-10-26,5FCK,1830.0,1.0,232.0,89.0,4.0,25.32,1.0,1.86,experimental,18.035,0.2372,0.18684,COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 5
5K72,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, HANGING DROP",,"2.5 M ammonium sulfate, 0.1 M Hepes pH 7.2",293.0,2016-05-25,2017-12-06,5K72,9146.0,4.0,1204.0,291.0,,137.36,1.0,2.22,experimental,63.49,0.225,0.215,IRAK4 in complex with Compound 21
5K75,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, HANGING DROP",,"2.5 ammonium sulfate, 0.1 M Hepes pH 7.2",293.0,2016-05-25,2017-12-06,5K75,9417.0,4.0,1204.0,406.0,,137.44,1.0,2.03,experimental,64.42,0.253,0.239,IRAK4 in complex with Compound 1
5K7G,X-RAY DIFFRACTION,2.51,51.07,"VAPOR DIFFUSION, HANGING DROP",7.2,"2.5 M ammonium sulfate, 0.1 M Hepes",293.0,2016-05-26,2017-12-06,5K7G,9351.0,4.0,1204.0,313.0,,137.8,1.0,2.23,experimental,47.04,0.227,0.206,IRAK4 in complex with AZ3862
5ZVA,X-RAY DIFFRACTION,2.42,53.92,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.05M sodium cacodylate, pH 6.5, and 30%(v/v) 2-methyl-2,4-pentanediol(MPD)",291.0,2018-05-09,2018-11-21,5ZVA,3415.0,3.0,428.0,115.0,1.0,53.24,1.0,2.3,experimental,50.96,0.208,0.161,APOBEC3F Chimeric Catalytic Domain in Complex with DNA(dC9)
5ZVB,X-RAY DIFFRACTION,2.5,50.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.05M sodium cacodylate, pH 6.5, and 30%(v/v) 2-methyl-2,4-pentanediol
(MPD)",291.0,2018-05-09,2018-11-21,5ZVB,3478.0,3.0,427.0,211.0,1.0,53.42,1.0,2,experimental,48.089,0.2203,0.1719,APOBEC3F Chimeric Catalytic Domain in Complex with DNA(dT9)
6F20,X-RAY DIFFRACTION,2.32,47.02,"VAPOR DIFFUSION, SITTING DROP",3.6,"27% PEG6000, 0.3M Lithium sulfate, 0.1M sodium acetate pH=3.6",277.0,2017-11-23,2018-03-07,6F20,2693.0,2.0,318.0,99.0,,37.73,1.0,2,experimental,30.722,0.23518,0.19727,Complex between MTH1 and compound 1 (a 7-azaindole-4-ester derivative)
6F23,X-RAY DIFFRACTION,2.28,46.2,"VAPOR DIFFUSION, HANGING DROP",3.6,"23% PEG 6000, 0.28M lithium sulfate, 0.1M sodium acetate pH 3.6",293.0,2017-11-23,2018-03-07,6F23,2877.0,2.0,318.0,199.0,,38.28,1.0,1.84,experimental,30.885,0.25872,0.22114,Complex between MTH1 and compound 16 (a 4-amino-7-azaindole derivative)
7UDQ,X-RAY DIFFRACTION,2.19,43.86,"VAPOR DIFFUSION, SITTING DROP",7.0,"Crystals were grown in a MRC SD2 plate set by a STP Labtech Mosquito. Protein at 17.89 mg/ml (390 uM) was incubated with 500 uM CA157 for 30 min at ambient temperature prior to setup. The drop producing this data set was 200 nL protein-CA157 solution was mixed with 300 nL of 0.6 M sodium succinate, pH 7",293.0,2022-03-20,2023-01-18,7UDQ,6354.0,2.0,786.0,266.0,,91.21,1.0,1.9,experimental,61.8219,0.2387,0.1916,Crystal structure of COQ8A-CA157 inhibitor complex in space group P1
7QHZ,X-RAY DIFFRACTION,2.38,48.36,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.20 M trimethylamine N-oxide, 0.1 M Tris-HCl pH8.5, 20% PEG MME 2000",298.0,2021-12-14,2022-11-23,7QHZ,2021.0,1.0,223.0,281.0,6.0,24.93,1.0,1.5,experimental,21.0381,0.219,0.1822,Crystal structure of KLK6 in complex with compound DKFZ917
6QY8,X-RAY DIFFRACTION,2.23,44.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% (w/v) PEG10000, 0.1M HEPES pH 7.5",293.0,2019-03-08,2020-03-25,6QY8,11395.0,4.0,1344.0,552.0,,160.82,1.0,1.7,experimental,15.532,0.29116,0.26321,Human CSNK2A2 bound to ERB-041
5QGT,X-RAY DIFFRACTION,4.36,71.82,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGT,1675.0,1.0,196.0,161.0,,22.68,1.0,1.97,experimental,42.198,0.2139,0.189,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000609a
5SGN,X-RAY DIFFRACTION,2.63,53.28,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGN,10777.0,4.0,1372.0,443.0,4.0,159.59,1.0,2.07,experimental,40.469,0.2221,0.1721,"Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethyl-6-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-7-(trifluoromethyl)imidazo[1,2-b]pyridazine"
8HE9,X-RAY DIFFRACTION,1.86,33.74,"VAPOR DIFFUSION, HANGING DROP",,"17.1 % v/v Polyethylene glycol 600, 50 mM MES pH 5.6, 8.6 % w/v Polyethylene glycol 4,000",293.0,2022-11-07,2023-12-13,8HE9,2128.0,1.0,255.0,130.0,6.0,28.81,1.0,1.55,experimental,,0.202,0.1794,Crystal structure of CTSB in complex with K777
8HEN,X-RAY DIFFRACTION,2.14,42.55,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Magnesium chloride hexahydrate, 0.1 M NaAc pH 5.2, 28% w/v PEG 3350",293.0,2022-11-08,2023-12-13,8HEN,2157.0,1.0,257.0,139.0,6.0,29.23,1.0,1.95,experimental,,0.2315,0.1854,Crystal structure of CTSB in complex with 212-148
5SGF,X-RAY DIFFRACTION,2.61,52.94,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGF,10561.0,4.0,1372.0,309.0,3.0,159.06,1.0,2.3,experimental,53.906,0.2567,0.1994,Crystal Structure of human phosphodiesterase 10 in complex with ethyl 1-methyl-5-(propylcarbamoyl)pyrazole-4-carboxylate
8P19,X-RAY DIFFRACTION,4.1,69.99,"VAPOR DIFFUSION, SITTING DROP",,"0.05M NaCl
0.1M Li2SO4
0.1M MES pH 6.4
14% PEG4000",293.0,2023-05-11,2024-05-22,8P19,2899.0,1.0,377.0,102.0,,44.23,1.0,2.45,experimental,,0.2217,0.1939,USP28 USP domain apo
5TWY,X-RAY DIFFRACTION,2.4,48.72,"VAPOR DIFFUSION, SITTING DROP",,PEG 4000,293.0,2016-11-15,2017-11-22,5TWY,4733.0,2.0,682.0,,,79.64,1.0,2.91,experimental,107.7423,0.3302,0.2861,Structure of Maternal Embryonic Leucine Zipper Kinase
6GVX,X-RAY DIFFRACTION,2.41,48.88,"VAPOR DIFFUSION, SITTING DROP",,"HEPES, PEG 3350",295.0,2018-06-21,2019-05-29,6GVX,5103.0,2.0,688.0,135.0,,80.37,1.0,2.24,experimental,,0.2396,0.2032,Crystal structure of Maternal Embryonic Leucine Zipper Kinase (MELK) in complex with dorsomorphin (Compound C)
8I18,X-RAY DIFFRACTION,1.91,35.52,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-01-13,2023-03-22,8I18,3167.0,2.0,312.0,415.0,,37.2,1.0,1.1,experimental,17.31,0.1693,0.1448,Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP at pH 7.7
8I19,X-RAY DIFFRACTION,1.87,34.16,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-01-13,2023-03-22,8I19,3231.0,2.0,312.0,386.0,,37.25,1.0,1.48,experimental,15.99,0.1901,0.1505,Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP at pH 8.0
8I1A,X-RAY DIFFRACTION,1.89,34.98,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-01-13,2023-03-22,8I1A,3202.0,2.0,312.0,397.0,,37.27,1.0,1.4,experimental,17.77,0.1916,0.1501,Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP at pH 8.6
8I1D,X-RAY DIFFRACTION,1.89,34.94,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-01-13,2023-03-22,8I1D,3219.0,2.0,312.0,323.0,,37.19,1.0,1.2,experimental,21.0,0.163,0.1361,Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 7.7
8I1E,X-RAY DIFFRACTION,1.89,35.04,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-01-13,2023-03-22,8I1E,3284.0,2.0,312.0,367.0,,37.22,1.0,1.1,experimental,19.77,0.1759,0.1424,Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 8.0
8I1F,X-RAY DIFFRACTION,1.89,35.06,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-01-13,2023-03-22,8I1F,3235.0,2.0,312.0,372.0,,37.24,1.0,1.05,experimental,17.56,0.162,0.1423,Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP at pH 8.6
8I1I,X-RAY DIFFRACTION,1.9,35.15,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, tris, NaCl",293.0,2023-01-13,2023-03-22,8I1I,3265.0,2.0,312.0,365.0,,37.17,1.0,1.2,experimental,20.6,0.1633,0.1355,Crystal structure of human MTH1(G2K/D120N mutant) in complex with 2-oxo-dATP at pH 7.7
8I1J,X-RAY DIFFRACTION,1.83,32.82,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, caps, NaCl",293.0,2023-01-13,2023-03-22,8I1J,3186.0,2.0,312.0,334.0,1.0,37.19,1.0,1.08,experimental,20.24,0.1742,0.1418,Crystal structure of human MTH1(G2K/D120N mutant) in complex with 2-oxo-dATP at pH 9.7
7WCV,X-RAY DIFFRACTION,2.87,57.11,"VAPOR DIFFUSION, SITTING DROP",,"100 mM sodium citrate, pH 5.6, 11.5% (w/v) polyethylene glycol (PEG) 3350,8% isopropanol.",289.0,2021-12-20,2022-07-06,7WCV,3419.0,1.0,491.0,26.0,,57.02,1.0,2.3,experimental,76.3443,0.2409,0.2025,Co-crystal structure of FTO bound to 6e
8IT9,X-RAY DIFFRACTION,2.91,57.68,"VAPOR DIFFUSION, HANGING DROP",,"100 mM sodium citrate, pH 5.4, 11.5% (w/v) polyethylene glycol (PEG) 3350, and 8% isopropanol",291.0,2023-03-22,2024-02-14,8IT9,3511.0,1.0,491.0,78.0,,57.07,1.0,2.14,experimental,41.946,0.2392,0.22159,Co-crystal structure of FTO bound to 22
5AXQ,X-RAY DIFFRACTION,2.09,41.09,VAPOR DIFFUSION,7.4,"200 mM HEPES pH 7.4, 100 mM mM  magnesium chloride hexahydrate, 27.4% PEG 3350",277.0,2015-07-31,2015-11-11,5AXQ,5604.0,2.0,676.0,401.0,,78.91,1.0,1.77,experimental,36.376,0.2109,0.1706,Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetrant PDE10A Inhibitor with 2-oxindole scaffold
5C1W,X-RAY DIFFRACTION,1.87,34.37,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298.0,2015-06-15,2015-09-30,5C1W,5636.0,2.0,724.0,458.0,,83.37,1.0,1.7,experimental,34.35,0.2292,0.2027,"PDE10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine"
5C28,X-RAY DIFFRACTION,1.88,34.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298.0,2015-06-15,2015-09-30,5C28,5776.0,2.0,724.0,575.0,,83.35,1.0,1.56,experimental,22.35,0.1956,0.1704,PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine
5C29,X-RAY DIFFRACTION,1.85,33.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298.0,2015-06-15,2015-09-30,5C29,5036.0,2.0,724.0,266.0,2.0,83.4,1.0,2.05,experimental,45.17,0.2337,0.2094,PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-N-propyl-pyrimidin-4-amine
5C2A,X-RAY DIFFRACTION,1.94,36.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298.0,2015-06-15,2015-09-30,5C2A,5391.0,2.0,724.0,133.0,1.0,83.79,1.0,2,experimental,45.77,0.2388,0.2083,"PDE10 complexed with 6-chloro-2-cyclopropyl-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-pyrimidin-4-amine"
6TPF,X-RAY DIFFRACTION,2.48,50.51,VAPOR DIFFUSION,,,277.0,2019-12-13,2020-06-10,6TPF,4741.0,2.0,582.0,71.0,,67.94,1.0,2.31,experimental,65.906,0.3268,0.2633,Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity
6PAF,X-RAY DIFFRACTION,2.16,43.14,"VAPOR DIFFUSION, HANGING DROP",,"Sitting Drop, Linbro tray, room temp, reservoir is 10% PEG 3350, 0.2M MgOAc , protein:reservoir is 1:1, streak seed soaking: 2ul 20%PEG 3350, 0.4M MgOAc added to 2ul protein, mix and add 0.3ul to drop, store at 295",295.0,2019-06-11,2020-01-15,6PAF,3935.0,1.0,432.0,492.0,,50.77,1.0,1.241,experimental,17.3398,0.1875,0.1718,Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors
6QVO,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,,"0.1 M sodium acetate pH 3.5, 26 % PEG3350, 0.2 M LiSO4",293.0,2019-03-04,2020-03-18,6QVO,5150.0,4.0,788.0,87.0,,92.22,1.0,2.45,experimental,56.268,0.2855,0.23765,Crystal structure of human MTH1 in complex with N6-methyl-dAMP
6CVQ,X-RAY DIFFRACTION,2.54,51.67,VAPOR DIFFUSION,7.5,"100 mM HEPES, 25% w/v polyethylene glycol 3350",277.0,2018-03-28,2018-07-04,6CVQ,4745.0,6.0,400.0,769.0,,55.44,1.0,1.65,experimental,,0.1677,0.1178,"Human Aprataxin (Aptx) H201Q bound to RNA-DNA, AMP and Zn product complex"
6HV2,X-RAY DIFFRACTION,2.35,47.58,VAPOR DIFFUSION,,"50 mM glycine, 20% PEG4000, 1 M ammonium formate, pH 9.4",293.0,2018-10-10,2019-01-30,6HV2,1469.0,2.0,173.0,77.0,,19.86,2.0,1.709,experimental,,0.263,0.2138,MMP-13 in complex with the peptide IMISF
5K9C,X-RAY DIFFRACTION,3.43,64.2,"VAPOR DIFFUSION, SITTING DROP",4.8,"0.1 M sodium acetate trihydrate pH 4.8
1.9 M ammonium sulfate
30% (v/v) glycerol",298.0,2016-05-31,2016-10-12,5K9C,3271.0,1.0,368.0,345.0,,41.5,1.0,1.66,experimental,23.5645,0.1496,0.131,Crystal structure of human dihydroorotate dehydrogenase with ML390
5FSI,X-RAY DIFFRACTION,2.01,38.74,,,25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5,,2016-01-06,2016-07-11,5FSI,1304.0,1.0,156.0,51.0,,18.49,1.0,1.63,experimental,20.31,0.2249,0.201,MTH1 substrate recognition: Complex with 8-oxo-dGTP.
6EQ2,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"23 % PEG3350, 0.2 M LI2SO4, 0.1 M SODIUM ACETATE PH 4.5",293.0,2017-10-12,2018-10-31,6EQ2,1403.0,1.0,182.0,157.0,,21.24,1.0,1.802,experimental,,0.209,0.1698,MTH1 in complex with fragment 6
5Y9M,X-RAY DIFFRACTION,2.25,45.31,"VAPOR DIFFUSION, SITTING DROP",8.5,"26% PEG 4000, 0.15 M Lithium sulfate monohydrate, 0.1 M TRIS hydrochloride (pH 8.5)",281.0,2017-08-25,2018-05-16,5Y9M,6256.0,2.0,678.0,826.0,,80.95,1.0,2.006,experimental,,0.2047,0.1714,Crystal structure of CK2a2 form 3
5YF9,X-RAY DIFFRACTION,2.13,42.3,"VAPOR DIFFUSION, SITTING DROP",8.5,"24%w/v PEG 4000, 0.15 M Lithium Sulfate mono hydrate, 0.1 M Tris-HCl (pH 8.5)",277.0,2017-09-20,2018-05-16,5YF9,6473.0,2.0,678.0,992.0,,81.33,1.0,1.89,experimental,,0.2631,0.2115,Crystal structure of CK2a2 form-2
6QGO,X-RAY DIFFRACTION,2.77,55.58,"VAPOR DIFFUSION, SITTING DROP",,"25% of of polyethylene glycol (PEG) 2000, 0.3 M sodium acetate, 0.1 M sodium cacodylate pH 6.5;",291.0,2019-01-12,2020-02-05,6QGO,3406.0,2.0,466.0,51.0,,50.21,1.0,2.599,experimental,,0.2359,0.1875,Crystal structure of APT1 S119A mutant bound to palmitic acid.
7NZY,X-RAY DIFFRACTION,2.37,48.06,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium malonate pH = 5.0, 20% (w/v) PEG 3350",294.0,2021-03-24,2022-10-05,7NZY,10173.0,4.0,1256.0,663.0,,147.76,1.0,1.85,experimental,44.93,0.2289,0.2049,Crystal structure of human Casein Kinase I delta in complex with CGS-15943
4D7D,X-RAY DIFFRACTION,2.53,51.47,MICROBATCH,5.0,MICROBATCH UNDER OIL WITH 11% PEG 3350 AND 60 MM SODIUM MALONATE PH 5.0,,2014-11-22,2015-09-23,4D7D,3775.0,1.0,487.0,10.0,,56.84,1.0,2.76,experimental,109.133,0.27778,0.2003,Cytochrome P450 3A4 bound to an inhibitor
6DA3,X-RAY DIFFRACTION,2.42,49.23,MICROBATCH,7.0,"peg 3350, sodium malonate",293.0,2018-05-01,2019-04-03,6DA3,3723.0,1.0,487.0,8.0,,56.88,1.0,2.37,experimental,,0.2654,0.2012,Human CYP3A4 bound to an inhibitor
6DA5,X-RAY DIFFRACTION,2.19,43.74,MICROBATCH,,"peg 3350, sodium malonate",293.0,2018-05-01,2019-04-03,6DA5,3728.0,1.0,487.0,5.0,,56.88,1.0,2.25,experimental,,0.2939,0.2164,Human CYP3A4 bound to an inhibitor
6DA8,X-RAY DIFFRACTION,2.19,43.94,MICROBATCH,,"peg 3500, sodium malonate",293.0,2018-05-01,2019-04-03,6DA8,3723.0,1.0,487.0,,,56.86,1.0,2.802,experimental,,0.2911,0.2156,Human CYP3A4 bound to an inhibitor
6DAA,X-RAY DIFFRACTION,2.22,44.53,MICROBATCH,,"peg 3350, sodium malonate",293.0,2018-05-01,2019-04-03,6DAA,3740.0,1.0,487.0,20.0,,56.88,1.0,2.15,experimental,,0.2581,0.2086,Human CYP3A4 bound to an inhibitor
6DAC,X-RAY DIFFRACTION,2.2,44.11,MICROBATCH,7.0,"peg 3350, malonate",293.0,2018-05-01,2019-04-03,6DAC,3792.0,1.0,487.0,9.0,,56.89,1.0,2.55,experimental,,0.274,0.209,Human CYP3A4 bound to an inhibitor
6DAG,X-RAY DIFFRACTION,2.21,44.4,MICROBATCH,,"PEG 3350, sodium malonate",293.0,2018-05-01,2019-04-03,6DAG,3724.0,1.0,487.0,,,56.89,1.0,2.8,experimental,,0.2919,0.2082,Human CYP3A4 bound to an inhibitor
7A1Z,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, SITTING DROP",,"Reservoir composition: 28 % (w/v) PEG6000, 0.9 M LiCl, 0.1 M, Tris/HCl, pH 8.5; drop composition prior to equilibration: 0.01 ml reservoir solution + 0.02 ml CK2alpha' (mutant Cys336Ser)/inhibitor MB002 mixture (0.180 ml 6 mg/ml CK2alpha'Cys336Ser, 0.5 M NaCl, 25 mM Tris/HCl, pH 8.5, mixed and pre-equilibrated with 0.02 ml 10 mM MB002 in dimethyl sulfoxide); the initial inhibitor MB002 was replaced by the inhibitor 6-bromo-5-chloro-1H-triazolo[4,5-b]pyridine by extensive crystal soaking.",293.0,2020-08-14,2020-12-09,7A1Z,3264.0,1.0,364.0,367.0,,43.52,1.0,1.024,experimental,17.21,0.1468,0.1347,"Crystal structure of human protein kinase CK2alpha' (CSNK2A2 gene product) in complex with the ATP-competitive inhibitor 6-bromo-5-chloro-1H-triazolo[4,5-b]pyridine"
6KHE,X-RAY DIFFRACTION,1.92,35.99,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M Bis-Tris pH 5.5, 0.2M MgCl2, 25% (w/v) PEG 3350",293.0,2019-07-15,2019-10-02,6KHE,2907.0,1.0,499.0,34.0,,60.56,1.0,2.8,experimental,53.4125,0.2606,0.1961,Crystal structure of CLK2 in complex with CX-4945
6UJ7,X-RAY DIFFRACTION,2.01,38.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes pH 7.5, 0.2 M NaCl, 25% PEG4000",292.0,2019-10-02,2021-05-05,6UJ7,6906.0,6.0,854.0,496.0,6.0,99.0,3.0,1.9,experimental,35.061,0.2378,0.1819,Crystal structure of HLA-B*07:02 with R140Q mutant IDH2 peptide
8TB5,X-RAY DIFFRACTION,2.06,40.29,"VAPOR DIFFUSION, HANGING DROP",8.5,"30% w/v PEG4,000, 200mM Sodium Acetate, 100mM Tris-HCl pH8.5",293.0,2023-06-28,2023-10-18,8TB5,4155.0,2.0,652.0,128.0,,73.87,1.0,2.32,experimental,40.01,0.2434,0.1842,TYK2 JH2 bound to Compound7
8TB6,X-RAY DIFFRACTION,2.05,39.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% w/v PEG4,000, 200mM Sodium Acetate, 100mM Tris-HCl pH8.5",293.0,2023-06-28,2023-10-18,8TB6,4285.0,2.0,652.0,242.0,1.0,73.72,1.0,1.96,experimental,29.22,0.2358,0.1925,TYK2 JH2 bound to Compound14
4XTR,X-RAY DIFFRACTION,2.67,53.9,"VAPOR DIFFUSION, HANGING DROP",7.0,"2 mM ATP and 2 mM MgCl2 with 15% PEG 3350, 25 mM succinic acid pH 7.0",293.0,2015-01-23,2015-03-18,4XTR,12729.0,7.0,1639.0,928.0,10.0,181.81,4.0,2.05,experimental,56.7877,0.2161,0.1872,Structure of Get3 bound to the transmembrane domain of Pep12
5K7I,X-RAY DIFFRACTION,2.55,51.85,"VAPOR DIFFUSION, HANGING DROP",7.2,"2.5 M ammonium sulfate, 0.1 M Hepes",293.0,2016-05-26,2017-12-06,5K7I,4497.0,2.0,602.0,77.0,,68.75,1.0,2.31,experimental,85.67,0.257,0.219,IRAK4 in complex with AZ3864
6CP2,X-RAY DIFFRACTION,2.95,58.29,"VAPOR DIFFUSION, HANGING DROP",9.0,"16% PEG 3000, 0.1 M Tris pH 9.0",298.0,2018-03-13,2018-08-01,6CP2,5957.0,3.0,774.0,29.0,,88.88,3.0,2.9,experimental,70.854,0.28807,0.20975,SidC in complex with UbcH7~Ub
6G0R,X-RAY DIFFRACTION,2.08,40.81,"VAPOR DIFFUSION, SITTING DROP",7.0,"20.0 % PEG 6K
10.0 % EtGly
0.1 M HEPES pH 7.0                                0.1 M MgCl2",277.0,2018-03-19,2018-11-28,6G0R,1267.0,2.0,138.0,145.0,,16.38,2.0,1.25,experimental,16.758,0.1749,0.1497,Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated POLR2A peptide (K775ac/K778ac)
5MCQ,X-RAY DIFFRACTION,3.65,66.27,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1M magnesium acetate, 0.1M sodium acetate, 8% (w/v) PEG8000",295.0,2016-11-10,2017-09-27,5MCQ,3887.0,2.0,431.0,586.0,3.0,48.09,2.0,1.82,experimental,33.565,0.22424,0.17774,CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE AND EXOSITE BINDING PEPTIDE INHIBITOR
8C3O,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, HANGING DROP",8.0,"18-22% PEG3350, 0,1-0,4M Ammonium Iodide, 0,1-0.4M Sodium Thiocyanate",293.0,2022-12-27,2023-11-22,8C3O,13027.0,2.0,1776.0,49.0,30.0,212.09,1.0,2.47,experimental,28.34,0.2711,0.2139,Crystal structure of autotaxin gamma and compound MEY-003
5GNT,X-RAY DIFFRACTION,2.53,51.43,"VAPOR DIFFUSION, HANGING DROP",,200 mM sodium sulfate decahydrate and 20% (w/v) PEG 3350,289.0,2016-07-24,2016-11-23,5GNT,3067.0,1.0,421.0,18.0,,47.84,1.0,2.665,experimental,,0.2738,0.206,BDLP-like folding of Mitofusin 1
6UJ8,X-RAY DIFFRACTION,2.03,39.48,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 0.2 M KI, 30% PEG4000",292.0,2019-10-02,2021-05-05,6UJ8,6620.0,6.0,854.0,170.0,6.0,100.36,3.0,2.25,experimental,42.004,0.2599,0.2156,Crystal structure of HLA-B*07:02 with wild-type IDH2 peptide
5CCM,X-RAY DIFFRACTION,2.2,44.11,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.10 M Magnesium formate, 0.1M Tris 8.0, 14% w/v PEG 3350",293.0,2015-07-02,2015-09-09,5CCM,3582.0,1.0,428.0,123.0,,50.32,1.0,2.3,experimental,34.062,0.2551,0.2005,Crystal structure of SMYD3 with SAM and EPZ030456
5NI2,X-RAY DIFFRACTION,2.8,56.1,LIQUID DIFFUSION,6.7,"22% (w/v) PEG 8000, 100 mM imidazole pH 6.7, 5 mM YbCl3",277.0,2017-03-23,2017-08-23,5NI2,5657.0,1.0,617.0,671.0,,70.86,1.0,1.501,experimental,,0.1963,0.1722,Crystal structure of human LTA4H mutant E271A in complex with LTA4 (crystal form I)
6IE3,X-RAY DIFFRACTION,2.03,39.35,"VAPOR DIFFUSION, HANGING DROP",7.5,"5% ethanol, 5% MPD, 100 mM NaF, 100 mM HepespH7.5",286.0,2018-09-13,2019-09-18,6IE3,2717.0,1.0,389.0,283.0,,43.99,1.0,1.97,experimental,31.318,0.2331,0.20253,Crystal structure of methyladenine demethylase
7ST8,X-RAY DIFFRACTION,1.93,36.42,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M CHES, pH 9.5, 20 % (w/v) PEG 8000",291.15,2021-11-12,2022-05-11,7ST8,3381.0,3.0,610.0,26.0,4.0,64.9,3.0,2.75,experimental,40.324,0.2699,0.2307,Crystal structure of 7H2.2 Fab in complex with SAS1B C-terminal region
8VXF,X-RAY DIFFRACTION,2.39,48.59,"VAPOR DIFFUSION, SITTING DROP",5.5,"12%-20% PEG 10 K, 0.1 M Bis Tris (pH 5.5), 0.1 M Ammonium Acetate",293.0,2024-02-04,2024-05-08,8VXF,4646.0,2.0,600.0,8.0,,70.31,2.0,2.28,experimental,,0.2707,0.2255,Structure of Casein kinase I isoform delta (CK1d) complexed with inhibitor 15
5TE0,X-RAY DIFFRACTION,3.37,63.47,"VAPOR DIFFUSION, SITTING DROP",6.5,"25 % PEG 3350, 0.1M BIS-TRIS, 0.2M Lithium Sulfate",293.0,2016-09-20,2016-11-02,5TE0,2830.0,1.0,347.0,294.0,,40.47,1.0,1.9,experimental,31.27,0.199,0.181,Crystal Structure of Adaptor Protein 2 Associated Kinase (AAK1) in complex with BIBF 1120
5LB3,X-RAY DIFFRACTION,2.41,48.94,VAPOR DIFFUSION,,"23% PEG6K, 0.15M lithium chloride, 2.5% ethylene glycol",293.0,2016-06-15,2016-07-06,5LB3,7932.0,2.0,890.0,991.0,,100.11,1.0,1.8,experimental,,0.2335,0.1949,Crystal structure of human RECQL5 helicase in complex with ADP/Mg.
6RCH,X-RAY DIFFRACTION,2.29,46.25,"VAPOR DIFFUSION, SITTING DROP",5.9,"25% PEG3350, 0.2M sodium sulfate, 0.1M citrate pH 5.9",277.15,2019-04-11,2020-03-25,6RCH,5794.0,2.0,592.0,776.0,,70.45,1.0,1.45,experimental,16.295,0.1783,0.1554,Crystal structure of Casein kinase I isoform delta (CK1 delta) complexed with SR4133 inhibitor
5TA2,X-RAY DIFFRACTION,2.18,43.65,VAPOR DIFFUSION,,"sodium citrate, pH 4.2
25% (w/v) PEG 3350",293.0,2016-09-09,2017-01-25,5TA2,1528.0,1.0,163.0,227.0,,18.42,1.0,1.48,experimental,13.5589,0.1834,0.1643,Discovery of a Potent Cyclophilin Inhibitor (Compound 7) based on Structural Simplification of Sanglifehrin A
5TA4,X-RAY DIFFRACTION,2.06,40.22,VAPOR DIFFUSION,8.5,"0.1 M Tris-HCl, pH 8.5
0.2 M potassium chloride
2.0 M ammonium sulfate",293.0,2016-09-09,2017-01-25,5TA4,1474.0,1.0,164.0,168.0,,18.56,1.0,1.5,experimental,15.416,0.2062,0.1759,Discovery of a Potent Cyclophilin Inhibitor (Compound 8) based on Structural Simplification of Sanglifehrin A
6BYH,X-RAY DIFFRACTION,2.51,51.03,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M PCTP buffer pH6, 25% (w/v) PEG 1500",293.0,2017-12-20,2018-07-18,6BYH,6235.0,9.0,897.0,70.0,,104.24,3.0,2.61,experimental,,0.294,0.235,Ubiquitin Variant (UbV.Fl11.1) bound to a human Skp1-Fbl11 fragment complex.
7THS,X-RAY DIFFRACTION,2.13,42.2,"VAPOR DIFFUSION, HANGING DROP",5.0,"13-18% PEG 4000, 150 mM Ammonium sulfate, 100 mM MES",293.0,2022-01-12,2023-01-18,7THS,4289.0,2.0,500.0,355.0,12.0,57.02,1.0,1.8,experimental,22.2901,0.208,0.1852,Macrocyclic plasmin inhibitor
6IIH,X-RAY DIFFRACTION,2.39,48.59,"VAPOR DIFFUSION, SITTING DROP",5.16,"100 mM Sodium phosphate monobasic , 100 mM potassium phosphate monobasic , 100 mM MES, 6.0 and 1M sodium chloride",293.0,2018-10-06,2019-08-14,6IIH,8078.0,2.0,986.0,819.0,,115.6,1.0,1.958,experimental,,0.2274,0.1796,crystal structure of mitochondrial calcium uptake 2(MICU2)
5KJK,X-RAY DIFFRACTION,3.23,61.91,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.1 M Tris-HCl, 5% ethanol",293.0,2016-06-20,2016-12-07,5KJK,3888.0,1.0,429.0,340.0,,50.85,1.0,1.93,experimental,41.28,0.203,0.178,SMYD2 in complex with AZ370
5KJL,X-RAY DIFFRACTION,3.21,61.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.1 M Tris-HCl, 5% ethanol",293.0,2016-06-20,2016-12-07,5KJL,3612.0,1.0,429.0,133.0,,49.94,1.0,2.7,experimental,50.17,0.236,0.172,SMYD2 in complex with AZ378
5KJM,X-RAY DIFFRACTION,3.25,62.18,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.1 M Tris-HCl, 5% ethanol",293.0,2016-06-20,2016-12-07,5KJM,3801.0,1.0,429.0,276.0,,50.54,1.0,2.19,experimental,46.27,0.214,0.176,SMYD2 in complex with AZ931
5KJN,X-RAY DIFFRACTION,3.18,61.28,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.1 M Tris-HCl, 5% ethanol",293.0,2016-06-20,2016-12-07,5KJN,3630.0,1.0,429.0,69.0,,51.06,1.0,2.72,experimental,57.18,0.225,0.162,SMYD2 in complex with AZ506
7KZ1,X-RAY DIFFRACTION,2.1,41.55,"VAPOR DIFFUSION, SITTING DROP",8.0,"PEG400, Tris-HCl",293.0,2020-12-09,2021-11-10,7KZ1,1875.0,3.0,181.0,158.0,,26.08,1.0,1.62,experimental,37.2099,0.2054,0.1818,Human MBD4 glycosylase domain bound to DNA containing an abasic site
4QHO,X-RAY DIFFRACTION,2.84,56.72,"VAPOR DIFFUSION, HANGING DROP",5.6,"100mM trisodium citrate, 8% PEG 3350, 4% tert-butanol, 8mg/ml protein, 1mM ZnSO4, 1mM inhibitor, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-05-28,2015-06-03,4QHO,3461.0,1.0,495.0,28.0,,57.21,1.0,2.37,experimental,86.97,0.2076,0.1769,Crystal structure of the human fat mass and obesity associated protein (FTO) in complex with CCO10
4QMU,X-RAY DIFFRACTION,2.1,41.34,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM JNJ-7706621, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMU,2542.0,1.0,310.0,203.0,,35.52,1.0,1.546,experimental,,0.2061,0.17832,"MST3 IN COMPLEX WITH JNJ-7706621, 4-({5-AMINO-1-[(2,6-DIFLUOROPHENYL)CARBONYL]-1H-1,2,4-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE"
7MGJ,X-RAY DIFFRACTION,3.45,64.36,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.3 M NaK tartrate, 0.1M
HEPES pH7",277.0,2021-04-12,2021-11-10,7MGJ,8178.0,4.0,1320.0,44.0,,150.38,1.0,2.95,experimental,53.23,0.2276,0.195,TNNI3K complexed with N-methyl-4-(4-(3-(3-(trifluoromethyl) phenyl) ureido) phenoxy)picolinamide
6AEC,X-RAY DIFFRACTION,2.47,50.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M Li2SO4",298.0,2018-08-04,2019-05-29,6AEC,3110.0,1.0,356.0,349.0,,41.25,1.0,1.72,experimental,20.151,0.22215,0.19146,Binary complex of human DNA Polymerase Mu with MnATP
7BO4,X-RAY DIFFRACTION,3.19,61.41,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2021-01-23,2022-03-02,7BO4,4619.0,1.0,529.0,95.0,3.0,63.66,1.0,2.401,experimental,65.25,0.2194,0.1848,Human Butyrylcholinesterase in complex with 3-(2-(butyl(2-cycloheptylethyl)amino)ethyl)-1H-indol-6-ol
7W8I,X-RAY DIFFRACTION,1.93,36.22,"VAPOR DIFFUSION, SITTING DROP",,"0.05 M Zinc acetate dihydrate, 20% w/v Polyethylene glycol 3,350",293.0,2021-12-07,2022-12-21,7W8I,1056.0,1.0,164.0,25.0,,18.41,1.0,1.943,experimental,52.812,0.2625,0.2261,Crystal structure of Zn bound human Focal Adhesion Targeting (FAT) domain of the Focal Adhesion Kinase
8DEA,X-RAY DIFFRACTION,2.13,42.25,"VAPOR DIFFUSION, HANGING DROP",5.8,"peg4k 25% , 0.1M MES 5.8 buffer",293.0,2022-06-20,2022-11-02,8DEA,6688.0,4.0,920.0,84.0,16.0,100.29,1.0,2.214,experimental,33.495,0.2998,0.225,Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors
5Z93,X-RAY DIFFRACTION,1.95,37.01,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES pH 6.5, 25% PEG 1000",291.0,2018-02-02,2019-02-06,5Z93,2427.0,2.0,293.0,222.0,,32.56,2.0,1.945,experimental,,0.2098,0.1608,Crystal Structure of SIRT3 in complex with H3K9bhb peptide
6RFK,X-RAY DIFFRACTION,3.42,64.0,"VAPOR DIFFUSION, HANGING DROP",,"0.1M BIS-TRIS propane pH 8.5, 24% PEG 3350, 0.275M Na Malonate",297.0,2019-04-15,2019-06-12,6RFK,2625.0,3.0,301.0,224.0,7.0,34.64,3.0,1.6,experimental,33.236,0.16314,0.12607,"Crystal structure of EGRCK-inhibited Gla-domainless fIXa (K148Q, R150Q variant)"
5V37,X-RAY DIFFRACTION,2.2,44.07,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.10 M Magnesium formate, 0.1M Tris 8.0, 14% w/v PEG 3350",293.0,2017-03-06,2018-03-07,5V37,4275.0,1.0,428.0,499.0,,50.62,1.0,1.42,experimental,18.09,0.2789,0.2276,Crystal structure of SMYD3 with SAM and EPZ028862
5LST,X-RAY DIFFRACTION,3.12,60.62,"VAPOR DIFFUSION, HANGING DROP",9.0,"Imidazole, Sodium formate",293.15,2016-09-05,2017-07-05,5LST,4693.0,1.0,693.0,,,76.48,1.0,2.75,experimental,108.8,0.2314,0.1828,Crystal structure of the human RecQL4 helicase.
5SIM,X-RAY DIFFRACTION,3.02,59.31,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIM,2956.0,1.0,343.0,267.0,1.0,39.93,1.0,1.75,experimental,30.103,0.1997,0.1734,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(2-methylpyrrolidine-1-carbonyl)-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide"
5SHA,X-RAY DIFFRACTION,2.6,52.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHA,10729.0,4.0,1372.0,406.0,4.0,159.52,1.0,2.24,experimental,46.608,0.2252,0.1689,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-[5-[3-(difluoromethyl)pyrrolidin-1-yl]-2-methyl-1,2,4-triazol-3-yl]ethyl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine"
6AK8,X-RAY DIFFRACTION,2.68,54.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 18% PEG4000",277.0,2018-08-30,2019-05-29,6AK8,3536.0,4.0,373.0,393.0,,46.33,1.0,1.74,experimental,26.93,0.20082,0.17401,Pre-catalytic Ternary Complex of Human DNA Polymerase Mu with Templating Adenine and Incoming Ca-8oxodGTP
6AK9,X-RAY DIFFRACTION,2.51,51.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 18% PEG 4000",277.0,2018-08-30,2019-05-29,6AK9,3523.0,4.0,373.0,384.0,,46.27,1.0,1.91,experimental,21.043,0.20361,0.16512,Pre-catalytic Ternary Complex of Human DNA Polymerase Mu with Templating Cytosine and Incoming Ca-8oxodGTP
6AKH,X-RAY DIFFRACTION,2.5,50.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 18% PEG 4000",277.0,2018-08-31,2019-05-29,6AKH,3589.0,4.0,373.0,461.0,,46.45,1.0,1.75,experimental,20.903,0.18984,0.16354,Pre-catalytic Ternary Complex of Human DNA Polymerase Mu with Templating Adenine and Incoming Mn-dUMPNPP
6IPD,X-RAY DIFFRACTION,2.47,50.13,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 18% PEG 4000",277.0,2018-11-03,2019-05-29,6IPD,3605.0,4.0,374.0,419.0,,46.19,1.0,1.7,experimental,17.671,0.21773,0.18684,Post-catalytic Complex of Human DNA Polymerase Mu with Templating Adenine and Mn-8oxodGMP
6IPE,X-RAY DIFFRACTION,2.49,50.53,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 18% PEG 4000",277.0,2018-11-03,2019-05-29,6IPE,3648.0,4.0,374.0,434.0,,46.18,1.0,1.7,experimental,16.574,0.20364,0.17279,Post-catalytic Complex of Human DNA Polymerase Mu with Templating Adenine and Mg-8oxodGMP
6IPG,X-RAY DIFFRACTION,2.49,50.54,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 18% PEG 4000",277.0,2018-11-03,2019-05-29,6IPG,3525.0,4.0,374.0,422.0,,46.15,1.0,1.62,experimental,25.27,0.2013,0.174,Post-catalytic Complex of Human DNA Polymerase Mu with Templating Cytosine and Mg-8oxodGMP
3WUS,X-RAY DIFFRACTION,3.43,64.12,"VAPOR DIFFUSION, HANGING DROP",9.0,"8.5% PEG 20000, 2% Dioxane, 300mM L-Arginine HCl, 85mM Na BICINE, pH 9, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-05-02,2015-06-24,3WUS,3139.0,2.0,380.0,7.0,2.0,45.87,1.0,2.54,experimental,54.789,0.25648,0.19979,Crystal Structure of the Vif-Binding Domain of Human APOBEC3F
5HX4,X-RAY DIFFRACTION,1.98,37.82,"VAPOR DIFFUSION, SITTING DROP",,"Tacsimate pH5.0, PEG3350, Glycerol",298.0,2016-01-29,2016-05-18,5HX4,3035.0,2.0,398.0,117.0,1.0,46.72,1.0,1.92,experimental,,0.2137,0.1848,Zinc-Free APOBEC3F Catalytic Domain Crystal Structure
5HX5,X-RAY DIFFRACTION,1.97,37.57,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, MgCl2",298.0,2016-01-29,2016-05-18,5HX5,2944.0,2.0,398.0,61.0,,46.85,1.0,2.33,experimental,,0.2644,0.2268,APOBEC3F Catalytic Domain Crystal Structure
4WY6,X-RAY DIFFRACTION,2.81,56.23,"VAPOR DIFFUSION, SITTING DROP",6.9,"20% PEG5000MME 200 mM NaI, 200 mM NaCitrate, PH 6.9, BACE (8.3 mg/ml in 20 mM Tris, 250 mM NaCl, pH 7.5)",298.0,2014-11-15,2015-03-04,4WY6,3302.0,1.0,415.0,314.0,3.0,47.7,1.0,2.1,experimental,42.4,0.2009,0.1849,Crystal structure of human BACE-1 bound to Compound 36
5HPK,X-RAY DIFFRACTION,4.45,72.35,"VAPOR DIFFUSION, HANGING DROP",,"Sodium cacodylate, NaCl, PEG 8000, 1-butanol",277.0,2016-01-20,2016-03-16,5HPK,3876.0,2.0,469.0,131.0,,55.3,2.0,2.431,experimental,,0.2268,0.2114,System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes: NEDD4L and UbV NL.1
7XUW,X-RAY DIFFRACTION,2.1,41.39,"VAPOR DIFFUSION, HANGING DROP",4.6,8% PEG 4000,278.0,2022-05-20,2023-06-14,7XUW,1149.0,1.0,146.0,94.0,,16.16,1.0,1.8,experimental,26.7718,0.2174,0.1928,Crystal structure of RPA70N-BLMp2 fusion
8PHV,X-RAY DIFFRACTION,2.59,52.58,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 8% tacsimate",277.0,2023-06-20,2023-08-16,8PHV,6817.0,4.0,934.0,195.0,,108.88,2.0,1.97,experimental,49.5,0.2216,0.1862,Structure of Human selenomethionylated Cdc123 bound to domain 3 of eIF2 gamma
5KX7,X-RAY DIFFRACTION,2.58,52.24,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289.0,2016-07-20,2016-08-17,5KX7,4159.0,2.0,602.0,,,68.24,1.0,2.8,experimental,92.8,0.25,0.211,Irak4-inhibitor co-structure
5AJQ,X-RAY DIFFRACTION,2.34,47.5,,8.1,"0.1M TRIS PH 8.1, 0.1M MAGNESIUM CHLORIDE, 30%(W/V) PEG 10000",,2015-02-26,2015-03-11,5AJQ,4349.0,2.0,590.0,86.0,1.0,68.03,1.0,2.2,experimental,63.681,0.25723,0.21679,Human LOK (STK10) in complex with Bosutinib
6O9O,X-RAY DIFFRACTION,2.22,44.53,"VAPOR DIFFUSION, SITTING DROP",,"Libro 24 well sitting drop tray.
Reservoir solution: 10% PEG 3350, 0.2M MgOAc
Drops composed of 2ul protein + 2 ul reservoir.
Frozen seed stock added to ensure nucleation.

Crystals should grow overnight at 22C and fully mature within 3 days
Apo crystals were soaked with inhibitor as follows:
1ul 100mM compound + 1ul well buffer
 Add 0.3ul to the drop
 Incubate at room temperature",295.0,2019-03-14,2020-03-18,6O9O,3833.0,1.0,432.0,396.0,,50.97,1.0,1.586,experimental,23.7103,0.2002,0.1723,Crystal Structure of SMYD3 with Potent and Selective Isoxazole Amide Inhibitor 1
6T6F,X-RAY DIFFRACTION,2.34,47.41,"VAPOR DIFFUSION, SITTING DROP",5.5,28% PEG3350 -- 0.1M bis-tris pH 5.5 -- 0.2M ammonium acetate,293.0,2019-10-18,2020-01-15,6T6F,4753.0,2.0,644.0,206.0,,74.16,1.0,1.97,experimental,53.7188,0.2376,0.2099,Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) bound to compound 8 (CS275)
6F1W,X-RAY DIFFRACTION,2.54,51.58,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES pH 5.5, 10 % (w/v) PEG 4000, 0.2 M lithium sulfate",293.0,2017-11-23,2019-03-13,6F1W,5242.0,2.0,628.0,415.0,,75.52,2.0,1.864,experimental,,0.2064,0.1809,Crystal structure of human Casein Kinase I delta in complex with compound 31a
4ZX2,X-RAY DIFFRACTION,2.36,47.95,"VAPOR DIFFUSION, HANGING DROP",8.0,"25% MPD, 6% PEG, 10 mM Tris, pH 8.0",289.0,2015-05-19,2016-04-27,4ZX2,3077.0,1.0,333.0,344.0,,38.43,1.0,1.23,experimental,10.248,0.175,0.16277,"Co-crystal structures of PP5 in complex with 5-methyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid"
5AXP,X-RAY DIFFRACTION,2.22,44.71,VAPOR DIFFUSION,8.0,"100 mM HEPES pH 8.0, 100 mM mM  magnesium chloride hexahydrate, 25.7% PEG 3350",277.0,2015-07-31,2015-11-11,5AXP,5506.0,2.0,676.0,313.0,,78.85,1.0,1.95,experimental,38.899,0.2335,0.1757,"Crystal structure of the catalytic domain of PDE10A complexed with 1-(2-fluoro-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one"
5B4K,X-RAY DIFFRACTION,2.11,41.73,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES pH 7.6, 100 mM magnesium chloride hexahydrate, 24.182% PEG 3350",277.0,2016-04-05,2016-06-29,5B4K,5336.0,2.0,676.0,149.0,,78.67,1.0,2.9,experimental,56.224,0.26051,0.17684,"Crystal structure of the catalytic domain of human PDE10A complexed with N-(4-((5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy)phenyl)-1H-benzimidazol-2-amine"
5B4L,X-RAY DIFFRACTION,2.05,39.98,"VAPOR DIFFUSION, SITTING DROP",7.88,"100 mM HEPES pH 7.88, 100 mM magnesium chloride hexahydrate, 25.7% PEG 3350",277.0,2016-04-05,2016-06-29,5B4L,5325.0,2.0,676.0,118.0,,78.95,1.0,2.4,experimental,51.983,0.28178,0.23306,"Crystal structure of the catalytic domain of human PDE10A complexed with 1-(cyclopropylmethyl)-5-(2-(2,3-dihydro-1H-imidazo[1,2-a]benzimidazol-1-yl)ethoxy)-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one"
7BPI,X-RAY DIFFRACTION,2.22,44.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes (pH 7.5), 0.2 M MgCl2, 18% PEG 3350, 50 mM 2-mercaptoethanol",277.0,2020-03-22,2021-01-27,7BPI,5239.0,2.0,644.0,118.0,,75.28,1.0,2.40008632403,experimental,25.8247858795,0.325599406744,0.251830445571,The crystal structue of PDE10A complexed with 14
6NMQ,X-RAY DIFFRACTION,3.2,61.56,"VAPOR DIFFUSION, SITTING DROP",,"2M AMMONIUM SULFATE/100MM IMIDAZOLE, 100 MM MAGNESIUM SULFATE/10% (V/V) GLYCEROL, pH 6.50, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2019-01-11,2019-04-24,6NMQ,1702.0,1.0,213.0,171.0,,24.23,1.0,1.58,experimental,17.556,0.25986,0.22247,Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase 2 (PHD2) in Complex with the Carboxamide Analog JNJ43058171
5SG8,X-RAY DIFFRACTION,2.62,53.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG8,10728.0,4.0,1372.0,476.0,4.0,158.86,1.0,2.16,experimental,42.77,0.2707,0.217,Crystal Structure of human phosphodiesterase 10 in complex with 5-butoxy-4-ethoxypyrimidin-2-amine
5SGQ,X-RAY DIFFRACTION,2.64,53.44,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGQ,10798.0,4.0,1372.0,530.0,4.0,159.04,1.0,2.04,experimental,39.715,0.2244,0.1771,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-(pyrimidin-5-ylamino)pyrazine-2-carboxylic acid
5SGU,X-RAY DIFFRACTION,2.65,53.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGU,10699.0,4.0,1372.0,412.0,4.0,159.09,1.0,2.14,experimental,44.517,0.2251,0.1848,"Crystal Structure of human phosphodiesterase 10 in complex with 12-methoxy-5,7-dimethyl-3-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,7,9,11-hexaene"
5SHE,X-RAY DIFFRACTION,2.61,52.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHE,10649.0,4.0,1372.0,421.0,4.0,158.7,1.0,2.19,experimental,43.998,0.2417,0.1865,"Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethylquinoxalin-6-amine"
5SHQ,X-RAY DIFFRACTION,2.61,52.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHQ,10771.0,4.0,1372.0,555.0,4.0,158.76,1.0,2.08,experimental,42.18,0.2215,0.1821,"Crystal Structure of human phosphodiesterase 10 in complex with 4-pyrrolidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine"
5SHW,X-RAY DIFFRACTION,2.62,53.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHW,10617.0,4.0,1372.0,357.0,4.0,158.91,1.0,2.19,experimental,47.649,0.2244,0.1784,"Crystal Structure of human phosphodiesterase 10 in complex with (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)methanol"
5SHX,X-RAY DIFFRACTION,2.63,53.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHX,10775.0,4.0,1372.0,519.0,4.0,158.86,1.0,2.16,experimental,42.367,0.2441,0.1953,Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-pyrrolidin-1-ylquinoxaline
5SIA,X-RAY DIFFRACTION,2.62,53.14,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIA,10574.0,4.0,1372.0,286.0,4.0,159.3,1.0,2.27,experimental,47.879,0.2396,0.1883,"Crystal Structure of human phosphodiesterase 10 in complex with 1-(2,3-dimethylquinoxalin-6-yl)-3-(3-methoxyphenyl)urea"
5SIK,X-RAY DIFFRACTION,2.6,52.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIK,10648.0,4.0,1372.0,394.0,4.0,158.78,1.0,2.1,experimental,46.049,0.2224,0.183,Crystal Structure of human phosphodiesterase 10 in complex with 5-(cyclopentylmethoxy)pyrimidin-2-amine
5SIV,X-RAY DIFFRACTION,2.59,52.43,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIV,10744.0,4.0,1372.0,508.0,4.0,159.09,1.0,2.2,experimental,40.438,0.2556,0.196,Crystal Structure of human phosphodiesterase 10 in complex with N-(thiophen-2-ylmethyl)quinoxaline-6-carboxamide
5SJ6,X-RAY DIFFRACTION,2.59,52.54,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJ6,10771.0,4.0,1372.0,446.0,4.0,159.01,1.0,2.15,experimental,42.967,0.2347,0.182,Crystal Structure of human phosphodiesterase 10 in complex with 4-(2-chloroquinazolin-4-yl)morpholine
5SJQ,X-RAY DIFFRACTION,2.63,53.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJQ,10664.0,4.0,1372.0,420.0,4.0,158.78,1.0,2.12,experimental,44.155,0.223,0.185,"Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-2,3-dimethylquinoxaline"
5SJV,X-RAY DIFFRACTION,2.67,53.94,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJV,10985.0,4.0,1372.0,705.0,4.0,159.27,1.0,1.94,experimental,36.086,0.2155,0.1731,Crystal Structure of human phosphodiesterase 10 in complex with 5-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]quinoxaline
5SKT,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKT,10836.0,4.0,1372.0,560.0,4.0,159.15,1.0,2.02,experimental,38.993,0.2239,0.1839,Crystal Structure of human phosphodiesterase 10 in complex with 7-(cyclopropylmethoxy)-2-methyl-4-pyrrolidin-1-ylquinazoline:hydrochloride
4ZSG,X-RAY DIFFRACTION,2.89,57.49,"VAPOR DIFFUSION, HANGING DROP",6.25,"4-6 % w/v PEG 6000, 0.1 M MES, 5 mM DTT",293.0,2015-05-13,2016-05-04,4ZSG,3188.0,1.0,347.0,344.0,,40.51,1.0,1.79,experimental,55.62,0.2352,0.2041,MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4ZSL,X-RAY DIFFRACTION,3.05,59.63,"VAPOR DIFFUSION, HANGING DROP",6.25,"4-6 % w/v PEG 6000, 0.1 M MES, 5 mM DTT",297.0,2015-05-13,2016-05-04,4ZSL,3068.0,1.0,341.0,276.0,,39.95,1.0,2.25,experimental,48.0,0.2192,0.1768,MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
5BYZ,X-RAY DIFFRACTION,3.24,62.05,"VAPOR DIFFUSION, HANGING DROP",,"11 % PEG4000
0.01 M MgCl2
0.18 M Na-Formiate
0.10 M MES, pH=6.50
0.01 M Tris/Cl, pH=8.50",277.0,2015-06-11,2016-05-04,5BYZ,3367.0,1.0,348.0,337.0,,40.84,1.0,1.65,experimental,17.515,0.19225,0.17367,ERK5 in complex with small molecule
6NFK,X-RAY DIFFRACTION,2.09,41.2,"VAPOR DIFFUSION, SITTING DROP",,"Sodium Iodide, PEG3350",293.0,2018-12-20,2019-12-25,6NFK,1607.0,1.0,193.0,74.0,1.0,23.16,1.0,1.86,experimental,,0.2379,0.1888,Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B with loop 7 from APOBEC3G bound to iodide
4XIB,X-RAY DIFFRACTION,2.69,54.26,"VAPOR DIFFUSION, HANGING DROP",7.6,"Protein at 6 mg/mL in 25 mM HEPES 7.4, 500 mM NaCl, 10% w/v glucose, 100 mM Arg, 2 mM TCEP
Precipitant: 1.5 M (NH4)2SO4, 20% v/v glycerol, HEPES pH 7.6
1:1 drop volume",293.15,2015-01-06,2015-03-18,4XIB,3008.0,2.0,391.0,108.0,,43.79,2.0,2.147,experimental,58.6979,0.2444,0.209,Crystal structure of the MZM-REP domains of Mind bomb 1 in complex with fly Delta N-box peptide
6GLL,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5, 20% DMSO, 10 mM compound",293.0,2018-05-23,2019-02-20,6GLL,3004.0,2.0,364.0,410.0,,42.89,1.0,1.395,experimental,,0.1991,0.1836,Crystal structure of hMTH1 N33A in complex with LW14 in the presence of acetate
6GLP,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5, 20% DMSO, 10 mM compound",293.0,2018-05-23,2019-02-20,6GLP,2942.0,2.0,364.0,382.0,2.0,42.96,1.0,1.5,experimental,,0.1985,0.1688,Crystal structure of hMTH1 N33G in complex with LW14 in the presence of acetate
6GLR,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5, 20% DMSO, 10 mM compound",293.0,2018-05-23,2019-02-20,6GLR,2992.0,2.0,364.0,370.0,2.0,43.36,1.0,1.601,experimental,,0.1988,0.1685,Crystal structure of hMTH1 N33G in complex with TH scaffold 1 in the presence of acetate
7N13,X-RAY DIFFRACTION,2.21,44.0,"VAPOR DIFFUSION, SITTING DROP",3.5,"23% (w/v) PEG 6k, 200 mM lithium sulfate, 100 mM sodium acetate pH 3.5",277.0,2021-05-26,2021-11-03,7N13,2988.0,2.0,316.0,302.0,,37.84,1.0,1.59,experimental,17.759,0.254,0.2116,Crystal structure of MTH1 in complex with compound 32
8A0T,X-RAY DIFFRACTION,2.18,43.45,"VAPOR DIFFUSION, SITTING DROP",,"30 % PEG6000, 0.1 M sodium acetate trihydrate pH 3.5, 0.2 M lithium sulphate",292.0,2022-05-30,2023-09-13,8A0T,2760.0,2.0,318.0,129.0,,38.22,1.0,1.9,experimental,30.239,0.25265,0.21164,MTH1 in complex with TH012532
7AUZ,X-RAY DIFFRACTION,2.42,49.07,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2020-11-03,2021-02-17,7AUZ,5522.0,1.0,613.0,625.0,,70.62,1.0,1.9,experimental,25.27,0.2055,0.1707,LTA4 hydrolase in complex with compound LYS006
7AV0,X-RAY DIFFRACTION,2.44,49.59,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2020-11-03,2021-02-17,7AV0,5529.0,1.0,613.0,633.0,,70.6,1.0,1.9,experimental,24.28,0.1937,0.155,LTA4 hydrolase in complex with compound R(13)
7AV1,X-RAY DIFFRACTION,2.42,49.1,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2020-11-03,2021-02-17,7AV1,5705.0,1.0,613.0,820.0,,70.27,1.0,1.79,experimental,22.41,0.1957,0.1567,LTA4 hydrolase in complex with fragment2
7AV2,X-RAY DIFFRACTION,2.41,48.98,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2020-11-03,2021-02-17,7AV2,5525.0,1.0,613.0,641.0,,70.25,1.0,1.95,experimental,23.78,0.2087,0.1611,LTA4 hydrolase in complex with fragment1
5VBN,X-RAY DIFFRACTION,2.39,48.56,"VAPOR DIFFUSION, SITTING DROP",,"50 mM sodium citrate, pH5.6, 0.70 M ammonium sulfate and 2 mM TCEP",295.0,2017-03-29,2017-08-02,5VBN,9058.0,4.0,1344.0,212.0,,152.69,2.0,2.35,experimental,46.0,0.264,0.225,Crystal Structure of human DNA polymerase epsilon B-subunit in complex with C-terminal domain of catalytic subunit
6YN9,X-RAY DIFFRACTION,2.03,39.48,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG MME 2000, 0.1M MES pH6.5
Protein at 12 mg/ml in 25mM HEPES pH 7.5, 50mM NaCl, 1mM TCEP, 100 mM Mg formate added prior to crystallization",298.0,2020-04-11,2020-06-24,6YN9,2943.0,1.0,404.0,66.0,,46.09,1.0,2.558,experimental,44.56,0.2512,0.2015,MALT1(329-728) in complex with a sulfonamide containing compound
5MBM,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, SITTING DROP",4.0,"0,1 M Na-citrate
15% PEG6000",293.0,2016-11-08,2017-12-20,5MBM,6499.0,4.0,854.0,143.0,12.0,92.58,2.0,2.76,experimental,63.33,0.2808,0.2556,Cathepsin B in complex with DARPin 8h6
7V10,X-RAY DIFFRACTION,2.22,44.52,"VAPOR DIFFUSION, HANGING DROP",5.0,"24% PEG 4000, 100mM Na Citrate pH 5.0",293.0,2022-05-11,2022-08-03,7V10,2053.0,1.0,238.0,95.0,4.0,27.62,1.0,1.798,experimental,21.9915,0.23,0.1902,Factor XIa in Complex with Compound 2d
7V11,X-RAY DIFFRACTION,2.21,44.39,"VAPOR DIFFUSION, HANGING DROP",5.0,"24% PEG 4000, 100mM Na Citrate pH 5.0",293.0,2022-05-11,2022-08-03,7V11,2171.0,1.0,238.0,213.0,4.0,27.58,1.0,1.472,experimental,23.4503,0.1751,0.1553,Factor XIa in Complex with Compound 2e
7V12,X-RAY DIFFRACTION,2.17,43.3,"VAPOR DIFFUSION, HANGING DROP",5.0,"24% PEG 4000, 100mM Na Citrate pH 5.0",293.0,2022-05-11,2022-08-03,7V12,2053.0,1.0,238.0,112.0,4.0,27.58,1.0,1.631,experimental,21.6644,0.2236,0.1835,Factor XIa in Complex with Compound 2f
5BYA,X-RAY DIFFRACTION,2.79,55.96,"VAPOR DIFFUSION, HANGING DROP",7.0,"12% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM ATP and 2 mM CdCl2. The crystals were transferred to a stabilizing buffer containing 22% (w/v) PEG 3350, 10 mM MgCl2, 0.1 M sodium acetate, pH 5.2 at 4 oC overnight, while ATP in the crystals was hydrolyzed to ADP. The crystals were soaked under the above stabilizing buffer for three days with 2 mM analog.",277.0,2015-06-10,2015-07-22,5BYA,3154.0,1.0,330.0,445.0,,39.48,1.0,1.9,experimental,22.557,0.199,0.1413,"Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 1,5-(PCP)2-IP4"
5BYB,X-RAY DIFFRACTION,2.81,56.24,"VAPOR DIFFUSION, HANGING DROP",7.0,"12% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM ATP and 2 mM CdCl2. The crystals were transferred to a stabilizing buffer containing 22% (w/v) PEG 3350, 10 mM MgCl2, 0.1 M sodium acetate, pH 5.2 at 4 oC overnight, while ATP in the crystals was hydrolyzed to ADP. The crystals were soaked under the above stabilizing buffer for three days with 2 mM analog.",277.0,2015-06-10,2015-07-22,5BYB,2893.0,1.0,330.0,206.0,,39.24,1.0,2.3,experimental,22.434,0.24638,0.18935,"Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 1,5-(PA)2-IP4"
5DGI,X-RAY DIFFRACTION,2.67,53.92,"VAPOR DIFFUSION, HANGING DROP",7.0,"12% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM ATP and 2 mM CdCl2. The crystals were transferred to a stabilizing buffer containing 22% (w/v) PEG 3350, 10 mM MgCl2, 0.1 M sodium acetate, pH 5.2 at 4 oC overnight,while ATP in the crystals was hydrolyzed to ADP. The crystals were soaked under the above stabilizing buffer for three days with 2 mM compound.",277.0,2015-08-27,2016-08-10,5DGI,3088.0,1.0,330.0,352.0,,39.37,1.0,1.85,experimental,28.079,0.20252,0.15005,"Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 3,5-(PCP)2-IP4"
8SDW,X-RAY DIFFRACTION,2.17,43.26,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.2 M Sodium nitrate, 20% w/v Polyethylene glycol 3,350, pH 6.8",277.15,2023-04-07,2023-06-28,8SDW,1651.0,1.0,181.0,296.0,,21.29,1.0,1.75,experimental,,0.21,0.19,Crystal structure of the non-myristoylated mutant [L8K]Arf1 in complex with a GDP analogue
6VLV,X-RAY DIFFRACTION,2.24,45.13,VAPOR DIFFUSION,5.0,"0.1 M CITRATE pH 5.0
32.0 w/v polyethylene glycol 4000",293.0,2020-01-27,2020-05-06,6VLV,2174.0,1.0,238.0,217.0,4.0,27.7,1.0,1.72,experimental,27.06,0.1984,0.1722,Factor XIa in complex with compound 11
5CXV,X-RAY DIFFRACTION,3.09,60.21,LIPIDIC CUBIC PHASE,,"33% PEG 300, 100 mM sodium acetate, and 100 mM Bis-Tris Propane (pH 8.0)",293.0,2015-07-29,2016-03-09,5CXV,3599.0,2.0,522.0,10.0,2.0,60.85,2.0,2.7,experimental,73.383,0.28204,0.23133,Structure of the human M1 muscarinic acetylcholine receptor bound to antagonist Tiotropium
5AYF,X-RAY DIFFRACTION,2.33,47.27,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris-HCl pH 8.5, 31% PEG 6000",277.0,2015-08-20,2016-04-27,5AYF,2135.0,1.0,263.0,179.0,,29.67,1.0,2.005,experimental,,0.2581,0.1936,Crystal structure of SET7/9 in complex with cyproheptadine
6UK4,X-RAY DIFFRACTION,3.23,61.91,"VAPOR DIFFUSION, HANGING DROP",6.3,"0.1 M sodium citrate, pH 6.3, 7.5% PEG6000, 0.2 M lithium nitrate",277.0,2019-10-04,2020-08-19,6UK4,6728.0,5.0,838.0,,8.0,96.44,5.0,2.7,experimental,73.93,0.2522,0.2196,Complex of T cell Receptor with HHAT Neoantigen Peptide KQWLVWLFL Presented by HLA-A206
6F4M,X-RAY DIFFRACTION,2.11,41.72,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 22.5 % PEG3350, 0.002 M MnCl2, 300 nl sitting drops (sample:well, 1:1 ratio)",298.0,2017-11-29,2018-04-04,6F4M,2179.0,1.0,235.0,207.0,,27.13,1.0,1.705,experimental,,0.1865,0.1696,Human JMJD5 in its apo form.
5ARG,X-RAY DIFFRACTION,2.45,49.9,,7.0,"22% PEG 3350, 100 MMOL HEPES PH 7.0. CRYO BUFFER CONTAINS AN ADDTIONAL 20% GLYCEROL AND 1 MMOL LIGAND. OTHER CRYSTALISATION REMARKS:4 MILLIMOLAR COFACTOR SAM ADDED AND MIXTURE INCUBATED FOR 2 HOURS AT 4 DEGREE CELSIUS PRIOR TO CRYSTALLIZATION. CO- COMPLEX WITH BAY-598 FORMED BY SOAKING SMYD2-SAM CRYSTALS WITH 5 MILLIMOLAR LIGAND FOR 4 DAYS.",277.0,2015-09-24,2016-04-27,5ARG,3680.0,1.0,433.0,137.0,1.0,50.9,1.0,1.99,experimental,55.525,0.27318,0.23001,SMYD2 in complex with SGC probe BAY-598
6YUH,X-RAY DIFFRACTION,2.16,43.12,"VAPOR DIFFUSION, HANGING DROP",8.25,"Tris buffer 0.1 M, pH 8.25
Magnesium acetate 0.1 M
PEG3350 16%",293.0,2020-04-27,2021-01-13,6YUH,3764.0,1.0,425.0,256.0,,50.1,1.0,1.93,experimental,28.0359,0.2295,0.1861,Crystal structure of SMYD3 with diperodon R enantiomer bound to allosteric site
6ZRB,X-RAY DIFFRACTION,2.21,44.33,"VAPOR DIFFUSION, HANGING DROP",8.25,"Protein was pre-incubated with the covalent inhibitor, 7 mg/mL and 0.4 mM, respectively, for 8 h at RT. Crystallization was performed in 2 uL hanging drops, 1:1 protein to reservoir ratio, reservoir: 16% PEG3350, 100 mM Tris (pH 8.25), 100 mM Mg(OAc)2). Protein crystals were cryoprotected in 20% PEG3350, 100 mM Tris (pH 8.25), 100 mM Mg(OAc)2, 10% DMSO and 10% glycerol.",298.0,2020-07-13,2022-07-27,6ZRB,3883.0,1.0,431.0,412.0,,50.43,1.0,1.55,experimental,21.465,0.1845,0.1654,Crystal structure of SMYD3 conjugate with piperidine-based covalent inhibitor EM127
7BJ1,X-RAY DIFFRACTION,2.18,43.62,"VAPOR DIFFUSION, HANGING DROP",8.25,"Protein: 50 mM Tris, 150 mM NaCl, 1 mM (S)-diperodon, 10% DMSO, pH 8.0; reservoir: 100 mM Tris, 50 mM magnesium acetate, 11% PEG3350, pH 8.25",293.0,2021-01-13,2021-03-03,7BJ1,4048.0,1.0,431.0,526.0,,50.75,1.0,1.61,experimental,30.1,0.21,0.1715,Crystal structure of SMYD3 with diperodon S enantiomer bound to allosteric site
8PPA,X-RAY DIFFRACTION,2.72,54.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.81 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 18 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking 2h with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 5 mM ligand, 3 mM AMP-PNP and 3 mM MnCl2.",291.0,2023-07-07,2024-02-28,8PPA,5013.0,2.0,558.0,371.0,,66.29,1.0,1.73,experimental,39.028,0.21823,0.19335,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with D-myo-inositol 1,4,6-trisphosphate/AMP-PNP/Mn"
8PPB,X-RAY DIFFRACTION,2.68,54.11,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.84 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 18 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking 2h with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 5 mM ligand, 3 mM ATP and 3 mM MnCl2.",291.0,2023-07-07,2024-02-28,8PPB,4984.0,2.0,558.0,346.0,,66.37,1.0,1.8,experimental,38.798,0.21606,0.19467,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with D-3-deoxy-myo-inositol 1,4,6-trisphosphate/ATP/Mn"
8PPC,X-RAY DIFFRACTION,2.69,54.29,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.80 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 9 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking 2h with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 5 mM ligand, 3 mM ATP and 3 mM MnCl2.",291.0,2023-07-07,2024-02-28,8PPC,4888.0,2.0,558.0,273.0,,66.3,1.0,1.92,experimental,42.024,0.21886,0.1932,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with L-chiro-inositol 2,3,5-trisphosphate/ATP/Mn"
8PPH,X-RAY DIFFRACTION,2.67,53.94,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.84 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 18 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking 2h with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 5 mM ligand, 3 mM ATP and 3 mM MnCl2.",291.0,2023-07-07,2024-02-28,8PPH,4911.0,2.0,558.0,338.0,,65.97,1.0,1.7,experimental,44.291,0.23069,0.19818,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with alpha-D-glucopyranosyl 1,3,4-trisphosphate/ATP/Mn"
8PPI,X-RAY DIFFRACTION,2.79,55.94,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.81 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 18 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking 2h with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 5 mM ligand, 3 mM ATP and 3 mM MnCl2.",291.0,2023-07-07,2024-02-28,8PPI,5135.0,2.0,558.0,472.0,,66.42,1.0,1.65,experimental,35.226,0.21405,0.18488,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with beta-D-glucopyranosylmethanol 3,4,1'-trisphosphate/ATP/Mn"
6H4A,X-RAY DIFFRACTION,2.03,39.41,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG 2000
0.1M Mes pH 6.5",293.0,2018-07-20,2019-02-13,6H4A,2918.0,1.0,404.0,43.0,,46.17,1.0,2.65,experimental,82.31,0.24,0.19,Human MALT1(329-728) in complex with MLT-748
4ZVZ,X-RAY DIFFRACTION,1.97,37.65,"VAPOR DIFFUSION, HANGING DROP",8.0,"25% MPD, 6% PEG, 10 mM Tris, pH 8.0",289.0,2015-05-18,2016-04-27,4ZVZ,10431.0,4.0,1332.0,283.0,,153.26,1.0,2,experimental,33.285,0.23517,0.20438,"Co-crystal structures of PP5 in complex with 5-methyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid"
5KO9,X-RAY DIFFRACTION,2.44,44.89,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M BTP, 2% Tacsimate, 20% PEG3350",293.0,2016-06-29,2016-08-24,5KO9,2292.0,1.0,277.0,186.0,,31.8,1.0,1.5,experimental,24.169,0.2093,0.1818,Crystal Structure of the SRAP Domain of Human HMCES Protein
6IMZ,X-RAY DIFFRACTION,2.04,39.61,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 1.8 mM ZnSO4, 6% sucrose, 0.1 M Bis-Tris pH 6.1",293.0,2018-10-24,2019-10-30,6IMZ,1471.0,1.0,163.0,64.0,,20.26,1.0,2.1,experimental,,0.2277,0.1982,Crystal structure of MTH1 in complex with 18-Crown-6
8Q9S,X-RAY DIFFRACTION,2.62,53.05,"VAPOR DIFFUSION, SITTING DROP",8.5,"THE CK2ALPHA' SOLUTION AFTER PROTEIN PURIFICATION (5 MG/ML CK2ALPHA' IN 500 MM NACL, 25 MM TRIS/HCl, PH 8.5) WAS MIXED IN 1:10 VOLUME RATIO WITH 10 MM SOLUTION OF THE INHIBITOR MB002 IN DMSO. THIS SOLUTION WAS MIXED IN 2:1 RATIO WITH RESERVOIR SOLUTION [900 MM LICL, 28 % (W/V) PEG 6000, 250 MM TRIS/HCL, PH 8.5] IN SITTING DROP PLATES (VAPOUR DIFFUSION). THE CRYSTAL GROWTH WAS INDUCED BY MICROSEEDING. THE CRYSTALS WERE OPTIMIZED BY MACROSEEDING. A CRYSTAL WAS PURGED TWICE WITH RESERVOIR SOLUTION BEFORE ADDING SGC-CK2-1 (10 MM IN DMSO) TO A FINAL CONCENTRATION OF 2.5 MM TO THE CRYSTAL MOTHOR LIQUOR FOR EXTENSIVE SOAKING AND REPLACEMENT OF THE INITIAL INHIBITOR MB002 BY SGC-CK2-1. ALL STEPS WERE PERFORMED AT A TEMPERATURE OF 293 K.",293.0,2023-08-21,2023-12-06,8Q9S,3111.0,1.0,364.0,253.0,,43.38,1.0,1.352,experimental,26.58,0.1688,0.1354,STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA'; CSNK2A2 GENE PRODUCT) IN COMPLEX WITH THE INHIBITOR SGC-CK2-1
7KVH,X-RAY DIFFRACTION,2.52,51.17,"VAPOR DIFFUSION, SITTING DROP",7.0,"PEG 3350, succinate",298.0,2020-11-28,2021-01-20,7KVH,7383.0,2.0,974.0,24.0,,113.82,1.0,2.791,experimental,,0.2775,0.2376,Human CYP3A4 bound to an inhibitor
7KVN,X-RAY DIFFRACTION,2.54,51.48,"VAPOR DIFFUSION, SITTING DROP",7.0,"PEG 3350, sodium malonate",298.0,2020-11-28,2021-01-20,7KVN,7488.0,2.0,974.0,61.0,,113.89,1.0,2.7,experimental,,0.2898,0.2478,Human CYP3A4 bound to an inhibitor
7KVO,X-RAY DIFFRACTION,2.59,52.43,MICROBATCH,7.0,"PEG 3350, sodium succinate",298.0,2020-11-28,2021-01-20,7KVO,7467.0,2.0,974.0,,,114.01,1.0,2.65,experimental,,0.2928,0.241,Human CYP3A4 bound to an inhibitor
5Q0F,X-RAY DIFFRACTION,3.18,61.27,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2017-05-01,2017-07-12,5Q0F,2199.0,2.0,262.0,193.0,5.0,31.3,2.0,2.12,experimental,29.9,0.197,0.185,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4R,5E,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-4-methyl-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate"
6NF0,X-RAY DIFFRACTION,2.14,42.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"Co-crystals were grown using the hanging drop vapor diffusion method by mixing the crystallization complex 1:1 with reservoir solution (100 mM HEPES pH 7.5, 10% (v/v) Isopropanol, 50 mM Sodium Acetate, and 12% (w/v) PEG 4,000)",293.0,2018-12-18,2019-05-01,6NF0,2429.0,1.0,312.0,18.0,,36.28,1.0,2.7,experimental,,0.264,0.2063,Nocturnin with bound NADPH substrate
6P6K,X-RAY DIFFRACTION,2.14,42.55,"VAPOR DIFFUSION, HANGING DROP",,"apo crystals :  room temp, Linbro tray, hanging drop, 1+1, reservoir is 10% PEG 3350, 0.2M MgOAc
seeding:  scratch seed
Soaks:  2ul of 200mM compound in DMSO mixed with 2x well solution (20% PEG3350, 0.4M MgOAc)",295.0,2019-06-04,2020-01-15,6P6K,3832.0,1.0,432.0,402.0,,50.59,1.0,1.55,experimental,25.2112,0.2142,0.1779,Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors
6DCC,X-RAY DIFFRACTION,3.61,65.9,"VAPOR DIFFUSION, HANGING DROP",4.2,"crystallization solution 0.2M Lithium sulfate, 0.1M phosphate/citrate, pH 4.2, 25% w/v PEG mixed 1:2 volume ratio to 10 mg/mL protein:RNA complex. Crystals were soaked in crystallization solution supplemented with 1.2mM MgCl2 for 2hrs prior to freezing.",277.0,2018-05-04,2018-12-19,6DCC,2664.0,2.0,345.0,91.0,,47.33,1.0,2.1,experimental,54.1953,0.1988,0.1748,Structure of methylphosphate capping enzyme methyltransferase domain in complex with 5' end of 7SK RNA
8A5M,X-RAY DIFFRACTION,2.82,56.38,"VAPOR DIFFUSION, SITTING DROP",5.0,1 M Sodium Potassium Phosphate pH 5,291.15,2022-06-15,2022-07-06,8A5M,2854.0,4.0,372.0,24.0,,42.65,2.0,2.918,experimental,54.013,0.2746,0.1931,TRIM7 PRYSPRY in complex with a MNV1-NS6 peptide LEALEFQ
8A8X,X-RAY DIFFRACTION,2.3,46.6,"VAPOR DIFFUSION, SITTING DROP",5.0,"1 M DL-Malic Acid pH 5, 0.1 M BIS-TRIS Propane pH 6.3",291.15,2022-06-24,2022-07-06,8A8X,2875.0,4.0,372.0,56.0,,42.33,2.0,2.37,experimental,28.428,0.2637,0.1885,TRIM7 PRYSPRY in complex with a MNV1-NS3 peptide HDDFGLQ
8BS9,X-RAY DIFFRACTION,2.68,54.19,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.3 M potassium formate, 14% (w/v) PEG 3350",291.0,2022-11-24,2023-07-12,8BS9,6874.0,4.0,842.0,671.0,,95.53,2.0,1.9,experimental,40.43,0.2094,0.171,Structure of USP36 in complex with Ubiquitin-PA
5MS4,X-RAY DIFFRACTION,1.98,37.99,"VAPOR DIFFUSION, HANGING DROP",5.6,"35% (v/v) tert-Butanol, 0.1 M tri-Na citrate/citric acid",291.0,2016-12-30,2018-01-17,5MS4,8120.0,8.0,928.0,1137.0,24.0,100.04,2.0,2.1,experimental,16.05,0.259,0.212,Kallikrein-related peptidase 8 leupeptin inhibitor complex
7AKR,X-RAY DIFFRACTION,2.3,46.61,"VAPOR DIFFUSION, SITTING DROP",,"100 mM TrisHCl (pH 8.5), 20% (w/v) PEG4000 and 200 mM MgCl2",293.15,2020-10-02,2021-06-16,7AKR,11206.0,4.0,1396.0,438.0,2.0,157.04,1.0,1.95,experimental,42.84,0.2106,0.187,Human ADP-ribosylserine hydrolase ARH3 mutant E41A in complex with ADP-ribose dimer
8CG9,X-RAY DIFFRACTION,2.24,45.01,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 1000, 0.1M MIB buffer",280.0,2023-02-03,2024-02-21,8CG9,2749.0,1.0,345.0,142.0,,40.03,1.0,1.68,experimental,40.0,0.2313,0.2229,Crystal structure of human DNA cross-link repair 1A in complex with a cyclic N-hydroxyurea inhibitor
5I9I,X-RAY DIFFRACTION,2.37,48.06,"VAPOR DIFFUSION, HANGING DROP",6.6,"0.1M MOPS pH 6.6, 0.4M Li2SO4, 27% (w/v) (NH4)2SO4, 1M Na-Ac, 1.4% 1,4-butanediol",293.0,2016-02-20,2016-06-15,5I9I,5649.0,2.0,776.0,6.0,,89.34,1.0,2.7,experimental,29.1156,0.2613,0.1909,Crystal structure of LP_PLA2 in complex with Darapladib
5W0U,X-RAY DIFFRACTION,2.95,58.26,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1 M MES at pH 6.2, 3%PEG3350, 10 mM CaCl2, 20mM dCMP",289.0,2017-05-31,2017-08-16,5W0U,9130.0,4.0,1122.0,2.0,,131.56,1.0,2.9,experimental,,0.2814,0.2509,Crystal structure of MBP fused activation-induced cytidine deaminase (AID) in complex with dCMP
5JAD,X-RAY DIFFRACTION,2.42,49.12,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.2M NaCl, 0.1M HEPES/NaOHpH=7.4, 28.8%w/v PEG 3350",297.0,2016-04-12,2016-05-25,5JAD,3135.0,1.0,388.0,143.0,,44.5,1.0,2.05,experimental,33.676,0.298,0.245,Compound binding to Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)discovered through fragment screening
7RK7,X-RAY DIFFRACTION,2.88,57.26,"VAPOR DIFFUSION, HANGING DROP",8.5,"16% PEG 3350, 2% tacsimate, 100mM Tris (pH 8.5)",298.0,2021-07-22,2022-11-02,7RK7,6295.0,5.0,851.0,82.0,7.0,97.04,5.0,2.54,experimental,89.53,0.2549,0.2111,The complex between TIL 1383i TCR and human Class I MHC HLA-A2 with the bound Tyrosinase(369-377)(N371D) nonameric peptide
5SG4,X-RAY DIFFRACTION,3.0,58.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG4,2756.0,1.0,343.0,150.0,1.0,39.9,1.0,2.3,experimental,42.609,0.222,0.1697,"Crystal Structure of human phosphodiesterase 10 in complex with 3-N-[2-(3-chlorophenyl)-1H-benzimidazol-5-yl]-2-methylpyrazole-3,4-dicarboxamide"
5SHO,X-RAY DIFFRACTION,2.97,58.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHO,2871.0,1.0,343.0,229.0,1.0,39.9,1.0,1.9,experimental,32.019,0.21,0.1792,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N-cyclopropyl-2-methyl-3-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide"
5SI1,X-RAY DIFFRACTION,3.04,59.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI1,2974.0,1.0,343.0,314.0,1.0,39.93,1.0,1.75,experimental,28.304,0.201,0.1747,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(morpholine-4-carbonyl)-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide, space group I23"
5SIL,X-RAY DIFFRACTION,3.0,58.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIL,2657.0,1.0,343.0,71.0,1.0,39.88,1.0,2.5,experimental,47.845,0.2309,0.1719,"Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-N-[2-(3,5-dimethylphenyl)-1H-benzimidazol-5-yl]-2-methylpyrazole-3-carboxamide"
5SIX,X-RAY DIFFRACTION,2.98,58.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIX,2717.0,1.0,343.0,85.0,1.0,40.03,1.0,2.29,experimental,52.057,0.2189,0.1822,"Crystal Structure of human phosphodiesterase 10 in complex with 5-[(3R)-3-fluoropyrrolidin-1-yl]-2-(3-methylquinoxalin-2-yl)-N-(oxan-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine"
5SK8,X-RAY DIFFRACTION,2.97,58.58,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SK8,2733.0,1.0,343.0,147.0,1.0,39.96,1.0,2.3,experimental,40.971,0.2334,0.1757,Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-N-(2-phenyl-1H-benzimidazol-5-yl)-2-propylpyrazole-3-carboxamide
5SKO,X-RAY DIFFRACTION,3.05,59.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKO,2731.0,1.0,343.0,158.0,1.0,40.02,1.0,2.1,experimental,41.127,0.2309,0.1935,"Crystal Structure of human phosphodiesterase 10 in complex with N-(3-imidazo[1,2-a]pyridin-2-ylphenyl)-1-methyl-3-(pyrimidin-5-ylamino)pyrazole-4-carboxamide"
5OX6,X-RAY DIFFRACTION,2.86,56.99,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.2 M Ammonium sulfate, 0.1 M Sodium acetate trihydrate pH 4.6, 25% w/v Polyethylene glycol 4000, Sitting drop (300 nl), protein-to-well ratio, 2:1",293.0,2017-09-06,2017-10-18,5OX6,1936.0,1.0,252.0,127.0,,28.83,1.0,1.99,experimental,54.0,0.2053,0.1743,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with Vadadustat
6FDZ,X-RAY DIFFRACTION,2.79,55.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 0.2 M MgCl2, 30% 2-propanol",277.0,2017-12-27,2018-08-01,6FDZ,2067.0,1.0,276.0,7.0,,32.35,1.0,2.55,experimental,58.642,0.30109,0.23043,Unc-51-Like Kinase 3 (ULK3) In Complex With Momelotinib
5SGL,X-RAY DIFFRACTION,2.64,53.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGL,10710.0,4.0,1372.0,378.0,4.0,159.96,1.0,2.28,experimental,45.308,0.2301,0.1808,"Crystal Structure of human phosphodiesterase 10 in complex with N-[(E)-(4-bromo-3,5-dimethoxyphenyl)methylideneamino]-2-ethoxy-2-(4-pyrazol-1-ylphenyl)acetamide"
5SH9,X-RAY DIFFRACTION,2.64,53.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SH9,10746.0,4.0,1372.0,427.0,4.0,159.58,1.0,2.06,experimental,40.346,0.2233,0.1715,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-[5-[(3R)-3-fluoropyrrolidin-1-yl]-2-methyl-1,2,4-triazol-3-yl]ethyl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine"
5SI0,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI0,10599.0,4.0,1372.0,255.0,4.0,159.97,1.0,2.27,experimental,55.639,0.2319,0.1796,"Crystal Structure of human phosphodiesterase 10 in complex with 7-methyl-2,5-bis[2-(1-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine"
5SIT,X-RAY DIFFRACTION,2.62,53.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIT,10698.0,4.0,1372.0,478.0,4.0,158.81,1.0,1.99,experimental,38.303,0.2263,0.1961,Crystal Structure of human phosphodiesterase 10 in complex with 6-methyl-N-(4-methylphenyl)pyrimidin-4-amine
5SJK,X-RAY DIFFRACTION,2.6,52.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJK,10669.0,4.0,1372.0,445.0,4.0,159.03,1.0,2.24,experimental,46.078,0.2345,0.1833,"Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dichloro-2,3,4,9-tetrahydropyrido[3,4-b]indol-1-one"
5SKR,X-RAY DIFFRACTION,2.64,53.34,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKR,10892.0,4.0,1372.0,597.0,4.0,159.45,1.0,1.99,experimental,38.813,0.2186,0.1787,Crystal Structure of human phosphodiesterase 10 in complex with 1-methyl-N-(2-methyl-5-pyridin-2-ylpyrazol-3-yl)-4-pyridin-4-ylpyrazole-3-carboxamide
4D76,X-RAY DIFFRACTION,2.79,55.86,,8.5,"2M AMMONIUM SULFATE, 0.1M TRIS-CL PH 8.5, 0.2M NACL",,2014-11-20,2016-01-20,4D76,2032.0,1.0,238.0,88.0,5.0,27.8,1.0,1.77,experimental,45.869,0.21032,0.18287,Human FXIa in complex with small molecule inhibitors.
4D7F,X-RAY DIFFRACTION,2.78,55.74,,8.5,"2M AMMONIUM SULFATE, 0.1M TRIS-CL PH 8.5, 0.2M NACL",,2014-11-24,2016-01-20,4D7F,2066.0,1.0,238.0,130.0,4.0,27.69,1.0,1.62,experimental,36.993,0.21054,0.18357,Human FXIa in complex with small molecule inhibitors.
6DND,X-RAY DIFFRACTION,2.35,47.64,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Sodium Acetate Trihydrate pH 4.5, 25% w/v PEG 3,350",298.0,2018-06-06,2018-11-14,6DND,6628.0,2.0,822.0,101.0,,93.08,1.0,2.1,experimental,57.577,0.26927,0.20832,Crystal structure of wild-type (WT) human Glutamate oxaloacetate transaminase 1 (GOT1)
8EEC,X-RAY DIFFRACTION,3.13,60.74,"VAPOR DIFFUSION, HANGING DROP",,0.4 M ammonium phosphate,292.0,2022-09-06,2024-03-27,8EEC,2553.0,1.0,343.0,94.0,,37.97,1.0,2.5,experimental,57.8319,0.2567,0.2084,Crystal structure of HPK1 citron-homology domain
7Z4V,X-RAY DIFFRACTION,2.5,50.84,"VAPOR DIFFUSION, SITTING DROP",,"22 % PEG 3350, 0.1 M Bis-tris propane pH 8.5, 0.2 M Potassium citrate, 10 % ethylene glycol",295.0,2022-03-04,2022-04-06,7Z4V,2549.0,1.0,297.0,162.0,,34.36,1.0,1.644,experimental,30.74,0.2834,0.2451,Structure of Serine-Threonine kinase STK25 in complex with compound
5T76,X-RAY DIFFRACTION,2.21,44.47,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5, 25% w/v PEG3350",290.0,2016-09-02,2016-11-30,5T76,1740.0,1.0,215.0,157.0,,23.75,1.0,2,experimental,,0.2576,0.2146,A fragment of a human tRNA synthetase
5SF2,X-RAY DIFFRACTION,3.03,59.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF2,2800.0,1.0,343.0,178.0,1.0,39.97,1.0,2.02,experimental,45.511,0.2292,0.1954,"Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(3-oxo-1,2-dihydroisoindol-5-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide"
7QRY,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",7.25,"1.1M sodium citrate, 0.1M HEPES 7.25",293.15,2022-01-12,2022-05-04,7QRY,5376.0,4.0,752.0,117.0,,84.86,1.0,2.07,experimental,49.382,0.2726,0.227,Crystal structure of B30.2 PRYSPRY domain of MID1
5B25,X-RAY DIFFRACTION,2.54,51.66,"VAPOR DIFFUSION, SITTING DROP",8.0,"1.75 M ammonium sulfate, 0.1 M Tris-HCl",277.0,2016-01-07,2016-02-03,5B25,11932.0,4.0,1352.0,911.0,,158.38,1.0,1.9,experimental,27.414,0.2028,0.1716,Crystal structure of human PDE1B with inhibitor 3
6VEI,X-RAY DIFFRACTION,2.5,50.88,"VAPOR DIFFUSION, SITTING DROP",4.0,"20% PEG 3350, 8% Tacsimate pH 4.0",293.0,2020-01-02,2020-02-05,6VEI,7591.0,2.0,850.0,638.0,,99.59,1.0,2.1,experimental,29.6,0.1952,0.1575,Crystal Structure of Human Cytosolic Isocitrate Dehydrogenase (IDH1) R132H Mutant in Complex with NADPH and AG-881 (Vorasidenib) Inhibitor
6VKJ,X-RAY DIFFRACTION,2.99,58.9,"VAPOR DIFFUSION, HANGING DROP",,"0.04M KH2PO4, 12% PEG 8000, 18% glycerol",289.15,2020-01-21,2021-01-27,6VKJ,2552.0,1.0,305.0,130.0,,34.45,1.0,2.105,experimental,54.1373,0.226,0.1809,Crystal structure of the G domain of human guanylate-binding protein 2 (hGBP2) in complex with GDP
8BZL,X-RAY DIFFRACTION,2.37,48.14,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris, 0.2 M Magnesium Chloride, 10 % PEG3350",291.0,2022-12-15,2023-12-27,8BZL,50949.0,34.0,6960.0,3426.0,2.0,777.6,15.0,2.14,experimental,47.647,0.2261,0.1962,Human 20S Proteasome in complex with peptide activator peptide BLM42
4Y2G,X-RAY DIFFRACTION,2.05,40.14,"VAPOR DIFFUSION, HANGING DROP",8.0,"Lithium chloride, Tris, PEG 6000",291.0,2015-02-09,2016-01-27,4Y2G,1724.0,2.0,231.0,3.0,,26.73,2.0,2.5,experimental,,0.2521,0.2149,Structure of BRCA1 BRCT domains in complex with Abraxas single phosphorylated peptide
8EJM,X-RAY DIFFRACTION,2.3,46.46,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, ammonium sulfate, HEPES buffer",293.0,2022-09-17,2022-12-14,8EJM,6133.0,2.0,760.0,273.0,,87.72,2.0,1.8,experimental,45.55,0.2244,0.1887,Crystal structure of human DEAH-box helicase DHX15 in complex with SUGP1 G-patch
5JAL,X-RAY DIFFRACTION,2.46,49.96,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.0M NaCl, 0.1M HEPES/NaOHpH=7.4, 28.8%w/v PEG 3350",297.0,2016-04-12,2016-05-25,5JAL,3369.0,1.0,388.0,342.0,,44.57,1.0,2.06,experimental,29.152,0.196,0.155,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAO,X-RAY DIFFRACTION,2.43,49.47,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",297.0,2016-04-12,2016-05-25,5JAO,3556.0,1.0,388.0,545.0,,44.57,1.0,2.06,experimental,27.504,0.213,0.156,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAP,X-RAY DIFFRACTION,2.44,49.69,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293.0,2016-04-12,2016-05-25,5JAP,3370.0,1.0,388.0,365.0,,44.63,1.0,2.46,experimental,37.331,0.246,0.173,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAR,X-RAY DIFFRACTION,2.44,49.66,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293.0,2016-04-12,2016-05-25,5JAR,3635.0,1.0,388.0,616.0,,44.65,1.0,2.11,experimental,28.844,0.204,0.144,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAS,X-RAY DIFFRACTION,2.43,49.4,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293.0,2016-04-12,2016-05-25,5JAS,3561.0,1.0,388.0,551.0,,44.63,1.0,2.06,experimental,30.58,0.222,0.155,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAT,X-RAY DIFFRACTION,2.46,50.06,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293.0,2016-04-12,2016-05-25,5JAT,3617.0,1.0,388.0,592.0,,44.66,1.0,2.04,experimental,29.655,0.199,0.14,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAU,X-RAY DIFFRACTION,2.44,49.64,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.4M NaCl, 28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4",293.0,2016-04-12,2016-05-25,5JAU,3569.0,1.0,388.0,542.0,,44.76,1.0,1.95,experimental,35.909,0.244,0.202,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5CHZ,X-RAY DIFFRACTION,2.01,36.02,"VAPOR DIFFUSION, HANGING DROP",7.5,21% ethylene glycol,295.0,2015-07-10,2016-07-20,5CHZ,1841.0,4.0,216.0,156.0,,29.81,1.0,1.83,experimental,26.669,0.20899,0.17369,Structure of wild-type human MBD4 bound to a G:T mismatch
6FAD,X-RAY DIFFRACTION,2.15,42.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.09 M (Sodium nitrate, 0.3 Sodium phosphate, 0.3 M ammonium sulphate), 0.1 M (Sodium HEPES, MOPS) buffer system, 50% v/v GOL_P4K mix [Morpheus HT96 C7, Molecular Dimensions]",277.0,2017-12-15,2019-09-25,6FAD,12099.0,8.0,2536.0,189.0,,287.93,2.0,2.801,experimental,,0.2574,0.1979,SR protein kinase 1 (SRPK1) in complex with the RGG-box of HSV1 ICP27
6FZM,X-RAY DIFFRACTION,2.35,47.71,"VAPOR DIFFUSION, SITTING DROP",6.5,"20% Poly(ethylene glycol) 3350, 0.2M sodium nitrate and 0.1M Bis-Tris-Propane",277.0,2018-03-15,2019-02-20,6FZM,3109.0,2.0,386.0,15.0,1.0,44.97,1.0,2.67,experimental,51.93,0.289,0.235,"Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor ITK6"
4X2L,X-RAY DIFFRACTION,2.8,56.04,"VAPOR DIFFUSION, SITTING DROP",6.9,"20% PEG5000MME, 200 mM NaI, 200 mM NaCitrate, PH 6.9, BACE (8.3 mg/ml in 20 mM Tris, 250 mM NaCl, pH 7.5)",298.0,2014-11-26,2015-03-04,4X2L,3054.0,1.0,415.0,92.0,3.0,47.42,1.0,2.55,experimental,41.78,0.2385,0.1884,Crystal structure of human BACE-1 bound to Compound 6
5DKW,X-RAY DIFFRACTION,3.66,69.64,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M HEPES, 30%(v/v) Jeffamine ED-2100 Reagent",277.0,2015-09-04,2016-02-24,5DKW,6146.0,8.0,696.0,205.0,,87.17,1.0,2.689,experimental,,0.2327,0.1837,Ternary crystal structure of polymerase lambda with a GA mispair at the primer terminus with Ca2+ in the active
6RA5,X-RAY DIFFRACTION,3.13,60.71,"VAPOR DIFFUSION, SITTING DROP",,"8% PEG 8K w/v, 0.1M PCTP (pH 8.0), 0.8% ethylene glycol v/v",298.0,2019-04-05,2020-05-06,6RA5,4384.0,2.0,612.0,53.0,,70.56,1.0,2.9,experimental,,,,Human tnik in complex with compound 9
6EP4,X-RAY DIFFRACTION,3.36,63.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 MES Buffer, 2.1 M ammonium sulfate",293.0,2017-10-10,2017-12-13,6EP4,4614.0,1.0,529.0,245.0,3.0,62.2,1.0,2.30005381157,experimental,49.960587464,0.216812272554,0.178719844894,Human butyrylcholinesterase in complex with decamethonium
6EQP,X-RAY DIFFRACTION,3.43,64.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 MES BUFFER, 2.1 M AMMONIUM SULFATE",293.0,2017-10-14,2017-12-13,6EQP,4647.0,1.0,529.0,237.0,3.0,62.61,1.0,2.34941708483,experimental,57.5565776099,0.237233561589,0.187639981938,Human butyrylcholinesterase in complex with ethopropazine
6X3R,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, HANGING DROP",8.5,"20 mM Tris-HCl, pH 8.5, 2 mM DTT, 2 mM EDTA, 20-35% PEG3350, 5% ethanol",277.0,2020-05-21,2020-06-24,6X3R,1420.0,1.0,167.0,167.0,,18.68,1.0,1.8,experimental,20.08,0.1974,0.1662,Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors
9BKS,X-RAY DIFFRACTION,1.87,34.15,"VAPOR DIFFUSION, SITTING DROP",7.5,"12.5% MPD, 12.5% PEG1000, 12.5% PEG3350, 0.1 M Sodium Hepes, MOPS pH 7.5, 0.09 M Sodium nitrate, 0.09 M Sodium phosphate dibasic, 0.09 M Ammonium sulfate",291.0,2024-04-29,2024-07-31,9BKS,770.0,1.0,80.0,82.0,,9.52,1.0,1.17,experimental,11.591,0.17251,0.14978,Crystal structure of the Human TRIP12 WWE domain (isoform 2) in complex with ADP
7CO8,X-RAY DIFFRACTION,2.08,40.77,VAPOR DIFFUSION,6.5,"KCL, BIS-TRIS, PEG 10000",298.0,2020-08-04,2021-06-30,7CO8,3558.0,4.0,500.0,383.0,,59.83,1.0,1.697,experimental,25.6482,0.1952,0.1791,Ternary complex of DNA polymerase Mu with 2-nt gapped DNA (T:dGMPNPP)
7COB,X-RAY DIFFRACTION,1.92,35.89,VAPOR DIFFUSION,8.0,"1,4-Dioxane, Tris-HCl, PEG 3350",298.0,2020-08-04,2021-06-30,7COB,3363.0,4.0,499.0,237.0,,59.43,1.0,1.797,experimental,35.0011,0.2038,0.1798,Ternary complex of DNA polymerase Mu (Q441A) with 1-nt gapped DNA (T:dGMPNPP)
7COC,X-RAY DIFFRACTION,1.93,36.34,VAPOR DIFFUSION,7.5,"Hexylene glycol, HEPES, PEG10000",298.0,2020-08-04,2021-06-30,7COC,3368.0,4.0,499.0,256.0,,59.39,1.0,1.9,experimental,33.5882,0.2115,0.1816,Ternary complex of DNA polymerase Mu (K438A/Q441A) with 1-nt gapped DNA (T:dGMPNPP)
6FUG,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 100 mM TRIS pH 8.5",293.0,2018-02-27,2018-06-06,6FUG,10121.0,6.0,1392.0,285.0,24.0,150.52,1.0,2.21,experimental,42.556,0.25905,0.22127,"Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol"
6FUJ,X-RAY DIFFRACTION,2.97,58.57,"VAPOR DIFFUSION, SITTING DROP",,"22-25% PEG3350, 100 mM HEPES pH 7.5, 2 mM inhibitor",293.0,2018-02-27,2018-06-06,6FUJ,10684.0,6.0,1392.0,257.0,26.0,149.28,1.0,2.25,experimental,45.821,0.24388,0.21761,"Complement factor D in complex with the inhibitor N-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)-3-methylbutanamide"
6EYF,X-RAY DIFFRACTION,3.21,61.68,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris pH 8.5, 2.15 M ammonium sulfate.",298.0,2017-11-12,2018-11-21,6EYF,4413.0,1.0,527.0,80.0,3.0,61.11,1.0,2.6,experimental,,0.2261,0.1813,Butyrylcolinesterase expressed in CHO cells co-crystallised with a rivastigmine analogue
6BJE,X-RAY DIFFRACTION,2.2,44.05,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M NaCitric pH 5.6, 15% PEG-3350",293.0,2017-11-06,2018-11-14,6BJE,3347.0,2.0,444.0,32.0,,48.03,1.0,2.7,experimental,,0.2641,0.2213,Crystal Structure of Lysophospholipase A2 Conjugated with Phenylmethylsulfonyl Fluoride
5KUL,X-RAY DIFFRACTION,2.78,55.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING DROP FORMAT.",291.0,2016-07-13,2016-09-07,5KUL,2018.0,1.0,164.0,260.0,,17.91,1.0,1.7,experimental,16.21,0.2193,0.181,"Human cyclophilin A at 100K, Data set 1"
5KUN,X-RAY DIFFRACTION,2.78,55.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KUN,2016.0,1.0,164.0,252.0,,17.91,1.0,1.7,experimental,17.749,0.2084,0.1737,"Human cyclophilin A at 100K, Data set 2"
5KUO,X-RAY DIFFRACTION,2.78,55.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-31,5KUO,2023.0,1.0,164.0,256.0,,17.91,1.0,1.7,experimental,18.5255,0.2142,0.1754,"Human cyclophilin A at 100K, Data set 3"
5KUQ,X-RAY DIFFRACTION,2.78,55.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KUQ,2042.0,1.0,164.0,244.0,,17.91,1.0,1.7,experimental,19.4634,0.2107,0.1695,"Human cyclophilin A at 100K, Data set 4"
5KUR,X-RAY DIFFRACTION,2.77,55.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-09-07,5KUR,2009.0,1.0,164.0,244.0,,17.91,1.0,1.7,experimental,20.6711,0.2074,0.1718,"Human cyclophilin A at 100K, Data set 5"
5KUS,X-RAY DIFFRACTION,2.77,55.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KUS,1968.0,1.0,164.0,240.0,,17.91,1.0,1.7,experimental,21.2644,0.213,0.1721,"Human cyclophilin A at 100K, Data set 6"
5KUU,X-RAY DIFFRACTION,2.77,55.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-31,5KUU,2002.0,1.0,164.0,247.0,,17.91,1.0,1.7,experimental,22.591,0.2077,0.1725,"Human cyclophilin A at 100K, Data set 7"
5KUV,X-RAY DIFFRACTION,2.78,55.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KUV,1983.0,1.0,164.0,230.0,,17.91,1.0,1.7,experimental,23.8265,0.194,0.1713,"Human cyclophilin A at 100K, Data set 8"
5KUW,X-RAY DIFFRACTION,2.78,55.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KUW,1978.0,1.0,164.0,232.0,,17.91,1.0,1.7,experimental,24.3238,0.2129,0.1736,"Human cyclophilin A at 100K, Data set 9"
5KUZ,X-RAY DIFFRACTION,2.82,56.31,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KUZ,1977.0,1.0,164.0,127.0,,17.91,1.0,1.7,experimental,21.0504,0.1844,0.1532,"Human cyclophilin A at 278K, Data set 1"
5KV0,X-RAY DIFFRACTION,2.81,56.28,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-31,5KV0,1945.0,1.0,164.0,129.0,,17.91,1.0,1.7,experimental,21.2997,0.1934,0.1551,"Human cyclophilin A at 278K, Data set 2"
5KV1,X-RAY DIFFRACTION,2.81,56.22,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KV1,1991.0,1.0,164.0,128.0,,17.91,1.0,1.7,experimental,20.8708,0.1982,0.1562,"Human cyclophilin A at 278K, Data set 3"
5KV2,X-RAY DIFFRACTION,2.81,56.24,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KV2,2046.0,1.0,164.0,127.0,,17.91,1.0,1.7,experimental,22.4761,0.2027,0.1551,"Human cyclophilin A at 278K, Data set 4"
5KV3,X-RAY DIFFRACTION,2.82,56.32,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KV3,1995.0,1.0,164.0,128.0,,17.91,1.0,1.7,experimental,22.0916,0.2008,0.1553,"Human cyclophilin A at 278K, Data set 5"
5KV4,X-RAY DIFFRACTION,2.82,56.31,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KV4,2032.0,1.0,164.0,128.0,,17.91,1.0,1.7,experimental,22.3612,0.2004,0.1597,"Human cyclophilin A at 278K, Data set 6"
5KV5,X-RAY DIFFRACTION,2.82,56.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KV5,2015.0,1.0,164.0,127.0,,17.91,1.0,1.7,experimental,20.0634,0.2101,0.1639,"Human cyclophilin A at 278K, Data set 7"
5KV6,X-RAY DIFFRACTION,2.81,56.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-10,5KV6,1890.0,1.0,164.0,129.0,,17.91,1.0,1.7,experimental,21.6713,0.2238,0.1692,"Human cyclophilin A at 278K, Data set 8"
5KV7,X-RAY DIFFRACTION,2.82,56.44,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291.0,2016-07-13,2016-08-31,5KV7,1936.0,1.0,164.0,127.0,,17.91,1.0,1.7,experimental,23.5278,0.2232,0.1744,"Human cyclophilin A at 278K, Data set 9"
5NOQ,X-RAY DIFFRACTION,2.71,54.55,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOQ,1479.0,1.0,165.0,159.0,,18.29,1.0,1.6,experimental,19.348,0.19617,0.16525,Structure of cyclophilin A in complex with 3-chloropyridin-2-amine
5NOR,X-RAY DIFFRACTION,2.75,55.32,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOR,1504.0,1.0,165.0,200.0,,18.25,1.0,1.8,experimental,16.579,0.20344,0.15997,Structure of cyclophilin A in complex with 3-methylpyridin-2-amine
5NOS,X-RAY DIFFRACTION,2.73,54.98,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOS,1484.0,1.0,165.0,193.0,,18.15,1.0,1.35,experimental,15.096,0.16478,0.13135,Structure of cyclophilin A in complex with 3-amino-1H-pyridin-2-one
5NOT,X-RAY DIFFRACTION,2.76,55.42,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOT,1459.0,1.0,165.0,146.0,,18.3,1.0,1.45,experimental,18.288,0.18349,0.15998,Structure of cyclophilin A in complex with 4-chloropyrimidin-5-amine
5NOV,X-RAY DIFFRACTION,2.62,53.12,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOV,1340.0,1.0,165.0,58.0,,18.15,1.0,2,experimental,31.94,0.26492,0.20625,Structure of cyclophilin A in complex with hexahydropyrimidine-2-thione
5NOW,X-RAY DIFFRACTION,2.82,56.36,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOW,1445.0,1.0,165.0,157.0,,18.15,1.0,1.48,experimental,17.979,0.21949,0.20166,"Structure of cyclophilin A in complex with pyridine-3,4-diamine"
5NOX,X-RAY DIFFRACTION,2.82,56.43,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOX,1560.0,1.0,165.0,250.0,,18.17,1.0,1.49,experimental,19.623,0.19876,0.16856,Structure of cyclophilin A in complex with 2-chloropyridin-3-amine
5NOY,X-RAY DIFFRACTION,2.83,56.49,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2017-04-13,2017-07-12,5NOY,1566.0,1.0,165.0,244.0,,18.19,1.0,1.43,experimental,18.09,0.18247,0.15743,"Structure of cyclophilin A in complex with 3,4-diaminobenzamide"
5NHY,X-RAY DIFFRACTION,2.24,45.12,"VAPOR DIFFUSION, SITTING DROP",,"22.7% PEG4000, 0.24 ammonium sulfate, 15% glycerol",277.0,2017-03-22,2017-07-19,5NHY,2763.0,2.0,318.0,155.0,,38.03,1.0,1.72,experimental,42.157,0.26191,0.22037,BAY-707 in complex with MTH1
6IJY,X-RAY DIFFRACTION,1.88,34.7,COUNTER-DIFFUSION,,"sodium citrate, cacodylate, sodium chloride, glycerol",293.0,2018-10-12,2019-02-20,6IJY,3387.0,2.0,312.0,340.0,,37.31,1.0,1.04,experimental,,0.1583,0.1334,Crystal structure of human MTH1(G2K/C87A/C104S mutant) in complex with 8-oxo-dGTP determined using a crystal obtained under microgravity
8TBG,X-RAY DIFFRACTION,2.29,46.26,"VAPOR DIFFUSION, SITTING DROP",8.0,"28% PEG4000, 0.1 M Tris, pH 8",291.0,2023-06-28,2024-02-07,8TBG,6398.0,4.0,666.0,851.0,,77.03,2.0,1.2,experimental,20.72,0.1918,0.1606,"Tricomplex of RMC-7977, HRAS WT, and CypA"
7SFG,X-RAY DIFFRACTION,2.8,56.05,"VAPOR DIFFUSION, SITTING DROP",5.1,"14-18% polyethylene glycol (PEG) 3350,  0.1 M citric acid (pH 5.1)",292.0,2021-10-03,2022-03-30,7SFG,7130.0,3.0,898.0,287.0,,107.14,1.0,2.43,experimental,55.61,0.2229,0.1796,Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Cofactor SAM
7A4B,X-RAY DIFFRACTION,3.18,61.3,"VAPOR DIFFUSION, SITTING DROP",,"1 MIKROLITER OF THE CK2ALPHA/INHIBITOR MIXTURE (COMPOSITION: 7 MG/ML CK2ALPHA ENZYME, 1 MILLIMOLAR INHIBITOR, 10 % DIMETHYL SULFOXIDE, 450 MM NACL, 22.5 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 1 MIKROLITER RESERVOIR SOLUTION (COMPOSITION: 25 % PEG3350, 0.2 M AMMONIUM SULPHATE, 0.1 M BIS-TRIS BUFFER, PH 5.5) FOLLOWED BY VAPOUR DIFFUSION EQUILIBRATION AGAINST THE RESERVOIR SOLUTION.",293.15,2020-08-19,2020-12-09,7A4B,6046.0,2.0,670.0,340.0,,81.74,1.0,2.06,experimental,39.63,0.2226,0.1911,"Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 5,6-dibromo-1H-triazolo[4,5-b]pyridine"
7A4C,X-RAY DIFFRACTION,3.22,61.83,"VAPOR DIFFUSION, SITTING DROP",,"1 MIKROLITER OF THE CK2ALPHA/INHIBITOR MIXTURE (COMPOSITION: 7 MG/ML CK2ALPHA ENZYME, 1 MILLIMOLAR INHIBITOR, 10 % DIMETHYL SULFOXIDE, 450 MM NACL, 22.5 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 1 MIKROLITER RESERVOIR SOLUTION (COMPOSITION: 25 % PEG3350, 0.2 M AMMONIUM SULPHATE, 0.1 M BIS-TRIS BUFFER, PH 5.5) FOLLOWED BY VAPOUR DIFFUSION EQUILIBRATION AGAINST THE RESERVOIR SOLUTION.",293.15,2020-08-19,2020-12-09,7A4C,5892.0,2.0,670.0,175.0,,81.7,1.0,2.502,experimental,45.89,0.2323,0.2062,"Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 5,6,7-tribromo-1H-triazolo[4,5-b]pyridine"
6DCB,X-RAY DIFFRACTION,3.54,65.3,"VAPOR DIFFUSION, HANGING DROP",4.2,"crystallization solution 0.214 M lithium sulfate, 0.1 M phosphate/citrate, pH 4.2, 17.25% w/v PEG 1,000 mixed 1:2 volume ratio to 10 mg/mL protein:RNA complex solution",277.0,2018-05-04,2018-12-19,6DCB,2799.0,2.0,345.0,149.0,,47.51,1.0,1.998,experimental,47.6433,0.1782,0.16,Structure of methylphosphate capping enzyme methyltransferase domain in complex with 5' end of 7SK RNA
6D66,X-RAY DIFFRACTION,2.96,58.38,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M DL-glutamic acid
0.2 M DL-alanine
0.2 M -glycine
0.2 M-DL-lysine
0.2 M DL-serine
0.1 M Tris: Bicine 
25% MPD
25% PEG1000
25% PEG3350",292.0,2018-04-20,2018-09-19,6D66,5428.0,2.0,656.0,307.0,,74.01,2.0,2.226,experimental,,0.2018,0.1594,Crystal structure of the human dual specificity 1 catalytic domain (C258S) as a maltose binding protein fusion in complex with the designed AR protein mbp3_16
5MBL,X-RAY DIFFRACTION,2.87,57.13,"VAPOR DIFFUSION, SITTING DROP",7.4,"buffer:
50mM Tris/HCl, 300mM NaCl, 0.05% Tween-20
precipitant:
0.1M MES, 1.8M NH4SO4",292.0,2016-11-08,2017-12-20,5MBL,3779.0,2.0,427.0,541.0,6.0,46.1,2.0,1.81,experimental,31.8,0.1931,0.1697,Cathepsin B in complex with DARPin 81
5QQO,X-RAY DIFFRACTION,3.2,61.53,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2019-05-20,2019-09-18,5QQO,2234.0,2.0,262.0,221.0,5.0,31.15,2.0,2,experimental,24.47,0.184,0.162,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazinan-3-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate"
5TX3,X-RAY DIFFRACTION,2.36,47.98,"VAPOR DIFFUSION, HANGING DROP",,PEG 4000,293.0,2016-11-15,2017-11-22,5TX3,5079.0,2.0,688.0,48.0,,80.25,1.0,2.9,experimental,88.09,0.2528,0.1818,Structure of Maternal Embryonic Leucine Zipper Kinase
7JU8,X-RAY DIFFRACTION,2.31,46.77,"VAPOR DIFFUSION, HANGING DROP",,"10% w/v PEG4000, 1 M ammonium formate, and 100 mM Tris, pH 8.0",293.0,2020-08-19,2021-08-04,7JU8,3138.0,2.0,342.0,371.0,,40.07,1.0,2,experimental,21.911,0.2642,0.1978,"X-ray structure of MMP-13 in Complex with 4-(1,2,3-thiadiazol-4-yl)pyridine"
5OE7,X-RAY DIFFRACTION,2.84,56.67,VAPOR DIFFUSION,,"1.9-2.1 M Ammonium sulphate, 100 mM bis-tris",298.0,2017-07-07,2017-09-27,5OE7,3077.0,2.0,419.0,,1.0,48.22,2.0,2.95,experimental,44.06,0.309,0.223,Structure of OTULIN bound to the Met1-linked diubiquitin activity probe
5EGM,X-RAY DIFFRACTION,2.81,56.17,"VAPOR DIFFUSION, HANGING DROP",9.0,"50 MM CHES, PH 9.0, 1.3 M TRI-SODIUM     
REMARK 280  CITRATE AND 3 MM COMPOUND (CROSS SEEDED WITH CRYSTALS GROWN FROM    
REMARK 280  50 MM TRIS, PH 7.2, 1.45 M AMMONIUM SULFATE, 2.0 M SODIUM           
REMARK 280  CHLORIDE AND 3 MM COMPOUND)",295.0,2015-10-27,2015-11-18,5EGM,2565.0,2.0,297.0,221.0,8.0,33.73,2.0,1.841,experimental,34.6,0.1714,0.148,Development of a novel tricyclic class of potent and selective FIXa inhibitors
5EO3,X-RAY DIFFRACTION,3.27,62.44,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM Tris HCl pH 7.5, 200mM NaCl, 5mM DTT",295.0,2015-11-10,2016-11-16,5EO3,1628.0,2.0,242.0,45.0,,27.03,1.0,2.6,experimental,53.346,0.2669,0.2158,Crystal Structure of Pelota C terminal domain from human
6MCQ,X-RAY DIFFRACTION,2.8,56.03,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES, pH 7.5, 23% PEG600, 0.1 M lithium chloride, 20 mM succinate, pH 7.0",288.0,2018-09-01,2019-09-04,6MCQ,11493.0,4.0,1420.0,116.0,,168.35,2.0,2.57,experimental,72.2474,0.245,0.1985,L. pneumophila effector kinase LegK7 in complex with human MOB1A
8A5W,X-RAY DIFFRACTION,3.01,59.1,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Na2SO4, 0.1 M Bis Tris Propane, pH 7,5, 20 % PEG 3350",293.0,2022-06-16,2023-03-29,8A5W,22746.0,8.0,3060.0,114.0,,337.36,2.0,2.78,experimental,46.91,0.2276,0.1821,Crystal structure of the human phosphoserine aminotransferase (PSAT) in complex with O-phosphoserine
5XQZ,X-RAY DIFFRACTION,2.34,47.4,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, HEPES, magnesium chloride",287.0,2017-06-07,2018-08-29,5XQZ,4415.0,4.0,522.0,248.0,,61.41,2.0,2.1,experimental,36.202,0.24374,0.15631,Structure of the MOB1-NDR2 complex
5TJX,X-RAY DIFFRACTION,2.17,43.42,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M potassium di-hydrogen phosphate, 21 % PEG 3350",296.0,2016-10-05,2016-12-21,5TJX,2244.0,1.0,263.0,334.0,4.0,30.14,1.0,1.408,experimental,19.3,0.1842,0.1626,Structure of human plasma kallikrein
4QO9,X-RAY DIFFRACTION,2.15,42.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM Danusertib, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-19,2015-07-29,4QO9,4838.0,2.0,620.0,185.0,,71.54,1.0,2.2,experimental,,0.2183,0.1604,MST3 IN COMPLEX WITH Danusertib
5IH4,X-RAY DIFFRACTION,2.79,55.95,"VAPOR DIFFUSION, SITTING DROP",9.5,"0.1 M Li2SO4, 0.7 - 0.8 M Na-K tartrate, 0.1 M CHES (pH 9.5)",277.15,2016-02-29,2016-04-13,5IH4,2643.0,1.0,294.0,257.0,,34.61,1.0,1.9,experimental,38.753,0.2267,0.1909,Human Casein Kinase 1 isoform delta apo (kinase domain)
6H0T,X-RAY DIFFRACTION,2.74,55.11,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, cacodylate, zinc acetate",293.0,2018-07-10,2019-03-27,6H0T,4161.0,1.0,547.0,112.0,2.0,61.59,1.0,1.9,experimental,46.12,0.246,0.2099,Crystal structure of native recombinant human bile salt activated lipase
6KBR,X-RAY DIFFRACTION,1.92,35.9,"VAPOR DIFFUSION, SITTING DROP",,"Lithium chloride, polyethylene glycol 3350",293.0,2019-06-26,2019-07-17,6KBR,2193.0,2.0,319.0,110.0,9.0,34.4,2.0,2,experimental,10.645,0.22584,0.18541,Crystal structure of Human KLK4 and SPINK2 derived KLK4 inhibitor complex
7SOL,X-RAY DIFFRACTION,2.75,55.23,"VAPOR DIFFUSION, HANGING DROP",,"20 % PEG 3350, 0.2 M NaF",291.0,2021-10-31,2022-11-02,7SOL,17964.0,4.0,2206.0,847.0,,250.26,2.0,2.25000635563,experimental,54.0402852294,0.205701836009,0.165797872043,"Crystal Structures of the bispecific ubiquitin/FAT10 activating enzyme, Uba6"
6QMR,X-RAY DIFFRACTION,1.99,38.17,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG MME 2000, 0.1M sodium thiocyanate",293.0,2019-02-08,2019-04-24,6QMR,10940.0,6.0,1524.0,320.0,24.0,164.85,1.0,2,experimental,21.421,0.2555,0.2198,"Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid"
5YR6,X-RAY DIFFRACTION,2.56,52.03,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M Bistris pH-6.2, 19% PEG 3350, 5% Glycerol",298.0,2017-11-08,2018-11-14,5YR6,2617.0,1.0,304.0,168.0,,34.69,1.0,1.75,experimental,32.038,0.2105,0.1801,Human methionine aminopeptidase type 1b (F309L mutant) in complex with TNP470
6WF5,X-RAY DIFFRACTION,2.17,43.2,"VAPOR DIFFUSION, SITTING DROP",,Co-crystallization: Naa50 apo protein (14.3 mg/ml) was incubated with compound 2 in a 1:3 molar ratio on ice for 60 min.  Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein:ligand complex,286.15,2020-04-03,2020-07-01,6WF5,2815.0,4.0,354.0,98.0,,40.55,2.0,2.04,experimental,35.3,0.274,0.222,Crystal structure of human Naa50 in complex with a truncated cofactor derived inhibitor (compound 2)
7Q7D,X-RAY DIFFRACTION,2.74,55.11,BATCH MODE,,"20 mg/ml protein in 25 mM HEPES pH 7.5, 500 mM NaCl, 0.5 mM TCEP was mixed 1:1.5 with precipitant solution (0.1 M HEPES 6.5, 0.2M ammonium acetate, 20% PEG 3350, 50mM sodium/potassium tartrate, 0.8mM quercetin). Batch grown crystals were subsequently mixed 1:1 with 100 mM ATP/50 mM magnesium chloride in DRAK2 crystallization buffer and incubated for half an hour.",295.0,2021-11-09,2022-11-16,7Q7D,2336.0,1.0,327.0,17.0,,37.86,1.0,2.6,experimental,76.79,0.2347,0.1923,Room temperature structure of the human Serine/Threonine Kinase 17B (STK17B/DRAK2) in complex with ATP/ADP at 111 MPa helium gas pressure in a sapphire capillary
7Q7E,X-RAY DIFFRACTION,2.79,55.86,BATCH MODE,,"20 mg/ml protein in 25 mM HEPES pH 7.5, 500 mM NaCl, 0.5 mM TCEP was mixed 1:1.5 with precipitant solution (0.1 M HEPES 6.5, 0.2M ammonium acetate, 20% PEG 3350, 50mM sodium/potassium tartrate, 0.8mM quercetin). Batch grown crystals were subsequently mixed 1:1 with 100 mM ATP/50 mM magnesium chloride in DRAK2 crystallization buffer and incubated for half an hour.",295.0,2021-11-09,2022-11-16,7Q7E,2322.0,1.0,327.0,11.0,,37.86,1.0,2.85,experimental,73.23,0.2392,0.1856,Room temperature structure of the human Serine/Threonine Kinase 17B (STK17B/DRAK2) in complex with ATP/ADP at atmospheric pressure in a sapphire capillary after high helium gas pressure release
7T39,X-RAY DIFFRACTION,2.15,42.78,"VAPOR DIFFUSION, SITTING DROP",7.4,"25%(w/v) PEG3350, 0.2M Ammonium Acetate, 0.1M Bis-Tris pH5.5",291.0,2021-12-07,2021-12-22,7T39,4657.0,1.0,720.0,1.0,,80.96,1.0,2.81,experimental,54.646,0.2686,0.228,Co-crystal structure of human PRMT9 in complex with MT221 inhibitor
5Q0E,X-RAY DIFFRACTION,3.44,64.27,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2017-05-01,2017-07-12,5Q0E,2187.0,1.0,244.0,197.0,4.0,29.33,1.0,2.12,experimental,28.07,0.196,0.173,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4S,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-4-methyl-2-oxo-1,3,4,5,6,7,8,10-octahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate"
5Q0H,X-RAY DIFFRACTION,3.43,64.16,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2017-05-01,2017-07-12,5Q0H,2070.0,1.0,244.0,136.0,4.0,28.85,1.0,2.5,experimental,30.41,0.21,0.168,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4R,5E,8S)-11-chloro-8-[(2,6-difluoro-4-methylbenzene-1-carbonyl)amino]-4-methyl-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate"
5QCL,X-RAY DIFFRACTION,3.47,64.6,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2017-08-10,2017-11-08,5QCL,2094.0,1.0,244.0,163.0,4.0,28.85,1.0,2.11,experimental,29.93,0.235,0.199,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid"
5QCM,X-RAY DIFFRACTION,3.48,64.64,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2017-08-10,2017-11-08,5QCM,2106.0,1.0,244.0,153.0,4.0,29.2,1.0,2.2,experimental,34.04,0.244,0.215,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-chloranyl-2-fluoranyl-6-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]phenyl]carbamate"
5QCN,X-RAY DIFFRACTION,3.42,64.09,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2017-08-10,2017-11-08,5QCN,2120.0,1.0,244.0,147.0,4.0,29.34,1.0,2.3,experimental,33.57,0.243,0.193,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-5-[(3~{S})-3-ethoxycarbonylpiperidin-1-yl]carbonyl-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid"
5WB6,X-RAY DIFFRACTION,3.42,64.08,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 MM SODIUM ACETATE, PH 4.6, 25%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE, then transferred to 100 MM TRIS-HCL, pH 7.0, 25%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277.0,2017-06-28,2017-08-02,5WB6,2115.0,1.0,244.0,142.0,4.0,29.22,1.0,2.35,experimental,35.7,0.236,0.199,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(11S)-11-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-6-fluoro-2-oxo-1,3,4,10,11,13-hexahydro-2H-5,9:15,12-di(azeno)-1,13-benzodiazacycloheptadecin-18-yl]carbamate"
6FNI,X-RAY DIFFRACTION,2.91,57.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"20 % PEG5000 MME, 0.15 M MgCl2, 15 % Glycerol, 0.1 M TRIS pH 7.5",291.0,2018-02-04,2018-08-08,6FNI,2408.0,1.0,297.0,235.0,,33.99,1.0,1.468,experimental,,0.2363,0.2243,Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with NVP-BHG712
6FNL,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"25 % PEG5000 MME, 15 % Glycerol, 0.1 M TRIS pH7.5",291.0,2018-02-04,2018-08-08,6FNL,2419.0,1.0,297.0,265.0,,33.49,1.0,1.269,experimental,,0.2135,0.1965,Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase
6T7F,X-RAY DIFFRACTION,2.46,50.08,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.85 M sodium citrate, 100 mM sodium chloride, 100 mM Tris-HCl pH 8.0",292.0,2019-10-21,2020-08-05,6T7F,3717.0,3.0,484.0,41.0,,55.22,3.0,2.58,experimental,78.285,0.2561,0.1951,RCR E3 ligase E2-Ubiquitin transthiolation intermediate
7KWA,X-RAY DIFFRACTION,2.22,44.55,EVAPORATION,,"6% PEG3350, 0.2M NH4Br",277.0,2020-11-30,2021-07-14,7KWA,3369.0,1.0,384.0,378.0,,44.86,1.0,1.572,experimental,27.9416,0.2095,0.1695,"Structure of DCN1 bound to N-((4S,5S)-3-(aminomethyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide"
5M36,X-RAY DIFFRACTION,3.7,66.72,"VAPOR DIFFUSION, SITTING DROP",5.6,0.17 M Ammonium acetate; 0.085 M Sodium citrate pH 5.6; 25.5% (w/v) PEG 4000; 15% (v/v) Glycerol,277.15,2016-10-14,2017-11-15,5M36,4009.0,4.0,534.0,67.0,,64.98,2.0,2.45,experimental,77.665,0.2736,0.2238,The molecular tweezer CLR01 stabilizes a disordered protein-protein interface
5SG2,X-RAY DIFFRACTION,2.6,52.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG2,10602.0,4.0,1372.0,397.0,4.0,158.41,1.0,2.15,experimental,45.32,0.2426,0.1851,"Crystal Structure of human phosphodiesterase 10 in complex with 3-methylimidazo[4,5-f]quinolin-2-amine"
5SII,X-RAY DIFFRACTION,2.64,53.41,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SII,10740.0,4.0,1372.0,428.0,4.0,159.54,1.0,2.18,experimental,44.263,0.2253,0.1749,"Crystal Structure of human phosphodiesterase 10 in complex with 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine"
5SKC,X-RAY DIFFRACTION,2.69,54.33,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKC,10420.0,4.0,1372.0,126.0,2.0,159.36,1.0,2.6,experimental,73.43,0.2423,0.2161,Crystal Structure of human phosphodiesterase 10 in complex with 6-methyl-N-(1-propan-2-ylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
6BX8,X-RAY DIFFRACTION,2.04,39.64,"VAPOR DIFFUSION, HANGING DROP",4.6,"0.2M Lithium Sulfate, 0.1M BIS-Tris-HCl pH 4.6, 25% v/v PEG 3350 (Anatrace Top96-27)",298.0,2017-12-18,2019-02-06,6BX8,9070.0,8.0,1216.0,821.0,35.0,136.14,2.0,1.98,experimental,30.0686,0.2211,0.1922,Human Mesotrypsin (PRSS3) Complexed with Tissue Factor Pathway Inhibitor Variant (TFPI1-KD1-K15R-I17C-I34C)
8AE4,X-RAY DIFFRACTION,2.41,48.86,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium citrate pH 4.5, 20% PEG 4000",277.0,2022-07-12,2022-09-28,8AE4,3694.0,2.0,423.0,323.0,,49.05,2.0,1.79,experimental,26.94,0.2079,0.1915,Crystal structure of human legumain in complex with Clitocypin 2
5V3H,X-RAY DIFFRACTION,3.12,60.52,"VAPOR DIFFUSION, HANGING DROP",8.0,"5% v/v Ethanol, 0.1 M Tris pH 7.5, 26% w/v PEG3350",293.0,2017-03-07,2018-04-25,5V3H,3782.0,1.0,444.0,129.0,,52.91,1.0,2.69,experimental,54.016,0.27,0.2175,Crystal structure of SMYD2 with SAM and EPZ033294
5TVP,X-RAY DIFFRACTION,2.9,57.54,"VAPOR DIFFUSION, SITTING DROP",4.2,"100 mM citrate-phosphate, 200mM NaCl, 12% (w/v) PEG3350",293.0,2016-11-09,2017-10-11,5TVP,18735.0,17.0,2201.0,690.0,,264.1,2.0,2.399,experimental,55.168,0.2332,0.1908,SUMO2 bound to Mouse Tdp2 catalytic domain with a 5'-phosphorylated DNA ternary complex
5SJW,X-RAY DIFFRACTION,2.62,53.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJW,11279.0,4.0,1372.0,949.0,4.0,159.71,1.0,1.95,experimental,34.65,0.2071,0.1725,Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-2-(2-methylpropyl)-N-(2-phenyl-1H-benzimidazol-5-yl)pyrazole-3-carboxamide
6YVW,X-RAY DIFFRACTION,2.79,56.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sample: (20 mg/ml PHD2 + 1 mM FeSO4 + 2 mM compound); Reservoir: 1.6-2.0 M (NH4)2SO4, 2-8% dioxane, 0.1 M MES-Na pH 6.5, and 1 mM FeSO4; Hanging drop (2 ul), protein-to-well ratio, 1:1, 293K",293.0,2020-04-28,2020-12-30,6YVW,1923.0,1.0,252.0,122.0,,28.55,1.0,1.97,experimental,59.1114,0.2081,0.187,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with monocyclic BB-328
7Q5V,X-RAY DIFFRACTION,1.9,35.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"Sample: 1.0 mM PHD2, 1.2 mM MnCl2, 2.0 mM NOG, 2 mM 3C, 2-4 mM HIF-2alpha-CODD; Reservoir: 0.31 M Magnesium formate (range: 0.25-0.39 M), 16.6% w/v polyethylene glycol 3350 (range: 18-22%); Sitting drop (200 nl): protein-to-well ratio, 1:1; Cryo-protectant: 15% v/v dilution of reservoir with glycerol",298.0,2021-11-04,2022-11-16,7Q5V,2486.0,2.0,253.0,277.0,1.0,29.21,2.0,1.17,experimental,23.6567,0.1792,0.157,HIF PROLYL HYDROXYLASE 2 (PHD2/EGLN1) IN COMPLEX WITH N-OXALYLGLYCINE (NOG) AND HIF-2 ALPHA CODD (523-542)
7Q5X,X-RAY DIFFRACTION,1.88,34.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"Sample: 1.0 mM PHD2, 1.2 mM MnCl2, 2.0 mM 2OG, 2 mM 3C, 2-4 mM HIF-2alpha-CODD; Reservoir: 0.33 M Magnesium formate (range: 0.25-0.39 M), 17.5% w/v polyethylene glycol 3350 (range: 18-22%); Sitting drop (200 nl): protein-to-well ratio, 1:1; Cryo-protectant: 15% v/v dilution of reservior solution with glycerol",298.0,2021-11-04,2022-11-16,7Q5X,2285.0,2.0,253.0,159.0,1.0,29.43,2.0,1.21,experimental,23.0209,0.1759,0.157,HIF PROLYL HYDROXYLASE 2 (PHD2/EGLN1) IN COMPLEX WITH 2-OXOGLUTARATE (2OG) AND HIF-2 ALPHA CODD (523-542)
6GJI,X-RAY DIFFRACTION,2.82,56.36,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2018-05-16,2018-11-07,6GJI,1578.0,1.0,165.0,225.0,,18.47,1.0,1.6,experimental,29.126,0.19071,0.15254,Cyclophilin A complexed with the tri-vector ligand 8.
6GJN,X-RAY DIFFRACTION,2.76,55.4,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, Tris-HCl",279.15,2018-05-16,2018-11-07,6GJN,1584.0,1.0,165.0,241.0,,18.75,1.0,1.7,experimental,17.689,0.2029,0.16954,Cyclophilin A complexed with tri-vector ligand 15.
7QBW,X-RAY DIFFRACTION,2.65,53.61,"VAPOR DIFFUSION, HANGING DROP",7.5,"HEPES 60mM, NaCl 50mM, TCEP 5mM, 10% PEG 3350, NaN3 1.5mM",293.0,2021-11-19,2022-11-30,7QBW,1396.0,1.0,165.0,135.0,,18.16,1.0,1.59,experimental,34.9493,0.1912,0.17,Human Cyclophilin A double mutant C52AK125C
6J7B,X-RAY DIFFRACTION,2.87,57.19,EVAPORATION,6.0,"20%PEG6000, 1M lithium chloride, 0.1M MES pH6.0",293.0,2019-01-17,2019-06-19,6J7B,2700.0,2.0,302.0,382.0,,35.36,2.0,1.618,experimental,,0.197,0.178,Crystal structure of VASH1-SVBP in complex with epoY
5SEW,X-RAY DIFFRACTION,2.88,57.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEW,2701.0,1.0,343.0,82.0,1.0,40.02,1.0,2.3,experimental,47.783,0.2292,0.1863,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[1-(2-methoxyethyl)-5-(methylcarbamoyl)pyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5NI6,X-RAY DIFFRACTION,2.46,50.0,LIQUID DIFFUSION,7.0,"22% (w/v) PEG 8000, 100 mM imidazole pH 7.0, 100 mM sodium acetate, 5 mM YbCl3",277.0,2017-03-23,2017-08-23,5NI6,5910.0,1.0,617.0,840.0,,71.04,1.0,1.54,experimental,,0.1908,0.1581,Crystal structure of human LTA4H mutant D375N in complex with LTA4
6H37,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",8.5,"25% v/v Peg3350, 0.2 M Ammonium acetate, 0.1 M Tris pH 8.5",293.0,2018-07-17,2018-12-19,6H37,2197.0,1.0,274.0,115.0,1.0,31.35,1.0,1.9,experimental,,0.236,0.194,The crystal structure of human carbonic anhydrase VII in complex with 4-(4-phenyl)-4-hydroxy-1-piperidine-1-carbonyl)benzenesulfonamide
6CPM,X-RAY DIFFRACTION,2.41,48.89,"VAPOR DIFFUSION, SITTING DROP",,"16% PEG3350, 100 mM MES, 200 mM CaCl2, 
cryoprotected with the identical buffer plus 25% glycerol",295.0,2018-03-13,2019-01-23,6CPM,7253.0,4.0,870.0,535.0,,99.52,2.0,2.011,experimental,,0.2117,0.1667,Structure of the USP15 deubiquitinase domain in complex with a third-generation inhibitory Ubv
8IPI,X-RAY DIFFRACTION,2.59,52.55,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG MME 2000, 0.2M Ammonium sulfate, 0.1 M sodium acetate (pH 5.5)",289.0,2023-03-14,2024-01-03,8IPI,2417.0,1.0,338.0,110.0,,37.77,1.0,2.1,experimental,,0.2291,0.1932,The apo structure of human mitochondrial methyltransferase METTL15
7KP6,X-RAY DIFFRACTION,2.19,43.76,VAPOR DIFFUSION,6.5,"50mM Bis-Tris (pH 6.5), 23 % (w/v) polyethylene glycol 3350, 100 mM MgCl2, and 2.5% Glycerol",298.0,2020-11-10,2022-02-09,7KP6,4626.0,2.0,574.0,279.0,,65.87,1.0,1.79,experimental,32.4276,0.2033,0.1779,Structure of Ack1 kinase in complex with a selective inhibitor
7L0G,X-RAY DIFFRACTION,2.37,48.0,"VAPOR DIFFUSION, HANGING DROP",,"0.225 M Potassium sodium tartrate tetrahydrate, 15% w/v Polyethylene glycol 3,350",291.0,2020-12-11,2021-03-24,7L0G,8269.0,8.0,1056.0,53.0,,119.21,2.0,2.54,experimental,53.323,0.22852,0.19456,Monobody 12VC1 Bound to HRAS(G12C)
5ZC4,X-RAY DIFFRACTION,3.0,58.94,"VAPOR DIFFUSION, HANGING DROP",7.0,100% Tacsimate,293.0,2018-02-14,2019-02-27,5ZC4,1294.0,2.0,152.0,78.0,,17.94,1.0,1.906,experimental,,0.1858,0.1662,Crystal Structure of RNF13 RING domain
8OYP,X-RAY DIFFRACTION,2.6,52.71,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris/Bicine pH 8.5, 30 mM sodium nitrate, 30 mM sodium phosphate dibasic, 30 mM ammonium sulphate, 11.25% v/v MPD; 11.25% PEG 1000; 11.25% w/v PEG 3350 with 5 mM CdCl2",293.15,2023-05-05,2023-10-18,8OYP,9397.0,4.0,1128.0,505.0,1.0,128.75,2.0,2.44,experimental,44.2121,0.2351,0.1697,Crystal structure of Ubiquitin specific protease 11 (USP11) in complex with a substrate mimetic
5VOE,X-RAY DIFFRACTION,3.3,62.73,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Bicine, 0.1 M Tris base, 0.1 M Carboxylic Acids, 10% PEG 20,000, 20% PEG 500 monomethyl ester",298.0,2017-05-02,2018-06-20,5VOE,3129.0,3.0,320.0,159.0,8.0,43.44,2.0,2,experimental,57.368,0.24841,0.21291,DesGla-XaS195A Bound to Aptamer 11F7t
6U5C,X-RAY DIFFRACTION,2.8,56.09,BATCH MODE,7.5,"100 mM HEPES, pH 7.5, 5 mM TCEP, 20% PEG3350",291.0,2019-08-27,2020-01-29,6U5C,1521.0,1.0,165.0,139.0,,18.04,1.0,1.62,experimental,26.29,0.1569,0.1362,RT XFEL structure of CypA solved using MESH injection system
6U5D,X-RAY DIFFRACTION,2.8,56.09,BATCH MODE,7.5,"100 mM HEPES, pH 7.5, 5 mM TCEP, 20% PEG3350",291.0,2019-08-27,2020-01-29,6U5D,1557.0,1.0,165.0,159.0,,18.04,1.0,1.65,experimental,26.78,0.1671,0.1434,RT XFEL structure of CypA solved using LCP injection system
6U5E,X-RAY DIFFRACTION,2.8,56.02,BATCH MODE,7.5,"100 mM HEPES, pH 7.5, 5 mM TCEP, 20% PEG3350",291.0,2019-08-27,2020-01-29,6U5E,1550.0,1.0,165.0,150.0,,18.04,1.0,1.56,experimental,29.62,0.1509,0.1348,RT XFEL structure of CypA solved using celloluse carrier media
5SJR,X-RAY DIFFRACTION,2.64,53.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJR,10766.0,4.0,1372.0,407.0,5.0,160.05,1.0,2.1,experimental,45.797,0.2633,0.2093,Crystal Structure of human phosphodiesterase 10 in complex with (2R)-2-[[3-cyano-2-[4-(2-ethoxyphenyl)phenyl]-6-fluoroquinolin-4-yl]amino]propanoic acid
5SJX,X-RAY DIFFRACTION,2.65,53.58,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJX,10977.0,4.0,1372.0,626.0,5.0,159.77,1.0,2.06,experimental,36.839,0.2367,0.1799,Crystal Structure of human phosphodiesterase 10 in complex with 2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline
5SKP,X-RAY DIFFRACTION,2.67,53.92,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKP,11028.0,4.0,1372.0,612.0,6.0,159.83,1.0,2,experimental,36.382,0.2301,0.1781,"Crystal Structure of human phosphodiesterase 10 in complex with [4-(2-methoxyphenyl)piperazin-1-yl]-(3-methyl-1-phenylthieno[2,3-c]pyrazol-5-yl)methanone"
5SKQ,X-RAY DIFFRACTION,2.63,53.31,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKQ,11008.0,4.0,1372.0,709.0,5.0,159.01,1.0,2,experimental,34.295,0.2353,0.1686,Crystal Structure of human phosphodiesterase 10 in complex with N-ethyl-6-(4-fluorophenyl)sulfanyl-N-methyl-9H-purin-2-amine
5SKS,X-RAY DIFFRACTION,2.61,52.94,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKS,10826.0,4.0,1372.0,506.0,5.0,160.0,1.0,2.31,experimental,39.278,0.214,0.1548,Crystal Structure of human phosphodiesterase 10 in complex with ethyl 1-[3-[3-(4-ethoxycarbonyl-5-methyl-imidazol-1-yl)phenoxy]phenyl]-5-methyl-imidazole-4-carboxylate
8HLQ,X-RAY DIFFRACTION,2.19,43.72,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG-3350, 0.1 M Tris-HCl pH 8.5",291.0,2022-11-30,2024-05-01,8HLQ,5730.0,2.0,706.0,12.0,,80.85,1.0,2.7,experimental,58.59,0.2816,0.226,Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Niraparib (MK-4827)
6WNL,X-RAY DIFFRACTION,2.45,49.8,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 mM MES pH 6.5, 0.1 M LiCl, 0.01 M MgCl2, 12% PEG 4000 (w/v)",300.0,2020-04-22,2020-07-01,6WNL,5995.0,2.0,750.0,207.0,,86.85,1.0,2.37,experimental,31.687,0.2803,0.2207,"human Artemis/SNM1C catalytic domain, crystal form 2"
5LAT,X-RAY DIFFRACTION,2.87,57.19,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.1 M tri-sodium citrate pH 5.6, 20% PEG 4000, 20% 2-propanol",293.0,2016-06-15,2016-08-31,5LAT,1983.0,1.0,252.0,186.0,1.0,28.65,1.0,1.9,experimental,33.0,0.1659,0.1504,HIF prolyl hydroxylase 2 (PHD2/EGLN1) P317R variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)
5LB6,X-RAY DIFFRACTION,2.9,57.68,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES-Na pH 6.5, 30% polyethylene glycol monomethyl ether 5000, 0.2 M ammonium sulphate",293.0,2016-06-15,2016-08-31,5LB6,1983.0,1.0,252.0,173.0,1.0,28.6,1.0,1.7,experimental,34.0,0.1682,0.1451,HIF prolyl hydroxylase 2 (PHD2/EGLN1) R371H variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)
5OX5,X-RAY DIFFRACTION,2.77,55.68,"VAPOR DIFFUSION, SITTING DROP",6.5,"1.5 M sodium citrate tribasic dehydrate pH 6.5, Sitting drop (300 nl), protein-to-well ratio, 1:1.",293.0,2017-09-06,2017-10-18,5OX5,1784.0,1.0,252.0,85.0,,28.47,1.0,2.251,experimental,58.0,0.2048,0.1747,"HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with CCT6, a GSK1278863-related compound"
7LWA,X-RAY DIFFRACTION,2.39,48.6,"VAPOR DIFFUSION, HANGING DROP",,20% PEG3350 and 0.1 M magnesium formate,293.0,2021-02-28,2021-07-14,7LWA,2174.0,2.0,358.0,25.0,,42.93,1.0,2.85,experimental,54.254,0.2506,0.2034,Human Exonuclease 5 crystal structure (T88E) in complex with ssDNA and Mg
6OL9,X-RAY DIFFRACTION,2.5,50.76,LIPIDIC CUBIC PHASE,,"Reconstituted in 10:1 monoolein:cholesterol mix, 100 mM D-L Malic acid pH 6.0, 220-280 mM ammonium tartrate dibasic, 37-41% PEG 400",293.0,2019-04-16,2019-12-11,6OL9,3279.0,1.0,480.0,7.0,2.0,56.73,1.0,2.541,experimental,93.8622,0.2573,0.2362,Structure of the M5 muscarinic acetylcholine receptor (M5-T4L) bound to tiotropium
5GYN,X-RAY DIFFRACTION,2.48,50.42,"VAPOR DIFFUSION, SITTING DROP",7.0,"16% PEG 4000, 20 mM magnesium chloride, 100 mM HEPES pH7.0",294.0,2016-09-23,2017-09-27,5GYN,2403.0,1.0,301.0,197.0,,32.22,1.0,1.995,experimental,,0.2339,0.196,Crystal structure of human pyridoxal 5'-phosphate phosphatase (Chronophin) mutant - C221S
5M6N,X-RAY DIFFRACTION,2.35,47.6,"VAPOR DIFFUSION, SITTING DROP",5.6,".65M (NH4)2SO4
10% Glycerol
.4M Li2SO4
.005M TCEP
.1M pH=5.6 Na3 citrate/HCl",291.0,2016-10-25,2017-05-24,5M6N,2065.0,2.0,236.0,349.0,,28.97,1.0,1.8,experimental,32.137,0.203,0.166,Small Molecule inhibitors of IAP
6Y4S,X-RAY DIFFRACTION,2.74,55.03,"VAPOR DIFFUSION, HANGING DROP",8.5,"2.9 M ammonium sulphate, 0.1 M HEPES, pH 8.5 and 0.5-2 %
PEG 3350",292.0,2020-02-23,2020-05-20,6Y4S,5277.0,3.0,672.0,82.0,18.0,74.94,1.0,2.23,experimental,56.26,0.242,0.219,Human kallikrein-related peptidase 7 (KLK7) in the unliganded state
5T53,X-RAY DIFFRACTION,3.89,68.37,"VAPOR DIFFUSION, HANGING DROP",7.5,"8% PEG 8000, 0.1M HEPES, pH 7.5 and 10 % ethylene glycol",298.15,2016-08-30,2016-11-09,5T53,1436.0,1.0,227.0,14.0,,27.12,1.0,2.699,experimental,,0.2852,0.2496,MOLECULAR BASIS FOR COHESIN ACETYLATION BY ESTABLISHMENT OF SISTER CHROMATID COHESION N-ACETYLTRANSFERASE ESCO1
4X7Q,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",7.0,Sodium Potassium Phosphate,298.0,2014-12-09,2015-02-11,4X7Q,3680.0,2.0,624.0,77.0,,69.53,1.0,2.33,experimental,41.034,0.2581,0.196,PIM2 kinase in complex with Compound 1s
5CVD,X-RAY DIFFRACTION,2.17,43.21,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M (NH4)Ac, 0.1 M Sodium citrate tribasic dihydrate, 28%(w/v) PEG 4000",291.0,2015-07-26,2015-11-25,5CVD,4625.0,4.0,504.0,734.0,,58.23,2.0,1.3,experimental,14.1414,0.16,0.1322,Crystal structure of human NRMT1 in complex with alpha-N-dimethylated human CENP-A peptide
5CWZ,X-RAY DIFFRACTION,2.44,49.54,"VAPOR DIFFUSION, SITTING DROP",6.2,"0.2M Ammonium sulfate, 0.1M Bis-tris (6.2), 35% PEG3350, 9% Ethylene glycol",293.0,2015-07-28,2016-07-27,5CWZ,6726.0,3.0,924.0,2.0,,105.23,1.0,2.9,experimental,,0.2814,0.2086,Crystal structure of the kinase domain of human TRAF2 and NCK-interacting protein kinase
5FJH,X-RAY DIFFRACTION,2.65,53.6,,7.25,"21% PEG 3350 5% 1,2-ETHANEDIOL 0.2 M NANO3 0.1 M BIS-TRIS PROPANE PH 7.25",,2015-10-09,2015-10-21,5FJH,6082.0,2.0,698.0,532.0,,82.03,1.0,2.1,experimental,,0.2249,0.1847,Crystal structure of human JMJD2C catalytic domain in complex with epitherapuetic compound 2-(((2-((2-(dimethylamino)ethyl) (ethyl)amino) -2-oxoethyl)amino)methyl)isonicotinic acid
5TZR,X-RAY DIFFRACTION,2.97,58.63,LIPIDIC CUBIC PHASE,7.7,"25-28%PEG 400, 0.2M sodium malonate, 0.1M Tris pH7.7",293.0,2016-11-22,2017-06-07,5TZR,3526.0,1.0,491.0,62.0,1.0,57.08,1.0,2.2,experimental,54.46,0.228,0.2,GPR40 in complex with partial agonist MK-8666
5UIT,X-RAY DIFFRACTION,2.58,52.39,"VAPOR DIFFUSION, HANGING DROP",,"1.6-1.8 M Ammonium Citrate, pH7.0",295.0,2017-01-14,2017-05-24,5UIT,5006.0,2.0,646.0,454.0,,73.69,1.0,1.84,experimental,41.71,0.218,0.1809,Crystal structure of IRAK4 in complex with compound 14
5UIU,X-RAY DIFFRACTION,2.53,51.33,"VAPOR DIFFUSION, HANGING DROP",,"1.6-1.8M Ammonium Citrate, pH7.0",295.0,2017-01-14,2017-05-24,5UIU,5020.0,2.0,646.0,393.0,,73.89,1.0,2.02,experimental,46.34,0.2044,0.1854,Crystal structure of IRAK4 in complex with compound 30
4U6J,X-RAY DIFFRACTION,2.58,52.31,"VAPOR DIFFUSION, HANGING DROP",6.0,"15% PEG MME  , 100mM HEPES PH6.0 ,",298.0,2014-07-29,2015-03-25,4U6J,3000.0,1.0,306.0,546.0,,34.85,1.0,1.56,experimental,22.61,0.176,0.125,HsMetAP in complex with methionine
4U75,X-RAY DIFFRACTION,2.6,52.72,"VAPOR DIFFUSION, HANGING DROP",6.0,"15% PEGMME, 100mM HEPES PH 6",298.0,2014-07-30,2015-03-25,4U75,2661.0,1.0,306.0,227.0,,34.84,1.0,1.94,experimental,25.89,0.218,0.168,HsMetAP (F309M) in complex with Methionine
5YR4,X-RAY DIFFRACTION,2.52,51.11,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1M Hepes pH-6.0, 19% PEG MME 2000",298.0,2017-11-08,2018-11-14,5YR4,2623.0,1.0,304.0,164.0,,34.93,1.0,1.82,experimental,31.543,0.2266,0.1731,Human methionine aminopeptidase type 1b (F309M mutant) in complex with TNP470
7O3B,X-RAY DIFFRACTION,2.92,57.88,VAPOR DIFFUSION,,"100 mM Acetate, pH 4.5, 100 mM NaCl,  30% PEG-200",292.0,2021-04-01,2021-09-15,7O3B,5678.0,6.0,783.0,104.0,,84.45,2.0,2.4,experimental,55.0,0.2395,0.1894,Crystal structure of the TTBK2-CEP164 complex bound to a camelid nanobody
5SH3,X-RAY DIFFRACTION,2.63,53.2,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SH3,10949.0,4.0,1372.0,621.0,4.0,159.63,1.0,1.98,experimental,36.297,0.2218,0.1705,"Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethyl-6-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-8-methylsulfonylimidazo[1,2-b]pyridazine"
5SIE,X-RAY DIFFRACTION,2.62,53.04,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIE,10650.0,4.0,1372.0,394.0,4.0,158.96,1.0,2.12,experimental,44.854,0.2204,0.1855,"Crystal Structure of human phosphodiesterase 10 in complex with 5-chloro-8-hydroxy-2-methyl-1,4-dihydropyrrolo[3,4-b]indol-3-one"
5SIN,X-RAY DIFFRACTION,2.65,53.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIN,10545.0,4.0,1372.0,252.0,2.0,159.35,1.0,2.4,experimental,47.346,0.2623,0.193,"Crystal Structure of human phosphodiesterase 10 in complex with N-(3-methyl-1-pyridin-2-ylthieno[2,3-c]pyrazol-5-yl)benzamide"
5SK2,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SK2,10701.0,4.0,1372.0,405.0,4.0,159.41,1.0,2.14,experimental,43.428,0.2291,0.1786,"Crystal Structure of human phosphodiesterase 10 in complex with 2-(4-fluorophenyl)-4-(2-isoquinolin-3-yloxyethyl)-5-methyl-1,3-oxazole"
5SK7,X-RAY DIFFRACTION,2.61,52.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SK7,10509.0,4.0,1372.0,263.0,4.0,159.14,1.0,2.29,experimental,50.068,0.2301,0.18,"Crystal Structure of human phosphodiesterase 10 in complex with 7-bromo-N,N-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine"
6T7P,X-RAY DIFFRACTION,2.69,54.33,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG10000, 200 mM Sodium phosphate (monobasic), corresponds to Nextal condition #87 from PEG series",293.0,2019-10-22,2020-07-08,6T7P,2447.0,1.0,242.0,267.0,4.0,28.92,1.0,1.416,experimental,24.8591,0.1878,0.1524,human plasmakallikrein protease domain in complex with active site directed inhibitor
6WJC,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"22-27% SOKALAN, HEPES(7.5), 0.1M NaCl",293.0,2020-04-13,2020-07-08,6WJC,4213.0,2.0,568.0,7.0,6.0,66.99,2.0,2.55,experimental,123.9659,0.2626,0.2445,Muscarinic acetylcholine receptor 1 - muscarinic toxin 7 complex
8JUC,X-RAY DIFFRACTION,3.84,67.95,"VAPOR DIFFUSION, SITTING DROP",,3.5 M Sodium formate pH 7.0,293.0,2023-06-26,2024-02-28,8JUC,1360.0,1.0,156.0,113.0,,18.17,1.0,1.54,experimental,,0.2367,0.2179,Identification of small-molecule binding sites of a ubiquitin-conjugating enzyme-UBE2T through fragment-based screening
8JVD,X-RAY DIFFRACTION,3.82,67.83,"VAPOR DIFFUSION, SITTING DROP",,3.5M sodium formate pH 7.0,293.0,2023-06-28,2024-02-28,8JVD,1350.0,1.0,156.0,99.0,,17.98,1.0,1.696,experimental,,0.255,0.2276,Identification of small-molecule binding sites of a ubiquitin-conjugating enzyme-UBE2T through fragment-based screening
6T6R,X-RAY DIFFRACTION,2.18,43.65,"VAPOR DIFFUSION, SITTING DROP",4.0,"PACT condition D1 (0.1M MMT, pH 4.0, 25% PEG 1500), MMT = DL-malic acid, MES monohydrate, Tris",293.0,2019-10-18,2020-03-18,6T6R,7988.0,1.0,922.0,945.0,1.0,107.13,1.0,1.67,experimental,31.03,0.194,0.169,"Human endoplasmic reticulum aminopeptidase 1 (ERAP1) in complex with (4aR,5S,6R,8S,8aR)-5-(2-(Furan-3-yl)ethyl)-8-hydroxy-5,6,8a-trimethyl-3,4,4a,5,6,7,8,8a-octahydronaphthalene-1-carboxylic acid"
7KVQ,X-RAY DIFFRACTION,2.59,52.43,"VAPOR DIFFUSION, SITTING DROP",8.0,"PEG 4000, HEPES, lithium sulfate",298.0,2020-11-28,2021-01-20,7KVQ,7468.0,2.0,974.0,,,114.29,1.0,2.75,experimental,,0.2795,0.2504,Human CYP3A4 bound to an inhibitor
7KVS,X-RAY DIFFRACTION,2.63,53.24,"VAPOR DIFFUSION, SITTING DROP",8.0,"PEG 4000, HEPES, lithium sulfate",298.0,2020-11-28,2021-01-20,7KVS,7470.0,2.0,974.0,47.0,,114.09,1.0,2.5,experimental,,0.2746,0.2347,Human CYP3A4 bound to an inhibitor
6GLE,X-RAY DIFFRACTION,1.71,28.15,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5, 20% DMSO, 10 mM compound",293.0,2018-05-23,2019-02-20,6GLE,1492.0,1.0,182.0,240.0,,21.37,1.0,1.402,experimental,,0.2151,0.1875,Crystal structure of hMTH1 in complex with TH scaffold 1 in the presence of acetate
6GLK,X-RAY DIFFRACTION,1.7,27.84,"VAPOR DIFFUSION, HANGING DROP",4.5,"23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5",293.0,2018-05-23,2019-02-20,6GLK,1402.0,1.0,182.0,158.0,,21.35,1.0,1.5,experimental,,0.2237,0.1851,Crystal structure of hMTH1 N33A in the presence of acetate
7ESF,X-RAY DIFFRACTION,1.81,32.0,"VAPOR DIFFUSION, SITTING DROP",4.0,"0.1 M Citric Acid pH 4.0, 30% PEG 6000",277.0,2021-05-10,2021-05-26,7ESF,1393.0,1.0,174.0,113.0,,20.37,1.0,1.55,experimental,16.016,0.215,0.1885,The Crystal Structure of human MTH1 from Biortus
5SGV,X-RAY DIFFRACTION,2.61,52.92,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGV,10998.0,4.0,1372.0,637.0,4.0,159.42,1.0,2,experimental,35.025,0.2235,0.189,Crystal Structure of human phosphodiesterase 10 in complex with 1-benzyl-3-(2-phenylpyrazol-3-yl)pyridazin-4-one
5SHJ,X-RAY DIFFRACTION,2.67,54.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHJ,10764.0,4.0,1372.0,446.0,4.0,159.72,1.0,2.3,experimental,37.947,0.2437,0.1887,Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[3-(phenylcarbamoyl)phenyl]pyrazole-3-carboxamide
5KOS,X-RAY DIFFRACTION,2.91,57.66,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 100 mM citrate, Buffer: 25 mM Tris pH 7.9, 150 mM NaCl, ligand was soaked for 18h at 5mM",293.0,2016-07-01,2016-11-16,5KOS,5472.0,2.0,674.0,209.0,6.0,76.46,1.0,2.41,experimental,47.926,0.2298,0.1847,"Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor"
5MOH,X-RAY DIFFRACTION,2.04,39.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2016-12-14,2017-05-24,5MOH,2983.0,1.0,328.0,164.0,,39.33,1.0,1.38,experimental,25.35,0.2026,0.1966,Crystal structure of CK2alpha with ZT0583 bound.
5MOV,X-RAY DIFFRACTION,1.98,37.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2016-12-14,2017-05-24,5MOV,2896.0,1.0,325.0,129.0,,38.88,1.0,2.2,experimental,33.6,0.2688,0.2057,Crystal structure of Ck2alpha with ZT0633 bound
5FJK,X-RAY DIFFRACTION,2.51,50.94,,7.25,"21% PEG 3350, 5% 1,2 ETHANEDIOL, 0.2 M NANO3, 0.1 M BIS-TRIS PROPANE PH 7.25",,2015-10-09,2015-10-21,5FJK,3149.0,1.0,349.0,350.0,,41.3,1.0,1.66,experimental,,0.1974,0.1592,"Crystal structure of human JMJD2C catalytic domain in complex 6-ethyl- 5-methyl-7-oxo-4,7-dihydropyrazolo(1,5-a)pyrimidine-3-carbonitrile"
7TXH,X-RAY DIFFRACTION,2.6,52.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M NaH2PO4 pH 6.5, 12% PEG 8000",293.0,2022-02-09,2022-06-22,7TXH,17319.0,6.0,1964.0,1715.0,,225.67,3.0,1.95,experimental,36.29,0.2103,0.1671,Human MRas Q71R in complex with human Shoc2 LRR domain M173I and human PP1Ca
5KR7,X-RAY DIFFRACTION,2.55,51.73,"VAPOR DIFFUSION, SITTING DROP",,"10-15% PEG 3350
0.2 magnesium chloride
0.1 HEPES pH 7.5",277.0,2016-07-07,2016-08-17,5KR7,6018.0,2.0,734.0,415.0,,85.42,1.0,1.9,experimental,26.056,0.2339,0.1924,KDM4C bound to pyrazolo-pyrimidine scaffold
8J1K,X-RAY DIFFRACTION,2.7,54.48,"VAPOR DIFFUSION, SITTING DROP",,"0.2M NH4 phosphate monobasic,0.1M Tris,8.5,50% MPD",293.0,2023-04-13,2024-04-17,8J1K,1629.0,1.0,218.0,30.0,,24.94,1.0,2.451,experimental,76.018,0.3084,0.242,co-crystal structure of non-carboxylic acid inhibitor with PHD2
5MAF,X-RAY DIFFRACTION,2.17,43.22,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1 M BIS TRIS pH 6.5, 0.6M NaCl",293.0,2016-11-03,2017-12-06,5MAF,2652.0,1.0,347.0,29.0,,40.87,1.0,2.8,experimental,56.237,0.25919,0.20965,Crystal structure of MELK in complex with an inhibitor
5MAG,X-RAY DIFFRACTION,2.26,45.28,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1 M BIS TRIS pH 6.5, 0.6M NaCl",293.0,2016-11-03,2017-12-06,5MAG,2698.0,1.0,347.0,82.0,,40.88,1.0,2.35,experimental,36.056,0.25242,0.19351,Crystal structure of MELK in complex with an inhibitor
4D6Z,X-RAY DIFFRACTION,2.55,51.8,,7.0,"CONDITION A3 FROM THE MORPHEUS CRYSTALLIZATION KIT (MOLECULAR DIMENSIONS), pH 7",,2014-11-19,2015-09-23,4D6Z,4044.0,1.0,487.0,190.0,,57.02,1.0,1.93,experimental,,0.2271,0.18,Cytochrome P450 3A4 bound to imidazole and an inhibitor
6ML1,X-RAY DIFFRACTION,2.37,48.15,"VAPOR DIFFUSION, SITTING DROP",6.5,"16% PEG3350, 100 mM MES 6.0, 250 mM CaCl2, cryoprotected with 18% PEG3350, 200 mM CaCl2, 100 mM MES pH 6.5 and 25% glycerol",295.0,2018-09-26,2019-01-23,6ML1,6889.0,5.0,908.0,393.0,,103.8,3.0,1.9,experimental,,0.2195,0.1894,Structure of the USP15 deubiquitinase domain in complex with an affinity-matured inhibitory Ubv
5ZOD,X-RAY DIFFRACTION,1.83,32.91,"VAPOR DIFFUSION, SITTING DROP",7.8,"PEG 3350, MgCl2, Tris, KCl",298.0,2018-04-13,2019-01-30,5ZOD,2204.0,1.0,333.0,162.0,,37.87,1.0,1.9,experimental,,0.2262,0.1965,Crystal Structure of hFen1 in apo form
6FIU,X-RAY DIFFRACTION,3.04,59.48,"VAPOR DIFFUSION, SITTING DROP",,"MGSO4, TRIS AND LIGAND, pH 8.5",277.0,2018-01-19,2019-01-30,6FIU,4047.0,1.0,536.0,142.0,,63.31,1.0,2.5,experimental,,0.2376,0.1757,"Human cytosolic 5'-nucleotidase II soaked with 10mM 2-(6-([1,1'-Biphenyl]-3-carboxamido)-9H-purin-9-yl)acetic acid"
6FIW,X-RAY DIFFRACTION,3.05,59.73,"VAPOR DIFFUSION, SITTING DROP",,"MGSO4, TRIS AND LIGAND, pH 8.5",277.0,2018-01-19,2019-01-30,6FIW,4082.0,1.0,536.0,137.0,,62.55,1.0,2.2,experimental,,0.2184,0.182,"Human cytosolic 5'-nucleotidase II co-crystallized with 10mM Sodium ((4-(3'-((7H-purin-6-yl)carbamoyl)-[1,1'-biphenyl]-3-yl)-1H-imidazol-1-yl) methyl) phosphonate"
5CLP,X-RAY DIFFRACTION,2.26,45.63,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-16,2016-07-27,5CLP,6220.0,2.0,704.0,448.0,,85.2,1.0,1.684,experimental,31.89,0.1933,0.1778,"Crystal Structure of CK2alpha with 3,4-dichlorophenethylamine bound"
5CS6,X-RAY DIFFRACTION,2.25,45.28,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-23,2016-07-27,5CS6,5795.0,2.0,704.0,225.0,,84.07,1.0,1.88,experimental,77.86,0.2158,0.2056,Crystal Structure of CK2alpha with Compound 3 bound
5CSH,X-RAY DIFFRACTION,2.24,45.05,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-23,2016-07-27,5CSH,6050.0,2.0,704.0,382.0,,84.94,1.0,1.59,experimental,45.32,0.2067,0.193,Crystal Structure of CK2alpha with Compound 4 bound
5CVH,X-RAY DIFFRACTION,2.22,44.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2015-07-26,2016-07-27,5CVH,5878.0,2.0,704.0,220.0,,85.22,1.0,1.848,experimental,61.23,0.2196,0.2031,Crystal Structure of CK2alpha
5ORH,X-RAY DIFFRACTION,2.2,44.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-16,2018-02-28,5ORH,5902.0,2.0,704.0,314.0,,84.04,1.0,1.75,experimental,39.49,0.227,0.208,The crystal structure of CK2alpha in complex with compound 2
5OS7,X-RAY DIFFRACTION,2.24,45.05,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-17,2018-02-28,5OS7,6053.0,2.0,704.0,405.0,,84.97,1.0,1.66,experimental,25.53,0.2475,0.2208,The crystal structure of CK2alpha in complex with compound 4
5OT6,X-RAY DIFFRACTION,2.23,44.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-21,2018-02-28,5OT6,5837.0,2.0,704.0,234.0,,83.75,1.0,1.94,experimental,53.78,0.241,0.219,The crystal structure of CK2alpha in complex with compound 19
5OUE,X-RAY DIFFRACTION,2.21,44.36,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-23,2018-02-28,5OUE,5945.0,2.0,704.0,298.0,,83.83,1.0,2.01,experimental,47.1,0.22,0.195,The crystal structure of CK2alpha in complex with compound 20
6EII,X-RAY DIFFRACTION,2.19,43.89,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-09-19,2018-02-28,6EII,5873.0,2.0,704.0,212.0,,84.23,1.0,1.935,experimental,45.19,0.2338,0.2077,The crystal structure of CK2alpha in complex with compound 18
6GMD,X-RAY DIFFRACTION,2.38,48.31,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2018-05-25,2018-06-06,6GMD,6033.0,2.0,704.0,385.0,,84.97,1.0,1.66,experimental,25.53,0.2475,0.2208,The crystal structure of CK2alpha in complex with compound 3
6V41,X-RAY DIFFRACTION,1.81,32.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.4 M sodium citrate, 0.1 M HEPES",291.0,2019-11-27,2019-12-25,6V41,648.0,2.0,78.0,20.0,2.0,9.25,2.0,1.603,experimental,22.062,0.215,0.1917,crystal structure of CDY1 chromodomain bound to H3K9me3
8AHG,X-RAY DIFFRACTION,2.43,48.94,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.8M Na/K tartrate
0.1M Tris pH 8.5",277.0,2022-07-21,2022-09-14,8AHG,2547.0,1.0,297.0,210.0,,33.6,1.0,1.885,experimental,38.439,0.2265,0.1785,PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery
8AHH,X-RAY DIFFRACTION,2.49,50.18,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.8M Na/K tartrate
0.1M Tris pH 8.5",277.0,2022-07-21,2022-09-14,8AHH,2477.0,1.0,297.0,147.0,,33.58,1.0,2.037,experimental,48.888,0.2501,0.1842,PAC FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery
8AHI,X-RAY DIFFRACTION,2.52,50.72,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.8M Na/K tartrate
0.1M Tris pH 8.5",277.0,2022-07-21,2022-09-14,8AHI,2475.0,1.0,297.0,152.0,,33.57,1.0,2.69,experimental,29.915,0.2489,0.1552,PAC-FragmentDEL: Photoactivated covalent capture of DNA encoded fragments for hit discovery
5YE8,X-RAY DIFFRACTION,2.39,48.47,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MOPS pH 6.6, 0.4M Li2SO4, 27% (w/v) (NH4)2SO4, 1M Na-Ac, 1.4% 1,4-butanediol",293.0,2017-09-15,2018-07-25,5YE8,5992.0,2.0,776.0,293.0,,88.23,1.0,1.851,experimental,20.2874,0.2119,0.1806,The crystal structure of Lp-PLA2 in complex with a novel inhibitor
7JQN,X-RAY DIFFRACTION,3.23,61.97,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.0 Ammonium Sulfate, 2%PEG400, 10mM CdCl2 pH 7.5",293.0,2020-08-11,2021-07-21,7JQN,3762.0,2.0,389.0,640.0,7.0,43.54,2.0,1.5,experimental,26.675,0.1613,0.1221,Crystal structure of the R64M mutant of Bauhinia Bauhinioides Kallikrein Inhibitor complexed with Human Kallikrein 4
7JQO,X-RAY DIFFRACTION,3.21,61.7,"VAPOR DIFFUSION, HANGING DROP",,"2.0M Ammounium Sulfate, 2% PEG400, 10mM CdCl2",293.0,2020-08-11,2021-07-21,7JQO,3679.0,2.0,389.0,577.0,8.0,43.58,2.0,1.6,experimental,25.21,0.1518,0.1123,Crystal structure of the R64D mutant of Bauhinia Bauhinioides Kallikrein Inhibitor complexed with Human Kallikrein 4
5JB8,X-RAY DIFFRACTION,2.21,44.29,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein-inhibitor complex, 
0.1M MES pH 6.5, 
18-20% PEG6000",293.0,2016-04-13,2016-06-01,5JB8,2532.0,2.0,293.0,256.0,8.0,33.07,2.0,1.45,experimental,32.3,0.1852,0.1516,Crystal structure of factor IXa variant K98T in complex with EGR-chloromethylketone
5JB9,X-RAY DIFFRACTION,2.27,45.78,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein/inhibitor complex
0.1 M MES pH 6.5
18% PEG6000",293.0,2016-04-13,2016-06-01,5JB9,2637.0,2.0,293.0,312.0,9.0,33.13,2.0,1.3,experimental,31.1078,0.1762,0.1509,Crystal structure of factor IXa K98T variant in complex with PPACK
5JBA,X-RAY DIFFRACTION,2.15,42.91,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein-inhibitor complex, 
0.1M MES pH 6.5, 
18% PEG6000",293.0,2016-04-13,2016-06-01,5JBA,2572.0,2.0,293.0,251.0,9.0,33.07,2.0,1.4,experimental,38.0092,0.179,0.1529,Crystal structure of factor IXa variant V16I K98T Y177T I212V in complex with PPACK
5JBB,X-RAY DIFFRACTION,2.2,44.18,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein-inhibitor complex, 
0.1M MES pH 6.5, 
20% PEG6000",293.0,2016-04-13,2016-06-01,5JBB,2552.0,2.0,293.0,269.0,9.0,33.01,2.0,1.56,experimental,36.2923,0.1901,0.1582,Crystal structure of factor IXa variant V16I K98T Y177T I213V in complex with EGR-chloromethylketone
4XY2,X-RAY DIFFRACTION,2.08,40.88,"VAPOR DIFFUSION, SITTING DROP",6.0,"Bis-tris propane, Magnesium sulfate, PEG3350",298.0,2015-02-02,2015-06-17,4XY2,5404.0,2.0,690.0,228.0,,79.82,1.0,2.03,experimental,37.604,0.25987,0.20539,Crystal structure of PDE10A in complex with ASP9436
5ZNL,X-RAY DIFFRACTION,2.12,41.77,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes (pH 7.5), 0.2M MgCl2, 18% PEG 3350, 50mM 2-mercaptoethanol",277.0,2018-04-09,2019-02-20,5ZNL,5149.0,2.0,646.0,80.0,,75.9,1.0,2.8,experimental,33.328,0.30662,0.23435,Crystal structure of PDE10A catalytic domain complexed with LHB-6
6IJH,X-RAY DIFFRACTION,2.11,41.59,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes (pH 7.5), 0.2M MgCl2, 18% PEG 3350, 50mM 2-mercaptoethanol",277.0,2018-10-10,2019-04-10,6IJH,5346.0,2.0,686.0,63.0,,79.9,1.0,2.6,experimental,36.758,0.31214,0.24019,Crystal structure of PDE10 in complex with inhibitor AF-399/14387019
6IJI,X-RAY DIFFRACTION,2.12,42.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes (pH 7.5), 0.2M MgCl2, 18% PEG 3350, 50mM 2-mercaptoethanol",277.0,2018-10-10,2019-04-10,6IJI,5224.0,2.0,648.0,54.0,,75.73,1.0,2.7,experimental,42.559,0.34084,0.25824,Crystal structure of PDE10 in complex with inhibitor 2b
6KDX,X-RAY DIFFRACTION,2.19,43.73,"VAPOR DIFFUSION, SITTING DROP",,"50mM Bis-tris propane pH6.0, 50mM Magnesium sulfate, 15% PEG 3350",296.0,2019-07-03,2019-08-14,6KDX,5306.0,2.0,690.0,20.0,,79.71,1.0,2.44,experimental,56.869,0.3009,0.2414,Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitor
6KE0,X-RAY DIFFRACTION,2.2,44.07,"VAPOR DIFFUSION, SITTING DROP",,"50mM Bis-tris propane pH 6.0, 50mM Magnesium sulfate, 15% PEG 3350",296.0,2019-07-03,2019-08-14,6KE0,5289.0,2.0,690.0,,,79.75,1.0,2.95,experimental,50.919,0.3022,0.2507,Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitor
6KO0,X-RAY DIFFRACTION,2.22,44.48,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes (pH 7.5), 0.2 M MgCl2, 18% PEG 3350, 50 mM 2-mercaptoethanol",277.0,2019-08-07,2020-04-01,6KO0,5367.0,2.0,644.0,196.0,,75.52,1.0,2.60002905998,experimental,30.0466415313,0.327303176933,0.214819538269,The crystal structue of PDE10A complexed with 1i
6KO1,X-RAY DIFFRACTION,2.23,44.84,VAPOR DIFFUSION,7.5,"0.1 M Hepes (pH 7.5), 0.2 M MgCl2, 18% PEG 3350, 50 mM 2-mercaptoethanol",277.0,2019-08-07,2020-04-01,6KO1,5262.0,2.0,644.0,92.0,,75.59,1.0,2.7,experimental,26.9051,0.3395,0.2329,The crystal structue of PDE10A complexed with 2d
5QTU,X-RAY DIFFRACTION,3.23,61.92,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2019-10-16,2019-12-25,5QTU,2084.0,2.0,262.0,103.0,5.0,31.02,2.0,2.53,experimental,22.99,0.236,0.176,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[1-(3-chloro-2-fluorophenyl)-5-methyl-1H-imidazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate"
6JD0,X-RAY DIFFRACTION,2.32,47.0,VAPOR DIFFUSION,,"PEG 4000, 2-propanol etc",293.0,2019-01-30,2020-02-05,6JD0,2941.0,1.0,360.0,156.0,3.0,45.01,1.0,1.805,experimental,37.8924,0.2148,0.1713,"Structure of mutant human cathepsin L, engineered for GAG binding"
6MAV,X-RAY DIFFRACTION,2.96,58.43,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Ammonium Acetate 0.1 M Bis-Tris: HCl, pH 5.5, 17 % (w/v) PEG 10,000",298.0,2018-08-28,2019-05-15,6MAV,2647.0,2.0,352.0,33.0,6.0,39.81,2.0,2.37,experimental,77.4715,0.2978,0.2171,Complex of tissue inhibitor of metalloproteinase-1 (TIMP-1) mutant L34G with matrix metalloproteinase-3 catalytic domain (MMP-3cd)
5A7G,X-RAY DIFFRACTION,2.5,50.8,,8.5,"CRYSTALS WERE GROWN AT 4C IN 0.1 M BICINE/TRIZMA BASE, PH 8.5, CONTAINING 0.03 M EACH OF DIETHYLENE GLYCOL, TRIETHYLENE GLYCOL, TETRAETHYLENE GLYCOL, PENTAETHYLENE GLYCOL, 10 % (W/V) PEG 4000, 20 % (V/V) GLYCEROL",277.0,2015-07-04,2016-01-13,5A7G,4828.0,1.0,532.0,695.0,2.0,58.88,1.0,1.48,experimental,31.014,0.17277,0.12916,Comparison of the structure and activity of glycosylated and aglycosylated Human Carboxylesterase 1
5SEO,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEO,10730.0,4.0,1372.0,446.0,4.0,159.34,1.0,2.1,experimental,44.466,0.2283,0.1829,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(5-methyl-2-phenyl-1H-imidazol-4-yl)ethyl]isoindole-1,3-dione"
7M2O,X-RAY DIFFRACTION,2.19,43.82,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris-HCL pH 8.5, 25 % (w/v) PEG 1000",298.0,2021-03-17,2021-07-14,7M2O,2971.0,1.0,387.0,201.0,,44.4,1.0,2.07,experimental,21.264,0.16607,0.12597,Crystal structure of Human Glycolate Oxidase with Inhibitor Compound 15
5EX0,X-RAY DIFFRACTION,3.25,62.2,"VAPOR DIFFUSION, HANGING DROP",7.5,3.4M NaAC,289.0,2015-11-23,2016-03-09,5EX0,3676.0,2.0,441.0,117.0,,51.33,2.0,2.7,experimental,36.4011,0.2251,0.1779,Crystal structure of human SMYD3 in complex with a MAP3K2 peptide
7CHM,X-RAY DIFFRACTION,3.33,63.07,"VAPOR DIFFUSION, SITTING DROP",6.0,"7-9% PEG 10000, 0.08-0.14 M magnesium acetate, 0.1 M MES pH 6.0",294.15,2020-07-06,2021-05-12,7CHM,2146.0,1.0,281.0,6.0,,33.09,1.0,2.65,experimental,82.7,0.2531,0.2077,Crystal structure of TTK kinase domain in complex with compound 8
7CHN,X-RAY DIFFRACTION,3.37,63.46,"VAPOR DIFFUSION, SITTING DROP",,"7-9% PEG 10000 
0.08-0.14 M magnesium acetate
0.1 M MES pH 6.0",294.15,2020-07-06,2021-05-12,7CHN,2250.0,1.0,282.0,49.0,,33.34,1.0,2.4,experimental,75.02,0.2556,0.2043,Crystal structure of TTK kinase domain in complex with compound 9
7CHT,X-RAY DIFFRACTION,3.29,62.58,"VAPOR DIFFUSION, SITTING DROP",6.0,"7-9% PEG 10000,  0.08-0.14 M magnesium acetate, 0.1 M MES pH 6.0",294.15,2020-07-06,2021-05-12,7CHT,2187.0,1.0,282.0,19.0,,33.39,1.0,2.4,experimental,75.15,0.2587,0.2096,Crystal structure of TTK kinase domain in complex with compound 30
7CIL,X-RAY DIFFRACTION,3.49,64.76,"VAPOR DIFFUSION, SITTING DROP",6.0,"7-9% PEG 10000, 0.08-0.14 M magnesium acetate, 0.1 M MES pH 6.0",294.15,2020-07-07,2021-05-12,7CIL,2201.0,1.0,281.0,25.0,,32.88,1.0,2.3,experimental,76.93,0.2461,0.2097,Crystal structure of TTK kinase domain in complex with compound 7
7CJA,X-RAY DIFFRACTION,3.53,65.12,"VAPOR DIFFUSION, SITTING DROP",6.0,"7-9% PEG 10000 
0.08-0.14 M magnesium acetate
0.1 M MES pH 6.0",294.15,2020-07-09,2021-05-12,7CJA,2213.0,1.0,283.0,13.0,,33.47,1.0,2.49,experimental,75.37,0.2533,0.2071,Crystal structure of TTK kinase domain in complex with compound 28
7CLH,X-RAY DIFFRACTION,3.64,66.17,"VAPOR DIFFUSION, SITTING DROP",6.0,"7-9% PEG 10000, 0.08-0.14 M magnesium acetate, 0.1 M MES pH 6.0",294.15,2020-07-21,2021-05-12,7CLH,2142.0,1.0,283.0,2.0,,33.4,1.0,2.9,experimental,77.36,0.2721,0.2035,Crystal structure of TTK kinase domain in complex with compound 19
5SEE,X-RAY DIFFRACTION,3.09,60.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEE,2621.0,1.0,343.0,22.0,1.0,39.94,1.0,2.35,experimental,52.097,0.2313,0.1865,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(2-pyridin-2-ylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5XUJ,X-RAY DIFFRACTION,2.21,39.57,"VAPOR DIFFUSION, SITTING DROP",,"50mM Bis-tris propane pH6.0, 50mM Magnesium sulfate, 15% PEG 3350, VAPOR DIFFUSION, VAPOR DIFFUSION, SITTING DROP, temperature 296K",296.0,2017-06-23,2018-03-14,5XUJ,5218.0,2.0,690.0,95.0,,79.64,1.0,2.44,experimental,52.393,0.27954,0.19825,"Crystal structure of PDE10A in complex with 7-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidine"
5OQU,X-RAY DIFFRACTION,2.35,47.63,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-14,2018-02-28,5OQU,5671.0,2.0,704.0,15.0,,85.08,1.0,2.324,experimental,73.53,0.2436,0.2197,The crystal structure of CK2alpha in complex with compound 5
5ORJ,X-RAY DIFFRACTION,2.24,44.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-16,2018-02-28,5ORJ,5815.0,2.0,704.0,144.0,,85.31,1.0,1.99,experimental,62.6,0.221,0.2,The crystal structure of CK2alpha in complex with compound 3
5ORK,X-RAY DIFFRACTION,2.24,44.98,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-16,2018-02-28,5ORK,5735.0,2.0,704.0,150.0,,84.2,1.0,2.143,experimental,63.05,0.2434,0.2156,The crystal structure of CK2alpha in complex with compound 6
5OT5,X-RAY DIFFRACTION,2.22,44.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-21,2018-02-28,5OT5,6035.0,2.0,704.0,309.0,,84.39,1.0,1.63,experimental,43.45,0.239,0.215,The crystal structure of CK2alpha in complex with compound 24
5OTD,X-RAY DIFFRACTION,2.31,46.76,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-21,2018-02-28,5OTD,6092.0,2.0,704.0,406.0,,84.34,1.0,1.57,experimental,38.58,0.2612,0.2479,The crystal structure of CK2alpha in complex with compound 25
5OTO,X-RAY DIFFRACTION,2.31,46.85,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-02-28,5OTO,6094.0,2.0,704.0,404.0,,84.39,1.0,1.51,experimental,38.34,0.2529,0.2393,The crystal structure of CK2alpha in complex with compound 30
5OUM,X-RAY DIFFRACTION,2.17,43.43,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-24,2018-02-28,5OUM,5757.0,2.0,704.0,187.0,,83.42,1.0,2.05,experimental,57.23,0.2485,0.2197,The crystal structure of CK2alpha in complex with compound 21
5OUU,X-RAY DIFFRACTION,2.2,44.2,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-25,2018-02-28,5OUU,5920.0,2.0,704.0,269.0,,84.12,1.0,1.81,experimental,49.2,0.203,0.186,The crystal structure of CK2alpha in complex with compound 22
5ZBQ,X-RAY DIFFRACTION,2.58,52.34,LIPIDIC CUBIC PHASE,7.4,"0.1 M Tris, pH 7.4-8.0, 30-40% (v/v) PEG400, 50-150 mM sodium tartrate and 100 uM UR-MK299",293.0,2018-02-12,2018-04-25,5ZBQ,3760.0,1.0,525.0,,2.0,61.21,1.0,2.7,experimental,87.93,0.247,0.225,The Crystal Structure of human neuropeptide Y Y1 receptor with UR-MK299
7CKK,X-RAY DIFFRACTION,3.02,63.3,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium citrate (pH 5.8), 12 % (w/v) polyethylene glycol 3350, 8 % isopropanol",293.0,2020-07-17,2021-07-21,7CKK,3467.0,1.0,473.0,71.0,,54.92,1.0,2.35,experimental,37.38,0.2643,0.2207,Structural complex of FTO bound with Dac51
5FSK,X-RAY DIFFRACTION,1.98,37.75,,,,,2016-01-06,2016-07-20,5FSK,1347.0,1.0,159.0,74.0,,18.84,1.0,1.56,experimental,23.38,0.2424,0.2038,MTH1 substrate recognition: Complex with 8-oxo-dGTP.
5FSL,X-RAY DIFFRACTION,2.01,38.74,,,25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5,,2016-01-06,2016-07-20,5FSL,1344.0,1.0,156.0,104.0,,18.25,1.0,1.24,experimental,15.92,0.2115,0.2015,MTH1 substrate recognition: Complex with a methylaminopurinone
6AA3,X-RAY DIFFRACTION,2.08,40.93,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 1.8 mM ZnSO4, 6% sucrose, 0.1 M Bis-Tris pH 6.1",293.0,2018-07-17,2019-03-06,6AA3,1367.0,1.0,163.0,29.0,,19.28,1.0,2.001,experimental,,0.2571,0.2101,Crystal structure of MTH1 in apo form (cocktail No. 1)
6AA4,X-RAY DIFFRACTION,2.07,40.44,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 1.8mM ZnSO4, 6% sucrose, 0.1M Bis-Tris pH 6.1",293.0,2018-07-17,2019-03-06,6AA4,1446.0,1.0,163.0,82.0,2.0,19.62,1.0,1.9,experimental,,0.2436,0.2056,Crystal structure of MTH1 in complex with alpha-mangostin (cocktail No. 9)
6EQ3,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"23 % PEG3350, 0.2 M LI2SO4, 0.1 M SODIUM ACETATE PH 4.5",293.0,2017-10-12,2018-10-31,6EQ3,1470.0,1.0,182.0,191.0,,21.43,1.0,1.798,experimental,,0.2234,0.1799,MTH1 in complex with fragment 9
6EQ4,X-RAY DIFFRACTION,1.7,27.68,"VAPOR DIFFUSION, HANGING DROP",4.5,"23 % PEG3350, 0.2 M LI2SO4, 0.1 M SODIUM ACETATE PH 4.5",293.0,2017-10-12,2018-10-31,6EQ4,1634.0,1.0,182.0,308.0,,21.51,1.0,1.4,experimental,,0.1874,0.1663,MTH1 in complex with fragment 8
6EQ5,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",4.5,"23 % PEG3350, 0.2 M LI2SO4, 0.1 M SODIUM ACETATE PH4.5",293.0,2017-10-12,2018-10-31,6EQ5,1341.0,1.0,182.0,101.0,,21.33,1.0,1.801,experimental,,0.2705,0.2095,MTH1 in complex with fragment 4
6EQ7,X-RAY DIFFRACTION,2.04,39.56,"VAPOR DIFFUSION, HANGING DROP",4.5,"23 % PEG3350, 0.2 M LI2SO4, 0.1 M SODIUM ACETATE PH4.5",293.0,2017-10-12,2018-10-31,6EQ7,1602.0,1.0,182.0,273.0,,21.43,1.0,1.5,experimental,,0.2042,0.1747,MTH1 in complex with fragment 11
6TYU,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Potassium formate, 20 % (w/v) PEG3350",295.0,2019-08-09,2019-11-27,6TYU,1956.0,2.0,247.0,193.0,,28.0,2.0,1.46862727205,experimental,32.8655062593,0.200770793241,0.178048002916,Structure of Ku80 von Willebrand domain complexed with MRI Ku Binding Motif
6VRF,X-RAY DIFFRACTION,2.81,56.26,VAPOR DIFFUSION,8.5,"0.1M TRIS pH 8.5, 10% glycerol and 2.0M Na/K phosphate",300.0,2020-02-07,2020-06-03,6VRF,5724.0,2.0,598.0,900.0,,70.61,1.0,1.5,experimental,,0.2092,0.1742,ADP bound TTBK2 kinase domain
5UY6,X-RAY DIFFRACTION,2.47,50.29,"VAPOR DIFFUSION, SITTING DROP",6.5,25% PEG 3350; 0.1M Bis-Tris; 0.2M ammonium acetate,293.0,2017-02-23,2017-03-29,5UY6,2642.0,1.0,291.0,370.0,1.0,33.51,1.0,1.7,experimental,29.33,0.182,0.16,Crystal Structure of the Human CAMKK2B
6OEA,X-RAY DIFFRACTION,3.02,59.23,"VAPOR DIFFUSION, SITTING DROP",5.5,"20% PEG3350, 0.1 M potassium chloride, 0.1 M Bis-Tris, 0.05 M magnesium chloride",293.0,2019-03-27,2019-04-10,6OEA,2457.0,3.0,294.0,46.0,,37.48,1.0,2.1,experimental,55.262,0.242,0.2081,Crystal structure of HMCES SRAP domain in complex with longer 3' overhang DNA
8A0S,X-RAY DIFFRACTION,2.02,39.21,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG6000, 0.1M Sodium Acetate pH4.0, 0.2 M Lithium Sulfate",292.0,2022-05-30,2023-09-20,8A0S,1509.0,1.0,159.0,130.0,,18.86,1.0,1.4,experimental,15.728,0.21188,0.18001,MTH1 in complex with TH013350
8A3A,X-RAY DIFFRACTION,2.0,38.37,"VAPOR DIFFUSION, SITTING DROP",,"32 % PEG 6000, 0.1 M sodium acetate trihydrate pH 3.7, 0.2 M lithium sulfate",292.0,2022-06-07,2023-09-20,8A3A,1438.0,1.0,159.0,136.0,,18.59,1.0,1.6,experimental,13.006,0.19313,0.16386,MTH1 in complex with TH013074
5SI4,X-RAY DIFFRACTION,2.65,53.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI4,10922.0,4.0,1372.0,449.0,4.0,159.81,1.0,2.39,experimental,47.153,0.238,0.1749,Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-naphthalen-1-ylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
7A49,X-RAY DIFFRACTION,3.16,61.11,"VAPOR DIFFUSION, SITTING DROP",,"1 MIKROLITER OF THE CK2ALPHA/INHIBITOR MIXTURE (COMPOSITION: 7 MG/ML CK2ALPHA ENZYME, 1 MILLIMOLAR INHIBITOR, 10 % DIMETHYL SULFOXIDE, 450 MM NACL, 22.5 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 1 MIKROLITER RESERVOIR SOLUTION (COMPOSITION: 25 % PEG3350, 0.2 M AMMONIUM SULPHATE, 0.1 M BIS-TRIS BUFFER, PH 5.5) FOLLOWED BY VAPOUR DIFFUSION EQUILIBRATION AGAINST THE RESERVOIR SOLUTION.",293.15,2020-08-19,2020-12-09,7A49,5925.0,2.0,670.0,219.0,,81.56,1.0,2.03,experimental,56.21,0.2159,0.189,"Crystal structure of human protein kinase CK2alpha (CSNK2A1 gene product) in complex with the ATP-competitive inhibitor 6-bromo-5-chloro-1H-triazolo[4,5-b]pyridine"
8GRD,X-RAY DIFFRACTION,2.94,58.18,"VAPOR DIFFUSION, HANGING DROP",5.1,"0.1 M sodium cacodylate (pH 5.1), 0.1 M calcium acetate, 10% (w/v) PEG 8000, 4 mM ADP, 4 mM CIT and 0.4 mM MgCl2",293.0,2022-09-01,2022-11-30,8GRD,5094.0,2.0,691.0,54.0,,76.23,2.0,2.699,experimental,50.1481,0.2418,0.194,Crystal structure of a constitutively active mutant of the alpha beta heterodimer of human IDH3 in complex with ADP and Mg
7B35,X-RAY DIFFRACTION,2.67,54.0,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 10 mg/ml in buffer 25 mM HEPES pH 7.5, 200 mM NaCl, 5% glycerol, 0.5 mM TCEP.
reservoir: 24% PEG 3550, 0.1M citrate pH 5.6.",293.0,2020-11-28,2020-12-16,7B35,4132.0,2.0,612.0,49.0,,70.17,1.0,2.40005138292,experimental,49.3716855479,0.26347576468,0.205015470048,MST3 in complex with compound MRIA13
4TKP,X-RAY DIFFRACTION,2.29,46.27,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.0 M ammonium sulfate, 0.1 M bis-tris",295.0,2014-05-27,2015-07-22,4TKP,1712.0,2.0,246.0,49.0,,27.77,2.0,2.08,experimental,56.6,0.2553,0.2243,Complex of Ubc13 with the RING domain of the TRIM5alpha retroviral restriction factor
6WK2,X-RAY DIFFRACTION,2.51,50.91,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2020-04-15,2020-06-17,6WK2,8779.0,4.0,1234.0,732.0,,141.69,2.0,1.76,experimental,32.11,0.2065,0.182,SETD3 mutant (N255V) in Complex with an Actin Peptide with His73 Replaced with Methionine
5SGR,X-RAY DIFFRACTION,2.64,53.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGR,10885.0,4.0,1372.0,585.0,4.0,159.41,1.0,2.04,experimental,38.981,0.2209,0.1766,Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-3-[(1-methyl-4-phenylimidazol-2-yl)methoxy]quinoxaline
5SH0,X-RAY DIFFRACTION,2.61,52.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SH0,10648.0,4.0,1372.0,332.0,4.0,159.77,1.0,2.29,experimental,46.951,0.2233,0.1787,"Crystal Structure of human phosphodiesterase 10 in complex with N-(1,3-dimethyl-2-oxobenzimidazol-5-yl)-2-[methylsulfonyl(naphthalen-1-yl)amino]acetamide"
5SI5,X-RAY DIFFRACTION,2.6,52.76,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI5,10665.0,4.0,1372.0,377.0,4.0,159.41,1.0,2.27,experimental,45.186,0.2244,0.1796,"Crystal Structure of human phosphodiesterase 10 in complex with N-(12-methoxy-5-methyl-3-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,7,9,11-hexaen-7-yl)methanesulfonamide"
5SIO,X-RAY DIFFRACTION,2.63,53.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIO,10737.0,4.0,1372.0,417.0,3.0,160.47,1.0,2.2,experimental,44.533,0.2334,0.1842,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(2-methylpyrrolidine-1-carbonyl)-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide"
5SIZ,X-RAY DIFFRACTION,2.61,52.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIZ,10842.0,4.0,1372.0,544.0,4.0,159.47,1.0,2.1,experimental,39.22,0.2228,0.1772,"Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-methoxy-N-[2-(3-pyridin-3-yl-1H-1,2,4-triazol-5-yl)ethyl]pyrazine-2-carboxamide"
5SJM,X-RAY DIFFRACTION,2.58,52.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJM,10498.0,4.0,1372.0,254.0,2.0,159.12,1.0,2.3,experimental,51.099,0.2421,0.1837,Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-phenylethyl)-5-pyridin-4-yl-1H-pyridin-2-one
5SK0,X-RAY DIFFRACTION,2.7,54.37,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SK0,10926.0,4.0,1372.0,626.0,4.0,159.54,1.0,2.02,experimental,39.415,0.1868,0.1618,Crystal Structure of human phosphodiesterase 10 in complex with N-[(3R)-1-(5-chloropyridin-2-yl)pyrrolidin-3-yl]-1-methyl-4-pyridin-4-ylpyrazole-3-carboxamide
5AX9,X-RAY DIFFRACTION,2.18,43.5,"VAPOR DIFFUSION, SITTING DROP",5.6,"24% PEG3350, 0.2M ammonium sulfate, 
0.1M Bis-tris (5.6)",293.0,2015-07-21,2016-07-27,5AX9,6921.0,3.0,924.0,107.0,,106.67,1.0,2.4,experimental,,0.2714,0.2045,Crystal structure of the kinase domain of human TRAF2 and NCK-interacting protein kinase in complex with compund 9
6YVZ,X-RAY DIFFRACTION,2.73,54.94,"VAPOR DIFFUSION, SITTING DROP",6.5,"Sample: (~20 mg/ml-1 PHD2 + 1 mM MnCl2 + 2 mM compound); Reservoir: 1.6-2.0 M (NH4)2SO4, 2-8% dioxane, 0.1 M MES-Na pH 6.5, and 1 mM MnCl2; Sitting drop (2 ul), protein-to-well ratio, 1:1, 293K",293.0,2020-04-29,2020-12-30,6YVZ,1852.0,1.0,252.0,89.0,1.0,28.54,1.0,1.91,experimental,57.7648,0.2035,0.1665,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with bicyclic JLS-367
6YW0,X-RAY DIFFRACTION,3.09,60.25,"VAPOR DIFFUSION, SITTING DROP",,"Sample: 18 mg/mL PHD2-Me + 1 mM FeSO4 + 2 mM compound; Reservoir: 1.7% polyethylene glycol 400, 15% glycerol, 1.7 M ammonium sulphate and 0.085 M HEPES-Na pH 7.5; Sitting drop (2 uL), protein-to-well ratio, 1:1",293.0,2020-04-29,2020-12-30,6YW0,1843.0,1.0,252.0,63.0,1.0,29.03,1.0,2.2,experimental,71.7747,0.2208,0.1923,"Lysine-N,N-Dimethylated HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with BB-287"
5YR7,X-RAY DIFFRACTION,2.58,52.38,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M Bistris pH-6.2, 19% PEG 3350, 5% Glycerol",298.0,2017-11-08,2018-11-14,5YR7,2495.0,1.0,328.0,71.0,,37.23,1.0,2.06,experimental,38.583,0.2662,0.1957,Human methionine aminopeptidase type 1b (F309L mutant)
7XF7,X-RAY DIFFRACTION,1.68,26.8,BATCH MODE,,"Na-acetate, PEG 6K, NaCl",277.5,2022-04-01,2022-04-13,7XF7,1244.0,1.0,130.0,200.0,4.0,14.94,1.0,1.55,experimental,17.6644,0.191,0.1686,Crystal Structure of Human Lysozyme Complexed with N-Acetyl-alpha-D-Glucosamine
7XF8,X-RAY DIFFRACTION,1.7,27.68,BATCH MODE,,"Na-acetate, PEG 6K, NaCl",277.5,2022-04-01,2022-04-13,7XF8,1253.0,1.0,130.0,209.0,4.0,14.94,1.0,1.6,experimental,20.7198,0.1844,0.1683,Crystal Structure of Human Lysozyme Complexed with N-Acetyl-alpha-D-Glucosamine
5SDY,X-RAY DIFFRACTION,3.0,58.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SDY,2805.0,1.0,343.0,206.0,1.0,39.95,1.0,2.2,experimental,38.963,0.223,0.1808,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[5-(dimethylcarbamoyl)-1-(2-methoxyethyl)pyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SE1,X-RAY DIFFRACTION,2.93,58.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE1,2676.0,1.0,343.0,88.0,1.0,39.91,1.0,2.3,experimental,49.329,0.2292,0.1845,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[3-(dimethylcarbamoyl)-1-methylpyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SET,X-RAY DIFFRACTION,2.99,58.92,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SET,2638.0,1.0,343.0,56.0,1.0,39.92,1.0,2.4,experimental,56.44,0.2287,0.1822,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(2-methyl-5-pyridin-2-ylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
8WSW,X-RAY DIFFRACTION,2.86,57.03,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES ,7.3,10% w/vPEG 8000, 8%v/v Ethylene glycol",277.0,2023-10-17,2023-11-15,8WSW,9472.0,4.0,1212.0,301.0,,141.17,1.0,2.5,experimental,59.277,0.2563,0.2093,The Crystal Structure of LIMK2a from Biortus
7Q1M,X-RAY DIFFRACTION,3.2,61.59,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2021-10-20,2022-11-16,7Q1M,4556.0,1.0,529.0,119.0,3.0,62.86,1.0,2.79,experimental,76.48,0.2371,0.1724,"Crystal structure of human butyrylcholinesterase in complex with N-[(2S)-3-[(cyclohexylmethyl)amino]-2-hydroxypropyl]-2,2-diphenylacetamide"
7Q1N,X-RAY DIFFRACTION,3.18,61.37,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2021-10-20,2022-11-16,7Q1N,4646.0,1.0,529.0,150.0,3.0,63.67,1.0,2.35,experimental,73.77,0.2261,0.1762,"Crystal structure of human butyrylcholinesterase in complex with N-[(2R)-3-[(cyclohexylmethyl)amino]-2-hydroxypropyl]-2,2-diphenylacetamide"
7Q1O,X-RAY DIFFRACTION,3.39,63.75,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2021-10-20,2022-11-16,7Q1O,4585.0,1.0,529.0,116.0,3.0,63.47,1.0,2.65,experimental,71.13,0.2073,0.1698,"Crystal structure of human butyrylcholinesterase in complex with N-[(2S)-3-[(cyclohexylmethyl)amino]-2-hydroxypropyl]-3,3-diphenylpropanamide"
7Q1P,X-RAY DIFFRACTION,3.36,63.41,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2021-10-20,2022-11-16,7Q1P,4586.0,1.0,529.0,145.0,3.0,63.32,1.0,2.35,experimental,66.66,0.2238,0.1723,"Crystal structure of human butyrylcholinesterase in complex with N-[(2R)-3-[(cyclohexylmethyl)amino]-2-hydroxypropyl]-3,3-diphenylpropanamide"
7QHE,X-RAY DIFFRACTION,3.19,61.4,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2021-12-12,2022-12-21,7QHE,4597.0,1.0,529.0,133.0,3.0,63.19,1.0,2.47,experimental,56.79,0.2236,0.1776,"Human Butyrylcholinesterase in complex with (S)-1-(4-((naphthalen-1-yl)carbamoyl)benzyl)-N-(3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)piperidine-3-carboxamide"
6YVX,X-RAY DIFFRACTION,2.71,54.71,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sample: (20 mg/ml PHD2 + 1 mM FeSO4 + 2 mM compound); Reservoir: 1.6-2.0 M (NH4)2SO4, 2-8% dioxane, 0.1 M MES-Na pH 6.5, and 1 mM FeSO4; hanging drop vapour diffusion",293.0,2020-04-28,2020-12-30,6YVX,1927.0,1.0,252.0,128.0,1.0,28.46,1.0,1.8,experimental,48.838,0.1892,0.1595,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with bicyclic BB-287
5M56,X-RAY DIFFRACTION,2.48,50.46,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN STOCK SOLUTION: 5.5 MG/ML CK2ALPHA'-D39G-C336S IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5;
INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO;
PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION; 
RESERVOIR SOLUTION: 25 % PEG4000, 15 % glycerol, 0.17 M sodium acetate, 0.08 M Tris/HCl, pH 8.5;
DROP SOLUTION BEFORE EQULIBRATION: 0.3 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.3 MICROLITER RESERVOIR SOLUTION",277.0,2016-10-20,2017-01-18,5M56,5987.0,2.0,728.0,378.0,,86.79,1.0,2.237,experimental,,0.2063,0.1635,"Monoclinic complex structure of human protein kinase CK2 catalytic subunit (isoform CK2alpha') with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21)"
8F15,X-RAY DIFFRACTION,2.44,49.67,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M TRIS pH 8, 30% v/v PEG 400",291.0,2022-11-04,2023-02-15,8F15,4113.0,6.0,453.0,332.0,,52.75,2.0,1.73,experimental,,0.2096,0.18,"Structure of the STUB1 TPR domain in complex with H202, an all-D Helicon Polypeptide"
7TUO,X-RAY DIFFRACTION,2.79,55.94,"VAPOR DIFFUSION, HANGING DROP",,"1.4M Sodium maleic acid, pH 8.0",293.0,2022-02-03,2023-02-15,7TUO,2896.0,1.0,385.0,205.0,,45.85,1.0,1.96,experimental,47.6014,0.2031,0.1777,Crystal structure analysis of human USP28 complex with a compound
4QMN,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM BOSUTINIB, 25 mM TRIS, PH 8.0, 50 MM HEPES, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMN,2457.0,1.0,310.0,134.0,,35.55,1.0,2.091,experimental,,0.2273,0.1761,MST3 in complex with BOSUTINIB
4QMZ,X-RAY DIFFRACTION,2.13,42.24,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM SUNITINIB, 25 mM TRIS, PH 8.0, 50 MM HEPES, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMZ,2540.0,1.0,310.0,207.0,,35.49,1.0,1.88,experimental,,0.2241,0.1676,MST3 IN COMPLEX WITH SUNITINIB
6Y6F,X-RAY DIFFRACTION,2.69,54.24,"VAPOR DIFFUSION, SITTING DROP",5.5,"16% PEG 3350, 0.1M NaCl, 0.1M bis-tris 5.5",277.15,2020-02-26,2020-03-11,6Y6F,2652.0,1.0,327.0,284.0,,37.92,1.0,1.98,experimental,26.682,0.2231,0.1819,Crystal structure of STK17B (DRAK2) in complex with PKIS43
6Y6H,X-RAY DIFFRACTION,2.68,54.14,"VAPOR DIFFUSION, SITTING DROP",6.0,"13% PEG 3350, 0.1M NaCl, 0.1M bis-tris 6.0",277.15,2020-02-26,2020-03-11,6Y6H,2653.0,1.0,327.0,172.0,,38.0,1.0,1.95,experimental,38.067,0.2116,0.1812,Crystal structure of STK17b (DRAK2) in complex with UNC-AP-194 probe
6ZJF,X-RAY DIFFRACTION,2.66,53.73,"VAPOR DIFFUSION, SITTING DROP",6.0,"19% PEG 3350, 0.1M NaCl, 0.1M bis-tris 6.0",277.15,2020-06-28,2020-07-29,6ZJF,2747.0,1.0,327.0,231.0,,37.79,1.0,1.75,experimental,31.099,0.21,0.1794,Crystal structure of STK17B (DRAK2) in complex with AP-229
5DSG,X-RAY DIFFRACTION,2.62,53.02,LIPIDIC CUBIC PHASE,,"Reconstituted in 10:1 monoolein:cholesterol mix. Precipitant solution: 20 - 40% PEG300, 100 mM MES, pH 5.5 - 7.5,  and 10 - 150 mM EDTA, pH 8.0",293.0,2015-09-17,2016-03-16,5DSG,6516.0,2.0,844.0,27.0,4.0,100.7,1.0,2.6,experimental,72.2251,0.2403,0.2265,Structure of the M4 muscarinic acetylcholine receptor (M4-mT4L) bound to tiotropium
5FV7,X-RAY DIFFRACTION,,,,7.5,"25% PEG3350, 0.1M MOPS 7.0, 5% 2-PROPANOL, 2% GLYCEROL, pH 7.5",,2016-02-03,2016-08-17,5FV7,4268.0,2.0,706.0,1.0,,80.36,1.0,2.84,experimental,24.792,0.30021,0.23387,Human Fen1 in complex with an N-hydroxyurea compound
5CLT,X-RAY DIFFRACTION,3.23,61.9,"VAPOR DIFFUSION, SITTING DROP",,"0.1M sodium formate , 3% PEG 3350",293.0,2015-07-16,2015-08-12,5CLT,15456.0,3.0,2004.0,,,233.05,1.0,2.79,experimental,39.0292,0.2393,0.1937,Crystal structure of human glycogen branching enzyme (GBE1) in complex with acarbose
5LBE,X-RAY DIFFRACTION,2.83,56.56,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 2.0 M ammonium sulphate, 7% v/v dioxane, 0.002 M MnCl2",293.0,2016-06-15,2016-08-31,5LBE,1847.0,1.0,252.0,103.0,1.0,28.57,1.0,1.749,experimental,53.0,0.1771,0.1644,HIF prolyl hydroxylase 2 (PHD2/EGLN1) G294E variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/FG2216)
5GNR,X-RAY DIFFRACTION,2.67,53.9,"VAPOR DIFFUSION, HANGING DROP",,"200 mM ammonium fluoride, 20% (w/v) PEG 3350",291.0,2016-07-24,2016-11-23,5GNR,3116.0,1.0,421.0,19.0,,47.78,1.0,2.65,experimental,,0.3016,0.2163,the structure of mini-MFN1 K88A in complex with GDP
7DHL,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, SITTING DROP",5.0,"Citric Acid, Ammonium dihydrogen phosphate, PEG 3350",293.0,2020-11-16,2021-02-03,7DHL,2361.0,1.0,313.0,14.0,,36.21,1.0,2.57,experimental,50.892,0.2535,0.1934,Crystal structure of FGFR3 in complex with pyrimidine derivative
6XJN,X-RAY DIFFRACTION,3.77,67.39,"VAPOR DIFFUSION, HANGING DROP",7.0,"3.5 M sodium formate pH 7, crystals transferred to cryo solution supplemented with 25% glycerol",293.15,2020-06-24,2021-06-30,6XJN,3397.0,1.0,439.0,85.0,,50.87,1.0,2.2,experimental,67.18,0.2369,0.2007,Human atlastin-1 (residues 1-439) bound to GDP-Mg2+ exhibits an ordered amino terminus
5D7N,X-RAY DIFFRACTION,2.61,52.92,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M magnesium chloride, 25 % (w/v) PEG 3350",277.0,2015-08-14,2015-12-02,5D7N,14318.0,6.0,1686.0,1257.0,,189.34,1.0,1.83,experimental,24.762,0.20316,0.17494,Crystal structure of human Sirt3 at an improved resolution
5GGF,X-RAY DIFFRACTION,2.88,57.24,"VAPOR DIFFUSION, HANGING DROP",6.5,1.4-1.6M Na malonate,277.0,2016-06-15,2016-08-10,5GGF,12790.0,3.0,1734.0,15.0,11.0,196.65,1.0,2.49,experimental,,0.2528,0.233,"Crystal structure of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase form II"
8F16,X-RAY DIFFRACTION,2.53,51.34,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M BICINE pH 8.5, 15% w/v PEG 1,500",291.0,2022-11-04,2023-02-15,8F16,2942.0,4.0,302.0,326.0,,35.3,2.0,1.56,experimental,29.1,0.226,0.195,"Structure of the STUB1 TPR domain in complex with H203, an all-D Helicon Polypeptide"
8F17,X-RAY DIFFRACTION,2.4,48.82,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M Sodium chloride, 0.1 M TRIS pH 8, 8% w/v PEG 6000",291.0,2022-11-04,2023-02-15,8F17,2426.0,4.0,302.0,52.0,,34.64,2.0,2.21,experimental,50.18,0.254,0.216,"Structure of the STUB1 TPR domain in complex with H204, an all-D Helicon Polypeptide"
7QPF,X-RAY DIFFRACTION,1.97,37.66,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Hepes, 18 % w/v PEG 3350",293.0,2022-01-04,2023-04-19,7QPF,5637.0,2.0,680.0,590.0,2.0,79.82,1.0,1.7,experimental,36.436,0.26815,0.21059,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate"
7QPM,X-RAY DIFFRACTION,2.03,39.29,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Hepes, 18% PEG3350",293.0,2022-01-05,2023-04-19,7QPM,5341.0,2.0,680.0,234.0,,80.13,1.0,2.4,experimental,38.644,0.24952,0.1741,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate"
7QPQ,X-RAY DIFFRACTION,2.03,39.42,"VAPOR DIFFUSION, HANGING DROP",8.9,"0.1 M Tris-HCl, 14% w/v PEG 3350, 5 mM CaCl2",293.0,2022-01-05,2023-04-19,7QPQ,5506.0,2.0,680.0,432.0,,80.08,1.0,2.2,experimental,40.979,0.24309,0.1842,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate"
7QPV,X-RAY DIFFRACTION,2.04,39.6,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris-HCl, 14% w/v PEG 3350, 5 mM CaCl2",293.0,2022-01-05,2023-04-19,7QPV,5189.0,2.0,680.0,166.0,1.0,80.07,1.0,2.3,experimental,40.356,0.2777,0.22717,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate"
7QQ4,X-RAY DIFFRACTION,2.01,38.9,"VAPOR DIFFUSION, HANGING DROP",8.9,"0.1 M Tris-HCl, 8 % w/v PEG 3350, 25 mM CaCl2, 1mM THP",293.0,2022-01-06,2023-04-19,7QQ4,5077.0,2.0,680.0,80.0,,80.1,1.0,2.45,experimental,34.078,0.27926,0.23026,"Discovery of Lu AF11167, a Phosphodiesterase 10A inhibitor clinical candidate"
5SGI,X-RAY DIFFRACTION,2.65,53.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-19,5SGI,11121.0,4.0,1372.0,686.0,5.0,159.75,1.0,1.97,experimental,33.716,0.2347,0.1816,Crystal Structure of human phosphodiesterase 10 in complex with 6-(3-methylphenoxy)-2-(4-pyridin-2-ylpiperazin-1-yl)-9H-purine
5SGP,X-RAY DIFFRACTION,2.64,53.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGP,11080.0,4.0,1372.0,721.0,3.0,159.83,1.0,1.95,experimental,33.788,0.2142,0.1716,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N-(2-methoxyethyl)-4-N,2-dimethyl-3-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide"
5SH8,X-RAY DIFFRACTION,2.64,53.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SH8,10928.0,4.0,1372.0,628.0,4.0,160.07,1.0,2,experimental,35.306,0.1858,0.16,Crystal Structure of human phosphodiesterase 10 in complex with 6-methyl-N-(5-methyl-2-phenylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SHS,X-RAY DIFFRACTION,2.64,53.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHS,10943.0,4.0,1372.0,532.0,6.0,159.48,1.0,2.3,experimental,42.6,0.2325,0.1631,"Crystal Structure of human phosphodiesterase 10 in complex with 3-(naphthalen-1-ylmethyl)-7-piperidin-1-yltriazolo[4,5-d]pyrimidine"
5SIF,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIF,10856.0,4.0,1372.0,549.0,4.0,160.98,1.0,2.2,experimental,37.861,0.2309,0.1817,"Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2,5-difluorophenyl)pyrazol-3-yl]-1-(3-methylsulfonylphenyl)pyridazin-4-one"
5SIH,X-RAY DIFFRACTION,2.65,53.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIH,11202.0,4.0,1372.0,767.0,5.0,159.81,1.0,1.9,experimental,29.949,0.2433,0.1938,Crystal Structure of human phosphodiesterase 10 in complex with 6-(3-methylphenyl)sulfanyl-2-(4-pyridin-2-ylpiperazin-1-yl)-9H-purine
5SIQ,X-RAY DIFFRACTION,2.66,53.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIQ,11154.0,4.0,1372.0,723.0,5.0,159.78,1.0,1.97,experimental,35.241,0.2236,0.1768,Crystal Structure of human phosphodiesterase 10 in complex with 2-ethyl-3-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]quinoxaline
5SJ3,X-RAY DIFFRACTION,2.64,53.44,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJ3,11098.0,4.0,1372.0,706.0,5.0,159.73,1.0,2.1,experimental,37.008,0.2336,0.1718,"Crystal Structure of human phosphodiesterase 10 in complex with [1-(4-chlorophenyl)-3-methylthieno[2,3-c]pyrazol-5-yl]-piperidin-1-ylmethanone"
5SJF,X-RAY DIFFRACTION,2.7,54.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJF,10879.0,4.0,1372.0,562.0,4.0,159.94,1.0,2.05,experimental,43.69,0.2274,0.1875,Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-quinolin-4-ylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5SJI,X-RAY DIFFRACTION,2.64,53.33,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJI,11217.0,4.0,1372.0,796.0,5.0,159.51,1.0,1.98,experimental,33.857,0.2245,0.1735,Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-2-methyl-N-(2-phenyl-1H-benzimidazol-5-yl)pyrazole-3-carboxamide
5SJJ,X-RAY DIFFRACTION,2.69,54.19,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJJ,11059.0,4.0,1372.0,705.0,5.0,159.39,1.0,2.1,experimental,37.177,0.2396,0.1736,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N-ethyl-5-[3-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine"
5SJO,X-RAY DIFFRACTION,2.62,53.04,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJO,10899.0,4.0,1372.0,538.0,4.0,161.0,1.0,2.1,experimental,38.739,0.2374,0.1928,"Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2,4-difluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one"
5SJS,X-RAY DIFFRACTION,2.61,52.94,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJS,10473.0,4.0,1372.0,168.0,3.0,159.75,1.0,2.7,experimental,59.866,0.2536,0.1733,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[4-(dimethylcarbamoyl)pyridin-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SJT,X-RAY DIFFRACTION,2.6,52.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJT,10994.0,4.0,1372.0,644.0,2.0,160.82,1.0,2.1,experimental,33.898,0.1787,0.1601,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N,4-N,2-trimethyl-3-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide"
5SK5,X-RAY DIFFRACTION,2.63,53.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SK5,10968.0,4.0,1372.0,640.0,3.0,159.83,1.0,1.95,experimental,35.436,0.2217,0.1893,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(morpholine-4-carbonyl)-N-(2-phenylimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide, space group H3"
5SK6,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SK6,10738.0,4.0,1372.0,412.0,4.0,159.71,1.0,2.2,experimental,46.589,0.2333,0.1879,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-N-[3-(1,3-benzoxazol-2-yl)phenyl]-2-methylpyrazole-3-carboxamide"
5SKD,X-RAY DIFFRACTION,2.64,53.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKD,10858.0,4.0,1372.0,511.0,3.0,160.97,1.0,2.3,experimental,38.428,0.1775,0.1625,"Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2,5-difluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one"
5SKF,X-RAY DIFFRACTION,2.61,52.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKF,10893.0,4.0,1372.0,552.0,3.0,160.94,1.0,2.1,experimental,36.103,0.1871,0.1708,"Crystal Structure of human phosphodiesterase 10 in complex with 3-[5-[1-(2,2-difluoro-1,3-benzodioxol-4-yl)-4-oxopyridazin-3-yl]pyrazol-1-yl]benzonitrile"
5SKH,X-RAY DIFFRACTION,2.61,52.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKH,10923.0,4.0,1372.0,584.0,4.0,160.93,1.0,2.1,experimental,36.867,0.2368,0.1939,Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(3-fluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5QBU,X-RAY DIFFRACTION,2.18,43.68,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QBU,3570.0,2.0,446.0,83.0,6.0,50.3,1.0,2.78,experimental,22.55,0.234,0.188,Crystal structure of human Cathepsin-S with bound ligand
5QBX,X-RAY DIFFRACTION,2.3,46.5,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QBX,3820.0,2.0,446.0,346.0,6.0,50.35,1.0,2.1,experimental,31.49,0.227,0.188,Crystal structure of human Cathepsin-S with bound ligand
5QBZ,X-RAY DIFFRACTION,2.33,47.25,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QBZ,1759.0,1.0,223.0,37.0,3.0,25.18,1.0,2.8,experimental,33.791,0.2529,0.1821,Crystal structure of human Cathepsin-S with bound ligand
5QC0,X-RAY DIFFRACTION,2.07,40.65,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC0,3803.0,2.0,446.0,311.0,6.0,50.36,1.0,1.9,experimental,28.89,0.257,0.213,Crystal structure of human Cathepsin-S with bound ligand
5QC1,X-RAY DIFFRACTION,2.16,43.12,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC1,3899.0,2.0,446.0,397.0,6.0,50.34,1.0,2.082,experimental,16.2604,0.2708,0.1989,Crystal structure of human Cathepsin-S with bound ligand
5QC2,X-RAY DIFFRACTION,2.1,41.55,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC2,3867.0,2.0,446.0,378.0,6.0,50.45,1.0,2.26,experimental,,0.21,0.142,Crystal structure of human Cathepsin-S with bound ligand
5QC3,X-RAY DIFFRACTION,2.18,43.49,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC3,4123.0,2.0,446.0,631.0,6.0,50.29,1.0,1.998,experimental,,0.2094,0.1498,Crystal structure of human Cathepsin-S with bound ligand
5QC5,X-RAY DIFFRACTION,2.15,42.87,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC5,3711.0,2.0,446.0,219.0,6.0,50.36,1.0,2.4,experimental,,0.256,0.18,Crystal structure of human Cathepsin-S with bound ligand
5QC6,X-RAY DIFFRACTION,2.25,45.35,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC6,4086.0,2.0,446.0,582.0,6.0,50.52,1.0,2.1,experimental,16.6,0.181,0.144,Crystal structure of human Cathepsin-S with bound ligand
5QC8,X-RAY DIFFRACTION,2.21,44.42,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC8,4040.0,2.0,446.0,553.0,6.0,50.35,1.0,1.74,experimental,13.79,0.198,0.167,Crystal structure of human Cathepsin-S with bound ligand
5QC9,X-RAY DIFFRACTION,2.25,45.41,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC9,4053.0,2.0,446.0,576.0,6.0,50.21,1.0,2,experimental,16.5,0.169,0.136,Crystal structure of human Cathepsin-S with bound ligand
5QCA,X-RAY DIFFRACTION,2.72,54.72,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCA,3852.0,2.0,446.0,355.0,6.0,50.88,1.0,2.29,experimental,26.14,0.217,0.178,Crystal structure of human Cathepsin-S with bound ligand
5QCB,X-RAY DIFFRACTION,2.25,45.33,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCB,3891.0,2.0,446.0,394.0,6.0,50.49,1.0,2.2,experimental,13.25,0.256,0.194,Crystal structure of human Cathepsin-S with bound ligand
5QCC,X-RAY DIFFRACTION,2.26,45.51,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCC,4118.0,2.0,446.0,634.0,6.0,50.46,1.0,1.8,experimental,14.71,0.169,0.144,Crystal structure of human Cathepsin-S with bound ligand
5QCE,X-RAY DIFFRACTION,2.17,43.28,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCE,3690.0,2.0,446.0,207.0,6.0,50.42,1.0,2.78,experimental,12.86,0.253,0.193,Crystal structure of human Cathepsin-S with bound ligand
5QCG,X-RAY DIFFRACTION,2.81,56.16,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCG,3683.0,2.0,446.0,196.0,6.0,50.62,1.0,2.7,experimental,,0.279,0.187,Crystal structure of human Cathepsin-S with bound ligand
7MYH,X-RAY DIFFRACTION,3.04,57.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M sodium citrate tribasic trihydrate, 0.1 M Bis-Tris propane, pH 7.5, 20% PEG3350",289.0,2021-05-21,2021-08-25,7MYH,2197.0,2.0,296.0,24.0,,33.06,2.0,2.394,experimental,61.592,0.2487,0.2063,Ubiquitin variant UbV.k.2 in complex with Ube2k
4WL4,X-RAY DIFFRACTION,2.09,41.18,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.6 M sodium citrate, Tris 50 mM",296.0,2014-10-06,2015-10-14,4WL4,2552.0,1.0,260.0,395.0,,29.59,1.0,1.1,experimental,15.743,0.1299,0.109,Crystal structure of human carbonic anhydrase II in complex with the 6-hydroxy-chromene-2-thione inhibitor
6HGY,X-RAY DIFFRACTION,1.9,35.33,VAPOR DIFFUSION,,"0.05M MES pH 6.0, 0.1M Na-Oxalate, 0.1M CaCl2",277.0,2018-08-23,2019-06-26,6HGY,1733.0,1.0,215.0,19.0,3.0,24.32,1.0,2.2,experimental,40.45,0.30996,0.25006,CRYSTAL STRUCTURE OF CATHEPSIN K WITH N-DESMETHYL THALASSOSPIRAMIDE C
6WI7,X-RAY DIFFRACTION,2.33,47.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM HEPES, pH 7.5, 20% PEG8000",277.15,2020-04-08,2021-04-14,6WI7,1956.0,1.0,211.0,273.0,,24.91,1.0,1.702,experimental,25.2751,0.1957,0.1646,RING1B-BMI1 fusion in closed conformation
5GVR,X-RAY DIFFRACTION,2.57,52.12,VAPOR DIFFUSION,,DL-malic acid,277.0,2016-09-06,2016-10-19,5GVR,1949.0,1.0,234.0,114.0,,26.31,1.0,1.5,experimental,30.416,0.20806,0.18069,Crystal structure of the DDX41 DEAD domain in an apo closed form
5DTM,X-RAY DIFFRACTION,3.46,64.48,VAPOR DIFFUSION,,"1.0M K/Na tartrate
0.1M Hepes pH6.8",293.0,2015-09-18,2016-06-15,5DTM,5626.0,2.0,668.0,463.0,,77.51,1.0,2.2,experimental,43.67,0.1991,0.1744,"Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]"
5DTQ,X-RAY DIFFRACTION,3.5,64.9,VAPOR DIFFUSION,,"1.6M K/Na tartrate, 0.1M Hepes pH6.6",293.0,2015-09-18,2016-06-15,5DTQ,5389.0,2.0,668.0,261.0,,77.52,1.0,2.61,experimental,55.95,0.2079,0.173,"Crystal structure of Dot1L in complex with inhibitor CPD3 [(2,6-dichlorophenyl)(quinolin-6-yl)methanone]"
5DTR,X-RAY DIFFRACTION,3.48,64.69,VAPOR DIFFUSION,,"1.2M K/Na tartrate, 0.1M Hepes pH6.6",293.0,2015-09-18,2016-06-15,5DTR,5430.0,2.0,668.0,315.0,,77.58,1.0,2.34,experimental,56.64,0.2104,0.1727,"Crystal structure of Dot1L in complex with inhibitor CPD5 [N-(2,6-dichlorophenyl)-4-methoxy-N-methylquinolin-6-amine]"
6TE6,X-RAY DIFFRACTION,3.5,64.87,VAPOR DIFFUSION,,"1.28 M Na/K-tartrate
0.1 M Hepes pH 6.6",293.0,2019-11-11,2019-12-11,6TE6,5623.0,2.0,668.0,428.0,,77.85,1.0,1.98,experimental,51.79,0.201,0.178,Crystal structure of Dot1L in complex with an inhibitor (compound 3).
6TEL,X-RAY DIFFRACTION,3.52,65.1,VAPOR DIFFUSION,,"1.28 M K/Na tartrate
0.1 M Hepes pH 7.0",293.0,2019-11-12,2019-12-11,6TEL,5314.0,2.0,668.0,239.0,,78.27,1.0,2.19,experimental,63.46,0.212,0.185,Crystal structure of Dot1L in complex with an inhibitor (compound 10).
5OTM,X-RAY DIFFRACTION,2.17,43.26,VAPOR DIFFUSION,3.7,"26% w/v PEG6000, 0.1 M Sodium acetate trihydrate pH 3.7, 0.2 M LiSO4, 3 mM O6-methyl-2'-dGTP, 2 mM TCEP",293.0,2017-08-22,2018-09-05,5OTM,2898.0,2.0,318.0,242.0,,38.06,1.0,1.8,experimental,24.366,0.24688,0.19612,Crystal structure of human MTH1 in complex with O6-methyl-dGMP
5LPN,X-RAY DIFFRACTION,2.93,58.07,"VAPOR DIFFUSION, HANGING DROP",,"6%-10% PEG8000
0.1M Imidazole",293.0,2016-08-14,2016-08-24,5LPN,3747.0,3.0,507.0,4.0,,59.35,2.0,2.8,experimental,,0.2866,0.244,Structure of human Rab10 in complex with the bMERB domain of Mical-1
7O2A,X-RAY DIFFRACTION,2.24,44.98,"VAPOR DIFFUSION, HANGING DROP",,"8 % PEG 3350, 50 mM magnesium formate, 100 mM Tris pH 7.5",293.0,2021-03-30,2021-07-07,7O2A,3950.0,1.0,428.0,483.0,,50.19,1.0,1.57,experimental,15.519,0.218,0.1888,X-RAY STRUCTURE OF SMYD3 IN COMPLEX WITH benzodiazepine-type inhibitor compound 15
7O2B,X-RAY DIFFRACTION,2.24,45.14,"VAPOR DIFFUSION, HANGING DROP",,"8 % PEG 3350, 50 mM magnesium formate, 100 mM Tris pH 7.5",293.0,2021-03-30,2021-07-07,7O2B,3669.0,1.0,428.0,203.0,,50.17,1.0,2.03,experimental,29.1249,0.258,0.204,X-RAY STRUCTURE OF SMYD3 in complex with benzodiazepine-type inhibitor 6
7O2C,X-RAY DIFFRACTION,2.22,44.51,"VAPOR DIFFUSION, HANGING DROP",,"8 % PEG 3350, 50 mM magnesium formate, 100 mM Tris pH 7.5",293.0,2021-03-30,2021-07-07,7O2C,4031.0,1.0,428.0,544.0,,50.17,1.0,1.52,experimental,18.237,0.2251,0.1575,X-RAY STRUCTURE OF SMYD3 IN COMPLEX WITH the benzodiazepine-based probe BAY-6035
4QNA,X-RAY DIFFRACTION,2.07,40.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM 2-(4,6- Diamino-1,3,5-triazin-2-yl)phenol, 25 mM TRIS, PH 8.0, 50 MM HEPES, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-17,2015-07-01,4QNA,2479.0,1.0,310.0,179.0,,35.23,1.0,1.849,experimental,,0.2148,0.1801,"MST3 IN COMPLEX WITH 2-(4,6-Diamino-1,3,5-triazin-2-yl)phenol"
5QBV,X-RAY DIFFRACTION,2.59,52.51,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QBV,4098.0,2.0,446.0,623.0,6.0,50.32,1.0,1.796,experimental,16.7347,0.1723,0.147,Crystal structure of human Cathepsin-S with bound ligand
5QBY,X-RAY DIFFRACTION,2.59,52.42,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QBY,3872.0,2.0,446.0,402.0,6.0,50.36,1.0,2.25,experimental,24.897,0.2037,0.1708,Crystal structure of human Cathepsin-S with bound ligand
5QC4,X-RAY DIFFRACTION,2.07,40.54,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QC4,4037.0,2.0,446.0,542.0,6.0,50.34,1.0,2,experimental,,0.21,0.152,Crystal structure of human Cathepsin-S with bound ligand
7TTL,X-RAY DIFFRACTION,2.49,50.7,"VAPOR DIFFUSION, HANGING DROP",6.0,10% Tacsimate,295.0,2022-02-01,2022-08-31,7TTL,21687.0,4.0,2764.0,476.0,,317.97,1.0,2.43,experimental,65.339,0.2748,0.2147,Stable-5-LOX elongated Ha2 (4 copies ASU)
5KW2,X-RAY DIFFRACTION,3.12,60.54,LIPIDIC CUBIC PHASE,,"0.1 M Tris HCl, pH 8.5, 30% PEG 400, 0.2 M ammonium formate.",298.0,2016-07-15,2018-05-02,5KW2,3237.0,1.0,491.0,52.0,1.0,53.73,1.0,2.76,experimental,41.374,0.2727,0.2304,The extra-helical binding site of GPR40 and the structural basis for allosteric agonism and incretin stimulation
5FS6,X-RAY DIFFRACTION,2.81,56.3,,7.5,"0.2 M AMMONIUM ACETATE, 0.1M HEPES, PH 7.5, AND 20% POLY-ETHYLENE GLYCOL 3350",,2015-12-30,2016-05-11,5FS6,8186.0,2.0,1030.0,907.0,,114.32,1.0,1.9,experimental,30.855,0.20689,0.17206,Crystal structure of the V243L mutant of human apoptosis inducing factor
8F14,X-RAY DIFFRACTION,2.78,55.81,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Lithium Sulfate, 0.1 M Bis-Tris pH 6.5, 25% w/v PEG 3350",291.0,2022-11-04,2023-02-15,8F14,1422.0,2.0,151.0,134.0,,17.72,2.0,1.69,experimental,34.7675,0.2357,0.1965,"Structure of the STUB1 TPR domain in complex with H201, an all-D Helicon Polypeptide"
7PUS,X-RAY DIFFRACTION,2.91,57.76,"VAPOR DIFFUSION, SITTING DROP",,"5 % (V/V) PEG 6000, 0.1 M MES (PH 6.0), 5 MM DTT",293.0,2021-09-30,2022-05-11,7PUS,2782.0,1.0,358.0,13.0,,41.44,1.0,2.59,experimental,59.589,0.2853,0.2192,ERK5 in complex with Pyrrole Carboxamide scaffold
6MEV,X-RAY DIFFRACTION,3.33,63.01,"VAPOR DIFFUSION, SITTING DROP",,"0.1M sodium citrate pH 5.6
1.0M ammonium phosphate monobasic",281.15,2018-09-07,2019-09-18,6MEV,23285.0,8.0,2728.0,670.0,,322.92,1.0,2.6,experimental,,0.2872,0.2291,Structure of JMJD6 bound to Mono-Methyl Arginine.
6Z51,X-RAY DIFFRACTION,2.45,49.89,"VAPOR DIFFUSION, SITTING DROP",,"24% PEG 3350, 0.2M potassium/sodium phosphate, 10% ethylene glycol",277.15,2020-05-26,2020-06-03,6Z51,3473.0,1.0,360.0,349.0,,43.99,1.0,1.92,experimental,20.177,0.2085,0.162,Crystal structure of CLK3 in complex with macrocycle ODS2002941
6Z53,X-RAY DIFFRACTION,2.48,50.32,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2 M Na/K phosphate, 10% ethylene glycol",277.15,2020-05-26,2020-06-03,6Z53,3511.0,1.0,360.0,391.0,,43.8,1.0,1.65,experimental,16.945,0.1945,0.167,Crystal structure of CLK3 in complex with macrocycle ODS2003128
6Z54,X-RAY DIFFRACTION,2.45,49.79,"VAPOR DIFFUSION, SITTING DROP",,"24% PEG 3350, 0.2M potassium/sodium phosphate, 10% ethylene glycol",277.15,2020-05-26,2020-06-03,6Z54,3499.0,1.0,360.0,407.0,,43.7,1.0,1.73,experimental,18.116,0.1961,0.1612,Crystal structure of CLK3 in complex with macrocycle ODS2003178
5QCD,X-RAY DIFFRACTION,2.49,50.66,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCD,2039.0,1.0,223.0,270.0,3.0,25.32,1.0,1.95,experimental,22.75,0.195,0.151,Crystal structure of human Cathepsin-S with bound ligand
7Q43,X-RAY DIFFRACTION,3.01,59.15,"VAPOR DIFFUSION, HANGING DROP",8.0,"hanging drop
20% PEG 3350
0.18M tris amonium citrate",293.15,2021-10-29,2022-11-16,7Q43,8934.0,6.0,1290.0,524.0,,137.0,2.0,2.4000234708,experimental,38.167441888,0.264969422568,0.202444119505,Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of dedicator of cytokinesis protein 10
6MGQ,X-RAY DIFFRACTION,2.66,58.55,"VAPOR DIFFUSION, HANGING DROP",8.6,"Final drop composition: 100mM Tris pH 8.60, 3.5% PEG 8000, 3% D-sorbitol, 5mg/mL ERAP1 preincubated with inhibitor",293.0,2018-09-14,2019-12-18,6MGQ,20671.0,6.0,2874.0,36.0,6.0,332.96,2.0,2.92,experimental,70.7,0.256,0.198,ERAP1 in the open conformation bound to 10mer phosphinic inhibitor DG014
6KDE,X-RAY DIFFRACTION,3.09,60.17,"VAPOR DIFFUSION, HANGING DROP",,0.2M calcium acetate (pH 7.5) and 20%(w/v) PEG3350,289.0,2019-07-02,2019-09-25,6KDE,9632.0,4.0,1394.0,,,153.14,2.0,2.999,experimental,75.1623,0.243,0.1942,Crystal structure of the alpha beta heterodimer of human IDH3 in complex with Ca(2+)
6JFK,X-RAY DIFFRACTION,2.4,48.69,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Lithium citrate tribasic tetrahydrate, 35% (V/V) Glycerol ethoxylate",293.15,2019-02-10,2019-11-13,6JFK,3657.0,1.0,438.0,171.0,,50.83,1.0,1.997,experimental,,0.2121,0.1763,GDP bound Mitofusin2 (MFN2)
5KVI,X-RAY DIFFRACTION,2.42,49.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES, pH 7.5, 50 mM NaCl, 24% PEG3350",291.0,2016-07-14,2016-11-16,5KVI,4194.0,1.0,543.0,455.0,,60.36,1.0,1.995,experimental,,0.1941,0.1567,Crystal structure of monomeric human apoptosis-inducing factor with E413A/R422A/R430A mutations
7AUD,X-RAY DIFFRACTION,2.84,56.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"Morpheus HT-96, Condition C9, Molecular Dimensions.
0.09 M NPS, 0.1M Buffer System, 30% Precipitant Mix 1
NPS = 0.3 M sodium nitrate, 0.3 M sodium phosphate dibasic, 0.3 M ammonium sulphate
Buffer System 1 = 1.0 M imidazole, MES monohydrate (acid) pH 6.5
60% Precipitant Mix 1 = 40% v/v PEG 500 MME, 20% w/v PEG 20000",277.15,2020-11-02,2020-12-16,7AUD,25271.0,12.0,3468.0,66.0,1.0,417.98,1.0,2.96,experimental,92.4605,0.269,0.2291,Structure of an engineered helicase domain construct for human Bloom syndrome protein (BLM)
6KL4,X-RAY DIFFRACTION,2.79,55.86,COUNTER-DIFFUSION,,"0.2M Sodium malonate pH 6.0, 20%w/v PEG 3,350",289.15,2019-07-29,2020-04-15,6KL4,4779.0,3.0,606.0,,,68.83,3.0,2.85,experimental,79.298,0.2618,0.1851,Crystal structure of MavC-UBE2N-Ub
6U0K,X-RAY DIFFRACTION,2.78,55.71,"VAPOR DIFFUSION, SITTING DROP",,2M Sodium Potassium Phosphate and 10% Glycerol,277.0,2019-08-14,2020-03-11,6U0K,5117.0,2.0,600.0,420.0,,70.45,1.0,1.744,experimental,40.546,0.2329,0.1909,TTBK2 kinase domain in complex with Compound 1
6VBA,X-RAY DIFFRACTION,2.37,48.07,"VAPOR DIFFUSION, HANGING DROP",8.5,"2mM TRIS pH 8.5, 20 mM Mgcl2, 21% PEG8000, ATA inhibitor was co-crystallized with the UDG protein with a concentration of circa 4mM in solution",291.0,2019-12-18,2021-03-03,6VBA,2129.0,1.0,223.0,259.0,,25.97,1.0,1.8,experimental,26.05,0.2336,0.1792,Structure of human Uracil DNA Glycosylase (UDG) bound to Aurintricarboxylic acid (ATA)
7F0W,X-RAY DIFFRACTION,2.57,52.09,"VAPOR DIFFUSION, SITTING DROP",7.8,"1.0 M sodium citrate, 0.1M Tris pH 7.0, 0.2M NaCl",298.0,2021-06-07,2021-06-23,7F0W,1479.0,1.0,169.0,126.0,,19.75,1.0,1.39,experimental,23.36,0.1896,0.1708,Crystal structure of KRAS-G12D bound to GDP with switch 1 open conformation
6EQQ,X-RAY DIFFRACTION,3.36,63.42,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES buffer, 2.1 M Ammonium sulfate",293.0,2017-10-15,2017-12-13,6EQQ,4610.0,1.0,529.0,209.0,3.0,62.82,1.0,2.40000447819,experimental,60.3772836568,0.195683987417,0.1707807062,Human butyrylcholinesterase in complex with huprine 19
5UP0,X-RAY DIFFRACTION,3.12,60.55,"VAPOR DIFFUSION, HANGING DROP",6.9,"3.1 M NaCl, 0.1 M HEPES pH 6.9",293.0,2017-02-01,2017-04-26,5UP0,2729.0,1.0,361.0,105.0,,41.74,1.0,2.04,experimental,,0.2262,0.197,"Crystal structure of human PDE1B catalytic domain in complex with inhibitor 3 (6-(4-chlorobenzyl)-8,9,10,11-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one)"
5SFC,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFC,10720.0,4.0,1372.0,408.0,4.0,159.64,1.0,2.18,experimental,46.086,0.2307,0.1831,Crystal Structure of human phosphodiesterase 10 in complex with
5SFE,X-RAY DIFFRACTION,2.65,53.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-19,5SFE,11102.0,4.0,1372.0,699.0,4.0,159.64,1.0,1.86,experimental,36.66,0.2206,0.1786,"Crystal Structure of human phosphodiesterase 10 in complex with 3-N-[2-(3-fluorophenyl)imidazo[1,2-a]pyrimidin-7-yl]-4-N,4-N,2-trimethylpyrazole-3,4-dicarboxamide"
5SFZ,X-RAY DIFFRACTION,2.62,53.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SFZ,10811.0,4.0,1372.0,504.0,4.0,159.56,1.0,2.16,experimental,39.198,0.2349,0.1905,"Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-3-(2-phenylpyrazol-3-yl)urea"
5SG0,X-RAY DIFFRACTION,2.64,53.38,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG0,10953.0,4.0,1372.0,639.0,4.0,159.66,1.0,2.06,experimental,35.317,0.2229,0.1891,"Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-3-(2-phenylpyrazol-3-yl)imidazolidin-2-one"
5SG1,X-RAY DIFFRACTION,2.71,54.58,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG1,10489.0,4.0,1372.0,187.0,4.0,159.4,1.0,2.41,experimental,62.651,0.2434,0.1788,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]quinoline"
5SG3,X-RAY DIFFRACTION,2.63,53.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG3,10952.0,4.0,1372.0,629.0,4.0,160.05,1.0,1.98,experimental,35.582,0.2279,0.1824,"Crystal Structure of human phosphodiesterase 10 in complex with N-[(E)-(4-bromo-3,5-dimethoxyphenyl)methylideneamino]-2-ethoxy-2-(4-morpholin-4-ylphenyl)acetamide"
5SG5,X-RAY DIFFRACTION,2.64,53.34,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG5,10629.0,4.0,1372.0,309.0,4.0,159.73,1.0,2.17,experimental,49.915,0.2285,0.1852,Crystal Structure of human phosphodiesterase 10 in complex with 1-[(4-methoxyphenyl)methyl]-3-(4-methylphenyl)-1-[(4-oxo-3H-quinazolin-2-yl)methyl]urea
5SG6,X-RAY DIFFRACTION,2.64,53.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG6,10811.0,4.0,1372.0,519.0,4.0,159.32,1.0,1.96,experimental,40.822,0.2191,0.1777,"Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine"
5SG7,X-RAY DIFFRACTION,2.68,54.19,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG7,10789.0,4.0,1372.0,514.0,,159.31,1.0,2.3,experimental,39.106,0.2298,0.1725,Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(2-fluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethyl)phenyl]pyridazin-4-one
5SG9,X-RAY DIFFRACTION,2.61,52.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SG9,10780.0,4.0,1372.0,492.0,4.0,159.28,1.0,2.13,experimental,41.871,0.2033,0.1764,Crystal Structure of human phosphodiesterase 10 in complex with 2-[(E)-2-(4-methyl-6-pyrrolidin-1-ylpyrimidin-2-yl)ethenyl]quinoline
5SGC,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGC,10702.0,4.0,1372.0,390.0,4.0,159.66,1.0,2.09,experimental,43.885,0.235,0.181,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)pyrazole-3-carboxamide"
5SGD,X-RAY DIFFRACTION,2.64,53.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGD,10465.0,4.0,1372.0,177.0,4.0,159.46,1.0,2.54,experimental,60.489,0.2571,0.1667,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(methoxymethyl)-2-methyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide"
5SGE,X-RAY DIFFRACTION,2.63,53.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGE,10645.0,4.0,1372.0,429.0,4.0,158.75,1.0,2.2,experimental,47.904,0.2241,0.1816,"Crystal Structure of human phosphodiesterase 10 in complex with 6H-imidazo[1,2-c]quinazolin-5-one"
5SGG,X-RAY DIFFRACTION,2.63,53.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGG,10880.0,4.0,1372.0,596.0,4.0,159.4,1.0,2.09,experimental,37.61,0.2308,0.1876,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[(4-chloro-3,5-dimethylpyridin-2-yl)methylsulfanyl]-6,7-dihydro-3H-furo[3,2-f]benzimidazole"
5SGH,X-RAY DIFFRACTION,2.6,52.78,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGH,10925.0,4.0,1372.0,613.0,4.0,159.63,1.0,1.97,experimental,37.525,0.2196,0.1766,"Crystal Structure of human phosphodiesterase 10 in complex with 4-[1-methyl-6-[(1-methyl-4-phenylimidazol-2-yl)methoxy]pyrazolo[3,4-d]pyrimidin-4-yl]morpholine"
5SGJ,X-RAY DIFFRACTION,2.64,53.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGJ,10601.0,4.0,1372.0,305.0,4.0,159.61,1.0,2.66,experimental,45.452,0.26,0.1816,"Crystal Structure of human phosphodiesterase 10 in complex with 6-[(3,6-dimethylpyridine-2-carbonyl)amino]-N-methyl-2-phenyl-3H-benzimidazole-5-carboxamide"
5SGK,X-RAY DIFFRACTION,2.63,53.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGK,10794.0,4.0,1372.0,478.0,4.0,159.69,1.0,2.13,experimental,42.842,0.2267,0.1847,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[(7R)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl]pyrazole-3-carboxamide"
5SGO,X-RAY DIFFRACTION,2.66,53.83,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGO,10736.0,4.0,1372.0,329.0,,159.44,1.0,2.3,experimental,45.279,0.224,0.1642,"Crystal Structure of human phosphodiesterase 10 in complex with N-[3-[3-[5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxypropoxy]phenyl]acetamide"
5SGS,X-RAY DIFFRACTION,2.65,53.64,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGS,10819.0,4.0,1372.0,523.0,4.0,159.29,1.0,2.03,experimental,42.385,0.2249,0.1773,Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-[2-(1-pyridin-2-ylpyrrolidin-3-yl)ethyl]quinoxaline
5SGT,X-RAY DIFFRACTION,2.63,53.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGT,10805.0,4.0,1372.0,485.0,4.0,159.71,1.0,2.26,experimental,41.731,0.2264,0.1939,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-[3-(4-methoxyphenyl)-4-oxoquinazolin-2-yl]ethyl]isoindole-1,3-dione"
5SGW,X-RAY DIFFRACTION,2.64,53.42,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGW,10981.0,4.0,1372.0,693.0,4.0,159.28,1.0,1.9,experimental,32.458,0.2164,0.1865,"Crystal Structure of human phosphodiesterase 10 in complex with 2-phenyl-6-(2-phenylpyrazol-3-yl)-3,4-dihydropyridazin-5-one"
5SGY,X-RAY DIFFRACTION,2.63,53.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGY,10670.0,4.0,1372.0,390.0,4.0,159.59,1.0,2.36,experimental,48.683,0.2406,0.1817,"Crystal Structure of human phosphodiesterase 10 in complex with 4-chloro-2-(2-methylpropyl)-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3-carboxamide"
5SGZ,X-RAY DIFFRACTION,2.62,52.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGZ,10699.0,4.0,1372.0,411.0,4.0,159.37,1.0,2.2,experimental,45.795,0.2225,0.1884,"Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-chlorophenyl)-12-methoxy-5-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,9,11-pentaen-7-one"
5SH1,X-RAY DIFFRACTION,2.64,53.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SH1,10876.0,4.0,1372.0,584.0,4.0,159.33,1.0,2.2,experimental,36.905,0.2313,0.1862,"Crystal Structure of human phosphodiesterase 10 in complex with 5-methyl-2-phenyl-4-(2-quinolin-8-yloxyethyl)-1,3-oxazole"
5SH2,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SH2,10702.0,4.0,1372.0,390.0,4.0,159.72,1.0,2.19,experimental,45.388,0.2204,0.18,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-morpholin-4-yl-1,3-benzothiazol-5-yl)pyrazole-3-carboxamide"
5SH4,X-RAY DIFFRACTION,2.64,53.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SH4,10864.0,4.0,1372.0,572.0,4.0,159.44,1.0,2.22,experimental,37.026,0.2453,0.1949,"Crystal Structure of human phosphodiesterase 10 in complex with 6-[(5-methoxy-3,4,6-trimethylpyridin-2-yl)methylsulfanyl]-5H-[1,3]dioxolo[4,5-f]benzimidazole"
5SH5,X-RAY DIFFRACTION,2.61,52.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SH5,10532.0,4.0,1372.0,260.0,4.0,159.07,1.0,2.3,experimental,51.042,0.2323,0.1803,Crystal Structure of human phosphodiesterase 10 in complex with 2-amino-4-cyclohexyloxyquinoline-3-carbonitrile
5SH6,X-RAY DIFFRACTION,2.61,52.78,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SH6,10918.0,4.0,1372.0,630.0,4.0,159.3,1.0,1.98,experimental,37.774,0.2174,0.1749,"Crystal Structure of human phosphodiesterase 10 in complex with 4-[2-(1-methylbenzimidazol-2-yl)ethyl]-2,3-dihydro-1,4-benzoxazepin-5-one"
5SHB,X-RAY DIFFRACTION,2.63,53.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHB,11074.0,4.0,1372.0,751.0,4.0,159.59,1.0,1.95,experimental,34.323,0.2149,0.1805,Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(3-bromophenyl)pyrazol-3-yl]-1-pyridin-4-ylpyridazin-4-one
5SHC,X-RAY DIFFRACTION,2.63,53.22,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHC,10520.0,4.0,1372.0,268.0,4.0,158.81,1.0,2.33,experimental,51.669,0.2248,0.1776,"Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-2-oxo-N-pyrimidin-5-ylpyridine-3-carboxamide"
5SHD,X-RAY DIFFRACTION,2.63,53.28,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHD,10542.0,4.0,1372.0,252.0,4.0,159.57,1.0,2.6,experimental,55.583,0.266,0.1786,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[4-(methylcarbamoyl)pyridin-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SHF,X-RAY DIFFRACTION,2.66,53.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHF,10788.0,4.0,1372.0,492.0,4.0,159.38,1.0,2.28,experimental,45.511,0.2225,0.1741,"Crystal Structure of human phosphodiesterase 10 in complex with 3,6-dimethyl-N-(2-phenylpyrazolo[1,5-a]pyridin-6-yl)pyridine-2-carboxamide"
5SHG,X-RAY DIFFRACTION,2.62,53.03,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHG,10747.0,4.0,1372.0,459.0,4.0,159.37,1.0,2.12,experimental,43.357,0.2255,0.185,"Crystal Structure of human phosphodiesterase 10 in complex with 3-(2-chlorophenyl)-12-methoxy-5-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-7-amine"
5SHH,X-RAY DIFFRACTION,2.66,53.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHH,10847.0,4.0,1372.0,559.0,4.0,159.44,1.0,2.15,experimental,38.098,0.2305,0.1914,"Crystal Structure of human phosphodiesterase 10 in complex with 7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]-6H-imidazo[4,5-g][1,3]benzothiazole"
5SHI,X-RAY DIFFRACTION,2.65,53.58,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHI,10840.0,4.0,1372.0,546.0,4.0,159.39,1.0,2.1,experimental,45.929,0.2233,0.1736,"Crystal Structure of human phosphodiesterase 10 in complex with 2,3,5-trimethyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]imidazo[1,2-a]pyridine"
5SHK,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHK,10740.0,4.0,1372.0,466.0,4.0,159.27,1.0,2,experimental,39.954,0.2181,0.1887,"Crystal Structure of human phosphodiesterase 10 in complex with N-(6-methylpyridin-2-yl)-5-pyridin-3-yl-1,7-naphthyridin-8-amine"
5SHM,X-RAY DIFFRACTION,2.63,53.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHM,10619.0,4.0,1372.0,297.0,4.0,159.51,1.0,2.26,experimental,48.224,0.2364,0.1863,Crystal Structure of human phosphodiesterase 10 in complex with N-[(3R)-1-(5-chloropyridin-2-yl)pyrrolidin-3-yl]-6-cyclopropyl-3-methoxypyrazine-2-carboxamide
5SHN,X-RAY DIFFRACTION,2.63,53.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHN,10930.0,4.0,1372.0,606.0,4.0,159.8,1.0,2.03,experimental,37.41,0.2337,0.1822,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-N-(1,3-oxazol-2-ylmethyl)-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3,4-dicarboxamide"
5SHP,X-RAY DIFFRACTION,2.68,54.08,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHP,10835.0,4.0,1372.0,543.0,4.0,159.41,1.0,2.18,experimental,39.744,0.2307,0.1868,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]-3H-imidazo[4,5-h]quinoline"
5SHT,X-RAY DIFFRACTION,2.63,53.29,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHT,10626.0,4.0,1372.0,344.0,4.0,159.46,1.0,2.27,experimental,51.778,0.2278,0.1766,"Crystal Structure of human phosphodiesterase 10 in complex with 8-chloro-5,7-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine"
5SHU,X-RAY DIFFRACTION,2.65,53.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHU,10923.0,4.0,1372.0,635.0,4.0,159.37,1.0,1.98,experimental,36.163,0.2212,0.1883,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]-3,5,6,7-tetrahydropyrrolo[3,2-f]benzimidazole"
5SHV,X-RAY DIFFRACTION,2.62,53.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHV,10810.0,4.0,1372.0,608.0,4.0,158.59,1.0,1.95,experimental,36.247,0.2337,0.1981,Crystal Structure of human phosphodiesterase 10 in complex with 1-(6-fluoropyridin-2-yl)piperidin-4-one
5SHZ,X-RAY DIFFRACTION,2.63,53.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SHZ,10423.0,4.0,1372.0,87.0,3.0,159.37,1.0,2.55,experimental,53.492,0.2425,0.181,Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(3-ethynylphenyl)pyrazol-3-yl]-1-phenylpyridazin-4-one
5SI2,X-RAY DIFFRACTION,2.59,52.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI2,10554.0,4.0,1372.0,304.0,4.0,159.22,1.0,2.4,experimental,51.822,0.2786,0.21,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(1-pyridin-2-ylpyrrolidin-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SI3,X-RAY DIFFRACTION,2.63,53.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI3,10647.0,4.0,1372.0,370.0,4.0,159.46,1.0,2.4,experimental,45.276,0.233,0.1983,"Crystal Structure of human phosphodiesterase 10 in complex with 1-methyl-5-[(2-phenylimidazo[1,2-a]pyrimidin-7-yl)carbamoyl]pyrazole-4-carboxylic acid"
5SI6,X-RAY DIFFRACTION,2.64,53.38,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI6,10950.0,4.0,1372.0,624.0,4.0,159.71,1.0,2,experimental,34.542,0.2214,0.1846,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-N-(6-cyano-2-phenylimidazo[1,2-a]pyridin-7-yl)-2-methylpyrazole-3-carboxamide"
5SI7,X-RAY DIFFRACTION,2.63,53.22,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI7,10817.0,4.0,1372.0,528.0,4.0,159.29,1.0,2.1,experimental,36.742,0.2333,0.1905,"Crystal Structure of human phosphodiesterase 10 in complex with 2-benzyl-6,6-dimethyl-1H-imidazo[4,5-h]isoquinoline-7,9-dione"
5SI8,X-RAY DIFFRACTION,2.62,53.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI8,10743.0,4.0,1372.0,417.0,4.0,159.83,1.0,2.1,experimental,42.518,0.2457,0.1957,"Crystal Structure of human phosphodiesterase 10 in complex with N-(6-cyano-2-phenylimidazo[1,2-a]pyridin-7-yl)-1-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide"
5SI9,X-RAY DIFFRACTION,2.68,54.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SI9,10899.0,4.0,1372.0,587.0,4.0,159.63,1.0,2.01,experimental,38.211,0.2216,0.1871,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N-(2-hydroxyethyl)-2-methyl-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3,4-dicarboxamide"
5SIB,X-RAY DIFFRACTION,2.64,53.46,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIB,10596.0,4.0,1372.0,316.0,4.0,159.53,1.0,2.54,experimental,52.474,0.2486,0.1715,"Crystal Structure of human phosphodiesterase 10 in complex with 3-methyl-6-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-2-(trifluoromethyl)imidazo[1,2-b]pyridazine"
5SID,X-RAY DIFFRACTION,2.65,53.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SID,10844.0,4.0,1372.0,512.0,4.0,159.6,1.0,1.98,experimental,36.933,0.2177,0.1724,"Crystal Structure of human phosphodiesterase 10 in complex with 5-chloro-2-[2-(6,8-dichloro-5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)ethyl]-1,3-benzothiazole"
5SIG,X-RAY DIFFRACTION,2.61,52.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIG,10798.0,4.0,1372.0,482.0,4.0,159.67,1.0,2.03,experimental,42.34,0.2234,0.1867,Crystal Structure of human phosphodiesterase 10 in complex with 1-[(4-methoxyphenyl)methyl]-1-[(4-oxo-3H-quinazolin-2-yl)methyl]-3-phenylurea
5SIJ,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIJ,10368.0,4.0,1372.0,76.0,4.0,159.34,1.0,2.55,experimental,65.965,0.2427,0.1746,"Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine"
5SIP,X-RAY DIFFRACTION,2.63,53.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIP,10799.0,4.0,1372.0,475.0,4.0,159.62,1.0,2.03,experimental,41.422,0.2265,0.1906,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3-carboxamide"
5SIR,X-RAY DIFFRACTION,2.67,53.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIR,10679.0,4.0,1372.0,415.0,4.0,159.39,1.0,2.5,experimental,46.147,0.2216,0.1859,"Crystal Structure of human phosphodiesterase 10 in complex with 3,6-dimethyl-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyridine-2-carboxamide"
5SIU,X-RAY DIFFRACTION,2.62,53.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIU,10790.0,4.0,1372.0,463.0,4.0,159.51,1.0,2.01,experimental,38.195,0.2116,0.1697,"Crystal Structure of human phosphodiesterase 10 in complex with 3-[2-(6,8-dichloro-5-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl)ethyl]-1H-quinoxalin-2-one"
5SIW,X-RAY DIFFRACTION,2.61,52.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIW,10764.0,4.0,1372.0,463.0,4.0,159.53,1.0,2.13,experimental,43.461,0.2254,0.1704,"5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-8-(trifluoromethyl)-[1,2,4]triazolo[1,5-c]pyrimidine"
5SIY,X-RAY DIFFRACTION,2.63,53.2,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SIY,10786.0,4.0,1372.0,464.0,4.0,159.86,1.0,2.03,experimental,39.67,0.2207,0.1747,"Crystal Structure of human phosphodiesterase 10 in complex with 5-[(3R)-3-fluoropyrrolidin-1-yl]-N-methyl-2-(3-methylquinoxalin-2-yl)-N-(oxan-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine"
5SJ1,X-RAY DIFFRACTION,2.62,53.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJ1,10880.0,4.0,1372.0,580.0,4.0,159.61,1.0,2.16,experimental,35.098,0.2364,0.1915,"Crystal Structure of human phosphodiesterase 10 in complex with 7-[(3,5-dimethyl-4-propan-2-yloxypyridin-2-yl)methylsulfinyl]-6H-imidazo[4,5-g][1,3]benzothiazole"
5SJ2,X-RAY DIFFRACTION,2.65,53.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJ2,10918.0,4.0,1372.0,616.0,4.0,159.55,1.0,1.99,experimental,38.622,0.2182,0.1759,"Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dichloro-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-4-carboxamide"
5SJ7,X-RAY DIFFRACTION,2.64,53.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJ7,10822.0,4.0,1372.0,530.0,4.0,159.49,1.0,2.14,experimental,42.384,0.2186,0.1962,"Crystal Structure of human phosphodiesterase 10 in complex with 7-[(5-methyl-4-propan-2-yloxypyridin-2-yl)methylsulfanyl]-6H-imidazo[4,5-g][1,3]benzothiazole"
5SJ8,X-RAY DIFFRACTION,2.62,53.03,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJ8,10533.0,4.0,1372.0,289.0,4.0,159.14,1.0,2.49,experimental,49.454,0.2009,0.1661,"Crystal Structure of human phosphodiesterase 10 in complex with 12-methoxy-5-methyl-3-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(13),3,5,7,9,11-hexaene-7-carbonitrile"
5SJ9,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJ9,10475.0,4.0,1372.0,195.0,4.0,159.57,1.0,2.39,experimental,54.909,0.2329,0.176,"Crystal Structure of human phosphodiesterase 10 in complex with N-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-3-propan-2-yl-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide"
5SJA,X-RAY DIFFRACTION,2.67,53.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJA,10877.0,4.0,1372.0,529.0,2.0,159.96,1.0,2.13,experimental,45.22,0.2289,0.1816,"Crystal Structure of human phosphodiesterase 10 in complex with N-(2-tert-butyl-5-methylpyrazol-3-yl)-1-phenyl-3-(pyridin-2-yloxymethyl)thieno[2,3-c]pyrazole-5-carboxamide"
5SJB,X-RAY DIFFRACTION,2.64,53.46,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJB,10895.0,4.0,1372.0,603.0,4.0,159.41,1.0,2.2,experimental,35.241,0.2334,0.1868,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]-3H-imidazo[4,5-f]quinoline"
5SJD,X-RAY DIFFRACTION,2.65,53.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJD,10824.0,4.0,1372.0,536.0,4.0,159.31,1.0,2.16,experimental,39.981,0.2274,0.1847,"Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-(3,5-dimethylpyrazol-1-yl)ethyl]-3-(2-phenylpyrazol-3-yl)urea"
5SJL,X-RAY DIFFRACTION,2.66,53.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJL,10699.0,4.0,1372.0,375.0,4.0,159.8,1.0,2.64,experimental,41.02,0.2438,0.2022,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[4-[(2-hydroxy-2-methylpropyl)carbamoyl]pyridin-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SJN,X-RAY DIFFRACTION,2.63,53.15,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJN,10723.0,4.0,1372.0,431.0,4.0,159.51,1.0,2.05,experimental,41.626,0.2265,0.1831,"Crystal Structure of human phosphodiesterase 10 in complex with 6,8-dichloro-2-[2-(6,7-dimethyl-1H-benzimidazol-2-yl)ethyl]-5-methyl-[1,2,4]triazolo[1,5-a]pyridine"
5SJP,X-RAY DIFFRACTION,2.62,53.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJP,10771.0,4.0,1372.0,455.0,4.0,159.79,1.0,2.25,experimental,48.057,0.2344,0.1733,Crystal Structure of human phosphodiesterase 10 in complex with ethyl N-[[4-[[4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carbonyl]amino]-6-methylpyridin-2-yl]carbamothioyl]carbamate
5SJU,X-RAY DIFFRACTION,2.65,53.51,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJU,11072.0,4.0,1372.0,638.0,4.0,159.77,1.0,1.97,experimental,38.152,0.2199,0.1762,"Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[4-(piperidin-1-ylmethyl)-1,3-thiazol-2-yl]-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide"
5SJY,X-RAY DIFFRACTION,2.67,53.87,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJY,10497.0,4.0,1372.0,196.0,4.0,159.66,1.0,2.2,experimental,47.554,0.2647,0.2018,"Crystal Structure of human phosphodiesterase 10 in complex with 4-bromo-2,5-dimethyl-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3-carboxamide"
5SJZ,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJZ,10723.0,4.0,1372.0,425.0,4.0,159.71,1.0,2.19,experimental,46.576,0.226,0.1703,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(morpholine-4-carbonyl)-N-(2-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide"
5SK1,X-RAY DIFFRACTION,2.6,52.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SK1,10647.0,4.0,1372.0,334.0,4.0,159.55,1.0,2.3,experimental,50.049,0.2384,0.1847,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N,2-dimethyl-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3,4-dicarboxamide"
5SK3,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SK3,10650.0,4.0,1372.0,326.0,4.0,159.49,1.0,2.32,experimental,50.825,0.2263,0.1688,"Crystal Structure of human phosphodiesterase 10 in complex with [2-cyclopropyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]imidazo[1,2-b]pyridazin-3-yl]methanol"
5SK4,X-RAY DIFFRACTION,2.64,53.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SK4,10936.0,4.0,1372.0,599.0,4.0,159.66,1.0,2,experimental,39.579,0.2237,0.1844,Crystal Structure of human phosphodiesterase 10 in complex with 6-methyl-3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5SKA,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKA,10858.0,4.0,1372.0,570.0,4.0,159.44,1.0,2.21,experimental,37.704,0.2418,0.1913,"Crystal Structure of human phosphodiesterase 10 in complex with 7-[(4-ethoxy-5-methylpyridin-2-yl)methylsulfanyl]-6H-imidazo[4,5-g][1,3]benzothiazole"
5SKB,X-RAY DIFFRACTION,2.62,53.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKB,10575.0,4.0,1372.0,367.0,4.0,158.66,1.0,2.35,experimental,49.029,0.2488,0.188,"Crystal Structure of human phosphodiesterase 10 in complex with 9-methoxy-3,5-dihydropyrimido[5,4-b]indol-4-one"
5SKE,X-RAY DIFFRACTION,2.62,53.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKE,10773.0,4.0,1372.0,457.0,4.0,159.74,1.0,2.2,experimental,41.445,0.2148,0.177,Crystal Structure of human phosphodiesterase 10 in complex with 2-tert-butyl-5-(pyrimidin-5-ylamino)-N-[3-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide
5SKG,X-RAY DIFFRACTION,2.62,53.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKG,10919.0,4.0,1372.0,611.0,4.0,159.63,1.0,2.03,experimental,38.753,0.2218,0.1835,"Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-6-(cyclopropylamino)-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-4-carboxamide"
5SKI,X-RAY DIFFRACTION,2.63,53.15,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKI,10810.0,4.0,1372.0,505.0,4.0,159.35,1.0,2.16,experimental,41.712,0.2275,0.1782,"Crystal Structure of human phosphodiesterase 10 in complex with N-[(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl]-2-methyl-5-phenyl-1,2,4-triazol-3-amine"
5SKK,X-RAY DIFFRACTION,2.62,53.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKK,10694.0,4.0,1372.0,378.0,4.0,159.71,1.0,2.15,experimental,45.353,0.2421,0.1902,Crystal Structure of human phosphodiesterase 10 in complex with N-[1-methyl-5-(methylcarbamoyl)pyrazol-4-yl]-6-[(3S)-oxolan-3-yl]-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide
5SKL,X-RAY DIFFRACTION,2.6,52.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKL,10746.0,4.0,1372.0,426.0,4.0,159.83,1.0,2.2,experimental,46.112,0.2336,0.1868,"Crystal Structure of human phosphodiesterase 10 in complex with N-(6-cyano-2-phenylimidazo[1,2-a]pyridin-7-yl)-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide"
5SKM,X-RAY DIFFRACTION,2.67,53.87,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKM,10943.0,4.0,1372.0,635.0,4.0,159.54,1.0,1.91,experimental,37.627,0.2213,0.1796,"Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-N,N-dimethyl-2-[2-(1-pyridin-2-ylpyrrolidin-3-yl)ethyl]quinazolin-4-amine"
5SKN,X-RAY DIFFRACTION,2.64,53.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKN,11102.0,4.0,1372.0,722.0,4.0,159.64,1.0,1.9,experimental,35.0,0.2224,0.1913,Crystal Structure of human phosphodiesterase 10 in complex with N-[3-[3-[2-(2-fluorophenyl)pyrazol-3-yl]-4-oxopyridazin-1-yl]phenyl]acetamide
5SKU,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKU,10858.0,4.0,1372.0,522.0,4.0,159.99,1.0,2.2,experimental,38.347,0.225,0.1812,"Crystal Structure of human phosphodiesterase 10 in complex with 3-[4-[2-[2-(2-ethoxy-4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy]naphthalen-1-yl]-2-methoxypropanoic acid"
5SKV,X-RAY DIFFRACTION,2.62,53.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SKV,10767.0,4.0,1372.0,475.0,4.0,159.81,1.0,2.6,experimental,38.674,0.255,0.1989,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[3-[(2-hydroxy-2-methylpropyl)carbamoyl]-1-methylpyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
6CQ7,X-RAY DIFFRACTION,4.35,71.74,"VAPOR DIFFUSION, HANGING DROP",,"0.5 M Ammonium Sulphate
0.1 M Sodium Citrate pH 5.6
1.1 M Lithium Sulphate",298.0,2018-03-14,2018-09-19,6CQ7,590.0,1.0,80.0,30.0,,8.43,1.0,2,experimental,60.496,0.25977,0.19625,The SH3 domain of MLK3 in complex with poly-proline peptide derived from Htt
7YUI,X-RAY DIFFRACTION,2.45,49.72,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Lithium chloride, 0.1 M Tris(pH 8), 20 %(w/v)PEG 8000",289.0,2022-08-17,2023-08-30,7YUI,4352.0,2.0,542.0,74.0,,61.72,2.0,2.599,experimental,57.7576,0.2575,0.2026,Crystal structure of HOIL-1L(195-423) in complex with the linear tetra-ubiquitin
7ARX,X-RAY DIFFRACTION,2.39,48.45,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes, 42 w/v% PEG200, pH 7.5",293.0,2020-10-26,2021-11-03,7ARX,2977.0,3.0,420.0,26.0,9.0,47.11,3.0,2.42,experimental,76.57,0.2849,0.256,Crystal structure of the catalytic fragment of masp-1 in complex with SFMI1
5MTJ,X-RAY DIFFRACTION,3.77,67.36,"VAPOR DIFFUSION, HANGING DROP",10.25,"2M Ammonium sulfate, 0.2M Lithium sulfate, 0.1M CAPS/NaOH pH10.25",291.0,2017-01-09,2017-04-05,5MTJ,1925.0,2.0,214.0,240.0,,24.57,2.0,1.949,experimental,,0.2231,0.1902,Yes1-SH2 in complex with monobody Mb(Yes_1)
7O7J,X-RAY DIFFRACTION,4.0,69.28,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M Tris/HCl (pH 8.0), 0.2 M MgCl2, and 8% PEG 8000 solution",288.0,2021-04-13,2021-11-24,7O7J,2995.0,1.0,404.0,15.0,,46.65,1.0,2.81,experimental,116.1661,0.2733,0.2459,Crystal structure of the human HIPK3 kinase domain bound to abemaciclib
6VBH,X-RAY DIFFRACTION,3.54,65.23,"VAPOR DIFFUSION, HANGING DROP",,"Mixed 1:1 with  40% AmSO4, 200 mM Imidizole/Malate Buffer pH 4.2,100 mM MgCl2",288.0,2019-12-18,2020-06-17,6VBH,2889.0,1.0,346.0,119.0,,41.56,1.0,1.995,experimental,80.6006,0.2444,0.2198,Human XPG endonuclease catalytic domain
,,,,"VAPOR DIFFUSION, HANGING DROP",,"Mixed 1:1 wit 24% AmSO4, 200 mM Imidizole/Malate Buffer pH 4.2, 250 mM MgCl2, 0.5 mM SmSO4, 10 mM DTT",288.0,,,,,,,,,,,,,,,,
,,,,"VAPOR DIFFUSION, HANGING DROP",,"Mixed 1:1 with 32% AmSO4, 10 mM DTT, 200 mM Imidizole/Malate Buffer pH 4.2, and 50 mM MgCl2",288.0,,,,,,,,,,,,,,,,
8K4Z,X-RAY DIFFRACTION,2.16,42.93,VAPOR DIFFUSION,7.5,"20% w/v Polyethylene glycol 3350,  100mM Bis-Tris propane pH7.5,  200mM Sodium iodide",293.0,2023-07-20,2024-04-17,8K4Z,1409.0,2.0,181.0,63.0,,20.55,2.0,1.7,experimental,18.838,0.2392,0.203,Crystal structure of human MMP-7 in complex with inhibitor
5HQ8,X-RAY DIFFRACTION,2.63,53.28,"VAPOR DIFFUSION, SITTING DROP",7.0,"Human SMYD3 (1-428) with SAM in the SAM-binding site was concentrated to 11.7 mg/mL in 25 mM Tris-HCl pH 8 and 150 mM NaCl.  Peptide (21st Century Biochemical) was solubilized in 100mM water.   Two ul peptide was added to 200 ul of protein (five fold molar excess of peptide) and allowed to complex with the protein overnight at 4C.  Crystals were obtained from a Hampton Index HT broad screen in sitting drops at 22C with condition H7 (0.15 DL-malic acid pH 7.0, 20% w/v PEG 3,350).   Crystals were flash frozen in 20 percent ethylene glycol in well  solution prior to data collection",295.0,2016-01-21,2016-03-30,5HQ8,7678.0,4.0,896.0,731.0,,104.23,2.0,1.72,experimental,,0.2011,0.1741,Co-crystal Structure of human SMYD3 with a MEKK2 peptide at 2.13A
4Y2B,X-RAY DIFFRACTION,2.81,56.22,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.6 - 0.8M (NH4)2SO4, 3mM mercaptoethanol, 10mM MgCl2, 10mM EDTA, 0.1M Tris HCl",277.0,2015-02-09,2015-04-08,4Y2B,2903.0,1.0,389.0,284.0,,44.95,1.0,2.2,experimental,27.483,0.19612,0.15779,"Co-crystal structure of 3-ethyl-2-(isopropylamino)-7-(pyridin-3-yl)thieno[3,2-d]pyrimidin-4(3H)-one bound to PDE7A"
5LUZ,X-RAY DIFFRACTION,2.7,54.8,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris-propane, 11% PEG 3350, 10% glycerol, 0.2M potassium thiocyanate",294.0,2016-09-12,2017-12-06,5LUZ,10950.0,6.0,1424.0,117.0,,164.29,2.0,2.7,experimental,55.723,0.26786,0.21558,Structure of Human Neurolysin (E475Q) in complex with neurotensin peptide products
5JJA,X-RAY DIFFRACTION,3.53,60.25,"VAPOR DIFFUSION, SITTING DROP",,0.1 M HEPES pH 7.5 and 20% PEG 3350,277.0,2016-04-22,2016-07-13,5JJA,5927.0,4.0,854.0,240.0,,98.73,2.0,2.35,experimental,44.293,0.2041,0.1795,Crystal structure of a PP2A B56gamma/BubR1 complex
5VYG,X-RAY DIFFRACTION,2.35,47.69,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris pH 8.5, 15% Glycerol, 1.6 M (NH4)2SO4, 5% 2,2,2-Trifluoroethanol",293.0,2017-05-25,2017-08-09,5VYG,1085.0,3.0,150.0,37.0,9.0,18.58,1.0,2.2,experimental,36.999,0.25895,0.21233,Crystal structure of hFA9 EGF repeat with O-glucose trisaccharide
7SCW,X-RAY DIFFRACTION,2.46,50.07,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.05M Magnesium acetate tetrahydrate, 0.1M MES (pH 6.5), 26% v/v PEG 400",298.0,2021-09-29,2022-05-18,7SCW,2275.0,2.0,283.0,188.0,,32.85,2.0,1.98,experimental,29.75,0.1921,0.156,KRAS full length wild-type in complex with RGL1 Ras association domain
5DEW,X-RAY DIFFRACTION,2.43,49.37,"VAPOR DIFFUSION, SITTING DROP",7.0,"crystals were grown at 19  C from 1.0 uL + 1.0 uL vapor diffusion drops containing 10 mg/mL protein, 1 mM ligand, 0.15 M DL-Malic Acid pH 7.0, 20% - 30% PEG 3350, 4% 1,3-Propanediol and 0.1 M Sodium Malonate, VAPOR DIFFUSION, SITTING DROP, temperature 292K",292.0,2015-08-26,2016-09-21,5DEW,5019.0,2.0,594.0,453.0,,67.58,1.0,1.9,experimental,,0.2153,0.1749,Crystal structure of PAK1 in complex with an inhibitor compound 5
5D7A,X-RAY DIFFRACTION,3.13,60.71,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2M Ammonium sulfate
0.1M Bis-tris (5.6)
15% PEG3350
7% Ethyleneglycol",293.0,2015-08-13,2016-08-17,5D7A,7021.0,3.0,924.0,7.0,,106.64,1.0,2.9,experimental,,0.2391,0.1842,Crystal structure of the kinase domain of TRAF2 and NCK-interacting protein kinase with NCB-0846
6FD3,X-RAY DIFFRACTION,2.55,51.76,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2M magnesium formate",293.0,2017-12-21,2018-01-03,6FD3,2705.0,1.0,300.0,276.0,,34.33,1.0,1.52,experimental,29.0289,0.1904,0.1751,Thiophosphorylated PAK3 kinase domain
7UXD,X-RAY DIFFRACTION,2.2,43.99,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG6000, 50 mM di-Sodium L-Malate; pH5.0, 30 mM CACL2",277.0,2022-05-05,2022-12-14,7UXD,1931.0,2.0,208.0,212.0,,25.88,1.0,1.5,experimental,36.7548,0.1944,0.1725,Crystal structure of APOBEC3G Catalytic domain complex with ssDNA containing 2'-deoxy Zebularine.
6R6W,X-RAY DIFFRACTION,3.2,61.59,"VAPOR DIFFUSION, HANGING DROP",6.5,Ammonium sulfate,293.0,2019-03-28,2020-01-15,6R6W,4521.0,1.0,526.0,91.0,3.0,62.85,1.0,2.474,experimental,66.7131,0.2268,0.1822,Structure of recombinant human butyrylcholinesterase in complex with a fluorescent NBD-based probe
6SAM,X-RAY DIFFRACTION,3.19,61.44,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2019-07-17,2020-04-29,6SAM,4521.0,1.0,529.0,86.0,3.0,63.03,1.0,2.5,experimental,60.96,0.241,0.188,"Structure of human butyrylcholinesterase in complex with 1-(2,3-dihydro-1H-inden2-yl)piperidin-3-yl N-phenyl carbamate"
4R7L,X-RAY DIFFRACTION,2.36,47.79,VAPOR DIFFUSION,6.8,"15% PEG 8000, 0.1mM Na-acetate, 0.1mM Imidazole, 5mM YbCL3, pH 6.8, VAPOR DIFFUSION, temperature 277K",277.0,2014-08-27,2015-11-25,4R7L,5341.0,1.0,631.0,426.0,,72.5,1.0,1.66,experimental,18.01,0.18546,0.15251,Structure of Human Leukotriene A4 Hydrolase in complex with inhibitor H1
4RSY,X-RAY DIFFRACTION,2.29,46.35,"VAPOR DIFFUSION, HANGING DROP",,"13% PEG 8000, 100mM Imidazole pH 6.0-6.8, 100mM Na Acetate, 5mM YbCl3, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-11-12,2015-12-02,4RSY,5042.0,1.0,631.0,156.0,,72.21,1.0,1.93,experimental,21.398,0.24801,0.1984,Crystal structures of the Human leukotriene A4 Hydrolase complex with a potential inhibitor H7
5SE0,X-RAY DIFFRACTION,2.65,53.51,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE0,10877.0,4.0,1372.0,553.0,4.0,159.78,1.0,2.01,experimental,36.822,0.2264,0.1932,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[2-(2-hydroxyethyl)-5-pyridin-2-ylpyrazol-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SFA,X-RAY DIFFRACTION,2.59,52.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFA,10607.0,4.0,1372.0,291.0,4.0,159.7,1.0,2.32,experimental,48.889,0.2269,0.1752,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-[(1-methyl-4-phenylimidazol-2-yl)methoxy]-N-(oxolan-3-yl)pyrazine-2-carboxamide
5SFB,X-RAY DIFFRACTION,2.66,53.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFB,10877.0,4.0,1372.0,586.0,4.0,159.54,1.0,1.98,experimental,38.978,0.223,0.1751,"Crystal Structure of human phosphodiesterase 10 in complex with N,2,3-trimethyl-6-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]imidazo[1,2-b]pyridazine-8-carboxamide"
7LSG,X-RAY DIFFRACTION,2.87,57.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"5% (+/-)-2-Methyl-2,4-pentanediol, 0.1M HEPES pH 7.5, 10% PEG 10000",295.0,2021-02-18,2021-04-07,7LSG,4306.0,3.0,543.0,325.0,5.0,58.94,3.0,1.86,experimental,34.93,0.2123,0.1867,Crystal structure of the human neutralizing antibody Fab fragment T025 bound to TBEV EDIII (Siberian Subtype)
5MRB,X-RAY DIFFRACTION,3.13,60.65,"VAPOR DIFFUSION, SITTING DROP",8.8,"Protein solution: 200 uM (7.2 mg/mL) Mps1, 250 uM Cpd-5. 
Reservoir solution: 15.5% (w/v) PEG 350 MME, 10 mM MgCl2, and 100 mM Tris/HCl",291.0,2016-12-22,2017-07-26,5MRB,2326.0,1.0,313.0,70.0,,37.54,1.0,2.2,experimental,61.265,0.2159,0.1732,Crystal structure of human Mps1 (TTK) in complex with Cpd-5
5NTT,X-RAY DIFFRACTION,3.44,64.26,"VAPOR DIFFUSION, SITTING DROP",7.4,"10.5% (w/v) PEG 350 MME, 10 mM MgCl2, and 100 mM Tris/HCl",291.0,2017-04-28,2017-07-26,5NTT,2367.0,1.0,287.0,32.0,,34.19,1.0,2.75,experimental,73.976,0.2298,0.1992,Crystal structure of human Mps1 (TTK) C604Y mutant in complex with NMS-P715
6N6K,X-RAY DIFFRACTION,2.55,51.72,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M sodium malonate (pH 5.5) and 15-20% polyethylene glycol 3350, 25% glycerol",277.0,2018-11-26,2019-06-12,6N6K,3929.0,4.0,414.0,556.0,,48.99,1.0,1.418,experimental,22.7865,0.1724,0.1531,Human REXO2 bound to pAG
5NQC,X-RAY DIFFRACTION,2.02,39.08,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium tartrate pH 5.6, 2.2 M (NH4)2SO4, 0.2 M NaSCN, 5 mM TCEP, 5 mM NMR154, 5% (v/v) DMSO",292.0,2017-04-19,2017-06-07,5NQC,3069.0,1.0,334.0,232.0,,40.43,1.0,2,experimental,,0.2472,0.1962,CK2alpha in complex with NMR154
5UIR,X-RAY DIFFRACTION,2.33,47.29,"VAPOR DIFFUSION, HANGING DROP",,"1.6-1.8M Ammonium Citrate, pH 7.0",295.0,2017-01-14,2017-05-24,5UIR,4405.0,2.0,646.0,32.0,,73.83,1.0,2.64,experimental,61.84,0.277,0.219,Crystal structure of IRAK4 in complex with compound 11
5ARF,X-RAY DIFFRACTION,2.41,49.0,,7.0,"SMYD2 CO-CRYSTALLIZED WITH 2 MMOL SAM. RESERVOIR 23% PEG 3350, 100 MMOL HEPES PH 7.0. CO-COMPLEX WITH INHIBITOR FORMED BY SOAKING SMYD2-SAM CRYSTALS WITH 5 MILLIMOLAR COMPOUND-2 FOR 1 HOUR. CRYO WITH ADDITIONAL 20% GLYCEROL AND 1 MMOL COMPOUND-2.",,2015-09-24,2016-04-27,5ARF,3610.0,1.0,433.0,127.0,2.0,50.77,1.0,1.92,experimental,52.97,0.30052,0.25747,SMYD2 in complex with small molecule inhibitor compound-2
6UBP,X-RAY DIFFRACTION,2.9,57.63,MICROBATCH,10.0,"100 mM sodium thiosulfate, 100 mM CAPS, pH 10.0, 20% w/v PEG8000",277.0,2019-09-12,2021-02-03,6UBP,6115.0,2.0,850.0,63.0,1.0,97.28,1.0,2.95,experimental,102.551,0.2641,0.2152,"Crystal structure of a photochemical intermediate of human indoleamine 2,3-dioxygenase 1 in complex with carbon monoxide and tryptophan"
4ZS2,X-RAY DIFFRACTION,2.97,58.54,"VAPOR DIFFUSION, HANGING DROP",,"100 mM sodium citrate (pH 5.8), 10% PEG 3350, 8% isopropanol",289.0,2015-05-13,2015-11-04,4ZS2,3641.0,1.0,478.0,90.0,1.0,55.47,1.0,2.16,experimental,49.999,0.22854,0.1976,Structural complex of FTO/fluorescein
7QE8,X-RAY DIFFRACTION,2.7,54.0,"VAPOR DIFFUSION, HANGING DROP",7.4,"1 ul protein solution (20 mg/mL in 20 mM HEPES, pH 7.4, 150 mM NaCl) + 1 ul well solution (15% PEG 4000, 0.3 M AS), cryo 15% PEG 4000, 0.3 M AS, 8% PEG 400",293.0,2021-12-01,2022-03-30,7QE8,4240.0,4.0,560.0,1.0,16.0,61.04,2.0,2.9,experimental,100.14,0.2431,0.2229,Human cationic trypsin (TRY1) complexed with serine protease inhibitor Kazal type 1 (SPINK1)
7QE9,X-RAY DIFFRACTION,2.71,54.53,"VAPOR DIFFUSION, HANGING DROP",7.4,"1 uL protein solution (20 mg/mL in 20 mM Hepes pH 7.4, 150 mM NaCl) + 1 uL well solution (15% PEG 4000, 0.3 M AS), cryo: 15% PEG 4000, 0.3 M AS, 8% PEG 400",293.0,2021-12-01,2022-03-30,7QE9,4515.0,4.0,570.0,231.0,16.0,62.06,2.0,2.1,experimental,50.032,0.2336,0.1927,Human cationic trypsin (TRY1) complexed with serine protease inhibitor Kazal type 1 N34S (SPINK1 N34S)
4YQH,X-RAY DIFFRACTION,2.2,43.97,BATCH MODE,,"magnesium chloride, PEG3350",291.0,2015-03-13,2015-04-29,4YQH,5273.0,2.0,642.0,48.0,,75.1,1.0,2.308,experimental,55.643,0.3007,0.2362,2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10A
4YS7,X-RAY DIFFRACTION,2.2,44.09,BATCH MODE,,"PEG3350, magnesium chloride",291.0,2015-03-16,2015-04-29,4YS7,5229.0,2.0,644.0,22.0,,75.36,1.0,2.502,experimental,55.511,0.3205,0.2338,"Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3H-imidazo[4,5-f]quinoline (compound 39) with PDE10A"
5NIE,X-RAY DIFFRACTION,2.69,54.3,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% (w/v) PEG MME 5000, 100 mM MES monohydrate pH 6.0, 150 mM Ammonium Sulfate",294.0,2017-03-23,2017-08-23,5NIE,14690.0,3.0,1851.0,154.0,,210.52,1.0,2.603,experimental,56.83,0.2909,0.2351,Crystal structure of human LTA4H mutant R563A in open conformation
8VLB,X-RAY DIFFRACTION,4.11,70.05,"VAPOR DIFFUSION, HANGING DROP",,"0.2M SODIUM CITRATE, 0.1M BIS-TRIS-PROPANE PH 6.5, 20% PEG3350",294.0,2024-01-11,2024-03-13,8VLB,4356.0,4.0,577.0,5.0,,66.49,4.0,2.9,experimental,,0.2581,0.208,Crystal structure of EloBC-VHL-CDO1 complex bound to compound 4 molecular glue
6F4O,X-RAY DIFFRACTION,2.33,47.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 15.0 % PEG3350, 0.002 M MnCl2, 300 nl sitting drops (sample:well, 2:1 ratio)",298.0,2017-11-29,2018-04-04,6F4O,2450.0,1.0,255.0,312.0,,29.9,1.0,1.28,experimental,26.0,0.1744,0.1457,Human JMJD5 in complex with Mn(II) and Succinate.
5AHO,X-RAY DIFFRACTION,3.22,61.82,,,0.4M K/NA(TART),,2015-02-06,2015-02-18,5AHO,2794.0,1.0,336.0,233.0,,38.7,1.0,2.16,experimental,,0.2257,0.2059,Crystal structure of human 5' exonuclease Apollo
8QMZ,X-RAY DIFFRACTION,2.04,39.79,"VAPOR DIFFUSION, SITTING DROP",7.0,"20% PEG6000, 10% ethylene glycol, 0.1M HEPES pH 7.0, 0.1M calcium chloride",293.0,2023-09-25,2024-02-14,8QMZ,11567.0,4.0,1468.0,841.0,,170.67,1.0,1.47,experimental,21.377,0.21408,0.18752,Soluble epoxide hydrolase in complex with RK4
6ENC,X-RAY DIFFRACTION,2.43,49.36,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1    SODIUM ACETATE, 0.005 M YBCL3",298.0,2017-10-04,2017-12-13,6ENC,5594.0,1.0,613.0,691.0,,70.42,1.0,1.95,experimental,26.31,0.1946,0.1607,LTA4 hydrolase in complex with Compound11
6END,X-RAY DIFFRACTION,2.43,49.36,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2017-10-04,2017-12-13,6END,5448.0,1.0,613.0,561.0,,70.31,1.0,2.24,experimental,24.82,0.2165,0.1629,LTA4 hydrolase in complex with Compound15
8QOW,X-RAY DIFFRACTION,2.4,48.82,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2023-09-29,2023-12-06,8QOW,5348.0,1.0,613.0,450.0,,70.45,1.0,2.35,experimental,22.87,0.2367,0.1815,LTA4 hydrolase in complex with compound 2(S)
8QPN,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2023-10-02,2023-12-06,8QPN,5434.0,1.0,613.0,539.0,,70.59,1.0,2,experimental,29.56,0.2234,0.1887,LTA4 hydrolase in complex with compound 6(S)
8QQ4,X-RAY DIFFRACTION,2.43,49.41,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2023-10-03,2023-12-06,8QQ4,5664.0,1.0,613.0,769.0,,70.59,1.0,1.6,experimental,22.58,0.1976,0.1734,LTA4 hydrolase in complex with compound 6(R)
5MW3,X-RAY DIFFRACTION,3.49,64.77,VAPOR DIFFUSION,,"1.4M K/Na tartrate, 0.1M Hepes pH6.6",293.0,2017-01-18,2017-03-22,5MW3,5584.0,2.0,668.0,374.0,,78.24,1.0,2.09,experimental,43.82,0.1926,0.1746,"Crystal structure of Dot1L in complex with inhibitor CPD1 [N6-(2,6-dichlorophenyl)-N6-(pent-2-yn-1-yl)quinoline-4,6-diamine] and inhibitor CPD2 [(R)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine]"
6JD8,X-RAY DIFFRACTION,1.8,31.66,VAPOR DIFFUSION,,"PEG 4000, 2-propanol",293.0,2019-01-31,2020-02-05,6JD8,2878.0,1.0,360.0,230.0,5.0,41.88,1.0,1.457,experimental,31.3457,0.2369,0.1916,Structure of a proline specific mutant of human cathepsin L
5DH4,X-RAY DIFFRACTION,1.98,37.9,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298.0,2015-08-29,2016-01-27,5DH4,5197.0,2.0,690.0,83.0,1.0,80.33,1.0,2.2,experimental,57.67,0.2325,0.2032,"PDE10 complexed with 5-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine"
5DH5,X-RAY DIFFRACTION,2.07,40.65,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298.0,2015-08-29,2016-01-27,5DH5,5406.0,2.0,690.0,167.0,,80.14,1.0,2,experimental,49.01,0.2325,0.2017,"PDE10 complexed with N-[(1-methylpyrazol-4-yl)methyl]-5-[[(1S,2S)-2-(2-pyridyl)cyclopropyl]methoxy]pyrazolo[1,5-a]pyrimidin-7-amine"
5K9R,X-RAY DIFFRACTION,2.23,44.73,VAPOR DIFFUSION,8.9,Crystals of human C-His tagged 448-759 PDE10a were grown in 0.1 M Tris-HCl pH 8.9 with ~14% w/v PEG 3350 and 5 mM CaCl2,293.0,2016-06-01,2016-08-24,5K9R,5157.0,2.0,624.0,59.0,1.0,73.4,1.0,2.7,experimental,37.883,0.32212,0.23646,PDE10a with imidazopyrazine inhibitor
4QMO,X-RAY DIFFRACTION,2.56,52.01,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM C16, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMO,2605.0,1.0,310.0,248.0,,35.66,1.0,1.898,experimental,,0.2044,0.1648,MST3 IN COMPLEX WITH Imidazolo-oxindole PKR inhibitor C16
6ST3,X-RAY DIFFRACTION,2.62,53.0,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M Ammonium acetate, 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 30% PEG 4000, Sitting drop (300 nl), protein-to-well ratio, 1:2, 293K",293.0,2019-09-10,2019-12-04,6ST3,3397.0,2.0,466.0,130.0,,53.05,1.0,2.426,experimental,49.777,0.2173,0.1924,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with 4-hydroxy-N-(4-phenoxybenzyl)-2-(1H-pyrazol-1-yl)pyrimidine-5-carboxamide
8SW6,X-RAY DIFFRACTION,2.67,53.93,VAPOR DIFFUSION,7.0,"0.1 M HEPES, pH 7.0, 0.1 M lithium sulfate, 30% w/v polyvinylpyrrolidone",289.0,2023-05-17,2024-05-29,8SW6,5698.0,4.0,684.0,530.0,,79.71,2.0,1.76,experimental,,0.2079,0.1746,Protein Phosphatase 1 in complex with PP1-specific Phosphatase targeting peptide (PhosTAP) version 3
5CVG,X-RAY DIFFRACTION,1.78,31.05,"VAPOR DIFFUSION, HANGING DROP",6.5,"92mM Mes pH 6.5, 33% glycerol ethoxylate, 750mM ammonium acetate",298.0,2015-07-26,2016-07-27,5CVG,3149.0,1.0,351.0,301.0,,41.62,1.0,1.25,experimental,18.75,0.1698,0.1532,Crystal Structure of CK2alpha with a novel closed conformation of the aD loop
5OTS,X-RAY DIFFRACTION,1.99,38.33,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-09-05,5OTS,3067.0,1.0,342.0,196.0,,41.98,1.0,1.9,experimental,29.65,0.2449,0.2029,The crystal structure of CK2alpha in complex with an analogue of compound 22
6A43,X-RAY DIFFRACTION,3.29,62.62,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.0M sodium acetate, 10mM ammonium sulfate, 1% Jeffamine M600",283.0,2018-06-19,2018-10-24,6A43,2930.0,1.0,300.0,59.0,,33.41,1.0,2.4,experimental,47.37,0.241,0.206,R1EN(5-225)-ubiquitin fusion
6A44,X-RAY DIFFRACTION,3.3,62.78,"VAPOR DIFFUSION, HANGING DROP",7.3,"2.0 M sodium acetate, 10 mM ammonium sulfate, 1% Jeffamine M600",283.0,2018-06-19,2018-10-24,6A44,2960.0,1.0,302.0,92.0,,33.6,1.0,2.4,experimental,51.19,0.237,0.189,R1EN(5-227)-ubiquitin fusion
5QQP,X-RAY DIFFRACTION,3.44,64.27,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2019-05-20,2019-09-18,5QQP,2143.0,1.0,244.0,226.0,4.0,28.74,1.0,2.08,experimental,21.76,0.19,0.162,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-1-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate"
5QTT,X-RAY DIFFRACTION,3.45,64.34,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277.0,2019-10-16,2019-12-25,5QTT,2126.0,1.0,244.0,175.0,4.0,28.99,1.0,2.23,experimental,25.59,0.226,0.185,"FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[5-amino-1-(3-chloro-2-fluorophenyl)-1H-pyrazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate"
8BJH,X-RAY DIFFRACTION,2.24,45.18,"VAPOR DIFFUSION, HANGING DROP",8.5,"30% PEG4000 0.2M LISO4 0.1M TRIS PH8.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2022-11-04,2023-09-20,8BJH,7980.0,2.0,966.0,958.0,,109.02,2.0,1.69,experimental,34.97,0.2118,0.1783,"chimera of the inactive ExoY Nucleotidyl Cyclase domain from Vibrio nigripulchritudo MARTX toxin, with the double mutation K3528M and K3535I, fused to a proline-Rich-Domain (PRD) and profilin, bound to Latrunculin B-ADP-Mg-actin"
8BJI,X-RAY DIFFRACTION,2.25,45.36,EVAPORATION,8.5,"30% peg 4000, 0.2 M Lithium Sulfate (LiSO4), 0.1 M TrisHCl pH8.5",293.0,2022-11-04,2023-09-20,8BJI,7926.0,2.0,966.0,944.0,,109.14,2.0,1.75,experimental,30.28,0.2121,0.1753,"chimera of ExoY Nucleotidyl Cyclase domain from Vibrio nigripulchritudo fused to a proline-Rich-Domain (PRD) and profilin, bound to ADP-Mg-actin and a sulfate ion"
7LW7,X-RAY DIFFRACTION,2.63,53.24,"VAPOR DIFFUSION, HANGING DROP",,20% PEG 3350 and 0.2 M lithium acetate,293.0,2021-02-27,2021-07-14,7LW7,2357.0,1.0,346.0,89.0,,39.67,1.0,2.5,experimental,41.6189,0.2245,0.1821,Human Exonuclease 5 crystal structure
4XBR,X-RAY DIFFRACTION,4.8,74.39,IN CELL,,In cellulo growth,310.15,2014-12-17,2015-12-02,4XBR,2536.0,1.0,366.0,,,41.8,1.0,2.94,experimental,71.705,0.22973,0.18909,In cellulo Crystal Structure of PAK4 in complex with Inka
5SF0,X-RAY DIFFRACTION,2.59,52.54,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF0,10774.0,4.0,1372.0,470.0,4.0,159.51,1.0,2.1,experimental,37.396,0.2421,0.1972,Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(3-pyridin-2-yl-1H-pyrazol-5-yl)pyrazole-3-carboxamide
6K2C,X-RAY DIFFRACTION,3.54,65.26,VAPOR DIFFUSION,,"100mM HEPES 7.5, 20% PEG 10000",296.0,2019-05-14,2020-03-04,6K2C,2362.0,1.0,393.0,23.0,,44.58,1.0,2.703,experimental,,0.2773,0.2373,Extended Hect domain of UBE3C E3 Ligase
5YV8,X-RAY DIFFRACTION,3.19,61.49,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium cacodylate (pH 6.0), 0.2M Sodium acetate, 22% PEG 8000, 0.03M glycyl-glycyl-glycine",293.0,2017-11-24,2018-12-05,5YV8,2419.0,1.0,298.0,277.0,,34.4,1.0,1.927,experimental,,0.2126,0.1637,Structure of CaMKK2 in complex with CKI-002
8TUC,X-RAY DIFFRACTION,2.62,49.22,"VAPOR DIFFUSION, HANGING DROP",6.5,"2.0 M (NH4)2S04, 2 M NaCl, 0.1 NaCacodylate",293.0,2023-08-16,2023-12-13,8TUC,2614.0,1.0,291.0,318.0,1.0,34.0,1.0,1.5,experimental,25.645,0.20678,0.16692,Unphosphorylated CaMKK2 in complex with CC-8977
6OJU,X-RAY DIFFRACTION,2.39,48.5,"VAPOR DIFFUSION, SITTING DROP",5.0,"Well solution 0.1 M Na Acetate, 1.55 M Na formate
Seed Solution (diluted 50:1) 0.2 M MgCl2, 20 % PEG 3350 
Drop ratio 3:2:1 Enzyme mix/well solution/ seed solution",295.15,2019-04-12,2019-06-19,6OJU,8992.0,4.0,1160.0,34.0,,135.64,1.0,2.884,experimental,,0.2494,0.2131,"Crystal structure of human thymidylate synthase Delta (7-29) in complex with dUMP and 2-amino-4-oxo-4,7-dihydro-pyrrolo[2,3-d]pyrimidine-methyl-phenyl-D-glutamic acid"
5D9Y,X-RAY DIFFRACTION,2.42,49.12,"VAPOR DIFFUSION, HANGING DROP",6.3,"21% PEGMME2000, 0.1M MES",277.0,2015-08-19,2015-11-04,5D9Y,4041.0,3.0,486.0,262.0,,59.15,1.0,1.971,experimental,33.6166,0.2482,0.2051,Crystal structure of TET2-5fC complex
5L9R,X-RAY DIFFRACTION,2.49,50.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES-Na pH 7.5, 2% v/v Polyethylene glycol 400, 2.0 M ammonium sulfate",293.0,2016-06-10,2016-08-31,5L9R,1917.0,1.0,252.0,132.0,,28.9,1.0,1.81,experimental,42.0,0.188,0.1561,HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with N-oxalylglycine (NOG)
6YA8,X-RAY DIFFRACTION,2.17,43.2,"VAPOR DIFFUSION, HANGING DROP",6.57,"0.1M MMT pH 6.57, 21% PEG 1500, 15% v/v Acetonitrile, 20mM MgCl2",291.15,2020-03-11,2020-05-27,6YA8,3917.0,2.0,503.0,302.0,,57.91,2.0,1.79,experimental,26.29,0.197,0.1656,Cdc7-Dbf4 bound to ADP-BeF3
6VZH,X-RAY DIFFRACTION,2.58,52.31,"VAPOR DIFFUSION, SITTING DROP",6.5,"27.5% PEG3350, 300 mM lithium sulfate, 0.1 M sodium tartrate, 0.1 M Bis-Tris, 0.1 M glycylglycine, cryoprotectant: 30% glycerol",293.0,2020-02-28,2020-03-11,6VZH,9695.0,4.0,1456.0,32.0,,166.2,1.0,2.55,experimental,63.234,0.2514,0.2157,Structure of Human Vaccinia-related Kinase 1 (VRK1) Bound to LDSM311
7BXG,X-RAY DIFFRACTION,2.73,54.96,VAPOR DIFFUSION,,"0.1 M sodium malonate, pH 7.0, 12% PEG3350",293.0,2020-04-19,2020-05-20,7BXG,4872.0,3.0,616.0,75.0,,69.91,3.0,2.705,experimental,42.6374,0.2432,0.1929,MavC-UBE2N-Ub complex
5NI4,X-RAY DIFFRACTION,2.39,48.57,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 20 000, 15% (w/v) PEG MME 550, 100 mM MES/imidazole pH 6.9, 20 mM of each alcohol (1,6-hexanediol, 1-butanol, (RS)-1,2-propanediol, 2-propanol, 1,4-butanediol, 1,3-propanediol)",294.0,2017-03-23,2017-08-23,5NI4,17165.0,3.0,1851.0,2082.0,,212.04,1.0,1.895,experimental,,0.2,0.1615,Crystal structure of human LTA4H mutant E271A in complex with LTA4 (crystal form II)
6WIC,X-RAY DIFFRACTION,2.45,49.74,"VAPOR DIFFUSION, SITTING DROP",5.6,"40-45.5 mM MES, pH 5.6, 0.16-0.182 M potassium chloride, 8.2-9.1 mM magnesium sulfate, 8.2-9.1% w/v PEG400",277.0,2020-04-09,2020-10-07,6WIC,3476.0,5.0,373.0,355.0,,46.18,1.0,1.55,experimental,24.42,0.1794,0.1655,Pre-catalytic quaternary complex of human Polymerase Mu on a complementary DNA double-strand break substrate
7R59,X-RAY DIFFRACTION,2.15,42.81,"VAPOR DIFFUSION, SITTING DROP",,100 mM Tris pH 9.5 and 20% PEG 3350,277.0,2022-02-10,2023-01-25,7R59,2981.0,1.0,351.0,199.0,,40.18,1.0,2,experimental,25.79,0.2378,0.187,PARP2 catalytic domain in complex with OUL245
5UX6,X-RAY DIFFRACTION,2.79,55.98,"VAPOR DIFFUSION, HANGING DROP",5.0,"16.5% v/v PEG3350, 0.05% w/v octyl-beta-D-glucoside, 0.5% v/v glycerol, and 100 mM sodium citrate pH 5.0",277.0,2017-02-22,2017-04-05,5UX6,6301.0,2.0,734.0,632.0,8.0,84.28,1.0,2.09,experimental,,0.228,0.182,Structure of Human POFUT1 in its apo form
4RI4,X-RAY DIFFRACTION,2.27,45.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM Tris-HCl, 25% PEG 8000, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-10-05,2015-03-11,4RI4,5141.0,2.0,612.0,535.0,,70.03,1.0,1.596,experimental,,0.1886,0.1631,Crystal structure of PTPN3 (PTPH1) Y676I mutant in complex with vanadate
8WXZ,X-RAY DIFFRACTION,2.09,41.15,"VAPOR DIFFUSION, SITTING DROP",,"0.12M monosaccharides, 0.1M imidazole/MES monohydrate pH 6.5, 20% v/v PEG 500, 10% w/v PEG 20000",293.15,2023-10-30,2024-08-07,8WXZ,9257.0,2.0,1173.0,301.0,,137.15,2.0,2.3,experimental,41.73,0.2505,0.2048,Falcilysin in complex with hemoglobin beta chain peptide
6UVV,X-RAY DIFFRACTION,2.6,52.64,VAPOR DIFFUSION,7.4,"100mM Sodium Cacodylate pH 7.4, 12% PEG 8K, 200mM Ammonium Sulfate",277.0,2019-11-04,2019-12-11,6UVV,7555.0,2.0,884.0,1199.0,6.0,99.38,1.0,1.63,experimental,19.656,0.1862,0.1411,BACE-1 in complex with compound #17
6TX3,X-RAY DIFFRACTION,4.05,69.63,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M MES pH 6, 25% v/v pentaerythritol propoxylate (5/4 PO/OH)",293.0,2020-01-13,2020-02-19,6TX3,4518.0,2.0,598.0,,,68.97,2.0,2.96,experimental,154.0346,0.2596,0.2292,HPF1 bound to catalytic fragment of PARP2
4Z8M,X-RAY DIFFRACTION,2.55,51.68,"VAPOR DIFFUSION, SITTING DROP",6.0,"6% (v/v) Tacsimate pH 6.0, 0.1 M MES pH 6.0, and 25% (w/v) polyethylene glycol 4000",291.0,2015-04-09,2015-09-23,4Z8M,2535.0,4.0,376.0,,,43.66,2.0,2.95,experimental,,0.2379,0.1865,Crystal structure of the MAVS-TRAF6 complex
5OOI,X-RAY DIFFRACTION,2.4,48.69,"VAPOR DIFFUSION, SITTING DROP",,"90 MIKROLITER ENZYME STOCK SOLUTION (5
MG/ML IN 500 MM NACL, 25 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 10
MIKROLITER 4P STOCK SOLUTION (10 MM 4P IN DMSO). THIS
MIXTURE WAS INCUBATED FOR 30 MIN AT ROOM TEMPERATURE. THE
RESERVOIR SOLUTION OF THE CRYSTALLIZATION EXPERIMENT WAS 25 % (W/
V) PEG3350, 0.2 M AMMONIUM ACETATE, 0.1 M HEPES BUFFER, PH 8.5.
PRIOR TO EQUILIBRATION THE CRYSTALLIZATION DROP WAS COMPOSED OF
1 MIKROLITER RESERVOIR SOLUTION PLUS 1 MIKROLITER ENZYME/4P
MIXTURE., VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-07,2017-12-27,5OOI,6050.0,2.0,728.0,443.0,,86.93,1.0,1.998,experimental,,0.2211,0.1738,STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA') IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
5JUW,X-RAY DIFFRACTION,3.58,65.68,"VAPOR DIFFUSION, SITTING DROP",4.6,"1.5 M ammonium sulfate, 0.1 M ammonium acetate",291.0,2016-05-10,2016-06-22,5JUW,2711.0,1.0,421.0,62.0,,48.39,1.0,2.28,experimental,46.253,0.2153,0.1886,complex of Dot1l with SS148
5KZ0,X-RAY DIFFRACTION,2.09,41.19,"VAPOR DIFFUSION, HANGING DROP",,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. EQUAL VOLUMES OF PURIFIED PROTEIN SOLUTION(APPROXIMATELY 13-15 MG/ML)CONTAINING 0.0011M INHIBITOR COMPOUND WERE COMBINED WITH A SOLUTION CONTAINING:  0.15M AMMONIUM SULFATE, 9-10.5% MONOMETHYLETHER PEG5K AND 0.1M MES IN THE PH RANGE 5.3-6.5",286.0,2016-07-22,2016-08-17,5KZ0,2527.0,1.0,327.0,196.0,,37.31,1.0,2.3,experimental,25.4667,0.2689,0.1805,"Structure of Human Anaplastic Lymphoma Kinase in Complex With 2-[(1R)-1-{[2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl]oxy}ethyl]-4-fluoro-N,N-dimethylbenzamide"
7JYT,X-RAY DIFFRACTION,2.41,48.89,VAPOR DIFFUSION,,"20 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 1 mM Benzamidine and 0.25 mM TCEP",293.0,2020-08-31,2021-01-20,7JYT,2320.0,1.0,322.0,63.0,,36.3,1.0,2,experimental,,0.2244,0.2077,hALK in complex with 3-(3-methyl-1H-pyrazol-5-yl)pyridine
7U5B,X-RAY DIFFRACTION,3.04,59.48,"VAPOR DIFFUSION, SITTING DROP",,"15% PEG4K, 0.1 M MgSO4 and 0.1 M sodium citrate pH 5.0",298.0,2022-03-02,2022-12-14,7U5B,9140.0,6.0,1336.0,122.0,15.0,145.87,3.0,2.371,experimental,75.722,0.2704,0.2216,Structure of Human KLK5 bound to anti-KLK5 Fab
7OJX,X-RAY DIFFRACTION,3.1,60.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"Crystals were grown in: 0.2 M sodium citrate, 0.1 M Bis Tris propane 7.5 and 20 % (w/v) PEG 3350. The crystallization drops were set as a 1:1 mixture of the protein complex solution and the precipitant solution.",292.0,2021-05-17,2022-01-12,7OJX,3739.0,5.0,512.0,50.0,,57.99,5.0,2.4,experimental,94.6641,0.236,0.1878,"E2 UBE2K covalently linked to donor Ub, acceptor di-Ub, and RING E3 primed for K48-linked Ub chain synthesis"
7SCD,X-RAY DIFFRACTION,3.01,59.1,"VAPOR DIFFUSION, SITTING DROP",,"0.2M ammonium tartrate, 20% (w/v) PEG3350",295.0,2021-09-27,2022-01-19,7SCD,3012.0,1.0,372.0,8.0,2.0,44.76,1.0,2.9,experimental,51.15,0.2524,0.2082,Ternary complex of fixed-arm Trx-3ost5 (I299E) with 8mer-1 octasaccharide substrate and co-factor product PAP
7SCE,X-RAY DIFFRACTION,2.9,57.6,"VAPOR DIFFUSION, SITTING DROP",4.6,"85mM sodium acetate pH 4.6, 0.17M ammonium acetate, 25.5% (w/v) PEG4000, 15% (v/v) ethylene glycol",295.0,2021-09-27,2022-01-19,7SCE,3060.0,1.0,372.0,53.0,2.0,44.84,1.0,2.75,experimental,31.26,0.246,0.1879,Ternary complex of fixed-arm Trx-3ost5 (I299E) with 8mer-2 octasaccharide substrate and co-factor product PAP
5H1Y,X-RAY DIFFRACTION,2.19,38.8,"VAPOR DIFFUSION, HANGING DROP",,"0.2M ammonium sulfate, 25% PEG 3,350, 0.1M Bis-Tris, pH 6.5",289.15,2016-10-13,2017-01-18,5H1Y,4028.0,2.0,562.0,158.0,,63.68,1.0,2.26,experimental,,0.2328,0.1857,Crystal structure of the DDX41 DEAD domain in complex with SO42- and Mg2+
5A3N,X-RAY DIFFRACTION,2.07,40.7,,8.0,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,2015-06-02,2015-07-08,5A3N,4159.0,1.0,481.0,404.0,,56.84,1.0,2,experimental,36.565,0.20335,0.18281,Crystal structure of human PLU-1 (JARID1B) in complex with KDOAM25a
6PJX,X-RAY DIFFRACTION,2.4,48.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"Sample- 25 mg/ml GRK5/CaM complex in buffer 20 mM Hepes, pH 7.2, 200 mM NaCl, 2 mM CaCl2, 1 mM DTT incubated with SGV in the presence of MgCl2.

Crystallization screening reservoir condition- 90% of (200 mM KCl, 50 mM Hepes pH 7.5, 30% 5/4 PO/OH) + 10% of (0.05% w/v L-Citrulline, 0.05% w/v Glycine, 0.05% w/v L-(-)-Threonine, 0.05% w/v L-(+)-Lysine, 0.05% w/v L-Alanine, 0.05% w/v L-Arginine, 0.05% w/v L-Asparagine monohydrate, 0.05% w/v L-Aspartic acid, 0.05% w/v L-Glutamic acid, 0.05% w/v L-Glutamine, 0.05% w/v L-Histidine, 0.05% w/v L-Isoleucine, 0.05% w/v L-Leucine, 0.05% w/v L-Methionine, 0.05% w/v L-Phenylalanine, 0.05% w/v L-Proline, 0.05% w/v L-Serine, 0.05% w/v L-Tryptophan, 0.05% w/v L-Tyrosine, 0.05% w/v L-Valine, 0.02 M HEPES sodium pH 6)",277.15,2019-06-28,2020-12-09,6PJX,5504.0,2.0,739.0,520.0,,85.08,2.0,1.96,experimental,35.47,0.23,0.196,Crystal Structure of G Protein-Coupled Receptor Kinase 5 (GRK5) in Complex with Calmodulin (CaM)
5IUI,X-RAY DIFFRACTION,2.12,42.05,"VAPOR DIFFUSION, SITTING DROP",8.6,"18% PEG 2000 MME, 0.1M Tris-HCl pH 8.6",277.0,2016-03-18,2016-05-18,5IUI,2578.0,1.0,327.0,186.0,,37.24,1.0,1.88,experimental,30.3485,0.2051,0.1794,Crystal Structure of Anaplastic Lyphoma Kinase (ALK) in complex with 4
6EDL,X-RAY DIFFRACTION,2.12,42.07,VAPOR DIFFUSION,,"20 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 1 mM Benzamidine and 0.25 mM TCEP",278.0,2018-08-09,2019-05-01,6EDL,2226.0,1.0,322.0,14.0,,36.4,1.0,2.799,experimental,,0.2824,0.227,"hALK in complex with compound 1 (S)-N-(1-(2,4-difluorophenyl)ethyl)-3-(3-methyl-1H-pyrazol-5-yl)imidazo[1,2-b]pyridazin-6-amine"
7JY4,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, SITTING DROP",,"18.25% PEG 3350, 2% Tacsimate pH 7.0, 0.09M Tris Cl, 0.01M Tris_base",293.0,2020-08-28,2021-01-20,7JY4,2354.0,1.0,322.0,37.0,,36.89,1.0,2.42,experimental,62.31,0.2554,0.2191,"hALK in complex with ((1S,2S)-1-(2,4-difluorophenyl)-2-(2-(3-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenoxy)cyclopropyl)methanamine"
7JYS,X-RAY DIFFRACTION,2.11,41.81,VAPOR DIFFUSION,8.0,"25 mM Tris pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 0.25 mM TCEP",293.0,2020-08-31,2021-01-20,7JYS,2306.0,1.0,322.0,55.0,,36.3,1.0,2.22,experimental,55.83,0.2528,0.2141,hALK in complex with 3-(3-chlorophenyl)-5-methyl-1H-pyrazole
5BXU,X-RAY DIFFRACTION,1.91,35.63,"VAPOR DIFFUSION, SITTING DROP",7.5,1.60 M tri-sodium citrate,292.0,2015-06-09,2016-06-29,5BXU,1576.0,2.0,173.0,161.0,,18.89,2.0,1.35,experimental,15.263,0.18634,0.15619,Human Tankyrase-2 in Complex with Macrocyclised Extended Peptide cp4n4m5
7UJV,X-RAY DIFFRACTION,1.7,27.68,"VAPOR DIFFUSION, HANGING DROP",7.5,32.5% (w/v) PEG 2000 MME,293.0,2022-03-31,2023-04-05,7UJV,2014.0,2.0,271.0,108.0,,30.42,2.0,1.8,experimental,29.036,0.2134,0.173,Structure of PHD2 in complex with HIF2a-CODD
6AY2,X-RAY DIFFRACTION,2.43,49.41,VAPOR DIFFUSION,,as published,295.0,2017-09-07,2017-12-27,6AY2,4202.0,2.0,510.0,237.0,12.0,56.74,1.0,1.6,experimental,20.342,0.1765,0.1613,Structure of CathB with covalently linked Compound 28
5SDU,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SDU,10890.0,4.0,1372.0,594.0,4.0,159.39,1.0,2.15,experimental,35.769,0.2352,0.1926,"Crystal Structure of human phosphodiesterase 10 in complex with 5-methyl-4-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-2-phenyl-1,3-oxazole"
5SF8,X-RAY DIFFRACTION,2.63,53.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF8,10889.0,4.0,1372.0,561.0,4.0,159.84,1.0,2.15,experimental,41.426,0.2254,0.1712,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[2-(5-phenyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)ethyl]pyrazole-3-carboxamide"
5SFD,X-RAY DIFFRACTION,2.62,53.08,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFD,10686.0,4.0,1372.0,424.0,4.0,159.37,1.0,2.05,experimental,38.44,0.231,0.182,"Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-(2-methyl-5-piperidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine"
5SFH,X-RAY DIFFRACTION,2.64,53.42,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFH,10627.0,4.0,1372.0,342.0,4.0,159.32,1.0,2.29,experimental,49.806,0.2213,0.1738,"Crystal Structure of human phosphodiesterase 10 in complex with N-cyclopropyl-5-[2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-N,1-dimethyl-1,2,4-triazol-3-amine"
5SFT,X-RAY DIFFRACTION,2.62,53.14,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFT,10495.0,4.0,1372.0,228.0,4.0,159.32,1.0,2.32,experimental,51.566,0.228,0.1761,"Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-(1-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine"
5SFW,X-RAY DIFFRACTION,2.62,53.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFW,10698.0,4.0,1372.0,419.0,4.0,159.37,1.0,2.15,experimental,48.893,0.2406,0.1818,"Crystal Structure of human phosphodiesterase 10 in complex with 5-ethyl-8-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine"
8V3P,X-RAY DIFFRACTION,2.23,44.8,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M DL-Malic acid, pH7.0, 0.1 M imidazole, pH7.0, 16% PEG MME 550",294.0,2023-11-28,2024-07-17,8V3P,3739.0,2.0,539.0,69.0,,61.14,2.0,2.36,experimental,,0.2253,0.2146,CCP5 in complex with Glu-P-peptide 2 transition state analog
8X88,X-RAY DIFFRACTION,3.3,62.78,"VAPOR DIFFUSION, SITTING DROP",,"2.4M Sodium malonate dibasic monohydrate,7",293.0,2023-11-27,2023-12-13,8X88,4742.0,2.0,608.0,43.0,,69.61,1.0,2.7,experimental,80.368,0.2561,0.1981,The Crystal Structure of TNIK from Biortus.
6O5H,X-RAY DIFFRACTION,2.29,46.26,"VAPOR DIFFUSION, SITTING DROP",,50 - 80 mM magnesium formate dihydrate and 24% - 29% PEG3350,295.15,2019-03-03,2019-12-04,6O5H,15143.0,3.0,1824.0,356.0,,208.11,1.0,2.84,experimental,25.759,0.2286,0.2186,The effect of modifier structure on the activation of leukotriene A4 hydrolase aminopeptidase activity.
4UP1,X-RAY DIFFRACTION,3.29,62.6,,,25% PEG 4000 30MM AMMONIUM SULFATE 20MM B-MERCAPTOETHANOL 100MM TRIS-HCL PH 9,,2014-06-11,2015-06-24,4UP1,9191.0,4.0,1252.0,,,144.27,1.0,2.991,experimental,74.9,0.2444,0.2141,Crystal structure of native human Thymidylate synthase in active form
5GGN,X-RAY DIFFRACTION,2.51,51.09,"VAPOR DIFFUSION, HANGING DROP",8.8,"Tris-HCl, PEG-6000",293.0,2016-06-16,2016-08-10,5GGN,2947.0,2.0,328.0,562.0,,35.93,1.0,1.211,experimental,,0.1657,0.1439,"Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GlcNAc-beta-pNP"
5XFC,X-RAY DIFFRACTION,2.47,50.24,BATCH MODE,7.0,"HEPES-NaOH, PEG4000",293.0,2017-04-10,2017-08-30,5XFC,2559.0,2.0,328.0,171.0,,36.13,1.0,1.4,experimental,26.0766,0.2067,0.1704,"Serial femtosecond X-ray structure of a stem domain of human O-mannose beta-1,2-N-acetylglucosaminyltransferase solved by Se-SAD using XFEL (refined against 13,000 patterns)"
6RCT,X-RAY DIFFRACTION,3.13,60.7,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 10% ethylene glycol, 0.2M sodium nitrate",277.15,2019-04-11,2019-05-01,6RCT,6234.0,2.0,720.0,225.0,,86.22,1.0,2.32,experimental,57.63,0.2433,0.206,Crystal structure of CLK3 in complex with T3-CLK
6Z52,X-RAY DIFFRACTION,3.05,59.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"20.0% PEG 3350, 0.20M NaI, 0.1M bis-tris propane pH 7.5, 10.0% ethylene glycol",277.15,2020-05-26,2020-06-03,6Z52,6635.0,2.0,720.0,575.0,,88.13,1.0,2.12,experimental,22.885,0.2301,0.1779,Crystal structure of CLK3 in complex with macrocycle ODS2003136
6Z55,X-RAY DIFFRACTION,2.99,58.93,"VAPOR DIFFUSION, SITTING DROP",7.0,"18% PEG 3350, 0.2M potassium/sodium phosphate, 0.1M bis-tris-propane pH 7.0, 10% ethylene glycol",277.15,2020-05-26,2020-06-03,6Z55,7168.0,2.0,720.0,929.0,,87.41,1.0,1.7,experimental,26.552,0.195,0.1565,Crystal structure of CLK3 in complex with macrocycle ODS2004070
7C3Z,X-RAY DIFFRACTION,2.64,53.48,"VAPOR DIFFUSION, HANGING DROP",,"polyethylene glycol
3,350 and 0.2 M potassium nitrate at pH 6.8",293.15,2020-05-14,2021-05-19,7C3Z,894.0,1.0,127.0,56.0,,14.34,1.0,1.957,experimental,,0.2629,0.2343,The structure of class II tumor suppressor protein H-REV107
6QCB,X-RAY DIFFRACTION,3.01,59.08,"VAPOR DIFFUSION, HANGING DROP",,"25 % PEG 3350
0.2 lithium sulphate
0.1 Bis-Tris pH 5.5",291.15,2018-12-27,2020-01-29,6QCB,3152.0,2.0,338.0,323.0,5.0,38.91,2.0,1.55,experimental,22.435,0.18977,0.16637,Crystal structure of human cathepsin D in complex with macrocyclic inhibitor 9
5FWE,X-RAY DIFFRACTION,2.64,53.44,"VAPOR DIFFUSION, SITTING DROP",7.5,"SITTING DROPS, 277 K, 0.15 M POTASSIUM BROMIDE, 30 % W/V PEG 2000 MME, pH 7.5",277.0,2016-02-15,2016-04-06,5FWE,6188.0,4.0,792.0,391.0,,91.99,2.0,2.05,experimental,47.8,0.2551,0.2342,"JMJD2A COMPLEXED WITH NI(II), NOG AND HISTONE H4(1-15)R3me2s PEPTIDE"
8AE7,X-RAY DIFFRACTION,2.03,39.49,"VAPOR DIFFUSION, SITTING DROP",,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",293.0,2022-07-12,2023-03-29,8AE7,3207.0,1.0,328.0,339.0,,39.95,1.0,1.28,experimental,20.2,0.2317,0.204,The strucuture of Compound 15 bound to CK2alpha
6W2L,X-RAY DIFFRACTION,3.09,60.21,"VAPOR DIFFUSION, SITTING DROP",8.5,"2.5 mM MgCl2, 3.3 mM IPP, 0.1 M Bicine, 10% v/v 2-propanol, 22% PEG 1500",298.0,2020-03-06,2020-08-19,6W2L,4036.0,2.0,544.0,107.0,,63.06,2.0,2.306,experimental,72.717,0.255,0.2123,Crystal structure of human dehydrodolichyl diphosphate synthase (NgBR/DHDDS) in complex with Mg and IPP
9BKR,X-RAY DIFFRACTION,1.85,33.41,"VAPOR DIFFUSION, SITTING DROP",8.5,"25 % P3350, 0.2 M Mg Cl, 0.1 M Tris pH 8.5",291.0,2024-04-29,2024-07-31,9BKR,765.0,1.0,80.0,56.0,,9.62,1.0,1.4,experimental,20.478,0.20764,0.16196,Crystal structure of the Human TRIP12 WWE domain (isoform 2) in complex with ATP
6MO6,X-RAY DIFFRACTION,2.98,58.79,"VAPOR DIFFUSION, HANGING DROP",4.6,"500 uL reservoir of 20% (w/v) glycerol, 0.1 M sodium acetate trihydrate pH 4.6, 0.3-0.5 M ammonium acetate, 7-10% (w/v) PEG 4,000, 0.1% (w/v) 1,2-diheptanoyl-sn-glycero-3-phosphocholine (DHPC), 310 uM decylubiquinone (DCQ; stock in 10% (w/v) DHPC) and 10 mM sodium thiosulfate pentahydrate. To the coverslip; apply 1 uL aliquot of 10.66% (w/v) 1-Oleoyl-rac-glycerol (monoolein; stock in ethanol) and air dry for 3 minutes. Add 1uL enzyme followed by 1uL reservoir condition (no mixing).",298.0,2018-10-04,2019-04-10,6MO6,13533.0,4.0,1656.0,277.0,4.0,191.54,1.0,2.59,experimental,39.568,0.2449,0.1869,Crystal structure of the selenomethionine-substituted human sulfide:quinone oxidoreductase
6MP5,X-RAY DIFFRACTION,3.07,59.91,"VAPOR DIFFUSION, HANGING DROP",4.6,"14% (w/v) PEG 4000, 10% (w/v) glycerol, 0.1M sodium acetate trihydrate pH 4.6, 0.5M ammonium acetate + 0.1% (w/v) 1,2-diheptanoyl-sn-glycero-3-phosphocholine (DHPC). Apply 1uL protein then 1uL condition (no mixing) to coverslip and seal.",298.0,2018-10-05,2019-04-10,6MP5,13260.0,4.0,1652.0,28.0,4.0,188.4,1.0,2.99,experimental,69.2723,0.2642,0.2082,Crystal structure of native human sulfide:quinone oxidoreductase
6P6G,X-RAY DIFFRACTION,2.22,44.53,"VAPOR DIFFUSION, HANGING DROP",,"Sitting Drop, Linbro tray, room temp, reservoir is 10% PEG 3350, 0.2M MgOAc ,
protein:reservoir is 1:1,
streak seed
soaking: 2ul 20%PEG 3350, 0.4M MgOAc added to 2ul protein, mix and add 0.3ul to drop, store at 295",295.0,2019-06-03,2020-01-15,6P6G,3833.0,1.0,432.0,396.0,,50.97,1.0,1.59,experimental,23.7103,0.2002,0.1723,Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors
4XNH,X-RAY DIFFRACTION,2.45,49.71,"VAPOR DIFFUSION, HANGING DROP",,"14% PEG 400, 0.1 M MES, pH 6.0",291.0,2015-01-15,2016-07-20,4XNH,10132.0,4.0,1276.0,672.0,,149.79,4.0,2.1,experimental,,0.2277,0.1682,Crystal structure of yeast N-terminal acetyltransferase NatE (IP6) in complex with a bisubstrate
8HL6,X-RAY DIFFRACTION,2.44,49.67,"VAPOR DIFFUSION, HANGING DROP",,"20 % PEG 1000, 0.1 M Na/K phosphate (pH 6.2), and 0.2M sodium chloride",295.0,2022-11-29,2023-07-12,8HL6,1761.0,1.0,235.0,96.0,,27.06,1.0,1.8,experimental,,0.2262,0.1918,Crystal structure of human valosin-containing protein methyltransferase
7QI0,X-RAY DIFFRACTION,2.04,39.74,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.20 M trimethylamine N-oxide, 0.1 M Tris-HCl pH8.5, 20% PEG MME 2000",298.0,2021-12-14,2022-11-23,7QI0,3503.0,2.0,446.0,158.0,12.0,49.67,1.0,1.88,experimental,50.2576,0.2325,0.1904,Crystal structure of KLK6 in complex with compound DKFZ918
5FAH,X-RAY DIFFRACTION,2.12,41.92,"VAPOR DIFFUSION, HANGING DROP",,"0.5 microlitre Protein solution were mixed with 0.5 microlitre RESERVOIR solution. PROTEIN SOLUTION: 24.6 MG/ML KALLIKREIN 7, 50 MM SODIUM ACETATE PH 5.6, 100 MM NACL, 2 MM INHIBITOR, 1.8% DMSO, RESERVOIR SOLUTION: 35% PEG 3350, 100 MM SODIUM ACETATE PH 4.8, 200 MM CALCIUM CHLORIDE. CRYO: FLASH FREEZING IN LIQUID NITROGEN WITHOUT ADDITIONAL CRYO SOLUTION.",293.0,2015-12-11,2016-10-26,5FAH,1989.0,1.0,224.0,223.0,6.0,24.97,1.0,1.1,experimental,17.17,0.1965,0.1875,KALLIKREIN-7 IN COMPLEX WITH COMPOUND1
5KSE,X-RAY DIFFRACTION,3.29,62.56,"VAPOR DIFFUSION, HANGING DROP",,"22% mPEG 2000, 20% saturated KCl, 5% ethylene glycol, 100 mM HEPES pH 7.5",288.0,2016-07-08,2017-06-28,5KSE,3698.0,4.0,382.0,173.0,,51.73,1.0,2.105,experimental,,0.245,0.2075,Flap endonuclease 1 (FEN1) R100A with 5'-flap substrate DNA and Sm3+
5UM9,X-RAY DIFFRACTION,3.23,61.95,"VAPOR DIFFUSION, HANGING DROP",,"6% MPEG 2K, 10% KCl, 50 mM HEPES pH 7.5, 2.5% Ethylene glycol, 1.06 mM SmSO4",283.0,2017-01-26,2017-06-28,5UM9,3529.0,4.0,383.0,35.0,,52.1,1.0,2.805,experimental,122.3541,0.2659,0.2078,Flap endonuclease 1 (FEN1) D86N with 5'-flap substrate DNA and Sm3+
5Z2C,X-RAY DIFFRACTION,3.3,62.76,"VAPOR DIFFUSION, HANGING DROP",4.0,"1.4M sodium formate, 0.1M sodium acetate",293.0,2018-01-02,2018-08-22,5Z2C,30546.0,9.0,4014.0,,,451.49,1.0,2.594,experimental,,0.2628,0.242,Crystal structure of ALPK-1 N-terminal domain in complex with ADP-heptose
5K26,X-RAY DIFFRACTION,2.31,48.53,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Na-Phosphate, 0.1 M K-Phosphate, 0.1 M MES 6.5, 1.5 M NaCl",298.0,2016-05-18,2017-12-13,5K26,1373.0,2.0,172.0,123.0,,18.92,1.0,1.2,experimental,21.026,0.16826,0.13712,Structure of the SH3 domain of MLK3 bound to peptide generated from phage display
8PPD,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.83 M sodium citrate, 0.1M Tris pH 8.5 and 0.1 M NaCl. 
Protein:precipitant ratio 1:1. 
Protein concentration: 18 mg/ml. 
Protein buffer: 20 mM Tris pH 7.5, 50 mM ammonium sulfate and 2 mM DTT. 
Soaking 2h with 1.5 M lithium sulfate, 0.1 M Tris pH 8.5, 10 mM ligand, 3 mM ATP and 3 mM MnCl2.",291.0,2023-07-07,2024-02-28,8PPD,4751.0,2.0,558.0,286.0,,66.42,1.0,1.77,experimental,39.839,0.23047,0.20191,"Human inositol 1,4,5-trisphosphate 3-kinase A (IP3K) catalytic domain in complex with DL-6-deoxy-6-hydroxy-methyl-scyllo-inositol 1,2,4-trisphosphate/ATP/Mn"
5M4U,X-RAY DIFFRACTION,3.32,62.99,"VAPOR DIFFUSION, SITTING DROP",6.5,"PROTEIN STOCK SOLUTION: 5.5 MG/ML CK2ALPHA'D39G-C336S IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5; 

INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO;

PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION;

RESERVOIR SOLUTION: 25 % PEG5000 MME, 0.2 M ammonium sulphate, 0.1 M MES buffer, pH 6.5; 

DROP SOLUTION BEFORE EQULIBRATION: 0.3 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.3 MICROLITER RESERVOIR SOLUTION",277.0,2016-10-19,2017-01-18,5M4U,3175.0,1.0,364.0,315.0,,43.94,1.0,2.195,experimental,,0.214,0.1704,"ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA') WITH THE INHIBITOR 4'-CARBOXY-6,8-CHLORO- FLAVONOL (FLC21)"
7XZR,X-RAY DIFFRACTION,3.07,59.89,"VAPOR DIFFUSION, SITTING DROP",,"ammonium acetate, MgSO4, Hepes-Na, PEG smear medium",298.0,2022-06-03,2022-10-26,7XZR,5337.0,4.0,648.0,186.0,,75.45,2.0,2.26,experimental,,0.226,0.182,Crystal structure of TNIK-AMPPNP-thiopeptide TP15 complex
7MNI,X-RAY DIFFRACTION,2.08,40.93,"VAPOR DIFFUSION, HANGING DROP",8.3,"20% w/v PEG4000, 0.22 M sodium chloride, 0.1 M Tris",294.0,2021-05-01,2022-06-15,7MNI,9442.0,4.0,1294.0,418.0,,143.79,2.0,2,experimental,61.7063,0.2084,0.1752,Crystal structure of the N-terminal domain of NUP88 in complex with NUP98 C-terminal Autoproteolytic Domain
4UF0,X-RAY DIFFRACTION,2.83,56.56,,6.5,"25% PEG3350, 0.1M BIS-TRIS PH 6.5",,2014-12-22,2015-01-14,4UF0,7696.0,2.0,956.0,488.0,,112.12,2.0,1.78,experimental,36.64,0.21517,0.14857,Crystal structure of JmjC domain of human histone demethylase UTY in complex with epitherapuetic compound 2-(((2-((2-(dimethylamino)ethyl) (ethyl)amino)-2-oxoethyl)amino)methyl)isonicotinic acid.
6CBX,X-RAY DIFFRACTION,2.19,43.85,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 0.2 M NH4SO4",291.0,2018-02-05,2018-03-14,6CBX,7344.0,2.0,868.0,366.0,,101.47,1.0,1.94,experimental,31.655,0.2229,0.1797,Crystal structure of human SET and MYND Domain Containing protein 2 with MTF1497
4N6O,X-RAY DIFFRACTION,2.4,48.85,"VAPOR DIFFUSION, SITTING DROP",6.5,"25 % PEG 4000, 
100 mM MES pH 6.5, 
200 mM potassium iodide, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2013-10-14,2015-02-11,4N6O,3359.0,2.0,409.0,279.0,1.0,48.21,2.0,1.8,experimental,24.407,0.2307,0.2087,Crystal structure of reduced legumain in complex with cystatin E/M
4XVU,X-RAY DIFFRACTION,2.25,45.36,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 25 mM succinic acid pH 7.0",298.0,2015-01-28,2015-03-18,4XVU,23945.0,14.0,3278.0,808.0,19.0,359.09,4.0,2.35,experimental,67.0967,0.2335,0.1971,Structure of Get3 bound to the transmembrane domain of Nyv1
8EI4,X-RAY DIFFRACTION,2.56,51.97,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M Sodium acetate, 0.1 M Sodium citrate pH 5.5, 5% w/v PEG 4000",291.0,2022-09-14,2023-10-25,8EI4,3210.0,2.0,395.0,35.0,,46.77,2.0,2.43,experimental,45.5991,0.2808,0.2192,"Crystal structure of the WWP1 HECT domain in complex with H302, a Helicon Polypeptide"
5E3C,X-RAY DIFFRACTION,2.54,51.65,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.056 Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic",293.0,2015-10-02,2016-04-13,5E3C,5835.0,2.0,731.0,29.0,,82.38,2.0,2.765,experimental,56.3,0.2528,0.204,Structure of human DPP3 in complex with hemorphin like opioid peptide IVYPW
5EHH,X-RAY DIFFRACTION,2.49,50.66,VAPOR DIFFUSION,8.2,"0.056 M Sodium phosphate monobasic monohydrate, 1.344 M Potassium phosphate dibasic, pH-8.2.",293.15,2015-10-28,2016-04-13,5EHH,6061.0,2.0,731.0,270.0,,82.27,2.0,2.38,experimental,37.4,0.237,0.1938,Structure of human DPP3 in complex with endomorphin-2.
5NGV,X-RAY DIFFRACTION,2.78,55.81,VAPOR DIFFUSION,5.4,"0.1M PHOSPHATE-CITRATE, 40% PEG 300",293.0,2017-03-20,2017-11-15,5NGV,2662.0,3.0,339.0,174.0,7.0,37.74,3.0,2,experimental,43.57,0.1982,0.1768,"CRYSTAL STRUCTURE OF THE Activin receptor type-2B LIGAND BINDING DOMAIN IN COMPLEX WITH BIMAGRUMAB FV, ORTHORHOMBIC CRYSTAL FORM"
8QN0,X-RAY DIFFRACTION,2.05,39.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"20% PEG5000MME, 0.1M bis-tris pH 6.5",293.0,2023-09-25,2024-02-14,8QN0,5667.0,2.0,734.0,449.0,,85.21,1.0,1.49,experimental,23.368,0.18698,0.16342,Soluble epoxide hydrolase in complex with RK3
6VI1,X-RAY DIFFRACTION,2.75,55.19,VAPOR DIFFUSION,6.5,"100 mM KCl, 25 mM MgCl2, 50 mM Na-Cacodylate trihydrate pH 6.0, 15% (v/v) 2-propanol",292.0,2020-01-11,2020-09-02,6VI1,22166.0,18.0,2946.0,836.0,24.0,319.73,3.0,2.4,experimental,51.7492,0.2394,0.1887,Structure of Fab4 bound to P22 TerL(1-33)
6EDC,X-RAY DIFFRACTION,3.27,62.38,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M NaCl, 0.1 M HEPES, pH 7.5, and 28% PEG400 (v/v)",293.0,2018-08-09,2019-05-29,6EDC,3499.0,3.0,400.0,,,53.15,1.0,2.712,experimental,,0.2776,0.239,hcGAS-16bp dsDNA complex
7RWF,X-RAY DIFFRACTION,1.92,35.95,"VAPOR DIFFUSION, HANGING DROP",7.5,"4.5mg/mL, 15% Jeffamine ED-2001, 0.1M HEPES pH7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2021-08-19,2022-08-24,7RWF,2602.0,1.0,299.0,165.0,,34.51,1.0,1.5,experimental,21.0979,0.2093,0.1917,Crystal structure of CDK2 in complex with TW8672
7S84,X-RAY DIFFRACTION,2.06,40.36,"VAPOR DIFFUSION, HANGING DROP",,"4.5mg/mL CDK2 crystalized in 50mM Na/K phosphate, 50mM Hepes Na, pH7.5 5% v/v PEG3350, soaked for overnight in 5mM TW8972 in 0.1M HEPES Na pH7.5  10% v/v PEG3350",291.0,2021-09-17,2022-09-28,7S84,2386.0,1.0,298.0,136.0,,34.32,1.0,2,experimental,35.3359,0.2441,0.1968,Crystal structure of CDK2 liganded with compound TW8972
6QHC,X-RAY DIFFRACTION,2.42,49.07,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-01-16,2019-02-06,6QHC,3682.0,2.0,446.0,216.0,12.0,49.52,1.0,1.87,experimental,32.16,0.236,0.199,Crystal Structure of Human Kallikrein 6 in complex with GSK358180B
6MCP,X-RAY DIFFRACTION,2.78,55.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES, pH 7.5, 21% PEG600, 0.2 M sodium chloride, 20 mM succinate",288.0,2018-09-01,2019-09-04,6MCP,11356.0,4.0,1420.0,109.0,,169.02,2.0,2.5,experimental,74.9598,0.2333,0.1943,L. pneumophila effector kinase LegK7 (AMP-PNP bound) in complex with human MOB1A
5MAH,X-RAY DIFFRACTION,2.15,42.76,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1 M BIS TRIS pH 6.5, 0.6M NaCl",293.0,2016-11-03,2017-12-06,5MAH,2737.0,1.0,347.0,96.0,,40.9,1.0,2,experimental,38.418,0.23715,0.18284,Crystal structure of MELK in complex with an inhibitor
8RFM,X-RAY DIFFRACTION,2.58,52.41,BATCH MODE,8.5,"0.1 M Tris pH 8.5, 0.2 M sodium acetate, 20% polyethylene glycol (PEG) 3350",293.0,2023-12-13,2024-05-29,8RFM,9030.0,4.0,1096.0,17.0,,128.1,1.0,2.7,experimental,65.395,0.24254,0.19848,Human NOQ1 enzyme in complex with NADH by serial crystallography
8RFN,X-RAY DIFFRACTION,2.71,54.58,BATCH MODE,8.5,"0.1 M Tris pH 8.5, 0.2 M sodium acetate, 20% polyethylene glycol (PEG) 3350",293.0,2023-12-13,2024-05-29,8RFN,8996.0,4.0,1096.0,75.0,,127.01,1.0,2.5,experimental,69.291,0.23869,0.19873,Human NOQ1 enzyme in its holo form by serial crystallography
6E3Z,X-RAY DIFFRACTION,2.52,51.13,VAPOR DIFFUSION,6.25,"17% PEG-4000, 0.1 M MES",293.0,2018-07-16,2019-09-11,6E3Z,9893.0,3.0,1296.0,820.0,9.0,146.19,1.0,1.94,experimental,47.1521,0.2125,0.179,Structure of Bace-1 in complex with Ligand 8
6KDQ,X-RAY DIFFRACTION,2.19,43.85,VAPOR DIFFUSION,5.7,"0.2M Ammonium acetate, 0.1M Sodium citrate dehydrate pH 5.7, 31% w/v PEG 4000",291.0,2019-07-02,2020-07-08,6KDQ,4522.0,4.0,500.0,656.0,,57.75,2.0,1.499,experimental,20.2055,0.1803,0.1575,Crystal structure of human NRMT1 in complex with alpha-N-monomethylated human CENP-A peptide
6QY9,X-RAY DIFFRACTION,2.24,45.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2 M potassium nitrate",277.0,2019-03-08,2019-04-17,6QY9,3072.0,1.0,336.0,284.0,,40.5,1.0,1.5,experimental,20.652,0.16477,0.12504,"Human CSNK2A2 bound to a Pyrrolo[2,3-d]pyrimidinyl inhibitor"
6OOV,X-RAY DIFFRACTION,2.94,58.22,"VAPOR DIFFUSION, SITTING DROP",7.5,"11% PEG 8K, 0.1M CaCl2, 0.1M Hepes",293.0,2019-04-23,2019-05-15,6OOV,4531.0,4.0,578.0,82.0,1.0,71.24,1.0,2.2,experimental,55.49,0.2192,0.1936,Crystal structure of HMCES SRAP domain in complex with palindromic 3' overhang DNA
6EHK,X-RAY DIFFRACTION,1.93,36.42,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-09-13,2018-02-28,6EHK,3051.0,1.0,342.0,206.0,,41.48,1.0,1.4,experimental,24.56,0.1939,0.1778,The crystal structure of CK2alpha in complex with CAM4712 and compound 37
6BRU,X-RAY DIFFRACTION,3.07,59.88,"VAPOR DIFFUSION, SITTING DROP",7.0,"22% PEG3350, 0.02M Lithium Sulfate, 0.1M Buffer system SBG pH 7.0",293.0,2017-12-01,2017-12-13,6BRU,10984.0,4.0,1456.0,1013.0,,166.15,1.0,1.8,experimental,30.321,0.21426,0.19455,Crystal Structure of the Human vaccinia-related kinase bound to a (S)-2-phenylaminopteridinone inhibitor
7S46,X-RAY DIFFRACTION,2.11,41.77,"VAPOR DIFFUSION, HANGING DROP",,0.1 M Tris-HCl (pH 8.5) and 0.5 M tri-sodium citrate,293.0,2021-09-08,2022-11-09,7S46,2444.0,2.0,357.0,67.0,,40.95,2.0,2.1,experimental,47.78,0.2197,0.1802,PAK4cat (D440N/S474E) in complex with Integrin beta5 760-770 peptide
7S48,X-RAY DIFFRACTION,2.12,41.93,"VAPOR DIFFUSION, HANGING DROP",,0.1 M Tris-HCl (pH 8.5) and 0.5 M tri-sodium citrate,293.0,2021-09-08,2022-11-09,7S48,2492.0,2.0,357.0,119.0,,40.48,2.0,1.9,experimental,40.958,0.2221,0.1795,PAK4cat in complex with Integrin beta5 760-770 peptide
5GK9,X-RAY DIFFRACTION,2.41,48.98,"VAPOR DIFFUSION, HANGING DROP",,"Tacsimate Tris-HCl, PEG 3350",289.0,2016-07-04,2017-03-29,5GK9,2480.0,2.0,326.0,25.0,,39.13,2.0,2.4,experimental,49.289,0.26,0.233,Crystal structure of human HBO1 in complex with BRPF2
5MW4,X-RAY DIFFRACTION,3.51,64.96,VAPOR DIFFUSION,,"0.92M  Lithium sulfate monohydrate, 0.1M Ammonium sulfate, 0.1M Sodium citrate tribasic dihydrate",293.0,2017-01-18,2017-03-22,5MW4,5286.0,2.0,668.0,277.0,,78.59,1.0,2.19,experimental,64.41,0.202,0.184,"Crystal structure of Dot1L in complex with inhibitor CPD7 [N-(3-(((R)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)(methyl)amino)propyl)-2-(3-(2-chloro-3-(2-methylpyridin-3-yl)benzo[b]thiophen-5-yl)ureido)acetamide]"
5JIX,X-RAY DIFFRACTION,2.14,42.49,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 400, 200 mM CaAc, 0.1M NaAc pH 4.5-4.8",277.0,2016-04-22,2017-05-03,5JIX,1360.0,1.0,152.0,119.0,,18.71,1.0,1.47,experimental,,0.1879,0.1647,PKG II's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-Br-cGMP
6BQ8,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.19,43.96,"VAPOR DIFFUSION, SITTING DROP",4.6,"30% MPD, 20 mM SrCl2, 100 mM NaOAc pH 4.6",277.0,2017-11-27,2018-03-21,6BQ8,1294.0,1.0,152.0,40.0,,18.09,1.0,"2, 2.2",experimental,38.16,0.245,0.199,Joint X-ray/neutron structure of PKG II CNB-B domain in complex with 8-pCPT-cGMP
,,,,,,,,,,,,,,,,,,,,38.16,0.288,0.232,
5N84,X-RAY DIFFRACTION,3.2,61.62,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl",293.0,2017-02-22,2017-05-31,5N84,2192.0,1.0,313.0,60.0,,36.72,1.0,2.3,experimental,67.332,0.26068,0.2045,TTK kinase domain in complex with Mps-BAY2b
6TN9,X-RAY DIFFRACTION,3.22,61.84,"VAPOR DIFFUSION, HANGING DROP",,"25% GLYCEROL, 1.2 M AS, 0.1 M",295.0,2019-12-06,2020-05-13,6TN9,2136.0,1.0,294.0,,,34.21,1.0,2.6,experimental,105.192,0.2647,0.2176,X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 16
6TNB,X-RAY DIFFRACTION,3.64,66.23,"VAPOR DIFFUSION, HANGING DROP",6.54,"1.2M Ammonium sulphate, 100mM sodium cacodylate pH 6.54m 25% glycerol",293.0,2019-12-06,2020-05-13,6TNB,2124.0,1.0,294.0,24.0,1.0,34.45,1.0,2.65,experimental,80.611,0.2616,0.2124,X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 41
6TNC,X-RAY DIFFRACTION,3.17,61.16,"VAPOR DIFFUSION, HANGING DROP",,"1 M AMMONIUMSULFATE, 25%                  GLYCEROL, 0.1 M MES PH 6.5",298.0,2019-12-06,2020-05-13,6TNC,2191.0,1.0,294.0,48.0,,34.28,1.0,2.3,experimental,71.291,0.2356,0.1861,X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 46
6TND,X-RAY DIFFRACTION,3.65,66.33,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG 3350, 180mM Magnesium formate, 25% glycerol",295.0,2019-12-06,2020-05-13,6TND,2166.0,1.0,294.0,39.0,,34.33,1.0,2.58,experimental,60.329,0.2494,0.1865,X-RAY STRUCTURE OF MPS1 IN COMPLEX WITH COMPOUND 79
5GRH,X-RAY DIFFRACTION,3.83,67.92,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES-Na, pH7.5, 50 mM MgCl2, 30%(v/v) PEGMME 550",293.0,2016-08-11,2017-02-15,5GRH,5065.0,2.0,693.0,,,75.57,2.0,2.8,experimental,58.397,0.2592,0.2239,Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+)
5GRL,X-RAY DIFFRACTION,3.44,64.24,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES-Na, pH 7.5, 12% (w/v) PEG 3350",293.0,2016-08-11,2017-02-15,5GRL,5077.0,2.0,693.0,,,76.22,2.0,2.79,experimental,39.353,0.2736,0.2262,"Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+), isocitrate and ADP"
6YXQ,X-RAY DIFFRACTION,2.91,57.79,"VAPOR DIFFUSION, HANGING DROP",,"MES-NaOH, pH 6.5, polyethylene glycol 3350, 2-methyl-2,4-pentanediol and methanol",277.15,2020-05-03,2020-09-30,6YXQ,4784.0,2.0,649.0,55.0,,74.47,2.0,2.7,experimental,96.04,0.2474,0.2044,Crystal structure of a DNA repair complex ASCC3-ASCC2
6BFD,X-RAY DIFFRACTION,2.59,52.57,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG8000, 0.2 M ammonium sulfate, 0.1 M sodium cacodylate, pH 7.4",276.0,2017-10-26,2017-11-15,6BFD,7351.0,2.0,884.0,974.0,6.0,99.26,1.0,1.62,experimental,21.27,0.196,0.173,BACE crystal structure with hydroxy pyrrolidine inhibitor
6BFE,X-RAY DIFFRACTION,2.58,52.32,"VAPOR DIFFUSION, HANGING DROP",,"17% PEG 8000, 0.2M ammonium sulfate, 0.1% cacodylate, pH 7.4",276.0,2017-10-26,2017-11-15,6BFE,7232.0,2.0,884.0,855.0,6.0,99.22,1.0,1.51,experimental,18.26,0.2,0.173,BACE crystal structure with hydroxy pyrrolidine inhibitor
6BFX,X-RAY DIFFRACTION,2.65,53.5,"VAPOR DIFFUSION, HANGING DROP",,"17% PEG 8000, 0.2M ammonium sulfate, 0.1M sodium cacodylate",277.0,2017-10-27,2017-11-15,6BFX,6949.0,2.0,884.0,759.0,6.0,98.95,1.0,1.99,experimental,25.95,0.233,0.198,BACE crystal structure with hydroxy pyrrolidine inhibitor
8JWJ,X-RAY DIFFRACTION,3.91,68.5,"VAPOR DIFFUSION, SITTING DROP",8.3,"MPD, Tris",277.0,2023-06-29,2023-12-20,8JWJ,6694.0,4.0,904.0,,,103.69,2.0,2.96,experimental,100.78,0.222,0.1941,PHD Finger Protein 7 (PHF7) in complex with UBE2D2
5MWA,X-RAY DIFFRACTION,2.28,46.19,"VAPOR DIFFUSION, SITTING DROP",5.5,"Protein solution: 20 mM Tris, 100 mM NaCl, 0,5 mM TCEP, pH7.5 (HCl) with 30mg/mL protein and 2,08% of a 50 mM inhibitor DMSO stock
 
Precipitant solution:
25% PEG3350 - 0,1M bis-tris pH 5.5",293.0,2017-01-18,2018-02-28,5MWA,1766.0,1.0,245.0,103.0,,27.84,1.0,1.55,experimental,18.49,0.2307,0.2035,"human sEH Phosphatase in complex with 3-4-3,4-dichlorophenyl-5-phenyl-1,3-oxazol-2-yl-benzoic-acid"
6QLX,X-RAY DIFFRACTION,2.92,57.87,"VAPOR DIFFUSION, HANGING DROP",6.1,"25mM ADA pH6.1, 400mM sodium chloride and 20% PEG 5k.mme",291.0,2019-02-01,2020-02-19,6QLX,2045.0,1.0,216.0,340.0,3.0,24.13,1.0,2.1,experimental,22.475,0.2373,0.1858,Cathepsin-K in complex with fluoro-oxa-azabicyclo[3.3.0]octanyl containing inhibitor
6BRC,X-RAY DIFFRACTION,2.52,51.2,"VAPOR DIFFUSION, SITTING DROP",6.0,"26% PEG 3350, 0.2 M Ammonium Sulphate, 0.1M sbg buffer pH 6.0",293.0,2017-11-30,2017-12-13,6BRC,4120.0,2.0,582.0,80.0,,67.34,1.0,2.2,experimental,46.729,0.26522,0.21319,Crystal Structure of the Human CAMKK2B in complex with AP26113-analog (ALK-IN-1)
5V83,X-RAY DIFFRACTION,2.16,43.08,"VAPOR DIFFUSION, HANGING DROP",,"6% PEG3350, 0.2M NH4Br",277.0,2017-03-21,2017-05-24,5V83,3245.0,1.0,384.0,293.0,,44.68,1.0,2.002,experimental,38.8967,0.2287,0.1713,Structure of DCN1 bound to NAcM-HIT
5V86,X-RAY DIFFRACTION,2.19,43.85,"VAPOR DIFFUSION, HANGING DROP",,"6% PEG3350, 0.2M NH4Br",277.0,2017-03-21,2017-05-24,5V86,3537.0,1.0,384.0,581.0,,44.61,1.0,1.374,experimental,27.3009,0.1951,0.1554,Structure of DCN1 bound to NAcM-OPT
5V88,X-RAY DIFFRACTION,2.26,45.58,"VAPOR DIFFUSION, HANGING DROP",,"6% PEG3350, 0.2M NH4Br",277.0,2017-03-21,2017-05-24,5V88,3462.0,1.0,384.0,472.0,,44.7,1.0,1.601,experimental,35.9045,0.1885,0.1593,Structure of DCN1 bound to NAcM-COV
6BG3,X-RAY DIFFRACTION,2.3,46.53,EVAPORATION,,"6% PEG3350, 0.2M NH4Br",277.0,2017-10-27,2018-09-26,6BG3,3711.0,1.0,384.0,678.0,,44.74,1.0,1.05,experimental,21.7765,0.1735,0.1555,"Structure of (3S,4S)-1-benzyl-4-(3-(3-(trifluoromethyl)phenyl)ureido)piperidin-3-yl acetate bound to DCN1"
6BG5,X-RAY DIFFRACTION,2.28,45.98,EVAPORATION,,"6% PEG3350, 0.2M NH4Br",277.0,2017-10-27,2018-09-26,6BG5,3748.0,1.0,384.0,692.0,,44.77,1.0,1.1,experimental,20.177,0.1723,0.1456,"Structure of 1-(benzo[d][1,3]dioxol-5-ylmethyl)-1-(1-propylpiperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)urea bound to DCN1"
8HEI,X-RAY DIFFRACTION,2.12,41.87,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Ammonium acetate, 0.1 M Sodium acetate trihydrate pH 4.6, 30% w/v Polyethylene glycol 4,000",293.0,2022-11-08,2023-12-13,8HEI,2262.0,1.0,257.0,266.0,6.0,28.82,1.0,1.55,experimental,,0.1726,0.1503,Crystal structure of CTSB in complex with E64d
7B30,X-RAY DIFFRACTION,2.6,52.74,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 10 mg/ml in buffer 25 mM HEPES pH 7.5, 200 mM NaCl, 5% glycerol and 0.5 mM TCEP.
Reservoir: 10% PEG 6000, 0.1M HEPES pH 7.0.",293.0,2020-11-28,2020-12-16,7B30,2178.0,1.0,306.0,108.0,,35.05,1.0,2.1,experimental,45.91,0.1963,0.1775,MST3 in complex with compound G-5555
6KGJ,X-RAY DIFFRACTION,3.82,67.78,"VAPOR DIFFUSION, SITTING DROP",,"0.4M ammonium sulfate, 0.1M sodium citrate tribasic dihydrate pH 5.6, 1.0M lithium sulfate monohydrate",293.0,2019-07-11,2020-01-22,6KGJ,3426.0,2.0,404.0,156.0,,46.43,1.0,1.8,experimental,26.6971,0.223,0.2111,M1Q-hNTAQ1 C28S
7LW9,X-RAY DIFFRACTION,2.41,48.99,"VAPOR DIFFUSION, HANGING DROP",,20 % PEG 3350 and 0.2 M ammonium acetate,293.0,2021-02-28,2021-07-14,7LW9,2328.0,2.0,358.0,32.0,,43.58,1.0,2.71,experimental,60.2075,0.2532,0.1937,"Human Exonuclease 5 crystal structure in complex with ssDNA, Sm, and Na"
4ZO5,X-RAY DIFFRACTION,2.21,44.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298.0,2015-05-06,2015-08-12,4ZO5,5227.0,2.0,646.0,22.0,,75.87,1.0,2.5,experimental,71.55,0.285,0.2382,"PDE10 complexed with 4-isopropoxy-2-(2-(3-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)isoindoline-1,3-dione"
7XV0,X-RAY DIFFRACTION,1.74,29.37,"VAPOR DIFFUSION, HANGING DROP",5.6,2000 mM Ammonium sulfate,278.0,2022-05-20,2023-06-14,7XV0,1170.0,2.0,146.0,125.0,,15.99,2.0,1.5,experimental,18.506,0.2003,0.1687,Crystal structure of RPA70N-BLMp1 fusion
6FNK,X-RAY DIFFRACTION,2.03,39.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"10 % PEG5000 MME, 0.15 M MgCl2, 15 % Glycerol, 0.1 M TRIS pH 7.5",291.0,2018-02-04,2018-08-08,6FNK,2687.0,1.0,297.0,372.0,,33.84,1.0,1.049,experimental,,0.2202,0.1983,"Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with a pyrazolo[3,4-d]pyrimidine fragment of NVP-BHG712"
7AKG,X-RAY DIFFRACTION,2.72,54.72,"VAPOR DIFFUSION, SITTING DROP",5.5,"10% PEG 3350, 0.2M NaCl and 0.1M bis-tris pH 5.5",277.15,2020-09-30,2020-12-02,7AKG,2627.0,1.0,327.0,193.0,,38.03,1.0,2.08,experimental,47.402,0.219,0.1856,Crystal structure of STK17B with bound dovitinib
6MWE,X-RAY DIFFRACTION,2.5,51.0,"VAPOR DIFFUSION, SITTING DROP",4.6,"JCSG+ screen e4: 1.26M ammonium sulphate: 200mM lithium sulphate, 100mM Tris pH 8.5: cryo: 25% EG in 3 steps",290.0,2018-10-29,2018-11-21,6MWE,4773.0,2.0,634.0,231.0,,74.0,1.0,2.05,experimental,36.96,0.166,0.148,CRYSTAL STRUCTURE OF TIE2 IN COMPLEX WITH DECIPERA COMPOUND DP1919
5FS9,X-RAY DIFFRACTION,2.83,56.58,,8.5,"0.2 M LITHIUM SULFATE, 0.1M TRIS, PH 8.5, AND 25% POLY-ETHYLENE GLYCOL 3350",,2015-12-31,2016-05-11,5FS9,7896.0,2.0,1030.0,541.0,,114.38,1.0,1.75,experimental,40.851,0.19995,0.17462,Crystal structure of the G338E mutant of human apoptosis inducing factor
7JHN,X-RAY DIFFRACTION,2.36,47.98,"VAPOR DIFFUSION, HANGING DROP",,"24% PEG1500, 20% glycerol",277.0,2020-07-21,2020-11-18,7JHN,2962.0,1.0,370.0,107.0,3.0,45.52,1.0,2.2,experimental,38.9464,0.2551,0.1955,"Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with UDP and trisaccharide GlcNAc-beta1-3Gal-beta1-4GlcNAc"
5SJG,X-RAY DIFFRACTION,2.64,53.33,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SJG,10883.0,4.0,1372.0,565.0,4.0,159.45,2.0,1.97,experimental,35.422,0.2242,0.1761,"Crystal Structure of human phosphodiesterase 10 in complex with 1-[2-[2-(5,8-dimethyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)ethyl]-1-methylimidazol-4-yl]pyrrolidin-2-one"
7PCJ,X-RAY DIFFRACTION,2.69,54.29,"VAPOR DIFFUSION, HANGING DROP",8.4,"Tris 0.1M, PEG 3350 15%, NaN3 3mM",293.0,2021-08-03,2022-07-13,7PCJ,3009.0,6.0,366.0,126.0,,41.45,3.0,1.91,experimental,37.155,0.2194,0.1771,X-ray structure of CypA-C52AK125C/CsA/aromatic foldamer complex
6GLG,X-RAY DIFFRACTION,1.73,28.97,"VAPOR DIFFUSION, HANGING DROP",4.5,"crystallized in: 23-27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5

soaked in: 27% PEG3350, 0.2 M LiSO4, 0.1 M sodium acetate pH 4.5, 20% DMSO, 10 mM compound",293.0,2018-05-23,2019-02-20,6GLG,1540.0,1.0,182.0,183.0,,21.32,1.0,1.313,experimental,,0.2107,0.1928,Crystal structure of hMTH1 F27A in complex with LW14 in the presence of acetate
5MCO,X-RAY DIFFRACTION,3.98,69.1,"VAPOR DIFFUSION, SITTING DROP",4.0,"0.1M ammonium acetate, 0.1M sodium acetate, 15% (w/v) PEG4000",295.0,2016-11-10,2017-09-27,5MCO,3330.0,2.0,422.0,197.0,3.0,47.62,2.0,2.49,experimental,33.492,0.22287,0.17494,CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE INHIBITOR GRL-8234 AND EXOSITE PEPTIDE
5SEL,X-RAY DIFFRACTION,2.61,52.83,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEL,10803.0,4.0,1372.0,503.0,4.0,159.57,1.0,2.2,experimental,39.276,0.2312,0.1838,Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-methyl-5-pyridin-2-ylpyrazol-3-yl)pyrazole-3-carboxamide
4CV9,X-RAY DIFFRACTION,3.69,66.7,,7.5,"0.2M NACO2H, 0.1M BTP PH 7.5, 15% W/V PEG3350, 1% DMSO AND 1MM 4-(4-METHYLPIPERAZIN-1-YL)-N-(2-OXO-5-(PYRIDIN-4-YL)-1, 2-DIHYDROPYRIDIN-3-YL)BENZAMIDE. 18 DEGREES C.",291.0,2014-03-24,2015-04-08,4CV9,2027.0,1.0,313.0,30.0,,36.97,1.0,2.5,experimental,85.88,0.2323,0.1854,MPS1 kinase with 3-aminopyridin-2-one inhibitors
4CVA,X-RAY DIFFRACTION,3.61,65.9,,7.5,"0.2M NACO2H, 0.1M BTP PH 7.5, 15% W/V PEG3350, 1% DMSO AND 1MM (N-(2-OXO-5-(PYRIDIN-4-YL)-1, 2-DIHYDROPYRIDIN-3-YL)-4-PIPERIDIN-1-YL)BENZAMIDE.",,2014-03-24,2015-04-08,4CVA,2035.0,1.0,313.0,28.0,,36.85,1.0,2.5,experimental,76.55,0.215,0.1897,MPS1 kinase with 3-aminopyridin-2-one inhibitors
5ENK,X-RAY DIFFRACTION,2.55,51.82,VAPOR DIFFUSION,,"10% PEG MME 5K, 9% PEG 8K, 0.2 M NH4I, 0.2 M Na-citrate pH 6.4",295.0,2015-11-09,2016-07-06,5ENK,2997.0,1.0,455.0,238.0,2.0,50.85,1.0,2.11,experimental,27.315,0.25365,0.23257,Compound 18
5ENM,X-RAY DIFFRACTION,2.56,51.99,VAPOR DIFFUSION,,"10% PEG MME 5K, 9% PEG 8K, 0.2 M NH4I, 0.2 M Na-citrate pH 6.4",295.0,2015-11-09,2016-10-05,5ENM,2889.0,1.0,455.0,131.0,2.0,50.84,1.0,1.98,experimental,34.341,0.28368,0.25469,Compound 10
5NR3,X-RAY DIFFRACTION,3.71,66.82,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298.0,2017-04-21,2018-05-30,5NR3,2318.0,2.0,300.0,171.0,,34.09,1.0,2.3,experimental,35.93,0.2379,0.1961,Human DNMT3B PWWP domain in complex with ethambutol
6HPR,X-RAY DIFFRACTION,1.89,34.94,"VAPOR DIFFUSION, SITTING DROP",,0.2 M ammonium fluoride and 15% (w/v) PEG 3350,292.0,2018-09-21,2018-12-12,6HPR,3018.0,4.0,374.0,222.0,,42.06,3.0,1.7,experimental,,0.1972,0.1704,Crystal structure of cIAP1 RING domain bound to UbcH5B-Ub and a non-covalent Ub
6DK3,X-RAY DIFFRACTION,2.35,47.59,"VAPOR DIFFUSION, HANGING DROP",8.0,"5% PEG 8000, 0.1 M Tris-HCL pH8.0",297.0,2018-05-28,2018-06-20,6DK3,3389.0,1.0,488.0,167.0,,54.11,1.0,2.04,experimental,45.721,0.2575,0.197,HUMAN MITOCHONDRIAL SERINE HYDROXYMETHYLTRANSFERASe 2
7FUP,X-RAY DIFFRACTION,4.32,71.55,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUP,2992.0,1.0,363.0,50.0,,42.75,1.0,2.411,experimental,65.8163,0.2267,0.1785,"Crystal Structure of human cyclic GMP-AMP synthase in complex with methyl 1-benzoyl-3-methyl-5-(1,2-oxazol-5-yl)pyrazole-4-carboxylate"
5TFC,X-RAY DIFFRACTION,2.34,47.48,MICROBATCH,7.5,"Protein buffer: 150 mM NaCl, 30% (v/v) glycerol, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5;
Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-24,2018-05-09,5TFC,1922.0,1.0,229.0,185.0,,26.07,1.0,1.92,experimental,,0.2007,0.1543,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with GTP
4N6N,X-RAY DIFFRACTION,2.41,48.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG 4000,  
100 mM MES pH 6.5,  
200 mM potassium iodide, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2013-10-14,2015-02-18,4N6N,3342.0,2.0,409.0,244.0,2.0,48.26,2.0,1.87,experimental,21.562,0.21937,0.21364,Crystal structure of oxidized legumain in complex with cystatin E/M
6EVM,X-RAY DIFFRACTION,2.67,53.88,"VAPOR DIFFUSION, SITTING DROP",6.5,"2.45 M ammonium sulphate, 10% DMSO, 2.5 mM Pro-9, 4% hexenediol, 100 mM MOPS",277.0,2017-11-02,2018-09-12,6EVM,955.0,2.0,111.0,106.0,,12.99,2.0,2,experimental,,0.2191,0.1696,Crystal structure of a Pro-9 complexed peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase
6H1H,X-RAY DIFFRACTION,2.37,48.02,"VAPOR DIFFUSION, HANGING DROP",7.5,"1 microliter of protein 50 mg/mL and 1 microliter of reservoir solution containing 0.1 M HEPES (pH 7.5), 8 % ethylene glycol, 20 % (w/v) PEG 8,000, placed over 200 microliters of reservoir solution",277.0,2018-07-11,2018-11-28,6H1H,2689.0,1.0,293.0,368.0,,33.21,1.0,1.54,experimental,24.76,0.183,0.159,Crystal structure of human Pirin in complex with compound 7 (PLX4720)
6H1I,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"1 microliter of protein 50 mg/mL and 1 microliter of reservoir solution containing 0.1 M HEPES (pH 7.5), 8 % ethylene glycol, 20 % (w/v) PEG 8,000, placed over 200 microliters of reservoir solution",277.0,2018-07-11,2018-11-28,6H1I,2587.0,1.0,293.0,283.0,,33.23,1.0,1.69,experimental,25.73,0.224,0.178,Crystal structure of human Pirin in complex with bisamide compound 2
6BLE,X-RAY DIFFRACTION,2.24,45.15,"VAPOR DIFFUSION, SITTING DROP",5.5,"28% PEG 3350; 0.07 M Ammonium Acetate; 0.1M SBG buffer pH 5.5 
cryo - 30% glycerol",293.0,2017-11-10,2017-11-29,6BLE,2203.0,1.0,291.0,90.0,,33.64,1.0,1.9,experimental,38.596,0.22652,0.18588,Crystal Structure of the Human CAMKK2B in complex with CP673451
8CNH,X-RAY DIFFRACTION,2.6,52.76,VAPOR DIFFUSION,,"0.1 M sodium acetate pH 4.8,
0.2 M trisodium citrate, 15%(w/v) PEG 4000, 10%(v/v) glycerol",277.0,2023-02-23,2023-04-26,8CNH,3809.0,1.0,475.0,125.0,,55.64,1.0,2,experimental,50.17,0.2367,0.1888,Crystal structure of human soluble adenylyl cyclase (sAC) in complex with inhibitor TDI-10512
8COJ,X-RAY DIFFRACTION,2.6,52.6,VAPOR DIFFUSION,,"0.2 M tripotassium citrate, 20%(w/v) PEG 3350",277.0,2023-02-28,2023-04-26,8COJ,3809.0,1.0,475.0,121.0,,55.33,1.0,2.1,experimental,53.91,0.2254,0.2008,Crystal structure of human soluble adenylyl cyclase catalytic domain in complex with the inhibitor TDI-10228
8COT,X-RAY DIFFRACTION,2.59,52.57,VAPOR DIFFUSION,,"0.2 M tripotassium citrate, 20%(w/v) PEG 3350",277.0,2023-02-28,2023-04-26,8COT,3849.0,1.0,475.0,124.0,,55.54,1.0,2.1,experimental,,0.2318,0.192,Complex of human soluble adenylyl cyclase 10 catalytic core with inhibitor TDI-10962
4QMS,X-RAY DIFFRACTION,2.1,41.34,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM DASATINIB, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMS,2494.0,1.0,310.0,170.0,,35.61,1.0,1.883,experimental,,0.2137,0.169,MST3 in complex with DASATINIB
5YE7,X-RAY DIFFRACTION,2.41,49.04,"VAPOR DIFFUSION, HANGING DROP",6.6,"0.1M MOPS pH 6.6, 0.4M Li2SO4, 27% (w/v) (NH4)2SO4, 1M Na-Ac, 1.4% 1,4-butanediol",293.0,2017-09-15,2018-07-25,5YE7,5824.0,2.0,776.0,52.0,,88.87,1.0,2.312,experimental,33.4991,0.2443,0.1807,The crystal structure of Lp-PLA2 in complex with a novel inhibitor
5YE9,X-RAY DIFFRACTION,2.4,48.76,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MOPS pH 6.6, 0.4M Li2SO4, 27% (w/v) (NH4)2SO4, 1M Na-Ac, 1.4% 1,4-butanediol",293.0,2017-09-15,2018-07-25,5YE9,6017.0,2.0,776.0,223.0,,89.01,1.0,1.876,experimental,25.7158,0.2008,0.1669,The crystal structure of Lp-PLA2 in complex with a novel inhibitor
5YEA,X-RAY DIFFRACTION,2.42,49.23,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MOPS pH 6.6, 0.4M Li2SO4, 27% (w/v) (NH4)2SO4, 1M Na-Ac, 1.4% 1,4-butanediol",293.0,2017-09-15,2018-07-25,5YEA,6230.0,2.0,776.0,395.0,,89.09,1.0,1.805,experimental,21.0212,0.2111,0.1769,The crystal structure of Lp-PLA2 in complex with a novel inhibitor
7TVF,X-RAY DIFFRACTION,2.81,56.22,"VAPOR DIFFUSION, SITTING DROP",,"Crystals originally grown in 15% PEG 1500, 0.1M MIB pH 4.2 (15mg/ml of SMP) were used to make seeds. Microseeded into a condition with a reservoir consisting of 17.8% PEG 3350, 136mM sodium sulfate with 1:10 dilution of seeds (7.5mg/ml of SMP) using a ratio of 200nl protein:133nl reservoir:67nl diluted seeds",293.15,2022-02-04,2022-05-04,7TVF,16911.0,6.0,2180.0,1046.0,,249.1,3.0,2.17,experimental,52.4903,0.2259,0.1988,Crystal structure of the SHOC2-MRAS-PP1CA (SMP) complex to a resolution of 2.17 Angstrom
5UYJ,X-RAY DIFFRACTION,2.43,49.37,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% PEG 3350, 20 mM Ammonium Sulphate, 0.1M Citric acid-Hepes-CHES buffer system",293.0,2017-02-24,2017-04-26,5UYJ,2593.0,1.0,291.0,338.0,1.0,33.47,1.0,1.6,experimental,22.3,0.171,0.153,Crystal Structure of the Human CAMKK2B
5IH5,X-RAY DIFFRACTION,2.71,54.69,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Li2SO4, 0.7 - 0.8 M Na-K tartrate, 0.1 M CHES",277.0,2016-02-29,2016-04-13,5IH5,2446.0,1.0,294.0,37.0,,34.9,1.0,2.25,experimental,73.678,0.26,0.24,Human Casein Kinase 1 isoform delta (kinase domain) in complex with Epiblastin A
5IH6,X-RAY DIFFRACTION,2.79,55.99,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Li2SO4, 0.7 - 0.8 M Na-K tartrate, 0.1 M CHES",277.0,2016-02-29,2016-04-13,5IH6,2409.0,1.0,294.0,22.0,,34.95,1.0,2.3,experimental,89.694,0.2599,0.2329,Human Casein Kinase 1 isoform delta (kinase domain) in complex with Epiblastin A derivative
6QLW,X-RAY DIFFRACTION,2.15,42.68,"VAPOR DIFFUSION, HANGING DROP",6.1,"25mM ADA pH6.1, 250mM sodium nitrate and 20% PEG 5k.mme",291.0,2019-02-01,2020-02-19,6QLW,7727.0,4.0,864.0,899.0,12.0,97.34,1.0,2,experimental,21.152,0.2252,0.1798,Cathepsin-K in complex with MIV-710
7JHM,X-RAY DIFFRACTION,2.38,48.32,"VAPOR DIFFUSION, HANGING DROP",,"24% PEG1500, 20% glycerol",277.0,2020-07-20,2020-11-18,7JHM,5960.0,2.0,740.0,241.0,6.0,90.13,1.0,2.19,experimental,42.353,0.2189,0.1889,"Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with N-acetyl-lactosamine"
5LBC,X-RAY DIFFRACTION,2.88,57.29,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 1.8 M ammonium sulphate, 5% v/v dioxane, 0.002 M MnCl2",293.0,2016-06-15,2016-08-31,5LBC,1965.0,1.0,252.0,138.0,,28.83,1.0,1.816,experimental,39.0,0.1809,0.1577,HIF prolyl hydroxylase 2 (PHD2/EGLN1) I280V/R281L/I292V variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/FG2216)
4Z55,X-RAY DIFFRACTION,2.04,39.83,"VAPOR DIFFUSION, HANGING DROP",7.6,"citric acid, bis-tris propane, PEG3350",277.0,2015-04-02,2016-02-03,4Z55,2562.0,1.0,339.0,197.0,,39.0,1.0,1.55,experimental,20.63,0.2081,0.1843,Anaplastic lymphoma kinase catalytic domain complexed with pyrazolopyrimidine derivative of LDK378
5FTO,X-RAY DIFFRACTION,2.3,47.0,,8.5,"18% PEG3350, 0.1 M TRIS/HCL PH 8.5",,2016-01-14,2016-04-06,5FTO,2567.0,1.0,315.0,182.0,,35.9,1.0,2.22,experimental,25.973,0.25701,0.19605,Crystal structure of the ALK kinase domain in complex with Entrectinib
6MX8,X-RAY DIFFRACTION,2.23,44.87,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M TRIS HCl pH 8.5, 19-27% PEG 3350, 2 mM TCEP",277.0,2018-10-30,2018-12-12,6MX8,2330.0,1.0,307.0,65.0,,35.07,1.0,1.96,experimental,45.539,0.2271,0.1829,Crystal structure of anaplastic lymphoma kinase (ALK) bound by Brigatinib
5TNT,X-RAY DIFFRACTION,2.78,55.82,"VAPOR DIFFUSION, HANGING DROP",9.0,"50 MM CHES, PH 9.0, 1.3 M TRI-SODIUM CITRATE AND 3 MM COMPOUND (CROSS SEEDED WITH CRYSTALS GROWN FROM REMARK 280 50 MM TRIS, PH 7.2, 1.45 M AMMONIUM SULFATE, 2.0 M SODIUM CHLORIDE AND 3 MM COMPOUND)",295.0,2016-10-14,2017-04-26,5TNT,2722.0,2.0,297.0,349.0,7.0,33.68,2.0,1.4,experimental,25.14,0.161,0.146,Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors
7XYH,X-RAY DIFFRACTION,2.46,50.07,"VAPOR DIFFUSION, SITTING DROP",8.0,"PEG 10000, Tris-HCl pH 8.0, Sucrose",277.0,2022-06-01,2023-01-18,7XYH,5752.0,2.0,678.0,164.0,,81.61,1.0,2.04,experimental,47.23,0.2822,0.231,Crystal structure of CK2a2 complexed with AG1112
5LKR,X-RAY DIFFRACTION,2.57,52.16,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.2M ammonium acetate, 18% PEG 4000, 20 mM Tris pH 7.4",293.0,2016-07-23,2016-12-14,5LKR,8751.0,2.0,1148.0,36.0,6.0,136.63,1.0,2.52,experimental,,0.2377,0.1855,Human Butyrylcholinesterase complexed with N-Propargyliperidines
6EZ2,X-RAY DIFFRACTION,2.97,58.55,"VAPOR DIFFUSION, HANGING DROP",7.4,"100 mM ammonium acetate, pH 7.40, 13% polyethylene glycol 3350",298.0,2017-11-14,2018-12-12,6EZ2,8524.0,2.0,1054.0,122.0,6.0,122.64,1.0,2.7,experimental,,0.2229,0.1856,Human butyrylcholinesterase carbamylated.
6O69,X-RAY DIFFRACTION,3.12,60.59,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.46-0.96 M sodium citrate, pH 6.0-7.5",295.0,2019-03-05,2019-05-01,6O69,4435.0,1.0,542.0,259.0,3.0,60.04,1.0,2.081,experimental,,0.2215,0.1864,Crystal Structure of Double Mutant L380R/F535K of Human Acetylcholinesterase
5ZIC,X-RAY DIFFRACTION,2.32,47.04,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1M Hepes (pH 7.0), 0.1M magnesium chloride, 15 % (w/v) PEG 4000",293.0,2018-03-14,2018-08-01,5ZIC,8253.0,2.0,1046.0,218.0,12.0,120.72,1.0,2.1,experimental,,0.2676,0.2147,Crystal structure of human GnT-V luminal domain in complex with acceptor sugar
7A1S,X-RAY DIFFRACTION,3.23,61.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6M AMMONIUM SULPHATE, 6% PEG 400, 0.1M HEPES PH 7.5",277.0,2020-08-13,2021-08-25,7A1S,3243.0,2.0,369.0,307.0,,43.55,2.0,2.01,experimental,59.46,0.2089,0.1804,"FACTOR INHIBITING HIF-1 ALPHA IN COMPLEX WITH ZN(II), 3-methyl-2-oxoglutarate, AND TANKYRASE-2 (TNKS2) FRAGMENT PEPTIDE (21-MER)"
6FYH,X-RAY DIFFRACTION,3.18,61.32,"VAPOR DIFFUSION, SITTING DROP",,0.8M Zn SO4 0.1M Na Acetat pH 4.0,293.0,2018-03-12,2018-07-11,6FYH,1522.0,2.0,200.0,5.0,1.0,23.41,2.0,2.906,experimental,,0.2656,0.2298,Disulfide between ubiquitin G76C and the E3 HECT ligase Huwe1
6X4N,X-RAY DIFFRACTION,2.79,55.96,"VAPOR DIFFUSION, HANGING DROP",8.5,"20 mM Tris-HCl, pH 8.5, 2 mM DTT, 2 mM EDTA, 20-35% PEG3350, 5% ethanol",277.0,2020-05-22,2020-06-24,6X4N,1495.0,1.0,167.0,207.0,,18.78,1.0,1.51,experimental,15.08,0.1805,0.1584,"Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: (2R,5S,11S,14S,18E)-2,11,17,17-tetramethyl-14-(propan-2-yl)-3-oxa-9,12,15,26,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(25),18,20(28),21,23,26-hexaene-4,10,13,16-tetrone (compound 24)"
6X4O,X-RAY DIFFRACTION,2.74,55.19,"VAPOR DIFFUSION, HANGING DROP",8.5,"20 mM Tris-HCl, pH 8.5, 2 mM DTT, 2 mM EDTA, 20-35% PEG3350, 5% ethanol",277.0,2020-05-22,2020-06-24,6X4O,1465.0,1.0,167.0,205.0,,18.75,1.0,1.5,experimental,22.39,0.1984,0.178,"Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: (2R,5S,11S,14S,18E)-2,11-dimethyl-14-(propan-2-yl)-3-oxa-9,12,15,21,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(26),18,20,22,24,27-hexaene-4,10,13,16-tetrone (compound 21)"
6X4P,X-RAY DIFFRACTION,2.79,55.92,"VAPOR DIFFUSION, HANGING DROP",,"20 mM Tris-HCl, pH 8.5, 2 mM DTT, 2 mM EDTA, 20-35% PEG3350, 5% ethanol",277.0,2020-05-22,2020-06-24,6X4P,1471.0,1.0,167.0,172.0,,18.78,1.0,1.5,experimental,18.02,0.1775,0.1607,"Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: (2R,5S,11S,14S,18E)-2,11,17,17-tetramethyl-14-(propan-2-yl)-15-oxa-3,9,12,26,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(25),18,20(28),21,23,26-hexaene-4,10,13,16-tetrone (compound 28)"
6X4Q,X-RAY DIFFRACTION,2.78,55.8,"VAPOR DIFFUSION, HANGING DROP",8.5,"20 mM Tris-HCl, pH 8.5, 2 mM DTT, 2 mM EDTA, 20-35% PEG 3350, 5% ethanol",277.0,2020-05-22,2020-06-24,6X4Q,1472.0,1.0,167.0,185.0,,18.79,1.0,1.8,experimental,19.35,0.1911,0.1634,"Human cyclophilin A bound to a series of acylcic and macrocyclic inhibitors: (2R,5S,11S,14S,18E)-14-cyclobutyl-2,11,17,17-tetramethyl-15-oxa-3,9,12,26,29-pentaazatetracyclo[18.5.3.1~5,9~.0~23,27~]nonacosa-1(25),18,20(28),21,23,26-hexaene-4,10,13,16-tetrone (compound 33)"
4ZFR,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2M sodium citrate tribasic diehydrate, 0.1M HEPES sodium, 20% v/v 2-propanol",293.0,2015-04-21,2015-10-14,4ZFR,2080.0,2.0,278.0,43.0,,31.15,2.0,1.72,experimental,38.31,0.237,0.201,Catalytic domain of Sst2 F403A mutant bound to ubiquitin
5SGX,X-RAY DIFFRACTION,2.64,53.43,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-12,5SGX,11221.0,4.0,1372.0,788.0,4.0,159.74,2.0,1.93,experimental,36.606,0.2159,0.1683,"Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-[2-methyl-5-[(2R)-2-(trifluoromethyl)pyrrolidin-1-yl]-1,2,4-triazol-3-yl]ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine"
5SHR,X-RAY DIFFRACTION,2.62,52.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-02-01,2022-10-19,5SHR,10790.0,4.0,1372.0,499.0,4.0,159.48,2.0,1.98,experimental,38.36,0.2301,0.182,"Crystal Structure of human phosphodiesterase 10 in complex with N-[(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl]-N,2-dimethyl-5-phenyl-1,2,4-triazol-3-amine"
4ZQ9,X-RAY DIFFRACTION,4.17,70.51,VAPOR DIFFUSION,,"PEG 6K, Sodium Citrate, Lithium Chloride",273.0,2015-05-08,2015-09-23,4ZQ9,5496.0,5.0,675.0,58.0,,86.24,1.0,2.6,experimental,,0.2295,0.2046,X-ray structure of AAV-2 OBD bound to AAVS1 site 3:1
5SDV,X-RAY DIFFRACTION,2.63,53.31,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SDV,10894.0,4.0,1372.0,582.0,4.0,159.78,1.0,2.15,experimental,36.574,0.2318,0.1752,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-N-(1,3-oxazol-4-ylmethyl)-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)pyrazole-3,4-dicarboxamide"
5SDW,X-RAY DIFFRACTION,2.69,54.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SDW,10544.0,4.0,1372.0,230.0,3.0,159.57,1.0,2.35,experimental,57.91,0.243,0.18,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N,4-N,2-trimethyl-3-N-(2-phenyl-1H-benzimidazol-5-yl)pyrazole-3,4-dicarboxamide"
5SDX,X-RAY DIFFRACTION,2.63,53.28,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SDX,10669.0,4.0,1372.0,381.0,4.0,159.41,1.0,2.19,experimental,44.251,0.2425,0.1868,Crystal Structure of human phosphodiesterase 10 in complex with 4-[6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]pyridin-2-yl]morpholine
5SDZ,X-RAY DIFFRACTION,2.64,53.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SDZ,10797.0,4.0,1372.0,501.0,4.0,159.88,1.0,2.35,experimental,45.521,0.2528,0.188,"Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[3-[2,3-dihydroxypropyl(methyl)carbamoyl]-1-methylpyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide"
5SE2,X-RAY DIFFRACTION,2.62,53.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE2,10759.0,4.0,1372.0,471.0,4.0,159.27,1.0,2.2,experimental,45.604,0.2211,0.1941,Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]quinoline
5SE3,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE3,10835.0,4.0,1372.0,543.0,4.0,159.41,1.0,2.14,experimental,39.938,0.2259,0.1798,"Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-4-carboxamide"
5SE4,X-RAY DIFFRACTION,2.66,53.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE4,10593.0,4.0,1372.0,297.0,4.0,159.45,1.0,2.5,experimental,51.62,0.2519,0.1854,"Crystal Structure of human phosphodiesterase 10 in complex with 5-cyclopropyl-7-methyl-2-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidine"
5SE5,X-RAY DIFFRACTION,2.61,52.87,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE5,10779.0,4.0,1372.0,471.0,4.0,159.59,1.0,2.08,experimental,42.853,0.2259,0.1858,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[1-methyl-5-(methylcarbamoyl)pyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide
5SE6,X-RAY DIFFRACTION,2.6,52.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE6,10930.0,4.0,1372.0,613.0,4.0,159.35,1.0,1.95,experimental,37.397,0.2193,0.177,"Crystal Structure of human phosphodiesterase 10 in complex with 2,9-dimethyl-6-[(1-methyl-4-phenylimidazol-2-yl)methoxy]purine"
5SE7,X-RAY DIFFRACTION,2.64,53.46,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE7,10882.0,4.0,1372.0,566.0,4.0,159.62,1.0,2.17,experimental,40.011,0.2322,0.1794,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide"
5SE8,X-RAY DIFFRACTION,2.66,53.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE8,10945.0,4.0,1372.0,641.0,4.0,159.59,1.0,1.99,experimental,35.55,0.217,0.173,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[2-(2-methyl-5-phenyl-1,2,4-triazol-3-yl)ethyl]pyrazole-3-carboxamide"
5SE9,X-RAY DIFFRACTION,2.64,53.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SE9,10986.0,4.0,1372.0,688.0,4.0,159.35,1.0,1.94,experimental,37.677,0.2192,0.1754,"Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethyl-6-[(1-methyl-4-phenylimidazol-2-yl)methoxy]imidazo[1,2-b]pyridazine"
5SEA,X-RAY DIFFRACTION,2.66,53.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEA,10899.0,4.0,1372.0,619.0,4.0,159.6,1.0,2,experimental,34.783,0.2277,0.1945,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-(2-phenylpyrazol-3-yl)-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SEB,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEB,10637.0,4.0,1372.0,349.0,4.0,159.3,1.0,2.28,experimental,51.651,0.2234,0.1742,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]quinoxaline"
5SEC,X-RAY DIFFRACTION,2.65,53.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEC,10739.0,4.0,1372.0,415.0,4.0,159.57,1.0,2.03,experimental,41.815,0.2248,0.1808,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(1,4-diphenylimidazol-2-yl)ethyl]-3-methylquinoxaline"
5SED,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SED,10682.0,4.0,1372.0,366.0,4.0,159.76,1.0,2.32,experimental,41.447,0.2422,0.1916,Crystal Structure of human phosphodiesterase 10 in complex with 4-[6-chloro-2-[(1-methyl-4-phenylimidazol-2-yl)methoxy]quinazolin-4-yl]morpholine
5SEF,X-RAY DIFFRACTION,2.64,53.34,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEF,10528.0,4.0,1372.0,247.0,4.0,159.37,1.0,2.29,experimental,54.924,0.2323,0.172,"Crystal Structure of human phosphodiesterase 10 in complex with 5,7,8-trimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine"
5SEG,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEG,10602.0,4.0,1372.0,274.0,4.0,160.1,1.0,2.29,experimental,51.273,0.2312,0.1743,Crystal Structure of human phosphodiesterase 10 in complex with 6-[(5-bromo-1-methyl-2-oxopyridine-3-carbonyl)amino]-N-(oxetan-3-yl)-2-phenyl-3H-benzimidazole-5-carboxamide
5SEH,X-RAY DIFFRACTION,2.65,53.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEH,10848.0,4.0,1372.0,536.0,4.0,159.65,1.0,2.1,experimental,39.13,0.2343,0.1916,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide"
5SEI,X-RAY DIFFRACTION,2.63,53.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEI,10665.0,4.0,1372.0,385.0,4.0,159.33,1.0,2.37,experimental,50.777,0.2345,0.1715,"Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-2-[(E)-2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethenyl]-[1,2,4]triazolo[1,5-a]pyridine"
5SEJ,X-RAY DIFFRACTION,2.63,53.28,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEJ,10562.0,4.0,1372.0,294.0,4.0,159.34,1.0,2.44,experimental,54.205,0.2429,0.1735,"Crystal Structure of human phosphodiesterase 10 in complex with 6-chloro-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyridine"
5SEK,X-RAY DIFFRACTION,2.66,53.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEK,10886.0,4.0,1372.0,594.0,4.0,159.33,1.0,2.15,experimental,39.998,0.1971,0.1635,Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]quinoxaline
5SEM,X-RAY DIFFRACTION,2.64,53.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEM,10775.0,4.0,1372.0,468.0,4.0,159.55,1.0,2.1,experimental,43.861,0.2276,0.1778,"Crystal Structure of human phosphodiesterase 10 in complex with 3-methyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]-2-(trifluoromethyl)imidazo[1,2-b]pyridazine"
5SEN,X-RAY DIFFRACTION,2.63,53.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEN,10790.0,4.0,1372.0,515.0,4.0,159.62,1.0,2.04,experimental,40.339,0.2507,0.212,Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(1-quinolin-2-ylimidazol-4-yl)pyrazole-3-carboxamide
5SEP,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEP,10848.0,4.0,1372.0,568.0,4.0,159.31,1.0,2.1,experimental,43.989,0.2262,0.1738,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(4-cyclopentyl-1-methylimidazol-2-yl)ethyl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine"
5SEQ,X-RAY DIFFRACTION,2.63,53.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEQ,10669.0,4.0,1372.0,394.0,4.0,159.37,1.0,2.18,experimental,50.454,0.2291,0.1723,"Crystal Structure of human phosphodiesterase 10 in complex with 5,6,8-trimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-a]pyrazine"
5SER,X-RAY DIFFRACTION,2.62,53.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SER,10625.0,4.0,1372.0,329.0,4.0,159.7,1.0,2.25,experimental,49.942,0.2329,0.1724,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N-(2-fluoroethyl)-4-N,2-dimethyl-3-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide"
5SES,X-RAY DIFFRACTION,2.64,53.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SES,10964.0,4.0,1372.0,652.0,4.0,159.63,1.0,2.11,experimental,34.006,0.2305,0.1721,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-(2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-7-yl)pyrazole-3-carboxamide"
5SEV,X-RAY DIFFRACTION,2.64,53.42,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEV,10651.0,4.0,1372.0,367.0,4.0,159.25,1.0,2.31,experimental,49.231,0.2313,0.1789,"Crystal Structure of human phosphodiesterase 10 in complex with 2,3,5-trimethyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]pyrazine"
5SEX,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEX,10842.0,4.0,1372.0,550.0,4.0,159.55,1.0,1.99,experimental,39.619,0.2183,0.1836,Crystal Structure of human phosphodiesterase 10 in complex with N-methyl-6-[(6-methylpyridine-2-carbonyl)amino]-2-phenyl-3H-benzimidazole-5-carboxamide
5SEY,X-RAY DIFFRACTION,2.63,53.15,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEY,10602.0,4.0,1372.0,278.0,4.0,159.49,1.0,2.29,experimental,50.258,0.2342,0.1726,"Crystal Structure of human phosphodiesterase 10 in complex with [2-cyclopropyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethynyl]imidazo[1,2-b]pyridazin-3-yl]methanol"
5SEZ,X-RAY DIFFRACTION,2.64,53.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEZ,10930.0,4.0,1372.0,638.0,4.0,159.52,1.0,1.99,experimental,36.516,0.2176,0.1758,"Crystal Structure of human phosphodiesterase 10 in complex with 2-chloro-6-ethyl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-4-carboxamide"
5SF1,X-RAY DIFFRACTION,2.64,53.39,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF1,10619.0,4.0,1372.0,327.0,4.0,159.47,1.0,2.11,experimental,44.643,0.2306,0.1838,"Crystal Structure of human phosphodiesterase 10 in complex with 2-(difluoromethyl)-3-methyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethynyl]imidazo[1,2-b]pyridazine"
5SF3,X-RAY DIFFRACTION,2.63,53.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF3,10764.0,4.0,1372.0,440.0,4.0,159.78,1.0,2.15,experimental,41.998,0.2236,0.1715,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)-4-N-(1H-pyrazol-5-ylmethyl)pyrazole-3,4-dicarboxamide"
5SF5,X-RAY DIFFRACTION,2.66,53.84,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF5,10925.0,4.0,1372.0,635.0,4.0,159.34,1.0,1.98,experimental,39.284,0.2233,0.1778,"Crystal Structure of human phosphodiesterase 10 in complex with 2,3-dimethyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]imidazo[1,2-b]pyridazine"
5SF6,X-RAY DIFFRACTION,2.63,53.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF6,10807.0,4.0,1372.0,520.0,4.0,159.55,1.0,2.03,experimental,37.434,0.2324,0.1792,"Crystal Structure of human phosphodiesterase 10 in complex with 6,7-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-N-propan-2-ylimidazo[2,1-f][1,2,4]triazin-4-amine"
5SF7,X-RAY DIFFRACTION,2.63,53.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF7,10857.0,4.0,1372.0,565.0,4.0,159.43,1.0,2.08,experimental,38.602,0.2287,0.1815,"Crystal Structure of human phosphodiesterase 10 in complex with 1-(2-chlorophenyl)-8-methoxy-3,4-dimethylimidazo[1,5-a]quinazolin-5-one"
5SF9,X-RAY DIFFRACTION,2.65,53.57,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF9,10473.0,4.0,1372.0,189.0,4.0,159.34,1.0,2.37,experimental,56.097,0.2293,0.175,Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-[(1-methyl-4-phenylimidazol-2-yl)methoxy]quinoxaline
5SFF,X-RAY DIFFRACTION,2.61,52.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFF,10720.0,4.0,1372.0,333.0,4.0,159.39,1.0,2.16,experimental,49.575,0.2267,0.1732,"Crystal Structure of human phosphodiesterase 10 in complex with [2-methyl-6-[2-(1-methyl-4-phenylimidazol-2-yl)ethynyl]imidazo[1,2-b]pyridazin-3-yl]methanol"
5SFG,X-RAY DIFFRACTION,2.67,53.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFG,10904.0,4.0,1372.0,620.0,4.0,159.76,1.0,2.31,experimental,36.407,0.1951,0.1599,Crystal Structure of human phosphodiesterase 10 in complex with N-[(3R)-1-(5-chloropyridin-2-yl)pyrrolidin-3-yl]-6-cyclopropyl-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5SFJ,X-RAY DIFFRACTION,2.61,52.85,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFJ,10581.0,4.0,1372.0,253.0,4.0,159.82,1.0,2.41,experimental,47.532,0.2448,0.1857,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-3-N-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)-4-N-(pyridin-2-ylmethyl)pyrazole-3,4-dicarboxamide"
5SFK,X-RAY DIFFRACTION,2.62,53.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFK,10692.0,4.0,1372.0,382.0,3.0,159.63,1.0,2.33,experimental,49.507,0.2484,0.1845,"Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-(pyrimidin-5-ylamino)-N-[1-(2,2,2-trifluoroethyl)pyrazol-3-yl]pyridine-2-carboxamide"
5SFL,X-RAY DIFFRACTION,2.61,52.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFL,10704.0,4.0,1372.0,380.0,4.0,159.82,1.0,2.13,experimental,45.405,0.2273,0.1867,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[5-[(2-hydroxy-2-methylpropyl)carbamoyl]-1-methylpyrazol-4-yl]-3-(pyrimidin-5-ylamino)pyrazine-2-carboxamide
5SFM,X-RAY DIFFRACTION,2.62,53.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFM,10628.0,4.0,1372.0,307.0,4.0,159.74,1.0,2.16,experimental,46.41,0.2344,0.1801,"Crystal Structure of human phosphodiesterase 10 in complex with 2-methyl-4-(morpholine-4-carbonyl)-N-(2-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)pyrazole-3-carboxamide"
5SFN,X-RAY DIFFRACTION,2.64,53.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFN,10780.0,4.0,1372.0,488.0,4.0,159.48,1.0,2.02,experimental,42.172,0.2224,0.1778,Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[2-(1-methylbenzimidazol-2-yl)ethyl]pyrazole-3-carboxamide
5SFO,X-RAY DIFFRACTION,2.61,52.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFO,10974.0,4.0,1372.0,674.0,4.0,159.6,1.0,1.96,experimental,34.299,0.2177,0.1759,Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-N-[2-(1-methyl-4-phenylimidazol-2-yl)ethyl]pyrazole-3-carboxamide
5SFP,X-RAY DIFFRACTION,2.64,53.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFP,10984.0,4.0,1372.0,662.0,4.0,159.41,1.0,2,experimental,33.747,0.2256,0.1869,"Crystal Structure of human phosphodiesterase 10 in complex with N-(2-chloropyridin-4-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxamide"
5SFQ,X-RAY DIFFRACTION,2.59,52.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFQ,10873.0,4.0,1372.0,585.0,4.0,159.36,1.0,2.21,experimental,35.344,0.2479,0.186,"Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-N-[1-(2,2-difluoroethyl)pyrazol-3-yl]-2-methylpyrazole-3-carboxamide"
5SFR,X-RAY DIFFRACTION,2.65,53.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFR,10933.0,4.0,1372.0,605.0,4.0,159.87,1.0,2.04,experimental,37.803,0.2127,0.1814,"Crystal Structure of human phosphodiesterase 10 in complex with 4-N-ethyl-3-N-[2-[3-(2-fluoroethoxy)phenyl]imidazo[1,2-a]pyrimidin-7-yl]-4-N,2-dimethylpyrazole-3,4-dicarboxamide"
5SFS,X-RAY DIFFRACTION,2.64,53.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFS,10606.0,4.0,1372.0,316.0,4.0,159.37,1.0,2.24,experimental,50.758,0.2516,0.1877,"Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-[2-methyl-5-[(3S)-3-methylpyrrolidin-1-yl]-1,2,4-triazol-3-yl]ethyl]-[1,2,4]triazolo[1,5-a]pyrazine"
5SFU,X-RAY DIFFRACTION,2.61,52.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFU,10552.0,4.0,1372.0,246.0,4.0,159.73,1.0,2.4,experimental,53.189,0.2562,0.1917,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-3-(pyrimidin-5-ylamino)-N-[4-(pyrrolidine-1-carbonyl)pyridin-3-yl]pyridine-2-carboxamide
5SFV,X-RAY DIFFRACTION,2.61,52.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFV,10759.0,4.0,1372.0,467.0,4.0,159.38,1.0,2.41,experimental,36.382,0.2489,0.1854,Crystal Structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-N-(1-cyclopentylpyrazol-3-yl)-2-methylpyrazole-3-carboxamide
5SFX,X-RAY DIFFRACTION,2.66,53.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFX,10789.0,4.0,1372.0,493.0,4.0,159.61,1.0,2.04,experimental,39.958,0.2225,0.1765,"Crystal Structure of human phosphodiesterase 10 in complex with N-(2-acetamido-1,3-benzothiazol-5-yl)-4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carboxamide"
5SFY,X-RAY DIFFRACTION,2.62,53.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFY,10703.0,4.0,1372.0,404.0,4.0,159.56,1.0,2.08,experimental,40.407,0.2249,0.1823,"Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[(E)-2-[2-methyl-5-(1H-pyrazol-4-yl)-1,2,4-triazol-3-yl]ethenyl]-[1,2,4]triazolo[1,5-a]pyrazine"
6AA5,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 1.8 mM ZnSO4, 6% sucrose, 0.1 M Bis-Tris pH 6.1",293.0,2018-07-17,2019-03-06,6AA5,1483.0,1.0,163.0,118.0,2.0,19.69,1.0,1.901,experimental,,0.2384,0.1908,Crystal structure of MTH1 in complex with 3-isomangostin
6EQ6,X-RAY DIFFRACTION,1.73,,"VAPOR DIFFUSION, HANGING DROP",4.5,"23 % PEG3350, 0.2 M LI2SO4, 0.1 M SODIUM ACETATE PH 4.5",293.0,2017-10-12,2018-10-31,6EQ6,1340.0,1.0,182.0,100.0,,21.47,1.0,2.002,experimental,,0.2547,0.1979,MTH1 in complex with fragment 1
4TVJ,X-RAY DIFFRACTION,2.4,48.74,"VAPOR DIFFUSION, SITTING DROP",8.5,"25% PEG3350, 0.1M Tris",277.0,2014-06-27,2015-07-08,4TVJ,5958.0,2.0,736.0,267.0,,84.8,1.0,2.1,experimental,27.879,0.23103,0.18763,HUMAN ARTD2 (PARP2) - CATALYTIC DOMAIN IN COMPLEX WITH OLAPARIB
5UKF,X-RAY DIFFRACTION,2.59,52.52,"VAPOR DIFFUSION, SITTING DROP",7.0,27.5% PEG 3350; 0.3M AmSO4; 0.1M HEPES pH 7.0,293.0,2017-01-22,2017-03-29,5UKF,9854.0,4.0,1452.0,551.0,,166.71,1.0,2.4,experimental,60.07,0.214,0.177,Crystal Structure of the Human Vaccinia-related Kinase 1 Bound to an Oxindole Inhibitor
5UVF,X-RAY DIFFRACTION,2.56,51.96,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG3350, 0.1M BISTRIS, 0.2M,  LITHIUM SULFATE, PH 6.5",293.0,2017-02-20,2017-03-22,5UVF,10449.0,4.0,1456.0,683.0,,167.21,1.0,2,experimental,52.86,0.204,0.173,Crystal Structure of the Human vaccinia-related kinase bound to BI-D1870
8C3P,X-RAY DIFFRACTION,2.18,43.45,"VAPOR DIFFUSION, HANGING DROP",8.0,"18-22 % PEG 3350, 0,1-0,4 M Ammonium Iodide, 0,1-0,4 M Sodium Thiocyanate",293.0,2022-12-28,2023-11-22,8C3P,13266.0,2.0,1776.0,510.0,30.0,209.57,1.0,2.38,experimental,42.72,0.28,0.2221,Crystal structure of autotaxin gamma in complex with LPA 18:1
5EOI,X-RAY DIFFRACTION,2.09,41.17,"VAPOR DIFFUSION, HANGING DROP",8.0,"2.4 M ammonium sulphate, Tris 50 mM, HgCl2 2mM",296.0,2015-11-10,2016-11-23,5EOI,2463.0,1.0,258.0,344.0,,29.47,1.0,1.8,experimental,18.379,0.2061,0.1471,Crystal structure of copper bound human Carbonic anhydrase II
5L8W,X-RAY DIFFRACTION,3.08,60.11,"VAPOR DIFFUSION, SITTING DROP",6.5,"3.2% PEG4000, 0.1mM MMT pH6.5, 0.1 mM TCEP.

Cryo- 30% Glycerol",293.0,2016-06-08,2016-09-28,5L8W,7287.0,3.0,1031.0,18.0,,117.67,3.0,2.79,experimental,72.405,0.25909,0.20835,Structure of USP12-UB-PRG/UAF1
8JJF,X-RAY DIFFRACTION,2.49,50.57,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Magnesium chloride hexahydrate, 0.1 M Tris pH 8.5, and 25 % (w/v) Polyethylene glycol (PEG) 3350",295.15,2023-05-30,2024-06-26,8JJF,1958.0,1.0,204.0,301.0,,23.47,1.0,1.51,experimental,18.9,0.1899,0.1728,Crystal structure of QE-hNTAQ1 C28S
8JJG,X-RAY DIFFRACTION,2.46,49.99,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Magnesium chloride hexahydrate, 0.1 M Tris pH 8.5, and 25 % (w/v) Polyethylene glycol (PEG) 3350",295.15,2023-05-30,2024-06-26,8JJG,1981.0,1.0,204.0,306.0,,23.53,1.0,1.45,experimental,18.09,0.1892,0.1699,Crystal structure of QW-hNTAQ1 C28S
8JJH,X-RAY DIFFRACTION,2.49,50.6,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Magnesium chloride hexahydrate, 0.1 M Tris pH 8.5, and 25 % (w/v) Polyethylene glycol (PEG) 3350",295.15,2023-05-30,2024-06-26,8JJH,1939.0,1.0,204.0,268.0,,23.48,1.0,1.61,experimental,18.36,0.1816,0.1614,Crystal structure of QH-hNTAQ1 C28S
5QCF,X-RAY DIFFRACTION,2.6,52.65,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCF,2012.0,1.0,223.0,254.0,3.0,25.4,1.0,2.1,experimental,18.878,0.1874,0.1576,Crystal structure of human Cathepsin-S with bound ligand
5QCI,X-RAY DIFFRACTION,2.56,51.89,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCI,2006.0,1.0,223.0,232.0,3.0,25.39,1.0,2.179,experimental,,0.1929,0.1575,Crystal structure of human Cathepsin-S with bound ligand
5YV9,X-RAY DIFFRACTION,3.25,62.11,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Na cocodylate pH 6.5, 0.2M Na acetate, 20% PEG 8000, 0.03M Glycyl-glycyl-glycine",293.0,2017-11-24,2018-12-05,5YV9,2211.0,1.0,298.0,79.0,,34.29,1.0,2.53,experimental,,0.2218,0.1675,Structure of CaMKK2 in complex with CKI-009
5YVA,X-RAY DIFFRACTION,3.24,66.38,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M sodium cocodylate pH 6.5, 0.2M sodium acetate, 20% PEG 8000",293.0,2017-11-24,2018-12-05,5YVA,2177.0,1.0,298.0,42.0,,34.34,1.0,2.574,experimental,,0.2204,0.1605,Structure of CaMKK2 in complex with CKI-010
5YVB,X-RAY DIFFRACTION,3.25,62.2,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M sodium cocodylate pH 6.5, 0.2M ammonium acetate, 32% PEG 8000",293.0,2017-11-24,2018-12-05,5YVB,2359.0,1.0,298.0,212.0,,34.53,1.0,2.02,experimental,,0.2154,0.1696,Structure of CaMKK2 in complex with CKI-011
5YVC,X-RAY DIFFRACTION,3.23,61.94,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1M sodium cocodylate pH 6.0, 0.2M sodium acetate, 20% PEG 8000, 0.03M xylitol",293.0,2017-11-24,2018-12-05,5YVC,2339.0,1.0,298.0,193.0,,34.48,1.0,2.02,experimental,,0.2111,0.1701,Structure of CaMKK2 in complex with CKI-012
6QAC,X-RAY DIFFRACTION,3.09,60.22,"VAPOR DIFFUSION, HANGING DROP",,"Ammonium Sulfate
MES pH 6.5",293.0,2018-12-19,2019-03-27,6QAC,4487.0,1.0,557.0,72.0,3.0,65.92,1.0,2.771,experimental,,0.255,0.1841,Human Butyrylcholinesterase in complex with (S)-2-(butylamino)-N-(3-cycloheptylpropyl)-3-(1H-indol-3-yl)propanamide
6T9P,X-RAY DIFFRACTION,3.17,61.21,"VAPOR DIFFUSION, HANGING DROP",,Ammonium Sulfate,293.0,2019-10-28,2020-07-15,6T9P,4438.0,1.0,529.0,56.0,3.0,62.33,1.0,2.7,experimental,71.73,0.2519,0.2101,"Human Butyrylcholinesterase in complex with 2-(N-hydroxyimino)-N-[(1R)-3-{4-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-1,2,3-triazol-1-yl}-1- phenylpropyl]acetamide"
6T9S,X-RAY DIFFRACTION,3.17,61.21,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2019-10-28,2020-07-15,6T9S,4438.0,1.0,529.0,56.0,3.0,62.33,1.0,2.7,experimental,72.16,0.2446,0.2091,"Human Butyrylcholinesterase in complex with 2-(N-hydroxyimino)-N-[(1S)-3-{4-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-1,2,3-triazol-1-yl}-1- phenylpropyl]acetamide"
6QP5,X-RAY DIFFRACTION,2.14,42.57,"VAPOR DIFFUSION, SITTING DROP",,30% PEG4000 -- 0.2M lithium sulfate -- 0.1M tris pH 8.5,293.0,2019-02-13,2020-03-04,6QP5,2311.0,1.0,322.0,194.0,,37.02,1.0,1.9,experimental,35.1966,0.2272,0.1919,Apo Human Calcium/Calmodulin-dependent kinase type 1D
6C9D,X-RAY DIFFRACTION,2.58,52.33,"VAPOR DIFFUSION, HANGING DROP",,"6-8% PEG8000, 0.2-0.3 M imidazole, pH 8.0-8.5",293.0,2018-01-26,2018-07-11,6C9D,6702.0,2.0,918.0,68.0,,105.87,1.0,2.499,experimental,77.8037,0.2514,0.2033,Crystal structure of KA1-autoinhibited MARK1 kinase
4WUY,X-RAY DIFFRACTION,2.64,53.42,"VAPOR DIFFUSION, SITTING DROP",9.0,"100 mM Tris HCl pH 8.6, 14% PEG 20K and 200 mM Sodium Chloride",281.0,2014-11-04,2015-04-08,4WUY,3794.0,1.0,441.0,436.0,,52.27,1.0,1.63,experimental,23.395,0.20013,0.15116,"Crystal Structure of Protein Lysine Methyltransferase SMYD2 in complex with LLY-507, a Cell-Active, Potent and Selective Inhibitor"
6U38,X-RAY DIFFRACTION,2.61,52.82,VAPOR DIFFUSION,,"0.1M Bicine pH9.0, 2% dioxane, 10% PEG 20000",277.0,2019-08-21,2019-11-06,6U38,7473.0,4.0,1875.0,58.0,16.0,202.7,3.0,2.73,experimental,57.73,0.243,0.227,PCSK9 in complex with a Fab and compound 8
7AB1,X-RAY DIFFRACTION,2.26,45.53,VAPOR DIFFUSION,8.5,"0.1M Tris pH 8.5, 4.3M NaCl",293.0,2020-09-05,2020-10-28,7AB1,2177.0,1.0,298.0,54.0,,35.15,1.0,1.93,experimental,52.816,0.2979,0.2344,Crystal structure of MerTK kinase domain in complex with Gilteritinib
5UWF,X-RAY DIFFRACTION,2.01,38.93,VAPOR DIFFUSION,7.5,"15%PEG3350,0.2M calcium acetate,20mM BME",293.0,2017-02-21,2017-04-26,5UWF,5741.0,2.0,688.0,438.0,,80.09,1.0,1.87,experimental,,0.2476,0.1886,Crystal structure of human PDE10A in complex with inhibitor 16d
5XUI,X-RAY DIFFRACTION,2.14,42.48,"VAPOR DIFFUSION, SITTING DROP",,"50mM Bis-tris propane pH6.0, 50mM Magnesium sulfate, 15% PEG 3350, VAPOR DIFFUSION, VAPOR DIFFUSION, SITTING DROP, temperature 296K",296.0,2017-06-23,2018-03-14,5XUI,5275.0,2.0,690.0,29.0,1.0,79.69,1.0,2.77,experimental,57.569,0.27195,0.18548,"Crystal structure of PDE10A in complex with 2-methyl-5-[2-([1,2,4]triazolo[1,5-a]pyrimidin-2-yl)et hyl]pyrazolo[1,5-a]pyrimidin-7-ol"
6WRE,X-RAY DIFFRACTION,2.58,52.4,"VAPOR DIFFUSION, HANGING DROP",7.5,20% (w/v) PEG 3350,293.0,2020-04-29,2020-05-13,6WRE,3168.0,2.0,384.0,128.0,,45.32,1.0,2,experimental,42.1002,0.22,0.1874,Crystal structure of mouse DXO in complex with 5'-OH RNA substrate mimic and calcium ion
6JPE,X-RAY DIFFRACTION,2.27,45.87,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES pH 5.5, 18% PEG4K, 0.15 M (NH4)2SO4, and 4% (v/v) formamide",298.0,2019-03-26,2020-05-06,6JPE,2858.0,1.0,311.0,467.0,,35.41,1.0,1.601,experimental,,0.1829,0.1519,Crystal structure of FGFR4 kinase domain with irreversible inhibitor 1
7WCW,X-RAY DIFFRACTION,2.24,45.05,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19 % PEG3350",277.0,2021-12-20,2022-03-30,7WCW,2530.0,1.0,309.0,123.0,,35.47,1.0,2.317,experimental,31.5034,0.2214,0.1763,Crystal structure of FGFR4(V550L) kinase domain with 7v
7WCX,X-RAY DIFFRACTION,2.24,45.18,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19 % PEG 3350",277.0,2021-12-20,2022-03-30,7WCX,2619.0,1.0,309.0,207.0,,35.58,1.0,2.175,experimental,30.627,0.2214,0.1701,Crystal structure of FGFR4(V550M) kinase domain with 7v
7YBO,X-RAY DIFFRACTION,2.08,40.95,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19 % PEG 3350",277.0,2022-06-29,2022-11-16,7YBO,2441.0,1.0,311.0,61.0,,35.94,1.0,2.307,experimental,37.0843,0.2543,0.2072,Crystal structure of FGFR4 kinase domain with 10z
7YBP,X-RAY DIFFRACTION,2.25,45.26,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19 % PEG 3350",277.0,2022-06-29,2022-11-16,7YBP,2576.0,1.0,309.0,162.0,,35.68,1.0,2.243,experimental,31.9968,0.2138,0.1763,Crystal structure of FGFR4(V550L) kinase domain with 10z
7YBX,X-RAY DIFFRACTION,2.24,45.03,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19 % PEG 3350",277.0,2022-06-30,2022-11-16,7YBX,2588.0,1.0,309.0,179.0,,35.6,1.0,2.233,experimental,27.0086,0.2203,0.1796,Crystal structure of FGFR4(V550M) kinase domain with 10z
6OBP,X-RAY DIFFRACTION,2.63,53.28,"VAPOR DIFFUSION, HANGING DROP",6.2,"14% PEG4000, 6% MPD, sodium/potassium phosphate",289.0,2019-03-21,2019-09-18,6OBP,4733.0,2.0,615.0,14.0,,71.28,2.0,2.7,experimental,,0.2577,0.1985,Reconstituted PP1 holoenzyme
8DWL,X-RAY DIFFRACTION,2.53,51.45,"VAPOR DIFFUSION, SITTING DROP",,"10% w/v PEG 8000, 20% v/v ethylene glycol, 0.1 M MES/imidazole pH 6.5, 0.03 M magnesium chloride, 0.03 M calcium chloride",289.0,2022-08-01,2023-02-15,8DWL,5332.0,4.0,690.0,145.0,,79.44,2.0,2,experimental,53.6259,0.2372,0.213,Inhibitor-3:PP1 coexpressed complex
5FYC,X-RAY DIFFRACTION,2.7,54.48,,6.0,0.1M BIS-TRIS PH 6.0 -- 0.15M AMMONIUM SULFATE -- 22% PEG3350,,2016-03-07,2016-03-16,5FYC,5946.0,2.0,762.0,305.0,,89.82,1.0,2.261,experimental,,0.2293,0.1873,Crystal structure of human JMJD2A in complex with succinate
5FYH,X-RAY DIFFRACTION,2.64,53.43,,6.0,0.1M BIS-TRIS PH 6.0 -- 0.15M AMMONIUM SULFATE -- 22% PEG3350,,2016-03-07,2016-03-23,5FYH,5796.0,2.0,762.0,178.0,,89.57,1.0,2.348,experimental,,0.2498,0.202,Crystal structure of human JMJD2A in complex with fumarate
5ZOE,X-RAY DIFFRACTION,2.33,47.21,"VAPOR DIFFUSION, SITTING DROP",7.8,"PEG 3350, MgCl2, Tris, KCl",298.0,2018-04-13,2019-01-30,5ZOE,3272.0,4.0,373.0,175.0,,49.85,1.0,1.95,experimental,47.5106,0.2271,0.215,Crystal Structure of D181A hFen1 in complex with DNA
5ZOF,X-RAY DIFFRACTION,2.28,46.01,"VAPOR DIFFUSION, SITTING DROP",7.8,"PEG 3350, MgCl2, Tris, KCl",298.0,2018-04-13,2019-01-30,5ZOF,3107.0,4.0,373.0,10.0,,49.84,1.0,2.249,experimental,56.5319,0.2688,0.2353,Crystal Structure of D181A/R192F hFen1 in complex with DNA
5ZOG,X-RAY DIFFRACTION,3.88,68.33,"VAPOR DIFFUSION, SITTING DROP",7.8,"PEG 3350, MgCl2, Tris, KCl",298.0,2018-04-13,2019-01-30,5ZOG,3359.0,4.0,383.0,85.0,,50.8,1.0,2.299,experimental,63.2635,0.2313,0.2087,Crystal Structure of R192F hFen1 in complex with DNA
5AP0,X-RAY DIFFRACTION,3.1,60.34,,7.5,"30% (V/V) PEG300, PH 7.5",,2015-09-14,2015-09-23,5AP0,2219.0,1.0,313.0,59.0,,38.34,1.0,2.15,experimental,74.03,0.2199,0.1842,Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP3,X-RAY DIFFRACTION,3.05,59.62,,7.5,"38% (V/V) PEG300, pH 7.5",,2015-09-14,2015-09-23,5AP3,2128.0,1.0,313.0,21.0,,38.12,1.0,2.7,experimental,88.73,0.2362,0.1899,Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP6,X-RAY DIFFRACTION,2.82,56.37,,7.5,"38% (V/V) PEG300, PH 7.5",,2015-09-14,2015-09-23,5AP6,2226.0,1.0,313.0,63.0,,37.37,1.0,2.1,experimental,64.45,0.2089,0.1822,Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP7,X-RAY DIFFRACTION,3.18,61.28,,8.0,"0.1M TRIS, PH 8.0, 0.2M MGCL2, 20% (W/ V) PEG6000",,2015-09-14,2015-09-23,5AP7,2174.0,1.0,313.0,41.0,,37.26,1.0,2.45,experimental,72.0,0.2343,0.186,Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5QCJ,X-RAY DIFFRACTION,2.5,50.76,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCJ,5823.0,3.0,669.0,602.0,9.0,75.7,1.0,2,experimental,34.986,0.22175,0.18545,Crystal structure of human Cathepsin-S with bound ligand
4UFB,X-RAY DIFFRACTION,3.0,58.0,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",,2015-03-16,2015-10-07,4UFB,22065.0,4.0,2516.0,1611.0,12.0,300.44,1.0,1.8,experimental,29.206,0.2351,0.20671,Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with Lys-Pro
6E99,X-RAY DIFFRACTION,3.05,59.66,"VAPOR DIFFUSION, HANGING DROP",6.6,5 to 27% methanol,277.0,2018-07-31,2018-11-14,6E99,3375.0,2.0,369.0,454.0,,43.2,2.0,1.88,experimental,34.52,0.23,0.207,Crystal structure of Protein Kinase A in complex with the PKI peptide and an amino-pyridinylbenzamide based inhibitor.
6R4T,X-RAY DIFFRACTION,2.56,51.87,"VAPOR DIFFUSION, SITTING DROP",,"23% PEG3350, 10% ethylene glycol, 200 mM Na/K tartrate",292.0,2019-03-24,2019-09-11,6R4T,6632.0,2.0,820.0,63.0,,98.82,1.0,2.35,experimental,,0.2394,0.2093,Crystal structure of the Pri1 subunit of human primase bound to vidarabine triphosphate
6R5D,X-RAY DIFFRACTION,2.52,51.2,"VAPOR DIFFUSION, SITTING DROP",,"23% PEG3350, 10% ethylene glycol, 200 mM Na/K tartrate",292.0,2019-03-24,2019-09-11,6R5D,7033.0,2.0,820.0,376.0,,99.46,1.0,1.95,experimental,,0.2145,0.1781,Crystal structure of the Pri1 subunit of human primase bound to dATP
6R5E,X-RAY DIFFRACTION,2.52,51.26,"VAPOR DIFFUSION, SITTING DROP",,"23% PEG3350, 10% ethylene glycol, 200 mM Na/K tartrate",292.0,2019-03-24,2019-09-11,6R5E,7007.0,2.0,820.0,364.0,,99.46,1.0,1.85,experimental,,0.2057,0.1784,Crystal structure of the Pri1 subunit of human primase bound to 2F-ATP
8HKO,X-RAY DIFFRACTION,2.06,40.16,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG-3350, 0.1 M Tris-HCl pH 8.5",291.0,2022-11-27,2024-05-01,8HKO,6309.0,2.0,706.0,623.0,,81.13,1.0,2.1,experimental,26.86,0.2108,0.1635,Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Rucaparib
5KOT,X-RAY DIFFRACTION,3.06,59.75,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 100 mM citrate, Buffer: 25 mM Tris pH 7.9, 150 mM NaCl, Ligand was soaked for 18h at 2mM",293.0,2016-07-01,2017-07-05,5KOT,5583.0,2.0,674.0,290.0,6.0,77.14,1.0,2.1,experimental,44.13,0.2027,0.1771,"Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor"
6M9T,X-RAY DIFFRACTION,2.66,53.72,LIPIDIC CUBIC PHASE,,"100 mM sodium citrate, pH 3.8-4.2, 10-35 mM magnesium sulfate, 20-23% v/v PEG400, 2.5% Jeffamine M-600",293.0,2018-08-24,2018-12-05,6M9T,3570.0,1.0,537.0,5.0,1.0,62.26,1.0,2.5,experimental,128.85,0.242,0.2,Crystal structure of EP3 receptor bound to misoprostol-FA
6KC4,X-RAY DIFFRACTION,2.15,42.77,"VAPOR DIFFUSION, HANGING DROP",6.8,"HEPES, sodium chloride, PEG 3350",293.0,2019-06-27,2019-09-04,6KC4,6401.0,12.0,654.0,1075.0,,76.24,2.0,1.37,experimental,20.8914,0.1855,0.1646,Crystal structure of human Fer SH2 domain bound to a phosphopeptide (DEpYENVD)
6SD9,X-RAY DIFFRACTION,2.34,47.54,"VAPOR DIFFUSION, SITTING DROP",8.0,"15 % 2-propanol, 17 % PEG4K, 0.1 M NaHEPES pH 8",293.0,2019-07-26,2019-08-14,6SD9,2165.0,1.0,309.0,55.0,,35.51,1.0,2.35,experimental,42.38,0.27,0.21,Crystal structure of wild-type cMET bound by foretinib
7BRH,X-RAY DIFFRACTION,3.8,67.59,"VAPOR DIFFUSION, HANGING DROP",,"Sodium malonate, MES",300.0,2020-03-29,2021-03-31,7BRH,7470.0,3.0,898.0,146.0,6.0,102.7,2.0,2.45,experimental,,0.2375,0.195,Atrial Natriuretic Peptide Receptor complexed with human Atrial Natriuretic Peptide
7BRJ,X-RAY DIFFRACTION,3.77,67.38,"VAPOR DIFFUSION, HANGING DROP",,"Sodium malonate, MES",300.0,2020-03-29,2021-03-31,7BRJ,7286.0,3.0,892.0,144.0,5.0,102.01,2.0,2.7,experimental,,0.2335,0.1927,Atrial Natriuretic Peptide Receptor complexed with deletion mutant of human Atrial Natriuretic Peptide[7-28]
7BRK,X-RAY DIFFRACTION,3.73,67.04,"VAPOR DIFFUSION, HANGING DROP",,"Sodium malonate, MES",300.0,2020-03-29,2021-03-31,7BRK,7388.0,3.0,893.0,110.0,6.0,102.02,2.0,2.85,experimental,,0.2309,0.1761,Atrial Natriuretic Peptide Receptor complexed with deletion mutant of human Atrial Natriuretic Peptide[5-27]
6FNJ,X-RAY DIFFRACTION,2.76,55.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"10 % PEG5000 MME, 0.15 M MgCl2, 15 % Glycerol, 0.1 M TRIS pH 7.5",291.0,2018-02-04,2018-08-08,6FNJ,5037.0,2.0,594.0,646.0,,68.05,1.0,1.239,experimental,,0.2244,0.2096,Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with an isomer of NVP-BHG712
7XZQ,X-RAY DIFFRACTION,2.73,54.96,"VAPOR DIFFUSION, SITTING DROP",,"Hepes-Na, NaCl, 1,4-butanediol",298.0,2022-06-03,2022-10-26,7XZQ,2697.0,2.0,324.0,132.0,,37.34,2.0,2.09,experimental,,0.255,0.196,Crystal structure of TNIK-thiopeptide TP1 complex
7B9B,X-RAY DIFFRACTION,2.76,55.38,"VAPOR DIFFUSION, SITTING DROP",,6% PEG20K -- 0.1M bicine pH 7.3,278.0,2020-12-14,2021-01-20,7B9B,2447.0,1.0,342.0,1.0,,38.67,1.0,2.8,experimental,80.58,0.321,0.2659,Crystal structure of human 5' exonuclease Appollo APO form
8B4T,X-RAY DIFFRACTION,2.1,41.31,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Sodium Acetate pH 5.5, 20% PEG 2000 MME",291.0,2022-09-21,2023-10-04,8B4T,2347.0,1.0,255.0,232.0,6.0,28.43,1.0,1.45,experimental,19.795,0.2081,0.1773,Human cathepsin B in complex with the carbamate inhibitor 7
6QGQ,X-RAY DIFFRACTION,2.51,50.9,"VAPOR DIFFUSION, HANGING DROP",,"25% of of polyethylene glycol (PEG) 2000 MME, 0.3 M sodium acetate, 0.1 M sodium cacodylate pH 6.5;",291.0,2019-01-12,2020-02-05,6QGQ,6865.0,4.0,933.0,132.0,,100.86,2.0,2.601,experimental,,0.238,0.1909,Crystal structure of APT1 C2S mutant bound to palmitic acid.
6H8P,X-RAY DIFFRACTION,2.5,50.78,VAPOR DIFFUSION,6.0,"0.1 M MIB buffer (malonic acid/imidazole/boric acid, pH 6.0) 25% w/v polyethylene glycol 1500",277.0,2018-08-03,2018-08-15,6H8P,6238.0,4.0,792.0,454.0,,92.81,2.0,1.983,experimental,56.0,0.2118,0.192,"JMJD2A/ KDM4A COMPLEXED WITH NI(II), NOG AND Histone H1.4(18-32)K26me3 peptide (15-mer)"
4N1N,X-RAY DIFFRACTION,2.79,55.97,"VAPOR DIFFUSION, HANGING DROP",8.0,"Tris, PEG8000, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2013-10-04,2015-08-12,4N1N,1459.0,1.0,165.0,149.0,,18.16,1.0,1.5,experimental,26.028,0.21283,0.1664,Structure of Cyclophilin A in complex with Benzamide.
4N1P,X-RAY DIFFRACTION,2.81,56.18,"VAPOR DIFFUSION, HANGING DROP",8.0,"Tris, PEG8000, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2013-10-04,2015-08-12,4N1P,1517.0,1.0,165.0,203.0,,18.4,1.0,1.9,experimental,22.824,0.25791,0.19663,Structure of Cyclophilin A in complex with Picolinamide.
4N1Q,X-RAY DIFFRACTION,2.86,57.06,"VAPOR DIFFUSION, HANGING DROP",8.0,"Tris, PEG8000, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2013-10-04,2015-08-12,4N1Q,1629.0,1.0,165.0,321.0,,18.16,1.0,1.65,experimental,21.858,0.22019,0.17981,Structure of Cyclophilin A in complex with cyclohexanecarboxamide.
4N1R,X-RAY DIFFRACTION,2.77,55.6,"VAPOR DIFFUSION, HANGING DROP",8.0,"Tris, PEG8000, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2013-10-04,2015-08-12,4N1R,1578.0,1.0,165.0,287.0,,18.21,1.0,1.8,experimental,25.663,0.22331,0.16975,Structure of Cyclophilin A in complex with benzenesulfonohydrazide.
4N1S,X-RAY DIFFRACTION,2.78,55.73,"VAPOR DIFFUSION, HANGING DROP",8.0,"Tris, PEG8000, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2013-10-04,2015-08-12,4N1S,1623.0,1.0,165.0,296.0,,18.31,1.0,1.47,experimental,20.556,0.22384,0.15565,Structure of Cyclophilin A in complex with benzohydrazide.
6GJJ,X-RAY DIFFRACTION,2.86,57.03,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2018-05-16,2018-11-07,6GJJ,1559.0,1.0,165.0,242.0,,18.33,1.0,1.38,experimental,27.445,0.18514,0.15201,Cyclophilin A complexed with tri-vector ligand 2.
6GJL,X-RAY DIFFRACTION,2.86,57.0,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, Tris-HCl",279.15,2018-05-16,2018-11-07,6GJL,1624.0,1.0,165.0,289.0,,18.37,1.0,1.16,experimental,21.864,0.19194,0.17727,Cyclophilin A complexed with tri-vector ligand 10.
6GJM,X-RAY DIFFRACTION,2.81,56.24,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2018-05-16,2018-11-07,6GJM,1571.0,1.0,165.0,253.0,,18.33,1.0,1.354,experimental,20.723,0.17784,0.16076,Cyclophilin A complexed with tri-vector ligand 4.
6GJP,X-RAY DIFFRACTION,2.82,56.38,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2018-05-16,2018-11-07,6GJP,1501.0,1.0,165.0,182.0,,18.34,1.0,1.94,experimental,29.249,0.23726,0.17495,Cyclophilin A complexed with tri-vector ligand 7.
6GJR,X-RAY DIFFRACTION,2.75,55.22,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 8000, Tris-HCl",279.15,2018-05-16,2018-11-07,6GJR,1485.0,1.0,165.0,161.0,,18.38,1.0,1.69,experimental,32.032,0.26183,0.20002,Cyclophilin A complexed with tri-vector ligand 9.
6GJY,X-RAY DIFFRACTION,2.74,55.18,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, Tris-HCl",279.15,2018-05-17,2018-11-07,6GJY,1662.0,1.0,165.0,300.0,,18.33,1.0,1.29,experimental,21.798,0.18791,0.16371,Cyclophilin A complexed with tri-vector ligand 5.
5UOS,X-RAY DIFFRACTION,5.25,76.6,"VAPOR DIFFUSION, SITTING DROP",9.5,"0.2 M NaCl, 0.1 M CHES:NaOH pH 9.5, 1.26 M (NH4)2SO4",277.0,2017-02-01,2017-06-07,5UOS,2148.0,1.0,241.0,75.0,,29.68,1.0,2.51,experimental,51.619,0.21384,0.17645,"Crystal Structure of CblC (MMACHC) (1-238), a human B12 processing enzyme, complexed with an Antivitamin B12"
6EVN,X-RAY DIFFRACTION,2.67,53.95,"VAPOR DIFFUSION, SITTING DROP",6.5,"2.45 M ammonium sulphate, 10% DMSO, 5 mM PPGPAGPPG, 5% D-galactose, 100 mM MOPS, pH 6.5",277.0,2017-11-02,2018-09-12,6EVN,960.0,2.0,111.0,91.0,,13.17,2.0,1.48,experimental,,0.1788,0.1631,Crystal structure of peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase complex with Pro-Pro-Gly-Pro-Ala-Gly-Pro-Pro-Gly.
6EVO,X-RAY DIFFRACTION,2.72,54.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"2.45 M ammonium sulphate, 10% DMSO, 5 mM PPGPRGPPG, 10 mM EDTA, 100 mM MOPS",277.0,2017-11-02,2018-09-12,6EVO,971.0,2.0,111.0,82.0,,13.18,2.0,1.55,experimental,,0.1802,0.1579,Crystal structure the peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase complexed with Pro-Pro-Gly-Pro-Arg-Gly-Pro-Pro-Gly.
6EVP,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, SITTING DROP",6.5,"2.45 M ammonium sulphate, 10% DMSO, 100 mM MOPS, 5 mM PPGPEGPPG, 5% PEG 400, 100 mM MOPS.",277.0,2017-11-02,2018-09-12,6EVP,894.0,2.0,111.0,49.0,,13.05,2.0,1.68,experimental,,0.2151,0.1827,Crystal structure the peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase complexed with Pro-Pro-Gly-Pro-Glu-Gly-Pro-Pro-Gly.
8JJI,X-RAY DIFFRACTION,2.45,49.85,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Magnesium chloride hexahydrate, 0.1 M Tris pH 8.5, and 25 % (w/v) Polyethylene glycol (PEG) 3350",295.15,2023-05-30,2024-06-26,8JJI,3448.0,2.0,408.0,156.0,,47.0,1.0,2.206,experimental,29.79,0.2286,0.2021,Crystal structure of QR-hNTAQ1 C28S
7ZUS,X-RAY DIFFRACTION,2.7,54.4,"VAPOR DIFFUSION, SITTING DROP",8.9,"15% (w/v) PEG 3350, 0.1 M Bis-Tris propane pH 8.9, 0.2 M sodium citrate tribasic dihydrate.",285.0,2022-05-13,2022-10-12,7ZUS,16842.0,9.0,2265.0,268.0,,273.34,1.0,2.26,experimental,71.064,0.2384,0.2008,Crystal structure of ternary complex of Pol theta polymerase domain
4D2S,X-RAY DIFFRACTION,3.33,63.05,VAPOR DIFFUSION,,"18% PEG3350, 5% ETHANOL, 0.1M NA CITRATE PH 6",,2014-05-12,2015-04-22,4D2S,1937.0,1.0,284.0,2.0,,33.09,1.0,2.5,experimental,28.35,0.221,0.179,Human TTK in complex with a Dyrk1B inhibitor
5UVC,X-RAY DIFFRACTION,2.42,49.08,"VAPOR DIFFUSION, SITTING DROP",5.9,"18% PEG MME 2000, 100mM MES pH 5.9, 17.5mM Ammonium Sulfate",273.0,2017-02-20,2017-07-26,5UVC,3847.0,1.0,547.0,72.0,,63.81,1.0,2.65,experimental,60.002,0.2603,0.2145,"Design, Synthesis, and Evaluation of the First Selective and Potent G-protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure"
5UPD,X-RAY DIFFRACTION,2.41,48.87,"VAPOR DIFFUSION, SITTING DROP",6.5,"20% PEG-5000-MME, 0.1 M bis-tris, 0.02 M sarcosine",293.0,2017-02-02,2017-02-15,5UPD,1892.0,1.0,233.0,144.0,,27.09,1.0,1.8,experimental,24.398,0.2182,0.1839,Methyltransferase domain of human Wolf-Hirschhorn Syndrome Candidate 1-Like protein 1 (WHSC1L1)
5EHO,X-RAY DIFFRACTION,2.9,57.63,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M BIS-TRIS Propane pH 7.5, 0.1M Sodium formate, 0.1M MgCl2, 20% PEG 3350",291.15,2015-10-28,2016-11-09,5EHO,2124.0,1.0,313.0,67.0,,36.62,1.0,2.18,experimental,64.37,0.2069,0.1897,"Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach"
7OVD,X-RAY DIFFRACTION,2.61,52.79,VAPOR DIFFUSION,,"0.2 M tripotassium citrate, 20%(w/v) PEG 3350",277.0,2021-06-14,2021-10-06,7OVD,3744.0,1.0,475.0,67.0,,55.5,1.0,2.2,experimental,63.23,0.2429,0.1991,Human soluble adenylyl cyclase in complex with the inhibitor TDI10229
6DU4,X-RAY DIFFRACTION,2.9,57.6,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris (pH 8.5), 20% glycerol, and 19% polyethylene (PEG)
10000",293.0,2018-06-19,2018-09-26,6DU4,3422.0,2.0,342.0,385.0,,45.58,1.0,1.7,experimental,,0.1726,0.1519,Crystal structure of hMettl16 catalytic domain in complex with MAT2A 3'UTR hairpin 1
5LXH,X-RAY DIFFRACTION,2.24,45.16,"VAPOR DIFFUSION, SITTING DROP",,"0.17 M AMSO4, 40 % PEG 4000, 15 % glycerol",293.0,2016-09-21,2017-02-08,5LXH,3467.0,6.0,399.0,218.0,,48.37,2.0,1.58,experimental,,0.2375,0.2053,GABARAP-L1 ATG4B LIR Complex
6OSP,X-RAY DIFFRACTION,2.53,51.35,"VAPOR DIFFUSION, HANGING DROP",7.0,"20% PEG 3350, 200mM Malic acid",293.0,2019-05-01,2020-04-29,6OSP,5409.0,2.0,788.0,224.0,,91.71,1.0,2.21,experimental,55.1703,0.2253,0.1773,Crystal Structure Analysis of PIP4K2A
5WZM,X-RAY DIFFRACTION,3.39,63.7,VAPOR DIFFUSION,,"2.2M Sodium chloride, 0.1M BIS-TRIS propane pH 7.0",277.0,2017-01-18,2018-01-24,5WZM,1094.0,1.0,121.0,105.0,7.0,14.37,1.0,2,experimental,28.801,0.226,0.1847,Crystal structure of human secreted phospholipase A2 group IIE
5LUD,X-RAY DIFFRACTION,2.79,55.88,"VAPOR DIFFUSION, HANGING DROP",8.0,"Tris, PEG8000",277.0,2016-09-08,2017-04-05,5LUD,1549.0,1.0,165.0,237.0,,18.15,1.0,1.25,experimental,17.751,0.21955,0.19342,"Structure of Cyclophilin A in complex with 2,3-Diaminopyridine"
5WC7,X-RAY DIFFRACTION,2.79,55.91,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 MM HEPES PH 7.5, 22% PEG 3350",291.0,2017-06-29,2018-04-18,5WC7,2236.0,1.0,165.0,234.0,,18.02,1.0,1.43,experimental,,0.1273,0.1037,CypA Mutant - I97V S99T C115S
6BTA,X-RAY DIFFRACTION,2.79,55.97,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 MM HEPES PH 7.5, 22% PEG 3350",291.0,2017-12-06,2018-04-18,6BTA,2039.0,1.0,165.0,160.0,,18.03,1.0,1.5,experimental,,0.146,0.1312,CypA Mutant - S99T C115S
5KUT,X-RAY DIFFRACTION,2.11,41.84,"VAPOR DIFFUSION, SITTING DROP",,"14 mg/mL protein, 0.2 M magnesium formate, 20% w/v PEG3350",294.0,2016-07-13,2016-09-21,5KUT,4332.0,3.0,567.0,379.0,2.0,62.17,1.0,1.693,experimental,,0.2385,0.2179,"hMiro2 C-terminal GTPase domain, GDP-bound"
6EVL,X-RAY DIFFRACTION,2.67,54.03,"VAPOR DIFFUSION, SITTING DROP",6.5,"2.45 M ammonium sulphate, 10% DMSO, 100 mM MOPS, pH 6.5",277.0,2017-11-02,2018-09-12,6EVL,939.0,1.0,102.0,122.0,,12.24,1.0,1.87,experimental,,0.2243,0.1818,Crystal structure of an unlignaded peptide-substrate-binding domain of human type II collagen prolyl 4-hydroxylase
5FYY,X-RAY DIFFRACTION,2.11,41.61,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-10,2016-03-23,5FYY,4092.0,1.0,479.0,235.0,,57.1,1.0,2.18,experimental,,0.2216,0.1867,Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 3-pyridin-3-ylaniline (N05798a) (ligand modelled based on PANDDA event map)
5FZ3,X-RAY DIFFRACTION,2.17,43.3,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-10,2016-03-23,5FZ3,3998.0,1.0,479.0,182.0,,56.59,1.0,2.5,experimental,,0.2171,0.171,"Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 3,6-Dihydroxybenzonorbornane (N08776b) (ligand modelled based on PANDDA event map)"
5FZ4,X-RAY DIFFRACTION,2.1,41.4,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-10,2016-03-23,5FZ4,4023.0,1.0,479.0,205.0,,56.63,1.0,2.07,experimental,,0.2343,0.1984,"Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment (3R)-1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]pyrrolidin-3-ol (N10057a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
5FZA,X-RAY DIFFRACTION,2.11,41.72,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-12,2016-03-30,5FZA,4124.0,1.0,479.0,283.0,,56.61,1.0,2.099,experimental,,0.228,0.1927,Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 2-piperidin-4-yloxy-5-(trifluoromethyl)pyridine (N10072a) (ligand modelled based on PANDDA event map)
4RVB,X-RAY DIFFRACTION,2.36,47.78,"VAPOR DIFFUSION, HANGING DROP",6.2,"13% PEG 8000, 100MM IMIDAZOLE PH 6.2, 100MM NAACETATE, 5MM YBCL3, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-11-25,2015-12-02,4RVB,5462.0,1.0,631.0,564.0,,72.4,1.0,1.93,experimental,14.344,0.17835,0.14415,Crystal Structure Analysis of the Human Leukotriene A4 Hydrolase
5TXK,X-RAY DIFFRACTION,2.87,57.16,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.95 M ammonium sulphate
0.1 M HEPES",296.0,2016-11-17,2018-05-09,5TXK,3875.0,2.0,448.0,683.0,,50.86,2.0,1.84,experimental,25.24,0.1834,0.1602,CRYSTAL STRUCTURE OF USP35 C450S IN COMPLEX WITH UBIQUITIN
7LW8,X-RAY DIFFRACTION,2.44,49.55,"VAPOR DIFFUSION, HANGING DROP",,16% PEG 3350 and 0.2 M lithium acetate,293.0,2021-02-28,2021-07-14,7LW8,2341.0,2.0,358.0,41.0,,43.01,1.0,2.88,experimental,39.7004,0.2586,0.2046,Human Exonuclease 5 crystal structure in complex with a ssDNA
6AKW,X-RAY DIFFRACTION,2.85,56.77,EVAPORATION,,"100 mM sodium citrate, 12% PEG 3350, 8% isopropanol",293.0,2018-09-04,2019-05-29,6AKW,3674.0,1.0,492.0,153.0,,57.05,1.0,2.2,experimental,,0.2544,0.2122,Crystal structure of RNA dioxygenase bound with an inhibitor
4Z84,X-RAY DIFFRACTION,2.31,46.83,"VAPOR DIFFUSION, HANGING DROP",7.0,"The droplets, containing 16 mg/ml protein 25 mM Bis-Tris-HCl, pH 7.0, 150 mM KCl, 1.5mM octanoyl-N-methylglucamide, 0.8 mM PKI peptide and 1mM of the pyrrolidine  inhibitor 34a, were equilibrated against 12-26 % (v/v) methanol.",277.0,2015-04-08,2015-12-02,4Z84,3378.0,2.0,371.0,457.0,,43.47,2.0,1.554,experimental,29.9211444025,0.23429993529,0.208221335319,PKAB3 in complex with pyrrolidine inhibitor 34a
5FY4,X-RAY DIFFRACTION,2.11,41.86,,7.0,"0.1M HEPES PH 7.0, 0.5M POTASSIUM PHOSPHATE DIBASIC, 0.5M SODIUM PHOSPHATE MONOBASIC",,2016-03-04,2017-03-22,5FY4,3996.0,1.0,479.0,237.0,1.0,56.1,1.0,2.1,experimental,,0.1927,0.1927,Crystal structure of the catalytic domain of human JARID1B in complex with succinate
5FY5,X-RAY DIFFRACTION,4.01,69.36,,7.0,PH 7.0,,2016-03-04,2017-03-22,5FY5,3841.0,1.0,479.0,75.0,1.0,56.35,1.0,2.47,experimental,,0.2299,0.1902,Crystal structure of the catalytic domain of human JARID1B in complex with fumarate
4Z0V,X-RAY DIFFRACTION,2.23,44.73,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M MgCl2
0.1M Tris pH 8.5
24% PEG 3350",277.0,2015-03-26,2015-06-17,4Z0V,3850.0,1.0,440.0,360.0,,50.23,1.0,1.78,experimental,21.18,0.201,0.1645,The structure of human PDE12 residues 161-609
5ZTY,X-RAY DIFFRACTION,2.9,63.03,LIPIDIC CUBIC PHASE,6.2,"100mM sodium cacodylate trihydrate pH 6.2, 40% PEG400, 400mM lithium sulfate monohydrate",293.0,2018-05-05,2019-01-30,5ZTY,3741.0,1.0,500.0,49.0,1.0,59.33,1.0,2.8,experimental,95.84,0.275,0.224,Crystal structure of human G protein coupled receptor
6SKD,X-RAY DIFFRACTION,2.18,43.6,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-08-15,2019-09-25,6SKD,3589.0,2.0,446.0,115.0,12.0,49.71,1.0,2.26,experimental,43.63,0.282,0.224,Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK3397892A
6CZ4,X-RAY DIFFRACTION,2.31,46.87,"VAPOR DIFFUSION, SITTING DROP",,"1.25 M Sodium dihydrogen phosphate, 0.89 M di-Potassium hydrogen phosphate, 0.2 M Lithium sulfate, 0.1 M CHES, pH 9.8, 13o C",286.0,2018-04-07,2018-06-20,6CZ4,2326.0,1.0,264.0,180.0,,30.77,1.0,1.5,experimental,28.7,0.209,0.203,"Structure of the PTK6 kinase domain bound to a type II inhibitor 2-{[(3R,4S)-3-fluoro-1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl]oxy}-5-(1-methyl-1H-imidazol-4-yl)pyridine-3-carboxamide"
6TUR,X-RAY DIFFRACTION,2.87,57.21,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 3350, 100 mM Citric acid pH 3.5",295.0,2020-01-08,2020-09-16,6TUR,10271.0,4.0,1420.0,,2.0,163.91,1.0,2.9,experimental,101.744,0.2814,0.2375,"human XPG, Apo1 form"
6D6I,X-RAY DIFFRACTION,2.77,55.58,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2M LiSO4, 25% PEG3350, 0.1 M Tris-HCl pH 8.5",293.0,2018-04-21,2019-07-17,6D6I,5118.0,6.0,772.0,,,87.08,3.0,2.551,experimental,114.7371,0.2963,0.2635,Ube2V1 in complex with ubiquitin variant Ubv.V1.1 and Ube2N/Ubc13
8YGY,X-RAY DIFFRACTION,2.39,48.45,"VAPOR DIFFUSION, SITTING DROP",,"0.2M (NH4)2SO4, 0.1M Bis-Tris pH6.5, 25% PEG3,350.",293.0,2024-02-27,2024-03-13,8YGY,2004.0,1.0,238.0,98.0,5.0,27.23,1.0,2.401,experimental,32.974,0.2451,0.1803,Structure of the KLK1 from Biortus.
5FYB,X-RAY DIFFRACTION,2.1,41.49,,7.5,"0.1M HEPES PH 7.5, 0.8M POTASSIUM PHOSPHATE DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,2016-03-05,2017-03-29,5FYB,4306.0,1.0,479.0,468.0,,57.45,1.0,1.87,experimental,,0.223,0.1905,Crystal structure of the catalytic domain of human JARID1B in complex with MC1648
5FYT,X-RAY DIFFRACTION,2.1,41.34,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-09,2016-03-23,5FYT,4207.0,1.0,479.0,360.0,,57.09,1.0,1.87,experimental,,0.2216,0.188,"Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment (5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-yl)acetic acid (N09996a)"
5FYU,X-RAY DIFFRACTION,2.1,41.44,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-09,2016-03-23,5FYU,4069.0,1.0,479.0,242.0,1.0,56.72,1.0,2.06,experimental,,0.2274,0.1937,"Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 3-Amino-4-methyl-1,3-dihydro-2H-indol-2-one (N10042a)"
5FYZ,X-RAY DIFFRACTION,2.11,41.62,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-10,2016-03-23,5FYZ,4164.0,1.0,479.0,344.0,,56.67,1.0,1.75,experimental,,0.2309,0.2015,"Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 2-(2-oxo-2,3-dihydro-1H-indol-3-yl)acetonitrile (N10063a)"
5FZ1,X-RAY DIFFRACTION,4.1,70.03,,7.5,PH 7.5,,2016-03-10,2016-05-04,5FZ1,4007.0,1.0,479.0,163.0,,56.74,1.0,2.39,experimental,,0.2224,0.1826,"Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 2,4-dichloro-N-pyridin-3-ylbenzamide (E48115b) (ligand modelled based on PANDDA event map)"
5FZE,X-RAY DIFFRACTION,2.07,40.73,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2017-03-29,5FZE,4059.0,1.0,479.0,258.0,,56.79,1.0,2.02,experimental,,0.2168,0.1842,Crystal structure of the catalytic domain of human JARID1B in complex with MC3960
5FZF,X-RAY DIFFRACTION,2.07,40.67,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2017-03-29,5FZF,4139.0,1.0,479.0,270.0,,57.55,1.0,1.97,experimental,,0.2114,0.1786,Crystal structure of the catalytic domain of human JARID1B in complex with MC3962
5FZI,X-RAY DIFFRACTION,2.09,41.11,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2017-03-29,5FZI,4223.0,1.0,479.0,265.0,1.0,57.16,1.0,1.95,experimental,,0.2215,0.1909,Crystal structure of the catalytic domain of human JARID1B in complex with MC3095
5LW9,X-RAY DIFFRACTION,4.26,71.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES PH 8.0, 0.8M                   POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE                 MONOBASIC",277.0,2016-09-15,2016-09-28,5LW9,3854.0,1.0,481.0,110.0,1.0,56.46,1.0,2.3,experimental,66.6067,0.2177,0.1847,Crystal structure of human JARID1B in complex with S40563a
5LWB,X-RAY DIFFRACTION,4.4,72.03,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.8M Pottassium Phosphate- dibasic, 0.8M Sodium Phosphate monobasic",277.0,2016-09-15,2016-10-26,5LWB,3894.0,1.0,481.0,153.0,2.0,56.67,1.0,2.39,experimental,57.4458,0.2177,0.1822,Crystal structure of human JARID1B in complex with S40650a
6EIU,X-RAY DIFFRACTION,4.28,71.29,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.8M Pottassium Phosphate-dibasic, 0.8M Sodium Phosphate monobasic",277.0,2017-09-19,2018-05-02,6EIU,3966.0,1.0,462.0,280.0,,54.64,1.0,1.88,experimental,43.3288,0.2209,0.1957,Crystal structure of KDM5B in complex with KDOPZ29a
6EIY,X-RAY DIFFRACTION,4.19,70.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.8M Pottassium Phosphate-dibasic, 0.8M Sodium Phosphate monobasic",277.0,2017-09-19,2018-05-02,6EIY,3916.0,1.0,461.0,185.0,2.0,54.14,1.0,2.15,experimental,55.6744,0.2154,0.1861,Crystal structure of KDM5B in complex with KDOPZ000034a.
6EJ0,X-RAY DIFFRACTION,4.17,70.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.8M Pottassium Phosphate-dibasic, 0.8M Sodium Phosphate monobasic",277.0,2017-09-19,2018-05-02,6EJ0,3868.0,1.0,458.0,177.0,1.0,53.95,1.0,2.06,experimental,56.8936,0.2104,0.1903,Crystal structure of KDM5B in complex with KDOPZ000049a.
6EJ1,X-RAY DIFFRACTION,4.31,71.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.8M Pottassium Phosphate-dibasic, 0.8M Sodium Phosphate monobasic",277.0,2017-09-19,2018-05-02,6EJ1,3933.0,1.0,459.0,244.0,1.0,53.87,1.0,2.07,experimental,49.7943,0.2175,0.1946,Crystal structure of KDM5B in complex with KDOPZ48a.
6EK6,X-RAY DIFFRACTION,4.17,70.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.8M Pottassium Phosphate-dibasic, 0.8M Sodium Phosphate monobasic",277.0,2017-09-25,2018-03-14,6EK6,3882.0,1.0,455.0,210.0,1.0,53.94,1.0,2.05,experimental,45.0013,0.2004,0.1794,Crystal structure of KDM5B in complex with S49195a.
6LP2,X-RAY DIFFRACTION,2.68,54.07,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, potassium citrate",291.0,2020-01-08,2021-01-13,6LP2,4985.0,3.0,614.0,141.0,,69.89,3.0,2.479,experimental,39.0475,0.2326,0.1751,Structure of Lpg2148/UBE2N-Ub complex
8Q6G,X-RAY DIFFRACTION,2.16,43.15,"VAPOR DIFFUSION, HANGING DROP",7.0,Sodium Formate,293.0,2023-08-11,2023-12-13,8Q6G,3577.0,1.0,424.0,402.0,,49.1,1.0,1.541,experimental,22.524,0.22134,0.16729,HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 8)
8Q6H,X-RAY DIFFRACTION,2.21,44.26,"VAPOR DIFFUSION, HANGING DROP",7.0,Sodium Formate,293.0,2023-08-11,2023-12-13,8Q6H,3420.0,1.0,424.0,249.0,,49.04,1.0,1.94,experimental,32.21,0.23679,0.16952,HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 11)
5W0B,X-RAY DIFFRACTION,3.74,67.12,"VAPOR DIFFUSION, SITTING DROP",,"0.8-1.0 M lithium sulfate, 0.075-0.2 M potassium iodide, 0.05-0.2 M trisodium citrate, pH 5-6",291.0,2017-05-30,2017-06-28,5W0B,8422.0,3.0,1167.0,22.0,,135.28,1.0,2.614,experimental,95.1683,0.255,0.2305,Structure of human TUT7 catalytic module (CM)
4OXC,X-RAY DIFFRACTION,1.86,34.04,LIQUID DIFFUSION,8.5,"PEG 4000, Sodium Acetate",293.0,2014-02-05,2015-02-11,4OXC,2502.0,4.0,444.0,48.0,,49.69,1.0,2.9,experimental,56.4,0.251,0.176,Crystal structure of XIAP BIR1 domain
5FDP,X-RAY DIFFRACTION,2.26,45.63,"VAPOR DIFFUSION, SITTING DROP",7.0,"20% Polyethylene glycol 3350, 10% ethylene glycol, 0.1M Bis-tris propane pH 6.5, 0.2M Sodium Acetate",293.15,2015-12-16,2016-06-08,5FDP,2603.0,1.0,337.0,271.0,,39.22,1.0,2.25,experimental,22.33,0.2685,0.1865,Structure of DDR1 receptor tyrosine kinase in complex with D2099 inhibitor at 2.25 Angstroms resolution.
6VXU,X-RAY DIFFRACTION,2.58,52.28,"VAPOR DIFFUSION, SITTING DROP",6.5,27.5% PEG3350; 300 mM LiSO4; 0.1 M SBG (each Sodium-tartrate + Bis-Tris + Glycylglycine) pH 6.5,293.0,2020-02-24,2021-03-03,6VXU,10525.0,4.0,1456.0,590.0,,167.59,1.0,2,experimental,39.26,0.203,0.184,Structure of Human Vaccinia-related Kinase 1 (VRK1) bound to ACH471
6E0R,X-RAY DIFFRACTION,2.11,41.72,VAPOR DIFFUSION,,"16.75% PEG 3350, 2.% Tacsimate pH 7.0, 0.1M Tris Cl",293.0,2018-07-06,2019-05-01,6E0R,2283.0,1.0,322.0,47.0,,36.5,1.0,2.303,experimental,,0.296,0.2375,"hALK in complex with compound 7 N-((1S)-1-(5-fluoropyridin-2-yl)ethyl)-1-(5-methyl-1H-pyrazol-3-yl)-3-(oxetan-3-ylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-6-amine"
6EBW,X-RAY DIFFRACTION,2.13,42.35,VAPOR DIFFUSION,,"14.25% PEG 3350, 2.% Tacsimate pH 7.0, 0.1M Tris Cl",293.0,2018-08-07,2019-05-01,6EBW,2228.0,1.0,322.0,25.0,,36.49,1.0,2.455,experimental,,0.2864,0.242,"hALK in complex with compound 9 (6-(((1S)-1-(5-Fluoropyridin-2-yl)ethyl)amino)-1-(3-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)(morpholin-4-yl)methanone"
6ZEJ,X-RAY DIFFRACTION,2.69,54.23,"VAPOR DIFFUSION, SITTING DROP",8.4,"20% PEG 3350, 0.2M Potassium Citrate",293.0,2020-06-16,2020-09-30,6ZEJ,17414.0,6.0,2178.0,674.0,,250.36,1.0,1.78,experimental,41.03,0.2714,0.2418,Structure of PP1-Phactr1 chimera [PP1(7-304) + linker (SGSGS) + Phactr1(526-580)]
5SF4,X-RAY DIFFRACTION,2.59,52.52,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SF4,10809.0,4.0,1372.0,493.0,4.0,159.89,1.0,2.25,experimental,40.878,0.2345,0.1847,Crystal Structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-N-[2-[2-(dimethylamino)ethyl]-5-pyridin-2-ylpyrazol-3-yl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide
5W0M,X-RAY DIFFRACTION,3.42,64.06,"VAPOR DIFFUSION, SITTING DROP",,"0.8-1.0 M lithium sulfate, 0.075-0.2 M potassium iodide, 0.05-0.2 M trisodium citrate, pH 5-6",291.0,2017-05-31,2017-06-28,5W0M,9325.0,6.0,1182.0,205.0,,139.65,1.0,2.298,experimental,65.9348,0.2287,0.1883,Structure of human TUT7 catalytic module (CM) in complex with U5 RNA
6FYM,X-RAY DIFFRACTION,2.74,55.18,"VAPOR DIFFUSION, SITTING DROP",,"20% Poly(ethylene glycol) 3350, 0.2M sodium nitrate",277.0,2018-03-12,2019-02-20,6FYM,6281.0,4.0,772.0,104.0,2.0,89.79,1.0,2.15,experimental,46.74,0.224,0.191,"Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor ITK1"
6W65,X-RAY DIFFRACTION,2.88,57.33,"VAPOR DIFFUSION, SITTING DROP",,"100mM Sodium citrate pH5.5, 18%w/v PEG3350",291.15,2020-03-16,2020-10-07,6W65,6183.0,3.0,831.0,279.0,,96.23,1.0,2.13,experimental,55.531,0.2247,0.1901,Human PARP16 in complex with RBN010860
5XFF,X-RAY DIFFRACTION,2.58,52.32,"VAPOR DIFFUSION, HANGING DROP",,0.65 M NH4H2PO4,277.0,2017-04-10,2018-09-05,5XFF,2158.0,1.0,311.0,5.0,,35.15,1.0,2.7,experimental,,0.3197,0.2652,Crystal structure of LY2874455 in complex of FGFR4 gatekeeper mutation (V550L)
6IUO,X-RAY DIFFRACTION,2.66,53.81,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES pH7.5, 1.3 M (NH4)2SO4",293.0,2018-11-29,2019-10-23,6IUO,2201.0,1.0,322.0,51.0,,36.42,1.0,2.3,experimental,36.63,0.232,0.186,Crystal structure of FGFR4 kinase domain in complex with a covalent inhibitor
6NVG,X-RAY DIFFRACTION,2.74,55.13,"VAPOR DIFFUSION, HANGING DROP",4.5,"100mM Bis-tris pH4.5, 200mM Lithium sulphate, 16% PEG 3350",291.0,2019-02-05,2019-07-10,6NVG,2171.0,1.0,300.0,76.0,,34.7,1.0,1.99,experimental,45.557,0.23295,0.20442,"FGFR4 complex with N-(3,5-dichloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)phenyl)acrylamide"
6NVH,X-RAY DIFFRACTION,2.76,55.45,"VAPOR DIFFUSION, HANGING DROP",,"100mM Bis-tris pH 4.5, 200mM lithium sulphate, 12% PEG3350",291.0,2019-02-05,2019-07-10,6NVH,2226.0,1.0,300.0,106.0,,34.55,1.0,1.9,experimental,39.829,0.23364,0.21225,"FGFR4 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide"
6NVI,X-RAY DIFFRACTION,2.73,55.0,"VAPOR DIFFUSION, HANGING DROP",4.5,"100mM bis-tris pH 4.5, 200mM lithium sulfate, 16% PEG 3350",291.0,2019-02-05,2019-07-10,6NVI,2065.0,1.0,300.0,37.0,,34.49,1.0,2.117,experimental,59.04,0.28053,0.24175,"FGFR4 complex with N-(3-chloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-5-fluorophenyl)acrylamide"
6NVJ,X-RAY DIFFRACTION,2.67,53.91,"VAPOR DIFFUSION, HANGING DROP",4.5,"100mM Bis-tris pH 4.5, 200mM Lithium sulphate, 16% PEG 3350",291.0,2019-02-05,2019-07-10,6NVJ,2101.0,1.0,300.0,13.0,,34.75,1.0,2.3,experimental,49.127,0.27123,0.22246,"FGFR4 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-fluorophenyl)acrylamide"
6NVK,X-RAY DIFFRACTION,2.71,54.58,"VAPOR DIFFUSION, SITTING DROP",4.5,"100mM Bis-tris pH4.5, 200mM Lithium sulfate, 16% PEG 3350",277.0,2019-02-05,2019-07-10,6NVK,2116.0,1.0,300.0,19.0,,34.66,1.0,2.3,experimental,48.107,0.26589,0.21358,"FGFR4 complex with BLU-554, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide"
5FS7,X-RAY DIFFRACTION,2.82,56.5,,8.5,"0.2 M LITHIUM SULFATE, 0.1M TRIS, PH 8.5, AND 25% POLY-ETHYLENE GLYCOL 3350",,2015-12-30,2016-05-11,5FS7,8238.0,2.0,1030.0,1081.0,,114.11,1.0,1.85,experimental,20.89,0.21691,0.17885,Crystal structure of the G262S mutant of human apoptosis inducing factor
8BVL,X-RAY DIFFRACTION,2.83,56.52,"VAPOR DIFFUSION, SITTING DROP",7.0,"200 mM magnesium chloride hexahydrate
100mM Tris-HCl pH 7.0
10% PEG 8000",291.0,2022-12-04,2023-01-18,8BVL,2340.0,2.0,290.0,76.0,,33.33,1.0,2.24,experimental,,0.2961,0.2341,Crystal structure of the IBR-RING2 domain of HOIL-1
8D58,X-RAY DIFFRACTION,3.11,60.39,"VAPOR DIFFUSION, HANGING DROP",,"50 mM MES pH 6.0, 6 mM MgCl2, 10 % isopropanol, 30% D-(+)-Galactose, 10 mM L-Glutathione reduced, 10 mM L-Glutathione oxidized",295.15,2022-06-04,2023-01-11,8D58,4400.0,2.0,651.0,60.0,,74.0,2.0,2.47,experimental,64.87,0.2293,0.2031,Crystal structure of human METTL1-WDR4 complex
7DE3,X-RAY DIFFRACTION,2.5,50.85,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,0.2M Ammonium acetate",277.0,2020-11-01,2021-11-10,7DE3,1625.0,1.0,194.0,170.0,,21.7,1.0,2.197,experimental,32.0887,0.2595,0.205,Human adenylate kinase 1 (hAK1) mutant-R128W
6P5B,X-RAY DIFFRACTION,2.4,48.82,"VAPOR DIFFUSION, HANGING DROP",9.0,"0.2 M Na Malonate, 25% PEG 3350, 10 mM NiCl2",298.0,2019-05-30,2020-05-27,6P5B,4894.0,3.0,617.0,197.0,,69.93,3.0,2.099,experimental,37.4283,0.2319,0.1949,Crystal Structure of MavC in Complex with Ub-UbE2N
6ULH,X-RAY DIFFRACTION,2.4,48.83,"VAPOR DIFFUSION, HANGING DROP",4.6,"0.1 M Sodium Acetate: HCl, pH 4.6
3.5 M Sodium Formate",294.0,2019-10-08,2020-05-27,6ULH,4906.0,3.0,617.0,272.0,1.0,69.98,3.0,1.968,experimental,39.8601,0.2265,0.1829,Structure of MavC in complex with its substrate in R3 spacegroup
6UMP,X-RAY DIFFRACTION,2.49,50.64,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodium formate, 20% w/v Polyethylene glycol 3,350",298.0,2019-10-10,2020-05-27,6UMP,4608.0,3.0,617.0,,1.0,69.98,3.0,2.8,experimental,67.3709,0.3038,0.2445,Crystal structure of MavC in complex with substrate mimic in P65 space group
6UMS,X-RAY DIFFRACTION,2.3,46.57,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M Potassium bromide, 30% (w/v) PEG 2000 MME",294.0,2019-10-10,2020-05-27,6UMS,4689.0,3.0,617.0,168.0,1.0,69.98,3.0,2.344,experimental,59.0283,0.2498,0.2111,Crystal structure of MavC in complex with its substrate mimic in C222(1) space group
6J8N,X-RAY DIFFRACTION,2.77,55.57,"VAPOR DIFFUSION, SITTING DROP",,"6% v/v Tacsimate pH6.0, 0.1M MES monohydrate pH 6.0, 25% PEG 4000",291.0,2019-01-20,2019-06-19,6J8N,4906.0,4.0,608.0,649.0,,70.92,2.0,1.95,experimental,,0.2102,0.1853,"Crystal structure of SVBP-VASH1 complex, mutation C169A of VASH1"
6J9H,X-RAY DIFFRACTION,2.96,58.51,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na citrate tribasic dihydrate pH 5.5, 16% PEG 8000, 0.01M Cadmium chloride hydrate",291.0,2019-01-22,2019-06-19,6J9H,4436.0,4.0,608.0,127.0,,70.98,2.0,2.31,experimental,,0.2709,0.2477,Crystal structure of SVBP-VASH1 complex
5N7V,X-RAY DIFFRACTION,3.14,60.82,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl",273.0,2017-02-21,2017-05-31,5N7V,2276.0,1.0,313.0,92.0,,37.24,1.0,2.52,experimental,88.663,0.27839,0.19442,TTK kinase domain in complex with MPI-0479605
5N87,X-RAY DIFFRACTION,3.14,60.82,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.",293.0,2017-02-23,2017-05-31,5N87,2253.0,1.0,313.0,100.0,,36.98,1.0,2.29,experimental,67.76,0.23829,0.19782,TTK kinase domain in complex with NTRC 0066-0
5N93,X-RAY DIFFRACTION,2.98,58.74,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.pH 6.3",293.0,2017-02-24,2017-05-31,5N93,2208.0,1.0,313.0,58.0,,36.54,1.0,2.1,experimental,71.373,0.26798,0.21561,TTK kinase domain in complex with TC-Mps1-12
5N9S,X-RAY DIFFRACTION,3.16,61.02,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.pH 6.3",293.0,2017-02-27,2017-05-31,5N9S,2233.0,1.0,313.0,66.0,,36.77,1.0,2.3,experimental,55.358,0.24485,0.19091,TTK kinase domain in complex with BAY 1161909
5NA0,X-RAY DIFFRACTION,3.22,61.8,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.pH 6.3",293.0,2017-02-27,2017-05-31,5NA0,2142.0,1.0,313.0,8.0,,36.97,1.0,2.9,experimental,83.95,0.27092,0.20663,TTK kinase domain in complex with a PEG-linked pyrimido-indolizine
5NAD,X-RAY DIFFRACTION,3.05,59.7,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.pH 6.3",293.0,2017-02-27,2017-05-31,5NAD,2158.0,1.0,313.0,9.0,,36.77,1.0,2.8,experimental,89.214,0.28967,0.20593,TTK kinase domain in complex with BAY 1217389
7YXT,X-RAY DIFFRACTION,3.0,59.06,"VAPOR DIFFUSION, HANGING DROP",6.2,"Well: 0.1M KH2PO4/K2HPO4 buffer at pH 6.2 supplemented with 17% of PEG 3350 solution

Protein: 5 mM HEPES/NaOH pH 7.6, 200 mM NaCl, 5 mM DTT",298.0,2022-02-16,2023-03-01,7YXT,12835.0,4.0,1620.0,686.0,,184.53,1.0,2.48,experimental,54.24,0.2586,0.1963,"Crystal structure of human Indoleamine-2,3-dioxygenase 1 (hIDO1) with different conformations for G261-G265 fragment"
6D1Y,X-RAY DIFFRACTION,2.34,47.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"Well volume: 25.0 uL
Well Ingredients:
Buffer: 0.1 M (5.0 uL of stock 0.5 M) ADA (pH 6.50)
Salt: 3.0 M (9.375 uL of stock 8.0 M) lithium nitrate

Plate setup temperature: 13 C
Plate incubation temperature: 4 C

Drop volume from well: 0.1 uL
Drop protein volume: 0.1 uL

Protein Formulation Composition:
Protein: (5.0 mg/mL) (0.14 mM)
Compound:  (3.00 mM)",277.0,2018-04-12,2018-05-02,6D1Y,2568.0,1.0,320.0,154.0,,36.46,1.0,1.93,experimental,18.77,0.2244,0.1766,"Crystal structure of Tyrosine-protein kinase receptor in complex with 2,4-dichloro-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)benzamide Inhibitor"
7NEU,X-RAY DIFFRACTION,2.74,55.14,"VAPOR DIFFUSION, SITTING DROP",6.25,"100mM MES, 300mM Ammonium Chloride, 35% PEG 3350",293.0,2021-02-04,2021-04-07,7NEU,3284.0,1.0,400.0,29.0,3.0,47.03,1.0,2.8,experimental,30.706,0.2817,0.2012,Inhibitor Complex with Thrombin Activatable Fibrinolysis Inhibitor (TAFIa)
7SLV,X-RAY DIFFRACTION,2.47,50.2,"VAPOR DIFFUSION, SITTING DROP",,"100 mM MES pH 6.1-6.7, 22-33% PEG-MME-2000, 10 mM TCEP",295.0,2021-10-25,2022-01-12,7SLV,4019.0,1.0,482.0,212.0,5.0,56.61,1.0,2.13,experimental,53.28,0.2234,0.1806,Vanin-1 complexed with Compound 3
7SLX,X-RAY DIFFRACTION,2.47,50.27,"VAPOR DIFFUSION, SITTING DROP",,"100 mM MES pH 6.1-6.7, 22-33% PEG-MME-2000, 10 mM TCEP",295.0,2021-10-25,2022-01-12,7SLX,4004.0,1.0,482.0,218.0,5.0,56.29,1.0,2.35,experimental,59.19,0.2172,0.1739,Vanin-1 complexed with Compound 11
6SYP,X-RAY DIFFRACTION,3.38,63.56,"VAPOR DIFFUSION, SITTING DROP",4.8,"32% PEG 400
0.2M KSCN
0.2M NaBr
0.1M acetate 4.8",293.0,2019-09-30,2019-10-09,6SYP,2846.0,1.0,395.0,146.0,,44.04,1.0,1.8,experimental,29.245,0.2026,0.1817,Human DHODH bound to inhibitor IPP/CNRS-A017
5EHY,X-RAY DIFFRACTION,3.11,60.42,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1m HEPES pH 7.5
30-45% PEG300",291.15,2015-10-29,2016-04-20,5EHY,2183.0,1.0,313.0,46.0,,38.94,1.0,2.26,experimental,73.41,0.2072,0.1854,"Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach"
5EI6,X-RAY DIFFRACTION,2.84,56.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M BIS-TRIS Propane, 0.2 M MgCl2, 0.2 M Sodium formate, 20% PEG 3350",291.15,2015-10-29,2016-04-20,5EI6,2154.0,1.0,313.0,72.0,,36.63,1.0,2.01,experimental,52.83,0.2205,0.1967,"Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach"
5A7O,X-RAY DIFFRACTION,2.62,53.0,,8.5,PEG3350 -- 0.1M TRIS PH 8.5 -- 0.25M AMMONIUM SULFATE,,2015-07-09,2016-01-13,5A7O,6094.0,2.0,762.0,316.0,,90.87,1.0,2.15,experimental,,0.2219,0.1819,Crystal structure of human JMJD2A in complex with compound 42
5A7P,X-RAY DIFFRACTION,2.66,53.78,,5.5,"28% PEG3350, 0.1M BIS-TRIS PH 5.5, 0.15M AMMONIUM SULFATE",,2015-07-09,2016-01-13,5A7P,6109.0,2.0,762.0,350.0,,90.42,1.0,2.28,experimental,,0.2362,0.1876,Crystal structure of human JMJD2A in complex with compound 36
5A7S,X-RAY DIFFRACTION,2.66,2.66,,8.5,30% PEG3350 -- 0.1M TRIS PH 8.5 -- 0.25M AMMONIUM SULFATE,,2015-07-09,2016-01-13,5A7S,6133.0,2.0,762.0,394.0,,90.53,1.0,2.2,experimental,,0.2275,0.1707,Crystal structure of human JMJD2A in complex with compound 44
7QHD,X-RAY DIFFRACTION,3.19,61.4,"VAPOR DIFFUSION, HANGING DROP",,Ammonium Sulfate,293.0,2021-12-12,2022-12-21,7QHD,4807.0,1.0,529.0,293.0,3.0,64.13,1.0,2.04,experimental,45.92,0.2044,0.1713,"Human Butyrylcholinesterase in complex with (S)-1-(4-((2-(1H-indol-3-yl)ethyl)carbamoyl)benzyl)-N-(3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)piperidine-3-carboxamide"
5LRW,X-RAY DIFFRACTION,2.12,41.99,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium acetate (pH 4.8), 6% (w/v) PEG 6K",291.0,2016-08-22,2016-10-19,5LRW,6238.0,4.0,744.0,621.0,,85.35,2.0,2,experimental,,0.2171,0.1761,Structure of Cezanne/OTUD7B OTU domain bound to ubiquitin
5FS8,X-RAY DIFFRACTION,2.45,49.75,,7.5,"0.2 M AMMONIUM ACETATE AND 20% POLY-ETHYLENE GLYCOL, pH 7.5",,2015-12-31,2016-05-11,5FS8,4578.0,1.0,515.0,647.0,,57.12,1.0,1.4,experimental,23.382,0.19247,0.16443,Crystal structure of the G308E mutant of human apoptosis inducing factor
5FV3,X-RAY DIFFRACTION,2.0,38.66,,7.5,"0.1M HEPES PH 7.5, 0.8M POTASSIUM PHOSPHATE DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,2016-02-02,2016-02-17,5FV3,3911.0,1.0,484.0,120.0,1.0,57.06,1.0,2.37,experimental,,0.235,0.1935,Crystal structure of human JARID1B construct c2 in complex with N- Oxalylglycine.
7E72,X-RAY DIFFRACTION,2.92,57.82,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Bis-Tris propane pH 8.5, 110 mM potassium dihydrogen phosphate, 15% (w/v) polyethylene glycol 3350",292.15,2021-02-25,2021-11-10,7E72,10494.0,6.0,1280.0,737.0,10.0,142.43,3.0,2.094,experimental,39.2863,0.2331,0.1826,Crystal structure of Tie2-agonistic antibody in complex with human Tie2 Fn2-3
5UOY,X-RAY DIFFRACTION,3.12,60.56,"VAPOR DIFFUSION, HANGING DROP",6.9,"3.1 M NaCl, 0.1 M HEPES pH 6.9",293.0,2017-02-01,2017-04-26,5UOY,2805.0,1.0,361.0,140.0,,42.3,1.0,1.82,experimental,,0.2209,0.1891,"Crystal structure of human PDE1B catalytic domain in complex with inhibitor 16j (6-(4-Methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one)"
6WE2,X-RAY DIFFRACTION,3.01,59.15,"VAPOR DIFFUSION, SITTING DROP",,0.2 M Ammonium sulfate; 0.1 M tri-Sodium citrate pH 5.6; 25 % w/v PEG 4000,291.15,2020-04-01,2021-03-24,6WE2,3120.0,2.0,378.0,18.0,2.0,44.13,1.0,2.66,experimental,43.163,0.29596,0.24591,"Human PARP14 (ARTD8), catalytic fragment in complex with RBN012759"
5IMX,X-RAY DIFFRACTION,2.08,40.81,"VAPOR DIFFUSION, SITTING DROP",8.5,"18% PEG 3350, 0.1 M Tris-HCl, PH 8.5",293.0,2016-03-07,2016-05-04,5IMX,2135.0,1.0,327.0,30.0,,37.49,1.0,2.12,experimental,48.517,0.2593,0.2105,Anaplastic lymphoma kinase (ALK) catalytic domain complexed with novel inhibitor 3-sulfonylpyrazol-4-amino pyrimidine
4QDV,X-RAY DIFFRACTION,2.42,49.14,"VAPOR DIFFUSION, HANGING DROP",,"22-25% PEG3350, 50 mM sodium chloride, 26% glycerol, crystals soaked in 1 mM compound overnight, VAPOR DIFFUSION, HANGING DROP",,2014-05-14,2015-05-20,4QDV,9663.0,4.0,1348.0,,,156.09,1.0,2.8,experimental,65.24,0.2499,0.2055,Dcps in complex with covalent ligand
5ZN0,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.0,38.45,VAPOR DIFFUSION,8.5,"0.1M Tris-HCl, 0.85M ammonium sulfate, 5% acetonitrile, 2mM DTT",293.0,2018-04-07,2018-11-21,5ZN0,3204.0,1.0,329.0,418.0,,39.54,1.0,"1.1, 1.9",experimental,32.7164,0.212,0.186,Joint X-ray/neutron structure of protein kinase ck2 alpha subunit
,,,,,,,,,,,,,,,,,,,,,0.247,0.188,
6ENM,X-RAY DIFFRACTION,2.0,38.53,"VAPOR DIFFUSION, SITTING DROP",8.5,"Drops: 1 micro-L  hMMP12 at 927 micro-M + 10 mM acetohydroxamic acid, LP168 at 1 milli-M and 1 micro-L precipitant.
Precipitant: 17% PEG 20K, 0.2 M imidazole malate, pH 8.5, 0.250 M NaCl
cryoprotectant: 27% PEG8K, 15% MPEG550, 10% glycerol, 90mM Tris-HCl, pH 8.0",293.0,2017-10-05,2018-05-16,6ENM,3015.0,2.0,318.0,400.0,,36.53,1.0,1.59,experimental,18.65,0.202,0.174,Crystal structure of MMP12 in complex with hydroxamate inhibitor LP168.
6J4V,X-RAY DIFFRACTION,3.1,60.32,EVAPORATION,8.2,"For crystallization of V2c-SVBP C58S in complex with the maTail peptide the components were mixed in a 1:3 molar ratio and incubated at room temperature for 24 h before setting up crystallization trials. The resulting V2c-SVBP S58C-maTail complex was crystallized in 1.4 M sodium/potassium phosphate, pH 8.2.",293.0,2019-01-10,2019-05-01,6J4V,2621.0,3.0,338.0,239.0,1.0,40.01,3.0,2.1,experimental,,0.1996,0.1688,Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
5GOE,X-RAY DIFFRACTION,2.55,51.75,"VAPOR DIFFUSION, HANGING DROP",,0.2M ammonium citrate tribasic and 20% PEG 3350,293.0,2016-07-26,2017-01-25,5GOE,3438.0,1.0,422.0,273.0,1.0,48.26,1.0,1.801,experimental,,0.2042,0.177,"Truncated mitofusin-1, GDP-bound"
7S47,X-RAY DIFFRACTION,1.85,33.36,"VAPOR DIFFUSION, HANGING DROP",,"100 mM sodium acetate pH 4.0, 0.7 M diammonium phosphate",293.0,2021-09-08,2022-11-09,7S47,2468.0,2.0,415.0,103.0,,47.49,2.0,2,experimental,36.138,0.2369,0.1935,Integrin beta5(743-774)-linker-PAK4cat(D440N/S474E)
5GGJ,X-RAY DIFFRACTION,2.34,47.52,"VAPOR DIFFUSION, HANGING DROP",8.8,"Tris-HCl, PEG-6000",293.0,2016-06-16,2016-08-10,5GGJ,2787.0,2.0,328.0,412.0,,35.85,1.0,1.424,experimental,,0.2086,0.1867,"Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with Man-alpha-pNP"
5GGL,X-RAY DIFFRACTION,2.29,46.29,"VAPOR DIFFUSION, HANGING DROP",8.8,"Tris-HCl, PEG-8000",293.0,2016-06-16,2016-08-10,5GGL,2665.0,2.0,328.0,313.0,,35.93,1.0,1.27,experimental,,0.1606,0.1448,"Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GlcNAc-alpha-pNP"
6J1Y,X-RAY DIFFRACTION,2.33,47.12,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Sodium malonate pH 5.0, 12% w/v Polyethyleneglycol 3350",289.15,2018-12-30,2019-07-24,6J1Y,6343.0,2.0,1038.0,10.0,,122.41,1.0,2.55,experimental,,0.2543,0.2081,Semi-open conformation E3 ligase
6R3E,X-RAY DIFFRACTION,3.77,67.37,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES, 0.2 M Li2SO4, 23-33% PEG3350",298.0,2019-03-20,2020-04-08,6R3E,2269.0,2.0,548.0,115.0,,62.33,1.0,2.269,experimental,,0.2635,0.2176,Human DNMT3B PWWP domain in complex with triisopropanolamine
7SS1,X-RAY DIFFRACTION,3.02,59.3,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M CHES: NaOH (pH 9.5), 10% (w/v) PEG 3000",293.0,2021-11-09,2022-11-16,7SS1,3625.0,2.0,482.0,,1.0,56.22,1.0,2.4,experimental,98.3947,0.2992,0.2482,The structure of NTMT1 in complex with compound GD433
5V18,X-RAY DIFFRACTION,2.25,45.3,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 335, 200 mM ASO4, 100 mM Bis-Tris pH 6.5",293.0,2017-03-01,2017-06-21,5V18,1765.0,1.0,239.0,32.0,,27.16,1.0,2.15,experimental,68.713,0.235,0.1905,"Structure of PHD2 in complex with 1,2,4-Triazolo-[1,5-a]pyridine"
4RY3,X-RAY DIFFRACTION,4.72,73.92,"VAPOR DIFFUSION, HANGING DROP",8.2,"2.5M sodium acetate, 0.1M Bis-Tris propane, 10% glycerol, pH 8.2, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-12-13,2015-01-28,4RY3,4775.0,1.0,648.0,,,74.05,1.0,2.802,experimental,48.9467,0.2433,0.2078,Crystal structure of human Fanconi-associated nuclease 1
4QOC,X-RAY DIFFRACTION,2.17,43.38,"VAPOR DIFFUSION, HANGING DROP",5.0,"100 mM Citrate, 
1.9-2.4 M Ammonium Sulfate, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-06-19,2015-05-06,4QOC,5403.0,6.0,576.0,603.0,,70.5,1.0,1.7,experimental,,0.253,0.238,"crystal structure of compound 16 bound to MDM2(17-111), {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-1-[(1S)-1-CYCLOPROPYL-2-(PYRROLIDIN-1-YLSULFONYL)ETHYL]-3-METHYL-2-OXOPIPERIDIN-3-YL}ACETIC ACID"
5LBF,X-RAY DIFFRACTION,2.72,54.86,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 1.8 M ammonium sulphate, 2% v/v dioxane, 0.002 M MnCl2",293.0,2016-06-16,2016-08-31,5LBF,1970.0,1.0,252.0,132.0,1.0,28.77,1.0,1.8995,experimental,51.0,0.1847,0.1595,HIF prolyl hydroxylase 2 (PHD2/EGLN1) K293K/G294E variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/FG2216)
5K9D,X-RAY DIFFRACTION,3.46,64.5,"VAPOR DIFFUSION, SITTING DROP",4.8,"0.1 M sodium acetate trihydrate pH 4.8
1.8 M ammonium sulfate
30% (v/v) glycerol",298.0,2016-05-31,2016-10-12,5K9D,3287.0,1.0,368.0,399.0,,41.71,1.0,1.7,experimental,19.4203,0.1601,0.1363,Crystal structure of human dihydroorotate dehydrogenase at 1.7 A resolution
6O60,X-RAY DIFFRACTION,2.18,43.47,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES pH6.0, 20%-22% (v/v) PEG 400",293.0,2019-03-04,2019-06-26,6O60,9299.0,4.0,1327.0,70.0,,149.9,4.0,2.503,experimental,,0.247,0.1941,Crystal structure of GGTase3-FBXL2-SKP1 complex
5QHT,X-RAY DIFFRACTION,1.99,38.18,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QHT,1800.0,1.0,183.0,192.0,,20.17,1.0,1.05,experimental,13.903,0.2133,0.1862,PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000065a
5QHU,X-RAY DIFFRACTION,1.99,38.17,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QHU,1703.0,1.0,183.0,190.0,,20.11,1.0,1.05,experimental,14.12,0.1656,0.1416,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMSOA000341b
5QHV,X-RAY DIFFRACTION,1.99,38.19,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QHV,1728.0,1.0,183.0,197.0,,20.2,1.0,1.05,experimental,13.855,0.2179,0.2029,PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000299a
5QHW,X-RAY DIFFRACTION,1.98,37.77,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QHW,1703.0,1.0,183.0,184.0,,20.19,1.0,1.12,experimental,16.201,0.1696,0.1367,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000347a
5QHX,X-RAY DIFFRACTION,1.98,37.73,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QHX,1702.0,1.0,183.0,167.0,,20.17,1.0,1.11,experimental,16.32,0.1705,0.1403,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000278a
5QHY,X-RAY DIFFRACTION,2.0,38.63,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QHY,1706.0,1.0,183.0,199.0,,20.14,1.0,1.17,experimental,19.117,0.1863,0.15,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000462a
5QHZ,X-RAY DIFFRACTION,2.01,38.83,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QHZ,1743.0,1.0,183.0,238.0,,20.2,1.0,1.15,experimental,15.11,0.174,0.1396,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000385a
5QI0,X-RAY DIFFRACTION,2.01,38.67,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI0,1739.0,1.0,183.0,209.0,,20.19,1.0,1.05,experimental,12.816,0.1566,0.1355,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000352a
5QI1,X-RAY DIFFRACTION,2.0,38.62,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI1,1720.0,1.0,183.0,196.0,,20.17,1.0,1.05,experimental,13.987,0.1723,0.148,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000474a
5QI2,X-RAY DIFFRACTION,2.01,38.77,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI2,1698.0,1.0,183.0,202.0,,20.2,1.0,1.08,experimental,16.121,0.1704,0.1435,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000110a
5QI3,X-RAY DIFFRACTION,2.0,38.64,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI3,1741.0,1.0,183.0,220.0,,20.18,1.0,1.05,experimental,12.445,0.1576,0.1399,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000475a
5QI4,X-RAY DIFFRACTION,1.98,37.91,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI4,1770.0,1.0,183.0,179.0,,20.16,1.0,1.2,experimental,18.019,0.2198,0.1901,PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000466a
5QI5,X-RAY DIFFRACTION,2.01,38.72,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI5,1725.0,1.0,183.0,210.0,,20.15,1.0,1.05,experimental,13.622,0.1652,0.1394,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000633a
5QI6,X-RAY DIFFRACTION,2.01,38.85,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI6,1782.0,1.0,183.0,201.0,,20.2,1.0,1.1,experimental,14.772,0.21,0.1938,PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000597a
5QI7,X-RAY DIFFRACTION,1.99,38.31,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI7,1744.0,1.0,183.0,203.0,,20.14,1.0,1.05,experimental,11.955,0.1627,0.1376,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000506a
5QI8,X-RAY DIFFRACTION,2.02,39.01,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI8,1834.0,1.0,183.0,184.0,,20.15,1.0,1.09,experimental,14.631,0.2207,0.2017,PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000605a
5QI9,X-RAY DIFFRACTION,2.0,38.6,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QI9,1842.0,1.0,183.0,208.0,,20.19,1.0,1.05,experimental,13.227,0.2187,0.1989,PanDDA analysis group deposition -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000711a
5QIA,X-RAY DIFFRACTION,2.0,38.56,"VAPOR DIFFUSION, SITTING DROP",7.4,"80 mM KBr, 30 % PEG2kMME",277.0,2018-05-21,2019-04-10,5QIA,1637.0,1.0,183.0,184.0,,20.18,1.0,1.14,experimental,18.296,0.1981,0.1585,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of human PARP14 Macrodomain 3 in complex with FMOPL000242a
5TRF,X-RAY DIFFRACTION,3.47,64.52,"VAPOR DIFFUSION, SITTING DROP",,2m2M Ammonium Sulfate and 0.2M Lithium Nitrate,293.0,2016-10-26,2016-11-09,5TRF,4453.0,5.0,545.0,263.0,,66.28,1.0,2.1,experimental,29.02,0.2084,0.185,MDM2 in complex with SAR405838
6WFK,X-RAY DIFFRACTION,2.72,54.85,"VAPOR DIFFUSION, SITTING DROP",5.0,"Compound 4a soaked into crystals of Naa50+CoA. CoA co-crystals: Naa50 apo protein (14.3 mg/ml) was incubated with CoA in a 1:3 molar ratio on ice for 60 min. Crystallization solution: 0.1 M Na acetate, pH5.0, 25% (w/v) PEG 3350, 10 mM Dithiothreitol (DTT), and 0.1% Dioxane",294.0,2020-04-03,2020-07-01,6WFK,4220.0,3.0,513.0,261.0,,62.67,1.0,1.87,experimental,47.48,0.222,0.2,Crystal structure of human Naa50 in complex with CoA and an inhibitor (compound 4a) identified using DNA encoded library technology
7RBQ,X-RAY DIFFRACTION,2.13,42.23,"VAPOR DIFFUSION, SITTING DROP",5.5,"25%(w/v)PEG3350, 0.1M Ammonium Sulphate, 0.1M Bis-Tris pH7.4",291.0,2021-07-06,2021-08-11,7RBQ,4758.0,1.0,719.0,65.0,,80.96,1.0,2.2,experimental,37.41,0.2706,0.2123,Co-crystal structure of human PRMT9 in complex with MT556 inhibitor
8AI7,X-RAY DIFFRACTION,3.2,61.6,"VAPOR DIFFUSION, HANGING DROP",,Ammonium Sulfate,293.0,2022-07-25,2023-02-01,8AI7,4632.0,1.0,529.0,202.0,3.0,63.13,1.0,2.13,experimental,65.82,0.2177,0.1771,"Structure of carbamoylated human butyrylcholinesterase upon reaction with 3-(((2-cycloheptylethyl)(methyl)amino)methyl)-1H-indol-7-yl N,N-dimethylcarbamate"
5GGO,X-RAY DIFFRACTION,2.38,48.26,"VAPOR DIFFUSION, HANGING DROP",8.8,"Tris-HCl, PEG-6000",293.0,2016-06-16,2016-08-10,5GGO,2732.0,2.0,328.0,364.0,,36.4,1.0,1.502,experimental,,0.2081,0.1752,"Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GalNac-beta1,3-GlcNAc-beta-pNP"
5HEX,X-RAY DIFFRACTION,2.83,56.54,VAPOR DIFFUSION,5.0,"protein conditions: 10mgs/mL, 50mM TRIS HCL, pH 7.5, 250mM NaCl, 2mM DTT, 2mM MgCl2. and 1mM cmpd30
Reservoir: 0.1M Na Citrate pH=5, 14% PEG 3350, 10 % ethylene glycol 
Cryo protectant 20% ethylene glycol in mother liquor",296.0,2016-01-06,2016-03-30,5HEX,13830.0,2.0,1846.0,83.0,,208.4,1.0,2.734,experimental,,0.2517,0.1899,"Crystal Structure of Human Hexokinase 2 with cmpd 30, a 2-amino-6-benzenesulfonamide glucosamine"
6LVS,X-RAY DIFFRACTION,2.08,40.87,"VAPOR DIFFUSION, SITTING DROP",,"0.2M HcooNa, 0.1M BICINE, 20% PEGmme 5000",295.15,2020-02-04,2020-03-18,6LVS,16510.0,6.0,2460.0,354.0,,285.9,1.0,2.73,experimental,46.577,0.27677,0.197,USP14 catalytic domain mutant C114S
7FAQ,X-RAY DIFFRACTION,2.58,52.32,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M magnesium sulfate, 0.1 M sodium cacodylate, pH 6.5, 17% PEG3350",277.0,2021-07-07,2022-05-18,7FAQ,2415.0,1.0,349.0,72.0,,40.79,1.0,2.20013606546,experimental,49.9247361213,0.272067669888,0.225164311103,Crystal structure of PDE5A in complex with inhibitor L1
7FAR,X-RAY DIFFRACTION,2.59,52.51,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M magnesium sulfate, 0.1 M sodium cacodylate, pH 6.5, 17% PEG3350",277.0,2021-07-07,2022-05-18,7FAR,2447.0,1.0,349.0,57.0,,40.8,1.0,2.40006470991,experimental,50.2141933494,0.249946221896,0.212773636809,Crystal structure of PDE5A in complex with inhibitor L12
6BP0,X-RAY DIFFRACTION,2.58,52.32,"VAPOR DIFFUSION, SITTING DROP",7.0,22% PEG3350; 0.02M Lithium Sulfate; 0.1M Buffer system SBG pH 7.0,293.0,2017-11-21,2017-12-06,6BP0,10972.0,4.0,1456.0,1007.0,,166.11,1.0,1.9,experimental,37.609,0.22589,0.1867,Crystal Structure of the Human vaccinia-related kinase 1 bound to (R)-2-phenylaminopteridinone inhibitor
6BTW,X-RAY DIFFRACTION,2.65,53.62,"VAPOR DIFFUSION, SITTING DROP",7.0,"22% PEG3350, 0.02M Lithium Sulfate, 0.1M Buffer system SBG pH 7.0",293.0,2017-12-07,2017-12-20,6BTW,10921.0,4.0,1456.0,979.0,,166.26,1.0,1.9,experimental,29.63,0.2147,0.18197,Crystal Structure of the Human vaccinia-related kinase bound to a phenyl-pteridinone inhibitor
6BU6,X-RAY DIFFRACTION,2.99,58.81,"VAPOR DIFFUSION, SITTING DROP",7.0,22% PEG3350; 0.02M Lithium Sulfate; 0.1M Buffer system SBG pH 7.0,293.0,2017-12-08,2017-12-20,6BU6,11259.0,4.0,1456.0,1169.0,,166.39,1.0,1.8,experimental,33.218,0.2125,0.18403,Crystal Structure of the Human vaccinia-related kinase bound to a bis-difluorophenol-aminopyridine inhibitor
6CFM,X-RAY DIFFRACTION,3.0,59.01,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG3350, 0.02M Lithium Sulfate, 0.1M Buffer system SBG pH 7.0",293.0,2018-02-15,2018-03-07,6CFM,10019.0,4.0,1456.0,190.0,,165.97,1.0,2.45,experimental,40.305,0.2446,0.20114,Crystal Structure of the Human vaccinia-related kinase bound to a propynyl-pteridinone inhibitor
6CQH,X-RAY DIFFRACTION,2.62,53.13,"VAPOR DIFFUSION, SITTING DROP",6.0,"25% PEG3350, 300 mM LiSO4, 0.1M SBG, pH 6.0, 30% glycerol",293.0,2018-03-15,2018-03-28,6CQH,10722.0,4.0,1456.0,644.0,,166.99,1.0,2.15,experimental,30.416,0.23885,0.20065,Crystal Structure of the Human vaccinia-related kinase bound to a N-propynyl-N-ethyl-dihydropteridine inhibitor
6CSW,X-RAY DIFFRACTION,2.59,52.57,"VAPOR DIFFUSION, SITTING DROP",7.0,27.5% PEG3350; 300 mM LiSO4; 0.1M SBG pH 7.0,293.0,2018-03-21,2018-04-04,6CSW,10829.0,4.0,1456.0,534.0,,168.61,1.0,2.25,experimental,35.987,0.23289,0.18757,Crystal Structure of the Human vaccinia-related kinase bound to a N-methyl-N-propyl-dihydropteridine inhibitor
6DD4,X-RAY DIFFRACTION,2.57,52.1,"VAPOR DIFFUSION, SITTING DROP",7.0,"27.5% PEG3350, 200 mM LiSO4, 0.1M SBG, pH 7.0",293.0,2018-05-09,2018-05-23,6DD4,10256.0,4.0,1456.0,229.0,,166.79,1.0,2.1,experimental,44.064,0.22555,0.19463,"Crystal Structure of the Human vaccinia-related kinase bound to a N,N-dipropyl-dihydropteridine inhibitor"
5BYY,X-RAY DIFFRACTION,2.97,58.58,"VAPOR DIFFUSION, SITTING DROP",,"0.01 M Tris 8.50
0.01 M MgCl2
13 % PEG4000
0.18 M Na-formiate
0.10 M MES, pH=6.50",293.0,2015-06-11,2016-05-04,5BYY,2791.0,1.0,346.0,17.0,,40.09,1.0,2.79,experimental,19.315,0.27285,0.22059,ERK5 IN COMPLEX WITH SMALL MOLECULE
6ZEF,X-RAY DIFFRACTION,2.76,55.38,"VAPOR DIFFUSION, SITTING DROP",5.25,"1M LiCl, 0.1 M tri-sodium citrate pH 5.25 and 10 % PEG 6000",293.0,2020-06-16,2020-09-30,6ZEF,5962.0,4.0,738.0,242.0,,85.59,2.0,1.94,experimental,41.0,0.2115,0.1815,Structure of PP1(7-300) bound to Phactr1 (516-580) at pH 5.25
5DWQ,X-RAY DIFFRACTION,2.44,49.68,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M Ammonium Sulfate, 0.1 M Tris pH 8.5, 18% w/v PEG 3350",291.0,2015-09-22,2015-11-25,5DWQ,11636.0,6.0,1436.0,352.0,,164.33,2.0,2.36,experimental,35.424,0.2571,0.2084,"Crystal structure of CARM1, sinefungin, and methylated H3 peptide (R17)"
8GMD,X-RAY DIFFRACTION,3.08,60.04,"VAPOR DIFFUSION, HANGING DROP",6.0,"1.2M AmSO4, 0.1M tri-Na Citrate pH 6.0, 3% isopropanol, 296K",296.0,2023-03-24,2023-07-12,8GMD,4617.0,2.0,636.0,85.0,,73.57,1.0,2.2,experimental,50.12,0.25,0.232,"CRYSTAL STRUCTURE OF AP2 ASSOCIATED KINASE 1 COMPLEXED WITH (5P)-3-({(8R)-5-[(4-aminopiperidin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-5-[2-(propan-2-yl)-2H-tetrazol-5-yl]phenol"
5NRR,X-RAY DIFFRACTION,3.73,67.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, 2% v/v Polyethylene glycol 400, 2.0 M Ammonium sulfate",298.0,2017-04-25,2018-05-30,5NRR,2614.0,2.0,300.0,340.0,,34.26,1.0,1.7,experimental,41.53,0.2132,0.1935,Human DNMT3B PWWP domain in complex with 5-[(2-Hydroxyethyl)(propyl)amino]-1-pentanol
5NRS,X-RAY DIFFRACTION,3.82,67.81,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298.0,2017-04-25,2018-05-30,5NRS,2237.0,2.0,300.0,60.0,,34.23,1.0,2.3,experimental,60.46,0.2477,0.1951,"Human DNMT3B PWWP domain in complex with N,N-bis(2-hydroxypropyl)ethanolamine"
5NRV,X-RAY DIFFRACTION,3.63,66.12,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298.0,2017-04-25,2018-06-13,5NRV,2348.0,2.0,300.0,183.0,,34.76,1.0,2.075,experimental,38.52,0.2435,0.2071,Human DNMT3B PWWP domain in complex with 6-dipropylamino-1-hexanol
5NV0,X-RAY DIFFRACTION,3.79,67.56,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298.0,2017-05-03,2018-05-30,5NV0,2270.0,2.0,300.0,73.0,,34.6,1.0,2.399,experimental,51.39,0.2435,0.1944,Human DNMT3B PWWP domain in complex with 4-(dipropylamino)butyronitrile
5NV2,X-RAY DIFFRACTION,3.77,67.38,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298.0,2017-05-03,2018-05-30,5NV2,2310.0,2.0,300.0,104.0,,34.51,1.0,2.029,experimental,50.7,0.2405,0.2013,"Human DNMT3B PWWP domain in complex with N-isopropyl-1,5-dimethylhexylamine (Metron S)"
5FWQ,X-RAY DIFFRACTION,2.23,44.75,"VAPOR DIFFUSION, HANGING DROP",,"PROTEIN SOLUTION: 10 MM TRIS-HCL, 25 MM KCL, 4-8 MG/ML PROTEIN (PH8); PRECIPITATE SOLUTION: 0,15M IMIDAZOL/HCL PH6.5; 0,1 M NAACETAT, 14% PEG8000, 5 MM YBCL3 AND 25 MM 5-CHLORO-3-HYDROXYPYRIDINE; HANGING DROP VAPOR-DIFFUSION AT 290.55 K",290.55,2016-02-19,2016-10-05,5FWQ,5279.0,1.0,633.0,407.0,,73.19,1.0,2.047,experimental,22.8,0.223,0.1934,Apo structure of human Leukotriene A4 hydrolase
8AVA,X-RAY DIFFRACTION,2.37,48.17,"VAPOR DIFFUSION, HANGING DROP",6.8,"12% PEG 8000, 100 mM sodium acetate, 5 mM ytterbium chloride, 100 mM imidazole pH 6.8",293.0,2022-08-26,2023-05-03,8AVA,5783.0,1.0,617.0,647.0,,71.76,1.0,1.354,experimental,18.376,0.1689,0.1456,Leukotriene A4 hydrolase in complex with 4-(4-benzylphenyl)-oxazol-2-amine
8AWH,X-RAY DIFFRACTION,2.38,48.25,"VAPOR DIFFUSION, HANGING DROP",6.8,"12% PEG 8000, 100 mM sodium acetate, 5 mM ytterbium chloride, 100 mM imidazole pH 6.8",293.0,2022-08-29,2023-05-03,8AWH,5693.0,1.0,617.0,579.0,,71.65,1.0,1.42,experimental,17.891,0.1871,0.156,Leukotriene A4 hydrolase in complex with 4-(4-Benzylphenyl)-selenazol-2-amine
6CG1,X-RAY DIFFRACTION,2.52,51.19,VAPOR DIFFUSION,,"20% PEG4K, 150mM NaCl, 50mMHEPES pH 7.3",293.0,2018-02-19,2018-04-18,6CG1,12175.0,4.0,1400.0,820.0,,164.53,1.0,2.16,experimental,40.985,0.2403,0.1749,Crystal Structure of KDM4A with Compound 14
6CG2,X-RAY DIFFRACTION,2.52,51.11,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG4K, 150mM NaCl, 50mM HEPES pH 7.3",293.0,2018-02-19,2018-04-18,6CG2,11860.0,4.0,1400.0,508.0,,164.67,1.0,2.34,experimental,43.884,0.2335,0.174,Crystal Structure of KDM4A with Compound 8
8CO7,X-RAY DIFFRACTION,2.61,52.81,VAPOR DIFFUSION,,"0.1 M sodium acetate pH 4.8,
0.2 M trisodium citrate, 15%(w/v) PEG 4000, 10%(v/v) glycerol",277.0,2023-02-27,2024-01-03,8CO7,4112.0,1.0,475.0,214.0,,55.97,1.0,1.9,experimental,,0.2335,0.1909,Crystal structure of human soluble adenylyl cyclase (sAC) in complex with inhibitor TDI-09066
5NUD,X-RAY DIFFRACTION,2.39,48.52,"VAPOR DIFFUSION, HANGING DROP",,"1MMEDTA, PH 8.0
                      LIQUID NITROGEN",293.0,2017-04-29,2018-04-04,5NUD,4396.0,2.0,614.0,162.0,,69.37,1.0,2.5,experimental,,,,FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
5NWZ,X-RAY DIFFRACTION,2.37,48.12,"VAPOR DIFFUSION, HANGING DROP",,"TRIS, 25% PEG3350.
                      1MM EDTA, PH8.0",293.0,2017-05-09,2018-04-04,5NWZ,4446.0,2.0,614.0,184.0,,69.58,1.0,2.37,experimental,,,,FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
6ZBN,X-RAY DIFFRACTION,2.41,49.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.15M Potassium thiocyanate pH 7, 20.5% PEG 3350, Sitting Drop (300 nL), protein-to-well ratio, 2:1, 298K",298.0,2020-06-08,2021-04-07,6ZBN,9865.0,6.0,1362.0,288.0,6.0,155.18,1.0,2.01,experimental,74.1576,0.2299,0.2052,"HIF Prolyl Hydroxylase 2 (PHD2/EGLN1) in complex with tert-butyl 6-(5-hydroxy-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-1-yl)nicotinate (IOX4)"
5X68,X-RAY DIFFRACTION,3.17,61.2,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris (pH 8.5), 13% polyethylene glycol 4000, and 15% glycerol",295.0,2017-02-21,2018-02-21,5X68,5908.0,2.0,782.0,131.0,,90.14,1.0,2.1,experimental,55.05,0.256,0.209,Crystal Structure of Human KMO
6X9J,X-RAY DIFFRACTION,2.79,55.96,"VAPOR DIFFUSION, SITTING DROP",5.1,"14-18% polyethylene glycol (PEG) 3350, 0.1 M citric acid (pH 5.1)",292.0,2020-06-02,2021-07-07,6X9J,7497.0,3.0,898.0,390.0,,107.81,1.0,1.79,experimental,56.73,0.2286,0.2002,Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3830052
6X9K,X-RAY DIFFRACTION,2.83,56.5,"VAPOR DIFFUSION, SITTING DROP",5.1,"14-18% polyethylene glycol (PEG) 3350, 0.1 M citric acid (pH 5.1)",292.0,2020-06-02,2021-07-07,6X9K,7297.0,3.0,898.0,189.0,,107.26,1.0,2.65,experimental,69.79,0.2279,0.1824,Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3685032A
7SFC,X-RAY DIFFRACTION,2.87,57.08,"VAPOR DIFFUSION, SITTING DROP",5.1,"14-18% polyethylene glycol (PEG) 3350,  0.1 M citric acid (pH 5.1)",292.0,2021-10-03,2022-03-30,7SFC,7762.0,3.0,898.0,508.0,,108.98,1.0,1.97,experimental,45.08,0.208,0.1763,Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3735967A
7SFD,X-RAY DIFFRACTION,2.79,55.85,"VAPOR DIFFUSION, SITTING DROP",5.1,"14-18% polyethylene glycol (PEG) 3350,  0.1 M citric acid (pH 5.1)",292.0,2021-10-03,2022-03-30,7SFD,7262.0,3.0,898.0,251.0,,107.5,1.0,2.09,experimental,60.91,0.2159,0.185,Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3543105A
7SFE,X-RAY DIFFRACTION,2.85,56.9,"VAPOR DIFFUSION, SITTING DROP",5.1,"14-18% polyethylene glycol (PEG) 3350,  0.1 M citric acid (pH 5.1)",292.0,2021-10-03,2022-03-30,7SFE,7338.0,3.0,898.0,225.0,,107.21,1.0,2.55,experimental,71.23,0.2363,0.2014,Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3830334A
7SFF,X-RAY DIFFRACTION,2.82,56.46,"VAPOR DIFFUSION, SITTING DROP",5.1,"14-18% polyethylene glycol (PEG) 3350,  0.1 M citric acid (pH 5.1)",292.0,2021-10-03,2022-03-30,7SFF,7425.0,3.0,898.0,350.0,,107.29,1.0,2.05,experimental,54.92,0.2169,0.1815,Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA and Inhibitor GSK3852279B
6QLM,X-RAY DIFFRACTION,2.03,39.27,"VAPOR DIFFUSION, HANGING DROP",6.1,"25mM ADA pH6.1, 300mM NaCl & 20% PEG 5k.mme",291.0,2019-02-01,2020-02-19,6QLM,4292.0,2.0,432.0,737.0,6.0,48.76,1.0,1.5,experimental,11.956,0.142,0.1011,Cathepsin-K in complex with MIV-701
4RLI,X-RAY DIFFRACTION,3.45,64.32,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate pH 4.8, 40 mM UDAO, 20.8 mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate, 1 mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-10-17,2015-11-04,4RLI,2764.0,1.0,390.0,30.0,,43.62,1.0,2.5,experimental,21.434,0.2056,0.1746,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A048
6LZL,X-RAY DIFFRACTION,3.63,66.14,"VAPOR DIFFUSION, HANGING DROP",4.8,"HEPES pH 7.7, NaCl, 20% Glycerol, EDTA, UDAO, DDAO",293.0,2020-02-19,2020-04-15,6LZL,2928.0,1.0,365.0,99.0,,40.55,1.0,1.98,experimental,30.005,0.2093,0.1851,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with Piperine
7ZY5,X-RAY DIFFRACTION,2.23,44.86,"VAPOR DIFFUSION, SITTING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-23,2022-10-12,7ZY5,5927.0,2.0,704.0,346.0,,83.49,1.0,1.82,experimental,40.86,0.2191,0.1989,Crystal structure of compound 2 bound to CK2alpha
7ZY8,X-RAY DIFFRACTION,2.22,44.63,"VAPOR DIFFUSION, SITTING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-24,2022-10-12,7ZY8,5893.0,2.0,704.0,311.0,,83.75,1.0,1.85,experimental,40.83,0.2189,0.1963,Crystal structure of compound 2 bound to CK2alpha
6WF3,X-RAY DIFFRACTION,2.75,55.26,"VAPOR DIFFUSION, SITTING DROP",,Naa50 apo protein (14.3 mg/ml) was incubated with compound 1 in a 1:3 molar ratio on ice for 60 min.  Reservoir solution containing 0.2 M ammonium sulfate and 30% (w/v) PEG 3K/4K was mixed 1:1 with protein/ligand complex,286.15,2020-04-03,2020-07-01,6WF3,8148.0,12.0,1062.0,354.0,,124.68,2.0,2.291,experimental,56.03,0.2434,0.208,Crystal structure of human Naa50 in complex with a cofactor derived inhibitor (compound 1)
5L2Q,X-RAY DIFFRACTION,2.44,49.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Tris-HCL 7.5
21% PEG 4000
6% Glycerol
5% Tert-butanol
200mM NaCl
1mM TCEP",293.0,2016-08-02,2017-02-01,5L2Q,8350.0,4.0,1280.0,66.0,,144.6,1.0,2.53,experimental,,0.2795,0.2576,Serine/threonine-protein kinase 40 (STK40) kinase homology domain
,,,,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Tris-HCL 7.5
18% PEG 4000
9% Tert-butanol
75mM NaCl
1mM TCEP",293.0,,,,,,,,,,,,,,,,
6TFI,X-RAY DIFFRACTION,2.56,51.94,"VAPOR DIFFUSION, HANGING DROP",8.0,"1 MICROLITER PROTEIN AT 12.1 MG/ML (IN 20 MILLIMOLAR TRIS PH 7.8, 250 MILLIMOLAR NACL, 2.5 MILLIMOLAR EDTA, 5% (V/V) GLYCEROL, 5 MM DTT), PREINCUBATED WITH 25 MILLIMOLAR COMPOUND 17 (FROM 500 MILLIMOLAR STOCK IN DMSO) for 24 hours at 277 K, MIXED WITH 1 MICROLITER OF RESERVOIR (100 MILLIMOLAR IMIDAZOLE PH 8.0, 20 % (V/V) MPD). CRYO BUFFER 100 MILLIMOLAR IMIDAZOLE PH 8.0, 30 % (V/V) MPD",277.0,2019-11-14,2020-11-11,6TFI,5425.0,2.0,688.0,360.0,,79.75,1.0,1.85,experimental,41.918,0.19932,0.17192,PXR IN COMPLEX WITH THROMBIN INHIBITOR COMPOUND 17
5L76,X-RAY DIFFRACTION,2.92,57.92,"VAPOR DIFFUSION, SITTING DROP",,20% PEG3350 -- 10% ethylene glycol -- 0.2M sodium malonate,293.0,2016-06-02,2017-05-10,5L76,3346.0,1.0,497.0,62.0,1.0,55.03,1.0,2.57,experimental,,0.2885,0.2318,"Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase domain (in apo form)"
5N3W,X-RAY DIFFRACTION,2.42,49.13,"VAPOR DIFFUSION, HANGING DROP",,"20 % PEG 8000, 0.1 M Sodium Acetate, 0.15 mM Imidazole pH7.8, 5 mM YbCl3",291.0,2017-02-09,2017-03-29,5N3W,5310.0,1.0,619.0,437.0,,71.02,1.0,2.3,experimental,26.975,0.28758,0.23946,Crystal structure of LTA4H bound to a selective inhibitor against LTB4 generation
6ZEI,X-RAY DIFFRACTION,2.25,45.37,"VAPOR DIFFUSION, SITTING DROP",8.4,20% (w/v) polyethylene glycol 3350 and 0.2 M NaBr,293.0,2020-06-16,2020-09-30,6ZEI,6822.0,4.0,816.0,691.0,,92.64,2.0,1.39,experimental,21.7,0.1579,0.1296,Structure of PP1-IRSp53 S455E chimera [PP1(7-304) + linker (G/S)x9 + IRSp53(449-465)] bound to Phactr1 (516-580)
5HMH,X-RAY DIFFRACTION,2.25,45.32,"VAPOR DIFFUSION, SITTING DROP",4.2,1.8-2.2 Ammonium sulfate,303.0,2016-01-16,2016-04-06,5HMH,1770.0,2.0,202.0,100.0,,24.77,1.0,1.79,experimental,53.03,0.2388,0.2113,"HDM2 in complex with a 3,3-Disubstituted Piperidine"
5HMI,X-RAY DIFFRACTION,2.21,44.39,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.8-2.2 M ammonium sulfate, 100 mM NaCitrate/Citric acid",303.0,2016-01-16,2016-04-06,5HMI,1789.0,2.0,208.0,108.0,,25.53,1.0,1.74,experimental,52.9,0.2289,0.2076,"HDM2 in complex with a 3,3-Disubstituted Piperidine"
6NVB,X-RAY DIFFRACTION,2.42,49.23,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.2M lithium sulfate, 0.1M sodium acetate, 22% PEG 8000
cryoprotectant = 1:1 glycerol : mother liquor",293.0,2019-02-04,2019-07-17,6NVB,7845.0,4.0,896.0,1074.0,24.0,96.8,1.0,1.636,experimental,21.54,0.1803,0.1541,Crystal structure of the inhibitor-free form of the serine protease kallikrein-4
4U3Y,X-RAY DIFFRACTION,1.99,38.32,"VAPOR DIFFUSION, SITTING DROP",8.3,"0.2 M potassium citrate, pH 8.3, 20% PEG 3350",292.0,2014-07-23,2016-01-06,4U3Y,5581.0,2.0,664.0,668.0,,75.82,1.0,1.45,experimental,23.83,0.2069,0.1826,Apo Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4)
6AAR,X-RAY DIFFRACTION,1.93,36.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.6 M ammonium sulfate, 0.1 M MES pH 6.5",293.0,2018-07-19,2019-07-24,6AAR,2392.0,1.0,293.0,192.0,,34.05,1.0,1.95,experimental,,0.2203,0.18,Crystal structure of DAPK1 in complex with purpurin
6WE3,X-RAY DIFFRACTION,2.77,55.62,"VAPOR DIFFUSION, SITTING DROP",,"1.6 M Ammonium sulfate, 0.1 M MES pH 6.5, 10% v/v Jeffamine M-600",291.15,2020-04-01,2021-03-24,6WE3,3334.0,2.0,388.0,158.0,1.0,46.59,1.0,1.95,experimental,42.385,0.2729,0.2369,"Human PARP14 (ARTD8), catalytic fragment in complex with compound 3"
6WE4,X-RAY DIFFRACTION,2.2,44.03,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Lithium nitrate, 14% w/v PEG 3350",291.15,2020-04-01,2021-03-24,6WE4,3315.0,2.0,388.0,200.0,1.0,45.64,1.0,1.6,experimental,36.118,0.275,0.2278,"Human PARP14 (ARTD8), catalytic fragment in complex with compound 2"
6EOX,X-RAY DIFFRACTION,2.11,41.76,"VAPOR DIFFUSION, SITTING DROP",8.5,"Drop: 1 micro-L (hMMP-12 at 855 micro-M + 1 milli-M hydroxamic acid + 1 milli-M LP165) and 1 micro-L reservoir solution.
Precipitant: 17% PEG 20K, 0.2M imidazole malate
250mM NaCl, pH 8.5.
Cryoprotection: 40% MPEG 5K, 10% 1,2-propanediol, 10% AAB (sodium acetate, ADA, bicine: 90% basic/10% acid), pH 8.0",293.0,2017-10-10,2018-05-16,6EOX,1576.0,1.0,159.0,197.0,,18.25,1.0,1.3,experimental,18.43,0.179,0.142,Crystal structure of MMP12 in complex with carboxylic inhibitor LP165.
6BYZ,X-RAY DIFFRACTION,4.13,70.24,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M HEPES, 12% Tacsimate, 20% PEGMME-5000, 10% 1,4-dioxane",298.0,2017-12-21,2019-04-03,6BYZ,16150.0,4.0,2044.0,389.0,,237.99,2.0,2.95624845742,experimental,60.7670774468,0.202629282797,0.160914089223,Structure of Cysteine-free Human Insulin-Degrading Enzyme in complex with Substrate-selective Macrocyclic Inhibitor 37
8CQY,X-RAY DIFFRACTION,2.78,55.81,"VAPOR DIFFUSION, SITTING DROP",,"20% w/v PEG 3350, 0.2 M NaSCN at pH 7",277.15,2023-03-07,2023-05-10,8CQY,808.0,2.0,126.0,22.0,,14.22,2.0,1.7,experimental,42.01,0.20258,0.16756,Crystal structure of the PTPN3 PDZ domain bound to the PBM TACE C-terminal peptide
7ZY0,X-RAY DIFFRACTION,2.03,39.32,"VAPOR DIFFUSION, SITTING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-23,2022-10-12,7ZY0,2970.0,1.0,328.0,165.0,,39.69,1.0,1.44,experimental,22.94,0.2139,0.1992,Crystal structure of compound 7 bound to CK2alpha
7F3M,X-RAY DIFFRACTION,2.26,45.61,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 18 % PEG 3350",277.15,2021-06-16,2022-01-12,7F3M,2545.0,1.0,311.0,144.0,,35.54,1.0,2.289,experimental,35.7311,0.2371,0.1869,Crystal structure of FGFR4 kinase domain with PRN1371
8XLQ,X-RAY DIFFRACTION,2.23,44.84,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-20% PEG3350",277.15,2023-12-26,2024-03-27,8XLQ,2590.0,1.0,311.0,201.0,,35.6,1.0,1.95,experimental,36.4847,0.2106,0.1668,FGFR4 kinase domain with a dual-warhead covalent inhibitor CXF-007
5VMP,X-RAY DIFFRACTION,2.57,52.07,VAPOR DIFFUSION,,"22% PEG4K, 100mM HEPES pH 7.5",293.0,2017-04-28,2017-09-27,5VMP,11619.0,4.0,1476.0,244.0,,173.65,1.0,2.48,experimental,41.597,0.2599,0.1931,Crystal Structure of Human KDM4 with Small Molecule Inhibitor QC5714
4ZKF,X-RAY DIFFRACTION,2.31,46.68,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, sodium chloride",293.0,2015-04-30,2015-06-17,4ZKF,4121.0,1.0,462.0,463.0,,51.95,1.0,1.82,experimental,22.36,0.1897,0.1657,Crystal structure of human phosphodiesterase 12
6ZDC,X-RAY DIFFRACTION,2.53,51.4,"VAPOR DIFFUSION, SITTING DROP",6.0,"100 mM MIB buffer, pH 6.0.
Protein at 5.5 mg/ml in 50 mM potassium phosphate, 50 mM KCl.
150 nl protein solution and 150 nl reservoir solution.",292.0,2020-06-14,2020-11-18,6ZDC,3092.0,1.0,382.0,185.0,,44.84,1.0,2.251,experimental,47.23,0.2234,0.1769,Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with nickel
5D6X,X-RAY DIFFRACTION,3.72,66.93,"VAPOR DIFFUSION, SITTING DROP",,"Protein Solution (30mg/ml KDM4A DTD, 20mM HEPES pH 7.5, 150mM NaCl and 0.5mM TCEP) mixed in a 1:1 ratio with the well solution (1.0M ammonium sulfate, 1% w/v peg3350 and 0.1M Bis-Tris pH5.5) Cryoprotected with additional 20% glycerol",293.0,2015-08-13,2015-11-25,5D6X,2236.0,2.0,242.0,242.0,,27.84,1.0,2.153,experimental,37.2003,0.1997,0.1586,Crystal structure of double tudor domain of human lysine demethylase KDM4A
8BU1,X-RAY DIFFRACTION,3.93,68.68,"VAPOR DIFFUSION, SITTING DROP",,"0.9 M ammonium citrate tribasic pH 7.0, NDSB-256 additive",293.0,2022-11-30,2023-09-13,8BU1,33919.0,9.0,4365.0,,2.0,499.44,3.0,2.98,experimental,104.35,0.2181,0.1934,Structure of DDB1 bound to DS17-engaged CDK12-cyclin K
5SEU,X-RAY DIFFRACTION,2.62,53.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SEU,10690.0,4.0,1372.0,358.0,4.0,159.47,1.0,2.09,experimental,45.701,0.238,0.1829,"Crystal Structure of human phosphodiesterase 10 in complex with 2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-6-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine"
7BU6,X-RAY DIFFRACTION,4.14,73.0,LIPIDIC CUBIC PHASE,,"100 mM HEPES, pH 7.5, 100-250 mM Sodium Sulfate, 39-43% PEG300, 10mM norepinephrine",293.0,2020-04-04,2020-12-02,7BU6,4578.0,2.0,644.0,3.0,3.0,73.89,2.0,2.7,experimental,68.86,0.2584,0.2318,Structure of human beta1 adrenergic receptor bound to norepinephrine and nanobody 6B9
5UKK,X-RAY DIFFRACTION,3.12,60.6,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM MES, 8-16% PEG3350, 0.8-1.2 M sodium chloride",277.0,2017-01-23,2017-04-05,5UKK,8161.0,3.0,1038.0,43.0,,118.92,3.0,2.6,experimental,79.624,0.2807,0.2207,Human GRK2 in complex with human G-beta-gamma subunits and CCG211998 (14ak)
5UKL,X-RAY DIFFRACTION,3.07,59.94,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM MES, 0.8-1.2 M sodium chloride, 8-16% PEG3350",277.0,2017-01-23,2017-04-05,5UKL,8685.0,3.0,1043.0,388.0,,119.54,3.0,2.15,experimental,55.457,0.2275,0.1821,Human GRK2 in complex with Gbetagamma subunits and CCG222886 (14bd)
6WFG,X-RAY DIFFRACTION,2.72,54.72,"VAPOR DIFFUSION, SITTING DROP",5.0,"Soak of compound into CoA bound crystals. Naa50 apo protein (14.3 mg/ml) was incubated with CoA in a 1:3 molar ratio on ice for 60 min. Crystallization solution: 0.1 M Na acetate, pH5.0, 25% (w/v) PEG 3350, 10 mM Dithiothreitol (DTT), and 0.1% Dioxane",294.15,2020-04-03,2020-07-01,6WFG,4064.0,3.0,513.0,142.0,,62.44,1.0,2.16,experimental,61.08,0.253,0.201,Crystal structure of human Naa50 in complex with an inhibitor (compound 3) identified using DNA encoded library technology
5M5A,X-RAY DIFFRACTION,2.35,47.64,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1M BIS TRIS pH 6.5, 0.6 M NaCl",293.0,2016-10-21,2017-12-06,5M5A,2731.0,1.0,347.0,106.0,,40.77,1.0,1.9,experimental,43.972,0.21366,0.18525,Crystal structure of MELK in complex with an inhibitor
5DGH,X-RAY DIFFRACTION,2.66,53.8,"VAPOR DIFFUSION, HANGING DROP",7.0,"12% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM AMP-PNP and 2 mM CdCl2. The crystals were transferred to a stabilizing buffer containing 22% (w/v) PEG 3350, 10 mM MgCl2, 0.1 M sodium acetate, pH 5.2 at 4 oC overnight. The crystals were soaked under the above stabilizing buffer for three days with 2 mM compound.",277.0,2015-08-27,2016-08-10,5DGH,2930.0,1.0,330.0,266.0,,39.43,1.0,2.1,experimental,24.654,0.2314,0.18671,Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMP-PNP and 5-(PCP)-IP5
4Z2B,X-RAY DIFFRACTION,2.32,47.07,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris Ph 8.5
15% Peg20000
25% Ethylene Glycol",295.0,2015-03-29,2015-06-17,4Z2B,4103.0,1.0,455.0,465.0,,52.0,1.0,1.8,experimental,21.79,0.2181,0.1815,The structure of human PDE12 residues 161-609 in complex with GSK3036342A
8B4V,X-RAY DIFFRACTION,3.75,67.16,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2022-09-21,2023-10-04,8B4V,4300.0,1.0,480.0,508.0,4.0,52.95,1.0,1.6,experimental,26.89,0.1658,0.1535,X-ray structure of furin (PCSK3) in complex with benzamidine
8B4W,X-RAY DIFFRACTION,3.75,67.17,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2022-09-21,2023-10-04,8B4W,4403.0,1.0,480.0,497.0,4.0,53.21,1.0,1.6,experimental,27.18,0.179,0.1659,X-ray structure of furin (PCSK3) in complex with 1H-isoindol-3-amine
8B4X,X-RAY DIFFRACTION,3.75,67.24,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2022-09-21,2023-10-04,8B4X,4276.0,2.0,485.0,462.0,4.0,53.27,2.0,1.6,experimental,28.95,0.1695,0.158,X-ray structure of furin (PCSK3) in complex with Guanidinomethyl-Phac-R-Tle-K-6-(aminomethyl)-3-amino-isoindol
8OYH,X-RAY DIFFRACTION,3.76,67.27,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2023-05-04,2024-03-13,8OYH,4092.0,2.0,485.0,340.0,4.0,53.27,2.0,1.8,experimental,36.56,0.188,0.1735,X-ray structure of furin (PCSK3) in complex with Guanidinomethyl-Phac-Can-Tle-Can-6-(aminomethyl)-3-amino-isoindol
5NQE,X-RAY DIFFRACTION,3.06,57.8,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2M Sodium-malonate",277.0,2017-04-20,2017-05-24,5NQE,3005.0,2.0,386.0,17.0,2.0,45.03,1.0,2.71,experimental,40.21,0.258,0.227,"Human PARP14 (ARTD8), catalytic fragment in complex with an N-aryl piperazine inhibitor"
8BZJ,X-RAY DIFFRACTION,2.51,51.0,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 11 mg/mL MST3 in 25 mM HEPES pH 7.5, 200 mM NaCl, 0.5 mM TCEP, 5% glycerol, with 1 mM inhibitor).
Crystallization buffer: 12% PEG 6000, 0.1 M HEPES pH 7.4.",293.0,2022-12-14,2023-01-18,8BZJ,4163.0,2.0,612.0,78.0,,70.08,1.0,2.52,experimental,57.9240676092,0.250313678016,0.182073055088,Human MST3 (STK24) kinase in complex with inhibitor MRLW5
6QAA,X-RAY DIFFRACTION,3.12,60.56,"VAPOR DIFFUSION, HANGING DROP",,"Ammonium Sulfate
MES pH 6.5",293.0,2018-12-19,2019-03-27,6QAA,4757.0,1.0,557.0,286.0,3.0,66.69,1.0,1.897,experimental,,0.2081,0.1764,Human Butyrylcholinesterase in complex with (S)-2-(butylamino)-N-(2-cycloheptylethyl)-3-(1H-indol-3-yl)propanamide
6QAB,X-RAY DIFFRACTION,3.06,59.76,"VAPOR DIFFUSION, HANGING DROP",,"Ammonium Sulfate
MES pH 6.5",293.0,2018-12-19,2019-03-27,6QAB,4533.0,1.0,557.0,68.0,3.0,66.64,1.0,2.49,experimental,,0.2362,0.1916,"Human Butyrylcholinesterase in complex with (S)-N-(1-((2-cycloheptylethyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-N,N-dimethylbutan-1-aminium"
6QAD,X-RAY DIFFRACTION,3.14,60.85,"VAPOR DIFFUSION, HANGING DROP",,"Ammonium sulfate
MES pH 6.5",293.0,2018-12-19,2019-03-27,6QAD,4530.0,1.0,557.0,65.0,3.0,66.64,1.0,2.497,experimental,,0.2344,0.1998,Human Butyrylcholinesterase in complex with ((S)-2-(butylamino)-N-(2-(4-(dimethylamino)cyclohexyl)ethyl)-3-(1H-indol-3-yl)propanamide
6WI2,X-RAY DIFFRACTION,2.88,57.23,VAPOR DIFFUSION,5.5,"0.1 M MES pH 5.5
22.5 % PEG 400",288.0,2020-04-08,2020-04-22,6WI2,6127.0,4.0,717.0,403.0,,85.75,4.0,1.95,experimental,41.8796,0.1849,0.1504,Structure of human mitochondrial complex Nfs1-ISCU2-ISD11 with E.coli ACP1 at 1.95 A resolution (NIAU)2. N-terminal mutation of ISCU2 (L35) traps Nfs1 Cys loop in the active site of ISCU2 without metal present.
6WIH,X-RAY DIFFRACTION,2.87,57.1,VAPOR DIFFUSION,5.5,"0.1 M MES pH 5.5
22.5 % PEG 400",288.0,2020-04-09,2020-05-13,6WIH,6188.0,4.0,717.0,431.0,,86.19,4.0,1.9,experimental,37.3947,0.1861,0.1506,N-terminal mutation of ISCU2 (L35H36) traps Nfs1 Cys loop in the active site of ISCU2 without metal present. Structure of human mitochondrial complex Nfs1-ISCU2(L35H36)-ISD11 with E.coli ACP1 at 1.9 A resolution (NIAU)2.
5GVS,X-RAY DIFFRACTION,2.26,45.64,"VAPOR DIFFUSION, SITTING DROP",,"tri-ammonium citrate,
PEG 3350",277.0,2016-09-06,2016-10-19,5GVS,6706.0,4.0,924.0,233.0,,103.56,1.0,2.2,experimental,24.482,0.27487,0.20722,Crystal structure of the DDX41 DEAD domain in an apo open form
6P5V,X-RAY DIFFRACTION,2.12,42.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"7% PEG3350, 0.2M NH4Br",277.0,2019-05-31,2019-09-11,6P5V,3477.0,1.0,384.0,419.0,,44.91,1.0,1.398,experimental,27.3644,0.2049,0.1712,"Structure of DCN1 bound to N-((4S,5S)-7-ethyl-4-(4-fluorophenyl)-3-methyl-6-oxo-1-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-5-yl)-3-methylbenzamide"
6P5W,X-RAY DIFFRACTION,2.12,42.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"6% PEG3350, 0.2M NH4Br",277.0,2019-05-31,2019-09-11,6P5W,3323.0,1.0,384.0,327.0,,44.76,1.0,1.69,experimental,29.5509,0.2217,0.1756,"Structure of DCN1 bound to 3-methyl-N-((4S,5S)-3-methyl-6-oxo-1-phenyl-4-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-b]pyridin-5-yl)benzamide"
6XOL,X-RAY DIFFRACTION,2.21,44.3,"VAPOR DIFFUSION, SITTING DROP",,"28-33 % PEG3350, 200 mM ammonium formate",293.0,2020-07-07,2021-06-02,6XOL,2990.0,1.0,386.0,133.0,,44.86,1.0,2.39,experimental,42.34,0.264,0.212,DCN1 bound to DI-1548
6XOM,X-RAY DIFFRACTION,2.07,40.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"28 - 33% PEG 3350, 200 mM ammonium formate",293.0,2020-07-07,2021-06-02,6XOM,3137.0,1.0,386.0,239.0,,45.02,1.0,2.1,experimental,31.47,0.243,0.195,DCN1 bound to 8
6XON,X-RAY DIFFRACTION,2.02,39.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"28-33% PEG 3350, 0.2 M ammonium formate",293.0,2020-07-07,2021-06-02,6XON,2877.0,1.0,386.0,58.0,,44.92,1.0,2.8,experimental,42.25,0.289,0.221,DCN1 bound to inhibitor 9
6XOO,X-RAY DIFFRACTION,2.14,42.47,"VAPOR DIFFUSION, SITTING DROP",7.5,"28-33% PEG 3350, 200 mM Ammonium formate",293.0,2020-07-07,2021-06-02,6XOO,3122.0,1.0,386.0,268.0,,44.86,1.0,2.06,experimental,32.25,0.242,0.197,DCN1 bound to DI-1859
6XOP,X-RAY DIFFRACTION,2.09,41.14,"VAPOR DIFFUSION, SITTING DROP",7.5,"28-33% PEG 3350, 0.2 M ammonium formate",293.0,2020-07-07,2021-06-02,6XOP,3150.0,1.0,386.0,291.0,,44.93,1.0,2.07,experimental,30.95,0.247,0.198,DCN1 bound to inhibitor 10
6XOQ,X-RAY DIFFRACTION,2.1,41.41,"VAPOR DIFFUSION, SITTING DROP",,"28-33% PEG 3350, 0.2 M ammonium formate",293.0,2020-07-07,2021-06-02,6XOQ,3136.0,1.0,386.0,261.0,,44.95,1.0,2.07,experimental,31.02,0.247,0.202,DCN1 covalently bound to inhibitor 4
5LX6,X-RAY DIFFRACTION,3.04,59.53,"VAPOR DIFFUSION, SITTING DROP",7.0,"12% PEG3350, 0.1 M Ammonium tartrate",277.0,2016-09-20,2017-01-11,5LX6,3456.0,2.0,382.0,360.0,,43.75,1.0,1.25,experimental,20.55,0.2126,0.2079,"Human PARP10 (ARTD10), catalytic fragment in complex with PARP inhibitor Veliparib"
5LSA,X-RAY DIFFRACTION,2.12,42.09,"VAPOR DIFFUSION, SITTING DROP",9.0,"AMMONIUM SULPHATE, CHES, PH 9",295.0,2016-08-24,2016-09-07,5LSA,2002.0,1.0,221.0,250.0,,25.14,1.0,1.5,experimental,12.995,0.2096,0.1673,human catechol O-methyltransferase in complex with SAM and DNC at 1.50A
6J71,X-RAY DIFFRACTION,3.45,64.3,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES monohydrate pH 6.5, 12% (w/v) PEG 20,000",289.0,2019-01-16,2019-02-27,6J71,6601.0,2.0,872.0,,26.0,95.89,2.0,2.918,experimental,82.1207,0.2668,0.208,HuA21-scFv in complex with the extracellular domain(ECD) of HER2
8UDT,X-RAY DIFFRACTION,3.19,61.49,"VAPOR DIFFUSION, HANGING DROP",,"0.20 M DL-Malic acid pH 5.00,
18.00 % (w/v) PEG 4000",293.0,2023-09-29,2024-02-07,8UDT,7021.0,3.0,891.0,120.0,,103.07,1.0,2.829,experimental,107.42,0.274,0.2623,The X-RAY co-crystal structure of human FGFR3 and KIN-3248
5Y80,X-RAY DIFFRACTION,2.39,48.48,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M ammonium sulfate,0.1 M sodium cacodylate trihydrate (pH 6.5), 15% PEG 8000",293.0,2017-08-18,2018-08-29,5Y80,3531.0,2.0,461.0,60.0,1.0,52.74,2.0,2.5,experimental,,0.2819,0.2295,Complex structure of cyclin G-associated kinase with gefitinib
6CVZ,X-RAY DIFFRACTION,2.32,47.08,"VAPOR DIFFUSION, HANGING DROP",8.0,"16% PEG 3500, 0.2 M Magnesium Chloride, 0.1 M Tris pH8.0",295.0,2018-03-29,2018-06-27,6CVZ,8013.0,3.0,1053.0,293.0,3.0,116.47,1.0,1.8,experimental,35.75,0.2387,0.2143,Crystal structure of the WD40-repeat of RFWD3
7FTG,X-RAY DIFFRACTION,2.1,41.41,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTG,6286.0,2.0,724.0,389.0,,86.29,1.0,1.73,experimental,53.2523,0.2296,0.1916,Crystal Structure of human cyclic GMP-AMP synthase in complex with cGAMP
4RI5,X-RAY DIFFRACTION,2.32,46.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris-HCl, 21% PEG 800, 5% glycerol, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-10-05,2015-03-11,4RI5,5496.0,2.0,612.0,757.0,,70.31,1.0,1.26,experimental,,0.1732,0.1591,Crystal structure of PTPN3 (PTPH1) D811E mutant in complex with metavanadate
5HFU,X-RAY DIFFRACTION,2.82,56.35,VAPOR DIFFUSION,6.0,"protein: 10mgs/mL in 50mM TrisHCL pH = 7.5, 250mM NaCl, 2mM DTT, 2mM MgCl2
Well solution: 0.1M Na Citrate pH = 6, 16 % PEG3350, 10 % Ethylene glycol
Cryo: 20 % ethylene glycol in well",296.0,2016-01-07,2016-03-30,5HFU,13964.0,2.0,1846.0,57.0,,208.3,1.0,2.923,experimental,,0.252,0.1824,"Crystal Structure of Human Hexokinase 2 with cmpd 27, a 2-amido-6-benzenesulfonamide glucosamine"
7K7L,X-RAY DIFFRACTION,3.03,59.35,VAPOR DIFFUSION,6.5,"2% PEG 3350, 0.1M MES pH 6.5, 0.2M NaCl",293.0,2020-09-23,2020-10-28,7K7L,8138.0,3.0,1038.0,,,118.68,3.0,2.539,experimental,71.2083,0.2436,0.2008,Structure of a hit for G Protein Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
7K7Z,X-RAY DIFFRACTION,3.04,59.5,VAPOR DIFFUSION,6.5,"2% PEG 3350, 0.1M MES pH 6.5, 0.2M NaCl",293.0,2020-09-24,2020-10-28,7K7Z,8204.0,3.0,1038.0,,,118.65,3.0,2.60608692764,experimental,72.4782885558,0.261883490594,0.204642341506,Structure of a hit for G Protein Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
5CU4,X-RAY DIFFRACTION,2.0,38.61,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2015-07-24,2016-07-27,5CU4,3151.0,1.0,328.0,300.0,,39.69,1.0,1.56,experimental,22.9,0.1951,0.1744,Crystal structure of CK2alpha bound to CAM4066
9GJ2,X-RAY DIFFRACTION,2.9,57.58,"VAPOR DIFFUSION, SITTING DROP",,"Cathepsin S (7 mg/ml) was mixed with an equal volume of reservoir and equilibrated against 20% (w/v) PEG4000, 0.2 M ammonium sulfate, 0.1 M sodium citrate pH 4.6. Crystals were soaked with ketoamide 13b in the presence of 5% (v/v) DMSO.",293.0,2024-08-20,2024-09-04,9GJ2,4041.0,2.0,484.0,446.0,6.0,55.31,1.0,1.15,experimental,16.47,0.1618,0.1513,Crystal structure of human cathepsin S produced in insect cells in complex with ketoamide 13b
4U40,X-RAY DIFFRACTION,2.12,42.1,"VAPOR DIFFUSION, SITTING DROP",8.3,"0.2 M potassium citrate, pH 8.3, 20% PEG 3350",292.0,2014-07-23,2016-01-06,4U40,4991.0,2.0,664.0,155.0,,76.32,1.0,2.3,experimental,56.5528,0.2615,0.1983,Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) Bound to AMPPNP
5J94,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M ammonium sulfate, 30% PEG 8000, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2016-04-08,2016-04-20,5J94,1877.0,1.0,223.0,132.0,3.0,24.89,1.0,2.22002456664,experimental,16.2828374542,0.233612539731,0.212338163696,Human cathepsin K mutant C25S in complex with the allosteric effector NSC13345
5JH3,X-RAY DIFFRACTION,2.24,45.15,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.2 M ammonium sulfate, 30% (w/v) PEG-8000",293.0,2016-04-20,2016-11-30,5JH3,1897.0,1.0,223.0,238.0,3.0,24.83,1.0,1.75,experimental,26.3967,0.2113,0.1869,Human cathepsin K mutant C25S
4QML,X-RAY DIFFRACTION,2.1,41.46,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM ANP-PNP, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QML,2446.0,1.0,310.0,156.0,,35.62,1.0,1.882,experimental,,0.2296,0.1895,MST3 in complex with AMP-PNP
4QMM,X-RAY DIFFRACTION,2.57,52.15,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM AT-9283, 25 mM TRIS, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMM,2541.0,1.0,310.0,186.0,,35.68,1.0,1.852,experimental,,0.1981,0.1413,"MST3 IN COMPLEX WITH AT-9283, 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM"
4QMP,X-RAY DIFFRACTION,2.5,50.89,,7.5,"12.5 mg/mL MST3, 1 mM CDK2 Inhibitor III, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMP,2536.0,1.0,310.0,185.0,,35.51,1.0,2,experimental,,0.2277,0.1769,"MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III, 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE"
4QMQ,X-RAY DIFFRACTION,2.55,51.83,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM CP-673451, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMQ,2551.0,1.0,310.0,182.0,,35.61,1.0,1.769,experimental,,0.2152,0.1764,MST3 in complex with CP-673451
4QMT,X-RAY DIFFRACTION,2.12,42.03,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM HESPERADIN, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMT,2567.0,1.0,310.0,241.0,,35.6,1.0,1.5,experimental,,0.1855,0.1505,MST3 in complex with HESPERADIN
4QMV,X-RAY DIFFRACTION,2.55,51.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM PF-03814735, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMV,2448.0,1.0,310.0,91.0,,35.62,1.0,2.4,experimental,,0.2264,0.1674,"MST3 IN COMPLEX WITH PF-03814735, N-{2-[(1S,4R)-6-{[4-(CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1,2,3,4-TETRAHYDRO-1,4-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE"
4QMW,X-RAY DIFFRACTION,2.12,42.03,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM PP-121, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMW,2518.0,1.0,310.0,177.0,,35.46,1.0,1.6,experimental,,0.2113,0.1765,"MST3 IN COMPLEX WITH PP-121, 1-CYCLOPENTYL-3-(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE"
4QMX,X-RAY DIFFRACTION,2.11,41.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM SARACATINIB,25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM, CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMX,2507.0,1.0,310.0,163.0,,35.57,1.0,1.882,experimental,,0.2185,0.1794,MST3 in complex with SARACATINIB
4QMY,X-RAY DIFFRACTION,2.1,41.43,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 mg/mL MST3, 1 mM STAUROSPORINE, 25 mM TRIS, PH 8.0, 50 MM HEPES pH 7.5, 125 mM SODIUM, CHLORIDE, 100 mM MAGNESIUM CHLORIDE, 15% PEG 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-06-16,2015-07-01,4QMY,2512.0,1.0,310.0,165.0,,35.59,1.0,1.883,experimental,,0.22,0.1799,MST3 IN COMPLEX WITH STAUROSPORINE
7B31,X-RAY DIFFRACTION,2.62,53.01,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 10 mg/ml in buffer 25 mM HEPES pH 7.5, 200 mM NaCl, 5% glycerol, 0.5 mM TCEP.
Reservoir: 16% PEG 6000, 0.1M HEPES pH 7.0.",293.0,2020-11-28,2020-12-16,7B31,2228.0,1.0,306.0,128.0,,35.06,1.0,1.8,experimental,36.82,0.2121,0.1769,MST3 in complex with compound MRIA9
7B32,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 10 mg/ml in buffer 25 mM HEPES pH 7.5, 200 mM NaCl, 5% glycerol, 0.5mM TCEP.
Reservoir: 20% PEG 3350, 0.1M bis-tris pH 6.5.",293.0,2020-11-28,2020-12-16,7B32,2224.0,1.0,306.0,144.0,,35.14,1.0,1.75,experimental,27.65,0.2033,0.1744,MST3 in complex with MRIA7
7B33,X-RAY DIFFRACTION,2.59,52.5,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 10 mg/ml in buffer 25 mM HEPES pH 7.5, 200 mM NaCl, 5% glycerol, 0.5 mM TCEP.
Reservoir: 19% PEG 3350, 0.1M bis-tris pH 6.8.",293.0,2020-11-28,2020-12-16,7B33,2197.0,1.0,306.0,102.0,,35.34,1.0,1.9,experimental,38.84,0.2084,0.1808,MST3 in complex with MRIA11
7B34,X-RAY DIFFRACTION,2.97,58.61,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 10 mg/ml in buffer 25 mM HEPES pH 7.5, 200 mM NaCl, 5% glycerol, 0.5 mM TCEP.
Reservoir: 14% PEG 6000, 0.1M HEPES pH 7.2.",293.0,2020-11-28,2020-12-16,7B34,2182.0,1.0,306.0,66.0,,35.51,1.0,2.1,experimental,46.97,0.2153,0.1892,MST3 in complex with compound MRIA12
8QLR,X-RAY DIFFRACTION,2.69,54.32,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 11 mg/mL MST3 in 25 mM HEPES pH 7.5, 200 mM NaCl, 0.5 mM TCEP, 5% glycerol) with 1 mM compound MR24.
Reservoir solution: 28% PEG 3350, 0.1 M citrate pH 5.6",293.0,2023-09-20,2023-11-08,8QLR,4328.0,2.0,612.0,200.0,,70.32,1.0,1.85,experimental,,0.2169,0.1796,Human MST3 (STK24) kinase in complex with inhibitor MR24
5QCH,X-RAY DIFFRACTION,2.84,56.76,"VAPOR DIFFUSION, SITTING DROP",4.5,"100MM SODIUM ACETATE PH 4.5, 200MM AMMONIUM ACETATE, 25% PEG 8000. PROTEIN CONCENTRATION 7 MG/ML, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-04,2017-12-20,5QCH,8240.0,4.0,892.0,1201.0,12.0,101.43,1.0,2.2,experimental,19.32,0.251,0.199,Crystal structure of human Cathepsin-S with bound ligand
5IOH,X-RAY DIFFRACTION,2.05,40.04,"VAPOR DIFFUSION, SITTING DROP",4.0,"100 mM Sodium Malonate, 12% PEG 3350",277.0,2016-03-08,2016-10-05,5IOH,5223.0,4.0,726.0,152.0,,82.37,2.0,2.566,experimental,,0.2152,0.1764,"RepoMan-PP1a (protein phosphatase 1, alpha isoform) holoenzyme complex"
6J6Y,X-RAY DIFFRACTION,2.52,56.29,"VAPOR DIFFUSION, HANGING DROP",4.5,"1.9M ammonium sulfate, 0.1M sodium acetate, pH 4.5",293.0,2019-01-16,2019-08-07,6J6Y,8410.0,6.0,1192.0,455.0,10.0,128.47,3.0,2.15,experimental,69.266,0.2582,0.193,FGFR4 D2 - Fab complex
5VIL,X-RAY DIFFRACTION,2.74,55.13,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 3350, 0.2M ammonium chloride, 0.1M Bis-Tris (pH 6.1-6.6), and 10% glycerol.",295.0,2017-04-17,2018-01-17,5VIL,8854.0,4.0,1172.0,138.0,,133.9,1.0,2.64,experimental,122.72,0.213,0.18,Crystal structure of ASK1 kinase domain with a potent inhibitor (analog 6)
7JHO,X-RAY DIFFRACTION,2.36,47.97,"VAPOR DIFFUSION, HANGING DROP",,"24% PEG1500, 20% glycerol",277.0,2020-07-21,2020-11-18,7JHO,6574.0,2.0,740.0,636.0,6.0,91.42,1.0,1.85,experimental,25.4806,0.2111,0.1649,"Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with UDP"
6F4P,X-RAY DIFFRACTION,2.28,46.16,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M Bis-Tris pH 6.0, 26.4 % PEG3350, 0.002 M MnCl2, 300 nl sitting drops (sample:well, 1:2 ratio)",298.0,2017-11-29,2018-04-04,6F4P,2549.0,2.0,271.0,337.0,,31.71,2.0,1.45,experimental,29.0,0.1682,0.1463,"Human JMJD5 in complex with MN, NOG and RPS6 (129-144) (complex-1)"
6IUP,X-RAY DIFFRACTION,2.27,45.77,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES pH5.5, 0.2M Li2SO4, 18% PEG3350",277.0,2018-11-29,2019-11-06,6IUP,2560.0,1.0,322.0,276.0,,36.48,1.0,2,experimental,19.5483,0.2277,0.1694,Crystal structure of FGFR4 kinase domain in complex with compound 5
6HXR,X-RAY DIFFRACTION,2.71,54.66,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% Poly(ethylene glycol) 3350, 0.2M ammonium acetate, 0.1M Bis-Tris, 1mM EB-47",277.0,2018-10-18,2019-10-30,6HXR,5634.0,3.0,894.0,,,101.82,1.0,2.9,experimental,91.94,0.2297,0.1993,Human PARP16 (ARTD15) IN COMPLEX WITH EB-47
5EI8,X-RAY DIFFRACTION,2.77,55.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M BIS-TRIS Propane
0.2 M NgCl2
0.2 M Sodium formate
20 % PEG3350",291.15,2015-10-29,2016-04-20,5EI8,2123.0,1.0,313.0,40.0,,36.76,1.0,2.17,experimental,64.52,0.2441,0.2141,"Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach"
6H3K,X-RAY DIFFRACTION,3.43,64.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Bis-Tris propane; 
0.1 M MgCl2
0.1 M Sodium formate
18-26% PEG3350",291.15,2018-07-19,2018-09-19,6H3K,2080.0,1.0,279.0,37.0,,33.0,1.0,2.48,experimental,103.23,0.231,0.208,"Introduction of a methyl group curbs metabolism of pyrido[3,4-d]pyrimidine MPS1 inhibitors and enables the discovery of the Phase 1 clinical candidate BOS172722."
5CSP,X-RAY DIFFRACTION,2.02,39.13,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2015-07-23,2016-07-27,5CSP,3132.0,1.0,328.0,293.0,,39.3,1.0,1.5,experimental,22.16,0.1857,0.1624,Crystal Structure of CK2alpha with Compound 5 bound
5CSV,X-RAY DIFFRACTION,2.01,38.71,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2015-07-23,2016-07-27,5CSV,3083.0,1.0,328.0,267.0,,39.29,1.0,1.375,experimental,25.17,0.195,0.1795,Crystal Structure of CK2alpha with Compound 6 bound
5CU6,X-RAY DIFFRACTION,2.02,39.23,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2015-07-24,2016-07-27,5CU6,3093.0,1.0,328.0,254.0,,39.66,1.0,1.36,experimental,24.44,0.209,0.1866,Crystal Structure of CK2alpha
5CVF,X-RAY DIFFRACTION,2.01,38.93,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2015-07-26,2016-07-27,5CVF,3065.0,1.0,328.0,213.0,,39.88,1.0,1.63,experimental,22.37,0.209,0.2009,Crystal Structure of CK2alpha with Compound 5 bound
5OSL,X-RAY DIFFRACTION,1.94,36.54,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-17,2018-02-28,5OSL,3124.0,1.0,342.0,234.0,,41.94,1.0,1.95,experimental,20.45,0.211,0.1629,The crystal structure of CK2alpha in complex with compound 7
5OSP,X-RAY DIFFRACTION,1.92,35.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-18,2018-09-05,5OSP,3108.0,1.0,342.0,229.0,,41.78,1.0,1.91,experimental,24.86,0.2134,0.1723,The crystal structure of CK2alpha in complex with an analogue of compound 1
5OSR,X-RAY DIFFRACTION,1.93,36.31,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-18,2018-09-05,5OSR,3156.0,1.0,342.0,285.0,,41.67,1.0,1.57,experimental,19.82,0.2091,0.1754,The crystal structure of CK2alpha in complex with an analogue of compound 1
5OSU,X-RAY DIFFRACTION,1.92,36.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-18,2018-09-05,5OSU,3113.0,1.0,342.0,265.0,,41.16,1.0,1.63,experimental,20.23,0.2098,0.1729,The crystal structure of CK2alpha in complex with analogues of compound 1
5OSZ,X-RAY DIFFRACTION,1.98,37.85,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-18,2018-02-28,5OSZ,3096.0,1.0,342.0,168.0,,42.08,1.0,2,experimental,26.05,0.241,0.1906,The crystal structure of CK2alpha in complex with compound 23
5OTI,X-RAY DIFFRACTION,1.91,35.68,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-02-28,5OTI,3078.0,1.0,342.0,200.0,,41.37,1.0,1.59,experimental,33.84,0.2322,0.1898,The crystal structure of CK2alpha in complex with compound 27
5OTQ,X-RAY DIFFRACTION,1.95,36.93,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-02-28,5OTQ,3145.0,1.0,342.0,249.0,,41.68,1.0,1.38,experimental,28.02,0.1981,0.1831,The crystal structure of CK2alpha in complex with compound 33
5OTR,X-RAY DIFFRACTION,1.94,36.71,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-02-28,5OTR,3205.0,1.0,342.0,307.0,,42.17,1.0,1.52,experimental,19.27,0.2024,0.1793,The crystal structure of CK2alpha in complex with compound 14
5OTY,X-RAY DIFFRACTION,1.94,36.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-02-28,5OTY,3057.0,1.0,342.0,186.0,,41.5,1.0,1.48,experimental,27.3,0.1922,0.1694,The crystal structure of CK2alpha in complex with CAM4712
5OTZ,X-RAY DIFFRACTION,1.95,36.78,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-22,2018-02-28,5OTZ,3135.0,1.0,342.0,264.0,,41.58,1.0,1.46,experimental,22.39,0.2108,0.1821,The crystal structure of CK2alpha in complex with compound 1
5OUL,X-RAY DIFFRACTION,1.94,36.69,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-08-24,2018-02-28,5OUL,3199.0,1.0,342.0,250.0,,42.43,1.0,1.34,experimental,25.1,0.2219,0.1976,The crystal structure of CK2alpha in complex with compound 9
5OYF,X-RAY DIFFRACTION,1.98,37.81,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-09-08,2018-02-28,5OYF,3086.0,1.0,342.0,201.0,,41.64,1.0,1.54,experimental,30.35,0.216,0.185,The crystal structure of CK2alpha in complex with compound 31
6GIH,X-RAY DIFFRACTION,2.04,39.68,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2018-05-11,2018-05-23,6GIH,2995.0,1.0,328.0,197.0,,39.41,1.0,1.96,experimental,23.45,0.215,0.18,Crystal Structure of CK2alpha with CAM187 bound
6WZY,X-RAY DIFFRACTION,2.44,49.62,"VAPOR DIFFUSION, HANGING DROP",5.7,"0.1M sodium citrate pH 5.7, 0.2M LiSO4 and 24-28% (w/v) PEG3350",298.0,2020-05-14,2020-09-16,6WZY,3770.0,3.0,388.0,542.0,3.0,45.48,3.0,1.5,experimental,24.07,0.204,0.174,Structure of DbNA(10) peptides bound to H-2Db MHC-I
6X00,X-RAY DIFFRACTION,2.41,48.89,"VAPOR DIFFUSION, HANGING DROP",5.7,"0.1M sodium citrate pH 5.7, 0.2M Li2SO4 and 24-28% (w/v) PEG3350",298.0,2020-05-14,2020-09-16,6X00,3764.0,3.0,392.0,585.0,3.0,45.58,3.0,1.55,experimental,20.84,0.215,0.184,Structure of DbNA(11) peptides bound to H-2Db MHC-I
7AB2,X-RAY DIFFRACTION,2.2,44.12,VAPOR DIFFUSION,8.5,"0.1M Tris pH 8.5, 4.3M NaCl",293.0,2020-09-05,2020-10-28,7AB2,2274.0,1.0,298.0,89.0,,35.16,1.0,1.78,experimental,48.966,0.2497,0.1933,Crystal structure of MerTK kinase domain in complex with UNC2025
7XHY,X-RAY DIFFRACTION,2.11,41.82,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein concentration 25 mg/mL

Protein storage buffer: 
Tris-HCl pH 8.0, 500 mM NaCl, 1 mM Tris(2-carboxyethyl)phosphine Hydrochloride (TCEP)

Mother Liquor: 0.1 M Tris-HCl pH 8.5, 4.3 M NaCl

Protein: Reservoir: Apo-Microseed = 300: 300: 100 nL or 400: 400: 100 nL 

Co-crystalization
2mM compound preincubation: 2Hours in ICE

Cryoprotectant solution:
0.1 M Tris-HCl pH 8.5, 2.5 M NaCl, 20% DMSO, 10 mM compounds",287.0,2022-04-11,2022-11-30,7XHY,2248.0,1.0,298.0,40.0,,35.07,1.0,2.16,experimental,47.47,0.2523,0.208,Crystal structure of MerTK Kinase domain with BMS794833
9B12,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,7.5,3:1 with reservoir solution containing 50% PEG 200 and 0.1 M HEPES pH 7.5,293.0,2024-03-12,2024-07-31,9B12,6089.0,10.0,808.0,187.0,,93.47,3.0,1.81,experimental,,0.2685,0.2313,"Structure of Optineurin bound to HOIP NZF1 domain and M1-linked diubiquitin, crystal form 1"
5DRT,X-RAY DIFFRACTION,3.48,64.67,VAPOR DIFFUSION,,"1.3M K/Na tartrate
0.1M Hepes pH7.2",293.0,2015-09-16,2016-06-15,5DRT,5220.0,2.0,668.0,177.0,,77.82,1.0,2.69,experimental,61.97,0.1967,0.1751,Crystal structure of Dot1L in complex with inhibitor CPD2 [2-(2-(5-((2-chlorophenoxy)methyl)-1H-tetrazol-1-yl)acetyl)-N-(4-chlorophenyl)hydrazinecarboxamide]
5DRY,X-RAY DIFFRACTION,3.52,65.08,VAPOR DIFFUSION,,"1.2M K/Na tartrate
0.1M Hepes pH7.2",293.0,2015-09-16,2016-06-15,5DRY,5486.0,2.0,668.0,302.0,,78.03,1.0,2.41,experimental,55.24,0.199,0.1771,Crystal structure of Dot1L in complex with inhibitor CPD3 [N-(1-(2-chlorophenyl)-1H-indol-6-yl)-2-(2-(5-(2-chlorophenyl)-1H-tetrazol-1-yl)acetyl)hydrazinecarboxamide]
5DSX,X-RAY DIFFRACTION,3.47,64.57,VAPOR DIFFUSION,,"1.4M K/Na tartrate tetrahydrate,  0.1M Hepes pH6.8",293.0,2015-09-17,2016-06-15,5DSX,5320.0,2.0,668.0,198.0,,77.96,1.0,2.41,experimental,62.83,0.2015,0.172,"Crystal structure of Dot1L in complex with inhibitor CPD10 [6'-chloro-1,4-dimethyl-5'-(2-methyl-6-((4-(methylamino)pyrimidin-2-yl)amino)-1H-indol-1-yl)-[3,3'-bipyridin]-2(1H)-one]"
5DT2,X-RAY DIFFRACTION,3.51,64.93,VAPOR DIFFUSION,,"1.4M lithium sulfate
0.1M sodium citrate tribasic dihydrate
0.3M ammonium sulfate",293.0,2015-09-17,2016-06-15,5DT2,5321.0,2.0,668.0,239.0,,78.14,1.0,2.3,experimental,58.16,0.2131,0.184,"Crystal structure of Dot1L in complex with inhibitor CPD11 [N4-methyl-N2-(2-methyl-1-(2-phenoxyphenyl)-1H-indol-6-yl)pyrimidine-2,4-diamine]"
6TEN,X-RAY DIFFRACTION,3.53,65.11,VAPOR DIFFUSION,,"1.5 M Li sulfate
0.1 M Hepes pH 7.0",293.0,2019-11-12,2019-12-11,6TEN,5487.0,2.0,668.0,246.0,,78.39,1.0,2.21,experimental,63.46,0.201,0.179,Crystal structure of Dot1L in complex with an inhibitor (compound 11).
6FXI,X-RAY DIFFRACTION,2.87,57.1,"VAPOR DIFFUSION, SITTING DROP",5.0,"16% PEG3350, 0.1 M Citrate-Bis-Tris-Propane, 3 mM 3-aminobenzamide",277.0,2018-03-09,2019-03-20,6FXI,3119.0,2.0,382.0,45.0,,44.01,1.0,2.6,experimental,36.8,0.245,0.21,"Human PARP10 (ARTD10), catalytic fragment in complex with 3-aminobenzamide and citrate"
5AP2,X-RAY DIFFRACTION,2.82,56.31,,7.5,"0.1M BIS-TRIS PROPANE PH 7.5, 22% (W/V) PEG3350, 0.1M MGCL2, 0.1M NA FORMATE CO-CRYSTAL WITH 1MM INHIBITOR",,2015-09-14,2015-09-23,5AP2,1950.0,1.0,313.0,,,36.58,1.0,2.8,experimental,120.73,0.2539,0.1945,Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
5AP4,X-RAY DIFFRACTION,3.1,60.32,,7.5,"38% (V/V) PEG300, PH 7.5",,2015-09-14,2015-09-23,5AP4,2093.0,1.0,313.0,20.0,,37.34,1.0,2.85,experimental,84.06,0.2263,0.1963,Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
4ZZX,X-RAY DIFFRACTION,2.2,44.6,,,"25% PEG4000, 0.2M MAGNESIUM CHLORIDE, 0.1 M TRIS PH 8.5, 277K",277.0,2015-04-15,2015-08-12,4ZZX,5927.0,2.0,726.0,312.0,,82.7,1.0,1.65,experimental,21.089,0.2441,0.21274,Structure of PARP2 catalytic domain bound to an isoindolinone inhibitor
5L0T,X-RAY DIFFRACTION,2.42,49.16,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG5000 MME, 50 mM MES pH 6.5, 10mM CaCl2, 250mM NaCl, 5% glycerol",295.0,2016-07-28,2017-08-09,5L0T,3825.0,2.0,399.0,482.0,7.0,47.65,2.0,1.43,experimental,30.8524,0.1734,0.1561,human POGLUT1 in complex with EGF(+) and UDP
6PZ1,X-RAY DIFFRACTION,2.95,58.3,MICROBATCH,10.0,"100 mM Sodium thiosulfate, 100 mM CAPS buffer pH 10.0, and 20% (w/v) PEG 8000",277.0,2019-07-31,2020-01-01,6PZ1,6317.0,2.0,850.0,188.0,1.0,97.97,1.0,2.65,experimental,83.542,0.2698,0.2201,"Crystal Structure of human Indoleamine 2,3-Dioxygenase 1 in complex with PF-06840003 in Active Site and Si site"
6X5Y,X-RAY DIFFRACTION,2.89,57.42,VAPOR DIFFUSION,,"0.1 mM Tris pH 8.0, 20% (w/v) PEG 6000",293.0,2020-05-27,2021-06-02,6X5Y,6023.0,2.0,788.0,22.0,1.0,89.52,1.0,2.65,experimental,83.571,0.2723,0.2399,IDO1 in complex with compound 4
5MBW,X-RAY DIFFRACTION,3.92,68.66,"VAPOR DIFFUSION, SITTING DROP",,"0.1M sodium chloride, 0.1M HEPES, 1.6M ammonium sulfate, 0.098M HEGA-9",273.0,2016-11-09,2017-09-27,5MBW,3168.0,2.0,419.0,34.0,3.0,47.06,2.0,2.95,experimental,73.289,0.21553,0.16289,CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH Pep#3
6NQU,X-RAY DIFFRACTION,3.71,66.87,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG3350 6%, 0.1M Ammonium citrate pH7.0",296.0,2019-01-21,2019-02-13,6NQU,5029.0,1.0,658.0,,,74.23,1.0,2.7,experimental,,0.2575,0.2189,Human LSD1 in complex with GSK2879552
7AHU,X-RAY DIFFRACTION,2.97,58.64,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium acetate, 0.1 M sodium cacodylate, pH 6.5, 18 % (w/v) PEG 8000",291.0,2020-09-25,2021-07-07,7AHU,11641.0,8.0,1474.0,444.0,26.0,163.74,4.0,2.6,experimental,46.5,0.2633,0.2027,Anti-FX Fab of mim8 in complex with human FXa
6H4Z,X-RAY DIFFRACTION,4.19,70.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 nL of protein is mixed with 200 nL of crystallisation solution containing 1.6 M Na/K phosphate, 0.1 M HEPES pH 7.5, and with 20 nL of seeds obtained in the same conditions. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",277.0,2018-07-23,2019-06-12,6H4Z,4130.0,1.0,481.0,307.0,,57.7,1.0,2.3,experimental,60.51,0.211,0.186,Crystal structure of human KDM5B in complex with compound 16a
6H50,X-RAY DIFFRACTION,4.03,69.47,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 nL of protein is mixed with 200 nL of crystallisation solution containing 1.6 M Na/K phosphate, 0.1 M HEPES pH 7.5, and with 20 nL of seeds obtained in the same conditions. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",277.0,2018-07-23,2019-06-12,6H50,4154.0,1.0,481.0,371.0,,56.68,1.0,2.19,experimental,54.77,0.206,0.182,Crystal structure of human KDM5B in complex with compound 34a
6H51,X-RAY DIFFRACTION,4.0,69.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 nL of protein is mixed with 200 nL of crystallisation solution containing 1.6 M Na/K phosphate, 0.1 M HEPES pH 7.5, and with 20 nL of seeds obtained in the same conditions. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",277.0,2018-07-23,2019-06-12,6H51,3992.0,1.0,481.0,288.0,,56.86,1.0,2.21,experimental,61.54,0.197,0.182,Crystal structure of human KDM5B in complex with compound 34f
6H52,X-RAY DIFFRACTION,4.01,69.29,VAPOR DIFFUSION,7.5,"100 nL of protein is mixed with 200 nL of crystallisation solution containing 1.6 M Na/K phosphate, 0.1 M HEPES pH 7.5, and with 20 nL of seeds obtained in the same conditions. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",277.0,2018-07-23,2019-06-12,6H52,4074.0,1.0,481.0,327.0,,56.95,1.0,2.14,experimental,58.98,0.203,0.185,Crystal structure of human KDM5B in complex with compound 34g
5IV4,X-RAY DIFFRACTION,2.3,47.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM sodium acetate pH 4.8
200 mM tri-sodium-citrate
15% (w/v) PEG 4000
10% (v/v) glycerol",277.15,2016-03-18,2016-08-17,5IV4,4164.0,1.0,475.0,358.0,,55.53,1.0,1.79,experimental,30.704,0.20626,0.15972,Crystal structure of the human soluble adenylyl cyclase in complex with the allosteric inhibitor LRE1
8GX2,X-RAY DIFFRACTION,1.6,22.95,"VAPOR DIFFUSION, HANGING DROP",,"100mM sodium acetate (pH 4.1), 15% (w/v) PEG 2000, 8mg/ml protein",289.15,2022-09-18,2023-09-20,8GX2,3805.0,2.0,666.0,363.0,6.0,76.55,1.0,2,experimental,32.1148,0.2316,0.1938,The crystal structure of human CtsL in complex with 14c
9B0Z,X-RAY DIFFRACTION,3.53,65.14,VAPOR DIFFUSION,8.5,"20% PEG 2K MME, 0.2 M TAO and 0.1 M Tris pH 8.5. Cryoprotected in mother liquor containing 20% glycerol",293.0,2024-03-12,2024-07-31,9B0Z,4625.0,7.0,708.0,45.0,1.0,80.21,3.0,2.41,experimental,71.98,0.2695,0.2208,"Structure of Optineurin bound to HOIP NZF1 domain and M1-linked diubiquitin, crystal form 2"
7VJL,X-RAY DIFFRACTION,2.43,49.37,"VAPOR DIFFUSION, HANGING DROP",,0.5m NH4H2PO4,277.0,2021-09-28,2022-02-23,7VJL,4186.0,2.0,602.0,,,68.51,1.0,2.90017299719,experimental,51.90497332,0.273007589253,0.204653382216,"The crystal structure of FGFR4 kinase domain in complex with N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-(2,2,2-trifluoroacetyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide"
5VDP,X-RAY DIFFRACTION,2.47,50.19,"VAPOR DIFFUSION, SITTING DROP",7.0,"18-20% PEG 3350, 0.2 M ammonium citrate pH 7",277.0,2017-04-03,2017-09-27,5VDP,6000.0,2.0,726.0,129.0,,87.03,1.0,2.3,experimental,47.1048,0.2429,0.1972,"Human cyclic GMP-AMP synthase (cGAS) in complex with 2',3'-cGAMP"
5VDS,X-RAY DIFFRACTION,2.56,51.95,"VAPOR DIFFUSION, SITTING DROP",7.0,"18-20% PEG 3350, 0.2 M ammonium citrate pH 7",277.0,2017-04-03,2017-09-27,5VDS,5698.0,2.0,726.0,90.0,,86.43,1.0,2.766,experimental,53.5442,0.2451,0.206,"Human cyclic GMP-AMP synthase (cGAS) in complex with 3',3'-cdUMP"
5VDT,X-RAY DIFFRACTION,2.51,50.98,"VAPOR DIFFUSION, SITTING DROP",7.0,"18-20% PEG 3350, 0.2 M ammonium citrate pH 7",277.0,2017-04-03,2017-09-27,5VDT,5931.0,2.0,726.0,146.0,,86.55,1.0,2.576,experimental,64.3928,0.2359,0.202,"Human cyclic GMP-AMP synthase (cGAS) in complex with 3',3'-cGAMP"
5VDU,X-RAY DIFFRACTION,2.57,52.1,"VAPOR DIFFUSION, SITTING DROP",7.0,"18-20% PEG 3350, 0.2 M ammonium citrate pH 7",277.0,2017-04-03,2017-09-27,5VDU,5734.0,2.0,726.0,52.0,,85.83,1.0,2.729,experimental,65.174,0.2521,0.2223,Human cyclic GMP-AMP synthase (cGAS) in complex with Compound F2
5VDV,X-RAY DIFFRACTION,2.52,51.24,"VAPOR DIFFUSION, SITTING DROP",7.0,"18-20% PEG 3350, 0.2 M ammonium citrate pH 7",277.0,2017-04-03,2017-09-27,5VDV,5467.0,2.0,726.0,66.0,,85.86,1.0,2.998,experimental,89.5952,0.2573,0.2049,Human cyclic GMP-AMP synthase (cGAS) in complex with Compound F3
5VDW,X-RAY DIFFRACTION,2.52,51.24,"VAPOR DIFFUSION, SITTING DROP",7.0,"18-20% PEG 3350, 0.2 M ammonium citrate pH 7",277.0,2017-04-03,2017-09-27,5VDW,5639.0,2.0,726.0,36.0,,85.72,1.0,2.711,experimental,61.5127,0.2571,0.2223,Human cyclic GMP-AMP synthase (cGAS) in complex with Compound F1
7OAM,X-RAY DIFFRACTION,2.36,47.91,"VAPOR DIFFUSION, SITTING DROP",8.5,"35% PEG 400, 0.2M MgCl2, 0.1M Tris",277.0,2021-04-19,2021-05-19,7OAM,3987.0,2.0,592.0,48.0,,68.81,1.0,2.65,experimental,49.289,0.2574,0.2218,Kinase domain of MERTK in complex with compound 8
8HLW,X-RAY DIFFRACTION,2.56,51.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris pH 8.5, 25% (w/v) Polyethylene glycol 3350",289.0,2022-12-01,2023-09-27,8HLW,2281.0,2.0,289.0,107.0,,32.32,2.0,2.5,experimental,,0.2431,0.1878,Crystal structure of SIRT3 in complex with H4K16la peptide
6D8Z,X-RAY DIFFRACTION,2.45,49.77,"VAPOR DIFFUSION, HANGING DROP",7.5,"14% PEG 3350, 100MM HEPES PH 7.5,
 HANGING DROP, 293K, VAPOR DIFFUSION, HANGING DROP",293.0,2018-04-27,2019-02-20,6D8Z,7525.0,3.0,957.0,26.0,,112.45,1.0,2.65,experimental,75.96,0.266,0.225,Crystal Structure of the C-terminal Guanine Nucleotide Exchange Factor Module of Human Trio
7ZX0,X-RAY DIFFRACTION,2.7,59.3,"VAPOR DIFFUSION, SITTING DROP",8.9,"15% (w/v) PEG 3350, 0.1 M Bis-Tris propane pH 8.9, 0.2 M sodium citrate tribasic dihydrate",285.0,2022-05-19,2022-10-12,7ZX0,32751.0,18.0,4530.0,1.0,,547.13,1.0,2.99,experimental,97.164,0.2519,0.218,Crystal structure of Pol theta polymerase domain in complex with compound 5
7ZX1,X-RAY DIFFRACTION,2.73,59.8,"VAPOR DIFFUSION, SITTING DROP",,"15% (w/v) PEG 3350, 0.1 M Bis-Tris propane pH 8.9, 0.2 M sodium citrate tribasic dihydrate",285.0,2022-05-19,2022-10-12,7ZX1,32843.0,18.0,4530.0,1.0,,548.35,1.0,2.829,experimental,93.617,0.2602,0.2281,Crystal structure of Pol theta polymerase domain in complex with compound 22
5Z94,X-RAY DIFFRACTION,2.95,58.37,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Li2SO4, 0.1M sodium citrate, pH 6.0, 19% PEG 3,350",291.0,2018-02-02,2019-02-06,5Z94,4995.0,4.0,596.0,507.0,,67.23,2.0,1.899,experimental,,0.1911,0.1607,Crystal Structure of SIRT3 in complex with H3K4bhb peptide
5EHL,X-RAY DIFFRACTION,2.93,58.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Bis Tris propane pH 7.5
0.2M MgCl2
0.2M Sodium formate
25% PEG3350",291.15,2015-10-28,2016-11-09,5EHL,2045.0,1.0,313.0,32.0,,36.39,1.0,2.66,experimental,70.46,0.2192,0.1888,"Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach"
5W85,X-RAY DIFFRACTION,2.86,57.02,"VAPOR DIFFUSION, HANGING DROP",,Null,293.0,2017-06-21,2017-10-11,5W85,4586.0,2.0,610.0,107.0,,69.41,1.0,2.25,experimental,65.66,0.251,0.227,"CRYSTAL STRUCTURE OF IRAK-4 WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)"
5UZV,X-RAY DIFFRACTION,2.54,51.55,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-27,2017-05-24,5UZV,3309.0,3.0,381.0,125.0,,47.37,1.0,2.45,experimental,,0.2539,0.2133,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rI)
5V04,X-RAY DIFFRACTION,2.6,52.74,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V04,3259.0,3.0,381.0,51.0,,47.37,1.0,2.65,experimental,,0.2558,0.2292,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rII)
5V05,X-RAY DIFFRACTION,2.65,53.52,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V05,3253.0,3.0,381.0,54.0,,47.48,1.0,2.902,experimental,,0.2484,0.1992,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rIII)
5V06,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V06,3232.0,3.0,381.0,21.0,,47.54,1.0,2.75,experimental,,0.2655,0.2185,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rIV)
5V07,X-RAY DIFFRACTION,2.62,53.12,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V07,3311.0,3.0,375.0,132.0,,46.76,1.0,2.15,experimental,,0.2197,0.1758,Crystal structure of human exonuclease 1 Exo1 (D173A) in complex with 5' recessed-end DNA (rV)
5V08,X-RAY DIFFRACTION,2.66,53.73,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V08,3215.0,3.0,375.0,41.0,,46.61,1.0,2.812,experimental,,0.2623,0.2147,Crystal structure of human exonuclease 1 Exo1 (D173A) in complex with 5' recessed-end DNA (rVI)
5V09,X-RAY DIFFRACTION,2.6,52.67,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V09,3310.0,3.0,381.0,99.0,,47.61,1.0,2.75,experimental,,0.2541,0.2181,Crystal structure of human exonuclease 1 Exo1 (D225A) in complex with 5' recessed-end DNA (rVII)
5V0A,X-RAY DIFFRACTION,2.43,49.29,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V0A,3304.0,3.0,380.0,96.0,,47.68,1.0,2.38,experimental,,0.247,0.211,Crystal structure of human exonuclease 1 Exo1 (D225A) in complex with 5' recessed-end DNA (rVIII)
5V0B,X-RAY DIFFRACTION,2.63,53.15,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V0B,3255.0,3.0,380.0,83.0,,47.18,1.0,2.63,experimental,,0.251,0.207,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (rIX)
5V0C,X-RAY DIFFRACTION,2.45,49.76,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V0C,3101.0,3.0,383.0,55.0,,47.97,1.0,2.58,experimental,,0.2725,0.229,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (f2I)
5V0D,X-RAY DIFFRACTION,2.33,47.21,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V0D,3280.0,4.0,383.0,70.0,,47.97,1.0,2.63,experimental,,0.237,0.205,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (f2II)
5V0E,X-RAY DIFFRACTION,2.45,49.9,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium acetate, pH 7.0, 10 mM potassium chloride, 2-4% PEG4000",290.0,2017-02-28,2017-05-24,5V0E,3285.0,3.0,386.0,54.0,,48.89,1.0,2.744,experimental,,0.2467,0.2038,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (f5I)
5D9K,X-RAY DIFFRACTION,2.51,51.04,VAPOR DIFFUSION,,"20% PEG3350, 0.075 M lithium citrate",291.0,2015-08-18,2015-09-02,5D9K,4599.0,2.0,660.0,103.0,,76.93,1.0,2.55,experimental,37.87,0.2269,0.1807,Rsk2 N-terminal Kinase in Complex with BI-D1870
5JA7,X-RAY DIFFRACTION,2.12,41.99,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.2 M ammonium sulfate, 30% (w/v) PEG-8000",293.0,2016-04-12,2016-11-30,5JA7,3939.0,2.0,446.0,445.0,6.0,49.96,1.0,1.61,experimental,18.4998,0.2201,0.1808,Human cathepsin K mutant C25S in complex with the allosteric effector NSC94914
6GH1,X-RAY DIFFRACTION,2.24,45.19,"VAPOR DIFFUSION, SITTING DROP",6.0,"2.4 M Ammonium Sulphate, 0.1 M MES, pH 6",293.5,2018-05-04,2018-08-08,6GH1,13387.0,12.0,1532.0,778.0,11.0,179.05,3.0,2.1,experimental,,0.2288,0.191,HLA-E*01:03 in complex with Mtb44
8ST9,X-RAY DIFFRACTION,2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2 M KSCN, 0.1 M bis-tris propane pH 7.5, 20% glycerol, and 10% ethylene glycol",295.0,2023-05-09,2023-07-12,8ST9,4191.0,4.0,508.0,128.0,1.0,58.49,2.0,2.5,experimental,39.98,0.2515,0.2036,Structure of E3 ligase NleL bound to ubiquitin
5D0R,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M SODIUM ACETATE PH 4.8, 0.2 M TRI-SODIUM-CITRATE, 15% (W/V) PEG 4000, 10% (V/V) GLYCEROL",277.0,2015-08-03,2016-03-16,5D0R,3953.0,1.0,475.0,214.0,,55.48,1.0,2.24,experimental,35.966,0.2437,0.1773,Crystal structure of human soluble Adenylyl Cyclase with the inhibitor bithionol
7Q8Y,X-RAY DIFFRACTION,2.8,56.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6M Na/K phosphate pH 7, 5% Glycerol, 0.1M tris 7.5",293.15,2021-11-11,2022-03-09,7Q8Y,5651.0,2.0,600.0,739.0,,69.99,1.0,1.6,experimental,19.081,0.2052,0.1777,Crystal structure of TTBK2 in complex with VNG2.73 (compound 42)
7Q8Z,X-RAY DIFFRACTION,2.81,56.15,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.6M Na/K phosphate pH 7, 5% Glycerol, 0.1M tris 8.5",293.15,2021-11-11,2022-03-09,7Q8Z,5645.0,2.0,600.0,726.0,,69.92,1.0,1.57,experimental,22.032,0.2033,0.1749,Crystal structure of TTBK2 in complex with VNG1.33 (compound 27)
7Q90,X-RAY DIFFRACTION,2.81,56.23,"VAPOR DIFFUSION, SITTING DROP",8.0,"1.6M Na/K phosphate pH 7, 5% Glycerol, 0.1M tris 8.0",293.15,2021-11-11,2022-03-09,7Q90,5710.0,2.0,600.0,789.0,,69.79,1.0,1.6,experimental,21.648,0.2202,0.19,Crystal structure of TTBK2 in complex with VNG1.63 (compound 32)
6NNQ,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 6000, 0.1M HEPES, pH 7.5",293.15,2019-01-15,2019-05-08,6NNQ,2540.0,2.0,302.0,48.0,,35.55,2.0,2.621,experimental,,0.2766,0.229,Non-covalent structure of SENP1 in complex with SUMO2
6M8Q,X-RAY DIFFRACTION,2.67,54.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"Reservoir solution: 100 mM Tris HCl pH 7.0; 0.4 M NaH2PO4; 1.466 K2HPO; 0.2 M NaCl
10 mg/mL 
Protein solution: CPSF3 protein in; 20 mM Hepes pH 7.7; 150 mM NaCl; 5 % glycerol; 1 mM DTT; 0.5 mM NVP-LTM531
Co-crystallization Protocol: 50 nL of protein mixed with 50 nL of reservoir solution. Crystals grew within 1 day with tetragonal bipyramidal habitus and reached a maximum size of 50 micrometers after 3 days.
Cryo-protection Protocol: supplemented reservoir solution with 10 and 20% glycerol, respectively, and subsequently added both solution within 5 min. Crystals incubate for another 5 min before harvesting.",294.0,2018-08-22,2019-11-27,6M8Q,7824.0,2.0,956.0,484.0,,110.23,1.0,2.49,experimental,51.97,0.2208,0.1625,Cleavage and Polyadenylation Specificity Factor Subunit 3 (CPSF3) in complex with NVP-LTM531
6OCF,X-RAY DIFFRACTION,3.72,66.96,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1 M sodium citrate tribasic dihydrate, pH 5.0, and 18% (w/v) PEG20000",293.15,2019-03-23,2019-06-26,6OCF,2698.0,2.0,297.0,168.0,,35.22,2.0,2.102,experimental,41.7347,0.222,0.1958,The crystal structure of VASH1-SVBP complex
6OCG,X-RAY DIFFRACTION,3.22,61.75,"VAPOR DIFFUSION, SITTING DROP",7.0,"5% (v/v) TacsimateTM, 0.1 M HEPES, pH 7.0, and 10% (w/v) polyethylene glycol monomethyl ether 5,000",293.15,2019-03-23,2019-06-26,6OCG,2764.0,2.0,273.0,338.0,,32.26,2.0,1.833,experimental,30.3425,0.2187,0.1771,Crystal structure of VASH1-SVBP complex bound with EpoY
8HKN,X-RAY DIFFRACTION,2.09,41.28,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG-3350, 0.1 M Tris-HCl pH 8.5",291.0,2022-11-27,2024-05-01,8HKN,5913.0,2.0,706.0,229.0,,81.06,1.0,2.5,experimental,45.09,0.2612,0.1815,Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to approved drug Fluzoparib
5JKG,X-RAY DIFFRACTION,2.57,52.1,"VAPOR DIFFUSION, HANGING DROP",,0.65M NH4H2PO4,277.0,2016-04-26,2016-10-05,5JKG,2171.0,1.0,311.0,38.0,,35.14,1.0,2.352,experimental,,0.2774,0.233,The crystal structure of FGFR4 kinase domain in complex with LY2874455
6JPJ,X-RAY DIFFRACTION,2.25,45.26,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES pH 5.5, 20% PEG 4000, 0.15M (NH4)2SO4, 4% (v/v) formamide",277.0,2019-03-27,2019-05-15,6JPJ,2444.0,1.0,311.0,45.0,,35.36,1.0,2.638,experimental,,0.2433,0.1953,Crystal structure of FGF401 in complex of FGFR4
7DTZ,X-RAY DIFFRACTION,2.32,46.99,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1M Bis-Tris, 20% PEG 3350, 0.2M LiSO4, pH 4.5",277.0,2021-01-07,2021-04-14,7DTZ,2721.0,1.0,309.0,331.0,,35.11,1.0,2.01,experimental,22.4882,0.1976,0.1651,FGFR4 complex with a covalent inhibitor
7WCT,X-RAY DIFFRACTION,2.24,45.05,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19 % PEG 3350",277.0,2021-12-20,2022-03-30,7WCT,2585.0,1.0,311.0,173.0,,35.73,1.0,2.106,experimental,33.3779,0.217,0.1822,Crystal structure of FGFR4 kinase domain with 7v
7YC1,X-RAY DIFFRACTION,2.22,44.59,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19 % PEG 3350",277.0,2022-06-30,2022-11-16,7YC1,2476.0,1.0,311.0,79.0,,35.48,1.0,2.535,experimental,31.4045,0.2259,0.1829,Crystal structure of FGFR4 kinase domain with 10d
7YC3,X-RAY DIFFRACTION,2.23,44.88,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19 % PEG 3350",277.0,2022-06-30,2022-11-16,7YC3,2655.0,1.0,311.0,234.0,,35.82,1.0,1.987,experimental,28.5586,0.196,0.1616,Crystal structure of FGFR4 kinase domain with 10t
6I3C,X-RAY DIFFRACTION,2.14,42.61,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.2M 1,6-Hexanediol; 0.2M 1-Butanol; 0.2M 1,2-Propanediol; 0.2M 2-Propanol; 0.2M 1,4-Butanediol; 0.2M 1,3-Propanediol), 0.1M Imidazole; MES monohydrate (acid) pH 6.5, 50% v/v pre-cipitant mix (25% v/v MPD; 25% PEG 1000; 25% PEG 3350) Morpheus condition D4",277.0,2018-11-05,2019-09-18,6I3C,1985.0,1.0,232.0,208.0,,26.59,1.0,1.336,experimental,,0.1702,0.1337,"Crystal structure of Human soluble catechol O-methyltransferase in complex with 3,5-dinitrocatechol and S-adensoyl-L-methionine"
6ASD,X-RAY DIFFRACTION,2.6,52.2,VAPOR DIFFUSION,7.5,"25% PEG-3350, 0.2 M ammonium acetate, 0.1 M HEPES",291.0,2017-08-24,2017-10-18,6ASD,920.0,3.0,71.0,58.0,,12.96,1.0,1.85,experimental,36.226,0.235,0.2016,Zinc finger region of human TET1 in complex with CpG DNA
5VEW,X-RAY DIFFRACTION,3.25,62.17,LIPIDIC CUBIC PHASE,,"0.4-0.45 M ammonium acetate, 0.1 M sodium cacodylate, pH 6.2-6.6, 35-38% PEG400, 3% w/v aminohexanoic acid",293.0,2017-04-05,2017-05-24,5VEW,6849.0,2.0,910.0,20.0,4.0,108.63,1.0,2.7,experimental,103.61,0.246,0.228,Structure of the human GLP-1 receptor complex with PF-06372222
5AP1,X-RAY DIFFRACTION,3.04,59.49,,6.5,"0.1M MES PH 6.5, 0.2M MGCL2, 10% (W/V) PEG4000, CO-CRYSTALLISED WITH 1MM INHIBITOR",,2015-09-14,2015-09-23,5AP1,2296.0,1.0,313.0,128.0,,37.3,1.0,2.05,experimental,69.04,0.2107,0.1945,Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
7S7L,X-RAY DIFFRACTION,2.82,56.32,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2M ammonium sulfate, 0.1M Bis-Tris pH 6.5, 25% w/v PEG 3350
Anatrace-Microlytic Top96 #65",310.0,2021-09-16,2022-03-16,7S7L,2726.0,2.0,357.0,79.0,6.0,40.77,2.0,2.34,experimental,55.6208,0.2392,0.2064,Complex of tissue inhibitor of metalloproteinases-1 (TIMP-1) mutant (L34G/M66S/E67Y/L133N/S155L) with matrix metalloproteinase-3 catalytic domain (MMP-3cd)
7JHL,X-RAY DIFFRACTION,2.37,48.05,"VAPOR DIFFUSION, HANGING DROP",,"24% PEG1500, 20% glycerol",277.0,2020-07-20,2020-11-18,7JHL,6021.0,2.0,740.0,276.0,6.0,90.37,1.0,2.26,experimental,39.0774,0.2241,0.1747,"Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with UDP-N-acetylglucosamine"
6FNM,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"25 % PEG5000 MME, 15 % Glycerol, 0.15 M MgCl2, 0.1 M TRIS pH7.5",291.0,2018-02-04,2018-08-08,6FNM,2680.0,1.0,297.0,355.0,,33.98,1.0,1.157,experimental,,0.1945,0.1838,Crystal Structure of Ephrin B4 (EphB4) Receptor Protein Kinase with Dasatinib
6A73,X-RAY DIFFRACTION,3.13,60.73,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium sulfate ,100mM Bis-Tris pH 5.5, 25%PEG 3350.",293.0,2018-07-02,2019-07-03,6A73,4973.0,2.0,608.0,171.0,,72.14,1.0,2.447,experimental,,0.2879,0.2473,Complex structure of CSN2 with IP6
5WZZ,X-RAY DIFFRACTION,2.18,43.62,"VAPOR DIFFUSION, HANGING DROP",8.0,"25% (w/v) PEG3350, 200 mM MgCl2, 100 mM Tris-Hcl",277.0,2017-01-19,2017-08-16,5WZZ,6512.0,8.0,840.0,216.0,,96.05,2.0,2.103,experimental,,0.2084,0.1845,The SIAH E3 ubiquitin ligases promote Wnt/ beta-catenin signaling through mediating Wnt-induced Axin degradation
8QZD,X-RAY DIFFRACTION,1.96,37.18,"VAPOR DIFFUSION, SITTING DROP",7.0,"25% PEG Smear High, 0.1M PIPES pH 7.0, 0.1M magnesium formate, 0.1M rubidium chloride",293.0,2023-10-27,2024-02-28,8QZD,3013.0,1.0,367.0,258.0,,43.22,1.0,1.3,experimental,18.14,0.18041,0.16279,Soluble epoxide hydrolase in complex with Epoxykinin
5MAJ,X-RAY DIFFRACTION,2.03,39.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG3350, 0.2M ammonium acetate, 0.1M HEPES",295.0,2016-11-03,2017-01-11,5MAJ,2167.0,1.0,220.0,399.0,3.0,24.66,1.0,1,experimental,17.517,0.16999,0.13639,"CATHEPSIN L IN COMPLEX WITH 4-[cyclopentyl(imidazo[1,2-a]pyridin-2-ylmethyl)amino]-6-morpholino-1,3,5-triazine-2-carbonitrile"
6EZP,X-RAY DIFFRACTION,2.4,48.8,"VAPOR DIFFUSION, SITTING DROP",3.5,"0.1 M citrate, 25% PEG3350",294.0,2017-11-16,2018-04-11,6EZP,1930.0,1.0,220.0,207.0,3.0,24.83,1.0,1.37,experimental,17.595,0.23336,0.21086,"CATHEPSIN L IN COMPLEX WITH (3S,14E)-19-chloro-N-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6(11),7,9,14,18(22),19-heptaene-3-carboxamide"
6B5C,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, HANGING DROP",8.0,0.1M TRIS pH 8.0 and 18% PEG 8000,293.0,2017-09-29,2018-05-23,6B5C,2385.0,1.0,307.0,53.0,,34.82,1.0,2.4,experimental,54.3312,0.2531,0.2151,Structural Basis for Katanin Self-Assembly
5IUG,X-RAY DIFFRACTION,2.04,39.81,"VAPOR DIFFUSION, SITTING DROP",8.6,"18% PEG2000 MME, 0.1 M Tris-HCl pH 8.6",277.0,2016-03-18,2016-05-18,5IUG,2465.0,1.0,327.0,192.0,,37.4,1.0,1.93,experimental,29.3488,0.2112,0.1829,Crystal Structure of Anaplastic Lymphoma Kinase (ALK) in complex with 5a
5IUH,X-RAY DIFFRACTION,2.07,40.55,"VAPOR DIFFUSION, SITTING DROP",8.6,"18% PEG 2000 MME, 0.1 M Tris-HCl pH 8.6",277.0,2016-03-18,2016-05-18,5IUH,2402.0,1.0,327.0,139.0,,37.39,1.0,2.1,experimental,34.4546,0.2208,0.1811,Crystal Structure of the Anaplastic Lymphoma Kinase (ALK) in complex with 5d
7JYR,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, SITTING DROP",,"18.25% PEG 3350, 2.0% Tacsimate pH 7.0, 0.09M Tris Cl, 0.01M Tris base",293.0,2020-08-31,2021-01-20,7JYR,2391.0,1.0,322.0,79.0,,36.52,1.0,2.32,experimental,,0.2474,0.214,"hALK in complex with 1-[(1R,2R)-1-(2,4-difluorophenyl)-2-[2-(5-methyl-1H-pyrazol-3-yl)-4-(trifluoromethyl)phenoxy]cyclopropyl]methanamine"
7SO5,X-RAY DIFFRACTION,2.54,51.61,"VAPOR DIFFUSION, SITTING DROP",,0.1 M TRIS pH 8.2 and 39% polyethylene glycol 400,293.0,2021-10-29,2022-05-11,7SO5,8436.0,3.0,972.0,752.0,4.0,109.37,3.0,1.797,experimental,30.8103,0.2229,0.185,Novel structural insights for a pair of monoclonal antibodies recognizing non-overlapping epitopes of the glucosyltransferase domain of Clostridium difficile toxin B
7FAI,X-RAY DIFFRACTION,2.5,50.73,"VAPOR DIFFUSION, HANGING DROP",,"22-27% PEG 3350, 0.15M sodium malate, pH 7.0",298.0,2021-07-06,2021-11-24,7FAI,11109.0,4.0,1344.0,251.0,,154.72,1.0,2.09749259173,experimental,25.8189564552,0.231685364763,0.194254515576,CARM1 bound with compound 9
7FAJ,X-RAY DIFFRACTION,2.55,51.69,"VAPOR DIFFUSION, HANGING DROP",,"22-27% PEG 3350, 0.15M sodium malate, pH 7.0",298.0,2021-07-06,2021-11-24,7FAJ,10952.0,4.0,1344.0,107.0,,154.68,1.0,2.24507255823,experimental,39.7674088481,0.239817714938,0.191270082835,CARM1 bound with compound 43
5WZS,X-RAY DIFFRACTION,3.38,63.63,VAPOR DIFFUSION,,"2.2 M Sodium chloride, 0.1 M BIS-TRIS propane pH 7.0",277.0,2017-01-18,2018-01-24,5WZS,1094.0,1.0,123.0,66.0,7.0,14.65,1.0,2.3,experimental,30.86,0.2655,0.215,Crystal structure of human secreted phospholipase A2 group IIE with Compound 8
5WZT,X-RAY DIFFRACTION,3.36,63.43,VAPOR DIFFUSION,,"2.2M Sodium chloride, 0.1M BIS-TRIS propane pH 7.0",277.0,2017-01-18,2018-01-24,5WZT,1068.0,1.0,123.0,50.0,7.0,14.64,1.0,2.4,experimental,32.773,0.2674,0.2186,Crystal structure of human secreted phospholipase A2 group IIE with Compound 14
5WZU,X-RAY DIFFRACTION,3.34,63.15,VAPOR DIFFUSION,,"2.2M Sodium chloride, 0.1M BIS-TRIS propane pH 7.0",277.0,2017-01-18,2018-01-24,5WZU,1128.0,1.0,123.0,91.0,7.0,14.7,1.0,2.2,experimental,29.379,0.2366,0.1954,Crystal structure of human secreted phospholipase A2 group IIE with Compound 24
5WZV,X-RAY DIFFRACTION,3.39,63.73,VAPOR DIFFUSION,,"2.2M Sodium chloride, 0.1M BIS-TRIS propane pH 7.0",277.0,2017-01-18,2018-01-24,5WZV,1139.0,1.0,123.0,102.0,7.0,14.8,1.0,2.2,experimental,30.496,0.2404,0.2082,Crystal structure of human secreted phospholipase A2 group IIE with Me-indoxam
7AWH,X-RAY DIFFRACTION,3.18,61.35,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,295.0,2020-11-08,2021-09-29,7AWH,4590.0,1.0,529.0,98.0,3.0,63.28,1.0,2.3,experimental,68.99,0.2218,0.1919,Crystal structure of human butyrylcholinesterase in complex with tert-butyl 3-(((2-((1-(benzenesulfonyl)-1H-indol-4-yl)oxy)ethyl)amino)methyl)piperidine-1-carboxylate
7AWI,X-RAY DIFFRACTION,3.17,61.17,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,295.0,2020-11-08,2021-09-29,7AWI,4547.0,1.0,529.0,97.0,3.0,63.02,1.0,2.3,experimental,66.5,0.2381,0.1949,Crystal structure of human butyrylcholinesterase in complex with tert-butyl 3-(((2-((1-benzyl-1H-indol-4-yl)oxy)ethyl)amino)methyl]piperidine-1-carboxylate
5ZF4,X-RAY DIFFRACTION,3.41,63.9,"VAPOR DIFFUSION, HANGING DROP",4.9,"100MM SODIUM ACETATE, 1.8-1.9M AMMONIUM SULPHATE, 40MM C11DAO, 20.8MM DDAO, 2MM DIHYDROOROTATE",293.0,2018-03-02,2018-09-26,5ZF4,3235.0,1.0,390.0,241.0,,44.3,1.0,1.66,experimental,20.814,0.18075,0.16752,Structure of human dihydroorotate dehydrogenase in complex with 275-10-COOMe
5ZF7,X-RAY DIFFRACTION,3.41,63.92,"VAPOR DIFFUSION, HANGING DROP",4.9,"100MM SODIUM ACETATE, 1.8-1.9M AMMONIUM SULPHATE, 40MM C11DAO, 20.8MM DDAO, 2MM DIHYDROOROTATE",293.0,2018-03-02,2018-09-26,5ZF7,3209.0,1.0,390.0,239.0,,44.01,1.0,1.79,experimental,24.007,0.18043,0.1623,Structure of human dihydroorotate dehydrogenase in complex with 277-9-OH
5ZF8,X-RAY DIFFRACTION,3.4,63.82,"VAPOR DIFFUSION, HANGING DROP",4.9,"100MM SODIUM ACETATE, 1.8-1.9M AMMONIUM SULPHATE, 40MM C11DAO, 20.8MM DDAO, 2MM DIHYDROOROTATE",293.0,2018-03-02,2018-09-26,5ZF8,3202.0,1.0,390.0,236.0,,44.17,1.0,1.7,experimental,21.988,0.18151,0.16777,Structure of human dihydroorotate dehydrogenase in complex with 277-11-OAc
5ZF9,X-RAY DIFFRACTION,3.41,63.96,"VAPOR DIFFUSION, HANGING DROP",4.9,"100MM SODIUM ACETATE, 1.8-1.9M AMMONIUM SULPHATE, 40MM C11DAO, 20.8MM DDAO, 2MM DIHYDROOROTATE",293.0,2018-03-02,2018-09-26,5ZF9,3227.0,1.0,390.0,237.0,,44.07,1.0,1.77,experimental,20.216,0.18124,0.16312,Structure of human dihydroorotate dehydrogenase in complex with 280-12
5ZFA,X-RAY DIFFRACTION,3.4,63.83,"VAPOR DIFFUSION, HANGING DROP",4.9,"100MM SODIUM ACETATE, 1.8-1.9M AMMONIUM SULPHATE, 40MM C11DAO, 20.8MM DDAO, 2MM DIHYDROOROTATE",293.0,2018-03-02,2018-09-26,5ZFA,3193.0,1.0,390.0,214.0,,44.12,1.0,1.75,experimental,22.886,0.183,0.16732,Structure of human dihydroorotate dehydrogenase in complex with 287-12-OCOiPr
5ZFB,X-RAY DIFFRACTION,3.42,64.0,"VAPOR DIFFUSION, HANGING DROP",4.9,"100MM SODIUM ACETATE, 1.8-1.9M AMMONIUM SULPHATE, 40MM C11DAO, 20.8MM DDAO, 2MM DIHYDROOROTATE",293.0,2018-03-02,2018-09-26,5ZFB,3160.0,1.0,390.0,183.0,,44.31,1.0,2,experimental,25.153,0.18943,0.16371,Structure of human dihydroorotate dehydrogenase in complex with ascofuranone (open-form)
8DWK,X-RAY DIFFRACTION,2.59,52.56,"VAPOR DIFFUSION, SITTING DROP",,"10% w/v PEG 8000, 20% v/v ethylene glycol, 0.1 M bicine/Trizma base pH 8.5, 0.03 M diethyleneglycol, 0.03 M triethyleneglycol, 0.03 M tetraethyleneglycol, 0.03 M pentaethyleneglycol",289.0,2022-08-01,2023-02-15,8DWK,5183.0,4.0,690.0,55.0,,79.28,2.0,2.5,experimental,58.4482,0.2381,0.2129,Inhibitor-3:PP1 reconstituted complex
8GBL,X-RAY DIFFRACTION,2.22,44.67,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES 6.5, 25% PEG 4K",293.0,2023-02-26,2024-06-05,8GBL,3909.0,2.0,542.0,116.0,,59.22,1.0,2.24,experimental,37.55,0.256,0.215,Structure of Apo Human SIRT5
8GBN,X-RAY DIFFRACTION,2.24,45.18,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES pH 6.5, 20% PEG 10K, 10 mM Praseodymium (III) acetate hydrate",293.0,2023-02-26,2024-06-05,8GBN,3910.0,2.0,542.0,92.0,,59.35,1.0,2.7,experimental,39.49,0.231,0.182,Structure of Apo Human SIRT5 P114T Mutant
6RXS,X-RAY DIFFRACTION,2.26,45.62,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M Bis-Tris, 0.03 M HCl, 23% PEG3350",291.0,2019-06-08,2020-04-15,6RXS,2002.0,2.0,265.0,220.0,,29.72,2.0,1.599,experimental,26.3026,0.2046,0.1791,"Crystal structure of CobB Ac3(A76G,Y92A, I131L, V187Y) in complex with H4K16-Acetyl peptide"
5D6Y,X-RAY DIFFRACTION,2.97,58.55,"VAPOR DIFFUSION, SITTING DROP",,"Protein-peptide Solution (30mg/ml KDM4A DTD and 3.5mg/ml peptide in 20mM HEPES pH 7.5, 150mM NaCl and 0.5mM TCEP) mixed in a 1:1 ratio with the well solution (1.2M sodium phosphate monobasic, 0.8M potassium phosphate dibasic, 0.1M CAPS/sodium hydroxide pH10.5, 0.2M lithium sulfate) Cryoprotected with additional 20% glycerol",293.0,2015-08-13,2016-02-10,5D6Y,5533.0,10.0,766.0,216.0,,86.84,2.0,2.287,experimental,59.3756,0.2947,0.2636,Crystal structure of double tudor domain of human lysine demethylase KDM4A complexed with histone H3K23me3
5EDH,X-RAY DIFFRACTION,2.83,56.59,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES-NaOH pH 7.5, 30% PEG550MME, 50mM MgCl2",295.0,2015-10-21,2016-03-09,5EDH,10830.0,4.0,1264.0,526.0,4.0,147.78,1.0,2.03,experimental,40.871,0.2266,0.186,"human PDE10A, 8-ethyl-5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine, 2.03A, H3, Rfree=22.7%"
5I2R,X-RAY DIFFRACTION,2.87,57.15,"VAPOR DIFFUSION, SITTING DROP",,none,295.0,2016-02-09,2016-03-09,5I2R,10855.0,4.0,1272.0,517.0,4.0,149.05,1.0,2.5,experimental,37.91,0.25,0.191,human PDE10A in complex with 3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
5SFI,X-RAY DIFFRACTION,2.63,53.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"5-20 mg/mL protein in 25mM HEPES/NaOH pH7.5, 150mM NaCl, 50mM BME mixed 1:1 with reservoir 0.1M HEPES/NaOH pH7.5, 30% PEG550MME, 50mM MgCl2",295.0,2022-01-21,2022-10-12,5SFI,10835.0,4.0,1372.0,541.0,4.0,159.57,1.0,2.01,experimental,37.874,0.2281,0.1699,"Crystal Structure of human phosphodiesterase 10 in complex with 5,8-dimethyl-2-[2-[2-methyl-5-(2-methylpyrrolidin-1-yl)-1,2,4-triazol-3-yl]ethyl]-[1,2,4]triazolo[1,5-a]pyrazine"
5K97,X-RAY DIFFRACTION,3.34,63.17,"VAPOR DIFFUSION, HANGING DROP",,"24% MPEG 2K, 20% KCl, 5% ethylene glycol, 100 mM HEPES pH 7.5",283.0,2016-05-31,2017-06-28,5K97,4176.0,5.0,382.0,623.0,,52.27,1.0,2.102,experimental,,0.2187,0.1824,Flap endonuclease 1 (FEN1) D233N with cleaved product fragment and Sm3+
5I35,X-RAY DIFFRACTION,2.44,49.61,"VAPOR DIFFUSION, HANGING DROP",7.5,"One part of ADCK3 R611K, 0.2 mM, AMPPNP 2 mM, MgCl2, 4mM, mixed with an equal volume of sodium polyacrylate 5100, 26%; magnesium chloride, 20 mM; HEPES, 100 mM, pH 7.5",293.0,2016-02-09,2016-08-17,5I35,3162.0,1.0,393.0,26.0,,46.43,1.0,2.3,experimental,76.273,0.25887,0.18346,Structure of the Human mitochondrial kinase COQ8A R611K with AMPPNP (Cerebellar Ataxia and Ubiquinone Deficiency Through Loss of Unorthodox Kinase Activity)
8E24,X-RAY DIFFRACTION,2.88,62.39,"VAPOR DIFFUSION, HANGING DROP",7.5,"16% PEG 3350, 0.2M diammonium tartrate, 2% glycerol",291.0,2022-08-13,2022-09-28,8E24,11101.0,6.0,1396.0,154.0,,170.67,1.0,2.34,experimental,79.29,0.2662,0.2314,Human DNA polymerase theta in complex with allosteric inhibitor
8AM1,X-RAY DIFFRACTION,3.39,63.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"AMMONIUM SULFATE 2.1 M, 2-(N-MORPHOLINO)- ETHANESULFONIC ACID 0.1 M",298.0,2022-08-02,2023-06-14,8AM1,4546.0,1.0,529.0,95.0,3.0,63.14,1.0,2.53,experimental,70.6,0.2242,0.188,"Human butyrylcholinesterase in complex with zinc and N,N,N-trimethyl-2-oxo-2-(2-(pyridin-2-ylmethylene)hydrazineyl)ethan-1-aminium"
4RE9,X-RAY DIFFRACTION,3.97,68.99,"VAPOR DIFFUSION, HANGING DROP",7.0,"10% PEG5000, 100 mM HEPES, 14% Tacsimate, 10% dioxane, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K",291.15,2014-09-22,2015-09-30,4RE9,15851.0,2.0,1980.0,93.0,,232.23,1.0,2.908,experimental,,0.2129,0.1592,Crystal structure of human insulin degrading enzyme (IDE) in complex with compound 71290
5UUU,X-RAY DIFFRACTION,3.5,64.88,"VAPOR DIFFUSION, SITTING DROP",5.6,"18% PEG MME 2000, 0.1 M MES pH 5.6, and 0.0175M Ammonium Sulfate",273.0,2017-02-17,2017-07-26,5UUU,3470.0,1.0,547.0,35.0,,64.09,1.0,2.7,experimental,77.691,0.257,0.2128,"Design, Synthesis, and Evaluation of the First Selective and Potent G-protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure"
6N6O,X-RAY DIFFRACTION,2.9,57.67,"VAPOR DIFFUSION, SITTING DROP",8.5,"100mM Tris pH 8.5, 300mM Sodium Acetate, 8% PEG 20k, 8% PEG 500 MME",277.0,2018-11-26,2019-05-15,6N6O,2010.0,1.0,285.0,3.0,1.0,33.78,1.0,2.6,experimental,56.113,0.2439,0.1999,Crystal structure of the human TTK in complex with an inhibitor
6ZEG,X-RAY DIFFRACTION,2.32,47.05,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% (w/v) polyethylene glycol 3350, 0.2 M KSCN and 0.1 M BIS-Tris propane pH 8.5",293.0,2020-06-16,2020-09-30,6ZEG,7225.0,4.0,816.0,844.0,,92.76,2.0,1.09,experimental,16.27,0.1403,0.1195,Structure of PP1-IRSp53 chimera [PP1(7-304) + linker (G/S)x9 + IRSp53(449-465)] bound to Phactr1 (516-580)
5F32,X-RAY DIFFRACTION,2.45,49.84,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2015-12-02,2016-01-20,5F32,11989.0,4.0,1440.0,766.0,,170.01,1.0,2.05,experimental,57.78,0.2031,0.1681,Crystal structure of human KDM4A in complex with compound 40
5F3C,X-RAY DIFFRACTION,2.49,50.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2015-12-02,2016-01-20,5F3C,12206.0,4.0,1440.0,1041.0,,170.44,1.0,2.06,experimental,56.67,0.1955,0.1606,Crystal structure of human KDM4A in complex with compound 52d
5F3E,X-RAY DIFFRACTION,2.47,50.19,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2015-12-02,2016-01-20,5F3E,11994.0,4.0,1440.0,1009.0,,170.02,1.0,2.16,experimental,44.55,0.2103,0.1623,Crystal structure of human KDM4A in complex with compound 54a
5F3I,X-RAY DIFFRACTION,2.46,50.03,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2015-12-02,2016-01-20,5F3I,11609.0,4.0,1440.0,613.0,,170.26,1.0,2.24,experimental,60.2,0.2129,0.1686,Crystal structure of human KDM4A in complex with compound 54j
6CMM,X-RAY DIFFRACTION,2.58,52.37,"VAPOR DIFFUSION, SITTING DROP",6.5,"30.25% PEG3350, 200 mM LiSO4, 0.1M SBG buffer pH 6.5",293.0,2018-03-05,2018-03-21,6CMM,10579.0,4.0,1456.0,474.0,,166.47,1.0,2.1,experimental,39.019,0.22201,0.19029,"Crystal Structure of the Human vaccinia-related kinase bound to a N,N-dipropynyl-dihydropteridine inhibitor"
6NPN,X-RAY DIFFRACTION,2.59,52.47,"VAPOR DIFFUSION, SITTING DROP",6.0,"27.5% PEG 3350, 20 mM Li2SO4, 0.1M SBG, pH 6.0",293.0,2019-01-18,2019-02-20,6NPN,10564.0,4.0,1456.0,618.0,,167.98,1.0,2.2,experimental,34.773,0.21796,0.18686,"Crystal Structure of the Human vaccinia-related kinase bound to a N,N-dipropynyl-dihydropteridine-3-hydroxyindazole inhibitor"
5GRE,X-RAY DIFFRACTION,3.08,60.0,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.2 M sodium citrate, pH 8.0, 20% (w/v) PEG 3350",293.0,2016-08-11,2017-02-15,5GRE,5142.0,2.0,693.0,58.0,,76.22,2.0,2.65,experimental,49.333,0.2414,0.1947,"Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+), citrate and ADP"
5GRF,X-RAY DIFFRACTION,3.6,65.8,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.2 M sodium citrate, pH 8.0, 20% (w/v) PEG 3350",293.0,2016-08-11,2017-02-15,5GRF,5214.0,2.0,693.0,127.0,,76.14,2.0,2.5,experimental,68.322,0.2475,0.2069,"Crystal structure of the alpha gamma mutant (gamma-K151A) of human IDH3 in complex with Mg(2+), citrate and ADP"
5GRI,X-RAY DIFFRACTION,3.48,64.62,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.2 M sodium citrate, pH 8.0, 20% (w/v) PEG 3350",293.0,2016-08-11,2017-02-15,5GRI,5165.0,2.0,693.0,111.0,,75.79,2.0,2.31,experimental,44.364,0.2712,0.2409,Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with Mg(2+) and citrate
7AAX,X-RAY DIFFRACTION,2.22,44.61,VAPOR DIFFUSION,7.5,"0.05M Tris pH 7.5, 4.4M NaCl",293.0,2020-09-05,2020-10-28,7AAX,2285.0,1.0,298.0,87.0,,35.05,1.0,1.762,experimental,47.515,0.2532,0.1992,Crystal structure of MerTK kinase domain in complex with LDC1267
7AAY,X-RAY DIFFRACTION,2.44,49.63,VAPOR DIFFUSION,6.2,"0.1M MES pH 6.2, 0.75M LiCl, 23% PEG 6k",293.0,2020-09-05,2020-10-28,7AAY,2323.0,1.0,294.0,117.0,,34.5,1.0,1.87,experimental,36.09,0.2239,0.1953,Crystal structure of MerTK kinase domain in complex with Merestinib
7AAZ,X-RAY DIFFRACTION,3.12,60.64,VAPOR DIFFUSION,8.5,"0.1M HEPES pH 6.6, 3.1M NaCl",293.0,2020-09-05,2020-11-04,7AAZ,2468.0,1.0,296.0,132.0,,34.92,1.0,1.855,experimental,39.466,0.219,0.1876,Crystal structure of MerTK in complex with a type 1.5 aminopyridine inhibitor
7AB0,X-RAY DIFFRACTION,2.19,43.72,VAPOR DIFFUSION,8.5,"0.1M Tris pH 8.5, 4.3M NaCl",293.0,2020-09-05,2020-10-28,7AB0,2284.0,1.0,298.0,132.0,,34.56,1.0,1.74,experimental,42.019,0.2465,0.2001,Apo crystal structure of the MerTK kinase domain
7BTT,X-RAY DIFFRACTION,2.17,43.33,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodium chloride, 25% w/v Polyethylene glycol 3,350, 0.1 M Tris pH 8.5",277.15,2020-04-02,2021-04-07,7BTT,2588.0,1.0,320.0,157.0,,36.5,1.0,1.86,experimental,36.87,0.2091,0.1867,A X-ray cocrystal structure of XMU-MP-5 bound to the ALK kinase domain
3WYX,X-RAY DIFFRACTION,2.85,56.87,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M ADA pH6.5, 0.3M potassium iodide, 12%(w/v) PEG8000, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-09-09,2015-04-08,3WYX,2030.0,1.0,321.0,5.0,,37.41,1.0,2.9,experimental,67.79,0.2725,0.2317,CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6-((3-(cyanomethoxy)-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-2-(cyclohexylamino)nicotinonitrile
3WZJ,X-RAY DIFFRACTION,3.04,59.51,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Tris hydrochloride pH7.5, 0.12M magnesium chloride, 8%(w/v) triethylene glycol 
, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-09-29,2015-02-11,3WZJ,2053.0,1.0,321.0,2.0,,37.35,1.0,2.75,experimental,63.813,0.282,0.2205,"CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6-(cyclohexylamino)-8-(((tetrahydro-2H-pyran-4-yl)methyl)amino)imidazo[1,2-b]pyridazin-3-yl)-N-cyclopropylbenzamide"
3WZK,X-RAY DIFFRACTION,2.98,58.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M PIPES pH6.5, 12.3%(w/v) PEG3350, 0.0818M magnesium sulfate, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-09-29,2015-02-11,3WZK,2067.0,1.0,321.0,33.0,,37.28,1.0,2.3,experimental,59.92,0.2799,0.2216,"CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N-cyclopropyl-4-(8-((thiophen-2-ylmethyl)amino)imidazo[1,2-a]pyrazin-3-yl)benzamide"
5EI2,X-RAY DIFFRACTION,2.73,55.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Bis-Tris propane
0.2 M MgCl2
0.2 M Sodium formate
20% PEG3350",291.15,2015-10-29,2016-04-20,5EI2,1994.0,1.0,313.0,13.0,,36.48,1.0,2.67,experimental,96.02,0.295,0.2358,"Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach"
6B4W,X-RAY DIFFRACTION,3.21,61.64,"VAPOR DIFFUSION, SITTING DROP",7.0,"100mM Sodium Cacodylate, 200mM Potassium Thiocyanate, 15% PEG 4K",277.0,2017-09-27,2017-10-25,6B4W,2116.0,1.0,303.0,,,35.52,1.0,2.9,experimental,60.947,0.25313,0.19126,TTK in Complex with Inhibitor
8P5I,X-RAY DIFFRACTION,3.51,64.98,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.3-0.8 M NaAcetate pH 6, 20-26% w/v PEG3350",277.15,2023-05-24,2024-06-05,8P5I,10079.0,4.0,1136.0,959.0,,130.55,1.0,1.829,experimental,30.298,0.1891,0.1657,Kinase domain of mutant human ULK1 in complex with compound XMD-17-51
7Y9C,X-RAY DIFFRACTION,2.26,45.46,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES monohydrate pH6.5, 12 % w/v PEG 20000, 0.2 M sodium thiocyanate",291.0,2022-06-24,2023-04-12,7Y9C,4940.0,4.0,576.0,394.0,,66.63,2.0,2.1,experimental,28.5783,0.2427,0.192,Crystal structure of METTL9 in complex with SLC39A5 peptide and SAH
7VA1,X-RAY DIFFRACTION,2.33,47.1,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Calcium chloride dihydrate
0.1 M Tris 8.0
20 %(w/v) PEG 6000",289.0,2021-08-27,2023-03-08,7VA1,6295.0,4.0,856.0,382.0,,93.83,1.0,1.74,experimental,36.89,0.2247,0.1964,Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with GDD-04-35
7WR0,X-RAY DIFFRACTION,2.3,46.5,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M potassium chloride",293.0,2022-01-26,2023-01-25,7WR0,1921.0,1.0,280.0,,,32.1,1.0,2.8,experimental,70.66,0.2659,0.2383,P32 of caspase-4 C258A mutant
5WWW,X-RAY DIFFRACTION,2.47,50.19,"VAPOR DIFFUSION, HANGING DROP",,"5% v/v Tacsimate pH 7.0, 0.1M HEPES pH 7.0, 10% w/v polyethylene glycol monomethyl ether 2000",293.0,2017-01-05,2017-08-23,5WWW,977.0,2.0,100.0,93.0,,12.41,1.0,1.798,experimental,26.3348,0.2091,0.172,Crystal structure of the KH1 domain of human RNA-binding E3 ubiquitin-protein ligase MEX-3C complex with RNA
6TXB,X-RAY DIFFRACTION,2.41,48.92,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2 M Sodium malonate, 20% PEG 3350",293.15,2020-01-14,2021-01-27,6TXB,3634.0,4.0,517.0,57.0,1.0,57.87,2.0,2.18,experimental,68.458,0.2465,0.2125,Crystal structure of Mindy1 mutant (P138A) in complex with Lys48 linked di-ubiquitin
6JFM,X-RAY DIFFRACTION,2.2,44.16,"VAPOR DIFFUSION, HANGING DROP",,"0.16 M Calcium acetate
0.08 M Sodium cacodylate PH 6.5
14.4% (W/V) PEG 8000
20% (V/V) Glycerol",293.15,2019-02-10,2019-11-13,6JFM,7099.0,2.0,876.0,268.0,,99.93,1.0,2.09,experimental,,0.2293,0.1758,Mitofusin2 (MFN2)_T111D
6LVM,X-RAY DIFFRACTION,2.27,45.79,"VAPOR DIFFUSION, SITTING DROP",5.0,"Citric Acid, PEG 8000",296.0,2020-02-04,2020-04-08,6LVM,2380.0,1.0,313.0,31.0,,36.41,1.0,2.53,experimental,56.476,0.2789,0.2074,Crystal structure of FGFR3 in complex with pyrimidine derivative
6QAE,X-RAY DIFFRACTION,3.05,59.72,"VAPOR DIFFUSION, HANGING DROP",,"Ammonium sulfate
MES pH 6.5",293.0,2018-12-19,2019-03-27,6QAE,4528.0,1.0,557.0,110.0,3.0,66.08,1.0,2.487,experimental,,0.2429,0.1972,"Human Butyrylcholinesterase in complex with (S)-N2-butyl-N1-(2-cycloheptylethyl)-3-(1H-indol-3-yl)-N1,N2-dimethylpropane-1,2-diamine"
6R6V,X-RAY DIFFRACTION,3.24,61.99,"VAPOR DIFFUSION, HANGING DROP",6.5,Ammonium sulfate,293.0,2019-03-28,2020-01-15,6R6V,4588.0,1.0,526.0,172.0,3.0,62.56,1.0,2.5,experimental,62.179,0.2581,0.1921,Structure of recombinant human butyrylcholinesterase in complex with a fluorescent coumarin-based probe
6XTA,X-RAY DIFFRACTION,3.18,61.3,"VAPOR DIFFUSION, HANGING DROP",,Ammonium Sulfate,293.0,2020-01-15,2020-10-28,6XTA,4480.0,1.0,529.0,56.0,3.0,62.59,1.0,2.5,experimental,74.81,0.2596,0.2086,Recombinant human butyrylcholinesterase in complex with (2S)-N-[2-(1-benzylazepan-4-yl)ethyl]-2-(butylamino)-3-(1H-indol-3-yl)propanamide
7CJ0,X-RAY DIFFRACTION,2.67,58.48,"VAPOR DIFFUSION, SITTING DROP",,"0.17 M Sodium acetate, 0.1 M Tris, pH8.5, 25% (v/v) PEG 4000, 20% (v/v) Glycerol",293.0,2020-07-09,2021-04-14,7CJ0,4696.0,8.0,670.0,69.0,,75.3,4.0,2.5,experimental,81.1957,0.2948,0.2577,Crystal structure of DNAJC9 HBD in complex with H3.3-H4 dimer and MCM2 HBD
6KFP,X-RAY DIFFRACTION,2.39,48.63,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, lithium chloride",293.0,2019-07-08,2020-04-01,6KFP,4753.0,3.0,607.0,,,68.99,3.0,2.92,experimental,53.62,0.2498,0.1932,Crystal structure of MavC ternary complex
5DEY,X-RAY DIFFRACTION,2.4,48.69,"VAPOR DIFFUSION, SITTING DROP",,"crystals were grown at 19  C from 1.0 uL + 1.0 uL vapor diffusion drops containing 10 mg/mL protein, 1 mM ligand, 0.15 M DL-Malic Acid pH 7.0, 20% - 30% PEG 3350, 4% 1,3-Propanediol and 0.1 M Sodium Malonate, VAPOR DIFFUSION, SITTING DROP, temperature 292K",292.0,2015-08-26,2016-01-27,5DEY,4762.0,2.0,594.0,195.0,1.0,67.56,1.0,2.1,experimental,,0.2275,0.1834,Crystal structure of PAK1 in complex with an inhibitor compound G-5555
5IME,X-RAY DIFFRACTION,2.36,47.79,"VAPOR DIFFUSION, SITTING DROP",7.0,"crystals were grown at 19  C from 1.0 uL + 1.0 uL vapor diffusion drops containing 10 mg/mL protein, 1 mM ligand, 0.15 M DL-Malic Acid, 20% - 30% PEG 3350, 4% 1,3-Propanediol and 0.1 M Sodium Malonate, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 292K",292.0,2016-03-06,2016-05-25,5IME,4625.0,2.0,600.0,182.0,,67.99,1.0,2.217,experimental,,0.2629,0.2244,Crystal structure of P21-activated kinase 1 (PAK1) in complex with compound 9
7AWG,X-RAY DIFFRACTION,3.2,61.58,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2020-11-08,2021-09-29,7AWG,4769.0,1.0,529.0,246.0,3.0,63.98,1.0,2,experimental,43.63,0.1974,0.1728,Crystal structure of human butyrylcholinesterase in complex with (2-((1-(benzenesulfonyl)-1H-indol-4-yl)oxy)ethyl)(benzyl)amine
5AEH,X-RAY DIFFRACTION,2.1,42.0,,9.0,"0.1M BICINE PH9.0, 20% PEG6K",,2015-08-31,2016-01-13,5AEH,3701.0,2.0,480.0,231.0,,55.65,1.0,1.85,experimental,35.354,0.27066,0.21603,Crystal structure of human tankyrase 2 in complex with OD332
6SAK,X-RAY DIFFRACTION,2.7,54.49,"VAPOR DIFFUSION, SITTING DROP",6.8,"19% (w/v) PEG 3,350, 200 mM Li2(SO4), 100 mM Bis-Tris pH 6.8",291.0,2019-07-17,2019-10-02,6SAK,6026.0,4.0,742.0,268.0,,85.64,2.0,2,experimental,53.45,0.2529,0.2152,Structure of the OTULINcat C129A - SNX27 PDZ domain complex.
5UXH,X-RAY DIFFRACTION,2.78,55.78,"VAPOR DIFFUSION, HANGING DROP",5.0,"16.5% v/v PEG3350, 0.05% w/v octyl-beta-D-glucoside, 0.5% v/v glycerol, and 100 mM sodium citrate pH 5.0. The ligand-bound structure was obtained by soaking crystals for 15 minutes in cryopreservation solution containing 2 mM GDP-Fucose immediately prior to freezing",277.0,2017-02-22,2017-04-05,5UXH,5709.0,2.0,734.0,72.0,8.0,85.37,1.0,2.41,experimental,,0.2924,0.2404,Structure of Human POFUT1 in complex with GDP-fucose
5CEN,X-RAY DIFFRACTION,1.94,36.51,"VAPOR DIFFUSION, HANGING DROP",7.7,"0.2 M magnesium acetate, 20% PEG 3350, 0.1 M HEPES pH 7.7",292.0,2015-07-07,2015-10-14,5CEN,2509.0,1.0,300.0,209.0,,34.02,1.0,1.7,experimental,26.21,0.2246,0.1851,Crystal structure of DLK (kinase domain)
7QFB,X-RAY DIFFRACTION,3.66,66.38,"VAPOR DIFFUSION, SITTING DROP",,"1.6 M Lithium sulfate, 1.4 M sodium malonate",293.0,2021-12-05,2022-11-02,7QFB,2741.0,2.0,326.0,163.0,,38.26,2.0,2.05,experimental,38.6283,0.1914,0.1593,Crystal structure of Protein Phosphatase 1 in complex with PP1-binding peptide from PTG
7LQD,X-RAY DIFFRACTION,2.84,56.73,VAPOR DIFFUSION,7.8,"0.05 M magnesium chloride hexahydrate, 0.05 M sodium citrate tribasic, 0.1 M Bis-Tris propane, pH 7.8, 22.5% PEG Smear High",293.0,2021-02-13,2022-02-16,7LQD,2357.0,1.0,313.0,134.0,,37.35,1.0,1.95,experimental,40.873,0.2462,0.1972,Structure of Human MPS1 (TTK) covalently bound to RMS-07 inhibitor
7MDP,X-RAY DIFFRACTION,3.57,65.56,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES pH 6.0, 21 % PEG 4K and 0.2 M lithium sulfate",292.0,2021-04-05,2022-03-16,7MDP,4860.0,3.0,610.0,143.0,4.0,68.9,3.0,1.96,experimental,57.5263,0.2288,0.1948,KRas G12C in complex with G-2897
4RLO,X-RAY DIFFRACTION,3.27,62.34,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris, 3.5M Sodium Formate, with staurosporine, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 288K",288.0,2014-10-17,2015-01-21,4RLO,4236.0,2.0,576.0,82.0,,67.27,1.0,2.527,experimental,,0.2221,0.1915,Human p70s6k1 with ruthenium-based inhibitor EM5
5H8B,X-RAY DIFFRACTION,3.13,60.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES, pH 6.5",293.0,2015-12-23,2016-02-10,5H8B,6052.0,2.0,666.0,260.0,,83.06,1.0,2.55,experimental,33.22,0.2165,0.1712,Crystal structure of CK2 with compound 2
5H8E,X-RAY DIFFRACTION,3.14,60.89,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES, pH 6.5",293.0,2015-12-23,2016-02-10,5H8E,6287.0,2.0,666.0,462.0,,83.58,1.0,2.15,experimental,32.01,0.1961,0.1648,Crystal structure of CK2 with compound 7h
5FWJ,X-RAY DIFFRACTION,2.78,55.78,,5.5,0.1M BIS-TRIS PH 5.5 -- 25% PEG3350 -- 0.25M MAGNESIUM CHLORIDE,,2016-02-17,2016-04-13,5FWJ,7658.0,2.0,942.0,607.0,,109.52,1.0,2.1,experimental,,0.1893,0.1551,Crystal structure of human JARID1C in complex with KDM5-C49
4XWO,X-RAY DIFFRACTION,2.4,48.7,"VAPOR DIFFUSION, HANGING DROP",,"13% PEG 3350, 25 mM succinic acid pH 7.0",298.0,2015-01-29,2015-03-25,4XWO,46513.0,28.0,6572.0,425.0,40.0,722.95,4.0,2.75,experimental,75.163,0.2472,0.1956,Structure of Get3 bound to the transmembrane domain of Sec22
8YLE,X-RAY DIFFRACTION,2.4,48.85,VAPOR DIFFUSION,6.5,"pH 6.5,0.1 M Amino acids,0.1 M Buffer System 1, 30.00% % v/v EDO_P8K",277.0,2024-03-06,2024-04-10,8YLE,3595.0,1.0,430.0,235.0,,49.76,1.0,1.86,experimental,30.67,0.2143,0.1833,Crystal structure of Werner syndrome helicase complexed with AMP-PCP
6TUV,X-RAY DIFFRACTION,2.4,48.67,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris-HCl, 200mM LiSO4.H2O, 30% PEG400",293.15,2020-01-08,2021-01-27,6TUV,3560.0,4.0,517.0,104.0,1.0,57.83,2.0,2.16,experimental,49.244,0.249,0.2075,Crystal structure of Mindy1 in complex with Lys48 linked di-ubiquitin
6TUS,X-RAY DIFFRACTION,3.06,59.76,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 3350, 100 mM Bis-Tris pH 6.5, 200 mM Amm. Sulfate.",295.0,2020-01-08,2020-09-16,6TUS,4823.0,2.0,711.0,54.0,,82.41,2.0,2.5,experimental,82.0475,0.2368,0.2029,"human XPG, Apo2 form"
6AC9,X-RAY DIFFRACTION,2.57,52.15,"VAPOR DIFFUSION, HANGING DROP",7.0,"27.5 % w/v PEG 3350, 0.2 M of ammonium sulfate, 0.1 M of HEPES (pH 7.0)",291.0,2018-07-25,2018-12-26,6AC9,11080.0,4.0,1480.0,889.0,,171.42,1.0,2.07,experimental,41.22,0.223,0.186,Crystal structure of human Vaccinia-related kinase 1 (VRK1) in complex with AMP-PNP
6ACO,X-RAY DIFFRACTION,2.01,38.78,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2M Sodium acetate trihydrate, 0.1M Sodium cacodylate trihydrate (pH 6.5), 30%(w/v) PEG8000",295.0,2018-07-26,2019-07-24,6ACO,2395.0,2.0,277.0,218.0,,30.43,2.0,1.71,experimental,29.941,0.217,0.16096,histone lysine desuccinylase Sirt5 in complex with succinyl peptide H2BK120
5F02,X-RAY DIFFRACTION,2.08,40.78,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MAGNESIUM FORMATE, 15 % PEG 3350",298.0,2015-11-27,2016-02-24,5F02,2023.0,1.0,220.0,222.0,3.0,24.87,1.0,1.43,experimental,23.742,0.19057,0.1432,"CATHEPSIN L IN COMPLEX WITH (2S,4R)-4-(2-Chloro-4-methoxy-benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide"
5MAE,X-RAY DIFFRACTION,1.97,37.56,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG3350, 0.1M Bis-Tris",295.0,2016-11-03,2017-01-11,5MAE,2154.0,1.0,220.0,346.0,3.0,24.81,1.0,1,experimental,16.088,0.18213,0.14722,"CATHEPSIN L IN COMPLEX WITH (2S,4R)-4-(2-Chloro-4-methoxy-benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]-pyrrolidine-2-car boxylic acid (1-cyano-cyclopropyl)-amide"
5K1A,X-RAY DIFFRACTION,2.33,47.32,"VAPOR DIFFUSION, HANGING DROP",5.0,"0.1 M sodium citrate, 7% PEG 3350, 0.15 M NaCl",277.0,2016-05-18,2016-07-20,5K1A,27654.0,8.0,4032.0,1581.0,,459.89,2.0,2.3,experimental,,0.2394,0.1875,Crystal structure of the UAF1-USP12 complex in C2 space group
8D3J,X-RAY DIFFRACTION,2.68,54.1,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris, pH 8.5, 0.34-0.38 M Li2SO4, 25-26% PEG3350",295.0,2022-06-01,2023-11-08,8D3J,6820.0,2.0,1086.0,172.0,,121.41,1.0,2.4,experimental,54.44,0.2144,0.192,Crystal structure of human Apoptosis-Inducing Factor (AIF) complexed with 6-fluoro-2-methylquinolin-4-amine
8D3N,X-RAY DIFFRACTION,2.64,53.4,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris, pH 8.5, 0.38 M Li2SO4, 21% PEG3350, 1 mM 7-chloroquinolin-4-amine",295.0,2022-06-01,2023-11-08,8D3N,6977.0,2.0,1086.0,283.0,,121.6,1.0,2.25,experimental,53.75,0.2366,0.2065,Crystal structure of human Apoptosis-Inducing Factor (AIF) complexed with 7-chloroquinolin-4-amine
4ZFT,X-RAY DIFFRACTION,2.49,50.71,"VAPOR DIFFUSION, SITTING DROP",6.4,"(0.04 M Citric acid, 0.06 M BIS-TRIS propane), 20% w/v PEG 3,350",293.0,2015-04-21,2015-10-14,4ZFT,4161.0,4.0,556.0,79.0,,62.59,2.0,2.304,experimental,,0.2348,0.1919,Catalytic domain of Sst2 F403W mutant bound to ubiquitin
6SKB,X-RAY DIFFRACTION,1.71,27.95,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-08-15,2019-09-25,6SKB,5624.0,3.0,867.0,273.0,18.0,96.55,1.0,1.84,experimental,35.02,0.229,0.196,Crystal Structure of Human Kallikrein 6 (N217D/I218Y/K224R) in complex with GSK3496783A
7QRZ,X-RAY DIFFRACTION,2.17,43.37,"VAPOR DIFFUSION, SITTING DROP",6.5,"18% High molecular weight PEG smears, 0.1M ADA pH 6.5, 0.2M ammonium sulfate",293.15,2022-01-12,2022-05-04,7QRZ,1555.0,1.0,190.0,134.0,,22.19,1.0,1.57,experimental,24.777,0.1921,0.1624,Crystal structure of B30.2 PRYSPRY domain of MID2
7OD1,X-RAY DIFFRACTION,2.39,48.56,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Sodium nitrate, 0.1 M Bis-Tris propane pH 8.5, 20 % PEG 3350",277.0,2021-04-28,2021-09-15,7OD1,6972.0,2.0,986.0,20.0,,116.57,1.0,2.45,experimental,76.8698,0.2617,0.2203,Crystal structure of RBR ubiquitin ligase ARIH2
5TVR,X-RAY DIFFRACTION,2.66,53.85,"VAPOR DIFFUSION, HANGING DROP",6.0,17.5% PEG-3350 and 0.1 M citrate pH 6.0,277.0,2016-11-09,2017-02-01,5TVR,6124.0,2.0,718.0,360.0,,84.08,1.0,2.093,experimental,,0.2236,0.1812,JMJD2A in complex with Ni(II) and alpha-Ketoglutarate
6IZQ,X-RAY DIFFRACTION,2.53,51.37,EVAPORATION,,"22-27% PEG 3350, 0.15M sodium malate, pH 7.0",298.0,2018-12-20,2019-12-25,6IZQ,10625.0,4.0,1332.0,55.0,,151.77,1.0,2.449,experimental,,0.2481,0.1905,PRMT4 bound with a bicyclic compound
5QCT,X-RAY DIFFRACTION,3.12,60.6,hanging drop,5.6,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS USING 1.0M AMMONIUM PHOSPHATE, 0.1M NA CITRATE PH 5.6
AS PRECIPITANT. PROTEIN STOCK WAS BACE MUT46B BATCH X 8.3MG/ML IN 10MM TRIS-HCL PH 7. 25MM NACL, WITH A 4-FOLD EXCESS OF
BMC001 ADDED FROM A 50MM STOCK SOLUTION IN DMSO (1.4% DMSO IN DROP). CRYO-PROTECTANT WAS 20% (V/V) 1,2-PROPANEDIOL, 80%
RESERVOIR SOLUTION.",292.0,2017-12-01,2020-06-03,5QCT,9374.0,3.0,1206.0,344.0,9.0,136.02,1.0,2.05,experimental,51.54,0.197,0.17,Crystal structure of BACE complex with BMC001
5QDA,X-RAY DIFFRACTION,3.1,60.28,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XII 8.45MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 4-FOLD EXCESS OF BMC013 ADDED FROM A 50MM STOCK
SOLUTION IN DMSO (1.4% DMSO IN DROP). CRYO-PROTECTANT WAS 20%(V/V) GLYCEROL, 80% (V/V) RESERVOIR SOLUTION",292.0,2017-12-01,2020-06-03,5QDA,9384.0,3.0,1206.0,345.0,9.0,135.88,1.0,2.1,experimental,53.85,0.209,0.181,Crystal structure of BACE complex with BMC013
6OD6,X-RAY DIFFRACTION,2.54,56.15,VAPOR DIFFUSION,6.25,"17% PEG-4000, 0.1M MES",293.0,2019-03-26,2019-09-25,6OD6,9375.0,3.0,1296.0,364.0,9.0,145.59,1.0,2,experimental,,0.2478,0.223,Structure of BACE-1 in complex with Ligand 13
4XS2,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate pH 7.4, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289.0,2015-01-21,2015-05-13,4XS2,9049.0,4.0,1204.0,33.0,,137.74,1.0,2.73,experimental,71.26,0.285,0.264,Irak4-inhibitor co-structure
6GL3,X-RAY DIFFRACTION,2.2,44.09,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium citrate, 
22% (w/v) PEG3350,
10 mM Manganese(II)chloride",293.0,2018-05-22,2018-08-15,6GL3,5333.0,2.0,772.0,15.0,,88.39,1.0,2.77,experimental,,0.333,0.276,Crystal structure of human Phosphatidylinositol 4-kinase III beta (PI4KIIIbeta) in complex with ligand 44
6O95,X-RAY DIFFRACTION,2.51,51.0,VAPOR DIFFUSION,,"2.6-2.9 M Ammonium Sulfate, Hepes",,2019-03-13,2019-05-22,6O95,10033.0,4.0,1280.0,836.0,,146.61,1.0,1.77,experimental,34.34,0.217,0.188,Structure of the IRAK4 kinase domain with compound 41
6O9D,X-RAY DIFFRACTION,2.51,50.9,VAPOR DIFFUSION,,"2.6-2.9 M Ammonium Sulfate, Hepes",277.0,2019-03-13,2019-05-22,6O9D,9296.0,4.0,1280.0,218.0,,146.29,1.0,2.51,experimental,47.18,0.239,0.195,Structure of the IRAK4 kinase domain with compound 5
6TI8,X-RAY DIFFRACTION,2.53,51.36,"VAPOR DIFFUSION, HANGING DROP",,"2.7 M AMS 0.1 M Hepes pH 7.1-7.7  
Protein Buffer:  25 mM HEPES pH 7.5, 1 mM EDTA, 1 mM TCEP, 5% Glycerol, 150 mM NaCl",298.0,2019-11-22,2020-10-28,6TI8,9494.0,4.0,1232.0,396.0,,140.34,1.0,2.32,experimental,68.53,0.281,0.249,IRAK4 IN COMPLEX WITH inhibitor
5V3G,X-RAY DIFFRACTION,2.84,56.7,"VAPOR DIFFUSION, HANGING DROP",7.3,0.1 M Bis-Tris Propane (pH-7.3) and 23% W/V PEG3350,289.0,2017-03-07,2017-08-23,5V3G,4712.0,7.0,606.0,116.0,,87.72,1.0,2.416,experimental,,0.2254,0.1731,PRDM9-allele-C ZnF8-13
8D1T,X-RAY DIFFRACTION,2.82,56.34,VAPOR DIFFUSION,,"0.1 M Tris pH 8.5, 22% PEG 4000, 4% 1,3-Butanediol",293.0,2022-05-27,2023-02-01,8D1T,5608.0,3.0,785.0,30.0,,88.21,3.0,2.94,experimental,92.9642,0.2942,0.2361,Crystal structure of human USP30 in complex with a covalent inhibitor 552 and a Fab
5EOK,X-RAY DIFFRACTION,2.59,52.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH7.5, 20% PEG1500",293.15,2015-11-10,2016-04-06,5EOK,4785.0,2.0,615.0,2.0,17.0,70.33,2.0,2.8,experimental,71.558,0.26412,0.20135,Human Plasma Coagulation Factor XI in complex with peptide P39
7TYD,X-RAY DIFFRACTION,2.26,45.5,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris (pH 5.5)
25% polyethylene glycol 3,350
3% 1,5-diaminopentane dihydrochloride",277.0,2022-02-12,2022-11-09,7TYD,2170.0,4.0,392.0,6.0,2.0,43.62,2.0,2.86,experimental,58.09,0.3063,0.2684,Crystal structure of FGFR4 domain 3 in complex with a de novo-designed mini-binder in P21 space group
5JCT,X-RAY DIFFRACTION,2.22,44.48,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES (pH7.5), 8% (v/v) Eythylene Glycol, 20% (w/v) PEG 8000",277.0,2016-04-15,2017-01-11,5JCT,2666.0,1.0,310.0,334.0,,35.19,1.0,1.73,experimental,32.2,0.204,0.171,Crystal Structure of Human Pirin in complex with a Chemical Probe pyrrolidine 24
6F06,X-RAY DIFFRACTION,1.92,35.85,"VAPOR DIFFUSION, SITTING DROP",5.5,"20% PEG3350, 0.05 M zinc acetate",294.0,2017-11-17,2018-04-11,6F06,3558.0,2.0,440.0,98.0,6.0,50.38,1.0,2.02,experimental,33.514,0.27428,0.20118,"CATHEPSIN L IN COMPLEX WITH (3S,14E)-8-(azetidin-3-yl)-19-chloro-N-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6,8,10,14,18(22),19-heptaene-3-carboxamide"
5Y7Z,X-RAY DIFFRACTION,2.35,47.57,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.17 M ammonium sulfate, 0.085 M sodium cacodylate trihydrate (pH 6.5), 25.5% PEG 8000, 15% glycerol",293.0,2017-08-18,2018-08-29,5Y7Z,6994.0,4.0,922.0,9.0,2.0,105.07,2.0,2.804,experimental,,0.288,0.2327,Complex structure of cyclin G-associated kinase with gefitinib
6SKC,X-RAY DIFFRACTION,2.19,43.79,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-08-15,2019-09-25,6SKC,3608.0,2.0,446.0,155.0,12.0,49.41,1.0,2.18,experimental,35.31,0.241,0.188,Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK3448330A
5FZ0,X-RAY DIFFRACTION,2.19,43.84,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-10,2016-04-06,5FZ0,3878.0,1.0,479.0,93.0,,56.57,1.0,2.42,experimental,,0.2332,0.1918,"Crystal structure of the catalytic domain of human JARID1B in complex with 2,5-dichloro-N-(pyridin-3-yl)thiophene-3-carboxamide (N08137b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
5FZM,X-RAY DIFFRACTION,2.1,41.41,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2017-03-29,5FZM,3897.0,1.0,479.0,111.0,,56.46,1.0,2.49,experimental,,0.2243,0.1828,"Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 5-(2-fluorophenyl)-1,3-oxazole-4-carboxylic acid (N09989b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
6QM0,X-RAY DIFFRACTION,2.06,40.35,"VAPOR DIFFUSION, HANGING DROP",6.1,"25mM ADA pH6.1, 250mM sodium nitrate and 20% PEG 5k.mme",291.0,2019-02-01,2020-02-19,6QM0,3932.0,2.0,432.0,528.0,6.0,48.67,1.0,1.9,experimental,24.819,0.174,0.1307,Cathepsin-K in complex with amino-oxaazabicyclo[3.3.0]octanyl containing inhibitor
8BFS,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",5.9,"0,1M NaCit, pH 5.9 2,1 M AmmSO4 0,1M Na/K tartrate",293.0,2022-10-26,2022-11-16,8BFS,2364.0,1.0,385.0,120.0,,43.95,1.0,1.95,experimental,29.298,0.2018,0.1664,Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) in complex with FZ326
8H0N,X-RAY DIFFRACTION,2.57,52.15,"VAPOR DIFFUSION, HANGING DROP",,"Bis-Tris, Lithium sulphate, PEG3350.",291.15,2022-09-30,2023-07-05,8H0N,4751.0,2.0,611.0,500.0,,68.58,2.0,1.8,experimental,34.13,0.2265,0.1932,Crystal structure of the human METTL1-WDR4 complex
5JIZ,X-RAY DIFFRACTION,1.99,38.34,"VAPOR DIFFUSION, HANGING DROP",4.6,"20 mM CaCl2, 100 mM NaOAc, 30% MPD, pH 4.6, at 4oC",277.0,2016-04-22,2017-05-03,5JIZ,1408.0,1.0,152.0,180.0,,18.65,1.0,1.5,experimental,,0.1984,0.1795,PKG II's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-pCPT-cGMP
7OAI,X-RAY DIFFRACTION,2.25,45.27,"VAPOR DIFFUSION, SITTING DROP",6.0,"12% high molecular weight PEG Smears, 0.1 M MES pH 6.0, 0.1 M magnesium acetate, 0.1 M KCl",293.15,2021-04-19,2021-05-19,7OAI,10192.0,4.0,1412.0,424.0,,161.23,1.0,2.3,experimental,34.913,0.213,0.1792,Crystal structure of pseudokinase CASK in complex with PFE-PKIS12
7OAJ,X-RAY DIFFRACTION,2.21,44.39,"VAPOR DIFFUSION, SITTING DROP",6.5,"9% medium molecular weight PED Smears, 0.1 M magnesium acetate, 10% ethylene glycol, 0.1 M MES, pH 6.5",293.15,2021-04-19,2021-05-19,7OAJ,10317.0,4.0,1412.0,549.0,,161.41,1.0,1.93,experimental,34.554,0.2238,0.1946,Crystal structure of pseudokinase CASK in complex with compound 7
7OAK,X-RAY DIFFRACTION,2.17,43.21,"VAPOR DIFFUSION, SITTING DROP",6.0,"12% high molecular weight PEG Smears, 0.1 M magnesium acetate, 0.1 M MES, pH 6.0",293.15,2021-04-19,2021-05-19,7OAK,10126.0,4.0,1412.0,394.0,,161.7,1.0,2.23,experimental,28.746,0.2635,0.2225,Crystal structure of pseudokinase CASK in complex with compound 26
7OAL,X-RAY DIFFRACTION,2.18,43.55,"VAPOR DIFFUSION, SITTING DROP",6.0,"9% high molecular weight PEG Smears, 0.1 M magnesium acetate, 0.1 M KCl, 0.1 M MES, pH 6.0",293.15,2021-04-19,2021-05-19,7OAL,10048.0,4.0,1412.0,336.0,,161.39,1.0,2.17,experimental,38.404,0.2744,0.2206,Crystal structure of pseudokinase CASK in complex with compound 25
7QDQ,X-RAY DIFFRACTION,2.25,45.39,"VAPOR DIFFUSION, SITTING DROP",6.0,"2.8M Ammonium Sulfate, 100mM MES",293.0,2021-11-29,2022-10-05,7QDQ,1084.0,1.0,92.0,102.0,,11.83,1.0,1.26,experimental,18.3177,0.2162,0.1821,Crystal Structure of HDM2 in complex with Caylin-1
7A1F,X-RAY DIFFRACTION,2.15,42.79,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2M Ammonium chloride",277.0,2020-08-12,2021-01-20,7A1F,5905.0,2.0,684.0,566.0,,78.87,1.0,1.8,experimental,31.9746,0.2226,0.1773,Crystal structure of human 5' exonuclease Appollo in complex with 5'dAMP
8B5F,X-RAY DIFFRACTION,2.09,41.25,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Sodium Acetate pH 5.5, 30% PEG 5000 MME",291.0,2022-09-22,2023-10-04,8B5F,2228.0,1.0,255.0,186.0,6.0,28.73,1.0,1.7,experimental,23.241,0.2051,0.1747,Human cathepsin B in complex with the carbamate inhibitor 31
5FY8,X-RAY DIFFRACTION,2.65,53.59,,6.0,0.1M BIS-TRIS PH 6.0 -- 0.15M AMMONIUM SULFATE -- 28% PEG3350,,2016-03-04,2016-03-16,5FY8,5864.0,2.0,762.0,196.0,,89.88,1.0,2.343,experimental,,0.2294,0.1851,Crystal structure of human JMJD2A in complex with D-threo-isocitrate
7B8I,X-RAY DIFFRACTION,3.22,61.78,"VAPOR DIFFUSION, SITTING DROP",,"Prior to crystallization, the enzyme was incubated with heparin decasaccharide; the composition of this preincubation solution was 5 mg/ml CK2alpha1-335, 1.4 mM Heparin decasaccharide, 340 mM NaCl, 25 mM Tris/HCl, pH 8.5. 4 microliter of this enzyme/heparin mixture was mixed with 1 microliter reservoir solution. The composition of the reservoir solution was 32 % (w/v) PEG4000, 0.2 M Lithium sulfate, 0.1 M Tris/HCl, pH 7.5. As a preparation of X-ray diffraction data collection, the crystals were transferred to a cryo solution composed of 32 % (w/v) PEG4000, 10 % (v/v) glycerol, 0.2 M lithium sulfate, 0.5 mM Heparin decasaccharide, 0.1 M Tris/HCl, pH 7.5.",293.15,2020-12-12,2021-02-03,7B8I,5924.0,2.0,670.0,143.0,,82.84,1.0,2.55,experimental,,0.2396,0.204,Tetragonal structure of human protein kinase CK2 catalytic subunit in complex with a heparin oligo saccharide
4Z2A,X-RAY DIFFRACTION,2.36,47.94,"VAPOR DIFFUSION, SITTING DROP",,"Well 13% PEG 8K, 0.110M K-dihydrogen phosphate, 0.1M HEPES pH 7.5, 350 uL protein with 350uL well drops, MRC sitting drop",277.0,2015-03-29,2016-05-04,4Z2A,4016.0,1.0,465.0,408.0,4.0,50.92,1.0,1.89,experimental,16.9953,0.1834,0.1479,Crystal structure of unglycosylated apo human furin @1.89A
6KG6,X-RAY DIFFRACTION,2.71,54.67,"VAPOR DIFFUSION, HANGING DROP",,"PEG 4000, Tris",291.0,2019-07-10,2020-04-01,6KG6,5025.0,3.0,614.0,209.0,,69.55,3.0,2.39,experimental,,0.2448,0.1902,Crystal structure of MavC/UBE2N-Ub complex
8IYA,X-RAY DIFFRACTION,2.56,51.97,"VAPOR DIFFUSION, SITTING DROP",,"1.0 M Lithium sulfate, 0.1 M MES pH6.5",291.0,2023-04-04,2024-01-03,8IYA,3913.0,6.0,528.0,36.0,3.0,59.96,2.0,2.43,experimental,53.92,0.2472,0.2047,Complex of SETDB1-derived peptide bound to UBE2E1
5FZ6,X-RAY DIFFRACTION,2.17,43.38,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-11,2016-03-23,5FZ6,4063.0,1.0,479.0,197.0,,56.75,1.0,2.33,experimental,,0.2186,0.1786,"Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment N05859b (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
5FZ7,X-RAY DIFFRACTION,2.15,42.92,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-11,2016-03-23,5FZ7,3979.0,1.0,479.0,174.0,,56.59,1.0,2.3,experimental,,0.2255,0.1844,"Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment ethyl 2-amino-4-thiophen-2-ylthiophene-3- carboxylate (N06131b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
5FZ9,X-RAY DIFFRACTION,2.18,43.62,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-12,2016-03-30,5FZ9,4181.0,1.0,479.0,230.0,,56.87,1.0,2.06,experimental,,0.2278,0.1951,"Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment thieno(3,2-b)thiophene-5-carboxylic acid (N06263b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
5FZB,X-RAY DIFFRACTION,2.17,43.28,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-12,2016-03-30,5FZB,3978.0,1.0,479.0,178.0,,56.68,1.0,2.18,experimental,,0.2274,0.194,"Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 4-Pyridylthiourea (N06275b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
5FZC,X-RAY DIFFRACTION,2.18,43.65,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2016-03-30,5FZC,4076.0,1.0,479.0,210.0,,56.85,1.0,2.05,experimental,,0.2253,0.1917,"Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 4,5-dihydronaphtho(1,2-b)thiophene-2- carboxylicacid (N11181a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
5FZG,X-RAY DIFFRACTION,2.09,41.19,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2017-03-29,5FZG,4128.0,1.0,479.0,268.0,,57.01,1.0,1.96,experimental,,0.2242,0.1868,Crystal structure of the catalytic domain of human JARID1B in complex with MC3948
5FZK,X-RAY DIFFRACTION,2.12,41.88,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2016-04-06,5FZK,4043.0,1.0,479.0,232.0,,56.41,1.0,2.05,experimental,,0.2382,0.2037,"Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment N,3-dimethyl-N-(pyridin-3-ylmethyl)-1,2-oxazole-5- carboxamide (N10051a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
5FZL,X-RAY DIFFRACTION,2.1,41.58,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2016-04-06,5FZL,3864.0,1.0,479.0,74.0,1.0,56.37,1.0,2.55,experimental,,0.2398,0.1912,"Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 3-methyl-N-pyridin-4-yl-1,2-oxazole-5-carboxamide (N09954a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
4XCU,X-RAY DIFFRACTION,2.03,39.39,"VAPOR DIFFUSION, HANGING DROP",8.5,"16% PEG 3350, 0.2M lithium sulfate, 0.1M bis-tris pH 4.5",277.0,2014-12-18,2015-04-01,4XCU,2513.0,1.0,300.0,172.0,,34.47,1.0,1.71,experimental,28.705,0.2427,0.1931,Crystal Structure of FGFR4 with an Irreversible Inhibitor
8KH6,X-RAY DIFFRACTION,2.22,44.5,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19% PEG 3350",277.0,2023-08-21,2024-07-31,8KH6,2412.0,1.0,311.0,132.0,,35.42,1.0,1.62,experimental,,0.2276,0.2037,Crystal structure of FGFR4 kinase domain with 8r
8KH7,X-RAY DIFFRACTION,2.23,44.79,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19% PEG 3350",277.0,2023-08-21,2024-07-31,8KH7,2655.0,1.0,311.0,336.0,,35.57,1.0,1.52,experimental,,0.1948,0.1644,Crystal structure of FGFR4 kinase domain with 8zc
8KH8,X-RAY DIFFRACTION,2.25,45.21,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 16-19% PEG3350",277.0,2023-08-21,2024-07-31,8KH8,2728.0,1.0,309.0,340.0,,35.39,1.0,1.49,experimental,,0.1965,0.1679,Crystal structure of FGFR4(V550L) kinase domain with 8z
6BUB,X-RAY DIFFRACTION,3.92,68.6,"VAPOR DIFFUSION, HANGING DROP",8.0,(NH4)2SO4,295.0,2017-12-09,2018-10-17,6BUB,1075.0,1.0,143.0,14.0,,16.93,1.0,2.604,experimental,47.7949,0.2734,0.2377,Crystal structure of the PI3KC2alpha PX domain in space group P432
7ZFG,X-RAY DIFFRACTION,2.31,46.8,"VAPOR DIFFUSION, SITTING DROP",6.5,"NaAcetate 2.5M, BisTris 0.1M",293.0,2022-04-01,2022-11-23,7ZFG,2072.0,2.0,317.0,38.0,,36.39,2.0,2.62,experimental,82.88,0.2605,0.1986,VDR complex with aromatic D-ring analog
7ZFX,X-RAY DIFFRACTION,2.33,47.1,"VAPOR DIFFUSION, SITTING DROP",8.0,"NaActetae 2.5M, Tris 0.1M",293.0,2022-04-01,2022-11-23,7ZFX,2095.0,2.0,317.0,48.0,,36.39,2.0,2.6,experimental,67.1394,0.2538,0.208,VDR complex with Aromatic-D-Ring Analog
7JK1,X-RAY DIFFRACTION,2.42,49.2,"VAPOR DIFFUSION, HANGING DROP",7.5,"225-250 mM CaCl2 
16-19% PEG 3350",293.0,2020-07-27,2021-06-30,7JK1,5429.0,6.0,766.0,92.0,,101.18,1.0,2.62,experimental,69.95,0.2858,0.2393,Human PrimPol inserting correct dCTP opposite the 8-oxoguanine lesion
7JKL,X-RAY DIFFRACTION,2.33,47.17,"VAPOR DIFFUSION, HANGING DROP",7.5,"225- 250 mM CaCl2, 16 -19% PEG 3350",293.0,2020-07-28,2021-06-30,7JKL,5482.0,6.0,768.0,105.0,,101.7,1.0,2.384,experimental,82.6032,0.277,0.2197,"Human PrimPol misinserting dATP opposite the 8-oxoguanine lesion (3'-end base of the primer strand is 2',3'-dideoxy-terminated)."
7JKP,X-RAY DIFFRACTION,2.36,47.88,"VAPOR DIFFUSION, HANGING DROP",7.5,"225- 250 mM CaCl2 
16 -19% PEG 3350",293.0,2020-07-28,2021-06-30,7JKP,5291.0,6.0,768.0,24.0,,101.64,1.0,2.592,experimental,96.1665,0.3066,0.2476,Human PrimPol misinserting dATP opposite the 8-oxoguanine lesion
7JL8,X-RAY DIFFRACTION,2.2,44.15,"VAPOR DIFFUSION, HANGING DROP",7.5,"225-250 mM CaCl2, 16-19% PEG 3350",293.0,2020-07-29,2021-06-30,7JL8,5171.0,6.0,768.0,161.0,,102.33,1.0,2.1,experimental,65.1446,0.2133,0.1871,Human PrimPol extending from the correct primer base C opposite the 8-oxoguanine lesion
7JLG,X-RAY DIFFRACTION,2.28,46.15,"VAPOR DIFFUSION, HANGING DROP",7.5,"225-250 mM CaCl2, 16-19% PEG 3350",293.0,2020-07-29,2021-06-30,7JLG,5351.0,6.0,768.0,131.0,,101.87,1.0,2.07,experimental,77.2255,0.2188,0.2007,Human PrimPol extending from the erroneous primer base A opposite the 8-oxoguanine lesion
5WN8,X-RAY DIFFRACTION,3.01,59.1,MICROBATCH,9.5,"100 mM Sodium thiosulfate, 100 mM CAPS buffer pH 9.5, and 20% (w/v) PEG 8000",277.0,2017-07-31,2017-12-06,5WN8,6164.0,2.0,850.0,148.0,1.0,97.69,1.0,2.5,experimental,80.291,0.25182,0.21347,"Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1"
6O1S,X-RAY DIFFRACTION,2.34,47.51,"VAPOR DIFFUSION, HANGING DROP",,"24% PEG 3350, 0.2M potassium dihydrogen phosphate",296.0,2019-02-21,2019-03-06,6O1S,2158.0,1.0,263.0,208.0,4.0,30.0,1.0,1.7,experimental,,0.201,0.1699,Structure of human plasma kallikrein protease domain with inhibitor
6LZZ,X-RAY DIFFRACTION,4.71,73.87,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES (pH 7.5), 2.5M Na formate, 5% xylitol",277.0,2020-02-19,2021-02-24,6LZZ,5504.0,2.0,644.0,180.0,2.0,77.1,1.0,2.40003752238,experimental,35.8080136684,0.295412615112,0.253419807951,Crystal structure of the PDE9 catalytic domain in complex with inhibitor 4a
5GGK,X-RAY DIFFRACTION,2.39,48.44,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris-HCl, PEG-10000",293.0,2016-06-16,2016-08-10,5GGK,2853.0,2.0,328.0,428.0,,36.36,1.0,1.3,experimental,,0.1755,0.1462,"Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with Man-beta-pNP"
7D0P,X-RAY DIFFRACTION,2.39,48.57,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES, pH 7.5, 12% w/v PEG 3350",289.0,2020-09-11,2021-07-07,7D0P,2579.0,2.0,326.0,99.0,,39.22,2.0,1.8,experimental,49.202,0.2256,0.1708,Crystal structure of human HBO1-BRPF2 in complex with propionyl-coenzyme A
7D0Q,X-RAY DIFFRACTION,2.42,49.19,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris, pH 8.5, 20% w/v PEG 6000",289.0,2020-09-11,2021-07-07,7D0Q,2593.0,2.0,326.0,54.0,,39.3,2.0,2.21,experimental,69.279,0.2435,0.186,Crystal structure of human HBO1-BRPF2 in complex with butyryl-coenzyme A
7D0R,X-RAY DIFFRACTION,2.43,49.34,"VAPOR DIFFUSION, HANGING DROP",,"0.03 M Citric acid, 0.07 M BIS-TRIS propane, pH 7.6, 20% w/v PEG 3350",289.0,2020-09-11,2021-07-07,7D0R,2591.0,2.0,326.0,89.0,,39.26,2.0,1.95,experimental,53.543,0.2308,0.1824,Crystal structure of human HBO1-BRPF2 in complex with crotonoyl-coenzyme A
6MON,X-RAY DIFFRACTION,3.16,61.07,"VAPOR DIFFUSION, HANGING DROP",7.5,"20.5% PEG 3350, 5.9% ethanol, 0.1M Tris pH 7.5",293.0,2018-10-04,2018-12-12,6MON,7074.0,4.0,872.0,7.0,,101.55,2.0,2.711,experimental,75.7222,0.2267,0.2105,Crystal structure of human SMYD2 in complex with Nle-peptide inhibitor
6QXU,X-RAY DIFFRACTION,2.37,48.19,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.0 M Ammonium Sulfate, 0.1 M HEPES pH 7.0, 0.5% w/v PEG 8000",277.0,2019-03-08,2019-08-14,6QXU,2155.0,1.0,211.0,336.0,,24.67,1.0,1.2,experimental,22.59,0.213,0.189,"Human TNKS1 in complex with 6,8-Difluoro-2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-3H-quinazolin-4-one"
8BJJ,X-RAY DIFFRACTION,2.36,47.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% peg3000
0.3M LiSO4
0.1M Tris pH8.5
3% Dioxane",291.0,2022-11-04,2023-09-20,8BJJ,7763.0,3.0,927.0,723.0,,104.96,3.0,1.699,experimental,33.36,0.1949,0.1751,"ExoY Nucleotidyl Cyclase domain from Vibrio nigripulchritudo MARTX toxin, bound to ATP-Mg-actin, human profilin 1 and a sulfate ion"
5CEO,X-RAY DIFFRACTION,1.99,38.14,"VAPOR DIFFUSION, HANGING DROP",7.7,"0.2 M magnesium acetate, 20% PEG 3350, 0.1 M HEPES pH 7.7",292.0,2015-07-07,2015-10-14,5CEO,2265.0,1.0,300.0,71.0,,34.46,1.0,2.28,experimental,51.41,0.2482,0.1871,"DLK in complex with inhibitor 2-((6-(3,3-difluoropyrrolidin-1-yl)-4-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)amino)isonicotinonitrile"
5CEP,X-RAY DIFFRACTION,2.02,39.06,"VAPOR DIFFUSION, HANGING DROP",7.7,"0.2 M magnesium acetate, 20% PEG 3350, 0.1 M HEPES pH 7.7",292.0,2015-07-07,2015-10-14,5CEP,2359.0,1.0,300.0,156.0,,34.37,1.0,1.99,experimental,36.68,0.2299,0.1722,DLK in complex with inhibitor N-(1-isopropyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl)-4-(trifluoromethyl)pyridin-2-amine
5CEQ,X-RAY DIFFRACTION,1.91,35.73,"VAPOR DIFFUSION, HANGING DROP",7.7,"0.2 M magnesium acetate, 20% PEG 3350, 0.1 M HEPES pH 7.7",292.0,2015-07-07,2015-10-14,5CEQ,2426.0,1.0,300.0,221.0,,34.41,1.0,1.911,experimental,22.04,0.2182,0.1688,DLK in complex with inhibitor 2-((1-cyclopentyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)amino)isonicotinonitrile
5ACB,X-RAY DIFFRACTION,2.41,48.96,,,"10% PEG8000, 0.2M MAGNESIUM CHLORIDE, 0.1M HEPES PH7.0",,2015-08-14,2016-06-15,5ACB,9073.0,4.0,1198.0,,,141.45,2.0,2.7,experimental,60.778,0.26187,0.2214,Crystal Structure of the Human Cdk12-Cyclink Complex
5KEZ,X-RAY DIFFRACTION,2.42,49.18,EVAPORATION,7.5,"53%-57% MPD, 0.1 M Na Cacodylate, pH 7.5",293.0,2016-06-10,2017-03-29,5KEZ,4317.0,2.0,507.0,274.0,5.0,57.24,2.0,1.83,experimental,,0.208,0.177,Selective and potent inhibition of the glycosidase human amylase by the short and extremely compact peptide piHA from mRNA display
6Y2V,X-RAY DIFFRACTION,1.84,33.16,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M Bis-Tris, 25% PEG3350, pH 5.5",277.0,2020-02-17,2020-07-22,6Y2V,1337.0,1.0,158.0,85.0,,18.31,1.0,2,experimental,30.64,0.2313,0.1826,Crystal structure of the double mutant L13R I16K of Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP)
6ZDK,X-RAY DIFFRACTION,2.61,53.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM  HEPES pH 7.5, 200 mM MgCl2, 30% v/v PEG 400 (Alfa Aesar), 1 mM Anderson-Evans polyoxotungstate TEW.
Protein at 10 mg/ml in 25 mM HEPES pH 7.0, 200 mM NaCl buffer.",292.0,2020-06-14,2020-11-18,6ZDK,3303.0,1.0,382.0,165.0,,49.89,1.0,2,experimental,32.842,0.235,0.1956,Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with HEPES and hexatungstotellurate(VI) TEW
5KQF,X-RAY DIFFRACTION,2.55,51.69,VAPOR DIFFUSION,6.4,"10% PEG5000 MME, 9% PEG8000, 0.2 M ammonium iodide, 0.2 M sodium citrate, pH 6.4",295.0,2016-07-06,2016-09-07,5KQF,3053.0,1.0,455.0,229.0,2.0,50.54,1.0,1.98,experimental,29.806,0.25127,0.22138,"(4~{S},6~{S})-4-[2,4-bis(fluoranyl)phenyl]-4-methyl-6-pyrimidin-5-yl-5,6-dihydro-1,3-thiazin-2-amine (compound 12) bound to BACE1"
8OWX,X-RAY DIFFRACTION,3.9,68.47,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M BisTRIS propane pH 6.5, 0.2 M sodium sulfate, 20 % PEG3350",293.15,2023-04-28,2024-05-08,8OWX,4001.0,2.0,550.0,,,65.74,1.0,2.601,experimental,,0.2504,0.2171,Crystal Structure of METTL6 bound to SAH
7BVQ,X-RAY DIFFRACTION,3.43,64.12,LIPIDIC CUBIC PHASE,,"100 mM Sodium citrate, pH 5, 150-170 mM lithium sulfate, 38-42% PEG300, 3% 1,3-butanediol",293.0,2020-04-11,2020-12-02,7BVQ,7377.0,2.0,924.0,121.0,4.0,108.35,1.0,2.5,experimental,72.69,0.2633,0.225,Structure of human beta1 adrenergic receptor bound to carazolol
6OG4,X-RAY DIFFRACTION,2.36,47.84,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M HEPES, pH 7.0, 2 M ammonium sulfate",293.0,2019-04-01,2019-07-24,6OG4,1739.0,3.0,251.0,128.0,6.0,29.27,2.0,1.7,experimental,32.39,0.2203,0.2029,plasminogen binding group A streptococcal M protein
6BGT,X-RAY DIFFRACTION,3.04,59.6,VAPOR DIFFUSION,6.5,"100 mM MES, pH 6.5, 18% PEG3350, 10% glycerol",293.0,2017-10-29,2018-10-31,6BGT,7806.0,3.0,1103.0,29.0,27.0,120.92,3.0,2.7,experimental,,0.2475,0.205,Structure of Trastuzumab Fab mutant in complex with Her2 extracellular domain
5A7N,X-RAY DIFFRACTION,2.72,54.76,,7.5,22% PEG3350 -- 0.1M BIS-TRIS PH 7.5 -- 0.25M AMMONIUM SULFATE,,2015-07-09,2016-01-13,5A7N,5977.0,2.0,762.0,293.0,,90.0,1.0,2.39,experimental,,0.2445,0.1828,Crystal structure of human JMJD2A in complex with compound 43
5A7Q,X-RAY DIFFRACTION,2.62,53.0,,6.5,28% PEG3350 -- 0.1M BIS-TRIS PH 6.5 -- 0.15M AMMONIUM SULFATE,,2015-07-09,2016-01-13,5A7Q,6044.0,2.0,762.0,329.0,,89.63,1.0,2,experimental,,0.2314,0.1938,Crystal structure of human JMJD2A in complex with compound 30
5FZH,X-RAY DIFFRACTION,2.17,43.71,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2016-05-25,5FZH,4087.0,1.0,479.0,231.0,,56.62,1.0,2.09,experimental,,0.2221,0.1889,"Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 4,5-dihydronaphtho(1,2-b)thiophene-2- carboxylicacid (N11181a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)"
5TOL,X-RAY DIFFRACTION,2.77,55.62,VAPOR DIFFUSION,6.4,,298.0,2016-10-18,2016-11-23,5TOL,2997.0,1.0,412.0,85.0,3.0,46.37,1.0,2.51,experimental,42.077,0.2569,0.2009,"CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 COMPLEXED WITH N-(3-((4AS,7AS)-2-AMINO-4,4A,5,6-TETRAHYDRO-7AH-FURO[2,3-D][1,3]THIAZIN-7A-YL)-4-FLUOROPHENYL)-5-BROMO-2-PYRIDINECARBOXAMIDE"
5NN0,X-RAY DIFFRACTION,3.18,61.33,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5
2.3 M Ammonium sulfate",293.0,2017-04-07,2018-03-14,5NN0,4858.0,1.0,529.0,314.0,3.0,64.49,1.0,2.1,experimental,,0.2064,0.1689,"Crystal structure of huBChE with N-((1-(2,3-dihydro-1H-inden-2-yl)piperidin-3-yl)methyl)-N-(2-(dimethylamino)ethyl)-2-naphthamide."
7AMZ,X-RAY DIFFRACTION,3.19,61.48,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2020-10-10,2021-05-26,7AMZ,4637.0,1.0,529.0,142.0,3.0,63.65,1.0,2.25,experimental,54.47,0.2199,0.1974,"Crystal structure of human Butyrylcholinesterase in complex with N-((2S,3R)-4-((2,2-dimethylpropyl)amino)-3-hydroxy-1-phenylbutan-2-yl)-2,2-diphenylacetamide"
8BR5,X-RAY DIFFRACTION,2.77,55.53,"VAPOR DIFFUSION, HANGING DROP",,none,293.0,2022-11-22,2024-01-31,8BR5,9350.0,4.0,1196.0,145.0,,136.68,1.0,2.7,experimental,57.762,0.2541,0.2146,Discovery of IRAK4 Inhibitor 41
8UCB,X-RAY DIFFRACTION,2.6,52.67,VAPOR DIFFUSION,,sodium malonate,293.0,2023-09-26,2024-06-26,8UCB,9638.0,4.0,1228.0,547.0,,140.3,1.0,1.85,experimental,41.04,0.243,0.2072,IRAK4 in complex with compound 8
8V2L,X-RAY DIFFRACTION,2.47,50.3,"VAPOR DIFFUSION, HANGING DROP",6.7,"0.1M MES, pH6.7, 0.2M Ammonium sulfate, 25% w/v PEG5000 MME",293.0,2023-11-22,2024-07-03,8V2L,9645.0,4.0,1308.0,338.0,,150.81,1.0,2.43,experimental,48.604,0.30246,0.25273,Crystal structure of IRAK4 kinase domain with compound 8
6N6I,X-RAY DIFFRACTION,2.53,51.43,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M sodium malonate (pH 5.5) and 15-20% polyethylene glycol 3350, 25% gylcerol",277.0,2018-11-26,2019-06-12,6N6I,3704.0,4.0,414.0,461.0,,49.26,1.0,1.431,experimental,18.3983,0.1781,0.1581,Human REXO2 bound to pGG
6N6J,X-RAY DIFFRACTION,2.56,51.87,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M sodium malonate (pH 5.5) and 15-20% polyethylene glycol 3350, 25% glycerol",277.0,2018-11-26,2019-06-12,6N6J,3862.0,4.0,414.0,495.0,,49.2,1.0,1.317,experimental,19.686,0.1701,0.1528,Human REXO2 bound to pAA
6DGF,X-RAY DIFFRACTION,2.03,39.4,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M MES buffer pH 6, 12% (w/v) PEG3350, 0.2M sodium sulfate",293.0,2018-05-17,2019-02-13,6DGF,3339.0,2.0,463.0,156.0,,53.34,2.0,2.34,experimental,,0.224,0.1759,Ubiquitin Variant bound to USP2
5IGO,X-RAY DIFFRACTION,2.07,40.7,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris 8.5, 16% PEG3350, 2%
Tacsimate 8.0.",294.0,2016-02-28,2016-04-20,5IGO,11580.0,8.0,1376.0,1256.0,,156.46,2.0,1.6,experimental,,0.2134,0.1894,WD40 domain of Arabidopsis thaliana E3 Ubiquitin Ligase COP1 in complex with peptide from Trib1
6TYW,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, SITTING DROP",,20 % (w/v) PEG3350,295.0,2019-08-09,2019-11-27,6TYW,2063.0,2.0,247.0,221.0,,28.2,2.0,1.69965540409,experimental,34.0836204142,0.21816164121,0.179346577365,Structure of Ku80 von Willebrand domain S229A mutant complexed with APLF Ku Binding Motif
8WU8,X-RAY DIFFRACTION,2.17,43.36,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Potassium iodine",293.0,2023-10-20,2024-02-14,8WU8,6171.0,4.0,850.0,,,95.34,4.0,2.81,experimental,,0.2669,0.2148,Crystal structure of the human RAD9-RAD1(F64A/M256A/F266A)-HUS1-RHINO(88-99) complex
7PUE,X-RAY DIFFRACTION,2.63,53.17,"VAPOR DIFFUSION, HANGING DROP",,"protein solution: 25 mM Hepes, 100 mM NaCl,1 mM DTT, 5 mM MgCl2 pH 7.8; 3 mM Amppnp; reservoir solution: 12% PEG3350, 200 mM NaF; soaking in res.sol.+ 10 mM Cpd3a, 10% DMSO",293.0,2021-09-29,2021-12-01,7PUE,2226.0,1.0,375.0,24.0,,43.23,1.0,2.506,experimental,86.98,0.2486,0.2135,Human serum and glucocorticoid-regulated kinase 1 in complex with pyrazolopyridine inhibitor 3a
8BJU,X-RAY DIFFRACTION,2.15,42.91,"VAPOR DIFFUSION, HANGING DROP",4.75,"6.0 % w/v PEG6000, 0.10M MES pH 4.75",277.0,2022-11-06,2023-05-31,8BJU,2333.0,1.0,285.0,207.0,,32.74,1.0,1.53,experimental,34.13,0.263,0.2206,"HUMAN WEE1 KINASE IN COMPLEX WITH INHIBITOR 1-[6-(1-Hydroxy-1-methyl-ethyl)-pyridin-2-yl]-2-(2-methoxy-phenyl)-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one"
4QKZ,X-RAY DIFFRACTION,2.21,44.24,"VAPOR DIFFUSION, HANGING DROP",6.0,"10 % PEG 6000, 0.2M MES/NAOH, 1M NA PHOSPHATE, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-06-10,2015-06-17,4QKZ,1469.0,1.0,163.0,146.0,,18.93,1.0,1.2,experimental,9.976,0.1937,0.16952,X-ray structure of the catalytic domain of MMP-8 with the inhibitor ML115
5H8X,X-RAY DIFFRACTION,2.13,42.29,"VAPOR DIFFUSION, HANGING DROP",6.0,"10 % PEG 6000, 0.2M MES/NAOH, 1M NA      
REMARK 280  PHOSPHATE, PH 6.0",293.0,2015-12-24,2016-11-02,5H8X,1508.0,1.0,163.0,161.0,,19.2,1.0,1.3,experimental,,0.2172,0.1951,Crystal structure of the complex MMP-8/BF471 (catechol inhibitor)
7W33,X-RAY DIFFRACTION,1.83,32.86,"VAPOR DIFFUSION, HANGING DROP",4.1,"100mM sodium acetate (pH 4.1), 15% (w/v) PEG 2000, protein concentration 8 mg/ml",289.15,2021-11-25,2023-05-31,7W33,1747.0,1.0,333.0,5.0,3.0,38.22,1.0,2.39,experimental,68.5029,0.261,0.2222,The crystal structure of human CtsL in complex with 14a
7W34,X-RAY DIFFRACTION,1.83,33.09,"VAPOR DIFFUSION, HANGING DROP",4.1,"100mM sodium acetate (pH 4.1), 15% (w/v) PEG 2000, protein concentration 8mg/ml",289.15,2021-11-25,2023-05-31,7W34,1741.0,1.0,333.0,,3.0,38.21,1.0,2.89,experimental,60.9398,0.3028,0.2482,The crystal structure of human CtsL in complex with 14b
5T4S,X-RAY DIFFRACTION,3.07,59.97,"VAPOR DIFFUSION, SITTING DROP",7.9,"26% PEG600, 0.06M citrate, 0.04M citric acid",293.0,2016-08-30,2016-10-26,5T4S,5287.0,2.0,678.0,141.0,6.0,75.53,1.0,2.64,experimental,60.785,0.2581,0.2048,Novel Approach of Fragment-Based Lead Discovery applied to Renin Inhibitors
8V3O,X-RAY DIFFRACTION,2.26,45.49,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M DL-Malic acid, pH7.0, 0.1 M imidazole, pH7.0, 16% PEG MME 550",294.0,2023-11-28,2024-07-17,8V3O,3976.0,2.0,539.0,139.0,1.0,61.45,2.0,2.3,experimental,,0.2269,0.2031,CCP5 in complex with Glu-P-peptide 1 transition state analog
9GII,X-RAY DIFFRACTION,3.77,67.36,"VAPOR DIFFUSION, SITTING DROP",,"2M ammonium sulfate,
0.1M bis-tris pH 6.5",293.0,2024-08-19,2024-09-04,9GII,1032.0,1.0,117.0,87.0,,13.64,1.0,1.7,experimental,28.102,0.2158,0.198,Jumonji domain-containing protein 2A with crystallization epitope mutation R913A
6AEJ,X-RAY DIFFRACTION,3.04,59.51,"VAPOR DIFFUSION, HANGING DROP",5.6,"10% (w/v) PEG 3350, 0.1M tri-sodium Citrate dehydrate pH5.6, 5.0mM 3-meT, 3.0mM NOG, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K",298.0,2018-08-05,2019-06-19,6AEJ,3431.0,1.0,470.0,,,54.51,1.0,2.8,experimental,81.625,0.2217,0.2073,Crystal structure of human FTO in complex with small-molecule inhibitors
6AK4,X-RAY DIFFRACTION,2.99,58.9,"VAPOR DIFFUSION, HANGING DROP",5.6,"10.0% (W/V) PEG 3350, 100 MM SODIUM
 CITRATE, PH 5.6, 7% TERT-BUTANOL, 1 MM ZNSO4, 1 MM COMPOUND,
 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K",298.0,2018-08-30,2019-07-10,6AK4,3379.0,1.0,470.0,,1.0,54.49,1.0,2.8,experimental,86.09,0.253,0.209,Crystal structure of human FTO in complex with small-molecule inhibitors
5YGI,X-RAY DIFFRACTION,2.58,52.34,"VAPOR DIFFUSION, HANGING DROP",,"1.2M Na/K phosphate, 25% glycerol, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2017-09-23,2018-09-26,5YGI,2825.0,1.0,348.0,53.0,,40.66,1.0,2.177,experimental,,0.2719,0.2247,Crystal structure of human FPPS in complex with an inhibitor THZ93
5EDG,X-RAY DIFFRACTION,2.84,56.76,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES/NaOH pH 7.5, 30% PEG550MME, 50mM MgCl2",295.0,2015-10-21,2016-03-09,5EDG,10625.0,4.0,1261.0,319.0,3.0,148.28,2.0,2.3,experimental,40.211,0.2614,0.2124,human PDE10A in complex with 3-(2-Chloro-5-phenyl-3H-imidazol-4-yl)-1-(3-trifluoromethoxy-phenyl)-1H-pyridazin-4-one at 2.30A
5EDI,X-RAY DIFFRACTION,2.86,56.92,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES-NaOH pH 7.5, 30% PEG550MME, 50mM MgCl2",295.0,2015-10-21,2016-03-09,5EDI,10768.0,4.0,1277.0,377.0,4.0,150.23,2.0,2.2,experimental,53.039,0.2347,0.1857,"human PDE10A, 6-Chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-2H-[1,2,4]triazol-3-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine, 2.20A, H3, Rfree=23.5%"
7WR6,X-RAY DIFFRACTION,2.17,43.42,"VAPOR DIFFUSION, SITTING DROP",9.0,"27% PEG 3350, 0.05M CAPSO pH 9.0",293.0,2022-01-26,2023-01-25,7WR6,3726.0,2.0,480.0,189.0,1.0,54.48,2.0,1.96,experimental,43.7,0.2283,0.1962,Crystal structure of ADP-riboxanated caspase-4 in complex with Af1521
7D5B,X-RAY DIFFRACTION,2.34,47.55,"VAPOR DIFFUSION, SITTING DROP",,"22.5 % PEG1500, 0.01 M Na Acetate pH 4.5, 0.06 M Na Citrate",293.0,2020-09-25,2021-03-31,7D5B,4382.0,2.0,498.0,535.0,3.0,54.68,2.0,1.31,experimental,23.868,0.2217,0.1952,"BACE2 xaperone complex with N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-thiadiazin-5-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide"
7D5U,X-RAY DIFFRACTION,2.27,45.78,"VAPOR DIFFUSION, SITTING DROP",,293K,293.0,2020-09-28,2021-03-31,7D5U,3815.0,2.0,500.0,132.0,3.0,54.67,2.0,2.04,experimental,68.533,0.2538,0.2072,"BACE2 xaperone complex with N-{3-[(9S)-7-amino-2,2-difluoro-9-(prop-1-yn-1-yl)-6-oxa-8-azaspiro[3.5]non-7-en-9-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide"
7N4N,X-RAY DIFFRACTION,2.32,46.96,"VAPOR DIFFUSION, SITTING DROP",7.0,"22.5% PEG-1500, 25 mM Bis-Tris Propane pH 7.0, 150 mM NaCl",293.0,2021-06-04,2021-10-06,7N4N,4389.0,2.0,500.0,470.0,3.0,54.93,2.0,1.41,experimental,25.057,0.207,0.163,BACE-2 in complex with ligand 36
4Y97,X-RAY DIFFRACTION,2.64,53.42,"VAPOR DIFFUSION, SITTING DROP",5.6,"The diffraction quality crystals are growing in 2-3 weeks in 100 mM ammonium acetate, 50 mM Na citrate pH 5.6, 10 - 10.4% w/v PEG 4000, 2 mM TCEP and 50 mM guanidine HCl.",295.0,2015-02-17,2015-04-15,4Y97,19724.0,8.0,3112.0,202.0,,349.35,2.0,2.51,experimental,50.7,0.257,0.218,Crystal Structure of human Pol alpha B-subunit in complex with C-terminal domain of catalytic subunit
5MQY,X-RAY DIFFRACTION,2.06,40.15,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG3350, 0.1M Bis-Tris",294.0,2016-12-21,2017-03-22,5MQY,2009.0,1.0,220.0,251.0,3.0,25.08,1.0,1.13,experimental,23.934,0.19898,0.14869,"CATHEPSIN L IN COMPLEX WITH 4-[1,3-benzodioxol-5-ylmethyl(2-phenoxyethyl)amino]-5-fluoropyrimidine-2-carbonitrile"
6TIA,X-RAY DIFFRACTION,2.58,52.39,"VAPOR DIFFUSION, HANGING DROP",,"2.7 M AMS 0.1 M Hepes pH 7.1-7.7  
Protein Buffer:  50mM HEPES pH 7.5, 300 mM NaCl, 0,02% OG, 1 mM TCEP, 10% Glycerol",298.0,2019-11-22,2020-10-28,6TIA,5064.0,2.0,616.0,195.0,,73.87,1.0,2.52,experimental,75.5,0.261,0.216,IRAK4 IN COMPLEX WITH inhibitor
5OC7,X-RAY DIFFRACTION,2.47,50.0,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Potassium thiocyanate, 30% (w/v) PEG MME 2000",291.0,2017-06-29,2017-12-27,5OC7,3599.0,4.0,450.0,253.0,,51.54,2.0,1.652,experimental,,0.2043,0.1742,Crystal structure of the pleckstrin-homology domain of Bcr-Abl in complex with monobody Mb(Bcr-PH_4).
5YDR,X-RAY DIFFRACTION,3.4,63.81,EVAPORATION,8.0,"20mM Tris-HCl, 200mM sodium acetate, 25% PEG 4000",291.0,2017-09-14,2018-02-21,5YDR,3340.0,3.0,400.0,235.0,,45.24,2.0,2.003,experimental,44.0152,0.2325,0.1985,Structure of DNMT1 RFTS domain in complex with ubiquitin
6PNX,X-RAY DIFFRACTION,2.57,56.68,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Hepes, pH 7.5, and 1.8 M (NH4)2SO4",292.0,2019-07-03,2020-01-22,6PNX,4952.0,2.0,648.0,249.0,,74.29,1.0,2.199,experimental,74.7675,0.2299,0.1928,Crystal Structure of an Asymmetric Dimer of FGF Receptor 3 Kinases Trapped in A-loop Tyrosine Transphosphorylation Reaction
5W2I,X-RAY DIFFRACTION,2.24,44.99,"VAPOR DIFFUSION, HANGING DROP",4.5,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol  at 298K.  To obtain complex structures, the apo crystal were further soaked under 35% (w/v) PEG 400, 0.1 M Li2SO4,  100 mM HEPES, pH 7.5 at 298K in the presence of 20 mM C4-analogue of PtdIns(4,5)P2, 10 mM Mg and 5mM ATP for 1 day.",298.0,2017-06-06,2017-09-13,5W2I,2270.0,1.0,257.0,182.0,,30.32,1.0,1.6,experimental,19.146,0.21525,0.16922,"Crystal structure of the core catalytic domain of human inositol phosphate multikinase soaked with C4-analogue of PtdIns(4,5)P2 and ADP"
6THW,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, HANGING DROP",,"AMS 0.1 M Hepes  & 
Protein Buffer:  25 mM HEPES pH 7.5, 1 mM EDTA, 1 mM TCEP, 5% Glycerol, 150 mM NaCl",298.0,2019-11-21,2020-10-28,6THW,4617.0,2.0,616.0,148.0,,69.93,1.0,2.44,experimental,82.72,0.271,0.241,IRAK4 in complex with inhibitor
6THX,X-RAY DIFFRACTION,2.68,54.17,"VAPOR DIFFUSION, HANGING DROP",,"25 mM HEPES pH 7.5, 1 mM EDTA, 1 mM TCEP, 5% Glycerol, 150 mM NaCl",298.0,2019-11-21,2020-10-28,6THX,4699.0,2.0,616.0,204.0,,69.94,1.0,1.99,experimental,66.54,0.254,0.231,IRAK4 in complex with inhibitor
6THZ,X-RAY DIFFRACTION,2.39,48.62,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG8K, 0.2 M NaAc 0.1 M Mes pH 6.4  
Protein Buffer:  25 mM HEPES pH 7.5, 1 mM EDTA, 1 mM TCEP, 5% Glycerol, 150 mM NaCl",298.0,2019-11-21,2020-10-28,6THZ,4542.0,2.0,616.0,106.0,,70.27,1.0,2.38,experimental,78.36,0.274,0.231,IRAK4 IN COMPLEX WITH inhibitor
8ATB,X-RAY DIFFRACTION,2.64,53.5,"VAPOR DIFFUSION, HANGING DROP",4.9,"0.1M sodium acetate buffer, 2.13-2.145M sodium malonate",293.0,2022-08-22,2023-11-29,8ATB,4594.0,2.0,596.0,94.0,,67.71,1.0,2.35,experimental,55.616,0.2601,0.2123,Discovery of IRAK4 Inhibitor 16
8BR7,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium acetate buffer at pH 4.9, 1.5-1.7M ammonium citrate and 0.02M hexaaminecobalt(III)chloride",293.0,2022-11-22,2024-01-31,8BR7,4461.0,2.0,596.0,41.0,,67.6,1.0,2.119,experimental,60.235,0.2879,0.2387,Discovery of IRAK4 Inhibitors BAY1834845 and BAY1830839
8ST8,X-RAY DIFFRACTION,2.2,44.12,"VAPOR DIFFUSION, HANGING DROP",,"22.5% PEG 8000, 0.2 M ammonium sulfate, 0.1 M sodium cacodylate pH 7.0, and 20% glycerol",295.0,2023-05-09,2023-07-12,8ST8,2383.0,2.0,272.0,218.0,,30.59,2.0,1.75,experimental,29.61,0.1963,0.1765,Structure of E3 ligase SopA bound to ubiquitin
5T9U,X-RAY DIFFRACTION,4.83,74.51,VAPOR DIFFUSION,8.5,"0.1 M Tris-HCl, pH 8.5
0.1 M potassium chloride
2.2 M ammonium sulfate",293.0,2016-09-09,2017-01-25,5T9U,5856.0,4.0,656.0,628.0,,74.2,1.0,2.301,experimental,31.7922,0.1925,0.1654,Discovery of a Potent Cyclophilin Inhibitor (Compound 3) based on Structural Simplification of Sanglifehrin A
5JNO,X-RAY DIFFRACTION,3.87,68.25,"VAPOR DIFFUSION, SITTING DROP",,"0.1 mM HEPES, pH=7.0
1.56 M ammonium sulphate",293.0,2016-04-30,2017-09-13,5JNO,1283.0,2.0,169.0,18.0,,19.47,2.0,2.2,experimental,58.618,0.23748,0.22151,Crystal structure of the BD1-NTPR complex from BEND3 and PICH
8RX3,X-RAY DIFFRACTION,2.43,49.45,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2024-02-06,2024-03-20,8RX3,5574.0,1.0,613.0,669.0,,70.53,1.0,1.85,experimental,26.68,0.1827,0.1549,LTA4 hydrolase in complex with CTX-4430
8RX7,X-RAY DIFFRACTION,2.43,49.28,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2024-02-06,2024-03-20,8RX7,5565.0,1.0,613.0,675.0,,70.29,1.0,1.85,experimental,24.59,0.1883,0.1576,LTA4 hydrolase in complex with compound2
8RX9,X-RAY DIFFRACTION,2.45,49.89,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.1 IMIDAZOLE PH 6.8, 0.1 SODIUM ACETATE, 0.005 M YBCL3",298.0,2024-02-06,2024-03-20,8RX9,5024.0,1.0,613.0,128.0,,70.58,1.0,2.9,experimental,55.0,0.3349,0.2634,LTA4 hydrolase in complex with compound3
6SQU,X-RAY DIFFRACTION,2.28,45.98,"VAPOR DIFFUSION, SITTING DROP",,"0.17 M Ammonium sulfate, 25.5 % PEG 4000, 15 % glycerol",289.0,2019-09-04,2021-01-13,6SQU,4781.0,2.0,632.0,47.0,,73.28,1.0,2.27,experimental,66.2948,0.2537,0.2008,"Crystal structure of human SHIP2 catalytic domain in complex with 1,2,4 Dimer"
6SRR,X-RAY DIFFRACTION,2.28,45.98,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Sodium citrate, 20 % w/v PEG 3000",289.0,2019-09-05,2021-01-13,6SRR,4831.0,2.0,632.0,33.0,,72.49,1.0,2.45,experimental,80.2604,0.2371,0.1865,Crystal structure of human SHIP2 catalytic domain
6H4V,X-RAY DIFFRACTION,2.59,52.52,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",293.0,2018-07-23,2019-06-12,6H4V,11784.0,4.0,1440.0,691.0,,169.97,1.0,2.15,experimental,61.31,0.211,0.176,Crystal structure of human KDM4A in complex with compound 34g
5DEU,X-RAY DIFFRACTION,2.36,47.91,"VAPOR DIFFUSION, HANGING DROP",6.4,"26% PEGMME2000,0.1M MES6.4",277.0,2015-08-26,2015-11-04,5DEU,4067.0,3.0,485.0,309.0,,59.1,1.0,1.801,experimental,45.98,0.212,0.1771,Crystal structure of TET2-5hmC complex
6KBE,X-RAY DIFFRACTION,1.99,38.31,EVAPORATION,,"0.2 M Sodium chloride, 0.1 M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3,350",291.0,2019-06-24,2020-06-24,6KBE,3257.0,2.0,405.0,137.0,,45.83,2.0,2.339,experimental,,0.2556,0.2006,Structure of Deubiquitinase
7DDZ,X-RAY DIFFRACTION,4.66,73.58,LIPIDIC CUBIC PHASE,,"0.1 M HEPES, pH 7.0-7.5, 250-350 mM (NH4)2SO4, and 20-30% PEG500DME, or 0.1 M MES, pH 6.0-6.5, 380-420 mM NH4 tartrate, and 24-26% PEG500DME",293.15,2020-10-30,2021-01-27,7DDZ,3487.0,1.0,665.0,,1.0,75.31,1.0,2.8,experimental,71.06,0.2891,0.2548,The Crystal Structure of Human Neuropeptide Y Y2 Receptor with JNJ-31020028
6R4U,X-RAY DIFFRACTION,2.49,50.55,"VAPOR DIFFUSION, SITTING DROP",,"23% PEG3350, 10% ethylene glycol, 200 mM Na/K tartrate",292.0,2019-03-24,2019-09-11,6R4U,6734.0,2.0,820.0,191.0,,98.9,1.0,2.2,experimental,,0.2232,0.1961,Crystal structure of the Pri1 subunit of human primase bound to fludarabine triphosphate
7AAJ,X-RAY DIFFRACTION,2.37,48.0,"VAPOR DIFFUSION, HANGING DROP",5.1,"25% polyethylene glycol 3350, 200 mM ammonium citrate",293.0,2020-09-04,2021-02-17,7AAJ,5239.0,2.0,726.0,161.0,,80.17,1.0,1.8,experimental,56.76,0.2944,0.249,Human porphobilinogen deaminase in complex with cofactor
7AAK,X-RAY DIFFRACTION,2.37,48.2,"VAPOR DIFFUSION, SITTING DROP",5.1,"polyethylene glycol 3350, ammonium citrate",293.0,2020-09-04,2021-02-17,7AAK,5918.0,2.0,726.0,507.0,,81.16,1.0,1.7,experimental,36.82,0.2128,0.1827,Human porphobilinogen deaminase R173W mutant crystallized in the ES2 intermediate state
7L0N,X-RAY DIFFRACTION,3.76,67.29,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.09 M Buffer System 3 pH 8.5 contains Tris (base); BICINE
27% Precipitant Mix 2 contains Ethylene glycol and PEG8000
0.1 M Ammonium sulfate",293.0,2020-12-11,2021-02-17,7L0N,26468.0,12.0,3366.0,232.0,29.0,380.02,6.0,2.78,experimental,86.099,0.3247,0.2904,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
5E33,X-RAY DIFFRACTION,2.51,51.04,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phospahte dibasic,
pH- 8.2",293.0,2015-10-01,2016-04-13,5E33,6339.0,2.0,731.0,519.0,1.0,82.28,2.0,1.837,experimental,37.0,0.2237,0.1815,Structure of human DPP3 in complex with met-enkephalin
5E3A,X-RAY DIFFRACTION,2.5,50.82,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.056M SODIUM PHOSPHATE MONOBASIC MONOHYDRATE, 1.344M POTASSIUM PHOSPHATE DIBASIC",293.0,2015-10-02,2016-04-13,5E3A,6165.0,2.0,731.0,363.0,1.0,82.26,2.0,2.05,experimental,37.2,0.2599,0.2088,Structure of human DPP3 in complex with opioid peptide leu-enkephalin
5W0N,X-RAY DIFFRACTION,3.46,64.47,"VAPOR DIFFUSION, SITTING DROP",,"0.8-1.0 M lithium sulfate, 0.075-0.2 M potassium iodide, 0.05-0.2 M trisodium citrate, pH 5-6",291.0,2017-05-31,2017-06-28,5W0N,9365.0,3.0,1209.0,218.0,,143.76,1.0,2.497,experimental,69.0815,0.2151,0.1867,Structure of human TUT7 catalytic module (CM) in complex with UMPNPP and U2 RNA
7AW2,X-RAY DIFFRACTION,2.26,45.56,VAPOR DIFFUSION,8.5,"0.5 mM protein was crystallised in 4.3 M sodium chloride, 0.1 M Tris pH 8.5 and soaked for 24 h  with 20 mM compound and 20 % DMSO",293.0,2020-11-06,2021-03-03,7AW2,2202.0,1.0,298.0,69.0,,34.8,1.0,2.1,experimental,65.54,0.238,0.207,MerTK kinase domain with type 1.5 inhibitor from a DNA-encoded library
7AW3,X-RAY DIFFRACTION,2.19,43.92,VAPOR DIFFUSION,8.5,"0.5 mM protein was crystallised in 4.3 M sodium chloride, 0.1 M Tris pH 8.5 and crystal soaked for 24 h  with 20 mM compound and 20 % DMSO",293.0,2020-11-06,2021-03-03,7AW3,2195.0,1.0,298.0,60.0,,34.88,1.0,1.99,experimental,51.15,0.245,0.216,MerTK kinase domain with type 1 inhibitor from a DNA-encoded library
7OLS,X-RAY DIFFRACTION,2.27,45.9,VAPOR DIFFUSION,,"0.1 M Tris pH 8.5, 4.3 M NaCl",293.0,2021-05-20,2021-09-15,7OLS,2291.0,1.0,298.0,107.0,,35.02,1.0,1.89,experimental,47.483,0.2819,0.2187,MerTK kinase domain with type 1.5 inhibitor containing a di-methyl pyrazole group
7OLV,X-RAY DIFFRACTION,2.19,43.96,VAPOR DIFFUSION,,"0.1 M Tris pH 8.5, 4.3 M NaCl",293.0,2021-05-20,2021-09-15,7OLV,2209.0,1.0,298.0,31.0,,35.04,1.0,2.13,experimental,61.622,0.2473,0.2078,"MerTK kinase domain with type 1.5 inhibitor containing a di-methyl, cyano pyrazole group"
7ZRY,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,,"1.0-1.3 M Na/K Tartrate, 0.1 M ADA pH 6.5",293.0,2022-05-06,2022-08-03,7ZRY,6339.0,2.0,1050.0,,,115.85,2.0,2.7,experimental,98.4218,0.2406,0.2204,Structure of the 2a splicing variant of the full-length human LSD1 bound to CoREST (delta305)
6HTY,X-RAY DIFFRACTION,2.54,51.52,"VAPOR DIFFUSION, HANGING DROP",8.0,"1 microliter protein at 12.1 mg/ml (in 20 millimolar Tris pH 7.8, 250 millimolar NaCl, 2.5 millimolar EDTA, 5% (v/v) glycerol, 5 mM DTT), preincubated with 10 millimolar compound 15 (from 200 millimolar stock in DMSO), mixed with 1 microliter of reservoir (100 mM imidazole pH 8.0, 17 % (v/v) MPD). Crystals additionally soaked in 20 millimolar compound 15 prior to data collection. cryo buffer 34% (v/v) MPD supplemented with 20 millimolar compound 15",277.0,2018-10-05,2019-12-04,6HTY,5181.0,2.0,688.0,148.0,,79.28,1.0,2.22,experimental,69.232,0.22611,0.1847,PXR in complex with P2X4 inhibitor compound 25
6BQP,X-RAY DIFFRACTION,2.27,45.83,"VAPOR DIFFUSION, SITTING DROP",7.0,22% PEG 3350; 0.21 M Ammonium Acetate; 0.1M CHC buffer pH 7.0,293.0,2017-11-28,2017-12-13,6BQP,2171.0,1.0,291.0,100.0,,33.63,1.0,1.95,experimental,39.761,0.22666,0.18922,Crystal Structure of the Human CAMKK2B in complex with Crenolanib
6BQQ,X-RAY DIFFRACTION,2.43,49.46,"VAPOR DIFFUSION, SITTING DROP",,22% PEG 3350; 0.21 M Ammonium Sulphate; 0.1M CHC buffer pH 7.5,293.0,2017-11-28,2017-12-13,6BQQ,2344.0,1.0,291.0,180.0,1.0,33.83,1.0,1.8,experimental,29.48,0.22768,0.19064,Crystal Structure of the Human CAMKK2B in complex with BI2526
7AK3,X-RAY DIFFRACTION,2.53,51.3,"VAPOR DIFFUSION, SITTING DROP",9.3,"23% PEG 6000, 0.1 M bicine",278.0,2020-09-29,2020-11-11,7AK3,2737.0,1.0,339.0,19.0,,39.99,1.0,2.5,experimental,72.692,0.2599,0.2108,CLK1 bound with CAF052
5VSE,X-RAY DIFFRACTION,2.54,51.64,VAPOR DIFFUSION,6.5,"20 % PEG3350, 10% glycerol, 0.2 M Sodium fluoride, Bis-Tris propane pH6.5",290.0,2017-05-11,2017-07-19,5VSE,4811.0,2.0,550.0,338.0,,65.56,1.0,1.6,experimental,38.6584,0.1906,0.1675,"Structure of human G9a SET-domain (EHMT2) in complex with inhibitor 17: N~2~-cyclopentyl-6,7-dimethoxy-N~2~-methyl-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine"
5W5Q,X-RAY DIFFRACTION,2.16,43.13,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 35% PEG 3350",293.0,2017-06-15,2018-06-20,5W5Q,5013.0,2.0,664.0,214.0,,76.18,1.0,2.33,experimental,55.71,0.2355,0.2095,"MAP4K4 in complex with inhibitor compound 12 (N3-methyl-10-(3-methyl-3-(5-methyloxazol-2-yl)but-1-yn-1-yl)-6,7-dihydro-5H-5,7-methanobenzo[c]imidazo[1,2-a]azepine-2,3-dicarboxamide)"
4U42,X-RAY DIFFRACTION,2.09,41.23,"VAPOR DIFFUSION, SITTING DROP",8.3,"0.2 M potassium citrate, pH 8.3, 20% PEG 3350",292.0,2014-07-23,2016-01-06,4U42,4528.0,2.0,664.0,47.0,,76.66,1.0,2.504,experimental,66.4944,0.3029,0.2272,MAP4K4 T181E Mutant Bound to inhibitor compound 1
4X4T,X-RAY DIFFRACTION,2.57,52.1,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2M NaK tartrate",290.0,2014-12-03,2015-02-11,4X4T,17131.0,9.0,1933.0,357.0,,248.82,1.0,2.5,experimental,70.4,0.229,0.186,Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a G70A arginyl-tRNA minihelix ending in CCACCA
8GX3,X-RAY DIFFRACTION,0.98,43.52,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.1M sodium acetate (pH 4.6), 8% (w/v) PEG 4000, 13mg/ml protein",293.15,2022-09-18,2023-09-20,8GX3,2951.0,1.0,714.0,301.0,,82.62,1.0,1.99,experimental,28.6894,0.215,0.1732,The crystal structure of human Calpain-1 protease core in complex with 14c
5LCU,X-RAY DIFFRACTION,2.18,54.34,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)

Reservoir: 16% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-06-22,2018-01-17,5LCU,3476.0,2.0,373.0,417.0,,43.85,2.0,1.579,experimental,,0.1915,0.1518,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a S-methyl-piperazine substituted Fasudil-derivative (Ligand 01)
8F7V,X-RAY DIFFRACTION,2.13,42.12,"VAPOR DIFFUSION, HANGING DROP",5.0,"13-18% PEG 4000, 150 mM Ammonium sulfate, 100 mM MES",293.0,2022-11-20,2023-02-08,8F7V,4270.0,2.0,500.0,377.0,12.0,57.19,1.0,1.65,experimental,25.1061,0.1867,0.1734,Macrocyclic plasmin inhibitor
5JBC,X-RAY DIFFRACTION,2.18,43.69,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein-inhibitor complex, 
0.1M MES pH 6.5, 
20% PEG6000",293.0,2016-04-13,2016-06-01,5JBC,2425.0,2.0,293.0,166.0,7.0,32.99,2.0,1.9,experimental,45.21,0.213,0.1659,Crystal structure of factor IXa variant V16I K98T Y177T I213V in complex with PPACK
8R1T,X-RAY DIFFRACTION,3.1,59.9,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM bis-tris-propane (pH 7.0), 10% ethylene glycol, 0.3% DMSO, 20% PEG3350, 200 mM Mg(OAc)2",291.15,2023-11-02,2024-03-20,8R1T,2405.0,2.0,327.0,128.0,,37.6,2.0,2,experimental,42.95,0.1795,0.1589,Pim1 in complex with 4-(4-aminophenethyl)benzoic acid and Pimtide
6ZBO,X-RAY DIFFRACTION,2.4,48.8,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.2M Potassium thiocyanate pH 7, 21% PEG 3350, Sitting drop (300 nL), protein-to-well ratio 2:1, 298K",298.0,2020-06-08,2021-04-07,6ZBO,10378.0,6.0,1362.0,625.0,,155.47,1.0,1.79,experimental,58.0728,0.2063,0.1804,"HIF Prolyl Hydroxylase 2 (PHD2/EGLN1) in Complex with 1-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol (Molidustat)"
5VT1,X-RAY DIFFRACTION,3.06,59.85,"VAPOR DIFFUSION, SITTING DROP",7.0,"24% PEG 8000, 0.1M magnesium acetate, 0.1M CHC buffer (citric acid, ches, hepes).",293.0,2017-05-15,2017-05-24,5VT1,2369.0,1.0,291.0,246.0,,33.52,1.0,1.9,experimental,33.95,0.185,0.161,Crystal Structure of the Human CAMKK2B bound to a thiadiazinone benzamide inhibitor
4XUC,X-RAY DIFFRACTION,2.53,51.41,VAPOR DIFFUSION,,"0.1M MES, pH 6.5, 0.1M NaOAc, 30% PEG 2000MME; MA000417 (PEGsII), drop b10 :100uM ligand, 11mg/ml protein",298.0,2015-01-25,2015-04-15,4XUC,2050.0,1.0,218.0,291.0,,25.14,1.0,1.8,experimental,20.192,0.2156,0.1736,Synthesis and evaluation of heterocyclic catechol mimics as inhibitors of catechol-O-methyltransferase (COMT): Structure with Cmpd18 (1-(biphenyl-3-yl)-3-hydroxypyridin-4(1H)-one)
5LXI,X-RAY DIFFRACTION,2.15,42.78,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MgCl2, 24.6 % PEG 400, 29.5 % PEG 8000, 0.1M TRIS 8.5",293.0,2016-09-21,2017-02-08,5LXI,2290.0,4.0,266.0,100.0,,32.38,2.0,1.44,experimental,,0.2299,0.1969,GABARAP-L1 ATG4B LIR Complex
5ZE3,X-RAY DIFFRACTION,2.96,58.44,"VAPOR DIFFUSION, HANGING DROP",,"28% PEG 2000, 100mM Li2SO4, 100mM HEPES, pH 7.6",291.0,2018-02-25,2018-04-11,5ZE3,7153.0,2.0,914.0,202.0,20.0,103.03,1.0,2.4,experimental,,0.2391,0.2171,Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state
7V8E,X-RAY DIFFRACTION,2.12,42.09,EVAPORATION,8.5,"0.2 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.5), and 25% (w/v) PEG3350",289.0,2021-08-22,2022-03-30,7V8E,5269.0,4.0,658.0,431.0,,74.35,2.0,1.9,experimental,37.54,0.2457,0.2009,Crystal structure of IpaH1.4 LRR domain bound to HOIL-1L UBL domain.
5XJV,X-RAY DIFFRACTION,2.03,39.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris-HCl (pH 8.5), 20% ethanol",291.0,2017-05-04,2018-04-11,5XJV,3081.0,2.0,370.0,414.0,,40.72,1.0,1.69,experimental,20.38,0.22057,0.17786,Two intermediate states of conformation switch in dual specificity phosphatase 13a
5MZL,X-RAY DIFFRACTION,3.1,60.29,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
NaCl
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-01,2018-02-14,5MZL,2375.0,2.0,327.0,120.0,,37.57,2.0,1.955,experimental,,0.1834,0.157,Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule N-quinolin-5-ylpyridine-3-carboxamide
5N4V,X-RAY DIFFRACTION,3.13,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
NaCl
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N4V,2469.0,2.0,327.0,158.0,,37.57,2.0,1.85,experimental,,0.1869,0.1637,"Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule 2-cyclopropyl-4,5-dimethylthieno[5,4-d]pyrimidine-6-carboxylic acid"
6GHM,X-RAY DIFFRACTION,2.67,53.89,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M TRIS pH 8.5
16 % PEG 8000",293.0,2018-05-08,2019-02-27,6GHM,8259.0,4.0,1086.0,245.0,,125.59,2.0,2.15,experimental,,0.2145,0.1769,Structure of PP1 alpha phosphatase bound to ASPP2
4ZZY,X-RAY DIFFRACTION,2.54,51.2,,,"25% PEG4000, 0.2M MAGNESIUM CLORIDE, 0.1 M TRIS PH 8.5",,2015-04-15,2015-08-12,4ZZY,2904.0,1.0,363.0,80.0,,41.5,1.0,2.2,experimental,26.354,0.28037,0.21618,Structure of human PARP2 catalytic domain bound to an isoindolinone inhibitor
5UBM,X-RAY DIFFRACTION,2.8,56.0,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris, pH 5.5, 25 % PEG 3350",277.0,2016-12-20,2017-11-08,5UBM,3936.0,3.0,541.0,126.0,16.0,61.25,3.0,2.5,experimental,,0.2223,0.1767,Crystal structure of human C1s in complex with inhibitor gigastasin
8DEG,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,7.7,"0.2M Magnesium Acetate, 0.1M HEPES pH 7.7, 18% PEG 3350",293.0,2022-06-20,2022-12-14,8DEG,2204.0,1.0,322.0,30.0,,36.88,1.0,2.79,experimental,50.248,0.2966,0.2484,Crystal structure of DLK in complex with inhibitor DN0011197
5L2Y,X-RAY DIFFRACTION,3.91,68.51,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2016-08-02,2016-09-28,5L2Y,2871.0,2.0,309.0,392.0,10.0,35.37,2.0,1.82,experimental,26.8,0.189,0.172,"Factor VIIa in complex with the inhibitor 1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl] cyclobutane-1-carboxylic acid"
5L2Z,X-RAY DIFFRACTION,3.44,64.27,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2016-08-02,2016-09-28,5L2Z,2832.0,2.0,312.0,334.0,8.0,35.66,2.0,1.79,experimental,26.8,0.203,0.181,"Factor VIIa in complex with the inhibitor 1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-7-yl]cyclohexane-1-carboxylic acid"
5L30,X-RAY DIFFRACTION,3.77,67.38,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2016-08-02,2016-09-28,5L30,2875.0,2.0,312.0,410.0,8.0,35.72,2.0,1.73,experimental,29.4,0.194,0.181,"Factor VIIa in complex with the inhibitor (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1H-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione"
7UXN,X-RAY DIFFRACTION,2.13,42.18,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Sodium acetate, 0.1 M Sodium cacodylate pH 6.5, 30% w/v PEG 8000.",291.15,2022-05-05,2022-12-28,7UXN,1603.0,2.0,178.0,197.0,,19.63,2.0,1.36,experimental,21.356,0.2166,0.1933,"Structure of PPIA in complex with FP29103, a Helicon Polypeptide"
6K9P,X-RAY DIFFRACTION,2.49,50.7,EVAPORATION,,"0.2 M Sodium chloride, 0.1 M HEPES pH 7.5, 25% w/v Polyethylene glycol 3,350",291.0,2019-06-17,2020-06-24,6K9P,2680.0,2.0,329.0,138.0,,37.26,2.0,2.047,experimental,,0.2101,0.1724,Structure of Deubiquitinase
6FHA,X-RAY DIFFRACTION,2.38,48.4,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG 4000, 0.2M ammonium sulfate, 0.1M sodium sulfate",292.15,2018-01-12,2019-01-30,6FHA,2479.0,1.0,337.0,54.0,,38.65,1.0,2.3,experimental,,0.267,0.2006,Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289A and S308A mutations
5VIO,X-RAY DIFFRACTION,2.75,55.23,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 3350, 0.2M ammonium chloride, 0.1M Bis-Tris (pH 6.1-6.6), and 10% glycerol.",295.0,2017-04-17,2018-01-17,5VIO,8875.0,4.0,1172.0,204.0,,133.1,1.0,2.84,experimental,109.84,0.216,0.179,Crystal structure of ASK1 kinase domain with a potent inhibitor (analog 13)
5WBV,X-RAY DIFFRACTION,2.59,52.49,"VAPOR DIFFUSION, SITTING DROP",8.0,"8-12% EtOH, 100mM Tris pH 8.0",291.0,2017-06-29,2017-07-19,5WBV,3586.0,2.0,546.0,31.0,,64.89,1.0,2.3,experimental,53.74,0.269,0.234,Crystal Structure of the SET Domain of Human SUV420H1 In Complex With Inhibitor
6YJU,X-RAY DIFFRACTION,2.27,45.74,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 8.0, 
0.3 M Li2SO4, 
30 % (w/v) PEG 3350, 
10 % (v/v) ethylene glycol",293.0,2020-04-04,2020-08-05,6YJU,8501.0,2.0,1030.0,241.0,12.0,120.5,1.0,1.96,experimental,51.702,0.2523,0.1999,"Crystal structure of MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation, in complex with UDP and biantennary pentasaccharide M592"
6YJV,X-RAY DIFFRACTION,2.23,44.77,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 8.0, 
0.3 M Li2SO4, 
30 % (w/v) PEG 3350, 
10 % (v/v) ethylene glycol",293.0,2020-04-04,2020-08-05,6YJV,8834.0,2.0,1030.0,509.0,12.0,120.92,1.0,1.7,experimental,43.149,0.2115,0.1754,"Crystal structure of unliganded MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation, in complex with UDP-2-deoxy-2-fluoroglucose and biantennary pentasaccharide M592"
4UX4,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-19,2015-06-10,4UX4,3830.0,2.0,480.0,378.0,,55.8,1.0,1.8,experimental,29.114,0.19837,0.16229,"Crystal structure of human tankyrase 2 in complex with 1-methyl-7-(4- methylphenyl)-5-oxo-5,6-dihydro-1,6-naphthyridin-1-ium"
4W5I,X-RAY DIFFRACTION,2.45,49.83,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",277.0,2014-08-18,2015-06-10,4W5I,3798.0,2.0,480.0,352.0,,55.69,1.0,1.95,experimental,27.67,0.1999,0.162,"Crystal structure of human tankyrase 2 in complex with 1-methyl-7-phenyl-1,2,3,4,5,6-hexahydro-1,6- naphthyridin-5-one"
4O8Z,X-RAY DIFFRACTION,2.63,53.21,,,,,2013-12-31,2015-04-22,4O8Z,2391.0,1.0,303.0,217.0,,34.62,1.0,2,experimental,32.239,0.20373,0.16737,"Crystal structure of human SIRT3 in complex with compound (2-butylbenzofuran-3-yl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)methanone"
6O8U,X-RAY DIFFRACTION,2.65,53.53,VAPOR DIFFUSION,,"2.3M-2.7M ammonium sulfate, 0.1M HEPES Na pH 7.0-7.3",292.0,2019-03-12,2019-05-22,6O8U,9672.0,4.0,1220.0,458.0,,139.03,1.0,1.8,experimental,41.754,0.255,0.231,Crystal structure of IRAK4 in complex with compound 23
6CNX,X-RAY DIFFRACTION,2.81,56.27,"VAPOR DIFFUSION, SITTING DROP",6.5,"30.25% PEG3350, 30mM LiSO4, 0.1M SBG (Sodium-tartrate, Bis-Tris, Glycylglycine)",293.15,2018-03-09,2018-04-04,6CNX,10931.0,4.0,1456.0,816.0,,167.52,1.0,2,experimental,31.898,0.21112,0.18707,Crystal Structure of the Human vaccinia-related kinase 1 (VRK1) bound to an N-propynyl-N-isopentyl-dihydropteridin inhibitor
5AUT,X-RAY DIFFRACTION,1.91,35.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AUT,2458.0,1.0,293.0,217.0,,34.1,1.0,1.7,experimental,,0.2024,0.1703,Crystal structure of DAPK1 in complex with ANS.
5AUU,X-RAY DIFFRACTION,1.92,35.81,"VAPOR DIFFUSION, HANGING DROP",6.5,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AUU,2421.0,1.0,293.0,180.0,,34.08,1.0,1.7,experimental,,0.2162,0.1791,Crystal structure of DAPK1 in complex with luteolin.
5AUV,X-RAY DIFFRACTION,1.91,35.56,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AUV,2508.0,1.0,293.0,258.0,,34.1,1.0,1.5,experimental,,0.1944,0.1749,Crystal structure of DAPK1 in complex with apigenin.
5AUX,X-RAY DIFFRACTION,1.91,35.44,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AUX,2514.0,1.0,293.0,263.0,,34.12,1.0,1.5,experimental,,0.2077,0.178,Crystal structure of DAPK1 in complex with kaempferol.
5AUY,X-RAY DIFFRACTION,1.9,35.38,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AUY,2364.0,1.0,293.0,113.0,,34.1,1.0,2,experimental,,0.2493,0.2066,Crystal structure of DAPK1 in complex with morin.
5AV0,X-RAY DIFFRACTION,1.89,34.95,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AV0,2441.0,1.0,293.0,192.0,,34.07,1.0,1.85,experimental,,0.2198,0.1868,"Crystal structure of DAPK1 in complex with 7,3',4'-trihydroxyisoflavone."
5AV1,X-RAY DIFFRACTION,1.91,35.53,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AV1,2509.0,1.0,293.0,273.0,,34.36,1.0,1.5,experimental,,0.2147,0.186,Crystal structure of DAPK1 in the presence of bromide ions.
5AV2,X-RAY DIFFRACTION,1.91,35.54,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AV2,2523.0,1.0,293.0,266.0,,34.64,1.0,1.502,experimental,,0.2088,0.182,Crystal structure of DAPK1-kaempferol complex in the presence of bromide ions.
5AV3,X-RAY DIFFRACTION,1.91,35.61,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AV3,2468.0,1.0,293.0,209.0,,35.22,1.0,1.9,experimental,,0.2327,0.1825,Crystal structure of DAPK1-kaempferol complex in the presence of iodide ions.
5J1T,X-RAY DIFFRACTION,2.42,49.14,"VAPOR DIFFUSION, HANGING DROP",6.5,"19 % PEG3350
200 mM ammonium sulfate
100 mM Bis-Tris/HCl pH 6.5",291.0,2016-03-29,2016-08-17,5J1T,5959.0,3.0,645.0,631.0,1.0,73.63,3.0,1.402,experimental,25.3491,0.1768,0.148,"TorsinAdeltaE-LULL1 complex, H. sapiens, bound to VHH-BS2"
5GGI,X-RAY DIFFRACTION,2.81,56.2,"VAPOR DIFFUSION, HANGING DROP",,NaKPO4,293.0,2016-06-16,2016-08-10,5GGI,7946.0,4.0,1178.0,101.0,8.0,134.11,2.0,2.6,experimental,,0.2385,0.1989,"Crystal structure of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with Mn, UDP and Mannosyl-peptide"
5NV7,X-RAY DIFFRACTION,3.8,67.62,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298.0,2017-05-03,2018-05-30,5NV7,2192.0,2.0,300.0,45.0,,34.14,1.0,2.568,experimental,56.54,0.2329,0.1979,"Human DNMT3B PWWP domain in complex with N1-(2-hydroxyethyl)-2-methyl-1,2-propanediamine"
6J1X,X-RAY DIFFRACTION,2.31,46.68,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris-HCl pH 7.0, 15% v/v reagent alcohol",289.15,2018-12-30,2019-07-24,6J1X,3710.0,1.0,550.0,54.0,,65.26,1.0,2.3,experimental,,0.2705,0.2195,WWP1 close conformation
6QMO,X-RAY DIFFRACTION,2.32,47.01,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2M magnesium formate",292.15,2019-02-07,2019-08-28,6QMO,2628.0,1.0,313.0,115.0,,36.87,1.0,1.87,experimental,,0.2236,0.1859,Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289E and S308A mutations
6ZJE,X-RAY DIFFRACTION,2.49,50.66,"VAPOR DIFFUSION, HANGING DROP",8.0,"Purified hAK3 was dialyzed against 30 mM MOPS buffer with 50 mM NaCl pH 7.0 and concentrated to 15-20 mg per ml. The resevoir contained 0.2 M CaCl2, 0.1 M Tris pH 8.0 and 20% PEG 6000. Drop size 1 plus 1 microliter. Cryo protection 30% PEG 6000",291.0,2020-06-28,2020-09-16,6ZJE,2299.0,1.0,227.0,314.0,,26.63,1.0,1.48,experimental,30.4604,0.1836,0.1433,"Crystal structure of human adenylate kinase 3, AK3, in complex with inhibitor Ap5A"
6N8G,X-RAY DIFFRACTION,2.72,54.83,"VAPOR DIFFUSION, HANGING DROP",,"1.6-1.7 M Sodium Malonate,  pH 7.0,  100-150 mM Sodium acetate,  10 mM DTT",296.0,2018-11-29,2018-12-12,6N8G,9674.0,4.0,1188.0,496.0,,136.31,1.0,2,experimental,49.999,0.2198,0.1743,IRAK4 bound to benzoxazole compound
8D3K,X-RAY DIFFRACTION,2.66,53.9,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris, pH 8.5, 0.36 M Li2SO4, 25-26% PEG3350",295.0,2022-06-01,2023-11-08,8D3K,6960.0,2.0,1086.0,245.0,,121.45,2.0,2.3,experimental,53.71,0.2197,0.1893,Crystal structure of human Apoptosis-Inducing Factor (AIF) complexed with 8-fluoro-2-methylquinolin-4-amine
6M3B,X-RAY DIFFRACTION,3.19,61.41,"VAPOR DIFFUSION, SITTING DROP",,"0.1% n-Octyl-beta-D-glucoside, 0.1M sodium citrate tribasic dehydrate pH 5.5, 22% (w/v) PEG 3350",291.0,2020-03-03,2020-07-08,6M3B,5892.0,4.0,842.0,139.0,15.0,92.51,4.0,2.2,experimental,65.4415,0.2475,0.2183,hAPC-c25k23 Fab complex
5EGY,X-RAY DIFFRACTION,2.41,49.04,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.056 M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic, pH- 8.2, 293K",293.0,2015-10-27,2016-04-13,5EGY,5769.0,1.0,726.0,22.0,1.0,81.64,1.0,2.741,experimental,,0.2542,0.2067,Structure of ligand free human DPP3 in closed form.
6G2A,X-RAY DIFFRACTION,2.04,39.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM magnesium acetate, 12 % (w/v) PEG8000, 100 mM MOPS pH 7.5",293.15,2018-03-22,2018-11-28,6G2A,3006.0,1.0,367.0,133.0,,41.47,1.0,1.8,experimental,30.432,0.22039,0.18143,Human [protein ADP-ribosylargenine] hydrolase ARH1 in complex with ADP-HPM
6YG2,X-RAY DIFFRACTION,2.47,50.17,"VAPOR DIFFUSION, SITTING DROP",7.8,"19% PEG3350, 
0.1 M ammonium acetate,
0.1 M tris, pH 7.8",277.15,2020-03-27,2020-08-12,6YG2,2629.0,1.0,307.0,182.0,,36.64,1.0,2,experimental,38.529,0.2304,0.1789,"Crystal structure of MKK7 (MAP2K7) in complex with ibrutnib, with covalent and allosteric binding modes"
8V1O,X-RAY DIFFRACTION,2.47,50.12,"VAPOR DIFFUSION, HANGING DROP",6.9,"0.2M Ammonium sulfate, 0.1M MES, pH6.9, 30% w/v PEG5000 MME",291.0,2023-11-21,2024-07-03,8V1O,9424.0,4.0,1308.0,118.0,,150.92,1.0,2.92,experimental,60.861,0.2655,0.21643,Crystal structure of IRAK4 kinase domain with compound 4
8V2F,X-RAY DIFFRACTION,2.49,50.64,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.8M ammonium citrate,
1.75mM compound (1.8% DMSO)",291.0,2023-11-22,2024-07-03,8V2F,10225.0,4.0,1308.0,619.0,,151.37,1.0,2.09,experimental,43.936,0.20754,0.16814,Crystal structure of IRAK4 kinase domain with compound 9
7YW5,X-RAY DIFFRACTION,2.22,44.68,VAPOR DIFFUSION,,"0.1 M BIS-TRIS propane pH9.0
 30% PEG 6000",291.0,2022-08-21,2024-01-17,7YW5,2573.0,2.0,388.0,24.0,,43.57,1.0,2.77,experimental,,0.2687,0.2585,Crystal Structure of the ITS1 processing by human ribonuclease ISG20L2 with mutation D327A
6X9I,X-RAY DIFFRACTION,2.96,58.43,"VAPOR DIFFUSION, SITTING DROP",5.1,"14-18% polyethylene glycol (PEG) 3350, 0.1 M citric acid (pH 5.1)",292.0,2020-06-02,2021-07-07,6X9I,6956.0,3.0,898.0,225.0,1.0,107.0,1.0,2.2,experimental,70.81,0.2252,0.1939,Human DNMT1(729-1600) Bound to Zebularine-Containing 12mer dsDNA
8ARJ,X-RAY DIFFRACTION,2.1,41.34,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M ammonium sulphate, 9-10.5% monomethyl ether poly (ethylene glycol) (MW 5000), and 0.1 M MES buffer pH 5.3 - 5.6",286.0,2022-08-17,2022-09-14,8ARJ,2221.0,1.0,321.0,63.0,,36.46,1.0,1.645,experimental,40.512,0.2287,0.1966,Anaplastic Lymphoma Kinase with a novel carboline inhibitor
5HG1,X-RAY DIFFRACTION,4.83,74.56,VAPOR DIFFUSION,,"protein: 6.6 mgs/mL, 10mM Tris HCL, pH=8, 0.1 M NaCl, 1mM DTT, 20mM MgCl2
Well: 0.2 M Na Citrate pH 5.5, 14-24 % PEG3350, 20 % ethylene glycol",296.0,2016-01-07,2016-03-30,5HG1,6613.0,1.0,922.0,8.0,,104.15,1.0,2.76,experimental,,0.2658,0.2177,"Crystal Structure of Human Hexokinase 2 with cmpd 1, a C-2-substituted glucosamine"
4TWN,X-RAY DIFFRACTION,1.91,35.73,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M sodium cacodylate pH 6.5, 0.15M ammonium sulfate, 22.5% PEG 3350",293.0,2014-07-01,2015-05-13,4TWN,2346.0,1.0,361.0,178.0,,40.99,1.0,1.706,experimental,,0.2127,0.1769,Human EphA3 Kinase domain in complex with Birb796
4TWO,X-RAY DIFFRACTION,1.97,37.57,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M sodium cacodylate pH 6.5, 0.15M ammonium sulfate, 22.5% PEG 3350",293.0,2014-07-01,2015-05-13,4TWO,2409.0,1.0,361.0,186.0,,40.83,1.0,2.047,experimental,,0.2006,0.1627,Human EphA3 Kinase domain in complex with compound 164
7CIZ,X-RAY DIFFRACTION,1.95,36.79,"VAPOR DIFFUSION, SITTING DROP",,"0.05 M Lithium sulfate, 0.05 M Sodium sulfate; 0.05 M Tris, pH 8.5, 30% (v/v) PEG400.",293.0,2020-07-08,2021-04-14,7CIZ,6707.0,12.0,978.0,741.0,,109.99,4.0,1.8,experimental,,0.2138,0.1706,Crystal structure of DNAJC9 HBD helix2 in complex with H3.3-H4 dimer and MCM2 HBD
7NX3,X-RAY DIFFRACTION,3.59,65.72,"VAPOR DIFFUSION, SITTING DROP",,"40mMPolyamines, 
0.1M Gly-Gly/AMPD pH8.5 
12.5% w/v PEG4000  
20% w/v 1,2,6-Hexanetriol",287.0,2021-03-17,2021-10-27,7NX3,10759.0,6.0,1676.0,,14.0,179.64,3.0,2.81,experimental,49.13,0.2664,0.2276,Crystal structure of ALK in complex with Fab324
5F2S,X-RAY DIFFRACTION,2.54,51.61,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2015-12-02,2016-01-20,5F2S,12312.0,4.0,1440.0,939.0,,171.47,1.0,2.08,experimental,39.24,0.191,0.1631,Crystal structure of human KDM4A in complex with compound 15
5F2W,X-RAY DIFFRACTION,2.45,49.81,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2015-12-02,2016-01-20,5F2W,11386.0,4.0,1440.0,215.0,,170.7,1.0,2.6,experimental,54.06,0.2256,0.1791,Crystal structure of human KDM4A in complex with compound 16
5F37,X-RAY DIFFRACTION,2.46,50.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2015-12-02,2016-01-20,5F37,12163.0,4.0,1440.0,771.0,,171.59,1.0,2.22,experimental,41.29,0.2088,0.1694,Crystal structure of human KDM4A in complex with compound 58
5F39,X-RAY DIFFRACTION,2.52,51.13,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2015-12-02,2016-01-20,5F39,11319.0,4.0,1440.0,325.0,,169.96,1.0,2.65,experimental,73.75,0.2097,0.169,Crystal structure of human KDM4A in complex with compound 37
5F3G,X-RAY DIFFRACTION,2.42,49.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2015-12-02,2016-01-20,5F3G,11155.0,4.0,1440.0,363.0,,170.32,1.0,2.5,experimental,53.42,0.2464,0.2027,Crystal structure of human KDM4A in complex with compound 53a
6H4O,X-RAY DIFFRACTION,2.45,49.76,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2018-07-23,2019-06-12,6H4O,11233.0,4.0,1440.0,467.0,,170.31,1.0,2.25,experimental,59.64,0.203,0.169,Crystal structure of human KDM4A in complex with compound 18a
6H4P,X-RAY DIFFRACTION,2.49,50.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",293.0,2018-07-23,2019-06-12,6H4P,11664.0,4.0,1440.0,658.0,,170.59,1.0,2.19,experimental,61.35,0.207,0.17,Crystal structure of human KDM4A in complex with compound 16a
6H4Q,X-RAY DIFFRACTION,2.45,49.72,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",293.0,2018-07-23,2019-06-12,6H4Q,12206.0,4.0,1440.0,993.0,,169.87,1.0,2.31,experimental,30.69,0.213,0.173,Crystal structure of human KDM4A in complex with compound 34a
6H4R,X-RAY DIFFRACTION,2.47,50.18,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",293.0,2018-07-23,2019-06-12,6H4R,11733.0,4.0,1440.0,747.0,,170.13,1.0,2.14,experimental,55.24,0.219,0.179,Crystal structure of human KDM4A in complex with compound 17f
6H4T,X-RAY DIFFRACTION,2.48,50.36,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",293.0,2018-07-23,2019-06-12,6H4T,11699.0,4.0,1440.0,759.0,,170.35,1.0,2.38,experimental,50.53,0.216,0.173,Crystal structure of human KDM4A in complex with compound 19a
6H4U,X-RAY DIFFRACTION,2.62,53.14,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",293.0,2018-07-23,2019-06-12,6H4U,11815.0,4.0,1440.0,721.0,,169.9,1.0,2.21,experimental,61.4,0.208,0.176,Crystal structure of human KDM4A in complex with compound 34b
6H4X,X-RAY DIFFRACTION,2.46,50.04,"VAPOR DIFFUSION, SITTING DROP",,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2018-07-23,2019-06-12,6H4X,11342.0,4.0,1440.0,482.0,,170.42,1.0,2.34,experimental,61.52,0.207,0.166,Crystal structure of human KDM4A in complex with compound 17b
6H4Y,X-RAY DIFFRACTION,2.47,50.13,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291.0,2018-07-23,2019-06-12,6H4Y,11366.0,4.0,1440.0,495.0,,170.51,1.0,2.38,experimental,70.1,0.209,0.174,Crystal structure of human KDM4A in complex with compound 17e
4TND,X-RAY DIFFRACTION,2.14,42.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 3350, 0.15 M Sodium Chloride, 0.1 M BIS-TRIS pH 6.5
Crystal growth and size improved by using micro-seeding technique",277.0,2014-06-04,2015-06-10,4TND,4832.0,1.0,590.0,510.0,,68.47,1.0,1.802,experimental,,0.2047,0.1726,Crystal Structure of G Protein-Coupled Receptor Kinase 5 in Complex with AMP-PNP
8AM2,X-RAY DIFFRACTION,3.22,61.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"AMMONIUM SULFATE 2.1 M, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID 0.1 M",298.0,2022-08-02,2023-06-14,8AM2,4608.0,1.0,529.0,181.0,3.0,62.76,1.0,2.5,experimental,53.41,0.2198,0.1702,"Human butyrylcholinesterase in complex with 2,2'-(((1E,1'E)-(2-phenylpyrimidine-4,6-diyl)bis(methaneylylidene))bis(hydrazin-1-yl-2-ylidene))bis(N,N,N-trimethyl-2-oxoethan-1-aminium)"
5IV3,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM sodium acetate pH 4.8
200 mM tri-sodium-citrate
15% (w/v) PEG 4000
10% (v/v) glycerol",277.15,2016-03-18,2016-08-17,5IV3,4005.0,1.0,475.0,267.0,,55.69,1.0,1.86,experimental,34.4,0.22308,0.17594,"Crystal structure of human soluble adenylyl cyclase in complex with alpha,beta-methyleneadenosine-5'-triphosphate and the allosteric inhibitor LRE1"
6F4Q,X-RAY DIFFRACTION,2.29,46.33,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M Bis-Tris pH 6.0, 19.3 % PEG3350, 0.002 M MnCl2, 300 nl sitting drops (sample:well, 1:1 ratio)",298.0,2017-11-29,2018-04-04,6F4Q,2609.0,2.0,271.0,373.0,1.0,31.9,2.0,1.12,experimental,22.0,0.1533,0.1392,"Human JMJD5 (Q275C) in complex with Mn(II), NOG and RPS6-A138C (129-144) (complex-2)"
4XSJ,X-RAY DIFFRACTION,2.91,57.72,"VAPOR DIFFUSION, HANGING DROP",5.5,"20% PEG 3350, 5% glycerol, 0.3 M ammonium sulphate and 0.1 M Bis-Tris-HCl (pH 5.5)",293.0,2015-01-22,2015-09-16,4XSJ,2480.0,1.0,262.0,431.0,,30.08,1.0,1.8,experimental,29.253,0.19,0.127,Crystal structure of the N-terminal domain of the human mitochondrial calcium uniporter fused with T4 lysozyme
5ZQM,X-RAY DIFFRACTION,2.88,57.35,"VAPOR DIFFUSION, HANGING DROP",,"0.4 M Calcium acetate 
20% (v/v) PEG 3,350",298.0,2018-04-19,2019-02-27,5ZQM,2343.0,1.0,309.0,8.0,,35.54,1.0,2.9,experimental,74.619,0.28514,0.24735,Crystal structure of human katanin AAA ATPase domain complex with ATPgammaS
7D85,X-RAY DIFFRACTION,2.26,45.61,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Sodium acetate, 20%(w/v) PEG 3350",298.0,2020-10-07,2021-04-07,7D85,9539.0,6.0,1276.0,39.0,16.0,138.36,3.0,2.5,experimental,38.33,0.2584,0.2026,Crystal structure of anti-ErbB3 Fab ISU104 in complex with human ErbB3 extracellular domain 3
5VO2,X-RAY DIFFRACTION,1.93,36.31,"VAPOR DIFFUSION, SITTING DROP",7.7,"20% PEG 3350, 0.2 M Mg Acetate, 0.1 M Hepes pH 7.7",293.0,2017-05-01,2017-10-04,5VO2,2226.0,1.0,300.0,35.0,,34.43,1.0,2.96,experimental,34.14,0.2637,0.1695,DLK in complex with inhibitor 5-(1-isopropyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)-3-(trifluoromethyl)pyridin-2-amine (compound 7)
6YZH,X-RAY DIFFRACTION,2.12,42.02,"VAPOR DIFFUSION, SITTING DROP",6.2,"12 %v/v PEGSH, 0.1 M Mg Acet, 
0.1 M KCl,0.1 M MES",298.0,2020-05-07,2021-05-19,6YZH,3481.0,2.0,408.0,354.0,,48.47,2.0,1.19,experimental,20.316,0.1899,0.1719,Crystal structure of P8C9 bound to CK2alpha
7R6T,X-RAY DIFFRACTION,2.38,48.25,"VAPOR DIFFUSION, HANGING DROP",,"28% PEG 4K, 0.2 M Ammonium Acetate, 0.1 M Na Citrate tribasic dihydrate pH 5.6",293.0,2021-06-23,2022-08-24,7R6T,7809.0,9.0,996.0,11.0,2.0,125.22,1.0,2.9,experimental,92.6,0.286,0.229,Human EXOG complexed with dRP-containing DNA
8CGO,X-RAY DIFFRACTION,3.11,60.51,"VAPOR DIFFUSION, HANGING DROP",,Ammonium Sulfate,293.0,2023-02-06,2023-06-14,8CGO,4588.0,1.0,529.0,100.0,3.0,63.45,1.0,2.65,experimental,69.9,0.2155,0.1776,Structure of human butyrylcholinesterase in complex with N-{[2-(benzyloxy)-3-methoxyphenyl]methyl}-N-[3-(2-fluorophenyl)propyl]cyclobutanamine
6K81,X-RAY DIFFRACTION,2.07,40.63,VAPOR DIFFUSION,,"Calcium acetate, PEG 3000",293.0,2019-06-11,2020-02-19,6K81,2316.0,2.0,431.0,77.0,,48.85,2.0,2.28,experimental,,0.2419,0.1897,Crystal structure of human VASH1-SVBP complex
6QIG,X-RAY DIFFRACTION,3.96,68.97,"VAPOR DIFFUSION, SITTING DROP",,"35% (v/v) pentaerythritol ethoxylate, 200 mM CaCl2, 100 mM HEPES, pH 6.5",293.0,2019-01-18,2019-09-04,6QIG,8264.0,3.0,1044.0,183.0,17.0,118.31,3.0,2.8,experimental,54.621,0.24715,0.2055,Metalloproteinase
6B1U,X-RAY DIFFRACTION,3.16,61.1,"VAPOR DIFFUSION, HANGING DROP",6.2,"8% PEG 3350, 0.1 M MgCl2, 1.0% glucose, 0.001% cocamidopropyl betaine and 0.1 M imidazole.",277.0,2017-09-19,2018-04-25,6B1U,14977.0,6.0,2342.0,171.0,,268.63,3.0,2.77,experimental,66.36,0.226,0.194,Structure of full-length human AMPK (a2b1g1) in complex with a small molecule activator SC4
7E6J,X-RAY DIFFRACTION,2.51,51.03,"VAPOR DIFFUSION, SITTING DROP",7.0,"100mM PCTP, 25% w/v PEG 1500",277.0,2021-02-22,2021-06-30,7E6J,3990.0,2.0,468.0,362.0,2.0,53.88,2.0,1.9,experimental,39.42,0.2134,0.1702,Aspartyl/Asparaginyl beta-hydroxylase (AspH) H725A in complex with Factor X peptide fragment (39mer-4Ser)
8IPK,X-RAY DIFFRACTION,2.56,51.92,"VAPOR DIFFUSION, HANGING DROP",,"42% PEG 600, 0.2 M imidazole malate, pH 5.5",289.0,2023-03-14,2024-01-03,8IPK,2534.0,1.0,338.0,99.0,,38.54,1.0,1.9,experimental,,0.2207,0.1823,The structure of human mitochondrial methyltransferase METTL15 with SAM
8VL9,X-RAY DIFFRACTION,4.09,69.96,"VAPOR DIFFUSION, HANGING DROP",,"0.2M SODIUM CITRATE, 0.1M BIS-TRIS-PROPANE PH 6.5, 20% PEG3350",294.0,2024-01-11,2024-03-13,8VL9,4466.0,4.0,577.0,120.0,,66.5,4.0,2.5,experimental,,0.216,0.184,Crystal structure of EloBC-VHL-CDO1 complex bound to compound 8 molecular glue
5D6W,X-RAY DIFFRACTION,3.72,66.98,"VAPOR DIFFUSION, SITTING DROP",4.6,"Protein Solution (30mg/ml KDM4A DTD, 20mM HEPES pH 7.5, 150mM NaCl and 0.5mM TCEP) mixed in a 1:1 ratio with the well solution (1.0M ammonium tartrate dibasic and 0.1M sodium acetate trihydrate pH4.6) Cryoprotected with additional 20% glycerol",293.0,2015-08-13,2015-11-25,5D6W,4350.0,4.0,484.0,515.0,,55.51,1.0,1.992,experimental,41.3238,0.1955,0.1679,Crystal structure of double tudor domain of human lysine demethylase KDM4A
6GVJ,X-RAY DIFFRACTION,2.07,40.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M Ammonium sulfate
20% (w/v) PEG8000
0.1 M MES-buffer, pH 6.5",293.0,2018-06-21,2019-01-09,6GVJ,2277.0,1.0,429.0,30.0,,49.5,1.0,2.41,experimental,50.838,0.2334,0.2012,Human Mps1 kinase domain with ordered activation loop
6AS7,X-RAY DIFFRACTION,2.89,57.44,"VAPOR DIFFUSION, SITTING DROP",4.6,"6MM COCL2, 2 MM TCEP, 50 MM NA ACETATE PH 4.6, 225 MM 1,6HEXADEDIOL",298.0,2017-08-23,2018-03-14,6AS7,7516.0,3.0,946.0,1.0,,113.57,1.0,2.95,experimental,57.6,0.301,0.259,CRYSTAL STRUCTURE OF THE CATALYTIC CORE OF HUMAN DNA POLYMERASE ALPHA IN TERNARY COMPLEX WITH AN DNA-PRIMED DNA TEMPLATE AND DCTP
6YI8,X-RAY DIFFRACTION,2.39,48.46,"VAPOR DIFFUSION, HANGING DROP",,"mixing 0.5 ul of protein solution (13 mg/ml in 50 mM HEPES pH 8.0, 100 mM NaCl, 3% glycerol, 1 mM TCEP and 2 mM roblitinib incubated for 1h on ice) with 0.5 ul of reservoir solution (13.5 % PEG 3350, 0.1 M (NH4)2SO4, 0.1 M NaAc pH 4.25)",277.0,2020-04-01,2020-09-30,6YI8,4672.0,2.0,614.0,238.0,,70.18,1.0,2.13,experimental,45.28,0.231,0.196,HUMAN FGFR4 KINASE DOMAIN (447-753) IN COMPLEX WITH ROBLITINIB
7F1E,X-RAY DIFFRACTION,3.37,63.52,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Sodium acetate pH5.2,  2.0M sodium formate",291.0,2021-06-09,2022-01-12,7F1E,3883.0,2.0,572.0,50.0,,67.78,1.0,2.589,experimental,51.4533,0.2265,0.1908,Structure of METTL6 bound with SAM
6ZFQ,X-RAY DIFFRACTION,2.11,41.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"100 mM bis-tris pH 5.5, 25% w/v PEG 3350.
Protein at 10 mg/ml in 25 mM HEPES pH 7.0, 200 mM NaCl buffer with 2.23 mM GlcIFG and 2.23 mM alpha-1,2-mannobiose (10 x molar ratio). 300 nl droplet (150 nl protein solution, 150 nl reservoir solution). The ligand additives are probably not required for crystallization.",292.0,2020-06-17,2020-11-18,6ZFQ,3419.0,1.0,382.0,456.0,,44.99,1.0,1.2,experimental,23.781,0.1812,0.1409,Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with bis-tris
8B75,X-RAY DIFFRACTION,2.61,52.88,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodiumacetate, 0.2 M trisodiumcitrate, 15% PEG4000, 10% Glycerol, 277 K",277.0,2022-09-28,2023-03-29,8B75,4141.0,1.0,475.0,306.0,,54.76,1.0,1.82,experimental,32.338,0.2457,0.2027,CRYSTAL STRUCTURE OF HUMAN SOLUBLE ADENYLYL CYCLASE IN COMPLEX WITH THE INHIBITOR TDI-011861
5ES1,X-RAY DIFFRACTION,3.14,60.88,VAPOR DIFFUSION,8.5,"20% (w/v) PEG 6000, 0.2 M MgCl2, 0.1 M Tris",292.0,2015-11-16,2015-12-02,5ES1,2325.0,1.0,328.0,8.0,,38.09,1.0,2.8,experimental,98.68,0.3109,0.239,CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4XUD,X-RAY DIFFRACTION,2.56,51.89,VAPOR DIFFUSION,7.0,"0.1M HEPES, 30% PEG 6000; MA000474 (JCSG core IV), drop e12 :100uM ligand, 12mg/ml protein",298.0,2015-01-25,2015-04-15,4XUD,1924.0,1.0,218.0,162.0,,25.18,1.0,2.4,experimental,24.293,0.241,0.1679,"Synthesis and evaluation of heterocyclic catechol mimics as inhibitors of catechol-O-methyltransferase (COMT): Structure with Cmpd32 ([1-(biphenyl-3-yl)-5-hydroxy-4-oxo-1,4-dihydropyridin-3-yl]boronic acid)"
4PRZ,X-RAY DIFFRACTION,2.25,45.26,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.0 M sodium citrate, 0.1 M HEPES, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 295K",295.0,2014-03-06,2015-01-21,4PRZ,2065.0,2.0,280.0,134.0,,32.4,2.0,2.123,experimental,,0.218,0.1897,Caspase-8 specific unnatural amino acid peptides
6YZ4,X-RAY DIFFRACTION,2.49,50.64,"VAPOR DIFFUSION, SITTING DROP",7.8,"16% PEG3350, 0.1 M tris pH 7.8, 0.25 M ammonium acetate",277.15,2020-05-06,2020-08-12,6YZ4,2727.0,1.0,307.0,310.0,,36.26,1.0,1.7,experimental,28.894,0.2061,0.1693,Crystal structure of MKK7 (MAP2K7) with ibrutinib bound at allosteric site
8TXE,X-RAY DIFFRACTION,2.18,43.56,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Sodium Acetate pH 4.5, 40% PEG 400",286.15,2023-08-23,2023-11-08,8TXE,3244.0,2.0,340.0,342.0,,40.96,1.0,1.35,experimental,14.65,0.2148,0.1882,Crystal structure of KRAS G12D in complex with GDP and compound 5
8TXH,X-RAY DIFFRACTION,2.17,43.41,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Sodium Acetate pH 4.5, 40% PEG 400",286.15,2023-08-23,2023-11-08,8TXH,3204.0,2.0,340.0,291.0,,41.06,1.0,1.2,experimental,14.0,0.2033,0.1904,Crystal structure of KRAS G12D in complex with GDP and compound 14
6HGT,X-RAY DIFFRACTION,2.48,50.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000.
Co-substrate analog NOG and H3R9 peptide were co-crystallised with the protein.",291.0,2018-08-23,2019-09-04,6HGT,11544.0,8.0,1500.0,465.0,,175.01,2.0,2.33,experimental,44.44,0.28,0.251,Crystal structure of human KDM4A complexed with co-substrate analog NOG and histone H3 peptide with K9R mutation
5DDZ,X-RAY DIFFRACTION,2.5,50.9,"VAPOR DIFFUSION, HANGING DROP",,0.4 M ammonium dihydrogen phosphate,289.0,2015-08-25,2016-09-07,5DDZ,2319.0,2.0,285.0,248.0,,32.09,2.0,1.5,experimental,25.138,0.1752,0.14624,Crystal structure of the RTA-c10-P2 complex
6HDN,X-RAY DIFFRACTION,4.04,69.56,VAPOR DIFFUSION,,1.2-1.5M ammonium sulphate and 20-25% PEG3350.,277.0,2018-08-18,2018-09-26,6HDN,1348.0,1.0,130.0,198.0,,16.16,1.0,1.9,experimental,57.076,0.22956,0.19378,"Crystal structure of human ATAD2 bromodomain in complex with 3-methyl-8-((8-methyl-8-azabicyclooctan-3-yl)amino)-1,7-naphthyridin-2(1H)-one"
6Z49,X-RAY DIFFRACTION,2.53,51.47,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M Bis-Tris pH 6.0, 0.2 M Magnesium chloride and 25% PEG 3350",293.15,2020-05-23,2021-06-02,6Z49,7949.0,4.0,1092.0,114.0,,125.56,1.0,2,experimental,42.468,0.2511,0.2153,Crystal structure of deubiquitinase Mindy2
5LYY,X-RAY DIFFRACTION,2.45,49.88,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293.0,2016-09-29,2016-12-21,5LYY,3244.0,1.0,388.0,232.0,,44.51,1.0,2.17,experimental,40.016,0.22523,0.1773,Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
7RP3,X-RAY DIFFRACTION,2.51,50.91,"VAPOR DIFFUSION, SITTING DROP",,"0.10% n-Octyl-B-D-glucoside, 0.1 M sodium citrate pH 5.5, 22% PEG 3350",292.0,2021-08-03,2022-03-16,7RP3,4902.0,3.0,612.0,290.0,4.0,67.68,3.0,2,experimental,51.3508,0.2339,0.1907,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP
6F3G,X-RAY DIFFRACTION,2.6,52.76,VAPOR DIFFUSION,,"50 mM Hepes pH 7.5, 0.02% octylglucoside, 10% glycerol, 0.3 M NaCl, 1 mM TCEP",293.0,2017-11-28,2018-05-23,6F3G,4540.0,2.0,590.0,71.0,,67.41,2.0,2.37,experimental,72.48,0.314,0.29,IRAK4 IN COMPLEX WITH inhibitor
6KC5,X-RAY DIFFRACTION,2.16,42.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM HEPES-Na (pH 7.5), 200 mM NaCl, 25% PEG 3,350",293.0,2019-06-27,2020-04-15,6KC5,1653.0,1.0,225.0,127.0,1.0,26.52,1.0,1.543,experimental,,0.2169,0.1982,HOIP-HOIPIN1 complex
6ZJ1,X-RAY DIFFRACTION,2.71,54.7,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES pH 7.5 - 8.1, 200 mM MgCl2, 25-27.5% v/v PEG 400, 1 mM TEW
Protein in 25 mM HEPES pH 7.0, 200 mM NaCl buffer at 10 mg/ml.",292.0,2020-06-27,2020-12-02,6ZJ1,3273.0,1.0,382.0,133.0,,48.72,1.0,1.957,experimental,40.367,0.2524,0.1838,Structure of an inactive E404Q variant of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with tetrasaccharide N-glycan fragment and hexatungstotellurate(VI) TEW
4U72,X-RAY DIFFRACTION,3.06,59.84,"VAPOR DIFFUSION, HANGING DROP",9.1,"12 % (W/V) PEG 8000, 0.2 M ammonium acetate, 1 mM 4-phenylimidazole, 0.1 M CHES",293.0,2014-07-30,2015-09-02,4U72,6471.0,2.0,812.0,335.0,1.0,93.66,1.0,2,experimental,27.393,0.2311,0.1857,"Crystal structure of 4-phenylimidazole bound form of human indoleamine 2,3-dioxygenase (A260G mutant)"
4U74,X-RAY DIFFRACTION,3.1,60.27,"VAPOR DIFFUSION, HANGING DROP",9.1,"12 % (W/V) PEG 8000, 0.2 M ammonium acetate, 1 mM 4-phenylimidazole, 0.1 M CHES",293.0,2014-07-30,2015-09-02,4U74,6421.0,2.0,812.0,307.0,1.0,93.71,1.0,2.31,experimental,33.992,0.2195,0.1713,"Crystal structure of 4-phenylimidazole bound form of human indoleamine 2,3-dioxygenase (G262A mutant)"
6VLU,X-RAY DIFFRACTION,2.24,45.14,VAPOR DIFFUSION,,"0.1 M citrate pH 5, 23% PEG4000, seeded.",293.0,2020-01-27,2020-05-06,6VLU,2144.0,1.0,238.0,216.0,4.0,27.55,1.0,1.6,experimental,20.789,0.2459,0.2013,Factor XIa in complex with compound 7
5K0K,X-RAY DIFFRACTION,2.21,44.37,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein at 32.5 mg/mL (in 20 mM Tris pH 8.0, 500 mM NaCl, 2mM BME) was incubated overnight with inhibitor at 2.5 mM final concentration, and then was mixed 1:1 with crystallization solution (27-33% (v/v) Peg 400, 200 mM MgCl2, 100 mM Tris pH 8.5).",285.2,2016-05-17,2017-01-11,5K0K,4217.0,2.0,626.0,28.0,,72.94,1.0,2.545,experimental,56.6,0.2543,0.1979,Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC2434
5VVT,X-RAY DIFFRACTION,2.72,54.75,EVAPORATION,,"0.024 M ammonium citrate tribasic (pH 7.0), 0.015 M MES monohydrate, 0.096 M potassium thiocyanate, 0.25 M Sodium acetate trihydrate, 0.037 M imidazole, 0.002 M zinc sulfate heptahydrate, 9.6 % w/v polyethylene glycol 3,350, 2.4 % w/v polyethylene glycol monomethyl ether 2,000, and 4% w/v polyethylene glycol monomethyl ether 550",293.0,2017-05-20,2017-09-27,5VVT,7040.0,4.0,1024.0,49.0,,117.99,2.0,2.8,experimental,70.712,0.29091,0.21134,Structural Investigations of the Substrate Specificity of Human O-GlcNAcase
7MXS,X-RAY DIFFRACTION,2.59,52.48,VAPOR DIFFUSION,,"100 mM sodium acetate, pH 7.0; 10 mM KCl; 2-4% PEG 4000",290.0,2021-05-19,2023-05-10,7MXS,3277.0,3.0,380.0,78.0,,47.29,1.0,2.798,experimental,99.5807,0.2473,0.2127,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (cr)
7MXV,X-RAY DIFFRACTION,2.65,53.66,VAPOR DIFFUSION,,"100 mM sodium acetate, pH 7.0; 10 mM KCl; 2mM CaCl2; 20 mM MnCl2; 2-4% PEG 4000",290.0,2021-05-19,2023-05-10,7MXV,3268.0,3.0,381.0,50.0,,47.59,1.0,2.211,experimental,78.7769,0.244,0.2208,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (ur)
7MXW,X-RAY DIFFRACTION,2.46,49.96,VAPOR DIFFUSION,,"100 mM sodium acetate, pH 7.0; 10 mM KCl; 2mM CaCl2; 20 mM MgCl2; 2-4% PEG 4000",290.0,2021-05-19,2023-05-10,7MXW,3264.0,3.0,381.0,35.0,,47.51,1.0,2.836,experimental,95.4167,0.2653,0.2192,Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (uf1)
7MXX,X-RAY DIFFRACTION,2.39,48.52,VAPOR DIFFUSION,,"100 mM sodium acetate, pH 7.0; 10 mM KCl; 2mM CaCl2; 20 mM MnCl2; 2-4% PEG 4000",290.0,2021-05-19,2023-05-10,7MXX,3229.0,3.0,380.0,35.0,,48.22,1.0,2.85,experimental,102.2851,0.2976,0.2577,Crystal structure of human exonuclease 1 Exo1 (R92A) in complex with 5' flap DNA (uf4)
8OUR,X-RAY DIFFRACTION,1.91,35.51,"VAPOR DIFFUSION, HANGING DROP",7.7,"20% PEG 3350, 0.2 M magnesium acetate, and 0.1 M HEPES/NaOH pH 7.5-7.9",291.0,2023-04-24,2023-07-26,8OUR,2304.0,1.0,300.0,123.0,,34.46,1.0,1.95,experimental,27.904,0.25461,0.1957,CRYSTAL STRUCTURE OF DLK IN COMPLEX WITH COMPOUND 16
8OUS,X-RAY DIFFRACTION,2.07,40.44,"VAPOR DIFFUSION, HANGING DROP",7.7,"20% PEG 3350, 0.2 M magnesium acetate, and 0.1 M HEPES/NaOH pH 7.5-7.9",291.0,2023-04-24,2023-07-26,8OUS,2297.0,1.0,300.0,119.0,,34.49,1.0,2.2,experimental,33.94,0.2517,0.17941,CRYSTAL STRUCTURE OF DLK IN COMPLEX WITH COMPOUND 19
6HYO,X-RAY DIFFRACTION,2.67,53.96,"VAPOR DIFFUSION, SITTING DROP",,"0.2M MgCl2. 0.1 M Na cacodylate pH 6.5, 20% PEG1000",293.0,2018-10-22,2019-05-08,6HYO,1414.0,1.0,137.0,171.0,,16.73,1.0,1.07,experimental,,0.1608,0.1416,Structure of ULK1 LIR motif bound to GABARAP
7ZY2,X-RAY DIFFRACTION,2.03,39.42,"VAPOR DIFFUSION, SITTING DROP",,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-23,2022-10-12,7ZY2,3151.0,1.0,328.0,241.0,,40.05,1.0,1.51,experimental,24.86,0.2104,0.1878,Crystal structure of compound 7 bound to CK2alpha
7ZYD,X-RAY DIFFRACTION,2.04,39.63,"VAPOR DIFFUSION, SITTING DROP",,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-24,2022-10-12,7ZYD,3006.0,1.0,328.0,156.0,,39.89,1.0,1.404,experimental,26.12,0.2139,0.1979,Structure of Compound 6 Bound to CK2alpha
7ZYO,X-RAY DIFFRACTION,2.01,38.81,"VAPOR DIFFUSION, SITTING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-25,2022-10-12,7ZYO,3174.0,1.0,328.0,283.0,,40.28,1.0,1.58,experimental,18.81,0.204,0.175,Compound 9 Bound to CK2alpha
7ZYR,X-RAY DIFFRACTION,2.02,39.15,"VAPOR DIFFUSION, SITTING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-25,2022-10-12,7ZYR,3153.0,1.0,328.0,265.0,,40.08,1.0,1.85,experimental,16.49,0.2094,0.1674,Compound 20 Bound to CK2alpha
8AEK,X-RAY DIFFRACTION,2.01,38.95,"VAPOR DIFFUSION, SITTING DROP",,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",293.0,2022-07-13,2022-10-12,8AEK,3111.0,1.0,328.0,260.0,,39.94,1.0,1.65,experimental,17.98,0.1983,0.1717,Structure of Compound 14 bound to CK2alpha
8AEM,X-RAY DIFFRACTION,2.03,39.48,"VAPOR DIFFUSION, SITTING DROP",,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",293.0,2022-07-13,2023-03-29,8AEM,3080.0,1.0,328.0,197.0,,40.08,1.0,1.6,experimental,23.02,0.2125,0.1886,Structure of Compound 13 bound to CK2alpha
5EDE,X-RAY DIFFRACTION,2.86,57.06,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES/NaOH pH 7.5, 30% PEG550MME, 50mM MgCl2",295.0,2015-10-21,2016-03-09,5EDE,11207.0,4.0,1263.0,780.0,6.0,148.32,2.0,2.2,experimental,29.656,0.2416,0.1835,"human PDE10A in complex with 1-(4-Chloro-phenyl)-3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide at 2.2A"
7QBL,X-RAY DIFFRACTION,1.84,33.13,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG 8000, 20% ethylene glycol, 0.02 M sodium formate, 0.02 M ammonium acetate, 0.02 M trisodium citrate, 0.02 M sodium potassium L-tartrate, 0.02 M sodium oxamate, 0.1 M MES/imidazole pH 6.5",289.0,2021-11-19,2022-01-26,7QBL,1727.0,1.0,215.0,47.0,3.0,23.84,1.0,2,experimental,34.95,0.2858,0.2173,Structure of cathepsin K in complex with the 3-cyano-3-aza-beta-amino acid inhibitor Gu2602
4URA,X-RAY DIFFRACTION,2.71,54.24,,5.9,"0.1M BIS-TRIS PH 5.9, 0.15M AMMONIUM SULFATE, 11% PEG3350",,2014-06-27,2015-06-17,4URA,5767.0,2.0,720.0,185.0,,84.59,1.0,2.23,experimental,,0.259,0.2067,Crystal structure of human JMJD2A in complex with compound 14a
5TVS,X-RAY DIFFRACTION,2.61,52.82,"VAPOR DIFFUSION, HANGING DROP",6.0,17.5% PEG-3350 and 0.1 M citrate pH 6.0,277.0,2016-11-09,2017-02-01,5TVS,5766.0,2.0,718.0,,2.0,83.78,1.0,2.745,experimental,,0.2667,0.2029,JMJD2A in complex with Ni(II)
5YDK,X-RAY DIFFRACTION,2.76,55.41,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris pH 7.6
21% PEG3350",293.0,2017-09-13,2018-03-07,5YDK,7771.0,12.0,960.0,278.0,2.0,110.39,3.0,2.505,experimental,,0.2595,0.2295,"Crystal structure of RNF168 UDM1 in complex with Lys63-linked diubiquitin, tetrameric form"
6G8F,X-RAY DIFFRACTION,2.55,51.75,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris-HCl (pH 8.5), Li2 SO4 (0.15-0.25 M), PEG 3350 (20-25% w/v)",277.0,2018-04-08,2018-10-10,6G8F,4038.0,1.0,531.0,241.0,,61.12,1.0,2.043,experimental,,0.2356,0.1931,Crystal structure of UTX complexed with GSK-J1
6SAD,X-RAY DIFFRACTION,4.88,74.8,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 400, magnesium chloride, HEPES, 1,1,1,3,3,3-hexafluoropropan-2-ol",293.15,2019-07-16,2020-01-22,6SAD,3808.0,3.0,502.0,41.0,,58.1,2.0,2.753,experimental,67.8707773822,0.271048351218,0.229798205408,Structure of 14-3-3 gamma in complex with double phosphorylated caspase-2 peptide on Ser139 and Ser164
7NNJ,X-RAY DIFFRACTION,2.5,50.92,"VAPOR DIFFUSION, SITTING DROP",7.5,2.75 M sodium formate,293.0,2021-02-24,2022-03-23,7NNJ,2257.0,2.0,280.0,105.0,1.0,33.54,1.0,1.755,experimental,47.3846,0.2447,0.1949,Crystal Structure of NUDT4 (Diphosphoinositol polyphosphate phosphohydrolase 2) in complex with 4-O-Bn-1-PCP-InsP4 (AMR2105)
6AAX,X-RAY DIFFRACTION,4.14,70.3,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.2M potassium chloride, 0.025M magnesium sulfate hydrate, 0.05M HEPES sodium, pH 7.0, 20% v/v polyethylene glycol 200",293.0,2018-07-19,2019-06-05,6AAX,5735.0,4.0,694.0,,,92.22,1.0,2.994,experimental,71.0973,0.2706,0.2222,Crystal structure of TFB1M and h45 with SAM in homo sapiens
5WMV,X-RAY DIFFRACTION,3.05,59.64,MICROBATCH,10.0,"100 mM Sodium thiosulfate, 100 mM pH 10.0 CAPS buffer, and 20% (w/v) PEG 8000",277.0,2017-07-31,2017-12-06,5WMV,6324.0,2.0,850.0,157.0,1.0,97.6,1.0,2.6,experimental,94.616,0.25998,0.2202,"Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1"
5WMX,X-RAY DIFFRACTION,3.05,59.68,MICROBATCH,10.0,"100 mM Sodium thiosulfate, 100 mM pH 10.0 CAPS buffer, and 20% (w/v) PEG 8000",277.0,2017-07-31,2017-12-06,5WMX,6277.0,2.0,850.0,131.0,1.0,97.42,1.0,2.69,experimental,99.372,0.25415,0.21448,"Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1"
8QLQ,X-RAY DIFFRACTION,2.21,44.38,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 11 mg/mL MST3 in 25 mM HEPES pH 7.5, 200 mM NaCl, 0.5 mM TCEP, 5% glycerol) with 3 mM macrocyclic inhibitor JA310.
Reservoir solution: 14% PEG 6K, 0.1 M HEPES pH 7.2. Drop ratio 1:2.",293.0,2023-09-20,2023-11-08,8QLQ,2462.0,1.0,306.0,236.0,,34.96,1.0,1.64,experimental,27.3372861575,0.227494078702,0.178725536175,Human MST3 (STK24) kinase in complex with macrocyclic inhibitor JA310
5BVK,X-RAY DIFFRACTION,2.33,47.29,VAPOR DIFFUSION,,"15-25% (W/V) PEG3350, 0.2M NH4I",277.0,2015-06-05,2015-08-05,5BVK,2382.0,1.0,324.0,113.0,,37.46,1.0,2.29,experimental,38.299,0.2324,0.1873,Fragment-based discovery of potent and selective DDR1/2 inhibitors
5CMF,X-RAY DIFFRACTION,2.33,47.2,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291.0,2015-07-16,2016-07-20,5CMF,2250.0,1.0,284.0,118.0,,33.89,1.0,1.95,experimental,40.613,0.2513,0.2106,GTA mutant with mercury - E303A
5CMG,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291.0,2015-07-16,2016-07-20,5CMG,2260.0,1.0,294.0,126.0,,35.1,1.0,1.83,experimental,38.755,0.209,0.1774,GTA mutant with mercury- E303C
5CMH,X-RAY DIFFRACTION,2.27,45.85,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291.0,2015-07-16,2016-07-20,5CMH,2326.0,1.0,295.0,191.0,,35.24,1.0,1.61,experimental,26.131,0.2105,0.1868,GTA mutant with mercury - E303D
5CMJ,X-RAY DIFFRACTION,2.27,45.93,VAPOR DIFFUSION,,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291.0,2015-07-16,2016-07-20,5CMJ,2383.0,1.0,294.0,178.0,,35.33,1.0,1.73,experimental,29.968,0.2004,0.173,GTA mutant with mercury - E303Q
5CQL,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291.0,2015-07-22,2016-10-26,5CQL,2263.0,1.0,294.0,126.0,,35.23,1.0,1.69,experimental,31.987,0.2065,0.1744,GTB mutant with mercury - E303A
5CQM,X-RAY DIFFRACTION,2.28,46.02,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291.0,2015-07-22,2016-10-26,5CQM,2355.0,1.0,295.0,200.0,,35.39,1.0,1.65,experimental,27.155,0.2061,0.1728,GTB mutant with mercury - E303C
5CQO,X-RAY DIFFRACTION,2.29,46.3,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291.0,2015-07-21,2016-10-26,5CQO,2315.0,1.0,295.0,185.0,,35.2,1.0,1.69,experimental,28.229,0.208,0.1774,GTB mutant with mercury - E303D
5CQP,X-RAY DIFFRACTION,2.29,46.3,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291.0,2015-07-21,2016-10-26,5CQP,2319.0,1.0,295.0,150.0,,35.22,1.0,1.83,experimental,33.527,0.2174,0.1768,GTB mutant with mercury - E303Q
7YNX,X-RAY DIFFRACTION,2.58,52.35,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH7.5, 0.1 M NaCl, 1.6 M Ammonium Sulfate",291.0,2022-08-01,2023-04-26,7YNX,3185.0,2.0,406.0,155.0,,47.64,1.0,2.3,experimental,32.4996,0.2636,0.2157,Crystal structure of Pirh2 bound to poly-Ala peptide
6G0I,X-RAY DIFFRACTION,2.54,51.63,"VAPOR DIFFUSION, SITTING DROP",8.0,"28% w/v PEG 3350, 0.1 M TRIS-Cl, pH 8.0 RT, 1 M Lithium Chloride
Soaked in 18 mM ascorbate.",291.0,2018-03-18,2018-11-21,6G0I,2378.0,1.0,331.0,116.0,,37.96,1.0,2,experimental,37.569,0.23328,0.18763,Active Fe-PP1
6G0J,X-RAY DIFFRACTION,2.57,52.15,"VAPOR DIFFUSION, SITTING DROP",8.0,"28% w/v PEG 3350, 0.1 M TRIS-Cl,pH 8.0 RT, 1 M Lithium Chloride.",291.0,2018-03-18,2018-11-21,6G0J,2384.0,1.0,331.0,114.0,,37.96,1.0,2.1,experimental,36.462,0.2364,0.20107,Inactive Fe-PP1
5O2D,X-RAY DIFFRACTION,2.01,38.89,VAPOR DIFFUSION,,"0.8M sodium phosphate monobasic, 0.8M potassium phosphate dibasic, 0.1M HEPES pH 7.5",293.0,2017-05-20,2017-11-08,5O2D,1654.0,1.0,200.0,130.0,,21.93,1.0,1.6,experimental,17.851,0.17406,0.13003,PARP14 Macrodomain 2 with inhibitor
8BZI,X-RAY DIFFRACTION,2.58,52.27,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 11 mg/mL MST3 in 25 mM HEPES pH 7.5, 200 mM NaCl, 0.5 mM TCEP, 5% glycerol, with 1 mM inhibitor).
Crystallization buffer: 20% PEG 3350, 0.1 M bis-tris pH 6.5.",293.0,2022-12-14,2023-01-18,8BZI,2373.0,1.0,306.0,221.0,,35.2,1.0,1.72,experimental,37.2487699881,0.195790856793,0.15183354662,Human MST3 (STK24) kinase in complex with inhibitor MR39
8QLS,X-RAY DIFFRACTION,2.59,52.46,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 11 mg/mL MST3 in 25 mM HEPES pH 7.5, 200 mM NaCl, 0.5 mM TCEP, 5% glycerol) with 1 mM compound MR26.
Reservoir solution: 10% PEG 6000, 0.1 M HEPES pH 7.2",293.0,2023-09-20,2023-11-08,8QLS,2468.0,1.0,306.0,259.0,,35.8,1.0,1.61,experimental,35.62,0.1841,0.1494,Human MST3 (STK24) kinase in complex with inhibitor MR26
8QLT,X-RAY DIFFRACTION,2.16,42.93,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 11 mg/mL MST3 in 25 mM HEPES pH 7.5, 200 mM NaCl, 0.5 mM TCEP, 5% glycerol) with 1 mM compound MR30.
Reservoir solution: 24% PEG 3350, 0.1M citrate pH 5.2",293.0,2023-09-20,2023-11-08,8QLT,2444.0,1.0,306.0,260.0,,35.31,1.0,1.47,experimental,29.75,0.1764,0.1515,Human MST3 (STK24) kinase in complex with inhibitor MR30
7S9X,X-RAY DIFFRACTION,2.06,40.15,"VAPOR DIFFUSION, HANGING DROP",,"4.5 mg/mL CDK2 crystalized in 50 mM sodium/potassium phosphate, 50 mM HEPES, pH 7.5, 5% v/v PEG3350, soaked overnight in 1 mM WN378 in 50 mM phosphate, 50 mM HEPES Na, 10% v/v PEG3350",291.0,2021-09-21,2022-10-05,7S9X,2198.0,1.0,298.0,17.0,,34.35,1.0,1.69,experimental,43.4128,0.2623,0.2301,Crystal structure of CDK2 liganded with compound WN378
7SA0,X-RAY DIFFRACTION,2.08,40.88,"VAPOR DIFFUSION, HANGING DROP",,"4.5mg/mL CDK2 crystalized in 50mM Na/KPO4, pH6.9, 50mM Hepes Na, pH7.5, 5% v/v PEG3350 were soaked overnight with 2.5mM EF4195 in 50mM Hepes Na, pH7.5, 10% v/v PEG3350",291.0,2021-09-21,2022-10-05,7SA0,2395.0,1.0,298.0,95.0,,34.97,1.0,1.59,experimental,37.0855,0.2186,0.1947,Crystal structure of CDK2 liganded with compound EF4195
4OEW,X-RAY DIFFRACTION,2.61,52.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"19-20%(w/v)PEG 3350, 200mM MgSO4, 100mM Tris-HCl, pH 7.5, vapor diffusion, hanging drop, temperature 293K",293.0,2014-01-14,2015-04-01,4OEW,2390.0,1.0,347.0,48.0,,40.73,1.0,2.44,experimental,29.68,0.2586,0.2062,Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors
4OEX,X-RAY DIFFRACTION,2.6,52.76,"VAPOR DIFFUSION, HANGING DROP",7.5,"19-20%(w/v)PEG 3350, 200mM MgSO4, 100mM Tris-HCl, pH 7.5, vapor diffusion, hanging drop, temperature 293K",293.0,2014-01-14,2015-04-01,4OEX,2577.0,1.0,347.0,164.0,,40.6,1.0,2.14,experimental,39.59,0.2396,0.1912,Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors
8W4S,X-RAY DIFFRACTION,2.62,53.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris-HCl, 0.2 M MgSO4, 20% PEG 3350",293.0,2023-08-24,2023-11-22,8W4S,2418.0,1.0,347.0,88.0,,40.58,1.0,1.848,experimental,,0.2446,0.2086,Crystal structure of PDE5A in complex with CVT-313
8W4T,X-RAY DIFFRACTION,2.66,53.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris-HCl, 0.2 M MgSO4, 20% PEG 3350",293.0,2023-08-24,2023-11-22,8W4T,2413.0,1.0,347.0,57.0,,40.6,1.0,2.199,experimental,,0.2684,0.2202,Crystal structure of PDE5A in complex with a novel inhibitor
5EOP,X-RAY DIFFRACTION,1.9,35.41,VAPOR DIFFUSION,7.0,"Malic acid/NaOH pH 7.0 
PEG 3350",289.0,2015-11-10,2016-08-17,5EOP,1131.0,1.0,121.0,125.0,3.0,13.94,1.0,1.35,experimental,18.766,0.19155,0.1474,Crystal structure of human Angiogenin at 1.35 Angstroms resolution
8SU8,X-RAY DIFFRACTION,2.32,47.06,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% PEG 3350, 100 mM Tris, pH 8.5, 100 mM KCl",293.0,2023-05-11,2023-12-06,8SU8,3967.0,2.0,485.0,74.0,,56.82,2.0,2.01,experimental,46.73,0.2381,0.2043,Co-crystal structure of KRIT1 with a 1-hydroxy 2-naphthaldehyde derivative (6-(furan-2-yl)-2-hydroxy-1-naphthaldehyde).
8T09,X-RAY DIFFRACTION,2.42,49.07,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 100mM Tris, pH 8.5, 100 mM KCl",293.0,2023-05-31,2023-12-13,8T09,3929.0,2.0,485.0,55.0,,56.78,2.0,2.15,experimental,46.36,0.2472,0.2005,Co-crystal structure of KRIT1 with a 1-hydroxy 2-naphthaldehyde derivative (6-ethynyl-2-hydroxy-1-naphthaldehyde)
8T7V,X-RAY DIFFRACTION,2.34,47.41,VAPOR DIFFUSION,,"20% PEG 3350, 100mM Tris, pH 8.5, 100mM KCl",293.0,2023-06-21,2023-12-06,8T7V,3935.0,2.0,487.0,26.0,,57.05,2.0,2.25,experimental,50.75,0.2502,0.2021,Co-crystal structure of KRIT1 with a 1-hydroxy 2-naphthaldehyde derivative (6-(furan-2-yl)-2-hydroxy-1-naphthaldehyde)
5V0N,X-RAY DIFFRACTION,2.8,56.07,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M MgSO4, 0.1 M Na citrate (pH varied from 5.0 to 6.0) and 14 % to 20 % PEG4000",293.15,2017-02-28,2017-05-03,5V0N,9715.0,3.0,1323.0,685.0,9.0,149.76,1.0,2.155,experimental,,0.2023,0.1611,BACE1 in complex with inhibitor 5g
6DHC,X-RAY DIFFRACTION,2.84,56.75,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M MgSO4, 0.1 M Na citrate (pH varied from 5.0 to 6.0) and 16 % to 22 % PEG4000",298.0,2018-05-19,2018-07-25,6DHC,9364.0,3.0,1323.0,245.0,9.0,149.53,1.0,2.85,experimental,,0.2183,0.1717,X-ray structure of BACE1 in complex with a bicyclic isoxazoline carboxamide as the P3 ligand
6L59,X-RAY DIFFRACTION,3.46,64.46,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium citrate, pH 5.5, and 24% (v/v) PEG400",299.0,2019-10-22,2020-04-29,6L59,5235.0,2.0,699.0,200.0,,77.36,2.0,2.254,experimental,50.6838,0.2265,0.2003,"Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with CIT, Mg and ATP binding at allosteric site and Mg, ATP binding at active site."
5HVY,X-RAY DIFFRACTION,2.9,62.96,VAPOR DIFFUSION,,20% PEG 3350 and 0.20 M sodium formate,293.0,2016-01-28,2016-04-20,5HVY,5067.0,2.0,693.0,159.0,,81.41,2.0,2.39,experimental,,0.22,0.18,CDK8/CYCC IN COMPLEX WITH COMPOUND 20
8HLY,X-RAY DIFFRACTION,2.0,38.44,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M BIS-TRIS pH at 6.5, 28% (w/v) Polyethylene glycol monomethyl ether 2000",291.0,2022-12-01,2023-09-27,8HLY,2370.0,2.0,287.0,169.0,,32.37,2.0,2,experimental,,0.2026,0.1559,Crystal structure of SIRT3 in complex with H3K23la peptide
4U41,X-RAY DIFFRACTION,2.0,38.54,"VAPOR DIFFUSION, SITTING DROP",8.3,"0.2 M potassium citrate, pH 8.3, 20% PEG 3350",292.0,2014-07-23,2016-01-06,4U41,4890.0,2.0,664.0,225.0,,76.27,1.0,2.2,experimental,44.2669,0.2593,0.1998,MAP4K4 Bound to inhibitor compound 1
6LXY,X-RAY DIFFRACTION,2.45,49.73,VAPOR DIFFUSION,,Ammonium sulphate,293.0,2020-02-12,2020-11-25,6LXY,9133.0,4.0,1220.0,282.0,,138.79,1.0,2.19,experimental,43.27,0.231,0.201,IRAK4 in complex with inhibitor
4ZHX,X-RAY DIFFRACTION,2.72,54.75,"VAPOR DIFFUSION, HANGING DROP",6.2,"8 % PEG 3350, 0.1 M MgCl2, 1.0 % glucose, 0.001 % cocamidopropyl betaine, 0.1 M imidazole",277.0,2015-04-27,2016-03-09,4ZHX,14587.0,6.0,2342.0,137.0,,268.12,3.0,2.99,experimental,69.7,0.243,0.2252,Novel binding site for allosteric activation of AMPK
6RBI,X-RAY DIFFRACTION,3.98,69.13,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.8 M Potassium Phosphate-dibasic, 0.8 M Sodium Phosphate monobasic",277.0,2019-04-10,2020-05-13,6RBI,3841.0,1.0,481.0,126.0,,56.25,1.0,2.21,experimental,56.0494,0.201,0.1842,Crystal structure of KDM5B in complex with 5-(1H-tetrazol-5-yl)quinolin-8-ol
5D9L,X-RAY DIFFRACTION,2.03,39.52,VAPOR DIFFUSION,,"20% PEG3350, 0.2 M lithium citrate",291.0,2015-08-18,2015-09-02,5D9L,2602.0,1.0,323.0,165.0,,37.55,1.0,2.15,experimental,20.39,0.2241,0.1651,Rsk2 N-terminal Kinase in Complex with bis-phenol pyrazole
6H4L,X-RAY DIFFRACTION,4.42,72.2,"VAPOR DIFFUSION, HANGING DROP",6.5,"MES pH 6.5
2M RbBr",293.0,2018-07-21,2019-08-07,6H4L,965.0,1.0,103.0,195.0,1.0,11.72,1.0,1.6,experimental,,0.2212,0.208,Structure of Titin M4 trigonal form
6TYZ,X-RAY DIFFRACTION,2.07,40.53,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5, 20% (w/v) PEG4000",298.0,2019-08-09,2019-11-27,6TYZ,1896.0,2.0,247.0,176.0,,28.28,2.0,1.51076626452,experimental,32.4861613002,0.202557392373,0.177990078727,Structure of Ku80 von Willebrand domain complexed with APLF Ku Binding Motif
4Z8L,X-RAY DIFFRACTION,2.2,44.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6 M NaH2PO4, 0.4 M K2HPO4, 0.1 M Sodium Phosphate/Citrate buffer, pH 4.2",298.0,2015-04-09,2015-06-17,4Z8L,7828.0,6.0,1134.0,114.0,,130.49,3.0,2.6,experimental,,0.2277,0.1992,Crystal structure of DCAF1/SIV-MND VPX/MND SAMHD1 NTD ternary complex
5DCZ,X-RAY DIFFRACTION,2.44,49.51,"VAPOR DIFFUSION, HANGING DROP",8.2,Crystals were obtained by hanging drop vapor diffusion at 22 deg in droplets consisting of 0.2 uL protein and 0.2 uL of 1.4-1.6 M Na/KPO4 pH 8.2,295.0,2015-08-24,2016-09-07,5DCZ,1768.0,1.0,231.0,116.0,,26.62,1.0,2.23,experimental,41.163,0.20176,0.18021,Tankyrase 2 complexed with a selective inhibitor
5WZW,X-RAY DIFFRACTION,3.39,63.67,VAPOR DIFFUSION,,"2.2M Sodium chloride, 0.1M BIS-TRIS propane pH 7.0",277.0,2017-01-18,2018-01-24,5WZW,1198.0,1.0,123.0,163.0,7.0,14.89,1.0,1.95,experimental,19.838,0.2552,0.2042,Crystal structure of human secreted phospholipase A2 group IIE with LY311727
6EPR,X-RAY DIFFRACTION,4.13,70.21,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M ammonium sulfate, 0.1M Bis-Tris pH 5.5",277.0,2017-10-12,2018-10-31,6EPR,1194.0,1.0,130.0,81.0,,16.04,1.0,2.053,experimental,,0.2323,0.1962,The ATAD2 bromodomain in complex with compound UZH-DS15
6EPS,X-RAY DIFFRACTION,4.13,70.22,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M ammonium sulfate, 0.1M Bis-Tris pH 5.5",277.0,2017-10-12,2018-10-31,6EPS,1183.0,1.0,130.0,81.0,,15.91,1.0,2.081,experimental,,0.2743,0.2276,The ATAD2 bromodomain in complex with compound UZH-DQ41
6EPW,X-RAY DIFFRACTION,4.08,69.86,"VAPOR DIFFUSION, HANGING DROP",,"2M ammonium sulfate, 0.1M Bis-Tris pH 5.5",277.0,2017-10-12,2018-10-31,6EPW,1176.0,1.0,130.0,46.0,,16.28,1.0,1.924,experimental,,0.2429,0.2227,The ATAD2 bromodomain in complex with compound UZH-DU32
7RWE,X-RAY DIFFRACTION,2.08,40.89,"VAPOR DIFFUSION, HANGING DROP",,"4.5mg/mL CDK2 protein crystalized at 0.1M Hepes Na, pH7.5, 10%PEG3350 condition, then soaked with 10mM GPHR787 for 24 hours",291.0,2021-08-19,2022-08-24,7RWE,2128.0,1.0,298.0,66.0,,34.58,1.0,1.59,experimental,30.2519,0.2384,0.2164,Crystal structure of CDK2 liganded with compound GPHR787
7RXO,X-RAY DIFFRACTION,2.08,40.82,"VAPOR DIFFUSION, HANGING DROP",,"4.5mg/mL of CDK2 protein crystalized in 50mM sodium/potassium phosphate, 50mM Hepes Na, pH 7.5, 7.5%PEG3350, then soak in 1mM WN333 for 48hours at 0.1M Hepes Na, pH7.5, 15%PEG3350",291.0,2021-08-23,2022-08-31,7RXO,2209.0,1.0,298.0,70.0,,34.38,1.0,1.38,experimental,31.0359,0.2332,0.2203,Crystal structure of CDK2 liganded with compound WN333
7S4T,X-RAY DIFFRACTION,1.95,36.78,"VAPOR DIFFUSION, HANGING DROP",,"4.5mg/mL CDK2,1mM EF2252 soaking 48hours at 0.1M Hepes Na, pH7.5, 10%(v/v)PEG3350",291.0,2021-09-09,2022-09-21,7S4T,2491.0,1.0,298.0,144.0,,34.4,1.0,1.91,experimental,19.3452,0.2185,0.1744,Crystal structure of CDK2 liganded with compound EF2252
7S7A,X-RAY DIFFRACTION,2.08,40.8,"VAPOR DIFFUSION, HANGING DROP",,"4.5mg/mL CDK2 protein crystalized under 25mM Na/K phosphate, 25mM Hepes Na, pH 7.5, 5% v/v PEG3350 was soaked overnight with 5mM EF3109 in 50mM Hepes Na, pH 7.5, 10% v/v PEG3350",291.0,2021-09-15,2022-09-28,7S7A,2351.0,1.0,298.0,115.0,,34.51,1.0,1.7,experimental,36.0614,0.2383,0.2058,Crystal structure of CDK2 liganded with compound EF3019
7S85,X-RAY DIFFRACTION,2.02,39.07,"VAPOR DIFFUSION, HANGING DROP",,"4.5 mg/mL CDK2 protein crystalized in 50 mM sodium/potassium phosphate, 50 mM HEPES, pH 7.5, 5% v/v PEG3350, soaked overnight in 5 mM WN316 in  50 mM HEPES Na, 10% v/v PEG3350",291.0,2021-09-17,2022-09-28,7S85,2298.0,1.0,298.0,37.0,,34.46,1.0,1.98,experimental,35.2093,0.2516,0.2032,Crystal structure of CDK2 liganded with compound WN316
7R3L,X-RAY DIFFRACTION,2.79,55.97,"VAPOR DIFFUSION, HANGING DROP",,". 0.17 M ammonium sulphate, 15% (v/v) glycerol, 27% (v/v) PEG 4000",295.0,2022-02-07,2023-01-25,7R3L,2869.0,2.0,386.0,145.0,2.0,44.88,1.0,2,experimental,23.308,0.2372,0.2025,PARP14 catalytic domain in complex with OUL40
5M8S,X-RAY DIFFRACTION,3.03,59.39,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290.0,2016-10-29,2018-01-31,5M8S,15622.0,4.0,1784.0,722.0,28.0,212.93,1.0,2.2,experimental,44.2635,0.2349,0.1936,Crystal structure of human tyrosinase related protein 1 mutant (T391V-R374S-Y362F) in complex with phenylthiourea (PTU)
5AJA,X-RAY DIFFRACTION,3.04,60.0,,,"0.16 M TRISODIUM CITRATE-HCL PH 5.2, 4% PEG 6000",,2015-02-20,2015-04-22,5AJA,3801.0,3.0,580.0,3.0,,65.99,3.0,2.649,experimental,87.6,0.227,0.1735,Crystal structure of mandrill SAMHD1 (amino acid residues 1-114) bound to Vpx isolated from mandrill and human DCAF1 (amino acid residues 1058-1396)
6YG1,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"27% PEG3350, 0.2 M potassium thiocyanate, 10% ethylene glycol, 0.1 M bis-tris propane, pH 7.5",277.15,2020-03-27,2020-08-12,6YG1,7697.0,3.0,1044.0,257.0,,120.41,1.0,2.22,experimental,63.77,0.2317,0.2037,"Crystal structure of MKK7 (MAP2K7) in an active state, allosterically triggered by the N-terminal helix"
4XCX,X-RAY DIFFRACTION,5.21,76.38,"VAPOR DIFFUSION, SITTING DROP",8.6,"2.4 M NACL, 0.1 M TRIS-HCL, PH 8.6,4% 1,3-PROPANEDIOL",293.0,2014-12-18,2015-01-14,4XCX,1733.0,1.0,249.0,17.0,,28.73,1.0,2.84,experimental,93.03,0.2491,0.2251,METHYLTRANSFERASE DOMAIN OF SMALL RNA 2'-O-METHYLTRANSFERASE
6H1E,X-RAY DIFFRACTION,2.32,46.97,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5,  
1.1-1.3 M Sodium Citrate",293.0,2018-07-11,2019-05-22,6H1E,2608.0,3.0,355.0,74.0,,39.11,3.0,1.9,experimental,35.97,0.2445,0.1959,Crystal structure of C21orf127-TRMT112 in complex with SAH and H4 peptide
5U6B,X-RAY DIFFRACTION,2.41,48.96,"VAPOR DIFFUSION, SITTING DROP",,"1.2 microL of the protein-ligand complex (1:3 ratio of protein:ligand) and 1.2 microL of the reservoir solution (0.1 M Tris, pH 8.5, 0.2 M MgCl2, 30 % (w/v) PEG-4000, 1-2 % (v/v) 1-butanol).",294.0,2016-12-07,2017-07-26,5U6B,9046.0,4.0,1228.0,,,141.32,1.0,2.84,experimental,56.98,0.239,0.211,Structure of the Axl kinase domain in complex with a macrocyclic inhibitor
5JNR,X-RAY DIFFRACTION,2.4,48.69,EVAPORATION,5.5,"7% PEG 10K, Bis Tris, Ammonium Acetate",293.0,2016-04-30,2017-03-29,5JNR,1462.0,1.0,160.0,157.0,,18.21,1.0,2,experimental,25.942,0.2136,0.1634,Crystal structure of human low molecular weight protein tyrosine phosphatase (LMPTP) type A
6Y2W,X-RAY DIFFRACTION,2.06,40.28,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2M Sodium acetate trihydrate, 0.1M Bis-Tris, 25% PEG3350, pH 6.5",277.0,2020-02-17,2020-07-22,6Y2W,1418.0,1.0,157.0,138.0,,17.95,1.0,1.77,experimental,33.93,0.1965,0.1634,Crystal structure of the single mutant I16K of Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP)
6QBG,X-RAY DIFFRACTION,2.99,58.91,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350
0.2 M lithium sulphate 
0.1 M Bis-Tris pH 5.5",291.15,2018-12-21,2020-01-29,6QBG,3002.0,2.0,339.0,252.0,4.0,39.12,2.0,1.8,experimental,29.169,0.247,0.1941,Crystal structure of human cathepsin D in complex with macrocyclic inhibitor 14
6QBH,X-RAY DIFFRACTION,3.0,58.94,"VAPOR DIFFUSION, HANGING DROP",,"25 % PEG 3350
0.2 M lithium sulphate
0.1 M Bis-Tris Ph 5.5",291.15,2018-12-21,2020-01-29,6QBH,2965.0,2.0,338.0,250.0,4.0,38.38,2.0,1.85,experimental,20.035,0.2072,0.1753,Crystal structure of human cathepsin D in complex with macrocyclic inhibitor 33
6W9A,X-RAY DIFFRACTION,3.06,59.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 3350,
100 mM Na/K phosphate,
100 mM bis-Tris propane",289.0,2020-03-22,2020-05-20,6W9A,3596.0,4.0,550.0,28.0,,61.87,2.0,2.3,experimental,62.9466,0.2186,0.18,RNF12 RING domain in complex with Ube2e2
4ZYF,X-RAY DIFFRACTION,2.17,43.22,"VAPOR DIFFUSION, HANGING DROP",4.5,"reservoir: 2M AmSulfate, 0.1M cictric acid, pH4.5, protein: 7mg/ml Hdm2 in 50mM TRIS pH8.0, 200mM NaCl, 1mM TCEP, 10% glycerol, drop: 1ul reservoir + 1ul protein",298.0,2015-05-21,2015-07-29,4ZYF,883.0,1.0,96.0,65.0,,11.85,1.0,1.8,experimental,24.274,0.2321,0.2267,Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with NVP-CGM097
4ZYI,X-RAY DIFFRACTION,2.16,43.0,"VAPOR DIFFUSION, HANGING DROP",4.7,"reservoir: 2.2M AmmoniumSulfate, 0.1M cictric acid, pH4.7. protein: 7mg/ml Hdm2 in 50mM TRIS pH8.0, 200mM NaCl, 1mM TCEP, 10% glycerol. drop: 1ul reservoir + 1ul protein",298.0,2015-05-21,2015-07-29,4ZYI,846.0,1.0,96.0,62.0,,11.75,1.0,1.67,experimental,27.286,0.2467,0.239,Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with cpd2
5BS0,X-RAY DIFFRACTION,2.5,50.72,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.2M Ammonium Chloride, 0.1M MES, 20% PEG 4000",291.0,2015-06-01,2016-03-02,5BS0,6635.0,5.0,822.0,10.0,8.0,94.37,5.0,2.4,experimental,56.084,0.2621,0.203,MAGE-A3 Reactive TCR in complex with Titin Epitope in HLA-A1
4U3Z,X-RAY DIFFRACTION,1.97,37.54,"VAPOR DIFFUSION, SITTING DROP",8.3,"0.2 M potassium citrate, pH 8.3, 20% PEG 3350",292.0,2014-07-23,2016-01-06,4U3Z,5145.0,2.0,664.0,411.0,,76.21,1.0,2.09,experimental,36.1921,0.249,0.1826,APO MAP4K4 T181E Phosphomimetic Mutant
6QTG,X-RAY DIFFRACTION,2.69,54.33,"VAPOR DIFFUSION, SITTING DROP",,"32-38% Morpheus Precipitant Mix 4
10 mmol/L Morpheus Buffer System 1
100 mM Morpheus Amino Acids Mix 2% DMSO",278.0,2019-02-25,2020-03-18,6QTG,5144.0,2.0,690.0,201.0,,80.67,2.0,2.7,experimental,56.98,0.231,0.201,Crystal structure of human CDK8/CYCC in complex with BI-1347
6QTJ,X-RAY DIFFRACTION,2.72,54.7,"VAPOR DIFFUSION, SITTING DROP",,"32-38% Morpheus Precipitant Mix 4
10 mmol/L Morpheus Buffer System 1  100 mM Morpheus Amino Acids Mix 
2% DMSO",278.0,2019-02-25,2020-03-18,6QTJ,5207.0,2.0,690.0,253.0,,80.67,2.0,2.48,experimental,54.23,0.22,0.185,Crystal structure of human CDK8/CYCC in complex with BI 919811
5T0K,X-RAY DIFFRACTION,2.33,47.26,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Bis-Tris propane (pH 7.5), 18% (w/v) PEG3350, 0.2 M NaF, and 5% (v/v) ethylene glycol",293.15,2016-08-16,2016-10-05,5T0K,5182.0,4.0,592.0,688.0,2.0,69.38,2.0,1.7,experimental,,0.1928,0.165,Structure of G9a SET-domain with H3K9M mutant peptide and SAM
7Q46,X-RAY DIFFRACTION,2.61,52.96,"VAPOR DIFFUSION, HANGING DROP",8.0,"hanging drop
20% PEG 3350
0.18M tris amonium citrate",293.15,2021-10-29,2022-11-16,7Q46,8894.0,6.0,1260.0,461.0,,133.86,2.0,2.46002538066,experimental,36.7000727827,0.245337109543,0.178644261638,Crystal structure of RCC1-Like domain 2 of ubiquitin ligase HERC2 in complex with DXDKDED motif of pericentriolar material 1 protein
6OCH,X-RAY DIFFRACTION,3.2,61.53,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium sulfate, 0.1 M Bis-tris, pH 5.5, and 25 % (w/v) PEG 3350",293.15,2019-03-23,2019-06-26,6OCH,5112.0,4.0,540.0,561.0,,64.09,2.0,2.003,experimental,34.0636,0.2293,0.1798,Crystal structure of VASH1-SVBP complex bound with parthenolide
5XQX,X-RAY DIFFRACTION,3.06,59.81,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.05M MgCl, 0.1M MES pH 6.5, 10% Iso-propanol, 5% PEG4K",293.0,2017-06-07,2017-08-09,5XQX,5214.0,2.0,643.0,178.0,,75.87,2.0,2.3,experimental,36.317,0.22186,0.1878,Human CDK8-CYCC in complex with compound 4: N-methyl-4-(4-pyridyl)-1H-pyrrole-2-carboxamide
5VVX,X-RAY DIFFRACTION,2.74,55.16,EVAPORATION,,"0.024 M ammonium citrate tribasic (pH 7.0), 0.015 M MES monohydrate, 0.096 M potassium thiocyanate, 0.25 M Sodium acetate trihydrate, 0.037 M imidazole, 0.002 M zinc sulfate heptahydrate, 9.6 % w/v polyethylene glycol 3,350, 2.4 % w/v polyethylene glycol monomethyl ether 2,000, and 4% w/v polyethylene glycol monomethyl ether 550",293.0,2017-05-21,2017-09-27,5VVX,7104.0,4.0,1034.0,13.0,,118.78,2.0,2.9,experimental,88.838,0.28221,0.19988,Structural Investigations of the Substrate Specificity of Human O-GlcNAcase
5TC0,X-RAY DIFFRACTION,2.2,44.03,"VAPOR DIFFUSION, HANGING DROP",8.5,"29% PEG 400, 0.2M MgCl2, 0,1M Tris pH 8.5",293.0,2016-09-13,2017-01-25,5TC0,4002.0,2.0,628.0,34.0,,72.42,1.0,2.24,experimental,56.147,0.2624,0.2275,Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate
5TD2,X-RAY DIFFRACTION,2.46,50.03,"VAPOR DIFFUSION, HANGING DROP",8.5,"29% PEG 400
0.2M MgCl2
0.1M Tris pH 8.5",293.0,2016-09-16,2017-01-25,5TD2,3953.0,2.0,570.0,24.0,,66.16,1.0,2.68,experimental,64.709,0.2999,0.2481,Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate
7CQE,X-RAY DIFFRACTION,2.42,49.19,VAPOR DIFFUSION,,"Protein 40mg/mL in 20mM Tris-Cl, pH 8.0, 500mM sodium chloride, 2mM DTT. inhibitor (5 mM final concentration) overnight, Mixed 1:1 with crystallization solution (100mM Tris-Cl, pH 8.5, 4M sodium chloride)",287.0,2020-08-10,2020-11-04,7CQE,4024.0,2.0,588.0,20.0,,68.65,1.0,2.69,experimental,38.415,0.2593,0.1968,Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with AZD-7762
7SUG,X-RAY DIFFRACTION,2.51,50.93,"VAPOR DIFFUSION, SITTING DROP",6.5,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2021-11-17,2022-01-12,7SUG,2416.0,1.0,297.0,235.0,,34.72,1.0,1.48,experimental,22.392,0.2538,0.2168,Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 09
5HES,X-RAY DIFFRACTION,3.08,60.08,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM bis-tris-propane pH 6.5, 200 mM sodium malonate, 20% PEG3350, 10% ethylene glycol",277.0,2016-01-06,2016-03-30,5HES,4782.0,2.0,614.0,179.0,,71.57,1.0,2.14,experimental,,0.226,0.18,"Human leucine zipper- and sterile alpha motif-containing kinase (ZAK, MLT, HCCS-4, MRK, AZK, MLTK) in complex with vemurafenib"
6HIE,X-RAY DIFFRACTION,4.13,70.24,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5",277.0,2018-08-29,2019-02-20,6HIE,1183.0,1.0,130.0,82.0,,15.95,1.0,2.05,experimental,,0.2387,0.2017,The ATAD2 bromodomain in complex with compound 17
6GH9,X-RAY DIFFRACTION,2.22,44.61,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M Hepes pH 7.0, 14% MPD",293.15,2018-05-06,2018-09-26,6GH9,5319.0,2.0,730.0,153.0,,84.08,1.0,2.09,experimental,59.0276,0.2517,0.2028,USP15 catalytic domain in complex with small molecule
5W7I,X-RAY DIFFRACTION,2.59,52.58,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Tris-HCl pH 7.5, 12.5% PEG-6000",277.0,2017-06-20,2017-08-09,5W7I,3878.0,4.0,498.0,175.0,,55.38,2.0,2.105,experimental,,0.2222,0.1759,X-ray structure of ankyrin repeat domain of DHHC17 in complex with Snap25b peptide
7XHF,X-RAY DIFFRACTION,2.55,51.85,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Sodium citrate tribasic dihydrate pH 5.0; 19 % w/v Polyethylene glycol 3,350",289.15,2022-04-08,2023-01-18,7XHF,2271.0,4.0,310.0,,,35.7,2.0,2.68,experimental,54.434,0.2543,0.2103,Crystal structure of the NTF2L domain of human G3BP1 in complex with the USP10 derived peptide
5LY2,X-RAY DIFFRACTION,2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",9.0,0.1 M bicine pH 9.0 and 10% w/v polyethylene glycol 6000,277.0,2016-09-23,2017-04-12,5LY2,12172.0,8.0,1580.0,503.0,,186.74,2.0,2.43,experimental,43.0,0.245,0.219,"JMJD2A/ KDM4A COMPLEXED WITH NI(II), NOG AND Macrocyclic PEPTIDE Inhibitor CP2_R6Kme3 (13-mer)"
6CBY,X-RAY DIFFRACTION,2.21,44.41,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 0.2 M NH4SO4",291.0,2018-02-05,2018-03-14,6CBY,6540.0,2.0,868.0,52.0,,101.17,1.0,2.55,experimental,52.24,0.258,0.199,Crystal structure of human SET and MYND Domain Containing protein 2 with MTF9975
7E58,X-RAY DIFFRACTION,3.46,64.46,MICROBATCH,,"2-propanol, sodium citrate, tribasic dihydrate pH 5.0, polyethylene glycol 10,000",289.15,2021-02-18,2021-05-05,7E58,8875.0,2.0,1182.0,37.0,,134.65,1.0,2.6,experimental,79.2679,0.2715,0.2546,interferon-inducible anti-viral protein 2
8UQ8,X-RAY DIFFRACTION,3.89,68.41,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystals were obtained by mixing 2 microliters of the protein fusion (9.5 mg/mL) in 10 mM HEPES, pH 7.5, 600 mM NaCl, 1 mM TCEP and 2 microliters of the reservoir solution containing 0.1 M HEPES, pH 7.5, 2.4 M NaCl",288.0,2023-10-23,2024-01-17,8UQ8,6965.0,2.0,874.0,192.0,,99.2,1.0,2.34,experimental,,0.2357,0.1959,Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 2-residue linker
8UQ9,X-RAY DIFFRACTION,3.93,68.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystals were obtained by mixing 2 microliters of the protein fusion (8.8 mg/mL) in 10 mM HEPES, pH 7.5, 600 mM NaCl, 1 mM TCEP and 2 microliters of the reservoir solution containing 0.1 M HEPES, pH 7.5, 2.4 M NaCl",288.0,2023-10-23,2024-01-17,8UQ9,7314.0,2.0,878.0,479.0,,100.03,1.0,2.3,experimental,,0.2056,0.1833,Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 4-residue linker
6BT1,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",8.5,"3', 5' Adenosine Diphosphate, Magnesium Chloride, Tris, Sodium Citrate, PEG 4000",294.0,2017-12-04,2018-05-16,6BT1,2613.0,1.0,313.0,263.0,,35.73,1.0,1.48,experimental,,0.1865,0.1511,Structure of the human Nocturnin catalytic domain
5U5R,X-RAY DIFFRACTION,2.95,58.36,"VAPOR DIFFUSION, HANGING DROP",,"0.600-0.625 M sodium citrate (pH 6) and 
10 mM DTT",291.0,2016-12-07,2018-03-14,5U5R,3646.0,2.0,521.0,332.0,,56.87,2.0,2.1,experimental,,0.207,0.1739,Crystal Structure and X-ray Diffraction Data Collection of Importin-alpha from Mus musculus Complexed with a PMS2 NLS Peptide
7V29,X-RAY DIFFRACTION,2.18,43.46,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M Bis-Tris (pH 4.5), 0.2 M Li2SO4, 20% PEG 3350",277.15,2021-08-07,2022-03-30,7V29,5107.0,2.0,622.0,421.0,,71.13,1.0,1.983,experimental,27.8686,0.241,0.1914,Crystal structure of FGFR4 with a dual-warhead covalent inhhibitor
6OBS,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% PEG6000, 1 M lithium chloride, 0.1 M MES, pH 6.0",289.0,2019-03-21,2019-09-18,6OBS,5191.0,2.0,598.0,505.0,,68.76,1.0,1.803,experimental,,0.2461,0.2042,PP1 Y134K
7AHZ,X-RAY DIFFRACTION,2.59,52.56,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M HEPES, 10 % w/v PEG 20000",292.0,2020-09-25,2021-01-20,7AHZ,9168.0,12.0,1196.0,356.0,,135.29,3.0,1.82,experimental,48.798,0.2305,0.1949,Crystal structure of Western clawed frog MDM2 RING domain homodimer bound to UbcH5B-Ub
6QN4,X-RAY DIFFRACTION,2.54,51.64,"VAPOR DIFFUSION, SITTING DROP",,"16% PEG 4000, 0.1 M Tris pH 8.5, 0.2 M sodium acetate",292.15,2019-02-08,2019-08-28,6QN4,2330.0,1.0,313.0,34.0,,36.85,1.0,2.5,experimental,,0.2661,0.2149,Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289E and S308E mutations
6L57,X-RAY DIFFRACTION,3.0,58.97,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium citrate, pH 8.0, and 20% (w/v) PEG3350, 2 mM ATP",299.0,2019-10-22,2020-04-29,6L57,5171.0,2.0,699.0,125.0,,76.85,2.0,2.302,experimental,56.9366,0.2338,0.1968,"Crystal structure of the alpha gamma heterodimer of human IDH3 in complex with CIT , Mg and ATP binding at allosteric site."
8Q6E,X-RAY DIFFRACTION,1.88,34.65,"VAPOR DIFFUSION, SITTING DROP",,"(10-35%) PEG 4K, 0.2 M ammonium acetate , 0.1 M sodium ammonium acetate trihydrate pH (4.1-5.6)",298.0,2023-08-11,2024-08-21,8Q6E,2161.0,2.0,253.0,246.0,,28.69,2.0,1.37,experimental,,0.2053,0.1797,"Aerobic crystal structure of HIF prolyl hydroxylase 2 (PHD2 181-407) in complex with Fe(III), 2-oxoglutarate (2OG) and HIF2alpha-CODD peptide"
8HLJ,X-RAY DIFFRACTION,2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG-3350, 0.1 M Tris-HCl pH 8.5",296.5,2022-11-30,2024-05-01,8HLJ,5819.0,2.0,706.0,183.0,,80.8,1.0,2.24,experimental,42.21,0.2467,0.1999,Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Olaparib (AZD2281)
8V42,X-RAY DIFFRACTION,2.56,52.04,"VAPOR DIFFUSION, SITTING DROP",7.0,"22% PEG3350, 20 mM Li2SO4, 0.1 M Buffer system SBG pH 7.0",293.0,2023-11-28,2024-09-04,8V42,9908.0,4.0,1456.0,142.0,,165.9,1.0,2.3,experimental,53.97,0.231,0.199,Structure of Human Vaccinia-related Kinase 1 (VRK1) Bound to ACH000400
6Z7V,X-RAY DIFFRACTION,2.84,56.74,"VAPOR DIFFUSION, HANGING DROP",,"50 mM potassium phosphate monobasic, 14% PEG 8000",293.15,2020-06-01,2021-06-09,6Z7V,8000.0,9.0,1078.0,38.0,,123.11,2.0,2.65,experimental,69.59,0.2543,0.2127,Crystal structure of Mindy2 (C266A) in complex with Lys48 linked di-ubiquitin (K48-Ub2)
8TVM,X-RAY DIFFRACTION,2.6,52.69,"VAPOR DIFFUSION, SITTING DROP",,Sodium Malonate,293.0,2023-08-18,2024-06-26,8TVM,9274.0,4.0,1228.0,275.0,,140.5,1.0,2.1,experimental,62.98,0.2465,0.2212,IRAK4 in complex with compound 24
8TVN,X-RAY DIFFRACTION,2.39,48.49,"VAPOR DIFFUSION, SITTING DROP",,Sodium Malonate,293.0,2023-08-18,2024-06-26,8TVN,9437.0,4.0,1228.0,445.0,,140.5,1.0,1.95,experimental,57.9,0.2425,0.2061,IRAK4 in complex with compound 23
8E23,X-RAY DIFFRACTION,3.15,60.97,"VAPOR DIFFUSION, HANGING DROP",7.5,18.5 % PEG 3350; 0.2M diammonium tartrate,291.0,2022-08-13,2022-09-28,8E23,10562.0,6.0,1396.0,91.0,,170.08,1.0,2.59,experimental,104.1841,0.2947,0.2468,Human DNA polymerase theta in complex with allosteric inhibitor
5W7J,X-RAY DIFFRACTION,2.57,52.21,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Glycine pH 9.0, 18.5% PEG-4000",277.0,2017-06-20,2017-08-09,5W7J,3811.0,4.0,498.0,97.0,,55.26,2.0,2.202,experimental,,0.2111,0.1701,X-ray structure of the E89A variant of ankyrin repeat domain of DHHC17 in complex with Snap25b peptide
6CPF,X-RAY DIFFRACTION,2.78,55.74,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystals were obtained by mixing 570 uM  Aurora A (18 mg/mL) in buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 20 mM MgCl2, 1 mM TCEP) in a 2:1 ratio with mother liquor (0.2 M Tris-HCl, pH 7.5, 0.2 M ammonium sulfate, 30% (w/v) PEG-3350).",291.15,2018-03-13,2018-06-27,6CPF,2093.0,1.0,285.0,6.0,,33.52,1.0,2.3,experimental,69.63,0.2587,0.2179,Structure of dephosphorylated Aurora A (122-403) bound to AMPPCP in an active conformation
6SH6,X-RAY DIFFRACTION,2.43,49.3,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.02 M 1,6-hexanediol, 0.02 M 1-butanol, 0.02 M (RS)-1,2-propanediol, 0.02 M 2-propanol, 0.02 M 1,4-butanediol, 0.02 M 1,3-propanediol, 0.1 M MES/imidazole pH 6.5, 10% w/v PEG 8000, 20% v/v ethylene glycol",291.15,2019-08-05,2020-04-22,6SH6,6159.0,2.0,756.0,299.0,,87.0,2.0,1.85,experimental,52.24,0.2443,0.2035,Crystal structure of the human DEAH-helicase DHX15 in complex with the NKRF G-patch bound to ADP
6EKN,X-RAY DIFFRACTION,2.16,43.15,"VAPOR DIFFUSION, SITTING DROP",10.0,"Protein: 1 micro-L MMP12 at 290 micro-M with 10 milli-M acetohydroxamate  + 0.1 Micro-L BE6 from 10 milii-M in 100% DMSO
Precipitant: 17% PEG 20K, 250 milli-M NaCl, 100 milii-M TRIS HCl, pH 10.0.
cryoprotectant: 40% (25 % di-ethylene glycol + 25 % glycerol + 25 % 1,2-propanediol) 10 % PEG 10K, 200 milli-M NaCl, 100 milli-M AAB (Na acetate,N-(2-Acetamido)iminodiacetic acid (ADA), Bicine)  10% acid/90% basic",293.0,2017-09-26,2018-05-16,6EKN,1548.0,1.0,159.0,151.0,,18.38,1.0,1.2,experimental,20.711,0.17523,0.1442,Crystal structure of MMP12 in complex with inhibitor BE7.
5CMI,X-RAY DIFFRACTION,2.24,45.07,"VAPOR DIFFUSION, HANGING DROP",,"30-40 mg/ml protein, 1% PEG (w/v) 4000, 4.5% MPD (v/v), 0.1 M ammonium sulfate, 0.07 M NaCl, 0.05 M ADA buffer, pH 7.5, 5 mM MnCl2 against a reservoir containing 2.7% (w/v) PEG 4000, 7% (v/v) MPD, 0.32 M ammonium sulfate, 0.25 M NaCl, and 0.2 M ADA pH 7.5",291.0,2015-07-16,2016-07-20,5CMI,2499.0,1.0,294.0,216.0,,34.31,1.0,1.85,experimental,29.97,0.2332,0.1809,GTA mutant without mercury - E303D
5CQN,X-RAY DIFFRACTION,2.25,45.29,"VAPOR DIFFUSION, HANGING DROP",,"30-40 mg/ml protein, 1% PEG (w/v) 4000, 4.5% MPD (v/v), 0.1 M ammonium sulfate, 0.07 M NaCl, 0.05 M ADA buffer, pH 7.5, 5 mM MnCl2 against a reservoir containing 2.7% (w/v) PEG 4000, 7% (v/v) MPD, 0.32 M ammonium sulfate, 0.25 M NaCl, and 0.2 M ADA pH 7.5",291.0,2015-07-22,2016-10-26,5CQN,2435.0,1.0,294.0,190.0,,34.26,1.0,1.61,experimental,25.467,0.2065,0.1839,GTB mutant without mercury - E303C
6Q8K,X-RAY DIFFRACTION,2.4,48.76,"VAPOR DIFFUSION, SITTING DROP",9.0,255 PEG 6000. 0.1 M bicine pH 9.0,277.0,2018-12-14,2019-02-20,6Q8K,2916.0,1.0,339.0,129.0,,39.98,1.0,2.29,experimental,35.14,0.25916,0.18779,CLK1 with bound pyridoquinazoline
6CJF,X-RAY DIFFRACTION,2.01,38.75,"VAPOR DIFFUSION, SITTING DROP",,"1.72 M ammonium sulfate, 1.4 M sodium chloride, 0.1 M sodium acetate pH 5.3, 10 mM DTT",293.0,2018-02-26,2018-05-23,6CJF,5849.0,2.0,748.0,365.0,,84.47,1.0,1.63,experimental,,0.1888,0.1632,Human dihydroorotate dehydrogenase bound to 4-quinoline carboxylic acid inhibitor 43
6VND,X-RAY DIFFRACTION,3.51,64.99,"VAPOR DIFFUSION, SITTING DROP",4.8,"2.5 M ammonium sulfate, 30% glycerol, 0.1 M sodium acetate, pH 4.8",293.0,2020-01-29,2020-11-04,6VND,3256.0,1.0,368.0,228.0,,42.54,1.0,1.97,experimental,37.39,0.1901,0.1554,"Quaternary Complex of human dihydroorotate dehydrogenase (DHODH) with flavin mononucleotide (FMN), orotic acid and AG-636"
7AVZ,X-RAY DIFFRACTION,2.25,45.41,VAPOR DIFFUSION,8.5,"4.0-4.5 M sodium chloride, 0.1 M Tris pH 8.5: 16 h soak with 20 % DMSO and 20 mM compound",293.0,2020-11-06,2021-03-03,7AVZ,2214.0,1.0,298.0,67.0,,34.86,1.0,2.04,experimental,60.3,0.229,0.206,MerTK kinase domain in complex with a bisaminopyrimidine inhibitor
7AW0,X-RAY DIFFRACTION,2.23,44.96,VAPOR DIFFUSION,8.5,"4.0-4.5 M sodium chloride, 0.1 M Tris pH 8.5: 16 h soak with 20 % DMSO and 20 mM compound",293.0,2020-11-06,2021-03-03,7AW0,2232.0,1.0,298.0,84.0,,34.74,1.0,1.893,experimental,51.53,0.233,0.202,MerTK kinase domain in complex with purine inhibitor
7AW1,X-RAY DIFFRACTION,2.33,47.23,VAPOR DIFFUSION,8.5,"4.0-4.5 M sodium chloride, 0.1 M Tris pH 8.5: 32 h soak with 20 % DMSO and 20 mM compound",293.0,2020-11-06,2021-03-03,7AW1,2229.0,1.0,298.0,80.0,,34.97,1.0,1.98,experimental,61.47,0.225,0.202,MerTK kinase domain in complex with a type 2 inhibitor
6GZS,X-RAY DIFFRACTION,2.2,44.14,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES (pH 6.0), 20% PEG 6000",291.0,2018-07-05,2018-11-14,6GZS,2714.0,2.0,348.0,184.0,,40.07,2.0,1.9,experimental,,0.2132,0.1811,Structure of Chlamydia trachomatis effector protein ChlaDUB1 bound to ubiquitin
7D36,X-RAY DIFFRACTION,2.78,55.79,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium citrate tribasic pH 6.5, 0.2 M ammonium iodide, 18.6% w/v PEG 5000MME",293.0,2020-09-18,2021-07-28,7D36,3128.0,1.0,416.0,172.0,3.0,47.61,1.0,2.3,experimental,44.425,0.2652,0.2129,"Crystal Structure of BACE1 in complex with N-{3-[(3S)-1-amino-5-fluoro-3-methyl-3,4-dihydro-2,6-naphthyridin-3-yl]-4-fluorophenyl}-5-cyano-3-methylpyridine-2-carboxamide"
6IN3,X-RAY DIFFRACTION,4.39,72.01,"VAPOR DIFFUSION, HANGING DROP",,"1.8 M ammonium sulfate, 22 mM acetic acid, 78 mM sodium acetate",293.0,2018-10-24,2019-10-30,6IN3,2753.0,1.0,336.0,103.0,,40.18,1.0,2.3,experimental,,0.2134,0.1869,Crystal structure of DOT1L in complex with 18-Crown-6
7X3P,X-RAY DIFFRACTION,2.47,50.27,"VAPOR DIFFUSION, HANGING DROP",,"23%-27% (v/v) PEG 3350, 0.1 M MES, pH 5.5-6.0, 0.1-0.2 M NaCl",289.0,2022-03-01,2023-09-06,7X3P,2543.0,1.0,277.0,393.0,,31.03,1.0,1.56,experimental,15.2122,0.1634,0.1388,Crystal structure of human SIRT5 in complex with diazirine inhibitor 9
6SH7,X-RAY DIFFRACTION,2.43,49.37,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M carboxylic acids, 0.1 M BICINE/Tris pH 8.5, 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD",291.15,2019-08-05,2020-04-22,6SH7,5745.0,2.0,756.0,34.0,,86.49,2.0,2.21,experimental,79.88,0.2508,0.209,Crystal structure of the human DEAH-helicase DHX15 in complex with the NKRF G-patch
5DSY,X-RAY DIFFRACTION,2.63,53.28,"VAPOR DIFFUSION, SITTING DROP",8.0,2.55-2.65 M NaCl and 0.1 M Tris,298.0,2015-09-17,2016-07-27,5DSY,8087.0,4.0,1120.0,51.0,,128.85,1.0,2.7,experimental,,0.248,0.1926,Crystal structure of constitutively active PARP-2
5BZ6,X-RAY DIFFRACTION,2.98,58.68,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG 3350, 0.1M Bis-Tris-HCl (pH 6.5), 0.2M ammonium sulfate",293.0,2015-06-11,2015-09-16,5BZ6,2078.0,1.0,262.0,41.0,,30.35,1.0,2.75,experimental,34.21,0.234,0.164,Crystal structure of the N-terminal domain single mutant (S92A) of the human mitochondrial calcium uniporter fused with T4 lysozyme
5KWH,X-RAY DIFFRACTION,3.11,60.46,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES",293.0,2016-07-18,2017-10-25,5KWH,6183.0,2.0,666.0,378.0,,83.17,1.0,2.12,experimental,35.54,0.208,0.181,Crystal structure of CK2
5N1V,X-RAY DIFFRACTION,3.19,61.39,"VAPOR DIFFUSION, SITTING DROP",,unknown,293.0,2017-02-06,2017-05-17,5N1V,5922.0,2.0,684.0,141.0,,84.61,1.0,2.52,experimental,57.55,0.2293,0.1868,Crystal structure of the protein kinase CK2 catalytic subunit in complex with pyrazolo-pyrimidine macrocyclic ligand
5T1H,X-RAY DIFFRACTION,3.16,61.05,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES",293.0,2016-08-19,2017-11-22,5T1H,6221.0,2.0,666.0,388.0,,83.37,1.0,2.11,experimental,41.49,0.203,0.178,Crystal structure of CK2
5ZIB,X-RAY DIFFRACTION,2.59,52.43,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.15M DL-malic acid (pH 7.0), 20% (w/v) polyethylene glycol (PEG) 3350",293.0,2018-03-14,2018-08-01,5ZIB,5019.0,1.0,626.0,294.0,9.0,71.81,1.0,1.9,experimental,,0.2243,0.1893,Crystal structure of human GnT-V luminal domain in apo form
6YA6,X-RAY DIFFRACTION,2.15,42.72,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M PCTP pH7, 18% PEG 1500, 8% MPD",291.15,2020-03-11,2020-05-27,6YA6,4072.0,2.0,503.0,464.0,,57.93,2.0,1.44,experimental,20.95,0.1933,0.1666,Minimal construct of Cdc7-Dbf4 bound to XL413
8OUT,X-RAY DIFFRACTION,1.94,36.46,"VAPOR DIFFUSION, HANGING DROP",7.7,"20% PEG 3350, 0.2 M magnesium acetate, 0.1 M HEPES/NaOH pH 7.5-7.9",291.0,2023-04-24,2023-07-26,8OUT,2267.0,1.0,300.0,82.0,,34.44,1.0,1.935,experimental,35.44,0.2288,0.1927,CRYSTAL STRUCTURE OF DLK IN COMPLEX WITH COMPOUND 22
6V63,X-RAY DIFFRACTION,3.05,59.67,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2019-12-04,2020-01-22,6V63,8985.0,4.0,1238.0,668.0,,143.94,2.0,2.02,experimental,27.59,0.1988,0.1661,SETD3 WT in Complex with an Actin Peptide with His73 Replaced with Glutamine
6NVQ,X-RAY DIFFRACTION,3.23,62.0,"VAPOR DIFFUSION, HANGING DROP",8.8,"19% PEG 3000, 0.1M Tris-HCl, 0.2M calcium chloride",293.0,2019-02-05,2019-05-22,6NVQ,2322.0,2.0,391.0,76.0,,44.44,2.0,2.1,experimental,57.224,0.21428,0.19751,Crystal structure of the VASH1-SVBP complex
5VGR,X-RAY DIFFRACTION,2.42,49.1,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M NaCl, 0.1 M Tris pH 8.5, 25% PEG3350, 25% glycerol",293.0,2017-04-11,2017-05-17,5VGR,6270.0,2.0,862.0,239.0,,99.24,1.0,2.096,experimental,,0.228,0.1975,"Human Atlastin-3, GDP-bound"
8Q64,X-RAY DIFFRACTION,1.87,34.05,"VAPOR DIFFUSION, SITTING DROP",,"10-35% PEG 4K, 0.2 M ammonium acetate and 0.1 M sodium ammonium acetate trihydrate pH (4.1-5.6)",298.0,2023-08-10,2024-08-21,8Q64,2177.0,2.0,252.0,238.0,,28.51,2.0,1.36,experimental,,0.2117,0.1901,Crystal structure of hydroxylated HIF2alpha-CODD peptide (523-542) bound to apo-HIF prolyl hydroxylase 2 (PHD2 181-407)
5AP5,X-RAY DIFFRACTION,3.09,60.23,,7.5,"38% (V/V) PEG300, PH 7.5",,2015-09-14,2015-09-23,5AP5,1997.0,1.0,313.0,6.0,,36.96,1.0,2.8,experimental,101.63,0.2457,0.2027,Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
7D4A,X-RAY DIFFRACTION,3.42,63.99,"VAPOR DIFFUSION, SITTING DROP",,"0.1M NaCl, 0.1M HEPES pH7.5, 1.6M (NH4)2SO4",293.0,2020-09-23,2020-10-07,7D4A,955.0,1.0,131.0,20.0,,15.14,1.0,2.201,experimental,52.144,0.2722,0.2297,The Crystal Structure of human JMJD2A Tudor domain from Biortus
4RMZ,X-RAY DIFFRACTION,2.6,52.77,EVAPORATION,6.4,"2.6 - 2.9 M ammonium sulfate, PH 6.4-7.9 , EVAPORATION, temperature 293K",293.0,2014-10-22,2016-01-13,4RMZ,4726.0,2.0,614.0,150.0,,70.23,1.0,2.2,experimental,41.829,0.29575,0.2357,Crystal Structure of IRAK-4
7QG3,X-RAY DIFFRACTION,2.48,50.35,EVAPORATION,,2.7 M AMS 0.1 M Hepes pH 7.1-7.7,298.0,2021-12-07,2022-05-04,7QG3,4548.0,2.0,616.0,30.0,,70.34,1.0,2.11,experimental,,0.304,0.272,IRAK4 in complex with inhibitor
7QG5,X-RAY DIFFRACTION,2.47,50.28,EVAPORATION,,2.5 M AMS 0.1 M Hepes pH 7.45,298.0,2021-12-07,2022-05-04,7QG5,4643.0,2.0,616.0,192.0,,70.22,1.0,2.3,experimental,69.71,0.275,0.2473,IRAK4 in complex with inhibitor
8ATN,X-RAY DIFFRACTION,2.78,55.92,"VAPOR DIFFUSION, SITTING DROP",4.9,"0.1M sodium acetate buffer pH 4.9, 1.5-1.7M ammonium citrate, 0.02M hexaaminecobalt(III)chloride",293.0,2022-08-23,2023-09-06,8ATN,4545.0,2.0,596.0,23.0,,67.5,1.0,2.171,experimental,77.038,0.3059,0.2384,Discovery of IRAK4 Inhibitor 38
8BR6,X-RAY DIFFRACTION,2.72,54.82,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium acetate buffer pH 4.9, 2.13-2.145M sodium malonate",293.0,2022-11-22,2024-01-31,8BR6,4621.0,2.0,596.0,106.0,,67.5,1.0,2.167,experimental,48.702,0.2513,0.2133,Discovery of IRAK4 Inhibitor 40
8TX0,X-RAY DIFFRACTION,2.81,56.3,"VAPOR DIFFUSION, SITTING DROP",,sodium malonate,293.0,2023-08-21,2024-06-26,8TX0,4762.0,2.0,614.0,222.0,,70.49,1.0,2,experimental,50.35,0.2383,0.2065,IRAK4 in complex with compound
6QML,X-RAY DIFFRACTION,2.67,54.04,"VAPOR DIFFUSION, SITTING DROP",5.5,"Drops set up in MRC 2 well, 96 well plate using a Mosquito crystallization robot. 100+100 nl drops.
Best crystals:
21% PEG 3350
0.15M KBr
0.1M Bis-Tris pH 5.5

Crystals grow also in KCl and AmSO4 (0.2 M), or with PEG 200 MME. Crystals can be obtained at 4C as well.",298.15,2019-02-07,2020-02-26,6QML,6397.0,6.0,758.0,235.0,,87.58,3.0,2.1,experimental,55.422,0.2332,0.1843,"UCHL3 in complex with synthetic, K27-linked diubiquitin"
8Q5S,X-RAY DIFFRACTION,1.86,34.1,"VAPOR DIFFUSION, SITTING DROP",,"(10-35%) PEG 4K, 0.2 M ammonium acetate, 0.1 M sodium ammonium acetate trihydrate pH (4.1-5.6)",298.0,2023-08-09,2024-08-21,8Q5S,2102.0,2.0,253.0,191.0,,28.52,2.0,1.49,experimental,,0.213,0.1892,Anaerobic crystal structure of apo-HIF prolyl hydroxylase 2 (PHD2 181-407)in complex with acetate (ACT) and HIF2alpha-CODD peptide
8Q6D,X-RAY DIFFRACTION,1.86,34.0,"VAPOR DIFFUSION, SITTING DROP",,"10-35% PEG 4K, 0.2 ammonium acetate, sodium ammonium acetate trihydrate pH (4.1-5.6)",298.0,2023-08-11,2024-08-21,8Q6D,2140.0,2.0,253.0,234.0,,28.55,2.0,1.4,experimental,,0.1899,0.1671,"Anaerobic crystal structure of HIF prolyl hydroxylase 2 (PHD2 181-407) in complex with HIF2alpha-CODD peptide (523-542), Fe(II) and 2-oxoglutarate (2OG)"
7AAG,X-RAY DIFFRACTION,2.63,53.25,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene glycol, 0.1 M HEPES pH 7.5",293.0,2020-09-04,2021-10-06,7AAG,11980.0,4.0,1456.0,878.0,,175.81,1.0,1.79,experimental,30.396,0.1967,0.1667,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-617
6NFG,X-RAY DIFFRACTION,2.44,49.59,"VAPOR DIFFUSION, SITTING DROP",7.0,"PROTEIN WAS CONCENTRATED TO 6 MG/ML,
AND THEN MIXED AT A 2:1 RATIO WITH PEG 3350 (18-20% V/V), 0.2 M
 AMMONIUM CITRATE (PH 7) IN A SITTING DROP WELL AT 277 K.
 CRYOPROTECTANT WAS MADE USING MOTHER LIQUOR AT A FINAL
 CONCENTRATION OF 23% PEG 3350, VAPOR DIFFUSION, SITTING DROP,
 TEMPERATURE 277K",277.15,2018-12-20,2019-01-23,6NFG,5598.0,2.0,724.0,177.0,,85.48,1.0,2.76,experimental,50.92,0.244,0.182,"CYCLIC GMP-AMP SYNTHASE in complex with compound 16 inhibitor: 7-hydroxy-N-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide"
6NFO,X-RAY DIFFRACTION,2.49,50.63,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN WAS CONCENTRATED TO 6 MG/ML,
AND THEN MIXED AT A 2:1 RATIO WITH PEG 3350 (18-20% V/V), 0.2 M
 AMMONIUM CITRATE (PH 7) IN A SITTING DROP WELL AT 277 K.
 CRYOPROTECTANT WAS MADE USING MOTHER LIQUOR AT A FINAL
 CONCENTRATION OF 23% PEG 3350, VAPOR DIFFUSION, SITTING DROP",277.0,2018-12-20,2019-01-23,6NFO,5447.0,2.0,724.0,27.0,,85.57,1.0,2.93,experimental,68.1,0.231,0.21,"CYCLIC GMP-AMP SYNTHASE in complex with compound 20 inhibitor: 7-hydroxy-N-[(2S)-1-hydroxypropan-2-yl]-5-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide"
5OHP,X-RAY DIFFRACTION,2.49,50.68,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.73 M sodium citrate, 0.1 M Hepes pH 7.0",291.0,2017-07-17,2017-09-20,5OHP,3731.0,3.0,488.0,52.0,,55.66,2.0,2.8,experimental,,0.2494,0.2158,Crystal structure of USP30 (C77A) in complex with Lys6-linked diubiquitin
5M0C,X-RAY DIFFRACTION,2.18,51.26,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
0.12 mM ligand solved in DMSO (100 mM Stock)

Reservoir: 14% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-10-04,2018-06-06,5M0C,3284.0,2.0,373.0,301.0,,43.74,2.0,1.734,experimental,,0.2004,0.1727,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the Fasudil-fragment isoquinoline-5-sulfonamide
6CJG,X-RAY DIFFRACTION,3.54,65.27,"VAPOR DIFFUSION, SITTING DROP",,"2.2 M Ammonium Acetate, 1.5 M sodium chloride, 0.1 M sodium cacodylate pH 5.3, 10 mM DTT",293.0,2018-02-26,2018-05-23,6CJG,2809.0,1.0,374.0,67.0,,42.2,1.0,2.851,experimental,,0.2061,0.17,Human dihydroorotate dehydrogenase bound to napthyridine inhibitor 46
4X6J,X-RAY DIFFRACTION,2.05,39.99,"VAPOR DIFFUSION, SITTING DROP",,"Potassium  chloride 0.2M,
HEPES 0.05M,
5/4 PO/OH 35%",295.0,2014-12-08,2015-09-09,4X6J,2004.0,1.0,215.0,230.0,3.0,24.26,1.0,1.59,experimental,18.432,0.2376,0.1832,Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.
7NXL,X-RAY DIFFRACTION,1.98,38.1,"VAPOR DIFFUSION, HANGING DROP",6.5,"Composition of reservoir solution was 0.1 M MES/imidazole buffer, containing: 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each NPS (a mix containing sodium nitrate, disodium hydrogen phosphate and ammonium sulfate) additives, pH 6.5.
Morpheus C4 condition",291.0,2021-03-18,2021-09-08,7NXL,1887.0,1.0,216.0,172.0,3.0,24.27,1.0,1.8,experimental,23.293,0.2094,0.1746,Structure of human cathepsin K in complex with the acrylamide inhibitor Gu3110
7NXM,X-RAY DIFFRACTION,1.963,37.38,"VAPOR DIFFUSION, HANGING DROP",6.5,"Composition of reservoir solution was 0.1 M MES/imidazole buffer, containing: 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each NPS (a mix containing sodium nitrate, disodium hydrogen phosphate and ammonium sulfate) additives, pH 6.5.
Morpheus C4 condition",291.0,2021-03-18,2021-09-08,7NXM,1913.0,1.0,216.0,184.0,3.0,24.3,1.0,1.72,experimental,17.819,0.1784,0.1602,Structure of human cathepsin K in complex with the selective activity-based probe Gu3416
5WWZ,X-RAY DIFFRACTION,2.5,50.83,"VAPOR DIFFUSION, SITTING DROP",,1.6M Ammonium sulfate,277.0,2017-01-05,2017-08-23,5WWZ,1855.0,3.0,258.0,40.0,,29.7,1.0,2.5,experimental,56.6324,0.2698,0.2263,Crystal structure of the KH2 domain of human RNA-binding E3 ubiquitin-protein ligase MEX-3C
4NXO,X-RAY DIFFRACTION,3.76,67.24,,7.0,"0.1M HEPES, pH 7.0, 10% Tacsimate, 10%Dioxane, 10% PEG-5000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K",291.15,2013-12-09,2015-10-07,4NXO,15913.0,2.0,1980.0,151.0,,232.18,1.0,2.73,experimental,,0.219,0.17,Crystal Structure of Insulin Degrading Enzyme in complex with BDM44768
8TXG,X-RAY DIFFRACTION,2.78,55.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"2.0 M Ammonium Sulfate, 15% ethylene glycol, 0.1 M Tris pH 8.5",286.15,2023-08-23,2023-11-08,8TXG,1591.0,1.0,170.0,148.0,,20.47,1.0,1.5,experimental,24.1,0.2232,0.1977,Crystal structure of KRAS G12D in complex with GDP and compound 8
7CM0,X-RAY DIFFRACTION,2.62,53.1,LIQUID DIFFUSION,,"4M Ammonium acetate, pH 7.0, 0.1M Bis-Tris propane",291.0,2020-07-23,2021-12-22,7CM0,10546.0,4.0,1308.0,156.0,2.0,151.86,1.0,2.2,experimental,44.65,0.3346,0.2903,Crystal structure of a glutaminyl cyclase in complex with NHV-1009
6HNY,X-RAY DIFFRACTION,1.96,37.35,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2018-09-17,2019-08-07,6HNY,3135.0,1.0,336.0,296.0,,40.83,1.0,1.65,experimental,26.8921,0.2063,0.1732,Human protein kinase CK2 alpha in complex with boldine
6WYS,X-RAY DIFFRACTION,3.77,67.34,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M sodium chloride, 1.6M ammonium sulfate, 0.1M HEPES pH 7.5",277.0,2020-05-13,2021-04-14,6WYS,4592.0,3.0,654.0,252.0,,71.84,1.0,2.229,experimental,57.4982,0.2133,0.188,Lon protease proteolytic domain
6WZV,X-RAY DIFFRACTION,3.74,67.08,"VAPOR DIFFUSION, SITTING DROP",9.0,"1.6M ammonium sulfate, 0.1M Bicine",293.0,2020-05-14,2021-04-14,6WZV,4416.0,3.0,654.0,84.0,,72.52,1.0,2.51,experimental,69.4967,0.2139,0.1768,Lon protease proteolytic domain
8FN8,X-RAY DIFFRACTION,2.03,39.43,"VAPOR DIFFUSION, HANGING DROP",,"20% w/v PEG3350, 100 mM Tris-HCl, pH 8.0",293.0,2022-12-27,2023-07-12,8FN8,2836.0,2.0,337.0,229.0,3.0,38.34,2.0,1.89,experimental,26.24,0.2053,0.164,Crystal structure of the C-terminal Fg domain of TNC with the single FN domain of PTPRZ
6AZV,X-RAY DIFFRACTION,3.01,59.16,VAPOR DIFFUSION,,"22% PEG-3350, 0.2 M NH4 citrate pH 7",298.0,2017-09-13,2018-03-21,6AZV,11312.0,4.0,1608.0,106.0,2.0,182.77,1.0,2.755,experimental,68.3118,0.2719,0.1947,IDO1/BMS-978587 crystal structure
6OAM,X-RAY DIFFRACTION,2.47,50.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES sodium pH 7.5, 0.8 M sodium phosphate monobasic monohydrate, 0.8 M sodium phosphate monobasic, 0.1M Cesium chloride",298.0,2019-03-17,2020-04-22,6OAM,5019.0,4.0,654.0,,,74.32,2.0,2.503,experimental,,0.3057,0.2832,Crystal Structure of ChlaDUB2 DUB domain
7QBQ,X-RAY DIFFRACTION,3.18,61.35,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2021-11-19,2022-11-30,7QBQ,4550.0,1.0,529.0,91.0,3.0,63.17,1.0,2.49,experimental,68.53,0.2238,0.1942,Human butyrylcholinesterase in complex with (Z)-N-benzyl-1-(8-hydroxyquinolin-2-yl)methanimine oxide
5JNS,X-RAY DIFFRACTION,2.32,46.96,EVAPORATION,8.0,"25% PEG 3350K, 200 mM NaCl",293.0,2016-04-30,2017-03-29,5JNS,1421.0,1.0,160.0,144.0,,18.38,1.0,1.8,experimental,28.12,0.2066,0.1648,Crystal structure of human low molecular weight protein tyrosine phosphatase (LMPTP) type A complexed with phosphate
5MY8,X-RAY DIFFRACTION,2.88,57.27,"VAPOR DIFFUSION, SITTING DROP",5.5,"22% broad-molecular-weight PEG smears (BMW PEG smears) and 0.1 M citrate, pH 5.5",277.15,2017-01-25,2017-05-10,5MY8,3511.0,1.0,383.0,396.0,,45.71,1.0,1.7,experimental,32.393,0.2002,0.16414,Crystal structure of SRPK1 in complex with SPHINX31
5KU8,X-RAY DIFFRACTION,3.12,60.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES",293.0,2016-07-13,2017-11-08,5KU8,6038.0,2.0,662.0,242.0,,82.84,1.0,2.22,experimental,35.02,0.216,0.183,Crystal structure of CK2
6X5J,X-RAY DIFFRACTION,3.77,67.36,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1M CITRIC ACID, 20% PEG 6000",277.0,2020-05-26,2020-06-24,6X5J,2461.0,2.0,297.0,131.0,7.0,34.33,2.0,2.513,experimental,64.08,0.2251,0.1985,Discovery of Hydroxy Pyrimidine Factor IXa Inhibitors
6EGF,X-RAY DIFFRACTION,4.95,75.13,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.6-1.9 M ammonium sulfate, 100 mM Hepes-NaOH at pH7",293.15,2018-08-19,2019-02-13,6EGF,2282.0,1.0,302.0,40.0,,34.44,1.0,2.61,experimental,,0.2292,0.2048,Crystal structure of the inactive unphosphorylated IRAK4 kinase domain bound to AMP-PNP
4UHL,X-RAY DIFFRACTION,2.7,53.7,,7.4,pH 7.4,,2015-03-24,2016-06-15,4UHL,30632.0,8.0,3568.0,928.0,,422.11,1.0,2.5,experimental,64.354,0.2371,0.19013,HUMAN STEROL 14-ALPHA DEMETHYLASE (CYP51) IN COMPLEX WITH VFV IN P1 SPACE GROUP
6CPE,X-RAY DIFFRACTION,2.41,48.96,"VAPOR DIFFUSION, SITTING DROP",7.4,"A 1:1 ratio protein:mother liquor was obtained by mixing 0.5 uL Aurora A (300  uM; 10 mg/mL) in 50 mM HEPES, pH 7.3, 500 mM ammonium acetate, 1 mM MgCl2, 5 mM TCEP) with 0.5  uL of 0.15 M Tris-HCl, pH 7.5, 0.15 M ammonium sulfate, 35% (w/v) PEG-3350",291.15,2018-03-13,2018-06-27,6CPE,2050.0,1.0,285.0,4.0,,33.15,1.0,2.45,experimental,78.56,0.2536,0.2142,"Structure of apo, dephosphorylated Aurora A (122-403) in an active conformation"
5LM2,X-RAY DIFFRACTION,2.73,54.86,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris pH 6.0, 0.1-0.2 M Na-Formate and 13-15% PEG3350",294.0,2016-07-28,2016-11-30,5LM2,5318.0,2.0,704.0,78.0,,81.45,1.0,2.54,experimental,,0.271,0.2147,Crystal Structure of HD-PTP phosphatase
8IJU,X-RAY DIFFRACTION,2.32,47.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 mM Na2PO4, 30 % (w/v) PEG3350",293.0,2023-02-28,2024-01-24,8IJU,3389.0,1.0,396.0,177.0,,46.97,1.0,1.82,experimental,32.51,0.2219,0.1843,ATP-dependent RNA helicase DDX39A (URH49delta41)
7POX,X-RAY DIFFRACTION,2.37,48.06,"VAPOR DIFFUSION, SITTING DROP",,"PEG6000, Bicine, pH = 8.5",297.15,2021-09-10,2022-05-04,7POX,3210.0,2.0,438.0,32.0,,50.57,1.0,2.5,experimental,55.804,0.2802,0.2479,"TNKS2 in complex with OM-1700, treated with H2O2"
5DYW,X-RAY DIFFRACTION,2.7,54.44,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.2 M ammonium acetate, 12% polyethylene glycol 4000.",293.0,2015-09-25,2017-01-18,5DYW,9234.0,2.0,1060.0,285.0,6.0,128.17,1.0,2.5,experimental,,0.2165,0.1899,Crystal structure of human butyrylcholinesterase in complex with N-((1-benzylpiperidin-3-yl)methyl)-N-(2-methoxyethyl)naphthalene-2-sulfonamide
6U7F,X-RAY DIFFRACTION,2.95,58.31,"VAPOR DIFFUSION, HANGING DROP",6.5,"9% PEG8000, 1 mM oxidized glutathione, 1 mM reduced glutathione, 5% glycerol, 100 mM MES, pH 6.5",298.0,2019-09-02,2019-11-13,6U7F,16575.0,4.0,2102.0,228.0,9.0,243.67,2.0,2.75,experimental,53.0345,0.2251,0.1904,HCoV-229E RBD Class IV in complex with human APN
7LFO,X-RAY DIFFRACTION,3.04,59.59,"VAPOR DIFFUSION, HANGING DROP",7.5,"140 g/L PEG8000, 100 mM HEPES, 200 mM magnesium acetate, pH 7.5",277.15,2021-01-18,2021-05-26,7LFO,2455.0,1.0,329.0,146.0,,38.46,1.0,1.94,experimental,47.258,0.243,0.2004,Protein Tyrosine Phosphatase 1B
6WK1,X-RAY DIFFRACTION,2.51,51.07,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2020-04-15,2020-06-17,6WK1,8952.0,4.0,1234.0,601.0,,144.64,2.0,1.89,experimental,28.19,0.2281,0.1947,SETD3 in Complex with an Actin Peptide with His73 Replaced with Methionine
6PK6,X-RAY DIFFRACTION,3.21,61.63,"VAPOR DIFFUSION, SITTING DROP",,"0.1M CAPSO pH 9.5, 20% PEG 8,000",293.0,2019-06-28,2019-08-28,6PK6,2881.0,1.0,351.0,141.0,,41.45,1.0,2.1,experimental,42.55,0.2165,0.189,Human PRPF4B bound to benzothiophene inhibitor 329
5XU8,X-RAY DIFFRACTION,1.96,37.18,"VAPOR DIFFUSION, SITTING DROP",7.0,"24.5% PEG3350, 0.2 M MgC12, 0.1 M Bis-Tris",295.0,2017-06-22,2018-02-28,5XU8,3568.0,2.0,432.0,261.0,,50.31,2.0,1.81,experimental,39.95,0.23827,0.17854,Crystal structure of human USP2 in complex with ubiquitin and 6-thioguanine
6I3D,X-RAY DIFFRACTION,2.01,38.82,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.1M amino acid stock (0.2M L-Na-Glutamate; 0.2M Alananine (racemic); 0.2M Glycine; 0.2M Lysine HCL (racemic); 0.2M Serine (racemic), 0.1M Imidazole; MES monohydrate (acid) pH 6.5, 50% v/v precipitant mix (25% v/v MPD; 25% PEG 1000; 25% PEG 3350) Morpheus condition H4",277.0,2018-11-05,2019-09-18,6I3D,4162.0,2.0,464.0,421.0,,53.15,1.0,1.45,experimental,,0.146,0.1188,"Crystal structure of Human soluble catechol O-methyltransferase in complex with 3,5-dinitrocatechol and Sinefungin"
7AT5,X-RAY DIFFRACTION,3.19,61.49,"VAPOR DIFFUSION, SITTING DROP",,"reservoir composition: 30 % (w/v) PEG8000, 0.2 M ammonium sulfate, 0.1 M sodium cacodylate, pH 6.5; crystallization drop composition before equilibration: 0.01 ml reservoir solution plus 0.02 ml enzyme stock solution (6 mg/ml enzyme, 0.5 M NaCl, 25 mM Tris/HCl, pH 8.5); the bivalent inhibitor KN2 was introduced by extensive soaking",293.0,2020-10-29,2021-08-04,7AT5,6207.0,2.0,698.0,422.0,,85.88,1.0,1.77,experimental,40.29,0.1947,0.1739,Structure of protein kinase ck2 catalytic subunit (csnk2a1 gene product) in complex with the bivalent inhibitor KN2
4UV0,X-RAY DIFFRACTION,3.1,60.0,,,"5MM HEPES, 30 MM NACL, 10 MM NA2SO4,0.5 MMDTT,25% (W/V) PEGMME2000",,2014-08-01,2015-08-12,4UV0,2462.0,1.0,323.0,91.0,,37.32,1.0,2.49,experimental,,0.2425,0.1931,Structure of a semisynthetic phosphorylated DAPK
5W7C,X-RAY DIFFRACTION,2.6,52.78,"VAPOR DIFFUSION, SITTING DROP",,"post-chymotrypsin; 1mM Triton X-100, 0.333 mM E. coli LPS Ra; 200 mM ammonium chloride, 100 mM sodium acetate pH 5.3, 20 % PEG 6000",293.0,2017-06-19,2018-01-03,5W7C,9075.0,4.0,1124.0,295.0,16.0,132.69,2.0,2.23,experimental,,0.2451,0.2115,"Human acyloxyacyl hydrolase (AOAH), proteolytically processed, S263A mutant, with LPS"
9EXW,X-RAY DIFFRACTION,2.63,53.15,"VAPOR DIFFUSION, SITTING DROP",,20 % ethanol.,293.0,2024-04-09,2024-05-29,9EXW,2265.0,2.0,348.0,49.0,,39.93,1.0,2.43,experimental,51.26,0.2838,0.2344,Crystal structure of the PWWP1 domain of NSD2 bound by compound 17.
6A0E,X-RAY DIFFRACTION,2.15,42.79,"VAPOR DIFFUSION, HANGING DROP",4.8,"PEG 3350, Potassium phosphate monobasic",295.0,2018-06-05,2019-12-11,6A0E,5612.0,2.0,636.0,593.0,1.0,72.14,1.0,1.947,experimental,,0.2235,0.1745,Crystal structure of human protein N-terminal asparagine amidohydrolase (NTAN1)
6A0I,X-RAY DIFFRACTION,2.13,42.18,"VAPOR DIFFUSION, HANGING DROP",4.8,"PEG 3350, potassium phosphate monobasic",295.0,2018-06-05,2019-12-11,6A0I,5474.0,2.0,636.0,442.0,1.0,73.87,1.0,1.996,experimental,,0.2108,0.164,Crystal structure of human protein N-terminal asparagine amidohydrolase (NTAN1) C75S mutant
6PU7,X-RAY DIFFRACTION,3.01,59.09,VAPOR DIFFUSION,,unavailable,293.0,2019-07-17,2019-12-04,6PU7,6372.0,2.0,786.0,215.0,1.0,90.56,1.0,2.43,experimental,45.46,0.2503,0.2004,"Human IDO1 in complex with compound 17 (N-{2-[(4-{N-[(7S)-4-fluorobicyclo[4.2.0]octa-1,3,5-trien-7-yl]-N'-hydroxycarbamimidoyl}-1,2,5-oxadiazol-3-yl)sulfanyl]ethyl}acetamide)"
8IE5,X-RAY DIFFRACTION,1.92,35.92,"VAPOR DIFFUSION, HANGING DROP",,"PEG 400, ammonium sulfate, Bis-tris pH 6.5",293.0,2023-02-15,2023-05-24,8IE5,2411.0,1.0,293.0,190.0,,34.14,1.0,1.803,experimental,,0.2105,0.182,Crystal structure of DAPK1 in complex with oxyresveratrol
8IE6,X-RAY DIFFRACTION,1.9,35.32,"VAPOR DIFFUSION, HANGING DROP",,"PEG 400, ammonium sulfate, Bis-tris pH 6.5",293.0,2023-02-15,2023-05-24,8IE6,2456.0,1.0,293.0,199.0,,34.23,1.0,1.701,experimental,,0.1954,0.1784,Crystal structure of DAPK1 in complex with pinostilbene
8IE7,X-RAY DIFFRACTION,1.88,34.72,"VAPOR DIFFUSION, HANGING DROP",,"PEG400, ammonium sulfate, Bis-tris pH 6.5",293.0,2023-02-15,2023-05-24,8IE7,2410.0,1.0,293.0,172.0,,34.24,1.0,1.849,experimental,,0.2107,0.179,Crystal structure of DAPK1 in complex with pterostilbene
8IE8,X-RAY DIFFRACTION,1.9,35.22,"VAPOR DIFFUSION, HANGING DROP",,"PEG400, ammonium sulfate, Bis-tris pH 6.5",293.0,2023-02-15,2023-05-24,8IE8,2431.0,1.0,293.0,179.0,,34.25,1.0,1.75,experimental,,0.2162,0.1845,Crystal structure of DAPK1 in complex with isorhapontigenin
6X5G,X-RAY DIFFRACTION,2.21,44.33,"VAPOR DIFFUSION, SITTING DROP",9.0,"10% w/v PEG 20000, 2% v/v 1,4-Dioxane, 0.1 M Bicine",277.0,2020-05-26,2020-12-23,6X5G,2389.0,2.0,290.0,107.0,,33.4,2.0,1.85,experimental,22.461,0.2265,0.1871,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and LRRC7 inhibitory domain
6ISU,X-RAY DIFFRACTION,2.27,45.72,"VAPOR DIFFUSION, HANGING DROP",,"18% PEG 3350 (w/v), 400 mM Ca(AC)2",291.15,2018-11-19,2019-02-06,6ISU,3314.0,3.0,382.0,292.0,,43.38,3.0,1.866,experimental,,0.2644,0.2091,Crystal structure of Lys27-linked di-ubiquitin in complex with its selective interacting protein UCHL3
4CRL,X-RAY DIFFRACTION,3.04,59.61,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG3350, 0.2M LITHIUM CHLORIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2014-02-27,2015-09-23,4CRL,5170.0,2.0,691.0,103.0,,81.29,2.0,2.4,experimental,31.69,0.25633,0.19908,Crystal structure of human CDK8-Cyclin C in complex with cortistatin A
5TMG,X-RAY DIFFRACTION,3.1,60.26,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 0.06M citrate, 0.04M citric acid",293.0,2016-10-12,2017-10-18,5TMG,5520.0,2.0,674.0,255.0,6.0,76.02,1.0,2.2,experimental,47.448,0.2104,0.1839,"Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active Renin Inhibitor"
5TMK,X-RAY DIFFRACTION,3.08,60.02,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 0.06M citrate, 0.04M citric acid",293.0,2016-10-13,2017-10-18,5TMK,5121.0,2.0,674.0,41.0,6.0,75.49,1.0,2.65,experimental,74.423,0.2356,0.1978,"Optimization of 3,5-Disubstitued Piperidine: Discovery of Non-Peptide mimetics as an Orally Active Renin Inhibitor"
4ZJI,X-RAY DIFFRACTION,2.77,55.56,"VAPOR DIFFUSION, HANGING DROP",,"Equal volumes (1.0 uL) of reservoir solution and protein solution were mixed. Reservoir solution: 17.2% (w/v) PEG3350, 0.2 M magnesium formate (dihydrate)",298.0,2015-04-29,2015-06-24,4ZJI,9330.0,4.0,1196.0,795.0,,135.19,1.0,1.99,experimental,33.21,0.2198,0.1909,PAK1 in complex with 2-chloro-5-ethyl-8-fluoro-11-(4-methylpiperazin-1-yl)-dibenzodiazepine
5DYT,X-RAY DIFFRACTION,2.97,58.55,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.2 M ammonium acetate, 12% polyethylene glycol 4000.",293.0,2015-09-25,2016-10-05,5DYT,9063.0,2.0,1060.0,232.0,6.0,126.47,1.0,2.55,experimental,,0.2324,0.1789,Crystal structure of human butyrylcholinesterase in complex with N-((1-benzylpiperidin-3-yl)methyl)-N-methylnaphthalene-2-sulfonamide
5DYY,X-RAY DIFFRACTION,2.97,58.55,"VAPOR DIFFUSION, SITTING DROP",,200 mM Sodium acetate 12% peg 4K,293.0,2015-09-25,2017-01-18,5DYY,9015.0,2.0,1060.0,233.0,6.0,125.77,1.0,2.65,experimental,,0.2444,0.1866,Crystal structure of human butyrylcholinesterase in complex with N-((1-benzylpiperidin-3-yl)methyl)naphthalene-2-sulfonamide
6I0B,X-RAY DIFFRACTION,3.1,60.38,"VAPOR DIFFUSION, HANGING DROP",,"MES pH 6.5
Ammonium Sulphate",293.0,2018-10-25,2019-03-27,6I0B,4566.0,1.0,529.0,114.0,3.0,63.29,1.0,2.384,experimental,,0.2439,0.1892,Human butyrylcholinesterase in complex with the S enantiomer of a chlorotacrine-tryptophan multi-target inhibitor.
7BGC,X-RAY DIFFRACTION,3.2,61.57,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES PH 6.5, 2.1 M AMMONIUM SULFATE",293.0,2021-01-06,2021-04-28,7BGC,4613.0,1.0,529.0,90.0,3.0,64.04,1.0,2.4,experimental,89.48,0.2471,0.2031,human butyrylcholinesterase in complex with a tacrine-methylanacardate hybrid inhibitor
5SY2,X-RAY DIFFRACTION,2.92,57.86,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 0.06M citrate, 0.04M citric acid",293.0,2016-08-10,2016-11-02,5SY2,5474.0,2.0,680.0,274.0,6.0,76.21,1.0,2.25,experimental,35.424,0.221,0.1847,Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors
6INE,X-RAY DIFFRACTION,2.62,53.12,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris-HCl pH 8.5, 20 % PEG 6000, 0.2 M Trimethylamine-N-oxide",277.0,2018-10-25,2019-03-20,6INE,3443.0,2.0,444.0,67.0,,52.35,2.0,2.6,experimental,47.0485,0.2372,0.1931,Crystal Structure of human ASH1L-MRG15 complex
6FWT,X-RAY DIFFRACTION,2.09,41.19,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Potassium Nitrate, 20% (w/v) PEG 3350",293.0,2018-03-07,2018-10-10,6FWT,2481.0,1.0,277.0,195.0,2.0,31.98,1.0,1.845,experimental,31.11,0.218,0.1659,"Crystal structure of human wild type beta-1,4-galactosyltransferase-1 (B4GalT1) in apo-open monomeric form"
5BVN,X-RAY DIFFRACTION,2.45,49.78,VAPOR DIFFUSION,,"10.0%w/v PEG 3350, 0.1M KNO3",277.0,2015-06-05,2015-08-12,5BVN,2448.0,1.0,324.0,171.0,,36.98,1.0,2.21,experimental,29.02,0.3275,0.2523,Fragment-based discovery of potent and selective DDR1/2 inhibitors
5BVO,X-RAY DIFFRACTION,2.52,51.22,VAPOR DIFFUSION,,"17.4%w/v PEG 3350, 0.2M NH4I",277.0,2015-06-05,2015-08-05,5BVO,2527.0,1.0,324.0,262.0,,37.75,1.0,1.98,experimental,44.129,0.2459,0.1948,Fragment-based discovery of potent and selective DDR1/2 inhibitors
9EXX,X-RAY DIFFRACTION,2.65,53.51,"VAPOR DIFFUSION, SITTING DROP",,30 % ethanol,293.0,2024-04-09,2024-05-29,9EXX,2408.0,2.0,348.0,119.0,,40.22,1.0,1.943,experimental,50.89,0.2651,0.2328,Crystal structure of the PWWP1 domain of NSD2 bound by compound 18.
7O1U,X-RAY DIFFRACTION,3.74,67.12,"VAPOR DIFFUSION, SITTING DROP",5.5,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2021-03-30,2021-09-01,7O1U,4375.0,1.0,480.0,519.0,4.0,53.19,1.0,1.7,experimental,26.23,0.1666,0.155,X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 1 (BEV241)
7O1W,X-RAY DIFFRACTION,3.74,67.1,"VAPOR DIFFUSION, SITTING DROP",5.5,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2021-03-30,2021-09-01,7O1W,4335.0,1.0,480.0,424.0,4.0,53.69,1.0,1.8,experimental,29.36,0.1791,0.16,X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 2 (mi307) soaked at 1 M NaCl
7O1Y,X-RAY DIFFRACTION,3.72,66.95,"VAPOR DIFFUSION, SITTING DROP",5.5,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2021-03-30,2021-09-01,7O1Y,4321.0,1.0,480.0,475.0,4.0,53.91,1.0,1.7,experimental,29.48,0.177,0.1622,X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 2 (mi307) soaked at 0.25 M NaCl
7O20,X-RAY DIFFRACTION,3.67,66.48,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2021-03-30,2021-09-01,7O20,4190.0,1.0,480.0,376.0,4.0,53.54,1.0,1.8,experimental,33.26,0.1761,0.1624,X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 3 (mi300)
7O22,X-RAY DIFFRACTION,3.69,66.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2021-03-30,2021-09-01,7O22,4130.0,1.0,480.0,427.0,4.0,53.15,1.0,1.8,experimental,33.5,0.1825,0.169,X-ray structure of furin in complex with the guanylhydrazone-based inhibitor 4 (mi359)
7QY0,X-RAY DIFFRACTION,3.72,66.91,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2022-01-27,2022-04-20,7QY0,4378.0,1.0,480.0,476.0,4.0,53.68,1.0,1.54,experimental,26.16,0.1725,0.1493,X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 1
7QY1,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2022-01-27,2022-04-20,7QY1,4387.0,1.0,480.0,483.0,4.0,53.77,1.0,1.45,experimental,25.78,0.1754,0.1502,X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 4
7QY2,X-RAY DIFFRACTION,3.71,66.87,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2022-01-27,2022-04-20,7QY2,4373.0,1.0,480.0,471.0,4.0,53.72,1.0,1.55,experimental,27.19,0.1877,0.1645,X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 2
5D5K,X-RAY DIFFRACTION,2.9,57.64,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.6-0.7M sodium citrate, 0.1M sodium citrate buffer pH 5.6, and 7-10mM DTT",295.0,2015-08-10,2016-06-22,5D5K,3697.0,2.0,564.0,324.0,,61.23,2.0,1.9,experimental,,0.1705,0.1504,Crystal Structure NLS from human PARP-2 complexed with Importin alpha delta IBB
4UEL,X-RAY DIFFRACTION,2.4,49.0,,,"100 MM BIS-TRIS-PROPANE PH 5.8, 300 MM NABR, 21% PEG3350. 4 DEGREES CELSIUS",277.0,2014-12-18,2015-03-04,4UEL,3999.0,3.0,534.0,234.0,,59.36,3.0,2.3,experimental,41.613,0.23426,0.19141,UCH-L5 in complex with ubiquitin-propargyl bound to the RPN13 DEUBAD domain
7FTL,X-RAY DIFFRACTION,2.59,52.54,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTL,2944.0,1.0,362.0,29.0,,42.77,1.0,2.2,experimental,75.9929,0.2868,0.2361,Crystal Structure of human cyclic GMP-AMP synthase in complex with 8-chloro-2-(2-hydroxyphenyl)quinoline-4-carboxylic acid
7FTS,X-RAY DIFFRACTION,2.62,53.11,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTS,2953.0,1.0,362.0,7.0,,42.87,1.0,2.215,experimental,84.9217,0.2814,0.2194,Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-bromo-N-[[2-fluoro-5-(1-methylpyrazol-4-yl)phenyl]methyl]-2-hydroxybenzamide
5W78,X-RAY DIFFRACTION,2.52,51.19,"VAPOR DIFFUSION, SITTING DROP",,"post-chymotrypsin; 100 mM sodium citrate pH 5, 20 % PEG 6000",293.0,2017-06-19,2018-01-03,5W78,4519.0,2.0,562.0,176.0,8.0,66.28,2.0,2.271,experimental,,0.2007,0.1659,"Human acyloxyacyl hydrolase (AOAH), proteolytically processed"
6FYV,X-RAY DIFFRACTION,2.64,53.45,"VAPOR DIFFUSION, SITTING DROP",6.5,"30% Pentaerythritol ethoxylate (15/4 EO/OH),0.05M Ammonium Sulfate, 0.05M TRIS",298.0,2018-03-12,2018-07-18,6FYV,2872.0,1.0,337.0,92.0,,40.33,1.0,2.46,experimental,59.556,0.2234,0.203,X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A
8P08,X-RAY DIFFRACTION,2.58,52.25,VAPOR DIFFUSION,,"18% PEG 3350
0.2M Na malonate pH 7",277.0,2023-05-09,2023-05-17,8P08,2747.0,1.0,339.0,53.0,,39.94,1.0,2.4,experimental,51.12,0.26,0.209,Crystal structure of human CLK1 in complex with Leucettinib-21
4YT6,X-RAY DIFFRACTION,3.89,68.4,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM calcium chloride, 17.5% w/v PEG6000",277.0,2015-03-17,2015-04-29,4YT6,2771.0,2.0,311.0,301.0,9.0,35.56,2.0,2.07,experimental,34.94,0.2018,0.1773,Factor VIIa in complex with the inhibitor 4-{[(R)-[5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl](4-phenyl-1H-imidazol-2-yl)methyl]amino}benzenecarboximidamide
4YT7,X-RAY DIFFRACTION,3.53,65.13,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM calcium chloride, 17.5% w/v PEG6000",277.0,2015-03-17,2015-04-29,4YT7,2691.0,2.0,311.0,248.0,8.0,35.51,2.0,2.3,experimental,29.71,0.1975,0.1731,Factor VIIa in complex with the inhibitor 2-(2-{(R)-[(4-carbamimidoylphenyl)amino][5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl]methyl}-1H-imidazol-4-yl)benzamide
5SY3,X-RAY DIFFRACTION,3.02,59.33,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 0.06M citrate, 0.04M citric acid",293.0,2016-08-10,2016-11-02,5SY3,5642.0,2.0,678.0,379.0,6.0,76.87,1.0,2.3,experimental,42.034,0.2367,0.1921,Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors
6B4K,X-RAY DIFFRACTION,2.45,49.85,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MIB buffer pH 5.0 (malonate, imidazole, borate), 13 % (w/v) PEG 1500",277.0,2017-09-26,2018-06-20,6B4K,7026.0,2.0,860.0,219.0,,98.68,1.0,2.2,experimental,,0.2484,0.2069,Crystal structure of human DDX19B(AMPPNP)
5WWX,X-RAY DIFFRACTION,2.02,39.18,"VAPOR DIFFUSION, SITTING DROP",,"0.04M Magnesium acetate tetrahydrate, 0.05M Sodium cacodylate trihydrate pH 6.0, 30% v/v (+/-)-2-Methyl-2,4-pentanediol",293.0,2017-01-05,2017-08-23,5WWX,876.0,2.0,91.0,62.0,,11.44,1.0,2,experimental,23.0942,0.218,0.1701,Crystal structure of the KH2 domain of human RNA-binding E3 ubiquitin-protein ligase MEX-3C complex with RNA
5KQG,X-RAY DIFFRACTION,2.26,45.53,"VAPOR DIFFUSION, HANGING DROP",,"25-30% PEGME 5000, 100 mM Bis-Tris, pH 6.0-6.5",293.0,2016-07-06,2016-10-12,5KQG,1526.0,1.0,178.0,228.0,,20.59,1.0,1.5,experimental,,0.1941,0.1672,Co-crystal structure of LMW-PTP in complex with 2-(benzothiazol-2-ylamino)-2-oxo-1-phenylethanesulfonic acid
5KQL,X-RAY DIFFRACTION,2.25,45.28,"VAPOR DIFFUSION, HANGING DROP",,"25-30% PEGME 5000, 100 mM Bis-Tris, pH 6.0-6.5",293.0,2016-07-06,2016-10-12,5KQL,1545.0,1.0,178.0,268.0,,20.53,1.0,1.45,experimental,,0.1765,0.164,Co-crystal structure of LMW-PTP in complex with 2-oxo-1-phenyl-2-(phenylamino)ethanesulfonic acid
6G28,X-RAY DIFFRACTION,2.2,44.03,"VAPOR DIFFUSION, SITTING DROP",,"200 mM magnesium formate, 20 % (w/v) PEG3350",293.15,2018-03-22,2018-11-28,6G28,3315.0,1.0,367.0,355.0,,41.4,1.0,1.23,experimental,19.97,0.15744,0.14506,Human [protein ADP-ribosylargenine] hydrolase ARH1 in complex with ADP-ribose
6GZD,X-RAY DIFFRACTION,3.02,59.23,"VAPOR DIFFUSION, SITTING DROP",8.0,"CSNK1A1 at a concentration of 5.8 mg/ml (50 mM Tris-HCl, 300 mM NaCl, 0.25 mM TCEP, pH 8.0) was pre-incubated with 0.7 mM (4.7-fold molar excess) of Mg2+-ATP (120 mM in UPW) for 1 h. 0.1 uL of the protein solution was then mixed with 0.1 uL of reservoir solution (0.10 M MES/NaOH pH 6.8, 10.0% 2-propanol, 26.0% PEG400) and equilibrated at 4 C over 0.06mL of reservoir solution. Well diffracting crystals appeared within 4 days and grew to full size over 23 days.",277.15,2018-07-03,2018-08-29,6GZD,2865.0,1.0,374.0,190.0,,45.22,1.0,2.28,experimental,58.303,0.22117,0.17496,Crystal structure of Human CSNK1A1 with A86
5ZGC,X-RAY DIFFRACTION,3.09,60.23,"VAPOR DIFFUSION, SITTING DROP",9.0,"0.1M Bicine pH 9.0, 10% PEG 6000",291.0,2018-03-08,2019-04-03,5ZGC,12436.0,12.0,1710.0,61.0,,191.01,2.0,2.9,experimental,72.3898,0.2798,0.2244,Crystal Structure of SIRT3 in complex with H4K16bhb peptide
5VD4,X-RAY DIFFRACTION,2.15,42.66,"VAPOR DIFFUSION, HANGING DROP",6.9,"5.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM RAC-IV-016",291.0,2017-04-01,2018-04-04,5VD4,2187.0,1.0,289.0,48.0,,33.39,1.0,2.02,experimental,44.9582,0.2453,0.2026,"CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV-016, a MK1775 analougue"
5VD5,X-RAY DIFFRACTION,2.18,43.62,"VAPOR DIFFUSION, HANGING DROP",6.9,"5.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM RAC-IV-050",291.0,2017-04-01,2018-04-04,5VD5,2168.0,1.0,289.0,61.0,,32.96,1.0,2.05,experimental,50.0282,0.2341,0.1952,"CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV-050, a MK1775 analougue"
5VD7,X-RAY DIFFRACTION,2.18,43.54,"VAPOR DIFFUSION, HANGING DROP",6.9,"5.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM RAC-IV-098",291.0,2017-04-01,2018-04-04,5VD7,2190.0,1.0,289.0,70.0,,33.06,1.0,2.08,experimental,50.4459,0.2479,0.2072,"CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV-098, a MK1775 analogue"
5VD8,X-RAY DIFFRACTION,2.2,43.98,"VAPOR DIFFUSION, HANGING DROP",6.9,"5.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM RAC-IV-099",291.0,2017-04-01,2018-04-04,5VD8,2185.0,1.0,289.0,68.0,,33.14,1.0,1.85,experimental,49.6555,0.2469,0.2033,"Crystal structure of human WEE1 kinase domain in complex with RAC-IV-099, a MK1775 analogue"
5VD9,X-RAY DIFFRACTION,2.19,43.73,"VAPOR DIFFUSION, HANGING DROP",6.9,"5.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM RAC-IV-097",291.0,2017-04-01,2018-04-04,5VD9,2182.0,1.0,289.0,62.0,,33.02,1.0,1.87,experimental,55.3207,0.2529,0.2016,"Crystal structure of human WEE1 kinase domain in complex with RAC-IV-097, a MK1775 analogue"
5VDA,X-RAY DIFFRACTION,2.19,43.8,"VAPOR DIFFUSION, HANGING DROP",6.9,"5.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM RAC-IV-101",291.0,2017-04-01,2018-04-04,5VDA,2185.0,1.0,289.0,83.0,,33.02,1.0,2.1,experimental,46.0356,0.2554,0.1906,"Crystal structure of human WEE1 kinase domain in complex with RAC-IV-101, a MK1775 analogue"
8RXR,X-RAY DIFFRACTION,3.6,65.84,"VAPOR DIFFUSION, SITTING DROP",8.0,"22.5 % PEG3350, 0.2 M ammonium acetate, 0.1 M HEPES pH 8.0",277.0,2024-02-07,2024-03-20,8RXR,9463.0,2.0,1200.0,590.0,,138.8,1.0,2.06,experimental,47.699,0.2245,0.1816,Crystal structure of VPS34 in complex with inhibitor SB02024
6V0M,X-RAY DIFFRACTION,2.39,48.54,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1 M sodium citrate tribasic dihydrate pH 5, 25 % (w/v) PEG3350",290.0,2019-11-18,2020-04-01,6V0M,1796.0,3.0,213.0,117.0,,24.49,1.0,1.8,experimental,37.716,0.26307,0.21927,Sterile alpha-motif from apoptosis signal-regulating kinase 3
6DQC,X-RAY DIFFRACTION,2.23,44.9,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2019-06-12,6DQC,2682.0,1.0,330.0,162.0,,38.7,1.0,1.755,experimental,,0.215,0.1907,LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N50 i.e. 2-(4-((2-(dimethylamino)ethyl)(ethyl)carbamoyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl)isonicotinic acid
6DQD,X-RAY DIFFRACTION,2.22,44.52,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2019-06-12,6DQD,2617.0,1.0,330.0,167.0,,38.84,1.0,1.987,experimental,,0.2174,0.1887,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N53 i.e. 2-(5-([1,1'-biphenyl]-3-yl)-4-(1-(2-(piperidin-1-yl)ethoxy)ethyl)-1H-pyrazol-1-yl)isonicotinic acid"
6DQE,X-RAY DIFFRACTION,2.22,44.66,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2019-06-12,6DQE,2632.0,1.0,330.0,244.0,,38.81,1.0,1.689,experimental,,0.1873,0.1748,LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N67 i.e. 2-(5-phenyl-4-(phenyl(2-(piperidin-1-yl)ethoxy)methyl)-1H-pyrazol-1-yl)isonicotinic acid
5ANL,X-RAY DIFFRACTION,2.88,57.3,,,"0.1 M TRIS, PH=7.5, 1.8 M AMMONIUM SULFATE",,2015-09-07,2016-04-13,5ANL,4416.0,1.0,601.0,85.0,,68.99,1.0,2.7,experimental,45.423,0.26667,0.20534,"Crystal structure of VPS34 in complex with (2S)-8-((3R)-3- Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3, 4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one, processed with the CrystalDirect automated mounting and cryo-cooling technology"
6I3U,X-RAY DIFFRACTION,3.09,60.13,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.4 M Sodium Malonate pH 7.0, 0.1 M Bis-Tris Propane pH 7.0",293.0,2018-11-07,2019-03-20,6I3U,4634.0,1.0,615.0,179.0,,70.64,1.0,2.09,experimental,42.587,0.23556,0.18869,Optimization of potent and selective ATM inhibitors suitable for a proof-of-concept study in Huntington's disease models
6G5W,X-RAY DIFFRACTION,2.49,50.63,VAPOR DIFFUSION,5.5,"100mM Citrate, 10mM NiCl2, 20% PEG 3350",277.0,2018-03-30,2019-04-10,6G5W,6233.0,2.0,718.0,447.0,,84.94,1.0,1.83,experimental,44.6793,0.2177,0.1763,Crystal Structure of KDM4A with compound YP-03-038
6JUT,X-RAY DIFFRACTION,1.86,33.72,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M Bis-Tris pH 5.5, 25% PEG3350, 0.2M NaCl",298.0,2019-04-15,2019-07-24,6JUT,2515.0,1.0,310.0,116.0,,35.9,1.0,2.1,experimental,,0.2222,0.1792,Crystal structure of ZAK in complex with compound 6k
6JUU,X-RAY DIFFRACTION,1.84,33.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris pH 6.5, 28% PEG2000MME",298.0,2019-04-15,2020-04-22,6JUU,2472.0,1.0,310.0,103.0,,35.87,1.0,1.903,experimental,,0.2097,0.1662,Crystal structure of ZAK in complex with compound 6r
7OVY,X-RAY DIFFRACTION,2.15,42.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"co-crystallization, with 100mM AHA and inhibitor JG-31 at 1.1 mM with reservoir: 17% PEG 20000, 0.2M  Imidazole malate pH 8.5, 250 mM NaCl.",293.0,2021-06-15,2021-10-27,7OVY,1670.0,1.0,159.0,257.0,,19.41,1.0,1.24,experimental,19.89,0.209,0.184,Crystal structure of a dimeric based inhibitor JG34 in complex with the MMP-12 catalytic domain
6MOM,X-RAY DIFFRACTION,2.57,52.2,"VAPOR DIFFUSION, SITTING DROP",8.0,"9.5 mg/ml IRAK4 (CID100300, Batch BOS047020B) in 20 mM Tris-HCl, pH 8.0, 1 mM DTT, with 1 mM BSI107659 (NCGC00371481) in DMSO, crystallization condition: Microlytic screen MCSG1, E10: 0.2 M ammonium tartrate dibasic, 20% PEG3350, cryoprotectant: 20% ethylene glycol with 1 mM compound, tray 286446 e10, puck: xvc2-1",289.0,2018-10-04,2019-10-16,6MOM,10331.0,4.0,1212.0,1011.0,,138.08,1.0,2.1,experimental,32.1855,0.2066,0.1672,"Crystal structure of human Interleukin-1 receptor associated Kinase 4 (IRAK 4, CID 100300) in complex with compound NCC00371481 (BSI 107591)"
5BV7,X-RAY DIFFRACTION,3.29,62.62,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M Hepes pH 7, 5% PEG 20000",293.0,2015-06-04,2015-12-16,5BV7,10030.0,5.0,1320.0,388.0,11.0,145.52,5.0,2.45,experimental,53.133,0.2415,0.1885,"Crystal structure of human LCAT (L4F, N5D) in complex with Fab of an agonistic antibody"
6PJJ,X-RAY DIFFRACTION,2.59,52.46,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES pH 7.5, 0.1M Na/K phosphate, 15% PEG smear high, 10% etylene glycol",293.0,2019-06-28,2019-08-28,6PJJ,10677.0,4.0,1404.0,226.0,,166.74,1.0,2.4,experimental,32.956,0.2402,0.1903,Human PRPF4B bound to benzothiophene inhibitor 224
8GZF,X-RAY DIFFRACTION,3.39,63.7,"VAPOR DIFFUSION, SITTING DROP",8.0,"4% v/v glycerol, 1.8 M NaCl",291.0,2022-09-26,2023-05-31,8GZF,4525.0,2.0,532.0,105.0,,62.68,1.0,2.5,experimental,,0.2409,0.1902,Crystal Structure of METTL9-SAH
8HEO,X-RAY DIFFRACTION,2.28,46.11,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Bis-tris propane pH 8.0, 24% PEG 6000",277.0,2022-11-08,2023-11-15,8HEO,3049.0,3.0,409.0,20.0,,46.25,2.0,2.53,experimental,,,0.207,Crystal structure of SIAH1 SBD bound to Axin2 peptide
4WUA,X-RAY DIFFRACTION,2.77,55.64,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1M sodium citrate, 0.2M ammonium acetate, 5%PEG6000",293.0,2014-10-31,2015-09-16,4WUA,2945.0,1.0,401.0,113.0,,46.18,1.0,2,experimental,36.412,0.23634,0.19661,Crystal structure of human SRPK1 complexed to an inhibitor SRPIN340
6CEN,X-RAY DIFFRACTION,2.34,47.48,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 20% w/v PEG5000MME",291.0,2018-02-12,2018-05-09,6CEN,2124.0,2.0,235.0,226.0,,27.11,2.0,1.61,experimental,25.933,0.2151,0.1789,Crystal Structure of WHSC1L1 in Complex with Inhibitor PEP21
6MLK,X-RAY DIFFRACTION,2.7,54.45,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 15% Ethylene glycol, 0.2M Na2HPO4",295.0,2018-09-27,2018-10-17,6MLK,5297.0,3.0,786.0,65.0,3.0,84.44,3.0,2.45,experimental,70.5827,0.2352,0.1749,Structure of Thioesterase from DEBS with a thioesterase-specific antibody
6OBQ,X-RAY DIFFRACTION,2.31,46.86,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% PEG6000, 1 M lithium chloride, 0.1 M MES",277.0,2019-03-21,2019-09-18,6OBQ,5142.0,4.0,612.0,290.0,,70.44,2.0,1.84,experimental,,0.2602,0.2302,PP1 H66K in complex with Microcystin LR
6OBR,X-RAY DIFFRACTION,2.39,48.62,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% PEG6000, 1 M lithium chloride, 0.1 M MES",289.0,2019-03-21,2019-09-18,6OBR,5223.0,4.0,612.0,349.0,,70.46,2.0,1.5,experimental,,0.2101,0.1878,PP1 Y134A in complex with Microcystin LR
6YG6,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, SITTING DROP",8.2,"19% PEG3350,  0.15 M ammonium acetate,
0.1 M tris, pH 8.2",293.15,2020-03-27,2020-08-12,6YG6,4807.0,2.0,614.0,163.0,2.0,71.5,1.0,2.15,experimental,62.631,0.2389,0.2036,Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor TL10-105
6YG7,X-RAY DIFFRACTION,2.28,45.97,"VAPOR DIFFUSION, SITTING DROP",8.5,"25% PEG3350, 0.1 M ammonium acetate,
0.1 M tris, pH 8.5",293.15,2020-03-27,2020-08-12,6YG7,4614.0,2.0,614.0,72.0,2.0,71.44,1.0,2.2,experimental,65.103,0.251,0.2074,Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor SB1-G-23
5YGX,X-RAY DIFFRACTION,3.0,58.94,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2M sodium citrate tribasic pH6.5, 0.2M ammonium iodide, 19.3%(w/v) PEG5000MME",293.0,2017-09-27,2018-08-08,5YGX,3292.0,1.0,416.0,277.0,3.0,47.64,1.0,2.2,experimental,34.329,0.207,0.1784,"Structure of BACE1 in complex with N-(3-((4R,5R,6S)-2-amino-6-(1,1-difluoroethyl)-5-fluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide"
6JT3,X-RAY DIFFRACTION,3.0,59.0,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium citrate tribasic pH 6.5, 0.2 M ammonium iodide, 20.3% w/v PEG 5000MME",293.15,2019-04-08,2019-10-30,6JT3,3188.0,1.0,416.0,199.0,3.0,47.24,1.0,2.4,experimental,35.613,0.2425,0.1866,"Crystal Structure of BACE1 in complex with N-{3-[(4R,5R,6R)-2-amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-5-(fluoromethoxy)pyrazine-2-carboxamide"
6ZDL,X-RAY DIFFRACTION,2.58,52.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM  HEPES pH 7.5, 200 mM MgCl2, 30% v/v PEG 400 (Alfa Aesar), 1 mM Anderson-Evans polyoxotungstate TEW.
Protein at 10 mg/ml in 25 mM HEPES pH 7.0, 200 mM NaCl buffer.",292.0,2020-06-14,2020-11-18,6ZDL,3204.0,1.0,382.0,113.0,,50.22,1.0,1.9,experimental,29.729,0.2234,0.1927,Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with GlcIFG and hexatungstotellurate(VI) TEW
6ZJ5,X-RAY DIFFRACTION,2.57,52.2,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES pH 7.5 - 8.1, 200 mM MgCl2, 25-27.5% v/v PEG 400, 1 mM TEW
Protein in 25 mM HEPES pH 7.0, 200 mM NaCl buffer at 10 mg/ml.",292.0,2020-06-27,2020-12-09,6ZJ5,3248.0,1.0,382.0,94.0,,50.71,1.0,2.269,experimental,29.85,0.2559,0.1882,Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with GlcDMJ and hexatungstotellurate(VI) TEW
7UW6,X-RAY DIFFRACTION,2.53,51.31,"VAPOR DIFFUSION, HANGING DROP",,"The crystallization buffer grid is 25-30% PEGME 5000 in 100 mM Bis-Tris, pH 6.0-6.5.

The final concentration of the ligand in the crystallization solution is 1 mM.",293.0,2022-05-02,2022-10-19,7UW6,1527.0,1.0,177.0,219.0,,20.38,1.0,1.5,experimental,28.6135,0.1945,0.1611,The co-crystal structure of low molecular weight protein tyrosine phosphatase (LMW-PTP) with a small molecule inhibitor SPAA-2
7N1J,X-RAY DIFFRACTION,2.64,53.45,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium chloride, 0.1 M MES (pH 6.0), 20% PEG 3,350",277.15,2021-05-27,2022-04-06,7N1J,2558.0,4.0,392.0,,2.0,43.62,2.0,2.99,experimental,59.93,0.2329,0.2086,Crystal structure of FGFR4 domain 3 in complex with a de novo-designed mini-binder
4RK8,X-RAY DIFFRACTION,3.43,64.14,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate pH 4.8, 40 mM UDAO, 20.8 mM, N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate, 1 mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-10-12,2015-11-11,4RK8,3206.0,1.0,390.0,249.0,,44.7,1.0,2.22,experimental,19.225,0.17659,0.14221,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A356
4RKA,X-RAY DIFFRACTION,3.41,63.89,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate pH 4.8, 40 mM UDAO, 20.8 mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate, 1 mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-10-12,2015-11-11,4RKA,2997.0,1.0,390.0,106.0,,44.2,1.0,2.71,experimental,17.782,0.2278,0.16325,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A347
4RR4,X-RAY DIFFRACTION,3.46,64.46,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate pH 4.8, 40 mM UDAO, 20.8 mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate, 1 mM inhibitor, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-11-06,2015-11-25,4RR4,3046.0,1.0,390.0,162.0,,43.94,1.0,2.38,experimental,21.959,0.20739,0.16409,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A367
4YLW,X-RAY DIFFRACTION,3.43,64.11,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM UDAO, 20.8mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate",293.0,2015-03-06,2016-03-09,4YLW,3071.0,1.0,390.0,154.0,,44.61,1.0,1.79,experimental,22.646,0.17822,0.15461,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with No.33 compound
4ZMG,X-RAY DIFFRACTION,3.44,64.28,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40 mM UDAO, 20.8 mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate, 1 mM inhibitor",293.0,2015-05-04,2016-05-04,4ZMG,3037.0,1.0,390.0,144.0,,43.86,1.0,1.9,experimental,18.978,0.19788,0.17644,Crystal structure of Human Dihydroorotate Dehydrogenase (DHODH) with DH03A338
5H2Z,X-RAY DIFFRACTION,3.44,64.28,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM C11DAO, 20.8mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8 M ammonium sulfate",293.0,2016-10-19,2017-03-01,5H2Z,2998.0,1.0,390.0,134.0,,43.92,1.0,1.58,experimental,25.213,0.18567,0.17036,Crystal structure of Human Dihydroorotate Dehydrogenase (DHODH) with 7GF
5MK0,X-RAY DIFFRACTION,2.18,43.54,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium tartrate dibasic, 20% PEG3350 and 0.1 M MMT buffer pH 9.0, 25% PEG1500",277.0,2016-12-02,2017-08-16,5MK0,6521.0,4.0,766.0,504.0,,86.57,2.0,1.765,experimental,,0.1929,0.1601,Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (Endofin peptide complex)
5F6D,X-RAY DIFFRACTION,2.74,55.08,VAPOR DIFFUSION,8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol 8000",294.0,2015-12-05,2016-04-27,5F6D,1614.0,1.0,157.0,266.0,,17.96,1.0,1.553,experimental,,0.1962,0.1706,Crystal structure of Ubc9 (K48A/K49A/E54A) complexed with Fragment 6
5F6E,X-RAY DIFFRACTION,2.75,55.28,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol",294.0,2015-12-05,2016-04-27,5F6E,1865.0,1.0,157.0,292.0,,17.79,1.0,1.12,experimental,,0.1699,0.154,Crystal Structure of human Ubc9 (K48A/K49A/E54A)
5F6U,X-RAY DIFFRACTION,2.75,55.29,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol",294.0,2015-12-07,2016-04-27,5F6U,1625.0,1.0,157.0,239.0,,18.01,1.0,1.552,experimental,,0.203,0.1755,Crystal Structure of Ubc9 (K48A/K49A/E54A) complexed with Fragment 8 (JSS190B146)
5F6V,X-RAY DIFFRACTION,2.71,54.63,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol 8000",294.0,2015-12-07,2016-04-27,5F6V,1582.0,1.0,157.0,228.0,,17.91,1.0,1.492,experimental,,0.1838,0.1519,Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 1 (biphenol from fragment cocktail screen)
5F6W,X-RAY DIFFRACTION,2.73,54.98,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol",294.0,2015-12-07,2016-04-27,5F6W,1537.0,1.0,157.0,244.0,,17.91,1.0,1.699,experimental,,0.2004,0.1718,Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 1 (biphenol)
5F6X,X-RAY DIFFRACTION,2.73,55.03,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol 8000",294.0,2015-12-07,2016-04-27,5F6X,1594.0,1.0,157.0,273.0,,17.91,1.0,1.56,experimental,11.124,0.19314,0.17428,Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 2 (mercaptobenzoxazole from cocktail screen)
5F6Y,X-RAY DIFFRACTION,2.71,54.68,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol 8000",294.0,2015-12-07,2016-04-27,5F6Y,1563.0,1.0,157.0,185.0,,17.91,1.0,1.14,experimental,10.817,0.17777,0.15559,Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 2 (mercaptobenzoxazole)
6G5X,X-RAY DIFFRACTION,2.51,50.98,VAPOR DIFFUSION,5.5,"100mM Citrate, 10mM NiCl2, 20% PEG 3350",277.0,2018-03-30,2019-04-10,6G5X,6389.0,2.0,718.0,566.0,,85.15,1.0,1.78,experimental,39.5807,0.2033,0.1701,Crystal Structure of KDM4A with compound YP-02-145
5XVE,X-RAY DIFFRACTION,1.98,37.84,"VAPOR DIFFUSION, SITTING DROP",8.0,"21% PEG3350, 8% Tacsimate (pH8.0)",295.0,2017-06-27,2018-02-28,5XVE,3761.0,2.0,432.0,356.0,,49.84,2.0,1.24,experimental,15.025,0.16403,0.14694,Crystal structure of human USP2 C276S mutant in complex with ubiquitin
4RYC,X-RAY DIFFRACTION,3.18,61.35,"VAPOR DIFFUSION, HANGING DROP",4.5,"HANGING DROP, VAPOR DIFFUSION, 20 DEG C, 1 UL PROTEIN + 1 UL RESERVOIR; PROTEIN SOLUTION: 31.7 MG/ML RENIN, 12.5 MM TRIS PH 8, 25 MM NACL; RESERVOIR SOLUTION: 21% PEG4000, 50 MM NACITRATE PH 4.5, 600 MM NACL; SOAKING: DROP PLUS 2.5 UL RESERVOIR SOLUTION PLUS 10 MM COMPOUND AND 10% DMSO FOR 30 MIN; CRYO: SOAKING SOLUTION PLUS 15% GLYCEROL, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-12-15,2015-03-25,4RYC,5503.0,2.0,680.0,222.0,6.0,76.22,1.0,2.45,experimental,51.7,0.2289,0.1905,"RENIN IN COMPLEXED WITH 4-methoxy-3-(3-methoxypropoxy)-N-{[(3S,4S)-4-{[(4-methylphenyl)sulfonyl]amino}pyrrolidin-3-yl]methyl}-N-(propan-2-yl)benzamide INHIBITOR"
4RYG,X-RAY DIFFRACTION,3.18,61.31,"VAPOR DIFFUSION, HANGING DROP",4.0,"HANGING DROP, VAPOR DIFFUSION, 1 UL PROTEIN + 1 UL RESERVOIR; PROTEIN SOLUTION: 9.4 MG/ML RENIN, 12.5 MM TRIS PH 8, 25 MM NACL; RESERVOIR SOLUTION: 18% PEG4000, 50 MM NACITRATE PH 4.0, 600 MM NACL; SOAKING: DROP PLUS 2.5 UL RESERVOIR SOLUTION PLUS 10 MM INHIBITOR 54 AND 10% DMSO FOR 20 MIN; CRYO: SOAKING SOLUTION PLUS 15% GLYCEROL, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-12-15,2015-03-25,4RYG,5442.0,2.0,680.0,149.0,6.0,76.3,1.0,2.65,experimental,57.42,0.2225,0.1829,"RENIN IN COMPLEXED WITH N-({(3S,4S)-4-[(benzylsulfonyl)amino]pyrrolidin-3-yl}methyl)-4-methoxy-3-(3-methoxypropoxy)-N-(propan-2-yl)benzamide INHIBITOR"
4RZ1,X-RAY DIFFRACTION,3.15,61.0,"VAPOR DIFFUSION, HANGING DROP",4.0,"REMARK: HANGING DROP, VAPOR DIFFUSION, 1 UL PROTEIN + 1 UL RESERVOIR; PROTEIN SOLUTION: 9.4 MG/ML RENIN, 12.5 MM TRIS PH 8, 25 MM NACL; RESERVOIR SOLUTION: 21% PEG4000, 50 MM NACITRATE PH 4.0, 400 MM NACL; SOAKING: DROP PLUS 2.5 UL RESERVOIR SOLUTION PLUS 10 MM compound AND 10% DMSO FOR 20 MIN; CRYO: SOAKING SOLUTION PLUS 15% GLYCEROL, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-12-18,2015-03-25,4RZ1,5463.0,2.0,680.0,178.0,6.0,76.26,1.0,2.6,experimental,56.94,0.2271,0.199,"RENIN IN COMPLEXED WITH (3S,4S)-4-({[4-methoxy-3-(3-methoxypropoxy)benzoyl](propan-2-yl)amino}methyl)pyrrolidin-3-yl benzylcarbamate INHIBITOR"
5BVW,X-RAY DIFFRACTION,2.33,47.28,VAPOR DIFFUSION,,"18.0%w/v PEG 3350, 0.2M NH4I",277.0,2015-06-05,2015-08-05,5BVW,2540.0,1.0,324.0,287.0,1.0,37.94,1.0,1.94,experimental,45.088,0.2335,0.1836,Fragment-based discovery of potent and selective DDR1/2 inhibitors
6OBU,X-RAY DIFFRACTION,2.44,49.62,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% PEG6000, 1 M lithium chloride, 0.1 M MES, pH 6.0",289.0,2019-03-21,2019-09-18,6OBU,5264.0,4.0,612.0,342.0,,71.26,2.0,1.95,experimental,,0.2019,0.1649,PP1 Y134K in complex with Microcystin LR
7BU7,X-RAY DIFFRACTION,4.51,72.73,LIPIDIC CUBIC PHASE,,"100mM HEPES, pH 7.5, 100-175mM (NH4)2SO4, 38-43% PEG400, 0.15M-0.2M Glycine",293.0,2020-04-04,2020-12-02,7BU7,4669.0,2.0,644.0,25.0,3.0,74.51,2.0,2.6,experimental,83.32,0.2698,0.2435,Structure of human beta1 adrenergic receptor bound to BI-167107 and nanobody 6B9
6DI0,X-RAY DIFFRACTION,2.26,45.56,"VAPOR DIFFUSION, HANGING DROP",6.9,ID : MSC2267302.1,294.0,2018-05-22,2018-10-17,6DI0,2736.0,1.0,271.0,344.0,,31.82,1.0,1.3,experimental,12.1909,0.2016,0.18,CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND
6FUL,X-RAY DIFFRACTION,2.53,51.45,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris-HCl (pH 8.5), Li2 SO4 (0.15-0.25 M), PEG 3350 (20-25% w/v)",277.0,2018-02-27,2018-10-10,6FUL,4555.0,1.0,531.0,627.0,,61.25,1.0,1.649,experimental,,0.2079,0.1764,Crystal structure of UTX complexed with 5-hydroxy-4-keto-1-methyl-picolinate
6BJI,X-RAY DIFFRACTION,2.28,46.04,SMALL TUBES,,"Spontaneous crystals were recovered from concentrated stocks of GTA/D302C (95-100 mg/mL) stored in 50 mM MOPS, pH 7.00, 0.1 M sodium chloride, 1 mM DTT, 5 mM manganese chloride, and kept at 277 K.",277.0,2017-11-06,2018-09-19,6BJI,2523.0,1.0,294.0,270.0,,34.4,1.0,1.54,experimental,21.503,0.2087,0.1811,Human ABO(H) blood group glycosyltransferase GTA D302C mutant
6JAT,X-RAY DIFFRACTION,2.9,57.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M HEPES/Sodium hydroxide, 0.2 M Ammonium sulfate, 20% PEG 8000, 10% 2-propanol",291.0,2019-01-25,2020-01-29,6JAT,8135.0,4.0,1042.0,84.0,,121.08,2.0,2.713,experimental,46.2428,0.2429,0.1995,Crystal structure of SETD3 bound to Actin peptide and SFG
6ZFN,X-RAY DIFFRACTION,2.07,40.5,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM sodium acetate pH 4.6, 200 mM ammonium sulfate, 12.8% PEG-MME 2000.
Protein at 10 mg/ml in 25 mM HEPES pH 7.0, 200 mM NaCl buffer with 2.3 mM GlcMan4OMe (10 x molar ratio). 500 nl protein solution and 500 nl reservoir solution.",279.0,2020-06-17,2020-11-18,6ZFN,3740.0,1.0,382.0,491.0,,45.23,1.0,1.1,experimental,14.999,0.1279,0.1063,"Structure of an inactive E404Q variant of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with 1-methyl alpha-1,2-mannobiose"
6ZK6,X-RAY DIFFRACTION,2.25,45.26,"VAPOR DIFFUSION, SITTING DROP",8.0,"PEG 3350, TRIS , lithium chloride",293.0,2020-06-29,2020-11-18,6ZK6,2434.0,1.0,331.0,128.0,,38.01,1.0,1.9,experimental,43.57,0.1944,0.1594,Protein Phosphatase 1 (PP1) T320E mutant
6FDK,X-RAY DIFFRACTION,2.05,39.91,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES pH 6.5, 12% PEG 20000",293.15,2017-12-25,2018-08-15,6FDK,2998.0,2.0,341.0,423.0,,39.07,2.0,1.6,experimental,23.148,0.20333,0.16955,Structure of Chlamydia trachomatis effector protein Cdu1 bound to ubiquitin
6I0C,X-RAY DIFFRACTION,3.12,60.55,"VAPOR DIFFUSION, HANGING DROP",,"MES pH 6.5
Ammonium Sulfate",293.0,2018-10-25,2019-03-27,6I0C,4498.0,1.0,529.0,56.0,3.0,63.01,1.0,2.675,experimental,,0.2515,0.19,Human butyrylcholinesterase in complex with the R enantiomer of a chlorotacrine-tryptophan multi-target inhibitor.
6O3I,X-RAY DIFFRACTION,2.64,53.33,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis Tris propane pH 6.5, 20% PEG 3350, 0.2 M potassium thiocyanate",293.0,2019-02-26,2019-07-17,6O3I,6180.0,2.0,840.0,91.0,1.0,96.69,1.0,2.69,experimental,74.28,0.2639,0.2163,Crystal Structure of Human IDO1 bound to navoximod (NLG-919)
5A80,X-RAY DIFFRACTION,2.69,54.29,,8.5,"30% PEG3350, 0.1M TRIS PH 8.5, 0.2M AMMONIUM SULFATE",,2015-07-11,2016-01-13,5A80,5779.0,2.0,762.0,136.0,,90.46,1.0,2.28,experimental,,0.2489,0.1901,Crystal structure of human JMJD2A in complex with compound 40
6OSH,X-RAY DIFFRACTION,2.04,39.75,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Na citrate tribasic
20% PEG3350",294.0,2019-05-01,2020-04-01,6OSH,2812.0,3.0,323.0,426.0,5.0,35.02,3.0,1.117,experimental,,0.1692,0.1621,Potent and Selective Antitumor Antibody Targeting a Membrane-Proximal Epitope of ROR2
6OSV,X-RAY DIFFRACTION,2.13,37.61,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.01 M Magnesium chloride hexahydrate, 0.005 M Nickel(II) chloride 
0.1 M HEPES sodium pH 7.0, 
15% w/v Polyethylene glycol 3,350",294.0,2019-05-02,2020-04-01,6OSV,2721.0,3.0,335.0,338.0,6.0,36.11,3.0,1.34,experimental,,0.189,0.162,Potent and Selective Antitumor Antibody Targeting a Membrane-Proximal Epitope of ROR2
7S7E,X-RAY DIFFRACTION,2.83,56.59,"VAPOR DIFFUSION, SITTING DROP",8.0,"18-24% PEG4000, 0.1 SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE",290.0,2021-09-15,2022-11-02,7S7E,3660.0,3.0,384.0,409.0,3.0,45.14,3.0,2.04,experimental,35.045,0.235,0.172,STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PEPTIDE
7S7F,X-RAY DIFFRACTION,2.88,57.3,"VAPOR DIFFUSION, SITTING DROP",8.0,"18-24% PEG4000, 0.1 SODIUM CITRATE, 20% ISOPROPANOL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE",290.0,2021-09-15,2022-11-02,7S7F,3795.0,3.0,384.0,497.0,3.0,45.2,3.0,1.88,experimental,31.267,0.2169,0.1684,STRUCTURE OF HLA-B*07:02 IN COMPLEX WITH DOT1L(998-1006) PHOSPHOPEPTIDE
6H4S,X-RAY DIFFRACTION,2.46,50.08,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",293.0,2018-07-23,2019-06-12,6H4S,11487.0,4.0,1440.0,640.0,,170.25,1.0,2.45,experimental,47.65,0.218,0.173,Crystal structure of human KDM4A in complex with compound 16m
6H4W,X-RAY DIFFRACTION,2.45,49.83,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",293.0,2018-07-23,2019-06-12,6H4W,10871.0,4.0,1440.0,176.0,,170.09,1.0,2.81,experimental,53.96,0.266,0.218,Crystal structure of human KDM4A in complex with compound 19d
8AF0,X-RAY DIFFRACTION,2.11,41.74,"VAPOR DIFFUSION, SITTING DROP",,"200 mM NaCl, 20 % (w/v) PEG6000, 100 mM Hepes pH 7.0",277.15,2022-07-15,2022-09-14,8AF0,2851.0,4.0,284.0,60.0,6.0,40.69,1.0,2.43,experimental,61.85,0.2681,0.2051,Crystal structure of human angiogenin and RNA duplex
6SEQ,X-RAY DIFFRACTION,3.05,59.63,"VAPOR DIFFUSION, SITTING DROP",6.5,"LMTK3 at 3.2 mg/ml in 20 mM Tris pH 7.5, 200 mM NaCl was crystallised with 70 mM bis-Tris Propane pH 6.5, 14 % w/v Polyethylene Glycol 3350, 14 mM Sodium/Potassium Phosphate, 30 % w/v sucrose",277.0,2019-07-30,2020-11-25,6SEQ,2588.0,1.0,1460.0,354.0,,153.8,1.0,2.1,experimental,25.01,0.262,0.194,Lemur tyrosine kinase 3 (LMTK3)
7W7O,X-RAY DIFFRACTION,2.12,42.0,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.1M sodium acetate (pH 4.6), 8% (w/v) PEG 4000, protein concentration 13mg/ml",293.15,2021-12-06,2023-06-07,7W7O,3020.0,1.0,334.0,314.0,,38.44,1.0,1.59,experimental,30.4564,0.1954,0.1634,The crystal structure of human Calpain-1 protease core in complex with 14a
7X79,X-RAY DIFFRACTION,0.98,25.94,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium acetate (pH 4.6), 8% (w/v) PEG 4000, protein concentration 13mg/ml",293.15,2022-03-09,2023-06-14,7X79,2934.0,1.0,714.0,311.0,,82.7,1.0,1.8,experimental,30.2757,0.2015,0.1659,The crystal structure of human Calpain-1 protease core in complex with 14b
7KH8,X-RAY DIFFRACTION,2.16,42.98,"VAPOR DIFFUSION, SITTING DROP",5.0,"PEG 3350, Potassium Nitrate, Bis-Tris",293.0,2020-10-20,2021-05-19,7KH8,3127.0,2.0,314.0,466.0,,36.61,1.0,1.3,experimental,18.557,0.1608,0.1254,Human LMPTP in complex with inhibitor
4UFU,X-RAY DIFFRACTION,2.4,49.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-19,2016-04-13,4UFU,3623.0,2.0,480.0,195.0,,55.91,1.0,2.1,experimental,43.188,0.21366,0.16896,Crystal structure of human tankyrase 2 in complex with TA-12
4UFY,X-RAY DIFFRACTION,2.5,50.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-20,2016-04-13,4UFY,3947.0,2.0,480.0,460.0,,55.89,1.0,1.7,experimental,24.074,0.19125,0.16727,Crystal structure of human tankyrase 2 in complex with TA-13
4UHG,X-RAY DIFFRACTION,2.5,50.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-24,2016-04-13,4UHG,4016.0,2.0,480.0,553.0,,55.68,1.0,1.7,experimental,20.837,0.20362,0.17514,Crystal structure of human tankyrase 2 in complex with TA-21
4UVN,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-07,2015-07-29,4UVN,3759.0,2.0,480.0,280.0,,55.94,1.0,2.2,experimental,17.507,0.2387,0.18423,"Crystal structure of human tankyrase 2 in complex with 5-amino-3-(4- chlorophenyl)-1,2-dihydroisoquinolin-1-one"
4UVO,X-RAY DIFFRACTION,2.45,50.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-07,2015-07-29,4UVO,3850.0,2.0,480.0,383.0,,55.92,1.0,1.85,experimental,18.083,0.19735,0.16633,"Crystal structure of human tankyrase 2 in complex with 5-amino-3-(4- methoxyphenyl)-1,2-dihydroisoquinolin-1-one"
4UVT,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-08,2015-07-29,4UVT,3802.0,2.0,480.0,368.0,,55.77,1.0,1.95,experimental,22.054,0.21306,0.16868,"Crystal structure of human tankyrase 2 in complex with 5-amino-4- methyl-1,2-dihydroisoquinolin-1-one"
4UVU,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-08,2015-07-29,4UVU,3694.0,2.0,480.0,259.0,,56.03,1.0,1.95,experimental,35.554,0.19183,0.17113,"Crystal structure of human tankyrase 2 in complex with 1-((4-(5- methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)phenyl)methyl)pyrrolidin-1- ium"
4UVV,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-08,2015-07-29,4UVV,3731.0,2.0,480.0,292.0,,55.93,1.0,1.9,experimental,35.195,0.19803,0.16623,"Crystal structure of human tankyrase 2 in complex with 3-(4- chlorophenyl)-5-methyl-1,2-dihydroisoquinolin-1-one"
4UVX,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-08,2015-07-29,4UVX,3686.0,2.0,480.0,256.0,,55.85,1.0,1.95,experimental,36.875,0.21121,0.1693,"Crystal structure of human tankyrase 2 in complex with 3-(4- chlorophenyl)-5-fluoro-1,2-dihydroisoquinolin-1-one"
4UVY,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-08,2015-07-29,4UVY,3869.0,2.0,480.0,414.0,,55.87,1.0,1.95,experimental,25.379,0.21538,0.17482,"Crystal structure of human tankyrase 2 in complex with 3-(4- chlorophenyl)-5-methoxy-1,2- dihydroisoquinolin-1-one"
4UVZ,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-08,2015-07-29,4UVZ,3959.0,2.0,480.0,480.0,,55.89,1.0,1.6,experimental,16.018,0.18851,0.16365,"Crystal structure of human tankyrase 2 in complex with 5-amino-3- phenyl-1,2-dihydroisoquinolin-1-one"
5AKU,X-RAY DIFFRACTION,2.4,49.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-05,2015-07-29,5AKU,3859.0,2.0,480.0,347.0,,56.04,1.0,1.8,experimental,28.82,0.19536,0.16898,"Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1,2, 3,4-tetrahydroquinazolin-4-one"
5AKW,X-RAY DIFFRACTION,2.4,49.0,,8.5,pH 8.5,,2015-03-05,2015-07-29,5AKW,3656.0,2.0,480.0,201.0,,55.72,1.0,2.07,experimental,29.431,0.2115,0.17603,"Crystal structure of TNKS2 in complex with 2-(4-chlorophenyl)-1,2,3,4- tetrahydroquinazolin-4-one"
5AL1,X-RAY DIFFRACTION,2.4,49.0,,8.5,pH 8.5,,2015-03-06,2015-07-29,5AL1,3882.0,2.0,480.0,397.0,,55.95,1.0,1.75,experimental,25.771,0.19761,0.16681,"Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1H, 2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one"
5AL2,X-RAY DIFFRACTION,2.4,49.0,,8.5,PH 8.5,,2015-03-06,2015-07-29,5AL2,3623.0,2.0,480.0,184.0,,55.74,1.0,1.9,experimental,28.071,0.21856,0.18503,"Crystal structure of TNKS2 in complex with 2-(4-(propan-2-yl)phenyl)- 1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one"
5AL3,X-RAY DIFFRACTION,2.4,49.0,,8.5,pH 8.5,,2015-03-06,2015-07-29,5AL3,3805.0,2.0,480.0,329.0,,56.1,1.0,1.75,experimental,26.239,0.19309,0.15873,"Crystal structure of TNKS2 in complex with 2-(2,4-dichlorophenyl)-1- methyl-1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one"
5AL4,X-RAY DIFFRACTION,2.4,49.0,,8.5,pH 8.5,,2015-03-06,2015-07-29,5AL4,3720.0,2.0,480.0,279.0,,55.8,1.0,1.9,experimental,27.65,0.19779,0.167,"Crystal structure of TNKS2 in complex with 2-(4-methylpiperazin-1-yl)- 3,4,5,6,7,8-hexahydroquinazolin-4-one"
5AL5,X-RAY DIFFRACTION,2.4,49.0,,8.5,pH 8.5,,2015-03-06,2015-07-29,5AL5,3720.0,2.0,480.0,270.0,,55.95,1.0,2.05,experimental,29.689,0.22253,0.17372,"Crystal structure of TNKS2 in complex with 2-(4-((pyridin-4-yl)methyl) piperazin-1-yl)-3,4,5,6,7,8-hexahydroquinazolin-4-one"
5LM1,X-RAY DIFFRACTION,2.65,53.53,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M KSCN, 20% PEG3350",294.0,2016-07-28,2016-11-30,5LM1,2742.0,2.0,372.0,31.0,,42.39,2.0,2.55,experimental,,0.2539,0.213,Crystal Structure of HD-PTP phosphatase in complex with UBAP1
6IRD,X-RAY DIFFRACTION,2.61,52.86,LIQUID DIFFUSION,6.5,"0.2M MgCl2, 0.1M BIS-TRIS pH6.5, 20% w/v Polyethylene glycol 3350",289.0,2018-11-12,2019-01-23,6IRD,3194.0,2.0,482.0,,,54.77,2.0,2.813,experimental,28.8551,0.3022,0.244,Complex structure of INADL PDZ89 and PLCb4 C-terminal CC-PBM
6JG0,X-RAY DIFFRACTION,2.86,56.92,"VAPOR DIFFUSION, HANGING DROP",5.5,"20% PEG3350, 5% glycerol, 0.3 M (NH4)2SO4, and 0.1 M Bis-Tris-HCl (pH 5.5)",293.0,2019-02-13,2020-02-19,6JG0,2098.0,1.0,262.0,77.0,,30.02,1.0,2.5,experimental,51.417,0.25903,0.18796,Crystal structure of the N-terminal domain single mutant (S92E) of the human mitochondrial calcium uniporter fused with T4 lysozyme
6WJY,X-RAY DIFFRACTION,2.84,56.68,VAPOR DIFFUSION,7.5,"0.1 mM Tris, 16% (w/v) PEG4000, 0.2 M NH4OAc",293.0,2020-04-14,2020-08-26,6WJY,6689.0,2.0,788.0,492.0,1.0,89.48,1.0,1.91,experimental,46.657,0.2076,0.1796,HUMAN IDO1 IN COMPLEX WITH COMPOUND 4-A
6WPE,X-RAY DIFFRACTION,3.0,59.06,VAPOR DIFFUSION,,"0.1 mM Tris pH 8.0, 20% (w/v) PEG6000, 0.2 M NaCl",293.0,2020-04-27,2021-03-10,6WPE,6253.0,2.0,788.0,155.0,1.0,89.59,1.0,2.43,experimental,,0.235,0.1979,HUMAN IDO1 IN COMPLEX WITH COMPOUND 4
7M7D,X-RAY DIFFRACTION,2.74,55.12,"VAPOR DIFFUSION, HANGING DROP",8.0,"100 mM Tris pH 8.0, 18% (w/v) PEG6000, 0.2 M NaCl",293.0,2021-03-27,2021-09-01,7M7D,6066.0,2.0,822.0,7.0,1.0,94.59,1.0,2.6,experimental,85.15,0.2352,0.2088,"Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with IACS-8968"
6FHB,X-RAY DIFFRACTION,2.93,57.99,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG 8000, 0.2M magnesium acetate",292.15,2018-01-12,2019-01-30,6FHB,2688.0,1.0,337.0,197.0,,39.16,1.0,1.75,experimental,,0.2215,0.187,Death-associated Protein Kinase 1 (DAPK1) catalytic and auto-regulatory domains with S289A and S308E mutations
8A16,X-RAY DIFFRACTION,2.52,51.13,"VAPOR DIFFUSION, SITTING DROP",,200 mM ammonium nitrate and 20% (w/v) PEG 3350,293.0,2022-05-31,2023-03-15,8A16,3809.0,2.0,516.0,,2.0,59.77,1.0,2.89,experimental,75.76,0.2881,0.2342,"Human PTPRM domains FN3-4, in spacegroup P212121"
7UXJ,X-RAY DIFFRACTION,2.18,43.54,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M Potassium bromide, 30% w/v Polyethylene glycol monomethyl ether 2,000",291.15,2022-05-05,2022-12-28,7UXJ,5881.0,8.0,712.0,355.0,,78.77,2.0,2.07,experimental,40.5793,0.2616,0.2244,"Structure of PPIA in complex with FP29102, a Helicon Polypeptide"
5VAC,X-RAY DIFFRACTION,2.34,47.49,"VAPOR DIFFUSION, HANGING DROP",,"50% polypropylene glycol 400, 5% DMSO, 0.1 M HEPES-NaOH (pH 6.0)",298.0,2017-03-24,2017-04-19,5VAC,1841.0,2.0,248.0,78.0,,28.56,2.0,1.949,experimental,,0.2281,0.1888,Crystal Structure of ATXR5 SET domain in complex with K36me3 histone H3 peptide
5O26,X-RAY DIFFRACTION,2.15,42.85,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 0.1M bis-tris pH 5.5",293.0,2017-05-19,2017-06-28,5O26,4489.0,2.0,568.0,165.0,,66.54,1.0,2.379,experimental,,0.2781,0.2284,Crystal structure of WNK3 kinase domain in a diphosphorylated state and in complex with AMP-PNP/Mg2+
5O2B,X-RAY DIFFRACTION,2.16,43.06,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 0.2M magnesium chloride, 0.1M bis-tris pH 5.5",293.0,2017-05-19,2017-06-28,5O2B,4330.0,2.0,570.0,252.0,,65.97,1.0,2.038,experimental,,0.2401,0.199,Crystal structure of WNK3 kinase domain in a diphosphorylated state and in a complex with the inhibitor PP-121
8XPN,X-RAY DIFFRACTION,2.2,44.05,"VAPOR DIFFUSION, SITTING DROP",,"15% PEG 2000 MME, 0.1M Bis-Tris propane pH6.9",293.0,2024-01-04,2024-03-06,8XPN,8768.0,3.0,1131.0,535.0,,130.58,1.0,2.1,experimental,35.216,0.216,0.1765,The Crystal Structure of USP8 from Biortus.
6V62,X-RAY DIFFRACTION,2.67,53.85,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2019-12-04,2020-01-15,6V62,4213.0,2.0,619.0,187.0,,70.96,2.0,2.36,experimental,37.58,0.2524,0.208,SETD3 double mutant (N255F/W273A) in Complex with an Actin Peptide with His73 Replaced with Lysine
5WMU,X-RAY DIFFRACTION,3.02,59.29,MICROBATCH,10.0,"100 mM Sodium thiosulfate, 100 mM pH 10.0 CAPS buffer, 20% (w/v) PEG 8000)",277.15,2017-07-31,2017-12-06,5WMU,6345.0,2.0,850.0,224.0,1.0,97.28,1.0,2.4,experimental,76.791,0.25791,0.21404,"Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase I"
6LKM,X-RAY DIFFRACTION,2.68,54.07,"VAPOR DIFFUSION, HANGING DROP",,"Sodium acetate buffer, PEG3350, Lithium sulfate",300.0,2019-12-19,2020-12-23,6LKM,10700.0,2.0,1338.0,26.0,,154.41,1.0,2.55,experimental,51.036,0.2771,0.2102,"Crystal structure of Ribonucleotide reductase R1 subunit, RRM1 in complex with 5-chloro-N-((1S,2R)-2-(6-fluoro-2,3-dimethylphenyl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-sulfonamide"
5IC6,X-RAY DIFFRACTION,2.11,41.62,"VAPOR DIFFUSION, HANGING DROP",4.6,"0.2 M ammonium fluoride, 0.1 M sodium acetate pH 4.6, 20% (w/v) PEG 10000",298.0,2016-02-22,2016-07-20,5IC6,3750.0,6.0,630.0,,,71.8,3.0,2.7,experimental,,0.241,0.1972,Crystal structure of caspase-7 DEVE peptide complex
7UXM,X-RAY DIFFRACTION,1.92,35.94,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M Potassium bromide, 30% w/v Polyethylene glycol monomethyl ether 2,000",291.15,2022-05-05,2022-12-28,7UXM,5172.0,6.0,552.0,669.0,,61.85,2.0,1.2,experimental,16.7783,0.1896,0.1612,"Structure of PPIA in complex with FP29092, a Helicon Polypeptide"
6ACE,X-RAY DIFFRACTION,2.35,47.61,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M sodium cacodylate (pH 5.5), 25%(w/v) PEG 4000",295.0,2018-07-26,2019-07-24,6ACE,2255.0,2.0,275.0,121.0,,30.35,2.0,1.98,experimental,30.467,0.26634,0.20269,histone lysine desuccinylase Sirt5 in complex with succinyl peptide H3K122
6I5I,X-RAY DIFFRACTION,2.54,51.55,"VAPOR DIFFUSION, SITTING DROP",9.0,"20% PEG 6000, 0.1M bicine pH 9.0",277.0,2018-11-13,2019-01-09,6I5I,3178.0,1.0,339.0,369.0,,40.68,1.0,1.6,experimental,23.596,0.19557,0.16399,"Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound 12h"
6YTA,X-RAY DIFFRACTION,2.4,48.66,"VAPOR DIFFUSION, SITTING DROP",8.0,"14% PEG 6k, 0.1M bicine",277.0,2020-04-24,2020-07-15,6YTA,2959.0,1.0,339.0,216.0,,39.95,1.0,2.3,experimental,21.79,0.2752,0.1896,CLK1 bound with imidazopyridazine (Cpd 1)
6YTE,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, SITTING DROP",9.0,"26% PEG 6k, 0.1M bicine",277.0,2020-04-24,2020-07-15,6YTE,3060.0,1.0,339.0,233.0,,39.83,1.0,2.3,experimental,23.657,0.2578,0.1805,CLK1 bound with benzothiazole Tg003 (Cpd 2)
6ZLN,X-RAY DIFFRACTION,2.59,52.54,"VAPOR DIFFUSION, SITTING DROP",9.0,"14% PEG 6k, 0.1M bicine",277.0,2020-06-30,2020-08-26,6ZLN,3260.0,1.0,339.0,407.0,,40.14,1.0,1.7,experimental,22.264,0.1993,0.1695,CLK1 bound with GW807982X (Cpd 8)
6N9D,X-RAY DIFFRACTION,2.88,57.3,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodium Acetate, 0.1 M Sodium Cacodylate: HCl, pH 6.5 18 % (w/v) PEG 8000",298.0,2018-12-03,2019-05-15,6N9D,2675.0,2.0,349.0,46.0,6.0,39.51,2.0,2.67,experimental,55.1126,0.258,0.184,Complex of tissue inhibitor of metalloproteinases-1 (TIMP-1) mutant (L34G/L133P/L151C/G154A) with matrix metalloproteinase-3 catalytic domain (MMP-3cd)
4TL0,X-RAY DIFFRACTION,2.79,55.91,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.15 ammonium sulfate, 0.1M TRIS, pH 8.0, 15%(w/v) PEG 4000",292.0,2014-05-28,2015-06-10,4TL0,2451.0,1.0,336.0,34.0,,38.91,1.0,2.7,experimental,45.71,0.2178,0.1678,Crystal structure of death-associated protein kinase 1 with a crucial phosphomimicking mutation
8DKS,X-RAY DIFFRACTION,2.79,55.92,"VAPOR DIFFUSION, SITTING DROP",,"The purified protein was used in crystallisation trials employing
both, a standard screen with approximately 1200 different conditions,
as well as crystallisation conditions identified using literature
data. Conditions initially obtained have been optimised using standard
strategies, systematically varying parameters critically influencing
crystallisation, such as temperature, protein concentration,
drop ratio, and others. These conditions were also refined by systematically
varying pH or precipitant concentrations.",293.0,2022-07-06,2022-08-03,8DKS,4561.0,2.0,920.0,55.0,,104.44,1.0,2.45,experimental,39.1074,0.26716,0.21375,IRAK4 IN COMPLEX WITH COMPOUND #3
7XGK,X-RAY DIFFRACTION,3.16,61.04,"VAPOR DIFFUSION, SITTING DROP",,"50mM Na citrate pH4.5, 18-26% PEG3350, 0.6M NaCl",293.0,2022-04-05,2022-08-31,7XGK,5389.0,2.0,680.0,65.0,6.0,74.98,1.0,2.4,experimental,52.785,0.2451,0.2017,Human renin in complex with compound1
7XGO,X-RAY DIFFRACTION,3.18,61.35,"VAPOR DIFFUSION, SITTING DROP",,"50mM Na citrate pH4.2, 18-26% PEG3350, 0.6M NaCl",293.0,2022-04-05,2022-08-31,7XGO,5455.0,2.0,680.0,148.0,6.0,74.98,1.0,2.1,experimental,41.204,0.2299,0.1932,Human renin in complex with compound2
7XGP,X-RAY DIFFRACTION,3.14,60.77,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na citrate pH4.2, 30% PEG3350, 0.6M NaCl",293.0,2022-04-05,2022-09-07,7XGP,5326.0,2.0,680.0,,6.0,74.98,1.0,2.65,experimental,69.423,0.2542,0.1983,Human renin in complex with compound3
6R4S,X-RAY DIFFRACTION,2.51,50.91,"VAPOR DIFFUSION, SITTING DROP",,"23% PEG3350, 10% ethylene glycol, 200 mM Na/K tartrate",292.0,2019-03-24,2019-09-11,6R4S,6541.0,2.0,820.0,44.0,,98.81,1.0,2.75,experimental,,0.2686,0.2275,Crystal structure of the Pri1 subunit of human primase bound to ATP
7JHI,X-RAY DIFFRACTION,2.38,48.33,"VAPOR DIFFUSION, HANGING DROP",,"24% PEG1500, 20% glycerol",277.0,2020-07-20,2020-11-18,7JHI,11532.0,4.0,1536.0,424.0,12.0,188.32,1.0,2.5,experimental,30.6588,0.2476,0.2016,"Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 iodide-derivative"
7JHK,X-RAY DIFFRACTION,2.43,49.32,"VAPOR DIFFUSION, HANGING DROP",,"24% PEG1500, 20% glycerol",277.0,2020-07-20,2020-11-18,7JHK,11700.0,4.0,1480.0,516.0,12.0,177.94,1.0,2.3436,experimental,37.6384,0.2173,0.1792,"Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 in unliganded form"
5BV6,X-RAY DIFFRACTION,2.02,39.24,"VAPOR DIFFUSION, HANGING DROP",4.6,"20 mM CaCl2, 100 mM NaOAc, 30% MPD",277.0,2015-06-04,2016-01-20,5BV6,1324.0,1.0,152.0,105.0,,17.9,1.0,1.94,experimental,,0.2109,0.1772,PKG II's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with cGMP
6KVX,X-RAY DIFFRACTION,2.99,58.85,"VAPOR DIFFUSION, HANGING DROP",,"20% (w/v) polyethylene glycol (PEG) 3350, 5% (v/v) glycerol, 0.3 M (NH4)2SO4, and 0.1 M Bis-Tris-HCl (pH 5.5)",293.0,2019-09-05,2020-05-27,6KVX,2047.0,1.0,261.0,,,29.97,1.0,2.85,experimental,,0.26218,0.1795,Crystal structure of the N-terminal domain single mutant (D119A) of the human mitochondrial calcium uniporter fused with T4 lysozyme
4UVL,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-07,2015-07-29,4UVL,3724.0,2.0,480.0,307.0,,55.65,1.0,2,experimental,22.161,0.21402,0.17253,"Crystal structure of human tankyrase 2 in complex with 5-amino-1,2- dihydroisoquinolin-1-one"
4UVS,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-08,2015-07-29,4UVS,3730.0,2.0,480.0,292.0,,55.58,1.0,2,experimental,16.5,0.21424,0.18164,"Crystal structure of human tankyrase 2 in complex with 5-amino-3- pentyl-1,2-dihydroisoquinolin-1-one"
4UVW,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K",277.0,2014-08-08,2015-07-29,4UVW,3596.0,2.0,480.0,181.0,,55.61,1.0,2.1,experimental,38.035,0.20981,0.17087,"Crystal structure of human tankyrase 2 in complex with 4,5-dimethyl-3- phenyl-1,2-dihydroisoquinolin-1-one"
4Y8D,X-RAY DIFFRACTION,2.01,38.75,"VAPOR DIFFUSION, SITTING DROP",6.2,"9% Broad-molecular weight PEG Smears (BMW PEG smears), 0.1M MES pH 6.2, 0.15M calcium chloride",293.15,2015-02-16,2015-04-08,4Y8D,6441.0,4.0,960.0,394.0,4.0,107.53,2.0,2.1,experimental,70.498,0.23154,0.19234,Crystal structure of Cyclin-G associated kinase (GAK) complexed with selective 12i inhibitor
5AUW,X-RAY DIFFRACTION,1.91,35.45,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AUW,2504.0,1.0,293.0,259.0,,34.1,1.0,1.5,experimental,,0.2112,0.1885,Crystal structure of DAPK1 in complex with quercetin.
5AUZ,X-RAY DIFFRACTION,1.91,35.57,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AUZ,2486.0,1.0,293.0,246.0,,34.07,1.0,1.6,experimental,,0.2058,0.1768,Crystal structure of DAPK1 in complex with genistein.
5AV4,X-RAY DIFFRACTION,1.91,35.5,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293.0,2015-06-10,2015-10-07,5AV4,2537.0,1.0,293.0,275.0,,34.39,1.0,1.4,experimental,,0.2276,0.1894,Crystal structure of DAPK1-genistein complex in the presence of bromide ions.
5FGK,X-RAY DIFFRACTION,3.26,62.27,"VAPOR DIFFUSION, HANGING DROP",,RESERVOIR SOLUTION : pH 6.90,293.0,2015-12-20,2016-02-03,5FGK,5225.0,2.0,630.0,190.0,,75.01,2.0,2.36,experimental,34.592,0.2369,,"CDK8-CYCC IN COMPLEX WITH 8-[3-(3-Amino-1H-indazol-6-yl)-5-chloro- pyridine-4-yl]-2,8-diaza-spiro[4.5]decan-1-one"
5HBE,X-RAY DIFFRACTION,3.09,60.27,"VAPOR DIFFUSION, HANGING DROP",6.9,RESERVOIR SOLUTION : pH 6.90,293.0,2015-12-31,2016-02-03,5HBE,5201.0,2.0,630.0,55.0,,74.87,2.0,2.38,experimental,37.069,0.2555,0.2287,"CDK8-CYCC IN COMPLEX WITH 8-[3-Chloro-5-(1-methyl-2,2-dioxo-2, 3-dihydro-1H-2l6-benzo[c]isothiazol-5-yl)-pyridin- 4-yl]-1-oxa-3,8-diaza-spiro[4.5]decan-2-one"
6KMR,X-RAY DIFFRACTION,2.92,61.68,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M succinic acid, pH 7.0, 15% PEG 3350",289.0,2019-08-01,2019-09-18,6KMR,2721.0,2.0,354.0,192.0,,39.4,2.0,2,experimental,37.9946,0.1918,0.1617,Crystal structure of human N6amt1-Trm112 in complex with SAM (space group P6122)
6BKU,X-RAY DIFFRACTION,2.4,48.69,"VAPOR DIFFUSION, SITTING DROP",6.2,"20% PEG smear medium, 0.2M sodium formate, 0.1M sodium-potassium phosphate, 10% glycerol",293.0,2017-11-09,2017-11-29,6BKU,2215.0,1.0,291.0,102.0,,33.56,1.0,2,experimental,44.588,0.23658,0.19271,Crystal Structure of the Human CAMKK2B bound to GSK650394
5HPE,X-RAY DIFFRACTION,2.31,46.69,VAPOR DIFFUSION,,"18% PEG, 8% ethylene glycol, 0.1M Hepes pH 7.5, 20mM hexamine cobolt chloride",277.0,2016-01-20,2016-07-27,5HPE,2747.0,1.0,350.0,105.0,,40.2,1.0,2.27,experimental,,0.2359,0.1684,Phosphatase domain of PP5 bound to a phosphomimetic Cdc37 substrate peptide
7CML,X-RAY DIFFRACTION,2.18,43.47,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Na/K PO4, 20% PEG3,350",293.0,2020-07-28,2020-08-12,7CML,5601.0,2.0,762.0,167.0,,87.82,1.0,2.15,experimental,36.292,0.3274,0.2842,The Crystal Structure of human JNK2 from Biortus.
5NVO,X-RAY DIFFRACTION,3.77,67.39,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298.0,2017-05-04,2018-05-30,5NVO,2189.0,2.0,300.0,70.0,,34.47,1.0,2.4,experimental,57.21,0.244,0.2066,Human DNMT3B PWWP domain in complex with choline
7CDC,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M N-(carbamoylmethyl)iminodiacetic acid, 1.23 M potassium sodium tartrate tetrahydrate",293.0,2020-06-19,2021-06-23,7CDC,6438.0,3.0,818.0,102.0,,92.28,3.0,2.64,experimental,82.643,0.23145,0.21069,Crystal structure of LSD1-CoREST in complex with PRSFLVRRP peptide
7CDD,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M N-(carbamoylmethyl)iminodiacetic acid, 1.23 M potassium sodium tartrate tetrahydrate",293.0,2020-06-19,2021-06-23,7CDD,6397.0,3.0,817.0,87.0,,92.19,3.0,2.76,experimental,84.366,0.22733,0.20449,Crystal structure of LSD1-CoREST in complex with PRSFLVRR peptide
7CDE,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M N-(carbamoylmethyl)iminodiacetic acid, 1.23 M potassium sodium tartrate tetrahydrate",293.0,2020-06-19,2021-06-23,7CDE,6438.0,3.0,818.0,63.0,,92.59,3.0,2.68,experimental,82.562,0.23301,0.20729,Crystal structure of LSD1-CoREST in complex with PRSFLVRKR peptide
7CDF,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M N-(carbamoylmethyl)iminodiacetic acid, 1.23 M potassium sodium tartrate tetrahydrate",293.0,2020-06-19,2021-06-23,7CDF,6459.0,3.0,818.0,103.0,,92.41,3.0,2.68,experimental,82.889,0.2406,0.21352,Crystal structure of LSD1-CoREST in complex with PRSFLVRRK peptide
7CDG,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M N-(carbamoylmethyl)iminodiacetic acid, 1.23 M potassium sodium tartrate tetrahydrate",293.0,2020-06-19,2021-06-23,7CDG,6411.0,3.0,818.0,52.0,,92.53,3.0,2.8,experimental,87.415,0.24204,0.21051,Crystal structure of LSD1-CoREST in complex with PRSFLVRRR peptide
8SW5,X-RAY DIFFRACTION,2.7,54.5,VAPOR DIFFUSION,5.6,"1 M ammonium dihydrogen phosphate, 100 mM tri-sodium citrate, pH 5.6",289.0,2023-05-17,2024-05-29,8SW5,5221.0,4.0,692.0,83.0,,80.23,2.0,2.39,experimental,,0.2516,0.2098,Protein Phosphatase 1 in complex with PP1-specific Phosphatase targeting peptide (PhosTAP) version 1
6BVA,X-RAY DIFFRACTION,2.5,50.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes pH 7.5, 0.2 M calcium chloride, 18% (w/v) PEG 6000",293.0,2017-12-12,2018-07-18,6BVA,4111.0,6.0,596.0,40.0,,68.92,3.0,2.66,experimental,,0.263,0.216,Ubiquitin Variant (UbV.Fl10.1) bound to a human Skp1-Fbl10 fragment complex.
5HLW,X-RAY DIFFRACTION,2.48,50.4,"VAPOR DIFFUSION, HANGING DROP",8.0,Tris 100mM-MPD20%-pH8,293.0,2016-01-15,2016-11-23,5HLW,2480.0,1.0,299.0,192.0,,34.48,1.0,1.97,experimental,38.36,,,Crystal structure of c-Met mutant Y1230H in complex with compound 14
7A62,X-RAY DIFFRACTION,2.83,56.6,"VAPOR DIFFUSION, HANGING DROP",6.25,"14% IN PEG 3350, 0.1 M IN PHOSPHATE BUFFER AT A PH OF 6.25 
PROTEIN : IN HEPES 5 MM AND NACL 200MM 
CRYOPROTECTION IN 20% OF GLYCEROL AND 20 MM OF SODIUM DITHIONITE, PH 7.6",293.0,2020-08-24,2020-12-16,7A62,12873.0,4.0,1620.0,695.0,,184.39,1.0,2.43796448682,experimental,39.8337568823,0.257286553269,0.211611041463,"Structure of human indoleamine-2,3-dioxygenase 1 (hIDO1) with a complete JK loop"
7NGE,X-RAY DIFFRACTION,3.04,59.59,"VAPOR DIFFUSION, HANGING DROP",6.0,"15.4% PEG 3350 
0.1M Phosphate buffer pH 6.0
Protein : 5mM HEPES pH 7.4, 200mM NaCl, 5mM DTT",293.0,2021-02-09,2021-12-29,7NGE,12992.0,4.0,1620.0,668.0,,188.34,1.0,2.3,experimental,54.55,0.2707,0.215,"Crystal structure of L-Trp/Indoleamine 2,3-dioxygenagse 1 (hIDO1) complex with the JK-loop refined in the closed conformation"
7P0N,X-RAY DIFFRACTION,2.81,56.72,"VAPOR DIFFUSION, HANGING DROP",6.4,"14.5% PEG 3350
0.1M Phosphate buffer
2mM L-Trp
Protein buffer : Hepes 5mM, 200mM NaCl, 5mM DTT
Cryoprotection: 20 mM sodium dithionite, 20% glycerol",298.0,2021-06-30,2021-12-29,7P0N,12712.0,4.0,1620.0,492.0,,187.52,1.0,2.5,experimental,58.73,0.2788,0.2151,"Crystal structure of L-Trp/Indoleamine 2,3-dioxygenagse 1 (hIDO1) complex with the JK-loop refined in the open conformation"
7P0R,X-RAY DIFFRACTION,2.81,56.22,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1M Phosphate buffer
15.4% PEG 3350
Protein buffer : 5mM Hepes, 200 mM NaCl, 5 mM DTT
Cryoprotection : 20% glycerol, 20 mM sodium dithionite",298.0,2021-06-30,2021-12-29,7P0R,12750.0,4.0,1620.0,497.0,,186.51,1.0,2.5,experimental,61.98,0.2851,0.218,"Crystal structure of L-Trp/Indoleamine 2,3-dioxygenase (hIDO1) complex with the JK-loop refined in the intermediate conformation"
6YJR,X-RAY DIFFRACTION,2.58,52.31,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Citrate pH 5.0
16% w/v PEG6000",293.0,2020-04-04,2020-08-05,6YJR,8052.0,2.0,1056.0,88.0,12.0,122.29,1.0,2.198,experimental,70.676,0.2625,0.2081,"Crystal structure of unliganded MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain."
8SHZ,X-RAY DIFFRACTION,2.07,40.62,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris, pH 8.5, 8% w/v PEG8000",298.15,2023-04-14,2024-04-24,8SHZ,2768.0,1.0,369.0,11.0,,43.04,1.0,2.4,experimental,,0.2581,0.2118,Structure of human cGAS
7S9H,X-RAY DIFFRACTION,2.74,55.03,"VAPOR DIFFUSION, SITTING DROP",,"1.8 M Malic acid, pH 7",291.0,2021-09-21,2022-08-03,7S9H,2175.0,1.0,237.0,319.0,,27.18,1.0,1.45,experimental,28.85,0.1841,0.1571,Cryogenic Human Hsp90a-NTD bound to EC144
5LZ2,X-RAY DIFFRACTION,2.44,49.63,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl,",293.0,2016-09-29,2016-12-21,5LZ2,3416.0,1.0,388.0,349.0,,44.48,1.0,2.1,experimental,27.191,0.22783,0.16738,Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ4,X-RAY DIFFRACTION,2.45,49.78,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293.0,2016-09-29,2016-12-21,5LZ4,3437.0,1.0,388.0,386.0,,44.55,1.0,2.07,experimental,28.141,0.21491,0.16116,Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ5,X-RAY DIFFRACTION,2.36,47.9,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293.0,2016-09-29,2016-12-21,5LZ5,3355.0,1.0,388.0,311.0,,44.61,1.0,2.05,experimental,31.922,0.23791,0.18356,Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ7,X-RAY DIFFRACTION,2.45,49.89,"VAPOR DIFFUSION, SITTING DROP",,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293.0,2016-09-29,2016-12-21,5LZ7,3348.0,1.0,388.0,329.0,,44.58,1.0,2.1,experimental,42.578,0.24251,0.18042,Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ8,X-RAY DIFFRACTION,2.28,46.14,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293.0,2016-09-29,2016-12-21,5LZ8,3225.0,1.0,388.0,200.0,,44.58,1.0,2.11,experimental,36.07,0.25538,0.19415,Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5LZ9,X-RAY DIFFRACTION,2.46,50.03,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.1M HEPES/NaOHpH=7.4, 1.3M NaCl, 32.0%w/v PEG 3350,",293.0,2016-09-29,2016-12-21,5LZ9,3267.0,1.0,388.0,252.0,,44.66,1.0,2.06,experimental,43.51,0.23296,0.18322,Fragment-based inhibitors of Lipoprotein associated Phospholipase A2
5Z5O,X-RAY DIFFRACTION,2.86,57.02,"VAPOR DIFFUSION, HANGING DROP",,"100mM Na-K Phosphate 6.2, 20 % MPD, 12mM (NH4)2SO4, 10% PEG 3350",293.0,2018-01-19,2018-09-26,5Z5O,3527.0,2.0,429.0,206.0,3.0,52.31,2.0,1.92,experimental,57.5072,0.2036,0.1621,Structure of Pycnonodysostosis disease related I249T mutant of human cathepsin K
5LAY,X-RAY DIFFRACTION,2.99,58.93,"VAPOR DIFFUSION, HANGING DROP",4.5,,277.0,2016-06-15,2016-11-02,5LAY,4950.0,6.0,570.0,98.0,,70.53,1.0,2.71,experimental,6.664,0.2917,0.2506,Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND 6g
6M88,X-RAY DIFFRACTION,2.17,43.24,"VAPOR DIFFUSION, HANGING DROP",6.0,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol at 298K. To obtain complex structure, the apo crystal was further soaked under 35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM HEPES, pH 7.5 at 298K in the presence of 2 mM myricetin for 3 days.",298.0,2018-08-21,2019-01-23,6M88,2153.0,1.0,261.0,177.0,,30.15,1.0,1.9,experimental,24.725,0.24428,0.17337,Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with myricetin
6M8A,X-RAY DIFFRACTION,2.37,43.7,"VAPOR DIFFUSION, HANGING DROP",6.0,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol at 298K. To obtain complex structure, the apo crystal was further soaked under 35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM HEPES, pH 7.5 at 298K in the presence of 2 mM luteolin for 3 days.",298.0,2018-08-21,2019-01-23,6M8A,2105.0,1.0,261.0,119.0,,30.11,1.0,1.75,experimental,27.036,0.24099,0.17336,Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with luteolin
6M8B,X-RAY DIFFRACTION,2.19,43.92,"VAPOR DIFFUSION, HANGING DROP",6.0,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol at 298K. To obtain complex structure, the apo crystal was further soaked under 35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM HEPES, pH 7.5 at 298K in the presence of 10 mM kaempferol for 3 days.",298.0,2018-08-21,2019-01-23,6M8B,2122.0,1.0,261.0,116.0,,30.11,1.0,1.8,experimental,25.18,0.223,0.169,Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with kaempferol
6M8C,X-RAY DIFFRACTION,2.21,44.41,"VAPOR DIFFUSION, HANGING DROP",6.0,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol at 298K. To obtain complex structure, the apo crystal was further soaked under 35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM HEPES, pH 7.5 at 298K in the presence of 10 mM isorhamnetin for 3 days.",298.0,2018-08-21,2019-01-23,6M8C,2113.0,1.0,261.0,119.0,,30.14,1.0,1.8,experimental,23.87,0.224,0.168,Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with isorhamnetin
6M8D,X-RAY DIFFRACTION,2.36,43.44,"VAPOR DIFFUSION, HANGING DROP",6.0,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol at 298K. To obtain complex structure, the apo crystal was further soaked under 35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM HEPES, pH 7.5 at 298K in the presence of 10 mM diosmetin for 3 days.",298.0,2018-08-21,2019-01-23,6M8D,2127.0,1.0,261.0,134.0,,30.13,1.0,2,experimental,30.474,0.23949,0.17314,Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with diosmetin
6M8E,X-RAY DIFFRACTION,2.22,44.59,"VAPOR DIFFUSION, HANGING DROP",6.0,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol at 298K. To obtain complex structure, the apo crystal was further soaked under 35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM HEPES, pH 7.5 at 298K in the presence of 10 mM rhametine for 3 days.",298.0,2018-08-21,2019-01-23,6M8E,2200.0,1.0,261.0,108.0,,30.14,1.0,2,experimental,30.315,0.24508,0.18431,Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with rhamnetin
6VBI,X-RAY DIFFRACTION,2.51,51.07,EVAPORATION,,"8% PEG3350, 0.2 M ammonium acetate, 0.1 M Na Acetate, pH 4.6",298.0,2019-12-18,2021-01-20,6VBI,5096.0,2.0,650.0,146.0,1.0,76.05,1.0,2.30000752706,experimental,29.4860807999,0.252496556648,0.189212588836,crystal structure of PDE5 in complex with a non-competitive inhibitor
6W7Z,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, HANGING DROP",,"15-20% PEG 3350, 100-200 mM ammonium formate",289.0,2020-03-19,2020-05-20,6W7Z,1960.0,2.0,251.0,146.0,,28.55,2.0,1.8,experimental,34.9294,0.2108,0.1779,RNF12 RING domain in complex with Ube2d2
7DD1,X-RAY DIFFRACTION,2.75,55.28,"VAPOR DIFFUSION, HANGING DROP",,"3% PEG 3350, 200mM Ammonium acetata, 100mM Sodium Citrate(pH 5.6), 4mM DTT",289.15,2020-10-27,2021-04-21,7DD1,3153.0,2.0,405.0,260.0,,46.27,2.0,2.05,experimental,28.642,0.2205,0.1802,Crystal structure of SRPK1 in complex with a peptide inhibitor
5HDX,X-RAY DIFFRACTION,2.94,58.19,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277.0,2016-01-05,2016-03-16,5HDX,6977.0,2.0,828.0,879.0,6.0,93.36,1.0,1.602,experimental,20.4182,0.1924,0.1763,"BACE-1 in complex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(4-ethoxy-5-fluoro-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium"
5HDZ,X-RAY DIFFRACTION,2.97,58.54,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277.0,2016-01-05,2016-03-16,5HDZ,6977.0,2.0,828.0,896.0,6.0,93.36,1.0,1.49,experimental,19.9315,0.2068,0.1942,"BACE-1 in complex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4-methyl-6-(methylthio)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium"
5HE7,X-RAY DIFFRACTION,2.95,58.32,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277.0,2016-01-05,2016-03-16,5HE7,6990.0,2.0,828.0,903.0,6.0,93.34,1.0,1.71,experimental,21.4985,0.2163,0.1895,"BACE-1 in complex with (4aR,7aS)-7a-(2,4-difluorophenyl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-2-imino-3-methyloctahydro-4H-pyrrolo[3,4-d]pyrimidin-4-one"
5HU1,X-RAY DIFFRACTION,2.99,58.89,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200MM NA/K TARTRATE, 100MM HEPES PH7",277.0,2016-01-27,2016-11-09,5HU1,7001.0,2.0,824.0,895.0,6.0,92.78,1.0,1.5,experimental,21.235,0.2006,0.1847,"BACE1 in complex with (R)-N-(3-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoropicolinamide"
6Y23,X-RAY DIFFRACTION,2.78,55.76,"VAPOR DIFFUSION, SITTING DROP",,"9.5 mg/ml protein in 20 mM HEPES pH 7.5, 200 mM NaCl, 1 mM TCEP. Precipitant: 100 mM Tris pH 8.0, 1.5 M ammonium sulphate.",277.0,2020-02-14,2020-09-02,6Y23,7259.0,3.0,1050.0,40.0,,117.91,1.0,2.58,experimental,47.65,0.2701,0.2252,DDR1 kinase autoinhibited by its juxtamembrane region
5CYS,X-RAY DIFFRACTION,2.71,54.65,"VAPOR DIFFUSION, SITTING DROP",6.0,"30% PEG 4000, 0.2M ammonium acetate, 0.1M sodium acetate",298.0,2015-07-30,2015-09-16,5CYS,2948.0,3.0,260.0,210.0,,40.25,1.0,2.45,experimental,75.25,0.2269,0.1654,Structure of the enzyme-product complex resulting from TDG action on a GcaC mismatch
7N93,X-RAY DIFFRACTION,2.26,45.66,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2M Bis-Tris pH 5.5, 0.1M Li2SO4, 26-28% PEG3350",295.0,2021-06-16,2022-07-06,7N93,5062.0,2.0,680.0,4.0,1.0,77.99,1.0,2.74,experimental,50.346,0.29,0.2115,P70 S6K1 IN COMPLEX WITH MSC2363318A-1
8PW1,X-RAY DIFFRACTION,2.37,48.13,"VAPOR DIFFUSION, SITTING DROP",,"2.49 M ammonium sulfate, 85 mM trisodium citrate",293.0,2023-07-19,2024-01-31,8PW1,16561.0,10.0,2270.0,227.0,,255.75,1.0,2.2,experimental,80.79,0.2712,0.2273,Structure of human UCHL1 in complex with CG341 inhibitor
5V4W,X-RAY DIFFRACTION,2.3,46.42,"VAPOR DIFFUSION, SITTING DROP",5.5,"15% PEG3350, 200 mM ammonium iodide, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2017-03-10,2017-05-31,5V4W,3569.0,1.0,458.0,225.0,,52.16,1.0,2.39,experimental,30.88,0.261,0.198,Human glucokinase in complex with novel indazole activator.
5V4X,X-RAY DIFFRACTION,2.22,44.59,"VAPOR DIFFUSION, SITTING DROP",,"15% PEG3350, 200 mM ammonium iodide, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2017-03-10,2017-05-31,5V4X,3551.0,1.0,458.0,219.0,,52.42,1.0,2.08,experimental,42.197,0.2503,0.1946,Human glucokinase in complex with novel pyrazole activator.
6E0E,X-RAY DIFFRACTION,2.91,57.74,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M Hepes pH7.0, 27% PEG1500",293.0,2018-07-06,2019-07-10,6E0E,3604.0,1.0,448.0,64.0,,50.75,1.0,2.7,experimental,55.307,0.27659,0.20284,Crystal structure of Glucokinase in complex with compound 6
5MY6,X-RAY DIFFRACTION,3.1,60.33,"VAPOR DIFFUSION, HANGING DROP",7.25,"100 mM HEPES pH 7.25, 10% 2-propanol, 22% PEG 4000",293.15,2017-01-25,2017-08-09,5MY6,5581.0,2.0,737.0,370.0,24.0,82.04,2.0,2.246,experimental,49.2832,0.2201,0.1848,Crystal structure of a HER2-Nb complex
6M06,X-RAY DIFFRACTION,2.5,50.77,"VAPOR DIFFUSION, HANGING DROP",6.6,"0.1 M MOPS pH 6.6, 0.4 M Li2SO4, 22.5-27% (w/v) (NH4)2SO4, 1 M Na-Ac, 1.4 % 1,4-butanediol",293.0,2020-02-20,2020-12-30,6M06,5983.0,2.0,742.0,172.0,,84.94,1.0,2.1,experimental,25.989,0.2201,0.1863,Crystal structure of Lp-PLA2 in complex with a novel covalent inhibitor
6M07,X-RAY DIFFRACTION,2.23,44.9,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS pH 6.6, 0.4 M Li2SO4, 22.5-27% (w/v) (NH4)2SO4, 1 M Na-Ac, 1.4 % 1,4-butanediol",293.0,2020-02-20,2020-12-30,6M07,5751.0,2.0,738.0,8.0,,85.37,1.0,2.64,experimental,38.382,0.249,0.2001,Crystal structure of Lp-PLA2 in complex with a novel covalent inhibitor
6M08,X-RAY DIFFRACTION,2.47,50.15,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS pH 6.6, 0.4 M Li2SO4, 22.5-27% (w/v) (NH4)2SO4, 1 M Na-Ac, 1.4 % 1,4-butanediol",293.0,2020-02-20,2020-12-30,6M08,5864.0,2.0,742.0,59.0,,85.07,1.0,2.19,experimental,31.109,0.2401,0.1927,Crystal structure of Lp-PLA2 in complex with a novel covalent inhibitor.
5M7F,X-RAY DIFFRACTION,2.79,56.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M sodium cacodylate pH 6.5, 0.2 M sodium chloride, 2 M ammonium sulphate",294.0,2016-10-27,2017-11-15,5M7F,5017.0,2.0,730.0,49.0,,81.99,1.0,2.78,experimental,45.78,0.26,0.22,Human porphobilinogen deaminase in complex with DPM cofactor
7CCX,X-RAY DIFFRACTION,1.97,37.63,"VAPOR DIFFUSION, SITTING DROP",8.3,"PEG 3350, diammonium hydrogen citrate, dithiothreitol",293.0,2020-06-18,2021-03-17,7CCX,4966.0,2.0,722.0,159.0,,79.61,1.0,1.84,experimental,48.75,0.2472,0.1942,Crystal structure of the holo form of human hydroxymethylbilane synthase
7CCY,X-RAY DIFFRACTION,2.08,40.92,"VAPOR DIFFUSION, SITTING DROP",8.3,"PEG 3350, diammonium hydrogen citrate, dithothreitol",293.0,2020-06-18,2021-03-17,7CCY,4991.0,2.0,722.0,64.0,,79.96,1.0,2.4,experimental,40.64,0.273,0.2017,Crystal structure of the 2-iodoporphobilinogen-bound holo form of human hydroxymethylbilane synthase
7CCZ,X-RAY DIFFRACTION,2.23,44.96,"VAPOR DIFFUSION, SITTING DROP",8.3,"PEG 3350, diammonium hydrogen citrate, dithiothreitol",293.0,2020-06-18,2021-03-17,7CCZ,5388.0,2.0,722.0,368.0,,80.44,1.0,1.79,experimental,34.85,0.2428,0.1982,Crystal structure of the ES2 intermediate form of human hydroxymethylbilane synthase
7CD0,X-RAY DIFFRACTION,2.29,46.26,"VAPOR DIFFUSION, SITTING DROP",8.3,"PEG 3350, diammonium hydrogen citrate, dithiothreitol",293.0,2020-06-18,2021-03-17,7CD0,5107.0,2.0,722.0,76.0,,80.8,1.0,2.31,experimental,57.52,0.2765,0.2272,Crystal structure of the 2-iodoporphobilinogen-bound ES2 intermediate form of human hydroxymethylbilane synthase
4R1V,X-RAY DIFFRACTION,2.12,41.95,,6.5,"PEG 8000, pH 6.5, VAPOR DIFFUSION, temperature 298K",298.0,2014-08-07,2015-03-18,4R1V,2770.0,1.0,291.0,349.0,,33.74,1.0,1.2,experimental,14.37,0.176,0.146,Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
5TUS,X-RAY DIFFRACTION,2.43,49.31,"VAPOR DIFFUSION, HANGING DROP",7.9,"0.1 M Tris-HCl pH 7.9, 0.2 M LiSO4, 19% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2016-11-07,2017-08-02,5TUS,11713.0,2.0,1584.0,33.0,,181.68,1.0,2.66,experimental,56.36,0.24967,0.19911,Potent competitive inhibition of human ribonucleotide reductase by a novel non-nucleoside small molecule
6J8Y,X-RAY DIFFRACTION,2.88,57.31,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Sodium citrate, Bis-tris propane pH 7.5",293.0,2019-01-21,2019-12-04,6J8Y,6267.0,4.0,858.0,68.0,1.0,96.37,4.0,2.4,experimental,,0.2581,0.2184,Crystal structure of the human RAD9-HUS1-RAD1-RHINO complex
7UAH,X-RAY DIFFRACTION,2.12,42.08,"VAPOR DIFFUSION, HANGING DROP",5.0,"13-18% PEG 4000, 150 mM Ammonium sulfate, 100 mM MES, 10% 1,2-butanediol",293.0,2022-03-12,2023-03-15,7UAH,4313.0,2.0,500.0,373.0,13.0,56.68,1.0,1.57,experimental,24.1206,0.1917,0.1749,Macrocyclic plasmin inhibitor
7KKQ,X-RAY DIFFRACTION,2.62,53.08,VAPOR DIFFUSION,,"Buffer: 0.1 M Sodium Citrate (pH 5.60)
Salt: 1.0 M ammonium formate
Precipitant: 23.0 %w/v PEG 4000",277.0,2020-10-27,2021-01-06,7KKQ,7686.0,4.0,852.0,833.0,,98.67,1.0,1.59,experimental,30.17,0.23,0.204,Structure of the catalytic domain of tankyrase 1 in complex with veliparib
6CZ2,X-RAY DIFFRACTION,3.14,60.88,"VAPOR DIFFUSION, SITTING DROP",8.0,"3.3 M Potassium acetate, 0.1 M bicine, pH 8, 13oC",288.0,2018-04-07,2018-06-27,6CZ2,2151.0,1.0,264.0,24.0,,30.33,1.0,2.5,experimental,52.0,0.246,0.203,Structure of the PTK6 kinase domain
6J8O,X-RAY DIFFRACTION,2.87,57.11,"VAPOR DIFFUSION, SITTING DROP",,"0.1M BIS-TRIS pH 6.5, 16% polyethylene glycol 10000",291.0,2019-01-20,2020-01-22,6J8O,2607.0,3.0,295.0,383.0,,34.26,3.0,1.855,experimental,,0.1945,0.177,Structure of a hypothetical protease
4Z68,X-RAY DIFFRACTION,1.9,35.22,"VAPOR DIFFUSION, HANGING DROP",,"ammonium sulfate, isopropanol",291.0,2015-04-04,2015-12-30,4Z68,1352.0,2.0,167.0,68.0,,18.53,2.0,1.859,experimental,20.6,0.2166,0.1698,Hybrid structural analysis of the Arp2/3 regulator Arpin identifies its acidic tail as a primary binding epitope
5I4H,X-RAY DIFFRACTION,2.17,43.33,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.11 M HEPES, pH 7.5, 2.14 M ammonium sulfate",277.0,2016-02-12,2016-04-13,5I4H,2030.0,2.0,218.0,246.0,3.0,24.58,2.0,1.42,experimental,21.83,0.1841,0.1626,Caught in the Act: The Crystal Structure of cleaved Cathepsin L bound to the active site of Cathepsin L
4ZPE,X-RAY DIFFRACTION,3.11,60.44,"VAPOR DIFFUSION, HANGING DROP",,"1.5M LITHIUM SULFATE, 0.1M HEPES BUFFER PH 7.50",293.0,2015-05-07,2015-08-05,4ZPE,3245.0,1.0,405.0,353.0,3.0,45.62,1.0,1.7,experimental,30.4007,0.2041,0.1879,"BACE1 in complex with 4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one"
4ZPF,X-RAY DIFFRACTION,3.08,60.08,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.5M LITHIUM SULFATE, 0.1M HEPES BUFFER,",293.0,2015-05-07,2015-08-05,4ZPF,3184.0,1.0,405.0,270.0,3.0,45.63,1.0,1.8,experimental,33.9503,0.2012,0.1813,"BACE1 in complex with 8-(3-((1-aminopropan-2-yl)oxy)benzyl)-4-(cyclohexylamino)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one"
4ZPG,X-RAY DIFFRACTION,3.11,60.44,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.5M LITHIUM SULFATE, 0.1M HEPES BUFFER,",293.0,2015-05-07,2015-08-05,4ZPG,3181.0,1.0,405.0,277.0,3.0,45.57,1.0,2,experimental,34.6358,0.1875,0.1692,"BACE1 in complex with 8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one"
5T1U,X-RAY DIFFRACTION,2.8,56.12,"VAPOR DIFFUSION, HANGING DROP",,"20 - 22.5% (w/v) PEG 5000 monomethylethyl (MME), 200 mM sodium citrate (pH 6.6), 200 mM ammonium iodide).",293.0,2016-08-22,2017-01-11,5T1U,3307.0,1.0,415.0,282.0,3.0,47.33,1.0,1.78,experimental,35.92,0.206,0.187,Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality
6W30,X-RAY DIFFRACTION,3.14,66.06,"VAPOR DIFFUSION, HANGING DROP",7.5,"140 g/L PEG8000, 100 mM HEPES, 200 mM magnesium acetate, pH 7.5",277.15,2020-03-08,2021-05-26,6W30,2547.0,1.0,329.0,170.0,,38.76,1.0,2.1,experimental,40.05,0.2388,0.1973,Protein Tyrosine Phosphatase 1B Bound to Amorphadiene
6T28,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,5.9,"0,1M NaCit, pH 5.9
2,05M AmmSO4
0,1M Na/K tartrate",293.0,2019-10-08,2019-11-13,6T28,2336.0,1.0,385.0,125.0,,43.84,1.0,1.55,experimental,19.177,0.1829,0.1573,Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) bound to compound 19 (CS640)
6T29,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",5.9,"0,1M NaCit, pH 5.9
2,05M AmmSO4
0,1M Na/K tartrate",293.0,2019-10-08,2019-11-13,6T29,2474.0,1.0,385.0,197.0,,44.11,1.0,1.484,experimental,17.818,0.1747,0.1355,Crystal structure of human calmodulin-dependent protein kinase 1D (CAMK1D) bound to compound 18 (CS587)
7GSU,X-RAY DIFFRACTION,3.33,63.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSU,2581.0,1.0,321.0,236.0,,37.85,1.0,1.65,experimental,36.303,0.2201,0.1885,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000382a
4YU9,X-RAY DIFFRACTION,2.75,55.24,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 1.6 M Ammonium Sulfate",281.0,2015-03-18,2015-08-05,4YU9,8775.0,3.0,987.0,939.0,,113.88,1.0,2.1,experimental,13.992,0.2542,0.21079,Crystal Structure of double mutant Y115E Y117E human Glutaminyl Cyclase
7WR1,X-RAY DIFFRACTION,2.68,54.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"5% PEG8000, 0.1M Tris-HCl pH 7.5, % 2-propanol",293.0,2022-01-26,2023-01-25,7WR1,6593.0,4.0,882.0,508.0,,100.92,2.0,2.13,experimental,39.07,0.1999,0.1704,P32 of caspase-4 C258A mutant in complex with OspC3 C-terminal ankyrin-repeat domain
6D20,X-RAY DIFFRACTION,2.29,46.35,"VAPOR DIFFUSION, HANGING DROP",8.0,"Well volume: 30.0 uL

Well Ingredients:
Polymer: 10.0 %w/v (6.0 uL of stock 50.0 %w/v) PEG 3350
Buffer: 16.0 %v/v (4.8 uL of stock 100.0 %v/v) tacsimate (pH 8.00)
Organic (non-volatile): 10.0 %v/v (3.0 uL of stock 100.0 %v/v) Ethylene glycol
Additive: 0.025 M (1.5 uL of stock 0.5 M) TCEP hydrochloride

Plate setup temperature: 13 C
Plate incubation temperature: 21 C

Drop volume from well: 0.2 uL
Drop protein volume: 0.4 uL

Protein: 6.30 mg/mL (0.17 mM)
Compound1: 1.00 mM (to aid crystallization).
Compound23 (allostric inhibitor): 1.3ul 50mM compound23 DMSO stock in 133ul protein  (0.50 mM)",294.0,2018-04-12,2018-05-02,6D20,2629.0,1.0,320.0,224.0,,36.88,1.0,1.94,experimental,28.71,0.2072,0.1703,"Crystal structure of Tyrosine-protein kinase receptor in complex with 5-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4(3H)-one and 5-{[2,4-dichloro-5-(pyridin-2-yl)benzene-1-carbonyl]amino}-N-(2-hydroxy-2-methylpropyl)-1-phenyl-1H-pyrazole-3-carboxamide Inhibitors"
5OWL,X-RAY DIFFRACTION,3.12,60.58,"VAPOR DIFFUSION, SITTING DROP",,"1 MIKROLITER OF THE CK2ALPHA/INHIBITOR MIXTURE (COMPOSITION: 7 MG/ML CK2ALPHA ENZYME, 1 MILLIMOLAR INHIBITOR, 10 % DIMETHYL SULFOXIDE, 450 MM NACL, 22.5 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 1 MIKROLITER RESERVOIR SOLUTION (COMPOSITION: 25 % PEG3350, 0.2 M AMMONIUM SULPHATE, 0.1 M BIS-TRIS BUFFER, PH 5.5) FOLLOWED BY VAPOUR DIFFUSION EQUILIBRATION  AGAINST THE RESERVOIR SOLUTION.",293.15,2017-09-01,2018-07-25,5OWL,5797.0,2.0,670.0,124.0,,81.69,1.0,2.23,experimental,,0.2488,0.2105,"Low salt structure of human protein kinase CK2alpha in complex with 3-aminopropyl-4,5,6,7-tetrabromobenzimidazol"
5VXA,X-RAY DIFFRACTION,2.68,54.07,"VAPOR DIFFUSION, HANGING DROP",8.0,"4.5 mg/mL hMesh1 D66K, 50 mM NADPH, 25 mM Tris (pH 8.0), 100 mM NaCl, 0.05% 2-mercaptoethanol, 0.5 mM ZnCl2, 100 mM ammonium acetate, 50 mM sodium citrate, 12.5% PEG 4000.",293.0,2017-05-23,2018-05-23,5VXA,3272.0,2.0,360.0,262.0,,43.14,1.0,2.1,experimental,,0.2055,0.1654,Structure of the human Mesh1-NADPH complex
6ZEH,X-RAY DIFFRACTION,2.26,45.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% (w/v) polyethylene glycol 3350, 0.2 M NaI and 0.1 M BIS-Tris propane pH 8.5",293.0,2020-06-16,2020-09-30,6ZEH,6778.0,4.0,812.0,655.0,,92.14,2.0,1.3,experimental,19.08,0.1693,0.1368,Structure of PP1-spectrin alpha II chimera [PP1(7-304) + linker (G/S)x9 + spectrin alpha II (1025-1039)] bound to Phactr1 (516-580)
6DKB,X-RAY DIFFRACTION,2.29,46.23,"VAPOR DIFFUSION, SITTING DROP",8.0,"Well volume: 30.0 uL
Drop volume from well: 0.2 uL
Drop protein volume: 0.4 uL

Well Ingredients:
Polymer: 10.0 %w/v (6.0 uL of stock 50.0 %w/v) PEG 3350
Buffer: 16.0 %v/v (4.8 uL of stock 100.0 %v/v) tacsimate (pH 8.00)
Organic (non-volatile): 10.0 %v/v (3.0 uL of stock 100.0 %v/v) Ethylene glycol
Additive: 0.025 M (1.5 uL of stock 0.5 M) TCEP hydrochloride

Plate setup temperature: 13 C
Plate incubation temperature: 21 C",294.0,2018-05-29,2018-07-11,6DKB,2222.0,1.0,320.0,1.0,,36.63,1.0,2.68,experimental,80.37,0.245,0.2159,"Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 10b."
6BQL,X-RAY DIFFRACTION,2.54,51.61,"VAPOR DIFFUSION, SITTING DROP",7.5,24% PEG 3350; 0.14 M Ammonium Acetate; 0.1M CHC buffer pH 7.5,293.0,2017-11-28,2017-12-13,6BQL,2333.0,1.0,291.0,112.0,,33.83,1.0,2,experimental,37.652,0.22531,0.18688,Crystal Structure of the Human CAMKK2B in complex with TAE-226
5HMK,X-RAY DIFFRACTION,2.17,43.24,"VAPOR DIFFUSION, SITTING DROP",4.0,"1.8-2.2 M ammonium sulfate, 100 mM Na Citrate/citric acid",303.0,2016-01-16,2016-04-06,5HMK,1612.0,2.0,218.0,54.0,,26.47,1.0,2.17,experimental,62.56,0.2612,0.2284,"HDM2 in complex with a 3,3-Disubstituted Piperidine"
6HP9,X-RAY DIFFRACTION,2.4,48.79,VAPOR DIFFUSION,,"1:2 protein to mother liquor

Protein: 
12 mg/ml in 50 mM HEPES pH 7.5, 300 mM NaCl, 0.5 mM TCEP, 2% DMSO, 1 mM compound

Mother liquor:
25% PEG 1500",277.0,2018-09-19,2019-01-30,6HP9,5041.0,2.0,630.0,374.0,,72.47,1.0,1.96,experimental,,0.2507,0.2046,"Structure of the kinase domain of human DDR1 in complex with a 2-Amino-2,3-Dihydro-1H-Indene-5-Carboxamide-based inhibitor"
5JAH,X-RAY DIFFRACTION,2.46,49.96,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.4M NaCl, 28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4",297.0,2016-04-12,2016-05-25,5JAH,3315.0,1.0,388.0,283.0,,44.38,1.0,2.06,experimental,33.788,0.222,0.175,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
5JAN,X-RAY DIFFRACTION,2.33,47.2,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.0M NaCl, 0.1M HEPES/NaOHpH=7.4, 28.8%w/v PEG 3350",297.0,2016-04-12,2016-05-25,5JAN,3130.0,1.0,388.0,131.0,,44.53,1.0,2.12,experimental,34.96,0.26693,0.22291,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening
6GHA,X-RAY DIFFRACTION,2.18,43.59,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris-Cl pH 8.5, 20% PEG 2000",293.15,2018-05-06,2018-09-26,6GHA,2734.0,1.0,365.0,131.0,,41.81,1.0,1.98,experimental,48.2582,0.2344,0.1979,USP15 catalytic domain structure
8SJ8,X-RAY DIFFRACTION,2.07,40.45,"VAPOR DIFFUSION, HANGING DROP",8.5,"5mM magnesium chloride, 0.1M Tris-HCl pH8.5, and 8% (w/v) PEG8000",298.15,2023-04-17,2024-04-24,8SJ8,2748.0,1.0,369.0,7.0,,43.91,1.0,2.5,experimental,,0.2711,0.2141,Structure of binary complex of human cGAS and bound ppp(2'-5')GpG
6MAJ,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, SITTING DROP",,Crystals were grown at 20 C in sitting drop plates in drops of 200 nL crystallant and 200 nL protein. The protein was at 2.5 mg/mL and the reservoir was 20% PEG 3350 with 244 mM diammonium tartrate.,293.0,2018-08-27,2019-12-25,6MAJ,2553.0,2.0,331.0,157.0,,39.37,2.0,2.139,experimental,,0.2374,0.1949,HBO1 is required for the maintenance of leukaemia stem cells
7D0O,X-RAY DIFFRACTION,2.37,48.14,"VAPOR DIFFUSION, HANGING DROP",,"Tacsimate Tris-HCl, PEG 3350",289.0,2020-09-11,2021-07-07,7D0O,2475.0,2.0,326.0,35.0,,38.42,2.0,2.51,experimental,39.155,0.2901,0.2457,Crystal structure of human HBO1-BRPF2 in apo form
7D0S,X-RAY DIFFRACTION,2.44,49.49,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M L-Proline, 0.1 M HEPES, pH 7.5, 24% w/v PEG 1500",289.0,2020-09-11,2021-07-07,7D0S,2484.0,2.0,326.0,11.0,,39.23,2.0,2.3,experimental,63.503,0.2565,0.2133,Crystal structure of human HBO1-BRPF2 in complex with succinyl-coenzyme A
7RSP,X-RAY DIFFRACTION,2.31,46.64,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Potassium/Sodium tartrate, 0.1M Bis-Tris propane pH7.5, 20% PEG3350
0.7% v/v 1-butanol",277.15,2021-08-11,2021-11-24,7RSP,9431.0,2.0,1224.0,696.0,,140.98,1.0,1.67,experimental,34.0671,0.2246,0.2078,Structure of the VPS34 kinase domain with compound 14
7RSV,X-RAY DIFFRACTION,2.37,48.15,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Potassium/Sodium tartrate
0.1M Bis-Tris propane pH7.5, 
20% PEG3350
0.7% v/v 1-butanol",277.15,2021-08-11,2021-11-24,7RSV,9557.0,2.0,1224.0,844.0,,141.1,1.0,1.78,experimental,34.5956,0.2143,0.1794,Structure of the VPS34 kinase domain with compound 5
5X8I,X-RAY DIFFRACTION,2.37,48.17,"VAPOR DIFFUSION, SITTING DROP",9.0,"2% (v/v) PEG 200, 20% (v/v) tacsimate (pH 7.0), 0.1M HEPES (pH 9.0)",291.0,2017-03-02,2017-08-16,5X8I,6078.0,2.0,692.0,630.0,,81.95,1.0,1.902,experimental,,0.2064,0.1661,Crystal structure of human CLK1 in complex with compound 25
5X5O,X-RAY DIFFRACTION,1.85,33.42,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M Trimethylamine N-oxide dehydrate, 0.1 M Tris, 20% w/v Polyethylene glycol monomethyl ether 2000, pH8.5",293.0,2017-02-17,2017-12-27,5X5O,2499.0,1.0,310.0,140.0,,35.86,1.0,1.868,experimental,,0.2264,0.1898,Crystal structure of ZAK in complex with compound D2829
5LAV,X-RAY DIFFRACTION,2.3,46.65,"VAPOR DIFFUSION, HANGING DROP",4.5,RESERVOIR SOLUTION : NULL,277.0,2016-06-15,2016-11-02,5LAV,840.0,1.0,93.0,32.0,,11.4,1.0,1.73,experimental,17.91,0.2733,0.2415,"Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) in complex with compound 6b"
8EQ5,X-RAY DIFFRACTION,2.03,39.44,"VAPOR DIFFUSION, SITTING DROP",8.0,"30% w/v PEG 2K MME, 0.1 M Tris, pH 8.0",293.0,2022-10-07,2023-04-26,8EQ5,2514.0,2.0,335.0,139.0,,38.76,2.0,1.8,experimental,39.3,0.225,0.183,Crystal structure of the N-terminal kinase domain of RSK2 in complex with SPRED2 (131-160)
6IN0,X-RAY DIFFRACTION,2.23,44.96,"VAPOR DIFFUSION, HANGING DROP",,"13% PEG2000 monomethyl ether, 0.1 M MES pH 6.5, 0.1 M sodium acetate",293.0,2018-10-24,2019-10-30,6IN0,2465.0,1.0,301.0,246.0,,34.6,1.0,1.501,experimental,,0.2294,0.1947,Crystal structure of EphA3 in complex with 18-Crown-6
6BSD,X-RAY DIFFRACTION,2.12,42.02,"VAPOR DIFFUSION, HANGING DROP",5.5,18% PEG 3350 and 0.1 M Bis-Tris pH 5.5,298.0,2017-12-02,2018-12-05,6BSD,2312.0,1.0,351.0,61.0,,39.74,1.0,2.606,experimental,,0.2552,0.1781,DDR1 bound to Dasatinib
8FAY,X-RAY DIFFRACTION,2.21,44.4,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris [pH 5.5]. 0.2 M Ammonium sulfate, 22% PEG 3350",293.15,2022-11-29,2024-05-29,8FAY,7492.0,6.0,962.0,465.0,,116.54,1.0,1.91,experimental,46.87,0.2087,0.1805,Human MUTYH adenine glycosylase bound to DNA containing a transition state analog (1N) paired with d(8-oxo-G)
5HNI,X-RAY DIFFRACTION,2.22,44.57,"VAPOR DIFFUSION, HANGING DROP",7.0,"Hepes 100mM, isopropanol 11%, PEG5000 MME 6%",277.0,2016-01-18,2016-11-23,5HNI,4345.0,2.0,624.0,379.0,,71.48,1.0,1.71,experimental,,0.245,0.227,CRYSTAL STRUCTURE OF CMET WT with compound 3
8AU3,X-RAY DIFFRACTION,3.63,66.17,VAPOR DIFFUSION,6.5,"3.4 M NaFormiate, 0.1 M MES",293.0,2022-08-25,2023-09-06,8AU3,4685.0,2.0,598.0,81.0,,69.04,1.0,2.26,experimental,71.664,0.2397,0.1967,"c-MET Y1234E,Y1235E mutant in complex with Tepotinib"
8AW1,X-RAY DIFFRACTION,2.4,47.5,VAPOR DIFFUSION,6.5,"PEG 8,000",298.0,2022-08-29,2023-09-06,8AW1,4550.0,2.0,598.0,237.0,,68.78,1.0,2.14,experimental,48.26,0.2411,0.2171,c-MET Y1235D mutant in complex with Tepotinib
4KBQ,X-RAY DIFFRACTION,3.46,64.43,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.7M ammonium citrate, 0.1M HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2013-04-23,2015-01-14,4KBQ,3559.0,4.0,480.0,52.0,,54.62,2.0,2.91,experimental,,0.2627,0.2236,Structure of the CHIP-TPR domain in complex with the Hsc70 Lid-Tail domains
9B0B,X-RAY DIFFRACTION,3.41,63.9,VAPOR DIFFUSION,8.5,"3:1 (protein:mother liquor: 10% PEG 8K, 20% ethylene glycol, 0.1 M Tris/Bicine pH 8.5, 0.03 M MgCl2 and 0.03 M CaCl2. cryoprotected in mother liquor containing 10% glycerol",293.0,2024-03-11,2024-07-31,9B0B,3638.0,6.0,444.0,283.0,,52.83,2.0,1.7,experimental,,0.2217,0.1961,Structure of Optineurin bound to HOIP NZF1 domain
7BO3,X-RAY DIFFRACTION,3.19,61.42,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2021-01-23,2022-03-02,7BO3,4561.0,1.0,529.0,118.0,3.0,63.05,1.0,2.2,experimental,58.55,0.217,0.1834,Human Butyrylcholinesterase in complex with N-(2-(1H-Indol-3-yl)ethyl)-2-cycloheptyl-N-methylethan-1-amine
7RSJ,X-RAY DIFFRACTION,2.6,52.6,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Potassium/Sodium tartrate
0.1M Bis-Tris propane pH7.5, 
20% PEG3350
0.7% v/v 1-butanol",277.15,2021-08-11,2021-11-24,7RSJ,4828.0,1.0,612.0,341.0,,70.73,1.0,1.881,experimental,42.3886,0.2029,0.1683,Structure of the VPS34 kinase domain with compound 14
6IE2,X-RAY DIFFRACTION,3.05,59.65,"VAPOR DIFFUSION, HANGING DROP",6.5,"5% PEG3350, 5% MPD, 100mM CaCl2, 200mM NaF, 100mM Bis-Tris pH6.5",286.0,2018-09-13,2019-09-18,6IE2,20660.0,8.0,3112.0,486.0,,352.71,1.0,2.8,experimental,52.212,0.25357,0.21644,Crystal structure of methyladenine demethylase
5IU2,X-RAY DIFFRACTION,2.38,48.3,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH 7, 1.7 m ammonium sulfate, 0.01 M proline. Protein solution (COT:compound 1:1) was mixed with an equal volume (1 uL) of reservoir solution. Equilibration was done over 500 uL reservoir solution.",298.0,2016-03-17,2016-08-24,5IU2,4999.0,2.0,664.0,150.0,,76.29,1.0,2.7,experimental,29.06,0.2579,0.2326,"Discovery of imidazoquinolines as a novel class of potent, selective and in vivo efficacious COT kinase inhibitors"
6I44,X-RAY DIFFRACTION,2.34,47.5,EVAPORATION,7.5,"0.1M carboxylic acid, 0.1M Hepes/mops pH 7.5, 12.5%MPD, 12.5%PEG1000, 12.5%PEG3350",293.0,2018-11-09,2019-03-06,6I44,5669.0,1.0,627.0,681.0,18.0,72.81,1.0,1.36,experimental,18.539,0.19591,0.16745,Allosteric activation of human prekallikrein by apple domain disc rotation
4Y64,X-RAY DIFFRACTION,1.94,36.7,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, ammonium sulfate, MOPS, MnCl2",293.0,2015-02-12,2015-09-16,4Y64,2715.0,1.0,354.0,346.0,,41.7,1.0,1.6,experimental,21.18,0.25835,0.18794,AAGlyB in complex with amino-acid analogues
8P04,X-RAY DIFFRACTION,2.31,46.78,"VAPOR DIFFUSION, SITTING DROP",7.0,"25% PEG3350, 0.2 Sodium Malonate pH7",277.0,2023-05-09,2023-05-17,8P04,2539.0,1.0,339.0,5.0,,39.96,1.0,2.6,experimental,,0.2588,0.2086,Crystal structure of human CLK1 in complex with Leucettinib-92
6D2Z,X-RAY DIFFRACTION,1.99,38.21,"VAPOR DIFFUSION, HANGING DROP",6.3,"100 mM bis-tris, 25% SOKALAN CP 42, 1.5% tetrahydrofuran",289.0,2018-04-14,2018-09-05,6D2Z,1721.0,2.0,193.0,161.0,,22.8,1.0,1.18,experimental,,0.1738,0.1454,"Structure of human Usb1 with uridine-adenosine, inactive H208Q mutant"
6D30,X-RAY DIFFRACTION,2.07,40.45,"VAPOR DIFFUSION, HANGING DROP",7.0,"100 mM Tris, 25% SOKALN CP 42, 10% tetrahydrofuran",277.0,2018-04-14,2018-09-05,6D30,1870.0,2.0,193.0,220.0,,22.78,1.0,1.17,experimental,,0.1717,0.1494,"Structure of human Usb1 with uridine-uridine, inactive H208Q mutant"
6L6E,X-RAY DIFFRACTION,2.96,58.46,"VAPOR DIFFUSION, HANGING DROP",,"0.2M MgSO4, 0.1M Na cacodylate pH 6.8, 18 % PEG 3350",277.0,2019-10-28,2020-09-02,6L6E,2730.0,1.0,335.0,87.0,,39.66,1.0,1.92,experimental,31.08,0.2074,0.1966,Human PDE5 catalytic core in complex with avanafil
7OPO,X-RAY DIFFRACTION,2.58,52.26,"VAPOR DIFFUSION, HANGING DROP",7.5,"12 %PEG 6000, HEPES pH 7.5, 0.75M NaCl in reservoir",293.0,2021-06-01,2022-02-02,7OPO,16458.0,12.0,2280.0,47.0,,261.22,2.0,2.75,experimental,86.04,0.2322,0.2087,RSK2 N-terminal kinase domain in complex with ORF45
5VO1,X-RAY DIFFRACTION,2.0,38.36,"VAPOR DIFFUSION, HANGING DROP",7.7,"20% PEG 3350, 0.2 M Mg Acetate, 0.1 M Hepes pH 7.7",293.0,2017-05-01,2017-10-04,5VO1,2350.0,1.0,300.0,151.0,,34.43,1.0,2.45,experimental,33.19,0.243,0.1664,DLK in complex with compound 10 (5-(1-isopropyl-5-(3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl)-1H-pyrazol-3-yl)-3-(trifluoromethyl)pyridin-2-amine)
5WXP,X-RAY DIFFRACTION,2.04,39.67,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2017-01-08,2018-07-11,5WXP,2065.0,2.0,257.0,69.0,6.0,29.14,2.0,1.75,experimental,39.39,0.249,0.213,Crystal structure of uPA in complex with upain-2-3-W3A
7CMZ,X-RAY DIFFRACTION,2.05,35.55,VAPOR DIFFUSION,,"Sodium phosphate monobasic monohydrate, Potassium phosphate dibasic",289.0,2020-07-29,2021-03-17,7CMZ,2159.0,2.0,252.0,289.0,1.0,28.54,2.0,1.695,experimental,14.848,0.215,0.1782,Crystal Structure of BRCT7/8 in Complex with the APS Motif of PHF8
6A0F,X-RAY DIFFRACTION,2.19,43.78,"VAPOR DIFFUSION, HANGING DROP",4.8,"PEG 3350, potassium phosphate monobasic",295.0,2018-06-05,2019-12-11,6A0F,5193.0,4.0,646.0,218.0,1.0,74.67,2.0,2.384,experimental,,0.2475,0.1956,Crystal structure of human protein N-terminal asparagine amidohydrolase (NTAN1) C75S mutant with Asn-Phe-Ala-Ala-Arg peptide
7QBR,X-RAY DIFFRACTION,3.29,62.63,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulfate,293.0,2021-11-19,2022-11-30,7QBR,4709.0,1.0,529.0,214.0,3.0,63.95,1.0,2.13,experimental,60.78,0.2138,0.1801,Human butyrylcholinesterase in complex with (Z)-N-tert-butyl-1-(8-(3-(4-(prop-2-yn-1-yl)piperazin-1-yl)propoxy)quinolin-2-yl)methanimine oxide
4R1Y,X-RAY DIFFRACTION,2.1,41.37,VAPOR DIFFUSION,6.5,"PEG8000, pH 6.5, VAPOR DIFFUSION, temperature 298K",298.0,2014-08-08,2015-03-18,4R1Y,2333.0,1.0,292.0,150.0,,34.18,1.0,2,experimental,,0.23806,0.17902,Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitor
7M98,X-RAY DIFFRACTION,3.05,59.66,"VAPOR DIFFUSION, HANGING DROP",,"2.0 M sodium phosphate monobasic monohydrate/potassium phosphate dibasic, pH 6.6",277.0,2021-03-30,2021-09-22,7M98,1406.0,2.0,167.0,203.0,,19.19,2.0,1.6,experimental,39.75,0.2187,0.194,ATAD2 bromodomain complexed with histone H4K5ac (res 1-10) ligand
8SDO,X-RAY DIFFRACTION,3.02,59.28,"VAPOR DIFFUSION, HANGING DROP",,"2.4 M sodium phosphate monobasic monohydrate/potassium phosphate dibasic, pH 6.4",277.0,2023-04-07,2024-06-05,8SDO,1308.0,2.0,167.0,168.0,,19.21,2.0,2.01,experimental,56.87,0.2305,0.2007,"ATAD2 bromodomain in complex with ""oncohistone"" mutation H4S1CK5ac (res 1-15) ligand"
8SDQ,X-RAY DIFFRACTION,2.95,58.32,"VAPOR DIFFUSION, SITTING DROP",,60% v/v TascimateTM pH 7.0,277.0,2023-04-07,2024-06-05,8SDQ,1396.0,2.0,167.0,210.0,,19.27,2.0,1.85,experimental,34.24,0.2384,0.205,ATAD2 bromodomain in complex with H4S1phK5ac (res 1-15) ligand
6UWY,X-RAY DIFFRACTION,3.22,61.8,"VAPOR DIFFUSION, HANGING DROP",8.8,"35-45% PEG400, 0.2 M lithium sulfate, 0.1 M Tris, pH 8.8",277.0,2019-11-05,2020-02-12,6UWY,11641.0,4.0,1444.0,11.0,,171.65,1.0,2.95,experimental,98.726,0.2271,0.1951,DYRK1A bound to a harmine derivative
5CE1,X-RAY DIFFRACTION,2.06,40.19,"VAPOR DIFFUSION, SITTING DROP",6.0,"Activated hepsin was incubated with 10 mM Benzamidine at 4 oC for 2 hours and concentrated to7 mg/ml using 10 KDa cut off centricon [Millipore]. 1microlit of protein was mixed with 1 microlit of reservoir buffer containing 100 mM sodium Cacodylate (6.0), 22% PEG 3350, and 200 mM ammonium fluoride. Plate clusters with a dimension of 50 micron m x 100 micron m were observed after 2 days of crystallization set up.",293.0,2015-07-06,2016-07-06,5CE1,2696.0,1.0,372.0,46.0,8.0,40.83,1.0,2.5,experimental,25.094,0.2815,0.18714,Crystal Structure of Serine protease Hepsin in complex with Inhibitor
7F0I,X-RAY DIFFRACTION,2.91,57.76,"VAPOR DIFFUSION, HANGING DROP",,"3.0M Na formate, 0.1M HEPES (pH 7.5), 5% xylitol",277.0,2021-06-04,2022-04-13,7F0I,5368.0,2.0,1066.0,116.0,,124.53,1.0,2.70000890032,experimental,30.0805812221,0.333696578959,0.270818453015,phosphodiesterase-9A in complex with inhibitor 4b
5B2L,X-RAY DIFFRACTION,2.23,44.82,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, sodium citrate tribasic, HEPES",310.0,2016-01-19,2016-04-06,5B2L,2411.0,1.0,324.0,66.0,,37.55,1.0,2.1,experimental,41.148,0.26352,0.19229,A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7
5Z1D,X-RAY DIFFRACTION,2.08,40.96,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, sodium citrate",277.0,2017-12-26,2019-01-02,5Z1D,2333.0,1.0,324.0,101.0,,37.5,1.0,2.28,experimental,46.462,0.25806,0.19227,MAP2K7 C276S mutant-inhibitor
6QFL,X-RAY DIFFRACTION,2.78,55.73,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodiumcitrate
20 % PEG3350",277.0,2019-01-10,2019-05-22,6QFL,2275.0,1.0,318.0,72.0,,36.15,1.0,2.2,experimental,,0.2468,0.2147,Structure of the mitogen activated kinase kinase 7 active conformation
6QFR,X-RAY DIFFRACTION,2.89,57.4,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodiumcitrate
20% PEG3350",277.0,2019-01-10,2019-05-22,6QFR,2118.0,1.0,318.0,88.0,,36.15,1.0,2.3,experimental,,0.2581,0.224,Structure of the mitogen activated kinase kinase 7 dfg-out conformation
6QFT,X-RAY DIFFRACTION,2.38,48.38,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodiumcitrate
20% PEG3350",277.0,2019-01-10,2019-05-22,6QFT,2165.0,1.0,318.0,34.0,,36.55,1.0,2.7,experimental,,0.2869,0.2361,Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidin 1b
6QG4,X-RAY DIFFRACTION,2.4,48.79,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodiumcitrate
0.2% PEG3350",277.0,2019-01-10,2019-05-22,6QG4,2114.0,1.0,318.0,40.0,,36.51,1.0,2.3,experimental,,0.2691,0.2339,Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine inhibitor 1h
6QG7,X-RAY DIFFRACTION,2.32,47.09,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodiumcitrate
20% PEG3350",277.0,2019-01-10,2019-05-22,6QG7,2285.0,1.0,318.0,95.0,,36.55,1.0,2.1,experimental,,0.2679,0.2337,Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1k
6QHO,X-RAY DIFFRACTION,2.77,55.65,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M soidumcitrate
20% PEG3350",277.0,2019-01-17,2019-05-22,6QHO,2094.0,1.0,318.0,7.0,,36.42,1.0,2.7,experimental,,0.2809,0.2214,Dual specificity mitogen-activated protein kinase kinase 7 in complex with pyrazolopyrimidine 1a
6QHR,X-RAY DIFFRACTION,2.79,55.9,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodiumcitrate
20% PEG3350",277.0,2019-01-17,2019-05-22,6QHR,2299.0,1.0,318.0,92.0,,36.54,1.0,2.52,experimental,,0.2938,0.237,Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1m
6YFZ,X-RAY DIFFRACTION,2.5,50.85,"VAPOR DIFFUSION, SITTING DROP",7.8,"19% PEG3350, 
0.15 M ammonium acetate, 0.1 M tris, pH 7.8",277.15,2020-03-27,2020-08-12,6YFZ,2619.0,1.0,307.0,233.0,,34.94,1.0,1.9,experimental,38.59,0.2373,0.1921,"Crystal structure of MKK7 (MAP2K7), apo form"
6YG0,X-RAY DIFFRACTION,2.55,51.73,"VAPOR DIFFUSION, SITTING DROP",8.2,"16% PEG3350,
0.25 M ammonium acetate, 0.1 M tris, pH 8.2",277.15,2020-03-27,2020-08-12,6YG0,2318.0,1.0,307.0,89.0,,34.99,1.0,2,experimental,60.822,0.2452,0.1943,"Crystal structure of S287D,T291D MKK7 (MAP2K7), apo form"
6YG3,X-RAY DIFFRACTION,2.29,46.4,"VAPOR DIFFUSION, SITTING DROP",8.2,"19% PEG3350, 0.25 M ammonium acetate, 
0.1 M tris, pH 8.2",277.15,2020-03-27,2020-08-12,6YG3,2309.0,1.0,307.0,117.0,,35.97,1.0,2.05,experimental,44.495,0.2351,0.1884,Crystal structure of MKK7 (MAP2K7) covalently bound with CPT1-70-1
6YG4,X-RAY DIFFRACTION,2.33,47.26,"VAPOR DIFFUSION, SITTING DROP",8.2,"19% PEG3350,  0.1 M ammonium acetate, 
0.1 M tris, pH 8.2",277.15,2020-03-27,2020-08-12,6YG4,2138.0,1.0,307.0,34.0,,35.61,1.0,2.3,experimental,65.022,0.2549,0.2106,Crystal structure of MKK7 (MAP2K7) in complex with K00007
6YG5,X-RAY DIFFRACTION,2.46,49.94,"VAPOR DIFFUSION, SITTING DROP",7.8,"16% PEG3350, 0.2 M ammonium acetate, 
0.1 M tris, pH 7.8",277.15,2020-03-27,2020-08-12,6YG5,2099.0,1.0,307.0,13.0,,35.36,1.0,2.4,experimental,77.071,0.2815,0.2307,Crystal structure of MKK7 (MAP2K7) in complex with ASC69
7CBX,X-RAY DIFFRACTION,2.46,50.0,"VAPOR DIFFUSION, SITTING DROP",,PEG3350,277.0,2020-06-15,2020-09-30,7CBX,2393.0,1.0,323.0,104.0,,37.29,1.0,2.061,experimental,40.38,0.2236,0.1816,Crystal structure of MAP2K7 complexed with a covalent inhibitor 12
6TW2,X-RAY DIFFRACTION,2.55,51.78,"VAPOR DIFFUSION, HANGING DROP",7.0,2.1 M SODIUM MALATE,277.0,2020-01-12,2020-02-05,6TW2,3257.0,1.0,341.0,216.0,,40.08,1.0,1.8,experimental,35.75,0.2225,0.1806,Re-refined crystal structure of di-phosphorylated human CLK1 in complex with a novel substituted indole inhibitor
5OKP,X-RAY DIFFRACTION,2.42,49.25,"VAPOR DIFFUSION, SITTING DROP",7.1,"50 mM HEPES pH 7.1, 17.5% PEG 1000",293.0,2017-07-25,2017-08-23,5OKP,3578.0,1.0,461.0,139.0,,52.97,1.0,1.85,experimental,33.328,0.20469,0.17787,Crystal structure of human SHIP2 Phosphatase-C2 double mutant F593D/L597D
6KHD,X-RAY DIFFRACTION,1.69,27.41,"VAPOR DIFFUSION, HANGING DROP",8.0,"8% (v/v) Tacsimate, 18% (w/v) PEG 3350, 3% (v/v) Glycerol",293.0,2019-07-15,2019-10-02,6KHD,7710.0,3.0,1452.0,22.0,,173.02,1.0,2.7,experimental,63.9783,0.2741,0.1998,Crystal structure of CLK1 in complex with CX-4945
8BE3,X-RAY DIFFRACTION,2.3,46.62,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350 21%, MES 0.1 M pH 6.0, NaCl 150mM",293.0,2022-10-21,2023-11-01,8BE3,4725.0,4.0,624.0,350.0,2.0,71.32,2.0,1.85,experimental,41.19,0.2303,0.2008,Crystal structure of KRasG12V-Nanobody84
6V7N,X-RAY DIFFRACTION,2.77,55.67,"VAPOR DIFFUSION, SITTING DROP",,"1.8 M Ammonium sulfate, 0.1 M CH3COONa, pH 5.5",298.0,2019-12-09,2020-06-17,6V7N,6241.0,2.0,768.0,155.0,2.0,89.24,1.0,2.62,experimental,58.59,0.222,0.185,"Crystal Structure of a human Lysosome Resident Glycoprotein, Lysosomal Acid Lipase, and its Implications in Cholesteryl Ester Storage Disease (CESD)"
6QFF,X-RAY DIFFRACTION,2.48,50.31,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-01-10,2019-05-08,6QFF,3910.0,2.0,444.0,420.0,12.0,49.47,1.0,1.64,experimental,26.38,0.214,0.186,Crystal Structure of Human Kallikrein 6 in complex with GSK144
6QFG,X-RAY DIFFRACTION,2.44,49.64,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-01-10,2019-05-08,6QFG,3852.0,2.0,446.0,350.0,12.0,49.92,1.0,1.68,experimental,31.23,0.219,0.191,Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK144
6QFH,X-RAY DIFFRACTION,2.26,45.55,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-01-10,2019-05-08,6QFH,3792.0,2.0,444.0,296.0,12.0,49.72,1.0,1.65,experimental,30.25,0.217,0.187,Crystal Structure of Human Kallikrein 6 (N217D/I218Y/K224R) in complex with GSK144.
6QH9,X-RAY DIFFRACTION,2.55,51.73,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-01-16,2019-02-06,6QH9,3721.0,2.0,446.0,233.0,12.0,49.97,1.0,2.27,experimental,30.54,0.248,0.204,Crystal Structure of Human Kallikrein 6 in complex with GSK3239861A
6QHA,X-RAY DIFFRACTION,2.47,50.24,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-01-16,2019-02-06,6QHA,3841.0,2.0,446.0,361.0,12.0,49.53,1.0,1.82,experimental,28.37,0.248,0.213,Crystal Structure of Human Kallikrein 6 in complex with GSK3205388B
6QHB,X-RAY DIFFRACTION,2.46,50.08,"VAPOR DIFFUSION, SITTING DROP",8.6,"100mM Tris-HCl pH 8.6, PEG 4000 18-28%",293.0,2019-01-16,2019-02-06,6QHB,3831.0,2.0,446.0,341.0,12.0,49.5,1.0,1.84,experimental,30.68,0.206,0.183,Crystal Structure of Human Kallikrein 6 in complex with GSK578724A
5L2S,X-RAY DIFFRACTION,2.28,46.13,"VAPOR DIFFUSION, SITTING DROP",,"1:1 (protein to well buffer) with well buffer containing:  0.1 M MES pH 6.0, 70 - 80 mM NH4NO3, 10 - 15% polyethyleneglycol 3350",286.15,2016-08-02,2016-08-24,5L2S,2148.0,1.0,307.0,21.0,,35.53,1.0,2.27,experimental,58.77,0.2488,0.206,The X-ray co-crystal structure of human CDK6 and Abemaciclib.
6LPG,X-RAY DIFFRACTION,2.17,43.19,"VAPOR DIFFUSION, SITTING DROP",,"0.16 M ammonium sulfate, 0.08 M Sodium acetate pH4.6, 20%(w/v) PEG4000, 20%(v/v) glycerol",293.0,2020-01-10,2020-10-21,6LPG,2358.0,2.0,323.0,76.0,,37.53,2.0,2.3,experimental,60.22,0.2362,0.1896,human VASH1-SVBP complex
4ZSM,X-RAY DIFFRACTION,2.69,54.35,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG8000, SODIUM CACODYLATE, AMMONIUM SULFATE",277.0,2015-05-13,2015-06-10,4ZSM,6633.0,2.0,884.0,491.0,6.0,98.37,1.0,1.96,experimental,33.165,0.25761,0.22677,BACE crystal structure with bicyclic aminothiazine fragment
4ZSP,X-RAY DIFFRACTION,2.66,53.77,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG8000, sodium cacodylate, ammonium sulfate",277.0,2015-05-13,2015-06-10,4ZSP,7048.0,2.0,884.0,849.0,6.0,98.77,1.0,1.91,experimental,32.621,0.24269,0.18874,BACE crystal structure with bicyclic aminothiazine inhibitor
4ZSQ,X-RAY DIFFRACTION,2.69,54.2,"VAPOR DIFFUSION, HANGING DROP",,"PEG8000, sodium cacodylate, ammonium sulfate",277.0,2015-05-13,2015-06-10,4ZSQ,6656.0,2.0,884.0,482.0,6.0,98.86,1.0,2.3,experimental,54.488,0.25798,0.20191,BACE crystal structure with tricyclic aminothiazine inhibitor
6Z19,X-RAY DIFFRACTION,2.18,43.59,"VAPOR DIFFUSION, SITTING DROP",5.5,"25 %v/v PEGSM, 0.2 M (NH4)2SO4, 0.1 M Na Cacod",298.0,2020-05-13,2021-05-26,6Z19,3223.0,2.0,336.0,254.0,,41.62,2.0,1.47,experimental,19.493,0.2208,0.1883,Crystal structure of P8C9 bound to CK2alpha
5A7W,X-RAY DIFFRACTION,2.69,54.37,,6.0,30% PEG3350 -- 0.1M BIS-TRIS PH 6.0 -- 0.25M AMMONIUM SULFATE,,2015-07-10,2016-01-13,5A7W,5600.0,2.0,762.0,75.0,,90.25,2.0,2.27,experimental,,0.2728,0.2249,Crystal structure of human JMJD2A in complex with compound 35
7OUP,X-RAY DIFFRACTION,2.49,50.58,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.056 M sodium phosphate monobasic monohydrate, 1.344 M potassium phosphate dibasic monohydrate",293.0,2021-06-12,2021-08-11,7OUP,5870.0,2.0,741.0,73.0,,83.39,2.0,2.65,experimental,53.65,0.2528,0.1972,Structure of human DPP3 in complex with a hydroxyethylene transition state peptidomimetic
6D65,X-RAY DIFFRACTION,2.99,58.84,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.15 M NaCl
0.1 M sodium cacodylate
2.0 M ammonium sulfate",292.0,2018-04-20,2018-09-19,6D65,11049.0,4.0,1378.0,606.0,,154.55,2.0,2.348,experimental,,0.2409,0.1851,Crystal structure of the human dual specificity phosphatase 1 catalytic domain (C258S) as a maltose binding protein fusion in complex with the designed AR protein off7
5M35,X-RAY DIFFRACTION,3.94,68.8,"VAPOR DIFFUSION, SITTING DROP",5.6,0.17 M Ammonium acetate; 0.085 M Sodium citrate pH 5.6; 25.5%(w/v) PEG 4000; 15%(v/v) Glycerol,277.15,2016-10-14,2017-11-15,5M35,3818.0,4.0,475.0,119.0,,54.99,3.0,2.38,experimental,55.997,0.2772,0.2243,The molecular tweezer CLR01 stabilizes a disordered protein-protein interface
9FSE,X-RAY DIFFRACTION,2.91,57.78,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 1.5 M LiSO4",298.15,2024-06-20,2024-07-10,9FSE,1768.0,1.0,238.0,11.0,7.0,27.05,1.0,2.48,experimental,68.67,0.2705,0.2365,Human ROR2 cysteine-rich domain (CRD) and Kringle domain
6GWR,X-RAY DIFFRACTION,2.2,44.14,"VAPOR DIFFUSION, SITTING DROP",,10% ethylene glycol -- 0.2M sodium sulfate -- 24% PEG3350 -- 0.1M bis-tris-propane pH 7.1,293.0,2018-06-25,2018-08-08,6GWR,5462.0,2.0,630.0,639.0,,74.14,1.0,2.07,experimental,,0.2372,0.2006,Structure of the kinase domain of human DDR1 in complex with a potent and selective inhibitor of DDR1 and DDR2
5ZHU,X-RAY DIFFRACTION,2.56,51.87,"VAPOR DIFFUSION, HANGING DROP",,"0.2M (NH4)2SO4, 0.1M HEPES pH7.0, 22.5% PEG 3350",289.0,2018-03-13,2018-05-23,5ZHU,4583.0,3.0,549.0,165.0,,63.12,1.0,2.202,experimental,,0.2544,0.2281,Crystal structure of the DNA-binding domain of human myelin-gene regulatory factor
5I3V,X-RAY DIFFRACTION,2.84,56.76,VAPOR DIFFUSION,6.6,"20% polyethylene glycol 5000 MME, 0.2 M ammonium iodide, 0.17 M sodium citrate (pH 6.6), 3% DMSO",298.0,2016-02-11,2016-03-30,5I3V,3410.0,1.0,411.0,454.0,3.0,46.7,1.0,1.62,experimental,16.294,0.2312,0.2091,Crystal structure of BACE1 in complex with aminoquinoline compound 1
5I3X,X-RAY DIFFRACTION,2.84,56.67,VAPOR DIFFUSION,6.0,"1.5 M ammonium sulfate, 0.2 M lithium chloride, 0.1 M MES (pH 6.0)",298.0,2016-02-11,2016-03-30,5I3X,3420.0,1.0,411.0,433.0,3.0,46.51,1.0,1.85,experimental,19.29,0.2124,0.1763,Crystal structure of BACE1 in complex with aminoquinoline inhibitor 6
6JSE,X-RAY DIFFRACTION,2.75,59.53,"VAPOR DIFFUSION, SITTING DROP",,"0.2M sodium citrate tribasic pH6.5, 0.2M ammonium iodide, 18.4%(w/v) PEG5000MME",293.0,2019-04-08,2019-08-28,6JSE,3181.0,1.0,416.0,217.0,3.0,47.7,1.0,2,experimental,36.627,0.2078,0.1885,"Crystal Structure of BACE1 in complex with N-(3-((4S,5R)-2-amino-4-methyl-5-phenyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide"
6JSF,X-RAY DIFFRACTION,2.79,60.28,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium citrate, 0.2 M ammonium iodide, 18.4%(w/v) polyethylene glycol 5000 monomethyl ether, pH 6.5",293.15,2019-04-08,2019-08-28,6JSF,3119.0,1.0,416.0,154.0,3.0,47.91,1.0,2.3,experimental,39.439,0.2127,0.1831,"Crystal Structure of BACE1 in complex with N-(3-((4S,5S)-2-amino-4-methyl-5-phenyl-5,6-dihydro-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide"
4S1G,X-RAY DIFFRACTION,3.18,61.28,"VAPOR DIFFUSION, HANGING DROP",5.0,"17%PEG3350, 200mM NaCl 
, VAPOR DIFFUSION, HANGING DROP, temperature 295K",295.0,2015-01-13,2015-02-25,4S1G,5499.0,2.0,680.0,294.0,6.0,75.83,1.0,2.1,experimental,46.1383,0.2255,0.2109,Renin in complex with (S)-1-(3-fluoro-5-(((S)-1-phenylethyl)carbamoyl)benzyl)-4-isopropyl-4-methyl-6-oxotetrahydropyrimidin-2(1H)-iminium
6P9F,X-RAY DIFFRACTION,2.5,50.72,"VAPOR DIFFUSION, HANGING DROP",,"20-26% PEG3350, 0.2 M magnesium chloride, 0.1 M Bis-Tris pH 5.5-6.5",298.0,2019-06-10,2019-07-17,6P9F,4288.0,2.0,570.0,23.0,,67.03,1.0,2.8,experimental,72.79,0.223,0.184,Crystal structure of RAR-related orphan receptor C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) in complex with a phenyl (3-phenylpyrrolidin-3-yl)sulfone inhibitor
5F5I,X-RAY DIFFRACTION,2.59,52.45,"VAPOR DIFFUSION, SITTING DROP",5.9,"0.1M bis-tris pH 5.9 , 0.15M ammonium sulfate , 13% PEG3350",277.0,2015-12-04,2015-12-30,5F5I,5813.0,2.0,726.0,152.0,,85.51,1.0,2.63,experimental,53.513,0.2433,0.2109,Crystal Structure of human JMJD2A complexed with KDOOA011340
6DMI,X-RAY DIFFRACTION,2.96,58.38,"VAPOR DIFFUSION, HANGING DROP",,"2.5M SODIUM FORMATE, 100MM HEPES",293.0,2018-06-05,2018-12-19,6DMI,3426.0,1.0,390.0,340.0,3.0,43.94,1.0,1.9,experimental,34.4303,0.2258,0.1924,A multiconformer ligand model of 5T5 bound to BACE-1
5EZX,X-RAY DIFFRACTION,3.07,59.99,"VAPOR DIFFUSION, HANGING DROP",,"2.5M SODIUM FORMATE, 100MM HEPES",293.0,2015-11-27,2016-02-24,5EZX,3370.0,1.0,390.0,340.0,3.0,43.94,1.0,1.9,experimental,33.623,0.2364,0.20816,"CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH {(1R,2R)-2-[(R)-2-Amino-4-(4-difluoromethoxy-phenyl)-4,5-dihydro-oxazol-4-yl]-cyclopropyl}-(5-chloro-pyridin-3-yl)-methanone"
5EZZ,X-RAY DIFFRACTION,3.06,59.75,"VAPOR DIFFUSION, SITTING DROP",7.0,"2.5M SODIUM FORMATE, 100MM HEPES",298.0,2015-11-27,2016-02-24,5EZZ,3277.0,1.0,390.0,262.0,2.0,43.97,1.0,2.1,experimental,42.454,0.23957,0.20467,CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-chloro-3-pyridyl)phenyl]-4-[4-(difluoromethoxy)-3-methyl-phenyl]-5H-oxazol-2-amine
5F00,X-RAY DIFFRACTION,3.15,61.01,"VAPOR DIFFUSION, SITTING DROP",7.0,"2.5M SODIUM FORMATE, 100MM HEPES",298.0,2015-11-27,2016-02-24,5F00,3265.0,1.0,390.0,295.0,3.0,43.9,1.0,1.95,experimental,30.896,0.26344,0.22033,"CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-[3-[(3-chloro-8-quinolyl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine"
8GVV,X-RAY DIFFRACTION,2.29,46.29,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 3350, 250 mM Sodium iodide",278.0,2022-09-15,2023-09-20,8GVV,2573.0,1.0,299.0,242.0,,35.14,1.0,1.8,experimental,31.7186,0.2273,0.1904,PTPN21 PTP domain C1108S mutant
8Y8Y,X-RAY DIFFRACTION,2.52,51.17,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.04 M citric acid, 0.04 M Bis-tris-propane pH 5.0, 13.8% polyethylene glycol 3350",291.0,2024-02-06,2024-07-10,8Y8Y,2438.0,1.0,293.0,149.0,,34.29,1.0,2.099,experimental,,0.25,0.1999,Crystal structure of the PTPN21 FERM domain
8R18,X-RAY DIFFRACTION,3.0,59.5,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM bis-tris-propane (pH 7.0), 10% ethylene glycol, 0.3% DMSO, 20% PEG3350, 200 mM Mg(OAc)2",291.15,2023-11-01,2024-03-20,8R18,2510.0,2.0,327.0,183.0,,37.66,2.0,1.89,experimental,39.14,0.1856,0.1596,Pim1 in complex with (E)-4-(4-hydroxystyryl)benzoic acid and Pimtide
5KGD,X-RAY DIFFRACTION,3.49,64.74,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293.0,2016-06-13,2017-08-09,5KGD,2454.0,1.0,276.0,128.0,,33.47,1.0,1.98,experimental,42.42,0.184,0.162,Crystal structure of PIM1 with inhibitor: 2-pyridin-3-yl-1~{H}-benzimidazole
5KGE,X-RAY DIFFRACTION,3.43,64.13,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293.0,2016-06-13,2017-08-09,5KGE,2365.0,1.0,276.0,56.0,,33.26,1.0,2.23,experimental,53.58,0.208,0.196,"Crystal structure of PIM1 with inhibitor: 5-(3,4-dichlorophenyl)-1~{H}-pyrazol-3-amine"
5KGG,X-RAY DIFFRACTION,3.43,64.19,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293.0,2016-06-13,2017-08-09,5KGG,2557.0,1.0,276.0,224.0,,33.63,1.0,1.95,experimental,31.95,0.17,0.159,Crystal structure of PIM1 with inhibitor: 2-(5-chloranyl-1~{H}-indol-3-yl)ethanamine
5KGI,X-RAY DIFFRACTION,3.53,65.12,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293.0,2016-06-13,2017-08-09,5KGI,2411.0,1.0,276.0,112.0,,33.11,1.0,2.13,experimental,50.22,0.186,0.172,"Crystal structure of PIM1 with inhibitor 2-[3,4-bis(chloranyl)phenoxy]ethanamine"
5KGK,X-RAY DIFFRACTION,3.58,65.62,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293.0,2016-06-13,2017-08-09,5KGK,2302.0,1.0,276.0,29.0,,32.66,1.0,2.66,experimental,64.01,0.206,0.187,Crystal structure of PIM1 with inhibitor: 3-(4-methoxyphenyl)-1~{H}-pyrazol-5-amine
5WZO,X-RAY DIFFRACTION,3.38,63.56,VAPOR DIFFUSION,,"2.2M Sodium chloride, 0.1M BIS-TRIS propane pH 7.0",277.0,2017-01-18,2018-01-24,5WZO,1232.0,1.0,123.0,194.0,7.0,14.85,1.0,1.9,experimental,18.662,0.2447,0.2082,"Crystal structure of human secreted phospholipase A2 group IIE, crystallized with calcium"
5Y5E,X-RAY DIFFRACTION,3.44,64.24,VAPOR DIFFUSION,,"2.2M Sodium chloride, 0.1M BIS-TRIS propane pH 7.0",277.0,2017-08-08,2018-06-20,5Y5E,1180.0,1.0,123.0,144.0,7.0,14.98,1.0,1.8,experimental,22.551,0.225,0.1926,Crystal structure of phospholipase A2 with inhibitor
6Y5P,X-RAY DIFFRACTION,3.64,66.23,"VAPOR DIFFUSION, SITTING DROP",7.6,"0.16M Calcium acetate hydrate, 0.08MSodium cacodylate pH 6.5, 14.4% w/v PEG 8000, 20% v/v Glycerol",292.0,2020-02-25,2020-09-30,6Y5P,4143.0,2.0,470.0,420.0,,54.22,1.0,1.74,experimental,44.4615,0.2137,0.1853,RING-DTC domain of Deltex1 bound to NAD
7N66,X-RAY DIFFRACTION,2.77,55.55,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2M Sodium Citrate Tribasic pH 6.5, 0.2M Ammonium Iodide, 20.3% w/v PEG-5000 MME",293.0,2021-06-07,2021-10-06,7N66,3238.0,1.0,416.0,238.0,3.0,47.88,1.0,2.1,experimental,33.014,0.2303,0.1957,BACE-1 in complex with ligand 12
6T8X,X-RAY DIFFRACTION,3.39,63.74,"VAPOR DIFFUSION, SITTING DROP",6.0,"1.3M NaMalonate, 0.1M Hepes pH6.0, 0.5% jeffamine ED2003",295.0,2019-10-25,2021-05-12,6T8X,13887.0,6.0,1914.0,35.0,,226.44,1.0,2.81,experimental,92.85,0.2472,0.2277,Crystal structure of MAPKAPK2 (MK2) complexed with PF-3644022 and 5-(4-bromophenyl)-N-[4-(1-piperazinyl)phenyl]-N-(2-pyridinylmethyl)-2-furancarboxamide
5N4R,X-RAY DIFFRACTION,3.13,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HHEPES
Li2SO4
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N4R,2376.0,2.0,327.0,133.0,,37.59,2.0,2.13,experimental,,0.1933,0.1601,Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 2-(azepan-1-yl)-1-(1H-indol-3-yl)propan-1-one
5N5L,X-RAY DIFFRACTION,3.1,60.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
Li2SO4
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-14,2018-03-07,5N5L,2455.0,2.0,327.0,168.0,,37.64,2.0,1.97,experimental,,0.1952,0.1601,Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and [2-oxo-2-(1H-pyrrol-2-yl)ethyl] 5-bromo-1H-indole-3-carboxylate
5NDT,X-RAY DIFFRACTION,3.14,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
NaCl
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-03-09,2018-05-16,5NDT,2393.0,2.0,327.0,124.0,,37.57,2.0,1.985,experimental,,0.1941,0.1602,"Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule (E)-3-(2-(thiophen-2-yl)vinyl)-3,4-dihydroquinoxalin-2(1H)-one"
7UP5,X-RAY DIFFRACTION,2.31,46.7,"VAPOR DIFFUSION, SITTING DROP",8.5,"The protein (10.1 mg/ml) was exchanged into 25 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol, 1 mM DTT using a GE (GE28-9180-04) spin column according to manufacturer's instructions. The protein was then diluted to 0.5 mg/ml in the same buffer and incubated with 150 micromolar UCB170414/BSI108592 for an hour on ice (~10 fold)and concentrated back down to 5 mg/ml. Crystals were produced by sitting drop vapor diffusion with an equal volume of the protein, Msk1-C terminal domain (PID7059-1, CID101276) and a crystallization buffer containing 12.5% PEG 1000, 12.5% PEG 3350, 12.5% MPD: 30mM of each sodium fluoride/iodide/bromide: 100 mM Na HEPES/MOPS pH 8.5 (tray ID 303042, well B12, Morpheus). Crystals were directly vitrified in in liquid N2. Puck ID QRL9-2",289.0,2022-04-14,2022-07-06,7UP5,4322.0,2.0,612.0,38.0,,70.23,1.0,2.8,experimental,50.6763,0.2678,0.2008,Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound pyrrolopyrimidine compound 23 (co-crystal)
6U25,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, HANGING DROP",,"20-26% PEG3350, 0.2 M MAGNESIUM          CHLORIDE, 0.1 M BIS-TRIS PH 5.5-6.5",298.0,2019-08-19,2019-11-06,6U25,2099.0,1.0,285.0,6.0,,33.63,1.0,2.61,experimental,58.1,0.247,0.206,CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS- RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH A TRICYCLIC INVERSE AGONIST
5O2C,X-RAY DIFFRACTION,2.87,57.15,"VAPOR DIFFUSION, SITTING DROP",,"18% PEG3350, 0.1 M Citrate pH 5",277.0,2017-05-19,2017-06-28,5O2C,3096.0,1.0,380.0,117.0,,44.09,1.0,2.4,experimental,44.3,0.2542,0.1851,Crystal structure of WNK3 kinase and CCT1 didomain in a unphosphorylated state
6IN4,X-RAY DIFFRACTION,1.9,35.4,"VAPOR DIFFUSION, HANGING DROP",,"1.8 M ammonium sulfate, 0.1 M MES pH 6.5, 100 mM 18-crown-6",293.0,2018-10-24,2019-10-30,6IN4,2386.0,1.0,293.0,235.0,,33.89,1.0,1.8,experimental,,0.218,0.1856,Crystal structure of apo DAPK1 in the presence of 18-crown-6
6U36,X-RAY DIFFRACTION,4.97,75.24,VAPOR DIFFUSION,,"0.1M Bicine pH9.0, 2% dioxane, 10% PEG 20000",277.0,2019-08-21,2019-11-06,6U36,7361.0,4.0,1875.0,28.0,16.0,202.91,3.0,2.7,experimental,73.79,0.251,0.24,PCSK9 in complex with a Fab and compound 14
5F01,X-RAY DIFFRACTION,3.02,59.23,"VAPOR DIFFUSION, SITTING DROP",7.0,"2.5M SODIUM FORMATE, 100MM HEPES",298.0,2015-11-27,2016-02-24,5F01,3598.0,1.0,390.0,409.0,3.0,44.16,1.0,1.52,experimental,26.806,0.2061,0.18604,"CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (1SR,2SR)-2-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-N-(3-chloroquinolin-8-yl)cyclopropanecarboxamide"
5T1W,X-RAY DIFFRACTION,2.73,54.95,"VAPOR DIFFUSION, HANGING DROP",,"20-22.5% (w/v) PEG 5000 monomethylethyl (MME), 200 mM sodium citrate (pH 6.6), 200 mM ammonium iodide",293.0,2016-08-22,2017-01-11,5T1W,2973.0,1.0,415.0,,3.0,47.72,1.0,2.96,experimental,16.88,0.2499,0.1782,Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality
5LRV,X-RAY DIFFRACTION,2.23,44.83,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M phosphate citrate (pH 4.2), 20% (w/v) PEG 8K, 0.2 M sodium chloride",291.0,2016-08-22,2016-10-19,5LRV,3356.0,3.0,470.0,3.0,,53.98,3.0,2.8,experimental,,0.2442,0.2072,Structure of Cezanne/OTUD7B OTU domain bound to Lys11-linked diubiquitin
5HBH,X-RAY DIFFRACTION,2.95,58.31,"VAPOR DIFFUSION, HANGING DROP",6.9,RESERVOIR SOLUTION : pH 6.90,293.0,2015-12-31,2016-02-03,5HBH,5093.0,2.0,634.0,21.0,,75.24,2.0,2.5,experimental,67.492,0.2683,0.2338,"CDK8-CYCC IN COMPLEX WITH 5-{5-Chloro-4-[1-(2-methoxy-ethyl)-1,8-diaza-spiro[4.5]dec-8-yl]-pyridin-3-yl}-1-methyl-1,3-dihydro-benzo[c]isothiazole 2,2-dioxide"
6R3S,X-RAY DIFFRACTION,3.0,58.99,VAPOR DIFFUSION,,"20% PEG3350, 0.2 M sodium formate, pH 6.9, VAPOR DIFFUSION, HANGING DROP, temperature 293.15K",293.15,2019-03-21,2020-04-08,6R3S,5358.0,2.0,693.0,213.0,,81.35,2.0,2.19,experimental,40.457,0.22679,0.20071,CRYSTAL STRUCTURE OF CDK8-CycC IN COMPLEX WITH COMPOUND 1
5I4O,X-RAY DIFFRACTION,2.22,44.54,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-ligand: 465 micro-M hMMP12 F171D E219Q, 0.020 M acetohydroxamic acid,  10% DMSO, 0.5 milli-M inhibitor (DC28).
Precipitant: 40.5% PEG4K,  10% dioxane, 2% ethylene glycol, 0.18 M imidazole piperidine, pH 8.5.
Cryoprotectant:40% cryomix CM12: (,25 % diethylene glycol + 12.5 % glycerol + 25 % 1,2-propanediol + 12.5 % 1,4-dioxane), 25% PEG 6K, 0.1 M TRIS HCl, pH 8.0.",293.0,2016-02-12,2016-07-06,5I4O,5591.0,4.0,636.0,473.0,,73.93,1.0,2.05,experimental,30.0,0.249,0.21,Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated triazole-linked carboxylate zinc-chelator water-soluble inhibitor (DC28).
6ELA,X-RAY DIFFRACTION,2.2,44.13,"VAPOR DIFFUSION, SITTING DROP",8.5,"protein solution: hMMP12 at 314 micro-M + 10 milli-M acetohydroxamate +  1 milli-M BE4, 10% DMSO
precipitant:  38% PEG 4K, 0.16 M imidazole piperidine,15% Dioxane, pH 8.5.
Cryoprotectant: 40% CM15 (12.5 % diethylene glycol + 12.5 % ethylene glycol + 12.5 % MPD + 12.5 % glycerol + 12.5 % 1,2-propanediol + 12.5 % 1,4-dioxane + 12.5 mM NDSB 201), 25% PEG 6K, 100 milli-M TRIS HCl, pH 7.0",293.0,2017-09-28,2018-05-16,6ELA,6202.0,4.0,636.0,872.0,,73.43,1.0,1.485,experimental,,0.2067,0.1714,Crystal structure of MMP12 in complex with inhibitor BE4.
5MJZ,X-RAY DIFFRACTION,2.26,45.57,"VAPOR DIFFUSION, SITTING DROP",7.4,"Apo- HD-PTPBro1 crystals were obtained in 0.2M L-Na-Glutamate, 0.2M Alanine, 0.2M Glycine, 0.2M Lysine HCl, 0.2M Serine, 0.1 M Imidazole; MES monohydrate at pH 6.5 and 30% Ethylene glycol, PEG8K.",277.0,2016-12-02,2017-08-16,5MJZ,6246.0,2.0,722.0,542.0,,81.44,1.0,1.867,experimental,,0.2161,0.176,Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (Apo structure)
7BRE,X-RAY DIFFRACTION,2.32,46.92,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1M Ammonium tartrate dibasic pH 7.0, 12%(w/v) Polyethylene glycol 3,350",277.0,2020-03-28,2020-07-22,7BRE,5867.0,6.0,752.0,,,86.68,3.0,2.803,experimental,52.2977,0.2646,0.2185,The crystal structure of MLL2 in complex with ASH2L and RBBP5
8R10,X-RAY DIFFRACTION,3.1,60.2,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM bis-tris-propane (pH 7.0), 10% ethylene glycol, 0.3% DMSO, 20% PEG3350, 200 mM Mg(OAc)2",291.15,2023-11-01,2024-03-20,8R10,2285.0,2.0,327.0,90.0,,37.5,2.0,2.2,experimental,43.24,0.2019,0.1695,Pim1 in complex with 4-(4-hydroxystyryl)benzoic acid and Pimtide
8R1N,X-RAY DIFFRACTION,3.1,59.9,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM bis-tris-propane (pH 7.0), 10% ethylene glycol, 0.3% DMSO, 20% PEG3350, 200 mM Mg(OAc)2",291.15,2023-11-02,2024-03-20,8R1N,2345.0,2.0,327.0,110.0,,37.51,2.0,2.21,experimental,39.89,0.1919,0.1613,Pim1 in complex with 4-(4-hydroxyphenethyl)benzoic acid and Pimtide
8R1P,X-RAY DIFFRACTION,3.1,60.5,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM bis-tris-propane (pH 7.0), 10% ethylene glycol, 0.3% DMSO, 20% PEG3350, 200 mM Mg(OAc)2",291.15,2023-11-02,2024-03-20,8R1P,2267.0,2.0,327.0,61.0,,37.5,2.0,2.45,experimental,48.38,0.2058,0.1764,Pim1 in complex with 6-bromobenzo[d]oxazol-2-amine and Pimtide
6BWY,X-RAY DIFFRACTION,,,BATCH MODE,,"100 mM HEPES pH7, 200 mM LiCl, and 20% (w/v) Polyethylene glycol (PEG) 6000",298.0,2017-12-15,2018-04-18,6BWY,11882.0,8.0,1564.0,57.0,,206.98,1.0,2.9,experimental,88.213,0.28692,0.23394,DNA substrate selection by APOBEC3G
6MFQ,X-RAY DIFFRACTION,2.33,47.14,"VAPOR DIFFUSION, HANGING DROP",5.0,Crystals were obtained in conditions containing 4% tacsimate pH 5 (v/v) and 25% PEG 3350 (w/v). The concentrated PMS2 G207E protein (7 mg/mL) was combined with 0.1ul of an additive (0.1 M calcium chloride dehydrate) prior to the addition of crystallization reagent in a 1:1 ratio.,289.15,2018-09-11,2019-02-06,6MFQ,4511.0,2.0,738.0,33.0,,82.0,1.0,2.6,experimental,50.2596,0.2316,0.2214,Crystal structure of a PMS2 variant
5ENN,X-RAY DIFFRACTION,3.26,62.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"200nL:200nL well to protein
0.2M Sodium Acetate
0.1M HEPES 7.5
20% PEG 3000",291.15,2015-11-09,2016-11-16,5ENN,8823.0,2.0,1250.0,279.0,,144.71,1.0,2.7,experimental,73.98,0.2007,0.1735,The crystal structure of Human VPS34 in complex with a selective and potent inhibitor
5N4N,X-RAY DIFFRACTION,3.15,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
NaCl
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N4N,2394.0,2.0,327.0,117.0,,37.43,2.0,2.09,experimental,,0.1879,0.1591,"Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 3,4-dimethyl-5-(1H-1,2,4-triazol-3-yl)thiophene-2-carbonitrile"
5N4O,X-RAY DIFFRACTION,3.11,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES, MgACE, Glycerol, DTT, BIS-TRIS-propane, PEG3350,  Ethylene-glycol, DMSO, Ethylene-glycol",277.0,2017-02-11,2018-02-28,5N4O,2289.0,2.0,327.0,85.0,,37.39,2.0,2.22,experimental,,0.1959,0.1815,Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule (E)-3-(p-tolyl)acrylic acid
5N4U,X-RAY DIFFRACTION,3.12,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
NaCl
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N4U,2348.0,2.0,327.0,93.0,,37.46,2.0,2.202,experimental,,0.1978,0.1636,"Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule 5-(2-amino-1,3-thiazol-4-yl)-1,3-dihydrobenzimidazol-2-one"
5N4X,X-RAY DIFFRACTION,3.14,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
MgCl2
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N4X,2346.0,2.0,327.0,107.0,,37.53,2.0,2.2,experimental,,0.2153,0.1766,"Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and fragment like molekule 4,5-dibromothiophene-2-carbohydrazide"
5N4Y,X-RAY DIFFRACTION,3.15,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
LiCl
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N4Y,2303.0,2.0,327.0,56.0,,37.43,2.0,2.56,experimental,,0.2177,0.1744,"Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 2,5-dihydro-1H-isothiochromeno[3,4-d]pyrazol-3-one"
5N4Z,X-RAY DIFFRACTION,3.15,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
LiCl
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N4Z,2375.0,2.0,327.0,107.0,,37.39,2.0,2.257,experimental,,0.2077,0.1789,Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule (E)-4-(4-hydroxyphenyl)but-3-en-2-one
5N50,X-RAY DIFFRACTION,3.15,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
CaCl2
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N50,2481.0,2.0,327.0,188.0,,37.44,2.0,1.92,experimental,,0.18,0.1584,Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 2-(4-chlorophenyl)sulfanylacetohydrazide
5N51,X-RAY DIFFRACTION,3.12,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
CaCl2
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N51,2346.0,2.0,327.0,109.0,,37.59,2.0,2.118,experimental,,0.207,0.1809,"Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule 3,4-Dibromothiophene-2-carboxylic acid"
5N52,X-RAY DIFFRACTION,3.09,60.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
MgCl2
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-11,2018-02-28,5N52,2273.0,2.0,327.0,86.0,,37.43,2.0,2.252,experimental,,0.2098,0.1697,"Crystal structure of human Pim-1 kinase in complex with a consensus peptide and fragment like molecule (E)-3-(2,3-dimethoxyphenyl)acrylic acid"
5N5M,X-RAY DIFFRACTION,3.16,61.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"HEPES
MgCl2
Glycerol
DTT
BIS-TRIS-propane
PEG3350
Ethylene-glycol
DMSO",277.0,2017-02-14,2018-03-07,5N5M,2425.0,2.0,327.0,138.0,,37.65,2.0,2.21,experimental,,0.2052,0.1659,Crystal structure of human Pim-1 kinase in complex with a consensuspeptide and (R)-3-(2-((isoquinolin-5-ylmethyl)(methyl)carbamoyl)phenyl)pyrrolidin-1-ium
5J1S,X-RAY DIFFRACTION,2.48,50.38,"VAPOR DIFFUSION, HANGING DROP",6.5,"13 % PEG 6000
5 % MPD
100 mM MES, pH 6.5",291.0,2016-03-29,2016-08-17,5J1S,5842.0,3.0,646.0,565.0,1.0,73.58,3.0,1.399,experimental,33.1887,0.1879,0.1433,"TorsinA-LULL1 complex, H. sapiens, bound to VHH-BS2"
6BT2,X-RAY DIFFRACTION,2.32,47.01,"VAPOR DIFFUSION, HANGING DROP",7.5,"Adenosine 5' Monophosphate, Magnesium Chloride, HEPES, Isopropanol, Sodium Acetate, PEG 4000",295.0,2017-12-04,2018-05-16,6BT2,4518.0,2.0,626.0,224.0,,71.65,1.0,2.411,experimental,,0.2241,0.1612,Structure of the human Nocturnin catalytic domain with bound sulfate anion
7ROV,X-RAY DIFFRACTION,1.93,36.3,"VAPOR DIFFUSION, SITTING DROP",6.5,100mM Bis-Tris and 25% PEG 4000,291.0,2021-08-02,2021-09-22,7ROV,3253.0,4.0,406.0,307.0,,47.53,2.0,1.32,experimental,19.76,0.2156,0.1937,KRAS G12D Mutant in complex with GMPPCP and cyclic peptide MP-9903
6MXT,X-RAY DIFFRACTION,3.8,67.64,LIPIDIC CUBIC PHASE,7.5,"31-34% PEG400, 100 mM HEPES, pH 7.5, 1% 1,2,3-heptanetriol",293.15,2018-10-31,2018-11-14,6MXT,4683.0,2.0,594.0,20.0,3.0,68.73,2.0,2.95934213525,experimental,53.7137652891,0.24486451981,0.204625198648,Crystal structure of human beta2 adrenergic receptor bound to salmeterol and Nb71
5HZE,X-RAY DIFFRACTION,2.45,49.75,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M Tris pH 8.0, 180 mM CaCl2, 14-18% PEG 4000. Co-crystallized with 1mM ATPgammaS (30 mM stock formulated in H2O). Crystals backsoaked for 2 weeks in 1 mM compound 3.3% DMSO final.",277.0,2016-02-02,2017-05-03,5HZE,2428.0,1.0,348.0,34.0,,39.36,1.0,2.4,experimental,69.241,0.28714,0.20053,Mek1 adopts DFG-out conformation when bound to an analog of E6201.
6Y5N,X-RAY DIFFRACTION,3.7,66.76,"VAPOR DIFFUSION, SITTING DROP",7.6,BCS condition 44 (Molecular dimensions),292.0,2020-02-25,2020-09-30,6Y5N,4123.0,2.0,470.0,520.0,,52.6,1.0,1.88,experimental,44.1315,0.2105,0.1871,RING-DTC domain of Deltex1
5A1F,X-RAY DIFFRACTION,4.18,70.37,,8.0,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,2015-04-29,2015-05-06,5A1F,3903.0,1.0,475.0,204.0,,56.14,1.0,2.1,experimental,47.6,0.22501,0.19931,Crystal structure of the catalytic domain of PLU1 in complex with N-oxalylglycine.
5DG5,X-RAY DIFFRACTION,2.69,54.0,"VAPOR DIFFUSION, SITTING DROP",,"Protein at 9.5mg/ml in 20 mM Tris pH 8.5, 100mM NaCl, 14mM 2-mercaptoethanol with 5-molar excess of compound; crystallization condition: 1.0M diammonium hydrogen phosphate, 0.2M sodium chloride, 0.1M citrate pH 5.0 and 7.5% glycerol",290.0,2015-08-27,2016-08-31,5DG5,4717.0,2.0,636.0,33.0,,73.0,1.0,2.6,experimental,43.412,0.2449,0.2036,CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP-4157
6TYT,X-RAY DIFFRACTION,1.99,38.07,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES NaOH pH 7.5, 25 % (w/v) PEG3350",295.0,2019-08-09,2019-11-27,6TYT,1645.0,3.0,265.0,4.0,,30.06,3.0,2.40348787647,experimental,83.3805343643,0.259533479025,0.22504942686,Structure of Ku80 von Willebrand domain S229A mutant complexed with APLF and XLF Ku Binding Motif
6BTZ,X-RAY DIFFRACTION,2.45,49.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 400, (NH4)2SO4",295.0,2017-12-08,2018-10-17,6BTZ,4717.0,4.0,524.0,405.0,,63.54,1.0,1.85,experimental,21.61,0.2148,0.1866,Crystal structure of the PI3KC2alpha C2 domain in space group C121
5A7J,X-RAY DIFFRACTION,2.61,52.89,,5.5,"0.2 M LI2SO4, 0.1 M BIS-TRIS PH 5.5 AND 25% PEG3350",,2015-07-06,2016-04-13,5A7J,5125.0,2.0,626.0,76.0,,73.8,1.0,2.9,experimental,39.21,0.2503,0.1996,"Crystal structure of INPP5B in complex with benzene 1,2,4,5- tetrakisphosphate"
6B9D,X-RAY DIFFRACTION,2.27,45.83,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium malonate pH 6, 20% PEG3350, 1 mM GDP, 2 mM MgCl2",293.15,2017-10-10,2017-12-06,6B9D,6247.0,2.0,916.0,281.0,,106.49,1.0,1.95,experimental,,0.2387,0.2045,Human ATL1 mutant - R77A bound to GDP
5H6Q,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M N-(2-Acetamido) iminodiacetic acid,  1.23 M potassium sodium tartrate tetrahydrate.",293.0,2016-11-14,2017-04-12,5H6Q,6402.0,3.0,830.0,42.0,,93.68,3.0,2.53,experimental,71.324,0.24675,0.22412,Crystal structure of LSD1-CoREST in complex with peptide 11
5H6R,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M N-(2-Acetamido) iminodiacetic acid (pH 5.5), 1.23 M potassium sodium tartrate tetrahydrate",293.0,2016-11-14,2017-04-12,5H6R,6432.0,3.0,830.0,69.0,,93.51,3.0,2.6,experimental,76.47,0.23102,0.21711,Crystal structure of LSD1-CoREST in complex with peptide 13
5X60,X-RAY DIFFRACTION,6.94,82.28,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M N-(2-acetamido)iminodiacetic acid, 1.23 M potassium sodium tartrate tetrahydrate.",293.0,2017-02-20,2017-04-12,5X60,6494.0,3.0,829.0,60.0,,93.45,3.0,2.69,experimental,75.272,0.23626,0.2214,Crystal structure of LSD1-CoREST in complex with peptide 9
5K16,X-RAY DIFFRACTION,2.52,51.24,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M Tris-HCl, 18% PEG 3350, 0.2 M Lithium Sulfate",277.0,2016-05-17,2016-07-20,5K16,5202.0,2.0,710.0,56.0,,82.83,1.0,2.599,experimental,,0.2459,0.1899,Crystal structure of free Ubiquitin-specific protease 12
6ZJB,X-RAY DIFFRACTION,2.08,40.96,"VAPOR DIFFUSION, HANGING DROP",5.6,"Purified hAK3 was dialyzed against 30 mM MOPS buffer with 50 mM NaCl pH 7.0 and concentrated to 15-20 mg per ml. The resevoir contained 20% isopropanol, 0.1 M NaCitrate pH 5.6 and 20% PEG 4000. Drop size 1 plus 1 microliter.",291.0,2020-06-28,2020-09-16,6ZJB,11581.0,6.0,1362.0,798.0,,159.34,1.0,1.822,experimental,37.9739,0.2565,0.1916,"Crystal structure of human adenylate kinase 3, AK3, in complex with inhibitor Gp5A"
6AZU,X-RAY DIFFRACTION,2.96,58.4,VAPOR DIFFUSION,,"20% PEG-3350, 0.2 M LiSO4, 0.1 M BT pH 5.5",298.0,2017-09-13,2018-03-21,6AZU,10993.0,4.0,1608.0,,1.0,183.87,1.0,2.822,experimental,48.99,0.2718,0.2107,Holo IDO1 crystal structure
6JKY,X-RAY DIFFRACTION,2.65,53.52,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Sodium thiocyanate, 20% w/v Polyethylene glycol 3,350",289.15,2019-03-03,2019-12-18,6JKY,9776.0,6.0,1232.0,63.0,,139.93,3.0,2.454,experimental,79.9412,0.2582,0.2087,Crystal structure of MvcA-UBE2N-Ub complex from Legionella pneumophila
8TRS,X-RAY DIFFRACTION,2.82,56.39,"VAPOR DIFFUSION, SITTING DROP",5.5,"200 mM ammonium chloride, 30% PEG600 (GRAS1 condition A8)",298.0,2023-08-10,2023-11-22,8TRS,4598.0,3.0,569.0,240.0,10.0,63.83,3.0,1.9,experimental,50.17,0.214,0.18,"Structure of the EphA2 CRD bound to FabS1CE_C1, trigonal form"
5YWR,X-RAY DIFFRACTION,2.46,50.05,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2M Magnesium fromate dihydrate, 20% PEG 3350 (w/v)",293.15,2017-11-30,2018-06-06,5YWR,2353.0,2.0,241.0,364.0,,27.57,2.0,1.47,experimental,,0.1842,0.1649,Crystal Structure of RING E3 ligase ZNRF1 in complex with Ube2N (Ubc13)
8TV1,X-RAY DIFFRACTION,3.12,60.52,"VAPOR DIFFUSION, SITTING DROP",7.0,"14% PEG 20K, 100 mm HEPES 7.0, 200 mM KSCN",298.0,2023-08-17,2024-06-26,8TV1,5620.0,3.0,756.0,61.0,12.0,82.2,3.0,2.6,experimental,66.12,0.2462,0.2016,Structure of the EphA2 LBDCRD bound to FabS1C_L1
5LHZ,X-RAY DIFFRACTION,2.36,47.78,"VAPOR DIFFUSION, SITTING DROP",6.0,"150nl Protein solution (41.87 mg/ml protein in 20 mM Tris pH 7.5, 150 mM NaCl, 2 mM DTT) and 50 nl mother liquor (100mM MES pH 6.0, 191.7 mM Zn acetate, 10% Isopropanol)",292.0,2016-07-13,2017-03-01,5LHZ,2342.0,6.0,357.0,5.0,,39.34,2.0,2.51,experimental,,0.2821,0.2496,PB3 Domain of Human PLK4 in Complex with Coiled-Coil Domain of STIL
5WI1,X-RAY DIFFRACTION,2.39,48.63,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 10K, sodium chloride, glycerol, Tris",277.0,2017-07-18,2018-01-10,5WI1,8000.0,2.0,982.0,538.0,,111.79,1.0,1.99,experimental,20.89,0.227,0.189,Crystal structure of human NAMPT with fragment 5: (3E)-3-[(phenylamino)methylidene]oxan-2-one
7CP0,X-RAY DIFFRACTION,2.75,55.23,"VAPOR DIFFUSION, SITTING DROP",6.0,"100 mM MES buffer pH 6.5, 46-67 mM NaOH, 100 mM ammonium sulfate",277.15,2020-08-05,2021-01-13,7CP0,8618.0,3.0,981.0,648.0,,113.78,1.0,1.7,experimental,17.651,0.2228,0.2054,Crystal Structure of double mutant Y115E Y117E human Secretory Glutaminyl Cyclase
5ED2,X-RAY DIFFRACTION,3.16,65.22,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES/NaOH, pH 6.5, 12% PEG20000",298.0,2015-10-20,2016-04-13,5ED2,8063.0,6.0,898.0,,,120.96,1.0,2.95,experimental,,0.2075,0.1879,Human Adenosine Deaminase Acting on dsRNA (ADAR2) mutant E488Q bound to dsRNA sequence derived from human GLI1 gene
5D5A,X-RAY DIFFRACTION,3.12,60.63,LIPIDIC CUBIC PHASE,,"30-35 %(v/v) PEG 400, 0.1-0.2 M Na2SO4, 0.1 M bis-tris propane pH 6.5-7.0 and 5-7 %(v/v) 1,4-butanediol",293.0,2015-08-10,2016-01-13,5D5A,3809.0,1.0,500.0,53.0,2.0,60.02,1.0,2.4826,experimental,,0.2623,0.2116,In meso in situ serial X-ray crystallography structure of the Beta2-adrenergic receptor at 100 K
6BRJ,X-RAY DIFFRACTION,2.28,46.08,"VAPOR DIFFUSION, HANGING DROP",5.5,18% PEG 3350 and 0.1 M Bis-Tris pH 5.5,298.0,2017-11-30,2018-12-05,6BRJ,2287.0,1.0,351.0,104.0,,39.72,1.0,2.231,experimental,,0.2225,0.1849,DDR1 bound to VX-680
6OSN,X-RAY DIFFRACTION,1.68,26.61,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Li acetate
20% PEG 3350",294.0,2019-05-01,2020-04-01,6OSN,835.0,1.0,98.0,165.0,3.0,11.02,1.0,1.083,experimental,,0.1609,0.1529,Potent and Selective Antitumor Antibody Targeting a Membrane-Proximal Epitope of ROR2
6Z8L,X-RAY DIFFRACTION,2.31,46.75,"VAPOR DIFFUSION, HANGING DROP",,60 % MPD,291.15,2020-06-02,2020-12-02,6Z8L,4436.0,1.0,496.0,366.0,5.0,57.59,1.0,1.40000369636,experimental,25.7573422784,0.154231229896,0.141978268676,Alpha-Amylase in complex with probe fragments
7BBD,X-RAY DIFFRACTION,3.22,61.75,"VAPOR DIFFUSION, SITTING DROP",,"MOPSO, Bis-Tris, PEG 4K, 1,2,6-hexanetriol, Li, Na, K",290.15,2020-12-17,2021-01-27,7BBD,4434.0,4.0,543.0,285.0,,61.2,4.0,2.2,experimental,52.09,0.2524,0.222,Crystal structure of monoubiquitinated TRIM21 RING (Ub-RING) In complex with ubiquitin charged Ube2N (Ube2N~Ub) and Ube2V2
5Z1E,X-RAY DIFFRACTION,2.39,48.6,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, sodium citrate",277.0,2017-12-26,2019-01-02,5Z1E,2504.0,1.0,324.0,116.0,,37.26,1.0,2.3,experimental,45.195,0.28345,0.19433,MAP2K7 C218S mutant-inhibitor
7OVK,X-RAY DIFFRACTION,2.45,49.74,"VAPOR DIFFUSION, HANGING DROP",,"180-220 mM sodium citrate,
15-25% PEG3350",277.0,2021-06-15,2022-07-20,7OVK,2091.0,1.0,318.0,40.0,,36.75,1.0,2.05,experimental,60.43,0.2444,0.2152,Protein kinase MKK7 in complex with 5-bromo-2-hydroxyphenyl-substituted pyrazolopyrimidine
7QBN,X-RAY DIFFRACTION,1.98,37.84,"VAPOR DIFFUSION, HANGING DROP",,"12.5% PEG 1000, 12.5% PEG 3350, 12.5% MPD, 0.03 M sodium nitrate, 0.03 M disodium hydrogen phosphate, 0.03 M ammonium sulfate, 0.1 M MES/imidazole pH 6.5",290.0,2021-11-19,2022-01-26,7QBN,2039.0,1.0,217.0,302.0,3.0,24.2,1.0,1.55,experimental,13.033,0.1665,0.1426,Structure of cathepsin K in complex with the azadipeptide nitrile inhibitor Gu1303
5NFJ,X-RAY DIFFRACTION,3.43,64.2,"VAPOR DIFFUSION, SITTING DROP",7.5,"Well solution: 12% PEG 1000, 28% glycerol, 1.5%(w/v) PEG 3350
Cryo: 25% propylene glycol
Protein concentration: 11 mg/mL",277.15,2017-03-14,2018-05-16,5NFJ,4772.0,3.0,606.0,217.0,,73.49,1.0,1.96,experimental,53.966,0.20648,0.18533,Crystal structure of the methyltransferase subunit of human mitochondrial Ribonuclease P (MRPP1) bound to S-adenosyl-methionine (SAM)
5J28,X-RAY DIFFRACTION,3.06,59.8,"VAPOR DIFFUSION, HANGING DROP",4.0,1.9 M Sodium Malonate pH 4.0,277.0,2016-03-29,2016-10-05,5J28,5393.0,4.0,702.0,232.0,,80.69,2.0,2,experimental,,0.1972,0.1538,"Ki67-PP1g (protein phosphatase 1, gamma isoform) holoenzyme complex"
5EOB,X-RAY DIFFRACTION,1.96,37.28,"VAPOR DIFFUSION, HANGING DROP",7.5,"19-20%(w/v)PEG 3350, 200mM MgSO4, 100mM Tris-HCl",293.0,2015-11-10,2016-10-19,5EOB,2408.0,1.0,319.0,119.0,,36.43,1.0,1.75,experimental,19.36,0.1974,0.1729,Crystal structure of CMET in complex with novel inhibitor
5HO6,X-RAY DIFFRACTION,2.27,45.91,"VAPOR DIFFUSION, HANGING DROP",8.5,Tris 100mM - MPD 20% - pH8.5,277.0,2016-01-19,2016-11-23,5HO6,2083.0,1.0,312.0,140.0,,35.86,1.0,1.97,experimental,,,,CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.
7B3Z,X-RAY DIFFRACTION,2.54,51.5,"VAPOR DIFFUSION, SITTING DROP",,"20 % PEG10000, 0.1 M Na-HEPES pH 7.5",293.0,2020-12-01,2020-12-09,7B3Z,2355.0,1.0,299.0,144.0,,34.19,1.0,1.8,experimental,37.64,0.215,0.193,Crystal structure of c-MET bound by compound 5
8AU5,X-RAY DIFFRACTION,2.34,47.49,VAPOR DIFFUSION,7.6,PEG 8000,293.0,2022-08-25,2023-09-06,8AU5,2176.0,1.0,299.0,3.0,,34.62,1.0,2.72,experimental,88.345,0.2778,0.2343,c-MET F1200I mutant in complex with Tepotinib
7FQL,X-RAY DIFFRACTION,1.76,30.28,"VAPOR DIFFUSION, SITTING DROP",6.5,"28.5mg/mL protein in 25mM HEPES/NaOH pH7, 300 mM NaCl, 200mM Trehalose incubated with 10-fold excess of ligand, then mixed 50-70% with 50-30% reservoir consisting of 20% v/v PEG smear broad, 0.1M MES/NaOH pH 6.5, total volume 200nL",293.0,2022-10-05,2023-10-11,7FQL,17343.0,8.0,3552.0,,,414.84,1.0,2.53,experimental,44.5462,0.2515,0.192,"Crystal Structure of human Legumain in complex with (2S)-N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[1-[4-[(2,4-difluorophenyl)methoxy]phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide"
8EDE,X-RAY DIFFRACTION,2.35,48.38,"VAPOR DIFFUSION, SITTING DROP",,"0.1M tri-Sodium citrate
2.4M Ammonium sulfate",294.15,2022-09-04,2023-09-20,8EDE,3670.0,2.0,446.0,208.0,,50.61,1.0,1.799,experimental,47.1589,0.2267,0.1928,Crystal structure of covalent inhibitor 2-chloro-N'-(N-(4-chlorophenyl)-N-methylglycyl)acetohydrazide bound to Ubiquitin C-terminal Hydrolase-L1
8C3D,X-RAY DIFFRACTION,2.32,46.98,"VAPOR DIFFUSION, SITTING DROP",,"30 % PEG-3350, 0.2 M CaCL2",293.0,2022-12-23,2023-09-27,8C3D,1913.0,2.0,218.0,237.0,3.0,23.93,2.0,2,experimental,11.37,0.2268,0.1959,Sulfonated Calpeptin is a promising drug candidate against SARS-CoV-2 infections
6SC5,X-RAY DIFFRACTION,2.54,51.54,"VAPOR DIFFUSION, SITTING DROP",,"Ammonium sulfate, sodium chloride, HEPES",293.0,2019-07-23,2019-11-27,6SC5,4786.0,3.0,616.0,105.0,2.0,70.63,2.0,2.1,experimental,56.86,0.2518,0.2191,dAb3/HOIP-RBR-Ligand2
6SC6,X-RAY DIFFRACTION,2.58,52.33,"VAPOR DIFFUSION, SITTING DROP",,"Ammonium sulfate, sodium chloride, HEPES",293.0,2019-07-23,2019-11-27,6SC6,4928.0,3.0,616.0,169.0,2.0,70.47,2.0,2.25,experimental,52.3047,0.2462,0.1993,dAb3/HOIP-RBR apo structure
6SC7,X-RAY DIFFRACTION,2.55,51.72,"VAPOR DIFFUSION, SITTING DROP",,"Ammonium sulfate, sodium chloride, HEPES",293.0,2019-07-23,2019-11-27,6SC7,4785.0,3.0,616.0,74.0,2.0,70.88,2.0,2.56,experimental,66.18,0.2674,0.2239,dAb3/HOIP-RBR-Ligand3
6SC8,X-RAY DIFFRACTION,2.59,52.45,"VAPOR DIFFUSION, SITTING DROP",,"Ammonium sulfate, sodium chloride, HEPES",293.0,2019-07-23,2019-11-27,6SC8,4848.0,3.0,616.0,151.0,2.0,70.62,2.0,2.106,experimental,66.1207,0.261,0.2187,dAb3/HOIP-RBR-Ligand4
6SC9,X-RAY DIFFRACTION,2.59,52.44,"VAPOR DIFFUSION, SITTING DROP",,"Ammonium sulfate, sodium chloride, HEPES",293.0,2019-07-23,2019-11-27,6SC9,4717.0,3.0,616.0,68.0,2.0,70.61,2.0,2.47,experimental,67.34,0.2524,0.2098,dAb3/HOIP-RBR-HOIPIN-8
6EN5,X-RAY DIFFRACTION,3.0,59.02,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",289.0,2017-10-04,2017-12-20,6EN5,23529.0,4.0,2516.0,2410.0,12.0,304.58,1.0,1.75,experimental,,0.1976,0.1728,Crystal structure A of the Angiotensin-1 converting enzyme N-domain in complex with a diprolyl inhibitor.
6FOL,X-RAY DIFFRACTION,4.15,70.38,"VAPOR DIFFUSION, HANGING DROP",,"25% (w/v) PEG 1500 and 0.1 M PCTP buffer pH 7.0 (sodium propionate, sodium cacodylate, and BIS-TRIS propane in the molar ratios 2:1:2, respectively)",293.0,2018-02-07,2019-01-30,6FOL,9259.0,8.0,1212.0,270.0,4.0,127.68,2.0,2.55,experimental,,0.2482,0.208,"Domain II of the human copper chaperone in complex with human Cu,Zn superoxide dismutase"
5HE0,X-RAY DIFFRACTION,3.47,64.51,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM MES, 0.8-1.2 M sodium chloride, 8-16% PEG3350",277.0,2016-01-05,2016-05-11,5HE0,8248.0,3.0,1051.0,36.0,,120.41,3.0,2.56,experimental,71.102,0.264,0.2017,Bovine GRK2 in complex with Gbetagamma subunits and CCG215022
5HE2,X-RAY DIFFRACTION,3.42,64.03,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM MES, 0.8-1.2 M sodium chloride, 8-16% PEG3350",277.0,2016-01-05,2016-05-11,5HE2,8290.0,3.0,1051.0,31.0,,120.45,3.0,2.79,experimental,70.769,0.2773,0.1981,Bovine GRK2 in complex with Gbetagamma subunits and CCG224406
5HE3,X-RAY DIFFRACTION,3.42,64.06,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM MES, 0.8-1.2 M sodium chloride, 8-16% PEG3350",277.0,2016-01-05,2016-05-11,5HE3,8263.0,3.0,1051.0,39.0,,120.49,3.0,2.74,experimental,75.206,0.2571,0.195,Bovine GRK2 in complex with Gbetagamma subunits and CCG224411
8PT8,X-RAY DIFFRACTION,2.68,54.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"8% PEG 3350, 0.1 M HEPES pH 7.5",293.0,2023-07-13,2024-07-24,8PT8,8359.0,3.0,1098.0,5.0,,128.01,1.0,2.78,experimental,,0.2184,0.2059,JNK1 covalently bound to RU135 cyclohexenone based inhibitor
8PTA,X-RAY DIFFRACTION,2.62,53.2,"VAPOR DIFFUSION, HANGING DROP",7.5,"12% PEG 3000, 2-4% MPD, 0.1 M HEPES pH 7.5",293.0,2023-07-13,2024-07-24,8PTA,8442.0,3.0,1098.0,27.0,,127.97,1.0,2.41,experimental,,0.2262,0.2097,JNK1 covalently bound to BD837 cyclohexenone based inhibitor
6K0X,X-RAY DIFFRACTION,3.03,59.45,"VAPOR DIFFUSION, SITTING DROP",5.6,0.2M ammonium acetate 0.1M sodium citrate tribasic dihydrate PH 5.6 30% Polyethylene glycol 4000,291.0,2019-05-07,2019-06-05,6K0X,2574.0,2.0,341.0,117.0,,37.66,2.0,2.2,experimental,,0.2135,0.1744,Structure of N6AMT1-TRMT112 Complex with SAM
8CNC,X-RAY DIFFRACTION,3.16,61.12,"VAPOR DIFFUSION, SITTING DROP",8.0,"1.3 M Na3Citrate, 0.1M Tris ph 8.0",293.0,2023-02-22,2024-03-06,8CNC,2667.0,2.0,329.0,172.0,,36.5,2.0,1.46,experimental,19.019,0.1833,0.15179,Structure of compound 1 bound KMT9
8QDG,X-RAY DIFFRACTION,3.16,61.02,"VAPOR DIFFUSION, SITTING DROP",,"1.2 M Na3Citrate, 0.1M Tris 7.5",293.15,2023-08-29,2024-09-11,8QDG,2702.0,2.0,329.0,167.0,,36.51,2.0,1.392,experimental,22.209,0.1794,0.1521,compound 1a bound KMT9 crystal structure
8QDI,X-RAY DIFFRACTION,3.17,61.23,"VAPOR DIFFUSION, SITTING DROP",,"1.1 M Na3Citrate, 0.1M HEPES 7.25",293.0,2023-08-29,2024-09-11,8QDI,2691.0,2.0,329.0,184.0,,36.54,2.0,1.467,experimental,24.636,0.1905,0.1576,compound 1b bound KMT9 crystal structure
5LA4,X-RAY DIFFRACTION,2.32,47.0,VAPOR DIFFUSION,7.0,"0.1 M Succinate pH 7.0
17% PEG3350
1:250 dilution seed stock

- Seed stock grown in 0.2M Ammonium Nitrate, 20% PEG3350",293.0,2016-06-13,2017-05-31,5LA4,4412.0,1.0,509.0,218.0,2.0,59.43,1.0,1.9,experimental,41.878,0.22729,0.18536,Crystal structure of apo human proheparanase
5LA7,X-RAY DIFFRACTION,2.27,45.85,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Succinate pH 7.0
17% PEG3350
1:250 dilution seed stock

Seed crystals grown in 0.2 M Ammonium Nitrate, 20% PEG3350",293.0,2016-06-13,2017-05-31,5LA7,4365.0,1.0,509.0,154.0,2.0,59.69,1.0,1.94,experimental,46.254,0.22321,0.18205,"Crystal structure of human proheparanase, in complex with glucuronic acid configured aziridine probe JJB355"
5INB,X-RAY DIFFRACTION,2.9,57.52,"VAPOR DIFFUSION, SITTING DROP",4.3,1 M Sodium Malonate,277.0,2016-03-07,2016-10-05,5INB,3128.0,2.0,351.0,304.0,,40.82,2.0,1.3,experimental,,0.1534,0.1324,"RepoMan-PP1g (protein phosphatase 1, gamma isoform) holoenzyme complex"
6KHS,X-RAY DIFFRACTION,3.28,62.45,"VAPOR DIFFUSION, SITTING DROP",,"1.26 Msodium phosphate monobasic monohydrate 
0.14 Mpotassium phosphate dibasic 
pH 5.6",291.0,2019-07-16,2020-07-15,6KHS,2701.0,2.0,339.0,215.0,,37.74,2.0,1.895,experimental,25.0376,0.2198,0.1874,Crystal structure of HEMK2/TRMT112 in complex with SAH and MEQ
6FGA,X-RAY DIFFRACTION,3.1,60.6,"VAPOR DIFFUSION, HANGING DROP",,100mM Bicine pH 9.0 and 5% w/v PEG 6000,277.0,2018-01-10,2019-06-12,6FGA,13206.0,15.0,1914.0,109.0,,214.16,2.0,2.82,experimental,90.688,0.29407,0.25283,"Crystal structure of TRIM21 E3 ligase, RING domain in complex with its cognate E2 conjugating enzyme UBE2E1"
6HDO,X-RAY DIFFRACTION,3.96,68.95,VAPOR DIFFUSION,,"0.1M trisHCl pH 7.0-8.0, 1.2-1.5M ammonium sulphate and 20-25% PEG3350",277.0,2018-08-18,2018-09-26,6HDO,1313.0,1.0,130.0,180.0,,16.3,1.0,2.61,experimental,48.947,0.23194,0.18427,"Crystal structure of human ATAD2 bromodomain in complex with 8-(((1R,2R,3R,5S)-2-(2-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)ethyl)-8-azabicyclo[3.2.1]octan-3-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)quinolin-2(1H)-one"
5JZV,X-RAY DIFFRACTION,3.73,67.03,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.01M MAGNESIUM CHLORIDE HEXAHYDRATE,
 0.05M MES MONOHYDRATE PH 5.6, 1.8M LITHIUM SULFATE MONOHYDRATE,
 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2016-05-17,2016-08-10,5JZV,1636.0,1.0,206.0,171.0,,24.0,1.0,2.07,experimental,34.76,0.235,0.19,The structure of D77G hCINAP-ADP
5BXO,X-RAY DIFFRACTION,1.85,33.61,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1 M tri-sodium citrate, pH 5.0, 3.2 M ammonium sulfate",292.0,2015-06-09,2016-06-29,5BXO,3203.0,4.0,348.0,280.0,,38.35,2.0,1.334,experimental,16.322,0.20273,0.17484,Human Tankyrase-2 in Complex with Macrocyclised Extended Peptide cp4n2m3
7MON,X-RAY DIFFRACTION,2.07,40.45,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M ammonium acetate
30%w/v PEG 4000
0.1 M trisodium citrate-citric acid pH 5.5",281.15,2021-05-03,2021-11-17,7MON,4544.0,2.0,603.0,105.0,,68.81,2.0,2.23,experimental,43.6036,0.2601,0.2089,Structure of human RIPK3-MLKL complex
7B1E,X-RAY DIFFRACTION,2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",5.2,"15% PEG 1,500 in water",292.0,2020-11-24,2021-04-28,7B1E,3402.0,1.0,402.0,412.0,3.0,45.18,1.0,1.62,experimental,26.7,0.211,0.189,BACE1 IN COMPLEX WITH compound 3 (NB-641)
7B1Q,X-RAY DIFFRACTION,2.11,41.69,"VAPOR DIFFUSION, HANGING DROP",6.0,"15% PEG 1,500 in water",292.0,2020-11-25,2021-04-28,7B1Q,3310.0,1.0,402.0,245.0,3.0,45.23,1.0,1.94,experimental,32.2,0.218,0.189,Crystal Structure of Human BACE-1 in Complex with Compound NB-360 (compound 54)
5JJ4,X-RAY DIFFRACTION,2.97,58.59,"VAPOR DIFFUSION, SITTING DROP",,"100mM MES pH 6.5, 200mM Calcium Acetate, 15%PEG8000",277.0,2016-04-22,2016-06-29,5JJ4,12734.0,3.0,1638.0,36.0,,186.71,1.0,2.807,experimental,,0.2318,0.1831,Crystal Structure of a Variant Human Activation-induced Deoxycytidine Deaminase as an MBP fusion protein
5KYD,X-RAY DIFFRACTION,2.2,44.0,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.2M Ammonium fluoride, 20% PEG3350",292.0,2016-07-21,2017-08-09,5KYD,3792.0,2.0,427.0,381.0,,49.19,2.0,1.62,experimental,29.9042,0.2133,0.1742,Crystal structure of USP7 catalytic domain [V302K] mutant in complex with ubiquitin
5OKO,X-RAY DIFFRACTION,2.21,44.35,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M PCB (sodium propionate, sodium cacodylate, and BIS-TRIS propane; 2:1:2 molar ratio) pH 7, 25% PEG 1500",293.0,2017-07-25,2017-08-23,5OKO,7228.0,2.0,922.0,288.0,,106.03,1.0,1.94,experimental,26.809,0.22872,0.18957,Crystal structure of human SHIP2 Phosphatase-C2 double mutant F593D/L597D
6WW3,X-RAY DIFFRACTION,1.99,38.08,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium chloride, 0.1 M Tris, pH 8.0 and 20% PEG 6000",298.0,2020-05-07,2020-08-05,6WW3,1091.0,2.0,120.0,129.0,,14.28,1.0,2.096,experimental,14.5705,0.2268,0.1847,Crystal structure of HERC2 ZZ domain in complex with SUMO1 tail
6HPH,X-RAY DIFFRACTION,2.24,45.1,"VAPOR DIFFUSION, SITTING DROP",,"Na-acetate, PEG 8K, PEG1K",277.0,2018-09-20,2019-01-23,6HPH,4308.0,1.0,418.0,857.0,,46.01,1.0,1.13,experimental,21.133,0.16304,0.12701,Crystal structure of human Pif1 helicase in complex with AMP-PNP
6HPT,X-RAY DIFFRACTION,2.48,50.34,"VAPOR DIFFUSION, SITTING DROP",,"Li2SO4, PEG 2K MME, MES",277.0,2018-09-21,2019-01-23,6HPT,4195.0,1.0,439.0,976.0,,48.05,1.0,1.44,experimental,34.849,0.19468,0.13372,"Crystal structure of human Pif1 helicase, apoform."
6ZJD,X-RAY DIFFRACTION,2.46,49.93,"VAPOR DIFFUSION, HANGING DROP",8.0,"Purified hAK3 was dialyzed against 30 mM MOPS buffer with 50 mM NaCl pH 7.0 and concentrated to 15-20 mg per ml. The resevoir contained 0.2 M MgCl2, 0.1 M Tris pH 8.0 and 20% PEG 6000. Drop size 1 plus 1 microliter. Cryo protection 30% PEG6000",291.0,2020-06-28,2020-09-16,6ZJD,2273.0,1.0,227.0,432.0,,26.31,1.0,1.75,experimental,19.8649,0.2195,0.1568,"Crystal structure of human adenylate kinase 3, AK3, in complex with inhibitor ATP"
7AVX,X-RAY DIFFRACTION,2.42,49.23,VAPOR DIFFUSION,8.5,"co-crystallisation of 0.3 mM protein with 0.5 mM compound (1 % DMSO) in 4.0 M sodium chloride, 0.1 M Tris pH 8.5",293.0,2020-11-06,2021-03-03,7AVX,4370.0,2.0,626.0,97.0,,72.88,1.0,2.44,experimental,45.9,0.2586,0.2138,MerTK kinase domain in complex with NPS-1034
7AW4,X-RAY DIFFRACTION,2.18,43.66,VAPOR DIFFUSION,7.5,"0.3 mM protein co-crystallised with 0.5 mM compound (1 % DMSO) in 25 % PEG3350, 0.2 M MgCl2, 0.1 M PCTP pH 7.5",293.0,2020-11-06,2021-03-03,7AW4,4524.0,2.0,626.0,281.0,,73.49,1.0,1.98,experimental,36.83,0.246,0.214,MerTK kinase domain with type 3 inhibitor from a DNA-encoded library
7E0P,X-RAY DIFFRACTION,2.82,56.39,"VAPOR DIFFUSION, HANGING DROP",,"15% to 23% PEG 8000, 0.2M ammonium acetate",293.0,2021-01-28,2021-07-21,7E0P,6012.0,2.0,784.0,8.0,1.0,90.15,1.0,2.635,experimental,74.285,0.266,0.1999,"Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with 4-(((6-Bromo-1H-indazol-4-yl)amino)methyl)phenol (2)"
7E0S,X-RAY DIFFRACTION,3.05,59.63,"VAPOR DIFFUSION, HANGING DROP",,"15% to 23% PEG 8000, 0.2M ammonium acetate",293.0,2021-01-28,2021-07-21,7E0S,6092.0,2.0,784.0,24.0,1.0,90.16,1.0,2.712,experimental,62.2609,0.2489,0.1884,"Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with (1R,2S)-2-(((6-Bromo-1H-indazol-4-yl)amino)methyl)cyclohexan-1-ol (23)"
8T0S,X-RAY DIFFRACTION,2.19,43.72,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG MME 5000, NaCl, etc.",293.0,2023-06-01,2024-06-05,8T0S,1837.0,2.0,192.0,167.0,,22.14,2.0,1.95,experimental,,0.2082,0.1739,Crystal structure of UBE2G2 adduct with phenethyl isothiocyanate (PEITC) at the Cys48 position
5I3Y,X-RAY DIFFRACTION,2.83,56.6,VAPOR DIFFUSION,5.5,"1.5 M ammonium sulfate, 0.2 M lithium chloride, 0.1 M bis-tris (pH 5.5)",298.0,2016-02-11,2016-03-30,5I3Y,3180.0,1.0,411.0,221.0,3.0,46.44,1.0,2.15,experimental,40.743,0.2377,0.1995,Crystal structure of BACE1 in complex with aminoquinoline inhibitor 9
6FUK,X-RAY DIFFRACTION,2.58,52.33,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris-HCl (pH 8.5), Li2 SO4 (0.15-0.25 M), PEG 3350 (20-25% w/v)",277.0,2018-02-27,2018-10-10,6FUK,4106.0,1.0,531.0,269.0,,61.1,1.0,2,experimental,,0.2283,0.1863,Crystal structure of UTX complexed with 5-carboxy-8-hydroxyquinoline
5ZZ2,X-RAY DIFFRACTION,3.07,59.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Cacodylate Sodium (pH 6.5), 0.2 M MgSO4, 18% PEG3350, 2.5% ethanol",298.0,2018-05-29,2018-09-19,5ZZ2,2496.0,1.0,326.0,41.0,,38.39,1.0,2.6,experimental,47.714,0.26436,0.20865,Crystal structure of PDE5 in complex with inhibitor LW1634
6ACB,X-RAY DIFFRACTION,2.81,56.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Cacodylate Sodium (pH6.5), 0.2 M MgSO4, 18% PEG3350, 2.5% ethanol",298.0,2018-07-26,2018-09-19,6ACB,2591.0,1.0,326.0,45.0,,38.54,1.0,2.8,experimental,41.812,0.26828,0.1976,Crystal structure of PDE5 in complex with inhibitor LW1805
6NTP,X-RAY DIFFRACTION,2.33,47.25,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES, 200 mM magnesium acetate, and 14% polyethylene glycol 8000, pH 7.5",277.0,2019-01-30,2020-01-22,6NTP,2576.0,1.0,448.0,224.0,,52.17,1.0,1.89,experimental,21.375,0.21175,0.17922,PTP1B Domain of PTP1B-LOV2 Chimera
5LRU,X-RAY DIFFRACTION,3.31,62.86,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris (pH 6.1), 0.2 M magnesium formate",291.0,2016-08-22,2016-10-19,5LRU,2233.0,1.0,318.0,90.0,,36.36,1.0,2.2,experimental,,0.2189,0.1984,Structure of Cezanne/OTUD7B OTU domain
8EBZ,X-RAY DIFFRACTION,2.11,41.59,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris pH 8.5, 20% PEG 400, 20% PEG 8000, 50 mM Magnesium Chloride",293.0,2022-08-31,2023-06-07,8EBZ,1622.0,1.0,170.0,186.0,,20.02,1.0,1.2,experimental,20.6357,0.1709,0.1591,Crystal Structure of GMPPNP-bound KRAS-G13D mutant at 1.2 Ang resolution
7UP8,X-RAY DIFFRACTION,2.31,46.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"Plate 320267f8, puck cnl-6-9.Screen:Morpheus_D8_F8_G8_Index_E7. To prepare the ligand complex, PID7059-1 was exchanged to 25 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol, 1 mM BME (dillution buffer) using a GE (GE28-9180-04) spin column. The protein was diluted to 1 mg/ml in dilution bufffer and 150 ?M UCB1710266 in 100% DMSO_D6 was added. The complex was incubated at 4 C for an hour, then excess ligand was removed by dialysis using a D-tube dialyzer in 250 ml dilution buffer, overnight at 4 ?C. The following day the protein was concentrated to 10.1 mg/ml and setup 200:100 ul protein:well solution. Crystals were flash frozen in 100% well solution",289.0,2022-04-14,2022-07-06,7UP8,4449.0,2.0,612.0,3.0,2.0,69.96,1.0,2.9,experimental,57.99,0.2625,0.1863,Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound pyrrolopyrimidine compound 27 (co-crystal)
4Y6D,X-RAY DIFFRACTION,1.86,33.75,"VAPOR DIFFUSION, HANGING DROP",,"16-20% PEG 6K, 50mM Mes-NaOH pH 5.7-6.0, 5 mM CaCl2, and 50 mM NaCl",293.0,2015-02-12,2015-09-30,4Y6D,2623.0,2.0,388.0,307.0,8.0,44.23,2.0,1.55,experimental,28.035,0.2334,0.1985,Factor Xa complex with GTC000101
4ZH8,X-RAY DIFFRACTION,1.9,35.34,"VAPOR DIFFUSION, HANGING DROP",,"16-20% PEG 6K, 50 mM Mes=NaOH pH 5.7-6.0, 5 mM CaCl2 and 50 mM NaCl",293.0,2015-04-24,2016-01-13,4ZH8,2541.0,2.0,387.0,271.0,8.0,44.18,2.0,1.8,experimental,27.687,0.2553,0.2065,Factor Xa complex with GTC000006
7B1P,X-RAY DIFFRACTION,2.13,42.25,"VAPOR DIFFUSION, HANGING DROP",5.5,"15% PEG 1,500 in water",292.0,2020-11-25,2021-04-28,7B1P,3338.0,1.0,402.0,336.0,3.0,45.25,1.0,1.77,experimental,16.1,0.211,0.186,Crystal Structure of Human BACE-1 in Complex with Compound 38a (NB-854)
6E0I,X-RAY DIFFRACTION,2.41,49.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes pH7.5, 28% PEG3350",293.0,2018-07-06,2019-07-10,6E0I,3895.0,1.0,458.0,327.0,,52.3,1.0,1.9,experimental,22.644,0.22873,0.19134,Crystal structure of Glucokinase in complex with compound 72
6KR4,X-RAY DIFFRACTION,3.12,60.58,"VAPOR DIFFUSION, SITTING DROP",7.5,"50mM Tris-HCl, 200mM NaCl, 1mM ethylenediaminetetraacetic acid, 1mM dithiothreitol",296.0,2019-08-20,2020-01-15,6KR4,24833.0,8.0,3620.0,161.0,,415.72,2.0,2.85,experimental,81.9738,0.2298,0.1915,Crystal structure of the liprin-alpha3_SAM123/LAR_D1D2 complex
5V7W,X-RAY DIFFRACTION,2.95,58.28,VAPOR DIFFUSION,,"20% PEG3350, 0.2M Sodium-malonate, pH 7.2-7.8",298.0,2017-03-20,2017-05-10,5V7W,3001.0,2.0,388.0,132.0,1.0,44.87,1.0,2.65,experimental,49.378,0.26595,0.20351,"Crystal structure of human PARP14 bound to 2-{[(1-methylpiperidin-4-yl)methyl]amino}-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one inhibitor"
4TNB,X-RAY DIFFRACTION,2.11,41.74,"VAPOR DIFFUSION, HANGING DROP",5.5,"21% PEG 3350, 0.15 M Sodium Chloride, 0.1 M BIS-TRIS pH 5.5",277.0,2014-06-03,2015-06-10,4TNB,4710.0,1.0,590.0,398.0,,68.25,1.0,2.113,experimental,,0.2319,0.1703,Crystal Structure of G Protein-Coupled Receptor Kinase 5 in Complex with Sangivamycin
6FT8,X-RAY DIFFRACTION,2.6,52.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.1 M sodium malonate",277.15,2018-02-20,2018-05-16,6FT8,3338.0,1.0,339.0,458.0,,40.27,1.0,1.45,experimental,26.987,0.19533,0.16411,Crystal structure of CLK1 in complex with inhibitor 8g
6ATD,X-RAY DIFFRACTION,2.29,46.28,"VAPOR DIFFUSION, SITTING DROP",9.1,"0.2 M sodium phosphate, 20% (w/v) PEG 3350",277.0,2017-08-28,2018-07-11,6ATD,7992.0,2.0,1056.0,180.0,2.0,121.52,1.0,2.5,experimental,,0.2453,0.1947,Oxidized SHP2 forms a disulfide bond between Cys367 and Cys459
4X8S,X-RAY DIFFRACTION,3.83,67.92,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2014-12-10,2015-03-25,4X8S,2685.0,2.0,309.0,273.0,9.0,35.04,2.0,2.1,experimental,33.31,0.199,0.1755,FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 4-BROMO-2-METHOXYPHENOL
4X8T,X-RAY DIFFRACTION,3.53,65.19,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2014-12-10,2015-03-25,4X8T,2502.0,2.0,309.0,143.0,8.0,34.74,2.0,2.2,experimental,39.71,0.2212,0.1978,"FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 7-chloro-3,4-dihydroisoquinolin-1(2H)-one"
4X8U,X-RAY DIFFRACTION,3.86,68.13,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2014-12-10,2015-03-25,4X8U,2694.0,2.0,309.0,269.0,9.0,34.94,2.0,2.1,experimental,30.13,0.2014,0.1735,FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-1H-INDOLE-2-CARBOXYLIC ACID
4ZXY,X-RAY DIFFRACTION,3.52,65.05,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2015-05-20,2015-07-22,4ZXY,2610.0,2.0,309.0,196.0,8.0,35.02,2.0,2.06,experimental,29.06,0.2108,0.1902,"FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione"
5LYH,X-RAY DIFFRACTION,2.75,55.21,"VAPOR DIFFUSION, SITTING DROP",6.8,"22.5% PEG3350, 0.225M Sodium malonate",293.0,2016-09-28,2016-12-21,5LYH,3090.0,2.0,386.0,19.0,2.0,45.35,1.0,2.17,experimental,61.287,0.21783,0.19535,"Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor H10"
6F9R,X-RAY DIFFRACTION,2.76,55.47,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent Cations, 30% PEG550MME/PEG20000",289.0,2017-12-15,2018-03-07,6F9R,11475.0,2.0,1258.0,748.0,6.0,151.09,1.0,1.85,experimental,,0.228,0.1984,Crystal structure of human Angiotensin-1 converting enzyme N-domain in complex with Sampatrilat-Asp.
6SQK,X-RAY DIFFRACTION,2.3,46.55,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 3,350 20%, Mg(CH3COO)2 200 mM, HEPES-NaOH pH 7.0 100 mM",293.0,2019-09-04,2020-09-30,6SQK,5584.0,4.0,774.0,215.0,,85.95,2.0,1.4,experimental,27.3722,0.2128,0.19,Crystal structure of mouse PRMT6 with modified H7-4 peptide
6DPQ,X-RAY DIFFRACTION,3.01,59.1,MICROBATCH,10.0,"100 mM sodium thiosulfate, 100 mM CAPS, pH 10.0, 200 mM sodium chloride, 20% w/v PEG8000",277.0,2018-06-09,2018-11-07,6DPQ,6074.0,2.0,850.0,120.0,1.0,97.16,1.0,2.94,experimental,109.659,0.2399,0.19069,"Mapping the binding trajectory of a suicide inhibitor in human indoleamine 2,3-dioxygenase 1"
6CNH,X-RAY DIFFRACTION,2.69,54.19,"VAPOR DIFFUSION, SITTING DROP",6.5,"18% PEG Smear High, 0.1 M N-(2-acetamido)iminodiacetic acid, 0.2 M ammonium sulfate",293.0,2018-03-08,2018-03-28,6CNH,2815.0,1.0,351.0,147.0,,41.82,1.0,2,experimental,40.44,0.20591,0.18221,Human PRPF4B in complex with Rebastinib
7FEH,X-RAY DIFFRACTION,2.09,41.01,"VAPOR DIFFUSION, HANGING DROP",6.6,"10 mg/mL protein, 1 mM Ligand, 2 %(v/v) DMSO, 21.0 %(w/v) PEG 2000 MME, 0.25 M NaNO3, 0.1 M BIS-TRIS propane (pH 6.6), 5.0 %(v/v) PEG 400",285.0,2021-07-20,2022-07-27,7FEH,2609.0,1.0,320.0,226.0,,36.84,1.0,1.61,experimental,24.9512,0.2057,0.1655,Crystal structure of human DDR1 in complex with CH5541127
4YV8,X-RAY DIFFRACTION,2.18,43.59,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 8000, 0.2M ammonium sulfate",294.15,2015-03-19,2016-05-04,4YV8,1855.0,2.0,220.0,169.0,3.0,24.31,2.0,2,experimental,,0.205,0.173,Crystal structure of cathepsin K bound to the covalent inhibitor lichostatinal
5HP2,X-RAY DIFFRACTION,2.5,50.71,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M ammonium acetate, 0.1 M Bis-Tris, pH 5.5, 17% PEG10000",298.0,2016-01-20,2016-04-13,5HP2,7216.0,4.0,852.0,1.0,,106.18,1.0,2.983,experimental,,0.2467,0.1667,Human Adenosine Deaminase Acting on dsRNA (ADAR2) bound to dsRNA sequence derived from S. cerevisiae BDF2 gene with AU basepair at reaction site
4YVA,X-RAY DIFFRACTION,2.22,44.62,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 8000, 0.2M Ammonium sulfate",294.15,2015-03-19,2016-05-04,4YVA,1766.0,1.0,215.0,125.0,3.0,23.62,1.0,1.8,experimental,,0.21,0.183,Cathepsin K co-crystallized with actinomycetes extract
5BWL,X-RAY DIFFRACTION,2.49,50.52,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris (pH 6.5), 20% PEG 3350",293.0,2015-06-08,2016-07-13,5BWL,2459.0,2.0,293.0,376.0,,32.24,2.0,1.548,experimental,,0.2359,0.2121,Crystal Structure of SIRT5 in Complex with a Coumarin-Labelled Succinyl Peptide
6ODA,X-RAY DIFFRACTION,2.69,54.19,"VAPOR DIFFUSION, HANGING DROP",5.3,"0.1M MES pH5.3, 5% PEG6000, 0.06M Gly-Gly-Gly, 4mM TCEP",291.0,2019-03-26,2020-04-01,6ODA,8516.0,3.0,1239.0,3.0,,139.42,1.0,2.88,experimental,56.341,0.24875,0.1988,Crystal structure of HDAC8 in complex with compound 2
7ZM0,X-RAY DIFFRACTION,2.32,46.87,"VAPOR DIFFUSION, SITTING DROP",,"2.3 M ammonium sulphate, 110 mM K3PO4 and 90 mM K2HPO4",293.0,2022-04-18,2022-09-14,7ZM0,16195.0,10.0,2270.0,331.0,,255.46,1.0,2.24,experimental,62.73,0.2878,0.2401,Structure of UCHL1 in complex with GK13S inhibitor
6WZW,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 30% PEG3350",290.0,2020-05-14,2021-04-07,6WZW,2128.0,1.0,226.0,256.0,,27.43,1.0,1.69,experimental,20.43,0.2063,0.164,Ash1L SET domain in complex with AS-85
8GI4,X-RAY DIFFRACTION,2.57,52.2,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, pH 7.5, 10% 2-propanol, 20% PEG4000",277.0,2023-03-13,2023-12-06,8GI4,6091.0,8.0,984.0,229.0,,109.83,1.0,2.06,experimental,,0.2338,0.209,Crystal structure of human LIMK2 PDZ domain
4X6H,X-RAY DIFFRACTION,1.86,33.85,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1 M Tri-Sodium Citrate, 2.4 M Ammonium Sulfate",295.0,2014-12-08,2015-09-23,4X6H,2120.0,1.0,215.0,290.0,3.0,24.74,1.0,1,experimental,13.26,0.1655,0.1548,Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.
4X6I,X-RAY DIFFRACTION,1.85,33.65,"VAPOR DIFFUSION, SITTING DROP",,"Lithium sulfate 0.2M,
Sodium acetate 0.1M,
Peg 8000 30%",295.0,2014-12-08,2015-09-30,4X6I,1909.0,1.0,215.0,201.0,3.0,24.38,1.0,1.87,experimental,8.629,0.237,0.181,Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.
4X4U,X-RAY DIFFRACTION,2.54,51.54,"VAPOR DIFFUSION, SITTING DROP",,"18.9% PEG3350, 0.27M NaK tartrate",290.0,2014-12-03,2015-02-11,4X4U,16346.0,8.0,1941.0,99.0,,252.68,1.0,2.7,experimental,84.59,0.2334,0.1827,Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a human MenBeta minihelix ending in CCACC
5V7T,X-RAY DIFFRACTION,2.94,58.22,VAPOR DIFFUSION,,"20% PEG3350, 0.2M Sodium-malonate, pH 7.2-7.8",298.0,2017-03-20,2017-05-03,5V7T,1507.0,1.0,194.0,67.0,1.0,22.56,1.0,2.3,experimental,65.976,0.29097,0.22098,"crystal structure of PARP14 bound to N-{4-[4-(diphenylmethoxy)piperidin-1-yl]butyl}[1,2,4]triazolo[4,3-b]pyridazin-6-amine inhibitor"
6L5N,X-RAY DIFFRACTION,2.6,52.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"7% MPD and 0.1M Bicine, pH8.5",293.0,2019-10-24,2020-06-17,6L5N,6518.0,4.0,784.0,156.0,,95.63,1.0,2.242,experimental,37.7253,0.233,0.1753,Crystal structure of human DEAD-box RNA helicase DDX21 at post-unwound state
6LJM,X-RAY DIFFRACTION,2.4,48.72,"VAPOR DIFFUSION, HANGING DROP",,"23%-27% (v/v) PEG 3350, 0.1 M MES, pH 5.5-6.0, 0.1-0.2 M NaCl",289.0,2019-12-17,2020-10-28,6LJM,2438.0,2.0,277.0,290.0,,30.34,2.0,1.78,experimental,22.65,0.197,0.165,Crystal structure of human Sirt5 in complex with the fluorogenic tetrapeptide substrate P13
6LJN,X-RAY DIFFRACTION,2.39,48.59,"VAPOR DIFFUSION, HANGING DROP",,"23%-27% (v/v) PEG 3350, 0.1 M MES, pH 5.5-6.0, 0.1-0.2 M NaCl",289.0,2019-12-17,2020-10-28,6LJN,2479.0,2.0,277.0,306.0,,30.45,2.0,1.8,experimental,23.76,0.212,0.173,Crystal structure of human Sirt5 in complex with the fluorogenic tetrapeptide substrate P15
8SI0,X-RAY DIFFRACTION,2.08,40.99,"VAPOR DIFFUSION, HANGING DROP",8.5,"5 mM magnesium chloride, 0.1 M Tris-HCl, pH 8.5, 8% w/v PEG8000",298.15,2023-04-14,2024-04-24,8SI0,2834.0,1.0,369.0,2.0,,43.71,1.0,2.7,experimental,,0.2796,0.2169,Structure of binary complex of human cGAS and bound cGAMP
5I0L,X-RAY DIFFRACTION,2.15,42.82,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-inhibitor complex:  hMMP12 0.631 milli-M + 0.010 M Acetohydroxamic acid + 0.005 M inhibitor DC27, 10% DMSO.
precipitant: 34% PEG 4K, 1.5 M imidazole piperidine, pH 8.5, Dioxane 25%
Cryoprotectant: 40% Cryomix: (12.5 % diethylene glycol + 12.5 % glycerol + 12.5 % 1,2-propanediol + 12.5 % 2,3-butanediol + 25 % DMSO + 30 % 1,4-dioxane), 25% MPEG 6K, 0.1 M AAB (Na acetate, ADA, Bicine: 10% acid/90% basic), pH 8.5",293.0,2016-02-04,2016-07-06,5I0L,3000.0,2.0,318.0,305.0,,37.71,1.0,2.45,experimental,,0.253,0.175,Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated arylsulfonamide carboxylate water-soluble inhibitor (DC27).
7BNS,X-RAY DIFFRACTION,2.3,46.62,"VAPOR DIFFUSION, SITTING DROP",6.5,"50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate",273.0,2021-01-22,2022-03-02,7BNS,2071.0,2.0,317.0,38.0,,36.26,2.0,2.7,experimental,71.2052,0.2599,0.1768,VDR complex with BXL-62
7BNU,X-RAY DIFFRACTION,2.29,46.32,"VAPOR DIFFUSION, SITTING DROP",6.5,"50 mM Bis-Tris pH 6.5, 1.6 M lithium sulfate and 50 mM magnesium sulfate",273.0,2021-01-22,2022-03-02,7BNU,2088.0,2.0,317.0,69.0,,36.29,2.0,2.4,experimental,74.0238,0.2611,0.1886,VDR complex with BXL-62
6C2I,X-RAY DIFFRACTION,2.82,56.36,"VAPOR DIFFUSION, HANGING DROP",,"20 % (w/v) PEG 5000 monomethylethyl ether (MME), 200 mM sodium citrate (pH 6.6) and 200 mM sodium iodide",293.0,2018-01-08,2018-02-21,6C2I,3412.0,1.0,411.0,384.0,3.0,46.85,1.0,1.95,experimental,28.5896,0.1838,0.1575,"Structure of Bace-1 (Beta-Secretase) in complex with : N-(3-((1R,5S,6R)-3-amino-5-methyl-2-oxa-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4-fluorophenyl)-5-methoxypyrazine-2-carboxamide"
6EIN,X-RAY DIFFRACTION,4.4,72.03,VAPOR DIFFUSION,7.5,"0.1M HEPES pH 7.5, 0.8M Pottassium Phosphate-dibasic, 0.8M Sodium Phosphate monobasic",277.0,2017-09-19,2018-05-02,6EIN,3785.0,1.0,481.0,213.0,2.0,56.26,1.0,2.11,experimental,46.31,0.225,0.196,Crystal structure of KDM5B in complex with S49365a.
6EHA,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"2.08 M AmSO4 
0.9 % (v/v) 1,6-hexanediol 
0.1 M HEPES pH 7.5",293.0,2017-09-12,2018-10-10,6EHA,3941.0,2.0,576.0,313.0,,67.57,1.0,2,experimental,25.538,0.23876,0.1892,Heme oxygenase 1 in complex with inhibitor
9BIV,X-RAY DIFFRACTION,2.46,50.01,BATCH MODE,7.5,"Ubc13-Mms2 heterodimer was concentrated to 12 mg/mL and stored in 50 mM Tris pH 7.5, 150 mM NaCl, 1mM TCEP. Complex was left to slowly equilibrate from 277K to 298 overnight",298.0,2024-04-24,2024-05-08,9BIV,2735.0,2.0,297.0,442.0,,33.54,2.0,1.68,experimental,,0.1766,0.1438,Crystal Structure of Ubc13 with a New Active Site Loop Conformation
5XDR,X-RAY DIFFRACTION,2.45,49.8,"VAPOR DIFFUSION, SITTING DROP",,"PEG4000, lithium sulfate, sodium acetate",293.0,2017-03-29,2017-06-21,5XDR,5586.0,1.0,690.0,90.0,,79.76,1.0,2,experimental,61.787,0.26911,0.22282,Crystal structure of human DEAH-box RNA helicase DHX15 in complex with ADP
5CQW,X-RAY DIFFRACTION,3.2,61.51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml CK2alpha, 1 mM Inhibitor, 10 %(v/v) DMSO, 250 mM NaCl, 12.5 mM Tris/HCl, pH 8.5; Reservoir: 25 %(w/v) PEG 3350, 0.2 M Lithiumsulfate, 0.1 M Bis-Tris/HCl, pH 5.5; drop: 1 Mikroliter pre-incubated CK2alpha/Inhibitor solution and 1 Mikroliter reservoir",298.0,2015-07-22,2015-09-09,5CQW,5893.0,2.0,670.0,154.0,,82.83,1.0,2.65,experimental,,0.2287,0.1824,Tetragonal Complex Structure of Protein Kinase CK2 Catalytic Subunit with a Benzotriazole-Based Inhibitor Generated by click-chemistry
5TQE,X-RAY DIFFRACTION,3.91,68.52,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2016-10-24,2017-02-01,5TQE,2834.0,2.0,309.0,368.0,9.0,35.42,2.0,1.9,experimental,27.72,0.2093,0.1836,"Factor VIIa in complex with the inhibitor (5R)-5-[(1-aminoisoquinolin-6-yl)amino]-19-(cyclopropylsulfonyl)-3-methyl-13-oxa-3,15-diazatricyclo[14.3.1.1~6,10~]henicosa-1(20),6(21),7,9,16,18-hexaene-4,14-dione"
5TQF,X-RAY DIFFRACTION,3.88,68.28,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2016-10-24,2017-02-01,5TQF,2845.0,2.0,309.0,367.0,9.0,35.4,2.0,1.85,experimental,28.19,0.2085,0.1833,"Factor VIIa in complex with the inhibitor (11R)-11-[(1-aminoisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-13-methyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione"
5TQG,X-RAY DIFFRACTION,3.94,68.75,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2016-10-24,2017-02-01,5TQG,2823.0,2.0,309.0,364.0,9.0,35.61,2.0,1.9,experimental,29.43,0.2041,0.183,"Factor VIIa in complex with the inhibitor (5R,11R)-11-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-7-(2,2-difluoroethoxy)-5,13-dimethyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione"
8VHL,X-RAY DIFFRACTION,3.55,65.39,VAPOR DIFFUSION,4.8,"0.10 M NaAcetat_pH4,8 2.30 M (NH4)2SO4 30 % Glycerol, 18% (w/v) PEG 4000, 0,1M Na3Citrate pH=5.75",293.0,2024-01-02,2024-04-03,8VHL,3225.0,1.0,369.0,291.0,,41.94,1.0,1.93,experimental,22.087,0.19903,0.16764,Structure of DHODH in Complex with Ligand 17
5JRT,X-RAY DIFFRACTION,2.86,57.0,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350 20%
0.1 MTris-HCl pH 8.5
0.2 M Ammonium Acetate",285.15,2016-05-06,2016-08-03,5JRT,550.0,1.0,77.0,40.0,,8.8,1.0,1.53,experimental,46.71,0.235,0.201,Crystal structure of the human Tankyrase 2 (TNKS2) SAM domain (DH902/924RE)
8PD6,X-RAY DIFFRACTION,1.85,33.42,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% (w/v) PEG 3550, 0.2 M MgCl2, 0.1 M HEPES",294.0,2023-06-11,2024-01-31,8PD6,1700.0,1.0,218.0,151.0,,24.8,1.0,1.3,experimental,16.655,0.1775,0.13866,Crystal structure of the TRIM58 PRY-SPRY domain in complex with TRIM-473
7QGB,X-RAY DIFFRACTION,2.73,54.96,"VAPOR DIFFUSION, SITTING DROP",6.5,"20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20 000, and 0.1 M buffering solution of imidazole/MES pH 6.5",290.0,2021-12-08,2022-10-19,7QGB,3263.0,1.0,399.0,269.0,,46.83,1.0,2.58,experimental,47.026,0.2344,0.1799,"H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE AT PH 6.5"
7QGC,X-RAY DIFFRACTION,2.68,54.05,"VAPOR DIFFUSION, SITTING DROP",5.5,"20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20 000, and 0.1 M buffering solution of imidazole/MES pH 6.5",290.0,2021-12-08,2022-09-28,7QGC,3448.0,1.0,399.0,330.0,,46.85,1.0,2.55,experimental,42.542,0.2315,0.1705,"H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE AT PH 5.5"
7QGD,X-RAY DIFFRACTION,2.76,55.43,"VAPOR DIFFUSION, SITTING DROP",8.5,"20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20 000, and 0.1 M buffering solution of Tris/BICINE pH 8.5",290.0,2021-12-08,2022-10-19,7QGD,3386.0,1.0,399.0,354.0,,47.32,1.0,2.3,experimental,41.833,0.2206,0.1791,"H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE AT PH 8.5"
7QGE,X-RAY DIFFRACTION,2.7,54.49,"VAPOR DIFFUSION, SITTING DROP",8.5,"20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20 000, and 0.1 M buffering solution of Tris/BICINE pH 8.5",290.0,2021-12-08,2022-10-19,7QGE,3519.0,1.0,399.0,374.0,,46.86,1.0,2.27,experimental,55.022,0.2054,0.1712,"H. SAPIENS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6,7,8-TETRABROMOBENZOTRIAZOLE (TBBt) AT PH 8.5"
5O21,X-RAY DIFFRACTION,2.8,56.02,"VAPOR DIFFUSION, SITTING DROP",,"22.5% PEG Smear Broad, 0.1 M sodium/potassium tartrate, 10% ethylene glycol, 0.1 M cacodylate pH 5.5",277.0,2017-05-19,2017-06-28,5O21,4836.0,2.0,570.0,370.0,,66.53,1.0,2.06,experimental,,0.2209,0.1799,Crystal structure of WNK3 kinase domain in a monophosphorylated state with chloride bound in the active site
4YII,X-RAY DIFFRACTION,2.05,39.87,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3000, MES",296.0,2015-03-02,2015-04-08,4YII,1768.0,2.0,245.0,64.0,,27.62,2.0,1.804,experimental,,0.2454,0.1963,Structure of an APC2-UBCH10 complex reveals distinctive cullin-RING ligase mechanism for Anaphase-promoting complex/Cyclosome
5B2K,X-RAY DIFFRACTION,2.6,52.78,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 3350, sodium citrate tribasic, Hepes",277.0,2016-01-19,2016-04-06,5B2K,2118.0,1.0,324.0,12.0,,37.0,1.0,2.75,experimental,45.804,0.32761,0.26987,A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7
6IB0,X-RAY DIFFRACTION,2.34,47.5,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodium Citrate, 20 % PEG3350",277.0,2018-11-28,2019-02-27,6IB0,2323.0,1.0,318.0,38.0,,36.64,1.0,2.6,experimental,,0.2713,0.227,The structure of MKK7 in complex with the covalent 4-amino-pyrazolopyrimidine 3a
6IB2,X-RAY DIFFRACTION,2.41,48.99,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Sodiumcitrate
20 % PEG3500",277.0,2018-11-28,2019-02-27,6IB2,2200.0,1.0,318.0,96.0,,36.62,1.0,2.1,experimental,,0.2501,0.2219,The structure of MKK7 in complex with the covalent 4-amino-pyrazolopyrimidine 4a
6KC6,X-RAY DIFFRACTION,2.27,45.71,"VAPOR DIFFUSION, SITTING DROP",8.0,"200 mM KCl, 20% PEG3,350",293.0,2019-06-27,2020-04-15,6KC6,9939.0,6.0,1350.0,269.0,,157.64,1.0,2.123,experimental,,0.2665,0.2112,HOIP-HOIPIN8 complex
5KYE,X-RAY DIFFRACTION,2.11,41.74,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES pH 7.5, 25% PEG3350, 0.2M Ammonium acetate",292.0,2016-07-21,2017-08-09,5KYE,7102.0,4.0,854.0,390.0,,98.55,2.0,1.97,experimental,39.2332,0.2226,0.1805,Crystal structure of USP7 catalytic domain [H294E] mutant in complex with ubiquitin
5BWN,X-RAY DIFFRACTION,1.98,37.89,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2M Ammonium tartrate dibasic (pH 7.0), 20% w/v PEG 3350, 0.01M Urea",293.0,2015-06-08,2016-07-13,5BWN,2338.0,2.0,319.0,111.0,,35.77,2.0,1.942,experimental,,0.2745,0.2261,Crystal Structure of SIRT3 with a H3K9 Peptide Containing a Myristoyl Lysine
9BHR,X-RAY DIFFRACTION,2.19,43.73,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M Magnesium formate",291.0,2024-04-21,2024-05-08,9BHR,5294.0,2.0,630.0,427.0,,72.32,1.0,1.62,experimental,20.418,0.18727,0.14789,Crystal structure of the WDR domain of human DCAF1 in complex with OICR-40155 compound
9BHS,X-RAY DIFFRACTION,2.17,43.33,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG2000 Monoethyl Ether, 0.2 M Potassium Bromide",291.0,2024-04-21,2024-05-01,9BHS,5537.0,2.0,630.0,501.0,,72.31,1.0,1.43,experimental,16.638,0.16957,0.1405,Crystal structure of the WDR domain of human DCAF1 in complex with OICR-9939 compound
5LKT,X-RAY DIFFRACTION,2.91,57.74,"VAPOR DIFFUSION, SITTING DROP",,"Tris, PEG MME 2000",277.0,2016-07-24,2016-11-02,5LKT,4960.0,1.0,578.0,384.0,2.0,68.59,1.0,2.04,experimental,44.449,0.20368,0.17708,Crystal structure of the p300 acetyltransferase catalytic core with butyryl-coenzyme A.
5LKX,X-RAY DIFFRACTION,3.1,60.27,"VAPOR DIFFUSION, SITTING DROP",,"Tris, PEG MME 2000, DMSO",277.0,2016-07-25,2016-11-02,5LKX,4748.0,1.0,578.0,171.0,2.0,68.45,1.0,2.52,experimental,55.942,0.23944,0.20671,Crystal structure of the p300 acetyltransferase catalytic core with propionyl-coenzyme A.
5TTG,X-RAY DIFFRACTION,2.76,55.48,"VAPOR DIFFUSION, SITTING DROP",5.6,"20% PEG 4000, 20% IProp, 0.1 M NaCitrate pH5.6",293.0,2016-11-03,2017-02-01,5TTG,5119.0,2.0,574.0,644.0,,68.28,1.0,1.66,experimental,21.363,0.1917,0.1707,Crystal structure of catalytic domain of GLP with MS012
5VAM,X-RAY DIFFRACTION,3.19,61.4,"VAPOR DIFFUSION, HANGING DROP",8.4,"100 mM Tris ph 8.4, 12% PEG8000, and 50mM NaCl",291.0,2017-03-27,2017-06-28,5VAM,4582.0,2.0,562.0,271.0,,64.91,1.0,2.1,experimental,35.45,0.223,0.192,BRAF in Complex with RAF709
5OWH,X-RAY DIFFRACTION,2.13,42.32,"VAPOR DIFFUSION, SITTING DROP",,"1 MIKROLITER OF A CK2ALPHA/INHIBITOR MIXTURE (COMPOSITION: 7 MG/ML CK2ALPHA ENZYME, 1 MILLIMOLAR         
INHIBITOR, 10 % DIMETHYL SULFOXIDE, 450 MM NACL, 22.5 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 1 MIKROLITER RESERVOIR SOLUTION (COMPOSITION: 4.4 M sodium chloride, 0.1 M SODIUM Acetate, PH 5.5) FOLLOWED BY VAPOUR DIFFUSION EQUILIBRATION AGAINST MICROLITER OF THE RESERVOIR SOLUTION.",293.15,2017-09-01,2018-07-25,5OWH,2883.0,1.0,335.0,48.0,,40.59,1.0,2.3,experimental,,0.2628,0.2192,"High salt structure of human protein kinase CK2alpha in complex with 3-aminopropyl-4,5,6,7-tetrabromobenzimidazol"
5JXY,X-RAY DIFFRACTION,2.4,48.82,"VAPOR DIFFUSION, SITTING DROP",,0.2M Ammonium Chloride and 20% PEG3350,,2016-05-13,2016-09-28,5JXY,2955.0,3.0,260.0,227.0,,40.3,1.0,1.71,experimental,35.1,0.231,0.1979,Enzyme-substrate complex of TDG catalytic domain bound to a G/U analog
6PXU,X-RAY DIFFRACTION,2.58,52.37,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium chloride, 20% w/v PEG3350",293.0,2019-07-27,2019-09-25,6PXU,9719.0,4.0,1128.0,562.0,9.0,132.55,2.0,2.007,experimental,42.0352,0.2189,0.1711,"Crystal structure of human GalNAc-T12 bound to a diglycosylated peptide, Mn2+, and UDP"
5GU4,X-RAY DIFFRACTION,1.95,36.78,"VAPOR DIFFUSION, HANGING DROP",,"2.8 M sodium acetate, tetrahydrate pH7.0
30%-35% glucose",289.0,2016-08-24,2016-11-02,5GU4,4333.0,4.0,620.0,213.0,,69.1,2.0,1.55,experimental,20.373,0.2554,0.2176,rRNA N-glycosylase RTA
6FYO,X-RAY DIFFRACTION,2.28,46.06,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% PEG3350,0.2M Ammonium Sulfate, 0.1M TRIS",298.0,2018-03-12,2018-07-18,6FYO,2942.0,1.0,339.0,144.0,,40.25,1.0,2.32,experimental,32.67,0.2335,0.2028,X-RAY STRUCTURE OF CLK1-KD(148-484)/Cpd-2 AT 2.32A
8G9E,X-RAY DIFFRACTION,2.65,53.53,"VAPOR DIFFUSION, HANGING DROP",7.0,"14% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM AMPPNP, 2 mM CdCl2, Soaking with 2mM 5-PCF2P-InsP5 under pH 5.2 for 3 days , VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2023-02-21,2024-01-03,8G9E,3012.0,1.0,330.0,369.0,,38.97,1.0,1.75,experimental,21.625,0.1752,0.1241,"Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMP-PNP and 5-(PCF2P)-IP5, an analog of 5-IP7"
6X27,X-RAY DIFFRACTION,2.78,55.71,"VAPOR DIFFUSION, SITTING DROP",4.0,"5.0% polyethylene glycol 6000, 0.1M citric acid",293.0,2020-05-20,2021-04-14,6X27,19050.0,12.0,2616.0,1591.0,,291.68,1.0,2.12,experimental,26.2282,0.1941,0.1572,Lon protease proteolytic domain complexed with bortezomib
7FQI,X-RAY DIFFRACTION,2.03,39.45,"VAPOR DIFFUSION, SITTING DROP",9.0,"23.4mg/mL deglycosylated protein in 25mM HEPES/NaOH pH7, 300 mM NaCl, 200mM Trehalose incubated with 10-fold excess of ligand, then mixed 50-70% with 50-30% reservoir consisting of 25% v/v PEG smear broad, 0.1M Bicine/NaOH pH 9.0, 10% v/v 2-Propanol, total volume 200nL",293.0,2022-10-05,2023-10-11,7FQI,7347.0,3.0,1332.0,634.0,,155.71,1.0,1.45,experimental,21.328,0.1891,0.1668,"Crystal Structure of human Legumain in complex with (2S)-N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[1-[4-[(2,4-difluorophenyl)methoxy]phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide"
6H1D,X-RAY DIFFRACTION,2.39,48.58,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5,
1.1-1.3 M sodium citrate",293.0,2018-07-11,2019-05-22,6H1D,2578.0,2.0,334.0,48.0,,37.0,2.0,1.94,experimental,29.2,0.2374,0.1868,Crystal structure of C21orf127-TRMT112 in complex with SAH
6EJE,X-RAY DIFFRACTION,2.56,52.02,"VAPOR DIFFUSION, HANGING DROP",7.5,"55-65% Morpheus Precipitant mix 2 (PEG8000 and Ethylene glycol)
0.1M Bicine/Tris buffer at pH 7.5
0.1M of NPS mix (0.033M of each)",293.0,2017-09-20,2018-05-02,6EJE,5680.0,2.0,763.0,111.0,6.0,87.45,2.0,2.43,experimental,50.0257,0.2349,0.1972,Human Xylosyltransferase 1 in complex with peptide PAAEGSGEQDFT
6KQU,X-RAY DIFFRACTION,3.45,64.38,VAPOR DIFFUSION,,"2.2M Sodium chloride, 0.1M BIS-TRIS propane pH 7.0",277.0,2019-08-18,2020-08-19,6KQU,1172.0,1.0,123.0,150.0,7.0,14.67,1.0,2,experimental,17.841,0.2385,0.1972,Crystal structure of phospholipase A2
5LYW,X-RAY DIFFRACTION,2.66,53.73,"VAPOR DIFFUSION, HANGING DROP",6.0,"24% methanol, 100 mM citrate",277.0,2016-09-28,2017-08-16,5LYW,3095.0,1.0,378.0,256.0,,42.89,1.0,1.69,experimental,40.44,0.193,0.171,CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR 6-((R)-2-o-Tolyloxymethyl-pyrrolidin-1-yl)-9H-purine
5LYX,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% methanol, 0.1 M citrate",277.0,2016-09-29,2017-08-16,5LYX,3014.0,1.0,378.0,129.0,,42.93,1.0,1.9,experimental,48.86,0.217,0.195,"CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR 5-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl-pyrrolidin-2-ylmethoxy)-isoquinoline"
5HOA,X-RAY DIFFRACTION,2.22,44.55,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris 100 mM, MPD 24%, pH8.5",277.0,2016-01-19,2016-11-23,5HOA,1907.0,1.0,312.0,59.0,,35.84,1.0,2.14,experimental,,,,Crystal structure of c-Met L1195V in complex with SAR125844
5HOR,X-RAY DIFFRACTION,2.24,45.13,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris 100mM, MPD 20%, pH8.5",277.0,2016-01-19,2016-11-23,5HOR,2089.0,1.0,312.0,95.0,,35.83,1.0,2.2,experimental,,,,Crystal structure of c-Met-M1250T in complex with SAR125844.
8B6M,X-RAY DIFFRACTION,2.65,53.5,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 22% w/v PEG3350, 200 mM Li2SO4, 250 mM NaCl, 20% v/v glycerol",277.15,2022-09-27,2023-10-11,8B6M,3703.0,4.0,438.0,200.0,,51.41,2.0,1.6,experimental,27.2,0.2194,0.1849,Tankyrase 2 in complex with an inhibitor
4ZYT,X-RAY DIFFRACTION,3.85,68.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277.0,2015-05-22,2016-04-20,4ZYT,1804.0,1.0,210.0,175.0,,23.55,1.0,1.702,experimental,22.6639,0.1827,0.1667,"Human GAR transformylase in complex with GAR and N-{4-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)benzyl]benzoyl}-L-glutamic acid (AGF23)"
4ZYU,X-RAY DIFFRACTION,3.88,68.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277.0,2015-05-22,2016-04-20,4ZYU,1737.0,1.0,210.0,124.0,,23.57,1.0,1.95,experimental,33.3889,0.2071,0.1789,"Human GAR transformylase in complex with GAR and N-{4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-butyl]benzoyl}-L-glutamic acid (AGF50)"
4ZYV,X-RAY DIFFRACTION,3.59,65.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277.0,2015-05-22,2016-04-20,4ZYV,1696.0,1.0,210.0,119.0,,23.56,1.0,2.053,experimental,35.8752,0.1923,0.1655,"Human GAR transformylase in complex with GAR and N-({5-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophen-2-yl}carbonyl)-L-glutamic acid (AGF71)"
4ZYW,X-RAY DIFFRACTION,3.86,68.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277.0,2015-05-22,2016-04-20,4ZYW,1695.0,1.0,210.0,104.0,,23.54,1.0,2.05,experimental,35.249,0.2024,0.1616,"Human GAR transformylase in complex with GAR and N-({5-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophen-2-yl}carbonyl)-L-glutamic acid (AGF94)"
4ZYX,X-RAY DIFFRACTION,3.88,68.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277.0,2015-05-22,2016-04-20,4ZYX,1864.0,1.0,210.0,208.0,,23.56,1.0,1.65,experimental,19.4058,0.1812,0.1585,"Human GAR transformylase in complex with GAR and (S)-2-({4-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)butyl]thiophene-2-carbonyl}amino)pentanedioic acid (AGF117)"
4ZYY,X-RAY DIFFRACTION,3.88,68.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277.0,2015-05-22,2016-04-20,4ZYY,1817.0,1.0,210.0,150.0,,23.56,1.0,1.85,experimental,27.8061,0.1959,0.1683,"Human GAR transformylase in complex with GAR and (S)-2-({5-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)butyl]thiophene-3-carbonyl}amino)pentanedioic acid (AGF118)"
4ZYZ,X-RAY DIFFRACTION,3.89,68.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277.0,2015-05-22,2016-04-20,4ZYZ,1868.0,1.0,210.0,203.0,,23.5,1.0,1.6,experimental,21.3294,0.1876,0.1646,"Human GAR transformylase in complex with GAR and (S)-2-(7-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanamido)pentanedioic acid (AGF145)"
4ZZ0,X-RAY DIFFRACTION,3.83,67.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277.0,2015-05-22,2016-04-20,4ZZ0,1877.0,1.0,210.0,196.0,,23.52,1.0,1.65,experimental,20.3105,0.1852,0.1598,"Human GAR transformylase in complex with GAR and (S)-2-(8-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanamido)pentanedioic acid (AGF147)"
8FDY,X-RAY DIFFRACTION,3.56,65.4,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris-HCl pH 7.5, 0.33 M NaCl, 16-21% PEG 4000, and 2% PEG 400",277.0,2022-12-05,2023-05-10,8FDY,1606.0,1.0,210.0,60.0,,23.57,1.0,2.06,experimental,,0.255,0.2106,Human GAR transformylase in complex with GAR substrate and AGF132 inhibitor
4YGY,X-RAY DIFFRACTION,3.38,63.6,"VAPOR DIFFUSION, SITTING DROP",7.0,"30% PEG 3350, 0.2 M magnesium acetate",298.0,2015-02-26,2015-09-16,4YGY,3044.0,4.0,402.0,62.0,,45.71,2.0,2.36,experimental,47.118,0.2462,0.1832,Crystal Structure of Human Scp1 bound to trans-proline peptidomimetic CTD phospho-Ser5 peptide
6P0J,X-RAY DIFFRACTION,2.21,44.23,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M calcium acetate, pH 5.5, 18-22% PEG3350",293.0,2019-05-17,2020-03-04,6P0J,1728.0,1.0,186.0,257.0,,21.79,1.0,1.31,experimental,17.76,0.156,0.1201,Crystal structure of GDP-bound human RalA
7E9V,X-RAY DIFFRACTION,2.56,56.94,"VAPOR DIFFUSION, SITTING DROP",,"2.5M  (NH4)2SO4, 0.1M Tris pH8.5",293.0,2021-03-05,2021-03-24,7E9V,1565.0,1.0,214.0,32.0,,24.45,1.0,2.1,experimental,48.109,0.2497,0.205,The Crystal Structure of human UMP-CMP kinase from Biortus.
7SSE,X-RAY DIFFRACTION,2.21,44.28,"VAPOR DIFFUSION, SITTING DROP",5.5,"30% PEG3350 ,0.1M Ammonium Sulphate, 0.1M Bis-Tris pH5.5",291.0,2021-11-10,2021-12-15,7SSE,4908.0,2.0,630.0,226.0,,71.54,1.0,1.62,experimental,26.441,0.2335,0.2056,Crystal structure of the WDR domain of human DCAF1 in complex with CYCA-117-70
9C1Q,X-RAY DIFFRACTION,3.21,61.7,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M Magnesium formate",291.0,2024-05-29,2024-08-07,9C1Q,2684.0,1.0,315.0,201.0,1.0,36.38,1.0,1.8,experimental,28.3,0.19136,0.15654,Crystal structure of the WDR domain of human DCAF1 in complex with OICR-39512 compound
8UQA,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystals were obtained by mixing 2 microliters of the protein fusion (8.0 mg/mL) in 10 mM HEPES, pH 7.5, 600 mM NaCl, 1 mM TCEP and 2 microliters of the reservoir solution containing 0.1 M HEPES, pH 7.5, 2.4 M NaCl",288.0,2023-10-23,2024-01-17,8UQA,3645.0,1.0,447.0,251.0,,49.87,1.0,2.049,experimental,,0.2305,0.192,Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 12-residue linker
8UQB,X-RAY DIFFRACTION,2.75,55.27,"VAPOR DIFFUSION, HANGING DROP",7.0,"Crystals were obtained by mixing 2 microliters of the protein fusion (12 mg/mL) in 10 mM HEPES, pH 7.5, 600 mM NaCl, 1 mM TCEP and 2 microliters of the reservoir solution containing 50 mM BIS-TRIS propane, pH 7.0, 1 M NaCl",288.0,2023-10-23,2024-01-17,8UQB,3207.0,1.0,455.0,43.0,,50.31,1.0,2.484,experimental,,0.2596,0.2182,Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 20-residue linker (crystallization condition 1)
8UQC,X-RAY DIFFRACTION,2.75,55.33,"VAPOR DIFFUSION, HANGING DROP",6.0,"Crystals were obtained by mixing 2 microliters of the protein fusion (12 mg/mL) in 10 mM HEPES, pH 7.5, 600 mM NaCl, 1 mM TCEP and 2 microliters of the reservoir solution containing 4% tacsimate, pH 6, 13.5% PEG3350",288.0,2023-10-23,2024-01-17,8UQC,3318.0,1.0,455.0,23.0,,50.17,1.0,2.61,experimental,,0.2521,0.2187,Crystal structure of RNF168 (RING)-UbcH5c fused to H2A-H2B via a 20-residue linker (crystallization condition 2)
6PDJ,X-RAY DIFFRACTION,2.44,49.68,"VAPOR DIFFUSION, HANGING DROP",10.5,"1.5 M ammonium sulfate, 120 mM lithium chloride, 10 mM nickel(II) chloride, 100 mM CAPS pH 10.5",291.0,2019-06-19,2019-10-09,6PDJ,2536.0,1.0,288.0,291.0,,34.32,1.0,1.81,experimental,27.25,0.217,0.167,Tyrosine-protein kinase LCK bound to Compound 11
6OIB,X-RAY DIFFRACTION,3.11,60.5,"VAPOR DIFFUSION, HANGING DROP",,"0.2M ammonium tartrate dibasic, 20% PEG 3350",293.15,2019-04-09,2020-01-15,6OIB,6770.0,2.0,836.0,190.0,,96.5,1.0,2.03,experimental,,0.2496,0.2089,Crystal structure of human Sulfide Quinone Oxidoreductase in complex with coenzyme Q
5F59,X-RAY DIFFRACTION,4.97,75.27,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris-HCl, pH8.5, 3M NaCl",277.0,2015-12-04,2016-02-24,5F59,1277.0,1.0,154.0,52.0,,18.45,1.0,2.801,experimental,36.0625,0.2286,0.1795,The crystal structure of MLL3 SET domain
7KHM,X-RAY DIFFRACTION,3.33,63.06,LIPIDIC CUBIC PHASE,,"50mM MES, pH 6.5, 50mM NaH2PO4, 30.3% PEG 300, 50mM DTT, 2.5% 2,5-hexanediol",293.0,2020-10-21,2022-02-02,7KHM,4650.0,2.0,660.0,14.0,,79.36,1.0,2.88,experimental,129.9206,0.3245,0.2938,Crystal structure of hDHHS20 bound to palmitoyl CoA
7V8G,X-RAY DIFFRACTION,2.36,47.87,EVAPORATION,8.0,"2%(v/v) 1,4-dioxane, 0.1 M Tris-HCl (pH 8.0), 15%(v/v) PEG 3,350",289.0,2021-08-23,2022-03-30,7V8G,4800.0,4.0,686.0,,,77.52,2.0,2.75,experimental,65.64,0.2781,0.2201,Crystal structure of HOIP RING1 domain bound to IpaH1.4 LRR domain
6ZFA,X-RAY DIFFRACTION,2.55,51.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM  HEPES pH 7.5, 200 mM MgCl2, 30% v/v PEG 400 (Alfa Aesar), 1 mM Anderson-Evans polyoxotungstate TEW.
Protein at 10 mg/ml in 25 mM HEPES pH 7.0, 200 mM NaCl buffer.",292.0,2020-06-16,2020-11-18,6ZFA,3275.0,1.0,382.0,137.0,,50.56,1.0,1.8,experimental,24.343,0.2166,0.1855,"Structure of the catalytic domain of human endo-alpha-mannosidase MANEA in complex with GlcIFG, alpha-1,2-mannobiose and hexatungstotellurate(VI) TEW"
7OTS,X-RAY DIFFRACTION,2.34,47.4,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Lithium sulfate, 35 % PEG 3350, 0.1 M MES pH 6.5, 0.5% beta-OG",295.0,2021-06-10,2021-06-23,7OTS,5057.0,2.0,594.0,293.0,,68.92,1.0,1.792,experimental,23.19,0.2661,0.2222,Crystal structure of human Monoacylglycerol Lipase ABHD6 in complex with oleic acid and octyl glucoside
6BTY,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, HANGING DROP",7.0,PEG 3350,295.0,2017-12-08,2018-10-17,6BTY,2241.0,2.0,262.0,184.0,,30.15,1.0,1.678,experimental,25.8,0.2284,0.1951,Crystal structure of the PI3KC2alpha C2 domain in space group P41212
4YWY,X-RAY DIFFRACTION,2.52,51.16,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES buffer pH 6.5, 1.6 M ammonium sulfate",281.0,2015-03-21,2015-08-05,4YWY,9269.0,3.0,1083.0,1301.0,,125.48,1.0,1.95,experimental,13.098,0.21101,0.16408,Crystal Structure of double mutant Y115E Y117E human Glutaminyl Cyclase in complex with inhibitor PBD-150
5A7I,X-RAY DIFFRACTION,4.96,75.2,,6.2,"10% GLYCEROL, 25% PROPANEDIOL AND 0.1 M SODIUM/POTASSIUM PHOSPHATE PH 6.2",,2015-07-06,2016-04-13,5A7I,2646.0,1.0,313.0,28.0,,37.37,1.0,2.89,experimental,71.185,0.22324,0.197,"Crystal structure of INPP5B in complex with biphenyl 3,3',4,4',5,5'- hexakisphosphate"
4YMJ,X-RAY DIFFRACTION,3.14,60.85,"VAPOR DIFFUSION, SITTING DROP",6.2,"2.5 M NACL, 0.1 M NA/K PHOSPHATE PH 6.2",294.0,2015-03-06,2015-06-03,4YMJ,4848.0,2.0,608.0,383.0,,70.69,1.0,2,experimental,,0.1993,0.1646,(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors
8TXY,X-RAY DIFFRACTION,3.0,58.98,VAPOR DIFFUSION,6.8,"24% PEG 400, 150 mM LiSO4, 100 mM MES ph 6.8",298.0,2023-08-24,2024-01-10,8TXY,5160.0,2.0,634.0,100.0,1.0,74.69,1.0,2.1,experimental,61.63,0.2665,0.2392,X-ray crystal structure of JRD-SIK1/2i-3 bound to a MARK2-SIK2 chimera
4UD7,X-RAY DIFFRACTION,2.8,56.0,,4.0,0.1 M SODIUM CITRATE PH 4.0 AND 15 % PEG8000,,2014-12-08,2016-01-13,4UD7,4008.0,8.0,520.0,262.0,,58.68,2.0,1.6,experimental,23.018,0.17838,0.13846,Structure of the stapled peptide YS-02 bound to MDM2
6MIW,X-RAY DIFFRACTION,2.64,53.48,"VAPOR DIFFUSION, SITTING DROP",6.5,Molecular Dimensions Morpheus HT condition D3,293.0,2018-09-20,2018-10-17,6MIW,589.0,1.0,91.0,19.0,,10.71,1.0,2,experimental,28.326,0.2118,0.1798,WWE domain of human HUWE1
7KD7,X-RAY DIFFRACTION,2.27,45.88,"VAPOR DIFFUSION, HANGING DROP",5.5,"100 mM BIS-TRIS pH 5.5, 2000 mM Ammonium sulfate",293.15,2020-10-08,2021-06-16,7KD7,3820.0,4.0,418.0,369.0,1.0,51.05,2.0,1.44,experimental,25.74,0.1829,0.1614,Crystal structure of human NatD (NAA40) bound to a bisubstrate analogue
6XP9,X-RAY DIFFRACTION,2.5,50.78,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Ammonium acetate, 0.1 M Sodium HEPES pH 7.5, 18-20 % w/v PEG 4000.Crystals were cryoprotected by supplementing the mother liquor with 20% (v/v) Glycerol and harvested by flash-cooling in liquid nitrogen",296.0,2020-07-08,2020-09-23,6XP9,4465.0,2.0,702.0,168.0,,80.89,1.0,2.27,experimental,60.68,0.2199,0.1949,"STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator peptide IN COMPLEX WITH (S,S)-1"
6C7Y,X-RAY DIFFRACTION,3.09,60.17,"VAPOR DIFFUSION, HANGING DROP",7.0,"100mM HEPES pH 7.0, 14% (w/v) PEG8000, 100mM magnesium acetate, 2mM TCEP",281.0,2018-01-23,2018-05-02,6C7Y,3135.0,2.0,403.0,35.0,,46.82,2.0,2.499,experimental,86.2543,0.2414,0.2067,Crystal structure of inhibitory protein SOCS1 in complex with JAK1 kinase domain
5WWQ,X-RAY DIFFRACTION,2.49,50.62,VAPOR DIFFUSION,8.6,"2% Dioxane, 0.1M Bicine, 18% (w/v) PEG 8000, 10 mM Yttrium(III) chloride hexahydrate",289.0,2017-01-04,2017-06-28,5WWQ,6846.0,2.0,954.0,,,105.81,1.0,2.815,experimental,54.2703,0.2667,0.2285,Crystal structure of human NSun6
6TG4,X-RAY DIFFRACTION,2.28,45.96,"VAPOR DIFFUSION, SITTING DROP",,"7.5-25% PEG 6000, Bicine, pH = 9.0",295.15,2019-11-15,2020-07-08,6TG4,3355.0,2.0,480.0,35.0,,55.65,1.0,2.76,experimental,44.877,0.2809,0.2296,Tankyrase 2 in complex with an inhibitor (OM-1700)
6TKM,X-RAY DIFFRACTION,2.6,52.65,"VAPOR DIFFUSION, SITTING DROP",,"7.5-25% PEG 6000, Bicine, pH = 9.0",295.15,2019-11-28,2020-07-08,6TKM,3378.0,2.0,480.0,31.0,,55.75,1.0,2.7,experimental,37.872,0.2714,0.237,Tankyrase 2 in complex with an inhibitor (OM-1800)
6TKN,X-RAY DIFFRACTION,2.17,43.3,"VAPOR DIFFUSION, SITTING DROP",,"7.5-25% PEG 6000, Bicine pH=9.0",295.15,2019-11-28,2020-07-08,6TKN,3475.0,2.0,480.0,103.0,,55.62,1.0,2.5,experimental,41.077,0.2487,0.209,Tankyrase 2 in complex with an inhibitor (OM-1000)
6TKP,X-RAY DIFFRACTION,2.2,44.08,"VAPOR DIFFUSION, SITTING DROP",,"7.5-25% PEG 6000, Bicine, pH = 9.0",295.15,2019-11-28,2020-07-08,6TKP,3500.0,2.0,480.0,120.0,,55.78,1.0,2.4,experimental,40.297,0.2457,0.2052,Tankyrase 2 in complex with an inhibitor (OM-1900)
6TKQ,X-RAY DIFFRACTION,2.21,44.22,"VAPOR DIFFUSION, SITTING DROP",,"7.5-25% PEG 6000, Bicine pH=9.0",295.15,2019-11-28,2020-07-08,6TKQ,3634.0,2.0,480.0,208.0,,55.71,1.0,2.5,experimental,32.103,0.2516,0.1991,Tankyrase 2 in complex with an inhibitor (OM-2700)
6TKR,X-RAY DIFFRACTION,2.53,51.42,"VAPOR DIFFUSION, SITTING DROP",,"7.5-25% PEG6000, Bicine pH=9.0",295.15,2019-11-28,2020-07-08,6TKR,3396.0,2.0,480.0,26.0,,55.75,1.0,2.75,experimental,50.105,0.2743,0.2208,Tankyrase 2 in complex with an inhibitor (OM-1704)
6TKS,X-RAY DIFFRACTION,2.16,42.98,"VAPOR DIFFUSION, SITTING DROP",,"7.5-25% PEG 6000, Bicine, pH=9.0",295.15,2019-11-28,2020-07-08,6TKS,3403.0,2.0,480.0,37.0,,55.75,1.0,2.5,experimental,53.242,0.2592,0.2138,Tankyrase 2 in complex with an inhibitor (OM-1720)
7SJ3,X-RAY DIFFRACTION,2.95,57.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"100mM MES pH 6.5, 10% PEG 8000, 200mM sodium acetate, 10mM TCEP",294.0,2021-10-15,2022-11-02,7SJ3,4100.0,2.0,570.0,45.0,,64.56,2.0,2.51,experimental,89.25,0.2335,0.1996,Structure of CDK4-Cyclin D3 bound to abemaciclib
4YH1,X-RAY DIFFRACTION,3.39,63.68,"VAPOR DIFFUSION, SITTING DROP",7.0,"30% PEG 3350, 0.2 M magnesium acetate",298.0,2015-02-26,2015-09-16,4YH1,3123.0,4.0,402.0,141.0,,45.71,2.0,2.2,experimental,33.578,0.2463,0.1925,Structure of Human Scp1 bound to cis-proline peptidomimetic CTD phospho-Ser5 peptide
7BCM,X-RAY DIFFRACTION,2.74,55.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG10,000
0.1 M HEPES pH 7.5",277.0,2020-12-20,2021-03-03,7BCM,4281.0,2.0,630.0,21.0,,72.75,1.0,2.3,experimental,33.79,0.308,0.243,The DDR1 Kinase Domain Bound To SR302
5L2I,X-RAY DIFFRACTION,2.25,45.24,"VAPOR DIFFUSION, SITTING DROP",,"1:1 (protein to well buffer) with well buffer containing:  0.1 M MES pH 6.0, 70 - 80 mM NH4NO3, 10 - 15% polyethyleneglycol 3350.",286.15,2016-08-01,2016-08-24,5L2I,2117.0,1.0,307.0,,,35.47,1.0,2.75,experimental,92.38,0.3037,0.2262,The X-ray co-crystal structure of human CDK6 and Palbociclib.
5L2T,X-RAY DIFFRACTION,2.26,45.56,"VAPOR DIFFUSION, SITTING DROP",,"1:1 (protein to well buffer) with well buffer containing:  0.1 M MES pH 6.0, 70 - 80 mM NH4NO3, 10 - 15% polyethyleneglycol 3350",286.15,2016-08-02,2016-08-24,5L2T,2107.0,1.0,307.0,2.0,,35.45,1.0,2.37,experimental,68.68,0.2576,0.2117,The X-ray co-crystal structure of human CDK6 and Ribociclib.
5LPE,X-RAY DIFFRACTION,1.93,36.23,"VAPOR DIFFUSION, SITTING DROP",5.6,"100 mM  ammonium sulphate, 100 mM MES",291.0,2016-08-12,2016-10-05,5LPE,3275.0,2.0,468.0,124.0,12.0,52.16,1.0,2.65,experimental,37.4763,0.2777,0.2198,Kallikrein-related peptidase 10 complex with Zn2+
5LPF,X-RAY DIFFRACTION,1.95,37.03,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.1 M ammonium sulphate, 0.1 M MES",291.0,2016-08-12,2016-10-05,5LPF,3277.0,2.0,468.0,135.0,12.0,52.13,1.0,2.7,experimental,31.2862,0.2849,0.2234,Kallikrein-related peptidase 10
7JXY,X-RAY DIFFRACTION,1.9,35.37,"VAPOR DIFFUSION, SITTING DROP",6.0,0.1M BisTRIS pH 6.0 and 35% PEG3350,293.0,2020-08-28,2021-05-19,7JXY,4645.0,2.0,664.0,35.0,,76.38,1.0,2.15,experimental,64.46,0.2411,0.2004,Structure of TTBK1 kinase domain in complex with Compound 18
7L3L,X-RAY DIFFRACTION,3.04,59.51,MICROBATCH,8.0,"0.1 M Tris (pH 8), 0.2 M NaCl, 20 % PEG 6000",291.0,2020-12-17,2021-02-17,7L3L,3894.0,4.0,498.0,,,58.76,2.0,2.8,experimental,,0.2335,0.2038,Structure of TRAF5 and TRAF6 RING Hetero dimer
6X3A,X-RAY DIFFRACTION,2.57,52.19,"VAPOR DIFFUSION, HANGING DROP",,"200 mM Magnesium formate, 20% (w/v) PEG 3350",293.0,2020-05-21,2021-05-26,6X3A,2745.0,1.0,314.0,312.0,,34.96,1.0,1.77,experimental,37.99,0.2395,0.195,Crystal structure of the FN4-FN6 domains of human PTPRD
6F9T,X-RAY DIFFRACTION,2.37,48.18,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.1 M MIB Buffer pH 4.0, 5% Glycerol, 15% PEG 3350",289.0,2017-12-15,2018-03-07,6F9T,5794.0,1.0,591.0,686.0,3.0,71.76,1.0,1.6,experimental,,0.187,0.1647,Crystal structure of human testis Angiotensin-1 converting enzyme in complex with Sampatrilat.
6L3R,X-RAY DIFFRACTION,2.5,50.84,"VAPOR DIFFUSION, HANGING DROP",,"Sodium acetate buffer, PEG3350, Lithium sulfate",300.0,2019-10-15,2020-10-28,6L3R,10971.0,2.0,1338.0,323.0,,154.64,1.0,2,experimental,25.462,0.2319,0.1892,"Crystal structure of Ribonucleotide reductase R1 subunit, RRM1 in complex with 4-bromo-N-((1S,2R)-2-(naphthalen-1-yl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)benzenesulfonamide"
6L7L,X-RAY DIFFRACTION,2.44,49.57,"VAPOR DIFFUSION, HANGING DROP",,"Sodium acetate buffer, PEG3350, Lithium sulfate",300.0,2019-11-01,2020-11-04,6L7L,10456.0,2.0,1338.0,177.0,,154.94,1.0,2.171,experimental,37.703,0.2472,0.1907,"Crystal structure of Ribonucleotide reductase R1 subunit, RRM1 in complex with 5-chloro-2-(N-((1S,2R)-2-(2,3-dihydro-1H-inden-4-yl)-1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl)sulfamoyl)benzamide"
6OB0,X-RAY DIFFRACTION,2.74,55.05,"VAPOR DIFFUSION, SITTING DROP",,"0.15M calcium acetate, 18% PEG3350",298.0,2019-03-19,2019-05-08,6OB0,17194.0,8.0,2316.0,226.0,40.0,267.06,2.0,2.81,experimental,67.92,0.233,0.198,Compound 2 bound structure of WT Lipoprotein Lipase in Complex with GPIHBP1 Mutant N78D N82D produced in HEK293-F cells
6J4O,X-RAY DIFFRACTION,3.37,63.45,EVAPORATION,8.2,"1.6 M sodium/potassium phosphate, pH 8.2",293.0,2019-01-10,2019-05-01,6J4O,2583.0,2.0,317.0,232.0,,38.64,2.0,2.3,experimental,,0.2239,0.1842,Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
6J4S,X-RAY DIFFRACTION,2.72,54.79,EVAPORATION,6.8,"full-length V2-SVBP complex at a concentration of 15 mg/mL was crystallized in 1.8 M sodium/potassium phosphate, pH 6.8",293.0,2019-01-10,2019-05-01,6J4S,2400.0,2.0,421.0,68.0,,48.71,2.0,2.8,experimental,,0.2271,0.172,Structural basis of tubulin detyrosination by vasohibins-SVBP enzyme complex and functional implications
8AE5,X-RAY DIFFRACTION,4.01,69.36,"VAPOR DIFFUSION, SITTING DROP",,"1.6 M Ammonium Sulfate, 500 mM LiCl",277.0,2022-07-12,2022-09-28,8AE5,7053.0,4.0,880.0,80.0,,102.62,2.0,2.29,experimental,93.69,0.2578,0.2212,Crystal structure of human legumain in complex with macrocypin 1a
8A3Q,X-RAY DIFFRACTION,2.13,42.21,COUNTER-DIFFUSION,5.5,"25% PEG 6K, 0.10 M MES, pH 6.5, 14 mg/mL protein including 20 mM Benzamidine. 1:1 ratio of protein to mother liquor at 1 + 1 microliters over a 500 microliter reservoir at 18 Celsius",291.0,2022-06-08,2022-11-02,8A3Q,2034.0,1.0,263.0,64.0,4.0,29.78,1.0,1.801,experimental,49.74,0.2725,0.2353,Human Plasma Kallekrein in complex with 14W
5LT6,X-RAY DIFFRACTION,1.89,34.96,"VAPOR DIFFUSION, HANGING DROP",,"0.1MHepes,pH7.3, 0.1MKSCN, 25-30%MPEG2000.",293.0,2016-09-06,2016-10-05,5LT6,4032.0,2.0,590.0,263.0,,69.61,1.0,2.05,experimental,59.623,0.231,0.179,Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
7P49,X-RAY DIFFRACTION,2.22,44.7,"VAPOR DIFFUSION, SITTING DROP",,"3 M AS, 0.1 M MES pH 6",293.0,2021-07-10,2022-06-22,7P49,13373.0,12.0,1540.0,650.0,12.0,182.4,3.0,2.05,experimental,42.02,0.2791,0.2373,HLA-E*01:03 in complex with Mtb14
5HVF,X-RAY DIFFRACTION,2.52,51.12,"VAPOR DIFFUSION, HANGING DROP",3.5,"0.1 M citric acid, 25 % w/v PEG 3350",293.0,2016-01-28,2016-06-22,5HVF,4062.0,2.0,520.0,33.0,4.0,60.62,2.0,2.85,experimental,62.45,0.2295,0.1919,Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-i83)
8K78,X-RAY DIFFRACTION,2.35,47.68,"VAPOR DIFFUSION, HANGING DROP",,25% PEG 8K,298.0,2023-07-26,2024-07-31,8K78,2397.0,1.0,309.0,62.0,,35.25,1.0,2.67,experimental,,0.2898,0.2386,Crystal structure of cMET kinase domain bound by TPX-0022
5SAY,X-RAY DIFFRACTION,2.31,46.7,"VAPOR DIFFUSION, SITTING DROP",6.5,"9.2 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed with reservoir consisting of 0.1M MES/NaOH pH 6.5, 0.2M KI, 25% PEG 4000",293.0,2021-06-22,2022-06-29,5SAY,4895.0,2.0,642.0,180.0,,75.75,1.0,2.19,experimental,38.2046,0.277,0.2019,"DDR1, N-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 2.190A, P1211, Rfree=27.7%"
6BY9,X-RAY DIFFRACTION,2.25,45.28,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BIS-TRIS pH6.5,3.0M NaCl",298.0,2017-12-20,2018-01-31,6BY9,1971.0,1.0,328.0,4.0,,35.63,1.0,2.3,experimental,102.03,0.238,0.217,Crystal structure of EHMT1
6XAZ,X-RAY DIFFRACTION,2.35,47.67,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium cacodylate pH 6.5, 2.0 M ammonium sulfate, 0.2 M NaCl",277.0,2020-06-05,2021-06-09,6XAZ,2146.0,2.0,260.0,150.0,,30.17,1.0,1.7,experimental,38.36,0.2593,0.2114,Structure of the PR domain from human PRDM5
6LN1,X-RAY DIFFRACTION,3.02,59.21,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Bis-Tris, 17% PEG 1500, 30% ethylene glycol",277.0,2019-12-28,2021-10-06,6LN1,5610.0,2.0,694.0,44.0,,81.48,1.0,2.699,experimental,65.7556,0.2769,0.2123,A natural inhibitor of DYRK1A for treatment of diabetes mellitus
6SWM,X-RAY DIFFRACTION,2.29,46.33,"VAPOR DIFFUSION, SITTING DROP",8.5,"28-31% PEG4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5-9.0",296.0,2019-09-22,2020-10-07,6SWM,4103.0,2.0,522.0,82.0,,58.33,1.0,2.77,experimental,46.333,0.3295,0.2723,selenol bound carbonic anhydrase I
8WTF,X-RAY DIFFRACTION,2.2,44.12,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Ammonium sulfate,0.1M BisTris,5.5,25% w/vPEG 3350",293.0,2023-10-18,2023-11-15,8WTF,2506.0,1.0,297.0,165.0,,33.96,1.0,2,experimental,31.171,0.2363,0.18,The Crystal Structure of IRAK4 from Biortus
7ZHN,X-RAY DIFFRACTION,2.31,46.86,"VAPOR DIFFUSION, SITTING DROP",,"14-23% PEG 3350, 0.2 M sodium acetate pH 7.0 and 0.1 M tris pH 7.5-9.0",293.15,2022-04-06,2023-04-19,7ZHN,2668.0,1.0,309.0,196.0,,36.31,1.0,1.85,experimental,30.351,0.2145,0.1903,Crystal structure of TTBK1 in complex with AMG28
7ZHO,X-RAY DIFFRACTION,2.35,47.62,"VAPOR DIFFUSION, SITTING DROP",,"14-23% PEG 3350, 0.2 M sodium acetate pH 7.0 and 0.1 M tris pH 7.5-9.0",293.15,2022-04-06,2023-04-19,7ZHO,2613.0,1.0,309.0,151.0,,36.15,1.0,2.08,experimental,34.753,0.2575,0.1957,Crystal structure of TTBK1 in complex with compound 3 (7-001)
7ZHP,X-RAY DIFFRACTION,2.34,47.42,"VAPOR DIFFUSION, SITTING DROP",,"14-23% PEG 3350, 0.2 M sodium acetate pH 7.0 and 0.1 M tris pH 7.5-9.0",293.15,2022-04-06,2023-04-19,7ZHP,2664.0,1.0,309.0,209.0,,36.34,1.0,1.8,experimental,31.494,0.218,0.1765,Crystal structure of TTBK1 in complex with compound 9 (7-005)
7ZHQ,X-RAY DIFFRACTION,2.3,46.63,"VAPOR DIFFUSION, SITTING DROP",,"14-23% PEG 3350, 0.2 M sodium acetate pH 7.0 and 0.1 M tris pH 7.5-9.0",293.15,2022-04-06,2023-04-19,7ZHQ,2665.0,1.0,309.0,183.0,,36.52,1.0,1.8,experimental,25.998,0.2117,0.1738,Crystal structure of TTBK1 in complex with compound 10 (7-009)
8GVL,X-RAY DIFFRACTION,2.64,53.43,"VAPOR DIFFUSION, HANGING DROP",,MPD,277.0,2022-09-15,2023-09-20,8GVL,4997.0,2.0,602.0,237.0,,70.57,1.0,2.1,experimental,50.1404,0.2296,0.1925,PTPN21 FERM
5EAK,X-RAY DIFFRACTION,2.87,57.09,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BIS-TRIS PH 6.5, 14% PEG3350, 200MM AMM.SULFATE",298.0,2015-10-16,2016-02-17,5EAK,4981.0,2.0,656.0,6.0,,76.51,1.0,2.8,experimental,33.29,0.254,0.195,Optimization of Microtubule Affinity Regulating Kinase (MARK) Inhibitors with Improved Physical Properties
5T0M,X-RAY DIFFRACTION,2.34,47.42,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris propane (pH 7.5), 18% (w/v) PEG3350, 0.2 M NaF, and 5% (v/v) ethylene glycol",293.15,2016-08-16,2016-10-05,5T0M,4891.0,4.0,592.0,352.0,2.0,69.73,2.0,1.896,experimental,,0.224,0.1845,A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading
6KZC,X-RAY DIFFRACTION,2.14,42.57,"VAPOR DIFFUSION, HANGING DROP",,"0.1MMES, pH
6.0, 0.15M (NH4)2SO4, 15% PEG 4000",277.0,2019-09-23,2019-10-09,6KZC,2493.0,1.0,312.0,205.0,,36.35,1.0,2,experimental,26.3988,0.2253,0.1869,"crystal structure of TRKc in complex with 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methyl-N-(3-((4- methylpiperazin-1-yl)methyl)-5- (trifluoromethyl)phenyl)benzamide"
6KZD,X-RAY DIFFRACTION,2.14,42.59,"VAPOR DIFFUSION, HANGING DROP",,"0.1MMES, pH
6.0, 0.15M (NH4)2SO4, 15% PEG 4000",277.0,2019-09-23,2019-10-09,6KZD,2604.0,1.0,312.0,300.0,,36.51,1.0,1.708,experimental,20.7559,0.1836,0.1587,"Crystal structure of TRKc in complex with 3-((6-(4-aminophenyl)imidazo[1,2-a]pyrazin-3-yl)ethynyl)- N-(3-isopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-2- methylbenzamide"
5ANQ,X-RAY DIFFRACTION,2.59,52.0,,,"0.233 M LITHIUM SULFATE, 24% PEG 3350, 0.1 M HEPES PH 7.5",,2015-09-07,2016-03-23,5ANQ,6125.0,2.0,718.0,351.0,,84.92,1.0,2,experimental,46.636,0.23242,0.18939,inhibitors of JumonjiC domain-containing histone demethylases
8JYR,X-RAY DIFFRACTION,2.63,53.19,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Sodium citrate pH5.5, 20% w/v PEG3000",293.0,2023-07-03,2024-03-13,8JYR,5232.0,3.0,642.0,475.0,8.0,70.77,3.0,1.69,experimental,38.2,0.2087,0.1734,Crystal structure of anti-HER2 antibody H2Mab-119 in complex with HER2 domain I
5I2Z,X-RAY DIFFRACTION,2.8,56.02,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-ligand:  hMMP12 F67D E219Q at 465 micro-M, 20 milli-M  acetohydroxamic acid in 0.020M Tris-HCl, 3 milli-M CaCl2, 0.2M NaCl, pH 7.5, 0.2 milli-M inhibitor (DC24) 10% DMSO
Precipitant: 35% PEG4K, 0.2M imidazole piperidine, 15% dioxane, pH 8.5.
Cryoprotectant: 
40% cryomix: (25 % diethylene glycol + 12.5 % glycerol + 25 % 1,2-propanediol + 12.5 % 1,4-dioxane) 25% PEG 6K, 100mM TRIS HCl, pH 8.0",293.0,2016-02-09,2016-07-06,5I2Z,5714.0,4.0,636.0,484.0,,74.73,1.0,2.3,experimental,,0.263,0.214,Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated triazole-linked carboxylate chelating water-soluble inhibitor (DC24).
5I3M,X-RAY DIFFRACTION,2.19,43.96,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-ligand: hMMP12 F67D E219Q 465 micro-M, 0.02M acetohydroxamic acid 0.5 milli-M inhibitor (DC31) 10% DMSO.
Precipitant: 32.4% PEG 4K, 8% dioxane, 0.2M imidazole piperidine, pH 8.5.
Cryoprotectant: 
40% cryomix:(12.5 % diethylene glycol + 12.5 % glycerol + 12.5 % 1,2-propanediol + 25 % DMSO + 25 % 1,4-dioxane) 12% PEG 4K, 10% Dioxane, 0.1 M imidazole piperidine pH 8.5.",293.0,2016-02-10,2016-07-06,5I3M,5646.0,4.0,636.0,432.0,,74.65,1.0,2.17,experimental,36.572,0.25324,0.20615,Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated thiourea-linked carboxylate zinc-chelator water-soluble inhibitor (DC31).
5I43,X-RAY DIFFRACTION,2.2,44.2,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-ligand: hMMP12 F171D E219Q 465 micro-M in 0.020 M Tris-HCl, 3 milli-M CaCl2, 0.2 M NaCl, 0.02 M acetohydroxamic acid, 10% DMSO, pH 7.5, 0.5 milli-M inhibitor (DC31).
Precipitant: 40% PEG4K, 9% dioxane, 0.18 M imidazole piperidine,  pH 8.5.
Cryoprotectant: 40% cryomix SM2:(12.5 % ethylene glycol + 12.5 % glycerol + 12.5 % 1,2-propanediol + 25 % DMSO + 37.5 % 1,4-dioxane), 22.5% MPEG 4K, 5% dioxane, 100 mM imidazole piperidine pH 8.5.",295.0,2016-02-11,2016-07-06,5I43,6013.0,4.0,636.0,604.0,,76.71,1.0,1.95,experimental,27.062,0.23323,0.20039,Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated triazole-linked carboxylate chelator water-soluble inhibitor (DC32).
5YCO,X-RAY DIFFRACTION,4.27,71.18,"VAPOR DIFFUSION, SITTING DROP",,"2 M ammonium sulfate, 0.1 M Tris pH 8.0",289.0,2017-09-07,2017-11-15,5YCO,8224.0,6.0,1110.0,324.0,1.0,124.6,2.0,2.199,experimental,48.4451,0.2201,0.2039,Complex structure of PCNA with UHRF2
8TBX,X-RAY DIFFRACTION,2.4,48.68,"VAPOR DIFFUSION, SITTING DROP",,"0.04M Potassium phosphate monobasic,16%w/v PEG 8K,20% v/v Glycerol",291.0,2023-06-29,2023-07-26,8TBX,3476.0,1.0,470.0,12.0,,52.91,1.0,2.71,experimental,47.552,0.28647,0.20257,Crystal structure of human DDX1 helicase in complex with ADP
5KOQ,X-RAY DIFFRACTION,3.0,59.01,"VAPOR DIFFUSION, SITTING DROP",7.6,"23% PEG600, 100 mM citric acid",293.0,2016-07-01,2016-11-02,5KOQ,5244.0,2.0,674.0,87.0,6.0,75.25,1.0,2.7,experimental,66.226,0.2515,0.2038,"Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor"
7OLX,X-RAY DIFFRACTION,2.27,45.86,VAPOR DIFFUSION,,"0.1 M Tris pH 8.5, 4.3 M NaCl",293.0,2021-05-20,2021-09-15,7OLX,2258.0,1.0,298.0,66.0,,35.09,1.0,1.98,experimental,58.651,0.251,0.2031,MerTK kinase domain with type 1.5 inhibitor containing a tri-methyl pyrazole group
4UXN,X-RAY DIFFRACTION,4.23,77.0,,6.5,PH 6.5,,2014-08-27,2015-02-25,4UXN,6374.0,2.0,1334.0,,,147.28,2.0,2.85,experimental,78.9,0.21509,0.20615,LSD1(KDM1A)-CoREST in complex with Z-Pro derivative of MC2580
6KGK,X-RAY DIFFRACTION,6.93,82.25,"VAPOR DIFFUSION, HANGING DROP",,"0.1M N-(carbamoylmethyl)iminodiacetic acid (pH 5.5), 1.23 M potassium sodium tartrate",293.0,2019-07-12,2020-03-25,6KGK,6383.0,2.0,809.0,53.0,,91.52,2.0,2.7,experimental,,0.2064,0.1772,LSD1-CoREST-S2101 five-membered ring adduct model
6KGL,X-RAY DIFFRACTION,6.93,82.25,"VAPOR DIFFUSION, HANGING DROP",,"0.1M N-(carbamoylmethyl)iminodiacetic acid (pH 5.5), 1.28 M potassium sodium tartrate",293.0,2019-07-12,2020-03-25,6KGL,6383.0,2.0,809.0,53.0,,91.52,2.0,2.7,experimental,92.34,0.2048,0.1772,LSD1-CoREST-S2101 N5 adduct model
6KGM,X-RAY DIFFRACTION,7.02,82.47,"VAPOR DIFFUSION, HANGING DROP",,"0.1M N-(carbamoylmethyl)iminodiacetic acid (pH 5.5), 1.28 M potassium sodium tartrate",293.0,2019-07-12,2020-03-25,6KGM,6396.0,2.0,809.0,54.0,,91.71,2.0,2.62,experimental,90.42,0.1947,0.1755,LSD1-CoREST-S2116 five-membered ring adduct model
6KGN,X-RAY DIFFRACTION,7.02,82.47,"VAPOR DIFFUSION, HANGING DROP",,"0.1M N-(carbamoylmethyl)iminodiacetic acid (pH 5.5), 1.28 M potassium sodium tartrate",293.0,2019-07-12,2020-03-25,6KGN,6396.0,2.0,809.0,54.0,,91.71,2.0,2.62,experimental,90.35,0.1944,0.1751,LSD1-CoREST-S2116 N5 adduct model
4W93,X-RAY DIFFRACTION,2.36,47.81,"VAPOR DIFFUSION, HANGING DROP",7.5,"58% MPD, 100 mM sodium cacodylate",300.0,2014-08-27,2015-07-15,4W93,4501.0,1.0,496.0,468.0,5.0,57.24,1.0,1.352,experimental,18.5,0.2113,0.1976,Human pancreatic alpha-amylase in complex with montbretin A
7A12,X-RAY DIFFRACTION,2.65,53.65,"VAPOR DIFFUSION, HANGING DROP",7.4,"200mM potassium phosphate pH 7.4, 100mM MnCl2, 5mM dithiothreitol (DTT) and 25-50% 2-methyl-2,4-pentanediol (MPD)",293.0,2020-08-11,2020-09-23,7A12,3266.0,1.0,371.0,305.0,1.0,42.75,1.0,2,experimental,36.66,0.198,0.178,CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GW557358X (COMPOUND 9)
7A13,X-RAY DIFFRACTION,2.69,54.28,"VAPOR DIFFUSION, HANGING DROP",7.4,"200mM potassium phosphate pH 7.4, 100mM MnCl2, 5mM dithiothreitol (DTT) and 25-50% 2-methyl-2,4-pentanediol (MPD).",293.0,2020-08-11,2020-09-23,7A13,3282.0,1.0,371.0,326.0,1.0,42.59,1.0,2.04,experimental,32.22,0.197,0.166,CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK1978537A (COMPOUND 27)
7SZL,X-RAY DIFFRACTION,3.08,60.13,"VAPOR DIFFUSION, HANGING DROP",,"2.4 M sodium malonate, pH 5.0",293.15,2021-11-28,2022-02-02,7SZL,1285.0,1.0,160.0,2.0,,18.92,1.0,2.3,experimental,82.89,0.2613,0.2385,Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1R10 (IL-1RAPL2)
6CKX,X-RAY DIFFRACTION,2.49,50.56,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES (PH 6.5), 18% PEG 3350,
 0.2 M MGCL2, AND 1 MM SARCOSINE, VAPOR DIFFUSION, HANGING DROP,
 TEMPERATURE 297K",298.0,2018-03-01,2018-08-29,6CKX,8720.0,4.0,1238.0,38.0,,145.34,2.0,2.8,experimental,85.84,0.251,0.208,"Structure of CDK12/CycK in complex with a small molecule inhibitor N-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-((1r,4r)-4-(quinazolin-2-ylamino)cyclohexyl)acetamide"
5ZZ4,X-RAY DIFFRACTION,2.34,47.36,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1M imidazole(pH7.0), 0.1 M Potassium thiocyanate, 30% w/v PEG MME 2000, 4% Polypropylene glycol P 400",277.0,2018-05-30,2018-09-26,5ZZ4,12800.0,6.0,1608.0,,,190.47,1.0,2.9,experimental,48.881,0.3165,0.222,Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2e
6ZFZ,X-RAY DIFFRACTION,3.09,60.2,LIPIDIC CUBIC PHASE,,"0.1M NaHEPES pH 7.4-7.8, 0.1M di-ammonium hydrogenphosphate, 30-38% PEG300",293.0,2020-06-18,2021-10-06,6ZFZ,3855.0,1.0,455.0,33.0,2.0,55.41,1.0,2.17,experimental,47.75,0.242,0.214,Structure of M1-StaR-T4L in complex with 77-LH-28-1 at 2.17A
6ZG4,X-RAY DIFFRACTION,3.05,59.72,LIPIDIC CUBIC PHASE,,"0.1M NaHEPES pH 7.4-7.8, 0.1M di-Ammonium hydrogenphosphate, 30-38% PEG300",293.0,2020-06-18,2021-10-06,6ZG4,3899.0,1.0,455.0,72.0,2.0,55.74,1.0,2.33,experimental,35.72,0.234,0.204,Structure of M1-StaR-T4L in complex with HTL0009936 at 2.35A
6ZG9,X-RAY DIFFRACTION,3.16,61.08,LIPIDIC CUBIC PHASE,,"0.1 NaHEPES pH 7.4-7.8, 0.1M di-ammonium hydrogenohosphate, 30-38% PEG300",293.0,2020-06-18,2021-10-06,6ZG9,3741.0,1.0,455.0,23.0,2.0,54.19,1.0,2.5,experimental,52.08,0.242,0.203,Structure of M1-StaR-T4L in complex with GSK1034702 at 2.5A
5KCO,X-RAY DIFFRACTION,2.38,48.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG-3350, 0.2M lithium sulfate, 0.1M bis-tris. Trypsin had been added to the protein stock solution.",291.0,2016-06-06,2016-07-27,5KCO,2017.0,1.0,225.0,143.0,,31.48,1.0,1.47,experimental,20.634,0.2154,0.1829,"SETDB1 in complex with an early stage, low affinity fragment candidate modelled at reduced occupancy"
6C90,X-RAY DIFFRACTION,3.59,65.72,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M sodium-potassium (L)-tartrate, 0.1 M Bis-Tris pH 6.5",291.0,2018-01-25,2018-05-30,6C90,6228.0,2.0,786.0,238.0,,90.11,2.0,2.2,experimental,,0.2214,0.1903,Human Mtr4 helicase in complex with ZCCHC8-CTD
7B8H,X-RAY DIFFRACTION,1.98,38.0,"VAPOR DIFFUSION, SITTING DROP",,"1 microliter protein stock solution (8 mg/ml CK2alpha, 2 mM Heparin dodecasaccharide, 285.7 mM NaCl, 15 mM Tris, pH 8.5) was mixed with 2.5 microliter reservoir solution (32 %(w/v) PEG4000, 0.2 M malonate, 0.1 M Tris, pH 7.5). The resulting drop was equilibrated against 800 microliter reservoir solution. After equilibration the crystallization process was initialized by addition of 150 nanoliter micro seeding suspension. CK2alpha/heparin crystals grown in this way were prepared for cryo diffractometry by soaking them into a cryo solution consisting of 32 % (w/v) PEG4000, 0.2 M NaCl, 0.5 mM Heparin dodecasaccharide.",293.15,2020-12-12,2021-02-03,7B8H,3319.0,1.0,335.0,331.0,,41.71,1.0,1.34,experimental,,0.1639,0.1536,Monoclinic structure of human protein kinase CK2 catalytic subunit in complex with a heparin oligo saccharide
5VZ5,X-RAY DIFFRACTION,3.63,66.0,VAPOR DIFFUSION,,"0.1M Hepes (7.5)
2M Ammonium sulfate
2% PEG400",295.0,2017-05-26,2018-03-21,5VZ5,3275.0,3.0,390.0,24.0,3.0,46.6,3.0,2.5901,experimental,,0.2653,0.2158,Crystal structure of an anaplastic lymphoma kinase-derived neuroblastoma tumor antigen bound to the Human Major Histocompatibility Complex Class I molecule HLA-B*1501
7UYK,X-RAY DIFFRACTION,3.49,64.77,"VAPOR DIFFUSION, SITTING DROP",,"10% w/v glycerol, 20% w/v ethanol",293.15,2022-05-06,2022-12-28,7UYK,2501.0,4.0,366.0,10.0,,41.46,2.0,2.7,experimental,81.62,0.2455,0.198,"Structure of RNF31 in complex with FP06655, a Helicon Polypeptide"
6TFP,X-RAY DIFFRACTION,3.45,64.31,"VAPOR DIFFUSION, SITTING DROP",,3.5 M sodium formate,293.0,2019-11-14,2020-03-04,6TFP,11545.0,5.0,1380.0,653.0,,162.65,1.0,2,experimental,58.88,0.204,0.186,"BTK in complex with LOU064, a potent and highly selective covalent inhibitor"
6EJA,X-RAY DIFFRACTION,2.48,50.35,"VAPOR DIFFUSION, HANGING DROP",7.5,"55-65% Morpheus Precipitant mix 2 (PEG8000 and Ethylene glycol)
0.1M Bicine/Tris buffer at pH 7.5
0.1M of NPS mix (0.033M of each)",293.0,2017-09-20,2018-05-02,6EJA,5776.0,2.0,763.0,225.0,7.0,87.34,2.0,1.94,experimental,56.5414,0.2125,0.1844,Human Xylosyltransferase 1 in complex with peptide QEEEYSGGGQGG
6EJB,X-RAY DIFFRACTION,2.56,51.94,"VAPOR DIFFUSION, HANGING DROP",7.5,"55-65% Morpheus Precipitant mix 2 (PEG8000 and Ethylene glycol)
0.1M Bicine/Tris buffer at pH 7.5
0.1M of NPS mix (0.033M of each)",293.0,2017-09-20,2018-05-02,6EJB,5623.0,2.0,763.0,10.0,6.0,87.32,2.0,2.557,experimental,44.3944,0.2795,0.2393,Human Xylosyltransferase 1 in complex with peptide QEEEGSAGGQGG
6EJD,X-RAY DIFFRACTION,2.6,52.63,"VAPOR DIFFUSION, HANGING DROP",,"55-65% Morpheus Precipitant mix 2 (PEG8000 and Ethylene glycol)
0.1M Bicine/Tris buffer at pH 7.5
0.1M of NPS mix (0.033M of each)",293.0,2017-09-20,2018-05-02,6EJD,5533.0,2.0,763.0,6.0,7.0,87.35,2.0,2.684,experimental,39.9548,0.2793,0.2441,Human Xylosyltransferase 1 in complex with peptide QEEEGSGGPQGG
6SHH,X-RAY DIFFRACTION,2.64,53.37,"VAPOR DIFFUSION, HANGING DROP",,"2.9 M ammonium sulphate, 0.1 M HEPES, pH 8.5, 0.5- 2 % PEG 3350",277.0,2019-08-06,2020-05-20,6SHH,15503.0,8.0,1792.0,1149.0,48.0,207.42,1.0,2,experimental,43.07,0.226,0.189,Human kallikrein 7 with aromatic coumarinic ester compound 1 covalently bound to H57
6SHI,X-RAY DIFFRACTION,2.65,53.65,"VAPOR DIFFUSION, HANGING DROP",8.5,"2.9 M ammonium sulphate, 0.1 M HEPES, pH 8.5, 0.5- 2 % PEG 3350",277.0,2019-08-06,2020-05-20,6SHI,16261.0,8.0,1792.0,1887.0,48.0,206.92,1.0,1.85,experimental,33.78,0.208,0.176,Human kallikrein 7 with aromatic coumarinic ester compound 2 covalently bound to H57
6SJU,X-RAY DIFFRACTION,2.65,53.64,"VAPOR DIFFUSION, HANGING DROP",8.5,"2.9 M ammonium sulphate, 0.1 M HEPES, pH 8.5, 0.5- 2 % PEG 3350",277.0,2019-08-13,2020-05-20,6SJU,15842.0,8.0,1792.0,1433.0,48.0,209.12,1.0,1.97,experimental,44.11,0.221,0.174,Human kallikrein 7 with aromatic coumarinic ester compound 3 covalently bound to H57
6ACL,X-RAY DIFFRACTION,2.3,46.52,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M sodium cacodylate (pH 5.5), 25% w/v PEG 4000",295.0,2018-07-26,2019-07-24,6ACL,2286.0,2.0,277.0,157.0,,30.36,2.0,1.92,experimental,29.842,0.22246,0.16893,histone lysine desuccinylase Sirt5 in complex with succinyl peptide H2AK95
6ACP,X-RAY DIFFRACTION,2.23,44.78,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M BIS-TRIS (pH 5.5), 25% w/v PEG 3350",295.0,2018-07-26,2019-07-24,6ACP,2108.0,2.0,274.0,9.0,,30.06,2.0,2.3,experimental,69.033,0.2851,0.20327,histone lysine desuccinylase Sirt5 in complex with succinyl peptide H4K91
5UM3,X-RAY DIFFRACTION,1.72,28.29,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5
25% PEG 4000",295.0,2017-01-26,2017-03-22,5UM3,669.0,1.0,75.0,92.0,,8.45,1.0,1.198,experimental,,0.1583,0.1369,Crystal structure of the V122L mutant of human UBR-box domain from UBR2
7EZG,X-RAY DIFFRACTION,3.12,60.6,"VAPOR DIFFUSION, SITTING DROP",9.0,PEGRX F7?25% PEG1500?0.1M BIS-Tris pH9.0?0.1M NaCl,298.0,2021-06-01,2022-01-12,7EZG,2407.0,1.0,305.0,170.0,1.0,36.17,1.0,1.9,experimental,37.01,0.2005,0.1791,The structure of the human METTL6 enzyme in complex with SAH
5O76,X-RAY DIFFRACTION,2.22,51.42,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M monosaccharides, 0.1 M Buffer 1 pH 6.5, 50% Precipitant 2, Morpheus screen",293.0,2017-06-08,2017-11-01,5O76,7879.0,6.0,970.0,235.0,,111.58,3.0,2.473,experimental,69.77,0.248,0.218,Structure of phosphoY371 c-CBL in complex with ZAP70-peptide and UbV.pCBL ubiquitin variant
6H42,X-RAY DIFFRACTION,2.64,53.46,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris pH 7.8
200 mM KBr
200 mM KSCN
3 % (w/v) PGA-LM
5 % PEG 4000",273.0,2018-07-20,2018-09-05,6H42,6158.0,2.0,786.0,99.0,,87.26,1.0,2.45,experimental,67.1975,0.2313,0.2024,crystal structure of the human TGT catalytic subunit QTRT1
4UEM,X-RAY DIFFRACTION,2.7,54.0,,,"100 MM BIS-TRIS-PROPANE PH 6.4, 230 MM NABR, 21% PEG3350. 4 DEGREES CELSIUS",277.0,2014-12-18,2015-03-04,4UEM,2989.0,2.0,458.0,,,50.8,2.0,2.82,experimental,,0.2813,0.2318,UCH-L5 in complex with the RPN13 DEUBAD domain
7UP7,X-RAY DIFFRACTION,2.26,45.5,"VAPOR DIFFUSION, SITTING DROP",8.0,"Crystals were produced by sitting drop vapor diffusion with an equal volume of the protein, Msk1-C terminal domain (PID7059-1, CID101276) at 5 mg/ml with 1.5mM UCB1590591/BSI106893 in 25mM HEPES pH 7.5, 150mM NaCl, 5% Glycerol, 5mM BME and a crystallization buffer containing 100mM sodium malonate pH 8.0, 100mM Tris pH 8.0, 30% w/v PEG 1000 (tray ID 305760, well F2, CID101276_fine1 screen). Crystals were soaked for 4 days in 2.5ul of reservoir with 1mM UCB1590956/BSI100006.Crystals were cryo protected with 20% EG + compound and vitrified in in liquid N2. Puck ID WJP9-1",289.0,2022-04-14,2022-07-20,7UP7,4324.0,2.0,612.0,23.0,2.0,70.24,1.0,2.8,experimental,54.16,0.2444,0.1813,Crystal structure of C-terminal Domain of MSK1 in complex with covalently bound with literature RSK2 inhibitor indazole cyanoacrylamide compound 26 (soak)
8BCH,X-RAY DIFFRACTION,3.35,63.23,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1M sodium citrate, 1.5M sodium malonate",291.15,2022-10-15,2023-03-08,8BCH,13884.0,1.0,1747.0,11.0,,199.88,1.0,2.87,experimental,119.71,0.3374,0.2815,Human Brr2 Helicase Region in complex with Sulfaguanidine
5KYC,X-RAY DIFFRACTION,2.08,40.87,"VAPOR DIFFUSION, HANGING DROP",4.0,"8% tacsimate pH 4.0, 20% PEG3350",292.0,2016-07-21,2017-08-09,5KYC,3958.0,2.0,427.0,500.0,,49.48,2.0,1.426,experimental,21.2826,0.1916,0.1701,Crystal structure of USP7 catalytic domain [V302K] mutant in complex with ubiquitin (malonate bound)
5KYF,X-RAY DIFFRACTION,2.15,42.85,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES pH 7.5, 25% PEG3350",292.0,2016-07-21,2017-08-09,5KYF,3888.0,2.0,427.0,468.0,,49.31,2.0,1.45,experimental,20.989,0.1852,0.1757,Crystal structure of USP7 catalytic domain [L299A] mutant in complex with ubiquitin
6VC9,X-RAY DIFFRACTION,3.02,59.3,"VAPOR DIFFUSION, SITTING DROP",,"0.1M sodium potassium phosphate pH 6.2, 35% 5-methyl-2,4-pentanediol, and 2.5% pentaerythritol ethoxylate",277.0,2019-12-20,2020-11-11,6VC9,6035.0,3.0,977.0,126.0,6.0,109.09,3.0,2.25,experimental,60.829,0.2785,0.2366,TB19 complex
5QCQ,X-RAY DIFFRACTION,3.1,60.26,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE IN WATER. PROTEIN STOCK WAS
BACE MUT46B BATCH XII 8.5MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 5-FOLD EXCESS OF BMC025 ADDED FROM A 50MM
STOCK SOLUTION IN 90% DMSO-D6 (1.8% DMSO IN DROP). A SOLUTION CONTAINING 1.2M AMMONIUM SULFATE, 25% GLYCEROL, 1MM BMC025
AND 1.8% DMSO WAS USED AS CRYO-PROTECTANT.",292.0,2017-12-01,2020-06-03,5QCQ,9515.0,3.0,1206.0,639.0,9.0,135.8,1.0,1.97,experimental,39.15,0.195,0.167,Crystal structure of BACE complex with BMC025
5QDC,X-RAY DIFFRACTION,3.05,59.7,hanging drop,5.0,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM PHOSPHATE, 0.1M SODIUM CITRATE PH
5.0. PROTEIN STOCK WAS BACE MUT46B BATCH XIV 7.4MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 6-FOLD EXCESS OF BMC019
ADDED FROM A 50MM STOCK SOLUTION IN DMSO. CRYO-PROTECTANT WAS 1.0M AMMONIUM PHOSPHATE, 0.1M SODIUM CITRATE,
25%(V/V)GLYCEROL, 2.0% DMSO, 1MM BMC019.",292.0,2017-12-01,2020-06-03,5QDC,9258.0,3.0,1206.0,329.0,9.0,135.94,1.0,2.1,experimental,51.11,0.195,0.171,Crystal structure of BACE complex with BMC019 hydrolyzed
8DY8,X-RAY DIFFRACTION,2.35,47.59,"VAPOR DIFFUSION, SITTING DROP",7.0,"2.4 M Ammonium Sulfate, 0.1 M HEPES",298.0,2022-08-03,2023-08-09,8DY8,3318.0,2.0,456.0,99.0,,50.79,1.0,2.1,experimental,,0.2645,0.2218,Crystal structure of the R178Q mutant of ubiquitin carboxy terminal hydrolase L1 (UCH-L1)
8OXG,X-RAY DIFFRACTION,2.88,57.27,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Ammonium sulfate, 0.1M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3,350",293.0,2023-05-02,2024-04-10,8OXG,6433.0,2.0,768.0,568.0,2.0,87.6,1.0,1.731,experimental,28.255,0.215,0.1811,"Crystal structure of human methionine aminopeptidase-2 complexed with (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl N-(trans-4-aminocyclohexyl)carbamate"
5HD0,X-RAY DIFFRACTION,2.95,58.36,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 200mM K/Na tatrate, 100mM Hepes, pH 7.0",277.0,2016-01-04,2016-03-16,5HD0,6997.0,2.0,828.0,865.0,6.0,93.7,1.0,1.65,experimental,23.8885,0.2302,0.2034,"BACE-1 in complex with (7aR)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5-fluoropyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium"
5HDU,X-RAY DIFFRACTION,2.94,58.2,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277.0,2016-01-05,2016-03-16,5HDU,7042.0,2.0,828.0,898.0,6.0,93.76,1.0,1.58,experimental,22.5027,0.2138,0.1922,"BACE-1 incomplex with (7aR)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5-fluoro-4-methoxypyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium"
5HDV,X-RAY DIFFRACTION,2.95,58.34,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277.0,2016-01-05,2016-03-16,5HDV,7039.0,2.0,828.0,947.0,6.0,93.48,1.0,1.71,experimental,21.6408,0.204,0.1823,"BACE-1 incomplex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium"
5HE4,X-RAY DIFFRACTION,2.94,58.15,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277.0,2016-01-05,2016-03-16,5HE4,7094.0,2.0,828.0,971.0,6.0,93.49,1.0,1.53,experimental,20.0398,0.2217,0.203,"BACE-1 in complex with (4aR,7aS)-7a-(2,6-difluorophenyl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium"
5HE5,X-RAY DIFFRACTION,2.94,58.22,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277.0,2016-01-05,2016-03-16,5HE5,7061.0,2.0,828.0,939.0,6.0,93.63,1.0,1.55,experimental,17.8706,0.2012,0.1851,"BACE-1 in complex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4-methyl-6-(methylamino)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium"
7XGJ,X-RAY DIFFRACTION,2.2,44.13,VAPOR DIFFUSION,7.0,"20 % w/v Polyethylene glycol 6,000,  100 mM HEPES pH 7.5,  200mM Magnesium chloride",293.0,2022-04-05,2022-06-29,7XGJ,4210.0,6.0,528.0,38.0,,60.14,2.0,2.8,experimental,38.475,0.28028,0.224,Crystal structure of human MMP-2 catalytic domain in complex with inhibitor
5J1V,X-RAY DIFFRACTION,2.45,49.86,"VAPOR DIFFUSION, SITTING DROP",,"30% 1,2-propanediol, 10% glycerol and 50 mM Na/K phosphate pH 7.2",277.15,2016-03-29,2016-05-04,5J1V,8082.0,3.0,1017.0,95.0,,119.56,1.0,2.52,experimental,71.461,0.24366,0.1991,"Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW29 (compound 13)"
7O50,X-RAY DIFFRACTION,2.26,45.57,"VAPOR DIFFUSION, SITTING DROP",4.5,22 % PEG 3350 and 0.1 M sodium acetate pH 4.5,293.0,2021-04-07,2021-09-22,7O50,4811.0,4.0,532.0,427.0,,62.21,2.0,1.9,experimental,22.3537685644,0.219472983595,0.192251827999,Crystal structure of human legumain in complex with Gly-Ser-Asn peptide
5V21,X-RAY DIFFRACTION,2.39,48.58,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M KSCN, 24% (v/v) PEG 2000 MME",293.0,2017-03-02,2017-03-22,5V21,2147.0,2.0,312.0,36.0,,36.6,2.0,2.415,experimental,,0.2693,0.204,Crystal structure of human SETD2 SET-domain in complex with H3K36M peptide and SAM
6N2W,X-RAY DIFFRACTION,2.34,47.44,"VAPOR DIFFUSION, SITTING DROP",6.0,8-10% Tacsimate,293.0,2018-11-14,2020-05-13,6N2W,10045.0,2.0,1382.0,171.0,,159.29,1.0,2.71,experimental,49.54,0.2626,0.2129,The structure of Stable-5-Lipoxygenase bound to NDGA
7OVI,X-RAY DIFFRACTION,2.46,49.91,"VAPOR DIFFUSION, HANGING DROP",,"180-220 mM sodium citrate,
15-25 % PEG3350",277.0,2021-06-15,2022-07-20,7OVI,2178.0,1.0,318.0,83.0,,36.59,1.0,1.95,experimental,58.2,0.2504,0.2092,Protein kinase MKK7 in complex with phenethyltriazole-substituted pyrazolopyrimidine
7OVJ,X-RAY DIFFRACTION,2.42,49.08,"VAPOR DIFFUSION, HANGING DROP",,"180-220 mM sodium citrate,
15-25 % PEG3350",277.0,2021-06-15,2022-07-20,7OVJ,2237.0,1.0,318.0,77.0,,36.66,1.0,2.35,experimental,57.81,0.2445,0.2017,Protein kinase MKK7 in complex with difluoro-phenethyltriazole-substituted pyrazolopyrimidine
7OVL,X-RAY DIFFRACTION,2.39,48.51,"VAPOR DIFFUSION, HANGING DROP",,"180-220 mM sodium citrate,
15-25 % PEG3350",277.0,2021-06-15,2022-07-20,7OVL,2203.0,1.0,318.0,3.0,,36.65,1.0,2.9,experimental,99.68,0.2703,0.2471,Protein kinase MKK7 in complex with methoxycyclohexyl-substituted indazole
7OVM,X-RAY DIFFRACTION,2.43,49.38,"VAPOR DIFFUSION, HANGING DROP",,"180-220 mM sodium citrate,
15-25 % PEG3350",277.0,2021-06-15,2022-07-20,7OVM,2211.0,1.0,318.0,1.0,,36.59,1.0,2.9,experimental,85.27,0.2858,0.2298,Protein kinase MKK7 in complex with cyclobutyl-substituted indazole
7OVN,X-RAY DIFFRACTION,2.46,49.95,"VAPOR DIFFUSION, HANGING DROP",,"180-220 mM sodium citrate,
15-25 % PEG3350",277.0,2021-06-15,2022-07-20,7OVN,2238.0,1.0,318.0,,,36.63,1.0,2.9,experimental,72.85,0.2572,0.2234,Protein kinase MKK7 in complex with tolyl-substituted indazole
5NUT,X-RAY DIFFRACTION,2.42,49.11,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LiSO4, 0.1 M Tris HCl, 24% PEG3350",277.0,2017-05-02,2018-03-14,5NUT,3831.0,2.0,480.0,297.0,,55.95,1.0,1.6,experimental,27.175,0.19852,0.17604,"Crystal structure of TNKS2 in complex with 2-[4-(propan-2-yloxy)phenyl]-3,4-dihydroquinazolin-4-one"
8F10,X-RAY DIFFRACTION,1.81,32.18,"VAPOR DIFFUSION, SITTING DROP",,"0.01 M tri-Sodium citrate, 33 % w/v PEG 6000",291.0,2022-11-04,2023-02-15,8F10,1062.0,2.0,114.0,105.0,,13.79,2.0,1.28,experimental,18.4648,0.1669,0.154,"Structure of the MDM2 P53 binding domain in complex with H102, an all-D Helicon Polypeptide"
5M6R,X-RAY DIFFRACTION,2.83,56.6,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.1 M Na HEPES pH 7.2, 0.9 M Na dihydrogen phosphate/0.9 M K dihydrogen phosphate",294.0,2016-10-25,2017-11-15,5M6R,5277.0,2.0,778.0,23.0,,87.64,1.0,2.73,experimental,91.53,0.246,0.197,Human porphobilinogen deaminase in complex with reaction intermediate
8OUU,X-RAY DIFFRACTION,2.35,47.56,"VAPOR DIFFUSION, SITTING DROP",,"2 M Na formate, 0.1 M Na acetate pH 4.6",293.0,2023-04-24,2023-07-05,8OUU,5064.0,2.0,618.0,432.0,,70.82,1.0,1.77,experimental,33.47,0.2251,0.2021,Crystal structure of D1228V c-MET bound by compound 29
5LSU,X-RAY DIFFRACTION,2.1,41.49,"VAPOR DIFFUSION, SITTING DROP",,"16.0%w/v PEG 3350, 0.1M NH4Cl",293.0,2016-09-05,2016-10-05,5LSU,4166.0,2.0,504.0,528.0,,58.76,1.0,2.14,experimental,53.711,0.238,0.171,Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5I25,X-RAY DIFFRACTION,3.01,58.88,VAPOR DIFFUSION,7.4,"PEG1500, HEPES pH 7.4., 0.2M NaCl",293.15,2016-02-08,2016-04-06,5I25,4842.0,2.0,615.0,53.0,17.0,69.68,2.0,2.85,experimental,74.251,0.28821,0.22639,human recombinant coagulation FXI in complex with a peptide derived from human high molecular weight kininogen (HKP)
6UVP,X-RAY DIFFRACTION,2.62,53.14,VAPOR DIFFUSION,,"100mM Sodium Cacodylate pH 7.4, 12% PEG 8K, 200mM Ammonium Sulfate",277.0,2019-11-04,2019-12-11,6UVP,7451.0,2.0,884.0,1106.0,6.0,100.62,1.0,1.56,experimental,18.445,0.1819,0.1378,BACE-1 in complex with compound #3
6UVY,X-RAY DIFFRACTION,2.61,52.93,VAPOR DIFFUSION,,"100mM Sodium Cacodylate pH 7.4, 12% PEG 8K, 200mM Ammonium Sulfate",277.0,2019-11-04,2019-12-11,6UVY,7444.0,2.0,884.0,1151.0,6.0,99.4,1.0,1.71,experimental,20.499,0.1779,0.1399,BACE-1 in complex with compound #18
6UWP,X-RAY DIFFRACTION,2.6,52.65,VAPOR DIFFUSION,,"100mM Sodium Cacodylate pH 7.4, 12% PEG 8K, 200mM Ammonium Sulfate",277.0,2019-11-05,2019-12-11,6UWP,7564.0,2.0,884.0,1030.0,6.0,99.65,1.0,1.29,experimental,16.661,0.1546,0.1343,BACE-1 in complex with compound #32
6UWV,X-RAY DIFFRACTION,2.6,52.72,VAPOR DIFFUSION,,"100mM Sodium Cacodylate pH 7.4, 14% PEG 8K, 200mM Ammonium Sulfate",281.0,2019-11-05,2019-12-11,6UWV,7518.0,2.0,884.0,1071.0,6.0,99.39,1.0,1.47,experimental,15.531,0.1595,0.137,BACE-1 in complex with compound #34
7MYI,X-RAY DIFFRACTION,2.59,52.46,"VAPOR DIFFUSION, SITTING DROP",,"100 mM sodium cacodylate pH 7.4, 12% PEG 8K, 200 mM ammonium sulfate",277.0,2021-05-21,2021-07-21,7MYI,7604.0,2.0,884.0,1186.0,6.0,98.76,1.0,1.25,experimental,16.304,0.1657,0.1398,BACE-1 in complex with compound #6
7MYR,X-RAY DIFFRACTION,2.61,52.86,"VAPOR DIFFUSION, SITTING DROP",,"100mM sodium cacodylate pH 7.4, 12% PEG 8K, 200mM ammonium sulfate",277.0,2021-05-21,2021-07-14,7MYR,7252.0,2.0,884.0,906.0,6.0,98.89,1.0,1.72,experimental,17.36,0.1958,0.1703,BACE-1 in complex with compound #18
6ZPQ,X-RAY DIFFRACTION,3.05,59.72,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent Cations, 30% PEG550MME/PEG20000",289.0,2020-07-09,2020-10-28,6ZPQ,22243.0,4.0,2516.0,1672.0,12.0,298.37,1.0,1.85,experimental,43.45,0.2136,0.1844,Crystal structure of the open conformation of Angiotensin-1 converting enzyme N-domain.
6ZPT,X-RAY DIFFRACTION,2.97,58.57,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent Cations, 30% PEG550MME/PEG20000",289.0,2020-07-09,2020-10-28,6ZPT,19941.0,4.0,2516.0,55.0,12.0,294.44,1.0,2.8,experimental,70.83,0.2778,0.2236,Crystal structure of the open conformation of S2_S'-mutant human Angiotensin-1 converting enzyme N-domain.
6H5X,X-RAY DIFFRACTION,2.84,56.69,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent Cations, 30% PEG550MME?PEG20000",289.0,2018-07-25,2018-11-07,6H5X,11194.0,2.0,1258.0,754.0,6.0,150.87,1.0,1.8,experimental,,0.2038,0.1644,Crystal structure of human Angiotensin-1 converting enzyme N-domain in complex with Omapatrilat.
8QHL,X-RAY DIFFRACTION,2.84,56.7,"VAPOR DIFFUSION, HANGING DROP",8.5,"30% PEG 550 MME/PEG 20000, 0.1 M Tris/Bicine pH 8.5, and 60 mM divalent cations (molecular dimensions screen, Morpheus A9)",289.15,2023-09-08,2023-11-22,8QHL,10738.0,4.0,1262.0,444.0,6.0,150.68,2.0,1.9,experimental,41.21,0.233,0.1883,Human Angiotensin-1 converting enzyme N-domain in complex with the lactotripeptide VPP
7T78,X-RAY DIFFRACTION,2.56,51.93,"VAPOR DIFFUSION, HANGING DROP",,"PEG 600, Hepes pH 7.5",298.0,2021-12-14,2022-03-02,7T78,7014.0,2.0,932.0,186.0,,106.09,1.0,2.4,experimental,43.36,0.2217,0.1854,"CRYSTAL STRUCTURE OF GLUCOKINASE (HEXOKINASE 4) COMPLEXED WITH LIGAND DIETHYL ({2-[3-(4-METHANESULFONYLPHENO XY)-5-{[(2S)-1-METHOXYPROPAN-2-YL]OXY}BENZAMIDO]-1,3-THIAZ OL-4-YL}METHYL)PHOSPHONATE"
7T79,X-RAY DIFFRACTION,2.71,54.54,"VAPOR DIFFUSION, HANGING DROP",,"PEG 600, Hepes pH 7.5",298.0,2021-12-14,2022-03-02,7T79,6627.0,2.0,932.0,82.0,,105.9,1.0,2.4,experimental,53.4,0.254,0.211,CRYSTAL STRUCTURE OF GLUCOKINASE (HEXOKINASE 4) COMPLEXED WITH LIGAND AKA DIETHYL {[3-(3-{[5-(AZETIDINE-1-CARBON YL)PYRAZIN-2-YL]OXY}-5-(PROPAN-2-YLOXY)BENZAMIDO)-1H- PYRAZOL-1-YL]METHYL}PHOSPHONATE
7PQS,X-RAY DIFFRACTION,2.89,57.5,"VAPOR DIFFUSION, SITTING DROP",5.0,"15% PEG Smear Broad, 0.1M cacodylate, 5% tacsimate, 10% ethylene glycol",278.0,2021-09-20,2021-12-15,7PQS,5947.0,2.0,766.0,304.0,,88.75,1.0,2.2,experimental,41.631,0.2356,0.199,SRPK1 in complex with MSC2711186
6V8K,X-RAY DIFFRACTION,2.49,50.61,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.24 mM HAT, 0.12 mM CoA, 0.75 mM ligand. 200+150 (+20) nL sitting drops.
Internal focus screen with microseeding. 17.5% MPD, 0.1 M Tris pH 8, 2.5 % PEG3350. Cryo 30% MPD, 5% PEG 3350, 1 mM ligand",277.0,2019-12-11,2020-04-01,6V8K,2704.0,1.0,323.0,92.0,,38.3,1.0,1.84,experimental,45.88,0.2134,0.1786,Crystal structure of the p300 acetyltransferase domain with peptide-competitive inhibitor 2
6I5H,X-RAY DIFFRACTION,2.54,51.67,"VAPOR DIFFUSION, SITTING DROP",9.0,"23% PEG 6000, 0.1M bicine",277.0,2018-11-13,2019-01-16,6I5H,2942.0,1.0,339.0,271.0,,40.35,1.0,1.49,experimental,22.957,0.20607,0.17762,Crystal structure of CLK1 in complex with furanopyrimidin VN412
6GU7,X-RAY DIFFRACTION,2.47,50.12,"VAPOR DIFFUSION, SITTING DROP",,"CONDITIONS AROUND 0.1M TRIS/BICINE (PH8.5), 10% PEG8K, 20% ETHYLENE GLYCOL PROTEIN AT 10-12 MG/ML, 0.5mM INHIBITOR",277.0,2018-06-19,2018-12-05,6GU7,11781.0,8.0,1544.0,13.0,,179.75,2.0,2.75,experimental,73.119,0.2737,0.22691,CDK1/Cks2 in complex with AZD5438
6J8F,X-RAY DIFFRACTION,2.5,50.85,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na citrate tribasic dihydrate pH 5.0, 18% PEG 20000",291.0,2019-01-18,2019-06-19,6J8F,2185.0,3.0,292.0,44.0,,33.99,3.0,2.283,experimental,,0.2369,0.1995,Crystal structure of SVBP-VASH1 with peptide mimic the C-terminal of alpha-tubulin
6FEW,X-RAY DIFFRACTION,2.1,41.33,"VAPOR DIFFUSION, SITTING DROP",5.5,"11.5 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed 3:1 in 600 nL with 0.1M Ca acetate, 12% PEG 8K, 0.1M Na cacodylate pH5.5",293.0,2018-01-03,2018-11-28,6FEW,2649.0,1.0,321.0,260.0,,36.95,1.0,1.44,experimental,31.1001,0.2413,0.2171,"DDR1, 2-[8-(1H-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-N-methylacetamide, 1.440A, P1211, Rfree=24.1%"
6FIL,X-RAY DIFFRACTION,2.38,48.42,"VAPOR DIFFUSION, SITTING DROP",5.5,"11.3 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed 1.3:1 with 90mM MES/NaOH pH6.5, 0.18M potassium iodide, 0.2M Li2SO4, 22.5% PEG 4K",293.0,2018-01-19,2018-11-28,6FIL,2659.0,1.0,321.0,252.0,1.0,37.08,1.0,1.73,experimental,34.3751,0.2454,0.1924,"DDR1, 2-[8-(1H-indazole-5-carbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]-N-methylacetamide, 1.730A, P212121, Rfree=24.5%"
6FIN,X-RAY DIFFRACTION,2.14,42.41,"VAPOR DIFFUSION, SITTING DROP",5.5,"11.3 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed 1.3:1 with 90mM MES/NaOH pH6.5, 0.18M potassium iodide, 0.2M Li2SO4, 22.5% PEG 4K",293.0,2018-01-19,2018-11-28,6FIN,2629.0,1.0,321.0,196.0,,38.02,1.0,1.67,experimental,37.1356,0.2279,0.198,"DDR1, 3-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-8-(1H-indazole-5-carbonyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one, 1.670A, P1211, Rfree=22.8%"
6FIO,X-RAY DIFFRACTION,2.8,56.15,"VAPOR DIFFUSION, SITTING DROP",5.5,"11.3 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed 1.3:1 with 90mM MES/NaOH pH6.5, 0.18M potassium iodide, 0.2M Li2SO4, 22.5% PEG 4K",293.0,2018-01-19,2018-11-28,6FIO,2630.0,1.0,321.0,128.0,,37.0,1.0,1.99,experimental,54.9566,0.2765,0.2137,"DDR1, 2-[1'-(1H-indazole-5-carbonyl)-4-methyl-2-oxospiro[indole-3,4'-piperidine]-1-yl]-N-(2,2,2-trifluoroethyl)acetamide, 1.990A, P6522, Rfree=27.7%"
6FIQ,X-RAY DIFFRACTION,2.14,42.44,"VAPOR DIFFUSION, SITTING DROP",5.5,"11.3 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed 1.3:1 with 90mM MES/NaOH pH6.5, 0.18M potassium iodide, 0.2M Li2SO4, 22.5% PEG 4K",293.0,2018-01-19,2018-11-28,6FIQ,2536.0,1.0,321.0,150.0,,37.09,1.0,1.79,experimental,40.7955,0.2378,0.199,"DDR1, 1-(1H-indazole-5-carbonyl)-5'-methoxy-1'-[2-oxo-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]ethyl]spiro[piperidine-4,3'-pyrrolo[3,2-b]pyridine]-2'-one, 1.790A, P212121, Rfree=23.8%"
5I3W,X-RAY DIFFRACTION,2.81,56.16,VAPOR DIFFUSION,6.6,"20% polyethylene glycol 5000 MME, 200 mM ammonium iodide, 170 mM sodium citrate (pH 6.6), 3% DMSO",298.0,2016-02-11,2016-03-30,5I3W,3338.0,1.0,411.0,321.0,2.0,46.88,1.0,2.15,experimental,25.301,0.2149,0.1799,Crystal structure of BACE1 in complex with 2-aminooxazoline-3-azaxanthene inhibitor 2
6K1Z,X-RAY DIFFRACTION,2.57,52.09,"VAPOR DIFFUSION, SITTING DROP",,"0.02M Citric acid/0.08M BIS-TRIS propane (pH 8.8), 16% w/v Polyethylene glycol 3350",293.15,2019-05-13,2019-06-12,6K1Z,4531.0,1.0,594.0,128.0,,68.37,1.0,2.307,experimental,,0.2668,0.2195,Crystal structure of farnesylated hGBP1
6TUY,X-RAY DIFFRACTION,4.29,71.3,VAPOR DIFFUSION,6.5,"20 degrees  C in 100 mM N-(2-
acetamido)iminodiacetic acid (pH 6.5) and 1.2 M Na-K tartrate",293.0,2020-01-08,2021-07-21,6TUY,6536.0,2.0,1338.0,36.0,,149.32,2.0,2.6,experimental,80.525,0.2229,0.2039,Human LSD1/CoREST bound to the quinazoline inhibitor MC4106
5WR7,X-RAY DIFFRACTION,3.11,60.52,VAPOR DIFFUSION,,"0.05-0.15M KH2PO4, 0.1M MES pH 6.25, 1.5-2.5M NaCl, 0.05-0.15M NaH2PO4, 0.01M TCEP HCl",277.0,2016-11-30,2017-12-06,5WR7,2394.0,1.0,304.0,28.0,,35.32,1.0,2.76,experimental,40.719,0.23434,0.20634,Crystal structure of Trk-A complexed with a selective inhibitor CH7057288
7AL7,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,6.5,"0.2 M Calcium acetate hydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 18% w/v Polyethylene glycol 8000",293.0,2020-10-05,2022-04-20,7AL7,2291.0,2.0,562.0,130.0,3.0,65.11,2.0,1.801,experimental,38.4789,0.2315,0.2088,The Crystal Structure of Human IL-18 in Complex With Human IL-18 Binding Protein
7B43,X-RAY DIFFRACTION,2.61,52.91,"VAPOR DIFFUSION, SITTING DROP",,"28 % PEGMME2000, 0.1 M bis-tris pH 6.5",293.0,2020-12-02,2020-12-09,7B43,4491.0,2.0,598.0,128.0,,68.32,1.0,1.87,experimental,27.59,0.248,0.2,Crystal structure of c-MET bound by compound 9
8OUV,X-RAY DIFFRACTION,2.34,47.51,VAPOR DIFFUSION,,"30 % PEG400, 0.1 M CaCl2, 0.1 M PCPT pH 4.5.",293.0,2023-04-24,2023-07-05,8OUV,5165.0,2.0,618.0,512.0,,70.39,1.0,1.783,experimental,29.69,0.2197,0.1912,Crystal structure of D1228V c-MET bound by compound 15
8OVZ,X-RAY DIFFRACTION,2.37,48.01,"VAPOR DIFFUSION, SITTING DROP",,"12 % PEG 8000, 200 mM NH4I, 0.1 M PCPT pH 7",293.0,2023-04-26,2023-07-05,8OVZ,4768.0,2.0,618.0,171.0,,72.86,1.0,2.206,experimental,41.47,0.2749,0.2245,Crystal structure of D1228V c-MET bound by compound 16
6SDD,X-RAY DIFFRACTION,2.87,57.09,"VAPOR DIFFUSION, SITTING DROP",,"8 % ethanol, 20 % PEG8K, 0.1 M PCPT pH 7.5",293.0,2019-07-26,2019-08-14,6SDD,2325.0,1.0,309.0,154.0,,35.43,1.0,1.93,experimental,35.83,0.23,0.21,Crystal structure of D1228V cMET bound by BMS-777607
7B44,X-RAY DIFFRACTION,2.54,51.6,"VAPOR DIFFUSION, SITTING DROP",,"25 % PEG3350, 0.2 M (NH4)2SO4, 0.1 M Na-HEPES pH 7.5",293.0,2020-12-02,2020-12-09,7B44,2532.0,1.0,299.0,266.0,,34.47,1.0,1.76,experimental,36.28,0.208,0.178,Crystal structure of c-MET bound by compound S1
7AUC,X-RAY DIFFRACTION,2.38,48.39,"VAPOR DIFFUSION, HANGING DROP",7.5,"Morpheus-HT, condition A8, Molecular Dimensions
0.06 M divalents, 37.5% Buffer System 2 and 37.5% Precipitant Mix 4
Divalents = 0.3M magnesium chloride, 0.3M calcium chloride
Buffer system 2 = 1M sodium HEPES, MOPS (acid) pH 7.5
75% Precipitant Mix 4 = 25% w/v MPD, 25% v/v PEG1000, 25% w/v PEG 3350",277.15,2020-11-02,2020-12-16,7AUC,4385.0,1.0,562.0,431.0,,65.59,1.0,1.53,experimental,32.6,0.2084,0.1891,Crystal structure of an engineered helicase domain construct for human Bloom syndrome protein (BLM)
5OWS,X-RAY DIFFRACTION,2.44,49.65,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350",277.0,2017-09-04,2018-05-02,5OWS,3815.0,2.0,480.0,310.0,,55.94,1.0,1.8,experimental,30.103,0.19398,0.16697,"Crystal structure of TNKS2 in complex with 2-[4-(4-methyl-2-oxoimidazolidin-4-yl)phenyl]-3,4-dihydroquinazolin-4-one"
8W1L,X-RAY DIFFRACTION,2.44,49.54,VAPOR DIFFUSION,6.5,"0.1 M MES, pH 6.5, 21.3% polyethylene glycol 3350 and 0.25 M ammonium sulfate",293.0,2024-02-16,2024-05-29,8W1L,2262.0,1.0,333.0,77.0,,38.64,1.0,2.26,experimental,76.12,0.2255,0.1723,Structure of CSF1R kinase domain in complex with Cpd 32
6JT4,X-RAY DIFFRACTION,2.73,59.96,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium citrate tribasic pH 6.5, 0.2 M ammonium iodide, 20.5% w/v PEG 5000MME",293.15,2019-04-08,2020-01-15,6JT4,3120.0,1.0,416.0,204.0,3.0,47.42,1.0,2.2,experimental,31.602,0.2339,0.1951,"Crystal Structure of BACE1 in complex with N-{3-[(4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-5-(fluoromethoxy)pyrazine-2-carboxamide"
6PZ4,X-RAY DIFFRACTION,3.05,59.63,"VAPOR DIFFUSION, HANGING DROP",6.6,"21% PEG 5000 MME, 190 mM Na citrate (pH 6.6), 190 mM ammonium iodide, 3% (v/v) DMSO",298.0,2019-07-31,2019-10-23,6PZ4,3404.0,1.0,411.0,368.0,3.0,46.92,1.0,1.85,experimental,21.006,0.2251,0.2023,co-crystal structure of BACE with inhibitor AM-6494
5M9T,X-RAY DIFFRACTION,2.87,57.19,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.01 M Na borate
1.1 M Na citrate",289.0,2016-11-02,2017-02-22,5M9T,2064.0,2.0,248.0,67.0,6.0,28.81,1.0,2.2,experimental,49.751,0.23596,0.18238,Human angiogenin ALS variant H114R
4Y62,X-RAY DIFFRACTION,1.93,36.17,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, ammonium sulfate, MOPS, MnCl2",293.0,2015-02-12,2015-09-16,4Y62,2683.0,1.0,354.0,324.0,,41.84,1.0,1.6,experimental,15.76,0.20054,0.17567,AAGlyB in complex with amino-acid analogues
4Y63,X-RAY DIFFRACTION,1.93,36.17,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350
ammonium sulfate
MOPS
MnCl2",293.0,2015-02-12,2015-09-16,4Y63,2765.0,1.0,354.0,377.0,,41.78,1.0,1.3,experimental,13.826,0.18333,0.15937,AAGlyB in complex with amino-acid analogues
6RB4,X-RAY DIFFRACTION,2.35,47.76,"VAPOR DIFFUSION, SITTING DROP",,"100mM Bis Tris propane pH 6.5, 24 % PEG 3350, 150 mM NaF",292.0,2019-04-09,2019-09-11,6RB4,3856.0,1.0,410.0,465.0,,49.03,1.0,1.5,experimental,,0.2148,0.1929,Crystal structure of the Pri1 subunit of human primase
6W36,X-RAY DIFFRACTION,3.31,62.89,LIQUID DIFFUSION,5.5,"1 M ammonium sulfate, 0.1 M Bis-Tris, pH 5.5, 1% PEG3350",293.0,2020-03-09,2020-05-06,6W36,2647.0,1.0,347.0,,,40.32,1.0,2.854,experimental,,0.2591,0.2149,Crystal structure of FAM46C
8ILZ,X-RAY DIFFRACTION,2.28,46.1,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Sodium acetate trihydrate, 0.1 M TRIS hydrochloride pH 9.0, 27% PEG 4000, 9% glycerol",291.0,2023-03-05,2023-04-26,8ILZ,930.0,1.0,103.0,104.0,,11.84,1.0,1.77,experimental,22.72,0.2138,0.1768,Crystal structure of the RRM domain of human SETD1B
4WPH,X-RAY DIFFRACTION,2.59,52.56,"VAPOR DIFFUSION, HANGING DROP",6.0,"PEG 3000, sodium citrate, L-proline",298.0,2014-10-18,2015-06-17,4WPH,5582.0,4.0,772.0,39.0,,90.45,2.0,2.92,experimental,76.499,0.2619,0.2328,Crystal structure of USP7 ubiquitin-like domains in compact conformation
7JJL,X-RAY DIFFRACTION,2.82,56.44,"VAPOR DIFFUSION, HANGING DROP",,"0.7 M sodium citrate, 0.01M DTT, 0.1M sodium HEPES pH 7",295.0,2020-07-27,2020-08-05,7JJL,3231.0,2.0,491.0,1.0,,54.27,2.0,2.6,experimental,66.286,0.2661,0.2039,Crystal structure of Importin Alpha 3 in complex with human LSD1 NLS
6JSZ,X-RAY DIFFRACTION,2.31,46.76,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M TRIS pH 8.0, 25% PEG 3350, pH 8.0",293.15,2019-04-08,2019-08-28,6JSZ,3920.0,2.0,497.0,299.0,3.0,54.42,2.0,1.53,experimental,28.96,0.237,0.2252,"BACE2 xaperone complex with N-{3-[(5R)-3-amino-5-methyl-9,9-dioxo-2,9lambda6-dithia-4-azaspiro[5.5]undec-3-en-5-yl]-4-fluorophenyl}-5-(fluoromethoxy)pyrazine-2-carboxamide"
5V2N,X-RAY DIFFRACTION,2.0,38.62,"VAPOR DIFFUSION, SITTING DROP",,"30% PEGMME 550, 5% ethylene glycol, and 100 mM TRIS (pH 8.2-8.8)",293.0,2017-03-05,2018-03-07,5V2N,1404.0,1.0,165.0,125.0,,18.69,1.0,2,experimental,41.562,0.2499,0.1831,Crystal Structure of APO Human SETD8
8T4V,X-RAY DIFFRACTION,1.88,34.71,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES 6.5, 25% PEG4K",293.0,2023-06-10,2024-03-13,8T4V,3211.0,2.0,374.0,337.0,,45.25,1.0,1.47,experimental,23.74,0.2112,0.1896,Crystal structure of compound 1 bound to K-Ras(G12D)
6I5K,X-RAY DIFFRACTION,2.58,52.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"24-28% 1,2-propanediol, 5% glycerol, 0.1M sodium/potassium phosphate",277.0,2018-11-13,2019-01-09,6I5K,8656.0,3.0,1017.0,222.0,,120.48,1.0,2.3,experimental,49.003,0.22405,0.19517,"Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound VN345 (derivative of compound 12h)"
6I5L,X-RAY DIFFRACTION,2.58,52.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"24-28% 1,2-propanediol, 5% glycerol, 0.1M sodium/potassium phosphate",277.0,2018-11-13,2019-01-09,6I5L,8558.0,3.0,1017.0,136.0,,120.67,1.0,2.55,experimental,51.62,0.22146,0.19345,"Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound VN316 (derivative of compound 12h)"
7YAW,X-RAY DIFFRACTION,2.58,52.35,"VAPOR DIFFUSION, HANGING DROP",,"0.05 M Magnesium acetate, 0.05 M Sodium acetate pH 5.0, 28% PEG400",298.0,2022-06-28,2023-08-09,7YAW,9900.0,4.0,1240.0,404.0,1.0,143.98,1.0,2.1,experimental,35.2366,0.2428,0.2067,Crystal structure of ZAK in complex with compound YH-180
7R2G,X-RAY DIFFRACTION,2.37,48.21,"VAPOR DIFFUSION, SITTING DROP",7.0,"Sodium Hepes 0.1M, pH 7.0, PEG8000 5%.",293.15,2022-02-04,2022-06-08,7R2G,6126.0,2.0,724.0,132.0,,88.62,1.0,1.98,experimental,51.027,0.2379,0.2041,USP15 D1D2 in catalytically-competent state bound to mitoxantrone stack (isoform 2)
6PZE,X-RAY DIFFRACTION,3.08,60.04,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M Hepes, pH 7.0 and 10% (w/v) polyethylene glycol 6000",293.0,2019-07-31,2019-12-04,6PZE,6995.0,3.0,847.0,590.0,13.0,94.47,3.0,2.3,experimental,,0.1973,0.1559,Crystal structure of human NA-45 Fab in complex with neuraminidase Y169aH mutant from A/Shanghai/2/2013 (H7N9)
5S7G,X-RAY DIFFRACTION,2.65,53.64,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7G,5209.0,2.0,602.0,437.0,,72.51,1.0,1.78,experimental,40.321,0.2516,0.2037,XChem group deposition -- Crystal Structure of human ACVR1 in complex with XS035844b
7PSU,X-RAY DIFFRACTION,3.16,61.11,"VAPOR DIFFUSION, SITTING DROP",,"The crystallization drops were composed of a 1:1 mix of the protein solution (5 mg/mL in 500 mM NaCl, 25 mM TRIS/HCl buffer, pH 8,5) and the reservoir solution containing [0.2 M lithium sulfate, 25 % (w/v) PEG 3350 and 0.1 M Bis/TRIS/HCl, pH 6.5]. The crystals were optimized by macroseeding and transferred into a cryo-protectant solution composed of 70 microliter of the reservoir solution and 30 microliter ethylene glycol.",293.0,2021-09-23,2022-03-23,7PSU,6392.0,2.0,822.0,688.0,,96.31,1.0,1.77,experimental,20.22,0.2183,0.1802,Structure of protein kinase CK2alpha mutant K198R associated with the Okur-Chung Neurodevelopmental Syndrome
7FQK,X-RAY DIFFRACTION,2.21,44.39,"VAPOR DIFFUSION, SITTING DROP",6.5,"28.5mg/mL protein in 25mM HEPES/NaOH pH7, 300 mM NaCl, 200mM Trehalose incubated with 10-fold excess of ligand, then mixed 50-70% with 50-30% reservoir consisting of 20% v/v PEG smear broad, 0.1M MES/NaOH pH 6.5, total volume 200nL",293.0,2022-10-05,2023-10-11,7FQK,9215.0,4.0,1776.0,537.0,,207.2,1.0,1.97,experimental,40.431,0.2325,0.194,"Crystal Structure of human Legumain in complex with (2S)-N-[(3S)-5-amino-1-(1,3-oxazol-2-yl)-5-oxopent-1-yn-3-yl]-1-[1-[4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide"
4YO4,X-RAY DIFFRACTION,1.92,36.1,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium chloride, 0.1 M HEPES, 1.6 M ammonium sulfate",295.0,2015-03-11,2015-05-06,4YO4,2672.0,1.0,294.0,241.0,,34.22,1.0,1.6,experimental,23.431,0.18499,0.15694,Crystal Structure of DAPK1 catalytic domain in complex with the hinge binding fragment phthalazine
4YPD,X-RAY DIFFRACTION,1.91,35.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 1.7 M ammonium sulfate",295.0,2015-03-12,2015-05-13,4YPD,2909.0,1.0,294.0,325.0,,34.02,1.0,1.4,experimental,24.216,0.1772,0.1551,Crystal Structure of DAPK1 catalytic domain in complex with the hinge binding fragment 4-methylpyridazine
5YA5,X-RAY DIFFRACTION,2.21,44.29,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Tris pH7.5, 15% glycerol, 12% MPD, 5% isopropanol, 15% PEG5Kmme",293.0,2017-08-30,2018-07-04,5YA5,2289.0,1.0,319.0,108.0,,36.4,1.0,1.89,experimental,38.1,0.2349,0.2114,CRYSTAL STRUCTURE OF c-MET IN COMPLEX WITH NOVEL INHIBITOR
6SDC,X-RAY DIFFRACTION,2.41,48.99,"VAPOR DIFFUSION, SITTING DROP",,"15 % 2-propanol, 10 % PEG4K, 0.1 M NaHEPES pH 8",293.0,2019-07-26,2019-08-14,6SDC,2563.0,1.0,309.0,282.0,,35.46,1.0,1.67,experimental,24.88,0.242,0.201,Crystal structure of D1228V cMET bound by foretinib
6SDE,X-RAY DIFFRACTION,2.34,47.34,"VAPOR DIFFUSION, SITTING DROP",,"15 % 2-propanol, 15 % PEG4K, 0.2 M PCPT pH 7.5",293.0,2019-07-26,2019-08-14,6SDE,2215.0,1.0,309.0,56.0,,35.19,1.0,2.49,experimental,69.55,0.273,0.203,Crystal structure of wild-type cMET bound by savolitinib
7VZE,X-RAY DIFFRACTION,2.84,56.64,"VAPOR DIFFUSION, SITTING DROP",,"0.15M calcium acetate hydrate, 24% (w/v) polyethylene glycol 3350, 4.5% w/v trimethylamine N-oxide dihydrate",291.0,2021-11-16,2022-03-02,7VZE,2944.0,8.0,404.0,14.0,2.0,45.41,2.0,2.882,experimental,,0.2343,0.1949,Crystal structure of PTPN4 PDZ bound to the PBM of HPV16 E6
7LMK,X-RAY DIFFRACTION,2.45,49.87,"VAPOR DIFFUSION, HANGING DROP",7.5,"13% PEG1500, 20 mM DTT and 200 mM L-proline, 0.1 M HEPES (pH 7.5)",277.0,2021-02-05,2021-02-17,7LMK,5147.0,8.0,684.0,30.0,,77.99,2.0,2.647,experimental,,0.2583,0.2058,Crystal structure of bovine DNMT1 BAH1 domain in complex with H4K20me3
7LMM,X-RAY DIFFRACTION,2.45,49.73,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES (pH 6.5) ,13% PEG1500, 20 mM DTT and 200 mM L-proline",277.0,2021-02-05,2021-02-17,7LMM,5206.0,8.0,684.0,36.0,,77.93,2.0,2.798,experimental,,0.2668,0.2066,Crystal structure of bovine DNMT1 BAH1 domain in complex with H4K20me2
5U7I,X-RAY DIFFRACTION,2.17,43.38,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.1 M Tris, pH 8.5, and 0.2 M MgCl2",294.0,2016-12-12,2017-06-28,5U7I,11826.0,4.0,1380.0,853.0,,162.73,1.0,2,experimental,27.34,0.2214,0.1938,PDE2 catalytic domain complexed with inhibitors
5U7J,X-RAY DIFFRACTION,2.24,44.98,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.1 M Tris, pH 8.5, and 0.2 M MgCl2",294.0,2016-12-12,2017-06-28,5U7J,12389.0,4.0,1380.0,1244.0,,162.56,1.0,1.9,experimental,30.15,0.2246,0.1943,PDE2 catalytic domain complexed with inhibitors
5U7K,X-RAY DIFFRACTION,2.2,44.14,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.1 M Tris, pH 8.5, and 0.2 M MgCl2",294.0,2016-12-12,2017-06-28,5U7K,11869.0,4.0,1380.0,632.0,,162.74,1.0,2.06,experimental,36.75,0.2547,0.1922,PDE2 catalytic domain complexed with inhibitors
6ISO,X-RAY DIFFRACTION,2.85,60.85,"VAPOR DIFFUSION, SITTING DROP",6.5,"12% PEG4K, 0.1 M sodium malonate, pH 6.5, 5% isopropanol",291.0,2018-11-17,2019-01-23,6ISO,12241.0,12.0,1692.0,181.0,,189.69,2.0,2.95,experimental,47.693,0.27519,0.22144,Human SIRT3 Recognizing H3K4cr
5C8W,X-RAY DIFFRACTION,2.14,42.59,"VAPOR DIFFUSION, HANGING DROP",5.0,"33 mM cGMP, 200 mM sodium malonate, 5-10% ethylene glycol, 20% PEG",293.0,2015-06-26,2016-01-20,5C8W,6575.0,6.0,858.0,712.0,,102.33,1.0,1.8,experimental,,0.1955,0.1621,PKG II's Amino Terminal Cyclic Nucleotide Binding Domain (CNB-A) in a complex with cGMP
4TY1,X-RAY DIFFRACTION,3.19,61.45,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.0M LiCl, 0.1M TRIS pH8.0, 20% PEG6K",277.0,2014-07-07,2015-02-04,4TY1,2299.0,1.0,286.0,40.0,,33.53,1.0,2.7,experimental,49.747,0.2375,0.181,Crystal structure of human Pim-1 kinase in complex with an aminooxadiazole-indole inhibitor.
5EOL,X-RAY DIFFRACTION,3.29,62.67,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.0M LiCl, 0.1M TRIS pH8.0, 20% PEG6K",277.0,2015-11-10,2016-05-04,5EOL,2367.0,1.0,286.0,103.0,,33.61,1.0,2.2,experimental,44.522,0.22332,0.19448,Crystal structure of human Pim-1 kinase in complex with a macrocyclic quinoxaline-pyrrolodihydropiperidinone inhibitor
7Z2L,X-RAY DIFFRACTION,2.83,56.5,"VAPOR DIFFUSION, HANGING DROP",6.2,"Well : 0.1M Phosphate buffer, pH= 6.2, PEG 3350 = 16%

Protein: 5mM Hepes, 200mM NaCl, 5mM DTT",293.0,2022-02-28,2023-03-22,7Z2L,13073.0,4.0,1620.0,904.0,,185.95,1.0,2.56,experimental,46.4,0.2441,0.1802,"Crystal structure of L-Kynurenine in the active site of human Indoleamine-2,3-dioxygenase 1 (hIDO1)"
6K3E,X-RAY DIFFRACTION,7.14,82.77,"VAPOR DIFFUSION, HANGING DROP",,36%  Tacsimate,291.0,2019-05-17,2020-05-20,6K3E,6483.0,2.0,802.0,8.0,,92.88,2.0,2.87,experimental,107.008,0.22282,0.18861,LSD1/Co-Rest structure with an inhibitor
6FHH,X-RAY DIFFRACTION,3.09,60.2,"VAPOR DIFFUSION, SITTING DROP",,"Bat FluA polymerase bound to the ends of the RNA promotor (5 prime end nts 1-16, 3 prime end nts 1-18) was co-crystallized in a 1:8 ratio with the thiophospho-serine-5 22-mer Pol II CTD peptide mimic in 0.8 M sodium-potassium phosphate at pH 5.0. Crystals were set at 4 C using seeding.",277.0,2018-01-14,2019-01-30,6FHH,18457.0,7.0,2401.0,137.0,,282.03,4.0,2.7,experimental,90.198,0.25763,0.2129,Crystal structure of bat influenza A/H17N10 polymerase with viral RNA promoter bound to a 22-mer modified Pol II CTD peptide with serine 5 thiophosphorylated.
6O02,X-RAY DIFFRACTION,2.52,51.13,"VAPOR DIFFUSION, SITTING DROP",,"0.12M Alcohols, 0.1M Buffer system 3 at PH 8.5 and 50% v/v Precipitant mix 2",291.0,2019-02-15,2020-08-19,6O02,3232.0,2.0,406.0,,,46.3,2.0,2.953,experimental,,0.258,0.2167,Monobody (MC3) bound to tyrosine kinase binding domain of E3 ubiquitin ligase CBL
7CCU,X-RAY DIFFRACTION,2.03,35.43,"VAPOR DIFFUSION, HANGING DROP",,"2.4 M ammonium sulfate, 0.1 M Tris-HCl pH 8.0, 14.4 mg/mL DAPK1, 2 mM resveratrol",293.0,2020-06-18,2021-01-20,7CCU,2487.0,1.0,293.0,224.0,,34.12,1.0,1.649,experimental,,0.1988,0.1749,Crystal structure of death-associated protein kinase 1 in complex with resveratrol
7CCV,X-RAY DIFFRACTION,1.99,34.22,"VAPOR DIFFUSION, HANGING DROP",,"2.0 M ammonium sulfate, 0.1 M Tris-HCl pH 7.0, 14.4 mg/mL DAPK1, 2 mM piceatannol",293.0,2020-06-18,2021-01-20,7CCV,2447.0,1.0,293.0,200.0,,34.14,1.0,1.753,experimental,,0.2083,0.1727,Crystal structure of death-associated protein kinase 1 in complex with piceatannol
8J9Q,X-RAY DIFFRACTION,2.92,57.89,"VAPOR DIFFUSION, HANGING DROP",7.0,0.1 M DL-malic acid (pH7.0) and 18% (w/v) polyethylene glycol 3350 (PEG3350),291.15,2023-05-04,2023-12-06,8J9Q,1754.0,3.0,219.0,55.0,,25.3,1.0,2.18,experimental,49.78,0.2688,0.2192,Crystal structure of UBR box of UBR4 apo
5U7D,X-RAY DIFFRACTION,2.21,44.45,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.1 M Tris, pH 8.5, and 0.2 M MgCl2",294.0,2016-12-12,2017-06-28,5U7D,9515.0,3.0,1035.0,1010.0,,122.37,1.0,1.75,experimental,32.7,0.197,0.1676,PDE2 catalytic domain complexed with inhibitors
5XIU,X-RAY DIFFRACTION,2.5,50.73,"VAPOR DIFFUSION, SITTING DROP",8.5,"25% PEG3350, 0.1 M Tris-HCl (pH8.5), 0.2 M Ammonium Acetate",293.0,2017-04-27,2018-03-07,5XIU,1156.0,2.0,125.0,151.0,,14.81,2.0,1.8,experimental,,0.2069,0.1693,Crystal structure of RNF168 UDM2 in complex with Lys63-linked diubiquitin
5JMY,X-RAY DIFFRACTION,2.53,51.46,"VAPOR DIFFUSION, HANGING DROP",,"6.5, 25% W/V PEG 3350.
                      2 MM MGCL2
                      AND PROTEIN SOLUTION WERE MIXED",293.0,2016-04-29,2016-06-15,5JMY,12295.0,2.0,1396.0,890.0,12.0,162.59,1.0,2,experimental,42.79,0.228,0.186,NEPRILYSIN COMPLEXED WITH LBQ657
6UMW,X-RAY DIFFRACTION,2.12,41.88,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium malonate, pH 4.6, 14% PEG3350",291.0,2019-10-10,2020-10-14,6UMW,2266.0,1.0,301.0,150.0,,34.85,1.0,1.982,experimental,22.0974,0.2212,0.1815,Crystal structure of hEphB1 bound with chlortetracycline
6GBX,X-RAY DIFFRACTION,2.44,49.6,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 0.4 M ammonium sulfate, 0.07 M sodium chloride",277.15,2018-04-16,2018-09-19,6GBX,8792.0,3.0,987.0,697.0,,115.21,1.0,1.72,experimental,15.516,0.18307,0.15819,Crystal structure of human glutaminyl cyclase variant Y115E-Y117E in complex with SEN177
7COZ,X-RAY DIFFRACTION,2.72,54.85,"VAPOR DIFFUSION, SITTING DROP",6.0,"100 mM MES buffer pH 6.0-6.5, 46-67 mM NaOH, 100 mM ammonium sulfate",277.15,2020-08-05,2021-01-13,7COZ,8762.0,3.0,981.0,776.0,,114.87,1.0,1.85,experimental,20.7969,0.2362,0.1955,Crystal Structure of double mutant Y115E Y117E human Secretory Glutaminyl Cyclase in complex with LSB-41
5M4C,X-RAY DIFFRACTION,1.96,37.33,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN STOCK SOLUTION: 6 MG/M CK2ALPHA1-335 IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5; 

INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO;

PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION;

RESERVOIR SOLUTION: 24 % (w/v) PEG8000, 0.2 M KCl;

DROP SOLUTION BEFORE EQULIBRATION: 0.3 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.3 MICROLITER RESERVOIR SOLUTION",293.0,2016-10-18,2017-01-18,5M4C,3069.0,1.0,335.0,228.0,,40.62,1.0,1.935,experimental,,0.1968,0.1565,"Complex structure of human protein kinase CK2 catalytic subunit with a thieno[2,3-d]pyrimidin inhibitor crystallized under low-salt conditions"
5M4F,X-RAY DIFFRACTION,1.96,37.21,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN STOCK SOLUTION: 6 MG/ML CK2ALPHA1-335 IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5; 

INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO;

PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION; 

RESERVOIR SOLUTION: 24 % PEG3350, 0.2 M KCl; 

DROP SOLUTION BEFORE EQULIBRATION: 0.5 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.5 MICROLITER RESERVOIR SOLUTION",293.0,2016-10-18,2017-01-18,5M4F,3248.0,1.0,335.0,384.0,,40.77,1.0,1.519,experimental,,0.1826,0.1628,"Complex structure of human protein kinase CK2 catalytic subunit with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21) crystallized under low-salt conditions"
5DE2,X-RAY DIFFRACTION,2.3,46.56,"VAPOR DIFFUSION, SITTING DROP",7.5,"The composition of the reservoir buffer was: 0.2M Potassium thiocyanate, 0.1M Bis-Tris propane pH 7.5, 20% (w/v) PEG 3350.",291.0,2015-08-25,2015-11-11,5DE2,4452.0,4.0,658.0,10.0,,75.77,2.0,2.78,experimental,66.35,0.2535,0.2059,Structural mechanism of Nek7 activation by Nek9-induced dimerisation
6DNO,X-RAY DIFFRACTION,2.12,41.95,VAPOR DIFFUSION,4.6,"0.4 M magnesium formate dihydrate, 0.1 M Sodium Acetate trihydrate",277.0,2018-06-07,2019-01-23,6DNO,2781.0,3.0,336.0,147.0,,38.63,3.0,1.45,experimental,,0.2096,0.1859,Crystal structure of Protein Phosphatase 1 (PP1) bound to the muscle glycogen-targeting subunit (Gm)
8PT9,X-RAY DIFFRACTION,2.64,53.4,"VAPOR DIFFUSION, HANGING DROP",7.5,"12% PEG 3000, 2-4% MPD, 0.1 M HEPES pH 7.5",293.0,2023-07-13,2024-07-24,8PT9,8391.0,3.0,1098.0,2.0,,127.88,1.0,2.7,experimental,,0.2253,0.2065,JNK1 covalently bound to BD838 cyclohexenone based inhibitor
5VVV,X-RAY DIFFRACTION,2.76,55.4,EVAPORATION,,"0.024 M ammonium citrate tribasic (pH 7.0), 0.015 M MES monohydrate, 0.096 M potassium thiocyanate, 0.25 M Sodium acetate trihydrate, 0.037 M imidazole, 0.002 M zinc sulfate heptahydrate, 9.6 % w/v polyethylene glycol 3,350, 2.4 % w/v polyethylene glycol monomethyl ether 2,000, and 4% w/v polyethylene glycol monomethyl ether 550",293.0,2017-05-20,2017-09-27,5VVV,7015.0,4.0,1034.0,35.0,,119.12,2.0,2.8,experimental,74.527,0.25684,0.19603,Structural Investigations of the Substrate Specificity of Human O-GlcNAcase
5L7F,X-RAY DIFFRACTION,2.48,50.34,"VAPOR DIFFUSION, SITTING DROP",9.5,"protein: MMP12-F171D-K241A  661 micro-M + 10 milli-M AHA, 10% DMSO, 0.5 milli-M fluorescent inhibitor (R47-CY5)
precipitant: 20% PEG4K, 2% gamma valerolactone, 0.2 milli-M TRIS pH 9.5
40% CM26 ((12.5 % diethylene glycol + 12.5 % ethylene glycol + 12.5 % glycerol + 25 % 2,3-butanediol + 12.5 % DMSO), 25% MPEG 6K",293.0,2016-06-03,2016-09-14,5L7F,3243.0,2.0,318.0,367.0,,39.87,1.0,1.8,experimental,21.924,0.19464,0.1756,"Crystal structure of MMP12 mutant K421A in complex with RXP470.1 conjugated with fluorophore Cy5,5 in space group P21."
4UT2,X-RAY DIFFRACTION,2.14,42.64,,9.0,"19.3 % PEG 3350, 200 MM NACL, 100 MM TRIS PH 9.0 SOAKING IN RESERVOIR ENRICHED BY 25MM ASCORBATE FOR 30 MINUTES CRYOPROTECTION 20% GLYCEROL",,2014-07-17,2015-07-22,4UT2,5002.0,2.0,646.0,235.0,,74.57,1.0,1.96,experimental,31.321,0.20065,0.16667,X-ray structure of the human PP1 gamma catalytic subunit treated with ascorbate
8C1F,X-RAY DIFFRACTION,2.68,54.06,VAPOR DIFFUSION,6.5,"30% PEG5000 MME, 0.1M (NH4)2SO4, 0.1 M MES 6.5: soaking: 31.5% PEG5000 MME, 0.09M (NH4)2SO4, 0.09 M MES 6.5, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C1F,2329.0,1.0,265.0,90.0,,32.9,1.0,1.924,experimental,49.07,0.2342,0.2047,Aurora A kinase in complex with TPX2-inhibitor 6
8C1G,X-RAY DIFFRACTION,2.52,51.28,VAPOR DIFFUSION,6.5,"30% PEG5000 MME, 0.1M (NH4)2SO4, 0.1 M MES 6.5: soaking: 31.5% PEG5000 MME, 0.09M (NH4)2SO4, 0.09 M MES 6.5, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C1G,2326.0,1.0,265.0,115.0,,32.77,1.0,1.96,experimental,45.22,0.225,0.199,Aurora A kinase in complex with TPX2-inhibitor 7
6THP,X-RAY DIFFRACTION,2.55,51.76,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH 6.5, 25% W/V PEG 3350, 2 mM MGCL2, 0.2 M Ammoniumacetate",293.0,2019-11-21,2020-02-12,6THP,11710.0,2.0,1392.0,352.0,12.0,161.73,1.0,2.54,experimental,40.631,0.2639,0.2051,Neprilysin in complex with the inhibitor (R)-4-(1-carboxy-3-(3'-chlorobiphenyl-4-yl)propan-2-ylamino)-4-oxobutanoic acid
5IAG,X-RAY DIFFRACTION,2.16,43.1,"VAPOR DIFFUSION, HANGING DROP",8.5,"Caspase-3 variants were crystallized in the presence of
Ac-DEVD-CMK.  PROTEINS WERE DIALYZED IN A BUFFER OF 10 MM TRIS-HCL, 
PH 8.5, 1 MM DTT. THE PROTEIN WAS CONCENTRATED TO 10 MG/ML USING AMICON 
ULTRAFREE CENTRIFUGAL FILTER DEVICES, AND INHIBITOR, AC-DEVD-CMK 
RECONSTITUTED IN DMSO, WAS THEN ADDED AT 5:1 WT:WT, INHIBITOR TO PEPTIDE. 
THE PROTEIN WAS DILUTED TO A CONCENTRATION OF 8 MG/ML BY ADDING 10 MM 
TRIS-HCL, PH 8.5, CONCENTRATED DTT AND CONCENTRATED NAN3 SO THAT THE 
FINAL BUFFER WAS 10 MM TRIS-HCL, PH 8.5, 10 MM DTT, 3 MM NAN3. 2 UL OF 
CONCENTRATED PROTEIN WAS MIXED 1:1 WITH WELL BUFFER THAT CONTAINED 100 MM 
SODIUM CITRATE, PH 5, 3 MM NAN3, 10 MM DTT AND 17% PEG 6000 W/V. SOLUTIONS 
WERE INCUBATED AT 18 DEG C USING THE HANGING DROP METHOD. CRYSTALS GREW 
WITHIN THREE DAYS FOR WILD- TYPE CASPASE-3 AND WITHIN TWO WEEKS FOR THE MUTANTS.",291.0,2016-02-21,2016-10-26,5IAG,2177.0,3.0,287.0,164.0,,32.71,3.0,1.98,experimental,,0.216,0.159,Caspase 3 V266Q
6CZO,X-RAY DIFFRACTION,3.43,68.14,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG 6000, 0.1 M HEPES, VAPOR
 DIFFUSION, TEMPERATURE 277K",277.0,2018-04-09,2019-01-23,6CZO,5075.0,4.0,722.0,60.0,,82.63,2.0,2.95,experimental,,0.213,0.169,The KNL1-PP1 Holoenzyme
5XHS,X-RAY DIFFRACTION,2.3,46.42,"VAPOR DIFFUSION, HANGING DROP",5.5,"23% PEG 3350, 0.1 M Bis-Tris pH 5.5, 0.2M NaCl",293.0,2017-04-24,2018-05-02,5XHS,2182.0,1.0,288.0,138.0,,32.11,1.0,2.19,experimental,,0.2243,0.1731,Crystal structure of SIRT5 complexed with a fluorogenic small-molecule substrate SuBKA
5E5R,X-RAY DIFFRACTION,2.38,48.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"1% (v/v) Tacsimate pH 7.0, 20% (w/v) PEG 3350, 50mM Imidazole-HCl pH 6.5",293.0,2015-10-09,2016-08-31,5E5R,7291.0,4.0,916.0,59.0,6.0,104.23,2.0,2.6,experimental,71.2232,0.249,0.1873,Crystal structure of the complex between Carbonic anhydrase-like domain of PTPRG and Immunoglobulin domains 2-3 of CNTN3
8XI7,X-RAY DIFFRACTION,2.38,48.34,"VAPOR DIFFUSION, SITTING DROP",,"2.1M ammonium sulfate, 2% PEG 400, 100mM HEPES, pH 7.0",293.0,2023-12-19,2024-03-06,8XI7,3728.0,2.0,446.0,231.0,,49.96,1.0,1.95,experimental,40.415,0.2311,0.1939,The Crystal Structure of UCHL1 from Biortus.
7NZC,X-RAY DIFFRACTION,2.4,47.5,VAPOR DIFFUSION,8.0,"0.2 M NaF, 22% PEG 3350",293.0,2021-03-23,2021-12-22,7NZC,684.0,1.0,63.0,138.0,,7.54,1.0,1.111,experimental,17.845,0.1775,0.1468,First SH3 domain of POSH (Plenty of SH3 Domains protein)
7NZD,X-RAY DIFFRACTION,2.6,53.0,VAPOR DIFFUSION,6.5,"0.1M MES pH 6.5, 23% PEG 4000",293.0,2021-03-23,2021-12-22,7NZD,633.0,1.0,63.0,91.0,,7.41,1.0,1.45,experimental,37.451,0.2275,0.1601,Fourth SH3 domain of POSH (Plenty of SH3 Domains protein)
6B9E,X-RAY DIFFRACTION,2.31,46.87,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH 5.5, 0.2 M ammonium sulfate, 22% PEG3350, 1 mM GDP, 2 mM MgCl2",293.15,2017-10-10,2017-12-06,6B9E,6349.0,2.0,916.0,198.0,,105.92,1.0,1.99,experimental,,0.2437,0.2028,Human ATL1 mutant - R77A / F151S bound to GDP
6H0B,X-RAY DIFFRACTION,2.84,56.73,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350
ammonium nitrate",291.0,2018-07-08,2018-10-10,6H0B,9606.0,3.0,1172.0,789.0,10.0,137.94,2.0,1.8,experimental,54.152,0.23806,0.18965,"Crystal structure of the human GalNAc-T4 in complex with UDP, manganese and the diglycopeptide 6."
5F6K,X-RAY DIFFRACTION,2.47,50.16,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM Na-Cacodylate, pH 6.5, 10% PEG 3350, 0.1 M MgCl2",277.0,2015-12-06,2016-02-24,5F6K,5829.0,7.0,749.0,225.0,,86.55,4.0,2.411,experimental,46.5872,0.2284,0.1804,Crystal structure of the MLL3-Ash2L-RbBP5 complex
6MIB,X-RAY DIFFRACTION,2.44,49.49,"VAPOR DIFFUSION, HANGING DROP",7.4,"16% PEG 3,350, 0.1 M Bis-Tris Propane, pH 7.4, 5% 1-Propanol",277.0,2018-09-19,2018-11-07,6MIB,3403.0,2.0,400.0,223.0,,45.89,2.0,1.8,experimental,22.898,0.20778,0.16016,Crystal structure of the ILK ATP-binding deficient mutant (L207W)/alpha-parvin core complex
6ICI,X-RAY DIFFRACTION,2.61,52.95,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Bicine-NaOH pH 9.2, 7% MPD",293.0,2018-09-06,2020-03-04,6ICI,4995.0,1.0,736.0,273.0,,84.14,1.0,2.3,experimental,44.48,0.2144,0.1721,Crystal structure of human MICAL3
8GNN,X-RAY DIFFRACTION,2.92,57.93,"VAPOR DIFFUSION, HANGING DROP",7.5,"Bis-Tris propane pH 7.5, sodium citrate, PEG 3350",293.0,2022-08-24,2023-03-08,8GNN,6546.0,4.0,849.0,252.0,1.0,95.5,4.0,2.119,experimental,,0.2625,0.2174,Crystal structure of the human RAD9-RAD1-HUS1-RAD17 complex
7E50,X-RAY DIFFRACTION,2.15,42.88,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Ammonium formate, 20 % polyethylene glycol 3350 pH 6.6",296.0,2021-02-16,2022-02-16,7E50,2401.0,2.0,334.0,138.0,9.0,36.83,2.0,1.95,experimental,49.15,0.2748,0.218,Crystal structure of human microplasmin in complex with kazal-type inhibitor AaTI
5M9M,X-RAY DIFFRACTION,2.35,47.73,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M ammonium sulphate
0.1 M bis-tris methane
25% PEG 3350",289.0,2016-11-01,2017-02-22,5M9M,4378.0,4.0,496.0,330.0,12.0,58.99,1.0,1.65,experimental,22.922,0.27046,0.23167,Human angiogenin PD variant Q77P
5J0F,X-RAY DIFFRACTION,2.29,46.32,EVAPORATION,,"0.17 M ammonium sulfate, 25.5 % w/v PEG 4K, 15 % v/v Glycerol",293.0,2016-03-28,2017-02-01,5J0F,1879.0,2.0,228.0,263.0,,22.98,1.0,1.25,experimental,20.982,0.1696,0.1293,"Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, circular permutant P4/5"
6HSK,X-RAY DIFFRACTION,3.13,60.72,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis Tris Propane pH 7.5, 0.2 M NaNO3, 17-21% PEG 3350",293.0,2018-10-01,2018-10-31,6HSK,6220.0,2.0,760.0,461.0,,85.3,1.0,2.096,experimental,,0.189,0.152,Crystal structure of a human HDAC8 L6 loop mutant complexed with Quisinostat
5KCH,X-RAY DIFFRACTION,2.38,48.35,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG-3350, 0.2M lithium sulfate, 0.1M bis-tris. Trypsin had been added to the protein stock solution.",291.0,2016-06-06,2016-07-27,5KCH,1910.0,1.0,225.0,115.0,,42.94,1.0,1.7,experimental,25.14,0.2575,0.215,"SETDB1 in complex with an early stage, low affinity fragment candidate modelled at reduced occupancy into weak electron density"
7ATU,X-RAY DIFFRACTION,2.43,49.4,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M citrate pH 5.9
0.2 M NaCl
8% jeffamine M-600
0.005 M iron chloride",277.0,2020-10-30,2020-12-23,7ATU,7875.0,4.0,1240.0,5.0,,145.9,1.0,2.8,experimental,59.79,0.3159,0.2401,The LIMK1 Kinase Domain Bound To LIJTF500025
6E9L,X-RAY DIFFRACTION,2.65,53.5,"VAPOR DIFFUSION, HANGING DROP",6.6,5 to 27% Methanol,277.0,2018-08-01,2018-11-14,6E9L,3067.0,2.0,369.0,140.0,,43.16,2.0,2.8,experimental,50.81,0.271,0.194,Crystal structure of Protein Kinase A in complex with the PKI peptide and a pyridinylbenzamide based inhibitor
5O23,X-RAY DIFFRACTION,3.64,66.22,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG Smear Medium, 0.2 M lithium sulfate, 0.1 M ADA pH 6.5",293.0,2017-05-19,2017-06-28,5O23,4727.0,2.0,570.0,224.0,,67.69,1.0,2.25,experimental,,0.2387,0.2052,Crystal structure of WNK3 kinase domain in a monophosphorylated apo state
7CCW,X-RAY DIFFRACTION,2.03,35.39,"VAPOR DIFFUSION, HANGING DROP",,"1.8 M ammonium sulfate, 0.1 M MES-NaOH pH 6.5, 14.4 mg/mL DAPK1, 2 mM resveratrol",293.0,2020-06-18,2021-01-20,7CCW,2596.0,1.0,293.0,262.0,,34.51,1.0,1.4,experimental,,0.1875,0.17,Crystal structure of death-associated protein kinase 1 in complex with resveratrol and MES
5C6C,X-RAY DIFFRACTION,2.24,44.98,"VAPOR DIFFUSION, HANGING DROP",,"200 mM calcium chloride, 200 mM cadmium chloride, 200 mM cobalt (II) chloride, 20% polyethylene glycol 3350",296.0,2015-06-22,2016-01-20,5C6C,1948.0,2.0,286.0,106.0,,34.89,1.0,2.05,experimental,,0.2426,0.1862,PKG II's Amino Terminal Cyclic Nucleotide Binding Domain (CNB-A) in a complex with cAMP
6EN6,X-RAY DIFFRACTION,3.03,59.39,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",289.0,2017-10-04,2018-03-07,6EN6,23488.0,4.0,2516.0,2381.0,12.0,304.45,1.0,1.8,experimental,,0.2263,0.1934,Crystal structure B of the Angiotensin-1 converting enzyme N-domain in complex with a diprolyl inhibitor.
5JNT,X-RAY DIFFRACTION,2.47,50.11,EVAPORATION,6.5,"20% PEG 3350, 200 mM NaCl, 40 mM MES",293.0,2016-04-30,2017-03-29,5JNT,1591.0,1.0,160.0,275.0,,18.64,1.0,1.45,experimental,15.964,0.1658,0.1346,Crystal structure of human low molecular weight protein tyrosine phosphatase (LMPTP) type A complexed with MES
6W9H,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, HANGING DROP",,"protein at 8-10mg/ml, with 0.2M MgCl2, 22% PEG3350, 0.1M Bis-Tris pH 5.5",295.0,2020-03-23,2020-04-29,6W9H,2211.0,1.0,285.0,134.0,,33.46,1.0,1.995,experimental,31.78,0.2579,0.1982,SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS
6W9I,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, HANGING DROP",,"protein at 8-10mg/ml, with 0.2M MgCl2, 22% PEG3350, 0.1M Bis-Tris pH 5.5",295.0,2020-03-23,2020-04-29,6W9I,2301.0,1.0,285.0,222.0,,33.3,1.0,1.608,experimental,27.62,0.2355,0.1933,SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS
7KXD,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG3350,
0.2 M MAGNESIUM CHLORIDE, 0.1 M BIS-TRIS PH 5.5,
VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K",298.0,2020-12-03,2021-01-20,7KXD,2252.0,1.0,285.0,203.0,,33.23,1.0,1.624,experimental,30.59,0.239,0.1991,"CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH {3,5-DICHLORO-4-[4-METHOXY-3-(PROPAN-2-YL)PHENOXY]PHENYL}METHANOL"
7KXE,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG3350,
0.2 M MAGNESIUM CHLORIDE, 0.1 M BIS-TRIS PH 5.5,
VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K",295.0,2020-12-03,2021-01-20,7KXE,2188.0,1.0,285.0,109.0,,33.33,1.0,2.42,experimental,33.49,0.2414,0.1883,"CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH {3,5-DICHLORO-4-[4-METHOXY-3-(PROPAN-2-YL)PHENOXY]PHENYL}METHANOL"
7KXF,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG3350,
0.2 M MAGNESIUM CHLORIDE, 0.1 M BIS-TRIS PH 5.5,
VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K",298.0,2020-12-03,2021-01-20,7KXF,2195.0,1.0,285.0,101.0,,33.42,1.0,2.141,experimental,33.7,0.2341,0.1939,"CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLEX WITH {3,5-DICHLORO-4-[4-METHOXY-3-(PROPAN-2-YL)PHENOXY]PHENYL}METHANOL"
5KQM,X-RAY DIFFRACTION,2.17,43.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"30% PEGME 5000, 0.2 M ammonium sulfate, 100 mM MES, pH=6.5",293.0,2016-07-06,2016-10-12,5KQM,1358.0,1.0,178.0,121.0,,20.43,1.0,1.91,experimental,,0.2281,0.1847,Co-crystal structure of LMW-PTP in complex with MES
5L79,X-RAY DIFFRACTION,2.38,48.41,"VAPOR DIFFUSION, SITTING DROP",6.8,"protein: hMMP12 689 micro-M + 10 milli-M hydroxamic acid in .2 M NaCl, .02 M TRIS pH 7.5, 3 milli-M CaCl2, 0.1 milli-M ZnCl2 + 1 milli-M RXP470.1-PEG-Cy5.5 
precipitant: 20% PEG4K, 2% dioxane, 0.2 milli-M TRIS pH 9.5
cryoprotectant:  40% CM26 (12.5 % diethylene glycol + 12.5 % ethylene glycol + 12.5 % glycerol + 25 % 2,3-butanediol + 12.5 % DMSO), 25% MPEG 6K, 100 milii-M bistrisPhosphate/Na citrate pH 6.8",293.0,2016-06-02,2016-09-14,5L79,1487.0,1.0,159.0,81.0,,20.12,1.0,2.07,experimental,,0.241,0.206,"Crystal structure of MMP12 in complex with RXP470.1 conjugated with fluorophore Cy5,5 in space group P21212."
7XHG,X-RAY DIFFRACTION,2.34,47.36,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Sodium acetate trihydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5, 30 % w/v Polyethylene glycol 8,000",289.15,2022-04-08,2023-01-18,7XHG,4526.0,7.0,586.0,41.0,,67.28,2.0,2.46,experimental,39.622,0.2746,0.206,Crystal structure of the NTF2L domain of human G3BP1 in complex with the Caprin-1 derived peptide
6W6C,X-RAY DIFFRACTION,3.06,59.85,EVAPORATION,,"0.2 M Ammonium sulfate, 0.1 M Tris pH 48.5, 20% PEG3350",285.0,2020-03-16,2020-07-08,6W6C,4669.0,2.0,626.0,243.0,,70.58,1.0,2.38,experimental,40.81,0.2431,0.1825,Structural and catalytic roles of human 18S rRNA methyltransferases DIMT1 in ribosome assembly and translation
8D7M,X-RAY DIFFRACTION,2.49,50.69,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M Succinic Acid (5.5)
22% PEG 3350",295.0,2022-06-07,2023-05-17,8D7M,5074.0,4.0,622.0,254.0,,72.15,2.0,2.25,experimental,,0.2333,0.1807,Human Casein kinase 1 delta in complex with phosphorylated human PERIOD2 FASP peptide
8D7N,X-RAY DIFFRACTION,2.49,50.54,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Succinic Acid (5.5)
15% PEG 3350",295.0,2022-06-07,2023-05-17,8D7N,5381.0,4.0,626.0,541.0,,72.75,2.0,1.66,experimental,,0.2061,0.1769,Human Casein kinase 1 delta in complex with phosphorylated human PERIOD2 FASP peptide
8D7O,X-RAY DIFFRACTION,2.48,50.46,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.13M Succinic Acid (5.5)
27%PEG3350",295.0,2022-06-07,2023-05-17,8D7O,5340.0,4.0,634.0,500.0,,73.75,2.0,1.65,experimental,,0.2094,0.1725,Human Casein kinase 1 delta in complex with phosphorylated human PERIOD2 FASP peptide
7QHW,X-RAY DIFFRACTION,5.54,77.78,"VAPOR DIFFUSION, HANGING DROP",5.6,"27%  PEG 4000, 200mM NH4SO4, 100 mM Na Citrate pH5.6 and 10 mM TCEP",293.0,2021-12-14,2022-10-26,7QHW,4924.0,2.0,586.0,73.0,,69.26,1.0,2.8,experimental,68.455,0.2285,0.2,TTBK1 kinase domain in complex with inhibitor 29
7W6L,X-RAY DIFFRACTION,2.23,50.04,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM sodium cacodylate, pH 6.5, 10% polyethylene glycol 3350, 0.1 M MgCl2",277.0,2021-12-01,2022-09-07,7W6L,5944.0,7.0,749.0,225.0,,86.55,4.0,2.26,experimental,41.942,0.2231,0.1872,The crystal structure of MLL3-RBBP5-ASH2L in complex with H3K4me0 peptide
7AVY,X-RAY DIFFRACTION,3.58,65.62,VAPOR DIFFUSION,6.5,"co-crystallisation of 0.3 mM protein with 0.5 mM compound (1 % DMSO) in 1.8 M lithium sulfate, 0.1 M PCTP pH 6.5",293.0,2020-11-06,2021-03-03,7AVY,2148.0,1.0,296.0,12.0,,34.74,1.0,2.31,experimental,99.07,0.249,0.228,MerTK kinase domain in complex with quinazoline-based inhbitor
5WY0,X-RAY DIFFRACTION,2.05,39.9,EVAPORATION,,"0.1 M Tris pH 7.5, 0.2 M Magnesium chloride, 10% (w/v) PEG 3350",290.0,2017-01-10,2018-01-17,5WY0,1741.0,1.0,230.0,115.0,,26.52,1.0,2.001,experimental,,0.2462,0.2035,Crystal structure of the methyltranferase domain of human HEN1 in complex with AdoMet
5MJB,X-RAY DIFFRACTION,3.42,64.08,"VAPOR DIFFUSION, SITTING DROP",,"18 % PEG3350, 0.1-0.2 M ammonium sulfate and 0.1 M PCTP (Sodium propionate, Sodium cacodylate trihydrate, Bis-Tris propane) buffer pH 6-9",293.0,2016-11-30,2017-05-17,5MJB,4709.0,2.0,610.0,220.0,,71.01,1.0,2.23,experimental,59.29,0.214,0.198,"Kinase domain of human EphB1, G703C mutant, covalently bound to a quinazoline-based inhibitor"
7T0Y,X-RAY DIFFRACTION,2.15,42.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% ethylene glycol; 10% PEG8000, 0.1 M imidazole; MES acid, 0.09 M Sodium fluoride; 0.09 M Sodium bromide; 0.09 M Sodium iodide",289.0,2021-11-30,2022-12-07,7T0Y,6081.0,4.0,692.0,483.0,,79.9,2.0,1.8,experimental,27.62,0.2462,0.2081,The Ribosomal RNA Processing 1B Protein Phosphatase-1 Holoenzyme
6TLL,X-RAY DIFFRACTION,2.68,54.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M sodium HEPES/MOPS buffer pH 7.5, 20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20000",290.0,2019-12-03,2020-12-16,6TLL,3799.0,1.0,399.0,435.0,,47.46,1.0,1.88,experimental,46.177,0.187,0.1597,"HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (tBBT)"
6TLO,X-RAY DIFFRACTION,2.75,55.19,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M sodium HEPES/MOPS buffer pH 7.5, 20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20000",290.0,2019-12-03,2020-12-16,6TLO,3995.0,1.0,399.0,551.0,,47.09,1.0,1.69,experimental,35.154,0.1713,0.1488,"HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,5,6-TRIBROMOBENZOTRIAZOLE"
6TLS,X-RAY DIFFRACTION,3.14,54.57,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M sodium HEPES/MOPS buffer pH 7.5, 20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20000",290.0,2019-12-03,2020-12-16,6TLS,4152.0,1.0,399.0,590.0,,47.14,1.0,1.46,experimental,32.477,0.1727,0.1539,"HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,6-DIBROMOBENZOTRIAZOLE"
6TLV,X-RAY DIFFRACTION,2.73,54.92,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M sodium HEPES/MOPS buffer pH 7.5, 20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20000",290.0,2019-12-03,2020-12-16,6TLV,4076.0,1.0,399.0,607.0,,46.81,1.0,1.67,experimental,34.744,0.1726,0.1444,HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5-BROMOBENZOTRIAZOLE
6G0O,X-RAY DIFFRACTION,2.11,41.75,"VAPOR DIFFUSION, SITTING DROP",7.0,"20.0 % PEG 6K
10.0 % EtGly
0.1 M HEPES pH 7.0
0.2 M LiCl",277.0,2018-03-19,2018-11-28,6G0O,1355.0,2.0,138.0,168.0,,16.73,2.0,1.4,experimental,16.198,0.1661,0.1336,Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated ATRX peptide (K1030ac/K1033ac)
5W0R,X-RAY DIFFRACTION,2.54,51.52,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.05 M sodium cacodylate at pH 5.5, 20 mM MgCl2, 10 mM CaCl2, 10 mM spermidine, 5% PEG3350",289.0,2017-05-31,2017-08-16,5W0R,8856.0,2.0,1098.0,179.0,,123.8,1.0,2.4,experimental,,0.2393,0.2193,Crystal structure of MBP fused activation-induced cytidine deaminase (AID) in complex with cacodylic acid
6GUU,X-RAY DIFFRACTION,3.8,67.61,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium nitrate
20 % PEG 3350
2 % benzamidine hydrochloride",277.0,2018-06-19,2019-10-09,6GUU,3394.0,2.0,482.0,,,57.43,1.0,2.95,experimental,117.22,0.263,0.2063,Structure of CHD5 PHD2 - tandem chromodomains
5UE4,X-RAY DIFFRACTION,2.28,45.99,VAPOR DIFFUSION,5.5,25% PEG 8K 1% glycerol 0.2 M ammonium sulfate 100 mM NaCacodylate,293.0,2016-12-29,2017-09-13,5UE4,3916.0,2.0,472.0,316.0,,54.14,1.0,1.8,experimental,32.84,0.2243,0.1991,proMMP-9desFnII complexed to JNJ0966 INHIBITOR
5BNJ,X-RAY DIFFRACTION,3.08,60.09,VAPOR DIFFUSION,6.9,"20% PEG3350, 0.2 M sodium formate, pH 6.9,",293.0,2015-05-26,2015-10-14,5BNJ,4929.0,2.0,690.0,57.0,,80.98,2.0,2.64,experimental,46.604,0.2734,0.2261,"CDK8/CYCC IN COMPLEX WITH 8-{3-Chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-pyridin- 4-yl}-2,8-diaza-spiro[4.5]decan-1-one"
5I5Z,X-RAY DIFFRACTION,3.1,59.4,"VAPOR DIFFUSION, HANGING DROP",6.9,"20% PEG3350, 0.2 M sodium formate, pH 6.9",293.0,2016-02-15,2016-04-13,5I5Z,5145.0,2.0,636.0,49.0,,75.23,2.0,2.6,experimental,42.716,0.27423,0.23741,"CDK8-CYCC IN COMPLEX WITH 8-(1-Methyl-2,2-dioxo-2,3-dihydro-1H-2l6-benzo[c]isothiazol-5-yl)-[1,6]naphthyridine-2-carboxylic acid methylamide"
5ICP,X-RAY DIFFRACTION,2.95,58.38,"VAPOR DIFFUSION, HANGING DROP",6.9,"20% PEG3350, 0.2 M sodium formate, pH 6.9",293.0,2016-02-23,2016-12-21,5ICP,5394.0,2.0,631.0,225.0,,75.16,2.0,2.18,experimental,52.441,0.21571,0.18351,"CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-Chloro-phenyl)-pyrrolidin-1-yl]-(5-methyl-imidazo[5,1-b][1,3,4]thiadiazol-2-yl)-methanone"
5IDN,X-RAY DIFFRACTION,3.1,59.6,"VAPOR DIFFUSION, HANGING DROP",6.9,"20% PEG 3350, 0.2 M sodium formate, pH 6.9",293.0,2016-02-24,2016-12-21,5IDN,5273.0,2.0,637.0,187.0,,75.58,2.0,2.26,experimental,38.236,0.25299,0.21989,"CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-Chloro-phenyl)-pyrrolidin-1-yl]-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-methanone"
5IDP,X-RAY DIFFRACTION,3.08,60.13,"VAPOR DIFFUSION, HANGING DROP",6.9,"20% PEG 3350, 0.2 M sodium formate, pH 6.9",293.0,2016-02-24,2016-12-21,5IDP,5175.0,2.0,638.0,66.0,,75.59,2.0,2.65,experimental,46.549,0.27232,0.23098,CDK8-CYCC IN COMPLEX WITH (3-Amino-1H-indazol-5-yl)-[(S)-2-(4-fluoro-phenyl)-piperidin-1-yl]-methanone
6H2V,X-RAY DIFFRACTION,3.32,62.96,"VAPOR DIFFUSION, HANGING DROP",5.6,"25% PEG 4,000; 0.2 M ammonium sulfate; 100 mM Na citrate pH 5.6",277.0,2018-07-16,2019-07-31,6H2V,5209.0,4.0,680.0,28.0,,79.69,2.0,2.49,experimental,75.81,0.249,0.213,"Crystal structure of human METTL5-TRMT112 complex, the 18S rRNA m6A1832 methyltransferase at 2.5A resolution"
6H2U,X-RAY DIFFRACTION,2.24,45.09,"VAPOR DIFFUSION, SITTING DROP",5.6,"25% PEG 4,000; 0.2 M ammonium sulfate; 100 mM Na citrate pH 5.6",277.0,2018-07-16,2019-07-31,6H2U,3009.0,2.0,334.0,320.0,,38.94,2.0,1.6,experimental,25.8144,0.2148,0.1857,"Crystal structure of human METTL5-TRMT112 complex, the 18S rRNA m6A1832 methyltransferase at 1.6A resolution"
6X0P,X-RAY DIFFRACTION,2.39,48.48,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris pH 8.5, 0.2 M MgCl2, 30% PEG4000",290.0,2020-05-17,2021-04-07,6X0P,8288.0,4.0,904.0,1071.0,,107.52,1.0,1.69,experimental,18.93,0.2129,0.1773,Ash1L SET domain Q2265A mutant in complex with AS-5
8UCC,X-RAY DIFFRACTION,2.8,56.08,VAPOR DIFFUSION,,sodium malonate,293.0,2023-09-26,2024-06-26,8UCC,4648.0,2.0,614.0,186.0,,69.97,2.0,1.8,experimental,42.78,0.2399,0.2084,IRAK4 in complex with compound 20
6WS5,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,162 mM triammonium citrate and 18% w/v PEG 3350,293.0,2020-04-30,2020-12-23,6WS5,2565.0,3.0,374.0,1.0,,42.99,3.0,2.472,experimental,70.0,0.2375,0.2014,Rational drug design of phenazopyridine derivatives as novel inhibitors of Rev1-CT
5XOF,X-RAY DIFFRACTION,2.2,44.18,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris-HCl pH8.5, 25% (w/v) PEG 6000",293.0,2017-05-28,2017-10-25,5XOF,4510.0,8.0,508.0,258.0,,60.36,2.0,1.963,experimental,,0.2692,0.2145,Crystal structure of human paired immunoglobulin-like type 2 receptor alpha with synthesized glycopeptide I
5CRV,X-RAY DIFFRACTION,2.55,51.75,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M Bis-Tris, 30%(w/v) polyethylene glycol 3350, 4%(v/v) acetonitrile",293.0,2015-07-23,2016-02-24,5CRV,6327.0,4.0,764.0,365.0,,86.0,2.0,2.001,experimental,,0.2408,0.2125,Crystal structure of the Bro domain of HD-PTP in a complex with the core region of STAM2
7FQH,X-RAY DIFFRACTION,1.4,11.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"26mg/mL deglycosylated protein in 25mM HEPES/NaOH pH7, 300 mM NaCl, 200mM Trehalose incubated with 10-fold excess of ligand, then mixed 50-70% with 50-30% reservoir consisting of 22.5% PEG smear low, 0.1M MES/NaOH, 10% v/v 2-Propanol, total volume 200nL",293.0,2022-10-05,2023-10-11,7FQH,6505.0,3.0,1332.0,88.0,,154.48,1.0,2.18,experimental,38.796,0.2724,0.2234,Crystal Structure of human Legumain in complex with (2S)-N-[(3S)-5-amino-5-oxopent-1-yn-3-yl]-1-[1-[4-(cyclopropylmethoxy)phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide
6FT9,X-RAY DIFFRACTION,2.49,50.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% 1,2-propanediol, 10% glycerol, 0.1 M sodium/potassium phosphate",277.15,2018-02-20,2018-05-16,6FT9,9019.0,3.0,1017.0,554.0,,120.77,1.0,1.87,experimental,42.145,0.20167,0.16635,Crystal structure of CLK1 in complex with inhibitor 16
6YJQ,X-RAY DIFFRACTION,1.55,20.52,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 8.0, 
0.3 M Li2SO4, 
30 % (w/v) PEG 3350, 
10 % (v/v) ethylene glycol",293.0,2020-04-04,2020-08-05,6YJQ,8372.0,2.0,1030.0,287.0,12.0,119.67,1.0,1.9,experimental,46.468,0.2371,0.1941,"Crystal structure of unliganded MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation"
6YJT,X-RAY DIFFRACTION,2.25,45.43,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 8.0, 
0.3 M Li2SO4, 
30 % (w/v) PEG 3350, 
10 % (v/v) ethylene glycol",293.0,2020-04-04,2020-08-05,6YJT,8688.0,2.0,1030.0,330.0,12.0,120.32,1.0,1.7,experimental,54.886,0.2228,0.1845,"Crystal structure of MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation, in complex with UDP"
5N7E,X-RAY DIFFRACTION,2.83,56.47,"VAPOR DIFFUSION, SITTING DROP",7.5,0.12 M monosaccharides (0.2M D-Glucose; 0.2M D-Mannose; 0.2M D-Galactose; 0.2M L-Fucose; 0.2M D-Xylose; 0.2M N-Acetyl-D-Glucosamine); 0.1 M buffer system 2 pH 7.5 (Sodium HEPES; MOPS (acid)); 50% precipitant mix 1 (40% v/v PEG 500* MME; 20 % w/v PEG 20000),291.0,2017-02-20,2017-12-27,5N7E,2602.0,2.0,314.0,348.0,,35.02,2.0,1.647,experimental,36.1086,0.2194,0.1833,Crystal structure of the Dbl-homology domain of Bcr-Abl in complex with monobody Mb(Bcr-DH_4).
4Z83,X-RAY DIFFRACTION,2.33,47.28,"VAPOR DIFFUSION, SITTING DROP",7.0,"The droplets, containing 16 mg/ml PKAB3, 25 mM Bis-Tris-HCl, pH 7.0, 150 mM KCl, 1.5mM octanoyl-N-methylglucamide and 0.8 mM PKI peptide, were equilibrated against 12-26 % (v/v) methanol.",277.0,2015-04-08,2015-12-02,4Z83,3294.0,2.0,370.0,375.0,,43.73,2.0,1.8,experimental,,0.2175,0.1798,PKAB3 in complex with pyrrolidine inhibitor 47a
7FQJ,X-RAY DIFFRACTION,2.01,38.88,"VAPOR DIFFUSION, SITTING DROP",7.8,"25.7mg/mL protein in 25mM HEPES/NaOH pH7, 300 mM NaCl, 200mM Trehalose incubated with 10-fold excess of ligand, then mixed 50-70% with 50-30% reservoir consisting of 20% v/v PEG smear high, 0.15M Li2SO4, 0.05M MgCL2, 0.1M HEPES/NaOH pH 7.8, total volume 200nL",293.0,2022-10-05,2023-10-11,7FQJ,7348.0,3.0,1332.0,667.0,,155.99,1.0,1.7,experimental,20.92,0.201,0.169,"Crystal Structure of human Legumain in complex with (2S)-N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[1-[4-[(2,4-difluorophenyl)methoxy]phenyl]cyclopropanecarbonyl]pyrrolidine-2-carboxamide"
6H5W,X-RAY DIFFRACTION,2.37,48.05,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.1 M MIB Buffer pH 4.0, 5% Glycerol, 16% PEG 3350",289.0,2018-07-25,2018-11-07,6H5W,5842.0,1.0,591.0,643.0,3.0,71.73,1.0,1.37,experimental,,0.1753,0.1452,Crystal structure of human Angiotensin-1 converting enzyme C-domain in complex with Omapatrilat.
6ZPU,X-RAY DIFFRACTION,2.31,46.73,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.1 M MIB pH 4.0, 5% glycerol, 15% PEG 3350",289.0,2020-07-09,2020-10-28,6ZPU,5248.0,1.0,597.0,279.0,3.0,71.29,1.0,2,experimental,39.6,0.2354,0.1906,Crystal structure of Angiotensin-1 converting enzyme C-domain with inserted symmetry molecule C-terminus.
4UI4,X-RAY DIFFRACTION,2.4,49.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-27,2016-04-13,4UI4,3603.0,4.0,478.0,165.0,,55.66,2.0,2.4,experimental,31.971,0.23059,0.17218,Crystal structure of human tankyrase 2 in complex with TA-29
5C5P,X-RAY DIFFRACTION,2.44,49.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"30-40% PEG 3350, 5% SATURATED AMMONIUM SULFATE, 0.1M TRIS PH 8.5",298.0,2015-06-21,2015-08-12,5C5P,3851.0,4.0,480.0,446.0,,55.7,2.0,1.75,experimental,27.9,0.202,0.18,CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR
5C5Q,X-RAY DIFFRACTION,2.43,49.31,"VAPOR DIFFUSION, SITTING DROP",8.5,"30-40% PEG 3350, 5% SATURATED AMMONIUM  SULFATE, 0.1M TRIS PH 8.5",298.0,2015-06-21,2015-08-12,5C5Q,3757.0,4.0,480.0,369.0,,55.67,2.0,2,experimental,32.2,0.22,0.191,CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR
5C5R,X-RAY DIFFRACTION,2.44,49.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"30-40% PEG 3350, 5% SATURATED AMMONIUM SULFATE, 0.1M TRIS PH 8.5",298.0,2015-06-21,2015-08-12,5C5R,3966.0,4.0,480.0,521.0,,55.59,2.0,1.55,experimental,22.0,0.202,0.188,CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR
7OLJ,X-RAY DIFFRACTION,2.69,54.31,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris pH=8.5, 200mM Lithium Sulphate, 20% PEG3350",277.15,2021-05-20,2021-12-08,7OLJ,3728.0,4.0,438.0,288.0,,50.82,2.0,1.8,experimental,34.561,0.2126,0.191,Tankyrase 2 in complex with an inhibitor (OUL219)
7OM1,X-RAY DIFFRACTION,2.67,53.92,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris pH=8.5, 200mM Lithium Sulphate, 22% PEG3350",277.15,2021-05-21,2021-12-08,7OM1,3811.0,4.0,438.0,357.0,,50.85,2.0,1.7,experimental,31.0,0.1967,0.1824,Tankyrase 2 in complex with an inhibitor (OUL220)
7OMC,X-RAY DIFFRACTION,2.63,53.29,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris pH=8.5, 200mM Lithium Sulphate, 20% PEG3350",277.15,2021-05-21,2021-12-08,7OMC,3622.0,4.0,438.0,211.0,,50.82,2.0,2.1,experimental,50.196,0.2261,0.1807,Tankyrase 2 in complex with an inhibitor (OUL228)
6B67,X-RAY DIFFRACTION,2.26,45.55,"VAPOR DIFFUSION, HANGING DROP",7.3,"Protein conc: 20 mg/ml
Protein buffer: 10 mM MES, pH 7.0, 150 mM NaCl, 2 mM TCEP and 2 mM MgCl2
Protein and cyclic peptide was dialyzed against above buffer and mixed at the 1:2 molar ratio
Precipitant: 0.1M HEPES (pH 7.3), 0.1M calcium acetate and 40% PEG400",293.0,2017-10-01,2018-04-11,6B67,7726.0,6.0,909.0,633.0,,101.95,2.0,2.2,experimental,,0.229,0.169,Human PP2Calpha (PPM1A) complexed with cyclic peptide c(MpSIpYVA)
8T72,X-RAY DIFFRACTION,1.81,31.96,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M NaBr, 20% PEG 3350",293.0,2023-06-19,2024-02-14,8T72,3979.0,3.0,534.0,163.0,,62.94,1.0,1.6,experimental,50.3754,0.2362,0.1917,Crystal structure of WT KRAS4a with bound GMPPNP and Mg ion
6PED,X-RAY DIFFRACTION,2.81,56.21,"VAPOR DIFFUSION, SITTING DROP",,2 M sodium/potassium phosphate,291.0,2019-06-20,2019-07-03,6PED,2372.0,2.0,376.0,,,41.81,2.0,2.3,experimental,54.211,0.2425,0.1921,Crystal structure of HEMK2-TRMT112 complex
6H45,X-RAY DIFFRACTION,2.66,53.7,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Tris pH 7.8
200 mM KBr
200 mM KSCN
3 % (w/v) PGA-LM
5 % (w/v) PEG 4000",293.0,2018-07-20,2018-09-05,6H45,6205.0,2.0,786.0,103.0,,87.64,1.0,2.4,experimental,58.0269,0.2396,0.2013,crystal structure of the human TGT catalytic subunit QTRT1 in complex with queuine
6YJS,X-RAY DIFFRACTION,2.16,43.01,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 8.0, 
0.3 M Li2SO4, 
30 % (w/v) PEG 3350, 
10 % (v/v) ethylene glycol
wXHPcQHrME",293.0,2020-04-04,2020-08-05,6YJS,8455.0,2.0,1030.0,466.0,12.0,121.9,1.0,1.6,experimental,34.716,0.2145,0.1841,"Crystal structure of MGAT5 (alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase V) luminal domain with a Lys329-Ile345 loop truncation, in complex with biantennary pentasaccharide M592"
6VZK,X-RAY DIFFRACTION,2.19,43.77,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 6000, 50 mM HEPES, 3-Aminobenzene-sulfonic acid, 5-Sulfosalicylic acid dihydrate,  p-Coumaric acid, PIPES, Terephthalic acid, Vanillic acid",277.0,2020-02-28,2020-04-22,6VZK,2092.0,1.0,268.0,5.0,,30.71,1.0,2.55,experimental,34.924,0.2944,0.2103,Crystal structure of human CaMKII-alpha (CAMK2A)kinase domain
5DQC,X-RAY DIFFRACTION,3.21,61.66,"VAPOR DIFFUSION, HANGING DROP",,"PEG400
Na citrate
MgSO4",293.0,2015-09-14,2016-02-17,5DQC,9054.0,3.0,1170.0,128.0,9.0,132.37,1.0,2.4651,experimental,60.0407,0.2352,0.1847,Co-crystal of BACE1 with compound 0211
6YYU,X-RAY DIFFRACTION,2.95,58.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM HEPES sodium, 10% v/v 2-Propanol, 20% w/v PEG 4000, 1 mM manganese chloride, 2 mM 2-oxoglutarate, 18 mg/ml protein",277.0,2020-05-06,2021-03-17,6YYU,3426.0,1.0,429.0,96.0,1.0,49.61,1.0,2.11,experimental,64.8,0.2313,0.2023,Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese and 2-oxoglutarate
6YYV,X-RAY DIFFRACTION,3.04,59.49,"VAPOR DIFFUSION, SITTING DROP",7.9,"200 mM magnesium acetate tetrahydrate, 20% w/v PEG 3350, 1 mM manganese chloride, 2 mM 3-methyl-2-oxoglutarate, 18 mg/ml protein",277.0,2020-05-06,2021-03-17,6YYV,3835.0,1.0,429.0,408.0,1.0,49.62,1.0,1.77,experimental,52.66,0.2084,0.1727,Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with manganese and 3-methyl-2-oxoglutarate
5JFR,X-RAY DIFFRACTION,2.72,54.72,"VAPOR DIFFUSION, HANGING DROP",7.0,"40% MPD, 0.1M Hepes pH 7.0",277.0,2016-04-19,2016-05-25,5JFR,3273.0,1.0,369.0,340.0,1.0,41.91,1.0,1.6,experimental,34.875,0.1714,0.1358,"Potent, Reversible MetAP2 Inhibitors via Fragment Based Drug Discovery"
4XDE,X-RAY DIFFRACTION,2.64,53.33,"VAPOR DIFFUSION, SITTING DROP",,"1.2 M Ammonium sulphate, 0.05 M tri-sodium citrate, 3%(w/v) isopropanol.",293.0,2014-12-19,2015-02-04,4XDE,1947.0,1.0,257.0,97.0,6.0,28.19,1.0,2.14,experimental,29.211,0.26235,0.22223,Coagulation Factor XII protease domain crystal structure
5EYC,X-RAY DIFFRACTION,2.04,39.77,"VAPOR DIFFUSION, HANGING DROP",7.8,"12% PEG 4000, 3% (v/v) ethanol, 6% (v/v) isopropanol, 40 mM beta-mercaptoethanol, 100 mM HEPES (pH 7.8)",293.0,2015-11-24,2016-02-10,5EYC,2589.0,1.0,309.0,255.0,,35.61,1.0,1.8,experimental,31.058,0.2472,0.1917,Crystal structure of c-Met in complex with naphthyridinone inhibitor 5
5EYD,X-RAY DIFFRACTION,2.04,39.68,"VAPOR DIFFUSION, HANGING DROP",7.8,"12% PEG 4000, 3% (v/v) ethanol, 6% (v/v) isopropanol, 40 mM beta-mercaptoethanol, 100 mM HEPES (pH 7.8)",293.0,2015-11-24,2016-02-10,5EYD,2598.0,1.0,309.0,247.0,,35.68,1.0,1.85,experimental,29.2,0.2489,0.1933,Crystal structure of c-Met in complex with AMG 337
4UDB,X-RAY DIFFRACTION,2.83,56.5,,8.5,"18% PEG4K, 0.14M LISO4, 85MM TRIS PH 8.5, 15% GLYCEROL",,2014-12-09,2015-11-25,4UDB,2227.0,2.0,287.0,60.0,,34.2,2.0,2.36,experimental,53.9,0.2181,0.1819,MR in complex with desisobutyrylciclesonide
6T36,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",7.0,"20% w/v PEG 3350, 0.2 M NaBr",277.15,2019-10-10,2021-01-20,6T36,880.0,2.0,1125.0,68.0,,128.6,2.0,1.86,experimental,43.0,0.2392,0.1953,Crystal structure of the PTPN3 PDZ domain bound to the HBV core protein C-terminal peptide
5L3D,X-RAY DIFFRACTION,4.3,82.0,"VAPOR DIFFUSION, HANGING DROP",5.6,"Tartrate 1-1.4 M, ADA 100 mM pH 5.6",298.0,2016-04-06,2016-05-04,5L3D,6408.0,2.0,1334.0,64.0,,146.87,2.0,2.6,experimental,79.843,0.21877,0.20759,Human LSD1/CoREST: LSD1 Y761H mutation
6A84,X-RAY DIFFRACTION,2.64,53.36,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH 8.5, 2.4M (NH4)2HPO4",277.0,2018-07-06,2019-04-03,6A84,1846.0,2.0,216.0,141.0,,25.14,2.0,1.98,experimental,,0.2136,0.1691,Tankyrase-2 in complex with compound 15d
6RK9,X-RAY DIFFRACTION,2.69,54.34,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM Bis-tris propane, 200 mM potassium thiocyanate, 20% PEG 3350, 2 mM N-oxalylglycine, 1 mM manganese chloride, 3.3 mM cyclic peptide, 18 mg/ml asph protein",277.0,2019-04-30,2019-05-08,6RK9,7223.0,3.0,877.0,230.0,2.0,101.22,2.0,2.292,experimental,54.2343,0.235,0.2107,"Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese, N-oxalylglycine and cyclic peptide substrate mimic of factor X"
5JOE,X-RAY DIFFRACTION,4.77,74.19,"VAPOR DIFFUSION, SITTING DROP",8.5,0.1M Tris pH 8.5; 30% w/v PEG 4000,292.15,2016-05-02,2016-08-17,5JOE,952.0,1.0,92.0,179.0,,10.64,1.0,2,experimental,,0.2184,0.1775,Crystal structure of I81 from titin
6B92,X-RAY DIFFRACTION,4.77,74.23,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M K2HPO4, 45 mM NaH2PO4; drop contained 4 uL of protein solution (27 mg/mL) and 2 uL of reservoir solution; 0.2 uL of 200 mM SAM solution (buffered in 50 mM Hepes pH7.5) was added to the drop with mature crystals. 25% ethylene glycol was used for cryo-protection",293.0,2017-10-09,2018-04-04,6B92,2386.0,1.0,294.0,181.0,,34.25,1.0,2.1,experimental,54.009,0.219,0.181,Crystal Structure of the N-terminal domain of human METTL16 in complex with SAH
7S8Y,X-RAY DIFFRACTION,2.68,54.1,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES, pH 7 and 1.6 M sodium citrate dihydrate",291.0,2021-09-20,2022-08-03,7S8Y,2212.0,1.0,237.0,255.0,,26.74,1.0,1.59,experimental,28.28,0.1913,0.1645,Cryogenic apo Human Hsp90a-NTD
7S8Z,X-RAY DIFFRACTION,2.81,56.28,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES, pH 7 and 1.6 sodium citrate dihydrate",291.0,2021-09-20,2022-08-03,7S8Z,1956.0,1.0,237.0,145.0,,26.74,1.0,1.64,experimental,31.18,0.1683,0.1499,Room-temperature apo Human Hsp90a-NTD
4ZSR,X-RAY DIFFRACTION,2.6,52.77,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG8000, sodium cacodylate, ammonium sulfate",277.0,2015-05-13,2015-06-10,4ZSR,7305.0,2.0,884.0,1049.0,6.0,98.67,1.0,1.65,experimental,15.61,0.20348,0.18752,BACE crystal structure with tricyclic aminothiazine inhibitor
7MYU,X-RAY DIFFRACTION,2.62,53.07,"VAPOR DIFFUSION, SITTING DROP",,"100mM sodium cacodylate pH 7.4, 12% PEG 8K, 200mM ammonium sulfate",277.0,2021-05-21,2021-07-21,7MYU,6990.0,2.0,884.0,730.0,6.0,99.03,1.0,1.94,experimental,24.129,0.2264,0.1866,BACE-1 in complex with compound #22
8BOP,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2022-11-15,2024-06-05,8BOP,6368.0,2.0,1015.0,,,112.58,2.0,2.74,experimental,,0.2619,0.2412,"LSD1-CoREST in complex with AW4, long soaking"
8F6S,X-RAY DIFFRACTION,5.58,77.96,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2022-11-17,2024-06-12,8F6S,6381.0,2.0,1015.0,,,112.9,2.0,2.91,experimental,,0.2443,0.2144,LSD1-CoREST in complex with T105
8FJ4,X-RAY DIFFRACTION,5.54,77.8,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2022-12-19,2024-06-26,8FJ4,6434.0,2.0,1015.0,,,113.47,2.0,2.76,experimental,,0.2477,0.224,"LSD1-CoREST in complex with T108, short soaking"
8FJ6,X-RAY DIFFRACTION,5.6,78.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2022-12-19,2024-06-26,8FJ6,6365.0,2.0,1015.0,,,112.55,2.0,2.63,experimental,,0.2405,0.2189,"LSD1-CoREST in complex with T108, long soaking"
8FQJ,X-RAY DIFFRACTION,5.58,77.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2023-01-06,2024-06-26,8FQJ,6365.0,2.0,1015.0,,,112.57,2.0,2.9,experimental,,0.2456,0.2178,"LSD1-CoREST in complex with T14, short soaking"
8FRI,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 M Sodium/Potassium Tartrate, 100 mM ADA pH 6.5",293.0,2023-01-07,2024-08-07,8FRI,6368.0,2.0,1015.0,,,112.58,2.0,2.8,experimental,,0.2412,0.2157,"LSD1-CoREST in complex with AW4, short soaking"
8FRQ,X-RAY DIFFRACTION,5.64,78.18,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2023-01-08,2024-08-07,8FRQ,6437.0,2.0,1015.0,,,112.57,2.0,2.89,experimental,,0.2409,0.2175,"LSD1-CoREST in complex with T14, long soaking"
8FRV,X-RAY DIFFRACTION,5.6,78.04,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Sodium/Potassium Tartrate, 100 mM ADA pH 6.5",298.0,2023-01-09,2024-08-07,8FRV,6361.0,2.0,1015.0,,,112.5,2.0,2.72,experimental,,0.2479,0.2187,"LSD1-CoREST in complex with T17, short soaking"
5L3E,X-RAY DIFFRACTION,,82.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.3 M Na/K Tartrate, 100 mM ADA",293.0,2016-04-10,2016-09-21,5L3E,6522.0,2.0,908.0,,,104.73,2.0,2.8,experimental,72.636,0.22447,0.20046,LSD1-CoREST1 in complex with quinazoline-derivative reversible inhibitor
5YJB,X-RAY DIFFRACTION,7.09,82.64,"VAPOR DIFFUSION, HANGING DROP",,"0.1M N-(2-ACETAMIDO)IMINODIACETIC ACID (PH 5.5), 1.23M POTASSIUM SODIUM TARTRATE TETRAHYDRATE",293.0,2017-10-10,2018-07-04,5YJB,6313.0,2.0,809.0,,,91.54,2.0,2.96,experimental,,0.219,0.189,LSD1-CoREST in complex with 4-[5-(piperidin-4-ylmethoxy)-2-(p-tolyl)pyridin-3-yl]benzonitrile
6W4K,X-RAY DIFFRACTION,7.24,83.0,"VAPOR DIFFUSION, HANGING DROP",6.5,1.3M Na Tartrate,298.0,2020-03-11,2020-10-21,6W4K,6223.0,2.0,791.0,22.0,,89.77,2.0,2.93,experimental,89.562,0.2352,0.1914,Crystal structure of Lysine Specific Demethylase 1 (LSD1) with CC-90011
7JXX,X-RAY DIFFRACTION,1.86,34.01,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M TRIS pH 8.5, 0.2M Na Acetate 20% PEG3350",295.0,2020-08-28,2021-05-19,7JXX,2774.0,1.0,332.0,291.0,,38.28,1.0,1.56,experimental,34.64,0.2126,0.1797,Structure of TTBK1 kinase domain in complex with Compound 3
5L9Z,X-RAY DIFFRACTION,2.49,50.64,"VAPOR DIFFUSION, SITTING DROP",5.5,"17% PEG3350
0.1 M MES 5.5
0.1 M MgCl2
200 nL:500 nL protein:drop ratio",293.0,2016-06-13,2017-05-31,5L9Z,4231.0,2.0,466.0,402.0,1.0,54.04,2.0,1.57,experimental,29.93,0.19334,0.16593,"Crystal structure of human heparanase nucleophile mutant (E343Q), in complex with unreacted glucuronic acid configured aziridine probe JJB355"
6ZDM,X-RAY DIFFRACTION,2.37,48.16,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES pH 5.5, 0.1 M MgCl2, 17% PEG3350",293.0,2020-06-14,2020-10-21,6ZDM,3930.0,2.0,466.0,191.0,1.0,53.71,2.0,1.714,experimental,39.659,0.2412,0.1788,"Crystal structure of human heparanase in complex with a N',6O'-bis-sulfated 4-methylumbelliferyl heparan sulfate disaccharide"
8B2N,X-RAY DIFFRACTION,2.07,40.46,"VAPOR DIFFUSION, SITTING DROP",,"The PotA:MMP-12 complex at 8.5 mg/mL in 2.5 mM calcium chloride, 150 mM sodium chloride, 20 mM Tris-HCl pH 7.5 was crystallised from 30% (w/v) PEG 3,000, 200 mM sodium chloride, 100 mM Tris-HCl pH 7.0.",293.0,2022-09-14,2022-12-21,8B2N,4246.0,4.0,506.0,289.0,4.0,56.99,2.0,1.85,experimental,40.97,0.228,0.19,Potempin A (PotA) from Tannerella forsythia in complex with the catalytic domain of human MMP-12
6JQR,X-RAY DIFFRACTION,3.35,63.26,VAPOR DIFFUSION,,"buffer, salt, precipitant",293.0,2019-04-01,2019-11-20,6JQR,2545.0,1.0,330.0,97.0,,39.34,1.0,2.2,experimental,54.61,0.213,0.179,Crystal structure of FLT3 in complex with gilteritinib
4RN2,X-RAY DIFFRACTION,2.44,49.52,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M BisTris (pH = 6.5), 4 mM tris(2-carboxyethyl)phosphine (TCEP), 8% PEG 3350, VAPOR DIFFUSION, SITTING DROP, temperature 294K",294.0,2014-10-22,2015-04-08,4RN2,5735.0,2.0,778.0,182.0,,87.79,1.0,2.39,experimental,40.07,0.2241,0.1867,Crystal structure of S39D HDAC8 in complex with a largazole analogue.
5CQU,X-RAY DIFFRACTION,2.02,39.11,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein solution: 6 mg/ml CK2alpha, 0.44 mM AMPPNP, 0.89 mM magnesium chloride, 250 mM NaCl, 12.5 mM Tris/HCl, pH 8.5; Reservoir: 30%(w/v) PEG4000, 0.2 M Lithiumsulfate, 0.1 M Tris/HCL, pH 8.5; the inhibitor JRJ was introduced by extensive soaking for one week",298.0,2015-07-22,2015-09-09,5CQU,2950.0,1.0,335.0,118.0,,41.14,1.0,2.35,experimental,,0.2514,0.196,Monoclinic Complex Structure of Protein Kinase CK2 Catalytic Subunit with a Benzotriazole-Based Inhibitor Generated by click-chemistry
5E8M,X-RAY DIFFRACTION,2.54,52.0,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES pH 5.5, 0.1 M MgCl2, 17% PEG3350",293.0,2015-10-14,2015-11-18,5E8M,4061.0,2.0,466.0,249.0,1.0,54.57,2.0,1.75,experimental,37.357,0.19989,0.16411,Crystal structure of human heparanase
5E97,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES [5.5]
0.1 M MgCl2
17% PEG3350",293.0,2015-10-14,2015-11-18,5E97,4171.0,2.0,466.0,397.0,1.0,54.22,2.0,1.63,experimental,29.499,0.19677,0.16571,Glycoside Hydrolase ligand structure 1
5E98,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES [5.5]
0.1 M MgCl2
17% PEG3350",293.0,2015-10-14,2015-11-18,5E98,3989.0,2.0,466.0,243.0,1.0,53.79,2.0,1.63,experimental,35.312,0.2063,0.1697,Crystal structure of human heparanase in complex with HepMer M04S02a
5E9B,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES [5.5]
0.1 M MgCl2 
17% PEG3350",293.0,2015-10-14,2015-11-18,5E9B,3955.0,2.0,466.0,201.0,1.0,53.91,2.0,1.88,experimental,40.236,0.2172,0.1781,Crystal structure of human heparanase in complex with HepMer M09S05a
5E9C,X-RAY DIFFRACTION,2.46,50.02,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES pH 5.5, 0.1 M MgCl2, 17% PEG3350",293.0,2015-10-15,2015-11-18,5E9C,3998.0,2.0,466.0,224.0,1.0,54.15,2.0,1.73,experimental,36.573,0.2105,0.17208,Crystal structure of human heparanase in complex with heparin tetrasaccharide dp4
5L9Y,X-RAY DIFFRACTION,2.49,50.56,VAPOR DIFFUSION,,"0.1 M MES pH 5.5, 0.1 M MgCl2, 17% PEG3350, 200:500 nl protein:well ratio",293.0,2016-06-13,2017-05-31,5L9Y,3957.0,2.0,466.0,227.0,1.0,53.63,2.0,1.88,experimental,40.063,0.2217,0.17925,"Crystal structure of human heparanase, in complex with glucuronic acid configured aziridine probe JJB355"
8VW4,X-RAY DIFFRACTION,2.66,53.68,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M NaCitrate, 20% PEG3350",293.0,2024-01-31,2024-07-03,8VW4,5301.0,2.0,620.0,171.0,,73.99,1.0,2.4,experimental,,0.2531,0.1988,Crystal structure of Cbl-b TKB bound to compound 26
5X8U,X-RAY DIFFRACTION,2.36,47.8,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Sodium acetate pH8.0, 4M ammonium acetate",277.0,2017-03-03,2017-06-07,5X8U,2283.0,2.0,273.0,204.0,,31.67,2.0,2,experimental,28.836,0.24704,0.20759,Crystal Structure of the wild Human ROR gamma Ligand Binding Domain.
5X8W,X-RAY DIFFRACTION,2.35,47.76,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Sodium acetate pH8.0, 4M ammonium acetate",277.0,2017-03-03,2017-06-07,5X8W,2221.0,2.0,273.0,152.0,,31.53,2.0,2.3,experimental,35.654,0.2296,0.21216,Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain.
5N5J,X-RAY DIFFRACTION,2.16,42.96,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris-HCl, 20% PEG 6000",293.0,2017-02-14,2017-11-01,5N5J,1408.0,1.0,158.0,141.0,,18.14,1.0,1.8,experimental,15.609,0.19533,0.12545,"Human MMP12 in complex with 3-(5-(1,2-dithiolan-3-yl)pentanamido)propane-1-sulfonate"
5N5K,X-RAY DIFFRACTION,2.15,42.88,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris-HCl, 20% PEG 6000",293.0,2017-02-14,2017-11-01,5N5K,1422.0,1.0,156.0,169.0,,17.92,1.0,1.8,experimental,16.315,0.22736,0.16721,"Human catalytic MMP-12 in complex with 5-(1,2-dithiolan-3-yl)-N-(3-hydroxypropyl)pentanamide"
6M14,X-RAY DIFFRACTION,2.64,53.34,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES pH 6.5, 0.2 M ammonium sulfate,22% PEG 5000",295.0,2020-02-24,2021-02-24,6M14,3734.0,2.0,420.0,349.0,,48.33,1.0,1.88001831059,experimental,30.1768193221,0.197539814327,0.16990566604,Crystal Structure of the BARD1 BRCT Mutant
5IE1,X-RAY DIFFRACTION,2.8,56.1,"VAPOR DIFFUSION, HANGING DROP",,"20% polyethylene glycol 5000 MME, 200 mM ammonium iodide, 170 mM sodium citrate (pH 6.6)",293.0,2016-02-24,2016-03-30,5IE1,3109.0,1.0,411.0,215.0,3.0,46.9,1.0,2.298,experimental,37.0094,0.2543,0.2135,"Crystal structure of BACE1 in complex with 3-(2-amino-6-(o-tolyl)quinolin-3-yl)-N-(3,3-dimethylbutyl)propanamide"
7D2X,X-RAY DIFFRACTION,2.73,54.87,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium citrate tribasic pH 6.5, 0.2 M ammonium iodide, 19.6% w/v PEG 5000MME",293.0,2020-09-17,2021-03-31,7D2X,3122.0,1.0,416.0,175.0,3.0,47.21,1.0,2.45,experimental,39.417,0.2285,0.1846,"Crystal Structure of BACE1 in complex with N-{3-[(4R)-2-amino-4-(prop-1-yn-1-yl)-5,6-dihydro-4H-1,3-oxazin-4-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide"
5EPB,X-RAY DIFFRACTION,4.08,69.86,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2015-11-11,2016-11-23,5EPB,1369.0,1.0,130.0,221.0,,16.25,1.0,1.5,experimental,30.9246,0.1857,0.1671,Crystal structure of the bromodomain of human ATAD2 in complex with Compound 49
5F3A,X-RAY DIFFRACTION,4.1,70.03,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5",277.0,2015-12-02,2016-12-14,5F3A,1187.0,1.0,130.0,93.0,,15.78,1.0,1.599,experimental,35.8647,0.21,0.1791,Crystal structure of the bromodomain of human ATAD2 in complex with Compound A14
5R4F,X-RAY DIFFRACTION,4.21,70.76,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-21,2020-05-13,5R4F,1395.0,1.0,130.0,226.0,,15.89,1.0,1.44,experimental,20.166,0.1766,0.1686,PanDDA analysis group deposition of ground-state model of ATAD2
8RU5,X-RAY DIFFRACTION,2.37,48.17,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG6000
10% ethylene glycol
0.1M tris pH 7.5
0.1M calcium chloride",293.0,2024-01-30,2024-03-06,8RU5,1230.0,1.0,130.0,133.0,,15.64,1.0,1.36,experimental,29.255,0.2214,0.2109,ATPase family AAA domain containing 2 with crystallization epitope mutations V1022R:Q1027E
5ZN1,X-RAY DIFFRACTION,2.0,38.58,VAPOR DIFFUSION,8.5,"0.1M Tris-HCl, 1.2M ammonium sulfate, 5% acetonitrile, 2mM DTT",293.0,2018-04-07,2018-11-21,5ZN1,3290.0,1.0,329.0,480.0,,39.54,1.0,1.05,experimental,,0.18,0.16,X-ray structure of protein kinase ck2 alpha subunit in D2O
5ZN4,X-RAY DIFFRACTION,1.99,38.2,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris-HCl, 1.2M ammonium sulfate, 5% acetonitrile, 2mM DTT",293.0,2018-04-07,2018-11-21,5ZN4,3040.0,1.0,329.0,265.0,,39.51,1.0,1.651,experimental,,0.2386,0.1971,X-ray structure of protein kinase ck2 alpha subunit H148N mutant
5ZN5,X-RAY DIFFRACTION,1.99,38.1,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris-HCl, 1.2M ammonium sulfate, 5% acetonitrile, 2mM DTT",293.0,2018-04-07,2018-11-21,5ZN5,3028.0,1.0,329.0,241.0,,39.6,1.0,1.7,experimental,,0.2223,0.1843,X-ray structure of protein kinase ck2 alpha subunit H148A mutant
7UP6,X-RAY DIFFRACTION,3.06,59.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"Crystals were produced by sitting drop vapor diffusion with an equal volume of the protein, Msk1-C terminal domain (PID6598-1, CID101276) at 4.91 mg/ml in 25mM HEPES pH 7.5, 150mM NaCl, 5% Glycerol, 5mM BME and a crystallization buffer containing 12.5% PEG 1000, 12.5% PEG 3350, 12.5% MPD: 20mM of each sodium formate, ammonium acetate, trisodium citrate, sodium-potassium tartrate, sodium oxamate: 100 mM MOPS / HEPES-Na pH 7.5 (tray ID 298849, well G8, Morpheus). Crystals were direly vitrified in in liquid N2. Puck ID BOW0-8",289.0,2022-04-14,2022-08-31,7UP6,2035.0,1.0,306.0,49.0,,35.14,1.0,2.6,experimental,61.88,0.209,0.166,Crystal structure of C-terminal domain of MSK1 in complex with in covalently bound literature RSK2 inhibitor pyrrolopyrimidine cyanoacrylamide compound 25 (co-crystal)
5N9T,X-RAY DIFFRACTION,2.4,48.69,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 4000, Li2 Sulfate, Tris",277.0,2017-02-27,2017-12-06,5N9T,6808.0,2.0,714.0,880.0,,84.71,1.0,1.73,experimental,42.66,0.224,0.161,"Crystal structure of USP7 in complex with a potent, selective and reversible small-molecule inhibitor"
8D95,X-RAY DIFFRACTION,1.97,37.0,"VAPOR DIFFUSION, HANGING DROP",5.8,PEG 6k,300.0,2022-06-09,2022-11-02,8D95,1742.0,1.0,230.0,56.0,4.0,25.01,1.0,2.166,experimental,30.734,0.2629,0.2018,Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors
8DG6,X-RAY DIFFRACTION,2.08,40.93,"VAPOR DIFFUSION, HANGING DROP",5.8,peg4k 20-30%,300.0,2022-06-23,2022-11-02,8DG6,1712.0,1.0,228.0,87.0,4.0,24.9,1.0,1.986,experimental,25.135,0.2512,0.1974,Scaffold Hopping via Ring Opening Enables Identification of Acyclic Compounds as New Complement Factor D Inhibitors
4RCD,X-RAY DIFFRACTION,2.83,56.54,VAPOR DIFFUSION,6.6,"21% polyethylene glycol 5000 monomethyl ether, 180 mM sodium citrate, pH 6.6, 200 mM ammonium iodide, VAPOR DIFFUSION, temperature 298K",298.0,2014-09-15,2015-01-21,4RCD,3316.0,1.0,411.0,370.0,3.0,46.83,1.0,1.9,experimental,30.512,0.251,0.2139,Crystal structure of BACE1 in complex with a 2-aminooxazoline 4-azaxanthene inhibitor
5UYU,X-RAY DIFFRACTION,2.81,56.19,VAPOR DIFFUSION,6.6,"21% polyethylene glycol 5000 MME, 180 mM sodium citrate (pH 6.6), 200 mM ammonium iodide, 3% (v/v) DMSO",298.0,2017-02-24,2017-05-17,5UYU,3329.0,1.0,411.0,370.0,3.0,47.0,1.0,1.9,experimental,29.7,0.228,0.2052,Crystal structure of BACE1 in complex with 2-aminooxazoline-3-azaxanthene compound 12
5CI7,X-RAY DIFFRACTION,2.02,38.99,"VAPOR DIFFUSION, HANGING DROP",5.0,"1.55 M sodium malonate pH 7.0, 0.35 M sodium malonate pH 5.0",298.0,2015-07-11,2015-08-26,5CI7,2464.0,1.0,287.0,156.0,,33.08,1.0,1.74,experimental,,0.2069,0.1688,Structure of ULK1 bound to a selective inhibitor
6F9V,X-RAY DIFFRACTION,2.81,56.16,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent Cations, 30% PEG550MME/PEG20000",289.0,2017-12-15,2018-03-07,6F9V,12014.0,2.0,1258.0,962.0,6.0,150.52,1.0,1.69,experimental,,0.2121,0.1834,Crystal structure of human Angiotensin-1 converting enzyme N-domain in complex with Sampatrilat.
8C14,X-RAY DIFFRACTION,3.6,65.8,VAPOR DIFFUSION,6.5,"5% DMSO, 0.2M MgSO4, 0.05 M HEPES 7.4: soaking: 0.2M MgSO4, 0.05M HEPES 7.4, 30% glycerol, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C14,2513.0,1.0,272.0,205.0,1.0,33.71,1.0,1.93,experimental,42.85,0.1944,0.1809,Aurora A kinase in complex with TPX2-inhibitor 9
6MAK,X-RAY DIFFRACTION,2.35,47.58,"VAPOR DIFFUSION, SITTING DROP",,"Protein at 2.5 mg/mL was added in equal volume ratio with reservoir, 200 nL plus 200 nL. The reservoir consisted of 22% PEG MME 2000 plus 57 mM diammonium tartrate. Plates were stored at 20 C.",293.0,2018-08-27,2019-12-25,6MAK,2512.0,2.0,331.0,24.0,,39.59,2.0,2.13,experimental,59.159,0.26434,0.21366,HBO1 is required for the maintenance of leukaemia stem cells
6NO8,X-RAY DIFFRACTION,3.44,64.2,EVAPORATION,8.5,"of 0.1 M Tris 8.5, 0.1-0.3M LiSO4, and 29-33% PEG 4000",292.0,2019-01-15,2019-11-27,6NO8,2305.0,1.0,273.0,51.0,,32.06,1.0,2.377,experimental,64.7072,0.2321,0.1847,"PIM1 in complex with Cpd9 ((R)-5-amino-N-(3-(4-aminoazepan-1-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide)"
6CXU,X-RAY DIFFRACTION,2.88,57.24,BATCH MODE,10.0,"0.1 M sodium thiosulfate, 0.1 M CAPS, pH 10, 20% PEG8000",277.0,2018-04-04,2018-06-27,6CXU,6341.0,2.0,850.0,219.0,1.0,97.38,1.0,2.49,experimental,90.902,0.24955,0.2012,"Structure of the S167H mutant of human indoleamine 2,3 dioxygenase in complex with tryptophan and cyanide"
6CXV,X-RAY DIFFRACTION,2.88,57.29,BATCH MODE,10.0,"0.1 M sodium thiosulfate, 0.1 M CAPS, pH 10, 20% PEG8000",277.0,2018-04-04,2018-06-27,6CXV,6312.0,2.0,850.0,228.0,1.0,97.7,1.0,2.6,experimental,76.92,0.26576,0.20814,"Structure of the S167H mutant of human indoleamine 2,3 dioxygenase in complex with tryptophan and cyanide"
8F8E,X-RAY DIFFRACTION,2.2,44.21,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG3350, 0.2M di-Ammonium Citrate",293.0,2022-11-21,2023-03-01,8F8E,5137.0,2.0,630.0,330.0,,72.26,1.0,1.55,experimental,22.966,0.20898,0.18123,Crystal structure of the WDR domain of human DCAF1 in complex with OICR-8268 compound
4WLR,X-RAY DIFFRACTION,2.63,53.27,"VAPOR DIFFUSION, SITTING DROP",6.6,"25% PEG 3350, 220 mM MgCl2,100 mM Bis-Tris",277.0,2014-10-07,2015-03-04,4WLR,3920.0,3.0,506.0,201.0,,56.83,3.0,1.997,experimental,,0.2273,0.1806,Crystal Structure of mUCH37-hRPN13 CTD-hUb complex
6YKD,X-RAY DIFFRACTION,3.02,59.25,COUNTER-DIFFUSION,6.3,"0.1 M imidazole pH 6.3
1 M sodium acetate",277.0,2020-04-06,2020-07-01,6YKD,2529.0,1.0,329.0,200.0,,38.27,1.0,1.86,experimental,43.51,0.1942,0.1584,Human Pim-1 kinase in complex with an inhibitor identified by virtual screening
5MJA,X-RAY DIFFRACTION,3.39,63.71,"VAPOR DIFFUSION, SITTING DROP",,"18 % PEG3350, 0.1-0.2 M ammonium sulfate, 0.1 M PCTP (Sodium propionate, Sodium cacodylate trihydrate, Bis-Tris propane) buffer pH 6-9",293.0,2016-11-30,2017-05-17,5MJA,4784.0,2.0,610.0,340.0,,70.63,1.0,2.14,experimental,52.05,0.236,0.2,Kinase domain of human EphB1 bound to a quinazoline-based inhibitor
6FER,X-RAY DIFFRACTION,2.29,46.34,"VAPOR DIFFUSION, SITTING DROP",7.0,"12.6 mg/mL protein in 20mM Tris/HCl pH7.5, 0.2M NaCl, 2mM TCEP, 0.02% NaN3, 50microM target ligand mixed 1:1 in 200 nL with 1M Na citrate ; 0.1M HEPES/NaOH pH7.0",293.0,2018-01-03,2018-11-28,6FER,27069.0,12.0,3708.0,,,435.19,1.0,2.87,experimental,64.0363,0.2868,0.2,"Crystal Structure of human DDR2 kinase in complex with 2-[4,5-difluoro-2-oxo-1'-(1H-pyrazolo[3,4-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-N-(2,2,2-trifluoroethyl)acetamide"
8Q1G,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sodium Tartrate 1.2M, ADA 0.1M,",293.0,2023-07-31,2024-05-15,8Q1G,6471.0,3.0,929.0,8.0,,104.61,3.0,2.6,experimental,,0.2551,0.2219,LSD1-CoREST bound to Acetylated K14 of Histone H3
6P0R,X-RAY DIFFRACTION,2.07,40.49,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2M NH4Formate",291.0,2019-05-17,2019-05-29,6P0R,3777.0,2.0,598.0,44.0,,69.36,1.0,2.4,experimental,42.46,0.2667,0.2123,Methyltransferase domain of human suppressor of variegation 3-9 homolog 2 (SUV39H2) in complex with OTS186935 inhibitor
6ODB,X-RAY DIFFRACTION,2.69,54.29,"VAPOR DIFFUSION, HANGING DROP",5.3,"0.1M MES pH5.3, 5% PEG6000, 0.12M Gly-Gly-Gly, 2mM TCEP",291.0,2019-03-26,2020-04-01,6ODB,8647.0,3.0,1239.0,90.0,,139.85,1.0,2.7,experimental,55.017,0.24068,0.19543,Crystal structure of HDAC8 in complex with compound 3
4WGK,X-RAY DIFFRACTION,2.89,57.48,"VAPOR DIFFUSION, HANGING DROP",4.6,"10% PEG 1000, 0.2M Lithium sulfate, 0.1M citrate phosphate buffer, pH 4.6",289.15,2014-09-18,2015-07-08,4WGK,11142.0,2.0,1376.0,494.0,6.0,155.83,1.0,2.582,experimental,,0.2227,0.1784,Crystal structure of human neutral ceramidase with Zn-bound phosphate
6KZI,X-RAY DIFFRACTION,3.61,65.96,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.4M potassium sodium tartrate tetrahydrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2019-09-24,2020-03-04,6KZI,2252.0,1.0,289.0,,,33.64,1.0,2.8,experimental,53.627,0.2332,0.1701,Crystal structure of Ser/Thr kinase Pim1 in complex with thioridazine derivatives
7L9Y,X-RAY DIFFRACTION,2.73,54.94,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M HEPES pH 7.0, 26% v/v Jeffamine ED-2001",291.0,2021-01-05,2021-04-21,7L9Y,6292.0,4.0,776.0,77.0,2.0,90.62,1.0,2.25,experimental,44.291,0.2984,0.266,"Human PARP14 (ARTD8), catalytic fragment in complex with RBN012042"
5FYS,X-RAY DIFFRACTION,2.12,42.06,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-09,2017-03-22,5FYS,4214.0,1.0,479.0,332.0,,56.75,1.0,1.89,experimental,,0.221,0.193,Crystal structure of the catalytic domain of human JARID1B in complex with D-2-hydroxyglutarate
5FYV,X-RAY DIFFRACTION,2.13,42.16,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-10,2017-03-22,5FYV,4222.0,1.0,479.0,317.0,1.0,56.89,1.0,1.87,experimental,,0.23,0.1976,Crystal structure of the catalytic domain of human JARID1B in complex with oxaloacetate
5FZ8,X-RAY DIFFRACTION,2.13,42.2,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-11,2017-03-22,5FZ8,4134.0,1.0,479.0,331.0,,56.46,1.0,1.86,experimental,,0.2365,0.201,Crystal structure of the catalytic domain of human JARID1B in complex with malate
5FZD,X-RAY DIFFRACTION,2.1,41.57,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-03-14,2017-03-22,5FZD,4150.0,1.0,479.0,276.0,,56.72,1.0,2.05,experimental,,0.235,0.1955,Crystal structure of the catalytic domain of human JARID1B in complex with L-2-hydroxyglutarate
4D3R,X-RAY DIFFRACTION,2.18,43.52,,,1.9M AMMONIUM SULFATE,,2014-10-23,2015-11-04,4D3R,1209.0,1.0,140.0,115.0,,15.57,1.0,1.67,experimental,16.567,0.19905,0.16091,Crystal structure of point mutated DUSP19 (I187A)
4RH5,X-RAY DIFFRACTION,1.89,34.95,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris-HCl, 21% PEG 8000, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-10-01,2015-03-11,4RH5,2588.0,2.0,315.0,258.0,,36.01,2.0,1.6,experimental,,0.2035,0.1738,Crystal structure of PTPN3 (PTPH1) in complex with Eps15 pTyr849 peptide
4RH9,X-RAY DIFFRACTION,1.91,35.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris-HCl, 21% PEG 8000, 5% glycerol, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-10-01,2015-03-11,4RH9,2557.0,2.0,315.0,196.0,,35.95,2.0,1.598,experimental,,0.2264,0.1945,"Crystal structure of PTPN3 (PTPH1) H812F, M883G mutant in complex with Eps15 pTyr849 peptide"
4RHG,X-RAY DIFFRACTION,1.91,35.55,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris-HCl, 21% PEG 8000, 5% glycerol, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-10-02,2015-03-11,4RHG,2594.0,2.0,315.0,213.0,,36.07,2.0,1.581,experimental,,0.2088,0.1831,"Crystal structure of PTPN3 (PTPH1) D811E, C842S mutant in complex with Eps15 pTyr849 peptide"
4S0G,X-RAY DIFFRACTION,1.87,34.29,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris-HCl, 26% PEG 8000, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-12-31,2015-03-11,4S0G,2435.0,2.0,315.0,137.0,,36.01,2.0,1.723,experimental,,0.2285,0.1823,Crystal structure of PTPN3 (PTPH1) in complex with Eps15 pTyr849 P850V peptide
6CZ3,X-RAY DIFFRACTION,3.14,60.84,"VAPOR DIFFUSION, SITTING DROP",7.5,"3.4 M Potassium acetate, 0.1 M bicine, pH 7.5, 13oC",288.0,2018-04-07,2018-06-20,6CZ3,2361.0,1.0,264.0,112.0,,31.16,1.0,1.8,experimental,37.5,0.213,0.196,"Structure of the PTK6 kinase domain bound to a type I inhibitor (3-fluoro-4-{[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]amino}phenyl)(morpholin-4-yl)methanone"
5QCS,X-RAY DIFFRACTION,3.11,60.44,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XII 8.45MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 2-FOLD EXCESS OF BMC024 ADDED FROM A 10MM STOCK
SOLUTION IN DMSO (2% DMSO IN DROP). CRYO-PROTECTANT WAS 1.2M AMMONIUM SULFATE, 25% GLYCEROL, 0.4MM BMC024, 4% DMSO.",292.0,2017-12-01,2020-06-03,5QCS,9242.0,3.0,1206.0,255.0,9.0,135.88,1.0,2.31,experimental,55.04,0.2,0.172,Crystal structure of BACE complex with BMC024
5QCZ,X-RAY DIFFRACTION,2.97,58.56,hanging drop,5.0,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS, FROM 1.0M AMMONIUM PHOSPHATE, 0.1M SODIUM CITRATE, PH
5.0. PROTEIN STOCK WAS BACE MUT46B BATCH XVI 7.0MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 6-FOLD EXCESS OF BMC015
ADDED FROM A 50MM STOCK SOLUTION IN 90% DMSO-D6 (1.7% DMSO IN DROP). A SOLUTION CONTAINING 1.2M AMMONIUM PHOSPHATE, 0.1M
SODIUM CITRATE PH 5.0, 25% GLYCEROL, 1MM BMC015 AND 1.8% DMSO WAS USED AS CRYO-PROTECTANT.",292.0,2017-12-01,2020-06-03,5QCZ,9195.0,3.0,1206.0,186.0,9.0,135.87,1.0,2.3,experimental,57.67,0.204,0.168,Crystal structure of BACE complex with BMC015
5QD0,X-RAY DIFFRACTION,2.91,57.67,hanging drop,5.0,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS, FROM 1.0M AMMONIUM PHOSPHATE, 0.1M SODIUM CITRATE, PH
5.0. PROTEIN STOCK WAS BACE MUT46B BATCH XIV 6.3MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 7-FOLD EXCESS OF BMC006
ADDED FROM A 50MM STOCK SOLUTION IN 90% DMSO-D6 (2.0% DMSO IN DROP). A SOLUTION CONTAINING 1.2M AMMONIUM PHOSPHATE, 0.1M
SODIUM CITRATE PH 5.0, 25% GLYCEROL, 1MM BMC006 AND 2.0% DMSO WAS USED AS CRYO-PROTECTANT.",292.0,2017-12-01,2020-06-03,5QD0,8981.0,3.0,1206.0,56.0,9.0,135.77,1.0,2.6,experimental,62.91,0.207,0.165,Crystal structure of BACE complex withBMC006
5QD4,X-RAY DIFFRACTION,3.12,60.64,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM PHOSPHATE, 0.1M SODIUM CITRATE PH
5.0. PROTEIN STOCK WAS BACE MUT46B BATCH XII 8.45MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 2.5-FOLD EXCESS OF
BMC023 ADDED FROM A 25MM STOCK SOLUTION IN DMSO (2% DMSO IN DROP). CRYO-PROTECTANT WAS 1.2M AMMONIUM PHOSPHATE, 0.1M
SODIUM CITRATE PH 5.0, 25% GLYCEROL, 0.5MM BMC023, 2% DMSO.",292.0,2017-12-01,2020-06-03,5QD4,9279.0,3.0,1206.0,219.0,9.0,136.35,1.0,2.112,experimental,,0.203,0.169,Crystal structure of BACE complex with BMC023
5NH3,X-RAY DIFFRACTION,2.98,58.7,"VAPOR DIFFUSION, SITTING DROP",,"0.1M sodium citrate tribasic dihydrate pH3.5
25% PEG 3350",293.0,2017-03-21,2017-11-15,5NH3,5263.0,6.0,724.0,361.0,14.0,81.32,3.0,2.35,experimental,39.78,0.2083,0.1658,CRYSTAL STRUCTURE OF THE Activin receptor type-2A LIGAND BINDING DOMAIN IN COMPLEX WITH BIMAGRUMAB FV
5EZV,X-RAY DIFFRACTION,2.7,54.38,"VAPOR DIFFUSION, HANGING DROP",6.2,"8 % PEG 3350, 0.1 M MgCl2, 1.0 % glucose, 0.001 % cocamidopropyl betaine, 0.1 M imidazole",277.0,2015-11-26,2016-03-09,5EZV,14682.0,6.0,2332.0,84.0,,267.84,3.0,2.99,experimental,68.78,0.2452,0.2243,X-ray crystal structure of AMP-activated protein kinase alpha-2/alpha-1 RIM chimaera (alpha-2(1-347)/alpha-1(349-401)/alpha-2(397-end) beta-1 gamma-1) co-crystallized with C2 (5-(5-hydroxyl-isoxazol-3-yl)-furan-2-phosphonic acid)
8AAU,X-RAY DIFFRACTION,2.84,56.76,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate pH 4.5, 0.2 M lithium sulfate, 12% PEG8K",277.0,2022-07-03,2022-08-10,8AAU,2432.0,1.0,310.0,99.0,,36.8,1.0,1.74,experimental,40.7,0.2399,0.2114,LIM Domain Kinase 1 (LIMK1) bound to LIMKi3
6OP9,X-RAY DIFFRACTION,3.08,60.06,"VAPOR DIFFUSION, HANGING DROP",6.7,"10% PEG 20000, 0.1M MES, pH 6.7",298.0,2019-04-24,2019-08-21,6OP9,2255.0,1.0,328.0,89.0,,37.47,1.0,2.501,experimental,,0.2302,0.1704,HER3 pseudokinase domain bound to bosutinib
4X4N,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, HANGING DROP",7.75,"18.6% PEG4000, 0.2M tri-Lithium Citrate, 0.05M Hepes pH 7.75, 0.08M Ammonium Sulfate",290.0,2014-12-03,2015-02-11,4X4N,16739.0,8.0,1928.0,,,247.32,1.0,2.953,experimental,46.99,0.2489,0.1914,Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a G70A arginyl-tRNA minihelix
5N9R,X-RAY DIFFRACTION,2.37,48.18,"VAPOR DIFFUSION, HANGING DROP",,"PEG 4000, Tris, Li2-Sulfate.",277.0,2017-02-27,2017-12-06,5N9R,6388.0,2.0,714.0,528.0,,84.62,1.0,2.23,experimental,63.04,0.212,0.148,"Crystal structure of USP7 in complex with a potent, selective and reversible small-molecule inhibitor"
6D3Y,X-RAY DIFFRACTION,2.33,47.17,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M 2-ethanesulfonic acid, 0.15 M ammonium sulfate, 13% PEG4000",293.0,2018-04-17,2019-01-23,6D3Y,2153.0,2.0,261.0,178.0,8.0,28.96,2.0,1.32,experimental,17.459,0.2132,0.191,Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma
4XMO,X-RAY DIFFRACTION,2.04,39.75,"VAPOR DIFFUSION, HANGING DROP",7.8,"12% PEG 4000, 100 mM HEPES, pH 7.8, 6% isopropanol, 3% ethanol, 40 mM beta-mercaptoethanol",298.0,2015-01-14,2015-03-11,4XMO,2629.0,1.0,309.0,292.0,,35.64,1.0,1.75,experimental,26.896,0.2383,0.1865,"Crystal structure of c-Met in complex with (R)-5-(8-fluoro-3-(1-fluoro-1-(3-methoxyquinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole"
4XYF,X-RAY DIFFRACTION,2.04,39.69,"VAPOR DIFFUSION, HANGING DROP",7.8,"13% PEG 4000, 100 mM HEPES, 6% (v/v) isopropanol, 3% (v/v) ethanol, 40 mM beta-mercaptoethanol",298.0,2015-02-02,2015-03-11,4XYF,2613.0,1.0,309.0,255.0,,35.66,1.0,1.85,experimental,29.0,0.2359,0.1858,"Crystal structure of c-Met in complex with (S)-5-(8-fluoro-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole"
7Y4T,X-RAY DIFFRACTION,2.97,58.58,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES (pH 7.8), 15-30% (v/v) PEG 8000",291.0,2022-06-16,2022-11-23,7Y4T,2318.0,1.0,309.0,97.0,,35.29,1.0,2.16,experimental,56.1684,0.2511,0.2146,Crystal structure of cMET kinase domain bound by compound 9I
7Y4U,X-RAY DIFFRACTION,2.9,57.63,"VAPOR DIFFUSION, HANGING DROP",7.8,"0.1 M HEPES (pH 7.8), 15-30% (v/v) PEG 8000",291.0,2022-06-16,2022-11-23,7Y4U,2302.0,1.0,309.0,59.0,,35.37,1.0,2.26,experimental,56.5179,0.2777,0.2382,Crystal structure of cMET kinase domain bound by compound 9Y
8ANS,X-RAY DIFFRACTION,1.93,36.34,"VAPOR DIFFUSION, SITTING DROP",,"15 % PEG10K, 100 mM PCPT pH 7.5",293.0,2022-08-05,2022-08-31,8ANS,2227.0,1.0,296.0,64.0,,34.01,1.0,2.01,experimental,36.46,0.277,0.2292,Crystal structure of D1228V c-MET bound by compound 1.
8GVJ,X-RAY DIFFRACTION,2.93,58.08,"VAPOR DIFFUSION, HANGING DROP",,25% PEG 8K,291.0,2022-09-15,2022-11-23,8GVJ,2322.0,1.0,309.0,32.0,,35.4,1.0,2.71,experimental,55.7089,0.2617,0.2185,Crystal structure of cMET kinase domain bound by D6808
8OV7,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,,"1.5 M LiCl, 0.1 M Na HEPES pH 7.5",293.0,2023-04-25,2023-07-05,8OV7,2513.0,1.0,309.0,244.0,,35.22,1.0,1.95,experimental,33.82,0.287,0.273,Crystal structure of D1228V c-MET bound by compound 10
8OW3,X-RAY DIFFRACTION,2.07,40.46,"VAPOR DIFFUSION, SITTING DROP",,"12 % PEG3350, 5 % EtOH, 0.2 M Li2SO4, 100 mM PCPT pH 5",293.0,2023-04-26,2023-07-05,8OW3,2105.0,1.0,309.0,53.0,,35.17,1.0,2.27,experimental,47.66,0.2953,0.2445,Crystal structure of wild-type c-MET bound by compound 2
4X8V,X-RAY DIFFRACTION,3.87,68.2,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2014-12-10,2015-03-25,4X8V,2583.0,2.0,309.0,140.0,8.0,35.31,2.0,2.5,experimental,30.77,0.2297,0.1931,"FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (methyl {3-[(2R)-1-{(2R)-2-(3,4-dimethoxyphenyl)-2-[(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)amino]acetyl}pyrrolidin-2-yl]-4-(propan-2-ylsulfonyl)phenyl}carbamate)"
6FBK,X-RAY DIFFRACTION,2.18,43.45,VAPOR DIFFUSION,7.5,20% PEG3350 -- 10% ethylene glycol -- 0.2M sodium fluoride,293.0,2017-12-19,2018-01-24,6FBK,774.0,2.0,121.0,14.0,,13.95,2.0,1.743,experimental,,0.3341,0.2844,Crystal structure of the human WNK2 CCT-like 1 domain in complex with a WNK1 RFXV peptide
5V1M,X-RAY DIFFRACTION,2.27,45.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% w/v PEG 20,000, 20% v/v glycerol, 100 mM bis-tris base, 50 mM HCl, and 10 mM disodium 5' UMP",289.0,2017-03-02,2017-08-16,5V1M,1788.0,1.0,191.0,158.0,,23.1,1.0,1.47,experimental,,0.1944,0.159,Structure of human Usb1 with uridine 5'-monophosphate
7BE6,X-RAY DIFFRACTION,2.55,51.71,VAPOR DIFFUSION,,"20% PEG 3350, 10% ethylene glycol, 0.1 M BisTrisPropane pH 6.5, 0.2 M sodium sulfate (50 nL protein and 100 nL reservoir)",293.0,2020-12-22,2021-03-03,7BE6,2654.0,1.0,315.0,158.0,,37.04,1.0,1.87081933411,experimental,33.7961154469,0.230440082701,0.186795116458,Structure of DDR1 receptor tyrosine kinase in complex with inhibitor SR159
8TH5,X-RAY DIFFRACTION,2.24,45.01,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M lithium sulfate, 0.1 M Tris pH 8.5, 25% PEG3350",277.15,2023-07-13,2024-03-20,8TH5,10350.0,17.0,1565.0,64.0,,177.35,2.0,2.62,experimental,34.173,0.33622,0.22566,Crystal Structure of the G3BP1 NTF2-like domain bound to the IDR1 of SARS-CoV-2 nucleocapsid protein P13L mutant
4V0V,X-RAY DIFFRACTION,2.63,53.27,,7.0,"2.4M SODIUM MALONATE, PH7.0",,2014-09-18,2015-03-25,4V0V,5493.0,4.0,660.0,422.0,,76.12,2.0,1.61,experimental,24.41,0.2029,0.1763,The crystal structure of mouse PP1G in complex with truncated human PPP1R15B (631-660)
4V0W,X-RAY DIFFRACTION,2.64,53.49,,7.5,"3 M NACL, 0.1 M HEPES, PH7.5",,2014-09-18,2015-03-25,4V0W,5701.0,4.0,678.0,609.0,,78.36,2.0,1.55,experimental,,0.2029,0.1727,The crystal structure of mouse PP1G in complex with truncated human PPP1R15B (631-669)
5AB2,X-RAY DIFFRACTION,2.19,43.8,,6.3,"7 %(W/V) PEG MW 8000, 20 %(V/V) ETHYLENE GLYCOL, 59 MM MES AND 41 MM IMIDAZOLE AT PH 6.3",,2015-07-31,2015-09-30,5AB2,15144.0,4.0,1946.0,102.0,4.0,230.87,2.0,2.729,experimental,82.4,0.2859,0.2228,Crystal structure of aminopeptidase ERAP2 with ligand
6TLR,X-RAY DIFFRACTION,2.72,,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M sodium HEPES/MOPS buffer pH 7.5, 20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20000",290.0,2019-12-03,2020-12-16,6TLR,3795.0,1.0,399.0,527.0,,46.89,1.0,1.64,experimental,35.248,0.1776,0.1486,"HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,7-DIBROMOBENZOTRIAZOLE"
7MXN,X-RAY DIFFRACTION,2.77,55.55,"VAPOR DIFFUSION, HANGING DROP",,"Crystallization of full-length human PRMT5/MEP50 complexed with cofactor site inhibitors was performed at 13 degrees Celsius by hanging-drop vapor-diffusion methods.  2.5 ul of a solution of 5:1 molar ratio of inhibitor compound to PRMT5/MEP50 complex (13 mg/mL) was mixed with 2.5 ul of reservoir solution containing 13-15% (w/v) PEG3350, 0.1M MES, pH 6.5-7.5, 0.25M NaCl, and 20% (v/v) ethylene glycol.  Microseeding from initial crystals produced crystals suitable for data collection.",286.0,2021-05-19,2021-11-17,7MXN,7580.0,2.0,1003.0,237.0,,112.71,2.0,2.55,experimental,78.34,0.2767,0.2363,PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06939999
8OEP,X-RAY DIFFRACTION,2.35,47.6,"VAPOR DIFFUSION, SITTING DROP",,"20% w/v PEG 3350, 0.2 M NaI at pH 7;",277.15,2023-03-11,2023-05-10,8OEP,1763.0,4.0,254.0,132.0,,28.96,2.0,1.87,experimental,45.16,0.2488,0.1983,Crystal structure of the PTPN3 PDZ domain bound to the HPV18 E6 oncoprotein C-terminal peptide
7O27,X-RAY DIFFRACTION,2.16,43.09,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-30,2021-09-15,7O27,3470.0,2.0,536.0,38.0,1.0,62.31,2.0,2.4,experimental,65.42,0.2541,0.2078,Crystal structure of the human METTL3-METTL14 complex bound to Compound 17 (ADO_AE_005)
5LSS,X-RAY DIFFRACTION,1.87,34.33,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1M KSCN, 31.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7",293.0,2016-09-05,2016-10-05,5LSS,2253.0,1.0,295.0,277.0,,34.78,1.0,1.79,experimental,30.648,0.22581,0.16154,Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LSX,X-RAY DIFFRACTION,2.2,44.1,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes, pH 7.3, 0.1MKSCN, 25-30%MPEG2000",293.0,2016-09-05,2016-10-05,5LSX,1894.0,1.0,295.0,7.0,,34.77,1.0,2.9,experimental,122.365,0.28025,0.17947,Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LSY,X-RAY DIFFRACTION,2.06,40.18,VAPOR DIFFUSION,,"0.1M Hepes, PH7.3, 0.1MKSCN, 25-30%MPEG2000",293.0,2016-09-05,2016-10-12,5LSY,2449.0,1.0,295.0,405.0,1.0,34.79,1.0,1.62,experimental,20.258,0.21469,0.1813,Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LSZ,X-RAY DIFFRACTION,2.1,41.41,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH7.3, 0.1MKSCN, 25-30%MPEG2000",293.0,2016-09-05,2016-10-05,5LSZ,2303.0,1.0,295.0,321.0,1.0,34.85,1.0,1.62,experimental,27.437,0.20053,0.17171,Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LT7,X-RAY DIFFRACTION,2.08,40.91,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes, PH7.3, 0.1MKSCN, 25-30%MPEG2000",293.0,2016-09-06,2016-10-05,5LT7,2444.0,1.0,295.0,442.0,1.0,34.85,1.0,1.51,experimental,22.029,0.1918,0.1686,Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5LT8,X-RAY DIFFRACTION,1.87,34.28,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES, PH7.3, 0.1MKSCN, 25-30%MPEG2000",293.0,2016-09-06,2016-10-05,5LT8,2170.0,1.0,295.0,293.0,,34.68,1.0,1.57,experimental,30.766,0.21551,0.17425,Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives
5T2W,X-RAY DIFFRACTION,2.04,39.62,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Ammonium Chloride",300.0,2016-08-24,2016-11-09,5T2W,2977.0,3.0,283.0,156.0,,43.12,1.0,2.2,experimental,41.66,0.226,0.1804,Structure of thymine DNA glycosylase bound to substrate analog 2'-F-5-formyl-dC
6U15,X-RAY DIFFRACTION,2.38,48.22,"VAPOR DIFFUSION, SITTING DROP",6.0,"PEG 3350, Ammonium Acetate, Sodium Acetate",295.0,2019-08-15,2019-11-20,6U15,2732.0,3.0,283.0,92.0,,43.11,1.0,2.4,experimental,65.55,0.213,0.199,Human thymine DNA glycosylase N140A mutant bound to DNA with 2'-F-5-carboxyl-dC substrate analog
6U16,X-RAY DIFFRACTION,2.37,48.03,"VAPOR DIFFUSION, SITTING DROP",6.0,"PEG 3350, Ammonium Acetate, Sodium Acetate",295.0,2019-08-15,2019-11-20,6U16,3185.0,3.0,284.0,308.0,,43.28,1.0,1.6,experimental,44.36,0.21,0.186,Human thymine DNA glycosylase N140A mutant bound to DNA with 5-carboxyl-dC substrate
6U17,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, SITTING DROP",6.0,"PEG3350, sodium Acetate, Ammonium acetate",295.0,2019-08-15,2019-11-20,6U17,2997.0,3.0,284.0,309.0,,43.21,1.0,1.55,experimental,51.84,0.224,0.189,Human thymine DNA glycosylase bound to DNA with 2'-F-5-carboxyl-dC substrate analog
5I9U,X-RAY DIFFRACTION,1.97,37.6,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M Amino Acids, 0.1 M Bicine/Trizma base pH 8.5",291.0,2016-02-21,2016-11-09,5I9U,2542.0,1.0,306.0,277.0,,34.52,1.0,1.889,experimental,,0.2244,0.1631,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase
5A3P,X-RAY DIFFRACTION,2.1,41.57,,8.0,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,2015-06-02,2015-06-10,5A3P,4321.0,1.0,479.0,543.0,,56.43,1.0,2.008,experimental,,0.2242,0.1874,Crystal structure of the catalytic domain of human PLU1 (JARID1B).
5A3T,X-RAY DIFFRACTION,2.07,40.7,,8.0,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,2015-06-02,2015-06-17,5A3T,4008.0,1.0,481.0,242.0,2.0,56.62,1.0,1.9,experimental,39.632,0.22039,0.19944,Crystal structure of human PLU-1 (JARID1B) in complex with KDM5-C49 (2-(((2-((2-(dimethylamino)ethyl)(ethyl)amino)-2-oxoethyl)amino)methyl) isonicotinic acid).
5A3W,X-RAY DIFFRACTION,2.07,40.7,,8.0,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,2015-06-03,2015-06-17,5A3W,3938.0,1.0,481.0,229.0,,56.35,1.0,2,experimental,,0.2161,0.1842,"Crystal structure of human PLU-1 (JARID1B) in complex with Pyridine-2, 6-dicarboxylic Acid (PDCA)"
5FUN,X-RAY DIFFRACTION,3.98,70.37,,8.0,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,2016-01-28,2016-04-13,5FUN,3898.0,1.0,481.0,166.0,,56.57,1.0,2.3,experimental,65.0,0.2117,0.1805,Crystal structure of human JARID1B in complex with GSK467
5FUP,X-RAY DIFFRACTION,2.01,38.94,,7.5,0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC,,2016-01-28,2016-03-23,5FUP,4267.0,1.0,479.0,493.0,,56.43,1.0,2.15,experimental,,0.2266,0.1825,Crystal structure of human JARID1B in complex with 2-oxoglutarate.
5EGB,X-RAY DIFFRACTION,3.12,60.61,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.055M Bis-Tris propane, 0.045M Citric Acid, 30% PEG3350",289.0,2015-10-26,2016-02-17,5EGB,1960.0,3.0,186.0,167.0,,30.13,1.0,1.977,experimental,,0.2196,0.1925,Human PRDM9 allele-A ZnF Domain with Associated Recombination Hotspot DNA Sequence II
8C5L,X-RAY DIFFRACTION,2.83,56.6,"VAPOR DIFFUSION, SITTING DROP",8.0,"90 mM SPG pH 8.0, 22.5% w/v PEG1500, 100 mM potassium chloride",298.0,2023-01-09,2024-01-10,8C5L,8752.0,4.0,1174.0,56.0,,129.04,2.0,2.6,experimental,73.65,0.2328,0.2003,NR2F6 ligand binding domain in complex with NSD1 peptide
4WNP,X-RAY DIFFRACTION,2.22,44.68,"VAPOR DIFFUSION, HANGING DROP",,"1.55 M sodium malonate pH 7.0,  0.35 M sodium malonate pH 5.0",298.0,2014-10-14,2015-01-14,4WNP,9214.0,4.0,1148.0,243.0,,131.05,1.0,1.88,experimental,43.4051,0.2264,0.1922,Structure of ULK1 bound to a potent inhibitor
4YC6,X-RAY DIFFRACTION,2.6,52.5,VAPOR DIFFUSION,8.3,"16-18% PEG 10 000, 0.1M imidazole pH 8.2 -8.4",277.0,2015-02-19,2015-05-20,4YC6,12339.0,8.0,1528.0,639.0,,178.6,2.0,2.6,experimental,95.396,0.267,0.2248,CDK1/CKS1
6BU0,X-RAY DIFFRACTION,2.52,51.1,"VAPOR DIFFUSION, HANGING DROP",7.5,PEG 8000,295.0,2017-12-08,2018-10-17,6BU0,3243.0,3.0,393.0,23.0,,47.75,1.0,2.427,experimental,58.7087,0.2501,0.2094,Crystal structure of the PI3KC2alpha C2 domain in complex with IP6
6VTM,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M lithium sulfate monohydrate, 0.1 M Tris, pH 8.5, 25% w/v PEG3350",293.0,2020-02-13,2020-04-22,6VTM,11227.0,8.0,1292.0,1002.0,12.0,147.62,2.0,1.6,experimental,22.33,0.209,0.174,Human Cathepsin-G Inhibited by S. aureus EapH1
5M8O,X-RAY DIFFRACTION,2.97,58.53,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290.0,2016-10-29,2017-07-12,5M8O,15209.0,4.0,1784.0,179.0,28.0,214.73,1.0,2.5,experimental,25.1858,0.2512,0.2043,Crystal structure of human tyrosinase related protein 1 in complex with tropolone
4RLP,X-RAY DIFFRACTION,3.32,62.95,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris, 3.5M Sodium Formate, with staurosporine, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 288K",288.0,2014-10-17,2015-01-21,4RLP,2114.0,1.0,288.0,27.0,,33.62,1.0,2.79,experimental,,0.2301,0.2063,Human p70s6k1 with ruthenium-based inhibitor FL772
6M89,X-RAY DIFFRACTION,2.18,43.59,"VAPOR DIFFUSION, HANGING DROP",6.0,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol at 298K. To obtain complex structure, the apo crystal was further soaked under 35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM HEPES, pH 7.5 at 298K in the presence of 2 mM quercetin for 3 days.",298.0,2018-08-21,2019-01-23,6M89,2097.0,1.0,261.0,122.0,,30.13,1.0,1.85,experimental,24.991,0.23445,0.17366,Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with quercetin
5LUA,X-RAY DIFFRACTION,2.34,47.41,"VAPOR DIFFUSION, SITTING DROP",,"22 % PEG 3350, 0.1 M sodium acetate pH 4.5",293.0,2016-09-08,2017-03-29,5LUA,4609.0,2.0,524.0,272.0,,61.87,1.0,2,experimental,27.4,0.252,0.222,Crystal structure of human legumain (AEP) in complex with compound 11b
5LUB,X-RAY DIFFRACTION,2.36,47.84,"VAPOR DIFFUSION, SITTING DROP",,"22 % PEG 3350, 0.1 M sodium acetate pH 4.5",293.0,2016-09-08,2017-03-29,5LUB,4587.0,2.0,524.0,253.0,,61.83,1.0,2.1,experimental,28.34,0.253,0.221,Crystal structure of human legumain (AEP) in complex with compound 11
5J1W,X-RAY DIFFRACTION,2.51,51.04,"VAPOR DIFFUSION, SITTING DROP",,"30% 1,2-propanediol, 10% glycerol and 50 mM Na/K phosphate pH 7.2",277.15,2016-03-29,2016-05-04,5J1W,8253.0,3.0,1017.0,114.0,,120.55,1.0,2.42,experimental,66.211,0.22784,0.18916,"Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW31 (compound 14)"
8TH1,X-RAY DIFFRACTION,1.78,30.89,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium thiocyanate, 20% PEG 3350",277.15,2023-07-13,2023-12-27,8TH1,4870.0,8.0,756.0,284.0,,84.48,2.0,1.8,experimental,28.429,0.23828,0.19809,Crystal Structure of the G3BP1 NTF2-like domain bound to the IDR1 of SARS-CoV-2 nucleocapsid protein D3L mutant
8P5K,X-RAY DIFFRACTION,3.5,64.88,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.3-0.8 M NaAcetate pH 6, 20-26% w/v PEG3350",277.15,2023-05-24,2024-06-05,8P5K,9566.0,4.0,1136.0,617.0,,130.88,1.0,2.209,experimental,40.344,0.2043,0.177,Kinase domain of mutant human ULK1 in complex with compound MRT68921
5BPY,X-RAY DIFFRACTION,2.3,46.43,"VAPOR DIFFUSION, HANGING DROP",8.0,"25% MEPEG5K, pH 8.0, 298K, Vapor Diffusion, Hanging Drop",298.0,2015-05-28,2015-09-23,5BPY,4284.0,2.0,534.0,118.0,,63.58,1.0,2.31,experimental,32.9,0.2423,0.214,Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide
4UI3,X-RAY DIFFRACTION,2.4,50.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-27,2016-04-13,4UI3,3786.0,4.0,478.0,357.0,,55.56,2.0,2,experimental,28.613,0.21069,0.16992,Crystal structure of human tankyrase 2 in complex with TA-26
4UI5,X-RAY DIFFRACTION,2.4,50.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-27,2016-04-13,4UI5,3989.0,4.0,478.0,502.0,,55.7,2.0,1.65,experimental,23.329,0.19522,0.16263,Crystal structure of human tankyrase 2 in complex with TA-41
4UI6,X-RAY DIFFRACTION,2.4,50.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-27,2016-04-13,4UI6,3890.0,4.0,478.0,427.0,,55.72,2.0,1.8,experimental,22.743,0.18555,0.15371,Crystal structure of human tankyrase 2 in complex with TA-47
4UI7,X-RAY DIFFRACTION,2.4,50.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-27,2016-04-13,4UI7,3885.0,4.0,480.0,431.0,,55.63,2.0,1.8,experimental,27.4,0.1998,0.16725,Crystal structure of human tankyrase 2 in complex with TA-49
4UI8,X-RAY DIFFRACTION,2.4,50.0,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,2015-03-27,2016-04-13,4UI8,3815.0,4.0,478.0,372.0,,55.6,2.0,2.05,experimental,24.341,0.21879,0.17747,Crystal structure of human tankyrase 2 in complex with TA-55
5N9K,X-RAY DIFFRACTION,1.96,37.29,"VAPOR DIFFUSION, SITTING DROP",5.6,"Prior to the crystallization the inhibitor was solubilized in 100 % DMSO in a concentration of 10 mM. Then, this inhibitor stock solution was mixed in a Ratio of 1:10 with human CK2alpha (construct 1-335; solved with a Protein concentration of 8-10 mg/ml in 500 mM sodium chloride, 25 mM Tris/HCl pH 8.5). 
After a short time of incubation this mixture were mixed with reservoir solution [32 % (w/v) PEG4000, 0.2 M ammonium acetate, 0.1 M citrate pH 5.6] in a ratio of 2.5:1. 3.5 microliter of this final mixture was then equilibrated against the reservoir solution. The crystal growth was induced by seeding with 150 nanoliter seed suspension after an equilibration time of two days.",293.0,2017-02-25,2018-02-28,5N9K,3147.0,1.0,335.0,249.0,,40.92,1.0,1.643,experimental,,0.1843,0.1638,"Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive, tight-binding dibenzofuran inhibitor TF107 (5)"
5N9L,X-RAY DIFFRACTION,1.93,36.38,"VAPOR DIFFUSION, SITTING DROP",5.6,"Prior to the crystallization TF was solubilized in 100 % DMSO in a concentration of 10 mM. TF was mixed with human CK2alpha (construct 1-335; 8-10 mg/ml in 500 mM sodium chloride, 25 mM Tris/HCl pH 8.5) in a ratio of 1:5. After a short time of incubation this mixture was mixed with reservoir solution [32 % (w/v) PEG4000, 0.2 M ammonium acetate, 0.1 M citrate pH 5.6] in a ratio of 5:2. 3.5 microliter of the resulting mixture was then equilibrated against the reservoir solution. The crystal growth was induced by seeding with 150 nanoliter seed suspension after an equilibration time of two days.",293.0,2017-02-25,2018-02-28,5N9L,3094.0,1.0,335.0,218.0,,40.94,1.0,1.79,experimental,,0.1992,0.1635,Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive dibenzofuran inhibitor TF (4b)
5N9N,X-RAY DIFFRACTION,1.93,36.43,"VAPOR DIFFUSION, SITTING DROP",5.6,"Prior to the crystallization the Inhibitor TF85 was solubilized in 100 % DMSO in a concentration of 10 mM. This TF85 stock solution was mixed with human CK2alpha (construct 1-335; Protein concentration 8-10 mg/ml in 500 mM sodium chloride, 25 mM Tris/HCl pH 8.5) in a ratio of 1:10. After a short time of incubation, this mixture was mixed with reservoir solution [32 % (w/v) PEG4000, 0.2 M ammonium acetate, 0.1 M citrate pH 5.6] in a ratio of 5:2. 3.5 microliter of these mixtures were then equilibrated against the reservoir solution. The crystal growth was induced by seeding with 150 nanoliter seeding suspension after an equilibration time of two days.",293.0,2017-02-25,2018-02-28,5N9N,3055.0,1.0,335.0,175.0,,41.23,1.0,1.841,experimental,,0.2011,0.167,"Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive, tight-binding dibenzofuran inhibitor TF85 (4a)"
8CCW,X-RAY DIFFRACTION,2.99,58.93,"VAPOR DIFFUSION, SITTING DROP",,"10 mg/ml human Sirt3-(118-399) in 20 mM Tris/HCl, pH 8.0, 150 mM NaCl, 5% (v/v) glycerol, 1 mM TCEP were incubated with 2 mM ac-Tat-46-54 for 60 min at 293.15 K. The complex was crystallized using the sitting-drop vapor-diffusion method at 293.15 K with 100 mM MES, pH 6.0, 30% (w/v) PEG 200, 5% (w/v) PEG 3000 as reservoir solution.",293.15,2023-01-27,2023-05-10,8CCW,2532.0,2.0,291.0,287.0,,32.63,2.0,1.65,experimental,36.94,0.2089,0.1807,Crystal structure of human Sirt3 in complex with an acetylated HIV1 Tat-46-54 substrate peptide
5K1V,X-RAY DIFFRACTION,2.87,57.18,VAPOR DIFFUSION,6.2,"9 %(w/v) PEG 8000, 20 %(v/v) ethylene glycol, 69 mM 2-(N-morpholino)ethanesulfonic acid (MES), 31 mM imidazole",277.0,2016-05-18,2017-03-29,5K1V,14637.0,2.0,1934.0,44.0,4.0,228.03,1.0,2.897,experimental,,0.273,0.2051,Crystal structure of Endoplasmic Reticulum aminopeptidase 2 (ERAP2) in complex with a diaminobenzoic acid derivative ligand.
6XIH,X-RAY DIFFRACTION,2.9,57.57,"VAPOR DIFFUSION, SITTING DROP",6.0,"6% polyethylene glycol 2000 MME , 20% glycerol, 0.1M MES, pH 6.0",277.0,2020-06-19,2020-08-12,6XIH,4101.0,2.0,590.0,45.0,,67.24,1.0,2.65,experimental,77.64,0.2917,0.221,Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp3 character and an exquisite selectivity profile
8BWG,X-RAY DIFFRACTION,2.61,52.9,"VAPOR DIFFUSION, SITTING DROP",,"Using a commercial crystal screen (HAMPTON RESEARCH, HR2-130) yielded a hit for monophosphorylated HRas under sitting drop conditions (drop size 600 nL) with a 1:1 ratio of protein solution (phospho-HRas 0.4 mM, RasGAP 0.4 mM, Na-HEPES 20 mM pH = 8.0, MgCl2 5 mM, NaF 20 mM) and precipitant (Na-citrate 100 mM pH = 5.6, Li2SO4 1.0 M, CaCl2 200 mM). After three rounds of microseeding well-formed single crystals were obtained using 2.0 uL sitting drops and a 1:1 ratio of protein buffer (HRas 400 uM, RasGAP 400 uM, MgCl2 5 mM, Na-HEPES 20 mM pH = 8.0, NaF 20 mM) and precipitant (Na-Citrate 100 mM pH = 5.6, Li2SO4 800 mM, CaCl2 200 mM). These were harvested using cryoprotectant (80% precipitant, 20% glycerol (v/v)) and sent for data collection.",293.0,2022-12-06,2023-09-27,8BWG,1500.0,1.0,166.0,131.0,,19.44,1.0,1.32,experimental,22.946,0.1739,0.1354,HRas (1-166) Y64 phosphorylation
5JI6,X-RAY DIFFRACTION,2.68,54.06,"VAPOR DIFFUSION, SITTING DROP",5.9,"24.% PEG MME 2000, 0.05M MES pH 5.9, 0.0175M Ammonium Sulfate",293.0,2016-04-21,2016-05-25,5JI6,3055.0,1.0,369.0,132.0,1.0,41.84,1.0,2.15,experimental,54.495,0.2297,0.1821,"Potent, Reversible MetAP2 Inhibitors via FBDD"
6QEJ,X-RAY DIFFRACTION,2.69,54.25,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% METHANOL, 0.1 M CITRATE, PH 6.0,",277.0,2019-01-07,2019-05-01,6QEJ,3395.0,1.0,378.0,447.0,1.0,43.07,1.0,1.62,experimental,25.32,0.184,0.167,"CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR Thiophene-2-sulfonic acid (4-fluoro-benzyl)-(4H-[1,2,4]triazol-3-ylmethyl)-amide"
7B8W,X-RAY DIFFRACTION,2.38,48.33,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Ammonium Citrate dibasic, 20% w/v PEG 3350",277.15,2020-12-13,2022-03-02,7B8W,8652.0,4.0,1240.0,8.0,,146.59,1.0,2.8,experimental,45.413,0.2862,0.2057,Structure of LIMK1 Kinase domain with allosteric inhibitor TH-470
5IPJ,X-RAY DIFFRACTION,3.34,63.19,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.0M LiCl, 0.1M TRIS pH8.0, 20% PEG6K",277.0,2016-03-09,2016-06-22,5IPJ,2434.0,1.0,286.0,164.0,,33.71,1.0,2.1,experimental,42.691,0.22114,0.17926,Crystal structure of human Pim-1 kinase in complex with a quinazolinone-pyrrolopyrrolone inhibitor.
6SH2,X-RAY DIFFRACTION,2.43,49.4,VAPOR DIFFUSION,,"Potassium nitrate, Sodium iodide,  PEG 3350",291.15,2019-08-05,2019-09-25,6SH2,5535.0,2.0,700.0,1.0,6.0,80.83,2.0,2.6,experimental,91.557,0.2866,0.2435,Crystal structure of human neprilysin E584D in complex with C-type natriuretic peptide.
5AMA,X-RAY DIFFRACTION,2.95,58.0,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",,2015-03-10,2016-01-13,5AMA,22267.0,4.0,2516.0,1890.0,12.0,299.94,1.0,1.8,experimental,23.805,0.21764,0.18675,Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 1-16
5BWO,X-RAY DIFFRACTION,1.89,35.01,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2M Ammonium formate, 20% PEG 3350",293.0,2015-06-08,2016-07-13,5BWO,2337.0,2.0,319.0,104.0,,35.82,2.0,2.376,experimental,,0.287,0.2393,Crystal Structure of Human SIRT3 in Complex with a Palmitoyl H3K9 Peptide
6WS0,X-RAY DIFFRACTION,1.73,28.86,"VAPOR DIFFUSION, HANGING DROP",,162 mM triammonium citrate and 18% w/v PEG 3350,293.0,2020-04-30,2020-12-23,6WS0,2492.0,3.0,374.0,11.0,,42.75,3.0,2.24,experimental,47.319,0.221,0.204,Rational drug design of phenazopyridine derivatives as novel inhibitors of Rev1-CT
5P9I,X-RAY DIFFRACTION,2.2,44.14,VAPOR DIFFUSION,7.0,"PEG 3350, sodium actate, BisTrisPropane",298.0,2016-09-20,2017-05-24,5P9I,2396.0,1.0,279.0,182.0,,32.92,1.0,1.11,experimental,17.81,0.2111,0.1957,BTK1 SOAKED WITH IBRUTINIB-Rev
4XEG,X-RAY DIFFRACTION,2.47,50.27,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% (w/v) PEG 4000, 0.2 M ammonium acetate, 0.1 M sodium acetate, pH 6.0",295.0,2014-12-23,2015-09-09,4XEG,3090.0,3.0,260.0,304.0,,40.49,1.0,1.72,experimental,38.544,0.2315,0.1882,Structure of the enzyme-product complex resulting from TDG action on a G/hmU mismatch
4Z47,X-RAY DIFFRACTION,2.44,49.6,"VAPOR DIFFUSION, SITTING DROP",6.0,"30% PEG 4000, 0.2M ammonium acetate, 0.1M sodium acetate",298.0,2015-04-01,2015-09-16,4Z47,3056.0,3.0,260.0,277.0,,40.44,1.0,1.45,experimental,37.444,0.1953,0.1403,Structure of the enzyme-product complex resulting from TDG action on a GU mismatch in the presence of excess base
4Z7B,X-RAY DIFFRACTION,2.66,48.62,"VAPOR DIFFUSION, SITTING DROP",6.0,"30% PEG 4000, 0.2M ammonium acetate, 0.1M sodium acetate",298.0,2015-04-07,2015-09-16,4Z7B,2821.0,3.0,260.0,144.0,,40.37,1.0,2.02,experimental,57.23,0.2325,0.1871,Structure of the enzyme-product complex resulting from TDG action on a GfC mismatch
4Z7Z,X-RAY DIFFRACTION,2.48,50.34,"VAPOR DIFFUSION, SITTING DROP",6.0,"30% PEG 4000, 0.2M ammonium acetate, 0.1M sodium acetate",298.0,2015-04-08,2015-09-16,4Z7Z,2953.0,3.0,260.0,209.0,,40.31,1.0,1.83,experimental,55.85,0.237,0.193,Structure of the enzyme-product complex resulting from TDG action on a GT mismatch in the presence of excess base
7KPL,X-RAY DIFFRACTION,2.5,50.77,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium malonate, pH 4.6, 14% PEG3350",291.0,2020-11-11,2021-03-10,7KPL,2110.0,1.0,279.0,36.0,,31.82,1.0,2.705,experimental,35.803,0.2496,0.1997,Crystal structure of hEphB1 in apo form
7KPM,X-RAY DIFFRACTION,2.49,50.56,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium malonate, pH 4.6, 14% PEG3350",291.0,2020-11-11,2021-03-10,7KPM,2347.0,1.0,279.0,254.0,,32.25,1.0,1.608,experimental,18.8469,0.1973,0.167,Crystal structure of hEphB1 bound with ADP
5TZ3,X-RAY DIFFRACTION,2.18,43.52,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2M MgCl2, 0.1M Tris, pH 8.4",293.0,2016-11-21,2017-02-22,5TZ3,11891.0,4.0,1376.0,792.0,,162.58,1.0,1.72,experimental,29.443,0.2327,0.1907,"CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX with [1,2,4]triazolo[1,5-a]pyrimidin-7-yl}-N-(naphthalene-2-yl)piperidine-3-carboxamide"
5TZA,X-RAY DIFFRACTION,2.2,44.2,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2M MgCl2, 0.1M Tris, pH 8.4",293.0,2016-11-21,2017-02-22,5TZA,12265.0,4.0,1376.0,1182.0,,162.52,1.0,1.7,experimental,23.6972,0.1965,0.1646,"CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A WITH 3-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-1-[(naphthalene-2-yl)carbonyl]piperidine"
5TZH,X-RAY DIFFRACTION,2.19,43.82,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2M MgCl2, 0.1M Tris, pH 8.4",293.0,2016-11-21,2017-02-22,5TZH,11904.0,4.0,1376.0,875.0,,162.53,1.0,1.6,experimental,27.5062,0.2559,0.2141,"CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 3,3-difluoro-1-[(4-fluorophenyl)carbonyl]-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine"
5TZW,X-RAY DIFFRACTION,2.19,43.9,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2M MgCl2, 0.1M Tris, pH 8.4",293.0,2016-11-22,2017-02-22,5TZW,12183.0,4.0,1376.0,1110.0,,162.6,1.0,1.59,experimental,27.2027,0.2246,0.1884,"CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3,4-difluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine"
5TZX,X-RAY DIFFRACTION,2.16,43.11,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2M MgCl2, 0.1M Tris, pH 8.4",293.0,2016-11-22,2017-02-22,5TZX,11716.0,4.0,1376.0,683.0,,162.67,1.0,1.9,experimental,22.632,0.3065,0.2475,"CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3-chloro-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine"
5TZZ,X-RAY DIFFRACTION,2.18,43.58,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2M MgCl2, 0.1M Tris, pH 8.4",293.0,2016-11-22,2017-02-22,5TZZ,12347.0,4.0,1376.0,1262.0,,162.85,1.0,1.6,experimental,24.564,0.2292,0.1946,"CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 1-[(3-bromo-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine"
5U00,X-RAY DIFFRACTION,2.22,44.52,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2M MgCl2, 0.1M Tris, pH 8.4",293.0,2016-11-22,2017-02-22,5U00,12219.0,4.0,1376.0,1012.0,,163.04,1.0,1.41,experimental,24.789,0.2279,0.1992,"CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 2A IN COMPLEX WITH 3,3-difluoro-1-[(4-fluoro-3-iodophenyl)carbonyl]-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine"
4UBA,X-RAY DIFFRACTION,3.07,59.99,VAPOR DIFFUSION,,"Reservoir: 30 %(w/v) PEG4000, 0.2 M ammonium acetate, 0.1 M trisodium citrate",293.0,2014-08-12,2015-07-01,4UBA,5715.0,2.0,670.0,45.0,,81.01,1.0,2.995,experimental,,0.2386,0.1872,"Low-salt structure of protein kinase CK2 catalytic subunit with 4'-carboxy-6,8-bromo-flavonol (FLC26)"
5JFS,X-RAY DIFFRACTION,3.0,62.95,VAPOR DIFFUSION,,"protein was concentrated to 10mg/ml. Crystals of complexes were grown using the hanging drop vapour diffusion method from 0.1M HEPES pH7.5, 0.1M MgCl2 and 10% EtOH at 4C",277.0,2016-04-19,2017-03-01,5JFS,2642.0,1.0,308.0,364.0,,35.55,1.0,2.07,experimental,31.97,0.1909,0.1699,Crystal structure of TrkA in complex with PF-00593174
5JFV,X-RAY DIFFRACTION,2.96,62.47,VAPOR DIFFUSION,,"protein was concentrated to 10mg/ml. Crystals of complexes were grown using the hanging drop vapour diffusion method from 0.1M HEPES pH7.5, 0.1M MgCl2 and 10% EtOH at 4C",277.0,2016-04-19,2017-03-01,5JFV,2618.0,1.0,308.0,341.0,,35.55,1.0,1.59,experimental,31.07,0.1915,0.1717,Crystal structure of TrkA in complex with PF-05206283
5JFW,X-RAY DIFFRACTION,2.94,62.16,VAPOR DIFFUSION,,"protein was concentrated to 10mg/ml. Crystals of complexes were grown using the hanging drop vapour diffusion method from 0.1M HEPES pH7.5, 0.1M MgCl2 and 10% EtOH at 4C",277.0,2016-04-19,2017-03-01,5JFW,2706.0,1.0,308.0,429.0,,35.53,1.0,1.52,experimental,25.82,0.2093,0.1786,Crystal structure of TrkA in complex with PF-05247452
5JFX,X-RAY DIFFRACTION,2.97,62.59,VAPOR DIFFUSION,,"protein was concentrated to 10mg/ml. Crystals of complexes were grown using the hanging drop vapour diffusion method from 0.1M HEPES pH7.5, 0.1M MgCl2 and 10% EtOH at 4C",277.0,2016-04-19,2017-03-01,5JFX,2571.0,1.0,308.0,306.0,,35.58,1.0,1.63,experimental,28.74,0.2315,0.2014,Crystal structure of TrkA in complex with PF-06273340
6EJ7,X-RAY DIFFRACTION,2.72,54.86,"VAPOR DIFFUSION, HANGING DROP",7.5,"55-65% Morpheus precipitant mix 2 (PEG8000 and ethylene glycol), 
0.1M Bicine/Tris buffer at pH 7.5
0.1 M of Morpheus NPS mix.",293.0,2017-09-20,2018-05-02,6EJ7,6221.0,2.0,763.0,366.0,6.0,89.29,2.0,2,experimental,45.9448,0.2298,0.1985,Human Xylosyltransferase 1 in complex with UDP-xylose and peptide QEEEGAGGGQGG
5CUH,X-RAY DIFFRACTION,2.2,44.03,"VAPOR DIFFUSION, SITTING DROP",7.25,"40% MPEG 5K, pH 7.25, 18% MPEG 2K",293.0,2015-07-24,2016-02-10,5CUH,3203.0,2.0,328.0,371.0,,38.48,1.0,1.83,experimental,18.239,0.21368,0.17253,Crystal structure MMP-9 complexes with a constrained hydroxamate based inhibitor LT4
4Z3A,X-RAY DIFFRACTION,2.57,52.17,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.2 M Ammonium chloride, 20% PEG 3350",298.0,2015-03-31,2015-09-16,4Z3A,2944.0,3.0,261.0,185.0,,40.19,1.0,1.72,experimental,49.76,0.226,0.199,Acetate-free structure of the enzyme-product complex resulting from TDG action on a GU mismatch
5FF8,X-RAY DIFFRACTION,2.21,44.26,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.2 M Ammonium chloride, 20% PEG 3350",298.0,2015-12-18,2016-09-28,5FF8,2978.0,3.0,295.0,235.0,,46.62,1.0,1.7,experimental,44.77,0.2175,0.1943,TDG enzyme-product complex
5HF7,X-RAY DIFFRACTION,2.41,49.0,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.2 M Ammonium chloride, 20% PEG 3350",298.0,2016-01-06,2016-09-28,5HF7,3076.0,3.0,283.0,330.0,,43.09,1.0,1.54,experimental,44.43,0.2143,0.1858,TDG enzyme-substrate complex
6QAS,X-RAY DIFFRACTION,2.36,47.96,"VAPOR DIFFUSION, SITTING DROP",5.6,"2.8 M Ammonium sulfate, 0.1 M citrate, pH 5.6",293.15,2018-12-19,2019-02-27,6QAS,5104.0,2.0,574.0,385.0,,68.94,1.0,1.75,experimental,31.23,0.19651,0.17013,Crystal structure of ULK1 in complexed with PF-03814735
7LC2,X-RAY DIFFRACTION,2.34,47.48,"VAPOR DIFFUSION, HANGING DROP",5.0,"100mM MMT buffer (DL-malic acid, MES and Tris base in 1:2:2 ratio) pH 5, 25% PEG (polyethylene glycol) 1500",293.0,2021-01-09,2021-07-28,7LC2,3833.0,4.0,516.0,23.0,,59.83,2.0,2.7,experimental,85.179,0.2874,0.2385,Crystal Structure of KRAS4b-Q61R (GMPPNP-bound) in complex with the RAS-binding domain (RBD) of SIN1
5KH6,X-RAY DIFFRACTION,2.54,51.57,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG-3350, 0.2M lithium sulfate, 0.1M bis-tris. Trypsin had been added to the protein stock solution.",291.0,2016-06-14,2016-09-21,5KH6,2017.0,1.0,211.0,160.0,,26.27,1.0,2.05,experimental,32.94,0.235,0.178,SETDB1 in complex with a fragment candidate
8FN9,X-RAY DIFFRACTION,1.99,38.31,"VAPOR DIFFUSION, HANGING DROP",,"20% w/v PEG2000 MME, 200 mM potassium thiocyanate",293.0,2022-12-27,2023-07-12,8FN9,11035.0,8.0,1360.0,572.0,12.0,156.73,2.0,1.8,experimental,35.38,0.2102,0.174,Crystal structure of the C-terminal Fg domain of TNR with the single FN domain of PTPRZ
7EQ2,X-RAY DIFFRACTION,2.41,49.02,EVAPORATION,,"40mM Lithium chloride, 20mM Magnesium chloride hexahydrate, 80mM NaCl, 2mM Hexammine cobalt(III) chloride, 40mM Sodium cacodylate trihydrate pH 5.5, 30% v/v (+/-)-2-Methyl-2,4-pentanediol",291.15,2021-04-28,2022-11-02,7EQ2,3366.0,2.0,368.0,372.0,,44.32,1.0,1.55090284637,experimental,19.7969176503,0.185187062179,0.160166333291,Crystal structure of GDP-bound Rab1a-T75D
6SUK,X-RAY DIFFRACTION,2.41,48.97,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2 M NH4Cl, 22% PEG3350",291.0,2019-09-15,2020-05-13,6SUK,6340.0,1.0,699.0,553.0,6.0,81.74,1.0,1.75,experimental,42.28,0.1997,0.1655,Crystal structure of Neprilysin in complex with Omapatrilat.
6SVY,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2M NH4Cl, 22 % w/v PEG3350",291.0,2019-09-19,2020-05-13,6SVY,5779.0,1.0,699.0,59.0,6.0,81.4,1.0,2.6,experimental,57.64,0.2544,0.2084,Crystal structure of Neprilysin in complex with Sampatrilat-ASP.
6XVP,X-RAY DIFFRACTION,2.38,48.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2 M NH4Cl, 22% PEG3350",291.0,2020-01-22,2020-05-13,6XVP,5751.0,1.0,699.0,39.0,6.0,81.64,1.0,2.65,experimental,61.47,0.2373,0.191,Crystal structure of Neprilysin in complex with Sampatrilat.
6F9U,X-RAY DIFFRACTION,2.36,47.85,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.1 M MIB Buffer pH 4.0, 5% Glycerol, 15% PEG 3350",289.0,2017-12-15,2018-03-07,6F9U,5331.0,1.0,591.0,344.0,3.0,70.99,1.0,1.9,experimental,,0.2088,0.1672,Crystal structure of human testis Angiotensin-1 converting enzyme in complex with Sampatrilat-Asp.
7PCD,X-RAY DIFFRACTION,2.03,39.56,VAPOR DIFFUSION,6.75,"18% PEG3350, 50mM ammonium tartrate, 150mM sodium tartrate and 100mM BIS-TRIS",293.0,2021-08-03,2022-07-27,7PCD,2340.0,1.0,327.0,108.0,,37.62,1.0,1.77,experimental,40.971,0.2406,0.2066,HER2 IN COMPLEX WITH A COVALENT INHIBITOR
5URJ,X-RAY DIFFRACTION,3.45,64.33,"VAPOR DIFFUSION, HANGING DROP",,"1.25-1.5M sodium malonate, 100mM sodium citrate pH 5.0-5.3, 10mg/ml BRR2",293.0,2017-02-10,2017-07-19,5URJ,13745.0,1.0,1738.0,14.0,,199.17,1.0,2.75,experimental,,0.2862,0.2373,Crystal structure of human BRR2 in complex with T-3905516
5URK,X-RAY DIFFRACTION,3.48,64.66,"VAPOR DIFFUSION, HANGING DROP",,"1.25-1.5 M sodium malonate, 100 mM sodium citrate pH 5.0-5.3, 10mg/ml BRR2",293.0,2017-02-10,2017-07-19,5URK,13657.0,1.0,1738.0,,,199.11,1.0,2.95,experimental,,0.2767,0.2325,Crystal structure of human BRR2 in complex with T-3935799
5M44,X-RAY DIFFRACTION,2.13,42.3,"VAPOR DIFFUSION, SITTING DROP",5.0,"Protein stock solution: 6 mg/ml CK2alpha1-335 in 0.5 M NaCl, 25 mM Tris/HCl, pH 8.5;
Inhibitor stock solution: 10 mM inhibitor in DMSO;
Protein/inhibitor complex solution: 90 microliter protein stock solution + 10 microliter inhibitor stock solution;
Reservoir solution: 4.2 M NaCl, 0.1 M sodium citrate, pH 5.0;
Drop solution before equlibration: 0.5 microliter  protein/inhibitor complex solution + 0.5 microliter reservoir solution",293.0,2016-10-18,2017-01-18,5M44,2820.0,1.0,335.0,11.0,,40.57,1.0,2.71,experimental,,0.2593,0.2186,"Complex structure of human protein kinase CK2 catalytic subunit with a thieno[2,3-d]pyrimidin inhibitor crystallized under high-salt conditions"
5M4I,X-RAY DIFFRACTION,2.19,43.85,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN STOCK SOLUTION: 6 MG/ML          
CK2ALPHA1-335 IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5;

INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO; 

PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION;

RESERVOIR SOLUTION: 4.3 M       
NACL, 0.1 M SODIUM CITRATE, PH 5.2;

DROP SOLUTION BEFORE EQULIBRATION: 0.5 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.5 MICROLITER RESERVOIR SOLUTION",293.0,2016-10-18,2017-01-18,5M4I,2936.0,1.0,335.0,110.0,,40.6,1.0,2.218,experimental,,0.2283,0.1881,"Complex structure of human protein kinase CK2 catalytic subunit with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21) crystallized under high-salt conditions"
6A1C,X-RAY DIFFRACTION,2.0,38.41,"VAPOR DIFFUSION, SITTING DROP",,ethyleneglycol,277.0,2018-06-07,2019-03-06,6A1C,3136.0,1.0,340.0,186.0,,42.53,1.0,1.68,experimental,23.406,0.19627,0.13751,Crystal structure of the CK2a1-go289 complex
4USE,X-RAY DIFFRACTION,3.0,59.0,,6.5,"50% (V/V) PEG 300, 0.1M CACODYLATE PH 6.5, 0.2M MGCL2",,2014-07-07,2015-07-22,4USE,4378.0,2.0,604.0,16.0,1.0,69.56,1.0,2.65,experimental,72.105,0.25145,0.22454,Human STK10 (LOK) with SB-633825
8TVK,X-RAY DIFFRACTION,1.87,34.39,"VAPOR DIFFUSION, HANGING DROP",,"200mM Na Acetate pH 3.6
100mM Tris pH 8.5
20% PEG 3350
1mM DTT",293.0,2023-08-18,2024-08-28,8TVK,1628.0,1.0,169.0,247.0,,19.79,1.0,1.04,experimental,,0.2048,0.1873,KRAS 1-169 G12C Mutant at 100k
8TXJ,X-RAY DIFFRACTION,1.89,35.07,"VAPOR DIFFUSION, HANGING DROP",,"200mM Na Acetate pH 3.6
100mM Tris pH 8.5
20% PEG 3350
1mM DTT",293.0,2023-08-23,2024-08-28,8TXJ,1522.0,1.0,169.0,141.0,,19.79,1.0,1.4,experimental,,0.206,0.1867,KRAS 1-169 G12C Mutant at 277k
8TXK,X-RAY DIFFRACTION,2.01,38.92,"VAPOR DIFFUSION, HANGING DROP",,"200mM Na Acetate pH 3.6
100mM Tris pH 8.5
20% PEG 3350
1mM DTT",293.0,2023-08-23,2024-08-28,8TXK,1527.0,1.0,169.0,146.0,,19.79,1.0,1.38,experimental,,0.2206,0.1949,KRAS 1-169 G12C Mutant at 240k
8TY2,X-RAY DIFFRACTION,1.98,37.76,"VAPOR DIFFUSION, HANGING DROP",,"200mM Na Acetate pH 3.6
100mM Tris pH 8.5
20% PEG 3350
1mM DTT",298.0,2023-08-24,2024-08-28,8TY2,1498.0,1.0,169.0,117.0,,19.79,1.0,1.41,experimental,,0.208,0.1805,KRAS 1-169 G12C Mutant at 293k
8TY8,X-RAY DIFFRACTION,1.96,37.38,"VAPOR DIFFUSION, HANGING DROP",,"200mM Na Acetate pH 3.6
100mM Tris pH 8.5
20% PEG 3350
1mM DTT",293.0,2023-08-24,2024-08-28,8TY8,1497.0,1.0,169.0,116.0,,19.79,1.0,1.4,experimental,,0.206,0.1824,KRAS 1-169 G12C Mutant at 310k
8TY9,X-RAY DIFFRACTION,1.96,37.32,"VAPOR DIFFUSION, HANGING DROP",,"200mM Na Acetate pH 3.6
100mM Tris pH 8.5
20% PEG 3350
1mM DTT",293.0,2023-08-24,2024-08-28,8TY9,1496.0,1.0,169.0,115.0,,19.79,1.0,1.43,experimental,,0.213,0.1919,KRAS 1-169 G12C Mutant at 313k
7QS1,X-RAY DIFFRACTION,2.23,44.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 10% ethylene glycol, 0.2M sodium sulfate",293.15,2022-01-12,2022-05-04,7QS1,3026.0,2.0,374.0,131.0,,42.76,1.0,1.93,experimental,44.167,0.2049,0.1683,Crystal structure of B30.2 PRYSPRY domain of TRIM11
5BRK,X-RAY DIFFRACTION,2.42,49.08,"VAPOR DIFFUSION, HANGING DROP",5.0,"0.2 M di-Ammonium citrate
20% (W/V) PEG 3,350",293.0,2015-05-31,2015-07-08,5BRK,2198.0,2.0,328.0,64.0,,39.12,2.0,2.3,experimental,,0.2205,0.1857,pMob1-Lats1 complex
6URQ,X-RAY DIFFRACTION,2.66,53.73,EVAPORATION,6.0,"100 mM Ammonium Sulfate, 10 mM DTT, 100 mM MES pH 6.0, 7% w/v PEG4000, 1% 1,6-Hexanediol",298.0,2019-10-24,2020-07-29,6URQ,5112.0,4.0,842.0,332.0,,92.42,2.0,2.05,experimental,40.14,0.2463,0.2042,Complex structure of human poly-ADP-ribosyltransferase TNKS1 ARC2-ARC3 and P antigen family member 4 (PAGE4)
8XEY,X-RAY DIFFRACTION,2.07,40.69,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH8.5, 25%PEG3,350",293.0,2023-12-13,2024-03-06,8XEY,2549.0,1.0,341.0,58.0,1.0,38.52,1.0,2.65,experimental,51.766,0.2803,0.2016,The Crystal Structure of C-terminal kinase domain of RSK2 from Biortus
7V8F,X-RAY DIFFRACTION,1.98,36.94,EVAPORATION,8.0,"2%(v/v) 1,4-dioxane, 0.1 M Tris-HCl (pH 8.0), 15%(w/v) PEG 3,350.",289.0,2021-08-22,2022-03-30,7V8F,2160.0,2.0,261.0,192.0,,29.96,2.0,1.66,experimental,30.76,0.198,0.1753,Crystal structure of UBE2L3 bound to HOIP RING1 domain.
6ODC,X-RAY DIFFRACTION,2.67,53.96,"VAPOR DIFFUSION, HANGING DROP",5.3,"0.1M MES pH5.3, 5% PEG6000, 0.14 M Gly-Gly-Gly, 2mM TCEP",291.0,2019-03-26,2020-04-01,6ODC,8657.0,3.0,1239.0,59.0,,139.64,1.0,2.8,experimental,76.315,0.23577,0.1944,Crystal structure of HDAC8 in complex with compound 30
6FEX,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, SITTING DROP",5.5,"11.3 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed 1.3:1 with 90mM MES/NaOH pH6.5, 0.18M potassium iodide, 0.2M Li2SO4, 22.5% PEG 4K",293.0,2018-01-03,2018-11-28,6FEX,2782.0,1.0,321.0,336.0,,37.91,1.0,1.291,experimental,20.8042,0.1737,0.1374,"DDR1, 2-[4-bromo-2-oxo-1'-(1H-pyrazolo[4,3-b]pyridine-5-carbonyl)spiro[indole-3,4'-piperidine]-1-yl]-N-(2,2,2-trifluoroethyl)acetamide, 1.291A, P212121, Rfree=17.4%"
5L2W,X-RAY DIFFRACTION,2.73,55.03,"VAPOR DIFFUSION, SITTING DROP",,"PEG20K, 180mM Mg(HCO2)2, 0.1M MES pH 6.0",286.15,2016-08-02,2016-08-24,5L2W,4727.0,2.0,606.0,75.0,,70.32,2.0,2.8,experimental,84.34,0.2463,0.1995,The X-ray co-crystal structure of human CDK2/CyclinE and Dinaciclib.
4YUR,X-RAY DIFFRACTION,2.62,53.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.2 M MgCl2, 30% PEG 400",297.0,2015-03-19,2015-06-17,4YUR,1805.0,1.0,278.0,12.0,,32.27,1.0,2.65,experimental,47.07,0.2695,0.1992,Crystal Structure of Plk4 Kinase Domain Bound to Centrinone
5VGI,X-RAY DIFFRACTION,2.52,51.11,VAPOR DIFFUSION,,"25% PEG 4000, 100mM HEPES pH 7.5",273.0,2017-04-11,2017-09-27,5VGI,11655.0,4.0,1480.0,243.0,,174.6,1.0,2.07,experimental,37.281,0.2485,0.1888,Crystal Structure of KDM4 with the Small Molecule Inhibitor QC6352
4ZYC,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",8.0,"reservoir: 2.2M ammonium sulphate, 0.2M KNa tartrate, protein: 10mg/ml Hdm2 in 50mM TRIS pH 8.0, 200mM NaCl, 1mM TCEP, 10% glycerol, drop: 0.2ul reservoir + 0.2ul protein",298.0,2015-05-21,2015-07-22,4ZYC,2338.0,3.0,288.0,104.0,,35.21,1.0,1.95,experimental,30.121,0.2587,0.2203,Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode: Hdm2 (MDM2) complexed with cpd5
7XW8,X-RAY DIFFRACTION,3.63,66.14,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M imidazole-HCl (pH 6.5), 10% PEG 3350, 10% 2-methyl-2,4-pentanediol and 50 mM ammonium formate",293.0,2022-05-26,2022-10-12,7XW8,5292.0,1.0,665.0,202.0,,75.05,1.0,2.28,experimental,50.805,0.2299,0.1981,"Crystal structure of Lysine Specific Demethylase 1 (LSD1) with TAK-418 distomer, FAD-adduct"
7OJO,X-RAY DIFFRACTION,2.38,48.41,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris pH=8.5, 200 mM Li2SO4, 24% PEG3350",277.15,2021-05-17,2022-06-01,7OJO,3486.0,4.0,438.0,149.0,,51.26,2.0,2.3,experimental,15.737,0.2769,0.232,Tankyrase 2 in complex with two small molecule fragments
7CM2,X-RAY DIFFRACTION,2.34,47.33,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris pH8.5, 25% PEG3,350",293.0,2020-07-24,2020-08-05,7CM2,5807.0,2.0,740.0,252.0,,86.77,1.0,2.25,experimental,44.569,0.236,0.1963,The Crystal Structure of human USP7 USP domain from Biortus
8D4Z,X-RAY DIFFRACTION,2.32,46.97,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.10 M Bis-Tris-Propane pH 8.50, 0.10 M K-formate, 26.0 % (w/v) PEG 3350",293.0,2022-06-03,2023-09-20,8D4Z,5593.0,2.0,722.0,101.0,,85.13,1.0,2.26,experimental,69.1612,0.26,0.203,Crystal structure of USP7 in complex with allosteric inhibitor FX1-3763
7P2L,X-RAY DIFFRACTION,2.72,54.83,LIPIDIC CUBIC PHASE,,"0.15-0.25 M ammonium phosphate dibasic, 22-24 % polyethylene glycol 400, either with 0.10 M 2-(N-morpholino)ethanesulfonic acid (MES) pH 6.7-6.8 or 0.1 M HEPES pH 6.8",295.0,2021-07-06,2021-09-08,7P2L,3271.0,1.0,464.0,7.0,1.0,52.28,1.0,2.54,experimental,69.807,0.2853,0.2267,thermostabilised 7TM domain of human mGlu5 receptor bound to photoswitchable ligand alloswitch-1
4XPN,X-RAY DIFFRACTION,3.19,61.39,"VAPOR DIFFUSION, SITTING DROP",6.8,"0.2 M Ammonium phosphate dibasic, 20% w/v Polyethylene glycol 3,350",277.0,2015-01-17,2015-07-01,4XPN,5174.0,4.0,684.0,223.0,,78.8,2.0,2.285,experimental,58.9756,0.205,0.159,Crystal Structure of Protein Phosphate 1 complexed with PP1 binding domain of GADD34
7MYJ,X-RAY DIFFRACTION,2.72,54.74,"VAPOR DIFFUSION, HANGING DROP",6.2,"8-10% PEG3350, 1% glucose, 0.1 M magnesium chloride, 0.1 M imidazole, 0.0005-0.003% CAPB",277.15,2021-05-21,2022-06-29,7MYJ,14740.0,6.0,2342.0,,,268.66,3.0,2.95,experimental,76.11,0.243,0.213,Structure of full length human AMPK (a2b1g1) in complex with a small molecule activator MSG011
5C5A,X-RAY DIFFRACTION,2.19,43.9,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Potassium iodide, 2.2M Ammonium Sulfate",293.0,2015-06-19,2016-06-29,5C5A,1842.0,2.0,184.0,172.0,,23.47,1.0,1.146,experimental,,0.1683,0.1531,Crystal Structure of HDM2 in complex with Nutlin-3a
6IGL,X-RAY DIFFRACTION,3.95,68.89,LIPIDIC CUBIC PHASE,5.0,"PEG 500DME, (NH4)2SO4 or NH4Cl",293.0,2018-09-25,2018-11-21,6IGL,4038.0,2.0,513.0,59.0,2.0,59.42,2.0,2.7,experimental,63.1481,0.2415,0.2066,Crystal Structure of human ETB receptor in complex with IRL1620
6FYP,X-RAY DIFFRACTION,2.43,49.47,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% PEG3350,0.2M Ammonium Sulfate, 0.1M TRIS",298.0,2018-03-12,2018-07-18,6FYP,2994.0,1.0,360.0,81.0,,42.6,1.0,2.29,experimental,47.057,0.2666,0.2276,"X-RAY STRUCTURE OF CLK3-KD(GP-[275-632], NON-PHOS.)/CX-4945 AT 2.29A"
6FYR,X-RAY DIFFRACTION,2.2,44.04,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG4000, 0.1M HEPES",298.0,2018-03-12,2018-07-18,6FYR,3573.0,1.0,360.0,529.0,,42.62,1.0,1.42,experimental,16.848,0.1892,0.1761,"X-RAY STRUCTURE OF CLK3-KD(GP-[275-632], NON-PHOS.)/Cpd-2 AT 1.42A"
6Z2V,X-RAY DIFFRACTION,2.24,45.14,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 3350, 0,2M KSCN,  
10% Ethylene Glycol, 0.1M bis-tris propane",278.0,2020-05-18,2020-07-29,6Z2V,2851.0,1.0,360.0,61.0,,42.81,1.0,2.6,experimental,35.266,0.2645,0.2019,CLK3 A319V mutant bound with beta-carboline KH-CARB13 (Cpd 3)
5SAU,X-RAY DIFFRACTION,2.38,48.42,"VAPOR DIFFUSION, SITTING DROP",6.5,"7.6 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed with reservoir consisting of 0.1M MES/NaOH pH 6.5, 0.2M KI, 25% PEG 4000",293.0,2021-06-22,2022-06-29,5SAU,2517.0,1.0,321.0,178.0,1.0,36.99,1.0,1.8,experimental,41.8181,0.2312,0.1991,"DDR1, 3-[2-(6-aminopyridin-3-yl)ethynyl]-N-[3-(trifluoromethyl)phenyl]benzamide, 1.800A, P212121, Rfree=23.1%"
5SAV,X-RAY DIFFRACTION,2.06,40.3,"VAPOR DIFFUSION, SITTING DROP",6.5,"7.6 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed with reservoir consisting of 0.1M MES/NaOH pH 6.5, 0.2M KI, 25% PEG 4000",293.0,2021-06-22,2022-06-29,5SAV,2666.0,1.0,321.0,264.0,,37.3,1.0,1.76,experimental,29.2725,0.2346,0.1925,"DDR1, N-[2-[3-(2-aminopyrimidin-5-yl)oxyphenyl]ethyl]-3-(trifluoromethoxy)benzamide, 1.760A, P212121, Rfree=23.5%"
5SAW,X-RAY DIFFRACTION,2.34,47.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"9.2 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed with reservoir consisting of 0.1M MES/NaOH pH 6.5, 0.2M KI, 25% PEG 4000",293.0,2021-06-22,2022-06-29,5SAW,2639.0,1.0,321.0,253.0,,38.15,1.0,1.601,experimental,22.7854,0.226,0.1994,"DDR1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-N-[3-(trifluoromethyl)phenyl]acetamide, 1.601A, P212121, Rfree=22.6%"
5SAX,X-RAY DIFFRACTION,2.34,47.36,"VAPOR DIFFUSION, SITTING DROP",6.5,"9.2 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed with reservoir consisting of 0.1M MES/NaOH pH 6.5, 0.2M KI, 25% PEG 4000",293.0,2021-06-22,2022-06-29,5SAX,2600.0,1.0,321.0,147.0,,37.9,1.0,1.902,experimental,45.566,0.2544,0.2094,"DDR1, 2-[3-(2-pyridin-3-ylethynyl)phenyl]-N-[3-(trifluoromethyl)phenyl]acetamide, 1.902A, second P212121 form, Rfree=25.4%, second form"
5SB0,X-RAY DIFFRACTION,2.53,51.47,"VAPOR DIFFUSION, SITTING DROP",5.5,"11.6 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed with reservoir consisting of 0.1M Sodium Citrate pH 5.5, 0.2M Sodium Acetate, 10% PEG 4000",293.0,2021-06-22,2022-06-29,5SB0,2434.0,1.0,321.0,119.0,1.0,37.09,1.0,1.97,experimental,45.6325,0.2556,0.2079,"DDR1, N-[[2-(2-pyridin-3-yloxyethyl)cyclohexyl]methyl]-3-(trifluoromethoxy)benzamide, 1.970A, P212121, Rfree=25.6%"
5SB1,X-RAY DIFFRACTION,2.42,49.21,"VAPOR DIFFUSION, SITTING DROP",6.0,"11.4 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed with reservoir consisting of 0.1M MES pH 6.0, 0.1M MgChloride, 8% PEG 6000",293.0,2021-06-22,2022-06-29,5SB1,2608.0,1.0,321.0,267.0,1.0,37.05,1.0,1.53,experimental,33.285,0.2145,0.1889,"DDR1, 4-chloro-N-[(3S,4R)-4-phenylpyrrolidin-3-yl]-3-(1H-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.530A, P212121, Rfree=21.4%"
5SB2,X-RAY DIFFRACTION,2.17,43.34,"VAPOR DIFFUSION, SITTING DROP",6.5,"11.5 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed with reservoir consisting of 0.1M MES/NaOH pH 6.5, 0.2M KI, 25% PEG 4000",293.0,2021-06-22,2022-06-29,5SB2,2542.0,1.0,321.0,206.0,1.0,37.56,1.0,1.6,experimental,35.8779,0.232,0.2074,"DDR1, 3-chloro-N-[(1R,2S)-2-phenylcyclopropyl]-5-(1H-pyrrolo[2,3-b]pyridin-5-yloxymethyl)benzamide, 1.600A, P212121, Rfree=23.2%"
5D2B,X-RAY DIFFRACTION,2.27,45.81,"VAPOR DIFFUSION, SITTING DROP",9.5,"Protein : hMMP12 F171D at 820 micro-M + 10 milli-M AHA + 0.708 milli-M inhibitor.
Precipitant : 20% PEG4000, 0.2 M TRIS pH 9.5
Cryoprotectant : 10 % diethylene glycol + 5 % glycerol + 10 % 1,2-propanediol + 5 % 1,4-dioxane + 25% PEG6000 +  0.1 M TRIS HCl pH 8.0",293.0,2015-08-05,2016-08-17,5D2B,1778.0,1.0,159.0,298.0,,18.52,1.0,1.2,experimental,,0.1747,0.1544,Crystal structure of a mutated catalytic domain of Human MMP12 in complex with an hydroxamate analogue of RXP470
5D3C,X-RAY DIFFRACTION,2.25,45.38,"VAPOR DIFFUSION, SITTING DROP",9.5,"Protein : MMP12 F67D K241A, 1 mili-M + 10 mili-M AHA
Drop : 1 micro-L protein + 0.2 micro-L inhibitor (5 mili-M in DMSO)
Precipitant : 20% PEG4000, 0.2 M TRIS pH 9.5
Cryoprotectant : 10 % diethylene glycol + 5 % glycerol + 10 % 2,3-butanediol + 5 % 1,4-dioxane +25% PEG6000,+ 100 mili-M TRIS HCl, pH 8.",293.0,2015-08-06,2016-08-17,5D3C,1682.0,1.0,159.0,274.0,,18.47,1.0,1.314,experimental,,0.1913,0.1526,Crystal structure of a double mutant catalytic domain of Human MMP12 in complex with an hydroxamate analogue of RXP470
5K28,X-RAY DIFFRACTION,2.67,53.91,"VAPOR DIFFUSION, HANGING DROP",6.4,1.4M NaMalonate pH 6.4,298.0,2016-05-18,2017-12-13,5K28,1114.0,2.0,128.0,136.0,,13.8,1.0,1.5,experimental,22.953,0.21328,0.18617,Structure of the unbound SH3 domain of MLK3
6QEF,X-RAY DIFFRACTION,2.6,52.7,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% METHANOL, 0.1 M CITRATE, PH 6.0",277.0,2019-01-07,2019-05-01,6QEF,3124.0,1.0,378.0,186.0,,43.35,1.0,1.79,experimental,38.52,0.195,0.175,CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR (S)-3-Hydroxy-2-oxo-1-phenyl-pyrrolidine-3-carboxylic acid 3-chloro-5-fluoro-benzylamide
6QEG,X-RAY DIFFRACTION,2.63,53.31,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% METHANOL, 0.1 M CITRATE, PH 6.0",277.0,2019-01-07,2019-05-01,6QEG,3062.0,1.0,378.0,179.0,,43.0,1.0,2.08,experimental,43.29,0.228,0.178,CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR 2-Oxo-1-phenyl-pyrrolidine-3-carboxylic acid (2-thiophen-2-yl-ethyl)-amide
6QEH,X-RAY DIFFRACTION,2.67,53.87,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% METHANOL, 0.1 M CITRATE, PH 6.0,",277.0,2019-01-07,2019-05-01,6QEH,3088.0,1.0,378.0,206.0,,42.85,1.0,2.17,experimental,37.4,0.22,0.184,CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR 5-Chloro-quinolin-8-ol
8ATL,X-RAY DIFFRACTION,2.82,56.4,"VAPOR DIFFUSION, HANGING DROP",4.9,"0.1M sodium acetate buffer pH 4.9, 2.13-2.145M sodium malonate",293.0,2022-08-23,2023-09-06,8ATL,4517.0,2.0,596.0,70.0,,67.58,2.0,2.464,experimental,56.279,0.2429,0.1988,Discovery of IRAK4 Inhibitor 23
8C15,X-RAY DIFFRACTION,2.53,51.46,VAPOR DIFFUSION,6.5,"30% PEG5000 MME, 0.1M (NH4)2SO4, 0.1 M MES 6.5: soaking: 31.5% PEG5000 MME, 0.09M (NH4)2SO4, 0.09 M MES 6.5, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C15,2251.0,1.0,265.0,40.0,,32.46,1.0,2.41,experimental,75.64,0.207,0.199,Aurora A kinase in complex with TPX2-inhibitor 3
8C1D,X-RAY DIFFRACTION,2.66,53.82,VAPOR DIFFUSION,6.5,"30% PEG5000 MME, 0.1M (NH4)2SO4, 0.1 M MES 6.5: soaking: 31.5% PEG5000 MME, 0.09M (NH4)2SO4, 0.09 M MES 6.5, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C1D,2291.0,1.0,265.0,83.0,,32.48,1.0,2.115,experimental,67.04,0.238,0.21,Aurora A kinase in complex with TPX2-inhibitor 9
8C1H,X-RAY DIFFRACTION,2.55,51.8,VAPOR DIFFUSION,6.5,"30% PEG5000 MME, 0.1M (NH4)2SO4, 0.1 M MES 6.5: soaking: 31.5% PEG5000 MME, 0.09M (NH4)2SO4, 0.09 M MES 6.5, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C1H,2294.0,1.0,265.0,77.0,,32.65,1.0,2.233,experimental,63.41,0.245,0.211,Aurora A kinase in complex with TPX2-inhibitor 8
8C1I,X-RAY DIFFRACTION,2.6,52.74,VAPOR DIFFUSION,6.5,"30% PEG5000 MME, 0.1M (NH4)2SO4, 0.1 M MES 6.5: soaking: 31.5% PEG5000 MME, 0.09M (NH4)2SO4, 0.09 M MES 6.5, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C1I,2249.0,1.0,265.0,14.0,,32.58,1.0,2.81,experimental,81.51,0.234,0.212,Aurora A kinase in complex with TPX2-inhibitor 10
8C1K,X-RAY DIFFRACTION,2.59,52.51,VAPOR DIFFUSION,6.5,"30% PEG5000 MME, 0.1M (NH4)2SO4, 0.1 M MES 6.5: soaking: 31.5% PEG5000 MME, 0.09M (NH4)2SO4, 0.09 M MES 6.5, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C1K,2264.0,1.0,273.0,39.0,,33.71,1.0,2.43,experimental,82.17,0.242,0.217,Aurora A kinase in complex with TPX2-inhibitor CAM2602
6MNH,X-RAY DIFFRACTION,2.04,39.78,"VAPOR DIFFUSION, SITTING DROP",8.5,"31% PEG 4K, 200mM calcium chloride, 100mM bis tris propane pH 8.5",281.0,2018-10-01,2019-03-27,6MNH,2412.0,1.0,287.0,232.0,,32.94,1.0,1.73,experimental,22.273,0.2278,0.1883,ULK1 Unc-51 like autophagy activating kinase in complex with inhibitor BTC
5BT3,X-RAY DIFFRACTION,2.3,46.49,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.1 M tri-sodium citrate dihydrate pH 5.6, 20% iso-propanol, 20% PEG 4000",277.0,2015-06-02,2015-07-01,5BT3,1205.0,1.0,116.0,189.0,,14.4,1.0,1.05,experimental,9.313,0.178,0.16498,Crystal structure of EP300 bromodomain in complex with SGC-CBP30 chemical probe
5M9P,X-RAY DIFFRACTION,2.3,46.58,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M ammonium sulphate
0.1 M bis-tris propane
25% PEG 3350",289.0,2016-11-02,2017-02-22,5M9P,1113.0,1.0,124.0,73.0,3.0,14.67,1.0,1.8,experimental,21.71,0.28522,0.23846,Human angiogenin ALS variant T80S
7FTT,X-RAY DIFFRACTION,2.51,50.96,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTT,5761.0,2.0,724.0,6.0,,85.75,1.0,2.235,experimental,57.1784,0.287,0.2088,Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-bromo-N-[[2-fluoro-5-(1-methylpyrazol-4-yl)phenyl]methyl]-2-hydroxybenzamide
5JHU,X-RAY DIFFRACTION,2.76,55.36,"VAPOR DIFFUSION, HANGING DROP",5.9,"30% MPD, 0.05M MES pH 5.9",277.0,2016-04-21,2016-05-25,5JHU,3243.0,1.0,369.0,313.0,1.0,41.99,1.0,1.8,experimental,31.468,0.1809,0.1381,"Potent, Reversible MetAP2 Inhibitors via FBDD"
6QEI,X-RAY DIFFRACTION,2.66,53.74,"VAPOR DIFFUSION, HANGING DROP",,"20% METHANOL, 0.1 M CITRATE, PH 6.0,",277.0,2019-01-07,2019-05-01,6QEI,3118.0,1.0,378.0,187.0,,43.29,1.0,1.8,experimental,45.29,0.209,0.189,"CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR 5,6-Difluoro-3-(2-isopropoxy-4-piperazin-1-yl-phenyl)-1H-indole-2-carboxylic acid amide"
5WDY,X-RAY DIFFRACTION,2.08,40.74,"VAPOR DIFFUSION, HANGING DROP",,"co-crystallization of protein/compound complex, reservoir solution: 100 mM Bis-Tris, pH 6.5, 20-25% PEG3350, 150-300 mM magnesium formate",298.0,2017-07-06,2017-08-16,5WDY,4348.0,2.0,558.0,33.0,,65.85,1.0,2.458,experimental,62.6978,0.2853,0.2275,Crystal structure of WNK1 in complex with 1-cyclohexyl-N-({6-fluoro-1-[2-(3-methoxyphenyl)pyridin-4-yl]-1H-indol-3-yl}methyl)methanamine (compound 6)
5AFG,X-RAY DIFFRACTION,2.72,54.85,,4.5,"100 MM SODIUM ACETATE, 1 M AMMONIUM DI-HYDROGEN PHOSPHATE, PH 4.5",,2015-01-22,2016-01-27,5AFG,913.0,2.0,109.0,88.0,,12.87,2.0,1.9,experimental,23.554,0.22616,0.17639,Structure of the Stapled Peptide Bound to Mdm2
5LAW,X-RAY DIFFRACTION,2.27,45.79,"VAPOR DIFFUSION, HANGING DROP",4.5,RESERVOIR SOLUTION : NULL,277.0,2016-06-15,2016-11-02,5LAW,920.0,1.0,94.0,43.0,,11.79,1.0,1.64,experimental,12.93,0.2158,0.1929,"Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND 14"
5LAZ,X-RAY DIFFRACTION,2.25,45.37,"VAPOR DIFFUSION, HANGING DROP",4.6,RESERVOIR SOLUTION : NULL,293.0,2016-06-15,2016-11-02,5LAZ,904.0,1.0,94.0,35.0,,11.74,1.0,1.66,experimental,16.249,0.2049,0.1809,"Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND BI-0252"
5LN2,X-RAY DIFFRACTION,2.15,42.78,"VAPOR DIFFUSION, HANGING DROP",5.0,"2.5M (NH4)2SO4, 0.1M NaCitrate",298.0,2016-08-02,2016-09-07,5LN2,961.0,1.0,96.0,116.0,,11.88,1.0,1.58,experimental,19.35,0.2474,0.2148,Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument
7QRV,X-RAY DIFFRACTION,2.1,41.31,"VAPOR DIFFUSION, SITTING DROP",6.5,"30% w/v PEG 5000 MME, 0.2 M Ammonium sulfate, 0.1M MES, pH 6.5",293.15,2022-01-12,2022-05-04,7QRV,9997.0,4.0,1124.0,1269.0,,122.89,1.0,1.45,experimental,16.27,0.1779,0.1518,Crystal structure of NHL domain of TRIM2 (full C-terminal)
6HNW,X-RAY DIFFRACTION,1.98,37.76,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2018-09-17,2019-08-07,6HNW,3018.0,1.0,336.0,212.0,,40.61,1.0,2,experimental,30.7231,0.2246,0.1884,Human protein kinase CK2 alpha in complex with coumestrol
7BU4,X-RAY DIFFRACTION,1.95,37.05,"VAPOR DIFFUSION, SITTING DROP",,Ethylene glycol,277.0,2020-04-04,2021-04-07,7BU4,3037.0,1.0,340.0,188.0,,40.85,1.0,1.7022731752,experimental,25.7310000682,0.222072251486,0.190507739694,Crystal structure of CK2a1 complexed with KY49
6DI1,X-RAY DIFFRACTION,2.27,45.81,"VAPOR DIFFUSION, HANGING DROP",,"RESERVOIR SOLUTION : 25% PEG 3350, 0.2M AMMONIUM ACETATE, 0.1M HEPES pH 6.9, 3% GLYCEROL                      
PROTEIN SOLUTION   : 10 mg/mL IN 20 mM TRIS, 50 mM NACL, 3 mM DTT, pH 8.0",294.0,2018-05-22,2018-10-17,6DI1,2660.0,1.0,271.0,397.0,,31.88,1.0,1.1,experimental,11.56,0.1861,0.1732,CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGAND
5I46,X-RAY DIFFRACTION,3.9,68.47,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2016-02-11,2016-06-22,5I46,2690.0,2.0,309.0,209.0,8.0,35.2,2.0,2.06,experimental,36.71,0.2386,0.2171,"Factor VIIA in complex with the inhibitor (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-hydroxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione"
4ZY5,X-RAY DIFFRACTION,2.41,49.02,"VAPOR DIFFUSION, SITTING DROP",8.0,"25% PEG 3500, 0.2M Ammonium Sulfate and 0.1M Tris pH 8",292.0,2015-05-21,2015-07-01,4ZY5,4564.0,2.0,602.0,63.0,1.0,68.07,1.0,2.35,experimental,,0.2295,0.1948,Crystal Structure of p21-activated kinase 1 in complex with an inhibitor compound 17
5NUH,X-RAY DIFFRACTION,3.04,59.54,"VAPOR DIFFUSION, HANGING DROP",8.0,"12% PEG 3350, 0.15 M tri-lithium-citrat, 1% 1.6 hexandiol",293.0,2017-04-30,2017-08-16,5NUH,3064.0,4.0,464.0,55.0,,54.43,2.0,2.78,experimental,,0.229,0.192,Crystal structure of SIVmac239 Nef bound to an engineered Hck SH3 domain
7WHU,X-RAY DIFFRACTION,2.24,45.12,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Ammonium sulfate, 0.1 M BIS-TRIS pH 5.5 and 25% w/v Polyethylene glycol 3350 (PEG3350)",297.0,2021-12-31,2022-07-06,7WHU,7019.0,8.0,1100.0,28.0,16.0,122.83,2.0,2.89,experimental,,0.3058,0.2523,Human Neutrophil Elastase in-complex with Ecotin Peptide
7JM5,X-RAY DIFFRACTION,2.64,53.43,"VAPOR DIFFUSION, SITTING DROP",,"tri-sodium citrate, PEG 3350",293.0,2020-07-31,2022-02-02,7JM5,5631.0,2.0,734.0,31.0,1.0,85.38,1.0,2.7,experimental,78.42,0.2437,0.1956,Crystal structure of KDM4B in complex with QC6352
4Y83,X-RAY DIFFRACTION,2.88,57.27,"VAPOR DIFFUSION, HANGING DROP",7.6,"Reservoir solution: 8% (w/v) PEG4000, 12% (v/v) ethylene glycol, 7% (v/v) iso-propanol",298.0,2015-02-16,2015-05-06,4Y83,6360.0,3.0,996.0,167.0,,113.87,1.0,2.89,experimental,61.77,0.2395,0.2017,"Crystal structure of COT kinase domain in complex with 5-(2-amino-5-(quinolin-3-yl)pyridin-3-yl)-1,3,4-oxadiazole-2(3H)-thione"
4Y85,X-RAY DIFFRACTION,2.4,48.68,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.1 M HEPES pH 7.2, 24% PEGMME 550, 0.05 M MgCl2",298.0,2015-02-16,2015-05-06,4Y85,7372.0,3.0,996.0,361.0,,113.85,1.0,2.33,experimental,34.49,0.2072,0.1772,"Crystal structure of COT kinase domain in complex with 5-(5-(1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-oxadiazol-2-amine"
7XJO,X-RAY DIFFRACTION,2.91,57.73,VAPOR DIFFUSION,7.5,"20 % w/v Polyethylene glycol 3,350,  100 mM BIS-TRIS propane pH 7.5,  200mM Potassium Sodium tartrate",293.0,2022-04-18,2022-06-29,7XJO,3044.0,4.0,354.0,242.0,,40.68,2.0,2,experimental,20.56,0.24285,0.19897,Crystal structure of human MMP-2 catalytic domain in complex with inhibitor
8H78,X-RAY DIFFRACTION,2.69,54.25,VAPOR DIFFUSION,,"16 % w/v Polyethylene glycol 8,000,  20 % v/v Glycerol, 40 mM Potassium di-hydrogen phosphate",293.0,2022-10-19,2023-01-18,8H78,2804.0,2.0,336.0,31.0,,40.05,1.0,2.4,experimental,34.291,0.31892,0.26515,Crystal structure of human MMP-2 catalytic domain in complex with inhibitor
7FTK,X-RAY DIFFRACTION,2.27,45.78,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTK,5801.0,2.0,724.0,20.0,,84.94,1.0,2.125,experimental,80.2971,0.2781,0.2123,Crystal Structure of apo human cyclic GMP-AMP synthase
7FTZ,X-RAY DIFFRACTION,2.52,51.27,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTZ,5912.0,2.0,724.0,84.0,,85.87,1.0,2.5,experimental,71.84,0.272,0.223,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[2-[3-[[(5-bromo-2-hydroxybenzoyl)amino]methyl]anilino]-1,3-thiazol-4-yl]acetic acid"
7FU5,X-RAY DIFFRACTION,2.48,50.31,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FU5,6003.0,2.0,724.0,103.0,,85.98,1.0,2.18,experimental,51.2282,0.2784,0.2206,Crystal Structure of human cyclic GMP-AMP synthase
7FUD,X-RAY DIFFRACTION,2.38,48.35,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FUD,5976.0,2.0,724.0,149.0,,85.83,1.0,2.026,experimental,68.629,0.2488,0.1944,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-benzyl-2-[[2-chloro-5-(1-methylpyrazol-3-yl)phenyl]methylamino]-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one"
7FUG,X-RAY DIFFRACTION,2.28,46.03,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FUG,5733.0,2.0,724.0,47.0,,85.83,1.0,2.106,experimental,82.2979,0.253,0.1985,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-benzyl-2-[[2-chloro-5-(1-methylpyrazol-3-yl)phenyl]methylamino]-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one"
5JLB,X-RAY DIFFRACTION,2.68,54.07,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M KSCN, 0.1 M Bis-Tris Propane, 20% PEG3350",277.0,2016-04-26,2016-11-02,5JLB,2482.0,2.0,293.0,330.0,,34.52,2.0,1.5,experimental,29.4487,0.1903,0.1642,Crystal structure of SETD2 bound to histone H3.3 K36I peptide
8OT5,X-RAY DIFFRACTION,2.55,51.79,"VAPOR DIFFUSION, SITTING DROP",,"30mM HEPES pH 7.5
150mM NaCl
1mM DTT
100mM Bis-Tris propane pH 6.5
200mM sodium iodide
20% w/v PEG3350",293.0,2023-04-20,2023-08-23,8OT5,5935.0,6.0,630.0,945.0,10.0,69.76,1.0,1.56,experimental,24.35,0.1912,0.1628,Crystal structure of the titin domain Fn3-85
8E0F,X-RAY DIFFRACTION,2.65,53.66,"VAPOR DIFFUSION, SITTING DROP",7.0,"50 mM MOPS pH 7.0, 17% (w/v) PEG 4000, 200 mM NaCl",298.0,2022-08-09,2022-10-26,8E0F,8056.0,4.0,1040.0,41.0,,130.01,1.0,2.7,experimental,88.2612,0.2305,0.1933,Human Adenosine Deaminase Acting on dsRNA (ADAR2-RD) bound to dsRNA containing a G-G pair adjacent to the target site
6GKG,X-RAY DIFFRACTION,2.6,52.76,VAPOR DIFFUSION,8.5,"Tris-HCl, PEG 4000, lithium sulfate",293.15,2018-05-20,2018-10-17,6GKG,14100.0,14.0,1920.0,,,222.17,2.0,2.847,experimental,,0.2871,0.2312,Structure of 14-3-3 gamma in complex with caspase-2 14-3-3 binding motif Ser164
6ERO,X-RAY DIFFRACTION,2.26,45.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"NaCl, PEG3350, HEPES",293.0,2017-10-18,2017-11-15,6ERO,4938.0,2.0,626.0,297.0,,71.69,1.0,1.75,experimental,,0.2138,0.192,Structure of human TFB2M
7XTL,X-RAY DIFFRACTION,1.82,32.58,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M lithium nitrate, 20%(w/v) PEG3350",293.0,2022-05-17,2022-09-28,7XTL,2359.0,2.0,344.0,22.0,,38.53,1.0,1.972,experimental,61.557,0.2663,0.2204,Crystal structure of the C-terminal domain of human N-acetylglucosaminyltransferase IVa
5VA9,X-RAY DIFFRACTION,2.63,53.18,"VAPOR DIFFUSION, SITTING DROP",7.0,"MPD 54%, 0.1 M sodium cacodylate.",293.0,2017-03-24,2018-03-28,5VA9,8417.0,4.0,1032.0,211.0,10.0,116.34,2.0,2.55,experimental,,0.2297,0.1958,Human pancreatic alpha amylase in complex with peptide inhibitor piHA-L5(d10Y)
7LJE,X-RAY DIFFRACTION,2.11,41.72,VAPOR DIFFUSION,5.5,"25% PEG 3350, 0.2 M Ammonium Acetate, 0.1 M Bis-Tris HCl pH 5.5",290.0,2021-01-29,2021-03-17,7LJE,11200.0,4.0,1392.0,493.0,,163.52,1.0,2.607,experimental,44.98,0.2651,0.2115,"Discovery of Spirohydantoins as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases"
5J0C,X-RAY DIFFRACTION,2.36,47.93,EVAPORATION,5.0,"0.1 M MIB buffer
pH 5.0
25 % w/v PEG 1500",293.0,2016-03-28,2017-02-01,5J0C,1771.0,2.0,228.0,192.0,,22.56,1.0,1.6,experimental,23.238,0.1863,0.1436,"Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, circular permutant P2/3"
5J0G,X-RAY DIFFRACTION,2.11,41.61,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M di-ammonium hydrogen citrate,
20 % w/v PEG 3350",293.0,2016-03-28,2017-02-01,5J0G,1600.0,2.0,226.0,24.0,,22.38,1.0,2.5,experimental,48.959,0.2354,0.1818,"Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, circular permutant P7/8"
5BTQ,X-RAY DIFFRACTION,2.21,44.35,"VAPOR DIFFUSION, HANGING DROP",7.4,"100mM HEPES
2.1M Ammonium sulfate
0.9% 1,6-hexanediol",293.0,2015-06-03,2016-06-08,5BTQ,3763.0,2.0,474.0,173.0,,55.92,1.0,2.08,experimental,30.208,0.22818,0.18269,Crystal structure of human heme oxygenase 1 H25R with biliverdin bound
7FTU,X-RAY DIFFRACTION,2.25,45.22,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTU,3177.0,1.0,362.0,179.0,,43.57,1.0,1.65,experimental,33.145,0.2471,0.2058,"Crystal Structure of human cyclic GMP-AMP synthase in complex with (Z)-N-[4-(4-chlorophenyl)sulfonylphenyl]-2-cyano-3-hydroxy-3-(5-methyl-1,2-oxazol-4-yl)prop-2-enamide"
9EPW,X-RAY DIFFRACTION,2.15,42.67,"VAPOR DIFFUSION, SITTING DROP",,0.2 M ammonia sulphate 0.1 M bis-tris pH 5.5 23-26% PEG 3350,293.0,2024-03-20,2024-05-01,9EPW,2779.0,1.0,338.0,33.0,,41.34,1.0,2.3,experimental,46.536,0.30791,0.25888,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC3336
7FTR,X-RAY DIFFRACTION,2.27,45.82,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTR,3234.0,1.0,362.0,194.0,,43.43,1.0,1.64,experimental,50.02,0.252,0.217,"Crystal Structure of human cyclic GMP-AMP synthase in complex with (Z)-N-(4-acetylphenyl)-2-cyano-3-hydroxy-3-(5-methyl-1,2-oxazol-4-yl)prop-2-enamide"
7FTX,X-RAY DIFFRACTION,4.19,70.67,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTX,2954.0,1.0,363.0,,,43.08,1.0,2.831,experimental,55.41,0.278,0.2429,Crystal Structure of apo human cyclic GMP-AMP synthase - hexagonal form
7O6X,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, SITTING DROP",,"22.5% PEG6000, Bicine pH=8.75",295.15,2021-04-12,2022-01-12,7O6X,3438.0,4.0,438.0,124.0,,50.84,2.0,2.2,experimental,38.595,0.2582,0.2112,Tankyrase 2 in complex with an inhibitor (OM-153)
5KYB,X-RAY DIFFRACTION,2.44,49.5,"VAPOR DIFFUSION, HANGING DROP",7.0,"1% Tryptone, 0.05M HEPES Na pH 7.0, 20% PEG3350",292.0,2016-07-21,2017-08-09,5KYB,5565.0,2.0,702.0,172.0,1.0,81.42,1.0,2.2,experimental,54.4187,0.2763,0.2128,Crystal structure of the apo-form of USP7 catalytic domain [V302K] mutant
6VN3,X-RAY DIFFRACTION,2.54,51.52,VAPOR DIFFUSION,,,277.0,2020-01-29,2020-04-29,6VN3,5485.0,2.0,700.0,10.0,1.0,81.9,1.0,2.73,experimental,77.803,0.2899,0.2224,USP7 IN COMPLEX WITH LIGAND COMPOUND 23
6VN4,X-RAY DIFFRACTION,2.66,53.81,VAPOR DIFFUSION,,,277.0,2020-01-29,2020-04-29,6VN4,5635.0,2.0,700.0,25.0,1.0,81.76,1.0,2.69,experimental,79.728,0.2999,0.2422,USP7 IN COMPLEX WITH LIGAND COMPOUND 1
6VN5,X-RAY DIFFRACTION,2.5,50.75,VAPOR DIFFUSION,,,277.0,2020-01-29,2020-04-29,6VN5,5551.0,2.0,700.0,5.0,1.0,81.67,1.0,2.9,experimental,82.634,0.2678,0.2135,USP7 IN COMPLEX WITH LIGAND COMPOUND 7
9C1W,X-RAY DIFFRACTION,2.8,56.06,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH 7.5, 20 % w/v PEG 8000",277.0,2024-05-29,2024-09-04,9C1W,3389.0,1.0,446.0,133.0,1.0,52.66,1.0,2,experimental,48.92,0.2416,0.2048,Structure of AKT2 with compound 3
7ACA,X-RAY DIFFRACTION,2.16,43.15,VAPOR DIFFUSION,,"Morpheus Screen D12

Morpheus Alcohol 10%
Morpheus Buffer 3
MPD_P1K_P3350 37.5% w/v",294.0,2020-09-10,2020-11-18,7ACA,6054.0,4.0,680.0,515.0,,81.13,1.0,1.57,experimental,28.63,0.205,0.189,CRYSTAL STRUCTURE OF AN ACTIVE KRAS G12D (GPPCP) DIMER IN COMPLEX WITH BI-5747
6F09,X-RAY DIFFRACTION,2.1,41.43,"VAPOR DIFFUSION, HANGING DROP",,0.1 M phosphate citrate pH 4.4; 40% PEG 300,298.15,2017-11-17,2018-03-07,6F09,7997.0,8.0,972.0,645.0,,111.69,2.0,1.594,experimental,,0.2247,0.18,Binary complex of 14-3-3 zeta with ubiquitin specific protease 8 (USP8) pSer718 peptide
6IL3,X-RAY DIFFRACTION,2.86,57.02,"VAPOR DIFFUSION, HANGING DROP",10.5,"0.2 M Lithium Sulfate, 0.1 M CAPS, pH 10.5, 1.2 M Sodium dihydrogen phosphate, 0.8 M Di-potassium hydrogen phosphate",291.0,2018-10-16,2018-12-12,6IL3,2708.0,1.0,370.0,33.0,,45.2,1.0,2.5,experimental,60.251,0.21863,0.183,Crystal structure of the FLT3 kinase bound to a small molecule inhibitor
8OTY,X-RAY DIFFRACTION,1.88,34.48,"VAPOR DIFFUSION, SITTING DROP",,"30mM HEPES pH 7.5
150mM NaCl
1mM DTT
100mM Sodium acetate
200mM CaCl
20% w/v PEG6000",293.0,2023-04-21,2023-08-23,8OTY,3434.0,4.0,416.0,277.0,,45.92,1.0,1.9,experimental,25.36,0.2508,0.2009,Crystal structure of the titin domain Fn3-90
7MNY,X-RAY DIFFRACTION,2.43,49.33,"VAPOR DIFFUSION, HANGING DROP",,"20% w/v PEG3350, 0.2 M sodium formate",294.0,2021-05-01,2022-06-15,7MNY,16688.0,12.0,2148.0,267.0,,248.39,2.0,2.7,experimental,84.0049,0.2618,0.2143,Crystal Structure of Nup358/RanBP2 Ran-binding domain 3 in complex with Ran-GPPNHP
7MNZ,X-RAY DIFFRACTION,2.33,47.23,"VAPOR DIFFUSION, HANGING DROP",7.0,"20% w/v PEG3350, 0.1 M ammonium sulfate, 0.1 M HEPES",294.0,2021-05-01,2022-06-15,7MNZ,17360.0,12.0,2130.0,473.0,,246.99,2.0,2.35,experimental,66.4518,0.2252,0.1833,Crystal Structure of Nup358/RanBP2 Ran-binding domain 4 in complex with Ran-GPPNHP
6MC1,X-RAY DIFFRACTION,3.4,63.84,"VAPOR DIFFUSION, HANGING DROP",7.5,"25% PEG 3350, 200 mM ammonium acetate, 100 mM HEPES",277.0,2018-08-30,2020-08-19,6MC1,7292.0,6.0,912.0,,,107.72,1.0,2.7,experimental,50.2663,0.2272,0.188,"Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor"
6NO9,X-RAY DIFFRACTION,3.45,64.36,EVAPORATION,8.5,"0.1 M Tris 8.5, 0.1-0.3M LiSO4, and 29-33% PEG 4000",292.0,2019-01-15,2019-02-27,6NO9,2405.0,1.0,273.0,146.0,,32.27,1.0,1.712,experimental,44.8973,0.2047,0.1678,"PIM1 in complex with Cpd16 (5-amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide)"
7N4R,X-RAY DIFFRACTION,2.28,45.94,"VAPOR DIFFUSION, SITTING DROP",,"0.1M BisTRIS pH 6.5, 0.2M Ammonium Acetate, 0.1M Guanidine HCl, 20% PEG2200 MME",277.0,2021-06-04,2022-05-18,7N4R,2310.0,1.0,269.0,188.0,,31.83,1.0,1.62,experimental,19.92,0.2221,0.1921,Bruton's tyrosine kinase in complex with compound 21
5LU8,X-RAY DIFFRACTION,2.66,53.84,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES PH 7.5, 0.2 M LITHIUM
 SULFATE MONOHYDRATE, 25 % PEG 3350, VAPOR DIFFUSION, SITTING
 DROP, TEMPERATURE 293K",293.0,2016-09-08,2017-03-29,5LU8,2294.0,2.0,269.0,84.0,,31.75,2.0,1.95,experimental,32.4,0.251,0.219,CRYSTAL STRUCTURE OF YVAD-CMK BOUND HUMAN LEGUMAIN (AEP) IN COMPLEX WITH COMPOUND 11B
5LU9,X-RAY DIFFRACTION,2.68,54.16,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES PH 7.5, 0.2 M LITHIUM SULFATE MONOHYDRATE, 25 % PEG 3350, VAPOR DIFFUSION, SITTING DROP",293.0,2016-09-08,2017-03-29,5LU9,2274.0,2.0,269.0,70.0,,31.48,2.0,2.27,experimental,39.37,0.273,0.244,Crystal structure of YVAD-cmk bound human legumain (AEP) in complex with compound 11
4UFA,X-RAY DIFFRACTION,2.8,56.8,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",,2015-03-16,2015-10-07,4UFA,10977.0,2.0,1258.0,776.0,6.0,149.8,1.0,1.8,experimental,28.59,0.22822,0.20232,Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with Ac-SD
6TT1,X-RAY DIFFRACTION,2.8,56.03,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent Cations, 30% PEG550MME/PEG20000",289.0,2019-12-23,2020-04-01,6TT1,10968.0,2.0,1258.0,795.0,6.0,149.97,1.0,1.8,experimental,42.62,0.2374,0.1995,Crystal structure of 'Res_S2 mutant human Angiotensin-1 converting enzyme N-domain in complex with 33RE.
6TT3,X-RAY DIFFRACTION,2.88,57.27,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent Cations, 30 % PEG550MME/PEG20000",289.0,2019-12-23,2020-04-01,6TT3,11226.0,2.0,1258.0,888.0,6.0,150.71,1.0,1.7,experimental,38.72,0.2212,0.1884,Crystal structure of 'Res_S2 mutant human Angiotensin-1 converting enzyme N-domain in complex with SG6.
6TT4,X-RAY DIFFRACTION,3.12,60.53,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent Cations, 30% PEG550MME/PEG20000",289.0,2019-12-23,2020-04-01,6TT4,11472.0,2.0,1258.0,989.0,6.0,150.98,1.0,1.8,experimental,40.4,0.2221,0.182,Crystal structure of 'Res_S2 mutant human Angiotensin-1 converting enzyme N-domain in complex with omapatrilat.
5DPV,X-RAY DIFFRACTION,2.77,55.58,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292.0,2015-09-14,2016-07-20,5DPV,2214.0,1.0,273.0,37.0,,32.55,1.0,2.285,experimental,86.69,0.2799,0.2216,Aurora A Kinase in Complex with AA35 and JNJ-7706621 in Space Group P6122
5DR6,X-RAY DIFFRACTION,2.82,56.31,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292.0,2015-09-15,2016-07-20,5DR6,2177.0,1.0,273.0,11.0,,32.53,1.0,2.534,experimental,87.418,0.27794,0.21795,Aurora A Kinase in Complex with AA30 and JNJ-7706621 in Space Group P6122
5DR9,X-RAY DIFFRACTION,2.81,56.28,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292.0,2015-09-15,2016-07-20,5DR9,2174.0,1.0,273.0,18.0,,32.56,1.0,2.47,experimental,92.92,0.2624,0.22482,Aurora A Kinase in Complex with AA29 and JNJ-7706621 in Space Group P6122
5OBR,X-RAY DIFFRACTION,2.73,54.9,"VAPOR DIFFUSION, HANGING DROP",7.0,"50 MM HEPES, 200 MM MAGNESIUM SULFATE,   20% PEG 3350",292.0,2017-06-29,2017-08-09,5OBR,2127.0,1.0,272.0,15.0,,32.18,1.0,2.62,experimental,,0.2919,0.2227,Aurora A kinase in complex with 2-(3-chloro-5-fluorophenyl)quinoline-4-carboxylic acid and JNJ-7706621
6G33,X-RAY DIFFRACTION,2.47,50.14,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% 1,2-propanediol, 5% glycerol and 0.1 M NaKPO4",277.15,2018-03-24,2018-04-18,6G33,8717.0,3.0,1017.0,341.0,,120.56,2.0,2.05,experimental,47.364,0.21829,0.18824,Crystal structure of CLK1 in complex with 5-iodotubercidin
6DQF,X-RAY DIFFRACTION,2.22,44.66,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2019-06-12,6DQF,2527.0,1.0,330.0,189.0,,38.41,1.0,1.688,experimental,,0.2068,0.1854,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N68 i.e. 2-(1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-2-yl)thieno[3,2-b]pyridine-7-carboxylic acid"
4QPS,X-RAY DIFFRACTION,1.93,36.43,VAPOR DIFFUSION,5.5,"25% PEG-3350, 0.2 M ammonium sulfate and 0.1 M BisTRIS pH 5.5, VAPOR DIFFUSION, temperature 291K",291.0,2014-06-24,2015-01-14,4QPS,4670.0,2.0,586.0,199.0,,67.32,1.0,1.8,experimental,29.7,0.2509,0.2074,Crystal structure of Jak3 complexed to N-[3-(6-Phenylamino-pyrazin-2-yl)-3H-benzoimidazol-5-yl]-acrylamide
7Y43,X-RAY DIFFRACTION,2.27,45.93,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M magnesium acetate tetrahydrate, 20% polyethylene glycol 3,350",293.0,2022-06-13,2023-01-18,7Y43,1331.0,3.0,114.0,138.0,,18.25,1.0,1.5,experimental,34.04,0.2352,0.2269,Crystal structure of the KAT6A WH domain and its bound double stranded DNA
7KXL,X-RAY DIFFRACTION,2.27,45.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.1M Bis Tris Propane, pH 7.5, 0.2M sodium acetate trihydrate",298.0,2020-12-04,2021-05-19,7KXL,2294.0,1.0,268.0,79.0,,32.08,1.0,1.84,experimental,30.22,0.229,0.1987,"BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED"
7KXN,X-RAY DIFFRACTION,2.32,46.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 3350
0.1 M Bis Tris Propane pH 7.5
0.2 M Sodium acetate trihydrate",298.0,2020-12-04,2021-05-19,7KXN,2566.0,1.0,267.0,270.0,,31.9,1.0,1.34,experimental,17.346,0.1965,0.1643,BTK1 SOAKED WITH COMPOUND 26
7KXO,X-RAY DIFFRACTION,2.33,47.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 3350
0.1 M Bis Tris Propane pH 7.5
0.2 M Sodium acetate trihydrate",298.0,2020-12-04,2021-05-19,7KXO,2382.0,1.0,267.0,130.0,,32.18,1.0,1.94,experimental,20.531,0.2484,0.2023,BTK1 SOAKED WITH COMPOUND 24
7KXP,X-RAY DIFFRACTION,2.45,49.78,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 3350
0.1 M Bis Tris Propane pH 7.5
0.2 M Sodium acetate trihydrate",298.0,2020-12-04,2021-05-19,7KXP,2635.0,1.0,271.0,270.0,,32.49,1.0,1.83,experimental,22.414,0.2149,0.1735,BTK1 SOAKED WITH COMPOUND 25
6KOF,X-RAY DIFFRACTION,2.83,56.6,"VAPOR DIFFUSION, HANGING DROP",6.0,"PEG3350, Ammonium fluoride,MES",291.0,2019-08-09,2020-03-25,6KOF,6177.0,2.0,806.0,139.0,,92.76,1.0,2.263,experimental,54.3475,0.2273,0.1946,"Crystal structure of indoleamine 2,3-dioxygenagse 1 (IDO1) in complex with compound 47"
6KPS,X-RAY DIFFRACTION,2.85,56.91,"VAPOR DIFFUSION, HANGING DROP",6.0,"PEG3350, Ammonium Fluoride, MES",291.0,2019-08-16,2020-03-25,6KPS,6082.0,2.0,806.0,72.0,,92.72,1.0,2.249,experimental,56.2609,0.2426,0.2038,"Crystal structure of indoleamine 2,3-dioxygenagse 1 (IDO1) in complex with compound 36"
7RRD,X-RAY DIFFRACTION,3.0,58.96,VAPOR DIFFUSION,,"0.1 MM TRIS PH 8.0, 20% (W/V) PEG6000, 0.2 M NACL",293.0,2021-08-09,2022-08-24,7RRD,6045.0,2.0,788.0,29.0,1.0,89.49,1.0,2.76,experimental,71.635,0.2613,0.2143,IDO1 IN COMPLEX WITH COMPOUND S-1
8OQ9,X-RAY DIFFRACTION,2.25,45.29,"VAPOR DIFFUSION, SITTING DROP",,"10mM Tris-HCl pH 7.5
50mM NaCl
0.5mM DTT
0.1M MES
10mM ZnCl2
20% (w/v) PEG6000",293.0,2023-04-11,2023-08-23,8OQ9,2711.0,3.0,315.0,370.0,,34.56,1.0,1.65,experimental,21.51,0.1919,0.1643,Crystal structure of the titin domain Fn3-56
8ORL,X-RAY DIFFRACTION,2.28,46.1,"VAPOR DIFFUSION, SITTING DROP",,"10mM Tris-HCl pH 7.5
50mM NaCl
0.5mM DTT
0.1M MES
10mM ZnCl2
20% (w/v) PEG6000",293.0,2023-04-14,2023-08-23,8ORL,2800.0,3.0,315.0,444.0,,34.54,1.0,1.43,experimental,20.88,0.1941,0.1587,Crystal structure of the S23226G missense variant of titin domain Fn3-56
5W2G,X-RAY DIFFRACTION,2.24,45.09,"VAPOR DIFFUSION, HANGING DROP",,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol",298.0,2017-06-06,2017-09-13,5W2G,2188.0,1.0,257.0,154.0,,29.43,1.0,1.8,experimental,24.613,0.21506,0.17066,Crystal structure of the core catalytic domain of human inositol phosphate multikinase
6KHF,X-RAY DIFFRACTION,2.4,48.65,"VAPOR DIFFUSION, HANGING DROP",7.0,"60% (v/v) Tacsimate pH 7.0, 0.025% dichloromethane",293.0,2019-07-15,2019-10-02,6KHF,2780.0,1.0,490.0,66.0,,59.02,1.0,2.598,experimental,49.9642,0.2837,0.2234,Crystal structure of CLK3 in complex with CX-4945
7A14,X-RAY DIFFRACTION,2.65,53.61,"VAPOR DIFFUSION, HANGING DROP",7.4,"200mM potassium phosphate pH 7.4, 100mM MnCl2, 5mM dithiothreitol (DTT) and 25-50% 2-methyl-2,4-pentanediol (MPD)",293.0,2020-08-11,2020-09-23,7A14,3259.0,1.0,371.0,294.0,1.0,42.63,1.0,2.14,experimental,40.58,0.2147,0.1791,CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK2218325A (COMPOUND 32)
7A15,X-RAY DIFFRACTION,2.69,54.35,"VAPOR DIFFUSION, HANGING DROP",7.4,"200mM potassium phosphate pH 7.4, 100mM MnCl2, 5mM dithiothreitol (DTT) and 25-50% 2-methyl-2,4-pentanediol (MPD)",293.0,2020-08-11,2020-09-23,7A15,3310.0,1.0,371.0,358.0,1.0,42.72,1.0,2.15,experimental,31.58,0.201,0.16,CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK2224863A (COMPOUND 42)
7A16,X-RAY DIFFRACTION,2.72,54.78,"VAPOR DIFFUSION, HANGING DROP",7.4,"200mM potassium phosphate pH 7.4, 100mM MnCl2, 5mM dithiothreitol (DTT) and 25-50% 2-methyl-2,4-pentanediol (MPD)",293.0,2020-08-11,2020-09-23,7A16,3347.0,1.0,371.0,395.0,1.0,42.7,1.0,1.9,experimental,31.96,0.216,0.187,CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK2229238A (COMPOUND 43)
4XH6,X-RAY DIFFRACTION,3.38,63.61,"VAPOR DIFFUSION, HANGING DROP",7.1,"1M NaOAc, 0.1M Imidazole",277.0,2015-01-05,2015-08-26,4XH6,2311.0,1.0,294.0,65.0,,34.26,1.0,2.04,experimental,31.325,0.22574,0.20026,Crystal structure of proto-oncogene kinase Pim1 bound to hispidulin
6TLP,X-RAY DIFFRACTION,2.66,,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M sodium HEPES/MOPS buffer pH 7.5, 20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20000",290.0,2019-12-03,2020-12-16,6TLP,3855.0,1.0,399.0,529.0,,46.79,1.0,1.93,experimental,35.503,0.1886,0.1533,"HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 5,6-DIBROMOBENZOTRIAZOLE"
6TLU,X-RAY DIFFRACTION,3.17,61.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M sodium HEPES/MOPS buffer pH 7.5, 20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20000",290.0,2019-12-03,2020-12-16,6TLU,3643.0,1.0,399.0,413.0,,46.86,1.0,1.81,experimental,45.287,0.1845,0.1639,"HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4,5-DIBROMOBENZOTRIAZOLE"
6TLW,X-RAY DIFFRACTION,3.16,61.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M sodium HEPES/MOPS buffer pH 7.5, 20 mM sodium formate, 20 mM ammonium acetate, 20 mM sodium citrate tribasic dihydrate, 20 mM sodium potassium tartrate tetrahydrate, 20 mM sodium oxamate, 20% polyethylene glycol 550 monomethyl ester, 10% polyethylene glycol 20000",290.0,2019-12-03,2020-12-16,6TLW,3728.0,1.0,399.0,472.0,,46.55,1.0,1.73,experimental,46.655,0.1873,0.1602,HUMAN CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4-BROMOBENZOTRIAZOLE
5VSB,X-RAY DIFFRACTION,2.36,47.9,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, NaFormate",293.0,2017-05-11,2017-12-20,5VSB,5703.0,2.0,706.0,353.0,,82.86,1.0,1.85,experimental,38.6858,0.2494,0.2346,Structure of DUB complex
6NCF,X-RAY DIFFRACTION,2.56,51.99,"VAPOR DIFFUSION, HANGING DROP",6.0,8-12% Tacsimate pH 6.0,295.0,2018-12-11,2020-05-13,6NCF,21871.0,4.0,2764.0,,,318.48,1.0,2.871,experimental,33.7875,0.2972,0.2747,The structure of Stable-5-Lipoxygenase bound to AKBA
5CEI,X-RAY DIFFRACTION,2.58,52.37,"VAPOR DIFFUSION, HANGING DROP",,20% PEG 3350 and 0.20 M sodium formate,293.0,2015-07-06,2016-02-10,5CEI,5374.0,2.0,693.0,181.0,,82.04,2.0,2.24,experimental,48.42,0.2267,0.1731,Crystal structure of CDK8:Cyclin C complex with compound 22
6T41,X-RAY DIFFRACTION,2.67,53.96,"VAPOR DIFFUSION, HANGING DROP",,20%(w/v) PEG-3350 and 0.2 M sodium formate,293.0,2019-10-11,2020-01-01,6T41,5262.0,2.0,693.0,144.0,,81.36,2.0,2.45,experimental,50.5402,0.2558,0.1827,CDK8/Cyclin C in complex with N-(4-chlorobenzyl)isoquinolin-4-amine
4WRS,X-RAY DIFFRACTION,3.37,63.46,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.0M LiCl, 0.1M TRIS, 20% PEG6K",277.0,2014-10-25,2015-02-04,4WRS,2411.0,1.0,286.0,142.0,,33.68,1.0,2.2,experimental,44.684,0.20781,0.17891,Crystal structure of human Pim-1 kinase in complex with an azaspiro pyrazinyl-indazole inhibitor.
4WSY,X-RAY DIFFRACTION,3.33,63.02,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.0M LiCl, 0.1M TRIS, 20% PEG6K",277.0,2014-10-28,2015-02-11,4WSY,2336.0,1.0,286.0,80.0,,33.5,1.0,2.3,experimental,53.659,0.22448,0.18155,Crystal structure of human Pim-1 kinase in complex with a thiazolamine-indazole inhibitor.
4WT6,X-RAY DIFFRACTION,3.4,63.83,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.0M LiCl, 0.1M TRIS, 20% PEG6K",277.0,2014-10-29,2015-02-11,4WT6,2401.0,1.0,286.0,143.0,,33.53,1.0,2.3,experimental,43.464,0.21109,0.17625,Crystal structure of human Pim-1 kinase in complex with a thiadiazolamine-indole inhibitor.
6BSK,X-RAY DIFFRACTION,3.46,64.41,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293.0,2017-12-03,2018-03-21,6BSK,2361.0,1.0,276.0,83.0,,32.72,1.0,2.573,experimental,46.16,0.1957,0.1696,Human PIM1 kinase in complex with compound 12b
6L11,X-RAY DIFFRACTION,3.54,65.21,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.4M potassium sodium tartrate tetrahydrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2019-09-27,2020-05-27,6L11,2370.0,1.0,289.0,117.0,,33.65,1.0,2.05,experimental,42.265,0.2398,0.213,Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L12,X-RAY DIFFRACTION,3.58,65.67,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.4M potassium sodium tartrate tetrahydrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2019-09-27,2020-05-27,6L12,2293.0,1.0,289.0,42.0,,33.62,1.0,1.87,experimental,39.683,0.2098,0.1968,Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L13,X-RAY DIFFRACTION,3.54,65.21,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.4M potassium sodium tartrate tetrahydrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2019-09-27,2020-05-27,6L13,2316.0,1.0,289.0,71.0,,33.62,1.0,2.24,experimental,35.482,0.2137,0.178,Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L14,X-RAY DIFFRACTION,3.6,65.87,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.4M potassium sodium tartrate tetrahydrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2019-09-27,2020-05-27,6L14,2292.0,1.0,289.0,59.0,,33.64,1.0,1.95,experimental,42.887,0.2094,0.1925,Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L15,X-RAY DIFFRACTION,3.58,65.61,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.4M potassium sodium tartrate tetrahydrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2019-09-27,2020-05-27,6L15,2225.0,1.0,289.0,2.0,,33.64,1.0,2.6,experimental,46.983,0.221,0.1819,Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L16,X-RAY DIFFRACTION,3.58,65.67,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.4M potassium sodium tartrate tetrahydrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2019-09-27,2020-05-27,6L16,2258.0,1.0,289.0,35.0,,33.67,1.0,2.1,experimental,41.657,0.2176,0.1979,Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6L17,X-RAY DIFFRACTION,3.55,65.31,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.4M potassium sodium tartrate tetrahydrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2019-09-27,2020-09-02,6L17,2427.0,1.0,289.0,180.0,,33.65,1.0,1.75,experimental,30.159,0.2049,0.1839,Crystal structure of Ser/Thr kinase Pim1 in complex with 10-DEBC derivatives
6VRV,X-RAY DIFFRACTION,3.62,66.02,VAPOR DIFFUSION,,"100 mM imidazole, 1.4M sodium acetate pH 6.4",292.0,2020-02-10,2020-11-04,6VRV,2481.0,1.0,274.0,244.0,,32.02,1.0,1.74,experimental,32.44,0.1966,0.1723,"Discovery of SARxxxx92, a pan-PIM kinase inhibitor, efficacious in a KG1 tumor model"
7QB2,X-RAY DIFFRACTION,3.1,60.5,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM bis-tris propane (pH 7.0), 10% ethylene glycol, 0.3% DMSO, 20% PEG3350, 200 mM MgOAc",291.15,2021-11-18,2022-11-30,7QB2,2314.0,2.0,326.0,87.0,,37.56,2.0,2.53,experimental,42.5,0.2019,0.1571,Pim1 in complex with (E)-4-((6-amino-1-methyl-2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide
7QFM,X-RAY DIFFRACTION,3.1,59.7,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM bis-tris propane (pH 7.0), 10% ethylene glycol, 0.3% DMSO, 20% PEG3350, 200 mM MgOAc",291.15,2021-12-06,2022-12-21,7QFM,2378.0,2.0,326.0,123.0,,37.53,2.0,1.95,experimental,43.25,0.1779,0.1583,Pim1 in complex with (E)-4-((2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide
7Z6U,X-RAY DIFFRACTION,3.1,60.5,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM bis-tris-propane (pH 7.0), 10% ethylene glycol, 0.3% DMSO, 20% PEG3350, 200 mM MgOAc",291.15,2022-03-14,2023-02-01,7Z6U,2303.0,2.0,327.0,94.0,,37.68,2.0,2.28,experimental,47.77,0.1908,0.1617,Pim1 in complex with (E)-4-((6-amino-2-oxoindolin-3-ylidene)methyl)benzoic acid and Pimtide
6LOT,X-RAY DIFFRACTION,2.64,53.39,"VAPOR DIFFUSION, HANGING DROP",6.7,"0.1 M PIPES, 30% PEG 3,350, 0.2 M Li2SO4",293.0,2020-01-07,2020-10-28,6LOT,1294.0,1.0,157.0,78.0,,17.91,1.0,1.69,experimental,25.5385,0.2192,0.1919,Crystal structure of DUSP22 mutant_N128D
6LOU,X-RAY DIFFRACTION,2.59,52.55,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.05 M arginine, 0.05 M glutamic acid, 0.4 M NaH2PO4, 1.6 M K2HPO4, 0.2 M NaCl",293.0,2020-01-07,2020-10-28,6LOU,1384.0,1.0,157.0,133.0,,17.92,1.0,1.5301,experimental,19.7138,0.1957,0.1717,Crystal structure of DUSP22 mutant_C88S/S93N
6LVQ,X-RAY DIFFRACTION,1.91,35.61,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 2 mM MnCl2, 0.1 mM VO4, 25% PEG 4000",293.0,2020-02-04,2020-10-28,6LVQ,1351.0,1.0,157.0,98.0,,17.93,1.0,1.38,experimental,20.2221,0.2287,0.2041,Crystal structure of DUSP22_VO4
7C8S,X-RAY DIFFRACTION,2.55,51.76,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES, 30% PEG 3,350, 0.2 M Li2SO4",293.0,2020-06-03,2020-10-28,7C8S,1400.0,1.0,157.0,154.0,,17.86,1.0,1.31,experimental,19.79,0.1965,0.1874,Crystal structure of DUSP22 mutant_N128A
5EX3,X-RAY DIFFRACTION,3.29,62.62,"VAPOR DIFFUSION, HANGING DROP",7.0,2.8M NaAC,293.0,2015-11-23,2016-03-09,5EX3,3617.0,2.0,445.0,96.0,,51.79,2.0,2.408,experimental,65.21,0.2227,0.1843,Crystal structure of human SMYD3 in complex with a VEGFR1 peptide
7UV5,X-RAY DIFFRACTION,2.32,47.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2 M sodium tartrate, 15% PEG3350",289.0,2022-04-29,2022-05-11,7UV5,3869.0,3.0,470.0,355.0,,53.42,3.0,1.45,experimental,37.802,0.1786,0.1364,"The crystal structure of Papain-Like Protease of SARS CoV-2, C111S/D286N mutant, in complex with a Lys48-linked di-ubiquitin"
7S90,X-RAY DIFFRACTION,2.7,54.51,"VAPOR DIFFUSION, SITTING DROP",,"1.8 Malic acid, pH 7",291.0,2021-09-20,2022-08-03,7S90,1833.0,1.0,237.0,154.0,,26.88,1.0,1.79,experimental,42.4,0.2141,0.1777,Cryogenic Human Hsp90a-NTD bound to adenine
7S95,X-RAY DIFFRACTION,2.8,56.08,"VAPOR DIFFUSION, SITTING DROP",,"1.8 M Malic acid, pH 7",291.0,2021-09-20,2022-08-03,7S95,1855.0,1.0,237.0,95.0,,26.88,1.0,1.71,experimental,46.01,0.191,0.16,Room-temperature Human Hsp90a-NTD bound to adenine
7S98,X-RAY DIFFRACTION,2.81,56.25,"VAPOR DIFFUSION, SITTING DROP",,"1.8 M Malic acid, pH 7",291.0,2021-09-20,2022-08-03,7S98,1911.0,1.0,237.0,160.0,,26.89,1.0,1.9,experimental,40.09,0.2162,0.186,Cryogenic Human Hsp90a-NTD bound to N6M
7S99,X-RAY DIFFRACTION,2.79,55.95,"VAPOR DIFFUSION, SITTING DROP",,"1.8 M Malic acid, pH 7",291.0,2021-09-20,2022-08-03,7S99,2254.0,1.0,237.0,133.0,,26.89,1.0,1.52,experimental,36.4,0.1809,0.167,Room-temperature Human Hsp90a-NTD bound to N6M
7S9F,X-RAY DIFFRACTION,2.89,57.37,"VAPOR DIFFUSION, SITTING DROP",,"1.8 M Malic acid, pH 7",291.0,2021-09-20,2022-08-03,7S9F,1993.0,1.0,237.0,100.0,,27.11,1.0,2.3,experimental,48.62,0.2461,0.2158,Cryogenic Human Hsp90a-NTD bound to BIIB021
7S9G,X-RAY DIFFRACTION,2.92,57.83,"VAPOR DIFFUSION, SITTING DROP",,"1.8 M Malic acid, pH 7",291.0,2021-09-21,2022-08-03,7S9G,2372.0,1.0,237.0,79.0,,27.08,1.0,1.79,experimental,51.49,0.1955,0.1759,Room-temperature Human Hsp90a-NTD bound to BIIB021
7S9I,X-RAY DIFFRACTION,2.9,57.57,"VAPOR DIFFUSION, SITTING DROP",,"1.8 M Malic acid, pH 7",291.0,2021-09-21,2022-08-03,7S9I,1949.0,1.0,237.0,92.0,,27.15,1.0,1.75,experimental,45.9,0.1914,0.1665,Room-temperature Human Hsp90a-NTD bound to EC144
7AI0,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, 0.075 M NaOAc, 0.1 M NaCl, 15 % w/v PEG Smear Medium",292.0,2020-09-25,2021-01-20,7AI0,5307.0,6.0,606.0,662.0,,68.89,3.0,1.559,experimental,20.479,0.1848,0.1335,Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 1)
7AI1,X-RAY DIFFRACTION,2.26,45.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.2 M NH4NO3, 20 % w/v PEG Smear Broad",292.0,2020-09-25,2021-01-20,7AI1,4764.0,6.0,606.0,278.0,,68.66,3.0,2.07,experimental,32.5,0.266,0.2121,Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 2)
5OHJ,X-RAY DIFFRACTION,1.8,31.5,"VAPOR DIFFUSION, HANGING DROP",4.5,"Drops comprised 2microliters protein solution mixed with reservoir buffer consisting of 100mM sodium acetate pH 4.5, 14% PEG400 and 50mM calcium acetate. After 2 days they were streak seeded with crystals obtained from rolipram complex seed stock. Crystals, up to 100 microns in largest dimension, grew from precipitate after 1-2 weeks. Crystals were transferred to a cryoprotectant solution (100mM sodium acetate pH 4.5, 14% PEG400, 50mM calcium acetate and 20% glycerol) then flash-frozen prior to X-ray data collection.",293.0,2017-07-17,2017-12-13,5OHJ,5699.0,2.0,842.0,165.0,,98.52,1.0,1.6,experimental,22.688,0.21153,0.1841,Human phosphodiesterase 4B catalytic domain in complex with a pyrrolidinyl inhibitor.
5I8A,X-RAY DIFFRACTION,2.76,55.47,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris pH 6.5, 2.3M Ammonium Acetate",298.0,2016-02-18,2017-08-09,5I8A,2242.0,1.0,296.0,44.0,,34.34,1.0,2.33,experimental,40.34,0.2094,0.1781,"TrkA with (6~{R})-3-methylsulfanyl-6-phenyl-1-(1~{H}-pyrazol-3-yl)-6,7-dihydro-5~{H}-thieno[3,4-c]pyridin-4-one"
6DKG,X-RAY DIFFRACTION,2.25,45.28,"VAPOR DIFFUSION, SITTING DROP",,"Compound 13b soaked for 30 min into preformed crystals of TrkA.
Well volume: 50.0 uL
Well Ingredients:
Polymer: 9.0 %w/v (9.0 uL of stock 50.0 %w/v) PEG 3350
Buffer: 15.8 %v/v (7.9 uL of stock 100.0 %v/v) tacsimate (pH 8.00)
Additive: 0.025 M (12.5 uL of stock 0.1 M) TCEP hydrochloride

Plate setup temperature: 13 C
Plate incubation temperature: 21 C

Drop volume from well: 0.0050 uL
Drop protein volume: 0.34 uL",294.0,2018-05-29,2018-07-11,6DKG,2340.0,1.0,320.0,62.0,,36.87,1.0,2.53,experimental,54.8,0.2254,0.1875,"Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 13b."
6DKI,X-RAY DIFFRACTION,2.28,46.08,"VAPOR DIFFUSION, SITTING DROP",8.0,"Well volume: 20.0 uL

Well Ingredients:
Polymer: 9.0 %w/v (3.6 uL of stock 50.0 %w/v) PEG 3350
Buffer: 15.8 %v/v (3.16 uL of stock 100.0 %v/v) tacsimate (pH 8.00)
Additive: 0.025 M (5.0 uL of stock 0.1 M) TCEP hydrochloride

Plate setup temperature: 13 C
Plate incubation temperature: 21 C

Drop volume from well: 0.01 uL
Drop protein volume: 0.2 uL
Protein: 6.30 mg/mL",294.0,2018-05-29,2018-07-11,6DKI,2398.0,1.0,320.0,97.0,,36.81,1.0,2.11,experimental,39.71,0.227,0.1837,"Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 19."
5EP6,X-RAY DIFFRACTION,1.83,32.76,"VAPOR DIFFUSION, SITTING DROP",7.0,"1% w/v Tryptone, 0.05 M HEPES sodium (pH 7.0), 12% w/v PEG 3350",291.15,2015-11-11,2016-09-28,5EP6,1599.0,4.0,210.0,101.0,,24.37,2.0,1.451,experimental,,0.2174,0.1867,The crystal structure of NAP1 in complex with TBK1
8OSD,X-RAY DIFFRACTION,1.72,28.49,"VAPOR DIFFUSION, SITTING DROP",,"30mM HEPES pH 7.5
150mM NaCl
1mM DTT
100mM Potassium thiocyanate
30% w/v PEG MME2000",293.0,2023-04-18,2023-08-23,8OSD,1714.0,2.0,218.0,83.0,,24.51,1.0,1.7,experimental,27.06,0.2602,0.2171,Crystal structure of the titin domain Fn3-49
5I9Y,X-RAY DIFFRACTION,1.97,37.46,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Hepes pH 6.5",291.0,2016-02-21,2016-11-09,5I9Y,2784.0,1.0,306.0,290.0,,35.14,1.0,1.228,experimental,,0.1795,0.1635,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with dasatinib
6EJ9,X-RAY DIFFRACTION,2.57,52.14,"VAPOR DIFFUSION, HANGING DROP",7.5,"55-65% Morpheus Precipitant mix 2 (PEG8000 and Ethylene glycol)
0.1M Bicine/Tris buffer at pH 7.5
0.1M of NPS mix (0.033M of each)",293.0,2017-09-20,2018-05-02,6EJ9,5800.0,2.0,762.0,187.0,6.0,87.34,2.0,2.02,experimental,49.6451,0.2245,0.2037,Human Xylosyltransferase 1 in complex with peptide QEPEGSGGGQGG
6EJC,X-RAY DIFFRACTION,2.57,52.06,"VAPOR DIFFUSION, HANGING DROP",7.5,"55-65% Morpheus Precipitant mix 2 (PEG8000 and Ethylene glycol)
0.1M Bicine/Tris buffer at pH 7.5
0.1M of NPS mix (0.033M of each)",293.0,2017-09-20,2018-05-02,6EJC,5669.0,2.0,763.0,58.0,6.0,87.37,2.0,2.057,experimental,35.8768,0.2726,0.2419,Human Xylosyltransferase 1 in complex with peptide QEEEGSGVGQGG
5LSP,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, HANGING DROP",8.5,"10% PEG 20,000, 20% PEG 550-MME, 0.1M Trizma/Bicine pH 8.5, 0.03M magnesium chloride, 0.03M calcium chloride",293.0,2016-09-05,2017-09-13,5LSP,10159.0,8.0,1368.0,88.0,20.0,149.68,4.0,2.605,experimental,,0.2565,0.2154,107_A07 Fab in complex with fragment of the Met receptor
5KZW,X-RAY DIFFRACTION,3.38,63.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 sodium HEPES, 2% (v/v) PEG 400, 2M ammonium sulfate",293.0,2016-07-25,2017-07-26,5KZW,7802.0,1.0,874.0,792.0,5.0,101.29,1.0,2,experimental,25.23,0.185,0.154,Crystal structure of human GAA
5MJY,X-RAY DIFFRACTION,2.15,42.81,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.1 M MMT buffer pH 9.0, 25% PEG1500",277.0,2016-12-02,2017-08-16,5MJY,12216.0,6.0,1488.0,491.0,,168.3,2.0,2.25,experimental,,0.2346,0.1869,Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (SARA complex structure)
5PAV,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAV,3072.0,2.0,318.0,446.0,9.0,36.18,2.0,1.4,experimental,26.37,0.1967,0.1888,Crystal Structure of Factor VIIa in complex with N-(6-aminopyridin-3-yl)-5-hydroxy-1-phenylpyrazole-4-carboxamide
5PB0,X-RAY DIFFRACTION,3.76,67.24,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PB0,2855.0,2.0,318.0,355.0,9.0,36.16,2.0,1.98,experimental,25.314,0.1931,0.1675,Crystal Structure of Factor VIIa in complex with 2-(4-ethoxy-3-methoxyphenyl)-2-(isoquinolin-6-ylamino)acetic acid
5EK2,X-RAY DIFFRACTION,3.01,59.19,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG, Ammonium Fluoride",291.0,2015-11-03,2015-12-23,5EK2,6157.0,2.0,806.0,92.0,1.0,92.6,1.0,2.68,experimental,69.0602,0.2314,0.1708,"Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue"
5EK3,X-RAY DIFFRACTION,2.82,56.45,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG, Ammonium Fluoride",291.0,2015-11-03,2015-12-23,5EK3,6320.0,2.0,806.0,248.0,1.0,92.57,1.0,2.209,experimental,57.0304,0.2319,0.1839,"Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue"
5EK4,X-RAY DIFFRACTION,2.83,56.61,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG, Ammonium Fluoride",291.0,2015-11-03,2015-12-23,5EK4,6123.0,2.0,806.0,94.0,,92.6,1.0,2.64,experimental,57.3557,0.2244,0.1832,"Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue"
6AZW,X-RAY DIFFRACTION,2.86,57.0,VAPOR DIFFUSION,,"16% PEG 8K, 0.2 M NH4 acetate, 0.1 M CHES pH 8.75",298.0,2017-09-13,2018-03-21,6AZW,5713.0,2.0,788.0,,1.0,89.48,1.0,2.78,experimental,,0.2986,0.2166,IDO1/FXB-001116 crystal structure
7RRB,X-RAY DIFFRACTION,2.99,58.83,VAPOR DIFFUSION,,"0.1 MM TRIS PH 8.0, 20% (W/V) PEG6000, 0.2 M NACL",293.0,2021-08-09,2022-03-16,7RRB,6032.0,2.0,788.0,13.0,1.0,89.49,1.0,2.69,experimental,82.451,0.2453,0.2093,IDO1 IN COMPLEX WITH COMPOUND 9
7RRC,X-RAY DIFFRACTION,2.84,56.75,VAPOR DIFFUSION,,"0.1 MM TRIS PH 8.0, 20% (W/V) PEG6000, 0.2 M NACL",293.0,2021-08-09,2022-03-16,7RRC,6280.0,2.0,788.0,201.0,1.0,89.6,1.0,2.18,experimental,61.531,0.2169,0.1865,IDO1 IN COMPLEX WITH COMPOUND 14
6BA4,X-RAY DIFFRACTION,2.34,47.45,"VAPOR DIFFUSION, HANGING DROP",7.0,"2 M NaCl, 0.1 M Tris pH 7.0, 0.22 M MgCl2",292.0,2017-10-12,2018-08-01,6BA4,2471.0,1.0,295.0,154.0,,36.19,1.0,1.949,experimental,,0.2128,0.1841,Crystal structure of MYST acetyltransferase domain in complex with Acetyl-CoA cofactor
8K00,X-RAY DIFFRACTION,1.77,30.69,"VAPOR DIFFUSION, HANGING DROP",,Ammonium sulate,277.0,2023-07-07,2023-09-13,8K00,1337.0,2.0,152.0,195.0,,16.41,2.0,1.4,experimental,,0.1988,0.1731,RPA70N-MRE11 fusion
5QOX,X-RAY DIFFRACTION,2.51,50.95,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOX,1331.0,1.0,167.0,83.0,,19.67,1.0,1.95,experimental,43.336,0.241,0.1905,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z2212124043
5TH6,X-RAY DIFFRACTION,2.1,41.44,"VAPOR DIFFUSION, SITTING DROP",5.0,"12% (v/v) PEG 8000
0.3 M lithium sulfate
0.1 M sodium acetate, pH 5.0",293.0,2016-09-29,2017-03-01,5TH6,7606.0,4.0,924.0,921.0,,104.85,1.0,1.7,experimental,16.3579,0.2346,0.2075,"Structure determination of a potent, selective antibody inhibitor of human MMP9 (apo MMP9)"
8YM7,X-RAY DIFFRACTION,7.08,82.63,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Sodium acetate pH 4.6
1.2 M Sodium malonate",293.0,2024-03-08,2024-05-22,8YM7,6308.0,2.0,794.0,,,90.12,2.0,2.83,experimental,,0.2476,0.2124,Crystal structure of Lysine Specific Demethylase 1 (LSD1) with JH-45
8ALK,X-RAY DIFFRACTION,2.23,44.97,"VAPOR DIFFUSION, SITTING DROP",,"MES 0.1M pH 5, PEG6000 5%",292.0,2022-08-01,2023-04-12,8ALK,4940.0,2.0,644.0,76.0,,73.84,2.0,2.15,experimental,59.06,0.2275,0.1813,Structure of the Legionella phosphocholine hydrolase Lem3 in complex with its substrate Rab1
6GT5,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris propane, 0.2 M pottassium-sodium tartrate, 20% PEG 3350",293.0,2018-06-15,2018-09-19,6GT5,4036.0,2.0,582.0,25.0,,66.69,1.0,2.45,experimental,57.14,0.24,0.182,METTL16 MTase domain (crystal form 2)
6N4T,X-RAY DIFFRACTION,2.33,47.32,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris, pH 8.2 - 8.7, 18 % - 22 % PEG800, 200 mM MgCl2",,2018-11-20,2019-10-02,6N4T,2117.0,1.0,241.0,180.0,3.0,27.64,1.0,1.945,experimental,16.252,0.2254,0.165,Crystal structure of Matriptase1 in complex with a peptidomimetic benzothiazole
7AMD,X-RAY DIFFRACTION,2.44,49.63,"VAPOR DIFFUSION, HANGING DROP",8.5,"10% (w/v) PEG 3350, 0.1M tris-HCl pH 8.5",293.0,2020-10-08,2020-10-28,7AMD,4705.0,1.0,612.0,210.0,,69.17,1.0,2.25,experimental,32.32,0.2104,0.1773,In situ assembly of choline acetyltransferase ligands by a hydrothiolation reaction reveals key determinants for inhibitor design
8FVS,X-RAY DIFFRACTION,2.31,46.7,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M Magnesium chloride hexahydrate, 0.1 M Tris 8.5, 25 % w/v Polyethylene glycol 3,350",291.0,2023-01-19,2024-01-24,8FVS,2447.0,2.0,232.0,346.0,,28.98,1.0,1.75,experimental,,0.1809,0.1524,Bromodomain of CBP liganded with CCS1477int
8T1Q,X-RAY DIFFRACTION,2.29,46.22,"VAPOR DIFFUSION, HANGING DROP",,"18-30% (w/v) PEG3350, 200-250 mM ammonium sulfate and 0.1 M Bis-Tris pH 6.3-6.7",293.0,2023-06-02,2023-11-08,8T1Q,3731.0,1.0,479.0,214.0,,55.17,1.0,1.7,experimental,42.08,0.2149,0.1833,Crystal structure of human CPSF73 catalytic segment in complex with compound 1
8T1R,X-RAY DIFFRACTION,2.28,46.13,"VAPOR DIFFUSION, HANGING DROP",,"18-30% (w/v) PEG3350, 200-250 mM ammonium sulfate and 0.1 M Bis-Tris pH 6.3-6.7",293.0,2023-06-02,2023-11-08,8T1R,3543.0,1.0,479.0,88.0,,55.16,1.0,2.2,experimental,51.93,0.2499,0.196,Crystal structure of human CPSF73 catalytic segment in complex with compound 2
8OWG,X-RAY DIFFRACTION,2.28,46.13,"VAPOR DIFFUSION, SITTING DROP",,"15 % PEG2000 MME, 0.1 M PCPT pH 6.5",293.0,2023-04-27,2023-07-05,8OWG,5818.0,3.0,927.0,113.0,,105.46,1.0,2.631,experimental,41.58,0.3292,0.2806,Crystal structure of D1228V c-MET bound by compound 2
6FHI,X-RAY DIFFRACTION,3.33,63.05,"VAPOR DIFFUSION, SITTING DROP",5.0,"Bat FluA polymerase bound to the ends of the RNA promotor (5 prime end nts 1-16, 3 prime end nts 1-18) was co-crystallized in a 1:8 ratio with the  serine 5 phosphorylated  19-mer Pol II CTD peptide mimic, with a truncated linker, in 0.8 M sodium-potassium phosphate at pH 5.0. Crystals were set at 4 C using seeding.",277.0,2018-01-14,2019-01-30,6FHI,18364.0,6.0,2376.0,,,278.8,4.0,2.8,experimental,81.201,0.26978,0.23016,Crystal structure of bat influenza A/H17N10 polymerase with viral RNA promoter bound to a 19-mer serine 5 phosphorylated Pol II CTD peptide with a truncated linker.
8OMW,X-RAY DIFFRACTION,2.25,45.23,"VAPOR DIFFUSION, SITTING DROP",,"10mM Tris-HCl pH 7.5
50mM NaCl
0.5mM DTT
0.1M TBG pH 9.0
25% w/v PEG 1500",293.0,2023-03-31,2023-08-23,8OMW,1114.0,1.0,109.0,260.0,,11.66,1.0,1.05,experimental,12.65,0.1775,0.149,Crystal structure of the titin domain Fn3-20
8OS3,X-RAY DIFFRACTION,1.98,37.91,"VAPOR DIFFUSION, SITTING DROP",,"30mM HEPES pH 7.5
50mM NaCl
0.5mM DTT
100mM sodium acetate pH 4.5
200mM Lithium sulphate
50% v/v PEG 400",293.0,2023-04-17,2023-08-23,8OS3,917.0,1.0,107.0,123.0,,11.7,1.0,1.68,experimental,26.8,0.2082,0.1657,Crystal structure of the titin domain Fn3-11
7XLP,X-RAY DIFFRACTION,2.43,49.39,"VAPOR DIFFUSION, HANGING DROP",7.75,"100 mM Tris (pH 7.75), 200 mM calcium chloride, 2% DMSO, 18-20% PEG 3350",277.0,2022-04-22,2023-03-01,7XLP,2458.0,1.0,348.0,73.0,,39.58,1.0,2.1,experimental,63.2445,0.2462,0.2186,MEK1 bound to DS03090629
7XNC,X-RAY DIFFRACTION,2.47,50.18,"VAPOR DIFFUSION, HANGING DROP",7.75,"100 mM Tris (pH 7.75), 200 mM calcium chloride, 2% DMSO, 18-20% PEG 3350",277.0,2022-04-28,2023-03-01,7XNC,2457.0,1.0,348.0,89.0,,39.51,1.0,2.1,experimental,53.8059,0.2512,0.2252,MEK1 bound to DS94070624
7R3Z,X-RAY DIFFRACTION,2.66,53.74,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris pH 8.5, 200 mM lithium sulfate, 20-24% PEG (w/v) PEG 3350",295.0,2022-02-08,2023-01-25,7R3Z,3484.0,4.0,438.0,78.0,,50.68,2.0,2.25,experimental,43.105,0.2449,0.1967,Tankyrase 2 catalytic domain in complex with OUL40
7SSK,X-RAY DIFFRACTION,2.52,51.28,VAPOR DIFFUSION,6.5,"20% PEG3350, 0.1 M MES pH 6.5",277.0,2021-11-11,2022-11-09,7SSK,4130.0,1.0,569.0,222.0,,66.81,1.0,2.36,experimental,42.975,0.235,0.1867,Human P300 complexed with a glycine-based inhibitor
7FD3,X-RAY DIFFRACTION,3.17,61.21,"VAPOR DIFFUSION, SITTING DROP",,"8% v/v tacsimate pH5.0, 12% w/v PEG3350",291.0,2021-07-15,2022-07-20,7FD3,1289.0,1.0,161.0,,,19.05,1.0,2.99,experimental,87.415,0.2825,0.2403,IL-1RAPL2 TIR domain
7XC0,X-RAY DIFFRACTION,2.26,45.6,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES-NaOH pH 6.5, 13%(v/v) PEGMME 550",291.0,2022-03-22,2022-07-06,7XC0,2512.0,1.0,291.0,189.0,,33.32,1.0,1.56,experimental,31.64,0.2073,0.1781,Crystal structure of Human RPTPH
6KMH,X-RAY DIFFRACTION,2.64,53.42,"VAPOR DIFFUSION, SITTING DROP",,"0.2M KI, 20% PEG 3350, pH 7.0",289.0,2019-07-31,2020-08-05,6KMH,6001.0,4.0,782.0,126.0,,90.43,2.0,2.4,experimental,46.9959,0.2241,0.1882,The crystal structure of CASK/Mint1 complex
8ABX,X-RAY DIFFRACTION,2.33,47.27,"VAPOR DIFFUSION, HANGING DROP",6.5,"40% PEG200, 100mM MES",293.0,2022-07-05,2022-08-24,8ABX,3357.0,1.0,404.0,141.0,,47.55,1.0,1.65,experimental,33.6008,0.21,0.192,Crystal structure of IDO1 in complex with Apoxidole-1
5AMC,X-RAY DIFFRACTION,2.85,57.0,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",,2015-03-10,2016-01-13,5AMC,11113.0,2.0,1258.0,886.0,6.0,150.03,2.0,1.65,experimental,30.142,0.24169,0.20772,Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta fluorogenic fragment 4-10
6UJ0,X-RAY DIFFRACTION,2.11,41.63,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M MES, pH = 6
1.26 M (NH4)2SO4",298.0,2019-10-01,2020-10-07,6UJ0,5918.0,4.0,934.0,172.0,6.0,100.11,2.0,2.15,experimental,46.0,0.2578,0.2198,Unbound BACE2 mutant structure
5ZJ6,X-RAY DIFFRACTION,2.19,43.75,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris-HCl (pH 8.5)
25 % (v/v) PEG 10,000",288.0,2018-03-19,2018-06-06,5ZJ6,5101.0,2.0,574.0,676.0,,66.17,1.0,1.696,experimental,21.5299,0.2401,0.2066,"Crystal structure of HCK kinase complexed with a pyrrolo-pyrimidine inhibitor 7-[trans-4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine"
5WHC,X-RAY DIFFRACTION,2.59,52.59,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 1000, 0.1M Tris-HCl 7.0",289.0,2017-07-16,2017-12-13,5WHC,5556.0,2.0,692.0,55.0,,80.79,1.0,2.548,experimental,74.0695,0.2603,0.2087,"USP7 in complex with Cpd2 (4-(3-(1-methylpiperidin-4-yl)-1,2,4-oxadiazol-5-yl)phenol)"
7MU7,X-RAY DIFFRACTION,3.04,59.58,VAPOR DIFFUSION,,"0.1M BisTRIS pH 5.5, 0.2M ammonium acetate, 3% sorbitol and 12% PEG3350",293.0,2021-05-14,2022-05-18,7MU7,4121.0,2.0,668.0,60.0,,76.11,1.0,2.298,experimental,,0.2416,0.2053,Ask1 bound to compound 3
6LJK,X-RAY DIFFRACTION,2.33,47.25,"VAPOR DIFFUSION, HANGING DROP",,"25%-27% (v/v) PEG 3350, 0.1 M MES, pH 5.5-6.0, 0.1-0.2 M NaCl",293.0,2019-12-17,2020-12-23,6LJK,2630.0,2.0,281.0,391.0,,30.77,2.0,1.394,experimental,15.0322,0.1582,0.1222,Crystal structure of human Sirt5 in complex with an internally quenched fluorescent substrate GluIQF
6VRE,X-RAY DIFFRACTION,2.74,55.14,VAPOR DIFFUSION,5.5,"0.1M BisTRIS pH 5.5, 0.2M ammonium acetate, 3% sorbitol and 12% PEG3350",300.0,2020-02-07,2020-05-06,6VRE,4111.0,2.0,582.0,77.0,,66.42,1.0,2.29,experimental,68.3043,0.24,0.19,Structure of ASK1 bound to BIO-1772961
8PVO,X-RAY DIFFRACTION,3.13,60.69,VAPOR DIFFUSION,5.5,0.2 M ammonia sulphate 0.1 M bis-tris pH 5.5 23-26% PEG 3350,293.0,2023-07-18,2023-09-20,8PVO,5839.0,2.0,676.0,148.0,,84.02,1.0,2.25,experimental,53.18,0.25252,0.20764,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric compound FG5
8PVP,X-RAY DIFFRACTION,3.15,60.9,VAPOR DIFFUSION,,0.2 M ammonia sulphate 0.1 M bis-tris pH 5.5 23-26% PEG 3350,293.0,2023-07-18,2023-09-20,8PVP,5499.0,2.0,676.0,30.0,,82.89,1.0,2.6,experimental,50.288,0.25346,0.22161,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric compound FGJG18
9EPV,X-RAY DIFFRACTION,3.15,60.99,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonia sulphate
0.1 M bis-tris pH 5.5 
23-26% PEG 3350",293.0,2024-03-20,2024-05-01,9EPV,5663.0,2.0,676.0,184.0,,83.41,1.0,2.3,experimental,37.86,0.24778,0.2146,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC333
9EPY,X-RAY DIFFRACTION,3.09,60.17,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M bis-tris pH 5.5 
23-26% (v/v) PEG 3350 
0.2 M ammonia sulphate",293.0,2024-03-20,2024-05-01,9EPY,5530.0,2.0,676.0,20.0,,83.52,1.0,2.65,experimental,71.729,0.26864,0.22642,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC3330
9EPZ,X-RAY DIFFRACTION,3.16,61.04,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M bis-tris pH 5.5 
23-26% (v/v) PEG 3350 
0.2 M ammonia sulphate",293.0,2024-03-20,2024-05-01,9EPZ,5677.0,2.0,676.0,76.0,,83.43,1.0,2.65,experimental,49.465,0.24473,0.21273,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC3337
7MLK,X-RAY DIFFRACTION,2.5,50.79,"VAPOR DIFFUSION, HANGING DROP",7.0,"8% (w/v) PEG 6000, 0.1 M CHES pH 9.75, 0.64 M Sodium Formate and AMP, 5 mM TCEP pH 7",286.0,2021-04-28,2022-05-04,7MLK,7270.0,1.0,968.0,,,113.0,1.0,2.91,experimental,105.29,0.2422,0.2054,Crystal structure of human PI3Ka (p110a subunit) with MMV085400 bound to the active site determined at 2.9 angstroms resolution
6GFN,X-RAY DIFFRACTION,2.9,57.6,"VAPOR DIFFUSION, HANGING DROP",,0.2 M di-sodium tartrate and 20% (w/v) PEG 3350,293.0,2018-05-01,2018-09-19,6GFN,2061.0,1.0,291.0,11.0,,33.73,1.0,2.86,experimental,93.39,0.222,0.181,METTL16 MTase domain
5HTI,X-RAY DIFFRACTION,2.19,43.9,"VAPOR DIFFUSION, HANGING DROP",7.1,"10-11% PEG5000MME, 11% isopropanol, 0.1M HEPES pH 7.1",293.0,2016-01-26,2017-02-01,5HTI,2571.0,1.0,319.0,215.0,,36.62,1.0,1.66,experimental,23.6161,0.2056,0.181,Crystal structure of c-Met kinase domain in complex with LXM108
5D1J,X-RAY DIFFRACTION,2.09,41.06,"VAPOR DIFFUSION, HANGING DROP",,"35% poly(ethylene glycol) 5000 monomethyl ester, 0.2 M ammonium acetate, 0.1 M HEPES, pH 7.0,",316.0,2015-08-04,2015-08-12,5D1J,2278.0,1.0,298.0,137.0,,34.36,1.0,1.8,experimental,35.56,0.2322,0.2013,"CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]-4-PIPERIDINECARBOXAMIDE (BMS-387032)"
5NOB,X-RAY DIFFRACTION,2.25,45.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M TMAO, 0.1M Tris, 20% PEG 2000 MME",277.0,2017-04-11,2017-11-29,5NOB,3536.0,2.0,480.0,179.0,,55.67,1.0,1.85,experimental,27.764,0.23657,0.20158,Crystal structure of human tankyrase 2 in complex with OD336
6FNH,X-RAY DIFFRACTION,2.75,55.32,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5 % MPD/PEG1000/PEG3350 (MD), 0.075 M Carboxylic Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH 8.5",291.0,2018-02-04,2018-08-08,6FNH,7371.0,3.0,918.0,646.0,,105.12,1.0,1.379,experimental,,0.2212,0.2057,"Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with a pyrazolo[3,4-d]pyrimidine fragment of NVP-BHG712"
5FA5,X-RAY DIFFRACTION,2.7,54.47,"VAPOR DIFFUSION, HANGING DROP",,"200 mM ammonium sulfate, 20-28% PEG 3350, 2 mM 5-deoxy-5-(methylthio)adenosine, 1 mM H4 peptide (1-20)",281.0,2015-12-10,2016-02-24,5FA5,7541.0,3.0,1037.0,168.0,,116.44,3.0,2.34,experimental,64.79,0.2213,0.177,Crystal Structure of PRMT5:MEP50 in complex with MTA and H4 peptide
9EY6,X-RAY DIFFRACTION,4.31,71.49,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 6000, zinc chloride, Tris-HCl pH 8.0",277.0,2024-04-09,2024-05-22,9EY6,4057.0,1.0,447.0,182.0,7.0,55.23,1.0,2.228,experimental,52.36,0.2127,0.1698,Crystal structure of human tyrosinase-related protein 1 (TYRP1)
9EY7,X-RAY DIFFRACTION,4.19,70.64,"VAPOR DIFFUSION, HANGING DROP",8.0,"PEG 6000, Zinc chloride, Tris-HCl pH8.0",277.0,2024-04-09,2024-05-22,9EY7,3845.0,1.0,447.0,58.0,7.0,54.23,1.0,2.61,experimental,61.61,0.2379,0.196,"Crystal structure of human tyrosinase-related protein 1 (TYRP1) in complex with (R)-2,4-dihydroxyphenylalanine"
6HEY,X-RAY DIFFRACTION,1.96,37.13,"VAPOR DIFFUSION, SITTING DROP",7.0,"37.5 % MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH 7.0",291.0,2018-08-20,2019-08-28,6HEY,2553.0,1.0,306.0,273.0,,34.99,1.0,1.367,experimental,,0.2002,0.1804,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATNK002
6Q7B,X-RAY DIFFRACTION,1.95,36.97,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5 % MPD_PEG1000_PEG3350 (Precipitant Mix 4 Morpheus), 100 mM Morpheus Amino Acids Mix, 100 mM Bis-Tris",291.0,2018-12-13,2020-01-15,6Q7B,2674.0,1.0,306.0,315.0,,34.99,1.0,1.009,experimental,,0.2025,0.1867,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL09
6Q7C,X-RAY DIFFRACTION,1.93,36.23,"VAPOR DIFFUSION, SITTING DROP",6.0,"37.5 % MPD_PEG1000_PEG3350, 100 mM Morpheus Amino Acids Mix, 100 mM Bis-Tris",291.0,2018-12-13,2020-01-15,6Q7C,2749.0,1.0,306.0,353.0,,35.0,1.0,1.049,experimental,,0.2118,0.1923,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL11
6Q7E,X-RAY DIFFRACTION,1.97,37.47,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD_PEG1000_PEG3350, 100 mM Alanine, 100 mM Morpheus Buffer System 3  (Tris/Bicine)",291.0,2018-12-13,2020-01-15,6Q7E,2687.0,1.0,306.0,315.0,,34.99,1.0,1.059,experimental,,0.2115,0.1922,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL14
6Q7F,X-RAY DIFFRACTION,1.95,37.02,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5 % MPD_PEG1000_PEG3350, 125 mM Morpheus Carboxylic Acids Mix, 100 mM Morpheus Buffer System 3 (Tris/Bicine)",291.0,2018-12-13,2020-01-15,6Q7F,2573.0,1.0,306.0,285.0,,34.99,1.0,1.204,experimental,,0.2104,0.1868,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATDL18
6Q7G,X-RAY DIFFRACTION,1.97,37.53,"VAPOR DIFFUSION, SITTING DROP",8.5,"30 % PEG3350, 100 mM Morpheus Amino Acids Mix, 100 mM Morpheus Buffer System 3 (Tris/Bicine)",291.0,2018-12-13,2020-01-15,6Q7G,2684.0,1.0,306.0,300.0,,34.99,1.0,1.047,experimental,,0.2009,0.1868,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with the NVP-BHG712 derivative ATHA01
5CRW,X-RAY DIFFRACTION,2.19,43.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% (w/v) PEG 3350, 0.1 M HEPES buffer (pH 7.5)",293.0,2015-07-23,2015-09-09,5CRW,2299.0,2.0,258.0,339.0,1.0,28.17,2.0,1.6,experimental,27.1,0.217,0.184,Crystal structure of the b'-a' domain of oxidized protein disulfide isomerase complexed with alpha-synuclein peptide (31-41)
6PAU,X-RAY DIFFRACTION,2.18,43.64,"VAPOR DIFFUSION, HANGING DROP",6.5,"8 mg/mL protein in a buffer of 25 mM Tris-HCl pH 7.5, 120 mM NaCl, 1 mM DTT, 1 mM MgCl2, mixed 1:1 with well solution of 22% PEG 8000, 0.1 M Bis-Tris pH 6.5",293.0,2019-06-11,2020-03-11,6PAU,3320.0,2.0,390.0,176.0,,47.11,2.0,1.93,experimental,,0.2177,0.1973,Structure of Human NMT2 with myristoyl-lysine peptide and CoA products
7B3Q,X-RAY DIFFRACTION,2.59,52.53,"VAPOR DIFFUSION, SITTING DROP",,"25 % PEG3350, 0.2 M (NH4)2SO4, 0.1 M Na-HEPES pH 7.5",293.0,2020-12-01,2020-12-09,7B3Q,2600.0,1.0,299.0,340.0,,34.11,1.0,1.75,experimental,24.56,0.192,0.171,Crystal structure of c-MET bound by compound 1
7B3T,X-RAY DIFFRACTION,2.55,51.75,"VAPOR DIFFUSION, SITTING DROP",,"25 % PEG8000, 0.2 M Li2SO4",273.0,2020-12-01,2020-12-09,7B3T,2135.0,1.0,299.0,44.0,,34.22,1.0,2.23,experimental,62.99,0.261,0.211,Crystal structure of c-MET bound by compound 2
7B3V,X-RAY DIFFRACTION,2.6,52.73,"VAPOR DIFFUSION, SITTING DROP",,"25 % PEG3350, 0.2 M (NH4)2SO4, PCPT pH 5.5",273.0,2020-12-01,2020-12-09,7B3V,2403.0,1.0,299.0,222.0,,34.04,1.0,1.93,experimental,28.99,0.248,0.225,Crystal structure of c-MET bound by compound 3
7B3W,X-RAY DIFFRACTION,3.12,60.53,"VAPOR DIFFUSION, SITTING DROP",,"8 % ethylene glycol, 10 % PEG8000, 0.1 M Na-HEPES pH 7.5",293.0,2020-12-01,2020-12-09,7B3W,2217.0,1.0,299.0,142.0,,34.1,1.0,2.02,experimental,41.11,0.261,0.232,Crystal structure of c-MET bound by compound 4
7B40,X-RAY DIFFRACTION,2.55,51.78,"VAPOR DIFFUSION, SITTING DROP",,"20 % PEG4000, 10 % isopropanol, 0.1 M Na-HEPES pH 7.5",293.0,2020-12-01,2020-12-09,7B40,2393.0,1.0,299.0,171.0,,34.14,1.0,1.76,experimental,36.83,0.232,0.196,Crystal structure of c-MET bound by compound 6
7B41,X-RAY DIFFRACTION,2.58,52.32,"VAPOR DIFFUSION, SITTING DROP",,"25 % PEG3350, 0.2 M MgCl2, 0.1 M bis-tris pH 5.5",293.0,2020-12-02,2020-12-09,7B41,2368.0,1.0,299.0,138.0,,34.16,1.0,1.97,experimental,42.06,0.233,0.196,Crystal structure of c-MET bound by compound 7
7B42,X-RAY DIFFRACTION,2.62,53.02,"VAPOR DIFFUSION, SITTING DROP",,"25 % PEG3350, 0.2 M MgCl2, 0.1 M bis-tris pH 6.5",293.0,2020-12-02,2020-12-09,7B42,2340.0,1.0,299.0,126.0,,34.16,1.0,1.8,experimental,39.8,0.225,0.202,Crystal structure of c-MET bound by compound 8
5T9W,X-RAY DIFFRACTION,2.62,53.1,VAPOR DIFFUSION,,"0.05 M monobasic potassium phosphate
20% (w/v) PEG 8000",293.0,2016-09-09,2017-01-25,5T9W,1509.0,1.0,164.0,211.0,,18.46,1.0,2,experimental,14.54,0.1841,0.1508,Discovery of a Potent Cyclophilin Inhibitor (Compound 5) based on Structural Simplification of Sanglifehrin A
5ZN2,X-RAY DIFFRACTION,1.99,38.23,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris-HCl, 1.2M ammonium sulfate, 5% acetonitrile, 2mM DTT",293.0,2018-04-07,2018-11-21,5ZN2,3183.0,1.0,329.0,425.0,,39.47,1.0,1.2,experimental,,0.1814,0.1517,X-ray structure of protein kinase ck2 alpha subunit H148A mutant
5ZN3,X-RAY DIFFRACTION,1.99,38.19,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris-HCl, 1.2M ammonium sulfate, 5% acetonitrile, 2mM DTT",293.0,2018-04-07,2018-11-21,5ZN3,3018.0,1.0,329.0,260.0,,39.48,1.0,1.5,experimental,,0.2302,0.1939,X-ray structure of protein kinase ck2 alpha subunit H148S mutant
7L1X,X-RAY DIFFRACTION,1.99,38.05,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM Tris-HCl pH 7.5
200 mM ammonium sulfate
21% PEG5000",293.0,2020-12-15,2021-08-11,7L1X,3043.0,1.0,334.0,221.0,,40.95,1.0,1.8,experimental,34.827,0.2212,0.1728,Structure of human CK2 alpha kinase (catalytic subunit) with the inhibitor 108600.
5I9V,X-RAY DIFFRACTION,1.93,36.31,"VAPOR DIFFUSION, SITTING DROP",,"33.75 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Buffer3 pH 8.5",291.0,2016-02-21,2016-11-09,5I9V,2578.0,1.0,306.0,251.0,,34.99,1.0,1.458,experimental,,0.1914,0.163,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with AGS
5I9W,X-RAY DIFFRACTION,1.96,37.16,"VAPOR DIFFUSION, SITTING DROP",,"30 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M HEPES pH 7.0",291.0,2016-02-21,2016-11-09,5I9W,2553.0,1.0,306.0,301.0,,35.09,1.0,1.359,experimental,,0.1796,0.1699,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with ANP
5I9Z,X-RAY DIFFRACTION,1.95,36.85,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Tris pH 6.5",291.0,2016-02-21,2016-11-09,5I9Z,2573.0,1.0,306.0,291.0,,35.0,1.0,1.698,experimental,,0.1995,0.1604,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with danusertib (PHA739358)
5IA1,X-RAY DIFFRACTION,1.95,37.03,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Bicin pH 7.6",291.0,2016-02-21,2016-11-09,5IA1,2255.0,1.0,306.0,136.0,,35.0,1.0,2.036,experimental,,0.223,0.1809,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with MLN8054
5IA2,X-RAY DIFFRACTION,1.98,37.76,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M Amino Acids, 0.1 M MES pH 7.0",291.0,2016-02-21,2016-11-09,5IA2,2672.0,1.0,306.0,260.0,,35.07,1.0,1.619,experimental,,0.1988,0.1625,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with compound 66
5IA3,X-RAY DIFFRACTION,1.96,37.34,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.2 M Amino Acids, 0.1 M Buffer3 pH 8.5",291.0,2016-02-21,2016-11-09,5IA3,2534.0,1.0,306.0,256.0,,34.91,1.0,1.788,experimental,,0.2036,0.1608,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with PD173955
5IA5,X-RAY DIFFRACTION,2.11,41.84,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Tris pH 6.5",291.0,2016-02-21,2016-11-09,5IA5,2397.0,1.0,306.0,146.0,,35.28,1.0,1.776,experimental,,0.2437,0.1973,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with golvatinib (E7050)
6FNF,X-RAY DIFFRACTION,1.86,33.83,"VAPOR DIFFUSION, SITTING DROP",7.5,"37.5 % MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Tris pH 7.5",291.0,2018-02-04,2018-08-08,6FNF,2310.0,1.0,306.0,119.0,,34.97,1.0,1.556,experimental,,0.2727,0.2351,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with NVP-BHG712
6FNG,X-RAY DIFFRACTION,1.95,37.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5 % MPD/PEG1000/PEG3350 (MD), 
0.2 M Lysine, 0.1 M Buffer System 3 (MD) pH 8.5",291.0,2018-02-04,2018-08-08,6FNG,2615.0,1.0,306.0,264.0,,35.34,1.0,1.038,experimental,,0.1869,0.1749,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with an isomer of NVP-BHG712
8PR7,X-RAY DIFFRACTION,3.38,63.56,"VAPOR DIFFUSION, SITTING DROP",,"0.06M Divalents, Buffer system 1 pH 6.5, 40% Ethylene glycol, 20% PEG 8000",291.0,2023-07-12,2024-07-24,8PR7,5920.0,6.0,896.0,87.0,,102.49,3.0,2.76,experimental,92.224,0.2564,0.2023,Aurora-A in complex with CEP192 and an inhibitory monobody
4YLQ,X-RAY DIFFRACTION,2.52,51.23,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1M NaCitrate, 16.6% PEG 3350, 12.5% 1-Propanol, with seeding",295.0,2015-03-05,2015-12-30,4YLQ,5540.0,3.0,620.0,575.0,15.0,73.03,3.0,1.4,experimental,26.4558,0.1737,0.1397,Crystal Structure of a FVIIa-Trypsin Chimera (FT) in Complex with Soluble Tissue Factor
6GU6,X-RAY DIFFRACTION,2.76,55.39,"VAPOR DIFFUSION, SITTING DROP",,"CONDITIONS AROUND 0.1M BIS-TRIS(PH6.5), 0.2M SODIUM NITRATE 20% PEG3350, PROTEIN AT 10-12 MG/ML, 0.5Mm INHIBITOR",277.0,2018-06-19,2018-12-05,6GU6,3058.0,2.0,386.0,86.0,,45.24,2.0,2.33,experimental,47.498,0.24586,0.20092,CDK1/Cks2 in complex with Dinaciclib
4V0X,X-RAY DIFFRACTION,2.67,54.02,,6.0,"2.0 M SODIUM MALONATE, PH6.0",,2014-09-18,2015-03-25,4V0X,2657.0,2.0,354.0,88.0,,40.9,2.0,1.85,experimental,45.24,0.2222,0.1766,The crystal structure of mouse PP1G in complex with truncated human PPP1R15B (631-684)
5OWT,X-RAY DIFFRACTION,2.27,45.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350",277.0,2017-09-04,2018-05-02,5OWT,3517.0,2.0,480.0,137.0,,55.78,1.0,2.2,experimental,44.728,0.23698,0.1883,"Crystal structure of TNKS2 in complex with (5S)-5-methyl-5-[4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]imidazolidine-2,4-dione"
7ZKS,X-RAY DIFFRACTION,3.01,59.1,VAPOR DIFFUSION,,"5 mM HEPES pH 7.4, 150 mM NaCl, 20 mM DTT",277.0,2022-04-13,2023-02-22,7ZKS,3030.0,1.0,387.0,168.0,,44.58,1.0,2.28,experimental,52.35,0.2897,0.2428,SRPK1 IN COMPLEX WITH INHIBITOR
4RN0,X-RAY DIFFRACTION,2.47,50.14,"VAPOR DIFFUSION, SITTING DROP",7.3,"0.1 M Imidazole (pH=7.0), 4 mM tris(2-carboxyethyl)phosphine (TCEP), 8% PEG 8000, pH 7.3, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-10-22,2015-04-08,4RN0,6546.0,2.0,778.0,750.0,,87.96,1.0,1.761,experimental,22.4,0.1621,0.1367,Crystal structure of S39D HDAC8 in complex with a largazole analogue.
4RN1,X-RAY DIFFRACTION,2.5,50.71,"VAPOR DIFFUSION, SITTING DROP",7.3,"0.1 M Imidazole (pH=7.0), 4 mM tris(2-carboxyethyl)phosphine (TCEP), 13% PEG 3350, pH 7.3, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-10-22,2015-04-08,4RN1,6040.0,2.0,778.0,349.0,,87.95,1.0,2.18,experimental,36.08,0.2125,0.1819,Crystal structure of S39D HDAC8 in complex with a largazole analogue.
6YU1,X-RAY DIFFRACTION,2.97,58.56,"VAPOR DIFFUSION, SITTING DROP",7.0,"18% PEG 3350, 0,2M Na/K PO4, 10% Ethylene Glycol",277.0,2020-04-25,2020-07-15,6YU1,6334.0,2.0,720.0,450.0,,87.4,1.0,1.9,experimental,27.445,0.2029,0.1756,CLK3 bound with beta-carboline KH-CARB13 (Cpd 3)
5VI6,X-RAY DIFFRACTION,2.14,42.56,"VAPOR DIFFUSION, SITTING DROP",8.0,35% dioxane,277.0,2017-04-14,2017-09-06,5VI6,3402.0,2.0,376.0,383.0,,42.74,2.0,1.237,experimental,,0.1433,0.1213,Crystal structure of histone deacetylase 8 in complex with trapoxin A
6E1F,X-RAY DIFFRACTION,1.7,27.75,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris, pH 6.5, 0.1 M potassium chloride, 1.5 M ammonium sulfate",293.0,2018-07-09,2019-07-10,6E1F,3437.0,4.0,356.0,383.0,,41.13,1.0,1.16,experimental,14.21,0.169,0.133,Crystal structure of the SWIRM domain of human histone lysine-specific demethylase LSD1
6BZ9,X-RAY DIFFRACTION,2.66,53.68,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium formate, 20% w/v PEG3350",277.0,2017-12-22,2018-06-13,6BZ9,2249.0,3.0,272.0,125.0,,30.89,3.0,1.796,experimental,,0.2104,0.178,Crystal structure of human caspase-1 in complex with Ac-FLTD-CMK
5L6W,X-RAY DIFFRACTION,4.09,69.9,"VAPOR DIFFUSION, SITTING DROP",,"35% pentaerythritol propoxylate 5/4, 0.1 M HEPES pH 7.5, 0.2 M potassium chloride",277.0,2016-05-31,2016-06-08,5L6W,3398.0,2.0,477.0,,,55.15,2.0,2.53,experimental,88.725,0.28395,0.22614,Structure Of the LIMK1-ATPgammaS-CFL1 Complex
6E21,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.71,54.63,"VAPOR DIFFUSION, SITTING DROP",,"100 mM MES, pH 6.5, 5 mM DTT, PEG4000",277.0,2018-07-10,2019-04-03,6E21,3121.0,2.0,376.0,152.0,,44.45,2.0,"2, 2.5",experimental,30.03,0.217,0.187,Joint X-ray/neutron structure of PKAc with products Sr2-ADP and phosphorylated peptide SP20
,,,,,,,,,,,,,,,,,,,,30.03,0.275,0.226,
8BA5,X-RAY DIFFRACTION,2.05,39.89,VAPOR DIFFUSION,,"17 % PEG 8000, 0.2 M Magnesiumsulfat, 0.1 M TRIS-HCl pH 7.5",291.15,2022-10-11,2022-11-23,8BA5,1216.0,1.0,144.0,120.0,,16.66,1.0,1.45,experimental,29.89,0.2129,0.1867,Crystal structure of the DNMT3A ADD domain
6BE6,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.26M Ammonium Sulfate
100mM HEPES pH 7.5
21.75 % PEG8000",295.0,2017-10-24,2017-12-27,6BE6,13995.0,4.0,1796.0,383.0,68.0,203.8,1.0,2.8,experimental,,0.2845,0.2363,ADAM10 Extracellular Domain
6XOG,X-RAY DIFFRACTION,2.19,43.74,VAPOR DIFFUSION,,"50 mM BisTris, pH 6.5, 50 mM Ammonium Sulfate, 30% pentaerythritol ethoxylate (Hampton Index 57)",293.0,2020-07-07,2021-03-10,6XOG,6931.0,3.0,1087.0,254.0,,122.17,3.0,1.98,experimental,45.146,0.24,0.2064,Structure of SUMO1-ML786519 adduct bound to SAE
4D3P,X-RAY DIFFRACTION,2.27,45.96,,,1.8M AMMONIUM SULFATE,,2014-10-23,2015-11-04,4D3P,1337.0,1.0,147.0,188.0,,16.4,1.0,1.27,experimental,8.807,0.17762,0.1551,crystal structure of point mutated DUSP19 (C150A)
6U3I,X-RAY DIFFRACTION,3.85,71.64,VAPOR DIFFUSION,8.5,"4 M ammonium acetate, 0.1 M Tris, pH 8.5, 3% v/v 1,8 diaminooctane",291.0,2019-08-21,2020-02-05,6U3I,7853.0,4.0,1148.0,26.0,17.0,124.9,4.0,2.9,experimental,57.58,0.217,0.179,Design of organo-peptides as bipartite PCSK9 antagonists
7W3L,X-RAY DIFFRACTION,3.63,66.08,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES (pH 6.6), 0.2M diammonium tartrate, 0.0005M TCEP, 10-12% PEG 3350",293.0,2021-11-25,2022-09-14,7W3L,5304.0,1.0,669.0,126.0,,76.07,1.0,2.51,experimental,74.15,0.216,0.178,"Crystal structure of LSD1 in complex with cis-4-Br-2,5-F2-PCPA (S1024)"
7GSV,X-RAY DIFFRACTION,3.28,62.54,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSV,2582.0,1.0,321.0,245.0,,37.63,1.0,1.92,experimental,42.606,0.22,0.184,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000830b
5XIT,X-RAY DIFFRACTION,2.39,48.58,"VAPOR DIFFUSION, HANGING DROP",6.5,"23% PEG MME 2000, 0.1 M Bis-Tris (pH 6.5), 10 mM Pr acetate",293.0,2017-04-27,2018-03-07,5XIT,3740.0,6.0,468.0,58.0,,54.71,3.0,2.25,experimental,,0.2391,0.2202,"Crystal structure of RNF168 UDM1 in complex with Lys63-linked diubiquitin, form II"
6BJD,X-RAY DIFFRACTION,2.01,38.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 8000, MES, calcium chloride",295.15,2017-11-06,2018-02-07,6BJD,10369.0,4.0,1528.0,86.0,,179.91,1.0,2.8,experimental,61.078,0.2643,0.2055,Crystal Structure of Human Calpain-3 Protease Core in Complex with E-64
7MEQ,X-RAY DIFFRACTION,2.24,45.09,"VAPOR DIFFUSION, HANGING DROP",7.0,"30.0% (w/v) Jeffamine ED-2001 7.0, 0.1 M  HEPES pH7.0",291.0,2021-04-07,2021-04-21,7MEQ,2643.0,1.0,395.0,118.0,6.0,44.5,1.0,1.95,experimental,54.14,0.225,0.192,Crystal structure of human TMPRSS2 in complex with Nafamostat
5QCO,X-RAY DIFFRACTION,3.01,59.11,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XIV 6.3MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 7-FOLD EXCESS OF BMC016 ADDED FROM A 50MM STOCK
SOLUTION IN DMSO (2.0% DMSO IN DROP). CRYO- PROTECTANT WAS 1.2M AMMONIUM SULFATE, 25%(V/V)GLYCEROL, 2.0% DMSO, 1MM
BMC016.",292.0,2017-12-01,2020-06-03,5QCO,9044.0,3.0,1206.0,15.0,9.0,136.04,1.0,2.7,experimental,76.65,0.217,0.169,Crystal structure of BACE complex with BMC016
5QCP,X-RAY DIFFRACTION,3.01,59.11,hanging drop,5.0,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM PHOSPHATE, 0.1M SODIUM CITRATE PH
5.0. PROTEIN STOCK WAS BACE MUT46B BATCH XIII 8.3MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 5-FOLD EXCESS OF
BMC018 ADDED FROM A 50MM STOCK SOLUTION IN DMSO (2.0% DMSO IN DROP). CRYO-PROTECTANT WAS 1.2M AMMONIUM PHOSPHATE, 0.1M
SODIUM CITRATE PH 5.0, 25%(V/V) GLYCEROL, 2.0% DMSO, 1MM BMC018.",292.0,2017-12-01,2020-06-03,5QCP,9264.0,3.0,1206.0,235.0,9.0,136.06,1.0,2.45,experimental,,0.195,0.164,Crystal structure of BACE complex with BMC018
5QCR,X-RAY DIFFRACTION,3.04,59.56,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS USING 1.0M UNBUFFERED AMMONIUM SULFATE AS PRECIPITANT.
PROTEIN STOCK WAS BACE MUT46B BATCH IX 8.1MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL WITH A 4-FOLD EXCESS OF BMC026 ADDED
FROM A 100MM STOCK SOLUTION IN DMSO. CRYO-PROTECTANT WAS 2.0M LI2SO4, 2%(V/V) PEG 400, 0.1M CITRATE PH 5.5, 0.5MM
BMC026, 1% DMSO.",292.0,2017-12-01,2020-06-03,5QCR,9297.0,3.0,1206.0,315.0,9.0,136.12,1.0,2.2,experimental,51.0,0.205,0.173,Crystal structure of BACE complex with BMC026
5QCV,X-RAY DIFFRACTION,3.11,60.4,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XII 8.45MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 3.8-FOLD EXCESS OF BMC012-AA-3 ADDED FROM A 50MM
STOCK SOLUTION IN DMSO (1.4% DMSO IN DROP). CRYO-PROTECTANT WAS 20%(V/V) GLYCEROL, 80% (V/V) RESERVOIR SOLUTION",292.0,2017-12-01,2020-06-03,5QCV,9234.0,3.0,1206.0,198.0,9.0,135.86,1.0,2.25,experimental,58.34,0.217,0.182,Crystal structure of BACE complex with BMC023
5QCW,X-RAY DIFFRACTION,3.05,59.69,sitting drop,5.5,"PROTEIN STOCK WAS BACE MUT46B (14-447)7.3MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL. CRYSTALLIZATION SOLUTION WAS 1.0M
AMMONIUM SULFATE IN WATER (JBS 6 A2). CRYSTALS WERE GROWN BY VAPOR DIFFUSION IN SITTING DROPS IN 96-WELL CORNING
MICROTITER PLATES. CRYO-PROTECTANT WAS 80% WELL SOLUTION, 20% 1,2-PROPANEDIOL.",292.0,2017-12-01,2020-06-03,5QCW,9365.0,3.0,1206.0,338.0,9.0,135.65,1.0,2.1,experimental,51.44,0.204,0.174,Crystal structure of BACE complex with BMC021
5QCX,X-RAY DIFFRACTION,3.11,60.44,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XII 8.45MG/ML IN 10MM TRIS-HCL PH 7.4,25MM NACL, WITH A 3.8-FOLD EXCESS OF BMC007 ADDED FROM A 50MM STOCK
SOLUTION IN DMSO (1.4% DMSO IN DROP). CRYO-PROTECTANT WAS 20%(V/V) 1,2-PROPANEDIOL, 80% (V/V) RESERVOIR SOLUTION.",292.0,2017-12-01,2020-06-03,5QCX,9290.0,3.0,1206.0,254.0,9.0,135.86,1.0,2.2,experimental,55.82,0.208,0.178,Crystal structure of BACE complex with BMC007
5QCY,X-RAY DIFFRACTION,3.08,60.11,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XII 8.45MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 5-FOLD EXCESS OF BMC008 ADDED FROM A 50MM STOCK
SOLUTION IN DMSO (2.0% DMSO IN DROP). CRYO- PROTECTANT WAS 1.2M AMMONIUM SULFATE, 25%(V/V)GLYCEROL, 2.0% DMSO, 1MM
BMC008.",292.0,2017-12-01,2020-06-03,5QCY,9510.0,3.0,1206.0,463.0,9.0,136.28,1.0,2.15,experimental,47.57,0.203,0.169,Crystal structure of BACE complex with BMC008
5QD2,X-RAY DIFFRACTION,3.07,59.88,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XII 8.45MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 5-FOLD EXCESS OF BMC017 ADDED FROM A 50MM STOCK
SOLUTION IN DMSO (2.0% DMSO IN DROP). CRYO- PROTECTANT WAS 1.2M AMMONIUM SULFATE, 25%(V/V)GLYCEROL, 2.0% DMSO, 1MM
BMC017.",292.0,2017-12-01,2020-06-03,5QD2,9309.0,3.0,1206.0,286.0,9.0,135.97,1.0,2.5,experimental,46.42,0.205,0.157,Crystal structure of BACE complex with BMC017
5QD6,X-RAY DIFFRACTION,3.01,59.1,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XII 8.45MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 5-FOLD EXCESS OF BMC004 ADDED FROM A 50MM STOCK
SOLUTION IN 90% DMSO, 10% H2O (1.8% DMSO IN DROP). CRYO-PROTECTANT WAS 1.2M AMMONIUM SULFATE, 25%(V/V) GLYCEROL, 1.8%
DMSO, 1MM BMC004.",292.0,2017-12-01,2020-06-03,5QD6,9195.0,3.0,1206.0,162.0,9.0,135.84,1.0,2.51,experimental,57.48,0.203,0.163,Crystal structure of BACE complex with BMC004
5QD7,X-RAY DIFFRACTION,3.05,59.61,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE IN WATER. PROTEIN STOCK WAS
BACE MUT46B BATCH XVI 7.0MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 6-FOLD EXCESS OF BMC014 ADDED FROM A 50MM
STOCK SOLUTION IN 90% DMSO-D6 (1.7% DMSO IN DROP). A SOLUTION CONTAINING 1.2M AMMONIUM SULFATE, 25% (V/V) GLYCEROL,
1.0MM BMC014 WAS USED AS CRYO-PROTECTANT.",292.0,2017-12-01,2020-06-03,5QD7,9341.0,3.0,1206.0,290.0,9.0,136.05,1.0,2.12,experimental,53.04,0.188,0.165,Crystal structure of BACE complex with BMC014
5QD8,X-RAY DIFFRACTION,3.15,60.96,hanging drop,,"HANGING DROP, VAPOR DIFFUSION, 1 UL PROTEIN + 1 UL RESERVOIR; PROTEIN SOLUTION: 9.3 MG/ML BACE MUT46B, 10 MM TRIS PH
7.4, 25 MM NACL, 1MM BMC003; RESERVOIR SOLUTION: 1.1M AMMONIUM SULFATE; CRYO: DROP PLUS 2 UL RESERVOIR SOLUTION PLUS 0.5
UL GLYCEROL.",292.0,2017-12-01,2020-06-03,5QD8,9132.0,3.0,1206.0,87.0,9.0,136.01,1.0,2.45,experimental,60.17,0.23,0.186,Crystal structure of BACE complex with BMC003
5QD9,X-RAY DIFFRACTION,3.02,59.31,hanging drop,,"CRYSTALS WERE GROWN AT 19C BY VAPOUR DIFFUSION IN HANGING DROPS FROM 1.0M AMMONIUM SULFATE. PROTEIN STOCK WAS BACE
MUT46B BATCH XIV 6.3MG/ML IN 10MM TRIS-HCL PH 7.4, 25MM NACL, WITH A 7-FOLD EXCESS OF BMC005 ADDED FROM A 50MM STOCK
SOLUTION IN DMSO (2.0% DMSO IN DROP). CRYO- PROTECTANT WAS 1.2M AMMONIUM SULFATE, 25%(V/V)GLYCEROL, 2.0% DMSO, 1MM
BMC005.",292.0,2017-12-01,2020-06-03,5QD9,9078.0,3.0,1206.0,61.0,9.0,135.92,1.0,2.602,experimental,62.8772,0.2108,0.165,Crystal structure of BACE complex with BMC005
6E4F,X-RAY DIFFRACTION,2.14,42.4,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2M imidazole pH 7.0
16% (w/v) PEG 4000
12.5% ethylene glycol",277.0,2018-07-17,2018-09-05,6E4F,2677.0,1.0,290.0,414.0,,34.49,1.0,1.15,experimental,17.88,0.15021,0.13064,Crystal structure of ARQ 531 in complex with the kinase domain of BTK
6J20,X-RAY DIFFRACTION,4.08,69.88,LIPIDIC CUBIC PHASE,,"100mM MES, pH 6.0-6.6, 25-35% PEG 400, 200-350mM ammonium tartrate dibasic",293.0,2018-12-30,2019-03-06,6J20,3184.0,1.0,441.0,,1.0,51.02,1.0,2.7,experimental,114.89,0.26,0.233,Crystal structure of the human NK1 substance P receptor
4Z4P,X-RAY DIFFRACTION,1.9,35.15,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris-HCl
20 % Ethanol",295.0,2015-04-02,2015-09-09,4Z4P,1422.0,1.0,166.0,60.0,,20.15,1.0,2.2,experimental,36.523,0.24247,0.19348,Structure of the MLL4 SET Domain
6N5C,X-RAY DIFFRACTION,2.71,54.65,"VAPOR DIFFUSION, HANGING DROP",7.0,"12% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM AMPPNP, 2 mM CdCl2, Soaking with 2mM 5PCF2-Am-InsP5 under pH 5.2 for 3 days , VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2018-11-21,2019-08-21,6N5C,2943.0,1.0,330.0,296.0,,39.4,1.0,1.95,experimental,31.212,0.21424,0.17525,Crystal structure of the catalytic domain of PPIP5K2 in complex with AMPPNP and 5-PCF2Am-InsP5
6K1S,X-RAY DIFFRACTION,2.84,56.64,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1M Na-Citrate, pH6.0
0.2M NaAc
12% PEG4000",293.0,2019-05-12,2019-06-19,6K1S,7548.0,2.0,995.0,101.0,1.0,112.56,2.0,2.6,experimental,74.99,0.275,0.212,Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase (PRMT5) Inhibitors
5UAB,X-RAY DIFFRACTION,2.07,40.52,"VAPOR DIFFUSION, SITTING DROP",7.8,"16.% PEG MME 5000, 15.% Isopropanol, 0.1M HEPES pH 7.8",293.0,2016-12-19,2017-05-31,5UAB,2495.0,1.0,343.0,158.0,,39.06,1.0,1.9,experimental,45.467,0.2291,0.1949,MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
9C1R,X-RAY DIFFRACTION,1.95,36.84,"VAPOR DIFFUSION, HANGING DROP",6.5,"22% PEG 3350
0.1M Bis-Tris pH6.5",293.0,2024-05-29,2024-08-21,9C1R,2741.0,1.0,307.0,292.0,,35.65,1.0,1.59,experimental,15.86,0.1947,0.1686,Crystal structure of mutant cMET D1228N kinase domain in complex with inhibitor compound 13
8K33,X-RAY DIFFRACTION,2.57,52.23,VAPOR DIFFUSION,8.5,"0.2 M Ammonium acetate, 0.1 M Tris pH 8.5, 25% w/v Polyethylene glycol 3,350",291.0,2023-07-14,2024-07-17,8K33,24896.0,24.0,3240.0,1188.0,12.0,341.46,2.0,2.13,experimental,,0.2649,0.2167,SOD1 and Nanobody1 complex
5MRV,X-RAY DIFFRACTION,2.74,55.08,"VAPOR DIFFUSION, HANGING DROP",7.0,"Drops were prepared by mixing equal volumes of protein solution (CPO:NvCI molar ratio, 1:0.5) at 5 mg/ml (in 5 mM Tris-HCl pH 7.3, 100 mM NaCl, 1 mM B-mercaptoetanol) and reservoir solution containning HEPES pH 7.0, 200 mM ammonium choride and 20% PEG6000.",291.15,2016-12-27,2018-01-17,5MRV,5995.0,3.0,763.0,521.0,9.0,89.01,2.0,1.854,experimental,,0.2082,0.1846,Crystal structure of human carboxypeptidase O in complex with NvCI
5QOH,X-RAY DIFFRACTION,2.6,52.77,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOH,1359.0,1.0,167.0,91.0,,19.62,1.0,1.93,experimental,37.38,0.2459,0.1856,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with XST00000847b
5QOI,X-RAY DIFFRACTION,2.55,51.72,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOI,1382.0,1.0,167.0,87.0,,19.59,1.0,1.99,experimental,37.769,0.2367,0.18,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000213a
5QOJ,X-RAY DIFFRACTION,2.6,52.67,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOJ,1324.0,1.0,167.0,78.0,,19.59,1.0,2.05,experimental,39.84,0.2482,0.1881,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOCR000171b
5QOK,X-RAY DIFFRACTION,2.53,51.47,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOK,1312.0,1.0,167.0,67.0,,19.67,1.0,2.28,experimental,39.123,0.2706,0.2026,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000294a
5QOL,X-RAY DIFFRACTION,2.54,51.48,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOL,1369.0,1.0,167.0,90.0,,19.64,1.0,1.85,experimental,35.659,0.2327,0.1842,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000435a
5QOM,X-RAY DIFFRACTION,2.52,51.24,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOM,1317.0,1.0,167.0,72.0,,19.73,1.0,1.87,experimental,46.212,0.2518,0.2001,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000576a
5QON,X-RAY DIFFRACTION,2.56,51.87,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QON,1350.0,1.0,167.0,88.0,,19.68,1.0,1.8,experimental,33.528,0.2521,0.195,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000446a
5QOO,X-RAY DIFFRACTION,2.58,52.3,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOO,1335.0,1.0,167.0,88.0,,19.62,1.0,1.56,experimental,35.528,0.2521,0.2023,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000144a
5QOP,X-RAY DIFFRACTION,2.6,52.61,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOP,1338.0,1.0,167.0,84.0,,19.63,1.0,1.86,experimental,33.769,0.2473,0.1987,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with NUOOA000023a
5QOQ,X-RAY DIFFRACTION,2.52,51.13,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOQ,1348.0,1.0,167.0,86.0,,19.64,1.0,1.49,experimental,32.344,0.2567,0.2116,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z2895259680
5QOR,X-RAY DIFFRACTION,2.5,50.8,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOR,1346.0,1.0,167.0,90.0,,19.66,1.0,1.95,experimental,40.788,0.2497,0.1958,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1203490773
5QOS,X-RAY DIFFRACTION,2.47,50.21,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOS,1377.0,1.0,167.0,89.0,,19.59,1.0,1.7,experimental,35.711,0.2519,0.1941,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1187701032
5QOT,X-RAY DIFFRACTION,2.48,50.37,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOT,1326.0,1.0,167.0,86.0,,19.66,1.0,1.68,experimental,38.049,0.2483,0.1953,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1592710382
5QOU,X-RAY DIFFRACTION,2.51,51.04,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOU,1279.0,1.0,167.0,60.0,,19.66,1.0,2.19,experimental,53.753,0.2516,0.1946,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z296300542
5QOV,X-RAY DIFFRACTION,2.48,50.45,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOV,1332.0,1.0,167.0,84.0,,19.62,1.0,1.65,experimental,33.456,0.2396,0.1948,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1699011516
5QOW,X-RAY DIFFRACTION,2.5,50.82,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-03-21,2019-05-08,5QOW,1334.0,1.0,167.0,86.0,,19.66,1.0,1.82,experimental,38.189,0.2518,0.1934,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z2895259675
5QOY,X-RAY DIFFRACTION,2.49,50.65,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QOY,1352.0,1.0,167.0,88.0,,19.68,1.0,1.69,experimental,34.21,0.2538,0.1981,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with YW-FY-378
5QOZ,X-RAY DIFFRACTION,2.48,50.35,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-03-21,2019-05-08,5QOZ,1355.0,1.0,167.0,93.0,,19.62,1.0,1.7,experimental,31.623,0.275,0.2167,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with PB1787571279
5QP0,X-RAY DIFFRACTION,2.53,51.4,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP0,1330.0,1.0,167.0,79.0,,19.66,1.0,2,experimental,48.16,0.2509,0.2012,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z454376544
5QP1,X-RAY DIFFRACTION,2.51,51.03,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP1,1335.0,1.0,167.0,84.0,,19.66,1.0,1.79,experimental,40.367,0.2682,0.2037,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1190363272
5QP2,X-RAY DIFFRACTION,2.48,50.45,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP2,1328.0,1.0,167.0,77.0,,19.66,1.0,1.83,experimental,45.942,0.2501,0.1931,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1170065264
5QP3,X-RAY DIFFRACTION,2.52,51.17,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP3,1359.0,1.0,167.0,87.0,,19.67,1.0,1.75,experimental,36.032,0.2623,0.2023,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1494850193
5QP4,X-RAY DIFFRACTION,2.49,50.56,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP4,1341.0,1.0,167.0,85.0,,19.75,1.0,1.71,experimental,39.997,0.2593,0.2038,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z450133538
5QP5,X-RAY DIFFRACTION,2.52,51.1,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP5,1292.0,1.0,167.0,60.0,,19.64,1.0,1.9,experimental,58.509,0.2526,0.202,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z2895259681
5QP6,X-RAY DIFFRACTION,2.5,50.82,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP6,1346.0,1.0,167.0,87.0,,19.66,1.0,1.65,experimental,36.885,0.257,0.2014,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z1662802141
5QP7,X-RAY DIFFRACTION,2.5,50.89,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP7,1338.0,1.0,167.0,89.0,,19.59,1.0,1.88,experimental,35.979,0.2597,0.1966,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with PB1230873739
5QP8,X-RAY DIFFRACTION,2.5,50.8,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP8,1367.0,1.0,167.0,92.0,,19.62,1.0,1.64,experimental,35.942,0.2647,0.2055,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with PB1787571279
5QP9,X-RAY DIFFRACTION,2.51,51.06,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QP9,1328.0,1.0,167.0,87.0,,19.64,1.0,1.72,experimental,36.291,0.2532,0.2015,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with Z100435060
5QPA,X-RAY DIFFRACTION,2.54,51.51,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QPA,1341.0,1.0,167.0,82.0,,19.64,1.0,1.61,experimental,43.501,0.256,0.2075,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000449a
5QPB,X-RAY DIFFRACTION,2.47,50.29,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QPB,1367.0,1.0,167.0,88.0,,19.69,1.0,1.68,experimental,34.146,0.2523,0.1982,PanDDA analysis group deposition -- Crystal Structure of DCP2 (NUDT20) in complex with FMOPL000701a
5QPC,X-RAY DIFFRACTION,2.55,51.85,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate, pH 4.5, 5-25% PEG3350",277.0,2019-02-22,2019-05-08,5QPC,1368.0,1.0,167.0,92.0,,19.5,1.0,1.66,experimental,31.935,0.236,0.197,Crystal Structure of DCP2 (NUDT20) after initial refinement with no ligand modelled (structure $n)
5P9M,X-RAY DIFFRACTION,2.18,43.65,VAPOR DIFFUSION,7.0,"PEG 3350, sodium actate, BisTrisPropane",298.0,2016-09-20,2017-05-24,5P9M,2408.0,1.0,279.0,185.0,,32.86,1.0,1.41,experimental,19.061,0.2005,0.1787,BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
7UY3,X-RAY DIFFRACTION,4.2,70.7,VAPOR DIFFUSION,7.5,"For co-crystallization with TL02-59, Fgr (3.2 mg/mL in 20 mM Tris-HCl, pH 8.3, 100 mM NaCl, and 2 mM TCEP) was mixed with 10 mM TL02-59 (in 100% DMSO) to a final concentration of 120 microM (0.6% DMSO final) and incubated for thirty minutes at 298 K.  Diffraction quality crystals were grown by sitting- and hanging-drop vapor diffusion at 277 K by mixing Fgr/TL02-59 in a 1:1 ratio with the mother liquor (0.1 M HEPES, pH 7.5, 0.8 M sodium phosphate, 0.8 M potassium phosphate and 1% 1,2-butanediol)",277.0,2022-05-06,2022-12-28,7UY3,3133.0,1.0,456.0,,,53.19,1.0,2.99,experimental,104.6638,0.2473,0.2031,Crystal structure of human Fgr tyrosine kinase in complex with TL02-59
8JOT,X-RAY DIFFRACTION,2.47,50.22,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG8K, 0.2 M MgCl and 0.1 M Tris, pH 7.5",277.15,2023-06-08,2024-03-27,8JOT,2722.0,1.0,354.0,312.0,,40.51,1.0,1.69,experimental,,0.2071,0.179,Crystal structure of CSF-1R kinase domain with sulfatinib
4ZLY,X-RAY DIFFRACTION,2.3,46.46,"VAPOR DIFFUSION, SITTING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5, 0.12M alcohol mixture",277.0,2015-05-01,2015-07-01,4ZLY,2679.0,1.0,270.0,382.0,,31.98,1.0,1.65,experimental,16.117,0.1965,0.163,Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragment
7PQV,X-RAY DIFFRACTION,1.24,54.0,BATCH MODE,,"The purified protein was used in crystallisation trials employing both, a standard screen with approximately 1200 different conditions, as well as crystallisation conditions identified using literature data. Condi- tions initially obtained have been optimised using standard strategies, systematically varying parameters critically influencing crystallisation, such as temperature, protein concentration, drop ratio, and others. These conditions were also refined by systematically varying pH or precipitant concentrations.",310.0,2021-09-20,2022-03-16,7PQV,2674.0,1.0,344.0,190.0,,39.02,1.0,2.13,experimental,34.619,0.2869,0.2353,MEK1 IN COMPLEX WITH COMPOUND 7
4ZLZ,X-RAY DIFFRACTION,2.28,46.13,"VAPOR DIFFUSION, SITTING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5, 0.12M alcohol mixture",277.0,2015-05-01,2015-07-01,4ZLZ,2602.0,1.0,270.0,338.0,,32.07,1.0,2,experimental,21.292,0.2408,0.1756,Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnoline
5BQ0,X-RAY DIFFRACTION,2.19,43.88,"VAPOR DIFFUSION, HANGING DROP",,,298.0,2015-05-28,2015-09-23,5BQ0,2576.0,1.0,283.0,304.0,,33.33,1.0,1.57,experimental,19.75,0.2186,0.1871,Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide
4YBI,X-RAY DIFFRACTION,2.65,53.57,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG8000, sodium cacodylate, ammonium sulfate",277.0,2015-02-18,2015-04-01,4YBI,6994.0,2.0,884.0,754.0,6.0,98.95,1.0,1.84,experimental,25.894,0.22253,0.1794,Crystal structure of BACE with amino thiazine inhibitor LY2811376
5W86,X-RAY DIFFRACTION,2.45,49.8,"VAPOR DIFFUSION, HANGING DROP",,,293.0,2017-06-21,2017-10-11,5W86,8915.0,4.0,1148.0,155.0,,133.27,1.0,2.61,experimental,30.74,0.264,0.209,"CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)"
6GR9,X-RAY DIFFRACTION,2.95,58.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"20 % PEG3350, 10 % ethylene glycol, 0.1 M bis-tris-propane pH 7.5, 0.2 M sodium sulfate",277.0,2018-06-10,2019-05-15,6GR9,2812.0,2.0,344.0,162.0,,41.03,2.0,2.25,experimental,44.179,0.22443,0.18165,Human AURKC INCENP complex bound to VX-680
7SLY,X-RAY DIFFRACTION,2.48,50.36,"VAPOR DIFFUSION, SITTING DROP",,"100 mM MES pH 6.1-6.7, 22-33% PEG-MME-2000, 10 mM TCEP",295.0,2021-10-25,2022-01-12,7SLY,3906.0,1.0,482.0,118.0,5.0,56.27,1.0,2.17,experimental,65.13,0.2228,0.19,Vanin-1 complexed with Compound 27
5LQF,X-RAY DIFFRACTION,2.39,48.46,"VAPOR DIFFUSION, SITTING DROP",6.7,"0.1M MES/IMIDAZOLE BUFFER (PH6.7),     6.5% MPD, 5% PEG4K, 10% PEG1K PROTEIN AT 10-12 MG/ML",277.0,2016-08-17,2017-01-11,5LQF,10580.0,6.0,1318.0,291.0,,153.23,3.0,2.06,experimental,47.072,0.25385,0.19764,CDK1/CyclinB1/CKS2 in complex with NU6102
5TQ6,X-RAY DIFFRACTION,2.32,47.08,VAPOR DIFFUSION,,"0.1 M Hepes, pH 7.5, 0.1 M sodium acetate, 30% PEG3350",293.0,2016-10-23,2017-01-11,5TQ6,4846.0,2.0,608.0,223.0,,72.5,1.0,2.06,experimental,19.884,0.28887,0.25723,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
5YGY,X-RAY DIFFRACTION,3.03,59.41,"VAPOR DIFFUSION, SITTING DROP",,"0.2M sodium citrate tribasic pH6.5, 0.2M ammonium iodide, 20.5%(w/v) PEG5000MME",293.0,2017-09-27,2018-05-23,5YGY,3190.0,1.0,416.0,199.0,3.0,47.69,1.0,2.3,experimental,40.327,0.2354,0.1912,"Crystal Structure of BACE1 in complex with (S)-N-(3-(2-amino-6-(fluoromethyl)-4 -methyl-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide"
5HNB,X-RAY DIFFRACTION,3.08,60.08,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG3350, 0.2M lithium chloride",293.0,2016-01-18,2016-04-27,5HNB,5261.0,2.0,636.0,131.0,,75.53,2.0,2.35,experimental,48.06,0.25243,0.21712,CDK8-CYCC IN COMPLEX WITH [6-Hydroxy-3-(3-methyl-benzyl)-1H-indazol-5-yl]-((S)-3-hydroxy-pyrrolidin-1-yl)-methanone
6Y0A,X-RAY DIFFRACTION,3.0,58.99,VAPOR DIFFUSION,,20% (wt/vol) polyethylene glycol 3350  0.2 M sodium formate,298.0,2020-02-07,2021-02-17,6Y0A,5358.0,2.0,689.0,213.0,,80.93,2.0,2.19,experimental,40.457,0.22679,0.20071,CRYSTAL STRUCTURE OF CDK8-CycC IN COMPLEX WITH BI00690300
8D7P,X-RAY DIFFRACTION,2.34,42.75,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.16M Succinic Acid (5.5)
23% PEG3350",295.0,2022-06-07,2023-05-17,8D7P,4999.0,4.0,638.0,135.0,,74.15,2.0,2.25,experimental,,0.2511,0.1963,Human Casein kinase 1 delta in complex with phosphorylated Drosophila PERIOD peptide
6RD0,X-RAY DIFFRACTION,2.31,46.81,"VAPOR DIFFUSION, SITTING DROP",8.0,"25% PEH 6000, 0.1 M Tris-HCl",293.0,2019-04-12,2020-02-19,6RD0,1444.0,1.0,159.0,165.0,,18.25,1.0,1.9,experimental,27.782,0.20885,0.16676,Human MMP12 catalytic domain in complex with AP280
6RLY,X-RAY DIFFRACTION,2.32,47.06,"VAPOR DIFFUSION, SITTING DROP",8.0,"25% PEG 6000, 0.1 M Tris-HCl",293.0,2019-05-03,2020-03-11,6RLY,1414.0,1.0,159.0,132.0,,18.29,1.0,2.2,experimental,25.625,0.22712,0.1778,Human MMP12 (catalytic domain) in complex with AP316
6EQS,X-RAY DIFFRACTION,2.27,45.9,"VAPOR DIFFUSION, SITTING DROP",5.5,"30% PEG3350, 0.2 M NaCl, 0.1 M Bis-Tris pH 5.5, 5% 1,3-butandiol",293.0,2017-10-15,2017-11-01,6EQS,10389.0,4.0,1100.0,1086.0,,126.44,1.0,1.32,experimental,21.373,0.20856,0.16025,Human Sirt5 in complex with stalled peptidylimidate intermediate of inhibitory compound 29
8D6D,X-RAY DIFFRACTION,2.87,57.13,"VAPOR DIFFUSION, HANGING DROP",8.25,"5.6 to 6.6% PEG3350, 0.2 M Na2SO4, 0.1 M Tris-HCl and 10% EG",293.0,2022-06-06,2022-07-27,8D6D,4110.0,2.0,622.0,33.0,,70.35,1.0,2.35,experimental,106.0445,0.2719,0.2406,Crystal Structure of Human Myt1 Kinase domain Bounded with compound 39
8D6F,X-RAY DIFFRACTION,2.8,56.13,"VAPOR DIFFUSION, HANGING DROP",8.25,"5.6 to 6.6% PEG3350, 0.2 M Na2SO4, 0.1 M Tris-HCl and 10% EG",293.0,2022-06-06,2022-07-27,8D6F,4171.0,2.0,622.0,22.0,,69.86,1.0,2.49,experimental,84.9863,0.2395,0.2147,Crystal Structure of Human Myt1 Kinase domain Bounded with Eph receptor inhibitor / compound 41
6NR5,X-RAY DIFFRACTION,3.85,68.04,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 3350 95, 0.1M Ammonium citrate pH6.5",296.0,2019-01-22,2019-07-17,6NR5,5002.0,1.0,658.0,,,74.2,1.0,2.9,experimental,,0.2732,0.2196,Human LSD1 in complex with Phenelzine sulfate
7UGI,X-RAY DIFFRACTION,2.64,53.45,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.05M Potassium phosphate monobasic 20% w/v Polyethylene glycol 8,000",292.0,2022-03-24,2023-04-12,7UGI,2181.0,2.0,232.0,120.0,,29.57,1.0,2,experimental,40.3292,0.2744,0.2158,Bromodomain of EP300 liganded with BMS-536924
6JSG,X-RAY DIFFRACTION,3.0,59.06,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium citrate, 0.2 M ammonium iodide, 18.8%(w/v) polyethylene glycol 5000 monomethyl ether, pH 6.5",293.15,2019-04-08,2019-08-28,6JSG,3167.0,1.0,416.0,184.0,3.0,47.36,1.0,2.3,experimental,44.366,0.229,0.1915,"Crystal Structure of BACE1 in complex with N-{3-[(4S)-2-amino-4-methyl-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-5-chloropyridine-2-carboxamide"
6JSN,X-RAY DIFFRACTION,3.0,59.06,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium citrate, 0.2 M ammonium iodide, 19%(w/v) polyethylene glycol 5000 monomethyl ether, pH 6.5",293.15,2019-04-08,2019-08-28,6JSN,3043.0,1.0,416.0,77.0,3.0,47.76,1.0,2.6,experimental,44.745,0.2585,0.2006,"Crystal Structure of BACE1 in complex with N-{3-[(5R)-3-amino-5-methyl-9,9-dioxo-2,9lambda6-dithia-4-azaspiro[5.5]undec-3-en-5-yl]-4-fluorophenyl}-5-(fluoromethoxy)pyrazine-2-carboxamide"
7D2V,X-RAY DIFFRACTION,2.8,56.07,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium citrate tribasic pH 6.5, 0.2 M ammonium iodide, 19.5% w/v PEG 5000MME",293.0,2020-09-17,2021-03-31,7D2V,3209.0,1.0,416.0,231.0,3.0,47.37,1.0,2.1,experimental,36.192,0.2453,0.2062,"Crystal Structure of BACE1 in complex with N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-5,6-dihydro-2H-1lambda6,2,4-thiadiazin-5-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide"
7D5A,X-RAY DIFFRACTION,2.76,55.39,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium citrate tribasic pH6.5, 0.2 M ammonium iodide, 18% w/v PEG 5000MME",293.0,2020-09-25,2021-03-31,7D5A,3111.0,1.0,416.0,234.0,3.0,47.19,1.0,2.2,experimental,35.923,0.2424,0.2069,"Crystal Structure of BACE1 in complex with N-{3-[(9S)-7-amino-2,2-difluoro-9-(prop-1-yn-1-yl)-6-oxa-8-azaspiro[3.5]non-7-en-9-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide"
7DCZ,X-RAY DIFFRACTION,2.78,55.69,"VAPOR DIFFUSION, SITTING DROP",6.6,"0.1 M Na3-citrate pH 6.6, 0.2 M NH4I, 30%(w/v) PEG 5000 MME",293.0,2020-10-27,2021-03-10,7DCZ,3172.0,1.0,416.0,161.0,3.0,47.36,1.0,2.3,experimental,22.011,0.2546,0.2131,"Crystal Structure of BACE1 in complex with N-{3-[(4S)-2-amino-4-methyl-4H-1,3-thiazin-4-yl]-4- fluorophenyl}-5-cyanopyridine-2-carboxamide"
6MT0,X-RAY DIFFRACTION,3.4,63.84,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.0M LiCl, 0.1M TRIS pH8.0, 20% PEG6K",277.0,2018-10-18,2019-01-16,6MT0,2441.0,1.0,286.0,174.0,,33.65,1.0,2.2,experimental,37.018,0.20835,0.17876,Crystal structure of human Pim-1 kinase in complex with a quinazolinone-pyrrolodihydropyrrolone inhibitor
6PF1,X-RAY DIFFRACTION,2.24,45.2,"VAPOR DIFFUSION, SITTING DROP",9.5,"0.1 M CHES pH 9.5,  30% w/v PEG 3000",277.0,2019-06-21,2019-10-23,6PF1,5315.0,2.0,676.0,86.0,,80.33,1.0,2.32,experimental,34.247,0.2473,0.1836,Crystal structure of the p300 acetyltransferase domain with allosteric inhibitor CPI-090 and CoA
6PGU,X-RAY DIFFRACTION,2.3,46.58,VAPOR DIFFUSION,,"20% MPD, 0.1 M Tris pH 8, 7.5% PEG-MME 5000",277.0,2019-06-24,2019-10-23,6PGU,5754.0,2.0,646.0,459.0,,76.19,1.0,1.72,experimental,34.731,0.2063,0.1652,Crystal structure of the p300 acetyltransferase domain with allosteric inhibitor CPI-076 and CoA
8GZC,X-RAY DIFFRACTION,3.02,59.21,"VAPOR DIFFUSION, HANGING DROP",7.0,"15% PEG3350, 0.1 M HEPES",277.0,2022-09-26,2023-01-11,8GZC,7280.0,2.0,908.0,281.0,,106.13,1.0,2,experimental,65.3943,0.2268,0.1945,Crystal structure of EP300 HAT domain in complex with compound 10
8X6R,X-RAY DIFFRACTION,2.65,53.64,"VAPOR DIFFUSION, SITTING DROP",6.5,"MES, ammonium sulfate, PEG550MME",293.0,2023-11-21,2024-01-17,8X6R,8575.0,6.0,1020.0,253.0,,122.7,1.0,1.85,experimental,28.568,0.29936,0.25257,KRasG12C in complex with inhibitor
7GSK,X-RAY DIFFRACTION,3.33,63.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSK,2587.0,1.0,321.0,244.0,,37.71,1.0,1.84,experimental,39.866,0.2356,0.1909,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000279a
5M9R,X-RAY DIFFRACTION,1.97,37.62,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Na/K tartrate
0.1 M Na cacodylate
20% PEG 4000",289.0,2016-11-02,2017-02-22,5M9R,2272.0,2.0,248.0,236.0,6.0,29.24,1.0,1.44,experimental,12.679,0.19544,0.17232,Human angiogenin ALS variant F100I
5UE3,X-RAY DIFFRACTION,2.3,46.58,VAPOR DIFFUSION,5.5,25% PEG 8K 1% glycerol 0.2 M ammonium sulfate 100 mM NaCacodylate,293.0,2016-12-29,2017-09-13,5UE3,4225.0,2.0,472.0,587.0,,54.19,1.0,1.599,experimental,,0.1838,0.1545,proMMP-9desFnII
4WTU,X-RAY DIFFRACTION,2.81,56.27,"VAPOR DIFFUSION, HANGING DROP",6.6,"21% PEG 5000 MME, 190 mM sodium citrate, 200 mM ammonium iodide",298.0,2014-10-30,2015-03-04,4WTU,3400.0,1.0,411.0,428.0,3.0,46.96,1.0,1.85,experimental,26.24,0.1957,0.1693,Crystal structure of BACE1 in complex with 2-aminooxazoline 3-aza-4-fluoro-xanthene inhibitor 22
4XKX,X-RAY DIFFRACTION,2.81,56.2,"VAPOR DIFFUSION, HANGING DROP",6.6,"20% polyethylene glycol 5000 MME, 200 mM ammonium iodide, 170 mM sodium citrate, pH 6.6, 3% dimethylsulfoxide, apo crystals soaked with 1 mM inhibitor for 4 h",298.0,2015-01-12,2015-02-04,4XKX,3341.0,1.0,411.0,423.0,3.0,46.96,1.0,1.8,experimental,25.32,0.2281,0.1923,Crystal structure of BACE1 in complex with 2-aminooxazoline 3-azaxanthene inhibitor 28
7FUC,X-RAY DIFFRACTION,2.56,51.86,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FUC,2925.0,1.0,362.0,,,42.86,1.0,2.52,experimental,123.42,0.291,0.253,Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-2-(morpholin-4-ylmethyl)-1H-benzimidazole-4-carboxylic acid
6QU2,X-RAY DIFFRACTION,3.23,61.89,"VAPOR DIFFUSION, SITTING DROP",8.75,"31% PEG 400, 0.25 M lithium sulfate and 0.1 M Tris, pH 8.75",277.0,2019-02-26,2020-03-18,6QU2,11911.0,4.0,1444.0,241.0,,171.99,1.0,2.9,experimental,48.558,0.2417,0.2018,Crystal structure of DYRK1A complexed with FC162 inhibitor
5KZX,X-RAY DIFFRACTION,3.38,63.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 sodium HEPES, 2% (v/v) PEG 400, 2M ammonium sulfate",293.0,2016-07-25,2017-07-26,5KZX,7802.0,1.0,874.0,792.0,5.0,101.29,1.0,2,experimental,25.23,0.185,0.154,Crystal structure of human GAA
8J9R,X-RAY DIFFRACTION,2.3,46.58,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris (pH5.6), 29% (w/v) polyethylene glycol 3350 (PEG3350), 0.2 M lithium sulfate monohydrate",291.15,2023-05-04,2023-12-06,8J9R,697.0,1.0,74.0,102.0,,8.62,1.0,1.65,experimental,19.04,0.2871,0.2342,Crystal structure of UBR box of YIFS-UBR4
5NP5,X-RAY DIFFRACTION,1.71,27.95,"VAPOR DIFFUSION, HANGING DROP",4.6,"1.8 M (NH4)2SO4, 0.1 M sodium acetate",293.0,2017-04-13,2018-05-16,5NP5,1084.0,2.0,122.0,94.0,,13.95,1.0,1.4,experimental,,0.1985,0.1719,Abl2 SH3 pTyr116/161
5QT1,X-RAY DIFFRACTION,2.4,48.79,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG-3350, 0.2M lithium sulfate, 0.1M Bis-tris",291.0,2019-06-25,2019-08-21,5QT1,1980.0,1.0,225.0,102.0,,26.9,1.0,1.58,experimental,23.455,0.2197,0.193,PanDDA analysis group deposition -- Partial occupancy interpretation of PanDDA event map: SETDB1 in complex with FMOMB000017a
5QT2,X-RAY DIFFRACTION,2.38,48.37,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG-3350, 0.2M lithium sulfate, 0.1M Bis-tris",291.0,2019-06-25,2019-08-21,5QT2,2016.0,1.0,225.0,101.0,,27.22,1.0,1.59,experimental,23.549,0.2172,0.194,PanDDA analysis group deposition -- Partial occupancy interpretation of PanDDA event map: SETDB1 in complex with FMOPL000074a
8K3L,X-RAY DIFFRACTION,2.63,53.23,VAPOR DIFFUSION,,"0.2 M Ammonium acetate, 0.1 M Sodium acetate trihydrate pH 4.6, 30% w/v
Polyethylene, glycol monomethyl ether 2,000",293.0,2023-07-16,2024-07-17,8K3L,8526.0,8.0,1120.0,350.0,8.0,119.24,2.0,2.3,experimental,,0.2347,0.195,SOD1 and Nanobody3 complex
7UFV,X-RAY DIFFRACTION,2.21,44.44,"VAPOR DIFFUSION, SITTING DROP",7.4,"20% PEG3350, 0.2M Potassium Fluoride",291.0,2022-03-23,2022-05-04,7UFV,4692.0,2.0,630.0,88.0,,72.35,1.0,1.9,experimental,42.3,0.254,0.204,Crystal structure of the WDR domain of human DCAF1 in complex with OICR-6766
8T73,X-RAY DIFFRACTION,2.23,44.95,"VAPOR DIFFUSION, SITTING DROP",,"100 mM  HEPES  pH 7.4, 2 M  ammonium sulfate , 0.1 M MgCl2.6H2O",293.0,2023-06-19,2024-02-14,8T73,3042.0,2.0,340.0,348.0,,39.69,1.0,1.5,experimental,28.8272,0.1879,0.1538,Crystal structure of KRAS4a-R151G with bound GDP and Mg ion
8P4Z,X-RAY DIFFRACTION,4.0,69.6,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.2 M ammonium acetate, 0.1 M sodium citrate, 12% w/v PEG 3350, 0.2 M NDSB-201",277.0,2023-05-23,2023-06-14,8P4Z,4580.0,2.0,608.0,27.0,,70.74,1.0,2.75,experimental,105.8,0.2513,0.2247,Crystal structure of the human CDK7 kinase domain in complex with LDC4297
5IZJ,X-RAY DIFFRACTION,2.52,51.12,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.4M lithium sulfate, 0.1M phosphate citrate pH 4.5, 17%-19% PEG 1.5K",277.15,2016-03-25,2016-07-20,5IZJ,6384.0,4.0,713.0,611.0,,85.99,3.0,1.85,experimental,21.696,0.22585,0.19708,Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1411
8SIV,X-RAY DIFFRACTION,2.28,45.95,"VAPOR DIFFUSION, SITTING DROP",6.5,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2023-04-17,2023-11-01,8SIV,2277.0,1.0,297.0,149.0,,34.52,1.0,1.759,experimental,30.16,0.2512,0.2097,Structure of Compound 2 bound to the CHK1 10-point mutant
5QXI,X-RAY DIFFRACTION,4.15,70.37,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXI,1514.0,1.0,130.0,226.0,,16.3,1.0,1.64,experimental,23.612,0.1773,0.1567,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC587
5QXJ,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXJ,1498.0,1.0,130.0,222.0,,16.14,1.0,1.46,experimental,23.386,0.1882,0.1722,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC578
5QXK,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXK,1492.0,1.0,130.0,227.0,,16.21,1.0,1.72,experimental,23.767,0.1836,0.159,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC581
5QXL,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXL,1485.0,1.0,130.0,224.0,,16.16,1.0,1.57,experimental,24.921,0.1746,0.1575,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF776
5QXM,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXM,1494.0,1.0,130.0,221.0,,16.34,1.0,1.5,experimental,23.764,0.1786,0.1641,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF789
5QXN,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXN,1481.0,1.0,130.0,212.0,,16.79,1.0,1.41,experimental,23.697,0.1903,0.1744,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF826
5QXO,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXO,1489.0,1.0,130.0,224.0,,16.21,1.0,1.47,experimental,23.011,0.1871,0.1712,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF848
5QXP,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXP,1488.0,1.0,130.0,225.0,,16.18,1.0,1.41,experimental,23.236,0.1903,0.1743,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with TCJ732
5QXQ,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXQ,1495.0,1.0,130.0,225.0,,16.14,1.0,1.55,experimental,23.861,0.1749,0.1654,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with TCJ779
5QXR,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXR,1483.0,1.0,130.0,224.0,,16.12,1.0,1.66,experimental,29.315,0.1916,0.1693,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF849
5QXS,X-RAY DIFFRACTION,4.21,70.75,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-03-09,2020-04-08,5QXS,1487.0,1.0,130.0,217.0,,16.27,1.0,1.62,experimental,31.562,0.1963,0.1735,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF852
5QXT,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXT,1476.0,1.0,130.0,216.0,,16.32,1.0,1.55,experimental,24.08,0.1762,0.1653,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with JKH47
5QXU,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXU,1493.0,1.0,130.0,222.0,,16.31,1.0,1.65,experimental,27.491,0.1958,0.1704,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with RZ373
5QXV,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXV,1482.0,1.0,130.0,221.0,,16.15,1.0,1.74,experimental,29.472,0.1984,0.1718,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC631
5QXW,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXW,1482.0,1.0,130.0,216.0,,16.23,1.0,1.78,experimental,26.683,0.1852,0.1652,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with RZ189
5QXX,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXX,1497.0,1.0,130.0,222.0,,16.12,1.0,1.58,experimental,24.942,0.1851,0.1658,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with RZ99
5QXY,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXY,1477.0,1.0,130.0,219.0,,16.18,1.0,1.54,experimental,23.401,0.1724,0.1626,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with JKH93A
5QXZ,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-11,2020-04-08,5QXZ,1491.0,1.0,130.0,223.0,,16.26,1.0,1.64,experimental,25.015,0.1797,0.1587,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with DF853
5QY0,X-RAY DIFFRACTION,4.2,70.68,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-03-09,2020-04-08,5QY0,1485.0,1.0,130.0,209.0,,16.36,1.0,1.89,experimental,31.247,0.1852,0.1567,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with PC591
5R4E,X-RAY DIFFRACTION,4.08,69.88,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6M Ammonium Sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-21,2020-04-08,5R4E,1555.0,1.0,130.0,339.0,,16.08,1.0,1.83,experimental,32.487,0.2637,0.217,PanDDA analysis group deposition -- Crystal Structure of ATAD2 in complex with RZ201
5R4V,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.2M ammonium sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-28,2020-05-13,5R4V,1449.0,1.0,130.0,237.0,,16.39,1.0,1.29,experimental,19.496,0.1526,0.1327,XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13475a
5R4W,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.2M ammonium sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-28,2020-05-13,5R4W,1422.0,1.0,130.0,223.0,,16.2,1.0,1.47,experimental,25.049,0.1612,0.1277,XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13501a
5R4X,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.2M ammonium sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-28,2020-05-13,5R4X,1409.0,1.0,130.0,232.0,,16.15,1.0,1.4,experimental,23.542,0.1589,0.1319,XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13413a
5R4Y,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.2M ammonium sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-28,2020-05-13,5R4Y,1412.0,1.0,130.0,221.0,,16.2,1.0,1.84,experimental,28.654,0.1977,0.1691,XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13612a
5R4Z,X-RAY DIFFRACTION,4.2,70.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.2M ammonium sulfate, 0.1M bis-tris pH 5.5",277.0,2020-02-28,2020-05-13,5R4Z,1397.0,1.0,130.0,221.0,,16.18,1.0,1.46,experimental,28.125,0.1619,0.13,XChem fragment screen -- CRYSTAL STRUCTURE OF THE BROMODOMAIN OF THE HUMAN ATAD2 in complex with N13605a
7PX5,X-RAY DIFFRACTION,4.08,69.86,"VAPOR DIFFUSION, HANGING DROP",,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2021-10-07,2022-11-02,7PX5,1194.0,1.0,130.0,96.0,,15.89,1.0,2.18,experimental,32.33,0.2461,0.2064,ATAD2 in complex with 1-Methyl-2-quinolone
6TUN,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris pH 8.5
25% PEG8000",293.0,2020-01-07,2020-11-11,6TUN,4125.0,4.0,548.0,151.0,,63.76,2.0,2.07,experimental,,0.2273,0.192,Helicase domain complex
8OO4,X-RAY DIFFRACTION,2.15,42.87,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG6K, 20 mM sodium citrate pH 5.1, 0.2 M sodium/potassium tartrate",293.0,2023-04-04,2023-07-12,8OO4,1051.0,1.0,123.0,56.0,3.0,14.38,1.0,1.99,experimental,23.288,0.3672,0.3077,X-ray structure of the adduct formed upon reaction of cisplatin with human angiogenin after 1 month soaking
7LZD,X-RAY DIFFRACTION,2.39,48.44,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Potassium thiocyanate, 0.1 M HEPES pH 7.5, 24% w/v PEG 2000 MME",293.0,2021-03-09,2021-09-22,7LZD,2177.0,1.0,278.0,152.0,,33.58,1.0,1.8,experimental,42.104,0.2182,0.193,Crystal Structure of SETD2 bound to Compound 35
7UMU,X-RAY DIFFRACTION,3.36,63.34,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES (pH 7.5)
200 mM ammonium acetate
25% (w/v) PEG 3350",277.0,2022-04-07,2022-10-05,7UMU,7315.0,6.0,912.0,,,107.33,1.0,2.51,experimental,49.49,0.2284,0.1973,"Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((5,6-dihydrobenzo[h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor"
6QY7,X-RAY DIFFRACTION,3.17,61.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% PEG6000, 2M sodium chloride",277.0,2019-03-08,2020-03-25,6QY7,5889.0,2.0,676.0,270.0,,81.23,1.0,2.1,experimental,53.464,0.23538,0.19604,Human CSNK2A1 bound to ERB-041
7MU6,X-RAY DIFFRACTION,2.49,50.51,"VAPOR DIFFUSION, SITTING DROP",,"0.1M BisTRIS pH 5.5, 0.2M ammonium acetate, 3% sorbitol and 12% PEG3350",294.0,2021-05-14,2024-07-17,7MU6,4341.0,2.0,668.0,267.0,,75.82,1.0,2.165,experimental,,0.2144,0.1895,Ask1 bound to compound 28
7PNP,X-RAY DIFFRACTION,2.3,46.43,"VAPOR DIFFUSION, SITTING DROP",,"Malic acid/NaOH pH 7.0, PEG 3350",289.0,2021-09-07,2022-05-04,7PNP,1033.0,1.0,123.0,58.0,3.0,14.15,1.0,1.8,experimental,39.883,0.25424,0.20145,Human Angiogenin mutant-S28A
7PNR,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, SITTING DROP",,"Malic acid/NaOH pH 7.0, PEG 3350",289.0,2021-09-07,2021-09-29,7PNR,1020.0,1.0,121.0,59.0,3.0,13.85,1.0,1.6,experimental,27.906,0.20103,0.18981,Human Angiogenin mutant-S28AT36AS37A
8FJH,X-RAY DIFFRACTION,2.2,44.19,"VAPOR DIFFUSION, SITTING DROP",5.5,"Ca(Ac)2 0.2 M pH 5.5
PEG 3350 18-22%",293.0,2022-12-19,2023-12-06,8FJH,1753.0,1.0,186.0,244.0,,22.29,1.0,1.54,experimental,20.14,0.1841,0.1494,Crystal structure of RalA in a covalent complex with SOF-531
8FJI,X-RAY DIFFRACTION,2.22,44.59,"VAPOR DIFFUSION, SITTING DROP",5.5,"Ca(Ac)2 0.1 M pH 5.5
PEG3350 18-22%",293.0,2022-12-19,2023-12-06,8FJI,1698.0,1.0,186.0,195.0,,22.27,1.0,1.48,experimental,17.29,0.2087,0.1833,Crystal structure of RalA in a covalent complex with SOF-367
5JOG,X-RAY DIFFRACTION,3.04,59.58,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 18.9 mg/ml protein in 50mM NaCl, 50mM Mes/NaOH pH 6.0, 10uM ZnCl2, 0.5 mM TCEP with 1mM compound
Crystallization solution: 35% MPD, 0.1M MES/NaOH pH 6.0, 0.2 M Li2SO4",277.0,2016-05-02,2016-11-02,5JOG,1826.0,1.0,257.0,27.0,,29.52,1.0,2.46,experimental,82.25,0.243,0.208,CRYSTAL STRUCTURE OF CSN5(2-257) IN COMPLEX WITH CNS5i-3
5JOH,X-RAY DIFFRACTION,3.09,60.21,"VAPOR DIFFUSION, SITTING DROP",6.0,"Protein solution: 15 mg/ml CSN5 in 50mM NaCl, 50mM Mes/NaOH pH 6.0, 10uM ZnCl2, 0.5 mM TCEP with 1mM ligand
Crystallization solution: 35% MPD, 0.2M LiSO4, 0.1 M MES/NaOH pH 6.0",277.0,2016-05-02,2016-11-02,5JOH,1825.0,1.0,257.0,29.0,,29.5,1.0,1.99,experimental,71.5,0.2482,0.2263,CRYSTAL STRUCTURE OF CSN5(2-257) IN COMPLEX WITH CNS5i-1b
5M5Q,X-RAY DIFFRACTION,3.12,60.63,"VAPOR DIFFUSION, SITTING DROP",6.0,"35% MPD, 0.2M LiSO4, 0,1 M Mes pH 6.0",277.0,2016-10-22,2017-01-11,5M5Q,1843.0,1.0,257.0,47.0,,29.68,1.0,2.2,experimental,68.84,0.219,0.197,COPS5(2-257) IN COMPLEX WITH A AZAINDOLE (COMPOUND 4)
6M1U,X-RAY DIFFRACTION,2.62,52.97,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris-HCl, pH 7.4, 20% (w/v) PEG3350, 200 mM sodium citrate, 4% (w/v) formamide and 5 mM dextran sulfate sodium salt.",293.0,2020-02-26,2020-04-01,6M1U,987.0,1.0,164.0,,,19.18,1.0,2.791,experimental,87.7021,0.263,0.2336,Crystal structure of the vertebrate conserved region (VCR) of human METTL16
7PL1,X-RAY DIFFRACTION,2.8,56.08,"VAPOR DIFFUSION, HANGING DROP",,"200 mM lithium sulfate, 20% PEG 1000, 100 mM phosphate-citrate buffer pH 4.2",277.15,2021-08-27,2021-09-15,7PL1,1897.0,1.0,252.0,184.0,,30.15,1.0,1.85,experimental,31.31,0.2121,0.1896,Crystal structure of human METTL1 bound to Sinefungin
7JUO,X-RAY DIFFRACTION,2.55,51.77,"VAPOR DIFFUSION, HANGING DROP",8.4,"0.2 M lithium citrate tribasic tetrahydrate, 17-19% PEG 3350, pH 8.4",277.0,2020-08-20,2021-09-01,7JUO,8096.0,8.0,944.0,151.0,,116.36,1.0,2.2,experimental,58.076,0.2758,0.2104,CBP bromodomain complexed with YF2-23
6SH1,X-RAY DIFFRACTION,2.3,46.42,VAPOR DIFFUSION,,"Potassium nitrate, sodium bromide, Bis-Tris propane, PEG 3350",291.15,2019-08-05,2019-09-25,6SH1,11723.0,2.0,1392.0,495.0,12.0,161.11,1.0,2.1,experimental,40.443,0.2614,0.2184,Crystal structure of substrate-free human neprilysin E584D.
6FFI,X-RAY DIFFRACTION,2.52,51.16,LIPIDIC CUBIC PHASE,6.8,"24-34% V/V PEG400, 0.2 M AMMONIUM PHOSPHATE DIBASIC, 0.1 M MES, PH 6.8",293.1,2018-01-08,2018-03-07,6FFI,3492.0,1.0,444.0,142.0,1.0,52.26,1.0,2.2,experimental,28.89,0.2693,0.2264,Crystal Structure of mGluR5 in complex with MMPEP at 2.2 A
7L1G,X-RAY DIFFRACTION,2.81,56.25,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium citrate pH 6.0, 0.2 M sodium acetate, 10-12% PEG 4000",277.0,2020-12-14,2021-04-14,7L1G,7677.0,2.0,995.0,133.0,1.0,113.03,2.0,2.47,experimental,77.41,0.255,0.214,PRMT5-MEP50 Complexed with SAM
5PAJ,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAJ,2808.0,2.0,318.0,280.0,8.0,35.88,2.0,1.7,experimental,24.376,0.2241,0.2,Crystal Structure of Factor VIIa in complex with 1-(1-aminoisoquinolin-6-yl)-3-benzylurea
5PAX,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAX,2856.0,2.0,318.0,381.0,8.0,36.0,2.0,1.36,experimental,16.897,0.1916,0.1816,"Crystal Structure of Factor VIIa in complex with 1-(2,6-difluorophenyl)-3-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]urea"
7W4X,X-RAY DIFFRACTION,2.21,44.45,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.1 M Hepes (pH 7.4), 0.1 M MgCl2, 15% PEG 3350, 10% isopropanol, and 25% ethylene glycol",277.0,2021-11-29,2022-03-16,7W4X,5558.0,2.0,746.0,262.0,,86.41,1.0,2.20007326465,experimental,32.9562702411,0.252792779593,0.228741688885,Crystal structure of PDE4D catalytic domain complexed with 17
5IVB,X-RAY DIFFRACTION,2.23,44.76,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-20,2016-07-27,5IVB,2657.0,1.0,330.0,259.0,,38.51,1.0,1.389,experimental,,0.2142,0.1823,A High Resolution Structure of a Linked KDM5A Jmj Domain with Alpha-Ketoglutarate
6ES1,X-RAY DIFFRACTION,2.24,45.0,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.160 mM HcA2 (8.27 mg/mL), 0.160 mM SV2CL4 (2.24 mg/mL), 2 mM Sialylated Thomsen-Friedenreich carbohydrate antigen (Sialyl-T). Reservoir solution: 200 mM CaCl2, 100 mM MES pH 6.0, 20 % PEG 6000",293.0,2017-10-19,2018-04-25,6ES1,4647.0,2.0,562.0,359.0,,65.58,2.0,2,experimental,27.539,0.22967,0.18139,Crystal structure of the binding domain from botulinum neurotoxin A2 bound to extracellular domain of human receptor SV2C
5CRU,X-RAY DIFFRACTION,2.21,44.26,"VAPOR DIFFUSION, SITTING DROP",7.3,"0.03 M HEPES sodium, 16%(w/v) polyethylene glycol 3350, 0.67%(w/v) tryptone, 0.03 M urea",293.0,2015-07-23,2016-02-24,5CRU,11411.0,4.0,1444.0,44.0,,162.88,1.0,2.4,experimental,,0.2594,0.22,Crystal structure of the Bro domain of HD-PTP
8Q5P,X-RAY DIFFRACTION,2.54,51.57,VAPOR DIFFUSION,,"0.1M TRIS pH 8.5, 16%w/v PEG 10000",293.0,2023-08-09,2024-04-24,8Q5P,2256.0,2.0,307.0,174.0,,36.04,2.0,1.814,experimental,48.44,0.2456,0.2163,Structure of the lysine methyltransferase SETD2 in complex with a peptide derived from human tyrosine kinase ACK1
8K3A,X-RAY DIFFRACTION,4.14,70.29,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Magnesium chloride, 0.1 M Sodium, citrate pH 5, 15%(w/v) PEG 4000",293.0,2023-07-14,2024-07-17,8K3A,2099.0,2.0,284.0,1.0,1.0,29.98,2.0,2.74,experimental,,0.2555,0.2341,SOD1 and Nanobody2 complex
6G2U,X-RAY DIFFRACTION,2.99,58.93,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 8000, MPD, NaCl, sodium phosphate",291.0,2018-03-23,2019-04-10,6G2U,24160.0,6.0,3030.0,1624.0,,340.12,1.0,2.93428699014,experimental,52.3493357802,0.248811017326,0.192935363307,Crystal structure of the human glutamate dehydrogenase 2 (hGDH2)
5XIS,X-RAY DIFFRACTION,3.02,59.22,"VAPOR DIFFUSION, SITTING DROP",8.5,"15% PEG3350, 0.1 M Tris-HCl (pH 8.5), 100 mM MgCl2",293.0,2017-04-27,2018-03-07,5XIS,4048.0,6.0,474.0,312.0,,54.84,3.0,1.78,experimental,,0.2451,0.2185,"Crystal structure of RNF168 UDM1 in complex with Lys63-linked diubiquitin, form I"
7O86,X-RAY DIFFRACTION,2.26,45.65,"VAPOR DIFFUSION, SITTING DROP",,"150nls Protein (1.4mgs/ml in 20 mM Tris.HCl pH 7.8, 50mM NaCl, 1mM DTT) was mixed with 50nl Morpheus A5 = 30mM Magnesium chloride hexahydrate, 30mM Calcium chloride dihydrate, 50mM Sodium HEPES, 50mM MOPS pH 7.5, 20% v/v PEG 500* MME, 10%  w/v PEG 20000.",293.0,2021-04-14,2021-09-22,7O86,1919.0,2.0,212.0,206.0,,23.07,1.0,1.73,experimental,34.62,0.2396,0.1988,1.73A X-ray crystal structure of the conserved C-terminal (CCT) of human SPAK
8FMJ,X-RAY DIFFRACTION,2.44,49.59,"VAPOR DIFFUSION, SITTING DROP",,"Tris 0.1 M pH 7.8 - 8.0
NaAc 0.2 M
PEG3350 30-34%",293.0,2022-12-23,2023-11-22,8FMJ,1737.0,1.0,176.0,200.0,,21.06,1.0,1.33,experimental,20.62,0.1665,0.1421,Crystal structure of human KRAS in space group R32
8XPV,X-RAY DIFFRACTION,1.98,37.98,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Sodium Acetate, 0.1M Sodium Cacodylate HCl pH6.5, 18% PEG 8000",293.0,2024-01-04,2024-01-24,8XPV,2511.0,1.0,305.0,251.0,,35.23,1.0,1.55,experimental,17.476,0.1903,0.1641,The Crystal Structure of EphA2 from Biortus.
7EEF,X-RAY DIFFRACTION,2.37,48.18,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, Ammonium sulphate, HEPES",295.15,2021-03-18,2021-07-07,7EEF,2272.0,1.0,304.0,22.0,,34.52,1.0,2.6,experimental,26.474,0.2797,0.244,Crystal structure of EphA7 mutant G656E
5CXA,X-RAY DIFFRACTION,2.29,46.18,"VAPOR DIFFUSION, SITTING DROP",10.0,"Protein:  hMMP12 F171D K241A at 608 micro-M + 10 milli-M AHA + 0.552 milli-M inhibitor. precipitant: 26% PEG4000, 3% dioxane, 0.114 M TRIS pH 10. cryoprotectant: 10 % diethylene glycol + 5 % glycerol + 10 % 2,3-butanediol + 5 % 1,4-dioxane, 25% PEG 6K, 0.1 M TRIS-HCl, pH 8.0",293.0,2015-07-28,2016-08-10,5CXA,1680.0,1.0,159.0,287.0,,18.45,1.0,1.3,experimental,,0.181,0.1403,Crystal structure of the catalytic domain of Human MMP12 in complex with a carboxylate inhibitor related to RXP470
7APG,X-RAY DIFFRACTION,2.48,50.35,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% PEG 3350, 0.1-0.2 M MgCl2 and 0.1 M MES, pH 5.5",277.15,2020-10-16,2020-12-02,7APG,9501.0,4.0,1176.0,337.0,,136.39,1.0,2.4,experimental,39.666,0.2557,0.2122,Crystal structure of JAK3 in complex with FM587 (compound 9a)
5CZM,X-RAY DIFFRACTION,2.23,44.89,"VAPOR DIFFUSION, SITTING DROP",9.5,"Protein : MMP12h F67D K241A 850 micro-M + 10mM AHA
Drop : 1 micro-L protein + 0.35 micro-l inhibitor(1.5 milli-M, DMSO)
Precipitant : 20% PEG4K, 0.2 M TRIS pH9.5
Cryo protectant : 5% diethylene glycol, 0% ethylene glycol, 5% MPD + 5% glycerol, 5% 2,3-butanediol, 5mM NDSB 201, 25% PEG 6K, 100mM TRIS HCl, pH 8.0",293.0,2015-07-31,2016-08-10,5CZM,1653.0,1.0,159.0,283.0,,18.63,1.0,1.303,experimental,,0.1739,0.1454,Crystal structure of a mutated catalytic domain of Human MMP12 in complex with RXP470
5WE8,X-RAY DIFFRACTION,2.14,42.4,"VAPOR DIFFUSION, HANGING DROP",,"co-crystallization of 10 mg/mL protein, 0.5 mM AMP-PNP, 1.5 mM manganese(II) chloride, 1 mM compound in
crystallization reservoir solution (100 mM HEPES, pH 7.5, 15-17% PEG3350, 100-300 mM calcium acetate)",298.0,2017-07-07,2017-08-16,5WE8,4748.0,2.0,558.0,264.0,,65.88,1.0,2.006,experimental,40.0299,0.2466,0.2025,Crystal structure of WNK1 in complex with N-{(3R)-1-[(4-chlorophenyl)methyl]pyrrolidin-3-yl}-2-(3-methoxyphenyl)-N-methylquinoline-4-carboxamide (compound 8)
5VPM,X-RAY DIFFRACTION,2.83,56.57,"VAPOR DIFFUSION, SITTING DROP",7.5,"19-22% PEG3350, 0.2M ammonium sulfate, 0.1M TRIS-HCl, pH 7.5",298.0,2017-05-05,2017-10-18,5VPM,5209.0,2.0,674.0,10.0,6.0,75.62,1.0,2.9,experimental,58.345,0.26045,0.20158,Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol
5EFN,X-RAY DIFFRACTION,2.44,49.66,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris, pH 6.5, 25% PEG3350",277.0,2015-10-24,2016-07-27,5EFN,6396.0,4.0,734.0,634.0,,82.1,2.0,1.804,experimental,,0.1941,0.1622,Crystal structure of Danio rerio histone deacetylase 6 catalytic domain 2 (H574A) in complex with histone H4 Lys6 tripeptide substrate
5B78,X-RAY DIFFRACTION,2.48,50.4,"VAPOR DIFFUSION, SITTING DROP",,"polyethylene glycol 4000,  lithium sulfate, Tris",291.0,2016-06-05,2016-10-26,5B78,1359.0,2.0,156.0,229.0,,17.96,2.0,1.4,experimental,,0.1869,0.1686,Crystal structure of MOZ double PHD finger mutant-S210D/N235R in complex with histone H3 crotonylation at K14
6LSB,X-RAY DIFFRACTION,2.21,44.29,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 1.4 M sodium citrate tribasic dehydrate.",291.0,2020-01-17,2020-11-18,6LSB,1228.0,2.0,157.0,89.0,,17.93,2.0,2,experimental,39.2595,0.2052,0.158,Crystal Structure of DPF domain of MOZ in complex with H3K14bz peptide
6D3Z,X-RAY DIFFRACTION,3.04,59.52,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1 M sodium acetate, 1 M sodium formate",293.0,2018-04-17,2019-01-23,6D3Z,2156.0,2.0,260.0,180.0,8.0,28.63,2.0,2,experimental,21.1671,0.2029,0.1669,Protease SFTI complex
6YPH,X-RAY DIFFRACTION,2.28,46.02,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M HEPES 7.5 pH, 10 %w/v PEG 8K, 8 %v/v Ethelyene glycol",298.0,2020-04-16,2020-07-15,6YPH,5929.0,2.0,684.0,312.0,,81.61,1.0,1.67,experimental,34.9,0.275,0.255,Crystal Structure of CK2alpha with Compound 2 bound
7ACQ,X-RAY DIFFRACTION,2.38,48.38,VAPOR DIFFUSION,,"200 mM CaCl2
100 mM MES pH6
PEG6000 20% W/v",278.0,2020-09-11,2020-11-18,7ACQ,4536.0,3.0,510.0,485.0,,60.9,1.0,1.86,experimental,,0.2097,0.1737,CRYSTAL STRUCTURE OF INACTIVE KRAS G12D (GDP) IN COMPLEX WITH THE SOAKED DIMERIC INHIBITOR BI-5747
6S22,X-RAY DIFFRACTION,2.57,52.21,"VAPOR DIFFUSION, SITTING DROP",,"Morpheus precipitant mix 4, nitrate phosphate buffer and Morpheus buffer System 1",291.0,2019-06-20,2019-12-25,6S22,4791.0,2.0,643.0,303.0,6.0,75.73,2.0,1.96,experimental,35.312,0.21589,0.17902,"Crystal structure of the TgGalNAc-T3 in complex with UDP, manganese and FGF23c"
5B5W,X-RAY DIFFRACTION,2.5,50.81,"VAPOR DIFFUSION, HANGING DROP",,PEG 4000,277.0,2016-05-24,2016-07-06,5B5W,1966.0,2.0,271.0,,,32.04,2.0,2.957,experimental,,0.2704,0.2336,Crystal structure of MOB1-LATS1 NTR domain complex
4WWY,X-RAY DIFFRACTION,2.47,50.14,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2M ammonium sulfate, 0.1M sodium cacodylate trihydrate, 30% PEG-8000",298.0,2014-11-12,2015-07-22,4WWY,4784.0,4.0,564.0,399.0,16.0,62.3,2.0,1.7,experimental,19.323,0.2069,0.1708,human cationic trypsin G193R mutant in complex with bovine pancreatic trypsin inhibitor
4WXV,X-RAY DIFFRACTION,2.28,45.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2M ammonium sulfate, 0.1 sodium cacodylate trihydrate, 30% PEG-8000",298.0,2014-11-14,2015-07-22,4WXV,4345.0,4.0,558.0,75.0,16.0,61.33,2.0,2.1,experimental,25.878,0.2809,0.2157,Human cationic trypsin K97D mutant in complex with bovine pancreatic trypsin inhibitor (BPTI)
5PAM,X-RAY DIFFRACTION,3.73,67.01,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAM,2898.0,2.0,318.0,344.0,9.0,36.0,2.0,1.6,experimental,24.793,0.19,0.1699,Crystal Structure of Factor VIIa in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(5-ethoxy-2-fluorophenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone
7BJD,X-RAY DIFFRACTION,2.3,46.46,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-14,2021-07-07,7BJD,2337.0,1.0,297.0,199.0,,34.5,1.0,2,experimental,37.141,0.1969,0.1622,Crystal structure of CHK1-10pt-mutant complex with compound 3
7BJH,X-RAY DIFFRACTION,2.33,47.1,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-14,2021-07-07,7BJH,2325.0,1.0,297.0,213.0,,34.29,1.0,1.8,experimental,32.839,0.2008,0.1711,Crystal structure of CHK1-10pt-mutant complex with compound 8
7BJJ,X-RAY DIFFRACTION,2.34,47.34,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-14,2021-07-07,7BJJ,2296.0,1.0,297.0,199.0,,34.26,1.0,1.8,experimental,41.891,0.1993,0.1717,Crystal structure of CHK1-10pt-mutant complex with compound 9
7BJM,X-RAY DIFFRACTION,2.31,46.83,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-14,2021-07-07,7BJM,2171.0,1.0,297.0,104.0,,34.39,1.0,2.3,experimental,49.083,0.2309,0.1753,Crystal structure of CHK1-10pt-mutant complex with compound 10
7BJO,X-RAY DIFFRACTION,2.34,47.51,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-14,2021-07-07,7BJO,2212.0,1.0,297.0,138.0,,34.38,1.0,2.3,experimental,39.804,0.2074,0.1625,Crystal structure of CHK1-10pt-mutant complex with compound 13
7BJR,X-RAY DIFFRACTION,2.33,47.23,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-14,2021-07-07,7BJR,2251.0,1.0,297.0,170.0,,34.35,1.0,1.9,experimental,39.4,0.1915,0.1685,Crystal structure of CHK1-10pt-mutant complex with compound 18
7BKO,X-RAY DIFFRACTION,2.51,51.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"10-30% PEG8K
0.1M HEPES pH 7.5
15% isopropanol",298.0,2021-01-16,2021-07-07,7BKO,2323.0,1.0,297.0,212.0,,34.28,1.0,2.3,experimental,51.648,0.3307,0.2415,Crystal structure of CHK1 complex with compound 9
8WMS,X-RAY DIFFRACTION,4.32,71.51,"VAPOR DIFFUSION, SITTING DROP",,"100  mM Tris-HCl (pH 7.0), 200 mM tri-potassium phosphate and 20% (w/v) PEG3,350",293.0,2023-10-04,2024-07-31,8WMS,708.0,2.0,106.0,,,12.59,2.0,2.4,experimental,80.77,0.2664,0.2329,Crystal structure of human DPPA3 in complex with human UHRF1 PHD domain
4USF,X-RAY DIFFRACTION,2.6,52.0,,6.0,"20% PEG6000, 10% ETHYLENE GLYCOL, 0.1 M MES PH 6.0, 0.1 M MGCL2",,2014-07-07,2015-07-22,4USF,5050.0,2.0,608.0,508.0,,69.98,1.0,1.75,experimental,30.735,0.22815,0.19685,Human SLK with SB-440719
7U4O,X-RAY DIFFRACTION,3.42,64.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM Tris, pH 7.5, 200 mM sodium acetate, 35% w/v PEG3350",277.0,2022-02-28,2022-10-05,7U4O,7357.0,6.0,912.0,,,106.86,1.0,2.3,experimental,45.62,0.2378,0.1993,"Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((9-propyl-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor"
7UN4,X-RAY DIFFRACTION,3.48,64.7,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris, pH 8.5, 200 mM ammonium acetate, 20% w/v PEG3350",277.0,2022-04-08,2022-10-05,7UN4,7149.0,6.0,912.0,,,106.61,1.0,2.7,experimental,80.62,0.263,0.2027,"Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((9-propyl-5,6-dihydrothieno[3,4-h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor"
8SIW,X-RAY DIFFRACTION,2.36,47.88,"VAPOR DIFFUSION, SITTING DROP",6.5,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2023-04-17,2023-11-01,8SIW,4465.0,2.0,594.0,205.0,,69.21,1.0,1.877,experimental,39.68,0.2581,0.2188,Structure of Compound 5 bound to the CHK1 10-point mutant
5VCR,X-RAY DIFFRACTION,2.48,50.44,"VAPOR DIFFUSION, HANGING DROP",,1.4 M ammonium sulfate,293.0,2017-03-31,2018-04-11,5VCR,6108.0,2.0,838.0,294.0,8.0,98.15,1.0,1.992,experimental,,0.208,0.1766,"Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase with bound uranium dioxide"
5EH2,X-RAY DIFFRACTION,3.2,61.53,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.058 M Bistris Propane, 0.042 M Citric acid, 20% PEG3350",289.0,2015-10-27,2016-02-17,5EH2,3655.0,6.0,372.0,122.0,,60.27,1.0,2.05,experimental,,0.2305,0.2008,Human PRDM9 allele-A ZnF Domain with Associated Recombination Hotspot DNA Sequence III
5EI9,X-RAY DIFFRACTION,3.04,59.53,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.058 M Bistris Propane, 0.042 M Citric acid, 25% PEG3350",289.0,2015-10-29,2016-02-17,5EI9,3706.0,6.0,372.0,168.0,,60.27,1.0,1.921,experimental,,0.2373,0.2144,Human PRDM9 allele-A ZnF Domain with Associated Recombination Hotspot DNA Sequence I
5ISO,X-RAY DIFFRACTION,2.55,51.79,"VAPOR DIFFUSION, HANGING DROP",7.2,"12% PEG3350, 300 mM Guanidine in 100mM PIPES buffer at pH 7.2.",277.0,2016-03-15,2017-03-29,5ISO,14898.0,6.0,2338.0,80.0,,268.85,3.0,2.63,experimental,,0.2296,0.1779,"STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR, A BENZIMIDAZOLE DERIVATIVE (991)"
6D3X,X-RAY DIFFRACTION,2.29,46.36,"VAPOR DIFFUSION, HANGING DROP",4.5,"21% PEG4000, 0.1 M magnesium chloride, 0.1 M sodium citrate",293.0,2018-04-17,2019-01-23,6D3X,4281.0,4.0,520.0,327.0,16.0,57.25,2.0,1.8,experimental,20.8373,0.2161,0.1888,Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma
6Q1U,X-RAY DIFFRACTION,2.33,47.32,"VAPOR DIFFUSION, HANGING DROP",5.0,"100 mM Sodium Citrate,
100 mM MgCl2,
18% PEG 4000",293.0,2019-08-06,2020-04-15,6Q1U,4101.0,4.0,526.0,172.0,12.0,57.79,2.0,2.3467,experimental,26.37,0.2874,0.2328,Structure of plasmin and peptide complex
6Z83,X-RAY DIFFRACTION,2.93,58.06,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonia sulphate
0.1 M bis-tris pH 5.5
23-26%  PEG 3350",293.0,2020-06-02,2020-07-29,6Z83,5881.0,2.0,718.0,275.0,,88.25,1.0,2.171,experimental,36.336,0.2446,0.214,CK2 alpha bound to chemical probe SGC-CK2-1
6Z84,X-RAY DIFFRACTION,3.08,60.07,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M bis-tris pH 5.5 
23-26% (v/v) PEG 3350
0.2 M ammonia sulphate",293.0,2020-06-02,2020-07-29,6Z84,5708.0,2.0,676.0,177.0,,82.55,1.0,2.5,experimental,39.771,0.2501,0.215,CK2 alpha bound to chemical probe SGC-CK2-1 derivative
7YBA,X-RAY DIFFRACTION,2.98,58.77,"VAPOR DIFFUSION, SITTING DROP",7.1,"0.2 M Ammonium acetate, 20% w/v Polyethylene glycol 3,350",277.0,2022-06-29,2023-07-05,7YBA,3579.0,1.0,429.0,222.0,1.0,49.62,1.0,1.86,experimental,57.47,0.2019,0.1814,Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with D-4-hydroxy-2-oxoglutarate
6VN8,X-RAY DIFFRACTION,3.07,59.91,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VN8,5179.0,2.0,616.0,267.0,,73.65,1.0,1.9,experimental,51.2203,0.2147,0.1842,JAK2 JH1 in complex with baricitinib
5TKB,X-RAY DIFFRACTION,2.55,51.69,"VAPOR DIFFUSION, SITTING DROP",,"100mM HEPES, pH 7.5, 35% Ethylene Glycol, 5% Glycerol, 22% PEG3350",293.0,2016-10-06,2016-12-28,5TKB,11083.0,4.0,1524.0,471.0,,177.95,1.0,2.16,experimental,40.63,0.209,0.188,CRYSTAL STRUCTURE OF HUMAN PHOSPHODIESTERASE 4D IN COMPLEX WITH A TETRAFLUORANLINE COMPOUND
8BIK,X-RAY DIFFRACTION,2.55,51.72,VAPOR DIFFUSION,7.2,"AMPK a2b1g1 (5 mg/ml: 38 uM) was combined with AMP (4-fold excess), staurosporine (1.2-fold excess) and activator 455 (3-fold excess): and crystallised at 20 C by mixing 2 ul of the protein solution with 1 ul of 8 % PEG3350, 0.3 M guanidine hydrochloride, 0.1 M PIPES buffer pH 7.2.",293.0,2022-11-02,2024-05-15,8BIK,15482.0,6.0,2320.0,482.0,,266.75,3.0,2.5,experimental,67.72,0.215,0.181,Crystal structure of human AMPK heterotrimer in complex with allosteric activator C455
5C9Z,X-RAY DIFFRACTION,3.0,59.01,"VAPOR DIFFUSION, HANGING DROP",6.1,"0.2 M Sodium acetate, 0.1 M Sodium citrate pH 6.1, 10% w/v PEG 4000",293.0,2015-06-29,2016-06-29,5C9Z,7692.0,2.0,995.0,123.0,1.0,112.48,2.0,2.36,experimental,60.484,0.2881,0.2366,Crystal structure of PRMT5:MEP50 with EPZ015866 and sinefungin
5MOT,X-RAY DIFFRACTION,1.99,38.15,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2016-12-14,2017-05-24,5MOT,2988.0,1.0,328.0,189.0,,39.48,1.0,2.09,experimental,25.98,0.2269,0.1878,Crystal structure of CK2alpha with ZT0627 bound
5LKZ,X-RAY DIFFRACTION,2.99,58.9,"VAPOR DIFFUSION, SITTING DROP",,"Tris, PEG MME 2000",277.0,2016-07-25,2016-11-02,5LKZ,4710.0,1.0,578.0,158.0,1.0,68.48,1.0,2.5,experimental,48.694,0.23386,0.19846,Crystal structure of the p300 acetyltransferase catalytic core with crotonyl-coenzyme A.
6QED,X-RAY DIFFRACTION,2.65,53.55,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% METHANOL, 0.1 M CITRATE, PH 6.0",277.0,2019-01-07,2019-05-01,6QED,3165.0,1.0,378.0,224.0,,43.37,1.0,1.8,experimental,40.4,0.198,0.175,"CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR (S)-3-Hydroxy-2-oxo-1-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyrrolidine-3-carboxylic acid 3-chloro-5-fluoro-benzylamide"
8CCZ,X-RAY DIFFRACTION,2.38,48.32,"VAPOR DIFFUSION, SITTING DROP",,"10 mg/ml human Sirt3-(118-399) in 20 mM Tris/HCl, pH 8.0, 150 mM NaCl, 5% (v/v) glycerol, 1 mM TCEP were incubated with 2 mM Tat-37-59 in 10% (v/v) DMSO for 60 min at 293.15 K. The complex was crystallized using the sitting-drop vapor-diffusion method at 293.15 K with 100 mM CHES, pH 9.0, 20% (w/v) PEG 8000 as reservoir solution.",293.15,2023-01-28,2023-05-10,8CCZ,5037.0,4.0,610.0,472.0,,68.29,2.0,1.95,experimental,38.87,0.2763,0.2269,Crystal structure of human Sirt3 in complex with an inhibiting HIV1 Tat-37-59 peptide
5UGD,X-RAY DIFFRACTION,2.05,40.14,"VAPOR DIFFUSION, HANGING DROP",5.0,"10 % (w/v) polyethylene glycol 6,000, 
4 % (v/v) 2-methyl-2,4-pentanediol, 
0.1M (2-(N-morpholino)ethanesulfonic acid)",293.0,2017-01-08,2017-05-31,5UGD,2179.0,1.0,251.0,266.0,6.0,28.06,1.0,1.38,experimental,17.58,0.1817,0.1603,Protease Inhibitor
5UGG,X-RAY DIFFRACTION,2.05,39.93,"VAPOR DIFFUSION, HANGING DROP",5.0,"10 % (w/v) polyethylene glycol 6,000, 
4 % (v/v) 2-methyl-2,4-pentanediol,
0.1M (2-(N-morpholino)ethanesulfonic acid)",293.0,2017-01-08,2017-05-31,5UGG,2389.0,1.0,251.0,316.0,6.0,28.11,1.0,1.2,experimental,14.55,0.176,0.164,Protease Inhibitor
7LC1,X-RAY DIFFRACTION,2.17,43.23,"VAPOR DIFFUSION, HANGING DROP",7.5,"200 mM ammonium sulfate, 100 mM HEPES (N-2-hydroxyethyl piperazine-N-ethane sulfonic acid) pH 7.5, 25% PEG 3350",293.0,2021-01-09,2021-08-04,7LC1,6057.0,4.0,814.0,42.0,,93.56,2.0,2.35,experimental,70.2582,0.2792,0.2314,Crystal Structure of KRAS4b (GMPPNP-bound) in complex with the RBD-PH domains of SIN1
5NSP,X-RAY DIFFRACTION,2.33,47.32,"VAPOR DIFFUSION, SITTING DROP",8.5,"24%/26% PEG3350, 0.2M Lithium sulfate, 0.1M Tris-HCl",277.0,2017-04-26,2017-11-29,5NSP,3524.0,4.0,480.0,93.0,,55.86,2.0,2.3,experimental,35.764,0.24717,0.18997,Crystal structure of TNKS2 in complex with OD334
5NSX,X-RAY DIFFRACTION,2.42,49.14,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24%          PEG3350, PH 8.5",277.0,2017-04-27,2018-03-07,5NSX,3646.0,4.0,480.0,197.0,,55.77,2.0,1.8,experimental,35.348,0.19998,0.17311,"Crystal structure of TNKS2 in complex with 2-(1H-indazol-5-yl)-3,4-dihydroquinazolin-4-one"
5NT0,X-RAY DIFFRACTION,2.41,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24% PEG3350",277.0,2017-04-27,2018-03-07,5NT0,3791.0,4.0,480.0,284.0,,55.81,2.0,1.75,experimental,31.951,0.19425,0.16843,"Crystal structure of TNKS2 in complex with 2-(3-aminophenyl)-3,4-dihydroquinazolin-4-one"
5NT4,X-RAY DIFFRACTION,2.39,48.64,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24% PEG3350",277.0,2017-04-27,2018-03-07,5NT4,3692.0,4.0,480.0,238.0,,55.86,2.0,1.9,experimental,31.597,0.20412,0.17324,"Crystal structure of TNKS2 in complex with 2-[4-(morpholin-4-yl)phenyl]-3,4-dihydroquinazolin-4-one"
5NVC,X-RAY DIFFRACTION,2.45,49.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %        PEG3350",277.0,2017-05-04,2018-03-14,5NVC,3826.0,4.0,480.0,311.0,,55.72,2.0,1.6,experimental,27.269,0.20216,0.17827,"Crystal structure of TNKS2 in complex with 2-(3-hydroxyphenyl)-3,4-dihydroquinazolin-4-one"
5NVE,X-RAY DIFFRACTION,2.43,49.44,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %         PEG3350",277.0,2017-05-04,2018-03-14,5NVE,3918.0,4.0,480.0,367.0,,55.87,2.0,1.5,experimental,24.326,0.1957,0.17821,"Crystal structure of TNKS2 in complex with 2-(4-ethoxyphenyl)-3,4-dihydroquinazolin-4-one"
5NVF,X-RAY DIFFRACTION,2.45,49.86,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 % PEG3350",277.0,2017-05-04,2018-03-14,5NVF,3915.0,4.0,480.0,409.0,,55.84,2.0,1.55,experimental,22.03,0.20117,0.17595,"Crystal structure of TNKS2 in complex with 2-[4-(pyridin-2-yl)phenyl]-3,4-dihydroquinazolin-4-one"
5NVH,X-RAY DIFFRACTION,2.44,49.5,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 % PEG3350",277.0,2017-05-04,2018-03-14,5NVH,3834.0,4.0,480.0,336.0,,56.05,2.0,1.6,experimental,25.026,0.20033,0.17785,"Crystal structure of TNKS2 in complex with 2-[4-(piperidin-1-yl)phenyl]-3,4-dihydroquinazolin-4-one"
5NWB,X-RAY DIFFRACTION,2.44,49.58,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %        PEG3350",277.0,2017-05-05,2018-05-02,5NWB,3877.0,4.0,480.0,348.0,,56.02,2.0,1.6,experimental,22.703,0.20512,0.17971,"Crystal structure of TNKS2 in complex with 2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-3,4-dihydroquinazolin-4-one"
5NWC,X-RAY DIFFRACTION,2.43,49.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %        PEG3350",277.0,2017-05-05,2018-05-02,5NWC,3868.0,4.0,480.0,339.0,,55.81,2.0,1.5,experimental,24.322,0.20618,0.18138,"Crystal structure of TNKS2 in complex with 2-(2-aminophenyl)-3,4-dihydroquinazolin-4-one"
5NWD,X-RAY DIFFRACTION,2.43,49.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %         
PEG3350",277.0,2017-05-05,2018-03-14,5NWD,3812.0,4.0,480.0,327.0,,55.83,2.0,1.45,experimental,24.148,0.19184,0.17726,"Crystal structure of TNKS2 in complex with 2-[4-(diethylamino)phenyl]-3,4-dihydroquinazolin-4-one"
5NWG,X-RAY DIFFRACTION,2.45,49.81,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %         PEG3350",277.0,2017-05-05,2018-03-14,5NWG,4147.0,4.0,480.0,460.0,,55.81,2.0,1.4,experimental,20.718,0.16905,0.14134,"Crystal structure of TNKS2 in complex with 7-chloro-2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-3,4-dihydroquinazolin-4-one"
5NXE,X-RAY DIFFRACTION,2.43,49.33,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 % PEG3350",277.0,2017-05-10,2018-03-21,5NXE,3881.0,4.0,480.0,325.0,,55.93,2.0,1.6,experimental,27.739,0.19719,0.1761,"Crystal structure of TNKS2 in complex with 2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-1,2,3,4-tetrahydroquinazolin-4-one"
7R5X,X-RAY DIFFRACTION,2.68,54.12,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris pH=8.5, 200mM Lithium Sulphate, 20% PEG3350",277.15,2022-02-11,2023-02-08,7R5X,3631.0,4.0,438.0,169.0,,50.68,2.0,2.052,experimental,35.436,0.2244,0.1887,Tankyrase 2 in complex with an inhibitor (OUL211)
5O74,X-RAY DIFFRACTION,2.27,45.73,"VAPOR DIFFUSION, HANGING DROP",5.5,"19% PEG 600, 100mM NaCitrate pH 5.5, protein concentration 22mg/ml",293.0,2017-06-08,2017-10-11,5O74,17004.0,12.0,2262.0,,,258.3,2.0,2.5,experimental,,0.266,0.2286,Crystal structure of human Rab1b covalently bound to the GEF domain of DrrA/SidM from Legionella pneumophila in the presence of GDP
5EPZ,X-RAY DIFFRACTION,2.38,48.29,VAPOR DIFFUSION,8.0,"0.1 M Tris/HCl buffer pH 8.0, 2.4 M ammonium sulphate",289.0,2015-11-12,2016-08-17,5EPZ,1104.0,1.0,120.0,98.0,3.0,14.26,1.0,1.85,experimental,19.759,0.21749,0.1833,Human Angiogenin in complex with sulphate anions at a basic solution
5M9A,X-RAY DIFFRACTION,1.83,32.85,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Na/K tartrate
20% PEG 3350",289.0,2016-11-01,2017-02-22,5M9A,995.0,1.0,124.0,30.0,3.0,14.47,1.0,1.95,experimental,30.859,0.29676,0.23241,Human angiogenin PD variant H13R
5M9C,X-RAY DIFFRACTION,3.13,60.75,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.4 M Na/K tartrate
0.1 M Na citrate
20 % PEG 4000",289.0,2016-11-01,2017-02-22,5M9C,1111.0,1.0,124.0,72.0,3.0,14.58,1.0,2.05,experimental,37.191,0.23057,0.18455,Human angiogenin ALS variant K40R
5M9G,X-RAY DIFFRACTION,3.18,61.35,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2 M Na/K tartrate
0.1 M HEPES
3% propanol
20% PEG 8000",289.0,2016-11-01,2017-02-22,5M9G,1047.0,1.0,124.0,32.0,3.0,14.58,1.0,2.28,experimental,48.37,0.27057,0.22015,Human angiogenin PD variant K54R
5M9J,X-RAY DIFFRACTION,3.17,61.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Na/K tartrate
0.1 M Na cacodylate
25% PEG 4000",289.0,2016-11-01,2017-02-22,5M9J,1143.0,1.0,124.0,99.0,3.0,14.45,1.0,1.9,experimental,31.218,0.21551,0.17772,Human angiogenin PD variant K60E
5M9Q,X-RAY DIFFRACTION,2.33,47.22,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M ammonium sulphate
0.1 M Na cacodylate
30% PEG 8000",289.0,2016-11-02,2017-02-22,5M9Q,1276.0,1.0,124.0,154.0,3.0,15.12,1.0,1.35,experimental,20.03,0.1793,0.15069,Human angiogenin PD variant R95Q
5M9S,X-RAY DIFFRACTION,3.12,60.62,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Na/K tartrate
0.1 M MES
20% PEG 4000",289.0,2016-11-02,2017-02-22,5M9S,1087.0,1.0,124.0,67.0,3.0,14.46,1.0,1.85,experimental,33.444,0.26447,0.20824,Human angiogenin ALS variant V103I
6IEH,X-RAY DIFFRACTION,2.79,55.91,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Glycine pH 9.0, 100 mM NaCl, 33% (w/v) polyethylene glycol 300 (PEG 300)",293.15,2018-09-14,2019-04-03,6IEH,7647.0,2.0,1084.0,32.0,,123.62,2.0,2.892,experimental,,0.2522,0.2355,Crystal structures of the hMTR4-NRDE2 complex
5ONI,X-RAY DIFFRACTION,3.2,61.62,"VAPOR DIFFUSION, SITTING DROP",,"90 MICROLITER ENZYME STOCK SOLUTION (6 MG/ML IN 500 MM NACL, 25 MM
TRIS/HCL, PH 8.5) WAS MIXED WITH 10 MIKROLITER 4P STOCK
SOLUTION (10 MM 4P IN DMSO). THIS MIXTURE WAS INCUBATED FOR 30
MIN AT ROOM TEMPERATURE. THE RESERVOIR SOLUTION OF THE
CRYSTALLIZATION EXPERIMENT WAS 25 % (W/V) PEG5000, 0.2 M
AMMONIUM SULPHATE, 0.1 M MES BUFFER, PH 6.5. PRIOR TO
EQUILIBRATION THE CRYSTALLIZATION DROP WAS COMPOSED OF 1
MICROLITER RESERVOIR SOLUTION PLUS 1 MICROLITER ENZYME/4P
MIXTURE., VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293.0,2017-08-03,2017-12-27,5ONI,6053.0,2.0,782.0,297.0,,92.29,1.0,2,experimental,,0.2042,0.1751,LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
7OOV,X-RAY DIFFRACTION,2.89,57.46,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG3350, 0.1 M ammonium sulfate, 0.1 M tris pH 8.5",277.15,2021-05-28,2021-08-04,7OOV,2499.0,2.0,323.0,149.0,,37.53,2.0,1.96,experimental,46.597,0.1947,0.1616,Crystal structure of PIM1 in complex with ARC-1411
7OOW,X-RAY DIFFRACTION,3.18,61.37,"VAPOR DIFFUSION, SITTING DROP",,"15%(w/v) PEG 10000, 0.2M magnesium chloride, 0.1M tris pH 7.9",277.15,2021-05-28,2021-08-04,7OOW,2541.0,2.0,322.0,214.0,,37.18,2.0,1.95,experimental,33.68,0.1838,0.1602,Crystal structure of PIM1 in complex with ARC-1415
7OOX,X-RAY DIFFRACTION,2.67,53.94,"VAPOR DIFFUSION, SITTING DROP",,"1 M ammonium phosphate dibasic, 0.1 M acetate pH 4.5",277.15,2021-05-28,2021-08-04,7OOX,2700.0,2.0,322.0,258.0,,37.37,2.0,1.97,experimental,28.624,0.2216,0.1789,Crystal structure of PIM1 in complex with ARC-3126
7XSV,X-RAY DIFFRACTION,3.24,61.99,"VAPOR DIFFUSION, HANGING DROP",8.0,0.4M POTASSIUM SODIUM TARTRATE,291.0,2022-05-15,2022-07-13,7XSV,2276.0,1.0,289.0,16.0,,33.65,1.0,2.66,experimental,69.231,0.2332,0.1927,Crystal Structures of PIM1 in Complex with Macrocyclic Compound H3
6EHU,X-RAY DIFFRACTION,2.11,41.84,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2017-09-15,2018-02-28,6EHU,6048.0,2.0,684.0,262.0,,84.23,1.0,1.95,experimental,40.76,0.218,0.189,The crystal structure of CK2alpha in complex with compound 32
8BGC,X-RAY DIFFRACTION,3.16,61.07,"VAPOR DIFFUSION, SITTING DROP",5.5,0.2 M ammonia sulphate 0.1 M bis-tris pH 5.5 23-26% PEG 3350,293.0,2022-10-27,2022-11-23,8BGC,5475.0,2.0,676.0,19.0,,82.28,1.0,2.8,experimental,58.28,0.2534,0.2225,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with compound 2 (AA-CS-9-003)
6QS1,X-RAY DIFFRACTION,2.71,54.66,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent cations, 30% PEG550MME/PEG20000",289.0,2019-02-20,2019-05-22,6QS1,11129.0,4.0,1280.0,645.0,6.0,152.63,2.0,1.8,experimental,,0.2323,0.2016,Crystal structure of human Angiotensin-1 converting enzyme N-domain in complex with BPPb
7Q24,X-RAY DIFFRACTION,2.75,55.34,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent cations, 30% PEG550MME/PEG20000",289.0,2021-10-23,2022-02-16,7Q24,10964.0,2.0,1258.0,511.0,6.0,151.12,1.0,2.0,experimental,42.95,0.2139,0.1851,Crystal structure of Angiotensin-1 converting enzyme N-domain in complex with dual ACE/NEP inhibitor AD011
7Q25,X-RAY DIFFRACTION,2.78,55.75,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent cations, 30% PEG550MME/PEG20000",289.0,2021-10-23,2022-02-16,7Q25,11242.0,2.0,1258.0,798.0,6.0,150.67,1.0,1.6,experimental,42.74,0.2123,0.188,Crystal structure of Angiotensin-1 converting enzyme N-domain in complex with dual ACE/NEP inhibitor AD012
7Q26,X-RAY DIFFRACTION,2.76,55.47,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris/Bicine pH 8.5, 0.06 M Divalent cations, 30% PEG550MME/PEG20000",289.0,2021-10-23,2022-02-16,7Q26,11150.0,2.0,1258.0,764.0,6.0,150.86,1.0,1.7,experimental,39.02,0.2154,0.195,Crystal structure of Angiotensin-1 converting enzyme N-domain in complex with dual ACE/NEP inhibitor AD013
6IIW,X-RAY DIFFRACTION,2.44,49.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES (pH 7.5), 70% (v/v) MPD",277.0,2018-10-07,2019-10-09,6IIW,699.0,2.0,78.0,96.0,,9.53,2.0,1.699,experimental,,0.1888,0.1763,Crystal structure of human UHRF1 PHD finger in complex with PAF15
7CE4,X-RAY DIFFRACTION,2.37,48.05,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% PEG 3350, 0.2 M lithium sulfate, 0.1 M Tris pH 8.5",277.0,2020-06-22,2021-05-12,7CE4,2055.0,2.0,240.0,275.0,,28.32,2.0,1.5,experimental,24.509,0.2027,0.1729,Tankyrase2 catalytic domain in complex with K-476
6GFK,X-RAY DIFFRACTION,2.35,47.6,"VAPOR DIFFUSION, HANGING DROP",5.6,"1.7M Ammonium Sulfate, 0.2M K/Na Tartrate, 0.1M Na Citrate",293.0,2018-04-30,2018-09-19,6GFK,5510.0,3.0,753.0,100.0,,87.65,1.0,2.3,experimental,67.16,0.228,0.195,delta-N METTL16 MTase domain
4YHF,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 0.2 M (NH4)SO4, and 30% (w/v) PEG 5000 MME",293.0,2015-02-27,2015-05-13,4YHF,4717.0,2.0,556.0,371.0,,67.17,1.0,2.2,experimental,,0.2079,0.1738,Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor
5I12,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, SITTING DROP",7.25,"protein solution: 415.2 micro-M MMP9 WT + 0.120 M Acetohydroxamic acid in 20 mM Tris pH 7.0 with 0.001 M inhibitor DC27 and 10% DMSO.
precipitant: 40% MPEG 5K ; 0.1 M bicine ; pH 7.25
sitting drops of 1 micro-L protein solution and 1 micro-L precipitant solution.
cryoprotectant:_40% cryomix CM2 (25 % di-ethylene glycol + 25 % glycerol + 25 % 1,2-propanediol), 10% PEG 10K, 200 milli-M NaCl, 100 milli-M Na propionate, Na cacodylate, Bis-Tris-propane (PCTP 50% acid/50% basic) pH 7.0 + 0.001 M inhibitor DC27.",293.0,2016-02-05,2016-07-06,5I12,1484.0,1.0,157.0,124.0,,18.82,1.0,1.59,experimental,,0.228,0.188,Crystal structure of the catalytic domain of MMP-9 in complex with a selective sugar-conjugated arylsulfonamide carboxylate water-soluble inhibitor (DC27).
5NKP,X-RAY DIFFRACTION,3.39,63.68,"VAPOR DIFFUSION, SITTING DROP",,6% PEG4K -- 0.1M acetate pH 5.1,277.0,2017-03-31,2017-05-03,5NKP,4551.0,4.0,606.0,43.0,2.0,65.99,2.0,2.8,experimental,38.0573,0.2472,0.2288,Crystal structure of the human KLHL3 Kelch domain in complex with a WNK3 peptide
5FW5,X-RAY DIFFRACTION,3.5,60.0,,,"0.1 M SODIUM ACETATE TRIHYDRATE PH 4.6, 2 M AMMONIUMSULFATE",,2016-02-12,2016-07-20,5FW5,2731.0,3.0,305.0,275.0,,35.66,2.0,1.92,experimental,38.2,0.2021,0.1672,Crystal structure of human G3BP1 in complex with Semliki Forest Virus nsP3-25 comprising two FGDF motives
5OMY,X-RAY DIFFRACTION,1.94,36.66,"VAPOR DIFFUSION, SITTING DROP",,"90 MIKROLITER ENZYME STOCK SOLUTION (6
MG/ML IN 500 MM NACL, 25 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 10
MIKROLITER 4P STOCK SOLUTION (10 MM 4P IN DMSO). THIS
MIXTURE WAS INCUBATED FOR 30 MIN AT ROOM TEMPERATURE. THE
RESERVOIR SOLUTION OF THE CRYSTALLIZATION EXPERIMENT WAS 4.2 M
NACL, 0.1 M CITRIC ACID, PH 5.5. PRIOR TO EQUILIBRATION THE
CRYSTALLIZATION DROP WAS COMPOSED OF 1 MIKROLITER RESERVOIR
SOLUTION PLUS 1 MIKROLITER ENZYME/4P MIXTURE., VAPOR DIFFUSION,
SITTING DROP, TEMPERATURE 293.15K",293.15,2017-08-02,2017-12-27,5OMY,2966.0,1.0,391.0,122.0,,45.75,1.0,1.95,experimental,,0.2208,0.1925,HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
4XGL,X-RAY DIFFRACTION,2.84,56.74,"VAPOR DIFFUSION, HANGING DROP",6.0,"potassium citrate, PEG3350, magnesium chloride",298.0,2014-12-31,2015-05-13,4XGL,3010.0,1.0,379.0,178.0,,44.37,1.0,1.8,experimental,61.5153,0.2276,0.1885,Structure of the nuclease subunit of human mitochondrial RNase P (MRPP3) at 1.8A
5J7C,X-RAY DIFFRACTION,2.37,48.06,"VAPOR DIFFUSION, HANGING DROP",8.8,"10% PEG 6000, 0.1 M Bicine, pH 8.8",293.0,2016-04-06,2016-08-17,5J7C,3482.0,4.0,462.0,52.0,8.0,51.26,2.0,2.535,experimental,37.52,0.2498,0.2176,A picomolar affinity FN3 domain in complex with hen egg-white lysozyme
7MCK,X-RAY DIFFRACTION,2.28,46.0,"VAPOR DIFFUSION, SITTING DROP",6.5,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2021-04-02,2021-06-16,7MCK,2365.0,1.0,297.0,194.0,,34.57,1.0,1.65,experimental,34.05,0.225,0.192,Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 18
6D40,X-RAY DIFFRACTION,2.3,46.58,"VAPOR DIFFUSION, HANGING DROP",5.5,"15% PEG4000, 0.1 M MES, 0.15 M ammonium sulfate",293.0,2018-04-17,2019-01-23,6D40,2207.0,2.0,262.0,197.0,9.0,28.98,2.0,1.43,experimental,24.9964,0.21,0.1856,Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma
5W2H,X-RAY DIFFRACTION,2.22,44.62,"VAPOR DIFFUSION, HANGING DROP",,"35% (w/v) PEG 400, 0.1 M Li2SO4, 100 mM MES Imidanzol buffer , pH 6.0, 50 mM beta-mercaptoethanol.To obtain complex structures, the apo crystal were further soaked under 35% (w/v) PEG 400, 0.1 M Li2SO4,  100 mM HEPES, pH 7.5 at 298K in the presence of 20 mM Ins(1,4,5)P3, 10 mM Mg and 5mM ATP for 1 day.",298.0,2017-06-06,2017-09-13,5W2H,2276.0,1.0,257.0,172.0,,30.42,1.0,1.9,experimental,25.704,0.22952,0.16343,"Crystal structure of the core catalytic domain of human inositol phosphate multikinase in complex with Ins(1,4,5)P3 and ADP"
8DQT,X-RAY DIFFRACTION,2.22,44.61,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.2M sodium citrate, 0.1M Hepes pH 7.8",293.0,2022-07-19,2023-06-21,8DQT,2590.0,1.0,311.0,133.0,,36.79,1.0,1.31,experimental,24.98,0.2242,0.1991,Human PDK1 kinase domain in complex with Valsartan
6DQ7,X-RAY DIFFRACTION,2.25,45.35,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2019-06-12,6DQ7,2585.0,1.0,330.0,202.0,,38.55,1.0,1.852,experimental,,0.2093,0.1918,"LINKED KDM5A JMJ DOMAIN BOUND TO THE POTENTIAL HYDROLYSIS PRODUCT OF INHIBITOR N45 i.e. 3-((6-(4-(2-cyano-3-methylbut-2-enoyl)-1,4-diazepan-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid"
6XOH,X-RAY DIFFRACTION,2.21,44.3,VAPOR DIFFUSION,,"50 mM BisTris, pH 6.5, 50 mM Ammonium Sulfate, 30% pentaerythritol ethoxylate (Hampton Index 57)",293.0,2020-07-07,2021-03-24,6XOH,6714.0,3.0,1087.0,188.0,,122.08,3.0,2.226,experimental,63.594,0.2436,0.1939,Structure of SUMO1-ML00789344 adduct bound to SAE
6QZH,X-RAY DIFFRACTION,2.9,57.6,LIPIDIC CUBIC PHASE,,"200 mM MES pH 6.0, 100 mM ammonium tartrate dibasic, 23-27 % (v/v) PEG 500 MME, 1 mM - 5 mM GSH/GSSG",293.0,2019-03-11,2019-09-04,6QZH,6116.0,1.0,785.0,149.0,1.0,89.29,1.0,2.1,experimental,,0.2416,0.1877,Structure of the human CC Chemokine Receptor 7 in complex with the intracellular allosteric antagonist Cmp2105 and the insertion protein Sialidase NanA
7UMV,X-RAY DIFFRACTION,4.37,71.87,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM Tris, pH 7.5, 200 mM ammonium acetate, 40% w/v PEG3350",277.0,2022-04-07,2022-10-05,7UMV,1395.0,1.0,152.0,144.0,,17.82,1.0,1.8,experimental,33.66,0.172,0.1543,"Structure of MAP kinase phosphatase 5 in complex with 3,3-dimethyl-1-((5,6-dihydropyrido[2,3-h]quinazolin-2-yl)thio)butan-2-one, an allosteric inhibitor"
8JIG,X-RAY DIFFRACTION,2.52,51.19,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bris-Tris, pH 6.0, 0.2M NaCl, 1mM TCEP, 2.2-2.4mM ammonium sulfate",291.0,2023-05-26,2024-05-29,8JIG,3194.0,2.0,424.0,144.0,,48.14,1.0,2.4,experimental,,0.2443,0.2076,A Novel UHRF1-Targeted Compound
8P81,X-RAY DIFFRACTION,2.88,57.3,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M MOPS pH 6.5, 30% PEG mix, 0.1 M NDSB",288.0,2023-05-31,2023-11-22,8P81,4568.0,2.0,619.0,24.0,,72.69,2.0,2.68,experimental,,0.2548,0.207,Crystal structure of human Cdk12/Cyclin K in complex with inhibitor SR-4835
5VCM,X-RAY DIFFRACTION,1.96,37.25,"VAPOR DIFFUSION, HANGING DROP",,"1.7 M ammonium sulfate, 100 mM HEPES, pH 7.5, 5 mM UDP, 5 mM manganese chloride",293.0,2017-03-31,2018-04-11,5VCM,6598.0,2.0,838.0,544.0,10.0,98.12,1.0,1.599,experimental,28.0761,0.2196,0.1857,"Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase with bound UDP and Manganese"
8ENK,X-RAY DIFFRACTION,2.56,51.91,"VAPOR DIFFUSION, SITTING DROP",,"0.025 M HEPES, pH 7.4, 0.2 M sodium chloride, and 18% PEG4000",293.0,2022-09-30,2023-08-16,8ENK,6879.0,5.0,871.0,17.0,,106.72,2.0,2.5,experimental,71.15,0.2529,0.2238,"Crystal structure of UAP56 in complex with Tho1, the yeast homolog of human SARNP"
8FLG,X-RAY DIFFRACTION,2.31,46.79,VAPOR DIFFUSION,,"bis-tris, ammonium salt, PEG",277.0,2022-12-21,2023-03-01,8FLG,2197.0,1.0,293.0,111.0,,34.36,1.0,2.2,experimental,25.66,0.2538,0.1952,Bruton's tyrosine kinase in complex with an orthosteric inhibitor
8FLH,X-RAY DIFFRACTION,2.3,46.51,VAPOR DIFFUSION,,"bis-tris, ammonium salt, PEG",277.0,2022-12-21,2023-03-01,8FLH,2520.0,1.0,283.0,305.0,,33.28,1.0,1.55,experimental,21.43,0.2285,0.1956,Bruton's tyrosine kinase in complex with an orthosteric inhibitor
8FLV,X-RAY DIFFRACTION,2.28,46.01,VAPOR DIFFUSION,,"bis-tris, ammonium salt, PEG",277.0,2022-12-22,2023-04-05,8FLV,2476.0,1.0,283.0,244.0,,33.45,1.0,1.3,experimental,17.64,0.2181,0.1941,Bruton's tyrosine kinase in complex with compound 34
7T1F,X-RAY DIFFRACTION,2.06,40.41,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M calcium chloride and 20% PEG3,350",277.0,2021-12-01,2022-12-14,7T1F,4160.0,3.0,510.0,183.0,,59.45,1.0,2.2,experimental,38.0422,0.2499,0.2106,Crystal structure of GDP-bound T50I mutant of human KRAS4B
7AKM,X-RAY DIFFRACTION,2.62,52.97,"VAPOR DIFFUSION, SITTING DROP",8.5,"200 mM Sodium citrate tribasic dihydrate, 100 mM Bis-Tris propane pH 8.5 and 20% w/v PEG 3350",287.15,2020-10-01,2021-04-14,7AKM,4903.0,2.0,596.0,435.0,,69.77,1.0,1.93,experimental,36.48,0.2419,0.1967,Crystal structure of CHK1 kinase domain in complex with ATPyS
7BJX,X-RAY DIFFRACTION,2.35,47.61,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-14,2021-07-07,7BJX,4160.0,2.0,594.0,131.0,,68.89,1.0,2.4,experimental,57.43,0.2603,0.2015,Crystal structure of CHK1-10pt-mutant complex with compound 26
6DI5,X-RAY DIFFRACTION,2.48,50.41,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2M AMMONIUM ACETATE, 0.1M HEPES pH 6.9, 3% GLYCEROL 
PROTEIN SOLUTION   : 10 mg/mL IN 20 mM TRIS, 50 mM NaCl, 3 mM DTT, pH 8.0",294.0,2018-05-22,2018-09-05,6DI5,2533.0,1.0,271.0,307.0,,32.13,1.0,1.42,experimental,12.364,0.1947,0.1778,CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR
6DI9,X-RAY DIFFRACTION,2.41,48.87,"VAPOR DIFFUSION, HANGING DROP",,"RESERVOIR SOLUTION : 25% PEG 3350, 0.2M AMMONIUM ACETATE, 0.1M HEPES pH 6.9, 3% GLYCEROL                      
PROTEIN SOLUTION   : 10 mg/mL IN 20 mM TRIS, 50 mM NaCl, 3 mM  DTT, pH 8.0",294.0,2018-05-23,2018-09-05,6DI9,2306.0,1.0,271.0,219.0,,32.13,1.0,1.25,experimental,13.453,0.2074,0.1934,CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR
7KXQ,X-RAY DIFFRACTION,2.28,45.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 3350
0.1 M Bis Tris Propane pH 7.5
0.2 M Sodium acetate trihydrate",298.0,2020-12-04,2021-05-19,7KXQ,2621.0,1.0,270.0,261.0,,32.26,1.0,1.38,experimental,17.132,0.1823,0.1507,BTK1 SOAKED WITH COMPOUND 30
7LTY,X-RAY DIFFRACTION,2.28,45.97,"VAPOR DIFFUSION, SITTING DROP",,"0.1M BisTRIS pH 6.5, 0.2M Ammonium Acetate, 0.1M Guanidine HCl, 20% PEG2200 MME",277.0,2021-02-20,2022-01-12,7LTY,2354.0,1.0,267.0,196.0,,31.76,1.0,1.69,experimental,22.18,0.208,0.1779,Bruton's tyrosine kinase in complex with compound 23
7Q27,X-RAY DIFFRACTION,2.35,47.69,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.1 M MIB pH 4.0, 5% glycerol, 16% PEG 3350",289.0,2021-10-23,2022-02-16,7Q27,5843.0,1.0,597.0,702.0,3.0,71.29,1.0,1.5,experimental,19.68,0.1781,0.1485,Crystal structure of Angiotensin-1 converting enzyme C-domain in complex with dual ACE/NEP inhibitor AD011
7Q28,X-RAY DIFFRACTION,2.31,46.81,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.1 M MIB pH 4.0, 5% glycerol, 15% PEG 3350",289.0,2021-10-23,2022-02-16,7Q28,5360.0,1.0,597.0,436.0,3.0,70.99,1.0,1.65,experimental,28.93,0.1831,0.1634,Crystal structure of Angiotensin-1 converting enzyme C-domain in complex with dual ACE/NEP inhibitor AD012
7Q29,X-RAY DIFFRACTION,2.29,46.38,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.1 M MIB pH 4.0, 5% glycerol, 15% PEG 3350",289.0,2021-10-23,2022-02-16,7Q29,5512.0,1.0,597.0,559.0,3.0,71.39,1.0,1.6,experimental,21.33,0.1843,0.1605,Crystal structure of Angiotensin-1 converting enzyme C-domain in complex with dual ACE/NEP inhibitor AD013
7Z70,X-RAY DIFFRACTION,2.38,48.27,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.1 M MIB pH 4.0, 5% glycerol, 15% PEG 3350",289.0,2022-03-14,2022-06-22,7Z70,5469.0,1.0,597.0,595.0,3.0,71.0,1.0,1.85,experimental,26.35,0.2134,0.1736,Crystal structure of Angiotensin-1 converting enzyme C-domain in complex with fosinoprilat
5EFQ,X-RAY DIFFRACTION,2.52,51.12,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris, pH 6.5, 25.5% PEG 3350, 0.35 M MgCl2",293.0,2015-10-24,2015-12-30,5EFQ,9353.0,4.0,1230.0,289.0,,145.02,2.0,2.0,experimental,,0.2474,0.1939,Crystal structure of human Cdk13/Cyclin K in complex with ADP-aluminum fluoride
5K7U,X-RAY DIFFRACTION,2.31,46.84,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8.0, 20% PEG3350",291.0,2016-05-26,2016-07-06,5K7U,4584.0,2.0,574.0,530.0,,65.7,2.0,1.7,experimental,,0.1873,0.1634,Crystal structure of the catalytic domains of Mettl3/Mettl14 complex with SAM
6TUA,X-RAY DIFFRACTION,3.0,59.06,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M lithium sulfate, 0.1 M HEPES 7.5",293.0,2020-01-04,2020-01-15,6TUA,2323.0,1.0,317.0,28.0,,36.57,1.0,2.38,experimental,40.74,0.2476,0.1937,The RYK Pseudokinase Domain
6LBX,X-RAY DIFFRACTION,2.33,47.25,VAPOR DIFFUSION,5.5,"0.1M Sodium Citrate/Citric Acid (pH 5.5), 20% PEG 3000",290.0,2019-11-15,2020-11-18,6LBX,2788.0,2.0,372.0,148.0,7.0,41.78,2.0,2.03,experimental,31.98,0.2277,0.1902,Crystal structure of HER2 Domain IV and Rb-H2
4UB7,X-RAY DIFFRACTION,2.23,44.79,VAPOR DIFFUSION,,4M sodium chloride,293.0,2014-08-12,2015-07-01,4UB7,3021.0,1.0,335.0,179.0,,40.61,1.0,2.1,experimental,,0.2187,0.1772,"High-salt structure of protein kinase CK2 catalytic subunit with 4'-carboxy-6,8-bromo-flavonol (FLC26) showing an extreme distortion of the ATP-binding loop combined with a pi-halogen bond"
5H8G,X-RAY DIFFRACTION,1.93,36.4,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES, pH 6.5",293.0,2015-12-23,2016-02-10,5H8G,3050.0,1.0,333.0,201.0,,41.51,1.0,2.0,experimental,19.1,0.1982,0.1589,Crystal structure of CK2 with compound 7b
6HOP,X-RAY DIFFRACTION,1.97,37.59,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2018-09-18,2019-10-02,6HOP,3209.0,1.0,336.0,344.0,,41.22,1.0,1.55,experimental,26.1456,0.189,0.1636,Human protein kinase CK2 alpha in complex with curcumin degradation products
6HOQ,X-RAY DIFFRACTION,1.98,37.96,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2018-09-18,2019-10-02,6HOQ,3224.0,1.0,336.0,379.0,,40.82,1.0,1.55,experimental,25.4688,0.1849,0.1604,Human protein kinase CK2 alpha in complex with ferulic acid
6HOR,X-RAY DIFFRACTION,1.98,37.74,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2018-09-18,2019-10-02,6HOR,3117.0,1.0,336.0,298.0,,40.7,1.0,1.8,experimental,27.6238,0.1993,0.1614,Human protein kinase CK2 alpha in complex with feruloylmethane
6HOT,X-RAY DIFFRACTION,1.98,37.85,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2018-09-18,2019-10-02,6HOT,3217.0,1.0,336.0,383.0,,40.74,1.0,1.5,experimental,23.101,0.1964,0.1701,Human protein kinase CK2 alpha in complex with ferulic aldehyde
6HOU,X-RAY DIFFRACTION,1.99,38.12,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2018-09-18,2019-10-02,6HOU,3096.0,1.0,336.0,282.0,,40.5,1.0,1.8,experimental,27.4001,0.2081,0.1723,Human protein kinase CK2 alpha in complex with vanillin
6GZY,X-RAY DIFFRACTION,2.46,50.07,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris HCl pH 8.5, 28% w/v PEG 4000, 0.2 M Li2SO4",291.0,2018-07-05,2019-01-30,6GZY,3509.0,2.0,446.0,207.0,,52.4,1.0,2.15,experimental,,0.246,0.1985,HOIP-fragment5 complex
7P99,X-RAY DIFFRACTION,1.89,35.05,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Potassium thiocyanate, 0.1M Sodium Acetate pH 5.0, 8% PEG20000, 8% PEG500MME",311.0,2021-07-26,2022-03-02,7P99,3000.0,2.0,439.0,176.0,,50.25,2.0,1.8,experimental,33.986,0.1974,0.1745,Structure of human USPL1 in complex with SUMO2
7W0S,X-RAY DIFFRACTION,2.52,51.21,LIQUID DIFFUSION,,"PEG 3350, potassium nitrate",291.15,2021-11-18,2022-08-10,7W0S,4883.0,6.0,552.0,672.0,,63.27,2.0,1.4,experimental,19.12,0.1685,0.1512,TRIM7 in complex with C-terminal peptide of 2C
5FPV,X-RAY DIFFRACTION,2.6,52.75,,5.9,"0.1M BIS-TRIS PH 5.9, 0.15M AMMONIUM SULFATE, 11% PEG3350",,2015-12-03,2016-01-13,5FPV,23005.0,8.0,2880.0,891.0,1.0,339.13,1.0,2.44,experimental,,0.2289,0.1955,Crystal structure of human JMJD2A in complex with compound KDOAM20A
4RZV,X-RAY DIFFRACTION,2.21,44.41,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M Tris pH 7.0, 18% (w/v) PEG2000 MME , VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-12-24,2016-08-10,4RZV,4318.0,2.0,562.0,,,65.01,1.0,2.994,experimental,,0.2671,0.2042,Crystal structure of the BRAF (R509H) kinase domain monomer bound to Vemurafenib
5I9X,X-RAY DIFFRACTION,1.97,37.51,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M MES pH 6.0",291.0,2016-02-21,2016-11-09,5I9X,2592.0,1.0,306.0,235.0,,35.24,1.0,1.427,experimental,,0.182,0.165,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with bosutinib (SKI-606)
5IA4,X-RAY DIFFRACTION,2.11,41.82,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M MES pH 6.0",291.0,2016-02-21,2016-11-09,5IA4,2358.0,1.0,306.0,131.0,,35.16,1.0,1.797,experimental,,0.2255,0.1886,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with foretinib (XL880)
4YYP,X-RAY DIFFRACTION,3.68,66.64,"VAPOR DIFFUSION, SITTING DROP",,"Thin needles grew in precipitant solution containing 100 mM Hepes, pH 7.0, 20 mM MgCl2 and 22% Poly(acrylic acid sodium salt) 5100. After extensive optimization and seeding plate-like crystals were grown in a drop consisting of 50% PLK4-PB3/STIL-CC complex solution, 33.3% precipitant solution (100 mM phosphate/citrate pH 4.2, 40% (v/v) Ethanol, 5% (w/v) PEG 1000) and 16.7% of seed stock solution.",291.0,2015-03-24,2015-07-29,4YYP,967.0,2.0,119.0,15.0,,13.45,2.0,2.6,experimental,89.61,0.2542,0.2174,Crystal structure of human PLK4-PB3 in complex with STIL-CC
7ZUP,X-RAY DIFFRACTION,2.9,57.53,"VAPOR DIFFUSION, SITTING DROP",,"15% PEG3350, 100 mM Na citrate, pH 5.4, 100mM Carboxylic acids",281.0,2022-05-12,2022-10-19,7ZUP,7691.0,2.0,995.0,217.0,1.0,112.27,2.0,2.01,experimental,30.724,0.2708,0.2188,Human PRMT5:MEP50 structure with Fragment (Example 18) and MTA Bound
7ZUQ,X-RAY DIFFRACTION,2.84,56.69,"VAPOR DIFFUSION, SITTING DROP",,"12.5% PEG3350, 100 mM Na citrate pH 5.4, 120 mM Ethylene glycols",281.0,2022-05-13,2022-10-19,7ZUQ,7639.0,2.0,995.0,140.0,1.0,112.11,2.0,2.48,experimental,35.613,0.2794,0.2265,HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZUU,X-RAY DIFFRACTION,2.9,57.57,"VAPOR DIFFUSION, SITTING DROP",,"13% PEG3350, 100 mM Na citrate, pH 5.4, 100mM Carboxylic acids",281.0,2022-05-13,2022-10-19,7ZUU,7685.0,2.0,995.0,204.0,1.0,112.55,2.0,2.09,experimental,29.549,0.2801,0.2283,HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZUY,X-RAY DIFFRACTION,2.92,57.94,"VAPOR DIFFUSION, SITTING DROP",,"13 % PEG3350, 100 mM Na citrate, pH 5.4, 4% Tacsimate pH 7.0",281.0,2022-05-13,2022-10-19,7ZUY,7730.0,2.0,995.0,256.0,1.0,112.11,2.0,2.0,experimental,31.269,0.2698,0.222,HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZV2,X-RAY DIFFRACTION,2.91,57.72,"VAPOR DIFFUSION, SITTING DROP",,"16% PEG3350, 100 mM Na citrate pH 5.4, 100mM Carboxylic acids",281.0,2022-05-13,2022-10-19,7ZV2,7706.0,2.0,995.0,232.0,1.0,112.11,2.0,2.01,experimental,33.111,0.2754,0.2323,HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
7ZVL,X-RAY DIFFRACTION,2.78,55.79,"VAPOR DIFFUSION, SITTING DROP",,"16% PEG3350, 100 mM Na citrate pH 5.4, 100mM Carboxylic acids",281.0,2022-05-16,2022-10-19,7ZVL,7594.0,2.0,995.0,135.0,2.0,112.14,2.0,2.39,experimental,65.392,0.286,0.2158,HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound
5AB0,X-RAY DIFFRACTION,2.19,38.45,,6.3,"6 %(W/V) PEG MW 8000, 25 %(V/V) ETHYLENE GLYCOL, 59 MM MES AND 41 MM IMIDAZOLE AT PH 6.3",,2015-07-31,2015-09-30,5AB0,15615.0,4.0,1954.0,403.0,5.0,231.9,2.0,2.5,experimental,56.3,0.258,0.1981,Crystal structure of aminopeptidase ERAP2 with ligand
5J6S,X-RAY DIFFRACTION,2.82,56.43,VAPOR DIFFUSION,6.3,"7 %(w/v) PEG 8000, 20 %(v/v) ethylene glycol, 59 mM MES, 41 mM imidazole",277.0,2016-04-05,2017-03-15,5J6S,15067.0,2.0,1934.0,49.0,5.0,229.26,1.0,2.8,experimental,,0.2756,0.2049,Crystal structure of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) in complex with a hydroxamic derivative ligand
4UX9,X-RAY DIFFRACTION,2.67,53.91,,,50 MM HEPES 150 MM NACL 2 MM MGSO4 1 MM TCEP 2.6 M NH4SO4,,2014-08-20,2015-03-25,4UX9,11697.0,8.0,1504.0,276.0,,177.52,2.0,2.34,experimental,66.7,0.2405,0.1999,Crystal structure of JNK1 bound to a MKK7 docking motif
5YD8,X-RAY DIFFRACTION,2.18,43.58,"VAPOR DIFFUSION, SITTING DROP",,PEG 3350,293.0,2017-09-12,2018-04-18,5YD8,5933.0,6.0,816.0,45.0,3.0,90.19,2.0,2.3,experimental,52.4,0.2645,0.21864,Crystal structure of human PCNA in complex with APIM of human ZRANB3
5MYA,X-RAY DIFFRACTION,2.7,54.0,"VAPOR DIFFUSION, SITTING DROP",,0.1 M Tris buffer at pH 7.0 - 8.5 and 14-20% PEG 3350 (w/v),294.0,2017-01-26,2017-04-26,5MYA,3972.0,2.0,666.0,63.0,,77.81,1.0,2.9,experimental,139.9,0.2772,0.2345,Homodimerization of Tie2 Fibronectin-like domains 1-3 in space group C2
8SV9,X-RAY DIFFRACTION,2.68,54.11,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.05 M Bis-Tris pH 5.5, 0.2 M (NH4)2SO4, 20% PEG3350",292.0,2023-05-15,2024-03-27,8SV9,4647.0,2.0,566.0,128.0,,65.74,1.0,2.3,experimental,,0.2469,0.2099,Crystal structure of ULK1 kinase domain with inhibitor MR-2088
5SYN,X-RAY DIFFRACTION,2.18,43.56,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 mM sodium citrate pH 5.5, 20-24% PEG 3350.",293.0,2016-08-11,2016-10-26,5SYN,7073.0,4.0,924.0,310.0,,101.25,1.0,1.64,experimental,22.553,0.25,0.22,"Cocrystal structure of the human acyl protein thioesterase 2 with an isoform-selective inhibitor, ML349"
6A1G,X-RAY DIFFRACTION,2.37,48.08,"VAPOR DIFFUSION, SITTING DROP",,20% w/v Polyethylene glycol monomethyl ether 2000,293.0,2018-06-07,2018-10-03,6A1G,5735.0,2.0,720.0,151.0,,84.48,1.0,2.15,experimental,59.901,0.27232,0.22463,Crystal structure of human DYRK1A in complex with compound 32
7AKB,X-RAY DIFFRACTION,2.31,46.65,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8k, 0.15M Ca acetate, 16% ethylene glycol, 0.1M MES buffer pH 6.5",293.0,2020-09-30,2021-05-26,7AKB,5552.0,2.0,718.0,83.0,,84.17,1.0,2.8,experimental,48.273,0.2478,0.1938,Structure of DYRK1A in complex with compound 56
5JHA,X-RAY DIFFRACTION,2.38,48.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"17%  PEG  4000,  250  mM  (NH4)2SO4, and  100mM  Tris  pH-7.5",293.0,2016-04-20,2017-03-15,5JHA,6652.0,1.0,960.0,70.0,,110.74,1.0,2.51,experimental,100.9621,0.246,0.2019,Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin2
5JHB,X-RAY DIFFRACTION,2.32,47.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"17%  PEG  4000,  250  mM  (NH4)2SO4 and  100mM  Tris  pH-7.5",293.0,2016-04-20,2017-03-15,5JHB,6652.0,1.0,960.0,32.0,,110.45,1.0,2.48,experimental,102.0387,0.2771,0.2307,Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin3
7E0G,X-RAY DIFFRACTION,3.61,65.96,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M imidazole/HCl (pH 7.0), 14% PEG 3350, 10% 2-methyl-2,4-pentanediol",293.0,2021-01-28,2021-03-24,7E0G,5303.0,1.0,665.0,208.0,,74.95,1.0,2.25,experimental,60.134,0.2382,0.1935,"Crystal structure of Lysine Specific Demethylase 1 (LSD1) with TAK-418, FAD-adduct"
8BOS,X-RAY DIFFRACTION,2.26,45.54,"VAPOR DIFFUSION, HANGING DROP",8.0,"precipitant: HEPES-Na 100 mM pH = 8.0, PEG3350 22% (w/v), (NH4)2SO4 20 mM, Gd-HCl 100 mM, NaF 20 mM
protein buffer: HRas 0.400 mM, RasGAP 0.400 mM, HEPES-Na 20 mM, NaF 20 mM
drop size: 5 uL, protein:precipitant ratio: 1:1.2",293.0,2022-11-15,2023-11-29,8BOS,3973.0,2.0,497.0,58.0,1.0,57.26,2.0,2.1,experimental,43.913,0.27994,0.19802,Transition state analogue complex of small G protein and its GAP effector
7MNW,X-RAY DIFFRACTION,2.51,50.97,"VAPOR DIFFUSION, HANGING DROP",,"20% w/v PEG3350, 0.2 M potassium sodium tartrate tetrahydrate",277.0,2021-05-01,2022-06-15,7MNW,11711.0,8.0,1428.0,402.0,,165.33,2.0,2.4,experimental,60.1529,0.242,0.1995,Crystal Structure of Nup358/RanBP2 Ran-binding domain 1 in complex with Ran-GPPNHP
5MP0,X-RAY DIFFRACTION,2.51,50.96,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate pH 4.5
25% PEG3350",277.0,2016-12-15,2017-06-28,5MP0,1245.0,1.0,166.0,60.0,,19.11,1.0,1.63,experimental,30.885,0.26178,0.21187,"Human m7GpppN-mRNA Hydrolase (DCP2, NUDT20) Catalytic Domain"
7LCU,X-RAY DIFFRACTION,2.25,45.43,VAPOR DIFFUSION,7.5,"PEG8000, potassium dihydrogen phosphate",277.0,2021-01-11,2022-01-12,7LCU,4057.0,1.0,490.0,352.0,5.0,54.37,1.0,1.24,experimental,14.5,0.1944,0.1764,"X-ray structure of Furin bound to BOS-318, a small molecule inhibitor"
7KXM,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 3350
0.1 M Bis Tris Propane pH 7.5
0.2 M Sodium acetate trihydrate",298.0,2020-12-04,2021-05-19,7KXM,2470.0,1.0,271.0,172.0,,32.17,1.0,1.33,experimental,24.45,0.247,0.2008,"BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED"
6AAK,X-RAY DIFFRACTION,2.72,54.87,VAPOR DIFFUSION,,"buffer, salt, precipitant",293.0,2018-07-18,2018-08-15,6AAK,8832.0,4.0,1148.0,71.0,,132.74,1.0,2.67,experimental,39.51,0.326,0.269,Crystal structure of JAK3 in complex with peficitinib
7FB7,X-RAY DIFFRACTION,3.15,60.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES (pH7.5), 45% v/v MPD, 0.2 M Ammonium acetate",277.0,2021-07-08,2022-01-05,7FB7,3182.0,2.0,310.0,554.0,,37.55,1.0,1.45,experimental,32.19,0.1733,0.1576,"Crystal structure of human UHRF1 TTD in complex with 5-amino-2,4-dimethylpyridine"
5DT0,X-RAY DIFFRACTION,2.64,53.46,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292.0,2015-09-17,2016-07-20,5DT0,2260.0,1.0,273.0,102.0,,32.2,1.0,2.15,experimental,66.8,0.2248,0.2101,Aurora A Kinase in Complex with JNJ-7706621 in Space Group P6122
8C1M,X-RAY DIFFRACTION,3.76,67.32,VAPOR DIFFUSION,6.5,"5% DMSO, 0.2M MgSO4, 0.05 M HEPES 7.4: soaking: 0.2M MgSO4, 0.05M HEPES 7.4, 30% glycerol, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C1M,2211.0,1.0,273.0,,,32.44,1.0,2.84,experimental,82.35,0.269,0.252,Aurora A kinase in complex with TPX2-inhibitor 2
6NJA,X-RAY DIFFRACTION,2.78,55.79,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.2-2.6M Na FORMATE, 0.1m Na CITRATE pH5.5",295.0,2019-01-02,2019-06-05,6NJA,2617.0,1.0,314.0,163.0,,36.1,1.0,1.92,experimental,41.276,0.234,0.1832,Structure of WT RET protein tyrosine kinase domain at 1.92A resolution.
6VN2,X-RAY DIFFRACTION,2.5,50.0,VAPOR DIFFUSION,,,277.0,2020-01-29,2020-04-29,6VN2,5603.0,2.0,700.0,14.0,1.0,82.03,1.0,2.93,experimental,92.042,0.2899,0.2219,USP7 IN COMPLEX WITH LIGAND COMPOUND 18
4X61,X-RAY DIFFRACTION,3.01,59.08,"VAPOR DIFFUSION, HANGING DROP",6.1,"0.2 M Sodium acetate, 0.1 M Sodium citrate pH 6.1, 10% w/v PEG 4000",293.0,2014-12-06,2015-04-22,4X61,7477.0,2.0,995.0,58.0,,112.5,2.0,2.85,experimental,65.5,0.2603,0.2055,Crystal structure of PRMT5:MEP50 with EPZ015666 and SAM
5KMI,X-RAY DIFFRACTION,2.39,48.43,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298.0,2016-06-27,2016-12-28,5KMI,2511.0,1.0,329.0,108.0,,37.66,1.0,1.87,experimental,38.19,0.2466,0.208,TrkA JM-kinase with 1-(9{H}-fluoren-9-yl)-3-(2-methyl-4-phenyl-pyrimidin-5-yl)urea
5KMJ,X-RAY DIFFRACTION,2.39,48.46,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298.0,2016-06-27,2016-12-28,5KMJ,2488.0,1.0,329.0,91.0,,37.61,1.0,2.04,experimental,39.05,0.2257,0.194,TrkA JM-kinase with {N}-(2-pyridylmethyl)-2-[2-(2-thienyl)indol-1-yl]acetamide
5KMK,X-RAY DIFFRACTION,2.38,48.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298.0,2016-06-27,2016-12-28,5KMK,2460.0,1.0,329.0,31.0,,37.66,1.0,2.24,experimental,57.75,0.2805,0.2238,TrkA JM-kinase with 2-fluoro-{N}-[2-(4-fluorophenyl)-6-methyl-3-pyridyl]-4-(trifluoromethyl)benzamide
5KML,X-RAY DIFFRACTION,2.41,49.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298.0,2016-06-27,2016-12-28,5KML,2431.0,1.0,330.0,63.0,,37.67,1.0,2.01,experimental,40.18,0.2318,0.2023,"TrkA JM-kinase with 1-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]urea"
5KMM,X-RAY DIFFRACTION,2.37,48.16,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298.0,2016-06-27,2016-12-28,5KMM,2431.0,1.0,329.0,43.0,,37.62,1.0,2.12,experimental,51.87,0.2642,0.2136,TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-(1-naphthyl)urea
5KMN,X-RAY DIFFRACTION,2.41,48.93,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298.0,2016-06-27,2016-12-28,5KMN,2449.0,1.0,330.0,88.0,,37.68,1.0,2.14,experimental,37.66,0.2223,0.1936,TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]urea
5KMO,X-RAY DIFFRACTION,2.39,48.46,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298.0,2016-06-27,2016-12-28,5KMO,2319.0,1.0,329.0,22.0,,37.57,1.0,2.67,experimental,40.63,0.2429,0.1935,TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-(2-pyridyl)urea
6SDB,X-RAY DIFFRACTION,5.77,78.67,"VAPOR DIFFUSION, SITTING DROP",,"1 M NH4H2PO4 pH 4.6, 100 mM sodium acetate",295.0,2019-07-26,2019-09-18,6SDB,6141.0,5.0,985.0,202.0,,106.19,1.0,2.8,experimental,67.11,0.2335,0.1914,Chimeric titin Z1Z2 functionalized with a KLER exogenous peptide from decorin
5CIU,X-RAY DIFFRACTION,3.35,63.3,"VAPOR DIFFUSION, SITTING DROP",6.5,1.6M SODIUM CITRATE TRIBASIC,298.0,2015-07-13,2016-03-30,5CIU,2266.0,4.0,330.0,163.0,,36.83,2.0,2.24,experimental,46.45,0.2588,0.2241,Structural basis of the recognition of H3K36me3 by DNMT3B PWWP domain
7M2F,X-RAY DIFFRACTION,2.0,38.4,VAPOR DIFFUSION,7.5,"20% PEG 10K, 0.1M HEPES",290.0,2021-03-16,2021-07-07,7M2F,2453.0,1.0,298.0,130.0,,34.44,1.0,1.632,experimental,32.54,0.2575,0.2109,CDK2 with compound 14 inhibitor with carboxylate
5TQ7,X-RAY DIFFRACTION,2.35,47.6,VAPOR DIFFUSION,7.5,"0.1 M Hepes, pH 7.5, 100 mM sodium acetate, 30% PEG3350",293.0,2016-10-23,2017-01-11,5TQ7,4761.0,2.0,608.0,218.0,,72.75,1.0,2.1,experimental,25.78,0.28575,0.2258,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
6VNE,X-RAY DIFFRACTION,3.17,61.23,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNE,4920.0,2.0,616.0,34.0,,73.96,1.0,2.32,experimental,76.4045,0.2563,0.2175,JAK2 JH1 in complex with Fedratinib
4WOH,X-RAY DIFFRACTION,2.4,48.6,"VAPOR DIFFUSION, HANGING DROP",8.5,"21 mg/mL protein incubated with 10 mM 4-ntirophenolphosphate well solution: 0.1M Tris pH 8.5, 0.2M magnesium chloride, 20% w/v polyethylene glycol 3350",293.0,2014-10-15,2015-02-18,4WOH,1543.0,1.0,166.0,193.0,,18.94,1.0,1.34,experimental,14.159,0.16499,0.14028,Structure of of human dual-specificity phosphatase 22 (E24A/K28A/K30A/C88S) complexed with 4-nitrophenolphosphate
6L1S,X-RAY DIFFRACTION,2.48,50.48,VAPOR DIFFUSION,8.0,"0.2M Imidazole, 0.4M NaH2PO4/1.6M K2HPO4, 0.2M NaCl",293.0,2019-09-30,2020-10-28,6L1S,1438.0,1.0,157.0,185.0,,17.89,1.0,1.3611,experimental,19.1077,0.1954,0.1797,Crystal structure of DUSP22 mutant_C88S
6LMY,X-RAY DIFFRACTION,2.5,50.82,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.2 M imidazole, 0.4 M NaH2PO4, 1.6 M K2HPO4, 0.2 M NaCl",293.0,2019-12-27,2020-10-28,6LMY,1359.0,1.0,157.0,111.0,,17.87,1.0,1.5,experimental,22.5903,0.2129,0.182,Crystal structure of DUSP22 mutant_C88S/S93A
6DXT,X-RAY DIFFRACTION,2.83,56.59,"VAPOR DIFFUSION, SITTING DROP",7.0,"1.5 M ammonium sulfate, 0.1 M bis-tris pH 7.0, 25% ethylene glycol (v/v), 1.1% DMSO (v/v)",291.0,2018-06-29,2018-08-08,6DXT,1945.0,2.0,242.0,170.0,1.0,27.67,1.0,1.95,experimental,25.318,0.2419,0.194,"Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with 3-(5-phenyl-1,3,4-oxadiazol-2-yl)propanoate"
8DD5,X-RAY DIFFRACTION,2.77,55.53,"VAPOR DIFFUSION, SITTING DROP",,"100 mM sodium chloride
100 mM HEPES (pH 6.64)
1.8 M ammonium sulfate",277.0,2022-06-17,2023-07-05,8DD5,2286.0,1.0,286.0,1.0,,34.24,1.0,2.58,experimental,79.44,0.263,0.232,Crystal structure of KAT6A in complex with inhibitor CTx-648 (PF-9363)
6KRO,X-RAY DIFFRACTION,2.58,52.32,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH 8.5, 1.6M (NH4)2HPO4",277.0,2019-08-22,2020-04-01,6KRO,1827.0,2.0,216.0,113.0,,25.37,2.0,1.9,experimental,42.05,0.2031,0.1717,Tankyrase-2 in complex with RK-582
7VQS,X-RAY DIFFRACTION,3.59,65.72,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES (pH 6.2-6.3), 0.2M diammonium tartrate, 0.0005M TCEP, 10-12% PEG 3350",293.0,2021-10-20,2022-06-01,7VQS,5181.0,1.0,669.0,,,75.93,1.0,2.94,experimental,98.99,0.2561,0.2126,Crystal structure of LSD1 in complex with compound 4
7VQT,X-RAY DIFFRACTION,3.56,65.46,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES (pH 6.2-6.3), 0.2M diammonium tartrate, 0.0005M TCEP, 10-12% PEG 3350",293.0,2021-10-20,2022-06-01,7VQT,5177.0,1.0,669.0,,,75.93,1.0,2.91,experimental,97.72,0.2582,0.2087,Crystal structure of LSD1 in complex with compound 5
7VQU,X-RAY DIFFRACTION,3.68,66.59,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES (pH 6.2-6.3), 0.2M diammonium tartrate, 0.0005M TCEP, 10-12% PEG 3350",293.0,2021-10-20,2022-06-01,7VQU,5170.0,1.0,669.0,,,75.93,1.0,2.94,experimental,122.25,0.2576,0.2192,Crystal structure of LSD1 in complex with compound S1427
5BX0,X-RAY DIFFRACTION,2.35,47.59,EVAPORATION,7.65,"PEG4000 20%
CaCl2 200mM
Glycerol 25%
ph7.7",277.0,2015-06-08,2015-12-23,5BX0,2470.0,1.0,348.0,,,39.11,1.0,2.93,experimental,94.55,0.2516,0.1973,An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery
8A5L,X-RAY DIFFRACTION,2.32,46.9,"VAPOR DIFFUSION, SITTING DROP",6.8,"1 M Sodium Potassium Tartrate, 0.1 M HEPES pH 6.8 (adjusted with HCl)",291.15,2022-06-15,2022-07-06,8A5L,1591.0,2.0,186.0,152.0,,21.31,2.0,1.622,experimental,17.412,0.1884,0.156,TRIM7 PRYSPRY in complex with a 2BC peptide TIEALFQ
6O46,X-RAY DIFFRACTION,3.1,60.27,"VAPOR DIFFUSION, HANGING DROP",,"1.8-2.0 M sodium/potassium phosphate, pH 8.0-8.4",293.0,2019-02-28,2020-03-11,6O46,4573.0,3.0,507.0,386.0,,59.51,1.0,1.9,experimental,36.04,0.2099,0.1729,Crystal structure of human KRAS P34R mutant in complex with GNP and Phosphate
7YAZ,X-RAY DIFFRACTION,1.84,33.31,"VAPOR DIFFUSION, HANGING DROP",,"0.05 M Magnesium acetate, 0.05 M Sodium acetate pH 5.0, 28% PEG400",298.0,2022-06-28,2023-08-09,7YAZ,2452.0,1.0,310.0,23.0,,36.01,1.0,2.54,experimental,42.8447,0.2518,0.1835,Crystal structure of ZAK in complex with compound YH-186
5HVJ,X-RAY DIFFRACTION,2.17,43.28,"VAPOR DIFFUSION, HANGING DROP",,"18-24% PEG 3350, 0.2 M potassium citrate",298.0,2016-01-28,2016-05-04,5HVJ,4720.0,2.0,630.0,70.0,,73.29,1.0,2.2,experimental,75.1,0.2522,0.2057,Crystal structure of LIMK1 D460N mutant in complex with AMP-PNP
8CB1,X-RAY DIFFRACTION,3.4,62.79,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.9 M AMMONIUM SULPHATE, 0.1 M HEPES, 2% V/V PEG400",293.0,2023-01-25,2023-09-13,8CB1,7846.0,2.0,872.0,785.0,5.0,102.04,2.0,1.75,experimental,40.587,0.1749,0.14224,"Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with N-PNT-DNM 15"
5WFJ,X-RAY DIFFRACTION,2.4,48.67,VAPOR DIFFUSION,,,293.0,2017-07-12,2017-10-04,5WFJ,2139.0,1.0,293.0,26.0,,33.59,1.0,2.48,experimental,52.96,0.255,0.2,THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
6DB3,X-RAY DIFFRACTION,2.25,45.41,"VAPOR DIFFUSION, HANGING DROP",8.0,"20% PEG 3350, 0.2M (NH4)2SO4, 2% phenylurea",298.0,2018-05-02,2018-11-28,6DB3,2461.0,1.0,321.0,263.0,,36.83,1.0,1.97,experimental,41.19,0.2236,0.1886,JAK3 with Cyanamide CP23
6DB4,X-RAY DIFFRACTION,2.19,43.87,"VAPOR DIFFUSION, HANGING DROP",8.0,"20% PEG 3350, 0.2M (NH4)2SO4, 2% phenylurea",298.0,2018-05-02,2018-11-28,6DB4,2506.0,1.0,321.0,294.0,,36.9,1.0,1.662,experimental,32.52,0.2157,0.1852,JAK3 with Cyanamide CP34
6XOI,X-RAY DIFFRACTION,2.21,44.31,VAPOR DIFFUSION,,"50 mM BisTris, pH 6.5, 50 mM Ammonium Sulfate, 30% pentaerythritol ethoxylate (Hampton Index 57)",293.0,2020-07-07,2021-03-24,6XOI,6165.0,3.0,1087.0,286.0,,122.04,3.0,2.0,experimental,40.672,0.2873,0.2388,Structure of SUMO1-ML00752641 adduct bound to SAE
6BPI,X-RAY DIFFRACTION,2.34,47.48,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG 3350, 0.2M LiSO4, 0.1M Bis-Tris pH 6.5",293.0,2017-11-23,2017-12-27,6BPI,2059.0,2.0,217.0,156.0,,26.13,2.0,1.64,experimental,25.147,0.19939,0.18785,Crystal structure of SETDB1 Tudor domain with aryl triazole fragment peptide conjugates
8PQH,X-RAY DIFFRACTION,2.02,39.24,"VAPOR DIFFUSION, HANGING DROP",,"10 mg/mL, 13% PEG3350, 200 mM KCl",293.15,2023-07-11,2023-12-27,8PQH,2496.0,1.0,352.0,22.0,,40.83,1.0,2.5,experimental,78.98,0.2486,0.2184,PDGFRA T674I mutant kinase domain in complex with avapritinib
7E0Q,X-RAY DIFFRACTION,2.9,57.53,"VAPOR DIFFUSION, HANGING DROP",,"15% to 23% PEG 8000, 0.2M ammonium acetate",293.0,2021-01-28,2021-07-21,7E0Q,6058.0,2.0,784.0,74.0,1.0,90.1,1.0,2.462,experimental,59.7314,0.2427,0.1896,"Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with (1S,2R)-2-(((6-Bromo-1H-indazol-4-yl)amino)methyl)cyclohexan-1-ol (22)"
7E0T,X-RAY DIFFRACTION,3.11,60.46,"VAPOR DIFFUSION, HANGING DROP",,"15% to 23% PEG 8000, 0.2M ammonium acetate",293.0,2021-01-28,2021-07-21,7E0T,6027.0,2.0,784.0,38.0,1.0,90.1,1.0,2.137,experimental,64.2554,0.2723,0.2129,"Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with (1R,2S)-2-(((5-bromo-1H-indazol-4-yl)amino)methyl)Cyclohexan-1-ol (36)"
7E0U,X-RAY DIFFRACTION,2.84,56.67,"VAPOR DIFFUSION, HANGING DROP",,"15% to 23% PEG 8000, 0.2M ammonium acetate",293.0,2021-01-28,2021-07-21,7E0U,6258.0,2.0,784.0,108.0,1.0,90.17,1.0,2.278,experimental,63.9333,0.2482,0.1897,"Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with 6-Bromo-N-(((1S,2S)-2-chlorocyclohexyl)methyl)-1H-indazol-4-amine (39)"
4UT3,X-RAY DIFFRACTION,2.46,49.96,,9.0,"7-12% PEG3350, 0.1 M BICINE, PH 9.0 SOAKING IN RESERVOIR ENRICHED WITH 50MM H2O2 FOR 10 MINS CRYOPROTECTION IN RESEVOIR ENRICHED WITH 25% MPD",,2014-07-17,2015-07-22,4UT3,4936.0,2.0,646.0,161.0,,74.52,2.0,2.19,experimental,47.211,0.21146,0.17336,X-ray structure of the human PP1 gamma catalytic subunit treated with hydrogen peroxide
8OO3,X-RAY DIFFRACTION,2.16,43.13,"VAPOR DIFFUSION, HANGING DROP",5.1,"10% PEG6K, 20 mM sodium citrate pH 5.1, 0.2 M sodium/potassium tartrate",293.0,2023-04-04,2023-07-12,8OO3,1124.0,1.0,123.0,94.0,3.0,14.62,1.0,1.76,experimental,20.824,0.2905,0.243,X-ray structure of the adduct formed upon reaction of cisplatin with human angiogenin after 5 days soaking
5KTU,X-RAY DIFFRACTION,2.22,44.55,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M magnesium chloride, 0.1 M Bis-Tris pH 6.5, and 25% polyethylene glycol (PEG) 3350",277.0,2016-07-12,2016-11-02,5KTU,2115.0,2.0,236.0,215.0,,28.32,1.0,1.38,experimental,26.338,0.2122,0.1915,Crystal structure of the bromodomain of human CREBBP bound to pyrazolopiperidine scaffold
6QBY,X-RAY DIFFRACTION,2.74,60.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2M Sodium formate
0.1M Bis-Tris propane pH 6.5
20% PEG3350",293.15,2018-12-24,2019-04-24,6QBY,4703.0,4.0,662.0,265.0,,77.82,2.0,2.09,experimental,53.52,0.23,0.19,Crystal structure of VASH 2 in complex with SVBP
5KBY,X-RAY DIFFRACTION,2.85,56.83,"VAPOR DIFFUSION, SITTING DROP",,"22.2% PEG MME 2000, 0.1M Bicine pH 8.5",277.0,2016-06-03,2016-07-13,5KBY,25867.0,4.0,2960.0,1597.0,20.0,350.4,1.0,2.24,experimental,50.867,0.215,0.1743,Crystal structure of dipeptidyl peptidase IV in complex with SYR-472
6GL9,X-RAY DIFFRACTION,1.95,36.89,"VAPOR DIFFUSION, SITTING DROP",,"24-30% PEG 3350, 0.1 M MES, pH 5.5-6.0 and 0.1-0.2 M MgCl2",277.15,2018-05-23,2018-06-27,6GL9,5182.0,2.0,588.0,321.0,,68.83,1.0,1.7,experimental,24.922,0.2438,0.20688,Crystal structure of JAK3 in complex with Compound 10 (FM475)
6BX6,X-RAY DIFFRACTION,2.37,48.15,"VAPOR DIFFUSION, HANGING DROP",9.5,"9-14 % ethanol, 5 mM magnesium chloride, 3-7 mM manganese chloride, 10 mM TCEP and 0.1 M Tris, pH 9.5.",293.0,2017-12-17,2018-05-09,6BX6,1879.0,1.0,276.0,,,32.07,1.0,2.9,experimental,111.75,0.28,0.252,AMP-Activated protein kinase (AMPK) inhibition by SBI-0206965: alpha 2 kinase domain bound to SBI-0206965
8C8J,X-RAY DIFFRACTION,2.6,52.73,"VAPOR DIFFUSION, SITTING DROP",5.6,"PEG8000, sodium citrate, 1,4 dioxane, ethylene glycol, dimethyl sulphoxide",293.0,2023-01-20,2023-12-20,8C8J,6441.0,3.0,853.0,219.0,,106.64,1.0,2.1,experimental,61.79,0.238,0.2079,Long Interspersed Nuclear Element 1 (LINE-1) reverse transcriptase ternary complex with hybrid duplex and dTTP
,,,,VAPOR DIFFUSION,5.6,"PEG8000, sodium citrate, 1,4 dioxane, ethylene glycol, dimethyl sulphoxide",293.0,,,,,,,,,,,,,,,,
,,,,VAPOR DIFFUSION,5.6,"PEG8000, sodium citrate, 1,4 dioxane, ethylene glycol, dimethyl sulphoxide",293.0,,,,,,,,,,,,,,,,
,,,,VAPOR DIFFUSION,5.6,"PEG8000, sodium citrate, 1,4 dioxane, ethylene glycol, dimethyl sulphoxide",293.0,,,,,,,,,,,,,,,,
,,,,VAPOR DIFFUSION,5.6,"PEG8000, sodium citrate, 1,4 dioxane, ethylene glycol, dimethyl sulphoxide",293.0,,,,,,,,,,,,,,,,
,,,,VAPOR DIFFUSION,5.6,"PEG8000, sodium citrate, 1,4 dioxane, ethylene glycol, dimethyl sulphoxide",293.0,,,,,,,,,,,,,,,,
7KL0,X-RAY DIFFRACTION,2.3,46.54,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M 1,3-bis(tris(hydroxymethyl)methylamino)propane, 0.1 M Ammonium sulfate, 20% PEG 6000, 19mM HECAMEG",277.0,2020-10-28,2020-12-23,7KL0,4682.0,4.0,580.0,131.0,,67.46,2.0,2.4,experimental,23.803,0.2584,0.2071,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)
7XM7,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, SITTING DROP",,20% PEG3350 0.2M NH4NO3 PH6.2,277.0,2022-04-25,2022-06-22,7XM7,3971.0,4.0,532.0,72.0,,64.9,1.0,2.36,experimental,39.523,0.2566,0.208,Crystal Structure of the CBP in complex with the Y08188
5NGE,X-RAY DIFFRACTION,2.37,48.17,"VAPOR DIFFUSION, SITTING DROP",8.0,"25% (w/v) polyethylene glycol (PEG) 1500, 100 mM MMT pH 8.0",293.0,2017-03-17,2017-10-18,5NGE,5128.0,2.0,710.0,48.0,1.0,83.36,1.0,2.35,experimental,59.541,0.27214,0.21448,"Crystal structure of USP7 in complex with the non-covalent inhibitor, FT671"
5UQV,X-RAY DIFFRACTION,2.61,52.78,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 1000, 0.1M Tris-HCl 7.0",289.0,2017-02-08,2017-10-25,5UQV,5382.0,2.0,736.0,,,85.61,1.0,2.84,experimental,76.24,0.293,0.239,USP7 in complex with GNE6640 (4-(2-amino-4-ethyl-5-(1H-indazol-5-yl)pyridin-3-yl)phenol)
5UQX,X-RAY DIFFRACTION,2.46,49.94,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 1000, 0.1M Tris-HCl 7.0",289.0,2017-02-08,2017-10-25,5UQX,5795.0,2.0,738.0,235.0,,85.97,1.0,2.23,experimental,53.678,0.2234,0.1879,"USP7 in complex with GNE6776 (6'-amino-4'-ethyl-5'-(4-hydroxyphenyl)-N-methyl-[3,3'-bipyridine]-6-carboxamide)"
8F13,X-RAY DIFFRACTION,2.95,58.3,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Potassium sodium tartrate, 0.1 M tri-Sodium citrate pH 5.6, 2.0 M Ammonium sulfate",291.0,2022-11-04,2023-02-15,8F13,1175.0,2.0,114.0,150.0,,13.81,2.0,1.4,experimental,29.8097,0.2078,0.1744,"Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide, alternative C-terminus"
5EYM,X-RAY DIFFRACTION,2.61,52.85,"VAPOR DIFFUSION, HANGING DROP",8.0,"18 % PEG 4000, 100 mM Tris, 300 mM NaCl",293.0,2015-11-25,2016-08-17,5EYM,4718.0,2.0,718.0,17.0,,81.16,1.0,2.7,experimental,19.644,0.3077,0.2426,MEK1 IN COMPLEX WITH BI 847325
7B3M,X-RAY DIFFRACTION,2.24,45.02,"VAPOR DIFFUSION, HANGING DROP",,"MEK1 was prepared in buffer containing 25 mM Tris pH 7.5, 150 mM NaCl, 5% glycerol and 1 mM TCEP at a concentration of 10 mg/ml  mixed with 2 mM MgCl2 and 2 mM AMP-PNP, and incubated at room temperature for 30 minutes. Crystals were obtained from hanging drops by mixing a 1:1 ratio of protein solution with well solution containing 2 M AmSO4, 0.1 M NaCl and 0.1 M Bis-tris pH 6.1-6.2 at room temperature.",293.0,2020-12-01,2021-03-03,7B3M,4995.0,2.0,652.0,153.0,,74.72,1.0,2.3,experimental,26.21,0.268,0.217,MEK1 in complex with compound 6
6EJ2,X-RAY DIFFRACTION,2.28,46.0,"VAPOR DIFFUSION, SITTING DROP",,"18% PEG 5k MME, 0.2M AmI, 0.2M sodium citrate pH 6.5",293.0,2017-09-20,2018-04-18,6EJ2,3256.0,1.0,501.0,258.0,3.0,56.19,1.0,1.46,experimental,36.19,0.2318,0.2063,BACE1 compound 28
6EJ3,X-RAY DIFFRACTION,3.09,60.22,VAPOR DIFFUSION,,"11% PEG 6k, 100mM NaOAc pH 5.0",293.0,2017-09-20,2018-04-18,6EJ3,3117.0,1.0,501.0,185.0,3.0,56.19,1.0,1.94,experimental,54.91,0.217,0.194,BACE1 compound 23
6FGY,X-RAY DIFFRACTION,2.18,43.55,"VAPOR DIFFUSION, HANGING DROP",5.5,"15% PEG 1,500 in water",292.0,2018-01-11,2018-06-06,6FGY,3270.0,1.0,396.0,254.0,3.0,44.48,1.0,1.54,experimental,23.3,0.226,0.204,"Crystal Structure of Human BACE-1 in Complex with amino-1,4-oxazine compound 4"
6JMF,X-RAY DIFFRACTION,2.68,54.03,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M BisTrisPropane, 0.2 M Sodium Salfate, 15% PEG 3350, 10% Ethylene glycol",277.0,2019-03-08,2019-06-12,6JMF,3140.0,1.0,375.0,158.0,,43.04,1.0,2.0,experimental,26.576,0.24082,0.19737,Crystal structure of human tyrosine-protein kinase Fes/Fps in complex with compound 4
6GR8,X-RAY DIFFRACTION,2.11,41.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M sodium chloride, 25% PEG3350, 0.1 M HEPES pH 7.5",277.0,2018-06-10,2019-05-15,6GR8,3166.0,2.0,344.0,311.0,,41.06,2.0,1.75,experimental,18.932,0.21626,0.17648,Human AURKC INCENP complex bound to BRD-7880
6WJ7,X-RAY DIFFRACTION,2.17,43.2,"VAPOR DIFFUSION, HANGING DROP",,"0.8 M Lithium Chloride 0.1 M Tris: HCl, pH 8.5 32 % (w/v) PEG 4000",293.0,2020-04-13,2020-08-19,6WJ7,2049.0,2.0,248.0,233.0,,28.36,2.0,1.42,experimental,23.95,0.188,0.165,The structure of NTMT1 in complex with compound C2A
8UI6,X-RAY DIFFRACTION,2.51,51.0,"VAPOR DIFFUSION, HANGING DROP",9.5,0.1 M CHES pH 9.5 and 14-20% PEG 8000 (w/v),293.0,2023-10-10,2024-05-15,8UI6,4343.0,2.0,579.0,20.0,8.0,65.95,2.0,2.65,experimental,58.74,0.2315,0.1745,"X-ray crystal structure of Toxoplasma gondii GalNAc-T3 in complex with UDP-GalNAc, Mn2+, and Muc5AC-3,13"
7C41,X-RAY DIFFRACTION,3.18,61.31,"VAPOR DIFFUSION, HANGING DROP",,"polyethylene glycol 3350, 0.2 M potassium nitrate at pH 6.8",293.15,2020-05-14,2021-05-19,7C41,5626.0,5.0,706.0,83.0,,83.06,2.0,2.276,experimental,,0.2834,0.2603,KRAS G12V and H-REV107 peptide complex
6S11,X-RAY DIFFRACTION,3.24,62.08,"VAPOR DIFFUSION, SITTING DROP",,20% PEG6000 -- 10% ethylene glycol -- 0.2M ammonium chloride,277.0,2019-06-18,2019-06-26,6S11,5807.0,2.0,722.0,397.0,,84.91,1.0,2.445,experimental,36.0879,0.2102,0.1708,Crystal Structure of DYRK1A with small molecule inhibitor
4PS1,X-RAY DIFFRACTION,2.33,47.24,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Sodium citrate, pH 5.5, 36% PEG600, VAPOR DIFFUSION, SITTING DROP, temperature 295K",295.0,2014-03-06,2015-01-21,4PS1,8582.0,8.0,1120.0,855.0,,129.23,2.0,1.731,experimental,,0.1846,0.1522,Caspase-8 specific unnatural amino acid peptides
4OBS,X-RAY DIFFRACTION,2.27,45.93,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.18 M sodium potassium tartrate, 18% PEG3350, 50 mM ammonium sulfate, 10 mM HEPES, pH 7.5, 3% MPD, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2014-01-07,2015-01-14,4OBS,5063.0,1.0,627.0,143.0,1.0,72.25,1.0,2.26,experimental,17.692,0.23522,0.1921,Crystal structure of human alpha-L-iduronidase in the P212121 form
7YI7,X-RAY DIFFRACTION,2.28,45.95,VAPOR DIFFUSION,4.0,"12% w/v Polyethylene glycol 3,350,  100 mM Sodium malonate pH 4.0",293.0,2022-07-15,2022-12-07,7YI7,3683.0,2.0,460.0,13.0,1.0,52.12,2.0,2.8,experimental,58.406,0.28125,0.21259,Crystal structure of Human HPSE1 in complex with inhibitor
7YJC,X-RAY DIFFRACTION,2.39,48.59,VAPOR DIFFUSION,6.3,"20% w/v Polyethylene glycol 3,350,  200 mM Ammonium chloride; pH 6.3",293.0,2022-07-19,2022-12-07,7YJC,3673.0,2.0,460.0,53.0,1.0,51.95,2.0,2.3,experimental,42.901,0.33932,0.273,Crystal structure of Human HPSE1 in complex with inhibitor
5M8Q,X-RAY DIFFRACTION,2.98,58.76,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290.0,2016-10-29,2017-07-12,5M8Q,14735.0,4.0,1784.0,4.0,28.0,210.39,1.0,2.85,experimental,57.1239,0.2754,0.2079,Crystal structure of human tyrosinase related protein 1 mutant (T391V-R374S-Y362F) in complex with kojic acid
5M8R,X-RAY DIFFRACTION,2.95,58.29,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290.0,2016-10-29,2017-07-12,5M8R,14806.0,4.0,1784.0,39.0,28.0,210.93,1.0,2.4,experimental,39.0087,0.2486,0.2001,Crystal structure of human tyrosinase related protein 1 (T391V-R374S-Y362F) in complex with mimosine
5M8T,X-RAY DIFFRACTION,2.98,58.79,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290.0,2016-10-29,2017-07-12,5M8T,15515.0,4.0,1784.0,577.0,28.0,213.38,1.0,2.35,experimental,43.5907,0.2254,0.1828,Crystal structure of human tyrosinase related protein 1 (T391V-R374S-Y362F) in complex with tropolone
8PYR,X-RAY DIFFRACTION,1.98,37.86,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M Hepes (pH 7.0), 12% (v/w) medium weight PEG mix of PEG6K and PEG4K, 10% ethylene-glycol, and 0.2 M NDSB",288.0,2023-07-26,2024-03-06,8PYR,12032.0,8.0,1732.0,384.0,2.0,197.24,4.0,2.15,experimental,,0.2415,0.2197,Crystal structure of the dual T-loop phosphorylated Cdk7/CycH/Mat1 complex
5MJ6,X-RAY DIFFRACTION,2.39,58.98,"VAPOR DIFFUSION, SITTING DROP",8.5,"18.8% (w/v) PEG of mean MW 20000, 37.6% (v/v) PEG monomethyl ether of mean MW 500, 50.2 mM Bicine, 43.8 mM Trizma base (pH of buffer mixture: 8.5) and 0.282 M each of the following halogens: Sodium fluoride, Sodium bromide and Sodium iodide",291.0,2016-11-30,2017-04-05,5MJ6,15376.0,2.0,1762.0,240.0,2.0,217.25,1.0,2.53,experimental,,0.2292,0.1738,Ligand-induced conformational change of Insulin-regulated aminopeptidase: insights on catalytic mechanism and active site plasticity.
7MNX,X-RAY DIFFRACTION,2.34,47.54,"VAPOR DIFFUSION, HANGING DROP",,"15% w/v PEG3350, 0.125 M magnesium formate",294.0,2021-05-01,2022-06-15,7MNX,16979.0,12.0,2148.0,384.0,,248.82,2.0,2.4,experimental,75.3795,0.2301,0.1918,Crystal Structure of Nup358/RanBP2 Ran-binding domain 2 in complex with Ran-GPPNHP
6B91,X-RAY DIFFRACTION,4.66,73.6,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M K2HPO4, 45 mM NaH2PO4; drop contained 4 uL of protein solution (27 mg/mL) and 2 uL of reservoir solution, 25% ethylene glycol was used for cryo-protection",293.0,2017-10-09,2018-04-04,6B91,2414.0,1.0,294.0,207.0,1.0,33.83,1.0,1.94,experimental,48.654,0.21,0.181,Crystal structure of the N-terminal domain of human METTL16
4WZ6,X-RAY DIFFRACTION,2.28,46.12,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M Magnesium Chloride, 0.1M Tris-HCl pH8.5, 33% PEG 4000",283.0,2014-11-18,2015-11-11,4WZ6,2106.0,1.0,290.0,48.0,,32.92,1.0,2.05,experimental,36.735,0.2391,0.1951,"Human CFTR aa389-678 (NBD1), deltaF508 with three solubilizing mutations, bound ATP"
4UUZ,X-RAY DIFFRACTION,,46.7,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1M HEPES PH7, 21% PEG3000",293.0,2014-08-01,2015-02-11,4UUZ,1682.0,3.0,309.0,,,34.8,3.0,2.9,experimental,131.95,0.2303,,MCM2-histone complex
8AN8,X-RAY DIFFRACTION,2.52,51.27,"VAPOR DIFFUSION, SITTING DROP",,"0.4 M am sulfate, PCPT pH 5.5",293.0,2022-08-04,2022-08-31,8AN8,4176.0,2.0,592.0,83.0,,68.35,1.0,2.394,experimental,41.24,0.298,0.2411,Crystal structure of wild-type c-MET bound by compound 7.
4R7H,X-RAY DIFFRACTION,2.45,49.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG8K, 0.2M MGCL AND 0.1M TRIS, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-08-27,2015-08-12,4R7H,2500.0,1.0,343.0,43.0,,39.06,1.0,2.8001,experimental,,0.2481,0.2208,"Crystal structure of FMS KINASE domain with a small molecular inhibitor, PLX3397"
5TQ8,X-RAY DIFFRACTION,2.22,44.7,VAPOR DIFFUSION,7.5,"0.1 M Hepes, pH 7.5, 100 mM sodium acetate, 30% PEG-3350",293.0,2016-10-23,2017-01-11,5TQ8,2666.0,1.0,298.0,234.0,,35.44,1.0,1.59,experimental,30.44,0.1923,0.1655,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
7FTJ,X-RAY DIFFRACTION,1.98,37.72,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTJ,3230.0,1.0,362.0,297.0,,42.51,1.0,1.461,experimental,32.5084,0.2101,0.1905,Crystal Structure of apo human cyclic GMP-AMP synthase
7FTW,X-RAY DIFFRACTION,2.57,52.09,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTW,2958.0,1.0,362.0,28.0,,42.86,1.0,2.208,experimental,84.9179,0.2608,0.2116,Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-bromo-2-hydroxy-N-[[3-(1-methylpyrazol-4-yl)phenyl]methyl]benzamide
7FTY,X-RAY DIFFRACTION,2.58,52.41,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTY,2957.0,1.0,362.0,33.0,,42.83,1.0,2.3,experimental,93.7,0.29,0.23,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(4-phenylphenyl)methylamino]-5-propyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one:2,2,2-trifluoroacetic acid"
7FU8,X-RAY DIFFRACTION,2.65,53.64,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FU8,3161.0,1.0,362.0,164.0,,42.87,1.0,1.718,experimental,53.2198,0.2271,0.1917,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(2-chloro-5-pyridin-4-ylphenyl)methylamino]-5-propyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one"
7FUL,X-RAY DIFFRACTION,2.12,41.96,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUL,3003.0,1.0,362.0,47.0,,42.89,1.0,2.296,experimental,55.0316,0.2732,0.1905,Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-3-[3-(methanesulfonamido)propyl]benzimidazole-4-carboxylic acid
7FUR,X-RAY DIFFRACTION,2.05,39.86,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUR,3199.0,1.0,362.0,169.0,,43.42,1.0,1.7,experimental,48.0909,0.2379,0.1885,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 1-[9-(6-aminopyridin-3-yl)-6,7-dichloro-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl]-2-hydroxyethanone"
7FTF,X-RAY DIFFRACTION,2.14,42.59,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTF,3229.0,1.0,362.0,192.0,,42.53,1.0,1.508,experimental,56.9023,0.2137,0.1788,Crystal Structure of apo human cyclic GMP-AMP synthase
7FTH,X-RAY DIFFRACTION,2.12,42.04,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTH,3003.0,1.0,362.0,4.0,,43.14,1.0,2.55,experimental,88.903,0.2559,0.1908,Crystal Structure of human cyclic GMP-AMP synthase in complex with cGAMP
7FTI,X-RAY DIFFRACTION,2.57,52.11,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FTI,3004.0,1.0,362.0,73.0,,42.69,1.0,2.0,experimental,63.06,0.272,0.227,Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-(4-fluorophenyl)-2-methylpyrazole-3-carboxylic acid
7FTM,X-RAY DIFFRACTION,2.13,42.23,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTM,3127.0,1.0,362.0,136.0,,42.97,1.0,1.698,experimental,60.9431,0.2321,0.1901,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[2-(4-fluoroanilino)-1,3-thiazol-4-yl]acetic acid"
7FTO,X-RAY DIFFRACTION,2.58,52.24,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTO,2911.0,1.0,362.0,23.0,,42.78,1.0,2.4,experimental,116.9,0.272,0.225,Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-5-fluoro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FTP,X-RAY DIFFRACTION,2.41,48.92,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTP,2902.0,1.0,362.0,5.0,,42.82,1.0,2.48,experimental,118.03,0.277,0.224,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(4-chlorophenyl)-10,11-dimethoxy-7-methyl-2,4,6-triazatricyclo[7.3.1.05,13]trideca-1(12),2,4,7,9(13),10-hexaene"
7FTQ,X-RAY DIFFRACTION,2.12,42.09,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTQ,2982.0,1.0,362.0,45.0,,42.87,1.0,2.08,experimental,72.73,0.253,0.213,Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-5-fluoro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FTV,X-RAY DIFFRACTION,2.59,52.5,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTV,2997.0,1.0,362.0,86.0,,42.83,1.0,1.875,experimental,70.2773,0.2533,0.2123,Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-bromo-2-hydroxy-N-(quinolin-6-ylmethyl)benzamide
7FU0,X-RAY DIFFRACTION,2.47,50.1,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FU0,3075.0,1.0,362.0,104.0,,42.86,1.0,1.969,experimental,57.5598,0.2801,0.2156,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(4-phenylphenyl)methylamino]-5-(trifluoromethyl)-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one"
7FU1,X-RAY DIFFRACTION,2.59,52.48,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FU1,2971.0,1.0,362.0,55.0,,42.9,1.0,2.074,experimental,72.7849,0.2757,0.2225,Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-[3-[[(5-bromo-2-hydroxybenzoyl)amino]methyl]phenyl]-2-methylpyrazole-3-carboxylic acid
7FU2,X-RAY DIFFRACTION,2.41,48.97,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FU2,2885.0,1.0,362.0,32.0,,42.78,1.0,2.3,experimental,93.89,0.287,0.249,Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-5-fluoro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FU3,X-RAY DIFFRACTION,2.07,40.47,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FU3,2972.0,1.0,362.0,73.0,,42.77,1.0,1.822,experimental,58.5103,0.2644,0.1937,Crystal Structure of human cyclic GMP-AMP synthase in complex with 8-chloro-2-(2-hydroxyphenyl)quinoline-4-carboxylic acid
7FU4,X-RAY DIFFRACTION,2.58,52.32,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FU4,2954.0,1.0,362.0,77.0,,42.85,1.0,1.926,experimental,72.636,0.2588,0.2073,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(2-fluoro-4-phenylphenyl)methylamino]-5-propyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one"
7FU6,X-RAY DIFFRACTION,2.53,51.47,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FU6,2898.0,1.0,362.0,19.0,,42.85,1.0,2.37,experimental,123.27,0.263,0.233,Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-benzyl-6-(2-chloro-4-methylphenyl)indazole-4-carboxylic acid
7FU7,X-RAY DIFFRACTION,2.56,51.92,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FU7,2924.0,1.0,362.0,27.0,,42.86,1.0,2.24,experimental,98.7999,0.2463,0.2227,Crystal Structure of human cyclic GMP-AMP synthase
7FU9,X-RAY DIFFRACTION,2.07,40.69,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FU9,3073.0,1.0,362.0,161.0,,42.87,1.0,1.668,experimental,51.1398,0.2584,0.1949,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(2-chloro-5-pyridin-4-ylphenyl)methylamino]-5-propyl-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one"
7FUA,X-RAY DIFFRACTION,2.0,38.48,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FUA,3161.0,1.0,362.0,253.0,,42.57,1.0,1.444,experimental,40.3856,0.2135,0.1868,Crystal Structure of human cyclic GMP-AMP synthase in complex with phosphate
7FUB,X-RAY DIFFRACTION,2.14,42.52,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FUB,3104.0,1.0,362.0,89.0,,43.38,1.0,1.981,experimental,50.5886,0.273,0.1882,Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-3-(pyridin-4-ylmethyl)benzimidazole-4-carboxylic acid
7FUE,X-RAY DIFFRACTION,2.58,52.31,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FUE,2950.0,1.0,362.0,17.0,,42.93,1.0,2.169,experimental,96.5576,0.2696,0.2059,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[[2-chloro-5-(1-methylpyrazol-3-yl)phenyl]methylamino]-5-(2-phenylethyl)-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one"
7FUF,X-RAY DIFFRACTION,2.64,53.37,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FUF,3010.0,1.0,362.0,89.0,,42.92,1.0,1.919,experimental,68.7372,0.2451,0.2029,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 5-benzyl-2-[[2-chloro-5-(1-methylpyrazol-3-yl)phenyl]methylamino]-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one"
7FUH,X-RAY DIFFRACTION,1.98,37.99,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FUH,2986.0,1.0,362.0,75.0,,42.57,1.0,1.944,experimental,59.0069,0.2503,0.1889,Crystal Structure of human cyclic GMP-AMP synthase in complex with phosphate
7FUK,X-RAY DIFFRACTION,2.13,42.23,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUK,3146.0,1.0,362.0,165.0,,42.86,1.0,1.606,experimental,36.9652,0.236,0.1907,Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-3-(2-phenylethyl)benzimidazole-4-carboxylic acid
7FUM,X-RAY DIFFRACTION,2.61,52.82,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUM,2920.0,1.0,362.0,53.0,,42.95,1.0,2.06,experimental,87.78,0.269,0.233,Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(4-benzylpiperazin-1-yl)methyl]-6-(2-chloro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FUN,X-RAY DIFFRACTION,2.53,51.45,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUN,2951.0,1.0,362.0,58.0,,43.9,1.0,2.07,experimental,93.27,0.294,0.24,Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(4-benzylpiperazin-1-yl)methyl]-6-(2-chloro-4-methylphenyl)-1H-benzimidazole-4-carboxylic acid
7FUO,X-RAY DIFFRACTION,2.66,53.78,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUO,2952.0,1.0,362.0,47.0,,42.87,1.0,1.81,experimental,61.8423,0.2592,0.1968,"Crystal Structure of human cyclic GMP-AMP synthase in complex with 2-[(2-chlorophenyl)methylamino]-5-[(2-fluoroanilino)methyl]-4H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one"
7FUQ,X-RAY DIFFRACTION,2.14,42.54,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUQ,3051.0,1.0,362.0,179.0,,42.83,1.0,1.757,experimental,44.107,0.2337,0.1854,Crystal Structure of human cyclic GMP-AMP synthase in complex with 6-(2-chloro-4-methylphenyl)-3-phenylbenzimidazole-4-carboxylic acid
5GNH,X-RAY DIFFRACTION,2.2,44.08,"VAPOR DIFFUSION, HANGING DROP",,"100mM HEPES pH 7.5, 10% (v/v) polyethylene glycol 6000",295.0,2016-07-21,2017-07-26,5GNH,8330.0,2.0,1142.0,32.0,,132.35,1.0,2.6,experimental,53.843,0.2576,0.20295,Myotubularin-related protein 2
8GCY,X-RAY DIFFRACTION,2.13,42.25,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Imidazole, 0.1 M MES monohydrate pH 6.5
0.09 M Sodium nitrate, 0.09 M Sodium phosphate dibasic, 0.09M Ammonium sulfate  

12.5% v/v MPD; 12.5% PEG1000; 12.5% w/v PEG 3350",291.0,2023-03-03,2023-03-22,8GCY,3233.0,1.0,391.0,143.0,,45.98,1.0,1.81,experimental,32.702,0.22962,0.19491,Co-crystal structure of CBL-B in complex with N-Aryl isoindolin-1-one inhibitor
7VVB,X-RAY DIFFRACTION,1.15,63.04,"VAPOR DIFFUSION, HANGING DROP",4.0,PEG 5000 MME,278.0,2021-11-05,2022-05-18,7VVB,2244.0,2.0,712.0,257.0,,81.5,2.0,1.7,experimental,33.0566,0.197,0.1727,Crystal Structure of KRas4A(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1
5LAB,X-RAY DIFFRACTION,2.26,45.26,"VAPOR DIFFUSION, SITTING DROP",8.0,"Tris, PEG6000, NNGH, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2016-06-14,2016-08-10,5LAB,1508.0,1.0,159.0,236.0,,18.18,1.0,1.34,experimental,21.754,0.1945,0.15515,Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor NNGH
8JYG,X-RAY DIFFRACTION,2.36,47.77,VAPOR DIFFUSION,5.5,"25% w/v Polyethylene glycol 3,350,  100 mM BIS-TRIS pH 5.5",293.0,2023-07-03,2023-09-20,8JYG,3998.0,2.0,462.0,208.0,1.0,54.1,2.0,2.0,experimental,32.783,0.2092,0.1656,Crystal structure of Human HPSE1 in complex with inhibitor
5EBB,X-RAY DIFFRACTION,3.15,56.74,"VAPOR DIFFUSION, SITTING DROP",7.2,"2.08 M disodium malonate pH 7.2, 0.23 M sodium thiocyanate and 0.01 M TCEP",298.0,2015-10-19,2016-01-20,5EBB,10414.0,3.0,1230.0,301.0,6.0,142.71,1.0,2.6,experimental,21.786,0.25474,0.23712,Structure of human sphingomyelinase phosphodiesterase like 3A (SMPDL3A) with Zn2+
7KJA,X-RAY DIFFRACTION,2.6,52.74,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M MgCl2, 0.1 M Bis-Tris pH5.5, 25% PEG 3350",287.0,2020-10-26,2021-02-03,7KJA,6472.0,2.0,780.0,615.0,,89.41,1.0,1.75,experimental,33.04,0.2175,0.1884,Crystal structure of the EphA2 intracellular KD-SAM domains
7KJC,X-RAY DIFFRACTION,2.55,51.69,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M MgCl2, 0.1 M Bis-Tris pH5.5, 25% PEG 3350",287.0,2020-10-26,2021-02-03,7KJC,6277.0,2.0,780.0,343.0,,89.4,1.0,2.3,experimental,43.08,0.2257,0.1884,Crystal structure of the EphA2 S901E mutant intracellular KD-SAM domains
5SAZ,X-RAY DIFFRACTION,2.4,48.78,"VAPOR DIFFUSION, SITTING DROP",6.5,"7.6 mg/mL protein in 20mM HEPES/NaOH pH7.5, 5mM DTT, 5% glycerol, 0.1M NaCl mixed with reservoir consisting of 0.1M MES/NaOH pH 6.5, 0.2M KI, 25% PEG 4000",293.0,2021-06-22,2022-06-29,5SAZ,2607.0,1.0,321.0,225.0,1.0,37.22,1.0,1.8,experimental,36.074,0.2244,0.1874,"DDR1, 3-chloro-N-[4-chloro-3-(1H-pyrrolo[2,3-b]pyridin-5-ylcarbamoyl)phenyl]-4-(2-hydroxyethylamino)benzamide, 1.802A, P212121, Rfree=22.2%"
5UAD,X-RAY DIFFRACTION,2.11,44.77,"VAPOR DIFFUSION, SITTING DROP",7.2,"19.% PEG 3350, 12.% Isopropanol, 0.1M HEPES pH 7.2",273.0,2016-12-19,2017-05-31,5UAD,2469.0,1.0,343.0,116.0,,39.03,1.0,2.25,experimental,49.075,0.2517,0.1961,MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
7V3R,X-RAY DIFFRACTION,2.19,43.92,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES, 8% isopropanol, 3 mM TECP, 16% PEG4000, pH7.5",293.0,2021-08-11,2022-08-17,7V3R,2475.0,1.0,319.0,216.0,,36.54,1.0,1.7,experimental,18.6094,0.1896,0.1675,Crystal structure of CMET in complex with a novel inhibitor
7V3S,X-RAY DIFFRACTION,2.18,43.67,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES, 8% isopropanol, 3mM TECP, 16% PEG4000, pH 7.5",293.0,2021-08-11,2022-08-17,7V3S,2530.0,1.0,319.0,281.0,,36.55,1.0,1.9,experimental,23.4174,0.1954,0.164,Crystal structure of CMET in complex with a novel inhibitor
6CZK,X-RAY DIFFRACTION,3.93,68.73,"VAPOR DIFFUSION, SITTING DROP",4.2,"0.1 M sodium phosphate dibasic, citric acid, pH 4.2, 2.0 M ammonium sulfate",293.0,2018-04-09,2018-08-08,6CZK,2957.0,1.0,335.0,333.0,4.0,39.45,1.0,2.001,experimental,,0.1996,0.1705,Crystal structure of wild-type human pro-cathepsin H
5CSF,X-RAY DIFFRACTION,2.32,47.04,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Hepes 7, 150 mM NaCl, 20% PEG6000",296.0,2015-07-23,2015-11-11,5CSF,1512.0,3.0,245.0,4.0,,28.12,2.0,2.4,experimental,,0.2907,0.2432,S100B-RSK1 crystal structure A
5CSI,X-RAY DIFFRACTION,2.35,47.62,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Hepes 7, 150 mM NaCl, 20% PEG6000",296.0,2015-07-23,2015-11-11,5CSI,1568.0,3.0,239.0,40.0,,27.44,2.0,2.13,experimental,,0.25,0.2048,S100B-RSK1 crystal structure A'
5CSJ,X-RAY DIFFRACTION,2.26,45.63,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Hepes 7, 150 mM NaCl, 20% PEG6000",296.0,2015-07-23,2015-11-11,5CSJ,1570.0,3.0,232.0,14.0,,26.65,2.0,2.7,experimental,,0.2764,0.2034,S100B-RSK1 crystal structure B
5CSN,X-RAY DIFFRACTION,2.5,50.76,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Hepes 7, 150 mM NaCl, 20% PEG6000",296.0,2015-07-23,2015-11-11,5CSN,1576.0,3.0,230.0,,,26.38,2.0,2.95,experimental,,0.2785,0.2514,S100B-RSK1 crystal structure C
5URM,X-RAY DIFFRACTION,3.32,62.92,"VAPOR DIFFUSION, HANGING DROP",,"1.25-1.5M sodium malonate, 100mM sodium citrate pH 5.0-5.3, 10mg/ml BRR2",293.0,2017-02-11,2017-07-19,5URM,27571.0,2.0,3476.0,102.0,,398.07,1.0,2.8,experimental,,0.2598,0.2121,Crystal structure of human BRR2 in complex with T-1206548
5HQ0,X-RAY DIFFRACTION,2.6,51.5,"VAPOR DIFFUSION, SITTING DROP",6.7,"0.1 M MES pH6.7, 6.55 MPD, 5% PEG4K, 10% PEG 1K",277.0,2016-01-21,2016-03-02,5HQ0,5551.0,3.0,659.0,368.0,,76.57,3.0,2.3,experimental,48.7092,0.2518,0.186,"Ternary complex of human proteins CDK1, Cyclin B and CKS2, bound to an inhibitor"
7U30,X-RAY DIFFRACTION,2.98,58.74,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M sodium citrate pH 6.0, 0.2 M sodium acetate, 10-12% PEG 4000",277.0,2022-02-25,2022-06-01,7U30,7578.0,2.0,970.0,94.0,1.0,109.46,2.0,2.6,experimental,89.67,0.208,0.21,PRMT5:MEP50 Complexed with Cyclonucleoside Compound 1
8BIN,X-RAY DIFFRACTION,1.97,37.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 10% ethylene glycol, 0.2M potassium thiocyanate",293.0,2022-11-02,2022-11-23,8BIN,2287.0,1.0,306.0,120.0,,35.26,1.0,1.5,experimental,17.938,0.17095,0.13166,Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with MR21
8BK0,X-RAY DIFFRACTION,1.97,37.43,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 10% ethylene glycol, 0.1M bis-tris-propane pH 6.5, 0.2M sodium nitrate",293.0,2022-11-08,2022-11-16,8BK0,2294.0,1.0,306.0,114.0,,35.31,1.0,1.7,experimental,21.743,0.19476,0.16676,Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with LDN-211904
8YHR,X-RAY DIFFRACTION,3.78,67.43,"VAPOR DIFFUSION, HANGING DROP",,"Sodium acetate (pH 4.8), Ammonium sulfate, Glycerol",293.0,2024-02-28,2024-05-22,8YHR,3084.0,1.0,387.0,270.0,,43.69,1.0,1.7,experimental,,0.1645,0.1459,DHODH in complex with furocoumavirin
6D5Y,X-RAY DIFFRACTION,2.11,41.81,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 10% isopropanol, and 0.1 M Hepes pH 7.5",277.0,2018-04-19,2019-02-27,6D5Y,2757.0,1.0,348.0,,,40.53,1.0,2.86,experimental,,0.2719,0.2197,Crystal structure of ERK2 G169D mutant
4Y72,X-RAY DIFFRACTION,2.45,49.74,VAPOR DIFFUSION,6.7,"Conditions around 0.1M MES/imidazole buffer (pH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K
Protein at 10-12 mg/ml",277.0,2015-02-13,2015-08-12,4Y72,5551.0,3.0,659.0,368.0,,76.57,3.0,2.3,experimental,48.7092,0.2519,0.1861,Human CDK1/CyclinB1/CKS2 With Inhibitor
6GU3,X-RAY DIFFRACTION,2.42,49.14,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES/IMIDAZOLE BUFFER (PH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K PROTEIN AT 10-12 MG/ML + 0.5mM Inhibitor",277.0,2018-06-19,2018-12-05,6GU3,5227.0,3.0,659.0,62.0,,76.59,3.0,2.65,experimental,45.621,0.25824,0.19485,CDK1/CyclinB/Cks2 in complex with AZD5438
7FHS,X-RAY DIFFRACTION,2.62,53.09,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Bis-Tris propane (pH 8.0), 200 mM Sodium fluoride and 18 % (w/v) PEG 3350",293.0,2021-07-30,2022-03-23,7FHS,11546.0,4.0,1444.0,252.0,,169.62,1.0,2.42,experimental,52.568,0.27494,0.23206,Crystal structure of DYRK1A in complex with RD0392
5WU1,X-RAY DIFFRACTION,2.53,51.43,"VAPOR DIFFUSION, HANGING DROP",,"Hepes pH 7.5, PEG3350, Tacsimate",277.0,2016-12-16,2017-05-31,5WU1,7569.0,2.0,1146.0,,,124.58,1.0,2.8,experimental,76.8,0.2969,0.2529,"Crystal structure of apo human Tut1, form I"
5WU2,X-RAY DIFFRACTION,2.53,51.3,"VAPOR DIFFUSION, HANGING DROP",,"Hepes pH 7.5, PEG3350, Tacsimate",277.0,2016-12-16,2017-05-31,5WU2,7584.0,2.0,1146.0,,,125.95,1.0,2.95,experimental,68.65,0.2938,0.246,"Crystal structure of human Tut1 bound with BaUTP, form I"
6D31,X-RAY DIFFRACTION,2.09,41.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM bis-tris, 25% SOKALAN CP 42, 0.9% tetrahydrofuran",289.0,2018-04-14,2018-09-05,6D31,1861.0,1.0,191.0,213.0,,22.66,1.0,1.2,experimental,,0.181,0.147,Structure of human Usb1 with adenosine 5'-monophosphate
6FLH,X-RAY DIFFRACTION,3.74,67.12,"VAPOR DIFFUSION, HANGING DROP",,0.1 M sodium acetate pH 4.6 and 2 M ammonium sulfate,293.0,2018-01-25,2018-11-07,6FLH,972.0,1.0,118.0,94.0,,12.08,1.0,1.79,experimental,31.433,0.1966,0.1698,"Monomeric Human Cu,Zn Superoxide dismutase, SOD1 7+7, apo form"
5V24,X-RAY DIFFRACTION,3.14,60.84,"VAPOR DIFFUSION, SITTING DROP",6.0,"6% polyethylene glycol 2000 MME, 0.1M MES, pH 6.0",277.0,2017-03-02,2017-03-29,5V24,4187.0,2.0,542.0,60.0,,61.65,1.0,2.5,experimental,69.477,0.2659,0.2343,Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy
5TH9,X-RAY DIFFRACTION,3.73,67.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"Drop:
8% (w/v) PEG 8000
0.1 M HEPES, pH 7.5
50% (v/v) Silver Bullet 21 (Hampton Research)

Reservoir:
22.5% (w/v) PEG 8000
0.1 M HEPES, pH 7.5",293.0,2016-09-29,2017-03-15,5TH9,13578.0,9.0,2025.0,140.0,10.0,223.7,3.0,2.999,experimental,42.7273,0.257,0.2182,"Structure determination of a potent, selective antibody inhibitor of human MMP9 (GS-5745 bound to MMP-9)"
5NJZ,X-RAY DIFFRACTION,1.95,36.96,"VAPOR DIFFUSION, SITTING DROP",7.0,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH7.0",291.0,2017-03-31,2017-06-07,5NJZ,2523.0,1.0,306.0,252.0,,34.93,1.0,1.768,experimental,,0.1988,0.1632,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1g
5NK0,X-RAY DIFFRACTION,1.92,36.06,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.175 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291.0,2017-03-31,2017-06-07,5NK0,2440.0,1.0,306.0,175.0,,34.93,1.0,1.597,experimental,,0.1938,0.1635,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1j
5NK1,X-RAY DIFFRACTION,1.95,36.8,"VAPOR DIFFUSION, SITTING DROP",6.0,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Bis-Tris pH6.0",291.0,2017-03-31,2017-06-07,5NK1,2670.0,1.0,306.0,277.0,,34.96,1.0,1.548,experimental,,0.1931,0.1669,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1k
5NK2,X-RAY DIFFRACTION,1.97,37.68,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.3 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291.0,2017-03-31,2017-06-07,5NK2,2665.0,1.0,306.0,221.0,,35.01,1.0,1.649,experimental,,0.1887,0.1563,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2b
5NK3,X-RAY DIFFRACTION,1.85,33.34,"VAPOR DIFFUSION, SITTING DROP",6.0,"37.5% MPD/PEG1000/PEG3350 (MD), 0.3 M Amino Acids Mix (MD), 0.1 M MES pH6.0",291.0,2017-03-31,2017-06-07,5NK3,2469.0,1.0,306.0,130.0,,34.98,1.0,1.586,experimental,,0.2278,0.1932,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1l
5NK4,X-RAY DIFFRACTION,1.97,37.58,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.275 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291.0,2017-03-31,2017-06-07,5NK4,2670.0,1.0,306.0,228.0,,35.03,1.0,1.45,experimental,,0.197,0.169,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2c
5NK5,X-RAY DIFFRACTION,1.97,37.59,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.2 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291.0,2017-03-31,2017-06-07,5NK5,2677.0,1.0,306.0,254.0,,34.94,1.0,1.329,experimental,,0.2015,0.1801,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1m
5NK6,X-RAY DIFFRACTION,1.98,37.8,"VAPOR DIFFUSION, SITTING DROP",5.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Bis-Tris pH5.5",291.0,2017-03-31,2017-06-07,5NK6,2698.0,1.0,306.0,257.0,,34.95,1.0,1.267,experimental,,0.1858,0.1714,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2d
5NK7,X-RAY DIFFRACTION,1.97,37.49,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.25 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291.0,2017-03-31,2017-06-07,5NK7,2601.0,1.0,306.0,227.0,,34.95,1.0,1.889,experimental,,0.1995,0.169,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2a
5NK8,X-RAY DIFFRACTION,1.93,36.23,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.075 M Carboxylic Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291.0,2017-03-31,2017-06-07,5NK8,2400.0,1.0,306.0,172.0,,35.0,1.0,1.761,experimental,,0.2056,0.1658,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2f
5NK9,X-RAY DIFFRACTION,1.96,37.36,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH6.5",291.0,2017-03-31,2017-06-07,5NK9,2653.0,1.0,306.0,261.0,,34.96,1.0,1.588,experimental,,0.1945,0.1621,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2e
5NKA,X-RAY DIFFRACTION,1.99,38.23,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.25 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291.0,2017-03-31,2017-06-07,5NKA,2519.0,1.0,306.0,227.0,,35.04,1.0,1.377,experimental,,0.182,0.1599,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2g
5NKB,X-RAY DIFFRACTION,1.97,37.43,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH6.5",291.0,2017-03-31,2017-06-07,5NKB,2687.0,1.0,306.0,281.0,,35.1,1.0,1.5,experimental,,0.191,0.159,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 4a
5NKC,X-RAY DIFFRACTION,1.97,37.49,"VAPOR DIFFUSION, SITTING DROP",6.0,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M MES pH6.0",291.0,2017-03-31,2017-06-07,5NKC,2659.0,1.0,306.0,241.0,,35.01,1.0,1.448,experimental,,0.191,0.1602,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2h
5NKD,X-RAY DIFFRACTION,1.96,37.22,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH6.5",291.0,2017-03-31,2017-06-07,5NKD,2638.0,1.0,306.0,231.0,,35.02,1.0,1.408,experimental,,0.224,0.1843,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2i
5NKE,X-RAY DIFFRACTION,1.98,37.72,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.3 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291.0,2017-03-31,2017-06-07,5NKE,2688.0,1.0,306.0,255.0,,35.01,1.0,1.39,experimental,,0.204,0.172,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3a
5NKF,X-RAY DIFFRACTION,1.96,37.39,"VAPOR DIFFUSION, SITTING DROP",6.0,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Bis-Tris pH6.0",291.0,2017-03-31,2017-06-07,5NKF,2855.0,1.0,306.0,326.0,,35.0,1.0,1.099,experimental,,0.1866,0.1707,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3b
5NKG,X-RAY DIFFRACTION,1.95,36.96,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Tris pH6.5",291.0,2017-03-31,2017-06-07,5NKG,2813.0,1.0,306.0,358.0,,34.96,1.0,1.1,experimental,,0.19,0.172,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3d
5NKH,X-RAY DIFFRACTION,1.96,37.29,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291.0,2017-03-31,2017-06-07,5NKH,2777.0,1.0,306.0,294.0,,35.02,1.0,1.29,experimental,,0.196,0.17,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3e
5NKI,X-RAY DIFFRACTION,1.94,36.45,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH6.5",291.0,2017-03-31,2017-06-07,5NKI,2483.0,1.0,306.0,222.0,,34.97,1.0,1.675,experimental,,0.1894,0.1604,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 4b
7KJB,X-RAY DIFFRACTION,2.91,57.78,"VAPOR DIFFUSION, SITTING DROP",7.0,"4.5% Tacsimate, 0.09 M HEPES pH 7.0, 9% PEG-MME 5K, 0.1 M CsCl",287.0,2020-10-26,2021-02-03,7KJB,2913.0,1.0,390.0,30.0,,44.18,1.0,2.8,experimental,57.16,0.246,0.1976,Crystal structure of the EphA2 S897E/S901E mutant intracellular KD-SAM domains
8BIO,X-RAY DIFFRACTION,1.97,37.46,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 10% ethylene glycol, 0.2M potassium thiocyanate",293.0,2022-11-02,2022-11-23,8BIO,2417.0,1.0,306.0,173.0,,35.7,1.0,1.6,experimental,21.313,0.1986,0.16312,Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with MRAL5
8QQY,X-RAY DIFFRACTION,1.97,37.49,VAPOR DIFFUSION,,"20% PEG3350
10% ethylene glycol
0.2M sodium iodide",293.0,2023-10-06,2023-11-22,8QQY,2395.0,1.0,306.0,150.0,,35.7,1.0,1.8,experimental,19.295,0.22328,0.189,Crystal structure of human Ephrin type-A receptor 2 (EPHA2) Kinase domain in complex with JG165
6VGL,X-RAY DIFFRACTION,3.05,59.72,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris, pH 5.5, 0.2 M sodium chloride, 25% PEG3350",291.0,2020-01-08,2021-01-13,6VGL,10594.0,4.0,1232.0,744.0,,147.05,1.0,1.9,experimental,44.5967,0.2168,0.1803,JAK2 JH1 in complex with ruxolitinib
6VNK,X-RAY DIFFRACTION,3.04,59.56,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNK,10264.0,4.0,1232.0,462.0,,147.05,1.0,2.0,experimental,51.6178,0.2442,0.2183,JAK2 JH1 in complex with PN4-073
7JJM,X-RAY DIFFRACTION,3.26,62.29,"VAPOR DIFFUSION, HANGING DROP",,"0.7 M sodium citrate, 0.01M DTT, 0.1M sodium HEPES pH 7",295.0,2020-07-27,2020-08-05,7JJM,3396.0,2.0,496.0,103.0,,54.15,2.0,2.06,experimental,50.7747,0.259,0.2199,Crystal structure of Importin alpha 2 in complex with LSD1 NLS
4XGM,X-RAY DIFFRACTION,2.81,56.27,"VAPOR DIFFUSION, HANGING DROP",7.0,"HEPES, PEG 6000, magnesium chloride",298.0,2014-12-31,2015-05-13,4XGM,2948.0,1.0,379.0,149.0,,44.37,1.0,1.98,experimental,63.5861,0.2263,0.1929,Structure of the nuclease subunit of human mitochondrial RNase P (MRPP3) at 1.98A
6N0P,X-RAY DIFFRACTION,2.95,58.37,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Tris ph 7.7, 12% PEG8000, and 100 mM NaCl",291.0,2018-11-07,2019-09-04,6N0P,4569.0,2.0,546.0,337.0,,63.28,1.0,2.37,experimental,39.06,0.233,0.194,BRAF in complex with N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (LXH254)
6N0Q,X-RAY DIFFRACTION,3.09,60.17,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Tris pH 8.3, 15% PEG8000, and 25% glycerol",291.0,2018-11-07,2019-10-23,6N0Q,4533.0,2.0,562.0,344.0,,64.68,1.0,2.04,experimental,42.23,0.213,0.181,"BRAF in complex with N-(4-methyl-3-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)phenyl)-3-(trifluoromethyl)benzamide."
6HKS,X-RAY DIFFRACTION,3.47,64.5,"VAPOR DIFFUSION, SITTING DROP",,"20% w/v PEG 3350
0.2 mM KI
pH 7",277.0,2018-09-07,2019-05-22,6HKS,4993.0,12.0,750.0,234.0,,85.38,2.0,2.19441072073,experimental,56.9100392383,0.246797249095,0.194138416618,Crystal structure of the PTPN3 PDZ domain bound to the HPV16 E6 oncoprotein C-terminal peptide
5KVT,X-RAY DIFFRACTION,2.8,55.9,VAPOR DIFFUSION,6.5,"VAPOR DIFFUSION, HANGING DROP, 
WELL SOLUTION: 0.1M BIS-TRIS, PH6.5, 2.6-3.0M AMMONIUMACETATE
TEMPERATURE 277K",277.0,2016-07-15,2017-12-27,5KVT,2364.0,1.0,293.0,11.0,,34.16,1.0,2.45,experimental,63.92,0.23856,0.19249,THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
5NZZ,X-RAY DIFFRACTION,3.06,59.83,"VAPOR DIFFUSION, HANGING DROP",8.5,"20% PEG3350, 0.1M magensium chloride, 0.1M magnesium sulphate, 0.1M Tris pH8.5",277.0,2017-05-15,2018-05-30,5NZZ,22057.0,8.0,3456.0,42.0,,387.38,2.0,2.6,experimental,61.1,0.2707,0.2187,Crystal structure of phosphorylated p38aMAPK in complex with TAB1
9EXY,X-RAY DIFFRACTION,2.33,47.15,"VAPOR DIFFUSION, SITTING DROP",,"Morpheus screen, condition G9",293.0,2024-04-09,2024-05-29,9EXY,2429.0,2.0,364.0,217.0,1.0,41.27,1.0,1.699,experimental,41.59,0.2479,0.2214,Crystal structure of the PWWP1 domain of NSD2 bound by compound 34.
4XX3,X-RAY DIFFRACTION,3.22,61.86,"VAPOR DIFFUSION, HANGING DROP",,"Reservoir 15% PEG3350, 625 mM NaCl and citrate buffer pH 4.6",295.0,2015-01-29,2015-02-18,4XX3,5479.0,2.0,680.0,277.0,6.0,75.76,1.0,2.4,experimental,45.9629,0.2243,0.2071,Renin in complex with (S)-1-(3-(benzylcarbamoyl)benzyl)-4-isopropyl-4-methyl-6-oxotetrahydropyrimidin-2(1H)-iminium
4XX4,X-RAY DIFFRACTION,3.25,62.17,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG3350, 625 mM NaCl and citrate buffer pH 4.6",295.0,2015-01-29,2015-02-18,4XX4,5410.0,2.0,680.0,207.0,6.0,75.59,1.0,2.4,experimental,46.9442,0.2293,0.2098,Renin in complex with (4S)-4-isopropyl-4-methyl-6-oxo-1-(3-(2-oxo-4-phenylpyrrolidin-1-yl)benzyl)tetrahydropyrimidin-2(1H)-iminium
7YRU,X-RAY DIFFRACTION,2.21,44.41,VAPOR DIFFUSION,,"2% Tacsimate pH 7.0, 0.1 M HEPES pH 7.5, 20% PEG 3350",298.0,2022-08-10,2023-05-17,7YRU,3913.0,3.0,551.0,55.0,9.0,59.97,3.0,2.6,experimental,49.498,0.2708,0.2453,ALK2 antibody complex
5VAL,X-RAY DIFFRACTION,2.84,56.65,"VAPOR DIFFUSION, HANGING DROP",8.4,"100 mM Tris ph 8.4, 12% PEG8000, and 100mM NaCl",291.0,2017-03-27,2017-06-28,5VAL,4371.0,2.0,562.0,272.0,,64.69,1.0,2.26,experimental,38.11,0.217,0.181,BRAF in Complex with N-(3-(tert-butyl)phenyl)-4-methyl-3-(6-morpholinopyrimidin-4-yl)benzamide
6ESM,X-RAY DIFFRACTION,2.08,40.82,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein: human MMP9 E402Q  300 micro-M
Precipitant: 31.5% MPEG 5K; .14 M imidazole piperidine; pH 8.5
Cryoprotectant: 40% CM2 (25% di-ethylene glycol + 25% glycerol + 25% 1,2-propanediol), 10% PEG 10K, 200 milli-M NaCl, 100milli-M PCTP 50/50",293.0,2017-10-23,2018-05-16,6ESM,1619.0,1.0,160.0,273.0,,18.66,1.0,1.104,experimental,,0.1722,0.1557,Crystal structure of MMP9 in complex with inhibitor BE4.
8BOX,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2022-11-15,2024-06-05,8BOX,6403.0,3.0,1024.0,,,113.69,3.0,2.82,experimental,,0.2287,0.2196,LSD1-CoREST in complex with AW4 and SNAG peptide
8F59,X-RAY DIFFRACTION,5.65,78.22,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2022-11-12,2024-06-12,8F59,6397.0,3.0,1024.0,,,113.61,3.0,2.8,experimental,,0.2344,0.2206,LSD1-CoREST in complex with AW2 and SNAG peptide
8ECR,X-RAY DIFFRACTION,2.15,42.92,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% PEG8000, 200 mM Magnesium chloride, 100 mM Tris-HCl pH 8.5",293.15,2022-09-02,2023-09-06,8ECR,3001.0,2.0,370.0,327.0,,43.23,1.0,1.42,experimental,24.62,0.1688,0.1471,KRAS4b WT 1-185 bound to GDP-Mg2+
4XCT,X-RAY DIFFRACTION,2.07,40.47,"VAPOR DIFFUSION, SITTING DROP",8.5,"protein: hMMP-9-WT at 337 micro-M with 120 milli-M acetohydroxamic acid. 
precipitant: 40.5% MPEG 5,000, 180 mM imidazole piperidine, pH 8.5.
Cryoprotectant: 40% CryoProtX-C1, 10% PEG 10K, 10% PCTP 50/50",293.0,2014-12-18,2015-04-22,4XCT,1688.0,1.0,157.0,239.0,,18.97,1.0,1.3,experimental,,0.231,0.1668,Crystal structure of a hydroxamate based inhibitor ARP101 (EN73) in complex with the MMP-9 catalytic domain.
8XPZ,X-RAY DIFFRACTION,2.18,43.63,"VAPOR DIFFUSION, SITTING DROP",,"0.5M LiCl, 0.1M Tris-HCl pH8.5, 28% PEG 6000",293.0,2024-01-04,2024-01-24,8XPZ,2436.0,1.0,332.0,39.0,,38.01,1.0,2.6,experimental,58.329,0.2733,0.2009,The Crystal Structure of TTBK1 from Biortus.
7FUI,X-RAY DIFFRACTION,2.32,46.89,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUI,3141.0,1.0,362.0,143.0,,43.57,1.0,1.74,experimental,39.251,0.2714,0.2081,"Crystal Structure of human cyclic GMP-AMP synthase in complex with (Z)-2-cyano-N-[4-(3-fluorophenyl)-5-methylsulfonylpyrimidin-2-yl]-3-hydroxy-3-(5-methyl-1,2-oxazol-4-yl)prop-2-enamide"
5PAE,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAE,2841.0,2.0,318.0,376.0,9.0,36.17,2.0,1.45,experimental,19.383,0.1875,0.1786,"Crystal Structure of Factor VIIa in complex with (2S)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]propanamide"
5PAG,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAG,2778.0,2.0,318.0,288.0,8.0,35.88,2.0,1.36,experimental,27.39,0.1937,0.1826,"Crystal Structure of Factor VIIa in complex with (2R)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-methylbutanamide;hydrobromide"
5PAR,X-RAY DIFFRACTION,3.78,67.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAR,2762.0,2.0,318.0,231.0,9.0,36.11,2.0,2.1,experimental,37.758,0.2195,0.1821,Crystal Structure of Factor VIIa in complex with 1H-benzimidazol-2-amine
5PB2,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-16,2017-06-21,5PB2,2887.0,2.0,318.0,346.0,8.0,35.76,2.0,1.45,experimental,17.747,0.2036,0.1958,"Crystal Structure of Factor VIIa in complex with 2-phenyl-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-3-ol"
5PB5,X-RAY DIFFRACTION,3.75,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-16,2017-06-21,5PB5,2762.0,2.0,318.0,314.0,8.0,35.87,2.0,1.84,experimental,23.166,0.1998,0.1853,"human factor VIIa in complex with 1-[[3-[5-hydroxy-4-(7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea at 1.84A"
5PA8,X-RAY DIFFRACTION,3.77,67.36,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PA8,2876.0,2.0,318.0,329.0,9.0,35.77,2.0,1.98,experimental,33.369,0.2041,0.1721,Crystal Structure of Factor VIIa in complex with cyclohexanamine
5PA9,X-RAY DIFFRACTION,3.76,67.26,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PA9,2908.0,2.0,318.0,343.0,10.0,35.68,2.0,1.55,experimental,18.289,0.1959,0.1836,Crystal Structure of Factor VIIa in complex with phenylmethanamine;hydrochloride
5PAA,X-RAY DIFFRACTION,3.76,67.25,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAA,2810.0,2.0,318.0,289.0,9.0,35.86,2.0,1.98,experimental,30.461,0.2145,0.1846,Crystal Structure of Factor VIIa in complex with cyclohexylmethanamine
5PAB,X-RAY DIFFRACTION,3.75,67.21,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAB,2792.0,2.0,318.0,288.0,8.0,36.25,2.0,1.99,experimental,26.796,0.2196,0.186,"Crystal Structure of Factor VIIa in complex with 1-[[3-[2-hydroxy-3-(1H-pyrrolo[3,2-c]pyridin-2-yl)phenyl]phenyl]methyl]-3-phenylurea"
5PAC,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAC,2908.0,2.0,318.0,391.0,8.0,36.04,2.0,1.5,experimental,15.859,0.2111,0.2018,human factor VIIa in complex with 5-hydroxy-N-(4-oxo-3H-quinazolin-6-yl)-1-[3-[(phenylcarbamoylamino)methyl]phenyl]pyrazole-4-carboxamide at 1.50A
5PAI,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAI,2819.0,2.0,318.0,342.0,8.0,35.95,2.0,1.73,experimental,19.972,0.1815,0.1638,"human factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-1-[3-[[(3,5-dimethyl-1,2-oxazol-4-yl)carbamoylamino]methyl]phenyl]-5-hydroxypyrazole-4-carboxamide at 1.73A"
5PAN,X-RAY DIFFRACTION,3.77,67.39,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAN,2816.0,2.0,318.0,339.0,8.0,36.12,2.0,1.62,experimental,23.252,0.179,0.1614,"Crystal Structure of Factor VIIa in complex with 5-hydroxy-N-(3-oxo-1,2-dihydroisoindol-5-yl)-1-[3-[(phenylcarbamoylamino)methyl]phenyl]pyrazole-4-carboxamide"
5PAO,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAO,2799.0,2.0,318.0,332.0,9.0,36.22,2.0,1.4,experimental,23.949,0.1882,0.1781,"Crystal Structure of Factor VIIa in complex with (2S)-2,3-dihydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]propanamide;hydrobromide"
5PAQ,X-RAY DIFFRACTION,3.82,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAQ,2929.0,2.0,318.0,385.0,9.0,36.04,2.0,1.59,experimental,27.325,0.194,0.1735,Crystal Structure of Factor VIIa in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(3-ethoxy-4-propan-2-yloxyphenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone
5PAS,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAS,2927.0,2.0,318.0,381.0,10.0,35.9,2.0,1.48,experimental,16.39,0.2063,0.1998,"Crystal Structure of Factor VIIa in complex with (2S)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylpropanamide"
5PAU,X-RAY DIFFRACTION,3.77,67.38,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAU,2914.0,2.0,318.0,363.0,9.0,36.08,2.0,1.55,experimental,25.033,0.204,0.1808,"Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]phenyl]acetamide;2,2,2-trifluoroacetic acid"
5PAY,X-RAY DIFFRACTION,3.76,67.24,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAY,2955.0,2.0,318.0,358.0,9.0,36.09,2.0,1.66,experimental,20.014,0.1943,0.182,"Crystal Structure of Factor VIIa in complex with 1-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea"
5PB1,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PB1,2917.0,2.0,318.0,378.0,9.0,36.21,2.0,1.9,experimental,21.492,0.2105,0.1897,Crystal Structure of Factor VIIa in complex with benzenecarboximidamide
5PB3,X-RAY DIFFRACTION,3.75,67.19,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-16,2017-06-21,5PB3,2885.0,2.0,318.0,348.0,9.0,36.14,2.0,1.9,experimental,23.534,0.2112,0.1911,"Crystal Structure of Factor VIIa in complex with 1-[[3-[4-(5-amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-5-hydroxypyrazol-1-yl]phenyl]methyl]-3-phenylurea"
5PB4,X-RAY DIFFRACTION,3.81,67.72,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-16,2017-06-21,5PB4,2623.0,2.0,318.0,209.0,8.0,35.92,2.0,2.43,experimental,39.13,0.2298,0.1998,"human factor VIIa in complex with 1-[[3-[5-hydroxy-3-methyl-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea at 2.43A"
5PB6,X-RAY DIFFRACTION,3.76,67.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-16,2017-06-21,5PB6,2888.0,2.0,318.0,362.0,8.0,36.09,2.0,1.9,experimental,21.801,0.2105,0.1876,"Crystal Structure of Factor VIIa in complex with N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]pentanamide"
5WFI,X-RAY DIFFRACTION,2.55,51.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"50 mM Tris, pH 7.5, 100 mM sodium chloride, 5 mM DTT, 0.2 M potassium formate, 20% PEG3350",295.0,2017-07-12,2018-08-01,5WFI,6696.0,4.0,758.0,638.0,3.0,86.08,2.0,1.851,experimental,,0.1973,0.1571,X-ray structure of MHV PLP2 (Cys1716Ser) catalytic mutant in complex with free ubiquitin
5JRS,X-RAY DIFFRACTION,2.27,45.79,VAPOR DIFFUSION,8.5,"PEG 5000, PEG 8000",298.0,2016-05-06,2016-08-31,5JRS,4141.0,2.0,534.0,167.0,,63.42,1.0,1.97,experimental,32.57,0.226,0.202,"CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -3,4-DIHYDROQUINAZOLIN-3-YL)PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE"
7AJS,X-RAY DIFFRACTION,2.34,47.5,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH6.5, 0.2M MgCl2",293.0,2020-09-29,2021-05-26,7AJS,6110.0,2.0,710.0,600.0,,82.88,1.0,2.15,experimental,27.523,0.1999,0.1609,Structure of DYRK1A in complex with compound 33
5TQ3,X-RAY DIFFRACTION,2.32,46.97,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes, pH 7.5, 0.1 M Sodium acetate, 30% PEG3350",293.0,2016-10-23,2017-01-11,5TQ3,4714.0,2.0,608.0,53.0,,72.49,1.0,2.69,experimental,36.719,0.27086,0.2164,Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin
7B9L,X-RAY DIFFRACTION,2.26,45.55,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained from hanging drops by mixing a 1:1 ratio of protein solution with well solution containing 2 M AmSO4, 0.1 M NaCl and 0.1 M Bis-tris pH 6.1-6.2",293.0,2020-12-14,2021-03-03,7B9L,5294.0,2.0,652.0,442.0,,74.93,1.0,1.7,experimental,40.17,0.214,0.193,MEK1 in complex with compound 23
5OKM,X-RAY DIFFRACTION,2.54,51.66,VAPOR DIFFUSION,7.0,"0.1 M BisTris propane pH 7, 0.2 M NaNO3, 20% PEG 3350, 0.025% CH2Cl2, 2 mM TCEP",293.0,2017-07-25,2017-08-23,5OKM,29931.0,8.0,3688.0,1564.0,,425.41,1.0,1.96,experimental,45.654,0.2075,0.1795,Crystal structure of human SHIP2 Phosphatase-C2
5OKN,X-RAY DIFFRACTION,2.59,52.5,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M Bis-Tris propane, pH 7.0, 0.4 M KSCN, 20% (w/v) PEG3350",293.0,2017-07-25,2017-08-23,5OKN,28076.0,8.0,3688.0,284.0,,425.4,1.0,2.65,experimental,60.007,0.24463,0.206,Crystal structure of human SHIP2 Phosphatase-C2 D607A mutant
5AGA,X-RAY DIFFRACTION,3.23,61.97,,,"19% PEG 3350, 0.2M POTASSIUM CITRATE TRIBASIC",,2015-01-29,2015-02-25,5AGA,6178.0,1.0,830.0,39.0,1.0,93.96,1.0,2.9,experimental,95.6,0.2644,0.2174,Crystal structure of the Helicase domain of human DNA polymerase theta in complex with AMPPNP
7UJP,X-RAY DIFFRACTION,2.31,46.69,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1 M Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane, 0.1 M Ammonium sulfate, 25% PEG 3350, 19mM Methyl 6-O-(N-heptylcarbamoyl)-alpha-D-glucopyranoside",277.0,2022-03-31,2022-04-13,7UJP,4591.0,4.0,580.0,45.0,,67.7,2.0,2.56,experimental,29.88,0.2808,0.2318,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B
7UJQ,X-RAY DIFFRACTION,2.32,46.89,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1 M Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane, 0.1 M Ammonium sulfate, 25% PEG 3350, 19mM Methyl 6-O-(N-heptylcarbamoyl)-alpha-D-glucopyranoside",277.0,2022-03-31,2022-04-13,7UJQ,4688.0,4.0,580.0,129.0,,67.37,2.0,2.25,experimental,24.97,0.2711,0.2199,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B
6U26,X-RAY DIFFRACTION,1.1,54.68,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Tris (pH 7.8) 200 mM NaCl, 15% PEG 3350,",295.0,2019-08-19,2019-11-06,6U26,4633.0,2.0,1414.0,320.0,12.0,153.24,1.0,1.53,experimental,28.77,0.213,0.187,PCSK9 in complex with compound 16
7JK7,X-RAY DIFFRACTION,3.2,61.51,"VAPOR DIFFUSION, HANGING DROP",,"0.7 M sodium citrate, 0.01M DTT, 0.1M sodium HEPES pH 7",295.0,2020-07-27,2020-08-05,7JK7,3538.0,2.0,496.0,150.0,,54.53,2.0,1.96,experimental,52.9818,0.2063,0.1812,Crystal structure of Importin alpha 2 in complex with LSD1 NLS S111E mutant
6S90,X-RAY DIFFRACTION,2.13,42.36,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris-HCL pH 8.5, 200 mM sodium formate, 50 mM CaCl2, 25% (w/v) PEGMME 5000",298.0,2019-07-11,2019-09-18,6S90,4712.0,2.0,532.0,467.0,,63.42,1.0,1.82,experimental,17.47,0.201,0.167,BTK in complex with an inhibitor
6C2Y,X-RAY DIFFRACTION,3.08,60.06,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM MES pH 6.0, 800 mM NaCl, 8% PEG 3350",277.0,2018-01-09,2018-04-25,6C2Y,8159.0,3.0,1106.0,42.0,,126.3,3.0,2.74,experimental,,0.2916,0.2443,Human GRK2 in complex with Gbetagamma subunits and CCG257142
6FT7,X-RAY DIFFRACTION,2.98,58.68,"VAPOR DIFFUSION, SITTING DROP",7.0,"21% PEG3350, 0.2 M sodium iodide,  0.1 M bis-tris-propane pH 7.0, 10% ethylene glycol",277.15,2018-02-20,2018-05-16,6FT7,6481.0,2.0,720.0,485.0,,87.65,1.0,2.02,experimental,42.83,0.23523,0.1917,Crystal structure of CLK3 in complex with compound 8a
5TZC,X-RAY DIFFRACTION,2.2,44.01,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2M MgCl2, 0.1M Tris, pH 8.4",293.0,2016-11-21,2017-02-22,5TZC,11475.0,4.0,1376.0,170.0,,162.85,1.0,2.36,experimental,30.215,0.2401,0.2005,"Crystal Structure of human PDE2a in complex with (5S)-1-[(3-bromo-4-fluorophenyl)carbonyl]-3,3-difluoro-5-{5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}piperidine"
5WG3,X-RAY DIFFRACTION,3.16,61.07,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM MES pH 6, 1.1 M NaCl, 8% PEG3350",277.0,2017-07-13,2017-12-27,5WG3,8184.0,3.0,1100.0,46.0,,125.43,3.0,2.896,experimental,,0.2483,0.1983,Human GRK2 in complex with Gbetagamma subunits and CCG258748
5HI2,X-RAY DIFFRACTION,2.24,45.02,"VAPOR DIFFUSION, HANGING DROP",6.8,"20% PEG 3350, and 0.2M Potassium Nitrate",292.0,2016-01-11,2016-04-06,5HI2,2050.0,1.0,283.0,29.0,,32.82,1.0,2.512,experimental,,0.2371,0.1851,BRAF Kinase domain b3aC loop deletion mutant in complex with sorafenib
8ZQ3,X-RAY DIFFRACTION,2.34,47.54,"VAPOR DIFFUSION, SITTING DROP",,"0.2M diammonium tartrate, 20% PEG3350, 0.1 M Ethylenediaminetetraacetic acid disodium salt dihydrate",289.0,2024-05-31,2024-06-26,8ZQ3,2551.0,2.0,412.0,8.0,,46.7,2.0,2.43,experimental,,0.2291,0.1942,Structure of ORP1L-RAB7A in the presence of GDP
5D6E,X-RAY DIFFRACTION,2.71,54.57,"VAPOR DIFFUSION, HANGING DROP",5.4,"Na Citrate, Tert-butanol",292.0,2015-08-12,2016-01-13,5D6E,3515.0,1.0,371.0,420.0,1.0,42.15,1.0,1.49,experimental,25.327,0.15559,0.11013,Structure of human methionine aminopeptidase 2 with covalent spiroepoxytriazole inhibitor (-)-31b
5D6F,X-RAY DIFFRACTION,2.74,55.05,"VAPOR DIFFUSION, HANGING DROP",5.6,"Na Citrate, Tert-butanol",292.0,2015-08-12,2016-01-13,5D6F,3522.0,1.0,371.0,507.0,1.0,42.22,1.0,1.55,experimental,19.881,0.18502,0.14683,Structure of human methionine aminopeptidase-2 complexed with spiroepoxytriazole inhibitor (+)-31b
5H09,X-RAY DIFFRACTION,2.3,46.58,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25 M ammonium formate, 12-22 % PEG 3350",293.0,2016-10-04,2017-10-04,5H09,3949.0,1.0,454.0,296.0,,52.54,1.0,1.945,experimental,45.5165,0.2227,0.1898,"Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-ethyl2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoate"
5H0B,X-RAY DIFFRACTION,2.34,47.44,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25 M ammonium formate, 12-22 % PEG 3350",293.0,2016-10-04,2017-10-11,5H0B,4033.0,1.0,454.0,382.0,,52.51,1.0,1.651,experimental,38.4663,0.2049,0.1802,"Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoic acid"
5H0E,X-RAY DIFFRACTION,2.31,46.66,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25M ammonium formate, 12-22% PEG 3350",293.0,2016-10-04,2017-10-04,5H0E,3847.0,1.0,454.0,196.0,,52.51,1.0,2.1,experimental,49.7425,0.2255,0.185,"Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanamide"
5H0G,X-RAY DIFFRACTION,2.32,46.93,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25 M ammonium formate, 12-22 % PEG 3350",293.0,2016-10-04,2017-10-04,5H0G,4025.0,1.0,454.0,373.0,,52.53,1.0,1.8,experimental,37.1622,0.2236,0.181,"Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-N,4-dimethylpentanamide"
5H0H,X-RAY DIFFRACTION,2.32,46.87,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25 M ammonium formate, 12-22 % PEG 3350",293.0,2016-10-04,2017-10-04,5H0H,4046.0,1.0,454.0,393.0,,52.54,1.0,1.72,experimental,37.3881,0.2239,0.185,"Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-N,N,4-trimethylpentanamide"
6X3O,X-RAY DIFFRACTION,2.28,45.99,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M BIS-TRIS CL pH 7.5, 18%w/vPEG 20,000, 5mM 4-(8-amino-3-((6R,8aS)-3-oxooctahydroindolizin-6-yl)imidazo[1,5-a]pyrazin-1-yl)-3-methoxy-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide, 5mM (S)-4-(8-amino-3-(1-(4-(dimethylamino)butanoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(thiazol-2-yl)benzamide, 10% v/v deuterated-DMSO",277.0,2020-05-21,2020-07-22,6X3O,4889.0,2.0,542.0,344.0,,65.36,1.0,1.9,experimental,33.5,0.2128,0.1794,Co-structure of BTK kinase domain with L-005191930 inhibitor
8GVZ,X-RAY DIFFRACTION,2.51,51.04,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES, pH 6.5, 1.6M potassium sodium tartrate tetrahydrate",298.0,2022-09-16,2023-09-20,8GVZ,3063.0,1.0,391.0,260.0,1.0,43.02,1.0,1.97,experimental,25.3689,0.2148,0.1774,Crystal structure of the human dihydroorotase domain in complex with the anticancer drug 5-fluorouracil
5P9F,X-RAY DIFFRACTION,2.26,45.64,VAPOR DIFFUSION,7.0,"PEG 3350, sodium actate, BisTrisPropane",298.0,2016-09-20,2017-05-24,5P9F,2657.0,1.0,279.0,288.0,,33.26,1.0,1.71,experimental,14.9,0.223,0.15,BTK IN COMPLEX WITH GDC-0834
6BG2,X-RAY DIFFRACTION,2.19,43.92,"VAPOR DIFFUSION, HANGING DROP",8.0,"23.2% PEG1500, 0.08 M PCTP, pH8.0, 0.5% w/v polyvinylpyrrolidone K15",295.0,2017-10-27,2018-10-31,6BG2,11857.0,4.0,1388.0,1455.0,,160.36,1.0,1.83,experimental,,0.2155,0.188,Crystal structure of cGMP-dependent protein kinase Ialpha (PKG Ialpha) catalytic domain in AMP-PNP bound state
6APX,X-RAY DIFFRACTION,3.76,67.29,"VAPOR DIFFUSION, HANGING DROP",5.9,"75 mM MES pH 5.9
2.4 M ammonium sulfate",292.0,2017-08-18,2017-11-01,6APX,4658.0,2.0,616.0,81.0,,67.9,2.0,2.491,experimental,,0.2365,0.2068,Crystal structure of human dual specificity phosphatase 1 catalytic domain (C258S) as a maltose binding protein fusion in complex with the monobody YSX1
6XHB,X-RAY DIFFRACTION,3.27,62.44,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM sodium cacodylate pH 6.5, 200 mM sodium citrate, 15% 2-propanol, 0.25% (w/v) n-octyl-beta-D-glucoside, 0.35 mM D-myo-phosphatidylinositol 3,4,5-triphosphate, and 0.25% (w/v) n-dodecyl-beta-D-maltoside",293.0,2020-06-18,2021-01-13,6XHB,2583.0,2.0,307.0,87.0,,36.25,2.0,2.5,experimental,62.1845,0.2213,0.1863,Crystal Structure of wild-type KRAS (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF (crystal form II)
7QRX,X-RAY DIFFRACTION,2.03,39.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% PEG3350, 10% ethylene glycol, 0.1M bis-tris-propane pH 8.5, 0.2M potassium thiocyanate",293.15,2022-01-12,2022-05-04,7QRX,4565.0,2.0,558.0,146.0,,62.63,1.0,2.2,experimental,35.363,0.2716,0.232,Crystal structure of NHL domain of TRIM71
4RX5,X-RAY DIFFRACTION,2.26,45.56,"VAPOR DIFFUSION, SITTING DROP",7.0,"PEG 10000, Li2SO4, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-12-08,2015-12-02,4RX5,2638.0,1.0,271.0,318.0,,32.81,1.0,1.356,experimental,,0.1786,0.16,Bruton's tyrosine kinase (BTK) with pyridazinone compound 23
5KUP,X-RAY DIFFRACTION,2.26,45.67,"VAPOR DIFFUSION, HANGING DROP",5.5,"PEG 10K, citrate, LiSO4",286.0,2016-07-13,2016-09-14,5KUP,2654.0,1.0,271.0,319.0,,32.81,1.0,1.389,experimental,,0.1772,0.1655,Bruton's tyrosine kinase (BTK) with pyridazinone compound 9
5VGO,X-RAY DIFFRACTION,2.27,45.76,"VAPOR DIFFUSION, HANGING DROP",5.5,"reservoir 0.1 M LiSO4, 0.1 M citric acid pH 5.5, 6% PEG 10K, 0.4% beta-octylglucoside

protein 8 mg/mL 10 mM Tris 8.5, 0.1 M NaCl, 0.5 mM TCEP, G-744 made 0.5 mM using 10 mM DMSO stock

drop 1:2 protein/reservoir.",286.0,2017-04-11,2017-07-05,5VGO,2605.0,1.0,271.0,272.0,,32.93,1.0,1.621,experimental,,0.1843,0.161,Bruton's tyrosine kinase (BTK) with compound G-744
6BIK,X-RAY DIFFRACTION,2.07,40.65,VAPOR DIFFUSION,7.0,"PEG 10000, Li2SO4, pH 7.0",277.0,2017-11-02,2018-11-07,6BIK,2417.0,1.0,287.0,178.0,,34.86,1.0,1.901,experimental,,0.2224,0.1609,BTK complex with compound 7
6BKW,X-RAY DIFFRACTION,2.11,41.7,VAPOR DIFFUSION,7.0,"PEG 10000, Li2SO4, pH 7.0",277.0,2017-11-09,2018-11-07,6BKW,2494.0,1.0,287.0,208.0,,35.12,1.0,1.499,experimental,25.8452,0.1895,0.1625,BTK complex with compound 12
6BLN,X-RAY DIFFRACTION,2.07,40.68,VAPOR DIFFUSION,,"PEG 10000, Li2SO4, pH 7.0",277.0,2017-11-10,2018-11-07,6BLN,2489.0,1.0,287.0,239.0,,34.76,1.0,1.3,experimental,23.8356,0.1764,0.156,BTK complex with compound 13
6W06,X-RAY DIFFRACTION,2.11,41.82,VAPOR DIFFUSION,,"bis-tris, ammonium salt, PEG",277.0,2020-02-29,2020-12-16,6W06,2401.0,1.0,293.0,179.0,,34.51,1.0,1.55,experimental,26.44,0.2249,0.1954,Bruton's tyrosine kinase in complex with compound 6
6U2P,X-RAY DIFFRACTION,2.69,54.21,VAPOR DIFFUSION,,"(10-22)% PEG 10000, 0.1M Tris, pH 8.5, 10% Ethylene Glycol, 1% BAM",303.0,2019-08-20,2019-11-06,6U2P,4547.0,2.0,1414.0,183.0,12.0,152.95,1.0,2.04,experimental,37.76,0.216,0.183,PCSK9 in complex with compound 5
5E2B,X-RAY DIFFRACTION,3.06,59.82,"VAPOR DIFFUSION, SITTING DROP",,"26% PEG3350, 16% tacsimate",277.0,2015-09-30,2015-10-28,5E2B,4288.0,4.0,494.0,385.0,,56.99,2.0,1.95,experimental,18.6,0.1875,0.1524,Crystal structure of NTMT1 in complex with N-terminally methylated PPKRIA peptide
4XSK,X-RAY DIFFRACTION,2.17,43.37,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.2 M ammonium sulfate, 5% PEG 400, 50 mM sodium citrate (pH 4.6)",298.0,2015-01-22,2016-02-03,4XSK,2108.0,1.0,246.0,121.0,5.0,28.43,1.0,1.5,experimental,18.238,0.20865,0.17394,"Structure of PAItrap, an uPA mutant"
6EJ8,X-RAY DIFFRACTION,2.54,51.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"55-65% Morpheus Precipitant mix 2 (PEG8000 and Ethylene glycol)
0.1M Bicine/Tris buffer at pH 7.5
0.1M of NPS mix (0.033M of each)",293.0,2017-09-20,2018-05-02,6EJ8,5890.0,2.0,767.0,232.0,6.0,88.06,2.0,2.09,experimental,55.3709,0.2231,0.1946,Human Xylosyltransferase 1 in complex with peptide QEEEGSGGGQGG
7AY9,X-RAY DIFFRACTION,3.09,60.23,VAPOR DIFFUSION,,"22-26% PEG 6000 ( w/v ), 0.2 M ammonium sulfate and 0.1 M MES (pH 6.5).",293.0,2020-11-11,2021-11-24,7AY9,6190.0,2.0,684.0,460.0,,85.45,1.0,2.25,experimental,35.66,0.207,0.166,Crystal structure of CK2 bound by compound 7
7AYA,X-RAY DIFFRACTION,3.08,60.0,VAPOR DIFFUSION,,"22-26% PEG 6000 ( w/v ), 0.2 M ammonium sulfate and 0.1 M MES (pH 6.5).",293.0,2020-11-11,2021-11-24,7AYA,5998.0,2.0,684.0,227.0,,85.37,1.0,2.45,experimental,39.37,0.229,0.191,Crystal structure of CK2 bound by compound 9
6N3O,X-RAY DIFFRACTION,2.65,53.64,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Na Citrate pH 5.6, 8% PEG 6K, 0.7 M LiCl, 1% Ethylene Glycol",293.0,2018-11-15,2019-10-09,6N3O,2116.0,1.0,317.0,17.0,,36.66,1.0,2.4,experimental,84.3,0.2544,0.1992,"Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents"
7YCE,X-RAY DIFFRACTION,2.67,53.89,"VAPOR DIFFUSION, SITTING DROP",6.5,"MES, ammonium sulfate, PEG550MME",293.0,2022-07-01,2022-08-10,7YCE,1518.0,1.0,170.0,95.0,,20.54,1.0,1.8,experimental,25.494,0.291,0.2737,KRas G12C in complex with Compound 7b
9ATU,X-RAY DIFFRACTION,2.87,57.17,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium acetate
0.1 M Tris-HCl (pH 8.0)
17% (w/v) PEG-10K",293.0,2024-02-27,2024-06-12,9ATU,8816.0,6.0,1088.0,338.0,16.0,123.34,2.0,2.05,experimental,,0.2372,0.1848,Bifunctional Inhibition of Neutrophil Elastase by Eap4 from S. aureus
7YB8,X-RAY DIFFRACTION,2.59,52.55,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.2 M lithium chloride, 20 % w/v Polyethylene glycol 6,000, 0.1 M Tris-HCl",277.0,2022-06-29,2023-07-05,7YB8,3750.0,2.0,468.0,119.0,2.0,53.98,2.0,1.98,experimental,49.63,0.2479,0.2191,Aspartyl/Asparaginyl beta-hydroxylase (AspH) oxygenase and TPR domains in complex with D-2-hydroxyglutarate and factor X-derived peptide (39mer-4Ser)
7LRZ,X-RAY DIFFRACTION,2.81,56.0,"VAPOR DIFFUSION, HANGING DROP",8.0,"Imidazole pH 8.0, 10% PEG 8000, 0.2 M Ca(OAc)2",289.15,2021-02-17,2021-11-24,7LRZ,2411.0,1.0,311.0,213.0,3.0,31.85,1.0,1.91,experimental,37.6674,0.2143,0.188,Structure of the Human ALK GRD
6GEV,X-RAY DIFFRACTION,2.04,39.71,"VAPOR DIFFUSION, SITTING DROP",,"0.9 M (NH4)2SO4, 3.5% 1,4-butanediol, 0.1 M CHES pH 9.5",293.0,2018-04-27,2019-01-09,6GEV,2426.0,2.0,320.0,210.0,,37.22,2.0,1.54,experimental,27.68,0.19,0.172,Mineralocorticoid receptor in complex with (s)-13
6YTW,X-RAY DIFFRACTION,2.95,58.26,"VAPOR DIFFUSION, SITTING DROP",7.0,"21% PEG 3350, 0,2M Na/K PO4, 10% Ethylene Glycol",277.0,2020-04-24,2020-07-15,6YTW,6343.0,2.0,720.0,534.0,,86.57,1.0,2.0,experimental,33.782,0.2269,0.1839,CLK3 bound with benzothiazole Tg003 (Cpd 2)
4R7I,X-RAY DIFFRACTION,2.37,48.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG8K, 0.2M MGCL AND 0.1M TRIS, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-08-27,2015-08-12,4R7I,2361.0,1.0,343.0,55.0,,39.13,1.0,2.75,experimental,,0.2359,0.2006,"Crystal structure of FMS kinase domain with a small molecular inhibitor, GLEEVEC"
7YCC,X-RAY DIFFRACTION,2.64,53.35,"VAPOR DIFFUSION, SITTING DROP",6.5,"MES, ammonium sulfate, PEG550MME",293.0,2022-07-01,2022-08-10,7YCC,4375.0,3.0,510.0,213.0,,61.29,1.0,1.79,experimental,35.302,0.255,0.2116,KRas G12C in complex with Compound 5c
7VKM,X-RAY DIFFRACTION,2.92,57.85,"VAPOR DIFFUSION, SITTING DROP",,"3.0M NaCl, 0.1M Bis-Tris pH 6.5",293.0,2021-09-30,2021-10-13,7VKM,2463.0,1.0,326.0,53.0,,37.34,1.0,2.55,experimental,60.159,0.25717,0.19893,Crystal structure of TrkA (G595R) kinase domain
6O36,X-RAY DIFFRACTION,3.07,59.93,"VAPOR DIFFUSION, HANGING DROP",8.2,"1.6-1.8 M sodium/potassium phosphate, pH 8.2",293.0,2019-02-26,2020-02-26,6O36,4358.0,3.0,504.0,189.0,,59.34,1.0,2.0,experimental,40.69,0.2219,0.1936,Crystal structure of human KRAS P34R mutant in complex with GNP
8JBN,X-RAY DIFFRACTION,3.05,59.69,"VAPOR DIFFUSION, HANGING DROP",7.8,"100mM HEPES, 9.5%(v/v) PEG 6000, 8.8%(v/v) ethylene glycol, soaking the crystal with 6.25 mM Cpd-1",277.0,2023-05-09,2024-02-28,8JBN,4996.0,2.0,590.0,371.0,,68.77,1.0,1.99,experimental,47.47,0.1978,0.1693,Vascular endothelial protein tyrosine phosphatase in complex with Cpd-1
8JBY,X-RAY DIFFRACTION,2.95,58.25,"VAPOR DIFFUSION, HANGING DROP",7.8,"100mM HEPES, 9.5%(v/v) PEG 6000, 8.8%(v/v) ethylene glycol, soaking the crystal with 6.25 mM Cpd-2",277.0,2023-05-10,2024-02-28,8JBY,4958.0,2.0,590.0,298.0,,69.26,1.0,1.99,experimental,56.36,0.2074,0.1834,Vascular endothelial protein tyrosine phosphatase in complex with Cpd-2
4YC3,X-RAY DIFFRACTION,2.49,50.55,VAPOR DIFFUSION,6.7,"0.1M MES/imidazole buffer (pH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K
Protein at 10-12 mg/ml",277.0,2015-02-19,2016-04-20,4YC3,5419.0,3.0,659.0,212.0,,76.45,3.0,2.7,experimental,40.9313,0.2595,0.2113,CDK1/CyclinB1/CKS2 Apo
6GU2,X-RAY DIFFRACTION,2.46,49.96,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES/IMIDAZOLE BUFFER (PH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K PROTEIN AT 10-12 MG/ML + 0.5mM Inhibitor",277.0,2018-06-19,2018-12-05,6GU2,5375.0,3.0,659.0,194.0,,76.62,3.0,2.0,experimental,47.989,0.23918,0.18944,CDK1/CyclinB/Cks2 in complex with Flavopiridol
6GU4,X-RAY DIFFRACTION,2.4,48.69,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES/IMIDAZOLE BUFFER (PH6.7), 6.5% MPD, 5% PEG4K, 10% PEG1K PROTEIN AT 10-12 MG/ML + 0.5mM Inhibitor",277.0,2018-06-19,2018-12-05,6GU4,5242.0,3.0,659.0,76.0,,76.6,3.0,2.73,experimental,51.626,0.25272,0.19665,CDK1/CyclinB/Cks2 in complex with CGP74514A
5C1Z,X-RAY DIFFRACTION,2.56,51.9,VAPOR DIFFUSION,5.5,"LiSO4, PEG3350",277.0,2015-06-15,2015-07-29,5C1Z,6943.0,2.0,810.0,711.0,,92.93,1.0,1.79,experimental,49.13,0.2123,0.1915,Parkin (UblR0RBR)
5C23,X-RAY DIFFRACTION,2.47,50.22,VAPOR DIFFUSION,5.5,"PEG3350, LiSO4",277.0,2015-06-15,2015-07-29,5C23,6424.0,2.0,810.0,313.0,,93.04,1.0,2.37,experimental,52.88,0.2406,0.2199,Parkin (S65DUblR0RBR)
5DMZ,X-RAY DIFFRACTION,2.6,52.72,"VAPOR DIFFUSION, SITTING DROP",7.6,"0.2 M NaCl, 15% PEG 3350",277.0,2015-09-09,2015-12-16,5DMZ,5606.0,2.0,730.0,24.0,,84.75,1.0,2.4,experimental,,0.2451,0.2105,Structure of human Bub1 kinase domain phosphorylated at Ser969
7KL2,X-RAY DIFFRACTION,2.36,47.79,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.15 M DL-Malic acid pH 7, 20% PEG 3350",277.0,2020-10-28,2020-12-23,7KL2,2245.0,2.0,290.0,6.0,,33.33,2.0,2.56,experimental,45.386,0.293,0.2439,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)
6TA7,X-RAY DIFFRACTION,2.24,45.0,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Sodium chloride, 0.1M Tris 8.0, 20% w/v PEG 4000 of the Proplex crystallization screen (Molecular Dimensions)",298.0,2019-10-29,2021-05-12,6TA7,6516.0,8.0,902.0,275.0,,103.47,2.0,1.93,experimental,60.84,0.2518,0.2067,CRYSTAL STRUCTURE OF HUMAN G3BP1-NTF2 IN COMPLEX WITH HUMAN CAPRIN1-DERIVED SOLOMON MOTIF
6YGN,X-RAY DIFFRACTION,2.74,55.17,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 8K, 0.1 MES pH6.5",293.15,2020-03-27,2021-04-07,6YGN,9185.0,2.0,1098.0,313.0,,126.23,1.0,2.4,experimental,46.75,0.2277,0.1716,Titin kinase and its flanking domains
4YU2,X-RAY DIFFRACTION,3.26,62.25,"VAPOR DIFFUSION, SITTING DROP",9.0,"31% PEG 400, 0.2 M lithium sulfate, 0.1 M Tris, pH 9.0",277.0,2015-03-18,2015-03-25,4YU2,11762.0,4.0,1444.0,306.0,,170.38,1.0,2.9,experimental,75.108,0.27715,0.24302,Crystal structure of DYRK1A with harmine-derivatized AnnH-75 inhibitor
6S1I,X-RAY DIFFRACTION,3.25,62.12,"VAPOR DIFFUSION, SITTING DROP",,37% PEG400 -- 0.2M lithium sulfate -- 0.1M tris pH 8.8,277.0,2019-06-18,2019-06-26,6S1I,12084.0,4.0,1444.0,647.0,,171.18,1.0,2.38,experimental,52.3464,0.2279,0.2006,Crystal Structure of DYRK1A with small molecule inhibitor
6GT6,X-RAY DIFFRACTION,3.69,66.64,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris.Cl pH 8.0, 1.5M AmSO4",292.15,2018-06-15,2019-07-17,6GT6,1910.0,1.0,253.0,59.0,7.0,28.27,1.0,2.54,experimental,40.686,0.2636,0.2115,Crystal structure of recombinant coagulation factor beta-XIIa
7Q8V,X-RAY DIFFRACTION,2.27,45.84,"VAPOR DIFFUSION, SITTING DROP",8.5,"29% PEG 3350, 0.2M sodium acetate, 0.1M tris 8.5",293.15,2021-11-11,2022-03-09,7Q8V,2484.0,1.0,309.0,75.0,,35.95,1.0,2.13,experimental,49.496,0.2444,0.1874,Crystal structure of TTBK1 in complex with VNG2.73 (compound 42)
8D6C,X-RAY DIFFRACTION,2.87,57.18,"VAPOR DIFFUSION, HANGING DROP",8.25,"5.6 to 6.6 % PEG3350, 0.2 M Na2SO4, 0.1 M Tris-HCl and 10% EG",293.0,2022-06-06,2022-07-27,8D6C,4225.0,2.0,622.0,9.0,,70.38,1.0,2.2,experimental,99.7787,0.2674,0.2414,Crystal Structure of Human Myt1 Kinase domain Bounded with compound 28
8D6E,X-RAY DIFFRACTION,2.78,55.8,"VAPOR DIFFUSION, HANGING DROP",8.25,"5.6 to 6.6% PEG3350, 0.2 M Na2SO4, 0.1 M Tris-HCl and 10% EG",293.0,2022-06-06,2022-07-27,8D6E,4414.0,2.0,622.0,94.0,,70.86,1.0,2.15,experimental,89.4569,0.2177,0.19,Crystal Structure of Human Myt1 Kinase domain Bounded with RP-6306
7QWK,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"100mM Bis Tris, 20 to 30 percent PEG3350, 200mM ammonium sulfate",293.0,2022-01-25,2022-05-04,7QWK,16000.0,8.0,2544.0,84.0,,296.9,1.0,2.3,experimental,50.4159,0.243,0.214,"GCN2 (EIF2ALPHA KINASE 4, E2AK4) IN COMPLEX WITH COMPOUND 2"
5KA4,X-RAY DIFFRACTION,2.51,50.9,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 17% PEG8000",277.0,2016-06-01,2017-03-08,5KA4,2295.0,1.0,306.0,80.0,,35.51,1.0,2.185,experimental,32.3853,0.2422,0.207,"Protein Tyrosine Phosphatase 1B T178A mutant, open state"
6BMU,X-RAY DIFFRACTION,2.27,45.73,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2017-11-15,2018-01-17,6BMU,8370.0,2.0,1052.0,489.0,,122.71,1.0,2.12,experimental,42.56,0.225,0.181,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitors SHP099 and SHP244
6BMW,X-RAY DIFFRACTION,2.28,46.16,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2017-11-15,2018-01-17,6BMW,8284.0,2.0,1052.0,442.0,,122.74,1.0,2.1,experimental,42.74,0.229,0.186,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitors SHP099 and SHP504
6BMY,X-RAY DIFFRACTION,2.27,45.75,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2017-11-15,2018-01-17,6BMY,8390.0,2.0,1052.0,478.0,,123.09,1.0,2.09,experimental,41.52,0.228,0.18,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitors SHP099 and SHP844
6P3W,X-RAY DIFFRACTION,4.19,70.66,"VAPOR DIFFUSION, HANGING DROP",,"0.49 M sodium phosphate monobasic
monohydrate and 0.91 M potassium phosphate dibasic",277.15,2019-05-24,2019-07-31,6P3W,8967.0,6.0,1124.0,50.0,,129.92,3.0,2.54,experimental,,0.2373,0.1981,Crystal structure of the Cyclin A-CDK2-ORC1 complex
6Q48,X-RAY DIFFRACTION,1.99,38.32,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM      
HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q48,2599.0,1.0,306.0,267.0,,35.06,1.0,1.03,experimental,16.686,0.21434,0.18798,CDK2 in complex with FragLite7
6Q49,X-RAY DIFFRACTION,1.99,38.2,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q49,2771.0,1.0,306.0,305.0,,35.01,1.0,1.0,experimental,23.835,0.19718,0.17524,CDK2 in complex with FragLite6
6Q4E,X-RAY DIFFRACTION,1.99,38.29,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q4E,2767.0,1.0,306.0,300.0,,35.18,1.0,1.06,experimental,19.395,0.20514,0.17901,CDK2 in complex with FragLite33
6Q4H,X-RAY DIFFRACTION,1.99,38.06,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q4H,2827.0,1.0,306.0,289.0,,35.12,1.0,1.0,experimental,18.136,0.20663,0.19098,CDK2 in complex with FragLite36
6Q4I,X-RAY DIFFRACTION,2.0,38.62,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q4I,2746.0,1.0,306.0,290.0,,35.14,1.0,1.11,experimental,16.638,0.19246,0.16487,CDK2 in complex with FragLite35
6Q4J,X-RAY DIFFRACTION,1.99,38.1,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q4J,2831.0,1.0,306.0,291.0,,35.15,1.0,1.05,experimental,15.701,0.18568,0.16564,CDK2 in complex with FragLite34
5C9C,X-RAY DIFFRACTION,2.59,52.5,"VAPOR DIFFUSION, SITTING DROP",,"26% PEG 3350, 50 MM AMMONIUM
 CITRATE, 50 MM SODIUM FLORIDE, 2 MG/ML PROTEIN, 5-FOLD MOLAR
 EXCESS DP4978; CRYSTAL ID 215552F10, SITTING DROP VAPOR
 DIFFUSION, TEMPERATURE 289K",289.0,2015-06-26,2015-07-15,5C9C,4153.0,2.0,614.0,135.0,,71.38,1.0,2.7,experimental,24.92,0.238,0.194,CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
7UIS,X-RAY DIFFRACTION,2.09,41.09,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M Bis-tris propane pH 6.5, 0.2 M Sodium chloride, 25% PEG 3350",277.0,2022-03-29,2022-04-06,7UIS,2207.0,2.0,290.0,,,33.33,2.0,2.58,experimental,39.422,0.2675,0.2173,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)
7UJR,X-RAY DIFFRACTION,1.99,38.29,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M 1,3-bis(tris(hydroxymethyl)methylamino)propane, 0.1 M Ammonium sulfate, 20% PEG 3350, 5% Ethanol",277.0,2022-03-31,2022-04-13,7UJR,2344.0,2.0,290.0,93.0,,33.59,2.0,1.95,experimental,28.074,0.2516,0.2093,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B
7UJS,X-RAY DIFFRACTION,2.36,47.83,"VAPOR DIFFUSION, HANGING DROP",6.6,"0.1M 1,3-bis(tris(hydroxymethyl)methylamino)propane, 0.1 M Ammonium sulfate, 20% PEG 3350",277.0,2022-03-31,2022-04-13,7UJS,2280.0,2.0,290.0,,,33.73,2.0,2.75,experimental,34.825,0.2622,0.1972,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B in complex with ADP
8F2P,X-RAY DIFFRACTION,2.81,56.25,"VAPOR DIFFUSION, HANGING DROP",4.6,"0.1 M sodium chloride, 0.1 M sodium acetate, pH 4.6, 12% v/v MPD",298.0,2022-11-08,2023-02-22,8F2P,1355.0,2.0,222.0,4.0,,26.15,2.0,2.63,experimental,,0.2518,0.2123,Nef SF2 dimerization mutant bound to Hck SH3
7Y4B,X-RAY DIFFRACTION,2.37,48.13,"VAPOR DIFFUSION, SITTING DROP",7.0,"22.5%(w/v) PEG 3000, 100mM Tris base/Hydrochloric acid, 200mM Calcium acetate",283.0,2022-06-14,2023-06-21,7Y4B,2570.0,2.0,298.0,168.0,,34.16,1.0,1.86,experimental,41.58,0.23,0.1836,Crystal structure of DUSP10 mutant_D59A
7Y4D,X-RAY DIFFRACTION,2.39,48.56,"VAPOR DIFFUSION, HANGING DROP",7.0,"22.5% (w/v) PEG 3000, 100 mM Tris base /Hydrochloric acid, 
200 mM Calcium acetate",283.0,2022-06-14,2023-06-21,7Y4D,2488.0,2.0,298.0,82.0,,34.22,1.0,2.18,experimental,49.4,0.23,0.1801,Crystal structure of DUSP10 mutant_S95A
7Y4E,X-RAY DIFFRACTION,2.27,45.87,"VAPOR DIFFUSION, HANGING DROP",7.0,"27.5% (w/v) PEG 3000, 100 mM Tris base /Hydrochloric acid, 
175mM Calcium acetate",283.0,2022-06-14,2023-06-21,7Y4E,2532.0,2.0,298.0,130.0,,34.16,1.0,1.93,experimental,43.67,0.2331,0.1951,Crystal structure of DUSP10 mutant_N130A
6G0S,X-RAY DIFFRACTION,2.12,41.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"20.0 % PEG3350
10.0 % EtGly
0.1 M bis-tris-propane pH 8.5
0.2M NaOOCCH3",277.0,2018-03-19,2018-11-28,6G0S,2450.0,3.0,265.0,245.0,,31.8,2.0,1.48,experimental,21.015,0.2095,0.1771,Crystal Structure of the first bromodomain of human BRD4 in complex with an acetylated SIRT7 peptide (K272ac/K275ac)
6NH9,X-RAY DIFFRACTION,2.13,42.16,"VAPOR DIFFUSION, HANGING DROP",10.5,"30% v/v PEG 400
0.1M CAPS",291.0,2018-12-21,2019-12-25,6NH9,2157.0,3.0,264.0,151.0,,30.36,1.0,1.85,experimental,,0.263,0.2261,Crystal structure of a human calcium/calmodulin dependent serine protein kinase (CASK) PDZ domain
5CSW,X-RAY DIFFRACTION,2.25,45.49,"VAPOR DIFFUSION, HANGING DROP",,PEG 3350,277.0,2015-07-23,2016-03-09,5CSW,4146.0,2.0,564.0,16.0,,65.13,1.0,2.66,experimental,24.932,0.282,0.2166,B-RAF in complex with Dabrafenib
5VDK,X-RAY DIFFRACTION,2.4,48.72,"VAPOR DIFFUSION, HANGING DROP",8.0,"14 MG/ML WEE2, 25 mM TRIS PH 8.0, 1 mM DTT, 0.2 M ammonium phosphate monobasic, 1.5 mM MK1775",291.0,2017-04-03,2017-08-23,5VDK,2103.0,1.0,297.0,7.0,,33.86,1.0,2.7,experimental,,0.2843,0.2253,Crystal structure of human WEE2 kinase domain in complex with MK1775
4WZV,X-RAY DIFFRACTION,2.29,46.31,"VAPOR DIFFUSION, SITTING DROP",7.25,"protein: 5mg/mL hMMP9-WT with 120 milli-M acetohydroxamic acid. Reservoir: 
36% MPEG 5K, 90mM bicine, pH 7.25. Cryoprotectant: 40% MPEG 5K, 5% Di-ethyleneglycol, 10% AAB buffer, pH 8.0",293.0,2014-11-20,2015-08-26,4WZV,3442.0,2.0,320.0,667.0,,38.44,1.0,1.65,experimental,,0.2295,0.176,Crystal structure of a hydroxamate based inhibitor EN140 in complex with the MMP-9 catalytic domain
8QWY,X-RAY DIFFRACTION,3.18,61.27,VAPOR DIFFUSION,5.5,"0.2 M ammonia sulphate 
0.1 M bis-tris pH 5.5 
23-26% PEG 335",293.0,2023-10-20,2024-01-17,8QWY,5447.0,2.0,676.0,16.0,,82.57,1.0,2.6,experimental,69.725,0.25095,0.21119,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 4-(6-((5-isopropoxy-2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acid
8C3Q,X-RAY DIFFRACTION,2.74,55.16,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris pH 5.5, 0.2 M ammonium acetate, 25% PEG3350",293.15,2022-12-28,2024-01-10,8C3Q,5746.0,2.0,740.0,190.0,,87.58,1.0,2.32,experimental,,0.21,0.1769,Crystal structure of DYRK1A in complex with rutin
8C3R,X-RAY DIFFRACTION,2.64,53.41,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris pH 5.5, 0.2 M ammonium acetate, 25% PEG3350",293.15,2022-12-28,2024-01-10,8C3R,6039.0,2.0,740.0,420.0,,87.56,1.0,2.06,experimental,,0.2091,0.1855,Crystal structure of DYRK1A in complex with gossypin
5F1K,X-RAY DIFFRACTION,3.05,59.68,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, 25% PEG3350",298.0,2015-11-30,2016-06-15,5F1K,6094.0,4.0,830.0,323.0,13.0,93.51,2.0,2.3,experimental,42.654,0.2313,0.198,human CD38 in complex with nanobody MU1053
5FVO,X-RAY DIFFRACTION,2.48,50.4,,5.8,"20-24% PEG3350, 0.1M MES 0.14-0.20M AMMONIUM ACETATE, 10% ETHYLENE GLYCOL, 30UM SDS 5 MM GSH, pH 5.8",,2016-02-10,2016-04-20,5FVO,3501.0,1.0,422.0,76.0,,50.04,1.0,2.12,experimental,59.06,0.2545,0.1978,Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(2-(5-(3-methoxypropylamino)pyridin-3-yl)ethyl)-4- methylpyridin-2-amine
5MN9,X-RAY DIFFRACTION,1.82,32.23,"VAPOR DIFFUSION, HANGING DROP",5.4,100 mM sodium acetate pH 5.4 and 18.5 % PEG3350,293.15,2016-12-13,2017-01-25,5MN9,1335.0,3.0,196.0,3.0,,22.09,2.0,2.05,experimental,58.638,0.22341,0.18268,Crystal structure of MINDY-1 tMIU in complex with K48-diUb
6ALC,X-RAY DIFFRACTION,2.23,44.86,VAPOR DIFFUSION,6.5,"0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350",277.0,2017-08-07,2018-08-08,6ALC,2215.0,2.0,228.0,274.0,,27.57,1.0,1.391,experimental,28.5625,0.2125,0.1888,"CREBBP bromodomain in complex with Cpd 4 (1-(1-(cyclopropylmethyl)-3-(1H-indol-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)"
7XH6,X-RAY DIFFRACTION,2.01,38.66,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES pH 7.5, 2% v/v Tacsimate pH 7.0, 20% w/v Polyethylene glycol 3350",277.0,2022-04-07,2022-07-27,7XH6,2083.0,2.0,266.0,84.0,,33.02,1.0,1.75,experimental,33.365,0.2265,0.1895,Crystal structure of CBP bromodomain liganded with CCS1477
6F7B,X-RAY DIFFRACTION,2.28,45.96,VAPOR DIFFUSION,7.26,"200mM MgCl2, 100mM Tris-HCl pH 7.26, 5% glycerol, 20% PEG 3350",277.0,2017-12-08,2018-12-19,6F7B,3055.0,1.0,361.0,169.0,,42.04,1.0,2.0,experimental,40.779,0.25374,0.19831,Crystal structure of the human Bub1 kinase domain in complex with BAY 1816032
6YPG,X-RAY DIFFRACTION,2.01,38.76,"VAPOR DIFFUSION, SITTING DROP",6.5,"112.5mM Mes, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2020-04-16,2020-07-15,6YPG,3004.0,1.0,328.0,205.0,,39.45,1.0,1.51,experimental,28.336,0.243,0.2374,Crystal Structure of CK2alpha with Compound 2 bound to second crystal form
5EQO,X-RAY DIFFRACTION,2.36,47.87,VAPOR DIFFUSION,6.0,"0.1 M sodium cacodylate pH 6.0
2.0 M ammonium sulphate",289.0,2015-11-13,2016-08-17,5EQO,1088.0,1.0,121.0,84.0,3.0,14.49,1.0,2.4,experimental,20.322,0.25005,0.18632,Human Angiogenin in complex with sulphate anions at an acidic solution
7UOH,X-RAY DIFFRACTION,2.9,57.61,"VAPOR DIFFUSION, SITTING DROP",,"11 %w/v PEG 4K
0.1 M Na3 Cititrate 5 pH
0.05 M Na Acetate",281.0,2022-04-12,2022-08-17,7UOH,7405.0,2.0,995.0,12.0,,112.41,2.0,2.7,experimental,78.14,0.2321,0.1967,"PRMT5/MEP50 crystal structure with MTA and an achiral, class 1, non-atropisomeric inhibitor bound"
7UY1,X-RAY DIFFRACTION,2.97,58.58,VAPOR DIFFUSION,,PEG/Buffer/Salt,291.0,2022-05-06,2022-10-05,7UY1,7458.0,2.0,995.0,47.0,,112.69,2.0,2.66,experimental,52.0,0.3,0.26,HUMAN PRMT5:MEP50 COMPLEX WITH MTA and Fragment 5 Bound
7UYF,X-RAY DIFFRACTION,2.95,58.26,VAPOR DIFFUSION,,"10% PEG 4000, 100 mM Sodium Acetate, 100 mM Sodium Citrate pH 5.4",281.0,2022-05-06,2022-10-05,7UYF,7442.0,2.0,995.0,73.0,,112.51,2.0,2.82,experimental,33.215,0.3149,0.2688,Human PRMT5:MEP50 structure with Fragment 4 and MTA Bound
8CSG,X-RAY DIFFRACTION,2.75,55.29,VAPOR DIFFUSION,,"13% PEG 4000, 100 mM Sodium Acetate pH 5.0",291.0,2022-05-12,2022-10-05,8CSG,7571.0,2.0,995.0,193.0,,112.58,2.0,2.48,experimental,28.69,0.2916,0.263,Human PRMT5:MEP50 structure with Fragment 1 and MTA Bound
8CTB,X-RAY DIFFRACTION,2.68,54.19,VAPOR DIFFUSION,,"10% PEG 8000, 100 mM Sodium Citrate 5.4, 100 mM Sodium Acetate",291.0,2022-05-13,2022-10-05,8CTB,7389.0,2.0,995.0,32.0,,112.1,2.0,2.61,experimental,54.43,0.2885,0.2465,Human PRMT5:MEP50 structure with Fragment 3 and MTA Bound
8VEW,X-RAY DIFFRACTION,2.76,55.37,VAPOR DIFFUSION,6.0,"10% PEG 4000, 0.2M magnesium chloride, 0.1M sodium citrate (pH 6.0)",291.0,2023-12-20,2024-04-24,8VEW,7442.0,2.0,995.0,41.0,1.0,112.45,2.0,2.69,experimental,70.332,0.26949,0.22042,Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 24
8VEX,X-RAY DIFFRACTION,2.7,54.42,VAPOR DIFFUSION,6.0,"10% PEG 4000, 0.2M magnesium chloride, 0.1M sodium citrate (pH 6.0)",291.0,2023-12-20,2024-04-24,8VEX,7467.0,2.0,995.0,59.0,1.0,112.45,2.0,2.79,experimental,88.96,0.26972,0.22641,Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 28
5JH5,X-RAY DIFFRACTION,2.22,39.22,"VAPOR DIFFUSION, HANGING DROP",7.25,"100 mM HEPES, 10 % 2-methyl-2,4-pentanediol, 10 mM NaCl",298.0,2016-04-20,2016-09-14,5JH5,5015.0,4.0,674.0,64.0,,78.55,4.0,2.55,experimental,,0.2573,0.2062,Structural Basis for the Hierarchical Assembly of the Core of PRC1.1
8E80,X-RAY DIFFRACTION,2.36,47.96,"VAPOR DIFFUSION, SITTING DROP",,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2022-08-25,2023-02-22,8E80,2363.0,1.0,297.0,236.0,,34.5,1.0,1.49,experimental,26.95,0.242,0.207,Structure of LRRK2-CHK1 10-pt. mutant complex with heteroaryl-1H-indazole LRRK2 inhibitor 14
8E81,X-RAY DIFFRACTION,2.37,48.02,"VAPOR DIFFUSION, SITTING DROP",,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2022-08-25,2023-02-22,8E81,2364.0,1.0,297.0,216.0,,34.51,1.0,1.62,experimental,31.99,0.232,0.2,Structure of LRRK2-CHK1 10-pt. mutant complex with heteroaryl-1H-indazole LRRK2 inhibitor 25
7NPM,X-RAY DIFFRACTION,1.94,36.58,"VAPOR DIFFUSION, HANGING DROP",5.1,"10 % PEG6K, 20 mM sodium citrate pH 5.1, 0.2 M sodium/potassium tartrate",298.0,2021-02-27,2022-03-23,7NPM,1142.0,1.0,121.0,84.0,3.0,14.68,1.0,1.86,experimental,25.6,0.2537,0.1782,X-ray structure of the adduct formed upon reaction of oxaliplatin with human angiogenin
6L5O,X-RAY DIFFRACTION,2.28,46.03,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% pEG3350, 0.2m Magnesium acetate",293.0,2019-10-24,2020-06-17,6L5O,3151.0,1.0,372.0,148.0,,42.28,1.0,1.8,experimental,20.8026,0.2096,0.1755,Crystal structure of human DEAD-box RNA helicase DDX21 at post-hydrolysis state
7XIJ,X-RAY DIFFRACTION,2.31,46.84,"VAPOR DIFFUSION, SITTING DROP",,0.2M MgCl2   0.1M  TrsHCl    30% PEG4000 PH7.5,277.0,2022-04-13,2022-06-08,7XIJ,1245.0,1.0,136.0,93.0,,16.99,1.0,1.82,experimental,27.716,0.2209,0.193,Crystal structure of CBP bromodomain liganded with Y08175
7O7K,X-RAY DIFFRACTION,2.82,56.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"14-16% PEG 4000, 0.1 M sodium citrate (pH 6.5) and 0.1 M ammonium sulfate",288.0,2021-04-13,2021-11-24,7O7K,6292.0,2.0,722.0,375.0,,87.29,1.0,1.82,experimental,47.5774,0.2049,0.1774,Crystal structure of the human DYRK1A kinase domain bound to abemaciclib
5H84,X-RAY DIFFRACTION,2.02,39.05,"VAPOR DIFFUSION, HANGING DROP",9.0,"20% (v/v) ethanol, 100 mM Tris, pH 9.0",293.0,2015-12-23,2016-03-23,5H84,1507.0,1.0,168.0,105.0,,20.48,1.0,2.0,experimental,19.664,0.19534,0.1637,Human Gcn5 bound to propionyl-CoA
6CZ1,X-RAY DIFFRACTION,2.09,41.26,"VAPOR DIFFUSION, HANGING DROP",8.5,"24-26% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride",289.0,2018-04-07,2019-04-10,6CZ1,6467.0,2.0,764.0,477.0,,85.47,1.0,1.68,experimental,27.27,0.218,0.187,Crystal structure of ATPase domain of Human GRP78 bound to Ver155008
6DWS,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, SITTING DROP",,"24 to 26% PEG 3350, 0.1 M Tris-HCl and 0.2 M NaCl (by microseeding with the initial crystals from 0.1 M Tris- HCl pH 8.5, 25% PEG 3350 and 0.1 M Na/K tartrate)",298.15,2018-06-27,2019-07-03,6DWS,6291.0,2.0,764.0,313.0,,85.17,1.0,1.9,experimental,42.29,0.248,0.213,"Crystal structure of human GRP78 in complex with (2R,3R,4S,5R)-2-(6-amino-8-((2-chlorobenzyl)amino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol"
6YPJ,X-RAY DIFFRACTION,2.04,39.59,"VAPOR DIFFUSION, SITTING DROP",6.5,"112.5mM Mes, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2020-04-16,2020-07-15,6YPJ,3050.0,1.0,328.0,223.0,,39.39,1.0,1.64,experimental,32.33,0.2323,0.195,Crystal Structure of CK2alpha with Compound 1 bound
5JZ6,X-RAY DIFFRACTION,3.02,59.32,"VAPOR DIFFUSION, SITTING DROP",7.0,"1mM MMT buffer (DL-Malic acid, MES, Tris base), 25% PEG1500, 1 mM MnCl2, 2 mM N-oxalylglycine, 18 mg/ml protein",277.0,2016-05-16,2017-05-24,5JZ6,3698.0,1.0,429.0,202.0,1.0,49.96,1.0,2.354,experimental,51.3736,0.2196,0.1861,Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese and L-malate
5JZA,X-RAY DIFFRACTION,2.95,58.33,"VAPOR DIFFUSION, SITTING DROP",9.0,"100 mM bicine, 100 mM sodium chloride, 27% PEG 550 MME, 1 mM manganese chloride, 2 mM N-oxalylglycine, 18 mg/ml protein",277.0,2016-05-16,2017-05-24,5JZA,3622.0,1.0,429.0,125.0,1.0,49.98,1.0,2.14,experimental,68.3722,0.1976,0.1751,Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese and N-oxalylglycine
5N94,X-RAY DIFFRACTION,2.69,54.3,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES monohydrate-imidazole
20mM sodium formate
20mM ammonium acetate
20mM sodium citrate tribasic hydrate
20mM sodium oxamate
20mM potassium sodium tartrate tetrahydrate",298.0,2017-02-24,2018-03-14,5N94,14015.0,4.0,1904.0,67.0,,221.61,1.0,2.428,experimental,,0.278,0.2119,Crystal Structure of Drosophila DHX36 helicase in complex with polyU
5N96,X-RAY DIFFRACTION,2.69,52.93,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES monohydrate-imidazole
20mM sodium formate
20mM ammonium acetate
20mM sodium citrate tribasic hydrate
20mM sodium oxamate
20mM potassium sodium tartrate tetrahydrate",298.0,2017-02-24,2018-03-14,5N96,14156.0,4.0,1908.0,129.0,,223.01,1.0,2.716,experimental,,0.2481,0.1797,Crystal Structure of Drosophila DHX36 helicase in complex with AGGGTTTTTT
5N98,X-RAY DIFFRACTION,2.69,53.49,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES monohydrate-imidazole
20mM sodium formate
20mM ammonium acetate
20mM sodium citrate tribasic hydrate
20mM sodium oxamate
20mM potassium sodium tartrate tetrahydrat",298.0,2017-02-24,2018-03-14,5N98,14157.0,4.0,1906.0,135.0,,222.45,1.0,2.756,experimental,,0.2365,0.1746,Crystal Structure of Drosophila DHX36 helicase in complex with TAGGGTTTT
5N9D,X-RAY DIFFRACTION,2.69,53.25,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES monohydrate-imidazole
20mM sodium formate
20mM ammonium acetate
20mM sodium citrate tribasic hydrate
20mM sodium oxamate
20mM potassium sodium tartrate tetrahydrate",298.0,2017-02-24,2018-03-14,5N9D,14301.0,4.0,1908.0,127.0,,223.11,1.0,2.71,experimental,,0.2469,0.1852,Crystal Structure of Drosophila DHX36 helicase in complex with GGGTTAGGGT
5KTX,X-RAY DIFFRACTION,2.58,52.24,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M potassium thiocyanate, 
0.1 M Bis-Tris pH 5.5, 
5% v/v ethylene glycol, 
23% PEG 3350",287.0,2016-07-12,2016-11-02,5KTX,1235.0,1.0,114.0,229.0,,14.17,1.0,1.27,experimental,15.7222,0.1721,0.1656,"CREBBP bromodomain in complex with Cpd59 ((S)-1-(3-((2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethanone)"
8QEL,X-RAY DIFFRACTION,3.39,63.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MOPS pH 7.5, 10% PEG 8000, 0.2 M magnesium acetate",293.0,2023-08-31,2023-09-13,8QEL,3498.0,2.0,446.0,,,52.27,2.0,2.451,experimental,80.68,0.278,0.2412,PKR kinase domain- eIF2alpha in complex with compound
6U2H,X-RAY DIFFRACTION,2.36,47.88,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 6000
Tris pH 7.5",291.0,2019-08-19,2019-08-28,6U2H,8161.0,4.0,1044.0,21.0,,119.76,2.0,2.5,experimental,95.6009,0.2632,0.2197,BRAF dimer bound to 14-3-3
8FDV,X-RAY DIFFRACTION,5.56,77.89,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2022-12-05,2024-06-12,8FDV,6425.0,3.0,1024.0,,,113.43,3.0,2.95,experimental,,0.252,0.2162,LSD1-CoREST in complex N-formyl FAD and SNAG peptide
5F21,X-RAY DIFFRACTION,2.1,41.56,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M Ammonium sulfate, 0.1 M BIS-TRIS, 25%(w/v) PEG3350",298.0,2015-12-01,2016-06-15,5F21,3163.0,2.0,411.0,273.0,7.0,46.42,2.0,1.9,experimental,27.244,0.2107,0.1625,human CD38 in complex with nanobody MU375
4RA2,X-RAY DIFFRACTION,3.07,59.97,,5.5,"15(v/v)% PEG8000, pH 5.5, 50mM K2HPO4, 15% 2mMDTT, VAPOR DIFFUSION, HANGING DROP, temperature 277.15K",277.15,2014-09-09,2015-05-13,4RA2,3042.0,1.0,367.0,214.0,,40.96,1.0,1.94,experimental,,0.224,0.196,PP2Ca
4RAF,X-RAY DIFFRACTION,3.12,60.61,"VAPOR DIFFUSION, HANGING DROP",5.5,"15%(v/v) PEG8000, pH 5.5, 50mM K2HPO4, 2mMDTT, VAPOR DIFFUSION, HANGING DROP, temperature 277.15K",277.15,2014-09-10,2015-08-26,4RAF,3068.0,1.0,367.0,253.0,,40.77,1.0,2.001,experimental,,0.2223,0.1943,Crystal structure of PP2Ca-D38A
4RAG,X-RAY DIFFRACTION,3.08,60.03,"VAPOR DIFFUSION, HANGING DROP",5.5,"15%(v/v) PEG8000, pH 5.5, 50mM K2HPO4, 2mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 277.15K",277.15,2014-09-10,2015-08-26,4RAG,3038.0,1.0,367.0,219.0,,40.83,1.0,1.85,experimental,,0.2297,0.1991,CRYSTAL STRUCTURE of PPC2A-D38K
7QUX,X-RAY DIFFRACTION,2.36,47.99,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M Ammonium sulfate, 30 % w/v PEG 4000",293.0,2022-01-19,2022-12-28,7QUX,3231.0,2.0,360.0,289.0,,43.59,2.0,1.48,experimental,33.211,0.2037,0.1797,Crystal structure of P7C8 bound to CK2alpha
6BH0,X-RAY DIFFRACTION,2.23,44.9,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BH0,2463.0,1.0,330.0,154.0,,38.49,1.0,1.985,experimental,,0.2187,0.1881,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR (R)-2-((2-chlorophenyl)(2-(piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N51)"
6BH1,X-RAY DIFFRACTION,2.2,44.12,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BH1,2527.0,1.0,330.0,160.0,,38.62,1.0,1.932,experimental,,0.1839,0.1597,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR (S)-2-((2-chlorophenyl)(2-(piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N52)"
6NJZ,X-RAY DIFFRACTION,3.48,64.63,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.09M BIS-TRIS pH5.5, 22.5% w/v PEG 3,350, 3% w/v 6-aminohexanoic acid",293.0,2019-01-04,2019-05-01,6NJZ,3341.0,4.0,408.0,209.0,4.0,47.01,2.0,1.9,experimental,57.3589,0.2069,0.1693,EphA2 LBD in complex with YSA-GSGSK-bio peptide
6NK0,X-RAY DIFFRACTION,2.33,47.17,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.09M BIS-TRIS pH5.5, 22.5% w/v PEG 3,350, 3% w/v 6-aminohexanoic acid",293.0,2019-01-04,2019-05-01,6NK0,3626.0,4.0,398.0,395.0,4.0,45.87,2.0,1.53,experimental,24.6,0.1771,0.1512,EphA2 LBD in complex with bA-WLA-Yam peptide
5ZA7,X-RAY DIFFRACTION,2.13,42.36,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2018-02-06,2018-12-19,5ZA7,2077.0,1.0,253.0,109.0,5.0,28.85,1.0,1.7,experimental,29.47,0.227,0.198,uPA-HMA
5ZA8,X-RAY DIFFRACTION,2.17,43.4,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2018-02-06,2018-12-19,5ZA8,2033.0,1.0,253.0,74.0,5.0,28.8,1.0,1.9,experimental,33.68,0.233,0.199,uPA-BB2-27F
5ZA9,X-RAY DIFFRACTION,2.15,42.74,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2018-02-07,2018-12-19,5ZA9,2068.0,1.0,253.0,106.0,5.0,28.84,1.0,1.62,experimental,28.54,0.236,0.217,uPA-BB2-50F
5ZAE,X-RAY DIFFRACTION,2.14,42.55,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2018-02-07,2018-12-19,5ZAE,2117.0,1.0,253.0,145.0,5.0,28.88,1.0,1.73,experimental,26.73,0.276,0.239,uPA-6F-HMA
5ZAF,X-RAY DIFFRACTION,2.18,43.67,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2018-02-07,2018-12-19,5ZAF,2085.0,1.0,253.0,127.0,5.0,28.79,1.0,1.65,experimental,27.58,0.236,0.205,uPA-BB2-28F
5ZAG,X-RAY DIFFRACTION,2.15,42.79,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2018-02-07,2018-12-19,5ZAG,2023.0,1.0,253.0,64.0,5.0,28.8,1.0,1.95,experimental,37.55,0.225,0.196,uPA-BB2-94F
5ZAH,X-RAY DIFFRACTION,2.14,42.43,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2018-02-07,2018-12-19,5ZAH,1964.0,1.0,253.0,3.0,5.0,28.83,1.0,2.98,experimental,66.14,0.268,0.168,uPA-BB2-30F
5ZAJ,X-RAY DIFFRACTION,2.14,42.42,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2018-02-07,2018-12-19,5ZAJ,2069.0,1.0,253.0,106.0,5.0,28.86,1.0,1.65,experimental,25.63,0.239,0.212,uPA-31F
7BW1,X-RAY DIFFRACTION,3.0,59.02,LIPIDIC CUBIC PHASE,,"30% v/v PEG600, 100mM tris-sodium citrate ph5.0, 100mM sodium chloride, 100mM Lithium sulfate",293.0,2020-04-13,2020-08-05,7BW1,2036.0,1.0,258.0,,1.0,30.36,1.0,2.8,experimental,75.84,0.2646,0.2391,Crystal structure of Steroid 5-alpha-reductase 2 in complex with Finasteride
5P9G,X-RAY DIFFRACTION,2.23,44.95,VAPOR DIFFUSION,7.0,"PEG 3350, sodium actate, BisTrisPropane",298.0,2016-09-20,2017-05-24,5P9G,2320.0,1.0,279.0,160.0,,32.93,1.0,1.75,experimental,26.58,0.2135,0.1775,Structure of BTK with RN486
5P9H,X-RAY DIFFRACTION,1.88,34.41,VAPOR DIFFUSION,7.0,"PEG 3350, sodium actate, BisTrisPropane",298.0,2016-09-20,2017-05-24,5P9H,2043.0,1.0,279.0,24.0,,32.95,1.0,1.95,experimental,61.16,0.313,0.2667,BTK1 COCRYSTALLIZED WITH RN983
5P9J,X-RAY DIFFRACTION,2.23,44.77,VAPOR DIFFUSION,7.0,"PEG 3350, sodium actate, BisTrisPropane",298.0,2016-09-20,2017-05-24,5P9J,2369.0,1.0,279.0,175.0,,32.77,1.0,1.08,experimental,19.644,0.2237,0.2093,BTK1 COCRYSTALLIZED WITH IBRUTINIB
5P9K,X-RAY DIFFRACTION,2.2,44.14,VAPOR DIFFUSION,7.0,"PEG 3350, sodium actate, BisTrisPropane",298.0,2016-09-20,2017-05-24,5P9K,2753.0,1.0,279.0,381.0,,32.83,1.0,1.28,experimental,19.5302,0.1946,0.18,CRYSTAL STRUCTURE OF BTK with CNX 774
5P9L,X-RAY DIFFRACTION,2.23,44.94,VAPOR DIFFUSION,7.0,"PEG 3350, sodium actate, BisTrisPropane",298.0,2016-09-20,2017-05-24,5P9L,2291.0,1.0,279.0,204.0,,32.75,1.0,1.25,experimental,15.725,0.2803,0.2649,BTK1 IN COMPLEX WITH CC 292
5V5Y,X-RAY DIFFRACTION,2.01,38.75,"VAPOR DIFFUSION, HANGING DROP",6.9,"9.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.1 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 12.5 % PEG 3350, 1 mM MK1775",291.0,2017-03-15,2017-08-23,5V5Y,2226.0,1.0,289.0,110.0,,33.22,1.0,1.9,experimental,36.8598,0.2147,0.1713,CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
6NYO,X-RAY DIFFRACTION,2.33,47.17,"VAPOR DIFFUSION, HANGING DROP",,"0.03 M potassium dihydrogen phosphate, 23% PEG 8,000",291.0,2019-02-11,2019-08-07,6NYO,2520.0,2.0,300.0,319.0,,34.63,2.0,1.502,experimental,,0.2022,0.1748,Crystal structure of a human Cdc34-ubiquitin thioester mimetic
5LVP,X-RAY DIFFRACTION,2.59,52.45,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.65 M Ammonium Sulfate, 1 M Na Citrate pH 5.7, 0.01 M DTT",293.0,2016-09-14,2016-10-19,5LVP,9538.0,8.0,1304.0,286.0,,149.72,2.0,2.5,experimental,,0.2257,0.1737,Human PDK1 Kinase Domain in Complex with an HM-Peptide Bound to the PIF-Pocket
6EP9,X-RAY DIFFRACTION,2.27,45.81,"VAPOR DIFFUSION, HANGING DROP",8.0,"33% PEG3350, 0.1M HEPES",293.0,2017-10-11,2018-08-22,6EP9,2374.0,1.0,283.0,189.0,,33.14,1.0,2.01,experimental,30.96,0.23916,0.19875,Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiperazine-1-carbonyl)anilino]-5-oxo-pyrazin-2-yl]phenyl]-4-(1-piperidyl)benzamide
7A4O,X-RAY DIFFRACTION,2.25,45.24,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-20,2021-06-30,7A4O,5836.0,2.0,764.0,261.0,,90.12,1.0,1.9,experimental,30.01,0.203,0.179,Structure of DYRK1A in complex with AMPNP
7A4W,X-RAY DIFFRACTION,2.28,46.17,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-20,2021-06-30,7A4W,5828.0,2.0,764.0,245.0,,89.54,1.0,2.7,experimental,48.912,0.2046,0.1623,Structure of DYRK1A in complex with compound 3
7A53,X-RAY DIFFRACTION,2.32,47.04,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-20,2021-06-30,7A53,5672.0,2.0,718.0,234.0,,83.74,1.0,2.2,experimental,49.444,0.2768,0.218,Structure of DYRK1A in complex with compound 7
7A55,X-RAY DIFFRACTION,2.25,45.34,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-20,2021-06-30,7A55,5842.0,2.0,764.0,269.0,,89.49,1.0,2.2,experimental,37.152,0.2251,0.1799,Structure of DYRK1A in complex with compound 8
7A5B,X-RAY DIFFRACTION,2.28,46.08,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-20,2021-06-30,7A5B,5836.0,2.0,764.0,267.0,,89.59,1.0,2.6,experimental,42.335,0.1917,0.1536,Structure of DYRK1A in complex with complex 10
7A5N,X-RAY DIFFRACTION,2.38,48.39,VAPOR DIFFUSION,7.5,"0.1M Hepes buffer at pH 7.5, 20% Peg4k, 0.2M MgCl2",293.0,2020-08-21,2021-06-30,7A5N,5470.0,2.0,718.0,63.0,,84.13,1.0,2.3,experimental,40.683,0.2851,0.2187,Structure of DYRK1A in complex with compound 34
6RW2,X-RAY DIFFRACTION,3.55,65.39,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium acetate
0.2M lithium sulphate
8-10% PEG 6000",293.0,2019-06-03,2020-04-08,6RW2,1633.0,2.0,211.0,43.0,3.0,24.35,2.0,2.26,experimental,41.752,0.2646,0.211,Bicycle Toxin Conjugate bound to EphA2
5KJ2,X-RAY DIFFRACTION,2.61,52.92,VAPOR DIFFUSION,,"25% (w/v) PEG3350, 0.2M Sodium Chloride, 0.1M BIS-TRIS buffer pH5.5",290.0,2016-06-17,2017-09-27,5KJ2,2884.0,1.0,348.0,259.0,,40.82,1.0,1.95,experimental,39.78,0.26,0.225,The novel p300/CBP inhibitor A-485 uncovers a unique mechanism of action to target AR in castrate resistant prostate cancer
5K5X,X-RAY DIFFRACTION,4.06,69.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES pH7.5, 1.6M (NH4)2SO4, 0.1M NaCl",293.0,2016-05-24,2016-08-17,5K5X,2918.0,1.0,356.0,148.0,,40.88,1.0,2.168,experimental,,0.2237,0.1916,Crystal structure of human PDGFRA
6XRN,X-RAY DIFFRACTION,2.45,49.8,SMALL TUBES,,"PEG 4000,  (NH4)2SO4, Na Form, Tris",277.0,2020-07-13,2021-11-03,6XRN,6730.0,1.0,949.0,,,109.21,1.0,2.96,experimental,129.132,0.2695,0.224,Crystal structure of human PI3K-gamma in complex with Compound 17
6V8N,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M Ammonium Sulfate, 0.1 M BisTris pH 5.5, 20% PEG 3350, streak-seed with loop",277.0,2019-12-11,2020-04-01,6V8N,2677.0,1.0,349.0,32.0,,41.08,1.0,2.3,experimental,49.162,0.2471,0.2004,Crystal structure of the p300 acetyltransferase domain with AcCoA competitive inhibitor 17
6R2W,X-RAY DIFFRACTION,2.55,51.72,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1 M sodium citrate, pH 5.6, 15.6 % (w/v) PEG 3350, 12 % (v/v) 1-Propanol",295.0,2019-03-19,2019-12-11,6R2W,5757.0,3.0,602.0,714.0,15.0,70.02,3.0,1.25,experimental,27.0879,0.1938,0.1702,Crystal structure of the super-active FVIIa variant VYT in complex with tissue factor
5O11,X-RAY DIFFRACTION,3.41,63.91,"VAPOR DIFFUSION, SITTING DROP",8.0,"Tris, potassium sodium tartrate tetrahydrate",293.0,2017-05-17,2017-11-01,5O11,2297.0,1.0,298.0,97.0,,35.17,1.0,2.4,experimental,43.251,0.21159,0.16461,Crystal structure of PIM1 kinase in complex with small-molecule inhibitor
4Z16,X-RAY DIFFRACTION,2.71,54.54,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-tris pH 6.5, 16% PEG 3350, 0.2 M ammonium sulfate, 5 mM TCEP",277.0,2015-03-26,2016-02-10,4Z16,9053.0,4.0,1264.0,46.0,,145.88,1.0,2.9,experimental,65.05,0.2401,0.2021,Crystal Structure of the Jak3 Kinase Domain Covalently Bound to N-(3-(((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)methyl)phenyl)acrylamide
7UJT,X-RAY DIFFRACTION,2.18,43.47,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M 1,3-bis(tris(hydroxymethyl)methylamino)propane, 0.2 M Sodium chloride, 25% PEG 3350",277.0,2022-03-31,2022-04-13,7UJT,2402.0,2.0,290.0,96.0,,33.95,2.0,2.1,experimental,25.904,0.2465,0.2034,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D) in complex with ATP
6BDT,X-RAY DIFFRACTION,2.0,38.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 8000, MES, calcium chloride",295.15,2017-10-24,2018-02-07,6BDT,10499.0,4.0,1528.0,113.0,,178.22,1.0,2.3,experimental,60.172,0.256,0.2219,Crystal Structure of Human Calpain-3 Protease Core Mutant-C129S
5C46,X-RAY DIFFRACTION,2.67,53.99,"VAPOR DIFFUSION, HANGING DROP",5.6,"PEG-4000, sodium citrate, ammonium sulfate, glycerol",290.0,2015-06-17,2016-01-20,5C46,5219.0,2.0,748.0,4.0,,86.13,2.0,2.65,experimental,82.1371,0.2461,0.2161,Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta in complex with GTP gamma S loaded Rab11
5XPI,X-RAY DIFFRACTION,3.17,64.93,"VAPOR DIFFUSION, SITTING DROP",5.2,2.7 M Na formate and 0.1 M Na acetate pH 5.2,293.0,2017-06-02,2018-04-25,5XPI,1315.0,1.0,157.0,116.0,,18.83,1.0,2.2,experimental,44.83,0.2186,0.2,Structure of UHRF1 TTD in complex with NV01
7A4R,X-RAY DIFFRACTION,2.3,46.52,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-20,2021-06-30,7A4R,6123.0,2.0,710.0,636.0,,82.69,1.0,1.8,experimental,20.051,0.1937,0.1621,Structure of DYRK1A in complex with compound 1
7A52,X-RAY DIFFRACTION,2.34,47.37,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-20,2021-06-30,7A52,6095.0,2.0,710.0,591.0,,82.92,1.0,2.1,experimental,28.371,0.2057,0.1653,Structure of DYRK1A in complex with compound 6
7AJM,X-RAY DIFFRACTION,2.3,46.63,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH6.5, 0.2M MgCl2",293.0,2020-09-29,2021-05-26,7AJM,6105.0,2.0,710.0,593.0,,82.9,1.0,2.4,experimental,29.405,0.2101,0.1616,Structure of DYRK1A in complex with compound 32
7AK2,X-RAY DIFFRACTION,2.4,48.7,"VAPOR DIFFUSION, SITTING DROP",5.5,"15% PEG 4K, 0.2M ammonium sulphate, 0.1M sodium DL-malate buffer pH 5.5",293.0,2020-09-29,2021-05-26,7AK2,5720.0,2.0,718.0,252.0,,84.19,1.0,2.1,experimental,39.554,0.2308,0.1966,Structure of DYRK1A in complex with compound 53
7AKA,X-RAY DIFFRACTION,2.36,47.82,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG4k, 0.2M Mg chloride, 0.1M MES buffer pH 6.5",293.0,2020-09-30,2021-05-26,7AKA,5813.0,2.0,718.0,318.0,,84.25,1.0,1.9,experimental,36.798,0.2113,0.1724,Structure of DYRK1A in complex with compound 54
7T4T,X-RAY DIFFRACTION,2.69,54.33,VAPOR DIFFUSION,8.0,0.1M Bis Tris propane pH 7.5 0.2M Sodium sulfate 20% PEG 3350,295.0,2021-12-10,2023-06-14,7T4T,7644.0,2.0,938.0,250.0,,108.28,1.0,2.08,experimental,54.31,0.221,0.188,Crystal Structure of cGMP-dependent Protein Kinase
7T4U,X-RAY DIFFRACTION,2.34,47.51,VAPOR DIFFUSION,8.0,0.1M MIB pH 9.0 25% PEG 1500,298.0,2021-12-10,2023-06-14,7T4U,7807.0,2.0,938.0,307.0,,107.39,1.0,1.99,experimental,43.94,0.26,0.214,Crystal Structure of cGMP-dependent Protein Kinase
7T4V,X-RAY DIFFRACTION,2.34,47.55,VAPOR DIFFUSION,8.0,0.1M SPG pH 8.0 25% PEG1500,289.0,2021-12-10,2023-06-14,7T4V,7632.0,2.0,938.0,107.0,,107.45,1.0,2.28,experimental,34.64,0.256,0.194,Crystal Structure of cGMP-dependent Protein Kinase
7T4W,X-RAY DIFFRACTION,2.33,47.3,VAPOR DIFFUSION,8.0,0.1M SPG pH 4.0 25% PEG1500,289.0,2021-12-10,2023-06-14,7T4W,7688.0,2.0,938.0,141.0,,107.42,1.0,2.23,experimental,36.09,0.267,0.204,Crystal Structure of cGMP-dependent Protein Kinase
5B0X,X-RAY DIFFRACTION,1.97,37.69,"VAPOR DIFFUSION, SITTING DROP",,ethylene glycol,277.0,2015-11-13,2016-03-30,5B0X,2942.0,1.0,340.0,138.0,,40.83,1.0,2.3,experimental,,0.234,0.218,Crystal structure of the CK2a/benzoic acid derivative complex
6L1Z,X-RAY DIFFRACTION,2.0,38.61,"VAPOR DIFFUSION, SITTING DROP",,Ethylene Glycol,277.0,2019-10-02,2020-02-26,6L1Z,2950.0,1.0,340.0,149.0,,40.78,1.0,1.90820949507,experimental,29.6611674599,0.21629499244,0.194197591942,Crystal structure of CK2a1 with hematein
6L21,X-RAY DIFFRACTION,1.94,36.73,"VAPOR DIFFUSION, SITTING DROP",,Ethylene glycol,277.0,2019-10-02,2020-02-26,6L21,2981.0,1.0,340.0,171.0,,40.71,1.0,2.05451776886,experimental,18.8998325875,0.224759089746,0.167511096531,Crystal structure of CK2a1 H160A with hematein
6L22,X-RAY DIFFRACTION,1.95,36.9,"VAPOR DIFFUSION, SITTING DROP",,25% Ethylene Glycol,277.0,2019-10-02,2020-02-26,6L22,3028.0,1.0,340.0,158.0,,40.8,1.0,2.12318084151,experimental,23.5842533527,0.242924126409,0.180247346967,Crystal structure of CK2a1 H115Y with hematein
6L23,X-RAY DIFFRACTION,2.01,38.9,"VAPOR DIFFUSION, SITTING DROP",,Ethylene glycol,277.0,2019-10-02,2021-03-31,6L23,3024.0,1.0,340.0,117.0,,41.35,1.0,1.9744942746,experimental,21.9822130972,0.228733919588,0.179110694155,Crystal structure of CK2a1 V116I with hematein
6L24,X-RAY DIFFRACTION,2.01,38.69,"VAPOR DIFFUSION, SITTING DROP",,Ethylene glycol,277.0,2019-10-02,2020-02-26,6L24,2949.0,1.0,340.0,85.0,,40.82,1.0,2.40009490218,experimental,30.5201596931,0.262989158332,0.183598204414,Crystal structure of CK2a1 H115Y/V116I with hematein
5WVO,X-RAY DIFFRACTION,2.89,57.43,"VAPOR DIFFUSION, HANGING DROP",6.0,"100mM Bis-Tris (pH 6.0), 200mM lithium sulfate monohydrate, 20% PEG 10000",277.0,2016-12-28,2017-11-15,5WVO,3362.0,4.0,439.0,197.0,1.0,49.12,3.0,1.997,experimental,,0.2387,0.1958,Crystal structure of DNMT1 RFTS domain in complex with K18/K23 mono-ubiquitylated histone H3
5TQ4,X-RAY DIFFRACTION,2.75,55.35,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Hepes, pH 7.5, 0.1 M sodium acetate, 30% PEG-3350",293.0,2016-10-23,2017-01-11,5TQ4,2530.0,1.0,298.0,109.0,,35.31,1.0,2.3,experimental,23.727,0.2792,0.24734,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
5TQ5,X-RAY DIFFRACTION,2.26,45.65,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes, pH 7.5, 0.1 M sodium acetate, 30% PEG-3350",293.0,2016-10-23,2017-01-11,5TQ5,2432.0,1.0,298.0,34.0,,35.25,1.0,2.3,experimental,17.0,0.33246,0.27933,Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
6A1F,X-RAY DIFFRACTION,2.47,50.15,"VAPOR DIFFUSION, SITTING DROP",,2.0M Ammonium sulfate,293.0,2018-06-07,2018-10-03,6A1F,3103.0,1.0,360.0,219.0,,42.89,1.0,1.5,experimental,18.336,0.1954,0.17743,Crystal structure of human DYRK1A in complex with compound 14
7AJ2,X-RAY DIFFRACTION,2.49,50.51,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH6.5; 0.2M MgCl2",293.0,2020-09-28,2021-05-26,7AJ2,2941.0,1.0,359.0,232.0,,41.92,1.0,2.1,experimental,45.008,0.2182,0.1748,Structure of DYRK1A in complex with compound 3
7AJ4,X-RAY DIFFRACTION,2.48,50.33,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH6.5, 0.2M MgCl2",293.0,2020-09-28,2021-05-26,7AJ4,2970.0,1.0,359.0,278.0,,41.95,1.0,2.0,experimental,32.677,0.2118,0.1695,Structure of DYRK1A in complex with compound 5
7AJ5,X-RAY DIFFRACTION,2.49,50.56,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH6.5, 0.2M MgCl2",293.0,2020-09-28,2021-05-26,7AJ5,2953.0,1.0,359.0,245.0,,41.94,1.0,2.0,experimental,39.5,0.2016,0.1716,Structure of DYRK1A in complex with compound 10
7AJ7,X-RAY DIFFRACTION,2.5,50.79,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH6.5, 0.2M MgCl2",293.0,2020-09-28,2021-05-26,7AJ7,2743.0,1.0,359.0,83.0,,41.96,1.0,2.9,experimental,59.553,0.2443,0.1832,Structure of DYRK1A in complex with compound 16
7AJ8,X-RAY DIFFRACTION,2.48,50.31,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH6.5, 0.2M MgCl2",293.0,2020-09-28,2021-05-26,7AJ8,2976.0,1.0,359.0,266.0,,41.93,1.0,2.0,experimental,36.722,0.2104,0.1727,Structure of DYRK1A in complex with compound 25
7AJA,X-RAY DIFFRACTION,2.49,50.54,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH6.5, 0.2M MgCl2",293.0,2020-09-28,2021-05-26,7AJA,2988.0,1.0,359.0,269.0,,42.0,1.0,2.2,experimental,34.986,0.206,0.1681,Structure of DYRK1A in complex with compound 28
7AJW,X-RAY DIFFRACTION,2.5,50.76,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH 6.5, 0.2M MgCl2",293.0,2020-09-29,2021-05-26,7AJW,2805.0,1.0,359.0,114.0,,42.08,1.0,2.8,experimental,52.686,0.237,0.1797,Structure of DYRK1A in complex with compound 46
7AKL,X-RAY DIFFRACTION,2.5,50.75,VAPOR DIFFUSION,6.5,"12% PEG3350, 0.1M MES buffer pH6.5, 0.2M MgCl2",293.0,2020-10-01,2021-05-26,7AKL,2935.0,1.0,359.0,242.0,,41.94,1.0,2.0,experimental,27.351,0.2102,0.167,Structure of DYRK1A in complex with compound 50
5M9V,X-RAY DIFFRACTION,3.2,61.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Na/K tartrate
0.1 M bis-tris propane
16% PEG 4000",289.0,2016-11-02,2017-02-22,5M9V,1146.0,1.0,124.0,110.0,3.0,14.7,1.0,1.7,experimental,32.177,0.23883,0.20873,Human angiogenin PD/ALS variant R121C
7SUH,X-RAY DIFFRACTION,2.31,46.68,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer PH 6.5, 20% ethylene glycol",293.0,2021-11-17,2022-01-12,7SUH,2220.0,1.0,297.0,97.0,,34.59,1.0,2.46,experimental,58.26,0.242,0.176,Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 15
6VDB,X-RAY DIFFRACTION,2.53,51.34,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M KSCN, 0.1 M Tris-HCl pH 8.5, and 26% PEG 3350",291.0,2019-12-24,2020-01-29,6VDB,2015.0,2.0,309.0,24.0,1.0,37.73,2.0,2.3,experimental,46.45,0.263,0.212,SETD2 in complex with a H3-variant super-substrate peptide
5EHP,X-RAY DIFFRACTION,2.28,46.04,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG 3350, 200mM Ammonium Phosphate",277.0,2015-10-28,2016-07-06,5EHP,8600.0,2.0,1052.0,654.0,,122.13,1.0,1.85,experimental,34.24,0.2084,0.1745,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP836
6BMR,X-RAY DIFFRACTION,2.29,46.22,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2017-11-15,2018-01-17,6BMR,8707.0,2.0,1052.0,736.0,,122.39,1.0,2.205,experimental,40.45,0.224,0.167,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP244
6BMX,X-RAY DIFFRACTION,2.29,46.23,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2017-11-15,2018-01-17,6BMX,8582.0,2.0,1052.0,639.0,,122.29,1.0,2.424,experimental,44.48,0.252,0.167,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP844
6MD7,X-RAY DIFFRACTION,2.26,45.67,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2018-09-04,2019-02-13,6MD7,8849.0,2.0,1052.0,732.0,,122.51,1.0,1.96,experimental,,0.209,0.17,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrimidinone 7
6MDB,X-RAY DIFFRACTION,2.27,45.77,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2018-09-04,2019-02-13,6MDB,8448.0,2.0,1052.0,524.0,,121.77,1.0,2.34,experimental,,0.236,0.175,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrazolo-pyrimidinone 5
6C9F,X-RAY DIFFRACTION,3.78,67.47,VAPOR DIFFUSION,,"0.1 M tri-sodium acetate pH 5.6, 0.2 M ammonium acetate, 15% w/v PEG 4000",293.0,2018-01-26,2018-11-28,6C9F,6991.0,3.0,1029.0,,,119.9,3.0,2.924,experimental,,0.2449,0.2279,AMP-activated protein kinase bound to pharmacological activator R734
6C9G,X-RAY DIFFRACTION,3.74,67.15,VAPOR DIFFUSION,,"0.1 M tri-sodium acetate pH 5.6, 0.2 M ammonium acetate, 15% w/v PEG 4000",293.0,2018-01-26,2018-11-28,6C9G,7170.0,3.0,1029.0,52.0,,119.94,3.0,2.7,experimental,,0.2401,0.2023,AMP-activated protein kinase bound to pharmacological activator R739
7EYX,X-RAY DIFFRACTION,1.75,29.68,"VAPOR DIFFUSION, SITTING DROP",,"30% (w/v) PEG-8000, 
0.1M Acetate pH 4.5, 0.2M Li2SO4 (final pH 4.7)",298.0,2021-06-01,2021-06-16,7EYX,1330.0,1.0,169.0,59.0,,19.73,1.0,1.82,experimental,18.86,0.2124,0.1731,Crystal structure of Mg-free KRAS-G12D bound to GDP
5O90,X-RAY DIFFRACTION,2.24,45.12,"VAPOR DIFFUSION, HANGING DROP",7.0,"20% PEG3350
0.2M Na/K Tartrate
0.1M pH7.0 Bis-Tris Propane",277.0,2017-06-15,2018-01-31,5O90,2599.0,2.0,389.0,8.0,,44.74,2.0,2.49,experimental,,0.2748,0.249,Crystal structure of a P38alpha T185G mutant in complex with TAB1 peptide.
5H0U,X-RAY DIFFRACTION,3.04,59.49,"VAPOR DIFFUSION, SITTING DROP",,"Ammonium nitrate, PEG3350",277.0,2016-10-07,2017-10-04,5H0U,1567.0,2.0,176.0,68.0,,21.44,2.0,2.239,experimental,,0.2538,0.1953,Crystal structure of the catalytic domain of membrane type 1 matrix metalloproteinase
7FCC,X-RAY DIFFRACTION,2.07,40.47,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium citrate, pH 5.6, 20%w/v PEG4000, 20% v/v 2-propanol",291.0,2021-07-14,2022-07-20,7FCC,1238.0,1.0,146.0,54.0,,16.83,1.0,2.144,experimental,34.5647,0.2431,0.1999,IL-1RAcPb TIR domain
5M0B,X-RAY DIFFRACTION,2.18,53.33,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)

Reservoir: 18% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-10-04,2018-06-06,5M0B,3596.0,2.0,373.0,515.0,,43.77,2.0,1.506,experimental,,0.1594,0.132,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a short-chained N-(2-aminoethyl)isoquinoline-5-sulfonamide) Fasudil-derivative (Ligand 03)
6CZS,X-RAY DIFFRACTION,3.97,69.0,"VAPOR DIFFUSION, SITTING DROP",4.2,"0.1 M sodium phosphate dibasic / citric acid, pH 4.2, 2.0 M ammonium sulfate",293.0,2018-04-09,2018-08-08,6CZS,3167.0,1.0,335.0,498.0,5.0,39.79,1.0,1.66,experimental,,0.2085,0.1813,Crystal structure of human pro-cathepsin H C26S mutant
5ITA,X-RAY DIFFRACTION,2.22,44.5,"VAPOR DIFFUSION, SITTING DROP",,PEG3350,291.1,2016-03-16,2016-08-10,5ITA,4177.0,2.0,594.0,99.0,,68.26,1.0,1.95,experimental,,0.244,0.195,Crystal Structure of BRAF Kinase Domain Bound to AZ-VEM
5V8V,X-RAY DIFFRACTION,2.7,54.51,"VAPOR DIFFUSION, SITTING DROP",7.5,"19-22% PEG3350, 200mM ammonium sulfate, 100mM TRIS-HCl, pH 7.5, 2mM inhibitor, 1% DMSO",277.0,2017-03-22,2017-10-18,5V8V,5355.0,2.0,674.0,69.0,6.0,76.43,1.0,2.6,experimental,,0.2533,0.1858,Crystal Structure of Human Renin in Complex with a biphenylpipderidinylcarbinol
4Z07,X-RAY DIFFRACTION,2.84,56.71,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.2 M ammonium sulfate, 17.5% PEG 8000 (w/v), 10% Isopropanol, 0.1 M HEPES, pH 8.0",295.0,2015-03-25,2016-04-13,4Z07,5474.0,3.0,786.0,330.0,,89.93,1.0,2.5,experimental,,0.2237,0.1623,Co-crystal structure of the tandem CNB (CNB-A/B) domains of human PKG I beta with cGMP
6C0T,X-RAY DIFFRACTION,2.36,47.84,"VAPOR DIFFUSION, HANGING DROP",7.5,"24%w/v PEG1500, 20%v/v glycerol, 3% w/v Trimethylamine N-oxide dihydrate",295.0,2018-01-02,2018-05-30,6C0T,2759.0,1.0,347.0,98.0,,40.26,1.0,1.98,experimental,,0.2438,0.2072,Crystal structure of cGMP-dependent protein kinase Ialpha (PKG Ialpha) catalytic domain bound with N46
7JVV,X-RAY DIFFRACTION,2.37,48.02,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, pH 8.0, 20% PEG6000, 4 mM TCEP",294.0,2020-08-24,2020-12-16,7JVV,6201.0,4.0,790.0,451.0,,89.05,2.0,1.84,experimental,19.7,0.197,0.164,Crystal structure of human histone deacetylase 8 (HDAC8) E66D/Y306F double mutation complexed with a tetrapeptide substrate
5MUT,X-RAY DIFFRACTION,3.7,66.75,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.2M KBr, 0.2M KSCN, 0.1M NaAc pH 5.2, 25% PEG 400, 2% PGA-LM",293.0,2017-01-14,2017-03-08,5MUT,3072.0,1.0,365.0,301.0,,40.86,1.0,1.75,experimental,12.8739,0.1979,0.1682,Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on hydroxylated azole scaffolds
5MVC,X-RAY DIFFRACTION,3.85,68.02,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.2M KBr, 0.2M KSCN, 0.1M NaAc pH 5.2, 35% PEG 400, 5% PGA-LM",293.0,2017-01-16,2017-03-08,5MVC,3076.0,1.0,390.0,288.0,,43.91,1.0,1.85,experimental,15.7472,0.1892,0.1618,Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on hydroxylated azole scaffolds
5MVD,X-RAY DIFFRACTION,3.87,68.22,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.2M KBr, 0.2M KSCN, 0.1M NaAc pH 5.2, 35% PEG 400, 5% PGA-LM",293.0,2017-01-16,2017-03-08,5MVD,2997.0,1.0,363.0,233.0,,40.71,1.0,1.95,experimental,16.4273,0.2016,0.1672,Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on hydroxylated azole scaffolds
6IDJ,X-RAY DIFFRACTION,3.39,63.76,"VAPOR DIFFUSION, HANGING DROP",4.9,"100 MM SODIUM ACETATE, 1.8-1.9 M         AMMONIUM SULPHATE, 40 MM C11DAO, 20.8 MM DDAO, 2 MM DIHYDROOROTATE,",293.0,2018-09-10,2019-09-11,6IDJ,3051.0,1.0,390.0,132.0,,44.08,1.0,1.9,experimental,29.991,0.17803,0.16256,Crystal structure of human DHODH in complex with ferulenol
6M2B,X-RAY DIFFRACTION,3.69,66.63,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM UDAO, 20.8mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate, pH 4.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2020-02-27,2021-03-03,6M2B,3059.0,1.0,390.0,145.0,,43.62,1.0,1.76,experimental,19.346,0.193,0.1676,Crystal structure of human dihydroorotate dehydrogenase (DHODH) with S416
6QU7,X-RAY DIFFRACTION,3.67,66.45,"VAPOR DIFFUSION, HANGING DROP",,"2.3 M NH4SO4, 0.1 M Na-acetate, 30% Glycerol",293.0,2019-02-26,2019-06-05,6QU7,3152.0,1.0,366.0,194.0,,41.29,1.0,1.52,experimental,23.278,0.17324,0.15152,Crystal structure of human DHODH in complex with BAY 2402234
6XAR,X-RAY DIFFRACTION,2.01,38.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"CBL/SLAP2 complex mixed in hanging drop with equal volume (200 nL) of 0.1 M Hepes pH 7.5, 10% (w/v) PEG8000",293.0,2020-06-04,2021-03-03,6XAR,5002.0,4.0,708.0,47.0,,81.88,2.0,2.501,experimental,48.5193,0.2934,0.2493,Structure of CBL tyrosine kinase binding domain (TKBD) with C-terminal tail of Src-like kinase protein 2 (SLAP2)
8CGC,X-RAY DIFFRACTION,2.34,47.45,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.3 M DL-Malic acid pH 7.0, 23.0% w/v PEG 3350",293.0,2023-02-03,2023-05-24,8CGC,2966.0,1.0,343.0,379.0,,39.24,1.0,1.925,experimental,32.398,0.2059,0.1516,Structure of CSF1R in complex with a pyrollopyrimidine (compound 23)
5NP3,X-RAY DIFFRACTION,1.86,33.86,"VAPOR DIFFUSION, HANGING DROP",7.0,1.8 M di-sodium-DL-malate,293.0,2017-04-13,2018-05-16,5NP3,1851.0,4.0,244.0,37.0,,27.07,1.0,2.0,experimental,,0.2344,0.2006,Abl2 SH3
7BHE,X-RAY DIFFRACTION,2.66,53.73,VAPOR DIFFUSION,4.83,"0.1 M Na citrate, 12% PEG4000, 0.2 M Li sulfate",293.0,2021-01-11,2021-11-24,7BHE,4319.0,4.0,576.0,463.0,20.0,62.55,2.0,2.297,experimental,34.4,0.2536,0.184,"DARPin_D5/Her3 domain 4 complex, monoclinic crystals"
5H86,X-RAY DIFFRACTION,2.03,39.53,"VAPOR DIFFUSION, HANGING DROP",7.8,"10% (v/v) 2-propanol, 3% glycerol, 100 mM HEPES, pH 7.8, and 11% (w/v) PEG 4,000",293.0,2015-12-23,2016-03-23,5H86,1485.0,1.0,168.0,88.0,,20.31,1.0,2.08,experimental,20.113,0.19421,0.15642,Human Gcn5 bound to butyryl-CoA
4RBL,X-RAY DIFFRACTION,3.37,63.53,"VAPOR DIFFUSION, HANGING DROP",9.5,"0.4 M potassium sodium, tartrate tetrahydrate, pH 9.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-09-12,2015-03-18,4RBL,2244.0,1.0,289.0,,,33.56,1.0,2.55,experimental,64.217,0.24866,0.18837,Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives
4RC2,X-RAY DIFFRACTION,3.36,63.44,"VAPOR DIFFUSION, HANGING DROP",9.5,"0.4 M potassium sodium tartrate tetrahydrate, pH 9.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-09-14,2015-03-18,4RC2,2254.0,1.0,289.0,,,33.65,1.0,2.096,experimental,41.426,0.24559,0.20803,Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives
4RC3,X-RAY DIFFRACTION,3.36,63.35,"VAPOR DIFFUSION, HANGING DROP",9.5,"0.4 M potassium sodium tartrate tetrahydrate, pH 9.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-09-14,2015-03-18,4RC3,2256.0,1.0,289.0,,,33.74,1.0,2.338,experimental,51.929,0.22211,0.19064,Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives
4RC4,X-RAY DIFFRACTION,3.37,63.5,"VAPOR DIFFUSION, HANGING DROP",9.5,"0.4 M potassium sodium tartrate tetrahydrate, pH 9.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-09-14,2015-03-18,4RC4,2254.0,1.0,289.0,,,33.65,1.0,2.651,experimental,45.282,0.24143,0.1889,Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives
8UN3,X-RAY DIFFRACTION,3.01,59.17,EVAPORATION,8.0,"0.2M Sodium Chloride, 0.1M Imidazole pH8.0, 0.4M Sodium di-hydrogen Phosphate, 1.6M Di-potassium Hydrogen Phosphate",277.0,2023-10-18,2023-12-20,8UN3,6119.0,4.0,672.0,430.0,,81.33,1.0,2.07,experimental,38.7432,0.1911,0.1623,"KRAS-G13D-GDP in complex with Cpd5 (1-((S)-10-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-11-chloro-7-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-3,4,13,13a-tetrahydropyrazino[2',1':3,4][1,4]oxazepino[5,6,7-de]quinazolin-2(1H)-yl)prop-2-en-1-one)"
5KCX,X-RAY DIFFRACTION,3.49,63.03,"VAPOR DIFFUSION, HANGING DROP",6.5,"protein stock: 6.26 mg/mL in Tris 20mM - DTT 5mM - NaCl 150mM - 0.5 mM inhibitor - pH8
crystallization solution: imidazole 0.1M - Na Acetate 0.6M - pH6.5
1:1 protein to solution ratio for hanging drop
freezing conditions: imidazole 0.1M - Na Acetate 1M - glycerol 20% - pH6.5",277.0,2016-06-07,2017-07-19,5KCX,2431.0,1.0,291.0,143.0,,34.13,1.0,2.2,experimental,,0.2112,0.1902,Pim-1 kinase in Complex with a Selective N-substituted 7-azaindole Inhibitor
9EQH,X-RAY DIFFRACTION,2.07,40.6,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MMT pH 6.0, 25 % PEG1500",289.0,2024-03-21,2024-05-15,9EQH,3642.0,1.0,447.0,105.0,,53.65,1.0,2.05,experimental,51.688,0.2749,0.2134,"WWP2 WW2-2,3-linker-HECT (WWP2-LH)"
5CGD,X-RAY DIFFRACTION,2.53,51.37,LIPIDIC CUBIC PHASE,6.8,"24-34% V/V PEG400, 0.2 M AMMONIUM  PHOSPHATE DIBASIC, 0.1 M MES, PH 6.8,",293.1,2015-07-09,2015-08-12,5CGD,3345.0,1.0,444.0,65.0,1.0,51.24,1.0,2.603,experimental,37.0,0.2853,0.2419,Structure of the human class C GPCR metabotropic glutamate receptor 5 transmembrane domain in complex with the negative allosteric modulator 3-chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile - (HTL14242)
4X4V,X-RAY DIFFRACTION,2.68,54.05,"VAPOR DIFFUSION, SITTING DROP",6.8,"23.2% PEG3350, 0.2M NaK tartrate, 0.1M MES pH 6.8",290.0,2014-12-03,2015-02-11,4X4V,8922.0,4.0,988.0,215.0,,134.06,1.0,2.6,experimental,47.8,0.2372,0.1841,Crystal structure of the A.fulgidus CCA-adding enzyme in complex with a human MenBeta minihelix ending in CCACC and AMPcPP
5AX3,X-RAY DIFFRACTION,1.95,36.82,"VAPOR DIFFUSION, SITTING DROP",5.5,"PEG3350, Sodium chloride",277.0,2015-07-14,2016-02-10,5AX3,2831.0,2.0,380.0,,,44.12,2.0,2.984,experimental,,0.2846,0.2364,Crystal structure of ERK2 complexed with allosteric and ATP-competitive inhibitors.
4XHK,X-RAY DIFFRACTION,3.06,59.75,VAPOR DIFFUSION,5.5,"0.1M BisTRIS pH 5.5, 0.2M NaCl, 1.5M Ammonium Sulfate",298.0,2015-01-05,2015-02-11,4XHK,2507.0,1.0,315.0,267.0,,36.37,1.0,1.9,experimental,30.688,0.1842,0.1561,PIM1 kinase in complex with Compound 1s
5DGZ,X-RAY DIFFRACTION,3.56,65.4,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 4000, 0.2M LiSO4, 0.1M Tris-HCl",289.0,2015-08-29,2015-10-28,5DGZ,2345.0,1.0,299.0,87.0,,35.03,1.0,2.502,experimental,47.0485,0.2129,0.1802,"Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors"
5DHJ,X-RAY DIFFRACTION,3.54,65.22,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 4000, 0.2M LiSO4, 0.1M Tris-HCl",289.0,2015-08-31,2015-10-28,5DHJ,2308.0,1.0,299.0,58.0,,34.85,1.0,2.457,experimental,49.673,0.2497,0.1881,"PIM1 in complex with Cpd4 (3-methyl-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine)"
5DIA,X-RAY DIFFRACTION,3.19,61.4,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 4000, 0.2M LiSO4, 0.1M Tris-HCl",289.0,2015-08-31,2015-10-28,5DIA,2460.0,1.0,299.0,219.0,,34.83,1.0,1.964,experimental,41.1516,0.2286,0.196,"PIM1 in complex with Cpd36 ((1S,3S)-N1-(6-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)pyridin-2-yl)cyclohexane-1,3-diamine)"
5KZI,X-RAY DIFFRACTION,3.27,62.37,"VAPOR DIFFUSION, HANGING DROP",8.0,"1.0M LiCl, 0.1M TRIS pH8.0, 20% PEG6K",277.0,2016-07-25,2016-11-09,5KZI,2426.0,1.0,286.0,170.0,,33.49,1.0,2.1,experimental,39.058,0.20469,0.17813,Crystal structure of human Pim-1 kinase in complex with an imidazopyridazine inhibitor.
5O12,X-RAY DIFFRACTION,3.57,65.54,"VAPOR DIFFUSION, SITTING DROP",8.0,"Tris, potassium sodium tartrate tetrahydrate",293.0,2017-05-17,2017-11-01,5O12,2211.0,1.0,298.0,53.0,,34.95,1.0,2.4,experimental,52.909,0.22273,0.17683,Crystal structure of PIM1 kinase in complex with small-molecule inhibitor
5O13,X-RAY DIFFRACTION,3.5,64.9,"VAPOR DIFFUSION, SITTING DROP",,"Tris, potassium sodium tartrate tetrahydrate",293.0,2017-05-17,2017-11-01,5O13,2290.0,1.0,298.0,91.0,,35.04,1.0,2.44,experimental,46.561,0.21405,0.15914,Crystal structure of PIM1 kinase in complex with small-molecule inhibitor
5TEL,X-RAY DIFFRACTION,3.51,64.91,VAPOR DIFFUSION,,"imidazole 0,1M - NaAcetate 0,7M - pH6,5",277.0,2016-09-22,2017-10-11,5TEL,2434.0,1.0,274.0,159.0,,32.13,1.0,2.214,experimental,,0.2071,0.1788,Pim-1 kinase in complex with a 7-azaindole
5TEX,X-RAY DIFFRACTION,3.52,65.09,VAPOR DIFFUSION,6.5,"imidazole 0,1M - NaAcetate 1M - pH6,5",277.0,2016-09-23,2017-10-11,5TEX,2390.0,1.0,274.0,123.0,,32.11,1.0,2.149,experimental,,0.2167,0.1813,Pim-1 kinase in complex with a 7-azaindole
5TOE,X-RAY DIFFRACTION,3.52,65.05,VAPOR DIFFUSION,,"0.1M imidazole, 1M NaAcetate, 20% glycerol pH 6.5",277.0,2016-10-17,2017-10-11,5TOE,2374.0,1.0,273.0,131.0,,31.81,1.0,2.301,experimental,,0.2327,0.1893,Pim-1 kinase in complex with a 7-azaindole
5TUR,X-RAY DIFFRACTION,2.45,49.79,VAPOR DIFFUSION,,"0.1M imidazole, 1M NaAcetate, 20% glycerol pH 6.5",277.0,2016-11-07,2017-10-11,5TUR,2236.0,1.0,404.0,3.0,,45.8,1.0,2.948,experimental,,0.2478,0.2045,Pim-1 kinase in complex with a 7-azaindole
5V80,X-RAY DIFFRACTION,3.52,65.06,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris 8.5, LiSO4, PEG 4000",289.0,2017-03-21,2018-04-18,5V80,2324.0,1.0,299.0,78.0,,34.93,1.0,2.252,experimental,47.1997,0.2122,0.1752,"PIM1 kinase in complex with Cpd1 (1-methyl-4-(3-(6-(piperazin-1-yl)pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridin-5-yl)piperazin-2-one)"
5V82,X-RAY DIFFRACTION,3.44,64.23,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris 8.5, LiSO4, PEG 4000",289.0,2017-03-21,2017-05-10,5V82,2395.0,1.0,299.0,142.0,,34.85,1.0,1.888,experimental,43.0209,0.1986,0.1815,"PIM1 kinase in complex with Cpd17 (1-(6-(4,4-difluoropiperidin-3-yl)pyridin-2-yl)-6-(6-methylpyrazin-2-yl)-1H-pyrazolo[4,3-c]pyridine)"
5VUA,X-RAY DIFFRACTION,3.27,62.43,"VAPOR DIFFUSION, HANGING DROP",5.5,"100MM CITRATE BUFFER, PH 5.5, 200MM  NACL, 1M NH4HPO4",293.0,2017-05-18,2017-12-13,5VUA,2467.0,1.0,298.0,215.0,,34.77,1.0,2.2,experimental,35.24,0.196,0.1655,Pim1 Kinase in complex with a benzofuranone inhibitor
5VUB,X-RAY DIFFRACTION,3.27,62.43,"VAPOR DIFFUSION, HANGING DROP",5.5,"100MM CITRATE BUFFER, PH 5.5, 200MM      NACL, 1M NH4HPO4",293.0,2017-05-18,2017-12-13,5VUB,2501.0,1.0,298.0,238.0,,34.69,1.0,2.0,experimental,32.39,0.1837,0.1603,Pim1 Kinase in complex with a benzofuranone inhibitor
5VUC,X-RAY DIFFRACTION,3.3,62.68,"VAPOR DIFFUSION, HANGING DROP",5.5,"100MM CITRATE BUFFER, PH 5.5, 200MM     NACL, 1M NH4HPO4",293.0,2017-05-18,2017-12-13,5VUC,2467.0,1.0,298.0,226.0,,34.69,1.0,2.0,experimental,34.2801,0.1986,0.1749,Pim1 Kinase in complex with a benzofuranone inhibitor
6VRU,X-RAY DIFFRACTION,3.59,65.77,VAPOR DIFFUSION,6.5,"0.1 M imidazole, 0.7 M Na Acetate, pH6.5",277.0,2020-02-10,2020-11-04,6VRU,2574.0,1.0,274.0,260.0,,32.1,1.0,2.07,experimental,30.8185,0.2024,0.1786,PIM-inhibitor complex 1
8AFR,X-RAY DIFFRACTION,3.0,59.4,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM bis-tris-propane (pH7.0), 10 % ethylene glycol, 0.3% DMSO, 20% PEG3350, 200 mM LiCl",291.15,2022-07-18,2023-02-01,8AFR,2316.0,2.0,323.0,111.0,,37.22,2.0,2.15,experimental,49.77,0.1909,0.1642,Pim1 in complex with 4-((6-hydroxybenzofuran-3-yl)methyl)benzoic acid and Pimtide
6E7I,X-RAY DIFFRACTION,1.9,35.23,"VAPOR DIFFUSION, SITTING DROP",,"PEG8000, HEPES",293.0,2018-07-26,2020-01-29,6E7I,4314.0,2.0,548.0,327.0,5.0,62.45,2.0,1.8,experimental,16.453,0.2155,0.16719,Human ppGalNAcT2 I253A/L310A Mutant with EA2 and UDP
5B75,X-RAY DIFFRACTION,2.48,50.37,"VAPOR DIFFUSION, SITTING DROP",,"polyethylene glycol 4000, lithium sulfate, Tris",290.0,2016-06-05,2016-10-26,5B75,1311.0,2.0,156.0,188.0,,17.99,2.0,1.704,experimental,,0.195,0.1696,Crystal structure of MOZ double PHD finger in complex with histone H3 butyrylation at K14
5B76,X-RAY DIFFRACTION,2.46,50.07,"VAPOR DIFFUSION, SITTING DROP",,"polyethylene glycol 4000,  lithium sulfate, Tris",290.0,2016-06-05,2016-10-26,5B76,1320.0,2.0,157.0,180.0,,18.18,2.0,1.653,experimental,,0.2365,0.1866,Crystal structure of MOZ double PHD finger domain in complex with histone H3 crotonylation at K14
5B77,X-RAY DIFFRACTION,2.44,49.67,"VAPOR DIFFUSION, SITTING DROP",,"polyethylene glycol 4000,  lithium sulfate, Tris",291.0,2016-06-05,2016-10-26,5B77,1294.0,2.0,156.0,187.0,,18.07,2.0,1.551,experimental,,0.204,0.174,Crystal structrue of MOZ double PHD finger in complex with histone H3 propionylation at K14
5F03,X-RAY DIFFRACTION,2.67,53.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 10000, 0.1 M HEPES",293.0,2015-11-27,2016-02-24,5F03,4704.0,2.0,490.0,689.0,8.0,55.85,1.0,1.94,experimental,15.628,0.20026,0.15494,TRYPTASE B2 IN COMPLEX WITH 5-(3-Aminomethyl-phenoxymethyl)-3-[3-(2-chloro-pyridin-3-ylethynyl)-phenyl]-oxazolidin-2-one; compound with trifluoro-acetic acid
6X5Q,X-RAY DIFFRACTION,2.01,38.69,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, 28% w/v PEG 4000",277.0,2020-05-26,2020-12-23,6X5Q,2355.0,2.0,288.0,96.0,,33.15,2.0,2.14,experimental,15.884,0.235,0.1893,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluA1
7RX6,X-RAY DIFFRACTION,2.26,45.48,"VAPOR DIFFUSION, HANGING DROP",,0.1 M Tris (pH 8.0) and 20% PEG3350,291.0,2021-08-21,2022-11-09,7RX6,4293.0,2.0,574.0,369.0,,65.25,2.0,1.8,experimental,25.0239,0.2189,0.1928,Structure of METTL3-METTL14(R298C) mutant methyltransferase complex
7RX7,X-RAY DIFFRACTION,2.32,46.97,"VAPOR DIFFUSION, HANGING DROP",,0.1 M Tris (pH 8.0) and 20% PEG3350,291.0,2021-08-21,2022-11-09,7RX7,4484.0,2.0,574.0,464.0,,65.25,2.0,1.645,experimental,24.6641,0.1877,0.1666,Structure of METTL3-METTL14(R298P) mutant methyltransferase complex
7RX8,X-RAY DIFFRACTION,2.31,46.84,"VAPOR DIFFUSION, HANGING DROP",,0.1 M Tris (pH 8.0) and 20% PEG3350,291.0,2021-08-21,2022-11-09,7RX8,4387.0,2.0,574.0,382.0,,65.29,2.0,1.85,experimental,28.3549,0.202,0.1711,Structure of METTL3-METTL14(R298H) mutant methyltransferase complex
6T6A,X-RAY DIFFRACTION,3.19,61.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"31% PEG 400, 0.2 M lithium sulfate and 0.1 M tris, pH 7.5",277.15,2019-10-18,2019-12-04,6T6A,11820.0,4.0,1444.0,306.0,,171.24,1.0,2.8,experimental,48.579,0.242,0.2054,Crystal structure of DYRK1A complexed with KuFal319 (compound 11)
7FHT,X-RAY DIFFRACTION,2.72,54.73,"VAPOR DIFFUSION, SITTING DROP",,"100mM BIS-TRIS propane, 200 mM Sodium fluoride, 22% PEG3350, pH 8.0",293.0,2021-07-30,2022-03-23,7FHT,11370.0,4.0,1444.0,159.0,,169.13,1.0,2.68,experimental,61.619,0.24938,0.18843,Crystal structure of DYRK1A in complex with RD0448
7KKO,X-RAY DIFFRACTION,2.45,49.81,VAPOR DIFFUSION,,"Salt: 0.4 M potassium acetate
Precipitant: 22.0 %w/v PEG 4000
Buffer: 0.1 M MES (pH 6.14)",277.0,2020-10-27,2021-01-06,7KKO,5802.0,3.0,639.0,529.0,,74.57,1.0,1.56,experimental,29.77,0.221,0.194,Structure of the catalytic domain of tankyrase 1 in complex with olaparib
6XAA,X-RAY DIFFRACTION,2.61,52.87,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% PEG4000, 0.2 M sodium acetate, 0.1 M Tris chloride, pH 8.5",293.0,2020-06-04,2020-06-17,6XAA,3023.0,2.0,394.0,32.0,,44.61,2.0,2.7,experimental,58.05,0.2599,0.2096,SARS CoV-2 PLpro in complex with ubiquitin propargylamide
8CQI,X-RAY DIFFRACTION,2.53,51.32,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES pH 5.5, 0.1M magnesium chloride, 18% PEG 3,350",293.0,2023-03-06,2024-01-10,8CQI,3827.0,2.0,466.0,135.0,1.0,53.92,2.0,2.1,experimental,41.776,0.25256,0.19878,Human heparanase in complex with inhibitor R3794
7KKP,X-RAY DIFFRACTION,2.5,50.85,VAPOR DIFFUSION,,"Buffer: 0.1 M Sodium acetate trihydrate (pH 5.50)
Salt: 0.2 M lithium sulfate monohydrate
Precipitant: 30.0 %v/v iso-propanol
Precipitant: 10.0 %w/v PEG 1500",277.0,2020-10-27,2021-01-06,7KKP,4013.0,2.0,426.0,540.0,,50.16,1.0,1.4,experimental,20.89,0.208,0.187,Structure of the catalytic domain of tankyrase 1 in complex with niraparib
4X4W,X-RAY DIFFRACTION,3.05,59.72,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.2M Ammonium Sulfate, 0.05M Na Citrate pH 5.5",290.0,2014-12-03,2015-02-11,4X4W,7348.0,2.0,832.0,833.0,,97.45,1.0,1.9,experimental,32.81,0.1958,0.1539,Crystal structure of the full-length human mitochondrial CCA-adding enzyme
7NWK,X-RAY DIFFRACTION,4.16,70.42,VAPOR DIFFUSION,,"14% PEG1000, 100 mM sodium potassium phosphate, pH 6.2, 500 mM NaCl, 4 mM TCEP",293.0,2021-03-16,2021-10-27,7NWK,4435.0,2.0,588.0,,,68.36,2.0,2.81,experimental,66.17,0.205,0.18,Crystal structure of CDK9-Cyclin T1 bound by compound 6
5LCP,X-RAY DIFFRACTION,2.15,54.12,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)

Reservoir: 18% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-06-22,2018-01-17,5LCP,3606.0,2.0,373.0,448.0,,43.87,2.0,1.433,experimental,,0.1659,0.1327,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with Fasudil (M77)
7WU8,X-RAY DIFFRACTION,2.14,42.4,"VAPOR DIFFUSION, HANGING DROP",7.4,"20mM Tris pH7.4, 250mM NaCl, 5% Glycerol",277.0,2022-02-07,2023-08-09,7WU8,5128.0,7.0,672.0,734.0,,74.46,1.0,1.599,experimental,27.133,0.2012,0.1765,Crystal structure of Harmonin-homology domain 2 (HHD2) of human RTEL1
6DUB,X-RAY DIFFRACTION,2.51,50.97,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG2000, 0.1 M potassium thiocyanate",291.0,2018-06-20,2018-07-25,6DUB,4160.0,4.0,456.0,314.0,,52.43,2.0,1.2,experimental,16.091,0.1778,0.154,Crystal structure of a methyltransferase
8BVO,X-RAY DIFFRACTION,2.5,50.77,"VAPOR DIFFUSION, SITTING DROP",,"24% (w/v) PEG 1500, 20% (w/v) glycerol",291.15,2022-12-05,2023-02-15,8BVO,1603.0,1.0,199.0,44.0,,22.25,1.0,2.55,experimental,78.67,0.2872,0.2235,Titin I110-I111 FnIII tandem from the MIR region (I/A5-I/A6)
8BW6,X-RAY DIFFRACTION,2.67,53.91,"VAPOR DIFFUSION, SITTING DROP",,0.1M Tris pH8 30% PEG 300,291.15,2022-12-06,2023-02-15,8BW6,866.0,1.0,99.0,36.0,1.0,11.62,1.0,1.95,experimental,61.89,0.2539,0.2174,Titin FnIII-domain I110 (I/A6) from the MIR region
8BXR,X-RAY DIFFRACTION,2.61,52.9,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES pH 6, 10% [w/v] PEG 6000",291.15,2022-12-09,2023-02-15,8BXR,2387.0,1.0,300.0,37.0,,33.68,1.0,2.7,experimental,69.26,0.2714,0.2254,Titin FnIII-domain I109-I111 (I/A4-A/A6) from the MIR region
6KGO,X-RAY DIFFRACTION,3.75,67.17,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES (pH 6.2-6.3), 0.2M diammonium tartrate, 0.0005M TCEP, 10% PEG3350",293.0,2019-07-12,2020-03-25,6KGO,5386.0,1.0,669.0,190.0,,76.1,1.0,2.25,experimental,63.15,0.2043,0.1733,LSD1-S2157 five-membered ring adduct model
6KGP,X-RAY DIFFRACTION,3.75,67.17,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES (pH 6.2-6.3), 0.2M diammonium tartrate, 0.0005M TCEP, 10% PEG3350",293.0,2019-07-12,2020-03-25,6KGP,5386.0,1.0,669.0,190.0,,76.1,1.0,2.25,experimental,62.58,0.2043,0.1731,LSD1-S2157 N5 adduct model
6BI7,X-RAY DIFFRACTION,2.81,56.17,"VAPOR DIFFUSION, HANGING DROP",,"hRev7/3 at 60 mg/mL in 5 mM HEPES, 100 mM NaCl, 10 mM DTT, pH=7.4 was mixed in a 1:1 ratio with a well solution consisting of 100 mM sodium citrate, 1M LiCl, 7.5% (w/v) PEG6000 at pH=4.75. Crystals were frozen in the reservoir solution with the addition of 20% (w/v) sucrose",289.15,2017-11-01,2018-08-01,6BI7,6445.0,8.0,1020.0,13.0,,117.86,2.0,2.8,experimental,94.6819,0.3213,0.2754,Crystal structure of Rev7-WT/Rev3 as a monomer under high-salt conditions
6NK2,X-RAY DIFFRACTION,4.15,70.33,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.09 M Sodium-Acetate pH 4.5, 22.5% w/v PEG 3,350, 3% w/v 6-aminohexanoic acid",293.0,2019-01-04,2019-05-01,6NK2,3247.0,4.0,402.0,160.0,4.0,46.11,2.0,2.2,experimental,47.18,0.2092,0.1882,EphA2 LBD in complex with bA-WLA-YRPK bio peptide
6I42,X-RAY DIFFRACTION,3.12,60.63,VAPOR DIFFUSION,7.0,"1.93 M tri-ammonium citrate, pH 7.0",293.0,2018-11-08,2020-02-19,6I42,1698.0,2.0,177.0,255.0,,19.25,2.0,1.38,experimental,24.349,0.1778,0.1631,Structure of the alpha-Synuclein PreNAC/Cyclophilin A-complex
5UQW,X-RAY DIFFRACTION,2.0,38.44,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris, 25% w/v PEG3350, pH 6.5",293.0,2017-02-08,2017-03-22,5UQW,2926.0,2.0,378.0,298.0,,43.91,1.0,1.5,experimental,16.818,0.15272,0.11666,Crystal structure of human KRAS G12V mutant in complex with GDP
7RP4,X-RAY DIFFRACTION,2.42,49.14,"VAPOR DIFFUSION, SITTING DROP",,"0.10% n-Octyl-B-D-glucoside, 0.1 M sodium citrate pH 5.5, 22% PEG 3350",292.0,2021-08-03,2022-03-16,7RP4,2978.0,2.0,340.0,148.0,,40.51,1.0,2.15,experimental,39.372,0.2526,0.2131,Crystal structure of KRAS G12C in complex with GNE-1952
8UN5,X-RAY DIFFRACTION,2.1,41.54,EVAPORATION,4.5,"0.1 M Sodium acetate pH 4.5, 30% w/v PEG 5,000MME",277.0,2023-10-18,2023-12-20,8UN5,3383.0,2.0,338.0,458.0,,41.13,1.0,1.31,experimental,,0.212,0.1782,"KRAS-G13D-GDP in complex with Cpd38 ((E)-1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-2-methylenetetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)-3-(1,2,3,4-tetrahydroisoquinolin-8-yl)prop-2-en-1-one)"
7OWD,X-RAY DIFFRACTION,2.02,39.0,"VAPOR DIFFUSION, SITTING DROP",4.2,"40 (v/v) PEG 300, 100 mM phosphate/citrate pH 4.2",291.0,2021-06-17,2021-10-20,7OWD,1349.0,2.0,162.0,97.0,,17.96,2.0,1.71,experimental,52.67,0.245,0.2136,Structure of CYLD CAP-Gly3 (467-552) bound to Ub; tetragonal space group
5DN3,X-RAY DIFFRACTION,3.62,66.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"50 mM HEPES, 200 mM magnesium sulfate, 20% PEG 3350",292.0,2015-09-09,2016-07-20,5DN3,2405.0,1.0,272.0,147.0,,32.51,1.0,2.05,experimental,45.62,0.203,0.1915,Aurora A in complex with ATP and AA35.
5DOS,X-RAY DIFFRACTION,2.65,53.64,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM Hepes pH7.4, 200 mM magnesium sulfate, 2-20% PEG 3350",292.0,2015-09-11,2016-07-20,5DOS,2173.0,1.0,273.0,,,32.69,1.0,2.98,experimental,113.17,0.2725,0.1976,Aurora A Kinase in Complex with AA35 and ATP in Space Group P6122
5DR2,X-RAY DIFFRACTION,2.58,52.27,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulphate, 2-20 PEG3350",292.0,2015-09-15,2016-07-20,5DR2,2223.0,1.0,273.0,9.0,,32.67,1.0,2.46,experimental,80.765,0.28495,0.22133,Aurora A Kinase in Complex with AA30 and ATP in Space Group P6122
5DT4,X-RAY DIFFRACTION,2.62,53.11,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG 3350",292.0,2015-09-17,2016-07-20,5DT4,2173.0,1.0,273.0,,,32.72,1.0,2.86,experimental,112.45,0.2559,0.1899,Aurora A Kinase in Complex with AA35 and ATP in Space Group P6122
5OBJ,X-RAY DIFFRACTION,2.75,55.22,"VAPOR DIFFUSION, HANGING DROP",7.0,"50 MM HEPES, 200 MM MAGNESIUM SULFATE,   20% PEG 3350",292.0,2017-06-28,2017-08-09,5OBJ,2186.0,1.0,272.0,3.0,,32.38,1.0,2.901,experimental,,0.2455,0.2137,Aurora A kinase in complex with 2-(3-fluorophenyl)quinoline-4-carboxylic acid and ATP
6O47,X-RAY DIFFRACTION,2.87,57.19,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.064 M sodium citrate 7.0, 0.1 M HEPES, pH 7.0, 10% PEG5000MME",293.0,2019-02-28,2019-05-29,6O47,3117.0,1.0,372.0,180.0,,44.77,1.0,2.196,experimental,,0.2214,0.1815,human cGAS core domain (K427E/K428E) bound with RU-521
7B7R,X-RAY DIFFRACTION,2.23,44.8,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained from hanging drops by mixing a 1:1 ratio of protein solution with well solution containing 2 M AmSO4, 0.1 M NaCl and 0.1 M Bis-tris pH 6.1-6.2",293.0,2020-12-11,2021-03-03,7B7R,5247.0,2.0,652.0,402.0,,75.0,1.0,1.7,experimental,36.62,0.218,0.194,MEK1 in complex with compound 4
7B94,X-RAY DIFFRACTION,2.22,44.53,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained from hanging drops by mixing a 1:1 ratio of protein solution with well solution containing 2 M AmSO4, 0.1 M NaCl and 0.1 M Bis-tris pH 6.1-6.2",293.0,2020-12-14,2021-03-03,7B94,5073.0,2.0,652.0,269.0,,75.04,1.0,2.0,experimental,52.2,0.265,0.216,MEK1 in complex with compound 6
8BM8,X-RAY DIFFRACTION,1.92,35.89,"VAPOR DIFFUSION, SITTING DROP",6.0,"37,5 % MPD_PEG1000_PEG3350, 100 mM Morpheus Amino Acids Mix, 100 mM Bis-Tris pH 6.0",291.0,2022-11-10,2024-06-05,8BM8,2460.0,1.0,306.0,103.0,,34.92,1.0,1.68,experimental,25.45,0.2249,0.1897,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 11
6C7D,X-RAY DIFFRACTION,2.21,44.47,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2 M magnesium chloride, 0.1 M Tris, pH 8.4",293.0,2018-01-22,2018-08-15,6C7D,11719.0,4.0,1368.0,646.0,,161.89,1.0,1.79,experimental,32.1304,0.2319,0.1868,"Crystal structure of human phosphodiesterase 2A with N-(1-adamantyl)-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide"
6C7E,X-RAY DIFFRACTION,2.18,43.65,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2 M magnesium chloride, 0.1 M Tris, pH 8.4",293.0,2018-01-22,2018-08-15,6C7E,12249.0,4.0,1368.0,1184.0,,161.41,1.0,1.43,experimental,25.6095,0.2006,0.1744,"Crystal structure of human phosphodiesterase 2A with 1-(2-chlorophenyl)-N,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide"
6C7G,X-RAY DIFFRACTION,2.26,45.46,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2 M magnesium chloride, 0.1 M Tris, pH 8.4",293.0,2018-01-22,2018-08-15,6C7G,11803.0,4.0,1368.0,676.0,,162.17,1.0,1.68,experimental,23.7675,0.2335,0.1973,"Crystal structure of human phosphodiesterase 2A with N-(1-adamantyl)-1-(2-chloro-5-isobutoxy-phenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide"
6C7I,X-RAY DIFFRACTION,2.18,43.58,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2 M magnesium chloride, 0.1 M Tris, pH 8.4",293.0,2018-01-22,2018-08-15,6C7I,12195.0,4.0,1368.0,995.0,,161.69,1.0,1.713,experimental,28.0838,0.2143,0.1713,"Crystal structure of human phosphodiesterase 2A with 1-(2-chloro-5-methoxy-phenyl)-N-isobutyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide"
6C7J,X-RAY DIFFRACTION,2.21,44.38,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2 M magnesium chloride, 0.1 M Tris, pH 8.4",293.0,2018-01-22,2018-08-15,6C7J,12048.0,4.0,1368.0,905.0,,161.86,1.0,1.85,experimental,29.2075,0.2302,0.1761,"Crystal structure of human phosphodiesterase 2A with 1-(5-tert-butoxy-2-chloro-phenyl)-N-isobutyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide"
5JLE,X-RAY DIFFRACTION,2.44,49.62,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M KSCN, 30% PEG2000mme",291.0,2016-04-27,2016-11-02,5JLE,1934.0,1.0,279.0,32.0,,32.62,1.0,2.4,experimental,73.7,0.2504,0.2085,Crystal structure of SETD2 bound to SAH
7LZB,X-RAY DIFFRACTION,2.41,48.9,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Potassium thiocyanate, 0.1M Tris pH 7.8, 25% w/v PEG 2000 MME",293.0,2021-03-09,2021-09-22,7LZB,1993.0,1.0,278.0,22.0,,32.97,1.0,2.28,experimental,72.212,0.2636,0.2054,Crystal Structure of SETD2 bound to Compound 2
7LZF,X-RAY DIFFRACTION,2.28,46.06,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Potassium thiocyanate, 0.1 M Tris pH 7.5, 18% w/v PEG 2000 MME",293.0,2021-03-09,2021-09-22,7LZF,2041.0,1.0,278.0,37.0,,33.06,1.0,2.47,experimental,62.722,0.263,0.2156,Crystal Structure of SETD2 bound to Compound 57
7TY2,X-RAY DIFFRACTION,2.19,43.85,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Potassium thiocyanate, 0.1 M HEPES 7.5, 18% w/v PEG 2000 MME",293.0,2022-02-11,2022-08-31,7TY2,1958.0,1.0,278.0,8.0,,32.95,1.0,2.438,experimental,,0.27,0.2126,Crystal Structure of SETD2 Bound to an Indole-based Inhibitor
7TY3,X-RAY DIFFRACTION,2.36,47.86,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Potassium thiocyanate, 0.1 M Tris pH 7.5, 18% w/v PEG 2000 MME",293.0,2022-02-11,2022-08-31,7TY3,2016.0,1.0,278.0,25.0,,33.01,1.0,2.3,experimental,64.88,0.2695,0.2136,Crystal Structure of SETD2 Bound to an Indole-based Inhibitor
6SLG,X-RAY DIFFRACTION,2.2,44.03,"VAPOR DIFFUSION, SITTING DROP",,"PegMME2K
HEPES pH 7.6
ammonium sulfate",293.0,2019-08-19,2019-11-20,6SLG,2935.0,2.0,386.0,199.0,,45.34,2.0,1.33,experimental,23.18,0.228,0.206,"HUMAN ERK2 WITH ERK1/2 INHIBITOR, AZD0364."
5T1A,X-RAY DIFFRACTION,2.81,61.86,LIPIDIC CUBIC PHASE,6.1,"Lipidic cubic phase made of monoolein and cholesterol, 100 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.5, 30-32% (v/v) PEG 400, 75-85 mM lithium sulfate",295.0,2016-08-18,2016-12-14,5T1A,3580.0,1.0,508.0,17.0,1.0,59.58,1.0,2.806,experimental,41.2114,0.2741,0.2335,Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists
7QQ6,X-RAY DIFFRACTION,2.66,53.76,"VAPOR DIFFUSION, HANGING DROP",6.0,100 mM MES pH6 with 20 per cent PEG 8000 and 200mM calcium acetate,293.0,2022-01-06,2022-03-02,7QQ6,8692.0,4.0,1280.0,45.0,,148.71,1.0,2.8,experimental,91.21,0.258,0.211,"GCN2 (EIF2ALPHA KINASE 4, E2AK4) IN COMPLEX WITH COMPOUND 1 (dovitinib)"
7QBM,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG 8000, 20% ethylene glycol, 0.02 M sodium formate, 0.02 M ammonium acetate, 0.02 M trisodium citrate, 0.02 M sodium potassium L-tartrate, 0.02 M sodium oxamate, 0.1 M MES/imidazole pH 6.5",290.0,2021-11-19,2022-01-26,7QBM,2492.0,2.0,290.0,233.0,3.0,33.06,2.0,1.88,experimental,34.616,0.234,0.1904,Structure of the activation intermediate of cathepsin K in complex with the 3-cyano-3-aza-beta-amino acid inhibitor Gu2602
7QBO,X-RAY DIFFRACTION,2.07,40.72,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG 8000, 20% ethylene glycol, 0.02 M sodium L-glutamate, 0.02 M DL-alanine, 0.02 M glycine, 0.02 M DL-lysine HCl, 0.02 M DL-serine, 0.1M MES/imidazole pH 6.5",290.0,2021-11-19,2022-01-26,7QBO,2579.0,2.0,290.0,293.0,3.0,33.28,2.0,1.9,experimental,23.299,0.2116,0.1643,Structure of the activation intermediate of cathepsin K in complex with the azadipeptide nitrile inhibitor Gu1303
5WG4,X-RAY DIFFRACTION,3.15,60.98,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM MES pH 6, 6% PEG 3350, 1 M NaCl",277.0,2017-07-13,2017-12-27,5WG4,8326.0,3.0,1100.0,143.0,,125.41,3.0,2.31,experimental,,0.2786,0.2337,Human GRK2 in complex with Gbetagamma subunits and CCG257284
6U7C,X-RAY DIFFRACTION,3.13,60.72,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM MES pH 6.0, 1.1 M NaCl, 6% PEG 3350",277.0,2019-09-02,2020-04-15,6U7C,8327.0,3.0,1100.0,76.0,,125.48,3.0,2.44,experimental,52.51,0.2624,0.2366,Human GRK2 in complex with Gbetagamma subunits and CCG258747
6EFK,X-RAY DIFFRACTION,2.0,38.4,"VAPOR DIFFUSION, HANGING DROP",,"0.4 M CaCl2, 0.1 M HEPES (pH 7.5), 25% PEG 4000",298.0,2018-08-16,2019-07-31,6EFK,2501.0,4.0,276.0,285.0,,31.73,2.0,1.5,experimental,,0.244,0.2108,Crystal structure of the human CHIP TPR domain in complex with a 5mer acetylated HSP70 peptide
6N3L,X-RAY DIFFRACTION,2.22,39.8,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris 8.5, 24% PEG3350, 450 mM NaFormate, 1% hexanediol",293.0,2018-11-15,2019-10-09,6N3L,3926.0,2.0,660.0,48.0,,76.64,1.0,2.61,experimental,59.547,0.2897,0.2228,"Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents"
6AY5,X-RAY DIFFRACTION,2.5,50.83,VAPOR DIFFUSION,6.5,"0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350",277.0,2017-09-07,2018-02-21,6AY5,1231.0,1.0,115.0,156.0,,14.51,1.0,1.44,experimental,25.0328,0.1838,0.1632,"CREBBP bromodomain in complex with Cpd17 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-3-methylbenzo[d]thiazol-2(3H)-one)"
6FH5,X-RAY DIFFRACTION,2.62,53.07,"VAPOR DIFFUSION, HANGING DROP",,"20 Percent PEG3350, 175 mM AmSO4, 10 mM DTT and 100 mM Hepes pH 7.4 to 7.9",293.0,2018-01-12,2019-01-30,6FH5,6562.0,1.0,966.0,16.0,,111.09,1.0,2.84,experimental,81.16,0.2957,0.2352,PI3Kg IN COMPLEX WITH Compound 7
7MNE,X-RAY DIFFRACTION,2.27,45.79,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 0.1 M Tris pH 7.8, 17% PEG",277.0,2021-04-30,2022-05-18,7MNE,2524.0,1.0,308.0,179.0,,36.3,1.0,1.6,experimental,24.86,0.1761,0.1632,"PTP1B P206G mutation, open state"
8BOC,X-RAY DIFFRACTION,2.17,43.26,"VAPOR DIFFUSION, SITTING DROP",8.5,"37,5 % MPD_PEG 1000_PEG 3350, 175 mM Morpheus Carboxylic acids Mix, 100 mM Sodium citrate tribasic dihydrate, 100 mM Morpheus Buffer System 3 pH 8.5",291.0,2022-11-15,2023-11-29,8BOC,2298.0,1.0,306.0,37.0,,35.03,1.0,1.9,experimental,46.98,0.2856,0.246,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 19
8BOD,X-RAY DIFFRACTION,1.96,37.09,"VAPOR DIFFUSION, SITTING DROP",6.0,"37,5 % Precipitant Mix 4 (25% (v/v) Hexylene glycol, 25% (w/v) Poly(ethylene glycol) 1000, 25% (w/v) Poly(ethylene glycol) 3350), 0.1M Mes pH 6.0, 0.1 M Amino acids mix (0.2 M DL-Alanine,
0.2M DL-Glutamic acid monohydrate, 0.2M
DL-Lysine monohydrochloride, 0.2M
DL-Serine, 0.2M Glycine)",291.0,2022-11-15,2023-03-08,8BOD,2557.0,1.0,306.0,299.0,,34.97,1.0,1.5,experimental,22.89,0.1854,0.1604,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 20
8BOF,X-RAY DIFFRACTION,1.92,35.98,"VAPOR DIFFUSION, SITTING DROP",8.5,"37,5 % Precipitant Mix 4 (25% (v/v) Hexylene glycol, 25% (w/v) Poly(ethylene glycol) 1000, 25% (w/v) Poly(ethylene glycol) 3350), 0.1M Buffer system 3 pH 8.5 (1M BICINE, 1M
Trizma base), 0.275 M Amino acids Mix (0.2 M DL-Alanine,0.2M DL-Glutamic acid monohydrate, 0.2M
DL-Lysine monohydrochloride, 0.2M
DL-Serine, 0.2M Glycine)",291.0,2022-11-15,2023-03-08,8BOF,2309.0,1.0,306.0,100.0,,34.91,1.0,1.82,experimental,28.83,0.2163,0.1857,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 12
8BOG,X-RAY DIFFRACTION,1.92,35.83,"VAPOR DIFFUSION, SITTING DROP",6.5,"37,5 % Precipitant Mix 4 (25% (v/v) Hexylene glycol, 25% (w/v) Poly(ethylene glycol) 1000, 25% (w/v) Poly(ethylene glycol) 3350), 
0.1M Bis-Tris pH 6.5, 
0.1 M Amino acids mix (0.2 M DL-Alanine,
0.2M DL-Glutamic acid monohydrate, 0.2M
DL-Lysine monohydrochloride, 0.2M
DL-Serine, 0.2M Glycine)",291.0,2022-11-15,2023-03-08,8BOG,2505.0,1.0,306.0,160.0,,34.97,1.0,1.47,experimental,24.99,0.18,0.1662,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 7
8BOH,X-RAY DIFFRACTION,1.94,36.48,"VAPOR DIFFUSION, SITTING DROP",6.5,"37,5 % Precipitant Mix 4 (25% (v/v) Hexylene glycol, 25% (w/v) Poly(ethylene glycol) 1000, 25% (w/v) Poly(ethylene glycol) 3350), 
0.1M Tris-HCl pH 6.5, 
0.1 M Amino acids mix (0.2 M DL-Alanine,
0.2M DL-Glutamic acid monohydrate, 0.2M
DL-Lysine monohydrochloride, 0.2M
DL-Serine, 0.2M Glycine)",291.0,2022-11-15,2023-03-08,8BOH,2522.0,1.0,306.0,184.0,,35.05,1.0,1.42,experimental,22.79,0.1742,0.158,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 8
8BOI,X-RAY DIFFRACTION,1.96,37.28,"VAPOR DIFFUSION, SITTING DROP",8.5,"37,5 % Precipitant Mix 4 (25% (v/v) Hexylene glycol, 25% (w/v) Poly(ethylene glycol) 1000, 25% (w/v) Poly(ethylene glycol) 3350), 0.1M Buffer system 3 pH 8.5 (1M BICINE, 1M
Trizma base), 0.15 M Carboxylic acids Mix (0.2M Ammonium acetate, 0.2M Potassium sodium tartrate tetrahydrate, 0.2M Sodium citrate tribasic dihydrate, 0.2M Sodium formate, 0.2M Sodium oxamate)",291.0,2022-11-15,2023-03-08,8BOI,2465.0,1.0,306.0,153.0,,35.08,1.0,1.63,experimental,23.99,0.2111,0.1791,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 9
8BOK,X-RAY DIFFRACTION,2.2,44.04,"VAPOR DIFFUSION, SITTING DROP",8.5,"37,5 % Precipitant Mix 4 (25% (v/v) Hexylene glycol, 25% (w/v) Poly(ethylene glycol) 1000, 25% (w/v) Poly(ethylene glycol) 3350), 0.1M Buffer system 3 pH 8.5 (1M BICINE, 1M
Trizma base), 0.175 M Carboxylic acids Mix (0.2M Ammonium acetate, 0.2M Potassium sodium tartrate tetrahydrate, 0.2M Sodium citrate tribasic dihydrate, 0.2M Sodium formate, 0.2M Sodium oxamate)",291.0,2022-11-15,2023-03-08,8BOK,2381.0,1.0,306.0,105.0,,34.96,1.0,2.02,experimental,58.43,0.2609,0.2155,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 11
8BOM,X-RAY DIFFRACTION,1.93,36.4,"VAPOR DIFFUSION, SITTING DROP",7.6,"37,5 % Precipitant Mix 4 (25% (v/v) Hexylene glycol, 25% (w/v) Poly(ethylene glycol) 1000, 25% (w/v) Poly(ethylene glycol) 3350), 0.1M Bicin pH 7.6, 0.1 M Amino acids mix (0.2 M DL-Alanine,
0.2M DL-Glutamic acid monohydrate, 0.2M
DL-Lysine monohydrochloride, 0.2M
DL-Serine, 0.2M Glycine)",291.0,2022-11-15,2023-03-08,8BOM,2530.0,1.0,306.0,218.0,,34.93,1.0,1.12,experimental,20.03,0.1768,0.1638,Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 14
6C7F,X-RAY DIFFRACTION,2.21,44.45,"VAPOR DIFFUSION, HANGING DROP",8.4,"17-19% PEG3350, 0.2 M magnesium chloride, 0.1 M Tris, pH 8.4",293.0,2018-01-22,2018-08-15,6C7F,8814.0,3.0,1026.0,568.0,,121.27,1.0,1.82,experimental,36.7351,0.2463,0.1952,"Crystal structure of human phosphodiesterase 2A with 1-(2-chloro-5-isobutoxy-phenyl)-N,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide"
7U0N,X-RAY DIFFRACTION,2.95,58.31,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris, pH 8.5, 20% PEG6000, 100 mM sodium chloride",295.0,2022-02-18,2022-03-30,7U0N,13116.0,4.0,1628.0,13.0,13.0,192.72,2.0,2.61,experimental,93.77,0.235,0.1884,Crystal structure of chimeric omicron RBD (strain BA.1) complexed with human ACE2
5M7M,X-RAY DIFFRACTION,2.4,48.67,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350 25%, 0.2M thiocyanate, 0.1M ammonium iodide",293.0,2016-10-28,2017-08-30,5M7M,5999.0,1.0,871.0,53.0,15.0,102.84,1.0,2.7,experimental,25.371,0.28426,0.22896,"Novel Imidazo[1,2-a]pyridine Derivatives with Potent Autotaxin/ENPP2 Inhibitor Activity"
4QL3,X-RAY DIFFRACTION,1.89,34.94,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2M Sodium Acetate pH4.5, 0.1M Tris pH 8.5, 28% PEG 3,350, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-06-10,2015-06-10,4QL3,1638.0,1.0,170.0,241.0,,19.9,1.0,1.041,experimental,12.71,0.1621,0.1383,Crystal Structure of a GDP-bound G12R Oncogenic Mutant of Human GTPase KRas
8FMI,X-RAY DIFFRACTION,1.84,33.12,"VAPOR DIFFUSION, SITTING DROP",,Ammonium Formate 0.2 M and PEG 3350 20%,293.0,2022-12-23,2023-11-29,8FMI,1717.0,1.0,170.0,278.0,,19.78,1.0,1.12,experimental,12.39,0.1473,0.1195,Crystal structure of human KRAS at 1.12 A
8STM,X-RAY DIFFRACTION,2.36,47.86,"VAPOR DIFFUSION, SITTING DROP",,2.2 M Ammonium Sulfate,293.0,2023-05-10,2023-08-23,8STM,5698.0,4.0,680.0,207.0,,79.24,1.0,2.0,experimental,38.77,0.19231,0.16264,"Crystal structure of KRAS-G75A mutant, GDP-bound"
7TRL,X-RAY DIFFRACTION,1.68,26.63,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M SPG buffer (2:7:7 molar ratio of succinic acid:sodium dihydrogen phosphate: glycine), 25% PEG 1,500",291.15,2022-01-29,2023-08-02,7TRL,835.0,2.0,106.0,34.0,,12.57,2.0,1.74,experimental,22.72,0.206,0.1623,Crystal structure of human BIRC2 BIR3 domain in complex with histone H3
6IPY,X-RAY DIFFRACTION,1.52,18.85,"VAPOR DIFFUSION, SITTING DROP",3.5,"0.1M Citric acid pH 3.5 and 25%(w/v) Polyethylene glycol 3,350",295.0,2018-11-05,2018-11-28,6IPY,584.0,1.0,81.0,31.0,,9.28,1.0,1.343,experimental,39.562,0.2013,0.181,His-tagged Fyn SH3 domain R96I mutant
5IL1,X-RAY DIFFRACTION,2.58,52.33,"VAPOR DIFFUSION, HANGING DROP",5.7,"PEG 8000, sodium citrate",291.0,2016-03-04,2016-05-25,5IL1,4336.0,2.0,512.0,337.0,,59.81,2.0,1.71,experimental,,0.2069,0.1798,Crystal structure of SAM-bound METTL3-METTL14 complex
5K7W,X-RAY DIFFRACTION,2.33,47.31,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M Tris pH 8.0, 20% PEG3350",291.0,2016-05-26,2016-07-06,5K7W,4587.0,2.0,574.0,554.0,,65.69,2.0,1.65,experimental,,0.1794,0.1598,Crystal structure of the catalytic domain of Mettl3/Mettl14 complex with SAH
4QBR,X-RAY DIFFRACTION,1.97,37.67,"VAPOR DIFFUSION, HANGING DROP",5.5,"25% PEG3350, 0.1M Bis-Tris-HCL, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-05-08,2015-05-13,4QBR,2486.0,4.0,288.0,216.0,,33.3,2.0,1.902,experimental,,0.2252,0.1779,Crystal structure of DNMT3a ADD domain G550D mutant bound to H3 peptide
7N4Q,X-RAY DIFFRACTION,2.29,46.4,"VAPOR DIFFUSION, SITTING DROP",,"0.1M BisTRIS pH 6.5, 0.2M Ammonium Acetate, 0.1M Guanidine HCl, 20% PEG2200 MME",277.0,2021-06-04,2022-05-18,7N4Q,2412.0,1.0,269.0,279.0,,31.87,1.0,1.5,experimental,24.59,0.2201,0.1886,Bruton's tyrosine kinase in complex with compound 45
7N4S,X-RAY DIFFRACTION,2.28,46.04,VAPOR DIFFUSION,,"0.1M BisTRIS pH 6.5, 0.2M Ammonium Acetate, 0.1M Guanidine HCl, 20% PEG2200 MME",277.0,2021-06-04,2022-05-18,7N4S,2113.0,1.0,269.0,33.0,,31.82,1.0,2.05,experimental,34.09,0.2763,0.2438,Bruton's tyrosine kinase in complex with compound 65
5LPK,X-RAY DIFFRACTION,2.71,54.59,EVAPORATION,6.5,"PEG 3350, NaCl",277.0,2016-08-13,2017-08-16,5LPK,7515.0,7.0,854.0,483.0,,105.14,1.0,2.1,experimental,41.958,0.2029,0.1764,Crystal structure of the bromodomain of human EP300 bound to the inhibitor XDM1
5IVJ,X-RAY DIFFRACTION,2.24,45.18,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-21,2016-07-27,5IVJ,2656.0,1.0,330.0,259.0,,38.59,1.0,1.569,experimental,,0.1894,0.1589,"Linked KDM5A Jmj Domain Bound to the Inhibitor N11 [3-({1-[2-(4,4-difluoropiperidin-1-yl)ethyl]-5-fluoro-1H-indazol-3-yl}amino)pyridine-4-carboxylic acid]"
6BGU,X-RAY DIFFRACTION,2.22,44.63,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BGU,2723.0,1.0,330.0,210.0,,38.95,1.0,1.684,experimental,,0.2082,0.1977,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(propoxy)methyl)-1H-pyrrolo[3,2-b]pyridine (Compound N9)"
6BGV,X-RAY DIFFRACTION,2.21,44.45,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BGV,2767.0,1.0,330.0,242.0,,39.19,1.0,1.592,experimental,,0.184,0.1677,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(2-(piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N40)"
6BGW,X-RAY DIFFRACTION,2.22,44.56,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BGW,2731.0,1.0,330.0,203.0,,38.99,1.0,1.644,experimental,,0.2131,0.1884,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(2-(4,4-difluoropiperidin-1-yl)ethoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid(Compound N41)"
6BGY,X-RAY DIFFRACTION,2.22,44.71,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BGY,2736.0,1.0,330.0,263.0,,38.91,1.0,1.22,experimental,,0.1933,0.1663,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(2-(1-methylpyrrolidin-2-yl)ethoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid(Compound 46)"
6BH3,X-RAY DIFFRACTION,2.24,45.17,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BH3,2654.0,1.0,330.0,226.0,,38.86,1.0,1.701,experimental,,0.2157,0.1947,LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR (S)-N-(1-(3-isopropyl-1H-pyrazole-5-carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide (Compound N55)
6DQ6,X-RAY DIFFRACTION,2.25,45.44,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2018-11-21,6DQ6,2665.0,1.0,330.0,222.0,,38.6,1.0,1.587,experimental,,0.2023,0.1798,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N44 i.e. 3-((2-(pyridin-2-yl)-6-(4-(vinylsulfonyl)-1,4-diazepan-1-yl)pyrimidin-4-yl)amino)propanoic acid"
6DQ9,X-RAY DIFFRACTION,2.24,45.13,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2018-11-21,6DQ9,2648.0,1.0,330.0,209.0,,38.84,1.0,1.748,experimental,,0.1983,0.1735,"Linked KDM5A JMJ Domain Bound to the Covalent Inhibitor N69 i.e. [2-((3-acrylamidophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid]"
7NX1,X-RAY DIFFRACTION,2.82,56.41,"VAPOR DIFFUSION, SITTING DROP",,"MOPSO/Bis-Tris pH 6.3
12% PEG 20000
25% Trimethyl propane 
2% w/v NDSB 195 
5mM YCl3 . 6H2O
5mM ErCl3 . 6H2O
5mM TbCl3 . 6H2O
5mM YbCl3 . 6H2O",287.0,2021-03-17,2021-10-27,7NX1,2224.0,1.0,322.0,173.0,3.0,33.12,1.0,1.3,experimental,22.39,0.1805,0.1594,TG domain of LTK
6UXY,X-RAY DIFFRACTION,2.88,57.29,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M sodium citrate pH 6.0, 0.2 M sodium acetate, 10-12% PEG 4000",277.0,2019-11-08,2020-08-19,6UXY,7575.0,2.0,995.0,231.0,,112.08,2.0,2.57,experimental,82.81,0.275,0.246,PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 8
8VEO,X-RAY DIFFRACTION,2.82,56.39,VAPOR DIFFUSION,6.0,"10% PEG 4000, 0.2M magnesium chloride, 0.1M sodium citrate (pH 6.0)",291.0,2023-12-20,2024-04-24,8VEO,7601.0,2.0,995.0,114.0,,112.85,2.0,2.03,experimental,,0.2775,0.2392,Crystal structure of PRMT5:MEP50 in complex with MTA
7L5O,X-RAY DIFFRACTION,2.36,47.86,VAPOR DIFFUSION,,"PEG 5000 MME, AMMONIUM SULFATE, MES",293.0,2020-12-22,2022-06-29,7L5O,2963.0,1.0,271.0,387.0,,32.73,1.0,1.21,experimental,15.715,0.178,0.1645,Crystal structure of the noncovalently bonded complex of rilzabrutinib with BTK
7JVM,X-RAY DIFFRACTION,2.45,49.83,"VAPOR DIFFUSION, SITTING DROP",,17% PEG 3350 and 200 mM ammonium phosphate,277.15,2020-08-21,2020-09-23,7JVM,8254.0,2.0,1050.0,352.0,,121.91,1.0,2.166,experimental,36.33,0.2356,0.1922,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor TNO155
6HTF,X-RAY DIFFRACTION,2.0,43.62,"VAPOR DIFFUSION, HANGING DROP",8.5,"Morpheus B12 BUFFER 0.09M Halogens 0,1M Buffer 3 pH 8.5 50% precipitant 4",291.0,2018-10-04,2020-05-20,6HTF,3041.0,2.0,391.0,126.0,1.0,44.35,2.0,2.102,experimental,,0.256,0.2105,Crystal structure of human Btk SH2 domain bound to rF10 repebody
4X60,X-RAY DIFFRACTION,3.04,59.59,"VAPOR DIFFUSION, HANGING DROP",6.1,"0.2 M Sodium acetate, 0.1 M Sodium citrate pH 6.1, 10% w/v PEG 4000",293.0,2014-12-06,2015-04-22,4X60,7623.0,2.0,995.0,138.0,,112.67,2.0,2.35,experimental,62.909,0.2537,0.202,Crystal structure of PRMT5:MEP50 with EPZ015666 and sinefungin
4OTF,X-RAY DIFFRACTION,2.26,45.6,"VAPOR DIFFUSION, HANGING DROP",5.6,"1 uL protein solution (8.1 mg/mL in 10 mM Tris pH 8.5, 100 mM NaCl, 0.5 mM TCEP, 1 mM GDC0834) and 1 uL reservoir solution of 14% PEG 4000, 0.2 M Ammonium Sulfate, 0.1 M Na Acetate-Acetate pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 286K",286.0,2014-02-13,2015-01-28,4OTF,2413.0,1.0,271.0,182.0,,32.62,1.0,1.95,experimental,21.566,0.20251,0.16533,Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834
6OMU,X-RAY DIFFRACTION,2.27,45.74,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.1 M Bis Tris Propane pH 7.5, 0.2 M Sodium acetate trihydrate",295.0,2019-04-19,2019-08-14,6OMU,2785.0,1.0,271.0,428.0,,32.06,1.0,1.41,experimental,10.287,0.226,0.1902,Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinib
6VXQ,X-RAY DIFFRACTION,2.12,42.05,VAPOR DIFFUSION,,"bis-tris, ammonium salt, PEG",277.0,2020-02-23,2020-12-16,6VXQ,2354.0,1.0,293.0,228.0,,34.38,1.0,1.4,experimental,15.63,0.2239,0.1838,Bruton's tyrosine kinase in complex with compound 5
6W07,X-RAY DIFFRACTION,2.08,40.93,VAPOR DIFFUSION,,"bis-tris, ammonium salt, PEG",277.0,2020-02-29,2020-12-16,6W07,2390.0,1.0,293.0,262.0,,34.41,1.0,1.51,experimental,15.44,0.2671,0.2292,Bruton's tyrosine kinase in complex with compound 1
7N5R,X-RAY DIFFRACTION,2.21,44.36,"VAPOR DIFFUSION, HANGING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5 and 0.12M alcohol mixture",277.0,2021-06-06,2021-09-08,7N5R,2554.0,1.0,283.0,296.0,,33.06,1.0,1.55,experimental,16.769,0.195,0.1713,Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor
7N5X,X-RAY DIFFRACTION,2.22,44.61,"VAPOR DIFFUSION, HANGING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5 and 0.12M alcohol mixture",277.0,2021-06-07,2021-09-08,7N5X,2535.0,1.0,283.0,260.0,,33.25,1.0,1.6,experimental,18.02,0.1877,0.1662,Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor
7N5Y,X-RAY DIFFRACTION,2.22,44.5,"VAPOR DIFFUSION, HANGING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5 and 0.12M alcohol mixture",277.0,2021-06-07,2021-09-08,7N5Y,2476.0,1.0,283.0,218.0,,33.19,1.0,1.85,experimental,17.138,0.2015,0.1627,"Fragment-Based Drug Design of a Novel, Covalent Bruton's Tyrosine Kinase Inhibitor"
7R61,X-RAY DIFFRACTION,2.24,45.19,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 3350,
0.1 M Bis Tris Propane pH 7.5,
0.2 M Sodium acetate trihydrate",295.0,2021-06-22,2021-10-06,7R61,2293.0,1.0,270.0,105.0,,32.11,1.0,1.52,experimental,21.268,0.241,0.2089,BTK in complex with 25A
8EJB,X-RAY DIFFRACTION,2.42,49.2,"VAPOR DIFFUSION, SITTING DROP",,"12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M sodium formate, 0.02 M ammonium acetate,
0.02 M trisodium citrate, 0.02 M sodium potassium l-tartrate, 0.02 M sodium oxamate 0.1 M MES/imidazole pH 6.5",277.0,2022-09-16,2023-02-15,8EJB,2571.0,1.0,270.0,298.0,,32.26,1.0,1.58,experimental,20.72,0.191,0.1681,Bruton's tyrosine kinase in complex with 3-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-5-[(3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazine-2-carboxamide
8TU3,X-RAY DIFFRACTION,2.15,42.69,"VAPOR DIFFUSION, SITTING DROP",,"bis-tris pH 6.5, ammonium tartrate, PEG 3350",277.0,2023-08-15,2024-06-26,8TU3,2190.0,1.0,283.0,79.0,,33.05,1.0,1.7,experimental,27.45,0.2767,0.2276,Bruton's tyrosine kinase in complex with covalent inhibitor compound 10
8TU4,X-RAY DIFFRACTION,2.32,46.88,"VAPOR DIFFUSION, SITTING DROP",,"bis-tris pH 6.5, ammonium tartrate, PEG 3350",277.0,2023-08-15,2024-06-26,8TU4,2210.0,1.0,283.0,90.0,,33.05,1.0,1.6,experimental,25.46,0.2588,0.2203,Bruton's tyrosine kinase in complex with covalent inhibitor compound 25
8TU5,X-RAY DIFFRACTION,2.09,41.28,"VAPOR DIFFUSION, SITTING DROP",,"bis-tris pH 6.5, ammonium tartrate, PEG 3350",277.0,2023-08-15,2024-06-26,8TU5,2042.0,1.0,283.0,35.0,,33.06,1.0,2.1,experimental,39.88,0.2724,0.2586,Bruton's tyrosine kinase in complex with covalent inhibitor compound 27
6GYT,X-RAY DIFFRACTION,4.37,71.83,EVAPORATION,,"1.6 M Ammonium Sulfate, 100 mM Bicine, pH 9.0",294.0,2018-07-01,2018-10-17,6GYT,2797.0,3.0,338.0,36.0,,39.66,3.0,2.5,experimental,,0.2882,0.2605,Transcription factor dimerization activates the p300 acetyltransferase
8TJC,X-RAY DIFFRACTION,2.33,47.31,VAPOR DIFFUSION,,"0.1 M Tris 8.8, 0.16 M Sodium acetate, 25% PEG4000,  15% glycerol",277.0,2023-07-20,2023-12-06,8TJC,11359.0,4.0,1588.0,123.0,12.0,190.31,1.0,2.2,experimental,,0.2753,0.2271,"Structure of human beta 1,3-N-acetylglucosaminyltransferase 2 with compound 8a"
6M2D,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.4 M Lithium sulfate monohydrate, 0.1 M BIS-TRIS pH 6.5, 25% w/v Polyethylene glycol 3350",291.0,2020-02-27,2021-04-07,6M2D,2911.0,6.0,342.0,312.0,,38.87,1.0,1.795,experimental,23.5384,0.2272,0.1716,MUL1-RING domain
5YY9,X-RAY DIFFRACTION,2.1,41.32,"VAPOR DIFFUSION, HANGING DROP",7.0,"00 mM Tris-HCl (pH 7.0), 200 mM tri-potassium phosphate and 20% (w/v) PEG 3350",293.0,2017-12-08,2018-12-12,5YY9,2414.0,4.0,334.0,24.0,,39.6,2.0,2.653,experimental,,0.2877,0.2309,Crystal structure of Tandem Tudor Domain of human UHRF1 in complex with LIG1-K126me3
5RW2,X-RAY DIFFRACTION,2.11,41.63,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RW2,4751.0,1.0,463.0,454.0,,53.32,1.0,1.22,experimental,14.849,0.201,0.1799,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2737076969
5RW3,X-RAY DIFFRACTION,2.11,41.62,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RW3,4745.0,1.0,463.0,442.0,,53.35,1.0,1.37,experimental,18.421,0.196,0.1707,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2064898339
5RW4,X-RAY DIFFRACTION,2.11,41.65,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RW4,4809.0,1.0,463.0,441.0,,53.36,1.0,1.31,experimental,17.738,0.1998,0.1755,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z19735192
5RW5,X-RAY DIFFRACTION,2.11,41.61,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RW5,4826.0,1.0,463.0,442.0,,53.36,1.0,1.38,experimental,19.272,0.1982,0.1732,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z69092635
5RW6,X-RAY DIFFRACTION,2.11,41.79,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RW6,4768.0,1.0,463.0,442.0,,53.32,1.0,1.32,experimental,17.767,0.1999,0.1759,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434816
5RW7,X-RAY DIFFRACTION,2.11,41.69,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RW7,4781.0,1.0,463.0,440.0,,53.33,1.0,1.23,experimental,16.894,0.1954,0.1786,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z86622311
5RW8,X-RAY DIFFRACTION,2.11,41.63,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RW8,4771.0,1.0,463.0,437.0,,53.36,1.0,1.27,experimental,17.017,0.1948,0.1752,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z28290384
5RW9,X-RAY DIFFRACTION,2.1,41.51,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RW9,4760.0,1.0,463.0,440.0,,53.45,1.0,1.45,experimental,19.185,0.2029,0.1726,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z203581214
5RWA,X-RAY DIFFRACTION,2.11,41.62,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWA,4780.0,1.0,463.0,460.0,,53.83,1.0,1.29,experimental,18.239,0.1887,0.167,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434812
5RWB,X-RAY DIFFRACTION,2.09,41.17,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWB,4733.0,1.0,463.0,457.0,,53.51,1.0,1.25,experimental,19.379,0.2068,0.1794,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434899
5RWC,X-RAY DIFFRACTION,2.11,41.59,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWC,4766.0,1.0,463.0,439.0,,53.34,1.0,1.4,experimental,15.829,0.2084,0.1835,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434879
5RWD,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWD,4748.0,1.0,463.0,442.0,,53.53,1.0,1.29,experimental,16.503,0.187,0.1671,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1675346324
5RWE,X-RAY DIFFRACTION,2.09,41.2,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWE,4717.0,1.0,463.0,436.0,,53.34,1.0,1.34,experimental,17.175,0.1949,0.1702,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434865
5RWF,X-RAY DIFFRACTION,2.12,41.94,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWF,4764.0,1.0,463.0,439.0,,53.34,1.0,1.35,experimental,17.167,0.2007,0.1782,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1983897532
5RWG,X-RAY DIFFRACTION,2.11,41.83,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWG,4764.0,1.0,463.0,442.0,,53.36,1.0,1.46,experimental,18.419,0.204,0.1745,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z17497990
5RWH,X-RAY DIFFRACTION,2.11,41.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWH,4765.0,1.0,463.0,438.0,,53.36,1.0,1.56,experimental,20.399,0.2079,0.1733,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1152242726
5RWI,X-RAY DIFFRACTION,2.12,41.91,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWI,4744.0,1.0,463.0,442.0,,53.33,1.0,1.29,experimental,17.28,0.1965,0.1772,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434926
5RWJ,X-RAY DIFFRACTION,2.11,41.59,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWJ,4791.0,1.0,463.0,449.0,,53.42,1.0,1.26,experimental,16.539,0.1986,0.1771,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434824
5RWK,X-RAY DIFFRACTION,2.1,41.55,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWK,4785.0,1.0,463.0,448.0,,53.32,1.0,1.32,experimental,18.273,0.1987,0.1733,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1267881672
5RWL,X-RAY DIFFRACTION,2.12,42.0,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWL,4796.0,1.0,463.0,443.0,,53.32,1.0,1.37,experimental,17.262,0.2073,0.1795,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1348371854
5RWM,X-RAY DIFFRACTION,2.12,42.04,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWM,4813.0,1.0,463.0,445.0,,53.52,1.0,1.36,experimental,17.812,0.2024,0.1779,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z136583524
5RWN,X-RAY DIFFRACTION,2.11,41.6,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWN,4766.0,1.0,463.0,440.0,,53.36,1.0,1.38,experimental,17.689,0.1984,0.1734,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1310876699
5RWO,X-RAY DIFFRACTION,2.1,41.47,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWO,4770.0,1.0,463.0,448.0,,53.35,1.0,1.29,experimental,17.569,0.2019,0.1815,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434898
5RWP,X-RAY DIFFRACTION,2.11,41.74,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWP,4803.0,1.0,463.0,438.0,,53.33,1.0,1.48,experimental,19.488,0.2093,0.1777,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z915492990
5RWQ,X-RAY DIFFRACTION,2.11,41.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWQ,4731.0,1.0,463.0,447.0,,53.33,1.0,1.32,experimental,19.429,0.1986,0.1747,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z44592329
5RWR,X-RAY DIFFRACTION,2.11,41.83,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWR,4780.0,1.0,463.0,442.0,,53.33,1.0,1.43,experimental,17.794,0.2003,0.1741,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434783
5RWS,X-RAY DIFFRACTION,2.11,41.6,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWS,4752.0,1.0,463.0,440.0,,53.41,1.0,1.28,experimental,16.115,0.1935,0.1739,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1478435544
5RWT,X-RAY DIFFRACTION,2.1,41.57,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWT,4745.0,1.0,463.0,441.0,,53.36,1.0,1.43,experimental,18.552,0.2037,0.1775,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z32327641
5RWU,X-RAY DIFFRACTION,2.11,41.69,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWU,4779.0,1.0,463.0,436.0,,53.32,1.0,1.37,experimental,17.425,0.1952,0.1711,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z57778470
5RWV,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWV,4772.0,1.0,463.0,434.0,,53.29,1.0,1.25,experimental,16.719,0.2017,0.1778,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1103351268
5RWW,X-RAY DIFFRACTION,2.09,41.14,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWW,4789.0,1.0,463.0,445.0,,53.36,1.0,1.16,experimental,15.335,0.19,0.1718,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2241115980
5RWX,X-RAY DIFFRACTION,2.1,41.34,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWX,4787.0,1.0,463.0,442.0,,53.35,1.0,1.34,experimental,18.01,0.1977,0.1729,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z44567722
5RWY,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWY,4730.0,1.0,463.0,447.0,,53.34,1.0,1.35,experimental,17.81,0.201,0.1747,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1259335913
5RWZ,X-RAY DIFFRACTION,2.09,41.24,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RWZ,4747.0,1.0,463.0,441.0,,53.35,1.0,1.42,experimental,19.115,0.1968,0.1709,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z57299529
5RX0,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX0,4809.0,1.0,463.0,441.0,,53.45,1.0,1.43,experimental,19.584,0.2013,0.1709,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z57258487
5RX1,X-RAY DIFFRACTION,2.1,41.44,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX1,4743.0,1.0,463.0,441.0,,53.53,1.0,1.31,experimental,18.392,0.1969,0.1751,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2466069494
5RX2,X-RAY DIFFRACTION,2.09,41.26,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX2,4723.0,1.0,463.0,435.0,,53.54,1.0,1.27,experimental,18.179,0.1945,0.171,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1827898537
5RX3,X-RAY DIFFRACTION,2.09,41.18,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX3,4729.0,1.0,463.0,448.0,,53.29,1.0,1.45,experimental,21.195,0.1987,0.1726,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1262327505
5RX4,X-RAY DIFFRACTION,2.1,41.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX4,4725.0,1.0,463.0,435.0,,53.6,1.0,1.35,experimental,18.004,0.195,0.1722,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1593306637
5RX5,X-RAY DIFFRACTION,2.11,41.71,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX5,4770.0,1.0,463.0,443.0,,53.34,1.0,1.28,experimental,22.16,0.2228,0.1959,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2443429438
5RX6,X-RAY DIFFRACTION,2.12,42.03,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX6,4793.0,1.0,463.0,441.0,,53.36,1.0,1.45,experimental,19.418,0.2019,0.1748,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z30620520
5RX7,X-RAY DIFFRACTION,2.11,41.72,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX7,4766.0,1.0,463.0,446.0,,53.3,1.0,1.36,experimental,17.771,0.2,0.1778,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1545196403
5RX8,X-RAY DIFFRACTION,2.09,41.24,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX8,4763.0,1.0,463.0,439.0,,53.6,1.0,1.34,experimental,18.019,0.1937,0.17,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434884
5RX9,X-RAY DIFFRACTION,2.1,41.45,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RX9,4765.0,1.0,463.0,438.0,,53.35,1.0,1.29,experimental,17.573,0.1985,0.176,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z54226095
5RXA,X-RAY DIFFRACTION,2.1,41.48,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXA,4808.0,1.0,463.0,446.0,,53.59,1.0,1.24,experimental,16.249,0.1874,0.1691,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434829
5RXB,X-RAY DIFFRACTION,2.11,41.57,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXB,4720.0,1.0,463.0,437.0,,53.31,1.0,1.58,experimental,17.845,0.213,0.1828,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434821
5RXC,X-RAY DIFFRACTION,2.09,41.27,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXC,4725.0,1.0,463.0,439.0,,53.56,1.0,1.59,experimental,18.374,0.2079,0.1784,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434868
5RXD,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXD,4793.0,1.0,463.0,441.0,,53.34,1.0,1.33,experimental,14.923,0.1908,0.1697,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z111810692
5RXE,X-RAY DIFFRACTION,2.06,40.41,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXE,4804.0,1.0,463.0,441.0,,53.31,1.0,1.25,experimental,15.991,0.1917,0.1732,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z240654968
5RXF,X-RAY DIFFRACTION,2.06,40.28,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXF,4808.0,1.0,463.0,443.0,,53.33,1.0,1.26,experimental,16.173,0.2145,0.192,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2074076908
5RXG,X-RAY DIFFRACTION,2.06,40.26,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXG,4725.0,1.0,463.0,441.0,,53.35,1.0,1.52,experimental,18.871,0.2062,0.1759,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434909
5RXH,X-RAY DIFFRACTION,2.04,39.85,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXH,4744.0,1.0,463.0,456.0,,53.52,1.0,1.42,experimental,17.038,0.2034,0.1795,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z939944666
5RXI,X-RAY DIFFRACTION,2.08,40.96,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXI,4767.0,1.0,463.0,442.0,,53.32,1.0,1.74,experimental,20.919,0.2343,0.1978,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2447286438
5RXJ,X-RAY DIFFRACTION,2.08,40.92,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXJ,4727.0,1.0,463.0,444.0,,53.3,1.0,1.52,experimental,17.598,0.1957,0.1713,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1722836661
5RXK,X-RAY DIFFRACTION,2.07,40.51,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXK,4474.0,1.0,463.0,444.0,,53.31,1.0,1.46,experimental,17.104,0.2003,0.1764,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434840
5RXL,X-RAY DIFFRACTION,2.08,40.99,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXL,4786.0,1.0,463.0,439.0,,53.34,1.0,1.49,experimental,19.181,0.2049,0.1795,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1673618163
5RXM,X-RAY DIFFRACTION,2.07,40.69,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXM,4767.0,1.0,463.0,439.0,,53.38,1.0,1.46,experimental,18.746,0.1992,0.1705,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434894
5RXO,X-RAY DIFFRACTION,2.08,40.99,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXO,4769.0,1.0,463.0,438.0,,53.34,1.0,1.71,experimental,21.472,0.2071,0.1723,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z68299550
5RXP,X-RAY DIFFRACTION,2.1,41.3,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXP,4793.0,1.0,463.0,438.0,,53.35,1.0,1.53,experimental,17.868,0.2018,0.1739,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434944
5RXQ,X-RAY DIFFRACTION,2.06,40.4,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXQ,4769.0,1.0,463.0,435.0,,53.3,1.0,1.65,experimental,21.44,0.2134,0.176,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z26548083
5RXR,X-RAY DIFFRACTION,2.08,40.84,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXR,4740.0,1.0,463.0,437.0,,53.26,1.0,1.4,experimental,16.714,0.194,0.1716,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1148747945
5RXS,X-RAY DIFFRACTION,2.09,41.05,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXS,4799.0,1.0,463.0,437.0,,53.56,1.0,1.37,experimental,15.814,0.1943,0.1726,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1818332938
5RXT,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXT,4778.0,1.0,463.0,441.0,,53.31,1.0,1.63,experimental,19.922,0.2176,0.1878,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z319545618
5RXU,X-RAY DIFFRACTION,2.06,40.36,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXU,4776.0,1.0,463.0,434.0,,53.32,1.0,1.64,experimental,25.676,0.2132,0.181,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434858
5RXV,X-RAY DIFFRACTION,2.08,40.95,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXV,4787.0,1.0,463.0,441.0,,53.26,1.0,1.5,experimental,16.231,0.2009,0.1728,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z45527714
5RXW,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXW,4789.0,1.0,463.0,441.0,,53.32,1.0,1.34,experimental,15.186,0.1972,0.1743,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2856434856
5RXX,X-RAY DIFFRACTION,2.09,41.17,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXX,4778.0,1.0,463.0,441.0,,53.32,1.0,1.43,experimental,15.135,0.1985,0.1736,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1275599911
5RXY,X-RAY DIFFRACTION,2.09,41.06,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXY,4738.0,1.0,463.0,437.0,,53.29,1.0,1.4,experimental,17.041,0.1933,0.1686,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z32014663
5RXZ,X-RAY DIFFRACTION,2.09,41.12,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RXZ,4801.0,1.0,463.0,437.0,,53.3,1.0,1.56,experimental,19.986,0.1952,0.1672,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z19739650
5RY0,X-RAY DIFFRACTION,2.08,40.82,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY0,4800.0,1.0,463.0,434.0,,53.35,1.0,1.98,experimental,17.673,0.2041,0.1577,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z275165822
5RY1,X-RAY DIFFRACTION,2.05,40.06,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY1,4818.0,1.0,463.0,453.0,,53.32,1.0,1.52,experimental,15.482,0.2528,0.2236,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2940170964
5RY2,X-RAY DIFFRACTION,2.07,40.46,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY2,4800.0,1.0,463.0,437.0,,53.31,1.0,1.54,experimental,20.35,0.2212,0.1893,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z19727416
5RY3,X-RAY DIFFRACTION,2.08,40.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY3,4806.0,1.0,463.0,443.0,,53.29,1.0,1.5,experimental,16.516,0.2077,0.1829,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2027158783
5RY4,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY4,4779.0,1.0,463.0,443.0,,53.33,1.0,1.47,experimental,17.588,0.198,0.1732,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z300245038
5RY5,X-RAY DIFFRACTION,2.1,41.53,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY5,4799.0,1.0,463.0,439.0,,53.42,1.0,1.54,experimental,18.847,0.2051,0.1774,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z166605480
5RY6,X-RAY DIFFRACTION,2.09,41.2,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY6,4762.0,1.0,463.0,436.0,,53.56,1.0,1.74,experimental,23.762,0.2157,0.1768,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z198194394
5RY7,X-RAY DIFFRACTION,2.09,41.06,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY7,4741.0,1.0,463.0,440.0,,53.3,1.0,1.6,experimental,21.296,0.2042,0.1724,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1267773591
5RY8,X-RAY DIFFRACTION,2.08,40.92,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY8,4795.0,1.0,463.0,445.0,,53.68,1.0,1.43,experimental,17.512,0.2057,0.1769,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1374778753
5RY9,X-RAY DIFFRACTION,2.07,40.7,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RY9,4734.0,1.0,463.0,437.0,,53.59,1.0,1.52,experimental,16.31,0.2066,0.1821,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z274575916
5RYA,X-RAY DIFFRACTION,2.08,40.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYA,4775.0,1.0,463.0,439.0,,53.77,1.0,1.32,experimental,19.15,0.2064,0.1792,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1741973467
5RYB,X-RAY DIFFRACTION,2.08,40.84,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYB,4779.0,1.0,463.0,437.0,,53.3,1.0,1.55,experimental,17.74,0.2158,0.1841,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z927400026
5RYC,X-RAY DIFFRACTION,2.1,41.44,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYC,4790.0,1.0,463.0,441.0,,53.28,1.0,1.56,experimental,18.459,0.2051,0.174,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z18197050
5RYD,X-RAY DIFFRACTION,2.09,41.01,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYD,4776.0,1.0,463.0,440.0,,53.37,1.0,1.6,experimental,20.072,0.2032,0.1753,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z955369596
5RYE,X-RAY DIFFRACTION,2.1,41.43,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYE,4789.0,1.0,463.0,437.0,,53.36,1.0,1.7,experimental,22.013,0.2696,0.2295,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z33545544
5RYF,X-RAY DIFFRACTION,2.08,40.9,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYF,4761.0,1.0,463.0,440.0,,53.28,1.0,1.49,experimental,18.903,0.1992,0.1717,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1266823232
5RYG,X-RAY DIFFRACTION,2.08,40.94,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYG,4803.0,1.0,463.0,443.0,,53.25,1.0,1.47,experimental,18.61,0.2048,0.1746,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z168883358
5RYH,X-RAY DIFFRACTION,2.1,41.39,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYH,4784.0,1.0,463.0,441.0,,53.32,1.0,1.72,experimental,23.753,0.2308,0.1938,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1212984951
5RYI,X-RAY DIFFRACTION,2.09,41.25,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYI,4758.0,1.0,463.0,434.0,,53.36,1.0,1.45,experimental,17.153,0.2021,0.1761,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z274555794
5RYJ,X-RAY DIFFRACTION,2.09,41.13,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYJ,4768.0,1.0,463.0,445.0,,53.29,1.0,1.42,experimental,16.984,0.203,0.1779,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z2177153697
5RYK,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYK,4740.0,1.0,463.0,440.0,,53.3,1.0,1.55,experimental,18.191,0.2218,0.1943,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1346370629
5RYL,X-RAY DIFFRACTION,2.07,40.65,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulfate, 100 mM MES/imidazole, pH 6.5, 20% PEG500 MME, 10% PEG20000",293.0,2020-10-30,2020-11-11,5RYL,4786.0,1.0,463.0,439.0,,53.3,1.0,1.55,experimental,20.924,0.2014,0.1726,INPP5D PanDDA analysis group deposition -- Crystal Structure of the phosphatase and C2 domains of SHIP1 in complex with Z1745658474
8PDH,X-RAY DIFFRACTION,2.09,41.18,"VAPOR DIFFUSION, SITTING DROP",6.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM MES/imidazole, 20 % PEG 500 MME, 10% PEG 20,000",293.0,2023-06-12,2023-06-28,8PDH,4342.0,1.0,463.0,482.0,,53.35,1.0,1.45,experimental,20.658,0.2018,0.144,The phosphatase and C2 domains of SHIP1 with covalent Z1742148362
6GG8,X-RAY DIFFRACTION,2.53,51.44,"VAPOR DIFFUSION, SITTING DROP",,"0.9M (NH4)2SO4, 0.1 M CHES pH9.5, 10% (v/v) of condition C8 of the Morpheus Screen (Molecular Dimension)",293.0,2018-05-03,2019-01-09,6GG8,2341.0,2.0,320.0,186.0,,37.07,2.0,1.8,experimental,28.16,0.228,0.206,Mineralocorticoid receptor in complex with (s)-13
9AY7,X-RAY DIFFRACTION,2.49,50.69,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.2M sodium acetate pH 8.0, 20% w/v PEG 3350",291.0,2024-03-07,2024-04-17,9AY7,4752.0,2.0,674.0,174.0,,77.46,2.0,2.41,experimental,58.5,0.2359,0.2012,Crystal structure of CRAF/MEK1 complex with NST-628 and inactive RAF
6VNL,X-RAY DIFFRACTION,3.06,59.8,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNL,10106.0,4.0,1232.0,215.0,,148.24,1.0,2.4,experimental,62.2147,0.2566,0.2168,JAK2 JH1 in complex with SG3-179
6VSN,X-RAY DIFFRACTION,3.03,59.43,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-02-11,2021-02-17,6VSN,10227.0,4.0,1232.0,474.0,,147.05,1.0,2.5,experimental,40.8852,0.252,0.1903,JAK2 JH1 in complex with BL2-110
5LI1,X-RAY DIFFRACTION,2.14,42.49,"VAPOR DIFFUSION, SITTING DROP",,"32% Peg 2000 MME, 0.08 M KSCN",293.0,2016-07-13,2016-09-14,5LI1,3109.0,2.0,374.0,197.0,,43.99,2.0,2.0,experimental,,0.2168,0.1504,Structure of a Par3-inhibitory peptide bound to PKCiota core kinase domain
5YYA,X-RAY DIFFRACTION,2.09,41.06,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris (pH 6.5), 200 mM ammonium acetate, 25% (w/v) polyethylene glycol (PEG) 3350",277.0,2017-12-08,2018-12-12,5YYA,1596.0,1.0,164.0,244.0,,19.5,1.0,1.7,experimental,,0.2055,0.1719,Crystal structure of Tandem Tudor Domain of human UHRF1
7KL1,X-RAY DIFFRACTION,2.3,46.53,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M 1,3-bis(tris(hydroxymethyl)methylamino)propane, 0.1 M Ammonium sulfate, 20% PEG 6000, 19mM HECAMEG",277.0,2020-10-28,2020-12-23,7KL1,4718.0,4.0,580.0,118.0,,67.91,2.0,2.4,experimental,25.653,0.2575,0.206,Cocrystal structure of human CaMKII-alpha (CAMK2A)kinase domain and GluN2B(S1303D)
6FYZ,X-RAY DIFFRACTION,2.22,44.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M BisTris, 18 to 24% PEG MME 5000",293.0,2018-03-13,2018-12-05,6FYZ,8256.0,3.0,1185.0,230.0,,129.87,1.0,2.15,experimental,28.716,0.2284,0.19264,Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor
4QBQ,X-RAY DIFFRACTION,2.12,41.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"29% PEGMME5000, 0.1M Bis-Tris Propane-HCL, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-05-08,2015-05-13,4QBQ,2299.0,3.0,282.0,104.0,1.0,32.1,2.0,2.406,experimental,,0.2304,0.1736,Crystal structure of DNMT3a ADD domain bound to H3 peptide
4QBS,X-RAY DIFFRACTION,2.06,40.2,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG3350, 0.1M Bis-Tris, 0.2M ammonium sulfate, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-05-08,2015-05-13,4QBS,1287.0,2.0,145.0,125.0,,16.85,2.0,1.8,experimental,,0.2032,0.1667,Crystal structure of DNMT3a ADD domain E545R mutant bound to H3T3ph peptide
6CAD,X-RAY DIFFRACTION,2.11,41.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"30% PEG 3350, 0.1M Bis-Tris Propane pH 6.5, 0.2M Sodium Nitrate",293.0,2018-01-30,2018-02-21,6CAD,3745.0,2.0,568.0,3.0,,65.44,1.0,2.55,experimental,97.9672,0.277,0.2547,Crystal structure of RAF kinase domain bound to the inhibitor 2a
6IWI,X-RAY DIFFRACTION,2.66,53.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris-HCl, 0.2 M MgSO4, 20% PEG 3350",293.0,2018-12-05,2019-12-11,6IWI,2461.0,1.0,347.0,146.0,,40.62,1.0,2.155,experimental,29.395,0.2265,0.1854,Crystal structure of PDE5A in complex with a novel inhibitor
6B8U,X-RAY DIFFRACTION,2.82,56.38,"VAPOR DIFFUSION, HANGING DROP",4.7,"10% PEG8000, 0.1 M sodium citrate pH 4.7, and 0.2 M sodium chloride",277.0,2017-10-09,2017-11-22,6B8U,4121.0,2.0,562.0,111.0,,64.73,1.0,2.68,experimental,41.24,0.2184,0.1784,Crystals Structure of B-Raf kinase domain in complex with an Imidazopyridinyl benzamide inhibitor
4YLJ,X-RAY DIFFRACTION,3.27,62.43,"VAPOR DIFFUSION, SITTING DROP",8.8,"37% PEG400, 0.2 M lithium sulfate, 0.1 M Tris, pH 8.8",277.0,2015-03-05,2015-03-25,4YLJ,11988.0,4.0,1444.0,247.0,,172.2,1.0,2.58,experimental,78.835,0.22203,0.1919,"Crystal structure of DYRK1A in complex with 10-Iodo-substituted 11H-indolo[3,2-c]quinoline-6-carboxylic acid inhibitor 5j"
5HRT,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG3350, calcium chloride, tris",293.0,2016-01-24,2016-04-06,5HRT,7677.0,2.0,865.0,459.0,15.0,109.7,1.0,1.997,experimental,,0.2018,0.1637,Crystal structure of mouse autotaxin in complex with a DNA aptamer
7Q9U,X-RAY DIFFRACTION,2.88,57.24,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulphate, 0.1 M tri sodium citrate pH 5.6, 15 % w/v PEG 4000",291.0,2021-11-14,2022-01-26,7Q9U,5483.0,4.0,670.0,152.0,,78.92,2.0,2.238,experimental,46.809,0.2545,0.1994,Crystal structure of the high affinity KRas mutant PDE6D complex
5VC3,X-RAY DIFFRACTION,2.08,40.83,"VAPOR DIFFUSION, HANGING DROP",6.9,"5.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5),7.5 % PEG 3350, 1 mM Bosutinib",291.0,2017-03-30,2017-08-23,5VC3,2196.0,1.0,289.0,72.0,,33.26,1.0,1.97,experimental,50.2264,0.2536,0.212,CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4RR2,X-RAY DIFFRACTION,3.05,59.72,"VAPOR DIFFUSION, SITTING DROP",8.5,"50 mM Tris-HCl pH 8.5, 7.5% v/v ethanol and 2 mM TCEP, VAPOR DIFFUSION, SITTING DROP, temperature 295K",295.0,2014-11-05,2015-01-21,4RR2,11896.0,4.0,1858.0,88.0,,218.23,2.0,2.65,experimental,53.2,0.271,0.229,Crystal structure of human primase
6WLY,X-RAY DIFFRACTION,2.11,41.79,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Tris-HCl, 2M Na acetate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K, 2mM peptide",295.0,2020-04-20,2020-06-24,6WLY,2573.0,2.0,356.0,135.0,,40.35,2.0,1.9,experimental,45.0861,0.2053,0.1861,PAK4 kinase domain in complex with LIMK1 Thr508 substrate peptide
5LPM,X-RAY DIFFRACTION,2.33,47.14,EVAPORATION,5.5,"NaCl, PEG 3350",277.0,2016-08-13,2017-08-16,5LPM,2465.0,2.0,232.0,333.0,,29.33,1.0,1.5,experimental,25.782,0.1871,0.1579,Crystal structure of the bromodomain of human Ep300 bound to the inhibitor XDM3d
5NU5,X-RAY DIFFRACTION,2.25,45.37,EVAPORATION,6.5,"KSCN, NaBr, PEG 6000, PEG 8000, PEG 10000",277.0,2017-04-28,2017-08-16,5NU5,2445.0,2.0,232.0,362.0,,28.7,1.0,1.6,experimental,20.09,0.1854,0.1624,Crystal structure of the human bromodomain of EP300 bound to the inhibitor XDM-CBP
7VHY,X-RAY DIFFRACTION,2.99,58.87,"VAPOR DIFFUSION, HANGING DROP",7.0,"15% PEG3350, 0.1 M HEPES (pH7.0)",277.0,2021-09-24,2022-04-27,7VHY,7299.0,2.0,908.0,310.0,,105.64,1.0,2.3,experimental,54.7465,0.2502,0.2122,Crystal structure of EP300 HAT domain in complex with compound (+)-3
7VHZ,X-RAY DIFFRACTION,3.05,59.64,"VAPOR DIFFUSION, HANGING DROP",7.0,"16% PEG3350, 0.1 M HEPES (pH 7.0)",277.0,2021-09-24,2022-04-27,7VHZ,7579.0,2.0,908.0,539.0,,106.07,1.0,2.0,experimental,48.9303,0.2188,0.191,Crystal structure of EP300 HAT domain in complex with compound 7
7VI0,X-RAY DIFFRACTION,2.96,58.5,"VAPOR DIFFUSION, HANGING DROP",7.0,"12% PEG3350, 0.1 M HEPES (pH 7.0)",277.0,2021-09-24,2022-04-27,7VI0,7551.0,2.0,908.0,507.0,3.0,106.17,1.0,2.1,experimental,46.9311,0.235,0.1993,Crystal structure of EP300 HAT domain in complex with compound 11
8FVF,X-RAY DIFFRACTION,2.89,57.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Sodium chloride, 0.1M HEPES pH7.5, 1.6M Ammonium sulfate",291.0,2023-01-18,2024-02-07,8FVF,2220.0,2.0,228.0,219.0,,29.1,1.0,2.1,experimental,,0.2389,0.1813,Bromodomain of EP300 liganded with CCS-1477
6NK1,X-RAY DIFFRACTION,2.28,45.98,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.09 M Sodium-Acetate pH 4.5, 22.5% w/v PEG 3,350, 3% w/v 6-aminohexanoic acid",293.0,2019-01-04,2019-05-01,6NK1,3683.0,4.0,402.0,411.0,4.0,46.22,2.0,1.55,experimental,24.67,0.1686,0.1457,EphA2 LBD in complex with bA-WLA-YRPKbio peptide
6CW2,X-RAY DIFFRACTION,5.52,77.72,MICROBATCH,8.5,"10 mM Tris-Cl pH 8.5, 200 mM Li2SO4, 25% w/v PEG3350",294.0,2018-03-29,2018-09-19,6CW2,5948.0,4.0,815.0,51.0,4.0,90.97,4.0,2.67,experimental,86.9959,0.2838,0.2501,"Crystal structure of a yeast SAGA transcriptional coactivator Ada2/Gcn5 HAT subcomplex, crystal form 1"
5PAT,X-RAY DIFFRACTION,3.75,67.18,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAT,2829.0,2.0,318.0,353.0,9.0,35.58,2.0,1.6,experimental,23.755,0.2166,0.1859,Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-(3-chlorophenyl)acetamide
7ATS,X-RAY DIFFRACTION,2.29,46.38,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350
0.1 M bis-tris-propane pH 7.5
0.2 M potassium thiocyanate
10% ethylene glycol",293.0,2020-10-30,2020-11-25,7ATS,1919.0,1.0,310.0,,,36.52,1.0,2.8,experimental,87.48,0.3122,0.2478,The LIMK1 Kinase Domain Bound To LIJTF500127
5NGF,X-RAY DIFFRACTION,2.5,50.88,"VAPOR DIFFUSION, SITTING DROP",7.5,"20 % (w/v) PEG3350, 100 mM Bis-Tris propane pH 7.5, 0.2 M sodium formate",293.0,2017-03-17,2017-10-18,5NGF,5183.0,2.0,710.0,18.0,1.0,83.46,1.0,2.33,experimental,73.06,0.2469,0.18802,"Crystal structure of USP7 in complex with the covalent inhibitor, FT827"
6U8Z,X-RAY DIFFRACTION,2.43,49.43,"VAPOR DIFFUSION, HANGING DROP",5.3,"0.2 M ammonium citrate, 15% PEG3350, pH 5.3",298.0,2019-09-06,2020-03-18,6U8Z,5228.0,1.0,603.0,474.0,,69.75,1.0,1.799,experimental,49.9468,0.2145,0.1738,Crystal Structure of Catalytic Domain of Human Phospholipase D1
6V90,X-RAY DIFFRACTION,2.48,50.44,"VAPOR DIFFUSION, SITTING DROP",,"INDEX F6. 0.1 M Bis-Tris pH 5.5, 0.2 M ammonium sulfate 25% w/v PEG 3350. The crystal was cryoprotected with MiTeGen Low Viscosity Cryo Oil",277.0,2019-12-12,2020-04-01,6V90,2752.0,1.0,349.0,92.0,,41.03,1.0,2.04,experimental,49.279,0.241,0.1975,Crystal structure of the p300 acetyltransferase domain with AcCoA competitive inhibitor 12
7SZQ,X-RAY DIFFRACTION,2.25,45.21,VAPOR DIFFUSION,9.5,"30% PEG400, 0.1 M CHES pH 9.5",277.0,2021-11-29,2022-11-09,7SZQ,2681.0,1.0,389.0,63.0,,45.45,1.0,2.8,experimental,38.5963,0.2348,0.1694,Human P300 complexed with an azaindazole inhibitor
6S14,X-RAY DIFFRACTION,2.72,54.8,"VAPOR DIFFUSION, SITTING DROP",,2M ammonium sulfate -- 0.1M citrate pH 5.7 -- 0.2M sodium/potassium tartrate,277.0,2019-06-18,2019-06-26,6S14,3370.0,1.0,361.0,543.0,,42.92,1.0,1.05,experimental,18.453,0.1625,0.1505,Crystal Structure of DYRK1A with small molecule inhibitor
6S17,X-RAY DIFFRACTION,2.69,54.24,"VAPOR DIFFUSION, SITTING DROP",,1.6M ammonium sulfate -- 0.1M citrate pH 5.3 -- 0.2M sodium/potassium tartrate,277.0,2019-06-18,2019-06-26,6S17,3373.0,1.0,361.0,449.0,,43.04,1.0,1.1,experimental,21.7222,0.1625,0.1491,Crystal Structure of DYRK1A with small molecule inhibitor
6S1B,X-RAY DIFFRACTION,2.74,55.15,"VAPOR DIFFUSION, SITTING DROP",,2.2M ammonium sulfate -- 0.1M citrate pH 5.3 -- 0.2M sodium/potassium tartrate,277.0,2019-06-18,2019-06-26,6S1B,3331.0,1.0,361.0,491.0,,42.95,1.0,1.3,experimental,21.3736,0.1786,0.1606,Crystal Structure of DYRK1A with small molecule inhibitor
6S1H,X-RAY DIFFRACTION,2.62,53.08,"VAPOR DIFFUSION, SITTING DROP",,1.8M ammonium sulfate -- 0.1M citrate pH 5.7 -- 0.2M sodium/potassium tartrate,277.0,2019-06-18,2019-06-26,6S1H,3541.0,1.0,361.0,534.0,,42.8,1.0,1.05,experimental,19.5206,0.1545,0.1404,Crystal Structure of DYRK1A with small molecule inhibitor
4ZJJ,X-RAY DIFFRACTION,2.73,54.99,"VAPOR DIFFUSION, HANGING DROP",,"Equal volumes (0.8 uL) of reservoir solution and protein solution were mixed. Reservoir solution: 16.8% (w/v) PEG3350, 0.2 M magnesium formate (dihydrate)",298.0,2015-04-29,2015-06-24,4ZJJ,9072.0,4.0,1196.0,765.0,,135.53,1.0,2.2,experimental,33.86,0.2384,0.2013,PAK1 in complex with (S)-N-(tert-butyl)-3-((2-chloro-5-ethyl-8-fluoro-dibenzodiazepin-11-yl)amino)pyrrolidine-1-carboxamide
6IG8,X-RAY DIFFRACTION,2.5,50.71,"VAPOR DIFFUSION, HANGING DROP",8.5,"11 mg/mL protein, 22.5-35% PEG 4000, 0.1M Tris-HCL pH 8.5, 0.2M MgCl2",277.0,2018-09-25,2019-08-07,6IG8,2901.0,1.0,324.0,373.0,,36.94,1.0,1.8,experimental,20.164,0.1922,0.156,"Crystal structure of CSF-1R kinase domain with a small molecular inhibitor, JTE-952"
6T2W,X-RAY DIFFRACTION,2.47,50.24,VAPOR DIFFUSION,5.5,"16% PEG3350, 0.15 M Ammonium Sulfate, 0.1 M PCTP pH 5.5",277.0,2019-10-09,2020-01-01,6T2W,2669.0,1.0,332.0,234.0,,38.1,1.0,1.7,experimental,28.09,0.187,0.166,Crystal structure of the CSF1R kinase domain with a dihydropurinone inhibitor (compound 4)
7K3D,X-RAY DIFFRACTION,2.36,47.86,"VAPOR DIFFUSION, HANGING DROP",,2.5 M Ammonium sulfate; 0.1 M MES pH 6.5,293.0,2020-09-11,2021-04-14,7K3D,3876.0,2.0,482.0,206.0,,56.54,1.0,2.34,experimental,26.2111,0.2594,0.2054,The structure of NTMT1 in complex with compound DC1-13
5WU3,X-RAY DIFFRACTION,2.52,51.22,"VAPOR DIFFUSION, HANGING DROP",,"Hepes pH 7.5, PEG3350, Tacsimate",277.0,2016-12-16,2017-05-31,5WU3,7599.0,2.0,1146.0,2.0,,125.72,1.0,2.703,experimental,68.11,0.2569,0.2288,"Crystal structure of human Tut1 bound with MgUTP, form II"
6BGP,X-RAY DIFFRACTION,2.03,39.28,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 8000, MES, calcium chloride",295.15,2017-10-29,2018-02-07,6BGP,10316.0,4.0,1528.0,50.0,,178.16,1.0,2.75,experimental,68.376,0.2584,0.2092,Crystal Structure of Human Calpain-3 Protease Core Mutant-C129A
4WXX,X-RAY DIFFRACTION,3.74,67.13,"VAPOR DIFFUSION, SITTING DROP",6.5,"45% PEG200, 50 mM CaCl2, 0.1 mM MES",289.0,2014-11-14,2015-07-15,4WXX,19035.0,2.0,2512.0,637.0,,285.63,1.0,2.622,experimental,,0.2453,0.2049,The crystal structure of human DNMT1(351-1600)
5E0V,X-RAY DIFFRACTION,2.05,39.88,"VAPOR DIFFUSION, HANGING DROP",4.6,"2.35 M ammonium sulfate, 100 mM sodium acetate pH 4.6, 40% (v/v) -1,3-Butanediol",298.0,2015-09-29,2016-04-20,5E0V,4129.0,4.0,554.0,99.0,2.0,61.19,2.0,2.074,experimental,,0.2292,0.202,Human PCNA variant (S228I) complexed with FEN1 at 2.1 Angstroms
7A4Z,X-RAY DIFFRACTION,2.5,50.74,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-20,2021-06-30,7A4Z,2940.0,1.0,359.0,234.0,,41.84,1.0,1.9,experimental,32.671,0.2151,0.1728,Structure of DYRK1A in complex with compound 4
7A51,X-RAY DIFFRACTION,2.47,50.13,VAPOR DIFFUSION,,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-20,2021-06-30,7A51,2949.0,1.0,359.0,243.0,,41.9,1.0,1.9,experimental,32.469,0.2196,0.1743,Structure of DYRK1A in complex with compound 5
7A5D,X-RAY DIFFRACTION,2.48,50.32,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-21,2021-06-30,7A5D,3026.0,1.0,359.0,304.0,,41.97,1.0,1.8,experimental,30.602,0.1978,0.1673,Structure of DYRK1A in complex with compound 16
7A5L,X-RAY DIFFRACTION,2.48,50.5,VAPOR DIFFUSION,6.5,"0.1M MES buffer at pH 6.5, 12% Peg3350, 0.2M MgCl2",293.0,2020-08-21,2021-06-30,7A5L,2922.0,1.0,359.0,204.0,,42.02,1.0,2.1,experimental,32.348,0.2193,0.1675,tructure of DYRK1A in complex with compound 24
6EG3,X-RAY DIFFRACTION,4.06,69.68,"VAPOR DIFFUSION, SITTING DROP",7.0,"100mM Tris pH7, 14% Ethanol",277.0,2018-08-17,2018-10-31,6EG3,4931.0,1.0,621.0,27.0,,70.32,1.0,2.84,experimental,78.03,0.2668,0.2287,Crystal structure of human BRM in complex with compound 15
7EVJ,X-RAY DIFFRACTION,2.24,45.08,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.2 M NH4H2PO4, 20% PEG 3350, pH 4.6, and 20% Gly",277.0,2021-05-21,2022-02-16,7EVJ,1026.0,1.0,133.0,33.0,,16.6,1.0,2.57,experimental,41.498,0.2093,0.1869,Crystal structure of CBP bromodomain liganded with 9c
6HM5,X-RAY DIFFRACTION,2.21,44.31,"VAPOR DIFFUSION, SITTING DROP",,"100 mM bicine/Trizma base pH 8.5, 300 mM diethyleneglycol, 300 mM triethyleneglycol, 300 mM tetraethyleneglycol, 300 mM pentaethyleneglycol, 10% w/v PEG 20000 and 20% v/v PEG MME 550",287.15,2018-09-12,2018-10-17,6HM5,2114.0,2.0,301.0,59.0,2.0,34.37,2.0,2.33003812226,experimental,51.5979895974,0.241491216096,0.201270613267,"Crystal structure of TOPBP1 BRCT0,1,2 in complex with a RAD9 phosphopeptide"
5CLS,X-RAY DIFFRACTION,2.74,55.08,"VAPOR DIFFUSION, SITTING DROP",5.4,"Na Citrate, Tert-butanol",292.0,2015-07-16,2016-01-13,5CLS,3351.0,1.0,371.0,329.0,1.0,42.51,1.0,1.75,experimental,22.373,0.18885,0.16001,Structure of human methionine aminopeptidase-2 complexed with spiroepoxytriazole inhibitor (+)-31a
4ZTH,X-RAY DIFFRACTION,2.16,43.17,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M Ammonium Acetate, 0.1 BisTris (pH 5.5), 17% PEG 10,000, VAPOR DIFFUSION, SITTING DROP, temperature 295K",295.0,2015-05-14,2016-06-22,4ZTH,3015.0,1.0,383.0,135.0,,44.54,1.0,2.15,experimental,48.68,0.24,0.181,Structure of human p38aMAPK-arylpyridazinylpyridine fragment complex used in inhibitor discovery
6GLA,X-RAY DIFFRACTION,1.93,36.35,"VAPOR DIFFUSION, SITTING DROP",,"24-30% PEG 3350, 0.1 M MES, pH 5.5-6.0 and 0.1-0.2 M MgCl2",277.15,2018-05-23,2018-06-27,6GLA,4925.0,2.0,588.0,233.0,,68.32,1.0,1.92,experimental,26.804,0.27339,0.22599,Crystal structure of JAK3 in complex with Compound 11 (FM481)
6GLB,X-RAY DIFFRACTION,1.94,36.5,"VAPOR DIFFUSION, SITTING DROP",,"24-30% PEG 3350, 0.1 M MES, pH 5.5-6.0 and 0.1-0.2 M MgCl2",277.15,2018-05-23,2018-06-27,6GLB,4932.0,2.0,588.0,242.0,,68.14,1.0,2.0,experimental,23.105,0.29026,0.2331,Crystal structure of JAK3 in complex with Compound 20 (FM484)
7JV8,X-RAY DIFFRACTION,2.4,48.82,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.10M SPG (Succinic Acid, Sodium Dihydrogen Phosphate and Glycine) pH=4.00, 19.00 %w/v PEG 1500",277.15,2020-08-20,2020-09-23,7JV8,16768.0,4.0,2116.0,502.0,16.0,237.9,1.0,2.46,experimental,45.205,0.279,0.2203,Human CD73 (ecto 5'-nucleotidase) in complex with compound 35
7WNM,X-RAY DIFFRACTION,2.81,56.0,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M magnesium chloride, 0.1 M MES (pH 6.0) and 8% w/v polyethylene glycol 6000",291.0,2022-01-18,2022-12-21,7WNM,6521.0,2.0,984.0,104.0,7.0,113.35,2.0,2.7,experimental,43.88,0.2225,0.1938,"Structure of SARS-CoV-2 Gamma variant receptor-binding domain complexed with high affinity human ACE2 mutant (T27F,R273Q)"
6SK9,X-RAY DIFFRACTION,2.88,57.33,"VAPOR DIFFUSION, SITTING DROP",,"50 mM Hepes, pH 7.5, 300 mM sodium chloride, 10 mM sodium phosphate, 5 mM dithiothreitol and 5% glycerol",279.0,2019-08-15,2020-06-17,6SK9,2032.0,1.0,279.0,91.0,,33.24,1.0,2.0,experimental,49.6367037345,0.219599199899,0.187889564471,Nek2 bound to purine compound 51
6HLB,X-RAY DIFFRACTION,3.77,67.33,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 2 M NaCL, 3% DMSO; RESERVOIR SOLUTION: 3-4M NaCL",293.15,2018-09-11,2019-02-06,6HLB,4028.0,2.0,491.0,338.0,3.0,54.39,2.0,2.0,experimental,,0.1874,0.1686,X-ray structure of furin in complex with the cyclic peptide c[succinyl-Phe-2-Nal-(Arg)4-Lys]-Arg-4-Amba
6HLD,X-RAY DIFFRACTION,3.78,67.46,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 2 M NaCL, 3% DMSO; RESERVOIR SOLUTION: 3-4M NaCL",293.15,2018-09-11,2019-02-06,6HLD,4067.0,2.0,489.0,343.0,3.0,54.06,2.0,2.1,experimental,,0.1959,0.17,X-ray structure of furin in complex with the cyclic peptide c[succinyl-Phe-2-Nal-(Arg)3-Lys]-Lys-4-Amba
6HLE,X-RAY DIFFRACTION,3.84,68.01,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 2 M NaCL, 3% DMSO; RESERVOIR SOLUTION: 3-4M NaCL",293.15,2018-09-11,2019-02-06,6HLE,4127.0,2.0,488.0,390.0,3.0,53.91,2.0,1.994,experimental,,0.1908,0.1667,X-ray structure of furin in complex with the P6-P2-cyclized peptide H-Lys-Arg-Arg-Tle-Lys-4-Amba
6HZA,X-RAY DIFFRACTION,3.64,66.19,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 2 M NaCL, 3% DMSO; RESERVOIR SOLUTION: 3-4M NaCL",293.15,2018-10-23,2019-02-06,6HZA,4150.0,2.0,487.0,416.0,3.0,53.73,2.0,1.9,experimental,,0.1859,0.1661,X-ray structure of furin in complex with the cyclic peptide c[glutaryl-Arg-Arg-Lys]-Arg-4-Amba
6HZB,X-RAY DIFFRACTION,3.66,66.41,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 2 M NaCL, 3% DMSO; RESERVOIR SOLUTION: 3-4M NaCL",293.15,2018-10-23,2019-02-06,6HZB,4150.0,2.0,487.0,418.0,3.0,53.7,2.0,1.9,experimental,,0.1824,0.1646,X-ray structure of furin in complex with the cyclic inhibitor c[glutaryl-Arg-Arg-Lys]-Lys-4-Amba
6HZC,X-RAY DIFFRACTION,3.65,66.33,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 2 M NaCL, 3% DMSO; RESERVOIR SOLUTION: 3-4M NaCL",293.15,2018-10-23,2019-02-06,6HZC,4162.0,2.0,488.0,411.0,3.0,53.98,2.0,1.9,experimental,,0.1833,0.1642,X-ray structure of furin in complex with the cyclic inhibitor c[glutaryl-BVK-Lys-Arg-Arg-Tle-Lys]-4-Amba
6HZD,X-RAY DIFFRACTION,3.64,66.22,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 2 M NaCL, 3% DMSO; RESERVOIR SOLUTION: 3-4M NaCL",293.15,2018-10-23,2019-02-06,6HZD,4163.0,2.0,488.0,418.0,3.0,53.89,2.0,1.9,experimental,,0.1827,0.1641,X-ray structure of furin in complex with the cyclic inhibitor c[glutaryl-Arg-Arg-Arg-Lys]-Arg-4-Amba
6JMD,X-RAY DIFFRACTION,3.68,66.54,"VAPOR DIFFUSION, HANGING DROP",,"hepes pH4.6, 2M AMMONIUM SULPHATE, 30% Glycerol",293.0,2019-03-08,2020-03-18,6JMD,3212.0,1.0,366.0,272.0,,41.29,1.0,1.781,experimental,,0.1768,0.1547,Crystal structure of human DHODH in complex with inhibitor 1223
6JME,X-RAY DIFFRACTION,3.67,66.49,"VAPOR DIFFUSION, HANGING DROP",,"hepes pH4.6, 2M AMMONIUM SULPHATE, 30% Glycerol",293.0,2019-03-08,2020-03-18,6JME,3246.0,1.0,366.0,278.0,,41.51,1.0,1.8,experimental,,0.1702,0.1482,Crystal structure of human DHODH in complex with inhibitor 0946
6LP6,X-RAY DIFFRACTION,3.67,66.49,"VAPOR DIFFUSION, HANGING DROP",,"hepes pH4.6
2M AMMONIUM SULPHATE
30%Glycerol",293.0,2020-01-09,2020-09-30,6LP6,3257.0,1.0,366.0,315.0,,41.56,1.0,1.795,experimental,26.26,0.178,0.1545,Crystal structure of human DHODH in complex with inhibitor 1214
6LP7,X-RAY DIFFRACTION,3.68,66.56,"VAPOR DIFFUSION, HANGING DROP",,"hepes pH4.6
2M AMMONIUM SULPHATE
30%Glycerol",293.0,2020-01-09,2020-09-30,6LP7,3172.0,1.0,366.0,284.0,,41.29,1.0,1.802,experimental,25.74,0.1705,0.1531,Crystal structure of human DHODH in complex with inhibitor 0944
6LP8,X-RAY DIFFRACTION,3.65,66.28,"VAPOR DIFFUSION, HANGING DROP",,"hepes pH4.6
2M AMMONIUM SULPHATE
30%Glycerol",293.0,2020-01-09,2020-09-30,6LP8,3222.0,1.0,366.0,280.0,,41.55,1.0,1.79,experimental,25.73,0.1743,0.1569,Crystal structure of human DHODH in complex with inhibitor 1243
5C16,X-RAY DIFFRACTION,2.36,47.8,"VAPOR DIFFUSION, HANGING DROP",,"Sodium-HEPES, PEG 20000",277.0,2015-06-13,2016-04-27,5C16,16506.0,4.0,2284.0,652.0,,262.18,1.0,2.07,experimental,,0.2735,0.2203,Myotubularin-related proetin 1
7RBR,X-RAY DIFFRACTION,2.78,55.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M di-sodium tartrate, 20% PEG-3350,",280.0,2021-07-06,2021-09-29,7RBR,3300.0,2.0,395.0,169.0,,44.88,2.0,1.88,experimental,43.873,0.2284,0.1867,"The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with a Lys48-linked di-ubiquitin"
6S1J,X-RAY DIFFRACTION,2.6,52.65,"VAPOR DIFFUSION, SITTING DROP",,2.2M ammonium sulfate -- 0.1M citrate pH 5.7 -- 0.2M sodium/potassium tartrate,277.0,2019-06-18,2019-06-26,6S1J,3172.0,1.0,361.0,312.0,,43.2,1.0,1.408,experimental,21.035,0.1758,0.1554,Crystal Structure of DYRK1A with small molecule inhibitor
8C0D,X-RAY DIFFRACTION,2.99,58.91,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.1M HEPES, 1.03M Li2SO4",292.0,2022-12-16,2023-12-27,8C0D,6518.0,6.0,944.0,7.0,1.0,108.19,3.0,2.564,experimental,47.927,0.2858,0.232,UFL1/DDRGK1 bound to UFC1
8E2M,X-RAY DIFFRACTION,2.27,45.85,"VAPOR DIFFUSION, HANGING DROP",6.5,"25-33% PEG-5000 MME, 100 mM MES pH 6.35-6.75, 200 mM Ammonium Sulfate",277.0,2022-08-15,2022-11-16,8E2M,2603.0,1.0,271.0,261.0,,32.27,1.0,1.904,experimental,18.945,0.1991,0.1539,Bruton's tyrosine kinase (BTK) with compound 13
4TRY,X-RAY DIFFRACTION,3.2,61.61,"VAPOR DIFFUSION, SITTING DROP",5.0,"100mM Sodium citrate pH5.0, 200mM Ammonium sulfate, 22% v/v PEG 10000",293.0,2014-06-18,2015-07-29,4TRY,9326.0,6.0,1176.0,43.0,9.0,131.93,2.0,2.75,experimental,54.999,0.2517,0.1795,Structure of BACE1 complex with a HEA-type inhibitor
5MXD,X-RAY DIFFRACTION,2.57,52.24,"VAPOR DIFFUSION, HANGING DROP",,PEG4000,293.0,2017-01-23,2018-02-14,5MXD,9015.0,3.0,1296.0,,9.0,145.17,1.0,2.52,experimental,80.783,0.28085,0.22695,BACE-1 IN COMPLEX WITH LIGAND 32397778
6AG7,X-RAY DIFFRACTION,2.18,43.66,"VAPOR DIFFUSION, SITTING DROP",,"50 mM sodium citrate, pH 4.6, and 2.0 M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2018-08-09,2019-08-14,6AG7,2033.0,1.0,245.0,80.0,5.0,27.86,1.0,1.9,experimental,35.086,0.22847,0.19769,The crystal structure of uPA in complex with HMA-55F
6XVD,X-RAY DIFFRACTION,2.04,39.76,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.05 M sodium citrate at pH 4.5, 1.95 M (NH4)2SO4, 0.05% NaN3, and 5% PEG400",293.0,2020-01-21,2020-02-19,6XVD,2210.0,2.0,265.0,165.0,6.0,29.81,2.0,1.4,experimental,14.578,0.2025,0.1863,Crystal structure of complex of urokinase and a upain-1 variant(W3F) in pH7.4 condition
7AZB,X-RAY DIFFRACTION,1.96,37.39,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M lithium sulphate monohydrate, 20 % PEG3350",293.0,2020-11-16,2020-11-25,7AZB,2151.0,2.0,321.0,10.0,1.0,35.52,2.0,2.62,experimental,71.67,0.299,0.21,Structure of DDR2 DS domain in complex with VHH
9ASS,X-RAY DIFFRACTION,3.14,60.84,"VAPOR DIFFUSION, SITTING DROP",,"0.01 M zinc sulfate heptahydrate
0.1M MES (pH 6.5)
25% (v/v) peg-550MME",293.0,2024-02-26,2024-06-12,9ASS,2751.0,2.0,326.0,246.0,4.0,36.89,2.0,1.75,experimental,,0.2124,0.1885,Crystal Structure of Neutrophil Elastase Inhibited by Eap4 from S. aureus
6RN7,X-RAY DIFFRACTION,2.77,55.61,"VAPOR DIFFUSION, HANGING DROP",5.0,"PEG 3350, 0.2 M Ammonium sulphate, 0.1 M Sodium acetate",293.0,2019-05-08,2019-08-28,6RN7,3125.0,3.0,353.0,270.0,5.0,41.21,3.0,1.66,experimental,22.28,0.192,0.175,DPP1 in complex with inhibitor
8XOV,X-RAY DIFFRACTION,2.89,57.49,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MgAC2, 0.1M Nacacodylate pH6.5, 15% PEG 6000",293.0,2024-01-02,2024-03-06,8XOV,2207.0,1.0,321.0,51.0,,37.47,1.0,2.55,experimental,64.192,0.2517,0.2032,The Crystal Structure of N-terminal kinase domain of human RSK-1 from Biortus.
5AQF,X-RAY DIFFRACTION,2.5,51.0,,8.5,"HSC70/BAG1 COMPLEX AT 10 MG/ML INCUBATED WITH 5 MM ADENOSINE, MIXED 1:1 WITH 16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQF,8689.0,4.0,1008.0,930.0,2.0,113.72,2.0,1.88,experimental,34.95,0.2076,0.1695,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
7QPI,X-RAY DIFFRACTION,1.92,35.91,"VAPOR DIFFUSION, SITTING DROP",8.5,"PEG 3350 25%, Tris 0.1M pH 8.5, magnesium chloride 0.2M",293.0,2022-01-04,2022-12-14,7QPI,2107.0,2.0,300.0,59.0,,34.46,2.0,2.5,experimental,36.3013,0.2559,0.1825,"Structure of lamprey VDR in complex with 1,25D3"
4TRW,X-RAY DIFFRACTION,3.26,62.24,"VAPOR DIFFUSION, SITTING DROP",5.0,"100mM Sodium citrate,
200mM Ammonium sulfate,
14%(v/v) PEG 10000",293.0,2014-06-18,2015-07-01,4TRW,9353.0,6.0,1182.0,49.0,9.0,132.2,2.0,2.85,experimental,55.86,0.2384,0.2076,Structure of BACE1 complex with a syn-HEA-type inhibitor
5EHR,X-RAY DIFFRACTION,2.27,45.82,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200mM Ammonium Phosphate",277.0,2015-10-28,2016-06-29,5EHR,8514.0,2.0,1052.0,670.0,,121.94,1.0,1.7,experimental,30.39,0.2207,0.1948,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP099
6BMV,X-RAY DIFFRACTION,2.31,46.78,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2017-11-15,2018-01-17,6BMV,8555.0,2.0,1052.0,647.0,,121.94,1.0,2.053,experimental,44.79,0.223,0.174,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP504
6MD9,X-RAY DIFFRACTION,2.28,46.01,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2018-09-04,2019-02-13,6MD9,8372.0,2.0,1052.0,661.0,,121.74,1.0,2.12,experimental,,0.272,0.218,NON-RECEPTOR PROTEIN TYROSINE PHOSPHATASE SHP2 IN COMPLEX WITH ALLOSTERIC INHIBITOR Isoxazolo-pyridinone 3
6MDA,X-RAY DIFFRACTION,2.29,46.32,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2018-09-04,2019-02-13,6MDA,8362.0,2.0,1052.0,668.0,,121.68,1.0,2.21,experimental,,0.251,0.188,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrazolo-pyridine 4
6MDC,X-RAY DIFFRACTION,2.3,46.55,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2018-09-04,2019-02-13,6MDC,8420.0,2.0,1052.0,587.0,,122.11,1.0,2.14,experimental,,0.239,0.194,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrazolo-pyrimidinone 1 SHP389
6MDD,X-RAY DIFFRACTION,2.3,46.53,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200MM AMMONIUM PHOSPHATE",277.0,2018-09-04,2019-02-13,6MDD,7986.0,2.0,1052.0,252.0,,121.48,1.0,2.05,experimental,,0.251,0.213,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Imidazo-pyridine 24
6C9H,X-RAY DIFFRACTION,3.81,67.69,VAPOR DIFFUSION,,0.2 M magnesium formate,293.0,2018-01-26,2018-11-28,6C9H,7501.0,3.0,1029.0,80.0,,119.82,3.0,2.65,experimental,,0.2423,0.2133,non-phosphorylated AMP-activated protein kinase bound to pharmacological activator R734
6FEK,X-RAY DIFFRACTION,2.36,47.84,"VAPOR DIFFUSION, SITTING DROP",4.4,"3.4 M sodium formate, and 0.1 M sodium acetate pH 4.4",289.0,2018-01-02,2018-02-28,6FEK,2343.0,1.0,299.0,33.0,,34.71,1.0,2.3,experimental,,0.2441,0.2007,Oncogenic point mutation of RET receptor tyrosine kinase
6YI1,X-RAY DIFFRACTION,3.08,60.08,"VAPOR DIFFUSION, HANGING DROP",,"1.6M ammonium sulfate, 0.1M MES pH 6.5, 4% (v/v) 1,4-Dioxane",298.0,2020-03-31,2020-07-01,6YI1,6178.0,5.0,670.0,428.0,,80.3,2.0,1.92,experimental,30.3477,0.1862,0.1593,Crystal structure of human glutaminyl cyclase in complex with Glu(gamma-hydrazide)-Phe-Ala
6D67,X-RAY DIFFRACTION,2.35,47.65,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M DL-GLUTAMIC ACID
0.2 M DL-ALANINE
0.2 M GLYCINE
0.2 M DL-LYSINE
0.2 M DL-SERINE
0.1 M TRIS; BICINE
25% MPD
25% PEG1000
25% PEG3350",292.0,2018-04-20,2018-09-19,6D67,5026.0,2.0,656.0,80.0,,72.62,2.0,2.55,experimental,,0.2517,0.1819,Crystal structure of the human dual specificity phosphatase 1 catalytic domain (C258S) as a maltose binding protein fusion (maltose bound form) in complex with the designed AR protein mbp3_16
7U8H,X-RAY DIFFRACTION,2.26,45.53,VAPOR DIFFUSION,,"30% PEG3350, 0.1 M bicine pH 8.5, 0.2 M ammonium sulfate",291.15,2022-03-08,2022-11-09,7U8H,6340.0,4.0,680.0,632.0,,80.37,1.0,1.702,experimental,28.4008,0.1991,0.1724,Discovery of a KRAS G12V Inhibitor in vivo Tool Compound starting from an HSQC-NMR based Fragment Hit
8AFD,X-RAY DIFFRACTION,2.24,44.99,VAPOR DIFFUSION,,"100mM PCB pH 5.9, 20% PEG 1500",297.0,2022-07-16,2022-11-09,8AFD,5797.0,4.0,680.0,394.0,,80.71,1.0,1.633,experimental,29.35,0.2654,0.2313,CRYSTAL STRUCTURE OF BIT-BLOCKED KRAS-G12V-S39C IN COMPLEX WITH COMPOUND 20a
5CYI,X-RAY DIFFRACTION,2.9,57.8,VAPOR DIFFUSION,,"Protein at 5 mg per ml. 
0.6 to 0.8 M KCl, 0.9 to 1.2 M (NH4)2SO4, and 100 mM HEPES (pH 7.0)",277.0,2015-07-30,2015-09-16,5CYI,9513.0,4.0,1126.0,492.0,,129.54,2.0,2.0,experimental,52.6654,0.2548,0.2267,CDK2/Cyclin A covalent complex with 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine (NU6300)
5NEV,X-RAY DIFFRACTION,2.81,56.29,"VAPOR DIFFUSION, SITTING DROP",7.0,"PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0)",277.0,2017-03-12,2017-03-29,5NEV,8966.0,4.0,1126.0,16.0,,129.59,2.0,2.97,experimental,80.244,0.26119,0.21767,CDK2/Cyclin A in complex with compound 73
6RIJ,X-RAY DIFFRACTION,3.42,64.08,"VAPOR DIFFUSION, SITTING DROP",6.5,"10% w/v PEG 4000, 20% v/v glycerol, 0.02 M sodium formate, 0.02 M ammonium acetate, 0.02 M trisodium citrate, 0.02 M sodium potassium L-tartrate, 0.02 M sodium oxamate, and 0.1 M MES/imidazole pH 6.5",291.0,2019-04-24,2020-07-22,6RIJ,9097.0,4.0,1114.0,174.0,,128.74,2.0,2.2,experimental,48.065,0.2376,0.2035,CDK2/cyclin A2 in complex with open-ring 5-nitrosopyrimidine inhibitor LC436
8QQG,X-RAY DIFFRACTION,4.39,71.97,VAPOR DIFFUSION,,"0.1 M Hepes pH 6.7, 3.9 M NaCl, 0.10 M SCN",293.0,2023-10-04,2024-01-24,8QQG,6597.0,3.0,825.0,80.0,,95.87,1.0,2.979,experimental,56.222,0.2612,0.2239,Structure of BRAF in Complex With Exarafenib (KIN-2787).
6NX1,X-RAY DIFFRACTION,2.51,50.99,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5, 150mM NaCl, 10-15%(V/V)PEG10K, Crystals were cryoprotected by supplementing the mother liquor with 15% (v/v) ethylene glycol and harvested by flash-cooling in liquid nitrogen",296.0,2019-02-07,2020-02-12,6NX1,4686.0,2.0,702.0,61.0,,80.73,1.0,2.27,experimental,62.86,0.2397,0.2107,"STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND-3 AKA 1,1,1,3,3,3-HEXAFLUORO-2-{4-[1-(4- LUOROBENZENESULFONYL)CYCLOPENTYL]PHENYL}PROPAN-2-OL"
7ACK,X-RAY DIFFRACTION,3.21,61.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% w/v PEG 8000, 20% v/v ethylene glycol, 0.03 M sodium nitrate, 0.03 M disodium hydrogen phosphate, 0.03 M ammonium sulfate, and 0.1 M MOPS/HEPES-Na, pH 7.5",291.0,2020-09-11,2021-03-24,7ACK,9743.0,4.0,1114.0,745.0,,128.82,2.0,1.8,experimental,38.396,0.2324,0.1969,"CDK2/cyclin A2 in complex with an imidazo[1,2-c]pyrimidin-5-one inhibitor"
5HTZ,X-RAY DIFFRACTION,2.96,58.44,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200MM NA/K TARTRATE, 100MM HEPES PH7",277.0,2016-01-27,2016-11-09,5HTZ,6949.0,2.0,824.0,802.0,6.0,92.78,1.0,1.95,experimental,26.1931,0.2307,0.1976,"BACE1 in complex with (S)-5-(3-chloro-5-(5-(prop-1-yn-1-yl)pyridin-3-yl)thiophen-2-yl)-2,5-dimethyl-1,2,4-thiadiazinan-3-iminium 1,1-dioxide"
8VW5,X-RAY DIFFRACTION,2.74,55.04,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Ca(OAc)2, 0.1 M NaCacodylate pH 6.5, 18% PEG8000",293.0,2024-01-31,2024-07-03,8VW5,5746.0,2.0,620.0,617.0,,73.89,2.0,1.76,experimental,,0.2041,0.1753,Crystal structure of Cbl-b TKB bound to compound 2
4XE4,X-RAY DIFFRACTION,3.64,66.19,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7.5,1.6M Ammonium sulphate, 2%(w/v) PEG1000.",293.0,2014-12-22,2015-02-04,4XE4,1894.0,1.0,255.0,78.0,5.0,28.35,1.0,2.4,experimental,,0.29504,0.21845,Coagulation Factor XII protease domain crystal structure
6DKW,X-RAY DIFFRACTION,2.92,57.81,"VAPOR DIFFUSION, SITTING DROP",,not available,294.0,2018-05-31,2018-07-11,6DKW,4606.0,2.0,616.0,73.0,,71.21,1.0,2.91,experimental,95.13,0.262,0.231,"Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 3."
6AO5,X-RAY DIFFRACTION,3.62,65.99,"VAPOR DIFFUSION, HANGING DROP",,"0.05 M NaCl, 0.1 M Hepes, 0.19 mM CYMAL-7, 1 mM TCEP, 40% PEG 400",293.0,2017-08-15,2017-11-08,6AO5,3372.0,2.0,455.0,,,53.54,2.0,2.955,experimental,60.0404,0.2564,0.2346,Crystal structure of human MST2 in complex with SAV1 SARAH domain
5OQ7,X-RAY DIFFRACTION,2.36,47.92,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-10,2017-10-25,5OQ7,4374.0,2.0,594.0,177.0,,68.9,1.0,2.1,experimental,38.817,0.3239,0.2553,Structure of CHK1 8-pt. mutant complex with arylbenzamide LRRK2 inhibitor
7SUJ,X-RAY DIFFRACTION,2.34,47.53,"VAPOR DIFFUSION, SITTING DROP",6.5,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2021-11-17,2022-01-12,7SUJ,4396.0,2.0,594.0,184.0,,69.23,1.0,2.299,experimental,54.64,0.2973,0.2327,Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 24
5A3X,X-RAY DIFFRACTION,2.6,53.0,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M KCL; 14% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2015-06-03,2016-06-29,5A3X,11323.0,4.0,1472.0,227.0,3.0,171.45,1.0,2.26,experimental,47.633,0.25867,0.23484,DYRK1A in complex with hydroxy benzothiazole fragment
5A4L,X-RAY DIFFRACTION,2.6,53.0,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.05M LICL; 10% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2015-06-10,2016-06-29,5A4L,11309.0,4.0,1472.0,278.0,1.0,171.46,1.0,2.73,experimental,20.446,0.26716,0.22141,DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
5A4Q,X-RAY DIFFRACTION,2.65,53.5,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M NACL; 16% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2015-06-11,2016-06-29,5A4Q,11318.0,4.0,1472.0,345.0,1.0,171.52,1.0,2.37,experimental,48.573,0.24251,0.2066,DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
5A4T,X-RAY DIFFRACTION,2.6,57.0,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M NACL; 16% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2015-06-15,2016-06-29,5A4T,11182.0,4.0,1472.0,178.0,1.0,171.48,1.0,2.15,experimental,45.41,0.2343,0.20351,DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
5A54,X-RAY DIFFRACTION,2.6,52.7,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M KCL; 14% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2015-06-16,2016-06-29,5A54,11063.0,4.0,1472.0,44.0,1.0,171.56,1.0,2.63,experimental,59.49,0.25461,0.22232,DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
6EIJ,X-RAY DIFFRACTION,2.63,53.24,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M KSCN; 0.05M KCl; 10% PEG 3350, pH 6.8",293.0,2017-09-19,2018-08-29,6EIJ,11489.0,4.0,1472.0,351.0,,172.48,1.0,2.42,experimental,50.255,0.24192,0.21341,DYRK1A in complex with HG-8-60-1
6EIP,X-RAY DIFFRACTION,2.61,52.88,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M KSCN; 0.05M LiCl; 10% PEG 3350, pH 6.8",293.0,2017-09-19,2018-08-29,6EIP,11243.0,4.0,1472.0,138.0,,172.3,1.0,2.56,experimental,52.174,0.2662,0.24145,DYRK1A in complex with XMD8-62e
6EIQ,X-RAY DIFFRACTION,2.57,52.22,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M KSCN; 0.1M NaCl; 12% PEG 3350, pH 6.8",293.0,2017-09-19,2018-08-29,6EIQ,11312.0,4.0,1472.0,244.0,1.0,172.31,1.0,2.3,experimental,55.491,0.25245,0.21812,DYRK1A in complex with XMD14-124
6EIS,X-RAY DIFFRACTION,2.66,53.76,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M KSCN, 0.1M KCl, 16% PEG 3350",293.0,2017-09-19,2018-08-29,6EIS,11510.0,4.0,1472.0,339.0,,172.31,1.0,2.36,experimental,,0.2615,0.221,DYRK1A in complex with JWC-055
6EIV,X-RAY DIFFRACTION,2.66,53.78,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M KSCN; 0.05M LiCl; 10% PEG 3350, pH 6.8",293.0,2017-09-19,2018-08-29,6EIV,11167.0,4.0,1472.0,124.0,1.0,172.47,1.0,2.68,experimental,,0.2355,0.1965,DYRK1A in complex with JWD-065
6EJ4,X-RAY DIFFRACTION,2.61,52.89,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M KSCN; 0.05M NaCl; 16% PEG 3350, pH 6.8",293.0,2017-09-20,2018-08-29,6EJ4,11022.0,4.0,1472.0,56.0,,171.76,1.0,2.88,experimental,57.455,0.27019,0.21999,DYRK1A in complex with XMD7-112
5CLM,X-RAY DIFFRACTION,2.87,57.11,"VAPOR DIFFUSION, HANGING DROP",,"12% (m/v) PEG4000, 100mM MES/NaOH pH 5.5",293.0,2015-07-16,2015-09-30,5CLM,3062.0,1.0,401.0,75.0,3.0,45.39,1.0,2.61,experimental,49.026,0.25003,0.1902,"1,4-Oxazine BACE1 inhibitors"
6S8S,X-RAY DIFFRACTION,2.8,56.03,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M CAPS pH 10.5, 1.2 M NaH2PO4, 0.8 M K2HPO4, 0.2 M Li2SO4",292.0,2019-07-10,2019-09-04,6S8S,3775.0,4.0,474.0,258.0,,57.05,2.0,2.21,experimental,40.05,0.226,0.179,Extended structure of the human DDX6 C-terminal domain in complex with an EDC3 FDF peptide
7W0Q,X-RAY DIFFRACTION,2.11,41.67,LIQUID DIFFUSION,,"PEG 3350, potassium nitrate",291.15,2021-11-18,2022-08-10,7W0Q,1692.0,2.0,184.0,226.0,,20.77,2.0,1.1,experimental,15.02,0.2112,0.1857,TRIM7 in complex with C-terminal peptide of 2C
7MNR,X-RAY DIFFRACTION,2.1,41.4,"VAPOR DIFFUSION, HANGING DROP",6.5,19% (w/v) PEG 3350; 0.1 M Bis-Tris,294.0,2021-05-01,2022-06-15,7MNR,2173.0,2.0,279.0,212.0,,31.73,2.0,1.8,experimental,41.3231,0.1958,0.1595,Crystal Structure of the ZnF3 of Nucleoporin NUP358/RanBP2 in complex with Ran-GDP
4WY1,X-RAY DIFFRACTION,2.16,43.1,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 200;0.1 M sodium acetate, pH 5.2-5.4; protein buffer is NaBorate, pH 8.5",298.0,2014-11-14,2015-03-04,4WY1,3505.0,1.0,404.0,380.0,3.0,45.44,1.0,1.98,experimental,35.93,0.2199,0.1672,Crystal structure of human BACE-1 bound to Compound 24B
5KR8,X-RAY DIFFRACTION,2.56,51.9,VAPOR DIFFUSION,6.4,"10% PEG5000 MME, 9% PEG8000, 0.2 M ammonium iodide, 0.2 M sodium citrate, pH 6.4",295.0,2016-07-07,2016-09-07,5KR8,2837.0,1.0,455.0,106.0,2.0,50.68,1.0,2.118,experimental,,0.244,0.2127,"(4~{S},6~{S})-4-[2,4-bis(fluoranyl)phenyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine (compound 5) bound to BACE1"
8VQR,X-RAY DIFFRACTION,2.79,55.85,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris (pH 8-8.5), 18-22% PEG 6000, 100 mM NaCl and ethylene glycol (0.5-2%)",295.0,2024-01-19,2024-05-01,8VQR,13126.0,4.0,1668.0,16.0,15.0,197.48,2.0,2.565,experimental,,0.2642,0.2138,Crystal structure of chimeric SARS-CoV-2 RBD complexed with chimeric raccoon dog ACE2
4YPS,X-RAY DIFFRACTION,3.26,62.23,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.8M (NH4)2SO4, 0.1M Citrate pH 5.0",277.0,2015-03-13,2015-06-03,4YPS,2255.0,1.0,303.0,50.0,,35.05,1.0,2.1012,experimental,67.0,0.2574,0.2008,(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors
6YW3,X-RAY DIFFRACTION,2.36,48.0,"VAPOR DIFFUSION, SITTING DROP",6.5,"Sample: 1.0 mM cPHD2, 1.5 mM MnCl2, 2.0 mM compound, 1.0 mM 3C, 2.0 mM CODD; Reservoir: 19-23% w/v polyethylene glycol 3350, 0.25 M lithium sulfate, 2 mM MnCl2; Sitting drop (2 ul), protein-to-well ratio, 1:1",293.0,2020-04-29,2020-12-30,6YW3,2123.0,3.0,266.0,116.0,,30.48,3.0,2.279,experimental,36.8484,0.2082,0.1878,"HIF PROLYL HYDROXYLASE 2 (PHD2/ EGLN1) in complex with N-Oxalyl Glycine (NOG), HIF-1ALPHA CODD (556-574) and a RaPID-derived cyclic peptide 3C (14-mer)"
4WHU,X-RAY DIFFRACTION,1.96,37.11,"VAPOR DIFFUSION, HANGING DROP",,obtained through screen with Hampton Research kits (HT and Index),277.0,2014-09-23,2015-10-28,4WHU,1038.0,1.0,119.0,13.0,,14.69,1.0,2.11,experimental,58.48,0.2612,0.2077,BROMO domain of CREB binding protein
6EQM,X-RAY DIFFRACTION,2.13,42.31,"VAPOR DIFFUSION, HANGING DROP",5.5,"15% PEG 1,500 in water",292.0,2017-10-13,2018-09-19,6EQM,3382.0,1.0,402.0,317.0,3.0,45.29,1.0,1.35,experimental,24.78,0.2001,0.1836,Crystal Structure of Human BACE-1 in Complex with CNP520
6WNY,X-RAY DIFFRACTION,2.79,55.95,"VAPOR DIFFUSION, HANGING DROP",6.6,"21% PEG 5000 MME, 190 mM ammonium iodide, 190 mM sodium citrate, 3% (v/v) DMSO",293.0,2020-04-23,2020-06-03,6WNY,3429.0,1.0,411.0,418.0,3.0,46.7,1.0,1.86,experimental,27.4,0.2094,0.1675,Crystal structure of BACE1 in complex with (Z)-fluoro-olefin containing compound 15
7F1D,X-RAY DIFFRACTION,2.76,55.41,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium citrate tribasic pH 6.5, 0.2 M ammonium iodide, 21% w/v PEG5000MME",293.0,2021-06-09,2022-02-23,7F1D,3216.0,1.0,416.0,266.0,3.0,47.34,1.0,2.05,experimental,35.447,0.222,0.1975,"Crystal Structure of BACE1 in complex with N-{3-[(4R,5R,6R)-2-amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-2H,3H-[1,4]dioxino[2,3-c]pyridine-7-carboxamide"
8GWR,X-RAY DIFFRACTION,3.37,63.5,"VAPOR DIFFUSION, HANGING DROP",,"1.5M sodium malonate pH 7, 4% jeffamine",296.0,2022-09-17,2022-12-21,8GWR,7700.0,2.0,1338.0,46.0,,147.38,1.0,2.801,experimental,,0.2362,0.2042,"Near full length Kidney type Glutaminase in complex with 2,2-Dimethyl-2,3-Dihydrobenzo[a] Phenanthridin-4(1H)-one (DDP)"
5T7L,X-RAY DIFFRACTION,2.64,53.39,"VAPOR DIFFUSION, HANGING DROP",,PEG-6000  10 to 30 % w/v and sodium citrate 0.1M at pH 4.7,298.0,2016-09-05,2016-10-12,5T7L,1138.0,2.0,143.0,13.0,,16.23,2.0,2.83,experimental,,0.2734,0.2002,Pt(II)-mediated copper-dependent interactions between ATOX1 and MNK1
6NQM,X-RAY DIFFRACTION,3.78,67.48,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 3350 8%, 0.1 M Ammonium citrate pH6.5",296.0,2019-01-21,2019-02-13,6NQM,5011.0,1.0,658.0,,,74.09,1.0,2.9,experimental,,0.2445,0.2125,Crystal structure of Human LSD1
8J81,X-RAY DIFFRACTION,2.51,50.97,"VAPOR DIFFUSION, SITTING DROP",4.5,"1M Sodium Acetate trihydrate pH4.5, 3.0 M Sodium Chrolide. Peptoid dissolved in DMSO was included. The final DMSO concentration was 2.4%",293.0,2023-04-28,2024-05-01,8J81,945.0,1.0,100.0,84.0,,12.61,1.0,1.35,experimental,19.95,0.1896,0.1692,MDM2 bound with a peptoid
7BJE,X-RAY DIFFRACTION,2.31,46.81,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-14,2021-07-07,7BJE,2296.0,1.0,297.0,208.0,,34.26,1.0,1.8,experimental,34.461,0.1988,0.1717,Crystal structure of CHK1-10pt-mutant complex with adenine
7BK1,X-RAY DIFFRACTION,2.34,47.54,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-15,2021-07-07,7BK1,2281.0,1.0,297.0,205.0,,34.53,1.0,2.0,experimental,33.568,0.2352,0.1899,Crystal structure of CHK1-10pt-mutant complex with compound 32
7BK2,X-RAY DIFFRACTION,2.36,47.82,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-15,2021-07-07,7BK2,2299.0,1.0,297.0,204.0,,34.59,1.0,2.0,experimental,32.682,0.1966,0.1576,Crystal structure of CHK1-10pt-mutant complex with compound 44
7BK3,X-RAY DIFFRACTION,2.36,47.92,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2021-01-15,2021-07-07,7BK3,2301.0,1.0,297.0,203.0,,34.59,1.0,2.0,experimental,32.305,0.2245,0.1705,Crystal structure of CHK1-10pt-mutant complex with compound 45
7BKN,X-RAY DIFFRACTION,2.24,45.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"10-30% PEG8K
0.1M HEPES pH 7.5
15% isopropanol",298.0,2021-01-16,2021-07-07,7BKN,2092.0,1.0,297.0,50.0,,34.38,1.0,2.74,experimental,49.77,0.28,0.2085,Crystal structure of CHK1 complex with adenine
6OAU,X-RAY DIFFRACTION,2.55,51.77,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Sodium Malonate, 20% PEG3350, 4% 2-propanol",298.0,2019-03-18,2019-05-08,6OAU,8092.0,4.0,1158.0,83.0,20.0,131.45,2.0,2.48,experimental,52.0,0.246,0.213,Apo Structure of WT Lipoprotein Lipase in Complex with GPIHBP1 Mutant N78D N82D produced in GnTI-deficient HEK293-F cells
6DFM,X-RAY DIFFRACTION,2.18,43.54,"VAPOR DIFFUSION, SITTING DROP",8.5,"Triclinic crystals of apo GRP78 were observed in 0.1 M Tris-HCl, 25% PEG3350, 0.1 M sodium/potassium tartrate. Initial crystals were then microseeded in 25% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride. These new apo monoclinic crystals were soaked with 5 mM 8-aminoadenosine for one week.",298.0,2018-05-15,2019-05-15,6DFM,6410.0,2.0,764.0,440.0,,84.88,1.0,2.14,experimental,40.5,0.231,0.187,Crystal structure of human GRP78 in complex with 8-aminoadenosine
6DFO,X-RAY DIFFRACTION,2.18,43.63,"VAPOR DIFFUSION, SITTING DROP",8.5,"Triclinic crystals of apo GRP78 were observed in 0.1 M Tris-HCl, 25% PEG3350, 0.1 M sodium/potassium tartrate. Initial crystals were then microseeded in 25% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride. These new apo monoclinic crystals were soaked with 5 mM 8-bromoadenosine for one week.",298.0,2018-05-15,2019-05-15,6DFO,6152.0,2.0,764.0,196.0,,85.0,1.0,2.54,experimental,41.31,0.251,0.187,Crystal structure of human GRP78 in complex with 8-bromoadenosine
7RT2,X-RAY DIFFRACTION,2.54,51.59,"VAPOR DIFFUSION, SITTING DROP",,"28% PEG8000, 100 mM sodium citrate, pH 5.0, 200 mM ammonium acetate",298.0,2021-08-12,2021-12-22,7RT2,1593.0,1.0,170.0,172.0,,20.55,1.0,1.59,experimental,23.1632,0.1796,0.1569,"Crystal Structure of KRAS G12D with compound 25 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-{[(2R,4R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidin-7-yl)naphthalen-2-ol) bound"
7RT4,X-RAY DIFFRACTION,2.36,47.99,"VAPOR DIFFUSION, SITTING DROP",,"PEG8000, sodium citrate, ammonium acetate",298.0,2021-08-12,2021-12-22,7RT4,1581.0,1.0,170.0,121.0,,20.43,1.0,2.1,experimental,29.8915,0.234,0.1758,"KRAS G12D in complex with Compound 5B (7-(8-chloronaphthalen-1-yl)-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-4-(piperazin-1-yl)pyrido[4,3-d]pyrimidine)"
7T47,X-RAY DIFFRACTION,2.2,43.99,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris, pH 5.5, 0.1 M sodium acetate, 8% v/v isopropanol, 22% PEG4000",298.0,2021-12-09,2022-03-16,7T47,1706.0,1.0,188.0,232.0,,23.31,1.0,1.27,experimental,16.81,0.1724,0.1523,KRAS G12D (GppCp) with MRTX-1133
5V22,X-RAY DIFFRACTION,2.47,50.25,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M KSCN, 24% (v/v) PEG 2000 MME",293.0,2017-03-02,2017-03-22,5V22,2195.0,2.0,312.0,85.0,,36.59,2.0,2.4,experimental,,0.257,0.195,Crystal structure of human SETD2 SET-domain in complex with H3K36M peptide and SAH
6X2P,X-RAY DIFFRACTION,2.71,54.61,"VAPOR DIFFUSION, HANGING DROP",,"17% (weight/vol) PEG3350, 100 mM Bis-Tris (pH 6.4), 200 mM ammonium nitrate, and 10 mM Spermine HCl",273.0,2020-05-20,2020-07-01,6X2P,11436.0,4.0,1397.0,492.0,,161.06,4.0,2.401,experimental,42.0903,0.2523,0.21,Crystal Structure of the Mek1NES peptide bound to CRM1
6X2S,X-RAY DIFFRACTION,2.71,54.54,"VAPOR DIFFUSION, HANGING DROP",,"17% (weight/vol) PEG3350, 100 mM Bis-Tris (pH 6.4), 200 mM ammonium nitrate, and 10 mM Spermine HCl",273.0,2020-05-20,2020-07-01,6X2S,11298.0,4.0,1396.0,341.0,,160.96,4.0,2.496,experimental,43.622,0.2464,0.1961,Crystal Structure of Mek1(NQ)NES peptide bound to CRM
6X2X,X-RAY DIFFRACTION,2.7,54.48,"VAPOR DIFFUSION, HANGING DROP",,"17% (weight/vol) PEG3350, 100 mM Bis-Tris (pH 6.4), 200 mM ammonium nitrate, and 10 mM Spermine HCl",273.0,2020-05-21,2020-07-01,6X2X,11454.0,4.0,1396.0,476.0,,160.92,4.0,2.458,experimental,41.8216,0.25,0.2,Crystal Structure of Mek1NES peptide bound to CRM1(E571K)
9BFB,X-RAY DIFFRACTION,2.87,57.16,VAPOR DIFFUSION,7.0,"100mM Hepes pH 7.0, 15 % PEG 8K, 10% Tacsimate",293.0,2024-04-17,2024-08-14,9BFB,2503.0,1.0,294.0,244.0,,33.86,1.0,1.92,experimental,29.06,0.1888,0.1639,Crystal structure of BRAF kinase domain with PF-07284890
5K7M,X-RAY DIFFRACTION,2.34,47.36,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M Tris pH 8.0, 20% PEG3350",291.0,2016-05-26,2016-07-06,5K7M,4486.0,2.0,574.0,488.0,,65.31,2.0,1.65,experimental,,0.1838,0.16,Crystal structure of the catalytic domains of Mettl3/Mettl14 complex
6BTN,X-RAY DIFFRACTION,2.67,53.86,VAPOR DIFFUSION,,8-12% PEG 3350 150-200mM KSCN 10mM spermidine,277.0,2017-12-07,2018-08-08,6BTN,3503.0,2.0,404.0,249.0,6.0,46.65,1.0,2.05,experimental,30.901,0.2264,0.1936,BMP1 complexed with a reverse hydroxymate - compound 1
6BTP,X-RAY DIFFRACTION,2.67,53.86,VAPOR DIFFUSION,,8-12% PEG 3350 150-200mM KSCN 10mM spermidine,277.0,2017-12-07,2018-08-08,6BTP,3613.0,2.0,402.0,360.0,6.0,46.71,1.0,1.93,experimental,26.822,0.2333,0.2026,BMP1 complexed with a hydroxamate
6PCW,X-RAY DIFFRACTION,2.92,57.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"25% PEG3350, 0.1 M TRIS pH8.5, 0.2 M magnesium chloride",293.0,2019-06-18,2019-07-24,6PCW,2376.0,2.0,327.0,67.0,,37.71,2.0,2.2,experimental,57.839,0.226,0.1742,Human PIM1 bound to benzothiophene inhibitor 213
7S0U,X-RAY DIFFRACTION,2.71,54.67,VAPOR DIFFUSION,,"100 mM Sodium Citrate pH 5.4, 15% PEG3350, 4% Tascimate pH 5.0",281.0,2021-08-31,2022-01-26,7S0U,7348.0,2.0,995.0,132.0,,112.22,2.0,2.01,experimental,52.94,0.2645,0.2309,PRMT5/MEP50 crystal structure with MTA and phthalazinone fragment bound
7S1Q,X-RAY DIFFRACTION,2.85,56.78,VAPOR DIFFUSION,,"100 mM Sodium Citrate pH 5, 18% PEG 4000, 150 mM Sodium Acetate",281.0,2021-09-02,2022-01-26,7S1Q,7365.0,2.0,995.0,18.0,,112.18,2.0,2.78,experimental,69.0,0.2476,0.2087,PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (Compound 9)
7S1R,X-RAY DIFFRACTION,2.87,57.13,VAPOR DIFFUSION,,"100 mM Sodium Citrate pH 5, 9% PEG 4000, 150 mM Sodium Acetate",281.0,2021-09-02,2022-01-26,7S1R,7777.0,2.0,995.0,380.0,,112.35,2.0,2.1,experimental,50.53,0.2225,0.1794,PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (compound (M)-31)
7S1S,X-RAY DIFFRACTION,2.85,56.87,VAPOR DIFFUSION,,"100 mM Sodium Citrate pH 5.4, 11% PEG 4000, 50 mM Sodium Acetate",281.0,2021-09-02,2022-01-26,7S1S,7459.0,2.0,995.0,64.0,,112.39,2.0,2.62,experimental,63.82,0.2332,0.2086,PRMT5/MEP50 crystal structure with MTA and MRTX-1719 bound
8VET,X-RAY DIFFRACTION,2.83,56.57,VAPOR DIFFUSION,6.5,"10% PEG 4000, 0.2M magnesium chloride, 0.1M MES (pH 6.5)",291.0,2023-12-20,2024-04-24,8VET,7477.0,2.0,995.0,29.0,,112.35,2.0,2.63,experimental,82.204,0.27691,0.22426,Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 1
8VEU,X-RAY DIFFRACTION,2.89,57.4,VAPOR DIFFUSION,6.0,"10% PEG 4000, 0.2M magnesium chloride, 0.1M sodium citrate (pH 6.0)",291.0,2023-12-20,2024-04-24,8VEU,7588.0,2.0,995.0,93.0,1.0,113.52,2.0,2.46,experimental,68.044,0.25027,0.20104,Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 23
8VEY,X-RAY DIFFRACTION,2.78,55.83,VAPOR DIFFUSION,6.0,"10% PEG 4000, 0.2M magnesium chloride, 0.1M sodium citrate (pH 6.0)",291.0,2023-12-20,2024-04-24,8VEY,7624.0,2.0,995.0,181.0,1.0,113.09,2.0,2.44,experimental,71.778,0.26136,0.22283,Crystal structure of PRMT5:MEP50 in complex with MTA and TNG908
8FJ7,X-RAY DIFFRACTION,5.6,78.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.2 Na/K Tartrate, 100 mM ADA pH 6.5",293.0,2022-12-19,2024-06-26,8FJ7,6400.0,3.0,1024.0,,,113.65,3.0,2.8,experimental,,0.2427,0.2217,LSD1-CoREST in complex with T108 and SNAG peptide
6YHR,X-RAY DIFFRACTION,2.56,51.91,"VAPOR DIFFUSION, SITTING DROP",6.5,"1M Na Acetate, 0.1 M Cacodylate pH 6.5",277.0,2020-03-30,2020-04-29,6YHR,4519.0,1.0,585.0,195.0,1.0,67.41,1.0,2.2,experimental,71.05,0.2363,0.1969,Crystal structure of Werner syndrome helicase
6PDI,X-RAY DIFFRACTION,2.92,57.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG6000, 0.1M TRIS pH7.5, 0.1M magnesium chloride, 10% ethylene glycol",293.0,2019-06-19,2019-07-24,6PDI,2497.0,2.0,327.0,144.0,,38.08,2.0,1.85,experimental,53.452,0.1931,0.1614,Human PIM1 bound to benzothiophene inhibitor 224
6PDN,X-RAY DIFFRACTION,2.99,58.89,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% PEG3350, 0.1 M bis-tris propane pH8.5, 0.2 M sodium fluoride, 10% ethylene glycol",293.0,2019-06-19,2019-07-24,6PDN,2391.0,2.0,327.0,91.0,,37.72,2.0,2.4,experimental,43.097,0.2234,0.1884,Human PIM1 bound to benzothiophene inhibitor 292
6OC0,X-RAY DIFFRACTION,3.72,66.92,"VAPOR DIFFUSION, HANGING DROP",4.5,"Ammonium sulfate, glycerol, DHO, DDAO, OSU-03012",293.0,2019-03-21,2019-11-13,6OC0,3168.0,1.0,369.0,232.0,,41.49,1.0,1.4,experimental,22.869,0.18409,0.15078,Crystal structure of human DHODH with OSU-03012
4ZBW,X-RAY DIFFRACTION,2.6,54.26,EVAPORATION,8.5,"0.2M sodium chloride,  25% PEG3350",293.0,2015-04-15,2015-07-01,4ZBW,3298.0,2.0,380.0,248.0,,44.98,1.0,2.2,experimental,41.3,0.251,0.2041,Crystal structure of death effector domain of Caspase8 in Homo Sapiens
6YUL,X-RAY DIFFRACTION,2.87,57.15,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M ammonia sulphate, 0.1 MES pH 6.5,  31-35% (v/v) polyethylene glycol PEG 5000 MME 
10 mg / mL protein",293.0,2020-04-27,2020-07-01,6YUL,5594.0,2.0,782.0,44.0,,92.06,1.0,2.4,experimental,56.533,0.2324,0.2168,CK2 alpha bound to Macrocycle
6YUM,X-RAY DIFFRACTION,2.71,54.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5
0.2 ammonia sulphate
30% PEG 5000 MME

10 mg/mL protein",293.0,2020-04-27,2020-07-01,6YUM,5421.0,2.0,782.0,2.0,,91.91,1.0,2.75,experimental,68.329,0.2838,0.2626,CK2 alpha bound to unclosed Macrocycle
6JOL,X-RAY DIFFRACTION,2.28,45.98,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Sodium citrate pH4.5, 20% PEG 4000",293.0,2019-03-22,2020-03-25,6JOL,2329.0,1.0,356.0,84.0,,41.08,1.0,1.9,experimental,,0.2356,0.214,Crystal structure of PDGFRA in complex with imatinib by co-crystallization
6DI3,X-RAY DIFFRACTION,2.36,47.89,"VAPOR DIFFUSION, HANGING DROP",,"RESERVOIR SOLUTION : 25% PEG 3350, 0.2M AMMONIUM ACETATE, 0.1M HEPES pH 6.9, 3% GLYCEROL                      
PROTEIN SOLUTION   : 10 mg/mL IN 20 mM TRIS, 50 mM NaCL, 3 mM       
DTT, pH 8.0",294.0,2018-05-22,2018-09-05,6DI3,2156.0,1.0,271.0,103.0,,32.04,1.0,2.0,experimental,32.793,0.2353,0.2001,CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND
6N9P,X-RAY DIFFRACTION,2.26,45.62,VAPOR DIFFUSION,7.5,"20% PEG 3350, 0.1 M Bis Tris Propane pH 7.5, 0.2 M Sodium acetate trihydrate",294.0,2018-12-03,2019-02-06,6N9P,2558.0,1.0,271.0,210.0,,32.02,1.0,2.23,experimental,15.172,0.24,0.177,Discovery of affinity-based probes for Btk occupancy assay
6NM4,X-RAY DIFFRACTION,2.38,48.3,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris, pH 6.0, 0.2 M ammonium acetate, 24.5% PEG3350",291.0,2019-01-10,2019-02-13,6NM4,3073.0,2.0,382.0,23.0,,45.46,1.0,2.58,experimental,61.466,0.2581,0.2072,Crystal structure of SAM-bound PRDM9 in complex with MRK-740 inhibitor
5AQY,X-RAY DIFFRACTION,2.4,48.8,,7.5,"17-28% (W/V) PEG3350, 0.1M HEPES PH 7.5, 2MM MGCL2, 2MM NAH2PO4 AND 5MM ADENOSINE",,2015-09-22,2016-10-05,5AQY,3417.0,1.0,394.0,321.0,,44.87,1.0,1.56,experimental,28.08,0.2036,0.174,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
6WEU,X-RAY DIFFRACTION,3.32,62.9,"VAPOR DIFFUSION, SITTING DROP",,"7.5 mg/mL protein against 19-22% PEG4000, 240-270 mM trilithium/triammonium/tripotassium citrate",281.0,2020-04-03,2020-09-09,6WEU,13105.0,2.0,1850.0,122.0,31.0,214.3,1.0,2.65,experimental,60.145,0.239,0.207,Crystal structures of human E-NPP 1: bound to adenosine-5'-thio-monophosphate
6WEV,X-RAY DIFFRACTION,3.26,62.23,"VAPOR DIFFUSION, SITTING DROP",,"7.5 mg/mL protein against 19-22% PEG4000, 240-270 mM trilithium/triammonium/tripotassium citrate",281.0,2020-04-03,2020-09-09,6WEV,13052.0,2.0,1850.0,20.0,32.0,214.52,1.0,2.9,experimental,62.639,0.2534,0.2112,"Crystal structures of human E-NPP 1: bound to N-{[1-(6,7-dimethoxy-5,8-dihydroquinazolin-4-yl)piperidin-4-yl]methyl}sulfuric diamide"
6WEW,X-RAY DIFFRACTION,3.36,63.35,"VAPOR DIFFUSION, SITTING DROP",,"7.5 mg/mL protein against 19-22% PEG4000, 240-270 mM trilithium/triammonium/tripotassium citrate",281.0,2020-04-03,2020-09-09,6WEW,13249.0,2.0,1850.0,185.0,32.0,215.04,1.0,2.73,experimental,51.507,0.2409,0.2102,Crystal structures of human E-NPP 1: bound to N-{4-[(7-methoxyquinolin-4-yl)oxy]phenyl}sulfuric diamide
7A47,X-RAY DIFFRACTION,3.54,65.21,"VAPOR DIFFUSION, HANGING DROP",6.0,1.1 M Sodium Citrate pH 6.0,293.0,2020-08-19,2021-10-13,7A47,4423.0,3.0,510.0,211.0,,61.3,1.0,2.16,experimental,43.22,0.2077,0.193,KRASG12C GDP form in complex with Cpd4
8DNJ,X-RAY DIFFRACTION,1.91,35.58,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.001M MgCl2, 0.1 M MES pH 6.5, 30% PEG 4000,  10% Ethanol",293.0,2022-07-11,2022-08-17,8DNJ,4418.0,3.0,552.0,199.0,,66.09,1.0,1.81,experimental,25.834,0.2889,0.2392,Crystal structure of human KRAS G12C covalently bound with AstraZeneca WO2020/178282A1 compound 76
6QSW,X-RAY DIFFRACTION,2.74,55.13,"VAPOR DIFFUSION, SITTING DROP",,"2.0 M ammonium sulfate, 0.1 M sodium acetate (pH 4.6), 2 mM inhibitor",293.0,2019-02-22,2019-03-27,6QSW,6884.0,3.0,873.0,500.0,15.0,100.74,1.0,1.64,experimental,21.87,0.1881,0.1567,"Complement factor B protease domain in complex with the reversible inhibitor N-(2-bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine."
6L03,X-RAY DIFFRACTION,2.08,40.76,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 4000, 0.2M KSCN, 10% ethelene glycol, 0.1M bis-tris propane",293.0,2019-09-25,2020-09-30,6L03,2523.0,2.0,316.0,79.0,,36.32,2.0,2.084,experimental,35.7581,0.2304,0.2102,structure of PTP-MEG2 and MUNC18-1-pY145 peptide complex
5F1O,X-RAY DIFFRACTION,2.4,48.79,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2M sodium acetate, 0.1M Tris-HCl, 25% PEG4000",298.0,2015-11-30,2016-06-15,5F1O,3165.0,2.0,418.0,207.0,7.0,47.58,2.0,2.2,experimental,34.51,0.2366,0.1679,human CD38 in complex with nanobody MU551
6WET,X-RAY DIFFRACTION,3.3,62.69,"VAPOR DIFFUSION, SITTING DROP",,"7.5 mg/mL protein against 19-22% PEG4000, 240-270 mM trilithium/triammonium/tripotassium citrate",281.0,2020-04-02,2020-09-09,6WET,12977.0,2.0,1850.0,72.0,31.0,214.01,1.0,2.6,experimental,68.659,0.2442,0.2104,Crystal structures of human E-NPP 1: apo
5VLO,X-RAY DIFFRACTION,2.35,47.64,"VAPOR DIFFUSION, SITTING DROP",,"CamKII S3-K301, in 20mM imidazole pH 8.5, 0.3M sodium chloride, 5mM TCEP, was concentrated to 36 mg/ml and flash frozen in liquid nitrogen for long term storage at -80 C in 10 uL aliquots.   The protein was thawed and diluted down to 12 mg/mL in the same buffer just prior to crystallization experiments.  Sitting drop vapor diffusion droplets were assembled with 250 nL of 12 mg/mL CamKII, 0.6 mM inhibitor and 250 nL of reservoir solution 24% peg 3350, 0.2 M ammonium tartrate, 0.1 M arginine.   Flat crystal plates (typically 0.03 mm x 0.2 mm x 0.4 mm in size) grew in 4-7 days at 20 C.   A crystal seed suspension was prepared with ten crushed crystals combined into 100 uL of reservoir solution and stored at -80 C.  A thirty fold seed dilution was prepared in the same solution for addition to protein droplets in a 1 to 1 volume ratio to enhance crystallization of difficult to crystallize inhibitors.",293.0,2017-04-25,2017-08-23,5VLO,5137.0,2.0,604.0,349.0,,70.32,1.0,2.05,experimental,41.0908881426,0.2261,0.1828,The structure of human CamKII with bound inhibitor
5MHQ,X-RAY DIFFRACTION,1.91,35.77,"VAPOR DIFFUSION, SITTING DROP",7.4,"10mg/ml CDK2
10% V/V PEG3350, 50 mM HEPES/NAOH, 50 mM NA/K PHOSPHATE, pH 7.5.",293.0,2016-11-25,2017-12-20,5MHQ,2799.0,1.0,306.0,343.0,,35.17,1.0,1.3,experimental,24.36,0.22597,0.1885,CCT068127 in complex with CDK2
7N1R,X-RAY DIFFRACTION,2.7,54.41,EVAPORATION,4.5,"18-22% PEG1000, 0.1 M phosphate citrate, pH 4.5, 0.2 M lithium sulfate, 2% w/v dioxane",293.0,2021-05-28,2022-01-12,7N1R,10811.0,2.0,1212.0,1068.0,,137.97,1.0,2.03,experimental,31.885,0.2232,0.1743,A novel and unique ATP hydrolysis to AMP by a human Hsp70 BiP
8PQI,X-RAY DIFFRACTION,2.04,39.82,"VAPOR DIFFUSION, HANGING DROP",,"5 mg/mL, 5% PEG3350, 200 mM KCl",293.15,2023-07-11,2023-12-27,8PQI,2406.0,1.0,352.0,8.0,,40.86,1.0,2.6,experimental,78.93,0.254,0.2308,PDGFRA T674I mutant kinase domain in complex with avapritinib derivative 9
8PQJ,X-RAY DIFFRACTION,1.85,33.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"10 mg/mL, 15% PEG3350, 100 mM Bis-Tris-Propane, pH 7.5",285.15,2023-07-11,2023-12-27,8PQJ,2836.0,1.0,352.0,204.0,,40.21,1.0,1.82,experimental,40.3,0.2151,0.1838,PDGFRA wild-type kinase domain
8PQK,X-RAY DIFFRACTION,2.41,49.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"10 mg/mL, 22% PEG3350, 100 mM Bis-Tris-Propane, pH 7.5",293.15,2023-07-11,2023-12-27,8PQK,2717.0,1.0,352.0,138.0,,40.23,1.0,2.0,experimental,37.56,0.2219,0.196,APO crystal structure of PDGFRA-T674I kinase domain
8D4Y,X-RAY DIFFRACTION,2.16,43.08,"VAPOR DIFFUSION, SITTING DROP",8.3,"0.1 M bicine/Trizma base pH 8.3, 10% w/v PEG 8000, 20% v/v ethylene glycol, 0.1 M mixture of carboxylic acids*, and 20 mM spermidine 

*Sodium Formate; Ammonium 
acetate; Sodium citrate tribasic 
dihydrate; Potassium sodium tartrate 
tetrahydrate; Sodium oxamate",277.15,2022-06-03,2022-12-21,8D4Y,3557.0,2.0,862.0,6.0,,98.54,1.0,2.9,experimental,90.0746,0.3012,0.2632,C-terminal SANT-SLIDE domain of human Chromodomain-helicase-DNA-binding protein 4 (CHD4)
7EVR,X-RAY DIFFRACTION,2.42,49.26,"VAPOR DIFFUSION, SITTING DROP",,"0.8M Potassium/Sodium phosphate, pH 7.5",293.0,2021-05-22,2021-10-20,7EVR,2279.0,4.0,274.0,332.0,,30.83,2.0,1.8,experimental,19.619,0.1979,0.1582,Crystal structure of hnRNP L RRM2 in complex with SETD2
3WOW,X-RAY DIFFRACTION,1.93,36.14,"VAPOR DIFFUSION, SITTING DROP",8.0,"25% ethylene glycol, pH 8, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-01-06,2015-02-04,3WOW,3008.0,1.0,340.0,134.0,,41.41,1.0,2.5,experimental,31.914,0.23964,0.18448,Crystal structure of human CK2a with AMPPNP
5D3Q,X-RAY DIFFRACTION,2.25,45.4,"VAPOR DIFFUSION, HANGING DROP",8.0,"Before crystallization set-ups, GG1 at a concentration of 10 mg/ml was supplemented with 2 mM GDP and 2 mM MgCl2 and incubated for 1 h on ice. GG1GDP was crystallized by hanging drop vapour diffusion mixing 1.5 ul protein solution with 1.5 ul reservoir solution containing 0.1 M Tris (pH 8.0), 26 % PEG 3350 and 0.2 M NaSCN. The drops were equilibrated against 700 ul of reservoir.",277.0,2015-08-06,2015-12-02,5D3Q,5864.0,2.0,690.0,609.0,,78.06,1.0,1.7,experimental,,0.2055,0.1727,Dynamin 1 GTPase-BSE fusion dimer complexed with GDP
6RU6,X-RAY DIFFRACTION,2.4,48.77,"VAPOR DIFFUSION, SITTING DROP",,"10-20% PEG 3350, 0.1-0.2 M sodium sulfate and 0.1 M citrate, pH 4.6-5.9",277.15,2019-05-27,2020-05-13,6RU6,4963.0,3.0,605.0,139.0,,71.87,2.0,2.05,experimental,50.924,0.257,0.2108,Crystal structure of Casein Kinase I delta (CK1d) in complex with monophosphorylated p63 PAD1P peptide
6RU7,X-RAY DIFFRACTION,2.38,48.37,"VAPOR DIFFUSION, SITTING DROP",,"10-20% PEG 3350, 0.1-0.2 M sodium sulfate and 0.1 M citrate, pH 4.6-5.9",277.15,2019-05-27,2020-05-13,6RU7,5330.0,4.0,624.0,224.0,,74.22,2.0,2.08,experimental,44.001,0.2182,0.1754,Crystal structure of Casein Kinase I delta (CK1d) in complex with double phosphorylated p63 PAD2P peptide
7MBJ,X-RAY DIFFRACTION,2.07,40.7,VAPOR DIFFUSION,4.5,"6% Tacsimate (pH 4.5), 18% PEG 3350",277.0,2021-03-31,2022-05-11,7MBJ,2395.0,2.0,268.0,361.0,4.0,30.55,1.0,1.26,experimental,23.17,0.197,0.1775,Crystal structure of cGMP dependent protein kinase I alpha (PKG I alpha)CNB-A domain with R177Q mutation
6ET4,X-RAY DIFFRACTION,3.67,66.47,"VAPOR DIFFUSION, HANGING DROP",4.8,"30% glycerol, 100 mM Sodium acetate pH 4.8, 2 M Ammoniumsulphate",293.0,2017-10-25,2018-03-28,6ET4,3320.0,1.0,367.0,257.0,,41.86,1.0,1.7,experimental,26.525,0.13809,0.10535,HUMAN DIHYDROOROTATE DEHYDROGENASE IN COMPLEX WITH NOVEL INHIBITOR
6GK0,X-RAY DIFFRACTION,3.64,66.25,"VAPOR DIFFUSION, SITTING DROP",4.8,"30% glycerol, 100 mM sodium acetate pH 4.8, 1.8 M Ammoniumsulphate, 40 mM DDAO, 6.4 mM C11DAO, 2 mM L-DHO, 1 mM Tenovin",293.0,2018-05-17,2019-11-27,6GK0,3212.0,1.0,367.0,228.0,,41.98,1.0,1.85,experimental,29.791,0.19301,0.16801,HUMAN DIHYDROOROTATE DEHYDROGENASE IN COMPLEX WITH CLASS III HISTONE DEACETYLASE INHIBITOR
7Z9J,X-RAY DIFFRACTION,4.1,69.98,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-03-21,2022-11-23,7Z9J,1385.0,1.0,130.0,180.0,,16.15,1.0,1.9,experimental,36.854,0.2213,0.1891,ATAD2 in complex with PepLite-Gly
7Z9N,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-03-21,2022-11-23,7Z9N,1320.0,1.0,130.0,183.0,,16.08,1.0,1.34,experimental,30.216,0.227,0.2078,ATAD2 in complex with PepLite-Val
8QWZ,X-RAY DIFFRACTION,3.17,61.26,VAPOR DIFFUSION,5.5,"0.2 M ammonia sulphate
0.1 M bis-tris pH 5.5 
23-26% PEG 3350",293.0,2023-10-20,2024-01-17,8QWZ,5470.0,2.0,676.0,44.0,,82.46,1.0,2.6,experimental,73.338,0.24488,0.20567,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 4-(6-(6-isopropoxy-1H-indol-1-yl)pyrazin-2-yl)benzoic acid
9EPX,X-RAY DIFFRACTION,3.16,61.04,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M bis-tris pH 5.5 
23-26% (v/v) PEG 3350 
0.2 M ammonia sulphate",293.0,2024-03-20,2024-05-01,9EPX,5643.0,2.0,676.0,67.0,,83.4,1.0,2.6,experimental,50.748,0.24636,0.21381,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with allosteric ligand FGC3331
6UBW,X-RAY DIFFRACTION,2.09,41.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"12% isopropanol, 10% PEG5000 MME, 0.06 M HEPES sodium, 0.04 M HEPES",293.0,2019-09-13,2020-02-12,6UBW,2564.0,1.0,343.0,166.0,,39.06,1.0,2.0,experimental,42.276,0.2246,0.1868,MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
5PAF,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAF,2943.0,2.0,318.0,356.0,9.0,36.39,2.0,1.5,experimental,25.07,0.185,0.165,"Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]-5-chlorophenyl]acetamide;2,2,2-trifluoroacetic acid"
5UQ2,X-RAY DIFFRACTION,2.63,53.19,"VAPOR DIFFUSION, SITTING DROP",,"1M lithium chloride, 12% PEG 6000, and 0.1M MES pH 6.2",295.0,2017-02-06,2017-07-05,5UQ2,3505.0,2.0,461.0,23.0,1.0,53.62,2.0,2.7,experimental,,0.2752,0.2121,Crystal structure of human Cdk2-Spy1 complex
6QSX,X-RAY DIFFRACTION,2.52,51.19,"VAPOR DIFFUSION, SITTING DROP",,"2.5 M ammonium sulfate, 0.1 mM sodium acetate (pH 4.6), 2 mM inhibitor",293.0,2019-02-22,2019-03-27,6QSX,4940.0,2.0,582.0,383.0,10.0,67.32,1.0,1.77,experimental,24.277,0.2198,0.1894,"Complement factor B protease domain in complex with the reversible inhibitor ((2S,4S)-1-((5,7-dimethyl-1H-indol-4-yl)methyl)-4-methoxypiperidin-2-yl)methanol."
4ZG6,X-RAY DIFFRACTION,2.42,49.2,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.4 M NaSCN",298.0,2015-04-22,2015-10-14,4ZG6,12830.0,2.0,1710.0,614.0,26.0,200.01,1.0,1.8,experimental,37.642,0.265,0.22039,Structural basis for inhibition of human autotaxin by four novel compounds
6G5G,X-RAY DIFFRACTION,3.5,65.1,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.2 M magnesium chloride, Tris pH 7.0, 10% w/v PEG 8000",294.0,2018-03-29,2019-01-16,6G5G,11548.0,3.0,2603.0,788.0,1.0,305.48,2.0,2.0,experimental,44.844,0.22339,0.18962,Crystal structure of an engineered Botulinum Neurotoxin type B mutant E1191M/S1199Y in complex with human synaptotagmin 2
5NN4,X-RAY DIFFRACTION,3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.9 M ammonium sulphate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293.0,2017-04-08,2017-10-25,5NN4,7880.0,1.0,872.0,776.0,5.0,102.1,1.0,1.83,experimental,26.421,0.17827,0.15366,"Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with N-acetyl-cysteine"
5NN6,X-RAY DIFFRACTION,3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.9 M ammonium sulphate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293.0,2017-04-08,2017-10-25,5NN6,7608.0,1.0,872.0,633.0,5.0,101.83,1.0,2.0,experimental,22.484,0.18376,0.1526,"Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with N-hydroxyethyl-1-deoxynojirimycin"
7Z39,X-RAY DIFFRACTION,2.01,38.84,"VAPOR DIFFUSION, SITTING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298.0,2022-03-01,2022-10-12,7Z39,3151.0,1.0,328.0,277.0,,39.82,1.0,1.6,experimental,25.792,0.2126,0.1638,Structure of Belumosudil bound to CK2alpha
5IBM,X-RAY DIFFRACTION,2.21,44.45,"VAPOR DIFFUSION, HANGING DROP",8.0,"100 mM Tris, 20% PEG 3350 and 1 mM TCEP",293.0,2016-02-22,2016-04-13,5IBM,8166.0,2.0,1052.0,367.0,,120.69,1.0,2.18,experimental,50.58,0.2397,0.1892,"Structure of S502P, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2"
5IBS,X-RAY DIFFRACTION,2.42,49.22,"VAPOR DIFFUSION, HANGING DROP",8.0,"100 mM Tris, 20% PEG 3350 and 1 mM TCEP",293.0,2016-02-22,2016-04-13,5IBS,8215.0,2.0,1052.0,396.0,,120.67,1.0,2.32,experimental,43.89,0.2379,0.1862,"Structure of E76Q, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2"
5M8L,X-RAY DIFFRACTION,3.03,59.47,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",295.15,2016-10-29,2017-07-12,5M8L,15126.0,4.0,1784.0,181.0,28.0,213.57,1.0,2.35,experimental,39.7985,0.2549,0.214,Crystal structure of human tyrosinase related protein 1
5M8M,X-RAY DIFFRACTION,3.03,59.41,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290.0,2016-10-29,2017-07-12,5M8M,15021.0,4.0,1784.0,43.0,28.0,214.04,1.0,2.65,experimental,39.6045,0.2494,0.1967,Crystal structure of human tyrosinase related protein 1 in complex with kojic acid
5M8N,X-RAY DIFFRACTION,3.01,59.09,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290.0,2016-10-29,2017-07-12,5M8N,15194.0,4.0,1784.0,272.0,28.0,213.21,1.0,2.6,experimental,45.6714,0.2745,0.2194,Crystal structure of human tyrosinase related protein 1 in complex with mimosine
5M8P,X-RAY DIFFRACTION,2.97,58.62,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290.0,2016-10-29,2017-07-12,5M8P,15116.0,4.0,1784.0,65.0,28.0,215.12,1.0,2.8,experimental,54.7576,0.262,0.2046,Crystal structure of human tyrosinase related protein 1 in complex with tyrosine
5WDP,X-RAY DIFFRACTION,2.81,56.17,"VAPOR DIFFUSION, SITTING DROP",6.0,"17% PEG8000, 200 mM calcium acetate, 100 mM MES/NaOH, pH 6.0",293.0,2017-07-05,2017-07-19,5WDP,1728.0,1.0,166.0,114.0,,19.48,1.0,1.35,experimental,,0.1536,0.145,H-Ras mutant L120A bound to GMP-PNP at 277K
5WDQ,X-RAY DIFFRACTION,2.57,52.08,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG8000, 200 mM calcium acetate, 100 mM MES/NaOH, pH 6.0",293.0,2017-07-05,2017-07-19,5WDQ,1783.0,1.0,170.0,166.0,,20.14,1.0,1.25,experimental,,0.15,0.1402,H-Ras mutant L120A bound to GMP-PNP at 100K
5TOZ,X-RAY DIFFRACTION,2.22,44.71,"VAPOR DIFFUSION, HANGING DROP",8.0,"20% PEG-3350, 0.2 M ammonium sulfate",298.0,2016-10-19,2016-11-09,5TOZ,2448.0,1.0,321.0,232.0,,36.93,1.0,1.98,experimental,42.56,0.2155,0.1826,JAK3 with covalent inhibitor PF-06651600
5TTU,X-RAY DIFFRACTION,2.2,44.19,"VAPOR DIFFUSION, SITTING DROP",8.0,"20% PEG 3350, 0.2M (NH4)2SO4, 2% phenylurea",298.0,2016-11-04,2017-02-22,5TTU,2427.0,1.0,321.0,230.0,,37.04,1.0,1.72,experimental,38.8,0.2116,0.1917,Jak3 with covalent inhibitor 7
6DUD,X-RAY DIFFRACTION,2.21,44.34,"VAPOR DIFFUSION, HANGING DROP",8.0,"20% PEG 3350, 0.2M (NH4)2SO4, 2% phenylurea",298.0,2018-06-20,2018-11-28,6DUD,2498.0,1.0,321.0,310.0,,36.92,1.0,1.66,experimental,37.36,0.215,0.184,JAK3 with cyanamide CP12
7FUJ,X-RAY DIFFRACTION,2.37,48.07,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals.",293.0,2023-02-08,2024-02-21,7FUJ,3271.0,1.0,362.0,205.0,,44.14,1.0,1.79,experimental,30.508,0.2537,0.1985,"Crystal Structure of human cyclic GMP-AMP synthase in complex with (Z)-2-cyano-N-[4-(3-fluorophenyl)-5-methylsulfonylpyrimidin-2-yl]-3-hydroxy-3-(5-methyl-1,2-oxazol-4-yl)prop-2-enamide"
6B3S,X-RAY DIFFRACTION,3.76,67.31,"VAPOR DIFFUSION, HANGING DROP",6.0,"50 mM sodium acetate, 200 mM potassium citrate, 15-20% PEG3350",293.0,2017-09-23,2017-12-06,6B3S,18965.0,12.0,2596.0,69.0,32.0,287.58,3.0,2.8,experimental,73.81,0.245,0.208,Crystal structure of the Fab fragment of necitumumab (Fab11F8) in complex with domain III from a cetuximab resistant variant of EGFR (sEGFRd3-S468R)
7JVN,X-RAY DIFFRACTION,2.27,45.9,"VAPOR DIFFUSION, SITTING DROP",,17% PEG 3350 and 200 mM ammonium phosphate,277.15,2020-08-21,2020-09-23,7JVN,8529.0,2.0,1050.0,738.0,,121.93,1.0,1.917,experimental,29.49,0.214,0.181,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Compound 24
6YPK,X-RAY DIFFRACTION,1.99,38.13,"VAPOR DIFFUSION, SITTING DROP",6.5,"112.5mM Mes, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2020-04-16,2020-07-15,6YPK,2966.0,1.0,328.0,144.0,,39.47,1.0,1.79,experimental,34.21,0.21,0.179,Crystal Structure of CK2alpha with GTP bound
6YPN,X-RAY DIFFRACTION,1.94,36.58,"VAPOR DIFFUSION, SITTING DROP",6.2,"20 %v/v PEGSM, 10 %v/v Glycerol, 0.2 M Na Form, 0.1 M Na-Phosphate",298.0,2020-04-16,2020-07-15,6YPN,3034.0,1.0,329.0,191.0,,40.46,1.0,1.58,experimental,28.828,0.2475,0.2052,Crystal Structure of CK2alpha with 2 molecules of ADP bound
7W67,X-RAY DIFFRACTION,2.05,45.51,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M Sodium chloride, 0.1 M HEPES, pH 7.5, 25% w/v polyethylene glycol 3350",277.0,2021-12-01,2022-09-07,7W67,3037.0,4.0,378.0,128.0,,43.59,4.0,2.194,experimental,48.0675,0.2219,0.175,The crystal structure of MLL1 (N3861I/Q3867L/C3882SS)-RBBP5-ASH2L in complex with H3K4me0 peptide
7FTN,X-RAY DIFFRACTION,3.37,63.54,"VAPOR DIFFUSION, SITTING DROP",7.0,"10-12 mg/mL protein in 25 mM Tris/HCl pH7.5, 500mM NaCl, 2mM TCEP, supplemented with 10x molar excess of ligand and, if needed, with 10 mM MgCl2 and 5mM ATP, then mixed 1:1 with reservoir of the Procomplex screen. Several conditions resulted in crystals",293.0,2023-02-08,2024-02-21,7FTN,3793.0,3.0,393.0,227.0,,52.14,1.0,2.001,experimental,48.6814,0.2255,0.1848,Crystal Structure of human cyclic GMP-AMP synthase in complex with propanedioic acid
7RPZ,X-RAY DIFFRACTION,2.39,48.47,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Sodium Citrate pH 4.2,29% PEG 8K, 200 mM Ammonium Acetate",293.0,2021-08-05,2021-12-22,7RPZ,1693.0,1.0,170.0,275.0,,20.43,1.0,1.3,experimental,17.72,0.1713,0.1489,KRAS G12D in complex with MRTX-1133
7RT1,X-RAY DIFFRACTION,2.39,48.51,VAPOR DIFFUSION,,"25% PEG8000, 100 mM sodium citrate, pH 5.4, 200 mM ammonium acetate",298.0,2021-08-12,2021-12-22,7RT1,1764.0,1.0,170.0,318.0,,20.86,1.0,1.27,experimental,13.8264,0.1678,0.1352,"Crystal Structure of KRAS G12D with compound 15 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}pyrido[4,3-d]pyrimidin-7-yl)naphthalen-2-ol) bound"
7RT5,X-RAY DIFFRACTION,2.37,48.1,VAPOR DIFFUSION,,"100 mM sodium citrate, pH 4.5, 26% PEG8000, 200 mM ammonium acetate",293.0,2021-08-12,2021-12-22,7RT5,1671.0,1.0,170.0,263.0,,20.4,1.0,1.29,experimental,20.0976,0.1872,0.1625,"Crystal structure of KRAS G12D with compound 36 (4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-{[(4s,7as)-tetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidine) bound"
8AZR,X-RAY DIFFRACTION,2.53,51.42,"VAPOR DIFFUSION, HANGING DROP",,"0.2mM Magnesiumchloride, 20% PEG 2000, 100mM sodium acetate pH 4.4",277.0,2022-09-06,2023-06-07,8AZR,1711.0,1.0,170.0,303.0,,20.29,1.0,1.6,experimental,16.54,0.2324,0.1794,KRAS in complex with precursor 1
8AZV,X-RAY DIFFRACTION,2.55,51.85,"VAPOR DIFFUSION, HANGING DROP",,"0.2mM Magnesium Chloride, 20% PEG 2000, 100mM sodium acetate pH 4.4",277.0,2022-09-06,2023-06-07,8AZV,1753.0,1.0,170.0,262.0,,20.37,1.0,1.05,experimental,20.75,0.1735,0.1546,KRAS in complex with BI-2865
8AZX,X-RAY DIFFRACTION,2.54,51.64,"VAPOR DIFFUSION, HANGING DROP",,"0.2mM Magnesium Chloride, 20% PEG 2000, 100mM sodium acetate pH 4.4",277.0,2022-09-06,2023-06-07,8AZX,1700.0,1.0,170.0,248.0,,20.42,1.0,1.04,experimental,21.24,0.197,0.1611,KRAS-G12C in complex with BI-2865
8AZZ,X-RAY DIFFRACTION,2.55,51.69,"VAPOR DIFFUSION, HANGING DROP",,"0.2mM Magnesium Chloride, 20% PEG 2000, 100mM sodium acetate pH 4.4",277.0,2022-09-06,2023-06-21,8AZZ,1736.0,1.0,170.0,265.0,,20.41,1.0,1.02,experimental,22.96,0.1669,0.145,KRAS-G12V in complex with BI-2865
8B00,X-RAY DIFFRACTION,2.54,51.56,"VAPOR DIFFUSION, HANGING DROP",,"0.2mM Magnesium Chloride, 20% PEG 2000, 100mM sodium acetate pH 4.4",277.0,2022-09-06,2023-06-07,8B00,1676.0,1.0,170.0,247.0,,20.49,1.0,1.04,experimental,21.03,0.161,0.1439,KRAS-G13D in complex with BI-2865
8B78,X-RAY DIFFRACTION,2.75,55.23,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350
LITHIUM SULFATE",293.0,2022-09-29,2023-07-12,8B78,1524.0,1.0,168.0,124.0,,20.11,1.0,1.11,experimental,20.835,0.2357,0.2236,KRasG12C ligand complex
8FMK,X-RAY DIFFRACTION,1.78,30.95,"VAPOR DIFFUSION, SITTING DROP",,"(NH)4Cl 0.2 M
PEG3350 20-24%",293.0,2022-12-23,2023-11-22,8FMK,1639.0,1.0,176.0,196.0,,20.81,1.0,1.48,experimental,24.35,0.2366,0.198,Crystal structure of human KRAS with extended switch I loop
8JGD,X-RAY DIFFRACTION,2.45,49.73,"VAPOR DIFFUSION, HANGING DROP",6.0,"200mM calcium acetate,100mM MES(PH 5.5-6.5),PEG 8000 16%-24%",277.0,2023-05-20,2024-01-31,8JGD,1684.0,1.0,169.0,258.0,,20.57,1.0,1.60037058083,experimental,21.9025173472,0.201474771249,0.168275647955,GDP-bound KRAS G12C in complex with YK-8S
8ONV,X-RAY DIFFRACTION,2.53,51.4,"VAPOR DIFFUSION, HANGING DROP",,"0.2mM MgCl2, 15-27% PEG 2000, 100mM sodium acetate pH=4.4",278.0,2023-04-04,2023-06-07,8ONV,1750.0,1.0,170.0,281.0,,20.42,1.0,1.01,experimental,20.14,0.1565,0.1336,KRAS-G13D in complex with BI-2493
8UN4,X-RAY DIFFRACTION,2.51,50.92,EVAPORATION,,"0.1M MMT pH 5.0, 25 % w/v Polyethylene glycol 1,500",291.0,2023-10-18,2023-12-20,8UN4,1649.0,1.0,170.0,182.0,,20.62,1.0,1.57,experimental,30.2325,0.2151,0.1901,KRAS-G13D-GDP in complex with Cpd36 ((E)-1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-2-methylenetetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)-3-(4-((dimethylamino)methyl)-5-methylpyridin-2-yl)prop-2-en-1-one)
7F1G,X-RAY DIFFRACTION,2.26,45.5,"VAPOR DIFFUSION, SITTING DROP",,not available,293.0,2021-06-09,2022-02-23,7F1G,3945.0,2.0,499.0,305.0,3.0,54.51,2.0,1.5,experimental,27.607,0.2446,0.2255,"BACE2 xaperone complex with N-{3-[(4R,5R,6R)-2-amino-5-fluoro-4,6-dimethyl-5,6-dihydro-4H-1,3-thiazin-4-yl]-4-fluorophenyl}-2H,3H-[1,4]dioxino[2,3-c]pyridine-7-carboxamide"
5JJY,X-RAY DIFFRACTION,2.66,58.68,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M KSCN, 0.1 M Bis-Tris Propane, 20% PEG3350",277.0,2016-04-25,2016-11-02,5JJY,2346.0,2.0,293.0,204.0,,34.47,2.0,2.053,experimental,36.5822,0.2131,0.1784,Crystal structure of SETD2 bound to histone H3.3 K36M peptide
6N33,X-RAY DIFFRACTION,2.31,46.83,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG8K, 0.2M MGCL2 AND 0.1M TRIS, PH 7.5",277.0,2018-11-14,2019-09-18,6N33,2447.0,1.0,343.0,133.0,,39.04,1.0,2.25,experimental,,0.2197,0.1807,"Crystal structure of fms kinase domain with a small molecular inhibitor, PLX5622"
7MFC,X-RAY DIFFRACTION,2.25,45.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"CSF1R at 4mg/ml with 0.5mM vimseltinib: Crystallization: 100mM Tris base / HCl pH 7.71, 18% PEG 8000, 100mM MgCl2: Cryo: 20% glycerol",289.0,2021-04-08,2021-11-24,7MFC,2204.0,1.0,343.0,15.0,,39.07,1.0,2.8,experimental,53.81,0.256,0.226,Crystal structure of CSF1R in complex with vimseltinib
5M3H,X-RAY DIFFRACTION,3.12,60.58,"VAPOR DIFFUSION, SITTING DROP",5.0,"Bat influenza polymerase at 10 mgs per ml in 50 mM HEPES NaOH, 500 mM NaCl, 5% (v/v) glycerol, 2 mM TCEP at pH 7.5 with 1:1 ratio of vRNA promoter and CTD peptide mixed with 0.7-1.5 M sodium/potassium phosphate at pH 5.0",278.0,2016-10-14,2016-12-21,5M3H,18529.0,7.0,2391.0,250.0,,281.1,4.0,2.5,experimental,,0.2449,0.21,Bat influenza A/H17N10 polymerase bound to four heptad repeats of serine 5 phosphorylated Pol II CTD
7PWD,X-RAY DIFFRACTION,3.29,62.59,"VAPOR DIFFUSION, HANGING DROP",5.5,"ethylene glycol, PEG 3350, MES, NaCl",277.0,2021-10-06,2021-10-20,7PWD,8410.0,3.0,1114.0,169.0,,127.49,3.0,2.6,experimental,73.697,0.2295,0.1917,Structure of an inhibited GRK2-G-beta and G-gamma complex
4ZG7,X-RAY DIFFRACTION,2.23,44.88,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2 M NaCl",298.0,2015-04-22,2015-10-14,4ZG7,6888.0,1.0,806.0,495.0,15.0,95.01,1.0,1.75,experimental,23.229,0.1947,0.1641,Structural basis for inhibition of human autotaxin by four novel compounds
8P05,X-RAY DIFFRACTION,3.13,60.65,VAPOR DIFFUSION,5.5,0.2 M ammonia sulphate 0.1 M bis-tris pH 5.5 23-26% PEG 3350,293.0,2023-05-09,2023-05-17,8P05,5564.0,2.0,676.0,35.0,,82.57,1.0,2.45,experimental,60.478,0.25499,0.20883,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with Leucettinib-92
8P06,X-RAY DIFFRACTION,3.16,61.09,VAPOR DIFFUSION,,0.2 M ammonia sulphate 0.1 M bis-tris pH 5.5 23-26% PEG 3350,293.0,2023-05-09,2023-06-21,8P06,5598.0,2.0,676.0,103.0,,82.14,1.0,2.4,experimental,58.84,0.23728,0.20158,"Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((2-(4H-1,2,4-triazol-4-yl)pyridin-4-yl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile"
8P07,X-RAY DIFFRACTION,3.13,60.74,VAPOR DIFFUSION,,0.2 M ammonia sulphate 0.1 M bis-tris pH 5.5 23-26% PEG 3350,293.0,2023-05-09,2023-05-17,8P07,5789.0,2.0,676.0,99.0,,82.77,1.0,2.4,experimental,61.686,0.25105,0.20401,"Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((3-(4H-1,2,4-triazol-4-yl)phenyl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile"
8P5G,X-RAY DIFFRACTION,3.62,65.98,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.3-0.8 M NaAcetate pH 6, 20-26% w/v PEG3350",277.15,2023-05-24,2024-06-05,8P5G,4739.0,2.0,568.0,291.0,,65.56,1.0,2.019,experimental,45.019,0.2269,0.1839,Kinase domain of wild type human ULK1 in complex with compound CCT241533
8P5H,X-RAY DIFFRACTION,3.46,64.49,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.3-0.8 M NaAcetate pH 6, 20-26% w/v PEG3350",277.15,2023-05-24,2024-06-05,8P5H,4800.0,2.0,568.0,348.0,,65.27,1.0,1.941,experimental,35.553,0.193,0.1698,Kinase domain of mutant human ULK1 in complex with compound CCT241533
8P5J,X-RAY DIFFRACTION,3.42,64.08,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.3-0.8 M NaAcetate pH 6, 20-26% w/v PEG3350",277.15,2023-05-24,2024-06-05,8P5J,4688.0,2.0,568.0,272.0,,65.31,1.0,2.164,experimental,46.156,0.2001,0.1676,Kinase domain of mutant human ULK1 in complex with compound WZ4003
8P5L,X-RAY DIFFRACTION,3.6,65.79,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.3-0.8 M NaAcetate pH 6, 20-26% w/v PEG3350",277.15,2023-05-24,2024-06-05,8P5L,4952.0,2.0,568.0,446.0,,65.27,1.0,1.836,experimental,32.223,0.2113,0.1756,Kinase domain of mutant human ULK1 in complex with compound MRT67307
9EZG,X-RAY DIFFRACTION,3.16,61.04,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M bis-tris pH 5.5 
23-26% (v/v) PEG 3350 
0.2 M ammonia sulphate",293.0,2024-04-12,2024-07-31,9EZG,5714.0,2.0,676.0,87.0,,83.24,1.0,2.18,experimental,53.415,0.24235,0.20907,"Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with 5-((4-((2-aminoethyl)(ethyl)amino)-3-(4H-1,2,4-triazol-4-yl)phenyl)amino)-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile"
5NN3,X-RAY DIFFRACTION,3.32,62.94,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.9 M ammonium sulfate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293.0,2017-04-08,2017-10-25,5NN3,7663.0,1.0,872.0,668.0,5.0,101.29,1.0,1.9,experimental,33.138,0.18874,0.16195,"Crystal structure of human lysosomal acid-alpha-glucosidase, GAA"
5NN5,X-RAY DIFFRACTION,3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.9 M ammonium sulphate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293.0,2017-04-08,2017-10-25,5NN5,7695.0,1.0,872.0,773.0,5.0,101.07,1.0,2.0,experimental,19.493,0.21809,0.18336,"Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with 1-deoxynojirimycin"
6J9J,X-RAY DIFFRACTION,3.03,59.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M potassium thiocyanate, 0.1M Bis-Tris propane,20% PEG 3350",277.0,2019-01-23,2020-02-26,6J9J,2396.0,2.0,271.0,260.0,,32.15,2.0,1.78,experimental,31.201,0.2056,0.1891,crystal structure of SESTD2 in complex with H3.3S31phK36M peptide
5TF9,X-RAY DIFFRACTION,2.12,41.95,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES, pH 7.5, 200 mM calcium acetate, 22% PEG3350",298.0,2016-09-24,2016-10-19,5TF9,4459.0,2.0,558.0,90.0,,65.9,1.0,2.5,experimental,46.0336,0.2658,0.1949,Crystal structure of WNK1 in complex with Mn2+AMPPNP and WNK476
7UYV,X-RAY DIFFRACTION,2.7,53.3,VAPOR DIFFUSION,,Crystals of human JAK3 in complex with the ligand were prepared according to established protocols,298.0,2022-05-07,2022-08-24,7UYV,9659.0,4.0,1164.0,438.0,,134.83,1.0,2.15,experimental,39.447,0.2629,0.2206,Crystal structure of JAK3 kinase domain in complex with compound 25
8S0N,X-RAY DIFFRACTION,2.89,57.47,"VAPOR DIFFUSION, SITTING DROP",8.0,"10 %w/v PEG 3000, 0.1 M imidazole (pH 8.0), 0.2 M lithium sulfate",291.0,2024-02-14,2024-06-26,8S0N,7251.0,4.0,1094.0,209.0,12.0,119.91,2.0,2.3,experimental,63.89,0.2458,0.2109,Crystal structure of the TMPRSS2 zymogen in complex with the nanobody A07
4WLQ,X-RAY DIFFRACTION,2.99,58.93,"VAPOR DIFFUSION, SITTING DROP",7.3,"20% PEG 3350, 200 mM Mg(OAC)2,100 mM HEPES",277.0,2014-10-07,2015-03-04,4WLQ,3082.0,2.0,427.0,,,47.92,2.0,2.85,experimental,112.4345,0.278,0.1918,Crystal structure of mUCH37-hRPN13 CTD complex
5LI9,X-RAY DIFFRACTION,2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",6.3,"25% Morpheus precipitant mix 4, 10% Morpheus Carboxylic acids, Morpheus Buffer system 1",293.0,2016-07-14,2016-09-14,5LI9,3036.0,1.0,350.0,244.0,,41.93,1.0,1.79,experimental,,0.2313,0.1877,Structure of a nucleotide-bound form of PKCiota core kinase domain
6NKP,X-RAY DIFFRACTION,2.21,44.3,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.09 M BIS-TRIS pH 5.5, 22.5% w/v PEG 3,350, 3% w/v 6-aminohexanoic acid",293.0,2019-01-07,2019-05-01,6NKP,3357.0,4.0,400.0,276.0,4.0,45.92,2.0,2.033,experimental,,0.2132,0.1675,EphA2 LBD in complex with bA-WLA-YSKbio peptide
5FBN,X-RAY DIFFRACTION,2.23,44.83,"VAPOR DIFFUSION, HANGING DROP",5.5,"20% v/v PEG 20000 0.1M NaCl 0.1M Na MES pH 6.5 2.5 mM mM (S)-4-(8-amino-3-(1-(4-(dimethylamino)butanoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(thiazol-2-yl)benzamide 5.0 mM (R)-4-(8-amino-3-(1-(3-methyloxetane-3-carbonyl)piperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",277.0,2015-12-14,2016-02-03,5FBN,5015.0,2.0,542.0,519.0,,66.56,1.0,1.8,experimental,23.103,0.22596,0.17945,BTK kinase domain with inhibitor 1
6NZM,X-RAY DIFFRACTION,2.21,44.38,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Ammonium Tartrate, 20% PEG3350",298.0,2019-02-14,2019-06-12,6NZM,4840.0,2.0,560.0,497.0,,66.04,1.0,1.72,experimental,25.329,0.2483,0.1755,Brutons tyrosine kinase in complex with compound 50.
6OCN,X-RAY DIFFRACTION,2.07,40.53,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium cacodylate, 52-58% MPD",293.0,2019-03-25,2020-02-12,6OCN,4664.0,1.0,496.0,530.0,5.0,56.85,1.0,1.147,experimental,,0.1166,0.0988,Montbretin A analogue M06-MbA in complex with Human pancreatic alpha-amylase
4ZMA,X-RAY DIFFRACTION,2.51,51.08,"VAPOR DIFFUSION, HANGING DROP",5.1,"0.1M Cacodylate,11% PEG 8000 , with seeding",295.0,2015-05-02,2015-12-30,4ZMA,4834.0,3.0,620.0,215.0,14.0,71.21,3.0,2.3,experimental,41.399,0.2947,0.2401,Crystal Structure of a FVIIa-Trypsin Chimera (ST) in Complex with Soluble Tissue Factor
7Q8W,X-RAY DIFFRACTION,2.31,46.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"26% PEG 3350, 0.2M sodium acetate, 0.1M tris 7.5",293.15,2021-11-11,2022-03-09,7Q8W,2503.0,1.0,309.0,80.0,,35.91,1.0,2.02,experimental,52.724,0.2255,0.1787,Crystal structure of TTBK1 in complex with VNG1.35 (compound 23)
5KAE,X-RAY DIFFRACTION,2.34,47.45,VAPOR DIFFUSION,7.3,"20% PEG 3350, 250 mM ammonium sulfate, 100 mM Tris (pH 7.3), 2 mM dithiothreitol",298.0,2016-06-01,2017-06-21,5KAE,6908.0,1.0,959.0,54.0,,110.55,1.0,2.65,experimental,66.35,0.2519,0.2007,Crystal structure of human PI3K-gamma in complex with quinoline-containing inhibitor 5g
6AUA,X-RAY DIFFRACTION,2.34,47.5,"VAPOR DIFFUSION, SITTING DROP",5.5,"100 MM CITRATE PH 5.5, 14% PEG 10, 000, 100 MM LI2SO4, 1 MM CGI2625",289.0,2017-08-31,2018-09-12,6AUA,2478.0,1.0,265.0,214.0,,31.8,1.0,1.66,experimental,17.6042,0.185,0.158,CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625
6FVF,X-RAY DIFFRACTION,2.01,38.67,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2018-03-02,2019-06-19,6FVF,3023.0,1.0,328.0,163.0,,40.03,1.0,1.47,experimental,34.1,0.222,0.2,The Structure of CK2alpha with CCh503 bound
6FVG,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2018-03-02,2019-06-19,6FVG,3061.0,1.0,328.0,191.0,,39.98,1.0,1.6,experimental,36.46,0.229,0.206,The Structure of CK2alpha with CCh507 bound
6JWA,X-RAY DIFFRACTION,2.01,38.75,"VAPOR DIFFUSION, SITTING DROP",,ethylene glycol,277.0,2019-04-19,2019-07-24,6JWA,2963.0,1.0,340.0,157.0,,41.24,1.0,1.781,experimental,,0.2247,0.1848,Crystal structure of CK2a1 with 5-iodotubercidin
6RB1,X-RAY DIFFRACTION,2.0,38.54,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2019-04-08,2020-04-08,6RB1,3161.0,1.0,336.0,310.0,,40.94,1.0,1.5,experimental,24.5243,0.1902,0.1652,Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 1
6RCB,X-RAY DIFFRACTION,1.89,34.96,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2019-04-11,2020-04-08,6RCB,3035.0,1.0,336.0,224.0,,40.75,1.0,2.05,experimental,29.6263,0.2257,0.1895,Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 14
6RCM,X-RAY DIFFRACTION,1.98,38.01,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2019-04-11,2020-04-08,6RCM,3243.0,1.0,336.0,368.0,,40.86,1.0,1.7,experimental,25.3616,0.2012,0.1612,Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 3
6RFE,X-RAY DIFFRACTION,1.96,37.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2019-04-13,2020-04-08,6RFE,3221.0,1.0,336.0,361.0,,40.95,1.0,1.54,experimental,24.1756,0.1975,0.1716,Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 4
6RFF,X-RAY DIFFRACTION,1.87,34.09,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2019-04-14,2020-04-08,6RFF,3153.0,1.0,336.0,307.0,,40.9,1.0,1.8,experimental,27.6361,0.1988,0.1604,Human protein kinase CK2 alpha in complex with 2-cyano-2-propenamide compound 7
5F6L,X-RAY DIFFRACTION,2.24,45.01,"VAPOR DIFFUSION, SITTING DROP",6.9,"200mM NaCl, 20% PEG 3350",277.0,2015-12-06,2016-02-24,5F6L,3192.0,3.0,369.0,361.0,,42.55,3.0,1.9,experimental,21.4602,0.2131,0.1663,The crystal structure of MLL1 (N3861I/Q3867L) in complex with RbBP5 and Ash2L
5EDS,X-RAY DIFFRACTION,2.38,48.35,"VAPOR DIFFUSION, HANGING DROP",7.3,"20% PEG 3350, 0.1 M Tris (pH 7.3), 0.25 M ammonium sulfate, 2 mM DTT",298.0,2015-10-21,2015-12-30,5EDS,6736.0,1.0,959.0,15.0,,110.51,1.0,2.8,experimental,73.5,0.2733,0.2077,Crystal structure of human PI3K-gamma in complex with benzimidazole inhibitor 5
5U7L,X-RAY DIFFRACTION,2.23,44.96,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.1 M Tris, pH 8.5, and 0.2 M MgCl2",294.0,2016-12-12,2017-06-28,5U7L,8376.0,3.0,1035.0,181.0,,122.24,1.0,2.38,experimental,32.379,0.2813,0.2085,PDE2 catalytic domain complexed with inhibitors
4Z3V,X-RAY DIFFRACTION,2.29,46.34,"VAPOR DIFFUSION, HANGING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5, 0.12M alcohol mixture",277.0,2015-03-31,2015-07-01,4Z3V,2740.0,1.0,283.0,406.0,,33.27,1.0,1.6,experimental,17.847,0.1975,0.1646,Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinase
5VFI,X-RAY DIFFRACTION,2.3,46.62,VAPOR DIFFUSION,6.5,"PEG 5000 MME
ammonium sulfate
MES pH 6.5",300.0,2017-04-07,2018-02-28,5VFI,2706.0,1.0,271.0,281.0,,32.95,1.0,1.59,experimental,13.999,0.21576,0.18592,Bruton's tyrosine kinase (BTK) with GDC-0853
6BKE,X-RAY DIFFRACTION,2.09,41.2,VAPOR DIFFUSION,,"30% PEG 300, Li2SO4, pH 7.0",277.0,2017-11-08,2018-11-07,6BKE,2397.0,1.0,287.0,155.0,,34.71,1.0,1.95,experimental,,0.21,0.188,BTK complex with compound 10
6BKH,X-RAY DIFFRACTION,2.09,41.01,VAPOR DIFFUSION,7.0,"PEG 10000, Li2SO4, pH 7.0",277.0,2017-11-08,2018-11-07,6BKH,2442.0,1.0,287.0,205.0,,34.79,1.0,1.792,experimental,28.6707,0.2008,0.1524,BTK complex with compound 11
6J6M,X-RAY DIFFRACTION,2.27,45.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M MIB buffer pH7, 25% (w/v) PEG 1500",293.0,2019-01-15,2019-10-23,6J6M,2734.0,1.0,269.0,441.0,,31.89,1.0,1.25,experimental,,0.1637,0.1574,Co-crystal structure of BTK kinase domain with Zanubrutinib
6XE4,X-RAY DIFFRACTION,2.11,41.74,VAPOR DIFFUSION,7.0,"PEG 10000, Li2SO4, pH 7.0",291.0,2020-06-11,2020-07-22,6XE4,2498.0,1.0,287.0,276.0,,34.56,1.0,1.6,experimental,26.5849,0.1804,0.1577,"BTK Fluorocyclopropyl amide inhibitor, Compound 25"
7LTZ,X-RAY DIFFRACTION,2.34,47.45,"VAPOR DIFFUSION, SITTING DROP",,"0.1M BisTRIS pH 6.5, 0.2M Ammonium Acetate, 0.1M Guanidine HCl, 20% PEG2200 MME",277.0,2021-02-20,2022-01-12,7LTZ,2499.0,1.0,267.0,263.0,,32.02,1.0,1.53,experimental,20.16,0.2129,0.179,Bruton's tyrosine kinase in complex with compound 51
5UOR,X-RAY DIFFRACTION,3.16,61.01,"VAPOR DIFFUSION, SITTING DROP",6.0,"6% polyethylene glycol 2000 MME , 0.1M MES, pH 6.0",277.0,2017-02-01,2017-06-07,5UOR,4229.0,2.0,540.0,75.0,,61.91,1.0,2.75,experimental,74.263,0.2673,0.2022,Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure
5UOX,X-RAY DIFFRACTION,3.17,61.16,"VAPOR DIFFUSION, SITTING DROP",6.0,"6% polyethylene glycol 2000 MME ,0.05M Ammonium Sulphate, 0.1M MES, pH 6.0",277.0,2017-02-01,2017-06-07,5UOX,4225.0,2.0,542.0,70.0,,61.81,1.0,2.5,experimental,76.267,0.253,0.228,Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure
5UP3,X-RAY DIFFRACTION,3.17,61.17,"VAPOR DIFFUSION, SITTING DROP",6.0,"7% polyethylene glycol 2000 MME , 0.05M Ammonium Sulphate, 0.05M MES, pH 6.0",277.0,2017-02-01,2017-06-07,5UP3,4031.0,2.0,542.0,2.0,,61.66,1.0,2.95,experimental,79.935,0.2888,0.2417,Structure-Based Design of ASK1 Inhibitors as Potential First-in-Class Agents for Heart Failure
5VC4,X-RAY DIFFRACTION,2.19,43.9,"VAPOR DIFFUSION, HANGING DROP",6.9,"5.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM Bosutinib-isomer",291.0,2017-03-30,2017-08-23,5VC4,2185.0,1.0,289.0,67.0,,33.07,1.0,2.1,experimental,48.805,0.2415,0.1934,Crystal structure of HUMAN WEE1 KINASE domain in complex with Bosutinib-isomer
5VC5,X-RAY DIFFRACTION,2.11,41.73,"VAPOR DIFFUSION, HANGING DROP",6.9,"9.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM PD-166285",291.0,2017-03-31,2017-08-23,5VC5,2221.0,1.0,289.0,84.0,,33.19,1.0,1.93,experimental,47.1873,0.2169,0.1763,Crystal structure of human WEE1 kinase domain in complex with PD-166285
5VC6,X-RAY DIFFRACTION,2.21,44.22,"VAPOR DIFFUSION, HANGING DROP",6.9,"5.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM PHA-848125",291.0,2017-03-31,2017-08-23,5VC6,2193.0,1.0,289.0,94.0,,32.96,1.0,2.0,experimental,37.6689,0.2645,0.22,crystal structure of human WEE1 kinase domain in complex with PHA-848125
5VD2,X-RAY DIFFRACTION,2.07,40.44,"VAPOR DIFFUSION, HANGING DROP",6.9,"9.0 MG/ML WEE1, 25 mM Na/K phosphate, 1 mM DTT, 0.05 M ammonium sulfate, 0.05 M Bis-tris (pH 5.5), 7.5 % PEG 3350, 1 mM PF-03814735",291.0,2017-04-01,2017-08-23,5VD2,2146.0,1.0,289.0,49.0,,33.08,1.0,2.05,experimental,53.7988,0.2555,0.2034,crystal structure of human WEE1 kinase domain in complex with PF-03814735
7N3U,X-RAY DIFFRACTION,2.16,42.94,"VAPOR DIFFUSION, SITTING DROP",8.0,20% PEG 20K,291.15,2021-06-02,2021-09-01,7N3U,2146.0,1.0,285.0,28.0,,32.7,1.0,2.65,experimental,71.916,0.2668,0.2169,Crystal structure of human WEE1 kinase domain in complex with ZN-c3
7SE7,X-RAY DIFFRACTION,2.96,58.46,"VAPOR DIFFUSION, HANGING DROP",,2.75-3.3 M Sodium Formate,293.0,2021-09-30,2022-02-09,7SE7,2004.0,1.0,242.0,189.0,,27.08,1.0,1.75,experimental,26.75,0.2094,0.1789,Crystal structure of human Fibrillarin in complex with S-adenosyl-L-methionine
8HTC,X-RAY DIFFRACTION,2.05,39.96,"VAPOR DIFFUSION, HANGING DROP",6.25,"100 mM sodium cacodylate, pH 6.25, 200 mM sodium acetate, 22% PEG 8000",289.0,2022-12-21,2023-11-22,8HTC,2416.0,2.0,314.0,108.0,1.0,35.4,2.0,2.2,experimental,42.6331,0.2468,0.1919,Crystal structure of a SeMet-labeled effector from Chromobacterium violaceum in complex with Ubiquitin
8HTF,X-RAY DIFFRACTION,2.08,40.81,"VAPOR DIFFUSION, HANGING DROP",6.25,"100 mM sodium cacodylate, pH 6.25, 200 mM sodium acetate, 22% PEG 8000, 25% glycerol",289.0,2022-12-21,2023-11-22,8HTF,2460.0,2.0,314.0,138.0,1.0,35.73,2.0,2.151,experimental,39.117,0.2234,0.1726,Crystal structure of an effector in complex with ubiquitin
8OGA,X-RAY DIFFRACTION,3.13,60.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Tris pH 7.5, 1.66M Lithium acetate",293.0,2023-03-19,2023-06-14,8OGA,2520.0,1.0,318.0,57.0,,36.82,1.0,2.2,experimental,59.031,0.2086,0.1853,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 6
8OGB,X-RAY DIFFRACTION,2.74,55.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Tris pH 7.5, 2.13M Lithium acetate",293.0,2023-03-19,2023-06-14,8OGB,2689.0,1.0,367.0,233.0,,42.42,1.0,2.27,experimental,39.147,0.2125,0.1682,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 8
7APF,X-RAY DIFFRACTION,1.98,37.91,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% PEG 3350, 0.1-0.2 M MgCl2, 0.1 M MES, pH 5.5",277.15,2020-10-16,2020-12-02,7APF,5072.0,2.0,588.0,300.0,,68.22,1.0,1.95,experimental,33.379,0.2549,0.2035,Crystal structure of JAK3 in complex with FM601 (compound 10a)
7Z5N,X-RAY DIFFRACTION,2.91,57.76,"VAPOR DIFFUSION, SITTING DROP",,"0,1M TRIS pH 7.7, 0,1M Li2SO4, 40% PEG300",293.15,2022-03-09,2023-03-22,7Z5N,21926.0,8.0,2960.0,206.0,,353.44,1.0,2.77,experimental,84.9253,0.2516,0.205,Crystal structure of DYRK1A in complex with CX-4945
7QHL,X-RAY DIFFRACTION,3.15,60.99,"VAPOR DIFFUSION, SITTING DROP",8.5,"70%: 10% w/v PEG 4,000, 20% v/v glycerol, 0.03 M NaNO3, 0.03 M Na2HPO4, 0.03 M (NH4)2SO4, 0.1 M Tris/Bicine pH 8.5
30%:20% w/v PEG 6000, 0.1 M Bicine, pH 9",291.15,2021-12-13,2022-07-06,7QHL,9960.0,4.0,1114.0,969.0,,129.58,2.0,1.7,experimental,31.558,0.2236,0.2001,"Crystal structure of Cyclin-dependent kinase 2/cyclin A in complex with 3,5,7-Substituted pyrazolo[4,3-d]pyrimidine inhibitor 24"
4XEV,X-RAY DIFFRACTION,2.42,49.12,"VAPOR DIFFUSION, SITTING DROP",6.5,"The 4 ul drop contained 2 ul protein/LD4 peptide mixture (20 mM MES pH 6.2, 1 mM protein, and 2 mM peptide) and 2 ul well solution (100 mM MES pH 6.5 and 25 % PEG 3000).",291.2,2014-12-24,2015-12-30,4XEV,2579.0,4.0,372.0,71.0,,40.25,2.0,2.0073,experimental,,0.2502,0.2039,"Fusion of Pyk2-FAT domain with Leupaxin LD1 motif, complexed with Leupaxin LD4 peptide"
6AXQ,X-RAY DIFFRACTION,2.44,49.67,VAPOR DIFFUSION,8.2,"3.545 M Formate, 100 mM Tris-HCl pH 8.2, 10% glycerol",289.0,2017-09-07,2018-02-21,6AXQ,4415.0,4.0,456.0,511.0,,55.42,1.0,1.3,experimental,17.7644,0.2161,0.1998,CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate)
8EDY,X-RAY DIFFRACTION,2.49,50.69,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG3350, 200 mM lithium citrate, 10 uM GDP, 1 mM magnesium chloride, 2 mM DTT, 20 mM sodium chloride, 10 mM Tris-HCl, pH 8",293.15,2022-09-06,2023-09-20,8EDY,1706.0,1.0,185.0,217.0,,21.57,1.0,1.18,experimental,17.08,0.1718,0.1617,KRAS4b A146T 1-185 bound to GDP
4WNO,X-RAY DIFFRACTION,2.0,38.64,"VAPOR DIFFUSION, HANGING DROP",,"1.55 M sodium malonate pH 7.0,  0.35 M sodium malonate pH 5.0",298.0,2014-10-14,2015-01-14,4WNO,2408.0,1.0,287.0,161.0,,32.68,1.0,1.56,experimental,,0.2076,0.1784,Structure of ULK1 bound to an inhibitor
5U5T,X-RAY DIFFRACTION,2.25,45.42,"VAPOR DIFFUSION, HANGING DROP",,"Using a PEG/salt combination as a precipitant. Briefly, EED was incubated with 10 mM B-nicotinamide adenine dinucleotide hydrate, 2 mM of a tightly binding proprietary compound, and 0.5 mM of a synthesized peptide which comprises the helix on EZH2 which interacts with EED. The crystals were grown using the vapor diffusion method. One uL of the protein mixture was combined with 1 uL of a precipitant comprised of 20% (w/v) PEG3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5, on a cover slip which was  suspended over a reservoir comprised of 0.5 mL of precipitant at 18 Celsius and sealed. The crystals grew in 4-6 days at 18 Celsius and then harvested and soaked in defined drops consisting of 30 uL of precipitant and 2 mM of compound for 24 h. Crystals were cryopreserved for data collection using a cryosolution consisting of 30% PEG 400 (v/v), 20% (w/v) PEG 3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5",291.0,2016-12-07,2017-01-11,5U5T,7161.0,4.0,794.0,1033.0,,92.92,2.0,1.6,experimental,28.38,0.2,0.168,"Crystal structure of EED in complex with H3K27Me3 peptide and 3-(benzo[d][1,3]dioxol-4-ylmethyl)piperidine-1-carboximidamide"
5A2S,X-RAY DIFFRACTION,2.1,40.0,,,"24% W/V PEG 3350, 0.2 M AMMONIUM ACETATE, 0.1 M BIS-TRIS PH 5.5, 10 MM PROLINE",,2015-05-22,2016-02-10,5A2S,5783.0,2.0,790.0,87.0,,86.55,1.0,2.65,experimental,21.947,0.25647,0.18523,"Potent, selective and CNS-penetrant tetrasubstituted cyclopropane class IIa histone deacetylase (HDAC) inhibitors"
7AJV,X-RAY DIFFRACTION,2.39,48.45,"VAPOR DIFFUSION, SITTING DROP",5.6,"12% PEG3350, 0.2M ammonium sulphate, 0.05M Mg sulphate, 0.05M Na citrate buffer pH 5.6",293.0,2020-09-29,2021-05-26,7AJV,5763.0,2.0,718.0,302.0,,84.04,1.0,2.1,experimental,32.945,0.2193,0.1805,Structure of DYRK1A in complex with compound 38
7AJY,X-RAY DIFFRACTION,2.4,48.85,"VAPOR DIFFUSION, SITTING DROP",6.5,"30% PegMME 5k, 0.1M ammonium sulphate, 0.1M ADA buffer pH 6.5",293.0,2020-09-29,2021-05-26,7AJY,5671.0,2.0,718.0,274.0,,84.15,1.0,2.2,experimental,33.603,0.2251,0.1832,Structure of DYRK1A in complex with compound 51
7AKE,X-RAY DIFFRACTION,2.4,48.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG 3350, 0.1M Hepes buffer pH 7.5, 0.2M ammonium acetate",293.0,2020-09-30,2021-05-26,7AKE,5722.0,2.0,718.0,245.0,,84.24,1.0,2.3,experimental,34.217,0.2837,0.2275,Structure of DYRK1A in complex with compound 58
6NY4,X-RAY DIFFRACTION,2.37,48.15,"VAPOR DIFFUSION, HANGING DROP",5.8,"30% PEG3350, 200 mM magnesium chloride, 100 mM Bis-Tris, pH 5.8",293.0,2019-02-11,2019-05-22,6NY4,2189.0,1.0,293.0,49.0,,33.59,1.0,2.33,experimental,56.28,0.241,0.215,Crystal structure of JAK3 kinase domain in complex with a pyrrolopyridazine carboxamide inhibitor
6RLQ,X-RAY DIFFRACTION,2.98,58.71,"VAPOR DIFFUSION, HANGING DROP",7.0,"30-50% PEG3350, 150mM Ammonium Sulphate",278.0,2019-05-02,2020-07-15,6RLQ,7351.0,2.0,992.0,34.0,,111.7,2.0,2.53,experimental,33.542,0.2994,0.23,CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ45031882
6XA9,X-RAY DIFFRACTION,3.4,63.78,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M lithium sulfate, 25% PEG3350, 0.1 M Bis-Tris chloride, pH 6.5",293.0,2020-06-04,2020-06-17,6XA9,8969.0,6.0,1194.0,30.0,,135.95,2.0,2.9,experimental,102.03,0.2305,0.1997,SARS CoV-2 PLpro in complex with ISG15 C-terminal domain propargylamide
4QT1,X-RAY DIFFRACTION,2.24,45.02,"VAPOR DIFFUSION, HANGING DROP",6.0,"30% PEG 3350, 0.1M MES, 0.2M MgCl, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-07-07,2015-05-27,4QT1,2329.0,1.0,314.0,82.0,,35.99,1.0,2.4,experimental,32.143,0.27256,0.20696,"JAK3 kinase domain in complex with 1-[(3S)-1-isobutylsulfonyl-3-piperidyl]-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)urea"
5VO6,X-RAY DIFFRACTION,2.32,47.05,VAPOR DIFFUSION,,,300.0,2017-05-02,2017-05-31,5VO6,2166.0,1.0,293.0,17.0,,33.63,1.0,2.65,experimental,45.47,0.284,0.209,CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
5NXC,X-RAY DIFFRACTION,2.32,46.97,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M HEPES pH 7.0
0.2 M MgCl2
10% PEG8K",277.0,2017-05-10,2017-05-24,5NXC,2208.0,1.0,310.0,44.0,,36.41,1.0,2.25,experimental,28.185,0.29837,0.23911,LIM Domain Kinase 1 (LIMK1) In Complex With PF-00477736
5CSX,X-RAY DIFFRACTION,2.39,48.58,"VAPOR DIFFUSION, HANGING DROP",,PEG 3350,277.0,2015-07-23,2016-03-09,5CSX,2166.0,1.0,282.0,27.0,,32.78,1.0,2.51,experimental,33.445,0.2825,0.2174,CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
6J3B,X-RAY DIFFRACTION,3.68,66.57,"VAPOR DIFFUSION, HANGING DROP",,"HEPES pH4.6, 2M AMMONIUM SULPHATE, 30% Glycerol",293.0,2019-01-04,2019-08-21,6J3B,3397.0,1.0,366.0,327.0,,42.22,1.0,1.6,experimental,,0.1764,0.1566,Crystal structure of human DHODH in complex with inhibitor 1289
8EI5,X-RAY DIFFRACTION,2.47,50.17,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1M Sodium acetate, 0.1M sodium citrate pH6.0, 10% PEG4000",291.0,2022-09-14,2023-10-25,8EI5,13513.0,8.0,1580.0,319.0,,189.78,2.0,2.6,experimental,39.6568,0.262,0.2132,"Crystal structure of the WWP2 HECT domain in complex with H301, a Helicon Polypeptide"
5HZN,X-RAY DIFFRACTION,2.97,58.63,"VAPOR DIFFUSION, HANGING DROP",6.25,"25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL",293.0,2016-02-02,2016-04-06,5HZN,19906.0,8.0,2432.0,551.0,,282.32,1.0,2.2,experimental,45.611,0.2178,0.194,Structure of NVP-AEW541 in complex with IGF-1R kinase
5X4L,X-RAY DIFFRACTION,2.5,50.88,VAPOR DIFFUSION,,"0.2M Calcium acetate hydrate pH7.5, 20% v/v PEG 3350",289.0,2017-02-13,2017-03-22,5X4L,4204.0,4.0,520.0,211.0,,59.69,2.0,2.402,experimental,,0.2343,0.185,Crystal structure of the UBX domain of human UBXD7 in complex with p97 N domain
7OY6,X-RAY DIFFRACTION,2.56,52.03,"VAPOR DIFFUSION, HANGING DROP",6.4,"15-20% PEG1000, 50 mM Mes 6.4, 100 mM KCl",293.0,2021-06-23,2022-03-02,7OY6,2798.0,1.0,359.0,29.0,,42.23,1.0,2.38,experimental,63.943,0.2704,0.1981,Crystal structure of human DYRK1A in complex with ARN25068
6RLL,X-RAY DIFFRACTION,3.0,59.06,"VAPOR DIFFUSION, SITTING DROP",7.5,20-30% PEG3350; 150mM Ammonium Sulfate,277.0,2019-05-02,2020-06-03,6RLL,7408.0,2.0,993.0,94.0,,111.74,2.0,2.22,experimental,34.864,0.2911,0.2508,CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ44064146
7BO7,X-RAY DIFFRACTION,2.8,56.02,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, 150mM ammonium sulfate",277.15,2021-01-24,2022-03-02,7BO7,7411.0,2.0,993.0,52.0,,112.28,2.0,2.83,experimental,64.138,0.25,0.205,CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJB44355437
6OQL,X-RAY DIFFRACTION,2.35,47.63,EVAPORATION,6.0,"13-17% PEG 3350, 80 mM NH4NO3, 100 mM MES pH 6.0",292.0,2019-04-26,2020-07-29,6OQL,2116.0,1.0,291.0,4.0,,33.51,1.0,2.707,experimental,123.3085,0.2529,0.2036,"CDK6 in complex with Cpd13 (R)-5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine"
6OQO,X-RAY DIFFRACTION,2.63,53.22,EVAPORATION,7.5,"17 % w/v PEG 3,350, 100 mM HEPES, pH 7.5, 200 mM NaCl, 20 mM L-Glutathione",292.0,2019-04-26,2020-07-29,6OQO,2239.0,1.0,291.0,73.0,,33.53,1.0,1.977,experimental,73.8988,0.2641,0.2155,"CDK6 in complex with Cpd24 N-(5-(6-ethyl-2,6-diazaspiro[3.3]heptan-2-yl)pyridin-2-yl)-5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)pyrimidin-2-amine"
7LG8,X-RAY DIFFRACTION,2.11,41.66,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 30% (w/v) PEG 3350",293.0,2021-01-19,2022-02-23,7LG8,9222.0,4.0,1324.0,13.0,,155.38,1.0,2.93,experimental,61.2507,0.2696,0.2354,EGFR (T79M/V948R) in complex with naquotinib and an allosteric inhibitor
7KJS,X-RAY DIFFRACTION,2.9,57.58,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M MES pH 6, .18 M magnesium formate, and 9.0 % (w/v) PEG 20000",294.15,2020-10-26,2021-06-23,7KJS,4702.0,2.0,589.0,144.0,,68.38,2.0,2.187,experimental,61.3,0.2776,0.2281,Crystal structure of CDK2/cyclin E in complex with PF-06873600
5VLP,X-RAY DIFFRACTION,3.82,67.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"ammonium acetate, 1,8diaminooctane",292.0,2017-04-25,2017-08-16,5VLP,7814.0,4.0,1154.0,6.0,17.0,125.32,4.0,2.9,experimental,53.48,0.209,0.171,PCSK9 complex with LDLR antagonist peptide and Fab7G7
5LVN,X-RAY DIFFRACTION,2.16,42.95,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 0.01 M DTT",293.0,2016-09-14,2016-10-19,5LVN,2640.0,1.0,311.0,263.0,,35.85,1.0,1.379,experimental,,0.1623,0.1337,Human PDK1 Kinase Domain in Complex with Adenosine Bound to the ATP-Binding Site
7UY0,X-RAY DIFFRACTION,2.96,58.4,VAPOR DIFFUSION,7.5,"For co-crystallization with A-419259, Fgr (3.2 mg/mL in 20 mM Tris-HCl, pH 8.3, 100 mM NaCl, and 2 mM TCEP) was mixed with 10 mM A-419259 (in 50% DMSO) to a final inhibitor concentration of 120 microM (0.3% DMSO final) and incubated for 30 min at 298 K prior to crystallization setup.  Crystals were grown by sitting- and hanging-drop vapor diffusion at 277 K by mixing Fgr/A-419259 in a 1:1 ratio with the mother liquor (0.2 M sodium/potassium phosphate, 0.1 M Bis-Tris propane, pH 7.5, and 16% PEG 3350).  To promote crystal growth, crystal seeds from initial needle-like crystals were added to the crystallization drops",277.0,2022-05-06,2022-12-28,7UY0,7349.0,2.0,912.0,50.0,,106.13,2.0,2.55,experimental,71.1545,0.2229,0.1865,Crystal structure of human Fgr tyrosine kinase in complex with A-419259
6VN6,X-RAY DIFFRACTION,2.5,50.87,VAPOR DIFFUSION,,,277.0,2020-01-29,2020-04-29,6VN6,5538.0,2.0,700.0,,1.0,82.1,1.0,2.99,experimental,99.577,0.2666,0.2194,USP7 IN COMPLEX WITH LIGAND COMPOUND 14
6HFA,X-RAY DIFFRACTION,1.8,31.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"90 mM HEPES, 1.26 M Na Citrate, 10% glycerol. Cryo: +30% Glycerol",298.0,2018-08-21,2020-07-08,6HFA,1647.0,4.0,218.0,65.0,,25.25,2.0,1.79,experimental,37.7329,0.2384,0.1908,Crystal structure of hDM2 in complex with a C-terminal triurea capped peptide chimera foldamer.
6MM1,X-RAY DIFFRACTION,2.5,50.73,"VAPOR DIFFUSION, SITTING DROP",,"0.2M potassium sodium tartrate
18% PEG 3350
0.1M HEPES, pH 8.0",277.0,2018-09-28,2019-10-02,6MM1,4629.0,4.0,544.0,525.0,,60.98,1.0,1.9,experimental,,0.223,0.174,Structure of the cysteine-rich region from human EHMT2
7KK3,X-RAY DIFFRACTION,2.56,52.04,VAPOR DIFFUSION,,"Buffer: 0.1 M Sodium Citrate (pH 5.60)
Salt: 1.0 M ammonium formate
Precipitant: 23.0 %w/v PEG 4000",294.0,2020-10-27,2021-01-06,7KK3,10984.0,4.0,1408.0,281.0,2.0,158.89,1.0,2.06,experimental,60.67,0.259,0.213,Structure of the catalytic domain of PARP1 in complex with talazoparib
6L5M,X-RAY DIFFRACTION,2.45,49.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"19% pEG3350, 0.18M ammonium citrate, 40mM myo-inositol",277.0,2019-10-24,2020-06-17,6L5M,14643.0,5.0,1885.0,58.0,,213.15,1.0,2.7,experimental,25.7,0.257,0.207,Crystal structure of human DEAD-box RNA helicase DDX21 in complex with AMP
7JWE,X-RAY DIFFRACTION,2.32,46.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM Tris pH 7.5, 250 mM (NH4)2SO4 and 20-22% PEG 4000",298.0,2020-08-25,2021-03-17,7JWE,6666.0,1.0,966.0,9.0,,111.34,1.0,2.55,experimental,88.8962,0.2529,0.209,Gedatolisib bound to the PI3Kg catalytic subunit p110 gamma
7JWZ,X-RAY DIFFRACTION,2.35,47.58,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM Tris pH 7.5, 250 mM (NH4)2SO4 and 20-22% PEG 4000",298.0,2020-08-26,2021-03-17,7JWZ,6792.0,1.0,966.0,,,111.26,1.0,2.65,experimental,100.3663,0.268,0.2272,IPI-549 bound to the PI3Kg catalytic subunit p110 gamma
5DNR,X-RAY DIFFRACTION,3.61,65.96,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM HEPES, 200 mM magnesium sulfate, 2-20% PEG 3350",292.0,2015-09-10,2016-07-20,5DNR,2354.0,1.0,272.0,120.0,,32.19,1.0,1.95,experimental,40.296,0.22552,0.2055,Aurora A Kinase in complex with ATP in space group P41212
5DRD,X-RAY DIFFRACTION,2.66,53.74,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292.0,2015-09-15,2016-07-20,5DRD,2152.0,1.0,273.0,,,32.34,1.0,2.13,experimental,59.809,0.26163,0.20592,Aurora A Kinase in Complex with ATP in Space Group P6122
5DT3,X-RAY DIFFRACTION,2.75,55.34,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20 % PEG3350",292.0,2015-09-17,2016-07-20,5DT3,2285.0,1.0,273.0,80.0,,32.55,1.0,2.33,experimental,73.91,0.2433,0.2081,Aurora A Kinase in Complex with ATP in Space Group P6122
8C6L,X-RAY DIFFRACTION,1.98,37.84,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2023-01-12,2024-04-24,8C6L,3187.0,1.0,336.0,356.0,,40.79,1.0,1.8,experimental,26.1634,0.209,0.1642,Human protein kinase CK2 alpha in complex with CK2-TN01
8C6M,X-RAY DIFFRACTION,2.0,38.5,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2023-01-12,2024-04-24,8C6M,3232.0,1.0,336.0,404.0,,40.69,1.0,1.8,experimental,23.9737,0.2021,0.1594,Human protein kinase CK2 alpha in complex with CK2-TN02
8C6N,X-RAY DIFFRACTION,1.99,38.34,"VAPOR DIFFUSION, SITTING DROP",8.5,"32% PEG4000, 0.2 M Lithium Sulfate",293.0,2023-01-12,2024-04-24,8C6N,3056.0,1.0,336.0,235.0,,40.77,1.0,2.05,experimental,29.4105,0.2182,0.1785,Human protein kinase CK2 alpha in complex with CK2-TN03
6DQ8,X-RAY DIFFRACTION,2.23,44.77,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2018-11-21,6DQ8,2773.0,1.0,330.0,253.0,,39.18,1.0,1.46,experimental,,0.21,0.186,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N49 i.e. 2-((2-chlorophenyl)(2-(1-methylpyrrolidin-2-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid"
6IPZ,X-RAY DIFFRACTION,2.22,44.62,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.08M Sodium acetate trihydrate pH 4.6, 1.6M Ammonium sulfate, 20%(v/v)  Glycerol",295.0,2018-11-05,2018-11-28,6IPZ,571.0,1.0,70.0,23.0,,8.38,1.0,1.576,experimental,49.1487,0.2088,0.1902,"Fyn SH3 domain R96W mutant, crystallized with 18-crown-6"
5KA1,X-RAY DIFFRACTION,2.47,50.21,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.1 M HEPES, pH 7.4, 0.2 M MgCl2, 18% PEG8000",277.0,2016-06-01,2017-03-01,5KA1,2559.0,1.0,289.0,200.0,,34.78,1.0,1.84,experimental,25.1847,0.1946,0.166,"Protein Tyrosine Phosphatase 1B Delta helix 7 mutant in complex with TCS401, closed state"
8EIE,X-RAY DIFFRACTION,2.23,44.74,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% PEG4000, 0.2 M sodium acetate, 0.1 M Tris-HCl pH 8.5, 20 mM sodium chloride, 1 mM magnesium chloride, 2 mM DTT, 2 mM GNP, 15 mg/ml KRAS K117N",293.15,2022-09-14,2023-09-20,8EIE,1495.0,1.0,185.0,108.0,,21.63,1.0,1.41,experimental,26.05,0.205,0.1817,KRAS4b K117N 1-185 bound to GNP-Mg2+
8T2H,X-RAY DIFFRACTION,2.27,45.86,"VAPOR DIFFUSION, HANGING DROP",6.0,"1.8 M sodium malonate, 1.3% PEG 400",298.0,2023-06-06,2024-05-15,8T2H,6053.0,2.0,730.0,354.0,,86.18,1.0,1.85,experimental,21.451,0.21303,0.16329,DYRK1A complex with DYR530
5L6E,X-RAY DIFFRACTION,2.24,45.19,"VAPOR DIFFUSION, HANGING DROP",,"22 % PEG 3350, 300 mM Mg acetate",293.0,2016-05-29,2016-10-12,5L6E,3933.0,2.0,516.0,358.0,1.0,59.86,2.0,1.901,experimental,,0.183,0.1572,Crystal structure of the human METTL3-METTL14 complex bound to SAM
6W7O,X-RAY DIFFRACTION,2.29,46.27,"VAPOR DIFFUSION, SITTING DROP",6.7,"50 mM ammonium sulfate,
100 mM Bis-Tris pH 6.7,
29% PE15/4",298.0,2020-03-19,2020-11-18,6W7O,6242.0,4.0,752.0,405.0,,89.16,2.0,2.17,experimental,35.9,0.24,0.196,Ternary complex structure - BTK cIAP compound 17
4ZY4,X-RAY DIFFRACTION,2.4,48.74,"VAPOR DIFFUSION, SITTING DROP",8.0,"25% PEG 3500, 0.2M Ammonium Sulfate and 0.1M Tris pH 8",292.0,2015-05-21,2015-07-01,4ZY4,4605.0,2.0,602.0,57.0,1.0,68.03,1.0,2.6,experimental,,0.2482,0.1921,Crystal structure of P21 activated kinase 1 in complex with an inhibitor compound 4
8XX1,X-RAY DIFFRACTION,3.73,67.01,"VAPOR DIFFUSION, SITTING DROP",,"1.1M Sodium malonate dibasic monohydrate, 0.1M HEPES pH 7, 0.5% v/v Jeffamine ED2003",293.0,2024-01-17,2024-03-06,8XX1,2596.0,1.0,318.0,207.0,,36.72,1.0,2.55,experimental,35.866,0.2454,0.1661,The Crystal Structure of MAPKAP kinase 2 domain from Biortus
8K5V,X-RAY DIFFRACTION,2.33,47.16,VAPOR DIFFUSION,,"25% w/v Polyethylene glycol 1500, 100mM SPG buffer pH5.0",293.0,2023-07-24,2023-12-06,8K5V,3951.0,2.0,484.0,211.0,,55.25,1.0,1.7,experimental,36.249,0.21665,0.1782,Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor
8K5W,X-RAY DIFFRACTION,2.25,45.32,VAPOR DIFFUSION,,"25% w/v Polyethylene glycol 1500, 100mM SPG buffer pH5.0",293.0,2023-07-24,2023-12-06,8K5W,3741.0,2.0,484.0,128.0,,55.87,1.0,2.0,experimental,36.422,0.27272,0.22488,Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor
8K5X,X-RAY DIFFRACTION,2.25,45.37,VAPOR DIFFUSION,,"25% w/v Polyethylene glycol 1500, 100mM SPG buffer pH5.0",293.0,2023-07-24,2023-12-06,8K5X,4039.0,2.0,484.0,287.0,,55.65,1.0,1.9,experimental,17.304,0.20643,0.17301,Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor
8K5Y,X-RAY DIFFRACTION,2.34,47.38,VAPOR DIFFUSION,,"25% w/v Polyethylene glycol 1500, 100mM SPG buffer pH5.0",293.0,2023-07-24,2023-12-06,8K5Y,4037.0,2.0,484.0,273.0,,55.71,1.0,1.52,experimental,22.724,0.19788,0.17617,Crystal structure of human proMMP-9 catalytic domain in complex with inhibitor
5L6O,X-RAY DIFFRACTION,2.26,45.58,"VAPOR DIFFUSION, SITTING DROP",8.5,"1,4-dioxane, Tris buffer, magnesium chloride",293.0,2016-05-30,2016-08-10,5L6O,2187.0,1.0,298.0,94.0,,34.12,1.0,1.88,experimental,68.56,0.206,0.189,EphB3 kinase domain covalently bound to an irreversible inhibitor (compound 3)
5L6P,X-RAY DIFFRACTION,2.52,51.28,"VAPOR DIFFUSION, SITTING DROP",8.5,"1,4-dioxane, Tris buffer, magnesium chloride",293.0,2016-05-30,2016-08-10,5L6P,2226.0,1.0,298.0,77.0,,34.13,1.0,2.26,experimental,55.84,0.232,0.205,EphB3 kinase domain covalently bound to an irreversible inhibitor (compound 6)
6NBW,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"15% PEG 3350, 50mM MES pH6.2, 50mM NH4NO3",290.0,2018-12-10,2020-01-29,6NBW,5593.0,3.0,749.0,204.0,,84.8,3.0,2.5,experimental,43.413,0.2086,0.1779,Ternary Complex of Beta/Gamma-Actin with Profilin and AnCoA-NAA80
5NN8,X-RAY DIFFRACTION,3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.9 M ammonium sulphate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293.0,2017-04-08,2017-10-25,5NN8,7292.0,1.0,872.0,290.0,5.0,102.41,1.0,2.45,experimental,30.355,0.21231,0.17422,"Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with acarbose"
7P2Z,X-RAY DIFFRACTION,3.4,63.0,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.9 M AMMONIUM SULPHATE, 0.1 M HEPES     
REMARK 280  PH 7.0, 2% V/V PEG400",293.0,2021-07-06,2022-07-13,7P2Z,7791.0,2.0,1744.0,778.0,5.0,198.27,1.0,1.85,experimental,28.703,0.1753,0.1485,"Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with cyclosulfamidate 4"
6UXX,X-RAY DIFFRACTION,2.86,56.99,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M sodium citrate pH 6.0, 0.2 M sodium acetate, 10-12% PEG 4000",277.0,2019-11-08,2020-08-19,6UXX,7355.0,2.0,995.0,57.0,,111.98,2.0,2.69,experimental,91.35,0.277,0.259,PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 1a
7KIB,X-RAY DIFFRACTION,2.86,57.06,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M sodium citrate pH 6.0, 0.2 M sodium acetate, 10-12% PEG 4000",277.0,2020-10-23,2021-04-21,7KIB,7922.0,2.0,995.0,424.0,1.0,113.08,2.0,2.52,experimental,66.74,0.245,0.193,"PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 4"
7KIC,X-RAY DIFFRACTION,2.88,57.32,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium citrate pH 6.0, 0.2 M sodium acetate, 10-12% PEG 4000",277.0,2020-10-23,2021-04-21,7KIC,7829.0,2.0,995.0,327.0,1.0,112.51,2.0,2.43,experimental,45.31,0.263,0.217,"PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 34"
7KID,X-RAY DIFFRACTION,2.89,57.45,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium citrate pH 6.0, 0.2 M sodium acetate, 10-12% PEG 4000",277.0,2020-10-23,2021-04-21,7KID,7750.0,2.0,995.0,260.0,1.0,112.36,2.0,2.5,experimental,47.8,0.279,0.259,"PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 72"
7S1P,X-RAY DIFFRACTION,2.66,53.7,VAPOR DIFFUSION,,"100 mM Sodium Citrate pH 5.4, 15% PEG 3350, 4% Tacsimate pH 5",281.0,2021-09-02,2022-03-16,7S1P,7342.0,2.0,995.0,130.0,,112.01,2.0,2.21,experimental,39.62,0.2498,0.2089,PRMT5/MEP50 crystal structure with sinefungin bound
7SER,X-RAY DIFFRACTION,2.88,57.34,VAPOR DIFFUSION,,"100 mM Sodium Citrate pH 5.4, 12% PEG 3350, 4% Tascimate pH 5",291.0,2021-10-01,2022-01-26,7SER,7648.0,2.0,995.0,231.0,,112.34,2.0,2.14,experimental,55.14,0.2526,0.2056,PRMT5/MEP50 with compound 30 bound
7SES,X-RAY DIFFRACTION,2.9,57.59,VAPOR DIFFUSION,,"100 mM Sodium Citrate pH 5, 10% PEG 4K, 50 mM Sodium Acetate (pH 7)",291.0,2021-10-01,2022-01-26,7SES,7464.0,2.0,995.0,46.0,,112.33,2.0,2.5,experimental,63.48,0.2449,0.2098,PRMT5/MEP50 with compound 29 bound
7A4Q,X-RAY DIFFRACTION,1.99,38.23,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2020-08-20,2022-06-08,7A4Q,2984.0,1.0,327.0,181.0,,39.23,1.0,1.42,experimental,23.84,0.22,0.195,The Crystal structure of RO4613269 bound to CK2alpha
7ZWE,X-RAY DIFFRACTION,2.0,38.43,VAPOR DIFFUSION,6.5,"112.5mM Mes, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-19,2023-05-31,7ZWE,2983.0,1.0,327.0,175.0,,39.37,1.0,1.47,experimental,22.9,0.226,0.194,The Crystal structure of GW8695 bound to CK2alpha
7ZWG,X-RAY DIFFRACTION,1.99,38.15,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-19,2023-05-31,7ZWG,3082.0,1.0,328.0,236.0,,39.61,1.0,1.31,experimental,24.7142,0.2027,0.1881,The Crystal structure of RO4493940 bound to CK2alpha
4PTG,X-RAY DIFFRACTION,3.05,59.61,VAPOR DIFFUSION,,"GSK-3   was mixed with a 10-fold molar excess of compound (1 mM final concentration). Crystals were grown at 20  C by vapor diffusion in the presence of 22% PEG 3350 and 3.0% w/v methanol. Crystals would nucleate within 1-3 days and continued to grow for an addition 5-10 days before harvesting., VAPOR DIFFUSION, temperature 293K",293.0,2014-03-10,2015-04-08,4PTG,5263.0,2.0,882.0,182.0,,99.22,1.0,2.361,experimental,,0.211,0.171,Structure of a carboxamine compound (26) (2-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) to GSK3b
6BFN,X-RAY DIFFRACTION,2.27,45.84,EVAPORATION,,"20% PEG3350, 0.2 M calcium chloride, 0.1 M HEPES, pH 7.0",289.0,2017-10-26,2017-12-06,6BFN,4912.0,2.0,684.0,156.0,,76.31,1.0,2.26,experimental,,0.2269,0.184,Crystal structure of human IRAK1
5MTM,X-RAY DIFFRACTION,3.81,67.72,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES pH6.5, 15 % PEG 20000",291.0,2017-01-10,2017-04-05,5MTM,1588.0,2.0,211.0,32.0,,23.41,2.0,2.405,experimental,,0.2568,0.2054,Monobody Mb(Lck_3) bound to Lck-SH2 domain
5MTN,X-RAY DIFFRACTION,5.32,76.88,"VAPOR DIFFUSION, HANGING DROP",,"0,2M Lithium sulfate / 0.1M TRIS pH8.5 / 10% PEG8K + 10%PEG1K",291.0,2017-01-10,2017-04-05,5MTN,1439.0,2.0,211.0,,,23.49,2.0,2.85,experimental,78.567,0.26503,0.22751,Monobody Mb(Lck_1) bound to Lck-Sh2
5VR3,X-RAY DIFFRACTION,2.58,52.44,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 2.0 M ammonium sulphate",293.15,2017-05-10,2018-02-14,5VR3,510.0,1.0,88.0,13.0,,9.64,1.0,2.102,experimental,,0.2244,0.2095,Crystal structure of the BRS domain of BRAF
6A32,X-RAY DIFFRACTION,1.93,36.36,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Bis-Tris pH 5.5, 27% PEG 3350",293.0,2018-06-14,2019-06-19,6A32,2794.0,1.0,356.0,93.0,,40.6,1.0,1.87,experimental,,0.24,0.2037,Crystal structure of PDGFRA kinase domain mutant T674I
6JOJ,X-RAY DIFFRACTION,3.99,69.18,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES pH6.9, 1.6M (NH4)2SO4, 0.1M NaCl",293.0,2019-03-22,2020-03-25,6JOJ,2785.0,1.0,356.0,35.0,,41.47,1.0,2.6,experimental,,0.2334,0.2235,Crystal structure of PDGFRA T674I in complex with crenolanib by soaking
6MJU,X-RAY DIFFRACTION,2.72,54.84,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.064 M sodium citrate 7.0, 0.1 M HEPES, pH 7.0, 10% PEG5000MME",293.0,2018-09-22,2019-05-29,6MJU,2774.0,1.0,372.0,26.0,,43.92,1.0,2.45,experimental,,0.2563,0.2224,human cGAS catalytic domain bound with the inhibitor G108
6MJW,X-RAY DIFFRACTION,2.71,54.55,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.064 M sodium citrate 7.0, 0.1 M HEPES, pH 7.0, 10% PEG5000MME",293.0,2018-09-23,2019-05-29,6MJW,2775.0,1.0,372.0,45.0,,43.94,1.0,2.405,experimental,,0.2572,0.2128,human cGAS catalytic domain bound with the inhibitor G150
6MJX,X-RAY DIFFRACTION,2.23,44.73,"VAPOR DIFFUSION, HANGING DROP",9.0,"0.1M Bicine 8.5, 10% PEG6000, final PH 9.0",293.0,2018-09-23,2019-05-29,6MJX,2801.0,1.0,372.0,,,44.23,1.0,2.6,experimental,,0.265,0.2212,human cGAS catalytic domain bound with cGAMP
4WV1,X-RAY DIFFRACTION,2.52,51.18,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, potassium nitrate",292.0,2014-11-04,2015-09-16,4WV1,8371.0,6.0,1086.0,149.0,10.0,118.29,3.0,2.362,experimental,,0.2441,0.1983,Crystal structure of the FGFR2 D2 domain in complex with Fab 2B.1.3
5IVC,X-RAY DIFFRACTION,2.22,44.53,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-20,2016-07-27,5IVC,2789.0,1.0,330.0,278.0,,38.63,1.0,1.573,experimental,,0.1839,0.1659,"Linked KDM5A Jmj Domain Bound to the Inhibitor N3 (4'-[(2-phenylethyl)carbamoyl][2,2'-bipyridine]-4-carboxylic acid)"
5IW0,X-RAY DIFFRACTION,2.24,45.09,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-21,2016-07-27,5IW0,2700.0,1.0,330.0,218.0,,38.8,1.0,1.63,experimental,,0.1918,0.1571,Linked KDM5A Jmj Domain Bound to the Inhibitor N19 [2-(5-((4-chloro-2-methylbenzyl)oxy)-1H-pyrazol-1-yl)isonicotinic acid]
6BGX,X-RAY DIFFRACTION,2.19,43.74,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BGX,2638.0,1.0,330.0,172.0,,38.74,1.0,1.882,experimental,,0.2356,0.1986,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)((4,4-difluorocyclohexyl)methoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid(Compound N42)"
6BGZ,X-RAY DIFFRACTION,2.24,45.1,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BGZ,2582.0,1.0,330.0,207.0,,38.59,1.0,1.688,experimental,,0.197,0.1865,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(2-(1-methyl-1H-imidazol-2-yl)ethoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N47)"
6BH2,X-RAY DIFFRACTION,2.26,45.58,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BH2,2577.0,1.0,330.0,207.0,,38.78,1.0,1.447,experimental,,0.2054,0.1883,LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR (R)-N-(1-(3-isopropyl-1H-pyrazole-5-carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide (Compound N54)
6BH5,X-RAY DIFFRACTION,2.21,44.41,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BH5,2638.0,1.0,330.0,236.0,,38.83,1.0,1.651,experimental,,0.216,0.1952,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 2-((2-chlorophenyl)(3-(piperidin-1-yl)propoxy)methyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid (Compound N48)"
5C9V,X-RAY DIFFRACTION,3.63,66.1,"VAPOR DIFFUSION, SITTING DROP",5.6,"1.8 M lithium sulphate, 0.01 M MgCl2, 0.05 M MES pH 5.6",291.0,2015-06-29,2015-07-22,5C9V,2486.0,1.0,330.0,81.0,,38.27,1.0,2.35,experimental,54.3,0.2287,0.1983,Structure of human Parkin G319A
6NID,X-RAY DIFFRACTION,1.94,36.73,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.01M tri-sodium citrate
33% (w/v) PEG 6000",291.0,2018-12-27,2020-01-01,6NID,2472.0,6.0,294.0,211.0,,34.37,2.0,1.86,experimental,,0.2396,0.1918,Crystal structure of a human calcium/calmodulin dependent serine protein kinase (CASK) PDZ domain in complex with Neurexin-1 peptide
5IXC,X-RAY DIFFRACTION,2.4,48.7,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES (pH 6.0-6.2), 50 mM sodium acetate, and 10-14% (v/v) PEG20K",277.0,2016-03-23,2016-06-08,5IXC,10961.0,2.0,1628.0,71.0,2.0,184.4,1.0,2.65,experimental,65.842,0.25068,0.23659,Human GIVD cytosolic phospholipase A2 in complex with Methyl gamma-Linolenyl Fluorophosphonate
5D3F,X-RAY DIFFRACTION,2.29,46.25,"VAPOR DIFFUSION, HANGING DROP",6.5,"HEPES, NaCl, DTT, PEG6000",277.0,2015-08-06,2016-03-16,5D3F,3652.0,3.0,488.0,,,56.57,2.0,2.74,experimental,,0.3026,0.2457,Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768 and stabilizer fusicoccin-A
8INL,X-RAY DIFFRACTION,3.63,66.16,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M MES (pH 6.5), 0.2M diammonium tartrate, 0.0005M TCEP, 14% PEG 3350",293.0,2023-03-10,2024-03-13,8INL,5251.0,1.0,669.0,57.0,,76.01,1.0,2.62,experimental,86.91,0.2159,0.1796,LSD1 in complex with S2172
6CRF,X-RAY DIFFRACTION,2.69,54.28,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES pH 6.5, 12% PEG 20,000, and 5% Sucrose",293.15,2018-03-17,2018-11-07,6CRF,7169.0,2.0,1052.0,208.0,,120.7,1.0,2.62,experimental,71.95,0.237,0.198,Crystal Structure of Shp2 E76K GOF Mutant in the Open Conformation
6CRG,X-RAY DIFFRACTION,2.23,44.81,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 8.5, 30% PEG 4000, and 0.2 M LiSO4",293.15,2018-03-17,2018-11-07,6CRG,7793.0,2.0,1052.0,92.0,,122.18,1.0,2.75,experimental,63.41,0.25,0.196,Crystal Structure of Shp2 E76K GOF Mutant in complex with SHP099
6BSM,X-RAY DIFFRACTION,3.83,67.92,VAPOR DIFFUSION,,"5% PEG3350, 200 mM KSCN, 10mM spermadine",277.0,2017-12-04,2018-08-08,6BSM,1744.0,1.0,201.0,107.0,3.0,23.46,1.0,2.33,experimental,57.112,0.2245,0.1923,BMP1 complexed with a reverse hydroxamate - compound 4
6CT9,X-RAY DIFFRACTION,3.2,61.54,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES-NaOH pH 7.0, 1.4 M sodium citrate",291.0,2018-03-22,2018-07-18,6CT9,3555.0,3.0,401.0,103.0,,53.35,1.0,2.26,experimental,,0.2282,0.1993,Structure of the human cGAS-DNA complex
6KGQ,X-RAY DIFFRACTION,3.73,67.05,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES (pH 7.5), 5% MPD, 3.5-4.0% PEG MME 2000",293.0,2019-07-12,2020-03-25,6KGQ,5340.0,1.0,669.0,164.0,,75.53,1.0,2.32,experimental,65.97,0.1969,0.1682,LSD1-FCPA-MPE five-membered ring adduct model
6KGR,X-RAY DIFFRACTION,3.73,67.05,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES (pH 7.5), 5% MPD, 3.5-4.0% PEG MME 2000",293.0,2019-07-12,2020-03-25,6KGR,5340.0,1.0,669.0,164.0,,75.53,1.0,2.32,experimental,66.02,0.1983,0.1682,LSD1-FCPA-MPE N5 adduct model
5OY6,X-RAY DIFFRACTION,2.4,48.78,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.3M magnesium formate, 0.1M bis-tris pH 5.5",277.0,2017-09-07,2017-09-27,5OY6,9043.0,4.0,1204.0,70.0,2.0,139.6,1.0,2.56,experimental,,0.2425,0.2111,Crystal structure of the ACVR1 (ALK2) kinase in complex with cyclical inhibitor OD36.
5FHT,X-RAY DIFFRACTION,2.49,50.58,"VAPOR DIFFUSION, SITTING DROP",,"MES, NaCl, KH2PO4, NaH2PO4",293.0,2015-12-22,2016-09-07,5FHT,2499.0,1.0,334.0,200.0,,36.53,1.0,1.95,experimental,34.372,0.22753,0.17488,HtrA2 protease mutant V226K
7X4H,X-RAY DIFFRACTION,1.94,36.49,"VAPOR DIFFUSION, SITTING DROP",,ethylene glycol,277.0,2022-03-02,2023-01-18,7X4H,3189.0,1.0,340.0,330.0,,41.03,1.0,1.77,experimental,15.14,0.2076,0.1686,Crystal structure of CK2a1 complexed with AG1112
6LLX,X-RAY DIFFRACTION,2.71,54.64,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES PH5.8 ,30% PEG6000 ,10mM DTT",293.0,2019-12-24,2020-11-25,6LLX,3837.0,2.0,430.0,426.0,,48.79,1.0,1.581,experimental,11.7893,0.2229,0.2001,Discovery of A Dual Inhibitor of NQO1 and GSTP1 for Treating Malignant Glioblastoma
6IBD,X-RAY DIFFRACTION,2.15,42.77,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M bis-tris, 14% (w/v) PEG 2000 MME, 12% (w/v) PEG 3350",293.0,2018-11-29,2019-01-16,6IBD,4116.0,1.0,463.0,374.0,,52.88,1.0,1.48,experimental,19.726,0.20054,0.17309,The Phosphatase and C2 domains of Human SHIP1
6NJI,X-RAY DIFFRACTION,2.44,49.66,"VAPOR DIFFUSION, SITTING DROP",7.14,"5.0MG/ML VCID7620 + 0.5MM T-049
 1MM DTT, 0.1MM ZNCL2, 0.1MM MGCL2 (BATCH 1214023) AGAINST
 OPTIMIZATION MATRIX BASED ON CONDITION MORPHEUS C8, 47.47%V/V
 OF 2X MORPHEUS-PPT4 (FINAL = 11.8% W/V PEG1,000 , 11.8% W/V
 PEG3,350 , 11.8% W/V MPD), 0.03M NPS (SODIUM NITRATE, DISODIUM
 HYDROGEN PHOSPHATE, AMMONIUM SULFATE), 0.1M HEPES PH 7.14,
 CRYO-PROTECTED - DIRECT (ZQV4-6); TRAY ID 236552B5, VAPOR
 DIFFUSION, SITTING DROP, TEMPERATURE 289K",289.0,2019-01-03,2019-05-08,6NJI,5333.0,2.0,740.0,69.0,,86.08,1.0,2.45,experimental,50.86,0.23,0.184,Crystal Structure of the PDE4D Catalytic Domain and UCR2 Regulatory Helix with T-49
6RU8,X-RAY DIFFRACTION,2.31,46.81,"VAPOR DIFFUSION, SITTING DROP",,"10-20% PEG 3350, 0.1-0.2 M sodium sulfate and 0.1 M citrate, pH 4.6-5.9",277.15,2019-05-27,2020-05-13,6RU8,10612.0,8.0,1232.0,525.0,,146.34,2.0,1.92,experimental,37.523,0.2106,0.1718,Crystal structure of Casein Kinase I delta (CK1d) in complex with triple phosphorylated p63 PAD3P peptide
5A4E,X-RAY DIFFRACTION,2.5,51.0,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M KCL; 14% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2015-06-08,2016-06-29,5A4E,10499.0,4.0,1472.0,90.0,2.0,171.51,1.0,2.68,experimental,57.057,0.26784,0.23577,DYRK1A in complex with methoxy benzothiazole fragment
6U7G,X-RAY DIFFRACTION,2.96,58.41,"VAPOR DIFFUSION, HANGING DROP",6.5,"9% PEG8000, 1 mM oxidized glutathione, 1 mM reduced glutathione, 5% glycerol, 100 mM MES, pH 6.5",298.0,2019-09-02,2019-11-13,6U7G,17357.0,4.0,2102.0,801.0,10.0,243.44,2.0,2.35,experimental,43.2781,0.2184,0.1786,HCoV-229E RBD Class V in complex with human APN
7LZ5,X-RAY DIFFRACTION,2.66,53.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 3350, 0.2 M ammonium sulfate, 0.1 M HEPES",293.0,2021-03-09,2022-03-16,7LZ5,1584.0,1.0,169.0,131.0,,19.8,1.0,1.5,experimental,17.24,0.1791,0.1639,Crystal structure of oncogenic KRAS Q61E GMPPCP-bound
4RVK,X-RAY DIFFRACTION,2.5,50.85,"VAPOR DIFFUSION, SITTING DROP",7.4,"HEPES, isopropanol, PEG 8000, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K",292.0,2014-11-26,2015-06-03,4RVK,2253.0,1.0,298.0,84.0,,34.53,1.0,1.85,experimental,25.424,0.29882,0.25306,"CHK1 kinase domain with diazacarbazole compound 8: N-[3-(6-cyano-9H-pyrrolo[2,3-b:5,4-c']dipyridin-3-yl)phenyl]acetamide"
4RVL,X-RAY DIFFRACTION,2.49,50.54,"VAPOR DIFFUSION, SITTING DROP",7.4,"HEPES, isopropanol, PEG 8000, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K",292.0,2014-11-26,2015-06-03,4RVL,2272.0,1.0,298.0,149.0,,34.49,1.0,1.85,experimental,30.096,0.21559,0.18242,"CHK1 kinase domain with diazacarbazole compound 7: 3-(2-hydroxyphenyl)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile"
5OOP,X-RAY DIFFRACTION,2.33,47.29,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer, pH 6.5, 20% ethylene glycol",293.0,2017-08-08,2017-10-25,5OOP,2354.0,1.0,297.0,222.0,,34.6,1.0,1.7,experimental,34.655,0.1971,0.1565,Structure of CHK1 10-pt. mutant complex with AMP-PNP
5OP2,X-RAY DIFFRACTION,2.38,48.35,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-09,2017-10-25,5OP2,2344.0,1.0,297.0,199.0,,34.57,1.0,1.9,experimental,33.797,0.2,0.1593,Structure of CHK1 10-pt. mutant complex with arylbenzamide LRRK2 inhibitor
5OP4,X-RAY DIFFRACTION,2.34,47.55,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-09,2017-10-25,5OP4,2275.0,1.0,297.0,169.0,,34.54,1.0,2.0,experimental,40.341,0.2047,0.1665,Structure of CHK1 10-pt. mutant complex with aminopyrimidine LRRK2 inhibitor
5OPR,X-RAY DIFFRACTION,2.31,46.65,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-10,2017-10-25,5OPR,2235.0,1.0,297.0,153.0,,34.47,1.0,1.95,experimental,41.893,0.2061,0.1636,Structure of CHK1 10-pt. mutant complex with aminopyridine LRRK2 inhibitor
5OPS,X-RAY DIFFRACTION,2.31,46.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-10,2017-10-25,5OPS,2224.0,1.0,297.0,138.0,,34.33,1.0,2.0,experimental,39.547,0.2015,0.1604,Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor
5OPU,X-RAY DIFFRACTION,2.31,46.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-10,2017-10-25,5OPU,2355.0,1.0,297.0,236.0,,34.38,1.0,1.55,experimental,33.448,0.2065,0.1698,Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor
5OPV,X-RAY DIFFRACTION,2.54,51.66,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-10,2017-10-25,5OPV,2309.0,1.0,297.0,202.0,,34.42,1.0,1.9,experimental,33.823,0.2045,0.164,Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor
5OQ8,X-RAY DIFFRACTION,2.35,47.74,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-10,2017-10-25,5OQ8,2272.0,1.0,297.0,146.0,,34.5,1.0,2.0,experimental,42.26,0.1998,0.165,Structure of CHK1 12-pt. mutant complex with arylbenzamide LRRK2 inhibitor
6FC8,X-RAY DIFFRACTION,2.38,48.43,"VAPOR DIFFUSION, HANGING DROP",,"16% Peg8k, 0.1M Caco pH 6.8, 0.15M AS",298.0,2017-12-20,2018-01-17,6FC8,2609.0,1.0,276.0,384.0,,32.31,1.0,1.61,experimental,17.39,0.225,0.191,CHK1 KINASE IN COMPLEX WITH COMPOUND 13
6FCF,X-RAY DIFFRACTION,2.56,51.93,"VAPOR DIFFUSION, HANGING DROP",,"16% Peg8k, 0.1M Caco pH 6.8, 0.15M AS",298.0,2017-12-20,2018-01-17,6FCF,2435.0,1.0,276.0,321.0,,32.37,1.0,1.85,experimental,19.64,0.232,0.2,CHK1 KINASE IN COMPLEX WITH COMPOUND 44
6FCK,X-RAY DIFFRACTION,2.42,49.1,"VAPOR DIFFUSION, HANGING DROP",,"16% Peg8k, 0.1M Caco pH 6.8, 0.15M AS",298.0,2017-12-20,2018-01-17,6FCK,2554.0,1.0,276.0,331.0,,32.27,1.0,1.9,experimental,21.7,0.214,0.174,CHK1 KINASE IN COMPLEX WITH COMPOUND 13
6YD2,X-RAY DIFFRACTION,3.7,66.74,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100MM MES, 200MM K/NAH2PO4, PH 5.5-6.0, 2 M NACL; RESERVOIR SOLUTION: 3-4M NACL",293.15,2020-03-20,2021-02-17,6YD2,4179.0,2.0,487.0,444.0,3.0,53.58,2.0,1.8,experimental,32.05,0.1771,0.1575,X-ray structure of furin in complex with the canavanine-based inhibitor 4-aminomethyl-phenylacetyl-canavanine-Tle-Arg-Amba
6YD3,X-RAY DIFFRACTION,3.72,66.96,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100MM MES, 200MM K/NAH2PO4, PH 5.5-6.0, 2 M NACL; RESERVOIR SOLUTION: 3-4M NACL",293.15,2020-03-20,2021-02-17,6YD3,4159.0,2.0,485.0,418.0,3.0,53.34,2.0,2.0,experimental,32.04,0.1854,0.1595,X-ray structure of furin in complex with the canavanine derived inhibitor 4-guanidinomethyl-phenylacetyl-Canavanine-Tle-Arg-Amba
6YD4,X-RAY DIFFRACTION,3.73,67.06,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100MM MES, 200MM K/NAH2PO4, PH 5.5-6.0, 2 M NACL; RESERVOIR SOLUTION: 3-4M NACL",291.15,2020-03-20,2021-02-17,6YD4,4237.0,2.0,485.0,477.0,3.0,53.37,2.0,1.7,experimental,31.24,0.1694,0.1532,X-ray structure of furin in complex with the canavanine-based inhibitor 4-guanidinomethyl-phenylacetyl-Canavanine-Tle-Canavanine-Amba
6YD7,X-RAY DIFFRACTION,3.74,67.08,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100MM MES, 200MM K/NAH2PO4, PH 5.5-6.0, 2 M NACL; RESERVOIR SOLUTION: 3-4M NACL",291.15,2020-03-20,2021-02-17,6YD7,4211.0,2.0,485.0,465.0,3.0,53.37,2.0,1.8,experimental,29.7,0.1709,0.1538,X-ray structure of furin in complex with the canavanine-based inhibitor 4-guanidinomethyl-phenylacetyl-Arg-Tle-Canavanine-Amba
7VPG,X-RAY DIFFRACTION,2.45,49.86,"VAPOR DIFFUSION, SITTING DROP",5.5,"100 mM Sodium citrate pH 5.5, 20% PEG 3350",293.0,2021-10-17,2022-01-19,7VPG,13136.0,12.0,1868.0,407.0,,211.37,3.0,2.49,experimental,45.21,0.2305,0.1855,Crystal structure of the C-terminal tail of SARS-CoV-1 Orf6 complex with human nucleoporin pair Rae1-Nup98
5N8R,X-RAY DIFFRACTION,2.69,54.3,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES monohydrate-imidazole
20mM sodium formate
20mM ammonium acetate
20mM sodium citrate tribasic hydrate
20mM sodium oxamate
20mM potassium sodium tartrate tetrahydrate",298.0,2017-02-24,2018-03-14,5N8R,14846.0,4.0,1906.0,833.0,,222.28,1.0,2.2,experimental,,0.2186,0.1761,Crystal Structure of Drosophilia DHX36 helicase in complex with GAGCACTGC
5WU4,X-RAY DIFFRACTION,2.56,51.94,"VAPOR DIFFUSION, HANGING DROP",,"Hepes pH 7.5, PEG3350, Tacsimate",297.0,2016-12-16,2017-05-31,5WU4,7595.0,2.0,1146.0,2.0,,125.77,1.0,2.8,experimental,82.66,0.2824,0.241,"Crystal structure of human Tut1 bound with MgATP, form II"
6RN9,X-RAY DIFFRACTION,2.76,55.47,"VAPOR DIFFUSION, HANGING DROP",5.0,"PEG 3350, 0.2 M Ammonium sulphate, 0.1 M Sodium acetate",293.0,2019-05-08,2019-08-28,6RN9,3003.0,3.0,353.0,159.0,5.0,41.2,3.0,1.9,experimental,24.07,0.209,0.185,DPP1 in complex with inhibitor
6RNE,X-RAY DIFFRACTION,2.77,55.59,"VAPOR DIFFUSION, HANGING DROP",5.0,"PEG 3350, 0.2 M Ammonium sulphate, 0.1 M Sodium acetate",293.0,2019-05-08,2019-08-28,6RNE,3143.0,3.0,353.0,227.0,5.0,41.52,3.0,1.65,experimental,20.11,0.203,0.18,DPP1 in complex with inhibitor
6RNI,X-RAY DIFFRACTION,2.79,55.89,"VAPOR DIFFUSION, HANGING DROP",5.0,"PEG 3350, 0.2 M Ammonium sulphate, 0.1 M Sodium acetate",293.0,2019-05-08,2019-08-28,6RNI,3039.0,3.0,354.0,168.0,5.0,41.5,3.0,1.54,experimental,22.05,0.209,0.196,DPP1 in complex with inhibitor
6QXK,X-RAY DIFFRACTION,2.99,58.86,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M NaNO3, 0.1M bis-tris propane pH 8.5, 20% PEG 3350, 10% ethylene glycol",277.0,2019-03-07,2019-04-24,6QXK,2418.0,2.0,327.0,134.0,,37.67,2.0,2.1,experimental,41.469,0.20081,0.17546,Human PIM1 bound to OX0999
4YNE,X-RAY DIFFRACTION,3.23,62.0,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.8M (NH4)2SO4, 0.1M Citrate pH 5.0",277.0,2015-03-09,2015-06-03,4YNE,2334.0,1.0,303.0,78.0,,35.19,1.0,2.0229,experimental,56.66,0.2163,0.1829,(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors
6PDO,X-RAY DIFFRACTION,2.86,56.98,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG3350, 0.1 M HEPES pH7.5, 0.2 M magnesium chloride",293.0,2019-06-19,2019-07-24,6PDO,2318.0,2.0,327.0,54.0,,37.54,2.0,2.4,experimental,66.072,0.223,0.1753,Human PIM1 bound to benzothiophene inhibitor 354
6PDP,X-RAY DIFFRACTION,2.76,55.38,"VAPOR DIFFUSION, SITTING DROP",8.5,"25% PEG3350, 0.1 M TRIS pH 8.5, 0.2 M lithium sulphate",293.0,2019-06-19,2019-07-24,6PDP,2276.0,2.0,327.0,19.0,,37.64,2.0,2.5,experimental,70.236,0.2297,0.1933,Human PIM1 bound to benzothiophene inhibitor 379
5ULM,X-RAY DIFFRACTION,2.34,47.46,"VAPOR DIFFUSION, SITTING DROP",7.6,"0.1 M Sodium Fluoride, 10 % PEG 3350,",290.0,2017-01-24,2017-03-01,5ULM,6450.0,2.0,786.0,343.0,,90.74,1.0,2.1,experimental,30.648,0.26716,0.23335,Structure of the ASK1 central regulatory region
4ZRT,X-RAY DIFFRACTION,2.68,54.03,"VAPOR DIFFUSION, HANGING DROP",7.5,"14.4% PEG 8000, 0.1 M HEPES (pH 7.5), 0.2 M MgCl2",277.0,2015-05-12,2015-06-24,4ZRT,2729.0,2.0,309.0,272.0,,36.28,2.0,1.74,experimental,24.687,0.20743,0.16835,PTP1BC215S bound to Nephrin peptide substrate
5NQA,X-RAY DIFFRACTION,2.87,57.15,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, ammonium nitrate",291.0,2017-04-19,2017-12-20,5NQA,10430.0,3.0,1172.0,1567.0,10.0,140.48,2.0,1.9,experimental,33.271,0.27393,0.22459,Crystal structure of GalNAc-T4 in complex with the monoglycopeptide 3
5G2N,X-RAY DIFFRACTION,2.46,50.01,,,"19% PEG4000,0.15M (NH4)2SO4, 0.1M TRIS PH7.5",,2016-04-11,2016-04-20,5G2N,6710.0,1.0,980.0,11.0,,112.68,1.0,2.68,experimental,70.627,0.28454,0.21142,X-ray structure of PI3Kinase Gamma in complex with Copanlisib
6WXJ,X-RAY DIFFRACTION,2.37,48.2,VAPOR DIFFUSION,,"0.1 M MES, pH 6.5, 21.3% polyethylene glycol 3350 and 0.25 M ammonium sulfate",294.0,2020-05-10,2021-02-10,6WXJ,2289.0,1.0,332.0,34.0,,38.18,1.0,2.62,experimental,91.328,0.2723,0.1807,CSF1R signaling is a regulator of pathogenesis in progressive MS
8BNQ,X-RAY DIFFRACTION,2.47,50.28,"VAPOR DIFFUSION, SITTING DROP",,"5% [v/v] polyethylene glycol 400 and 40% [v/v] 2-methyl-2,4-pentanediol (MPD)",277.15,2022-11-14,2023-04-12,8BNQ,4839.0,2.0,608.0,132.0,,67.21,1.0,2.3,experimental,63.34,0.2578,0.1975,Crystal structure of the FnIII-tandem A84-A86 from the A-band of titin
7BHF,X-RAY DIFFRACTION,2.65,53.66,VAPOR DIFFUSION,4.74,"0.1 M Na citrate, 10% PEG4000, 0.2 M Li sulfate",293.0,2021-01-11,2021-11-24,7BHF,4590.0,4.0,576.0,690.0,20.0,62.22,2.0,1.997,experimental,31.28,0.2432,0.1981,"DARPin_D5/Her3 domain 4 complex, orthorhombic crystals"
6VJJ,X-RAY DIFFRACTION,1.88,34.67,"VAPOR DIFFUSION, SITTING DROP",,"0.09M Halogens, 0.1M Imidazole.MES pH 6.5, 37.5% MPD, PEG 1000 and PEG 3350",293.0,2020-01-16,2020-11-25,6VJJ,2222.0,2.0,250.0,145.0,,29.33,2.0,1.4,experimental,21.1196,0.1949,0.1645,Crystal Structure of wild-type KRAS4b (GMPPNP-bound) in complex with RAS-binding domain (RBD) of RAF1/CRAF
7K6M,X-RAY DIFFRACTION,2.66,53.72,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 6000, 0.1 M CHES pH 9.75, 0.64 M sodium formate, 5 mM TCEP pH 7, 50 mM Tris pH 8.0, 100 mM NaCl, 2% Ethylene Glycol",286.0,2020-09-21,2021-01-06,7K6M,7204.0,1.0,946.0,262.0,,110.48,1.0,2.413,experimental,63.4,0.2323,0.1944,Crystal structure of PI3Kalpha selective Inhibitor PF-06843195
7K6N,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 6000, 0.1 M CHES pH 9.75, 0.64 M sodium formate, 5 mM TCEP pH 7",286.0,2020-09-21,2021-01-06,7K6N,6892.0,1.0,946.0,172.0,,110.47,1.0,2.77,experimental,55.54,0.2347,0.1999,Crystal structure of PI3Kalpha selective Inhibitor 11-1575
7K6O,X-RAY DIFFRACTION,2.52,51.24,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 6000, 0.1 M CHES pH 9.75, 0.64 M sodium formate, 5 mM TCEP pH 7",286.0,2020-09-21,2021-01-06,7K6O,6442.0,1.0,946.0,71.0,,110.44,1.0,2.738,experimental,81.55,0.2618,0.2305,Crystal structure of PI3Kalpha inhibitor 10-5429
7ZUN,X-RAY DIFFRACTION,2.91,57.78,VAPOR DIFFUSION,7.6,"20% PEG 3350K, 0.3 M NACL, 0.1 M TRIS-HCL PH 7.6",293.0,2022-05-12,2022-10-05,7ZUN,2262.0,1.0,314.0,46.0,,36.25,1.0,2.5,experimental,47.926,0.235,0.1744,Crystal structure of PIM1 in complex with a Pyrrolo-Pyrazinone compound
6D22,X-RAY DIFFRACTION,3.1,60.32,VAPOR DIFFUSION,,0.1M tri-Sodium citrate + 20% PEG3K,294.0,2018-04-12,2018-05-02,6D22,2553.0,1.0,307.0,165.0,,34.97,1.0,2.46,experimental,37.404,0.2361,0.1755,Crystal structure of Tyrosine-protein kinase receptor
6NPT,X-RAY DIFFRACTION,2.57,52.25,"VAPOR DIFFUSION, HANGING DROP",,"The protein at a concentration of 10 mg/ml was mixed with 2mM of the ligand (diluted from 100 mM DMSO stock solution) for 1 hour on ice and crystallized at 4 deg C (hanging drop) from:
0.10 M KH2PO4/ 0.10 M NaH2PO4/ 0.10 M MES/NaOH pH 6.00 and 1.90 M NaCl (cryo: 25% glycerol in reservoir), or
18.00 % (w/v) PEG 3350, 0.20 M CaCl2, 0.10 M, MES pH=6.50 (cryo: direct).",277.15,2019-01-18,2019-05-22,6NPT,2422.0,1.0,305.0,73.0,,35.22,1.0,2.19,experimental,52.878,0.27646,0.22334,TRK-A IN COMPLEX WITH LIGAND 1
6PL1,X-RAY DIFFRACTION,2.68,54.12,"VAPOR DIFFUSION, HANGING DROP",,"20mM Tris/HCl, pH=8.5, 50mM NaCl, 2mM DTT, 0.5mM PMSF",277.15,2019-06-30,2019-10-09,6PL1,2445.0,1.0,311.0,57.0,,35.92,1.0,2.03,experimental,44.938,0.26029,0.21688,TRK-A IN COMPLEX WITH LIGAND 1B
6PMA,X-RAY DIFFRACTION,2.69,54.26,"VAPOR DIFFUSION, HANGING DROP",,"0.10M KH2PO4/ 0.10M NaH2PO4/ 0.1M MES/NaOH pH = 6.00 and 1.9M NaCl (cryo: 25% glycerol in reservoir), or 18% (w/v) PEG 3350, 0.2M CaCl2, 0.10M, MES pH = 6.50 (cryo: direct).",277.0,2019-07-01,2020-02-26,6PMA,2381.0,1.0,311.0,25.0,,35.91,1.0,2.53,experimental,41.149,0.2663,0.2045,TRK-A IN COMPLEX WITH LIGAND
6PMB,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, HANGING DROP",,"0.10M KH2PO4/ 0.10M NaH2PO4/ 0.1M MES/NaOH pH = 6.00 and 1.9M NaCl (cryo: 25% glycerol in reservoir), or 18% (w/v) PEG 3350, 0.2M CaCl2, 0.10M, MES pH = 6.50 (cryo: direct)",277.0,2019-07-01,2020-02-26,6PMB,2363.0,1.0,311.0,22.0,,35.78,1.0,2.81,experimental,32.054,0.2821,0.2139,TRK-A IN COMPLEX WITH LIGAND 1a
6PMC,X-RAY DIFFRACTION,2.83,56.55,"VAPOR DIFFUSION, HANGING DROP",,"0.10M KH2PO4/ 0.10M NaH2PO4/ 0.1M MES/NaOH pH = 6.00 and 1.9M NaCl (cryo: 25% glycerol in reservoir), or 18% (w/v) PEG 3350, 0.2M CaCl2, 0.10M, MES pH = 6.50 (cryo: direct)",277.0,2019-07-01,2020-02-26,6PMC,2384.0,1.0,311.0,35.0,,35.88,1.0,2.19,experimental,35.826,0.2984,0.2459,TRK-A IN COMPLEX WITH LIGAND 1a
7VKN,X-RAY DIFFRACTION,2.94,58.1,"VAPOR DIFFUSION, SITTING DROP",,"3.0M NaCl, 0.1M Bis-Tris pH 6.5",293.0,2021-09-30,2021-10-13,7VKN,2449.0,1.0,326.0,16.0,,38.17,1.0,2.7,experimental,78.034,0.25615,0.18239,Crystal structure of TrkA (G595R) kinase with repotrectinib
7VKO,X-RAY DIFFRACTION,2.9,57.59,"VAPOR DIFFUSION, SITTING DROP",,"0.1M citric acid PH 5.0, 8M ammonium sulfate",293.0,2021-09-30,2021-10-13,7VKO,2435.0,1.0,326.0,21.0,,38.07,1.0,2.9,experimental,95.454,0.26738,0.18412,Crystal structure of TrkA kinase with repotrectinib
6DQ4,X-RAY DIFFRACTION,2.26,45.59,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2018-11-21,6DQ4,2855.0,1.0,330.0,247.0,,39.29,1.0,1.392,experimental,,0.2162,0.1829,LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR GSK-J1
6DQB,X-RAY DIFFRACTION,2.24,45.2,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2018-11-21,6DQB,2590.0,1.0,330.0,144.0,,39.91,1.0,1.791,experimental,,0.2005,0.1689,"LINKED KDM5A JMJ DOMAIN FORMING COVALENT BOND TO INHIBITOR N71 i.e. 2-((3-(4-(dimethylamino)but-2-enamido)phenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid"
5F0Q,X-RAY DIFFRACTION,2.94,58.1,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.18 M lithium sulfate, 50 mM sodium citrate, 2 mM TCEP, 0.1 M sodium malonate, 0.1 M Hepes-NaOH (pH 7.0), 19.7% PEG 8,000 and 0.02 M magnesium chloride",295.0,2015-11-28,2016-03-23,5F0Q,3838.0,6.0,418.0,65.0,,56.25,1.0,2.21,experimental,63.8,0.258,0.223,Crystal structure of C-terminal domain of the human DNA primase large subunit with bound DNA template/RNA primer
5PAK,X-RAY DIFFRACTION,3.77,67.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAK,2969.0,2.0,318.0,389.0,10.0,35.69,2.0,1.56,experimental,17.436,0.2025,0.1852,Crystal Structure of Factor VIIa in complex with N-[[4-(aminomethyl)-2-(2-amino-2-oxoethoxy)phenyl]methyl]-2-(4-hydroxyphenyl)-2-methoxyacetamide;hydrochloride
5PAW,X-RAY DIFFRACTION,3.77,67.39,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277.0,2016-11-10,2017-06-21,5PAW,2721.0,2.0,318.0,243.0,9.0,35.59,2.0,2.2,experimental,34.438,0.2199,0.1841,"Crystal Structure of Factor VIIa in complex with isoquinoline-1,6-diamine"
4ZXX,X-RAY DIFFRACTION,3.93,68.7,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277.0,2015-05-20,2015-07-22,4ZXX,2509.0,2.0,309.0,71.0,8.0,35.05,2.0,2.6,experimental,27.83,0.2482,0.2177,FACTOR VIIA IN COMPLEX WITH THE INHIBITOR N-{3-[(2R)-1-{(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-phenylacetyl}pyrrolidin-2-yl]-4-(propan-2-ylsulfonyl)phenyl}acetamide
5AQJ,X-RAY DIFFRACTION,2.46,49.96,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQJ,12359.0,6.0,1512.0,876.0,3.0,170.26,2.0,1.96,experimental,55.11,0.2212,0.1903,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQN,X-RAY DIFFRACTION,2.45,49.83,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQN,11530.0,6.0,1512.0,235.0,3.0,169.78,2.0,2.45,experimental,59.37,0.228,0.1927,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQO,X-RAY DIFFRACTION,2.45,49.79,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQO,12097.0,6.0,1512.0,671.0,3.0,170.87,2.0,2.12,experimental,51.16,0.2101,0.1797,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQP,X-RAY DIFFRACTION,2.46,49.95,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQP,11954.0,6.0,1512.0,588.0,3.0,170.12,2.0,2.08,experimental,51.25,0.209,0.1813,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQQ,X-RAY DIFFRACTION,2.46,49.94,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQQ,11141.0,6.0,1512.0,58.0,2.0,168.87,2.0,2.72,experimental,57.59,0.2409,0.1952,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQR,X-RAY DIFFRACTION,2.47,50.24,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQR,12112.0,6.0,1512.0,650.0,3.0,170.89,2.0,1.91,experimental,42.3,0.2365,0.208,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5KAD,X-RAY DIFFRACTION,2.26,45.63,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 17.5% PEG8000",277.0,2016-06-01,2017-03-01,5KAD,4972.0,2.0,612.0,322.0,,71.99,1.0,1.9,experimental,22.5984,0.2049,0.1759,"Protein Tyrosine Phosphatase 1B N193A mutant in complex with TCS401, closed state"
5DKH,X-RAY DIFFRACTION,2.45,49.77,"VAPOR DIFFUSION, SITTING DROP",7.0,"20% PEG 6K, 10% ethyleneglycol, 0.1 Hepes pH 7, 0.01M ZnCl2",277.15,2015-09-03,2016-09-14,5DKH,3037.0,3.0,369.0,177.0,,44.38,1.0,1.7,experimental,33.035,0.24144,0.19912,Crystal structure of the bromodomain of human BRM (SMARCA2) in complex with a hydroxyphenyl propenone inhibitor 17
5TFA,X-RAY DIFFRACTION,2.36,47.83,MICROBATCH,7.5,"Protein buffer: 150 mM NaCl, 30% (v/v) glycerol, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5;
Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-24,2018-05-09,5TFA,1954.0,1.0,229.0,215.0,,26.02,1.0,1.87,experimental,,0.1951,0.1578,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dUTP
5TFB,X-RAY DIFFRACTION,2.39,48.58,MICROBATCH,7.5,"Protein buffer: 150 mM NaCl, 30% (v/v) glycerol, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5
Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-24,2018-05-09,5TFB,1890.0,1.0,229.0,209.0,,26.09,1.0,1.87,experimental,,0.1991,0.1502,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with 7-methyl-GTP
5TFD,X-RAY DIFFRACTION,2.38,48.33,MICROBATCH,,"Protein buffer: 150 mM NaCl, 30% (v/v) glycerol, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5;
Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-24,2018-05-09,5TFD,1891.0,1.0,229.0,210.0,,26.03,1.0,1.891,experimental,,0.1945,0.1609,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with CTP
5TFF,X-RAY DIFFRACTION,2.38,48.36,MICROBATCH,7.5,"Protein buffer: 150 mM NaCl, 30% (v/v) glycerol, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5;
Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-25,2018-05-09,5TFF,1877.0,1.0,229.0,196.0,,26.03,1.0,1.891,experimental,,0.1897,0.1595,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with UTP
5TFG,X-RAY DIFFRACTION,2.38,48.26,MICROBATCH,,"Protein buffer: 150 mM NaCl, 30% (v/v) glycerol, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5;
Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-25,2018-05-09,5TFG,1877.0,1.0,229.0,190.0,,26.05,1.0,1.91,experimental,,0.1836,0.1563,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with 5-methyl-UTP
5TFI,X-RAY DIFFRACTION,2.36,47.82,MICROBATCH,7.5,"Protein buffer: 150 mM NaCl, 10% (v/v) glycerol,10% (v/v) Ethylene glycol, 10mM MgCl2, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5. Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-25,2018-05-09,5TFI,1900.0,1.0,229.0,192.0,,26.06,1.0,1.891,experimental,,0.2012,0.1583,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dGTP
5TFJ,X-RAY DIFFRACTION,2.38,48.24,MICROBATCH,7.5,"Protein buffer: 150 mM NaCl, 10% (v/v) glycerol,10% (v/v) Ethylene glycol, 10mM MgCl2, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5. Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-25,2018-05-09,5TFJ,1876.0,1.0,229.0,196.0,,26.02,1.0,1.85,experimental,,0.1853,0.162,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dCTP
7TLG,X-RAY DIFFRACTION,2.13,42.15,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 30% PEG 4K",293.0,2022-01-18,2022-08-03,7TLG,3206.0,2.0,340.0,342.0,,40.76,1.0,1.80000720583,experimental,21.2162748316,0.233295099519,0.179014574786,Crystal Structure of small molecule beta-lactone 5 covalently bound to K-Ras(G12S)
5FBO,X-RAY DIFFRACTION,2.28,46.08,"VAPOR DIFFUSION, HANGING DROP",5.5,"5.5 v/v PEG 10000, 0.1M Ammonium Acetate, 0.1M Bis-Tris Cl pH 6.5, 2.5 mM(S)-4-(8-amino-3-(1-(4-(dimethylamino)butanoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(thiazol-2-yl)benzamide",277.0,2015-12-14,2016-03-23,5FBO,2259.0,1.0,271.0,86.0,,32.7,1.0,1.894,experimental,44.3,0.236,0.211,BTK-inhibitor co-structure
6X3N,X-RAY DIFFRACTION,2.29,46.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-TRIS pH 6.5, 0.1M NaCl, 15% w/v PEG 20K 5mM TCEP Cl, 4mM (S)-4-(8-amino-3-(1-(4-(dimethylamino)butanoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(thiazol-2-yl)benzamide",277.0,2020-05-21,2020-07-22,6X3N,2235.0,1.0,271.0,74.0,,32.65,1.0,1.95,experimental,46.72,0.2417,0.2136,Co-structure of BTK kinase domain with L-005085737 inhibitor
6X3P,X-RAY DIFFRACTION,2.27,45.71,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris.Cl at pH 6.5, 2 mM TCEP Cl, 6% w/v PEG 20K, 10mM (S)-4-(8-amino-3-(1-(4-(dimethylamino)butanoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(thiazol-2-yl)benzamide, 5%v/v deuterated-DMSO,protein:precipitant volume ratio=1:2",277.0,2020-05-21,2020-07-22,6X3P,2509.0,1.0,271.0,202.0,,33.05,1.0,1.34,experimental,15.17,0.2174,0.2041,Co-structure of BTK kinase domain with L-005298385 inhibitor
5ED1,X-RAY DIFFRACTION,2.44,55.1,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES/NaOH, pH 6.5, 9% w/v PEG3350, 13% glycerol, 0.015 M NAD",298.0,2015-10-20,2016-04-13,5ED1,7277.0,4.0,852.0,33.0,,106.17,1.0,2.77,experimental,,0.2234,0.1627,Human Adenosine Deaminase Acting on dsRNA (ADAR2) mutant E488Q bound to dsRNA sequence derived from S. cerevisiae BDF2 gene
7W0T,X-RAY DIFFRACTION,2.43,49.48,LIQUID DIFFUSION,,"ammonium acetate, magnesium acetate tetrahydrate, HEPES sodium, polyethylene glycol",291.15,2021-11-18,2022-08-10,7W0T,4819.0,6.0,552.0,625.0,,62.3,2.0,1.57,experimental,21.77,0.1864,0.1683,TRIM7 in complex with C-terminal peptide of 2C
6PP9,X-RAY DIFFRACTION,3.39,67.29,"VAPOR DIFFUSION, HANGING DROP",6.4,"100 mM Bis-Tris pH 6.4, 200 mM Ammonium Sulfate, and 22% PEG3350",293.0,2019-07-05,2019-10-09,6PP9,4858.0,2.0,680.0,72.0,,77.76,2.0,2.59,experimental,53.5009,0.2455,0.2207,Crystal structure of BRAF:MEK1 complex
5IF1,X-RAY DIFFRACTION,4.15,70.33,"VAPOR DIFFUSION, HANGING DROP",7.0,"100mM HEPES, 5mM DTT, 0.5 mM Kcl, 875mM ammonium sulfate",277.15,2016-02-25,2016-04-27,5IF1,9059.0,4.0,1126.0,121.0,,129.12,2.0,2.61,experimental,60.552,0.23632,0.18743,Crystal structure apo CDK2/cyclin A
8YA8,X-RAY DIFFRACTION,2.39,53.39,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2 M Potassium sulfate, 20% (v/v) PEG 3350",296.15,2024-02-08,2024-02-28,8YA8,4365.0,7.0,630.0,48.0,,68.16,1.0,2.85,experimental,,0.2684,0.2391,The crystal structure of human Rtel1 HHD2 domain
7SS8,X-RAY DIFFRACTION,2.58,52.34,VAPOR DIFFUSION,6.5,"20% PEG3350, 0.1 M MES pH 6.5",277.0,2021-11-10,2022-11-09,7SS8,4103.0,1.0,569.0,205.0,,66.92,1.0,2.15,experimental,39.67,0.2297,0.1997,Human P300 complexed with a proline-based inhibitor
7Z9U,X-RAY DIFFRACTION,4.02,69.41,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-03-21,2022-11-23,7Z9U,1296.0,1.0,130.0,113.0,1.0,16.41,1.0,1.76,experimental,42.31,0.2271,0.2047,ATAD2 in complex with Acetyl-Lys
6HZV,X-RAY DIFFRACTION,2.52,51.3,VAPOR DIFFUSION,,"30% PEG3350, 0.1M BIS-TRIS, 0.2M MgCl, pH 6.0",277.0,2018-10-24,2019-10-23,6HZV,8789.0,4.0,1140.0,107.0,,132.38,1.0,2.46,experimental,37.51,0.27533,0.22278,HUMAN JAK3 IN COMPLEX WITH LASW959 PROTEIN IN COMPLEX WITH LIGAND
6T8U,X-RAY DIFFRACTION,2.78,55.79,"VAPOR DIFFUSION, SITTING DROP",,"2.4M AMMONIUM SULPHATE, 0.1 M SODIUM ACETATE PH 4.6",298.0,2019-10-25,2020-03-04,6T8U,6423.0,3.0,873.0,45.0,15.0,100.61,1.0,2.84,experimental,25.84,0.2389,0.1976,"Complement factor B in complex with 5-Bromo-3-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-7-methyl-1H-indol-4-amine"
4U6A,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M MES pH 6.0, 0.1 M ammonium tartrate, 12-16% w/v PEG 3350",293.0,2014-07-28,2015-07-08,4U6A,1806.0,1.0,258.0,94.0,,30.44,1.0,2.37,experimental,46.03,0.248,0.191,X-ray crystal structure of human TNKS in complex with a small molecule inhibitor
8SUV,X-RAY DIFFRACTION,2.16,43.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.05 M Magnesium sulfate heptahydrate, 0.1 M HEPES, 28 % v/v PEG Smear Medium",293.0,2023-05-13,2024-03-20,8SUV,4819.0,8.0,604.0,404.0,,69.77,2.0,1.63,experimental,32.37,0.2903,0.2741,CHIP-TPR in complex with the C-terminus of CHIC2
4X7K,X-RAY DIFFRACTION,2.92,57.86,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.18M Na/K Tartrate, 5% PEG-3350, 0.1M HEPES pH 7.0",277.0,2014-12-09,2015-01-28,4X7K,2466.0,1.0,317.0,262.0,,37.62,1.0,1.8,experimental,30.17,0.1957,0.1762,"Co-crystal Structure of PERK bound to 4-{2-amino-3-[5-fluoro-2-(methylamino)quinazolin-6-yl]-4-methylbenzoyl}-1-methyl-2,5-diphenyl-1,2-dihydro-3H-pyrazol-3-one inhibitor"
4X7L,X-RAY DIFFRACTION,2.93,58.08,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.18M Na/K Tartrate, 0.1M MES pH 6.5",277.0,2014-12-09,2015-01-28,4X7L,2476.0,1.0,317.0,267.0,,37.6,1.0,1.9,experimental,33.258,0.1932,0.1705,"Co-crystal Structure of PERK bound to 4-{2-amino-4-methyl-3-[2-(methylamino)-1,3-benzothiazol-6-yl]benzoyl}-1-methyl-2,5-diphenyl-1,2-dihydro-3H-pyrazol-3-one inhibitor"
6FMD,X-RAY DIFFRACTION,3.37,63.47,"VAPOR DIFFUSION, HANGING DROP",5.2,"0.2M KBr, 0.2M KSCN, 0.1M NaAc pH 5.2, 25% PEG 400, 2% PGA-LM",293.0,2018-01-30,2018-07-11,6FMD,3128.0,1.0,395.0,155.0,,45.64,1.0,1.58,experimental,26.408,0.1597,0.1368,"Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold"
6J3C,X-RAY DIFFRACTION,3.66,66.41,"VAPOR DIFFUSION, HANGING DROP",,"hepes pH4.6, 2M AMMONIUM SULPHATE, 30% Glycerol",293.0,2019-01-04,2019-08-21,6J3C,3166.0,1.0,366.0,282.0,,41.36,1.0,1.851,experimental,,0.1951,0.1689,Crystal structure of human DHODH in complex with inhibitor 1291
7K2U,X-RAY DIFFRACTION,3.53,65.2,VAPOR DIFFUSION,,"0.10 M NaAcetate pH 4.8, 2.30 M (NH4)2SO4, 30 % Glycerol, 18% (w/v) PEG 4000, 0.1M Na3Citrate pH5.75",293.0,2020-09-09,2020-10-21,7K2U,3255.0,1.0,369.0,269.0,,41.96,1.0,1.73,experimental,26.958,0.179,0.1649,DHODH IN COMPLEX WITH LIGAND 13
6GVA,X-RAY DIFFRACTION,2.57,52.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"10% w/v PEG 20000, 20% v/v PEG MME 550, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide, and 0.1 M bicine/Trizma base, pH 8.5",291.0,2018-06-20,2019-05-01,6GVA,4638.0,2.0,557.0,160.0,1.0,64.94,2.0,2.15,experimental,39.552,0.2403,0.1943,"CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR4455"
5JO3,X-RAY DIFFRACTION,2.23,44.87,VAPOR DIFFUSION,7.4,"20% PEG 4K
10% Isopropanol
0.1M Hepes pH 7.4",293.0,2016-05-01,2017-05-03,5JO3,3006.0,1.0,326.0,367.0,,38.14,1.0,1.49,experimental,15.199,0.20141,0.17998,PDE5A for NaV1.7
5X93,X-RAY DIFFRACTION,2.84,56.75,LIPIDIC CUBIC PHASE,6.0,"PEG 500 DME, (NH4)2SO4, MOPS",293.0,2017-03-05,2017-08-16,5X93,3842.0,1.0,464.0,106.0,2.0,57.56,1.0,2.2,experimental,57.1766,0.2387,0.2106,Human endothelin receptor type-B in complex with antagonist K-8794
6QPJ,X-RAY DIFFRACTION,2.15,42.82,"VAPOR DIFFUSION, SITTING DROP",,"20 mM MES pH 6.5
0.1M Magnesium sulfate
20 % PEG 3350",298.0,2019-02-14,2019-09-25,6QPJ,1133.0,1.0,161.0,72.0,,18.31,1.0,2.315,experimental,,0.2425,0.1796,Human CLOCK PAS-A domain
7ZKX,X-RAY DIFFRACTION,3.66,66.44,VAPOR DIFFUSION,,"5 mM HEPES pH 7.5, 150 mM NaCl, 20 mM DTT",293.0,2022-04-13,2023-02-22,7ZKX,2984.0,1.0,619.0,133.0,,71.52,1.0,2.06,experimental,57.306,0.2075,0.1793,SRPK2 IN COMPLEX WITH INHIBITOR
8BFU,X-RAY DIFFRACTION,2.56,51.89,"VAPOR DIFFUSION, SITTING DROP",,"12.5% (w/v) PEG 4K, 20% (v/v) 1,2,6-hexanetriol, 90 mM LiNaK, 0.1 M MOPSO/bis-tris pH 6.5",291.0,2022-10-26,2023-02-15,8BFU,7237.0,1.0,946.0,51.0,,109.98,1.0,2.41,experimental,90.04,0.2792,0.2431,Crystal structure of the apo p110alpha catalytic subunit from homo sapiens
8OW2,X-RAY DIFFRACTION,2.61,52.81,"VAPOR DIFFUSION, SITTING DROP",,"12.5% (w/v) PEG 4K, 20% (v/v) 1,2,6-hexanetriol, 50 mM Polyamines, 0.1 M MOPSO/bis-tris pH 6.5",291.0,2023-04-26,2023-05-24,8OW2,7376.0,1.0,946.0,36.0,,110.43,1.0,2.57,experimental,83.11,0.2714,0.2128,Crystal structure of the p110alpha catalytic subunit from homo sapiens in complex with activator 1938
6T8V,X-RAY DIFFRACTION,2.46,50.06,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 0.1M HEPES PH 7.5, 5 mM inhibitor",298.0,2019-10-25,2020-03-04,6T8V,4632.0,2.0,582.0,109.0,10.0,67.25,1.0,2.29,experimental,24.576,0.2539,0.2023,"Complement factor B in complex with (S)-5,7-Dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1H-indole"
6T8W,X-RAY DIFFRACTION,2.47,50.14,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 0.1M BIS-TRIS PH 6.5, 0.2M        
AMMONIUM SULFATE, 0.1 MM ZNCL2, 1 mM inhibitor",298.0,2019-10-25,2020-03-04,6T8W,4909.0,2.0,582.0,343.0,10.0,67.16,1.0,1.7,experimental,28.47,0.2383,0.1975,"Complement factor B in complex with (-)-4-(1-((5,7-Dimethyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid"
6U9K,X-RAY DIFFRACTION,2.63,53.29,"VAPOR DIFFUSION, SITTING DROP",,2.2 M Sodium Malonate pH 7.0,277.0,2019-09-09,2020-07-01,6U9K,2560.0,2.0,316.0,167.0,,37.97,1.0,2.0,experimental,35.25,0.244,0.207,MLL1 SET N3861I/Q3867L bound to inhibitor 18 (TC-5153)
6U9M,X-RAY DIFFRACTION,2.67,53.88,"VAPOR DIFFUSION, SITTING DROP",,2.2 M Sodium Malonate pH 7.0,277.0,2019-09-09,2020-07-01,6U9M,2551.0,2.0,316.0,164.0,,37.77,1.0,2.05,experimental,35.85,0.252,0.221,MLL1 SET N3861I/Q3867L bound to inhibitor 16 (TC-5109)
5WF5,X-RAY DIFFRACTION,2.88,57.22,LIPIDIC CUBIC PHASE,,"100 mM sodium citrate pH 5, 24-27% (v/v)
polyethylene glycol (PEG) 400, 30-80 mM MgCl 2 , 5% (v/v) Jeffamine M-600 pH 7 (Hampton)",296.0,2017-07-11,2018-02-21,5WF5,3565.0,1.0,504.0,3.0,4.0,58.05,1.0,2.6,experimental,,0.2509,0.2138,Agonist bound human A2a adenosine receptor with D52N mutation at 2.60 A resolution
5WF6,X-RAY DIFFRACTION,2.9,57.54,LIPIDIC CUBIC PHASE,,"100 mM sodium citrate pH 5, 24-27% (v/v)
polyethylene glycol (PEG) 400, 30-80 mM MgCl 2 , 5% (v/v) Jeffamine M-600 pH 7 (Hampton)",293.0,2017-07-11,2018-02-21,5WF6,3473.0,1.0,504.0,2.0,4.0,57.67,1.0,2.9,experimental,,0.2877,0.2525,Agonist bound human A2a adenosine receptor with S91A mutation at 2.90 A resolution
7OK3,X-RAY DIFFRACTION,2.17,43.29,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M (NH4)F, 20 % PEG3350, 67 mg/mL KRasG13C-edaGDP, 0.1 uL reservoir + 0.1 uL protein solution",293.0,2021-05-17,2022-08-03,7OK3,1611.0,1.0,170.0,187.0,,20.02,1.0,1.6,experimental,27.867,0.2001,0.158,Crystal Structure of KRasG13C in Complex with Nucleotide-based Covalent Inhibitor edaGDP
7OK4,X-RAY DIFFRACTION,2.22,44.66,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M (NH4)F, 20 % PEG3350, 70 mg/mL KRas-bdaGDP, 0.1 uL reservoir + 0.1 uL protein solution",293.0,2021-05-17,2022-08-03,7OK4,1482.0,1.0,170.0,106.0,,20.05,1.0,1.7,experimental,37.3486,0.1824,0.1653,Crystal Structure of KRasG13C in Complex with Nucleotide-based covalent Inhibitor bdaGDP
5OXG,X-RAY DIFFRACTION,2.81,56.29,"VAPOR DIFFUSION, SITTING DROP",6.5,18% PEG8000 -- 0.2M calcium acetate -- 0.1M cacodylate pH 6.5,277.0,2017-09-06,2017-09-20,5OXG,9848.0,4.0,1204.0,353.0,2.0,140.08,1.0,2.13,experimental,45.974,0.23243,0.20611,Crystal structure of the ACVR1 (ALK2) kinase in complex with LDN-212854
6TTP,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 200 mM Magnesium acetate",295.0,2019-12-30,2020-03-04,6TTP,3676.0,2.0,1036.0,212.0,1.0,117.12,2.0,2.0,experimental,44.38,0.2274,0.1932,Crystal structure of the human METTL3-METTL14 complex bound to Compound 1/Adenosine (DHU_M3M_023)
6BN5,X-RAY DIFFRACTION,2.24,45.14,"VAPOR DIFFUSION, HANGING DROP",8.6,"100 mM Tris pH 8.6, 20% PEG 3350, 1 mM TCEP",298.15,2017-11-16,2017-12-13,6BN5,7517.0,2.0,1052.0,191.0,,121.24,1.0,2.22,experimental,45.16,0.2917,0.236,Non-receptor Protein Tyrosine Phosphatase SHP2 F285S in Complex with Allosteric Inhibitor JLR-2
7AKO,X-RAY DIFFRACTION,2.59,52.47,"VAPOR DIFFUSION, SITTING DROP",,"200 mM Sodium citrate tribasic dihydrate, 100 mM Bis-Tris propane pH 6.5 and 20% w/v PEG 3350",287.15,2020-10-01,2021-04-14,7AKO,4982.0,4.0,632.0,314.0,,73.94,2.0,1.8,experimental,40.63,0.2351,0.19,Crystal structure of CHK1 kinase domain in complex with a CLASPIN phosphopeptide
6IGK,X-RAY DIFFRACTION,2.92,57.91,LIPIDIC CUBIC PHASE,6.0,"PEG 500DME, Ammonium citrate tribasic",293.0,2018-09-25,2018-11-21,6IGK,4385.0,2.0,519.0,175.0,4.0,63.08,2.0,2.0,experimental,47.0245,0.2271,0.1834,Crystal Structure of human ETB receptor in complex with Endothelin-3
4OGB,X-RAY DIFFRACTION,2.68,54.03,"VAPOR DIFFUSION, HANGING DROP",,"20% (w/v) PEG 3350, 25% (v/v) ethylene glycol, 10% (v/v) isopropanol and 100 mM HEPES pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 294K",294.0,2014-01-15,2015-01-21,4OGB,11286.0,4.0,1444.0,432.0,,171.27,1.0,2.032,experimental,38.32,0.2435,0.2024,Crystal structure of the catalytic domain of PDE4D2 with compound 2
8UWP,X-RAY DIFFRACTION,2.36,47.94,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.1M Tris pH 8.2, 0.2M NH4SO4, 20% PEG8000, 2mM DTT",291.0,2023-11-07,2023-11-22,8UWP,3851.0,2.0,450.0,201.0,,54.75,1.0,1.77,experimental,31.305,0.24243,0.19887,Crystal structure of SETDB1 Tudor domain in complex with MR46747
5TJQ,X-RAY DIFFRACTION,1.83,32.76,VAPOR DIFFUSION,6.0,"0.1 M MMT (DL-malic acid, MES, Tris-base in molar ratio of 1:2:2) pH 6.0, 25% PEG1500",298.0,2016-10-04,2017-05-31,5TJQ,3064.0,1.0,447.0,11.0,,53.44,1.0,2.75,experimental,87.323,0.317,0.2249,"Structure of WWP2 2,3-linker-HECT"
6W92,X-RAY DIFFRACTION,1.93,36.35,"VAPOR DIFFUSION, HANGING DROP",5.75,"0.1 M Bis-Tris, pH = 5.5, 25 % w/v PEG 3350",295.0,2020-03-21,2021-02-24,6W92,1493.0,1.0,164.0,224.0,,19.21,1.0,1.3,experimental,15.07,0.1849,0.1737,Human UHRF1 TTD domain
5ACK,X-RAY DIFFRACTION,2.2,44.0,,7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 0.01 M DTT",,2015-08-17,2015-10-21,5ACK,2828.0,1.0,311.0,332.0,,36.59,1.0,1.24,experimental,21.2,0.1655,0.1416,Human PDK1 Kinase Domain in Complex with Allosteric Compound 7 Bound to the PIF-Pocket
5LVL,X-RAY DIFFRACTION,2.16,43.12,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 0.01 M DTT",293.0,2016-09-14,2016-10-19,5LVL,2822.0,1.0,311.0,277.0,,36.0,1.0,1.4,experimental,,0.178,0.1529,Human PDK1 Kinase Domain in Complex with Compound PS653 Bound to the ATP-Binding Site
7TLK,X-RAY DIFFRACTION,2.16,42.99,"VAPOR DIFFUSION, HANGING DROP",8.7,"0.1 M Tris, 0.2 M CaCl2, 25% PEG 4K",293.0,2022-01-18,2022-08-03,7TLK,3213.0,2.0,338.0,487.0,,39.54,1.0,1.71102224586,experimental,16.3305950355,0.205085961436,0.16906361931,Crystal Structure of K-Ras(G12S)
8STN,X-RAY DIFFRACTION,2.26,45.6,"VAPOR DIFFUSION, SITTING DROP",,2.2 M Ammonium Sulfate,293.0,2023-05-10,2023-08-23,8STN,2735.0,2.0,340.0,59.0,,39.83,1.0,2.03,experimental,40.642,0.18261,0.15997,"Crystal structure of KRAS-G12D/G75A mutant, GDP-bound"
5AIK,X-RAY DIFFRACTION,2.7,54.0,,7.5,"0.2M NA/KPO4, 20% PEG 3350, 10% ETHYLENE GLYCOL, pH 7.5",,2015-02-15,2015-02-25,5AIK,11321.0,4.0,1528.0,64.0,,180.51,1.0,2.7,experimental,40.729,0.25222,0.22681,Human DYRK1A in complex with LDN-211898
6FLG,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, HANGING DROP",7.7,"0.1 M HEPES 7.7, 20% PEG3350",293.0,2018-01-25,2018-04-18,6FLG,4301.0,3.0,576.0,56.0,1.0,64.83,2.0,2.5,experimental,78.898,0.31055,0.24158,Crystal structure of zebrafish Sirtuin 5 in complex with 3(S)-(naphthylthio)succinyl-CPS1 peptide
7M0X,X-RAY DIFFRACTION,3.38,63.56,"VAPOR DIFFUSION, HANGING DROP",6.4,"100 mM Bis-Tris pH 6.4, 200 mM Ammonium Sulfate, and 22% PEG3350",293.0,2021-03-11,2021-04-21,7M0X,4955.0,2.0,680.0,171.0,,77.84,2.0,2.47,experimental,48.58,0.2151,0.1781,Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and PD0325901
6BSL,X-RAY DIFFRACTION,2.67,53.98,VAPOR DIFFUSION,,"8-12% PEG3350, 150-200 KSCN, 10mM spermadine",277.0,2017-12-04,2018-08-08,6BSL,3822.0,2.0,404.0,525.0,6.0,47.12,1.0,1.45,experimental,17.452,0.2093,0.1925,BMP1 complexed with a reverse hydroxymate - compound 22
6BTO,X-RAY DIFFRACTION,2.68,54.12,VAPOR DIFFUSION,,8-12% PEG 3350 150-200mM KSCN 10mM spermidine,277.0,2017-12-07,2018-08-08,6BTO,3585.0,2.0,404.0,333.0,6.0,47.04,1.0,2.05,experimental,21.349,0.2445,0.2076,"BMP1 complexed with (2~{S})-2-[[(1~{R},3~{S},4~{S})-2-[(2~{R})-2-[2-(oxidanylamino)-2-oxidanylidene-ethyl]heptanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]carbonylamino]-2-phenyl-ethanoic acid"
6BTQ,X-RAY DIFFRACTION,2.67,54.0,VAPOR DIFFUSION,,8-12% PEG 3350 150-200mM KSCN 10mM spermidine,277.0,2017-12-07,2018-08-08,6BTQ,3759.0,2.0,404.0,420.0,6.0,47.22,1.0,1.75,experimental,26.366,0.2058,0.1833,BMP1 complexed with a hydroxamate - compound 2
7JHP,X-RAY DIFFRACTION,2.21,44.42,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M ammonium acetate, 0.1 M Bis-Tris, pH 5.5, 17% w/v PEG10000",291.0,2020-07-21,2020-08-05,7JHP,2311.0,2.0,299.0,48.0,,34.86,2.0,2.766,experimental,50.88,0.2637,0.211,Crystal structure of HRas in complex with the Ras-binding and cysteine-rich domains of CRaf-kinase
8P8H,X-RAY DIFFRACTION,2.13,42.24,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M CHES pH 9.5, 30% PEG 3000",293.0,2023-06-01,2024-06-12,8P8H,4279.0,7.0,679.0,60.0,,73.9,1.0,2.3,experimental,47.233,0.257,0.2142,Crystal structure of HHD2 domain of hRTEL1
5WBH,X-RAY DIFFRACTION,2.77,55.58,"VAPOR DIFFUSION, HANGING DROP",7.0,tacsimate,289.0,2017-06-29,2017-12-20,5WBH,4442.0,6.0,536.0,334.0,,63.52,2.0,1.75,experimental,37.909,0.2102,0.1931,Structure of the FRB domain of mTOR bound to a substrate recruitment peptide of S6K1
7Q6H,X-RAY DIFFRACTION,2.13,42.32,VAPOR DIFFUSION,,8-20% PEG3350 and 0.2-0.3M ammonium sulphate (AS). 2% phenylurea,293.0,2021-11-07,2022-02-02,7Q6H,2782.0,1.0,327.0,374.0,,37.77,1.0,1.749,experimental,32.526,0.2202,0.1827,HUMAN JAK3 KINASE DOMAIN WITH 1-(4-((2-((1-methyl-1H-pyrazol-4-yl)amino)quinazolin-8-yl)amino)piperidin-1-yl)ethan-1-one
8T71,X-RAY DIFFRACTION,2.29,46.31,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium iodide, 2.2 M ammonium sulfate",293.0,2023-06-19,2024-02-14,8T71,2967.0,2.0,356.0,147.0,,41.82,2.0,1.8,experimental,35.0368,0.2115,0.1783,Crystal Structure of WT KRAS4a with bound GDP and Mg ion
5D2D,X-RAY DIFFRACTION,4.26,71.12,"VAPOR DIFFUSION, HANGING DROP",4.5,"HEPES, NaCl, DTT, Li2SO4, Glycine, K2HPO4",277.0,2015-08-05,2016-03-16,5D2D,4041.0,3.0,488.0,196.0,,56.72,2.0,2.1,experimental,,0.2202,0.1931,Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768
6OC1,X-RAY DIFFRACTION,3.05,59.67,"VAPOR DIFFUSION, HANGING DROP",8.2,Sodium Phosphate,293.0,2019-03-21,2019-11-13,6OC1,2891.0,1.0,369.0,36.0,,41.39,1.0,2.7,experimental,67.459,0.29394,0.22985,Crystal structure of human DHODH with TAK-632
5VCX,X-RAY DIFFRACTION,2.46,49.98,"VAPOR DIFFUSION, HANGING DROP",7.5,"6.9 MG/ML MYT1, 25 mM HEPES, 100 MM SODIUM CHLORIDE, 0.5 mM DTT, 0.1 M CALCIUM CHLORIDE, 0.05 M TRIS pH 8.5, 10 % PEG 4000, 1 mM SARACATINIB",291.0,2017-04-01,2017-08-23,5VCX,2303.0,1.0,311.0,32.0,,35.1,1.0,2.7,experimental,54.6016,0.2436,0.2013,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
5VCZ,X-RAY DIFFRACTION,2.11,41.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"14 MG/ML MYT1, 50 mM HEPES PH 7.5, 0.5 mM DTT, 0.05 M POTASSIUM CHLORIDE, 17.5 (V/V) % pentaerythritol propoxylate (5/4 PO/OH), 1.5 mM osutinib isomer",291.0,2017-04-01,2017-08-23,5VCZ,2604.0,1.0,311.0,236.0,,35.45,1.0,1.5,experimental,24.4034,0.1814,0.1478,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Bosutinib isomer
5VD0,X-RAY DIFFRACTION,2.07,40.72,"VAPOR DIFFUSION, HANGING DROP",7.5,"14 MG/ML MYT1, 50 mM HEPES PH 7.5, 0.5 mM DTT, 0.05 M POTASSIUM CHLORIDE, 17.5 (V/V) % pentaerythritol propoxylate (5/4 PO/OH), 1.5 mM  MK1775",291.0,2017-04-01,2017-08-23,5VD0,2389.0,1.0,311.0,68.0,,35.1,1.0,2.13,experimental,43.8782,0.231,0.1952,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
5VD1,X-RAY DIFFRACTION,2.13,42.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"14 MG/ML MYT1, 50 mM HEPES PH 7.5, 0.5 mM DTT, 0.05 M POTASSIUM CHLORIDE, 17.5 (V/V) % pentaerythritol propoxylate (5/4 PO/OH), 1.5 mM PHA-848125",291.0,2017-04-01,2017-08-23,5VD1,2540.0,1.0,311.0,202.0,,35.06,1.0,1.7,experimental,28.1278,0.1944,0.1465,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA-848125
5VD3,X-RAY DIFFRACTION,2.1,41.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"14 MG/ML MYT1, 50 mM HEPES PH 7.5, 0.5 mM DTT, 0.05 M POTASSIUM CHLORIDE, 17.5 (V/V) % pentaerythritol propoxylate (5/4 PO/OH), 1.5 mM SARACATINIB",291.0,2017-04-01,2017-08-23,5VD3,2496.0,1.0,311.0,166.0,,35.27,1.0,1.8,experimental,,0.2041,0.1664,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (de-phosphorylated) IN COMPLEX WITH SARACATINIB
8D59,X-RAY DIFFRACTION,2.46,50.03,"VAPOR DIFFUSION, HANGING DROP",5.7,"50 mM Sodium cacodylate pH 5.7, 1.5 M Lithium sulfate, 10 mM Magnesium sulfate",295.15,2022-06-04,2023-01-11,8D59,1703.0,1.0,262.0,53.0,,31.27,1.0,2.26,experimental,53.48,0.2295,0.2073,Crystal structure of human METTL1 in complex with SAM
8G5E,X-RAY DIFFRACTION,2.21,44.23,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% (w/v) PEG8000, 0.2M Sodium Chloride, 0.1M Hepes, pH 7.5, 5% MPD",291.0,2023-02-13,2023-02-22,8G5E,1874.0,1.0,225.0,100.0,,26.8,1.0,1.98,experimental,26.015,0.24856,0.20091,Crystal Structure of SETDB1 Tudor domain in complex with UNC6535
6AYW,X-RAY DIFFRACTION,2.33,47.14,"VAPOR DIFFUSION, SITTING DROP",,"CamKII S3-K301, in 20mM imidazole pH 8.5, 0.3M sodium chloride, 5mM TCEP, was concentrated to 36 mg/ml and flash frozen in liquid nitrogen for long term storage at -80 C in 10 microL aliquots. The protein was thawed and diluted down to 12 mg/mL in the same buffer just prior to crystallization experiments. Sitting drop vapor diffusion droplets were assembled with 250 nL of 12 mg/mL CamKII, 0.6 mM inhibitor and 250 nL of reservoir solution 24% peg 3350, 0.2 M ammonium tartrate, 0.1 M arginine. Flat crystal plates (typically 0.03 mm x 0.2 mm x 0.4 mm in size) grew in 4-7 days at 20 C. A crystal seed suspension was prepared with ten crushed crystals combined into 100 uL of reservoir solution and stored at -80 C. A thirty fold seed dilution was prepared in the same solution for addition to protein droplets in a 1 to 1 volume ratio to enhance crystallization of difficult to crystallize inhibitors.",293.0,2017-09-08,2017-11-15,6AYW,5043.0,2.0,604.0,259.0,,70.01,1.0,2.05,experimental,38.2,0.2669,0.1985,The structure of human CamKII with bound inhibitor
6BCD,X-RAY DIFFRACTION,2.7,53.2,"VAPOR DIFFUSION, HANGING DROP",5.25,"well solution containing 100 mM sodium citrate, 1.6 M ammonium sulfate, pH=5.25 was mixed at 1:1 ratio with protein at 45 mg/mL in 5 mM HEPES, 100 mM NaCl, 10 mM DTT, pH=7.4",289.15,2017-10-20,2018-08-01,6BCD,2086.0,2.0,255.0,187.0,,29.37,2.0,1.43,experimental,29.8026,0.1974,0.1749,Crystal structure of Rev7-K44A/R124A/A135D in complex with Rev3-RBM2 (residues 1988-2014)
8GW0,X-RAY DIFFRACTION,2.5,50.84,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M DL-Malic acid, pH 6.0, 1.6M potassium sodium tartrate tetrahydrate",298.0,2022-09-16,2023-09-20,8GW0,3068.0,1.0,391.0,265.0,1.0,43.03,1.0,1.64,experimental,28.769,0.1905,0.1696,Crystal structure of the human dihydroorotase domain in complex with malic acid
7EKE,X-RAY DIFFRACTION,3.24,62.03,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES, pH 6.5, 10% w/v PEG 5000 MME, 12% v/v1-Propanol",291.0,2021-04-05,2021-11-03,7EKE,6465.0,2.0,832.0,,7.0,96.85,2.0,2.7,experimental,45.71,0.2407,0.2119,Structure of SARS-CoV-2 spike receptor-binding domain F486L mutation complexed with human ACE2
7EKH,X-RAY DIFFRACTION,3.18,61.31,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES, pH 6.5, 10% w/v PEG 5000 MME, 12% v/v1-Propanol",291.0,2021-04-05,2021-11-03,7EKH,6717.0,2.0,832.0,250.0,7.0,96.87,2.0,2.4,experimental,45.67,0.228,0.2098,Structure of SARS-CoV-2 spike receptor-binding domain Y453F mutation complexed with human ACE2
7AYM,X-RAY DIFFRACTION,2.07,40.44,"VAPOR DIFFUSION, HANGING DROP",,"1.2 M tri-sodium citrate, 0.1 M Tris pH 8.5",293.0,2020-11-12,2020-12-16,7AYM,2273.0,1.0,337.0,8.0,,39.05,1.0,2.12,experimental,26.24,0.289,0.236,Structure of DDR2 Kinase domain in complex with IBZ3
6SLM,X-RAY DIFFRACTION,2.89,57.46,"VAPOR DIFFUSION, HANGING DROP",,"200mM tri-lithium citrate, 20% PEG 33350
protein concentration: 30mg/ml
cryo condition: 35% glycerol",293.0,2019-08-20,2020-09-09,6SLM,4281.0,1.0,551.0,31.0,,61.62,1.0,2.8,experimental,85.21,0.2682,0.23,Crystal structure of full-length HPV31 E6 oncoprotein in complex with LXXLL peptide of ubiquitin ligase E6AP
8UJF,X-RAY DIFFRACTION,2.7,54.53,"VAPOR DIFFUSION, HANGING DROP",9.5,0.1 M CHES pH 9.5 and 14-20% PEG 8000 (w/v),293.0,2023-10-11,2024-05-15,8UJF,8476.0,3.0,1142.0,24.0,12.0,129.78,2.0,2.87,experimental,51.88,0.2741,0.2173,"X-ray crystal structure of Toxoplasma gondii GalNAc-T3 in complex with UDP-GalNAc, Mn2+, and Muc5AC-3,13"
5DLS,X-RAY DIFFRACTION,2.8,55.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"10-15% PEG8K, 0.1 M Hepes pH
7.5, and 15% (v/v) 2-propanol.",292.0,2015-09-07,2015-10-14,5DLS,2198.0,1.0,297.0,109.0,,34.78,1.0,2.15,experimental,50.399,0.22163,0.16507,"Identification of Novel, in vivo Active Chk1 Inhibitors Utilizing Structure Guided Drug Design"
7SUF,X-RAY DIFFRACTION,2.51,50.93,"VAPOR DIFFUSION, SITTING DROP",6.5,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2021-11-17,2022-01-12,7SUF,2416.0,1.0,297.0,235.0,,34.69,1.0,1.48,experimental,22.392,0.2538,0.2168,Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 06
7SUI,X-RAY DIFFRACTION,2.34,47.34,"VAPOR DIFFUSION, SITTING DROP",,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2021-11-17,2022-01-12,7SUI,2266.0,1.0,297.0,99.0,,34.64,1.0,2.119,experimental,48.4,0.2525,0.1953,Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 22
6AUB,X-RAY DIFFRACTION,2.31,46.73,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 MM IMIDAZOLE PH 7.0, 14% PEG 10,000, 200 MM LI2SO4, 10 MM BETA MERCAPTOETHANOL, 0.75% (W/V) s-BOG",289.0,2017-08-31,2018-09-12,6AUB,2368.0,1.0,264.0,182.0,,31.73,1.0,1.65,experimental,21.1996,0.199,0.166,CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815
7PPX,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES pH 7.0, 2.4 AmSO4, ATAD2~5 mg mL-1.",293.0,2021-09-15,2022-09-21,7PPX,1343.0,1.0,130.0,163.0,,16.57,1.0,1.35,experimental,32.546,0.2306,0.2108,ATAD2 in complex with FragLite3
7QU7,X-RAY DIFFRACTION,3.97,69.04,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-01-17,2022-11-23,7QU7,1213.0,1.0,130.0,57.0,1.0,16.14,1.0,2.13,experimental,59.121,0.2806,0.2183,ATAD2 in complex with FragLite16
7QUK,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-01-18,2022-11-23,7QUK,1279.0,1.0,130.0,140.0,,15.89,1.0,1.47,experimental,31.643,0.2304,0.202,ATAD2 in complex with FragLite1
7QUM,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-01-18,2023-03-01,7QUM,1334.0,1.0,130.0,163.0,,16.25,1.0,1.5,experimental,32.315,0.2233,0.1973,ATAD2 in complex with FragLite2
7QWO,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-01-25,2022-11-23,7QWO,1265.0,1.0,130.0,138.0,,16.15,1.0,1.5,experimental,41.941,0.2725,0.2392,ATAD2 in complex with FragLite6
7QX1,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-01-26,2022-11-23,7QX1,1300.0,1.0,130.0,161.0,,16.43,1.0,1.49,experimental,34.025,0.2424,0.2046,ATAD2 in complex with FragLite7
7QXT,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-01-27,2022-11-23,7QXT,1315.0,1.0,130.0,153.0,,16.02,1.0,1.51,experimental,45.639,0.2558,0.2218,ATAD2 in complex with FragLite10
7QYK,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-01-28,2023-03-22,7QYK,1333.0,1.0,130.0,174.0,,16.37,1.0,1.43,experimental,29.761,0.2124,0.1956,ATAD2 in complex with FragLite18
7QYL,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-01-28,2022-11-23,7QYL,1318.0,1.0,130.0,127.0,,16.44,1.0,1.44,experimental,33.702,0.2437,0.22,ATAD2 in complex with FragLite23
7QZM,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-01-31,2023-03-22,7QZM,1287.0,1.0,130.0,141.0,,16.4,1.0,1.45,experimental,34.054,0.2423,0.2077,ATAD2 in complex with FragLite28
7QZY,X-RAY DIFFRACTION,3.99,69.2,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-02-01,2023-03-22,7QZY,1267.0,1.0,130.0,118.0,,16.35,1.0,1.93,experimental,40.093,0.2453,0.1973,ATAD2 in complex with FragLite29
7QZZ,X-RAY DIFFRACTION,4.04,69.55,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-02-01,2022-12-07,7QZZ,1203.0,1.0,130.0,49.0,1.0,16.3,1.0,2.52,experimental,62.564,0.2399,0.2031,ATAD2 in complex with FragLite31
7R00,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-02-01,2022-12-07,7R00,1368.0,1.0,130.0,177.0,,16.26,1.0,1.48,experimental,32.147,0.2367,0.2067,ATAD2 in complex with FragLite33
7R05,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-02-01,2022-11-23,7R05,1364.0,1.0,130.0,206.0,,16.09,1.0,1.53,experimental,35.161,0.2156,0.1907,ATAD2 in complex with PepLite-Ile
7R0Y,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-02-02,2022-11-23,7R0Y,1392.0,1.0,130.0,230.0,,16.03,1.0,1.43,experimental,34.361,0.2135,0.1951,ATAD2 in complex with PepLite-Glu
7Z9H,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-03-21,2022-11-23,7Z9H,1337.0,1.0,130.0,180.0,,16.22,1.0,1.34,experimental,31.198,0.2269,0.2099,ATAD2 in complex with PepLite-Asp
7Z9I,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-03-21,2022-11-23,7Z9I,1340.0,1.0,130.0,201.0,,16.05,1.0,1.5,experimental,34.712,0.2193,0.1896,ATAD2 in complex with PepLite-Ala
7Z9O,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-03-21,2022-11-23,7Z9O,1318.0,1.0,130.0,180.0,,16.19,1.0,1.47,experimental,35.912,0.2176,0.201,ATAD2 in complex with PepLite-Tyr
7Z9S,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BisTris pH 6-7, 1.7-2.1M Ammonium sulphate",293.0,2022-03-21,2022-11-23,7Z9S,1373.0,1.0,130.0,197.0,,16.31,1.0,1.5,experimental,35.981,0.2362,0.2039,ATAD2 in complex with PepLite-Arg
7EKC,X-RAY DIFFRACTION,3.2,61.53,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES, pH 6.5, 12% w/v PEG 20000",291.0,2021-04-05,2021-11-03,7EKC,6569.0,2.0,832.0,50.0,7.0,97.55,2.0,2.8,experimental,53.64,0.2252,0.2141,Structure of SARS-CoV-2 Gamma variant spike receptor-binding domain complexed with human ACE2
7EKF,X-RAY DIFFRACTION,3.28,62.49,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES, pH 6.5, 10% w/v PEG 5000 MME, 12% v/v1-Propanol",291.0,2021-04-05,2021-11-03,7EKF,6521.0,2.0,832.0,,7.0,97.36,2.0,2.85,experimental,73.01,0.2238,0.2081,Structure of SARS-CoV-2 Alpha variant spike receptor-binding domain complexed with human ACE2
7EKG,X-RAY DIFFRACTION,3.33,63.02,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES, pH 6.5, 12% w/v PEG 20000",291.0,2021-04-05,2021-11-03,7EKG,6534.0,2.0,832.0,21.0,7.0,97.56,2.0,2.63,experimental,73.16,0.2484,0.2138,Structure of SARS-CoV-2 Beta variant spike receptor-binding domain complexed with human ACE2
6HRP,X-RAY DIFFRACTION,2.26,45.61,"VAPOR DIFFUSION, HANGING DROP",8.0,"33% PEG3350, 0.1M HEPES",293.0,2018-09-28,2019-03-20,6HRP,2630.0,1.0,283.0,444.0,,33.16,1.0,1.12,experimental,15.453,0.19243,0.17391,"CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4-dihydroisoquinolin-1-one"
6HRT,X-RAY DIFFRACTION,2.26,45.69,"VAPOR DIFFUSION, HANGING DROP",8.0,"33% PEG3350, 0.1M HEPES",293.0,2018-09-28,2019-03-20,6HRT,2573.0,1.0,283.0,385.0,,33.19,1.0,1.36,experimental,17.209,0.20081,0.17748,"CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-yl)-9-hydroxy-6-methyl-4-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-azatricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,11,13-pentaen-5-one"
6EIF,X-RAY DIFFRACTION,2.65,53.62,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M KSCN; 0.1M NaCl; 14% PEG 3350, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2017-09-19,2018-08-29,6EIF,11105.0,4.0,1472.0,234.0,,172.02,1.0,2.22,experimental,46.94,0.25049,0.21836,DYRK1A in complex with XMD7-117
6EIR,X-RAY DIFFRACTION,2.57,52.23,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M KSCN; 0.1 M NaCl; 10% PEG 3350, pH 6.8",293.0,2017-09-19,2018-08-29,6EIR,11161.0,4.0,1472.0,111.0,,172.59,1.0,2.4,experimental,48.756,0.25813,0.23371,DYRK1A in complex with XMD15-27-2
6O8I,X-RAY DIFFRACTION,2.39,48.53,VAPOR DIFFUSION,,Unkown,298.0,2019-03-11,2019-04-03,6O8I,2447.0,1.0,269.0,248.0,,31.8,1.0,1.42,experimental,24.03,0.222,0.192,BTK In Complex With Inhibitor
5ZC5,X-RAY DIFFRACTION,2.17,43.4,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2018-02-15,2018-12-19,5ZC5,2023.0,1.0,253.0,60.0,5.0,28.85,1.0,1.9,experimental,37.68,0.235,0.203,uPA-NU-09F
7RBS,X-RAY DIFFRACTION,3.71,66.85,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.02 M MgCl2, 0.1 M HEPES buffer, 22% poly(acrylicacid sodium salt) 5100",289.0,2021-07-06,2021-09-29,7RBS,18482.0,10.0,2385.0,54.0,1.0,266.49,2.0,2.98,experimental,76.102,0.2358,0.1951,"The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with human ISG15"
8H6P,X-RAY DIFFRACTION,3.0,59.09,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium citrate pH 6.5, 10% PEG3350",291.15,2022-10-18,2023-02-22,8H6P,4700.0,2.0,569.0,50.0,,66.07,2.0,2.44,experimental,78.41,0.2924,0.2211,"Complex structure of CDK2/Cyclin E1 and a potent, selective macrocyclic inhibitor"
6RAV,X-RAY DIFFRACTION,2.54,51.59,"VAPOR DIFFUSION, SITTING DROP",,"24 % (w/v) PEG3350, 0.2 M ammonium acetate, 0.1 M Bis-Tris (pH 5.5), 2mM inhibitor",293.0,2019-04-08,2019-04-17,6RAV,4922.0,2.0,582.0,366.0,10.0,67.37,1.0,1.7,experimental,31.753,0.2267,0.1952,"Complement factor B protease domain in complex with the reversible inhibitor 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid"
5EG2,X-RAY DIFFRACTION,3.16,61.03,"VAPOR DIFFUSION, HANGING DROP",8.4,"1:1 ratio of protein solution to crystallization solution.
Protein solution: 4.0-8.0 mg/mL protein, 2.5 mM AdoMet, 2.0 mM TAF10 peptide, and 2.0 mM TCEP
Crystallant solution: 0.99 - 1.02 M sodium citrate, 12 - 22 mM nickel (II) chloride, and 100 mM imidazole pH 8.4",293.0,2015-10-26,2016-01-13,5EG2,2282.0,2.0,272.0,316.0,,30.74,2.0,1.55,experimental,29.5651,0.1712,0.1467,SET7/9 N265A in complex with AdoHcy and TAF10 peptide
6AAJ,X-RAY DIFFRACTION,2.74,55.16,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate(pH6.5), 100mM ammonium phosphate, 20% PEG4000",293.0,2018-07-18,2018-08-15,6AAJ,4665.0,2.0,598.0,42.0,,70.93,1.0,2.37,experimental,59.196,0.26163,0.20819,Crystal structure of JAK2 in complex with peficitinib
7QXY,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2022-01-27,2022-04-20,7QXY,4386.0,1.0,480.0,661.0,2.0,53.0,1.0,1.478,experimental,24.97,0.1823,0.1705,X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 3
7QXZ,X-RAY DIFFRACTION,3.8,67.66,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NAH2PO4, PH 5.5, 2 M NACL; RESERVOIR SOLUTION: 3.0-3.2M NACL",293.15,2022-01-27,2022-04-13,7QXZ,4278.0,1.0,480.0,568.0,3.0,52.89,1.0,1.8,experimental,27.27,0.2173,0.1815,X-ray structure of furin in complex with the dichlorophenylpyridine-based inhibitor 5
6CW3,X-RAY DIFFRACTION,2.41,48.93,MICROBATCH,7.0,"100 mM succinic acid pH 7.0, 15% w/v PEG3350",294.0,2018-03-29,2018-09-19,6CW3,11837.0,8.0,1650.0,662.0,8.0,183.55,4.0,1.98,experimental,62.9619,0.2273,0.2025,"Crystal structure of a yeast SAGA transcriptional coactivator Ada2/Gcn5 HAT subcomplex, crystal form 2"
8GH7,X-RAY DIFFRACTION,1.82,32.39,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 35% isopropanol and 18% PEG 4000",293.0,2023-03-09,2023-07-05,8GH7,1709.0,4.0,206.0,90.0,,24.6,2.0,1.75,experimental,,0.2091,0.1775,142D6 bound to BIR3-XIAP
6G3P,X-RAY DIFFRACTION,2.5,50.81,VAPOR DIFFUSION,,"50 mM TRIS pH 9.0, 23% PEG3350",293.0,2018-03-26,2019-06-26,6G3P,4067.0,4.0,612.0,53.0,,72.28,1.0,2.8,experimental,34.27,0.262,0.219,X-ray structure of seleno-methionine labelled NSD3-PWWP1
6G3T,X-RAY DIFFRACTION,2.84,56.67,VAPOR DIFFUSION,,"100 mM HEPES pH 7.8, 28% PEG3350, 2% PEG200, 1.5% 1,2-Butandiol",293.0,2018-03-26,2019-06-26,6G3T,4080.0,4.0,612.0,137.0,,72.62,1.0,2.53,experimental,53.46,0.274,0.229,X-ray structure of NSD3-PWWP1
7KKE,X-RAY DIFFRACTION,2.27,45.85,VAPOR DIFFUSION,8.5,"25% PEG3350, 200MM LITHIUM SULFATE, 10   
REMARK 280  MM DTT, 10 MM EDTA, 100 MM TRIS, PH 8.5, VAPOR DIFFUSION,           
REMARK 280  HANGING DROP, TEMPERATURE 298K",298.0,2020-10-27,2021-03-24,7KKE,6825.0,1.0,971.0,23.0,,111.66,1.0,2.81,experimental,86.79,0.2637,0.1936,Phosphoinositide 3-Kinase gamma bound to a thiazole inhibitor
5USZ,X-RAY DIFFRACTION,2.21,44.39,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-02-14,2017-06-07,5USZ,2349.0,1.0,289.0,214.0,,33.78,1.0,2.103,experimental,,0.2235,0.1718,JAK2 JH2 in complex with JNJ-7706621
5UT4,X-RAY DIFFRACTION,2.23,44.84,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-02-14,2017-06-07,5UT4,2241.0,1.0,289.0,111.0,,33.87,1.0,2.0,experimental,,0.2198,0.1786,JAK2 JH2 in complex with NVP-BSK805
5UT6,X-RAY DIFFRACTION,2.2,44.05,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-02-14,2017-06-07,5UT6,2466.0,1.0,289.0,280.0,,34.03,1.0,1.645,experimental,,0.2059,0.1664,JAK2 JH2 in complex with a diaminopyrimidine
6T3C,X-RAY DIFFRACTION,2.23,44.79,VAPOR DIFFUSION,8.0,"20 % PEG3350, 0.175 M ammonium sulfate, 0.001 M TCEP, 0.1 M Hepes pH 8.0",293.0,2019-10-10,2020-01-01,6T3C,6499.0,1.0,966.0,,,111.11,1.0,2.62,experimental,,0.235,0.2,Crystal structure of PI3Kgamma in complex with DNA-PK inhibitor AZD7648
6XRL,X-RAY DIFFRACTION,2.51,51.07,VAPOR DIFFUSION,,"PEG 4000,  (NH4)2SO4, Na Form, Tris",277.0,2020-07-13,2020-09-16,6XRL,6827.0,1.0,949.0,4.0,,109.47,1.0,2.99,experimental,127.957,0.2694,0.2023,Crystal structure of human PI3K-gamma in complex with inhibitor IPI-549
7EW9,X-RAY DIFFRACTION,2.26,45.47,EVAPORATION,8.5,"0.2 M sodium acetate, 0.1 M Tris, pH 8.5, 26 % (w/v) PEG 3350",293.15,2021-05-25,2021-12-29,7EW9,4450.0,3.0,510.0,276.0,,60.54,1.0,2.13,experimental,39.1453,0.2568,0.2009,GDP-bound KRAS G12D in complex with TH-Z816
7EWA,X-RAY DIFFRACTION,2.2,44.17,EVAPORATION,8.5,"0.2 M sodium acetate, 0.1 M Tris, pH 8.5, 26 % (w/v) PEG 3350",297.0,2021-05-25,2021-12-29,7EWA,4239.0,3.0,510.0,169.0,,60.72,1.0,2.25,experimental,43.4692,0.2584,0.203,GDP-bound KRAS G12D in complex with TH-Z827
7EWB,X-RAY DIFFRACTION,2.2,44.17,EVAPORATION,,"0.2 M sodium acetate, 0.1 M Tris, pH 8.5, 26 % (w/v) PEG 3350",297.0,2021-05-25,2021-12-29,7EWB,4576.0,3.0,510.0,317.0,,61.22,1.0,1.99,experimental,31.239,0.246,0.1949,GDP-bound KRAS G12D in complex with TH-Z835
6E6P,X-RAY DIFFRACTION,1.94,36.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"152 mM Calcium Acetate, 22.8% PEG 3350, 9.5% stabilization buffer (20 mM HEPES pH 7.5, 50 mM NaCl, 20 mM MgCl2), Crystals were grown in 2uL by 2 uL drops of mother liquor to protein (22 mg/mL), Cryoprotectant: 70% glycerol and 30% mother liquor",291.15,2018-07-25,2019-07-31,6E6P,4118.0,3.0,498.0,225.0,,58.91,1.0,1.93,experimental,36.2982,0.237,0.184,"HRAS G13D bound to GppNHp (Ha,b,c13GNP)"
8JNA,X-RAY DIFFRACTION,1.91,35.73,"VAPOR DIFFUSION, SITTING DROP",8.0,"1.0M tri-sodium citrate, 0.1M imidazole, pH 8.0",293.0,2023-06-06,2024-06-19,8JNA,633.0,1.0,94.0,30.0,,10.52,1.0,1.7,experimental,41.79,0.2717,0.2515,"CRAF ras-binding domain chimera, apo form"
8JNB,X-RAY DIFFRACTION,2.14,42.61,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.5M ammonium sulfate, 1.0M lithium sulfate, 0.1M sodium citrate, pH 5.6",293.0,2023-06-06,2024-06-19,8JNB,738.0,1.0,94.0,73.0,,10.89,1.0,1.62,experimental,30.32,0.2422,0.2039,"CRAF ras-binding domain chimera, ligand complex"
5KA3,X-RAY DIFFRACTION,3.45,64.37,"VAPOR DIFFUSION, SITTING DROP",,"0.1 HEPES, pH 7.8, 0.2 M MgCl2, 20.5% PEG8000",277.0,2016-06-01,2017-03-08,5KA3,2533.0,1.0,306.0,122.0,,36.11,1.0,2.141,experimental,39.2286,0.2367,0.2005,"Protein Tyrosine Phosphatase 1B YAYA (Y152A, Y153A) mutant in complex with TCS401, closed state"
8GC7,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.06 M Magnesium chloride hexahydrate,
0.06 M Calcium chloride dihydrate, 0.1M Imidazole, 0.1M MES monohydrate, 24% v/v PEG 500 MME, 12 % w/v PEG 20000, pH 6.5",277.0,2023-03-01,2024-01-31,8GC7,2483.0,1.0,270.0,249.0,,32.05,1.0,1.9,experimental,12.92,0.2269,0.192,Bruton's tyrosine kinase in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyrazine-2-carboxamide
8GC8,X-RAY DIFFRACTION,2.3,46.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"20%(v/v) 2-propanol, 0.1M HEPES pH 7.5, 10% PEG 4000",293.0,2023-03-01,2024-01-31,8GC8,2212.0,1.0,270.0,133.0,,32.28,1.0,1.75,experimental,32.11,0.2232,0.1948,Bruton's tyrosine kinase L528W mutant in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyrazine-2-carboxamide
4NCT,X-RAY DIFFRACTION,2.6,52.65,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.05M LiCl; 10% PEG 3350, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2013-10-25,2015-04-01,4NCT,11425.0,4.0,1472.0,211.0,4.0,172.98,2.0,2.597,experimental,49.922,0.24946,0.20805,Human DYRK1A in complex with PKC412
5HU0,X-RAY DIFFRACTION,2.94,58.1,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200MM NA/K TARTRATE, 100MM HEPES PH7",277.0,2016-01-27,2016-11-09,5HU0,7109.0,2.0,824.0,925.0,6.0,93.01,1.0,1.83,experimental,17.5195,0.1985,0.169,BACE1 in complex with 4-(3-(furan-2-carboxamido)phenyl)-1-methyl-5-oxo-4-phenylimidazolidin-2-iminium
6NFH,X-RAY DIFFRACTION,2.27,45.85,"VAPOR DIFFUSION, SITTING DROP",6.5,"31% w/v PEG5000 MME, 0.1 M MES, pH 6.5, 0.1 M ammonium sulfate",277.0,2018-12-20,2019-03-13,6NFH,2703.0,1.0,271.0,276.0,,32.46,1.0,1.4,experimental,14.678,0.2054,0.1558,"BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxypropoxy]phenyl}amino)-5,8-dihydropteridine-6,7-dione"
6NFI,X-RAY DIFFRACTION,2.44,49.63,"VAPOR DIFFUSION, SITTING DROP",6.5,"31% w/v PEG5000 MME, 0.1 M MES, pH 6.5, 0.1 M ammonium sulfate",277.0,2018-12-20,2019-03-13,6NFI,2093.0,1.0,268.0,33.0,,31.97,1.0,2.41,experimental,55.476,0.24764,0.21674,"BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazol-6-yl)methanesulfonamide"
7YC9,X-RAY DIFFRACTION,2.35,47.71,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Sodium cacodylate trihydrate pH 7.0, 0.2M Ammonium sulfate, 26% PEG8000",277.0,2022-07-01,2023-05-17,7YC9,2598.0,1.0,269.0,332.0,,31.93,1.0,1.4,experimental,13.88,0.1874,0.1656,Co-crystal structure of BTK kinase domain with inhibitor
8FLL,X-RAY DIFFRACTION,1.98,37.99,"VAPOR DIFFUSION, SITTING DROP",5.5,"31% PEG3350, 0.3 M ammonium sulfate, 0.1 M Bis-Tris pH 5.5",293.0,2022-12-21,2023-03-01,8FLL,2396.0,1.0,273.0,168.0,,32.76,1.0,1.498,experimental,27.54,0.2019,0.185,Crystal structure of BTK kinase domain in complex with pirtobrutinib
8FLN,X-RAY DIFFRACTION,1.99,38.18,"VAPOR DIFFUSION, SITTING DROP",5.5,"32% PEG3350, 0.3 M ammonium sulfate, 0.1 M Tis-Tris pH 5.5",293.0,2022-12-21,2023-03-01,8FLN,2403.0,1.0,273.0,181.0,,32.74,1.0,1.334,experimental,28.29,0.1991,0.1931,Crystal structure of BTK C481S kinase domain in complex with pirtobrutinib
8U2D,X-RAY DIFFRACTION,2.58,52.38,"VAPOR DIFFUSION, SITTING DROP",7.5,"30% EDO_P8K, 0.03M NaF, 0.03M, NaBr, 0.03M NaI, 0.05M Sodium HEPES, 0.05M MOPS pH 7.5",277.0,2023-09-05,2024-01-31,8U2D,2418.0,1.0,270.0,161.0,,32.36,1.0,1.95,experimental,28.43,0.2384,0.1905,"Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-3-(3-methylphenyl)-1-oxopropan-2-yl]-1H-indazole-5-carboxamide"
8U2E,X-RAY DIFFRACTION,2.5,50.82,"VAPOR DIFFUSION, SITTING DROP",6.5,"30% EDO_P8K, 0.03M NaN03, 0.03M Na2HPO4 0.03M (NH4)2SO4, 0.05M Imidazole, 0.05M MES pH 6.5",277.0,2023-09-05,2024-01-31,8U2E,2475.0,1.0,270.0,214.0,,32.34,1.0,1.9,experimental,23.28,0.2377,0.1908,"Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-3-(3-methylphenyl)-1-oxopropan-2-yl]-1H-indazole-5-carboxamide"
5J48,X-RAY DIFFRACTION,2.42,49.23,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 400, 200 mM CaAc, 0.1M NaAc pH 4.5-4.8",277.0,2016-03-31,2017-04-12,5J48,2386.0,2.0,270.0,280.0,,31.53,1.0,1.49,experimental,,0.1891,0.1634,PKG I's Carboyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-pCPT-cGMP
8RIJ,X-RAY DIFFRACTION,2.37,48.1,"VAPOR DIFFUSION, SITTING DROP",,not known,293.0,2023-12-18,2024-02-21,8RIJ,1403.0,1.0,158.0,126.0,,18.24,1.0,1.96,experimental,30.522,0.21904,0.17279,Discovery of the first orally bioavailable ADAMTS7 inhibitor BAY-9835
7KKM,X-RAY DIFFRACTION,2.33,47.16,VAPOR DIFFUSION,,"Precipitant: 20.0 %v/v Ethylene glycol
Precipitant: 10.0 %w/v PEG 4000
Salt: 0.1 M Sodium chloride
Buffer: 0.1 M MES (pH 6.00)",277.0,2020-10-27,2021-01-06,7KKM,7235.0,4.0,852.0,753.0,,97.69,1.0,1.58,experimental,27.22,0.233,0.195,Structure of the catalytic domain of tankyrase 1
6GUB,X-RAY DIFFRACTION,2.95,58.25,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor",277.0,2018-06-19,2018-12-05,6GUB,9046.0,4.0,1140.0,72.0,,131.15,2.0,2.52,experimental,46.819,0.23822,0.19543,CDK2/CyclinA in complex with Flavopiridol
6GUC,X-RAY DIFFRACTION,2.94,58.12,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor",277.0,2018-06-19,2018-12-05,6GUC,9518.0,4.0,1140.0,537.0,,130.83,2.0,2.0,experimental,44.106,0.22315,0.19165,CDK2/CyclinA in complex with SU9516
6GUF,X-RAY DIFFRACTION,2.97,58.6,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor",277.0,2018-06-19,2018-12-05,6GUF,9172.0,4.0,1140.0,124.0,,131.12,2.0,2.65,experimental,49.682,0.25503,0.20289,CDK2/CyclinA in complex with CGP74514A
5K9V,X-RAY DIFFRACTION,2.54,51.58,"VAPOR DIFFUSION, SITTING DROP",7.8,"0.1 M Tris, pH 7.8, 0.2 M MgCl2, 18% PEG8000",277.0,2016-06-01,2017-03-01,5K9V,2496.0,1.0,306.0,213.0,,36.1,1.0,1.898,experimental,29.8523,0.2059,0.1733,"Protein Tyrosine Phosphatase 1B (1-301), open state"
5K9W,X-RAY DIFFRACTION,3.38,63.58,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 20% PEG8000",277.0,2016-06-01,2017-03-01,5K9W,2628.0,1.0,306.0,171.0,,36.21,1.0,2.01,experimental,29.4658,0.2148,0.1848,"Protein Tyrosine Phosphatase 1B (1-301) in complex with TCS401, closed state"
5KA0,X-RAY DIFFRACTION,2.5,50.71,"VAPOR DIFFUSION, SITTING DROP",7.8,"0.1 M HEPES, pH 7.8, 0.2 M MgCl2, 12% PEG8000",277.0,2016-06-01,2017-03-01,5KA0,2515.0,1.0,289.0,213.0,,34.25,1.0,1.991,experimental,26.9813,0.211,0.1646,"Protein Tyrosine Phosphatase 1B Delta helix 7, open state"
5KA2,X-RAY DIFFRACTION,3.35,63.24,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 24% PEG8000",277.0,2016-06-01,2017-03-08,5KA2,2408.0,1.0,306.0,149.0,,35.88,1.0,2.071,experimental,35.2707,0.2382,0.2037,"Protein Tyrosine Phosphatase 1B YAYA (Y152A, Y153A) mutant, open state"
5KA7,X-RAY DIFFRACTION,3.39,63.71,"VAPOR DIFFUSION, SITTING DROP",7.6,"0.1 M Tris, pH 7.6, 0.2 M MgCl2, 24% PEG8000",277.0,2016-06-01,2017-03-08,5KA7,2604.0,1.0,306.0,165.0,,36.18,1.0,2.061,experimental,29.1872,0.2137,0.1834,"Protein Tyrosine Phosphatase 1B T178A mutant in complex with TCS401, closed state"
5KA9,X-RAY DIFFRACTION,3.48,64.63,"VAPOR DIFFUSION, SITTING DROP",7.8,"0.1 M Tris, 0.2 M mgCl2, 18.5% PEG8000",277.0,2016-06-01,2017-03-01,5KA9,2655.0,1.0,306.0,189.0,,36.13,1.0,2.07,experimental,30.993,0.2302,0.1887,"Protein Tyrosine Phosphatase 1B L192A mutant in complex with TCS401, open state"
5KAA,X-RAY DIFFRACTION,2.49,50.64,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M HEPES, pH 8.0, 0.2 M MgCl2, 19% PEG8000",277.0,2016-06-01,2017-03-08,5KAA,2520.0,1.0,289.0,206.0,,34.08,1.0,1.968,experimental,25.843,0.2104,0.1728,"Protein Tyrosine Phosphatase 1B Delta helix 7, P185G mutant, open state"
5KAB,X-RAY DIFFRACTION,2.46,49.94,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 22% PEG8000",277.0,2016-06-01,2017-03-08,5KAB,2487.0,1.0,289.0,161.0,,34.25,1.0,1.968,experimental,29.2647,0.2092,0.1781,"Protein Tyrosine Phosphatase 1B Delta helix 7, P185G mutant in complex with TCS401, open state"
5KAC,X-RAY DIFFRACTION,2.51,51.04,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris, pH 7.4, 0.2 M MgCl2, 18% PEG8000",277.0,2016-06-01,2017-03-08,5KAC,2463.0,1.0,306.0,202.0,,36.06,1.0,1.9,experimental,31.7259,0.2109,0.1681,"Protein Tyrosine Phosphatase 1B P185G mutant, open state"
6B90,X-RAY DIFFRACTION,3.36,63.34,"VAPOR DIFFUSION, HANGING DROP",7.5,"well solution: PEG 8000, magnesium acetate, Hepes, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2017-10-09,2018-06-20,6B90,2997.0,1.0,321.0,294.0,,37.95,1.0,1.95,experimental,32.3237,0.1926,0.158,Multiconformer model of apo WT PTP1B with glycerol at 100 K (ALTERNATIVE REFINEMENT OF PDB 1SUG showing conformational heterogeneity)
7AAM,X-RAY DIFFRACTION,2.5,53.0,"VAPOR DIFFUSION, HANGING DROP",6.0,"100 mM Bis-Tris-propane (pH=6.0), 20% (w/v) PEG 3350, 200 mM sodium citrate.
LYP-CTH peptide was soaked into preformed crystals of the F-BAR domain of PSTPIP1.",298.0,2020-09-04,2022-02-23,7AAM,4925.0,3.0,605.0,162.0,,71.09,2.0,2.15,experimental,33.12,0.2409,0.2049,Crystal structure of the F-BAR domain of PSTIPIP1 bound to the CTH domain of the phosphatase LYP
5GRN,X-RAY DIFFRACTION,1.61,23.71,"VAPOR DIFFUSION, SITTING DROP",,"0.2M KCl, 20% PEG 3350, pH 7.0",293.0,2016-08-11,2017-08-16,5GRN,2716.0,1.0,356.0,382.0,,41.28,1.0,1.77,experimental,,0.1793,0.157,Crystal structure of PDGFRA in Complex with WQ-C-159
7SQ2,X-RAY DIFFRACTION,3.04,59.57,"VAPOR DIFFUSION, HANGING DROP",6.0,"7% PEG 6000, 100 mM Hepes, 1 mM CaCl2, 100 mM magnesium acetate",291.0,2021-11-04,2021-11-17,7SQ2,8957.0,2.0,1212.0,215.0,,139.17,2.0,2.6,experimental,91.472,0.26334,0.19924,Reprocessed and refined structure of Phospholipase C-beta and Gq signaling complex
7TRM,X-RAY DIFFRACTION,4.21,70.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Bis-Tris Propane, 0.2 M Sodium Citrate, and 20% PEG3350",277.15,2022-01-29,2023-08-02,7TRM,807.0,1.0,94.0,45.0,,11.58,1.0,2.4,experimental,37.56,0.2252,0.1741,Crystal structure of human BIRC2 BIR3 domain in complex with inhibitor LCL-161
7XE1,X-RAY DIFFRACTION,3.5,64.88,"VAPOR DIFFUSION, SITTING DROP",,"320mM Ammonium citrate, 22% PEG 3350",293.0,2022-03-29,2022-09-14,7XE1,13150.0,2.0,1586.0,1004.0,,182.06,1.0,2.07,experimental,46.32,0.192,0.164,Crystal structure of LSD2 in complex with cis-4-Br-PCPA
7XE2,X-RAY DIFFRACTION,3.45,64.33,"VAPOR DIFFUSION, SITTING DROP",,"300mM Ammonium citrate, 24% PEG 3350",288.0,2022-03-29,2022-09-14,7XE2,13126.0,2.0,1586.0,969.0,,183.22,1.0,2.05,experimental,46.77,0.194,0.167,Crystal structure of LSD2 in complex with trans-4-Br-PCPA
5H3Q,X-RAY DIFFRACTION,3.97,68.99,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.2M Sodium Tartrate, 100mM Tris-HCl pH 8.5, 5 mM DTT",293.0,2016-10-26,2017-02-22,5H3Q,2550.0,1.0,324.0,94.0,,37.33,1.0,2.1,experimental,45.184,0.2151,0.1884,Crystal Structure of TrkA kinase with ligand
6NSP,X-RAY DIFFRACTION,2.66,53.87,"VAPOR DIFFUSION, HANGING DROP",,"0.1M KH2PO4/ 0.1M NaH2PO4/ 0.1M MES/NaOH pH 6.0 and 1.9M NaCl (cryo: 25% glycerol in reservoir), or 18% (w/v) PEG 3350, 0.2M CaCl2, 0.1M, MES pH = 6.50 (cryo: direct).",277.0,2019-01-25,2019-05-22,6NSP,2435.0,1.0,297.0,46.0,,34.13,1.0,2.31,experimental,50.252,0.25498,0.1874,TRK-A IN COMPLEX WITH LIGAND 9
6NSS,X-RAY DIFFRACTION,2.54,51.61,"VAPOR DIFFUSION, HANGING DROP",,"0.10M KH2PO4/ 0.10M NaH2PO4/ 0.1M MES/NaOH pH = 6.00 and 1.9M NaCl (cryo: 25% glycerol in reservoir), or 18% (w/v) PEG 3350, 0.2M CaCl2, 0.10M, MES pH = 6.50 (cryo: direct).",277.0,2019-01-25,2019-05-22,6NSS,2595.0,1.0,311.0,132.0,,35.8,1.0,1.97,experimental,32.164,0.21805,0.18063,TRK-A IN COMPLEX WITH LIGAND 6
5JAX,X-RAY DIFFRACTION,1.94,36.76,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 400, 200 mM CaAc, 0.1M NaAc pH 4.5-4.8",301.0,2016-04-12,2017-04-19,5JAX,1173.0,1.0,135.0,127.0,,15.51,1.0,1.486,experimental,,0.199,0.166,PKG I's Carboyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-Br-cGMP
5JD7,X-RAY DIFFRACTION,1.72,32.83,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 400, 200 mM CaAc, 0.1M NaAc pH 4.5-4.8.",277.0,2016-04-15,2017-08-09,5JD7,1102.0,1.0,135.0,80.0,,15.43,1.0,1.749,experimental,,0.2265,0.1934,PKG I's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with PET-cGMP
7SSB,X-RAY DIFFRACTION,1.18,,VAPOR DIFFUSION,8.5,"0.1 M Tris 8.5 20 % v/v Glycerol ethoxylate, 3 % v/v Polyethyleneimine",295.0,2021-11-10,2022-08-24,7SSB,1175.0,1.0,268.0,155.0,,31.01,1.0,1.4,experimental,13.74,0.225,0.21,Co-structure of PKG1 regulatory domain with compound 33
6PAW,X-RAY DIFFRACTION,2.6,52.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris-HCl, pH 6.5, 0.6 M sodium chloride, 14.3% PEG3350",292.15,2019-06-12,2020-06-17,6PAW,12988.0,8.0,1888.0,,,217.27,2.0,2.953,experimental,57.7375,0.2884,0.2486,Crystal structure of DAPK2 S308A Calcium/Calmodulin complex
8F0Z,X-RAY DIFFRACTION,2.22,44.59,"VAPOR DIFFUSION, SITTING DROP",7.0,3.5 M Sodium Formate pH 7.0,291.0,2022-11-04,2023-02-15,8F0Z,1006.0,2.0,114.0,67.0,,13.33,2.0,1.61,experimental,35.5855,0.2423,0.2209,"Structure of the MDM2 P53 binding domain in complex with H101, an all-D Helicon Polypeptide"
8F12,X-RAY DIFFRACTION,2.94,58.18,"VAPOR DIFFUSION, SITTING DROP",,"3.2 M Ammonium sulfate, 0.1 M Citrate pH 5.0",291.0,2022-11-04,2023-02-15,8F12,1073.0,2.0,114.0,77.0,,13.5,2.0,1.86,experimental,37.1299,0.2415,0.2148,"Structure of the MDM2 P53 binding domain in complex with H103, an all-D Helicon Polypeptide"
6JZC,X-RAY DIFFRACTION,2.35,47.57,"VAPOR DIFFUSION, HANGING DROP",7.0,"HEPES, Ammonium sulphate, potassium chloride",291.15,2019-05-01,2019-07-17,6JZC,5020.0,4.0,886.0,260.0,,102.57,2.0,2.201,experimental,,0.2148,0.1809,Structural basis of tubulin detyrosination
7RT3,X-RAY DIFFRACTION,2.46,50.05,VAPOR DIFFUSION,,"28% PEG8000, 100 mM sodium citrate, pH 4.6, 100 mM ammonium acetate",298.0,2021-08-12,2021-12-22,7RT3,1687.0,1.0,170.0,269.0,,20.39,1.0,1.56,experimental,21.5202,0.1988,0.1642,"Crystal Structure of KRAS G12D with compound 24 (4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-{[(2S,4S,7aR)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidin-7-yl)naphthalen-2-ol) bound"
6FFH,X-RAY DIFFRACTION,2.68,54.04,LIPIDIC CUBIC PHASE,6.8,"24-34% V/V PEG400, 0.2 M AMMONIUM PHOSPHATE DIBASIC, 0.1 M MES, PH 6.8",293.1,2018-01-08,2018-03-07,6FFH,3371.0,1.0,444.0,13.0,1.0,52.09,1.0,2.65,experimental,51.0754,0.2669,0.2435,Crystal Structure of mGluR5 in complex with Fenobam at 2.65 A
7JV9,X-RAY DIFFRACTION,2.53,51.39,"VAPOR DIFFUSION, HANGING DROP",4.25,"12.50 %w/v PEG 1500, 0.10M SPG (Succinic Acid, Sodium Dihydrogen Phosphate and Glycine) pH=4.25",277.15,2020-08-20,2020-09-23,7JV9,8185.0,2.0,1050.0,55.0,8.0,118.63,1.0,2.7,experimental,57.627,0.2789,0.2092,Human CD73 (ecto 5'-nucleotidase) in complex with compound 12
7UGL,X-RAY DIFFRACTION,2.51,51.08,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M DL-Glutamic acid monohydrate; 0.1 M DL-Alanine; 0.1 M Glycine; 0.1 M DL-Lysine monohydrochloride; 0.1 M DL-Serine, 0.1 M Imidazole, 0.1 M MES monohydrate (pH 6.5), 12 % (v/v) Ethylene glycol, 6% w/v PEG 8000",292.0,2022-03-24,2023-04-12,7UGL,2369.0,2.0,232.0,283.0,,29.67,1.0,1.5,experimental,20.4804,0.1811,0.1604,Bromodomain of CBP liganded with BMS-536924 and SGC-CBP30
8FUP,X-RAY DIFFRACTION,2.29,46.2,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulfate, 30% w/v Polyethylene glycol 8000",292.0,2023-01-18,2024-02-07,8FUP,2340.0,2.0,232.0,304.0,,29.49,1.0,1.7,experimental,,0.2125,0.186,Bromodomain of CBP liganded with BMS-536924 and CCS-1477
8D4U,X-RAY DIFFRACTION,2.66,53.84,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES (pH 7.5),
0.2M Lithium Sulfate,
25%(w/v) PEG-3350",293.0,2022-06-02,2022-12-21,8D4U,5216.0,4.0,636.0,342.0,8.0,70.05,2.0,1.9,experimental,46.7506,0.2296,0.1996,Crystal Structure of Neutrophil Elastase Inhibited by Eap2 from S. aureus
7TB1,X-RAY DIFFRACTION,2.0,38.4,"VAPOR DIFFUSION, SITTING DROP",,"3 M NaCl, 0.1 M TRIS pH 8.5",277.0,2021-12-21,2022-07-27,7TB1,2468.0,4.0,300.0,267.0,,33.91,2.0,1.785,experimental,24.27,0.2784,0.2239,Crystal structure of STUB1 with a macrocyclic peptide
8EHZ,X-RAY DIFFRACTION,2.35,47.57,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1M Sodium acetate, 0.1M sodium citrate pH6.0, 10% PEG4000",291.0,2022-09-14,2023-10-25,8EHZ,2279.0,4.0,302.0,18.0,,34.71,2.0,2.06,experimental,60.7906,0.2694,0.2409,"Crystal structure of the STUB1 TPR domain in complex with H317, a Helicon Polypeptide"
4U7Y,X-RAY DIFFRACTION,2.25,45.4,"VAPOR DIFFUSION, SITTING DROP",7.3,2.58 M Na-malonate,299.0,2014-07-31,2015-02-11,4U7Y,722.0,2.0,115.0,6.0,,13.32,2.0,2.502,experimental,,0.2713,0.2252,Structure of the complex of VPS4B MIT and IST1 MIM
6G24,X-RAY DIFFRACTION,2.3,46.58,VAPOR DIFFUSION,,"100mM Morpheus Buffer 3, 30% P550MME_P20K, 10% Morpheus Ethylene glycols",277.0,2018-03-22,2019-06-26,6G24,1134.0,1.0,136.0,85.0,,16.5,1.0,2.1,experimental,36.83,0.235,0.202,X-ray structure of NSD3-PWWP1 in complex with compound 3
6G25,X-RAY DIFFRACTION,2.3,46.59,VAPOR DIFFUSION,,"100mM Morpheus Buffer 3, 30% P550MME_P20K, 10% Morpheus Ethylene glycols",277.0,2018-03-22,2019-06-26,6G25,1192.0,1.0,136.0,126.0,,16.51,1.0,1.432,experimental,33.69,0.229,0.206,X-ray structure of NSD3-PWWP1 in complex with compound 4
6G27,X-RAY DIFFRACTION,2.35,47.65,VAPOR DIFFUSION,,"100mM Morpheus Buffer 3, 30% P550MME_P20K, 10% Morpheus Ethylene glycols",277.0,2018-03-22,2019-06-26,6G27,1142.0,1.0,136.0,101.0,,16.54,1.0,1.65,experimental,41.52,0.227,0.206,X-ray structure of NSD3-PWWP1 in complex with compound 5
6G29,X-RAY DIFFRACTION,2.28,46.05,VAPOR DIFFUSION,,"100mM Morpheus Buffer 3, 30% P550MME_P20K, 10% Morpheus Ethylene glycols",277.0,2018-03-22,2019-06-26,6G29,1176.0,1.0,136.0,108.0,,16.54,1.0,1.7,experimental,38.36,0.21,0.195,X-ray structure of NSD3-PWWP1 in complex with compound 6
6G2B,X-RAY DIFFRACTION,2.24,45.21,VAPOR DIFFUSION,,"100mM Morpheus Buffer 3, 30% P550MME_P20K, 10% Morpheus Ethylene glycols",277.0,2018-03-22,2019-06-26,6G2B,1211.0,1.0,136.0,140.0,,16.51,1.0,1.61,experimental,30.78,0.225,0.199,X-ray structure of NSD3-PWWP1 in complex with compound 8
6G2C,X-RAY DIFFRACTION,2.28,46.09,VAPOR DIFFUSION,,"100mM Morpheus Buffer 3, 30% P550MME_P20K, 10% Morpheus Ethylene glycols",277.0,2018-03-22,2019-06-26,6G2C,1167.0,1.0,136.0,109.0,,16.53,1.0,1.76,experimental,33.69,0.23,0.201,X-ray structure of NSD3-PWWP1 in complex with compound 9
6G2E,X-RAY DIFFRACTION,2.28,46.06,VAPOR DIFFUSION,,"100mM Morpheus Buffer 3, 30% P550MME_P20K, 10% Morpheus Ethylene glycols",277.0,2018-03-23,2019-06-26,6G2E,1139.0,1.0,136.0,84.0,,16.56,1.0,1.85,experimental,43.04,0.252,0.209,X-ray structure of NSD3-PWWP1 in complex with compound 13
6G2F,X-RAY DIFFRACTION,2.31,46.69,VAPOR DIFFUSION,,"100mM Morpheus Buffer 3, 30% P550MME_P20K, 10% Morpheus Ethylene glycols",277.0,2018-03-23,2019-06-26,6G2F,1146.0,1.0,136.0,92.0,,16.59,1.0,1.74,experimental,44.01,0.211,0.197,X-ray structure of NSD3-PWWP1 in complex with compound 16
6G2O,X-RAY DIFFRACTION,2.21,44.26,VAPOR DIFFUSION,,"100mM Morpheus Buffer 3, 30% P550MME_P20K, 10% Morpheus Ethylene glycols",277.0,2018-03-23,2019-06-26,6G2O,1153.0,1.0,136.0,96.0,,16.63,1.0,1.81,experimental,37.45,0.224,0.193,X-ray structure of NSD3-PWWP1 in complex with compound BI-9321
5VA6,X-RAY DIFFRACTION,2.48,50.42,"VAPOR DIFFUSION, HANGING DROP",,"50% polypropylene glycol 400, 5% DMSO, 0.1 M HEPES-NaOH (pH 6.0)",277.0,2017-03-24,2017-04-19,5VA6,3713.0,4.0,494.0,159.0,,56.75,2.0,2.4,experimental,35.32,0.297,0.2457,CRYSTAL STRUCTURE OF ATXR5 IN COMPLEX WITH HISTONE H3.1 MONO-METHYLATED ON R26
4RYD,X-RAY DIFFRACTION,2.86,56.93,"VAPOR DIFFUSION, SITTING DROP",8.5,"50mM Tris, 2.8M sodium formate, 15mM Cymal-7, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-12-15,2015-05-27,4RYD,23768.0,12.0,2922.0,2034.0,18.0,320.52,2.0,2.15,experimental,,0.2186,0.1862,X-ray structure of human furin in complex with the competitive inhibitor para-guanidinomethyl-Phac-R-Tle-R-Amba
8D4Q,X-RAY DIFFRACTION,3.23,61.95,"VAPOR DIFFUSION, HANGING DROP",5.2,"0.1M sodium citrate (pH 5.2),
12% (w/v) PEG-6000",293.0,2022-06-02,2022-12-21,8D4Q,5211.0,4.0,636.0,223.0,8.0,71.29,2.0,2.2,experimental,48.5277,0.2168,0.1809,Crystal Structure of Neutrophil Elastase Inhibited by Eap1 from S. aureus
6NEC,X-RAY DIFFRACTION,2.23,44.95,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.6 M Na FORMATE
0.1M Na CITRATE PH5.5",297.0,2018-12-17,2019-06-05,6NEC,5002.0,2.0,628.0,241.0,,72.59,1.0,1.87,experimental,41.026,0.23188,0.19428,STRUCTURE OF RET PROTEIN TYROSINE KINASE DOMAIN IN COMPLEX WITH NINTEDANIB
5OO1,X-RAY DIFFRACTION,1.68,26.89,"VAPOR DIFFUSION, HANGING DROP",,"15% w/v Jeffamine ED-2003, 50 mM HEPES, 50 mM sodium/potassium phosphate",298.0,2017-08-04,2018-08-29,5OO1,2261.0,1.0,303.0,72.0,,34.54,1.0,2.0,experimental,39.814,0.23619,0.18481,"Cdk2(F80C, C177A) covalent adduct with C37 at F80C"
5OO3,X-RAY DIFFRACTION,1.99,38.16,"VAPOR DIFFUSION, HANGING DROP",,"9 - 15% w/v, 50 mM HEPES, 50 mM sodium/potassium phosphate",298.0,2017-08-05,2018-08-29,5OO3,2585.0,1.0,303.0,276.0,,34.53,1.0,1.73,experimental,33.251,0.2491,0.1843,"Cdk2(F80C, C177A) with covalent ligand at F80C"
6Q3B,X-RAY DIFFRACTION,2.15,42.69,"VAPOR DIFFUSION, SITTING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM     
 HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-04,2019-03-20,6Q3B,2557.0,1.0,306.0,216.0,,35.15,1.0,1.11,experimental,20.881,0.24882,0.20977,CDK2 in complex with FragLite2
6Q3C,X-RAY DIFFRACTION,1.97,37.5,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM        HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5.",293.0,2018-12-04,2019-03-20,6Q3C,2694.0,1.0,306.0,281.0,,35.1,1.0,1.29,experimental,25.147,0.17813,0.1405,CDK2 in complex with FragLite1
6Q3F,X-RAY DIFFRACTION,1.97,37.51,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM      HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5.",293.0,2018-12-04,2019-03-20,6Q3F,2732.0,1.0,306.0,301.0,,34.98,1.0,1.18,experimental,25.539,0.18857,0.1613,CDK2 in complex with FragLite2
6Q4B,X-RAY DIFFRACTION,2.0,38.47,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q4B,2733.0,1.0,306.0,314.0,,34.92,1.0,1.12,experimental,22.825,0.20326,0.17272,CDK2 in complex with FragLite13
6Q4C,X-RAY DIFFRACTION,1.96,37.24,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q4C,2645.0,1.0,306.0,230.0,,34.97,1.0,1.73,experimental,28.759,0.22267,0.17999,CDK2 in complex with FragLite16
6Q4D,X-RAY DIFFRACTION,1.93,36.18,"VAPOR DIFFUSION, HANGING DROP",,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q4D,2778.0,1.0,306.0,307.0,,36.23,1.0,1.07,experimental,17.447,0.17688,0.15626,CDK2 in complex with FragLite31
6Q4F,X-RAY DIFFRACTION,1.97,37.46,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q4F,2812.0,1.0,306.0,310.0,,34.92,1.0,1.21,experimental,25.927,0.20515,0.16732,CDK2 in complex with FragLite32
6Q4K,X-RAY DIFFRACTION,1.95,37.04,"VAPOR DIFFUSION, HANGING DROP",7.4,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-12-05,2019-03-20,6Q4K,2812.0,1.0,306.0,317.0,,35.43,1.0,1.06,experimental,19.66,0.16216,0.14312,CDK2 in complex with FragLite38
8FOW,X-RAY DIFFRACTION,2.06,40.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG 3350, 20% ethylene glycol, 50mM HEPES, pH 7.5",291.0,2023-01-03,2023-05-31,8FOW,2379.0,1.0,298.0,94.0,,34.82,1.0,1.6,experimental,,0.2214,0.2041,Ternary complex of CDK2 with small molecule ligands TW8672 and Dinaciclib
8FP0,X-RAY DIFFRACTION,2.07,40.58,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG 3350, 20% ethylene glycol, 50mM HEPES, pH 7.5",291.0,2023-01-03,2023-05-31,8FP0,2362.0,1.0,298.0,91.0,,34.78,1.0,1.6,experimental,,0.2404,0.2113,Ternary complex of CDK2 with small molecule ligands TW8672 and Roscovitine
6FKY,X-RAY DIFFRACTION,2.63,53.24,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.4, 20% PEG3350",293.0,2018-01-25,2018-03-21,6FKY,4344.0,4.0,584.0,55.0,1.0,65.86,2.0,2.98,experimental,67.667,0.27485,0.19785,Crystal structure of zebrafish Sirtuin 5 in complex with 3-(benzylthio)succinyl-CPS1 peptide
7ZH8,X-RAY DIFFRACTION,3.22,61.85,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS (pH = 8.5), 0.1 M Li2SO4, 34 % (v/v) PEG300, 12 mg/ml Protein, Dropsize (resovoir + Protein) 2 + 4",277.0,2022-04-05,2022-11-09,7ZH8,12103.0,4.0,1528.0,519.0,,185.02,1.0,2.3,experimental,58.33,0.2351,0.1988,DYRK1a in Complex with a Bromo-Triazolo-Pyridine
6OIE,X-RAY DIFFRACTION,2.6,52.72,"VAPOR DIFFUSION, HANGING DROP",,1.1-1.3 M sodium citrate tribasic and 0.1 M sodium hepes,291.0,2019-04-09,2019-11-20,6OIE,2192.0,4.0,270.0,220.0,,30.84,2.0,2.075,experimental,,0.2191,0.1659,The double PHD finger (DPF) of MORF in complex with histone H3K14cr
5WP1,X-RAY DIFFRACTION,2.31,46.75,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.1-1.3 M ammonium sulfate, 2% PEG500 MME, 0.1 M HEPES/NaOH, crystals soaked in precipitant solution containing 1.5 mM DHC in 2.5% DMSO for one week",290.0,2017-08-03,2018-08-08,5WP1,3199.0,1.0,357.0,339.0,,41.8,1.0,1.4,experimental,,0.1796,0.1413,"Complex of ERK2 with 5,7-dihydroxychromone"
5K0H,X-RAY DIFFRACTION,2.46,50.05,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, 12-18 % PEG6000, 5 mM CaCl2",293.0,2016-05-17,2016-07-06,5K0H,2412.0,2.0,285.0,143.0,8.0,32.52,2.0,2.2,experimental,47.6,0.261,0.214,Human factor Xa in complex with synthetic inhibitor benzylsulfonyl-dSer(Benzyl)-Gly-4-amidinobenzylamide
8EI0,X-RAY DIFFRACTION,2.49,50.7,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulfate, 30% w/v PEG 8000",291.0,2022-09-14,2023-10-25,8EI0,1350.0,2.0,147.0,130.0,,17.2,2.0,1.47,experimental,26.3905,0.2119,0.1921,"Crystal structure of the STUB1 TPR domain in complex with H318, a Helicon Polypeptide"
5U9M,X-RAY DIFFRACTION,2.58,52.41,"VAPOR DIFFUSION, HANGING DROP",,"25 % PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",298.0,2016-12-16,2017-05-31,5U9M,5857.0,4.0,802.0,120.0,1.0,85.93,2.0,2.35,experimental,,0.2349,0.1861,Copper-Zinc Superoxide Dismutase is Activated through a Sulfenic Acid Intermediate at a Copper-ion Entry Site
4Z6A,X-RAY DIFFRACTION,2.78,55.76,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1M NaCitrate, 16.6% PEG 3350, 12.5% 1-Propanol, with seeding",295.0,2015-04-04,2015-12-30,4Z6A,4491.0,3.0,552.0,230.0,13.0,62.62,3.0,2.25,experimental,48.914,0.2405,0.1882,Crystal Structure of a FVIIa-Trypsin Chimera (YT) in Complex with Soluble Tissue Factor
5VCY,X-RAY DIFFRACTION,2.11,41.77,"VAPOR DIFFUSION, HANGING DROP",7.5,"14 MG/ML MYT1, 50 mM HEPES PH 7.5, 0.5 mM DTT, 0.05 M POTASSIUM CHLORIDE, 17.5 (V/V) % pentaerythritol propoxylate (5/4 PO/OH), 1.5 mM BOSUTINIB",291.0,2017-04-01,2017-08-23,5VCY,2627.0,1.0,311.0,237.0,,35.4,1.0,1.56,experimental,25.3139,0.1778,0.1397,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
5IEV,X-RAY DIFFRACTION,2.07,40.62,"VAPOR DIFFUSION, HANGING DROP",7.8,"7.25% PEG 4000, 0.2M ammonium acetate, 100mM Hepes pH 7.8",293.15,2016-02-25,2016-04-27,5IEV,2489.0,1.0,298.0,154.0,,34.41,1.0,2.03,experimental,21.564,0.2615,0.19515,Crystal structure of BAY 1000394 (Roniciclib) bound to CDK2
6VO7,X-RAY DIFFRACTION,2.93,58.03,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris-HCL, 0.7 M Na Citrate, pH 8.5",293.0,2020-01-30,2021-02-03,6VO7,1135.0,1.0,144.0,26.0,,16.8,1.0,2.31,experimental,50.74,0.2552,0.1968,Crystal structure of PI3K-alpha Ras Binding Domain (RBD)
6JZE,X-RAY DIFFRACTION,2.64,53.44,"VAPOR DIFFUSION, HANGING DROP",,"BIS-TRIS propane, Sodium formate",291.15,2019-05-01,2019-08-07,6JZE,2520.0,2.0,397.0,77.0,,48.4,2.0,2.51,experimental,52.59,0.266,0.221,Crystal structure of VASH2-SVBP complex with the magic triangle I3C
5YWS,X-RAY DIFFRACTION,1.99,38.09,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1M SODIUM ACETATE TRIHYDRATE PH 4.5,
 30%(V/V) POLYETHYLENE GLYCOL 300, VAPOR DIFFUSION, HANGING DROP,
 TEMPERATURE 293K",293.0,2017-11-30,2018-05-23,5YWS,4734.0,4.0,596.0,413.0,,73.27,1.0,2.0,experimental,,0.226,0.189,Crystal structure of TREX1 in complex with a Y structured DNA
5YWV,X-RAY DIFFRACTION,1.86,33.91,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1M MES MONOHYDRATE PH 6.0, 20%(W/V)
 POLYETHYLENE GLYCOL MONOMETHYL ETHER 2,000, VAPOR DIFFUSION,
 HANGING DROP, TEMPERATURE 293K",293.0,2017-11-30,2018-05-23,5YWV,3848.0,4.0,532.0,174.0,,60.7,1.0,2.3,experimental,,0.22,0.159,Crystal structure of TREX1 in complex with a inosine contained ssDNA
9FMM,X-RAY DIFFRACTION,2.49,50.53,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M sodium citrate pH 5.5, 20% w/v PEG 3000",293.0,2024-06-06,2024-07-17,9FMM,11357.0,2.0,1460.0,152.0,6.0,172.31,1.0,2.5,experimental,60.61,0.2651,0.2126,Structure of human ACE2 in complex with a fluorinated small molecule inhibitor
5AQG,X-RAY DIFFRACTION,2.46,49.92,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQG,11841.0,6.0,1512.0,465.0,3.0,170.14,2.0,2.24,experimental,48.14,0.2217,0.1916,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
8EI7,X-RAY DIFFRACTION,2.25,45.41,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2M magnesium chloride, 0.1M Bis-tris pH7.5, 30% PEG3350",291.0,2022-09-14,2023-10-25,8EI7,6764.0,3.0,771.0,194.0,,93.34,2.0,2.22,experimental,47.9493,0.2638,0.1999,"Crystal structure of the WWP2 HECT domain in complex with H304, a Helicon Polypeptide"
8B54,X-RAY DIFFRACTION,3.17,61.17,"VAPOR DIFFUSION, SITTING DROP",,"70%: 10% w/v PEG 4,000, 20% v/v glycerol, 0.03 M NaNO3, 0.03 M Na2HPO4, 0.03 M (NH4)2SO4, 0.1 M Tris/Bicine pH 8.5
30%:0.8 M sodium phosphate monobasic monohydrate, 0.8 M potassium phosphate monobasic, 0.1 M Sodium HEPES, pH7.5",291.15,2022-09-21,2023-03-29,8B54,9257.0,4.0,1114.0,314.0,,128.95,2.0,2.6,experimental,39.612,0.2874,0.2328,"CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR6768"
4UUH,X-RAY DIFFRACTION,2.34,47.42,,6.0,"0.1 M MES PH 6.0, 0.1 M AMMONIUM TARTARATE, 12-16% W/V PEG 3350",,2014-07-28,2015-07-08,4UUH,1809.0,1.0,258.0,101.0,,30.43,1.0,2.52,experimental,41.19,0.2176,0.1662,X-ray crystal structure of human TNKS in complex with a small molecule inhibitor
8HFP,X-RAY DIFFRACTION,1.97,37.5,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.0 M ammonium sulfate
0.1 M Bis-Tris, pH 5.5",293.15,2022-11-11,2023-11-22,8HFP,2568.0,4.0,370.0,110.0,,42.93,2.0,1.82,experimental,34.278,0.22662,0.18615,Crystal structure of the methyl-CpG-binding domain of SETDB2 in complex with the cysteine-rich domain of C11orf46 protein
4D1X,X-RAY DIFFRACTION,2.05,39.98,,,"10 MM HEPES, 20 MM NACL, PH 7.4",,2014-05-05,2015-03-18,4D1X,2298.0,1.0,298.0,118.0,,34.26,1.0,2.1,experimental,,0.2376,0.1937,CDK2 in complex with Luciferin
4D1Z,X-RAY DIFFRACTION,2.1,41.41,,,"0 MM HEPES, 20 MM NACL, PH 7.4",,2014-05-05,2015-03-18,4D1Z,2200.0,1.0,298.0,146.0,,34.53,1.0,1.851,experimental,,0.2254,0.1933,CDK2 in complex with a Luciferin derivate
5ANE,X-RAY DIFFRACTION,1.99,38.19,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,2015-09-07,2016-04-13,5ANE,2550.0,1.0,298.0,173.0,,34.13,1.0,1.7,experimental,22.965,0.25178,0.20431,Crystal structure of CDK2 in complex with 6-methoxy-7H-purine processed with the CrystalDirect automated mounting and cryo-cooling technology
5ANG,X-RAY DIFFRACTION,2.05,40.11,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,2015-09-07,2016-04-13,5ANG,2256.0,1.0,298.0,82.0,,34.24,1.0,1.9,experimental,32.998,0.23569,0.19665,Crystal structure of CDK2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed with the CrystalDirect automated mounting and cryo-cooling technology
5ANI,X-RAY DIFFRACTION,2.01,38.78,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,2015-09-07,2016-04-13,5ANI,2352.0,1.0,298.0,88.0,,34.13,1.0,1.9,experimental,41.111,0.23258,0.18767,Crystal structure of CDK2 in complex with 6-chloro-7H-purine processed with the CrystalDirect automated mounting and cryo-cooling technology
5ANJ,X-RAY DIFFRACTION,2.03,39.45,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,2015-09-07,2016-04-13,5ANJ,2499.0,1.0,298.0,146.0,,34.22,1.0,1.6,experimental,25.249,0.22919,0.19651,Crystal structure of CDK2 in complex with N-(9H-purin-6-yl)thiophene- 2-carboxamide processed with the CrystalDirect automated mounting and cryo-cooling technology
5ANK,X-RAY DIFFRACTION,1.87,34.33,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,2015-09-07,2016-04-13,5ANK,2337.0,1.0,298.0,115.0,,34.22,1.0,1.9,experimental,48.579,0.2359,0.19488,"Crystal structure of CDK2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide processed with the CrystalDirect automated mounting and cryo-cooling technology"
5JQ5,X-RAY DIFFRACTION,2.02,39.08,"VAPOR DIFFUSION, HANGING DROP",7.8,"0.1M AMMONIUM ACETATE, PH 7.8, 6% PEG 3350",277.0,2016-05-04,2017-02-08,5JQ5,2494.0,1.0,298.0,152.0,,34.43,1.0,1.94,experimental,19.233,0.24104,0.18108,Crystal structure of CDK2 in complex with inhibitor ICEC0942
5JQ8,X-RAY DIFFRACTION,2.04,39.62,"VAPOR DIFFUSION, HANGING DROP",7.8,"0.1M AMMONIUM ACETATE, PH 7.8, 6% PEG 3350",277.0,2016-05-04,2017-02-08,5JQ8,2437.0,1.0,298.0,174.0,,34.37,1.0,1.94,experimental,23.828,0.25976,0.19358,Crystal structure of CDK2 in complex with inhibitor ICEC0943
5OO0,X-RAY DIFFRACTION,1.99,38.3,"VAPOR DIFFUSION, HANGING DROP",,"15% w/v Jeffamine ED-2003, 50 mM HEPES, 50 mM sodium/potassium phosphate",294.0,2017-08-04,2018-03-14,5OO0,2625.0,1.0,303.0,318.0,,34.64,1.0,1.6,experimental,22.29,0.20035,0.17158,Cdk2(WT) covalent adduct with D28 at C177
5OSJ,X-RAY DIFFRACTION,2.01,38.92,"VAPOR DIFFUSION, HANGING DROP",,"15% w/v Jeffamine ED-2003, 50 mM HEPES, 50 mM sodium/potassium phosphate",298.0,2017-08-17,2018-03-14,5OSJ,2618.0,1.0,303.0,287.0,,34.68,1.0,1.83,experimental,22.214,0.22198,0.17378,Cdk2(WT) with covalent adduct at C177
5OSM,X-RAY DIFFRACTION,1.98,37.82,"VAPOR DIFFUSION, HANGING DROP",,"15% w/v Jeffamine ED-2003, 50 mM HEPES, 50 mM sodium/potassium phosphate",298.0,2017-08-17,2018-03-14,5OSM,2671.0,1.0,303.0,332.0,,34.56,1.0,1.77,experimental,22.042,0.20611,0.16217,"Cdk2(F80C, C177A) with covalent adduct at C80"
6GUH,X-RAY DIFFRACTION,1.97,37.62,"VAPOR DIFFUSION, HANGING DROP",,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-06-19,2018-12-05,6GUH,2548.0,1.0,306.0,156.0,,35.26,1.0,1.5,experimental,33.24,0.2433,0.19893,CDK2 in complex with AZD5438
6GUK,X-RAY DIFFRACTION,2.0,38.37,"VAPOR DIFFUSION, HANGING DROP",,"10MG/ML CDK2 10% V/V PEG3350, 50 MM HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2018-06-19,2018-12-05,6GUK,2490.0,1.0,306.0,211.0,,35.15,1.0,1.3,experimental,28.149,0.23204,0.20415,CDK2 in complex with CGP74514A
6YL1,X-RAY DIFFRACTION,1.99,38.19,"VAPOR DIFFUSION, HANGING DROP",,"Protein: 8 mg/mL in pH 6.2 phosphate buffer
Resovoir: 8-12% PEG3350, HEPES 0.1 M (pH 7.5-8.5)
1:1",293.0,2020-04-06,2020-07-22,6YL1,2409.0,1.0,303.0,119.0,,34.61,1.0,1.66,experimental,35.84,0.2685,0.2212,Cdk2(F80C) with Covalent Adduct TK37 at F80C
6YL6,X-RAY DIFFRACTION,1.96,37.21,"VAPOR DIFFUSION, HANGING DROP",,"Protein solution: 8 mg/mL, 100 mM phosphate buffer (pH6.2)
Reservoir solution: 8-12% PEG3350, HEPES (0.1 M pH 7.5 - 8.5)",298.0,2020-04-06,2020-07-22,6YL6,2642.0,1.0,303.0,217.0,,34.31,1.0,1.7,experimental,29.7,,0.1815,Cdk2(F80C)
6YLK,X-RAY DIFFRACTION,1.99,38.09,"VAPOR DIFFUSION, HANGING DROP",,"Protein solution: 8 mg/mL in 100 mM pH 6.2 phosphate buffer
Reservoir solution: 8-12% PEG3350, 100 mM HEPES pH 7.5-8.15",298.0,2020-04-07,2020-07-22,6YLK,2461.0,1.0,303.0,118.0,,34.59,1.0,1.65,experimental,39.28,0.2648,0.216,Cdk2(F80C) with Covalent Adduct TK22 at F80C
8UV0,X-RAY DIFFRACTION,2.04,39.84,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris pH 8.5, 16% PEG 2000 MME, 0.2 M trimethylamine N-oxide",293.0,2023-11-02,2024-02-14,8UV0,2290.0,1.0,297.0,122.0,,34.33,1.0,1.55,experimental,27.907,0.2034,0.155,Discovery of (4-Pyrazolyl)-2-Aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2
6GK4,X-RAY DIFFRACTION,2.18,43.59,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M Potassium bromide, 30% w/v Polyethylene glycol monomethyl ether 2,000",293.0,2018-05-18,2019-06-19,6GK4,6870.0,6.0,1042.0,237.0,4.0,115.47,3.0,2.91,experimental,51.78,0.2946,0.2464,Human NBD1 of CFTR in complex with nanobodies D12 and T8
5E3H,X-RAY DIFFRACTION,2.77,55.59,"VAPOR DIFFUSION, HANGING DROP",7.5,"25% w/v PEG3350, 0.25 M sodium thiocyanate, 100 mM MOPS, pH 7.8, 3% v/v 2,2,2-trifluoroethanol",293.0,2015-10-02,2015-11-18,5E3H,5517.0,3.0,723.0,,,89.27,1.0,2.7,experimental,,0.2679,0.2335,Structural Basis for RNA Recognition and Activation of RIG-I
6F5E,X-RAY DIFFRACTION,3.55,65.4,"VAPOR DIFFUSION, SITTING DROP",6.8,"PEG 10000 3% w/v 
Hepes 0.1 M, pH 6.8 
Additives (0.033% w/v)
1,5-Naphthalene-
disulfonic acid disodium salt 
2,5-Pyridinedicarboxylic acid 
3,5-Dinitrosalicylic acid",277.0,2017-12-01,2017-12-13,6F5E,5283.0,3.0,709.0,,,79.61,3.0,2.7,experimental,,0.2261,0.2005,"Crystal structure of DARPin-DARPin rigid fusion, variant DD_D12_10_47 in complex JNK1a1 and JIP1 peptide"
8EQ9,X-RAY DIFFRACTION,3.7,66.76,"VAPOR DIFFUSION, SITTING DROP",,"12% PEG3350, 4% tacsimate pH7.0",277.0,2022-10-07,2022-11-30,8EQ9,2149.0,1.0,317.0,24.0,,37.22,1.0,2.86,experimental,78.336,0.2772,0.239,Co-crystal structure of PERK with compound 11
7KNX,X-RAY DIFFRACTION,2.49,50.53,"VAPOR DIFFUSION, SITTING DROP",6.2,"0.1 MES-NaOH pH 6.2, 0.9 M trisodium citrate",293.0,2020-11-06,2021-12-08,7KNX,9995.0,4.0,1296.0,560.0,,148.87,1.0,2.7,experimental,55.537,0.329,0.2596,Crystal structure of SND1 in complex with C-26-A6
6B16,X-RAY DIFFRACTION,2.44,49.58,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 3500, 0.2M Ammonium Sulfate and 0.1M Tris pH 8",292.0,2017-09-16,2017-10-25,6B16,4515.0,2.0,602.0,46.0,1.0,67.96,1.0,2.285,experimental,,0.2496,0.2015,P21-activated kinase 1 in complex with a 4-azaindole inhibitor
8GM5,X-RAY DIFFRACTION,2.68,53.71,VAPOR DIFFUSION,6.5,"Cocktail:16.55% PEG-3350, 0.2 M NaF, 100 mM BisTris-Propane
Protein solution: 10.3 mg/mL 20 mM Tris pH 7.5, 100 mM NaCl, 3 mM CaCl2, 1mM TCEP, 1.5 m Inhibitor , 3.1 % DMSO
2protein/1cocktail (0.2 ul total)",295.15,2023-03-24,2023-05-31,8GM5,4651.0,2.0,679.0,240.0,,77.96,2.0,2.12,experimental,42.27,0.225,0.181,"Functional construct of the Eukaryotic elongation factor 2 kinase bound to Calmodulin, ADP and to the A-484954 inhibitor and showing two conformations for the 498-520 loop"
5O6C,X-RAY DIFFRACTION,3.38,63.63,"VAPOR DIFFUSION, HANGING DROP",6.7,"23.3 mM Na2HPO4
23.3 mM (NH4)2SO4
23.3 mM NaNO3
18 % PEG500 MME
9 % PEG20000",277.0,2017-06-06,2018-04-18,5O6C,2251.0,1.0,263.0,257.0,,30.11,1.0,1.75,experimental,28.7,0.1957,0.17192,Crystal Structure of a threonine-selective RCR E3 ligase
5IVE,X-RAY DIFFRACTION,2.24,45.15,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-20,2016-07-27,5IVE,2592.0,1.0,330.0,196.0,,38.22,1.0,1.783,experimental,,0.2055,0.1747,"Linked KDM5A Jmj Domain Bound to the Inhibitor N8 ( 5-methyl-7-oxo-6-(propan-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile)"
5IVF,X-RAY DIFFRACTION,2.22,44.71,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-20,2016-07-27,5IVF,2625.0,1.0,330.0,172.0,,38.35,1.0,1.683,experimental,,0.2017,0.1688,"Linked KDM5A Jmj Domain Bound to the Inhibitor N10 8-(1-methyl-1H-imidazol-4-yl)-2-(4,4,4-trifluorobutoxy)pyrido[3,4-d]pyrimidin-4-ol"
5IVV,X-RAY DIFFRACTION,2.22,44.6,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-21,2016-07-27,5IVV,2683.0,1.0,330.0,291.0,,38.27,1.0,1.848,experimental,,0.2042,0.1692,"Linked KDM5A Jmj Domain Bound to the Inhibitor N12 [3-((1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)amino)isonicotinic acid]"
5IVY,X-RAY DIFFRACTION,2.25,45.26,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-21,2016-07-27,5IVY,2708.0,1.0,330.0,254.0,,38.29,1.0,1.45,experimental,,0.209,0.1859,Linked KDM5A Jmj Domain Bound to the Inhibitor N16 [3-(2-(4-chlorophenyl)acetamido)isonicotinic acid]
5IWF,X-RAY DIFFRACTION,2.23,44.87,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289.0,2016-03-22,2016-07-27,5IWF,2432.0,1.0,330.0,101.0,,38.31,1.0,2.289,experimental,,0.2435,0.192,Linked KDM5A Jmj Domain Bound to the Inhibitor 2-(((2-((2-(dimethylamino)ethyl)(ethyl)amino)-2-oxoethyl)amino)methyl)isonicotinamid
5J07,X-RAY DIFFRACTION,2.12,41.95,EVAPORATION,5.0,"0.1 M MIB buffer
pH 5.0
25 % w/v PEG 1500",293.0,2016-03-27,2017-02-01,5J07,1679.0,2.0,230.0,85.0,,22.64,1.0,2.0,experimental,49.806,0.2306,0.1927,"Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, circular permutant P1/2"
9EY8,X-RAY DIFFRACTION,2.95,58.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"Sodium bromide, Bis-Tris propane, PEG 3350",277.0,2024-04-09,2024-05-01,9EY8,16585.0,4.0,1800.0,999.0,28.0,223.73,1.0,2.2,experimental,43.57,0.2327,0.1891,Crystal structure of human tyrosinase-related protein 1 (TYRP1) in complex with (s)-amino-L-tyrosine
4W5A,X-RAY DIFFRACTION,2.29,46.31,"VAPOR DIFFUSION, SITTING DROP",,"13-20% PEG 4000, 0.1 M MES, 3 mM MgCl2",277.0,2014-08-17,2015-01-21,4W5A,3229.0,6.0,432.0,19.0,,50.03,2.0,2.6,experimental,69.4,0.2597,0.2211,Complex structure of ATRX ADD bound to H3K9me3S10ph peptide
6EPJ,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.0 M ammonium sulfate 
0.1 M Bis-tris pH 5.5",277.0,2017-10-11,2018-10-31,6EPJ,1346.0,1.0,130.0,191.0,,16.16,1.0,1.652,experimental,,0.2123,0.1771,The ATAD2 bromodomain in complex with compound 6
6EPU,X-RAY DIFFRACTION,4.06,69.68,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5",277.0,2017-10-12,2018-10-31,6EPU,1240.0,1.0,130.0,139.0,,15.8,1.0,1.8,experimental,,0.2184,0.192,The ATAD2 bromodomain in complex with compound 2
6EPV,X-RAY DIFFRACTION,4.07,69.79,"VAPOR DIFFUSION, HANGING DROP",,"2M ammonium sulfate, 0.1M Bis-Tris pH 5.5",277.0,2017-10-12,2018-10-31,6EPV,1182.0,1.0,130.0,82.0,,15.79,1.0,1.793,experimental,,0.2174,0.2101,The ATAD2 bromodomain in complex with compound 5
6EPX,X-RAY DIFFRACTION,4.09,69.9,"VAPOR DIFFUSION, HANGING DROP",,"2M ammonium sulfate, 0.1M Bis-Tris pH 5.5",277.0,2017-10-12,2018-10-31,6EPX,1222.0,1.0,130.0,97.0,,16.07,1.0,1.84,experimental,,0.2191,0.2046,The ATAD2 bromodomain in complex with compound 3
6HI3,X-RAY DIFFRACTION,3.91,68.57,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5",277.0,2018-08-29,2019-02-20,6HI3,1050.0,1.0,130.0,7.0,,15.78,1.0,2.4,experimental,,0.3368,0.2924,The ATAD2 bromodomain in complex with compound 4
6HIA,X-RAY DIFFRACTION,4.04,69.53,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5",277.0,2018-08-29,2019-02-20,6HIA,1258.0,1.0,130.0,153.0,,15.9,1.0,1.897,experimental,,0.2315,0.2051,The ATAD2 bromodomain in complex with compound 13
5ZKQ,X-RAY DIFFRACTION,3.54,65.23,LIPIDIC CUBIC PHASE,,"HEPES, PEG 400, MgSO4",293.0,2018-03-25,2018-06-20,5ZKQ,5568.0,2.0,876.0,2.0,2.0,104.42,1.0,2.9,experimental,85.97,0.235,0.203,Crystal structure of the human platelet-activating factor receptor in complex with ABT-491
9CYO,X-RAY DIFFRACTION,3.29,66.97,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13.5% PEG 8000, 2% ethanol",277.0,2024-08-02,2024-08-21,9CYO,2485.0,1.0,321.0,104.0,,37.47,1.0,1.94,experimental,44.35,0.2015,0.1695,Crystal structure of wild-type human PTP1B (PTPN1) at room temperature (298 K)
9CYP,X-RAY DIFFRACTION,3.3,66.94,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13.5% PEG 8000, 2% ethanol",277.0,2024-08-02,2024-08-21,9CYP,2476.0,1.0,321.0,94.0,,37.45,1.0,1.99,experimental,42.08,0.2139,0.182,Crystal structure of I19V mutant human PTP1B (PTPN1) at room temperature (298 K)
9CYQ,X-RAY DIFFRACTION,3.3,66.89,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13.5% PEG 8000, 2% ethanol",277.0,2024-08-02,2024-08-21,9CYQ,2425.0,1.0,321.0,61.0,,37.5,1.0,2.3,experimental,47.26,0.2073,0.1623,Crystal structure of Q78R mutant human PTP1B (PTPN1) at room temperature (298 K)
9CYR,X-RAY DIFFRACTION,3.3,67.06,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13.5% PEG 8000, 2% ethanol",277.0,2024-08-02,2024-08-21,9CYR,2555.0,1.0,321.0,140.0,,37.41,1.0,1.65,experimental,42.24,0.1858,0.1665,Crystal structure of D245G mutant human PTP1B (PTPN1) at room temperature (298 K)
8AFC,X-RAY DIFFRACTION,3.16,61.04,VAPOR DIFFUSION,,"100mM NaAc pH 5, 1.5M Ammoniumsulfate",277.0,2022-07-16,2022-11-09,8AFC,2668.0,2.0,338.0,38.0,1.0,39.82,1.0,2.41,experimental,67.77,0.2656,0.2112,CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 12
7ZYK,X-RAY DIFFRACTION,2.02,39.06,"VAPOR DIFFUSION, SITTING DROP",,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298.0,2022-05-25,2022-12-07,7ZYK,3112.0,1.0,328.0,207.0,,39.96,1.0,1.31,experimental,22.36,0.2064,0.1903,Compound 9 Bound to CK2alpha
7SE8,X-RAY DIFFRACTION,3.04,59.59,"VAPOR DIFFUSION, HANGING DROP",,2.75-3.3 M Sodium Formate,293.0,2021-09-30,2022-02-09,7SE8,3994.0,2.0,484.0,315.0,,54.32,1.0,1.75,experimental,27.44,0.2136,0.1877,Crystal structure of human Fibrillarin in complex with fragment 1 from cocktail soak
7SE9,X-RAY DIFFRACTION,3.03,59.36,"VAPOR DIFFUSION, HANGING DROP",,2.75-3.3 M Sodium Formate,293.0,2021-09-30,2022-02-09,7SE9,4019.0,2.0,484.0,353.0,,54.32,1.0,1.75,experimental,27.91,0.2216,0.1871,Crystal structure of human Fibrillarin in complex with compound 1 from single soak
7SEC,X-RAY DIFFRACTION,3.01,59.14,"VAPOR DIFFUSION, HANGING DROP",,2.75-3.3 M Sodium Formate,293.0,2021-09-30,2022-02-09,7SEC,3717.0,2.0,484.0,115.0,,54.41,1.0,1.9,experimental,39.98,0.2663,0.2225,Crystal structure of human Fibrillarin in complex with compound 1a
5LCQ,X-RAY DIFFRACTION,2.15,53.1,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)

Reservoir: 18% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-06-22,2018-01-17,5LCQ,3720.0,2.0,373.0,551.0,,43.82,2.0,1.423,experimental,,0.171,0.1411,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with long-chain Fasudil-derivative (Ligand 05)
5LCR,X-RAY DIFFRACTION,2.18,53.8,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (100 mM Stock)

Reservoir: 14% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-06-22,2018-01-17,5LCR,3444.0,2.0,373.0,392.0,,43.91,2.0,1.565,experimental,,0.1965,0.1549,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with open-chain Fasudil-derivative (Ligand 04)
5LCT,X-RAY DIFFRACTION,2.15,55.36,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)

Reservoir: 19% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-06-22,2018-01-17,5LCT,3491.0,2.0,373.0,412.0,,43.81,2.0,1.615,experimental,,0.1742,0.1427,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a R-methyl-piperazine substituted Fasudil-derivative (Ligand 02)
5M0U,X-RAY DIFFRACTION,2.18,53.69,"VAPOR DIFFUSION, HANGING DROP",6.9,"10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)

Reservoir: 23% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-10-05,2018-06-06,5M0U,3323.0,2.0,373.0,305.0,,43.75,2.0,1.667,experimental,,0.1893,0.1524,Apostructure structure of cAMP-dependent Protein Kinase (PKA) from CHO cells with a peptidic inhibitor fragment
5M71,X-RAY DIFFRACTION,2.15,54.71,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)

Reservoir: 19% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-10-26,2018-06-06,5M71,3535.0,2.0,373.0,460.0,,43.68,2.0,1.488,experimental,,0.1761,0.1472,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with an (R)-methyl substitued Fasudil-derivative.
6OBX,X-RAY DIFFRACTION,2.08,40.96,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM sodium cacodylate, 52-58% MPD",293.0,2019-03-21,2020-02-12,6OBX,4632.0,1.0,496.0,516.0,5.0,57.03,1.0,1.3,experimental,,0.1227,0.0987,Montbretin A analogue M10-MbA in complex with Human pancreatic alpha-amylase
7AHS,X-RAY DIFFRACTION,2.39,48.5,"VAPOR DIFFUSION, SITTING DROP",,"25 % w/v Polyethylene glycol 3,350, 100 mM BIS-TRIS pH 5.5, 200 mM lithium sulfate",293.15,2020-09-25,2021-03-24,7AHS,9852.0,4.0,1092.0,910.0,,128.1,1.0,2.05,experimental,51.39,0.2351,0.1833,titin-N2A Ig81-Ig83
6NJJ,X-RAY DIFFRACTION,2.14,42.65,"VAPOR DIFFUSION, SITTING DROP",6.3,"8.8MG/ML VCID7620 + 0.5MM BPN-
 014770 (EBSI4045) IN A PROTEIN SOLUTION CONTAINING 10MM HEPES
 PH 7.5, 100MM NACL, 1MM DTT, 0.1MM ZNCL2, 0.1MM MGCL2 (BATCH
 1214057) AGAINST OPTIMIZATION SCREEN TET_MPC8_JCH7 (OPT SCREEN
 BASED ON MORPHEUS C8 AND JCSG H7); 6.25% W/V PEG1,000, 20.91%
 W/V PEG3350, 6.25% W/V MPD, 0.2M AMMONIUM SULFATE, 0.1MM BIS-
 TRIS PH 6.3, CRYO-PROTECTED - 20% ETHYLENE GLYCOL, CRYSTAL
 TRACKING ID 247599D11 (WEV9-9), PH 6.30, VAPOR DIFFUSION,
 SITTING DROP, TEMPERATURE 289K",298.0,2019-01-03,2019-05-08,6NJJ,11283.0,4.0,1480.0,505.0,,173.35,1.0,2.3,experimental,31.06,0.214,0.167,Crystal Structure of the PDE4D Catalytic Domain and UCR2 Regulatory Helix with BPN14770
6WFJ,X-RAY DIFFRACTION,3.3,62.67,"VAPOR DIFFUSION, SITTING DROP",,"7.5 mg/mL protein against 19-22% PEG4000, 240-270 mM trilithium/triammonium/tripotassium citrate",281.0,2020-04-03,2020-09-09,6WFJ,13320.0,2.0,1850.0,214.0,32.0,215.26,1.0,2.5,experimental,60.345,0.2223,0.1994,Crystal structures of human E-NPP 1: apo
4ZIM,X-RAY DIFFRACTION,2.95,58.34,"VAPOR DIFFUSION, HANGING DROP",6.5,"100mM MES buffer, 100mM NaCl, 28% (w/v) PEG3350, 2mM DTT and 200mM tri-sodium citrate",295.0,2015-04-28,2015-06-03,4ZIM,5118.0,2.0,642.0,262.0,,76.67,1.0,2.65,experimental,38.0,0.2742,0.202,CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1-CARBOXAMIDE INHIBITOR
5USY,X-RAY DIFFRACTION,2.52,51.24,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1M Sodium citrate, pH 5.6
0.2 M Ammonium sulfate
30% PEG 4,000",293.0,2017-02-14,2017-06-07,5USY,5438.0,2.0,632.0,657.0,,76.34,1.0,2.0,experimental,,0.2158,0.1757,JAK2 JH1 in complex with JNJ-7706621
8BX9,X-RAY DIFFRACTION,2.45,49.81,"VAPOR DIFFUSION, HANGING DROP",8.2,"0.1 M Gly-Gly pH 8.2, 1.6 M Na-malonate",295.0,2022-12-08,2023-12-20,8BX9,5580.0,2.0,632.0,499.0,,75.47,1.0,1.4,experimental,22.56,0.2228,0.1913,Crystal structure of JAK2 JH1 in complex with ilginatinib
8JMX,X-RAY DIFFRACTION,2.86,57.06,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris-HCl (pH 8.5), 0.2 M lithium sulfate and 25% w/v PEG 3350",293.0,2023-06-05,2023-10-18,8JMX,1956.0,1.0,263.0,,,30.89,1.0,2.95020177482,experimental,84.2022464107,0.306254454324,0.222438457861,The crystal structure of human aurka kinase domain in complex with AURKA-A2
7K27,X-RAY DIFFRACTION,2.46,50.03,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Magnesium chloride hexahydrate, 0.1 M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3,350",291.0,2020-09-08,2021-09-22,7K27,2364.0,1.0,265.0,256.0,,31.8,1.0,1.5,experimental,28.7846,0.1753,0.1597,"Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ATR inhibitor AZ20"
7NMZ,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD, 0.03M of each NPS (sodium nitrate, sodium phosphate dibasic, ammonium sulfate), 0.1Mbicine/Trizma base pH 8.5, 30% sacharose",293.15,2021-02-23,2021-07-21,7NMZ,3907.0,3.0,597.0,189.0,,67.82,2.0,2.303,experimental,43.92,0.2346,0.1993,Structure of 14-3-3 eta in complex with Nedd4-2(335-455) containing two 14-3-3 binding motifs Ser342 and Ser448
4Y14,X-RAY DIFFRACTION,2.31,46.76,"VAPOR DIFFUSION, SITTING DROP",7.4,"Tris, pH 7.4, 20% PEG8000, 0.2 M MgCl2",277.0,2015-02-06,2015-08-05,4Y14,5375.0,2.0,616.0,539.0,,73.16,1.0,1.898,experimental,25.0077,0.2059,0.1661,Structure of protein tyrosine phosphatase 1B complexed with inhibitor (PTP1B:CPT157633)
7BOS,X-RAY DIFFRACTION,2.07,40.7,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES pH 7.0, 30% v/v Jeffamine ED-2001",293.0,2020-03-19,2021-03-24,7BOS,2428.0,2.0,298.0,113.0,,34.09,2.0,1.7,experimental,32.799,0.2626,0.2226,"Human SIRT2 in complex with myristoyl thiourea inhibitor, No.13"
7BOT,X-RAY DIFFRACTION,2.03,39.41,"VAPOR DIFFUSION, SITTING DROP",,"0.15M Potassium bromide, 30% (w/v) Polyethylene glycol monomethyl ether 2000",293.0,2020-03-19,2021-03-24,7BOT,2365.0,2.0,298.0,106.0,,34.02,2.0,1.7,experimental,52.484,0.3196,0.2508,"Human SIRT2 in complex with myristoyl thiourea inhibitor, No.23"
5AQH,X-RAY DIFFRACTION,2.5,50.76,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQH,4023.0,2.0,504.0,216.0,1.0,56.83,2.0,2.0,experimental,36.91,0.2277,0.1841,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
6BOJ,X-RAY DIFFRACTION,2.16,43.03,"VAPOR DIFFUSION, SITTING DROP",7.5,"5.0mg/ml of PDE4D-UCR2 (CID7620) + 0.5mM BPN5004 against 8.75% w/v PEG1,000, 6.25% w/v PEG3,350, 6.25% w/v MPD, 0.015M NPS (sodium nitrate, disodium hydrogen phosphate, ammonium sulfate), 0.05M MOPS/HEPES-Na pH 7.5, 20% v/v ethanol, 0.05M Phosphate-citrate pH 4.2",289.0,2017-11-20,2018-08-22,6BOJ,12021.0,4.0,1480.0,1132.0,,172.7,1.0,1.7,experimental,21.14,0.186,0.161,Crystal Structure of the PDE4D Catalytic Domain and UCR2 Regulatory Helix with BPN5004
8AFB,X-RAY DIFFRACTION,2.02,39.08,VAPOR DIFFUSION,,"10% PEG8000, 10% PEG1000",277.0,2022-07-16,2022-11-09,8AFB,1523.0,1.0,170.0,133.0,,20.41,1.0,1.12,experimental,14.73,0.222,0.202,CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 23 (BI-0474)
6WTQ,X-RAY DIFFRACTION,2.11,41.79,"VAPOR DIFFUSION, HANGING DROP",5.0,"0.1 M SODIUM CITRATE PH 6.5, 27% PEG 8000 AND 0.2 M AMMONIUM ACETATE.
REMARK 280  6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K",291.0,2020-05-03,2021-05-05,6WTQ,2242.0,1.0,309.0,60.0,,36.97,1.0,1.79968475557,experimental,43.3181747434,0.212725846763,0.191494477759,Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 4
6SPW,X-RAY DIFFRACTION,2.02,39.21,"VAPOR DIFFUSION, SITTING DROP",,"1 MIKROLITER OF THE CK2ALPHA/ARC3140
MIXTURE (COMPOSITION: 7 MG/ML CK2ALPHA ENZYME, 1 MILLIMOLAR ARC3140, 10 % DIMETHYL SULFOXIDE, 450 MM NACL, 22.5 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 2.5 MIKROLITER RESERVOIR SOLUTION (COMPOSITION: 30 % PEG4000, 0.2 M AMMONIUM ACETATE, 0.1 M SODIUM CITRATE, PH 5.6) FOLLOWED BY VAPOUR DIFFUSION EQUILIBRATION AGAINST MICROLITER OF THE RESERVOIR SOLUTION.",293.15,2019-09-03,2020-01-29,6SPW,3321.0,4.0,412.0,293.0,,50.04,2.0,1.599,experimental,,0.196,0.1645,Structure of protein kinase CK2 catalytic subunit with the CK2beta-competitive bisubstrate inhibitor ARC3140
7X6Y,X-RAY DIFFRACTION,2.4,48.64,LIQUID DIFFUSION,,"Potassium sodium tartrate tetrahydrate, Tris",291.15,2022-03-08,2022-08-10,7X6Y,1617.0,2.0,181.0,221.0,,20.43,2.0,1.39,experimental,19.17,0.1654,0.1426,TRIM7 in complex with C-terminal peptide of NSP5
7X6Z,X-RAY DIFFRACTION,2.42,49.11,LIQUID DIFFUSION,,"DL-Malic acid, PEG3350",291.15,2022-03-08,2022-08-10,7X6Z,1620.0,2.0,180.0,219.0,,20.38,2.0,1.43,experimental,22.16,0.1722,0.1434,TRIM7 in complex with C-terminal peptide of NSP12
7X70,X-RAY DIFFRACTION,2.43,49.38,LIQUID DIFFUSION,,"Potassium sodium tartrate, Lithium sulfate, Tris-HCl",291.15,2022-03-08,2022-08-10,7X70,1650.0,2.0,179.0,242.0,,20.25,2.0,1.25,experimental,18.76,0.1703,0.1419,TRIM7 in complex with C-terminal peptide of NSP8
7NTH,X-RAY DIFFRACTION,4.03,69.48,"VAPOR DIFFUSION, SITTING DROP",7.6,"0.30 M Sodium Chloride, 0.60 M Sodium Citrate, 0.10 M Tris-HCl pH 7.6",293.0,2021-03-09,2021-04-07,7NTH,2856.0,1.0,315.0,350.0,,36.41,1.0,1.97,experimental,54.84,0.2247,0.1803,Structure of TAK1 in complex with compound 54
7NTI,X-RAY DIFFRACTION,4.03,69.48,"VAPOR DIFFUSION, SITTING DROP",7.9,"0.60 M Sodium Chloride, 0.60 M Sodium Citrate, 0.10 M Tris-HCl pH 7.9",293.0,2021-03-09,2021-04-07,7NTI,2526.0,1.0,315.0,84.0,,36.57,1.0,1.98,experimental,61.914,0.2491,0.2205,Structure of TAK1 in complex with compound 22
5FXS,X-RAY DIFFRACTION,2.41,49.01,,,,,2016-03-02,2016-10-19,5FXS,2730.0,1.0,308.0,274.0,,35.85,1.0,1.9,experimental,18.307,0.21356,0.18086,IGFR-1R complex with a pyrimidine inhibitor.
5KA8,X-RAY DIFFRACTION,3.6,65.88,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M HEPES, pH 8.0, 0.2 M MgCl2, 19% PEG8000",277.0,2016-06-01,2017-03-01,5KA8,2544.0,1.0,306.0,201.0,,35.87,1.0,1.971,experimental,33.9245,0.2316,0.1883,"Protein Tyrosine Phosphatase 1B L192A mutant, open state"
6B8E,X-RAY DIFFRACTION,3.41,63.88,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 16% PEG 8000, 2% ethanol, 10% glycerol",277.0,2017-10-06,2018-06-20,6B8E,3021.0,1.0,321.0,294.0,,37.84,1.0,1.82,experimental,33.4582,0.1997,0.1708,Multiconformer model of apo WT PTP1B with glycerol at 180 K
6B8T,X-RAY DIFFRACTION,3.52,65.01,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 16% PEG 8000, 2% ethanol, 10% glycerol",277.0,2017-10-09,2018-06-20,6B8T,3149.0,1.0,321.0,240.0,,37.74,1.0,1.85,experimental,40.1592,0.2123,0.1674,Multiconformer model of apo WT PTP1B with glycerol at 240 K
7L9X,X-RAY DIFFRACTION,2.36,47.87,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM NH4SO4, 100 mM Hepes pH 7.5, 10% PEG 4000",291.15,2021-01-05,2021-04-14,7L9X,2326.0,1.0,446.0,33.0,,50.04,1.0,2.81,experimental,94.66,0.2669,0.2092,Structure of VPS4B in complex with an allele-specific covalent inhibitor
5F8T,X-RAY DIFFRACTION,2.4,48.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG 3350, 0.1M Hepes, pH 7.5, 20mM (NH4)2SO4",298.0,2015-12-09,2016-12-14,5F8T,2111.0,2.0,249.0,107.0,5.0,28.58,2.0,1.75,experimental,30.21,0.245,0.231,The crystal structure of human Plasma Kallikrein in complex with its peptide inhibitor pkalin-2
5F8X,X-RAY DIFFRACTION,2.41,49.0,"VAPOR DIFFUSION, SITTING DROP",8.5,"23% PEG 3350, 0.1M TRIS-HCL, PH 8.5, 20MM (NH4)2SO4, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K",298.0,2015-12-09,2016-12-14,5F8X,2204.0,2.0,249.0,195.0,5.0,28.95,2.0,1.55,experimental,21.91,0.243,0.221,The crystal structure of human plasma kallikrein in complex with its peptide inhibitor pkalin-3
5F8Z,X-RAY DIFFRACTION,2.42,49.09,"VAPOR DIFFUSION, SITTING DROP",8.5,"28% PEG 3350, 0.1M TRIS-HCL PH8.5, 20MM (NH4)2SO4, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K",298.0,2015-12-09,2016-12-14,5F8Z,2207.0,2.0,249.0,201.0,6.0,28.62,2.0,1.5,experimental,19.358,0.21747,0.17933,The crystal structure of human Plasma Kallikrein in complex with its peptide inhibitor pkalin-1
8DHF,X-RAY DIFFRACTION,3.58,65.65,VAPOR DIFFUSION,4.8,"0.10 M Sodium Acetate pH 4.8, 2.30 M (NH4)2SO4, 30% Glycerol, 18% (w/v) PEG 4000, 0.1M Trisodium Citrate pH 5.75",293.0,2022-06-27,2022-08-17,8DHF,3087.0,1.0,369.0,169.0,,42.57,1.0,1.78,experimental,33.061,0.1808,0.1617,DHODH IN COMPLEX WITH LIGAND 11
8DHG,X-RAY DIFFRACTION,3.58,65.69,VAPOR DIFFUSION,4.8,"0.10 M Sodium Acetate pH 4.8, 2.30 M (NH4)2SO4, 30% Glycerol",293.0,2022-06-27,2022-08-17,8DHG,3319.0,1.0,369.0,340.0,,41.52,1.0,1.85,experimental,35.531,0.1861,0.1619,DHODH IN COMPLEX WITH LIGAND 19
8DHH,X-RAY DIFFRACTION,3.61,65.92,VAPOR DIFFUSION,4.8,"0.10 M Sodium Acetate pH4.8, 2.30 M (NH4)2SO4, 30% Glycerol",293.0,2022-06-27,2022-08-17,8DHH,3193.0,1.0,369.0,284.0,,41.51,1.0,2.02,experimental,39.505,0.2156,0.1856,DHODH IN COMPLEX WITH LIGAND 29
9BKM,X-RAY DIFFRACTION,3.65,66.29,VAPOR DIFFUSION,,"0.10 M NaAcetat_pH4.8, 2.30 M (NH4)2SO4, 30 % Glycerol, 18% (w/v) PEG 4000, 0.1M Na3Citrate pH=5.75",293.0,2024-04-29,2024-07-03,9BKM,3103.0,1.0,369.0,262.0,,41.5,1.0,2.08,experimental,34.763,0.22795,0.19063,DHODH in complex with Ligand 10
9BKN,X-RAY DIFFRACTION,3.66,,VAPOR DIFFUSION,,"0.10 M NaAcetate pH=4.8, 2.0 M (NH4)2SO4, 30 % Glycerol",293.0,2024-04-29,2024-07-03,9BKN,3414.0,1.0,367.0,379.0,,41.42,1.0,1.3,experimental,22.771,0.15205,0.12884,DHODH in complex with Ligand 16
9BKO,X-RAY DIFFRACTION,3.67,,VAPOR DIFFUSION,,"0.10 M NaAcetate pH 4.8, 2.0 M (NH4)2SO4, 30 % Glycerol",293.0,2024-04-29,2024-07-03,9BKO,3388.0,1.0,367.0,338.0,,41.82,1.0,1.44,experimental,24.047,0.17007,0.14221,DHODH in complex with Ligand 26
6SQC,X-RAY DIFFRACTION,2.39,48.63,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG6000, 100 mM Tris pH 8 and 10 mM ZnCl2",298.0,2019-09-03,2020-09-30,6SQC,3759.0,2.0,471.0,156.0,,51.96,2.0,2.28,experimental,50.72,0.2741,0.2277,Crystal structure of complex between nuclear coactivator binding domain of CBP and [1040-1086]ACTR containing alpha-methylated Leu1055 and Leu1076
6T6D,X-RAY DIFFRACTION,2.92,57.9,"VAPOR DIFFUSION, SITTING DROP",4.9,"0.1M citrate pH 4.9, 1M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2019-10-18,2019-10-30,6T6D,9146.0,4.0,1204.0,30.0,2.0,140.82,1.0,2.56,experimental,73.66,0.2717,0.2217,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2149
5G3M,X-RAY DIFFRACTION,2.22,44.63,,,"40% PEG 400, 0.1 M BIS-TRIS PH 6.0",,2016-04-29,2016-09-14,5G3M,2177.0,2.0,246.0,101.0,16.0,29.74,1.0,1.85,experimental,20.746,0.23222,0.1985,Discovery of a novel secreted phospholipase A2 (sPLA2) inhibitor.
5OW8,X-RAY DIFFRACTION,2.23,44.75,"VAPOR DIFFUSION, HANGING DROP",,"37-45% PEG400
0.1M bis-Tris pH 5.6-5.9",293.0,2017-08-31,2018-08-01,5OW8,2132.0,2.0,246.0,107.0,16.0,29.28,1.0,1.9,experimental,23.132,0.2523,0.2157,Indole-2 carboxamides as selective secreted phospholipase A2 type X (sPLA2-X) inhibitors
5OWC,X-RAY DIFFRACTION,2.3,46.58,"VAPOR DIFFUSION, HANGING DROP",,"37-45% PEG400
0.1M bis-Tris pH 5.6-5.9",293.0,2017-08-31,2018-08-01,5OWC,2119.0,2.0,244.0,89.0,16.0,28.87,1.0,1.75,experimental,28.331,0.2208,0.1827,Indole-2 carboxamides as selective secreted phospholipase A2 type X (sPLA2-X) inhibitors
6G5J,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"37-45% PEG400
0.1M bis-Tris pH 5.6-5.9",295.0,2018-03-29,2018-09-05,6G5J,2174.0,2.0,330.0,136.0,16.0,37.83,1.0,1.85,experimental,23.567,0.22779,0.19392,Secreted phospholipase A2 type X in complex with ligand
8WJY,X-RAY DIFFRACTION,2.12,41.98,"VAPOR DIFFUSION, SITTING DROP",,SM5-E1+30%Gly,298.0,2023-09-26,2023-11-22,8WJY,2625.0,1.0,311.0,271.0,,35.1,1.0,1.88,experimental,28.242,0.21718,0.17193,PKMYT1_Cocrystal_Cpd 4
8GW3,X-RAY DIFFRACTION,3.08,60.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"2% (v/v) Tacsimate pH7.0, 0.1M HEPES pH 7.5, 20%(w/v) PEG3350",289.0,2022-09-16,2023-09-20,8GW3,9458.0,4.0,1304.0,419.0,,146.96,1.0,2.05,experimental,46.87,0.2582,0.2213,Crystal structure of human TAK1 kinase domain fused with TAB1
8FE5,X-RAY DIFFRACTION,2.71,54.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"200 mM Lithium Sulfate, 100 mM HEPES 7.5, 25% PEG 3350",277.15,2022-12-05,2023-10-18,8FE5,7076.0,4.0,850.0,17.0,,100.27,2.0,2.51,experimental,58.08,0.2432,0.1901,Structure of J-PKAc chimera complexed with Aplithianine B
5G15,X-RAY DIFFRACTION,2.86,57.04,"VAPOR DIFFUSION, SITTING DROP",6.5,"AURORA A AND MONOBODIES WERE ALIQUOTED IN STORAGE BUFFER (20MM TRISHCL, 200MM NACL, 10% (V/V) GLYCEROL, 20MM MGCL2, 5MM TCEP, PH 7.50) AND KEPT AT -80C. AMPPCP WAS PREPARED FRESH FROM POWDER THE DAY OF CRYSTALLIZATION IN CONCENTRATIONS OF 100-120MM IN STORAGE BUFFER. CRYSTALS OF AURA IN COMPLEX WITH AMPPCP AND ACTIVATING MONOBODY, MB1, WERE OBTAINED BY COMBINING 0.5UL OF [300UM AURA WITH 5MM AMPPCP AND 300UM MB1] WITH 0.5UL OF MOTHER LIQUOR (0.1M MES SODIUM SALT PH 6.50, 0.2M AMMONIUM SULFATE, 4% (V/V) 1,3-PROPANEDIOL, 30% (W/V) PEG8000). CRYSTALS WERE GROWN AT 18C BY VAPOR DIFFUSION AND THE SITTING DROP METHOD. THE CRYSTALS WERE WASHED WITH MOTHER LIQUOR AND FLASH FROZEN IN LIQUID NITROGEN IN PREPARATION FOR DATA COLLECTION.",291.0,2016-03-23,2018-03-14,5G15,3087.0,2.0,378.0,145.0,,44.18,2.0,2.06,experimental,34.133,0.27388,0.22687,Structure Aurora A (122-403) bound to activating monobody Mb1 and AMPPCP
6SPX,X-RAY DIFFRACTION,1.99,38.08,"VAPOR DIFFUSION, SITTING DROP",,"1 microliter of the CK2alpha/ARC1502 mixture (composition: 7 mg/ml CK2alpha enzyme, 1 mM ARC1502, 10 % dimethyl sulfoxide, 450 mM NaCl, 25 mM Tris/HCl, pH 8.5) was mixed with 2.5 mikroliter reservoir solution (composition: 30 % PEG4000, 0.2 M ammonium acetate, 0.1 M sodium citrate, pH 5.6) followed by vapour diffusion equilibration against 100 microliter of the reservoir solution.",293.0,2019-09-03,2020-01-29,6SPX,3011.0,2.0,342.0,152.0,,41.48,2.0,1.994,experimental,,0.2228,0.1841,Structure of protein kinase CK2 catalytic subunit in complex with the CK2beta-competitive bisubstrate inhibitor ARC1502
5ZQO,X-RAY DIFFRACTION,2.67,53.99,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M Bis-Tris pH 6.5, 2% PEG MME 550, 1.8M ammonium sulfate",277.0,2018-04-19,2019-04-03,5ZQO,1872.0,2.0,216.0,152.0,,25.39,2.0,2.06,experimental,,0.203,0.163,Tankyrase-2 in complex with compound 1a
5ZQP,X-RAY DIFFRACTION,2.67,53.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH 8.5, 2.4M (NH4)2HPO4",277.0,2018-04-19,2019-04-03,5ZQP,1826.0,2.0,216.0,114.0,,25.21,2.0,1.99,experimental,,0.205,0.173,Tankyrase-2 in complex with compound 12
5ZQQ,X-RAY DIFFRACTION,2.69,54.36,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH 8.5, 2.4M (NH4)2HPO4",277.0,2018-04-19,2019-04-03,5ZQQ,1806.0,2.0,216.0,100.0,,25.13,2.0,2.29,experimental,,0.224,0.163,Tankyrase-2 in complex with compound 52
5ZQR,X-RAY DIFFRACTION,2.62,53.02,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH 8.5, 2.4M (NH4)2HPO4",277.0,2018-04-19,2019-04-03,5ZQR,1861.0,2.0,216.0,141.0,,25.37,2.0,1.75,experimental,,0.19,0.163,Tankyrase-2 in complex with compound 40c
8YTE,X-RAY DIFFRACTION,2.69,54.3,VAPOR DIFFUSION,,"0.1 M Tris pH 8.5, , 25% w/v Polyethylene glycol 3,350, 0.2 M ammonium acetate",293.0,2024-03-25,2024-07-10,8YTE,1864.0,4.0,232.0,91.0,2.0,26.39,2.0,2.26,experimental,29.8,0.24947,0.19668,Crystal Structure of TrkA D5 domain in complex with macrocyclic peptide
6ZGC,X-RAY DIFFRACTION,2.79,55.96,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.26M sodium phosphate monobasic
0.14M potassium phosphate dibasic",277.0,2020-06-18,2020-07-29,6ZGC,9244.0,4.0,1204.0,20.0,2.0,141.99,1.0,2.67,experimental,60.89,0.2595,0.2122,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound Saracatinib (AZD0530)
8BE4,X-RAY DIFFRACTION,3.26,62.26,"VAPOR DIFFUSION, SITTING DROP",,"14% PEG 1000, Tris 0.1 M pH 7.0",293.0,2022-10-21,2023-11-01,8BE4,6622.0,3.0,825.0,551.0,1.0,95.09,3.0,1.9,experimental,41.67,0.1986,0.1749,Crystal structure of SOS1-KRasG12V-Nanobody14
5D3E,X-RAY DIFFRACTION,3.09,60.23,"VAPOR DIFFUSION, SITTING DROP",7.5,"HEPES, NaCl, DTT, (NH4)2SO4, Poly(acrylic acid sodium salt 2100",293.0,2015-08-06,2016-03-16,5D3E,11713.0,9.0,1566.0,141.0,,180.43,2.0,2.75,experimental,63.19,0.2436,0.202,Crystal structure of human 14-3-3 gamma in complex with CFTR R-domain peptide pS768-pS795
5TJ7,X-RAY DIFFRACTION,2.05,40.02,VAPOR DIFFUSION,,"0.1 M potassium thiocyanate, 30% PEG monomethyl ether 2000",291.0,2016-10-03,2017-05-31,5TJ7,15912.0,4.0,1788.0,996.0,,213.93,1.0,2.6,experimental,23.905,0.2836,0.2072,"Structure of WWP2 WW2-2,3-linker-HECT aa 334-398 linked to 485-865"
5S75,X-RAY DIFFRACTION,2.6,52.65,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S75,5766.0,2.0,602.0,776.0,,72.77,1.0,1.3,experimental,17.822,0.1729,0.155,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010913a
5S76,X-RAY DIFFRACTION,2.59,52.55,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S76,5793.0,2.0,602.0,788.0,,72.52,1.0,1.31,experimental,16.749,0.1734,0.1548,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010916a
5S77,X-RAY DIFFRACTION,2.6,52.6,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S77,5737.0,2.0,602.0,802.0,,72.52,1.0,1.31,experimental,18.008,0.1851,0.1646,XChem group deposition -- Crystal Structure of human ACVR1 in complex with XS035133b
5S78,X-RAY DIFFRACTION,2.6,52.78,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S78,5672.0,2.0,602.0,775.0,,72.37,1.0,1.3,experimental,18.254,0.1774,0.1595,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010934a
5S79,X-RAY DIFFRACTION,2.6,52.61,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S79,5594.0,2.0,602.0,680.0,,72.46,1.0,1.5,experimental,24.24,0.206,0.1793,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010910a
5S7A,X-RAY DIFFRACTION,2.6,52.72,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7A,5796.0,2.0,602.0,784.0,,72.53,1.0,1.3,experimental,17.551,0.1802,0.1587,XChem group deposition -- Crystal Structure of human ACVR1 in complex with PK012456b
5S7B,X-RAY DIFFRACTION,2.59,52.49,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7B,5619.0,2.0,602.0,706.0,,72.73,1.0,1.32,experimental,22.292,0.1952,0.1676,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000329d
5S7C,X-RAY DIFFRACTION,2.59,52.52,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7C,5690.0,2.0,602.0,731.0,,72.47,1.0,1.31,experimental,17.054,0.179,0.1603,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000274c
5S7D,X-RAY DIFFRACTION,2.62,53.04,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7D,5857.0,2.0,602.0,799.0,,72.57,1.0,1.31,experimental,17.267,0.1854,0.1642,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010923a
5S7E,X-RAY DIFFRACTION,2.59,52.56,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7E,5837.0,2.0,602.0,829.0,,72.59,1.0,1.32,experimental,21.702,0.1893,0.1671,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010930a
5S7F,X-RAY DIFFRACTION,2.59,52.59,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7F,5783.0,2.0,602.0,777.0,,72.6,1.0,1.31,experimental,17.214,0.1693,0.1498,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010935a
5S7H,X-RAY DIFFRACTION,2.58,52.35,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7H,5814.0,2.0,602.0,787.0,,72.49,1.0,1.3,experimental,18.111,0.1799,0.1568,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010914a
5S7I,X-RAY DIFFRACTION,2.59,52.46,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7I,5804.0,2.0,602.0,678.0,,73.74,1.0,1.3,experimental,16.597,0.1765,0.1567,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010928a
5S7J,X-RAY DIFFRACTION,2.58,52.3,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7J,5765.0,2.0,602.0,803.0,,72.35,1.0,1.31,experimental,19.228,0.1809,0.1577,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000893d
5S7O,X-RAY DIFFRACTION,2.6,52.76,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7O,5793.0,2.0,602.0,790.0,,72.26,1.0,1.43,experimental,22.985,0.1887,0.1642,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM007391c
5S7P,X-RAY DIFFRACTION,2.58,52.35,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7P,5638.0,2.0,602.0,764.0,,72.19,1.0,1.31,experimental,19.283,0.176,0.1573,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010937a
5S7R,X-RAY DIFFRACTION,2.6,52.72,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7R,5750.0,2.0,602.0,729.0,,73.47,1.0,1.46,experimental,19.461,0.1977,0.172,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010918a
5S7S,X-RAY DIFFRACTION,2.6,52.63,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7S,5925.0,2.0,602.0,844.0,,72.64,1.0,1.3,experimental,15.686,0.1714,0.1517,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010921a
5S7V,X-RAY DIFFRACTION,2.59,52.48,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7V,5758.0,2.0,602.0,786.0,,72.26,1.0,1.31,experimental,17.441,0.1722,0.1532,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010942a
5S7X,X-RAY DIFFRACTION,2.58,52.3,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7X,5716.0,2.0,602.0,771.0,,72.59,1.0,1.3,experimental,17.282,0.1691,0.1503,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM000376d
5S7Z,X-RAY DIFFRACTION,2.58,52.35,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S7Z,5793.0,2.0,602.0,794.0,,72.94,1.0,1.3,experimental,19.982,0.1841,0.1619,XChem group deposition -- Crystal Structure of human ACVR1 in complex with NU074488b
5S80,X-RAY DIFFRACTION,2.57,52.21,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S80,5632.0,2.0,602.0,668.0,,72.67,1.0,1.67,experimental,23.63,0.2305,0.1955,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010946a
5S87,X-RAY DIFFRACTION,2.59,52.58,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S87,5743.0,2.0,602.0,803.0,,72.45,1.0,1.3,experimental,17.564,0.1809,0.1602,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010953a
5S88,X-RAY DIFFRACTION,2.6,52.69,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S88,5775.0,2.0,602.0,819.0,,72.36,1.0,1.31,experimental,18.553,0.1787,0.1595,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010954a
5S89,X-RAY DIFFRACTION,2.59,52.58,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1M citrate pH 6.0, 1.4M ammonium sulfate, 0.2M sodium/potassium tartrate",277.0,2020-12-11,2021-06-23,5S89,5786.0,2.0,602.0,795.0,,72.45,1.0,1.3,experimental,16.809,0.1738,0.1553,XChem group deposition -- Crystal Structure of human ACVR1 in complex with FM010957a
6SRH,X-RAY DIFFRACTION,2.68,54.14,"VAPOR DIFFUSION, SITTING DROP",6.0,0.1M citrate pH 6.0 -- 1.4M ammonium sulfate -- 0.2M sodium/potassium tartrate,277.0,2019-09-05,2019-09-18,6SRH,5942.0,2.0,602.0,844.0,,72.5,1.0,1.25,experimental,24.02,0.1601,0.1324,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2117
6SZM,X-RAY DIFFRACTION,2.66,53.81,"VAPOR DIFFUSION, SITTING DROP",5.5,"2M ammonium sulfate, 0.1M bis-tris pH 5.5",277.0,2019-10-02,2019-10-16,6SZM,5654.0,2.0,602.0,694.0,,71.76,1.0,1.42,experimental,24.18,0.1883,0.1519,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2009
6T8N,X-RAY DIFFRACTION,2.19,43.78,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M citrate pH 5.5
1.2M ammonium sulfate
0.4M sodium/potassium tartrate",277.0,2019-10-24,2019-11-27,6T8N,4993.0,2.0,602.0,157.0,,70.86,1.0,1.77,experimental,32.01,0.237,0.203,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K3007
7A21,X-RAY DIFFRACTION,2.65,53.65,"VAPOR DIFFUSION, SITTING DROP",7.4,"16% PEG8K, 15% glycerol, 0.08M potassium phosphate dibasic",293.0,2020-08-14,2020-09-16,7A21,4928.0,2.0,602.0,139.0,,70.19,1.0,2.14,experimental,37.704,0.256,0.2076,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2158
6U2G,X-RAY DIFFRACTION,3.29,62.65,"VAPOR DIFFUSION, HANGING DROP",6.5,"Ammonium sulfate, MES, PEK 8000",293.0,2019-08-19,2019-08-28,6U2G,4633.0,2.0,701.0,33.0,,79.88,2.0,2.886,experimental,79.0371,0.2757,0.229,BRAF-MEK complex with AMP-PCP bound to BRAF
6MOZ,X-RAY DIFFRACTION,3.24,62.0,"VAPOR DIFFUSION, HANGING DROP",7.0,"HEPES pH 7.5, monobasic sodium phosphate and monobasic potassium phosphate",298.0,2018-10-05,2019-06-19,6MOZ,8118.0,2.0,994.0,112.0,4.0,113.45,1.0,2.1,experimental,,0.2278,0.1998,Structure of acid-beta-glucosidase in complex with an aromatic pyrrolidine iminosugar inhibitor
6WTO,X-RAY DIFFRACTION,2.1,41.39,"VAPOR DIFFUSION, HANGING DROP",5.0,"1.6-2.4 M sodium malonate, pH 5",291.0,2020-05-03,2021-05-05,6WTO,2328.0,1.0,309.0,104.0,,36.91,1.0,1.74,experimental,45.2045,0.218,0.1973,Human JAK2 JH1 domain in complex with Baricitinib
8YTD,X-RAY DIFFRACTION,3.03,59.4,VAPOR DIFFUSION,,25% v/v ethylene glycol,277.0,2024-03-25,2024-07-10,8YTD,1103.0,3.0,135.0,50.0,1.0,15.38,3.0,2.34,experimental,28.21,0.27596,0.21842,Crystal Structure of TrkA D5 domain in complex with two different macrocyclic peptides
7KKN,X-RAY DIFFRACTION,2.37,48.09,VAPOR DIFFUSION,,"Buffer: 0.1 M MES (pH 6.50)
Precipitant: 15.0 %w/v PEG 8000
Precipitant: 40.0 %v/v iso-propanol",277.0,2020-10-27,2021-01-06,7KKN,7871.0,4.0,852.0,951.0,,99.6,1.0,1.48,experimental,22.68,0.215,0.184,Structure of the catalytic domain of tankyrase 1 in complex with talazoparib
6VNB,X-RAY DIFFRACTION,3.1,60.32,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNB,5092.0,2.0,616.0,160.0,,73.87,1.0,2.19,experimental,57.9509,0.2612,0.2162,JAK2 JH1 in complex with BL2-084
6VNC,X-RAY DIFFRACTION,3.06,59.79,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNC,4971.0,2.0,616.0,43.0,,73.87,1.0,2.3,experimental,71.7999,0.2686,0.226,JAK2 JH1 in complex with BL2-096
6VNF,X-RAY DIFFRACTION,3.03,59.38,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNF,5108.0,2.0,616.0,152.0,,74.02,1.0,2.06,experimental,61.1712,0.2221,0.1929,JAK2 JH1 in complex with MA9-086
6VNG,X-RAY DIFFRACTION,3.06,59.76,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNG,4969.0,2.0,616.0,85.0,,74.0,1.0,2.5,experimental,59.2892,0.2506,0.2121,JAK2 JH1 in complex with PN2-118
6VNH,X-RAY DIFFRACTION,3.02,59.22,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNH,4960.0,2.0,616.0,42.0,,74.04,1.0,2.4,experimental,68.6403,0.2665,0.2299,JAK2 JH1 in complex with PN2-123
6VNI,X-RAY DIFFRACTION,3.08,60.04,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNI,5080.0,2.0,616.0,203.0,,74.0,1.0,2.1,experimental,55.3187,0.2572,0.2134,JAK2 JH1 in complex with PN3-115
6VNJ,X-RAY DIFFRACTION,3.04,59.58,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNJ,5201.0,2.0,616.0,264.0,,73.74,1.0,1.9,experimental,50.9264,0.211,0.1847,JAK2 JH1 in complex with PN4-014
6VNM,X-RAY DIFFRACTION,3.08,60.11,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-01-29,2021-02-17,6VNM,5123.0,2.0,616.0,201.0,,73.74,1.0,2.2,experimental,56.1698,0.2385,0.1983,JAK2 JH1 in complex with SY5-103
6VS3,X-RAY DIFFRACTION,3.02,59.32,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 0.2 M NaCl, 25% PEG 3350",291.0,2020-02-10,2021-02-17,6VS3,5305.0,2.0,616.0,373.0,,73.87,1.0,2.0,experimental,43.0899,0.2184,0.1845,JAK2 JH1 in complex with BL2-057
8CX5,X-RAY DIFFRACTION,2.04,39.73,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES 6.5
30% w/v PEG 4K",298.0,2022-05-19,2022-08-31,8CX5,3086.0,2.0,340.0,205.0,,41.34,1.0,1.72,experimental,24.0,0.2211,0.1885,"Crystal Structure of small molecule alpha,beta-ketoamide 4 covalently bound to K-Ras(G12R)"
6P0P,X-RAY DIFFRACTION,2.38,48.3,"VAPOR DIFFUSION, SITTING DROP",4.6,"1.9 mg/mL protein incubated with compound for 30 minutes on ice prior to setup with 30% PEG1500, 0.1 M sodium acetate, pH 4.6, 0.2 M ammonium sulfate",298.0,2019-05-17,2020-03-25,6P0P,4128.0,2.0,550.0,161.0,8.0,62.63,1.0,2.55,experimental,33.433,0.24889,0.18037,"Human beta-tryptase co-crystal structure with 5-{4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl}-2-(3'-{4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl}-[1,1'-biphenyl]-3-yl)-2-hydroxy-2H-1,3,2-benzodioxaborol-2-uide"
7KFN,X-RAY DIFFRACTION,2.76,54.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM MES:NaOH pH 6.5, 18% PEG 20,000",298.0,2020-10-14,2021-06-16,7KFN,7110.0,4.0,852.0,252.0,,106.24,1.0,2.5,experimental,46.536,0.2256,0.1707,Structure of Human Adenosine Deaminase Acting on dsRNA (ADAR2) bound to dsRNA containing a 2'-deoxy Benner's Base Z opposite the edited base
6J5L,X-RAY DIFFRACTION,3.11,60.42,"VAPOR DIFFUSION, SITTING DROP",5.3,"0.65 M Ammonium sulfate, 0.1 M Sodium Citrate pH 5.3",293.0,2019-01-11,2019-07-17,6J5L,2220.0,1.0,303.0,32.0,,34.74,1.0,2.3,experimental,69.112,0.25078,0.22312,"Crystal structure of Trk-A in complex with the Pan-Trk Kinase Inhibitor, compound 10e"
6PL2,X-RAY DIFFRACTION,2.66,53.78,"VAPOR DIFFUSION, HANGING DROP",,20mM Tris/HCl,277.15,2019-06-30,2019-09-04,6PL2,2464.0,1.0,311.0,56.0,,35.88,1.0,2.59,experimental,41.233,0.27414,0.1957,TRK-A IN COMPLEX WITH LIGAND 1a
6PL4,X-RAY DIFFRACTION,2.55,51.75,"VAPOR DIFFUSION, HANGING DROP",,pH 8.5,277.15,2019-06-30,2020-07-01,6PL4,2570.0,1.0,311.0,110.0,,35.91,1.0,2.06,experimental,49.695,0.23866,0.19891,TRK-A IN COMPLEX WITH LIGAND 1
8J5W,X-RAY DIFFRACTION,2.61,52.83,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Na2HPO4/KH2PO4 (pH 6.2), 2M NaCl",289.0,2023-04-24,2023-09-20,8J5W,2417.0,1.0,313.0,,,36.12,1.0,2.28041464539,experimental,56.0588333871,0.265992005805,0.216913692069,"The crystal structure of TrkA(F589L) kinase in complex with N-(3-cyclopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4^6-methyl-14-oxo-5-oxa-13-aza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide"
8J5X,X-RAY DIFFRACTION,2.62,52.98,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Na2HPO4/KH2PO4 (pH 6.2), 2M NaCl",289.0,2023-04-24,2023-09-20,8J5X,2589.0,1.0,299.0,200.0,,34.67,1.0,2.09192247704,experimental,37.7677335303,0.220112735617,0.180103673153,"The crystal structure of TrkA(G595R) kinase in complex with N-(3-cyclopropyl-5-((4-methylpiperazin-1-yl)methyl)phenyl)-4^6-methyl-14-oxo-5-oxa-13-aza-1(3,6)-imidazo[1,2-b]pyridazina-4(1,3)-benzenacyclotetradecaphan-2-yne-4^5-carboxamide"
5JH6,X-RAY DIFFRACTION,3.8,67.64,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.65-0.75 M sodium citrate, 0.2 M NaCl, 0.1 M Tris, and 5mM adenosine. Adenosine bound TAK1-TAB1 crystals are backsoaked with inhibitor",293.0,2016-04-20,2017-02-15,5JH6,2343.0,1.0,314.0,3.0,,35.93,1.0,2.365,experimental,,0.2528,0.2251,Crystal structure of TL10-92 bound to TAK1-TAB1
5JK3,X-RAY DIFFRACTION,3.96,68.91,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.65-0.75 M sodium citrate, 0.2 M NaCl, 0.1 M Tris, and 5mM adenosine. Adenosine bound TAK1-TAB1 crystals are backsoaked with inhibitor, pH 7.0",293.0,2016-04-25,2017-02-15,5JK3,2172.0,1.0,314.0,,,35.83,1.0,2.371,experimental,,0.2658,0.2348,Crystal structure of TL11-128 bound to TAK1-TAB1
5LHD,X-RAY DIFFRACTION,2.91,57.66,"VAPOR DIFFUSION, SITTING DROP",,"50 mM Imidazol-HCl pH 8.0, 20% PEG6000",294.0,2016-07-11,2017-04-05,5LHD,31338.0,4.0,3800.0,665.0,8.0,454.61,1.0,2.6,experimental,,0.2141,0.1815,Structure of glycosylated human aminopeptidase N
6ZC9,X-RAY DIFFRACTION,2.7,54.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 400, magnesium chloride, HEPES, hexafluoro-2-propanol",293.15,2020-06-10,2021-07-21,6ZC9,7979.0,8.0,976.0,546.0,,113.19,2.0,1.89895988606,experimental,44.8045996391,0.239347564833,0.211915834691,Structure of 14-3-3 gamma in complex with Nedd4-2 14-3-3 binding motif Ser448
5DX1,X-RAY DIFFRACTION,2.38,48.32,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M Ammonium Sulfate, 0.1 M Tris pH 8.5, 18% w/v PEG 3350",291.0,2015-09-23,2015-11-25,5DX1,12231.0,8.0,1472.0,490.0,,168.08,2.0,1.93,experimental,30.504,0.238,0.1958,"Crystal structure of CARM1, sinefungin, and PABP1 peptide (R455)"
5AQS,X-RAY DIFFRACTION,2.43,49.47,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQS,8112.0,4.0,1008.0,496.0,2.0,112.86,2.0,2.0,experimental,15.1,0.2605,0.2079,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQK,X-RAY DIFFRACTION,2.37,48.09,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5, 25% (V/V) GLYCEROL AND 100 MM GDP FROM 1 M STOCK AT PH 7.5",,2015-09-22,2016-10-05,5AQK,3933.0,2.0,504.0,124.0,1.0,57.28,2.0,2.09,experimental,37.13,0.232,0.1862,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQT,X-RAY DIFFRACTION,2.45,49.83,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQT,4047.0,2.0,504.0,210.0,1.0,57.02,2.0,1.9,experimental,40.54,0.2224,0.1803,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQU,X-RAY DIFFRACTION,2.41,48.97,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQU,4074.0,2.0,504.0,217.0,1.0,57.28,2.0,1.92,experimental,50.74,0.2014,0.1782,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQV,X-RAY DIFFRACTION,2.43,49.38,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQV,4168.0,2.0,504.0,269.0,1.0,57.3,2.0,1.75,experimental,44.46,0.1969,0.1793,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5VCV,X-RAY DIFFRACTION,2.11,41.6,"VAPOR DIFFUSION, HANGING DROP",7.5,"6.9 MG/ML MYT1, 25 mM HEPES, 100 MM SODIUM CHLORIDE, 0.5 mM DTT, 0.1 M CALCIUM CHLORIDE, 0.05 M TRIS pH 8.5, 10 % PEG 4000, 1 mM Dasatinib",291.0,2017-04-01,2017-08-23,5VCV,2458.0,1.0,311.0,178.0,,35.2,1.0,1.92,experimental,28.4245,0.1968,0.1555,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Dasatinib
6YR9,X-RAY DIFFRACTION,2.67,53.95,"VAPOR DIFFUSION, HANGING DROP",7.5,"15% PEG 3350, 0.2 M Na acetate",294.0,2020-04-19,2021-02-10,6YR9,8734.0,4.0,1128.0,175.0,4.0,131.23,1.0,1.925,experimental,38.36,0.2183,0.1917,"FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-(2-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-phenyl)-methanesulfonamide"
6YVS,X-RAY DIFFRACTION,2.84,56.63,"VAPOR DIFFUSION, HANGING DROP",7.5,15% PEG 3350,294.0,2020-04-28,2021-02-10,6YVS,9136.0,4.0,1128.0,622.0,4.0,130.91,1.0,1.81,experimental,39.23,0.2146,0.1915,"FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 5-{4-[(Pyridin-3-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one"
6YVY,X-RAY DIFFRACTION,2.82,56.34,"VAPOR DIFFUSION, HANGING DROP",7.5,15% PEG 3350,294.0,2020-04-28,2021-02-10,6YVY,9023.0,4.0,1128.0,507.0,4.0,131.15,1.0,1.918,experimental,39.24,0.2353,0.2141,"FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide"
6YXV,X-RAY DIFFRACTION,3.02,59.29,"VAPOR DIFFUSION, HANGING DROP",,15% PEG 3350,294.0,2020-05-04,2021-02-10,6YXV,8654.0,4.0,1128.0,138.0,4.0,131.11,1.0,2.298,experimental,60.78,0.232,0.202,FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-{3-[(2-phenylamino-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl]-pyridin-2-yl}-methanesulfonamide
4X93,X-RAY DIFFRACTION,4.01,69.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM HEPES pH 7.5, 30% PEG MME 550, 50 mM MgCl2",277.0,2014-12-11,2015-03-25,4X93,6388.0,2.0,760.0,91.0,2.0,88.96,1.0,2.6,experimental,62.707,0.2182,0.1986,Crystal structure of Lysosomal Phospholipase A2 crystallized in the presence of methyl arachidonyl fluorophosphonate (tetragonal form)
8C1E,X-RAY DIFFRACTION,3.62,66.06,VAPOR DIFFUSION,6.5,"5% DMSO, 0.2M MgSO4, 0.05 M HEPES 7.4: soaking: 0.2M MgSO4, 0.05M HEPES 7.4, 30% glycerol, 10% DMSO, 5 mM compound",298.0,2022-12-20,2024-01-10,8C1E,2279.0,1.0,272.0,73.0,,32.38,1.0,2.798,experimental,48.803,0.2388,0.1726,Aurora A kinase in complex with TPX2-inhibitor 9
6GQ7,X-RAY DIFFRACTION,2.63,53.18,VAPOR DIFFUSION,,"20% PEG3350, 175 mM AmSO4, 10 mM DTT and 100 mM Hepes",293.0,2018-06-07,2018-06-20,6GQ7,6562.0,1.0,966.0,16.0,,111.09,1.0,2.84,experimental,81.16,0.2957,0.2352,PI3Kg IN COMPLEX WITH INH
4QAP,X-RAY DIFFRACTION,3.39,63.71,"VAPOR DIFFUSION, HANGING DROP",7.0,"8-24% (w/v) polyethylene glycol 4000, 100mM Hepes (pH 7.0), 200mM magnesium acetate, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-05-05,2015-02-11,4QAP,2659.0,1.0,299.0,129.0,,34.97,1.0,1.903,experimental,,0.242,0.209,The second sphere residue T263 is important for function and activity of PTP1B through modulating WPD loop
4QBW,X-RAY DIFFRACTION,3.48,64.7,"VAPOR DIFFUSION, HANGING DROP",7.0,"18-24% (w/v) polyethylene glycol 4000, 100mM Hepes (pH 7.0), 200mM magnesium acetate, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-05-08,2015-02-11,4QBW,2730.0,1.0,299.0,130.0,,34.96,1.0,1.912,experimental,,0.2385,0.2064,The second sphere residue T263 is important for function and activity of PTP1B through modulating WPD loop
7QFT,X-RAY DIFFRACTION,1.91,35.52,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.20 M trimethylamine N-oxide, 0.1 M Tris-HCl pH8.5, 20% PEG MME 2000",298.0,2021-12-06,2022-11-09,7QFT,3926.0,4.0,456.0,440.0,12.0,50.77,2.0,1.47,experimental,20.8,0.2042,0.1719,Crystal structure of KLK6 in complex with compound 16a
7QFV,X-RAY DIFFRACTION,1.92,36.02,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.20 M trimethylamine N-oxide, 0.1 M Tris-HCl pH8.5, 20% PEG MME 2000",298.0,2021-12-06,2022-10-26,7QFV,3842.0,4.0,456.0,364.0,12.0,50.81,2.0,1.56,experimental,22.8981,0.2112,0.1761,Crystal structure of KLK6 in complex with compound 17a
6BFK,X-RAY DIFFRACTION,2.21,44.34,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-26,2018-02-21,6BFK,4530.0,6.0,568.0,535.0,,64.74,3.0,1.753,experimental,,0.1798,0.1527,Caspase-3 Mutant- T245A
5G55,X-RAY DIFFRACTION,2.21,44.24,,,,,2016-05-20,2016-08-03,5G55,6951.0,1.0,966.0,44.0,,111.18,1.0,2.45,experimental,50.529,0.32206,0.254,3-Quinoline Carboxamides inhibitors of Pi3K
5T23,X-RAY DIFFRACTION,2.81,56.29,"VAPOR DIFFUSION, HANGING DROP",,"100mM Hepes pH 7.7-8.2, 18-19% PEG3350, 175mM (NH4)2SO4, 10mM DTT",293.0,2016-08-23,2017-04-19,5T23,6581.0,1.0,966.0,17.0,,111.13,1.0,2.78,experimental,86.127,0.33923,0.25469,PI3Kg IN COMPLEX WITH 5d
6GJS,X-RAY DIFFRACTION,2.62,53.0,"VAPOR DIFFUSION, SITTING DROP",,"0.1M SPG pH 4.0, 25 % PEG 1500",293.0,2018-05-16,2019-06-26,6GJS,3928.0,3.0,521.0,426.0,2.0,57.84,3.0,1.95,experimental,35.53,0.2123,0.1773,Human NBD1 of CFTR in complex with nanobodies D12 and T4
6QJ7,X-RAY DIFFRACTION,2.57,52.09,"VAPOR DIFFUSION, HANGING DROP",,"5mM MES, 5mM Bis-Tris-propane, 75mM LiCl, 1mM DTT, 0.1mM EDTA, 1.4mM PKA-peptide, 1.4mM MEGA-8, 14% Et-OH as well solution",293.0,2019-01-23,2020-02-12,6QJ7,3320.0,2.0,371.0,338.0,,43.4,2.0,1.69,experimental,41.29,0.214,0.178,Difluorophenyl diacylhydrazides: Potent inhibitors of Serum- and Glucocorticoid-inducible Kinase 1 (SGK1)
6BHH,X-RAY DIFFRACTION,2.35,47.64,VAPOR DIFFUSION,7.5,"25% PEG3350, 0.2 M lithium sulfate, 0.1 M HEPES",291.0,2017-10-30,2017-11-22,6BHH,2010.0,2.0,257.0,221.0,,29.59,2.0,1.85,experimental,23.469,0.2374,0.1925,Crystal structure of SETDB1 with a modified H3 peptide
5TQS,X-RAY DIFFRACTION,1.95,36.98,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium acetate (pH 5.5), 22% PEG MME 5000",277.0,2016-10-24,2017-04-19,5TQS,3803.0,8.0,448.0,268.0,,53.98,2.0,1.876,experimental,36.9937,0.237,0.1885,Phospholipase C gamma-1 C-terminal SH2 domain bound to a phosphopeptide derived from the receptor tyrosine kinase ErbB2
5WGB,X-RAY DIFFRACTION,2.9,57.65,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5
0.3 M Ammonium Acetate
20 mM Calcium Acetate
20 mM CaCl2
19 % isopropanol",285.0,2017-07-13,2017-07-26,5WGB,3247.0,3.0,594.0,,,67.46,3.0,2.75,experimental,,0.2553,0.2127,Crystal Structure of the Human mitochondrial Cysteine Desulfurase in complex with ISD11 and E. coli ACP1 protein at 2.75A
7ZSN,X-RAY DIFFRACTION,,74.8,"VAPOR DIFFUSION, SITTING DROP",,"15.00 % w/v Polyethylene glycol 8,000; 500 mM Lithium sulfate; 100 mM Sodium acetate; pH 4.6; 1 mM TEW",291.15,2022-05-07,2023-05-17,7ZSN,2298.0,1.0,289.0,38.0,,37.52,1.0,2.36,experimental,66.426,0.2587,0.2204,human purine nucleoside phosphorylase in complex with JS-379
4O9I,X-RAY DIFFRACTION,2.82,56.43,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2M Ammonium citrate, 20% PEG3350, pH 7.0 , VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-01-02,2015-07-08,4O9I,1511.0,1.0,202.0,25.0,,25.0,1.0,2.6,experimental,56.179,0.26373,0.21106,Structure of CHD4 double chromodomains depicts cooperative folding for DNA binding
7XE3,X-RAY DIFFRACTION,3.48,64.66,"VAPOR DIFFUSION, SITTING DROP",,"330mM Ammonium citrate, 26% PEG 3350",293.0,2022-03-29,2022-09-14,7XE3,12142.0,2.0,1586.0,212.0,,181.0,1.0,2.82,experimental,68.22,0.222,0.177,"Crystal structure of LSD2 in complex with cis-4-Br-2,5-F2-PCPA (S1024)"
7NCF,X-RAY DIFFRACTION,3.46,64.44,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% v/v isopropanol, 0.2 M NaCl and 0.1 M HEPES, pH 7.5",293.15,2021-01-28,2021-03-03,7NCF,2927.0,1.0,367.0,23.0,,42.76,1.0,2.72,experimental,89.316,0.2514,0.1948,Crystal structure of HIPK2 in complex with MU135 (compound 21e)
5CVE,X-RAY DIFFRACTION,2.19,43.78,"VAPOR DIFFUSION, SITTING DROP",5.7,"0.2 M (NH4)Ac, 0.1 M Sodium citrate tribasic dihydrate, 24%(w/v) PEG 4000",291.0,2015-07-26,2015-11-25,5CVE,4578.0,4.0,504.0,754.0,,57.72,2.0,1.5,experimental,17.9526,0.1795,0.1526,Crystal Structure of human NRMT1 in complex with dimethylated fly H2B peptide and SAH
6U2F,X-RAY DIFFRACTION,3.78,71.15,VAPOR DIFFUSION,8.5,"4 M ammonium acetate, 0.1 M Tris, pH 8.5, 3% v/v 1,8 diaminooctane",291.0,2019-08-19,2020-02-05,6U2F,7825.0,4.0,1148.0,13.0,17.0,124.81,4.0,2.94,experimental,60.57,0.209,0.174,PCSK9-Fab 7G7 complex bound to cis-1-amino-4-phenylcyclohexaneacyl-WNLK(hR)IGLLR - NH2
7UJX,X-RAY DIFFRACTION,2.72,54.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 4000, 0.05 M MES pH 5.2, 0.05 M MgCl2, and 0.005 M DTT",293.0,2022-03-31,2022-12-07,7UJX,3547.0,2.0,369.0,497.0,,43.51,2.0,2.4,experimental,29.76,0.1765,0.1282,"Structure of cAMP-dependent protein kinase using a MD-MX procedure, produced using 2.4 Angstrom data"
7V0G,X-RAY DIFFRACTION,2.72,54.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 4000, 0.05 M MES pH 5.2, 0.05 M MgCl2, and 0.005 M DTT",293.0,2022-05-10,2022-12-07,7V0G,3611.0,2.0,369.0,496.0,,43.51,2.0,1.63,experimental,30.32,0.1625,0.1163,"Structure of cAMP-dependent protein kinase using a MD-MX procedure, produced using 1.63 Angstrom data"
7O08,X-RAY DIFFRACTION,2.15,42.78,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-25,2021-09-01,7O08,3843.0,2.0,536.0,319.0,1.0,62.34,2.0,2.0,experimental,35.3,0.226,0.189,Crystal structure of the human METTL3-METTL14 complex bound to Compound 5 (ADO_AB_075)
7O09,X-RAY DIFFRACTION,2.16,43.07,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-25,2021-09-01,7O09,3855.0,2.0,536.0,349.0,1.0,62.37,2.0,1.8,experimental,34.49,0.2251,0.1928,Crystal structure of the human METTL3-METTL14 complex bound to Compound 7 (ADO_AC_074)
7O0L,X-RAY DIFFRACTION,2.17,43.38,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-26,2021-09-01,7O0L,3808.0,2.0,536.0,279.0,1.0,62.38,2.0,1.9,experimental,38.62,0.2263,0.196,Crystal structure of the human METTL3-METTL14 complex bound to Compound 8 (ADO_AC_093)
7O29,X-RAY DIFFRACTION,2.17,43.32,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-30,2021-09-01,7O29,3502.0,2.0,536.0,29.0,1.0,62.32,2.0,2.75,experimental,56.95,0.2554,0.2023,Crystal structure of the human METTL3-METTL14 complex bound to Compound 20 (ADO_AD_044)
7O2E,X-RAY DIFFRACTION,2.15,42.66,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-30,2021-09-01,7O2E,3460.0,2.0,536.0,24.0,1.0,62.32,2.0,2.5,experimental,62.27,0.273,0.2057,Crystal structure of the human METTL3-METTL14 complex bound to Compound 21 (ADO_AD_089)
7O2F,X-RAY DIFFRACTION,2.18,43.52,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-30,2021-09-01,7O2F,3722.0,2.0,536.0,217.0,1.0,62.34,2.0,2.1,experimental,40.33,0.2421,0.1971,Crystal structure of the human METTL3-METTL14 complex bound to Compound 22 (UZH2)
8SPH,X-RAY DIFFRACTION,2.77,55.58,"VAPOR DIFFUSION, SITTING DROP",8.2,"100 mM Tris, pH 8.2, 24% PEG6000, 150 mM sodium chloride, 10% ethylene glycol",298.0,2023-05-03,2023-08-02,8SPH,13162.0,4.0,1628.0,29.0,13.0,192.48,2.0,2.71,experimental,71.67,0.2829,0.2188,Crystal structure of chimeric omicron RBD (strain XBB.1) complexed with human ACE2
4X94,X-RAY DIFFRACTION,3.23,61.94,"VAPOR DIFFUSION, HANGING DROP",3.0,"100 mM citric acid pH 3, 0.8 M ammonium sulfate ; crystallized in the presence of methyl arachidonyl fluorophosphonate",277.0,2014-12-11,2015-03-11,4X94,3149.0,1.0,380.0,34.0,1.0,44.72,1.0,2.7,experimental,50.566,0.2211,0.177,Crystal structure of Lysosomal Phospholipase A2 crystallized in the presence of methyl arachidonyl fluorophosphonate (hexagonal form)
6GJU,X-RAY DIFFRACTION,2.07,40.52,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Sodium sulfate, 20% w/v PEG 3350",293.0,2018-05-17,2019-06-26,6GJU,3251.0,3.0,550.0,83.0,2.0,60.73,3.0,2.6,experimental,77.58,0.2435,0.2204,human NBD1 of CFTR in complex with nanobodies T2a and T4
7TLE,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"0.1 M sodium acetate, 30% w/v PEG MME 2K, 0.2 M ammonium sulfate",293.0,2022-01-18,2022-08-03,7TLE,1515.0,1.0,169.0,89.0,,20.38,1.0,1.98716752773,experimental,29.5360900052,0.233787340602,0.189088453173,Crystal Structure of small molecule beta-lactone 1 covalently bound to K-Ras(G12S)
6SYF,X-RAY DIFFRACTION,2.06,40.3,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1 M trisodium citrate pH 5.0, 30% PEG8000",293.15,2019-09-27,2020-08-12,6SYF,5858.0,12.0,680.0,518.0,4.0,76.16,3.0,1.9,experimental,30.76,0.263,0.2129,Human Ubc9 with covalent isopeptide ligand
5IL0,X-RAY DIFFRACTION,2.55,51.69,"VAPOR DIFFUSION, HANGING DROP",5.7,"PEG 8000, sodium citrate",291.0,2016-03-04,2016-05-25,5IL0,4347.0,2.0,512.0,331.0,,59.43,2.0,1.882,experimental,,0.205,0.1747,Crystal structural of the METTL3-METTL14 complex for N6-adenosine methylation
8OG9,X-RAY DIFFRACTION,2.83,56.49,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES pH6.5, 2.13M Lithium acetate",293.0,2023-03-19,2023-06-14,8OG9,2450.0,1.0,367.0,11.0,,42.4,1.0,2.945,experimental,57.668,0.2404,0.1905,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 4
8OO5,X-RAY DIFFRACTION,3.12,60.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.91M LiSO4, 0.1M Tris pH 7.5",293.0,2023-04-04,2023-05-24,8OO5,2548.0,1.0,318.0,77.0,,37.32,1.0,2.25,experimental,40.928,0.22018,0.18052,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 13
7LTX,X-RAY DIFFRACTION,2.05,40.04,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 30% (w/v) PEG 3350",293.0,2021-02-20,2022-02-23,7LTX,9883.0,4.0,1324.0,157.0,,155.23,1.0,2.3,experimental,55.3065,0.216,0.1859,EGFR (T790M/V948R) in complex with quinazolinone allosteric inhibitor
5WLE,X-RAY DIFFRACTION,1.82,32.27,"VAPOR DIFFUSION, HANGING DROP",8.4,"0.1 mM Tris and 24% PEG 6,000",277.15,2017-07-26,2017-10-04,5WLE,608.0,2.0,75.0,79.0,,8.8,2.0,1.952,experimental,,0.1862,0.1451,Crystal structure of the PPS PHD finger in complex with H3K4me3
7P32,X-RAY DIFFRACTION,3.4,64.0,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.9 M AMMONIUM SULPHATE, 0.1 M HEPES     
PH 7.0, 2% V/V PEG400",293.0,2021-07-06,2022-07-13,7P32,7681.0,1.0,872.0,680.0,5.0,100.88,1.0,1.82,experimental,29.022,0.1754,0.15,"Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with cyclosulfamidate 6"
5AQL,X-RAY DIFFRACTION,2.47,50.19,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQL,8593.0,4.0,1008.0,908.0,,112.98,2.0,1.69,experimental,32.16,0.1965,0.1687,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AQM,X-RAY DIFFRACTION,2.44,49.54,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQM,8751.0,4.0,1008.0,1017.0,2.0,113.0,2.0,1.63,experimental,28.51,0.1952,0.168,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5CF5,X-RAY DIFFRACTION,2.91,57.66,"VAPOR DIFFUSION, HANGING DROP",6.5,"100MM MES BUFFER, 100MM NACL, 28% (W/V) PEG3350, 2MM DTT AND 200MM TRI-SODIUM CITRATE",295.0,2015-07-08,2015-08-26,5CF5,5094.0,2.0,642.0,238.0,,76.63,1.0,2.45,experimental,49.27,0.1994,0.1865,"CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-7-[(DIMETHYL-1,3-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.02,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE"
5CF6,X-RAY DIFFRACTION,3.0,58.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"100MM MES BUFFER, 100MM NACL, 28% (W/V) PEG3350, 2MM DTT AND 200MM TRI-SODIUM CITRATE",295.0,2015-07-08,2015-08-26,5CF6,4992.0,2.0,642.0,211.0,,76.53,1.0,2.5,experimental,47.77,0.2139,0.1865,"CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-[(2S)-2,3-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-3,5,8,10-TETRAAZATRICYCLO [7.3.0.02,6]DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE"
7SEA,X-RAY DIFFRACTION,2.98,58.76,"VAPOR DIFFUSION, HANGING DROP",,2.75-3.3 M Sodium Formate,293.0,2021-09-30,2022-02-09,7SEA,1901.0,1.0,242.0,94.0,,27.15,1.0,1.91,experimental,33.75,0.2289,0.1957,Crystal structure of human Fibrillarin in complex with compound 2 from cocktail soak
8OGC,X-RAY DIFFRACTION,2.7,54.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Tris pH 7.5, 2.18M Lithium acetate",293.0,2023-03-19,2023-06-14,8OGC,2706.0,1.0,367.0,193.0,,43.03,1.0,2.09,experimental,34.24,0.2015,0.1713,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 11
6SZ5,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",7.4,"30 mM Tris-HCl at pH 7.4, 2.5 mM CaCl2 and 2.5% (v/v) glycerol",293.0,2019-10-02,2019-12-11,6SZ5,1362.0,3.0,1587.0,32.0,,181.25,2.0,2.23,experimental,40.282,0.2937,0.219,Human calmodulin bound to a peptide of human NADPH oxidase 5
8AKB,X-RAY DIFFRACTION,2.61,52.94,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AKB,4522.0,2.0,604.0,31.0,,69.44,1.0,2.13,experimental,51.57,0.2608,0.2112,Human Sirt6 in complex with ADP-ribose and fragment 4-nitrocatechol
5BRM,X-RAY DIFFRACTION,2.51,50.91,"VAPOR DIFFUSION, HANGING DROP",7.0,2.4 M Na Malonate,293.0,2015-05-31,2015-07-08,5BRM,8912.0,15.0,1341.0,6.0,,158.75,2.0,2.651,experimental,56.5769,0.2681,0.2441,Structural basis for Mob1-dependent activation of the core Mst-Lats kinase cascade in Hippo signaling
6M0J,X-RAY DIFFRACTION,3.44,64.29,"VAPOR DIFFUSION, HANGING DROP",,"0.1M MES, PEG5000mme",298.0,2020-02-21,2020-03-18,6M0J,6571.0,2.0,832.0,80.0,7.0,97.14,2.0,2.45,experimental,65.8102,0.2269,0.192,Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with ACE2
6DHW,X-RAY DIFFRACTION,2.64,53.33,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM TRIS-HCl pH 8.5, 400 mM LiSO4, 18% PEG3350",289.0,2018-05-21,2018-12-19,6DHW,2948.0,2.0,384.0,107.0,1.0,45.45,1.0,2.013,experimental,38.8875,0.2113,0.1806,Crystal structure of primase iron-sulfur domain (266-457)
6BH4,X-RAY DIFFRACTION,2.25,45.39,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2), 0-20% glycerol, 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2017-10-29,2018-03-28,6BH4,2483.0,1.0,330.0,126.0,,38.85,1.0,2.047,experimental,,0.2182,0.1972,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR 5-(1-(tert-butyl)-1H-pyrazol-4-yl)-6-isopropyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile (Compound N75/CPI-48)"
6DQA,X-RAY DIFFRACTION,2.21,44.35,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2018-11-21,6DQA,2551.0,1.0,330.0,156.0,,38.78,1.0,1.888,experimental,,0.2007,0.1695,"Linked KDM5A JMJ Domain Bound to Inhibitor N70 i.e.[2-((3-aminophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid]"
6CMQ,X-RAY DIFFRACTION,2.64,53.48,"VAPOR DIFFUSION, SITTING DROP",,"100 mM ammonium formate, 22% PEG 3,350 and 1.5% xylitol",291.0,2018-03-06,2018-11-14,6CMQ,12518.0,4.0,1708.0,2.0,,196.53,1.0,2.9,experimental,48.8,0.2764,0.2491,Structure of human SHP2 without N-SH2 domain
6CWX,X-RAY DIFFRACTION,3.42,63.93,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM potassium formate, pH 7.5, 300 mM magnesium sulfate, 4.5% PEG 300, 4.5% PEG 400, 4.5% PEG 1000, 4.5% PEG 4000, and 4.5% PEG 8000",291.15,2018-03-31,2018-04-18,6CWX,1862.0,2.0,343.0,100.0,,37.24,2.0,2.25,experimental,54.096,0.2322,0.2134,Crystal structure of human ribonuclease P/MRP proteins Rpp20/Rpp25
7B7S,X-RAY DIFFRACTION,3.19,61.42,"VAPOR DIFFUSION, SITTING DROP",,"80% Morpheus condition 35 containing: 10% w/v PEG 4,000, 20% v/v glycerol, 0.03 M NaNO3, 0.03 M Na2HPO4, 0.03 M (NH4)2SO4, 0.1 M Tris/Bicine pH 8.5 and 20% of JCSG+ condition 59 containing: 14.4 % w/v PEG 8,000, 20% v/v Glycerol, 0.16 M calcium acetate, 0.08 M sodium cacodylate pH 6.5",291.0,2020-12-11,2021-08-04,7B7S,8888.0,4.0,1114.0,77.0,,128.65,2.0,2.54,experimental,37.521,0.2906,0.246,"CDK2/cyclin A2 in complex with 3H-pyrazolo[4,3-f]quinoline-based derivative HSD1368"
6LZG,X-RAY DIFFRACTION,3.29,62.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES pH 6.5,10%w/v PEG 5000 MME,12% v/v 1-propanol",291.0,2020-02-19,2020-03-18,6LZG,6790.0,2.0,805.0,322.0,7.0,93.5,2.0,2.5,experimental,44.01,0.2156,0.1884,Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2
4X7H,X-RAY DIFFRACTION,2.88,57.29,"VAPOR DIFFUSION, HANGING DROP",6.5,"14% PEG 3350, 0.3M Sodium Sulfate, 0.1M BTP pH 6.5",277.0,2014-12-09,2015-02-04,4X7H,2388.0,1.0,317.0,183.0,,37.58,1.0,2.0,experimental,45.115,0.2136,0.2014,"Co-crystal Structure of PERK bound to N-{5-[(6,7-dimethoxyquinolin-4-yl)oxy]pyridin-2-yl}-1-methyl-3-oxo-2-phenyl-5-(pyridin-4-yl)-2,3-dihydro-1H-pyrazole-4-carboxamide inhibitor"
4X7N,X-RAY DIFFRACTION,2.91,57.75,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.4M Na/K Tartrate, 0.1M HEPES pH 7.0",277.0,2014-12-09,2015-01-28,4X7N,2255.0,1.0,317.0,73.0,,37.49,1.0,2.35,experimental,28.947,0.2454,0.2092,"Co-crystal Structure of PERK bound to 4-[2-amino-4-methyl-3-(2-methylquinolin-6-yl)benzoyl]-1-methyl-2,5-diphenyl-1,2-dihydro-3H-pyrazol-3-one inhibitor"
4X7O,X-RAY DIFFRACTION,3.59,65.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.15M NaCl, 0.1M MES pH 6.5, 12% PEG-3350",277.0,2014-12-09,2015-01-28,4X7O,2078.0,1.0,317.0,23.0,,37.3,1.0,2.65,experimental,93.33,0.2261,0.1987,"Co-crystal Structure of PERK bound to 1-[5-(4-amino-2,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydro-1H-indol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone inhibitor"
5LVO,X-RAY DIFFRACTION,2.18,43.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 0.01 M DTT",293.0,2016-09-14,2016-10-19,5LVO,2837.0,1.0,311.0,399.0,,36.56,1.0,1.09,experimental,,0.157,0.1352,Human PDK1 Kinase Domain in Complex with Allosteric Compound PSE10 Bound to the PIF-Pocket
5DFP,X-RAY DIFFRACTION,2.5,50.74,"VAPOR DIFFUSION, HANGING DROP",7.0,"1 uL of PAK1 (9 mg/ml) with 1 uL of crystallization solution (0.1 M HEPES pH 7.0, 1 M NaCl, 25% PEG 3350, 10 mM DTT) at 4C",277.0,2015-08-27,2016-01-27,5DFP,2522.0,1.0,297.0,203.0,,33.96,1.0,2.2,experimental,,0.2464,0.1903,Crystal structure of PAK1 in complex with an inhibitor compound FRAX1036
7OO7,X-RAY DIFFRACTION,2.05,40.06,VAPOR DIFFUSION,,50mM HEPES 100mM NaCl 2mM MgSO4,293.0,2021-05-26,2022-04-20,7OO7,2966.0,2.0,338.0,159.0,,40.38,1.0,1.48,experimental,18.11,0.2258,0.1898,KRasG12C ligand complex
4X7J,X-RAY DIFFRACTION,2.84,56.75,"VAPOR DIFFUSION, HANGING DROP",7.5,0.6M Na/K Tartrate,277.0,2014-12-09,2015-01-28,4X7J,2268.0,1.0,317.0,106.0,,37.45,1.0,2.3,experimental,50.066,0.2251,0.1949,Co-crystal Structure of PERK with 2-amino-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4-methyl-3-[2-(methylamino)quinazolin-6-yl]benzamide inhibitor
5N8S,X-RAY DIFFRACTION,2.69,54.3,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES monohydrate-imidazole
20mM sodium formate
20mM ammonium acetate
20mM sodium citrate tribasic hydrate
20mM sodium oxamate
20mM potassium sodium tartrate tetrahydrate",298.0,2017-02-24,2018-03-14,5N8S,14069.0,4.0,1920.0,,,226.64,1.0,2.88,experimental,,0.2847,0.2073,Crystal Structure of Drosophila DHX36 helicase in complex with polyT
5A0B,X-RAY DIFFRACTION,2.84,56.65,,,"15% PEG6000, 0.2M AMMONIUM CITRATE",,2015-04-17,2015-08-19,5A0B,1783.0,1.0,218.0,71.0,4.0,24.9,1.0,2.23,experimental,24.272,0.21816,0.17271,Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
7MOV,X-RAY DIFFRACTION,2.51,50.9,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 7.4, 0.2 M Magnesium Chloride, 21.5% PEG 8000",277.0,2021-05-03,2022-05-18,7MOV,5176.0,2.0,616.0,491.0,,72.69,1.0,1.65,experimental,30.89,0.1933,0.1653,PTP1B 1-301 F225Y-R199N mutations
6R4A,X-RAY DIFFRACTION,2.55,51.78,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2019-03-22,2019-05-08,6R4A,2340.0,1.0,285.0,127.0,,34.05,1.0,1.937,experimental,,0.2339,0.1905,Aurora-A in complex with shape-diverse fragment 55
6M9H,X-RAY DIFFRACTION,2.19,43.95,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2018-08-23,2018-09-05,6M9H,2438.0,1.0,289.0,269.0,,33.61,1.0,1.79,experimental,,0.2063,0.1706,JAK2 JH2 in complex with diaminopyrimidine JAK040
6BC8,X-RAY DIFFRACTION,2.32,46.92,"VAPOR DIFFUSION, HANGING DROP",5.0,"well solution containing 100 mM sodium acetate, 200 mM NaCl, 1.4 M ammonium sulfate was mixed at 1:1 ratio with protein at 45 mg/mL in 5 mM HEPES, 100 mM NaCl, 10 mM DTT, pH=7.4",292.15,2017-10-20,2018-08-01,6BC8,2032.0,2.0,255.0,140.0,,29.69,2.0,1.68,experimental,47.572,0.223,0.181,Crystal structure of Rev7-R124A/Rev3-RBM2 (residues 1988-2014) complex
5KBQ,X-RAY DIFFRACTION,2.5,50.74,"VAPOR DIFFUSION, HANGING DROP",7.6,"0.2M ammonium sulphate, 16% PEG 3350, 0.1M Hepes (pH 7.6)",293.0,2016-06-03,2016-09-28,5KBQ,4483.0,2.0,578.0,49.0,,65.15,1.0,2.58,experimental,86.82,0.23,0.175,Pak1 in complex with bis-anilino pyrimidine inhibitor
5KBR,X-RAY DIFFRACTION,2.46,50.1,"VAPOR DIFFUSION, HANGING DROP",7.6,"0.2M ammonium sulphate, 16% PEG 3350, 0.1M Hepes (pH 7.6)",293.0,2016-06-03,2016-09-28,5KBR,4198.0,2.0,578.0,72.0,1.0,65.48,1.0,2.36,experimental,91.42,0.255,0.195,Pak1 in complex with 7-azaindole inhibitor
7A1W,X-RAY DIFFRACTION,2.06,40.29,"VAPOR DIFFUSION, SITTING DROP",7.0,PEG 3350 20% - Na2HPO4 200mM - pH7,293.0,2020-08-14,2021-10-13,7A1W,1525.0,1.0,170.0,111.0,,20.53,1.0,1.76,experimental,26.5,0.2365,0.2001,KRASG12C GDP form in complex with Cpd3
7A1X,X-RAY DIFFRACTION,1.88,34.48,"VAPOR DIFFUSION, SITTING DROP",8.5,TRIS 100mM - PEG 4K 23% - Na Acet 100mM - pH8.5,277.0,2020-08-14,2021-10-13,7A1X,1675.0,1.0,170.0,263.0,,20.04,1.0,1.32,experimental,13.61,0.1739,0.148,KRASG12C GDP form in complex with Cpd1
7A1Y,X-RAY DIFFRACTION,2.52,51.28,"VAPOR DIFFUSION, SITTING DROP",7.5,HEPES 100mM - (NH4)2SO4 2.25M - pH7.5,293.0,2020-08-14,2021-10-13,7A1Y,1490.0,1.0,170.0,96.0,,20.2,1.0,2.004,experimental,25.63,0.21,0.1888,KRASG12C GDP form in complex with Cpd2
7KMR,X-RAY DIFFRACTION,2.08,40.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.5 M sodium malonate, 0.1 M HEPES, pH 7.5",300.0,2020-11-03,2021-11-10,7KMR,1521.0,1.0,210.0,136.0,,24.15,1.0,1.51,experimental,28.9888,0.1967,0.1615,Crystal structure analysis of human KRAS mutant
8DNK,X-RAY DIFFRACTION,2.99,58.85,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS pH 8.5, 2.0 M Ammonium sulfate",293.0,2022-07-11,2022-08-17,8DNK,1469.0,1.0,184.0,42.0,,22.2,1.0,2.23,experimental,39.259,0.2354,0.1809,Crystal structure of human KRAS G12C covalently bound with Taiho WO2020/085493A1 compound 6
5AQX,X-RAY DIFFRACTION,2.32,47.07,,7.5,"17-28% (W/V) PEG3350, 0.1 M HEPES PH 7.5, 2 MM MGCL2, 2 MM NAH2PO4 AND 5 MM ADENOSINE, THEN BACKSOAKED WITH 100 MM INHIBITOR (20% DMSO) FOR 16H AT 18 DEGREES C",291.0,2015-09-22,2016-10-05,5AQX,3055.0,1.0,394.0,107.0,,43.77,1.0,2.12,experimental,38.92,0.2273,0.194,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
5AR0,X-RAY DIFFRACTION,2.08,40.73,,7.5,"17-28% (W/V) PEG3350, 0.1 M HEPES PH 7.5, 2 MM MGCL2, 2 MM NAH2PO4 AND 5 MM INHIBITOR",,2015-09-22,2016-05-11,5AR0,3123.0,1.0,394.0,203.0,,44.09,1.0,1.9,experimental,26.22,0.2104,0.1725,HSP72 with adenosine-derived inhibitor
6TKA,X-RAY DIFFRACTION,2.37,48.06,"VAPOR DIFFUSION, SITTING DROP",,"1.45 M Potassium Sodium Tartrate
0.1 M Tris pH 8.5",293.0,2019-11-28,2020-03-04,6TKA,5889.0,2.0,743.0,208.0,,84.07,2.0,1.91,experimental,38.52,0.2332,0.1845,Crystal structure of human O-GlcNAc transferase bound to substrate 7 and a peptide from HCF-1 pro-repeat 2 (11-26)
7L5P,X-RAY DIFFRACTION,2.44,49.72,VAPOR DIFFUSION,,PEG 5000 MME AMMONIUM SULFATE MES,293.0,2020-12-22,2022-06-29,7L5P,4792.0,2.0,542.0,223.0,,64.94,1.0,2.14,experimental,27.536,0.2582,0.2237,Crystal structure of the covalently bonded complex of rilzabrutinib with BTK
5MO9,X-RAY DIFFRACTION,2.27,44.47,"VAPOR DIFFUSION, SITTING DROP",8.5,"6% w/v PEG 3350, 25 mM Tris pH 8.5",293.0,2016-12-14,2017-08-02,5MO9,4337.0,3.0,593.0,169.0,7.0,64.52,3.0,2.594,experimental,47.98,0.224,0.19,Structure of human TrkB receptor ligand binding domain in complex with the Fab frgment of antibody AB20
5C11,X-RAY DIFFRACTION,3.67,66.47,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.02 M sodium l-glutamate, 0.02 M dl-alanine, 0.02 M glycine, 0.02 M dl-lysine HCl, 0.02 M dl-serine, 0.1 M Tris, 0.1 M Bicine, PH8.5, 12.5% MPD, 12.5%  PEG 1K, 12.5%  PEG 3350",277.0,2015-06-12,2015-11-25,5C11,457.0,2.0,62.0,,1.0,7.12,2.0,2.803,experimental,95.2107,0.2789,0.2455,Crystal Structure of Jarid1a PHD finger bound to histone H3C4me3 peptide
7GTW,X-RAY DIFFRACTION,3.32,62.94,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GTW,2745.0,1.0,321.0,323.0,,37.47,1.0,1.51,experimental,36.3569,0.2061,0.1849,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster1"
7GTX,X-RAY DIFFRACTION,3.31,62.84,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GTX,2622.0,1.0,321.0,297.0,,37.47,1.0,1.51,experimental,38.2885,0.2217,0.2002,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster2"
7GTY,X-RAY DIFFRACTION,3.34,63.13,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GTY,2616.0,1.0,321.0,291.0,,37.47,1.0,1.54,experimental,39.0877,0.2213,0.197,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster3"
7GTZ,X-RAY DIFFRACTION,3.3,62.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GTZ,2563.0,1.0,321.0,238.0,,37.47,1.0,1.6,experimental,41.8709,0.2406,0.2138,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster5"
7GU0,X-RAY DIFFRACTION,3.37,63.46,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU0,2619.0,1.0,321.0,294.0,,37.47,1.0,1.66,experimental,39.5768,0.2124,0.1937,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster6"
7GU1,X-RAY DIFFRACTION,3.35,63.28,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU1,2636.0,1.0,321.0,311.0,,37.47,1.0,1.59,experimental,39.0015,0.2174,0.1987,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster7"
7GU2,X-RAY DIFFRACTION,3.4,63.85,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU2,2555.0,1.0,321.0,230.0,,37.47,1.0,1.8,experimental,46.0985,0.2428,0.2123,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster8"
7GU3,X-RAY DIFFRACTION,3.37,63.52,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU3,2559.0,1.0,321.0,234.0,,37.47,1.0,1.74,experimental,44.7989,0.2293,0.1978,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster9"
7GU4,X-RAY DIFFRACTION,3.31,62.84,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU4,2618.0,1.0,321.0,293.0,,37.47,1.0,1.59,experimental,39.257,0.2239,0.195,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster11"
7GU5,X-RAY DIFFRACTION,3.33,63.04,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU5,2612.0,1.0,321.0,287.0,,37.47,1.0,1.52,experimental,38.5948,0.2273,0.2004,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster12"
7GU6,X-RAY DIFFRACTION,3.31,62.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU6,2605.0,1.0,321.0,280.0,,37.47,1.0,1.56,experimental,39.5554,0.2181,0.1978,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster14"
7GU7,X-RAY DIFFRACTION,3.25,62.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU7,2538.0,1.0,321.0,213.0,,37.47,1.0,1.7,experimental,41.9312,0.2156,0.1982,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster15"
7GU8,X-RAY DIFFRACTION,3.28,62.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU8,2609.0,1.0,321.0,284.0,,37.47,1.0,1.59,experimental,38.5132,0.223,0.2004,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster16"
7GU9,X-RAY DIFFRACTION,3.35,63.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GU9,2612.0,1.0,321.0,287.0,,37.47,1.0,1.53,experimental,39.5331,0.2164,0.2007,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster17"
7GUA,X-RAY DIFFRACTION,3.35,63.33,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GUA,2597.0,1.0,321.0,272.0,,37.47,1.0,1.63,experimental,42.1057,0.2267,0.2021,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster18"
7GUB,X-RAY DIFFRACTION,3.43,64.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GUB,2465.0,1.0,321.0,140.0,,37.47,1.0,1.94,experimental,47.7148,0.3035,0.2695,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster19"
7GUC,X-RAY DIFFRACTION,3.38,63.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-05,2024-01-31,7GUC,2564.0,1.0,321.0,239.0,,37.47,1.0,1.78,experimental,45.7491,0.2237,0.1997,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster20"
6B95,X-RAY DIFFRACTION,3.13,60.71,VAPOR DIFFUSION,7.5,"well solution: 0.2 M magnesium acetate tetrahydrate, 20% PEG 3350",277.0,2017-10-10,2018-06-20,6B95,2541.0,1.0,321.0,135.0,,37.74,1.0,1.95,experimental,54.6943,0.2307,0.1858,Multiconformer model of K197C PTP1B tethered to compound 2 at 100 K
6XEA,X-RAY DIFFRACTION,3.28,61.27,"VAPOR DIFFUSION, HANGING DROP",8.2,"tris hydrochloride pH 8.2, magnesium acetate tetrahydrate, PEG 8000 and benzamidine",277.15,2020-06-12,2021-12-15,6XEA,2676.0,1.0,321.0,213.0,,37.71,1.0,1.549,experimental,32.4575,0.1992,0.1868,Crystal Structure of the PTP1B YopH WPD loop Chimera 3 bound to vanadate
6XED,X-RAY DIFFRACTION,3.29,61.4,"VAPOR DIFFUSION, HANGING DROP",7.8,"tris hydrochloride pH 7.8, magnesium acetate tetrahydrate, PEG 8000 and benzamidine",295.0,2020-06-12,2021-12-15,6XED,2743.0,1.0,321.0,290.0,,38.04,1.0,1.795,experimental,32.6017,0.179,0.157,Crystal Structure of the PTP1B YopH WPD loop Chimera 3 bound to tungstate
6XEF,X-RAY DIFFRACTION,3.27,61.12,"VAPOR DIFFUSION, HANGING DROP",7.8,"tris hydrochloride pH 7.8, magnesium acetate tetrahydrate, PEG 8000 and benzamidine",277.15,2020-06-12,2021-12-15,6XEF,2598.0,1.0,321.0,137.0,,37.78,1.0,2.048,experimental,49.3354,0.2028,0.1814,Crystal structure of the PTP1B YopH WPD loop Chimera 4 bound to vanadate
6XEG,X-RAY DIFFRACTION,3.18,61.28,"VAPOR DIFFUSION, HANGING DROP",7.8,"tris hydrochloride pH 7.8, magnesium acetate tetrahydrate, PEG 8000 and benzamidine",295.0,2020-06-12,2021-12-15,6XEG,2529.0,1.0,321.0,89.0,,37.89,1.0,2.549,experimental,47.2032,0.2072,0.1613,Crystal structure of the PTP1B YopH WPD loop Chimera 4 bound to tungstate
5QDE,X-RAY DIFFRACTION,3.32,62.97,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDE,5667.0,1.0,321.0,270.0,,37.7,1.0,1.764,experimental,36.8258,0.2132,0.1792,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000740a
5QDF,X-RAY DIFFRACTION,3.31,62.89,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDF,6546.0,1.0,321.0,289.0,,37.69,1.0,1.712,experimental,34.2787,0.204,0.1768,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000295a
5QDG,X-RAY DIFFRACTION,3.33,63.03,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDG,8122.0,1.0,321.0,277.0,,37.7,1.0,1.79,experimental,38.952,0.2069,0.1801,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000294a
5QDH,X-RAY DIFFRACTION,3.32,62.99,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDH,6121.0,1.0,321.0,297.0,,37.62,1.0,1.682,experimental,34.1903,0.2573,0.2371,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000004a
5QDI,X-RAY DIFFRACTION,3.33,63.05,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDI,8151.0,1.0,321.0,261.0,,37.87,1.0,1.623,experimental,38.4712,0.2183,0.1883,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000157a
5QDJ,X-RAY DIFFRACTION,3.32,62.95,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDJ,6726.0,1.0,321.0,296.0,,37.98,1.0,1.761,experimental,35.1018,0.2081,0.1818,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000211a
5QDK,X-RAY DIFFRACTION,3.34,63.19,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDK,7703.0,1.0,321.0,305.0,,37.69,1.0,1.555,experimental,37.6971,0.2096,0.1851,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000069a
5QDL,X-RAY DIFFRACTION,3.33,63.02,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDL,5665.0,1.0,321.0,227.0,,37.71,1.0,1.833,experimental,44.7659,0.2118,0.1901,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000072a
5QDM,X-RAY DIFFRACTION,3.29,62.61,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDM,8896.0,1.0,321.0,607.0,,37.71,1.0,2.647,experimental,49.3852,0.2454,0.1814,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000074a
5QDN,X-RAY DIFFRACTION,3.3,62.67,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDN,5459.0,1.0,321.0,213.0,,37.7,1.0,1.821,experimental,40.3677,0.2132,0.1931,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000163a
5QDO,X-RAY DIFFRACTION,3.28,62.45,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDO,8713.0,1.0,321.0,215.0,,37.62,1.0,1.792,experimental,40.5414,0.2194,0.1951,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOCR000171b
5QDP,X-RAY DIFFRACTION,3.29,62.63,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDP,6081.0,1.0,321.0,264.0,,37.64,1.0,1.744,experimental,37.3757,0.2119,0.1798,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000207a
5QDQ,X-RAY DIFFRACTION,3.34,63.2,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDQ,8168.0,1.0,321.0,250.0,,37.59,1.0,1.575,experimental,40.9032,0.2301,0.2053,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000847b
5QDR,X-RAY DIFFRACTION,3.34,63.12,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDR,9121.0,1.0,321.0,260.0,,37.7,1.0,1.784,experimental,41.7242,0.2128,0.1842,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000089a
5QDS,X-RAY DIFFRACTION,3.34,63.22,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDS,7981.0,1.0,321.0,254.0,,37.96,1.0,1.751,experimental,40.5219,0.2056,0.181,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000108a
5QDT,X-RAY DIFFRACTION,3.32,62.9,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDT,9122.0,1.0,321.0,235.0,,37.69,1.0,1.821,experimental,41.6783,0.2157,0.1828,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000475a
5QDU,X-RAY DIFFRACTION,3.32,62.97,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDU,6613.0,1.0,321.0,283.0,,38.3,1.0,1.672,experimental,36.8396,0.2046,0.1823,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000466a
5QDV,X-RAY DIFFRACTION,3.38,63.61,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDV,8998.0,1.0,321.0,231.0,,37.69,1.0,1.773,experimental,43.5364,0.214,0.1921,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000574a
5QDW,X-RAY DIFFRACTION,3.34,63.19,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDW,9158.0,1.0,321.0,153.0,,37.66,1.0,2.212,experimental,45.7267,0.221,0.186,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000465a
5QDX,X-RAY DIFFRACTION,3.35,63.32,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDX,8973.0,1.0,321.0,219.0,,37.7,1.0,2.062,experimental,37.8978,0.2734,0.2379,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000484a
5QDY,X-RAY DIFFRACTION,3.38,63.57,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDY,9284.0,1.0,321.0,206.0,,37.65,1.0,1.835,experimental,46.0513,0.2267,0.1983,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000599c
5QDZ,X-RAY DIFFRACTION,3.34,63.23,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QDZ,6250.0,1.0,321.0,183.0,,37.71,1.0,2.141,experimental,43.7809,0.2249,0.1791,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000435a
5QE0,X-RAY DIFFRACTION,3.29,62.58,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE0,9102.0,1.0,321.0,176.0,,37.93,1.0,1.98,experimental,43.3581,0.2345,0.1983,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000648a
5QE1,X-RAY DIFFRACTION,3.33,63.08,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE1,7111.0,1.0,321.0,295.0,,37.72,1.0,1.685,experimental,33.998,0.2029,0.1831,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000645a
5QE2,X-RAY DIFFRACTION,3.35,63.27,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE2,9467.0,1.0,321.0,237.0,,37.68,1.0,1.787,experimental,44.8432,0.2208,0.1916,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000398a
5QE3,X-RAY DIFFRACTION,3.34,63.18,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE3,8964.0,1.0,321.0,250.0,,37.71,1.0,1.742,experimental,41.0899,0.2239,0.1963,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000449a
5QE4,X-RAY DIFFRACTION,3.34,63.22,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE4,7793.0,1.0,321.0,253.0,,37.58,1.0,1.852,experimental,43.1577,0.2161,0.1857,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000514a
5QE5,X-RAY DIFFRACTION,3.33,63.08,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE5,8578.0,1.0,321.0,267.0,,37.85,1.0,1.773,experimental,39.9734,0.2119,0.1828,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000632a
5QE6,X-RAY DIFFRACTION,3.29,62.66,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE6,5669.0,1.0,321.0,228.0,,37.69,1.0,1.774,experimental,42.7408,0.2117,0.1954,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000608a
5QE7,X-RAY DIFFRACTION,3.32,62.9,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE7,7628.0,1.0,321.0,222.0,,37.63,1.0,1.713,experimental,42.1966,0.233,0.213,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000601a
5QE8,X-RAY DIFFRACTION,3.33,63.03,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE8,8116.0,1.0,321.0,228.0,,38.2,1.0,1.813,experimental,41.5993,0.2137,0.1851,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000127a
5QE9,X-RAY DIFFRACTION,3.33,63.05,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QE9,5716.0,1.0,321.0,281.0,,37.7,1.0,1.692,experimental,40.0685,0.2068,0.1863,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000232a
5QEA,X-RAY DIFFRACTION,3.34,63.15,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEA,9179.0,1.0,321.0,256.0,,37.7,1.0,1.743,experimental,42.4398,0.2182,0.1852,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000733a
5QEB,X-RAY DIFFRACTION,3.35,63.33,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEB,8294.0,1.0,321.0,261.0,,37.69,1.0,1.733,experimental,41.9109,0.2144,0.1899,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000639a
5QEC,X-RAY DIFFRACTION,3.33,63.1,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEC,8496.0,1.0,321.0,275.0,,37.7,1.0,1.673,experimental,38.8122,0.2165,0.1852,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000270a
5QED,X-RAY DIFFRACTION,3.32,62.93,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QED,7385.0,1.0,321.0,272.0,,37.98,1.0,1.755,experimental,38.016,0.2066,0.1831,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000538a
5QEE,X-RAY DIFFRACTION,3.26,62.23,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEE,5830.0,1.0,321.0,131.0,,37.71,1.0,1.932,experimental,46.0529,0.2292,0.2009,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000240a
5QEF,X-RAY DIFFRACTION,3.32,62.95,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEF,7113.0,1.0,321.0,319.0,,37.87,1.0,1.605,experimental,34.3195,0.2124,0.1867,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000134a
5QEG,X-RAY DIFFRACTION,3.28,62.55,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEG,8704.0,1.0,321.0,202.0,,37.9,1.0,1.97,experimental,44.6836,0.2359,0.1957,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000278a
5QEH,X-RAY DIFFRACTION,3.33,63.02,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEH,5556.0,1.0,321.0,220.0,,37.69,1.0,1.941,experimental,39.9238,0.2301,0.197,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000323a
5QEI,X-RAY DIFFRACTION,3.31,62.85,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEI,5827.0,1.0,321.0,262.0,,37.95,1.0,1.743,experimental,37.5897,0.216,0.1902,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_PKTTA024495b
5QEJ,X-RAY DIFFRACTION,3.34,63.14,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEJ,9056.0,1.0,321.0,217.0,,37.66,1.0,1.924,experimental,45.9098,0.2422,0.2012,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA001247b
5QEK,X-RAY DIFFRACTION,3.33,63.04,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEK,8801.0,1.0,321.0,226.0,,37.61,1.0,1.904,experimental,43.0742,0.252,0.2187,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOZE000092b
5QEL,X-RAY DIFFRACTION,3.31,62.87,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEL,7621.0,1.0,321.0,280.0,,37.64,1.0,1.654,experimental,39.4399,0.2125,0.1872,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000675b
5QEM,X-RAY DIFFRACTION,3.31,62.8,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEM,7932.0,1.0,321.0,255.0,,38.1,1.0,1.754,experimental,39.2949,0.2156,0.19,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000217b
5QEN,X-RAY DIFFRACTION,3.35,63.25,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEN,8573.0,1.0,321.0,262.0,,37.69,1.0,1.775,experimental,41.4624,0.209,0.1802,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000955b
5QEO,X-RAY DIFFRACTION,3.32,63.0,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEO,8519.0,1.0,321.0,267.0,,37.67,1.0,1.721,experimental,41.0556,0.217,0.1887,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000657b
5QEP,X-RAY DIFFRACTION,3.33,63.06,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEP,8755.0,1.0,321.0,224.0,,37.74,1.0,1.774,experimental,44.3454,0.2157,0.1864,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000692b
5QEQ,X-RAY DIFFRACTION,3.3,62.69,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEQ,8938.0,1.0,321.0,181.0,,37.69,1.0,1.972,experimental,46.4292,0.2219,0.1972,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000245b
5QER,X-RAY DIFFRACTION,3.31,62.82,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QER,5940.0,1.0,321.0,192.0,,37.96,1.0,1.733,experimental,40.4576,0.2339,0.2039,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000847b
5QES,X-RAY DIFFRACTION,3.33,63.12,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QES,7057.0,1.0,321.0,248.0,,37.67,1.0,1.745,experimental,39.6353,0.2044,0.1832,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000141a
5QET,X-RAY DIFFRACTION,3.33,63.01,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QET,7688.0,1.0,321.0,258.0,,37.77,1.0,1.724,experimental,39.4963,0.2118,0.183,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000017a
5QEU,X-RAY DIFFRACTION,3.35,63.32,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEU,9310.0,1.0,321.0,245.0,,37.69,1.0,1.735,experimental,43.4163,0.2169,0.1893,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000149a
5QEV,X-RAY DIFFRACTION,3.28,62.45,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEV,8337.0,1.0,321.0,207.0,,37.66,1.0,1.723,experimental,43.4176,0.2154,0.1896,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000603b
5QEW,X-RAY DIFFRACTION,3.29,62.64,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEW,6575.0,1.0,321.0,183.0,,37.65,1.0,1.826,experimental,43.8725,0.2306,0.2125,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000470b
5QEX,X-RAY DIFFRACTION,3.33,63.03,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEX,8286.0,1.0,321.0,295.0,,37.72,1.0,1.673,experimental,38.4105,0.2051,0.1794,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000123a
5QEY,X-RAY DIFFRACTION,3.35,63.24,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEY,5474.0,1.0,321.0,258.0,,37.71,1.0,1.775,experimental,39.9678,0.2077,0.1839,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000708a
5QEZ,X-RAY DIFFRACTION,3.33,63.1,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QEZ,6925.0,1.0,321.0,783.0,,37.69,1.0,1.654,experimental,41.6104,0.219,0.1958,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000713b
5QF0,X-RAY DIFFRACTION,3.34,63.19,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF0,8289.0,1.0,321.0,273.0,,38.08,1.0,1.707,experimental,38.3865,0.2121,0.1871,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000216b
5QF1,X-RAY DIFFRACTION,3.37,63.45,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF1,9048.0,1.0,321.0,216.0,,37.61,1.0,1.844,experimental,46.6814,0.2184,0.1876,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000272b
5QF2,X-RAY DIFFRACTION,3.36,63.44,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF2,8390.0,1.0,321.0,268.0,,37.73,1.0,1.772,experimental,42.8843,0.2102,0.1848,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000187a
5QF3,X-RAY DIFFRACTION,3.35,63.25,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF3,7044.0,1.0,321.0,266.0,,37.71,1.0,1.563,experimental,37.9912,0.2162,0.1928,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000194a
5QF4,X-RAY DIFFRACTION,3.35,63.23,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF4,5744.0,1.0,321.0,208.0,,37.64,1.0,1.832,experimental,45.3889,0.2263,0.1935,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000144a
5QF5,X-RAY DIFFRACTION,3.31,62.89,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF5,5806.0,1.0,321.0,234.0,,37.64,1.0,1.725,experimental,39.4935,0.2021,0.1863,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA001440b
5QF6,X-RAY DIFFRACTION,3.28,62.55,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF6,7331.0,1.0,321.0,244.0,,37.67,1.0,1.765,experimental,41.4411,0.2083,0.192,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000281b
5QF7,X-RAY DIFFRACTION,3.31,62.84,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF7,5363.0,1.0,321.0,257.0,,37.67,1.0,1.75,experimental,39.385,0.2107,0.1819,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000951b
5QF8,X-RAY DIFFRACTION,3.39,63.69,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF8,9405.0,1.0,321.0,164.0,,37.66,1.0,1.987,experimental,55.3485,0.2353,0.2059,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000114a
5QF9,X-RAY DIFFRACTION,3.41,63.97,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QF9,6779.0,1.0,321.0,262.0,,37.66,1.0,1.94,experimental,55.9559,0.2664,0.2154,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000242a
5QFA,X-RAY DIFFRACTION,3.39,63.68,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFA,7160.0,1.0,321.0,270.0,,37.67,1.0,1.742,experimental,40.2891,0.2238,0.2019,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000752b
5QFB,X-RAY DIFFRACTION,3.31,62.82,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFB,8526.0,1.0,321.0,224.0,,37.65,1.0,1.851,experimental,41.8054,0.2087,0.1811,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_PKOOA000283c
5QFC,X-RAY DIFFRACTION,3.32,62.97,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFC,8633.0,1.0,321.0,233.0,,37.72,1.0,1.841,experimental,42.7043,0.2131,0.1809,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000140a
5QFD,X-RAY DIFFRACTION,3.33,63.12,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFD,7265.0,1.0,321.0,283.0,,37.71,1.0,1.693,experimental,34.3339,0.2325,0.2029,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000505a
5QFE,X-RAY DIFFRACTION,3.33,63.02,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFE,7763.0,1.0,321.0,281.0,,37.95,1.0,1.563,experimental,38.4618,0.2123,0.1903,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000509a
5QFF,X-RAY DIFFRACTION,3.32,63.0,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFF,7359.0,1.0,321.0,290.0,,37.97,1.0,1.703,experimental,36.4739,0.2143,0.1887,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000515a
5QFG,X-RAY DIFFRACTION,3.33,63.01,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFG,6101.0,1.0,321.0,302.0,,37.73,1.0,1.654,experimental,34.4744,0.2226,0.1934,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000523a
5QFH,X-RAY DIFFRACTION,3.31,62.86,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFH,8812.0,1.0,321.0,278.0,,37.65,1.0,1.591,experimental,38.7424,0.2155,0.191,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000525a
5QFI,X-RAY DIFFRACTION,3.31,62.79,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFI,7236.0,1.0,321.0,275.0,,37.74,1.0,1.68,experimental,39.3681,0.2183,0.189,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000531a
5QFJ,X-RAY DIFFRACTION,3.39,63.75,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFJ,6739.0,1.0,321.0,795.0,,37.68,1.0,1.954,experimental,51.5081,0.2307,0.191,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000814b
5QFK,X-RAY DIFFRACTION,3.33,63.05,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFK,8857.0,1.0,321.0,250.0,,37.95,1.0,1.594,experimental,38.185,0.2128,0.1891,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000509a
5QFL,X-RAY DIFFRACTION,3.35,63.26,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFL,7699.0,1.0,321.0,234.0,,38.02,1.0,1.824,experimental,42.0384,0.2136,0.1852,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000206a
5QFM,X-RAY DIFFRACTION,3.37,63.51,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFM,8934.0,1.0,321.0,233.0,,37.7,1.0,1.83,experimental,46.4825,0.2284,0.1997,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000269a
5QFN,X-RAY DIFFRACTION,3.37,63.45,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFN,7942.0,1.0,321.0,283.0,,38.15,1.0,1.675,experimental,37.1381,0.2069,0.1839,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000324a
5QFO,X-RAY DIFFRACTION,3.34,63.21,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFO,8454.0,1.0,321.0,227.0,,37.6,1.0,1.851,experimental,45.4068,0.2194,0.1893,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000644b
5QFP,X-RAY DIFFRACTION,3.37,63.45,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFP,9312.0,1.0,321.0,191.0,,37.68,1.0,1.771,experimental,50.0446,0.2285,0.2027,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000293a
5QFQ,X-RAY DIFFRACTION,3.31,62.9,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFQ,6485.0,1.0,321.0,270.0,,37.73,1.0,1.621,experimental,39.4005,0.2146,0.1906,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000491a
5QFR,X-RAY DIFFRACTION,3.31,62.89,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFR,8700.0,1.0,321.0,244.0,,37.94,1.0,1.622,experimental,40.9151,0.2232,0.1962,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000497a
5QFS,X-RAY DIFFRACTION,3.39,63.74,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFS,9333.0,1.0,321.0,181.0,,37.68,1.0,1.853,experimental,50.7869,0.2278,0.2067,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOMB000293a
5QFT,X-RAY DIFFRACTION,3.38,63.61,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFT,5621.0,1.0,321.0,157.0,,37.65,1.0,1.96,experimental,45.5118,0.2372,0.1897,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000683b
5QFU,X-RAY DIFFRACTION,3.33,63.08,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFU,7352.0,1.0,321.0,271.0,,37.97,1.0,1.613,experimental,40.1037,0.2146,0.1936,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000487a
5QFV,X-RAY DIFFRACTION,3.32,62.91,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFV,8700.0,1.0,321.0,246.0,,37.73,1.0,1.641,experimental,39.806,0.2277,0.1895,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000491a
5QFW,X-RAY DIFFRACTION,3.32,62.92,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFW,7116.0,1.0,321.0,234.0,,37.7,1.0,1.662,experimental,40.4113,0.2209,0.1934,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000497a
5QFX,X-RAY DIFFRACTION,3.3,62.7,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFX,5824.0,1.0,321.0,182.0,,37.68,1.0,1.824,experimental,48.1265,0.2215,0.2026,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000953b
5QFY,X-RAY DIFFRACTION,3.32,62.94,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFY,7960.0,1.0,321.0,248.0,,37.69,1.0,1.769,experimental,39.9028,0.2123,0.1843,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000396a
5QFZ,X-RAY DIFFRACTION,3.32,63.0,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QFZ,7707.0,1.0,321.0,253.0,,37.92,1.0,1.723,experimental,38.984,0.2156,0.1837,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000711a
5QG0,X-RAY DIFFRACTION,3.35,63.3,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG0,8131.0,1.0,321.0,245.0,,37.66,1.0,1.753,experimental,40.9598,0.2089,0.1853,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_XST00000280c
5QG1,X-RAY DIFFRACTION,3.35,63.32,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG1,8900.0,1.0,321.0,177.0,,37.69,1.0,2.209,experimental,42.2477,0.2297,0.1928,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000619a
5QG2,X-RAY DIFFRACTION,3.36,63.35,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG2,8567.0,1.0,321.0,240.0,,37.68,1.0,2.122,experimental,37.4933,0.2508,0.2155,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000275a
5QG3,X-RAY DIFFRACTION,3.33,63.08,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG3,6405.0,1.0,321.0,318.0,,37.73,1.0,1.654,experimental,34.7238,0.2011,0.1819,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000662a
5QG4,X-RAY DIFFRACTION,3.31,62.82,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG4,9030.0,1.0,321.0,254.0,,37.71,1.0,1.788,experimental,41.7235,0.2236,0.1907,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000666a
5QG5,X-RAY DIFFRACTION,3.26,62.21,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG5,9052.0,1.0,321.0,128.0,,37.59,1.0,2.07,experimental,46.7953,0.2259,0.2056,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA000811b
5QG6,X-RAY DIFFRACTION,3.3,62.73,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG6,7344.0,1.0,321.0,275.0,,37.68,1.0,1.734,experimental,37.9617,0.208,0.1847,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMSOA001176b
5QG7,X-RAY DIFFRACTION,3.33,63.11,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG7,7235.0,1.0,321.0,260.0,,37.72,1.0,1.811,experimental,38.1264,0.2246,0.1882,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000611a
5QG8,X-RAY DIFFRACTION,3.35,63.27,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG8,6087.0,1.0,321.0,282.0,,37.7,1.0,1.634,experimental,36.9411,0.2052,0.1858,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000555a
5QG9,X-RAY DIFFRACTION,3.34,63.12,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QG9,8666.0,1.0,321.0,252.0,,37.99,1.0,1.671,experimental,40.2983,0.2266,0.1976,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000595a
5QGA,X-RAY DIFFRACTION,3.31,62.89,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QGA,8636.0,1.0,321.0,264.0,,37.72,1.0,1.653,experimental,40.0566,0.2155,0.1933,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000540a
5QGB,X-RAY DIFFRACTION,3.32,62.96,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QGB,8045.0,1.0,321.0,286.0,,37.74,1.0,1.552,experimental,37.5203,0.2089,0.186,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000628a
5QGC,X-RAY DIFFRACTION,3.34,63.2,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QGC,6311.0,1.0,321.0,300.0,,37.73,1.0,1.586,experimental,35.7381,0.2106,0.1834,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000650a
5QGD,X-RAY DIFFRACTION,3.33,63.05,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QGD,5491.0,1.0,321.0,263.0,,37.72,1.0,1.661,experimental,39.8105,0.2322,0.1922,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000611a
5QGE,X-RAY DIFFRACTION,3.36,63.34,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QGE,8108.0,1.0,321.0,258.0,,37.69,1.0,1.703,experimental,39.1384,0.2226,0.1925,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOPL000619a
5QGF,X-RAY DIFFRACTION,3.32,62.94,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2018-08-30,2018-10-10,5QGF,8968.0,1.0,321.0,329.0,,38.0,1.0,1.513,experimental,34.8431,0.2132,0.1897,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with compound_FMOOA000539a
6BAI,X-RAY DIFFRACTION,3.07,59.88,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 10-26% PEG 8000, 2% ethanol",277.0,2017-10-12,2018-06-20,6BAI,2502.0,1.0,321.0,109.0,,37.44,1.0,1.95,experimental,61.7679,0.2569,0.2061,Multiconformer model of apo K197C PTP1B at 100 K
6XE8,X-RAY DIFFRACTION,3.17,59.92,"VAPOR DIFFUSION, HANGING DROP",8.5,"tris hydrochloride pH 8.5, magnesium acetate tetrahydrate, PEG 8000 and benzamidine",277.15,2020-06-12,2021-12-15,6XE8,2561.0,1.0,321.0,142.0,,37.62,1.0,1.952,experimental,49.8204,0.1852,0.1632,Crystal Structure of the PTP1B YopH WPD loop Chimera 3 apo form
6XEE,X-RAY DIFFRACTION,3.25,60.79,"VAPOR DIFFUSION, HANGING DROP",7.8,"tris hydrochloride pH 7.8, magnesium acetate tetrahydrate, PEG 8000 and benzamidine",295.0,2020-06-12,2021-12-15,6XEE,2482.0,1.0,321.0,87.0,,37.84,1.0,2.501,experimental,57.299,0.2148,0.173,Crystal Structure of the PTP1B YopH WPD loop Chimera 4 apo form
5N7D,X-RAY DIFFRACTION,3.03,59.44,"VAPOR DIFFUSION, SITTING DROP",5.0,"8% PEG 400, 100 mM acetate buffer",296.0,2017-02-20,2017-11-08,5N7D,6750.0,3.0,903.0,220.0,,102.2,2.0,2.3,experimental,,0.2271,0.1906,MAGI-1 complexed with a RSK1 peptide
5N7F,X-RAY DIFFRACTION,2.92,57.93,"VAPOR DIFFUSION, SITTING DROP",8.5,"14% PEG 8000, 200 mM MgCl2, 100 mM TRIS",296.0,2017-02-20,2017-11-08,5N7F,7311.0,3.0,903.0,634.0,,102.45,2.0,2.3,experimental,,0.2401,0.1862,MAGI-1 complexed with a pRSK1 peptide
6AKR,X-RAY DIFFRACTION,2.93,58.02,EVAPORATION,,"0.1M HEPES, 18% PEG3350, 25% ethylene glycol, 10% isopropanol, pH 7.5",277.15,2018-09-03,2020-02-12,6AKR,11030.0,4.0,1456.0,404.0,,168.73,1.0,2.326,experimental,,0.2204,0.1873,Crystal structure of the PDE4D catalytic domain in complex with osthole
5VCW,X-RAY DIFFRACTION,2.84,56.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"6.9 MG/ML MYT1, 25 mM HEPES, 100 MM SODIUM CHLORIDE, 0.5 mM DTT, 0.05 M MES pH 6.5, 0.8 M Magnesium sulfate, 2 mM Pelitinib",291.0,2017-04-01,2017-08-23,5VCW,4571.0,2.0,622.0,52.0,,70.66,1.0,2.25,experimental,69.7286,0.2457,0.1956,CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH Pelitinib
6CTA,X-RAY DIFFRACTION,3.2,61.54,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES-NaOH pH 7.0, 1.4 M sodium citrate",291.0,2018-03-22,2018-07-18,6CTA,3473.0,3.0,401.0,21.0,,53.91,1.0,2.779,experimental,,0.2455,0.2108,Structure of the human cGAS-DNA complex with ATP
7G81,X-RAY DIFFRACTION,2.54,51.48,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G81,4168.0,2.0,430.0,443.0,,50.85,2.0,1.51,experimental,26.55,0.216,0.1925,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474512
7VV8,X-RAY DIFFRACTION,3.2,61.58,"VAPOR DIFFUSION, HANGING DROP",,"PEG20000, 0.1M Sodim citrate. pH 5.0",277.0,2021-11-04,2022-05-18,7VV8,2285.0,2.0,254.0,279.0,,29.3,2.0,1.7,experimental,27.1099,0.1988,0.1796,Crystal Structure of HRasQ61L(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1
7VV9,X-RAY DIFFRACTION,3.16,62.91,"VAPOR DIFFUSION, HANGING DROP",5.0,"PEG 20000, Sodium citrate",278.0,2021-11-05,2022-05-18,7VV9,2307.0,2.0,256.0,312.0,,29.66,2.0,1.6,experimental,29.6144,0.2003,0.1815,Crystal Structure of HRas(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1
7VVG,X-RAY DIFFRACTION,3.18,62.73,"VAPOR DIFFUSION, HANGING DROP",5.0,PEG2000,278.0,2021-11-06,2022-05-18,7VVG,2309.0,2.0,253.0,305.0,,29.27,2.0,1.7,experimental,31.0448,0.2018,0.1778,Crystal Structure of HRasG12V(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1
6NJH,X-RAY DIFFRACTION,2.15,42.89,"VAPOR DIFFUSION, SITTING DROP",6.5,"4.6MG/ML VCID7620 + 0.5MM T-048-1
 1MM DTT, 0.1MM ZNCL2, 0.1MM MGCL2 (BATCH 1214013) AGAINST
 SPARSE MATRIX CONDITION MORPHEUS C4, 12.5% W/V PEG1,000 ,
 12.5% W/V PEG3,350 , 12.5% W/V MPD , 0.03M NPS (SODIUM
 NITRATE, DISODIUM HYDROGEN PHOSPHATE, AMMONIUM SULFATE), 0.1M
 MES/IMIDAZOLE PH 6.5, CRYO-PROTECTED - DIRECT (QYM9-2), VAPOR
 DIFFUSION, SITTING DROP, TEMPERATURE 289K",289.0,2019-01-03,2019-05-08,6NJH,11211.0,4.0,1480.0,563.0,,172.25,1.0,2.15,experimental,27.97,0.21,0.172,Crystal Structure of the PDE4D Catalytic Domain and UCR2 Regulatory Helix with T-48
5DXA,X-RAY DIFFRACTION,2.42,49.14,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M Ammonium Sulfate, 0.1 M Tris pH 8.5, 18% w/v PEG 3350",291.0,2015-09-23,2015-11-25,5DXA,12100.0,7.0,1453.0,505.0,,166.15,2.0,2.07,experimental,28.571,0.244,0.1981,"Crystal structure of CARM1, sinefungin, and methylated PABP1 peptide (R460)"
6IBO,X-RAY DIFFRACTION,3.17,61.14,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.45 M K2HPO4, 8 mM EDTA and 1% xylitol",293.0,2018-11-30,2019-07-24,6IBO,5895.0,2.0,732.0,318.0,,82.74,2.0,2.17,experimental,54.861,0.25368,0.20086,Catalytic deficiency of O-GlcNAc transferase leads to X-linked intellectual disability
5U9D,X-RAY DIFFRACTION,2.3,46.5,"VAPOR DIFFUSION, SITTING DROP",,"Polyethylene glycols (PEG3350 / PEG5000MME), (NH4)2SO4 and MES buffer at pH6.0-6.7",298.0,2016-12-16,2017-01-18,5U9D,2842.0,1.0,271.0,339.0,,32.48,1.0,1.33,experimental,16.333,0.1783,0.1484,Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-encoded chemical library
7UFK,X-RAY DIFFRACTION,2.86,56.99,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Tris, pH 8.5, 18-22% PEG6000, 100 mM sodium chloride",298.0,2022-03-22,2022-10-19,7UFK,13092.0,4.0,1628.0,22.0,13.0,192.5,2.0,2.38,experimental,77.96,0.2353,0.1919,Crystal structure of chimeric omicron RBD (strain BA.2) complexed with human ACE2
5UT0,X-RAY DIFFRACTION,2.18,43.67,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-02-14,2017-06-07,5UT0,2398.0,1.0,289.0,246.0,,33.82,1.0,2.102,experimental,,0.2258,0.1676,JAK2 JH2 in complex with AT9283
5UT5,X-RAY DIFFRACTION,2.19,43.84,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-02-14,2017-06-07,5UT5,2436.0,1.0,289.0,253.0,,34.05,1.0,1.9,experimental,,0.2005,0.1598,JAK2 JH2 in complex with GLPG0634
5AQI,X-RAY DIFFRACTION,2.44,49.65,,8.5,"16-26% (W/V) PEG3350, 0.1 M K-NA TARTRATE, 0.1 M TRIS.HCL PH 8.5 AND 25% (V/V) GLYCEROL",,2015-09-22,2016-10-05,5AQI,7875.0,4.0,1008.0,255.0,2.0,113.35,2.0,1.98,experimental,30.35,0.2424,0.1717,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
6TPA,X-RAY DIFFRACTION,3.06,59.81,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 200mM NaFormate, 3% Butanediol",298.0,2019-12-12,2020-11-18,6TPA,4914.0,2.0,690.0,88.0,,81.88,2.0,2.8,experimental,50.7182,0.2636,0.2257,CDK8/CyclinC in complex with drug ETP-50775
5WQA,X-RAY DIFFRACTION,2.49,50.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES (pH 7.4), 0.1M MgCl2, 15% PEG3350, 10% isopropanol, 25% ethylene glycol",277.0,2016-11-24,2017-02-22,5WQA,5675.0,2.0,668.0,181.0,,78.27,1.0,2.3,experimental,29.044,0.25151,0.21719,Crystal structure of PDE4D catalytic domain complexed with Selaginpulvilins K
7F2K,X-RAY DIFFRACTION,1.65,25.63,VAPOR DIFFUSION,,"0.1 M HEPES (pH 7.4), 0.1 M MgCl2, 15% PEG3350, 10% isopropanol, and 25% ethylene glycol",277.0,2021-06-11,2021-10-20,7F2K,5538.0,2.0,1014.0,288.0,,116.88,1.0,2.10001966681,experimental,27.2593589744,0.256955453423,0.208256947539,Crystal structure of PDE4D catalytic domain complexed with compound 17a
7F2L,X-RAY DIFFRACTION,1.65,25.44,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES (pH 7.4), 0.1 M MgCl2, 15% PEG3350, 10% isopropanol, and 25% ethylene glycol",277.0,2021-06-11,2021-10-20,7F2L,5650.0,2.0,1014.0,380.0,,117.1,1.0,2.10111436093,experimental,23.4953769912,0.250751806557,0.208295535264,Crystal structure of PDE4D catalytic domain complexed with compound 18a
7F2M,X-RAY DIFFRACTION,1.62,24.1,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES (pH 7.4), 0.1 M MgCl2, 15% PEG3350, 10% isopropanol, and 25% ethylene glycol",277.0,2021-06-11,2021-10-20,7F2M,5661.0,2.0,1014.0,325.0,,117.1,1.0,2.20004160481,experimental,25.7586682878,0.246751805764,0.197984745252,Crystal structure of PDE4D catalytic domain complexed with compound 18d
5SYT,X-RAY DIFFRACTION,3.83,67.87,VAPOR DIFFUSION,7.5,"24% PEG3350, 170 mM ammonium sulfate, 15% glycerol, 50 mM HEPES, pH 7.5",286.0,2016-08-11,2016-11-02,5SYT,4006.0,1.0,480.0,160.0,,60.96,1.0,2.0,experimental,41.6363,0.249,0.218,Crystal Structure of ZMPSTE24
6EXW,X-RAY DIFFRACTION,3.23,61.94,EVAPORATION,5.9,"12% PEG 3350, 0.22 M MgCl2, 0.1M BISTris",293.0,2017-11-10,2018-08-08,6EXW,1827.0,2.0,244.0,155.0,,29.85,1.0,2.2,experimental,35.787,0.2514,0.191,Crystal structure of cIAP1-BIR3 in complex with a covalently bound SM
8ZU2,X-RAY DIFFRACTION,2.55,51.7,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.8 M Ammonium sulfate,100 mM 
Sodium citrate,pH 5.5",277.0,2024-06-07,2024-09-11,8ZU2,2457.0,1.0,287.0,304.0,,32.22,1.0,1.79888582046,experimental,25.1737194985,0.221898753519,0.178076821488,Crystal Structure of Human Myt1 Kinase domain Bounded with compound 8g
8FE2,X-RAY DIFFRACTION,2.68,54.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"200 mM Lithium sulfate, 100 mM HEPES 7.5,  20%  PEG 3350",277.15,2022-12-05,2023-10-18,8FE2,7057.0,4.0,850.0,41.0,,100.24,2.0,2.34,experimental,58.26,0.2508,0.1964,Structure of J-PKAc chimera complexed with Aplithianine A
6NMB,X-RAY DIFFRACTION,2.06,40.22,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.03 M sodium nitrate, 0.03 M sodium phosphate, 0.03 M ammonium sulfate, 0.1 M Tris bicine, 25% v/v PEG500, 10% v/v PEG20000",293.0,2019-01-10,2019-03-06,6NMB,8028.0,4.0,1124.0,302.0,20.0,128.91,1.0,2.3,experimental,30.12,0.2712,0.221,Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator
7SHQ,X-RAY DIFFRACTION,2.33,47.3,MICROBATCH,6.9,"Cocktail solution:
Peg3350: 24%
MgCl2: 300 mM
BisTris pH 6.9: 100 mM
Protein Solution:
11 mg/mL CaM-eEF2Kp1/1
Tris pH 7.5: 20 mM 
NaCl: 0.1 M
CaCl2: 3mM
TCEP: 1mM
MgCl2: 1.5 mM
AMPPNP: 1.0 mM

Crystallization conditions: 1/1 Protein/Cocktail under Paraffin Oil in a Greiner 72-Well microbatch plate",298.15,2021-10-11,2022-04-06,7SHQ,5268.0,2.0,679.0,143.0,,77.37,2.0,2.34,experimental,33.65,0.252,0.2293,Structure of a functional construct of eukaryotic elongation factor 2 kinase in complex with calmodulin.
5IEX,X-RAY DIFFRACTION,2.04,39.67,"VAPOR DIFFUSION, HANGING DROP",7.8,"10% PEG 3350, 0.2M ammonium acetate, 100mM HEPES pH 7.8",293.15,2016-02-25,2016-04-27,5IEX,2434.0,1.0,298.0,92.0,,34.42,1.0,2.03,experimental,31.553,0.25396,0.20316,"Crystal structure of (R,S)-S-{4-[(5-Bromo-4-{[(2R,3R)-2-hydroxy-1-methylpropyl]oxy}- pyrimidin-2-yl)amino]phenyl}-S-cyclopropylsulfoximide bound to CDK2"
5IEY,X-RAY DIFFRACTION,2.02,39.18,"VAPOR DIFFUSION, HANGING DROP",7.8,"7.25% PEG 4000, 0.2 M ammonium acetate, 0.2 M HEPES pH 7.8",293.15,2016-02-25,2016-04-27,5IEY,2557.0,1.0,298.0,193.0,,34.31,1.0,1.66,experimental,39.682,0.22502,0.17963,Crystal structure of a CDK inhibitor bound to CDK2
6GES,X-RAY DIFFRACTION,2.18,43.69,"VAPOR DIFFUSION, SITTING DROP",7.5,"34% PEG 4k, 0.2M Li2SO4, 0.1M tris 7.5",277.14,2018-04-27,2019-02-27,6GES,6149.0,2.0,760.0,312.0,,88.45,1.0,2.07,experimental,45.749,0.21261,0.16954,Crystal structure of ERK1 covalently bound to SM1-71
6H6R,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.0,"3.1M NaCl
.1M pH=8 HEPES/NaOH",293.0,2018-07-30,2018-08-22,6H6R,1115.0,1.0,127.0,197.0,,15.21,1.0,2.03,experimental,41.736,0.243,0.212,Fragment Derived XIAP inhibitor
8G25,X-RAY DIFFRACTION,2.2,44.06,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES, 0.2 M lithium sulfate, 26% w/v PEG3350",293.0,2023-02-03,2023-04-26,8G25,13335.0,9.0,1674.0,633.0,21.0,185.52,3.0,1.8,experimental,,0.2827,0.2482,Crystal Structure of Cathepsin-G and Neutrophil Elastase Inhibited by S. aureus EapH2 at pH 7.5
6Q96,X-RAY DIFFRACTION,3.51,64.96,"VAPOR DIFFUSION, HANGING DROP",,"2.2M AmSO4, 0.2M citrate",298.0,2018-12-17,2019-05-15,6Q96,1746.0,2.0,192.0,204.0,,23.59,1.0,1.8,experimental,30.287,0.2196,0.2,"HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 12 AT 1.8A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes"
6Q9L,X-RAY DIFFRACTION,2.07,40.44,"VAPOR DIFFUSION, HANGING DROP",8.0,"2.7M AmSO4, 0.2M NaI, 0.2M NaCl, 0.2M TRIS",298.0,2018-12-18,2019-05-15,6Q9L,1914.0,2.0,192.0,266.0,,23.92,1.0,1.13,experimental,11.377,0.1898,0.1782,"HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 9 AT 1.13A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes"
6Q9O,X-RAY DIFFRACTION,1.91,35.72,"VAPOR DIFFUSION, HANGING DROP",8.0,"2.4M AmSO4, 0.1M NaCitrate, 0.2M NaCl, 0.1M TRIS",298.0,2018-12-18,2019-05-15,6Q9O,1819.0,2.0,192.0,186.0,,23.45,1.0,1.21,experimental,12.183,0.1558,0.1447,"HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 10 AT 1.21A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes"
4UV7,X-RAY DIFFRACTION,2.8,56.0,,,,,2014-08-05,2015-10-14,4UV7,8385.0,3.0,1065.0,370.0,28.0,118.52,3.0,2.1,experimental,46.354,0.24759,0.20199,The complex structure of extracellular domain of EGFR and GC1118A
7QQL,X-RAY DIFFRACTION,2.81,56.17,"VAPOR DIFFUSION, SITTING DROP",,0.1 M Succinic acid pH 7.0 15% w/v PEG 3350,298.0,2022-01-10,2022-04-20,7QQL,9838.0,6.0,1257.0,223.0,,143.48,2.0,2.44,experimental,66.7492,0.2295,0.1953,The PDZ domain of SNTG2 complexed with the phosphorylated PDZ-binding motif of RSK1
5ABD,X-RAY DIFFRACTION,2.91,57.75,VAPOR DIFFUSION,7.5,"VAPOR DIFFUSION METHOD, MOTHER LIQUOR: 1.5MICROM VERGFR1-D2, 15MM TRIS/HCL PH 8.1, 25MM NACL, 5MM CUSO4 RESERVOIR: 19.5% (W/V) PEG8000, 100MM SA,",291.0,2015-08-05,2016-09-28,5ABD,2541.0,3.0,285.0,224.0,3.0,33.28,1.0,1.995,experimental,48.4,0.2216,0.1785,CRYSTAL STRUCTURE OF VEGFR-1 DOMAIN 2 IN PRESENCE OF CU
5UVG,X-RAY DIFFRACTION,2.03,39.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 400, calcium chloride, glycerol, HEPES",289.15,2017-02-20,2017-06-28,5UVG,2966.0,1.0,371.0,212.0,,41.39,1.0,1.849,experimental,24.93,0.1969,0.1625,Crystal structure of the human neutral sphingomyelinase 2 (nSMase2) catalytic domain with insertion deleted and calcium bound
5K6J,X-RAY DIFFRACTION,2.23,44.9,VAPOR DIFFUSION,,RESERVOIR SOLUTION : NULL,293.0,2016-05-24,2017-05-31,5K6J,2898.0,1.0,323.0,139.0,,38.86,1.0,1.86,experimental,25.317,0.2347,0.2047,Human Phospodiesterase 4B in complex with pyridyloxy-benzoxaborole based inhibitor
5EZ0,X-RAY DIFFRACTION,2.45,49.83,"VAPOR DIFFUSION, SITTING DROP",10.5,"1.2 M SODIUM DI-HYDROGEN PHOSPHATE 0.8 M DI-POTASSIUM HYDROGEN PHOSPHATE 0.1M CAPS
0.2 M Lithium sulfate
0.67 M Non-Detergent Sulfobetaine (NDSB) 201",291.0,2015-11-26,2016-06-08,5EZ0,3204.0,8.0,472.0,95.0,2.0,52.07,2.0,2.35,experimental,45.07,0.2517,0.2284,CRYSTAL STRUCTURE OF THE PTPN4 PDZ DOMAIN COMPLEXED WITH THE PDZ BINDING MOTIF OF THE MITOGEN ACTIVATED PROTEIN KINASE P38GAMMA.
5J7S,X-RAY DIFFRACTION,4.04,69.55,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.75M NaCitrate, 0.1M Tris-HCL, 0.2M NaCl, pH 7.0, 5mM Adenosine; Adenosine bound TAK1-TAB1 crystals are backsoaked with inhibitor.",293.0,2016-04-06,2017-02-15,5J7S,2261.0,1.0,314.0,,,35.93,1.0,2.368,experimental,,0.2402,0.2282,Crystal structure of SM1-71 bound to TAK1-TAB1
5J8I,X-RAY DIFFRACTION,3.97,69.02,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.75M NaCitrate, 0.1M Tris-HCL, 0.2M NaCl, pH 7.0, 5mM Adenosine;",293.0,2016-04-07,2017-02-15,5J8I,2334.0,1.0,314.0,,,35.93,1.0,2.404,experimental,,0.2444,0.2226,Crystal structure of TL11-113 bound to TAK1-TAB1
5J9L,X-RAY DIFFRACTION,4.24,70.97,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.75M NaCitrate, 0.1M Tris-HCL, 0.2M NaCl, pH 7.0, 5mM Adenosine",293.0,2016-04-10,2017-02-15,5J9L,2328.0,1.0,307.0,10.0,,35.25,1.0,2.7515,experimental,,0.243,0.2127,Crystal structure of CPT1691 bound to TAK1-TAB1
6LUB,X-RAY DIFFRACTION,3.35,63.32,VAPOR DIFFUSION,7.0,"1.0 M Succinic Acid, 1.0 %(w/v) Polyethylene glycol monomethyl ether 2000, 0.1 M HEPES",294.0,2020-01-27,2020-10-07,6LUB,2495.0,1.0,329.0,92.0,,38.0,1.0,2.315,experimental,60.6602,0.2255,0.1856,Crystal Structure of EGFR(L858R/T790M/C797S) in complex with CH7233163
7VDU,X-RAY DIFFRACTION,2.07,40.74,"VAPOR DIFFUSION, HANGING DROP",7.0,"12% (w/v)  PEG 3350, 0.10  M  MES pH=7.00",277.0,2021-09-07,2022-03-09,7VDU,2671.0,1.0,300.0,230.0,,34.58,1.0,1.53,experimental,24.955,0.2175,0.1764,The structure of cyclin-dependent kinase 2 (CDK2) in complex with Compound 1
8OY2,X-RAY DIFFRACTION,2.11,41.79,VAPOR DIFFUSION,7.0,"MES pH7.0, PEG3350, ammonium acetate",277.0,2023-05-03,2023-11-29,8OY2,2282.0,1.0,300.0,39.0,,34.55,1.0,2.618,experimental,50.555,0.28261,0.21971,Human cyclin-dependent kinase 2 in complex with inhibitor HB-29260
8RU8,X-RAY DIFFRACTION,2.04,39.6,"VAPOR DIFFUSION, SITTING DROP",,"12% 1,2-Propanediol
.12% 1,3-Propanediol
.12% 1,4-Butanediol
.12M 1,6-Hexanediol
.12% 1-Butanol
.12% 2-Propanol
30% MPEG 500
10% PEG 20000
.1M pH=7.5 MOPS/NaHEPES",277.0,2024-01-30,2024-06-26,8RU8,2581.0,1.0,306.0,290.0,,35.17,1.0,1.51,experimental,28.809,0.2408,0.2033,A crystal form of a human CDK2-CDK7 chimera
8SKN,X-RAY DIFFRACTION,2.16,43.14,"VAPOR DIFFUSION, SITTING DROP",,"0.05 M potassium chloride, 0.01 M magnesium chloride, 15% w/v PEG6000",277.0,2023-04-20,2023-08-30,8SKN,5484.0,2.0,764.0,158.0,,86.16,1.0,2.41,experimental,43.259,0.25555,0.20563,Crystal structure of compound 3-bound human Dynamin-1-like protein GTPase-BSE fusion
6ZND,X-RAY DIFFRACTION,1.98,37.76,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.2 M MgCl2, 0.1 M Tris-HCl pH 8.0 and 20 % PEG 3350",293.0,2020-07-06,2020-07-22,6ZND,5537.0,2.0,706.0,201.0,,83.84,1.0,2.35,experimental,25.992,0.2906,0.2146,"[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2 Inhibitors"
6BDL,X-RAY DIFFRACTION,2.35,47.57,"VAPOR DIFFUSION, HANGING DROP",6.0,"0.1 M PCTP, pH6.0, 25% w/v PEG1500",295.0,2017-10-23,2018-10-24,6BDL,5680.0,2.0,694.0,469.0,,79.09,1.0,1.96,experimental,,0.2217,0.2087,Crystal structure of cGMP-dependent protein kinase Ialpha (PKG Ialpha) catalytic domain in apo state
8EI8,X-RAY DIFFRACTION,2.28,46.1,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2M Magnesium Chloride, 0.1M Bis-Tris pH 6.5, 20% PEG3350",291.0,2022-09-14,2023-10-25,8EI8,3355.0,2.0,395.0,,,47.72,2.0,2.9,experimental,61.1609,0.3067,0.2366,"Crystal structure of the WWP2 HECT domain in complex with H308, a Helicon Polypeptide"
7QPB,X-RAY DIFFRACTION,3.04,59.59,"VAPOR DIFFUSION, HANGING DROP",5.5,"12% PEG 8000, 0.1 M sodium cacodylate, 0.1 M calcium acetate pH 5.5",277.0,2022-01-03,2023-09-27,7QPB,3753.0,6.0,486.0,57.0,2.0,56.11,2.0,2.342,experimental,,0.2626,0.2149,Catalytic C-lobe of the HECT-type ubiquitin ligase E6AP in complex with a hybrid foldamer-peptide macrocycle
7C3N,X-RAY DIFFRACTION,2.05,40.06,"VAPOR DIFFUSION, HANGING DROP",6.0,"50mM Pipes pH6.0, 1.1M sodium malonate, 1.6% glycerol, 10mM DTT",277.15,2020-05-13,2020-06-24,7C3N,2718.0,1.0,315.0,267.0,,36.16,1.0,1.98,experimental,27.97,0.1943,0.1685,Crystal structure of JAK3 in complex with Delgocitinib
7PC8,X-RAY DIFFRACTION,3.96,68.97,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M Lithium sulfate, 0.05 M Magnesium chloride hexahydrate ,0.1 M HEPES 7.8, 20 % v/v PEG Smear High",293.0,2021-08-03,2022-04-20,7PC8,6914.0,4.0,848.0,221.0,,96.88,2.0,2.5,experimental,61.7162,0.2318,0.2023,The PDZ domain of SNTG1 complexed with the phosphomimetic mutant PDZ-binding motif of RSK1
5M75,X-RAY DIFFRACTION,2.18,53.78,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)

Reservoir: 18% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-10-26,2018-06-06,5M75,3492.0,2.0,373.0,398.0,,43.72,2.0,1.538,experimental,,0.1739,0.1448,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a (S)-methyl substitued Fasudil-derivative
5KTW,X-RAY DIFFRACTION,2.09,41.04,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M potassium thiocyanate, 
0.1 M Bis-Tris pH 5.5, 
5% v/v ethylene glycol, 
23% PEG 3350",277.0,2016-07-12,2016-11-02,5KTW,3581.0,3.0,342.0,594.0,,42.32,1.0,1.087,experimental,15.0416,0.1758,0.1625,"CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N-isopropylbenzamide)"
6Q9H,X-RAY DIFFRACTION,2.13,42.2,"VAPOR DIFFUSION, HANGING DROP",,"2.2M AmSO4, 0.2M NH4PO4",298.0,2018-12-18,2019-05-15,6Q9H,843.0,1.0,96.0,59.0,,11.57,1.0,2.0,experimental,23.585,0.2661,0.2334,"HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 11 AT 2.0A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes"
7R60,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 3350,
0.1 M Bis Tris Propane pH 7.5,
0.2 M Sodium acetate trihydrate",295.0,2021-06-22,2021-10-06,7R60,2372.0,1.0,271.0,185.0,,32.04,1.0,1.94,experimental,15.228,0.2646,0.216,BTK in complex with 18A
5TTV,X-RAY DIFFRACTION,2.14,42.57,"VAPOR DIFFUSION, SITTING DROP",8.0,"20% PEG 3350, 0.2M (NH4)2SO4, 2% phenylurea",298.0,2016-11-04,2017-02-22,5TTV,2374.0,1.0,321.0,125.0,,36.81,1.0,1.93,experimental,32.16,0.25,0.1919,Jak3 with covalent inhibitor 6
6DA4,X-RAY DIFFRACTION,2.15,42.73,"VAPOR DIFFUSION, HANGING DROP",8.0,"20% PEG 3350, 0.2M (NH4)2SO4, 2% phenylurea",298.0,2018-05-01,2018-11-28,6DA4,2260.0,1.0,321.0,18.0,,36.92,1.0,2.9,experimental,50.16,0.263,0.2271,JAK3 with Cyanamide CP10
7NXV,X-RAY DIFFRACTION,2.87,57.11,VAPOR DIFFUSION,5.0,"10% PEG4000, 0.1M Acetate",293.0,2021-03-19,2021-09-29,7NXV,10650.0,6.0,1350.0,50.0,4.0,153.54,3.0,2.55,experimental,36.137,0.2478,0.2159,Crystal structure of the complex of DNase I/G-actin/PPP1R15A_582-621
9FYF,X-RAY DIFFRACTION,3.11,60.44,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M bis-tris pH 5.5 
23-26% (v/v) PEG 3350 
0.2 M ammonia sulphate",293.0,2024-07-03,2024-09-11,9FYF,5673.0,2.0,676.0,44.0,,83.08,1.0,2.7,experimental,57.646,0.24896,0.20199,Crystal structure of human Casein Kinase II subunit alpha (CK2a1) in complex with TR06772818
7E9K,X-RAY DIFFRACTION,2.66,53.77,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris-HCl (pH 8.0 or 8.5), 12-16% PEG 8000, 1% tacsimate (pH 7.0)",277.0,2021-03-04,2021-05-05,7E9K,18493.0,6.0,2202.0,908.0,16.0,256.19,2.0,2.05,experimental,40.9,0.2407,0.2022,Crystal Structure of POMGNT2 in complex with UDP and mono-mannosyl peptide (379Man long peptide)
8G65,X-RAY DIFFRACTION,2.39,48.47,VAPOR DIFFUSION,6.2,"Reservoir solution: 50 mM MES (pH 6.2), 14% PEG6000, 50 mM MgCl2;
Protein solution: 10.3 mg/ml PTP-1B 1-298 in 25 mM Hepes pH 7.2, 150 mM NaCl, 1 mM EDTA, 2 mM DTT",278.0,2023-02-14,2023-04-26,8G65,5587.0,2.0,596.0,642.0,,69.95,1.0,1.45,experimental,24.011,0.18836,0.13438,Wildtype PTP1b in complex with DES4799
8G67,X-RAY DIFFRACTION,2.38,48.26,VAPOR DIFFUSION,6.2,"Reservoir solution: 50 mM MES (pH 6.2), 14% PEG6000, 50 mM MgCl2;
Protein solution: 10.3 mg/ml PTP-1B 1-298 in 25 mM Hepes pH 7.2, 150 mM NaCl, 1 mM EDTA, 2 mM DTT",278.0,2023-02-14,2023-04-26,8G67,5376.0,2.0,596.0,542.0,,70.13,1.0,1.53,experimental,33.014,0.22259,0.1544,Wildtype PTP1b in complex with DES4884
8G6A,X-RAY DIFFRACTION,2.29,46.18,VAPOR DIFFUSION,6.2,"Reservoir solution: 50 mM MES (pH 6.2), 14% PEG6000, 50 mM MgCl2,
Protein solution: 10.3 mg/ml PTP-1B 1-298 in 25 mM Hepes pH 7.2, 150 mM NaCl, 1 mM EDTA, 2 mM DTT",278.0,2023-02-14,2023-04-26,8G6A,5136.0,2.0,596.0,365.0,,70.34,1.0,1.62,experimental,32.603,0.21686,0.17801,Wildtype PTP1b in complex with DES6016
6TWN,X-RAY DIFFRACTION,2.57,52.09,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.1M Na citrate pH 5.6, 20% Isopropanol and 20% PEG4K",277.0,2020-01-13,2021-05-12,6TWN,4993.0,4.0,652.0,167.0,,69.33,2.0,2.28,experimental,41.3,0.2618,0.2144,Crystal structure of Talin1 R7R8 in complex with CDK1 (206-223)
4YLK,X-RAY DIFFRACTION,2.49,50.67,"VAPOR DIFFUSION, SITTING DROP",5.6,"2 M ammonium sulfate, 0.1 M citrate, pH 5.6, 0.2 M potassium/sodium tartrate",277.0,2015-03-05,2015-03-25,4YLK,3572.0,1.0,361.0,557.0,,43.95,1.0,1.4,experimental,15.023,0.17671,0.15485,"Crystal structure of DYRK1A in complex with 10-Chloro-substituted 11H-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5s"
4YLL,X-RAY DIFFRACTION,2.5,50.71,"VAPOR DIFFUSION, SITTING DROP",5.6,"2 M ammonium sulfate, 0.1 M citrate, pH 5.6, 0.2 M potassium/sodium tartrate",277.0,2015-03-05,2015-03-25,4YLL,3513.0,1.0,361.0,577.0,,43.59,1.0,1.4,experimental,14.565,0.17163,0.15053,"Crystal structure of DYRK1AA in complex with 10-Bromo-substituted 11H-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5t"
7Z6C,X-RAY DIFFRACTION,3.74,67.11,"VAPOR DIFFUSION, HANGING DROP",,"Ammonium sulfate 2 M, 100 mM sodium acetate pH 4.8, 30% glycerol.",293.0,2022-03-11,2022-10-12,7Z6C,3128.0,1.0,366.0,212.0,,41.08,1.0,1.85,experimental,31.4075,0.1902,0.1771,"Crystal structure of human Dihydroorotate Dehydrogenase in complex with the inhibitor 2-Hydroxy-N-(2-ispropyl-5-methyl-4-phenoxyphenyl)pyrazolo[1,5-a]pyridine-3-carboxamide."
8VHM,X-RAY DIFFRACTION,3.6,65.82,VAPOR DIFFUSION,4.8,"0.10 M NaAcetate pH 4.8, 2.30 M (NH4)2SO4, 30% Glycerol",293.0,2024-01-02,2024-04-03,8VHM,3125.0,1.0,369.0,210.0,,41.34,1.0,2.26,experimental,10.775,0.228,0.196,Structure of DHODH in Complex with Fragment 2
6C1S,X-RAY DIFFRACTION,2.35,47.69,"VAPOR DIFFUSION, HANGING DROP",8.5,"25% PEG3350, 200MM Lithium Sulfate, 10 MM DTT, 10 MM EDTA, 100 MM Tris",298.0,2018-01-05,2018-06-27,6C1S,6869.0,1.0,971.0,151.0,,112.03,1.0,2.31,experimental,87.57,0.257,0.197,Phosphoinositide 3-Kinase gamma bound to an pyrrolopyridinone Inhibitor
7XBI,X-RAY DIFFRACTION,2.54,51.48,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Na2HPO4/KH2PO4 pH=6.2, 2M NaCl",277.0,2022-03-21,2023-03-29,7XBI,2527.0,1.0,311.0,72.0,,35.99,1.0,2.16,experimental,47.8983,0.2464,0.1881,The crystal structure of human TrkA kinase bound to the inhibitor
6AY3,X-RAY DIFFRACTION,2.28,46.05,VAPOR DIFFUSION,6.5,"0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350",277.0,2017-09-07,2018-02-21,6AY3,2456.0,2.0,230.0,329.0,,28.46,1.0,1.391,experimental,18.1426,0.2372,0.2017,"CREBBP bromodomain in complex with Cpd16 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1H-indole-3-carboxamide)"
7UGE,X-RAY DIFFRACTION,2.48,50.44,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Lithium sulfate monohydrate, 0.1M BIS-TRIS pH6.5, 25% w/v Polyethylene glycol 3,350",292.0,2022-03-24,2023-04-12,7UGE,2267.0,2.0,232.0,216.0,,28.72,1.0,2.004,experimental,21.6623,0.1971,0.1644,Bromodomain of CBP liganded with BMS-536924
5BWZ,X-RAY DIFFRACTION,2.43,49.38,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M BisTris (pH 6.5), 6% (w/v) PEG 8000, 4 mM TCEP",294.0,2015-06-08,2016-06-08,5BWZ,6469.0,2.0,778.0,777.0,,87.41,1.0,1.59,experimental,,0.16,0.142,Crystal structure of S39E HDAC8 in complex with Droxinostat
6XRM,X-RAY DIFFRACTION,2.43,49.31,VAPOR DIFFUSION,,"PEG 4000,  (NH4)2SO4, Na Form, Tris",277.0,2020-07-13,2020-09-16,6XRM,6804.0,1.0,949.0,28.0,,109.42,1.0,2.88,experimental,133.485,0.3049,0.2411,Crystal structure of human PI3K-gamma in complex with Compound 4
5ODT,X-RAY DIFFRACTION,2.82,56.46,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 2 M Ammonium sulphate",292.0,2017-07-06,2018-03-14,5ODT,2577.0,2.0,329.0,140.0,,39.13,2.0,2.021,experimental,,0.2111,0.1778,Aurora-A in complex with TACC3
5W0L,X-RAY DIFFRACTION,1.94,36.58,VAPOR DIFFUSION,6.5,"100 mM Bis-Tris pH 5.5, 200-300 mM KSCN, 21-25% PEG 3350",277.0,2017-05-31,2018-03-07,5W0L,2225.0,2.0,296.0,243.0,,36.28,1.0,1.549,experimental,23.0636,0.2294,0.1925,"CREBBP Bromodomain in complex with Cpd10 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)"
7KPY,X-RAY DIFFRACTION,2.29,46.29,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris, pH 5.5
25% w/v Polyethylene glycol 3,350",292.0,2020-11-12,2021-05-19,7KPY,2246.0,2.0,232.0,202.0,,28.84,1.0,1.7,experimental,26.24,0.2388,0.2019,Crystal structure of CBP bromodomain liganded with UMB298 (compound 23)
7XI0,X-RAY DIFFRACTION,2.03,39.32,"VAPOR DIFFUSION, SITTING DROP",,"0.2M NaAc, 20% w/v Polyethylene glycol, 3350   PH 7.3",277.0,2022-04-11,2022-07-27,7XI0,2130.0,2.0,266.0,134.0,,33.07,1.0,1.62,experimental,21.745,0.2244,0.1919,Crystal structure of CBP bromodomain liganded with CCS150
5TF8,X-RAY DIFFRACTION,2.35,47.66,MICROBATCH,7.5,"Protein buffer:containing 150 mM NaCl, 30% (v/v) glycerol, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5, Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-24,2018-05-09,5TF8,1956.0,1.0,229.0,208.0,,26.03,1.0,1.861,experimental,,0.187,0.153,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dTTP
6XYR,X-RAY DIFFRACTION,3.52,65.1,"VAPOR DIFFUSION, SITTING DROP",,"8% PEG 8000, 200 mM LiCl2, 100 mM Tris pH 8.0, 15% Glycerol",293.15,2020-01-31,2020-12-09,6XYR,2955.0,1.0,361.0,135.0,,41.59,1.0,2.079,experimental,55.491,0.2357,0.1905,Structure of the T4Lnano fusion protein
8SSO,X-RAY DIFFRACTION,2.52,51.09,"VAPOR DIFFUSION, SITTING DROP",5.5,Crystals of AurA in complex with Mb2 and danusertib were obtained by combining 0.5 ul of 300 uM (10 mg/mL) AurA + 315 uM (4 mg/mL) Mb2 + 1 mM danusertib with 0.5 ul of 0.1 M BIS-TRIS pH 5.5 + 0.2 M Ammonium acetate + 25 percent PEG3350. Crystals were grown at 18 degC by sitting drop. Crystals were harvested and subsequently flash frozen,291.15,2023-05-08,2023-09-06,8SSO,6219.0,4.0,756.0,536.0,,86.82,2.0,1.97,experimental,49.21,0.2343,0.1917,AurA bound to danusertib and inhibiting monobody Mb2
7E9L,X-RAY DIFFRACTION,2.46,49.9,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris-HCl (pH 8.0 or 8.5), 12-16% PEG 8000, 1% tacsimate (pH 7.0)",277.0,2021-03-04,2021-05-05,7E9L,9056.0,3.0,1092.0,465.0,8.0,127.1,2.0,2.1,experimental,50.08,0.2338,0.1855,Crystal Structure of POMGNT2 in complex with UDP and mono-mannosyl peptide (379Man short peptide)
7VPH,X-RAY DIFFRACTION,2.5,50.83,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Sodium citrate pH 5.5, 20% PEG 3350",293.0,2021-10-17,2022-01-19,7VPH,12567.0,12.0,1864.0,56.0,,210.68,3.0,2.8,experimental,,0.2442,0.1924,Crystal structure of the C-terminal tail of SARS-CoV-2 Orf6 complex with human nucleoporin pair Rae1-Nup98
5TGK,X-RAY DIFFRACTION,2.37,48.02,MICROBATCH,7.5,"Protein buffer: 150 mM NaCl, 10% (v/v) glycerol,10% (v/v) Ethylene glycol, 10mM MgCl2, 1 mM TCEP, and 20 mM Na-HEPES, pH 7.5. Precipitant buffer: 40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-28,2018-05-09,5TGK,1848.0,1.0,229.0,172.0,,26.04,1.0,1.912,experimental,,0.1978,0.1546,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with dATP
5F4N,X-RAY DIFFRACTION,2.72,54.73,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350
DL-malic acid",291.15,2015-12-03,2016-05-25,5F4N,2450.0,1.0,273.0,314.0,,32.63,1.0,1.91,experimental,27.42,0.1883,0.1489,Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
7MN7,X-RAY DIFFRACTION,3.29,62.63,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 7.4. 0.2 M Magnesium Chloride, 19.5% peg8000",277.0,2021-04-30,2022-05-18,7MN7,2792.0,1.0,308.0,252.0,,36.68,1.0,1.95,experimental,33.47,0.1901,0.1555,PTP1B F225Y in complex with TCS401
7MN9,X-RAY DIFFRACTION,2.44,49.63,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, .1 M Tris pH 7.6, 18.5% PEG",277.0,2021-04-30,2022-05-18,7MN9,2722.0,1.0,289.0,357.0,,33.98,1.0,1.24,experimental,25.57,0.1801,0.1622,PTP1B 1-284 F225Y-R199N
7MNA,X-RAY DIFFRACTION,2.41,48.99,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 7.4, 0.2 M MgCl2, 16% PEG",277.0,2021-04-30,2022-05-18,7MNA,2503.0,1.0,289.0,210.0,,34.13,1.0,1.47,experimental,22.67,0.1941,0.1698,PTP1B 1-284 F225Y-R199N in complex with TCS401
7MND,X-RAY DIFFRACTION,3.31,62.8,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 0.1 M Tris pH 7.8, 20% PEG 8000",277.0,2021-04-30,2022-05-18,7MND,2579.0,1.0,308.0,136.0,,36.51,1.0,2.29,experimental,27.69,0.203,0.1664,PTP1B L204A in complex with TCS401
7MNF,X-RAY DIFFRACTION,2.29,46.24,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 0.1 M Tris pH 7.8, 19.5% PEG",277.0,2021-04-30,2022-05-18,7MNF,2542.0,1.0,308.0,243.0,,36.38,1.0,1.7,experimental,23.34,0.2021,0.182,PTP1B P206G in complex with TCS401
7MOU,X-RAY DIFFRACTION,2.44,49.54,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, .1 M Tris pH 7.8, 16.5% PEG",277.0,2021-05-03,2022-05-18,7MOU,2619.0,1.0,289.0,229.0,,33.96,1.0,1.48,experimental,22.37,0.1801,0.1715,PTP1B F225Y-R199N-L195R
7MOW,X-RAY DIFFRACTION,3.28,62.52,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 0.1 M Tris pH 8, 17.5% PEG 8000",277.0,2021-05-03,2022-05-18,7MOW,2779.0,1.0,308.0,259.0,,36.52,1.0,1.8,experimental,29.61,0.1757,0.1547,PTP1B F225I in complex with TCS401
7S4F,X-RAY DIFFRACTION,3.37,63.51,"VAPOR DIFFUSION, SITTING DROP",7.5,"2uL of protein solution (12 mg/mL PTP1B F182Q in 10 mM Tris pH 7.5, 25 mM NaCl, 0.2 mM EDTA and 3 mM DTT), 0.5 uL sucrose 30% (w/v) and 3 uL of precipitant solution (0.1 M Hepes pH 7.5, 0.2 M magnesium acetate and 15-20% polyethylene glycol 8000). The well solution was 500 uL of precipitant solution.",277.0,2021-09-08,2022-09-21,7S4F,2792.0,1.0,298.0,315.0,,35.15,1.0,1.65,experimental,33.31,0.2031,0.1798,Protein Tyrosine Phosphatase 1B - F182Q mutant bound with Hepes
6UUQ,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Sodium cacodylate, 12% Peg 8000, 0.1 M Calcium acetate",298.0,2019-10-31,2020-09-09,6UUQ,2936.0,2.0,356.0,313.0,1.0,41.12,2.0,1.849,experimental,24.993,0.2049,0.1635,Structure of Calcineurin bound to RCAN1
7PI4,X-RAY DIFFRACTION,2.87,57.1,VAPOR DIFFUSION,,"0.05M CaCl, 0.1M MES pH 6.5, 45%v/v, PEG200",293.0,2021-08-19,2021-09-29,7PI4,5240.0,4.0,629.0,150.0,,74.4,4.0,2.24,experimental,53.214,0.2512,0.1953,FAK Protac GSK215 in complex with FAK and pVHL:ElonginC:ElonginB
5W0E,X-RAY DIFFRACTION,1.89,34.93,VAPOR DIFFUSION,6.5,"0.2M MgCl2, 0.1M Bis-Tris pH6.5, 22% PEG3350",277.0,2017-05-30,2018-02-21,5W0E,1153.0,1.0,148.0,133.0,,18.16,1.0,1.41,experimental,21.7129,0.2599,0.2285,"CREBBP bromodomain in complex with Cpd19 (3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-N-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide)"
6ALB,X-RAY DIFFRACTION,2.9,57.63,VAPOR DIFFUSION,6.5,"0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350",277.0,2017-08-07,2018-10-17,6ALB,1853.0,1.0,233.0,39.0,,28.46,1.0,2.053,experimental,66.3373,0.2425,0.2212,"CREBBP bromodomain in complex with Cpd 30 (1-(3-(3-(1-methyl-1H-pyrazol-4-yl)isoquinolin-8-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)"
7XNG,X-RAY DIFFRACTION,2.2,44.06,"VAPOR DIFFUSION, SITTING DROP",,20% PEG3350 0.2M KSCN  0.1M HEPES PH8.5,277.0,2022-04-28,2022-06-01,7XNG,2023.0,2.0,266.0,46.0,,32.85,1.0,2.35,experimental,32.441,0.2419,0.1913,Crystal structure of CBP bromodomain liganded with Y08092(31g)
6C83,X-RAY DIFFRACTION,2.23,44.94,"VAPOR DIFFUSION, SITTING DROP",6.5,"Crystals of dephosphorylated Aurora A (122-403) in complex with Monobody Mb2 and AMPPCP were obtained by mixing  a 1:1 ratio of 0.24mM Aurora A, 0.25mM Mb2 and 2.5mM AMPPCP in 20mM TrisHCl pH 7.5, 200mM NaCl,20mM MgCl2, 10% glycerol, 5mM TCEP with mother liquor (0.1M Bis-Tris pH 5.5, 0.2M NaCl, 25% (w/v) PEG 3350",291.15,2018-01-24,2019-02-27,6C83,4937.0,4.0,756.0,,,86.7,2.0,2.55,experimental,73.75,0.3221,0.2637,Structure of Aurora A (122-403) bound to inhibitory Monobody Mb2 and AMPPCP
4RVM,X-RAY DIFFRACTION,2.52,51.17,"VAPOR DIFFUSION, SITTING DROP",7.4,"Hepes, isopropanol, PEG 8000, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 292K",292.0,2014-11-26,2015-06-03,4RVM,2320.0,1.0,298.0,148.0,,34.57,1.0,1.86,experimental,31.269,0.24248,0.20125,CHK1 kinase domain with diazacarbazole compound 19
5OOR,X-RAY DIFFRACTION,2.29,46.17,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-08,2017-10-25,5OOR,2448.0,1.0,297.0,246.0,,34.6,1.0,1.9,experimental,17.686,0.2078,0.1645,Structure of CHK1 10-pt. mutant complex with staurosporine
5OOT,X-RAY DIFFRACTION,2.36,47.97,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-08,2017-10-25,5OOT,2246.0,1.0,297.0,126.0,,34.66,1.0,2.1,experimental,40.023,0.2237,0.1757,Structure of CHK1 10-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor
5OP5,X-RAY DIFFRACTION,2.31,46.7,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-09,2017-10-25,5OP5,2326.0,1.0,297.0,219.0,,34.43,1.0,1.9,experimental,38.87,0.2057,0.1599,Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor
5OP7,X-RAY DIFFRACTION,2.31,46.68,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-09,2017-10-25,5OP7,2318.0,1.0,297.0,197.0,,34.57,1.0,1.8,experimental,36.629,0.2154,0.1658,Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor
5OPB,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-09,2017-10-25,5OPB,2371.0,1.0,297.0,235.0,,34.54,1.0,1.55,experimental,32.468,0.1893,0.1635,Structure of CHK1 10-pt. mutant complex with indazole LRRK2 inhibitor
5OQ5,X-RAY DIFFRACTION,2.39,48.64,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-10,2017-10-25,5OQ5,2447.0,1.0,297.0,287.0,,34.81,1.0,1.4,experimental,32.723,0.1852,0.1687,Structure of CHK1 8-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor
5OQ6,X-RAY DIFFRACTION,2.35,47.65,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293.0,2017-08-10,2017-10-25,5OQ6,2279.0,1.0,297.0,165.0,,34.7,1.0,1.95,experimental,40.027,0.1918,0.1578,Structure of CHK1 12-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor
4TQN,X-RAY DIFFRACTION,1.94,36.63,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M  MES pH 6.5, 0.1M MgCl2, 20% PEG 6000, 10% EtGly",277.0,2014-06-11,2015-06-24,4TQN,997.0,1.0,119.0,58.0,,14.74,1.0,1.7,experimental,23.261,0.199,0.1813,Crystal structure of the bromodomain of human CREBBP in complex with UL04
5W0F,X-RAY DIFFRACTION,1.94,36.56,VAPOR DIFFUSION,6.5,"0.2 M Li2SO4, 0.1M Bis-Tris pH 6.5, 19% PEG3350",277.0,2017-05-30,2018-03-07,5W0F,1151.0,1.0,148.0,116.0,,18.08,1.0,1.6,experimental,25.1247,0.206,0.1849,"CREBBP Bromodomain in complex with Cpd3 ((S)-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(tetrahydrofuran-3-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one)"
5W0Q,X-RAY DIFFRACTION,2.09,41.08,VAPOR DIFFUSION,6.5,"0.1M Bis-Tris pH 6.5, 0.2M Li2SO4, 25% PEG3350",277.0,2017-05-31,2018-03-07,5W0Q,1127.0,1.0,148.0,121.0,,18.14,1.0,1.7,experimental,28.4237,0.213,0.1876,"CREBBP Bromodomain in complex with Cpd17 (N,2,7-trimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide)"
5XXH,X-RAY DIFFRACTION,2.16,43.16,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% PEG 3350, 0.2M MgCl2, 0.1M Tris HCl, PH 8.5",277.0,2017-07-04,2018-06-13,5XXH,1132.0,1.0,133.0,122.0,,16.31,1.0,1.62,experimental,17.71,0.208,0.191,Crystal Structure Analysis of the CBP
7WX2,X-RAY DIFFRACTION,2.39,48.57,EVAPORATION,8.5,"PEG3350, NaNO3, ethylene glycol",289.0,2022-02-14,2022-06-08,7WX2,1220.0,1.0,121.0,191.0,,14.85,1.0,1.24,experimental,17.167,0.1995,0.1812,CBP-BrD complexed with NEO2734
5SX4,X-RAY DIFFRACTION,3.1,60.27,"VAPOR DIFFUSION, HANGING DROP",,"2.0 M AmSO4, 100 mM MES 6.5  and 5% peg 400",293.0,2016-08-09,2016-10-05,5SX4,9504.0,6.0,1272.0,117.0,15.0,140.07,3.0,2.8,experimental,54.6188,0.2661,0.2233,Crystal Structure of panitumumab in complex with epidermal growth factor receptor domain 3.
5SX5,X-RAY DIFFRACTION,3.07,59.94,"VAPOR DIFFUSION, HANGING DROP",,"2.0 M AmSO4, 100 mM MES 6.5  and 5% peg 400",293.0,2016-08-09,2016-10-05,5SX5,9644.0,6.0,1272.0,139.0,14.0,141.23,3.0,2.5,experimental,55.5934,0.2498,0.2257,Crystal Structure of panitumumab in complex with epidermal growth factor receptor domain 3 mutant S468R.
8T7Q,X-RAY DIFFRACTION,2.35,47.71,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 3350,100 mM Tris-HCl (pH 8.5), 300 mM Ammonium Sulfate",277.0,2023-06-21,2023-10-11,8T7Q,8261.0,2.0,1052.0,313.0,,121.42,1.0,2.1,experimental,40.96,0.2622,0.2046,"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors"
8T8Q,X-RAY DIFFRACTION,2.36,47.93,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG3350, 0.3 M Ammonium Sulfate, 0.1 M Tris (pH 8.5)",277.0,2023-06-23,2023-10-11,8T8Q,8320.0,2.0,1052.0,259.0,,121.39,1.0,2.27,experimental,46.68,0.2489,0.1917,"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors"
7P74,X-RAY DIFFRACTION,2.54,51.58,"VAPOR DIFFUSION, HANGING DROP",,"100mM ammonium sulfate, 100mM sodium formate, 25% PEG smear broad",293.0,2021-07-19,2022-07-27,7P74,3675.0,2.0,436.0,232.0,,49.82,2.0,1.9,experimental,46.2206,0.2107,0.181,The PDZ domain of SYNJ2BP complexed with the phosphorylated PDZ-binding motif of RSK1
7PPL,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG 20000, 100mM HEPES buffer pH 7.5, 50mM EDTA",277.0,2021-09-14,2022-09-07,7PPL,2578.0,2.0,297.0,160.0,,34.9,2.0,1.53,experimental,30.07,0.1972,0.1762,"SHP2 catalytic domain in complex with IRS1 (625-639) phosphopeptide (pTyr-632, pSer-636)"
8D5B,X-RAY DIFFRACTION,2.46,49.97,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Sodium cacodylate pH 5.7, 1.5 M Lithium sulfate, 10 mM Magnesium sulfate",295.15,2022-06-04,2023-01-11,8D5B,1792.0,1.0,262.0,144.0,,31.35,1.0,1.93,experimental,36.9,0.2122,0.1808,Crystal structure of human METTL1 in complex with SAH
8ZTX,X-RAY DIFFRACTION,2.55,51.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.8 M Ammonium sulfate,100 mM 
Sodium citrate,pH 5.5",277.0,2024-06-07,2024-09-11,8ZTX,2409.0,1.0,288.0,260.0,,32.14,1.0,1.70033228795,experimental,33.7770651635,0.215765414735,0.180794346867,Crystal Structure of Human Myt1 Kinase domain Bounded with compound 6b
8ZUD,X-RAY DIFFRACTION,2.55,51.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.8 M Ammonium sulfate,100 mM 
Sodium citrate,pH 6.5",277.0,2024-06-08,2024-09-11,8ZUD,2423.0,1.0,287.0,231.0,,32.13,1.0,1.5051008788,experimental,32.4496558341,0.237756545815,0.202858375722,Crystal Structure of Human Myt1 Kinase domain Bounded with compound 8f
8ZUL,X-RAY DIFFRACTION,2.55,51.7,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.8 M Ammonium sulfate,100 mM 
Sodium citrate,pH 5.5",277.0,2024-06-09,2024-09-11,8ZUL,2386.0,1.0,287.0,210.0,,32.13,1.0,1.80026162696,experimental,33.6865695572,0.21916359869,0.185853061644,Crystal Structure of Human Myt1 Kinase domain Bounded with compound 8m
4Y71,X-RAY DIFFRACTION,1.87,34.22,"VAPOR DIFFUSION, HANGING DROP",,"16 - 20 % PEG 6000, 50 mM MES-NaOH (pH 5.7-6.0), 5 mM calcium chloride,  50 mM sodium chloride",293.0,2015-02-13,2015-09-30,4Y71,2503.0,2.0,388.0,191.0,8.0,44.31,2.0,1.8,experimental,34.74,0.2404,0.197,Factor Xa complex with GTC000398
4Y7A,X-RAY DIFFRACTION,1.93,36.22,"VAPOR DIFFUSION, HANGING DROP",,"18% PEG 6000,  100 mM MES PH 5.75, 10 mM calcium chloride",293.0,2015-02-13,2015-09-30,4Y7A,2515.0,2.0,388.0,215.0,8.0,44.3,2.0,1.99,experimental,35.769,0.2362,0.1889,Factor Xa complex with GTC000422
4Y7B,X-RAY DIFFRACTION,1.88,34.59,"VAPOR DIFFUSION, HANGING DROP",5.75,"18% PEG 6000,  100 mM MES PH 5.75, 10 mM calcium chloride",293.0,2015-02-13,2015-09-30,4Y7B,2622.0,2.0,388.0,327.0,8.0,44.36,2.0,1.79,experimental,24.345,0.2124,0.1739,Factor Xa complex with GTC000441
8P35,X-RAY DIFFRACTION,2.61,52.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium salt, pH 7.5, 25 %(w/v) PEG 2000 MME",293.0,2023-05-17,2023-11-29,8P35,4651.0,6.0,600.0,180.0,,64.86,1.0,2.2,experimental,42.85,0.25,0.22,Mutant human titin immunoglobulin-like 21 domain - C3575S
6G30,X-RAY DIFFRACTION,2.51,51.06,"VAPOR DIFFUSION, SITTING DROP",,"0.08M L-Na-Glutamate; 0.08M Alanine (racemic); 0.08M Glycine; 0.08M Lysine HCl (racemic); 0.08M Serine (racemic), 0.08M Tris, 0.08M BICINE, 10% v/v MPD; 10% PEG 1000; 10% w/v PEG 3350 at pH 8.5",293.0,2018-03-23,2019-04-10,6G30,2193.0,1.0,306.0,,,35.5,1.0,2.418,experimental,,0.2729,0.2265,Crystal structure of the p97 D2 domain in a helical split-washer conformation
8SIX,X-RAY DIFFRACTION,2.37,48.15,"VAPOR DIFFUSION, SITTING DROP",6.5,"11% PEG 8000, 15-20% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid",293.0,2023-04-17,2023-11-01,8SIX,2346.0,1.0,297.0,214.0,,34.6,1.0,1.55,experimental,30.4,0.238,0.206,Structure of Compound 13 bound to the CHK1 10-point mutant
7LVJ,X-RAY DIFFRACTION,1.96,37.22,"VAPOR DIFFUSION, SITTING DROP",8.0,"20% PEG 3350, 200mM Potassium Sodium Tartrate tetrahydrate",281.0,2021-02-25,2022-03-02,7LVJ,1807.0,1.0,257.0,196.0,,30.01,1.0,1.5,experimental,23.198,0.23,0.1977,CASP8 isoform G DED domain
8E4X,X-RAY DIFFRACTION,2.63,53.24,"VAPOR DIFFUSION, SITTING DROP",7.0,"50 mM MOPS pH 7.0, 100 mM NaCl, 13% PEG 4000",298.0,2022-08-19,2022-10-26,8E4X,8029.0,4.0,1040.0,38.0,,129.98,1.0,2.8,experimental,110.7111,0.2394,0.195,Human Adenosine Deaminase Acting on dsRNA (ADAR2-R2D) bound to dsRNA containing a G:3-deaza dA pair adjacent to the target site
6J3P,X-RAY DIFFRACTION,1.98,37.98,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium acetate, 0.1 M Tris pH 8.5, 25% w/v Polyethylene glycol 3,350",293.0,2019-01-05,2019-05-01,6J3P,2128.0,2.0,270.0,286.0,,32.79,1.0,1.598,experimental,,0.1811,0.1545,"Crystal structure of the human GCN5 bromodomain in complex with compound (R,R)-36n"
8GM4,X-RAY DIFFRACTION,2.64,53.11,VAPOR DIFFUSION,6.2,"Cocktail:16.55% PEG-3350, 200 mM NaF, 100 mM BisTris-Propane
Protein sol: 10.3 mg/mL 20 mM Tris pH 7.5, 100 mM NaCl, 3 mM CaCl2, 1mM TCEP, 0.3 mM ADP, 0.3 m Inhibitor , 0.7 % DMSO
2protein/1cocktail (0.2 ul total)",295.15,2023-03-24,2023-05-31,8GM4,4639.0,2.0,679.0,362.0,,77.96,2.0,2.12,experimental,48.69,0.2376,0.2071,Functional construct of the Eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor
7T1L,X-RAY DIFFRACTION,1.87,34.35,"VAPOR DIFFUSION, SITTING DROP",8.5,1.3 M Sodium Citrate Tribasic Dihydrate and 100 mM Bis-Tris Propane (pH=8.5),293.0,2021-12-02,2022-08-24,7T1L,1877.0,4.0,214.0,184.0,,24.22,2.0,1.35,experimental,22.59,0.1973,0.164,Crystal structure of a superbinder Fes SH2 domain (sFesS) in complex with a high affinity phosphopeptide
7N42,X-RAY DIFFRACTION,2.46,49.95,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M MgCl2, 0.1 M Bis-Tris pH 5.5, 15% PEG 3,350",291.0,2021-06-03,2021-06-09,7N42,2349.0,1.0,265.0,263.0,,31.98,1.0,1.9,experimental,25.8183,0.2036,0.1607,Crystal structure of the tandem bromodomain of human TAF1 (TAF1-T) bound to ZS1-681
7T2I,X-RAY DIFFRACTION,2.43,49.47,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M MgCl2, 0.1 M Bis-Tris pH 5.5, 15% PEG 3,350",291.0,2021-12-04,2022-01-19,7T2I,2315.0,1.0,265.0,252.0,,31.65,1.0,1.89,experimental,29.4014,0.1993,0.1655,"Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-588"
5LWV,X-RAY DIFFRACTION,3.98,69.14,"VAPOR DIFFUSION, SITTING DROP",,1.3M Ammonium tartrate diabasic; 0.1M Tris pH8.5,291.0,2016-09-19,2017-07-12,5LWV,6302.0,1.0,749.0,665.0,,84.47,1.0,1.9,experimental,30.491,0.19933,0.16943,Human OGT in complex with UDP and fused substrate peptide (HCF1)
5VND,X-RAY DIFFRACTION,2.75,55.3,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG10000, 0.1M MES pH6.2, 0.3M Ammonium Sulphate, 5% Ethylene glycol",298.0,2017-04-30,2017-05-24,5VND,5106.0,2.0,618.0,245.0,,72.73,1.0,2.2,experimental,51.934,0.22333,0.17822,Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to H3B-6527
5HEZ,X-RAY DIFFRACTION,3.68,66.6,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.9 M sodium malonate, 10 mM ZnCl2",291.0,2016-01-06,2016-11-09,5HEZ,10024.0,4.0,1208.0,110.0,,146.16,1.0,2.66,experimental,67.77,0.2384,0.2169,JAK2 kinase (JH1 domain) mutant P1057A in complex with TG101209
4TOS,X-RAY DIFFRACTION,2.08,40.79,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris pH7.5, 0.2M sodium Acetate, 30% PEG4000",293.15,2014-06-06,2015-05-20,4TOS,3522.0,2.0,472.0,216.0,,54.44,1.0,1.802,experimental,,0.2107,0.1808,Crystal structure of Tankyrase 1 with 355
8RI2,X-RAY DIFFRACTION,2.79,55.94,"VAPOR DIFFUSION, SITTING DROP",7.0,"protein: well = 1: 1
well: 1.94 M Ammonium citrate pH 7.0
protein: 7 mg/ml protein copurified with 1 uM inhibitor",298.0,2023-12-18,2024-01-17,8RI2,4004.0,1.0,550.0,80.0,,65.02,1.0,2.8,experimental,84.07,0.2702,0.2242,Crystal structure of NLRP3 in complex with inhibitor NP3-562
5E8T,X-RAY DIFFRACTION,2.05,40.11,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E8T,2632.0,1.0,307.0,217.0,,35.44,1.0,1.7,experimental,22.29,0.1895,0.1686,TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
5E8W,X-RAY DIFFRACTION,2.06,40.18,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E8W,2628.0,1.0,307.0,171.0,,35.82,1.0,1.86,experimental,26.07,0.1861,0.1674,TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
5E8X,X-RAY DIFFRACTION,1.85,33.54,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E8X,2556.0,1.0,307.0,161.0,,35.79,1.0,1.45,experimental,25.82,0.2097,0.1904,"TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F) IN COMPLEX WITH STAUROSPORINE"
5QTZ,X-RAY DIFFRACTION,2.08,40.75,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2019-11-19,2020-02-05,5QTZ,2667.0,1.0,307.0,187.0,,35.78,1.0,1.83,experimental,24.26,0.1999,0.169,"TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[1-(2,2-DIFLUOROETHYL)-4-(6-METHYLPYRIDIN-2-YL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-A]PYRIDINE"
5QU0,X-RAY DIFFRACTION,2.1,41.33,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2019-11-19,2020-02-05,5QU0,2703.0,1.0,307.0,218.0,,35.64,1.0,1.67,experimental,22.48,0.206,0.177,"TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[4-(3-CHLORO-4-FLUOROPHENYL)-1-(2-HYDROXYETHYL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE"
6VHG,X-RAY DIFFRACTION,2.8,56.04,"VAPOR DIFFUSION, HANGING DROP",4.6,"1.8M ammonium sulfate, 0.1M sodium acetate pH 4.6",293.15,2020-01-09,2020-02-26,6VHG,2414.0,1.0,311.0,133.0,,36.5,1.0,2.303,experimental,35.13,0.2377,0.2028,"Crystal structure of phosphorylated RET tyrosine kinase domain complexed with a pyrazolo[1,5-a]pyrimidine inhibitor"
7T1K,X-RAY DIFFRACTION,2.97,58.6,"VAPOR DIFFUSION, SITTING DROP",5.5,2.4 M Sodium Malonate (pH 5.5) and 2% PEG300,293.0,2021-12-02,2022-08-24,7T1K,1036.0,2.0,110.0,123.0,,12.81,2.0,1.25,experimental,18.56,0.1781,0.1517,Crystal structure of a superbinder Fes SH2 domain (sFes1) in complex with a high affinity phosphopeptide
6VFF,X-RAY DIFFRACTION,2.62,53.08,"VAPOR DIFFUSION, HANGING DROP",7.0,"50mM MOPS pH 7.0, 20% w/v PEG 4000, 100 mM NaCl",298.0,2020-01-03,2020-07-01,6VFF,7870.0,4.0,1040.0,36.0,,129.96,1.0,2.8,experimental,81.4,0.2483,0.1965,Dimer of Human Adenosine Deaminase Acting on dsRNA (ADAR2) mutant E488Q bound to dsRNA sequence derived from human GLI1 gene
5F36,X-RAY DIFFRACTION,4.08,69.86,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5",277.0,2015-12-02,2016-12-14,5F36,1208.0,1.0,130.0,101.0,,15.8,1.0,1.5,experimental,35.3911,0.1895,0.169,Crystal structure of the bromodomain of human ATAD2 in complex with Compound A12
6EPT,X-RAY DIFFRACTION,4.13,70.25,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M ammonium sulfate, 0.1M Bis-Tris pH 5.5",277.0,2017-10-12,2018-10-31,6EPT,1277.0,1.0,130.0,131.0,,16.24,1.0,1.65,experimental,,0.2262,0.2018,The ATAD2 bromodomain in complex with compound 12
6YB4,X-RAY DIFFRACTION,4.06,69.73,"VAPOR DIFFUSION, SITTING DROP",,"0.1M trisHCl pH 7.0-8.0, 1.2-1.5M ammonium sulphate",277.0,2020-03-15,2020-05-06,6YB4,1394.0,1.0,130.0,222.0,,16.35,1.0,1.85,experimental,30.81,0.2152,0.1902,"Crystal structure of human ATAD2 bromodomain in complex with N-(4-bromo-3-(3-methylpyrrolidin-1-yl)sulfonyl)phenyl)-2-(-4-cyclopropyl-4-methyl-2,5-dioxoimidazolidin-1-yl)acetamide"
7Q6U,X-RAY DIFFRACTION,4.02,69.42,VAPOR DIFFUSION,6.25,"ATAD2 (981-1108) at 12 mg/ml in 25 mM Tris pH 9.7, 300 mM NaCl, 0.5 mM TCEP crystallised from 20% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.25. Ligands were introduced by soaking, cryo-protection with 20 % glycerol.",298.0,2021-11-09,2022-01-19,7Q6U,1333.0,1.0,130.0,192.0,,16.11,1.0,1.95,experimental,31.25,0.1993,0.1858,Crystal structure of the bromodomain of ATAD2 with phenol HTS hit (cpd 6)
7Q6V,X-RAY DIFFRACTION,4.03,69.51,VAPOR DIFFUSION,6.25,"ATAD2 (981-1108) at 12 mg/ml in 25 mM Tris pH 9.7, 300 mM NaCl, 0.5 mM TCEP crystallised from 20% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.25. Ligands were introduced by soaking, cryo-protection with 20 % glycerol.",293.0,2021-11-09,2022-01-19,7Q6V,1318.0,1.0,130.0,182.0,,16.1,1.0,1.96,experimental,31.09,0.2057,0.1871,Crystal structure of the bromodomain of ATAD2 with triazolopyridine (cpd 14)
7Q6W,X-RAY DIFFRACTION,4.05,69.65,VAPOR DIFFUSION,6.25,"ATAD2 (981-1108) at 12 mg/ml in 25 mM Tris pH 9.7, 300 mM NaCl, 0.5 mM TCEP crystallised from 20% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.25. Ligands were introduced by soaking, cryo-protection with 20 % glycerol.",293.0,2021-11-09,2022-01-19,7Q6W,1310.0,1.0,130.0,167.0,,16.2,1.0,1.96,experimental,32.66,0.2103,0.1904,Crystal structure of the bromodomain of ATAD2 with triazolopyridazine (cpd 22)
6X8E,X-RAY DIFFRACTION,2.01,38.7,EVAPORATION,7.5,"0.1 M HEPES pH 7.5, 0.1 M sodium acetate trihydrate, and 30-35% PEG-3350",298.0,2020-06-01,2020-11-25,6X8E,5210.0,2.0,596.0,519.0,,70.95,1.0,1.75,experimental,28.04,0.2254,0.1808,Crystal structure of JAK2 with Compound 11
5MRD,X-RAY DIFFRACTION,2.17,43.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 10 MM DTT",293.0,2016-12-22,2017-01-18,5MRD,2793.0,1.0,310.0,343.0,,36.52,1.0,1.41,experimental,,0.1742,0.1402,Human PDK1-PKCiota Kinase Chimera in Complex with Allosteric Compound PS267 Bound to the PIF-Pocket
5CF4,X-RAY DIFFRACTION,2.94,52.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"100MM MES BUFFER, 100MM NACL, 28% (w/v) PEG3350, 2MM DTT AND 200MM TRI-SODIUM CITRATE",295.0,2015-07-08,2015-08-26,5CF4,5049.0,2.0,642.0,249.0,,76.55,1.0,2.38,experimental,34.51,0.2527,0.2522,"CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE"
5CF8,X-RAY DIFFRACTION,3.0,58.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"100MM MES BUFFER, 100MM NACL, 28% (w/v) PEG3350, 2MM DTT, AND 200MM TRI-SODIUM CITRATE",295.0,2015-07-08,2015-08-26,5CF8,5295.0,2.0,602.0,493.0,,72.26,1.0,1.8,experimental,35.18,0.2038,0.1908,"CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE"
6G3C,X-RAY DIFFRACTION,2.37,48.11,"VAPOR DIFFUSION, HANGING DROP",8.0,"24% PEG4000, 0.1M Magnesium Acetate, 0.1M Tris",277.0,2018-03-24,2019-03-27,6G3C,4823.0,2.0,544.0,462.0,,63.9,1.0,1.6,experimental,23.8146,0.22,0.195,Crystal Structure of JAK2-V617F pseudokinase domain in complex with Compound 2
6Q42,X-RAY DIFFRACTION,1.95,36.77,VAPOR DIFFUSION,8.5,"32% (w/v) PEG4K, 0.8M Lithium chloride, Tris-HCl",291.0,2018-12-05,2020-04-15,6Q42,2316.0,2.0,252.0,339.0,15.0,28.46,1.0,1.9,experimental,,0.225,0.175,Crystal Structure of Human Pancreatic Phospholipase A2
7QGO,X-RAY DIFFRACTION,2.6,52.6,"VAPOR DIFFUSION, HANGING DROP",5.7,"10 mM MRS4602, 10 microM ZnCl2, 10 % PEG 4.000 0.1 M BisTris pH 5.7, 20 % PEG200",291.0,2021-12-09,2022-02-16,7QGO,4276.0,1.0,541.0,149.0,4.0,60.44,1.0,2.206,experimental,80.45,0.2921,0.2388,"Human CD73 (ecto 5'-nucleotidase) in complex with MRS4602 (a 3-methyl-CMPCP derivative, compound 21 in paper) in the closed state (crystal form III)"
8R7G,X-RAY DIFFRACTION,2.23,44.76,"VAPOR DIFFUSION, SITTING DROP",4.2,"5% PEG1000, 40% ethanol, 0.1M citrate pH 4.2",277.0,2023-11-24,2024-04-03,8R7G,9015.0,4.0,1204.0,97.0,1.0,140.0,1.0,2.09,experimental,60.52,0.2533,0.2267,Crystal structure of the kinase domain of ACVR1 (ALK2) with M4K2234
8QW6,X-RAY DIFFRACTION,2.95,58.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"200 mM sodium citrate, 100 mM BIS-TRIS propane pH 8.5, 20% w/v polyethylene glycol 3350",277.0,2023-10-18,2023-12-06,8QW6,7996.0,8.0,1066.0,48.0,,124.45,4.0,2.2,experimental,48.29,0.2949,0.255,Crystal Structure of compound 3 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB
8QW7,X-RAY DIFFRACTION,2.82,56.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"200 mM Lithium sulfate monohydrate, 100 mM BIS-TRIS propane pH 5.5, 25% w/v polyethylene glycol 3350",277.0,2023-10-18,2023-12-06,8QW7,7650.0,8.0,1066.0,23.0,,124.47,4.0,2.36,experimental,59.05,0.2726,0.2459,Crystal Structure of compound 4 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB
4ZY6,X-RAY DIFFRACTION,2.44,49.53,"VAPOR DIFFUSION, SITTING DROP",8.0,"25% PEG 3500, 0.2M Ammonium Sulfate and 0.1M Tris pH 8",292.0,2015-05-21,2015-07-01,4ZY6,4707.0,2.0,602.0,244.0,1.0,68.0,1.0,2.15,experimental,60.5,0.2389,0.187,Crystal structure of P21-activated kinase 1 in complex with an inhibitor compound 29
5LWM,X-RAY DIFFRACTION,2.01,38.83,"VAPOR DIFFUSION, SITTING DROP",,"18-25% PEG 3350, 0.1-0.2 M MgCl2 and 0.1 M MES, pH 5.5-6.1",277.15,2016-09-18,2016-10-26,5LWM,2612.0,1.0,294.0,213.0,,34.35,1.0,1.55,experimental,28.241,0.20443,0.16341,Crystal structure of JAK3 in complex with Compound 4 (FM381)
5LWN,X-RAY DIFFRACTION,2.01,38.77,"VAPOR DIFFUSION, SITTING DROP",,"18-25% PEG 3350, 0.1-0.2 M MgCl2 and 0.1 M MES, pH 5.5-6.1",277.15,2016-09-18,2016-10-26,5LWN,2646.0,1.0,294.0,194.0,,34.81,1.0,1.6,experimental,30.243,0.20931,0.16644,Crystal structure of JAK3 in complex with Compound 5 (FM409)
6QBA,X-RAY DIFFRACTION,2.49,50.63,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Zn acetate
0.1 M imidazole pH 8 
20% PEG 3K",295.15,2018-12-20,2020-06-03,6QBA,2182.0,2.0,246.0,209.0,3.0,29.28,2.0,1.8,experimental,36.65,0.2207,0.1881,Crystal Structure of Retinol-Binding Protein 4 (RBP4) in complex with non-retinoid ligand A1120 and engineered binding scaffold
4W6E,X-RAY DIFFRACTION,2.86,56.92,"VAPOR DIFFUSION, SITTING DROP",5.0,"1.4 Sodium Formate, 0.1 Sodium Acetate pH 5",293.0,2014-08-20,2015-05-13,4W6E,1950.0,1.0,211.0,226.0,,24.75,1.0,1.95,experimental,40.85,0.2541,0.2047,Human Tankyrase 1 with small molecule inhibitor
5JDE,X-RAY DIFFRACTION,2.2,44.18,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris HCl pH 8.5, 30% [w/v] PEG 4000, 0.2 M MgCl2",292.0,2016-04-16,2016-09-14,5JDE,4369.0,2.0,530.0,280.0,,59.41,1.0,1.9,experimental,,0.2189,0.1714,Crystal structure of I9-I11 tandem from titin (P1)
4XVR,X-RAY DIFFRACTION,1.91,35.63,"VAPOR DIFFUSION, HANGING DROP",7.5,"139mM Ca(OAc)2, 22.6% PEG 3350, 13% stabilization buffer at pH 7.5",291.15,2015-01-27,2015-06-17,4XVR,1314.0,1.0,166.0,42.0,,19.45,1.0,2.031,experimental,42.23,0.2857,0.2218,H-Ras Y137F
5JYO,X-RAY DIFFRACTION,5.27,76.65,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris propane (pH 7), 3% DMSO, 1.8 M LiSO4",293.0,2016-05-15,2016-08-03,5JYO,20485.0,8.0,2664.0,1237.0,,295.36,1.0,2.098,experimental,,0.213,0.1897,Allosteric inhibition of Kidney Isoform of Glutaminase
6Q1N,X-RAY DIFFRACTION,3.27,62.36,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M (NH4)2SO4, 0.1 M Bis Tris (pH 4.9) containing 0.1 M CsCl",291.15,2019-08-05,2020-08-19,6Q1N,8359.0,2.0,994.0,355.0,4.0,116.14,1.0,2.526,experimental,39.5061,0.2383,0.195,Glucocerebrosidase in complex with pharmacological chaperone IMX8
6Q1P,X-RAY DIFFRACTION,3.27,62.42,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M (NH4)2SO4, 0.1 M Bis Tris (pH 4.9) containing 0.1 M CsCl",291.15,2019-08-05,2020-08-19,6Q1P,8174.0,2.0,994.0,145.0,4.0,116.06,1.0,2.796,experimental,43.8092,0.2404,0.1988,Glucocerebrosidase in complex with pharmacological chaperone norIMX8
6VW1,X-RAY DIFFRACTION,2.95,58.37,"VAPOR DIFFUSION, SITTING DROP",,"Tris, PEG 6000, and 100 mM NaCl.",293.0,2020-02-18,2020-03-04,6VW1,13180.0,4.0,1628.0,26.0,13.0,192.75,2.0,2.68,experimental,108.85,0.2288,0.197,Structure of SARS-CoV-2 chimeric receptor-binding domain complexed with its receptor human ACE2
4OBR,X-RAY DIFFRACTION,3.29,62.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.01 M HEPES, pH 7.5, 0.26 M sodium potassium tartrate, 20% PEG3350, 50 mM ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2014-01-07,2015-01-14,4OBR,10073.0,2.0,1254.0,106.0,2.0,145.7,1.0,2.46,experimental,39.549,0.23929,0.20232,Crystal structure of human alpha-L-iduronidase complex with alpha-L-iduronic acid
6WOI,X-RAY DIFFRACTION,2.21,44.37,"VAPOR DIFFUSION, HANGING DROP",7.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution 400 mM LiCl, 30% (w/v) PEG 8000, 20% (v/v) isopropanol, 100mM NaAc, pH 4.5, 20 mM MgCl2 and 80 mM NaF in present of 2mM 1,5-IP8, and transferred into 400 mM LiCl, 30% (w/v) PEG 8000, 20% (v/v) isopropanol, 100mM HEPES, pH 7.0, 20 mM MgCl2 and 80 mM NaF for 30 second.",293.0,2020-04-24,2021-03-03,6WOI,1292.0,1.0,169.0,131.0,,20.45,1.0,1.5,experimental,17.432,0.1673,0.1449,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 1-Diphosphoinositol pentakisphosphate, Mg, and Fluoride ion, presoaked with 1,5-IP8, Mg and Fluoride for 30 seconds"
6BL8,X-RAY DIFFRACTION,3.16,61.13,VAPOR DIFFUSION,,"100 mM sodium citrate, pH 5.6, 1850 mM ammonium sulfate, 140 mM potassium sodium tartrate",295.0,2017-11-09,2018-03-07,6BL8,4547.0,2.0,544.0,262.0,,64.08,1.0,2.5,experimental,43.44,0.204,0.175,Predicting the Conformational Variability of Abl Tyrosine Kinase Using Molecular Dynamics Simulations and Markov State Models
7AYI,X-RAY DIFFRACTION,2.54,51.61,"VAPOR DIFFUSION, SITTING DROP",,18% PEG 3350 and 5% Tacsimate pH 7,277.15,2020-11-12,2021-01-13,7AYI,2039.0,1.0,285.0,,,33.28,1.0,2.86,experimental,120.994,0.2974,0.2516,Crystal structure of Aurora A in complex with 7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-one derivative (compound 2a)
4Y76,X-RAY DIFFRACTION,1.89,34.76,"VAPOR DIFFUSION, HANGING DROP",5.75,"18% PEG 6000, 100 mm MES PH 5.75, 10 mm calcium chloride",293.0,2015-02-13,2015-09-30,4Y76,2483.0,2.0,388.0,211.0,8.0,44.35,2.0,2.0,experimental,35.024,0.2362,0.1874,Factor Xa complex with GTC000401
4Y79,X-RAY DIFFRACTION,1.89,34.92,"VAPOR DIFFUSION, HANGING DROP",5.75,"18% PEG 6000,  100 mM MES PH5.75, 10 mM calcium chloride",293.0,2015-02-13,2015-09-30,4Y79,2518.0,2.0,388.0,237.0,8.0,44.27,2.0,2.1,experimental,33.704,0.2161,0.1752,Factor Xa complex with GTC000406
5MG2,X-RAY DIFFRACTION,1.93,36.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"20%PEG 10K, 0.20 M NaCl, 0.1M citrate/phosphate pH 4.2",277.15,2016-11-20,2017-05-03,5MG2,1302.0,1.0,137.0,85.0,,16.5,1.0,1.75,experimental,41.255,0.22039,0.18633,Crystal structure of the second bromodomain of human TAF1 in complex with BAY-299 chemical probe
7LL4,X-RAY DIFFRACTION,2.81,56.29,"VAPOR DIFFUSION, HANGING DROP",,1.8M Sodium Malonate pH 6.0,293.0,2021-02-03,2022-01-12,7LL4,2775.0,1.0,297.0,281.0,,35.52,1.0,1.31,experimental,23.8286,0.1942,0.1773,High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-114.
7LL5,X-RAY DIFFRACTION,2.81,56.29,"VAPOR DIFFUSION, HANGING DROP",,1.8M Sodium Malonate pH 6.0,293.0,2021-02-03,2022-01-12,7LL5,2805.0,1.0,293.0,367.0,,35.12,1.0,1.5,experimental,23.6495,0.221,0.1949,High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-150.
7REE,X-RAY DIFFRACTION,2.83,56.52,"VAPOR DIFFUSION, HANGING DROP",,1.8M Sodium Malonate pH 6.5,291.0,2021-07-12,2021-09-01,7REE,2814.0,1.0,297.0,371.0,,35.54,1.0,1.38,experimental,17.9605,0.2052,0.1732,High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to YM2-059
7RN6,X-RAY DIFFRACTION,2.68,54.08,"VAPOR DIFFUSION, HANGING DROP",,1.8M Sodium Malonate pH 6.5,291.0,2021-07-29,2021-11-03,7RN6,2495.0,1.0,298.0,203.0,,35.63,1.0,1.5,experimental,24.4269,0.2136,0.1892,High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to type-II inhibitor BBT594
8G24,X-RAY DIFFRACTION,2.19,43.83,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris, 0.2 M sodium chloride, 26% w/v PDB3350",293.0,2023-02-03,2023-04-26,8G24,4426.0,3.0,558.0,163.0,7.0,62.26,3.0,1.82,experimental,,0.2491,0.212,Crystal Structure of Cathepsin-G and Neutrophil Elastase Inhibited by S. aureus EapH2 at pH 5.5
5E1B,X-RAY DIFFRACTION,3.05,59.62,"VAPOR DIFFUSION, SITTING DROP",,"26% PEG3350, 16% tacsimate",277.0,2015-09-29,2015-10-28,5E1B,4368.0,4.0,494.0,436.0,,57.12,2.0,1.65,experimental,16.708,0.1759,0.1507,Crystal structure of NRMT1 in complex with SPKRIA peptide
5E1D,X-RAY DIFFRACTION,3.04,59.48,"VAPOR DIFFUSION, SITTING DROP",,"26% PEG3350, 16% tacsimate",277.0,2015-09-29,2015-10-28,5E1D,4372.0,4.0,494.0,389.0,,57.28,2.0,1.45,experimental,16.446,0.1688,0.1536,NTMT1 in complex with YPKRIA peptide
5E1M,X-RAY DIFFRACTION,3.06,59.76,"VAPOR DIFFUSION, SITTING DROP",,"26% PEG3350, 16% tacsimate",277.0,2015-09-29,2015-10-28,5E1M,4308.0,4.0,494.0,417.0,,57.05,2.0,1.75,experimental,18.374,0.1882,0.1611,Crystal structure of NTMT1 in complex with PPKRIA peptide
5E1O,X-RAY DIFFRACTION,3.06,59.86,"VAPOR DIFFUSION, SITTING DROP",,"26% PEG3350, 16% tacsimate",277.0,2015-09-29,2015-10-28,5E1O,4221.0,4.0,494.0,387.0,,57.08,2.0,2.0,experimental,21.142,0.1888,0.1512,Crystal structure of NTMT1 in complex with RPKRIA peptide
5E2A,X-RAY DIFFRACTION,2.98,58.79,"VAPOR DIFFUSION, SITTING DROP",,"26% PEG3350, 16% tacsimate",277.0,2015-09-30,2015-10-28,5E2A,4297.0,4.0,494.0,426.0,,57.15,2.0,1.75,experimental,17.264,0.184,0.1571,Crystal structure of NTMT1 in complex with N-terminally methylated SPKRIA peptide
5DV2,X-RAY DIFFRACTION,3.18,61.35,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes, 1.1M ammonium tartrate, 0.2M NDSB-201",293.0,2015-09-21,2016-05-18,5DV2,2924.0,1.0,398.0,192.0,,45.46,1.0,2.07,experimental,,0.2072,0.1826,Crystal structure of human CNOT6L in complex with cytidine-5'-monophosphate
6S55,X-RAY DIFFRACTION,4.07,69.78,"VAPOR DIFFUSION, SITTING DROP",,"0.1M trisHCl pH 7.0-8.0, 1.2-1.5M ammonium sulphate and 20-25% PEG3350",278.0,2019-06-30,2019-08-21,6S55,1360.0,1.0,130.0,220.0,,16.24,1.0,2.09,experimental,36.062,0.24328,0.18353,"Crystal structure of human ATAD2 bromodomain in complex with N-(4-bromo-3-((3-methylpiperidin-1-yl)sulfonyl)phenyl)-2-(2,5-dioxoimidazolidin-1-yl)acetamide"
6S56,X-RAY DIFFRACTION,3.99,69.15,"VAPOR DIFFUSION, SITTING DROP",,"0.1M trisHCl pH 7.0-8.0, 1.2-1.5M ammonium sulphate and 20-25% PEG3350",278.0,2019-06-30,2019-08-21,6S56,1346.0,1.0,130.0,195.0,,16.26,1.0,2.01,experimental,40.602,0.2763,0.22036,"Crystal structure of human ATAD2 bromodomain in complex with N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)-2-(2,5-dioxo-3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalen]-1-yl)acetamide"
6S57,X-RAY DIFFRACTION,4.07,69.79,"VAPOR DIFFUSION, SITTING DROP",,"0.1M trisHCl pH 7.0-8.0, 1.2-1.5M ammonium sulphate and 20-25% PEG3350",278.0,2019-06-30,2019-08-21,6S57,1327.0,1.0,130.0,183.0,,16.14,1.0,1.82,experimental,38.714,0.19995,0.17308,"Crystal structure of human ATAD2 bromodomain in complex withN-(3-(azepan-1-ylsulfonyl)-4-methylphenyl)-2-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)acetamide"
4QEG,X-RAY DIFFRACTION,2.25,45.31,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M CaCl2, 30% PEG 3350, 0.1 M Tris, 3% Isopropanol, pH 7.5, VAPOR DIFFUSION, SITTING DROP",,2014-05-16,2015-07-22,4QEG,825.0,1.0,91.0,121.0,,10.3,1.0,2.0,experimental,,0.2312,0.1834,Crystal structure of domain I10 from titin (space group P41)
5JDD,X-RAY DIFFRACTION,2.54,51.6,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris Propane pH 8.5, 20% [w/v] PEG 3350, 0.2 M sodium acetate",292.0,2016-04-16,2016-09-14,5JDD,2673.0,1.0,265.0,542.0,,29.71,1.0,1.53,experimental,,0.1965,0.1615,Crystal structure of I9-I11 tandem from titin (P212121)
7FQM,X-RAY DIFFRACTION,3.29,62.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQM,2644.0,1.0,321.0,179.0,,37.69,1.0,1.94,experimental,44.16,0.1966,0.1605,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000619a
7FQN,X-RAY DIFFRACTION,3.3,62.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQN,2642.0,1.0,321.0,177.0,,37.7,1.0,2.04,experimental,44.344,0.2097,0.1668,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000497a
7FQO,X-RAY DIFFRACTION,3.3,62.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQO,2644.0,1.0,321.0,177.0,,37.73,1.0,1.93,experimental,43.849,0.2004,0.162,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000523a
7FQP,X-RAY DIFFRACTION,3.3,62.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQP,2644.0,1.0,321.0,178.0,,37.71,1.0,1.88,experimental,38.844,0.2069,0.1769,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000505a
7FQQ,X-RAY DIFFRACTION,3.29,62.64,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQQ,2642.0,1.0,321.0,176.0,,37.72,1.0,1.88,experimental,42.047,0.2043,0.17,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000611a
7FQR,X-RAY DIFFRACTION,3.3,62.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQR,2673.0,1.0,321.0,174.0,,37.71,1.0,1.9,experimental,42.375,0.2062,0.1759,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000666a
7FQS,X-RAY DIFFRACTION,3.3,62.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQS,2661.0,1.0,321.0,177.0,,37.7,1.0,2.12,experimental,46.993,0.2209,0.1652,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000555a
7FQT,X-RAY DIFFRACTION,3.35,63.23,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQT,2642.0,1.0,321.0,176.0,,37.68,1.0,2.54,experimental,53.386,0.2368,0.1775,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000293a
7FQU,X-RAY DIFFRACTION,3.29,62.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQU,2749.0,1.0,321.0,172.0,,37.65,1.0,1.86,experimental,40.401,0.2229,0.1828,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000470b
7FQV,X-RAY DIFFRACTION,3.31,62.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQV,2646.0,1.0,321.0,178.0,,37.59,1.0,2.04,experimental,41.585,0.2227,0.1873,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with XST00000847b
7FQW,X-RAY DIFFRACTION,3.3,62.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQW,2633.0,1.0,321.0,173.0,,37.62,1.0,2.17,experimental,45.666,0.2329,0.1862,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOCR000171b
7FQX,X-RAY DIFFRACTION,3.31,62.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQX,2639.0,1.0,321.0,177.0,,37.63,1.0,2.46,experimental,48.947,0.2145,0.1672,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000601a
7FQY,X-RAY DIFFRACTION,3.3,62.76,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-19,2022-11-23,7FQY,2655.0,1.0,321.0,177.0,,37.68,1.0,2.13,experimental,46.049,0.21,0.163,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000278a
7FQZ,X-RAY DIFFRACTION,3.3,62.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-20,2022-11-23,7FQZ,2599.0,1.0,321.0,169.0,,37.77,1.0,2.09,experimental,47.765,0.2085,0.1665,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000203a
7FRE,X-RAY DIFFRACTION,3.31,62.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-20,2022-11-23,7FRE,2630.0,1.0,321.0,180.0,,37.47,1.0,1.85,experimental,41.349,0.1902,0.1585,PanDDA analysis group deposition -- Crystal structure of PTP1B after initial refinement with no ligand modeled
7FRF,X-RAY DIFFRACTION,3.3,62.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRF,2629.0,1.0,321.0,173.0,,37.7,1.0,2.15,experimental,46.9,0.219,0.1763,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000089a
7FRG,X-RAY DIFFRACTION,3.29,62.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRG,2651.0,1.0,321.0,179.0,,37.67,1.0,1.84,experimental,45.45,0.1976,0.164,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z31222641
7FRH,X-RAY DIFFRACTION,3.3,62.76,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRH,2637.0,1.0,321.0,178.0,,37.59,1.0,1.84,experimental,37.483,0.194,0.1624,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z2856434762
7FRI,X-RAY DIFFRACTION,3.3,62.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRI,2637.0,1.0,321.0,179.0,,37.71,1.0,1.86,experimental,40.817,0.1949,0.1608,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z321318226
7FRJ,X-RAY DIFFRACTION,3.3,62.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRJ,2641.0,1.0,321.0,181.0,,37.62,1.0,1.8,experimental,41.33,0.1968,0.1636,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z2856434770
7FRK,X-RAY DIFFRACTION,3.3,62.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRK,2621.0,1.0,321.0,177.0,,37.64,1.0,1.8,experimental,39.846,0.1892,0.1583,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z30820160
7FRL,X-RAY DIFFRACTION,3.3,62.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRL,2633.0,1.0,321.0,180.0,,37.63,1.0,1.79,experimental,40.476,0.1918,0.1619,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z2856434917
7FRM,X-RAY DIFFRACTION,3.3,62.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRM,2626.0,1.0,321.0,176.0,,37.71,1.0,1.91,experimental,39.993,0.1915,0.1597,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z509756472
7FRN,X-RAY DIFFRACTION,3.3,62.76,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRN,2642.0,1.0,321.0,177.0,,37.69,1.0,1.85,experimental,41.162,0.1986,0.1638,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z915492990
7FRO,X-RAY DIFFRACTION,3.3,62.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRO,2637.0,1.0,321.0,177.0,,37.62,1.0,1.93,experimental,41.497,0.1876,0.1578,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z744754722
7FRP,X-RAY DIFFRACTION,3.29,62.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRP,2623.0,1.0,321.0,176.0,,37.69,1.0,1.77,experimental,42.314,0.2029,0.1695,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with XST00000245b
7FRQ,X-RAY DIFFRACTION,3.29,62.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-24,2022-11-23,7FRQ,2640.0,1.0,321.0,173.0,,37.89,1.0,2.01,experimental,46.699,0.2169,0.1695,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with XST00000217b
7FRR,X-RAY DIFFRACTION,3.29,62.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-25,2022-11-23,7FRR,2728.0,1.0,321.0,166.0,,37.63,1.0,1.83,experimental,41.83,0.214,0.175,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with Z2856434906
7FRS,X-RAY DIFFRACTION,3.3,62.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-26,2022-11-23,7FRS,2630.0,1.0,321.0,180.0,,37.47,1.0,1.83,experimental,40.734,0.1901,0.16,PanDDA analysis group deposition of ground-state model of PTP1B
7FRT,X-RAY DIFFRACTION,3.3,62.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-26,2022-11-23,7FRT,2630.0,1.0,321.0,180.0,,37.47,1.0,1.86,experimental,39.475,0.1902,0.1597,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster 1"
7FRU,X-RAY DIFFRACTION,3.29,62.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.3 M magnesium acetate, 13.5% PEG 8000, 2% ethanol, and 1 mM BME",293.0,2022-10-26,2022-11-23,7FRU,2630.0,1.0,321.0,180.0,,37.47,1.0,1.98,experimental,46.455,0.2128,0.1659,"PanDDA analysis group deposition of ground-state model of PTP1B, using pre-clustering, cluster 2"
7MM1,X-RAY DIFFRACTION,3.26,62.29,"VAPOR DIFFUSION, HANGING DROP",,"100mM HEPES (pH 6.8 - 7.6), 250mM magnesium acetate, 11-15% PEG8000 (w/v), 10% glycerol (v/v), 6% ethanol (v/v),  0.1% BME (v/v). TCS401 was co-crystallized using a >5-fold molar excess.",277.0,2021-04-29,2021-05-12,7MM1,2793.0,1.0,321.0,159.0,,37.86,1.0,1.85,experimental,34.16,0.1385,0.129,PTP1B in complex with TCS401 by Native S-SAD at Room Temperature
7KK6,X-RAY DIFFRACTION,2.29,46.39,VAPOR DIFFUSION,,"Buffer: 0.1 M HEPES (pH 7.00)
Precipitant: 3.0 M Ammonium sulfate",277.0,2020-10-27,2021-01-06,7KK6,5734.0,2.0,704.0,172.0,,79.65,1.0,2.06,experimental,42.47,0.271,0.206,Structure of the catalytic domain of PARP1 in complex with veliparib
6D06,X-RAY DIFFRACTION,2.6,57.76,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES:NaOH pH 6.5, 14% PEG 20,000",298.0,2018-04-10,2019-02-20,6D06,6877.0,4.0,852.0,48.0,,106.17,1.0,2.55,experimental,64.39,0.25518,0.19012,Human ADAR2d E488Y mutant complexed with dsRNA containing an abasic site opposite the edited base
6U2N,X-RAY DIFFRACTION,2.69,54.25,VAPOR DIFFUSION,,"(10-22)% PEG 10000, 0.1M Tris, pH 8.5, 10% Ethylene Glycol, 1% BAM",303.0,2019-08-20,2019-11-06,6U2N,4387.0,2.0,1414.0,125.0,12.0,152.62,1.0,2.15,experimental,47.23,0.234,0.19,PCSK9 in complex with compound 4
6U3X,X-RAY DIFFRACTION,2.88,57.22,"VAPOR DIFFUSION, SITTING DROP",,"10-22% PEG 10K, 0.1M Tris, pH 8.5, 10% ethylene glycol, 1% BAM",303.0,2019-08-22,2019-11-06,6U3X,4439.0,2.0,1414.0,69.0,12.0,152.51,1.0,2.64,experimental,47.5,0.284,0.248,PCSK9 in complex with compound 2
4W5S,X-RAY DIFFRACTION,2.85,56.78,"VAPOR DIFFUSION, HANGING DROP",6.5,"15% Peg 3350, PCTP Buffer pH 6.5, 100 mM MgCl2",293.0,2014-08-18,2015-05-13,4W5S,1799.0,1.0,211.0,89.0,,24.66,1.0,2.8,experimental,46.71,0.2632,0.1974,Tankyrase in complex with compound
8DSO,X-RAY DIFFRACTION,3.99,70.22,"VAPOR DIFFUSION, SITTING DROP",9.0,"0.1 M BTP pH 9, 4M potassium formate, and 2% PEG MME 2K",293.0,2022-07-22,2023-03-08,8DSO,2837.0,2.0,376.0,72.0,,44.61,2.0,2.334,experimental,70.79,0.2918,0.2423,"Structure of cIAP1, BTK and BCCov"
5WXT,X-RAY DIFFRACTION,2.17,43.3,"VAPOR DIFFUSION, SITTING DROP",,"50 mM sodium citrate, pH 4.6, and 2.0 M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2017-01-08,2018-07-11,5WXT,2017.0,1.0,253.0,52.0,5.0,28.89,1.0,2.1,experimental,43.693,0.266,0.21346,Crystal structure of uPA-S195A in complex with S2444
6AG2,X-RAY DIFFRACTION,2.06,40.32,"VAPOR DIFFUSION, SITTING DROP",,"2.0M ammonium sulfate, 50mM sodium citrate (pH 4.6), 5% PEG 400",298.0,2018-08-09,2019-09-18,6AG2,2062.0,1.0,253.0,102.0,5.0,28.84,1.0,1.77,experimental,22.966,0.25221,0.21951,uPA-HMA
6AG3,X-RAY DIFFRACTION,2.15,42.92,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2018-08-09,2019-09-18,6AG3,1971.0,1.0,253.0,14.0,5.0,28.78,1.0,2.48,experimental,47.81,0.267,0.196,"Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide"
6L04,X-RAY DIFFRACTION,2.12,42.02,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5%
PEG 400",298.0,2019-09-26,2020-09-30,6L04,2037.0,1.0,245.0,72.0,5.0,28.03,1.0,2.21,experimental,36.87,0.217,0.183,Crystal structure of uPA_H99Y in complex with 31F
6L05,X-RAY DIFFRACTION,2.16,42.98,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5%
PEG 400",298.0,2019-09-26,2020-09-30,6L05,2026.0,1.0,245.0,62.0,5.0,28.0,1.0,2.49,experimental,35.23,0.261,0.175,Crystal structure of uPA_H99Y in complex with 50F
4XX5,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, HANGING DROP",8.5,"25% PEG3350, 200 MM LITHIUM SULFATE,10 MM DTT, 10 MM EDTA, 100 MM TRIS",298.0,2015-01-29,2015-08-05,4XX5,6870.0,1.0,966.0,5.0,,111.06,1.0,2.76,experimental,58.3277,0.2742,0.1981,Structure of PI3K gamma in complex with an inhibitor
4XZ4,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, HANGING DROP",8.5,"25% PEG3350, 200MM Lithium Sulfate, 10 MM DTT, 10 MM EDTA, 100 MM Tris",298.0,2015-02-03,2016-02-03,4XZ4,6871.0,1.0,966.0,6.0,,111.06,1.0,2.6,experimental,46.165,0.26197,0.19891,Structure of PI3K gamma in complex with an inhibitor
5H43,X-RAY DIFFRACTION,2.89,57.38,"VAPOR DIFFUSION, HANGING DROP",,"3%(v/v) Tacsimate pH5.0, 0.1M Sodium citrate tribasic dehydrate pH5.6, 16%(w/v) PEG 3350",293.15,2016-10-28,2017-10-25,5H43,3614.0,3.0,454.0,146.0,,49.49,3.0,2.3,experimental,68.447,0.24253,0.21144,Structural and mechanistical studies of the nuclear import by Importin-alpha
6GDM,X-RAY DIFFRACTION,2.3,46.54,"VAPOR DIFFUSION, SITTING DROP",7.2,"35.0%w/v MPEG 2000, 0.2M (NH4)2SO4, 0.1M HEPES/NaOHpH=7.2, 0.02M Mercaptoethanol",293.0,2018-04-24,2018-05-30,6GDM,3295.0,1.0,368.0,394.0,,43.64,1.0,1.91,experimental,33.486,0.24265,0.18204,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6GDQ,X-RAY DIFFRACTION,2.31,46.73,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4, 33.0%w/v MPEG 2000, 0.1M HEPES/NaOHpH=7.2, 0.02M Mercaptoethanol",293.0,2018-04-24,2018-05-30,6GDQ,3068.0,1.0,368.0,231.0,,43.54,1.0,1.86,experimental,37.598,0.226,0.18,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6GE0,X-RAY DIFFRACTION,2.31,46.86,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4, 33.0%w/v MPEG 2000, 0.1M HEPES/NaOHpH=7.2, 0.02M Mercaptoethanol",293.0,2018-04-25,2018-05-30,6GE0,3298.0,1.0,368.0,404.0,,43.59,1.0,1.82,experimental,39.662,0.21,0.162,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
8VQ3,X-RAY DIFFRACTION,2.9,57.63,"VAPOR DIFFUSION, SITTING DROP",,"0.21 M sodium citrate tribasic dihydrate, 19.09% PEG3350",295.0,2024-01-17,2024-01-31,8VQ3,4880.0,2.0,583.0,310.0,,67.74,2.0,1.84,experimental,46.2,0.2169,0.1993,CDK2-CyclinE1 in complex with allosteric inhibitor I-198.
8VQ4,X-RAY DIFFRACTION,3.0,58.94,"VAPOR DIFFUSION, SITTING DROP",,"0.21 M sodium citrate tribasic dihydrate, 19.5% PEG3350",294.0,2024-01-17,2024-01-31,8VQ4,4789.0,2.0,583.0,226.0,,67.77,2.0,1.9,experimental,49.14,0.2186,0.1915,CDK2-CyclinE1 in complex with allosteric inhibitor I-125A.
6AUD,X-RAY DIFFRACTION,2.41,48.89,VAPOR DIFFUSION,8.5,"PEG 3350, 0.2M NH4SO4, 0.1M Tris-HCl 8.5",289.0,2017-08-31,2017-11-15,6AUD,7121.0,1.0,966.0,291.0,,111.18,1.0,2.015,experimental,,0.2331,0.2027,"PI3K-gamma K802T in complex with Cpd 8 10-((1-(tert-butyl)piperidin-4-yl)sulfinyl)-2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine"
7Z61,X-RAY DIFFRACTION,2.34,47.51,VAPOR DIFFUSION,8.0,"20 % PEG3350, 0.175 M ammonium sulfate, 0.001 M TCEP, 0.1 M Hepes pH 8.0",293.0,2022-03-10,2022-07-13,7Z61,6778.0,1.0,966.0,,,111.12,1.0,2.738,experimental,141.29,0.2757,0.2174,Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 18)
7NPI,X-RAY DIFFRACTION,4.02,69.4,"VAPOR DIFFUSION, SITTING DROP",,"3% w/v Dextran sulphate sodium salt
0.1 M BICINE pH 8.5
15% w/v PEG 20,000",293.15,2021-02-26,2021-09-15,7NPI,33767.0,42.0,4571.0,16.0,,518.48,2.0,2.81,experimental,68.21,0.2877,0.2284,Crystal structure of Mindy2 (C266A) in complex with Lys48-linked penta-ubiquitin (K48-Ub5)
7ACD,X-RAY DIFFRACTION,2.14,42.51,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2020-09-10,2020-10-28,7ACD,3625.0,2.0,536.0,123.0,1.0,62.41,2.0,2.5,experimental,44.88,0.2317,0.1874,Crystal structure of the human METTL3-METTL14 complex with compound T30 (UZH1a)
8FP5,X-RAY DIFFRACTION,2.04,39.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG 3350, 10% ethylene glycol, 50mM HEPES, pH 7.5",291.0,2023-01-04,2023-05-31,8FP5,2529.0,1.0,298.0,146.0,,34.57,1.0,1.7,experimental,,0.2304,0.1942,CDK2 liganded with ATP and Mg2+
6TYV,X-RAY DIFFRACTION,2.09,41.19,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Na-HEPES pH 7.5, 25 % (w/v) PEG3000",295.0,2019-08-09,2019-11-27,6TYV,1807.0,2.0,247.0,113.0,,28.12,2.0,1.92611100742,experimental,46.2047717462,0.234844595656,0.192609532857,Structure of Ku80 von Willebrand domain complexed with WRN Ku Binding Motif
6XIC,X-RAY DIFFRACTION,2.58,52.36,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% PEG3350, 200mM CaCl2, 100mM MES pH 6",291.0,2020-06-19,2020-11-18,6XIC,3280.0,3.0,438.0,303.0,3.0,48.01,3.0,1.377,experimental,20.54,0.2214,0.2034,PCSK9(deltaCRD) in complex with cyclic peptide 40
6XID,X-RAY DIFFRACTION,2.58,52.34,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% PEG3350, 200mM CaCl2, 100mM MES pH 6",291.0,2020-06-19,2020-11-18,6XID,3290.0,3.0,441.0,329.0,3.0,48.22,3.0,1.482,experimental,22.13,0.2049,0.1868,PCSK9(deltaCRD) in complex with cyclic peptide 51
6XIE,X-RAY DIFFRACTION,2.56,51.87,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% PEG3350, 200mM CaCl2, 100mM MES pH 6",291.0,2020-06-19,2020-11-18,6XIE,3210.0,3.0,439.0,344.0,3.0,48.03,3.0,1.43,experimental,28.27,0.2214,0.1993,PCSK9(deltaCRD) in complex with cyclic peptide 77
6XIF,X-RAY DIFFRACTION,2.49,50.63,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% PEG3350, 200mM CaCl2, 100mM MES pH 6",291.0,2020-06-19,2020-11-18,6XIF,3121.0,3.0,439.0,268.0,3.0,48.07,3.0,1.774,experimental,32.32,0.2037,0.1867,PCSK9(deltaCRD) in complex with cyclic peptide 83
7MF0,X-RAY DIFFRACTION,2.98,58.76,VAPOR DIFFUSION,5.6,"15% MPD, 10% PEG 8K, 0.1M MgCl2, 0.1M sodium citrate pH 5.6",293.0,2021-04-08,2021-05-19,7MF0,2155.0,1.0,317.0,,,37.27,1.0,2.809,experimental,90.189,0.2725,0.232,"Co-crystal structure of PERK with inhibitor (R)-2-amino-N-cyclopropyl-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)nicotinamide"
6VPG,X-RAY DIFFRACTION,2.93,58.08,EVAPORATION,7.0,"0.1 M HEPES pH 7, 0.9 M KCl, 1.08 M ammonium sulfate, 12% glycerol",298.0,2020-02-03,2020-08-05,6VPG,2436.0,1.0,292.0,63.0,,34.76,1.0,2.64,experimental,,0.2453,0.1991,TPX2 residues 7-20 fused to Aurora A residues 116-389 in complex with AMP-PNP
6JUX,X-RAY DIFFRACTION,2.66,53.68,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES, 1.5 M Ammonium sulfate",293.0,2019-04-15,2020-04-15,6JUX,2600.0,1.0,299.0,182.0,,34.93,1.0,1.75,experimental,40.837,0.226,0.194,Crystal structure of human ALK2 kinase domain with R206H mutation in complex with RK-71807
7DPJ,X-RAY DIFFRACTION,2.56,51.89,"VAPOR DIFFUSION, HANGING DROP",,"PEG400, SODIUM ACETATE, CALCIUM        
 ACETATE",293.0,2020-12-19,2021-07-28,7DPJ,1368.0,1.0,171.0,65.0,,19.96,1.0,1.976,experimental,22.144,0.221,0.1895,H-Ras Q61L in complex with GppNHp (state 1) after structural transition by humidity control
9ATK,X-RAY DIFFRACTION,2.54,51.48,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium citrate (pH 5.5)
12% (w/v) PEG-6K",293.0,2024-02-27,2024-06-12,9ATK,17989.0,12.0,2196.0,767.0,28.0,250.34,3.0,2.11,experimental,,0.2325,0.1786,BIFUNCTIONAL INHIBITION OF NEUTROPHIL ELASTASE AND CATHEPSIN G by Eap4 of S. aureus
7XB0,X-RAY DIFFRACTION,3.29,62.62,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M ammonium acetate, 0.1 M Bis-Tris",291.0,2022-03-19,2022-07-06,7XB0,6557.0,2.0,791.0,,7.0,93.24,2.0,2.9,experimental,58.03,0.2552,0.2156,Crystal structure of Omicron BA.2 RBD complexed with hACE2
7XB1,X-RAY DIFFRACTION,3.11,60.45,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M Imidazole pH7.0, 12% w/v Polyethylene glycol 20000",291.0,2022-03-19,2022-07-06,7XB1,6652.0,2.0,791.0,50.0,7.0,93.68,2.0,2.7,experimental,50.39,0.248,0.214,Crystal structure of Omicron BA.3 RBD complexed with hACE2
5FXQ,X-RAY DIFFRACTION,2.36,47.85,,,,,2016-03-02,2016-10-19,5FXQ,2623.0,1.0,308.0,242.0,,35.62,1.0,2.3,experimental,36.221,0.27481,,IGFR-1R complex with a pyrimidine inhibitor.
5FXR,X-RAY DIFFRACTION,2.41,48.99,,,,,2016-03-02,2016-10-19,5FXR,2599.0,1.0,308.0,194.0,,35.59,1.0,2.4,experimental,43.009,0.29442,0.22709,IGFR-1R complex with a pyrimidine inhibitor.
7ABE,X-RAY DIFFRACTION,2.63,53.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene glycol, 0.1 M HEPES pH 7.5",293.0,2020-09-07,2021-10-06,7ABE,11744.0,4.0,1456.0,762.0,,173.85,1.0,1.83,experimental,36.868,0.2082,0.1789,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-769
7ABJ,X-RAY DIFFRACTION,2.64,53.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene glycol, 0.1 M HEPES pH 7.5",293.0,2020-09-07,2021-10-06,7ABJ,11436.0,4.0,1456.0,534.0,,173.21,1.0,2.11,experimental,47.934,0.2178,0.1809,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-1361
4XVQ,X-RAY DIFFRACTION,1.88,34.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"152mM Ca(OAc)2, 24.8% PEG 3350, 4.8% stabilization buffer at pH 7.5.",291.15,2015-01-27,2015-06-17,4XVQ,1394.0,1.0,166.0,82.0,,19.5,1.0,1.887,experimental,29.64,0.2536,0.2025,H-Ras Y137E
5IL2,X-RAY DIFFRACTION,2.66,53.7,"VAPOR DIFFUSION, HANGING DROP",5.7,"PEG 8000, sodium citrate",291.0,2016-03-04,2016-05-25,5IL2,4393.0,2.0,512.0,376.0,1.0,59.85,2.0,1.606,experimental,,0.1992,0.1848,Crystal structure of SAH-bound METTL3-METTL14 complex
5B6C,X-RAY DIFFRACTION,2.33,47.18,"VAPOR DIFFUSION, HANGING DROP",7.5,"21%(w/v) PEG 8000, 2.9mM n-nonyl-beta-thiomaltoside, 0.1M HEPES, pH 7.5",293.15,2016-05-26,2017-01-04,5B6C,1740.0,2.0,185.0,274.0,,20.94,2.0,1.55,experimental,17.623,0.1995,0.15797,Structural Details of Ufd1 binding to p97
6BGQ,X-RAY DIFFRACTION,2.14,42.54,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-29,2018-02-21,6BGQ,4363.0,6.0,568.0,326.0,,65.26,3.0,1.97,experimental,,0.2244,0.1804,Caspase-3 Mutant - S150D
6K1Q,X-RAY DIFFRACTION,4.22,70.88,LIPIDIC CUBIC PHASE,7.5,"30% PEG300, 150 mM NaH2PO4,10 mM TCEP, 100 mM Bis-tris",293.0,2019-05-11,2019-07-17,6K1Q,3541.0,1.0,464.0,34.0,1.0,55.93,1.0,2.7,experimental,83.7693,0.2653,0.2216,Human endothelin receptor type-B in complex with inverse agonist IRL2500
7ANQ,X-RAY DIFFRACTION,2.39,48.51,"VAPOR DIFFUSION, SITTING DROP",,"Protein: Purified PCSK9/P1.40 complex at 5.3 mg/ml Precipitant: 10% PEG 4.000, 0.2M imidazole malate, pH 7.0 Cryoprotectant: 40% SM3 (25 % diethylene glycol + 25 % ethylene glycol + 25 % glycerol + 25 % 1,4-dioxane) 25% PEG 4.000, 0.2M imidazole malate, pH 7.0",293.0,2020-10-12,2021-10-20,7ANQ,2819.0,2.0,358.0,114.0,10.0,39.52,2.0,2.2,experimental,52.02,0.256,0.213,Complete PCSK9 C-ter domain in complex with VHH P1.40
6YQ1,X-RAY DIFFRACTION,2.79,55.93,"VAPOR DIFFUSION, HANGING DROP",7.5,"15% PEG 3350, 0.2 M Na acetate",293.0,2020-04-16,2021-02-10,6YQ1,9732.0,4.0,1128.0,922.0,4.0,131.42,1.0,1.784,experimental,30.99,0.2139,0.183,"FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-(3-{[2-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide"
6E7K,X-RAY DIFFRACTION,2.87,57.18,"VAPOR DIFFUSION, SITTING DROP",,"200 mM magnesium acetate, 20% PEG3350",293.0,2018-07-26,2018-12-19,6E7K,8045.0,4.0,1158.0,16.0,21.0,132.62,2.0,2.8,experimental,94.934,0.23545,0.19534,Structure of the lipoprotein lipase GPIHBP1 complex that mediates plasma triglyceride hydrolysis
5E7R,X-RAY DIFFRACTION,4.07,69.77,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.65-0.75 M sodium citrate pH 7.0, 0.2 M NaCl, 0.1 M Tris pH 7.0, and 5mM adenosine. Adenosine bound TAK1-TAB1 crystals are backsoaked with inhibitor",293.0,2015-10-13,2016-09-21,5E7R,2253.0,1.0,314.0,52.0,,35.95,1.0,2.11,experimental,,0.2456,0.22,Crystal structure of TL10-81 bound to TAK1-TAB1
5V5N,X-RAY DIFFRACTION,4.04,69.52,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.75M NaCitrate, 0.1M Tris-HCL, 0.2M NaCl, pH 7.0, 10mM DTT. 20% Ethyleneglycol as cryoprotectant.",293.0,2017-03-14,2017-08-30,5V5N,2489.0,1.0,307.0,115.0,,35.1,1.0,2.006,experimental,,0.222,0.1925,Crystal structure of Takinib bound to TAK1
7S4E,X-RAY DIFFRACTION,2.68,54.05,"VAPOR DIFFUSION, HANGING DROP",7.85,"0.1 M HEPES, pH 7.85, 13% PEG 3350, 0.2 M sodium formate",277.15,2021-09-08,2022-10-05,7S4E,7652.0,8.0,974.0,90.0,,114.29,4.0,2.25,experimental,61.139,0.2587,0.219,Crystal Structure of ligand ACBi1 in complex with bromodomain of human Smarca2 and pVHL:ElonginC:ElonginB complex
8G68,X-RAY DIFFRACTION,2.26,45.58,VAPOR DIFFUSION,6.2,"Reservoir solution: 50 mM MES (pH 6.2), 14% PEG6000, 50 mM MgCl2;
Protein solution: 10.3 mg/ml PTP-1B 1-298 in 25 mM Hepes pH 7.2, 150 mM NaCl, 1 mM EDTA, 2 mM DTT",278.0,2023-02-14,2023-04-26,8G68,4983.0,2.0,596.0,237.0,,69.84,1.0,1.82,experimental,37.002,0.25441,0.20316,Wildtype PTP1b in complex with DES5742
5D1B,X-RAY DIFFRACTION,2.4,48.81,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM BisTris (pH 6.5), 10% (w/v) PEG 35000, 4 mM TCEP",294.0,2015-08-04,2015-10-21,5D1B,5594.0,2.0,778.0,17.0,,87.5,1.0,2.9,experimental,,0.228,0.193,Crystal structure of G117E HDAC8 in complex with TSA
5D1C,X-RAY DIFFRACTION,2.42,49.13,"VAPOR DIFFUSION, SITTING DROP",8.0,"100 mM Tris (pH 8.0), 10% (w/v) PEG 3350, 4 mM TCEP",294.0,2015-08-04,2015-10-21,5D1C,6892.0,4.0,790.0,819.0,,88.37,2.0,1.422,experimental,,0.167,0.1464,Crystal structure of D233G-Y306F HDAC8 in complex with a tetrapeptide substrate
5FCW,X-RAY DIFFRACTION,2.51,50.98,"VAPOR DIFFUSION, HANGING DROP",5.3,"4% PEG 3350, 50 mM buffer (MES, pH 5.3)",298.0,2015-12-15,2016-10-26,5FCW,6128.0,2.0,766.0,414.0,,86.9,1.0,1.979,experimental,,0.2157,0.1719,HDAC8 Complexed with a Hydroxamic Acid
5THS,X-RAY DIFFRACTION,2.43,49.31,"VAPOR DIFFUSION, SITTING DROP",,"100 mM imidazole (pH 7.0), 15% w/v PEG 35000, 4 mM TCEP",294.0,2016-09-30,2016-12-21,5THS,6054.0,2.0,778.0,303.0,,88.2,1.0,1.9,experimental,,0.2083,0.1767,Crystal Structure of G302A HDAC8 in complex with M344
5THU,X-RAY DIFFRACTION,2.5,50.81,"VAPOR DIFFUSION, SITTING DROP",,"100 mM BisTris (pH 6.5), 10% w/v PEG 35000, 4 mM TCEP",277.0,2016-09-30,2016-12-21,5THU,5988.0,2.0,778.0,391.0,,87.58,1.0,1.95,experimental,,0.2002,0.1753,Crystal Structure of G304A HDAC8 in complex with M344
5THV,X-RAY DIFFRACTION,2.37,48.2,"VAPOR DIFFUSION, SITTING DROP",,"200 mM BisTris (pH 6.5), 13% w/v PEG 4000, 4 mM TCEP",294.0,2016-09-30,2016-12-21,5THV,6052.0,2.0,778.0,349.0,,89.01,1.0,1.868,experimental,,0.2097,0.1724,Crystal Structure of G305A HDAC8 in complex with M344
6BFL,X-RAY DIFFRACTION,2.17,43.3,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-26,2018-02-21,6BFL,2244.0,3.0,283.0,212.0,,32.17,3.0,1.87,experimental,,0.1897,0.1541,"Caspase-3 Mutant- D9A,D28A,T245D"
6BFO,X-RAY DIFFRACTION,2.13,42.39,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-26,2018-02-21,6BFO,2394.0,3.0,284.0,285.0,,32.69,3.0,1.54,experimental,,0.1742,0.1505,Caspase-3 Mutant- T245D
6BG1,X-RAY DIFFRACTION,2.16,43.01,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-27,2018-02-21,6BG1,2252.0,3.0,284.0,198.0,,32.32,3.0,1.88,experimental,,0.1927,0.1625,"Caspase-3 Mutant - D9A,D28A,S150E"
6BGR,X-RAY DIFFRACTION,2.16,42.97,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-29,2018-02-21,6BGR,2106.0,3.0,283.0,132.0,,32.42,3.0,2.16,experimental,,0.2341,0.1744,Caspase-3 Mutant - S150E
6BGS,X-RAY DIFFRACTION,2.15,42.76,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-29,2018-02-21,6BGS,2385.0,3.0,284.0,293.0,,32.42,3.0,1.6,experimental,,0.1769,0.1511,Caspase-3 Mutant - S150Y
6BHA,X-RAY DIFFRACTION,2.17,43.23,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-30,2018-02-21,6BHA,2282.0,3.0,284.0,203.0,,32.34,3.0,1.603,experimental,,0.1843,0.1597,Caspase-3 Mutant - T152V
5OCA,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",8.3,"0.1 M Tris-HCl, 0.2 M Sodium acetate, 10-15% PEG 4000, 3-6% Dextran sodium salt (Mr 5000), pH 8.3, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2017-06-30,2017-09-20,5OCA,8500.0,4.0,1121.0,788.0,16.0,120.34,4.0,2.3,experimental,,0.1951,0.1672,PCSK9:Fab Complex with Dextran Sulfate
4XX9,X-RAY DIFFRACTION,2.18,43.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"Precipitant: 0.1M HEPES, pH 7.5, 1.2M Na Citrate. Protein (21 mg/mL): 25mM Tris, pH 7.5, 0.5M NaCl, 1mM DTT, 15mM EDTA, 15mM ATP",291.0,2015-01-29,2015-10-21,4XX9,2774.0,1.0,310.0,276.0,,36.83,1.0,1.4,experimental,22.2821,0.1651,0.1286,Crystal structure of PDK1 in complex with ATP and the PIF-pocket ligand RF4
6CMP,X-RAY DIFFRACTION,2.16,39.04,"VAPOR DIFFUSION, SITTING DROP",,"200 mM lithium nitrate, 20% PEG 3,350",291.0,2018-03-06,2018-11-14,6CMP,8652.0,2.0,1064.0,763.0,,122.06,1.0,1.8,experimental,34.52,0.2306,0.2012,Closed structure of inactive SHP2 mutant C459E
6HWO,X-RAY DIFFRACTION,2.62,53.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES pH 7.5",293.0,2018-10-12,2019-07-24,6HWO,11546.0,4.0,1456.0,590.0,,174.3,1.0,1.99,experimental,43.247,0.25539,0.19819,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-1335
6HK3,X-RAY DIFFRACTION,3.44,64.21,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.2M potassium fluoride
22% PEG 3350",293.0,2018-09-05,2019-07-17,6HK3,5946.0,3.0,708.0,192.0,,82.44,2.0,2.35,experimental,56.4885,0.2335,0.2041,Crystal structure of GSK-3B in complex with pyrazine inhibitor C44
7BPY,X-RAY DIFFRACTION,2.83,56.51,VAPOR DIFFUSION,,"0.1 M Tris (pH 8.5), 30 %(w/v) PEG3350",277.0,2020-03-23,2020-11-11,7BPY,4644.0,4.0,576.0,103.0,,66.27,2.0,2.09,experimental,36.8841,0.2155,0.1933,X-ray structure of human PPARalpha ligand binding domain-clofibric acid-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization
6I6R,X-RAY DIFFRACTION,2.38,48.4,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 0.26 M Sodium potassium tartrate, 20 % w/v PEG3350",293.0,2018-11-15,2018-12-05,6I6R,9957.0,2.0,1254.0,243.0,2.0,143.04,1.0,2.02,experimental,37.352,0.23985,0.21293,New Irreversible a-l-Iduronidase Inhibitors and Activity-Based Probes
5IJ7,X-RAY DIFFRACTION,2.18,43.63,"VAPOR DIFFUSION, SITTING DROP",6.6,"24.0 %w/v PEG monomethyl ether 2000,
0.0050 M TCEP hydrochloride, 0.1 M Bis_tris (pH 6.60)",286.0,2016-03-01,2016-05-04,5IJ7,15642.0,6.0,2392.0,36.0,1.0,275.96,3.0,2.62,experimental,68.45,0.238,0.1912,Structure of Hs/AcPRC2 in complex with a pyridone inhibitor
5IJ8,X-RAY DIFFRACTION,2.25,45.23,"VAPOR DIFFUSION, SITTING DROP",5.8,"24.0 %w/v PEG monomethyl ether 2000, 0.0050 M TCEP hydrochloride, 0.1 M MES (pH 5.80)",286.0,2016-03-01,2016-05-04,5IJ8,15580.0,6.0,2392.0,,3.0,275.86,3.0,2.99,experimental,69.73,0.2396,0.1881,Structure of the primary oncogenic mutant Y641N Hs/AcPRC2 in complex with a pyridone inhibitor
7SE6,X-RAY DIFFRACTION,2.98,58.71,"VAPOR DIFFUSION, HANGING DROP",,2.75-3.3 M Sodium Formate,293.0,2021-09-30,2022-02-09,7SE6,1870.0,1.0,242.0,71.0,,26.73,1.0,1.99,experimental,50.34,0.2595,0.2263,Crystal structure of human Fibrillarin in ligand-free state
7SEB,X-RAY DIFFRACTION,2.99,58.92,"VAPOR DIFFUSION, HANGING DROP",,2.75-3.3 M Sodium Formate,293.0,2021-09-30,2022-02-09,7SEB,1941.0,1.0,242.0,136.0,,26.98,1.0,1.81,experimental,36.71,0.2328,0.1942,Crystal structure of human Fibrillarin in complex with compound 2 from single soak
7SED,X-RAY DIFFRACTION,3.0,59.02,"VAPOR DIFFUSION, HANGING DROP",,2.75-3.3 M Sodium Formate,293.0,2021-09-30,2022-02-09,7SED,1878.0,1.0,242.0,89.0,,26.97,1.0,1.9,experimental,38.56,0.2249,0.1886,Crystal structure of human Fibrillarin in complex with compound 2a
8OG5,X-RAY DIFFRACTION,2.75,55.21,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES pH6.5, 2.13M Lithium acetate",293.0,2023-03-19,2023-06-14,8OG5,2657.0,1.0,367.0,207.0,,42.68,1.0,2.2,experimental,49.263,0.2354,0.1968,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 1
8OG6,X-RAY DIFFRACTION,2.78,55.73,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1M Tris pH 7.0, 2.13M Lithium acetate",293.0,2023-03-19,2023-06-14,8OG6,2657.0,1.0,367.0,197.0,,42.35,1.0,2.245,experimental,47.665,0.2308,0.2027,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 1
8OG7,X-RAY DIFFRACTION,2.72,54.8,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES pH6.5, 2.13M Lithium acetate",293.0,2023-03-19,2023-06-14,8OG7,2602.0,1.0,367.0,162.0,,42.17,1.0,2.64,experimental,46.697,0.20598,0.15759,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 2
8OG8,X-RAY DIFFRACTION,2.69,54.35,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES pH6.5, 2.13M Lithium acetate",293.0,2023-03-19,2023-06-14,8OG8,2659.0,1.0,367.0,173.0,,42.49,1.0,2.11,experimental,30.084,0.2125,0.1736,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 3
8OOD,X-RAY DIFFRACTION,2.67,53.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"2.13M LiSO4, 0.1M Tris pH 7.5",293.0,2023-04-05,2023-05-24,8OOD,3022.0,1.0,367.0,316.0,,43.87,1.0,1.497,experimental,20.866,0.186,0.17,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 15
6QH3,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M magnesium chloride, 0.1 M hepes pH 7.5, 25% PEG 3350",293.0,2019-01-15,2019-07-17,6QH3,2270.0,2.0,312.0,,,35.08,1.0,2.9,experimental,,0.23,0.1843,Catalytic domain of the human ubiquitin-conjugating enzyme UBE2S C118M
6C4D,X-RAY DIFFRACTION,2.24,45.18,VAPOR DIFFUSION,7.2,"0.25 M ammonium iodide, 0.03 M glycyl-glycyl-glycine and polyethylene glycol (PEG) 3350 15-25%",277.0,2018-01-11,2018-03-21,6C4D,8649.0,4.0,1188.0,46.0,,136.23,1.0,2.52,experimental,71.72,0.29643,0.23625,Structure based design of RIP1 kinase inhibitors
8ROM,X-RAY DIFFRACTION,2.58,52.4,"VAPOR DIFFUSION, SITTING DROP",6.0,"1.6 M Na/K phosphate, pH 6, 10% DMSO",293.0,2024-01-11,2024-04-10,8ROM,1732.0,1.0,202.0,136.0,2.0,23.7,1.0,1.69,experimental,34.06,0.2066,0.1815,Crystal structure of human FAD synthase PAPS domain in complex with FAD
5DV4,X-RAY DIFFRACTION,3.2,61.58,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes, 1.1M ammonium tartrate, 0.2M NDSB-201",293.0,2015-09-21,2016-10-26,5DV4,3144.0,1.0,398.0,304.0,,45.95,1.0,1.8,experimental,,0.2162,0.1897,Crystal structure of human CNOT6L in complex with neomycin
5H08,X-RAY DIFFRACTION,2.6,52.68,"VAPOR DIFFUSION, SITTING DROP",8.5,"10%(w/v) PEG8000, 20%(v/v) ethylene glycol, 30mM sodium fluoride, 30mM sodium bromide, 30mM sodium iodide. NAZ2329 was soaked into the crystal.",277.0,2016-10-04,2017-07-26,5H08,2322.0,1.0,298.0,14.0,,34.46,1.0,2.53,experimental,39.25,0.29689,0.21029,Human PTPRZ D1 domain complexed with NAZ2329
5MOY,X-RAY DIFFRACTION,2.63,53.23,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 8000, 65 mM Hepes",285.0,2016-12-14,2017-03-15,5MOY,4346.0,2.0,564.0,76.0,1.0,66.06,2.0,2.302,experimental,,0.2512,0.1947,Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C
6PCK,X-RAY DIFFRACTION,2.4,48.77,"VAPOR DIFFUSION, HANGING DROP",4.6,"12 - 18% PEG 8000, 150 - 300 mM LiSO4, 0.1 M sodium acetate, pH 4.6",290.15,2019-06-17,2020-04-29,6PCK,1406.0,1.0,148.0,220.0,,17.95,1.0,1.2,experimental,,0.1726,0.1568,Crystal structure of human diphosphoinositol polyphosphate phosphohydrolase 1 in complex with 1-IP7
6PCL,X-RAY DIFFRACTION,2.47,50.25,"VAPOR DIFFUSION, HANGING DROP",4.6,"12 - 18% PEG 8000, 150 - 300 mM LiSO4, 0.1 M sodium acetate, pH 4.6",290.15,2019-06-17,2020-04-29,6PCL,1356.0,1.0,148.0,160.0,,18.0,1.0,1.3,experimental,,0.1609,0.1429,Crystal structure of human diphosphoinositol polyphosphate phosphohydrolase 1 in complex with 5-IP7
6D8E,X-RAY DIFFRACTION,3.5,64.86,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES(pH 6.5),
1.0 M sodium citrate",298.0,2018-04-26,2018-07-18,6D8E,2412.0,1.0,327.0,12.0,,37.79,1.0,2.537,experimental,,0.2426,0.2087,Discovery of a Highly Potent and Broadly Effective EGFR and HER2 Exon 20 Insertion Mutant Inhibitor
9ASX,X-RAY DIFFRACTION,2.36,47.85,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M  ammonium citrate
0.1 M  imidazole (pH 6.8)
22% (w/v) peg-2kMME",293.0,2024-02-26,2024-06-12,9ASX,4519.0,3.0,541.0,205.0,7.0,61.69,3.0,1.96,experimental,,0.2284,0.1926,BIFUNCTIONAL INHIBITION OF NEUTROPHIL ELASTASE AND CATHEPSIN G by Eap3 of S. aureus
5E8V,X-RAY DIFFRACTION,2.53,51.44,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mm TRIS-HCl, PH 8.5, 150 mm MgCl2, 24%(w/v) PEG4000, 20%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E8V,2468.0,1.0,316.0,188.0,,35.93,1.0,1.69,experimental,31.25,0.2194,0.1926,"TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A)"
6QA5,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, SITTING DROP",9.0,"0.1 M PCTP (Propionic acid, Cacodylate, Bis-tris propane) buffer pH 9.0 25 % w/v PEG 1500",277.0,2018-12-18,2020-01-15,6QA5,3535.0,1.0,429.0,126.0,1.0,49.84,1.0,2.655,experimental,50.0,0.2239,0.1972,Aspartyl/Asparaginyl beta-hydroxylase (AspH) H679A in the apo form
4P44,X-RAY DIFFRACTION,3.31,62.79,"VAPOR DIFFUSION, HANGING DROP",8.0,"34% (v/v) pentaerythritol propoxylate PO/OH 5/4, 2 % (w/v) PEG 3350, and 100 mM Tris-HCl, pH 8.0",288.0,2014-03-11,2015-05-20,4P44,6554.0,1.0,707.0,603.0,,83.06,1.0,1.75,experimental,26.414,0.18723,0.16279,X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a phosphoramidate inhibitor JRB-4-81
8DSF,X-RAY DIFFRACTION,2.16,43.14,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.17 M Sodium Acetate, 0.085 M TrisBase pH 8.5, 25.5% w/v PEG 4000, 15% v/v glycerol",298.0,2022-07-22,2023-03-08,8DSF,3617.0,4.0,396.0,419.0,,49.96,1.0,1.5,experimental,25.15,0.2268,0.1889,Structure of cIAP1 with BCCov
6DQ5,X-RAY DIFFRACTION,2.23,44.74,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4, 0.1 M Tris-HCl (pH 8.6-9.2) 0-20% glycerol 25 mM (Na/K) dibasic/monobasic phosphate",289.0,2018-06-10,2018-11-21,6DQ5,2443.0,1.0,330.0,102.0,,38.4,1.0,1.89,experimental,,0.2539,0.2271,"LINKED KDM5A JMJ DOMAIN BOUND TO THE INHIBITOR N43 i.e. 3-((6-(4-acryloyl-1,4-diazepan-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid"
6AU3,X-RAY DIFFRACTION,2.46,50.08,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG3350, 0.2M LiSO4, 0.1M Bis-Tris pH 6.5",293.0,2017-08-30,2017-09-27,6AU3,1864.0,1.0,213.0,118.0,,25.58,1.0,1.8,experimental,28.895,0.1903,0.1787,Crystal structure of SETDB1 Tudor domain with aryl triazole fragments
7MX1,X-RAY DIFFRACTION,2.36,47.84,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M. CaCl2, 15% PEG-3350",291.0,2021-05-17,2022-03-30,7MX1,4208.0,4.0,486.0,470.0,,56.48,2.0,1.64,experimental,45.6897,0.2041,0.1754,PLK-1 polo-box domain in complex with a high affinity macrocycle synthesized using a novel glutamic acid analog
5WCF,X-RAY DIFFRACTION,2.9,57.55,"VAPOR DIFFUSION, HANGING DROP",8.5,"15% PEG 8000, 0.2M MgCl2, 0.1M Tris-HCl pH8.5",291.0,2017-06-30,2017-08-02,5WCF,2768.0,1.0,376.0,102.0,1.0,43.02,1.0,1.98,experimental,45.069,0.2082,0.1997,Human HMT1 hnRNP methyltransferase-like protein 6 (S. cerevisiae)
6PW8,X-RAY DIFFRACTION,2.15,42.85,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M zinc chloride, 20% PEG3350",293.0,2019-07-22,2020-07-22,6PW8,1189.0,2.0,141.0,92.0,,15.78,2.0,1.95,experimental,38.06,0.2495,0.2172,Hydrocarbon-Stapled Paxillin Peptide Bound to the Focal Adhesion Targeting (FAT) Domain of the Focal Adhesion Kinase (FAK)
6UE6,X-RAY DIFFRACTION,2.17,43.22,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M potassium thiocyanate",291.0,2019-09-20,2019-11-13,6UE6,7347.0,8.0,1128.0,,,130.79,1.0,2.4,experimental,60.96,0.252,0.235,PWWP1 domain of NSD2 in complex with MR837
5ZOP,X-RAY DIFFRACTION,4.01,69.32,EVAPORATION,7.5,"PEG 3350, iso-propanol",295.0,2018-04-13,2018-10-10,5ZOP,3101.0,2.0,411.0,118.0,,44.5,2.0,2.698,experimental,36.1537,0.2354,0.2161,Crystal structure of histone deacetylase 4 (HDAC4) in complex with a SMRT corepressor SP2 fragment
8AOG,X-RAY DIFFRACTION,2.3,46.55,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOG,3271.0,1.0,368.0,455.0,,43.23,1.0,1.603,experimental,26.228,0.2201,0.1735,Non-specific covalent inhibitor(17) of ERK2
5ZAN,X-RAY DIFFRACTION,2.81,56.3,EVAPORATION,,"0.22M Sodium citrate tribasic dihydrate pH 6.0, 10%(v/v) 2-Propanol, 22(w/v) Polyethylene glycol 4,000",293.0,2018-02-07,2019-02-13,5ZAN,2008.0,1.0,281.0,,,32.99,1.0,2.85,experimental,100.013,0.28128,0.25512,Crystal Structure of Aurora-A in complex with a new Quinazoline inhibitor
6B8X,X-RAY DIFFRACTION,3.54,65.27,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 16% PEG 8000, 2% ethanol, 10% glycerol",277.0,2017-10-09,2018-06-20,6B8X,3260.0,1.0,321.0,225.0,,37.71,1.0,1.74,experimental,31.4347,0.2059,0.1752,Multiconformer model of apo WT PTP1B with glycerol at 278 K
7GS7,X-RAY DIFFRACTION,3.3,62.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GS7,2577.0,1.0,321.0,247.0,,37.72,1.0,1.66,experimental,35.749,0.2232,0.1919,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000621a
7GS8,X-RAY DIFFRACTION,3.32,62.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GS8,2675.0,1.0,321.0,239.0,,38.5,1.0,1.67,experimental,34.106,0.2089,0.1825,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000466a
7GS9,X-RAY DIFFRACTION,3.38,63.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GS9,2546.0,1.0,321.0,246.0,,37.66,1.0,1.96,experimental,41.915,0.263,0.2226,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000631a
7GSA,X-RAY DIFFRACTION,3.34,63.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSA,2588.0,1.0,321.0,250.0,,37.67,1.0,1.72,experimental,37.76,0.2281,0.1946,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000260a
7GSB,X-RAY DIFFRACTION,3.34,63.15,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSB,2587.0,1.0,321.0,244.0,,37.71,1.0,1.72,experimental,37.725,0.2249,0.1885,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000438a
7GSC,X-RAY DIFFRACTION,3.3,62.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSC,2582.0,1.0,321.0,240.0,,37.71,1.0,1.69,experimental,35.604,0.2276,0.1929,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000729a
7GSD,X-RAY DIFFRACTION,3.37,63.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSD,2563.0,1.0,321.0,245.0,,37.66,1.0,1.8,experimental,42.096,0.2305,0.1986,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000605a
7GSE,X-RAY DIFFRACTION,3.33,63.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSE,2589.0,1.0,321.0,246.0,,37.71,1.0,1.89,experimental,41.778,0.2348,0.1993,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000383a
7GSF,X-RAY DIFFRACTION,3.33,63.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSF,2584.0,1.0,321.0,242.0,,37.72,1.0,1.78,experimental,40.438,0.2275,0.1951,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000421a
7GSG,X-RAY DIFFRACTION,3.32,63.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSG,2578.0,1.0,321.0,239.0,,37.68,1.0,1.9,experimental,39.207,0.2304,0.1877,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000316a
7GSH,X-RAY DIFFRACTION,3.4,63.78,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSH,2577.0,1.0,321.0,235.0,,37.7,1.0,1.88,experimental,46.484,0.2369,0.201,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000530a
7GSI,X-RAY DIFFRACTION,3.29,62.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSI,2585.0,1.0,321.0,234.0,,37.82,1.0,1.71,experimental,36.229,0.2271,0.1962,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000046b
7GSJ,X-RAY DIFFRACTION,3.32,62.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSJ,2573.0,1.0,321.0,243.0,,37.7,1.0,1.77,experimental,35.494,0.2307,0.1947,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000543a
7GSL,X-RAY DIFFRACTION,3.33,63.09,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSL,2582.0,1.0,321.0,246.0,,37.64,1.0,1.77,experimental,37.617,0.2255,0.1905,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000274b
7GSM,X-RAY DIFFRACTION,3.3,62.76,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSM,2573.0,1.0,321.0,247.0,,37.66,1.0,2.03,experimental,40.262,0.254,0.1958,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000437b
7GSN,X-RAY DIFFRACTION,3.32,62.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSN,2588.0,1.0,321.0,248.0,,37.69,1.0,1.87,experimental,40.398,0.2289,0.1884,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000519b
7GSO,X-RAY DIFFRACTION,3.33,63.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSO,2587.0,1.0,321.0,244.0,,37.73,1.0,1.72,experimental,40.256,0.2301,0.1947,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000029a
7GSQ,X-RAY DIFFRACTION,3.35,63.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSQ,2692.0,1.0,321.0,244.0,,37.91,1.0,1.73,experimental,37.888,0.2169,0.186,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000149a
7GSR,X-RAY DIFFRACTION,3.29,62.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSR,2579.0,1.0,321.0,239.0,,37.67,1.0,1.69,experimental,35.922,0.2248,0.1945,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000055b
7GST,X-RAY DIFFRACTION,3.29,62.64,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GST,2578.0,1.0,321.0,239.0,,37.68,1.0,1.64,experimental,36.807,0.2269,0.1921,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000056a
7GSW,X-RAY DIFFRACTION,3.31,62.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSW,2578.0,1.0,321.0,239.0,,37.66,1.0,1.79,experimental,38.144,0.2242,0.1908,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000422b
7GSX,X-RAY DIFFRACTION,3.31,62.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSX,2593.0,1.0,321.0,242.0,,37.82,1.0,1.67,experimental,35.202,0.2225,0.1976,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA001440b
7GSY,X-RAY DIFFRACTION,3.38,63.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSY,2579.0,1.0,321.0,239.0,,37.66,1.0,1.97,experimental,36.702,0.2748,0.2382,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA001175b
7GSZ,X-RAY DIFFRACTION,3.39,63.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GSZ,2556.0,1.0,321.0,245.0,,37.67,1.0,1.91,experimental,44.292,0.2409,0.1996,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000686b
7GT0,X-RAY DIFFRACTION,3.31,62.87,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT0,2581.0,1.0,321.0,245.0,,37.74,1.0,1.76,experimental,39.743,0.2253,0.1934,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000275a
7GT1,X-RAY DIFFRACTION,3.39,63.72,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT1,2585.0,1.0,321.0,241.0,,37.74,1.0,1.91,experimental,42.504,0.2225,0.19,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000209a
7GT2,X-RAY DIFFRACTION,3.39,63.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT2,2577.0,1.0,321.0,240.0,,37.67,1.0,1.9,experimental,46.147,0.2393,0.2,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000752b
7GT3,X-RAY DIFFRACTION,3.31,62.84,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT3,2590.0,1.0,321.0,244.0,,37.76,1.0,1.59,experimental,33.883,0.2295,0.1985,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000527a
7GT4,X-RAY DIFFRACTION,3.31,62.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT4,2584.0,1.0,321.0,243.0,,37.71,1.0,1.75,experimental,35.247,0.2408,0.2019,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000528a
7GT5,X-RAY DIFFRACTION,3.34,63.14,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT5,2595.0,1.0,321.0,230.0,,38.07,1.0,1.61,experimental,37.549,0.2334,0.2002,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000529a
7GT6,X-RAY DIFFRACTION,3.34,63.19,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT6,2585.0,1.0,321.0,241.0,,37.73,1.0,1.66,experimental,37.388,0.2276,0.1996,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000530a
7GT7,X-RAY DIFFRACTION,3.39,63.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT7,2575.0,1.0,321.0,235.0,,37.68,1.0,1.84,experimental,43.187,0.2309,0.1998,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA001181b
7GT8,X-RAY DIFFRACTION,3.38,63.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT8,2566.0,1.0,321.0,243.0,,37.67,1.0,1.91,experimental,41.288,0.2423,0.2078,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA001439b
7GT9,X-RAY DIFFRACTION,3.38,63.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GT9,2568.0,1.0,321.0,242.0,,37.64,1.0,1.9,experimental,47.749,0.2432,0.2012,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000463b
7GTA,X-RAY DIFFRACTION,3.41,63.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTA,2570.0,1.0,321.0,231.0,,37.68,1.0,2.06,experimental,48.707,0.2387,0.1996,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000065a
7GTB,X-RAY DIFFRACTION,3.38,63.64,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTB,2583.0,1.0,321.0,246.0,,37.63,1.0,1.86,experimental,38.883,0.2397,0.2085,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMSOA000899b
7GTC,X-RAY DIFFRACTION,3.37,63.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTC,2587.0,1.0,321.0,226.0,,37.97,1.0,1.92,experimental,42.669,0.2301,0.1955,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00001145b
7GTD,X-RAY DIFFRACTION,3.38,63.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTD,2585.0,1.0,321.0,246.0,,37.7,1.0,1.91,experimental,41.548,0.2295,0.1877,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000110a
7GTE,X-RAY DIFFRACTION,3.38,63.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTE,2576.0,1.0,321.0,240.0,,37.64,1.0,1.9,experimental,45.513,0.2307,0.1967,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000646b
7GTF,X-RAY DIFFRACTION,3.38,63.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTF,2572.0,1.0,321.0,237.0,,37.6,1.0,1.97,experimental,40.535,0.2592,0.2155,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000754b
7GTG,X-RAY DIFFRACTION,3.36,63.37,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTG,2585.0,1.0,321.0,238.0,,37.77,1.0,1.69,experimental,41.104,0.2326,0.1974,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000684a
7GTH,X-RAY DIFFRACTION,3.35,63.28,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTH,2586.0,1.0,321.0,243.0,,37.71,1.0,1.66,experimental,36.552,0.2347,0.2004,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000637a
7GTI,X-RAY DIFFRACTION,3.36,63.38,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTI,2578.0,1.0,321.0,245.0,,37.74,1.0,1.66,experimental,37.55,0.2336,0.2018,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000571a
7GTJ,X-RAY DIFFRACTION,3.35,63.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTJ,2581.0,1.0,321.0,242.0,,37.66,1.0,1.83,experimental,32.828,0.233,0.196,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000280c
7GTK,X-RAY DIFFRACTION,3.34,63.13,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTK,2581.0,1.0,321.0,239.0,,37.73,1.0,1.76,experimental,35.999,0.2331,0.1965,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000552a
7GTL,X-RAY DIFFRACTION,3.3,62.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTL,2587.0,1.0,321.0,241.0,,37.76,1.0,1.83,experimental,41.748,0.2449,0.2008,PanDDA analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000554a
7GTM,X-RAY DIFFRACTION,3.3,62.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTM,2586.0,1.0,321.0,245.0,,37.71,1.0,1.72,experimental,35.796,0.2291,0.1971,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000543a
7GTN,X-RAY DIFFRACTION,3.34,63.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTN,2590.0,1.0,321.0,248.0,,37.7,1.0,1.66,experimental,37.077,0.2293,0.1991,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000625a
7GTO,X-RAY DIFFRACTION,3.33,63.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTO,2571.0,1.0,321.0,240.0,,37.71,1.0,1.65,experimental,36.127,0.2306,0.1991,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOOA000602a
7GTP,X-RAY DIFFRACTION,3.36,63.42,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTP,2665.0,1.0,321.0,216.0,,37.66,1.0,2.47,experimental,43.694,0.2522,0.1958,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000688a
7GTQ,X-RAY DIFFRACTION,3.38,63.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTQ,2585.0,1.0,321.0,247.0,,37.65,1.0,2.09,experimental,50.509,0.2387,0.2062,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000311a
7GTR,X-RAY DIFFRACTION,3.35,63.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTR,2585.0,1.0,321.0,242.0,,37.71,1.0,1.78,experimental,39.614,0.2308,0.2025,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000587a
7GTS,X-RAY DIFFRACTION,3.32,62.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTS,2560.0,1.0,321.0,222.0,,37.65,1.0,1.8,experimental,38.962,0.2361,0.2031,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000604a
7GTT,X-RAY DIFFRACTION,3.3,62.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTT,2567.0,1.0,321.0,225.0,,37.72,1.0,1.93,experimental,39.443,0.2371,0.2005,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOPL000148a
7GTU,X-RAY DIFFRACTION,3.29,62.66,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTU,2570.0,1.0,321.0,226.0,,37.74,1.0,2.08,experimental,45.45,0.2236,0.1891,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with FMOMB000297a
7GTV,X-RAY DIFFRACTION,3.32,62.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2024-01-03,2024-01-24,7GTV,2573.0,1.0,321.0,231.0,,37.69,1.0,1.72,experimental,36.951,0.2359,0.2043,PanDDA Analysis group deposition -- Crystal structure of PTP1B in complex with XST00000765c
7MNC,X-RAY DIFFRACTION,2.21,44.31,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 0.1 M Tris pH 8, 16% PEG 8000",277.0,2021-04-30,2022-05-18,7MNC,2331.0,1.0,308.0,103.0,,36.05,1.0,1.85,experimental,32.67,0.2036,0.1738,PTP1B L204A
7RIN,X-RAY DIFFRACTION,3.29,62.6,"VAPOR DIFFUSION, HANGING DROP",,"100mM HEPES (pH 6.8 - 7.6), 250mM magnesium acetate, 11-15% PEG8000 (w/v), 10% glycerol (v/v), 6% ethanol (v/v), 0.1% BME (v/v).",277.0,2021-07-20,2021-07-28,7RIN,3024.0,1.0,321.0,160.0,,37.59,1.0,1.85,experimental,43.45,0.1538,0.1318,Apo PTP1B by Native S-SAD at Room Temperature
8DU7,X-RAY DIFFRACTION,3.69,62.64,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M MgCl2, 0.1 M HEPES pH 7.0, 12-14.5% PEG 4000",277.15,2022-07-27,2022-08-17,8DU7,2462.0,1.0,284.0,63.0,,33.15,1.0,2.4,experimental,57.87,0.2371,0.1952,Room-temperature serial synchrotron crystallography (SSX) structure of apo PTP1B
4XEF,X-RAY DIFFRACTION,2.23,44.83,"VAPOR DIFFUSION, SITTING DROP",8.5,"400 nl drop contained 200 nl protein/LD1 peptide mixture (20 mM MES, pH 6.2, 1 mM protein, and 2 mM peptide) and 200 nl well solution (100 mM Tris, pH 8.5, 0.2 M MgCl2, and 30% PEG 4000).",291.0,2014-12-23,2015-12-23,4XEF,2442.0,6.0,358.0,12.0,,39.81,2.0,2.5,experimental,,0.266,0.224,Pyk2-FAT complexed with Leupaxin LD motif LD1
8FE7,X-RAY DIFFRACTION,4.69,73.79,"VAPOR DIFFUSION, HANGING DROP",,"1.9M Ammonium Sulfate, 0.1M Tris pH 8.5, 1% Xylitol",293.0,2022-12-05,2023-08-09,8FE7,22788.0,8.0,2940.0,,,332.22,2.0,2.98,experimental,74.39,0.2174,0.1862,Crystal structure of human O-GlcNAc transferase (OGT) in complex with an exosite-binding peptide (SMG9) and UDP-GlcNAc
5E6H,X-RAY DIFFRACTION,2.18,43.54,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.5 M Ammonium sulfate
100mM Tris-HCl, pH 8.5
12% glycerol",289.0,2015-10-09,2015-12-16,5E6H,2529.0,1.0,330.0,100.0,,38.33,1.0,2.238,experimental,,0.2199,0.1791,A Linked Jumonji Domain of the KDM5A Lysine Demethylase
5OQ4,X-RAY DIFFRACTION,2.2,44.0,VAPOR DIFFUSION,7.5,"16% PEG 4000, 250mM (NH4)2SO4 and 100mM Tris pH7.5",290.15,2017-08-10,2017-09-06,5OQ4,6851.0,1.0,966.0,36.0,,111.36,1.0,2.7,experimental,64.057,0.26422,0.19643,"PQR309 - a Potent, Brain-Penetrant, Orally Bioavailable, pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology"
6GJD,X-RAY DIFFRACTION,2.31,46.68,"VAPOR DIFFUSION, SITTING DROP",7.3,"0.1M Hepes,pH7.3, 0.2M ammonium sulphate, 34% MPEG200, 0.02Mmercaptoethanol",293.0,2018-05-16,2019-01-02,6GJD,3251.0,1.0,368.0,327.0,,44.31,1.0,1.58,experimental,37.296,0.21,0.167,Erk2 signalling protein
7NQQ,X-RAY DIFFRACTION,2.33,47.19,"VAPOR DIFFUSION, HANGING DROP",,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2021-03-02,2021-10-06,7NQQ,3166.0,1.0,368.0,289.0,,43.56,1.0,1.943,experimental,37.221,0.2277,0.1745,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2"
7NQW,X-RAY DIFFRACTION,2.32,46.87,"VAPOR DIFFUSION, HANGING DROP",,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2021-03-02,2021-10-06,7NQW,3318.0,1.0,368.0,423.0,,43.43,1.0,1.775,experimental,30.483,0.2064,0.1649,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2"
7NR8,X-RAY DIFFRACTION,2.31,46.82,"VAPOR DIFFUSION, HANGING DROP",,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2021-03-03,2021-10-06,7NR8,3343.0,1.0,368.0,417.0,,43.77,1.0,1.627,experimental,28.908,0.2135,0.1709,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2"
8AOA,X-RAY DIFFRACTION,2.29,46.29,"VAPOR DIFFUSION, HANGING DROP",,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOA,3367.0,1.0,368.0,473.0,,43.21,1.0,1.62,experimental,29.27,0.2315,0.1799,Covalent and non-covalent inhibitor of ERK2 (two sites)
6Q3M,X-RAY DIFFRACTION,3.53,65.12,VAPOR DIFFUSION,,"0.12M Diethyleneglycol,
0.12M Triethylene-glycol, 
0.12M Tetraethyleneglycol, 
0.12M Pentaethyleneglycol,
20% v/v Ethylene glycol, 
10 % w/v PEG 8000,
Sodium HEPES, MOPS pH = 7.5",277.0,2018-12-04,2019-12-25,6Q3M,7457.0,4.0,952.0,177.0,,116.28,1.0,2.52,experimental,,0.2626,0.23,Structure of CHD4 PHD2 - tandem chromodomains
5J5X,X-RAY DIFFRACTION,2.49,50.64,"VAPOR DIFFUSION, HANGING DROP",7.0,"18% PEG3350, 0.2M LiSO4",277.15,2016-04-04,2016-07-20,5J5X,2976.0,2.0,359.0,26.0,,42.36,2.0,2.6,experimental,62.934,0.30895,0.23678,Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1416
6Z36,X-RAY DIFFRACTION,2.61,52.9,"VAPOR DIFFUSION, SITTING DROP",5.2,"0.1M Citrate pH 5.2, 1.2M ammonium sulphate, 0.2M sodiuim/potassium tartarate.",277.0,2020-05-19,2020-05-27,6Z36,5473.0,2.0,602.0,593.0,,71.71,1.0,1.37,experimental,22.56,0.1905,0.1487,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2118
5APA,X-RAY DIFFRACTION,4.47,72.52,,,"50MM SODIUM MALATE, 20% PEG3350, 3% DEXTRAN SULFATE, 20MM NISO4",,2015-09-15,2015-09-23,5APA,1769.0,1.0,220.0,139.0,1.0,25.9,1.0,2.05,experimental,,0.1855,0.1529,Crystal structure of human aspartate beta-hydroxylase isoform a
6XCG,X-RAY DIFFRACTION,2.31,46.82,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.6 M ammonium sulfate, 0.01 M magnesium chloride, 0.1 M HEPES, pH 7.5",291.0,2020-06-08,2020-07-22,6XCG,3893.0,3.0,423.0,608.0,,49.77,1.0,1.64,experimental,21.766,0.222,0.1778,Histone-lysine N-methyltransferase NSD2-PWWP1 with compound UNC6934
5NWX,X-RAY DIFFRACTION,2.25,44.09,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M sodium acetate, 0.1 M sodium cacodylate, pH 6.5, 30% PEG 8000, 5% PEG 400",293.0,2017-05-08,2017-12-13,5NWX,884.0,2.0,164.0,8.0,,18.26,2.0,2.51,experimental,46.36,0.23546,0.18352,Insight into the molecular recognition mechanism of the coactivator NCoA1 by STAT6
4YSI,X-RAY DIFFRACTION,3.2,61.51,"VAPOR DIFFUSION, HANGING DROP",8.5,"30% PEG4K, 0.2M LiSO4, 0.1M TrisHCl",277.0,2015-03-17,2016-02-03,4YSI,1466.0,2.0,151.0,267.0,,17.59,2.0,1.02,experimental,18.6359,0.16,0.1539,Structure of USP7 with a novel viral protein
4X90,X-RAY DIFFRACTION,3.28,62.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES pH 7.5, 3.5% PEG 8000, 28% MPD, 300 mM (NH4)2HPO4",277.0,2014-12-11,2015-03-11,4X90,14133.0,4.0,1520.0,1065.0,4.0,179.15,1.0,1.84,experimental,26.422,0.1733,0.1541,Crystal structure of Lysosomal Phospholipase A2
4X91,X-RAY DIFFRACTION,3.23,61.91,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES pH 7.5, 3.5% PEG 8000, 28% MPD, 300 mM (NH4)2HPO4",277.0,2014-12-11,2015-03-11,4X91,13227.0,4.0,1520.0,513.0,13.0,179.92,1.0,2.3,experimental,35.152,0.2136,0.1833,Crystal structure of Lysosomal Phospholipase A2 in complex with Isopropyl dodec-11-enylfluorophosphonate (IDFP)
4X97,X-RAY DIFFRACTION,2.84,56.75,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES pH 7.5, 3.5% PEG 8000, 28% MPD, 300 mM (NH4)2HPO4",277.0,2014-12-11,2015-03-11,4X97,12763.0,4.0,1520.0,232.0,6.0,178.87,1.0,2.65,experimental,39.398,0.2191,0.1794,Crystal structure of Lysosomal Phospholipase A2 in complex with methyl arachidonyl fluorophosphonate (MAFP)
7LP1,X-RAY DIFFRACTION,2.78,55.73,"VAPOR DIFFUSION, SITTING DROP",4.6,"3.6M ammonium nitrate, 5% glycerol, and 0.1M sodium acetate at pH 4.6",293.15,2021-02-11,2021-07-28,7LP1,395.0,1.0,39.0,43.0,,5.01,1.0,1.35,experimental,20.39,0.2135,0.1836,Structure of Nedd4L WW3 domain
5DC5,X-RAY DIFFRACTION,2.32,46.88,"VAPOR DIFFUSION, SITTING DROP",7.3,"100 mM imidazole (pH 7.0), 15% (w/v) PEG 1500, and 4 mM TCEP",294.0,2015-08-23,2016-02-03,5DC5,5923.0,2.0,778.0,274.0,,87.29,1.0,1.94,experimental,,0.2103,0.1819,Crystal structure of D176N HDAC8 in complex with M344
5DC6,X-RAY DIFFRACTION,2.39,48.59,"VAPOR DIFFUSION, SITTING DROP",8.0,"100 mM Tris (pH 8.0), 13% (w/v) PEG 8000, and 4 mM TCEP",289.0,2015-08-23,2016-02-03,5DC6,6823.0,4.0,790.0,610.0,,88.59,2.0,1.553,experimental,,0.1663,0.1467,Crystal structure of D176N-Y306F HDAC8 in complex with a tetrapeptide substrate
5DC7,X-RAY DIFFRACTION,2.35,47.76,"VAPOR DIFFUSION, SITTING DROP",8.0,"100 mM Tris (pH 8.0), 15% (w/v) PEG 10000, and 4 mM TCEP",294.0,2015-08-23,2016-02-03,5DC7,6008.0,4.0,790.0,253.0,,88.6,2.0,2.3,experimental,,0.216,0.1695,Crystal structure of D176A-Y306F HDAC8 in complex with a tetrapeptide substrate
5DC8,X-RAY DIFFRACTION,2.41,48.95,"VAPOR DIFFUSION, SITTING DROP",8.0,"100 mM Tris (pH 8.0), 10% (w/v) PEG 35000, and 4 mM TCEP",289.0,2015-08-23,2016-02-03,5DC8,7394.0,4.0,790.0,872.0,,88.44,2.0,1.3,experimental,,0.1489,0.1282,Crystal structure of H142A-Y306F HDAC8 in complex with a tetrapeptide substrate
7JVU,X-RAY DIFFRACTION,2.42,49.07,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M imidazole, pH 7.0, 15% PEG35000, 4 mM TCEP",294.0,2020-08-24,2020-12-16,7JVU,6405.0,2.0,778.0,635.0,,87.69,1.0,1.5004765401,experimental,22.8636882906,0.184587196948,0.164399381995,Crystal structure of human histone deacetylase 8 (HDAC8) I45T mutation complexed with SAHA
8ELK,X-RAY DIFFRACTION,2.34,47.38,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
HEPES",291.15,2022-09-26,2023-09-06,8ELK,1443.0,1.0,189.0,154.0,,21.99,1.0,1.8,experimental,25.8921,0.1948,0.1701,HRAS R97F Crystal Form 1
8ELR,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"Calcium Acetate
PEG3350,
Magnesium Chloride,
HEPES,
Sodium Chloride,
DTT",291.15,2022-09-26,2023-09-06,8ELR,1419.0,1.0,189.0,74.0,,21.93,1.0,2.05,experimental,34.1893,0.244,0.188,HRAS R97F Crystal Form 2
8ELS,X-RAY DIFFRACTION,2.41,49.04,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
HEPES,
Calcium Chloride,
Magnesium Chloride",277.15,2022-09-26,2023-09-06,8ELS,1475.0,1.0,189.0,108.0,,21.86,1.0,2.267,experimental,35.1,0.2115,0.1622,HRAS R97A Crystal Form 1 R-state
8ELT,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
DTT",291.15,2022-09-26,2023-09-06,8ELT,1485.0,1.0,189.0,123.0,,21.87,1.0,1.66,experimental,31.3189,0.2386,0.1976,HRAS R97G Crystal Form 2
8ELU,X-RAY DIFFRACTION,2.41,48.94,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
DTT",291.15,2022-09-26,2023-09-06,8ELU,1453.0,1.0,189.0,143.0,,21.83,1.0,1.93,experimental,31.5248,0.209,0.177,HRAS R97G Crystal form 1
8ELV,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
DTT",291.15,2022-09-26,2023-09-06,8ELV,1408.0,1.0,189.0,73.0,,21.91,1.0,2.153,experimental,29.8145,0.2698,0.1842,HRAS R97I Crystal Form 2
8ELW,X-RAY DIFFRACTION,2.36,47.88,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Sodium Chloride,
Magnesium Chloride,
HEPES",291.15,2022-09-26,2023-09-06,8ELW,1540.0,1.0,189.0,145.0,,21.89,1.0,1.699,experimental,22.41,0.1863,0.1604,HRAS R97A Crystal Form 1 T-State
8ELX,X-RAY DIFFRACTION,2.43,49.37,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
DTT",291.15,2022-09-26,2023-09-06,8ELX,1488.0,1.0,189.0,143.0,,21.89,1.0,1.975,experimental,22.1579,0.2864,0.2273,HRAS R97I Crystal Form 1
8ELY,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
DTT",291.15,2022-09-26,2023-09-06,8ELY,1495.0,1.0,189.0,138.0,,21.95,1.0,1.75,experimental,26.1132,0.2268,0.1787,HRAS R97M Crystal Form 2
8EM0,X-RAY DIFFRACTION,2.44,49.53,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
DTT",291.15,2022-09-26,2023-09-06,8EM0,1483.0,1.0,189.0,137.0,,21.88,1.0,2.109,experimental,31.5257,0.2009,0.1557,HRAS R97V Crystal Form 1
8FG3,X-RAY DIFFRACTION,1.91,35.61,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
DTT",291.15,2022-12-12,2023-09-06,8FG3,1503.0,1.0,166.0,166.0,,19.38,1.0,1.49,experimental,21.13,0.2473,0.206,HRAS R97L Crystal Form 2
8FG4,X-RAY DIFFRACTION,2.81,56.26,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
DTT",291.15,2022-12-12,2023-09-06,8FG4,1499.0,1.0,166.0,143.0,,19.44,1.0,1.85,experimental,37.37,0.2271,0.1907,HRAS R97L Crystal Form 1
8AK6,X-RAY DIFFRACTION,2.61,52.91,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AK6,4575.0,2.0,604.0,55.0,,69.85,1.0,1.98,experimental,50.628,0.2217,0.181,Human Sirt6 in complex with ADP-ribose and fragment sulfamethoxazole
7FB6,X-RAY DIFFRACTION,1.96,37.36,"VAPOR DIFFUSION, HANGING DROP",,"0.2M MgCl2, 22% (w/v) PEG 3350",287.15,2021-07-08,2022-10-12,7FB6,2363.0,2.0,322.0,155.0,,33.79,1.0,1.8,experimental,20.86,0.213,0.1843,"C57D/C146D mutant of Human Cu, Zn Superoxide Dismutase (SOD1)"
8QUG,X-RAY DIFFRACTION,2.82,56.4,"VAPOR DIFFUSION, HANGING DROP",5.5,"25% PEG3350, 0.1 M BisTris, 0.27M NH4Ac",277.0,2023-10-16,2023-12-06,8QUG,1637.0,1.0,170.0,204.0,,20.3,1.0,1.56,experimental,37.31,0.222,0.191,KRAS-G12C in Complex with Compound 1
5AJP,X-RAY DIFFRACTION,2.56,51.98,,,,,2015-02-26,2015-03-11,5AJP,4841.0,2.0,588.0,611.0,5.0,69.07,2.0,1.65,experimental,28.104,0.18558,0.15598,Crystal structure of the active form of GalNAc-T2 in complex with UDP and the glycopeptide MUC5AC-13
6EKM,X-RAY DIFFRACTION,2.01,38.85,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M sodium formate, 0.1 M ammonium acetate, 0.1 M sodium citrate tribasic 
dehydrate, 0.1 M sodium potassium tartrate tetrahydrate, 0.1 M sodium oxamate, 0.1 M Imidazole - 
MES monohydrate (acid) pH 6.5 and 12.5% v/v MPD, 12.5% PEG 1000, 12.5% w/v PEG 3350",293.0,2017-09-26,2018-10-10,6EKM,1839.0,2.0,239.0,21.0,,27.68,2.0,2.76,experimental,55.843,0.25843,0.23009,Crystal structure of mammalian Rev7 in complex with human Rev3 second binding site
5EYZ,X-RAY DIFFRACTION,3.37,63.55,"VAPOR DIFFUSION, SITTING DROP",6.0,"23% PEG 8000, 0.1 M MES PH 6.0, 0.2 M CALCIUM ACETATE, 0.143 MM AMMONIUM SULFATE",291.0,2015-11-26,2016-06-08,5EYZ,3176.0,8.0,480.0,109.0,2.0,52.95,2.0,2.09,experimental,65.36,0.2395,0.2291,CRYSTAL STRUCTURE OF THE PTPN4 PDZ DOMAIN COMPLEXED WITH THE TAILORED PEPTIDE CYTO8-RETEV
5WDO,X-RAY DIFFRACTION,2.82,56.4,"VAPOR DIFFUSION, SITTING DROP",,"16% PEG3350, 100 mM calcium acetate, pH 7.5",293.0,2017-07-05,2017-07-19,5WDO,1695.0,1.0,170.0,129.0,,19.98,1.0,1.65,experimental,,0.1684,0.1416,H-Ras bound to GMP-PNP at 277K
4YTC,X-RAY DIFFRACTION,2.35,47.69,"VAPOR DIFFUSION, HANGING DROP",,"1.7-2.1M dl-malic acid, pH 7.0, 2mM DTT",293.0,2015-03-17,2015-08-12,4YTC,2498.0,1.0,296.0,91.0,,35.24,1.0,2.16,experimental,36.24,0.2128,0.1898,Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease
4YTF,X-RAY DIFFRACTION,2.33,47.22,"VAPOR DIFFUSION, HANGING DROP",,"1.7-2.1 M DL-malic acid pH 7.0, 2mM DTT",293.0,2015-03-17,2015-08-12,4YTF,2578.0,1.0,296.0,168.0,,35.31,1.0,1.78,experimental,27.68,0.2132,0.1825,Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases
4YTH,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, HANGING DROP",,"1.7-2.1 DL -malic acid pH 7.0, 2mM DTT",293.0,2015-03-17,2015-08-12,4YTH,2565.0,1.0,296.0,132.0,,35.32,1.0,2.04,experimental,33.52,0.2152,0.1837,Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases
4YTI,X-RAY DIFFRACTION,2.41,49.05,"VAPOR DIFFUSION, HANGING DROP",,"1.7-2.1 DL-malic acid pH 7.0, 2mM DTT",293.0,2015-03-17,2015-08-12,4YTI,2453.0,1.0,296.0,37.0,,35.29,1.0,2.52,experimental,40.16,0.2172,0.2072,Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease
5UT1,X-RAY DIFFRACTION,2.2,44.08,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-02-14,2017-06-07,5UT1,2363.0,1.0,289.0,218.0,,33.88,1.0,1.95,experimental,,0.2015,0.1627,JAK2 JH2 in complex with BI-D1870
5UT2,X-RAY DIFFRACTION,2.19,43.81,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-02-14,2017-06-07,5UT2,2440.0,1.0,289.0,273.0,,33.76,1.0,1.75,experimental,,0.201,0.161,JAK2 JH2 in complex with PRT062607
5UT3,X-RAY DIFFRACTION,2.2,43.99,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-02-14,2017-06-07,5UT3,2480.0,1.0,289.0,327.0,,33.72,1.0,1.501,experimental,,0.1698,0.1553,JAK2 JH2 in complex with IKK-2 Inhibitor VI
5WIJ,X-RAY DIFFRACTION,2.5,50.83,"VAPOR DIFFUSION, HANGING DROP",8.0,"200 mM Sodium Acetate, 100 mM Tris-HCl, 18%-30%(w/v) polyethylene glycol 4000.",277.0,2017-07-19,2018-08-01,5WIJ,2331.0,1.0,277.0,101.0,,32.1,1.0,2.04,experimental,,0.231,0.2083,JAK2 Pseudokinase in complex with NU6140
5WIK,X-RAY DIFFRACTION,2.46,50.02,"VAPOR DIFFUSION, HANGING DROP",8.0,"200 mM Sodium Acetate, 100 mM Tris-HCl, 18%-30%(w/v) polyethylene glycol 4000",277.0,2017-07-19,2018-08-01,5WIK,2254.0,1.0,277.0,21.0,,32.07,1.0,2.6,experimental,,0.2509,0.2063,JAK2 Pseudokinase in complex with BI-D1870
5WIL,X-RAY DIFFRACTION,2.5,50.71,"VAPOR DIFFUSION, HANGING DROP",8.0,"200 mM Sodium Acetate, 100 mM Tris-HCl, 18%-30%(w/v) polyethylene glycol 4000.",277.0,2017-07-19,2018-08-01,5WIL,2304.0,1.0,277.0,92.0,,32.04,1.0,2.2,experimental,,0.2312,0.1994,JAK2 Pseudokinase in complex with AZD7762
5WIM,X-RAY DIFFRACTION,2.46,50.02,"VAPOR DIFFUSION, HANGING DROP",8.0,"200 mM Sodium Acetate, 100 mM Tris-HCl, 18%-30%(w/v) polyethylene glycol 4000.",277.0,2017-07-19,2018-08-01,5WIM,2255.0,1.0,277.0,22.0,,32.06,1.0,2.55,experimental,,0.2584,0.2086,JAK2 Pseudokinase in complex with AT9283
5WIN,X-RAY DIFFRACTION,2.49,50.69,"VAPOR DIFFUSION, HANGING DROP",8.0,"200 mM Sodium Acetate, 100 mM Tris-HCl, 18%-30%(w/v) polyethylene glycol 4000.",277.0,2017-07-19,2018-08-01,5WIN,2246.0,1.0,277.0,20.0,,32.08,1.0,2.38,experimental,,0.244,0.22,JAK2 Pseudokinase in complex with JNJ7706621
6WTP,X-RAY DIFFRACTION,2.19,43.8,"VAPOR DIFFUSION, HANGING DROP",5.0,"0.1 M SODIUM CITRATE PH 6.0, 27% PEG 8000 AND 0.2 M AMMONIUM ACETATE.
REMARK 280  6.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K",291.0,2020-05-03,2021-05-05,6WTP,2129.0,1.0,309.0,21.0,,37.07,1.0,2.5,experimental,72.0744,0.288,0.2377,Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 3
7JYO,X-RAY DIFFRACTION,2.32,47.0,VAPOR DIFFUSION,,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.15,2020-08-31,2021-07-14,7JYO,2138.0,1.0,289.0,72.0,,33.56,1.0,2.16127225177,experimental,29.7219421899,0.246396242352,0.1850969384,JAK2 JH2 in complex with JAK064
7JYQ,X-RAY DIFFRACTION,2.32,47.0,VAPOR DIFFUSION,,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.15,2020-08-31,2021-07-14,7JYQ,2256.0,1.0,289.0,155.0,,33.65,1.0,1.85941610301,experimental,22.9612738479,0.221029742103,0.179378584566,JAK2 JH2 in complex with JAK020
8BPV,X-RAY DIFFRACTION,2.46,50.08,"VAPOR DIFFUSION, HANGING DROP",8.2,"1.6 M Na-malonate, 0.1 M Gly-Gly pH 8.2",295.0,2022-11-18,2023-11-29,8BPV,2760.0,1.0,317.0,203.0,,37.8,1.0,1.7,experimental,32.75,0.1977,0.1717,Crystal structure of JAK2 JH1 in complex with pacritinib
5TF7,X-RAY DIFFRACTION,2.38,48.3,MICROBATCH,7.5,"40% (v/v) PEG 400, 100 mM NH4Cl, and 100 mM MES, pH 6",279.0,2016-09-24,2018-05-09,5TF7,1870.0,1.0,229.0,168.0,,26.06,1.0,1.931,experimental,,0.1995,0.1569,Nucleotide-binding domain 1 of the human cystic fibrosis transmembrane conductance regulator (CFTR) with ATP
8SSP,X-RAY DIFFRACTION,2.82,56.41,"VAPOR DIFFUSION, HANGING DROP",6.5,"Crystals of AurA in complex with Mb1 and danusertib were obtained by combining 2 uL of 300 uM (10 mg/mL) AurA + 315 uM (4 mg/mL) Mb1 + 2 mM AMPPCP + 4 mM MgCl2 with 2 ul reservoir of 0.1 M MES pH 6.5 + 0.2 M Ammonium sulfate + 4% (v/v) 1,3-propanediol + 15-18% PEG 8000. Streak seeding was used to obtain bigger crystals. Crystals were grown at 18 degC by hanging drop",291.15,2023-05-08,2023-09-06,8SSP,3083.0,2.0,380.0,112.0,,44.82,2.0,2.6,experimental,51.63,0.2566,0.1977,AurA bound to danusertib and activating monobody Mb1
6O1G,X-RAY DIFFRACTION,3.03,59.37,"VAPOR DIFFUSION, HANGING DROP",,0.1 M Hepes pH 7.5 0.1 M Sodium Citrate 25 % PEG 3350,296.0,2019-02-19,2019-03-06,6O1G,4796.0,1.0,638.0,139.0,18.0,72.31,1.0,2.2,experimental,,0.2401,0.2006,Full length human plasma kallikrein with inhibitor
6P5S,X-RAY DIFFRACTION,2.84,56.7,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 0.2 M KSCN",298.0,2019-05-30,2019-07-31,6P5S,2691.0,1.0,390.0,65.0,,45.33,1.0,2.194,experimental,,0.238,0.1977,HIPK2 kinase domain bound to CX-4945
6WOC,X-RAY DIFFRACTION,2.18,43.61,"VAPOR DIFFUSION, HANGING DROP",7.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution of 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 80 mM NaF, 20 mM MgCl2 in present of 2mM 5-IP7 for 2 days, and transferred into 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 20 mM MgCl2 for 1min.",293.0,2020-04-24,2021-03-03,6WOC,1330.0,1.0,169.0,162.0,,20.43,1.0,1.35,experimental,16.805,0.1638,0.138,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5-diphosphoinositol pentakisphosphate and Mg, presoaked with 5-IP7, Mg and Fluoride, soaking 1min in the absence of Fluoride."
6WOD,X-RAY DIFFRACTION,2.21,44.36,"VAPOR DIFFUSION, HANGING DROP",7.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution of 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 80 mM NaF, 20 mM MgCl2 in present of 2mM 5-IP7 for 2 days, and transferred into 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 20 mM MgCl2 for 2min.",293.0,2020-04-24,2021-03-03,6WOD,1345.0,1.0,169.0,173.0,,20.3,1.0,1.35,experimental,16.976,0.1564,0.1328,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with inositol hexakisphosphate and Mg, presoaked with 5-IP7, Mg and Fluoride, soaking 2min in the absence of Fluoride."
6WOE,X-RAY DIFFRACTION,2.21,44.42,"VAPOR DIFFUSION, HANGING DROP",7.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution of 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 80 mM NaF, 20 mM MgCl2 in present of 2mM 5-IP7 for 2 days, and transferred into 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 20 mM MgCl2 for 10min.",293.0,2020-04-24,2021-03-03,6WOE,1410.0,1.0,169.0,173.0,,20.3,1.0,1.4,experimental,16.651,0.1519,0.1267,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with inositol hexakisphosphate and Mg, presoaked with 5-IP7, Mg and Fluoride, soaking 10min in the absence of Fluoride."
6WOF,X-RAY DIFFRACTION,2.21,44.38,"VAPOR DIFFUSION, HANGING DROP",7.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution of 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 80 mM NaF, 20 mM MgCl2 in present of 2mM 5-IP7 for 2 days, and transferred into 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 20 mM MgCl2 for 20 min.",293.0,2020-04-24,2021-03-03,6WOF,1327.0,1.0,169.0,158.0,,20.35,1.0,1.6,experimental,16.326,0.1484,0.1227,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with inositol hexakisphosphate and Mg, presoaked with 5-IP7, Mg and Fluoride, soaking 20min in the absence of Fluoride."
5GGP,X-RAY DIFFRACTION,2.21,44.36,"VAPOR DIFFUSION, HANGING DROP",6.0,"MES-NaOH, LiCl2, Na acetate, PEG-6000",293.0,2016-06-16,2016-08-10,5GGP,2703.0,4.0,348.0,278.0,,37.98,2.0,1.599,experimental,,0.2464,0.2161,"Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GlcNAc-beta1,2-Man-peptide"
6JGM,X-RAY DIFFRACTION,2.04,39.85,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8.0, 0.1M NaCl, 20% PEG monomethyl ether 550",293.0,2019-02-14,2020-02-26,6JGM,2324.0,1.0,299.0,48.0,,34.49,1.0,2.3,experimental,41.699,0.29036,0.21386,Crystal structure of CDK2 IN complex with Inhibitor NU-6140
8ERN,X-RAY DIFFRACTION,2.12,42.05,"VAPOR DIFFUSION, HANGING DROP",7.5,"15-20% PEG 4K,
50mM Hepes pH 7.5
50mM Ammonium Acetate",292.0,2022-10-12,2023-10-18,8ERN,2476.0,1.0,299.0,107.0,,34.66,1.0,1.64,experimental,35.52,0.2503,0.2075,Cyclin-free CDK2 in complex with Cpd21
7N3T,X-RAY DIFFRACTION,3.25,62.2,"VAPOR DIFFUSION, SITTING DROP",6.2,"0.4 M ammonium sulfate, 0.1 M bis-tris pH 6.2, 16% PEG 3350.",295.0,2021-06-01,2022-04-20,7N3T,6886.0,4.0,880.0,262.0,12.0,103.4,2.0,1.84,experimental,42.37,0.2425,0.2143,TrkA ECD complex with designed miniprotein ligand
5WH5,X-RAY DIFFRACTION,2.58,52.39,EVAPORATION,7.5,"The ~10mg/ml PDE4D2 (86-413) was stored in a buffer of 20 mM Tris.base, pH 7.5, 50 mM NaCl, 1 mM 2-mercaptoethanol, 1 mM EDTA and mixed with 2 mM (R)- or (S)-5. They were crystallized at 4C by hanging drop against a well buffer of 0.1 M HEPES pH 7.5, 15% PEG3350, 30% ethylene glycol, and 10% isopropanol.",277.0,2017-07-14,2018-07-18,5WH5,5707.0,2.0,654.0,388.0,,76.25,1.0,1.8,experimental,26.926,0.2141,0.1931,Crystal structure of the PDE4D2 catalytic domain in complex with inhibitor (R)-Zl-n-91
5WH6,X-RAY DIFFRACTION,,,EVAPORATION,7.5,"The ~10mg/ml PDE4D2 (86-413) was stored in a buffer of 20 mM Tris.base, pH 7.5, 50 mM NaCl, 1 mM 2-mercaptoethanol, 1 mM EDTA and mixed with 2 mM (R)- or (S)-5. They were crystallized at 4C by hanging drop against a well buffer of 0.1 M HEPES pH 7.5, 15% PEG3350, 30% ethylene glycol, and 10% isopropanol.",277.0,2017-07-14,2018-07-18,5WH6,5702.0,2.0,1014.0,384.0,,116.55,1.0,1.6,experimental,28.358,0.2243,0.20619,Crystal structure of PDE4D2 in complex with inhibitor (S_Zl-n-91)
6KJZ,X-RAY DIFFRACTION,2.55,51.86,VAPOR DIFFUSION,7.4,"0.1 M HEPES (pH 7.4), 0.1 M MgCl2, 15-20% PE G3350, 10% isopropanol, 25% ethylene glycol",277.0,2019-07-23,2020-03-18,6KJZ,5645.0,2.0,656.0,278.0,,76.67,1.0,2.20000094865,experimental,34.2062049023,0.246253774685,0.201308334149,Crystal structure of PDE4D catalytic domain complexed with compound 1
6KK0,X-RAY DIFFRACTION,2.57,52.12,VAPOR DIFFUSION,7.4,".1 M HEPES (pH 7.4), 0.1 M MgCl2, 15-20% PEG 3350, 10% isopropanol, 25% ethylene glycol",277.0,2019-07-23,2020-03-18,6KK0,5634.0,2.0,652.0,299.0,,76.41,1.0,2.20008760676,experimental,28.5701106052,0.247173095303,0.197869701281,Crystal structure of PDE4D catalytic domain complexed with compound 4e
7W4Y,X-RAY DIFFRACTION,2.25,45.32,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.1 M Hepes (pH 7.4), 0.1 M MgCl2, 15% PEG3350, 10% isopropanol, 25% ethylene glycol",277.0,2021-11-29,2022-03-16,7W4Y,5771.0,2.0,746.0,480.0,,86.47,1.0,2.10002940118,experimental,22.8378426616,0.24396145707,0.196501567225,Crystal structure of PDE4D catalytic domain complexed with 33a
5THT,X-RAY DIFFRACTION,2.36,47.89,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES (pH 7.5), 22% w/v PEG 6000, 4 mM TCEP",294.0,2016-09-30,2016-12-21,5THT,11469.0,4.0,1556.0,211.0,,176.46,1.0,2.407,experimental,,0.2123,0.1802,Crystal Structure of G303A HDAC8 in complex with M344
5QQD,X-RAY DIFFRACTION,2.38,48.25,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQD,3128.0,2.0,360.0,339.0,,41.3,2.0,1.91,experimental,35.516,0.2586,0.2059,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with Z56880342
5QQE,X-RAY DIFFRACTION,2.37,48.21,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQE,3140.0,2.0,360.0,339.0,,41.48,2.0,1.95,experimental,45.461,0.2841,0.2182,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-531-494
5QQF,X-RAY DIFFRACTION,2.34,47.47,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQF,3127.0,2.0,360.0,339.0,,41.31,2.0,2.26,experimental,52.975,0.2699,0.1977,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-004-412-710
5QQG,X-RAY DIFFRACTION,2.39,48.46,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQG,3141.0,2.0,360.0,339.0,,41.48,2.0,2.23,experimental,52.72,0.2742,0.197,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-541-216
5QQH,X-RAY DIFFRACTION,2.37,47.99,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQH,3136.0,2.0,360.0,338.0,,41.46,2.0,2.09,experimental,41.256,0.2631,0.1995,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-020-096-465
5QQI,X-RAY DIFFRACTION,2.34,47.5,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQI,3135.0,2.0,360.0,339.0,,41.4,2.0,2.08,experimental,41.402,0.2767,0.2188,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-178-994
5QQJ,X-RAY DIFFRACTION,2.35,47.72,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQJ,3139.0,2.0,360.0,337.0,,41.47,2.0,1.9,experimental,37.634,0.2687,0.2118,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-587-558
5QQK,X-RAY DIFFRACTION,2.35,47.74,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQK,3142.0,2.0,360.0,339.0,,41.49,2.0,2.24,experimental,44.67,0.2656,0.1999,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-359-835
5QQL,X-RAY DIFFRACTION,2.33,47.12,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQL,3137.0,2.0,360.0,339.0,,41.44,2.0,2.25,experimental,54.901,0.2702,0.1911,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-565-301
5QQM,X-RAY DIFFRACTION,2.35,47.64,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQM,3138.0,2.0,360.0,339.0,,41.43,2.0,2.02,experimental,37.948,0.2731,0.2113,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-009-565-325
5QQN,X-RAY DIFFRACTION,2.35,47.56,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 24% PEG 3350,293.15,2019-05-03,2019-12-18,5QQN,3138.0,2.0,360.0,339.0,,41.44,2.0,2.26,experimental,43.381,0.2786,0.205,PanDDA analysis group deposition -- Crystal Structure of Kalirin/Rac1 in complex with MolPort-010-382-606
6NTC,X-RAY DIFFRACTION,3.46,64.4,"VAPOR DIFFUSION, SITTING DROP",6.5,"30% PEG4000, 200mM NH4SO4, 100mM Na CaCo pH 6.5",293.15,2019-01-28,2020-03-04,6NTC,1658.0,2.0,252.0,5.0,,29.19,2.0,2.9,experimental,145.1335,0.2781,0.2517,Crystal Structure of G12V HRas-GppNHp bound in complex with the engineered RBD variant 1 of CRAF Kinase protein
5OSY,X-RAY DIFFRACTION,2.21,44.41,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris-HCl pH 7.6, 31% w/v PEG 4000",291.0,2017-08-18,2018-05-02,5OSY,5432.0,2.0,602.0,467.0,,71.95,1.0,2.06,experimental,,0.2266,0.1781,Human Decapping Scavenger enzyme (hDcpS) in complex with m7G(5'S)ppSp(5'S)G mRNA 5' cap analog
6VYJ,X-RAY DIFFRACTION,1.92,36.01,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Bis-Tris, pH 5.75, 35 % w/v PEG 3350. The crystals were cryo-preserved by 25% glucose",277.0,2020-02-26,2021-01-27,6VYJ,1398.0,1.0,164.0,154.0,,19.61,1.0,1.39,experimental,23.88,0.226,0.1976,Human UHRF1 TTD domain in complex with a fragment
7BF2,X-RAY DIFFRACTION,1.77,30.53,"VAPOR DIFFUSION, HANGING DROP",4.5,"25% PEG 1500, 0.1 M SPG buffer pH 4-5. 
CaM-CKBpeptide ratios of 1:4",293.0,2020-12-31,2021-07-21,7BF2,1523.0,3.0,185.0,87.0,,21.52,2.0,1.43,experimental,35.196,0.2281,0.2006,Ca2+-Calmodulin in complex with human muscle form creatine kinase peptide in extended 1:2 binding mode
5N7G,X-RAY DIFFRACTION,3.38,63.62,"VAPOR DIFFUSION, SITTING DROP",8.5,"14% PEG 8000, 200 mM MgCl2, 100 mM TRIS",296.0,2017-02-20,2017-11-08,5N7G,5939.0,3.0,861.0,,,97.86,2.0,2.95,experimental,,0.2635,0.2102,MAGI-1 complexed with a synthetic pRSK1 peptide
5U62,X-RAY DIFFRACTION,2.26,45.67,"VAPOR DIFFUSION, HANGING DROP",,"Using a PEG/salt combination as a precipitant. Briefly, EED was incubated with 10 mM B-nicotinamide adenine dinucleotide hydrate, 2 mM of a tightly binding proprietary compound, and 0.5 mM of a synthesized peptide which comprises the helix on EZH2 which interacts with EED. The crystals were grown using the vapor diffusion method. One uL of the protein mixture was combined with 1 uL of a precipitant comprised of 20% (w/v) PEG3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5, on a cover slip which was  suspended over a reservoir comprised of 0.5 mL of precipitant at 18 Celsius and sealed. The crystals grew in 4-6 days at 18 Celsius and then harvested and soaked in defined drops consisting of 30 uL of precipitant and 2 mM of compound for 24 h. Crystals were cryopreserved for data collection using a cryosolution consisting of 30% PEG 400 (v/v), 20% (w/v) PEG 3350, 0.2 M potassium iodide, and 0.1M Tris-HCl, pH 8.5.",291.0,2016-12-07,2017-01-11,5U62,6983.0,4.0,794.0,800.0,,93.03,2.0,1.9,experimental,31.23,0.208,0.168,"Crystal structure of EED in complex with H3K27Me3 peptide and 6-(benzo[d][1,3]dioxol-4-ylmethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine"
4ZGA,X-RAY DIFFRACTION,2.23,44.93,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.3 M KSCN",298.0,2015-04-22,2015-10-14,4ZGA,5870.0,1.0,863.0,18.0,12.0,100.53,1.0,2.6,experimental,66.977,0.27421,0.20794,Structural basis for inhibition of human autotaxin by four novel compounds
5WCI,X-RAY DIFFRACTION,2.38,48.26,"VAPOR DIFFUSION, SITTING DROP",5.0,"20% PEG 3350, 0.2 M Na malonate pH5.0",291.0,2017-06-30,2017-07-26,5WCI,2704.0,1.0,295.0,242.0,,35.63,1.0,1.78,experimental,24.099,0.2183,0.1826,Human MYST histone acetyltransferase 1
5M51,X-RAY DIFFRACTION,2.4,48.82,"VAPOR DIFFUSION, HANGING DROP",,"3 % PEG 8000, 50 mM Tris pH 8.5",293.0,2016-10-20,2016-11-09,5M51,2187.0,1.0,279.0,99.0,,33.03,1.0,1.899,experimental,,0.2567,0.222,Nek2 bound to arylaminopurine compound 8
5M53,X-RAY DIFFRACTION,2.36,47.98,"VAPOR DIFFUSION, HANGING DROP",,"3 % PEG 8000, 50 mM Tris pH 8.5",293.0,2016-10-20,2016-11-09,5M53,2365.0,1.0,279.0,199.0,,33.99,1.0,1.9,experimental,,0.2352,0.196,Nek2 bound to arylaminopurine inhibitor 11
5M55,X-RAY DIFFRACTION,2.59,52.43,"VAPOR DIFFUSION, HANGING DROP",,"3 % PEG 8000, 50 mM Tris pH 8.5",293.0,2016-10-20,2016-11-02,5M55,2084.0,1.0,279.0,101.0,,33.29,1.0,2.4,experimental,,0.2486,0.1876,Nek2 bound to arylaminopurine 71
5M57,X-RAY DIFFRACTION,2.41,49.0,"VAPOR DIFFUSION, HANGING DROP",,"3 % PEG 8000, 50 mM Tris pH 8.5",293.0,2016-10-20,2016-11-23,5M57,2133.0,1.0,279.0,40.0,,33.03,1.0,2.3,experimental,,0.2742,0.2186,Nek2 bound to arylaminopurine 6
6SGD,X-RAY DIFFRACTION,2.71,54.66,"VAPOR DIFFUSION, HANGING DROP",8.5,"50 mM Tris pH 8.5, 3% PEG 8000",291.0,2019-08-04,2020-06-17,6SGD,2084.0,1.0,279.0,136.0,,33.07,1.0,2.0,experimental,37.47,0.2338,0.1977,Nek2 kinase covalently bound to 2-arylamino-6-ethynylpurine inhibitor 24
6SGI,X-RAY DIFFRACTION,2.73,54.91,"VAPOR DIFFUSION, HANGING DROP",8.5,"50 mM Tris pH 8.5, 3% PEG 8000",291.0,2019-08-05,2020-06-17,6SGI,2184.0,1.0,279.0,134.0,,33.09,1.0,2.3,experimental,42.66,0.2658,0.2129,Nek2 kinase bound to inhibitor 96
6SGK,X-RAY DIFFRACTION,2.77,55.61,"VAPOR DIFFUSION, HANGING DROP",8.5,"50 mM Tris pH 8.5, 3% PEG 8000",291.0,2019-08-05,2020-06-17,6SGK,2179.0,1.0,279.0,197.0,,32.9,1.0,2.0,experimental,33.9,0.2227,0.1954,Nek2 kinase bound to inhibitor 102
5FP6,X-RAY DIFFRACTION,2.25,45.0,,7.4,"PROTEIN CONCENTRATION: 13.6 MG/ML, pH 7.4",,2015-11-27,2015-12-23,5FP6,2544.0,1.0,298.0,337.0,,34.46,1.0,1.85,experimental,30.85,0.2403,0.207,"Structure of cyclin-dependent kinase 2 with small-molecule ligand 3-(4,7-dichloro-1H-indol-3-yl)prop-2-yn-1-ol (AT17833) in an alternate binding site."
5K4J,X-RAY DIFFRACTION,2.04,39.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 4K, 50 mM Hepes pH7.5, 50 mM Ammonia Acetate",292.0,2016-05-20,2016-07-06,5K4J,2559.0,1.0,299.0,237.0,,34.49,1.0,1.6,experimental,,0.2231,0.1751,Crystal Structure of CDK2 in complex with compound 22
6INL,X-RAY DIFFRACTION,2.04,39.79,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8.0, 0.1M NaCl, 20% PEG monomethyl ether 550",298.0,2018-10-25,2019-10-30,6INL,2376.0,1.0,299.0,153.0,,34.46,1.0,1.75,experimental,30.253,0.24969,0.19579,Crystal structure of CDK2 IN complex with Inhibitor CVT-313
7NVQ,X-RAY DIFFRACTION,2.04,39.73,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG3350, 0.1M MES pH 7.0",278.0,2021-03-15,2021-06-16,7NVQ,2400.0,1.0,300.0,48.0,,34.7,1.0,2.05,experimental,34.155,0.2879,0.2373,Aerosol-soaked human cdk2 crystals with Staurosporine
6BHD,X-RAY DIFFRACTION,2.32,47.01,VAPOR DIFFUSION,7.5,"25% PEG3350, 0.2 M sodium chloride, 0.1 M HEPES, 5% glycerol",291.0,2017-10-30,2017-12-06,6BHD,2174.0,2.0,257.0,203.0,,29.53,2.0,1.25,experimental,16.006,0.1829,0.1474,Crystal structure of SETDB1 with a modified H3 peptide
6BHE,X-RAY DIFFRACTION,2.26,45.56,VAPOR DIFFUSION,7.5,"25% PEG3350, 0.2 M sodium chloride, 0.1 M HEPES, 5% glycerol",291.0,2017-10-30,2017-12-06,6BHE,2078.0,2.0,257.0,149.0,,29.53,2.0,1.35,experimental,19.566,0.1725,0.1345,Crystal structure of SETDB1 with a modified H3 peptide
6BHG,X-RAY DIFFRACTION,2.35,47.65,VAPOR DIFFUSION,6.5,"20% PEG5000 MME, 0.1 M Bis-Tris",291.0,2017-10-30,2017-12-06,6BHG,2069.0,2.0,257.0,223.0,,29.48,2.0,1.45,experimental,20.631,0.1761,0.133,Crystal structure of SETDB1 with a modified H3 peptide
6BHI,X-RAY DIFFRACTION,2.36,47.8,VAPOR DIFFUSION,7.5,"25% PEG3350, 0.2 M lithium sulfate, 0.1 M HEPES",291.0,2017-10-30,2017-12-06,6BHI,2116.0,2.0,255.0,225.0,,29.39,2.0,1.4,experimental,17.643,0.1872,0.1476,Crystal structure of SETDB1 with a modified H3 peptide
5T18,X-RAY DIFFRACTION,2.32,46.91,VAPOR DIFFUSION,7.0,"25% PEG8K + 3% MEPEG5K + 0.2M TRIS-HCL, PH 7.0",298.0,2016-08-18,2017-03-08,5T18,2166.0,1.0,267.0,147.0,,31.78,1.0,1.5,experimental,24.9,0.223,0.203,"Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-fluoro-5-[3-(8-fluoro-1-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)-2-methylphenyl]-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1h-carbazole-8-carboxamide"
7N5O,X-RAY DIFFRACTION,2.21,44.36,"VAPOR DIFFUSION, HANGING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5 and 0.12M alcohol mixture",277.0,2021-06-06,2021-09-08,7N5O,2607.0,1.0,283.0,297.0,,33.1,1.0,1.25,experimental,16.232,0.1959,0.1786,Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitor
5TJ8,X-RAY DIFFRACTION,2.06,40.26,VAPOR DIFFUSION,6.0,"0.1 M MMT (DL-malic acid, MES, Tris-base in molar ratio of 1:2:2) pH 6.0, 25% PEG1500",298.0,2016-10-03,2017-06-07,5TJ8,3510.0,1.0,447.0,52.0,,53.46,1.0,2.3,experimental,69.023,0.3162,0.2151,"Structure of WWP2 WW2-2,3-linker-HECT (no WW2 observed)"
7F90,X-RAY DIFFRACTION,2.32,0.47,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1m Bis-tris ph5.5,45%PEG4000",296.0,2021-07-03,2022-09-14,7F90,6292.0,6.0,4496.0,189.0,,492.66,3.0,2.39,experimental,44.0392,0.2581,0.2196,Crystal structure of SARS auxiliary protein in complex with human nuclear protein
6BG0,X-RAY DIFFRACTION,2.26,45.53,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-27,2018-02-21,6BG0,4244.0,6.0,566.0,346.0,,64.46,3.0,2.125,experimental,,0.2011,0.1606,"Caspase-3 Mutant - D9A,D28A,S150D"
6BG4,X-RAY DIFFRACTION,2.25,45.42,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-27,2018-02-21,6BG4,4222.0,6.0,566.0,362.0,,64.85,3.0,1.87,experimental,,0.2067,0.1635,Caspase-3 Mutant- T152D
6BGK,X-RAY DIFFRACTION,2.18,43.68,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-28,2018-02-21,6BGK,4580.0,6.0,568.0,522.0,,64.83,3.0,1.87,experimental,,0.2109,0.1593,"Caspase-3 Mutant- D9A,D28A,T152D"
6BH9,X-RAY DIFFRACTION,2.14,42.5,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-30,2018-02-21,6BH9,4390.0,6.0,568.0,435.0,,64.76,3.0,1.94,experimental,,0.1887,0.1457,Caspase-3 Mutant - T152A
6EOU,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Na-HEPES and 0.1 M MOPS-HCl pH 7,5, 0.04 M diethylene glycol, 0.04 M triethylene glycol, 0.04 M tetraethylene glycol, 0.04 M pentaethylene glycol, 20 % v/v ethylene glycol and 10 % w/v PEG 4000",295.2,2017-10-10,2018-05-09,6EOU,2988.0,1.0,388.0,280.0,,43.54,1.0,1.75,experimental,37.879,0.22681,0.19101,O-GlcNAc transferase TPR domain with the intellectual disability associated mutation L254F
4OR9,X-RAY DIFFRACTION,3.11,60.48,"VAPOR DIFFUSION, HANGING DROP",5.8,"100mM MES, pH 5.8, 7% PEG3350, VAPOR DIFFUSION, HANGING DROP, temperature 294K",294.0,2014-02-11,2015-05-20,4OR9,4855.0,2.0,714.0,251.0,,80.87,2.0,2.23,experimental,,0.2148,0.1827,Crystal structure of human calcineurin
6T9T,X-RAY DIFFRACTION,2.37,48.05,VAPOR DIFFUSION,,"100 mM Sodium acetate pH 4.6, 2 M Sodium formate, protein concentration 7 mg/ml",291.0,2019-10-28,2020-11-18,6T9T,2159.0,1.0,241.0,211.0,3.0,27.14,1.0,1.69,experimental,25.5897796376,0.201903857021,0.170323632146,"Matriptase in complex with the synthetic inhibitor (S)-3-(3-(4-(3-(tert-butyl)ureido)piperidin-1-yl)-2-((3'-fluoro-4'-(hydroxymethyl)-[1,1'-biphenyl])-3-sulfonamido)-3-oxopropyl)benzimidamide (MI-1904)"
8G1W,X-RAY DIFFRACTION,2.23,44.76,"VAPOR DIFFUSION, SITTING DROP",4.5,"2M sodium formate, 100 sodium acetate",291.0,2023-02-03,2024-02-07,8G1W,2240.0,3.0,251.0,258.0,3.0,28.05,3.0,1.2,experimental,,0.1658,0.1484,Crystal Structure Matriptase (C731S) in Complex with Inhibitor VD4162B
6CWU,X-RAY DIFFRACTION,3.16,66.81,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES, 200 mM magnesium acetate, and 14% polyethylene glycol 8000, pH 7.5",277.15,2018-03-31,2018-10-31,6CWU,2709.0,1.0,329.0,352.0,,38.48,1.0,2.08,experimental,45.536,0.29122,0.25472,Protein Tyrosine Phosphatase 1B F135Y mutant
6CWV,X-RAY DIFFRACTION,3.17,66.93,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES, 200 mM magnesium acetate, and 14% polyethylene glycol 8000, pH 7.5",277.15,2018-03-31,2018-10-24,6CWV,2576.0,1.0,329.0,220.0,,38.48,1.0,1.98002287694,experimental,39.2253048481,0.246377958586,0.204635027207,Protein Tyrosine Phosphatase 1B A122S mutant
7L0C,X-RAY DIFFRACTION,3.17,61.15,VAPOR DIFFUSION,7.5,"0.1 M tris hydrochloride pH 7.5-8.5, 0.2 M magnesium acetate tetrahydrate, and 20-25 % PEG 8000",277.0,2020-12-11,2021-05-12,7L0C,2668.0,1.0,321.0,278.0,,37.3,1.0,1.8,experimental,29.9711,0.1748,0.1631,Ligand-free PTP1B T177G
7L0H,X-RAY DIFFRACTION,3.18,61.32,VAPOR DIFFUSION,7.5,"0.1 M tris hydrochloride pH 7.5-8.5, 0.2 M magnesium acetate tetrahydrate, and 20-25 % PEG 8000",277.0,2020-12-11,2021-05-12,7L0H,2566.0,1.0,321.0,136.0,,37.41,1.0,2.1,experimental,49.4431,0.2079,0.178,Vanadate-bound PTP1B T177G
7T36,X-RAY DIFFRACTION,2.44,49.52,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M MgCl2, 0.1 M Bis-Tris pH 5.5, 15% PEG 3,350",291.0,2021-12-07,2022-01-19,7T36,2273.0,1.0,265.0,204.0,,31.5,1.0,1.65,experimental,30.1843,0.2027,0.18,Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 bound to ZS1-322
8BI9,X-RAY DIFFRACTION,1.71,28.21,"VAPOR DIFFUSION, SITTING DROP",,"16% (v/v) tert-butanol, 0.1 M sodium citrate pH 3.9",277.0,2022-11-01,2022-12-21,8BI9,823.0,4.0,92.0,79.0,,10.48,1.0,1.44,experimental,17.9827115008,0.183407647785,0.151544646339,Structure of a cyclic beta-hairpin peptide derived from neuronal nitric oxide synthase (T112W/T116E variant)
7KK5,X-RAY DIFFRACTION,2.54,51.64,VAPOR DIFFUSION,,"Salt: 0.2 M Ammonium sulfate
Buffer: 0.1 M HEPES (pH 7.50)
Precipitant: 25.0 %w/v PEG 3350",294.0,2020-10-27,2021-01-06,7KK5,11827.0,4.0,1408.0,917.0,2.0,160.47,1.0,1.7,experimental,38.64,0.238,0.206,Structure of the catalytic domain of PARP1 in complex with niraparib
5ORL,X-RAY DIFFRACTION,2.74,55.03,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5; 0.5 M NaCl; 0.2 M MgCl2; 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORL,2388.0,1.0,265.0,197.0,,31.61,1.0,1.69,experimental,34.2313,0.2383,0.2046,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORN,X-RAY DIFFRACTION,2.8,56.05,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORN,2235.0,1.0,265.0,59.0,,31.45,1.0,2.19,experimental,61.3723,0.2615,0.1995,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORO,X-RAY DIFFRACTION,2.8,55.99,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORO,2248.0,1.0,265.0,63.0,,31.51,1.0,2.12,experimental,59.6358,0.2808,0.2204,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORP,X-RAY DIFFRACTION,2.76,55.43,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORP,2244.0,1.0,265.0,69.0,,31.55,1.0,2.19,experimental,58.9207,0.2733,0.2068,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORR,X-RAY DIFFRACTION,2.79,55.92,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris, pH 8.5; 0.5 M NaCl; 0.2 M MgCl2; 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORR,2281.0,1.0,265.0,99.0,,31.59,1.0,2.09,experimental,52.7137,0.2561,0.199,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORS,X-RAY DIFFRACTION,2.79,55.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORS,2307.0,1.0,265.0,123.0,,31.55,1.0,1.98,experimental,47.8867,0.2573,0.207,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORT,X-RAY DIFFRACTION,2.81,56.16,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORT,2231.0,1.0,265.0,43.0,,31.6,1.0,2.56,experimental,52.64,0.2752,0.2043,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORV,X-RAY DIFFRACTION,2.74,55.06,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORV,2275.0,1.0,265.0,98.0,,31.55,1.0,1.88,experimental,47.6308,0.2677,0.2108,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORW,X-RAY DIFFRACTION,2.8,56.04,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORW,2262.0,1.0,265.0,83.0,,31.54,1.0,2.0,experimental,54.3111,0.2696,0.2147,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORX,X-RAY DIFFRACTION,2.78,55.78,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORX,2294.0,1.0,265.0,117.0,,31.53,1.0,1.88,experimental,47.1858,0.2696,0.2199,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORY,X-RAY DIFFRACTION,2.79,55.86,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORY,2243.0,1.0,265.0,60.0,,31.58,1.0,1.99,experimental,61.3357,0.2654,0.2043,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5ORZ,X-RAY DIFFRACTION,2.76,55.48,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5ORZ,2302.0,1.0,265.0,91.0,,31.62,1.0,1.92,experimental,56.5727,0.2443,0.1972,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS0,X-RAY DIFFRACTION,2.79,55.84,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5OS0,2333.0,1.0,265.0,141.0,,31.51,1.0,1.74,experimental,43.1512,0.2635,0.2173,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS1,X-RAY DIFFRACTION,2.77,55.63,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5OS1,2309.0,1.0,265.0,111.0,,31.57,1.0,1.9,experimental,47.2626,0.25,0.201,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS2,X-RAY DIFFRACTION,2.78,55.78,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5OS2,2285.0,1.0,265.0,123.0,,31.42,1.0,1.92,experimental,39.3632,0.2509,0.2111,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS3,X-RAY DIFFRACTION,2.77,55.61,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5OS3,2328.0,1.0,265.0,150.0,,31.44,1.0,1.81,experimental,43.968,0.238,0.2018,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS4,X-RAY DIFFRACTION,2.71,54.61,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5OS4,2317.0,1.0,265.0,138.0,,31.6,1.0,1.88,experimental,42.3239,0.2398,0.2037,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS5,X-RAY DIFFRACTION,2.76,55.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5OS5,2324.0,1.0,268.0,125.0,,32.0,1.0,1.74,experimental,50.3667,0.2363,0.1969,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OS6,X-RAY DIFFRACTION,2.73,54.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-16,2017-11-01,5OS6,2244.0,1.0,265.0,65.0,,31.48,1.0,2.2,experimental,55.1535,0.2773,0.2124,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OSD,X-RAY DIFFRACTION,2.73,55.01,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-17,2017-11-01,5OSD,2284.0,1.0,267.0,97.0,,31.9,1.0,1.99,experimental,54.8167,0.2395,0.1957,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OSE,X-RAY DIFFRACTION,2.76,55.43,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-17,2017-11-01,5OSE,2303.0,1.0,265.0,116.0,,31.49,1.0,1.9,experimental,53.6501,0.237,0.1895,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
5OSF,X-RAY DIFFRACTION,2.77,55.66,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2017-08-17,2017-11-01,5OSF,2272.0,1.0,265.0,84.0,,31.52,1.0,1.89,experimental,55.1139,0.2541,0.2018,Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment
6HJJ,X-RAY DIFFRACTION,2.55,51.76,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M lithium sulfate,
0.1 M sodium acetate pH 4.5, 50 % w/v polyethylene glycol 400;",295.0,2018-09-04,2018-10-03,6HJJ,2179.0,1.0,285.0,76.0,,33.88,1.0,2.13,experimental,,0.2692,0.2088,Crystal structure of Aurora-A L210C catalytic domain in complex with ASDO6 ligand
6HJK,X-RAY DIFFRACTION,2.67,54.0,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium sulfate, 0.1 M tri-sodium citrate pH 5.6, 25 % w/v polyethylene glycol 4000",295.0,2018-09-04,2018-10-03,6HJK,2054.0,1.0,285.0,18.0,,33.52,1.0,2.4,experimental,,0.2523,0.2169,Crystal Structure of Aurora-A L210C catalytic domain in complex with ASDO2
6R49,X-RAY DIFFRACTION,2.58,52.31,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2019-03-22,2019-05-08,6R49,2222.0,1.0,285.0,73.0,,33.73,1.0,2.209,experimental,,0.24,0.1919,Aurora-A in complex with shape-diverse fragment 39
6R4B,X-RAY DIFFRACTION,2.56,51.91,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2019-03-22,2019-05-08,6R4B,2256.0,1.0,285.0,61.0,,33.88,1.0,2.15,experimental,,0.2301,0.1886,Aurora-A in complex with shape-diverse fragment 56
6R4C,X-RAY DIFFRACTION,2.56,51.94,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2019-03-22,2019-05-01,6R4C,2284.0,1.0,285.0,84.0,,33.84,1.0,2.04,experimental,,0.2257,0.1856,Aurora-A in complex with shape-diverse fragment 57
6R4D,X-RAY DIFFRACTION,2.6,52.77,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298.0,2019-03-22,2019-05-08,6R4D,2296.0,1.0,285.0,102.0,,33.79,1.0,2.009,experimental,,0.2329,0.195,Aurora-A in complex with shape-diverse fragment 58
7AYH,X-RAY DIFFRACTION,2.56,51.96,"VAPOR DIFFUSION, SITTING DROP",,"24% PEG 3350, 0.2 M sodium malonate pH 7",277.15,2020-11-12,2021-01-13,7AYH,2031.0,1.0,285.0,,,33.31,1.0,2.8,experimental,132.566,0.3126,0.2726,Crystal structure of Aurora A in complex with 7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-one derivative (compound 2c)
6NIF,X-RAY DIFFRACTION,2.38,48.39,"VAPOR DIFFUSION, HANGING DROP",,"100 mM HEPES, pH 7.0, 1.1 M sodium malonate, 0.5% Jeffamine ED-2001",289.0,2018-12-27,2019-09-11,6NIF,1859.0,1.0,260.0,147.0,,28.73,1.0,2.002,experimental,,0.2658,0.2264,crystal structure of human REV7-RAN complex
4OA7,X-RAY DIFFRACTION,2.13,42.13,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Bis-Tris, 0.2 M MgCl2 and 25% PEG3350, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2014-01-03,2015-01-07,4OA7,7048.0,4.0,860.0,352.0,,100.05,1.0,2.301,experimental,,0.2831,0.2254,Crystal structure of Tankyrase1 in complex with IWR1
6BFJ,X-RAY DIFFRACTION,2.16,43.16,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-26,2018-02-21,6BFJ,2419.0,3.0,284.0,350.0,,32.43,3.0,1.543,experimental,,0.1622,0.142,"Caspase-3 Mutant - T245D,S249D"
7FCZ,X-RAY DIFFRACTION,2.09,41.21,"VAPOR DIFFUSION, HANGING DROP",,"0.25 M ammonium iodide, 0.03 M glycyl-glycyl-glycine and 15-25% PEG3350.",277.0,2021-07-15,2022-01-19,7FCZ,4085.0,2.0,594.0,82.0,,68.25,1.0,2.21,experimental,38.4808,0.2567,0.2345,Crystal Structure of human RIPK1 kinase domain in complex with a novel inhibitor
7FD0,X-RAY DIFFRACTION,2.15,42.86,"VAPOR DIFFUSION, HANGING DROP",,"0.25 M ammonium iodide, 0.03 M glycyl-glycyl-glycine and 15-25% PEG3350",277.0,2021-07-15,2022-01-19,7FD0,4309.0,2.0,594.0,219.0,,68.34,1.0,2.0,experimental,32.6319,0.2655,0.2311,Crystal Structure of human RIPK1 kinase domain in complex with a novel inhibitor
5I6V,X-RAY DIFFRACTION,2.23,44.93,VAPOR DIFFUSION,,"0.2M Sodium Malonate, pH7.0, 20% w/v PEG3350",297.0,2016-02-16,2016-04-13,5I6V,8927.0,2.0,1050.0,1108.0,,120.56,1.0,1.87,experimental,,0.2317,0.2014,"Structure of F285S, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2"
6OL4,X-RAY DIFFRACTION,3.37,63.53,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-04-15,2020-03-25,6OL4,2782.0,1.0,296.0,171.0,,34.72,1.0,2.15,experimental,,0.2574,0.2156,"Protein Tyrosine Phosphatase 1B (1-301), F182A mutant, apo state"
6OLQ,X-RAY DIFFRACTION,3.41,63.94,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-04-16,2019-08-07,6OLQ,2757.0,1.0,297.0,225.0,,34.9,1.0,2.1,experimental,,0.2344,0.2031,"Protein Tyrosine Phosphatase 1B (1-301), P188A mutant, apo state"
6OLV,X-RAY DIFFRACTION,3.41,63.93,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-04-17,2019-08-07,6OLV,2549.0,1.0,296.0,226.0,,34.78,1.0,2.1,experimental,,,,"Protein Tyrosine Phosphatase 1B (1-301), P185A mutant, apo state"
6OMY,X-RAY DIFFRACTION,3.36,63.39,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-04-19,2019-08-07,6OMY,2688.0,1.0,297.0,239.0,,34.75,1.0,2.1,experimental,,0.2052,0.1861,"Protein Tyrosine Phosphatase 1B (1-301), P180A mutant, apo state"
6PFW,X-RAY DIFFRACTION,3.32,62.99,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-06-22,2019-08-07,6PFW,2555.0,1.0,297.0,129.0,,34.8,1.0,2.34,experimental,,0.2474,0.2093,"Protein Tyrosine Phosphatase 1B (1-301), T177A mutant, apo state"
6PG0,X-RAY DIFFRACTION,3.38,63.64,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-06-23,2019-08-07,6PG0,2683.0,1.0,297.0,239.0,,35.07,1.0,2.1,experimental,,0.2251,0.1947,"Protein Tyrosine Phosphatase 1B (1-301), P188A mutant, vanadate bound state"
6PGT,X-RAY DIFFRACTION,3.35,63.24,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-06-24,2019-08-07,6PGT,2708.0,1.0,298.0,250.0,,35.06,1.0,2.2,experimental,,0.2301,0.1882,"Protein Tyrosine Phosphatase 1B (1-301), T177A mutant, vanadate bound state"
6PHA,X-RAY DIFFRACTION,3.28,62.53,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-06-25,2019-08-07,6PHA,2616.0,1.0,297.0,152.0,,35.27,1.0,2.299,experimental,,0.2765,0.2241,"Protein Tyrosine Phosphatase 1B (1-301), F182A mutant, vanadate bound state"
6PHS,X-RAY DIFFRACTION,3.31,62.81,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-06-25,2019-08-07,6PHS,2555.0,1.0,297.0,128.0,,34.86,1.0,2.129,experimental,,0.2412,0.1976,"Protein Tyrosine Phosphatase 1B (1-301), P185A mutant, vanadate bound state"
6PM8,X-RAY DIFFRACTION,3.38,63.66,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes,  0.2 M magnesium acetate and 15-20% polyethylene glycol 8000",277.0,2019-07-01,2019-08-07,6PM8,2730.0,1.0,297.0,275.0,,34.95,1.0,2.06,experimental,,0.2195,0.1952,"Protein Tyrosine Phosphatase 1B (1-301), P180A mutant, vanadate bound state"
4XJ0,X-RAY DIFFRACTION,2.92,57.94,EVAPORATION,7.5,"10% PEG3350, 0.2 M proline, and 0.1 M HEPES pH7.5, in a 24-well Linbro plates",277.0,2015-01-08,2015-09-16,4XJ0,5788.0,2.0,698.0,120.0,,82.26,1.0,2.58,experimental,82.76,0.2438,0.2084,Crystal structure of ERK2 in complex with an inhibitor 14K
8BI8,X-RAY DIFFRACTION,2.77,55.56,"VAPOR DIFFUSION, SITTING DROP",,"25% (w/v) PEG3350, 0.1 M bis-tris, pH 5.5",277.0,2022-11-01,2022-12-21,8BI8,444.0,2.0,46.0,38.0,,4.98,1.0,1.59,experimental,31.0686918595,0.236529729554,0.208614950995,Structure of a cyclic beta-hairpin peptide derived from neuronal nitric oxide synthase
7KPU,X-RAY DIFFRACTION,2.26,45.49,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-tris, pH 5.5,
2M Ammonium sulfate",291.0,2020-11-12,2021-06-16,7KPU,3788.0,4.0,418.0,422.0,,51.06,2.0,1.43,experimental,20.26,0.1827,0.1626,Crystal structure of human NatD (NAA40) bound to a bisubstrate analogue with a C-3 linker
7AUV,X-RAY DIFFRACTION,2.33,47.31,"VAPOR DIFFUSION, HANGING DROP",7.3,"0.2M (NH4)2SO4
32% MPEG 2000
.02M Mercaptoethanol
.1M pH=7.2 HEPES/NaOH",291.0,2020-11-03,2021-10-06,7AUV,3386.0,1.0,368.0,467.0,,43.5,1.0,1.76,experimental,29.57,0.229,0.167,The structure of ERK2 in complex with dual inhibitor ASTX029
8AOH,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOH,3275.0,1.0,368.0,480.0,,43.32,1.0,1.6,experimental,21.721,0.2137,0.1699,Specific covalent inhibitor(18) of ERK2
8AOJ,X-RAY DIFFRACTION,2.31,46.65,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.2M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOJ,3363.0,1.0,368.0,488.0,,43.29,1.0,1.12,experimental,22.533,0.2027,0.1791,Specific covalent inhibitor of ERK2
4R0I,X-RAY DIFFRACTION,2.26,45.65,"VAPOR DIFFUSION, HANGING DROP",8.3,"0.1M Tris pH 8.3 0.2M MgCl2, 20% PEG8000 , VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-07-31,2015-02-11,4R0I,2006.0,2.0,245.0,83.0,4.0,27.44,2.0,1.9,experimental,18.697,0.28857,0.21976,CRYSTAL STRUCTURE of MATRIPTASE in COMPLEX WITH INHIBITOR
6BQD,X-RAY DIFFRACTION,2.81,56.28,VAPOR DIFFUSION,5.0,8% Tacsimate pH 5.0 and 20% PEG3350,277.0,2017-11-27,2019-02-20,6BQD,2209.0,2.0,260.0,54.0,,30.88,1.0,2.136,experimental,50.2059,0.2264,0.1851,"TAF1-BD2 bromodomain in complex with (E)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-N,N-dimethylbenzamide"
5MK1,X-RAY DIFFRACTION,2.14,42.48,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.1 M Tris pH 7.8, 5%  (poly-glutamic acid low molecular weight polymer) 20% PEG3350",277.0,2016-12-02,2017-08-16,5MK1,11890.0,8.0,1516.0,167.0,,171.23,2.0,2.5,experimental,,0.2263,0.1759,Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (CHMP4A peptide complex structure)
6EY2,X-RAY DIFFRACTION,2.73,54.95,EVAPORATION,7.5,"10% PEG 400, 0.2 M MgCl2, 0.1M Hepes-Na",293.0,2017-11-10,2018-08-08,6EY2,6885.0,8.0,1168.0,85.0,4.0,136.29,1.0,2.7,experimental,71.01,0.28408,0.2351,Crystal structure of XIAP-BIR3 in complex with a cIAP1-selective SM
3WZD,X-RAY DIFFRACTION,2.45,49.91,VAPOR DIFFUSION,9.5,"0.1M CHES,5-20% PEG 8000, pH 9.5, VAPOR DIFFUSION, temperature 277K",277.0,2014-09-24,2015-05-27,3WZD,2554.0,1.0,309.0,213.0,,36.82,1.0,1.57,experimental,29.321,0.21188,0.18089,KDR in complex with ligand lenvatinib
6NFT,X-RAY DIFFRACTION,2.87,57.17,"VAPOR DIFFUSION, SITTING DROP",,"2 M sodium/potassium phosphate pH 7.0, 1.1% DMSO (v/v), 25% ethylene glycol (v/v)",298.0,2018-12-20,2019-01-02,6NFT,2136.0,2.0,242.0,245.0,1.0,27.8,1.0,1.65,experimental,17.248,0.2062,0.1802,Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with (4-oxoquinazolin-3(4H)-yl)acetic acid
6C02,X-RAY DIFFRACTION,2.65,53.61,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1M HEPES pH 7, 8% PEG 8000",293.0,2017-12-27,2018-05-02,6C02,14922.0,2.0,1676.0,1305.0,32.0,200.54,1.0,1.942,experimental,,0.1974,0.1657,"Human ectonucleotide pyrophosphatase / phosphodiesterase 3 (ENPP3, NPP3, CD203c), inactive (T205A), N594S, with alpha,beta-methylene-ATP (AMPCPP)"
6PZP,X-RAY DIFFRACTION,2.76,55.42,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium formate, 20% w/v PEG3350",277.0,2019-08-01,2020-08-05,6PZP,2269.0,2.0,266.0,156.0,,30.61,2.0,1.94,experimental,47.2287,0.2079,0.1671,Crystal structure of caspase-1 in complex with VX-765
7K03,X-RAY DIFFRACTION,2.45,49.76,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2 M Magnesium acetate tetrahydrate, 0.1 M Sodium cacodylate trihydrate, 20% Polyethylene glycol 8,000",291.0,2020-09-03,2021-09-22,7K03,2444.0,1.0,265.0,359.0,,31.63,1.0,1.6,experimental,22.5989,0.1805,0.1523,Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 bound to ATR kinase inhibitor AZD6738
5AJN,X-RAY DIFFRACTION,2.57,52.08,,,,,2015-02-26,2015-03-11,5AJN,4809.0,2.0,587.0,555.0,5.0,68.55,2.0,1.67,experimental,23.836,0.23216,0.19563,Crystal structure of the inactive form of GalNAc-T2 in complex with the glycopeptide MUC5AC-Cys13
5AJO,X-RAY DIFFRACTION,2.56,52.04,,,,,2015-02-26,2015-03-11,5AJO,5120.0,2.0,588.0,792.0,5.0,69.79,2.0,1.48,experimental,21.137,0.1806,0.1576,"Crystal structure of the inactive form of GalNAc-T2 in complex with the glycopeptide MUC5AC-3,13"
5UPK,X-RAY DIFFRACTION,2.34,47.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES pH 7.5, 22% PEG1,000",295.0,2017-02-03,2017-12-27,5UPK,4070.0,3.0,579.0,25.0,,66.56,3.0,2.4,experimental,68.109,0.26364,0.2179,"CDC42 binds PAK4 via an extended GTPase-effector interface - 3 peptide: PAK4cat, PAK4-N45, CDC42"
4D2R,X-RAY DIFFRACTION,2.41,48.86,VAPOR DIFFUSION,,"20% PEF3350, 0.2M MGCL2, 0.1M PCTP PH 7.5",,2014-05-12,2015-04-22,4D2R,2602.0,1.0,302.0,221.0,,35.05,1.0,2.1,experimental,28.35,0.221,0.179,Human IGF in complex with a Dyrk1B inhibitor
7TD5,X-RAY DIFFRACTION,2.95,58.3,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG3350, 100 mM (NH4)2SO4, 50mM HEPES 6.8",289.0,2021-12-30,2022-11-16,7TD5,16191.0,10.0,2638.0,,1.0,304.79,5.0,2.994,experimental,,0.2299,0.1957,Structure of human PRC2-EZH1 containing phosphorylated SUZ12
6HK4,X-RAY DIFFRACTION,3.37,63.54,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.2M potassium fluoride
22% PEG 3350",293.0,2018-09-05,2019-07-17,6HK4,6019.0,3.0,709.0,237.0,,83.01,2.0,2.5,experimental,62.4119,0.2492,0.2098,Crystal structure of GSK-3B in complex with pyrazine inhibitor C22
6C0U,X-RAY DIFFRACTION,4.09,69.94,"VAPOR DIFFUSION, HANGING DROP",7.5,"16% (w/v) PEG8000, 0.04 M potassium phosphate (monobasic), 20% (v/v) glycerol",295.0,2018-01-02,2018-05-30,6C0U,2776.0,1.0,354.0,34.0,,41.98,1.0,2.65,experimental,,0.2432,0.2077,Crystal structure of cAMP-dependent protein kinase Calpha subunit bound with N46
5MLJ,X-RAY DIFFRACTION,2.55,51.7,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium acetate, 0.1 M Tris pH 8.5, 25% w/v Polyethylene glycol 3,350",277.0,2016-12-06,2017-12-20,5MLJ,2229.0,2.0,224.0,366.0,,27.45,1.0,1.8,experimental,17.319,0.21101,0.16669,"Bromodomain of Human GCN5 with 4-bromo-2-methyl-5-(((3R,5R)-1-methyl-5-phenylpiperidin-3-yl)amino)pyridazin-3(2H)-one"
5D1D,X-RAY DIFFRACTION,2.42,49.23,"VAPOR DIFFUSION, SITTING DROP",8.0,"100 mM Tris (pH 8.0), 10% (w/v) PEG 35000, 4 mM TCEP",294.0,2015-08-04,2015-10-21,5D1D,5986.0,4.0,790.0,272.0,,88.43,2.0,2.011,experimental,,0.2064,0.1749,Crystal structure of P91L-Y306F HDAC8 in complex with a tetrapeptide substrate
7JVW,X-RAY DIFFRACTION,2.36,47.93,"VAPOR DIFFUSION, SITTING DROP",5.3,"0.1 M MES, pH 5.3, 3% PEG1500, 4 mM TCEP",294.0,2020-08-24,2020-12-16,7JVW,5611.0,2.0,778.0,145.0,,87.57,1.0,2.40301779656,experimental,40.6687983774,0.254332779861,0.195250273152,Crystal structure of human histone deacetylase 8 (HDAC8) G320R mutation complexed with M344
6KD5,X-RAY DIFFRACTION,3.14,64.9,VAPOR DIFFUSION,7.5,"0.1M HEPES(pH7.5), 2.4M Ammonium Sulfate",288.0,2019-06-30,2020-06-24,6KD5,3130.0,3.0,423.0,81.0,9.0,49.19,3.0,2.6,experimental,33.142,0.23567,0.18395,Crystal structure of the extracellular domain of MSPL/TMPRSS13 in complex with dec-RVKR-cmk inhibitor
5VLA,X-RAY DIFFRACTION,2.17,43.35,"VAPOR DIFFUSION, SITTING DROP",8.0,"calcium acetate, PEG 6000",292.0,2017-04-25,2017-08-16,5VLA,3000.0,2.0,490.0,127.0,3.0,53.42,2.0,2.4,experimental,36.17,0.267,0.209,Short PCSK9 delta-P' complex with Fusion2 peptide
5VLH,X-RAY DIFFRACTION,2.23,44.86,"VAPOR DIFFUSION, SITTING DROP",8.0,"calcium acetate, PEG 6000",292.0,2017-04-25,2017-08-16,5VLH,2914.0,3.0,489.0,,4.0,53.19,3.0,2.86,experimental,71.47,0.253,0.2,Short PCSK9 delta-P' complex with peptide Pep1
5VLK,X-RAY DIFFRACTION,2.2,44.08,"VAPOR DIFFUSION, SITTING DROP",8.0,"calcium acetate, PEG 6000",292.0,2017-04-25,2017-08-16,5VLK,3095.0,3.0,486.0,213.0,3.0,52.8,3.0,2.2,experimental,33.642,0.23703,0.19537,Short PCSK9 delta-P' complex with shrunken peptide bearing homo-Arginine
5VLL,X-RAY DIFFRACTION,2.21,44.46,"VAPOR DIFFUSION, SITTING DROP",8.0,"calcium acetate, PEG 6000",292.0,2017-04-25,2017-08-16,5VLL,3007.0,3.0,489.0,89.0,4.0,53.2,3.0,2.37,experimental,46.36,0.244,0.182,Short PCSK9 delta-P' complex with peptide Pep3
4QP3,X-RAY DIFFRACTION,2.8,56.13,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG3350, 0.2 M proline, and 0.1 M HEPES pH7.5, in a 24-well Linbro plates incubated at 4C, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-06-22,2015-09-23,4QP3,5703.0,2.0,738.0,162.0,,85.79,1.0,2.599,experimental,,0.2675,0.2214,Crystal Structure of ERK2 in complex with (S)-2-((9H-purin-6-yl)amino)-3-phenylpropan-1-ol
4QP4,X-RAY DIFFRACTION,2.0,38.38,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG3350, 0.2 M proline, and 0.1 M HEPES pH7.5, in a 24-well Linbro plates incubated at 4C, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-06-22,2015-09-23,4QP4,5861.0,2.0,738.0,305.0,,85.53,1.0,2.2,experimental,,0.2352,0.1866,Crystal Structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine
4QP7,X-RAY DIFFRACTION,1.99,38.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG3350, 0.2 M proline, and 0.1 M HEPES pH7.5, in a 24-well Linbro plates incubated at 4C, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-06-22,2015-09-23,4QP7,5664.0,2.0,738.0,144.0,,85.47,1.0,2.249,experimental,,0.2434,0.2057,"Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine"
5GLF,X-RAY DIFFRACTION,2.03,39.36,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG 3350, BIS-TRIS PH 6.5, 0.2M
 MGCL2, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2016-07-11,2016-11-09,5GLF,6171.0,8.0,784.0,408.0,,89.22,2.0,2.25,experimental,37.36,0.23,0.189,Structural insights into the interaction of p97 N-terminal domain and SHP motif in Derlin-1 rhomboid pseudoprotease
8ODR,X-RAY DIFFRACTION,2.29,46.3,"VAPOR DIFFUSION, SITTING DROP",8.5,"LiSO4, Tris pH8.5, PEG 4000",293.0,2023-03-09,2023-06-07,8ODR,1788.0,2.0,255.0,,,29.58,2.0,2.85,experimental,65.45,0.2579,0.2212,Mimetic of UBC9-SUMO1
7Q6T,X-RAY DIFFRACTION,4.11,70.06,VAPOR DIFFUSION,6.25,"ATAD2 (981-1108) at 12 mg/ml in 25 mM Tris pH 9.7, 300 mM NaCl, 0.5 mM TCEP crystallised from 20% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.25. Ligands were introduced by soaking, cryo-protection with 20 % glycerol.",293.0,2021-11-09,2022-01-19,7Q6T,1281.0,1.0,130.0,131.0,,16.21,1.0,2.05,experimental,33.26,0.2155,0.1971,Crystal structure of the bromodomain of ATAD2 with AZ13824374
8S0L,X-RAY DIFFRACTION,2.65,53.54,"VAPOR DIFFUSION, SITTING DROP",7.0,"20 %w/v PEG 3350, 0.05 M HEPES (pH 7.0), 1 %w/v Tryptone, 0.001 %w/v NaN3",291.0,2024-02-14,2024-06-26,8S0L,4420.0,2.0,545.0,401.0,10.0,59.97,2.0,1.8,experimental,,0.2154,0.1769,Crystal structure of the TMPRSS2 zymogen in complex with the nanobody A07
8G26,X-RAY DIFFRACTION,2.22,44.64,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, 0.2 M magnesium chloride, 25% PEG3350",293.0,2023-02-03,2023-04-26,8G26,4496.0,3.0,558.0,219.0,7.0,62.49,3.0,1.85,experimental,,0.2376,0.2028,Crystal Structure of Cathepsin-G and Neutrophil Elastase Inhibited by S. aureus EapH2 at pH 8.5
5HG5,X-RAY DIFFRACTION,2.09,41.05,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M (5.0 uL of stock 1.0 M) Sodium acetate trihydrate (pH 7.50), 20.0 %w/v (20.0 uL of stock 50.0 %w/v) PEG 8000, 10.0 %v/v (5.0 uL of stock 100.0 %v/v) iso-propanol, 0.2 M (2.8571428571 uL of stock 3.5 M) Ammonium sulfate",286.0,2016-01-08,2016-02-03,5HG5,2849.0,1.0,329.0,335.0,,38.24,1.0,1.52,experimental,21.2,0.224,0.205,"EGFR (L858R, T790M, V948R) in complex with N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide"
5HG8,X-RAY DIFFRACTION,2.05,39.97,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M (5.0 uL of stock 1.0 M) HEPES (pH 7.50), 0.2 M (2.8571428571 uL of stock 3.5 M) Ammonium sulfate, 20.0 %w/v (20.0 uL of stock 50.0 %w/v) PEG 8000, 10.0 %v/v (5.0 uL of stock 100.0 %v/v) iso-propanol",286.0,2016-01-08,2016-02-03,5HG8,2716.0,1.0,329.0,209.0,,38.24,1.0,1.42,experimental,21.2,0.213,0.208,"EGFR (L858R, T790M, V948R) in complex with N-[3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide"
5UBR,X-RAY DIFFRACTION,2.65,53.6,VAPOR DIFFUSION,,,293.0,2016-12-21,2017-02-08,5UBR,7136.0,1.0,944.0,158.0,,110.28,1.0,2.4,experimental,67.31,0.246,0.2,"CRYSTAL STRUCTURE OF PI3K ALPHA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2,4] TRIAZIN-4-AMINE DERIVIATINE"
6ZR5,X-RAY DIFFRACTION,2.61,52.84,"VAPOR DIFFUSION, HANGING DROP",8.8,"10% PEG 20000, 20% PEG MME550, 0.03M MgCl2, 0.03M CaCl2, 0.1 M bicine/Trizma base, pH 8.8",277.0,2020-07-10,2020-11-18,6ZR5,6152.0,4.0,812.0,125.0,,94.48,2.0,2.699,experimental,82.7472,0.2562,0.182,Crystal structure of JNK1 in complex with ATF2(19-58)
7VDR,X-RAY DIFFRACTION,2.74,55.12,EVAPORATION,5.5,"0.1M MES pH 5.5, 0.3M MgCl2, 20% PEG3350",291.0,2021-09-07,2022-03-09,7VDR,7028.0,4.0,1002.0,69.0,,114.88,2.0,2.55,experimental,78.045,0.2558,0.2188,The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 13
6WO7,X-RAY DIFFRACTION,2.16,43.1,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in condition of 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 20 mM MgCl2 and 80 mM NaF in present of 2mM 5-IP7",293.0,2020-04-24,2021-03-03,6WO7,1341.0,1.0,169.0,172.0,,20.45,1.0,1.4,experimental,16.167,0.168,0.139,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5-Diphosphoinositol pentakisphosphate (5-IP7), Mg, and Fluoride ion"
6WO8,X-RAY DIFFRACTION,2.19,43.9,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution of 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 20 mM MgCl2 and 80 mM NaF in present of 2mM 5-PP-IP4",293.0,2020-04-24,2021-03-03,6WO8,1304.0,1.0,169.0,159.0,,20.43,1.0,1.7,experimental,22.941,0.2164,0.1486,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5-diphosphoinositol 1,3,4,6-tetrakisphosphate (5-PP-IP4), Mg, and Fluoride ion"
6WO9,X-RAY DIFFRACTION,2.26,45.55,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution of 200 mM Li2SO4, 25% (w/v) PEG 8000, 10% (v/v) isopropanol, 75mM NaAc, pH 5.5, 25 mM HEPES, pH 7.0, 20 mM MgCl2 and 80 mM NaF in present of 4mM 1-IP7",293.0,2020-04-24,2021-03-03,6WO9,1253.0,1.0,169.0,89.0,,20.49,1.0,2.0,experimental,26.03,0.2282,0.181,Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 1-diphosphoinositol pentakisphosphate (1-IP7) and Mg
6WOA,X-RAY DIFFRACTION,2.25,45.22,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution of 200 mM Li2SO4, 25% (w/v) PEG 8000, 10% (v/v) isopropanol, 75mM NaAc, pH 5.5, 25 mM HEPES, pH 7.0, 20 mM MgCl2 and 80 mM NaF in present of 4mM 2-IP7",293.0,2020-04-24,2021-03-03,6WOA,1339.0,1.0,169.0,145.0,,20.51,1.0,1.5,experimental,16.703,0.1481,0.1289,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 2-Diphosphoinositol pentakisphosphate (2-IP7), Mg, and Fluoride ion"
6WOB,X-RAY DIFFRACTION,2.12,42.05,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution of 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 20 mM MgCl2 and 80 mM NaF in present of 2mM 4-IP7",293.0,2020-04-24,2021-03-03,6WOB,1311.0,1.0,169.0,133.0,,20.45,1.0,1.45,experimental,17.64,0.2028,0.1602,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 4-diphosphoinositol pentakisphosphate (4-IP7), Mg, and Fluoride ion"
8G9D,X-RAY DIFFRACTION,2.22,44.57,"VAPOR DIFFUSION, HANGING DROP",5.5,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution 200mM LiCl, 20% PEG8000, 20% isopropanol, 100mM HEPES 7.0, 20mM MgCl2 in the present of 2mM 5-PCF2Am-IP7",293.0,2023-02-21,2024-01-03,8G9D,1321.0,1.0,172.0,133.0,,20.23,1.0,1.6,experimental,15.776,0.22527,0.19118,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5- phosphonodifluoroacetamide inositol pentakisphosphate (5-PCF2Am-InsP5), an analogue of 5-InsP7"
5K1I,X-RAY DIFFRACTION,2.59,52.45,VAPOR DIFFUSION,7.5,"19% PEG 3350, 36 % Ethylene Glycol and 10 % Isopropanol as a precipitant",293.0,2016-05-18,2016-12-21,5K1I,21443.0,8.0,2608.0,210.0,,304.37,1.0,2.61,experimental,30.959,0.2583,0.1913,PDE4 crystal structure in complex with small molecule inhibitor
8EQE,X-RAY DIFFRACTION,3.58,65.62,"VAPOR DIFFUSION, SITTING DROP",,4% tacsimate pH 7.0 and 12% PEG 3350,293.0,2022-10-07,2022-11-30,8EQE,2148.0,1.0,317.0,6.0,,37.29,1.0,2.559,experimental,78.053,0.2873,0.2242,Co-crystal structure of PERK with compound 26
8RZY,X-RAY DIFFRACTION,2.16,43.15,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-13,2024-03-20,8RZY,8538.0,2.0,1074.0,294.0,,124.14,1.0,1.91,experimental,52.238,0.2201,0.17576,A fragment-based inhibitor of SHP2
7QS9,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"0.15m KBr, 30% w/v PEG 2000",293.15,2022-01-13,2022-08-31,7QS9,1543.0,4.0,260.0,124.0,,27.51,2.0,1.8,experimental,22.73,0.2874,0.2382,Structural basis on the interaction of Scribble PDZ domains with the Tick Born encephalitis virus (TBEV) NS5 protein
5TTS,X-RAY DIFFRACTION,2.2,44.05,"VAPOR DIFFUSION, SITTING DROP",8.0,"20% PEG 3350, 0.2M (NH4)2SO4, 2% phenylurea",298.0,2016-11-04,2017-02-22,5TTS,2366.0,1.0,321.0,184.0,,36.82,1.0,2.34,experimental,47.46,0.2633,0.2022,Jak3 with covalent inhibitor 4
5ZOO,X-RAY DIFFRACTION,3.92,68.63,EVAPORATION,7.5,"PEG 3350, iso-propanol",295.0,2018-04-13,2018-11-14,5ZOO,3317.0,2.0,417.0,279.0,,45.2,2.0,1.85,experimental,,0.1753,0.1554,Crystal structure of histone deacetylase 4 (HDAC4) in complex with a SMRT corepressor SP1 fragment
4UWC,X-RAY DIFFRACTION,2.83,56.5,,,"20% PEG8000, 20% ETHYLENE GLYCOL, 0.2M AMMONIUM SULPHATE, 0.1M PCTP PH 6.75",,2014-08-11,2015-09-02,4UWC,5120.0,2.0,618.0,339.0,,72.46,1.0,1.96,experimental,51.54,0.2058,0.1774,Fibroblast growth factor receptor 1 kinase in complex with JK-P3
5EDM,X-RAY DIFFRACTION,5.16,73.5,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, pH 6.5 and 1.6 M MgSO4",293.0,2015-10-21,2016-01-20,5EDM,5005.0,1.0,568.0,464.0,12.0,67.01,1.0,2.2,experimental,59.17,0.236,0.196,Crystal structure of prothrombin deletion mutant residues 154-167 ( Form I )
6NSV,X-RAY DIFFRACTION,2.08,40.94,"VAPOR DIFFUSION, HANGING DROP",,"0.05 M CaCl2, 0.1 M HEPES pH 7, 28% PEG 4K, 0.01 M CoCl2",298.0,2019-01-25,2019-07-31,6NSV,2447.0,4.0,272.0,234.0,,31.86,2.0,1.305,experimental,,0.2427,0.2141,Crystal structure of the human CHIP TPR domain in complex with a 5mer acetylated optimized peptide
8CNN,X-RAY DIFFRACTION,2.52,51.2,"VAPOR DIFFUSION, SITTING DROP",,"Protein buffer (phospho-HRas pY64 0.4 mM, RasGAP 0.4 mM, Na-HEPES 20 mM pH = 8.0, MgCl2 5 mM, NaF 20 mM) was mixed with precipitant in a 1:1 ratio with a total drop size of 600 nL. The precipitant solution consits of:  100 mM NaOAc, pH = 4.5, 200 mM Li2SO4, 50% PEG400 (v/v). Protein crystals were soaked in precipitant solutions containing 50-100 mM BeCl2 and subsequently flash-frozen using 20% glycerol as cryoprotectant.",277.0,2023-02-23,2023-09-27,8CNN,1561.0,1.0,166.0,123.0,,20.17,1.0,1.48,experimental,22.508,0.18838,0.16384,BeF3 Phospho-HRas GSA complex
8ELZ,X-RAY DIFFRACTION,2.43,49.4,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350,
Calcium Acetate,
Magnesium Chloride,
Sodium Chloride,
DTT",291.15,2022-09-26,2023-09-06,8ELZ,1537.0,1.0,189.0,165.0,,22.06,1.0,1.961,experimental,28.5357,0.202,0.1565,HRAS R97M Crystal Form 1
7QSA,X-RAY DIFFRACTION,2.32,47.06,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Sodium nitrate, 0.1M Bis-Tris propane pH7.5, 20% w/v PEG 3350",293.15,2022-01-13,2022-08-31,7QSA,1313.0,3.0,192.0,60.0,,20.45,2.0,2.02,experimental,47.71,0.2874,0.2527,Structural basis on the interaction of Scribble PDZ domains with the Tick Born encephalitis virus (TBEV) NS5 protein
5EPP,X-RAY DIFFRACTION,3.03,59.42,"VAPOR DIFFUSION, SITTING DROP",6.5,"20% PEG 3350, 0.1 M Bis-Tris Propane pH 6.5, 0.2 M Sodium Acetate",293.0,2015-11-12,2016-09-14,5EPP,1616.0,2.0,199.0,127.0,,22.81,2.0,1.88,experimental,,0.2095,0.1768,"Structural Insights into the Interaction of p97 N-terminus Domain and VBM Motif in Rhomboid Protease, RHBDL4"
6CMR,X-RAY DIFFRACTION,2.17,43.19,"VAPOR DIFFUSION, SITTING DROP",,"15% PEG 20,000 and 10 mM potassium hydrogen tartrate",291.0,2018-03-06,2018-11-14,6CMR,3952.0,1.0,532.0,79.0,,61.34,1.0,2.21,experimental,58.13,0.2605,0.2242,Closed structure of active SHP2 mutant E76D bound to SHP099 inhibitor
4XEK,X-RAY DIFFRACTION,2.47,50.19,"VAPOR DIFFUSION, SITTING DROP",9.0,"4 ul drop contained 2 ul protein/LD4 peptide mixture (20 mM MES, pH 6.2, 1 mM protein, and 2 mM peptide) and 2 ul well solution (100 mM Tris pH 9.0 and 45 % PEG 600)",291.2,2014-12-24,2015-12-30,4XEK,1212.0,2.0,158.0,67.0,,17.32,2.0,1.793,experimental,,0.2312,0.2083,Pyk2-FAT domain in complex with leupaxin LD4 motif
4PS0,X-RAY DIFFRACTION,2.37,48.02,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.15 M sodium citrate, pH 5.5, 14% PEG 6000, 0.3% sodium azide, 0.01 M DTT, VAPOR DIFFUSION, SITTING DROP, temperature 295K",295.0,2014-03-06,2015-01-21,4PS0,4443.0,4.0,580.0,476.0,,66.85,2.0,1.63,experimental,,0.1792,0.153,Caspase-8 specific unnatural amino acid peptides
7O0M,X-RAY DIFFRACTION,2.16,43.03,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-26,2021-09-15,7O0M,3541.0,2.0,536.0,113.0,1.0,62.38,2.0,2.39,experimental,50.21,0.248,0.1965,Crystal structure of the human METTL3-METTL14 complex bound to Compound 9 (ADO_AD_023)
7O0P,X-RAY DIFFRACTION,2.17,43.26,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-26,2021-09-15,7O0P,3492.0,2.0,536.0,33.0,1.0,62.3,2.0,2.7,experimental,55.57,0.2625,0.2021,Crystal structure of the human METTL3-METTL14 complex bound to Compound 10 (ADO_AD_022)
7O0Q,X-RAY DIFFRACTION,2.17,43.37,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-26,2021-09-15,7O0Q,3447.0,2.0,536.0,51.0,1.0,62.31,2.0,2.49,experimental,64.32,0.2778,0.2173,Crystal structure of the human METTL3-METTL14 complex bound to Compound 12 (ADO_AD_066)
7O0R,X-RAY DIFFRACTION,2.16,43.01,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-26,2021-09-15,7O0R,3648.0,2.0,536.0,175.0,1.0,62.33,2.0,2.3,experimental,40.97,0.2473,0.1944,Crystal structure of the human METTL3-METTL14 complex bound to Compound 15 (ADO_AE_026)
7O28,X-RAY DIFFRACTION,2.14,42.53,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-30,2021-09-15,7O28,3457.0,2.0,536.0,25.0,1.0,62.35,2.0,2.47,experimental,68.11,0.2535,0.2045,Crystal structure of the human METTL3-METTL14 complex bound to Compound 19 (ADO_AE_009)
7O2H,X-RAY DIFFRACTION,2.16,43.02,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-30,2021-09-15,7O2H,3437.0,2.0,536.0,53.0,1.0,62.32,2.0,2.5,experimental,64.7,0.2746,0.2106,Crystal structure of the human METTL3-METTL14 complex bound to Compound 13 (ADO_AD_091)
7CMR,X-RAY DIFFRACTION,1.5,18.14,"VAPOR DIFFUSION, SITTING DROP",,"0.2M LiCl, 0.1M Hepes pH7, 20% PEG6,000",293.0,2020-07-28,2020-08-12,7CMR,2246.0,1.0,475.0,62.0,,54.69,1.0,2.2,experimental,44.592,0.2632,0.2178,The Crystal Structure of human MYST1 from Biortus.
5LVM,X-RAY DIFFRACTION,2.13,42.35,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 10 MM DTT",293.0,2016-09-14,2016-10-19,5LVM,2712.0,1.0,311.0,314.0,,35.68,1.0,1.26,experimental,,0.1549,0.1335,Human PDK1 Kinase Domain in Complex with Adenine Bound to the ATP-Binding Site
7VDP,X-RAY DIFFRACTION,2.77,55.66,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M MES pH 5.5, 0.3M MgCl2, 20% PEG3350",291.0,2021-09-07,2022-03-09,7VDP,7321.0,4.0,1002.0,372.0,,115.32,2.0,2.09,experimental,63.908,0.2287,0.2009,The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 1
5E8S,X-RAY DIFFRACTION,2.09,41.02,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E8S,2669.0,1.0,306.0,269.0,,34.94,1.0,1.45,experimental,18.44,0.1878,0.171,TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
5E8Z,X-RAY DIFFRACTION,2.08,40.99,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E8Z,2647.0,1.0,307.0,213.0,,35.59,1.0,1.51,experimental,23.29,0.207,0.1819,TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3-AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE
5E90,X-RAY DIFFRACTION,2.1,41.42,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E90,2595.0,1.0,307.0,161.0,,35.65,1.0,2.05,experimental,27.39,0.2179,0.1756,"TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F, S280T,Y282F,S287N,A350C,L352F) IN COMPLEX WITH 3-AMINO-6- [4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE"
5QIK,X-RAY DIFFRACTION,2.07,40.49,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2018-08-05,2018-10-31,5QIK,2722.0,1.0,307.0,246.0,,35.72,1.0,1.58,experimental,19.91,0.1904,0.1651,"TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(6-fluoropyridin-3-yl)-4-oxo-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl]pyridin-2-yl}acetamide"
5QIM,X-RAY DIFFRACTION,2.11,41.74,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2018-08-05,2018-10-31,5QIM,2645.0,1.0,306.0,203.0,,35.39,1.0,1.75,experimental,25.52,0.1884,0.1683,"TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(5-METHOXYPYRIDIN-2-YL)-1H-PYRROLO[3,2-B] PYRIDIN-2-YL]PYRIDIN-2-YL}ACETAMIDE"
6NE7,X-RAY DIFFRACTION,2.92,57.8,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.2-2.6M Na FORMATE,
0.1M CITRATE pH 5.5",299.0,2018-12-17,2019-06-05,6NE7,2616.0,1.0,314.0,133.0,,36.32,1.0,1.99,experimental,38.123,0.24921,0.20341,Structure of G810A mutant of RET protein tyrosine kinase domain.
7Q5T,X-RAY DIFFRACTION,2.37,48.14,"VAPOR DIFFUSION, SITTING DROP",8.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME",293.0,2021-11-04,2021-11-24,7Q5T,13506.0,12.0,1710.0,334.0,,195.55,2.0,2.2,experimental,63.047,0.255,0.2075,The tandem SH2 domains of SYK with a bound FCER1G diphospho-ITAM peptide
6V5T,X-RAY DIFFRACTION,2.03,39.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes pH 7.5,
25% PEG 8000",298.0,2019-12-04,2020-05-13,6V5T,2470.0,1.0,290.0,103.0,4.0,33.76,1.0,2.1,experimental,38.791,0.2297,0.1772,Crystal structure of human prethrombin-2 with tryptophans replaced by 5-F-tryptophan
5CGP,X-RAY DIFFRACTION,2.14,42.4,"VAPOR DIFFUSION, HANGING DROP",,"15-20% PEG 8000, 0.2M CaAcetate, 0.1 M cacodylate ph 6-7",293.0,2015-07-09,2016-04-20,5CGP,1053.0,1.0,119.0,59.0,,14.68,1.0,1.96,experimental,17.15,0.2493,0.2092,Selective pharmacological inhibition of the CREB binding protein bromodomain regulates inflammatory cytokines in macrophages and RGS4 in neurons
5I8B,X-RAY DIFFRACTION,2.36,47.94,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH 8,
 0.2 M sodium thiocyanate 
19-23% PEG 3350",277.0,2016-02-18,2016-04-20,5I8B,2207.0,1.0,264.0,206.0,,32.5,1.0,1.5218,experimental,38.3686,0.2002,0.1898,"CBP in complex with Cpd23 ((R)-6-(3-(benzyloxy)phenyl)-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one)"
5I8G,X-RAY DIFFRACTION,2.34,47.41,"VAPOR DIFFUSION, HANGING DROP",8.0,"containing 0.1 M Bis-Tris pH 8, 
0.2 M sodium thiocyanate 
19-23% PEG 3350",277.0,2016-02-18,2016-04-20,5I8G,2221.0,1.0,264.0,213.0,,32.63,1.0,1.41,experimental,34.3308,0.2105,0.1888,"CBP in complex with Cpd637 ((R)-4-methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one)"
5AQW,X-RAY DIFFRACTION,2.37,48.2,,7.5,"17-28% (W/V) PEG3350, 0.1 M HEPES PH 7.5, 2 MM MGCL2, 2 MM NAH2PO4 AND 5 MM ADENOSINE, THEN BACKSOAKED WITH 100 MM INHIBITOR (20% DMSO) FOR 16H AT 18 DEGREES C",291.0,2015-09-22,2016-10-05,5AQW,3468.0,1.0,394.0,424.0,,44.49,1.0,1.53,experimental,25.17,0.1849,0.161,Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues
7NI9,X-RAY DIFFRACTION,2.15,42.77,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-11,2021-10-20,7NI9,3674.0,2.0,536.0,195.0,1.0,62.39,2.0,2.2,experimental,39.74,0.228,0.1922,Crystal structure of the human METTL3-METTL14 complex with compound UOZ058
8WRA,X-RAY DIFFRACTION,2.36,47.94,"VAPOR DIFFUSION, SITTING DROP",,"0.15M Na formate, 14% PEG3350",277.0,2023-10-13,2023-11-15,8WRA,2399.0,1.0,285.0,300.0,,32.24,1.0,1.45,experimental,14.006,0.2129,0.1916,The Crystal Structure of CASP1 from Biortus
5TEY,X-RAY DIFFRACTION,2.59,52.15,"VAPOR DIFFUSION, SITTING DROP",8.5,"23% PEG 4K, 0.2 M MgCl2, 0.1 M Tris pH8.5",293.0,2016-09-23,2016-11-23,5TEY,3839.0,2.0,997.0,197.0,1.0,113.7,2.0,1.8,experimental,27.842,0.2241,0.1977,Human METTL3-METTL14 complex
7O2X,X-RAY DIFFRACTION,2.16,42.98,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-03-31,2021-04-07,7O2X,3494.0,2.0,536.0,34.0,1.0,62.16,2.0,2.8,experimental,41.65,0.2741,0.2079,Crystal structure of the human METTL3-METTL14 complex with compound T180
8G69,X-RAY DIFFRACTION,2.27,45.74,VAPOR DIFFUSION,6.2,"Reservoir solution: 50 mM MES (pH 6.2), 14% PEG6000, 50 mM MgCl2;
Protein solution: 10.3 mg/ml PTP-1B 1-298 in 25 mM Hepes pH 7.2, 150 mM NaCl, 1 mM EDTA, 2 mM DTT",278.0,2023-02-14,2023-04-26,8G69,5278.0,2.0,596.0,360.0,,69.99,1.0,1.53,experimental,24.808,0.19844,0.16933,Wildtype PTP1b in complex with DES5743
7VIJ,X-RAY DIFFRACTION,3.95,68.85,"VAPOR DIFFUSION, SITTING DROP",,"2% v/v Tacsimate pH 7.0, 0.1M imidazole pH 7.0, 8% w/v polyethylene glycol 3350, 5% v/v 2-propanol",277.0,2021-09-27,2022-08-24,7VIJ,4396.0,1.0,529.0,56.0,,61.8,1.0,2.3,experimental,75.0186,0.2628,0.218,Crystal structure of USP7-HUBL domain
7XPY,X-RAY DIFFRACTION,3.68,66.57,"VAPOR DIFFUSION, SITTING DROP",7.0,"2% v/v Tacsimate pH 7.0, 0.1 M Imidazole pH 7.0, 8% w/v Polyethylene glycol 3350, 5% v/v 2-Propanol",277.0,2022-05-06,2022-08-24,7XPY,4400.0,1.0,548.0,29.0,,64.57,1.0,2.35,experimental,80.329,0.2658,0.224,Crystal structure of USP7 in complex with its inhibitor
6PYS,X-RAY DIFFRACTION,2.61,52.87,VAPOR DIFFUSION,,not available,293.0,2019-07-30,2019-08-28,6PYS,7558.0,1.0,945.0,166.0,,110.61,1.0,2.19,experimental,57.165,0.2591,0.2239,"Human PI3Kalpha in complex with Compound 2-10 ((3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3-dihydro-2H-indol-2-one)"
7K71,X-RAY DIFFRACTION,2.57,52.05,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 6000, 0.1 M CHES pH 9.75, 0.64 M sodium formate, 5 mM TCEP pH 7",286.0,2020-09-21,2021-01-06,7K71,5905.0,1.0,946.0,,,110.24,1.0,2.9,experimental,95.58,0.2586,0.2431,Crystal structure of PI3Kalpha inhibitor 4-0686
8EXL,X-RAY DIFFRACTION,2.21,44.24,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M MES buffer pH 6.2, 16% PEG 20,000, 0.1M KCl",291.0,2022-10-25,2022-11-30,8EXL,7425.0,1.0,1080.0,282.0,,126.41,1.0,1.989,experimental,48.575,0.2251,0.1871,Crystal structure of PI3K-alpha in complex with taselisib
8EXO,X-RAY DIFFRACTION,2.2,43.98,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M MES buffer pH 6.2, 16% PEG 20,000, 0.1M KCl",291.0,2022-10-25,2022-11-30,8EXO,7594.0,1.0,1080.0,178.0,,126.38,1.0,2.46,experimental,59.67,0.242,0.193,Crystal structure of PI3K-alpha in complex with compound 19
8EXU,X-RAY DIFFRACTION,2.19,43.93,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M MES buffer pH 6.2, 16% PEG 20,000, 0.1M KCl",291.0,2022-10-25,2022-11-30,8EXU,7493.0,1.0,1080.0,90.0,,126.4,1.0,2.68,experimental,64.26,0.241,0.196,Crystal structure of PI3K-alpha in complex with compound 30
8EXV,X-RAY DIFFRACTION,2.21,44.32,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1M MES buffer pH 6.2, 16% PEG 20,000, 0.1M KCl",291.0,2022-10-25,2022-11-30,8EXV,7448.0,1.0,1080.0,71.0,,126.36,1.0,2.48,experimental,60.62,0.258,0.205,Crystal structure of PI3K-alpha in complex with compound 32
7OZB,X-RAY DIFFRACTION,2.65,53.66,"VAPOR DIFFUSION, SITTING DROP",6.7,"0.185M ammonium sulfate, 20% v/v ethylene glycol, 17% w/v PEG 8000, 0.1M PCPT",291.0,2021-06-27,2021-12-01,7OZB,4847.0,2.0,618.0,184.0,,71.99,1.0,1.71,experimental,39.414,0.2442,0.2088,"FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 38."
7OZD,X-RAY DIFFRACTION,2.67,53.92,"VAPOR DIFFUSION, SITTING DROP",6.7,"0.185M ammonium sulfate, 20% v/v ethylene glycol, 17% w/v PEG 8000, 0.1M PCPT",291.0,2021-06-27,2021-12-01,7OZD,4748.0,2.0,618.0,201.0,,72.01,1.0,1.82,experimental,44.319,0.2412,0.1995,"FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 34."
7OZF,X-RAY DIFFRACTION,2.7,54.4,"VAPOR DIFFUSION, SITTING DROP",6.7,"0.185M ammonium sulfate, 20% v/v ethylene glycol, 17% w/v PEG 8000, 0.1M PCPT",291.0,2021-06-28,2021-12-01,7OZF,4747.0,2.0,618.0,183.0,,71.4,1.0,1.82,experimental,46.193,0.2425,0.204,"FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 19."
5L6D,X-RAY DIFFRACTION,2.23,44.94,"VAPOR DIFFUSION, HANGING DROP",,"22% PEG 3350, 300 mM Mg acetate",293.0,2016-05-29,2016-10-12,5L6D,4001.0,2.0,516.0,399.0,1.0,59.84,2.0,1.852,experimental,,0.1916,0.157,Crystal structure of the human METTL3-METTL14 complex bound to SAH
6TTT,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 200 mM Magnesium acetate",295.0,2019-12-30,2020-03-04,6TTT,3619.0,2.0,1036.0,161.0,1.0,117.15,2.0,2.3,experimental,49.72,0.2394,0.1902,Crystal structure of the human METTL3-METTL14 complex bound to Compound 2 (ASI_M3M_140)
6TTV,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 200 mM Magnesium acetate",295.0,2019-12-30,2020-03-04,6TTV,3626.0,2.0,1036.0,163.0,1.0,117.13,2.0,2.14,experimental,45.93,0.2439,0.1976,Crystal structure of the human METTL3-METTL14 complex bound to Compound 3 (ASI_M3M_138)
6TTW,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 200 mM Magnesium acetate",295.0,2019-12-30,2020-03-04,6TTW,3681.0,2.0,1036.0,234.0,1.0,117.21,2.0,2.2,experimental,39.3,0.2285,0.1845,Crystal structure of the human METTL3-METTL14 complex bound to Compound 4 (ASI_M3M_047)
6TTX,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 200 mM Magnesium acetate",295.0,2019-12-30,2020-03-04,6TTX,3768.0,2.0,1036.0,320.0,1.0,117.23,2.0,2.0,experimental,36.87,0.2173,0.1914,Crystal structure of the human METTL3-METTL14 complex bound to Compound 5 (ASI_M3M_051)
6TU1,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 200 mM Magnesium acetate",295.0,2019-12-31,2020-03-04,6TU1,3620.0,2.0,1036.0,177.0,1.0,117.13,2.0,2.31,experimental,46.39,0.2339,0.1949,Crystal structure of the human METTL3-METTL14 complex bound to Compound 8 (ASI_M3M_091)
6Y4G,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2020-02-20,2020-03-04,6Y4G,3871.0,2.0,1036.0,382.0,1.0,117.23,2.0,1.9,experimental,32.94,0.2175,0.1834,Crystal structure of the human METTL3-METTL14 complex bound to Sinefungin
8BN8,X-RAY DIFFRACTION,2.24,45.08,"VAPOR DIFFUSION, SITTING DROP",8.0,"150 MM MAGNESIUM ACETATE, 22% W/V PEG 3350",295.0,2022-11-13,2023-09-20,8BN8,3735.0,2.0,509.0,83.0,1.0,59.21,2.0,2.213,experimental,47.357,0.2442,0.1842,METTL3-METTL14 heterodimer bound to the SAM competitive small molecule inhibitor STM3006
7ZRR,X-RAY DIFFRACTION,2.03,39.48,"VAPOR DIFFUSION, SITTING DROP",4.3,"5% PEG400, 50mM Citrato pH 4.3, 1.8 M (NH4)2SO4, 20% Ethylene glycol",293.0,2022-05-05,2023-11-15,7ZRR,2277.0,2.0,300.0,125.0,5.0,34.33,2.0,1.64,experimental,24.776,0.2391,0.2012,Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inhibitor UK965
5O8K,X-RAY DIFFRACTION,2.13,42.37,"VAPOR DIFFUSION, HANGING DROP",7.5,"25% PEG 2000 MME, 0.8M sodium formate, 0.1M tris-HCl pH 7.5",293.0,2017-06-13,2018-06-27,5O8K,1851.0,2.0,239.0,37.0,,27.62,2.0,1.8,experimental,,0.2888,0.2552,Crystal structure of mammalian Rev7 in complex with Rev3 1875-1895
5A82,X-RAY DIFFRACTION,4.01,69.36,,7.5,"0.1M TRISHCL PH 7.0-8.0, 1.2-1.5M AMMONIUM SULPHATE AND 20-25% PEG3350",,2015-07-11,2015-08-12,5A82,1365.0,1.0,130.0,197.0,,16.16,1.0,1.86,experimental,31.89,0.20769,0.18115,"Crystal structure of human ATAD2 bromodomain in complex with 4-(3R,4R) -4-(3-methyl-2-oxo-1,2-dihydro-1,7-naphthyridin-8-yl)aminopiperidin-3- yloxymethyl)-1-thiane-1,1-dione"
6DXH,X-RAY DIFFRACTION,3.58,65.62,"VAPOR DIFFUSION, SITTING DROP",7.0,"1.5 M ammonium sulfate, 0.1 M bis-tris pH 7.0, 25% ethylene glycol (v/v), 2.25% DMSO (v/v)",291.0,2018-06-28,2018-07-18,6DXH,981.0,1.0,121.0,54.0,1.0,13.83,1.0,2.0,experimental,34.154,0.2512,0.2138,Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with 4-(4-tert-butylphenyl)-4-oxobutanoate
6P9G,X-RAY DIFFRACTION,3.73,67.05,"VAPOR DIFFUSION, SITTING DROP",6.8,"1.75 M ammonium sulfate, 0.2 M sodium acetate, 0.1 M sodium cacodylate, 1.1% v/v dimethyl sulfoxide, 25% v/v ethylene glycol",291.0,2019-06-10,2019-09-18,6P9G,936.0,1.0,121.0,13.0,1.0,13.82,1.0,2.1,experimental,38.743,0.2477,0.2241,Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with 2-(4-oxoquinazolin-3(4H)-yl)propanoic acid
7Z6L,X-RAY DIFFRACTION,2.15,42.9,"VAPOR DIFFUSION, HANGING DROP",7.5,"33% (v/v) glycerol ethoxylate, 0.2 M ammonium chloride, 0.1 M HEPES, pH 7.5",277.0,2022-03-12,2022-09-07,7Z6L,3734.0,4.0,486.0,64.0,,56.84,4.0,2.24,experimental,52.75,0.232,0.189,Crystal structure of PROTAC 5 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
7Z76,X-RAY DIFFRACTION,2.87,57.17,"VAPOR DIFFUSION, SITTING DROP",5.8,"14.5 % PEG 3350, 0.1 M BIS-TRIS propane pH 5.8, 100 mM sodium iodide",293.0,2022-03-15,2022-09-14,7Z76,4396.0,4.0,486.0,672.0,,57.77,4.0,1.32,experimental,27.12,0.202,0.178,Crystal structure of compound 10 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
7Z77,X-RAY DIFFRACTION,2.52,51.13,"VAPOR DIFFUSION, SITTING DROP",7.5,"20 % PEG 3350, 0.1 M BIS_TRIS propane pH 7.5, 200 mM sodium formate",293.0,2022-03-15,2022-09-14,7Z77,3875.0,4.0,486.0,100.0,,56.83,4.0,1.97,experimental,55.34,0.251,0.213,Crystal structure of compound 6 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
6B96,X-RAY DIFFRACTION,2.05,39.95,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH7.5, 12% PEG8000",293.0,2017-10-10,2017-11-22,6B96,6011.0,2.0,746.0,334.0,,88.4,1.0,1.88,experimental,33.39,0.2067,0.1754,Crystal Structure of PDE2 in complex with compound 16
6B97,X-RAY DIFFRACTION,2.03,39.32,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH7.5, 12% PEG8000",293.0,2017-10-10,2017-11-22,6B97,6008.0,2.0,746.0,328.0,,88.4,1.0,1.76,experimental,31.03,0.22,0.19,Crystal structure of PDE2 in complex with complex 9
6B98,X-RAY DIFFRACTION,1.99,38.19,"VAPOR DIFFUSION, HANGING DROP",,"12% PEG8000, 0.1M Hepes pH7.5,  1mM TCEP",293.0,2017-10-10,2017-11-22,6B98,5833.0,2.0,746.0,231.0,,87.96,1.0,1.97,experimental,38.08,0.24,0.199,PDE2 in complex with compound 1
4QSY,X-RAY DIFFRACTION,2.57,52.2,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG3000, 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 295.0K",295.0,2014-07-06,2015-07-08,4QSY,962.0,2.0,121.0,53.0,,13.75,2.0,2.1,experimental,,0.2291,0.2,SHP2 SH2 domain in complex with GAB1 peptide
7NHG,X-RAY DIFFRACTION,2.17,43.2,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-10,2021-10-20,7NHG,3521.0,2.0,536.0,117.0,1.0,62.26,2.0,2.5,experimental,45.62,0.2784,0.2195,Crystal structure of the human METTL3-METTL14 complex with compound ASI_M3M_041
7NHH,X-RAY DIFFRACTION,2.17,43.23,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-10,2021-10-20,7NHH,3578.0,2.0,536.0,168.0,1.0,62.37,2.0,2.1,experimental,49.19,0.2496,0.2072,Crystal structure of the human METTL3-METTL14 complex with compound UOZ002
7NHI,X-RAY DIFFRACTION,2.15,42.89,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-10,2021-09-01,7NHI,3804.0,2.0,536.0,329.0,1.0,62.29,2.0,1.85,experimental,35.6,0.2218,0.1981,Crystal structure of the human METTL3-METTL14 complex with compound UOZ004
7NHJ,X-RAY DIFFRACTION,2.17,43.33,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-10,2021-10-20,7NHJ,3654.0,2.0,536.0,154.0,1.0,62.2,2.0,2.16,experimental,49.22,0.2746,0.2175,Crystal structure of the human METTL3-METTL14 complex with compound DHU_M3M_154
7NHV,X-RAY DIFFRACTION,2.13,42.37,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-11,2021-10-20,7NHV,3756.0,2.0,536.0,269.0,1.0,62.37,2.0,1.91,experimental,38.72,0.2119,0.1956,Crystal structure of the human METTL3-METTL14 complex with compound UOZ016
7NI7,X-RAY DIFFRACTION,2.17,43.38,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-11,2021-10-20,7NI7,3581.0,2.0,536.0,75.0,1.0,62.46,2.0,2.5,experimental,47.25,0.2837,0.2081,Crystal structure of the human METTL3-METTL14 complex with compound UOZ031
7NI8,X-RAY DIFFRACTION,2.14,42.41,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-11,2021-10-20,7NI8,3654.0,2.0,536.0,179.0,1.0,62.35,2.0,2.2,experimental,43.15,0.2497,0.2017,Crystal structure of the human METTL3-METTL14 complex with compound UOZ040a
7NIA,X-RAY DIFFRACTION,2.12,41.86,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-11,2021-10-20,7NIA,3614.0,2.0,536.0,150.0,1.0,62.39,2.0,2.3,experimental,45.51,0.2351,0.1938,Crystal structure of the human METTL3-METTL14 complex with compound UOZ059a
7NID,X-RAY DIFFRACTION,2.11,41.77,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-02-11,2021-10-20,7NID,3593.0,2.0,536.0,133.0,1.0,62.39,2.0,2.3,experimental,46.1,0.242,0.2023,Crystal structure of the human METTL3-METTL14 complex with compound UOZ078
7OED,X-RAY DIFFRACTION,2.16,43.16,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OED,3759.0,2.0,536.0,266.0,1.0,62.31,2.0,2.0,experimental,37.86,0.2281,0.1858,Crystal structure of the human METTL3-METTL14 complex with compound UOZ019a
7OEE,X-RAY DIFFRACTION,2.14,42.46,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OEE,3524.0,2.0,536.0,54.0,1.0,62.31,2.0,2.7,experimental,49.13,0.2577,0.1935,Crystal structure of the human METTL3-METTL14 complex with compound UOZ019b
7OEF,X-RAY DIFFRACTION,2.14,42.65,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OEF,3731.0,2.0,536.0,196.0,1.0,62.37,2.0,2.03,experimental,45.84,0.2349,0.1942,Crystal structure of the human METTL3-METTL14 complex with compound UOZ038
7OEG,X-RAY DIFFRACTION,2.13,42.37,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OEG,3504.0,2.0,536.0,53.0,1.0,62.35,2.0,2.79,experimental,47.28,0.2697,0.1978,Crystal structure of the human METTL3-METTL14 complex with compound UOZ040b
7OEH,X-RAY DIFFRACTION,2.17,43.37,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OEH,3683.0,2.0,536.0,207.0,1.0,62.39,2.0,2.01,experimental,47.28,0.2286,0.2025,Crystal structure of the human METTL3-METTL14 complex with compound UOZ059b
7OEI,X-RAY DIFFRACTION,2.15,42.76,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OEI,3490.0,2.0,536.0,74.0,1.0,62.36,2.0,2.48,experimental,55.8,0.254,0.1986,Crystal structure of the human METTL3-METTL14 complex with compound UOZ083
7OEJ,X-RAY DIFFRACTION,2.17,43.2,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OEJ,3688.0,2.0,536.0,170.0,1.0,62.33,2.0,2.3,experimental,39.85,0.2354,0.1876,Crystal structure of the human METTL3-METTL14 complex with compound UOZ090
7OEK,X-RAY DIFFRACTION,2.15,42.83,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OEK,3816.0,2.0,536.0,296.0,1.0,62.41,2.0,1.9,experimental,35.71,0.2231,0.1912,Crystal structure of the human METTL3-METTL14 complex with compound UOZ091
7OEL,X-RAY DIFFRACTION,2.15,42.85,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OEL,3851.0,2.0,536.0,344.0,1.0,62.41,2.0,1.86,experimental,33.27,0.213,0.1866,Crystal structure of the human METTL3-METTL14 complex with compound UOZ097
7OEM,X-RAY DIFFRACTION,2.17,43.2,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-05-03,2021-10-20,7OEM,3640.0,2.0,536.0,166.0,1.0,62.51,2.0,2.2,experimental,46.55,0.2576,0.2066,Crystal structure of the human METTL3-METTL14 complex with compound UOZ120
7OQL,X-RAY DIFFRACTION,2.15,42.73,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-06-03,2021-10-20,7OQL,3502.0,2.0,536.0,60.0,1.0,62.42,2.0,2.5,experimental,53.56,0.2539,0.2066,Crystal structure of the human METTL3-METTL14 complex with compound UOZ094
7OQP,X-RAY DIFFRACTION,2.16,43.06,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 400mM Mg acetate",295.0,2021-06-03,2021-10-20,7OQP,3693.0,2.0,536.0,212.0,1.0,62.47,2.0,2.0,experimental,42.92,0.2308,0.1976,Crystal structure of the human METTL3-METTL14 complex with compound UOZ113
8PW9,X-RAY DIFFRACTION,2.23,44.85,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 0.4M Magnesium acetate",295.0,2023-07-19,2023-11-08,8PW9,3648.0,2.0,518.0,130.0,1.0,60.21,2.0,2.3,experimental,49.52,0.2354,0.1935,Crystal structure of the human METTL3-METTL14 in complex with a bisubstrate analogue (BA1)
8PWA,X-RAY DIFFRACTION,2.23,44.78,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 0.4M Magnesium acetate",295.0,2023-07-19,2023-11-08,8PWA,3742.0,2.0,518.0,218.0,1.0,60.32,2.0,2.1,experimental,43.61,0.2249,0.1906,Crystal structure of the human METTL3-METTL14 in complex with a bisubstrate analogue (BA4)
8PWB,X-RAY DIFFRACTION,2.21,44.33,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 0.4M Magnesium acetate",295.0,2023-07-19,2023-11-08,8PWB,3518.0,2.0,518.0,60.0,1.0,60.15,2.0,2.5,experimental,51.29,0.2444,0.2001,Crystal structure of the human METTL3-METTL14 in complex with a bisubstrate analogue (BA6)
7T0P,X-RAY DIFFRACTION,2.29,46.18,"VAPOR DIFFUSION, HANGING DROP",,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.0,2021-11-30,2022-06-15,7T0P,4663.0,2.0,578.0,311.0,,67.63,1.0,2.04,experimental,21.2521,0.2474,0.1945,JAK2 JH2 IN COMPLEX WITH JAK315
8BM2,X-RAY DIFFRACTION,2.53,51.31,"VAPOR DIFFUSION, HANGING DROP",8.2,"1.7 M Na-malonate, 0.1 M Gly-Gly pH 8.2",295.0,2022-11-10,2023-11-22,8BM2,5620.0,2.0,634.0,532.0,,75.59,1.0,1.5,experimental,26.34,0.2021,0.1773,Crystal structure of JAK2 JH1 in complex with gandotinib
8BPW,X-RAY DIFFRACTION,2.54,51.57,"VAPOR DIFFUSION, HANGING DROP",8.2,"2 M Na-malonate, 0.1 M Gly-Gly pH 8.2",295.0,2022-11-18,2023-11-29,8BPW,5576.0,2.0,634.0,535.0,,75.53,1.0,1.8,experimental,29.57,0.1966,0.1612,Crystal structure of JAK2 JH1 in complex with lestaurtinib
8BXC,X-RAY DIFFRACTION,2.49,50.64,"VAPOR DIFFUSION, HANGING DROP",8.2,"0.1 M Gly-Gly pH 8.2, 2 M Na-malonate",295.0,2022-12-08,2023-12-20,8BXC,5273.0,2.0,632.0,375.0,,75.75,1.0,1.9,experimental,28.54,0.212,0.1837,Crystal structure of JAK2 JH1 in complex with itacitinib
8C0A,X-RAY DIFFRACTION,2.22,44.67,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M Tris pH 8.0, 21% PEG4000, 0.1M Na-acetate",277.0,2022-12-16,2023-12-27,8C0A,4862.0,2.0,578.0,433.0,2.0,67.0,1.0,1.7,experimental,30.97,0.2375,0.194,Crystal structure of JAK2 JH2-R683S
8FNY,X-RAY DIFFRACTION,2.6,52.43,VAPOR DIFFUSION,7.5,"100 mM Bis-trispropane, 100 mM NaF, 20.5 % w/v PEG-3350 (2protein/1solution)",293.0,2022-12-28,2023-05-03,8FNY,9391.0,4.0,1358.0,309.0,,156.36,2.0,2.22,experimental,35.33,0.229,0.2079,Nucleotide-bound structure of a functional construct of eukaryotic elongation factor 2 kinase.
6ACR,X-RAY DIFFRACTION,2.6,52.63,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES, 1.6 M Ammonium sulfate",293.0,2018-07-27,2019-03-20,6ACR,4903.0,2.0,602.0,97.0,,70.33,1.0,2.01,experimental,33.93,0.2568,0.2131,Crystal structure of human ALK2 kinase domain with R206H mutation in complex with RK-59638
7C3G,X-RAY DIFFRACTION,2.56,51.9,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES pH 7.6-8.0, 1.5-1.6 M ammonium sulfate",293.0,2020-05-12,2021-03-03,7C3G,5335.0,2.0,602.0,469.0,,71.88,1.0,1.802,experimental,32.697,0.2266,0.1851,Crystal structure of human ALK2 kinase domain with R206H mutation in complex with a bicyclic pyrazole inhibitor RK-73134
6B8Z,X-RAY DIFFRACTION,3.63,66.16,VAPOR DIFFUSION,7.5,"well solution: 0.3 M magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% beta-mercaptoethanol, 13-14% PEG 8000, 2% ethanol",277.0,2017-10-09,2018-06-20,6B8Z,2677.0,1.0,321.0,167.0,,38.09,1.0,1.8,experimental,47.7507,0.1991,0.1687,Multiconformer model of WT PTP1B with BB3 at 273 K
8EXI,X-RAY DIFFRACTION,3.44,64.23,"VAPOR DIFFUSION, SITTING DROP",,"12% PEG 8K, 0.15 M Magnesium Acetate, 0.1 M MES (pH 6.5)",281.15,2022-10-25,2023-07-05,8EXI,2584.0,1.0,298.0,160.0,,34.77,1.0,1.599,experimental,31.7486,0.2139,0.1911,Crystal structure of apo PTP1B D181A/Q262A phosphatase domain
6XVJ,X-RAY DIFFRACTION,2.22,44.63,VAPOR DIFFUSION,8.5,"25 % PEG550MME, 0.1 M NaCl, 0.1 M TRIS buffer pH 8.5",293.0,2020-01-22,2020-05-27,6XVJ,2684.0,1.0,322.0,205.0,,37.48,1.0,1.78,experimental,36.22,0.215,0.178,Crystal structure of the KDR (VEGFR2) kinase domain in complex with a type-II inhibitor
6XVK,X-RAY DIFFRACTION,2.24,45.08,VAPOR DIFFUSION,6.5,"11 % PEG8000, 0.1 M PCTP buffer pH 6.5",293.0,2020-01-22,2020-05-27,6XVK,2463.0,1.0,322.0,33.0,,37.53,1.0,1.99,experimental,75.99,0.244,0.206,Crystal structure of the KDR (VEGFR2) kinase domain in complex with a type-II inhibitor bearing an acrylamide
7CMW,X-RAY DIFFRACTION,2.32,46.96,"VAPOR DIFFUSION, HANGING DROP",7.0,"2.2 M DL-malic acid pH 7.0,
0.1 M BIS-TRIS propane pH 7.0",293.0,2020-07-29,2020-12-16,7CMW,5648.0,2.0,708.0,82.0,,80.04,1.0,2.7,experimental,18.49,0.2583,0.2038,Complex structure of PARP1 catalytic domain with pamiparib
5WEV,X-RAY DIFFRACTION,2.5,50.89,"VAPOR DIFFUSION, HANGING DROP",6.0,"25-30% w/v PEG 8000
0.2M Ammonium Acetate
0.1M Na Citrate pH 6.0",291.0,2017-07-10,2017-09-06,5WEV,2624.0,1.0,319.0,139.0,,37.72,1.0,1.854,experimental,27.966,0.19401,0.16553,Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model
6AG9,X-RAY DIFFRACTION,2.15,42.71,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2018-08-09,2019-09-18,6AG9,2110.0,1.0,253.0,149.0,5.0,28.85,1.0,1.63,experimental,30.1965,0.2062,0.182,"Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2- carboxamide"
6JYP,X-RAY DIFFRACTION,2.15,42.8,"VAPOR DIFFUSION, SITTING DROP",,"0.05M sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2019-04-27,2020-05-13,6JYP,2020.0,1.0,246.0,50.0,5.0,28.15,1.0,2.25,experimental,50.97,0.254,0.193,Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide
6JYQ,X-RAY DIFFRACTION,2.14,42.55,"VAPOR DIFFUSION, SITTING DROP",,"0.05M sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400",298.0,2019-04-27,2020-05-13,6JYQ,2060.0,1.0,246.0,86.0,5.0,28.18,1.0,1.75,experimental,36.04,0.263,0.227,Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide
6WTN,X-RAY DIFFRACTION,2.09,41.16,"VAPOR DIFFUSION, HANGING DROP",5.0,"1.6-2.4 M sodium malonate, pH 5",291.0,2020-05-03,2021-05-05,6WTN,2416.0,1.0,309.0,93.0,,36.9,1.0,1.83,experimental,41.6108,0.2084,0.1872,Human JAK2 JH1 domain in complex with Ruxolitinib
7Q7L,X-RAY DIFFRACTION,2.12,42.01,"VAPOR DIFFUSION, SITTING DROP",,1.46-1.60 M trisodium citrate (untitrated),293.0,2021-11-09,2022-02-02,7Q7L,2637.0,1.0,316.0,195.0,,37.9,1.0,1.97,experimental,42.36,0.1956,0.1705,JAK2 in complex with 4-(2-amino-8-{[(2S)-1-hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluorophenol
7TEU,X-RAY DIFFRACTION,2.55,51.84,"VAPOR DIFFUSION, HANGING DROP",4.0,"200 mM potassium phosphate monobasic, 21% (w/v) PEG 3350",291.0,2022-01-05,2023-06-21,7TEU,2506.0,1.0,317.0,200.0,,37.79,1.0,1.45,experimental,20.82,0.2071,0.1935,Crystal structure of JAK2 JH1 with type II inhibitor YLIU-04-105-1
6P8F,X-RAY DIFFRACTION,2.67,58.97,"VAPOR DIFFUSION, SITTING DROP",7.0,"100mM Tris (7.0)
17% PEG 3350
100 mM CaCl2 
10 mM MgCl2",295.0,2019-06-07,2019-12-25,6P8F,4498.0,3.0,633.0,,,72.19,3.0,2.89,experimental,,0.2422,0.1862,Crystal structure of CDK4 in complex with CyclinD1 and P27
8FO6,X-RAY DIFFRACTION,2.49,50.6,VAPOR DIFFUSION,5.9,"100 mM Bis-trispropane, 200 mM NaF, 17.6% PEG-3350 (2protein 1solution)",293.0,2022-12-29,2023-05-03,8FO6,4849.0,2.0,679.0,107.0,,77.25,2.0,2.553,experimental,60.06,0.2314,0.2169,Nucleotide-free structure of a functional construct of eukaryotic elongation factor 2 kinase.
6HWT,X-RAY DIFFRACTION,2.19,43.86,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2, 20-30 % PEG4000, 40mM BOG",293.0,2018-10-15,2019-04-17,6HWT,3051.0,1.0,362.0,205.0,,42.94,1.0,1.7,experimental,,0.2345,0.2021,Crystal structure of p38alpha in complex with a reduced photoswitchable 2-Azothiazol-based Inhibitor (compound 31)
6HWU,X-RAY DIFFRACTION,2.32,46.92,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2, 20-30 % PEG4000, 40mM BOG",293.0,2018-10-15,2019-04-17,6HWU,2859.0,1.0,362.0,65.0,,42.94,1.0,2.3,experimental,,0.2466,0.1905,Crystal structure of p38alpha in complex with a photoswitchable 2-Azothiazol-based Inhibitor (compound 2)
6HWV,X-RAY DIFFRACTION,2.17,43.42,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2, 20-30 % PEG4000, 40mM BOG",293.0,2018-10-15,2019-04-17,6HWV,3127.0,1.0,362.0,270.0,,42.95,1.0,1.7,experimental,,0.1969,0.1796,Crystal structure of p38alpha in complex with a photoswitchable 2-Azoimidazol-based Inhibitor (compound 3)
5IZ5,X-RAY DIFFRACTION,3.45,64.34,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Bis-Tris-propane (pH 7.0-7.5), 1.4-1.5 M Lithium Sulphate",290.0,2016-03-24,2016-06-08,5IZ5,12571.0,2.0,1628.0,432.0,1.0,183.91,1.0,2.2,experimental,55.63,0.23781,0.22322,Human GIVD cytosolic phospholipase A2
5VEM,X-RAY DIFFRACTION,3.22,61.83,"VAPOR DIFFUSION, HANGING DROP",6.5,"MES, PEG 6000, MPD",298.0,2017-04-05,2017-09-20,5VEM,9771.0,3.0,1248.0,160.0,,149.0,1.0,2.6,experimental,,0.2266,0.196,"Human ectonucleotide pyrophosphatase / phosphodiesterase 5 (ENPP5, NPP5)"
5WXF,X-RAY DIFFRACTION,1.81,31.95,"VAPOR DIFFUSION, SITTING DROP",,"50 mM sodium citrate, pH 4.6, and 2.0 M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2017-01-07,2018-07-11,5WXF,2221.0,2.0,265.0,180.0,6.0,29.9,2.0,1.46,experimental,18.78,0.245,0.209,Crystal structure of uPA in complex with upain-2-2
5YC6,X-RAY DIFFRACTION,2.16,43.1,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate (pH 4.6), 2.0M ammonium sulfate supplemented with 5% PEG 400",298.0,2017-09-06,2018-10-03,5YC6,2190.0,1.0,246.0,214.0,5.0,28.3,1.0,1.18,experimental,18.26,0.228,0.197,The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH4.6
6WU8,X-RAY DIFFRACTION,2.03,39.45,"VAPOR DIFFUSION, HANGING DROP",8.0,"300 mM potassium formate, 14% w/v PEG3350",293.0,2020-05-04,2021-03-17,6WU8,8318.0,2.0,1072.0,228.0,,123.74,1.0,2.4,experimental,41.3443,0.2704,0.2095,Structure of human SHP2 in complex with inhibitor IACS-13909
6GI6,X-RAY DIFFRACTION,2.49,50.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"1.5M ammonium sulfate, 0.1M sodium chloride, 0.1M bis-tris pH 6.5",277.0,2018-05-10,2018-05-23,6GI6,2583.0,1.0,301.0,149.0,,35.83,1.0,1.98,experimental,,0.2625,0.2132,Crystal structure of the ACVR1 (ALK2) kinase in complex with a Quinazolinone based ALK2 inhibitor with a 5-methyl core.
6GIP,X-RAY DIFFRACTION,2.61,53.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.5M ammonium sulfate, 0.1M tris pH 8.5, 4% glycerol",293.0,2018-05-14,2018-05-23,6GIP,2517.0,1.0,301.0,104.0,,35.35,1.0,2.17,experimental,,0.2389,0.1951,"Crystal structure of the ACVR1 (ALK2) kinase in complex with a Quinazolinone based ALK2 inhibitor with a 2, 5-dimethyl core."
6C3E,X-RAY DIFFRACTION,2.01,38.82,VAPOR DIFFUSION,7.0,"0.25 M ammonium iodide, 0.03 M glycyl-glycyl-glycine and polyethylene glycol (PEG) 3350",277.0,2018-01-09,2018-03-21,6C3E,4195.0,2.0,594.0,32.0,,67.7,1.0,2.6,experimental,44.744,0.30665,0.259,CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
6Q7S,X-RAY DIFFRACTION,2.27,45.85,"VAPOR DIFFUSION, HANGING DROP",7.2,"02M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-13,2019-06-26,6Q7S,3138.0,1.0,368.0,312.0,,42.84,1.0,1.73,experimental,31.889,0.23988,0.18364,ERK2 mini-fragment binding
7UKZ,X-RAY DIFFRACTION,3.27,62.43,"VAPOR DIFFUSION, HANGING DROP",,"1.75M NH4SO4, 0.1M Tris-HCl pH 7.5",293.0,2022-04-03,2022-10-26,7UKZ,13429.0,6.0,1914.0,,,222.47,1.0,2.6,experimental,73.768,0.2361,0.2224,CDK11 in complex with small molecule inhibitor OTS964
7WR4,X-RAY DIFFRACTION,2.66,53.72,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 0.1 M HEPES pH 7.4, 0.2 M Ammonium sulfate, 0.3 M NDSB-195",293.0,2022-01-26,2023-01-25,7WR4,6565.0,3.0,859.0,,,98.65,3.0,2.75,experimental,93.86,0.2698,0.2321,Crystal structure of OspC3-calmodulin-caspase-4 complex
5MK3,X-RAY DIFFRACTION,2.06,40.33,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Potassium thiocyanate, 0.1 M Bis-Tris propane pH 6.5, 20% PEG 3350",277.0,2016-12-02,2017-08-16,5MK3,12582.0,8.0,1516.0,780.0,,171.24,2.0,2.0,experimental,,0.235,0.1975,Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro 1 domain (CHMP4C peptide complex structure)
5NGU,X-RAY DIFFRACTION,2.25,45.4,VAPOR DIFFUSION,,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",293.0,2017-03-20,2017-04-19,5NGU,2756.0,1.0,381.0,14.0,,44.58,1.0,2.74,experimental,53.34,0.262,0.267,Human Erk2 with an Erk1/2 inhibitor
5NHF,X-RAY DIFFRACTION,2.22,44.68,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298.0,2017-03-21,2017-04-19,5NHF,2767.0,1.0,381.0,73.0,,44.48,1.0,2.14,experimental,50.08,0.259,0.247,Human Erk2 with an Erk1/2 inhibitor
5NHH,X-RAY DIFFRACTION,2.24,45.03,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298.0,2017-03-21,2017-04-19,5NHH,3055.0,1.0,381.0,217.0,,44.57,1.0,1.94,experimental,34.02,0.22,0.18,Human Erk2 with an Erk1/2 inhibitor
5NHJ,X-RAY DIFFRACTION,2.26,45.6,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298.0,2017-03-21,2017-04-19,5NHJ,2961.0,1.0,381.0,187.0,,44.47,1.0,2.12,experimental,38.79,0.207,0.201,Human Erk2 with an Erk1/2 inhibitor
5NHL,X-RAY DIFFRACTION,2.27,45.76,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298.0,2017-03-21,2017-04-19,5NHL,2881.0,1.0,381.0,127.0,,44.4,1.0,2.07,experimental,48.29,0.237,0.209,Human Erk2 with an Erk1/2 inhibitor
5NHO,X-RAY DIFFRACTION,2.28,46.05,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298.0,2017-03-22,2017-04-19,5NHO,2807.0,1.0,381.0,87.0,,44.4,1.0,2.24,experimental,64.43,0.231,0.198,Human Erk2 with an Erk1/2 inhibitor
5NHP,X-RAY DIFFRACTION,2.52,51.1,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298.0,2017-03-22,2017-04-19,5NHP,2933.0,1.0,381.0,203.0,,44.48,1.0,1.99,experimental,35.2,0.221,0.198,Human Erk2 with an Erk1/2 inhibitor
5NHV,X-RAY DIFFRACTION,2.25,45.23,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298.0,2017-03-22,2017-04-19,5NHV,2975.0,1.0,381.0,176.0,,44.32,1.0,2.0,experimental,37.64,0.2283,0.1828,Human Erk2 with an Erk1/2 inhibitor
6QLZ,X-RAY DIFFRACTION,2.18,43.6,"VAPOR DIFFUSION, SITTING DROP",7.0,"100mM Hepes pH 7.0
10% (w/v) PEG 6000",293.0,2019-02-01,2020-02-19,6QLZ,2213.0,3.0,303.0,11.0,,33.39,1.0,2.343,experimental,63.5,,,IDOL F3ab subdomain
7JJG,X-RAY DIFFRACTION,2.51,50.95,"VAPOR DIFFUSION, HANGING DROP",,"0.01 M Co(II) chloride, 0.1 M Sodium acetate trihydrate (pH 4.6), 1 M 1,6-Hexanediol",291.0,2020-07-25,2021-07-28,7JJG,1311.0,1.0,137.0,155.0,,16.45,1.0,1.6,experimental,26.1453,0.1948,0.1688,Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ATR kinase inhibitor AZ20
6NAS,X-RAY DIFFRACTION,2.33,47.1,"VAPOR DIFFUSION, HANGING DROP",6.5,"16% Peg3350, 0.1 MES pH 6.5, 0.2M NH4NO3",290.0,2018-12-06,2020-01-29,6NAS,5529.0,3.0,750.0,6.0,,85.14,3.0,2.9,experimental,44.1477,0.2388,0.184,Ternary Complex of Ac-Alpha-Actin with Profilin and AcCoA-NAA80
7KEN,X-RAY DIFFRACTION,3.17,61.2,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES, 200 mM magnesium acetate, 14% PEG8000",277.0,2020-10-11,2021-03-10,7KEN,2820.0,1.0,329.0,187.0,,38.34,1.0,1.8,experimental,38.766,0.24369,0.20351,"Protein Tyrosine Phosphatase 1B, D289A mutant, apo state"
7PPM,X-RAY DIFFRACTION,2.46,50.07,"VAPOR DIFFUSION, HANGING DROP",5.5,"10% PEG 20000, 100mM Citrate buffer pH 5.5, EDTA 50mM",277.0,2021-09-14,2022-09-07,7PPM,2459.0,2.0,295.0,124.0,,34.39,2.0,1.48,experimental,39.34,0.1961,0.1645,"SHP2 catalytic domain in complex with IRS1 (889-901) phosphopeptide (pSer-892, pTyr-896)"
4ORA,X-RAY DIFFRACTION,2.98,58.75,"VAPOR DIFFUSION, HANGING DROP",5.8,"100 mM MES, pH 5.8, 9% PEG 3350, 4% Glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 294K",294.0,2014-02-11,2015-05-20,4ORA,4614.0,2.0,714.0,45.0,,80.9,2.0,2.747,experimental,,0.249,0.1991,Crystal structure of a human calcineurin mutant
5SZ9,X-RAY DIFFRACTION,3.09,60.14,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 0.06M citrate, 0.04M citric acid",293.0,2016-08-12,2016-11-02,5SZ9,5359.0,2.0,678.0,159.0,6.0,75.95,1.0,2.85,experimental,50.09,0.2322,0.1842,Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors
6B8J,X-RAY DIFFRACTION,2.19,43.89,"VAPOR DIFFUSION, HANGING DROP",,7-12% (w:v) PEG 6000 and 5-8% MPD (v:v),290.0,2017-10-08,2017-11-08,6B8J,3018.0,2.0,424.0,203.0,,48.04,2.0,2.595,experimental,,0.2466,0.2121,Co-structure of human glycogen synthase kinase beta with a selective (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine inhibitor
8CM9,X-RAY DIFFRACTION,4.68,73.72,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M potassium phosphate dibasic, 5 % xylitol and 10 mM EDTA",291.0,2023-02-18,2023-10-04,8CM9,22438.0,8.0,2920.0,236.0,,329.29,2.0,2.8,experimental,58.798,0.224,0.1964,Structure of human O-GlcNAc transferase in complex with UDP and tP11
7S5G,X-RAY DIFFRACTION,2.34,47.35,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% PEG3350, 200mM CaCl2, 100mM MES pH 6",291.0,2021-09-10,2021-11-03,7S5G,3066.0,3.0,439.0,126.0,3.0,48.07,3.0,2.041,experimental,26.68,0.2856,0.2274,PCSK9 in complex with compound 19
5HG9,X-RAY DIFFRACTION,1.86,33.81,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M (2.5 uL of stock 4.0 M) Ammonium sulfate, 20.0 %w/v (20.0 uL of stock 50.0 %w/v) PEG 8000, 0.1 M (5.0 uL of stock 1.0 M) HEPES (pH 7.50), 10.4545454545 %v/v (5.2272727272 uL of stock 100.0 %v/v) iso-propanol",286.0,2016-01-08,2016-02-03,5HG9,2510.0,1.0,329.0,136.0,,38.49,1.0,2.15,experimental,29.9,0.241,0.188,"EGFR (L858R, T790M, V948R) in complex with 1-[(3R,4R)-3-[({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-(trifluoromethyl)pyrrolidin-1-yl]prop-2-en-1-one"
5ETF,X-RAY DIFFRACTION,2.81,56.23,"VAPOR DIFFUSION, SITTING DROP",,25% (w/v) PEG 3350 and 0.1 mM Bis-Tris pH6.5,293.0,2015-11-17,2016-10-26,5ETF,3040.0,2.0,375.0,223.0,,43.0,2.0,2.4,experimental,,0.231,0.1629,Structure of dead kinase MAPK14 with bound the KIM domain of MKK6
5SXN,X-RAY DIFFRACTION,3.08,60.12,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 0.06M citrate, 0.04M citric acid",293.0,2016-08-09,2016-11-02,5SXN,5745.0,2.0,678.0,494.0,6.0,75.62,1.0,2.1,experimental,40.262,0.2327,0.1951,Structure-based design of a new series of N-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors
5L0N,X-RAY DIFFRACTION,2.04,39.7,"VAPOR DIFFUSION, HANGING DROP",4.0,"0.8 M Lithium sulfate monohydrate.  0.1 M Sodium acetate trihydrate pH 4.0,  4% v/v Polyethylene glycol 200",277.0,2016-07-27,2017-08-02,5L0N,1173.0,1.0,135.0,141.0,,15.67,1.0,1.285,experimental,,0.1821,0.1671,PKG I's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with RP-cGMP
6TKY,X-RAY DIFFRACTION,2.48,50.5,EVAPORATION,7.5,"25% (w/v) PEG 3350, 200 mM potassium acetate, 8% (v/v) 1,1,1,3,3,3-Hexafluoro-2-propanol.",293.0,2019-11-29,2020-01-22,6TKY,9543.0,4.0,1291.0,231.0,,148.3,3.0,2.55,experimental,45.26,0.2464,0.1884,Crystal structure of the DHR2 domain of DOCK10 in complex with CDC42
6CMS,X-RAY DIFFRACTION,2.11,37.78,"VAPOR DIFFUSION, SITTING DROP",9.0,"100 mM bicine pH 9, 100 mM NaCl, 19 % PEG MME 550",291.0,2018-03-06,2018-11-14,6CMS,4125.0,1.0,532.0,67.0,,61.36,1.0,2.68,experimental,56.2,0.2651,0.2046,Closed structure of active SHP2 mutant E76K bound to SHP099 inhibitor
6L8U,X-RAY DIFFRACTION,2.22,44.48,"VAPOR DIFFUSION, SITTING DROP",,"20% (w/v) PEG3350, 200 mM CaCl2.",293.0,2019-11-07,2019-12-25,6L8U,7482.0,4.0,1136.0,7.0,,131.34,1.0,2.925,experimental,46.3074,0.2704,0.2119,Crystal structure of human BCDIN3D in complex with SAH
5XZR,X-RAY DIFFRACTION,2.11,37.72,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M Sodium formate, 0.1 M Bicine pH 8.5, 15% w/v PEG 5000MME",291.0,2017-07-13,2017-12-13,5XZR,4124.0,1.0,557.0,2.0,,64.24,1.0,2.8,experimental,61.1661,0.2809,0.2404,The atomic structure of SHP2 E76A mutant in complex with allosteric inhibitor 9b
9ESA,X-RAY DIFFRACTION,2.5,50.73,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH5.5, 0.025-0.05 M ammonium sulphate, 9-12% PEG3350",293.0,2024-03-26,2024-09-11,9ESA,5297.0,4.0,722.0,56.0,,83.75,2.0,2.8,experimental,69.968,0.294,0.2279,Aurora-C with SER mutation in complex with INCENP peptide
4S3N,X-RAY DIFFRACTION,3.02,59.25,"VAPOR DIFFUSION, HANGING DROP",8.5,"200 mM trisodium citrate, 150 mM NaCl, 12% PEG 3350, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293.15K",293.15,2015-02-26,2015-03-25,4S3N,3795.0,3.0,411.0,292.0,,53.39,1.0,2.0,experimental,,0.2113,0.1818,Crystal structure of human OAS3 domain I in complex with dsRNA
4UJ1,X-RAY DIFFRACTION,2.55,51.81,"VAPOR DIFFUSION, HANGING DROP",,"10MG/ML PROTEIN, 25MM BISTRIS/MES PH6.9, 50MM KCL, 1.5MM OCTANOYL-N-METHYLGLUCAMIDE, 1MM PROTEIN KINASE INHIBITOR PEPTIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K",277.0,2015-04-07,2016-04-13,4UJ1,3327.0,2.0,371.0,357.0,,43.51,2.0,1.768,experimental,,0.2014,0.1665,Protein Kinase A in complex with an Inhibitor
4UJ2,X-RAY DIFFRACTION,2.47,50.15,"VAPOR DIFFUSION, HANGING DROP",,"10MG/ML PROTEIN, 25MM BISTRIS/MES PH6.9, 50MM KCL, 1.5MM OCTANOYL-N-METHYLGLUCAMIDE, 1MM PROTEIN KINASE INHIBITOR PEPTIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K",277.0,2015-04-07,2016-04-13,4UJ2,3132.0,2.0,371.0,187.0,,43.6,2.0,2.019,experimental,,0.2092,0.1615,Protein Kinase A in complex with an Inhibitor
4UJ9,X-RAY DIFFRACTION,2.55,51.79,"VAPOR DIFFUSION, HANGING DROP",,"10MG/ML PROTEIN, 25MM BISTRIS/MES PH6.9, 50MM KCL, 1.5MM OCTANOYL-N-METHYLGLUCAMIDE, 1MM PROTEIN KINASE INHIBITOR PEPTIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K",277.0,2015-04-09,2016-04-13,4UJ9,3447.0,2.0,371.0,455.0,,43.66,2.0,1.87,experimental,,0.2065,0.1647,Protein Kinase A in complex with an Inhibitor
4UJA,X-RAY DIFFRACTION,2.52,51.12,"VAPOR DIFFUSION, HANGING DROP",,"10MG/ML PROTEIN, 25MM BISTRIS/MES PH6.9, 50MM KCL, 1.5MM OCTANOYL-N-METHYLGLUCAMIDE, 1MM PROTEIN KINASE INHIBITOR PEPTIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K",277.0,2015-04-09,2016-04-13,4UJA,3264.0,2.0,371.0,294.0,,43.64,2.0,1.93,experimental,,0.206,0.1637,Protein Kinase A in complex with an Inhibitor
4UJB,X-RAY DIFFRACTION,2.56,52.03,"VAPOR DIFFUSION, HANGING DROP",,"10MG/ML PROTEIN, 25MM BISTRIS/MES PH6.9, 50MM KCL, 1.5MM OCTANOYL-N-METHYLGLUCAMIDE, 1MM PROTEIN KINASE INHIBITOR PEPTIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K",277.0,2015-04-09,2016-04-13,4UJB,3467.0,2.0,371.0,420.0,,43.69,2.0,1.949,experimental,,0.19,0.1546,Protein Kinase A in complex with an Inhibitor
5SVH,X-RAY DIFFRACTION,3.12,60.6,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M potassium sulfate
2.3M Ammonium sulphate",295.0,2016-08-06,2018-05-09,5SVH,1181.0,2.0,145.0,100.0,,17.17,2.0,2.05,experimental,,0.242,0.2063,Crystal structure of the KIX domain of CBP in complex with a MLL/c-Myb chimera
7OFV,X-RAY DIFFRACTION,2.47,50.11,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.10 M Na Acet, pH 4.50, 1.20 M K2HPO4, 0.80 M NaH2PO4",277.0,2021-05-05,2021-08-11,7OFV,1894.0,2.0,191.0,303.0,2.0,22.28,2.0,1.43,experimental,20.129,0.2065,0.149,NMR-guided design of potent and selective EphA4 agonistic ligands
5XWD,X-RAY DIFFRACTION,3.54,65.23,"VAPOR DIFFUSION, SITTING DROP",6.0,"MES buffer (pH 6.0), zinc acetate, PEG8000",293.0,2017-06-29,2018-02-28,5XWD,6623.0,3.0,903.0,,27.0,102.39,3.0,2.894,experimental,,0.3309,0.2768,Crystal structure of the complex of 059-152-Fv and EGFR-ECD
6S24,X-RAY DIFFRACTION,2.56,52.02,"VAPOR DIFFUSION, SITTING DROP",,"Morpheus precipitant mix 4, nitrate phosphate buffer and Morpheus buffer System 1",291.0,2019-06-20,2019-12-25,6S24,4756.0,2.0,645.0,201.0,6.0,76.04,2.0,2.12,experimental,41.609,0.23738,0.19119,"Crystal structure of the TgGalNAc-T3 in complex with UDP, manganese and the peptide 3"
7O45,X-RAY DIFFRACTION,2.51,51.06,"VAPOR DIFFUSION, HANGING DROP",7.5,0.2M NaBr; 0.1M bis-tris-propane pH 7.5; 20% PEG 3350,288.0,2021-04-05,2022-04-13,7O45,4065.0,4.0,584.0,129.0,,67.25,1.0,2.1,experimental,53.627,0.2281,0.2,Crystal structure of ADD domain of the human DNMT3B methyltransferase
6WBW,X-RAY DIFFRACTION,2.43,49.43,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2020-03-27,2020-05-06,6WBW,10250.0,3.0,1128.0,1121.0,,131.75,1.0,1.46,experimental,26.28,0.197,0.172,Structure of Human HDAC2 in complex with an ethyl ketone inhibitor
6WBZ,X-RAY DIFFRACTION,2.48,50.31,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2020-03-28,2020-05-06,6WBZ,10534.0,3.0,1128.0,1271.0,,133.02,1.0,1.32,experimental,24.48,0.192,0.172,Structure of Human HDAC2 in complex with an ethyl ketone inhibitor containing a spiro-bicyclic group
7JS8,X-RAY DIFFRACTION,2.52,51.18,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2020-08-14,2021-08-11,7JS8,10368.0,3.0,1128.0,1151.0,,132.93,1.0,1.634,experimental,27.61,0.1896,0.1665,STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ETHYL KETONE INHIBITOR CONTAINING A SPIRO-BICYCLIC GROUP (COMPOUND 22)
7KBH,X-RAY DIFFRACTION,2.46,49.93,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2020-10-02,2020-12-30,7KBH,9702.0,3.0,1131.0,528.0,,132.42,1.0,2.68,experimental,38.72,0.2207,0.1495,Structure of Human HDAC2 in complex with a 2-substituted benzamide inhibitor (compound 16)
7MOS,X-RAY DIFFRACTION,2.47,50.26,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2021-05-03,2021-07-14,7MOS,10335.0,3.0,1128.0,1084.0,,133.07,1.0,1.704,experimental,27.87,0.2084,0.1827,Structure of HDAC2 in complex with a macrocyclic inhibitor (compound 4)
7MOT,X-RAY DIFFRACTION,2.47,50.28,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2021-05-03,2021-07-14,7MOT,10381.0,3.0,1128.0,1142.0,,132.7,1.0,1.54,experimental,22.81,0.2032,0.1781,Structure of HDAC2 in complex with an inhibitor (compound 9)
7MOX,X-RAY DIFFRACTION,2.48,50.47,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2021-05-03,2021-07-14,7MOX,10329.0,3.0,1128.0,1072.0,,132.93,1.0,1.69,experimental,27.55,0.2021,0.176,Structure of HDAC2 in complex with an inhibitor (compound 14)
7MOY,X-RAY DIFFRACTION,2.48,50.37,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2021-05-03,2021-07-14,7MOY,10323.0,3.0,1128.0,1057.0,,133.06,1.0,1.78,experimental,29.35,0.2083,0.1782,Structure of HDAC2 in complex with an inhibitor (compound 19)
7MOZ,X-RAY DIFFRACTION,2.47,50.22,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2021-05-03,2021-07-14,7MOZ,10430.0,3.0,1128.0,1167.0,,133.22,1.0,1.543,experimental,23.06,0.2005,0.1758,Structure of HDAC2 in complex with a macrocyclic inhibitor (compound 25)
6WOH,X-RAY DIFFRACTION,2.19,43.74,"VAPOR DIFFUSION, HANGING DROP",6.0,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution of 200 mM LiCl, 20% (w/v) PEG 8000, 20% (v/v) isopropanol, 100 mM HEPES, pH 7.0, 20 mM MgCl2 and 80 mM NaF in present of 2mM 1,5-PCP-IP4",293.0,2020-04-24,2021-03-03,6WOH,1279.0,1.0,169.0,110.0,,20.55,1.0,1.7,experimental,17.066,0.2161,0.185,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 1,5-di-methylenebisphosphonate inositol tetrakisphosphate (1,5-PCP-IP4)"
6HR2,X-RAY DIFFRACTION,2.66,53.69,"VAPOR DIFFUSION, HANGING DROP",6.0,"20% (w/v) PEG1500, 0.1 M MIB Buffer, pH 6.0",277.0,2018-09-26,2019-06-12,6HR2,8048.0,8.0,940.0,404.0,,110.47,4.0,1.76,experimental,56.7,0.236,0.216,Crystal structure of PROTAC 2 in complex with the bromodomain of human SMARCA4 and pVHL:ElonginC:ElonginB
5I85,X-RAY DIFFRACTION,3.62,66.02,"VAPOR DIFFUSION, SITTING DROP",,"phosphocholine soaked in well solution containing 1.5 M ammonium sulfate, 0.1 M sodium acetate pH 5.0-5.5, 12% glycerol.",294.0,2016-02-18,2016-09-07,5I85,4660.0,1.0,583.0,261.0,8.0,69.07,1.0,2.5,experimental,,0.2218,0.1903,aSMase with zinc and phosphocholine
5C1D,X-RAY DIFFRACTION,3.22,61.84,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.45 M Potassium diohydrogen phosphate, 8 mM EDTA, 1% xylitol (reservoir). 1.45 M Potassium diohydrogen phosphate, 8 mM EDTA, 1% xylitol, 0.5 M Ammonium sulfate (drop)",294.15,2015-06-13,2015-08-05,5C1D,5865.0,2.0,731.0,254.0,,82.53,2.0,2.05,experimental,45.3,0.22864,0.19461,Human OGT in complex with UDP-5S-GlcNAc and substrate peptide (RB2L)
4QPA,X-RAY DIFFRACTION,2.77,55.54,,,,,2014-06-22,2015-09-23,4QPA,5594.0,2.0,738.0,,,85.96,1.0,2.85,experimental,,0.2526,0.2118,"Crystal Structure of ERK2 in complex with 7-(1-benzyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazine"
5ANR,X-RAY DIFFRACTION,2.32,47.01,,8.0,"50 MM TRIS PH 8.0, 35% MPD",,2015-09-08,2015-10-21,5ANR,5205.0,3.0,680.0,276.0,,77.98,3.0,2.102,experimental,,0.2319,0.1931,Structure of a human 4E-T - DDX6 - CNOT1 complex
6U9N,X-RAY DIFFRACTION,2.58,52.27,"VAPOR DIFFUSION, SITTING DROP",,2.2 M Sodium Malonate pH 7.0,277.0,2019-09-09,2020-07-01,6U9N,2508.0,2.0,316.0,191.0,,37.74,1.0,1.95,experimental,31.8,0.248,0.227,MLL1 SET N3861I/Q3867L bound to inhibitor 14 (TC-5139)
6U9R,X-RAY DIFFRACTION,2.64,53.41,"VAPOR DIFFUSION, SITTING DROP",,2.1 M Sodium Malonate pH 7.0,277.0,2019-09-09,2020-07-01,6U9R,2490.0,2.0,316.0,146.0,,37.74,1.0,2.1,experimental,34.7,0.255,0.214,MLL1 SET N3861I/Q3867L bound to inhibitor 12 (TC-5140)
8S1M,X-RAY DIFFRACTION,2.56,51.96,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.17 M ammonium acetate
0.085 M sodium citrate
25.5% PEG 4000
15% Glycerol",293.0,2024-02-15,2024-08-14,8S1M,1134.0,1.0,145.0,26.0,,17.03,1.0,2.05,experimental,72.05,0.2298,0.2033,Crystal structure of human GABARAP fused to EGFR (1076-1099)
6G5F,X-RAY DIFFRACTION,5.44,77.4,"VAPOR DIFFUSION, SITTING DROP",7.0,"1.1 M sodium malonate dibasic monohydrate, HEPES pH 7.0, 0.5% v/v Jeffamine ED-2003",294.0,2018-03-29,2019-01-16,6G5F,11000.0,3.0,2603.0,268.0,1.0,304.98,2.0,2.5,experimental,73.562,0.23182,0.20173,Crystal structure of an engineered Botulinum Neurotoxin type B mutant E1191M/S1199Y in complex with human synaptotagmin 1
5W0O,X-RAY DIFFRACTION,2.48,50.37,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M ammonium acetate, 0.1 M trisodium citrate, pH 5.5, 14% PEG400",291.0,2017-05-31,2017-06-28,5W0O,6085.0,4.0,808.0,50.0,,100.07,1.0,2.488,experimental,78.5625,0.2542,0.2054,Structure of human TUT7 catalytic module (CM) in complex with dsRNA
4US0,X-RAY DIFFRACTION,3.57,65.59,,,,,2014-07-02,2015-03-04,4US0,5565.0,2.0,672.0,493.0,,78.39,2.0,2.17,experimental,42.1,0.2123,0.1856,The crystal structure of H-Ras and SOS in complex with ligands
6RQ4,X-RAY DIFFRACTION,2.31,46.74,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",291.0,2019-05-15,2019-12-04,6RQ4,3096.0,1.0,368.0,333.0,,43.1,1.0,1.96,experimental,41.782,0.232,0.175,Inhibitor of ERK2
5BNW,X-RAY DIFFRACTION,2.21,44.34,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.3 M DL-Malic acid pH 6.4, 0.1 M Bis-Tris propane pH 6.4 supplemented with crystal seeds grown out of the same condition.",294.0,2015-05-26,2015-08-05,5BNW,5656.0,2.0,736.0,78.0,,82.94,2.0,2.4,experimental,45.84,0.23517,0.18736,The active site of O-GlcNAc transferase imposes constraints on substrate sequence
4ZZN,X-RAY DIFFRACTION,2.36,47.97,,,,,2015-04-10,2015-05-27,4ZZN,3153.0,1.0,350.0,365.0,,41.25,1.0,1.33,experimental,23.28,0.2023,0.1703,Human ERK2 in complex with an inhibitor
4ZZO,X-RAY DIFFRACTION,2.38,48.32,,,,,2015-04-10,2015-05-27,4ZZO,2975.0,1.0,350.0,224.0,,41.26,1.0,1.63,experimental,25.58,0.2373,0.1846,Human ERK2 in complex with an irreversible inhibitor
6B74,X-RAY DIFFRACTION,3.32,63.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"30 mM HEPES, 0.2 M NH4I, 0.2 M AmSO4",291.0,2017-10-03,2018-03-21,6B74,1952.0,2.0,252.0,51.0,7.0,28.33,2.0,2.323,experimental,71.4168,0.222,0.1899,Structures of the two-chain human plasma Factor XIIa co-crystallized with potent inhibitors
6B77,X-RAY DIFFRACTION,3.27,62.0,"VAPOR DIFFUSION, SITTING DROP",7.0,"30 mM HEPES, 0.2 M NH4I, 0.2 M NH4S04",291.0,2017-10-03,2018-03-21,6B77,2015.0,2.0,252.0,97.0,6.0,28.38,2.0,2.37,experimental,,0.2176,0.1736,Structures of the two-chain human plasma factor XIIa co-crystallized with potent inhibitors
7LP2,X-RAY DIFFRACTION,2.1,41.54,"VAPOR DIFFUSION, SITTING DROP",6.5,"2.0M Ammonium Sulfate, 0.1M BIS-TRIS",293.0,2021-02-11,2021-07-28,7LP2,1307.0,6.0,159.0,107.0,,19.5,2.0,1.88,experimental,27.71,0.2279,0.1854,Structure of Nedd4L WW3 domain
5ETY,X-RAY DIFFRACTION,2.14,42.57,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.1M Na-Succinate pH 5.8, 6% PEG MME 5000",298.0,2015-11-18,2016-06-22,5ETY,6777.0,4.0,1028.0,74.0,,119.15,1.0,2.9,experimental,55.05,0.3054,0.255,Crystal Structure of human Tankyrase-1 bound to K-756
6DTK,X-RAY DIFFRACTION,3.65,66.27,"VAPOR DIFFUSION, SITTING DROP",,2-3 M Ammonium sulfate or Sodium malonate,298.0,2018-06-17,2019-06-19,6DTK,12729.0,5.0,1625.0,1356.0,10.0,165.02,1.0,2.0,experimental,38.62,0.19,0.156,Heterodimers of FALS mutant SOD enzyme
6B9M,X-RAY DIFFRACTION,2.71,54.66,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Succinic acid pH7.0, 15% (v/v) Polyethylene glycol 3350",277.0,2017-10-10,2018-02-14,6B9M,4312.0,4.0,500.0,535.0,,57.68,2.0,1.68,experimental,,0.2066,0.1821,Crystal structure of UHRF1 TTD domain in complex with the polybasic region
5E1S,X-RAY DIFFRACTION,2.5,50.81,"VAPOR DIFFUSION, HANGING DROP",7.3,"25% PEG 8000, 0.1M TRIS pH 7.3, 50mM NaCl, 5 mM DTT",293.0,2015-09-30,2015-10-14,5E1S,2445.0,1.0,308.0,137.0,,35.48,1.0,2.264,experimental,48.74,0.262,0.2126,The Crystal structure of INSR Tyrosine Kinase in complex with the Inhibitor BI 885578
6LUD,X-RAY DIFFRACTION,3.33,63.04,VAPOR DIFFUSION,7.7,"0.96 M Succinic Acid, 1.0 %(w/v) Polyethylene glycol monomethyl ether 2000, 0.1 M HEPES",294.0,2020-01-27,2020-10-07,6LUD,2478.0,1.0,329.0,53.0,,37.83,1.0,2.05,experimental,54.2224,0.2215,0.2065,Crystal Structure of EGFR(L858R/T790M/C797S) in complex with Osimertinib
6OCQ,X-RAY DIFFRACTION,2.07,40.53,"VAPOR DIFFUSION, HANGING DROP",7.5,"24 % PEG 4000, 0.1 M ammonium acetate, 0.1 M HEPES pH 7.5",277.0,2019-03-25,2019-05-08,6OCQ,4235.0,2.0,606.0,4.0,,69.88,1.0,2.793,experimental,72.2768,0.2681,0.2028,Crystal structure of RIP1 kinase in complex with a pyrrolidine
4WB7,X-RAY DIFFRACTION,3.13,60.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"70mM sodium cacodylate pH 6.5, 150mM magnesium acetate, 20mM zinc chloride, 5% glycerol, 11.5% PEG 8000",295.0,2014-09-02,2015-01-21,4WB7,8153.0,4.0,850.0,998.0,,101.63,2.0,1.9,experimental,40.43,0.1879,0.1499,Crystal structure of a chimeric fusion of human DnaJ (Hsp40) and cAMP-dependent protein kinase A (catalytic alpha subunit)
5JGA,X-RAY DIFFRACTION,3.86,68.14,"VAPOR DIFFUSION, HANGING DROP",7.7,"1.7M sodium potassium phosphate, 20%(v/v) Glycerol as cryoprotectant",294.0,2016-04-19,2016-07-27,5JGA,2534.0,1.0,315.0,186.0,,36.0,1.0,2.0,experimental,40.658,0.2213,0.1952,Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 11c
5JGB,X-RAY DIFFRACTION,3.99,69.18,"VAPOR DIFFUSION, HANGING DROP",7.7,"1.7M sodium potassium phosphate, 20%(v/v) Glycerol as cryoprotectant",293.0,2016-04-20,2016-07-27,5JGB,2355.0,1.0,315.0,33.0,,36.02,1.0,2.8,experimental,48.586,0.2437,0.2006,Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 10
7KIA,X-RAY DIFFRACTION,2.81,56.18,"VAPOR DIFFUSION, SITTING DROP",4.0,"12% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0",298.0,2020-10-23,2021-02-10,7KIA,4952.0,2.0,616.0,223.0,,72.05,1.0,2.22,experimental,48.065,0.2232,0.1988,Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 19
8I0M,X-RAY DIFFRACTION,2.21,44.41,EVAPORATION,,"0.2 M BIS-TRIS pH 7.0, 20% PEG 4,000",293.0,2023-01-11,2024-01-24,8I0M,2080.0,1.0,301.0,,,34.56,1.0,2.7772,experimental,76.013,0.2816,0.203,Structure of CDK6 in complex with inhibitor
7TAM,X-RAY DIFFRACTION,2.63,53.3,"VAPOR DIFFUSION, HANGING DROP",8.0,"29% PEG 3350, 0.2 M calcium chloride, 0.1 M TRIS hydrochloride",295.15,2021-12-21,2022-12-28,7TAM,1559.0,1.0,166.0,127.0,,19.45,1.0,1.87,experimental,31.8271,0.201,0.1741,HRas G12V in complex with GDP
7OG9,X-RAY DIFFRACTION,1.98,38.0,BATCH MODE,7.5,"40 mM Tris HCL, 10 mM MgCl2, 2 mM DTE, 26-30 % PEG-400",298.0,2021-05-06,2022-02-09,7OG9,1511.0,1.0,166.0,103.0,,19.57,1.0,1.75,experimental,28.72,0.217,0.158,GTPase HRAS under ambient pressure
7OGA,X-RAY DIFFRACTION,1.92,35.83,BATCH MODE,7.5,"40 mM Tris HCL, 10 mM MgCl2, 2 mM DTE, 26-30 % PEG-400",298.0,2021-05-06,2022-02-09,7OGA,1473.0,1.0,166.0,81.0,,19.57,1.0,1.9,experimental,36.34,0.235,0.171,GTPase HRAS under 200 MPa pressure
7OGB,X-RAY DIFFRACTION,1.9,35.14,BATCH MODE,7.5,"40 mM Tris HCL, 10 mM MgCl2, 2 mM DTE, 26-30 % PEG-400",298.0,2021-05-06,2022-02-09,7OGB,1522.0,1.0,166.0,106.0,,19.96,1.0,1.85,experimental,24.22,0.236,0.177,GTPase HRAS under 500 MPa pressure
7OGC,X-RAY DIFFRACTION,1.91,35.6,BATCH MODE,7.5,"40 mM Tris HCL, 10 mM MgCl2, 2 mM DTE, 26-30 % PEG-400",298.0,2021-05-06,2022-02-09,7OGC,1599.0,1.0,166.0,163.0,,19.96,1.0,1.7,experimental,18.39,0.221,0.161,GTPase HRAS under 650 MPa pressure
7OGD,X-RAY DIFFRACTION,1.96,37.11,BATCH MODE,7.5,"40 mM Tris HCL, 10 mM MgCl2, 2 mM DTE, 26-30 % PEG-400",298.0,2021-05-06,2022-02-09,7OGD,1461.0,1.0,166.0,82.0,,19.59,1.0,1.95,experimental,27.67,0.25,0.181,GTPase HRAS mutant D33K under ambient pressure
7OGE,X-RAY DIFFRACTION,1.92,36.0,BATCH MODE,7.5,"40 mM Tris HCL, 10 mM MgCl2, 2 mM DTE, 26-30 % PEG-400",298.0,2021-05-06,2022-02-09,7OGE,1451.0,1.0,166.0,81.0,,19.59,1.0,2.1,experimental,29.26,0.263,0.173,GTPase HRAS mutant D33K under 200 MPa pressure
7OGF,X-RAY DIFFRACTION,1.87,34.11,BATCH MODE,7.5,"40 mM Tris HCL, 10 mM MgCl2, 2 mM DTE, 26-30 % PEG-400",298.0,2021-05-06,2022-02-09,7OGF,1618.0,1.0,166.0,210.0,,19.97,1.0,1.8,experimental,19.27,0.333,0.242,GTPase HRAS mutant D33K under 900 MPa pressure
8OSM,X-RAY DIFFRACTION,1.88,34.7,BATCH MODE,7.5,"40 MM TRIS HCL, 10 MM MGCL2, 2 MM DTE,
26-30 % PEG-400",293.0,2023-04-19,2024-05-08,8OSM,1434.0,1.0,166.0,62.0,,19.57,1.0,2.05,experimental,35.79,0.2241,0.1712,GTPASE HRAS IN COMPLEX WITH ZN-CYCLEN AT 200 MPA PRESSURE
8OSN,X-RAY DIFFRACTION,1.92,35.94,BATCH MODE,7.5,"40 MM TRIS HCL, 10 MM MGCL2, 2 MM DTE, 26-30 % PEG-400",293.0,2023-04-19,2024-05-08,8OSN,1499.0,1.0,166.0,78.0,,19.57,1.0,1.8,experimental,28.74,0.2154,0.1757,GTPASE HRAS IN COMPLEX WITH ZN-CYCLEN AT AMBIENT PRESSURE
8OSO,X-RAY DIFFRACTION,1.82,,BATCH MODE,7.5,"40 MM TRIS HCL, 10 MM MGCL2, 2 MM DTE,
26-30 % PEG-400",293.0,2023-04-19,2024-05-08,8OSO,1426.0,1.0,166.0,40.0,,19.81,1.0,2.5,experimental,24.21,0.2804,0.2331,GTPase HRAS in complex with Zn-cyclen under 500 MPa pressure
8PFL,X-RAY DIFFRACTION,2.42,49.23,"VAPOR DIFFUSION, SITTING DROP",,"30% Jeffamine ED-2001
0.1 M Hepes pH 7",293.0,2023-06-16,2024-04-24,8PFL,3695.0,1.0,431.0,350.0,,49.36,1.0,1.8,experimental,35.67,0.2255,0.1968,Crystal structure of WRN helicase domain in complex with 3
8PFO,X-RAY DIFFRACTION,2.42,49.08,"VAPOR DIFFUSION, SITTING DROP",,"25.5 % PEG 4000
0.17 M ammonium sulfate
15 % glycerol",293.0,2023-06-16,2024-04-24,8PFO,3575.0,1.0,431.0,216.0,,49.39,1.0,1.9,experimental,40.15,0.2478,0.2066,Crystal structure of WRN helicase domain in complex with HRO761
8PFP,X-RAY DIFFRACTION,2.09,41.04,"VAPOR DIFFUSION, SITTING DROP",,"20 % PEG3350
0.2 M Sodium citrate tribasic dihydrate",293.0,2023-06-16,2024-04-24,8PFP,3395.0,1.0,431.0,205.0,,49.33,1.0,1.6,experimental,32.55,0.2384,0.2118,Crystal structure of WRN helicase domain in complex with ATPgammaS
6HAX,X-RAY DIFFRACTION,2.53,51.34,"VAPOR DIFFUSION, HANGING DROP",7.75,"13% (w/v) PEG 3350, 0.2 M sodium formate, 0.1 M HEPES, pH 8.0",277.0,2018-08-09,2019-06-12,6HAX,7780.0,8.0,972.0,213.0,,114.56,4.0,2.35,experimental,51.93,0.268,0.232,Crystal structure of PROTAC 2 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
6HAY,X-RAY DIFFRACTION,2.61,52.79,"VAPOR DIFFUSION, HANGING DROP",7.75,"18% (w/v) PEG 3350, 0.2 M sodium formate, 0.1 M HEPES, pH 7.75",277.0,2018-08-09,2019-06-12,6HAY,8033.0,8.0,972.0,300.0,,115.1,4.0,2.24,experimental,55.66,0.223,0.192,Crystal structure of PROTAC 1 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
3WZE,X-RAY DIFFRACTION,2.97,58.68,VAPOR DIFFUSION,8.0,"10-25% PEG 3350, Na3Citrate, 0.1M Bis-Tris propane, pH 8.0, VAPOR DIFFUSION, temperature 277K",277.0,2014-09-24,2015-05-27,3WZE,2587.0,1.0,309.0,107.0,,36.02,1.0,1.9,experimental,48.93,0.22406,0.18479,KDR in complex with ligand sorafenib
5FLF,X-RAY DIFFRACTION,2.7,54.6,,7.5,"20 PEG 400, 0.75 M AMMONIUM SULPHATE, 0.1 M MAGNESIUM CHLORIDE, 0.1 M HEPES PH 7.5",,2015-10-26,2016-03-30,5FLF,11786.0,5.0,1550.0,364.0,,177.74,1.0,2.58,experimental,,0.2545,0.1937,DISEASE LINKED MUTATION IN FGFR
6GUE,X-RAY DIFFRACTION,2.81,56.23,"VAPOR DIFFUSION, HANGING DROP",,"PROTEIN AT 5MG PER ML. 0.6 TO 0.8M KCL, 0.9 TO 1.2M (NH402SO4, AND 100MM HEPES (PH 7.0), 0.5mM Inhibitor",277.0,2018-06-19,2018-12-05,6GUE,9499.0,4.0,1140.0,539.0,,131.13,3.0,1.99,experimental,38.543,0.23425,0.19652,CDK2/CyclinA in complex with AZD5438
8CGP,X-RAY DIFFRACTION,3.02,59.25,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1M MMT (Malic acid, MES, Tris) 25% w/v PEG 1500 20% EG",278.15,2023-02-06,2024-01-31,8CGP,15164.0,2.0,1746.0,212.0,1.0,215.84,1.0,2.62,experimental,46.43,0.231,0.1695,Insulin regulated aminopeptidase (IRAP) in complex with an allosteric aryl sulfonamide inhibitor
7SIY,X-RAY DIFFRACTION,3.46,64.49,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Ammonium formate, 20% PEG3350",293.0,2021-10-15,2022-11-09,7SIY,2912.0,2.0,311.0,372.0,,36.07,2.0,1.48,experimental,51.84,0.2209,0.2085,cCBL TKB domain in complex with pZAP70 peptide
4UWY,X-RAY DIFFRACTION,2.37,48.03,,7.5,"20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4",,2014-08-15,2015-02-25,4UWY,4722.0,2.0,620.0,145.0,,70.83,1.0,2.305,experimental,,0.2666,0.2114,FGFR1 Apo structure
6YT6,X-RAY DIFFRACTION,2.32,46.91,"VAPOR DIFFUSION, HANGING DROP",9.0,"16-20 % PEG 3350, 0.1 M TRIS, pH 9.0",294.0,2020-04-23,2021-02-10,6YT6,4567.0,2.0,564.0,361.0,2.0,65.58,1.0,1.537,experimental,32.88,0.2118,0.19,"FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-methanesulfonamide"
5F5E,X-RAY DIFFRACTION,2.53,51.36,"VAPOR DIFFUSION, HANGING DROP",7.0,"35% Tacsimate, pH 7.0",277.0,2015-12-04,2016-02-24,5F5E,1325.0,1.0,158.0,142.0,,18.69,1.0,1.802,experimental,45.1431,0.2363,0.2017,The Crystal Structure of MLL1 SET domain with N3816I/Q3867L mutation
6UNS,X-RAY DIFFRACTION,2.27,45.91,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.05 M PIPES pH 7, 0.01 M DTT, 10 %w/v PEG 4000",298.0,2019-10-13,2021-07-07,6UNS,4594.0,2.0,660.0,10.0,,76.93,1.0,2.3,experimental,37.84,0.2618,0.2123,Kinase domain of ALK2-K492A/K493A with LDN-193189
7R7D,X-RAY DIFFRACTION,2.04,39.83,VAPOR DIFFUSION,8.0,"300 mM potassium formate, 14% w/v PEG3350",293.0,2021-06-24,2021-10-27,7R7D,8251.0,2.0,1072.0,229.0,,123.92,1.0,2.6,experimental,44.4737,0.2595,0.2038,Structure of human SHP2 in complex with compound 22
7R7I,X-RAY DIFFRACTION,2.04,39.71,"VAPOR DIFFUSION, HANGING DROP",8.0,"300 mM potassium formate, 14% w/v PEG3350",293.0,2021-06-24,2021-10-27,7R7I,7963.0,2.0,1072.0,6.0,,123.75,1.0,2.85,experimental,40.3504,0.2917,0.2315,Structure of human SHP2 in complex with compound 27
5QGG,X-RAY DIFFRACTION,4.29,71.35,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGG,1669.0,1.0,196.0,166.0,,22.66,1.0,1.91,experimental,36.771,0.2236,0.1901,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000693a
5QGH,X-RAY DIFFRACTION,4.29,71.33,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGH,1667.0,1.0,196.0,167.0,,22.7,1.0,1.82,experimental,36.375,0.2167,0.1914,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000420a
5QGI,X-RAY DIFFRACTION,4.34,71.66,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGI,1668.0,1.0,196.0,170.0,,22.68,1.0,1.95,experimental,39.686,0.2236,0.1917,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000710a
5QGJ,X-RAY DIFFRACTION,4.35,71.75,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGJ,1675.0,1.0,196.0,177.0,,22.68,1.0,1.95,experimental,39.652,0.2144,0.1859,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000706a
5QGK,X-RAY DIFFRACTION,4.36,71.78,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGK,1688.0,1.0,196.0,162.0,,23.01,1.0,1.81,experimental,37.418,0.2555,0.2258,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000679a
5QGL,X-RAY DIFFRACTION,4.56,73.0,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGL,1666.0,1.0,196.0,168.0,,22.68,1.0,2.27,experimental,47.781,0.2494,0.1989,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000275a
5QGM,X-RAY DIFFRACTION,4.33,71.56,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGM,1664.0,1.0,196.0,161.0,,22.74,1.0,1.96,experimental,41.501,0.2206,0.1904,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-160
5QGN,X-RAY DIFFRACTION,4.31,71.48,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGN,1691.0,1.0,196.0,166.0,,23.08,1.0,1.95,experimental,37.312,0.2112,0.1913,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-210
5QGO,X-RAY DIFFRACTION,4.32,71.54,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGO,1671.0,1.0,196.0,170.0,,22.72,1.0,1.82,experimental,40.04,0.2235,0.2004,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-220
5QGP,X-RAY DIFFRACTION,4.59,73.2,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGP,1647.0,1.0,196.0,146.0,,22.72,1.0,2.09,experimental,44.168,0.2238,0.1864,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-221
5QGQ,X-RAY DIFFRACTION,4.33,71.59,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGQ,1800.0,1.0,196.0,179.0,,22.66,1.0,1.95,experimental,34.415,0.2269,0.2019,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with OX-65
5QGR,X-RAY DIFFRACTION,4.32,71.54,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGR,1667.0,1.0,196.0,156.0,,22.91,1.0,1.96,experimental,42.554,0.2438,0.2126,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000022a
5QGS,X-RAY DIFFRACTION,4.28,71.23,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGS,1694.0,1.0,196.0,175.0,,22.71,1.0,1.55,experimental,32.119,0.1951,0.1642,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000476a
5QGU,X-RAY DIFFRACTION,4.3,71.39,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGU,1685.0,1.0,196.0,168.0,,22.72,1.0,1.71,experimental,32.177,0.2206,0.1986,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with FMOPL000747a
5QGV,X-RAY DIFFRACTION,4.12,70.16,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGV,1686.0,1.0,196.0,160.0,,22.75,1.0,1.59,experimental,31.948,0.2103,0.1948,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with UNUYB062989
5QGW,X-RAY DIFFRACTION,4.3,71.37,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGW,1673.0,1.0,196.0,156.0,,22.71,1.0,1.94,experimental,38.961,0.2077,0.1868,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000154
5QGX,X-RAY DIFFRACTION,4.1,69.97,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGX,1684.0,1.0,196.0,160.0,,22.75,1.0,1.61,experimental,31.275,0.2079,0.1972,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000155
5QGY,X-RAY DIFFRACTION,4.1,70.03,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGY,1674.0,1.0,196.0,158.0,,22.72,1.0,1.72,experimental,34.763,0.2104,0.1938,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000158
5QGZ,X-RAY DIFFRACTION,4.08,69.88,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QGZ,1683.0,1.0,196.0,160.0,,22.74,1.0,1.65,experimental,32.737,0.2105,0.1948,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000161
5QH0,X-RAY DIFFRACTION,4.09,69.91,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH0,1683.0,1.0,196.0,161.0,,22.7,1.0,1.57,experimental,31.373,0.2059,0.1958,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000180
5QH1,X-RAY DIFFRACTION,4.07,69.78,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH1,1685.0,1.0,196.0,162.0,,22.73,1.0,1.65,experimental,32.79,0.2031,0.1929,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000181
5QH2,X-RAY DIFFRACTION,4.08,69.85,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH2,1675.0,1.0,196.0,159.0,,22.7,1.0,1.74,experimental,34.038,0.2094,0.1972,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000188
5QH3,X-RAY DIFFRACTION,4.08,69.87,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH3,1699.0,1.0,196.0,158.0,,22.97,1.0,1.65,experimental,32.894,0.2051,0.1958,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000191
5QH4,X-RAY DIFFRACTION,4.16,70.41,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH4,1675.0,1.0,196.0,159.0,,22.7,1.0,1.67,experimental,29.51,0.2184,0.201,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000220a
5QH5,X-RAY DIFFRACTION,4.21,70.77,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH5,1675.0,1.0,196.0,161.0,,22.67,1.0,1.85,experimental,38.076,0.211,0.1905,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000224a
5QH6,X-RAY DIFFRACTION,4.11,70.08,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH6,1678.0,1.0,196.0,162.0,,22.7,1.0,2.0,experimental,32.872,0.2152,0.1849,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000259a
5QH7,X-RAY DIFFRACTION,4.12,70.13,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH7,1669.0,1.0,196.0,154.0,,22.69,1.0,1.74,experimental,35.513,0.2188,0.1992,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000194a
5QHB,X-RAY DIFFRACTION,4.16,70.47,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QHB,1668.0,1.0,196.0,156.0,,22.72,1.0,1.57,experimental,35.569,0.213,0.2,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with RK4-332
5QHC,X-RAY DIFFRACTION,4.4,72.05,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QHC,1667.0,1.0,196.0,152.0,,22.78,1.0,2.21,experimental,41.295,0.2282,0.1886,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with RK4-337
5QHE,X-RAY DIFFRACTION,4.21,70.77,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QHE,1676.0,1.0,196.0,158.0,,22.73,1.0,1.74,experimental,37.725,0.2189,0.1981,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with RK4-350
5QHF,X-RAY DIFFRACTION,4.15,70.39,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QHF,1690.0,1.0,196.0,162.0,,22.87,1.0,1.67,experimental,32.241,0.2125,0.1944,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NUOOA000301a
5QHG,X-RAY DIFFRACTION,4.21,70.82,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QHG,1656.0,1.0,196.0,139.0,,22.84,1.0,1.92,experimental,47.613,0.2328,0.2016,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NU000442a
5QHH,X-RAY DIFFRACTION,4.14,70.26,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QHH,1717.0,1.0,196.0,179.0,,22.83,1.0,1.52,experimental,30.764,0.2052,0.1904,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with NU000443a
6NVL,X-RAY DIFFRACTION,2.61,52.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"90 mM NPS salt mixture (30 mM sodium nitrate, 30 mM sodium phosphate dibasic, 30 mM ammonium sulfatesulfate), 100 mM HEPES/MOPS pH 7.5, and 50% v/v of a precipitant mixture of 40% v/v PEG 500 MME and 20 % w/v PEG 20,000",291.0,2019-02-05,2019-07-10,6NVL,8407.0,4.0,1236.0,42.0,,143.12,1.0,2.7,experimental,37.898,0.26289,0.21272,"FGFR1 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide"
8XOY,X-RAY DIFFRACTION,3.1,60.32,"VAPOR DIFFUSION, SITTING DROP",,"0.2M MgCl2, 0.1M Bis-Tris pH6.5, 25% PEG 3350",293.0,2024-01-02,2024-01-24,8XOY,2960.0,1.0,322.0,408.0,,38.1,1.0,1.55,experimental,18.053,0.1841,0.1591,The Crystal Structure of PTP1B from Biortus.
6EIX,X-RAY DIFFRACTION,2.21,44.35,"VAPOR DIFFUSION, SITTING DROP",6.5,0.1M MES pH 6.5 -- 12%(w/v) PEG 20000,293.0,2017-09-19,2017-09-27,6EIX,2598.0,1.0,340.0,64.0,,39.43,1.0,2.3,experimental,33.214,0.24944,0.18825,Crystal structure of the kinase domain of the Q207E mutant of ACVR1 (ALK2) in complex with a 2-aminopyridine inhibitor K02288
6CHG,X-RAY DIFFRACTION,4.34,71.68,"VAPOR DIFFUSION, HANGING DROP",,"Sodium Tartrate, PEG20000, ATP",277.0,2018-02-22,2018-08-22,6CHG,10637.0,7.0,1435.0,10.0,,164.2,6.0,2.985,experimental,,0.2708,0.228,Crystal structure of the yeast COMPASS catalytic module
5T19,X-RAY DIFFRACTION,3.11,60.4,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MgCl2, 0.1M Bis-Tris pH 6.3-6.5, 23-27% PEG 3350",278.0,2016-08-18,2017-04-12,5T19,2626.0,1.0,323.0,165.0,,38.02,1.0,2.1001,experimental,31.261,0.1918,0.1509,"Structure of PTP1B complexed with N-(3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methyl-[1,1'-biphenyl]-4-yl)acetamide"
7MKZ,X-RAY DIFFRACTION,2.3,46.42,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M TRIS, PH 7.4, 0.2 M MGCL2, 16%     
PEG8000",277.0,2021-04-27,2022-05-18,7MKZ,2629.0,1.0,308.0,279.0,,36.23,1.0,1.4,experimental,26.17,0.173,0.156,"PTP1B F225Y mutant, open state"
7MNB,X-RAY DIFFRACTION,3.37,63.51,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 7.4, 0.2 M Magnesium Chloride, 16.5% peg8000",277.0,2021-04-30,2022-05-18,7MNB,2664.0,1.0,308.0,197.0,,36.49,1.0,2.2,experimental,38.23,0.199,0.1635,PTP1B F225Y-R199N-L195R in complex with TCS401
8SKL,X-RAY DIFFRACTION,3.11,60.47,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Ammonium Tartrate,
20% w/v PEG 3350",278.0,2023-04-20,2023-08-02,8SKL,2716.0,1.0,322.0,231.0,,38.19,1.0,1.55,experimental,,0.1935,0.1764,PTP1B in complex with 182
7CJB,X-RAY DIFFRACTION,2.26,45.51,EVAPORATION,6.5,"sodium cacodylate pH 6.5, 100 mM magnesium acetate, 15%(w/v) PEG 6000",289.0,2020-07-09,2021-07-14,7CJB,11190.0,16.0,1600.0,,,180.32,4.0,2.8,experimental,51.478,0.2594,0.2199,VHL recognizes hydroxyproline in RIPK1
4QP1,X-RAY DIFFRACTION,2.76,55.45,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG3350, 0.2 M proline, and 0.1 M HEPES pH7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-06-22,2015-09-23,4QP1,5850.0,2.0,738.0,186.0,,85.84,1.0,2.7,experimental,,0.2545,0.2033,Crystal structure of ERK2 in complex with N-cyclohexyl-9H-purin-6-amine
4QP2,X-RAY DIFFRACTION,2.78,55.83,,7.5,"10% PEG3350, 0.2 M proline, and 0.1 M HEPES pH7.5, in a 24-well Linbro plates incubated at 4C, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-06-22,2015-09-23,4QP2,5778.0,2.0,738.0,320.0,,85.49,1.0,2.23,experimental,,0.234,0.183,Crystal Structure of ERKs in complex with 5-chlorobenzo[d]oxazol-2-amine
4QP8,X-RAY DIFFRACTION,2.0,38.54,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG3350, 0.2 M proline, and 0.1 M HEPES pH7.5, in a 24-well Linbro plates incubated at 4C, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-06-22,2015-09-23,4QP8,5669.0,2.0,738.0,137.0,,85.62,1.0,2.446,experimental,,0.2488,0.204,"Crystal Structure of ERK2 in complex with 2-(1H-pyrazol-4-yl)-7-(pyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazine"
7VXG,X-RAY DIFFRACTION,2.23,44.74,"VAPOR DIFFUSION, SITTING DROP",8.2,"100mM Tris-HCl pH 8.2, 12% (vol/vol) PEG 4000, 20mM DTT",295.0,2021-11-12,2022-03-23,7VXG,15586.0,4.0,2104.0,380.0,,242.93,1.0,2.1,experimental,,0.3249,0.2698,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor TK-453
8PSR,X-RAY DIFFRACTION,2.96,58.4,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M Na-citrate  pH 5.5, 20% PEG 8000",293.0,2023-07-13,2024-07-24,8PSR,3351.0,2.0,383.0,286.0,,44.87,2.0,1.85,experimental,,0.2091,0.1817,ERK2 covalently bound to SynthRevD-12-opt artificial peptide
5HX6,X-RAY DIFFRACTION,2.04,39.84,VAPOR DIFFUSION,7.5,"Well solution 26 % PEG 4K, 0.1 M HEPES pH 7.5; co-crystallized with NEC-4 and cmpd 8 back soaked into crystals at 5mM concentration
Cryo was transfer 6 % to 25 % glycerol added to well solution",310.0,2016-01-29,2016-03-02,5HX6,4198.0,2.0,606.0,29.0,,69.95,1.0,2.23,experimental,53.63,0.2476,0.199,"Crystal structure of RIP1 kinase with a benzo[b][1,4]oxazepin-4-one"
6JZD,X-RAY DIFFRACTION,2.48,50.33,"VAPOR DIFFUSION, HANGING DROP",7.0,"HEPES, potassium chloride, Ammonium sulphate",291.15,2019-05-01,2019-07-17,6JZD,2418.0,3.0,458.0,16.0,,52.54,3.0,2.479,experimental,,0.2296,0.1793,Crystal structure of peptide-bound VASH2-SVBP complex
5M0L,X-RAY DIFFRACTION,2.15,51.9,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (100 mM Stock)
Reservoir: 16% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-10-05,2018-06-06,5M0L,3406.0,2.0,373.0,400.0,,43.9,2.0,1.465,experimental,,0.1728,0.1525,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the methylated Fasudil-derived fragment N-methylisoquinoline-5-sulfonamide (Ligand 02)
5M6V,X-RAY DIFFRACTION,2.15,54.27,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)

Reservoir: 18% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-10-26,2018-06-06,5M6V,3618.0,2.0,373.0,452.0,,43.66,2.0,1.418,experimental,,0.174,0.1435,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a double methylated Fasudil-derivative
5M6Y,X-RAY DIFFRACTION,2.15,54.56,"VAPOR DIFFUSION, HANGING DROP",6.9,"Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)

Reservoir: 20% Methanol

0.003 mL drop volume, 0.4 mL reservoir volume",277.15,2016-10-26,2018-06-06,5M6Y,3591.0,2.0,373.0,433.0,,43.76,2.0,1.367,experimental,,0.1663,0.1441,Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a methylisoquinoline Fasudil-derivative
8PT5,X-RAY DIFFRACTION,2.42,49.3,"VAPOR DIFFUSION, HANGING DROP",5.5,"10% PEG8000, 0.1 M Na-citrate pH 5.5",293.0,2023-07-13,2024-07-24,8PT5,2917.0,1.0,364.0,86.0,,42.62,1.0,1.95,experimental,,0.2354,0.2039,ERK2 covelently bound to RU187 cyclohexenone based inhibitor
6G8X,X-RAY DIFFRACTION,2.32,46.87,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.1M HEPES/NaOHpH=7.2, 34.0%w/v MPEG 2000, 0.02M Mercaptoethanol, 0.2M (NH4)2SO4",293.0,2018-04-10,2018-05-30,6G8X,3247.0,1.0,368.0,436.0,,43.08,1.0,1.76,experimental,28.125,0.217,0.165,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G91,X-RAY DIFFRACTION,2.31,46.71,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.1M HEPES/NaOHpH=7.2, 34.0%w/v MPEG 2000, 0.02M Mercaptoethanol, 0.2M (NH4)2SO4",293.0,2018-04-10,2018-05-30,6G91,3298.0,1.0,368.0,468.0,,42.96,1.0,1.8,experimental,31.708,0.22,0.166,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G92,X-RAY DIFFRACTION,2.32,46.91,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4, 0.1M HEPES/NaOHpH=7.2, 34.0%w/v MPEG 2000, 0.02M Mercaptoethanol",293.0,2018-04-10,2018-05-30,6G92,3358.0,1.0,368.0,522.0,,43.04,1.0,1.99,experimental,33.173,0.227,0.164,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G93,X-RAY DIFFRACTION,2.31,46.84,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.1M HEPES/NaOHpH=7.2, 34.0%w/v MPEG 2000, 0.02M Mercaptoethanol, 0.2M (NH4)2SO4",293.0,2018-04-10,2018-05-30,6G93,3259.0,1.0,368.0,402.0,,43.38,1.0,1.67,experimental,42.519,0.213,0.171,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G97,X-RAY DIFFRACTION,2.31,46.77,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.3M (NH4)2SO4, 32.0%w/v MPEG 2000, 0.1M HEPES/NaOHpH=7.2, 0.02M Mercaptoethanol",293.0,2018-04-10,2018-05-30,6G97,3341.0,1.0,368.0,474.0,,43.53,1.0,1.9,experimental,34.548,0.223,0.16,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G9A,X-RAY DIFFRACTION,2.3,46.53,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.3M (NH4)2SO4, 32.0%w/v MPEG 2000, 0.1M HEPES/NaOHpH=7.2, 0.02M Mercaptoethanol",293.0,2018-04-10,2018-05-30,6G9A,3342.0,1.0,368.0,508.0,,43.3,1.0,1.91,experimental,40.717,0.25,0.178,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G9D,X-RAY DIFFRACTION,2.3,46.59,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.3M (NH4)2SO4, 32.0%w/v MPEG 2000, 0.1M HEPES/NaOHpH=7.2, 0.02M Mercaptoethanol",293.0,2018-04-10,2018-05-30,6G9D,3353.0,1.0,368.0,465.0,,43.49,1.0,1.8,experimental,35.905,0.223,0.166,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G9H,X-RAY DIFFRACTION,2.32,46.97,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.3M (NH4)2SO4, 32.0%w/v MPEG 2000, 0.1M HEPES/NaOHpH=7.2, 0.02M Mercaptoethanol",293.0,2018-04-10,2018-05-30,6G9H,3317.0,1.0,368.0,456.0,,43.41,1.0,1.73,experimental,34.003,0.213,0.162,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G9J,X-RAY DIFFRACTION,2.29,46.25,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.3M (NH4)2SO4, 32.0%w/v MPEG 2000, 0.1M HEPES/NaOHpH=7.2, 0.02M Mercaptoethanol",293.0,2018-04-10,2018-05-30,6G9J,3306.0,1.0,368.0,403.0,,43.4,1.0,1.98,experimental,38.051,0.212,0.159,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G9K,X-RAY DIFFRACTION,2.27,45.88,"VAPOR DIFFUSION, SITTING DROP",7.2,"2M (NH4)2SO4
34% MPEG 2000
.02M Mercaptoethanol
.1M pH=7.2 HEPES/NaOH",293.0,2018-04-11,2018-05-30,6G9K,3283.0,1.0,368.0,408.0,,43.44,1.0,1.94,experimental,38.631,0.223,0.16,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G9M,X-RAY DIFFRACTION,2.31,46.76,"VAPOR DIFFUSION, SITTING DROP",7.2,"2M (NH4)2SO4
32% MPEG 2000
.02M Mercaptoethanol
.1M pH=7.2 HEPES/NaOH",293.0,2018-04-11,2018-05-30,6G9M,3333.0,1.0,368.0,481.0,,43.36,1.0,1.86,experimental,36.971,0.206,0.157,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6G9N,X-RAY DIFFRACTION,2.3,46.55,"VAPOR DIFFUSION, SITTING DROP",7.2,"2M (NH4)2SO4
34% MPEG 2000
.02M Mercaptoethanol
.1M pH=7.2 HEPES/NaOH",293.0,2018-04-11,2018-05-30,6G9N,3464.0,1.0,368.0,558.0,,43.68,1.0,1.76,experimental,31.364,0.218,0.165,"Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2"
6BSH,X-RAY DIFFRACTION,3.73,67.03,"VAPOR DIFFUSION, HANGING DROP",,"Sodium citrate pH 5.2, CaCl2, PEG400",295.0,2017-12-03,2018-01-03,6BSH,8875.0,4.0,1047.0,115.0,,131.6,2.0,2.649,experimental,,0.2273,0.1892,Structure of HIV-1 RT complexed with RNA/DNA hybrid in the RNA hydrolysis mode
6NW2,X-RAY DIFFRACTION,1.96,37.23,VAPOR DIFFUSION,,"0.1M Bis Tris Propane pH 6.5, 0.2M Sodium Iodide, 20% PEG3350",277.0,2019-02-05,2019-05-01,6NW2,4289.0,2.0,620.0,201.0,,71.56,1.0,2.0,experimental,,0.2613,0.2088,Structure of human RIPK1 kinase domain in complex with compound 11
6MHM,X-RAY DIFFRACTION,2.66,53.71,"VAPOR DIFFUSION, HANGING DROP",4.3,"0.2 M sodium-phosphate-citrate, pH 4.3, 0.275 M lithium sulfate, and 18% polyethylene glycol 1000",298.0,2018-09-18,2019-01-23,6MHM,6208.0,4.0,768.0,79.0,4.0,92.45,2.0,2.743,experimental,51.0869,0.2616,0.2141,Crystal structure of human acid ceramidase in covalent complex with carmofur
5LMK,X-RAY DIFFRACTION,2.94,58.14,"VAPOR DIFFUSION, HANGING DROP",,ammonium sulphate; potassium chloride; sodium Hepes pH7.5,277.0,2016-08-01,2017-01-25,5LMK,9043.0,4.0,1112.0,230.0,,128.5,3.0,2.4,experimental,40.22,0.24863,0.21156,Structure of phopsho-CDK2-cyclin A in complex with an ATP-competitive inhibitor
5JXH,X-RAY DIFFRACTION,3.67,66.49,"VAPOR DIFFUSION, SITTING DROP",,"crystallization solution: 100 mM MES, 200 mM K/NaH2PO4, pH 5.5-6.0, 3-4 M NaCl, 3% DMSO; reservoir solution: 3-4 M NaCl",293.15,2016-05-13,2016-10-05,5JXH,4261.0,2.0,487.0,534.0,3.0,53.39,2.0,2.0,experimental,,0.1853,0.1566,Structure the proprotein convertase furin in complex with meta-guanidinomethyl-Phac-RVR-Amba at 2.0 Angstrom resolution.
6H22,X-RAY DIFFRACTION,2.17,43.42,"VAPOR DIFFUSION, SITTING DROP",,"1.1 M sodium malonate dibasic, 0.1 M HEPES pH 7.0, 0.5% v/v Jeffamine ED-2003",292.15,2018-07-12,2019-07-31,6H22,1965.0,4.0,222.0,191.0,,25.9,2.0,2.006,experimental,30.0421,0.2384,0.2107,Crystal structure of Mdm2 bound to a stapled peptide
8S07,X-RAY DIFFRACTION,2.17,43.21,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-13,2024-03-20,8S07,8996.0,2.0,1074.0,760.0,,124.57,1.0,1.83,experimental,44.852,0.2119,0.1795,A fragment-based inhibitor of SHP2
4TOR,X-RAY DIFFRACTION,1.93,36.2,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Bis-Tris propane, 0.2M sodium bromide, 25% PEG3350",293.15,2014-06-06,2015-05-20,4TOR,7777.0,4.0,944.0,824.0,,110.75,1.0,1.501,experimental,,0.2068,0.1772,Crystal structure of Tankyrase 1 with IWR-8
7NA1,X-RAY DIFFRACTION,2.48,50.47,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 100 mM citrate pH 3.5",285.0,2021-06-19,2021-11-10,7NA1,1675.0,2.0,218.0,107.0,,26.44,1.0,2.3,experimental,45.284,0.3542,0.2554,HDM2 in complex with compound 2
4R6E,X-RAY DIFFRACTION,2.51,50.94,"VAPOR DIFFUSION, SITTING DROP",5.5,"20% PEG-3350, 0.16M Ammonium Sulfate, 0.08M Bis-Tris, 0.001M Niraparib, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-08-25,2015-09-09,4R6E,11285.0,4.0,1432.0,154.0,2.0,162.74,1.0,2.2,experimental,58.05,0.2179,0.2022,Human artd1 (parp1) - catalytic domain in complex with inhibitor niraparib
7UAD,X-RAY DIFFRACTION,2.7,54.42,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 0.2 M ammonium sulfate, 0.1 M Tris, pH 8.5",290.0,2022-03-12,2023-07-26,7UAD,2444.0,1.0,324.0,145.0,,38.35,1.0,2.044,experimental,51.37,0.2452,0.2033,Crystal structure of human PTPN2 with inhibitor ABBV-CLS-484
5HYN,X-RAY DIFFRACTION,2.82,56.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG3350, 400mM Ammonian Citrate pH6.5",291.0,2016-02-01,2016-05-11,5HYN,35028.0,20.0,5068.0,,,586.82,5.0,2.95,experimental,,0.2733,0.2191,Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide
6GRA,X-RAY DIFFRACTION,2.6,52.76,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M potassium citrate, 0.1 M Bis-Tris propane pH 7.5, 20% PEG 3350, 10% ethylene glycol",277.0,2018-06-10,2019-05-15,6GRA,2022.0,1.0,285.0,3.0,,33.54,1.0,2.6,experimental,75.206,0.26859,0.21005,Human AURKA bound to BRD-7880
7CL0,X-RAY DIFFRACTION,4.4,72.06,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M (NH4)2SO4, 0.1 M Mes pH 6.5, 20% W/v PEG 8000",291.15,2020-07-20,2021-02-24,7CL0,2710.0,2.0,364.0,234.0,,42.31,2.0,2.53,experimental,45.614,0.2479,0.2064,Crystal structure of human SIRT6
5AWX,X-RAY DIFFRACTION,2.63,53.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"10% (w/v) PEG8000, 20% (v/v) ethylene glycol, 30mM sodium fluoride, 30mM sodium bromide, 30mM sodium iodide",277.0,2015-07-10,2016-02-17,5AWX,2540.0,1.0,298.0,247.0,,34.27,1.0,1.86,experimental,22.281,0.22094,0.18563,Crystal structure of Human PTPRZ D1 domain
7KEY,X-RAY DIFFRACTION,3.6,65.81,"VAPOR DIFFUSION, HANGING DROP",7.7,"12% PEG 3350, 100 mM magnesium acetate, 3% ethanol",293.0,2020-10-13,2022-01-19,7KEY,2496.0,1.0,282.0,135.0,,33.0,1.0,1.771,experimental,34.42,0.2064,0.1989,"Protein Tyrosine Phosphatase 1B, Apo"
7KLX,X-RAY DIFFRACTION,3.6,65.79,"VAPOR DIFFUSION, HANGING DROP",7.7,"12% PEG 3350, 100 mM magnesium acetate, 3% ethanol",293.0,2020-11-01,2022-01-19,7KLX,2453.0,1.0,282.0,118.0,,33.06,1.0,1.839,experimental,40.15,0.2049,0.1962,Protein Tyrosine Phosphatase 1B with inhibitor
4ORC,X-RAY DIFFRACTION,3.07,59.96,"VAPOR DIFFUSION, HANGING DROP",6.1,"100mM MES, pH 6.1, 10% PEG3350, 0.2M CaCl2, VAPOR DIFFUSION, HANGING DROP, temperature 294K",294.0,2014-02-11,2015-05-20,4ORC,4432.0,2.0,714.0,41.0,,80.96,2.0,2.7,experimental,,0.2603,0.2153,Crystal structure of mammalian calcineurin
7JSP,X-RAY DIFFRACTION,2.49,50.57,"VAPOR DIFFUSION, HANGING DROP",,"0.01 M Co(II) chloride, 0.1 M Sodium acetate trihydrate (pH 4.6), 1 M 1,6-Hexanediol",291.0,2020-08-15,2021-08-25,7JSP,1269.0,1.0,137.0,117.0,,16.46,1.0,1.7,experimental,37.9774,0.2049,0.1733,Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ATR kinase inhibitor AZD6738
7K0D,X-RAY DIFFRACTION,2.36,47.81,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulfate, 0.1 M MES monohydrate, 30% Polyethylene glycol monomethyl ether 5,000",291.0,2020-09-04,2021-09-22,7K0D,2014.0,1.0,265.0,9.0,,31.49,1.0,2.2,experimental,87.3031,0.2486,0.2297,"Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to mTORC1/2 inhibitor AZD3147"
7K1P,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES (pH 7.5), 10% PEG 8,000, 8% Ethylene glycol",291.0,2020-09-08,2021-09-22,7K1P,1116.0,1.0,137.0,23.0,1.0,16.35,1.0,2.45,experimental,71.06,0.22,0.194,Crystal structure of the second bromodomain (BD2) of human TAF1 bound to bromosporine
7L6X,X-RAY DIFFRACTION,3.28,62.54,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Amino acids, 0.1M Buffer system 1 pH 6.5, 30% v/v precipitant mix 3 (morpheus screen 2-39)",293.0,2020-12-24,2021-06-30,7L6X,2126.0,1.0,265.0,1.0,,31.52,1.0,2.75,experimental,105.4565,0.2499,0.2086,"Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to GNE-371"
6SMA,X-RAY DIFFRACTION,2.4,48.0,"VAPOR DIFFUSION, SITTING DROP",7.2,"24% PEG Smear Broad
0.1 M Tris-HCl pH 7.2
0.1 M KSCN
0.1M NaBr",293.15,2019-08-21,2020-04-08,6SMA,5236.0,3.0,654.0,110.0,12.0,74.15,1.0,2.59,experimental,41.02,0.2579,0.2152,Crystal structure of Human Neutrophil Elastase (HNE) in complex with the 3-Oxo-beta-Sultam inhibitor LMC249
5HT6,X-RAY DIFFRACTION,2.2,44.01,"VAPOR DIFFUSION, SITTING DROP",,"0.2M NH4Cl, 12 % (w/v) PEG 3350",293.0,2016-01-26,2016-11-16,5HT6,2011.0,2.0,276.0,80.0,,32.21,1.0,2.093,experimental,,0.2424,0.2089,Crystal structure of the SET domain of the human MLL5 methyltransferase
6IW6,X-RAY DIFFRACTION,2.95,58.32,"VAPOR DIFFUSION, SITTING DROP",7.0,"100 mM Hepes-NaOH, pH 7.0, 20% (w/v) PEG 3350, 3% MPD, 200 mM Ammonium Citrate and 3% (w/v) 1,5-Diaminopentane dihydrochloride",293.0,2018-12-04,2019-04-24,6IW6,7285.0,2.0,896.0,89.0,,104.66,1.0,2.402,experimental,69.8829,0.2371,0.21,Crystal structure of the Lin28-interacting module of human TUT4
7OGJ,X-RAY DIFFRACTION,3.03,59.39,"VAPOR DIFFUSION, SITTING DROP",,"200 mM lithium sulfate, 20% PEG 1000, 100 mM phosphate-citrate buffer pH 4.2",277.15,2021-05-06,2021-05-19,7OGJ,4092.0,2.0,504.0,581.0,,60.3,1.0,1.59,experimental,31.22,0.2147,0.1933,Crystal structure of human METTL1 in complex with SAH
7UG1,X-RAY DIFFRACTION,1.91,35.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"50 mM sodium/potassium phosphate, pH 7.5, 50 mM HEPES, pH 7.5, 5% v/v PEG3350",291.0,2022-03-23,2023-04-12,7UG1,2587.0,1.0,306.0,204.0,,35.59,1.0,1.84,experimental,25.7971,0.2422,0.1821,CDK2 liganded with para chloro ANS
8FEC,X-RAY DIFFRACTION,2.73,54.93,"VAPOR DIFFUSION, HANGING DROP",7.5,"200 mM Lithium sulfate, 100 mM HEPES 7.5, 25% PEG 3350",277.15,2022-12-06,2023-10-18,8FEC,7064.0,4.0,850.0,,,100.31,3.0,2.7,experimental,77.68,0.2874,0.2079,Structure of J-PKAc chimera complexed with Aplithianine derivative
6BRW,X-RAY DIFFRACTION,2.17,43.32,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-12-01,2018-08-15,6BRW,2255.0,1.0,289.0,130.0,,33.69,1.0,2.031,experimental,,0.2496,0.1944,JAK2 JH2 in complex with XMU-MP-1
6BS0,X-RAY DIFFRACTION,2.21,44.23,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-12-01,2018-08-22,6BS0,2451.0,1.0,289.0,302.0,,33.62,1.0,1.541,experimental,,0.1946,0.1601,JAK2 JH2 in complex with 63552444
6BSS,X-RAY DIFFRACTION,2.19,43.74,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris, pH 8.0
0.2M Sodium acetate
12-20% PEG 4,000",277.0,2017-12-04,2018-08-15,6BSS,2271.0,1.0,289.0,153.0,,33.62,1.0,2.1,experimental,,0.2354,0.1919,JAK2 JH2 in complex with NU6102
5I4N,X-RAY DIFFRACTION,2.63,53.22,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M TRIS, 0.2M SODIUM ACETATE, 22% PEG 4000",277.0,2016-02-12,2016-04-13,5I4N,2436.0,1.0,290.0,186.0,,33.87,1.0,1.54,experimental,,0.1929,0.1736,Crystal Structure of the E596A V617F Mutant JAK2 Pseudokinase Domain Bound to Mg-ATP
7UYW,X-RAY DIFFRACTION,2.52,51.21,VAPOR DIFFUSION,,Crystals of human JAK2 in complex with the ligand were prepared according to established protocols,298.0,2022-05-07,2022-08-24,7UYW,2376.0,1.0,291.0,28.0,,34.8,1.0,2.51,experimental,42.702,0.2595,0.2054,Crystal structure of JAK2 kinase domain in complex with compound 30
6OBF,X-RAY DIFFRACTION,2.17,43.23,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.15,2019-03-20,2020-03-25,6OBF,2240.0,1.0,289.0,142.0,,33.66,1.0,1.71,experimental,,0.2218,0.1975,JAK2 JH2 in complex with JAK179
6OCC,X-RAY DIFFRACTION,2.23,44.93,"VAPOR DIFFUSION, HANGING DROP",,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.15,2019-03-22,2020-03-25,6OCC,2091.0,1.0,289.0,49.0,,33.7,1.0,2.03,experimental,,0.2718,0.2248,JAK2 JH2 in complex with JAK190
8BX6,X-RAY DIFFRACTION,2.49,50.51,"VAPOR DIFFUSION, HANGING DROP",8.2,"0.1 M Gly-Gly pH 8.2, 1.6 M Na-malonate",295.0,2022-12-08,2023-12-20,8BX6,2772.0,1.0,316.0,240.0,,37.71,1.0,1.5,experimental,28.25,0.202,0.1735,Crystal structure of JAK2 JH1 in complex with cerdulatinib
8BXH,X-RAY DIFFRACTION,2.44,49.69,"VAPOR DIFFUSION, HANGING DROP",8.2,"0.1 M Gly-Gly pH 8.2, 2.1 M Na-malonate",295.0,2022-12-08,2023-12-20,8BXH,2880.0,1.0,316.0,246.0,,37.78,1.0,1.3,experimental,25.29,0.1681,0.1453,Crystal structure of JAK2 JH1 in complex with momelotinib
6P38,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"PEG 2000, Trimethylamine N-oxide dihydrate, Tris pH 8.5",293.0,2019-05-23,2020-05-27,6P38,1077.0,1.0,137.0,,,16.42,1.0,2.8,experimental,103.5489,0.2193,0.2058,Crystal Structure Analysis of TAF1 Bromodomain
7JJH,X-RAY DIFFRACTION,4.24,71.0,"VAPOR DIFFUSION, HANGING DROP",,"0.8 M Succinic Acid, pH 7.0",291.0,2020-07-25,2021-01-27,7JJH,2341.0,1.0,265.0,229.0,1.0,31.4,1.0,2.1,experimental,46.8533,0.2198,0.1875,"Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human TAF1"
8JWZ,X-RAY DIFFRACTION,2.98,58.69,LIPIDIC CUBIC PHASE,6.6,"100 mM sodium cacodylate trihydrate pH 6.6, 120 mM ammonium tartrate dibasic, 32% PEG 40",291.0,2023-06-29,2023-08-16,8JWZ,4191.0,1.0,481.0,252.0,4.0,60.8,1.0,2.37,experimental,35.55,0.2403,0.1889,Crystal structure of A2AR-T4L in complex with AB928
6CT2,X-RAY DIFFRACTION,2.25,45.4,"VAPOR DIFFUSION, SITTING DROP",,"0.196 M MgCl2, 19.5 % PEG 3350, and 0.1 M bis-tris chloride at pH 5.5",281.0,2018-03-22,2018-08-01,6CT2,2449.0,1.0,295.0,135.0,,35.01,1.0,2.128,experimental,,0.2355,0.2005,MYST histone acetyltransferase KAT6A/B in complex with WM-1119
8PQ9,X-RAY DIFFRACTION,1.93,36.4,"VAPOR DIFFUSION, HANGING DROP",8.5,"6.6 mg/mL, 10% PEG8000, 20% Ethylen glycole, 30 mM NaI, 30 mM NaF, 30 mM NaBr, 100 mM Bicine, pH 8.5",285.15,2023-07-11,2023-12-27,8PQ9,5232.0,2.0,654.0,486.0,,75.48,1.0,1.7,experimental,41.49,0.2044,0.1905,c-KIT kinase domain in complex with avapritinib
8PQG,X-RAY DIFFRACTION,2.24,45.19,"VAPOR DIFFUSION, HANGING DROP",6.5,"6 mg/mL, 25% PEG3350, 200 mM Na-citrate, 100 mM Bis-Tris-Propane, pH 6.5",293.15,2023-07-11,2023-12-27,8PQG,4730.0,2.0,654.0,42.0,,75.41,1.0,2.4,experimental,67.59,0.2311,0.2061,c-KIT T670I mutated kinase domain in complex with avapritinib
5F94,X-RAY DIFFRACTION,3.83,67.87,VAPOR DIFFUSION,,Crystals grown in the presence of 25% PEG 1500 and 0.1 M MMT pH 4.0,298.0,2015-12-09,2016-02-03,5F94,5318.0,2.0,700.0,38.0,,80.31,1.0,2.51,experimental,,0.2257,0.1887,Crystal structure of GSK3b in complex with Compound 15: 2-[(cyclopropylcarbonyl)amino]-N-(4-methoxypyridin-3-yl)pyridine-4-carboxamide
5F95,X-RAY DIFFRACTION,3.76,67.27,VAPOR DIFFUSION,,Crystals grown in the presence of 25% PEG 1500 and 0.1 M MMT pH 4.0,298.0,2015-12-09,2016-02-03,5F95,5170.0,2.0,700.0,69.0,,80.4,1.0,2.525,experimental,,0.2424,0.2015,Crystal structure of GSK3b in complex with Compound 18: 2-[(cyclopropylcarbonyl)amino]-N-(4-phenylpyridin-3-yl)pyridine-4-carboxamide
8DJC,X-RAY DIFFRACTION,3.23,61.95,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES pH 6.0, 20.0 %w/v PEG6K, 0.2 M NH4Cl",293.0,2022-06-30,2023-03-22,8DJC,5235.0,2.0,882.0,81.0,,99.42,1.0,2.463,experimental,48.87,0.2419,0.2156,"CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH (4S)-N-{4-[(2S)-2-methylmorpholin-4-yl] pyridin-3-yl}-2-phenylimidazo[1,2-b]pyridazine-8-carboxamide"
8DJD,X-RAY DIFFRACTION,3.03,59.47,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.0, 20.0 %w/v PEG6K, 0.2 M LiCl",295.0,2022-06-30,2023-03-22,8DJD,5500.0,2.0,882.0,257.0,,99.31,1.0,2.205,experimental,45.77,0.2218,0.2083,"CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 3-[(CYCLOPROPYLMETHYL)AMINO] -N-(4-PHENYLPYRIDIN-3-YL)IMIDAZO[1,2-B]PYRIDAZINE-8-CARBOX AMIDE"
8DJE,X-RAY DIFFRACTION,3.12,60.64,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M MES pH 6.0, 20.0 %w/v PEG6K, 0.2 M NH4Cl",293.0,2022-06-30,2023-03-22,8DJE,5558.0,2.0,882.0,203.0,,99.36,1.0,2.374,experimental,51.48,0.2266,0.2,"CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 3-[(CYCLOPROPYLMETHYL)AMINO] -N-(4-PHENYLPYRIDIN-3-YL)IMIDAZO[1,2-B]PYRIDAZINE-8-CARBOX AMIDE"
4X2G,X-RAY DIFFRACTION,2.12,41.96,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris-HCl, 240 mM Li2SO4, 24% PEG 4000, pH 7.5",293.0,2014-11-26,2015-08-12,4X2G,2805.0,1.0,305.0,315.0,,35.35,1.0,1.51,experimental,18.26,0.1853,0.1648,Selection of fragments for kinase inhibitor design: decoration is key
7B7N,X-RAY DIFFRACTION,2.63,53.23,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1M Na-malonate pH 5, 14.2% PEG 3350 , 14 mM adenosine-5'-triphosphate disodium salt hydrate",291.0,2020-12-11,2020-12-30,7B7N,7234.0,3.0,1080.0,54.0,9.0,121.38,3.0,2.69,experimental,76.67,0.2649,0.2226,Human herpesvirus-8 gH/gL in complex with EphA2
7TN4,X-RAY DIFFRACTION,2.17,43.34,"VAPOR DIFFUSION, HANGING DROP",5.0,"10% w/v PEG8000, 10% v/v isopropanol, 200 mM lithium sulfate, 100 mM sodium acetate, pH 5.0, 5 mM IP6, soaked in 200 mM lithium chloride, 20% w/v PEG8000, 20% v/v isopropanol, 100 mM sodium acetate, pH 5.0, 20 mM magnesium chloride, 100 mM sodium fluoride in presence of ZmITPK1 reaction solution with 1,2,3,4,5-IP5",293.0,2022-01-20,2022-06-15,7TN4,1279.0,1.0,172.0,134.0,,20.32,1.0,1.85,experimental,19.449,0.2173,0.1825,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 3-diphosphoinositol 1,2,4,5-tetrakisphosphate (3-PP-IP4), Mg and Fluoride ion"
8T98,X-RAY DIFFRACTION,2.5,50.89,"VAPOR DIFFUSION, HANGING DROP",,"10% w/v PEG8000, 10% v/v isopropanol, 200 mM lithium sulfate, 100 mM sodium acetate, pH 5.0, 5 mM IP6, soaked in 200 mM lithium chloride, 20% w/v PEG8000, 20% v/v isopropanol, 100 mM sodium acetate, pH 5.0, 20 mM magnesium chloride, 100 mM sodium fluoride in presence of TvIPK reaction solution with scyllo-IP5",298.0,2023-06-23,2023-11-15,8T98,1452.0,1.0,148.0,230.0,,17.94,1.0,1.3,experimental,16.911,0.17181,0.14912,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with Scyllo-3-PP-(1,2,4,5)IP4, Mg, and Fluoride ion"
8T99,X-RAY DIFFRACTION,2.5,50.82,"VAPOR DIFFUSION, HANGING DROP",,"10% w/v PEG8000, 10% v/v isopropanol, 200 mM lithium sulfate, 100 mM sodium acetate, pH 5.0, 5 mM IP6, soaked in 200 mM lithium chloride, 20% w/v PEG8000, 20% v/v isopropanol, 100 mM sodium acetate, pH 5.0, 20 mM magnesium chloride, 100 mM sodium fluoride in presence of TvIPK reaction solution with L-scyllo-(1,2,3,4)IP4",298.0,2023-06-23,2023-11-15,8T99,1410.0,1.0,148.0,207.0,,17.94,1.0,1.5,experimental,18.491,0.18271,0.156,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with Scyllo-L-1,4-[PP]2-(2,3)IP2, Mg, and Fluoride ion"
6TVN,X-RAY DIFFRACTION,2.17,43.36,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS 8.5 pH, 32.5% w/v PEG 3350, 200mM MgCl2",298.0,2020-01-10,2020-11-25,6TVN,5240.0,4.0,676.0,36.0,,80.96,1.0,2.31,experimental,53.75,0.257,0.225,"Crystal Structure of 5-bromoindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase"
6TUH,X-RAY DIFFRACTION,2.23,44.92,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS 8.5 pH, 32.5% w/v PEG 3350, 200mM MgCl2",298.0,2020-01-07,2020-11-25,6TUH,5181.0,4.0,676.0,80.0,2.0,80.98,1.0,2.25,experimental,71.72,0.276,0.236,The PH domain of Bruton's tyrosine kinase mutant R28C
6YYG,X-RAY DIFFRACTION,2.27,45.71,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS 8.5 pH, 32.5% w/v PEG 3350, 200mM MgCl2 500 mM NaCl",298.0,2020-05-05,2021-05-12,6YYG,5487.0,4.0,676.0,202.0,,80.89,1.0,1.95,experimental,41.561,0.2988,0.2304,"Crystal Structure of 5-(trifluoromethoxy)indoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase mutant R28C"
5DF6,X-RAY DIFFRACTION,1.98,37.9,VAPOR DIFFUSION,,"20% PEG-3350, 0.2 M ammonium formate",291.0,2015-08-26,2015-09-23,5DF6,1928.0,3.0,281.0,110.0,,31.76,2.0,1.78,experimental,30.51,0.248,0.194,Crystal structure of PTPN11 tandem SH2 domains in complex with a TXNIP peptide
7KHG,X-RAY DIFFRACTION,2.93,58.02,"VAPOR DIFFUSION, SITTING DROP",,"1.6M ammonium sulfate, 2.0M sodium Chloride and 0.1M Bis-Tris, pH 6.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293.0,2020-10-21,2021-07-07,7KHG,2832.0,1.0,335.0,190.0,,38.46,1.0,2.15,experimental,36.4077,0.2033,0.1818,"Crystal structure of KIT kinase domain with a small molecule inhibitor, PLX3397"
5A14,X-RAY DIFFRACTION,2.85,56.8,,7.5,"10%(W/V) PEG4000, 0.1M HEPES PH 7.5, 0.05M AMMONIUM SULPHATE",,2015-04-27,2015-07-22,5A14,2443.0,1.0,299.0,133.0,,35.01,1.0,2.0,experimental,41.743,0.24017,0.1944,Human CDK2 with type II inhibitor
6OQI,X-RAY DIFFRACTION,2.03,39.45,EVAPORATION,7.5,"10-12% PEG 4K, 50 mM Hepes pH7.5, 50 mM Ammonia Acetate",292.0,2019-04-26,2020-07-29,6OQI,2474.0,1.0,299.0,103.0,,34.56,1.0,2.0,experimental,53.7083,0.2411,0.1975,"CDK2 in complex with Cpd14 (5-fluoro-4-(4-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-3-yl)-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine)"
7RA5,X-RAY DIFFRACTION,2.05,39.93,VAPOR DIFFUSION,,"PEG3350, MES pH 7",277.0,2021-06-30,2021-11-03,7RA5,2458.0,1.0,300.0,171.0,,34.54,1.0,1.67,experimental,28.64,0.2739,0.2252,CDK2 IN COMPLEX WITH COMPOUND 4
7UXK,X-RAY DIFFRACTION,2.21,44.27,"VAPOR DIFFUSION, HANGING DROP",,"Crystallization buffer: 0.1 M BICINE pH 9.2, 2% v/v 1,4-Dioxane, 6% w/v PEG 20000",291.15,2022-05-05,2022-12-28,7UXK,2085.0,2.0,310.0,,,35.68,2.0,2.63,experimental,70.0,0.3,0.261,"Structure of CDK2 in complex with FP24322, a Helicon Polypeptide"
7ZPC,X-RAY DIFFRACTION,1.99,38.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"10MG/ML CDK2 10% V/V PEG3350, 50 MM      
HEPES/NAOH, 50 MM NA/K PHOSPHATE, PH 7.5",293.0,2022-04-27,2023-02-01,7ZPC,2734.0,1.0,306.0,277.0,,35.08,1.0,1.4,experimental,26.987,0.2211,0.2014,CDK2 in complex 9K-DOS
8CUR,X-RAY DIFFRACTION,2.02,39.15,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.2 M sodium chloride, 0.1 M MES, pH 6.0, 20% PEG6000",295.0,2022-05-17,2023-04-05,8CUR,2352.0,1.0,298.0,85.0,,34.51,1.0,2.2,experimental,,0.2674,0.1975,Crystal structure of Cdk2 in complex with Cyclin A inhibitor 6-[(E)-2-(4-chlorophenyl)ethenyl]-2-{[(2R)-3-(4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]carbamoyl}quinoline-4-carboxylic acid
6E2P,X-RAY DIFFRACTION,3.94,68.76,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, pH 6.5, 0.2 M magnesium chloride, 5-10% PEG4000, 10% ethylene glycol",277.15,2018-07-11,2018-08-08,6E2P,7601.0,4.0,1118.0,27.0,,129.1,2.0,2.83,experimental,106.19,0.2426,0.2274,Structure of human JAK2 FERM/SH2 in complex with Leptin Receptor
8EQD,X-RAY DIFFRACTION,3.43,64.15,"VAPOR DIFFUSION, HANGING DROP",,"100 mM HEPES pH 7.0, 180 mM Na/K tartrate, 9% PEG3350",277.0,2022-10-07,2022-11-30,8EQD,2137.0,1.0,317.0,,,37.24,1.0,2.92,experimental,93.984,0.2796,0.246,Co-crystal structure of PERK with compound 24
6KN0,X-RAY DIFFRACTION,2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",,"150 mM KBr, 30% (w/v) polyethylene glycol mono-methyester 2000",293.0,2019-08-02,2020-03-11,6KN0,6974.0,6.0,906.0,,,100.58,3.0,2.793,experimental,,0.2997,0.2403,caspase-1 P20/P10 C285A in complex with human GSDMD-C domain
5L9V,X-RAY DIFFRACTION,2.18,43.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M ammonium chloride, 20 % w/v polyethylene glycol 3350",293.0,2016-06-11,2016-08-31,5L9V,3864.0,4.0,542.0,224.0,4.0,60.06,2.0,1.829,experimental,40.0,0.1904,0.1694,HIF prolyl hydroxylase 2 (PHD2-R281C/P317C) cross-linked to HIF-1alpha NODD-L397C/D412C and N-oxalylglycine (NOG) (complex-1)
6LVK,X-RAY DIFFRACTION,2.75,55.24,"VAPOR DIFFUSION, SITTING DROP",8.5,"Tris, Ammonium sulfate, PEG 8000",296.0,2020-02-04,2020-04-08,6LVK,4810.0,2.0,626.0,122.0,,73.35,1.0,2.29,experimental,32.682,0.247,0.2035,"Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative"
6LVL,X-RAY DIFFRACTION,2.75,55.28,"VAPOR DIFFUSION, SITTING DROP",8.5,"Tris, Ammonium sulfate, PEG 8000",296.0,2020-02-04,2020-04-08,6LVL,4678.0,2.0,626.0,,,73.16,1.0,2.98,experimental,26.484,0.2506,0.2019,"Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative"
7Z1G,X-RAY DIFFRACTION,4.23,70.96,"VAPOR DIFFUSION, SITTING DROP",,"1.0 M Sodium acetate trihydrate 0.1 M Imidazole pH 6.5, 0.2 M di-Sodium malonate",293.15,2022-02-24,2023-03-08,7Z1G,2909.0,1.0,364.0,88.0,,42.5,1.0,2.85,experimental,79.6962,0.2283,0.203,Crystal structure of nonphosphorylated (Tyr216) GSK3b in complex with CX-4945
6TSE,X-RAY DIFFRACTION,2.05,39.89,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS 8.5 pH, 32.5% w/v PEG 3350, 200mM MgCl2, 500mM NaCl",298.0,2019-12-20,2020-11-25,6TSE,2934.0,2.0,338.0,224.0,,40.68,1.0,1.41,experimental,28.53,0.224,0.201,"Crystal Structure of 1-methylindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase mutant R28C"
5UDY,X-RAY DIFFRACTION,3.61,65.94,VAPOR DIFFUSION,,"sodium iodide, PEG 3350",293.0,2016-12-28,2017-03-22,5UDY,3457.0,1.0,422.0,163.0,,53.35,1.0,2.6,experimental,,0.207,0.1788,"Human alkaline sphingomyelinase (alk-SMase, ENPP7, NPP7)"
6TT2,X-RAY DIFFRACTION,2.08,40.93,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS 8.5 pH, 32.5% w/v PEG 3350, 200mM MgCl2, 500mM NaCl",298.0,2019-12-23,2020-11-25,6TT2,2952.0,2.0,338.0,243.0,,40.04,1.0,1.36,experimental,30.03,0.234,0.203,The PH domain of Bruton's tyrosine kinase mutant R28C
6YYF,X-RAY DIFFRACTION,2.01,38.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS 8.5 pH, 32.5% w/v PEG 3350, 200mM MgCl2 500 mM NaCl",298.0,2020-05-05,2021-05-12,6YYF,2698.0,2.0,338.0,104.0,,40.37,1.0,1.93,experimental,42.591,0.2485,0.1895,"Crystal Structure of 5-chloroindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase mutant R28C"
6YYK,X-RAY DIFFRACTION,2.1,41.55,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS 8.5 pH, 32.5% w/v PEG 3350, 200mM MgCl2 500 mM NaCl",298.0,2020-05-05,2021-05-12,6YYK,2683.0,2.0,338.0,30.0,,40.2,1.0,2.04,experimental,67.47,0.2964,0.2275,"Crystal Structure of 1,5-dimethylindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosine kinase mutant R28C"
5BX6,X-RAY DIFFRACTION,2.51,51.02,"VAPOR DIFFUSION, HANGING DROP",7.0,"The droplets, containing 10 mg/ml PKA.
25 mM Bis-Tris-HCl, pH 7.0, 150 mM KCl, 1.5mM octanoyl-N-methylglucamide and 0.8 mM PKI peptide, were equilibrated against 12-26 % (v/v) methanol.",277.0,2015-06-08,2016-09-14,5BX6,3276.0,2.0,371.0,226.0,,43.65,2.0,1.89,experimental,,0.2178,0.1696,PKA in complex with a halogenated phthalazinone fragment compound.
5BX7,X-RAY DIFFRACTION,2.53,51.33,"VAPOR DIFFUSION, HANGING DROP",7.0,"The droplets, containing 10 mg/ml PKA.
25 mM Bis-Tris-HCl, pH 7.0, 150 mM KCl, 1.5mM octanoyl-N-methylglucamide and 0.8 mM PKI peptide, were equilibrated against 12-26 % (v/v) methanol.",277.0,2015-06-08,2016-09-14,5BX7,3273.0,2.0,371.0,202.0,,43.58,2.0,1.89,experimental,,0.2262,0.1751,PKA in complex with a benzothiophene fragment compound.
6FRX,X-RAY DIFFRACTION,2.56,51.92,"VAPOR DIFFUSION, HANGING DROP",,"PKA-AU6 at 10mg/ml in 25mM BisTRIS/HCl (pH7.0), 150mM KCl, 1.5mM octanoyl-N-methylglucamide and 0.8mM PKI was equilibrated against 12-26% (v/v) methanol.",277.0,2018-02-16,2019-03-13,6FRX,3194.0,2.0,371.0,261.0,,43.45,2.0,1.88,experimental,,0.2264,0.1895,PKA variant as Aurora B mimic in complex with a dianilinopyrimidine inhibitor
5Y18,X-RAY DIFFRACTION,2.12,41.87,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M sodium citrate, pH6.5, 0.2M ammonium acetate,  30% PEG4000",289.0,2017-07-19,2018-05-30,5Y18,866.0,2.0,118.0,52.0,,13.68,2.0,2.202,experimental,37.305,0.2192,0.1865,Crystal structure of DAXX helical bundle domain in complex with ATRX
7KBG,X-RAY DIFFRACTION,2.46,50.08,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M AMMONIUM SULFATE, 0.1 M HEPES PH 7.5",293.0,2020-10-02,2020-12-30,7KBG,10406.0,3.0,1128.0,1126.0,,133.32,1.0,1.26,experimental,20.04,0.1964,0.1841,Structure of Human HDAC2 in complex with a 2-substituted benzamide inhibitor (compound 20)
7MS5,X-RAY DIFFRACTION,2.84,56.71,"VAPOR DIFFUSION, SITTING DROP",,1 M sodium/potassium phosphate pH 6.9,298.0,2021-05-10,2021-06-09,7MS5,2078.0,2.0,242.0,215.0,1.0,28.18,1.0,1.98,experimental,20.24,0.2163,0.1822,"Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with 4-(4-(4-(3,4-difluoro-phenyl)-piperidin-1-ylsulfonyl)-phenyl)-4-oxo-butanoic acid"
7MS7,X-RAY DIFFRACTION,2.84,56.67,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M magnesium acetate",298.0,2021-05-10,2021-06-09,7MS7,2218.0,2.0,242.0,261.0,1.0,27.76,1.0,1.45,experimental,20.619,0.1808,0.1694,Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with (5-((4-(4-chlorophenyl)piperidin-1-yl)sulfonyl)picolinoyl)glycine
6ZIW,X-RAY DIFFRACTION,3.95,68.82,"VAPOR DIFFUSION, SITTING DROP",5.5,"1 M lithium sulphate
0.5 M ammonium sulphate
0.1 M citrate pH 5.5",277.0,2020-06-26,2020-07-22,6ZIW,2171.0,1.0,316.0,62.0,,37.19,1.0,2.18,experimental,63.03,0.2503,0.216,The IRAK3 Pseudokinase Domain Bound To ATPgammaS
5BUE,X-RAY DIFFRACTION,2.26,45.47,"VAPOR DIFFUSION, HANGING DROP",,"RESERVOIR SOLUTION : 0.2M MAGNESIUM FORMATE, 20% PEG 3350 
          
PROTEIN SOLUTION   : 20.7MG/ML IN 20MM TRIS PH 7.5, 150MM NACL, 1MM TCEP(NO GLYCEROL)                          

SOAKING PROTOCOL: COMPOUND WAS INCUBATED WITH THE PROTEIN AT 1MM FINAL CONCENTRATION BEFORE SETUP.  EQUAL VOLUMES OF PROTEIN AND CRYSTALLANT WERE ADDED TO COVERSLIP            

CRYO PROTOCOL : SOAKING BUFFER: 0.2M MAGNESIUM FORMATE, 20% PEG 3350, 20% GLYCEROL, 2MM COMPOUND A CRYSTAL WAS TRANSFERRED TO A 5UL SOAKING BUFFER ON A SCREWED CUP LID. 100UL  OF RESERVOIR VOLUME WAS USED TO KEEP THE DROP FROM DRYING-OUT",291.0,2015-06-03,2015-07-15,5BUE,2846.0,1.0,361.0,122.0,,41.91,1.0,2.4,experimental,34.68,0.2299,0.1824,ERK2 complexed with N-benzylpyridone tetrahydroazaindazole
5BUI,X-RAY DIFFRACTION,2.26,45.58,"VAPOR DIFFUSION, HANGING DROP",,"RESERVOIR SOLUTION : 200MM CALCIUM ACETATE; 20% PEG3350             

PROTEIN SOLUTION   : 20.7MG/ML IN 20MM TRIS PH 7.5, 150MM NACL,1MM TCEP(NO GLYCEROL)                          
FORMATION METHOD   : CO-CRYSTALLIZATION                             
PROTOCOL           : COMPOUND (NVP-LLG040) WAS INCUBATED WITH THE PROTEIN AT 1MM FINAL CONCENTRATION BEFORE SETUP.  EQUAL VOLUMES OF PROTEIN AND    
CRYSTALLANT WERE ADDED TO COVERSLIP            
METHOD: VAPOR DIFFUSION - HANGING DROP                 
TEMPERATURE: 291.0                                          
CRYO PROTOCOL: MOTHER LIQUOR (200MM CALCIUM ACETATE; 20% PEG3350) + 20% GLYCEROL",291.0,2015-06-03,2015-07-15,5BUI,3062.0,1.0,361.0,296.0,,41.82,1.0,2.12,experimental,34.81,0.2218,0.1693,ERK2 complexed with 2-pyridiyl tetrahydroazaindazole
5BUJ,X-RAY DIFFRACTION,2.26,45.58,"VAPOR DIFFUSION, HANGING DROP",,"RESERVOIR SOLUTION: 20% PEG 3350, 20MM MAGNESIUM FORMATE,          

PROTEIN SOLUTION 20MM TRIS PH 7.5, 150 MM NACL, 1MM TCEP        

FORMATION METHOD: SOAKING                                        

PROTOCOL: Low affinity compound WAS INCUBATED WITH THE PROTEIN AT 2MM FINAL CONCENTRATION BEFORE SETUP. EQUAL VOLUMES OF PROTEIN AND CRYSTALLANT WERE ADDED TO COVER-SLIP. CRYSTAL APPEAR AFTER SEVEAL DAYS.   EXCHANGE SOAKING WAS PERFORMED USING 2MM COMPOUND AT LEAST OVERNIGHT.                            

METHOD: VAPOR DIFFUSION - HANGING DROP                 

TEMPERATURE: 291.0                                          

CRYO PROTOCOL: MOTHER LIQUOR (200MM AMMONIUM SULFATE; 30% PEG MME 5K) + 20% GLYCEROL",291.0,2015-06-03,2015-07-15,5BUJ,3097.0,1.0,361.0,396.0,,41.76,1.0,1.85,experimental,30.08,0.2064,0.1712,ERK2 complexed with a N-H tetrahydroazaindazole
4QP9,X-RAY DIFFRACTION,2.0,38.61,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG3350, 0.2 M proline, and 0.1 M HEPES pH7.5, in a 24-well Linbro plates incubated at 4C, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-06-22,2015-09-23,4QP9,2869.0,1.0,369.0,109.0,,42.85,1.0,2.001,experimental,,0.227,0.1843,"Crystal Structure of ERK2 in complex with 7-(1-propyl-1H-pyrazol-4-yl)-2-(pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazine"
5LCK,X-RAY DIFFRACTION,2.44,49.6,BATCH MODE,7.2,"2M (NH4)2SO4
32% MPEG 2000
.02M Mercaptoethanol
.1M pH=7.2 HEPES/NaOH",293.0,2016-06-22,2016-07-20,5LCK,3395.0,1.0,360.0,484.0,,42.41,1.0,1.89,experimental,34.813,0.212,0.164,A Clickable Covalent ERK 1/2 Inhibitor
8AO3,X-RAY DIFFRACTION,2.31,46.74,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.2M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AO3,3165.0,1.0,368.0,348.0,,43.04,1.0,1.778,experimental,24.708,0.2094,0.1693,Specific covalent inhibitor of ERK2
8AOB,X-RAY DIFFRACTION,2.3,46.5,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOB,3067.0,1.0,368.0,393.0,,42.97,1.0,1.623,experimental,28.571,0.2191,0.1879,Specific covalent inhibitor(12) of ERK2
8U8J,X-RAY DIFFRACTION,2.96,58.45,"VAPOR DIFFUSION, HANGING DROP",9.0,"36% PEG 3350,
0.1M Tris pH 9.0",293.0,2023-09-18,2024-03-27,8U8J,3131.0,1.0,354.0,231.0,,41.5,1.0,2.1,experimental,27.69,0.2266,0.1773,Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #16
8U8K,X-RAY DIFFRACTION,2.97,58.57,"VAPOR DIFFUSION, HANGING DROP",8.8,"32% PEG 3350,
0.1M Tris pH 8.8",293.0,2023-09-18,2024-03-27,8U8K,3138.0,1.0,354.0,250.0,,41.56,1.0,2.1,experimental,27.13,0.2129,0.1741,Co-crystal structure of phosphorylated ERK2 in complex with ERK1/2 inhibitor #8
5EW9,X-RAY DIFFRACTION,2.07,40.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"30% PEG3350, 100 mM Bis-Tris",294.0,2015-11-20,2016-01-20,5EW9,2196.0,1.0,271.0,74.0,,32.0,1.0,2.181,experimental,,0.2374,0.1855,Crystal Structure of Aurora A Kinase Domain Bound to MK-5108
8GDT,X-RAY DIFFRACTION,2.38,48.3,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M sodium cacodylate, 25% w/v PEG4000, pH 6.5",298.0,2023-03-06,2024-09-11,8GDT,1668.0,2.0,210.0,135.0,9.0,24.42,2.0,1.401,experimental,25.859,0.2304,0.218,Heligmosomoides polygyrus TGF-beta Mimic 6 Domain 3 (TGM6-D3) Bound to Human TGF-beta Type II Receptor Extracellular Domain
7NXE,X-RAY DIFFRACTION,2.12,42.02,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 4000, 0.1M TrisHCl pH 8.5, 0.2M sodium acetate",293.0,2021-03-18,2021-06-09,7NXE,1929.0,3.0,252.0,32.0,,29.75,2.0,2.1,experimental,62.95,0.3138,0.2496,Structure of the Phospholipase C gamma 1 tSH2 domain in complex with a phosphorylated KSHV pK15 peptide
6BBV,X-RAY DIFFRACTION,2.08,40.96,"VAPOR DIFFUSION, HANGING DROP",,"28% PEG-3350, 0.1 M sodium acetate, 0.1M Hepes, pH 7.5",293.0,2017-10-19,2018-01-17,6BBV,2575.0,1.0,298.0,172.0,,35.2,1.0,1.8,experimental,24.32,0.2146,0.1755,Crystal Structure of JAK2 in complex with compound 25
8BA2,X-RAY DIFFRACTION,2.75,55.29,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 17% PEG4000, 0.2M Na-acetate",277.0,2022-10-11,2023-02-01,8BA2,2602.0,1.0,289.0,288.0,1.0,34.17,1.0,1.5,experimental,27.43,0.2041,0.1768,Crystal structure of JAK2 JH2-V617F in complex with Z902-A1
6HR1,X-RAY DIFFRACTION,2.67,54.01,VAPOR DIFFUSION,7.8,"24% w/v PEG 3350
0.2 M di-Ammonium tartrate 
10% v/v Glycerol",293.0,2018-09-26,2020-04-08,6HR1,6986.0,2.0,868.0,366.0,,99.94,1.0,1.901,experimental,36.7914,0.2136,0.1806,Crystal structure of the YFPnano fusion protein
7KIE,X-RAY DIFFRACTION,2.84,56.75,"VAPOR DIFFUSION, SITTING DROP",4.0,"15% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0",298.0,2020-10-23,2021-02-10,7KIE,4951.0,2.0,616.0,165.0,,72.11,1.0,2.47,experimental,52.7,0.2293,0.2006,Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 3
7MS6,X-RAY DIFFRACTION,2.87,57.11,"VAPOR DIFFUSION, SITTING DROP",,"2 M ammonium sulfate, 0.2 M sodium acetate, 0.1 M HEPES pH 7.5, 5% MPD",298.0,2021-05-10,2021-06-09,7MS6,1074.0,1.0,121.0,137.0,,14.18,1.0,1.55,experimental,12.457,0.1638,0.1478,Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with (2-fluoro-4-((4-phenylpiperidin-1-yl)sulfonyl)benzoyl)glycine
6UNP,X-RAY DIFFRACTION,3.68,66.55,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M Na Cacodylate, pH 6.0, 0.3 M Ammonium sulfate, 22% w/v PEG 8000",277.0,2019-10-13,2021-07-07,6UNP,4994.0,2.0,726.0,94.0,,85.83,1.0,2.3,experimental,59.92,0.2112,0.1885,Crystal structure of the kinase domain of BMPR2-D485G
6SM5,X-RAY DIFFRACTION,2.62,53.1,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium citrate tribasic, 0.1 M bistros propane 8.4 and 20 % PEG 3350",291.0,2019-08-21,2021-01-13,6SM5,1557.0,2.0,213.0,21.0,,23.26,2.0,2.75,experimental,32.9141762171,0.276452644706,0.219127249237,MbC/SHP1-C-SH2 complex
7AAA,X-RAY DIFFRACTION,2.34,47.34,VAPOR DIFFUSION,8.5,"2.45 M ammonium sulfate, 0.1 M Tris pH 8.5",293.0,2020-09-04,2021-01-13,7AAA,5841.0,2.0,704.0,358.0,,79.13,1.0,1.74,experimental,32.4,0.227,0.204,Crystal structure of the catalytic domain of human PARP1 (apo)
7BIV,X-RAY DIFFRACTION,3.33,63.05,"VAPOR DIFFUSION, SITTING DROP",6.0,"2.4M (NH4)2SO4
.1M pH=6 MES/NaOH",277.0,2021-01-13,2021-04-07,7BIV,925.0,1.0,98.0,91.0,,12.13,1.0,1.64,experimental,36.965,0.237,0.227,Inhibitor of MDM2-p53 Interaction
7BJ6,X-RAY DIFFRACTION,3.33,63.03,"VAPOR DIFFUSION, SITTING DROP",6.0,"2.4M (NH4)2SO4
.1M pH=6 MES/NaOH",277.0,2021-01-14,2021-04-07,7BJ6,919.0,1.0,98.0,101.0,,12.22,1.0,1.59,experimental,36.685,0.258,0.225,Inhibitor of MDM2-p53 Interaction
5E8Y,X-RAY DIFFRACTION,2.58,52.3,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mm TRIS-HCl, PH 8.5, 150 mm MgCl2, 24%(w/v) PEG4000, 20%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E8Y,2385.0,1.0,316.0,89.0,,36.31,1.0,2.05,experimental,42.63,0.2272,0.1968,"TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH STAUROSPORINE"
5E91,X-RAY DIFFRACTION,2.57,52.2,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mm TRIS-HCl, PH 8.5, 150 mm MgCl2, 24%(w/v) PEG4000, 20%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E91,2336.0,1.0,316.0,53.0,,36.26,1.0,2.42,experimental,57.9,0.2422,0.2078,"TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE"
5E92,X-RAY DIFFRACTION,2.57,52.2,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mm TRIS-HCl, PH 8.5, 150 mm MgCl2, 24%(w/v) PEG4000, 20%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E92,2387.0,1.0,316.0,84.0,,36.4,1.0,2.08,experimental,48.92,0.2312,0.2026,"TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH AMPPNP"
5QIN,X-RAY DIFFRACTION,2.54,51.52,"VAPOR DIFFUSION, HANGING DROP",8.5,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2018-08-05,2018-10-31,5QIN,2540.0,1.0,316.0,218.0,,36.32,1.0,1.57,experimental,30.22,0.2026,0.1869,"TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN IN COMPLEX WITH N- {4-[3-(6-METHOXYPYRIDIN-3-YL)-1H-PYRROLO[3,2-B]PYRIDIN-2- YL]PYRIDIN-2-YL}ACETAMIDE"
6I6X,X-RAY DIFFRACTION,2.11,41.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 0.26 M Sodium potassium tartrate, 20 % w/v PEG3350",293.0,2018-11-15,2018-12-05,6I6X,10186.0,2.0,1254.0,294.0,2.0,145.02,2.0,2.39,experimental,41.978,0.21605,0.19063,New Irreversible a-l-Iduronidase Inhibitors and Activity-Based Probes
6WG5,X-RAY DIFFRACTION,3.16,61.05,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Na/K tartrate, 20% PEG 3350, cryo-protected with 20% glycerol",293.0,2020-04-04,2020-08-12,6WG5,4228.0,1.0,512.0,204.0,2.0,59.34,1.0,2.6,experimental,56.9656,0.2136,0.1742,"Human ectonucleoside triphosphate diphosphohydrolase 4 (ENTPD4, NTPDase 4)"
7OPM,X-RAY DIFFRACTION,2.44,49.57,"VAPOR DIFFUSION, HANGING DROP",8.3,"0.1M Tris pH 8.3, 20% PEG 8000 with 1.25 M NaCl in reservoir",293.0,2021-06-01,2022-02-02,7OPM,3208.0,3.0,396.0,39.0,,46.37,3.0,2.45,experimental,77.717,0.2535,0.2352,Phosphorylated ERK2 in complex with ORF45
7VDQ,X-RAY DIFFRACTION,2.71,54.69,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M MES pH 5.5, 0.3M MgCl2, 20% PEG3350",291.0,2021-09-07,2022-03-09,7VDQ,6944.0,4.0,1002.0,7.0,,114.29,2.0,2.91,experimental,89.173,0.2839,0.2523,The structure of cyclin-dependent kinase 5 (CDK5) in complex with p25 and Compound 7
7XC1,X-RAY DIFFRACTION,2.78,55.69,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% PEG3350
0.1M HEPES pH 7.5
0.25M L-proline
glycerol",277.0,2022-03-22,2023-03-22,7XC1,6010.0,2.0,736.0,178.0,,86.79,1.0,2.09,experimental,66.72,0.271,0.2296,Crystal structure of ERK2 with an allosteric inhibitor 3
6XV6,X-RAY DIFFRACTION,2.4,48.73,"VAPOR DIFFUSION, HANGING DROP",7.5,"85 mM HEPES pH 7.5, 85 mM sodium chloride, 1.36 M (NH4)2SO4, 15% glycerol",293.0,2020-01-21,2020-10-28,6XV6,14138.0,6.0,1896.0,504.0,,217.35,1.0,1.75,experimental,31.337,0.2246,0.2003,Human Sirt6 3-318 in complex with ADP-ribose
6XVG,X-RAY DIFFRACTION,2.38,48.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"85 mM HEPES pH 7.5, 85 mM sodium chloride, 1.36 M (NH4)2SO4, 15% glycerol",293.0,2020-01-22,2020-10-28,6XVG,13647.0,6.0,1896.0,169.0,,219.43,1.0,2.1,experimental,53.293,0.2298,0.2044,Human Sirt6 3-318 in complex with ADP-ribose and the activator MDL-801
5MTX,X-RAY DIFFRACTION,2.14,42.57,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.3
20-30 % PEG4000
25 mM BOG",293.15,2017-01-11,2017-09-06,5MTX,2892.0,1.0,360.0,134.0,,42.52,1.0,1.8,experimental,34.787,0.23332,0.18773,Dibenzooxepinone inhibitor 12b in complex with p38 MAPK
5MTY,X-RAY DIFFRACTION,2.13,42.31,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.3
20-30 % PEG4000
25 mM BOG",293.15,2017-01-11,2017-09-06,5MTY,2733.0,1.0,360.0,36.0,,42.48,1.0,2.31,experimental,40.616,0.27131,0.21895,Dibenzosuberone inhibitor 8e in complex with p38 MAPK
5N63,X-RAY DIFFRACTION,2.31,46.78,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2,
20-30 % PEG4000",293.15,2017-02-14,2017-09-20,5N63,2696.0,1.0,360.0,32.0,,41.69,1.0,2.4,experimental,,0.2282,0.1946,Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9c
5N64,X-RAY DIFFRACTION,2.34,47.33,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,2017-02-14,2017-09-20,5N64,2730.0,1.0,360.0,44.0,,41.68,1.0,2.4,experimental,,0.2407,0.2043,Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9g
5N65,X-RAY DIFFRACTION,2.17,43.42,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,2017-02-14,2017-09-20,5N65,2914.0,1.0,360.0,175.0,,42.04,1.0,2.0,experimental,,0.2163,0.1921,Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9h
5N66,X-RAY DIFFRACTION,2.39,48.48,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,2017-02-14,2017-09-20,5N66,2770.0,1.0,360.0,20.0,,42.24,1.0,2.4,experimental,,0.2377,0.2062,Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9j
5N67,X-RAY DIFFRACTION,2.35,47.61,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,2017-02-14,2017-09-20,5N67,2886.0,1.0,360.0,198.0,,41.81,1.0,1.9,experimental,,0.222,0.1895,Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9l
5N68,X-RAY DIFFRACTION,2.37,48.16,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,2017-02-14,2017-09-20,5N68,2854.0,1.0,360.0,161.0,,41.77,1.0,1.85,experimental,,0.2203,0.1977,Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9m
5L8J,X-RAY DIFFRACTION,2.3,46.59,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1 M citric acid pH 5.0, 20% PEG 6000",295.0,2016-06-08,2016-07-20,5L8J,3041.0,2.0,402.0,197.0,2.0,46.56,2.0,1.68,experimental,,0.231,0.1993,Aurora-A kinase domain in complex with vNAR-D01 S93R
5L8K,X-RAY DIFFRACTION,2.43,49.48,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M ammonium sulfate, 0.1 M bis-Tris pH 5.5, 25 % PEG 3350",295.0,2016-06-08,2016-07-20,5L8K,3246.0,2.0,402.0,280.0,2.0,46.97,2.0,1.79,experimental,,0.2351,0.1902,Aurora-A kinase domain in complex with vNAR-D01 (crystal form 2)
5L8L,X-RAY DIFFRACTION,3.03,59.4,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.2 M ammonium sulfate, 0.1 M sodium acetate pH 4.6, 12.5 % PEG 4000",295.0,2016-06-08,2016-07-20,5L8L,3488.0,2.0,402.0,348.0,2.0,47.14,2.0,1.67,experimental,,0.2233,0.191,Aurora-A kinase domain in complex with vNAR-D01 (crystal form 1)
8PT0,X-RAY DIFFRACTION,2.41,49.0,"VAPOR DIFFUSION, HANGING DROP",8.5,"30% PEG3350, 0.1 M Tris pH 8.5.",293.0,2023-07-13,2024-07-24,8PT0,3340.0,1.0,364.0,297.0,,42.65,1.0,1.65,experimental,,0.2069,0.1768,ERK2 covelently bound to RU75 cyclohexenone based inhibitor
8PT3,X-RAY DIFFRACTION,2.49,50.7,"VAPOR DIFFUSION, HANGING DROP",8.5,"10% PEG8000, 0.1 M Tris pH 8.5",293.0,2023-07-13,2024-07-24,8PT3,3032.0,1.0,364.0,152.0,,42.82,1.0,1.8,experimental,,0.2222,0.1867,ERK2 covelently bound to RU77 cyclohexenone based inhibitor
6Q4M,X-RAY DIFFRACTION,3.19,61.38,VAPOR DIFFUSION,,"1.45 M K2HPO4, 8 mM EDTA and 1% xylitol.",293.0,2018-12-06,2019-12-25,6Q4M,5948.0,1.0,723.0,370.0,,81.84,1.0,2.2,experimental,50.781,0.19886,0.17464,Crystal structure of the O-GlcNAc transferase Asn648Tyr mutation
5V60,X-RAY DIFFRACTION,3.07,59.99,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 45% v/v polypropylene glycol P400",277.0,2017-03-15,2017-07-26,5V60,3053.0,1.0,356.0,82.0,,42.36,1.0,2.18,experimental,52.442,0.2262,0.1906,Phospho-ERK2 bound to AMP-PCP
4ZZM,X-RAY DIFFRACTION,2.41,48.94,,,,,2015-04-10,2015-05-27,4ZZM,2865.0,1.0,350.0,121.0,,41.21,1.0,1.89,experimental,35.19,0.2544,0.2073,Human ERK2 in complex with an irreversible inhibitor
7NR3,X-RAY DIFFRACTION,2.31,46.74,"VAPOR DIFFUSION, HANGING DROP",,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2021-03-02,2021-10-06,7NR3,3185.0,1.0,368.0,361.0,,43.28,1.0,1.897,experimental,32.662,0.2364,0.1837,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2"
7NR5,X-RAY DIFFRACTION,2.31,46.82,"VAPOR DIFFUSION, HANGING DROP",,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2021-03-03,2021-10-06,7NR5,3232.0,1.0,368.0,352.0,,43.52,1.0,1.766,experimental,27.647,0.2226,0.1736,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2"
7NR9,X-RAY DIFFRACTION,2.34,47.39,"VAPOR DIFFUSION, HANGING DROP",,"0.25M (NH4)2SO4
33% MPEG 2000
.02M Mercaptoethanol
.1M pH=7.2 HEPES/NaOH",291.0,2021-03-03,2021-10-06,7NR9,3082.0,1.0,368.0,289.0,,43.22,1.0,1.906,experimental,37.55,0.3081,0.245,"Discovery of ASTX029, a clinical candidate which modulates the phosphorylation and catalytic activity of ERK1/2"
5AQZ,X-RAY DIFFRACTION,2.41,48.89,,7.5,"17-28% (W/V) PEG3350, 0.1 M HEPES PH 7.5, 2 MM MGCL2, 2 MM NAH2PO4 AND 5 MM INHIBITOR",,2015-09-22,2016-05-11,5AQZ,3484.0,1.0,394.0,432.0,,43.75,1.0,1.65,experimental,33.75,0.2213,0.1862,HSP72 with adenosine-derived inhibitor
6QFE,X-RAY DIFFRACTION,2.97,58.59,"VAPOR DIFFUSION, SITTING DROP",5.6,"100mM Sodium Citrate pH 5.6, 20% PEG 4K, 5% Glycerol, 10% Iso-propanol",293.0,2019-01-10,2019-05-08,6QFE,4083.0,2.0,454.0,393.0,12.0,52.52,1.0,1.67,experimental,30.43,0.242,0.211,Crystal Structure of Human Kallikrein 5 in complex with GSK144
5V62,X-RAY DIFFRACTION,2.92,57.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris-Bicine pH 8.5, 0.02 M each of 1,6-Hexanediol, 1-Butanol, 1,2-Propanediol, 2-Propanol, 1,4-Butanediol, 1,3-Propanediol, 20% v/v PEG550MME, 10% w/v PEG20,000",277.0,2017-03-15,2017-07-26,5V62,3411.0,2.0,372.0,256.0,,44.3,2.0,1.9,experimental,41.355,0.2033,0.1709,Phospho-ERK2 bound to bivalent inhibitor SBP3
7Z78,X-RAY DIFFRACTION,2.23,44.78,"VAPOR DIFFUSION, SITTING DROP",,"8% ethylene glycol, 25% PEG 6000, 0.1 M HEPES pH 8.0 and 10 mM zinc chloride",293.0,2022-03-15,2022-09-14,7Z78,3291.0,3.0,369.0,427.0,,44.8,1.0,1.32,experimental,29.14,0.21,0.187,Crystal structure of compound 4 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB
8AK5,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AK5,4559.0,2.0,604.0,40.0,,69.87,1.0,2.12,experimental,52.265,0.2217,0.1912,Human Sirt6 in complex with ADP-ribose and fragment pyroglutamic acid
8JMZ,X-RAY DIFFRACTION,2.46,49.98,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES pH 6.6,34% PEG 8000,0.2 M ammonium sulfate",277.15,2023-06-05,2024-03-27,8JMZ,5278.0,2.0,620.0,445.0,,72.54,1.0,1.988,experimental,,0.2048,0.1634,FGFR1 kinase domain with sulfatinib
5UGL,X-RAY DIFFRACTION,2.08,40.86,"VAPOR DIFFUSION, HANGING DROP",,"25 mM HEPES pH7.5, 15%-25% w/v PEG4000, 0.2-0.3 M NH4SO3",293.0,2017-01-09,2017-02-22,5UGL,4705.0,2.0,648.0,182.0,,75.39,1.0,1.861,experimental,,0.2581,0.219,Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation
8BE6,X-RAY DIFFRACTION,3.22,61.75,"VAPOR DIFFUSION, HANGING DROP",,"sodium formate 3 M, Tris 100mM pH 8.0",277.0,2022-10-21,2023-04-26,8BE6,5071.0,3.0,701.0,20.0,,81.25,3.0,2.89880249261,experimental,85.7265821798,0.272647863941,0.220464709466,Crystal structure of SOS1-HRas-peptidomimetic2
8BE8,X-RAY DIFFRACTION,3.54,65.26,"VAPOR DIFFUSION, HANGING DROP",,"sodium formate 3 M, Tris 100mM pH 8.0",277.0,2022-10-21,2023-04-26,8BE8,5300.0,3.0,702.0,196.0,,81.87,3.0,2.4,experimental,58.43,0.2369,0.2069,Crystal structure of SOS1-HRas-peptidomimetic4
8BE9,X-RAY DIFFRACTION,3.52,65.01,"VAPOR DIFFUSION, HANGING DROP",,"sodium formate 3 M, Tris 100mM pH 8.0",277.0,2022-10-21,2023-04-26,8BE9,5296.0,3.0,702.0,124.0,,82.29,3.0,2.51,experimental,62.68,0.2285,0.19,Crystal structure of SOS1-HRas-peptidomimetic5
8BEA,X-RAY DIFFRACTION,3.53,65.16,"VAPOR DIFFUSION, HANGING DROP",,"sodium formate 3 M, Tris 100mM pH 8.0",277.0,2022-10-21,2023-04-26,8BEA,5486.0,3.0,700.0,337.0,,81.49,3.0,2.47,experimental,47.34,0.2334,0.1882,Crystal structure of SOS1-HRas-peptidomimetic10
6FDO,X-RAY DIFFRACTION,2.52,51.27,"VAPOR DIFFUSION, SITTING DROP",,Morpheus D2,298.0,2017-12-26,2019-01-30,6FDO,4675.0,2.0,706.0,61.0,,81.46,1.0,2.6,experimental,81.33,0.25,0.195,Rio2 structure
8OEG,X-RAY DIFFRACTION,2.34,47.47,"VAPOR DIFFUSION, HANGING DROP",4.6,"50 mM CALCIUM ACETATE, 20% PEG 400,      
100 mM SODIUM ACETATE",298.0,2023-03-10,2023-04-26,8OEG,2881.0,1.0,421.0,116.0,,49.26,1.0,1.89,experimental,22.371,0.19509,0.15774,PDE4B bound to MAPI compound 92a
6G2V,X-RAY DIFFRACTION,2.47,50.2,"VAPOR DIFFUSION, SITTING DROP",,"0.08M L-Na-Glutamate; 0.08M Alanine (racemic); 0.08M Glycine; 0.08M Lysine HCl (racemic); 0.08M Serine (racemic), 0.08M Tris, 0.08M BICINE, 10% v/v MPD; 10% PEG 1000; 10% w/v PEG 3350 at pH 8.5",293.0,2018-03-23,2019-04-10,6G2V,2307.0,1.0,275.0,130.0,,31.94,1.0,1.903,experimental,,0.2367,0.1966,Crystal structure of the p97 D2 domain in a helical split-washer conformation
6G2W,X-RAY DIFFRACTION,2.36,47.8,"VAPOR DIFFUSION, SITTING DROP",,"0.08M L-Na-Glutamate; 0.08M Alanine (racemic); 0.08M Glycine; 0.08M Lysine HCl (racemic); 0.08M Serine (racemic), 0.08M Tris, 0.08M BICINE, 10% v/v MPD; 10% PEG 1000; 10% w/v PEG 3350 at pH 8.5",293.0,2018-03-23,2019-04-10,6G2W,2209.0,1.0,306.0,12.0,,35.54,1.0,2.678,experimental,,0.3243,0.2367,Crystal structure of the p97 D2 domain in a helical split-washer conformation
6G2X,X-RAY DIFFRACTION,2.42,49.21,"VAPOR DIFFUSION, SITTING DROP",,"0.08M L-Na-Glutamate; 0.08M Alanine (racemic); 0.08M Glycine; 0.08M Lysine HCl (racemic); 0.08M Serine (racemic), 0.08M Tris, 0.08M BICINE, 10% v/v MPD; 10% PEG 1000; 10% w/v PEG 3350 at pH 8.5",293.0,2018-03-23,2019-04-10,6G2X,2298.0,1.0,306.0,77.0,,35.75,1.0,2.078,experimental,,0.2455,0.2045,Crystal structure of the p97 D2 domain in a helical split-washer conformation
6G2Y,X-RAY DIFFRACTION,2.51,51.02,"VAPOR DIFFUSION, SITTING DROP",,"0.08M L-Na-Glutamate; 0.08M Alanine (racemic); 0.08M Glycine; 0.08M Lysine HCl (racemic); 0.08M Serine (racemic), 0.08M Tris, 0.08M BICINE, 10% v/v MPD; 10% PEG 1000; 10% w/v PEG 3350 at pH 8.5",,2018-03-23,2019-04-10,6G2Y,2209.0,1.0,303.0,12.0,,35.33,1.0,2.153,experimental,,0.2475,0.2195,Crystal structure of the p97 D2 domain in a helical split-washer conformation
6G2Z,X-RAY DIFFRACTION,2.38,48.22,"VAPOR DIFFUSION, SITTING DROP",,"0.08M L-Na-Glutamate; 0.08M Alanine (racemic); 0.08M Glycine; 0.08M Lysine HCl (racemic); 0.08M Serine (racemic), 0.08M Tris, 0.08M BICINE, 10% v/v MPD; 10% PEG 1000; 10% w/v PEG 3350 at pH 8.5",293.0,2018-03-23,2019-04-10,6G2Z,2242.0,1.0,306.0,49.0,,35.48,1.0,1.923,experimental,,0.2467,0.2234,Crystal structure of the p97 D2 domain in a helical split-washer conformation
6BA2,X-RAY DIFFRACTION,2.31,46.79,"VAPOR DIFFUSION, HANGING DROP",7.0,"2 M NaCl, 0.1 M Tris pH 7.0, 0.22 M MgCl2",293.0,2017-10-11,2018-08-01,6BA2,2366.0,1.0,295.0,143.0,,35.4,1.0,1.85003821102,experimental,29.4680609733,0.228016935366,0.193825526814,Crystal structure of MYST acetyltransferase domain in complex with inhibitor
6OWH,X-RAY DIFFRACTION,2.54,51.6,"VAPOR DIFFUSION, HANGING DROP",7.0,"20% PEG 3350, 2% Tacsimate pH 7.0, 0.1 M HEPES pH 7.0",292.0,2019-05-09,2020-04-01,6OWH,2344.0,1.0,273.0,48.0,,32.89,1.0,2.0,experimental,,0.2253,0.1914,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 92
5JTI,X-RAY DIFFRACTION,3.61,65.9,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH 5.5
0.2 M Magnesium Chloride
25%  PEG 3350",285.15,2016-05-09,2016-08-03,5JTI,2924.0,6.0,474.0,62.0,,53.12,1.0,2.9,experimental,53.1,0.232,0.193,"Crystal structure of the human Tankyrase 1 (TNKS) SAM domain (D1055R), crystal form 2"
5MMV,X-RAY DIFFRACTION,2.26,45.56,VAPOR DIFFUSION,,"0.1 M HEPES (pH 7.4), 2 M (NH4)2SO4, and 25 mM DTT",277.0,2016-12-12,2017-12-20,5MMV,2176.0,2.0,268.0,120.0,,30.92,2.0,2.15,experimental,50.54,0.249,0.197,Crystal structure of human Caspase-1 with 2-((2-naphthoyl)-L-valyl)-4-hydroxy-N-((3S)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-2-azabicyclo[2.2.2]octane-3-carboxamide (Compound 1)
5MTK,X-RAY DIFFRACTION,2.76,55.5,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES (pH 7.4), 2 M (NH4)2SO4 and 25 mM DTT",277.0,2017-01-09,2018-02-28,5MTK,2069.0,2.0,268.0,17.0,,30.87,2.0,2.53,experimental,62.39,0.299,0.243,"Crystal structure of human Caspase-1 with (3S,6S,10aS)-N-((2S,3S)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-6-(isoquinoline-1-carboxamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide (PGE-3935199)"
6F6R,X-RAY DIFFRACTION,4.63,73.43,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES (pH7.4), 2 M (NH4)2SO4 and 25 mM DTT",277.0,2017-12-06,2018-05-02,6F6R,2463.0,2.0,268.0,253.0,,31.03,2.0,1.8,experimental,41.04,0.205,0.173,"Crystal structure of human Caspase-1 with N-{3-[1-((S)-2-Hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl}-4-(quinoxalin-2-ylamino)-benzamide"
8SC8,X-RAY DIFFRACTION,2.34,47.33,"VAPOR DIFFUSION, HANGING DROP",8.2,"0.2 M Lithium Sulfate, 0.1 M TRIS-HCl pH 8.2, 15% w/v PEG 4000",293.0,2023-04-05,2024-06-12,8SC8,6863.0,1.0,966.0,89.0,,111.66,1.0,2.687,experimental,98.219,0.2533,0.1951,Structure of PI3KG in complex with MTX-531
4ZG9,X-RAY DIFFRACTION,3.18,61.27,"VAPOR DIFFUSION, SITTING DROP",6.0,"10% PEG 3350, 4% Tacsimate pH 6.0",298.0,2015-04-22,2015-10-14,4ZG9,12241.0,2.0,1726.0,51.0,27.0,201.57,1.0,2.95,experimental,59.088,0.2438,0.1792,Structural basis for inhibition of human autotaxin by four novel compounds
5H14,X-RAY DIFFRACTION,2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide",293.0,2016-10-08,2017-01-25,5H14,6850.0,4.0,792.0,412.0,2.0,92.84,2.0,1.9,experimental,30.78,0.2225,0.1916,EED in complex with an allosteric PRC2 inhibitor EED666
4PRY,X-RAY DIFFRACTION,2.11,41.68,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Sodium citrate, pH 5.5, 12% PEG6000, VAPOR DIFFUSION, SITTING DROP, temperature 295K",295.0,2014-03-06,2015-01-21,4PRY,2249.0,2.0,290.0,192.0,,33.21,2.0,1.7,experimental,,0.1868,0.1549,Caspase-8 specific unnatural amino acid peptides
7TVJ,X-RAY DIFFRACTION,2.26,45.64,VAPOR DIFFUSION,5.0,"0.1 M sodium citrate tribasic dihydrate, 2% Tascimate, 16% PEG3350",292.0,2022-02-05,2023-02-15,7TVJ,5801.0,4.0,796.0,224.0,2.0,91.16,2.0,2.39,experimental,34.15,0.2588,0.2291,Crystal Structure of Monobody Mb(SHP2PTP_13)/SHP2 PTP Domain Complex
5IX0,X-RAY DIFFRACTION,2.51,51.07,"VAPOR DIFFUSION, SITTING DROP",5.5,"PEG 400, potassium phosphate",293.0,2016-03-23,2016-08-31,5IX0,10004.0,3.0,1107.0,839.0,,131.25,1.0,1.72,experimental,27.193,0.2004,0.17978,HDAC2 WITH LIGAND BRD7232
6QLY,X-RAY DIFFRACTION,3.28,62.47,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris pH 8.5, 
20mM MgSO4, 
4% (w/v) ethylene glycol,
12% (w/v) 2-Methyl-2,4-pentanediol (MPD)",293.0,2019-02-01,2020-02-19,6QLY,2662.0,1.0,346.0,38.0,,39.16,1.0,2.5,experimental,113.0,0.247,0.216,IDOL FERM domain
5E8U,X-RAY DIFFRACTION,2.04,39.69,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2015-10-14,2016-05-11,5E8U,2576.0,1.0,307.0,125.0,,35.5,1.0,2.03,experimental,31.27,0.2228,0.1793,"TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F)"
8TO3,X-RAY DIFFRACTION,2.07,40.61,"VAPOR DIFFUSION, HANGING DROP",5.5,"Bis-Tris (100mM), 25% PEG-3350 and TCEP (5mM)",298.0,2023-08-02,2024-08-28,8TO3,9648.0,4.0,1312.0,100.0,,152.23,1.0,2.49,experimental,,0.2687,0.2292,EGFR(T790M/V948R) in complex with LN5461
7F60,X-RAY DIFFRACTION,0.41,42.96,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1m Bis-tris ph5.5,45%PEG4000",296.0,2021-06-23,2022-09-14,7F60,6151.0,6.0,4492.0,,,492.15,3.0,2.85,experimental,40.8356,0.2756,0.2357,Crystal structure of auxiliary protein in complex with human nuclear protein
4ZTQ,X-RAY DIFFRACTION,2.58,52.41,"VAPOR DIFFUSION, HANGING DROP",,"0.3 M Ammonium citrate dibasic, 
25% PEG 3350",292.0,2015-05-14,2016-07-20,4ZTQ,2009.0,1.0,285.0,3.0,,33.43,1.0,2.8,experimental,78.903,0.24624,0.20131,Human Aurora A catalytic domain bound to FK932
4ZTR,X-RAY DIFFRACTION,2.6,52.74,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M Tris pH 8.0, 
28% PEG 4k",292.0,2015-05-15,2016-07-20,4ZTR,2020.0,1.0,285.0,2.0,,33.41,1.0,2.85,experimental,90.759,0.26781,0.21185,Human Aurora A catalytic domain bound to FK1141
4ZTS,X-RAY DIFFRACTION,2.81,56.22,"VAPOR DIFFUSION, HANGING DROP",7.5,"5% MPD, 0.1 M Hepes pH 7.5, 10% PEG 10K",292.0,2015-05-15,2016-07-20,4ZTS,2054.0,1.0,285.0,10.0,,33.55,1.0,2.9,experimental,78.503,0.2493,0.21105,Human Aurora A catalytic domain bound to FK1142
5AAF,X-RAY DIFFRACTION,2.56,52.07,,8.9,"0.1 M TRIS PH 8.9, 0.2 M LITHIUM SULFATE, 30 % PEG 4000",,2015-07-24,2015-09-02,5AAF,2037.0,1.0,285.0,,,33.36,1.0,2.78,experimental,,0.2871,0.2397,Aurora A kinase bound to an imidazopyridine inhibitor (14a)
5AAG,X-RAY DIFFRACTION,2.56,51.93,,8.9,0.1 M TRIS PH 8.9 0.2 M LITHIUM SULFATE 30 % PEG 4000,,2015-07-24,2015-09-02,5AAG,2006.0,1.0,285.0,,,33.41,1.0,2.85,experimental,,0.2602,0.2134,Aurora A kinase bound to an imidazopyridine inhibitor (14b)
5EW3,X-RAY DIFFRACTION,2.33,47.25,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M MES pH6.5, 8% w/v PEG 8000, 0.02M LITHIUM ACETATE",290.0,2015-11-20,2015-12-16,5EW3,4453.0,2.0,632.0,76.0,,73.13,1.0,2.5,experimental,62.95,0.2535,0.2184,Human Vascular Endothelial Growth Factor Receptor 2 (KDR) Kinase Domain in complex with AAL993
5KXA,X-RAY DIFFRACTION,2.01,38.71,"VAPOR DIFFUSION, SITTING DROP",7.0,"20% PEG 3350, 0.1 M Sodium Acetate pH 7",293.0,2016-07-20,2016-11-09,5KXA,5971.0,1.0,863.0,5.0,12.0,100.0,1.0,2.59,experimental,53.771,0.24733,0.17328,Selective Inhibition of Autotaxin is Effective in Mouse Models of Liver Fibrosis
5X94,X-RAY DIFFRACTION,2.17,43.29,"VAPOR DIFFUSION, SITTING DROP",,"31% PEG 4000, 0.1 M Tris-HCl",293.0,2017-03-05,2017-09-13,5X94,3546.0,6.0,492.0,22.0,,56.09,2.0,2.6,experimental,,0.2459,0.1569,Crystal structure of SHP2_SH2-CagA EPIYA_D peptide complex
7RCT,X-RAY DIFFRACTION,2.38,48.38,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Sodium Chloride
0.1 M BIS-TRIS propane pH 8.5
11% PEG 1500",291.0,2021-07-08,2021-09-01,7RCT,8806.0,2.0,1050.0,693.0,1.0,121.44,1.0,1.8,experimental,41.06,0.2252,0.1845,Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor RMC-4550
7XHQ,X-RAY DIFFRACTION,2.25,45.31,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris-HCl,  pH 8.5, 13%-18% PEG 4000",295.0,2022-04-09,2023-02-15,7XHQ,7664.0,2.0,1050.0,470.0,1.0,121.42,1.0,2.2,experimental,34.8876,0.2746,0.2388,Small-molecule Allosteric Regulation Mechanism of SHP2
8CBH,X-RAY DIFFRACTION,2.23,44.96,"VAPOR DIFFUSION, HANGING DROP",9.0,"14.00 %w/v PEG 3350, 0.20 M NH4 Acetate, 0.10  M Tris pH=9.00",293.15,2023-01-25,2023-04-26,8CBH,8210.0,2.0,1052.0,242.0,,121.58,1.0,2.24,experimental,44.743,0.26379,0.21589,SHP2 in complex with a novel allosteric inhibitor
8RZW,X-RAY DIFFRACTION,2.2,44.03,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-13,2024-03-20,8RZW,8596.0,2.0,1074.0,502.0,,124.13,1.0,2.02,experimental,50.892,0.27183,0.21556,A fragment-based inhibitor of SHP2
8S01,X-RAY DIFFRACTION,2.27,45.77,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-13,2024-03-20,8S01,8663.0,2.0,1074.0,420.0,2.0,124.16,1.0,2.17,experimental,54.533,0.23148,0.18028,A fragment-based inhibitor of SHP2
8S04,X-RAY DIFFRACTION,2.19,43.93,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-13,2024-03-20,8S04,8702.0,2.0,1074.0,524.0,,124.22,1.0,1.89,experimental,45.284,0.2234,0.1886,A fragment-based inhibitor of SHP2
8S06,X-RAY DIFFRACTION,2.16,43.13,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-13,2024-03-20,8S06,8574.0,2.0,1074.0,368.0,,124.07,1.0,2.19,experimental,57.935,0.23838,0.1773,A fragment-based inhibitor of SHP2
8S0H,X-RAY DIFFRACTION,2.25,45.42,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-14,2024-03-20,8S0H,8990.0,2.0,1074.0,785.0,2.0,124.58,1.0,1.99,experimental,44.227,0.25397,0.20397,A fragment-based inhibitor of SHP2
8S0I,X-RAY DIFFRACTION,2.18,43.67,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-14,2024-03-20,8S0I,8608.0,2.0,1074.0,442.0,,124.19,1.0,1.929,experimental,52.528,0.2236,0.1934,A fragment-based inhibitor of SHP2
8S0J,X-RAY DIFFRACTION,2.21,44.22,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-14,2024-03-20,8S0J,8665.0,2.0,1074.0,448.0,2.0,124.44,1.0,1.89,experimental,46.417,0.24227,0.20004,A fragment-based inhibitor of SHP2
8S0K,X-RAY DIFFRACTION,2.19,43.96,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-14,2024-03-20,8S0K,8961.0,2.0,1074.0,741.0,,124.55,1.0,1.84,experimental,41.139,0.22788,0.18131,A fragment-based inhibitor of SHP2
8S0P,X-RAY DIFFRACTION,2.16,43.03,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-14,2024-03-20,8S0P,8863.0,2.0,1074.0,696.0,,124.55,1.0,2.0,experimental,52.429,0.2438,0.1963,A fragment-based inhibitor of SHP2
8S0Q,X-RAY DIFFRACTION,2.19,43.86,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-14,2024-03-20,8S0Q,9035.0,2.0,1074.0,822.0,1.0,124.57,1.0,1.872,experimental,40.537,0.2359,0.193,A fragment-based inhibitor of SHP2
8S0S,X-RAY DIFFRACTION,2.19,43.78,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-14,2024-03-20,8S0S,8486.0,2.0,1074.0,459.0,2.0,124.62,1.0,1.94,experimental,47.359,0.25846,0.21494,A fragment-based inhibitor of SHP2
8T6D,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, SITTING DROP",,"19% PEG 3350,100 mM Tris-HCl (pH 8.5), 300 mM Ammonium Sulfate",277.0,2023-06-15,2023-10-11,8T6D,8483.0,2.0,1052.0,259.0,,122.44,1.0,2.4,experimental,39.1,0.296,0.2387,"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors"
8T6G,X-RAY DIFFRACTION,2.3,46.41,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 3350,100 mM Tris-HCl (pH 8.5), 300 mM Ammonium Sulfate",277.0,2023-06-15,2023-10-11,8T6G,9133.0,2.0,1052.0,741.0,,122.91,1.0,1.84,experimental,32.88,0.2448,0.2107,"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors"
8WX7,X-RAY DIFFRACTION,2.22,44.65,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH 7.5, 0.2 M ammonium sulphate, 28 % w/v PEG3350",291.0,2023-10-27,2024-08-14,8WX7,8345.0,2.0,1052.0,314.0,,123.19,1.0,2.02,experimental,41.431,0.24599,0.19463,Crystal structure of SHP2 in complex with JAB-3186
4XHU,X-RAY DIFFRACTION,2.76,55.44,VAPOR DIFFUSION,6.0,"200mM sodium acetate
100mM calcium cacodylate
15% PEG8000",298.0,2015-01-06,2015-09-30,4XHU,6826.0,4.0,924.0,248.0,2.0,103.9,2.0,2.089,experimental,,0.2105,0.1825,The complex structure of Timeless_PAB and PARP-1_catalytic domain
5IWG,X-RAY DIFFRACTION,2.54,51.52,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG 400, potassium phosphate",293.0,2016-03-22,2016-08-31,5IWG,9747.0,3.0,1104.0,697.0,,129.27,1.0,1.66,experimental,23.947,0.20778,0.18502,HDAC2 WITH LIGAND BRD4884
7MK1,X-RAY DIFFRACTION,2.45,49.8,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG3350, 0.01 M Na acetate pH 4.8",285.15,2021-04-21,2021-11-03,7MK1,4454.0,4.0,332.0,418.0,,59.58,1.0,1.9,experimental,47.59,0.2196,0.1884,Structure of a protein-modified aptamer complex
5OYJ,X-RAY DIFFRACTION,3.64,66.25,"VAPOR DIFFUSION, HANGING DROP",6.4,"0.2 M calcium acetate monohydrate, 15% PEG 4000, 0.1 M sodium cacodylate pH 6.4, cryoprotected with 15% trehalose",293.15,2017-09-10,2018-03-14,5OYJ,6506.0,4.0,806.0,270.0,4.0,93.56,2.0,2.38,experimental,,0.2288,0.1779,Crystal structure of VEGFR-2 domains 4-5 in complex with DARPin D4b
5C27,X-RAY DIFFRACTION,2.13,42.13,EVAPORATION,5.5,"1.75 M ammonium sulfate, 0.1 M sodium citrate, 0.1 M sodium acetate pH 5.5",298.0,2015-06-15,2015-10-07,5C27,2519.0,2.0,304.0,198.0,,36.28,2.0,2.15,experimental,40.54,0.2251,0.1772,Crystal structure of SYK in complex with compound 2
6QCI,X-RAY DIFFRACTION,1.87,34.19,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris, pH 8.0, 0.2 M lithium sulphate, PEG 4000",293.0,2018-12-28,2019-05-01,6QCI,2453.0,4.0,444.0,61.0,,49.96,1.0,2.3,experimental,43.301,0.3032,0.26357,Structure of XIAP-BIR1 V86E mutant
5EDU,X-RAY DIFFRACTION,2.44,49.49,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium sodium tartrate, 20% PEG3350",277.0,2015-10-22,2016-07-27,5EDU,11179.0,2.0,1490.0,58.0,,164.62,1.0,2.79,experimental,,0.2754,0.2126,Crystal structure of human histone deacetylase 6 catalytic domain 2 in complex with trichostatin A
6I8Z,X-RAY DIFFRACTION,2.56,51.87,"VAPOR DIFFUSION, SITTING DROP",6.0,"7%PEG1500, 100 mM SPG buffer, 5 mg/mL",277.0,2018-11-21,2019-02-20,6I8Z,2395.0,1.0,281.0,256.0,1.0,32.8,1.0,1.99,experimental,33.75,0.222,0.183,Crystal structure of PTK2 in complex with BI-4464.
5L0R,X-RAY DIFFRACTION,2.33,47.14,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG5000 MME, 50 mM MES pH 6.5, 2mM CaCl2, 250mM NaCl, 5% glycerol",295.0,2016-07-28,2017-08-09,5L0R,3700.0,2.0,399.0,351.0,7.0,47.62,2.0,1.5,experimental,32.5202,0.1707,0.1489,human POGLUT1 in complex with Notch1 EGF12 and UDP
6P5M,X-RAY DIFFRACTION,4.01,69.31,"VAPOR DIFFUSION, SITTING DROP",5.1,"0.8 M trisodium citrate, 0.1 M citrate, pH 5.1",293.0,2019-05-30,2020-01-15,6P5M,12788.0,4.0,1620.0,45.0,,185.5,1.0,2.65,experimental,57.52,0.225,0.1934,"Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Anti-Tumor Agent"
4RDD,X-RAY DIFFRACTION,2.2,44.13,,7.4,"20% PEG3350, 33 mM citric acid, 67 mM BIS-TRIS propane, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-09-18,2015-07-01,4RDD,2547.0,1.0,275.0,368.0,,32.66,1.0,1.601,experimental,,0.2011,0.1751,Co-crystal structure of SHP2 in complex with a Cefsulodin derivative
5BK8,X-RAY DIFFRACTION,1.99,38.34,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG3350, 200 mM LiCl",293.0,2019-06-01,2020-04-08,5BK8,4259.0,1.0,536.0,231.0,,61.79,1.0,2.25,experimental,31.3359,0.262,0.1982,Cancer-associated SHP2/T507K mutant
7R75,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,8.0,"300 mM potassium formate, 14% w/v PEG3350",293.0,2021-06-24,2021-10-27,7R75,4018.0,1.0,536.0,,,61.85,1.0,2.83,experimental,45.1935,0.2889,0.2249,Structure of human SHP2 in complex with compound 16
5FI4,X-RAY DIFFRACTION,2.27,45.8,"VAPOR DIFFUSION, HANGING DROP",,"12.5% PEG 3350, 125 mM KSCN
Drops were 5uL protein: 3uL well solutions
and streak seeded.",303.15,2015-12-22,2016-02-03,5FI4,10476.0,2.0,1397.0,263.0,,164.5,2.0,2.5,experimental,52.92,0.2452,0.1938,"Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model"
5J8C,X-RAY DIFFRACTION,2.2,44.12,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2M Ammonium Chloride
28% PEG 3350
0.1M BisTris-HCL pH 6.5",293.0,2016-04-07,2016-07-20,5J8C,2250.0,1.0,307.0,77.0,,36.3,1.0,2.17,experimental,44.13,0.2337,0.1905,"Human MOF C316S, E350Q crystal structure"
5J8F,X-RAY DIFFRACTION,2.19,43.77,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.28M Ammonium Chloride
26%PEG 3350
0.1M BisTris-HCl pH 6.5",293.0,2016-04-07,2016-07-20,5J8F,2057.0,1.0,307.0,19.0,,36.2,1.0,2.6,experimental,41.09,0.2757,0.2391,Human MOF K274P crystal structure
7QGS,X-RAY DIFFRACTION,1.66,25.78,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M HEPES pH 6.5, PEG 6K 35%",293.0,2021-12-10,2022-05-11,7QGS,1210.0,2.0,154.0,41.0,,17.49,2.0,2.0,experimental,79.04,0.245,0.2208,Crystal structure of p300 CH1 domain in complex with CITIF (a CITED2-HIF-1alpha hybrid)
4ZSA,X-RAY DIFFRACTION,2.67,54.01,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG",277.0,2015-05-13,2015-06-17,4ZSA,4850.0,2.0,616.0,266.0,,71.07,1.0,2.0,experimental,42.8897,0.2541,0.2036,Crystal structure of FGFR1 kinase domain in complex with 7n
6ITJ,X-RAY DIFFRACTION,2.74,55.17,VAPOR DIFFUSION,,"0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG",277.0,2018-11-23,2019-10-23,6ITJ,4847.0,2.0,616.0,238.0,,70.9,1.0,1.994,experimental,29.8482,0.2437,0.1992,Crystal structure of FGFR1 kinase domain in complex with compound 3
5HHW,X-RAY DIFFRACTION,2.58,52.24,VAPOR DIFFUSION,7.5,"18% Peg3000, 0.1M Tris pH7.5",298.0,2016-01-11,2016-04-13,5HHW,2800.0,1.0,307.0,320.0,,35.45,1.0,1.79,experimental,22.18,0.1979,0.1707,"Crystal structure of insulin receptor kinase domain in complex with cis-(R)-7-(3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-((tetrahydro-2H-pyran-2-yl)methoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine."
5JR2,X-RAY DIFFRACTION,2.29,46.3,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M MgCl2, 0.1 M Bis-Tris pH 6.5, 25% PEG 3,350, 3% 1,6-hexanediol",293.0,2016-05-05,2016-07-06,5JR2,7210.0,8.0,768.0,687.0,12.0,89.02,2.0,1.75,experimental,22.711,0.20416,0.17036,Crystal structure of the EphA4 LBD in complex with APYd3 peptide inhibitor
5G4C,X-RAY DIFFRACTION,2.23,44.88,"VAPOR DIFFUSION, HANGING DROP",7.2,"12% PEG 8K, 0.1 M HEPES, PH 7.5, 5% ISOPROPANOL",291.0,2016-05-09,2017-05-03,5G4C,5153.0,4.0,656.0,326.0,,75.86,2.0,2.1,experimental,,0.2198,0.183,Human SIRT2 catalyse short chain fatty acyl lysine
7BQ4,X-RAY DIFFRACTION,2.15,42.79,VAPOR DIFFUSION,,"0.1 M Tris (pH 8.0), 30 %(w/v) PEG3350",277.0,2020-03-23,2020-11-11,7BQ4,2328.0,2.0,288.0,103.0,,33.1,2.0,1.62,experimental,22.7557,0.2145,0.188,X-ray structure of human PPARalpha ligand binding domain-eicosapentaenoic acid (EPA)-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization
8HUQ,X-RAY DIFFRACTION,2.15,42.91,VAPOR DIFFUSION,,"0.1 M Tris (pH 8.5), 25%(w/v) PEG3350",277.0,2022-12-24,2023-08-09,8HUQ,2283.0,2.0,288.0,85.0,,33.18,2.0,1.65,experimental,34.4439,0.2135,0.1864,X-ray structure of human PPAR alpha ligand binding domain-elafibranor-SRC1 coactivator peptide co-crystals obtained by soaking
9C54,X-RAY DIFFRACTION,2.32,47.06,"VAPOR DIFFUSION, HANGING DROP",6.5,"7% w/v PEG 8000, 14% v/v ethylene glycol, 25mM sodium l-glutamate, 25mM dl-alanine, 25mM glycine, 25mM dl-lysine HCl, 25mM dl-serine, 100mM MES/imidazole pH6.5",293.0,2024-06-05,2024-09-04,9C54,2565.0,1.0,315.0,205.0,,36.72,1.0,2.05,experimental,49.27,0.2352,0.1864,Crystal structure of human PTPN2 catalytic domain
9C55,X-RAY DIFFRACTION,2.32,46.91,"VAPOR DIFFUSION, HANGING DROP",6.5,"100mM MES/imidazole pH6.5, 7% w/v Peg 8000, 14% v/v ethylene glycol, 30mM sodium l-glutamate, 30mM dl-alanine, 30mM glycine, 30mM dl-lysine HCl, 30mM dl-serine",293.0,2024-06-05,2024-09-04,9C55,2550.0,1.0,315.0,173.0,,37.33,1.0,2.36,experimental,53.45,0.2339,0.1988,Crystal structure of human PTPN2 in complex with active site inhibitor
9C56,X-RAY DIFFRACTION,2.34,47.51,"VAPOR DIFFUSION, HANGING DROP",6.5,"100mM MES/imidazole pH6.5, 8% w/v PEG 8000, 16% v/v ethylene glycol, 35mM sodium l-glutamate, 35mM dl-alanine, 35mM glycine, 35mM dl-lysine HCl, 35mM dl-serine",293.0,2024-06-05,2024-09-04,9C56,2568.0,1.0,315.0,156.0,,37.46,1.0,2.43,experimental,53.67,0.2461,0.1986,Crystal structure of human PTPN2 in complex with allosteric inhibitor
5NFU,X-RAY DIFFRACTION,2.15,42.74,VAPOR DIFFUSION,7.0,"0.1 M HEPES 7
30% Jeffamine ED-2001",293.0,2017-03-16,2018-05-16,5NFU,2024.0,2.0,241.0,178.0,,27.85,2.0,1.809,experimental,,0.202,0.1681,The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with LHSpTA peptide
7QGJ,X-RAY DIFFRACTION,2.29,46.34,"VAPOR DIFFUSION, SITTING DROP",5.5,"8 mg/mL protein
23% PEG Smear broad, 0.1 Na/K tartrate, 12 % Ethylenglycol, cacodylate pH 5.5",293.0,2021-12-08,2022-02-09,7QGJ,1477.0,2.0,166.0,137.0,,19.74,1.0,1.3,experimental,23.141,0.1552,0.1424,Apo structure of BIR2 Domain of BIRC2
7OZY,X-RAY DIFFRACTION,2.73,54.98,"VAPOR DIFFUSION, SITTING DROP",7.6,"25% w/v PEG 3350, 0.1 M ammonium sulfate, 0.1 M HEPES",291.0,2021-06-29,2021-12-01,7OZY,4541.0,2.0,606.0,76.0,,70.61,1.0,2.28,experimental,50.923,0.2959,0.2403,FGFR2 kinase domain (residues 461-763) in complex with 38.
5JU5,X-RAY DIFFRACTION,3.63,66.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Bis-Tris pH 5.5
0.2 M Magnesium chloride
PEG 3350 25%",285.15,2016-05-10,2016-08-03,5JU5,2879.0,6.0,474.0,24.0,,53.12,1.0,2.5,experimental,65.21,0.211,0.191,"Crystal structure of the human Tankyrase 1 (TNKS) SAM domain (D1055R), crystal form 1"
6SQR,X-RAY DIFFRACTION,2.48,50.46,VAPOR DIFFUSION,,"0.1 M Tris-HCl, pH 8.5, 20% (v/v) PEG Smear High",292.0,2019-09-04,2020-05-06,6SQR,9560.0,12.0,1151.0,420.0,,132.41,6.0,2.18,experimental,,0.227,0.166,Crystal structure of Cat MDM2-S429E RING domain bound to UbcH5B-Ub
7VTO,X-RAY DIFFRACTION,2.46,49.98,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris pH 8.5, 0.2 MgCl2, 24% PEG 3350, 5 mM TCEP",277.0,2021-10-30,2022-11-02,7VTO,4264.0,2.0,602.0,10.0,1.0,68.21,1.0,2.59,experimental,73.48,0.2519,0.235,The crystal structure of PAK1 with the inhibitor GW8510
7LWH,X-RAY DIFFRACTION,2.67,53.86,"VAPOR DIFFUSION, HANGING DROP",,"600 mM imidazole (pH 6.5), 15% (w/v) polyethylene glycol 3,350",293.15,2021-03-01,2021-08-11,7LWH,3350.0,2.0,362.0,423.0,,43.16,2.0,1.606,experimental,33.45,0.2325,0.205,Human neurofibromin 2/merlin residues 1-339 in complex with LATS1
7F5N,X-RAY DIFFRACTION,2.14,42.4,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.15 M Ammonium nitrate, 0.1 M MES (pH-6.0), 20% v/v PEG smear medium, 5% v/v Ethylene glycol and 5.5 mM lysine dipeptide additive",291.0,2021-06-22,2021-12-29,7F5N,7601.0,3.0,951.0,410.0,,110.79,1.0,1.93,experimental,24.787,0.2376,0.1834,Crystal structure of TCPTP catalytic domain
7F5O,X-RAY DIFFRACTION,2.31,46.68,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Bis-Tris Propane (pH-7.5), 0.2 M Sodium Iodide, 20% w/v PEG 3350, 10% v/v Ethylene glycol and 0.9 mM Mitoxantrone additive",291.0,2021-06-22,2021-12-29,7F5O,7514.0,3.0,915.0,553.0,,107.21,1.0,1.7,experimental,19.305,0.241,0.1989,Crystal structure of PTPN2 catalytic domain
5ONE,X-RAY DIFFRACTION,2.54,51.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"18% PEG 3350, 0.2 M Ammonium citrate, 0.1 M bis-tris, pH 7.5",277.15,2017-08-03,2017-09-06,5ONE,2125.0,1.0,285.0,10.0,,33.48,1.0,2.6,experimental,86.745,0.25962,0.20829,Crystal structure of Aurora-A in complex with FMF-03-145-1 (compound 2)
8JF4,X-RAY DIFFRACTION,2.89,57.44,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M lithium sulfate, 0.1 M TRIS pH 8.5, 25% w/v PEG 3350",293.0,2023-05-17,2024-02-14,8JF4,2016.0,1.0,263.0,,,31.12,1.0,2.89288354365,experimental,70.0,0.299660770841,0.234016952431,The crystal structure of human AURKA kinase domain in complex with AURKA-compound 9
8JG8,X-RAY DIFFRACTION,2.79,55.85,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M lithium sulfate, 0.1 M TRIS pH 8.5, 25% w/v PEG 3350",293.0,2023-05-19,2024-04-17,8JG8,2026.0,1.0,263.0,,,30.93,1.0,2.90002335195,experimental,71.4362974987,0.269597504328,0.238913482981,The crystal structure of human aurka kinase domain in the complex with aurka-compound 25
5QIL,X-RAY DIFFRACTION,2.03,39.35,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2018-08-05,2018-10-31,5QIL,2599.0,1.0,307.0,156.0,,35.52,1.0,1.98,experimental,27.44,0.2098,0.1692,"TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-{4-[3-(6-METHOXYPYRIDIN-3-YL)-1H-PYRROLO[3,2-B]PYRIDIN-2-YL]PYRIDIN-2-YL}ACETAMIDE"
6B8Y,X-RAY DIFFRACTION,1.97,37.58,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277.0,2017-10-09,2018-02-07,6B8Y,2657.0,1.0,307.0,204.0,,35.54,1.0,1.65,experimental,24.91,0.208,0.179,"TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3-fluoropyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine"
6QST,X-RAY DIFFRACTION,2.78,55.8,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris propane pH 7.5, 0.02 M Sodium/potassium phosphate, 20% w/v PEG 3350",277.0,2019-02-22,2020-03-18,6QST,4171.0,4.0,476.0,327.0,,58.68,1.0,2.1,experimental,,0.2189,0.1871,Structure of CREBBP bromodomain with compound 2 bound
7FB9,X-RAY DIFFRACTION,3.45,64.38,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium acetate-HCl (pH 4.5), 21% (w/v) PEG 3350",287.15,2021-07-08,2022-10-12,7FB9,14044.0,14.0,2254.0,7.0,13.0,235.19,1.0,2.7,experimental,41.74,0.2473,0.2303,"Crystal Structure of Human Cu, Zn Superoxide Dismutase (SOD1)"
6W74,X-RAY DIFFRACTION,2.02,39.15,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Magnesium Acetate Tetrahydrate, 20% w/v PEG3350",298.0,2020-03-18,2020-11-18,6W74,775.0,1.0,99.0,51.0,,12.56,1.0,2.11,experimental,43.34,0.258,0.187,Structure of cIAP with compound 15
4YK0,X-RAY DIFFRACTION,2.15,42.84,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M Bis-Tris, pH 6.5
27% PEG3350
0.1M magnesium chloride",277.0,2015-03-03,2016-04-20,4YK0,3866.0,4.0,456.0,343.0,,55.41,1.0,1.65,experimental,20.906,0.2694,0.2444,Crystal structure of the CBP bromodomain in complex with CPI098
6FRF,X-RAY DIFFRACTION,2.81,56.25,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Sodium Citrate, pH 5.6, 1.3 M Ammonium Sulfate",277.0,2018-02-15,2018-08-29,6FRF,4329.0,4.0,476.0,391.0,,58.67,1.0,2.1,experimental,,0.2283,0.1759,Crystal structure of CREBBP bromodomain complexd with PA10
8FV2,X-RAY DIFFRACTION,2.77,55.55,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.056M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic",293.0,2023-01-18,2024-02-07,8FV2,4673.0,4.0,464.0,463.0,,59.2,1.0,1.87,experimental,,0.2259,0.1897,Bromodomain of CBP liganded with CCS-1477
8G6T,X-RAY DIFFRACTION,2.25,45.38,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.01 M Nickel(II) chloride hexahydrate, 0.1 M Tris pH 8.5, 20% w/v Polyethylene glycol monomethyl ether 2,000",292.0,2023-02-15,2024-02-21,8G6T,4316.0,4.0,464.0,304.0,,58.13,1.0,1.75,experimental,,0.2219,0.1902,Bromodomain of CBP liganded with inhibitor iCBP2
8GA2,X-RAY DIFFRACTION,2.26,45.57,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M Magnesium chloride hexahydrate; 0.1 M TRIS hydrochloride pH 8.5; 30% w/v Polyethylene glycol 4,000",292.0,2023-02-22,2024-02-28,8GA2,4225.0,4.0,464.0,190.0,,57.45,1.0,1.85,experimental,,0.2252,0.1905,Bromodomain of CBP liganded with inhibitor iCBP5
6SQM,X-RAY DIFFRACTION,2.27,45.75,"VAPOR DIFFUSION, SITTING DROP",,"8% Ethylene glycol, 0.1M HEPES pH 7.5, 10% PEG 8000",277.15,2019-09-04,2020-09-30,6SQM,3425.0,3.0,357.0,523.0,,44.14,1.0,1.8,experimental,,0.269,0.208,Crystal structure of CREBBP bromodomain complexed with LA36
6YIK,X-RAY DIFFRACTION,3.42,64.06,"VAPOR DIFFUSION, SITTING DROP",7.5,"21% PEG3350
15% ethylene glycol
0.25M sodium formate",277.0,2020-04-01,2020-04-15,6YIK,3453.0,3.0,357.0,385.0,,44.74,1.0,1.7,experimental,32.625,0.184,0.156,Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand
8G9C,X-RAY DIFFRACTION,2.23,44.87,"VAPOR DIFFUSION, HANGING DROP",5.5,"10% (w/v) PEG 8000, 10% (v/v) isopropanol, 200 mM Li2SO4, 75 mM NaAc, pH 5.5 and 25 mM HEPES, pH 7.0 and soaking in solution 200mM LiCl, 20% PEG8000, 20% isopropanol, 100mM HEPES 7.0, 20mM MgCl2, 100mM NaF in the present of 2mM 5-PCF2P-IP7",293.0,2023-02-21,2024-01-03,8G9C,1294.0,1.0,172.0,111.0,,20.46,1.0,1.4,experimental,19.827,0.18762,0.16959,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5- difluoromethylenebisphosphonate inositol pentakisphosphate (5-PCF2P-IP5), an analogue of 5-InsP7"
8TF9,X-RAY DIFFRACTION,2.46,49.91,"VAPOR DIFFUSION, HANGING DROP",5.0,"10% w/v PEG8000, 10% v/v isopropanol, 200 mM lithium sulfate, 100 mM sodium acetate, pH 5.0, 5 mM IP6, soaked in 200 mM lithium chloride, 20% w/v PEG8000, 20% v/v isopropanol, 100 mM sodium acetate, pH 5.0, 20 mM magnesium chloride, 100 mM sodium fluoride in presence of TvIPK reaction solution with myo-IP6",297.0,2023-07-09,2023-11-15,8TF9,1339.0,1.0,148.0,164.0,,18.02,1.0,1.55,experimental,22.894,0.18782,0.16142,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with myo-5-IP7, produced upon myo-IP6 phosphorylation by TvI"
8TFA,X-RAY DIFFRACTION,2.47,50.29,"VAPOR DIFFUSION, HANGING DROP",,"10% w/v PEG8000, 10% v/v isopropanol, 200 mM lithium sulfate, 100 mM sodium acetate, pH 5.0, 5 mM IP6, soaked in 200 mM lithium chloride, 20% w/v PEG8000, 20% v/v isopropanol, 100 mM sodium acetate, pH 5.0, 20 mM magnesium chloride, 100 mM sodium fluoride in presence of TvIPK reaction solution with 2-OH-IP5",296.0,2023-07-09,2023-11-15,8TFA,1365.0,1.0,148.0,183.0,,17.9,1.0,1.4,experimental,24.223,0.1686,0.15375,"Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with myo-5-PP-IP4, produced upon myo-(2OH)-IP5 phosphorylation by TvIPK"
5DBM,X-RAY DIFFRACTION,2.56,51.98,"VAPOR DIFFUSION, SITTING DROP",9.0,"0.1 M BICINE:NaOH pH 9.0, 20% (w/v) PEG 6000 (CPI703)",277.0,2015-08-21,2016-04-20,5DBM,3333.0,3.0,354.0,355.0,,42.87,1.0,1.86,experimental,24.308,0.2202,0.1723,Crystal structure of the CBP bromodomain in complex with CPI703
7B55,X-RAY DIFFRACTION,2.43,49.37,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES pH 6.0, 20% w/v PEG4000, 0.2 M Lithium Sulfate",277.0,2020-12-03,2022-06-22,7B55,3334.0,2.0,390.0,383.0,,44.2,2.0,1.6,experimental,40.7,0.2138,0.1972,Crystal structure of CaMKII-actinin complex bound to MES
7B56,X-RAY DIFFRACTION,2.45,49.85,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES pH 6.0, 20% w/v PEG4000, 0.2 M Lithium Sulfate",277.0,2020-12-03,2022-06-22,7B56,3416.0,2.0,390.0,441.0,,44.53,2.0,1.45,experimental,30.22,0.2154,0.1901,Crystal structure of CaMKII-actinin complex bound to AMPPNP
7B57,X-RAY DIFFRACTION,2.48,50.32,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES pH 6.0, 20% w/v PEG4000, 0.2 M Lithium Sulfate",277.0,2020-12-03,2022-06-22,7B57,3227.0,2.0,390.0,302.0,,44.45,2.0,1.95,experimental,43.8,0.2474,0.2031,Crystal structure of CaMKII-actinin complex bound to ADP
7U01,X-RAY DIFFRACTION,2.13,42.29,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1M sodium acetate pH4.5, 3M NaCl",293.0,2022-02-17,2023-02-22,7U01,3267.0,4.0,636.0,91.0,,67.83,1.0,2.29707910798,experimental,69.786072096,0.260416175608,0.213740512015,Structure of CD148 fibronectin type III domain 2
8B8U,X-RAY DIFFRACTION,2.23,44.9,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 15% PEG4000, 0.2M Na-acetate",277.0,2022-10-05,2023-02-01,8B8U,4873.0,2.0,578.0,429.0,2.0,67.51,1.0,1.5,experimental,27.98,0.2594,0.2224,Crystal structure of JAK2 JH2-V617F in complex with HTS-A3
5NDD,X-RAY DIFFRACTION,3.04,59.52,LIPIDIC CUBIC PHASE,5.8,"0.1 M sodium citrate/citrate acid pH 5.5-6.2, 0.2 M ammonium phosphate dibasic, 38-43 % (w/v) PEG400 and 1 mM AZ8838",293.0,2017-03-08,2017-05-03,5NDD,4531.0,1.0,619.0,10.0,1.0,69.91,1.0,2.801,experimental,,0.2639,0.2224,Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ8838 at 2.8 angstrom resolution
5MQE,X-RAY DIFFRACTION,2.02,39.22,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350",277.0,2016-12-20,2017-04-19,5MQE,2166.0,2.0,238.0,213.0,,28.85,1.0,1.65,experimental,,0.2253,0.1834,Crystal structure of CREBBP bromodomain complexed with CBP006
5MQG,X-RAY DIFFRACTION,2.01,38.77,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350",277.0,2016-12-20,2017-04-19,5MQG,2283.0,2.0,238.0,269.0,,28.78,1.0,1.35,experimental,,0.1912,0.1711,Crystal structure of CREBBP bromodomain complexed with CBP015
5MQK,X-RAY DIFFRACTION,2.04,39.83,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M KSCN, 20% PEG3350, 10% EG",277.0,2016-12-20,2017-04-19,5MQK,2211.0,2.0,238.0,211.0,,28.79,1.0,1.53,experimental,,0.2102,0.1839,Crystal structure of CREBBP bromodomain complexed with CBP019
6SXX,X-RAY DIFFRACTION,2.18,43.67,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG3350, 0.2 M Potassium thiocyanate, 5% EtGly",277.0,2019-09-26,2020-07-29,6SXX,1940.0,2.0,238.0,81.0,,28.95,1.0,2.01,experimental,52.99,0.2533,0.1955,Crystal structure of the bromodomain of human CREBBP in complex with ACA007
6NBE,X-RAY DIFFRACTION,2.58,52.36,"VAPOR DIFFUSION, HANGING DROP",6.5,"16% Peg3350, 0.1 MES pH 6.5, 0.2M NH4NO3",290.0,2018-12-07,2020-04-15,6NBE,6046.0,3.0,750.0,459.0,,85.09,3.0,2.0,experimental,36.62,0.184,0.159,Ternary Complex of Ac-Alpha-Actin with Profilin and CoA-NAA80
5MME,X-RAY DIFFRACTION,2.06,40.37,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Cacodylate, pH6.5, 0.2 M Calcium acetate, 18% PEG8000",277.0,2016-12-09,2017-12-20,5MME,2466.0,2.0,238.0,388.0,,29.19,1.0,1.35,experimental,,0.1761,0.1636,Crystal structure of CREBBP bromodomain complexd with US46C
6UNQ,X-RAY DIFFRACTION,2.34,47.39,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES 6.5 pH, 20 %v/v Ethylene glycol, 7 %w/v PEG 8000",298.0,2019-10-13,2021-07-07,6UNQ,2325.0,1.0,330.0,3.0,,38.72,1.0,2.4,experimental,71.48,0.2826,0.2178,Kinase domain of ALK2-K493A with AMPPNP
6UNR,X-RAY DIFFRACTION,2.35,47.66,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.05 M PIPES 7 pH, 0.01 M DTT, 10 %w/v PEG 4000",298.0,2019-10-13,2021-07-07,6UNR,2236.0,1.0,330.0,12.0,,38.76,1.0,2.2,experimental,74.05,0.3025,0.2435,Kinase domain of ALK2-K492A/K493A with AMPPNP
6DRW,X-RAY DIFFRACTION,2.46,50.01,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Glycyl-glycine pH 8.0
2.5 M Sodium Malonate pH 6.0",295.0,2018-06-13,2018-07-18,6DRW,2473.0,1.0,316.0,121.0,,37.79,1.0,2.303,experimental,,0.2552,0.2143,JAK2 JH1 in complex with JNJ-7706621 (Crystal Form 2)
5AEP,X-RAY DIFFRACTION,2.29,46.32,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.5-2.2 M SODIUM MALONATE PH 7, HANGING DROP AT 20 DEGREES CELSIUS",293.0,2015-01-08,2015-04-29,5AEP,2588.0,1.0,298.0,154.0,,35.55,1.0,1.95,experimental,,0.21335,0.17114,Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders
5L3A,X-RAY DIFFRACTION,3.16,60.0,"VAPOR DIFFUSION, HANGING DROP",,"2.1M Na Malonate pH 6.0/6.5, 0.1M glycine pH 8.2",277.0,2016-04-06,2016-04-27,5L3A,2454.0,1.0,295.0,45.0,,34.74,1.0,1.98,experimental,40.346,0.27657,0.2333,Fragment-based discovery of 6-arylindazole JAK inhibitors
6TPD,X-RAY DIFFRACTION,2.77,55.57,"VAPOR DIFFUSION, HANGING DROP",,"2.1M Na Malonate pH 6.0/6.5, 0.1M glycine pH 8.2",277.0,2019-12-13,2020-06-10,6TPD,2523.0,1.0,289.0,120.0,,34.18,1.0,1.99,experimental,25.233,0.27759,0.22341,Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity
7Q7I,X-RAY DIFFRACTION,2.17,43.29,"VAPOR DIFFUSION, SITTING DROP",,1.46-1.60 M trisodium citrate (untitrated),293.0,2021-11-09,2022-02-02,7Q7I,2754.0,1.0,316.0,298.0,,37.8,1.0,1.78,experimental,30.96,0.222,0.187,JAK2 in complex with 4-{8-methoxy-2-[(1-methyl-1H-pyrazol-4-yl)amino]quinazolin-6-yl}phenol
7Q7K,X-RAY DIFFRACTION,2.16,42.96,"VAPOR DIFFUSION, SITTING DROP",,1.46-1.60 M trisodium citrate (untitrated),293.0,2021-11-09,2022-02-02,7Q7K,2759.0,1.0,316.0,307.0,,37.72,1.0,1.61,experimental,36.22,0.204,0.183,JAK2 in complex with 4-(2-amino-8-methoxyquinazolin-6-yl)phenol
7Q7W,X-RAY DIFFRACTION,2.11,41.62,"VAPOR DIFFUSION, SITTING DROP",,1.46-1.60 M trisodium citrate (untitrated),293.0,2021-11-09,2022-02-02,7Q7W,2645.0,1.0,316.0,175.0,,37.92,1.0,1.85,experimental,42.32,0.227,0.179,JAK2 in complex with 4-(2-{[5-(dimethylamino)pentyl]amino}-8-{[(2S)-1-hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluorophenol
7SZW,X-RAY DIFFRACTION,2.32,47.0,"VAPOR DIFFUSION, HANGING DROP",,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.15,2021-11-29,2024-09-04,7SZW,2228.0,1.0,289.0,118.0,,33.62,1.0,1.90646266564,experimental,21.2111497036,0.225748378017,0.192806573713,JAK2 JH2 in complex with JAK249
7T1T,X-RAY DIFFRACTION,2.21,44.27,"VAPOR DIFFUSION, HANGING DROP",,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.0,2021-12-02,2022-05-25,7T1T,2305.0,1.0,289.0,129.0,,33.66,1.0,2.08,experimental,23.2314,0.2282,0.181,JAK2 JH2 IN COMPLEX WITH JAK292
8B8N,X-RAY DIFFRACTION,2.4,48.71,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 20% PEG4000, 0.2M Na-acetate",277.0,2022-10-04,2023-02-01,8B8N,2267.0,1.0,289.0,65.0,1.0,33.87,1.0,2.0,experimental,60.24,0.2548,0.2092,Crystal structure of JAK2 JH2-V617F in complex with Cdk2 inhibitor IV
8B99,X-RAY DIFFRACTION,2.61,52.8,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 22% PEG4000, 0.2M Na-acetate",277.0,2022-10-05,2023-02-01,8B99,2522.0,1.0,289.0,274.0,1.0,33.86,1.0,1.6,experimental,35.41,0.2108,0.1891,Crystal structure of JAK2 JH2-V617F in complex with JNJ-7706621
8B9E,X-RAY DIFFRACTION,2.61,52.88,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 20% PEG4000, 0.2M Na-acetate",277.0,2022-10-05,2023-02-01,8B9E,2647.0,1.0,289.0,353.0,1.0,33.81,1.0,1.5,experimental,31.55,0.1938,0.1689,Crystal structure of JAK2 JH2-V617F in complex with Z902-A3
8B9H,X-RAY DIFFRACTION,2.18,43.63,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 20% PEG4000, 0.2M Na-acetate",277.0,2022-10-06,2023-02-01,8B9H,2388.0,1.0,289.0,177.0,1.0,33.83,1.0,1.5,experimental,37.88,0.2085,0.1806,Crystal structure of JAK2 JH2 in complex with Z902-A3
8BA3,X-RAY DIFFRACTION,2.07,40.49,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 16% PEG4000, 0.2M Na-acetate",277.0,2022-10-11,2023-02-01,8BA3,2642.0,1.0,289.0,265.0,1.0,34.09,1.0,1.4,experimental,26.68,0.1965,0.1737,Crystal structure of JAK2 JH2 in complex with Bemcentinib
8BAB,X-RAY DIFFRACTION,2.61,52.82,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 20% PEG4000, 0.2M Na-acetate",277.0,2022-10-11,2023-02-01,8BAB,2584.0,1.0,289.0,281.0,1.0,34.26,1.0,1.55,experimental,30.33,0.2028,0.1747,Crystal structure of JAK2 JH2-V617F in complex with CB76
8BAK,X-RAY DIFFRACTION,2.75,55.31,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 20% PEG4000, 0.2M Na-acetate",277.0,2022-10-11,2023-02-01,8BAK,2507.0,1.0,289.0,200.0,1.0,34.14,1.0,1.65,experimental,39.54,0.2066,0.1841,Crystal structure of JAK2 JH2-V617F in complex with Reversine
8C09,X-RAY DIFFRACTION,1.95,36.9,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris pH 8.5, 26% PEG4000, 0.2 M Na-acetate",277.0,2022-12-16,2023-12-27,8C09,2272.0,1.0,289.0,108.0,1.0,33.15,1.0,1.9,experimental,38.82,0.2569,0.2212,Crystal structure of JAK2 JH2-I559F
8EX1,X-RAY DIFFRACTION,2.41,49.05,"VAPOR DIFFUSION, HANGING DROP",7.5,"HEPES, PEG 3350",277.0,2022-10-24,2023-02-01,8EX1,2504.0,1.0,289.0,322.0,,33.61,1.0,1.5,experimental,22.23,0.1905,0.1685,Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with Reversine
8EX2,X-RAY DIFFRACTION,2.56,51.89,"VAPOR DIFFUSION, HANGING DROP",7.5,"HEPES, PEG 10K",277.0,2022-10-24,2023-02-01,8EX2,2446.0,1.0,289.0,222.0,,33.75,1.0,1.9,experimental,24.71,0.2031,0.1689,Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with HTSA3
5EIC,X-RAY DIFFRACTION,2.03,39.35,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2015-10-29,2016-11-16,5EIC,2227.0,2.0,238.0,215.0,,29.0,1.0,1.5,experimental,23.1454,0.209,0.1726,Crystal structure of the bromodomain of human CREBBP in complex with AYC
5MPK,X-RAY DIFFRACTION,2.09,41.15,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES-Na, pH7.5, 0.2 M MgCl2, 25% P3350",277.0,2016-12-16,2018-01-17,5MPK,2022.0,2.0,238.0,127.0,,29.32,1.0,1.9,experimental,,0.2391,0.1828,Crystal structure of CREBBP bromodomain complexed with DK19
6FQO,X-RAY DIFFRACTION,1.97,37.58,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M KSCN, 20% PEG3350, 10% EG",277.0,2018-02-14,2018-08-29,6FQO,2336.0,2.0,238.0,285.0,,29.49,1.0,1.35,experimental,,0.1941,0.1709,Crystal structure of CREBBP bromodomain complexd with DT29
6FR0,X-RAY DIFFRACTION,2.01,38.78,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Hepes, pH7.5, 0.2 M LiSO4, 25% PEG3350",277.0,2018-02-15,2018-08-29,6FR0,2164.0,2.0,238.0,181.0,,29.4,1.0,1.5,experimental,,0.2023,0.1783,Crystal structure of CREBBP bromodomain complexd with PB08
7XHE,X-RAY DIFFRACTION,2.02,38.97,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Sodium malonate pH 7.0, 20% w/v Polyethylene glycol 3350",277.0,2022-04-08,2022-07-27,7XHE,2195.0,2.0,266.0,163.0,,33.01,1.0,1.59,experimental,22.583,0.231,0.1869,Crystal structure of CBP bromodomain liganded with CCS151
8FXA,X-RAY DIFFRACTION,2.25,45.41,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M Magnesium chloride hexahydrate, 0.1 M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3350",291.0,2023-01-24,2024-02-07,8FXA,2424.0,2.0,232.0,341.0,,29.21,1.0,1.65,experimental,,0.1801,0.1458,Bromodomain of CBP liganded with iCBP4
6Z4Y,X-RAY DIFFRACTION,2.6,52.77,"VAPOR DIFFUSION, SITTING DROP",,"15%(w/v) PEG 3350, 0.2M ammonium citrate",277.15,2020-05-26,2020-06-03,6Z4Y,2300.0,1.0,285.0,108.0,,34.08,1.0,2.25,experimental,32.853,0.2573,0.2063,Crystal structure of Aurora A (STK6) in complex with macrocycle ODS2003208
7UKV,X-RAY DIFFRACTION,3.45,64.4,"VAPOR DIFFUSION, HANGING DROP",,"1.0 M Sodium Citrate, 0.1 M MES pH 6.0",298.0,2022-04-02,2022-11-23,7UKV,2380.0,1.0,328.0,42.0,,37.95,1.0,2.4,experimental,66.2994,0.2433,0.2111,Wild type EGFR in complex with Lazertinib (YH25448)
6X1G,X-RAY DIFFRACTION,2.4,48.8,MICROBATCH,9.5,"25 mM CHES pH 9.5, 25% (w/v) PEG 8000",293.0,2020-05-18,2020-11-25,6X1G,6578.0,4.0,804.0,311.0,,91.48,2.0,1.6,experimental,45.588,0.2182,0.181,Crystal structure of a GEF domain from the Orientia tsutsugamushi protein OtDUB in complex with Rac1
6XDM,X-RAY DIFFRACTION,2.48,50.49,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2020-06-11,2020-07-29,6XDM,10502.0,3.0,1128.0,1281.0,,132.74,1.0,1.56,experimental,22.76,0.1886,0.1674,STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ARYL KETONE INHIBITOR
6XEB,X-RAY DIFFRACTION,2.47,50.23,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2020-06-12,2020-08-12,6XEB,10437.0,3.0,1128.0,1188.0,,132.7,1.0,1.5,experimental,23.86,0.1929,0.1715,STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND E)
6XEC,X-RAY DIFFRACTION,2.48,50.47,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2020-06-12,2020-08-12,6XEC,10267.0,3.0,1128.0,1040.0,,132.86,1.0,1.701,experimental,30.25,0.2032,0.1752,STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND O)
7LTK,X-RAY DIFFRACTION,2.44,49.66,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2021-02-19,2021-05-05,7LTK,10165.0,3.0,1128.0,1039.0,,131.66,1.0,1.59,experimental,32.38,0.198,0.172,STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN INHIBITOR THAT LACKS A ZINC BINDING GROUP (COMPOUND 12)
7LTL,X-RAY DIFFRACTION,2.46,50.02,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2021-02-19,2021-05-05,7LTL,10339.0,3.0,1128.0,1129.0,,133.12,1.0,1.49,experimental,27.4,0.195,0.17,STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN INHIBITOR LACKING A ZINC BINDING GROUP (COMPOUND 19)
6TN8,X-RAY DIFFRACTION,2.65,53.57,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6M ammonium sulfate, 10%(v/v) dioxane, 0.1M MES pH 6.5",277.0,2019-12-06,2019-12-18,6TN8,2483.0,1.0,301.0,88.0,,35.62,1.0,1.63,experimental,42.02,0.2624,0.2278,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound BI-9564
7NNS,X-RAY DIFFRACTION,2.71,54.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.4M ammonium sulfate, 0.1M tris pH 7.5, 8% glycerol.",293.0,2021-02-25,2021-04-07,7NNS,2569.0,1.0,301.0,116.0,,36.0,1.0,2.14,experimental,28.5963,0.2689,0.2284,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound Momelotinib
5LA9,X-RAY DIFFRACTION,3.04,59.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 2.0 M ammonium sulfate",293.0,2016-06-14,2016-08-31,5LA9,3530.0,4.0,542.0,74.0,4.0,60.15,2.0,2.813,experimental,37.7,0.2785,0.2513,HIF prolyl hydroxylase 2 (PHD2-R281C/V314C) cross-linked to HIF-1alpha NODD-L397C/D412C and N-oxalylglycine (NOG) (complex-2)
5L9B,X-RAY DIFFRACTION,2.04,39.85,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M Magnesium chloride hexahydrate, 0.1 M BIS-TRIS pH 5.5, 25% w/v polyethylene glycol 3350",293.0,2016-06-10,2016-08-31,5L9B,3987.0,4.0,542.0,298.0,,60.87,2.0,1.95,experimental,25.0,0.1865,0.1573,HIF PROLYL HYDROXYLASE 2 (PHD2/ EGLN1) IN COMPLEX WITH 2-OXOGLUTARATE (2OG) AND HIF-1ALPHA CODD (556-574)
8FXN,X-RAY DIFFRACTION,2.18,43.58,"VAPOR DIFFUSION, SITTING DROP",,"0.03M Sodium nitrate, 0.03 Sodium phosphate dibasic, 0.03M Ammonium sulfate, 0.1 M Imidazole, 0.1 M MES pH 6.5, 20% v/v PEG 500 MME; 10% w/v PEG 20000",292.0,2023-01-25,2024-02-07,8FXN,1062.0,1.0,116.0,58.0,,14.61,1.0,2.0,experimental,,0.2425,0.1967,Bromodomain of CBP liganded with iCBP7
8TO4,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, HANGING DROP",5.5,"25% PEG-3350, Bis-Tris 0.1 M",298.0,2023-08-02,2024-08-28,8TO4,9471.0,4.0,1312.0,70.0,,152.77,1.0,2.99,experimental,,0.231,0.1711,EGFR(T790M/V948R) in complex with the allosteric inhibitor FRF-06-057
4TS8,X-RAY DIFFRACTION,2.28,46.09,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M MES pH 6.5, 0.1M MgCl2, 20% PEG 3350 10% EtGly",277.0,2014-06-18,2015-07-01,4TS8,1010.0,1.0,119.0,98.0,,14.6,1.0,2.0,experimental,19.1886,0.2535,0.2087,Crystal structure of the bromodomain of human CREBBP in complex with XZ08
5MPZ,X-RAY DIFFRACTION,2.08,40.93,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 0.1 M Bis-Tris, pH 6.5, 5% v/v ethylene glycol, 23% PEG3350",277.0,2016-12-19,2017-05-10,5MPZ,1146.0,1.0,119.0,154.0,,14.61,1.0,1.4,experimental,,0.1763,0.1577,Crystal structure of CREBBP bromodomain complexed with CBP007
6FQT,X-RAY DIFFRACTION,2.05,40.12,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Hepes, pH7.5, 0.2 M LiSO4, 25% PEG3350",277.0,2018-02-14,2019-03-13,6FQT,1061.0,1.0,119.0,75.0,,15.08,1.0,1.8,experimental,,0.2546,0.1961,Crystal structure of CREBBP bromodomain complexd with DR46
6SQE,X-RAY DIFFRACTION,2.29,46.28,"VAPOR DIFFUSION, SITTING DROP",,"0.2M MgCl2, 25% PEG 3350, 0.1M BisTris pH 5.5",277.15,2019-09-03,2020-09-30,6SQE,1243.0,1.0,119.0,250.0,,14.87,1.0,1.506,experimental,,0.1906,0.1607,Crystal structure of CREBBP bromodomain complexed with KD341
6SQF,X-RAY DIFFRACTION,2.32,46.89,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES pH 6.5, 12% PEG 20000",277.15,2019-09-03,2020-09-30,6SQF,1136.0,1.0,119.0,145.0,,14.79,1.0,2.006,experimental,,0.2146,0.1808,Crystal structure of CREBBP bromodomain complexed with LB32A
6YIL,X-RAY DIFFRACTION,2.2,44.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350
10% ethylene glycol
0.2M sodium acetate",277.0,2020-04-01,2020-04-15,6YIL,1160.0,1.0,119.0,154.0,,14.64,1.0,1.22,experimental,12.75,0.1511,0.1321,Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand
6YIM,X-RAY DIFFRACTION,2.2,44.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350
10% ethylene glycol
0.2M sodium fluoride",277.0,2020-04-01,2020-04-15,6YIM,1174.0,1.0,119.0,163.0,,14.65,1.0,1.23,experimental,12.85,0.167,0.1397,Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand
7ZRQ,X-RAY DIFFRACTION,,27.04,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Na+-HEPES, 0.1 M MOPS (acid), pH 7.5, 0.03 M magnesium chloride hexahydrate, 0.03 M calcium chloride dihydrate, 12.5% v/v MPD; 12.5% PEG 1000; 12.5% w/v PEG 3350",292.0,2022-05-04,2022-12-28,7ZRQ,1352.0,2.0,170.0,40.0,,19.42,2.0,1.68,experimental,29.842,0.2439,0.2052,1.68 Angstrom crystal structure of Ca/CaM-E140G:CaMKIIdelta peptide complex
5LPJ,X-RAY DIFFRACTION,2.46,49.91,EVAPORATION,6.5,"LiSO4, PEG 3350",277.0,2016-08-13,2017-08-16,5LPJ,1259.0,1.0,119.0,211.0,,14.54,1.0,1.65,experimental,24.7367,0.1959,0.1673,Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM1
5LPL,X-RAY DIFFRACTION,2.24,45.01,EVAPORATION,7.5,"NaCl, PEG 3350",277.0,2016-08-13,2017-08-16,5LPL,1214.0,1.0,119.0,173.0,,14.6,1.0,1.65,experimental,25.5432,0.2099,0.1626,Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM3c
5NRW,X-RAY DIFFRACTION,2.25,45.42,EVAPORATION,6.5,"LiSO4, PEG 3350, ethylene glycol",277.0,2017-04-25,2017-08-16,5NRW,1203.0,1.0,119.0,170.0,,14.81,1.0,1.7,experimental,17.886,0.2599,0.2193,Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM4
5NU3,X-RAY DIFFRACTION,2.5,50.77,EVAPORATION,6.5,"LiSO4, PEG 3350, ethylene glycol",277.0,2017-04-28,2017-08-16,5NU3,1269.0,1.0,119.0,185.0,,15.05,1.0,1.75,experimental,19.4934,0.1998,0.168,Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM-CBP
6DMK,X-RAY DIFFRACTION,2.13,42.14,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.20M NaNO3, 20.0% PEG 3350, 10.0% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2018-06-05,2018-12-19,6DMK,1078.0,1.0,113.0,80.0,,14.1,1.0,1.66,experimental,38.8892,0.2339,0.1997,A multiconformer ligand model of an isoxazolyl-benzimidazole ligand bound to the bromodomain of human CREBBP
5ENG,X-RAY DIFFRACTION,2.4,48.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2015-11-09,2016-11-23,5ENG,1255.0,1.0,119.0,191.0,,14.69,1.0,1.3,experimental,15.1463,0.1725,0.1641,Crystal structure of the bromodomain of human CREBBP in complex with UP39
5EP7,X-RAY DIFFRACTION,2.02,39.22,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2015-11-11,2016-11-23,5EP7,1290.0,1.0,119.0,213.0,,14.5,1.0,1.198,experimental,14.4881,0.1762,0.166,Crystal structure of the bromodomain of human CREBBP in complex with UN32
5H85,X-RAY DIFFRACTION,2.04,39.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.15M KSCN, 20% PEG 3350, 10% EtGly",277.0,2015-12-23,2017-01-11,5H85,1236.0,1.0,119.0,220.0,,14.52,1.0,1.701,experimental,16.5709,0.1985,0.1611,Crystal structure of the bromodomain of human CREBBP in complex with UO37D
5J0D,X-RAY DIFFRACTION,2.22,44.59,VAPOR DIFFUSION,7.5,"25% PEG3350, 0.2 M MgCl2, 0.1M BisTris pH 7.5",277.0,2016-03-28,2016-10-05,5J0D,1153.0,1.0,119.0,127.0,,14.89,1.0,1.05,experimental,19.092,0.19736,0.17828,Crystal structure of the bromodomain of human CREBBP in complex with a benzoxazepine compound
5MMG,X-RAY DIFFRACTION,2.38,48.42,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M KSCN, 10% Ethylene Glycol, 20% PEG3350",277.0,2016-12-09,2017-12-20,5MMG,1310.0,1.0,119.0,238.0,,14.6,1.0,1.23,experimental,,0.163,0.1571,Crystal structure of CREBBP bromodomain complexed with UT07C
5MPN,X-RAY DIFFRACTION,2.13,42.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M MgCl2, 0.1 M Bis-Tris, pH6.5, 5% EG, 23% PEG3350",277.0,2016-12-16,2018-01-17,5MPN,1273.0,1.0,119.0,204.0,,14.96,1.0,1.23,experimental,,0.1674,0.1582,Crystal structure of CREBBP bromodomain complexed with FA26
5NLK,X-RAY DIFFRACTION,2.34,47.52,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Buffer System 3, pH8.5, 37.50% v/v MPD_P1K_P3350, 0.09 M NPS",277.0,2017-04-04,2018-02-21,5NLK,1102.0,1.0,119.0,110.0,,14.67,1.0,1.8,experimental,,0.2163,0.1768,Crystal structure of CREBBP bromodomain complexd with US13A
5OWK,X-RAY DIFFRACTION,2.15,42.73,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES, pH6.5, 0.1 M MgCl2, 20% PEG6K, 10% EG",277.0,2017-09-01,2018-08-29,5OWK,1227.0,1.0,119.0,229.0,,14.65,1.0,1.25,experimental,,0.1761,0.1621,Crystal structure of CREBBP bromodomain complexed with DSPB2A002
5TB6,X-RAY DIFFRACTION,2.04,39.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.15M KSCN
15% PEG 3350
5% EtGly",277.0,2016-09-11,2016-10-12,5TB6,1185.0,1.0,119.0,157.0,,14.54,1.0,1.79,experimental,13.875,0.2435,0.1716,"Structure of bromodomain of CREBBP with a pyrazolo[4,3-c]pyridin fragment"
6FQU,X-RAY DIFFRACTION,2.48,50.5,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M KSCN, 20% PEG3350, 10% EG",277.0,2018-02-14,2018-08-29,6FQU,1219.0,1.0,119.0,190.0,,14.58,1.0,1.43,experimental,,0.1896,0.1656,Crystal structure of CREBBP bromodomain complexd with DR09
8FXE,X-RAY DIFFRACTION,2.51,51.08,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M Sodium chloride, 0.1 M Tris pH 8.5, 25% w/v Polyethylene glycol 3350",292.0,2023-01-24,2024-02-07,8FXE,1239.0,1.0,119.0,168.0,,14.9,1.0,1.55,experimental,,0.1864,0.156,Bromodomain of CBP liganded with iCBP6
8FXO,X-RAY DIFFRACTION,2.29,46.18,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M Sodium acetate trihydrate, 0.1 M TRIS hydrochloride pH 8.5, 30% w/v Polyethylene glycol 4000",292.0,2023-01-25,2024-02-07,8FXO,1119.0,1.0,116.0,116.0,,14.4,1.0,1.74,experimental,,0.2049,0.1762,Bromodomain of CBP liganded with iCBP8
6EZF,X-RAY DIFFRACTION,2.4,48.85,"VAPOR DIFFUSION, SITTING DROP",8.25,"25 % PEG4000
0.10 M Tris 8.25
0.20 M LiSO4",298.0,2017-11-15,2018-04-04,6EZF,3416.0,1.0,353.0,351.0,,42.04,1.0,1.5,experimental,17.619,0.19804,0.15135,PDE2 in complex with molecule 5
5XSU,X-RAY DIFFRACTION,2.5,50.86,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 7.5, 1% PEG400, 2.1M (NH4)2SO4",293.0,2017-06-15,2018-04-25,5XSU,9894.0,4.0,1420.0,164.0,2.0,161.06,1.0,2.4,experimental,45.8354,0.2741,0.2211,novel orally efficacious inhibitors complexed with PARP1
8PST,X-RAY DIFFRACTION,2.44,49.6,"VAPOR DIFFUSION, HANGING DROP",5.5,20% PEG8000. 0.1 M Na-citrate pH 5.5,293.0,2023-07-13,2024-07-24,8PST,2921.0,1.0,364.0,137.0,,42.44,1.0,1.9,experimental,,0.224,0.1904,ERK2 covelently bound to RU60 cyclohexenone based inhibitor
8PSW,X-RAY DIFFRACTION,2.49,50.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"30% PEG1000, 0.1M HEPES pH 7.5",293.0,2023-07-13,2024-07-24,8PSW,2912.0,1.0,364.0,105.0,,42.52,1.0,2.0,experimental,53.46,0.2147,0.1892,ERK2 covalently bound to RU67 cyclohexenone based inhibitor
8PSY,X-RAY DIFFRACTION,2.55,51.7,"VAPOR DIFFUSION, HANGING DROP",5.5,"30% PEG1000, 0.1M Na-citrate pH 5.5",293.0,2023-07-13,2024-07-24,8PSY,2832.0,1.0,364.0,19.0,,42.52,1.0,2.55,experimental,,0.2318,0.1897,ERK2 covelently bound to RU68 cyclohexenone based inhibitor
8PT1,X-RAY DIFFRACTION,2.42,49.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG8000, 0.1 M HEPES pH 7.5",293.0,2023-07-13,2024-07-24,8PT1,3206.0,1.0,364.0,214.0,,42.56,1.0,1.8,experimental,,0.2064,0.1791,ERK2 covelently bound to RU76 cyclohexenone based inhibitor
7AD0,X-RAY DIFFRACTION,2.36,47.94,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1 M Bis-Tris pH 5.5 with 0.2 M NaCl and 25% PEG 3350,277.0,2020-09-13,2020-10-28,7AD0,5145.0,12.0,624.0,165.0,,73.16,2.0,2.07,experimental,49.976,0.2385,0.1871,X-ray structure of Mdm2 with modified p53 peptide
6Q7K,X-RAY DIFFRACTION,2.28,45.95,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-13,2019-03-27,6Q7K,3103.0,1.0,368.0,284.0,,42.73,1.0,1.84,experimental,34.718,0.26315,0.21091,ERK2 mini-fragment binding
6Q7T,X-RAY DIFFRACTION,2.25,45.37,"VAPOR DIFFUSION, SITTING DROP",7.2,"02M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-13,2019-06-26,6Q7T,3114.0,1.0,368.0,308.0,,42.82,1.0,1.6,experimental,28.425,0.22672,0.18084,ERK2 mini-fragment binding
6QA1,X-RAY DIFFRACTION,2.28,45.98,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-18,2019-06-26,6QA1,3166.0,1.0,368.0,309.0,,43.31,1.0,1.58,experimental,22.681,0.203,0.166,ERK2 mini-fragment binding
6QA3,X-RAY DIFFRACTION,2.26,45.53,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-18,2019-06-26,6QA3,3118.0,1.0,368.0,316.0,,42.78,1.0,1.57,experimental,27.287,0.217,0.171,ERK2 mini-fragment binding
6QA4,X-RAY DIFFRACTION,2.25,45.29,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4
34% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-18,2019-06-26,6QA4,3205.0,1.0,368.0,393.0,,43.03,1.0,1.6,experimental,27.656,0.215,0.173,ERK2 mini-fragment binding
6QAG,X-RAY DIFFRACTION,2.23,44.94,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4
34% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-19,2019-03-27,6QAG,2990.0,1.0,368.0,182.0,,42.98,1.0,2.07,experimental,35.964,0.235,0.184,ERK2 mini-fragment binding
6QAH,X-RAY DIFFRACTION,2.29,46.38,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4
34% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-19,2019-06-26,6QAH,3051.0,1.0,368.0,244.0,,42.79,1.0,1.58,experimental,29.596,0.212,0.181,ERK2 mini-fragment binding
6QAL,X-RAY DIFFRACTION,2.29,46.38,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4
34% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-19,2019-03-27,6QAL,3092.0,1.0,368.0,304.0,,43.18,1.0,1.57,experimental,27.939,0.223,0.178,ERK2 mini-fragment binding
6QAQ,X-RAY DIFFRACTION,2.28,46.04,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4
34% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-19,2019-03-27,6QAQ,3174.0,1.0,368.0,289.0,,43.16,1.0,1.58,experimental,30.095,0.229,0.188,ERK2 mini-fragment binding
6QAW,X-RAY DIFFRACTION,2.3,46.56,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.2M (NH4)2SO4
34% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2018-12-19,2019-03-27,6QAW,3119.0,1.0,368.0,330.0,,42.96,1.0,1.84,experimental,30.412,0.221,0.174,ERK2 mini-fragment binding
5OC8,X-RAY DIFFRACTION,2.16,43.04,"VAPOR DIFFUSION, HANGING DROP",5.0,"3M AmSO4, 0.1M citrate",298.0,2017-06-29,2018-08-22,5OC8,911.0,1.0,96.0,83.0,,11.75,1.0,1.56,experimental,24.069,0.2603,0.237,"HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A"
5BVD,X-RAY DIFFRACTION,2.29,46.33,"VAPOR DIFFUSION, SITTING DROP",,"20mM Mg Sulfate, 20% PEG 3350",293.0,2015-06-05,2015-09-09,5BVD,3049.0,1.0,361.0,288.0,,42.42,1.0,1.9,experimental,,0.2068,0.1702,Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5BVE,X-RAY DIFFRACTION,2.27,45.76,"VAPOR DIFFUSION, SITTING DROP",,"20mM Mg Sulfate, 20% PEG 3350",293.0,2015-06-05,2015-09-09,5BVE,3029.0,1.0,361.0,264.0,,42.33,1.0,2.0,experimental,,0.2198,0.1725,Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5BVF,X-RAY DIFFRACTION,2.22,44.65,"VAPOR DIFFUSION, SITTING DROP",,"20mM Mg Sulfate, 20% PEG 3350",293.0,2015-06-05,2015-09-09,5BVF,2948.0,1.0,361.0,209.0,,42.43,1.0,1.9,experimental,,0.2206,0.1806,Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase
5LCJ,X-RAY DIFFRACTION,2.31,46.65,BATCH MODE,7.2,".2M (NH4)2SO4
32% MPEG 2000
.02M Mercaptoethanol
.1M pH=7.2 HEPES/NaOH",297.0,2016-06-22,2016-07-20,5LCJ,3450.0,1.0,368.0,535.0,,43.33,1.0,1.78,experimental,35.814,0.212,0.162,In-Gel Activity-Based Protein Profiling of a Clickable Covalent Erk 1/2 Inhibitor
6GJB,X-RAY DIFFRACTION,2.29,46.4,"VAPOR DIFFUSION, SITTING DROP",7.3,"0.2M ammonium sulphate, 34% MPEG2000, 0.1MHepes, pH7.3, 0.02M mercaptoethanol",293.0,2018-05-16,2019-01-02,6GJB,3332.0,1.0,368.0,402.0,,43.69,1.0,1.82,experimental,41.752,0.206,0.164,Erk2 signalling protein
6OPG,X-RAY DIFFRACTION,2.99,58.81,"VAPOR DIFFUSION, HANGING DROP",8.8,"36% PEG3350, 0.1 M Tris pH 8.8
10mg/mL protein.",293.0,2019-04-25,2019-07-31,6OPG,3050.0,1.0,354.0,159.0,,41.69,1.0,2.9,experimental,48.336,0.23907,0.15635,phosphorylated ERK2 with AMP-PNP
6OPH,X-RAY DIFFRACTION,2.99,58.8,"VAPOR DIFFUSION, HANGING DROP",9.0,"36% PEG3350, 100mM bicine pH 9.0",293.0,2019-04-25,2019-07-31,6OPH,2902.0,1.0,354.0,17.0,,41.57,1.0,2.4,experimental,55.747,0.24287,0.19291,phosphorylated ERK2 with GDC-0994
5JTH,X-RAY DIFFRACTION,1.93,36.38,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Sodium Acetate pH 4.6, 25%(w/v) PEG 4000, 20mM CaCl2",295.0,2016-05-09,2017-07-19,5JTH,1560.0,2.0,171.0,131.0,,19.3,2.0,1.84,experimental,31.784,0.1964,0.1567,Crystal structure of E67A calmodulin - CaM:RM20 analog complex
6VKK,X-RAY DIFFRACTION,2.42,49.09,"VAPOR DIFFUSION, SITTING DROP",8.0,"2M Ammonium Sulfate, 5% PEG 400, 100 mM Tris",298.0,2020-01-21,2020-06-17,6VKK,11126.0,4.0,1488.0,169.0,2.0,168.72,1.0,2.1,experimental,55.022,0.2607,0.2391,Crystal Structure of human PARP-1 CAT domain bound to inhibitor rucaparib
6P8E,X-RAY DIFFRACTION,2.77,55.61,MICROBATCH,,"100mM Tris (7.0)
200mM MgCl2
25%PEG 8000",295.0,2019-06-07,2019-12-25,6P8E,4709.0,3.0,623.0,194.0,,71.21,3.0,2.3,experimental,,0.2222,0.1724,Crystal structure of CDK4 in complex with CyclinD1 and P27
6P8G,X-RAY DIFFRACTION,2.72,54.71,MICROBATCH,,"100mM Tris (7.0)
200mM MgCl2
10% PEG 8000",295.0,2019-06-07,2019-12-25,6P8G,4408.0,3.0,623.0,,,71.06,3.0,2.8,experimental,,0.2747,0.2213,Crystal structure of CDK4 in complex with CyclinD1 and P27
7W7X,X-RAY DIFFRACTION,3.1,60.38,"VAPOR DIFFUSION, HANGING DROP",,1.0 M (NH4)2SO4 and 0.1 M HEPES (pH 7.0).,293.0,2021-12-06,2022-04-27,7W7X,4766.0,2.0,544.0,454.0,,64.26,1.0,2.00000937681,experimental,38.8330415441,0.194598028559,0.168323023125,The crystal structure of human abl1 kinase domain in complex with ABL1-A11
5ETC,X-RAY DIFFRACTION,2.91,57.79,"VAPOR DIFFUSION, SITTING DROP",,"1.5 to 1.6 M (NH4)2SO4, 50mM MgCl2 and 50 mM TRIS/HCl pH 8.0",293.0,2015-11-17,2016-01-20,5ETC,3062.0,1.0,363.0,192.0,,41.81,1.0,2.422,experimental,,0.2425,0.1944,Structure of inactive MAPK14 with ordered Activation Loop
5JXG,X-RAY DIFFRACTION,3.73,67.05,"VAPOR DIFFUSION, SITTING DROP",,"crystallization solution: 100 mM MES, 200 mM K/NaH2PO4, pH 5.5-6.0, 3-4 M NaCl, 3% DMSO; reservoir solution: 3-4 M NaCl",293.15,2016-05-13,2016-10-05,5JXG,4360.0,1.0,482.0,645.0,3.0,52.73,1.0,1.8,experimental,,0.1733,0.154,Structure of the unliganded form of the proprotein convertase furin.
5JXI,X-RAY DIFFRACTION,3.76,67.3,"VAPOR DIFFUSION, SITTING DROP",,"crystallization solution: 100 mM MES, 200 mM K/NaH2PO4, pH 5.5-6.0, 3-4 M NaCl, 3% DMSO; reservoir solution: 3-4 M NaCl",293.15,2016-05-13,2016-10-05,5JXI,4164.0,1.0,482.0,521.0,3.0,52.63,1.0,2.0,experimental,,0.1851,0.1576,Structure of the unliganded form of the proprotein convertase furin in presence of EDTA.
5MIM,X-RAY DIFFRACTION,3.75,67.2,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100 MM MES, 200 MM K/NAH2PO4, PH 5.5-6.0, 3-4 M NACL, 3% DMSO; RESERVOIR SOLUTION: 3-4 M NACL",293.15,2016-11-28,2017-05-10,5MIM,4275.0,1.0,482.0,486.0,3.0,53.81,1.0,1.9,experimental,,0.1838,0.1647,"Xray structure of human furin bound with the 2,5-dideoxystreptamine derived small molecule inhibitor 1n"
5N23,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, HANGING DROP",7.5,12-26 % (v/v) methanol,277.15,2017-02-07,2018-03-14,5N23,3131.0,2.0,372.0,133.0,,43.64,2.0,2.088,experimental,,0.239,0.1875,Protein kinase A mutants as surrogate model for Aurora B with AT9283 inhibitor
6YSX,X-RAY DIFFRACTION,2.77,55.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate pH 7.5
350mM NaCl
27% PEG 8000",277.0,2020-04-23,2021-05-12,6YSX,2679.0,3.0,307.0,247.0,4.0,36.2,3.0,1.48,experimental,26.2084,0.1617,0.1334,Thrombin in complex with 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide (j80)
6QYX,X-RAY DIFFRACTION,2.3,46.51,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5, 
0.2 M KF, 
13%-17% (w/v) PEG 3350, 
25 mM beta-D-octyl glucoside (bOG)",277.0,2019-03-10,2020-04-01,6QYX,2970.0,1.0,366.0,204.0,,42.51,1.0,1.66,experimental,37.548,0.24233,0.18485,p38(alpha) MAP kinase with the activation loop of ERK2
4WB5,X-RAY DIFFRACTION,2.65,53.56,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% PEG 6000, 0.1M HEPES pH 7.5",295.0,2014-09-02,2015-01-21,4WB5,3481.0,2.0,370.0,405.0,,43.54,2.0,1.641,experimental,31.54,0.1956,0.1633,Crystal structure of human cAMP-dependent protein kinase A (catalytic alpha subunit)
4WB8,X-RAY DIFFRACTION,2.67,53.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% PEG 8000, 0.1M HEPES pH 7.5",295.0,2014-09-02,2015-01-21,4WB8,3549.0,2.0,357.0,515.0,,42.46,2.0,1.55,experimental,28.52,0.1844,0.1631,"Crystal structure of human cAMP-dependent protein kinase A (catalytic alpha subunit), exon 1 deletion"
6G54,X-RAY DIFFRACTION,2.91,57.66,"VAPOR DIFFUSION, SITTING DROP",5.9,0.9M Li2SO4 and 0.1M citrate 5.9,277.15,2018-03-29,2019-02-27,6G54,3145.0,1.0,361.0,195.0,,43.03,1.0,2.05,experimental,55.794,0.22096,0.18322,Crystal structure of ERK2 covalently bound to SM1-71
6E2Q,X-RAY DIFFRACTION,3.55,65.39,"VAPOR DIFFUSION, HANGING DROP",7.6,"100 mM Tris, pH 7.6, 2-4% PEG8000",277.15,2018-07-11,2018-08-08,6E2Q,16599.0,8.0,2264.0,145.0,,258.98,2.0,2.65,experimental,,0.2625,0.2253,Structure of human JAK2 FERM/SH2 in complex with Erythropoietin Receptor
7X4U,X-RAY DIFFRACTION,2.89,57.46,"VAPOR DIFFUSION, SITTING DROP",6.5,"Bis-Tris, Ammonium Sulfate, PEG 3350",277.0,2022-03-03,2023-03-08,7X4U,3194.0,1.0,368.0,186.0,,43.64,1.0,1.98,experimental,48.69,0.2349,0.1968,Crystal structure of ERK2 with an allosteric inhibitor 2
6DMG,X-RAY DIFFRACTION,2.44,49.61,VAPOR DIFFUSION,6.5,"100 mM MES buffer, pH 6.5, 26-28% PEG-MME 2000, 200 mM ammonium sulfate and 20 mM 2-mercaptoethanol, vapor diffusion, temperature 298K",298.0,2018-06-05,2018-12-19,6DMG,3090.0,1.0,347.0,170.0,,41.42,1.0,2.2,experimental,39.8081,0.2361,0.1864,A multiconformer ligand model of EK6 bound to ERK2
8AO2,X-RAY DIFFRACTION,2.29,46.17,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AO2,3162.0,1.0,368.0,333.0,,42.91,1.0,1.796,experimental,25.183,0.2189,0.1698,Specific covalent inhibitor (3) of ERK2
8AO4,X-RAY DIFFRACTION,2.3,46.48,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AO4,3197.0,1.0,368.0,374.0,,43.12,1.0,1.825,experimental,27.831,0.2219,0.1732,Specific covalent inhibitor (5) of ERK2
8AO5,X-RAY DIFFRACTION,2.32,46.88,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AO5,3185.0,1.0,368.0,411.0,,43.22,1.0,1.595,experimental,29.025,0.214,0.1801,Specific covalent inhibitor (6) of ERK2
8AO6,X-RAY DIFFRACTION,2.31,46.83,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AO6,3240.0,1.0,368.0,428.0,,43.21,1.0,1.811,experimental,29.739,0.2215,0.172,electrophilic inhibitor (7) of ERK2
8AO7,X-RAY DIFFRACTION,2.28,45.96,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AO7,3264.0,1.0,368.0,375.0,,43.09,1.0,1.61,experimental,30.125,0.2128,0.1782,Specific covalent inhibitor (8) of ERK2
8AO8,X-RAY DIFFRACTION,2.28,46.17,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AO8,3190.0,1.0,368.0,347.0,,42.99,1.0,1.697,experimental,23.097,0.2114,0.1721,Specific covalent inhibitor(9) of ERK2
8AO9,X-RAY DIFFRACTION,2.3,46.54,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AO9,3297.0,1.0,368.0,457.0,,43.18,1.0,1.624,experimental,26.199,0.2324,0.1811,Specific covalent inhibitor(10) of ERK2
8AOC,X-RAY DIFFRACTION,2.3,46.48,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOC,3363.0,1.0,368.0,480.0,,43.05,1.0,1.62,experimental,28.211,0.2174,0.1776,Specific covalent inhibitor of ERK2
8AOD,X-RAY DIFFRACTION,2.3,46.53,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOD,3114.0,1.0,368.0,326.0,,43.21,1.0,1.62,experimental,20.683,0.2267,0.1886,Specific covalent inhibitor(14) of ERK2
8AOE,X-RAY DIFFRACTION,2.31,46.68,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOE,3255.0,1.0,368.0,456.0,,43.0,1.0,1.687,experimental,30.238,0.2297,0.1855,Specific covalent inhibitor(15) of ERK2
8AOF,X-RAY DIFFRACTION,2.3,46.61,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOF,3318.0,1.0,368.0,492.0,,42.94,1.0,1.615,experimental,25.644,0.2183,0.1742,Specific covalent inhibitor(16) of ERK2
8AOI,X-RAY DIFFRACTION,2.3,46.52,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.25M (NH4)2SO4
33% MPEG 2000
0.02M Mercaptoethanol
0.1M pH=7.2 HEPES/NaOH",293.0,2022-08-08,2022-09-28,8AOI,3319.0,1.0,368.0,409.0,,43.25,1.0,1.602,experimental,24.325,0.202,0.1618,Specific covalent inhibitor(19) of ERK2
5A8Y,X-RAY DIFFRACTION,2.31,46.64,,,,,2015-07-17,2016-08-03,5A8Y,1945.0,1.0,218.0,212.0,4.0,25.03,1.0,1.9,experimental,18.75,0.22131,0.16058,Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
6NRF,X-RAY DIFFRACTION,2.51,51.02,EVAPORATION,7.5,"~20% PEG 3350, 0.2 M ammonium sulfate or sodium citrate, 100 mM Hepes pH 7.5",298.0,2019-01-23,2019-08-14,6NRF,2078.0,1.0,271.0,106.0,1.0,30.84,1.0,2.0,experimental,41.997,0.2308,0.1884,Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT103
6NRI,X-RAY DIFFRACTION,2.54,51.55,EVAPORATION,7.5,"~20% PEG 3350, 0.2 M ammonium sulfate or sodium citrate, 100 mM Hepes pH 7.5",298.0,2019-01-23,2019-08-14,6NRI,2014.0,1.0,271.0,56.0,1.0,30.76,1.0,2.2,experimental,56.441,0.2375,0.1849,Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT83
7T2U,X-RAY DIFFRACTION,2.15,42.73,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG3350, 0.1M Bis-Tris (pH 6.5)",295.0,2021-12-06,2022-09-14,7T2U,9762.0,6.0,1296.0,204.0,,144.6,2.0,2.1,experimental,37.666,0.2999,0.2451,SARS-CoV2 3C-Like protease complexed with Nemo peptide
7LSZ,X-RAY DIFFRACTION,2.2,44.18,"VAPOR DIFFUSION, SITTING DROP",,"23% PEGMME 2,000, 0.2 M magnesium chloride, 0.1M sodium cacodylate pH 6.5",277.0,2021-02-18,2021-03-03,7LSZ,1988.0,1.0,293.0,324.0,,33.91,1.0,1.7,experimental,26.602,0.1875,0.1743,Hsp90a N-terminal inhibitor
7LT0,X-RAY DIFFRACTION,2.19,43.95,"VAPOR DIFFUSION, SITTING DROP",,"23% PEGMME 2,000, 0.2 M magnesium chloride, 0.1M sodium cacodylate pH 6.5",277.0,2021-02-18,2021-03-03,7LT0,1985.0,1.0,293.0,323.0,,33.88,1.0,1.697,experimental,27.6164,0.204,0.1759,Hsp90a N-terminal inhibitor
7UR3,X-RAY DIFFRACTION,2.11,41.6,"VAPOR DIFFUSION, SITTING DROP",,"25% PEGMME 2000, 0.2 M magnesium chloride, and 0.1 M sodium cacodylate pH 6.5",293.0,2022-04-21,2022-12-28,7UR3,1864.0,1.0,293.0,198.0,,33.92,1.0,1.6,experimental,31.5138,0.1885,0.1742,Hsp90 alpha inhibitor
5X7B,X-RAY DIFFRACTION,2.2,43.99,"VAPOR DIFFUSION, SITTING DROP",,"29%(w/v) PEG4000, 0.1 M Tris-HCl, 0.13 M sodium acetate",293.0,2017-02-24,2017-09-13,5X7B,1633.0,3.0,246.0,2.0,,27.84,2.0,2.45,experimental,,0.278,0.2252,Crystal structure of SHP2_SH2-CagA EPIYA_C peptide complex
8B6Q,X-RAY DIFFRACTION,2.33,47.27,VAPOR DIFFUSION,,"0.1 M MES pH 6.0, 0.2 M calcium acetate, 18% (m/v) PEG 8000",293.0,2022-09-27,2023-10-11,8B6Q,3699.0,1.0,472.0,3.0,,53.22,1.0,2.6,experimental,89.43,0.3182,0.2806,"X-ray structure of the haloalkane dehalogenase HaloTag7 with an insertion of Calmodulin-M13 fusion at position 154-156 that mimic the structure of CaProLa, an calcium gated protein labeling technology"
6AVM,X-RAY DIFFRACTION,3.2,61.54,"VAPOR DIFFUSION, SITTING DROP",9.5,"PEG 8000, NaCl, CHES (N-Cyclohexyl-2-aminoethanesulfonic acid), TRIS, MgCl2, d4T triphosphate",277.0,2017-09-03,2018-08-15,6AVM,18287.0,8.0,2096.0,661.0,,263.62,2.0,2.502,experimental,92.9455,0.2291,0.191,STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 9.5 WITH CROSS-LINKING TO SECOND BASE TEMPLATE OVERHANG
6AVT,X-RAY DIFFRACTION,3.2,61.55,"VAPOR DIFFUSION, SITTING DROP",9.5,"PEG 8000, NaCl, CHES (N-Cyclohexyl-2-aminoethanesulfonic acid), TRIS, MgCl2, d4T triphosphate",277.0,2017-09-04,2018-08-15,6AVT,18254.0,8.0,2096.0,628.0,,263.62,2.0,2.603,experimental,94.5233,0.2113,0.1789,STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 9.5 WITH CROSS-LINKING TO FIRST BASE TEMPLATE OVERHANG
6XVB,X-RAY DIFFRACTION,2.42,49.11,VAPOR DIFFUSION,6.2,"9 % PEG8000, 18 % ethylene glycol, 10 % MORPHEUS halogens, 0.1 M Imidazole-MES buffer pH 6.2",293.0,2020-01-21,2020-05-27,6XVB,4803.0,2.0,656.0,94.0,,75.75,1.0,2.15,experimental,66.71,0.223,0.192,Crystal structure of the kinase domain of human c-KIT with a cyclic imidate inhibitor covalently bound to Cys788
4PVG,X-RAY DIFFRACTION,1.99,38.08,"VAPOR DIFFUSION, HANGING DROP",7.7,"30% w/v polyethylene glycol 3350, 100 mM NaCl, 1mM L88N79 and 100mM HEPES (pH 7.7) , VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2014-03-17,2015-04-15,4PVG,2183.0,1.0,298.0,18.0,,35.62,1.0,2.4,experimental,,0.2865,0.2361,Crystal structure of protein tyrosine phosphatase Shp2 catalytic domain complex with small molecular compound L88N79
6XVA,X-RAY DIFFRACTION,2.41,48.99,VAPOR DIFFUSION,7.5,"10 % PEG4000, 20 % glycerol, 10 % MORPHEUS carboxylic acids, 0.1 M HEPES-MOPS buffer pH 7.5",293.0,2020-01-21,2020-05-27,6XVA,4751.0,2.0,656.0,75.0,,75.69,1.0,2.3,experimental,51.86,0.245,0.196,Crystal structure of the kinase domain of human c-KIT in complex with a type-II inhibitor bearing an acrylamide
5FRI,X-RAY DIFFRACTION,2.08,40.99,"VAPOR DIFFUSION, SITTING DROP",,"SITTING DROP METHOD. DROPS PROTEIN-PRECIPITANT 1-1, PROTEIN: 10MG/ML ALK5, PRECIPITANT: 20-30% PEG8K, 100 MM PCTP BUFFER PH 8.5-9.2, 0.2 M NAAC",,2015-12-17,2016-07-27,5FRI,2684.0,1.0,301.0,241.0,,34.84,1.0,2.0,experimental,19.132,0.19345,0.16189,ALK5 in complex witha an N-(4-anilino-2-pyridyl)acetamide inhibitor.
8FF8,X-RAY DIFFRACTION,3.14,60.83,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M MES pH 6.0, 20.0 %w/v PEG6K, 0.2 M NH4Cl, 293K",293.0,2022-12-08,2023-06-07,8FF8,5622.0,2.0,882.0,227.0,,99.37,1.0,2.33,experimental,51.67,0.2171,0.1966,CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 2-[(4-CYANOPHENYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIMIDINE-4-CARBOXAMIDE
6J3O,X-RAY DIFFRACTION,2.97,58.58,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES pH 8.2, 26% PEG10000 (v/v), 4% glycol",277.0,2019-01-05,2019-05-01,6J3O,1843.0,2.0,280.0,44.0,,33.81,1.0,2.11,experimental,,0.257,0.23,Crystal structure of the human PCAF bromodomain in complex with compound 12
7BQ1,X-RAY DIFFRACTION,2.16,43.05,VAPOR DIFFUSION,,"0.1 M Tris (pH 8.0), 25 %(w/v) PEG3350",277.0,2020-03-23,2020-11-11,7BQ1,2339.0,2.0,288.0,108.0,,33.05,2.0,1.521,experimental,23.6485,0.2133,0.1939,X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin)-SRC1 coactivator peptide co-crystals obtained by co-crystallization
7BQ2,X-RAY DIFFRACTION,2.14,42.45,VAPOR DIFFUSION,,"0.1M Tris (pH 8.0), 25%(w/v) PEG3350",277.0,2020-03-23,2020-11-11,7BQ2,2344.0,2.0,288.0,111.0,,33.29,2.0,1.52,experimental,23.1362,0.2059,0.1825,X-ray structure of human PPARalpha ligand binding domain-pemafibrate-SRC1 coactivator peptide co-crystals obtained by soaking
7R9V,X-RAY DIFFRACTION,2.61,52.83,"VAPOR DIFFUSION, HANGING DROP",,"PEG6000 8%, 0.6 M sodium formate, 0.1 M CHES pH 9.4, 5 mM TCEP",291.0,2021-06-29,2022-04-06,7R9V,6631.0,1.0,948.0,,,110.82,1.0,2.69,experimental,114.06,0.2919,0.2526,Structure of PIK3CA with covalent inhibitor 19
7R9Y,X-RAY DIFFRACTION,2.62,53.03,"VAPOR DIFFUSION, HANGING DROP",,"PEG6000 8%, 0.6 M sodium formate, 0.1 M CHES pH 9.4, 5 mM TCEP",291.0,2021-06-29,2022-04-06,7R9Y,6620.0,1.0,948.0,,,110.83,1.0,2.85,experimental,109.05,0.2875,0.2473,Structure of PIK3CA with covalent inhibitor 22
5A5N,X-RAY DIFFRACTION,4.03,69.48,,,"50MM BIS-TRIS PROPANE, PH7, 300MM NACL, 1MM DTT, 10% GLYCEROL",,2015-06-20,2015-07-22,5A5N,1354.0,1.0,130.0,211.0,,16.01,1.0,1.95,experimental,32.945,0.19596,0.18001,"Crystal structure of human ATAD2 bromodomain in complex with (2S)-2,6- diacetamido-N-methylhexanamide"
5A5O,X-RAY DIFFRACTION,4.04,69.57,,,"0.1M TRISHCL PH 7.0-8.0, 1.2-1.5M AMMONIUM SULPHATE,20-25% PEG3350",,2015-06-20,2015-07-22,5A5O,1369.0,1.0,130.0,227.0,,15.89,1.0,2.04,experimental,37.16,0.19888,0.17688,"Crystal structure of human ATAD2 bromodomain in complex with 3-methyl- 1,2-dihydroquinolin-2-one"
5A5P,X-RAY DIFFRACTION,4.03,69.48,,,"0.1M TRISHCL PH 7.0-8.0, 1.2-1.5M AMMONIUM SULPHATE,20-25% PEG3350",,2015-06-20,2015-07-22,5A5P,1340.0,1.0,130.0,215.0,,15.92,1.0,2.03,experimental,28.414,0.20805,0.18759,"Crystal structure of human ATAD2 bromodomain in complex with 8-2-(dimethylamino)ethylamino-3-methyl-1,2-dihydroquinolin-2-one"
5A5Q,X-RAY DIFFRACTION,4.08,69.83,,,"0.1M TRISHCL PH 7.0-8.0, 1.2-1.5M AMMONIUM SULPHATE,20-25% PEG3350",,2015-06-20,2015-07-22,5A5Q,1384.0,1.0,130.0,236.0,,16.03,1.0,1.97,experimental,26.392,0.25244,0.22145,"Crystal structure of human ATAD2 bromodomain in complex with 3-methyl- 8-piperidin-4-ylamino-1,2-dihydro-1,7-naphthyridin-2-one hydrochloride"
5A81,X-RAY DIFFRACTION,4.08,69.88,,,,,2015-07-11,2015-08-12,5A81,1349.0,1.0,130.0,204.0,,16.14,1.0,2.03,experimental,32.306,0.21938,0.19659,"Crystal structure of human ATAD2 bromodomain in complex with 8-(3R,4R) -3-(cyclohexylmethoxy)piperidin-4-yl-amino-3-methyl-1,2-dihydro-1,7- naphthyridin-2-one"
4P7U,X-RAY DIFFRACTION,2.044,39.9,"VAPOR DIFFUSION, HANGING DROP",5.0,"100 mM sodium citrate, 30% PEG 2000",298.0,2014-03-27,2015-06-24,4P7U,1006.0,1.0,112.0,90.0,6.0,12.96,1.0,1.502,experimental,22.3415,0.2058,0.1705,Extracellular domain of type II Transforming Growth Factor Beta receptor in complex with NDSB-201
5DXT,X-RAY DIFFRACTION,2.6,52.3,"VAPOR DIFFUSION, HANGING DROP",,PEG 20000,293.0,2015-09-23,2016-01-27,5DXT,7417.0,1.0,962.0,198.0,,112.5,1.0,2.25,experimental,70.252,0.26196,0.22721,p110alpha with GDC-0326
6GVH,X-RAY DIFFRACTION,2.45,49.69,"VAPOR DIFFUSION, SITTING DROP",,none,293.0,2018-06-21,2019-10-02,6GVH,7577.0,1.0,962.0,127.0,,112.4,1.0,2.74,experimental,84.7,0.246,0.19,"Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-4-chloro-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine"
6GVI,X-RAY DIFFRACTION,2.57,52.19,"VAPOR DIFFUSION, SITTING DROP",,none,293.0,2018-06-21,2019-10-02,6GVI,7448.0,1.0,962.0,27.0,,112.38,1.0,2.9,experimental,111.99,0.232,0.18,"Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine"
6FOA,X-RAY DIFFRACTION,2.75,55.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"55-65% precipitant mix 2 (PEG8000 and ethylene glycol), 

100 mM Bicine/Tris buffer at pH 7.5 
100 mM of a sodium nitrate/sodium phosphate/ammonium sulphate mix.",293.0,2018-02-06,2018-05-02,6FOA,5998.0,1.0,751.0,465.0,6.0,86.46,1.0,1.869,experimental,37.4618,0.222,0.1953,Human Xylosyltransferase 1 apo structure
6BDV,X-RAY DIFFRACTION,2.14,42.51,"VAPOR DIFFUSION, HANGING DROP",4.9,"Crystals were obtained at 18 C by the hanging drop vapor diffusion method using 4 mL drops that contained equal volumes of protein and reservoir solutions over a 0.5 mL solution of 100 mM sodium citrate, pH 4.9-5.2, 8-18 % PEG 6000 (w/v), 10 mM DTT, and 3 mM NaN3. Crystals appeared within 3-5 days and were briefly immersed in a cryogenic solution containing 10% MPD (2-methylpentane-2,4-diol) and 90% reservoir solution.",291.0,2017-10-24,2018-02-14,6BDV,2163.0,3.0,283.0,175.0,,32.31,3.0,1.938,experimental,,0.1963,0.1587,Crystal structure of Caspase 3 S150A
5BUG,X-RAY DIFFRACTION,3.13,60.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 1.25 M L-tartrat, 7.5% glycerol",293.0,2015-06-03,2015-10-07,5BUG,11129.0,4.0,1256.0,751.0,4.0,149.83,1.0,2.4,experimental,62.403,0.2106,0.1752,Crystal structure of human phosphatase PTEN oxidized by H2O2
5BZX,X-RAY DIFFRACTION,3.15,60.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 1.25 M L-tartrat, 7.5% glycerol",293.0,2015-06-11,2015-10-07,5BZX,11230.0,4.0,1256.0,880.0,4.0,149.91,1.0,2.5,experimental,59.842,0.2037,0.1752,Crystal structure of human phosphatase PTEN treated with a bisperoxovanadium complex
5BZZ,X-RAY DIFFRACTION,3.16,61.06,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 1.25 M L-tartrate, 7.5% glycerol",293.0,2015-06-11,2015-10-07,5BZZ,11268.0,4.0,1256.0,890.0,,149.83,1.0,2.2,experimental,58.472,0.2207,0.192,Crystal structure of human phosphatase PTEN in its reduced state
6HEP,X-RAY DIFFRACTION,2.25,45.35,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Tris, 25% v/v PEG350 MME",278.0,2018-08-20,2018-10-24,6HEP,8373.0,6.0,996.0,735.0,,114.88,2.0,1.86,experimental,,0.251,0.201,Crystal structure of human 14-3-3 beta in complex with CFTR R-domain peptide pS753-pS768
6MA1,X-RAY DIFFRACTION,2.29,46.32,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.1 M Sodium Citrate Tribasic Dihydrate, 0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2018-08-25,2018-10-17,6MA1,5666.0,2.0,739.0,41.0,,83.16,2.0,2.75,experimental,73.9031,0.2403,0.199,Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor 4a
6MA2,X-RAY DIFFRACTION,3.1,60.36,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.05 M Sodium Citrate Tribasic Dihydrate, 0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2018-08-25,2018-10-17,6MA2,5951.0,2.0,739.0,298.0,,83.12,2.0,2.1,experimental,38.0775,0.218,0.1853,Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor ent-1a
6MA3,X-RAY DIFFRACTION,3.08,60.01,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.05 M Sodium Citrate Tribasic Dihydrate, 0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2018-08-25,2018-10-17,6MA3,6008.0,2.0,739.0,350.0,,83.2,2.0,2.0,experimental,35.7646,0.2117,0.1858,Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor 2a
6MA4,X-RAY DIFFRACTION,3.1,60.38,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.05 M Sodium Citrate Tribasic Dihydrate, 0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2018-08-25,2018-10-17,6MA4,6064.0,2.0,739.0,401.0,,83.21,2.0,2.0,experimental,34.6358,0.2204,0.1908,Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor 3a
6MA5,X-RAY DIFFRACTION,3.13,60.68,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.05 M Sodium Citrate Tribasic Dihydrate, 0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2018-08-25,2018-10-17,6MA5,6056.0,2.0,739.0,393.0,,83.12,2.0,2.0,experimental,37.0169,0.2104,0.18,Crystal structure of human O-GlcNAc transferase bound to a peptide from HCF-1 pro-repeat 2 (11-26) and inhibitor 1a
6GQO,X-RAY DIFFRACTION,2.38,48.36,"VAPOR DIFFUSION, SITTING DROP",8.5,"8 % PEG 8000, 0.1 M Tris pH 8.5",293.0,2018-06-07,2018-09-19,6GQO,2647.0,1.0,322.0,128.0,,37.47,1.0,1.87,experimental,47.98,0.207,0.172,Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 18)
6GQP,X-RAY DIFFRACTION,2.35,47.68,"VAPOR DIFFUSION, SITTING DROP",7.8,"7 % PEG 8000, 0.1 M PCTP (sodium propionate, sodium cacodylate trihydrate, bis-tris propane) pH 7.8",293.0,2018-06-07,2018-09-19,6GQP,2506.0,1.0,322.0,72.0,,37.42,1.0,2.09,experimental,47.99,0.234,0.199,Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 23)
6GQQ,X-RAY DIFFRACTION,2.32,46.96,"VAPOR DIFFUSION, SITTING DROP",7.2,"5 % PEG 8000, 0.1 M PCTP (sodium propionate, sodium cacodylate trihydrate, bis-tris propane) pH 7.2",293.0,2018-06-07,2018-09-19,6GQQ,2739.0,1.0,322.0,241.0,,37.44,1.0,1.52,experimental,30.07,0.204,0.177,Crystal structure of human KDR (VEGFR2) kinase domain in complex with AZD3229-analogue (compound 35)
6XL4,X-RAY DIFFRACTION,2.06,40.26,"VAPOR DIFFUSION, HANGING DROP",5.5,"25% PEG 3350, 0.1 M Bis-Tris",298.0,2020-06-28,2021-06-30,6XL4,9977.0,4.0,1312.0,273.0,,152.41,1.0,2.06,experimental,40.7071,0.252,0.2145,EGFR(T790M/V948R) in complex with AZD9291 and DDC4002
7TD9,X-RAY DIFFRACTION,2.7,54.44,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein in buffer: 20 mM Hepes pH 7.5, 150 mM NaCl, 0.5 mM TCEP, at a concentration of 15.55 mg/ml (1.03 mM) 

Reservoir solution contains: Jeffamine ED-2001 pH 7.0 at 30%, Tris-HCl pH 8.5 at 0.1 M, 5% v/v Ethyl acetate",277.0,2021-12-30,2022-08-17,7TD9,3163.0,3.0,390.0,229.0,,46.09,1.0,1.61,experimental,29.413,0.2422,0.2063,G-059 bound to the SMARCA4 (BRG1) Bromodomain
5MHP,X-RAY DIFFRACTION,2.4,48.81,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350 15%, thiocyanate 0.4 M and ammonium iodide 0.1 M",293.0,2016-11-25,2017-08-30,5MHP,6390.0,1.0,871.0,160.0,14.0,102.85,1.0,2.43,experimental,41.347,0.24473,0.20671,"Novel Imidazo[1,2-a]pyridine Derivatives with Potent Autotaxin/ENPP2 Inhibitor Activity"
5EW8,X-RAY DIFFRACTION,2.68,54.11,"VAPOR DIFFUSION, HANGING DROP",6.75,"18-20% PEG8000, 200mM Ammonium sulphate, 100mM PCTP, 20% (v/v) ethylene glycol",277.0,2015-11-20,2016-03-30,5EW8,5145.0,2.0,618.0,526.0,,71.45,1.0,1.63,experimental,37.37,0.2059,0.1854,FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
8AKE,X-RAY DIFFRACTION,2.6,52.79,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AKE,4586.0,2.0,604.0,96.0,,69.42,1.0,1.82,experimental,35.089,0.2237,0.1767,Human Sirt6 in complex with ADP-ribose and fragment nicotinamide
5O49,X-RAY DIFFRACTION,2.68,54.19,"VAPOR DIFFUSION, SITTING DROP",,"18-20% (w/v) PEG8000, 200mM ammonium sulphate, 100mM PCTP pH 6.75 and 20% (v/v) ethylene glycol",277.0,2017-05-26,2018-02-07,5O49,4520.0,2.0,618.0,131.0,,71.47,1.0,1.91,experimental,,0.22,,Human FGF in complex with a covalent inhibitor
7WCL,X-RAY DIFFRACTION,2.37,48.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"18% (w/v) PEG 8000, 0.2 M LiSO4, 0.1 M MES (pH 6.5)",277.15,2021-12-20,2022-09-14,7WCL,4795.0,2.0,620.0,90.0,,72.08,1.0,2.495,experimental,44.4646,0.2301,0.1931,Crystal structure of FGFR1 kinase domain with Pemigatinib
8XLO,X-RAY DIFFRACTION,2.7,54.45,"VAPOR DIFFUSION, HANGING DROP",,"18% (w/v) PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5",277.15,2023-12-26,2024-03-27,8XLO,4664.0,2.0,620.0,37.0,,72.34,1.0,2.36,experimental,,0.2545,0.2079,FGFR1 kinase domain with a dual-warhead covalent inhibitor CXF-007
8XZ7,X-RAY DIFFRACTION,2.37,48.05,"VAPOR DIFFUSION, HANGING DROP",,"18% PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5",277.0,2024-01-20,2024-06-26,8XZ7,5195.0,2.0,620.0,362.0,,71.96,1.0,1.75,experimental,,0.2251,0.1865,FGFR1 kinase domain with a covalent inhibitor 10h
8Y22,X-RAY DIFFRACTION,2.64,53.46,"VAPOR DIFFUSION, HANGING DROP",,"18% PEG 8000, 0.2 M Li2SO4, and 0.1 M MES, pH 6.5",277.0,2024-01-25,2024-06-26,8Y22,4711.0,2.0,616.0,38.0,,71.84,1.0,2.792,experimental,,0.2597,0.1937,FGFR1 kinase domain with a covalent inhibitor 9g
6NYH,X-RAY DIFFRACTION,2.12,42.07,VAPOR DIFFUSION,,"0.1 M Bis Tris Propane buffer (pH 6.5), 0.2 M sodium iodide, 20% PEG3350",277.0,2019-02-11,2019-05-29,6NYH,4295.0,2.0,592.0,201.0,,68.85,1.0,2.1,experimental,,0.2464,0.2025,Structure of human RIPK1 kinase domain in complex with GNE684
8I2N,X-RAY DIFFRACTION,2.4,48.66,"VAPOR DIFFUSION, HANGING DROP",7.9,"0.2 M Sodium chloride, 0.1 M Tris pH 7.9, 23% w/v Polyethylene glycol 3350",289.0,2023-01-14,2024-01-31,8I2N,4415.0,2.0,588.0,66.0,,67.89,1.0,2.29,experimental,65.05,0.2447,0.2152,The RIPK1 kinase domain in complex with QY7-2B compound
6OCO,X-RAY DIFFRACTION,2.65,53.59,VAPOR DIFFUSION,,"16.60 % PEG6000
0.10 M KCl
0.10 M MES pH=6.00",293.0,2019-03-25,2019-12-11,6OCO,9029.0,2.0,1185.0,14.0,,137.57,2.0,2.58,experimental,61.731,0.296,0.2589,HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 6
6OCU,X-RAY DIFFRACTION,2.67,54.02,VAPOR DIFFUSION,,"16% PEG6000
0.10 M KCl
0.10 M MES pH 6.0",293.0,2019-03-25,2019-12-11,6OCU,8803.0,2.0,1232.0,,,142.97,2.0,2.77,experimental,97.984,0.2873,0.2192,HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 29
5AM6,X-RAY DIFFRACTION,2.7,56.0,,8.0,"20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4",,2015-03-10,2015-03-18,5AM6,4887.0,2.0,620.0,256.0,,71.51,1.0,1.96,experimental,44.849,0.25179,0.21367,Native FGFR1 with an inhibitor
5AM7,X-RAY DIFFRACTION,2.74,56.0,,8.0,"20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4",,2015-03-10,2015-03-18,5AM7,4912.0,2.0,620.0,217.0,,71.57,1.0,1.957,experimental,,0.2542,0.1983,FGFR1 mutant with an inhibitor
5ZV2,X-RAY DIFFRACTION,2.83,56.5,VAPOR DIFFUSION,7.0,"17.70 % PEG-5000-MME, 0.20 M (NH4)2SO4, 0.10 M Tris pH 7.00, Cryo 25% Ethylenglycole in reservoir solution.",277.0,2018-05-09,2018-07-11,5ZV2,4594.0,2.0,610.0,8.0,,70.5,1.0,2.86,experimental,84.096,0.26931,0.2126,FGFR-1 in complex with ligand lenvatinib
6MZQ,X-RAY DIFFRACTION,2.26,45.46,"VAPOR DIFFUSION, HANGING DROP",,"MPEG 5000, sodium cacodylate, ammonium sulfate",291.0,2018-11-05,2019-01-16,6MZQ,4298.0,2.0,622.0,169.0,,71.54,1.0,2.0,experimental,42.725,0.22984,0.19434,TAS-120 in reversible binding mode with FGFR1
6MZW,X-RAY DIFFRACTION,2.26,45.59,"VAPOR DIFFUSION, HANGING DROP",,"MPEG 5000, ammonium sulfate, sodium cacodylate",291.0,2018-11-05,2019-01-16,6MZW,4124.0,2.0,622.0,48.0,,71.7,1.0,2.2,experimental,49.226,0.29695,0.24099,TAS-120 covalent complex with FGFR1
6I2U,X-RAY DIFFRACTION,2.47,50.25,"VAPOR DIFFUSION, SITTING DROP",,"0.03 M MgCl2.6H20, 0.03 M CaCl2.2H20, 0.1 M MOPS/HEPES-Na pH 7.5, 20% (v/v) PEG 500 MME, 10% (w/v) PEG 20 000",295.0,2018-11-02,2019-10-02,6I2U,2201.0,1.0,285.0,26.0,,34.29,1.0,2.5,experimental,,0.2521,0.2044,Aurora-A kinase domain in complex with Coenzyme A
7OCV,X-RAY DIFFRACTION,2.36,47.98,"VAPOR DIFFUSION, HANGING DROP",7.0,"26% PEG 3350, 0.1 M HEPES, pH 7.0",277.0,2021-04-28,2021-07-28,7OCV,2135.0,1.0,211.0,334.0,,24.7,1.0,1.432,experimental,23.89,0.2096,0.1857,"Human TNKS1 in complex with 3-[4-(1-Hydroxy-1-methyl-ethyl)-phenyl]-6-methyl-2H-pyrrolo[1,2-a]pyrazin-1-one"
8GDS,X-RAY DIFFRACTION,3.79,67.52,"VAPOR DIFFUSION, HANGING DROP",,,293.0,2023-03-06,2023-05-10,8GDS,12153.0,4.0,1584.0,43.0,,185.05,1.0,2.71,experimental,52.85,0.2477,0.2175,"CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE 2 (ROCK2) IN COMPLEX WITH 4-(4-(2-(2,3-DIHYDRO-1H- INDOL-1-YL)-2-OXOETHYL)PHENYL)-1(2H)-PHTHALAZINONE"
7YDX,X-RAY DIFFRACTION,2.29,46.38,"VAPOR DIFFUSION, HANGING DROP",,"0.25M ammonium iodide, 0.03M glycyl-glycyl-glycine, 23% polyethylene glycol (PEG) 3350",277.0,2022-07-04,2023-04-19,7YDX,4393.0,2.0,588.0,65.0,,68.79,1.0,2.642,experimental,42.1556,0.2892,0.2603,Crystal structure of human RIPK1 kinase domain in complex with compound RI-962
5G1X,X-RAY DIFFRACTION,2.49,50.6,,9.0,"100 MM BICINE PH 9.0, 20% PEG 6000",,2016-03-31,2016-11-16,5G1X,2588.0,2.0,348.0,197.0,,40.62,2.0,1.72,experimental,28.09,0.1951,0.1762,Crystal structure of Aurora-A kinase in complex with N-Myc
7TAB,X-RAY DIFFRACTION,1.88,34.74,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein in buffer: 20 mM Hepes pH 7.5, 150 mM NaCl, 0.5 mM TCEP, at a concentration of 15.55 mg/ml (1.03 mM) 

Reservoir solution contains: Jeffamine ED-2001 pH 7.0 at 30%, Tris-HCl pH 8.5 at 0.1 M, 4% PEG 400",277.0,2021-12-20,2022-08-17,7TAB,1170.0,1.0,130.0,126.0,,15.37,1.0,1.16,experimental,13.091,0.2009,0.1798,G-925 bound to the SMARCA4 (BRG1) Bromodomain
7ZRT,X-RAY DIFFRACTION,2.01,38.91,"VAPOR DIFFUSION, SITTING DROP",4.3,"7% PEG400, 50mM Citrato, 1.8 M (NH4)2SO4; 20% Ethylene glycol",293.0,2022-05-05,2023-11-15,7ZRT,2245.0,2.0,270.0,119.0,5.0,31.3,2.0,1.8,experimental,23.9,0.229,0.208,Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inhibitor UK970
7K6F,X-RAY DIFFRACTION,3.71,66.82,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Carboxylic acid (0.02M Sodium formate; 0.02M Ammonium acetate; 0.02M Sodium citrate tribasic dihydrate; 0.02M Potassium sodium tartrate tetrahydrate; 0.02M Sodium oxamate), 0.1M Buffer system 1 pH 6.5 (Imidazole; MES monohydrate), 30% precipitant mix 3 (20% v/v Glycerol; 10% w/v PEG 4000)",291.0,2020-09-20,2021-09-22,7K6F,2327.0,1.0,265.0,246.0,1.0,31.56,1.0,1.86,experimental,48.3034,0.2035,0.1801,"Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 in complex with MES (2-(N-morpholino)ethanesulfonic acid)"
5JI0,X-RAY DIFFRACTION,2.34,47.48,"VAPOR DIFFUSION, SITTING DROP",,Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate,296.0,2016-04-21,2017-04-26,5JI0,4370.0,4.0,569.0,231.0,,64.57,3.0,1.98,experimental,46.949,0.246,0.19206,"PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid"
7Y1G,X-RAY DIFFRACTION,2.69,54.28,"VAPOR DIFFUSION, SITTING DROP",8.4,"25 mM Tris, pH 8.4/ 20% PEG3350/ 0.05 M Zn Acetate/ 25 mM Glycine",293.0,2022-06-08,2022-09-28,7Y1G,5780.0,2.0,702.0,255.0,,82.63,1.0,2.3,experimental,35.917,0.2369,0.1855,Crystal structure of human PRKACA complexed with DS01080522
5K5N,X-RAY DIFFRACTION,2.68,54.07,"VAPOR DIFFUSION, HANGING DROP",6.5,"Protein storage conditions: 20 mM Tris pH 7.8, 5% (v/v) glycerol, 200 mM NaCl, 1 mM TCEP, 0.5 mM EDTA, 0.5% DMSO, and 0.2 mM PF-4802367, Well solution: 18-23% (w/v) PEG MME 5000, 100-150 mM ammonium sulfate, and 100 mM MES pH 6.5, Crystallization set-up: 0.5 + 0.5 uL drops over a well-solution of 200 uL",295.0,2016-05-23,2016-09-21,5K5N,5484.0,2.0,740.0,149.0,,85.17,1.0,2.2,experimental,58.0,0.2287,0.2038,"Crystal structure of GSK-3beta complexed with PF-04802367, a highly selective brain-penetrant kinase inhibitor"
5FE5,X-RAY DIFFRACTION,3.39,63.71,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2015-12-16,2016-01-13,5FE5,2130.0,2.0,238.0,228.0,,29.23,1.0,2.12,experimental,45.8,0.2511,0.20513,Crystal structure of human PCAF bromodomain in complex with fragment MB093 (fragment 7)
5FE6,X-RAY DIFFRACTION,3.38,63.6,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2015-12-16,2016-01-13,5FE6,2164.0,2.0,238.0,246.0,,29.21,1.0,1.77,experimental,45.06,0.21248,0.17941,Crystal structure of human PCAF bromodomain in complex with fragment ZB1916 (fragment 10)
5FE7,X-RAY DIFFRACTION,3.42,64.04,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2015-12-16,2016-01-13,5FE7,2033.0,2.0,238.0,172.0,,28.8,1.0,2.08,experimental,52.764,0.21278,0.17148,Crystal structure of human PCAF bromodomain in complex with fragment ZB2216 (fragment 11)
5FE8,X-RAY DIFFRACTION,3.36,63.39,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2015-12-16,2016-01-13,5FE8,2107.0,2.0,238.0,234.0,,29.15,1.0,2.1,experimental,44.247,0.23252,0.19344,Crystal structure of human PCAF bromodomain in complex with compound SL1126 (compound 12)
5LVQ,X-RAY DIFFRACTION,3.41,63.94,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2016-09-14,2016-10-26,5LVQ,1983.0,2.0,238.0,127.0,,28.97,1.0,2.05,experimental,62.896,0.21795,0.18045,"Crystal structure of human PCAF bromodomain in complex with compound-D (CPD-D), N-methyl-2-(tetrahydro-2H-pyran-4-yloxy)benzamide"
7P4S,X-RAY DIFFRACTION,2.81,56.3,VAPOR DIFFUSION,,"30% w/v EDO_P8K, 0.1M Morpheus buffer 2 and 10% morpheus alcohols",278.0,2021-07-13,2021-10-13,7P4S,1262.0,1.0,137.0,120.0,,16.7,1.0,2.17,experimental,63.24,0.2736,0.2017,BROMODOMAIN OF HUMAN TAF1 (2) WITH naphthyridinone compound
7PG6,X-RAY DIFFRACTION,2.39,48.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"10% PEG 5000, 160 mM KSCN and 100 mM sodium cacodylate pH 6.5",293.0,2021-08-13,2022-08-24,7PG6,10727.0,2.0,1355.0,59.0,,159.28,2.0,2.49943744477,experimental,70.0,0.240324192397,0.187252392396,Crystal Structure of PI3Kalpha in complex with the inhibitor NVP-BYL719
6GVF,X-RAY DIFFRACTION,2.63,53.21,"VAPOR DIFFUSION, SITTING DROP",,,293.0,2018-06-21,2019-10-02,6GVF,7480.0,1.0,945.0,69.0,,110.29,1.0,2.5,experimental,102.47,0.244,0.193,"Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine"
7JIU,X-RAY DIFFRACTION,2.64,53.36,VAPOR DIFFUSION,,NOT AVAILABLE,293.0,2020-07-23,2021-06-30,7JIU,7738.0,1.0,946.0,293.0,,110.56,1.0,2.12,experimental,46.35,0.2459,0.2118,HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 2F
5U8L,X-RAY DIFFRACTION,2.07,40.71,"VAPOR DIFFUSION, SITTING DROP",,"Salt: 0.2 M Ammonium sulfate
Buffer: 0.1 M HEPES (pH 7.50)
Precipitant: 20.0 %w/v PEG 8000
Precipitant: 5.7 %v/v  iso-propanol",277.0,2016-12-14,2017-01-25,5U8L,2673.0,1.0,329.0,263.0,,38.31,1.0,1.6,experimental,22.5,0.202,0.189,Crystal structure of EGFR kinase domain in complex with a sulfonyl fluoride probe XO44
5LVV,X-RAY DIFFRACTION,3.22,61.78,"VAPOR DIFFUSION, SITTING DROP",8.5,"3.5M sodium formate, 0.1M Tris pH 8.5",291.0,2016-09-14,2017-07-12,5LVV,5771.0,1.0,749.0,40.0,,84.87,1.0,2.54,experimental,72.052,0.24466,0.19331,Human OGT in complex with UDP and fused substrate peptide (Tab1)
8B5Y,X-RAY DIFFRACTION,2.44,49.58,"VAPOR DIFFUSION, HANGING DROP",8.5,"21.00 %w/v PEG 3350, 0.30 M K Form",293.15,2022-09-25,2023-01-18,8B5Y,9403.0,2.0,1052.0,844.0,,122.62,1.0,1.83,experimental,33.608,0.2182,0.1773,SHP2 in complex with allosteric imidazopyrazine inhibitor
8S0O,X-RAY DIFFRACTION,2.16,43.14,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.5M K formate
15% PEG 3350
0.1M pH=8 Bis-Tris propane/HCl",293.0,2024-02-14,2024-03-20,8S0O,8994.0,2.0,1074.0,784.0,,124.81,1.0,1.834,experimental,39.768,0.2361,0.1937,A fragment-based inhibitor of SHP2
6KQQ,X-RAY DIFFRACTION,2.92,57.81,"VAPOR DIFFUSION, SITTING DROP",6.5,"18% PEG 8000, 100mM sodium cacodylate, pH 6.5, 200mM calcium Acetate",290.0,2019-08-18,2020-09-02,6KQQ,4138.0,2.0,446.0,513.0,,52.88,1.0,1.8,experimental,23.15,0.2012,0.1632,NSD1 SET domain in complex with BT3 and SAM
5H19,X-RAY DIFFRACTION,2.24,45.04,"VAPOR DIFFUSION, SITTING DROP",6.0,"0.1 M Bis-Tris, 0.2 M MgCl2, 20% PEG 3350",293.0,2016-10-08,2017-01-25,5H19,3394.0,2.0,396.0,228.0,,46.36,2.0,1.9,experimental,27.53,0.2154,0.1766,EED in complex with PRC2 allosteric inhibitor EED162
5WUK,X-RAY DIFFRACTION,2.52,51.15,"VAPOR DIFFUSION, SITTING DROP",,"10% polyethylene glycol (PEG) 6000, 0.1M Bicine(pH9.0)",293.0,2016-12-19,2017-05-03,5WUK,3592.0,2.0,394.0,340.0,1.0,46.35,2.0,2.03,experimental,27.7,0.191,0.16,Crystal structure of EED [G255D] in complex with EZH2 peptide and EED226 compound
4UND,X-RAY DIFFRACTION,2.69,54.0,,6.6,"39% PEGMME2000, 0.2M KSCN, 0.1M HEPES, pH 6.6",,2014-05-27,2015-06-17,4UND,5677.0,2.0,746.0,70.0,,84.5,1.0,2.2,experimental,60.941,0.2464,0.22644,HUMAN ARTD1 (PARP1) - CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR TALAZOPARIB
7AAC,X-RAY DIFFRACTION,2.28,45.96,VAPOR DIFFUSION,8.5,"2.5 M ammonium sulfate, 0.1 M Tris pH 8.5",293.0,2020-09-04,2021-01-13,7AAC,6013.0,2.0,704.0,482.0,,79.31,1.0,1.593,experimental,24.21,0.242,0.21,Crystal structure of the catalytic domain of human PARP1 in complex with veliparib
7AAD,X-RAY DIFFRACTION,2.26,45.69,VAPOR DIFFUSION,8.5,"2.5 M ammonium sulfate, 0.1 M Tris pH 8.5",293.0,2020-09-04,2021-01-13,7AAD,5644.0,2.0,704.0,105.0,,79.78,1.0,2.21,experimental,39.33,0.254,0.223,Crystal structure of the catalytic domain of human PARP1 in complex with olaparib
5GJD,X-RAY DIFFRACTION,3.85,68.06,"VAPOR DIFFUSION, HANGING DROP",7.7,"1.7M sodium potassium phosphate, 20%(v/v) Glycerol as cryoprotectant",293.0,2016-06-29,2016-11-16,5GJD,2298.0,1.0,315.0,16.0,,36.02,1.0,2.79,experimental,74.242,0.2451,0.1984,Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 2
5GJF,X-RAY DIFFRACTION,3.84,67.99,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.94M sodium potassium phosphate, 20%(v/v) Glycerol as cryoprotectant",294.0,2016-06-29,2016-11-16,5GJF,2367.0,1.0,315.0,13.0,1.0,36.13,1.0,2.89,experimental,64.998,0.2336,0.1977,Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 3
5GJG,X-RAY DIFFRACTION,3.99,69.18,"VAPOR DIFFUSION, HANGING DROP",7.7,"1.7M sodium potassium phosphate, 20%(v/v) Glycerol as cryoprotectant",294.0,2016-06-29,2016-11-16,5GJG,2302.0,1.0,315.0,36.0,,36.11,1.0,2.61,experimental,59.236,0.221,0.1806,Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 4
5NPR,X-RAY DIFFRACTION,3.33,63.0,"VAPOR DIFFUSION, HANGING DROP",6.4,"Reservoir solution: 1.45 M K2HPO4, 8 mM EDTA, 1% xylitol

Drop solution: 1.45 M K2HPO4, 8 mM EDTA, 1% xylitol, 0.5 M (NH4)2SO4, crystal seeds

Seeds were generated from crystals grown in 1.3 M DL-Malic acid, 0.1 M Bis-Tris propane pH 6.4",295.0,2017-04-18,2018-05-16,5NPR,5939.0,2.0,726.0,362.0,,81.68,2.0,1.85,experimental,46.58,0.23641,0.20497,The human O-GlcNAc transferase in complex with a thiol-linked bisubstrate inhibitor
5NPS,X-RAY DIFFRACTION,3.34,63.0,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.3 M DL-Malic acid, 0.1 M Bis-Tris propane pH 6.4 + seeds generated out of this condition",295.0,2017-04-18,2018-05-16,5NPS,6064.0,2.0,727.0,478.0,,81.72,2.0,1.68,experimental,36.148,0.22143,0.19277,The human O-GlcNAc transferase in complex with a bisubstrate inhibitor
6NRG,X-RAY DIFFRACTION,2.5,50.73,EVAPORATION,7.5,"~20% PEG 3350, 0.2 M ammonium sulfate or sodium citrate, 100 mM Hepes pH 7.5",298.0,2019-01-23,2019-08-14,6NRG,2147.0,1.0,271.0,147.0,1.0,31.07,1.0,1.7,experimental,38.602,0.1821,0.159,Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT57
6NRJ,X-RAY DIFFRACTION,2.56,51.92,EVAPORATION,7.5,"~20% PEG 3350, 0.2 M ammonium sulfate or sodium citrate, 100 mM Hepes pH 7.5",298.0,2019-01-23,2019-08-14,6NRJ,2116.0,1.0,271.0,127.0,1.0,31.09,1.0,1.65,experimental,34.032,0.1913,0.1677,Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT93
6NRH,X-RAY DIFFRACTION,2.51,51.04,EVAPORATION,7.5,"~20% PEG 3350, 0.2 M ammonium sulfate or sodium citrate, 100 mM Hepes pH 7.5",298.0,2019-01-23,2019-08-14,6NRH,2244.0,1.0,271.0,211.0,1.0,31.1,1.0,1.5,experimental,32.831,0.158,0.1291,Crystal Structure of human PARP-1 ART domain bound inhibitor UTT63
8U0H,X-RAY DIFFRACTION,2.41,49.06,"VAPOR DIFFUSION, HANGING DROP",6.9,"0.49M Sodium phosphate monobasic monohydrate, 0.91M Potassium phosphate dibasic",296.0,2023-08-29,2024-09-04,8U0H,5135.0,2.0,648.0,385.0,,78.03,1.0,1.93,experimental,38.32,0.1917,0.1726,Crystal structure of PTPN2 with a PROTAC
5LAQ,X-RAY DIFFRACTION,2.35,47.6,"VAPOR DIFFUSION, HANGING DROP",4.6,"50 mM calcium acetate, 20% PEG 400, 100 mM sodium acetate",293.0,2016-06-14,2018-03-14,5LAQ,2862.0,1.0,421.0,85.0,,49.29,1.0,2.4,experimental,51.062,0.24084,0.17113,Crystal structure of human phosphodiesterase 4B catalytic domain with inhibitor NPD-001
5UB5,X-RAY DIFFRACTION,2.36,47.79,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% (v/v) PEG5000 MME, 50 mM MES pH 6.5, 2mM CaCl2, 250mM NaCl, 5% (v/v) 2-methyl-2,4-pentanediol",295.0,2016-12-20,2017-08-09,5UB5,3698.0,2.0,399.0,337.0,7.0,47.72,2.0,2.089,experimental,32.9548,0.1931,0.1526,human POGLUT1 in complex with human Notch1 EGF12 S458T mutant and UDP
5HKM,X-RAY DIFFRACTION,3.35,63.33,"VAPOR DIFFUSION, HANGING DROP",8.6,"100 mM TRIS-HCl, 1.8 M NH4-sulfate",298.0,2016-01-14,2016-06-08,5HKM,2345.0,1.0,309.0,76.0,,35.93,1.0,2.1,experimental,34.68,0.273,0.19,DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
5HO8,X-RAY DIFFRACTION,2.91,57.71,"VAPOR DIFFUSION, HANGING DROP",8.6,"100 mM Tris-HCl, 1.8 M NH4-sulfate",298.0,2016-01-19,2016-06-08,5HO8,2375.0,1.0,309.0,38.0,,36.08,1.0,2.7,experimental,55.18,0.229,0.182,DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
4Y6Q,X-RAY DIFFRACTION,2.09,41.01,"VAPOR DIFFUSION, SITTING DROP",,PEG 2000,293.0,2015-02-13,2016-01-06,4Y6Q,9467.0,4.0,1172.0,247.0,,136.15,1.0,1.9,experimental,22.28,0.267,0.231,Human SIRT2 in complex with 2-O-myristoyl-ADP-ribose
7CJT,X-RAY DIFFRACTION,2.84,56.7,"VAPOR DIFFUSION, HANGING DROP",,"0.1%w/v n-Octyl-B-D-glucoside
0.1 M Sodium citrate trihydrate,pH 5.5
22% PEG3350",289.0,2020-07-13,2021-04-14,7CJT,6993.0,4.0,960.0,15.0,,112.33,1.0,2.474,experimental,,0.2764,0.2043,"Crystal Structure of SETDB1 Tudor domain in complexed with (R,R)-59"
5UGX,X-RAY DIFFRACTION,2.04,39.65,"VAPOR DIFFUSION, HANGING DROP",,"25 mM HEPES (pH 7.5), 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium sulfate",293.0,2017-01-10,2017-02-22,5UGX,4692.0,2.0,648.0,38.0,,75.52,1.0,2.349,experimental,,0.2749,0.2151,Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 Harboring a E565A/D650V double Gain-of-Function Mutation
5UHN,X-RAY DIFFRACTION,2.08,40.82,"VAPOR DIFFUSION, HANGING DROP",,"25 mM HEPES (pH 7.5), 15-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate",293.0,2017-01-11,2017-02-22,5UHN,4405.0,2.0,648.0,2.0,,75.4,1.0,2.909,experimental,,0.3112,0.2541,Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring a N549H/E565A Double Gain-of-Function Mutation
5UI0,X-RAY DIFFRACTION,2.87,57.16,"VAPOR DIFFUSION, HANGING DROP",,"25 mM HEPES pH 7.5, 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate",293.0,2017-01-12,2017-02-22,5UI0,5150.0,2.0,648.0,258.0,,75.09,1.0,2.05,experimental,,0.2067,0.1822,Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring an E565A/K659M Double Gain-of-Function Mutation
7BF1,X-RAY DIFFRACTION,1.77,30.7,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 1500, 0.1 M SPG buffer pH 4-5. 
CaM-CKBpeptide ratios of 1:4",293.0,2020-12-31,2021-07-21,7BF1,1639.0,3.0,185.0,148.0,,21.46,2.0,1.24,experimental,23.434,0.1863,0.1351,Ca2+-Calmodulin in complex with peptide from brain-type creatine kinase in extended 1:2 binding mode
8PO4,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, SITTING DROP",,PEG8k,293.15,2023-07-03,2024-06-05,8PO4,5251.0,2.0,656.0,341.0,,75.91,1.0,1.621,experimental,31.59,0.2433,0.2092,"Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 33 bound to EGFR[V948R]"
7LP3,X-RAY DIFFRACTION,2.31,46.79,"VAPOR DIFFUSION, SITTING DROP",,"1.6M (NH4)2SO4, 0.1M Potassium Sodium Tartrate, 5% glycerol, 0.1M Sodium Acetate",310.0,2021-02-11,2021-07-28,7LP3,976.0,4.0,102.0,96.0,,12.57,2.0,1.61,experimental,19.41,0.2097,0.1779,Structure of Nedd4L WW3 domain
5LBO,X-RAY DIFFRACTION,2.63,53.19,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES",293.0,2016-06-16,2018-03-14,5LBO,11475.0,4.0,1456.0,553.0,,172.82,1.0,2.25,experimental,45.341,0.20965,0.17365,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-001
6RCW,X-RAY DIFFRACTION,2.65,53.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene glycol, 0.1 M HEPES pH 7.5",293.0,2019-04-11,2019-07-24,6RCW,11520.0,4.0,1456.0,658.0,,172.55,1.0,2.08,experimental,44.968,0.2211,0.17248,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-053
8S31,X-RAY DIFFRACTION,2.83,56.53,"VAPOR DIFFUSION, SITTING DROP",,"50 mM MES (pH 6.0), 20 mM Sodium Oxalate, 1.2 M Sodium Malonate",291.0,2024-02-19,2024-08-21,8S31,4013.0,4.0,506.0,211.0,,58.54,2.0,2.134,experimental,40.06,0.2244,0.195,Crystal structure of human PLK1 Polo-Box Domain in complex with Mis18BP1
6S9C,X-RAY DIFFRACTION,3.5,64.84,"VAPOR DIFFUSION, HANGING DROP",7.5,"10 % PEG 10000
8 % ethylene glycol
0.1 M HEPES",293.0,2019-07-12,2019-11-20,6S9C,2486.0,1.0,329.0,20.0,,37.89,1.0,2.73,experimental,64.013,0.2248,0.2002,EGFR-KINASE IN COMPLEX WITH COMPOUND 5
6S9D,X-RAY DIFFRACTION,3.54,65.26,"VAPOR DIFFUSION, HANGING DROP",7.5,"10 % PEG 10000
8 % ethylene glycol
0.1 M HEPES",293.0,2019-07-12,2019-11-20,6S9D,2483.0,1.0,329.0,47.0,,37.9,1.0,2.67,experimental,45.539,0.2237,0.1936,EGFR-KINASE IN COMPLEX WITH COMPOUND 6
8OWZ,X-RAY DIFFRACTION,2.11,41.58,"VAPOR DIFFUSION, SITTING DROP",,"25 % PEG 3,350 , 0.1 M Bis-Tris pH 6.5",298.0,2023-04-28,2023-11-15,8OWZ,2749.0,1.0,304.0,230.0,,35.68,1.0,1.65,experimental,27.04,0.1975,0.1683,Crystal structure of human Sirt2 in complex with a triazole-based SirReal
8HUK,X-RAY DIFFRACTION,2.84,56.75,VAPOR DIFFUSION,,"0.1 M Tris (pH 8.5), 25%(w/v) PEG3350",277.0,2022-12-24,2023-08-09,8HUK,4222.0,3.0,561.0,,,64.0,2.0,2.981,experimental,100.2106,0.2537,0.1974,X-ray structure of human PPAR alpha ligand binding domain-lanifibranor-SRC1 coactivator peptide co-crystals obtained by soaking
8S30,X-RAY DIFFRACTION,1.89,35.08,"VAPOR DIFFUSION, SITTING DROP",,"0.09 M Halogen mix (NaF, NaBr, NaI), 0.1 M buffer
system 2 (Sodium HEPES and MOPS) (pH7.5), 37% precipitant mix
MPD_P1K_P3350 (MPD (racemic), PEG 1K, PEG 3350)",291.0,2024-02-19,2024-08-21,8S30,1833.0,2.0,249.0,85.0,,28.76,2.0,1.94,experimental,35.5,0.2707,0.2169,Crystal structure of human PLK1 Polo-Box Domain in complex with Mis18
7KJM,X-RAY DIFFRACTION,2.11,41.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"30% isopropanol, 15% PEG 8000, 0.1 M imidazole pH 6.5",294.0,2020-10-26,2021-11-17,7KJM,1866.0,4.0,194.0,172.0,,23.72,2.0,1.4,experimental,,0.2099,0.1843,CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA)
6MBJ,X-RAY DIFFRACTION,2.52,51.1,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.2 M Ammonium acetate, 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 30% w/v Polyethylene glycol 4,000",292.0,2018-08-30,2018-12-19,6MBJ,8891.0,4.0,1228.0,611.0,,142.42,2.0,1.78,experimental,,0.2234,0.1994,"SETD3, a Histidine Methyltransferase, in Complex with an Actin Peptide and SAH, P21 Crystal Form"
6MBK,X-RAY DIFFRACTION,2.18,43.61,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M Ammonium sulfate, 0.1 M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3,350",292.0,2018-08-30,2018-12-19,6MBK,9190.0,4.0,1228.0,833.0,,141.47,2.0,1.69,experimental,,0.2431,0.2276,"SETD3, a Histidine Methyltransferase, in Complex with an Actin Peptide and SAH, First P212121 Crystal Form"
6OX1,X-RAY DIFFRACTION,3.08,60.12,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2019-05-13,2019-08-21,6OX1,9045.0,4.0,1228.0,748.0,,141.34,2.0,1.949,experimental,,0.2011,0.1701,SETD3 in Complex with an Actin Peptide with Target Histidine Partially Methylated
6OX2,X-RAY DIFFRACTION,2.52,51.11,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2019-05-13,2019-08-21,6OX2,8766.0,4.0,1228.0,514.0,,141.4,2.0,2.089,experimental,,0.2391,0.1992,SETD3in Complex with an Actin Peptide with the Target Histidine Fully Methylated
6OX3,X-RAY DIFFRACTION,3.03,59.4,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2019-05-13,2019-08-21,6OX3,8954.0,4.0,1236.0,594.0,,143.62,2.0,1.785,experimental,,0.2465,0.2079,SETD3 in Complex with an Actin Peptide with His73 Replaced with Lysine
6OX4,X-RAY DIFFRACTION,2.53,51.4,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2019-05-13,2019-08-21,6OX4,8630.0,4.0,1228.0,434.0,,142.15,2.0,2.294,experimental,,0.2364,0.1879,A SETD3 Mutant (N255A) in Complex with an Actin Peptide
7BQ3,X-RAY DIFFRACTION,2.31,46.84,VAPOR DIFFUSION,,"0.1M Tris (pH 8.5), 25%(w/v) PEG3350",277.0,2020-03-23,2020-11-11,7BQ3,2248.0,2.0,288.0,41.0,,33.21,2.0,1.98,experimental,36.1825,0.2371,0.1928,X-ray structure of human PPARalpha ligand binding domain-GW7647-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization
5C26,X-RAY DIFFRACTION,2.14,42.55,VAPOR DIFFUSION,5.5,"1.75 M ammonium sulfate, 0.1 M sodium citrate, 0.1 M sodium acetate pH 5.5",295.0,2015-06-15,2015-10-07,5C26,2504.0,2.0,305.0,183.0,,36.23,2.0,1.95,experimental,37.63,0.2148,0.1848,Crystal structure of SYK in complex with compound 1
8AK7,X-RAY DIFFRACTION,2.6,52.69,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AK7,4737.0,2.0,604.0,189.0,,70.47,1.0,1.81,experimental,44.156,0.2332,0.2008,Human Sirt6 in complex with ADP-ribose and fragment 6-O-methylguanine
8AK8,X-RAY DIFFRACTION,2.6,52.68,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AK8,4759.0,2.0,604.0,199.0,,70.67,1.0,1.73,experimental,37.573,0.1929,0.1615,Human Sirt6 in complex with ADP-ribose and fragment 4-hydroxybenzamide
8AK9,X-RAY DIFFRACTION,2.61,52.89,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AK9,4672.0,2.0,604.0,101.0,,70.41,1.0,1.95,experimental,49.374,0.2229,0.1869,Human Sirt6 in complex with ADP-ribose and fragment Isatin
8AKA,X-RAY DIFFRACTION,2.6,52.63,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AKA,4703.0,2.0,604.0,140.0,,70.75,1.0,1.77,experimental,37.869,0.2074,0.1786,Human Sirt6 in complex with ADP-ribose and fragment cis-resveratrol
8AKC,X-RAY DIFFRACTION,2.6,52.8,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AKC,4640.0,2.0,604.0,121.0,,69.99,1.0,1.83,experimental,38.294,0.2063,0.1876,Human Sirt6 in complex with ADP-ribose and fragment 3-(acetylamino)thiophene-2-carboxylic acid
8AKD,X-RAY DIFFRACTION,2.6,52.69,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AKD,4658.0,2.0,604.0,147.0,,69.74,1.0,1.76,experimental,40.839,0.202,0.1762,Human Sirt6 in complex with ADP-ribose and fragment 1-methyl-L-histidine
8AKF,X-RAY DIFFRACTION,2.59,52.6,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AKF,4564.0,2.0,604.0,51.0,,69.86,1.0,1.97,experimental,43.132,0.225,0.1839,Human Sirt6 in complex with ADP-ribose and fragment 3-aminobenzamide
8AKG,X-RAY DIFFRACTION,2.6,52.76,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-07-29,2023-08-16,8AKG,4750.0,2.0,604.0,181.0,,70.93,1.0,1.82,experimental,36.079,0.1929,0.1734,"Human Sirt6 in complex with ADP-ribose and fragment 4-amino-6-chlorobenzene-1,3-disulfonamide"
8BL0,X-RAY DIFFRACTION,2.62,53.01,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-11-09,2023-11-22,8BL0,4772.0,2.0,604.0,218.0,,70.62,1.0,1.82,experimental,40.314,0.2393,0.2014,Human Sirt6 in complex with the inhibitor S6023 and ADP-ribose
8BL1,X-RAY DIFFRACTION,2.65,53.68,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2022-11-09,2023-11-22,8BL1,4634.0,2.0,604.0,77.0,,70.62,1.0,2.06,experimental,41.867,0.2163,0.1783,Human Sirt6 in complex with the inhibitor S6039 and ADP-ribose
6C01,X-RAY DIFFRACTION,2.79,55.87,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1M buffer PCB (QIAGEN PACT suite), 25% PEG 1500",293.0,2017-12-27,2018-05-02,6C01,14750.0,2.0,1676.0,944.0,32.0,203.61,1.0,2.3,experimental,,0.2138,0.1743,"Human ectonucleotide pyrophosphatase / phosphodiesterase 3 (ENPP3, NPP3, CD203c)"
5MAR,X-RAY DIFFRACTION,2.45,49.74,"VAPOR DIFFUSION, HANGING DROP",5.8,"15-18 % PEG 10,000, 0.1M ammonium acetate, and 0.1M Bis-Tris pH 5.8",293.0,2016-11-04,2017-03-15,5MAR,5494.0,2.0,606.0,476.0,,71.7,1.0,1.89,experimental,38.23,0.1943,0.1732,"Structure of human SIRT2 in complex with 1,2,4-Oxadiazole inhibitor and ADP ribose."
4ZJV,X-RAY DIFFRACTION,2.43,49.3,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris
0.2 M Ammonium acetate
25% PEG3350",298.0,2015-04-29,2015-08-12,4ZJV,5274.0,4.0,802.0,96.0,,90.88,2.0,2.7,experimental,45.178,0.23197,0.17854,crystal structure of EGFR kinase domain in complex with Mitogen-inducible gene 6 protein
6T2D,X-RAY DIFFRACTION,2.15,42.84,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M TRIS pH 8, 0.2M Ammonium Sulfate, 30% PEG-3350",295.0,2019-10-08,2020-01-29,6T2D,1018.0,2.0,100.0,124.0,,12.44,2.0,1.8,experimental,20.772,0.2257,0.1323,Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions
5O4A,X-RAY DIFFRACTION,2.74,55.1,"VAPOR DIFFUSION, HANGING DROP",,"18-20% (w/v) PEG8000, 200mM ammonium sulphate, 100mM PCTP pH 6.75 and 20% (v/v) ethylene glycol",277.0,2017-05-26,2018-02-07,5O4A,4759.0,2.0,618.0,190.0,,71.61,1.0,2.01,experimental,62.79,0.225,0.217,Human FGF in complex with a covalent inhibitor
6YOJ,X-RAY DIFFRACTION,2.06,40.28,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG 3350, 0.1 M TRIS, pH 8.6",293.0,2020-04-14,2021-02-10,6YOJ,2614.0,1.0,282.0,365.0,1.0,32.8,1.0,1.361,experimental,16.96,0.1984,0.1706,"FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-3,4-dihydro-1H-quinolin-2-one"
7A8Q,X-RAY DIFFRACTION,2.66,53.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene glycol, 0.1 M HEPES pH 7.5",293.0,2020-08-30,2021-10-06,7A8Q,11327.0,4.0,1456.0,467.0,,172.36,1.0,2.24,experimental,54.493,0.2292,0.1866,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-654
7A9V,X-RAY DIFFRACTION,2.64,53.35,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES pH 7.5",293.0,2020-09-02,2021-10-06,7A9V,11373.0,4.0,1456.0,536.0,,171.87,1.0,2.17,experimental,46.425,0.2292,0.189,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-635
7AB9,X-RAY DIFFRACTION,2.66,53.78,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene glycol, 0.1 M HEPES pH 7.5",293.0,2020-09-07,2021-10-06,7AB9,11323.0,4.0,1456.0,490.0,,171.85,1.0,2.19,experimental,48.68,0.2229,0.1851,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-656
7ABD,X-RAY DIFFRACTION,2.63,53.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene glycol, 0.1 M HEPES pH 7.5",293.0,2020-09-07,2021-10-06,7ABD,11302.0,4.0,1456.0,466.0,,172.07,1.0,2.41,experimental,47.651,0.2266,0.1728,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-768
5WPB,X-RAY DIFFRACTION,2.21,44.36,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291.0,2017-08-04,2017-08-23,5WPB,928.0,1.0,102.0,93.0,,12.13,1.0,1.55,experimental,9.957,0.1621,0.1427,Crystal structure of fragment 3-(3-(pyridin-2-ylmethoxy)quinoxalin-2-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
5LXM,X-RAY DIFFRACTION,3.63,66.11,"VAPOR DIFFUSION, SITTING DROP",,MORPHEUS Crystallization Screen condition C1,295.0,2016-09-22,2016-11-02,5LXM,2615.0,2.0,322.0,77.0,,38.57,2.0,2.08,experimental,74.378,0.2429,0.1996,Crystal structure of Aurora-A bound to a hydrocarbon-stapled proteomimetic of TPX2
6AU2,X-RAY DIFFRACTION,2.45,49.82,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG3350, 0.2M LiSO4, 0.1M Bis-Tris pH 6.5",293.0,2017-08-30,2017-10-11,6AU2,2058.0,1.0,213.0,182.0,,26.1,1.0,1.63,experimental,23.047,0.208,0.1885,Crystal structure of SETDB1 Tudor domain with aryl triazole fragments
5UZK,X-RAY DIFFRACTION,2.69,54.33,VAPOR DIFFUSION,7.0,"2% MPD, VAPOR DIFFUSION, HANGING DROP",277.0,2017-02-26,2018-03-07,5UZK,3195.0,2.0,369.0,275.0,,43.26,2.0,2.3,experimental,38.9,0.253,0.188,Crystal Structure of PKA bound to an pyrrolo pyridine inhibitor
7W5O,X-RAY DIFFRACTION,2.78,55.74,"VAPOR DIFFUSION, SITTING DROP",7.0,"Tacsimate, HEPES, PEGMME5000",277.0,2021-11-30,2022-02-23,7W5O,5973.0,2.0,736.0,119.0,,87.0,1.0,2.35,experimental,68.79,0.2788,0.2254,Crystal structure of ERK2 with an allosteric inhibitor
5ML5,X-RAY DIFFRACTION,2.07,40.54,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2, 
20-30 % PEG4000,
50 mM BOG",293.15,2016-12-06,2017-04-05,5ML5,2821.0,1.0,360.0,103.0,,42.71,1.0,1.9,experimental,26.764,0.23964,0.19293,Human p38alpha MAPK in complex with imidazolyl pyridine inhibitor 11b
6QE1,X-RAY DIFFRACTION,2.25,45.32,"VAPOR DIFFUSION, HANGING DROP",9.0,"PEG 3000, Calcium Chloride, CHES",293.0,2019-01-03,2020-01-29,6QE1,2869.0,1.0,362.0,154.0,,42.32,1.0,1.85,experimental,27.87,0.22154,0.1793,P38 alpha complex with AR117046
6SFO,X-RAY DIFFRACTION,2.3,46.55,"VAPOR DIFFUSION, SITTING DROP",6.5,"5% HMW PEG smears, 0.1M MES",278.0,2019-08-01,2019-09-11,6SFO,2933.0,1.0,361.0,215.0,,41.97,1.0,1.75,experimental,36.909,0.2362,0.1909,MAPK14 with bound inhibitor SR-318
5HLP,X-RAY DIFFRACTION,3.02,59.27,"VAPOR DIFFUSION, SITTING DROP",6.0,"10% (W/V) PEG 5000 MME, 50 mM citric acid and 50 mM bis-tris propane, pH 5.0, 5 mM TCEP",298.0,2016-01-15,2016-05-25,5HLP,5486.0,2.0,848.0,104.0,,95.19,1.0,2.45,experimental,54.142,0.2398,0.187,X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
5ETI,X-RAY DIFFRACTION,2.89,57.44,"VAPOR DIFFUSION, SITTING DROP",,3.5 M Na Formate pH 7.0,293.0,2015-11-17,2016-01-20,5ETI,2918.0,1.0,366.0,51.0,,42.03,1.0,2.8,experimental,,0.2253,0.1751,Structure of dead kinase MAPK14
5OMG,X-RAY DIFFRACTION,2.38,48.43,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2, 
20-30 % PEG4000,
50 mM BOG",293.15,2017-07-31,2019-03-13,5OMG,2942.0,1.0,360.0,172.0,,41.96,1.0,2.0,experimental,34.297,0.24519,0.18241,p38alpha in complex with pyrazolobenzothiazine inhibitor COXP4M12
5OMH,X-RAY DIFFRACTION,2.27,45.81,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2,
20-30 % PEG4000,
50 mM BOG",293.15,2017-07-31,2019-03-13,5OMH,2547.0,1.0,360.0,7.0,,41.69,1.0,2.5,experimental,63.876,0.27716,0.215,p38alpha in complex with pyrazolobenzothiazine inhibitor COXH11
6ZWP,X-RAY DIFFRACTION,2.21,44.23,"VAPOR DIFFUSION, SITTING DROP",5.8,"15% MMW PegSmear
0.1 M MES",278.0,2020-07-28,2020-08-12,6ZWP,2708.0,1.0,361.0,97.0,,41.99,1.0,1.9,experimental,46.639,0.2511,0.213,p38a bound with SR348
6ATH,X-RAY DIFFRACTION,2.73,55.0,"VAPOR DIFFUSION, HANGING DROP",7.2,"HEPES, Lithium Sulfate",291.15,2017-08-29,2018-09-12,6ATH,5178.0,3.0,631.0,399.0,,72.55,3.0,1.82,experimental,28.0,0.1873,0.1711,Cdk2/cyclin A/p27-KID-deltaC
6WOG,X-RAY DIFFRACTION,2.13,42.36,"VAPOR DIFFUSION, HANGING DROP",4.5,"200 mM Li2SO4, 18% (w/v) PEG 8000, 5% (v/v) isopropanol, 100mM NaAc, pH 4.5",293.0,2020-04-24,2021-03-03,6WOG,1268.0,1.0,169.0,121.0,,20.38,1.0,1.5,experimental,17.211,0.1873,0.1506,Diphosphoinositol polyphosphate phosphohydrolase 1 (DIPP1/NUDT3) in complex with 5-methylenebisphosphonate inositol pentakisphosphate (5-PCP-IP5)
4ZXT,X-RAY DIFFRACTION,2.28,46.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.1-1.3 M ammonium sulfate, 2% PEG500 MME, 0.1 M HEPES/NaOH, crystals soaked in precipitant solution containing 2.5 mM catechol in 2.5% DMSO for one week",293.0,2015-05-20,2016-05-25,4ZXT,3205.0,1.0,360.0,299.0,,42.11,1.0,2.0,experimental,,0.1834,0.153,Complex of ERK2 with catechol
5K4I,X-RAY DIFFRACTION,2.28,46.05,EVAPORATION,7.5,"10% PEG3350, 0.2 M proline, 0.1 M HEPES pH 7.5",277.0,2016-05-20,2016-07-06,5K4I,3032.0,1.0,352.0,251.0,,41.39,1.0,1.76,experimental,,0.2317,0.1809,Crystal Structure of ERK2 in complex with compound 22
8ERD,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, HANGING DROP",7.5,"15-20% PEG 4K, 
50mM Hepes pH 7.5 
50mM Ammonium Acetate",292.0,2022-10-11,2023-10-18,8ERD,2513.0,1.0,299.0,197.0,,34.54,1.0,1.33,experimental,33.97,0.2302,0.1979,Cyclin-free CDK2 in complex with Cpd17
9FR2,X-RAY DIFFRACTION,2.25,45.36,"VAPOR DIFFUSION, SITTING DROP",,25% PEG3350 -- 0.1M HEPES pH 7.5,293.15,2024-06-18,2024-09-11,9FR2,2385.0,1.0,299.0,133.0,,34.47,1.0,1.6,experimental,31.08,0.22259,0.18605,CDK2 in complex with WEIZ-WX-04-001
6V6L,X-RAY DIFFRACTION,2.12,42.06,"VAPOR DIFFUSION, HANGING DROP",,7-12% (w:v) PEG 6000 and 5-8% MPD (v:v),290.0,2019-12-05,2020-01-15,6V6L,3150.0,1.0,420.0,423.0,,47.51,1.0,2.19,experimental,29.4,0.234,0.203,"Co-structure of human glycogen synthase kinase beta with 1-(6-((2-((6-amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one"
6FEB,X-RAY DIFFRACTION,2.51,50.99,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES",293.0,2017-12-31,2019-04-10,6FEB,5772.0,2.0,728.0,302.0,,86.99,1.0,1.93,experimental,39.066,0.19608,0.1599,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-1086
8PO2,X-RAY DIFFRACTION,2.16,42.97,"VAPOR DIFFUSION, SITTING DROP",,"PEG 8K 15%w/v pH 0, PCPT 0.1M pH 8.5",293.15,2023-07-03,2024-06-05,8PO2,4810.0,3.0,996.0,228.0,,114.29,1.0,2.28,experimental,44.88,0.2458,0.1936,"Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 33 bound to EGFRinsNPG [V948R]"
8J2P,X-RAY DIFFRACTION,2.61,52.86,"VAPOR DIFFUSION, HANGING DROP",6.5,20% PEG 3350,291.0,2023-04-15,2023-09-20,8J2P,6736.0,2.0,856.0,318.0,,94.99,1.0,2.09,experimental,,0.2346,0.1912,Crystal structure of PML B-box2
8KA0,X-RAY DIFFRACTION,2.38,48.25,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris-HCl (pH 8.5), 32.5% (w/v) PEG 4000 and 0.15 M sodium acetate.
10 mM NAD+ soaking",293.0,2023-08-02,2024-07-10,8KA0,18350.0,8.0,2268.0,616.0,,259.63,2.0,2.35,experimental,55.8,0.263,0.217,Crystal structure of Vibrio vulnificus RID-dependent transforming NADase domain (RDTND)/calmodulin-binding domain of Rho inactivation domain (RID-CBD) complexed with Ca2+-bound calmodulin and a nicotinamide adenine dinucleotide (NAD+)
6OAV,X-RAY DIFFRACTION,2.31,46.85,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.15,2019-03-18,2020-03-25,6OAV,2181.0,1.0,289.0,103.0,,33.44,1.0,1.939,experimental,,0.236,0.2001,JAK2 JH2 in complex with JAK146
6OBB,X-RAY DIFFRACTION,2.23,44.9,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.15,2019-03-20,2020-03-25,6OBB,2217.0,1.0,289.0,118.0,,33.49,1.0,1.904,experimental,,0.2252,0.1958,JAK2 JH2 in complex with JAK170
6OBL,X-RAY DIFFRACTION,2.17,43.33,"VAPOR DIFFUSION, HANGING DROP",,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.15,2019-03-21,2020-03-25,6OBL,2068.0,1.0,289.0,42.0,,33.51,1.0,2.061,experimental,,0.239,0.1975,JAK2 JH2 in complex with JAK168
6XJK,X-RAY DIFFRACTION,2.32,47.0,VAPOR DIFFUSION,,"0.1M TRIS, PH 8.0 0.2M SODIUM ACETATE, 0.001 M TCEP, 12-24% PEG 4,000",277.15,2020-06-24,2020-11-25,6XJK,2074.0,1.0,289.0,62.0,1.0,33.52,1.0,2.02350796538,experimental,28.526027831,0.272510925489,0.22727044529,JAK2 JH2 in complex with JAK067
6MOB,X-RAY DIFFRACTION,3.34,63.2,"VAPOR DIFFUSION, SITTING DROP",,"12 mg/mL Kit1 protein in 20 mM Tris pH 8.0, 0.25 M sodium chloride, 5 mM imidazole, 5 mM DTT, 1 mM EDTA, crystallant: 2.5 M ammonium nitrate, 0.1 M sodium acetate, pH 4.6, 5-fold molar excess DP2976, Crystal ID 204905d1",289.0,2018-10-04,2019-07-31,6MOB,2888.0,1.0,312.0,311.0,,36.67,1.0,1.8,experimental,25.35,0.21,0.181,Crystal structure of KIT1 in complex with DP2976 via co-crystallization
6QNS,X-RAY DIFFRACTION,2.6,53.9,"VAPOR DIFFUSION, SITTING DROP",,"20% v/v PEG6000, 0.1 M MES pH 6.0, 0.2 M sodium chloride",294.15,2019-02-12,2020-02-26,6QNS,3986.0,2.0,463.0,85.0,,56.95,2.0,2.4,experimental,65.14,0.22872,0.19945,Crystal structure of the binding domain of Botulinum Neurotoxin type B mutant I1248W/V1249W in complex with human synaptotagmin 1 and GD1a receptors
6VKO,X-RAY DIFFRACTION,2.61,52.82,"VAPOR DIFFUSION, SITTING DROP",6.5,"2M Ammonium Sulfate, Bis-Tris pH6.5",298.0,2020-01-21,2020-06-17,6VKO,10970.0,4.0,1488.0,31.0,3.0,169.38,1.0,2.8,experimental,90.658,0.3122,0.2843,Crystal Structure of human PARP-1 CAT domain bound to inhibitor UKTT15
6VKQ,X-RAY DIFFRACTION,2.61,52.84,"VAPOR DIFFUSION, SITTING DROP",8.0,"2M Ammonium Sulfate, 5% PEG 400, 100 mM Tris pH 8",298.0,2020-01-21,2020-06-17,6VKQ,10910.0,4.0,1488.0,,3.0,169.59,1.0,2.9,experimental,78.53,0.3531,0.3233,Crystal Structure of human PARP-1 CAT domain bound to inhibitor EB-47
5C8M,X-RAY DIFFRACTION,3.74,67.12,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292.0,2015-06-25,2015-10-28,5C8M,2457.0,1.0,331.0,,,37.98,1.0,2.9,experimental,91.6,0.252,0.2087,"EGFR kinase domain mutant ""TMLR"" with compound 17"
5CAQ,X-RAY DIFFRACTION,3.46,64.46,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, erthylene glycol",292.0,2015-06-29,2015-10-28,5CAQ,2533.0,1.0,331.0,79.0,,38.04,1.0,2.5,experimental,58.96,0.2244,0.1831,"EGFR kinase domain mutant ""TMLR"" with compound 33"
5UGB,X-RAY DIFFRACTION,3.51,64.99,"VAPOR DIFFUSION, SITTING DROP",,"Buffer: 0.1 M MES (pH 6.90)
Salt: 1.2 M Potassium sodium tartrate tetrahydrate",294.0,2017-01-07,2017-03-22,5UGB,2492.0,1.0,329.0,8.0,,37.93,1.0,2.53,experimental,63.9,0.251,0.215,Crystal structure of the EGFR kinase domain in complex with 4-(4-{[2-{[(3S)-1-acetylpyrrolidin-3-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl]amino}phenyl)-1-methylpiperazin-1-ium
6VH4,X-RAY DIFFRACTION,3.51,65.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.4 M Sodium Citrate, 0.1 M MES",298.0,2020-01-09,2020-04-22,6VH4,2405.0,1.0,327.0,33.0,,37.79,1.0,2.8,experimental,58.1335,0.23,0.1952,Wild type EGFR in complex with LN2380
5UQ0,X-RAY DIFFRACTION,2.4,48.83,"VAPOR DIFFUSION, HANGING DROP",,"20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate",291.0,2017-02-05,2017-02-22,5UQ0,3972.0,2.0,622.0,7.0,,71.09,1.0,2.3,experimental,52.737,0.29351,0.2343,"FGFR1 kinase domain complex with fragment 2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxamide"
6C18,X-RAY DIFFRACTION,2.3,46.56,"VAPOR DIFFUSION, HANGING DROP",,"20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate",291.0,2018-01-04,2019-01-16,6C18,4214.0,2.0,622.0,17.0,,71.99,1.0,2.3,experimental,44.145,0.26668,0.22269,FGFR1 kinase complex with inhibitor SN37115
6C19,X-RAY DIFFRACTION,2.24,45.19,"VAPOR DIFFUSION, HANGING DROP",,"20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate",291.0,2018-01-04,2019-01-16,6C19,4318.0,2.0,622.0,88.0,,71.93,1.0,2.12,experimental,34.98,0.23852,0.20545,FGFR1 kinase complex with inhibitor SN36985
6C1B,X-RAY DIFFRACTION,2.48,50.38,"VAPOR DIFFUSION, HANGING DROP",,"20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate",291.0,2018-01-04,2019-01-16,6C1B,4201.0,2.0,622.0,67.0,,71.96,1.0,2.0,experimental,45.888,0.25504,0.22045,FGFR1 kinase complex with inhibitor SN37118
6C1C,X-RAY DIFFRACTION,2.48,50.35,"VAPOR DIFFUSION, HANGING DROP",,"20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate",291.0,2018-01-04,2019-01-16,6C1C,4326.0,2.0,622.0,54.0,,72.07,1.0,2.15,experimental,42.59,0.27,0.226,FGFR1 kinase complex with inhibitor SN37116
6C1O,X-RAY DIFFRACTION,2.36,47.98,"VAPOR DIFFUSION, HANGING DROP",,"20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate",291.0,2018-01-05,2019-01-16,6C1O,4171.0,2.0,622.0,14.0,,72.12,1.0,2.29,experimental,60.93,0.276,0.237,FGFR1 kinase domain complexed with FIIN-1
7E73,X-RAY DIFFRACTION,2.42,49.3,"VAPOR DIFFUSION, SITTING DROP",7.0,"100mM HEPES pH 7.0, 1.4M ammonium sulfate, 13% glycerol",291.0,2021-02-25,2022-03-02,7E73,2939.0,1.0,363.0,102.0,,41.8,1.0,2.28,experimental,32.96,0.2392,0.1781,Crystal structure of human ERK2 mutant (Y36H)
7E75,X-RAY DIFFRACTION,2.39,48.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES/MOPS pH 7.5, 20% (v/v) PEGMME 550, 10% (w/v) PEG 20000, 20mM D-glycine, 20mM D-lysine",291.0,2021-02-25,2022-03-02,7E75,2923.0,1.0,363.0,71.0,,41.77,1.0,2.481,experimental,37.69,0.2656,0.1839,Crystal structure of human ERK2 mutant (G37C)
6Z4B,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"27.5 % PEG3350, 100 mM MgSO4, 4 % ethylen glycole, 4.7 mg/mL EGFR-T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2020-05-25,2020-11-11,6Z4B,4325.0,2.0,666.0,25.0,,78.66,1.0,2.5,experimental,59.2924,0.2513,0.2207,Crystal Structure of EGFR-T790M/V948R in Complex with Osimertinib and EAI045
6Z4D,X-RAY DIFFRACTION,,34.9,"VAPOR DIFFUSION, HANGING DROP",,"27.5 % PEG3350, 100 mM MgSO4, 2 % ethylen glycole, 5.0 mg/mL EGFR-T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2020-05-25,2020-11-11,6Z4D,4500.0,2.0,666.0,174.0,,77.59,1.0,2.0,experimental,52.2716,0.2214,0.1931,Crystal Structure of EGFR-T790M/V948R in Complex with Mavelertinib and EAI001
7A2A,X-RAY DIFFRACTION,1.91,35.73,"VAPOR DIFFUSION, HANGING DROP",,"25 % PEG3350, 100 mM MgSO4, 4 % ethylen glycole, 5.0 mg/mL EGFR-T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2020-08-17,2020-11-11,7A2A,4385.0,2.0,666.0,116.0,,77.9,1.0,1.9,experimental,57.8185,0.2171,0.1943,Crystal Structure of EGFR-T790M/V948R in Complex with Spebrutinib and EAI001
7PG5,X-RAY DIFFRACTION,2.38,48.25,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG 5K MME (w/v), 160 nM KSCN, 100 mM sodium cacodylate pH 6.5.",293.15,2021-08-13,2022-08-24,7PG5,10787.0,2.0,1355.0,152.0,,159.1,2.0,2.20029074868,experimental,66.2856298507,0.24560820669,0.19642042793,Crystal Structure of PI3Kalpha
6WXN,X-RAY DIFFRACTION,2.11,41.72,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M BisTris, 25% PEG-3350",298.0,2020-05-11,2021-05-19,6WXN,9883.0,4.0,1312.0,244.0,,151.76,1.0,1.76,experimental,35.3366,0.2355,0.208,EGFR(T790M/V948R) in complex with LN3844
5YU9,X-RAY DIFFRACTION,2.2,44.04,"VAPOR DIFFUSION, HANGING DROP",5.0,"0.1 M sodium citrate (pH 5.0), 12% PEG 10000, 3% dioxane, 5 mM TCEP",293.0,2017-11-21,2017-12-27,5YU9,10782.0,4.0,1324.0,950.0,,152.47,1.0,1.95,experimental,,0.2215,0.2019,Crystal structure of EGFR 696-1022 T790M in complex with Ibrutinib
8SWE,X-RAY DIFFRACTION,2.77,55.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"27 % PEG 4000, 0.1 M Hepes pH7.5, 0.252 M Ammonium Sulfate, 0.05 M GSH GSSG",291.15,2023-05-18,2024-02-14,8SWE,4844.0,2.0,632.0,153.0,,73.72,1.0,2.24,experimental,46.73,0.2496,0.2112,FGFR2 Kinase Domain Bound to Reversible Inhibitor Cmpd 3
4RWI,X-RAY DIFFRACTION,2.33,47.24,"VAPOR DIFFUSION, HANGING DROP",6.4,"0.1 M sodium cacodylate pH 6.4, 30% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-12-04,2015-04-15,4RWI,4613.0,2.0,634.0,82.0,,72.52,1.0,2.292,experimental,34.5232,0.2362,0.1854,"Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M), apo"
4RWJ,X-RAY DIFFRACTION,2.34,47.35,"VAPOR DIFFUSION, HANGING DROP",6.4,"0.1 M sodium cacodylate pH 6.4, 22% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-12-04,2015-04-22,4RWJ,4692.0,2.0,634.0,87.0,,73.38,1.0,2.489,experimental,32.6641,0.25,0.1999,"Crystal Structure of FGFR1 (C488A, C584S) in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)"
4RWK,X-RAY DIFFRACTION,2.29,46.21,"VAPOR DIFFUSION, HANGING DROP",6.6,"0.1 M MES pH 6.6, 34% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-12-04,2015-04-15,4RWK,4559.0,2.0,634.0,7.0,,73.47,1.0,2.982,experimental,32.804,0.2986,0.2376,"Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M) in complex with N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)"
4RWL,X-RAY DIFFRACTION,2.59,52.59,"VAPOR DIFFUSION, HANGING DROP",6.6,"0.1 M sodium cacodylate pH 6.6, 34% PEG 8000, 0.2 M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-12-04,2015-04-15,4RWL,4451.0,2.0,634.0,50.0,,72.99,1.0,2.193,experimental,47.8932,0.2555,0.2068,"Crystal structure of FGFR1 (C488A, C584C) in complex with 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide (E3810)"
5UR1,X-RAY DIFFRACTION,2.47,50.13,"VAPOR DIFFUSION, HANGING DROP",,"20% MPEG 5000, 0.1 M sodium cacodylate pH 7.5, 0.2 M ammonium sulfate",291.0,2017-02-09,2017-05-31,5UR1,4301.0,2.0,622.0,52.0,,71.99,1.0,2.2,experimental,41.735,0.27658,0.22715,FGFR1 kinase domain complex with SN37333 in reversible binding mode
5Z0S,X-RAY DIFFRACTION,2.71,54.58,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG",277.0,2017-12-20,2018-12-26,5Z0S,4556.0,2.0,616.0,57.0,,70.99,1.0,2.45,experimental,41.6378,0.2747,0.2252,Crystal structure of FGFR1 kinase domain in complex with a novel inhibitor
8PNZ,X-RAY DIFFRACTION,3.32,62.97,"VAPOR DIFFUSION, SITTING DROP",,0.68M Na3Cit pHed to pH 7.5 using conc HCl,293.15,2023-07-03,2024-06-05,8PNZ,2529.0,1.0,329.0,10.0,,37.94,1.0,2.51,experimental,79.97,0.2845,0.2259,"Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 16 bound to EGFR"
8PO0,X-RAY DIFFRACTION,3.79,67.51,"VAPOR DIFFUSION, SITTING DROP",,Sodium Citrate,293.15,2023-07-03,2024-06-05,8PO0,2503.0,1.0,332.0,3.0,,38.18,1.0,2.523,experimental,96.52,0.3755,0.3151,"Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 12 bound to EGFRinsNPG"
7ZYM,X-RAY DIFFRACTION,3.45,64.3,"VAPOR DIFFUSION, HANGING DROP",,"1.4 K-Na-tartrate, 100 mM Na-MES (pH 6.5),
3.5 mg/mL EGFR-WT (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP) pH 8.0) 1 ul reservoir + 1 ul solution",293.0,2022-05-25,2023-05-03,7ZYM,2548.0,1.0,333.0,22.0,,38.3,1.0,2.5,experimental,70.43,0.2237,0.1923,Crystal Structure of EGFR-T790M/C797S in Complex with Brigatinib
6X0S,X-RAY DIFFRACTION,2.64,53.46,"VAPOR DIFFUSION, HANGING DROP",,"18% PEG3350, 200 mM lithium sulfate, 0.7 mM cadmium chloride, 100 mM Bis-Tris, pH 6.3",291.0,2020-05-17,2021-05-19,6X0S,5818.0,3.0,777.0,322.0,21.0,85.74,1.0,1.898,experimental,19.46,0.2509,0.2146,"Structure of human plasma factor XIIa in complex with (2S)-4-(5-chloro-1,3-benzoxazol-2-yl)-1-(N,3-dicyclohexyl-D-alanyl)-N-[(thiophen-2-yl)methyl]piperazine-2-carboxamide (compound 7)"
6X0T,X-RAY DIFFRACTION,2.64,53.44,"VAPOR DIFFUSION, HANGING DROP",6.3,"18% PEG3350, 200 mM lithium sulfate, 0.7 mM cadmium chloride, 100 mM Bis-Tris, pH 6.3",291.0,2020-05-17,2021-05-19,6X0T,5816.0,3.0,777.0,303.0,21.0,85.77,1.0,1.388,experimental,10.82,0.3112,0.2889,"Structure of human plasma factor XIIa in complex with (2S)-1-(N,3-dicyclohexyl-D-alanyl)-4-[(4R,5S)-4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-yl]-N-[(thiophen-2-yl)methyl]piperazine-2-carboxamide (compound 8h)"
7WQQ,X-RAY DIFFRACTION,2.16,43.07,"VAPOR DIFFUSION, HANGING DROP",,"0.05M Bis-Tris Propane pH 5.0, 0.05M Citric acid, 18% PEG 3350",277.0,2022-01-25,2023-01-25,7WQQ,2060.0,2.0,278.0,142.0,,32.11,2.0,1.9,experimental,38.6659,0.2056,0.166,Retinoic acid receptor alpha mutant - N299H
6CKZ,X-RAY DIFFRACTION,2.01,38.79,"VAPOR DIFFUSION, SITTING DROP",5.4,"1:1 dilution with 0.10 M sodium citrate, pH 5.4, 15.2 % PEG6000, 0.010 M DTT, 0.02% NaN3.",295.0,2018-03-01,2019-03-06,6CKZ,2212.0,3.0,291.0,206.0,,33.58,3.0,1.5,experimental,,0.1714,0.1531,Human caspase-3 in complex with Ac-DW3-KE
6CL0,X-RAY DIFFRACTION,2.0,38.61,"VAPOR DIFFUSION, SITTING DROP",5.0,"1:1 dilution with 0.10 M sodium citrate, pH 5.0, 13.6 % PEG6000, 0.010 M DTT, 0.02% NaN3",295.0,2018-03-01,2019-03-06,6CL0,2366.0,3.0,291.0,249.0,,33.69,3.0,1.5,experimental,,0.164,0.1402,Human caspase-3 in complex with Ac-ATS009-KE
5F9F,X-RAY DIFFRACTION,2.9,57.64,"VAPOR DIFFUSION, HANGING DROP",,"23% (w/v) PEG 3350, 0.3 M NaSCN, 100 mM MOPS (pH 7.8)",293.0,2015-12-09,2016-01-13,5F9F,34918.0,12.0,4314.0,126.0,,525.58,1.0,2.601,experimental,,0.2594,0.2028,Crystal structure of RIG-I helicase-RD in complex with 24-mer blunt-end hairpin RNA
7AAB,X-RAY DIFFRACTION,,,VAPOR DIFFUSION,5.5,"0.4 M ammonium sulfate, 25 % PEG3350, 0.1 M PCTP pH 5.5",293.0,2020-09-04,2021-01-13,7AAB,5507.0,2.0,704.0,21.0,1.0,80.09,1.0,2.8,experimental,66.52,0.224,0.202,Crystal structure of the catalytic domain of human PARP1 in complex with inhibitor EB-47
5JMO,X-RAY DIFFRACTION,2.33,47.2,"VAPOR DIFFUSION, SITTING DROP",,".1 M sodium acetate, pH 5.6, 16-18% PEG 3350",293.15,2016-04-29,2016-12-07,5JMO,9905.0,6.0,1210.0,769.0,8.0,132.68,3.0,1.998,experimental,,0.1971,0.163,X-ray structure of furin in complex with the inhibitory antibody Nb14
7RTG,X-RAY DIFFRACTION,2.17,43.41,"VAPOR DIFFUSION, SITTING DROP",6.9,"0.49 M sodium phosphate monobasic monohydrate, 0.91 M potassium phosphate dibasic, pH 6.9",293.15,2021-08-13,2022-01-12,7RTG,5588.0,2.0,744.0,24.0,,83.76,1.0,2.591,experimental,42.3522,0.2608,0.2014,Crystal Structure of the Human Adenosine Deaminase 1
7S5H,X-RAY DIFFRACTION,1.76,30.01,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% PEG3350, 200mM CaCl2, 100mM MES pH 6",291.0,2021-09-10,2021-11-03,7S5H,2702.0,3.0,439.0,205.0,3.0,48.08,3.0,1.272,experimental,21.53,0.2089,0.2056,PCSK9(deltaCRD) in complex with cyclic peptide 35
4UFD,X-RAY DIFFRACTION,2.46,50.09,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2015-03-16,2016-01-27,4UFD,2720.0,3.0,299.0,307.0,4.0,35.73,3.0,1.429,experimental,19.9,0.1587,0.1336,Thrombin in complex with 4-(((1-((2S)-1-((2R)-2-(benzylsulfonylamino)- 3-phenyl-propanoyl)pyrrolidin-2-yl)-1-oxo-ethyl)amino)methyl) benzamidine
7ZRP,X-RAY DIFFRACTION,2.43,49.47,"VAPOR DIFFUSION, SITTING DROP",,"200 mM Zinc acetate, 100 mM Imidazole pH8.0, 18% PEG3000",292.0,2022-05-04,2022-12-28,7ZRP,2719.0,4.0,340.0,36.0,,39.91,2.0,2.65,experimental,66.088,0.2724,0.2071,2.65 Angstrom crystal structure of Ca/CaM:CaMKIIdelta peptide complex
6E6E,X-RAY DIFFRACTION,2.53,51.44,"VAPOR DIFFUSION, SITTING DROP",7.5,0.1M Magnesium Formate Dihydrate; 15% PEG3350,293.0,2018-07-24,2019-07-31,6E6E,17919.0,8.0,2208.0,435.0,,258.04,1.0,2.15,experimental,46.64,0.2849,0.2499,"DGY-06-116, a novel and selective covalent inhibitor of SRC kinase"
5HG7,X-RAY DIFFRACTION,1.85,33.35,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M (5.0 uL of stock 1.0 M) HEPES (pH 7.50), 0.2 M (2.5 uL of stock 4.0 M) Ammonium sulfate, 10.0 %v/v (5.0 uL of stock 100.0 %v/v) iso-propanol, 20.0 %w/v (20.0 uL of stock 50.0 %w/v) PEG 8000",286.0,2016-01-08,2016-01-27,5HG7,2505.0,1.0,329.0,219.0,,38.11,1.0,1.85,experimental,24.3,0.246,0.215,"EGFR (L858R, T790M, V948R) in complex with 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988)"
8C7W,X-RAY DIFFRACTION,2.66,53.86,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.6M ammonium sulfate, 0.1M tris pH 8.5, 4% glycerol",277.0,2023-01-17,2023-02-08,8C7W,2611.0,1.0,301.0,178.0,,35.92,1.0,2.26,experimental,32.59,0.2392,0.207,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2304
8C7Z,X-RAY DIFFRACTION,2.67,53.9,"VAPOR DIFFUSION, SITTING DROP",8.0,"1.7 M Ammonium sulphate, 0.1M tris pH 8, 8% glycerol",277.0,2023-01-18,2023-02-01,8C7Z,2614.0,1.0,301.0,166.0,,36.17,1.0,2.23,experimental,36.86,0.2613,0.2136,Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound M4K2308
6YIJ,X-RAY DIFFRACTION,2.95,58.37,"VAPOR DIFFUSION, SITTING DROP",8.3,"20% ethylene glycol
21% PEG6K
0.1M tris pH 8.3
0.125M lithium chloride",277.0,2020-04-01,2020-04-15,6YIJ,7177.0,7.0,833.0,224.0,,102.4,1.0,2.2,experimental,44.856,0.2693,0.2022,Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand
6GWE,X-RAY DIFFRACTION,2.8,56.0,"VAPOR DIFFUSION, SITTING DROP",,"25% ethylene glycol
100 mM MES pH 6.2
15% w/v PEG 3350",293.0,2018-06-23,2019-09-25,6GWE,4975.0,4.0,590.0,150.0,8.0,69.82,2.0,2.3,experimental,48.5223,0.244,0.186,Crystal structure of Thrombin bound to P2 macrocycle
5TCD,X-RAY DIFFRACTION,3.69,66.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"sodium iodide, PEG 3350",295.0,2016-09-14,2017-03-22,5TCD,3555.0,1.0,422.0,205.0,,55.64,1.0,2.4,experimental,,0.2081,0.1727,Human alkaline sphingomyelinase (ENPP7) in complex with phosphocholine
6T7H,X-RAY DIFFRACTION,2.88,57.3,"VAPOR DIFFUSION, SITTING DROP",,"18 % w/v PEG 4000 
0.1 M Tris pH 9.0 
0.3 M Sodium acetate trihydrate 
20 % v/v Ethylene glycol",293.0,2019-10-22,2020-09-30,6T7H,5024.0,4.0,590.0,153.0,8.0,69.67,2.0,2.32,experimental,51.097,0.2392,0.1939,Crystal structure of Thrombin in complex with macrocycle N14-PR4-A
7PRJ,X-RAY DIFFRACTION,1.44,,VAPOR DIFFUSION,,"0.01 M Zinc chloride, 0.1 M Sodium acetate pH 5.0, 20 % (w/v) PEG 6000",292.15,2021-09-21,2022-10-05,7PRJ,522.0,1.0,71.0,59.0,2.0,8.66,1.0,1.2,experimental,20.8,0.2385,0.1922,Factor XII Fibronectin type II (FXII FnII) domain
8S3R,X-RAY DIFFRACTION,2.53,51.36,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG6000, 0.10 M KCL, 0.10 M MES",293.0,2024-02-20,2024-07-03,8S3R,8929.0,2.0,1187.0,69.0,,137.99,2.0,2.28,experimental,74.287,0.26963,0.20308,HUMAN PI3KDELTA IN COMPLEX WITH PYRIDAZINONE INHIBITOR 7
5MK2,X-RAY DIFFRACTION,2.15,42.79,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.2 M CaCl2, 0.1 M MES pH 6.0, 20% PEG 6K",277.0,2016-12-02,2017-08-16,5MK2,6498.0,3.0,742.0,666.0,,83.86,2.0,1.7,experimental,,0.2032,0.1692,Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (CHMP4B peptide complex structure)
8QJT,X-RAY DIFFRACTION,2.06,40.22,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 6K, 6% ethylene glycol, 10 mM ZnCl2",295.0,2023-09-13,2024-01-17,8QJT,3047.0,3.0,369.0,143.0,,44.78,1.0,2.568,experimental,58.14,0.263,0.2025,BRM (SMARCA2) Bromodomain in complex with ligand 10
8CIE,X-RAY DIFFRACTION,2.12,41.91,VAPOR DIFFUSION,,"0.1 M tri-sodium citrate, 1.1 M lithium sulfate, 0.4 M ammonium sulfate",293.0,2023-02-09,2023-06-14,8CIE,2260.0,1.0,304.0,37.0,,35.68,1.0,2.2,experimental,58.18,0.3098,0.2876,Crystal structure of the human CDKL5 kinase domain with compound YL-354
6P68,X-RAY DIFFRACTION,3.28,62.54,"VAPOR DIFFUSION, HANGING DROP",6.5,"1:1 mix of protein + reservoir
Protein at ~15 mg/mL formulated in: 20mM Tris pH 8, 20mM NaCl, 2mM TCEP
Reservoir:
14-18% PEG 10K
0.3 M (NH4)2SO4
0.1 M MES pH 6.5
5% ethylene glycol",277.0,2019-06-03,2019-06-19,6P68,6913.0,3.0,927.0,4.0,,107.07,1.0,2.9,experimental,108.867,0.30265,0.22561,Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 22.
5V61,X-RAY DIFFRACTION,2.91,57.69,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 45% v/v polypropylene glycol P400",277.0,2017-03-15,2017-07-26,5V61,3197.0,2.0,384.0,92.0,,45.7,2.0,2.2,experimental,60.12,0.212,0.176,Phospho-ERK2 bound to bivalent inhibitor SBP2
7A6K,X-RAY DIFFRACTION,1.76,29.93,"VAPOR DIFFUSION, HANGING DROP",,"25.0 % PEG3350, 100 mM MgSO4, 4 % ethylen glycole, 6.8 mg/mL EGFR-T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2020-08-25,2022-02-23,7A6K,8458.0,4.0,1332.0,137.0,,154.88,1.0,2.0,experimental,51.6092,0.2202,0.1919,Crystal Structure of EGFR-T790M/V948R in Complex with TAK-788
6RLN,X-RAY DIFFRACTION,2.35,47.66,"VAPOR DIFFUSION, SITTING DROP",6.5,"100mM MES (pH 6.5), 25% PEG 8k",277.0,2019-05-02,2019-07-03,6RLN,4360.0,2.0,606.0,25.0,,69.99,1.0,2.87,experimental,99.26,0.2318,0.1939,Crystal structure of RIP1 kinase in complex with GSK3145095
6G3O,X-RAY DIFFRACTION,2.35,47.7,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M TRIS, pH 9.15, 54 %(w/v) PEG 400",293.0,2018-03-26,2018-06-27,6G3O,9438.0,3.0,1110.0,469.0,,129.53,1.0,2.27,experimental,53.51,0.219,0.172,"Crystal structure of human HDAC2 in complex with (R)-6-[3,4-Dioxo-2-(4-trifluoromethoxy-phenylamino)-cyclobut-1-enylamino]-heptanoic acid hydroxyamide"
7FIC,X-RAY DIFFRACTION,2.88,57.34,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2 M lithium sulfate, 0.1 M BIS-TRIS pH 5.5, 25% w/v PEG 3350",298.0,2021-07-31,2022-06-08,7FIC,2035.0,1.0,265.0,6.0,,31.31,1.0,2.32,experimental,90.24,0.274,0.2356,Reversible lysine-targeted probes reveal residence time-based kinase selectivity in vivo
5FOE,X-RAY DIFFRACTION,2.15,42.82,,,,,2015-11-19,2016-01-27,5FOE,7818.0,2.0,1000.0,531.0,10.0,116.98,1.0,1.98,experimental,35.795,0.24607,0.20044,Crystal structure of the C. elegans Protein O-fucosyltransferase 2 (CePOFUT2) double mutant (R298K-R299K) in complex with GDP and the human TSR1 from thrombospondin 1
5DC4,X-RAY DIFFRACTION,1.88,34.46,"VAPOR DIFFUSION, HANGING DROP",7.83,0.1M Imidazole pH 7.83 and 3.5M NaCl,291.0,2015-08-23,2016-03-02,5DC4,1717.0,2.0,218.0,206.0,,24.09,2.0,1.48,experimental,15.81,0.18965,0.14447,"CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL A"
5DC9,X-RAY DIFFRACTION,2.91,57.71,"VAPOR DIFFUSION, HANGING DROP",8.5,0.1M Imidazole pH 8.5 and 3.4M NaCl,292.0,2015-08-23,2016-03-02,5DC9,1829.0,2.0,218.0,232.0,,24.6,2.0,1.56,experimental,18.977,0.1706,0.13652,"CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL B"
7ZYU,X-RAY DIFFRACTION,3.35,63.29,VAPOR DIFFUSION,,"3.6 M sodium formate, Bis-Tris 0.1M pH=6.7, 10% w/v Glycerol, 30% w/v 1,8-Diaminooctane(additive).",293.0,2022-05-25,2022-06-01,7ZYU,2054.0,2.0,272.0,10.0,1.0,29.83,2.0,2.43,experimental,78.11,0.2498,0.2166,HDAC6 ZnF domain inhibitor - DARPin (Designed Ankyrin repeat protein) F10
4TWP,X-RAY DIFFRACTION,3.37,63.55,"VAPOR DIFFUSION, SITTING DROP",7.0,"0.1 M HEPES (pH 7.00)
15.0 %w/v PEG 3350
0.01 M Magnesium chloride hexahydrate
0.0050 M Nickel(II) chloride hexahydrate
5.0 %v/v Glycerol",286.15,2014-07-01,2015-02-11,4TWP,4617.0,2.0,542.0,189.0,,63.91,1.0,2.4,experimental,58.02,0.2414,0.2117,The crystal structure of human abl1 T315I gatekeeper mutant kinase domain in complex with axitinib
4WA9,X-RAY DIFFRACTION,3.09,60.15,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.1 M Ammonium Chloride
20.0 %w/v PEG 3350
5.0 %v/v Ethylene glycol",294.15,2014-08-28,2015-02-11,4WA9,4556.0,2.0,572.0,305.0,,66.85,1.0,2.2,experimental,,0.2123,0.1731,The crystal structure of human abl1 wild type kinase domain in complex with axitinib
6TFU,X-RAY DIFFRACTION,2.3,46.52,"VAPOR DIFFUSION, HANGING DROP",,"32.5 % PEG3350, 100 mM MgSO4, 3 % ethylen glycole 7.2 mg/mL EGFR T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2019-11-14,2020-09-30,6TFU,4200.0,2.0,666.0,69.0,,77.29,1.0,2.0,experimental,55.8425,0.233,0.2017,Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 14d
6TFV,X-RAY DIFFRACTION,2.3,46.44,"VAPOR DIFFUSION, HANGING DROP",,"27.5 % PEG3350, 100 mM MgSO4, 4 % ethylen glycole 7.0 mg/mL EGFR T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2019-11-14,2020-09-30,6TFV,4649.0,2.0,666.0,251.0,,77.65,1.0,1.5,experimental,28.7298,0.2028,0.1827,Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18b
6TFW,X-RAY DIFFRACTION,2.29,46.19,"VAPOR DIFFUSION, HANGING DROP",,"30 % PEG3350, 100 mM MgSO4, 4 % ethylen glycole 7.0 mg/mL EGFR T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2019-11-14,2020-09-30,6TFW,4265.0,2.0,666.0,55.0,,77.7,1.0,2.0,experimental,58.5162,0.2447,0.2229,Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18d
6TFY,X-RAY DIFFRACTION,2.32,47.08,"VAPOR DIFFUSION, HANGING DROP",,"30 % PEG3350, 100 mM MgSO4, 3 % ethylen glycole 7.0 mg/mL EGFR T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2019-11-14,2020-09-30,6TFY,4558.0,2.0,666.0,210.0,,77.55,1.0,1.7,experimental,42.3012,0.2119,0.1923,Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 18c
6TFZ,X-RAY DIFFRACTION,2.31,46.83,"VAPOR DIFFUSION, HANGING DROP",,"30 % PEG3350, 100 mM MgSO4, 4 % ethylen glycole 7.5 mg/mL EGFR T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2019-11-14,2020-09-30,6TFZ,4593.0,2.0,666.0,218.0,,77.76,1.0,1.8,experimental,34.9242,0.2065,0.1741,Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 19
6TG0,X-RAY DIFFRACTION,2.28,46.05,"VAPOR DIFFUSION, HANGING DROP",,"27.5 % PEG3350, 100 mM MgSO4, 3 % ethylen glycole 7.0 mg/mL EGFR T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2019-11-14,2020-09-30,6TG0,4777.0,2.0,666.0,348.0,,77.71,1.0,1.5,experimental,24.5292,0.1875,0.1737,Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21a
6TG1,X-RAY DIFFRACTION,2.39,48.58,"VAPOR DIFFUSION, HANGING DROP",,"27.5 % PEG3350, 100 mM MgSO4, 2 % ethylen glycole 7.0 mg/mL EGFR T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2019-11-14,2020-09-30,6TG1,4576.0,2.0,666.0,225.0,,77.95,1.0,1.6,experimental,39.9919,0.1976,0.1815,Crystal Structure of EGFR T790M/V948R in Complex with Covalent Pyrrolopyrimidine 21b
8D73,X-RAY DIFFRACTION,2.12,42.11,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.10 M sodium acetate, pH 5.8, 0.30 M potassium acetate, 15% glycerol, 9% PEG 8000",285.0,2022-06-07,2022-07-27,8D73,5741.0,2.0,696.0,674.0,,80.6,1.0,2.17,experimental,50.276,0.2853,0.1914,Crystal Structure of EGFR LRTM with compound 7
8D76,X-RAY DIFFRACTION,2.14,42.45,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1 M sodium acetate pH 5.3, 0.2 M potassium acetate, 3% PEG 8000.",285.0,2022-06-07,2022-07-27,8D76,5778.0,2.0,696.0,609.0,,81.24,1.0,2.4,experimental,61.506,0.26,0.156,Crystal Structure of EGFR LRTM with compound 24
7BPZ,X-RAY DIFFRACTION,2.8,56.1,VAPOR DIFFUSION,,"0.1 M Tris (pH 8.5), 25 %(w/v) PEG3350",277.0,2020-03-23,2020-11-11,7BPZ,4384.0,4.0,576.0,8.0,,66.13,2.0,2.43,experimental,62.7159,0.2421,0.2009,X-ray structure of human PPARalpha ligand binding domain-bezafibrate-SRC1 coactivator peptide co-crystals obtained by soaking
7BQ0,X-RAY DIFFRACTION,2.83,56.53,VAPOR DIFFUSION,,"0.1M Tris (pH 8.5), 25 %(w/v) PEG3350",277.0,2020-03-23,2020-11-11,7BQ0,4839.0,4.0,576.0,200.0,,66.68,2.0,1.771,experimental,34.8344,0.2173,0.1899,X-ray structure of human PPARalpha ligand binding domain-fenofibric acid-SRC1 coactivator peptide co-crystals obtained by delipidation and co-crystallization
5XDK,X-RAY DIFFRACTION,3.4,63.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.07 M HEPES pH7.5, 0.9 M tri-sodium citrate, 5 mM TCEP.",293.0,2017-03-28,2017-12-13,5XDK,2544.0,1.0,331.0,107.0,,38.21,1.0,2.346,experimental,,0.2482,0.2171,Crystal structure of EGFR 696-1022 T790M in complex with CO-1686
5XDL,X-RAY DIFFRACTION,3.26,62.32,"VAPOR DIFFUSION, HANGING DROP",7.8,"0.1 M HEPES pH 7.8, 40% PEG 400, 0.15 M NaCl, 5 mM tris(2-carboxyethyl)-phosphine (TCEP)",293.0,2017-03-28,2017-12-13,5XDL,2343.0,1.0,331.0,19.0,,38.24,1.0,2.7,experimental,,0.2558,0.2093,Crystal structure of EGFR 696-1022 L858R in complex with CO-1686
4Y6L,X-RAY DIFFRACTION,2.33,47.23,"VAPOR DIFFUSION, SITTING DROP",,PEG 3350,293.0,2015-02-13,2016-01-06,4Y6L,5057.0,4.0,600.0,522.0,,68.4,2.0,1.6,experimental,16.193,0.23241,0.20712,Human SIRT2 in complex with myristoylated peptide (H3K9myr)
8PO1,X-RAY DIFFRACTION,3.43,64.13,"VAPOR DIFFUSION, SITTING DROP",,"PEG 8K 10%w/v pH 0, NH4I 0.2M pH 0, PCPT 0.1M pH 7.5",293.15,2023-07-03,2024-06-05,8PO1,2409.0,1.0,332.0,142.0,,40.85,1.0,2.11,experimental,46.22,0.2748,0.2519,"Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 22 bound to EGFRinsNPG [V948R]"
8PO3,X-RAY DIFFRACTION,2.15,42.66,"VAPOR DIFFUSION, SITTING DROP",,"PEG 8K 12%w/v pH 0, PCPT 0.1M pH 5.5",293.15,2023-07-03,2024-06-05,8PO3,2510.0,1.0,330.0,224.0,,38.12,1.0,2.13,experimental,23.67,0.2688,0.2191,"Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 18 bound to EGFR[V948R]"
5FED,X-RAY DIFFRACTION,3.44,64.0,"VAPOR DIFFUSION, SITTING DROP",7.9,"1.35M potassium sodium tartrate, 0.1M HEPES pH 7.9",293.0,2015-12-16,2016-07-27,5FED,2373.0,1.0,328.0,27.0,,37.83,1.0,2.651,experimental,,0.2175,0.1849,EGFR kinase domain in complex with a covalent aminobenzimidazole inhibitor.
5FEE,X-RAY DIFFRACTION,3.41,64.0,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.2M potassium sodium tartrate, 0.1M HEPES pH 7.5",294.0,2015-12-16,2016-07-27,5FEE,2353.0,1.0,328.0,11.0,,37.86,1.0,2.7,experimental,,0.2293,0.1881,EGFR kinase domain T790M mutant in complex with a covalent aminobenzimidazole inhibitor.
6JRX,X-RAY DIFFRACTION,3.38,63.59,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH8.5, 40% PEG400, 0.15 M NaCl, 5 mM tris(2-carboxyethyl)-phosphine (TCEP)",298.0,2019-04-06,2020-04-15,6JRX,2498.0,1.0,331.0,64.0,,38.25,1.0,2.201,experimental,,0.2392,0.2094,EGFR T790M/C797S in complex with compound 6i
7AEM,X-RAY DIFFRACTION,3.33,63.03,VAPOR DIFFUSION,7.5,Tris sodium citrate 0.68M,293.0,2020-09-17,2021-04-07,7AEM,2536.0,1.0,346.0,8.0,,39.91,1.0,2.65,experimental,90.01,0.221,0.198,Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series
7KK4,X-RAY DIFFRACTION,2.17,43.39,VAPOR DIFFUSION,,"Salt: 0.2 M Magnesium chloride hexahydrate
Buffer: 0.1 M Tris (pH 8.50)
Precipitant: 30.0 %w/v PEG 4000",294.0,2020-10-27,2021-01-06,7KK4,5601.0,2.0,704.0,160.0,,79.55,1.0,1.96,experimental,52.52,0.266,0.217,Structure of the catalytic domain of PARP1 in complex with olaparib
5KH3,X-RAY DIFFRACTION,2.1,41.38,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291.0,2016-06-14,2016-07-27,5KH3,952.0,1.0,107.0,86.0,,13.22,1.0,1.6,experimental,15.362,0.1907,0.1572,"Crystal structure of fragment (3-(5-Chloro-1,3-benzothiazol-2-yl)propanoic acid) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain"
5KH7,X-RAY DIFFRACTION,2.09,41.11,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291.0,2016-06-14,2016-07-27,5KH7,967.0,1.0,107.0,117.0,,12.37,1.0,1.7,experimental,9.628,0.1827,0.1461,Crystal structure of fragment (3-[6-Oxo-3-(3-pyridinyl)-1(6H)-pyridazinyl]propanoic acid) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6CE6,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",4.6,"2 M Na-formate, 0.2 M Na-acetate pH4.6, 5 % ethylene glycol",291.0,2018-02-11,2018-02-28,6CE6,934.0,1.0,107.0,113.0,,12.47,1.0,1.6,experimental,10.939,0.1961,0.1717,"Structure of HDAC6 zinc-finger ubiquitin binding domain soaked with 3,3'-(benzo[1,2-d:5,4-d']bis(thiazole)-2,6-diyl)dipropionic acid"
6CE8,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",4.6,"2 M Na-formate, 0.2 M Na-acetate pH4.6, 5 % ethylene glycol",291.0,2018-02-11,2018-02-28,6CE8,921.0,1.0,107.0,104.0,,12.32,1.0,1.55,experimental,12.856,0.168,0.1477,Crystal structure of fragment 2-(Benzo[d]thiazol-2-yl)acetic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6CEA,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",4.6,"2 M Na-formate, 0.2 M Na-acetate pH4.6, 5 % ethylene glycol",291.0,2018-02-11,2018-02-28,6CEA,913.0,1.0,107.0,90.0,,12.33,1.0,1.6,experimental,11.377,0.1979,0.1638,Crystal structure of fragment 3-(quinolin-2-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6CEC,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",4.6,"2 M Na-formate, 0.2 M Na-acetate pH4.6, 5 % ethylene glycol",291.0,2018-02-11,2018-02-28,6CEC,888.0,1.0,107.0,69.0,,12.36,1.0,1.55,experimental,15.839,0.186,0.1619,Crystal structure of fragment 3-(3-Methoxy-2-quinoxalinyl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain
6CED,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",4.6,"2 M Na-formate, 0.2 M Na-acetate pH4.6, 5 % ethylene glycol",291.0,2018-02-11,2018-02-28,6CED,882.0,1.0,107.0,72.0,,12.36,1.0,1.7,experimental,18.646,0.1908,0.1528,"Crystal structure of fragment 3-(3-Methyl-4-oxo-3,4-dihydroquinazolin-2-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain"
6CEE,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",4.6,"2 M Na-formate, 0.2 M Na-acetate pH4.6, 5 % ethylene glycol",291.0,2018-02-11,2018-02-28,6CEE,897.0,1.0,107.0,87.0,,12.36,1.0,1.55,experimental,12.359,0.1694,0.153,"Crystal structure of fragment 3-(1-Methyl-2-oxo-1,2-dihydroquinoxalin-3-yl)propionic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain"
5AM8,X-RAY DIFFRACTION,2.95,58.0,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",,2015-03-10,2016-01-13,5AM8,22316.0,8.0,2544.0,1829.0,12.0,302.59,2.0,1.9,experimental,25.005,0.22382,0.18543,Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 4-10
6GN1,X-RAY DIFFRACTION,2.84,56.68,"VAPOR DIFFUSION, HANGING DROP",7.0,"reservoir 0,1 M HEPES pH 7.0, 22% v/v PEG 8000, 8% ethylenglycol, 5mg/ml GSK3B (in 25 mM TRIS, 250 mM NaCl, 10 % Glycerol, pH 8), 1ul reservoir + 1ul protein solution",293.0,2018-05-29,2018-06-20,6GN1,5613.0,2.0,736.0,109.0,,84.32,1.0,2.6,experimental,,0.2589,0.2217,Crystal Structure of Glycogen synthase kinase-3 beta (GSK3B) in Complex with PIK-75
5LJ0,X-RAY DIFFRACTION,3.98,69.06,"VAPOR DIFFUSION, SITTING DROP",,"0.1M trisHCl, pH 7.0-8.0, 1.2-1.5M ammonium sulphate, 20-25% PEG3350,277K",277.0,2016-07-17,2016-08-31,5LJ0,1424.0,1.0,130.0,249.0,,16.33,1.0,1.82,experimental,31.982,0.18256,0.17378,"Crystal structure of human ATAD2 bromodomain in complex with 8-(((3R,4R,5S)-3-((4,4-difluorocyclohexyl)methoxy)-5-methoxypiperidin-4-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1H)-one"
6OIO,X-RAY DIFFRACTION,2.51,50.97,"VAPOR DIFFUSION, HANGING DROP",7.0,"20% PEG 3350, 2% Tacsimate pH 7.0, 0.1 M HEPES pH 7.0",292.0,2019-04-09,2019-07-03,6OIO,2443.0,1.0,273.0,105.0,,32.56,1.0,1.7,experimental,22.685,0.22092,0.19276,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 60
6L66,X-RAY DIFFRACTION,2.32,47.01,EVAPORATION,6.5,"0.1M MES, pH 6.5, 6%-20% (w/v) PEG 10000",291.15,2019-10-28,2020-11-04,6L66,2673.0,2.0,310.0,177.0,,36.06,2.0,2.169,experimental,41.3592,0.2339,0.1738,Sirtuin 2 protein with H3K18 myristoylated peptide and intact NAD molecule
5TO8,X-RAY DIFFRACTION,2.33,47.2,"VAPOR DIFFUSION, SITTING DROP",,"19% PEG1000, 100 mM LiSulfate, 50 mM Disodium hydrogen phosphate, 50 mM Citric Acid",293.0,2016-10-17,2016-12-21,5TO8,2049.0,1.0,282.0,83.0,,33.14,1.0,1.9849,experimental,,0.235,0.2032,Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency
5TOB,X-RAY DIFFRACTION,2.3,46.48,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG3350, 100 mM Bis-Tris pH 5.5, 100 mM MgCl2",298.0,2016-10-17,2017-11-29,5TOB,2067.0,1.0,282.0,122.0,,33.09,1.0,2.117,experimental,,0.2615,0.2061,Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency
8YHI,X-RAY DIFFRACTION,2.14,42.61,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Hepes  pH7.5, 2% PEG 400, 2.0M (NH4)2SO4",293.0,2024-02-28,2024-03-13,8YHI,2470.0,1.0,288.0,185.0,1.0,33.23,1.0,1.75,experimental,30.129,0.2266,0.1925,The Crystal Structure of SHP1 from Biortus.
5E2Q,X-RAY DIFFRACTION,2.49,50.58,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.056 M sodium phosphate monobasic monohydrate, 1.344 M potassium phosphate dibasic monohydrate",293.0,2015-10-01,2016-04-13,5E2Q,6000.0,2.0,734.0,165.0,,82.66,2.0,2.404,experimental,38.5,0.2473,0.2062,Structure of human DPP3 in complex with angiotensin-II
5IZF,X-RAY DIFFRACTION,2.65,53.6,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M BisTris pH7.0, 0.2M amminium sulfate, 20%-24% PEG 3350",277.15,2016-03-25,2016-07-20,5IZF,2915.0,2.0,357.0,44.0,1.0,41.99,2.0,2.1,experimental,63.48,0.27,0.23,Complex of PKA with the bisubstrate protein kinase inhibitor ARC-1408
8SSN,X-RAY DIFFRACTION,2.52,51.21,"VAPOR DIFFUSION, HANGING DROP",8.0,Crystals of AblFL in complex with SKI and asciminib were obtained by combining 0.3 ul of 600 uM AblFL + 700 uM SKI + 700 uM asciminib (~32 mg/ml) in 5 percent DMSO with 0.4 ul reservoir of 0.1 M Tris-HCl pH 8 + 1.75 M Ammonium sulfate + 2 percent (v/v) polypropylene glycol 400 (PPG 400). The final stock of complex was concentrated from 1 uM AblFL with ~1.2 uM SKI/asciminib after incubation at 4 degree C for 6 h. Screening around this condition yielded crystals in a transparent diamond-shaped or plate-shaped crystals. Crystals were grown at 18 degree C by sitting drop for a few days. The crystals were transferred to a drop of fresh reservoir containing 20 percent Xylitol with matching concentration of inhibitors in 5 percent DMSO for few seconds for cryo-protection,291.15,2023-05-08,2023-09-06,8SSN,6667.0,2.0,896.0,51.0,,104.66,1.0,2.86,experimental,,0.348,0.2977,Abl kinase in complex with SKI and asciminib
8TGD,X-RAY DIFFRACTION,2.98,58.74,"VAPOR DIFFUSION, SITTING DROP",6.8,"0.5 M NaCl, 0.1 M MES-NaOH pH 6.8, 5% w/v PEG 3350",293.0,2023-07-12,2023-09-06,8TGD,21180.0,4.0,2722.0,140.0,,321.76,2.0,2.928,experimental,132.68,0.2516,0.2175,"STX-478, a Mutant-Selective, Allosteric Inhibitor bound to H1047R PI3Kalpha"
4XEY,X-RAY DIFFRACTION,2.15,42.72,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.1M sodium citrate, 8% PEG 8000",293.0,2014-12-25,2015-04-01,4XEY,5180.0,2.0,816.0,,,94.7,1.0,2.891,experimental,,0.2593,0.2308,Crystal structure of an SH2-kinase domain construct of c-Abl tyrosine kinase
6NPE,X-RAY DIFFRACTION,2.96,58.42,VAPOR DIFFUSION,,"20 mM Tris-HCl [pH 8.0]
 100 mM NaCl
3 mM DTT, and 5% (v/v) glycerol.

1-3 % PEG300,
2M AmSO4
Cryo: 20% glycerol",277.0,2019-01-17,2019-03-13,6NPE,4564.0,2.0,596.0,179.0,,71.83,1.0,2.15,experimental,38.9698,0.2122,0.186,"C-abl Kinase domain with the activator(cmpd6), 2-cyano-N-(4-(3,4-dichlorophenyl)thiazol-2-yl)acetamide"
5H15,X-RAY DIFFRACTION,2.3,46.57,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide",293.0,2016-10-08,2017-01-25,5H15,6732.0,4.0,792.0,319.0,2.0,92.68,2.0,2.27,experimental,26.84,0.2357,0.1826,EED in complex with PRC2 allosteric inhibitor EED709
5H24,X-RAY DIFFRACTION,2.28,46.07,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide",293.0,2016-10-14,2017-01-25,5H24,6497.0,4.0,792.0,96.0,2.0,92.44,2.0,2.5,experimental,34.99,0.255,0.187,EED in complex with PRC2 allosteric inhibitor compound 8
5H25,X-RAY DIFFRACTION,2.33,47.18,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, 16% PEG 8000, 10 mM beta-Nicotinamide mononucleotide",293.0,2016-10-14,2017-01-25,5H25,6390.0,4.0,792.0,4.0,2.0,92.49,2.0,2.88,experimental,49.26,0.274,0.184,EED in complex with PRC2 allosteric inhibitor compound 11
7QJG,X-RAY DIFFRACTION,2.3,46.43,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 8.0, 16% PEG 8000",293.0,2021-12-16,2022-04-13,7QJG,6799.0,4.0,790.0,398.0,2.0,92.64,2.0,1.8,experimental,27.88,0.2185,0.1871,EED in complex with PRC2 allosteric inhibitor compound 6
7QJU,X-RAY DIFFRACTION,2.29,46.2,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 8.0, 16% PEG 8000",293.0,2021-12-17,2022-04-13,7QJU,7038.0,4.0,790.0,603.0,2.0,92.64,2.0,1.8,experimental,26.08,0.2131,0.1867,EED in complex with PRC2 allosteric inhibitor compound 7
6MTW,X-RAY DIFFRACTION,2.57,52.09,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM sodium cacodylate pH 5.6, 6% isopropanol, 250 mM zinc acetate, 2 mM 1-hydroxy-2-azelaoyl-sn-glycero-3-phosphocholine",277.0,2018-10-22,2019-03-20,6MTW,6446.0,2.0,760.0,342.0,4.0,87.72,1.0,1.999,experimental,,0.2848,0.2475,Lysosomal Phospholipase A2 in complex with Zinc
5JLV,X-RAY DIFFRACTION,3.06,59.83,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium acetate pH 4.6, 20% PEG 3350, 0.2 M ammonium phosphate monobasic, 4% polypropylene glycol P 400",291.0,2016-04-27,2016-06-15,5JLV,9428.0,4.0,1090.0,659.0,,128.92,2.0,2.0,experimental,,0.2158,0.1755,Receptor binding domain of Botulinum neurotoxin A in complex with human glycosylated SV2C
8GK5,X-RAY DIFFRACTION,2.15,42.9,"VAPOR DIFFUSION, HANGING DROP",5.7,"0.1 M Bis-Tris pH 5.7, 30% (w/v) PEG 3350",293.0,2023-03-17,2024-06-26,8GK5,9905.0,4.0,1324.0,132.0,,155.03,1.0,2.3,experimental,,0.2515,0.2224,EGFR(T790M/V948R) kinase in complex with osimertinib and benzimidazole allosteric inhibitor
6GLC,X-RAY DIFFRACTION,2.32,40.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5% (w/v) PEG 1000, 12.5% (w/v) PEG 3350, 12.5% (v/v) MPD, 0.03 M of each sodium nitrate, disodium hydrogen phosphate, ammonium sulphate, 0.1 M MOPS/HEPES-Na (pH 7.5)",291.0,2018-05-23,2018-06-13,6GLC,3245.0,2.0,465.0,165.0,,52.53,2.0,1.8,experimental,,0.2054,0.1799,Structure of phospho-Parkin bound to phospho-ubiquitin
5N2W,X-RAY DIFFRACTION,2.27,45.87,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris pH 8.5, 200mM TMAO, PEG MME 2000",277.0,2017-02-08,2017-04-19,5N2W,3681.0,2.0,481.0,29.0,,54.95,2.0,2.68,experimental,60.35,0.243,0.198,WT-Parkin and pUB complex
5H17,X-RAY DIFFRACTION,2.29,46.27,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M Tris, 16% PEG 8000,10 mM beta-Nicotinamide mononucleotide",293.0,2016-10-08,2017-01-25,5H17,3276.0,2.0,396.0,121.0,1.0,46.33,2.0,2.3,experimental,42.38,0.2391,0.1893,EED in complex with PRC2 allosteric inhibitor EED210
7QK4,X-RAY DIFFRACTION,2.25,45.23,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris pH 6.0, 0.2 M MgCl2, 20% PEG 3350",293.0,2021-12-17,2022-04-13,7QK4,3436.0,2.0,395.0,290.0,,46.33,2.0,1.602,experimental,23.97,0.2057,0.1818,EED in complex with PRC2 allosteric inhibitor compound 22 (MAK683)
5UG8,X-RAY DIFFRACTION,1.84,33.11,"VAPOR DIFFUSION, SITTING DROP",,"Salt: 0.2 M Ammonium sulfate
Precipitant: 11.4 %w/v PEG 8000
Buffer: 0.1 M HEPES (pH 7.50)
Precipitant: 10.0 %v/v iso-propanol",286.0,2017-01-07,2017-03-22,5UG8,2632.0,1.0,329.0,279.0,,38.56,1.0,1.46,experimental,23.1,0.207,0.192,"Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(1-methyl-1H-pyrazol-4-yl)amino]-9-(propan-2-yl)-9H-purin-2-yl}pyrrolidin-3-yl]propanamide"
5UG9,X-RAY DIFFRACTION,1.84,33.05,"VAPOR DIFFUSION, SITTING DROP",,"Salt: 0.2 M Ammonium sulfate
Precipitant: 14.1 %w/v PEG 8000
Buffer: 0.1 M HEPES (pH 7.50)
Precipitant: 10.0 %v/v iso-propanol",294.0,2017-01-07,2017-03-22,5UG9,2664.0,1.0,329.0,302.0,,38.51,1.0,1.33,experimental,20.8,0.205,0.194,"Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-(propan-2-yl)-9H-purin-2-yl}pyrrolidin-3-yl]propanamide"
5UGA,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",,"Salt: 0.2 M Ammonium sulfate
Precipitant: 20.0 %w/v PEG 8000
Buffer: 0.1 M HEPES (pH 7.50)
Precipitant: 13.6 %v/v iso-propanol",296.0,2017-01-07,2017-03-22,5UGA,2530.0,1.0,329.0,160.0,,38.53,1.0,1.82,experimental,28.7,0.264,0.233,"Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with 4-(4-{[2-{[(3S)-1-acetylpyrrolidin-3-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl]amino}phenyl)-1-methylpiperazin-1-ium"
5LGR,X-RAY DIFFRACTION,2.32,47.08,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris-HCl pH 8.5 100 mM
PEG 3350 14 %
Ammonium Sulfate 200 mM",293.0,2016-07-08,2017-03-22,5LGR,12311.0,8.0,1492.0,765.0,,171.08,2.0,2.0,experimental,42.9158,0.2337,0.192,Crystal structure of mouse CARM1 in complex with ligand P1C3u
6I3F,X-RAY DIFFRACTION,3.3,62.74,"VAPOR DIFFUSION, SITTING DROP",7.6,"1.76M Ammonium sulfate
0.1M Tris, pH7.6",293.0,2018-11-06,2018-12-26,6I3F,6136.0,2.0,798.0,170.0,3.0,90.45,2.0,2.55,experimental,40.386,0.23392,0.20621,Crystal structure of the complex of human angiotensinogen and renin at 2.55 Angstrom
5CNO,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",8.0,"ammonium nitrate, PEG 3350",293.0,2015-07-17,2015-07-29,5CNO,5579.0,3.0,990.0,541.0,,113.93,1.0,1.55,experimental,,0.2029,0.1749,Crystal structure of the EGFR kinase domain mutant V924R
7KD6,X-RAY DIFFRACTION,3.19,61.45,"VAPOR DIFFUSION, HANGING DROP",7.5,"16% PEG 3350, 0.2 M sodium thiocyanate (NaSCN), 0.02% sodium azide (NaN3)",296.0,2020-10-08,2021-10-13,7KD6,19073.0,20.0,2548.0,165.0,73.0,295.39,5.0,2.6,experimental,87.37,0.221,0.189,Insulin Receptor L1-CR plus alphaCT fragment in co-complex with Fv 83-7 and single-chain insulin SCI-b
5A0C,X-RAY DIFFRACTION,2.4,48.71,,,"0.1M MES AT PH6.5,1.2M SODIUMMALONATE",,2015-04-17,2015-08-19,5A0C,3848.0,2.0,436.0,334.0,8.0,50.28,1.0,2.1,experimental,27.223,0.21279,0.16302,Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
7ZTL,X-RAY DIFFRACTION,3.01,59.13,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS pH 8.5, 0.4 M MgCl2, 25% PEG 3350",293.15,2022-05-11,2023-01-18,7ZTL,2589.0,2.0,371.0,210.0,,44.18,2.0,1.9,experimental,45.71,0.1931,0.1634,Crystal structure of a covalently linked Aurora-A N-Myc complex
6F5M,X-RAY DIFFRACTION,2.68,54.16,"VAPOR DIFFUSION, SITTING DROP",,"HLE from human blood was purchased from SERVA as a lyophilisate in the presence of sodium acetate puffer, pH 5.5. The lyophilisate was disolved in water so that the HLE concentration was 5 mg/ml (170 micromolar) and the acetate concentration 250 millimolar. 120 microliter dissolved HNE lysophilisate was mixed with 6 microliter inhibitor solution (10 mM in DMSO). 1 microliter of the resulting HLE/inhibitor mixture was mixed with 0.5 microliter reservoir solution which was composed of 20 % PEG MME 5000, 0.2 M potassium sulphate. Repeated seeding was necessary to get usable crystals. In the final seeding step the reservoir was composed of 20 % PEG MME 5000, 0.2 M sodium sulphate.",293.0,2017-12-01,2018-08-08,6F5M,3645.0,2.0,436.0,44.0,8.0,51.58,1.0,2.7,experimental,,0.2336,0.1758,Crystal structure of highly glycosylated human leukocyte elastase in complex with a thiazolidinedione inhibitor
5X2C,X-RAY DIFFRACTION,2.61,52.93,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Bis-Tris 5.0, 22.5% PEG 3350, 5mM TCEP",293.0,2017-01-31,2018-02-21,5X2C,5597.0,2.0,662.0,526.0,,77.04,1.0,2.05,experimental,,0.2018,0.1747,Crystal structure of EGFR 696-1022 T790M/V948R in complex with SKLB(5)
6OIN,X-RAY DIFFRACTION,2.5,50.76,VAPOR DIFFUSION,7.0,"20% PEG 3350, 2% Tacsimate pH 7.0, 0.1 M HEPES pH 7.0",292.0,2019-04-09,2019-07-03,6OIN,2453.0,1.0,273.0,99.0,,32.64,1.0,1.7,experimental,23.105,0.22048,0.19722,Crystal structure of MYST acetyltransferase domain in complex with inhibitor CTX-124143
6OIP,X-RAY DIFFRACTION,2.51,51.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.2 M K/Na Tartrate",292.0,2019-04-09,2019-07-03,6OIP,2527.0,1.0,273.0,188.0,,32.75,1.0,1.8,experimental,,0.2219,0.1847,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 34
6OIQ,X-RAY DIFFRACTION,2.52,51.27,"VAPOR DIFFUSION, HANGING DROP",7.0,"20% PEG 3350, 2% Tacsimate pH 7.0, 0.1 M HEPES pH 7.0",292.0,2019-04-09,2019-07-03,6OIQ,2514.0,1.0,273.0,165.0,,32.67,1.0,1.75,experimental,21.121,0.2269,0.18405,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 63
6OIR,X-RAY DIFFRACTION,2.52,51.2,"VAPOR DIFFUSION, SITTING DROP",7.0,"20% PEG 3350, 2% Tacsimate pH 7.0, 0.1 M HEPES pH 7.0",292.0,2019-04-09,2019-07-03,6OIR,2417.0,1.0,273.0,68.0,,32.67,1.0,2.03,experimental,25.191,0.22073,0.19104,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 62
6OWI,X-RAY DIFFRACTION,2.5,50.81,"VAPOR DIFFUSION, HANGING DROP",7.0,"20% PEG3350, 2% Tacsimate pH 7.0, 0.1 M HEPES pH 7.0",292.0,2019-05-09,2020-04-01,6OWI,2389.0,1.0,273.0,120.0,,32.59,1.0,1.75,experimental,,0.2352,0.1956,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 85
6PD8,X-RAY DIFFRACTION,2.51,51.06,"VAPOR DIFFUSION, HANGING DROP",6.5,"27% PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",292.0,2019-06-18,2020-04-01,6PD8,2268.0,1.0,272.0,42.0,,32.57,1.0,2.738,experimental,,0.2447,0.1927,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 39
6PD9,X-RAY DIFFRACTION,2.54,51.52,"VAPOR DIFFUSION, HANGING DROP",6.5,"27% PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",292.0,2019-06-18,2020-04-01,6PD9,2247.0,1.0,272.0,19.0,,32.59,1.0,2.8,experimental,,0.2674,0.2123,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 60
6PDA,X-RAY DIFFRACTION,2.47,50.22,"VAPOR DIFFUSION, HANGING DROP",6.5,"27% PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",292.0,2019-06-18,2020-04-01,6PDA,2318.0,1.0,272.0,84.0,,32.7,1.0,2.448,experimental,,0.2257,0.1771,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 74
6PDB,X-RAY DIFFRACTION,2.5,50.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"27% PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",292.0,2019-06-18,2020-04-01,6PDB,2335.0,1.0,272.0,101.0,,32.7,1.0,2.42,experimental,,0.2209,0.1856,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 80
6PDC,X-RAY DIFFRACTION,2.52,51.19,"VAPOR DIFFUSION, HANGING DROP",6.5,"27% PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",292.0,2019-06-18,2020-04-01,6PDC,2441.0,1.0,272.0,189.0,,32.67,1.0,1.96,experimental,,0.2053,0.1771,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 42
6PDD,X-RAY DIFFRACTION,2.52,51.14,"VAPOR DIFFUSION, HANGING DROP",6.5,"27% PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",292.0,2019-06-18,2020-04-01,6PDD,2441.0,1.0,272.0,197.0,,32.68,1.0,2.15,experimental,,0.2119,0.1709,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 41
6PDE,X-RAY DIFFRACTION,2.49,50.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"27% PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",292.0,2019-06-18,2020-04-01,6PDE,2375.0,1.0,272.0,143.0,,32.68,1.0,2.22,experimental,,0.2093,0.1823,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 40
6PDF,X-RAY DIFFRACTION,2.48,50.41,"VAPOR DIFFUSION, HANGING DROP",6.5,"27% PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",292.0,2019-06-18,2020-04-01,6PDF,2357.0,1.0,272.0,124.0,,32.69,1.0,2.22,experimental,,0.2022,0.1801,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 55
6PDG,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"27% PEG 3350, 0.2 M ammonium sulfate, 0.1 M bis-tris pH 6.5",292.0,2019-06-18,2020-04-01,6PDG,2400.0,1.0,272.0,165.0,,32.71,1.0,1.919,experimental,,0.2131,0.1912,Crystal structure of MYST acetyltransferase domain in complex with inhibitor 83
7NUS,X-RAY DIFFRACTION,2.36,47.79,"VAPOR DIFFUSION, SITTING DROP",,"2.2 M AmSO4, 0.2 M NaAcetate",298.0,2021-03-13,2021-09-22,7NUS,3159.0,6.0,333.0,488.0,,39.4,2.0,1.45,experimental,12.38,0.1965,0.1766,"X-RAY STRUCTURE OF HDM2/CMR19 AT 1.45A: Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors"
8PQD,X-RAY DIFFRACTION,1.96,37.24,"VAPOR DIFFUSION, HANGING DROP",8.0,"6 mg/mL, 10% PEG6000, 200 mM LiCl, 100 mM Tris, pH 8.0, cryo-protected with 20% PEG400 in reservoir directly added to crystallization drop",285.15,2023-07-11,2023-12-27,8PQD,5448.0,2.0,654.0,602.0,,75.47,1.0,1.5,experimental,34.63,0.1943,0.1746,c-KIT kinase domain in complex with avapritinib derivative 10
8J25,X-RAY DIFFRACTION,2.5,50.85,"VAPOR DIFFUSION, HANGING DROP",6.5,22% PEG 3350,291.0,2023-04-14,2023-09-20,8J25,3248.0,1.0,428.0,42.0,,47.49,1.0,2.6,experimental,,0.2478,0.2042,Crystal structure of PML B-box2 mutant
8HV3,X-RAY DIFFRACTION,3.39,63.67,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M TRIS pH 8.5, 0.15M Sodium citrate, 25%PEG400",292.0,2022-12-26,2023-12-13,8HV3,2556.0,1.0,331.0,134.0,,38.17,1.0,2.4,experimental,44.518,0.24993,0.21202,Crystal structure of EGFR_DMX in complex with covalently bound fragment 4
8HV4,X-RAY DIFFRACTION,3.36,63.45,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M TRIS pH 8.5, 0.15M Sodium citrate, 25%PEG400",292.0,2022-12-26,2023-12-13,8HV4,2571.0,1.0,331.0,148.0,,38.26,1.0,2.2,experimental,42.537,0.27492,0.23692,Crystal structure of EGFR_TMX in complex with covalently bound fragment 4
8HV6,X-RAY DIFFRACTION,3.3,62.75,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M TRIS pH 8.5, 0.15M Sodium citrate, 25%PEG400",292.0,2022-12-26,2023-12-13,8HV6,2584.0,1.0,331.0,149.0,,38.21,1.0,2.2,experimental,36.427,0.29574,0.24702,Crystal structure of EGFR_TMX in complex with covalently bound fragment 8
8HV7,X-RAY DIFFRACTION,3.38,63.56,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M TRIS pH 8.5, 0.15M Sodium citrate, 25%PEG400",292.0,2022-12-26,2023-12-13,8HV7,2512.0,1.0,331.0,90.0,,38.26,1.0,2.69,experimental,41.047,0.29019,0.21839,Crystal structure of EGFR_TMX in complex with covalently bound fragment 9
8HV9,X-RAY DIFFRACTION,3.34,63.23,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M TRIS pH 8.5, 0.15M Sodium citrate, 25%PEG400",292.0,2022-12-26,2023-12-13,8HV9,2564.0,1.0,331.0,108.0,,38.23,1.0,2.5,experimental,40.059,0.27418,0.25316,Crystal structure of EGFR_TMX in complex with covalently bound fragment 12
5NJ9,X-RAY DIFFRACTION,2.28,45.96,"VAPOR DIFFUSION, SITTING DROP",8.0,,293.0,2017-03-28,2017-10-04,5NJ9,17131.0,6.0,1898.0,2192.0,,205.76,3.0,1.25,experimental,12.982,0.1822,0.1494,E. coli Microcin-processing metalloprotease TldD/E with DRVY angiotensin fragment bound
7ZZP,X-RAY DIFFRACTION,1.91,35.66,"VAPOR DIFFUSION, SITTING DROP",,"39% PEG 300
0.1M pH=8.4 CHES/NaOH",293.0,2022-05-25,2022-09-21,7ZZP,10034.0,3.0,1494.0,838.0,,172.99,1.0,1.52,experimental,22.558,0.1736,0.1531,Structure of HDAC2 complexed with an inhibitory ligand
6QCD,X-RAY DIFFRACTION,2.63,53.22,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2018-12-27,2019-12-25,6QCD,4921.0,2.0,604.0,345.0,,70.45,1.0,1.84,experimental,37.0,0.2023,0.1682,Human Sirt6 in complex with ADP-ribose and the activator quercetin
6QCE,X-RAY DIFFRACTION,2.63,53.34,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2018-12-27,2019-12-25,6QCE,4806.0,2.0,604.0,224.0,,70.55,1.0,1.9,experimental,44.115,0.18692,0.15164,Human Sirt6 in complex with ADP-ribose and the activator isoquercetin
6QCH,X-RAY DIFFRACTION,2.63,53.2,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2018-12-28,2019-12-25,6QCH,4640.0,2.0,604.0,117.0,,70.3,1.0,2.1,experimental,50.493,0.19964,0.16328,Human Sirt6 in complex with ADP-ribose and the activator cyanidin
8PQA,X-RAY DIFFRACTION,1.93,36.21,"VAPOR DIFFUSION, HANGING DROP",,"3 mg/mL, 23% PEG3350, 150 mM Na2-tartrate",291.15,2023-07-11,2023-12-27,8PQA,5224.0,2.0,654.0,474.0,,75.11,1.0,1.65,experimental,45.06,0.214,0.1877,c-KIT kinase domain in complex with avapritinib derivative 4
8PQC,X-RAY DIFFRACTION,1.95,36.8,"VAPOR DIFFUSION, HANGING DROP",6.5,"6.6 mg/mL, 750 mM Na3-citrate, 100 mM Hepes, pH 6.5",293.15,2023-07-11,2023-12-27,8PQC,5176.0,2.0,654.0,371.0,,75.44,1.0,1.77,experimental,33.95,0.2063,0.1814,c-KIT kinase domain in complex with avapritinib derivative 9
8PQE,X-RAY DIFFRACTION,2.04,39.6,"VAPOR DIFFUSION, HANGING DROP",9.5,"7.5 mg/mL, 12% PEG8000 20% Ethylen glycole, 30 mM NaI, 30 mM NaF, 30 mM NaBr, 100 mM Tris-Bicine, pH 9.5",285.15,2023-07-11,2023-12-27,8PQE,4607.0,2.0,654.0,137.0,,75.67,1.0,2.0,experimental,62.55,0.2556,0.2135,c-KIT kinase domain in complex with avapritinib derivative 11
8PQF,X-RAY DIFFRACTION,1.9,35.35,"VAPOR DIFFUSION, HANGING DROP",,"3 mg/mL, 21% PEG3350, 125 mM Li3-citrate",285.15,2023-07-11,2023-12-27,8PQF,5033.0,2.0,654.0,284.0,,75.5,1.0,1.9,experimental,47.66,0.2186,0.1957,c-KIT kinase domain in complex with avapritinib derivative 12
5USQ,X-RAY DIFFRACTION,2.16,42.95,"VAPOR DIFFUSION, SITTING DROP",9.2,"16 % PEG 8000
100mM CHES pH 9.2",293.0,2017-02-13,2017-04-12,5USQ,2545.0,1.0,299.0,104.0,,34.7,1.0,2.55,experimental,28.686,0.2305,0.1792,ALK-5 kinase inhibitor complex
5A09,X-RAY DIFFRACTION,2.28,46.1,,,"28%PEG4000, 0.1MTRIS/HCL AT PH 8.2, 0.7MLICL",,2015-04-17,2015-08-19,5A09,1910.0,1.0,218.0,179.0,4.0,24.73,1.0,1.81,experimental,25.866,0.23944,0.18235,Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
5A0A,X-RAY DIFFRACTION,2.28,45.98,,,"28%PEG4000,0.1MTRIS/HCL AT PH 8.2,0.7MLICL",,2015-04-17,2015-08-19,5A0A,1905.0,1.0,218.0,182.0,4.0,24.91,1.0,1.78,experimental,30.91,0.20427,0.17007,Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
5A8X,X-RAY DIFFRACTION,2.36,47.88,,,,,2015-07-17,2016-08-03,5A8X,1819.0,1.0,218.0,118.0,4.0,24.73,1.0,2.23,experimental,17.443,0.22284,0.17377,Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
5A8Z,X-RAY DIFFRACTION,2.32,47.02,,,,,2015-07-17,2016-08-03,5A8Z,1790.0,1.0,218.0,91.0,4.0,24.7,1.0,2.0,experimental,22.703,0.23644,0.18993,Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor
6NUC,X-RAY DIFFRACTION,2.62,53.05,"VAPOR DIFFUSION, SITTING DROP",9.5,"40% (v/v) PEG 600, 100 mM CHES/ Sodium hydroxide pH 9.5, 0.2 M MgCl2",298.0,2019-01-31,2019-07-03,6NUC,4801.0,3.0,576.0,436.0,,66.38,3.0,1.9,experimental,,0.194,0.163,Structure of Calcineurin in complex with NHE1 peptide
6NUF,X-RAY DIFFRACTION,2.6,52.65,"VAPOR DIFFUSION, SITTING DROP",,"40% (v/v) PEG 600, 100 mM CHES/ Sodium hydroxide pH 9.5, 0.2 M MgCl2",298.0,2019-01-31,2019-07-03,6NUF,4837.0,3.0,576.0,471.0,,66.51,3.0,1.9,experimental,,0.209,0.169,Structure of Calcineurin in complex with NHE1 peptide
6NUU,X-RAY DIFFRACTION,2.49,50.6,"VAPOR DIFFUSION, SITTING DROP",9.5,"40% (v/v) PEG 600, 100 mM CHES/ Sodium hydroxide pH 9.5, 0.2 M MgCl2",298.0,2019-02-02,2019-07-03,6NUU,4566.0,3.0,576.0,256.0,,66.2,3.0,2.3,experimental,,0.243,0.195,Structure of Calcineurin mutant in complex with NHE1 peptide
4WB6,X-RAY DIFFRACTION,2.65,53.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG 8000, 0.1M HEPES pH 7.5",295.0,2014-09-02,2015-01-21,4WB6,6203.0,4.0,740.0,197.0,,87.17,3.0,2.1,experimental,,0.2371,0.1878,Crystal structure of a L205R mutant of human cAMP-dependent protein kinase A (catalytic alpha subunit)
4X9R,X-RAY DIFFRACTION,2.0,38.56,"VAPOR DIFFUSION, HANGING DROP",8.0,"Frozen stocks of protein at 37 mg/mL in 10 mM TRIS pH8, 0.5 M NaCl, 10 mM DTT were thawed and diluted to 10 mg/ml with the same buffer.  Complexes with each of three macrocycle compounds (3b, 3c and 4b) were prepared by adding 100 mM stocks of the macrocycle in DMSO directly to the diluted protein to achieve a final concentration of 1 mM. Crystals were grown by hanging drop vapor diffusion, with drops made by mixing equal volumes of protein-macrocycle complex and well solution containing 2-6% PEG-3350. Crystals were cryo-protected by quickly dipping in a solution of 37.5% ethylene glycol in well solution and frozen in liquid nitrogen",291.0,2014-12-11,2015-07-29,4X9R,2114.0,2.0,243.0,189.0,,28.25,2.0,1.398,experimental,,0.1789,0.1493,PLK-1 polo-box domain in complex with Bioactive Imidazolium-containing phosphopeptide macrocycle 3B
4X9V,X-RAY DIFFRACTION,1.85,33.52,"VAPOR DIFFUSION, HANGING DROP",8.0,"Frozen stocks of protein at 37 mg/mL in 10 mM TRIS pH8, 0.5 M NaCl, 10 mM DTT were thawed and diluted to 10 mg/ml with the same buffer.  Complexes with each of three macrocycle compounds (3b, 3c and 4b) were prepared by adding 100 mM stocks of the macrocycle in DMSO directly to the diluted protein to achieve a final concentration of 1 mM. Crystals were grown by hanging drop vapor diffusion, with drops made by mixing equal volumes of protein-macrocycle complex and well solution containing 2-6% PEG-3350. Crystals were cryo-protected by quickly dipping in a solution of 37.5% ethylene glycol in well solution and frozen in liquid nitrogen",291.0,2014-12-11,2015-07-29,4X9V,2045.0,2.0,243.0,146.0,,28.27,2.0,1.429,experimental,,0.1731,0.1392,PLK-1 polo-box domain in complex with Bioactive Imidazolium-containing phosphopeptide macrocycle 3C
4X9W,X-RAY DIFFRACTION,1.92,36.02,VAPOR DIFFUSION,8.0,"Frozen stocks of protein at 37 mg/mL in 10 mM TRIS pH8, 0.5 M NaCl, 10 mM DTT were thawed and diluted to 10 mg/ml with the same buffer.  Complexes with each of three macrocycle compounds (3b, 3c and 4b) were prepared by adding 100 mM stocks of the macrocycle in DMSO directly to the diluted protein to achieve a final concentration of 1 mM. Crystals were grown by hanging drop vapor diffusion, with drops made by mixing equal volumes of protein-macrocycle complex and well solution containing 2-6% PEG-3350. Crystals were cryo-protected by quickly dipping in a solution of 37.5% ethylene glycol in well solution and frozen in liquid nitrogen.",291.0,2014-12-11,2015-07-29,4X9W,2049.0,2.0,242.0,73.0,,28.19,2.0,1.798,experimental,,0.2388,0.1944,PLK-1 polo-box domain in complex with Bioactive Imidazolium-containing phosphopeptide macrocycle 4C
7PPN,X-RAY DIFFRACTION,2.37,48.03,"VAPOR DIFFUSION, HANGING DROP",5.5,"10% PEG 20000, 100 mM Citrate buffer pH 5.5, 50 mM EDTA",277.0,2021-09-14,2022-09-07,7PPN,2400.0,2.0,298.0,50.0,,34.92,2.0,1.9,experimental,52.43,0.2069,0.1801,"SHP2 catalytic domain in complex with CD28 (183-198) phosphopeptide (pTyr-191, p-Thr-195)"
8HUM,X-RAY DIFFRACTION,2.91,57.73,VAPOR DIFFUSION,,"0.1 M HEPES (pH 7.5), 1.0 M trisodium citrate",293.0,2022-12-24,2023-08-09,8HUM,2359.0,2.0,294.0,4.0,,34.15,2.0,2.29,experimental,60.6091,0.2504,0.2057,X-ray structure of human PPAR gamma ligand binding domain-lanifibranor-SRC1 coactivator peptide co-crystals obtained by co-crystallization
8PQB,X-RAY DIFFRACTION,1.92,35.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"6.6 mg/mL, 1 M Na3-citrate, 100 mM Hepes, pH 6.5",285.15,2023-07-11,2023-12-27,8PQB,2410.0,1.0,327.0,154.0,,37.72,1.0,1.87,experimental,41.03,0.2339,0.198,c-KIT kinase domain in complex with avapritinib derivative 8
6Y4Q,X-RAY DIFFRACTION,1.97,37.52,VAPOR DIFFUSION,,"10% w/v PEG 8000 (precipitant), 0.1 M Tris-HCl pH 7.0 (buffer), 0.2 M Magnesium chloride hexahydrate (salt)",291.0,2020-02-22,2020-05-20,6Y4Q,2005.0,4.0,210.0,126.0,,25.38,2.0,1.63,experimental,30.76,0.229,0.194,Structure of a stapled peptide bound to MDM2
7G80,X-RAY DIFFRACTION,2.55,51.72,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G80,4107.0,2.0,430.0,391.0,,50.56,2.0,1.671,experimental,35.59,0.2301,0.2032,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1041785508
7G83,X-RAY DIFFRACTION,2.53,51.31,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G83,4206.0,2.0,430.0,451.0,,50.99,2.0,1.31,experimental,25.0,0.2054,0.1855,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z108545814
7G84,X-RAY DIFFRACTION,2.52,51.25,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G84,4125.0,2.0,430.0,406.0,,50.61,2.0,1.811,experimental,27.16,0.2322,0.1945,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1102357527
7G85,X-RAY DIFFRACTION,2.53,51.45,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G85,4107.0,2.0,430.0,380.0,,51.08,2.0,1.735,experimental,30.67,0.223,0.1958,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496
7G86,X-RAY DIFFRACTION,2.53,51.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G86,4115.0,2.0,430.0,382.0,,51.02,2.0,1.699,experimental,30.79,0.2293,0.2007,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1137725943
7G87,X-RAY DIFFRACTION,2.55,51.75,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G87,4154.0,2.0,430.0,422.0,,50.81,2.0,2.053,experimental,36.79,0.2414,0.1906,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148165337
7G88,X-RAY DIFFRACTION,2.53,51.36,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G88,4082.0,2.0,430.0,366.0,,50.57,2.0,1.869,experimental,33.22,0.2442,0.2029,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1148747945
7G89,X-RAY DIFFRACTION,2.53,51.35,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G89,4093.0,2.0,430.0,372.0,,50.65,2.0,1.901,experimental,31.63,0.2436,0.2031,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1192341021
7G8A,X-RAY DIFFRACTION,2.52,51.23,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8A,4152.0,2.0,430.0,419.0,,50.9,2.0,1.5,experimental,27.27,0.2107,0.1872,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100642432
7G8B,X-RAY DIFFRACTION,2.53,51.43,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8B,4189.0,2.0,430.0,429.0,,51.28,2.0,1.42,experimental,26.7,0.2161,0.1903,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z100643660
7G8C,X-RAY DIFFRACTION,2.56,51.91,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8C,3825.0,2.0,430.0,287.0,,50.6,2.0,2.176,experimental,43.36,0.2552,0.2024,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1037511924
7G8D,X-RAY DIFFRACTION,2.53,51.33,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8D,3904.0,2.0,430.0,341.0,,50.94,2.0,1.937,experimental,39.12,0.2359,0.1969,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104474228
7G8E,X-RAY DIFFRACTION,2.54,51.64,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8E,4017.0,2.0,430.0,371.0,,50.66,2.0,1.79,experimental,34.0,0.2231,0.1981,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z104479710
7G8F,X-RAY DIFFRACTION,2.53,51.42,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8F,4146.0,2.0,430.0,438.0,,50.53,2.0,1.42,experimental,27.39,0.2149,0.1922,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079168976
7G8G,X-RAY DIFFRACTION,2.51,51.06,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8G,4046.0,2.0,430.0,317.0,,50.95,2.0,1.92,experimental,44.64,0.251,0.2086,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z111529496
7G8H,X-RAY DIFFRACTION,2.53,51.3,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8H,4095.0,2.0,430.0,344.0,,51.19,2.0,1.67,experimental,33.19,0.2177,0.193,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198180782
7G8I,X-RAY DIFFRACTION,2.49,50.52,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8I,3667.0,2.0,430.0,165.0,,50.47,2.0,2.468,experimental,53.57,0.2731,0.2085,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1198316457
7G8J,X-RAY DIFFRACTION,2.49,50.67,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8J,4028.0,2.0,430.0,348.0,,50.41,2.0,1.986,experimental,36.78,0.2813,0.2268,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1216861874
7G8K,X-RAY DIFFRACTION,2.49,50.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8K,4096.0,2.0,430.0,377.0,,51.16,2.0,1.491,experimental,32.5,0.2156,0.1909,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1217131798
7G8L,X-RAY DIFFRACTION,2.52,51.14,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8L,4103.0,2.0,430.0,380.0,,51.37,2.0,1.6,experimental,32.08,0.2285,0.198,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1251207602
7G8M,X-RAY DIFFRACTION,2.49,50.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8M,3870.0,2.0,430.0,269.0,,50.53,2.0,2.029,experimental,51.46,0.2598,0.2094,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1255459547
7G8N,X-RAY DIFFRACTION,2.51,51.07,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8N,3858.0,2.0,430.0,264.0,,50.49,2.0,2.32,experimental,48.48,0.2829,0.2145,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1262549981
7G8O,X-RAY DIFFRACTION,2.5,50.83,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8O,4115.0,2.0,430.0,379.0,,50.96,2.0,1.579,experimental,30.8,0.2298,0.2024,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1267800292
7G8P,X-RAY DIFFRACTION,2.47,50.28,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8P,3714.0,2.0,430.0,167.0,,50.34,2.0,2.209,experimental,77.87,0.324,0.2585,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269184613
7G8Q,X-RAY DIFFRACTION,2.51,50.96,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8Q,4139.0,2.0,430.0,408.0,,50.97,2.0,1.561,experimental,28.17,0.2071,0.1863,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1269220427
7G8S,X-RAY DIFFRACTION,2.5,50.84,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8S,4093.0,2.0,430.0,376.0,,51.03,2.0,1.6,experimental,32.14,0.2216,0.1933,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270393711
7G8T,X-RAY DIFFRACTION,2.5,50.76,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8T,4144.0,2.0,430.0,432.0,,50.82,2.0,1.385,experimental,24.41,0.1983,0.1798,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1273312142
7G8W,X-RAY DIFFRACTION,2.53,51.31,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8W,4075.0,2.0,430.0,371.0,,50.72,2.0,1.939,experimental,34.05,0.2504,0.2082,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416193393
7G8X,X-RAY DIFFRACTION,2.5,50.84,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8X,3948.0,2.0,430.0,325.0,,50.72,2.0,1.711,experimental,35.84,0.2274,0.1989,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1416571195
7G8Y,X-RAY DIFFRACTION,2.5,50.79,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8Y,4044.0,2.0,430.0,344.0,,50.79,2.0,1.75,experimental,32.23,0.2221,0.192,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1449748885
7G8Z,X-RAY DIFFRACTION,2.51,50.91,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8Z,4141.0,2.0,430.0,421.0,,50.94,2.0,1.509,experimental,27.08,0.2207,0.1935,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1493056027
7G90,X-RAY DIFFRACTION,2.49,50.62,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G90,3868.0,2.0,430.0,279.0,,50.67,2.0,1.911,experimental,45.06,0.2489,0.2095,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509195674
7G91,X-RAY DIFFRACTION,2.52,51.29,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G91,3886.0,2.0,430.0,208.0,,50.52,2.0,2.292,experimental,49.49,0.2529,0.2012,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1509257513
7G92,X-RAY DIFFRACTION,2.49,50.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G92,4039.0,2.0,430.0,332.0,,50.84,2.0,1.872,experimental,32.07,0.2374,0.1979,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1545313172
7G93,X-RAY DIFFRACTION,2.52,51.22,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G93,4088.0,2.0,430.0,375.0,,50.83,2.0,1.693,experimental,29.21,0.2254,0.1981,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1565771450
7G94,X-RAY DIFFRACTION,2.49,50.65,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G94,4081.0,2.0,430.0,374.0,,50.97,2.0,1.47,experimental,32.17,0.2244,0.1914,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1575337975
7G95,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G95,4129.0,2.0,430.0,375.0,,51.32,2.0,1.551,experimental,30.02,0.218,0.1928,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z165170770
7G96,X-RAY DIFFRACTION,2.47,50.25,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G96,3642.0,2.0,430.0,59.0,,50.51,2.0,2.3,experimental,62.977,0.2657,0.1979,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1203730981
7G98,X-RAY DIFFRACTION,2.48,50.42,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G98,3478.0,2.0,430.0,124.0,,50.01,2.0,2.878,experimental,70.25,0.2946,0.209,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z4605084898
7G9A,X-RAY DIFFRACTION,2.47,50.11,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9A,3739.0,2.0,430.0,199.0,,50.42,2.0,2.583,experimental,58.99,0.295,0.2071,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102113-001
7G9B,X-RAY DIFFRACTION,2.48,50.31,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9B,3757.0,2.0,430.0,231.0,,50.2,2.0,2.553,experimental,62.63,0.2984,0.2058,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102116-001
7G9C,X-RAY DIFFRACTION,2.49,50.62,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9C,3776.0,2.0,430.0,176.0,,50.68,2.0,2.686,experimental,52.04,0.2742,0.1945,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102141-001
7G9D,X-RAY DIFFRACTION,2.46,50.07,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9D,3748.0,2.0,430.0,213.0,,50.36,2.0,2.659,experimental,53.69,0.2862,0.1949,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102179-001
7G9E,X-RAY DIFFRACTION,2.49,50.51,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9E,3907.0,2.0,430.0,294.0,,50.56,2.0,2.151,experimental,47.74,0.2918,0.2197,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102197-001
7G9F,X-RAY DIFFRACTION,2.47,50.15,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9F,3750.0,2.0,430.0,219.0,,50.56,2.0,1.935,experimental,63.6,0.2603,0.2184,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102209-001
7G9G,X-RAY DIFFRACTION,2.45,49.82,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9G,3817.0,2.0,430.0,210.0,,50.48,2.0,2.079,experimental,67.87,0.2865,0.2317,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102236-001
7G9H,X-RAY DIFFRACTION,2.45,49.89,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9H,3749.0,2.0,430.0,151.0,,50.3,2.0,2.746,experimental,66.87,0.2737,0.2015,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102245-001
7G9I,X-RAY DIFFRACTION,2.46,50.04,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9I,3959.0,2.0,430.0,274.0,,50.51,2.0,2.202,experimental,50.83,0.2738,0.2122,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102253-001
7G9J,X-RAY DIFFRACTION,2.5,50.79,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G9J,3791.0,2.0,430.0,205.0,,50.59,2.0,1.97,experimental,53.61,0.245,0.2132,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102281-001
6GGN,X-RAY DIFFRACTION,2.17,43.34,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.5M (NH4)2SO4, 0.1M NaCitrate",298.0,2018-05-03,2018-09-26,6GGN,878.0,1.0,96.0,52.0,,11.74,1.0,2.0,experimental,31.882,0.2304,0.2214,"In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor"
5T68,X-RAY DIFFRACTION,1.89,34.87,"VAPOR DIFFUSION, SITTING DROP",8.5,"14-18% PEG3350, 100 mM Tris pH 8.5 using a seed stock that was grown in PEG 3350 13-20% and 100 mM Tris pH 8.5",293.0,2016-09-01,2016-10-26,5T68,4224.0,2.0,582.0,23.0,,68.41,1.0,2.93,experimental,60.04,0.281,0.183,"Crystal structure of Syk catalytic domain in complex with a furo[3,2-d]pyrimidine"
5B7V,X-RAY DIFFRACTION,2.7,53.3,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 10000, (NH4)2SO4, BIS-TRIS",277.0,2016-06-09,2016-06-22,5B7V,4580.0,2.0,620.0,75.0,,71.43,1.0,2.15,experimental,59.3475,0.256,0.223,Human FGFR1 kinase in complex with CH5183284
5DC0,X-RAY DIFFRACTION,2.04,39.82,"VAPOR DIFFUSION, HANGING DROP",8.0,0.1M sodium tartrate pH=8 and 25% w/v polyethylene glycol 3350,291.0,2015-08-22,2016-03-02,5DC0,1518.0,2.0,214.0,55.0,,23.44,2.0,2.23,experimental,25.722,0.24386,0.19129,CRYSTAL STRUCTURE OF MONOBODY GG3/ABL1 SH2 DOMAIN COMPLEX
7Q5U,X-RAY DIFFRACTION,2.91,57.67,"VAPOR DIFFUSION, SITTING DROP",6.0,"100 mM MMT buffer, 30% PEG 1000",293.0,2021-11-04,2021-11-24,7Q5U,14063.0,12.0,1710.0,613.0,,196.17,2.0,2.4,experimental,45.203,0.2588,0.2165,The tandem SH2 domains of SYK with a bound CD3G diphospho-ITAM peptide
6ES0,X-RAY DIFFRACTION,2.48,50.41,"VAPOR DIFFUSION, SITTING DROP",,25% PEG Smear Low -- 0.1M MES pH 6.5 -- 0.05M magnesium acetate -- 0.05M magnesium chloride,293.0,2017-10-19,2018-02-21,6ES0,4901.0,2.0,634.0,195.0,,73.75,1.0,2.38,experimental,,0.2576,0.2135,Crystal structure of the kinase domain of human RIPK2 in complex with the activation loop targeting inhibitor CS-R35
6UL8,X-RAY DIFFRACTION,3.71,66.85,"VAPOR DIFFUSION, HANGING DROP",7.5,"85 mM Tris, pH 7.5, 200 mM calcium chloride, 10% PEG400, 5% glycerol, in 24 well Linbro trays at 22 degrees C. Crystals were frozen directly from the tray using paraffin oil as a cryoprotectant.",295.0,2019-10-07,2019-12-04,6UL8,4631.0,2.0,612.0,121.0,,71.14,1.0,2.68,experimental,65.189,0.22,0.1831,"RIP2 kinase catalytic domain complex with (5S,6S,8R)-2-(benzo[d]thiazol-5-yl)-6-hydroxy-4,5,6,7,8,9-hexahydro-5,8-methanopyrazolo[1,5-a][1,3]diazocine-3-carboxamide"
6AQR,X-RAY DIFFRACTION,2.39,48.58,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M HEPES pH 7.0
17% PEG3350
0.1 M ammonium sulfate",293.0,2017-08-21,2018-07-04,6AQR,6575.0,5.0,843.0,264.0,,96.32,5.0,2.1,experimental,34.399,0.2488,0.2013,SAGA DUB module Ubp8(C146A)/Sgf11/Sus1/Sgf73 bound to monoubiquitin
5NJE,X-RAY DIFFRACTION,2.03,39.39,VAPOR DIFFUSION,,"200 mM K/Na Tartrate, 10-20 % PEG3350",298.0,2017-03-28,2018-05-16,5NJE,1738.0,1.0,237.0,15.0,,27.58,1.0,1.978,experimental,,0.2657,0.2239,The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with Alpha-Bromo-3-Iodotoluene.
5NMM,X-RAY DIFFRACTION,2.01,38.81,VAPOR DIFFUSION,,"200 mM K/Na Tartrate, 20% PEG3350",293.0,2017-04-06,2018-02-21,5NMM,1763.0,1.0,237.0,34.0,,27.58,1.0,2.02,experimental,,0.237,0.1924,The structure of the polo-box domain (PBD) of Plk1 in complex with Alpha-Bromo-3-Iodotoluene.
6V64,X-RAY DIFFRACTION,2.02,39.18,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2 M Na/K tartrate pH 7.5
14% PEG 3350",298.0,2019-12-04,2020-05-13,6V64,2423.0,2.0,289.0,108.0,4.0,33.96,2.0,2.29,experimental,41.0,0.277,0.197,Crystal structure of human thrombin bound to ppack with tryptophans replaced by 5-F-tryptophan
6QCN,X-RAY DIFFRACTION,2.66,53.73,"VAPOR DIFFUSION, HANGING DROP",5.8,"14% PEG 10,000, 0.1M ammonium acetate pH 5.8",293.0,2018-12-29,2019-12-25,6QCN,4859.0,2.0,608.0,28.0,,70.53,1.0,2.23,experimental,49.105,0.23405,0.20926,Human Sirt2 in complex with ADP-ribose and the inhibitor quercetin
5JDU,X-RAY DIFFRACTION,2.29,46.3,"VAPOR DIFFUSION, HANGING DROP",6.9,200 mM KCl and 20% PEG 3350,295.0,2016-04-17,2016-07-13,5JDU,5158.0,4.0,584.0,622.0,8.0,68.03,2.0,1.7,experimental,27.943,0.206,0.18077,Crystal structure for human thrombin mutant D189A
5WJJ,X-RAY DIFFRACTION,2.16,43.13,"VAPOR DIFFUSION, SITTING DROP",7.4,"18.% PEG 3350, 0.06M MES, 0.04M MES_Na",293.0,2017-07-23,2018-01-17,5WJJ,3160.0,1.0,365.0,380.0,,42.17,1.0,1.6,experimental,22.054,0.23712,0.20033,"Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[1,2-b]pyridazine-based p38 MAP Kinase Inhibitors"
6ANL,X-RAY DIFFRACTION,2.17,43.35,"VAPOR DIFFUSION, SITTING DROP",7.4,"15.% PEG 8000, 0.08M NP_HEPES, 0.02M NP_HEPES_Na",293.0,2017-08-14,2018-01-17,6ANL,2994.0,1.0,365.0,230.0,,42.11,1.0,2.0,experimental,37.713,0.2634,0.2058,"Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[1,2-b]pyridazine-based p38 MAP Kinase Inhibitors"
8VXE,X-RAY DIFFRACTION,2.15,42.72,VAPOR DIFFUSION,5.0,"10% PEG6000, 0.1 MES/NaOH pH 5.0",277.0,2024-02-04,2024-05-08,8VXE,2848.0,1.0,387.0,151.0,,45.24,1.0,1.85,experimental,46.929,0.28853,0.2179,Structure of p38 alpha (Mitogen-activated protein kinase 14) complexed with inhibitor 6
5MJT,X-RAY DIFFRACTION,2.5,50.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM Sodium dihydrogen phosphate ph 7.5, 350 mM NaCl, 27% PEG 8000",277.0,2016-12-01,2017-12-20,5MJT,2659.0,3.0,307.0,215.0,4.0,36.58,3.0,1.4,experimental,,0.1722,0.1479,"Thrombin Mutant A190S in complex with (S) -1 - ((R) -2-amino-3,3-diphenylpropanoyl) -N- (3-chlorobenzyl) pyrrolidine-2-carboxamide"
5MLS,X-RAY DIFFRACTION,2.5,51.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM Sodium dihydrogen phosphate ph 7.5, 350 mM NaCl, 27% PEG 8000",277.0,2016-12-07,2017-12-20,5MLS,2620.0,3.0,307.0,189.0,4.0,36.6,3.0,1.62,experimental,,0.18,0.16,Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(3-chlorobenzyl)pyrrolidine-2-carboxamide
5MM6,X-RAY DIFFRACTION,2.7,53.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM sodium dihydrogen phosphate ph 7.5, 350 mM NaCl, 27% PEG 8000",277.0,2016-12-08,2017-12-20,5MM6,2657.0,3.0,307.0,224.0,4.0,36.59,3.0,1.29,experimental,,0.1421,0.1234,Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide
8ZJV,X-RAY DIFFRACTION,3.18,61.34,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M Lithium Sulfate monohydrate, 0.1 M Bis-Tris pH 5.5, 25% w/v Polyethylene Glycol 3350",277.0,2024-05-15,2024-05-29,8ZJV,3207.0,1.0,351.0,304.0,,41.76,1.0,1.8,experimental,33.22,0.22,0.19,Crystal Structure of the ERK2 complexed with 5-Iodotubercidin
7XTY,X-RAY DIFFRACTION,2.35,47.59,VAPOR DIFFUSION,6.8,"0.1M citric acid (pH 3.5), 3M NaCl",289.0,2022-05-18,2023-05-17,7XTY,1563.0,4.0,212.0,131.0,,22.26,2.0,2.1,experimental,27.2849,0.2402,0.1935,Crystal Structure of the second PDZ domain from human PTPN13 in complex with APC peptide
5FP5,X-RAY DIFFRACTION,2.35,47.0,,7.4,10MM HEPES/NAOH PH7.4 15MM NACL PROTEIN CONCENTRATION: 8.6 MG/ML,,2015-11-27,2015-12-09,5FP5,2420.0,1.0,298.0,321.0,,34.3,1.0,2.16,experimental,32.09,0.253,0.1866,Structure of cyclin-dependent kinase 2 with small-molecule ligand 4- fluorobenzoic acid (AT222) in an alternate binding site.
6NR0,X-RAY DIFFRACTION,2.49,55.04,"VAPOR DIFFUSION, HANGING DROP",5.0,"Mixed solution of 0.44 mM protein (in buffer of 20 mM Tris/HCl pH 7.5, 160 mM NaCl) 2.5 mM NAD+, 2.5 mM Glucose-TM-1beta with an equal volume of well solution of 2 M (NH4)2SO4, 80 mM Na Acetate/HCl pH 5.0",293.0,2019-01-22,2020-01-22,6NR0,4966.0,2.0,638.0,134.0,,75.38,1.0,2.45,experimental,51.87,0.2562,0.2202,SIRT2(56-356) with covalent intermediate between mechanism-based inhibitor Glucose-TM-1beta and 1'-SH ADP-ribose
7OTE,X-RAY DIFFRACTION,2.51,51.08,"VAPOR DIFFUSION, SITTING DROP",8.0,"Tris 20 mM pH 8, 150 mM Sodium chloride, 1 mM DTT, 2-propanol and PEG 4.000",293.0,2021-06-10,2022-06-22,7OTE,4388.0,2.0,586.0,82.0,,69.28,1.0,2.49,experimental,43.689,0.2521,0.1751,Src Kinase Domain in complex with ponatinib
7N9G,X-RAY DIFFRACTION,2.88,57.36,"VAPOR DIFFUSION, SITTING DROP",,Ammonium dihydrogen phosphate,277.15,2021-06-17,2022-04-27,7N9G,6307.0,3.0,813.0,206.0,,97.52,1.0,2.2,experimental,52.067,0.2511,0.2174,Crystal structure of the Abl 1b Kinase domain in complex with Dasatinib and Imatinib
5UMM,X-RAY DIFFRACTION,1.84,33.2,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M sodium cacodylate pH 5.5, 25% PEG (w/v) 4000",298.0,2017-01-27,2018-01-31,5UMM,1646.0,4.0,194.0,73.0,,23.21,2.0,1.65,experimental,32.574,0.23112,0.17795,CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3
6WHN,X-RAY DIFFRACTION,2.46,50.07,"VAPOR DIFFUSION, HANGING DROP",,"40% (v/v) PEG600 and 100mM CHES 
pH 9.5",293.0,2020-04-08,2021-04-21,6WHN,10346.0,6.0,1179.0,968.0,,137.32,2.0,1.54,experimental,24.19,0.1924,0.1628,Histone deacetylases complex with peptide macrocycles
6WHO,X-RAY DIFFRACTION,2.39,48.62,"VAPOR DIFFUSION, HANGING DROP",,40 % PEG600 and 100mM CHES pH 9.5,293.0,2020-04-08,2021-04-21,6WHO,9863.0,6.0,1179.0,562.0,,137.26,2.0,2.2,experimental,41.74,0.2207,0.1842,Histone deacetylases complex with peptide macrocycles
6WHQ,X-RAY DIFFRACTION,2.38,48.34,"VAPOR DIFFUSION, HANGING DROP",,40% (v/v) PEG600 and 100mM CHES pH 9.5,293.0,2020-04-08,2021-04-21,6WHQ,9729.0,6.0,1179.0,488.0,,136.62,2.0,2.35,experimental,50.62,0.2413,0.1955,Histone deacetylases complex with peptide macrocycles
6WHZ,X-RAY DIFFRACTION,2.32,47.07,"VAPOR DIFFUSION, HANGING DROP",,40% (v/v) PEG600 and 100mM CHES pH 9.5,293.0,2020-04-08,2021-04-21,6WHZ,9197.0,6.0,1179.0,106.0,,135.9,2.0,2.9,experimental,64.33,0.2813,0.227,Histone deacetylases complex with peptide macrocycles
6WI3,X-RAY DIFFRACTION,2.37,48.01,"VAPOR DIFFUSION, HANGING DROP",,40% (v/v) PEG600 and 100mM CHES pH 9.5,293.0,2020-04-08,2021-04-21,6WI3,9658.0,6.0,1182.0,448.0,,137.08,2.0,2.35,experimental,45.43,0.254,0.1966,Histone deacetylases complex with peptide macrocycles
7ZZS,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"40% PEG 300
0.1M pH=8.6 CHES/NaOH",293.0,2022-05-26,2022-09-21,7ZZS,9670.0,3.0,1494.0,570.0,,172.87,1.0,1.88,experimental,44.138,0.2068,0.1664,HDAC2 complexed with an inhibitory ligand
6EO8,X-RAY DIFFRACTION,2.58,52.25,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 4000, 0.1M HEPES pH7.0, 0.75M NaCl, 0.04% NaN3, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2017-10-09,2017-12-13,6EO8,2463.0,3.0,307.0,80.0,4.0,36.58,3.0,1.94,experimental,33.265,0.24757,0.20991,Crystal structure of thrombin in complex with a novel glucose-conjugated potent inhibitor
6EO9,X-RAY DIFFRACTION,2.41,48.98,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 4000, 0.1M HEPES pH7.0, 0.75M NaCl, 0.04% NaN3, VAPOR DIFFUSION, HANGING DROP, temperature 277K, temperature 293K",293.0,2017-10-09,2017-12-13,6EO9,2531.0,3.0,307.0,118.0,4.0,36.74,3.0,1.84,experimental,30.563,0.24775,0.19799,Crystal structure of thrombin in complex with a novel glucose-conjugated potent inhibitor
6FJT,X-RAY DIFFRACTION,2.65,53.53,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4, pH 7.5
350 mM NaCl
2mM benzamidine
at a concentration of 10 mg/mL thrombin",278.0,2018-01-23,2019-02-06,6FJT,2749.0,3.0,290.0,254.0,4.0,34.55,3.0,1.27,experimental,,0.1509,0.133,4-chloro-benzamidine in complex with thrombin
8DJI,X-RAY DIFFRACTION,1.98,38.0,"VAPOR DIFFUSION, HANGING DROP",,"100 mM HEPES pH 7.0, 19 to 31 % (w/v) PEG 3350, and 1-5 mM zinc chloride",291.0,2022-06-30,2022-08-10,8DJI,797.0,2.0,126.0,60.0,,14.22,2.0,1.97,experimental,34.7233,0.2578,0.2308,Ternary complex of SUMO1 with the SIM of PML and zinc
8GB4,X-RAY DIFFRACTION,2.15,42.71,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Bis-Tris pH 5.5, 30% (w/v) PEG 3350",293.0,2023-02-24,2024-03-13,8GB4,9858.0,4.0,1324.0,111.0,,155.14,1.0,2.59,experimental,,0.2535,0.2291,EGFR(T790M/V948R) kinase in complex with benzimidazole allosteric inhibitor
5MKX,X-RAY DIFFRACTION,3.73,67.05,"VAPOR DIFFUSION, SITTING DROP",,Morpheus condition 37,278.0,2016-12-05,2017-12-20,5MKX,2240.0,2.0,238.0,360.0,,29.12,1.0,1.68,experimental,30.631,0.20645,0.18194,1.68A STRUCTURE PCAF BROMODOMAIN WITH 4-chloro-2-methyl-5-(methylamino)pyridazin-3(2H)-one
7SME,X-RAY DIFFRACTION,2.97,58.27,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, pH 6.5, 4% PEG400, 1.6 M ammonium sulfate",277.0,2021-10-25,2022-06-29,7SME,2883.0,2.0,381.0,31.0,,44.66,2.0,2.64,experimental,,0.2771,0.2241,p107 pocket domain complexed with HDAC1 peptide
6NPV,X-RAY DIFFRACTION,2.97,58.56,VAPOR DIFFUSION,,"1 - 3 % PEG 400
0.1 HEPES pH 7.5
2M AmSO4",277.0,2019-01-18,2019-03-13,6NPV,4670.0,2.0,596.0,261.0,,72.05,1.0,1.86,experimental,27.6141,0.2066,0.1817,"C-abl Kinase domain with the activator(cmpd51), N-(1-(3,4-dichlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1H-pyrazol-3-yl)isonicotinamide"
6XV1,X-RAY DIFFRACTION,2.61,52.91,"VAPOR DIFFUSION, HANGING DROP",5.7,"100 mM Bis-Tris pH 5.7, 1.6 M (NH4)2SO4, and 10% PEG 400",293.0,2020-01-21,2020-10-28,6XV1,4595.0,2.0,604.0,87.0,,69.89,1.0,1.95,experimental,37.461,0.1645,0.1496,Human Sirt6 13-308 in complex with ADP-ribose and the activator MDL-801
4R3P,X-RAY DIFFRACTION,3.27,62.37,"VAPOR DIFFUSION, HANGING DROP",7.5,"40% PEG400, 0.15M Sodium chloride, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298.0,2014-08-17,2015-08-12,4R3P,2559.0,2.0,330.0,54.0,,37.92,2.0,2.905,experimental,,0.2398,0.2078,Crystal structures of EGFR in complex with Mig6
7UXI,X-RAY DIFFRACTION,1.8,31.67,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris pH 8.5, 25% w/v PEG 2,000MME",291.15,2022-05-05,2022-12-28,7UXI,2456.0,2.0,316.0,66.0,,36.09,2.0,2.07,experimental,40.5748,0.2636,0.2101,"Structure of CDK2 in complex with FP19711, a Helicon Polypeptide"
6NPU,X-RAY DIFFRACTION,2.99,58.84,VAPOR DIFFUSION,,"1 - 3 % PEG 400
2M AmSO4
0.1 HEPES pH 7.5
cryo: 20% Glycerol",277.0,2019-01-18,2019-03-13,6NPU,4456.0,2.0,596.0,72.0,,71.64,1.0,2.33,experimental,34.84,0.2342,0.1934,"C-abl Kinase domain with the activator(cmpd29), N-(1-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)acetamide"
6G5K,X-RAY DIFFRACTION,2.5,50.5,"VAPOR DIFFUSION, SITTING DROP",7.5,0.1 M Amino acids 0.1 M Buffer System 2 7.5 50 % v/v Precipitant Mix 1,294.0,2018-03-29,2019-01-16,6G5K,7923.0,4.0,964.0,439.0,,115.26,2.0,2.0,experimental,43.992,0.23545,0.19361,Crystal structure of the binding domain of Botulinum Neurotoxin type B in complex with human synaptotagmin 1
6DU3,X-RAY DIFFRACTION,3.35,63.32,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 3350
0.2 M Magnesium acetate",298.0,2018-06-19,2018-09-26,6DU3,3016.0,4.0,384.0,18.0,,44.24,2.0,2.58,experimental,38.2103,,,Structure of Scp1 D96N bound to REST-pS861/4 peptide
5DKC,X-RAY DIFFRACTION,3.34,63.15,"VAPOR DIFFUSION, SITTING DROP",7.0,"19% PEG 6K, 4% ethyleneglycol, 0.01M ZnCl2",277.15,2015-09-03,2015-10-14,5DKC,1047.0,1.0,123.0,114.0,,14.77,1.0,1.6,experimental,31.676,0.21115,0.1937,Crystal structure of the bromodomain of human BRM (SMARCA2) in complex with PFI-3 chemical probe
5CNN,X-RAY DIFFRACTION,2.5,50.74,"VAPOR DIFFUSION, HANGING DROP",5.5,"PEG 6000, morpholineethanesulfonic acid, ammonium chloride",293.0,2015-07-17,2015-07-29,5CNN,5200.0,2.0,700.0,273.0,,80.33,1.0,1.9,experimental,,0.2114,0.182,Crystal structure of the EGFR kinase domain mutant I682Q
7A6J,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"20.0 % PEG3350, 100 mM MgSO4, 4 % ethylen glycole, 7.5 mg/mL EGFR-T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2020-08-25,2022-02-23,7A6J,4433.0,2.0,666.0,142.0,,77.55,1.0,2.0,experimental,48.7592,0.2159,0.1902,Crystal Structure of EGFR-T790M/V948R in Complex with Poziotinib
7ZYQ,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, HANGING DROP",,"27.5 % PEG3350, 100 mM MgSO4, 2 % ethylen glycole, 6.4 mg/mL EGFR-T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2022-05-25,2023-05-03,7ZYQ,4375.0,2.0,666.0,129.0,,77.53,1.0,2.1,experimental,50.739,0.223,0.1978,Crystal Structure of EGFR-T790M/V948R in Complex with Reversible Aminopyrimidine 13
8BCY,X-RAY DIFFRACTION,2.65,53.58,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG6000, 0.10 M KCL, 0.10 M MES",293.0,2022-10-17,2023-05-10,8BCY,8956.0,2.0,1187.0,30.0,,137.92,2.0,2.43,experimental,77.927,0.2634,0.2235,HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 13
6CEF,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",4.6,"2 M Na-formate, 0.2 M Na-acetate pH4.6, 5 % ethylene glycol",291.0,2018-02-11,2018-02-28,6CEF,902.0,1.0,107.0,90.0,,12.34,1.0,1.8,experimental,12.606,0.1809,0.1501,"Crystal structure of fragment 3-(1,3-Benzothiazol-2-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain"
7F7W,X-RAY DIFFRACTION,2.27,45.72,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris, pH 8.0 0.2M Sodium acetate, 12-20% PEG 4000",289.0,2021-06-30,2022-03-30,7F7W,4762.0,2.0,550.0,237.0,2.0,64.2,1.0,1.83,experimental,42.41,0.2383,0.2068,JAK2-JH2
8BA4,X-RAY DIFFRACTION,2.29,46.2,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M Tris pH 8, 20% PEG4000, 0.2M Na-acetate",277.0,2022-10-11,2023-02-01,8BA4,4560.0,2.0,578.0,203.0,3.0,66.84,1.0,2.1,experimental,44.49,0.2743,0.2157,Crystal structure of JAK2 JH2-V617F in complex with Bemcentinib
4ZAU,X-RAY DIFFRACTION,3.37,63.54,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M MES, 1 M sodium citrate",291.0,2015-04-14,2015-11-11,4ZAU,2218.0,1.0,330.0,4.0,,38.06,1.0,2.8,experimental,59.318,0.24411,0.19344,AZD9291 complex with wild type EGFR
5HIB,X-RAY DIFFRACTION,3.48,64.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2016-01-11,2016-04-06,5HIB,2546.0,1.0,331.0,,,37.93,1.0,2.85,experimental,62.89,0.2388,0.1949,"EGFR kinase domain mutant ""TMLR"" with a pyrazolopyrimidine inhibitor"
5HIC,X-RAY DIFFRACTION,3.48,64.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2016-01-11,2016-04-06,5HIC,2561.0,1.0,331.0,99.0,,38.07,1.0,2.6,experimental,61.33,0.2325,0.1894,"EGFR kinase domain mutant ""TMLR"" with a imidazopyridinyl-aminopyrimidine inhibitor"
6JWL,X-RAY DIFFRACTION,3.23,61.91,"VAPOR DIFFUSION, HANGING DROP",7.8,"0.1M HEPES pH 7.8, 40% PEG 400, 0.15M NaCl, 5mM TCEP",293.0,2019-04-21,2020-04-22,6JWL,2557.0,1.0,331.0,66.0,,38.16,1.0,2.551,experimental,,0.2416,0.2067,Crystal structure of EGFR 696-1022 L858R in complex with AZD9291
6JX4,X-RAY DIFFRACTION,3.43,64.14,"VAPOR DIFFUSION, HANGING DROP",8.0,"38% PEG 300, 150 mM KCl, 0.1 M HEPES (pH 8.0), 50mM Glycyl-glycyl-glycine, 5 mM Co-enzyme A (pH 8.0), 2 mM TCEP.",293.0,2019-04-22,2020-04-22,6JX4,2524.0,1.0,331.0,52.0,,38.15,1.0,2.531,experimental,,0.2454,0.2107,Crystal structure of EGFR 696-1022 T790M in complex with AZD9291 prepared by soaking
6S89,X-RAY DIFFRACTION,3.3,62.67,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.35 K-Na-tartrate, 100 mM Na-MES (pH 6.5), 2 % 1,3-Propanediol, 5.5 mg/ml EGFR T790M/C797 (in 100 mM NaCl, 25mM Tris-HCl, 10 % Glycerol, 1mM TCEP, pH 8.0), 1 ul reservoir + 1 ul protein solution",293.0,2019-07-09,2019-10-16,6S89,2444.0,1.0,333.0,,,38.41,1.0,2.701,experimental,80.0011,0.2337,0.1882,Crystal Structure of EGFR-T790M/C797S in Complex with Covalent Pyrrolopyrimidine 19g
6S8A,X-RAY DIFFRACTION,3.35,63.26,"VAPOR DIFFUSION, HANGING DROP",,"1.15 K-Na-tartrate, 100 mM Na-MES (pH 6.5), 2 % 1,3-Propanediol, 5.3 mg/ml EGFR T790M/C797 (in 100 mM NaCl, 25mM Tris-HCl, 10 % Glycerol, 1mM TCEP, pH 8.0), 1 ul reservoir + 1 ul protein solution",293.0,2019-07-09,2019-10-16,6S8A,2477.0,1.0,333.0,2.0,,38.42,1.0,2.6,experimental,84.1026,0.2074,0.1855,Crystal Structure of EGFR-T790M/C797S in Complex with Covalent Pyrrolopyrimidine 19h
8V8V,X-RAY DIFFRACTION,2.7,54.47,"VAPOR DIFFUSION, SITTING DROP",,"0.6 M Sodium Formate, 0.1 M Citrate pH 5.0",293.0,2023-12-06,2024-03-20,8V8V,20130.0,4.0,2704.0,110.0,,318.77,2.0,2.61,experimental,,0.2879,0.2372,PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 7).
7PC7,X-RAY DIFFRACTION,2.86,57.06,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris 8.5,  22 % v/v PEG Smear Broad",293.0,2021-08-03,2022-04-20,7PC7,6965.0,4.0,848.0,405.0,,96.87,2.0,2.1,experimental,56.4524,0.2183,0.1852,The PDZ domain of SNTG1 complexed with the acetylated PDZ-binding motif of PTEN
8EX0,X-RAY DIFFRACTION,2.33,47.12,"VAPOR DIFFUSION, HANGING DROP",9.5,"CHES, PEG 3000",277.0,2022-10-24,2023-02-01,8EX0,2339.0,1.0,289.0,131.0,,33.54,1.0,1.85,experimental,33.69,0.2276,0.1749,Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with CDK2-IV
8FYU,X-RAY DIFFRACTION,1.85,33.64,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M CaCl2, 0.1 M HEPES (pH 7.4). 28% PEG 4K",298.0,2023-01-26,2023-08-30,8FYU,2356.0,4.0,276.0,185.0,,31.35,2.0,1.84839139202,experimental,25.9315874363,0.243637622496,0.203977935651,Crystal structure of the human CHIP-TPR domain in complex with a 10mer acetylated tau peptide
8GCK,X-RAY DIFFRACTION,2.0,34.46,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M CaCl2, 0.1 M HEPES pH 7.4, 25% PEG 3350",298.0,2023-03-02,2024-03-06,8GCK,2394.0,4.0,270.0,227.0,,30.74,2.0,1.36823537069,experimental,21.5993112746,0.209939305154,0.192428531184,Crystal structure of the human CHIP-TPR domain in complex with a 6mer acetylated tau peptide
5UK8,X-RAY DIFFRACTION,2.34,47.42,"VAPOR DIFFUSION, HANGING DROP",7.2,"3 UL OF PROTEIN WAS MIXED WITH 5 UL OF WELL SOLUTION CONTAINING 12% PEG 3350 AND 120 MM POTASSIUM THIOCYANATE, PH 7.2, VAPOR DIFFUSION, HANGING DROP,
TEMPERATURE   303.15K",303.15,2017-01-20,2017-06-14,5UK8,10364.0,2.0,1367.0,185.0,,160.83,2.0,2.5,experimental,70.38,0.24,0.198,The co-structure of (R)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2-(1H-indol-4-yl)pyrimidin-4-yl)-3-methylmorpholine and a rationally designed PI3K-alpha mutant that mimics ATR
5UKJ,X-RAY DIFFRACTION,2.33,47.13,"VAPOR DIFFUSION, HANGING DROP",7.2,"3 UL OF PROTEIN WAS MIXED WITH 5 UL OF WELL SOLUTION CONTAINING 12% PEG 3350 AND 120 MM POTASSIUM  THIOCYANATE, PH 7.2, VAPOR DIFFUSION, HANGING DROP,",303.15,2017-01-23,2017-05-10,5UKJ,10424.0,2.0,1367.0,212.0,,160.82,2.0,2.8,experimental,63.17,0.252,0.187,"The co-structure of N,N-dimethyl-4-[(6R)-6-methyl-5-(1H-pyrrolo[2,3- b]pyridin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5- a]pyrazin-3-yl]benzenesulfonamide and a rationally designed PI3K-alpha mutant that mimics ATR"
6BHV,X-RAY DIFFRACTION,2.15,42.72,"VAPOR DIFFUSION, SITTING DROP",,"PARP-1 CATdeltaHD (30 mg/ml) was crystallized in the presence of 1.6 mM BAD in 24 to 29% PEG 3350, 0.2 M NaCl, 0.1 M Bis-Tris pH 5.5",293.0,2017-10-31,2018-02-28,6BHV,7704.0,4.0,1084.0,72.0,,122.66,1.0,2.3,experimental,74.854,0.22233,0.19771,Human PARP-1 bound to NAD+ analog benzamide adenine dinucleotide (BAD)
5XGI,X-RAY DIFFRACTION,2.4,48.69,"VAPOR DIFFUSION, SITTING DROP",,"0.15M Lithium sulfate, 0.1M Tris-HCl pH 8.5, 28%(W/V) PEG2000MME",291.15,2017-04-13,2018-04-25,5XGI,10818.0,2.0,1329.0,102.0,,157.22,2.0,2.56,experimental,76.637,0.29043,0.23947,Crystal structure of PI3K complex with an inhibitor
5XGH,X-RAY DIFFRACTION,2.4,48.68,"VAPOR DIFFUSION, SITTING DROP",,"0.15M Lithium sulfate, 0.1M Tris-HCl pH 8.5, 28%(W/V) PEG2000MME",291.15,2017-04-13,2018-04-25,5XGH,10540.0,2.0,1325.0,18.0,,156.2,2.0,2.97,experimental,88.005,0.28012,0.2306,Crystal structure of PI3K complex with an inhibitor
5UGW,X-RAY DIFFRACTION,3.22,61.79,"VAPOR DIFFUSION, SITTING DROP",,"50 mM Tris 8.5
0.8 M LiSo4
10 mM GSH/GSSG
3% 1,6-hexanediol",283.0,2017-01-10,2017-02-08,5UGW,1300.0,1.0,175.0,23.0,,20.11,1.0,2.31,experimental,61.161,0.209,0.19729,STRUCTURE OF THE HUMAN TELOMERASE THUMB DOMAIN
7JTC,X-RAY DIFFRACTION,2.47,50.28,"VAPOR DIFFUSION, SITTING DROP",,"0.01 M Co(II) chloride, 0.1 M Sodium acetate trihydrate (pH 4.6), 1 M 1,6-Hexanediol",291.0,2020-08-17,2021-08-25,7JTC,1131.0,1.0,137.0,17.0,,16.35,1.0,2.05,experimental,47.7817,0.2317,0.2015,Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ZS1-322
7LB0,X-RAY DIFFRACTION,2.46,49.98,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M MgCl2, 0.1 M Bis-Tris pH 6.5, 25% PEG 3350",293.0,2021-01-07,2021-07-14,7LB0,2240.0,1.0,265.0,180.0,,31.44,1.0,2.33,experimental,30.5345,0.2199,0.1973,"Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-295"
7LB1,X-RAY DIFFRACTION,2.57,52.22,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M MgCl2, 0.1 M Bis-Tris pH 5.5, 15% PEG 3350",293.0,2021-01-07,2021-07-14,7LB1,2369.0,1.0,265.0,198.0,,32.62,1.0,1.35,experimental,27.0521,0.1795,0.1632,"Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-585"
7LB2,X-RAY DIFFRACTION,2.44,49.66,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M MgCl2, 0.1 M Bis-Tris pH 5.5, 15% PEG 3350",293.0,2021-01-07,2021-07-14,7LB2,2270.0,1.0,265.0,168.0,,32.01,1.0,1.7,experimental,29.0171,0.1997,0.1719,"Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-589"
7DV6,X-RAY DIFFRACTION,2.5,50.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"12-22% PEG4000,3% Ethylene Glycol,16% glycerol, 160 mM MgCl2, 80 mM TrisHCl at pH 7.5-9.3,The 9.2 mg/mL of TGFbetaRII protein was incubated with 1mM compound at 277K for 1-2 hr",277.0,2021-01-12,2021-06-16,7DV6,2653.0,1.0,323.0,202.0,,37.14,1.0,2.39,experimental,46.599,0.22391,0.15967,Discovery of Functionally Selective Transforming Growth Factor beta Type II Receptor (TGF-beta RII) Inhibitors as Anti-Fibrosis Agents
4ZGG,X-RAY DIFFRACTION,3.01,59.13,"VAPOR DIFFUSION, SITTING DROP",8.0,"5.00% polyethylene glycol 6000, 0.1M TRIS pH 8.0",277.0,2015-04-22,2015-05-20,4ZGG,1735.0,1.0,190.0,201.0,,20.83,1.0,1.23,experimental,17.4434,0.1339,0.1164,Crystal structure of a DJ-1 (PARK7) from Homo sapiens at 1.23 A resolution
6DXX,X-RAY DIFFRACTION,3.04,59.54,VAPOR DIFFUSION,,0.2 M NaSCN and 20 % PEG 3350,293.0,2018-07-01,2018-09-26,6DXX,8324.0,6.0,1023.0,200.0,3.0,120.49,2.0,2.7,experimental,,0.2461,0.2056,"Human N-acylethanolamine-hydrolyzing acid amidase (NAAA) in complex with non-covalent benzothiazole-piperazine inhibitor ARN19702, in presence of Triton X-100"
6P3A,X-RAY DIFFRACTION,3.95,68.84,"VAPOR DIFFUSION, SITTING DROP",,"PEG8000, Tris pH 8.0",293.0,2019-05-23,2020-05-27,6P3A,2124.0,2.0,274.0,2.0,1.0,32.89,1.0,2.99,experimental,103.9829,0.2862,0.2548,Crystal Structure Analysis of TAF1 Bromodomain
5MO4,X-RAY DIFFRACTION,2.44,49.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"Reservoir: 18 % (W/V) PEG 3350, 0.2 M POTASSIUM FORMATE, 0.1 M TRIS PH 7.5
Protein: 35.7 MG/ML   20 MM TRIS PH 8, 200 MM NACL, 2 MM TCEP
Protocol: 0.6 UL protein solution plus 0.6 UL reservoir solution",298.0,2016-12-13,2017-04-05,5MO4,3770.0,1.0,495.0,307.0,,57.16,1.0,2.17,experimental,36.73,0.217,0.1818,ABL1 kinase (T334I_D382N) in complex with asciminib and nilotinib
5N38,X-RAY DIFFRACTION,2.53,51.3,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris pH 8.5, 200mM TMAO, PEG MME 2000",277.0,2017-02-08,2017-04-19,5N38,3633.0,2.0,481.0,55.0,,54.93,2.0,2.6,experimental,53.75,0.236,0.1865,S65DParkin and pUB complex
6ED6,X-RAY DIFFRACTION,3.04,59.55,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.0 M ammonium sulfate, 0.1 M Bis-Tris pH 5.5",290.0,2018-08-08,2018-11-14,6ED6,6199.0,2.0,830.0,110.0,,96.81,1.0,2.86,experimental,83.87,0.247,0.204,Crystal structure of Rock2 with a pyridinylbenzamide based inhibitor
6ZS2,X-RAY DIFFRACTION,2.25,45.31,"VAPOR DIFFUSION, HANGING DROP",,"Crystallization buffer: 20% medium-molecular-weight PEG smear, 0.1 M Tris pH 8.5",293.0,2020-07-15,2020-10-07,6ZS2,2298.0,2.0,242.0,266.0,,29.13,1.0,1.57,experimental,16.3242338323,0.215317979354,0.178958143499,Crystal Structure of the bromodomain of human transcription activator BRG1 (SMARCA4) in complex with 2-(6-amino-5-(piperazin-1-yl)pyridazin-3-yl)phenol
8KA1,X-RAY DIFFRACTION,2.47,50.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% (w/v) PEG 3350, 0.1 M HEPES-NaOH (pH 7.5), 0.28 M MgCl2, and 6 mM MnCl2",293.0,2023-08-02,2024-07-10,8KA1,17066.0,8.0,2268.0,18.0,,259.18,2.0,2.82,experimental,54.533,0.3415,0.27143,Crystal structure of Vibrio vulnificus RID-dependent transforming NADase domain (RDTND)/calmodulin-binding domain of Rho inactivation domain (RID-CBD) complexed with Ca2+-free calmodulin
4R5W,X-RAY DIFFRACTION,2.66,53.83,"VAPOR DIFFUSION, SITTING DROP",5.5,"21% PEG-3350, 0.17M Ammonium Sulfate, 0.09M Bis-Tris, 1mM XAV939, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-08-22,2015-09-02,4R5W,5644.0,2.0,716.0,11.0,,81.7,1.0,2.84,experimental,49.28,0.2451,0.1923,Human artd1 (parp1) - catalytic domain in complex with inhibitor xav939
6WJQ,X-RAY DIFFRACTION,2.12,42.06,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG 3350, Ammonium Acetate, Bis-tris",291.0,2020-04-14,2021-01-13,6WJQ,4752.0,4.0,660.0,49.0,,72.13,2.0,2.71,experimental,40.8027,0.2517,0.2234,Crystal structure of WDR5 in complex with the WIN peptide of PDPK1
4ZKS,X-RAY DIFFRACTION,2.07,40.7,"VAPOR DIFFUSION, SITTING DROP",4.6,"50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG400",298.0,2015-04-30,2016-05-18,4ZKS,2114.0,2.0,259.0,89.0,5.0,29.06,2.0,1.85,experimental,31.097,0.24457,0.19599,The crystal structure of upain-1-W3A in complex with inactive uPA (uPA-S195A) at pH7.4
5WXQ,X-RAY DIFFRACTION,2.05,39.98,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2017-01-08,2018-07-11,5WXQ,2137.0,2.0,267.0,103.0,6.0,29.92,2.0,1.79,experimental,26.32,0.212,0.188,Crystal structure of uPA in complex with upain-2-4
5WXR,X-RAY DIFFRACTION,2.09,41.04,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2017-01-08,2018-07-11,5WXR,2131.0,2.0,267.0,106.0,6.0,29.8,2.0,1.75,experimental,21.6,0.234,0.194,Crystal structure of uPA in complex with upain-2-4-W3A
5WXS,X-RAY DIFFRACTION,2.12,41.9,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2017-01-08,2018-07-11,5WXS,2000.0,1.0,253.0,35.0,5.0,28.77,1.0,2.3,experimental,56.81,0.266,0.185,Crystal structure of uPA in complex with S2444
7DZD,X-RAY DIFFRACTION,2.14,42.62,"VAPOR DIFFUSION, SITTING DROP",,"2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400",298.0,2021-01-25,2021-07-14,7DZD,2063.0,1.0,245.0,98.0,5.0,28.07,1.0,2.0,experimental,18.26,0.231,0.192,Crystal structure of uPA in complex with cleaved camostat
7KK2,X-RAY DIFFRACTION,2.28,46.02,VAPOR DIFFUSION,,"Buffer: 0.1 M bicine (pH 9.00)
Precipitant: 2.4 M Ammonium sulfate",277.0,2020-10-27,2021-01-06,7KK2,6052.0,2.0,704.0,512.0,,79.35,1.0,1.695,experimental,31.8,0.2381,0.204,Structure of the catalytic domain of PARP1
6P39,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"PEG1000, Tris pH 8.0",293.0,2019-05-23,2020-05-27,6P39,1080.0,1.0,138.0,,1.0,16.48,1.0,2.941,experimental,99.8515,0.2123,0.1926,Crystal Structure Analysis of TAF1 Bromodomain
5TO3,X-RAY DIFFRACTION,3.0,60.0,"VAPOR DIFFUSION, HANGING DROP",7.0,100 mM HEPES and 20% PEG 8000,293.0,2016-10-16,2017-03-29,5TO3,3477.0,2.0,455.0,93.0,13.0,52.18,2.0,2.34,experimental,47.7,0.255,0.214,Crystal structure of thrombin mutant W215A/E217A fused to EGF456 of thrombomodulin via a 31-residue linker and bound to PPACK
6NPZ,X-RAY DIFFRACTION,2.5,50.87,VAPOR DIFFUSION,7.5,"12.5% PEG3350, 0.1 M HEPES-HCl, 0.2 M ammonium acetate",277.0,2019-01-18,2019-01-30,6NPZ,6057.0,4.0,736.0,475.0,,86.89,2.0,2.12,experimental,39.787,0.241,0.1853,Crystal structure of Akt1 (aa 123-480) kinase with a bisubstrate
4X1Q,X-RAY DIFFRACTION,2.1,41.44,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400",298.0,2014-11-25,2015-03-25,4X1Q,2060.0,2.0,257.0,20.0,7.0,29.06,2.0,2.28,experimental,44.22,0.2868,0.20521,The crystal structure of mupain-1 in complex with murinised human uPA at pH7.4
4X1R,X-RAY DIFFRACTION,2.06,40.15,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400",298.0,2014-11-25,2015-03-25,4X1R,2070.0,2.0,257.0,32.0,6.0,29.11,2.0,2.1,experimental,57.458,0.27282,0.21036,The crystal structure of mupain-1-12 in complex with murinised human uPA at pH7.4
4X1S,X-RAY DIFFRACTION,2.11,41.63,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400",298.0,2014-11-25,2015-10-28,4X1S,2092.0,2.0,257.0,67.0,6.0,29.06,2.0,1.9,experimental,,0.249,0.205,The crystal structure of mupain-1-16-D9A in complex with murinised human uPA at pH7.4
4ZHL,X-RAY DIFFRACTION,2.1,41.52,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.0M ammonium sulfate, 50mM sodium citrate, pH 4.6, 5% polyethylene glycol (PEG) 400",298.0,2015-04-25,2015-09-16,4ZHL,2080.0,2.0,257.0,50.0,4.0,29.0,2.0,2.06,experimental,46.977,0.26237,0.21978,The crystal structure of mupain-1-IG in complex with murinised human uPA at pH7.4
4ZHM,X-RAY DIFFRACTION,2.06,40.23,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.0M ammonium sulfate, 50mM sodium citrate, pH 4.6, 5% polyethylene glycol (PEG) 400",298.0,2015-04-25,2015-09-16,4ZHM,2090.0,2.0,257.0,57.0,6.0,29.04,2.0,1.9,experimental,40.003,0.26415,0.22343,The crystal structure of mupain-1--16-IG in complex with murinised human uPA at pH7.4
5WXO,X-RAY DIFFRACTION,2.07,40.57,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400",298.0,2017-01-08,2018-07-11,5WXO,2109.0,2.0,265.0,82.0,6.0,29.69,2.0,1.64,experimental,27.45,0.221,0.18,Crystal structure of uPA in complex with upain-2-2-W3A
5Z1C,X-RAY DIFFRACTION,2.16,43.15,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate (pH 4.6), 2.0M ammonium sulfate supplemented with 5% PEG 400",298.0,2017-12-25,2018-12-26,5Z1C,2138.0,1.0,245.0,161.0,5.0,27.82,1.0,1.45,experimental,30.576,0.14284,0.11791,The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4
7VM4,X-RAY DIFFRACTION,2.15,42.84,"VAPOR DIFFUSION, SITTING DROP",,"2.0 M ammonium sulfate, 5% PEG400, 20 mM sodium citrate, pH 4.6",298.0,2021-10-07,2022-10-12,7VM4,2079.0,1.0,245.0,114.0,5.0,28.07,1.0,2.01,experimental,25.5,0.224,0.175,Crystal structure of uPA in complex with nafamostat
7VM5,X-RAY DIFFRACTION,2.14,42.43,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.0 M ammonium sulfate, 5% PEG 400, 20 mM sodium citrate, pH 4.6",298.0,2021-10-07,2022-10-12,7VM5,2045.0,1.0,246.0,80.0,5.0,28.04,1.0,1.97,experimental,25.5,0.247,0.191,Crystal structure of uPA in complex with 4-guanidinobenzoic acid
6KX2,X-RAY DIFFRACTION,2.93,58.04,"VAPOR DIFFUSION, SITTING DROP",4.5,"10 mg/mL mutant, 0.2M NaCl; 0.1M acetate Na (pH 4.5) and 1.26M ammonium sulfate",289.0,2019-09-09,2020-08-19,6KX2,1711.0,1.0,181.0,272.0,,20.88,1.0,1.454,experimental,22.978,0.2104,0.1842,Crystal structure of GDP bound RhoA protein
8KDX,X-RAY DIFFRACTION,2.59,52.5,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.2 M Sodium citrate tribasic dehydrated, 0.1 M Tris buffer pH8.5",293.15,2023-08-10,2024-02-28,8KDX,724.0,2.0,76.0,133.0,,8.5,2.0,1.01,experimental,13.965,0.1854,0.1728,Tau-S214 Phosphorylation Inhibits Fyn Kinase Interaction and Increases the Decay Time of NMDAR-mediated Current
8XOX,X-RAY DIFFRACTION,2.33,47.15,"VAPOR DIFFUSION, SITTING DROP",,"0.2M LiCl2, 0.1M Tris pH8.0, 20% PEG 6000",293.0,2024-01-02,2024-01-24,8XOX,2392.0,1.0,277.0,207.0,,32.88,1.0,1.9,experimental,28.469,0.2298,0.1693,The Crystal Structure of FAK2 from Biortus.
8YGX,X-RAY DIFFRACTION,2.33,47.27,"VAPOR DIFFUSION, SITTING DROP",,"0.2M MgCl2, 0.1M Bis-Tris pH5.5-5.9, 19-29% PEG3,350,1mM TCEP",293.0,2024-02-27,2024-03-13,8YGX,2274.0,1.0,277.0,204.0,,32.19,1.0,2.0,experimental,25.084,0.2703,0.2067,Structure of the PYK2 from Biortus.
5EBT,X-RAY DIFFRACTION,2.44,49.53,"VAPOR DIFFUSION, HANGING DROP",5.8,"14% PEG 20K, 0.1 M PCPT pH5.8",298.0,2015-10-19,2016-03-02,5EBT,7283.0,4.0,840.0,378.0,,99.02,1.0,2.24,experimental,30.05,0.2078,0.171,Tankyrase 1 with Phthalazinone 2
5ECE,X-RAY DIFFRACTION,2.56,52.01,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG 3350, 0.1 M MES pH 6.5, 0.2 Sodium Acetate",298.0,2015-10-20,2015-11-25,5ECE,7057.0,4.0,852.0,348.0,,99.33,1.0,2.2,experimental,37.93,0.2237,0.1812,Tankyrase 1 with Phthalazinone 1
6DXW,X-RAY DIFFRACTION,3.25,62.18,VAPOR DIFFUSION,,"1 M LiCl, 0.1 M MES pH 6 and 10 % PEG 6000",293.0,2018-07-01,2018-09-26,6DXW,11496.0,4.0,1364.0,856.0,,158.17,1.0,2.3,experimental,,0.1933,0.1673,Human N-acylethanolamine-hydrolyzing acid amidase (NAAA) precursor (C126A)
5AMB,X-RAY DIFFRACTION,2.85,57.0,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/ BICINE PH 8.5, 30 % PEG550MME/PEG20000",,2015-03-10,2016-01-13,5AMB,11095.0,4.0,1274.0,872.0,6.0,151.27,2.0,1.55,experimental,,0.18115,0.1575,Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 35-42
5B8D,X-RAY DIFFRACTION,2.17,43.26,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291.0,2016-06-14,2016-07-27,5B8D,999.0,1.0,107.0,79.0,,12.4,1.0,1.05,experimental,13.189,0.1464,0.1283,"Crystal structure of a low occupancy fragment candidate (N-(4-Methyl-1,3-thiazol-2-yl)propanamide) bound adjacent to the ubiquitin binding pocket of the HDAC6 zinc-finger domain"
5M6U,X-RAY DIFFRACTION,3.32,62.99,"VAPOR DIFFUSION, HANGING DROP",7.5,,293.0,2016-10-26,2017-02-01,5M6U,7700.0,2.0,1735.0,,,199.77,2.0,2.85,experimental,110.982,0.3089,0.2555,HUMAN PI3KDELTA IN COMPLEX WITH LASW1579
7LM2,X-RAY DIFFRACTION,2.7,53.4,VAPOR DIFFUSION,,"12-14% PEG6000, 100 MM MES/NAOH, PH 5.75, 5 MM DTT",293.0,2021-02-05,2021-04-21,7LM2,9075.0,2.0,1189.0,8.0,,138.29,2.0,2.79,experimental,97.127,0.2895,0.2405,HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 3C
4RKJ,X-RAY DIFFRACTION,2.1,41.49,"VAPOR DIFFUSION, HANGING DROP",7.3,"0.2 M K formate and 21% PEG3350, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-10-13,2015-03-11,4RKJ,2567.0,2.0,293.0,229.0,4.0,33.96,2.0,1.7,experimental,35.353,0.2071,0.15612,Crystal structure of thrombin mutant S195T (free form)
4RKO,X-RAY DIFFRACTION,2.11,41.65,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, pH 6.5, 15% PEG 6000 and 5% MPD, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-10-13,2015-03-11,4RKO,2572.0,2.0,301.0,145.0,5.0,35.73,2.0,1.84,experimental,40.172,0.20224,0.16609,Crystal structure of thrombin mutant S195T bound with PPACK
4UD9,X-RAY DIFFRACTION,2.5,50.8,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2014-12-09,2015-08-26,4UD9,2815.0,3.0,299.0,292.0,4.0,35.73,3.0,1.124,experimental,20.1,0.1408,0.1254,Thrombin in complex with 5-chlorothiophene-2-carboxamide
4UE7,X-RAY DIFFRACTION,2.48,50.49,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2014-12-16,2015-08-26,4UE7,2814.0,3.0,298.0,327.0,4.0,35.71,3.0,1.129,experimental,17.9,0.1394,0.1235,Thrombin in complex with 1-amidinopiperidine
5AF9,X-RAY DIFFRACTION,2.46,49.97,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2015-01-20,2015-08-26,5AF9,2775.0,3.0,299.0,286.0,4.0,35.72,3.0,1.18,experimental,20.6,0.1372,0.1214,Thrombin in complex with 4-Methoxy-N-(2-pyridinyl)benzamide
5AFY,X-RAY DIFFRACTION,2.5,50.71,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2015-01-27,2015-08-26,5AFY,2780.0,3.0,299.0,327.0,4.0,35.49,3.0,1.12,experimental,18.9,0.1382,0.122,Thrombin in complex with 3-chloro-benzamide
5AHG,X-RAY DIFFRACTION,2.47,50.2,,7.5,"SEE MATERIAL AND METHODS SECTION OF PUBLICATION, pH 7.5",,2015-02-06,2015-08-26,5AHG,2741.0,3.0,299.0,304.0,4.0,35.48,3.0,1.24,experimental,19.9,0.144,0.123,Thrombin in complex with ((4-chlorophenyl)sulfamoyl))diemethylamine
5C56,X-RAY DIFFRACTION,3.79,67.52,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG3350, 0.2M Sodium Bromide",277.0,2015-06-19,2015-07-08,5C56,4446.0,2.0,569.0,6.0,,66.34,2.0,2.685,experimental,76.2301,0.263,0.2155,Crystal structure of USP7/HAUSP in complex with ICP0
7XMK,X-RAY DIFFRACTION,2.35,47.67,"VAPOR DIFFUSION, HANGING DROP",,"0.25M ammonium iodide, 0.03M glycyl-glycyl-glycine, 23% polyethylene glycol (PEG) 3350",277.0,2022-04-26,2023-04-26,7XMK,4333.0,2.0,588.0,141.0,,68.18,1.0,2.376,experimental,39.648,0.2585,0.2243,Crystal structure of human RIPK1 kinase domain in complex with compound SKLB923
6AC5,X-RAY DIFFRACTION,1.79,31.26,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.2 M ammonium sulfate, 100 mM Bis-Tris  pH 5.5",293.0,2018-07-25,2019-05-01,6AC5,926.0,1.0,111.0,111.0,1.0,13.26,1.0,1.451,experimental,,0.1894,0.1558,Crystal structure of RIPK1 death domain GlcNAcylated by EPEC effector NleB
7A0V,X-RAY DIFFRACTION,2.61,52.83,"VAPOR DIFFUSION, SITTING DROP",5.0,"15% PEG 4000, 0.1 M sodium citrate pH 5, 10% 2-propanol",293.0,2020-08-11,2020-12-30,7A0V,10975.0,6.0,1443.0,359.0,3.0,164.01,2.0,2.3,experimental,47.27,0.2523,0.1964,Crystal structure of the 5-phosphatase domain of Synaptojanin1 in complex with a nanobody
5Y2F,X-RAY DIFFRACTION,4.97,72.47,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M (NH4)2SO4, 0.1 M Mes pH 6.5, 20% W/v PEG 8000",291.15,2017-07-25,2018-11-07,5Y2F,2669.0,2.0,325.0,132.0,,38.68,2.0,2.53,experimental,69.863,0.21664,0.17505,Human SIRT6 in complex with allosteric activator MDL-801
4YES,X-RAY DIFFRACTION,2.62,53.13,"VAPOR DIFFUSION, SITTING DROP",6.5,"28 % PEG 2000 MMe, 100mM BisTris",277.0,2015-02-24,2015-06-17,4YES,2620.0,3.0,308.0,231.0,4.0,36.16,3.0,1.5,experimental,30.4147,0.234,0.209,Thrombin in complex with (S)-(4-chloro-2-((1-(5-methyl-1H-pyrrole-2-carbonyl)pyrrolidine-2-carboxamido)methyl)phenyl)methanaminium
5LV0,X-RAY DIFFRACTION,2.7,54.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris-propane, 11% PEG 3350, 10% glycerol, 0.2M potassium thiocyanate",294.0,2016-09-12,2017-12-06,5LV0,10786.0,4.0,1384.0,59.0,,158.61,2.0,2.7,experimental,66.215,0.26049,0.20958,Structure of Human Neurolysin (E475Q) in complex with amyloid-beta 35-40 peptide product
5LMA,X-RAY DIFFRACTION,2.11,41.76,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Sodium formate.",293.0,2016-07-29,2016-09-14,5LMA,2786.0,1.0,277.0,453.0,,32.73,1.0,1.43,experimental,18.816,0.183,0.1559,HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
6HM7,X-RAY DIFFRACTION,2.16,43.04,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG 3350, bistrispropane, sodium bromide",293.0,2018-09-12,2018-10-10,6HM7,2561.0,1.0,276.0,326.0,,32.89,1.0,1.64,experimental,27.959,0.2101,0.172,CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A 2-(PHENOXYMETHYL)PYRIDINE INHIBITOR
5VXZ,X-RAY DIFFRACTION,3.52,65.03,"VAPOR DIFFUSION, HANGING DROP",8.4,"0.7 M Li2SO4, 0.1 M Tris.HCl (pH 8.4)",295.0,2017-05-24,2017-06-21,5VXZ,7703.0,4.0,994.0,194.0,8.0,111.26,2.0,2.3,experimental,61.421,0.2472,0.1984,High-affinity AXL decoy receptor
7U99,X-RAY DIFFRACTION,3.41,63.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 1.1 M Sodium Citrate",293.0,2022-03-10,2022-11-23,7U99,2490.0,1.0,331.0,24.0,,38.26,1.0,2.5,experimental,69.706,0.2139,0.187,EGFR kinase in complex with a macrocyclic inhibitor
7U9A,X-RAY DIFFRACTION,3.43,64.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 1.1 M Sodium Citrate",293.0,2022-03-10,2022-11-23,7U9A,2417.0,1.0,331.0,24.0,,38.16,1.0,2.6,experimental,69.2666,0.226,0.1941,EGFR in complex with a macrocyclic inhibitor
8SC7,X-RAY DIFFRACTION,3.42,64.01,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.05 M Sodium Succinate pH 7.0, 0.1 M HEPES-NaOH pH 6.7",285.0,2023-04-05,2024-06-12,8SC7,2922.0,1.0,330.0,217.0,,38.14,1.0,1.984,experimental,57.55,0.2156,0.1859,Structure of EGFR in complex with MTX-531
5CZH,X-RAY DIFFRACTION,3.26,62.29,"VAPOR DIFFUSION, HANGING DROP",7.6,"0.1M HEPES 7.6, 0.15M NACL, 40%
 PEG400, 5MM TCEP, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2015-07-31,2015-09-30,5CZH,2574.0,2.0,340.0,63.0,,38.93,2.0,2.8,experimental,,0.22,0.192,EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
5X26,X-RAY DIFFRACTION,3.42,64.04,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH7.8, 40% PEG400, 0.15M NaCl, 5mM tris(2-carboxyethyl)-phosphine (TCEP)",293.0,2017-01-31,2018-02-07,5X26,2444.0,1.0,327.0,38.0,,37.83,1.0,2.951,experimental,,0.2215,0.1956,Crystal structure of EGFR 696-1022 L858R in complex with SKLB(3)
5X27,X-RAY DIFFRACTION,3.43,64.12,"VAPOR DIFFUSION, HANGING DROP",7.8,"0.1M Hepes pH 7.8, 40% PEG 400, 0.15M NaCl, 5mM tris(2-carboxyethyl)-phosphine (TCEP)",293.0,2017-01-31,2018-02-07,5X27,2443.0,1.0,327.0,31.0,,37.85,1.0,2.952,experimental,,0.2384,0.2034,Crystal structure of EGFR 696-1022 L858R in complex with SKLB(5)
5X28,X-RAY DIFFRACTION,3.44,64.22,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH7.8, 40% PEG400, 0.15M NaCl, 5mM tris(2-carboxyethyl)-phosphine (TCEP)",293.0,2017-01-31,2018-02-07,5X28,2489.0,1.0,327.0,42.0,,37.87,1.0,2.952,experimental,,0.2504,0.2094,Crystal structure of EGFR 696-1022 L858R in complex with SKLB(6)
6JX0,X-RAY DIFFRACTION,4.25,71.09,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.3 M Ammonium tartrate dibasic, 0.1 M BIS-TRIS propane pH 7.0",293.0,2019-04-21,2020-04-22,6JX0,2495.0,1.0,331.0,131.0,,39.26,1.0,2.53,experimental,,0.2217,0.1915,Crystal structure of EGFR 696-1022 T790M in complex with AZD9291 prepared by co-crystallization
6JXT,X-RAY DIFFRACTION,3.02,59.34,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Potassium sodium tartrate tetrahydrate, 20% w/v Polyethylene glycol 3350",293.0,2019-04-25,2020-04-29,6JXT,2319.0,1.0,331.0,49.0,,37.98,1.0,2.307,experimental,,0.2393,0.2165,Crystal structure of EGFR 696-1022 WT in complex with AZD9291 prepared by cocrystallization
7A6I,X-RAY DIFFRACTION,2.2,44.06,"VAPOR DIFFUSION, HANGING DROP",,"27.5 % PEG3350, 200 mM MgSO4, 4 % ethylen glycole, 7.5 mg/mL EGFR-T790M/V948R (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0) 1 ul reservoir + 1 ul protein solution)",293.0,2020-08-25,2022-02-23,7A6I,2275.0,1.0,333.0,21.0,,38.84,1.0,2.4,experimental,58.5084,0.2391,0.2022,Crystal Structure of EGFR-T790M/V948R in Complex with LDC8201
7B85,X-RAY DIFFRACTION,3.3,62.77,"VAPOR DIFFUSION, HANGING DROP",,"1.6 K-Na-tartrate, 100 mM Na-MES (pH 7.0),
6.2 mg/mL EGFR-WT (im 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP, pH 8.0, 1 ul reservoir + 1 ul solution

Soaking-Experiment",293.0,2020-12-12,2022-02-23,7B85,2476.0,1.0,333.0,6.0,,38.66,1.0,2.5,experimental,82.8126,0.244,0.2147,Crystal Structure of EGFR-WT in Complex with TAK-788
7TVD,X-RAY DIFFRACTION,3.64,66.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"28% PEG 400, 0.1 M Na Hepes pH 7.5, 0.2 M Calcium Chloride",289.15,2022-02-04,2022-02-16,7TVD,2338.0,1.0,335.0,,,38.24,1.0,2.96,experimental,104.92,0.2774,0.2403,Crystal structure of the kinase domain of EGFR exon-19 (del-747-749) mutant
7ZYN,X-RAY DIFFRACTION,3.34,63.18,"VAPOR DIFFUSION, HANGING DROP",,"1.5 K-Na-tartrate, 100 mM Na-MES (pH 6.0),
3.9 mg/mL EGFR-WT (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP) pH 8.0) 1 ul reservoir + 1 ul solution",293.0,2022-05-25,2023-05-03,7ZYN,2579.0,1.0,333.0,64.0,,38.41,1.0,2.3,experimental,67.02,0.2232,0.1913,Crystal Structure of EGFR-T790M/C797S in Complex with WZ4002
7ZYP,X-RAY DIFFRACTION,3.15,60.95,"VAPOR DIFFUSION, HANGING DROP",,"1.5 K-Na-tartrate, 100 mM Na-MES (pH 7.5),
5.5 mg/mL EGFR-WT (in 100 mM NaCl, 25 mM Tris-HCl, 10 % glycerol, 1 mM TCEP) pH 8.0) 1 ul reservoir + 1 ul solution",293.0,2022-05-25,2023-05-03,7ZYP,2320.0,1.0,333.0,2.0,,38.43,1.0,2.8,experimental,87.25,0.2281,0.1987,Crystal Structure of EGFR-T790M/C797S in Complex with Reversible Aminopyrimidine 9
6FDI,X-RAY DIFFRACTION,2.65,53.54,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES",293.0,2017-12-24,2019-04-10,6FDI,11886.0,4.0,1456.0,831.0,,174.66,1.0,1.9,experimental,31.576,0.19998,0.17357,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-226
6FE7,X-RAY DIFFRACTION,2.63,53.21,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES",293.0,2017-12-29,2019-04-10,6FE7,11789.0,4.0,1456.0,670.0,,176.33,1.0,2.0,experimental,40.372,0.20001,0.16963,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-356
6FET,X-RAY DIFFRACTION,2.6,52.73,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES",293.0,2018-01-03,2019-04-24,6FET,11731.0,4.0,1456.0,625.0,,176.36,1.0,1.88,experimental,40.058,0.19932,0.17148,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-1439
6FT0,X-RAY DIFFRACTION,2.64,53.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES pH 7.5",293.0,2018-02-20,2019-03-20,6FT0,11547.0,4.0,1456.0,575.0,,174.15,1.0,2.1,experimental,43.88,0.22216,0.17073,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-425
6FTA,X-RAY DIFFRACTION,2.65,53.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES pH 7.5",293.0,2018-02-20,2019-03-20,6FTA,11415.0,4.0,1456.0,484.0,,173.35,1.0,2.34,experimental,52.888,0.24012,0.18122,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-3098
6FW3,X-RAY DIFFRACTION,2.65,53.65,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES",293.0,2018-03-05,2019-03-20,6FW3,11966.0,4.0,1456.0,941.0,,174.89,1.0,1.78,experimental,31.367,0.21436,0.17724,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-007
6IAG,X-RAY DIFFRACTION,2.63,53.26,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES pH 7.5",293.0,2018-11-26,2019-12-18,6IAG,11530.0,4.0,1456.0,655.0,,172.73,1.0,2.0,experimental,35.584,0.24614,0.19994,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-637
6IBF,X-RAY DIFFRACTION,2.61,52.92,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES pH 7.5",293.0,2018-11-29,2019-12-18,6IBF,11470.0,4.0,1456.0,528.0,,173.71,1.0,2.31,experimental,42.327,0.26234,0.20326,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-417
6E37,X-RAY DIFFRACTION,3.15,60.98,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.45 M potassium phosphate dibasic
10 mM EDTA
1% xylitol",293.0,2018-07-13,2019-11-06,6E37,5795.0,2.0,737.0,191.0,,83.02,2.0,2.531,experimental,,0.2112,0.1671,O-GlcNAc Transferase in complex with covalent inhibitor
5KPK,X-RAY DIFFRACTION,2.98,58.78,"VAPOR DIFFUSION, SITTING DROP",7.0,"Reservoir: 0.15 M DL-malic acid, pH 7.0, 20% w/v PEG3350",298.0,2016-07-04,2018-03-14,5KPK,5836.0,2.0,848.0,240.0,,95.05,1.0,2.4,experimental,55.822,0.2236,0.167,Glycogen Synthase Kinase 3 beta Complexed with BRD0209
5KPL,X-RAY DIFFRACTION,2.64,53.47,"VAPOR DIFFUSION, SITTING DROP",6.5,"Reservoir: 0.1 M Bis-Tris, pH 6.5, 25% w/v PEG3350",298.0,2016-07-04,2018-03-14,5KPL,5573.0,2.0,848.0,97.0,,95.0,1.0,2.6,experimental,70.589,0.2438,0.1785,Glycogen Synthase Kinase 3 beta Complexed with BRD0705
5KPM,X-RAY DIFFRACTION,2.96,58.4,"VAPOR DIFFUSION, SITTING DROP",7.0,"Reservoir: 0.2 M sodium acetate, pH 7.0, 20% w/v PEG3350",298.0,2016-07-04,2018-03-14,5KPM,5644.0,2.0,848.0,63.0,,95.11,1.0,2.69,experimental,63.918,0.2401,0.1749,Glycogen Synthase Kinase 3 beta Complexed with BRD3731
6GJO,X-RAY DIFFRACTION,3.01,59.15,VAPOR DIFFUSION,8.1,"100 mM Tris Acetate pH 8.1, 125 mM NaCl, 15-20% PEG8K",277.0,2018-05-16,2019-03-27,6GJO,5648.0,2.0,828.0,48.0,,92.98,1.0,2.91,experimental,19.03,0.237,0.217,Crystal Structure of Glycogen Synthase Kinase-3 beta in Complex with BI-91BS
6Y9S,X-RAY DIFFRACTION,2.7,54.46,VAPOR DIFFUSION,,"0.10 M TrisAc pH8.25
26 % PEG 8K
0.13 M NaCl",277.0,2020-03-10,2020-05-20,6Y9S,5853.0,2.0,700.0,282.0,,80.73,1.0,2.03,experimental,41.632,0.2493,0.2025,"Crystal structure of GSK-3b in complex with the imidazo[1,5-a]pyridine-3-carboxamide inhibitor 16"
7E0Z,X-RAY DIFFRACTION,2.14,42.6,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Bis-Tris, pH 6.5, 25% PEG 3350",298.15,2021-01-28,2022-04-27,7E0Z,3050.0,2.0,370.0,238.0,,43.29,2.0,2.162,experimental,30.8797,0.2276,0.179,Crystal structure of PKAc-PLN complex
7E12,X-RAY DIFFRACTION,2.21,44.34,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M NaCl, 0.1 M HEPES, pH 7.5, 25% PEG 3350",298.15,2021-01-28,2022-04-27,7E12,2727.0,2.0,370.0,23.0,,43.35,2.0,2.796,experimental,37.9307,0.2518,0.2029,Crystal structure of PKAc-A11E complex
5NEI,X-RAY DIFFRACTION,1.98,37.81,VAPOR DIFFUSION,,"10% PEG 3350, 100 mM Na/K tartrate",292.0,2017-03-10,2018-02-21,5NEI,1799.0,1.0,237.0,11.0,,27.83,1.0,2.68,experimental,,0.2476,0.1987,The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with JES107
7S0Y,X-RAY DIFFRACTION,2.91,57.67,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium cacodylate (pH 6.6), 2.4 M ammonium sulfate, and 2.5% (v/v) Jeffamine M-600 (pH 7.0)",291.0,2021-08-31,2021-09-08,7S0Y,5920.0,2.0,722.0,23.0,,84.92,2.0,2.79,experimental,77.173,0.25924,0.21437,Structures of TcdB in complex with Cdc42
7B6F,X-RAY DIFFRACTION,2.87,57.08,"VAPOR DIFFUSION, SITTING DROP",,"protein solution: 10 mg/ml in buffer 25mM HEPES, pH 7.5, 200mM NaCl, 5% glycerol, 0.5mM TCEP
reservoir:12% PEG 8000, 1 mM MgCl2, 0.5M NaCl and 0.1M Tris pH 8.0",293.0,2020-12-07,2020-12-16,7B6F,2928.0,1.0,365.0,185.0,,42.37,1.0,2.05,experimental,43.91,0.2093,0.1739,GSK3-beta in complex with compound (S)-5c
6Y9R,X-RAY DIFFRACTION,3.01,59.14,VAPOR DIFFUSION,,"18 % PEG8000
0.13 M NaCl
0.10 M Tris_Acetat_7.5
5 mM TCEP",277.0,2020-03-10,2020-05-20,6Y9R,3045.0,1.0,350.0,133.0,,40.58,1.0,2.08,experimental,53.315,0.2261,0.1891,Crystal structure of GSK-3b in complex with the 1H-indazole-3-carboxamide inhibitor 2
6FTW,X-RAY DIFFRACTION,2.65,53.55,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES pH 7.5",293.0,2018-02-24,2019-03-20,6FTW,11460.0,4.0,1456.0,551.0,,172.64,1.0,2.16,experimental,47.953,0.23314,0.18194,Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-048
5J19,X-RAY DIFFRACTION,2.81,56.26,EVAPORATION,5.5,"PEG 3350, NaCOOH",289.0,2016-03-29,2016-06-15,5J19,3705.0,4.0,498.0,106.0,,57.54,2.0,2.0,experimental,33.93,0.2356,0.213,phospho-Pon binding-induced Plk1 dimerization
6BLF,X-RAY DIFFRACTION,2.06,40.18,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES pH 7.5, 15% PEG 8000, 2% Ethylene Glycol, 10 mM TCEP",293.0,2017-11-10,2018-11-14,6BLF,5973.0,2.0,746.0,212.0,,88.56,1.0,2.11,experimental,36.44,0.228,0.185,"PDE2 complexed with 2-[6-fluoro-8-methylsulfonyl-9-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]-1,2,3,4-tetrahydrocarbazol-1-yl]acetic acid"
4UWB,X-RAY DIFFRACTION,2.7,54.0,,,"20% PEG8000, 20% ETHLYENE GLYCOL, 0.2M AMMONIUM SULPHATE, 0.1M PCTP PH 6.75",,2014-08-11,2015-09-02,4UWB,4931.0,2.0,618.0,193.0,,71.44,1.0,2.31,experimental,54.516,0.27172,0.22892,Fibroblast growth factor receptor 1 kinase in complex with JK-P5
6P69,X-RAY DIFFRACTION,2.7,54.51,"VAPOR DIFFUSION, HANGING DROP",,"1:1 mix of protein + reservoir
Protein at ~15 mg/mL formulated in: 20mM Tris pH 8, 20mM NaCl, 2mM TCEP
Reservoir:
14-18% PEG 10K
0.3 M (NH4)2SO4
0.1 M MES pH 6.5
5% ethylene glycol",277.0,2019-06-03,2019-06-19,6P69,4936.0,2.0,618.0,248.0,,71.91,1.0,2.2,experimental,34.094,0.24498,0.18576,Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 11.
8UKV,X-RAY DIFFRACTION,3.89,68.35,"VAPOR DIFFUSION, HANGING DROP",7.4,"70-90 micromolar protein, 15-20% PEG 3350, 100 mM ammonium phosphate, pH 7.4,  +20% PEG400 for cryo",293.0,2023-10-15,2024-06-19,8UKV,6739.0,4.0,996.0,,26.0,111.44,2.0,2.94,experimental,,0.2524,0.2149,Crystal structure of nanobody/VHH domain of 34E5 in complex with the extracellular region of the epidermal growth factor variant III (EGFRvIII)
6GQJ,X-RAY DIFFRACTION,2.49,50.56,"VAPOR DIFFUSION, SITTING DROP",7.5,"10 % PEG 4000, 20 % glycerol, 0.1 M HEPES-MOPS pH 7.5, 
0.02 M sodium formate, 0.02 M ammonium acetate, 0.02 M sodium citrate tribasic dihydrate, 0.02 M sodium potassium tartrate tetrahydrate, 0.02 M sodium oxamate",293.0,2018-06-07,2018-09-19,6GQJ,4992.0,2.0,654.0,217.0,,75.34,1.0,2.33,experimental,56.94,0.217,0.181,Crystal structure of human c-KIT kinase domain in complex with AZD3229-analogue (compound 18)
6GQK,X-RAY DIFFRACTION,2.74,55.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"10 % PEG 8000, 20 % ethylene glycol, 0.1 M Tris-BICINE pH 8.5, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",293.0,2018-06-07,2018-09-19,6GQK,5064.0,2.0,656.0,222.0,,75.53,1.0,2.31,experimental,56.94,0.22,0.187,Crystal structure of human c-KIT kinase domain in complex with AZD3229-analogue (compound 23)
4X2F,X-RAY DIFFRACTION,2.11,41.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris-HCl, 240 mM Li2SO4, 24% PEG 4000, pH 7.5",293.0,2014-11-26,2015-10-28,4X2F,2761.0,1.0,305.0,263.0,,35.23,1.0,1.49,experimental,19.2,0.1911,0.1632,Selection of fragments for kinase inhibitor design: decoration is key
4YC8,X-RAY DIFFRACTION,3.08,60.1,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 22% PEG 3350, 100 mM NaOAc",293.0,2015-02-19,2016-03-02,4YC8,4189.0,2.0,574.0,11.0,,68.02,1.0,2.9,experimental,35.42,0.24,0.1964,C-Helix-Out Binding of Dasatinib Analog to c-Abl Kinase
6L65,X-RAY DIFFRACTION,2.21,44.31,EVAPORATION,6.5,"0.1M MES, pH 6.5, 6%-20% (w/v) PEG 10000",293.1,2019-10-28,2020-11-04,6L65,2768.0,2.0,312.0,377.0,,35.63,2.0,1.8,experimental,20.5053,0.2184,0.1769,Sirtuin 2 protein with H3K18 myristoylated peptide
6SUP,X-RAY DIFFRACTION,2.81,56.22,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.1 M sodium chloride, 0.1 M magnesium chloride, 0.1 M tri-sodium citrate pH 5.5, 12 % PEG 4000
Seeding: 0.1 M magnesium chloride, 0.1 M tri-sodium acetate pH 4.6, 12 % PEG 6000",293.15,2019-09-16,2019-12-04,6SUP,18283.0,1.0,2128.0,1279.0,1.0,240.9,1.0,2.0,experimental,,0.32,0.287,Crystal Structure of TcdB2-TccC3-Cdc42
6ITM,X-RAY DIFFRACTION,2.09,41.18,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2M Ammonium acetate, 0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350",291.0,2018-11-23,2019-11-27,6ITM,4004.0,4.0,508.0,33.0,,60.22,2.0,2.5,experimental,45.246,0.2418,0.1918,Crystal structure of FXR in complex with agonist XJ034
6XUY,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, HANGING DROP",5.7,"100 mM Bis-Tris pH 5.7, 1.6 M (NH4)2SO4, and 10% PEG 400",293.0,2020-01-21,2020-10-28,6XUY,4538.0,2.0,604.0,49.0,,69.53,1.0,2.13,experimental,38.214,0.179,0.1607,Human Sirt6 13-308 in complex with ADP-ribose
5QHA,X-RAY DIFFRACTION,4.09,69.94,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-09-21,2019-03-27,5QHA,1675.0,1.0,196.0,175.0,,22.58,1.0,1.57,experimental,30.8,0.233,0.194,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with PCM-0102951
5T3P,X-RAY DIFFRACTION,2.68,54.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.8M Sodium phosphate monobasic, 0.8M pottassium phosphate dibasic, 0.1M HEPES pH 7.5",277.0,2016-08-26,2017-09-13,5T3P,5567.0,3.0,708.0,314.0,,80.75,1.0,2.03,experimental,51.3431,0.225,0.1774,Crystal structure of Human Peroxisomal coenzyme A diphosphatase NUDT7
7ZZT,X-RAY DIFFRACTION,1.85,33.68,"VAPOR DIFFUSION, SITTING DROP",,"40% PEG 300
0.1M pH=8.6 CHES/NaOH",293.0,2022-05-26,2022-09-21,7ZZT,10137.0,3.0,1494.0,1016.0,,172.02,1.0,1.56,experimental,26.338,0.1733,0.148,Ligand binding to HDAC2
7ZZU,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"43% PEG 300
0.1M pH=8.8 CHES/NaOH",293.0,2022-05-26,2022-09-21,7ZZU,9617.0,3.0,1494.0,413.0,,172.94,1.0,1.85,experimental,25.873,0.1818,0.1537,Inhibitory Ligand binding to HDAC2
7ZZW,X-RAY DIFFRACTION,1.86,33.7,"VAPOR DIFFUSION, SITTING DROP",,"41% PEG 300
0.1M pH=8.8 CHES/NaOH",293.0,2022-05-26,2022-09-21,7ZZW,9657.0,3.0,1494.0,507.0,,173.1,1.0,1.73,experimental,31.794,0.1891,0.1643,Ligand binding to HDAC2
8A0B,X-RAY DIFFRACTION,,33.75,"VAPOR DIFFUSION, SITTING DROP",,"41% PEG 300
.1M pH=8.8 CHES/NaOH",293.0,2022-05-27,2022-09-21,8A0B,9884.0,3.0,1494.0,813.0,,171.94,1.0,1.746,experimental,32.91,0.188,0.165,Inhibitor binding to HDAC2
7LTG,X-RAY DIFFRACTION,2.44,49.66,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5",293.0,2021-02-19,2021-05-05,7LTG,9853.0,3.0,1128.0,666.0,,132.61,1.0,1.8,experimental,29.5,0.198,0.168,STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH APICIDIN
7ZZO,X-RAY DIFFRACTION,2.47,50.14,"VAPOR DIFFUSION, SITTING DROP",,"38% PEG 300
0.1M pH=8.8 CHES/NaOH",293.0,2022-05-25,2022-09-21,7ZZO,9833.0,3.0,1494.0,807.0,,171.31,1.0,2.0,experimental,25.66,0.225,0.1718,HDAC2 in complex with an inhibitor
7ZZR,X-RAY DIFFRACTION,,,"VAPOR DIFFUSION, SITTING DROP",,"41% PEG 300
0.1M pH=8.8 CHES/NaOH",293.0,2022-05-26,2022-09-21,7ZZR,9995.0,3.0,1494.0,908.0,,172.24,1.0,2.168,experimental,24.331,0.2467,0.1884,HDAC2 in complex with inhibitory ligand
6ZCR,X-RAY DIFFRACTION,2.06,40.22,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",278.0,2020-06-12,2021-06-23,6ZCR,2346.0,1.0,299.0,151.0,,35.3,1.0,1.73,experimental,34.68,0.218,0.188,SYK Kinase domain in complex with azabenzimidazole inhibitor 7
6ZCU,X-RAY DIFFRACTION,2.06,40.22,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",277.0,2020-06-12,2021-06-23,6ZCU,2346.0,1.0,299.0,151.0,,35.3,1.0,1.73,experimental,34.68,0.218,0.188,syk in complex with 57262_SYKB-AZ13344324-2
5O33,X-RAY DIFFRACTION,2.43,49.37,"VAPOR DIFFUSION, SITTING DROP",4.2,"0.1M citrate pH4.2, 0.2M sodium chloride, 18% (W/V) PEG 8000",293.0,2017-05-23,2017-05-31,5O33,3144.0,2.0,357.0,282.0,,41.58,2.0,1.64,experimental,,0.2398,0.2067,A structure of the GEF Kalirin DH1 domain in complex with the small GTPase Rac1
7G82,X-RAY DIFFRACTION,2.51,51.07,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G82,4186.0,2.0,430.0,421.0,,51.27,2.0,1.409,experimental,27.26,0.2092,0.1877,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1079512010
7G8R,X-RAY DIFFRACTION,2.52,51.15,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8R,4157.0,2.0,430.0,432.0,,50.77,2.0,1.44,experimental,27.04,0.2073,0.1867,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z1270087714
7G8U,X-RAY DIFFRACTION,2.53,51.31,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8U,3700.0,2.0,430.0,137.0,,50.31,2.0,2.44,experimental,55.23,0.2937,0.2239,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z131833926
7G8V,X-RAY DIFFRACTION,2.5,50.74,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G8V,4143.0,2.0,430.0,421.0,,50.83,2.0,1.451,experimental,27.57,0.2193,0.1939,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z133716556
7G97,X-RAY DIFFRACTION,2.51,50.96,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G97,3450.0,2.0,430.0,87.0,,49.96,2.0,2.3,experimental,36.521,0.249,0.1898,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with Z57899718
7G99,X-RAY DIFFRACTION,2.48,50.5,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris, 2.6M sodium formate",293.0,2023-06-22,2023-07-12,7G99,4002.0,2.0,430.0,281.0,,51.16,2.0,1.78,experimental,48.76,0.2366,0.2063,ARHGEF2 PanDDA analysis group deposition -- ARHGEF2 and RhoA in complex with PCM-0102102-001
8AM0,X-RAY DIFFRACTION,2.29,46.37,"VAPOR DIFFUSION, HANGING DROP",8.1,"0.10 M Bis-Tris-Propane pH 8.10, 0.20 M Na 3 -citrate, 10.00 %(w/v) PEG 3350",293.0,2022-08-02,2023-12-13,8AM0,10845.0,2.0,1361.0,189.0,,160.45,2.0,2.818,experimental,69.9,0.3,0.2854,Crystal structure of human T1061E PI3Kalpha in complex with its regulatory subunit and the inhibitor GDC-0077 (Inavolisib)
,,,,"VAPOR DIFFUSION, HANGING DROP",8.1,"0.10 M Bis-Tris-Propane pH 8.10, 0.20 M Na 3 -citrate, 10.00 %(w/v) PEG 3350",293.0,,,,,,,,,,,,,,,,
,,,,"VAPOR DIFFUSION, HANGING DROP",8.1,"0.10 M Bis-Tris-Propane pH 8.10, 0.20 M Na 3 -citrate, 10.00 %(w/v) PEG 3350",293.0,,,,,,,,,,,,,,,,
5NG3,X-RAY DIFFRACTION,2.91,57.77,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 8.5, 0.5 mM (NH4)2SO4",293.0,2017-03-16,2017-06-28,5NG3,9229.0,4.0,1216.0,53.0,,141.63,2.0,2.6,experimental,69.882,0.26869,0.23167,Structure of inactive kinase RIP2K(K47R)
5I81,X-RAY DIFFRACTION,3.7,66.72,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.5 M ammonium sulfate, 0.1 M sodium acetate pH 5.0-5.5, 12% glycerol",294.0,2016-02-18,2016-09-07,5I81,4588.0,1.0,583.0,176.0,8.0,69.16,1.0,2.25,experimental,,0.2047,0.1837,aSMase with zinc
6J1Z,X-RAY DIFFRACTION,2.14,42.56,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES sodium pH 7.5, 10% v/v 2-Propanol, 20% w/v PEG 4000",289.15,2018-12-30,2019-07-24,6J1Z,2952.0,1.0,481.0,21.0,,57.13,1.0,2.7,experimental,,0.291,0.2069,WWP2 semi-open conformation
6KX3,X-RAY DIFFRACTION,2.88,57.22,"VAPOR DIFFUSION, SITTING DROP",4.5,"10 mg/mL mutant, 0.2M NaCl, 0.1M acetate Na (pH 4.5), 1.26M ammonium sulfate",289.0,2019-09-09,2020-08-19,6KX3,1477.0,1.0,181.0,82.0,,21.14,1.0,1.981,experimental,41.2361,0.2677,0.2207,Crystal structure of RhoA protein with covalent inhibitor DC-Rhoin
7TNH,X-RAY DIFFRACTION,2.4,49.0,"VAPOR DIFFUSION, SITTING DROP",6.5,"CSF1R at 10.7 mg/mL in 50 mM Tris pH 7.5, 200 mM NaCl, 5% glycerol with 5-fold excess of arylamide compound against 10% PEG 10,000, 0.1 M MES pH 6.5 and 0.1 M magnesium acetate soaked over two nights with 1 mM DP-6233 and 20% ethylene glycol as cryo",295.0,2022-01-21,2022-08-24,7TNH,2122.0,1.0,338.0,9.0,,39.08,1.0,2.7,experimental,71.98,0.269,0.215,Crystal structure of CSF1R kinase domain in complex with DP-6233
6AAW,X-RAY DIFFRACTION,1.93,36.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 % w/v Polyethylene glycol 8,000, 100 mM HEPES pH 7.5, 200 mM Ammonium sulfate, 10 % v/v 2-Propanol",298.0,2018-07-19,2019-07-24,6AAW,878.0,2.0,138.0,34.0,,15.52,2.0,2.0,experimental,26.041,0.22336,0.18412,Mdm2 in complex with a D amino Acid Containing Stapled Peptide
6I3S,X-RAY DIFFRACTION,2.25,45.48,"VAPOR DIFFUSION, HANGING DROP",4.5,"2.10 M (NH4)2SO4, 0.10 M Na acetate",293.0,2018-11-07,2018-12-19,6I3S,890.0,1.0,94.0,47.0,,11.75,1.0,1.77,experimental,18.208,0.2392,0.1884,Crystal structure of MDM2 in complex with compound 13.
7BIR,X-RAY DIFFRACTION,3.34,63.12,"VAPOR DIFFUSION, SITTING DROP",6.5,"2M (NH4)2SO4
5% PEG 400
.1M pH=6.5 Na MES/HCl",277.0,2021-01-13,2021-04-07,7BIR,904.0,1.0,98.0,91.0,,11.93,1.0,2.02,experimental,45.868,0.243,0.219,Inhibitor of MDM2-p53 Interaction
7BIT,X-RAY DIFFRACTION,2.87,57.16,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.5M (NH4)2SO4
15% Glycerol
.1M pH=8.5 Tris Cl/NaOH",277.0,2021-01-13,2021-04-07,7BIT,880.0,1.0,114.0,58.0,,13.46,1.0,2.13,experimental,53.673,0.307,0.255,Inhibitor of MDM2-p53 Interaction
7BMG,X-RAY DIFFRACTION,3.32,62.91,"VAPOR DIFFUSION, SITTING DROP",,2.2M (NH4)2SO4,277.0,2021-01-20,2021-04-07,7BMG,911.0,1.0,98.0,105.0,,11.88,1.0,1.83,experimental,35.855,0.251,0.229,Inhibitor of MDM2-p53 Interaction
7NA4,X-RAY DIFFRACTION,1.8,31.8,VAPOR DIFFUSION,,undisclosed,293.0,2021-06-19,2021-11-10,7NA4,870.0,1.0,110.0,29.0,,13.35,1.0,1.84,experimental,30.99,0.2173,0.191,HDM2 in complex with compound 63
5ETA,X-RAY DIFFRACTION,2.39,48.61,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 0.1M Tris/HCl pH 8.5, 25-28% PEG 3350",293.0,2015-11-17,2016-10-26,5ETA,5685.0,4.0,752.0,13.0,1.0,86.31,2.0,2.8,experimental,,0.2903,0.2188,Structure of MAPK14 with bound the KIM domain of the Toxoplasma protein GRA24
4U1P,X-RAY DIFFRACTION,1.79,31.39,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS/Na HEPES pH 7.5, 0.12 M monosaccharide mixture, PEG 1000, 12.5%(w/v) PEG 3350 and 12.5%(v/v) MPD",293.0,2014-07-16,2015-07-29,4U1P,1166.0,2.0,133.0,185.0,,17.15,2.0,1.4,experimental,,0.1875,0.1511,Human Fyn-SH2 domain in complex with a synthetic high-affinity phospho-peptide
6EDF,X-RAY DIFFRACTION,2.0,37.6,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M magnesium acetate",291.0,2018-08-09,2018-08-29,6EDF,693.0,1.0,79.0,61.0,,8.94,1.0,1.4,experimental,12.097,0.1721,0.1434,Fragment of a tyrosine-protein kinase
5SVE,X-RAY DIFFRACTION,2.67,53.88,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1 M HEPES pH 7.0
15% Peg 4000",298.0,2016-08-05,2017-01-11,5SVE,4339.0,3.0,558.0,53.0,,64.45,3.0,2.596,experimental,,0.2394,0.1948,Structure of Calcineurin in complex with NFATc1 LxVP peptide
4ZOG,X-RAY DIFFRACTION,3.18,61.37,"VAPOR DIFFUSION, SITTING DROP",6.6,"PEG MME2000 (31% w/v), MES (100 mM, pH 6.5) and sodium acetate (260mM).",277.0,2015-05-06,2016-09-14,4ZOG,4479.0,2.0,566.0,125.0,,66.89,1.0,2.3,experimental,,0.2332,0.1842,VX-680/MK-0457 binds to human ABL1 also in inactive DFG conformations.
5E8E,X-RAY DIFFRACTION,2.98,58.7,VAPOR DIFFUSION,4.2,"100MM SODIUM PHOSPHATE/CITRATE, PH 4.2, 40% PEG300",298.0,2015-10-14,2015-10-28,5E8E,6373.0,4.0,739.0,407.0,10.0,85.48,4.0,1.9,experimental,35.109,0.24414,0.20112,Crystal structure of thrombin bound to an exosite 1-specific IgA Fab
6QDZ,X-RAY DIFFRACTION,2.26,45.65,"VAPOR DIFFUSION, HANGING DROP",9.0,"PEG 3000, Calcium Chloride, CHES",293.0,2019-01-03,2020-01-29,6QDZ,2865.0,1.0,362.0,157.0,,42.32,1.0,1.73,experimental,27.854,0.2463,0.20346,P38 alpha complex with AR117045
5O8U,X-RAY DIFFRACTION,2.32,47.03,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000",293.15,2017-06-14,2017-09-06,5O8U,2725.0,1.0,360.0,79.0,,41.77,1.0,2.0,experimental,34.502,0.25236,0.20264,Covalent Inhibitor 4b bound to the Lipid Pocket of p38alpha Mutant S252C
5O8V,X-RAY DIFFRACTION,2.28,46.03,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000",293.15,2017-06-14,2017-09-06,5O8V,2708.0,1.0,360.0,79.0,,41.77,1.0,2.0,experimental,43.332,0.26906,0.20598,Covalent Inhibitor 4a bound to the Lipid Pocket of p38alpha Mutant S251C
4R3C,X-RAY DIFFRACTION,2.17,43.25,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.075M Ammonium Acetate, 0.1M BisTris (pH 5.5), 16% PEG 10000, VAPOR DIFFUSION, SITTING DROP, temperature 295K",295.0,2014-08-14,2015-02-25,4R3C,3063.0,1.0,383.0,153.0,,45.07,1.0,2.06,experimental,46.096,0.21669,0.1755,Crystal structure of p38 alpha MAP kinase in complex with a novel isoform selective drug candidate
5MZ3,X-RAY DIFFRACTION,2.95,58.32,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG8000, 20mM Mg acetate and 0.1M Hepes pH7",293.0,2017-01-30,2017-11-15,5MZ3,3123.0,1.0,369.0,279.0,,42.9,1.0,2.15,experimental,34.79,0.197,0.165,"P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide]"
5TBE,X-RAY DIFFRACTION,1.95,36.93,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, 21-29 % PEG4000, 25 mM BOG",293.0,2016-09-12,2017-04-19,5TBE,2706.0,1.0,360.0,36.0,,41.96,1.0,2.44,experimental,37.457,0.25381,0.18634,Human p38alpha MAP Kinase in Complex with Dibenzosuberone Compound 2
5TCO,X-RAY DIFFRACTION,2.29,46.3,"VAPOR DIFFUSION, HANGING DROP",6.2,"100 mM MES, 22% PEG4000, 50 mM n-BOG",293.0,2016-09-15,2017-04-19,5TCO,2742.0,1.0,360.0,58.0,,42.45,1.0,2.1,experimental,,0.2697,0.2145,Human p38 MAP Kinase in Complex with Dibenzosuberone Compound 1
5XYX,X-RAY DIFFRACTION,3.12,60.63,"VAPOR DIFFUSION, HANGING DROP",7.5,"Sodium citrate, Ammonium sulfate, HEPES",298.0,2017-07-11,2018-01-17,5XYX,2754.0,1.0,380.0,,,43.81,1.0,2.61,experimental,34.214,0.26044,0.21553,The structure of p38 alpha in complex with a triazol inhibitor
5XYY,X-RAY DIFFRACTION,3.02,59.29,"VAPOR DIFFUSION, HANGING DROP",7.5,"Sodium citrate, Ammonium sulfate, HEPES",298.0,2017-07-11,2018-01-17,5XYY,3126.0,1.0,380.0,320.0,,43.83,1.0,1.7,experimental,,0.2007,0.1786,The structure of p38 alpha in complex with a triazol inhibitor
6M95,X-RAY DIFFRACTION,2.01,38.66,"VAPOR DIFFUSION, SITTING DROP",7.4,"16.% PEG 3350, 0.06M MES, 0.04M MES_Na",277.15,2018-08-22,2019-04-17,6M95,3018.0,1.0,388.0,310.0,,45.04,1.0,1.8,experimental,22.72,0.2084,0.1724,"Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridine-2-one based p38 MAP Kinase Inhibitors by scaffold hopping: compound 1"
6M9L,X-RAY DIFFRACTION,2.03,39.54,"VAPOR DIFFUSION, SITTING DROP",7.4,"24.% PEG MME 5000, 0.1M MES_Na",277.2,2018-08-23,2019-04-17,6M9L,2843.0,1.0,388.0,156.0,,45.06,1.0,2.45,experimental,24.22,0.2697,0.2134,"Structure-based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridine-2-one based p38 MAP Kinase Inhibitors by scaffold hopping - compound 10"
6OHD,X-RAY DIFFRACTION,2.04,48.9,"VAPOR DIFFUSION, SITTING DROP",,"20.% PEG 3350, 0.1M MES_Na",277.0,2019-04-05,2019-11-20,6OHD,2767.0,1.0,388.0,62.0,,45.08,1.0,2.5,experimental,47.4,0.2529,0.211,P38 in complex with T-3220137
6SFI,X-RAY DIFFRACTION,2.28,46.02,"VAPOR DIFFUSION, SITTING DROP",6.2,"25% MMW PEG smears, 0.1M MES pH 6.2",277.15,2019-08-01,2019-09-11,6SFI,3177.0,1.0,361.0,353.0,,41.9,1.0,1.6,experimental,23.891,0.2025,0.175,Crystal structure of p38 alpha in complex with compound 75 (MCP33)
6SFJ,X-RAY DIFFRACTION,2.41,48.91,"VAPOR DIFFUSION, SITTING DROP",6.2,"17.5% MMW PEG smears, 0.1M MES pH 6.2",277.15,2019-08-01,2019-09-11,6SFJ,2989.0,1.0,361.0,181.0,,41.9,1.0,1.95,experimental,40.521,0.2267,0.1847,Crystal structure of p38 alpha in complex with compound 77 (MCP41)
6SFK,X-RAY DIFFRACTION,2.38,48.22,"VAPOR DIFFUSION, SITTING DROP",6.0,"17.5% MMW PEG smears, 0.1M MES pH 6.0",277.15,2019-08-01,2019-09-11,6SFK,3012.0,1.0,361.0,213.0,,42.2,1.0,1.8,experimental,37.609,0.2184,0.1806,Crystal structure of p38 alpha in complex with compound 81 (MCP42)
7SXF,X-RAY DIFFRACTION,2.7,54.51,"VAPOR DIFFUSION, SITTING DROP",,"0.2M calcium acetate, 0.1M BisTRIS pH 7.0, 5% Glycerol and 17% PEG3350",289.0,2021-11-23,2023-06-14,7SXF,2931.0,2.0,362.0,101.0,,41.66,2.0,1.94,experimental,61.37,0.2347,0.2011,BIO-2895 (BRD0705) bound GSK3alpha-axin complex
7SXG,X-RAY DIFFRACTION,2.78,55.72,"VAPOR DIFFUSION, SITTING DROP",,"0.2M calcium acetate, 0.1M BisTRIS pH 7.0, 5% Glycerol and 17% PEG3350",289.0,2021-11-23,2023-06-14,7SXG,2783.0,2.0,361.0,27.0,,41.65,2.0,2.4,experimental,72.9,0.2612,0.2315,BIO-8546 bound GSK3alpha-axin complex
8H7F,X-RAY DIFFRACTION,3.11,60.46,"VAPOR DIFFUSION, HANGING DROP",,"1.5M (NH4)2 SO4, 0.1M HEPES (PH 7.0) and 4% v/v 1,3-Propanediol.",293.0,2022-10-20,2023-03-01,8H7F,4441.0,2.0,554.0,195.0,,64.91,1.0,2.4501342407,experimental,39.8427698956,0.234153850318,0.203775710345,The crystal structure of human abl1 kinase domain in complex with abl1-B-EBA
8H7H,X-RAY DIFFRACTION,3.06,59.85,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M (NH4)2SO4, 0.1 M HEPES (pH 7.0) and 4% v/v 1,3-propanediol",293.0,2022-10-20,2023-03-22,8H7H,4737.0,2.0,554.0,474.0,,65.02,1.0,2.27789711576,experimental,25.6573189228,0.220547655789,0.182442800513,The crystal structure of human abl1 kinase domain in complex with abl1-A-EBA
5GTZ,X-RAY DIFFRACTION,3.45,64.34,"VAPOR DIFFUSION, HANGING DROP",,"150 mM KCl, 0.1 M HEPES pH 8.0, 38% PEG 300, 50mM Glycyl-glycyl-glycine, 10 mM Co-enzyme A (pH 8.0), 2 mM TCEP",293.0,2016-08-24,2017-09-06,5GTZ,2648.0,1.0,331.0,50.0,,38.69,1.0,2.999,experimental,,0.2302,0.1887,Crystal structure of EGFR 696-1022 T790M in complex with JTS-1-39
5ZTO,X-RAY DIFFRACTION,3.64,66.23,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.05M HEPES pH 8.0, 0.2M ZnSO4, 25% PEG 600",298.0,2018-05-04,2019-06-12,5ZTO,2351.0,1.0,331.0,38.0,,38.29,1.0,2.649,experimental,,0.2724,0.2314,Crystal structure of EGFR 696-1022 T790M/C797S in complex with D3003
8F1H,X-RAY DIFFRACTION,3.47,64.53,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH=6.5, 1.1 M Sodium Citrate",293.0,2022-11-05,2023-11-08,8F1H,2514.0,1.0,331.0,11.0,,38.23,1.0,2.8,experimental,,0.2122,0.1845,EGFR kinase in complex with TAS6417 (CLN-081)
8F1Y,X-RAY DIFFRACTION,3.42,63.98,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH=6.5, 1.1 M Sodium Citrate",293.0,2022-11-06,2023-11-08,8F1Y,2389.0,1.0,331.0,7.0,,38.32,1.0,2.75,experimental,75.6135,0.2282,0.2049,EGFR kinase in complex with poziotinib
8F1Z,X-RAY DIFFRACTION,3.45,64.4,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 1.1 M Sodium Citrate",293.0,2022-11-06,2023-11-08,8F1Z,2586.0,1.0,331.0,50.0,,38.49,1.0,2.4,experimental,63.3732,0.2116,0.1917,EGFR kinase in complex with Bayer #33
5KH9,X-RAY DIFFRACTION,2.17,43.26,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291.0,2016-06-14,2016-07-27,5KH9,973.0,1.0,107.0,79.0,,12.44,1.0,1.07,experimental,14.755,0.1503,0.1356,"Crystal structure of a low occupancy fragment candidate (5-[(4-Isopropylphenyl)amino]-6-methyl-1,2,4-triazin-3(2H)-one) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain"
5C8N,X-RAY DIFFRACTION,3.45,64.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292.0,2015-06-25,2015-10-28,5C8N,2550.0,1.0,331.0,106.0,,38.07,1.0,2.401,experimental,53.917,0.25822,0.20209,"EGFR kinase domain mutant ""TMLR"" with compound 23"
5CAL,X-RAY DIFFRACTION,3.45,64.36,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292.0,2015-06-29,2015-10-28,5CAL,2440.0,1.0,331.0,,,37.93,1.0,2.7,experimental,67.19,0.2274,0.2047,"EGFR kinase domain mutant ""TMLR"" with compound 24"
5CAN,X-RAY DIFFRACTION,3.5,64.83,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292.0,2015-06-29,2015-10-28,5CAN,2451.0,1.0,331.0,4.0,,38.04,1.0,2.8,experimental,69.8,0.2317,0.1961,"EGFR kinase domain mutant ""TMLR"" with compound 27"
5CAO,X-RAY DIFFRACTION,3.68,66.6,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethlyene glycol",292.0,2015-06-29,2015-10-28,5CAO,2450.0,1.0,331.0,5.0,,37.97,1.0,2.6,experimental,81.9,0.2305,0.2021,"EGFR kinase domain mutant ""TMLR"" with compound 29"
5CAP,X-RAY DIFFRACTION,3.67,66.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292.0,2015-06-29,2015-10-28,5CAP,2525.0,1.0,331.0,42.0,,38.16,1.0,2.4,experimental,71.66,0.2131,0.1905,"EGFR kinase domain mutant ""TMLR"" with compound 30"
5CAS,X-RAY DIFFRACTION,3.46,64.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292.0,2015-06-29,2015-10-28,5CAS,2574.0,1.0,331.0,134.0,,38.13,1.0,2.1,experimental,60.42,0.2091,0.1825,"EGFR kinase domain mutant ""TMLR"" with compound 41a"
5CAU,X-RAY DIFFRACTION,3.47,64.52,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292.0,2015-06-29,2015-10-28,5CAU,2526.0,1.0,331.0,101.0,,38.13,1.0,2.25,experimental,63.95,0.211,0.1864,"EGFR kinase domain mutant ""TMLR"" with compound 41b"
5CAV,X-RAY DIFFRACTION,3.47,64.51,"VAPOR DIFFUSION, HANGING DROP",7.0,sodium/potassium tartrate,292.0,2015-06-30,2015-10-28,5CAV,2484.0,1.0,331.0,2.0,,38.13,1.0,2.73,experimental,77.73,0.2313,0.197,EGFR kinase domain with compound 41a
5EDP,X-RAY DIFFRACTION,3.66,66.39,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2015-10-21,2015-12-02,5EDP,2366.0,1.0,331.0,,,37.55,1.0,2.9,experimental,75.62,0.2441,0.1998,EGFR kinase (T790M/L858R) apo
5EDQ,X-RAY DIFFRACTION,3.66,66.44,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2015-10-21,2015-12-02,5EDQ,2420.0,1.0,331.0,,,37.93,1.0,2.8,experimental,66.66,0.2415,0.2076,"EGFR kinase (T790M/L858R) with inhibitor compound 15: ~{N}-(7-chloranyl-1~{H}-indazol-3-yl)-7,7-dimethyl-2-(1~{H}-pyrazol-4-yl)-5~{H}-furo[3,4-d]pyrimidin-4-amine"
5EDR,X-RAY DIFFRACTION,3.66,66.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2015-10-21,2015-12-02,5EDR,2493.0,1.0,331.0,57.0,,37.91,1.0,2.6,experimental,77.17,0.2151,0.1906,"EGFR kinase (T790M/L858R) with inhibitor compound 27: ~{N}-(1~{H}-indazol-3-yl)-7,7-dimethyl-2-(2-methylpyrazol-3-yl)-5~{H}-furo[3,4-d]pyrimidin-4-amine"
5EM5,X-RAY DIFFRACTION,3.67,66.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2015-11-05,2015-12-30,5EM5,2438.0,1.0,331.0,8.0,,38.02,1.0,2.65,experimental,67.33,0.2229,0.2123,"EGFR kinase domain mutant ""TMLR"" with pyridone compound 2: 4-[2-(4-chlorophenyl)ethylamino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide"
5EM6,X-RAY DIFFRACTION,3.47,64.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2015-11-05,2015-12-30,5EM6,2464.0,1.0,331.0,6.0,,38.07,1.0,2.78,experimental,50.75,0.229,0.1947,"EGFR kinase domain mutant ""TMLR"" with pyridone compound 19: 4-[(2-azanylpyrimidin-4-yl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide"
5EM7,X-RAY DIFFRACTION,3.46,64.46,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2015-11-05,2015-12-30,5EM7,2474.0,1.0,331.0,,,38.08,1.0,2.81,experimental,74.04,0.2159,0.1888,"EGFR kinase domain mutant ""TMLR"" with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide"
5EM8,X-RAY DIFFRACTION,3.56,65.48,"VAPOR DIFFUSION, HANGING DROP",7.0,sodium/potassium tartrate,292.0,2015-11-05,2015-12-30,5EM8,2449.0,1.0,331.0,,,38.08,1.0,2.8,experimental,88.27,0.229,0.1894,EGFR kinase domain with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide
5GMP,X-RAY DIFFRACTION,3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",8.0,"150mM KCl, 0.1M HEPES (pH 8.0), 38% PEG 300, 50mM Glycyl-glycyl-glycine, 10mM Co-enzyme A (pH 8.0), 2mM TCEP",293.0,2016-07-14,2017-06-28,5GMP,2437.0,1.0,331.0,31.0,,38.18,1.0,2.797,experimental,,0.2408,0.2121,Crystal structure of EGFR 696-1022 T790M in complex with XTF-262
5GNK,X-RAY DIFFRACTION,3.06,59.83,"VAPOR DIFFUSION, HANGING DROP",6.5,"4.8M NaNO3 ,0.1M B-Tris propone pH 6.5, 5mM TCEP",293.0,2016-07-21,2017-04-05,5GNK,2660.0,1.0,297.0,239.0,,36.2,1.0,1.796,experimental,,0.1766,0.1652,Crystal structure of EGFR 696-988 T790M in complex with LXX-6-34
5HCX,X-RAY DIFFRACTION,3.51,64.92,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2016-01-04,2016-09-07,5HCX,2432.0,1.0,331.0,7.0,,38.08,1.0,2.6,experimental,72.8,0.2229,0.1922,"EGFR kinase domain mutant ""TMLR"" with azabenzimidazole compound 7"
5HCY,X-RAY DIFFRACTION,3.5,64.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2016-01-04,2016-09-07,5HCY,2555.0,1.0,331.0,90.0,,38.2,1.0,2.46,experimental,57.17,0.2207,0.1757,"EGFR kinase domain mutant ""TMLR"" with 3-carboxamide azaindole compound 13"
5HCZ,X-RAY DIFFRACTION,3.49,64.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292.0,2016-01-04,2016-09-07,5HCZ,2462.0,1.0,331.0,10.0,,38.2,1.0,2.62,experimental,60.8,0.2269,0.1941,"EGFR kinase domain mutant ""TMLR"" with 3-azetidinyl azaindazole compound 21"
5J9Y,X-RAY DIFFRACTION,3.39,63.75,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, 
900 mM - 1100 mM Na/K-tartrate",293.0,2016-04-11,2016-08-17,5J9Y,2452.0,1.0,323.0,12.0,,37.36,1.0,2.8,experimental,74.174,0.2375,0.1826,EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1b
5J9Z,X-RAY DIFFRACTION,3.39,63.75,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES,
900 mM - 1100 mM Na/K-tartrate",293.0,2016-04-11,2016-08-17,5J9Z,2384.0,1.0,325.0,21.0,,37.55,1.0,2.5,experimental,60.698,0.2391,0.1961,EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1a
5XGM,X-RAY DIFFRACTION,3.47,64.51,"VAPOR DIFFUSION, HANGING DROP",9.5,"0.1M NaCl,0.05M Glycine pH 9.5, 39% PEG 300",293.0,2017-04-14,2017-10-11,5XGM,2301.0,1.0,331.0,24.0,,38.03,1.0,2.952,experimental,,0.2318,0.2026,Crystal structure of EGFR 696-1022 T790M in complex with Go6976
5ZWJ,X-RAY DIFFRACTION,2.41,48.9,"VAPOR DIFFUSION, HANGING DROP",,"26% PEG 4000, 0.1 M KCl, 0.05 M Tris pH 7.5-8.0",293.0,2018-05-15,2018-07-25,5ZWJ,2115.0,1.0,355.0,24.0,,41.22,1.0,2.9,experimental,,0.2718,0.2551,Crystal structure of EGFR 675-1022 T790M/C797S/V948R in complex with EAI045
6JRJ,X-RAY DIFFRACTION,3.61,65.94,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M HEPES pH 8.5, 40% PEG 400, 0.15 M NaCl, 5 mM tris(2-carboxyethyl)-phosphine (TCEP)",298.0,2019-04-04,2020-04-15,6JRJ,2364.0,1.0,331.0,32.0,,38.09,1.0,2.943,experimental,,0.2465,0.2029,The structure of co-crystals of 8r-B-EGFR T790M/C797S complex
6JRK,X-RAY DIFFRACTION,3.5,64.87,"VAPOR DIFFUSION, HANGING DROP",8.0,"38% PEG 300, 150 mM KCl, 0.1 M HEPES (pH 8.0), 50 mM Gly3, 5 mM Co-enzyme A (pH 8.0), 2 mM TCEP",298.0,2019-04-04,2020-04-15,6JRK,2316.0,1.0,331.0,22.0,,38.08,1.0,2.796,experimental,,0.2356,0.1959,The structure of co-crystals of 8r-B-EGFR WT complex
6JZ0,X-RAY DIFFRACTION,3.4,63.8,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.0M Ammonium citrate tribase, 0.1M Bis-Tris propane, pH7.0",291.0,2019-04-30,2019-12-04,6JZ0,2530.0,1.0,326.0,2.0,,37.78,1.0,2.86,experimental,65.3579,0.2476,0.1905,Crystal structure of EGFR kinase domain in complex with compound 78
6VHN,X-RAY DIFFRACTION,3.54,65.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.4M Sodium Citrate, 0.1 M MES",298.0,2020-01-10,2020-04-22,6VHN,2410.0,1.0,327.0,92.0,,37.78,1.0,2.4,experimental,55.8014,0.2003,0.1988,Wild type EGFR in complex with LN2057
7AEI,X-RAY DIFFRACTION,3.27,62.43,VAPOR DIFFUSION,7.5,Trisodium citrate 0.68M,293.0,2020-09-17,2021-06-02,7AEI,2581.0,1.0,329.0,11.0,,38.06,1.0,2.65,experimental,94.79,0.234,0.194,Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series
7T4I,X-RAY DIFFRACTION,3.52,65.03,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Bis-tris pH 6.5, 0.2M lithium sulfate, 24% PEG 3350",293.0,2021-12-10,2022-12-07,7T4I,2574.0,1.0,328.0,54.0,,37.95,1.0,2.61,experimental,83.632,0.2382,0.1815,Crystal Structure of wild type EGFR in complex with TAK-788
5HU9,X-RAY DIFFRACTION,2.35,47.59,"VAPOR DIFFUSION, HANGING DROP",8.0,"0.1M  Potassium thiocyanate, 28% PEG2000",293.0,2016-01-27,2016-07-13,5HU9,2751.0,1.0,277.0,365.0,,33.95,1.0,1.529,experimental,,0.1961,0.1857,Crystal structure of ABL1 in complex with CHMFL-074
7W7Y,X-RAY DIFFRACTION,3.11,60.49,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M (NH4)2 SO4, 0.1M HEPES (pH 7.0) and 4%(v/v) 1,3-Propanediol.",293.0,2021-12-06,2022-04-27,7W7Y,4741.0,2.0,552.0,384.0,,64.96,1.0,2.20003021871,experimental,37.4462999786,0.201239799431,0.174910741354,The crystal structure of human abl1 kinase domain in complex with ABL2-A5
6NTU,X-RAY DIFFRACTION,2.8,56.0,EVAPORATION,5.6,"~20% PEG 3350, 0.2 M ammonium sulfate, 10% DMSO (plus 20% sucrose in cryo), 100 mM sodium citrate pH 5.6",298.0,2019-01-30,2020-02-05,6NTU,2125.0,1.0,271.0,102.0,,31.42,1.0,1.8,experimental,39.93,0.1864,0.1775,Crystal Structure of human PARP-1 ART domain bound to inhibitor UKTT-15
7KFA,X-RAY DIFFRACTION,2.28,45.97,"VAPOR DIFFUSION, SITTING DROP",8.0,"20.0% PEG-6000, 0.1M TRIS",293.0,2020-10-13,2021-11-10,7KFA,4463.0,3.0,683.0,99.0,11.0,73.97,3.0,2.45,experimental,51.55,0.2417,0.1892,PCSK9 in complex with PCSK9i a 13mer cyclic peptide LDLR disruptor
6GPG,X-RAY DIFFRACTION,2.68,54.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M MOPS pH 7.5, 17.5 % (w/v) PEG 3350, 0.25 M NaSCN, 3 % (v/v) 2,2,2 trifluoroethanol",293.0,2018-06-05,2018-08-08,6GPG,5812.0,3.0,742.0,,,90.94,1.0,2.894,experimental,,0.2597,0.2096,Structure of the RIG-I Singleton-Merten syndrome variant C268F
5JFD,X-RAY DIFFRACTION,2.5,51.38,"VAPOR DIFFUSION, HANGING DROP",7.0,"20 mM Sodium dihydrogen phosphate ph 7.5, 
350 mM NACl, 27% PEG 8000,",277.0,2016-04-19,2017-05-24,5JFD,2783.0,3.0,307.0,266.0,4.0,36.53,3.0,1.46,experimental,,0.1633,0.13,Thrombin in complex with (S)-N-(2-(aminomethyl)-5-chlorobenzyl)-1-((benzylsulfonyl)-D-arginyl)pyrrolidine-2-carboxamide
5LCE,X-RAY DIFFRACTION,2.5,50.2,"VAPOR DIFFUSION, HANGING DROP",7.0,"20 mM Sodium dihydrogen phosphate ph 7.5, 
350 mM NaCl
27% PEG 8000",277.0,2016-06-21,2017-07-26,5LCE,2791.0,3.0,307.0,279.0,4.0,36.63,3.0,1.39,experimental,,0.1678,0.14,Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(5-chloro-2-(hydroxymethyl)benzy l)pyrrolidine-2-carboxamide
5LPD,X-RAY DIFFRACTION,2.5,50.0,"VAPOR DIFFUSION, HANGING DROP",7.0,"20 mM Sodium dihydrogen phosphate ph 7.5, 350 mM NaCl, 27% PEG 8000",277.0,2016-08-12,2017-07-26,5LPD,2736.0,3.0,307.0,255.0,4.0,36.38,3.0,1.5,experimental,,0.1701,0.1492,Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(2-(aminomethyl)-5-chlorobenzyl) pyrrolidine-2-carboxamide
6HSX,X-RAY DIFFRACTION,2.54,51.6,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM Sodium dihydrogen phosphate pH 7.5, 350 mM NaCl, 27% PEG 8000",277.0,2018-10-02,2019-10-23,6HSX,2640.0,3.0,306.0,229.0,4.0,36.45,3.0,1.56,experimental,28.05,0.1835,0.1623,Thrombin in Complex with a D-Phe-Pro-diaminopyridine derivative
6ANQ,X-RAY DIFFRACTION,3.15,60.94,"VAPOR DIFFUSION, SITTING DROP",9.5,"PEG 8000, NaCl, CHES (N-Cyclohexyl-2-aminoethanesulfonic acid), TRIS, MgCl2, d4T triphosphate",277.0,2017-08-14,2018-08-15,6ANQ,18272.0,8.0,2096.0,646.0,,263.62,2.0,2.586,experimental,89.785,0.2189,0.1796,STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 8.5
6ASW,X-RAY DIFFRACTION,3.19,61.49,"VAPOR DIFFUSION, SITTING DROP",9.5,"PEG 8000, NaCl, CHES (N-Cyclohexyl-2-aminoethanesulfonic acid), TRIS, MgCl2, d4T triphosphate",277.0,2017-08-25,2018-08-15,6ASW,18269.0,8.0,2096.0,643.0,,263.62,2.0,2.605,experimental,94.1117,0.22,0.179,STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) TERNARY COMPLEX WITH A DOUBLE STRANDED DNA AND AN INCOMING D4TTP AT PH 9.0
8I5V,X-RAY DIFFRACTION,2.87,57.21,"VAPOR DIFFUSION, SITTING DROP",6.5,"ammonium sulfate, sodium cacodylate, PEG 8000, glycerol",293.0,2023-01-26,2023-03-15,8I5V,4169.0,2.0,466.0,516.0,,52.98,2.0,1.726,experimental,,0.2078,0.1785,DOCK10 mutant L1903Y complexed with Rac1
8I5W,X-RAY DIFFRACTION,2.91,57.67,"VAPOR DIFFUSION, SITTING DROP",6.5,"ammonium sulfate, sodium cacodylate, PEG 8000, glycerol",293.0,2023-01-26,2023-03-15,8I5W,3793.0,2.0,466.0,144.0,,52.93,2.0,2.432,experimental,,0.28,0.2195,Crystal structure of the DHR-2 domain of DOCK10 in complex with Rac1
6OX0,X-RAY DIFFRACTION,3.04,59.49,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2019-05-13,2019-08-21,6OX0,8858.0,4.0,1228.0,645.0,,141.65,2.0,1.755,experimental,,0.2249,0.2062,SETD3 in Complex with an Actin Peptide with Sinefungin Replacing SAH as Cofactor
6ROY,X-RAY DIFFRACTION,1.82,32.39,"VAPOR DIFFUSION, SITTING DROP",7.1,"31.7% (w/v) PEG3350, 0.1 M HEPES, 0.233 M MgSO4",291.0,2019-05-13,2020-02-19,6ROY,1822.0,4.0,230.0,26.0,,26.38,2.0,2.1,experimental,35.16,0.2785,0.22525,Structure of the N-SH2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in complex with the phosphorylated immune receptor tyrosine-based inhibitory motif
6ROZ,X-RAY DIFFRACTION,1.85,34.3,"VAPOR DIFFUSION, SITTING DROP",7.1,"31.7% (w/v) PEG 3350, 0.1 M HEPES, 0.233 M MgSO4",293.0,2019-05-13,2020-02-19,6ROZ,1808.0,4.0,230.0,,,26.34,2.0,2.89,experimental,70.991,0.28462,0.23943,Structure of the N-SH2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in complex with the phosphorylated immune receptor tyrosine-based switch motif
5NJA,X-RAY DIFFRACTION,2.29,46.17,"VAPOR DIFFUSION, SITTING DROP",8.0,,293.0,2017-03-28,2017-10-04,5NJA,17151.0,6.0,1896.0,2217.0,,205.45,3.0,1.4,experimental,16.345,0.1712,0.1303,E. coli Microcin-processing metalloprotease TldD/E with angiotensin analogue bound
6MBL,X-RAY DIFFRACTION,2.11,41.62,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M Sodium chloride, 0.1 M BIS-TRIS pH 5.5, 25% w/v Polyethylene glycol 3,350",292.0,2018-08-30,2018-12-19,6MBL,4252.0,2.0,614.0,139.0,,70.55,2.0,2.197,experimental,,0.2272,0.1824,"SETD3, a Histidine Methyltransferase, in Complex with an Actin Peptide and SAH, Second P212121 Crystal Form"
6OX5,X-RAY DIFFRACTION,2.2,44.09,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M ammonium acetate, 0.1 M sodium citrate tribasic dihydrate pH 5.6 and 30% (w/v) polyethylene glycol 4000",292.0,2019-05-13,2019-08-21,6OX5,4294.0,2.0,617.0,235.0,,70.75,2.0,2.098,experimental,,0.2048,0.1627,A SETD3 Mutant (N255A) in Complex with an Actin Peptide with His73 Replaced with Lysine
4UFE,X-RAY DIFFRACTION,2.47,50.3,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, PH 7.5",,2015-03-16,2016-01-27,4UFE,2730.0,3.0,299.0,290.0,4.0,35.52,3.0,1.593,experimental,21.8,0.1817,0.1578,Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-butyl)-3-phenyl-propanamide
4UFF,X-RAY DIFFRACTION,2.5,50.71,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2015-03-16,2016-01-27,4UFF,2658.0,3.0,299.0,224.0,4.0,35.52,3.0,1.55,experimental,22.9,0.1874,0.16,Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-ethyl)-N-methyl-3-phenyl- propanamide
4UFG,X-RAY DIFFRACTION,2.47,50.3,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2015-03-17,2016-01-27,4UFG,2672.0,3.0,299.0,234.0,4.0,35.54,3.0,1.65,experimental,19.9,0.1865,0.1618,Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-((1S)-2-((4- carbamimidoylphenyl)methylamino)-1-methyl-2-oxo-ethyl)-N-methyl-3- phenyl-propanamide ethane
5LMB,X-RAY DIFFRACTION,2.18,43.66,"VAPOR DIFFUSION, SITTING DROP",6.8,"PEG1500, HEPES, TACSIMATE, GLYCEROL",293.0,2016-07-29,2016-09-14,5LMB,4811.0,2.0,554.0,394.0,,65.7,1.0,1.95,experimental,43.673,0.2281,0.1751,HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
8BNT,X-RAY DIFFRACTION,2.53,51.36,"VAPOR DIFFUSION, SITTING DROP",8.5,"2.6 M sodium formate, 100 mM Tris",293.0,2022-11-25,2022-12-07,8BNT,4183.0,2.0,430.0,455.0,,50.65,2.0,1.4,experimental,19.506,0.1751,0.1297,The DH domain of ARHGEF2 bound to RhoA
7AOS,X-RAY DIFFRACTION,2.33,47.23,"VAPOR DIFFUSION, SITTING DROP",,"24% PEG 3350, 0.2M Na acetate, 0.1M Bis Tris Propane pH 7.0",293.0,2020-10-15,2021-08-04,7AOS,3795.0,4.0,558.0,13.0,,63.57,3.0,2.55,experimental,75.71,0.2623,0.205,crystal structure of the RARalpha/RXRalpha ligand binding domain heterodimer in complex with a fragment of SRC1 coactivator
4RX7,X-RAY DIFFRACTION,2.26,45.57,VAPOR DIFFUSION,6.0,"20% PEG 3350, 0.2M ammonium formate, pH 6.0, vapor diffusion, temperature 293K",293.0,2014-12-09,2015-03-18,4RX7,2353.0,1.0,289.0,164.0,,34.2,1.0,1.8,experimental,30.54,0.2034,0.1806,SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor
4RX8,X-RAY DIFFRACTION,2.27,45.73,VAPOR DIFFUSION,7.3,"20% PEG 3350, 0.2M potassium formate, pH 7.3, vapor diffusion, temperature 293K",293.0,2014-12-09,2015-03-18,4RX8,2422.0,1.0,289.0,227.0,,34.22,1.0,1.59,experimental,21.59,0.2071,0.1739,SYK Catalytic Domain Complexed with a Potent Triazine Inhibitor2
4RX9,X-RAY DIFFRACTION,2.26,45.56,VAPOR DIFFUSION,6.0,"20% PEG 3350, 0.2M ammonium formate, pH 6.0, vapor diffusion, temperature 293K",293.0,2014-12-09,2015-03-18,4RX9,2416.0,1.0,290.0,204.0,,34.29,1.0,1.75,experimental,27.41,0.1965,0.1739,SYK Catalytic Domain Complexed with a Potent Pyrimidine Inhibitor
4YJP,X-RAY DIFFRACTION,1.98,38.02,"VAPOR DIFFUSION, HANGING DROP",6.8,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP",293.0,2015-03-03,2015-09-30,4YJP,2374.0,1.0,281.0,197.0,,33.17,1.0,1.83,experimental,39.304,0.2576,0.1922,THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
5T31,X-RAY DIFFRACTION,2.76,55.36,"VAPOR DIFFUSION, SITTING DROP",6.5,"20% PEG MME 5,000 and 0.1 M Bis-Tris pH 6.5",293.0,2016-08-24,2018-02-21,5T31,5203.0,2.0,840.0,,,94.43,1.0,2.85,experimental,79.21,0.26797,0.196,Exploiting an Asp-Glu switch in Glycogen Synthase Kinase 3 to design paralog selective inhibitors for use in acute myeloid leukemia
4ZKN,X-RAY DIFFRACTION,2.08,40.94,"VAPOR DIFFUSION, SITTING DROP",4.6,"50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG 400",298.0,2015-04-30,2016-05-18,4ZKN,2234.0,2.0,259.0,175.0,6.0,29.71,2.0,1.36,experimental,17.955,0.26463,0.22759,The crystal structure of upain-1-W3A in complex with uPA at pH5.5
4ZKO,X-RAY DIFFRACTION,2.14,42.61,"VAPOR DIFFUSION, SITTING DROP",4.6,"50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG 400",298.0,2015-04-30,2016-05-18,4ZKO,2225.0,3.0,259.0,213.0,5.0,29.62,3.0,1.29,experimental,16.784,0.22497,0.21026,The crystal structure of upain-1-W3A in complex with uPA at pH7.4
4ZKR,X-RAY DIFFRACTION,2.16,43.05,"VAPOR DIFFUSION, SITTING DROP",,"50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG400",298.0,2015-04-30,2016-05-18,4ZKR,2168.0,2.0,259.0,191.0,5.0,29.6,2.0,1.36,experimental,17.51,0.234,0.207,The crystal structure of upain-1-W3A in complex with uPA at pH9.0
4X1N,X-RAY DIFFRACTION,2.05,39.92,"VAPOR DIFFUSION, SITTING DROP",4.6,"2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400",298.0,2014-11-25,2015-03-25,4X1N,2102.0,2.0,257.0,65.0,5.0,29.1,2.0,1.8,experimental,39.92,0.27619,0.22971,The crystal structure of mupain-1-16 in complex with murinised human uPA at pH7.4
5YC7,X-RAY DIFFRACTION,2.17,43.22,"VAPOR DIFFUSION, SITTING DROP",,"50mM sodium citrate (pH 4.6), 2.0M ammonium sulfate supplemented with 5% PEG 400",298.0,2017-09-06,2018-10-03,5YC7,1995.0,1.0,246.0,39.0,5.0,28.0,1.0,2.0,experimental,55.99,0.26158,0.21192,The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH7.4
7A17,X-RAY DIFFRACTION,2.42,49.27,"VAPOR DIFFUSION, SITTING DROP",5.5,"15% PEG 3350, 0.1 M sodium citrate pH 5.5, 13% ethanol",293.0,2020-08-12,2020-12-30,7A17,10780.0,6.0,1403.0,71.0,3.0,160.28,5.0,2.73,experimental,43.603,0.25744,0.19578,"Crystal structure of the 5-phosphatase domain of Synaptojanin1 bound to its substrate diC8-PI(3,4,5)P3 in complex with a nanobody"
5YCP,X-RAY DIFFRACTION,2.77,55.65,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate (pH 7.0),296.0,2017-09-07,2018-09-12,5YCP,2316.0,2.0,299.0,85.0,,34.54,2.0,2.0,experimental,44.458,0.23338,0.20132,Human PPARgamma ligand binding domain complexed with Rosiglitazone
5CZI,X-RAY DIFFRACTION,3.19,61.4,"VAPOR DIFFUSION, HANGING DROP",7.6,"0.1M HEPES 7.6, 0.15M NACL, 40%
 PEG400, 5MM TCEP, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293.0,2015-07-31,2015-09-30,5CZI,2646.0,2.0,340.0,129.0,,38.96,2.0,2.6,experimental,,0.225,0.183,EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
8UKW,X-RAY DIFFRACTION,1.6,60.0,"VAPOR DIFFUSION, HANGING DROP",,"7 mg/ml protein, 27.5% PEG 3350, 50 mM Na Citrate pH 5.0",293.15,2023-10-15,2024-06-12,8UKW,4871.0,2.0,714.0,117.0,26.0,80.74,1.0,2.39,experimental,,0.2436,0.2149,Crystal structure the extracellular region of the epidermal growth factor receptor variant III (EGFRvIII) at pH 5.0
7SI1,X-RAY DIFFRACTION,3.31,62.9,VAPOR DIFFUSION,7.0,"0.1 M MES pH 7.0, 1M Na/K Tartrate",292.0,2021-10-12,2022-10-26,7SI1,2843.0,1.0,331.0,267.0,,38.04,1.0,1.6,experimental,27.99,0.2146,0.1923,Crystal structure of apo EGFR kinase domain
5TIU,X-RAY DIFFRACTION,2.24,45.16,"VAPOR DIFFUSION, SITTING DROP",,"16% PEG3350, 0.1M Tris pH 7.1-7.4",277.15,2016-10-03,2017-01-11,5TIU,2421.0,1.0,291.0,248.0,,34.19,1.0,1.49,experimental,29.23,0.2033,0.185,Crystal structure of SYK kinase domain with inhibitor
6FIC,X-RAY DIFFRACTION,4.13,70.23,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5, 4.2 M NaCl",293.0,2018-01-17,2018-01-31,6FIC,2122.0,1.0,280.0,93.0,,36.24,1.0,2.18,experimental,40.443,0.23595,0.20148,Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem
7KXZ,X-RAY DIFFRACTION,3.4,63.78,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 0.8 M sodium citrate",293.0,2020-12-06,2022-01-19,7KXZ,2474.0,1.0,331.0,43.0,,38.21,1.0,2.4,experimental,65.5016,0.2188,0.1901,Active conformation of EGFR kinase in complex with BI-4020
8DSW,X-RAY DIFFRACTION,3.62,66.0,"VAPOR DIFFUSION, HANGING DROP",,"0.2M potassium fluoride
20 % PEG 3350",298.0,2022-07-23,2023-09-27,8DSW,2543.0,1.0,335.0,23.0,,39.03,1.0,2.39,experimental,62.45,0.2463,0.192,"Crystal structure of EGFR kinase domain, Exon20 Insertion FQEA mutant"
8F1X,X-RAY DIFFRACTION,3.41,63.88,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH=6.5, 1.1 M Sodium Citrate",293.0,2022-11-06,2023-11-08,8F1X,2639.0,1.0,331.0,45.0,,38.22,1.0,2.3,experimental,,0.2259,0.2037,EGFR kinase in complex with mobocertinib (TAK-788)
8HV1,X-RAY DIFFRACTION,3.38,63.57,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M TRIS pH 8.5, 0.15M Sodium citrate, 25%PEG400",292.0,2022-12-26,2023-12-13,8HV1,2518.0,1.0,331.0,72.0,,38.23,1.0,2.4,experimental,61.464,0.21884,0.18914,Crystal structure of EGFR_DMX in complex with covalently bound fragment 1
8HV2,X-RAY DIFFRACTION,3.41,63.9,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.1M TRIS pH 7.0, 1.2M Sodium citrate",292.0,2022-12-26,2023-12-13,8HV2,2391.0,1.0,331.0,29.0,,37.78,1.0,2.8,experimental,80.348,0.21645,0.17741,Crystal structure of EGFR_wt in complex with covalently bound fragment 4
8HV5,X-RAY DIFFRACTION,3.36,63.4,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M TRIS pH 8.5, 0.15M Sodium citrate, 25%PEG400",292.0,2022-12-26,2023-12-13,8HV5,2546.0,1.0,331.0,108.0,,38.15,1.0,2.2,experimental,57.309,0.22445,0.18577,Crystal structure of EGFR_DMX in complex with compound 7
8HV8,X-RAY DIFFRACTION,3.32,62.9,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M TRIS pH 8.5, 0.15M Sodium citrate, 25%PEG400",292.0,2022-12-26,2023-12-13,8HV8,2503.0,1.0,331.0,78.0,,38.12,1.0,2.4,experimental,40.424,0.28257,0.2315,Crystal structure of EGFR_TMX in complex with covalently bound fragment 10
8HVA,X-RAY DIFFRACTION,3.39,63.67,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M TRIS pH 8.5, 0.15M Sodium citrate, 25%PEG400",293.0,2022-12-26,2023-12-13,8HVA,2395.0,1.0,331.0,,,37.81,1.0,2.77,experimental,69.759,0.25135,0.24237,Crystal structure of EGFR_TMX in complex with covalently bound compound 14
8HY7,X-RAY DIFFRACTION,3.47,64.58,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES, pH 7.0, 10% (W/V) PEG 10000, 10%(V/V) Ethylene glycol",293.0,2023-01-06,2023-08-23,8HY7,2437.0,1.0,330.0,26.0,,37.99,1.0,2.91,experimental,,0.2505,0.1948,"EGFR kinase domain mutant ""TMLR"" with compound 28f"
7WZC,X-RAY DIFFRACTION,2.08,40.86,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES, pH6.0, 30% PEG 600, 5% PEG 1000, 10% glycerol",289.0,2022-02-17,2023-02-22,7WZC,1569.0,1.0,185.0,117.0,,21.5,1.0,1.7994492129,experimental,22.7305161955,0.264065073643,0.204621538564,An open conformation Form2 of switch II for RhoA GDP-bound state
8FPW,X-RAY DIFFRACTION,2.31,46.85,"VAPOR DIFFUSION, HANGING DROP",8.0,"20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0",277.0,2023-01-05,2024-06-05,8FPW,1756.0,1.0,183.0,231.0,,21.25,1.0,1.4,experimental,,0.2079,0.1781,Crystal structure of tumor related RhoA mutant A161V in complex with GDP
8FPX,X-RAY DIFFRACTION,2.31,46.82,"VAPOR DIFFUSION, HANGING DROP",8.0,"20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0",277.0,2023-01-05,2024-06-05,8FPX,1700.0,1.0,183.0,197.0,,21.16,1.0,1.47,experimental,,0.2249,0.1914,Crystal structure of tumor related RhoA mutant A161P in complex with GDP
7ER2,X-RAY DIFFRACTION,3.46,64.41,"VAPOR DIFFUSION, HANGING DROP",8.0,"38% PEG 300, 150 mM KCl, 0.1 M HEPES (pH 8.0)",293.0,2021-05-05,2022-04-20,7ER2,2366.0,1.0,331.0,16.0,,38.05,1.0,2.662,experimental,56.5444,0.2417,0.1949,Crystal structure of EGFR 696-1022 T790M/C797S in complex with LS_2_40
7VRA,X-RAY DIFFRACTION,3.39,63.71,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.05M CaCl2, 0.1M B-Tris pH 6.2, 24% PEG 550MME, 5mM TCEP",293.0,2021-10-22,2022-06-08,7VRA,2368.0,1.0,331.0,12.0,,38.07,1.0,2.41,experimental,66.3609,0.2452,0.2197,The crystal structure of EGFR T790M/C797S with the inhibitor HC5476
7VRE,X-RAY DIFFRACTION,3.48,64.65,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M HEPES pH 8.5, 40% PEG 400, 0.15 M NaCl, 5 mM tris(2-carboxyethyl)-phosphine (TCEP)",293.0,2021-10-22,2022-06-08,7VRE,2501.0,1.0,331.0,8.0,,38.12,1.0,2.507,experimental,69.2874,0.2421,0.1991,The crystal structure of EGFR T790M/C797S with the inhibitor HCD2892
8A27,X-RAY DIFFRACTION,1.84,32.98,"VAPOR DIFFUSION, SITTING DROP",6.0,"20% PEG Smear Medium, 0.1M MES, 0.15 ammonium nitrate, 5% ethylene glycol",293.0,2022-06-02,2022-10-19,8A27,2742.0,1.0,326.0,371.0,,38.21,1.0,1.07,experimental,16.31,0.1599,0.1244,"EGFR kinase domain in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide"
8A2A,X-RAY DIFFRACTION,2.27,45.74,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% PEG Smear Medium, 0.1 M sodium cacodylate, 0.2 M ammonium sulfate",293.0,2022-06-03,2022-10-19,8A2A,2756.0,1.0,326.0,221.0,,38.0,1.0,1.43,experimental,30.325,0.2233,0.188,"EGFR kinase domain in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide (form 2)"
8A2B,X-RAY DIFFRACTION,2.36,47.92,"VAPOR DIFFUSION, SITTING DROP",8.0,"25% PEG Smear High, 0.1M Tris, 0.2M magnesium chloride, 10% glycerole",293.0,2022-06-03,2022-10-19,8A2B,2428.0,1.0,326.0,168.0,,38.0,1.0,1.69,experimental,32.128,0.2576,0.2098,"EGFR kinase domain (L858R/V948R) in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide"
8G63,X-RAY DIFFRACTION,3.32,63.0,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.4 M Sodium Citrate, 0.1 M MES",298.0,2023-02-14,2023-10-11,8G63,2289.0,1.0,327.0,29.0,,37.72,1.0,2.5,experimental,,0.2566,0.2078,Ralimetinib (LY2228820) in complex with wild type EGFR
8TJL,X-RAY DIFFRACTION,3.42,64.03,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 0.8 M sodium citrate",293.0,2023-07-22,2024-02-14,8TJL,2481.0,1.0,331.0,14.0,,37.95,1.0,2.7,experimental,,0.2323,0.1958,EGFR kinase in complex with pyrazolopyrimidine covalent inhibitor
5UGC,X-RAY DIFFRACTION,1.8,31.73,"VAPOR DIFFUSION, SITTING DROP",,"Salt: 0.2 M Ammonium sulfate
Precipitant: 19.5 %w/v PEG 8000
Buffer: 0.1 M HEPES (pH 7.50)
Precipitant: 10.0 %v/v iso-propanol",294.0,2017-01-08,2017-03-22,5UGC,2542.0,1.0,329.0,190.0,,38.53,1.0,1.58,experimental,30.5,0.223,0.199,"Crystal structure of the EGFR kinase domain (L858R, T790M, V948R) in complex with a covalent inhibitor N-[(3R,4R)-4-fluoro-1-{6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-methyl-9H-purin-2-yl}pyrrolidin-3-yl]propanamide"
6VEP,X-RAY DIFFRACTION,3.33,63.01,"VAPOR DIFFUSION, HANGING DROP",,"Protein: 4.5 mg/ml in 10 mM HEPES pH 7.5
Well condition: 16% PEG 3350, 0.2 M sodium thiocyanate",300.0,2020-01-02,2020-06-03,6VEP,19318.0,24.0,2572.0,18.0,76.0,299.39,6.0,2.9,experimental,101.68,0.2253,0.1932,Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7
7JUL,X-RAY DIFFRACTION,2.26,45.58,VAPOR DIFFUSION,,"1:1 volume of well solution: 100 mM Bis-Tris propane pH 7.0, 1.2 M DL-malic acid",293.15,2020-08-20,2021-08-11,7JUL,2652.0,1.0,349.0,10.0,,40.89,1.0,2.53,experimental,68.482,0.2339,0.1836,"Crystal structure of non phosphorylated PTEN (n-crPTEN-13sp-T1, SDTTDSDPENEG)"
5XGJ,X-RAY DIFFRACTION,2.4,48.77,"VAPOR DIFFUSION, SITTING DROP",,"0.15M Lithium sulfate, 0.1M Tris-HCl pH 8.5, 28%(W/V) PEG2000MME",291.15,2017-04-13,2018-04-25,5XGJ,10430.0,2.0,1326.0,24.0,,156.13,2.0,2.97,experimental,98.564,0.27917,0.2311,Crystal structure of PI3K complex with an inhibitor
8SBC,X-RAY DIFFRACTION,2.25,45.31,"VAPOR DIFFUSION, HANGING DROP",7.2,"RESERVOIR SOLUTION : 12%-20% PEG 3350, 0.125M-0.20M KSCN            
PROTEIN SOLUTION   : 20MM TRIS PH 7.2, 200MM NACL, 1% BETAINE,      
1% ETHYLENE GLYCOL, 0.02% CHAPS, 5MM DTT,      
PROTEIN IS 7.4 MG/ML                           
FORMATION METHOD   : SOAKING                                        
PROTOCOL           : SET UP APO XTALS DROPS IN 1:1 RATIO IN 30C,    
REMARK 280                       XTALS GROW OVERNIGHT, THEN ADD 2MM OF STOCK           CPD AND INCUBATE FOR A FEW HOURS            METHOD             : VAPOR DIFFUSION - HANGING DROP                 
TEMPERATURE        : 303.0                                          
CRYO PROTOCOL      : 20% ETHYLENE GLYCOL PLUS WELL SOLUTION",303.0,2023-04-03,2023-07-19,8SBC,9749.0,2.0,1367.0,34.0,,160.92,2.0,2.3,experimental,,0.2711,0.2407,"Co-structure of Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and brain penetrant inhibitors"
6E16,X-RAY DIFFRACTION,3.66,66.44,BATCH MODE,,"20% (w/w) PEG8000, 0.2M ammonium sulfare, and 0.1M HEPES pH7.5",291.0,2018-07-09,2019-10-02,6E16,1693.0,1.0,267.0,15.0,,28.51,1.0,2.4,experimental,56.2219,0.2199,0.1767,Ternary structure of c-Myc-TBP-TAF1
6SSB,X-RAY DIFFRACTION,2.48,50.35,"VAPOR DIFFUSION, SITTING DROP",6.4,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",293.0,2019-09-06,2020-09-30,6SSB,2277.0,1.0,299.0,170.0,,35.33,1.0,2.08,experimental,50.22,0.225,0.197,syk in complex with compound 30
5XY1,X-RAY DIFFRACTION,2.77,55.6,"VAPOR DIFFUSION, HANGING DROP",7.5,"23% PEG3350, 0.1M NaCl and 0.1M HEPES pH 7.5",277.0,2017-07-05,2017-08-02,5XY1,2070.0,1.0,279.0,4.0,,32.2,1.0,2.7,experimental,70.837,0.26011,0.21366,Crystal structure of Lyn kinase domain in complex with N-(1H-indazol-6-yl)-8-(piperidin-4-yloxy)-6-propylquinazolin-2-amine
6CYM,X-RAY DIFFRACTION,2.52,51.22,BATCH MODE,,"For complex formation, 2 mg human alpha-thrombin (7.1 mg/mL in 50% v/v glycerol) were mixed with 0.5 mM Compound 1 in DMSO and dialyzed overnight into a solution of 20 mM sodium citrate and 1.3 mM Na2SO4 (pH 5.8). After dialysis, another 0.5 mM compound were added and left to incubate at room temperature for 1 h. The protein was centrifuged for 5 min at 4 deg C and 8000x RCF. The pellet, including about 120 uL of buffer, was mixed with 100 uL of a solution containing 50 mM sodium phosphate (pH 7.3), 190 mM sodium chloride, and 0.2 mM Compound 1. The crystal used for data collection was grown from the JCSG+ screen in well A10. The crystal was grown at 20 deg C using a MRC 3-well plate and in a 150 + 150 nL drop with a reservoir of 0.2 M potassium formate and 20% w/v PEG-3350.",294.0,2018-04-06,2018-05-09,6CYM,4614.0,4.0,574.0,22.0,8.0,66.74,2.0,2.9,experimental,69.84,0.254,0.176,Reversible Covalent Direct Thrombin Inhibitors
6PXJ,X-RAY DIFFRACTION,2.45,49.78,"VAPOR DIFFUSION, HANGING DROP",,"200 mM Mg formate, 20% PEG 3350",295.0,2019-07-26,2019-12-18,6PXJ,4968.0,4.0,590.0,463.0,9.0,67.94,2.0,1.7,experimental,32.968,0.2031,0.1727,Crystal structure of human thrombin mutant I16T
8G43,X-RAY DIFFRACTION,2.27,45.72,"VAPOR DIFFUSION, SITTING DROP",,"2 M sodium formate, 0.2 M sodium acetate pH4.6, 5 % ethylene glycol",291.0,2023-02-08,2023-05-03,8G43,900.0,1.0,107.0,89.0,,12.42,1.0,1.55,experimental,12.136,0.177,0.16074,"Structure of HDAC6 zinc-finger ubiquitin binding domain in complex with 3-(3-(2-(methylamino)-2-oxoethyl)-4-oxo-3,4-dihydroquinazolin-2-yl)propanoic acid"
8G44,X-RAY DIFFRACTION,2.13,42.21,"VAPOR DIFFUSION, SITTING DROP",,"2 M sodium formate, 0.2 M sodium acetate pH4.6, 5 % ethylene glycol",291.0,2023-02-08,2023-05-03,8G44,907.0,1.0,107.0,106.0,,12.49,1.0,1.55,experimental,9.851,0.19314,0.16425,"Structure of HDAC6 zinc-finger ubiquitin binding domain in complex with 3-(3-(2-(benzylamino)-2-oxoethyl)-4-oxo-3,4-dihydroquinazolin-2-yl)propanoic acid"
8G45,X-RAY DIFFRACTION,2.13,42.21,"VAPOR DIFFUSION, SITTING DROP",,"2 M sodium formate, 0.2 M sodium acetate pH4.6, 5 % ethylene glycol",291.0,2023-02-08,2023-05-03,8G45,860.0,1.0,107.0,56.0,,12.56,1.0,1.62,experimental,29.165,0.19036,0.16003,Structure of HDAC6 zinc-finger ubiquitin binding domain in complex with SGC-UBD253 chemical probe
8IKV,X-RAY DIFFRACTION,2.16,43.16,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M Potassium bromide, 30% w/v Polyethylene glycol monomethyl ether 2,000",291.0,2023-03-01,2024-09-11,8IKV,6328.0,4.0,804.0,258.0,,91.59,2.0,2.35,experimental,44.93,0.2169,0.1981,"pUbl depleted phospho-Parkin(K211N,R163D) in complex with pUb"
5NN2,X-RAY DIFFRACTION,2.05,40.1,VAPOR DIFFUSION,,"200 mM K/Na Tartrate, 10-20% PEG3350",293.0,2017-04-07,2018-02-21,5NN2,1830.0,1.0,232.0,83.0,,27.0,1.0,1.81,experimental,,0.2186,0.1872,The structure of the polo-box domain (PBD) of Plk1 in complex with Z228588490
5KPN,X-RAY DIFFRACTION,2.35,47.59,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-07-05,2016-12-21,5KPN,5601.0,2.0,704.0,,,79.75,1.0,2.3,experimental,25.485,0.29293,0.23323,"Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor"
5KPO,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-07-05,2016-12-21,5KPO,5599.0,2.0,704.0,,,79.73,1.0,2.65,experimental,41.811,0.30275,0.23753,"Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor"
5KPP,X-RAY DIFFRACTION,2.35,47.73,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-07-05,2016-11-30,5KPP,5752.0,2.0,700.0,174.0,,79.29,1.0,2.33,experimental,48.719,0.28354,0.23889,"Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor"
5KPQ,X-RAY DIFFRACTION,2.35,47.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-07-05,2016-12-14,5KPQ,5633.0,2.0,700.0,59.0,,79.21,1.0,2.55,experimental,58.227,0.28195,0.23289,"Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor"
5WRQ,X-RAY DIFFRACTION,2.31,46.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-12-03,2017-01-25,5WRQ,5612.0,2.0,704.0,,,79.78,1.0,2.65,experimental,41.706,0.29741,0.25347,"Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor"
5WRY,X-RAY DIFFRACTION,2.27,45.75,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-12-04,2017-01-25,5WRY,5911.0,2.0,704.0,305.0,,79.75,1.0,2.3,experimental,28.112,0.27453,0.22805,"Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor"
5WRZ,X-RAY DIFFRACTION,2.33,47.2,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-12-04,2017-01-25,5WRZ,5584.0,2.0,704.0,,,79.4,1.0,2.2,experimental,22.801,0.27962,0.23042,Structure of human PARP1 catalytic domain bound to a phthalazinone inhibitor
5WS0,X-RAY DIFFRACTION,2.32,47.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-12-04,2017-01-25,5WS0,5586.0,2.0,704.0,,,79.42,1.0,2.6,experimental,25.776,0.27713,0.21225,Structure of human PARP1 catalytic domain bound to a benzoimidazole inhibitor
5WS1,X-RAY DIFFRACTION,2.3,46.54,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-12-04,2017-01-25,5WS1,5586.0,2.0,704.0,,,79.42,1.0,1.9,experimental,22.509,0.27332,0.23304,Structure of human PARP1 catalytic domain bound to a benzoimidazole inhibitor
5WTC,X-RAY DIFFRACTION,2.34,47.46,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298.0,2016-12-11,2017-01-25,5WTC,5612.0,2.0,704.0,,,79.81,1.0,2.2,experimental,22.524,0.26578,0.22333,"Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor"
6XVW,X-RAY DIFFRACTION,2.37,48.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS pH 8.5, 20% (w/w) PEG 2.000 MME, 0.01 M NiCl2",293.0,2020-01-22,2020-06-03,6XVW,5908.0,2.0,708.0,354.0,,81.03,1.0,2.0,experimental,54.66,0.2647,0.2295,Catalytic domain of human PARP-1 in complex with the inhibitor MC2050
7ONR,X-RAY DIFFRACTION,2.4,48.72,VAPOR DIFFUSION,9.5,"2.4 M ammonium sulfate, 0.2 M tri-sodium citrate, 0.1 M PCTP pH 9.5",293.0,2021-05-25,2021-09-15,7ONR,5968.0,2.0,704.0,431.0,,79.72,1.0,2.05,experimental,38.53,0.213,0.188,PARP1 catalytic domain in complex with 8-chloroquinazolinone-based inhibitor (compound 9)
7ONS,X-RAY DIFFRACTION,2.34,47.46,VAPOR DIFFUSION,9.5,"2.6 M ammonium sulfate, 0.1 M Tris pH 8.5",293.0,2021-05-25,2021-09-15,7ONS,5954.0,2.0,704.0,418.0,,79.84,1.0,1.97,experimental,29.6,0.223,0.195,PARP1 catalytic domain in complex with isoquinolone-based inhibitor (compound 16)
7ONT,X-RAY DIFFRACTION,2.35,47.67,VAPOR DIFFUSION,9.5,"2.5 M ammonium sulfate, 0.1 M Tris pH 8.5",293.0,2021-05-25,2021-09-15,7ONT,6006.0,2.0,704.0,468.0,,79.63,1.0,1.853,experimental,33.37,0.2438,0.2131,PARP1 catalytic domain in complex with a selective pyridine carboxamide-based inhibitor (compound 22)
6PX5,X-RAY DIFFRACTION,3.6,65.6,"VAPOR DIFFUSION, HANGING DROP",6.5,"10 mM zinc sulfate, 100 mM MES, pH 6.5, 25% PEG 550 MME",293.0,2019-07-24,2019-09-04,6PX5,3223.0,2.0,411.0,53.0,7.0,47.75,2.0,2.4,experimental,76.733,0.2821,0.2234,CRYSTAL STRUCTURE OF HUMAN MEIZOTHROMBIN DESF1 MUTANT S195A bound with PPACK
8CRC,X-RAY DIFFRACTION,1.91,35.58,"VAPOR DIFFUSION, HANGING DROP",6.0,"12% (w/v) PEG 3350, 0.1 M MES",295.0,2023-03-08,2023-08-16,8CRC,1951.0,1.0,228.0,180.0,,26.77,1.0,1.65,experimental,37.48,0.2186,0.1771,Structure of human Plk1 PBD in complex with Allopole-A
8YHF,X-RAY DIFFRACTION,1.86,34.0,"VAPOR DIFFUSION, SITTING DROP",,"0.02M K/Na PO4, 0.1M Bis-Tris propane pH6.5, 20% PEG3350",293.0,2024-02-28,2024-03-13,8YHF,2847.0,1.0,343.0,351.0,,39.38,1.0,1.4,experimental,18.27,0.1924,0.1661,The Crystal Structure of the Type I TGF beta receptor from Biortus.
8YHL,X-RAY DIFFRACTION,2.07,40.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MgAC2, 0.1M MES pH6.5, 10% PEG10,000",293.0,2024-02-28,2024-03-13,8YHL,2868.0,1.0,306.0,351.0,,35.58,1.0,1.47,experimental,18.485,0.1932,0.1634,The Crystal Structure of Tgf-Beta Type I Receptor (Alk5) from Biortus
5A00,X-RAY DIFFRACTION,2.74,54.7,,,"2M AMMONIUM SULFATE, 2% PEG400 0.1 M TRIS PH 8.0 TEMPERATURE 277K -",277.0,2015-04-15,2015-08-12,5A00,2737.0,1.0,362.0,22.0,,41.01,1.0,2.75,experimental,74.588,0.27963,0.20504,Structure of human PARP1 catalytic domain bound to an isoindolinone inhibitor
6GQL,X-RAY DIFFRACTION,2.52,51.15,"VAPOR DIFFUSION, SITTING DROP",6.2,"9 % PEG 3350, 18 % glycerol, 0.1 M PCTP pH 6.2, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",293.0,2018-06-07,2018-09-19,6GQL,5021.0,2.0,656.0,298.0,,75.56,1.0,2.01,experimental,46.63,0.222,0.201,Crystal structure of human c-KIT kinase domain in complex with AZD3229-analogue (compound 35)
6GQM,X-RAY DIFFRACTION,2.42,49.2,"VAPOR DIFFUSION, SITTING DROP",6.2,"9 % PEG 8000, 18 % ethylene glycol, 0.1 M PCTP pH 6.2, 0.03 M sodium fluoride, 0.03 M sodium bromide, 0.03 M sodium iodide",293.0,2018-06-07,2018-09-19,6GQM,4972.0,2.0,656.0,280.0,,75.7,1.0,2.0,experimental,51.01,0.23,0.203,"Crystal structure of human c-KIT kinase domain in complex with a small molecule inhibitor, AZD3229"
8X3S,X-RAY DIFFRACTION,1.81,32.11,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M lithium sulfate monohydrate, 0.1 M HEPES at pH 7.5, 25% w/v polyethylene glycol 3350",289.0,2023-11-14,2024-05-29,8X3S,2554.0,2.0,348.0,125.0,,37.94,2.0,1.87,experimental,,0.2586,0.224,Crystal structure of human WDR5 in complex with PTEN
6HH1,X-RAY DIFFRACTION,2.38,48.32,"VAPOR DIFFUSION, HANGING DROP",7.4,"9.3 mg/mL protein in 250 mM NaCl, 25 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.5 mM TCEP, 1.2 mM 3G8, 0.1% w/w V8 protease. 800 nL of protein was mixed with 800 nL of crystallization solution (0.1 M Tris-HCl pH 9.1, 1.5 M diammonium hydrogen phosphate) and incubated over 0.4 mL crystallization solution in 24 well VDX plates. Crystals were cryo-protected with 20% v/v ethylene glycol.",293.0,2018-08-24,2019-09-18,6HH1,2576.0,1.0,303.0,122.0,,34.67,1.0,2.25,experimental,62.078,0.2734,0.2045,Structure of c-Kit with allosteric inhibitor 3G8
5NN1,X-RAY DIFFRACTION,2.02,39.19,VAPOR DIFFUSION,,"200 mM Na/K Tartrate, 10-20% PEG3350",298.0,2017-04-07,2018-02-21,5NN1,1833.0,1.0,237.0,90.0,,27.29,1.0,1.785,experimental,,0.2446,0.2048,The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1)
6HAZ,X-RAY DIFFRACTION,2.81,56.16,"VAPOR DIFFUSION, SITTING DROP",6.1,"25% (w/v) PEG 6000, 0.1 M HEPES, pH 6.1, 0.01M zinc chloride, 0.01 M cobalt (III) hexamine chloride, 8% (v/v) ethylene glycol",277.0,2018-08-09,2019-06-12,6HAZ,2243.0,2.0,246.0,341.0,,29.44,1.0,1.31,experimental,27.14,0.193,0.178,Crystal structure of the bromodomain of human SMARCA2 in complex with SMARCA-BD ligand
5HGV,X-RAY DIFFRACTION,3.16,61.02,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.6 M Lithium Sulfate, 0.1 M Bis Tris Propane pH 7.0",298.0,2016-01-08,2016-09-14,5HGV,11958.0,4.0,1466.0,772.0,,165.69,2.0,2.05,experimental,32.3017,0.2374,0.2172,"Structure of an O-GlcNAc transferase point mutant, D554N in complex with peptide"
6HOY,X-RAY DIFFRACTION,2.62,53.06,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2018-09-18,2018-11-14,6HOY,4902.0,2.0,604.0,333.0,,70.36,1.0,1.7,experimental,34.477,0.18465,0.15441,Human Sirt6 in complex with ADP-ribose and the inhibitor trichostatin A
7LEN,X-RAY DIFFRACTION,2.64,53.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"8 mg/ml protein, 100 mM HEPES (pH 7.5), 12% PEG3350, with 3% (w/v) D-(+)-trehalose dihydrate",293.15,2021-01-14,2021-11-17,7LEN,8423.0,4.0,1110.0,,40.0,127.32,2.0,2.9,experimental,86.6232,0.2946,0.2368,Crystal structure of the epidermal growth factor receptor extracellular region with R84K mutation in complex with epiregulin crystallized with trehalose
8YKI,X-RAY DIFFRACTION,2.31,46.86,"VAPOR DIFFUSION, HANGING DROP",,"18% w/v PEG 3350, 0.2M (NH4)2 TARTRATE",293.0,2024-03-05,2024-06-12,8YKI,4330.0,2.0,634.0,10.0,,73.48,1.0,2.79,experimental,88.27,0.2879,0.2403,FGFR-1 in complex with ligand tasurgratinib
7CC2,X-RAY DIFFRACTION,2.93,57.98,"VAPOR DIFFUSION, HANGING DROP",,"7 % w/v Polyethylene glycol 8000, 100 mM MES pH 6.5, 20 % v/v Ethylene glycol",277.15,2020-06-16,2021-06-09,7CC2,4348.0,2.0,620.0,45.0,,72.59,1.0,2.723,experimental,46.1251,0.2418,0.1922,Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors
7DT2,X-RAY DIFFRACTION,2.74,55.17,"VAPOR DIFFUSION, HANGING DROP",7.0,"1% Tryptone, 0.05M Hepes sodium pH 7, 
20% w/v Polyethylene glycol 3350",277.15,2021-01-04,2021-06-09,7DT2,4458.0,2.0,620.0,164.0,,72.68,1.0,2.3,experimental,44.1429,0.2371,0.2058,Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors
7T4J,X-RAY DIFFRACTION,2.11,41.65,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 8000, 200mM Ammonium Citrate, 100mM MES pH 6.5",293.0,2021-12-10,2022-12-07,7T4J,4681.0,2.0,662.0,95.0,,77.0,1.0,2.2,experimental,76.126,0.2775,0.2244,Crystal Structure of EGFR_D770_N771insNPG/V948R in complex with TAK-788
5OL0,X-RAY DIFFRACTION,2.06,40.24,"VAPOR DIFFUSION, SITTING DROP",7.5,100mM Na Hepes pH7.5; 25% PEG2000 MME,295.0,2017-07-26,2018-02-28,5OL0,4626.0,4.0,684.0,239.0,,75.16,2.0,1.99,experimental,41.374,0.22577,0.16713,Structure of Leishmania infantum Silent Information Regulator 2 related protein 1 (LiSIR2rp1) in complex with acetylated p53 peptide
5FE0,X-RAY DIFFRACTION,3.38,63.58,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2015-12-16,2016-01-13,5FE0,1973.0,2.0,238.0,149.0,,28.72,1.0,2.3,experimental,53.776,0.24622,0.20921,Crystal structure of human PCAF bromodomain in complex with acetyllysine
5FE1,X-RAY DIFFRACTION,3.52,65.09,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2015-12-16,2016-01-13,5FE1,2007.0,2.0,238.0,153.0,,28.73,1.0,2.22,experimental,44.942,0.24083,0.20831,Crystal structure of human PCAF bromodomain in complex with fragment BR004 (fragment 1)
5FE2,X-RAY DIFFRACTION,3.37,63.55,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2015-12-16,2016-01-13,5FE2,1942.0,2.0,238.0,116.0,,28.89,1.0,2.25,experimental,47.21,0.23651,0.2067,Crystal structure of human PCAF bromodomain in complex with fragment BR013 (fragment 3)
5FE3,X-RAY DIFFRACTION,3.4,63.83,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2015-12-16,2016-01-13,5FE3,2145.0,2.0,238.0,256.0,,29.05,1.0,2.12,experimental,41.77,0.23693,0.19801,Crystal structure of human PCAF bromodomain in complex with fragment MB360 (fragment 4)
5FE4,X-RAY DIFFRACTION,3.36,63.44,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,2015-12-16,2016-01-13,5FE4,2083.0,2.0,238.0,214.0,,29.01,1.0,2.15,experimental,43.317,0.23175,0.18934,Crystal structure of human PCAF bromodomain in complex with fragment MB364 (fragment 5)
8W13,X-RAY DIFFRACTION,2.51,51.04,EVAPORATION,7.0,"0.1M tris pH7.0,2M NaCl,0.22M MgCl2",291.0,2024-02-15,2024-09-11,8W13,2606.0,1.0,278.0,217.0,,33.86,1.0,1.81,experimental,27.105,0.20352,0.16415,"Crystal structure of MYST acetyltransferase domain in complex with N-(1-(5-bromo-2-methoxyphenyl)-1H-1,2,3-triazol-4-yl)-2-methoxybenzenesulfonamide"
7A2K,X-RAY DIFFRACTION,2.66,53.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"4.5M sodium formate, 0.1M Hepes",298.0,2020-08-18,2021-08-25,7A2K,2021.0,4.0,240.0,131.0,,27.27,1.0,1.5,experimental,44.1676,0.2358,0.2019,Crystal structure of the Fyn SH3 domain in space group P1 at pH 7.5
7A2N,X-RAY DIFFRACTION,2.68,54.12,"VAPOR DIFFUSION, SITTING DROP",4.0,"4.5 M sodium formate, 0.1 sodium acetate",298.0,2020-08-18,2021-08-25,7A2N,2182.0,4.0,240.0,243.0,,27.88,1.0,1.4,experimental,18.4293,0.2035,0.1698,Crystal structure of the Fyn SH3 domain A95S-D99T mutant in space group P21
6TCU,X-RAY DIFFRACTION,3.03,59.37,"VAPOR DIFFUSION, HANGING DROP",,"18% (w/v) PEG8000
0.13 M NaCl
0.1 M Tris Acetate pH 8.0",277.0,2019-11-06,2020-09-16,6TCU,2940.0,1.0,355.0,87.0,,40.89,1.0,2.14,experimental,67.693,0.2397,0.2019,Glycogen synthase kinase-3 beta (GSK3b) in complex with ligand 1
4YJO,X-RAY DIFFRACTION,2.07,40.55,"VAPOR DIFFUSION, HANGING DROP",6.8,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP",293.0,2015-03-03,2015-09-30,4YJO,2462.0,1.0,281.0,235.0,,33.2,1.0,1.6,experimental,32.433,0.2299,0.1838,THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
4YJT,X-RAY DIFFRACTION,2.11,41.74,"VAPOR DIFFUSION, HANGING DROP",6.0,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP",293.0,2015-03-03,2015-09-30,4YJT,2593.0,1.0,281.0,315.0,,33.34,1.0,1.52,experimental,24.51,0.2083,0.1743,THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
8TGP,X-RAY DIFFRACTION,2.18,43.52,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M MES monohydrate pH 6.5 (NaOH), 20% w/v PEG 4,000",293.0,2023-07-12,2024-01-24,8TGP,2337.0,2.0,336.0,78.0,,38.23,2.0,1.76,experimental,28.58,0.2304,0.1902,Crystal structure of SIRT2 with FAM-PEG4-H4K16(myristoyl) peptide
5U2J,X-RAY DIFFRACTION,2.75,55.26,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.1 M sodium citrate tribasic, 0.1 M sodium hepes",293.0,2016-11-30,2017-04-12,5U2J,2221.0,4.0,254.0,266.0,,28.94,2.0,1.6,experimental,,0.2384,0.1907,MORF double PHD finger (DPF) in complex with histone H3K14bu
6E69,X-RAY DIFFRACTION,2.94,58.15,"VAPOR DIFFUSION, SITTING DROP",5.0,"0.3 M ammonium citrate, pH 5.0, 14% w/v PEG3350",295.0,2018-07-24,2019-07-24,6E69,6978.0,4.0,872.0,267.0,16.0,98.01,1.0,2.33,experimental,39.77,0.241,0.193,Ortho-substituted phenyl sulfonyl fluoride and fluorosulfate as potent elastase inhibitory fragments
7A2J,X-RAY DIFFRACTION,2.66,53.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"4.5M sodium formate, 0.1M Hepes",298.0,2020-08-18,2021-08-25,7A2J,1003.0,2.0,120.0,78.0,,13.61,1.0,1.5,experimental,46.7575,0.2466,0.2121,Crystal structure of the Fyn SH3 domain in space group C21 at pH 7.5
7A2L,X-RAY DIFFRACTION,2.65,53.54,"VAPOR DIFFUSION, SITTING DROP",4.0,"3.5M sodium formate, 0.1M sodium acetate",298.0,2020-08-18,2021-08-25,7A2L,970.0,2.0,120.0,44.0,,13.7,1.0,1.9,experimental,52.5814,0.2606,0.207,Crystal structure of the Fyn SH3 domain mutant E129Q in space group C21 at pH 4.0
7A2M,X-RAY DIFFRACTION,2.66,53.83,"VAPOR DIFFUSION, SITTING DROP",4.0,"4.5 M sodium formate, 0.1 sodium acetate",298.0,2020-08-18,2021-08-25,7A2M,1050.0,2.0,120.0,91.0,,13.81,1.0,1.5,experimental,42.1828,0.255,0.2126,Crystal structure of the Fyn SH3 domain A95S-D99T mutant in C21 space group
6V6M,X-RAY DIFFRACTION,2.3,46.61,"VAPOR DIFFUSION, HANGING DROP",8.3,"20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0",277.0,2019-12-05,2020-12-09,6V6M,1720.0,1.0,183.0,249.0,,21.3,1.0,1.39,experimental,19.8698,0.2359,0.2126,Crystal structure of an inactive state of GMPPNP-bound RhoA
6V6U,X-RAY DIFFRACTION,2.33,47.21,"VAPOR DIFFUSION, HANGING DROP",8.3,"20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0",277.0,2019-12-06,2020-12-23,6V6U,1704.0,1.0,183.0,201.0,,21.22,1.0,1.16,experimental,20.6756,0.1846,0.1701,Crystal structure of RhoA-GDP with novel Switch I conformation
6V6V,X-RAY DIFFRACTION,2.31,46.64,"VAPOR DIFFUSION, HANGING DROP",8.3,"20-24% PEG8K, 15% Dioxane, 0.1M Tris pH8.0",277.0,2019-12-06,2020-12-23,6V6V,1663.0,1.0,183.0,178.0,,21.26,1.0,1.4,experimental,29.248,0.2234,0.2018,Crystal structure of oncogenic RhoA mutant G14V complexed with GDP
4RSS,X-RAY DIFFRACTION,2.12,42.11,"VAPOR DIFFUSION, HANGING DROP",8.5,"10-20% (v/v) PEG 3350, 100mM Tris-HCl (pH 8.5) 
, VAPOR DIFFUSION, HANGING DROP, temperature 277K",277.0,2014-11-11,2015-10-21,4RSS,2414.0,1.0,290.0,178.0,,34.32,1.0,1.83,experimental,32.173,0.24869,0.21189,Crystal structure of tyrosine-protein kinase SYK with an inhibitor
6KZU,X-RAY DIFFRACTION,1.77,30.39,"VAPOR DIFFUSION, HANGING DROP",7.5,"800 mM Sodium di-hydrogen phosphate, 800 mM di-Potassium hydrogen phosphate, 100 mM HEPES pH 7.5",289.0,2019-09-25,2019-10-16,6KZU,891.0,2.0,134.0,61.0,,15.4,2.0,1.79,experimental,33.102,0.2361,0.199,Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity: A novel stapled alpha-helical peptide modality
5X16,X-RAY DIFFRACTION,2.43,49.38,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Sodium citrate tribasic dihydrate pH 5.6, 35% v/v tert-Butanol",277.15,2017-01-24,2018-07-04,5X16,2588.0,1.0,316.0,224.0,,35.87,1.0,1.97,experimental,33.496,0.2316,0.18408,Sirt6 apo structure
7A2R,X-RAY DIFFRACTION,1.99,38.15,"VAPOR DIFFUSION, SITTING DROP",6.0,"1.5 ammonium sulfate, 0.1M MES",298.0,2020-08-18,2021-08-25,7A2R,621.0,1.0,62.0,120.0,,6.93,1.0,1.05,experimental,12.7549,0.1732,0.1614,Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant at pH 6.0
7A2S,X-RAY DIFFRACTION,1.98,37.78,"VAPOR DIFFUSION, SITTING DROP",5.0,"2.0 ammonium sulfate, 0.1M sodium acetate",298.0,2020-08-18,2021-08-25,7A2S,621.0,1.0,62.0,117.0,,6.93,1.0,1.02,experimental,12.53,0.1748,0.1593,Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant at pH 5.0
7A2T,X-RAY DIFFRACTION,2.01,38.87,"VAPOR DIFFUSION, SITTING DROP",4.0,"1 ammonium sulfate, 0.1M sodium acetate",298.0,2020-08-18,2021-08-25,7A2T,596.0,1.0,61.0,100.0,,6.93,1.0,1.22,experimental,17.2614,0.2026,0.1702,Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant at pH 4.0
7A2U,X-RAY DIFFRACTION,2.62,53.05,"VAPOR DIFFUSION, SITTING DROP",4.5,"1.5 M ammonium sulfate, 0.1 sodium acetate",298.0,2020-08-18,2021-08-25,7A2U,533.0,1.0,60.0,55.0,,6.88,1.0,1.7,experimental,24.57,0.1996,0.1624,Crystal structure of the Fyn SH3 domain L112V-S114N-S115T at pH 4.5
7A2V,X-RAY DIFFRACTION,2.57,52.17,"VAPOR DIFFUSION, SITTING DROP",4.0,"1.5 M ammonium sulfate, 0.1 sodium acetate",298.0,2020-08-18,2021-08-25,7A2V,521.0,1.0,60.0,37.0,,6.82,1.0,1.81,experimental,33.253,0.2195,0.2111,Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E129Q at pH 4.0
7A2Z,X-RAY DIFFRACTION,2.09,41.21,"VAPOR DIFFUSION, SITTING DROP",6.0,"1 M ammonium sulfate, 0.1 sodium acetate",298.0,2020-08-18,2021-08-25,7A2Z,678.0,2.0,72.0,97.0,,8.1,2.0,1.14,experimental,19.1827,0.1948,0.163,Crystal structure of the Fyn SH3 domain L112V-S114N-S115T-E121L-R123H mutant in complex with VSL12 at pH 6.0
5OAZ,X-RAY DIFFRACTION,2.47,50.29,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.65 M Ammonium sulphate, 0.1 M Hepes and 6% PEG 300",298.0,2017-06-25,2017-07-12,5OAZ,1020.0,2.0,126.0,124.0,,14.34,1.0,1.03,experimental,19.5644,0.1628,0.1446,Crystal structure of the Abl-SH3 domain at pH 7.5
5DY4,X-RAY DIFFRACTION,2.96,58.46,"VAPOR DIFFUSION, SITTING DROP",7.0,27 % PEG 3350,278.0,2015-09-24,2016-01-13,5DY4,2649.0,1.0,304.0,183.0,,35.65,1.0,1.77,experimental,33.455,0.21286,0.17494,Crystal structure of human Sirt2 in complex with a brominated 2nd generation SirReal inhibitor and NAD+
7SXH,X-RAY DIFFRACTION,2.43,49.46,"VAPOR DIFFUSION, SITTING DROP",,"0.2M calcium acetate, 0.1M BisTRIS pH 7.0, 5% Glycerol and 17% PEG3350",289.0,2021-11-23,2023-06-14,7SXH,2945.0,2.0,363.0,124.0,,41.93,2.0,2.09,experimental,57.64,0.2554,0.2138,BIO-8546 bound GSK3beta-axin complex
7SXJ,X-RAY DIFFRACTION,2.5,50.72,"VAPOR DIFFUSION, SITTING DROP",,"0.2M calcium acetate, 0.1M BisTRIS pH 7.0, 5% Glycerol and 17% PEG3350",293.0,2021-11-23,2023-06-14,7SXJ,3082.0,2.0,368.0,213.0,,42.25,2.0,1.85,experimental,47.94,0.2034,0.1838,BIO-2895 (BRD0705) bound GSK3beta-axin complex
6HCS,X-RAY DIFFRACTION,,36.33,"VAPOR DIFFUSION, SITTING DROP",5.0,"PEG 6000, lithium chloride, sodium chloride",293.0,2018-08-16,2018-12-05,6HCS,5239.0,8.0,768.0,243.0,,88.25,2.0,2.0,experimental,,0.2944,0.2602,Crystal structure of CaM-peptide complex containing AzF at position 108
5QH8,X-RAY DIFFRACTION,4.19,70.61,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH8,1702.0,1.0,196.0,159.0,,22.56,1.0,1.75,experimental,36.452,0.2259,0.2038,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with PCM-0102558
5QH9,X-RAY DIFFRACTION,4.16,70.44,"VAPOR DIFFUSION, SITTING DROP",5.5,0.1M bis-tris pH 5.5 -- 0.1M ammonium acetate -- 5%(w/v) PEG10K,293.0,2018-05-15,2019-03-27,5QH9,1707.0,1.0,196.0,196.0,,22.53,1.0,1.72,experimental,30.06,0.2058,0.1835,PanDDA analysis group deposition of models with modelled events (e.g. bound ligands) -- Crystal Structure of NUDT7 in complex with PCM-0102716
5GSA,X-RAY DIFFRACTION,2.29,46.34,EVAPORATION,8.0,"0.1 M TRIS, 16% PEG 8000",293.0,2016-08-15,2017-02-01,5GSA,6586.0,4.0,792.0,180.0,2.0,92.7,2.0,2.49,experimental,41.73,0.255,0.1817,EED in complex with an allosteric PRC2 inhibitor
5JXJ,X-RAY DIFFRACTION,3.69,66.65,"VAPOR DIFFUSION, SITTING DROP",,"crystallization solution: 100 mM MES, 200 mM K/NaH2PO4, pH 5.5-6.0, 3-4 M NaCl, 3% DMSO; reservoir solution: 3-4 M NaCl",293.15,2016-05-13,2016-10-05,5JXJ,4185.0,2.0,487.0,461.0,3.0,53.35,2.0,2.0,experimental,,0.1889,0.1668,Structure of the proprotein convertase furin complexed to meta-guanidinomethyl-Phac-RVR-Amba in presence of EDTA
4ZOP,X-RAY DIFFRACTION,2.35,47.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"12% PEG 3350, 120MM KSCN, 6UL PROTEIN TO 4UL WELL WITH STREAK SEEDING AT 18C , PH 7.5, VAPOR DIFFUSION, HANGING DROP",303.0,2015-05-06,2016-05-18,4ZOP,10201.0,2.0,1364.0,127.0,,160.46,2.0,2.62,experimental,68.91,0.258,0.1926,Co-crystal Structure of Lipid Kinase PI3K alpha with a selective phosphatidylinositol-3 kinase alpha inhibitor
5E7I,X-RAY DIFFRACTION,2.79,55.97,"VAPOR DIFFUSION, HANGING DROP",5.0,"PEG 3350, sodium citrate",291.0,2015-10-12,2015-12-02,5E7I,10060.0,3.0,1356.0,,,153.28,1.0,2.223,experimental,46.72,0.2591,0.2257,Crystal structure of the active catalytic core of the human DEAD-box protein DDX3
8A2D,X-RAY DIFFRACTION,1.8,31.79,"VAPOR DIFFUSION, SITTING DROP",6.5,"20% PEG Smear High, 0.1M MES",293.0,2022-06-03,2022-10-19,8A2D,2770.0,1.0,326.0,387.0,,38.27,1.0,1.11,experimental,15.73,0.1788,0.1632,"EGFR kinase domain (L858R/V948R) in complex with 2-[4-(difluoromethyl)-6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-7-methyl-indazol-2-yl]-2-spiro[6,7-dihydropyrrolo[1,2-c]imidazole-5,1'-cyclopropane]-1-yl-N-thiazol-2-yl-acetamide"
6EQV,X-RAY DIFFRACTION,3.67,66.45,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 3-4M NaCl, 3% DMSO; RESERVOIR SOLUTION: 3-4 M NaCl",293.15,2017-10-16,2018-02-28,6EQV,4212.0,2.0,487.0,510.0,3.0,53.3,2.0,1.895,experimental,,0.1821,0.1637,X-ray structure of the proprotein convertase furin bound with the competitive inhibitor Phac-Cit-Val-Arg-Amba
6EQW,X-RAY DIFFRACTION,3.66,66.42,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 3-4 M NaCL, 3% DMSO; RESERVOIR SOLUTION: 3-4M NaCL",293.15,2017-10-16,2018-02-28,6EQW,4183.0,2.0,487.0,486.0,3.0,53.36,2.0,1.994,experimental,,0.1842,0.1619,X-ray structure of the proprotein convertase furin bound with the competitive inhibitor 4-aminomethyl-phenylacetyl-Arg-Val-Arg-Amba
6EQX,X-RAY DIFFRACTION,3.66,66.36,"VAPOR DIFFUSION, SITTING DROP",,"100mM MES, 200mM K/NaH2PO4, PH 5.5-6.0, 3-4 M NaCL, 3% DMSO; RESERVOIR SOLUTION: 3-4M NaCL",293.15,2017-10-16,2018-02-28,6EQX,4186.0,2.0,488.0,471.0,3.0,53.51,2.0,1.994,experimental,,0.1837,0.162,X-ray structure of the proprotein convertase furin bound with the competitive inhibitor Arg-Arg-Arg-Val-Arg-Amba
6T53,X-RAY DIFFRACTION,2.52,51.26,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4, 350 mM NaCl, 27% (w/v) PEG8000",277.0,2019-10-15,2020-11-18,6T53,2823.0,3.0,306.0,290.0,4.0,36.82,3.0,1.35,experimental,19.31,0.1506,0.1294,Thrombin in Complex with a D-Phe-Pro-p-benzylamine derivative
6T54,X-RAY DIFFRACTION,2.54,51.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4, 350 mM NaCl, 27% (w/v) PEG8000",277.0,2019-10-15,2020-11-18,6T54,2598.0,3.0,306.0,226.0,4.0,36.32,3.0,1.57,experimental,22.46,0.1702,0.1377,Thrombin in Complex with a D-Phe-Pro-2-bromothiophene Derivative
6Y02,X-RAY DIFFRACTION,2.86,57.05,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate ph 7.5
350mM NaCl
27% PEG 8000",277.0,2020-02-06,2021-02-17,6Y02,2661.0,3.0,307.0,207.0,4.0,36.55,3.0,1.48,experimental,26.3973,0.164,0.1391,Thrombin in complex with 13k
6YQV,X-RAY DIFFRACTION,2.77,55.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate pH 7.5
350mM NaCl
27% PEG 8000",277.0,2020-04-18,2021-04-28,6YQV,2663.0,3.0,307.0,243.0,4.0,36.31,3.0,1.45,experimental,25.224,0.1632,0.132,Thrombin in complex with 5-chlorothiophene-2-sulfonamide (j94)
5JZY,X-RAY DIFFRACTION,2.5,50.2,"VAPOR DIFFUSION, HANGING DROP",7.0,"20 mM Sodium dihydrogen phosphate ph 7.5, 
350 mM NaCl, 
27% PEG 8000",277.0,2016-05-17,2017-06-07,5JZY,2881.0,3.0,307.0,332.0,4.0,36.42,3.0,1.27,experimental,,0.1423,0.1202,Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide
6GBW,X-RAY DIFFRACTION,2.47,50.0,"VAPOR DIFFUSION, HANGING DROP",7.0,"20 mM sodium dihydrogen phosphate ph 7.5
350 mM NaCl
27% PEG 8000",277.0,2018-04-16,2019-04-24,6GBW,2761.0,3.0,307.0,245.0,4.0,36.43,3.0,1.45,experimental,,0.1645,0.1318,Thrombin in complex with MI2100 ((S)-N-(2-(aminomethyl)-5-chlorobenzyl)-1-((benzylsulfonyl)-L-arginyl)pyrrolidine-2-carboxamide)
6ROT,X-RAY DIFFRACTION,2.48,50.0,"VAPOR DIFFUSION, HANGING DROP",7.0,"20mM sodium dihydrogen phosphate ph 7.5
350mM NaCl
27% PEG 8000",277.0,2019-05-13,2019-11-27,6ROT,2765.0,3.0,301.0,247.0,4.0,35.93,3.0,1.339,experimental,,0.1574,0.1371,Thrombin in complex with MI2105
6TDT,X-RAY DIFFRACTION,2.51,51.07,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM Sodium dihydrogen phosphate, 350 mM NaCl, 27% (w/v) PEG 8000",277.0,2019-11-10,2020-05-13,6TDT,2704.0,3.0,306.0,253.0,4.0,36.24,3.0,1.53,experimental,21.16,0.1769,0.1596,Thrombin in Complex with a D-DiPhe-Pro-p-pyridine derivative
6ZUH,X-RAY DIFFRACTION,2.52,51.16,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M phosphate buffer pH 7.5, 
27% PEG 8000, 100 mM NaCl",283.0,2020-07-22,2020-08-26,6ZUH,2705.0,3.0,306.0,311.0,4.0,36.03,3.0,1.7,experimental,26.847,0.2178,0.1781,Crystal Structure of Thrombin in complex with compound17
5GIM,X-RAY DIFFRACTION,2.37,48.14,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.1M HEPES, 20-25% PEG 8000",277.0,2016-06-24,2017-05-03,5GIM,2626.0,4.0,325.0,185.0,4.0,37.04,4.0,2.09,experimental,25.098,0.2159,0.1792,Crystal structure of thrombin-avathrin complex
6PXQ,X-RAY DIFFRACTION,2.99,58.9,"VAPOR DIFFUSION, HANGING DROP",,200 mM di-Na phosphate and 20% PEG 3350,295.0,2019-07-26,2019-12-18,6PXQ,2266.0,2.0,292.0,,4.0,33.75,2.0,2.8,experimental,88.695,0.2924,0.2586,Crystal structure of human thrombin mutant D194A
5VLR,X-RAY DIFFRACTION,2.6,53.2,VAPOR DIFFUSION,,"NULL, VAPOR DIFFUSION, TEMPERATURE
 293K",300.0,2017-04-26,2017-06-07,5VLR,8448.0,2.0,1183.0,24.0,,137.48,2.0,2.8,experimental,87.32,0.279,0.208,CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A TRIFLUORO-ETHYL-PYRAZOL-PYROLOTRIAZINE INHIBITOR
5DXU,X-RAY DIFFRACTION,2.6,53.2,"VAPOR DIFFUSION, HANGING DROP",,PEG,293.0,2015-09-23,2016-01-27,5DXU,8955.0,2.0,1212.0,4.0,,140.76,2.0,2.64,experimental,83.578,0.28419,0.24783,p110delta/p85alpha with GDC-0326
5T8F,X-RAY DIFFRACTION,2.64,53.45,"VAPOR DIFFUSION, HANGING DROP",,PEG,293.0,2016-09-07,2017-01-11,5T8F,8537.0,2.0,1184.0,1.0,,137.53,2.0,2.91,experimental,77.62,0.304,0.242,p110delta/p85alpha with taselisib (GDC-0032)
6G6W,X-RAY DIFFRACTION,2.66,53.83,"VAPOR DIFFUSION, HANGING DROP",7.5,PEG,293.0,2018-04-03,2018-11-07,6G6W,8842.0,2.0,1242.0,6.0,,144.59,2.0,2.72,experimental,96.97,0.2601,0.2181,HUMAN PI3KDELTA IN COMPLEX WITH LIGAND LASW1976
7JIS,X-RAY DIFFRACTION,2.62,53.09,VAPOR DIFFUSION,,"16% PEG6000, 0.10 M KCL, 0.10 M MES pH 6.0",293.0,2020-07-23,2020-12-30,7JIS,8938.0,2.0,1187.0,18.0,,137.96,2.0,2.42,experimental,77.666,0.2671,0.2206,HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 2F
5MFP,X-RAY DIFFRACTION,2.59,52.45,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2016-11-18,2016-12-28,5MFP,4719.0,2.0,604.0,178.0,,70.46,1.0,1.98,experimental,33.575,0.18493,0.1572,Human Sirt6 in complex with activator UBCS58
5MFZ,X-RAY DIFFRACTION,2.59,52.49,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2016-11-19,2016-12-28,5MFZ,4546.0,2.0,604.0,51.0,,69.65,1.0,2.1,experimental,39.104,0.20806,0.16726,Human Sirt6 in complex with small molecule UBCS40
5MGN,X-RAY DIFFRACTION,2.64,53.38,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293.0,2016-11-21,2016-12-28,5MGN,4556.0,2.0,604.0,88.0,,69.96,1.0,2.07,experimental,31.893,0.19175,0.1437,Human Sirt6 in complex with activator UBCS38
4X3O,X-RAY DIFFRACTION,2.36,47.85,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 3350, 0.1M HEPES, 5% Glycerol",300.0,2014-12-01,2016-01-13,4X3O,2911.0,2.0,309.0,300.0,,35.88,2.0,1.5,experimental,18.811,0.1566,0.1211,Sirt2 in complex with a myristoyl peptide
4X3P,X-RAY DIFFRACTION,2.38,48.39,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 3350, 0.1M HEPES, 5% Glycerol",300.0,2014-12-01,2016-01-13,4X3P,2834.0,2.0,309.0,257.0,,35.94,2.0,1.8,experimental,22.59,0.1732,0.154,Sirt2 in complex with a myristoyl peptide
5UBT,X-RAY DIFFRACTION,2.6,53.2,VAPOR DIFFUSION,,,293.0,2016-12-21,2017-02-08,5UBT,8531.0,2.0,1181.0,13.0,,137.16,2.0,2.83,experimental,104.62,0.268,0.215,"CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2,4] TRIAZIN-4-AMINE DERIVIATINE"
6PYR,X-RAY DIFFRACTION,2.61,52.91,VAPOR DIFFUSION,,"12-14% PEG6000, 100 mM MES/NaOH, pH 5.75, 5 mM DTT",293.0,2019-07-30,2019-08-28,6PYR,9064.0,2.0,1187.0,67.0,,137.93,2.0,2.21,experimental,78.765,0.2591,0.2207,"Human PI3Kdelta in complex with Compound 2-10 ((3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3-dihydro-2H-indol-2-one)"
6PYU,X-RAY DIFFRACTION,2.63,53.19,VAPOR DIFFUSION,,not available,293.0,2019-07-30,2019-08-28,6PYU,8927.0,2.0,1187.0,12.0,,137.86,2.0,2.54,experimental,106.112,0.2916,0.2397,"Human PI3Kdelta in complex with Compound 4-2 ((3S)-1'-(cyclopropanecarbonyl)-5-(quinoxalin-6-yl)spiro[indole-3,2'-pyrrolidin]-2(1H)-one)"
7LQ1,X-RAY DIFFRACTION,2.62,53.12,VAPOR DIFFUSION,,"16% PEG6000, 0.10 M KCL, 0.10 M MES PH 6.0",293.0,2021-02-12,2022-02-16,7LQ1,9190.0,2.0,1213.0,7.0,,141.07,2.0,2.96,experimental,90.701,0.2805,0.2131,HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 28
8YGZ,X-RAY DIFFRACTION,2.5,50.83,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Li2SO4, 0.1M Tris-HCl pH8.5, 30% PEG4,000",293.0,2024-02-27,2024-03-13,8YGZ,2542.0,1.0,314.0,176.0,,36.31,1.0,2.1,experimental,44.21,0.254,0.1949,The Crystal Structure of TGF beta R2 kinase domain from Biortus.
8RRQ,X-RAY DIFFRACTION,2.08,41.0,VAPOR DIFFUSION,6.5,"20% PEG 3350, 0.1 M bis tris propane pH 6.5, 0.2 M Na formate",277.0,2024-01-23,2024-04-24,8RRQ,2373.0,1.0,282.0,178.0,,33.38,1.0,1.6,experimental,25.887,0.2107,0.1766,Crystal structure of human SYK in complex with compound 24
8RRZ,X-RAY DIFFRACTION,2.09,41.03,VAPOR DIFFUSION,6.5,"20% PEG 3350, 0.1 M bis tris propane pH 6.5, 0.2 M Na formate",277.0,2024-01-24,2024-04-24,8RRZ,2335.0,1.0,282.0,129.0,,33.5,1.0,1.75,experimental,27.308,0.2145,0.1802,Crystal structure of SYK kinase in complex with compound 1
7PVQ,X-RAY DIFFRACTION,2.12,41.89,"VAPOR DIFFUSION, SITTING DROP",6.0,"1.8M  ammonium sulfate, 0.1M MES",298.0,2021-10-05,2022-09-14,7PVQ,1061.0,2.0,118.0,147.0,,13.3,1.0,1.55,experimental,17.5483,0.2737,0.2314,Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in the space group P21221
7PVS,X-RAY DIFFRACTION,2.1,41.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"2.6 M  ammonium sulfate, 5% PEG200, 10% Glicerol, 40mM LiCl, 0.1M MES",283.0,2021-10-05,2022-09-14,7PVS,1166.0,2.0,118.0,141.0,,14.15,1.0,1.05,experimental,14.3649,0.1843,0.1688,Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in presence of PEG 200
6ZQS,X-RAY DIFFRACTION,2.32,47.06,"VAPOR DIFFUSION, HANGING DROP",6.5,"14% PEG 3350, 0.1 M cacodylate ph 6.5",277.0,2020-07-10,2020-11-18,6ZQS,3268.0,2.0,382.0,351.0,,44.37,2.0,1.95,experimental,44.28,0.2234,0.1753,Crystal structure of double-phosphorylated p38alpha with ATF2(83-102)
7WGO,X-RAY DIFFRACTION,2.97,58.63,VAPOR DIFFUSION,,"0.1 M Tris (pH 8.0), 1.1 M trisodium citrate",293.0,2021-12-28,2022-05-25,7WGO,2357.0,2.0,294.0,8.0,,34.07,2.0,2.36,experimental,59.158,0.2253,0.1949,X-ray structure of human PPAR gamma ligand binding domain-bezafibrate co-rystals obtained by co-crystallization
7WGP,X-RAY DIFFRACTION,2.98,58.69,VAPOR DIFFUSION,,"0.1 M Tris (pH 8.0), 1.1 M trisodium citrate",293.0,2021-12-28,2022-05-25,7WGP,2322.0,2.0,294.0,,,34.67,2.0,2.53,experimental,65.1647,0.2686,0.2089,X-ray structure of human PPAR gamma ligand binding domain-fenofibric acid co-crystals obtained by co-crystallization
7WGQ,X-RAY DIFFRACTION,2.87,57.09,VAPOR DIFFUSION,,"0.1 M HEPES (pH 7.5), 1.1 M trisodium citrate",293.0,2021-12-28,2022-05-25,7WGQ,2350.0,2.0,294.0,3.0,,34.2,2.0,2.43,experimental,60.6654,0.2518,0.2067,X-ray structure of human PPAR gamma ligand binding domain-pemafibrate co-crystals obtained by co-crystallization
8HUP,X-RAY DIFFRACTION,2.94,58.14,VAPOR DIFFUSION,,"0.1 M Tris (pH 8.0), 1.1 M trisodium citrate",293.0,2022-12-24,2023-08-09,8HUP,2361.0,2.0,294.0,,,34.16,2.0,2.36,experimental,58.8298,0.2338,0.2049,X-ray structure of human PPAR gamma ligand binding domain-seladelpar-SRC1 coactivator peptide co-crystals obtained by co-crystallization
7PVR,X-RAY DIFFRACTION,2.06,40.21,"VAPOR DIFFUSION, SITTING DROP",6.0,"1.8M  ammonium sulfate, 0.1M MES",298.0,2021-10-05,2022-09-14,7PVR,522.0,1.0,59.0,68.0,,6.65,1.0,1.65,experimental,25.9286,0.2087,0.1739,Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in the space group P41
7PW2,X-RAY DIFFRACTION,2.05,40.02,"VAPOR DIFFUSION, SITTING DROP",7.0,"2.0 M ammonium sulfate, 0.1M HEPES",298.0,2021-10-05,2022-09-14,7PW2,478.0,1.0,60.0,51.0,,6.72,1.0,1.1,experimental,27.5203,0.2014,0.183,Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E mutant
7W28,X-RAY DIFFRACTION,2.25,45.26,"VAPOR DIFFUSION, SITTING DROP",8.5,"30%(w/v) PEG4000, 0.1 M Tris base/Hydrochloric acid 8.5, 0.2M Lithium sulfate.",289.0,2021-11-22,2022-10-05,7W28,4596.0,2.0,515.0,514.0,,59.71,2.0,1.79,experimental,36.7786,0.2115,0.1743,Crystal Structure of SETD3-SAH in complex with betaA-4PyrAla73 peptide
7W29,X-RAY DIFFRACTION,2.22,44.59,"VAPOR DIFFUSION, SITTING DROP",9.0,"20%(w/v) PEG6000, 0.1M Bicine/Sodium hydroxide 9.0",289.0,2021-11-23,2022-10-05,7W29,4057.0,2.0,515.0,38.0,,59.49,2.0,2.9,experimental,39.7263,0.2792,0.237,Crystal Structure of SETD3-SAH in complex with betaA-Orn73 peptide
6NMW,X-RAY DIFFRACTION,2.22,44.71,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Na citrate, 3.2 M NaCl",298.0,2019-01-12,2019-04-17,6NMW,578.0,1.0,69.0,40.0,,8.08,1.0,1.199,experimental,,0.1827,0.1725,Crystal structure of the human Lyn SH3 domain
5ONR,X-RAY DIFFRACTION,2.31,46.86,EVAPORATION,6.0,"50 mM MES: 45% DMSO: 0.7-0.9 M NaCl: 0-0.4 M CdCl2: reservoir solution
containing 30-40% ammonium sulphate",293.0,2017-08-04,2018-08-29,5ONR,2835.0,2.0,319.0,369.0,,34.97,2.0,1.39,experimental,19.2183,0.1993,0.1787,Alzheimer's Amyloid-Beta Peptide Fragment 1-40 in Complex with Thermolysin
5C67,X-RAY DIFFRACTION,3.08,60.09,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M ammonium sulfate, 0.1 M Tris pH 7.5, and 20% PEG-1000",298.0,2015-06-22,2016-05-04,5C67,4289.0,4.0,610.0,87.0,16.0,66.78,2.0,1.83,experimental,33.583,0.26679,0.22324,Human Mesotrypsin in complex with amyloid precursor protein inhibitor variant APPI-M17G/I18F/F34V
8BJT,X-RAY DIFFRACTION,2.96,58.48,"VAPOR DIFFUSION, HANGING DROP",6.5,"16% w/v PEG4000, 0.1 M Na citrate pH 6.50, 0.6 M Mg acetate, 0.0003 M Zn acetate",277.0,2022-11-06,2023-04-26,8BJT,2429.0,1.0,294.0,22.0,,34.45,1.0,2.188,experimental,50.82,0.2547,0.2002,"Structure of human PLK1 in complex with 2-Allyl-1-[6-(1-hydroxy-1-methyl-ethyl)-pyridin-2-yl]-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one"
6VOV,X-RAY DIFFRACTION,2.18,43.7,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 100mM Tris pH 8.5",293.0,2020-01-31,2020-03-11,6VOV,4488.0,2.0,562.0,177.0,,66.26,1.0,1.95,experimental,25.32,0.2675,0.2171,Crystal structure of Syk in complex with GS-9876
7MSO,X-RAY DIFFRACTION,2.32,47.04,EVAPORATION,5.5,"0.1 M Bis-Tris pH 5.5, 2.75 M NaCl",298.0,2021-05-11,2022-03-02,7MSO,4015.0,4.0,486.0,328.0,,56.28,2.0,1.85,experimental,32.3968,0.21,0.1629,Crystal Structure of Polo Box Domain in Complex with Cyclic Peptide Inhibitor
6ZC0,X-RAY DIFFRACTION,2.22,44.54,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",277.0,2020-06-09,2021-06-23,6ZC0,2234.0,1.0,299.0,124.0,,35.25,1.0,1.97,experimental,42.89,0.229,0.192,SYK Kinase domain in complex with azabenzimidazole inhibitor 2b
6ZCP,X-RAY DIFFRACTION,2.2,44.12,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",278.0,2020-06-11,2021-06-23,6ZCP,2198.0,1.0,299.0,89.0,,35.29,1.0,2.2,experimental,55.59,0.234,0.212,SYK Kinase domain in complex with azabenzimidazole inhibitor 2b
6ZCQ,X-RAY DIFFRACTION,2.22,44.7,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",278.0,2020-06-11,2021-06-23,6ZCQ,2304.0,1.0,299.0,199.0,,35.34,1.0,2.32,experimental,42.94,0.244,0.189,SYK Kinase domain in complex with diamine inhibitor 5
6ZCS,X-RAY DIFFRACTION,2.27,45.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",278.0,2020-06-12,2021-06-23,6ZCS,2500.0,1.0,299.0,350.0,,35.31,1.0,1.47,experimental,29.18,0.208,0.19,SYK Kinase domain in complex with azabenzimidazole inhibitor 3
6ZCX,X-RAY DIFFRACTION,2.18,43.59,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",278.0,2020-06-12,2021-06-23,6ZCX,2427.0,1.0,299.0,309.0,,35.34,1.0,1.66,experimental,31.0,0.229,0.189,SYK Kinase domain in complex with azabenzimidazole inhibitor 18
6ZCY,X-RAY DIFFRACTION,2.19,43.88,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",278.0,2020-06-12,2021-06-23,6ZCY,2391.0,1.0,299.0,297.0,,35.33,1.0,1.81,experimental,30.68,0.223,0.188,SYK Kinase domain in complex with diamine inhibitor 16
5CY3,X-RAY DIFFRACTION,2.17,43.38,"VAPOR DIFFUSION, SITTING DROP",7.1,"PEG 3350 20%, ammonium acetate 0.2M",293.0,2015-07-30,2015-09-23,5CY3,2415.0,1.0,291.0,193.0,,34.2,1.0,1.76,experimental,26.13,0.1947,0.1699,SYK catalytic domain complexed with a potent and orally bioavailable benzisothiazole inhibitor
8BI2,X-RAY DIFFRACTION,2.09,41.25,"VAPOR DIFFUSION, SITTING DROP",6.4,"0.1M Na3Cit pH 6.4, 16% PEG3350, 0.2M KH2PO4",274.0,2022-11-01,2023-06-14,8BI2,2284.0,1.0,299.0,179.0,,35.34,1.0,1.508,experimental,31.93,0.2355,0.2034,Syk kinase domain in complex with macrocyclic inhibitor 20a
7Q5W,X-RAY DIFFRACTION,2.93,58.01,"VAPOR DIFFUSION, SITTING DROP",8.5,"30 mM sodium nitrate, 30 mM dibasic sodium phosphate, 30 mM ammonium sulphate, 100 mM Tris/BICINE, 10% PEG 20,000, 20% PEG 500 MME",293.0,2021-11-04,2021-11-24,7Q5W,13517.0,12.0,1710.0,303.0,,195.41,2.0,2.2,experimental,61.064,0.2663,0.2336,The tandem SH2 domains of SYK with a bound TYROBP diphospho-ITAM peptide
5TA6,X-RAY DIFFRACTION,2.39,48.62,"VAPOR DIFFUSION, SITTING DROP",,"0.95 mM succinic acid, 1.7% PEG2000 MME, 0.4 mM zinc acetate, 100 mM HEPES, pH 7.0,  temperature 277K",277.0,2016-09-09,2017-02-22,5TA6,2534.0,1.0,358.0,108.0,,41.2,1.0,2.5,experimental,52.34,0.2598,0.1788,"Crystal structure of PLK1 in complex with a novel 5,6-dihydroimidazolo[1,5-f]pteridine inhibitor."
5TA8,X-RAY DIFFRACTION,2.45,49.83,"VAPOR DIFFUSION, SITTING DROP",,"0.95 mM succinic acid, 1.7% PEG2000 MME, 0.4 mM zinc acetate, 100 mM HEPES, pH 7.0, temperature 277K",277.0,2016-09-09,2017-02-22,5TA8,2462.0,1.0,358.0,43.0,,41.19,1.0,2.6,experimental,94.267,0.2467,0.1815,"Crystal structure of PLK1 in complex with a novel 5,6-dihydroimidazolo[1,5-f]pteridine inhibitor"
6AX4,X-RAY DIFFRACTION,1.9,35.24,"VAPOR DIFFUSION, HANGING DROP",,"Well solution: 0.2 M Calcium Chloride, 12.5% PEG-3350
Protein: 10 mg/ml PBD-macrocycle complex in 0.5 M Sodium Chloride, 10 mM TRIS pH 8.0, 0.4 M ammonium acetate
1:1 mix of protein complex and well solution",291.0,2017-09-06,2018-09-12,6AX4,2155.0,2.0,242.0,266.0,,28.24,2.0,1.45,experimental,23.217,0.1656,0.1319,Plk-1 polo-box domain in complex with histidine N(tau)-cyclized Macrocycle 5b.
7UD6,X-RAY DIFFRACTION,3.41,63.93,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.7 M magnesium formate, 0.1 M bis-tris propone pH 7.0.",297.0,2022-03-18,2023-01-11,7UD6,2098.0,1.0,293.0,2.0,,33.06,1.0,2.59,experimental,,0.2779,0.2466,Designed Enzyme SH3-588 (Catechol O-methyltransferase catalytic domain and Src homology 3 binding domain fusion)
7APJ,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, SITTING DROP",5.0,"200 mM malonate, pH 5.0, 16% PEG 3350",295.0,2020-10-16,2021-08-25,7APJ,4259.0,2.0,566.0,163.0,1.0,65.29,2.0,2.05,experimental,58.66,0.2519,0.211,Structure of autoinhibited Akt1 reveals mechanism of PIP3-mediated activation
7U2Z,X-RAY DIFFRACTION,3.96,68.95,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG3350, Sodium Chloride, Hepes",293.0,2022-02-25,2022-04-27,7U2Z,5747.0,2.0,696.0,144.0,,79.82,1.0,2.21,experimental,54.117,0.2662,0.247,Crystal structure of human GSK3B in complex with G12
7U31,X-RAY DIFFRACTION,3.95,68.84,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG3350, Sodium Chloride, Hepes",293.0,2022-02-25,2022-04-27,7U31,5689.0,2.0,700.0,63.0,,80.4,1.0,2.38,experimental,63.599,0.2759,0.2423,Crystal structure of human GSK3B in complex with G5
7U33,X-RAY DIFFRACTION,3.97,69.03,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG3350, Sodium Chloride, Hepes",293.0,2022-02-25,2022-04-27,7U33,5697.0,2.0,702.0,67.0,,80.64,1.0,2.6,experimental,72.568,0.2641,0.2313,Crystal structure of human GSK3B in complex with ARN9133
7U36,X-RAY DIFFRACTION,3.94,68.74,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG3350, Sodium Chloride, Hepes",293.0,2022-02-25,2022-04-27,7U36,5654.0,2.0,702.0,25.0,,80.62,1.0,2.75,experimental,73.386,0.2753,0.2381,Crystal structure of human GSK3B in complex with ARN1484
8GI3,X-RAY DIFFRACTION,2.03,39.5,MICROBATCH,5.1,"0.2 M Ammonium citrate dibasic (pH 5.1), 20% PEG3350",293.2,2023-03-13,2024-03-20,8GI3,1640.0,1.0,196.0,185.0,,22.52,1.0,1.52,experimental,13.318,0.20947,0.17057,Crystal structure of RhoA mutant L69P complexed with GDP
8GI6,X-RAY DIFFRACTION,2.04,39.68,MICROBATCH,5.7,"0.1 M Na acetate (pH 5.7), 0.5 mM Na citrate, 26% PEG4000, 5% glycerol",293.15,2023-03-13,2024-03-20,8GI6,1640.0,1.0,196.0,182.0,,22.58,1.0,1.4,experimental,12.222,0.18173,0.15306,Crystal structure of RhoA mutant L69R complexed with GDP
7WZA,X-RAY DIFFRACTION,2.12,41.92,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2M potassium formate",289.0,2022-02-17,2023-02-22,7WZA,1686.0,1.0,185.0,211.0,,21.4,1.0,1.50028778245,experimental,19.0578590928,0.219733346012,0.187176443169,An open conformation Form 1 of switch II for RhoA
4R8M,X-RAY DIFFRACTION,2.08,40.96,"VAPOR DIFFUSION, HANGING DROP",7.5,"25%(v/v) PEG3350, 0.1M Hepes buffer, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293.0,2014-09-02,2015-03-11,4R8M,4647.0,4.0,648.0,27.0,,73.94,2.0,2.1,experimental,46.717,0.27332,0.22091,Human SIRT2 crystal structure in complex with BHJH-TM1
5Y0Z,X-RAY DIFFRACTION,2.17,43.2,"VAPOR DIFFUSION, SITTING DROP",5.5,"25%(w/v) PEG 3350, 0.1M BisTris, pH 5.5",293.0,2017-07-19,2018-07-25,5Y0Z,4817.0,2.0,586.0,144.0,,67.49,1.0,2.0,experimental,28.401,0.24202,0.21022,"Human SIRT2 in complex with a specific inhibitor, NPD11033"
5Y5N,X-RAY DIFFRACTION,2.65,53.56,VAPOR DIFFUSION,,"0.1M Bis-Tris buffer pH 5.5 
15%(w/v) PEG5000 MME",289.0,2017-08-09,2017-09-06,5Y5N,2418.0,1.0,336.0,102.0,,38.23,1.0,2.3,experimental,,0.252,0.256,Crystal structure of human Sirtuin 2 in complex with a selective inhibitor
5EA1,X-RAY DIFFRACTION,2.36,47.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG1000 (12.5%), PEG3350 (12.5%), MPD (12.5%)",277.0,2015-10-15,2016-03-16,5EA1,3244.0,3.0,396.0,212.0,,47.19,1.0,2.0,experimental,31.6186,0.2276,0.1921,Crystal Structure of SMARCA4 bromodomain in complex with MPD
8ASF,X-RAY DIFFRACTION,2.86,56.95,"VAPOR DIFFUSION, SITTING DROP",4.5,"100 mM sodium acetate, 50 mM magnesium chloride hexahydrate, 8% w/v PEG
3350, pH 4.5",293.0,2022-08-19,2024-03-06,8ASF,4661.0,4.0,590.0,59.0,8.0,69.02,2.0,2.58,experimental,41.458,0.24,0.195,Crystal structure of Thrombin in complex with macrocycle T1
5NP2,X-RAY DIFFRACTION,2.12,41.91,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.8 M sodium citrate, 0.1 M sodium cacodylate",293.0,2017-04-13,2018-05-16,5NP2,1048.0,2.0,122.0,73.0,,13.82,1.0,1.6,experimental,,0.2219,0.1891,Abl1 SH3 pTyr89/134
5ONP,X-RAY DIFFRACTION,2.36,47.79,EVAPORATION,6.0,"50 mM MES: 45% DMSO: 0.7-0.9 M NaCl: 0-0.4 M CdCl2: reservoir solution
containing 30-40% ammonium sulphate",293.0,2017-08-04,2018-08-29,5ONP,2916.0,2.0,321.0,424.0,,35.21,2.0,1.34,experimental,18.1855,0.1799,0.161,Alzheimer's Amyloid-Beta Peptide Fragment 1-40 in Complex with Cd-substituted Thermolysin
5ONQ,X-RAY DIFFRACTION,2.35,47.64,EVAPORATION,6.0,"50 mM MES: 45% DMSO: 0.7-0.9 M NaCl: 0-0.4 M CdCl2: reservoir solution
containing 30-40% ammonium sulphate",293.0,2017-08-04,2018-08-29,5ONQ,2909.0,2.0,321.0,393.0,,35.36,2.0,1.17,experimental,14.6381,0.1716,0.1625,Alzheimer's Amyloid-Beta Peptide Fragment 29-40 in Complex with Cd-substituted Thermolysin
6CM4,X-RAY DIFFRACTION,2.87,57.13,LIPIDIC CUBIC PHASE,,"100 mM Tris-HCl, pH 7.8, 230 mM lithium nitrate, 25% PEG400, 4% 1,3-butanediol",293.0,2018-03-02,2018-03-14,6CM4,3236.0,1.0,430.0,16.0,2.0,50.46,1.0,2.867,experimental,,0.2492,0.2259,Structure of the D2 Dopamine Receptor Bound to the Atypical Antipsychotic Drug Risperidone
4PX9,X-RAY DIFFRACTION,2.02,39.22,"VAPOR DIFFUSION, HANGING DROP",7.6,"50 mM Hepes 7.6; 7% PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 291K",291.0,2014-03-22,2015-03-11,4PX9,6346.0,3.0,876.0,,,100.35,1.0,2.31,experimental,71.1,0.285,0.255,DEAD-box RNA helicase DDX3X Domain 1 with N-terminal ATP-binding Loop
4XG3,X-RAY DIFFRACTION,2.12,42.09,"VAPOR DIFFUSION, HANGING DROP",8.5,"10~20% (v/v) PEG3350, 100 mM Tris-HCl",278.0,2014-12-30,2015-12-30,4XG3,4531.0,2.0,580.0,149.0,,68.78,1.0,2.3,experimental,43.888,0.22591,0.19779,Crystal structure of an inhibitor-bound Syk
4XG8,X-RAY DIFFRACTION,2.11,41.64,"VAPOR DIFFUSION, HANGING DROP",8.5,"10~20%(v/v) PEG3350, 100 mM Tris-HCl",278.0,2014-12-30,2015-12-30,4XG8,4238.0,2.0,580.0,32.0,,68.65,1.0,2.4,experimental,56.362,0.27487,0.24739,Crystal structure of an inhibitor-bound Syk
4XG9,X-RAY DIFFRACTION,2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",8.5,"10~20%(v/v) PEG3350, 100 mM Tris-HCl",278.0,2014-12-30,2015-12-30,4XG9,4325.0,2.0,580.0,3.0,,68.68,1.0,2.91,experimental,49.781,0.24104,0.2085,Crystal structure of an inhibitor-bound Syk
5GHV,X-RAY DIFFRACTION,2.07,40.64,"VAPOR DIFFUSION, HANGING DROP",8.5,"10~20%(V/V) PEG3350, 100 MM TRIS-HCL",278.0,2016-06-20,2016-07-06,5GHV,4408.0,2.0,580.0,20.0,,68.76,1.0,2.8,experimental,43.35,0.227,0.217,Crystal structure of an inhibitor-bound Syk
5Y5U,X-RAY DIFFRACTION,2.09,41.14,"VAPOR DIFFUSION, HANGING DROP",,"10-20% PEG 3350, 100mM Tris-HCl, pH 8.5",277.0,2017-08-09,2018-06-27,5Y5U,4373.0,2.0,586.0,67.0,,69.22,1.0,2.14,experimental,40.694,0.25989,0.23793,Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor
8XB9,X-RAY DIFFRACTION,1.98,37.98,"VAPOR DIFFUSION, SITTING DROP",,"31% PEG3350, 0.1M Bis Tris pH 5.8",293.0,2023-12-06,2023-12-27,8XB9,1903.0,1.0,237.0,90.0,,27.35,1.0,1.95,experimental,44.155,0.2448,0.1885,The Crystal Structure of polo-box domain of PLK1 from Biortus.
4YJQ,X-RAY DIFFRACTION,2.1,41.56,"VAPOR DIFFUSION, HANGING DROP",6.0,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP",293.0,2015-03-03,2015-09-30,4YJQ,2547.0,1.0,281.0,323.0,,33.25,1.0,1.34,experimental,19.19,0.1835,0.161,SYK kinase domain in complex with inhibitor GTC000224
4YJR,X-RAY DIFFRACTION,2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",6.0,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP",293.0,2015-03-03,2015-09-30,4YJR,2592.0,1.0,281.0,347.0,,33.23,1.0,1.32,experimental,18.53,0.1801,0.1555,SYK kinase domain in complex with inhibitor GTC000225
4YJS,X-RAY DIFFRACTION,1.95,36.8,"VAPOR DIFFUSION, HANGING DROP",6.8,"32.5% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM DTT",293.0,2015-03-03,2015-09-30,4YJS,2255.0,1.0,281.0,120.0,,33.1,1.0,2.22,experimental,49.491,0.2257,0.1696,THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
4YJU,X-RAY DIFFRACTION,2.09,41.21,"VAPOR DIFFUSION, HANGING DROP",6.8,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP",293.0,2015-03-03,2015-09-30,4YJU,2557.0,1.0,281.0,279.0,,33.24,1.0,1.67,experimental,28.33,0.2009,0.1665,THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
5CXZ,X-RAY DIFFRACTION,2.44,49.68,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350 15%, cesium chloride 0.15M",293.0,2015-07-29,2015-09-16,5CXZ,2301.0,1.0,289.0,138.0,,34.12,1.0,1.7,experimental,27.62,0.208,0.1945,SYK catalytic domain complexed with naphthyridine inhibitor
8W31,X-RAY DIFFRACTION,2.99,58.85,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.2 M Sodium Chloride, 0.1M HEPES pH 7.5, 25% (w/v) PEG 3350",277.0,2024-02-21,2024-08-21,8W31,3051.0,3.0,390.0,32.0,,44.58,2.0,2.5,experimental,89.24,0.2937,0.2397,Crystal structure of parkin (R0RB):2pUb with activator compound
5FN7,X-RAY DIFFRACTION,4.26,71.0,,8.0,"0.1M TRIS, PH=8, 2.4M (NH4)2SO4, 6% ETHYLENE GLYCOL",,2015-11-10,2016-03-23,5FN7,2977.0,2.0,372.0,105.0,10.0,44.99,1.0,2.3,experimental,58.89,0.2385,0.2015,"Crystal structure of human CD45 extracellular region, domains d1-d2"
6L71,X-RAY DIFFRACTION,2.33,47.32,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES, pH 6.5, 6%-20% (w/v) PEG 10000",291.0,2019-10-30,2021-03-31,6L71,2761.0,2.0,310.0,223.0,3.0,36.74,2.0,2.109,experimental,34.6187,0.2235,0.1673,Sirtuin 2 demyristoylation native intermediate I & II mixture
6L72,X-RAY DIFFRACTION,2.37,48.01,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES, pH=6.5, 6%-20% (w/v) PEG10000",291.0,2019-10-30,2021-03-31,6L72,2472.0,1.0,304.0,71.0,,35.24,1.0,2.501,experimental,39.3181,0.2434,0.1764,Sirtuin 2 demyristoylation native final product
8IKM,X-RAY DIFFRACTION,2.04,39.69,"VAPOR DIFFUSION, SITTING DROP",,"0.3 M Sodium nitrate, 0.3 Sodium phosphate dibasic, 0.3 M Ammonium sulfate,1.0 M 8.5 Tris (base), BICINE, 25% v/v MPD; 25% PEG 1000, 25% w/v PEG 3350",291.0,2023-02-28,2024-09-11,8IKM,3052.0,3.0,468.0,96.0,,52.79,3.0,1.92,experimental,60.224,0.2325,0.2048,Trans complex of phospho parkin
6I51,X-RAY DIFFRACTION,2.52,51.24,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4, pH 7.5
350 mM NaCl
2 mM benzamidine
at a conc. of 10 mg/ml thrombin",278.0,2018-11-12,2019-11-20,6I51,2645.0,3.0,307.0,208.0,4.0,36.08,3.0,1.4,experimental,,0.1689,0.1447,Thrombin in complex with fragment J02
4UDW,X-RAY DIFFRACTION,2.45,49.7,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2014-12-12,2015-08-26,4UDW,2808.0,3.0,297.0,311.0,4.0,35.33,3.0,1.16,experimental,21.0,0.1413,0.1238,"Thrombin in complex with 1-(2R)-2-amino-3-phenyl-propanoyl-N-(2, 5dichlorophenyl)methylpyrrolidine-2-carboxamide"
4UEH,X-RAY DIFFRACTION,2.49,50.57,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2014-12-17,2015-08-26,4UEH,2809.0,3.0,299.0,340.0,4.0,35.21,3.0,1.16,experimental,22.0,0.1383,0.1207,Thrombin in complex with benzamidine
5MF6,X-RAY DIFFRACTION,2.59,52.45,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, Bis-Tris buffer pH 5.7",293.0,2016-11-17,2016-12-28,5MF6,4701.0,2.0,604.0,174.0,,70.11,1.0,1.87,experimental,32.836,0.21957,0.18988,Human Sirt6 in complex with activator UBCS039
7TZ7,X-RAY DIFFRACTION,2.31,46.85,"VAPOR DIFFUSION, HANGING DROP",,"0.15M Potassium Thiocyanate, 20% PEG 3350",303.15,2022-02-15,2022-05-18,7TZ7,10019.0,2.0,1365.0,31.0,,160.63,2.0,2.41,experimental,90.6423,0.2773,0.2389,PI3K alpha in complex with an inhibitor
6CCY,X-RAY DIFFRACTION,2.28,46.05,"VAPOR DIFFUSION, HANGING DROP",,16% PEG 3350 and 200mM Ammonium Formate,277.0,2018-02-07,2018-05-02,6CCY,2755.0,1.0,343.0,56.0,,40.53,1.0,2.18,experimental,58.86,0.276,0.2352,Crystal structure of Akt1 in complex with a selective inhibitor
5WBN,X-RAY DIFFRACTION,2.09,41.07,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291.0,2017-06-29,2017-08-02,5WBN,1036.0,1.0,107.0,149.0,,16.26,1.0,1.64,experimental,9.104,0.1675,0.1319,"Crystal structure of fragment 3-(3-Benzyl-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazolin-6-yl)propanoic acid bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain"
5FO8,X-RAY DIFFRACTION,3.4,63.9,,,"100MM AMMONIUM CITRATE 7% PEG 3350 5MM GLUTATHIONE 50MM BIS-TRIS PROPANE, PH 6.5",,2015-11-18,2016-04-06,5FO8,13810.0,3.0,1812.0,492.0,14.0,206.93,3.0,2.4,experimental,67.0,0.2188,0.1879,Crystal Structure of Human Complement C3b in Complex with MCP (CCP1-4)
4XG2,X-RAY DIFFRACTION,2.06,40.21,"VAPOR DIFFUSION, HANGING DROP",8.5,"10~20%(v/v) PEG3350, 100 mM Tris-HCl",278.0,2014-12-30,2015-12-30,4XG2,2198.0,1.0,290.0,82.0,,33.9,1.0,2.21,experimental,43.142,0.22681,0.20312,Crystal structure of ligand-free Syk
5CXH,X-RAY DIFFRACTION,2.39,48.49,"VAPOR DIFFUSION, SITTING DROP",7.3,"20% PEG3350, 0.2M potassium fluoride, no buffer pH 7.3",277.0,2015-07-29,2015-09-23,5CXH,2485.0,1.0,289.0,214.0,,34.07,1.0,1.9,experimental,25.85,0.2052,0.1746,SYK catalytic domain complexed with a potent orally bioavailable thiazole inhibitor
5Y5T,X-RAY DIFFRACTION,2.08,40.77,"VAPOR DIFFUSION, HANGING DROP",,"10-20% PEG 3350, 100mM Tris-HCl, pH 8.5",277.0,2017-08-09,2018-06-27,5Y5T,2341.0,1.0,293.0,162.0,,34.64,1.0,1.8,experimental,41.174,0.2344,0.19391,Crystal structures of spleen tyrosine kinase in complex with a novel inhibitor
4YKN,X-RAY DIFFRACTION,2.94,58.18,"VAPOR DIFFUSION, HANGING DROP",,"ethylenene glycol, PIP2",277.0,2015-03-04,2015-06-17,4YKN,9679.0,1.0,1383.0,94.0,,163.38,1.0,2.9,experimental,,0.2472,0.2015,Pi3K alpha lipid kinase with Active Site Inhibitor
6RSU,X-RAY DIFFRACTION,3.26,62.28,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES pH 7.5, 5-8% PEG 8000",294.0,2019-05-22,2020-04-01,6RSU,5103.0,1.0,663.0,,,76.74,1.0,2.75,experimental,85.74,0.3508,0.2893,TBK1 in complex with Inhibitor compound 35
7KEV,X-RAY DIFFRACTION,2.28,45.97,"VAPOR DIFFUSION, SITTING DROP",8.0,"20.0% PEG-6000, 0.1M TRIS",293.0,2020-10-12,2021-11-24,7KEV,4387.0,3.0,684.0,17.0,12.0,74.06,3.0,2.8,experimental,54.88,0.2804,0.2258,PCSK9 in complex with a cyclic peptide LDLR disruptor
6GHK,X-RAY DIFFRACTION,2.73,54.87,"VAPOR DIFFUSION, SITTING DROP",5.5,"22.5% PEG 3350, 0.18M ammonium sulfate,  0.09M Bis-Tris",277.0,2018-05-08,2019-05-22,6GHK,5848.0,2.0,716.0,208.0,,81.75,1.0,2.28,experimental,,0.2265,0.1869,Human PARP1 (ARTD1) - Catalytic domain in complex with inhibitor ME0527
7Q63,X-RAY DIFFRACTION,2.68,54.12,"VAPOR DIFFUSION, SITTING DROP",,"200 mM, potassium thiocyanate, 12.5% glycerol, 23% PEG3350",293.0,2021-11-05,2021-11-24,7Q63,6380.0,3.0,795.0,324.0,,90.45,1.0,1.9,experimental,52.278,0.2643,0.217,The tandem SH2 domains of SYK
5DS3,X-RAY DIFFRACTION,2.82,56.32,"VAPOR DIFFUSION, SITTING DROP",5.5,"20-25% PEG 3350, 0.2 M Ammonium Sulfate, 0.1 M Bis-Tris, pH 5.5",298.0,2015-09-16,2016-07-27,5DS3,1988.0,1.0,271.0,27.0,1.0,30.87,1.0,2.6,experimental,59.488,0.25087,0.19998,Crystal structure of constitutively active PARP-1
5XSR,X-RAY DIFFRACTION,3.64,66.19,"VAPOR DIFFUSION, HANGING DROP",,"80mM NaCl, 1.9M (NH4)2SO4",293.0,2017-06-15,2018-04-25,5XSR,2744.0,1.0,355.0,155.0,1.0,40.09,1.0,2.3,experimental,47.0058,0.2334,0.2128,novel orally efficacious inhibitors complexed with PARP1
5XST,X-RAY DIFFRACTION,3.63,66.09,"VAPOR DIFFUSION, HANGING DROP",,"80mM NaCl, 1.9M (NH4)2SO4",283.0,2017-06-15,2018-04-25,5XST,2722.0,1.0,350.0,47.0,1.0,39.57,1.0,2.3,experimental,65.815,0.2356,0.202,novel orally efficacious inhibitors complexed with PARP1
5XXK,X-RAY DIFFRACTION,2.28,46.07,"VAPOR DIFFUSION, SITTING DROP",6.4,"0.04M Citric acid, 0.06M Bis-Tris propane pH 6.4, 20% (v/v) PEG 3350",289.0,2017-07-04,2017-12-27,5XXK,1877.0,4.0,268.0,124.0,,30.38,2.0,1.66,experimental,32.326,0.2088,0.18749,Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids
7NA2,X-RAY DIFFRACTION,1.99,38.27,VAPOR DIFFUSION,,undisclosed,293.0,2021-06-19,2021-11-10,7NA2,1735.0,2.0,220.0,82.0,,26.28,1.0,1.86,experimental,33.682,0.2585,0.186,HDM2 in complex with compound 56
4YJV,X-RAY DIFFRACTION,2.12,42.03,"VAPOR DIFFUSION, HANGING DROP",6.0,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP",293.0,2015-03-03,2015-10-14,4YJV,2583.0,1.0,281.0,343.0,,33.26,1.0,1.652,experimental,23.68,0.2223,0.1748,THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
7NG7,X-RAY DIFFRACTION,2.03,39.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"6% PEG3350, 300mM Ammonium acetate, 0.1M HEPES pH7.5, 10mM TCEP",293.0,2021-02-08,2021-09-15,7NG7,2477.0,1.0,287.0,223.0,,33.33,1.0,1.5,experimental,17.634,0.2133,0.18,Src kinase bound to eCF506 trapped in inactive conformation
4WNM,X-RAY DIFFRACTION,2.2,44.01,"VAPOR DIFFUSION, SITTING DROP",,"100 mM MES pH 5.3, 150 mM Ammonium sulfate, and 22% PEG 3350",278.0,2014-10-13,2016-01-20,4WNM,2226.0,1.0,299.0,16.0,,35.42,1.0,2.5,experimental,48.453,0.26,0.2039,SYK catalytic domain in complex with a potent triazolopyridine inhibitor
5EW1,X-RAY DIFFRACTION,2.73,55.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"28% MPEG 2000, 
0.1 M Bis/Tris pH 6.5",298.0,2015-11-20,2016-11-30,5EW1,3214.0,4.0,337.0,74.0,4.0,47.7,2.0,2.95,experimental,50.954,0.208,0.1555,Human thrombin sandwiched between two DNA aptamers: HD22 and HD1-deltaT3
5FMV,X-RAY DIFFRACTION,3.28,62.48,,8.0,"14% W/V PEG8K, 0.2M (NH4)2SO4, PH=8",,2015-11-09,2016-03-23,5FMV,5811.0,2.0,722.0,,16.0,86.21,1.0,2.9,experimental,107.38,0.249,0.2259,"Crystal structure of human CD45 extracellular region, domains d1-d4"
5Z02,X-RAY DIFFRACTION,1.92,36.02,"VAPOR DIFFUSION, HANGING DROP",,"0.2 Ammonium acetate, 20% ammonium sulfate",291.0,2017-12-18,2018-01-03,5Z02,802.0,1.0,110.0,33.0,,13.54,1.0,1.35,experimental,24.094,0.2544,0.2258,Crystal structure of HIS6-tagged Mdm2 with nutlin-3a
5ZXF,X-RAY DIFFRACTION,2.41,49.0,"VAPOR DIFFUSION, HANGING DROP",,"0.2M NaOAc, 1.2M AmSO4, Seeding.",291.0,2018-05-19,2018-08-22,5ZXF,797.0,1.0,87.0,36.0,,10.85,1.0,1.25,experimental,20.887,0.2431,0.2178,The 1.25A Crystal structure of His6-tagged Mdm2 in complex with nutlin-3a
5OAI,X-RAY DIFFRACTION,2.71,54.6,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 20% (w/v) PEG 5000 MME",277.15,2017-06-22,2019-02-13,5OAI,873.0,1.0,97.0,41.0,,11.9,1.0,2.0,experimental,,0.2273,0.2156,Structure of MDM2 with low molecular weight inhibitor
6T2E,X-RAY DIFFRACTION,2.02,39.23,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.056 M Sodium phosphate monobasic monohydrate, 1.344 M Potassium phosphate dibasic, pH8.2",295.0,2019-10-08,2020-01-29,6T2E,849.0,2.0,100.0,25.0,,11.85,2.0,2.4,experimental,26.401,0.2902,0.2124,Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions
6T2F,X-RAY DIFFRACTION,2.06,40.42,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M TRIS pH 8, 0.2M Trimethyl N-oxide dihydrate, 20% PEG-2000",295.0,2019-10-08,2020-01-29,6T2F,888.0,2.0,100.0,51.0,,12.1,2.0,2.09,experimental,32.701,0.2715,0.1945,Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions
7NA3,X-RAY DIFFRACTION,1.92,36.0,VAPOR DIFFUSION,,undisclosed,293.0,2021-06-19,2021-11-10,7NA3,858.0,1.0,110.0,11.0,,13.49,1.0,2.21,experimental,55.29,0.2191,0.1957,HDM2 in complex with compound 62
5DKD,X-RAY DIFFRACTION,2.98,58.78,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.1 M Bis Tris pH 7.2, 0.1 M ammonium acetate, 0.1 M ZnCl2, 15% PEG smear high (mixture from PEG8k to 20k)",277.15,2015-09-03,2015-10-14,5DKD,2002.0,2.0,242.0,101.0,,29.61,1.0,2.0,experimental,32.2,0.29729,0.26773,Crystal structure of the bromodomain of human BRG1 (SMARCA4) in complex with PFI-3 chemical probe
5X3S,X-RAY DIFFRACTION,2.28,46.12,"VAPOR DIFFUSION, HANGING DROP",5.5,"15% PEG 6000, 0.1M sodium citrate",291.0,2017-02-07,2017-12-20,5X3S,3753.0,4.0,470.0,7.0,,54.48,2.0,2.899,experimental,38.6935,0.2441,0.2025,Crystal structure of mouse Plk1-PBD in complex with phosphopeptide from HEF1 (799-809)
5E7J,X-RAY DIFFRACTION,2.43,49.42,"VAPOR DIFFUSION, HANGING DROP",5.0,"PEG 3000, sodium citrate",291.0,2015-10-12,2015-12-02,5E7J,3446.0,1.0,452.0,,,51.44,1.0,2.23,experimental,37.4013,0.2637,0.2298,Crystal structure of the active catalytic core of the human DEAD-box protein DDX3 bound to AMP
5E7M,X-RAY DIFFRACTION,2.91,57.7,"VAPOR DIFFUSION, HANGING DROP",5.0,"PEG-3000, sodium citrate",291.0,2015-10-12,2015-12-02,5E7M,3390.0,1.0,452.0,5.0,,51.6,1.0,2.304,experimental,100.35,0.284,0.2247,Crystal structure of the active catalytic core of the human DEAD-box protein DDX3 bound to AMPPNP
4RMG,X-RAY DIFFRACTION,2.91,57.71,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1 M KSCN, 30% (wt/vol) PEG MME 2,000, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-10-21,2015-02-25,4RMG,2523.0,1.0,304.0,99.0,,35.57,1.0,1.88,experimental,37.891,0.24733,0.20231,Human Sirt2 in complex with SirReal2 and NAD+
4RMH,X-RAY DIFFRACTION,2.07,40.49,"VAPOR DIFFUSION, SITTING DROP",9.0,"2.8 M ammonium sulfate, pH 9.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-10-21,2015-02-25,4RMH,2691.0,2.0,311.0,243.0,,35.63,2.0,1.42,experimental,21.173,0.18797,0.18066,Human Sirt2 in complex with SirReal2 and Ac-Lys-H3 peptide
4RMI,X-RAY DIFFRACTION,2.13,42.26,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% (wt/vol) PEG 3,350, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277.0,2014-10-21,2015-02-25,4RMI,2465.0,2.0,307.0,156.0,,35.33,2.0,1.45,experimental,17.311,0.28237,0.25984,Human Sirt2 in complex with SirReal1 and Ac-Lys-OTC peptide
8JOQ,X-RAY DIFFRACTION,2.09,41.25,"VAPOR DIFFUSION, SITTING DROP",,"0.1M malate MES Tris buffer pH 6.5, 25% polyethylene glycol 1500",291.0,2023-06-08,2023-10-11,8JOQ,1943.0,2.0,233.0,117.0,,26.96,2.0,1.796,experimental,,0.2497,0.2056,Plk1 polo-box domain bound to HPV18 L2 residues 209-215 with pThr213
8JOY,X-RAY DIFFRACTION,2.04,39.84,"VAPOR DIFFUSION, SITTING DROP",,"0.1M malate MES Tris buffer pH 6.5, 25% polyethylene glycol 1500",291.0,2023-06-09,2023-10-11,8JOY,1813.0,2.0,233.0,17.0,,27.03,2.0,2.61,experimental,52.63,0.2546,0.1978,Plk1 polo-box domain bound to HPV4 L2 residues 251-257 with pThr255
8ASE,X-RAY DIFFRACTION,2.65,53.52,"VAPOR DIFFUSION, HANGING DROP",5.5,"100 mM Bis-Tris,
200 mM ammonium sulfate, 25% w/v PEG 3350 pH 5.5",293.0,2022-08-19,2023-11-29,8ASE,4760.0,4.0,590.0,77.0,8.0,69.76,2.0,2.55,experimental,45.5826,0.25,0.2,Crystal structure of Thrombin in complex with macrocycle T3
7UVA,X-RAY DIFFRACTION,2.22,44.65,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris-Cl, pH 8.5, 150 mM lithium sulfate, 20% PEG3350",293.0,2022-04-29,2023-02-22,7UVA,7117.0,6.0,824.0,429.0,,96.92,3.0,1.98,experimental,30.473,0.23701,0.18285,Crystal structure of KDM2A histone demethylase catalytic domain in complex with an H3C36 peptide modified by UNC8015
5W59,X-RAY DIFFRACTION,2.76,55.37,"VAPOR DIFFUSION, HANGING DROP",8.0,"100 mM Tris, pH 8.0, 8% w/v PEG20000, 0.3 M sodium chloride, 40 mM L-proline",291.0,2017-06-14,2017-08-16,5W59,2944.0,2.0,401.0,90.0,2.0,45.72,2.0,2.498,experimental,,0.2211,0.1709,Crystal structure of a monomeric human FGF9 in complex with the ectodomain of human FGFR1c
4XJJ,X-RAY DIFFRACTION,2.26,45.55,"VAPOR DIFFUSION, HANGING DROP",5.0,"100 mM sodium citrate, 30% PEG 2000",298.0,2015-01-08,2015-06-24,4XJJ,1023.0,1.0,112.0,111.0,7.0,13.0,1.0,1.4,experimental,21.0997,0.1853,0.153,Extracellular domain of type II Transforming Growth Factor Beta receptor in complex with 2-(2-Hydroxyethyl)NDSB-201
5TT7,X-RAY DIFFRACTION,2.36,47.83,"VAPOR DIFFUSION, SITTING DROP",8.7,"1.2M Potassium Na Tartrate, 0.1M Tris pH 8.7",293.0,2016-11-01,2016-11-30,5TT7,2416.0,1.0,289.0,145.0,,34.05,1.0,1.77,experimental,29.668,0.2345,0.2062,"Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)"
7US1,X-RAY DIFFRACTION,2.93,57.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Bis-Tris propane pH 7.5, 20.5% PEG3350, 0.2M NaI",277.15,2022-04-22,2022-06-22,7US1,3122.0,3.0,388.0,39.0,,44.24,2.0,2.484,experimental,77.6442,0.2584,0.2294,Structure of parkin (R0RB) bound to two phospho-ubiquitin molecules
8VMG,X-RAY DIFFRACTION,4.36,71.8,"VAPOR DIFFUSION, HANGING DROP",5.5,"100 mM MES, pH 5.5, 1.9 M ammonium sulfate, 200 mM sodium chloride, cryoprotectant: 25% ethylene glycol",298.0,2024-01-13,2024-08-28,8VMG,6672.0,4.0,848.0,158.0,,101.72,2.0,2.45,experimental,79.85,0.2301,0.1947,Crystal structure of GSK-3 26-383 bound to Axin 383-435
6T52,X-RAY DIFFRACTION,2.53,51.29,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4, 350 mM NaCl, 27% (w/v) PEG8000",277.0,2019-10-15,2020-11-18,6T52,2617.0,3.0,306.0,216.0,4.0,36.16,3.0,1.45,experimental,26.43,0.1607,0.1296,Thrombin in Complex with a D-Phe-Pro-imidazole derivative
6T57,X-RAY DIFFRACTION,2.56,52.0,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4, 350 mM NaCl, 27% (w/v) PEG8000",277.0,2019-10-15,2020-11-18,6T57,2545.0,3.0,306.0,156.0,4.0,36.32,3.0,1.57,experimental,34.77,0.2131,0.1926,Thrombin in Complex with a D-Phe-Pro-N-amidinopiperidine Derivative
6T8A,X-RAY DIFFRACTION,2.87,57.11,"VAPOR DIFFUSION, HANGING DROP",7.0,"20 mM sodium dihydrogen phosphate ph 7.5
350 mM NaCl
27 % PEG 8000",277.0,2019-10-24,2020-11-18,6T8A,2704.0,3.0,306.0,258.0,4.0,36.58,3.0,1.62,experimental,26.721,0.1853,0.1596,Thrombin in complex with diphenyl ((4-carbamimidoylphenyl)((S)-1-((R)-3-cyclohexyl 2-((phenylmethyl)sulfonamido)propanoyl)pyrrolidine-2-carboxamido)methyl)phosphonate (MI-492)
6Y9H,X-RAY DIFFRACTION,2.85,56.89,"VAPOR DIFFUSION, HANGING DROP",,"20mM sodium dihydrogen phosphate ph 7.5
350mM NaCl
27% PEG 8000",277.0,2020-03-09,2021-03-31,6Y9H,2771.0,4.0,310.0,266.0,4.0,36.38,4.0,1.48,experimental,22.3901,0.1697,0.1375,Thrombin in complex with D-Phe-Pro-m-Trifluoromethylbenzylamide derivative (phe2)
6YB6,X-RAY DIFFRACTION,2.84,56.77,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate ph 7.5
350mM NaCl
27% PEG 8000",277.0,2020-03-16,2021-03-31,6YB6,2799.0,4.0,310.0,251.0,4.0,36.36,4.0,1.33,experimental,22.9854,0.1526,0.1309,"Thrombin in complex with D-Phe-Pro-3-chloro-1,3-dihydroxybenzylamide derivative (13c)"
6YHG,X-RAY DIFFRACTION,2.4,49.21,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate ph 7.5
350mM NaCl
27% PEG 8000",277.0,2020-03-29,2021-04-07,6YHG,2936.0,3.0,307.0,303.0,4.0,36.3,3.0,1.33,experimental,17.8975,0.1451,0.1233,Thrombin in complex with D-Phe-Pro-m-methoxybenzylamide derivative (16a)
6YHJ,X-RAY DIFFRACTION,2.42,49.14,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate ph 7.5
350mM NaCl
27% PEG 8000",277.0,2020-03-30,2021-04-14,6YHJ,2963.0,3.0,307.0,294.0,4.0,36.71,3.0,1.44,experimental,23.489,0.1541,0.1274,Thrombin in complex with D-Phe-Pro-2-chlorothiophen derivative (16e)
6YMP,X-RAY DIFFRACTION,2.77,55.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate ph 7.5
350mM NaCl
27% PEG 8000",277.0,2020-04-09,2021-04-21,6YMP,2734.0,3.0,307.0,266.0,4.0,36.15,3.0,1.42,experimental,23.6945,0.1538,0.1312,Thrombin in complex with 3-((5-(tert-butyl)isoxazol-3-yl)methyl)oxetan-3-amine (j54)
6YN3,X-RAY DIFFRACTION,2.78,55.86,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate pH 7.5
350mM NaCl
27% PEG 8000",277.0,2020-04-10,2021-04-21,6YN3,2664.0,3.0,307.0,240.0,4.0,36.08,3.0,1.49,experimental,24.2437,0.1666,0.1384,Thrombin in complex with 4-hydroxybenzamide (j89)
6YSJ,X-RAY DIFFRACTION,2.76,55.48,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate pH 7.5
350mM NaCl
27% PEG 8000",277.0,2020-04-22,2021-05-12,6YSJ,2667.0,3.0,307.0,237.0,4.0,36.28,3.0,1.45,experimental,24.8816,0.1676,0.1338,Thrombin in complex with 2-amino-1-(4-bromophenyl)ethan-1-one (j10)
6ZGO,X-RAY DIFFRACTION,2.83,56.54,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate ph 7.5
350mM NaCl
27% PEG 8000",277.0,2020-06-19,2021-06-30,6ZGO,2539.0,3.0,307.0,161.0,4.0,36.3,3.0,1.79,experimental,34.9541,0.225,0.1852,Thrombin in complex with D-Phe-Pro-2-chlorofuran derivative (13l)
7AC9,X-RAY DIFFRACTION,2.77,55.58,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM sodium dihydrogen phosphate pH 7.5
350mM NaCl
27% PEG 8000",277.0,2020-09-10,2021-10-06,7AC9,2698.0,3.0,307.0,239.0,4.0,36.12,3.0,1.393,experimental,26.0632,0.1632,0.1402,Thrombin in complex with D-arginine (j77)
6T3Q,X-RAY DIFFRACTION,2.5,50.87,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4 (pH 7.5), 350 mM NaCl, 27% (w/v) PEG8000",277.0,2019-10-11,2020-05-13,6T3Q,2714.0,3.0,306.0,257.0,4.0,36.19,3.0,1.33,experimental,18.58,0.1458,0.1252,Thrombin in Complex with a D-Phe-Pro-2-aminopyridine derivative
6T4A,X-RAY DIFFRACTION,2.5,50.89,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4 (pH 7.5), 350 mM NaCl, 27% (w/v) PEG8000",277.0,2019-10-13,2020-05-13,6T4A,2701.0,3.0,306.0,262.0,4.0,36.19,3.0,1.31,experimental,17.44,0.148,0.1271,Thrombin in Complex with a D-Phe-Pro-p-aminopyridine derivative
6T89,X-RAY DIFFRACTION,2.92,57.94,"VAPOR DIFFUSION, HANGING DROP",7.0,"20 mM sodium dihydrogen phosphate ph 7.5
350 mM NaCl
27 % PEG 8000",277.0,2019-10-24,2020-11-18,6T89,2525.0,3.0,307.0,176.0,4.0,36.37,3.0,2.0,experimental,32.0044,0.2152,0.172,"Thrombin in complex with (S)-N-(tert-butyl)-4-(3-(3-carbamimidoylphenyl)-2-((2',4'-dimethoxy-[1,1'-biphenyl])-3-sulfonamido)propanoyl)piperazine-1-carboxamide (MI-498)"
6Z8V,X-RAY DIFFRACTION,3.9,68.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"200 mM KCl, 35% v/v pentaerythritol propoxylate, 50 mM HEPES, pH 7.5",293.0,2020-06-02,2021-01-27,6Z8V,2828.0,3.0,310.0,202.0,4.0,39.22,2.0,1.58,experimental,27.472,0.2057,0.1797,"X-ray structure of the complex between human alpha thrombin and a thrombin binding aptamer variant (TBA-3L), which contains 1-beta-D-lactopyranosyl residue in the side chain of Thy3 at N3."
6Z8W,X-RAY DIFFRACTION,3.9,68.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"200 mM KCl, 35% v/v pentaerythritol propoxylate, 50  mM HEPES, pH 7.5",293.0,2020-06-02,2021-01-27,6Z8W,2796.0,3.0,310.0,200.0,4.0,39.22,2.0,1.73,experimental,32.949,0.2072,0.178,"X-ray structure of the complex between human alpha thrombin and a thrombin binding aptamer variant (TBA-3G), which contains 1-beta-D-glucopyranosyl residue in the side chain of Thy3 at N3."
6Z8X,X-RAY DIFFRACTION,3.88,68.3,"VAPOR DIFFUSION, HANGING DROP",5.6,"18% v/v 2-propanol, 18% w/v PEG 4000, 100 mM tri-sodium citrate, pH 5.6",293.0,2020-06-02,2021-01-27,6Z8X,2511.0,3.0,310.0,3.0,4.0,39.19,2.0,2.53,experimental,69.54,0.2915,0.2448,"X-ray structure of the complex between human alpha thrombin and a thrombin binding aptamer variant (TBA-3Leu), which contains leucyl amide in the side chain of Thy3 at N3."
8BW5,X-RAY DIFFRACTION,2.96,61.8,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 8000 20% w/v, magnesium acetate 0.2 M, sodium cacodylate 0.1 M, pH 6.5",293.0,2022-12-06,2023-07-19,8BW5,3347.0,3.0,336.0,21.0,4.0,48.93,2.0,2.8,experimental,77.137,0.2517,0.20627,X-ray structure of the complex between human alpha thrombin and the duplex/quadruplex aptamer M08s-1_41mer
6ICT,X-RAY DIFFRACTION,2.74,55.15,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Magnesium acetate tetrahydrate
0.1M Sodium cacodylate trihydrate pH 6.5
20% Polyethylene glycol 8000",291.0,2018-09-07,2019-02-27,6ICT,16956.0,8.0,2108.0,1114.0,,244.36,2.0,1.952,experimental,,0.2138,0.1784,Structure of SETD3 bound to SAH and methylated actin
6M3I,X-RAY DIFFRACTION,2.42,49.21,VAPOR DIFFUSION,,"0.1 M Tris-pH 7.0, 0.2 M magnesium formate dehydrate, 20% w/v PEG 3350.",300.0,2020-03-03,2021-03-03,6M3I,4702.0,2.0,599.0,323.0,,67.67,2.0,1.98,experimental,31.03,0.2064,0.175,Crystal structure of HPF1/PARP1 complex
4XG4,X-RAY DIFFRACTION,2.08,40.91,"VAPOR DIFFUSION, HANGING DROP",8.5,"10~20%(v/v) PEG3350, 100 mM Tris-HCl",278.0,2014-12-30,2015-12-30,4XG4,2253.0,1.0,290.0,70.0,,34.36,1.0,2.3,experimental,45.297,0.22843,0.19352,Crystal structure of an inhibitor-bound Syk
4XG6,X-RAY DIFFRACTION,2.13,42.39,"VAPOR DIFFUSION, HANGING DROP",8.5,"10~20%(v/v) PEG3350, 100 mM Tris-HCl",278.0,2014-12-30,2015-12-30,4XG6,2291.0,1.0,290.0,64.0,,34.27,1.0,2.4,experimental,42.939,0.23015,0.1895,Crystal structure of an inhibitor-bound Syk
4XG7,X-RAY DIFFRACTION,2.13,42.16,"VAPOR DIFFUSION, HANGING DROP",8.5,"10~20%(v/v) PEG3350, 100 mM Tris-HCl",278.0,2014-12-30,2015-12-30,4XG7,2407.0,1.0,290.0,195.0,,34.29,1.0,1.76,experimental,33.304,0.24246,0.22287,Crystal structure of an inhibitor-bound Syk
6ICV,X-RAY DIFFRACTION,2.88,57.36,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES sodium pH 7.5
2% Polyethylene glycol 400
2.0M Ammonium sulfate",291.0,2018-09-07,2019-02-27,6ICV,8493.0,4.0,1054.0,591.0,,122.15,2.0,2.15,experimental,,0.205,0.1675,Structure of SETD3 bound to SAH and unmodified actin
8IKT,X-RAY DIFFRACTION,1.98,38.02,"VAPOR DIFFUSION, SITTING DROP",,"0.3 M Sodium nitrate, 0.3 Sodium phosphate dibasic, 0.3 M Ammonium sulfate, Imidazole, MES monohydrate (acid), 25% v/v MPD, 25% PEG 1000, 25% w/v PEG 3350",291.0,2023-03-01,2024-09-11,8IKT,3088.0,3.0,463.0,52.0,,52.31,3.0,2.6,experimental,63.575,0.2358,0.2125,Ternary trans-complex of phospho-parkin with cis ACT and pUb
6XI2,X-RAY DIFFRACTION,4.29,71.32,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M potassium/sodium tartrate, 0.1 M Bis-Tris, pH 7.9, 10% PEG8000",291.0,2020-06-19,2021-04-21,6XI2,17188.0,6.0,2142.0,148.0,15.0,246.84,6.0,2.57,experimental,48.964,0.2373,0.2135,Apo form of POMGNT2
6RFO,X-RAY DIFFRACTION,2.2,44.1,"VAPOR DIFFUSION, SITTING DROP",,"1.8 M ammonium sulfate, 0.1 M Bis-tris pH 6.8 or 6.5, 2% (w/v) PEG 550",293.0,2019-04-15,2020-05-27,6RFO,2762.0,1.0,372.0,173.0,,42.86,1.0,1.7,experimental,36.37,0.21874,0.1563,ERK2 MAP kinase with the activation loop of p38alpha
7LVS,X-RAY DIFFRACTION,1.74,29.3,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 6.87, 28% PEG 4000",293.0,2021-02-26,2021-07-28,7LVS,1253.0,2.0,167.0,36.0,,19.0,2.0,2.02,experimental,59.75,0.2406,0.2107,The CBP TAZ1 Domain in Complex with a CITED2-HIF-1-Alpha Fusion Peptide
7ZW8,X-RAY DIFFRACTION,2.48,50.48,VAPOR DIFFUSION,7.25,"9% (w/v) PEG 8K,  0.1 M HEPES",293.0,2022-05-19,2023-02-22,7ZW8,2483.0,1.0,327.0,40.0,,37.69,1.0,2.119,experimental,76.56,0.2498,0.2087,Identification of M4205 a highly selective inhibitor of cKIT mutations for unresectable metastatic or recurrent GIST
7T1U,X-RAY DIFFRACTION,2.13,42.38,"VAPOR DIFFUSION, SITTING DROP",4.0,"80 uM Zinc Acetate, 12% PEG3350, 100 mM Sodium Acetate (pH 4.0), and 2% 1,3-butanediol",293.0,2021-12-02,2022-08-24,7T1U,1806.0,4.0,236.0,18.0,,27.55,2.0,2.65,experimental,56.06,0.2702,0.2184,Crystal structure of a superbinder Src SH2 domain (sSrcF) in complex with a high affinity phosphopeptide
6ATE,X-RAY DIFFRACTION,2.11,41.66,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, pH 6.5, 16%-20% PEG 3350, 350 mM - 420mM NaOAc",293.0,2017-08-28,2019-02-27,6ATE,2155.0,1.0,286.0,64.0,,33.18,1.0,2.402,experimental,,0.2282,0.193,SRC kinase bound to covalent inhibitor
8JF3,X-RAY DIFFRACTION,2.84,58.32,"VAPOR DIFFUSION, HANGING DROP",6.5,"300 mM Sodium Acetate, 0.1 M MES pH 7.5, 4% PEG3350",293.0,2023-05-17,2024-02-14,8JF3,3853.0,2.0,566.0,,,65.87,1.0,2.84647631109,experimental,38.2139186642,0.316930785964,0.274171879585,C-Src in complex with compound 9
4TN7,X-RAY DIFFRACTION,2.23,44.77,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Li-citrate
18-30% PEG 3350",293.0,2014-06-03,2015-05-13,4TN7,7105.0,6.0,824.0,404.0,,96.82,3.0,2.2,experimental,,0.2794,0.2294,Crystal structure of mouse KDM2A-H3K36ME-NO complex
4WVP,X-RAY DIFFRACTION,2.18,43.51,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M Tris pH8, 0.8M ammonium sulfate",293.0,2014-11-06,2015-02-11,4WVP,2051.0,2.0,224.0,202.0,4.0,26.43,2.0,1.63,experimental,18.125,0.1689,0.1384,Crystal structure of an activity-based probe HNE complex
5ABW,X-RAY DIFFRACTION,2.34,47.41,,,,,2015-08-10,2015-08-19,5ABW,2067.0,1.0,218.0,363.0,4.0,24.52,1.0,1.6,experimental,15.551,0.19422,0.15791,Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases
8JWV,X-RAY DIFFRACTION,2.54,51.49,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES, pH 7.5, 8% PEG 4000,  10% isopropanol, 0.1 M BaCl2",277.0,2023-06-29,2024-07-03,8JWV,2435.0,1.0,325.0,18.0,,37.49,1.0,2.9,experimental,44.299,0.2537,0.217,Untethered R0RBR
6ICJ,X-RAY DIFFRACTION,2.27,45.85,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M NH4 Acetate, 0.1 M HEPES 7.5 pH, 25 %w/v PEG 3350",291.0,2018-09-06,2019-09-11,6ICJ,2122.0,2.0,297.0,25.0,,34.64,2.0,2.483,experimental,,0.282,0.23,Crystal structure of PPARgamma with compound BR102375K
5DY5,X-RAY DIFFRACTION,2.9,57.66,"VAPOR DIFFUSION, SITTING DROP",7.4,"17.5 % (wt/v) PEG 3350, 0.1 M HEPES",277.0,2015-09-24,2016-01-20,5DY5,2687.0,1.0,304.0,238.0,,35.43,1.0,1.95,experimental,30.184,0.20495,0.18989,Crystal structure of human Sirt2 in complex with a SirReal probe fragment
5YQL,X-RAY DIFFRACTION,2.15,42.78,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Magnesium Formate, 23-30% (v/v) Polyethylene glycol 3350",293.0,2017-11-07,2018-10-17,5YQL,2783.0,1.0,306.0,382.0,,35.05,1.0,1.601,experimental,,0.1853,0.1577,Crystal structure of Sirt2 in complex with selective inhibitor A2I
5YQM,X-RAY DIFFRACTION,2.14,42.49,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES PH6.8, 25%-30% PEG 3350",293.0,2017-11-07,2018-10-17,5YQM,2662.0,1.0,306.0,281.0,,35.21,1.0,1.735,experimental,,0.2196,0.1826,Crystal structure of Sirt2 in complex with selective inhibitor A29
5YQN,X-RAY DIFFRACTION,2.12,41.92,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES PH7.4, 30% PEG 3350",293.0,2017-11-07,2018-10-17,5YQN,2639.0,1.0,306.0,296.0,,35.12,1.0,1.6,experimental,,0.2038,0.1735,Crystal structure of Sirt2 in complex with selective inhibitor L55
5YQO,X-RAY DIFFRACTION,2.14,42.42,"VAPOR DIFFUSION, HANGING DROP",,2.1M DL-malic acid PH7.0,293.0,2017-11-07,2018-10-17,5YQO,2690.0,1.0,306.0,353.0,,35.02,1.0,1.483,experimental,,0.1928,0.1692,Crystal structure of Sirt2 in complex with selective inhibitor L5C
6ILQ,X-RAY DIFFRACTION,2.07,40.63,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M MgCl2, 0.1 M TRIS 8.5 pH, 27 %w/v PEG 3350",291.0,2018-10-19,2019-09-11,6ILQ,2147.0,2.0,297.0,63.0,,34.43,2.0,2.408,experimental,,0.3035,0.2157,Crystal structure of PPARgamma with compound BR101549
6KTN,X-RAY DIFFRACTION,2.7,54.5,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate (pH 7.0),296.0,2019-08-28,2020-02-05,6KTN,2283.0,2.0,299.0,30.0,,34.59,2.0,2.752,experimental,44.711,0.2563,0.2205,Human PPARgamma ligand-binding domain R288A mutant in complex with imatinib
6HHF,X-RAY DIFFRACTION,2.18,43.63,"VAPOR DIFFUSION, HANGING DROP",5.2,"1.25 mM Na-acetate, 3.75 mM Na-citrate, 15% v/v PEG 2000 MME, pH 5.2, 3 mg/mL Akt1 (in 25 mM TRIS, 100 mM NaCl, 10 % Glycerol, 5 mM DTT, pH 7.5), 1 uL reservoir + 1 uL protein solution",293.0,2018-08-28,2019-03-20,6HHF,3082.0,1.0,446.0,3.0,1.0,52.34,1.0,2.9,experimental,,0.2736,0.2305,Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor Borussertib
6HHG,X-RAY DIFFRACTION,2.22,44.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.25 mM Na-acetate, 3.75 mM Na-citrate, 15% v/v PEG 2000 MME, pH 7.5, 3 mg/mL Akt1 (in 25 mM TRIS, 100 mM NaCl, 10 % Glycerol, 5 mM DTT, pH 7.5), 1 uL reservoir + 1 uL protein solution",293.0,2018-08-28,2019-02-20,6HHG,3313.0,1.0,446.0,77.0,1.0,52.38,1.0,2.3,experimental,,0.2461,0.2104,Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 27
6HHJ,X-RAY DIFFRACTION,2.2,44.02,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.25 mM Na-acetate, 3.75 mM Na-citrate, 15 % v/v PEG 2000 MME, pH 7.5, 3 mg/mL Akt1 (in 25 mM TRIS, 100 mM NaCl, 10 % Glycerol, 5 mM DTT, pH 7.5), 1ul reservoir + 1ul protein solution",293.0,2018-08-28,2019-02-20,6HHJ,3544.0,1.0,446.0,120.0,1.0,52.36,1.0,2.3,experimental,,0.2435,0.222,Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 24b
5TR6,X-RAY DIFFRACTION,2.43,49.32,"VAPOR DIFFUSION, SITTING DROP",6.1,"0.7M Potassium Na Tartrate, 0.06M MES_Na, 0.04M MES",293.0,2016-10-25,2016-11-30,5TR6,2387.0,1.0,289.0,132.0,,34.1,1.0,1.93,experimental,35.14,0.2172,0.1933,"Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)"
8HAQ,X-RAY DIFFRACTION,3.0,59.04,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS pH 7.0, 18% PEG 3350, 5% Glycerol, 5 mM TCEP",293.0,2022-10-26,2023-11-01,8HAQ,4085.0,2.0,554.0,84.0,,64.47,1.0,2.27,experimental,,0.2499,0.2074,The complex of Src with GW8510
5NHU,X-RAY DIFFRACTION,3.0,59.0,"VAPOR DIFFUSION, SITTING DROP",5.0,"Drops consisting of equal volumes (1 microliter) of protein complex (at 6.4 mg/mL) and precipitant solution (0.1M PCTP pH 5.0, 25% w/v PEG 1500) equilibrated against a 300 microliter reservoir.",293.0,2017-03-22,2017-06-14,5NHU,9088.0,9.0,1131.0,730.0,15.0,129.18,3.0,1.45,experimental,,0.203,0.1792,HUMAN ALPHA THROMBIN COMPLEXED WITH ANOPHELES GAMBIAE cE5 ANTICOAGULANT
8JN8,X-RAY DIFFRACTION,1.89,34.78,"VAPOR DIFFUSION, HANGING DROP",,"0.2M tri-Lithium citrate, 20%(w/v) PEG 3350",289.0,2023-06-06,2024-06-12,8JN8,3981.0,1.0,536.0,337.0,,60.3,1.0,1.902,experimental,,0.2535,0.2097,Crystal structure of c-Src in complex with covalent inhibitor DC-Srci-6668
8JN9,X-RAY DIFFRACTION,1.89,34.86,"VAPOR DIFFUSION, HANGING DROP",,"0.2M tri-Lithium citrate, 20%(w/v) PEG 3350",289.0,2023-06-06,2024-06-12,8JN9,3633.0,1.0,536.0,5.0,,60.33,1.0,2.724,experimental,,0.2785,0.1986,Crystal structure of c-Src in complex with covalent inhibitor LW-Srci-8
6KDT,X-RAY DIFFRACTION,3.74,67.11,"VAPOR DIFFUSION, HANGING DROP",,2.2 M sodium formate,278.0,2019-07-02,2020-02-19,6KDT,7895.0,4.0,980.0,160.0,,113.6,2.0,2.87,experimental,,0.2422,0.1938,Crystal structure of human DNMT3B (Q772R)-DNMT3L complex
5AFZ,X-RAY DIFFRACTION,2.49,50.6,,7.5,"SEE MATERIALS AND METHODS SECTION OF PUBLICATION, pH 7.5",,2015-01-27,2015-08-26,5AFZ,2645.0,3.0,299.0,219.0,4.0,35.5,3.0,1.53,experimental,25.0,0.1741,0.145,Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-propyl)-3-phenyl-propanamide
6TKG,X-RAY DIFFRACTION,2.23,44.8,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5, 0.2 M ammonium acetate, 25 % (w/v) PEG 3350",293.0,2019-11-28,2020-11-04,6TKG,2903.0,3.0,348.0,310.0,4.0,40.18,3.0,1.35,experimental,27.88,0.195,0.1641,Tsetse thrombin inhibitor in complex with human alpha-thrombin - orthorhombic form at 12keV
6TKH,X-RAY DIFFRACTION,2.33,47.3,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5, 0.2 M ammonium acetate, 25 % (w/v) PEG 3350",293.0,2019-11-28,2020-11-04,6TKH,2719.0,3.0,348.0,169.0,4.0,40.27,3.0,1.9,experimental,37.11,0.2003,0.1606,Tsetse thrombin inhibitor in complex with human alpha-thrombin - orthorhombic form at 7keV
6TKL,X-RAY DIFFRACTION,2.25,45.4,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5, 0.2 M ammonium acetate, 28 % (w/v) PEG 3350",293.0,2019-11-28,2020-11-04,6TKL,2844.0,3.0,348.0,256.0,4.0,40.19,3.0,1.3,experimental,30.88,0.1758,0.1455,Non-cleavable tsetse thrombin inhibitor in complex with human alpha-thrombin
6EVV,X-RAY DIFFRACTION,4.81,74.41,"VAPOR DIFFUSION, HANGING DROP",7.0,"Tacsimate 50 % v/v, pH 7.0",293.0,2017-11-02,2018-10-24,6EVV,3183.0,3.0,321.0,129.0,4.0,44.22,2.0,2.5,experimental,48.197,0.2054,0.1691,"X-ray structure of the complex between human alpha thrombin and NU172, a duplex/quadruplex 26-mer DNA aptamer, in the presence of potassium ions."
6GN7,X-RAY DIFFRACTION,5.05,75.63,"VAPOR DIFFUSION, HANGING DROP",7.0,"Tacsimate 50 % v/v, pH 7.0",293.0,2018-05-30,2018-10-17,6GN7,3146.0,3.0,321.0,110.0,4.0,44.05,2.0,2.8,experimental,52.146,0.203,0.1589,"X-ray structure of the complex between human alpha thrombin and NU172, a duplex/quadruplex 26-mer DNA aptamer, in the presence of sodium ions."
5VK0,X-RAY DIFFRACTION,2.53,51.46,"VAPOR DIFFUSION, HANGING DROP",6.5,"1340 mM ammonium sulfate,
6.7% glycerol, 50 mM magnesium sulfate,
100 mM imidazole pH 6.5",294.0,2017-04-20,2018-04-25,5VK0,10147.0,24.0,1188.0,418.0,,138.82,2.0,1.8,experimental,26.736,0.24656,0.19793,Crystal structure of human MDM2 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI
4Z4C,X-RAY DIFFRACTION,2.1,41.45,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Tris, Isopropanol, Phenol, Magnesium",293.0,2015-04-02,2015-09-23,4Z4C,7321.0,3.0,891.0,279.0,,108.14,1.0,2.303,experimental,,0.2186,0.1693,Human Argonaute2 Bound to t1-C Target RNA
4Z4E,X-RAY DIFFRACTION,2.11,41.66,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Tris, Isopropanol, Phenol, Magnesium",293.0,2015-04-02,2015-09-23,4Z4E,7558.0,3.0,891.0,533.0,,108.11,1.0,1.8,experimental,,0.1854,0.1575,Human Argonaute2 Bound to t1-U Target RNA
5KI6,X-RAY DIFFRACTION,2.21,44.46,"VAPOR DIFFUSION, HANGING DROP",9.0,"PEG 3350, Phenol, Tris, Spermine, Isopropanol",293.0,2016-06-16,2016-07-20,5KI6,6756.0,2.0,880.0,105.0,,104.56,1.0,2.153,experimental,,0.2697,0.2375,Human Argonaute-2 bound to a guide RNA with a nucleobase modification at position 1
6MFN,X-RAY DIFFRACTION,2.58,52.32,"VAPOR DIFFUSION, HANGING DROP",8.0,"10% PEG3350, 50 mM Tris, pH 8.0, 20 mM magnesium chloride, 75 mM phenol",293.0,2018-09-11,2019-08-07,6MFN,6910.0,3.0,902.0,87.0,,111.15,1.0,2.5,experimental,,0.2468,0.209,Human Argonaute2-miR-27a bound to HSUR1 target RNA
8T7C,X-RAY DIFFRACTION,2.53,51.38,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Magnesium Formate, 15 % w/v PEG 3350",291.0,2023-06-20,2024-06-26,8T7C,8400.0,1.0,1166.0,190.0,,136.16,1.0,2.55,experimental,56.755,0.2816,0.2268,Crystal structure of human phospholipase C gamma 2
8GWH,X-RAY DIFFRACTION,2.8,56.14,"VAPOR DIFFUSION, HANGING DROP",5.0,"sodium acetate, PEG 4000",278.0,2022-09-17,2023-09-20,8GWH,2570.0,2.0,304.0,142.0,1.0,35.41,2.0,2.0,experimental,46.8635,0.2097,0.181,PTPN21 PTP domain C1108S mutant in complex with SRC pTyr530 peptide
4Z4D,X-RAY DIFFRACTION,2.12,41.93,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Tris, Isopropanol, Phenol, Magnesium",293.0,2015-04-02,2015-09-23,4Z4D,7654.0,3.0,891.0,554.0,,108.23,1.0,1.6,experimental,,0.189,0.1631,Human Argonaute2 Bound to t1-G Target RNA
6S9W,X-RAY DIFFRACTION,2.2,44.08,"VAPOR DIFFUSION, HANGING DROP",7.0,"1.25 mM Na-acetate, 3.75 mM Na-citrate, 24% v/v PEG 2000 MME, pH 7.0, 3 mg/mL Akt1 (in 25 mM TRIS, 100 mM NaCl, 10% v/v Glycerol, 5 mM DTT, pH 7.5), 1 uL reservoir + 1 uL protein solution",293.0,2019-07-15,2019-10-16,6S9W,3451.0,1.0,446.0,12.0,,52.31,1.0,2.3,experimental,70.9623,0.2625,0.2071,Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 16a
6S9X,X-RAY DIFFRACTION,2.24,45.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.25 mM Na-acetate, 3.75 mM Na-citrate, 15% v/v PEG 2000 MME, pH 7.5, 3 mg/mL Akt1 (in 25 mM TRIS, 100 mM NaCl, 10% v/v Glycerol, 5 mM DTT, pH 7.5), 1 uL reservoir + 1 uL protein solution",293.0,2019-07-15,2019-10-16,6S9X,3223.0,1.0,446.0,12.0,1.0,52.4,1.0,2.6,experimental,99.2954,0.2343,0.2128,Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor 15c
7NH4,X-RAY DIFFRACTION,2.21,44.35,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.25 mM Na-acetate, 3.75 mM Na-citrate, 12% v/v PEG 2000 MME, pH 6.5, 3 mg/mL Akt1 (in 25 mM TRIS, 100 mM NaCl, 10% v/v Glycerol, 5 mM DTT, pH 7.5), 1 uL reservoir + 1 uL protein solution",293.0,2021-02-10,2021-09-08,7NH4,3110.0,1.0,446.0,15.0,1.0,52.43,1.0,2.3,experimental,81.99,0.2457,0.2228,Co-Crystal Structure of Akt1 in Complex with Covalent-Allosteric Akt Inhibitor 3
7NH5,X-RAY DIFFRACTION,2.22,44.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.25 mM Na-acetate, 3.75 mM Na-citrate, 18% v/v PEG 2000 MME, pH 6.5, 3 mg/mL Akt1 (in 25 mM TRIS, 100 mM NaCl, 10% v/v Glycerol, 5 mM DTT, pH 7.5), 1 uL reservoir + 1 uL protein solution",293.0,2021-02-10,2021-09-08,7NH5,3301.0,1.0,446.0,83.0,1.0,52.39,1.0,1.9,experimental,57.66,0.2284,0.1998,Co-Crystal Structure of Akt1 in Complex with Covalent-Allosteric Akt Inhibitor 6
5KCV,X-RAY DIFFRACTION,2.36,47.78,"VAPOR DIFFUSION, HANGING DROP",7.5,"16% butanol, 10mM ammonium sulfate, 0.1% 2-mercaptoethanol, 15% ethylene glycol, 50mM Tris, pH 7.5",277.0,2016-06-07,2016-06-29,5KCV,2874.0,1.0,460.0,79.0,1.0,53.99,1.0,2.7,experimental,67.735,0.2686,0.20961,"Crystal structure of allosteric inhibitor, ARQ 092, in complex with autoinhibited form of AKT1"
8SZP,X-RAY DIFFRACTION,2.78,55.74,"VAPOR DIFFUSION, HANGING DROP",6.0,"200 mM Lithium sulfate, 100 mM MES pH 6, 20% (w/v) PEG 4000; 5 mM ADP and 50 mM magnesium chloride in protein solution",291.0,2023-05-30,2023-08-02,8SZP,13893.0,2.0,2020.0,134.0,,231.51,1.0,2.62,experimental,87.946,0.2736,0.2194,Human DHX9 bound to ADP
8VME,X-RAY DIFFRACTION,2.93,58.01,MICRODIALYSIS,7.5,"10% PEG35000, 20 mM Tris, pH 7.5, 300 mM sodium chloride, 5% glycerol, 10 mM magnesium chloride, 200 uM ATP, 5 mM DTT",277.0,2024-01-13,2024-08-28,8VME,3308.0,3.0,417.0,174.0,,48.37,3.0,2.3,experimental,72.36,0.2298,,Crystal structure of the GSK-3/Axin complex bound to a phosphorylated beta-catenin T41A peptide
8VMF,X-RAY DIFFRACTION,2.92,57.89,MICRODIALYSIS,7.5,"10% PEG35000, 20 mM Tris, pH 7.5, 300 mM sodium chloride, 5% glycerol, 10 mM magnesium chloride, 5 mM DTT, 200 uM ADP, 200 uM aluminum nitrate, 1.2 mM sodium fluoride",277.0,2024-01-13,2024-08-28,8VMF,3226.0,3.0,416.0,131.0,,48.04,3.0,2.5,experimental,68.34,0.2506,0.2091,Crystal structure of a transition-state mimic of the GSK-3/Axin complex bound to a beta-catenin S45D peptide
8PY3,X-RAY DIFFRACTION,2.17,43.38,"VAPOR DIFFUSION, SITTING DROP",6.5,"25 % PEG 3,350, 0.22 M Bis-Tris pH 6.5",298.0,2023-07-24,2024-06-19,8PY3,2662.0,1.0,304.0,211.0,,35.52,1.0,1.65,experimental,,0.1849,0.1659,"Crystal structure of human Sirt2 in complex with a 1,2,4-oxadiazole based inhibitor"
6HUE,X-RAY DIFFRACTION,2.51,51.07,"VAPOR DIFFUSION, SITTING DROP",,"100mM BIS-TRIS pH 5.5, 200mM LiSO4 and 20% PEG3350",277.0,2018-10-07,2018-10-17,6HUE,6333.0,2.0,810.0,157.0,,92.98,1.0,2.85,experimental,64.964,0.25486,0.22284,ParkinS65N
7MYX,X-RAY DIFFRACTION,1.82,32.43,VAPOR DIFFUSION,7.5,"1.28 M Sodium Citrate, 0.1 M Hepes pH 7.5, 0.01 M Praseodymium(III) Acetate",298.0,2021-05-22,2022-11-09,7MYX,1069.0,1.0,121.0,111.0,,14.46,1.0,1.39,experimental,17.77,0.2041,0.1754,Crystal structure of the PH domain (R86A) of Akt1
5A2M,X-RAY DIFFRACTION,2.78,55.75,,7.5,"SEE MATERIALS&METHODS OF PUBLICATION, pH 7.5",,2015-05-20,2016-06-01,5A2M,2672.0,3.0,299.0,234.0,4.0,35.57,3.0,1.4,experimental,23.0,0.1594,0.1365,Thrombin Inhibitor
6T55,X-RAY DIFFRACTION,2.52,51.28,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4, 350 mM NaCl, 27% (w/v) PEG8000",277.0,2019-10-15,2020-11-18,6T55,2694.0,3.0,306.0,251.0,4.0,35.94,3.0,1.39,experimental,25.25,0.1721,0.1538,Thrombin in Complex with Methylbenzylamine
6T56,X-RAY DIFFRACTION,2.54,51.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4, 350 mM NaCl, 27% (w/v) PEG8000",277.0,2019-10-15,2020-11-18,6T56,2671.0,3.0,306.0,225.0,4.0,36.04,3.0,1.31,experimental,23.52,0.1632,0.1403,Thrombin in Complex with Benzylamine
6ZUG,X-RAY DIFFRACTION,2.57,52.14,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M phosphate buffer pH 7.5, 
27% PEG 8000, 100 mM NaCl",283.0,2020-07-22,2020-08-26,6ZUG,2733.0,3.0,298.0,330.0,4.0,35.18,3.0,1.8,experimental,41.386,0.2117,0.1689,Crystal Structure of Thrombin in complex with compound10
6ZUN,X-RAY DIFFRACTION,2.48,50.48,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M phosphate buffer pH 7.5, 
27% PEG 8000, 100 mM NaCl",283.0,2020-07-23,2020-08-26,6ZUN,2688.0,3.0,306.0,298.0,4.0,35.95,3.0,1.793,experimental,57.292,0.2622,0.2265,Crystal Structure of Thrombin in complex with compound20a
6ZUU,X-RAY DIFFRACTION,2.5,50.82,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M phosphate buffer pH 7.5, 
27% PEG 8000, 100 mM NaCl",283.0,2020-07-23,2020-10-07,6ZUU,2648.0,3.0,306.0,258.0,4.0,35.95,3.0,1.94,experimental,35.132,0.212,0.1637,Crystal structure of Thrombin in complex with compound30
6ZUW,X-RAY DIFFRACTION,2.51,51.06,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M phosphate buffer pH 7.5, 
27% PEG 8000, 100 mM NaCl",283.0,2020-07-23,2020-08-26,6ZUW,2642.0,3.0,306.0,247.0,4.0,36.02,3.0,2.0,experimental,35.252,0.2135,0.1658,Crystal Structure of Thrombin in complex with compound40
6ZUX,X-RAY DIFFRACTION,2.53,51.35,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M phosphate buffer pH 7.5, 
27% PEG 8000, 100 mM NaCl",283.0,2020-07-23,2020-08-26,6ZUX,2685.0,3.0,306.0,292.0,4.0,35.99,3.0,1.94,experimental,28.009,0.206,0.1621,Crystal Structure of Thrombin in complex with compound42a
6ZV7,X-RAY DIFFRACTION,2.48,50.45,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M phosphate buffer pH 7.5, 
27% PEG 8000, 100 mM NaCl",283.0,2020-07-24,2020-08-26,6ZV7,2655.0,3.0,306.0,262.0,4.0,35.99,3.0,1.94,experimental,29.767,0.1902,0.1518,Crystal Structure of Thrombin in complex with compound42b
6ZV8,X-RAY DIFFRACTION,2.42,49.17,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M phosphate buffer pH 7.5, 
27% PEG 8000, 100 mM NaCl",283.0,2020-07-24,2020-08-26,6ZV8,2646.0,3.0,306.0,258.0,4.0,36.01,3.0,1.7,experimental,18.885,0.2473,0.203,Crystal Structure of Thrombin in complex with compound51
5DO4,X-RAY DIFFRACTION,3.14,60.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"5% [w/v] PEG-6000, 2.5% v/v (+/-)-2-Methyl-2,4-pentanediol, 50 mM HEPES",291.0,2015-09-10,2016-09-14,5DO4,3095.0,3.0,319.0,163.0,4.0,43.28,2.0,1.859,experimental,34.446,0.2236,0.189,Thrombin-RNA aptamer complex
7S25,X-RAY DIFFRACTION,2.85,56.92,"VAPOR DIFFUSION, HANGING DROP",7.5,"15-17% PEG 5K MME, 0.1 M HEPES/NaOH pH 7.5, 5% (v/v) tacsimate pH 7.5",293.0,2021-09-03,2022-10-05,7S25,11418.0,4.0,1584.0,128.0,,184.47,1.0,2.337,experimental,95.04,0.2706,0.2394,ROCK1 IN COMPLEX WITH LIGAND G4998
7S26,X-RAY DIFFRACTION,2.96,58.45,"VAPOR DIFFUSION, HANGING DROP",7.5,"15-17% PEG 5K MME, 0.1 M HEPES/NaOH pH 7.5, 5% (v/v) tacsimate pH 7.5",293.0,2021-09-03,2022-10-05,7S26,11460.0,4.0,1592.0,69.0,,185.55,1.0,2.744,experimental,124.5,0.2685,0.2469,ROCK1 IN COMPLEX WITH LIGAND G5018
4Z4F,X-RAY DIFFRACTION,2.13,42.26,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Tris, Isopropanol, Phenol, Magnesium",293.0,2015-04-02,2015-09-23,4Z4F,7032.0,3.0,891.0,16.0,,107.83,1.0,2.8,experimental,,0.233,0.1839,Human Argonaute2 Bound to t1-DAP Target RNA
4Z4G,X-RAY DIFFRACTION,2.13,42.2,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Tris, Isopropanol, Phenol, Magnesium",293.0,2015-04-02,2015-09-23,4Z4G,7112.0,3.0,891.0,105.0,,107.91,1.0,2.7,experimental,,0.2244,0.1786,Human Argonaute2 Bound to t1-Inosine Target RNA
4Z4H,X-RAY DIFFRACTION,2.12,41.87,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Tris, Isopropanol, Phenol, Magnesium",293.0,2015-04-02,2015-09-23,4Z4H,7166.0,3.0,891.0,135.0,,107.94,1.0,2.504,experimental,,0.2113,0.1721,Human Argonaute2 A481T Mutant Bound to t1-A Target RNA
4Z4I,X-RAY DIFFRACTION,2.1,41.36,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Tris, Isopropanol, Phenol, Magnesium",293.0,2015-04-02,2015-09-23,4Z4I,7027.0,3.0,891.0,23.0,,107.87,1.0,2.801,experimental,,0.2332,0.1918,Human Argonaute2 A481T Mutant Bound to t1-G Target RNA
5JS1,X-RAY DIFFRACTION,2.19,43.78,"VAPOR DIFFUSION, HANGING DROP",9.0,"16% PEG 3350, 50mM Phenol, 10% Isopropanol, 5mM Magnesium Chloride, 100mM Tris",293.0,2016-05-07,2016-07-20,5JS1,6715.0,2.0,880.0,52.0,,104.27,1.0,2.499,experimental,,0.2475,0.2165,Human Argonaute2 Bound to an siRNA
5JS2,X-RAY DIFFRACTION,2.29,46.31,"VAPOR DIFFUSION, HANGING DROP",9.0,"12% PEG 3350, 75mM Phenol, 12% Isopropanol, 100mM Tris",293.0,2016-05-07,2016-07-20,5JS2,6593.0,2.0,865.0,11.0,,99.65,1.0,2.954,experimental,,0.2611,0.2223,Human Argonaute-2 Bound to a Modified siRNA
5TX4,X-RAY DIFFRACTION,2.24,45.18,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes, pH 7.5, 60 % v/v (+/-)-2-Methyl-2,4-pentanediol",298.0,2016-11-15,2017-03-01,5TX4,1657.0,2.0,208.0,82.0,10.0,23.73,2.0,1.876,experimental,,0.2222,0.1935,"Derivative of mouse TGF-beta2, with a deletion of residues 52-71 and K25R, R26K, L51R, A74K, C77S, L89V, I92V, K94R T95K, I98V single amino acid substitutions, bound to human TGF-beta type II receptor ectodomain residues 15-130"
5LYO,X-RAY DIFFRACTION,2.45,49.79,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES 6.5, 2.0 M ammonium sulfate",293.0,2016-09-28,2017-10-25,5LYO,6136.0,3.0,795.0,167.0,11.0,89.42,1.0,2.498,experimental,,0.2629,0.2144,Crystal structure of the zymogen matriptase catalytic domain
6BUU,X-RAY DIFFRACTION,2.68,54.18,VAPOR DIFFUSION,7.5,"20% PEG 3000, 0.1M Hepes HCL, 0.2M Ammonium sulfate",277.0,2017-12-11,2018-08-22,6BUU,5780.0,4.0,694.0,238.0,,82.05,2.0,2.4,experimental,37.814,0.2296,0.1831,Crystal structure of AKT1 (aa 144-480) with a bisubstrate
6IJR,X-RAY DIFFRACTION,2.32,46.89,"VAPOR DIFFUSION, SITTING DROP",6.5,60% (v/v) Tacsimate,295.0,2018-10-11,2019-10-16,6IJR,4799.0,4.0,598.0,24.0,,69.51,2.0,2.85,experimental,87.947,0.26601,0.23601,Human PPARgamma ligand binding domain complexed with SB1495
5DSH,X-RAY DIFFRACTION,2.67,54.01,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2M sodium malonate pH 7.0,297.0,2015-09-17,2016-09-21,5DSH,2205.0,2.0,303.0,25.0,,34.95,2.0,2.95,experimental,85.374,0.25743,0.20477,Human PPARgamma ligand binding dmain complexed with SB1406 in a covalent bonded form
5DV3,X-RAY DIFFRACTION,2.68,54.16,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2M sodium malonate pH 7.0,297.0,2015-09-21,2016-09-21,5DV3,2252.0,2.0,303.0,25.0,,34.95,2.0,2.75,experimental,78.177,0.22995,0.20168,Human PPARgamma ligand binding dmain complexed with SB1405 in a covalent bonded form
5DV6,X-RAY DIFFRACTION,2.69,54.24,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2M sodium malonate pH 7.0,297.0,2015-09-21,2016-09-21,5DV6,2234.0,2.0,303.0,32.0,,34.78,2.0,2.8,experimental,82.811,0.24409,0.20801,Human PPARgamma ligand binding dmain complexed with SB1404 in a covalent bonded form
5DV8,X-RAY DIFFRACTION,2.72,54.86,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.19M sodium acetate trihydrate, 0.1M sodium cacodylate pH 6.5, 26% PEG 8000",297.0,2015-09-21,2016-09-21,5DV8,2330.0,2.0,303.0,39.0,,35.19,2.0,2.75,experimental,59.267,0.24311,0.1916,Human PPARgamma ligand binding dmain complexed with SB1451 in a covalent bonded form
5DVC,X-RAY DIFFRACTION,2.7,54.41,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate pH 7.0,297.0,2015-09-21,2016-09-21,5DVC,2383.0,2.0,303.0,87.0,,35.19,2.0,2.3,experimental,58.373,0.241,0.19644,Human PPARgamma ligand binding dmain complexed with SB1453 in a covalent bonded form
5DWL,X-RAY DIFFRACTION,2.66,53.8,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate pH7.0,297.0,2015-09-22,2016-09-21,5DWL,2378.0,2.0,303.0,73.0,,35.15,2.0,2.2,experimental,65.194,0.23825,0.20579,Human PPARgamma ligand binding dmain in complex with SR1664
7CXF,X-RAY DIFFRACTION,2.68,54.16,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate (pH 7.0),295.0,2020-09-01,2021-09-01,7CXF,2359.0,2.0,299.0,61.0,,34.35,2.0,2.35,experimental,38.006,0.2693,0.2292,The ligand-free structure of human PPARgamma LBD C285Y mutant in the presence of the SRC-1 coactivator peptide
7CXH,X-RAY DIFFRACTION,2.8,56.09,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate (pH 7.0),295.0,2020-09-01,2021-09-01,7CXH,2391.0,2.0,299.0,90.0,,34.19,2.0,2.3,experimental,34.35,0.257,0.212,The ligand-free structure of human PPARgamma LBD Q286E mutant in the presence of the SRC-1 coactivator peptide
7CXI,X-RAY DIFFRACTION,2.71,54.59,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate (pH 7.0),295.0,2020-09-01,2021-09-01,7CXI,2230.0,2.0,299.0,26.0,,34.3,2.0,2.3,experimental,41.091,0.2761,0.2434,The ligand-free structure of human PPARgamma LBD F287Y mutant in the presence of the SRC-1 coactivator peptide
7CXJ,X-RAY DIFFRACTION,2.74,59.33,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate (pH 7.0),295.0,2020-09-01,2021-09-01,7CXJ,2187.0,2.0,299.0,19.0,,34.13,2.0,2.65,experimental,39.247,0.2753,0.2392,The ligand-free structure of human PPARgamma LBD R288C mutant in the presence of the SRC-1 coactivator peptide
7CXK,X-RAY DIFFRACTION,2.72,54.79,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate (pH 7.0),295.0,2020-09-01,2021-09-01,7CXK,2303.0,2.0,299.0,77.0,,34.27,2.0,2.2,experimental,38.16,0.2636,0.2369,The ligand-free structure of human PPARgamma LBD R288H mutant in the presence of the SRC-1 coactivator peptide
7CXL,X-RAY DIFFRACTION,2.86,56.94,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate (pH 7.0),295.0,2020-09-01,2021-09-01,7CXL,2248.0,2.0,299.0,36.0,,34.31,2.0,2.7,experimental,42.634,0.255,0.2381,The ligand-free structure of human PPARgamma LBD S289C mutant in the presence of the SRC-1 coactivator peptide
5YCN,X-RAY DIFFRACTION,2.79,55.97,"VAPOR DIFFUSION, SITTING DROP",6.5,1.6 M sodium citrate tribasic dihydrate (pH 6.5),296.0,2017-09-07,2018-09-12,5YCN,2353.0,2.0,299.0,113.0,,34.67,2.0,2.15,experimental,46.324,0.22832,0.20772,Human PPARgamma ligand binding domain complexed with Lobeglitazone
6IJS,X-RAY DIFFRACTION,2.83,56.6,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate,295.0,2018-10-11,2019-10-16,6IJS,2332.0,2.0,290.0,82.0,,33.8,2.0,2.15,experimental,54.354,0.24113,0.20372,Human PPARgamma ligand binding domain complexed with SB1494
6JQ7,X-RAY DIFFRACTION,3.04,59.51,"VAPOR DIFFUSION, SITTING DROP",7.0,60% (v/v) Tacsimate (pH 7.0),296.0,2019-03-29,2019-10-16,6JQ7,2233.0,2.0,299.0,48.0,,34.19,2.0,2.55,experimental,39.596,0.25652,0.22026,The ligand-free structure of human PPARgamma LBD in the presence of the SRC-1 coactivator peptide
6KTM,X-RAY DIFFRACTION,2.72,54.9,"VAPOR DIFFUSION, SITTING DROP",7.0,2.2 M sodium malonate (pH 7.0),296.0,2019-08-28,2020-02-05,6KTM,2194.0,2.0,299.0,20.0,,34.1,2.0,2.7,experimental,72.077,0.2575,0.2166,The ligand-free structure of human PPARgamma ligand-binding domain R288A mutant in the presence of the SRC-1 coactivator peptide
5NX1,X-RAY DIFFRACTION,2.49,50.57,VAPOR DIFFUSION,,"0.2M Ammonium Sulfate, 0.1M Bis-Tris pH 5.5, 25% Polyethylene Glycol 3350",293.0,2017-05-09,2018-05-30,5NX1,2759.0,4.0,385.0,195.0,12.0,42.88,4.0,1.853,experimental,,0.2255,0.1839,Combinatorial Engineering of Proteolytically Resistant APPI Variants that Selectively Inhibit Human Kallikrein 6 for Cancer Therapy
5NX3,X-RAY DIFFRACTION,2.4,48.67,"VAPOR DIFFUSION, SITTING DROP",,"0.1M tri-Na Citrate pH 5.6, 20% 2-propanol , 20% Polyethylene Glycol 4000",293.0,2017-05-09,2018-05-30,5NX3,2697.0,4.0,385.0,142.0,12.0,42.94,4.0,2.296,experimental,,0.2261,0.1749,Combinatorial Engineering of Proteolytically Resistant APPI Variants that Selectively Inhibit Human Kallikrein 6 for Cancer Therapy
5T7B,X-RAY DIFFRACTION,2.24,44.97,VAPOR DIFFUSION,,"100 mM Tris pH=9.0, 10% PEG 3350 (w/v), 8% 2-propanol (v/v), 0.12 M phenol",290.0,2016-09-02,2016-12-14,5T7B,6702.0,2.0,882.0,9.0,,104.4,1.0,2.529,experimental,,0.2383,0.1935,Argonaute-2 - 5'-(E)-vinylphosphonate 2'-O-methyl-uridine modified mrTTR guide RNA complex
5CMX,X-RAY DIFFRACTION,2.23,44.86,"VAPOR DIFFUSION, HANGING DROP",7.0,"0.2  M  sodium  malonate  pH  7,  18  %  PEG  3350",293.0,2015-07-17,2016-01-13,5CMX,2958.0,3.0,326.0,70.0,4.0,44.1,2.0,2.98,experimental,54.54,0.231,0.166,X-ray structure of the complex between human alpha thrombin and a duplex/quadruplex 31-mer DNA aptamer
7ZKO,X-RAY DIFFRACTION,2.62,56.9,"VAPOR DIFFUSION, HANGING DROP",7.0,"PEG 3350 30% w/v, 0.2 M sodium malonate, pH 7.0",293.0,2022-04-13,2022-11-30,7ZKO,2820.0,4.0,325.0,15.0,4.0,45.54,2.0,2.5,experimental,77.887,0.2954,0.2459,X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding aptamer (TBA-NNp/DDp) - Crystal form delta
7C62,X-RAY DIFFRACTION,2.74,59.28,"VAPOR DIFFUSION, SITTING DROP",,2.1 M DL-Malic acid pH 7.0,293.0,2020-05-21,2020-07-08,7C62,1545.0,1.0,206.0,151.0,,22.02,1.0,2.027,experimental,27.223,0.1736,0.152,The Crystal Structure of Parkinson disease protein 7 (DJ-1) from Biortus
6N4O,X-RAY DIFFRACTION,2.47,50.28,"VAPOR DIFFUSION, HANGING DROP",8.0,"26% MPD, 5% PEG 3350, 50 mM imidazole pH 8",293.0,2018-11-19,2019-05-08,6N4O,7064.0,3.0,898.0,,,109.78,1.0,2.899,experimental,,0.2573,0.2073,Human Argonaute2-miR-122 bound to a seed and supplementary paired target
6CBD,X-RAY DIFFRACTION,2.14,42.52,"VAPOR DIFFUSION, HANGING DROP",8.2,"14% PEG 3350, 0.1 M Tris pH 8.2, 12% Isopropanol, 10 mM MgCl2, L-tryptophan to saturation",293.0,2018-02-02,2018-04-18,6CBD,7213.0,3.0,891.0,279.0,,108.33,1.0,2.203,experimental,,0.2154,0.1757,Crystal Structure of Human Argonaute2 Bound to Three Tryptophans
9BEZ,X-RAY DIFFRACTION,2.46,49.95,"VAPOR DIFFUSION, SITTING DROP",,Drops were equal volumes of 15 mg/ml protein and 2.1M DL-Malic acid. The reservoir was 2.1M DL-Malic acid. Using MRC drop plates.,291.15,2024-04-16,2024-07-10,9BEZ,3265.0,3.0,408.0,66.0,,46.78,1.0,1.9,experimental,36.86,0.2885,0.2504,MID domain of human Argo2 bound to RNA
9BF2,X-RAY DIFFRACTION,2.53,51.29,"VAPOR DIFFUSION, SITTING DROP",,"Drop was 1:1 15 mg/ml MID-UMP and 1.4M sodium citrate tribasic dihydrate, 0.1M HEPES pH7.5",291.15,2024-04-16,2024-07-10,9BF2,3606.0,3.0,408.0,474.0,,46.35,1.0,1.59,experimental,,0.1869,0.1633,MID domain of Ago2 bound to UMP
7YMF,X-RAY DIFFRACTION,2.34,47.51,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES pH 6.5, 1.5 M Sodium Formate , 50 mM Magnesium chloride",293.0,2022-07-28,2024-01-03,7YMF,3523.0,2.0,481.0,189.0,,54.44,2.0,2.3,experimental,34.01,0.244,0.1852,Crystal Structure of DDX3X449_450ET>DP
7PA2,X-RAY DIFFRACTION,2.88,57.29,"VAPOR DIFFUSION, SITTING DROP",9.0,"0.1 M Bicine pH 9.0
10% (w/v) PEG 20 000
2% (w/v) 1,4-dioxane",293.0,2021-07-28,2022-08-10,7PA2,1577.0,1.0,192.0,168.0,1.0,20.5,1.0,1.21,experimental,19.332,0.1547,0.1324,PARK7 with inhibitor 8RK64
7PA3,X-RAY DIFFRACTION,2.82,56.44,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Ammonium sulfate
0.1 M Bis-Tris pH 5.5
25% (w/v) PEG 3350",293.0,2021-07-28,2022-08-10,7PA3,1509.0,1.0,192.0,104.0,1.0,20.5,1.0,1.42,experimental,31.274,0.2138,0.1741,PARK7 with covalent inhibitor JYQ-88
6EGS,X-RAY DIFFRACTION,2.51,51.09,"VAPOR DIFFUSION, SITTING DROP",,"PEG6000, Hepes",291.0,2017-09-12,2018-04-11,6EGS,7662.0,2.0,1006.0,60.0,10.0,116.06,1.0,2.7,experimental,73.516,0.22104,0.20627,Crystal structure of the GalNAc-T2 F104S mutant in complex with UDP-GalNAc
5L6N,X-RAY DIFFRACTION,2.01,38.75,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MMT buffer pH 7.0, 30% (w/v) PEG 1500",293.0,2016-05-30,2017-03-29,5L6N,2747.0,3.0,330.0,233.0,4.0,38.15,3.0,1.627,experimental,,0.1985,0.1666,Disulfated madanin-thrombin complex
6TKI,X-RAY DIFFRACTION,2.92,57.9,"VAPOR DIFFUSION, SITTING DROP",,"0.05 M sodium cacodylate pH 6.5, 0.01 M magnesium sulfate, 2 M ammonium sulfate",293.0,2019-11-28,2020-11-04,6TKI,2555.0,3.0,348.0,169.0,4.0,40.08,3.0,1.8,experimental,48.68,0.2143,0.1812,Tsetse thrombin inhibitor in complex with human alpha-thrombin - tetragonal form at 12.7keV
6TKJ,X-RAY DIFFRACTION,3.06,59.9,"VAPOR DIFFUSION, SITTING DROP",,"0.05 M sodium cacodylate pH 6.5, 0.01 M magnesium sulfate, 2 M ammonium sulfate",293.0,2019-11-28,2020-11-04,6TKJ,2440.0,3.0,348.0,20.0,4.0,40.06,3.0,2.81,experimental,81.42,0.2441,0.1701,Tsetse thrombin inhibitor in complex with human alpha-thrombin - tetragonal form at 7keV
6EO6,X-RAY DIFFRACTION,4.16,70.44,"VAPOR DIFFUSION, HANGING DROP",,"18% W/V PEG4000, 20% V/V 2-PROPANOL,
 0.2 M SODIUM CITRATE",281.0,2017-10-09,2017-10-25,6EO6,3230.0,3.0,310.0,412.0,4.0,39.56,2.0,1.69,experimental,30.399,0.16832,0.14531,X-ray structure of the complex between human alpha-thrombin and modified 15-mer DNA aptamer containing 5-(3-(2-(1H-indol-3-yl)acetamide-N-yl)-1-propen-1-yl)-2'-deoxyuridine residue
6EO7,X-RAY DIFFRACTION,4.19,70.65,"VAPOR DIFFUSION, HANGING DROP",,"25% W/V PEG4000, 24% V/V 2-PROPANOL,
 0.2 M SODIUM CITRATE",281.0,2017-10-09,2017-10-18,6EO7,2992.0,3.0,310.0,232.0,4.0,39.44,2.0,2.24,experimental,44.27,0.20848,0.16052,X-ray structure of the complex between human alpha-thrombin and modified 15-mer DNA aptamer containing 5-(3-(acetamide-N-yl)-1-propen-1-yl)-2'-deoxyuridine residue
7ZKM,X-RAY DIFFRACTION,2.2,48.6,"VAPOR DIFFUSION, HANGING DROP",5.6,"PEG 4000 20% w/v, 2-propanol 20% v/v, trisodium citrate 0.1 M, pH 5.6",293.0,2022-04-13,2022-11-30,7ZKM,3120.0,4.0,325.0,44.0,4.0,47.67,2.0,2.0,experimental,62.661,0.2523,0.2262,X-ray structure of the complex between human alpha thrombin and a pseudo-cyclic thrombin binding aptamer (TBA-NNp/DDp) - Crystal form beta
8D71,X-RAY DIFFRACTION,2.15,42.77,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris 8, 0.01 MgCl2, 0.1M Phenol,15% PEG 3350, 10% Isoproponal",293.15,2022-06-07,2023-05-03,8D71,6780.0,2.0,880.0,63.0,,104.21,1.0,2.5,experimental,67.3405,0.2802,0.223,Human Ago2 bound to miR122(21nt)
4ZZJ,X-RAY DIFFRACTION,4.85,74.62,"VAPOR DIFFUSION, HANGING DROP",,"5% v/v Tacsimate, pH .00.1 M HEPES pH 7.0 and 10% w/v PEG 5000 MME",298.0,2015-05-22,2015-07-15,4ZZJ,2961.0,2.0,363.0,44.0,,42.52,2.0,2.7403,experimental,,0.2214,0.1825,SIRT1/Activator/Substrate Complex
8PW8,X-RAY DIFFRACTION,2.22,44.65,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 0.4M Magnesium acetate",295.0,2023-07-19,2023-11-08,8PW8,3621.0,2.0,518.0,133.0,1.0,60.28,2.0,2.3,experimental,45.56,0.2467,0.1963,Crystal structure of the human METTL3-METTL14 in complex with a bisubstrate analogue (BA2)
8EIC,X-RAY DIFFRACTION,2.3,46.45,"VAPOR DIFFUSION, SITTING DROP",,4M Sodium formate,291.0,2022-09-14,2023-10-25,8EIC,4799.0,3.0,651.0,11.0,,72.09,3.0,2.62,experimental,71.399,0.2694,0.2258,"Crystal structure of beta-catenin and the MDM2 p53-binding domain in complex with H330, a Helicon Polypeptide"
5IP5,X-RAY DIFFRACTION,3.07,59.99,MICROBATCH,6.5,"1.5 M sodium potassium tartrate, 3.5 M ammonium sulfate, 0.1 M Na-Cacodylate",295.0,2016-03-09,2017-03-15,5IP5,1571.0,1.0,189.0,191.0,,20.3,1.0,1.66,experimental,13.826,0.16391,0.14199,Human DJ-1 complexed with Na-K-tartrate
4Y6O,X-RAY DIFFRACTION,2.33,47.1,"VAPOR DIFFUSION, SITTING DROP",,PEG 3350,293.0,2015-02-13,2016-01-06,4Y6O,4977.0,4.0,600.0,424.0,,68.36,2.0,1.6,experimental,16.931,0.23457,0.20631,Human SIRT2 in complex with myristoylated peptide (TNF-alphaK20myr)
8PPW,X-RAY DIFFRACTION,2.85,56.86,"VAPOR DIFFUSION, SITTING DROP",,"22.3% (v/v) PEG3350, 230 mM KNO3",293.0,2023-07-10,2024-01-31,8PPW,1592.0,1.0,191.0,217.0,1.0,20.32,1.0,1.53,experimental,35.94,0.1821,0.1642,Structure of human PARK7 in complex with GK16S
8PQ0,X-RAY DIFFRACTION,2.83,56.47,"VAPOR DIFFUSION, SITTING DROP",,"18.6% (v/v) PEG3350, 170 mM NaNO3",293.0,2023-07-10,2024-01-31,8PQ0,1608.0,1.0,191.0,240.0,1.0,20.31,1.0,1.48,experimental,36.2,0.1816,0.1478,Structure of human PARK7 in complex with GK16R
7MJ5,X-RAY DIFFRACTION,3.32,62.94,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M magnesium acetate, 9 % PEG 8000",298.0,2021-04-19,2021-12-22,7MJ5,16237.0,18.0,1986.0,1163.0,24.0,227.93,3.0,2.15,experimental,43.0751,0.1927,0.1645,complex of human thrombin with XC-43
6T3M,X-RAY DIFFRACTION,2.6,52.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"20 mM NaH2PO4 (pH 7.5), 350 mM NaCl, 27% (w/v) PEG 8000",277.0,2019-10-11,2020-11-18,6T3M,2712.0,3.0,306.0,248.0,4.0,36.47,3.0,1.38,experimental,20.1,0.1579,0.1327,Thrombin in Complex with a D-Phe-Pro-p-phenol derivative
6WLX,X-RAY DIFFRACTION,2.13,42.21,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Tris-HCl, 2M Na acetate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K, 5mM peptide",295.0,2020-04-20,2020-06-24,6WLX,2407.0,2.0,353.0,54.0,,39.99,2.0,2.2,experimental,56.5011,0.2292,0.1967,PAK4 kinase domain in complex with beta-catenin Ser675 substrate peptide
8D6J,X-RAY DIFFRACTION,2.15,42.67,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris 8, 0.01 MgCl2, 0.1M Phenol,15% PEG 3350, 10% Isoproponal.",293.15,2022-06-06,2023-05-03,8D6J,6774.0,2.0,880.0,50.0,,104.29,1.0,2.5,experimental,66.08,0.2841,0.232,Human Ago2 bound to miR122(21nt) with PIWI loop swapped to AtAgo10 sequence
7C6B,X-RAY DIFFRACTION,2.6,52.74,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M imidazole pH8.0, 0.2M NaCl, 0.46M NaH2PO4, 1.84M K2HPO4",277.15,2020-05-21,2020-11-25,7C6B,3520.0,3.0,417.0,283.0,,48.03,1.0,1.7,experimental,42.944,0.2286,0.1944,Crystal structure of Ago2 MID domain in complex with 6-(3-(2-carboxyethyl)phenyl)purine riboside monophosphate
7D7U,X-RAY DIFFRACTION,2.61,52.82,"VAPOR DIFFUSION, SITTING DROP",8.0,"0.1M imidazole pH8.0, 0.2M NaCl, 0.46M NaH2PO4, 1.84M K2HPO4",277.15,2020-10-06,2020-11-25,7D7U,3401.0,3.0,417.0,210.0,,47.67,1.0,2.0,experimental,29.892,0.247,0.2043,Crystal structure of Ago2 MID domain in complex with 8-Br-adenosin-5'-monophosphate
